Dossier zur Nutzenbewertung gemäß § 35a SGB V

Resmetirom (Rezdiffra®)

Madrigal Pharmaceuticals EU Limited

Modul 4 A – Anhang 4-G

Resmetirom ist indiziert in Kombination mit Ernährung und Bewegung zur Behandlung von Erwachsenen mit nicht zirrhotischer, nicht alkoholischer Steatohepatitis (MASH), bei denen eine mäßige bis fortgeschrittene Leberfibrose (Fibrosestadien F2 bis F3) besteht.

Weitere Analysen zu den in Abschnitt 4.3.1.3 gezeigten Ergebnissen

Stand: 15.09.2025

Table Of Contents

AMNOG Table P1.2.1 NASH Resolution Response (P1): Summary of Results at Week 52; by Age (Label Population) --->42

AMNOG Table P1.3.1 NASH Resolution Response (P1): Summary of Results at Week 52; by Sex (Label Population) --->45

AMNOG Table P1.4.1 NASH Resolution Response (P1): Summary of Results at Week 52; by Region (Label Population) --->48

AMNOG Table P1.5.1 NASH Resolution Response (P1): Summary of Results at Week 52; by Weight (Label Population) --->51

AMNOG Table P1.6.1 NASH Resolution Response (P1): Summary of Results at Week 52; by BMI (Label Population) --->54

AMNOG Table P1.7.1 NASH Resolution Response (P1): Summary of Results at Week 52; by Diabetes Status at Baseline (Label Population) --->58

AMNOG Table P1.8.1 NASH Resolution Response (P1): Summary of Results at Week 52; by Fibrosis Stage at Baseline (Label Population) --->61

AMNOG Table P1.9.1 NASH Resolution Response (P1): Summary of Results at Week 52; by Baseline GLP-1 Analogues (Label Population) --->64

AMNOG Table P1.10.1 NASH Resolution Response (P1): Summary of Results at Week 52; by Thyroxine at Baseline (Label Population) --->67

AMNOG Table P1.11.1 NASH Resolution Response (P1): Summary of Results at Week 52; by Weight Change at Week 52 (Label Population) --->70

AMNOG Table P1.12.1 NASH Resolution Response (P1): Summary of Results at Week 52; by SHBG at Week 52 (Label Population) --->74

AMNOG Table P1.13.1 NASH Resolution Response (P1): Summary of Results at Week 52; by Reduction in MRI-PDFF at Week 16 (Label Population) --->77

AMNOG Table P1.14a.1 NASH Resolution Response (P1): Summary of Results at Week 52; by Genetic NASH SNP - PNPLA3 (Label Population) --->80

AMNOG Table P1.14b.1 NASH Resolution Response (P1): Summary of Results at Week 52; by Genetic NASH SNP - TM6SF2 (Label Population) --->84

AMNOG Table P1.14c.1 NASH Resolution Response (P1): Summary of Results at Week 52; by Genetic NASH SNP - TMC4 (Label Population) --->88

AMNOG Table P1.15.1 NASH Resolution Response (P1): Summary of Results at Week 52; by Statin Status (Label Population) --->92

Table Of Contents

AMNOG Table P2.2.1 Fibrosis Response (P2): Summary of Results at Week 52; by Age (Label Population) --->95

AMNOG Table P2.2.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by Age (Label Population) --->98

AMNOG Table P2.2.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by Age (Label Population) --->101

AMNOG Table P2.3.1 Fibrosis Response (P2): Summary of Results at Week 52; by Sex (Label Population) --->104

AMNOG Table P2.3.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by Sex (Label Population) --->107

AMNOG Table P2.3.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by Sex (Label Population) --->110

AMNOG Table P2.4.1 Fibrosis Response (P2): Summary of Results at Week 52; by Region (Label Population) --->113

AMNOG Table P2.4.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by Region (Label Population) --->116

AMNOG Table P2.4.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by Region (Label Population) --->119

AMNOG Table P2.5.1 Fibrosis Response (P2): Summary of Results at Week 52; by Weight (Label Population) --->122

AMNOG Table P2.5.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by Weight (Label Population) --->125

Table Of Contents

AMNOG Table P2.5.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by Weight (Label Population) --->128

AMNOG Table P2.6.1 Fibrosis Response (P2): Summary of Results at Week 52; by BMI (Label Population) --->131

AMNOG Table P2.6.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by BMI (Label Population) --->135

AMNOG Table P2.6.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by BMI (Label Population) --->139

AMNOG Table P2.7.1 Fibrosis Response (P2): Summary of Results at Week 52; by Diabetes Status at Baseline (Label Population) --->143

AMNOG Table P2.7.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by Diabetes Status at Baseline (Label Population) --->146

AMNOG Table P2.7.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by Diabetes Status at Baseline (Label Population) --->149

AMNOG Table P2.8.1 Fibrosis Response (P2): Summary of Results at Week 52; by Fibrosis Stage at Baseline (Label Population) --->152

AMNOG Table P2.8.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by Fibrosis Stage at Baseline (Label Population) --->155

AMNOG Table P2.8.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by Fibrosis Stage at Baseline (Label Population) --->158

Table Of Contents

AMNOG Table P2.9.1 Fibrosis Response (P2): Summary of Results at Week 52; by Baseline GLP-1 Analogues (Label Population) --->161

AMNOG Table P2.9.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by Baseline GLP-1 Analogues (Label Population) --->164

AMNOG Table P2.9.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by Baseline GLP-1 Analogues (Label Population) --->167

AMNOG Table P2.10.1 Fibrosis Response (P2): Summary of Results at Week 52; by Thyroxine at Baseline (Label Population) --->170

AMNOG Table P2.10.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by Thyroxine at Baseline (Label Population) --->173

AMNOG Table P2.10.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by Thyroxine at Baseline (Label Population) --->176

AMNOG Table P2.11.1 Fibrosis Response (P2): Summary of Results at Week 52; by Weight Change at Week 52 (Label Population) --->179

AMNOG Table P2.11.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by Weight Change at Week 52 (Label Population) --->183

AMNOG Table P2.11.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by Weight Change at Week 52 (Label Population) --->187

AMNOG Table P2.12.1 Fibrosis Response (P2): Summary of Results at Week 52; by SHBG at Week 52 (Label Population) --->191

AMNOG Table P2.12.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by SHBG at Week 52 (Label Population) --->194

Table Of Contents

AMNOG Table P2.12.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by SHBG at Week 52 (Label Population) --->197

AMNOG Table P2.13.1 Fibrosis Response (P2): Summary of Results at Week 52; by Reduction in MRI-PDFF at Week 16 (Label Population) --->200

AMNOG Table P2.13.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by Reduction in MRI-PDFF at Week 16 (Label Population) --->203

AMNOG Table P2.13.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by Reduction in MRI-PDFF at Week 16 (Label Population) --->206

AMNOG Table P2.14a.1 Fibrosis Response (P2): Summary of Results at Week 52; by Genetic NASH SNP - PNPLA3 (Label Population) --->209

AMNOG Table P2.14a.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by Genetic NASH SNP - PNPLA3 (Label Population) --->213

AMNOG Table P2.14a.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by Genetic NASH SNP - PN PLA3 (Label Population) --->217

AMNOG Table P2.14b.1 Fibrosis Response (P2): Summary of Results at Week 52; by Genetic NASH SNP - TM6SF2 (Label Population) --->221

AMNOG Table P2.14b.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by Genetic NASH SNP – TM6SF2 (Label Population) --->225

AMNOG Table P2.14b.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by Genetic NASH SNP – TM 6SF2 (Label Population) --->229

Table Of Contents

AMNOG Table P2.14c.1 Fibrosis Response (P2): Summary of Results at Week 52; by Genetic NASH SNP - TMC4 (Label Population) --->233

AMNOG Table P2.14c.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by Genetic NASH SNP – TMC4 (Label Population) --->237

AMNOG Table P2.14c.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by Genetic NASH SNP – TMC4 (Label Population) --->241

AMNOG Table P2.15.1 Fibrosis Response (P2): Summary of Results at Week 52; by Statin Status (Label Population) --->245

AMNOG Table P2.15.1a 1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52; by Statin Status (Label Population) --->248

AMNOG Table P2.15.1b 1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52; by Statin Status (Label Population) --->251

AMNOG Table S1.2.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by Age (Label Population) --->254

AMNOG Table S1.2.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Age (Label Population) --->275

AMNOG Table S1.2.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Age (Label Population) --->296

AMNOG Table S1.3.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by Sex (Label Population) --->308

AMNOG Table S1.3.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Sex (Label Population) --->329

Table Of Contents

AMNOG Table S1.3.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Sex (Label Population) --->350

AMNOG Table S1.4.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by Region (Label Population) --->362

AMNOG Table S1.4.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Region (Label Population) --->383

AMNOG Table S1.4.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Region (Label Population) --->404

AMNOG Table S1.5.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by Weight (Label Population) --->417

AMNOG Table S1.5.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Weight (Label Population) --->438

AMNOG Table S1.5.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Weight (Label Population) --->459

AMNOG Table S1.6.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by BMI (Label Population) --->470

AMNOG Table S1.6.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by BMI (Label Population) --->501

AMNOG Table S1.6.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by BMI (Label Population) --->532

Table Of Contents

AMNOG Table S1.7.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by Diabetes Status at Baseline (Label Population) --->548

AMNOG Table S1.7.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Diabetes Status at Baseline (Label Population) --->569

AMNOG Table S1.7.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Diabetes Status at Baseline (Label Population) --->590

AMNOG Table S1.8.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by Fibrosis Stage at Baseline (Label Population) --->603

AMNOG Table S1.8.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Fibrosis Stage at Baseline (Label Population) --->624

AMNOG Table S1.8.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Fibrosis Stage at Baseline (Label Population) --->645

AMNOG Table S1.9.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by Baseline GLP-1 Analogues (Label Population) --->658

AMNOG Table S1.9.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Baseline GLP-1 Analogues (Label Population) --->679

AMNOG Table S1.9.2 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Baseline GLP-1 Analogues (Label Population) --->700

Table Of Contents

AMNOG Table S1.9.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Baseline GLP-1 Analogues (Label Population) --->709

AMNOG Table S1.10.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by Thyroxine at Baseline (Label Population) --->722

AMNOG Table S1.10.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Thyroxine at Baseline (Label Population) --->743

AMNOG Table S1.10.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Thyroxine at Baseline (Label Population) --->764

AMNOG Table S1.11.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by Weight Change at Week 52 (Label Population) --->777

AMNOG Table S1.11.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Weight Change at Week 52 (Label Population) --->808

AMNOG Table S1.11.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Weight Change at Week 52 (Label Population) --->839

AMNOG Table S1.12.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by SHBG at Week 52 (Label Population) --->858

AMNOG Table S1.12.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by SHBG at Week 52 (Label Population) --->879

AMNOG Table S1.12.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by SHBG at Week 52 (Label Population) --->900

Table Of Contents

AMNOG Table S1.13.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by Reduction in MRI-PDFF at Week 16 (Label Population) --->913

AMNOG Table S1.13.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Reduction in MRI-PD FF at Week 16 (Label Population) --->934

AMNOG Table S1.13.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Reduction in MRI-PDFF at Week 16 (Label Population) --->955

AMNOG Table S1.14a.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by Genetic NASH SNP - PNPLA3 (Label Population) --->966

AMNOG Table S1.14a.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Genetic NASH SNP - PNPLA3 (Label Population) --->997

AMNOG Table S1.14a.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Genetic NASH SNP - PNPLA3 (Label Population) --->1028

AMNOG Table S1.14b.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by Genetic NASH SNP – TM6SF2 (Label Population) --->1044

AMNOG Table S1.14b.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Genetic NASH SNP – TM6SF2 (Label Population) --->1075

AMNOG Table S1.14b.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Genetic NASH SNP – TM6SF2 (Label Population) --->1106

Table Of Contents

AMNOG Table S1.14c.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by Genetic NASH SNP – TMC4 (Label Population) --->1124

AMNOG Table S1.14c.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Genetic NASH SNP – TMC4 (Label Population) --->1155

AMNOG Table S1.14c.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Genetic NASH SNP – TMC4 (Label Population) --->1186

AMNOG Table S1.15.1.1 TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary; by Statin Status (Label Population) --->1205

AMNOG Table S1.15.1.2 TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary by Statin Status (Label Population) --->1226

AMNOG Table S1.15.3 TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Statin Status (Label Population) --->1247

AMNOG Table S2.2.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by Age (Label Population) --->1260

AMNOG Table S2.3.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by Sex (Label Population) --->1262

AMNOG Table S2.4.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by Region (Label Population) --->1264

Table Of Contents

AMNOG Table S2.5.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by Weight (Label Population) --->1266

AMNOG Table S2.6.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by BMI (Label Population) --->1268

AMNOG Table S2.7.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by Diabetes Status at Baseline (Label Population) --->1271

AMNOG Table S2.8.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by Fibrosis Stage at Baseline (Label Population) --->1273

AMNOG Table S2.9.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by Baseline GLP-1 Analogues (Label Population) --->1275

AMNOG Table S2.10.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by Thyroxine at Baseline (Label Population) --->1277

AMNOG Table S2.11.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by Weight Change at Week 52 (Label Population) --->1279

AMNOG Table S2.12.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by SHBG at Week 52 (Label Population) --->1282

AMNOG Table S2.13.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by Reduction in MRI-PDFF at Week 16 (Label Population) --->1284

Table Of Contents

AMNOG Table S2.14a.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by Genetic NASH SNP - PNPLA3 (Label Population) --->1286

AMNOG Table S2.14b.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by Genetic NASH SNP – TM6SF2 (Label Population) --->1289

AMNOG Table S2.14c.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by Genetic NASH SNP – TMC4 (Label Population) --->1292

AMNOG Table S2.15.1 TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade; by Statin Status (Label Population) --->1295

AMNOG Table S4.2.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Age (Label Population) --->1297

AMNOG Table S4.3.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Sex (Label Population) --->1299

AMNOG Table S4.4.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Region (Label Population) --->1301

AMNOG Table S4.5.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Weight (Label Population) --->1303

AMNOG Table S4.6.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by BMI (Label Population) --->1305

Table Of Contents

AMNOG Table S4.7.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Diabetes Status at Baseline (Label Population) --->1308

AMNOG Table S4.8.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Fibrosis Stage at Baseline (Label Population) --->1310

AMNOG Table S4.9.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Baseline GLP-1 Analogues (Label Population) --->1312

AMNOG Table S4.10.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Thyroxine at Baseline (Label Population) --->1314

AMNOG Table S4.11.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Weight Change at Week 52 (Label Population) --->1316

AMNOG Table S4.12.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by SHBG at Week 52 (Label Population) --->1319

AMNOG Table S4.13.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Reduction in MRI-PDFF at Week 16 (Label Population) --->1321

AMNOG Table S4.14a.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Genetic NASH SNP - PNPLA3 (Label Population) --->1323

AMNOG Table S4.14b.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Genetic NASH SNP – TM6SF2 (Label Population) --->1326

Table Of Contents

AMNOG Table S4.14c.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Genetic NASH SNP – TMC4 (Label Population) --->1329

AMNOG Table S4.15.1 SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Statin Status (Label Population) --->1332

AMNOG Table SE21.2.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by Age (Label Population) --->1334

AMNOG Table SE21.2.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by Age (Label Population) --->1354

AMNOG Table SE21.2.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by Age (Label Population) --->1357

AMNOG Table SE21.2.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Age (Label Population) --->1376

AMNOG Table SE21.3.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by Sex (Label Population) --->1397

AMNOG Table SE21.3.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by Sex (Label Population) --->1417

AMNOG Table SE21.3.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by Sex (Label Population) --->1420

AMNOG Table SE21.3.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Sex (Label Population) --->1439

AMNOG Figure SE21.3.5 Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component; by Sex; (Label Population) --->1460

Table Of Contents

AMNOG Table SE21.4.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by Region (Label Population) --->1462

AMNOG Table SE21.4.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by Region (Label Population) --->1482

AMNOG Table SE21.4.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by Region (Label Population) --->1485

AMNOG Table SE21.4.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Region (Label Population) --->1504

AMNOG Table SE21.5.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by Weight (Label Population) --->1525

AMNOG Table SE21.5.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by Weight (Label Population) --->1545

AMNOG Table SE21.5.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by Weight (Label Population) --->1548

AMNOG Table SE21.5.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Weight (Label Population) --->1567

AMNOG Table SE21.6.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by BMI (Label Population) --->1588

AMNOG Table SE21.6.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by BMI (Label Population) --->1618

AMNOG Table SE21.6.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by BMI (Label Population) --->1622

AMNOG Table SE21.6.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by BMI (Label Population) --->1650

Table Of Contents

AMNOG Table SE21.7.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by Diabetes Status at Baseline (Label Population) --->1681

AMNOG Table SE21.7.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by Diabetes Status at Baseline (Label Population) --->1701

AMNOG Table SE21.7.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by Diabetes Status at Baseline (Label Population) --->1704

AMNOG Table SE21.7.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Diabetes Status at Baseline (Label Population) --->1723

AMNOG Table SE21.8.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by Fibrosis Stage at Baseline (Label Population) --->1744

AMNOG Table SE21.8.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by Fibrosis Stage at Baseline (Label Population) --->1764

AMNOG Table SE21.8.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by Fibrosis Stage at Baseline (Label Population) --->1767

AMNOG Table SE21.8.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Fibrosis Stage at Baseline (Label Population) --->1786

AMNOG Table SE21.9.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by Baseline GLP-1 Analogues (Label Population) --->1807

Table Of Contents

AMNOG Table SE21.9.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by Baseline GLP-1 Analogues (Label Population) --->1827

AMNOG Table SE21.9.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by Baseline GLP-1 Analogues (Label Population) --->1830

AMNOG Table SE21.9.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Baseline GLP-1 Analogues (Label Population) --->1849

AMNOG Table SE21.10.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by Thyroxine at Baseline (Label Population) --->1870

AMNOG Table SE21.10.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by Thyroxine at Baseline (Label Population) --->1890

AMNOG Table SE21.10.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by Thyroxine at Baseline (Label Population) --->1893

AMNOG Table SE21.10.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Thyroxine at Baseline (Label Population) --->1912

AMNOG Figure SE21.10.5 Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component; by Thyroxine at Baseline (Label Population) --->1933

AMNOG Table SE21.11.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by Weight Change at Week 52 (Label Population) --->1935

Table Of Contents

AMNOG Table SE21.11.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by Weight Change at Week 52 (Label Population) --->1965

AMNOG Table SE21.11.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by Weight Change at Week 52 (Label Population) --->1969

AMNOG Table SE21.11.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Weight Change at Week 52 (Label Population) --->1997

AMNOG Table SE21.12.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by SHBG at Week 52 (Label Population) --->2028

AMNOG Table SE21.12.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by SHBG at Week 52 (Label Population) --->2048

AMNOG Table SE21.12.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by SHBG at Week 52 (Label Population) --->2051

AMNOG Table SE21.12.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by SHBG at Week 52 (Label Population) --->2070

AMNOG Table SE21.13.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by Reduction in MRI-PDFF at Week 16 (Label Population) --->2091

AMNOG Table SE21.13.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by Reduction in MRI-PDFF at Week 16 (Label Population) --->2111

Table Of Contents

AMNOG Table SE21.13.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by Reduction in MRI-PDFF at Week 16 (Label Population) --->2114

AMNOG Table SE21.13.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Reduction in MRI-PDFF at Week 16 (Label Population) --->2133

AMNOG Table SE21.14a.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by Genetic NASH SNP - PNPLA3 (Label Population) --->2154

AMNOG Table SE21.14a.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; byGenetic NASH SNP - PNPLA3 (Label Population) --->2184

AMNOG Table SE21.14a.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by Genetic NASH SNP - PNPLA3 (Label Population) --->2188

AMNOG Table SE21.14a.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Genetic NASH SNP - PNPLA3 (Label Population) --->2216

AMNOG Figure SE21.14a.5 Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component; by Genetic NASH SNP - PNPLA3 (Label Population) --->2247

AMNOG Table SE21.14b.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by Genetic NASH SNP – TM6SF2 (Label Population) --->2253

AMNOG Table SE21.14b.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by Genetic NASH SNP – TM6SF2 (Label Population) --->2283

Table Of Contents

AMNOG Table SE21.14b.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by Genetic NASH SNP – TM6 SF2 (Label Population) --->2287

AMNOG Table SE21.14b.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Genetic NASH SNP – TM6S F2 (Label Population) --->2315

AMNOG Figure SE21.14b.5 Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component; by Genetic NASH SNP - TM6SF2 (La bel Population) --->2346

AMNOG Table SE21.14c.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by Genetic NASH SNP – TMC4 (Label Popu lation) --->2349

AMNOG Table SE21.14c.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by Genetic NASH SNP – TMC4 (Label Populat ion) --->2379

AMNOG Table SE21.14c.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by Genetic NASH SNP – TMC 4 (Label Population) --->2383

AMNOG Table SE21.14c.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Genetic NASH SNP – TMC4 (Label Population) --->2411

AMNOG Table SE21.15.1 Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component; by Statin Status (Label Population) - -->2442

AMNOG Table SE21.15.2 Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model; by Statin Status (Label Population) ---> 2462

Table Of Contents

AMNOG Table SE21.15.3 Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component; by Statin Status (Label Population) --->2465

AMNOG Table SE21.15.4 Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Statin Status (Label Population) --->2484

AMNOG Table SE22.2.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by Age (Label Population) --->2505

AMNOG Table SE22.2.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by Age (Label Population) --->2525

AMNOG Table SE22.2.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age (Label Population) --->2546

AMNOG Table SE22.3.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by Sex (Label Population) --->2567

AMNOG Table SE22.3.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by Sex (Label Population) --->2587

AMNOG Table SE22.3.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Sex (Label Population) --->2608

AMNOG Figure SE22.3.5 Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component; by Sex (Label Population) --->2629

Table Of Contents

AMNOG Table SE22.4.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by Region (Label Population) --->2639

AMNOG Table SE22.4.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by Region (Label Population) --->2659

AMNOG Table SE22.4.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Region (Label Population) --->2680

AMNOG Figure SE22.4.5 Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component; by Region (Label Population) --->2701

AMNOG Table SE22.5.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by Weight (Label Population) --->2703

AMNOG Table SE22.5.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by Weight (Label Population) --->2723

AMNOG Table SE22.5.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Weight (Label Population) --->2744

AMNOG Table SE22.6.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by BMI (Label Population) --->2765

AMNOG Table SE22.6.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by BMI (Label Population) --->2795

Table Of Contents

AMNOG Table SE22.6.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by BMI (Label Population) --->2826

AMNOG Table SE22.7.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by Diabetes Status at Baseline (Label Population) --->2857

AMNOG Table SE22.7.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by Diabetes Status at Baseline (Label Population) --->2877

AMNOG Table SE22.7.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Diabetes Status at Baseline (Label Population) --->2898

AMNOG Table SE22.8.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by Fibrosis Stage at Baseline (Label Population) --->2919

AMNOG Table SE22.8.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by Fibrosis Stage at Baseline (Label Population) --->2939

AMNOG Table SE22.8.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Fibrosis Stage at Baseline (Label Population) --->2960

AMNOG Table SE22.9.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by Baseline GLP-1 Analogues (Label Population) --->2981

AMNOG Table SE22.9.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by Baseline GLP-1 Analogues (Label Population) --->3001

Table Of Contents

AMNOG Table SE22.9.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Baseline GLP-1 Analogues (Label Population) --->3022

AMNOG Table SE22.10.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by Thyroxine at Baseline (Label Population) --->3043

AMNOG Table SE22.10.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by Thyroxine at Baseline (Label Population) --->3063

AMNOG Table SE22.10.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Thyroxine at Baseline (Label Population) --->3084

AMNOG Figure SE22.10.5 Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component; by Thyroxine at Baseline (Label Population) --->3105

AMNOG Table SE22.11.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by Weight Change at Week 52 (Label Population) --->3109

AMNOG Table SE22.11.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by Weight Change at Week 52 (Label Population) --->3139

AMNOG Table SE22.11.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Weight Change at Week 52 (Label Population) --->3170

AMNOG Table SE22.12.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by SHBG at Week 52 (Label Population) --->3201

Table Of Contents

AMNOG Table SE22.12.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by SHBG at Week 52 (Label Population) --->3221

AMNOG Table SE22.12.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by SHBG at Week 52 (L abel Population) --->3242

AMNOG Table SE22.13.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by Reduction in MRI-PDFF at Week 16 (Label Population) --->3263

AMNOG Table SE22.13.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by Reduction in MRI-PDFF at Week 16 (Label Population) --->3283

AMNOG Table SE22.13.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Reduction in MRI-P DFF at Week 16 (Label Population) --->3304

AMNOG Figure SE22.13.5 Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component; by Reduction in MRI-PDFF at Week 16 (Label Population) --->3325

AMNOG Table SE22.14a.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by Genetic NASH SNP - PNPLA3 (La bel Population) --->3333

AMNOG Table SE22.14a.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by Genetic NASH SNP - PNPLA3 (Label Population) --->3363

AMNOG Table SE22.14a.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Genetic NASH SNP - PNPLA3 (Label Population) --->3394

Table Of Contents

AMNOG Figure SE22.14a.5 Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component; by Genetic NASH SNP - PNPLA3 (Label Population) --->3425

AMNOG Table SE22.14b.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by Genetic NASH SNP – TM6SF2 (Label Population) --->3431

AMNOG Table SE22.14b.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by Genetic NASH SNP – TM6SF2 (Label Population) --->3461

AMNOG Table SE22.14b.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Genetic NASH SNP – TM6SF2 (Label Population) --->3492

AMNOG Table SE22.14c.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by Genetic NASH SNP – TMC4 (Label Population) --->3523

AMNOG Table SE22.14c.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by Genetic NASH SNP – TMC4 (Label Population) --->3553

AMNOG Table SE22.14c.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Genetic NASH SNP – TMC4 (Label Population) --->3584

AMNOG Table SE22.15.1 Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component; by Statin Status (Label Population) --->3615

AMNOG Table SE22.15.2 Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component; by Statin Status (Label Population) --->3635

Table Of Contents

AMNOG Table SE22.15.3 Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Statin Status (Label Population) --->3656

AMNOG Table SE23.2.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by Age (Label Population) --->3677

AMNOG Table SE23.2.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by Age (Label Population) --->3691

AMNOG Table SE23.2.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by Age (Label Population) --->3694

AMNOG Table SE23.2.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by Age (Label Population) --->3707

AMNOG Table SE23.3.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by Sex (Label Population) --->3722

AMNOG Table SE23.3.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by Sex (Label Population) --->3736

AMNOG Table SE23.3.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by Sex (Label Population) --->3739

AMNOG Table SE23.3.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by Sex (Label Population) --->3752

AMNOG Figure SE23.3.5 Chronic Liver Disease Questionnaire-NASH (SE23): Mean Profile of Results by Domain; by Sex (Label Population) --->3767

Table Of Contents

AMNOG Table SE23.4.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by Region (Label Population) --->3769

AMNOG Table SE23.4.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by Region (Label Population) --->3783

AMNOG Table SE23.4.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by Region (Label Population) --->3786

AMNOG Table SE23.4.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by Region (Label Population) --->3799

AMNOG Table SE23.5.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by Weight (Label Population) --->3814

AMNOG Table SE23.5.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by Weight (Label Population) --->3828

AMNOG Table SE23.5.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by Weight (Label Population) --->3831

AMNOG Table SE23.5.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by Weight (Label Population) --->3844

AMNOG Table SE23.6.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by BMI (Label Population) --->3859

AMNOG Table SE23.6.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by BMI (Label Population) --->3880

Table Of Contents

AMNOG Table SE23.6.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by BMI (Label Population) --->3884

AMNOG Table SE23.6.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by BMI (Label Population) --->3903

AMNOG Table SE23.7.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by Diabetes Status at Baseline (Label Population) --->3925

AMNOG Table SE23.7.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by Diabetes Status at Baseline (Label Population) --->3939

AMNOG Table SE23.7.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by Diabetes Status at Baseline (Label Population) --->3942

AMNOG Table SE23.7.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by Diabetes Status at Baseline (Label Population) --->3955

AMNOG Table SE23.8.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by Fibrosis Stage at Baseline (Label Population) --->3970

AMNOG Table SE23.8.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by Fibrosis Stage at Baseline (Label Population) --->3984

AMNOG Table SE23.8.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by Fibrosis Stage at Baseline (Label Population) --->3987

Table Of Contents

AMNOG Table SE23.8.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by Fibrosis Stage at Baseline (Label Population) --->4000

AMNOG Table SE23.9.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by Baseline GLP-1 Analogues (Label Population) --->4015

AMNOG Table SE23.9.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by Baseline GLP-1 Analogues (Label Population) --->4029

AMNOG Table SE23.9.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by Baseline GLP-1 Analogues (Label Population) --->4032

AMNOG Table SE23.9.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by Baseline GLP-1 Analogues (Label Population) --->4045

AMNOG Table SE23.10.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by Thyroxine at Baseline (Label Population) --->4060

AMNOG Table SE23.10.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by Thyroxine at Baseline (Label Population) --->4074

AMNOG Table SE23.10.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by Thyroxine at Baseline (Label Population) --->4077

AMNOG Table SE23.10.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by Thyroxine at Baseline (Label Population) --->4090

Table Of Contents

AMNOG Table SE23.11.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by Weight Change at Week 52 (Label Population) --->4105

AMNOG Table SE23.11.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by Weight Change at Week 52 (Label Population) --->4126

AMNOG Table SE23.11.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by Weight Change at Week 52 (Label Population) --->4130

AMNOG Table SE23.11.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by Weight Change at Week 52 (Label Population) --->4149

AMNOG Table SE23.12.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by SHBG at Week 52 (Label Population) --->4171

AMNOG Table SE23.12.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by SHBG at Week 52 (Label Population) --->4185

AMNOG Table SE23.12.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by SHBG at Week 52 (Label Population) --->4188

AMNOG Table SE23.12.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by SHBG at Week 52 (Label Population) --->4201

AMNOG Table SE23.13.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by Reduction in MRI-PDFF at Week 16 (Label Population) --->4216

Table Of Contents

AMNOG Table SE23.13.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by Reduction in MRI-PDFF at Week 16 (Label Population) --->4230

AMNOG Table SE23.13.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by Reduction in MRI-PDFF at Week 16 (Label Population) --->4233

AMNOG Table SE23.13.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by Reduction in MRI-PDFF a t Week 16 (Label Population) --->4246

AMNOG Table SE23.14a.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by Genetic NASH SNP - PNPLA3 (Label P opulation) --->4261

AMNOG Table SE23.14a.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by Genetic NASH SNP - PNPLA3 (La bel Population) --->4282

AMNOG Table SE23.14a.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by Genetic NASH SNP - PN PLA3 (Label Population) --->4286

AMNOG Table SE23.14a.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by Genetic NASH SNP - PNP LA3 (Label Population) --->4305

AMNOG Figure SE23.14a.5 Chronic Liver Disease Questionnaire-NASH (SE23): Mean Profile of Results by Domain; by Genetic NASH SNP – PNPLA3 (L abel Population) --->4327

AMNOG Table SE23.14b.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by Genetic NASH SNP – TM6SF2 (Label P opulation) --->4330

Table Of Contents

AMNOG Table SE23.14b.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by Genetic NASH SNP – TM6SF2 (Label Population) --->4351

AMNOG Table SE23.14b.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by Genetic NASH SNP – TM6SF2 (Label Population) --->4355

AMNOG Table SE23.14b.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by Genetic NASH SNP – TM6SF2 (Label Population) --->4374

AMNOG Figure SE23.14b.5 Chronic Liver Disease Questionnaire-NASH (SE23): Mean Profile of Results by Domain; by Genetic NASH SNP – TM6SF2 (Label Population) --->4396

AMNOG Table SE23.14c.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by Genetic NASH SNP – TMC4 (Label Population) --->4399

AMNOG Table SE23.14c.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by Genetic NASH SNP – TMC4 (Label Population) --->4420

AMNOG Table SE23.14c.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by Genetic NASH SNP – TMC4 (Label Population) --->4424

AMNOG Table SE23.14c.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by Genetic NASH SNP – TMC4 (Label Population) --->4443

AMNOG Table SE23.15.1 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain; by Statin Status (Label Population) --->4465

Table Of Contents

AMNOG Table SE23.15.2 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model; by Statin Status (Label Population) --->4479

AMNOG Table SE23.15.3 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain; by Statin Status (Label Population) --->4482

AMNOG Table SE23.15.4 Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain; by Statin Status (Label Population) --->4495

AMNOG Table SE24.2.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by Age (Label Population) --->4510

AMNOG Table SE24.2.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Age (Label Population) --->4518

AMNOG Table SE24.2.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by Age (Label Population) --->4527

AMNOG Table SE24.3.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by Sex (Label Population) --->4536

AMNOG Table SE24.3.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Sex (Label Population) --->4544

AMNOG Table SE24.3.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by Sex (Label Population) --->4553

Table Of Contents

AMNOG Table SE24.4.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by Region (Label Population) --->4562

AMNOG Table SE24.4.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Region (Label Population) --->4570

AMNOG Table SE24.4.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by Region (Label Population) --->4579

AMNOG Table SE24.5.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by Weight (Label Population) --->4588

AMNOG Table SE24.5.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Weight (Label Population) --->4596

AMNOG Table SE24.5.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by Weight (Label Population) --->4605

AMNOG Table SE24.6.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by BMI (Label Population) --->4614

AMNOG Table SE24.6.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by BMI (Label Population) --->4626

AMNOG Table SE24.6.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by BMI (Label Population) --->4639

Table Of Contents

AMNOG Table SE24.7.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by Diabetes Status at Baseline (Label Population) --->4652

AMNOG Table SE24.7.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Diabetes Status at Baseline (Label Population) --->4660

AMNOG Table SE24.7.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by Diabetes Status at Baseline (Label Population) --->4669

AMNOG Table SE24.8.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by Fibrosis Stage at Baseline (Label Population) --->4678

AMNOG Table SE24.8.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Fibrosis Stage at Baseline (Label Population) --->4686

AMNOG Table SE24.8.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by Fibrosis Stage at Baseline (Label Population) --->4695

AMNOG Figure SE24.8.5 Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain; by Fibrosis Stage at Baseline (Label Population) --->4704

AMNOG Table SE24.9.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by Baseline GLP-1 Analogues (Label Population) --->4706

AMNOG Table SE24.9.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Baseline GLP-1 Analogues (Label Population) --->4714

Table Of Contents

AMNOG Table SE24.9.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by Baseline GLP-1 Analogues (Label Population) --->4723

AMNOG Figure SE24.9.5 Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain; by Baseline GLP-1 Analogues (Label Population) --->4732

AMNOG Table SE24.10.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by Thyroxine at Baseline (Label Population) --->4734

AMNOG Table SE24.10.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Thyroxine at Baseline (Label Population) --->4742

AMNOG Table SE24.10.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by Thyroxine at Baseline (Label Population) --->4751

AMNOG Figure SE24.10.5 Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain; by Thyroxine at Baseline (Label Population) --->4760

AMNOG Table SE24.11.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by Weight Change at Week 52 (Label Population) --->4762

AMNOG Table SE24.11.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Weight Change at Week 52 (Label Population) --->4774

AMNOG Table SE24.11.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by Weight Change at Week 52 (Label Population) --->4787

Table Of Contents

AMNOG Table SE24.12.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by SHBG at Week 52 (Label Population) --->4800

AMNOG Table SE24.12.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by SHBG at Week 52 (Label Population) --->4808

AMNOG Table SE24.12.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by SHBG at Week 52 (Label Population) --->4817

AMNOG Table SE24.13.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by Reduction in MRI-PDFF at Week 16 (Label Population) --->4826

AMNOG Table SE24.13.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Reduction in MRI-PDFF at Week 16 (Label Population) --->4834

AMNOG Table SE24.13.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by Reduction in MRI-PDFF at Week 16 (Label Population) --->4843

AMNOG Table SE24.14a.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by Genetic NASH SNP - PNPLA3 (Label Population) --->4852

AMNOG Table SE24.14a.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Genetic NASH SNP - PNPLA3 (Label Population) --->4864

AMNOG Table SE24.14a.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by Genetic NASH SNP - PNPLA3 (Label Population) --->4877

Table Of Contents

AMNOG Figure SE24.14a.5 Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain; by Genetic NASH SNP - PNPLA3 (Label Population) --->4890

AMNOG Table SE24.14b.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by Genetic NASH SNP – TM6SF2 (Label Population) --->4893

AMNOG Table SE24.14b.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Genetic NASH SNP – TM6SF2 (Label Population) --->4905

AMNOG Table SE24.14b.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by Genetic NASH SNP – TM6SF2 (Label Population) --->4918

AMNOG Figure SE24.14b.5 Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain; by Genetic NASH SNP - TM6SF2 (Label Population) --->4931

AMNOG Table SE24.14c.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by Genetic NASH SNP – TMC4 (Label Population) --->4934

AMNOG Table SE24.14c.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Genetic NASH SNP – TMC4 (Label Population) --->4946

AMNOG Table SE24.14c.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by Genetic NASH SNP – TMC4 (Label Population) --->4959

AMNOG Table SE24.15.1 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain; by Statin Status (Label Population) --->4972

Table Of Contents

AMNOG Table SE24.15.2 Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Statin Status (Label Population) --->4980

AMNOG Table SE24.15.3 Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain; by Statin Status (Label Population) --->4989

AMNOG Table P1.2.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Age
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

AMNOG Table P1.2.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Age
(Label Population)

Age: < 65 years
Total Subjects with Event of Interest in Subgroup Category: 123

Statistic/Category	MGL-3196 80 mg (N=123)	MGL-3196 100 mg (N=126)	Placebo (N=222)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	29 (23.6)	26 (20.6)	13 (5.9)
0.5 - (1,0) or (0,1)	12 (9.8)	23 (18.3)	20 (9.0)
0 - (0,0)	82 (66.7)	77 (61.1)	189 (85.1)
Average Percentage of Responders [2]	28.5	29.8	10.4
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	18.2 (3.87)	19.9 (3.73)	
95% CI of the difference	(10.6, 25.8)	(12.6, 27.2)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.29	0.25	
95% CI of the inverse odds ratio	(0.19, 0.43)	(0.16, 0.38)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.36	0.34	
95% CI of the inverse risk ratio	(0.26, 0.51)	(0.24, 0.47)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.0921	0.6362	

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P1.2.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Age
(Label Population)

Age: >= 65 years
Total Subjects with Event of Interest in Subgroup Category: 34

Statistic/Category	MGL-3196 80 mg (N=41)	MGL-3196 100 mg (N=25)	Placebo (N=78)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	10 (24.4)	5 (20.0)	4 (5.1)
0.5 - (1,0) or (0,1)	9 (22.0)	3 (12.0)	3 (3.8)
0 - (0,0)	22 (53.7)	17 (68.0)	71 (91.0)
Average Percentage of Responders [2]	35.4	26.0	7.1
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	28.2 (6.69)	20.6 (7.02)	
95% CI of the difference	(15.1, 41.3)	(6.8, 34.3)	
p-value	<0.0001	0.0032	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.15	0.17	
95% CI of the inverse odds ratio	(0.07, 0.31)	(0.06, 0.43)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.21	0.24	
95% CI of the inverse risk ratio	(0.11, 0.40)	(0.12, 0.49)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.0921	0.6362	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P1.3.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Sex
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

AMNOG Table P1.3.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Sex
(Label Population)

Sex: Male
Total Subjects with Event of Interest in Subgroup Category: 67

Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=86)	Placebo (N=131)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	11 (26.2)	14 (16.3)	9 (6.9)
0.5 - (1,0) or (0,1)	8 (19.0)	19 (22.1)	6 (4.6)
0 - (0,0)	23 (54.8)	53 (61.6)	116 (88.5)
Average Percentage of Responders [2]	35.7	27.3	9.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	26.7 (5.94)	18.7 (4.57)	
95% CI of the difference	(15.0, 38.3)	(9.8, 27.7)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.18	0.25	
95% CI of the inverse odds ratio	(0.10, 0.33)	(0.14, 0.43)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.26	0.33	
95% CI of the inverse risk ratio	(0.16, 0.41)	(0.21, 0.51)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.2862	0.7265	

AMNOG Table P1.3.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Sex
(Label Population)

Sex: Female
Total Subjects with Event of Interest in Subgroup Category: 90

Statistic/Category	MGL-3196 80 mg (N=122)	MGL-3196 100 mg (N=65)	Placebo (N=169)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	28 (23.0)	17 (26.2)	8 (4.7)
0.5 - (1,0) or (0,1)	13 (10.7)	7 (10.8)	17 (10.1)
0 - (0,0)	81 (66.4)	41 (63.1)	144 (85.2)
Average Percentage of Responders [2]	28.3	31.5	9.8
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	18.6 (4.13)	21.6 (4.81)	
95% CI of the difference	(10.5, 26.7)	(12.1, 31.0)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.27	0.23	
95% CI of the inverse odds ratio	(0.17, 0.43)	(0.14, 0.39)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.34	0.31	
95% CI of the inverse risk ratio	(0.23, 0.50)	(0.21, 0.47)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.2862	0.7265	

AMNOG Table P1.4.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Region
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

AMNOG Table P1.4.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Region
(Label Population)

Region: US
Total Subjects with Event of Interest in Subgroup Category: 108

Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=119)	Placebo (N=196)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	21 (23.1)	24 (20.2)	12 (6.1)
0.5 - (1,0) or (0,1)	14 (15.4)	19 (16.0)	18 (9.2)
0 - (0,0)	56 (61.5)	76 (63.9)	166 (84.7)
Average Percentage of Responders [2]	30.8	28.2	10.7
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	20.6 (4.30)	18.0 (3.88)	
95% CI of the difference	(12.2, 29.0)	(10.3, 25.6)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.25	0.28	
95% CI of the inverse odds ratio	(0.16, 0.40)	(0.18, 0.44)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.33	0.37	
95% CI of the inverse risk ratio	(0.23, 0.48)	(0.26, 0.52)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.3470	0.1309	

AMNOG Table P1.4.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Region
(Label Population)

Region: Ex-US
Total Subjects with Event of Interest in Subgroup Category: 49

Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=104)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	18 (24.7)	7 (21.9)	5 (4.8)
0.5 - (1,0) or (0,1)	7 (9.6)	7 (21.9)	5 (4.8)
0 - (0,0)	48 (65.8)	18 (56.3)	94 (90.4)
Average Percentage of Responders [2]	29.5	32.8	7.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	22.4 (5.38)	25.5 (6.29)	
95% CI of the difference	(11.9, 33.0)	(13.1, 37.8)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.19	0.17	
95% CI of the inverse odds ratio	(0.10, 0.36)	(0.08, 0.35)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.25	0.23	
95% CI of the inverse risk ratio	(0.14, 0.43)	(0.13, 0.41)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.3470	0.1309	

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P1.5.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Weight
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; NE = Not estimable.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P1.5.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Weight
(Label Population)

Weight: > 200 lbs
Total Subjects with Event of Interest in Subgroup Category: 92

Statistic/Category	MGL-3196 80 mg (N=51)	MGL-3196 100 mg (N=151)	Placebo (N=184)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	12 (23.5)	31 (20.5)	7 (3.8)
0.5 - (1,0) or (0,1)	5 (9.8)	26 (17.2)	11 (6.0)
0 - (0,0)	34 (66.7)	94 (62.3)	166 (90.2)
Average Percentage of Responders [2]	28.4	29.1	6.8
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	21.5 (4.69)	22.5 (3.67)	
95% CI of the difference	(12.3, 30.7)	(15.3, 29.7)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.19	0.17	
95% CI of the inverse odds ratio	(0.10, 0.34)	(0.10, 0.27)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.24	0.23	
95% CI of the inverse risk ratio	(0.15, 0.39)	(0.15, 0.35)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.0813	NE	

AMNOG Table P1.5.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Weight
(Label Population)

Weight: <= 200 lbs
Total Subjects with Event of Interest in Subgroup Category: 65

Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=0)	Placebo (N=116)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	27 (23.9)	0	10 (8.6)
0.5 - (1,0) or (0,1)	16 (14.2)	0	12 (10.3)
0 - (0,0)	70 (61.9)	0	94 (81.0)
Average Percentage of Responders [2]	31.0	0	13.8
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	17.2 (5.03)	NE	
95% CI of the difference	(7.3, 27.0)	NE	
p-value	0.0006	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.36	NE	
95% CI of the inverse odds ratio	(0.22, 0.57)	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.45	NE	
95% CI of the inverse risk ratio	(0.31, 0.65)	NE	
p-value	<0.0001	NE	
p-value of Breslow-Day Test for Homogeneity [5]	0.0813	NE	

AMNOG Table P1.6.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by BMI
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; NE = Not estimable.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

AMNOG Table P1.6.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by BMI
(Label Population)

BMI: <25 kg/m2
Total Subjects with Event of Interest in Subgroup Category: 6

Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	5 (71.4)	0	0
0.5 - (1,0) or (0,1)	0	0	1 (12.5)
0 - (0,0)	2 (28.6)	0	7 (87.5)
Average Percentage of Responders [2]	71.4	0	6.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	62.3 (17.97)	NE	
95% CI of the difference	(27.1, 97.5)	NE	
p-value	0.0521	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.08	NE	
95% CI of the inverse odds ratio	(0.01, 0.45)	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.28	NE	
95% CI of the inverse risk ratio	(0.11, 0.71)	NE	
p-value	0.0028	NE	
p-value of Breslow-Day Test for Homogeneity [5]	0.1120	NE	

AMNOG Table P1.6.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2
Total Subjects with Event of Interest in Subgroup Category: 25

Statistic/Category	MGL-3196 80 mg (N=46)	MGL-3196 100 mg (N=0)	Placebo (N=62)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	11 (23.9)	0	3 (4.8)
0.5 - (1,0) or (0,1)	5 (10.9)	0	6 (9.7)
0 - (0,0)	30 (65.2)	0	53 (85.5)
Average Percentage of Responders [2]	29.3	0	9.7
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	19.4 (6.90)	NE	
95% CI of the difference	(5.9, 32.9)	NE	
p-value	0.0059	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.26	NE	
95% CI of the inverse odds ratio	(0.12, 0.55)	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.34	NE	
95% CI of the inverse risk ratio	(0.19, 0.63)	NE	
p-value	0.0003	NE	
p-value of Breslow-Day Test for Homogeneity [5]	0.1120	NE	

AMNOG Table P1.6.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by BMI
(Label Population)

BMI: >= 30 kg/m2
Total Subjects with Event of Interest in Subgroup Category: 126

Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=151)	Placebo (N=230)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	23 (20.7)	31 (20.5)	14 (6.1)
0.5 - (1,0) or (0,1)	16 (14.4)	26 (17.2)	16 (7.0)
0 - (0,0)	72 (64.9)	94 (62.3)	200 (87.0)
Average Percentage of Responders [2]	27.9	29.1	9.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	18.0 (3.82)	19.8 (3.54)	
95% CI of the difference	(10.6, 25.5)	(12.9, 26.8)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.27	0.24	
95% CI of the inverse odds ratio	(0.18, 0.42)	(0.16, 0.36)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.35	0.32	
95% CI of the inverse risk ratio	(0.24, 0.50)	(0.23, 0.45)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.1120	NE	

AMNOG Table P1.7.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

AMNOG Table P1.7.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes
Total Subjects with Event of Interest in Subgroup Category: 105

Statistic/Category	MGL-3196 80 mg (N=116)	MGL-3196 100 mg (N=100)	Placebo (N=198)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	26 (22.4)	20 (20.0)	11 (5.6)
0.5 - (1,0) or (0,1)	18 (15.5)	17 (17.0)	13 (6.6)
0 - (0,0)	72 (62.1)	63 (63.0)	174 (87.9)
Average Percentage of Responders [2]	30.2	28.5	8.8
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	21.3 (3.96)	19.9 (3.97)	
95% CI of the difference	(13.5, 29.1)	(12.1, 27.7)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.22	0.23	
95% CI of the inverse odds ratio	(0.14, 0.35)	(0.14, 0.37)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.29	0.30	
95% CI of the inverse risk ratio	(0.20, 0.43)	(0.21, 0.45)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.5745	0.7408	

AMNOG Table P1.7.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No
Total Subjects with Event of Interest in Subgroup Category: 52

Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=51)	Placebo (N=102)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	13 (27.1)	11 (21.6)	6 (5.9)
0.5 - (1,0) or (0,1)	3 (6.3)	9 (17.6)	10 (9.8)
0 - (0,0)	32 (66.7)	31 (60.8)	86 (84.3)
Average Percentage of Responders [2]	30.2	30.4	10.8
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	19.3 (6.09)	19.6 (5.69)	
95% CI of the difference	(7.4, 31.2)	(8.5, 30.8)	
p-value	0.0015	0.0006	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.28	0.26	
95% CI of the inverse odds ratio	(0.15, 0.53)	(0.14, 0.49)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.36	0.35	
95% CI of the inverse risk ratio	(0.22, 0.59)	(0.22, 0.58)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.5745	0.7408	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P1.8.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist and Baseline type 2 diabetes status as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

AMNOG Table P1.8.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only
Total Subjects with Event of Interest in Subgroup Category: 71

Statistic/Category	MGL-3196 80 mg (N=62)	MGL-3196 100 mg (N=53)	Placebo (N=111)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	14 (22.6)	16 (30.2)	10 (9.0)
0.5 - (1,0) or (0,1)	11 (17.7)	11 (20.8)	9 (8.1)
0 - (0,0)	37 (59.7)	26 (49.1)	92 (82.9)
Average Percentage of Responders [2]	31.5	40.6	13.1
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	18.4 (5.73)	27.4 (6.30)	
95% CI of the difference	(7.2, 29.7)	(15.1, 39.8)	
p-value	0.0013	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.33	0.22	
95% CI of the inverse odds ratio	(0.19, 0.56)	(0.13, 0.38)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.41	0.32	
95% CI of the inverse risk ratio	(0.27, 0.64)	(0.21, 0.49)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.1518	0.6038	

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P1.8.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only
Total Subjects with Event of Interest in Subgroup Category: 86

Statistic/Category	MGL-3196 80 mg (N=102)	MGL-3196 100 mg (N=98)	Placebo (N=189)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	25 (24.5)	15 (15.3)	7 (3.7)
0.5 - (1,0) or (0,1)	10 (9.8)	15 (15.3)	14 (7.4)
0 - (0,0)	67 (65.7)	68 (69.4)	168 (88.9)
Average Percentage of Responders [2]	29.4	23.0	7.4
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	22.1 (4.05)	15.5 (3.66)	
95% CI of the difference	(14.1, 30.0)	(8.4, 22.7)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.19	0.26	
95% CI of the inverse odds ratio	(0.12, 0.31)	(0.16, 0.44)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.25	0.32	
95% CI of the inverse risk ratio	(0.16, 0.38)	(0.21, 0.50)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.1518	0.6038	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P1.9.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

AMNOG Table P1.9.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues
Total Subjects with Event of Interest in Subgroup Category: 28

Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=22)	Placebo (N=38)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	5 (19.2)	6 (27.3)	2 (5.3)
0.5 - (1,0) or (0,1)	8 (30.8)	5 (22.7)	2 (5.3)
0 - (0,0)	13 (50.0)	11 (50.0)	34 (89.5)
Average Percentage of Responders [2]	34.6	38.6	7.9
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	25.1 (8.76)	30.8 (9.59)	
95% CI of the difference	(7.9, 42.2)	(12.0, 49.5)	
p-value	0.0073	0.0020	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.18	0.13	
95% CI of the inverse odds ratio	(0.07, 0.51)	(0.05, 0.38)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.26	0.20	
95% CI of the inverse risk ratio	(0.11, 0.60)	(0.09, 0.48)	
p-value	0.0005	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.3908	0.1886	

AMNOG Table P1.9.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues
Total Subjects with Event of Interest in Subgroup Category: 129

Statistic/Category	MGL-3196 80 mg (N=138)	MGL-3196 100 mg (N=129)	Placebo (N=262)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	34 (24.6)	25 (19.4)	15 (5.7)
0.5 - (1,0) or (0,1)	13 (9.4)	21 (16.3)	21 (8.0)
0 - (0,0)	91 (65.9)	83 (64.3)	226 (86.3)
Average Percentage of Responders [2]	29.3	27.5	9.7
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	19.7 (3.61)	17.9 (3.45)	
95% CI of the difference	(12.7, 26.8)	(11.2, 24.7)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.26	0.27	
95% CI of the inverse odds ratio	(0.17, 0.38)	(0.18, 0.40)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.33	0.35	
95% CI of the inverse risk ratio	(0.24, 0.45)	(0.25, 0.48)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.3908	0.1886	

AMNOG Table P1.10.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Thyroxine at Baseline
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

AMNOG Table P1.10.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes
Total Subjects with Event of Interest in Subgroup Category: 14

Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=42)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	3 (15.8)	1 (6.3)	1 (2.4)
0.5 - (1,0) or (0,1)	3 (15.8)	3 (18.8)	3 (7.1)
0 - (0,0)	13 (68.4)	12 (75.0)	38 (90.5)
Average Percentage of Responders [2]	23.7	15.6	6.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	17.7 (8.58)	10.2 (8.51)	
95% CI of the difference	(0.9, 34.5)	(-6.5, 26.9)	
p-value	0.0246	0.1379	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.25	0.28	
95% CI of the inverse odds ratio	(0.09, 0.71)	(0.07, 1.11)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.31	0.36	
95% CI of the inverse risk ratio	(0.13, 0.74)	(0.12, 1.05)	
p-value	0.0067	0.0648	
p-value of Breslow-Day Test for Homogeneity [5]	0.7506	0.6642	

AMNOG Table P1.10.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No
Total Subjects with Event of Interest in Subgroup Category: 143

Statistic/Category	MGL-3196 80 mg (N=145)	MGL-3196 100 mg (N=135)	Placebo (N=258)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	36 (24.8)	30 (22.2)	16 (6.2)
0.5 - (1,0) or (0,1)	18 (12.4)	23 (17.0)	20 (7.8)
0 - (0,0)	91 (62.8)	82 (60.7)	222 (86.0)
Average Percentage of Responders [2]	31.0	30.7	10.1
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	20.8 (3.63)	20.6 (3.58)	
95% CI of the difference	(13.7, 27.9)	(13.6, 27.6)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.25	0.24	
95% CI of the inverse odds ratio	(0.17, 0.37)	(0.16, 0.36)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.33	0.33	
95% CI of the inverse risk ratio	(0.24, 0.45)	(0.24, 0.45)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.7506	0.6642	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P1.11.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

AMNOG Table P1.11.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss
Total Subjects with Event of Interest in Subgroup Category: 50

Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=34)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	11 (36.7)	14 (45.2)	8 (23.5)
0.5 - (1,0) or (0,1)	6 (20.0)	6 (19.4)	5 (14.7)
0 - (0,0)	13 (43.3)	11 (35.5)	21 (61.8)
Average Percentage of Responders [2]	46.7	54.8	30.9
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	17.3 (10.97)	26.7 (10.73)	
95% CI of the difference	(-4.2, 38.9)	(5.7, 47.7)	
p-value	0.1592	0.0334	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.50	0.31	
95% CI of the inverse odds ratio	(0.24, 1.02)	(0.14, 0.68)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.64	0.53	
95% CI of the inverse risk ratio	(0.41, 1.01)	(0.35, 0.81)	
p-value	0.0533	0.0035	
p-value of Breslow-Day Test for Homogeneity [5]	0.0284	0.3775	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P1.11.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain
Total Subjects with Event of Interest in Subgroup Category: 14

Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	4 (33.3)	1 (12.5)	2 (15.4)
0.5 - (1,0) or (0,1)	0	6 (75.0)	1 (7.7)
0 - (0,0)	8 (66.7)	1 (12.5)	10 (76.9)
Average Percentage of Responders [2]	33.3	50.0	19.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	13.7 (15.17)	30.5 (14.34)	
95% CI of the difference	(-16.0, 43.4)	(2.4, 58.6)	
p-value	0.5470	0.1687	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.63	0.28	
95% CI of the inverse odds ratio	(0.22, 1.81)	(0.07, 1.09)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.71	0.48	
95% CI of the inverse risk ratio	(0.34, 1.49)	(0.23, 1.00)	
p-value	0.3757	0.0502	
p-value of Breslow-Day Test for Homogeneity [5]	0.0284	0.3775	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P1.11.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable
Total Subjects with Event of Interest in Subgroup Category: 92

Statistic/Category	MGL-3196 80 mg (N=108)	MGL-3196 100 mg (N=87)	Placebo (N=219)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	24 (22.2)	16 (18.4)	6 (2.7)
0.5 - (1,0) or (0,1)	15 (13.9)	14 (16.1)	17 (7.8)
0 - (0,0)	69 (63.9)	57 (65.5)	196 (89.5)
Average Percentage of Responders [2]	29.2	26.4	6.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	22.6 (3.69)	19.6 (3.64)	
95% CI of the difference	(15.4, 29.9)	(12.4, 26.7)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.17	0.19	
95% CI of the inverse odds ratio	(0.10, 0.27)	(0.11, 0.31)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.22	0.25	
95% CI of the inverse risk ratio	(0.15, 0.34)	(0.17, 0.39)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.0284	0.3775	

AMNOG Table P1.12.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by SHBG at Week 52
(Label Population)

Abbreviations: CFB = Change from Baseline; NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; NE = Not estimable; SHBG = Sex Hormone Binding Globulin.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

AMNOG Table P1.12.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB
Total Subjects with Event of Interest in Subgroup Category: 77

Statistic/Category	MGL-3196 80 mg (N=88)	MGL-3196 100 mg (N=67)	Placebo (N=0)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	24 (27.3)	22 (32.8)	0
0.5 - (1,0) or (0,1)	16 (18.2)	15 (22.4)	0
0 - (0,0)	48 (54.5)	30 (44.8)	0
Average Percentage of Responders [2]	36.4	44.0	0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	NE	NE	
95% CI of the difference	NE	NE	
p-value	NE	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [5]	NE	NE	

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P1.12.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB
Total Subjects with Event of Interest in Subgroup Category: 78

Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=263)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	14 (23.0)	9 (15.8)	16 (6.1)
0.5 - (1,0) or (0,1)	5 (8.2)	11 (19.3)	23 (8.7)
0 - (0,0)	42 (68.9)	37 (64.9)	224 (85.2)
Average Percentage of Responders [2]	27.0	25.4	10.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	16.5 (4.42)	14.5 (4.37)	
95% CI of the difference	(7.9, 25.2)	(5.9, 23.0)	
p-value	0.0001	0.0009	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.31	0.34	
95% CI of the inverse odds ratio	(0.19, 0.51)	(0.20, 0.58)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.39	0.42	
95% CI of the inverse risk ratio	(0.26, 0.57)	(0.28, 0.63)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	NE	NE	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P1.13.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; CFB = Change from Baseline; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

AMNOG Table P1.13.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB
Total Subjects with Event of Interest in Subgroup Category: 77

Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=75)	Placebo (N=30)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	21 (28.0)	23 (30.7)	2 (6.7)
0.5 - (1,0) or (0,1)	12 (16.0)	15 (20.0)	4 (13.3)
0 - (0,0)	42 (56.0)	37 (49.3)	24 (80.0)
Average Percentage of Responders [2]	36.0	40.7	13.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	23.2 (8.70)	27.6 (8.70)	
95% CI of the difference	(6.2, 40.3)	(10.5, 44.6)	
p-value	0.0285	0.0081	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.28	0.23	
95% CI of the inverse odds ratio	(0.13, 0.63)	(0.10, 0.52)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.39	0.35	
95% CI of the inverse risk ratio	(0.20, 0.75)	(0.18, 0.67)	
p-value	0.0017	0.0002	
p-value of Breslow-Day Test for Homogeneity [5]	0.9628	0.1810	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P1.13.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB
Total Subjects with Event of Interest in Subgroup Category: 46

Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=178)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	8 (19.0)	3 (12.0)	9 (5.1)
0.5 - (1,0) or (0,1)	7 (16.7)	3 (12.0)	16 (9.0)
0 - (0,0)	27 (64.3)	19 (76.0)	153 (86.0)
Average Percentage of Responders [2]	27.4	18.0	9.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	17.7 (5.15)	8.1 (5.74)	
95% CI of the difference	(7.6, 27.8)	(-3.1, 19.4)	
p-value	0.0003	0.0363	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.28	0.46	
95% CI of the inverse odds ratio	(0.15, 0.51)	(0.21, 1.02)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.34	0.53	
95% CI of the inverse risk ratio	(0.21, 0.56)	(0.28, 0.99)	
p-value	<0.0001	0.0550	
p-value of Breslow-Day Test for Homogeneity [5]	0.9628	0.1810	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P1.14a.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; SNP = Single Nucleotide Polymorphism.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

AMNOG Table P1.14a.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation
Total Subjects with Event of Interest in Subgroup Category: 53

Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=44)	Placebo (N=95)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	18 (38.3)	11 (25.0)	10 (10.5)
0.5 - (1,0) or (0,1)	4 (8.5)	5 (11.4)	5 (5.3)
0 - (0,0)	25 (53.2)	28 (63.6)	80 (84.2)
Average Percentage of Responders [2]	42.6	30.7	13.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	30.0 (7.13)	18.2 (6.49)	
95% CI of the difference	(16.0, 43.9)	(5.5, 30.9)	
p-value	<0.0001	0.0048	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.19	0.30	
95% CI of the inverse odds ratio	(0.11, 0.35)	(0.16, 0.58)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.30	0.42	
95% CI of the inverse risk ratio	(0.19, 0.46)	(0.26, 0.66)	
p-value	<0.0001	0.0002	
p-value of Breslow-Day Test for Homogeneity [5]	0.7139	0.3305	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P1.14a.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous
Total Subjects with Event of Interest in Subgroup Category: 65

Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=72)	Placebo (N=125)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	12 (16.0)	15 (20.8)	3 (2.4)
0.5 - (1,0) or (0,1)	10 (13.3)	13 (18.1)	12 (9.6)
0 - (0,0)	53 (70.7)	44 (61.1)	110 (88.0)
Average Percentage of Responders [2]	22.7	29.9	7.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	15.0 (4.35)	21.9 (4.64)	
95% CI of the difference	(6.5, 23.6)	(12.8, 31.0)	
p-value	0.0005	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.28	0.17	
95% CI of the inverse odds ratio	(0.16, 0.52)	(0.09, 0.32)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.34	0.25	
95% CI of the inverse risk ratio	(0.20, 0.57)	(0.15, 0.42)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.7139	0.3305	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 4 of 4
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P1.14a.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous
Total Subjects with Event of Interest in Subgroup Category: 31

Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	8 (26.7)	4 (18.2)	3 (4.8)
0.5 - (1,0) or (0,1)	5 (16.7)	6 (27.3)	5 (7.9)
0 - (0,0)	17 (56.7)	12 (54.5)	55 (87.3)
Average Percentage of Responders [2]	35.0	31.8	8.7
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	24.2 (7.87)	23.7 (7.77)	
95% CI of the difference	(8.8, 39.6)	(8.4, 38.9)	
p-value	0.0016	0.0029	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.24	0.19	
95% CI of the inverse odds ratio	(0.11, 0.53)	(0.08, 0.47)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.31	0.26	
95% CI of the inverse risk ratio	(0.17, 0.58)	(0.13, 0.55)	
p-value	0.0001	0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.7139	0.3305	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P1.14b.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; SNP = Single Nucleotide Polymorphism.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

AMNOG Table P1.14b.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation
Total Subjects with Event of Interest in Subgroup Category: 124

Statistic/Category	MGL-3196 80 mg (N=122)	MGL-3196 100 mg (N=112)	Placebo (N=221)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	29 (23.8)	26 (23.2)	14 (6.3)
0.5 - (1,0) or (0,1)	16 (13.1)	20 (17.9)	19 (8.6)
0 - (0,0)	77 (63.1)	66 (58.9)	188 (85.1)
Average Percentage of Responders [2]	30.3	32.1	10.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	19.5 (3.92)	21.1 (3.96)	
95% CI of the difference	(11.8, 27.2)	(13.3, 28.8)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.28	0.24	
95% CI of the inverse odds ratio	(0.18, 0.42)	(0.16, 0.37)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.36	0.34	
95% CI of the inverse risk ratio	(0.26, 0.49)	(0.24, 0.47)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.2927	0.7861	

AMNOG Table P1.14b.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous
Total Subjects with Event of Interest in Subgroup Category: 21

Statistic/Category	MGL-3196 80 mg (N=25)	MGL-3196 100 mg (N=24)	Placebo (N=61)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	7 (28.0)	3 (12.5)	2 (3.3)
0.5 - (1,0) or (0,1)	2 (8.0)	4 (16.7)	3 (4.9)
0 - (0,0)	16 (64.0)	17 (70.8)	56 (91.8)
Average Percentage of Responders [2]	32.0	20.8	5.7
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	26.6 (7.85)	16.8 (7.07)	
95% CI of the difference	(11.2, 42.0)	(2.9, 30.6)	
p-value	0.0009	0.0114	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.15	0.19	
95% CI of the inverse odds ratio	(0.06, 0.37)	(0.07, 0.54)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.20	0.24	
95% CI of the inverse risk ratio	(0.09, 0.44)	(0.10, 0.60)	
p-value	<0.0001	0.0009	
p-value of Breslow-Day Test for Homogeneity [5]	0.2927	0.7861	

Madrigal Pharmaceuticals, Inc. Page 4 of 4
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P1.14b.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous
Total Subjects with Event of Interest in Subgroup Category: 4

Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	2 (40.0)	1 (50.0)	0
0.5 - (1,0) or (0,1)	1 (20.0)	0	0
0 - (0,0)	2 (40.0)	1 (50.0)	1 (100)
Average Percentage of Responders [2]	50.0	50.0	0.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	100.0 (44.72)	NE	
95% CI of the difference	(12.3, 187.7)	NE	
p-value	0.3711	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.20	0.33	
95% CI of the inverse odds ratio	(0.02, 1.65)	(0.01, 11.94)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.50	0.67	
95% CI of the inverse risk ratio	(0.18, 1.38)	(0.15, 2.98)	
p-value	0.1939	0.6171	
p-value of Breslow-Day Test for Homogeneity [5]	0.2927	0.7861	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 1 of 4
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P1.14c.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; SNP = Single Nucleotide Polymorphism.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P1.14c.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation
Total Subjects with Event of Interest in Subgroup Category: 45

Statistic/Category	MGL-3196 80 mg (N=51)	MGL-3196 100 mg (N=45)	Placebo (N=87)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	9 (17.6)	10 (22.2)	4 (4.6)
0.5 - (1,0) or (0,1)	7 (13.7)	9 (20.0)	6 (6.9)
0 - (0,0)	35 (68.6)	26 (57.8)	77 (88.5)
Average Percentage of Responders [2]	24.5	32.2	8.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	16.1 (5.72)	24.5 (6.17)	
95% CI of the difference	(4.9, 27.3)	(12.4, 36.6)	
p-value	0.0042	0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.30	0.19	
95% CI of the inverse odds ratio	(0.15, 0.58)	(0.09, 0.38)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.34	0.26	
95% CI of the inverse risk ratio	(0.19, 0.63)	(0.15, 0.46)	
p-value	0.0003	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.8509	0.6682	

AMNOG Table P1.14c.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous
Total Subjects with Event of Interest in Subgroup Category: 76

Statistic/Category	MGL-3196 80 mg (N=71)	MGL-3196 100 mg (N=65)	Placebo (N=139)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	22 (31.0)	14 (21.5)	10 (7.2)
0.5 - (1,0) or (0,1)	8 (11.3)	12 (18.5)	10 (7.2)
0 - (0,0)	41 (57.7)	39 (60.0)	119 (85.6)
Average Percentage of Responders [2]	36.6	30.8	10.8
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	26.2 (5.40)	21.3 (5.07)	
95% CI of the difference	(15.6, 36.8)	(11.4, 31.3)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.20	0.23	
95% CI of the inverse odds ratio	(0.12, 0.34)	(0.13, 0.40)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.29	0.32	
95% CI of the inverse risk ratio	(0.19, 0.43)	(0.21, 0.49)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.8509	0.6682	

AMNOG Table P1.14c.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous
Total Subjects with Event of Interest in Subgroup Category: 28

Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	7 (23.3)	6 (21.4)	2 (3.5)
0.5 - (1,0) or (0,1)	4 (13.3)	3 (10.7)	6 (10.5)
0 - (0,0)	19 (63.3)	19 (67.9)	49 (86.0)
Average Percentage of Responders [2]	30.0	26.8	8.8
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	19.7 (7.54)	16.5 (7.42)	
95% CI of the difference	(4.9, 34.5)	(2.0, 31.1)	
p-value	0.0121	0.0271	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.26	0.30	
95% CI of the inverse odds ratio	(0.11, 0.60)	(0.13, 0.70)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.34	0.38	
95% CI of the inverse risk ratio	(0.18, 0.67)	(0.19, 0.76)	
p-value	0.0011	0.0050	
p-value of Breslow-Day Test for Homogeneity [5]	0.8509	0.6682	

AMNOG Table P1.15.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Statin Status
(Label Population)

Abbreviations: NASH = nonalcoholic steatohepatitis; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: If there is a zero count in one treatment arm in the respective subgroup category and in the treatment arm in the respective subgroup category without the zero count, (1) the event is occurring in at least 5% of patients, or (2) the event is occurring in at least 10 patients AND in at least 1% of patients, a zero-count correction value of 0.5 is added to each cell frequency of the corresponding table before the respective estimates, 95% CIs, and p-values are calculated. If this rule is not fulfilled, then only the absolute risk difference and 95% CI is calculated, and other statistics are represented in the output by a '-'.

AMNOG Table P1.15.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline
Total Subjects with Event of Interest in Subgroup Category: 66

Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=87)	Placebo (N=144)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	13 (18.1)	13 (14.9)	9 (6.3)
0.5 - (1,0) or (0,1)	7 (9.7)	16 (18.4)	8 (5.6)
0 - (0,0)	52 (72.2)	58 (66.7)	127 (88.2)
Average Percentage of Responders [2]	22.9	24.1	9.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	13.9 (4.64)	15.2 (4.36)	
95% CI of the difference	(4.8, 23.0)	(6.7, 23.8)	
p-value	0.0027	0.0006	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.33	0.32	
95% CI of the inverse odds ratio	(0.19, 0.58)	(0.19, 0.54)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.40	0.39	
95% CI of the inverse risk ratio	(0.25, 0.64)	(0.25, 0.60)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.1604	0.2224	

AMNOG Table P1.15.1
NASH Resolution Response (P1): Summary of Results at Week 52;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline
Total Subjects with Event of Interest in Subgroup Category: 91

Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
NASH Resolution Responders at Week 52, n (%) [1]			
1 - (1,1)	26 (28.3)	18 (28.1)	8 (5.1)
0.5 - (1,0) or (0,1)	14 (15.2)	10 (15.6)	15 (9.6)
0 - (0,0)	52 (56.5)	36 (56.3)	133 (85.3)
Average Percentage of Responders [2]	35.9	35.9	9.9
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	25.8 (4.75)	26.2 (5.00)	
95% CI of the difference	(16.5, 35.1)	(16.4, 36.0)	
p-value	<0.0001	<0.0001	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.20	0.18	
95% CI of the inverse odds ratio	(0.12, 0.32)	(0.10, 0.30)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.27	0.28	
95% CI of the inverse risk ratio	(0.18, 0.41)	(0.19, 0.41)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.1604	0.2224	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.2.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Age
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.2.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Age
(Label Population)

Age: < 65 years
Total Subjects with Event of Interest in Subgroup Category: 147

Statistic/Category	MGL-3196 80 mg (N=123)	MGL-3196 100 mg (N=126)	Placebo (N=222)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	24 (19.5)	21 (16.7)	21 (9.5)
0.5 - (1,0) or (0,1)	20 (16.3)	32 (25.4)	29 (13.1)
0 - (0,0)	79 (64.2)	73 (57.9)	172 (77.5)
Average Percentage of Responders [2]	27.6	29.4	16.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	11.8 (4.01)	13.3 (3.90)	
95% CI of the difference	(3.9, 19.6)	(5.7, 21.0)	
p-value	0.0034	0.0006	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.50	0.46	
95% CI of the inverse odds ratio	(0.34, 0.72)	(0.32, 0.67)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.57	0.55	
95% CI of the inverse risk ratio	(0.42, 0.77)	(0.41, 0.73)	
p-value	0.0003	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.1090	0.1173	

AMNOG Table P2.2.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Age
(Label Population)

Age: >= 65 years
Total Subjects with Event of Interest in Subgroup Category: 30

Statistic/Category	MGL-3196 80 mg (N=41)	MGL-3196 100 mg (N=25)	Placebo (N=78)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	10 (24.4)	2 (8.0)	6 (7.7)
0.5 - (1,0) or (0,1)	6 (14.6)	1 (4.0)	5 (6.4)
0 - (0,0)	25 (61.0)	22 (88.0)	67 (85.9)
Average Percentage of Responders [2]	31.7	10.0	10.9
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	21.5 (6.85)	1.9 (6.57)	
95% CI of the difference	(8.1, 34.9)	(-10.9, 14.8)	
p-value	0.0022	0.4239	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.26	0.66	
95% CI of the inverse odds ratio	(0.13, 0.51)	(0.25, 1.77)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.35	0.72	
95% CI of the inverse risk ratio	(0.20, 0.59)	(0.33, 1.56)	
p-value	<0.0001	0.4287	
p-value of Breslow-Day Test for Homogeneity [5]	0.1090	0.1173	

AMNOG Table P2.2.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Age
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.2.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Age
(Label Population)

Age: < 65 years
Total Subjects with Event of Interest in Subgroup Category: 138

Statistic/Category	MGL-3196 80 mg (N=123)	MGL-3196 100 mg (N=126)	Placebo (N=222)
Responders at Week 52, n (%) [1]			
1 - (1,1)	21 (17.1)	19 (15.1)	15 (6.8)
0.5 - (1,0) or (0,1)	21 (17.1)	31 (24.6)	31 (14.0)
0 - (0,0)	81 (65.9)	76 (60.3)	176 (79.3)
Average Percentage of Responders [2]	25.6	27.4	13.7
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	11.9 (3.75)	13.6 (3.67)	
95% CI of the difference	(4.6, 19.3)	(6.4, 20.8)	
p-value	0.0015	0.0002	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.46	0.42	
95% CI of the inverse odds ratio	(0.31, 0.68)	(0.29, 0.63)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.53	0.50	
95% CI of the inverse risk ratio	(0.38, 0.73)	(0.37, 0.69)	
p-value	0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.0872	0.1516	

AMNOG Table P2.2.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Age
(Label Population)

Age: >= 65 years
Total Subjects with Event of Interest in Subgroup Category: 29

Statistic/Category	MGL-3196 80 mg (N=41)	MGL-3196 100 mg (N=25)	Placebo (N=78)
Responders at Week 52, n (%) [1]			
1 - (1,1)	10 (24.4)	2 (8.0)	5 (6.4)
0.5 - (1,0) or (0,1)	6 (14.6)	1 (4.0)	5 (6.4)
0 - (0,0)	25 (61.0)	22 (88.0)	68 (87.2)
Average Percentage of Responders [2]	31.7	10.0	9.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	22.8 (6.75)	2.8 (6.44)	
95% CI of the difference	(9.5, 36.0)	(-9.8, 15.4)	
p-value	0.0010	0.3331	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.23	0.60	
95% CI of the inverse odds ratio	(0.11, 0.46)	(0.23, 1.62)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.31	0.66	
95% CI of the inverse risk ratio	(0.18, 0.54)	(0.30, 1.46)	
p-value	<0.0001	0.3289	
p-value of Breslow-Day Test for Homogeneity [5]	0.0872	0.1516	

AMNOG Table P2.2.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Age
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.2.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Age
(Label Population)

Age: < 65 years
Total Subjects with Event of Interest in Subgroup Category: 147

Statistic/Category	MGL-3196 80 mg (N=123)	MGL-3196 100 mg (N=126)	Placebo (N=222)
Responders at Week 52, n (%) [1]			
1 - (1,1)	23 (18.7)	21 (16.7)	20 (9.0)
0.5 - (1,0) or (0,1)	21 (17.1)	32 (25.4)	30 (13.5)
0 - (0,0)	79 (64.2)	73 (57.9)	172 (77.5)
Average Percentage of Responders [2]	27.2	29.4	15.8
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	11.6 (3.96)	13.6 (3.87)	
95% CI of the difference	(3.8, 19.4)	(6.0, 21.2)	
p-value	0.0034	0.0004	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.50	0.45	
95% CI of the inverse odds ratio	(0.34, 0.73)	(0.31, 0.65)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.57	0.54	
95% CI of the inverse risk ratio	(0.42, 0.77)	(0.40, 0.72)	
p-value	0.0003	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.1074	0.1103	

AMNOG Table P2.2.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Age
(Label Population)

Age: >= 65 years
Total Subjects with Event of Interest in Subgroup Category: 30

Statistic/Category	MGL-3196 80 mg (N=41)	MGL-3196 100 mg (N=25)	Placebo (N=78)
Responders at Week 52, n (%) [1]			
1 - (1,1)	10 (24.4)	2 (8.0)	6 (7.7)
0.5 - (1,0) or (0,1)	6 (14.6)	1 (4.0)	5 (6.4)
0 - (0,0)	25 (61.0)	22 (88.0)	67 (85.9)
Average Percentage of Responders [2]	31.7	10.0	10.9
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	21.5 (6.85)	1.9 (6.57)	
95% CI of the difference	(8.1, 34.9)	(-10.9, 14.8)	
p-value	0.0022	0.4239	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.26	0.66	
95% CI of the inverse odds ratio	(0.13, 0.51)	(0.25, 1.77)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.35	0.72	
95% CI of the inverse risk ratio	(0.20, 0.59)	(0.33, 1.56)	
p-value	<0.0001	0.4287	
p-value of Breslow-Day Test for Homogeneity [5]	0.1074	0.1103	

AMNOG Table P2.3.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Sex
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.3.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Sex
(Label Population)

Sex: Male
Total Subjects with Event of Interest in Subgroup Category: 68

Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=86)	Placebo (N=131)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	9 (21.4)	11 (12.8)	8 (6.1)
0.5 - (1,0) or (0,1)	7 (16.7)	20 (23.3)	13 (9.9)
0 - (0,0)	26 (61.9)	55 (64.0)	110 (84.0)
Average Percentage of Responders [2]	29.8	24.4	11.1
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	18.9 (5.75)	13.9 (4.33)	
95% CI of the difference	(7.6, 30.2)	(5.4, 22.4)	
p-value	0.0009	0.0015	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.29	0.36	
95% CI of the inverse odds ratio	(0.16, 0.53)	(0.21, 0.61)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.37	0.44	
95% CI of the inverse risk ratio	(0.23, 0.59)	(0.29, 0.67)	
p-value	<0.0001	0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.1016	0.3690	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.3.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Sex
(Label Population)

Sex: Female
Total Subjects with Event of Interest in Subgroup Category: 109

Statistic/Category	MGL-3196 80 mg (N=122)	MGL-3196 100 mg (N=65)	Placebo (N=169)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	25 (20.5)	12 (18.5)	19 (11.2)
0.5 - (1,0) or (0,1)	19 (15.6)	13 (20.0)	21 (12.4)
0 - (0,0)	78 (63.9)	40 (61.5)	129 (76.3)
Average Percentage of Responders [2]	28.3	28.5	17.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	11.0 (4.44)	10.9 (5.19)	
95% CI of the difference	(2.3, 19.7)	(0.7, 21.1)	
p-value	0.0135	0.0355	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.53	0.53	
95% CI of the inverse odds ratio	(0.36, 0.79)	(0.33, 0.86)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.61	0.62	
95% CI of the inverse risk ratio	(0.44, 0.83)	(0.43, 0.88)	
p-value	0.0018	0.0089	
p-value of Breslow-Day Test for Homogeneity [5]	0.1016	0.3690	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.3.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Sex
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.3.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Sex
(Label Population)

Sex: Male
Total Subjects with Event of Interest in Subgroup Category: 64

Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=86)	Placebo (N=131)
Responders at Week 52, n (%) [1]			
1 - (1,1)	7 (16.7)	10 (11.6)	6 (4.6)
0.5 - (1,0) or (0,1)	9 (21.4)	19 (22.1)	13 (9.9)
0 - (0,0)	26 (61.9)	57 (66.3)	112 (85.5)
Average Percentage of Responders [2]	27.4	22.7	9.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	18.0 (5.35)	13.7 (4.13)	
95% CI of the difference	(7.5, 28.5)	(5.6, 21.8)	
p-value	0.0007	0.0010	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.28	0.34	
95% CI of the inverse odds ratio	(0.15, 0.52)	(0.19, 0.58)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.35	0.41	
95% CI of the inverse risk ratio	(0.21, 0.58)	(0.26, 0.64)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.1599	0.4320	

AMNOG Table P2.3.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Sex
(Label Population)

Sex: Female
Total Subjects with Event of Interest in Subgroup Category: 103

Statistic/Category	MGL-3196 80 mg (N=122)	MGL-3196 100 mg (N=65)	Placebo (N=169)
Responders at Week 52, n (%) [1]			
1 - (1,1)	24 (19.7)	11 (16.9)	14 (8.3)
0.5 - (1,0) or (0,1)	18 (14.8)	13 (20.0)	23 (13.6)
0 - (0,0)	80 (65.6)	41 (63.1)	132 (78.1)
Average Percentage of Responders [2]	27.0	26.9	15.1
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	12.0 (4.25)	11.7 (4.87)	
95% CI of the difference	(3.7, 20.4)	(2.1, 21.2)	
p-value	0.0046	0.0165	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.48	0.49	
95% CI of the inverse odds ratio	(0.31, 0.72)	(0.30, 0.79)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.55	0.56	
95% CI of the inverse risk ratio	(0.39, 0.77)	(0.38, 0.83)	
p-value	0.0004	0.0036	
p-value of Breslow-Day Test for Homogeneity [5]	0.1599	0.4320	

AMNOG Table P2.3.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Sex
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.3.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Sex
(Label Population)

Sex: Male
Total Subjects with Event of Interest in Subgroup Category: 68

Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=86)	Placebo (N=131)
Responders at Week 52, n (%) [1]			
1 - (1,1)	8 (19.0)	11 (12.8)	8 (6.1)
0.5 - (1,0) or (0,1)	8 (19.0)	20 (23.3)	13 (9.9)
0 - (0,0)	26 (61.9)	55 (64.0)	110 (84.0)
Average Percentage of Responders [2]	28.6	24.4	11.1
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	17.7 (5.66)	13.9 (4.33)	
95% CI of the difference	(6.5, 28.8)	(5.4, 22.4)	
p-value	0.0016	0.0015	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.31	0.36	
95% CI of the inverse odds ratio	(0.17, 0.57)	(0.21, 0.61)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.38	0.44	
95% CI of the inverse risk ratio	(0.24, 0.62)	(0.29, 0.67)	
p-value	0.0001	0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.1571	0.4010	

AMNOG Table P2.3.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Sex
(Label Population)

Sex: Female
Total Subjects with Event of Interest in Subgroup Category: 109

Statistic/Category	MGL-3196 80 mg (N=122)	MGL-3196 100 mg (N=65)	Placebo (N=169)
Responders at Week 52, n (%) [1]			
1 - (1,1)	25 (20.5)	12 (18.5)	18 (10.7)
0.5 - (1,0) or (0,1)	19 (15.6)	13 (20.0)	22 (13.0)
0 - (0,0)	78 (63.9)	40 (61.5)	129 (76.3)
Average Percentage of Responders [2]	28.3	28.5	17.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	11.3 (4.41)	11.2 (5.14)	
95% CI of the difference	(2.6, 19.9)	(1.1, 21.3)	
p-value	0.0104	0.0291	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.52	0.52	
95% CI of the inverse odds ratio	(0.35, 0.78)	(0.32, 0.84)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.60	0.60	
95% CI of the inverse risk ratio	(0.43, 0.82)	(0.42, 0.87)	
p-value	0.0013	0.0070	
p-value of Breslow-Day Test for Homogeneity [5]	0.1571	0.4010	

AMNOG Table P2.4.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Region
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.4.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Region
(Label Population)

Region: US
Total Subjects with Event of Interest in Subgroup Category: 121

Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=119)	Placebo (N=196)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	17 (18.7)	17 (14.3)	22 (11.2)
0.5 - (1,0) or (0,1)	15 (16.5)	29 (24.4)	21 (10.7)
0 - (0,0)	59 (64.8)	73 (61.3)	153 (78.1)
Average Percentage of Responders [2]	26.9	26.5	16.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	11.0 (4.54)	9.9 (4.05)	
95% CI of the difference	(2.1, 19.9)	(2.0, 17.8)	
p-value	0.0153	0.0145	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.51	0.55	
95% CI of the inverse odds ratio	(0.33, 0.78)	(0.37, 0.81)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.59	0.63	
95% CI of the inverse risk ratio	(0.42, 0.82)	(0.46, 0.85)	
p-value	0.0021	0.0027	
p-value of Breslow-Day Test for Homogeneity [5]	0.0638	0.3432	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.4.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Region
(Label Population)

Region: Ex-US
Total Subjects with Event of Interest in Subgroup Category: 56

Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=104)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	17 (23.3)	6 (18.8)	5 (4.8)
0.5 - (1,0) or (0,1)	11 (15.1)	4 (12.5)	13 (12.5)
0 - (0,0)	45 (61.6)	22 (68.8)	86 (82.7)
Average Percentage of Responders [2]	30.8	25.0	11.1
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	20.3 (5.38)	13.9 (6.15)	
95% CI of the difference	(9.8, 30.9)	(1.8, 25.9)	
p-value	0.0002	0.0167	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.29	0.36	
95% CI of the inverse odds ratio	(0.17, 0.50)	(0.18, 0.75)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.36	0.44	
95% CI of the inverse risk ratio	(0.23, 0.56)	(0.25, 0.78)	
p-value	<0.0001	0.0051	
p-value of Breslow-Day Test for Homogeneity [5]	0.0638	0.3432	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.4.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Region
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.4.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Region
(Label Population)

Region: US
Total Subjects with Event of Interest in Subgroup Category: 113

Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=119)	Placebo (N=196)
Responders at Week 52, n (%) [1]			
1 - (1,1)	15 (16.5)	15 (12.6)	15 (7.7)
0.5 - (1,0) or (0,1)	15 (16.5)	28 (23.5)	25 (12.8)
0 - (0,0)	61 (67.0)	76 (63.9)	156 (79.6)
Average Percentage of Responders [2]	24.7	24.4	14.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	11.2 (4.21)	10.3 (3.76)	
95% CI of the difference	(3.0, 19.5)	(3.0, 17.7)	
p-value	0.0077	0.0060	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.47	0.50	
95% CI of the inverse odds ratio	(0.30, 0.74)	(0.33, 0.76)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.55	0.58	
95% CI of the inverse risk ratio	(0.38, 0.78)	(0.42, 0.80)	
p-value	0.0010	0.0011	
p-value of Breslow-Day Test for Homogeneity [5]	0.0788	0.3355	

AMNOG Table P2.4.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Region
(Label Population)

Region: Ex-US
Total Subjects with Event of Interest in Subgroup Category: 54

Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=104)
Responders at Week 52, n (%) [1]			
1 - (1,1)	16 (21.9)	6 (18.8)	5 (4.8)
0.5 - (1,0) or (0,1)	12 (16.4)	4 (12.5)	11 (10.6)
0 - (0,0)	45 (61.6)	22 (68.8)	88 (84.6)
Average Percentage of Responders [2]	30.1	25.0	10.1
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	20.5 (5.31)	14.8 (6.12)	
95% CI of the difference	(10.1, 30.9)	(2.8, 26.8)	
p-value	0.0002	0.0108	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.27	0.33	
95% CI of the inverse odds ratio	(0.15, 0.48)	(0.16, 0.69)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.34	0.41	
95% CI of the inverse risk ratio	(0.21, 0.54)	(0.23, 0.72)	
p-value	<0.0001	0.0023	
p-value of Breslow-Day Test for Homogeneity [5]	0.0788	0.3355	

AMNOG Table P2.4.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Region
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.4.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Region
(Label Population)

Region: US
Total Subjects with Event of Interest in Subgroup Category: 121

Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=119)	Placebo (N=196)
Responders at Week 52, n (%) [1]			
1 - (1,1)	17 (18.7)	17 (14.3)	21 (10.7)
0.5 - (1,0) or (0,1)	15 (16.5)	29 (24.4)	22 (11.2)
0 - (0,0)	59 (64.8)	73 (61.3)	153 (78.1)
Average Percentage of Responders [2]	26.9	26.5	16.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	11.3 (4.51)	10.2 (4.02)	
95% CI of the difference	(2.5, 20.1)	(2.3, 18.0)	
p-value	0.0122	0.0114	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.50	0.54	
95% CI of the inverse odds ratio	(0.32, 0.77)	(0.36, 0.80)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.58	0.62	
95% CI of the inverse risk ratio	(0.41, 0.81)	(0.45, 0.84)	
p-value	0.0016	0.0020	
p-value of Breslow-Day Test for Homogeneity [5]	0.0881	0.3669	

AMNOG Table P2.4.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Region
(Label Population)

Region: Ex-US
Total Subjects with Event of Interest in Subgroup Category: 56

Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=104)
Responders at Week 52, n (%) [1]			
1 - (1,1)	16 (21.9)	6 (18.8)	5 (4.8)
0.5 - (1,0) or (0,1)	12 (16.4)	4 (12.5)	13 (12.5)
0 - (0,0)	45 (61.6)	22 (68.8)	86 (82.7)
Average Percentage of Responders [2]	30.1	25.0	11.1
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	19.6 (5.32)	13.9 (6.15)	
95% CI of the difference	(9.2, 30.0)	(1.8, 25.9)	
p-value	0.0003	0.0167	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.30	0.36	
95% CI of the inverse odds ratio	(0.17, 0.51)	(0.18, 0.75)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.37	0.44	
95% CI of the inverse risk ratio	(0.23, 0.58)	(0.25, 0.78)	
p-value	<0.0001	0.0051	
p-value of Breslow-Day Test for Homogeneity [5]	0.0881	0.3669	

AMNOG Table P2.5.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Weight
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.5.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Weight
(Label Population)

Weight: > 200 lbs
Total Subjects with Event of Interest in Subgroup Category: 104

Statistic/Category	MGL-3196 80 mg (N=51)	MGL-3196 100 mg (N=151)	Placebo (N=184)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	7 (13.7)	23 (15.2)	17 (9.2)
0.5 - (1,0) or (0,1)	8 (15.7)	33 (21.9)	16 (8.7)
0 - (0,0)	36 (70.6)	95 (62.9)	151 (82.1)
Average Percentage of Responders [2]	21.6	26.2	13.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	7.6 (5.14)	12.6 (3.77)	
95% CI of the difference	(-2.5, 17.7)	(5.3, 20.0)	
p-value	0.1061	0.0008	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.58	0.44	
95% CI of the inverse odds ratio	(0.33, 1.00)	(0.29, 0.65)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.63	0.52	
95% CI of the inverse risk ratio	(0.41, 0.99)	(0.38, 0.71)	
p-value	0.0462	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.3927	NE	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.5.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Weight
(Label Population)

Weight: <= 200 lbs
Total Subjects with Event of Interest in Subgroup Category: 73

Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=0)	Placebo (N=116)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	27 (23.9)	0	10 (8.6)
0.5 - (1,0) or (0,1)	18 (15.9)	0	18 (15.5)
0 - (0,0)	68 (60.2)	0	88 (75.9)
Average Percentage of Responders [2]	31.9	0	16.4
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	15.8 (5.05)	NE	
95% CI of the difference	(6.0, 25.7)	NE	
p-value	0.0017	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.41	NE	
95% CI of the inverse odds ratio	(0.26, 0.64)	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.50	NE	
95% CI of the inverse risk ratio	(0.35, 0.72)	NE	
p-value	<0.0001	NE	
p-value of Breslow-Day Test for Homogeneity [5]	0.3927	NE	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.5.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Weight
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.5.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Weight
(Label Population)

Weight: > 200 lbs
Total Subjects with Event of Interest in Subgroup Category: 98

Statistic/Category	MGL-3196 80 mg (N=51)	MGL-3196 100 mg (N=151)	Placebo (N=184)
Responders at Week 52, n (%) [1]			
1 - (1,1)	5 (9.8)	21 (13.9)	12 (6.5)
0.5 - (1,0) or (0,1)	10 (19.6)	32 (21.2)	18 (9.8)
0 - (0,0)	36 (70.6)	98 (64.9)	154 (83.7)
Average Percentage of Responders [2]	19.6	24.5	11.4
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	7.8 (4.65)	13.2 (3.56)	
95% CI of the difference	(-1.3, 17.0)	(6.2, 20.1)	
p-value	0.0648	0.0002	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.54	0.39	
95% CI of the inverse odds ratio	(0.30, 0.96)	(0.26, 0.59)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.59	0.46	
95% CI of the inverse risk ratio	(0.37, 0.96)	(0.33, 0.66)	
p-value	0.0346	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.4261	NE	

AMNOG Table P2.5.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Weight
(Label Population)

Weight: <= 200 lbs
Total Subjects with Event of Interest in Subgroup Category: 69

Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=0)	Placebo (N=116)
Responders at Week 52, n (%) [1]			
1 - (1,1)	26 (23.0)	0	8 (6.9)
0.5 - (1,0) or (0,1)	17 (15.0)	0	18 (15.5)
0 - (0,0)	70 (61.9)	0	90 (77.6)
Average Percentage of Responders [2]	30.5	0	14.7
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	16.3 (4.91)	NE	
95% CI of the difference	(6.7, 25.9)	NE	
p-value	0.0011	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.38	NE	
95% CI of the inverse odds ratio	(0.24, 0.60)	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.46	NE	
95% CI of the inverse risk ratio	(0.32, 0.68)	NE	
p-value	<0.0001	NE	
p-value of Breslow-Day Test for Homogeneity [5]	0.4261	NE	

AMNOG Table P2.5.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Weight
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.5.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Weight
(Label Population)

Weight: > 200 lbs
Total Subjects with Event of Interest in Subgroup Category: 104

Statistic/Category	MGL-3196 80 mg (N=51)	MGL-3196 100 mg (N=151)	Placebo (N=184)
Responders at Week 52, n (%) [1]			
1 - (1,1)	7 (13.7)	23 (15.2)	17 (9.2)
0.5 - (1,0) or (0,1)	8 (15.7)	33 (21.9)	16 (8.7)
0 - (0,0)	36 (70.6)	95 (62.9)	151 (82.1)
Average Percentage of Responders [2]	21.6	26.2	13.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	7.6 (5.14)	12.6 (3.77)	
95% CI of the difference	(-2.5, 17.7)	(5.3, 20.0)	
p-value	0.1061	0.0008	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.58	0.44	
95% CI of the inverse odds ratio	(0.33, 1.00)	(0.29, 0.65)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.63	0.52	
95% CI of the inverse risk ratio	(0.41, 0.99)	(0.38, 0.71)	
p-value	0.0462	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.3771	NE	

AMNOG Table P2.5.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Weight
(Label Population)

Weight: <= 200 lbs
Total Subjects with Event of Interest in Subgroup Category: 73

Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=0)	Placebo (N=116)
Responders at Week 52, n (%) [1]			
1 - (1,1)	26 (23.0)	0	9 (7.8)
0.5 - (1,0) or (0,1)	19 (16.8)	0	19 (16.4)
0 - (0,0)	68 (60.2)	0	88 (75.9)
Average Percentage of Responders [2]	31.4	0	15.9
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	15.9 (4.96)	NE	
95% CI of the difference	(6.1, 25.6)	NE	
p-value	0.0014	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.40	NE	
95% CI of the inverse odds ratio	(0.26, 0.64)	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.49	NE	
95% CI of the inverse risk ratio	(0.34, 0.71)	NE	
p-value	<0.0001	NE	
p-value of Breslow-Day Test for Homogeneity [5]	0.3771	NE	

AMNOG Table P2.6.1
Fibrosis Response (P2): Summary of Results at Week 52;
by BMI
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.6.1
Fibrosis Response (P2): Summary of Results at Week 52;
by BMI
(Label Population)

BMI: <25 kg/m2
Total Subjects with Event of Interest in Subgroup Category: 6

Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	4 (57.1)	0	2 (25.0)
0.5 - (1,0) or (0,1)	0	0	0
0 - (0,0)	3 (42.9)	0	6 (75.0)
Average Percentage of Responders [2]	57.1	0	25.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	24.6 (18.14)	NE	
95% CI of the difference	(-10.9, 60.2)	NE	
p-value	0.3955	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.38	NE	
95% CI of the inverse odds ratio	(0.09, 1.59)	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.63	NE	
95% CI of the inverse risk ratio	(0.34, 1.19)	NE	
p-value	0.1859	NE	
p-value of Breslow-Day Test for Homogeneity [5]	0.2571	NE	

AMNOG Table P2.6.1
Fibrosis Response (P2): Summary of Results at Week 52;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2
Total Subjects with Event of Interest in Subgroup Category: 33

Statistic/Category	MGL-3196 80 mg (N=46)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	11 (23.9)	0	3 (4.8)
0.5 - (1,0) or (0,1)	9 (19.6)	0	10 (16.1)
0 - (0,0)	26 (56.5)	0	49 (79.0)
Average Percentage of Responders [2]	33.7	0	12.9
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	20.8 (7.03)	NE	
95% CI of the difference	(7.0, 34.6)	NE	
p-value	0.0038	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.29	NE	
95% CI of the inverse odds ratio	(0.15, 0.57)	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.38	NE	
95% CI of the inverse risk ratio	(0.22, 0.66)	NE	
p-value	0.0003	NE	
p-value of Breslow-Day Test for Homogeneity [5]	0.2571	NE	

Madrigal Pharmaceuticals, Inc. Page 4 of 4
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.6.1
Fibrosis Response (P2): Summary of Results at Week 52;
by BMI
(Label Population)

BMI: >= 30 kg/m2
Total Subjects with Event of Interest in Subgroup Category: 138

Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=151)	Placebo (N=230)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	19 (17.1)	23 (15.2)	22 (9.6)
0.5 - (1,0) or (0,1)	17 (15.3)	33 (21.9)	24 (10.4)
0 - (0,0)	75 (67.6)	95 (62.9)	184 (80.0)
Average Percentage of Responders [2]	24.8	26.2	14.8
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	10.0 (3.99)	11.3 (3.57)	
95% CI of the difference	(2.2, 17.8)	(4.3, 18.3)	
p-value	0.0101	0.0016	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.53	0.49	
95% CI of the inverse odds ratio	(0.35, 0.79)	(0.34, 0.70)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.59	0.57	
95% CI of the inverse risk ratio	(0.42, 0.82)	(0.43, 0.76)	
p-value	0.0015	0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.2571	NE	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.6.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by BMI
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.6.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by BMI
(Label Population)

BMI: <25 kg/m2
Total Subjects with Event of Interest in Subgroup Category: 6

Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Responders at Week 52, n (%) [1]			
1 - (1,1)	4 (57.1)	0	2 (25.0)
0.5 - (1,0) or (0,1)	0	0	0
0 - (0,0)	3 (42.9)	0	6 (75.0)
Average Percentage of Responders [2]	57.1	0	25.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	24.6 (18.14)	NE	
95% CI of the difference	(-10.9, 60.2)	NE	
p-value	0.3955	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.38	NE	
95% CI of the inverse odds ratio	(0.09, 1.59)	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.63	NE	
95% CI of the inverse risk ratio	(0.34, 1.19)	NE	
p-value	0.1859	NE	
p-value of Breslow-Day Test for Homogeneity [5]	0.1843	NE	

AMNOG Table P2.6.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2
Total Subjects with Event of Interest in Subgroup Category: 30

Statistic/Category	MGL-3196 80 mg (N=46)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Responders at Week 52, n (%) [1]			
1 - (1,1)	10 (21.7)	0	1 (1.6)
0.5 - (1,0) or (0,1)	9 (19.6)	0	10 (16.1)
0 - (0,0)	27 (58.7)	0	51 (82.3)
Average Percentage of Responders [2]	31.5	0	9.7
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	21.8 (6.60)	NE	
95% CI of the difference	(8.9, 34.7)	NE	
p-value	0.0017	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.23	NE	
95% CI of the inverse odds ratio	(0.11, 0.49)	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.31	NE	
95% CI of the inverse risk ratio	(0.17, 0.57)	NE	
p-value	<0.0001	NE	
p-value of Breslow-Day Test for Homogeneity [5]	0.1843	NE	

AMNOG Table P2.6.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by BMI
(Label Population)

BMI: >= 30 kg/m2
Total Subjects with Event of Interest in Subgroup Category: 131

Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=151)	Placebo (N=230)
Responders at Week 52, n (%) [1]			
1 - (1,1)	17 (15.3)	21 (13.9)	17 (7.4)
0.5 - (1,0) or (0,1)	18 (16.2)	32 (21.2)	26 (11.3)
0 - (0,0)	76 (68.5)	98 (64.9)	187 (81.3)
Average Percentage of Responders [2]	23.4	24.5	13.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	10.2 (3.78)	11.4 (3.40)	
95% CI of the difference	(2.8, 17.6)	(4.7, 18.1)	
p-value	0.0055	0.0008	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.49	0.46	
95% CI of the inverse odds ratio	(0.33, 0.75)	(0.31, 0.67)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.55	0.54	
95% CI of the inverse risk ratio	(0.39, 0.79)	(0.39, 0.73)	
p-value	0.0008	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.1843	NE	

AMNOG Table P2.6.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by BMI
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.6.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by BMI
(Label Population)

BMI: <25 kg/m2
Total Subjects with Event of Interest in Subgroup Category: 6

Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Responders at Week 52, n (%) [1]			
1 - (1,1)	4 (57.1)	0	2 (25.0)
0.5 - (1,0) or (0,1)	0	0	0
0 - (0,0)	3 (42.9)	0	6 (75.0)
Average Percentage of Responders [2]	57.1	0	25.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	24.6 (18.14)	NE	
95% CI of the difference	(-10.9, 60.2)	NE	
p-value	0.3955	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.38	NE	
95% CI of the inverse odds ratio	(0.09, 1.59)	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.63	NE	
95% CI of the inverse risk ratio	(0.34, 1.19)	NE	
p-value	0.1859	NE	
p-value of Breslow-Day Test for Homogeneity [5]	0.2428	NE	

AMNOG Table P2.6.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2
Total Subjects with Event of Interest in Subgroup Category: 33

Statistic/Category	MGL-3196 80 mg (N=46)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Responders at Week 52, n (%) [1]			
1 - (1,1)	10 (21.7)	0	2 (3.2)
0.5 - (1,0) or (0,1)	10 (21.7)	0	11 (17.7)
0 - (0,0)	26 (56.5)	0	49 (79.0)
Average Percentage of Responders [2]	32.6	0	12.1
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	20.5 (6.75)	NE	
95% CI of the difference	(7.3, 33.7)	NE	
p-value	0.0039	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.29	NE	
95% CI of the inverse odds ratio	(0.14, 0.57)	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.37	NE	
95% CI of the inverse risk ratio	(0.21, 0.65)	NE	
p-value	0.0003	NE	
p-value of Breslow-Day Test for Homogeneity [5]	0.2428	NE	

AMNOG Table P2.6.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by BMI
(Label Population)

BMI: >= 30 kg/m2
Total Subjects with Event of Interest in Subgroup Category: 138

Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=151)	Placebo (N=230)
Responders at Week 52, n (%) [1]			
1 - (1,1)	19 (17.1)	23 (15.2)	22 (9.6)
0.5 - (1,0) or (0,1)	17 (15.3)	33 (21.9)	24 (10.4)
0 - (0,0)	75 (67.6)	95 (62.9)	184 (80.0)
Average Percentage of Responders [2]	24.8	26.2	14.8
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	10.0 (3.99)	11.3 (3.57)	
95% CI of the difference	(2.2, 17.8)	(4.3, 18.3)	
p-value	0.0101	0.0016	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.53	0.49	
95% CI of the inverse odds ratio	(0.35, 0.79)	(0.34, 0.70)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.59	0.57	
95% CI of the inverse risk ratio	(0.42, 0.82)	(0.43, 0.76)	
p-value	0.0015	0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.2428	NE	

AMNOG Table P2.7.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.7.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes
Total Subjects with Event of Interest in Subgroup Category: 114

Statistic/Category	MGL-3196 80 mg (N=116)	MGL-3196 100 mg (N=100)	Placebo (N=198)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	26 (22.4)	15 (15.0)	13 (6.6)
0.5 - (1,0) or (0,1)	22 (19.0)	18 (18.0)	20 (10.1)
0 - (0,0)	68 (58.6)	67 (67.0)	165 (83.3)
Average Percentage of Responders [2]	31.9	24.0	11.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	20.3 (4.08)	12.3 (3.91)	
95% CI of the difference	(12.3, 28.3)	(4.7, 20.0)	
p-value	<0.0001	0.0016	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.28	0.42	
95% CI of the inverse odds ratio	(0.19, 0.42)	(0.27, 0.65)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.36	0.49	
95% CI of the inverse risk ratio	(0.26, 0.51)	(0.34, 0.70)	
p-value	<0.0001	0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.0006	0.3208	

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.7.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No
Total Subjects with Event of Interest in Subgroup Category: 63

Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	8 (16.7)	8 (15.7)	14 (13.7)
0.5 - (1,0) or (0,1)	4 (8.3)	15 (29.4)	14 (13.7)
0 - (0,0)	36 (75.0)	28 (54.9)	74 (72.5)
Average Percentage of Responders [2]	20.8	30.4	20.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	0.1 (6.45)	9.8 (6.27)	
95% CI of the difference	(-12.5, 12.8)	(-2.5, 22.1)	
p-value	0.9819	0.1178	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.99	0.59	
95% CI of the inverse odds ratio	(0.55, 1.80)	(0.34, 1.02)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.99	0.68	
95% CI of the inverse risk ratio	(0.62, 1.59)	(0.46, 1.01)	
p-value	0.9769	0.0578	
p-value of Breslow-Day Test for Homogeneity [5]	0.0006	0.3208	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.7.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.7.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes
Total Subjects with Event of Interest in Subgroup Category: 110

Statistic/Category	MGL-3196 80 mg (N=116)	MGL-3196 100 mg (N=100)	Placebo (N=198)
Responders at Week 52, n (%) [1]			
1 - (1,1)	23 (19.8)	13 (13.0)	10 (5.1)
0.5 - (1,0) or (0,1)	23 (19.8)	20 (20.0)	21 (10.6)
0 - (0,0)	70 (60.3)	67 (67.0)	167 (84.3)
Average Percentage of Responders [2]	29.7	23.0	10.4
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	19.4 (3.88)	12.6 (3.70)	
95% CI of the difference	(11.8, 27.0)	(5.3, 19.9)	
p-value	<0.0001	0.0007	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.27	0.39	
95% CI of the inverse odds ratio	(0.18, 0.42)	(0.25, 0.62)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.35	0.45	
95% CI of the inverse risk ratio	(0.24, 0.49)	(0.31, 0.66)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.0051	0.3512	

AMNOG Table P2.7.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No
Total Subjects with Event of Interest in Subgroup Category: 57

Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Responders at Week 52, n (%) [1]			
1 - (1,1)	8 (16.7)	8 (15.7)	10 (9.8)
0.5 - (1,0) or (0,1)	4 (8.3)	12 (23.5)	15 (14.7)
0 - (0,0)	36 (75.0)	31 (60.8)	77 (75.5)
Average Percentage of Responders [2]	20.8	27.5	17.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	3.6 (6.05)	10.3 (5.90)	
95% CI of the difference	(-8.3, 15.4)	(-1.3, 21.9)	
p-value	0.5541	0.0809	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.79	0.54	
95% CI of the inverse odds ratio	(0.43, 1.46)	(0.31, 0.96)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.83	0.63	
95% CI of the inverse risk ratio	(0.51, 1.36)	(0.41, 0.96)	
p-value	0.4577	0.0353	
p-value of Breslow-Day Test for Homogeneity [5]	0.0051	0.3512	

AMNOG Table P2.7.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.7.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes
Total Subjects with Event of Interest in Subgroup Category: 114

Statistic/Category	MGL-3196 80 mg (N=116)	MGL-3196 100 mg (N=100)	Placebo (N=198)
Responders at Week 52, n (%) [1]			
1 - (1,1)	25 (21.6)	15 (15.0)	12 (6.1)
0.5 - (1,0) or (0,1)	23 (19.8)	18 (18.0)	21 (10.6)
0 - (0,0)	68 (58.6)	67 (67.0)	165 (83.3)
Average Percentage of Responders [2]	31.5	24.0	11.4
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	20.1 (4.02)	12.6 (3.87)	
95% CI of the difference	(12.2, 28.0)	(5.0, 20.2)	
p-value	<0.0001	0.0011	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.28	0.41	
95% CI of the inverse odds ratio	(0.18, 0.42)	(0.26, 0.64)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.36	0.48	
95% CI of the inverse risk ratio	(0.26, 0.50)	(0.33, 0.69)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.0006	0.2890	

AMNOG Table P2.7.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No
Total Subjects with Event of Interest in Subgroup Category: 63

Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Responders at Week 52, n (%) [1]			
1 - (1,1)	8 (16.7)	8 (15.7)	14 (13.7)
0.5 - (1,0) or (0,1)	4 (8.3)	15 (29.4)	14 (13.7)
0 - (0,0)	36 (75.0)	28 (54.9)	74 (72.5)
Average Percentage of Responders [2]	20.8	30.4	20.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	0.1 (6.45)	9.8 (6.27)	
95% CI of the difference	(-12.5, 12.8)	(-2.5, 22.1)	
p-value	0.9819	0.1178	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.99	0.59	
95% CI of the inverse odds ratio	(0.55, 1.80)	(0.34, 1.02)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.99	0.68	
95% CI of the inverse risk ratio	(0.62, 1.59)	(0.46, 1.01)	
p-value	0.9769	0.0578	
p-value of Breslow-Day Test for Homogeneity [5]	0.0006	0.2890	

AMNOG Table P2.8.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist and Baseline type 2 diabetes status as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.8.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only
Total Subjects with Event of Interest in Subgroup Category: 69

Statistic/Category	MGL-3196 80 mg (N=62)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	11 (17.7)	11 (20.8)	10 (9.0)
0.5 - (1,0) or (0,1)	12 (19.4)	11 (20.8)	14 (12.6)
0 - (0,0)	39 (62.9)	31 (58.5)	87 (78.4)
Average Percentage of Responders [2]	27.4	31.1	15.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	12.3 (5.52)	15.5 (5.80)	
95% CI of the difference	(1.5, 23.1)	(4.2, 26.9)	
p-value	0.0254	0.0074	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.48	0.39	
95% CI of the inverse odds ratio	(0.28, 0.81)	(0.22, 0.69)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.55	0.50	
95% CI of the inverse risk ratio	(0.35, 0.85)	(0.33, 0.75)	
p-value	0.0058	0.0010	
p-value of Breslow-Day Test for Homogeneity [5]	0.6047	0.3929	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.8.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only
Total Subjects with Event of Interest in Subgroup Category: 108

Statistic/Category	MGL-3196 80 mg (N=102)	MGL-3196 100 mg (N=98)	Placebo (N=189)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	23 (22.5)	12 (12.2)	17 (9.0)
0.5 - (1,0) or (0,1)	14 (13.7)	22 (22.4)	20 (10.6)
0 - (0,0)	65 (63.7)	64 (65.3)	152 (80.4)
Average Percentage of Responders [2]	29.4	23.5	14.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	15.1 (4.42)	9.2 (4.09)	
95% CI of the difference	(6.5, 23.8)	(1.2, 17.2)	
p-value	0.0006	0.0241	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.40	0.54	
95% CI of the inverse odds ratio	(0.26, 0.61)	(0.35, 0.84)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.48	0.61	
95% CI of the inverse risk ratio	(0.35, 0.67)	(0.43, 0.87)	
p-value	<0.0001	0.0058	
p-value of Breslow-Day Test for Homogeneity [5]	0.6047	0.3929	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.8.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist and Baseline type 2 diabetes status as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.8.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only
Total Subjects with Event of Interest in Subgroup Category: 67

Statistic/Category	MGL-3196 80 mg (N=62)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Responders at Week 52, n (%) [1]			
1 - (1,1)	10 (16.1)	10 (18.9)	6 (5.4)
0.5 - (1,0) or (0,1)	12 (19.4)	11 (20.8)	18 (16.2)
0 - (0,0)	40 (64.5)	32 (60.4)	87 (78.4)
Average Percentage of Responders [2]	25.8	29.2	13.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	12.5 (5.13)	15.5 (5.40)	
95% CI of the difference	(2.4, 22.5)	(4.9, 26.1)	
p-value	0.0149	0.0041	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.45	0.37	
95% CI of the inverse odds ratio	(0.26, 0.78)	(0.21, 0.67)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.51	0.47	
95% CI of the inverse risk ratio	(0.33, 0.81)	(0.30, 0.73)	
p-value	0.0038	0.0007	
p-value of Breslow-Day Test for Homogeneity [5]	0.5251	0.4756	

AMNOG Table P2.8.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only
Total Subjects with Event of Interest in Subgroup Category: 100

Statistic/Category	MGL-3196 80 mg (N=102)	MGL-3196 100 mg (N=98)	Placebo (N=189)
Responders at Week 52, n (%) [1]			
1 - (1,1)	21 (20.6)	11 (11.2)	14 (7.4)
0.5 - (1,0) or (0,1)	15 (14.7)	21 (21.4)	18 (9.5)
0 - (0,0)	66 (64.7)	66 (67.3)	157 (83.1)
Average Percentage of Responders [2]	27.9	21.9	12.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	15.7 (4.23)	9.8 (3.89)	
95% CI of the difference	(7.5, 24.0)	(2.2, 17.4)	
p-value	0.0002	0.0119	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.36	0.49	
95% CI of the inverse odds ratio	(0.23, 0.55)	(0.31, 0.78)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.43	0.55	
95% CI of the inverse risk ratio	(0.30, 0.62)	(0.38, 0.81)	
p-value	<0.0001	0.0022	
p-value of Breslow-Day Test for Homogeneity [5]	0.5251	0.4756	

AMNOG Table P2.8.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist and Baseline type 2 diabetes status as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.8.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only
Total Subjects with Event of Interest in Subgroup Category: 69

Statistic/Category	MGL-3196 80 mg (N=62)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Responders at Week 52, n (%) [1]			
1 - (1,1)	10 (16.1)	11 (20.8)	10 (9.0)
0.5 - (1,0) or (0,1)	13 (21.0)	11 (20.8)	14 (12.6)
0 - (0,0)	39 (62.9)	31 (58.5)	87 (78.4)
Average Percentage of Responders [2]	26.6	31.1	15.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	11.5 (5.44)	15.5 (5.80)	
95% CI of the difference	(0.9, 22.2)	(4.2, 26.9)	
p-value	0.0338	0.0074	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.50	0.39	
95% CI of the inverse odds ratio	(0.29, 0.85)	(0.22, 0.69)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.56	0.50	
95% CI of the inverse risk ratio	(0.36, 0.87)	(0.33, 0.75)	
p-value	0.0094	0.0010	
p-value of Breslow-Day Test for Homogeneity [5]	0.4869	0.4281	

AMNOG Table P2.8.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only
Total Subjects with Event of Interest in Subgroup Category: 108

Statistic/Category	MGL-3196 80 mg (N=102)	MGL-3196 100 mg (N=98)	Placebo (N=189)
Responders at Week 52, n (%) [1]			
1 - (1,1)	23 (22.5)	12 (12.2)	16 (8.5)
0.5 - (1,0) or (0,1)	14 (13.7)	22 (22.4)	21 (11.1)
0 - (0,0)	65 (63.7)	64 (65.3)	152 (80.4)
Average Percentage of Responders [2]	29.4	23.5	14.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	15.4 (4.39)	9.5 (4.05)	
95% CI of the difference	(6.8, 24.0)	(1.6, 17.4)	
p-value	0.0004	0.0191	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.39	0.53	
95% CI of the inverse odds ratio	(0.26, 0.59)	(0.34, 0.82)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.47	0.60	
95% CI of the inverse risk ratio	(0.34, 0.66)	(0.42, 0.85)	
p-value	<0.0001	0.0044	
p-value of Breslow-Day Test for Homogeneity [5]	0.4869	0.4281	

AMNOG Table P2.9.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.9.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues
Total Subjects with Event of Interest in Subgroup Category: 28

Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=22)	Placebo (N=38)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	6 (23.1)	4 (18.2)	1 (2.6)
0.5 - (1,0) or (0,1)	7 (26.9)	5 (22.7)	5 (13.2)
0 - (0,0)	13 (50.0)	13 (59.1)	32 (84.2)
Average Percentage of Responders [2]	36.5	29.5	9.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	27.8 (8.93)	20.3 (8.62)	
95% CI of the difference	(10.3, 45.3)	(3.4, 37.2)	
p-value	0.0035	0.0201	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.18	0.25	
95% CI of the inverse odds ratio	(0.07, 0.48)	(0.09, 0.68)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.26	0.32	
95% CI of the inverse risk ratio	(0.12, 0.58)	(0.14, 0.73)	
p-value	0.0003	0.0049	
p-value of Breslow-Day Test for Homogeneity [5]	0.0468	0.1473	

AMNOG Table P2.9.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues
Total Subjects with Event of Interest in Subgroup Category: 149

Statistic/Category	MGL-3196 80 mg (N=138)	MGL-3196 100 mg (N=129)	Placebo (N=262)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	28 (20.3)	19 (14.7)	26 (9.9)
0.5 - (1,0) or (0,1)	19 (13.8)	28 (21.7)	29 (11.1)
0 - (0,0)	91 (65.9)	82 (63.6)	207 (79.0)
Average Percentage of Responders [2]	27.2	25.6	15.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	11.7 (3.77)	10.0 (3.65)	
95% CI of the difference	(4.3, 19.1)	(2.9, 17.2)	
p-value	0.0019	0.0059	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.49	0.53	
95% CI of the inverse odds ratio	(0.35, 0.70)	(0.37, 0.77)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.57	0.61	
95% CI of the inverse risk ratio	(0.43, 0.75)	(0.46, 0.81)	
p-value	<0.0001	0.0007	
p-value of Breslow-Day Test for Homogeneity [5]	0.0468	0.1473	

AMNOG Table P2.9.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.9.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues
Total Subjects with Event of Interest in Subgroup Category: 27

Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=22)	Placebo (N=38)
Responders at Week 52, n (%) [1]			
1 - (1,1)	5 (19.2)	4 (18.2)	1 (2.6)
0.5 - (1,0) or (0,1)	7 (26.9)	5 (22.7)	5 (13.2)
0 - (0,0)	14 (53.8)	13 (59.1)	32 (84.2)
Average Percentage of Responders [2]	32.7	29.5	9.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	24.2 (8.63)	20.3 (8.62)	
95% CI of the difference	(7.3, 41.1)	(3.4, 37.2)	
p-value	0.0090	0.0201	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.22	0.25	
95% CI of the inverse odds ratio	(0.08, 0.57)	(0.09, 0.68)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.29	0.32	
95% CI of the inverse risk ratio	(0.13, 0.65)	(0.14, 0.73)	
p-value	0.0013	0.0049	
p-value of Breslow-Day Test for Homogeneity [5]	0.1695	0.1979	

AMNOG Table P2.9.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues
Total Subjects with Event of Interest in Subgroup Category: 140

Statistic/Category	MGL-3196 80 mg (N=138)	MGL-3196 100 mg (N=129)	Placebo (N=262)
Responders at Week 52, n (%) [1]			
1 - (1,1)	26 (18.8)	17 (13.2)	19 (7.3)
0.5 - (1,0) or (0,1)	20 (14.5)	27 (20.9)	31 (11.8)
0 - (0,0)	92 (66.7)	85 (65.9)	212 (80.9)
Average Percentage of Responders [2]	26.1	23.6	13.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	12.9 (3.56)	10.4 (3.41)	
95% CI of the difference	(5.9, 19.9)	(3.7, 17.1)	
p-value	0.0003	0.0023	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.43	0.49	
95% CI of the inverse odds ratio	(0.30, 0.63)	(0.33, 0.72)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.50	0.56	
95% CI of the inverse risk ratio	(0.37, 0.68)	(0.41, 0.76)	
p-value	<0.0001	0.0002	
p-value of Breslow-Day Test for Homogeneity [5]	0.1695	0.1979	

AMNOG Table P2.9.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.9.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues
Total Subjects with Event of Interest in Subgroup Category: 28

Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=22)	Placebo (N=38)
Responders at Week 52, n (%) [1]			
1 - (1,1)	6 (23.1)	4 (18.2)	1 (2.6)
0.5 - (1,0) or (0,1)	7 (26.9)	5 (22.7)	5 (13.2)
0 - (0,0)	13 (50.0)	13 (59.1)	32 (84.2)
Average Percentage of Responders [2]	36.5	29.5	9.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	27.8 (8.93)	20.3 (8.62)	
95% CI of the difference	(10.3, 45.3)	(3.4, 37.2)	
p-value	0.0035	0.0201	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.18	0.25	
95% CI of the inverse odds ratio	(0.07, 0.48)	(0.09, 0.68)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.26	0.32	
95% CI of the inverse risk ratio	(0.12, 0.58)	(0.14, 0.73)	
p-value	0.0003	0.0049	
p-value of Breslow-Day Test for Homogeneity [5]	0.0462	0.1552	

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.9.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues
Total Subjects with Event of Interest in Subgroup Category: 149

Statistic/Category	MGL-3196 80 mg (N=138)	MGL-3196 100 mg (N=129)	Placebo (N=262)
Responders at Week 52, n (%) [1]			
1 - (1,1)	27 (19.6)	19 (14.7)	25 (9.5)
0.5 - (1,0) or (0,1)	20 (14.5)	28 (21.7)	30 (11.5)
0 - (0,0)	91 (65.9)	82 (63.6)	207 (79.0)
Average Percentage of Responders [2]	26.8	25.6	15.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	11.5 (3.72)	10.2 (3.62)	
95% CI of the difference	(4.2, 18.8)	(3.1, 17.3)	
p-value	0.0019	0.0047	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.49	0.52	
95% CI of the inverse odds ratio	(0.35, 0.71)	(0.36, 0.76)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.57	0.60	
95% CI of the inverse risk ratio	(0.43, 0.75)	(0.45, 0.80)	
p-value	<0.0001	0.0005	
p-value of Breslow-Day Test for Homogeneity [5]	0.0462	0.1552	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.10.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Thyroxine at Baseline
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.10.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes
Total Subjects with Event of Interest in Subgroup Category: 16

Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=42)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	4 (21.1)	3 (18.8)	3 (7.1)
0.5 - (1,0) or (0,1)	1 (5.3)	3 (18.8)	2 (4.8)
0 - (0,0)	14 (73.7)	10 (62.5)	37 (88.1)
Average Percentage of Responders [2]	23.7	28.1	9.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	16.7 (9.26)	20.8 (9.71)	
95% CI of the difference	(-1.5, 34.8)	(1.7, 39.8)	
p-value	0.0606	0.0330	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.33	0.24	
95% CI of the inverse odds ratio	(0.13, 0.83)	(0.09, 0.66)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.39	0.33	
95% CI of the inverse risk ratio	(0.19, 0.82)	(0.15, 0.71)	
p-value	0.0115	0.0044	
p-value of Breslow-Day Test for Homogeneity [5]	0.6352	0.2396	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.10.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No
Total Subjects with Event of Interest in Subgroup Category: 161

Statistic/Category	MGL-3196 80 mg (N=145)	MGL-3196 100 mg (N=135)	Placebo (N=258)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	30 (20.7)	20 (14.8)	24 (9.3)
0.5 - (1,0) or (0,1)	25 (17.2)	30 (22.2)	32 (12.4)
0 - (0,0)	90 (62.1)	85 (63.0)	202 (78.3)
Average Percentage of Responders [2]	29.3	25.9	15.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	13.8 (3.72)	10.2 (3.58)	
95% CI of the difference	(6.5, 21.1)	(3.2, 17.2)	
p-value	0.0002	0.0044	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.45	0.53	
95% CI of the inverse odds ratio	(0.32, 0.63)	(0.37, 0.76)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.53	0.60	
95% CI of the inverse risk ratio	(0.40, 0.69)	(0.46, 0.80)	
p-value	<0.0001	0.0005	
p-value of Breslow-Day Test for Homogeneity [5]	0.6352	0.2396	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.10.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Thyroxine at Baseline
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.10.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes
Total Subjects with Event of Interest in Subgroup Category: 14

Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=42)
Responders at Week 52, n (%) [1]			
1 - (1,1)	4 (21.1)	3 (18.8)	2 (4.8)
0.5 - (1,0) or (0,1)	1 (5.3)	1 (6.3)	3 (7.1)
0 - (0,0)	14 (73.7)	12 (75.0)	37 (88.1)
Average Percentage of Responders [2]	23.7	21.9	8.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	17.2 (9.05)	14.7 (9.59)	
95% CI of the difference	(-0.5, 34.9)	(-4.1, 33.5)	
p-value	0.0457	0.0953	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.31	0.28	
95% CI of the inverse odds ratio	(0.12, 0.78)	(0.09, 0.82)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.37	0.37	
95% CI of the inverse risk ratio	(0.17, 0.77)	(0.16, 0.83)	
p-value	0.0078	0.0174	
p-value of Breslow-Day Test for Homogeneity [5]	0.5746	0.5502	

AMNOG Table P2.10.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No
Total Subjects with Event of Interest in Subgroup Category: 153

Statistic/Category	MGL-3196 80 mg (N=145)	MGL-3196 100 mg (N=135)	Placebo (N=258)
Responders at Week 52, n (%) [1]			
1 - (1,1)	27 (18.6)	18 (13.3)	18 (7.0)
0.5 - (1,0) or (0,1)	26 (17.9)	31 (23.0)	33 (12.8)
0 - (0,0)	92 (63.4)	86 (63.7)	207 (80.2)
Average Percentage of Responders [2]	27.6	24.8	13.4
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	14.2 (3.52)	11.2 (3.39)	
95% CI of the difference	(7.3, 21.1)	(4.6, 17.9)	
p-value	<0.0001	0.0009	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.41	0.47	
95% CI of the inverse odds ratio	(0.29, 0.59)	(0.32, 0.69)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.48	0.55	
95% CI of the inverse risk ratio	(0.36, 0.65)	(0.40, 0.74)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.5746	0.5502	

AMNOG Table P2.10.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Thyroxine at Baseline
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.10.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes
Total Subjects with Event of Interest in Subgroup Category: 16

Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=42)
Responders at Week 52, n (%) [1]			
1 - (1,1)	4 (21.1)	3 (18.8)	3 (7.1)
0.5 - (1,0) or (0,1)	1 (5.3)	3 (18.8)	2 (4.8)
0 - (0,0)	14 (73.7)	10 (62.5)	37 (88.1)
Average Percentage of Responders [2]	23.7	28.1	9.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	16.7 (9.26)	20.8 (9.71)	
95% CI of the difference	(-1.5, 34.8)	(1.7, 39.8)	
p-value	0.0606	0.0330	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.33	0.24	
95% CI of the inverse odds ratio	(0.13, 0.83)	(0.09, 0.66)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.39	0.33	
95% CI of the inverse risk ratio	(0.19, 0.82)	(0.15, 0.71)	
p-value	0.0115	0.0044	
p-value of Breslow-Day Test for Homogeneity [5]	0.6331	0.2505	

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.10.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No
Total Subjects with Event of Interest in Subgroup Category: 161

Statistic/Category	MGL-3196 80 mg (N=145)	MGL-3196 100 mg (N=135)	Placebo (N=258)
Responders at Week 52, n (%) [1]			
1 - (1,1)	29 (20.0)	20 (14.8)	23 (8.9)
0.5 - (1,0) or (0,1)	26 (17.9)	30 (22.2)	33 (12.8)
0 - (0,0)	90 (62.1)	85 (63.0)	202 (78.3)
Average Percentage of Responders [2]	29.0	25.9	15.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	13.6 (3.68)	10.4 (3.56)	
95% CI of the difference	(6.4, 20.9)	(3.4, 17.4)	
p-value	0.0002	0.0035	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.45	0.52	
95% CI of the inverse odds ratio	(0.32, 0.64)	(0.36, 0.75)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.53	0.60	
95% CI of the inverse risk ratio	(0.40, 0.69)	(0.45, 0.79)	
p-value	<0.0001	0.0004	
p-value of Breslow-Day Test for Homogeneity [5]	0.6331	0.2505	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.11.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.11.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss
Total Subjects with Event of Interest in Subgroup Category: 44

Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=34)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	12 (40.0)	7 (22.6)	5 (14.7)
0.5 - (1,0) or (0,1)	3 (10.0)	9 (29.0)	8 (23.5)
0 - (0,0)	15 (50.0)	15 (48.4)	21 (61.8)
Average Percentage of Responders [2]	45.0	37.1	26.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	18.3 (10.39)	6.2 (9.63)	
95% CI of the difference	(-2.0, 38.7)	(-12.6, 25.1)	
p-value	0.1299	0.5124	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.46	0.74	
95% CI of the inverse odds ratio	(0.22, 0.96)	(0.34, 1.62)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.61	0.82	
95% CI of the inverse risk ratio	(0.38, 0.96)	(0.50, 1.36)	
p-value	0.0365	0.4592	
p-value of Breslow-Day Test for Homogeneity [5]	0.5965	0.7122	

AMNOG Table P2.11.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain
Total Subjects with Event of Interest in Subgroup Category: 11

Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	2 (16.7)	2 (25.0)	1 (7.7)
0.5 - (1,0) or (0,1)	1 (8.3)	2 (25.0)	3 (23.1)
0 - (0,0)	9 (75.0)	4 (50.0)	9 (69.2)
Average Percentage of Responders [2]	20.8	37.5	19.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	3.4 (13.57)	16.1 (14.94)	
95% CI of the difference	(-23.2, 30.0)	(-13.2, 45.3)	
p-value	0.8976	0.4184	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.88	0.54	
95% CI of the inverse odds ratio	(0.29, 2.69)	(0.17, 1.75)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.91	0.66	
95% CI of the inverse risk ratio	(0.41, 2.00)	(0.30, 1.47)	
p-value	0.8199	0.3287	
p-value of Breslow-Day Test for Homogeneity [5]	0.5965	0.7122	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.11.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable
Total Subjects with Event of Interest in Subgroup Category: 122

Statistic/Category	MGL-3196 80 mg (N=108)	MGL-3196 100 mg (N=87)	Placebo (N=219)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	20 (18.5)	14 (16.1)	21 (9.6)
0.5 - (1,0) or (0,1)	22 (20.4)	22 (25.3)	23 (10.5)
0 - (0,0)	66 (61.1)	51 (58.6)	175 (79.9)
Average Percentage of Responders [2]	28.7	28.7	14.8
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	14.1 (4.15)	13.9 (4.31)	
95% CI of the difference	(5.9, 22.2)	(5.5, 22.3)	
p-value	0.0007	0.0011	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.43	0.43	
95% CI of the inverse odds ratio	(0.29, 0.64)	(0.28, 0.65)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.50	0.52	
95% CI of the inverse risk ratio	(0.36, 0.70)	(0.37, 0.71)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.5965	0.7122	

AMNOG Table P2.11.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.11.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss
Total Subjects with Event of Interest in Subgroup Category: 43

Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=34)
Responders at Week 52, n (%) [1]			
1 - (1,1)	12 (40.0)	7 (22.6)	5 (14.7)
0.5 - (1,0) or (0,1)	3 (10.0)	9 (29.0)	7 (20.6)
0 - (0,0)	15 (50.0)	15 (48.4)	22 (64.7)
Average Percentage of Responders [2]	45.0	37.1	25.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	20.0 (10.43)	7.7 (9.63)	
95% CI of the difference	(-0.5, 40.4)	(-11.2, 26.6)	
p-value	0.1001	0.4236	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.42	0.69	
95% CI of the inverse odds ratio	(0.20, 0.90)	(0.31, 1.51)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.57	0.78	
95% CI of the inverse risk ratio	(0.36, 0.92)	(0.47, 1.30)	
p-value	0.0218	0.3558	
p-value of Breslow-Day Test for Homogeneity [5]	0.5637	0.7328	

AMNOG Table P2.11.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain
Total Subjects with Event of Interest in Subgroup Category: 10

Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Responders at Week 52, n (%) [1]			
1 - (1,1)	1 (8.3)	1 (12.5)	1 (7.7)
0.5 - (1,0) or (0,1)	2 (16.7)	3 (37.5)	2 (15.4)
0 - (0,0)	9 (75.0)	4 (50.0)	10 (76.9)
Average Percentage of Responders [2]	16.7	31.3	15.4
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	1.1 (12.98)	16.4 (14.35)	
95% CI of the difference	(-24.3, 26.5)	(-11.7, 44.5)	
p-value	0.9656	0.4054	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.96	0.49	
95% CI of the inverse odds ratio	(0.30, 3.06)	(0.14, 1.71)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.97	0.60	
95% CI of the inverse risk ratio	(0.41, 2.30)	(0.25, 1.46)	
p-value	0.9417	0.2738	
p-value of Breslow-Day Test for Homogeneity [5]	0.5637	0.7328	

AMNOG Table P2.11.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable
Total Subjects with Event of Interest in Subgroup Category: 114

Statistic/Category	MGL-3196 80 mg (N=108)	MGL-3196 100 mg (N=87)	Placebo (N=219)
Responders at Week 52, n (%) [1]			
1 - (1,1)	18 (16.7)	13 (14.9)	14 (6.4)
0.5 - (1,0) or (0,1)	22 (20.4)	20 (23.0)	27 (12.3)
0 - (0,0)	68 (63.0)	54 (62.1)	178 (81.3)
Average Percentage of Responders [2]	26.9	26.4	12.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	14.3 (3.86)	13.7 (4.01)	
95% CI of the difference	(6.7, 21.9)	(5.9, 21.6)	
p-value	0.0002	0.0005	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.39	0.40	
95% CI of the inverse odds ratio	(0.26, 0.59)	(0.26, 0.62)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.46	0.48	
95% CI of the inverse risk ratio	(0.33, 0.65)	(0.34, 0.68)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.5637	0.7328	

AMNOG Table P2.11.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.11.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss
Total Subjects with Event of Interest in Subgroup Category: 44

Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=34)
Responders at Week 52, n (%) [1]			
1 - (1,1)	12 (40.0)	7 (22.6)	5 (14.7)
0.5 - (1,0) or (0,1)	3 (10.0)	9 (29.0)	8 (23.5)
0 - (0,0)	15 (50.0)	15 (48.4)	21 (61.8)
Average Percentage of Responders [2]	45.0	37.1	26.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	18.3 (10.39)	6.2 (9.63)	
95% CI of the difference	(-2.0, 38.7)	(-12.6, 25.1)	
p-value	0.1299	0.5124	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.46	0.74	
95% CI of the inverse odds ratio	(0.22, 0.96)	(0.34, 1.62)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.61	0.82	
95% CI of the inverse risk ratio	(0.38, 0.96)	(0.50, 1.36)	
p-value	0.0365	0.4592	
p-value of Breslow-Day Test for Homogeneity [5]	0.5999	0.6915	

AMNOG Table P2.11.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain
Total Subjects with Event of Interest in Subgroup Category: 11

Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Responders at Week 52, n (%) [1]			
1 - (1,1)	2 (16.7)	2 (25.0)	1 (7.7)
0.5 - (1,0) or (0,1)	1 (8.3)	2 (25.0)	3 (23.1)
0 - (0,0)	9 (75.0)	4 (50.0)	9 (69.2)
Average Percentage of Responders [2]	20.8	37.5	19.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	3.4 (13.57)	16.1 (14.94)	
95% CI of the difference	(-23.2, 30.0)	(-13.2, 45.3)	
p-value	0.8976	0.4184	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.88	0.54	
95% CI of the inverse odds ratio	(0.29, 2.69)	(0.17, 1.75)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.91	0.66	
95% CI of the inverse risk ratio	(0.41, 2.00)	(0.30, 1.47)	
p-value	0.8199	0.3287	
p-value of Breslow-Day Test for Homogeneity [5]	0.5999	0.6915	

AMNOG Table P2.11.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable
Total Subjects with Event of Interest in Subgroup Category: 122

Statistic/Category	MGL-3196 80 mg (N=108)	MGL-3196 100 mg (N=87)	Placebo (N=219)
Responders at Week 52, n (%) [1]			
1 - (1,1)	19 (17.6)	14 (16.1)	20 (9.1)
0.5 - (1,0) or (0,1)	23 (21.3)	22 (25.3)	24 (11.0)
0 - (0,0)	66 (61.1)	51 (58.6)	175 (79.9)
Average Percentage of Responders [2]	28.2	28.7	14.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	13.9 (4.09)	14.1 (4.27)	
95% CI of the difference	(5.9, 21.9)	(5.8, 22.5)	
p-value	0.0007	0.0008	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.43	0.42	
95% CI of the inverse odds ratio	(0.29, 0.64)	(0.27, 0.64)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.50	0.51	
95% CI of the inverse risk ratio	(0.36, 0.70)	(0.37, 0.70)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.5999	0.6915	

AMNOG Table P2.12.1
Fibrosis Response (P2): Summary of Results at Week 52;
by SHBG at Week 52
(Label Population)

Abbreviations: CFB = Change from Baseline; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; SHBG = Sex Hormone Binding Globulin.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.12.1
Fibrosis Response (P2): Summary of Results at Week 52;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB
Total Subjects with Event of Interest in Subgroup Category: 71

Statistic/Category	MGL-3196 80 mg (N=88)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	24 (27.3)	12 (17.9)	0
0.5 - (1,0) or (0,1)	16 (18.2)	19 (28.4)	0
0 - (0,0)	48 (54.5)	36 (53.7)	0
Average Percentage of Responders [2]	36.4	32.1	0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	NE	NE	
95% CI of the difference	NE	NE	
p-value	NE	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [5]	NE	NE	

AMNOG Table P2.12.1
Fibrosis Response (P2): Summary of Results at Week 52;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB
Total Subjects with Event of Interest in Subgroup Category: 104

Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=263)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	9 (14.8)	11 (19.3)	27 (10.3)
0.5 - (1,0) or (0,1)	10 (16.4)	13 (22.8)	34 (12.9)
0 - (0,0)	42 (68.9)	33 (57.9)	202 (76.8)
Average Percentage of Responders [2]	23.0	30.7	16.7
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	5.8 (4.81)	12.4 (5.03)	
95% CI of the difference	(-3.6, 15.3)	(2.6, 22.3)	
p-value	0.2249	0.0101	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.70	0.49	
95% CI of the inverse odds ratio	(0.43, 1.12)	(0.31, 0.78)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.75	0.59	
95% CI of the inverse risk ratio	(0.51, 1.09)	(0.42, 0.82)	
p-value	0.1322	0.0026	
p-value of Breslow-Day Test for Homogeneity [5]	NE	NE	

AMNOG Table P2.12.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by SHBG at Week 52
(Label Population)

Abbreviations: CFB = Change from Baseline; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.12.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB
Total Subjects with Event of Interest in Subgroup Category: 71

Statistic/Category	MGL-3196 80 mg (N=88)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Responders at Week 52, n (%) [1]			
1 - (1,1)	22 (25.0)	11 (16.4)	0
0.5 - (1,0) or (0,1)	18 (20.5)	20 (29.9)	0
0 - (0,0)	48 (54.5)	36 (53.7)	0
Average Percentage of Responders [2]	35.2	31.3	0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	NE	NE	
95% CI of the difference	NE	NE	
p-value	NE	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [5]	NE	NE	

AMNOG Table P2.12.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB
Total Subjects with Event of Interest in Subgroup Category: 94

Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=263)
Responders at Week 52, n (%) [1]			
1 - (1,1)	8 (13.1)	10 (17.5)	20 (7.6)
0.5 - (1,0) or (0,1)	9 (14.8)	11 (19.3)	36 (13.7)
0 - (0,0)	44 (72.1)	36 (63.2)	207 (78.7)
Average Percentage of Responders [2]	20.5	27.2	14.4
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	5.7 (4.46)	11.3 (4.74)	
95% CI of the difference	(-3.0, 14.5)	(2.1, 20.6)	
p-value	0.1975	0.0166	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.67	0.49	
95% CI of the inverse odds ratio	(0.41, 1.11)	(0.30, 0.79)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.72	0.57	
95% CI of the inverse risk ratio	(0.48, 1.08)	(0.40, 0.83)	
p-value	0.1179	0.0038	
p-value of Breslow-Day Test for Homogeneity [5]	NE	NE	

AMNOG Table P2.12.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by SHBG at Week 52
(Label Population)

Abbreviations: CFB = Change from Baseline; N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.12.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB
Total Subjects with Event of Interest in Subgroup Category: 71

Statistic/Category	MGL-3196 80 mg (N=88)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Responders at Week 52, n (%) [1]			
1 - (1,1)	23 (26.1)	12 (17.9)	0
0.5 - (1,0) or (0,1)	17 (19.3)	19 (28.4)	0
0 - (0,0)	48 (54.5)	36 (53.7)	0
Average Percentage of Responders [2]	35.8	32.1	0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	NE	NE	
95% CI of the difference	NE	NE	
p-value	NE	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [5]	NE	NE	

AMNOG Table P2.12.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB
Total Subjects with Event of Interest in Subgroup Category: 104

Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=263)
Responders at Week 52, n (%) [1]			
1 - (1,1)	9 (14.8)	11 (19.3)	26 (9.9)
0.5 - (1,0) or (0,1)	10 (16.4)	13 (22.8)	35 (13.3)
0 - (0,0)	42 (68.9)	33 (57.9)	202 (76.8)
Average Percentage of Responders [2]	23.0	30.7	16.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	6.0 (4.78)	12.6 (4.99)	
95% CI of the difference	(-3.3, 15.4)	(2.8, 22.4)	
p-value	0.2070	0.0086	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.69	0.48	
95% CI of the inverse odds ratio	(0.43, 1.11)	(0.30, 0.77)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.74	0.58	
95% CI of the inverse risk ratio	(0.51, 1.08)	(0.42, 0.81)	
p-value	0.1192	0.0022	
p-value of Breslow-Day Test for Homogeneity [5]	NE	NE	

AMNOG Table P2.13.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: N = number of subjects in Label Population; CFB = Change from Baseline; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.13.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB
Total Subjects with Event of Interest in Subgroup Category: 79

Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	20 (26.7)	18 (24.0)	5 (16.7)
0.5 - (1,0) or (0,1)	12 (16.0)	20 (26.7)	4 (13.3)
0 - (0,0)	43 (57.3)	37 (49.3)	21 (70.0)
Average Percentage of Responders [2]	34.7	37.3	23.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	9.4 (8.75)	15.9 (8.43)	
95% CI of the difference	(-7.8, 26.6)	(-0.6, 32.4)	
p-value	0.3864	0.1176	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.65	0.47	
95% CI of the inverse odds ratio	(0.33, 1.29)	(0.23, 0.96)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.73	0.61	
95% CI of the inverse risk ratio	(0.43, 1.24)	(0.37, 1.00)	
p-value	0.2173	0.0384	
p-value of Breslow-Day Test for Homogeneity [5]	0.5617	0.0776	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.13.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB
Total Subjects with Event of Interest in Subgroup Category: 56

Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=178)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	5 (11.9)	0	19 (10.7)
0.5 - (1,0) or (0,1)	7 (16.7)	6 (24.0)	19 (10.7)
0 - (0,0)	30 (71.4)	19 (76.0)	140 (78.7)
Average Percentage of Responders [2]	20.2	12.0	16.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	5.4 (5.58)	-3.8 (6.48)	
95% CI of the difference	(-5.6, 16.3)	(-16.5, 8.9)	
p-value	0.2299	0.7503	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.66	1.20	
95% CI of the inverse odds ratio	(0.36, 1.19)	(0.53, 2.72)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.71	1.17	
95% CI of the inverse risk ratio	(0.43, 1.15)	(0.58, 2.35)	
p-value	0.1665	0.6640	
p-value of Breslow-Day Test for Homogeneity [5]	0.5617	0.0776	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.13.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: N = number of subjects in Label Population; CFB = Change from Baseline; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.13.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB
Total Subjects with Event of Interest in Subgroup Category: 77

Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Responders at Week 52, n (%) [1]			
1 - (1,1)	18 (24.0)	16 (21.3)	5 (16.7)
0.5 - (1,0) or (0,1)	14 (18.7)	20 (26.7)	4 (13.3)
0 - (0,0)	43 (57.3)	39 (52.0)	21 (70.0)
Average Percentage of Responders [2]	33.3	34.7	23.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	8.3 (8.58)	13.0 (8.31)	
95% CI of the difference	(-8.5, 25.1)	(-3.3, 29.3)	
p-value	0.4513	0.2098	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.69	0.54	
95% CI of the inverse odds ratio	(0.35, 1.36)	(0.27, 1.09)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.76	0.66	
95% CI of the inverse risk ratio	(0.45, 1.28)	(0.40, 1.09)	
p-value	0.2796	0.0892	
p-value of Breslow-Day Test for Homogeneity [5]	0.8518	0.1745	

AMNOG Table P2.13.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB
Total Subjects with Event of Interest in Subgroup Category: 49

Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=178)
Responders at Week 52, n (%) [1]			
1 - (1,1)	4 (9.5)	0	12 (6.7)
0.5 - (1,0) or (0,1)	7 (16.7)	5 (20.0)	21 (11.8)
0 - (0,0)	31 (73.8)	20 (80.0)	145 (81.5)
Average Percentage of Responders [2]	17.9	10.0	12.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	5.9 (4.96)	-2.5 (5.82)	
95% CI of the difference	(-3.8, 15.7)	(-13.9, 8.9)	
p-value	0.1299	0.5211	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.58	1.03	
95% CI of the inverse odds ratio	(0.31, 1.10)	(0.44, 2.39)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.63	1.02	
95% CI of the inverse risk ratio	(0.37, 1.08)	(0.49, 2.15)	
p-value	0.0961	0.9522	
p-value of Breslow-Day Test for Homogeneity [5]	0.8518	0.1745	

AMNOG Table P2.13.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: N = number of subjects in Label Population; CFB = Change from Baseline; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.13.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB
Total Subjects with Event of Interest in Subgroup Category: 79

Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Responders at Week 52, n (%) [1]			
1 - (1,1)	19 (25.3)	18 (24.0)	5 (16.7)
0.5 - (1,0) or (0,1)	13 (17.3)	20 (26.7)	4 (13.3)
0 - (0,0)	43 (57.3)	37 (49.3)	21 (70.0)
Average Percentage of Responders [2]	34.0	37.3	23.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	8.9 (8.66)	15.9 (8.43)	
95% CI of the difference	(-8.1, 25.8)	(-0.6, 32.4)	
p-value	0.4182	0.1176	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.67	0.47	
95% CI of the inverse odds ratio	(0.34, 1.32)	(0.23, 0.96)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.74	0.61	
95% CI of the inverse risk ratio	(0.44, 1.26)	(0.37, 1.00)	
p-value	0.2482	0.0384	
p-value of Breslow-Day Test for Homogeneity [5]	0.6378	0.0843	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.13.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB
Total Subjects with Event of Interest in Subgroup Category: 56

Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=178)
Responders at Week 52, n (%) [1]			
1 - (1,1)	5 (11.9)	0	18 (10.1)
0.5 - (1,0) or (0,1)	7 (16.7)	6 (24.0)	20 (11.2)
0 - (0,0)	30 (71.4)	19 (76.0)	140 (78.7)
Average Percentage of Responders [2]	20.2	12.0	15.7
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	5.7 (5.51)	-3.6 (6.40)	
95% CI of the difference	(-5.1, 16.5)	(-16.1, 9.0)	
p-value	0.2024	0.7188	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.64	1.18	
95% CI of the inverse odds ratio	(0.35, 1.17)	(0.52, 2.67)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.69	1.15	
95% CI of the inverse risk ratio	(0.42, 1.13)	(0.57, 2.32)	
p-value	0.1428	0.6967	
p-value of Breslow-Day Test for Homogeneity [5]	0.6378	0.0843	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.14a.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; SNP = Single Nucleotide Polymorphism.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.14a.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation
Total Subjects with Event of Interest in Subgroup Category: 57

Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	14 (29.8)	11 (25.0)	7 (7.4)
0.5 - (1,0) or (0,1)	4 (8.5)	8 (18.2)	13 (13.7)
0 - (0,0)	29 (61.7)	25 (56.8)	75 (78.9)
Average Percentage of Responders [2]	34.0	34.1	14.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	19.4 (6.58)	20.0 (6.57)	
95% CI of the difference	(6.5, 32.3)	(7.1, 32.9)	
p-value	0.0033	0.0024	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.33	0.33	
95% CI of the inverse odds ratio	(0.18, 0.59)	(0.18, 0.60)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.42	0.42	
95% CI of the inverse risk ratio	(0.27, 0.67)	(0.27, 0.66)	
p-value	0.0002	0.0002	
p-value of Breslow-Day Test for Homogeneity [5]	0.3925	0.2658	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.14a.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous
Total Subjects with Event of Interest in Subgroup Category: 69

Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=72)	Placebo (N=125)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	9 (12.0)	9 (12.5)	12 (9.6)
0.5 - (1,0) or (0,1)	16 (21.3)	12 (16.7)	11 (8.8)
0 - (0,0)	50 (66.7)	51 (70.8)	102 (81.6)
Average Percentage of Responders [2]	22.7	20.8	14.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	8.2 (4.89)	6.3 (4.80)	
95% CI of the difference	(-1.4, 17.8)	(-3.1, 15.7)	
p-value	0.0875	0.1576	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.59	0.62	
95% CI of the inverse odds ratio	(0.35, 0.98)	(0.36, 1.08)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.64	0.69	
95% CI of the inverse risk ratio	(0.42, 0.98)	(0.45, 1.06)	
p-value	0.0373	0.0940	
p-value of Breslow-Day Test for Homogeneity [5]	0.3925	0.2658	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.14a.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous
Total Subjects with Event of Interest in Subgroup Category: 39

Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	8 (26.7)	3 (13.6)	7 (11.1)
0.5 - (1,0) or (0,1)	4 (13.3)	9 (40.9)	8 (12.7)
0 - (0,0)	18 (60.0)	10 (45.5)	48 (76.2)
Average Percentage of Responders [2]	33.3	34.1	17.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	14.0 (8.52)	17.9 (8.63)	
95% CI of the difference	(-2.7, 30.7)	(0.9, 34.8)	
p-value	0.0831	0.0444	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.47	0.38	
95% CI of the inverse odds ratio	(0.23, 0.95)	(0.17, 0.84)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.56	0.49	
95% CI of the inverse risk ratio	(0.33, 0.95)	(0.28, 0.86)	
p-value	0.0335	0.0147	
p-value of Breslow-Day Test for Homogeneity [5]	0.3925	0.2658	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.14a.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; SNP = Single Nucleotide Polymorphism.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.14a.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation
Total Subjects with Event of Interest in Subgroup Category: 53

Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Responders at Week 52, n (%) [1]			
1 - (1,1)	12 (25.5)	10 (22.7)	6 (6.3)
0.5 - (1,0) or (0,1)	6 (12.8)	8 (18.2)	11 (11.6)
0 - (0,0)	29 (61.7)	26 (59.1)	78 (82.1)
Average Percentage of Responders [2]	31.9	31.8	12.1
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	19.7 (6.31)	20.0 (6.30)	
95% CI of the difference	(7.3, 32.1)	(7.6, 32.3)	
p-value	0.0018	0.0014	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.30	0.30	
95% CI of the inverse odds ratio	(0.16, 0.55)	(0.16, 0.56)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.38	0.38	
95% CI of the inverse risk ratio	(0.23, 0.62)	(0.23, 0.62)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.3727	0.2227	

AMNOG Table P2.14a.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous
Total Subjects with Event of Interest in Subgroup Category: 65

Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=72)	Placebo (N=125)
Responders at Week 52, n (%) [1]			
1 - (1,1)	9 (12.0)	8 (11.1)	9 (7.2)
0.5 - (1,0) or (0,1)	14 (18.7)	12 (16.7)	13 (10.4)
0 - (0,0)	52 (69.3)	52 (72.2)	103 (82.4)
Average Percentage of Responders [2]	21.3	19.4	12.4
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	8.6 (4.66)	6.4 (4.55)	
95% CI of the difference	(-0.5, 17.7)	(-2.5, 15.3)	
p-value	0.0610	0.1257	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.55	0.59	
95% CI of the inverse odds ratio	(0.32, 0.93)	(0.34, 1.05)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.60	0.66	
95% CI of the inverse risk ratio	(0.38, 0.94)	(0.42, 1.04)	
p-value	0.0238	0.0763	
p-value of Breslow-Day Test for Homogeneity [5]	0.3727	0.2227	

AMNOG Table P2.14a.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous
Total Subjects with Event of Interest in Subgroup Category: 38

Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Responders at Week 52, n (%) [1]			
1 - (1,1)	7 (23.3)	3 (13.6)	4 (6.3)
0.5 - (1,0) or (0,1)	5 (16.7)	9 (40.9)	10 (15.9)
0 - (0,0)	18 (60.0)	10 (45.5)	49 (77.8)
Average Percentage of Responders [2]	31.7	34.1	14.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	16.4 (7.91)	20.9 (7.99)	
95% CI of the difference	(0.9, 31.9)	(5.2, 36.5)	
p-value	0.0304	0.0083	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.39	0.31	
95% CI of the inverse odds ratio	(0.19, 0.82)	(0.14, 0.69)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.48	0.40	
95% CI of the inverse risk ratio	(0.27, 0.84)	(0.22, 0.73)	
p-value	0.0102	0.0029	
p-value of Breslow-Day Test for Homogeneity [5]	0.3727	0.2227	

AMNOG Table P2.14a.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; SNP = Single Nucleotide Polymorphism.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.14a.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation
Total Subjects with Event of Interest in Subgroup Category: 57

Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Responders at Week 52, n (%) [1]			
1 - (1,1)	14 (29.8)	11 (25.0)	7 (7.4)
0.5 - (1,0) or (0,1)	4 (8.5)	8 (18.2)	13 (13.7)
0 - (0,0)	29 (61.7)	25 (56.8)	75 (78.9)
Average Percentage of Responders [2]	34.0	34.1	14.2
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	19.4 (6.58)	20.0 (6.57)	
95% CI of the difference	(6.5, 32.3)	(7.1, 32.9)	
p-value	0.0033	0.0024	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.33	0.33	
95% CI of the inverse odds ratio	(0.18, 0.59)	(0.18, 0.60)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.42	0.42	
95% CI of the inverse risk ratio	(0.27, 0.67)	(0.27, 0.66)	
p-value	0.0002	0.0002	
p-value of Breslow-Day Test for Homogeneity [5]	0.4361	0.3075	

AMNOG Table P2.14a.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous
Total Subjects with Event of Interest in Subgroup Category: 69

Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=72)	Placebo (N=125)
Responders at Week 52, n (%) [1]			
1 - (1,1)	9 (12.0)	9 (12.5)	11 (8.8)
0.5 - (1,0) or (0,1)	16 (21.3)	12 (16.7)	12 (9.6)
0 - (0,0)	50 (66.7)	51 (70.8)	102 (81.6)
Average Percentage of Responders [2]	22.7	20.8	13.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	8.6 (4.83)	6.7 (4.74)	
95% CI of the difference	(-0.9, 18.1)	(-2.6, 15.9)	
p-value	0.0702	0.1297	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.57	0.60	
95% CI of the inverse odds ratio	(0.34, 0.95)	(0.34, 1.05)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.62	0.67	
95% CI of the inverse risk ratio	(0.41, 0.95)	(0.44, 1.03)	
p-value	0.0282	0.0730	
p-value of Breslow-Day Test for Homogeneity [5]	0.4361	0.3075	

AMNOG Table P2.14a.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous
Total Subjects with Event of Interest in Subgroup Category: 39

Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Responders at Week 52, n (%) [1]			
1 - (1,1)	7 (23.3)	3 (13.6)	7 (11.1)
0.5 - (1,0) or (0,1)	5 (16.7)	9 (40.9)	8 (12.7)
0 - (0,0)	18 (60.0)	10 (45.5)	48 (76.2)
Average Percentage of Responders [2]	31.7	34.1	17.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	12.7 (8.37)	17.9 (8.63)	
95% CI of the difference	(-3.7, 29.1)	(0.9, 34.8)	
p-value	0.1035	0.0444	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.50	0.38	
95% CI of the inverse odds ratio	(0.24, 1.01)	(0.17, 0.84)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.59	0.49	
95% CI of the inverse risk ratio	(0.34, 0.99)	(0.28, 0.86)	
p-value	0.0501	0.0147	
p-value of Breslow-Day Test for Homogeneity [5]	0.4361	0.3075	

AMNOG Table P2.14b.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; SNP = Single Nucleotide Polymorphism.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.14b.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation
Total Subjects with Event of Interest in Subgroup Category: 139

Statistic/Category	MGL-3196 80 mg (N=122)	MGL-3196 100 mg (N=112)	Placebo (N=221)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	27 (22.1)	20 (17.9)	22 (10.0)
0.5 - (1,0) or (0,1)	18 (14.8)	26 (23.2)	26 (11.8)
0 - (0,0)	77 (63.1)	66 (58.9)	173 (78.3)
Average Percentage of Responders [2]	29.5	29.5	15.8
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	13.6 (4.11)	12.9 (4.06)	
95% CI of the difference	(5.6, 21.7)	(4.9, 20.9)	
p-value	0.0009	0.0015	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.45	0.47	
95% CI of the inverse odds ratio	(0.31, 0.66)	(0.32, 0.69)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.54	0.56	
95% CI of the inverse risk ratio	(0.40, 0.72)	(0.42, 0.75)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.8802	0.4090	

AMNOG Table P2.14b.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous
Total Subjects with Event of Interest in Subgroup Category: 23

Statistic/Category	MGL-3196 80 mg (N=25)	MGL-3196 100 mg (N=24)	Placebo (N=61)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	4 (16.0)	2 (8.3)	4 (6.6)
0.5 - (1,0) or (0,1)	4 (16.0)	3 (12.5)	6 (9.8)
0 - (0,0)	17 (68.0)	19 (79.2)	51 (83.6)
Average Percentage of Responders [2]	24.0	14.6	11.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	13.3 (7.71)	4.1 (7.26)	
95% CI of the difference	(-1.8, 28.4)	(-10.2, 18.3)	
p-value	0.0563	0.3880	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.38	0.59	
95% CI of the inverse odds ratio	(0.17, 0.86)	(0.24, 1.44)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.44	0.63	
95% CI of the inverse risk ratio	(0.22, 0.89)	(0.29, 1.36)	
p-value	0.0196	0.2404	
p-value of Breslow-Day Test for Homogeneity [5]	0.8802	0.4090	

Madrigal Pharmaceuticals, Inc. Page 4 of 4
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.14b.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous
Total Subjects with Event of Interest in Subgroup Category: 3

Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	0	1 (50.0)	0
0.5 - (1,0) or (0,1)	2 (40.0)	0	0
0 - (0,0)	3 (60.0)	1 (50.0)	1 (100)
Average Percentage of Responders [2]	20.0	50.0	0.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	NE	NE	
95% CI of the difference	NE	NE	
p-value	>0.9999	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.20	0.33	
95% CI of the inverse odds ratio	(0.00, 28.47)	(0.01, 11.94)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.60	0.67	
95% CI of the inverse risk ratio	(0.08, 4.54)	(0.15, 2.98)	
p-value	0.5637	0.6171	
p-value of Breslow-Day Test for Homogeneity [5]	0.8802	0.4090	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.14b.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; SNP = Single Nucleotide Polymorphism.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.14b.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation
Total Subjects with Event of Interest in Subgroup Category: 132

Statistic/Category	MGL-3196 80 mg (N=122)	MGL-3196 100 mg (N=112)	Placebo (N=221)
Responders at Week 52, n (%) [1]			
1 - (1,1)	25 (20.5)	18 (16.1)	15 (6.8)
0.5 - (1,0) or (0,1)	18 (14.8)	26 (23.2)	30 (13.6)
0 - (0,0)	79 (64.8)	68 (60.7)	176 (79.6)
Average Percentage of Responders [2]	27.9	27.7	13.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	14.2 (3.87)	13.5 (3.80)	
95% CI of the difference	(6.7, 21.8)	(6.1, 20.9)	
p-value	0.0002	0.0004	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.41	0.42	
95% CI of the inverse odds ratio	(0.28, 0.60)	(0.28, 0.63)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.49	0.51	
95% CI of the inverse risk ratio	(0.36, 0.67)	(0.37, 0.69)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.9005	0.4933	

AMNOG Table P2.14b.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous
Total Subjects with Event of Interest in Subgroup Category: 21

Statistic/Category	MGL-3196 80 mg (N=25)	MGL-3196 100 mg (N=24)	Placebo (N=61)
Responders at Week 52, n (%) [1]			
1 - (1,1)	3 (12.0)	2 (8.3)	4 (6.6)
0.5 - (1,0) or (0,1)	5 (20.0)	3 (12.5)	4 (6.6)
0 - (0,0)	17 (68.0)	19 (79.2)	53 (86.9)
Average Percentage of Responders [2]	22.0	14.6	9.8
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	12.8 (7.44)	5.9 (7.17)	
95% CI of the difference	(-1.8, 27.4)	(-8.1, 20.0)	
p-value	0.0527	0.2623	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.37	0.49	
95% CI of the inverse odds ratio	(0.16, 0.85)	(0.19, 1.24)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.42	0.53	
95% CI of the inverse risk ratio	(0.20, 0.88)	(0.24, 1.20)	
p-value	0.0180	0.1264	
p-value of Breslow-Day Test for Homogeneity [5]	0.9005	0.4933	

AMNOG Table P2.14b.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous
Total Subjects with Event of Interest in Subgroup Category: 3

Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Responders at Week 52, n (%) [1]			
1 - (1,1)	0	1 (50.0)	0
0.5 - (1,0) or (0,1)	2 (40.0)	0	0
0 - (0,0)	3 (60.0)	1 (50.0)	1 (100)
Average Percentage of Responders [2]	20.0	50.0	0.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	NE	NE	
95% CI of the difference	NE	NE	
p-value	>0.9999	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.20	0.33	
95% CI of the inverse odds ratio	(0.00, 28.47)	(0.01, 11.94)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.60	0.67	
95% CI of the inverse risk ratio	(0.08, 4.54)	(0.15, 2.98)	
p-value	0.5637	0.6171	
p-value of Breslow-Day Test for Homogeneity [5]	0.9005	0.4933	

AMNOG Table P2.14b.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; SNP = Single Nucleotide Polymorphism.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.14b.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation
Total Subjects with Event of Interest in Subgroup Category: 139

Statistic/Category	MGL-3196 80 mg (N=122)	MGL-3196 100 mg (N=112)	Placebo (N=221)
Responders at Week 52, n (%) [1]			
1 - (1,1)	26 (21.3)	20 (17.9)	21 (9.5)
0.5 - (1,0) or (0,1)	19 (15.6)	26 (23.2)	27 (12.2)
0 - (0,0)	77 (63.1)	66 (58.9)	173 (78.3)
Average Percentage of Responders [2]	29.1	29.5	15.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	13.5 (4.06)	13.1 (4.04)	
95% CI of the difference	(5.5, 21.4)	(5.2, 21.0)	
p-value	0.0009	0.0012	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.45	0.46	
95% CI of the inverse odds ratio	(0.31, 0.66)	(0.31, 0.68)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.54	0.55	
95% CI of the inverse risk ratio	(0.40, 0.72)	(0.41, 0.74)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.8791	0.3982	

AMNOG Table P2.14b.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous
Total Subjects with Event of Interest in Subgroup Category: 23

Statistic/Category	MGL-3196 80 mg (N=25)	MGL-3196 100 mg (N=24)	Placebo (N=61)
Responders at Week 52, n (%) [1]			
1 - (1,1)	4 (16.0)	2 (8.3)	4 (6.6)
0.5 - (1,0) or (0,1)	4 (16.0)	3 (12.5)	6 (9.8)
0 - (0,0)	17 (68.0)	19 (79.2)	51 (83.6)
Average Percentage of Responders [2]	24.0	14.6	11.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	13.3 (7.71)	4.1 (7.26)	
95% CI of the difference	(-1.8, 28.4)	(-10.2, 18.3)	
p-value	0.0563	0.3880	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.38	0.59	
95% CI of the inverse odds ratio	(0.17, 0.86)	(0.24, 1.44)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.44	0.63	
95% CI of the inverse risk ratio	(0.22, 0.89)	(0.29, 1.36)	
p-value	0.0196	0.2404	
p-value of Breslow-Day Test for Homogeneity [5]	0.8791	0.3982	

Madrigal Pharmaceuticals, Inc. Page 4 of 4
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.14b.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous
Total Subjects with Event of Interest in Subgroup Category: 3

Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Responders at Week 52, n (%) [1]			
1 - (1,1)	0	1 (50.0)	0
0.5 - (1,0) or (0,1)	2 (40.0)	0	0
0 - (0,0)	3 (60.0)	1 (50.0)	1 (100)
Average Percentage of Responders [2]	20.0	50.0	0.0
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	NE	NE	
95% CI of the difference	NE	NE	
p-value	>0.9999	NE	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.20	0.33	
95% CI of the inverse odds ratio	(0.00, 28.47)	(0.01, 11.94)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.60	0.67	
95% CI of the inverse risk ratio	(0.08, 4.54)	(0.15, 2.98)	
p-value	0.5637	0.6171	
p-value of Breslow-Day Test for Homogeneity [5]	0.8791	0.3982	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.14c.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; SNP = Single Nucleotide Polymorphism.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.14c.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation
Total Subjects with Event of Interest in Subgroup Category: 43

Statistic/Category	MGL-3196 80 mg (N=51)	MGL-3196 100 mg (N=45)	Placebo (N=87)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	7 (13.7)	8 (17.8)	6 (6.9)
0.5 - (1,0) or (0,1)	6 (11.8)	7 (15.6)	9 (10.3)
0 - (0,0)	38 (74.5)	30 (66.7)	72 (82.8)
Average Percentage of Responders [2]	19.6	25.6	12.1
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	7.1 (5.74)	13.3 (6.22)	
95% CI of the difference	(-4.2, 18.3)	(1.1, 25.5)	
p-value	0.1621	0.0315	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.58	0.42	
95% CI of the inverse odds ratio	(0.30, 1.10)	(0.22, 0.79)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.63	0.48	
95% CI of the inverse risk ratio	(0.36, 1.09)	(0.28, 0.82)	
p-value	0.0953	0.0066	
p-value of Breslow-Day Test for Homogeneity [5]	0.0991	0.3100	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.14c.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous
Total Subjects with Event of Interest in Subgroup Category: 82

Statistic/Category	MGL-3196 80 mg (N=71)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	19 (26.8)	11 (16.9)	12 (8.6)
0.5 - (1,0) or (0,1)	11 (15.5)	15 (23.1)	14 (10.1)
0 - (0,0)	41 (57.7)	39 (60.0)	113 (81.3)
Average Percentage of Responders [2]	34.5	28.5	13.7
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	21.1 (5.37)	15.8 (5.06)	
95% CI of the difference	(10.6, 31.7)	(5.9, 25.8)	
p-value	<0.0001	0.0018	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.30	0.36	
95% CI of the inverse odds ratio	(0.18, 0.48)	(0.21, 0.61)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.39	0.45	
95% CI of the inverse risk ratio	(0.26, 0.57)	(0.30, 0.67)	
p-value	<0.0001	0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.0991	0.3100	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.14c.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous
Total Subjects with Event of Interest in Subgroup Category: 40

Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	5 (16.7)	4 (14.3)	8 (14.0)
0.5 - (1,0) or (0,1)	7 (23.3)	7 (25.0)	9 (15.8)
0 - (0,0)	18 (60.0)	17 (60.7)	40 (70.2)
Average Percentage of Responders [2]	28.3	26.8	21.9
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	6.6 (8.33)	4.4 (8.31)	
95% CI of the difference	(-9.7, 23.0)	(-11.9, 20.7)	
p-value	0.4052	0.5754	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.72	0.78	
95% CI of the inverse odds ratio	(0.36, 1.43)	(0.37, 1.64)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.77	0.84	
95% CI of the inverse risk ratio	(0.46, 1.30)	(0.50, 1.41)	
p-value	0.3318	0.5123	
p-value of Breslow-Day Test for Homogeneity [5]	0.0991	0.3100	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table P2.14c.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; SNP = Single Nucleotide Polymorphism.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.14c.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation
Total Subjects with Event of Interest in Subgroup Category: 39

Statistic/Category	MGL-3196 80 mg (N=51)	MGL-3196 100 mg (N=45)	Placebo (N=87)
Responders at Week 52, n (%) [1]			
1 - (1,1)	5 (9.8)	8 (17.8)	5 (5.7)
0.5 - (1,0) or (0,1)	7 (13.7)	6 (13.3)	8 (9.2)
0 - (0,0)	39 (76.5)	31 (68.9)	74 (85.1)
Average Percentage of Responders [2]	16.7	24.4	10.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	6.0 (5.37)	13.8 (6.07)	
95% CI of the difference	(-4.5, 16.5)	(1.9, 25.7)	
p-value	0.1895	0.0226	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.59	0.38	
95% CI of the inverse odds ratio	(0.29, 1.19)	(0.20, 0.74)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.63	0.44	
95% CI of the inverse risk ratio	(0.34, 1.16)	(0.25, 0.77)	
p-value	0.1377	0.0036	
p-value of Breslow-Day Test for Homogeneity [5]	0.0864	0.2812	

AMNOG Table P2.14c.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous
Total Subjects with Event of Interest in Subgroup Category: 78

Statistic/Category	MGL-3196 80 mg (N=71)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Responders at Week 52, n (%) [1]			
1 - (1,1)	18 (25.4)	10 (15.4)	8 (5.8)
0.5 - (1,0) or (0,1)	11 (15.5)	15 (23.1)	16 (11.5)
0 - (0,0)	42 (59.2)	40 (61.5)	115 (82.7)
Average Percentage of Responders [2]	33.1	26.9	11.5
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	21.8 (5.10)	16.2 (4.72)	
95% CI of the difference	(11.8, 31.8)	(6.9, 25.4)	
p-value	<0.0001	0.0006	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.26	0.32	
95% CI of the inverse odds ratio	(0.16, 0.44)	(0.19, 0.56)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.34	0.40	
95% CI of the inverse risk ratio	(0.23, 0.51)	(0.26, 0.62)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.0864	0.2812	

AMNOG Table P2.14c.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous
Total Subjects with Event of Interest in Subgroup Category: 39

Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Responders at Week 52, n (%) [1]			
1 - (1,1)	5 (16.7)	3 (10.7)	6 (10.5)
0.5 - (1,0) or (0,1)	7 (23.3)	8 (28.6)	10 (17.5)
0 - (0,0)	18 (60.0)	17 (60.7)	41 (71.9)
Average Percentage of Responders [2]	28.3	25.0	19.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	9.6 (8.06)	5.6 (7.80)	
95% CI of the difference	(-6.2, 25.4)	(-9.7, 20.9)	
p-value	0.2218	0.4669	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.60	0.72	
95% CI of the inverse odds ratio	(0.30, 1.23)	(0.33, 1.54)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.67	0.78	
95% CI of the inverse risk ratio	(0.39, 1.16)	(0.44, 1.37)	
p-value	0.1567	0.3957	
p-value of Breslow-Day Test for Homogeneity [5]	0.0864	0.2812	

AMNOG Table P2.14c.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel; SNP = Single Nucleotide Polymorphism.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.14c.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation
Total Subjects with Event of Interest in Subgroup Category: 43

Statistic/Category	MGL-3196 80 mg (N=51)	MGL-3196 100 mg (N=45)	Placebo (N=87)
Responders at Week 52, n (%) [1]			
1 - (1,1)	6 (11.8)	8 (17.8)	6 (6.9)
0.5 - (1,0) or (0,1)	7 (13.7)	7 (15.6)	9 (10.3)
0 - (0,0)	38 (74.5)	30 (66.7)	72 (82.8)
Average Percentage of Responders [2]	18.6	25.6	12.1
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	6.0 (5.64)	13.3 (6.22)	
95% CI of the difference	(-5.0, 17.1)	(1.1, 25.5)	
p-value	0.2110	0.0315	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.62	0.42	
95% CI of the inverse odds ratio	(0.32, 1.20)	(0.22, 0.79)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.67	0.48	
95% CI of the inverse risk ratio	(0.38, 1.17)	(0.28, 0.82)	
p-value	0.1577	0.0066	
p-value of Breslow-Day Test for Homogeneity [5]	0.0712	0.2886	

AMNOG Table P2.14c.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous
Total Subjects with Event of Interest in Subgroup Category: 82

Statistic/Category	MGL-3196 80 mg (N=71)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Responders at Week 52, n (%) [1]			
1 - (1,1)	19 (26.8)	11 (16.9)	11 (7.9)
0.5 - (1,0) or (0,1)	11 (15.5)	15 (23.1)	15 (10.8)
0 - (0,0)	41 (57.7)	39 (60.0)	113 (81.3)
Average Percentage of Responders [2]	34.5	28.5	13.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	21.5 (5.32)	16.3 (4.99)	
95% CI of the difference	(11.1, 32.0)	(6.5, 26.1)	
p-value	<0.0001	0.0011	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.29	0.34	
95% CI of the inverse odds ratio	(0.18, 0.47)	(0.20, 0.59)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.37	0.43	
95% CI of the inverse risk ratio	(0.25, 0.55)	(0.29, 0.66)	
p-value	<0.0001	<0.0001	
p-value of Breslow-Day Test for Homogeneity [5]	0.0712	0.2886	

AMNOG Table P2.14c.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous
Total Subjects with Event of Interest in Subgroup Category: 40

Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Responders at Week 52, n (%) [1]			
1 - (1,1)	5 (16.7)	4 (14.3)	8 (14.0)
0.5 - (1,0) or (0,1)	7 (23.3)	7 (25.0)	9 (15.8)
0 - (0,0)	18 (60.0)	17 (60.7)	40 (70.2)
Average Percentage of Responders [2]	28.3	26.8	21.9
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	6.6 (8.33)	4.4 (8.31)	
95% CI of the difference	(-9.7, 23.0)	(-11.9, 20.7)	
p-value	0.4052	0.5754	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.72	0.78	
95% CI of the inverse odds ratio	(0.36, 1.43)	(0.37, 1.64)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.77	0.84	
95% CI of the inverse risk ratio	(0.46, 1.30)	(0.50, 1.41)	
p-value	0.3318	0.5123	
p-value of Breslow-Day Test for Homogeneity [5]	0.0712	0.2886	

AMNOG Table P2.15.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Statin Status
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.15.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline
Total Subjects with Event of Interest in Subgroup Category: 70

Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=87)	Placebo (N=144)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	12 (16.7)	12 (13.8)	7 (4.9)
0.5 - (1,0) or (0,1)	7 (9.7)	16 (18.4)	16 (11.1)
0 - (0,0)	53 (73.6)	59 (67.8)	121 (84.0)
Average Percentage of Responders [2]	21.5	23.0	10.4
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	11.1 (4.55)	11.8 (4.20)	
95% CI of the difference	(2.2, 20.0)	(3.6, 20.1)	
p-value	0.0128	0.0045	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.43	0.41	
95% CI of the inverse odds ratio	(0.25, 0.74)	(0.24, 0.69)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.49	0.48	
95% CI of the inverse risk ratio	(0.30, 0.77)	(0.31, 0.73)	
p-value	0.0020	0.0006	
p-value of Breslow-Day Test for Homogeneity [5]	0.9227	0.4153	

AMNOG Table P2.15.1
Fibrosis Response (P2): Summary of Results at Week 52;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline
Total Subjects with Event of Interest in Subgroup Category: 107

Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Fibrosis Responders at Week 52, n (%) [1]			
1 - (1,1)	22 (23.9)	11 (17.2)	20 (12.8)
0.5 - (1,0) or (0,1)	19 (20.7)	17 (26.6)	18 (11.5)
0 - (0,0)	51 (55.4)	36 (56.3)	118 (75.6)
Average Percentage of Responders [2]	34.2	30.5	18.6
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	14.9 (5.10)	11.9 (5.42)	
95% CI of the difference	(4.9, 24.9)	(1.3, 22.5)	
p-value	0.0034	0.0282	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.45	0.52	
95% CI of the inverse odds ratio	(0.30, 0.69)	(0.32, 0.83)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.55	0.61	
95% CI of the inverse risk ratio	(0.40, 0.76)	(0.43, 0.86)	
p-value	0.0002	0.0065	
p-value of Breslow-Day Test for Homogeneity [5]	0.9227	0.4153	

AMNOG Table P2.15.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Statin Status
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.15.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline
Total Subjects with Event of Interest in Subgroup Category: 65

Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=87)	Placebo (N=144)
Responders at Week 52, n (%) [1]			
1 - (1,1)	11 (15.3)	11 (12.6)	7 (4.9)
0.5 - (1,0) or (0,1)	7 (9.7)	15 (17.2)	14 (9.7)
0 - (0,0)	54 (75.0)	61 (70.1)	123 (85.4)
Average Percentage of Responders [2]	20.1	21.3	9.7
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	10.4 (4.45)	10.9 (4.12)	
95% CI of the difference	(1.7, 19.1)	(2.8, 19.0)	
p-value	0.0167	0.0076	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.43	0.42	
95% CI of the inverse odds ratio	(0.25, 0.76)	(0.24, 0.71)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.49	0.48	
95% CI of the inverse risk ratio	(0.30, 0.79)	(0.31, 0.75)	
p-value	0.0029	0.0012	
p-value of Breslow-Day Test for Homogeneity [5]	0.7247	0.7564	

AMNOG Table P2.15.1a
1-Stage Fibrosis Response with No Worsening in Any NAS Component (P2): Summary of Results at Week 52;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline
Total Subjects with Event of Interest in Subgroup Category: 102

Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Responders at Week 52, n (%) [1]			
1 - (1,1)	20 (21.7)	10 (15.6)	13 (8.3)
0.5 - (1,0) or (0,1)	20 (21.7)	17 (26.6)	22 (14.1)
0 - (0,0)	52 (56.5)	37 (57.8)	121 (77.6)
Average Percentage of Responders [2]	32.6	28.9	15.4
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	16.5 (4.75)	13.5 (4.98)	
95% CI of the difference	(7.1, 25.8)	(3.7, 23.3)	
p-value	0.0005	0.0067	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.39	0.45	
95% CI of the inverse odds ratio	(0.25, 0.60)	(0.27, 0.73)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.48	0.53	
95% CI of the inverse risk ratio	(0.34, 0.68)	(0.37, 0.78)	
p-value	<0.0001	0.0012	
p-value of Breslow-Day Test for Homogeneity [5]	0.7247	0.7564	

AMNOG Table P2.15.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Statin Status
(Label Population)

Abbreviations: N = number of subjects in Label Population; n = number of subjects in the category; SD = standard deviation; CI = confidence interval; CMH = Cochran-Mantel-Haenszel.
[1] The ordered pair indicates (result according to pathologist A, result according to pathologist B). 1 indicates yes/responder; 0 indicates no/non-responder.
[2] The average percentage of responders is the sum of the responder values (1, 0.5, 0) divided by the number of subjects in the Label Population.
[3] The difference in percentage of responders is estimated by averaging the CMH estimates of the difference in percentage of responders for each pathologist and the 95% CI is constructed using the associated variance for this estimate (See SAP Appendix E for details). The p-value is obtained from the CMH test using table scores to compare the active and placebo treatments.
[4] The inverse odds ratio, inverse risk ratio, 95% CIs, and p-values were obtained using a stratified CMH approach, with pathologist, Baseline type 2 diabetes status and fibrosis stage at baseline as the stratification factors. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[5] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients with no valid biopsy within the Week 52 window are considered non-responders for the Week 52 analysis, as are patients who experience a composite clinical endpoint (e.g., liver transplant, death) prior to their Week 52 biopsy.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table P2.15.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline
Total Subjects with Event of Interest in Subgroup Category: 70

Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=87)	Placebo (N=144)
Responders at Week 52, n (%) [1]			
1 - (1,1)	12 (16.7)	12 (13.8)	7 (4.9)
0.5 - (1,0) or (0,1)	7 (9.7)	16 (18.4)	16 (11.1)
0 - (0,0)	53 (73.6)	59 (67.8)	121 (84.0)
Average Percentage of Responders [2]	21.5	23.0	10.4
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	11.1 (4.55)	11.8 (4.20)	
95% CI of the difference	(2.2, 20.0)	(3.6, 20.1)	
p-value	0.0128	0.0045	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.43	0.41	
95% CI of the inverse odds ratio	(0.25, 0.74)	(0.24, 0.69)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.49	0.48	
95% CI of the inverse risk ratio	(0.30, 0.77)	(0.31, 0.73)	
p-value	0.0020	0.0006	
p-value of Breslow-Day Test for Homogeneity [5]	0.9163	0.4508	

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table P2.15.1b
1-Stage Fibrosis Response with No Worsening in Activity (P2): Summary of Results at Week 52;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline
Total Subjects with Event of Interest in Subgroup Category: 107

Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Responders at Week 52, n (%) [1]			
1 - (1,1)	21 (22.8)	11 (17.2)	19 (12.2)
0.5 - (1,0) or (0,1)	20 (21.7)	17 (26.6)	19 (12.2)
0 - (0,0)	51 (55.4)	36 (56.3)	118 (75.6)
Average Percentage of Responders [2]	33.7	30.5	18.3
Difference in percentage of responders, CMH, MGL-3196 treatment group - placebo (SD) [3]	14.8 (5.03)	12.2 (5.37)	
95% CI of the difference	(4.9, 24.6)	(1.7, 22.8)	
p-value	0.0033	0.0226	
Inverse odds ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.45	0.51	
95% CI of the inverse odds ratio	(0.30, 0.69)	(0.32, 0.82)	
Inverse risk ratio, CMH, MGL-3196 treatment group / Placebo [4]	0.55	0.60	
95% CI of the inverse risk ratio	(0.39, 0.76)	(0.42, 0.85)	
p-value	0.0002	0.0050	
p-value of Breslow-Day Test for Homogeneity [5]	0.9163	0.4508	

Program: t-p01-00-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Events n:				
Total TEAEs	882	867	1636	3385
Total Serious TEAEs	26	25	73	124
Total TEAEs Leading to Discontinuation of Study Drug	16	12	16	44
Total TEAEs Related to Study Drug	110	94	127	331
Total TEAEs >= Grade 3 Severity	30	34	89	153
Patients n (%):				
Any TEAE	116 (93.5)	114 (90.5)	214 (95.5)	444 (93.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	0.44		
95% CI of the odds ratio	(0.26, 1.76)	(0.19, 1.06)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	0.95		
95% CI of the risk ratio	(0.93, 1.03)	(0.89, 1.01)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.99	-5.06		
95% CI of the absolute risk difference	(-7.09, 3.11)	(-10.85, 0.74)		
p-value	0.4227	0.0612		
p-value of Breslow-Day Test for Homogeneity [2]	0.0394	0.0535		
Any Serious TEAE	13 (10.5)	15 (11.9)	31 (13.8)	59 (12.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.84		
95% CI of the odds ratio	(0.37, 1.45)	(0.44, 1.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76	0.86		
95% CI of the risk ratio	(0.41, 1.39)	(0.48, 1.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.36	-1.93		
95% CI of the absolute risk difference	(-10.39, 3.68)	(-9.17, 5.31)		
p-value	0.3671	0.6071		
p-value of Breslow-Day Test for Homogeneity [2]	0.4638	0.2561		

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Any TEAEs >= Grade 3 Severity	18 (14.5)	18 (14.3)	46 (20.5)	82 (17.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.66	0.64		
95% CI of the odds ratio	(0.36, 1.19)	(0.36, 1.17)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	0.70		
95% CI of the risk ratio	(0.43, 1.16)	(0.42, 1.15)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.02	-6.25		
95% CI of the absolute risk difference	(-14.17, 2.13)	(-14.33, 1.83)		
p-value	0.1651	0.1465		
p-value of Breslow-Day Test for Homogeneity [2]	0.7823	0.0044		
Any TEAEs <= Grade 2 Severity	115 (92.7)	114 (90.5)	214 (95.5)	443 (93.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	0.44		
95% CI of the odds ratio	(0.24, 1.51)	(0.19, 1.06)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	0.95		
95% CI of the risk ratio	(0.92, 1.03)	(0.89, 1.01)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.79	-5.06		
95% CI of the absolute risk difference	(-8.10, 2.51)	(-10.85, 0.74)		
p-value	0.2719	0.0612		
p-value of Breslow-Day Test for Homogeneity [2]	0.0728	0.2890		
Any TEAEs leading to Study-Drug Discontinuation	10 (8.1)	11 (8.7)	15 (6.7)	36 (7.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.22	1.33		
95% CI of the odds ratio	(0.53, 2.81)	(0.59, 3.00)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.20	1.30		
95% CI of the risk ratio	(0.56, 2.60)	(0.62, 2.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.37	2.03		
95% CI of the absolute risk difference	(-4.44, 7.17)	(-3.88, 7.95)		
p-value	0.6360	0.4862		
p-value of Breslow-Day Test for Homogeneity [2]	0.4380	0.0823		

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Any TEAEs leading to Study Discontinuation	3 (2.4)	7 (5.6)	8 (3.6)	18 (3.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67	1.59		
95% CI of the odds ratio	(0.17, 2.57)	(0.56, 4.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	1.56		
95% CI of the risk ratio	(0.18, 2.51)	(0.58, 4.19)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.15	1.98		
95% CI of the absolute risk difference	(-4.79, 2.48)	(-2.70, 6.66)		
p-value	0.5563	0.3790		
p-value of Breslow-Day Test for Homogeneity [2]	0.3075	0.2402		
Any Fatal TEAEs	1 (0.8)	1 (0.8)	1 (0.4)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	1.78		
95% CI of the odds ratio	(0.11, 29.24)	(0.11, 28.77)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	1.78		
95% CI of the risk ratio	(0.11, 28.63)	(0.11, 28.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.36	0.35		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.43, 2.13)		
p-value	0.6705	0.6791		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	46 (37.1)	45 (35.7)	64 (28.6)	155 (32.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.47	1.39		
95% CI of the odds ratio	(0.93, 2.35)	(0.87, 2.21)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.30	1.25		
95% CI of the risk ratio	(0.95, 1.77)	(0.91, 1.71)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.53	7.14		
95% CI of the absolute risk difference	(-1.83, 18.88)	(-3.10, 17.39)		
p-value	0.1014	0.1660		
p-value of Breslow-Day Test for Homogeneity [2]	0.1620	0.7700		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.45	-0.45		
95% CI of the absolute risk difference	(-1.32, 0.43)	(-1.32, 0.43)		
p-value	0.4562	0.4526		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (0.8)	2 (1.6)	2 (0.9)	5 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90	1.79		
95% CI of the odds ratio	(0.08, 10.05)	(0.25, 12.87)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90	1.78		
95% CI of the risk ratio	(0.08, 9.86)	(0.25, 12.47)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.09	0.69		
95% CI of the absolute risk difference	(-2.09, 1.91)	(-1.81, 3.20)		
p-value	0.9335	0.5574		
p-value of Breslow-Day Test for Homogeneity [2]	0.2431	0.2446		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (1.6)	6 (4.8)	6 (2.7)	14 (3.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	1.82		
95% CI of the odds ratio	(0.12, 3.00)	(0.57, 5.76)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	1.78		
95% CI of the risk ratio	(0.12, 2.94)	(0.59, 5.40)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.07	2.08		
95% CI of the absolute risk difference	(-4.13, 2.00)	(-2.19, 6.36)		
p-value	0.5252	0.3039		
p-value of Breslow-Day Test for Homogeneity [2]	0.9930	0.3207		

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	4 (3.2)	3 (1.3)	7 (1.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.42		
95% CI of the odds ratio	NE	(0.53, 10.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.37		
95% CI of the risk ratio	NE	(0.54, 10.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.34	1.84		
95% CI of the absolute risk difference	(-2.84, 0.17)	(-1.58, 5.25)		
p-value	0.1956	0.2391		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5212		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	30 (24.2)	23 (18.3)	52 (23.2)	105 (22.2)
Grade 2	68 (54.8)	73 (57.9)	116 (51.8)	257 (54.2)
Grade 3	17 (13.7)	17 (13.5)	38 (17.0)	72 (15.2)
Grade 4	0	0	7 (3.1)	7 (1.5)
Grade 5	1 (0.8)	1 (0.8)	1 (0.4)	3 (0.6)

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	28 (22.6)	24 (19.0)	39 (17.4)	91 (19.2)
Grade 2	17 (13.7)	19 (15.1)	23 (10.3)	59 (12.4)
Grade 3	1 (0.8)	2 (1.6)	1 (0.4)	4 (0.8)
Grade 4	0	0	1 (0.4)	1 (0.2)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (0.8)	1 (0.8)	1 (0.4)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	1.78		
95% CI of the odds ratio	(0.11, 29.24)	(0.11, 28.77)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	1.78		
95% CI of the risk ratio	(0.11, 28.63)	(0.11, 28.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.36	0.35		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.43, 2.13)		
p-value	0.6705	0.6791		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.8)	0	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	0.79		
95% CI of the absolute risk difference	NE	(-0.76, 2.34)		
p-value	NE	0.1818		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (0.8)	0	1 (0.4)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	NE		
95% CI of the odds ratio	(0.11, 29.24)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	NE		
95% CI of the risk ratio	(0.11, 28.63)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.36	-0.45		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.32, 0.43)		
p-value	0.6705	0.4526		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (0.8)	1 (0.8)	1 (0.4)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	1.78		
95% CI of the odds ratio	(0.11, 29.24)	(0.11, 28.77)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	1.78		
95% CI of the risk ratio	(0.11, 28.63)	(0.11, 28.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.36	0.35		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.43, 2.13)		
p-value	0.6705	0.6791		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	1 (0.8)	4 (1.8)	5 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.44		
95% CI of the odds ratio	NE	(0.05, 3.98)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.44		
95% CI of the risk ratio	NE	(0.05, 3.93)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.79	-0.99		
95% CI of the absolute risk difference	(-3.52, -0.05)	(-3.32, 1.33)		
p-value	0.1345	0.4528		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.8)	3 (1.3)	4 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.59		
95% CI of the odds ratio	NE	(0.06, 5.73)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.59		
95% CI of the risk ratio	NE	(0.06, 5.64)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.34	-0.55		
95% CI of the absolute risk difference	(-2.84, 0.17)	(-2.71, 1.61)		
p-value	0.1956	0.6448		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.45	-0.45		
95% CI of the absolute risk difference	(-1.32, 0.43)	(-1.32, 0.43)		
p-value	0.4562	0.4526		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (0.8)	3 (1.3)	4 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.59		
95% CI of the odds ratio	NE	(0.06, 5.73)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.59		
95% CI of the risk ratio	NE	(0.06, 5.64)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.34	-0.55		
95% CI of the absolute risk difference	(-2.84, 0.17)	(-2.71, 1.61)		
p-value	0.1956	0.6448		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Events n:				
Total TEAEs	317	155	521	993
Total Serious TEAEs	3	7	23	33
Total TEAEs Leading to Discontinuation of Study Drug	2	8	9	19
Total TEAEs Related to Study Drug	45	32	32	109
Total TEAEs >= Grade 3 Severity	4	11	17	32
Patients n (%):				
Any TEAE	42 (97.7)	24 (96.0)	69 (87.3)	135 (91.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	6.09	3.48		
95% CI of the odds ratio	(0.75, 49.27)	(0.42, 28.62)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.12	1.10		
95% CI of the risk ratio	(1.02, 1.23)	(0.98, 1.23)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	10.33	8.66		
95% CI of the absolute risk difference	(1.73, 18.94)	(-1.96, 19.28)		
p-value	0.0570	0.2199		
p-value of Breslow-Day Test for Homogeneity [2]	0.0394	0.0535		
Any Serious TEAE	3 (7.0)	6 (24.0)	12 (15.2)	21 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42	1.76		
95% CI of the odds ratio	(0.11, 1.57)	(0.58, 5.32)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.46	1.58		
95% CI of the risk ratio	(0.14, 1.54)	(0.66, 3.77)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.21	8.81		
95% CI of the absolute risk difference	(-19.20, 2.77)	(-9.71, 27.33)		
p-value	0.1869	0.3102		
p-value of Breslow-Day Test for Homogeneity [2]	0.4638	0.2561		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 13 of 21
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Any TEAEs >= Grade 3 Severity	4 (9.3)	8 (32.0)	9 (11.4)	21 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	3.66		
95% CI of the odds ratio	(0.23, 2.76)	(1.23, 10.89)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82	2.81		
95% CI of the risk ratio	(0.27, 2.50)	(1.21, 6.50)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.09	20.61		
95% CI of the absolute risk difference	(-13.25, 9.07)	(1.03, 40.19)		
p-value	0.7208	0.0152		
p-value of Breslow-Day Test for Homogeneity [2]	0.7823	0.0044		
Any TEAEs <= Grade 2 Severity	41 (95.3)	22 (88.0)	69 (87.3)	132 (89.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.97	1.06		
95% CI of the odds ratio	(0.62, 14.23)	(0.27, 4.21)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.09	1.01		
95% CI of the risk ratio	(0.98, 1.21)	(0.85, 1.19)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.01	0.66		
95% CI of the absolute risk difference	(-1.66, 17.67)	(-14.04, 15.36)		
p-value	0.1560	0.9309		
p-value of Breslow-Day Test for Homogeneity [2]	0.0728	0.2890		
Any TEAEs leading to Study-Drug Discontinuation	2 (4.7)	7 (28.0)	6 (7.6)	15 (10.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	4.73		
95% CI of the odds ratio	(0.11, 3.08)	(1.42, 15.81)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.61	3.69		
95% CI of the risk ratio	(0.13, 2.90)	(1.37, 9.95)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.94	20.41		
95% CI of the absolute risk difference	(-11.53, 5.64)	(1.86, 38.95)		
p-value	0.5303	0.0072		
p-value of Breslow-Day Test for Homogeneity [2]	0.4380	0.0823		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Any TEAEs leading to Study Discontinuation	0	4 (16.0)	3 (3.8)	7 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.83		
95% CI of the odds ratio	NE	(1.00, 23.26)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.21		
95% CI of the risk ratio	NE	(1.01, 17.57)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.80	12.20		
95% CI of the absolute risk difference	(-8.01, 0.42)	(-2.77, 27.18)		
p-value	0.1957	0.0338		
p-value of Breslow-Day Test for Homogeneity [2]	0.3075	0.2402		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	23 (53.5)	10 (40.0)	23 (29.1)	56 (38.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.80	1.62		
95% CI of the odds ratio	(1.29, 6.05)	(0.64, 4.14)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.84	1.37		
95% CI of the risk ratio	(1.18, 2.86)	(0.76, 2.48)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	24.37	10.89		
95% CI of the absolute risk difference	(6.41, 42.34)	(-10.77, 32.55)		
p-value	0.0080	0.3081		
p-value of Breslow-Day Test for Homogeneity [2]	0.1620	0.7700		

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (2.3)	1 (4.0)	0	2 (1.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.33	4.00		
95% CI of the absolute risk difference	(-2.18, 6.83)	(-3.68, 11.68)		
p-value	0.1735	0.0741		
p-value of Breslow-Day Test for Homogeneity [2]	0.2431	0.2446		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	1 (2.3)	4 (16.0)	3 (3.8)	8 (5.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	4.83		
95% CI of the odds ratio	(0.06, 5.98)	(1.00, 23.26)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.61	4.21		
95% CI of the risk ratio	(0.07, 5.71)	(1.01, 17.57)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.47	12.20		
95% CI of the absolute risk difference	(-7.64, 4.70)	(-2.77, 27.18)		
p-value	0.6627	0.0338		
p-value of Breslow-Day Test for Homogeneity [2]	0.9930	0.3207		

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	3 (12.0)	2 (2.5)	5 (3.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.25		
95% CI of the odds ratio	NE	(0.82, 33.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.74		
95% CI of the risk ratio	NE	(0.84, 26.78)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.53	9.47		
95% CI of the absolute risk difference	(-6.00, 0.93)	(-3.73, 22.67)		
p-value	0.2928	0.0538		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5212		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	9 (20.9)	3 (12.0)	17 (21.5)	29 (19.7)
Grade 2	29 (67.4)	13 (52.0)	43 (54.4)	85 (57.8)
Grade 3	4 (9.3)	8 (32.0)	9 (11.4)	21 (14.3)
Grade 4	0	0	0	0
Grade 5	0	0	0	0

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	13 (30.2)	5 (20.0)	14 (17.7)	32 (21.8)
Grade 2	9 (20.9)	4 (16.0)	9 (11.4)	22 (15.0)
Grade 3	1 (2.3)	1 (4.0)	0	2 (1.4)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Events n:				
Total TEAEs	873	863	1618	3354
Total Serious TEAEs	26	25	73	124
Total TEAEs Leading to Discontinuation of Study Drug	13	11	12	36
Total TEAEs Related to Study Drug	110	94	126	330
Total TEAEs >= Grade 3 Severity	29	34	86	149
Patients n (%):				
Any TEAE	115 (92.7)	114 (90.5)	212 (94.6)	441 (93.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.72	0.54		
95% CI of the odds ratio	(0.30, 1.77)	(0.23, 1.24)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	0.96		
95% CI of the risk ratio	(0.92, 1.04)	(0.90, 1.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.90	-4.17		
95% CI of the absolute risk difference	(-7.34, 3.53)	(-10.08, 1.75)		
p-value	0.4757	0.1387		
p-value of Breslow-Day Test for Homogeneity [2]	0.0432	0.0810		
Any Serious TEAE	13 (10.5)	15 (11.9)	31 (13.8)	59 (12.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.84		
95% CI of the odds ratio	(0.37, 1.45)	(0.44, 1.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76	0.86		
95% CI of the risk ratio	(0.41, 1.39)	(0.48, 1.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.36	-1.93		
95% CI of the absolute risk difference	(-10.39, 3.68)	(-9.17, 5.31)		
p-value	0.3671	0.6071		
p-value of Breslow-Day Test for Homogeneity [2]	0.4638	0.2561		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Any TEAEs >= Grade 3 Severity	17 (13.7)	18 (14.3)	43 (19.2)	78 (16.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67	0.70		
95% CI of the odds ratio	(0.36, 1.23)	(0.39, 1.28)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	0.74		
95% CI of the risk ratio	(0.43, 1.20)	(0.45, 1.23)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.49	-4.91		
95% CI of the absolute risk difference	(-13.44, 2.47)	(-12.91, 3.09)		
p-value	0.1944	0.2451		
p-value of Breslow-Day Test for Homogeneity [2]	0.5083	0.0198		
Any TEAEs <= Grade 2 Severity	114 (91.9)	114 (90.5)	212 (94.6)	440 (92.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.65	0.54		
95% CI of the odds ratio	(0.27, 1.54)	(0.23, 1.24)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	0.96		
95% CI of the risk ratio	(0.91, 1.03)	(0.90, 1.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.71	-4.17		
95% CI of the absolute risk difference	(-8.33, 2.92)	(-10.08, 1.75)		
p-value	0.3203	0.1387		
p-value of Breslow-Day Test for Homogeneity [2]	0.0829	0.4037		
Any TEAEs leading to Study-Drug Discontinuation	7 (5.6)	10 (7.9)	11 (4.9)	28 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.16	1.67		
95% CI of the odds ratio	(0.44, 3.07)	(0.69, 4.05)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.15	1.62		
95% CI of the risk ratio	(0.46, 2.89)	(0.71, 3.70)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.73	3.03		
95% CI of the absolute risk difference	(-4.22, 5.69)	(-2.48, 8.53)		
p-value	0.7670	0.2526		
p-value of Breslow-Day Test for Homogeneity [2]	0.6324	0.1918		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Any TEAEs leading to Study Discontinuation	3 (2.4)	7 (5.6)	8 (3.6)	18 (3.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67	1.59		
95% CI of the odds ratio	(0.17, 2.57)	(0.56, 4.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	1.56		
95% CI of the risk ratio	(0.18, 2.51)	(0.58, 4.19)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.15	1.98		
95% CI of the absolute risk difference	(-4.79, 2.48)	(-2.70, 6.66)		
p-value	0.5563	0.3790		
p-value of Breslow-Day Test for Homogeneity [2]	0.3075	0.2402		
Any Fatal TEAEs	1 (0.8)	1 (0.8)	1 (0.4)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	1.78		
95% CI of the odds ratio	(0.11, 29.24)	(0.11, 28.77)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	1.78		
95% CI of the risk ratio	(0.11, 28.63)	(0.11, 28.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.36	0.35		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.43, 2.13)		
p-value	0.6705	0.6791		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	46 (37.1)	45 (35.7)	63 (28.1)	154 (32.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.51	1.42		
95% CI of the odds ratio	(0.95, 2.40)	(0.89, 2.26)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.32	1.27		
95% CI of the risk ratio	(0.97, 1.80)	(0.93, 1.74)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.97	7.59		
95% CI of the absolute risk difference	(-1.37, 19.31)	(-2.64, 17.82)		
p-value	0.0840	0.1401		
p-value of Breslow-Day Test for Homogeneity [2]	0.1771	0.8018		

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.45	-0.45		
95% CI of the absolute risk difference	(-1.32, 0.43)	(-1.32, 0.43)		
p-value	0.4562	0.4526		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (0.8)	2 (1.6)	2 (0.9)	5 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90	1.79		
95% CI of the odds ratio	(0.08, 10.05)	(0.25, 12.87)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90	1.78		
95% CI of the risk ratio	(0.08, 9.86)	(0.25, 12.47)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.09	0.69		
95% CI of the absolute risk difference	(-2.09, 1.91)	(-1.81, 3.20)		
p-value	0.9335	0.5574		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2446		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (1.6)	6 (4.8)	6 (2.7)	14 (3.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	1.82		
95% CI of the odds ratio	(0.12, 3.00)	(0.57, 5.76)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	1.78		
95% CI of the risk ratio	(0.12, 2.94)	(0.59, 5.40)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.07	2.08		
95% CI of the absolute risk difference	(-4.13, 2.00)	(-2.19, 6.36)		
p-value	0.5252	0.3039		
p-value of Breslow-Day Test for Homogeneity [2]	0.9930	0.3207		

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	4 (3.2)	3 (1.3)	7 (1.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.42		
95% CI of the odds ratio	NE	(0.53, 10.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.37		
95% CI of the risk ratio	NE	(0.54, 10.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.34	1.84		
95% CI of the absolute risk difference	(-2.84, 0.17)	(-1.58, 5.25)		
p-value	0.1956	0.2391		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5212		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	29 (23.4)	23 (18.3)	53 (23.7)	105 (22.2)
Grade 2	69 (55.6)	73 (57.9)	116 (51.8)	258 (54.4)
Grade 3	16 (12.9)	17 (13.5)	35 (15.6)	68 (14.3)
Grade 4	0	0	7 (3.1)	7 (1.5)
Grade 5	1 (0.8)	1 (0.8)	1 (0.4)	3 (0.6)

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	28 (22.6)	24 (19.0)	38 (17.0)	90 (19.0)
Grade 2	17 (13.7)	19 (15.1)	23 (10.3)	59 (12.4)
Grade 3	1 (0.8)	2 (1.6)	1 (0.4)	4 (0.8)
Grade 4	0	0	1 (0.4)	1 (0.2)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (0.8)	1 (0.8)	1 (0.4)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	1.78		
95% CI of the odds ratio	(0.11, 29.24)	(0.11, 28.77)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	1.78		
95% CI of the risk ratio	(0.11, 28.63)	(0.11, 28.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.36	0.35		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.43, 2.13)		
p-value	0.6705	0.6791		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.8)	0	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	0.79		
95% CI of the absolute risk difference	NE	(-0.76, 2.34)		
p-value	NE	0.1818		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	1 (0.8)	0	1 (0.4)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	NE		
95% CI of the odds ratio	(0.11, 29.24)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	NE		
95% CI of the risk ratio	(0.11, 28.63)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.36	-0.45		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.32, 0.43)		
p-value	0.6705	0.4526		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE - Adjudicated Event	1 (0.8)	1 (0.8)	1 (0.4)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	1.78		
95% CI of the odds ratio	(0.11, 29.24)	(0.11, 28.77)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	1.78		
95% CI of the risk ratio	(0.11, 28.63)	(0.11, 28.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.36	0.35		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.43, 2.13)		
p-value	0.6705	0.6791		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE - Adjudicated Event	0	1 (0.8)	4 (1.8)	5 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.44		
95% CI of the odds ratio	NE	(0.05, 3.98)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.44		
95% CI of the risk ratio	NE	(0.05, 3.93)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.79	-0.99		
95% CI of the absolute risk difference	(-3.52, -0.05)	(-3.32, 1.33)		
p-value	0.1345	0.4528		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.8)	3 (1.3)	4 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.59		
95% CI of the odds ratio	NE	(0.06, 5.73)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.59		
95% CI of the risk ratio	NE	(0.06, 5.64)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.34	-0.55		
95% CI of the absolute risk difference	(-2.84, 0.17)	(-2.71, 1.61)		
p-value	0.1956	0.6448		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.45	-0.45		
95% CI of the absolute risk difference	(-1.32, 0.43)	(-1.32, 0.43)		
p-value	0.4562	0.4526		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (0.8)	3 (1.3)	4 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.59		
95% CI of the odds ratio	NE	(0.06, 5.73)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.59		
95% CI of the risk ratio	NE	(0.06, 5.64)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.34	-0.55		
95% CI of the absolute risk difference	(-2.84, 0.17)	(-2.71, 1.61)		
p-value	0.1956	0.6448		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: < 65 years

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=126) n (%)	Placebo (N=224) n (%)	Overall (N=474) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Events n:				
Total TEAEs	313	151	515	979
Total Serious TEAEs	3	7	23	33
Total TEAEs Leading to Discontinuation of Study Drug	2	7	8	17
Total TEAEs Related to Study Drug	44	32	32	108
Total TEAEs >= Grade 3 Severity	2	10	17	29
Patients n (%):				
Any TEAE	42 (97.7)	24 (96.0)	69 (87.3)	135 (91.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	6.09	3.48		
95% CI of the odds ratio	(0.75, 49.27)	(0.42, 28.62)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.12	1.10		
95% CI of the risk ratio	(1.02, 1.23)	(0.98, 1.23)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	10.33	8.66		
95% CI of the absolute risk difference	(1.73, 18.94)	(-1.96, 19.28)		
p-value	0.0570	0.2199		
p-value of Breslow-Day Test for Homogeneity [2]	0.0432	0.0810		
Any Serious TEAE	3 (7.0)	6 (24.0)	12 (15.2)	21 (14.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42	1.76		
95% CI of the odds ratio	(0.11, 1.57)	(0.58, 5.32)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.46	1.58		
95% CI of the risk ratio	(0.14, 1.54)	(0.66, 3.77)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.21	8.81		
95% CI of the absolute risk difference	(-19.20, 2.77)	(-9.71, 27.33)		
p-value	0.1869	0.3102		
p-value of Breslow-Day Test for Homogeneity [2]	0.4638	0.2561		

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Any TEAEs >= Grade 3 Severity	2 (4.7)	7 (28.0)	9 (11.4)	18 (12.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38	3.02		
95% CI of the odds ratio	(0.08, 1.84)	(0.99, 9.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.41	2.46		
95% CI of the risk ratio	(0.09, 1.81)	(1.02, 5.92)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.74	16.61		
95% CI of the absolute risk difference	(-16.16, 2.68)	(-2.34, 35.55)		
p-value	0.2142	0.0449		
p-value of Breslow-Day Test for Homogeneity [2]	0.5083	0.0198		
Any TEAEs <= Grade 2 Severity	41 (95.3)	22 (88.0)	69 (87.3)	132 (89.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.97	1.06		
95% CI of the odds ratio	(0.62, 14.23)	(0.27, 4.21)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.09	1.01		
95% CI of the risk ratio	(0.98, 1.21)	(0.85, 1.19)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.01	0.66		
95% CI of the absolute risk difference	(-1.66, 17.67)	(-14.04, 15.36)		
p-value	0.1560	0.9309		
p-value of Breslow-Day Test for Homogeneity [2]	0.0829	0.4037		
Any TEAEs leading to Study-Drug Discontinuation	2 (4.7)	6 (24.0)	5 (6.3)	13 (8.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.72	4.67		
95% CI of the odds ratio	(0.13, 3.89)	(1.29, 16.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	3.79		
95% CI of the risk ratio	(0.15, 3.63)	(1.26, 11.37)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.68	17.67		
95% CI of the absolute risk difference	(-9.95, 6.60)	(0.09, 35.25)		
p-value	0.7034	0.0123		
p-value of Breslow-Day Test for Homogeneity [2]	0.6324	0.1918		

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Any TEAEs leading to Study Discontinuation	0	4 (16.0)	3 (3.8)	7 (4.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.83		
95% CI of the odds ratio	NE	(1.00, 23.26)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.21		
95% CI of the risk ratio	NE	(1.01, 17.57)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.80	12.20		
95% CI of the absolute risk difference	(-8.01, 0.42)	(-2.77, 27.18)		
p-value	0.1957	0.0338		
p-value of Breslow-Day Test for Homogeneity [2]	0.3075	0.2402		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	23 (53.5)	10 (40.0)	23 (29.1)	56 (38.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.80	1.62		
95% CI of the odds ratio	(1.29, 6.05)	(0.64, 4.14)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.84	1.37		
95% CI of the risk ratio	(1.18, 2.86)	(0.76, 2.48)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	24.37	10.89		
95% CI of the absolute risk difference	(6.41, 42.34)	(-10.77, 32.55)		
p-value	0.0080	0.3081		
p-value of Breslow-Day Test for Homogeneity [2]	0.1771	0.8018		

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	1 (4.0)	0	1 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	4.00		
95% CI of the absolute risk difference	NE	(-3.68, 11.68)		
p-value	NE	0.0741		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2446		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	1 (2.3)	4 (16.0)	3 (3.8)	8 (5.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	4.83		
95% CI of the odds ratio	(0.06, 5.98)	(1.00, 23.26)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.61	4.21		
95% CI of the risk ratio	(0.07, 5.71)	(1.01, 17.57)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.47	12.20		
95% CI of the absolute risk difference	(-7.64, 4.70)	(-2.77, 27.18)		
p-value	0.6627	0.0338		
p-value of Breslow-Day Test for Homogeneity [2]	0.9930	0.3207		

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	3 (12.0)	2 (2.5)	5 (3.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.25		
95% CI of the odds ratio	NE	(0.82, 33.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.74		
95% CI of the risk ratio	NE	(0.84, 26.78)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.53	9.47		
95% CI of the absolute risk difference	(-6.00, 0.93)	(-3.73, 22.67)		
p-value	0.2928	0.0538		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5212		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	9 (20.9)	4 (16.0)	17 (21.5)	30 (20.4)
Grade 2	31 (72.1)	13 (52.0)	43 (54.4)	87 (59.2)
Grade 3	2 (4.7)	7 (28.0)	9 (11.4)	18 (12.2)
Grade 4	0	0	0	0
Grade 5	0	0	0	0

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	13 (30.2)	5 (20.0)	14 (17.7)	32 (21.8)
Grade 2	10 (23.3)	4 (16.0)	9 (11.4)	23 (15.6)
Grade 3	0	1 (4.0)	0	1 (0.7)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Age
(Label Population)

Age: >= 65 years

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=79) n (%)	Overall (N=147) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.2.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Age
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.

AMNOG Table S1.2.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Age
(Label Population)

Age: < 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=126) Patients n (%)	 Events n	Placebo (N=224) Patients n (%)	 Events n	Overall (N=474) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	31 (25.0)	51	41 (32.5)	59	38 (17.0)	48	110 (23.2)	158
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.63		2.36					
95% CI of the odds ratio	(0.95, 2.79)		(1.42, 3.93)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.47		1.92					
95% CI of the risk ratio	(0.97, 2.24)		(1.31, 2.81)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.04		15.58					
95% CI of the absolute risk difference	(-1.03, 17.10)		(6.03, 25.12)					
p-value	0.0718		0.0008					
p-value of Breslow-Day Test for Homogeneity [2]	0.6307		0.3377					
Nausea	34 (27.4)	42	17 (13.5)	19	31 (13.8)	37	82 (17.3)	98
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.35		0.97					
95% CI of the odds ratio	(1.36, 4.07)		(0.51, 1.83)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.98		0.97					
95% CI of the risk ratio	(1.28, 3.06)		(0.56, 1.69)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.58		-0.35					
95% CI of the absolute risk difference	(4.52, 22.64)		(-7.83, 7.14)					
p-value	0.0019		0.9278					
p-value of Breslow-Day Test for Homogeneity [2]	0.9985		0.4489					

AMNOG Table S1.2.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Age
(Label Population)

Age: < 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=126) Patients n (%)	 Events n	Placebo (N=224) Patients n (%)	 Events n	Overall (N=474) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	19 (15.3)	21	7 (5.6)	7	13 (5.8)	14	39 (8.2)	42
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.94		0.95					
95% CI of the odds ratio	(1.40, 6.18)		(0.37, 2.46)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.64		0.96					
95% CI of the risk ratio	(1.35, 5.16)		(0.39, 2.34)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.52		-0.25					
95% CI of the absolute risk difference	(2.48, 16.56)		(-5.29, 4.79)					
p-value	0.0032		0.9236					
p-value of Breslow-Day Test for Homogeneity [2]	0.0855		0.5975					
Abdominal discomfort	1 (0.8)	1	2 (1.6)	2	9 (4.0)	10	12 (2.5)	13
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.19		0.39					
95% CI of the odds ratio	(0.02, 1.55)		(0.08, 1.81)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.20		0.40					
95% CI of the risk ratio	(0.03, 1.57)		(0.09, 1.80)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.21		-2.43					
95% CI of the absolute risk difference	(-6.23, -0.20)		(-5.80, 0.94)					
p-value	0.0859		0.2109					
p-value of Breslow-Day Test for Homogeneity [2]	0.5122		0.6073					

AMNOG Table S1.2.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Age
(Label Population)

Age: < 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=126) Patients n (%)	 Events n	Placebo (N=224) Patients n (%)	 Events n	Overall (N=474) Patients n (%)	 Events n
General disorders and administration site conditions	26 (21.0)	39	25 (19.8)	35	61 (27.2)	73	112 (23.6)	147
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71		0.66					
95% CI of the odds ratio	(0.42, 1.20)		(0.39, 1.12)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.77		0.73					
95% CI of the risk ratio	(0.51, 1.15)		(0.48, 1.10)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.26		-7.39					
95% CI of the absolute risk difference	(-15.50, 2.97)		(-16.47, 1.69)					
p-value	0.1962		0.1232					
p-value of Breslow-Day Test for Homogeneity [2]	0.7648		0.5247					
Skin and subcutaneous tissue disorders								
Pruritus	15 (12.1)	19	5 (4.0)	7	15 (6.7)	16	35 (7.4)	42
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.92		0.58					
95% CI of the odds ratio	(0.90, 4.07)		(0.20, 1.62)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81		0.59					
95% CI of the risk ratio	(0.91, 3.57)		(0.22, 1.59)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.40		-2.73					
95% CI of the absolute risk difference	(-1.21, 12.01)		(-7.45, 2.00)					
p-value	0.0856		0.2912					
p-value of Breslow-Day Test for Homogeneity [2]	0.8761		0.4016					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.2.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Age
(Label Population)

Age: < 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=126) Patients n (%)	 Events n	Placebo (N=224) Patients n (%)	 Events n	Overall (N=474) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	8 (6.5)	8	15 (11.9)	19	10 (4.5)	12	33 (7.0)	39
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.48		2.89					
95% CI of the odds ratio	(0.57, 3.84)		(1.26, 6.65)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.45		2.67					
95% CI of the risk ratio	(0.59, 3.57)		(1.23, 5.76)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.99		7.44					
95% CI of the absolute risk difference	(-3.11, 7.09)		(1.17, 13.71)					
p-value	0.4227		0.0095					
p-value of Breslow-Day Test for Homogeneity [2]	0.2207		0.6514					
Renal and urinary disorders	3 (2.4)	4	18 (14.3)	21	20 (8.9)	25	41 (8.6)	50
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.25		1.70					
95% CI of the odds ratio	(0.07, 0.87)		(0.86, 3.35)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.27		1.60					
95% CI of the risk ratio	(0.08, 0.89)		(0.88, 2.91)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.51		5.36					
95% CI of the absolute risk difference	(-11.12, -1.90)		(-1.80, 12.52)					
p-value	0.0192		0.1220					
p-value of Breslow-Day Test for Homogeneity [2]	0.5048		0.4744					

AMNOG Table S1.2.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Age
(Label Population)

Age: < 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=126) Patients n (%)	 Events n	Placebo (N=224) Patients n (%)	 Events n	Overall (N=474) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	3 (2.4)	3	4 (3.2)	4	15 (6.7)	18	22 (4.6)	25
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.35		0.46					
95% CI of the odds ratio	(0.10, 1.22)		(0.15, 1.41)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		0.47					
95% CI of the risk ratio	(0.11, 1.22)		(0.16, 1.40)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.28		-3.52					
95% CI of the absolute risk difference	(-8.52, -0.03)		(-8.00, 0.96)					
p-value	0.0845		0.1628					
p-value of Breslow-Day Test for Homogeneity [2]	0.3481		0.2367					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.2.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Age
(Label Population)

Age: < 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=126) Patients n (%)	 Events n	Placebo (N=224) Patients n (%)	 Events n	Overall (N=474) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	2 (1.6)	2	0	0	9 (4.0)	13	11 (2.3)	15
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		NE					
95% CI of the odds ratio	(0.08, 1.84)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40		NE					
95% CI of the risk ratio	(0.09, 1.83)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.40		-4.02					
95% CI of the absolute risk difference	(-5.80, 0.99)		(-6.59, -1.45)					
p-value	0.2194		0.0226					
p-value of Breslow-Day Test for Homogeneity [2]	0.6452		NE					

AMNOG Table S1.2.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Age
(Label Population)

Age: >= 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=43) Patients n (%)	 Events n	MGL-3196 100 mg (N=25) Patients n (%)	 Events n	Placebo (N=79) Patients n (%)	 Events n	Overall (N=147) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	11 (25.6)	22	10 (40.0)	21	11 (13.9)	13	32 (21.8)	56
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.13		4.12					
95% CI of the odds ratio	(0.83, 5.42)		(1.48, 11.46)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.84		2.87					
95% CI of the risk ratio	(0.87, 3.88)		(1.39, 5.95)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.66		26.08					
95% CI of the absolute risk difference	(-3.45, 26.77)		(5.41, 46.74)					
p-value	0.1096		0.0046					
p-value of Breslow-Day Test for Homogeneity [2]	0.6307		0.3377					
Nausea	9 (20.9)	9	4 (16.0)	7	8 (10.1)	9	21 (14.3)	25
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.35		1.69					
95% CI of the odds ratio	(0.83, 6.62)		(0.46, 6.17)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.07		1.58					
95% CI of the risk ratio	(0.86, 4.97)		(0.52, 4.81)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	10.80		5.87					
95% CI of the absolute risk difference	(-3.06, 24.66)		(-9.96, 21.71)					
p-value	0.0997		0.4231					
p-value of Breslow-Day Test for Homogeneity [2]	0.9985		0.4489					

AMNOG Table S1.2.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Age
(Label Population)

Age: >= 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=43) Patients n (%)	 Events n	MGL-3196 100 mg (N=25) Patients n (%)	 Events n	Placebo (N=79) Patients n (%)	 Events n	Overall (N=147) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	1 (2.3)	1	2 (8.0)	2	4 (5.1)	4	7 (4.8)	7
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45		1.63					
95% CI of the odds ratio	(0.05, 4.13)		(0.28, 9.48)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.46		1.58					
95% CI of the risk ratio	(0.05, 3.98)		(0.31, 8.12)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.74		2.94					
95% CI of the absolute risk difference	(-9.35, 3.87)		(-8.75, 14.62)					
p-value	0.4662		0.5831					
p-value of Breslow-Day Test for Homogeneity [2]	0.0855		0.5975					
Abdominal discomfort	0	0	1 (4.0)	2	4 (5.1)	4	5 (3.4)	6
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.19		0.78					
95% CI of the odds ratio	(0.01, 3.67)		(0.08, 7.33)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.20		0.79					
95% CI of the risk ratio	(0.01, 3.67)		(0.09, 6.75)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.49		-1.06					
95% CI of the absolute risk difference	(-10.43, 1.45)		(-10.14, 8.01)					
p-value	0.2241		0.8285					
p-value of Breslow-Day Test for Homogeneity [2]	0.5122		0.6073					

AMNOG Table S1.2.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Age
(Label Population)

Age: >= 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=43) Patients n (%)	 Events n	MGL-3196 100 mg (N=25) Patients n (%)	 Events n	Placebo (N=79) Patients n (%)	 Events n	Overall (N=147) Patients n (%)	 Events n
General disorders and administration site conditions	9 (20.9)	13	4 (16.0)	4	24 (30.4)	31	37 (25.2)	48
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.61		0.44					
95% CI of the odds ratio	(0.25, 1.46)		(0.14, 1.41)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69		0.53					
95% CI of the risk ratio	(0.35, 1.35)		(0.20, 1.37)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.45		-14.38					
95% CI of the absolute risk difference	(-25.28, 6.38)		(-31.97, 3.21)					
p-value	0.2617		0.1577					
p-value of Breslow-Day Test for Homogeneity [2]	0.7648		0.5247					
Skin and subcutaneous tissue disorders								
Pruritus	7 (16.3)	9	3 (12.0)	3	8 (10.1)	10	18 (12.2)	22
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.73		1.21					
95% CI of the odds ratio	(0.58, 5.14)		(0.30, 4.96)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.61		1.19					
95% CI of the risk ratio	(0.63, 4.13)		(0.34, 4.13)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.15		1.87					
95% CI of the absolute risk difference	(-6.73, 19.04)		(-12.50, 16.24)					
p-value	0.3228		0.7907					
p-value of Breslow-Day Test for Homogeneity [2]	0.8761		0.4016					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.2.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Age
(Label Population)

Age: >= 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=43) Patients n (%)	 Events n	MGL-3196 100 mg (N=25) Patients n (%)	 Events n	Placebo (N=79) Patients n (%)	 Events n	Overall (N=147) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	0	0	1 (4.0)	1	2 (2.5)	2	3 (2.0)	3
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		1.60					
95% CI of the odds ratio	NE		(0.14, 18.47)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		1.58					
95% CI of the risk ratio	NE		(0.15, 16.70)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.53		1.47					
95% CI of the absolute risk difference	(-6.00, 0.93)		(-6.96, 9.89)					
p-value	0.2928		0.7022					
p-value of Breslow-Day Test for Homogeneity [2]	0.2207		0.6514					
Musculoskeletal and connective tissue disorders								
Pain in extremity	4 (9.3)	5	0	0	9 (11.4)	10	13 (8.8)	15
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80		0.15					
95% CI of the odds ratio	(0.23, 2.76)		(0.01, 2.59)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82		0.16					
95% CI of the risk ratio	(0.27, 2.50)		(0.01, 2.69)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.09		-9.95					
95% CI of the absolute risk difference	(-13.25, 9.07)		(-18.79, -1.11)					
p-value	0.7208		0.1315					
p-value of Breslow-Day Test for Homogeneity [2]	0.3481		0.2367					

AMNOG Table S1.2.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Age
(Label Population)

Age: >= 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=43) Patients n (%)	 Events n	MGL-3196 100 mg (N=25) Patients n (%)	 Events n	Placebo (N=79) Patients n (%)	 Events n	Overall (N=147) Patients n (%)	 Events n
Renal and urinary disorders	2 (4.7)	2	2 (8.0)	3	7 (8.9)	8	11 (7.5)	13
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		0.89					
95% CI of the odds ratio	(0.10, 2.53)		(0.17, 4.61)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.52		0.90					
95% CI of the risk ratio	(0.11, 2.42)		(0.20, 4.07)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.21		-0.86					
95% CI of the absolute risk difference	(-13.09, 4.67)		(-13.20, 11.48)					
p-value	0.3954		0.8939					
p-value of Breslow-Day Test for Homogeneity [2]	0.5048		0.4744					
Injury, poisoning and procedural complications								
Contusion	0	0	0	0	1 (1.3)	1	1 (0.7)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.27		-1.27					
95% CI of the absolute risk difference	(-3.73, 1.20)		(-3.73, 1.20)					
p-value	0.4588		0.5719					
p-value of Breslow-Day Test for Homogeneity [2]	0.6452		NE					

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Events n:				
Total TEAEs	268	518	854	1640
Total Serious TEAEs	5	23	32	60
Total TEAEs Leading to Discontinuation of Study Drug	2	10	8	20
Total TEAEs Related to Study Drug	17	64	43	124
Total TEAEs >= Grade 3 Severity	8	34	40	82
Patients n (%):				
Any TEAE	38 (88.4)	77 (89.5)	120 (90.9)	235 (90.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76	0.86		
95% CI of the odds ratio	(0.25, 2.30)	(0.34, 2.13)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	0.98		
95% CI of the risk ratio	(0.86, 1.10)	(0.90, 1.08)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.54	-1.37		
95% CI of the absolute risk difference	(-13.30, 8.23)	(-9.49, 6.74)		
p-value	0.6256	0.7368		
p-value of Breslow-Day Test for Homogeneity [2]	0.4294	0.8644		
Any Serious TEAE	4 (9.3)	13 (15.1)	21 (15.9)	38 (14.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.54	0.94		
95% CI of the odds ratio	(0.18, 1.68)	(0.44, 2.00)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58	0.95		
95% CI of the risk ratio	(0.21, 1.61)	(0.50, 1.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.61	-0.79		
95% CI of the absolute risk difference	(-17.30, 4.08)	(-10.60, 9.02)		
p-value	0.2823	0.8747		
p-value of Breslow-Day Test for Homogeneity [2]	0.6721	0.9866		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Any TEAEs >= Grade 3 Severity	6 (14.0)	18 (20.9)	28 (21.2)	52 (19.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	0.98		
95% CI of the odds ratio	(0.23, 1.57)	(0.50, 1.91)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.66	0.99		
95% CI of the risk ratio	(0.29, 1.48)	(0.58, 1.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.26	-0.28		
95% CI of the absolute risk difference	(-19.74, 5.23)	(-11.35, 10.79)		
p-value	0.2961	0.9602		
p-value of Breslow-Day Test for Homogeneity [2]	0.6482	0.6195		
Any TEAEs <= Grade 2 Severity	36 (83.7)	75 (87.2)	120 (90.9)	231 (88.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	0.68		
95% CI of the odds ratio	(0.19, 1.40)	(0.29, 1.62)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.92	0.96		
95% CI of the risk ratio	(0.80, 1.06)	(0.87, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.19	-3.70		
95% CI of the absolute risk difference	(-19.26, 4.89)	(-12.29, 4.90)		
p-value	0.1882	0.3848		
p-value of Breslow-Day Test for Homogeneity [2]	0.1870	0.9036		
Any TEAEs leading to Study-Drug Discontinuation	2 (4.7)	9 (10.5)	8 (6.1)	19 (7.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76	1.81		
95% CI of the odds ratio	(0.15, 3.70)	(0.67, 4.89)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.77	1.73		
95% CI of the risk ratio	(0.17, 3.48)	(0.69, 4.30)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.41	4.40		
95% CI of the absolute risk difference	(-8.91, 6.09)	(-3.24, 12.05)		
p-value	0.7295	0.2359		
p-value of Breslow-Day Test for Homogeneity [2]	0.7086	0.9125		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Any TEAEs leading to Study Discontinuation	0	5 (5.8)	4 (3.0)	9 (3.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.98		
95% CI of the odds ratio	NE	(0.52, 7.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.92		
95% CI of the risk ratio	NE	(0.53, 6.95)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.03	2.78		
95% CI of the absolute risk difference	(-5.95, -0.11)	(-2.96, 8.53)		
p-value	0.2482	0.3126		
p-value of Breslow-Day Test for Homogeneity [2]	0.3839	0.8341		
Any Fatal TEAEs	0	1 (1.2)	1 (0.8)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the odds ratio	NE	(0.10, 24.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.53		
95% CI of the risk ratio	NE	(0.10, 24.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.76	0.41		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.30, 3.11)		
p-value	0.5671	0.7591		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
Any Treatment-related TEAE	10 (23.3)	25 (29.1)	27 (20.5)	62 (23.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.18	1.59		
95% CI of the odds ratio	(0.52, 2.69)	(0.85, 2.99)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14	1.42		
95% CI of the risk ratio	(0.60, 2.15)	(0.89, 2.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.80	8.62		
95% CI of the absolute risk difference	(-11.58, 17.18)	(-3.19, 20.42)		
p-value	0.6960	0.1446		
p-value of Breslow-Day Test for Homogeneity [2]	0.4644	0.9907		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	3 (3.5)	0	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	3.49		
95% CI of the absolute risk difference	NE	(-0.39, 7.37)		
p-value	NE	0.0307		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0471		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	4 (4.7)	3 (2.3)	7 (2.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.10		
95% CI of the odds ratio	NE	(0.46, 9.61)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.05		
95% CI of the risk ratio	NE	(0.47, 8.92)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.27	2.38		
95% CI of the absolute risk difference	(-4.82, 0.27)	(-2.75, 7.50)		
p-value	0.3187	0.3303		
p-value of Breslow-Day Test for Homogeneity [2]	0.4173	0.7686		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	2 (2.3)	1 (0.8)	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.12		
95% CI of the odds ratio	NE	(0.28, 34.94)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.07		
95% CI of the risk ratio	NE	(0.28, 33.34)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.76	1.57		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-1.94, 5.08)		
p-value	0.5671	0.3314		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.9382		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	15 (34.9)	16 (18.6)	30 (22.7)	61 (23.4)
Grade 2	17 (39.5)	43 (50.0)	62 (47.0)	122 (46.7)
Grade 3	6 (14.0)	17 (19.8)	25 (18.9)	48 (18.4)
Grade 4	0	0	2 (1.5)	2 (0.8)
Grade 5	0	1 (1.2)	1 (0.8)	2 (0.8)

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	8 (18.6)	12 (14.0)	18 (13.6)	38 (14.6)
Grade 2	2 (4.7)	10 (11.6)	9 (6.8)	21 (8.0)
Grade 3	0	3 (3.5)	0	3 (1.1)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (1.2)	1 (0.8)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the odds ratio	NE	(0.10, 24.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.53		
95% CI of the risk ratio	NE	(0.10, 24.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.76	0.41		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.30, 3.11)		
p-value	0.5671	0.7591		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.2)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.16		
95% CI of the absolute risk difference	NE	(-1.10, 3.43)		
p-value	NE	0.2143		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.8)	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.76	-0.76		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.24, 0.72)		
p-value	0.5671	0.4185		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	1 (1.2)	1 (0.8)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the odds ratio	NE	(0.10, 24.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.53		
95% CI of the risk ratio	NE	(0.10, 24.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.76	0.41		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.30, 3.11)		
p-value	0.5671	0.7591		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
Other MACE AE – Adjudicated Event	0	1 (1.2)	1 (0.8)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the odds ratio	NE	(0.10, 24.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.53		
95% CI of the risk ratio	NE	(0.10, 24.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.76	0.41		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.30, 3.11)		
p-value	0.5671	0.7591		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2572		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.2)	1 (0.8)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the odds ratio	NE	(0.10, 24.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.53		
95% CI of the risk ratio	NE	(0.10, 24.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.76	0.41		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.30, 3.11)		
p-value	0.5671	0.7591		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3429		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (1.2)	1 (0.8)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the odds ratio	NE	(0.10, 24.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.53		
95% CI of the risk ratio	NE	(0.10, 24.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.76	0.41		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.30, 3.11)		
p-value	0.5671	0.7591		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3429		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Events n:				
Total TEAEs	931	504	1303	2738
Total Serious TEAEs	24	9	64	97
Total TEAEs Leading to Discontinuation of Study Drug	16	10	17	43
Total TEAEs Related to Study Drug	138	62	116	316
Total TEAEs >= Grade 3 Severity	26	11	66	103
Patients n (%):				
Any TEAE	120 (96.8)	61 (93.8)	163 (95.3)	344 (95.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.47	0.75		
95% CI of the odds ratio	(0.43, 5.00)	(0.22, 2.58)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	0.98		
95% CI of the risk ratio	(0.97, 1.06)	(0.92, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.45	-1.48		
95% CI of the absolute risk difference	(-2.98, 5.89)	(-8.12, 5.17)		
p-value	0.5330	0.6449		
p-value of Breslow-Day Test for Homogeneity [2]	0.4294	0.8644		
Any Serious TEAE	12 (9.7)	8 (12.3)	22 (12.9)	42 (11.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.95		
95% CI of the odds ratio	(0.34, 1.53)	(0.40, 2.26)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	0.96		
95% CI of the risk ratio	(0.39, 1.46)	(0.45, 2.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.19	-0.56		
95% CI of the absolute risk difference	(-10.42, 4.04)	(-9.99, 8.87)		
p-value	0.3973	0.9085		
p-value of Breslow-Day Test for Homogeneity [2]	0.6721	0.9866		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Any TEAEs >= Grade 3 Severity	16 (12.9)	8 (12.3)	27 (15.8)	51 (14.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.79	0.75		
95% CI of the odds ratio	(0.41, 1.54)	(0.32, 1.75)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82	0.78		
95% CI of the risk ratio	(0.46, 1.45)	(0.37, 1.63)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.89	-3.48		
95% CI of the absolute risk difference	(-10.93, 5.16)	(-13.16, 6.20)		
p-value	0.4880	0.5014		
p-value of Breslow-Day Test for Homogeneity [2]	0.6482	0.6195		
Any TEAEs <= Grade 2 Severity	120 (96.8)	61 (93.8)	163 (95.3)	344 (95.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.47	0.75		
95% CI of the odds ratio	(0.43, 5.00)	(0.22, 2.58)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	0.98		
95% CI of the risk ratio	(0.97, 1.06)	(0.92, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.45	-1.48		
95% CI of the absolute risk difference	(-2.98, 5.89)	(-8.12, 5.17)		
p-value	0.5330	0.6449		
p-value of Breslow-Day Test for Homogeneity [2]	0.1870	0.9036		
Any TEAEs leading to Study-Drug Discontinuation	10 (8.1)	9 (13.8)	13 (7.6)	32 (8.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.07	1.95		
95% CI of the odds ratio	(0.45, 2.52)	(0.79, 4.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.06	1.82		
95% CI of the risk ratio	(0.48, 2.34)	(0.82, 4.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.46	6.24		
95% CI of the absolute risk difference	(-5.76, 6.69)	(-3.04, 15.53)		
p-value	0.8838	0.1405		
p-value of Breslow-Day Test for Homogeneity [2]	0.7086	0.9125		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Any TEAEs leading to Study Discontinuation	3 (2.4)	6 (9.2)	7 (4.1)	16 (4.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58	2.38		
95% CI of the odds ratio	(0.15, 2.29)	(0.77, 7.38)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	2.25		
95% CI of the risk ratio	(0.16, 2.24)	(0.79, 6.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.67	5.14		
95% CI of the absolute risk difference	(-5.69, 2.34)	(-2.50, 12.78)		
p-value	0.4328	0.1223		
p-value of Breslow-Day Test for Homogeneity [2]	0.3839	0.8341		
Any Fatal TEAEs	1 (0.8)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.81	NE		
95% CI of the absolute risk difference	(-0.77, 2.38)	NE		
p-value	0.2395	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
Any Treatment-related TEAE	59 (47.6)	30 (46.2)	60 (35.1)	149 (41.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.68	1.59		
95% CI of the odds ratio	(1.05, 2.69)	(0.89, 2.83)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.36	1.32		
95% CI of the risk ratio	(1.03, 1.79)	(0.94, 1.83)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	12.49	11.07		
95% CI of the absolute risk difference	(1.16, 23.83)	(-3.01, 25.14)		
p-value	0.0308	0.1179		
p-value of Breslow-Day Test for Homogeneity [2]	0.4644	0.9907		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.6)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.58	-0.58		
95% CI of the absolute risk difference	(-1.73, 0.56)	(-1.73, 0.56)		
p-value	0.3937	0.5367		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	2 (1.6)	0	2 (1.2)	4 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.39	NE		
95% CI of the odds ratio	(0.19, 9.97)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.38	NE		
95% CI of the risk ratio	(0.20, 9.66)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.44	-1.17		
95% CI of the absolute risk difference	(-2.30, 3.18)	(-2.78, 0.44)		
p-value	0.7452	0.3812		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0471		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	3 (2.4)	6 (9.2)	6 (3.5)	15 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	2.80		
95% CI of the odds ratio	(0.17, 2.78)	(0.87, 9.01)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	2.63		
95% CI of the risk ratio	(0.18, 2.70)	(0.88, 7.86)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.09	5.72		
95% CI of the absolute risk difference	(-4.95, 2.77)	(-1.84, 13.28)		
p-value	0.5912	0.0739		
p-value of Breslow-Day Test for Homogeneity [2]	0.4173	0.7686		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	5 (7.7)	4 (2.3)	9 (2.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.48		
95% CI of the odds ratio	NE	(0.90, 13.39)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.29		
95% CI of the risk ratio	NE	(0.91, 11.87)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.34	5.35		
95% CI of the absolute risk difference	(-4.60, -0.07)	(-1.51, 12.22)		
p-value	0.0864	0.0551		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.9382		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	24 (19.4)	10 (15.4)	39 (22.8)	73 (20.3)
Grade 2	80 (64.5)	43 (66.2)	97 (56.7)	220 (61.1)
Grade 3	15 (12.1)	8 (12.3)	22 (12.9)	45 (12.5)
Grade 4	0	0	5 (2.9)	5 (1.4)
Grade 5	1 (0.8)	0	0	1 (0.3)

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	33 (26.6)	17 (26.2)	35 (20.5)	85 (23.6)
Grade 2	24 (19.4)	13 (20.0)	23 (13.5)	60 (16.7)
Grade 3	2 (1.6)	0	1 (0.6)	3 (0.8)
Grade 4	0	0	1 (0.6)	1 (0.3)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (0.8)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.81	NE		
95% CI of the absolute risk difference	(-0.77, 2.38)	NE		
p-value	0.2395	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (0.8)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.81	NE		
95% CI of the absolute risk difference	(-0.77, 2.38)	NE		
p-value	0.2395	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (0.8)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.81	NE		
95% CI of the absolute risk difference	(-0.77, 2.38)	NE		
p-value	0.2395	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
Other MACE AE – Adjudicated Event	0	0	3 (1.8)	3 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.75	-1.75		
95% CI of the absolute risk difference	(-3.72, 0.21)	(-3.72, 0.21)		
p-value	0.1382	0.2825		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2572		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (1.2)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.17	-1.17		
95% CI of the absolute risk difference	(-2.78, 0.44)	(-2.78, 0.44)		
p-value	0.2269	0.3812		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3429		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.6)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.58	-0.58		
95% CI of the absolute risk difference	(-1.73, 0.56)	(-1.73, 0.56)		
p-value	0.3937	0.5367		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (1.2)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.17	-1.17		
95% CI of the absolute risk difference	(-2.78, 0.44)	(-2.78, 0.44)		
p-value	0.2269	0.3812		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3429		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.3.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Events n:				
Total TEAEs	264	514	849	1627
Total Serious TEAEs	5	23	32	60
Total TEAEs Leading to Discontinuation of Study Drug	1	9	7	17
Total TEAEs Related to Study Drug	17	64	43	124
Total TEAEs >= Grade 3 Severity	7	33	39	79
Patients n (%):				
Any TEAE	38 (88.4)	77 (89.5)	119 (90.2)	234 (89.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83	0.93		
95% CI of the odds ratio	(0.28, 2.48)	(0.38, 2.29)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	0.99		
95% CI of the risk ratio	(0.87, 1.11)	(0.91, 1.09)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.78	-0.62		
95% CI of the absolute risk difference	(-12.63, 9.07)	(-8.84, 7.61)		
p-value	0.7387	0.8826		
p-value of Breslow-Day Test for Homogeneity [2]	0.5590	0.8985		
Any Serious TEAE	4 (9.3)	13 (15.1)	21 (15.9)	38 (14.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.54	0.94		
95% CI of the odds ratio	(0.18, 1.68)	(0.44, 2.00)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58	0.95		
95% CI of the risk ratio	(0.21, 1.61)	(0.50, 1.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.61	-0.79		
95% CI of the absolute risk difference	(-17.30, 4.08)	(-10.60, 9.02)		
p-value	0.2823	0.8747		
p-value of Breslow-Day Test for Homogeneity [2]	0.6721	0.9866		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Any TEAEs >= Grade 3 Severity	5 (11.6)	17 (19.8)	27 (20.5)	49 (18.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	0.96		
95% CI of the odds ratio	(0.18, 1.42)	(0.49, 1.89)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57	0.97		
95% CI of the risk ratio	(0.23, 1.38)	(0.56, 1.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.83	-0.69		
95% CI of the absolute risk difference	(-20.62, 2.97)	(-11.56, 10.18)		
p-value	0.1934	0.9017		
p-value of Breslow-Day Test for Homogeneity [2]	0.5540	0.7789		
Any TEAEs <= Grade 2 Severity	36 (83.7)	75 (87.2)	119 (90.2)	230 (88.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56	0.74		
95% CI of the odds ratio	(0.21, 1.51)	(0.32, 1.75)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.93	0.97		
95% CI of the risk ratio	(0.80, 1.07)	(0.88, 1.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.43	-2.94		
95% CI of the absolute risk difference	(-18.58, 5.72)	(-11.64, 5.76)		
p-value	0.2497	0.4976		
p-value of Breslow-Day Test for Homogeneity [2]	0.2580	0.8649		
Any TEAEs leading to Study-Drug Discontinuation	1 (2.3)	8 (9.3)	7 (5.3)	16 (6.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43	1.83		
95% CI of the odds ratio	(0.05, 3.56)	(0.64, 5.25)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	1.75		
95% CI of the risk ratio	(0.06, 3.46)	(0.66, 4.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.98	4.00		
95% CI of the absolute risk difference	(-8.89, 2.93)	(-3.23, 11.23)		
p-value	0.4169	0.2542		
p-value of Breslow-Day Test for Homogeneity [2]	0.3563	0.6635		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Any TEAEs leading to Study Discontinuation	0	5 (5.8)	4 (3.0)	9 (3.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.98		
95% CI of the odds ratio	NE	(0.52, 7.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.92		
95% CI of the risk ratio	NE	(0.53, 6.95)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.03	2.78		
95% CI of the absolute risk difference	(-5.95, -0.11)	(-2.96, 8.53)		
p-value	0.2482	0.3126		
p-value of Breslow-Day Test for Homogeneity [2]	0.3839	0.8341		
Any Fatal TEAEs	0	1 (1.2)	1 (0.8)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the odds ratio	NE	(0.10, 24.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.53		
95% CI of the risk ratio	NE	(0.10, 24.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.76	0.41		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.30, 3.11)		
p-value	0.5671	0.7591		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
Any Treatment-related TEAE	10 (23.3)	25 (29.1)	27 (20.5)	62 (23.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.18	1.59		
95% CI of the odds ratio	(0.52, 2.69)	(0.85, 2.99)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14	1.42		
95% CI of the risk ratio	(0.60, 2.15)	(0.89, 2.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.80	8.62		
95% CI of the absolute risk difference	(-11.58, 17.18)	(-3.19, 20.42)		
p-value	0.6960	0.1446		
p-value of Breslow-Day Test for Homogeneity [2]	0.4326	0.9622		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	3 (3.5)	0	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	3.49		
95% CI of the absolute risk difference	NE	(-0.39, 7.37)		
p-value	NE	0.0307		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0471		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	4 (4.7)	3 (2.3)	7 (2.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.10		
95% CI of the odds ratio	NE	(0.46, 9.61)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.05		
95% CI of the risk ratio	NE	(0.47, 8.92)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.27	2.38		
95% CI of the absolute risk difference	(-4.82, 0.27)	(-2.75, 7.50)		
p-value	0.3187	0.3303		
p-value of Breslow-Day Test for Homogeneity [2]	0.4173	0.7686		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	2 (2.3)	1 (0.8)	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.12		
95% CI of the odds ratio	NE	(0.28, 34.94)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.07		
95% CI of the risk ratio	NE	(0.28, 33.34)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.76	1.57		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-1.94, 5.08)		
p-value	0.5671	0.3314		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.9382		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	15 (34.9)	17 (19.8)	30 (22.7)	62 (23.8)
Grade 2	18 (41.9)	43 (50.0)	62 (47.0)	123 (47.1)
Grade 3	5 (11.6)	16 (18.6)	24 (18.2)	45 (17.2)
Grade 4	0	0	2 (1.5)	2 (0.8)
Grade 5	0	1 (1.2)	1 (0.8)	2 (0.8)

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	8 (18.6)	12 (14.0)	18 (13.6)	38 (14.6)
Grade 2	2 (4.7)	10 (11.6)	9 (6.8)	21 (8.0)
Grade 3	0	3 (3.5)	0	3 (1.1)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (1.2)	1 (0.8)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the odds ratio	NE	(0.10, 24.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.53		
95% CI of the risk ratio	NE	(0.10, 24.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.76	0.41		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.30, 3.11)		
p-value	0.5671	0.7591		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.2)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.16		
95% CI of the absolute risk difference	NE	(-1.10, 3.43)		
p-value	NE	0.2143		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	0	0	1 (0.8)	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.76	-0.76		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.24, 0.72)		
p-value	0.5671	0.4185		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
Serious 3-PT MACE AE - Adjudicated Event	0	1 (1.2)	1 (0.8)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the odds ratio	NE	(0.10, 24.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.53		
95% CI of the risk ratio	NE	(0.10, 24.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.76	0.41		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.30, 3.11)		
p-value	0.5671	0.7591		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
Other MACE AE - Adjudicated Event	0	1 (1.2)	1 (0.8)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the odds ratio	NE	(0.10, 24.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.53		
95% CI of the risk ratio	NE	(0.10, 24.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.76	0.41		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.30, 3.11)		
p-value	0.5671	0.7591		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2572		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.2)	1 (0.8)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the odds ratio	NE	(0.10, 24.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.53		
95% CI of the risk ratio	NE	(0.10, 24.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.76	0.41		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.30, 3.11)		
p-value	0.5671	0.7591		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3429		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (1.2)	1 (0.8)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the odds ratio	NE	(0.10, 24.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.53		
95% CI of the risk ratio	NE	(0.10, 24.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.76	0.41		
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.30, 3.11)		
p-value	0.5671	0.7591		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3429		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43) n (%)	MGL-3196 100 mg (N=86) n (%)	Placebo (N=132) n (%)	Overall (N=261) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Events n:				
Total TEAEs	922	500	1284	2706
Total Serious TEAEs	24	9	64	97
Total TEAEs Leading to Discontinuation of Study Drug	14	9	13	36
Total TEAEs Related to Study Drug	137	62	115	314
Total TEAEs >= Grade 3 Severity	24	11	64	99
Patients n (%):				
Any TEAE	119 (96.0)	61 (93.8)	162 (94.7)	342 (95.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.32	0.85		
95% CI of the odds ratio	(0.43, 4.05)	(0.25, 2.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	0.99		
95% CI of the risk ratio	(0.96, 1.07)	(0.92, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.23	-0.89		
95% CI of the absolute risk difference	(-3.58, 6.05)	(-7.62, 5.84)		
p-value	0.6236	0.7888		
p-value of Breslow-Day Test for Homogeneity [2]	0.5590	0.8985		
Any Serious TEAE	12 (9.7)	8 (12.3)	22 (12.9)	42 (11.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.95		
95% CI of the odds ratio	(0.34, 1.53)	(0.40, 2.26)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	0.96		
95% CI of the risk ratio	(0.39, 1.46)	(0.45, 2.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.19	-0.56		
95% CI of the absolute risk difference	(-10.42, 4.04)	(-9.99, 8.87)		
p-value	0.3973	0.9085		
p-value of Breslow-Day Test for Homogeneity [2]	0.6721	0.9866		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Any TEAEs >= Grade 3 Severity	14 (11.3)	8 (12.3)	25 (14.6)	47 (13.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.74	0.82		
95% CI of the odds ratio	(0.37, 1.50)	(0.35, 1.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.77	0.84		
95% CI of the risk ratio	(0.42, 1.42)	(0.40, 1.77)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.33	-2.31		
95% CI of the absolute risk difference	(-11.02, 4.36)	(-11.89, 7.27)		
p-value	0.4046	0.6473		
p-value of Breslow-Day Test for Homogeneity [2]	0.5540	0.7789		
Any TEAEs <= Grade 2 Severity	119 (96.0)	61 (93.8)	162 (94.7)	342 (95.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.32	0.85		
95% CI of the odds ratio	(0.43, 4.05)	(0.25, 2.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	0.99		
95% CI of the risk ratio	(0.96, 1.07)	(0.92, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.23	-0.89		
95% CI of the absolute risk difference	(-3.58, 6.05)	(-7.62, 5.84)		
p-value	0.6236	0.7888		
p-value of Breslow-Day Test for Homogeneity [2]	0.2580	0.8649		
Any TEAEs leading to Study-Drug Discontinuation	8 (6.5)	8 (12.3)	9 (5.3)	25 (6.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.24	2.53		
95% CI of the odds ratio	(0.47, 3.31)	(0.93, 6.86)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.23	2.34		
95% CI of the risk ratio	(0.49, 3.09)	(0.94, 5.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.19	7.04		
95% CI of the absolute risk difference	(-4.28, 6.66)	(-1.61, 15.70)		
p-value	0.6655	0.0615		
p-value of Breslow-Day Test for Homogeneity [2]	0.3563	0.6635		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Any TEAEs leading to Study Discontinuation	3 (2.4)	6 (9.2)	7 (4.1)	16 (4.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58	2.38		
95% CI of the odds ratio	(0.15, 2.29)	(0.77, 7.38)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	2.25		
95% CI of the risk ratio	(0.16, 2.24)	(0.79, 6.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.67	5.14		
95% CI of the absolute risk difference	(-5.69, 2.34)	(-2.50, 12.78)		
p-value	0.4328	0.1223		
p-value of Breslow-Day Test for Homogeneity [2]	0.3839	0.8341		
Any Fatal TEAEs	1 (0.8)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.81	NE		
95% CI of the absolute risk difference	(-0.77, 2.38)	NE		
p-value	0.2395	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
Any Treatment-related TEAE	59 (47.6)	30 (46.2)	59 (34.5)	148 (41.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.72	1.63		
95% CI of the odds ratio	(1.07, 2.76)	(0.91, 2.91)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.38	1.34		
95% CI of the risk ratio	(1.05, 1.82)	(0.96, 1.87)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.08	11.65		
95% CI of the absolute risk difference	(1.76, 24.39)	(-2.41, 25.71)		
p-value	0.0236	0.0990		
p-value of Breslow-Day Test for Homogeneity [2]	0.4326	0.9622		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.6)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.58	-0.58		
95% CI of the absolute risk difference	(-1.73, 0.56)	(-1.73, 0.56)		
p-value	0.3937	0.5367		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (0.8)	0	2 (1.2)	3 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	NE		
95% CI of the odds ratio	(0.06, 7.66)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	NE		
95% CI of the risk ratio	(0.06, 7.52)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.36	-1.17		
95% CI of the absolute risk difference	(-2.62, 1.89)	(-2.78, 0.44)		
p-value	0.7589	0.3812		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0471		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	3 (2.4)	6 (9.2)	6 (3.5)	15 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	2.80		
95% CI of the odds ratio	(0.17, 2.78)	(0.87, 9.01)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	2.63		
95% CI of the risk ratio	(0.18, 2.70)	(0.88, 7.86)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.09	5.72		
95% CI of the absolute risk difference	(-4.95, 2.77)	(-1.84, 13.28)		
p-value	0.5912	0.0739		
p-value of Breslow-Day Test for Homogeneity [2]	0.4173	0.7686		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	5 (7.7)	4 (2.3)	9 (2.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.48		
95% CI of the odds ratio	NE	(0.90, 13.39)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.29		
95% CI of the risk ratio	NE	(0.91, 11.87)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.34	5.35		
95% CI of the absolute risk difference	(-4.60, -0.07)	(-1.51, 12.22)		
p-value	0.0864	0.0551		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.9382		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	23 (18.5)	10 (15.4)	40 (23.4)	73 (20.3)
Grade 2	82 (66.1)	43 (66.2)	97 (56.7)	222 (61.7)
Grade 3	13 (10.5)	8 (12.3)	20 (11.7)	41 (11.4)
Grade 4	0	0	5 (2.9)	5 (1.4)
Grade 5	1 (0.8)	0	0	1 (0.3)

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	33 (26.6)	17 (26.2)	34 (19.9)	84 (23.3)
Grade 2	25 (20.2)	13 (20.0)	23 (13.5)	61 (16.9)
Grade 3	1 (0.8)	0	1 (0.6)	2 (0.6)
Grade 4	0	0	1 (0.6)	1 (0.3)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (0.8)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.81	NE		
95% CI of the absolute risk difference	(-0.77, 2.38)	NE		
p-value	0.2395	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (0.8)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.81	NE		
95% CI of the absolute risk difference	(-0.77, 2.38)	NE		
p-value	0.2395	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (0.8)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.81	NE		
95% CI of the absolute risk difference	(-0.77, 2.38)	NE		
p-value	0.2395	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2439	NE		
Other MACE AE – Adjudicated Event	0	0	3 (1.8)	3 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.75	-1.75		
95% CI of the absolute risk difference	(-3.72, 0.21)	(-3.72, 0.21)		
p-value	0.1382	0.2825		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2572		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (1.2)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.17	-1.17		
95% CI of the absolute risk difference	(-2.78, 0.44)	(-2.78, 0.44)		
p-value	0.2269	0.3812		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3429		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.6)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.58	-0.58		
95% CI of the absolute risk difference	(-1.73, 0.56)	(-1.73, 0.56)		
p-value	0.3937	0.5367		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (1.2)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.17	-1.17		
95% CI of the absolute risk difference	(-2.78, 0.44)	(-2.78, 0.44)		
p-value	0.2269	0.3812		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3429		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.3.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Sex
(Label Population)

Sex: Female

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=171) n (%)	Overall (N=360) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.3.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Sex
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.

AMNOG Table S1.3.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Sex
(Label Population)

Sex: Male

System Organ Class Preferred Term	MGL-3196 80 mg (N=43) Patients n (%)	 Events n	MGL-3196 100 mg (N=86) Patients n (%)	 Events n	Placebo (N=132) Patients n (%)	 Events n	Overall (N=261) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	11 (25.6)	24	27 (31.4)	44	12 (9.1)	13	50 (19.2)	81
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.44		4.58					
95% CI of the odds ratio	(1.39, 8.51)		(2.17, 9.67)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.81		3.45					
95% CI of the risk ratio	(1.34, 5.91)		(1.85, 6.44)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	16.49		22.30					
95% CI of the absolute risk difference	(2.56, 30.42)		(11.34, 33.27)					
p-value	0.0054		<0.0001					
p-value of Breslow-Day Test for Homogeneity [2]	0.0494		0.1194					
Nausea	6 (14.0)	7	5 (5.8)	6	4 (3.0)	4	15 (5.7)	17
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	5.19		1.98					
95% CI of the odds ratio	(1.39, 19.37)		(0.52, 7.57)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.60		1.92					
95% CI of the risk ratio	(1.36, 15.56)		(0.53, 6.95)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	10.92		2.78					
95% CI of the absolute risk difference	(0.16, 21.68)		(-2.96, 8.53)					
p-value	0.0074		0.3126					
p-value of Breslow-Day Test for Homogeneity [2]	0.1044		0.5627					

AMNOG Table S1.3.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Sex
(Label Population)

Sex: Male

System Organ Class Preferred Term	MGL-3196 80 mg (N=43) Patients n (%)	 Events n	MGL-3196 100 mg (N=86) Patients n (%)	 Events n	Placebo (N=132) Patients n (%)	 Events n	Overall (N=261) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Abdominal discomfort	0	0	2 (2.3)	2	7 (5.3)	8	9 (3.4)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.19		0.43					
95% CI of the odds ratio	(0.01, 3.44)		(0.09, 2.10)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.20		0.44					
95% CI of the risk ratio	(0.01, 3.46)		(0.09, 2.06)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.50		-2.98					
95% CI of the absolute risk difference	(-9.52, 0.51)		(-7.95, 2.00)					
p-value	0.2126		0.2802					
p-value of Breslow-Day Test for Homogeneity [2]	0.4559		0.9938					
Vomiting	2 (4.7)	2	3 (3.5)	3	0	0	5 (1.9)	5
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.65		3.49					
95% CI of the absolute risk difference	(-1.64, 10.95)		(-0.39, 7.37)					
p-value	0.0127		0.0307					
p-value of Breslow-Day Test for Homogeneity [2]	0.0549		0.0437					

AMNOG Table S1.3.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Sex
(Label Population)

Sex: Male

System Organ Class Preferred Term	MGL-3196 80 mg (N=43) Patients n (%)	 Events n	MGL-3196 100 mg (N=86) Patients n (%)	 Events n	Placebo (N=132) Patients n (%)	 Events n	Overall (N=261) Patients n (%)	 Events n
General disorders and administration site conditions	8 (18.6)	12	18 (20.9)	28	30 (22.7)	41	56 (21.5)	81
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78		0.90					
95% CI of the odds ratio	(0.33, 1.85)		(0.47, 1.74)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82		0.92					
95% CI of the risk ratio	(0.41, 1.65)		(0.55, 1.54)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.12		-1.80					
95% CI of the absolute risk difference	(-17.78, 9.53)		(-12.98, 9.38)					
p-value	0.5690		0.7543					
p-value of Breslow-Day Test for Homogeneity [2]	0.5896		0.1369					
Renal and urinary disorders	1 (2.3)	1	9 (10.5)	10	19 (14.4)	24	29 (11.1)	35
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.14		0.70					
95% CI of the odds ratio	(0.02, 1.09)		(0.30, 1.62)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.16		0.73					
95% CI of the risk ratio	(0.02, 1.17)		(0.35, 1.53)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-12.07		-3.93					
95% CI of the absolute risk difference	(-19.56, -4.57)		(-12.74, 4.89)					
p-value	0.0308		0.3968					
p-value of Breslow-Day Test for Homogeneity [2]	0.1675		0.0048					

AMNOG Table S1.3.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Sex
(Label Population)

Sex: Male

System Organ Class Preferred Term	MGL-3196 80 mg (N=43) Patients n (%)	 Events n	MGL-3196 100 mg (N=86) Patients n (%)	 Events n	Placebo (N=132) Patients n (%)	 Events n	Overall (N=261) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders								
Pruritus	0	0	3 (3.5)	3	12 (9.1)	14	15 (5.7)	17
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11		0.36					
95% CI of the odds ratio	(0.01, 1.91)		(0.10, 1.32)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.12		0.38					
95% CI of the risk ratio	(0.01, 2.00)		(0.11, 1.32)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.26		-5.60					
95% CI of the absolute risk difference	(-14.13, -2.40)		(-11.85, 0.65)					
p-value	0.0686		0.1102					
p-value of Breslow-Day Test for Homogeneity [2]	0.0021		0.1546					
Rash	1 (2.3)	1	9 (10.5)	10	4 (3.0)	5	14 (5.4)	16
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76		3.74					
95% CI of the odds ratio	(0.08, 7.01)		(1.11, 12.56)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.77		3.45					
95% CI of the risk ratio	(0.09, 6.68)		(1.10, 10.86)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.70		7.43					
95% CI of the absolute risk difference	(-6.08, 4.67)		(0.34, 14.53)					
p-value	0.8096		0.0235					
p-value of Breslow-Day Test for Homogeneity [2]	0.7056		0.6077					

AMNOG Table S1.3.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Sex
(Label Population)

Sex: Male

System Organ Class Preferred Term	MGL-3196 80 mg (N=43) Patients n (%)	 Events n	MGL-3196 100 mg (N=86) Patients n (%)	 Events n	Placebo (N=132) Patients n (%)	 Events n	Overall (N=261) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	2 (4.7)	2	2 (2.3)	2	7 (5.3)	9	11 (4.2)	13
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87		0.43					
95% CI of the odds ratio	(0.17, 4.36)		(0.09, 2.10)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.88		0.44					
95% CI of the risk ratio	(0.19, 4.06)		(0.09, 2.06)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.65		-2.98					
95% CI of the absolute risk difference	(-8.02, 6.71)		(-7.95, 2.00)					
p-value	0.8665		0.2802					
p-value of Breslow-Day Test for Homogeneity [2]	0.3896		0.7243					

AMNOG Table S1.3.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Sex
(Label Population)

Sex: Male

System Organ Class Preferred Term	MGL-3196 80 mg (N=43) Patients n (%)	 Events n	MGL-3196 100 mg (N=86) Patients n (%)	 Events n	Placebo (N=132) Patients n (%)	 Events n	Overall (N=261) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	1 (2.3)	1	0	0	2 (1.5)	2	3 (1.1)	3
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.55		NE					
95% CI of the odds ratio	(0.14, 17.50)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.53		NE					
95% CI of the risk ratio	(0.14, 16.51)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.81		-1.52					
95% CI of the absolute risk difference	(-4.15, 5.77)		(-3.60, 0.57)					
p-value	0.7222		0.2515					
p-value of Breslow-Day Test for Homogeneity [2]	0.1314		NE					

AMNOG Table S1.3.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Sex
(Label Population)

Sex: Female

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=65) Patients n (%)	 Events n	Placebo (N=171) Patients n (%)	 Events n	Overall (N=360) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	31 (25.0)	49	24 (36.9)	36	37 (21.6)	48	92 (25.6)	133
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21		2.12					
95% CI of the odds ratio	(0.70, 2.08)		(1.14, 3.95)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.16		1.71					
95% CI of the risk ratio	(0.76, 1.75)		(1.11, 2.62)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.36		15.29					
95% CI of the absolute risk difference	(-6.44, 13.17)		(2.03, 28.54)					
p-value	0.4985		0.0166					
p-value of Breslow-Day Test for Homogeneity [2]	0.0494		0.1194					
Nausea	37 (29.8)	44	16 (24.6)	20	35 (20.5)	42	88 (24.4)	106
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.65		1.27					
95% CI of the odds ratio	(0.97, 2.82)		(0.65, 2.49)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.46		1.20					
95% CI of the risk ratio	(0.98, 2.18)		(0.72, 2.02)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.37		4.15					
95% CI of the absolute risk difference	(-0.70, 19.44)		(-7.95, 16.24)					
p-value	0.0644		0.4892					
p-value of Breslow-Day Test for Homogeneity [2]	0.1044		0.5627					

AMNOG Table S1.3.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Sex
(Label Population)

Sex: Female

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=65) Patients n (%)	 Events n	Placebo (N=171) Patients n (%)	 Events n	Overall (N=360) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	18 (14.5)	20	6 (9.2)	6	17 (9.9)	18	41 (11.4)	44
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.54		0.92					
95% CI of the odds ratio	(0.76, 3.12)		(0.35, 2.45)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.46		0.93					
95% CI of the risk ratio	(0.78, 2.72)		(0.38, 2.25)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.57		-0.71					
95% CI of the absolute risk difference	(-3.08, 12.23)		(-9.06, 7.63)					
p-value	0.2304		0.8694					
p-value of Breslow-Day Test for Homogeneity [2]	0.0549		0.0437					
Abdominal discomfort	1 (0.8)	1	1 (1.5)	2	6 (3.5)	6	8 (2.2)	9
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.22		0.43					
95% CI of the odds ratio	(0.03, 1.88)		(0.05, 3.64)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.23		0.44					
95% CI of the risk ratio	(0.03, 1.89)		(0.05, 3.57)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.70		-1.97					
95% CI of the absolute risk difference	(-5.88, 0.47)		(-6.04, 2.10)					
p-value	0.1323		0.4254					
p-value of Breslow-Day Test for Homogeneity [2]	0.4559		0.9938					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.3.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Sex
(Label Population)

Sex: Female

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=65) Patients n (%)	 Events n	Placebo (N=171) Patients n (%)	 Events n	Overall (N=360) Patients n (%)	 Events n
General disorders and administration site conditions	27 (21.8)	40	11 (16.9)	11	55 (32.2)	63	93 (25.8)	114
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59		0.43					
95% CI of the odds ratio	(0.34, 1.00)		(0.21, 0.89)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68		0.53					
95% CI of the risk ratio	(0.45, 1.01)		(0.29, 0.94)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.39		-15.24					
95% CI of the absolute risk difference	(-20.48, -0.30)		(-26.73, -3.75)					
p-value	0.0493		0.0198					
p-value of Breslow-Day Test for Homogeneity [2]	0.5896		0.1369					
Skin and subcutaneous tissue disorders								
Pruritus	22 (17.7)	28	5 (7.7)	7	11 (6.4)	12	38 (10.6)	47
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.14		1.21					
95% CI of the odds ratio	(1.46, 6.74)		(0.40, 3.63)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.76		1.20					
95% CI of the risk ratio	(1.39, 5.48)		(0.43, 3.31)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.31		1.26					
95% CI of the absolute risk difference	(3.65, 18.97)		(-6.19, 8.71)					
p-value	0.0024		0.7310					
p-value of Breslow-Day Test for Homogeneity [2]	0.0021		0.1546					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.3.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Sex
(Label Population)

Sex: Female

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=65) Patients n (%)	 Events n	Placebo (N=171) Patients n (%)	 Events n	Overall (N=360) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	7 (5.6)	7	7 (10.8)	10	8 (4.7)	9	22 (6.1)	26
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.22		2.46					
95% CI of the odds ratio	(0.43, 3.46)		(0.85, 7.08)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21		2.30					
95% CI of the risk ratio	(0.45, 3.24)		(0.87, 6.09)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.97		6.09					
95% CI of the absolute risk difference	(-4.18, 6.12)		(-2.08, 14.26)					
p-value	0.7091		0.0866					
p-value of Breslow-Day Test for Homogeneity [2]	0.7056		0.6077					
Musculoskeletal and connective tissue disorders								
Pain in extremity	5 (4.0)	6	2 (3.1)	2	17 (9.9)	19	24 (6.7)	27
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		0.29					
95% CI of the odds ratio	(0.14, 1.06)		(0.06, 1.28)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.41		0.31					
95% CI of the risk ratio	(0.15, 1.07)		(0.07, 1.30)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.91		-6.86					
95% CI of the absolute risk difference	(-11.58, -0.24)		(-13.01, -0.72)					
p-value	0.0565		0.0834					
p-value of Breslow-Day Test for Homogeneity [2]	0.3896		0.7243					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.3.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Sex
(Label Population)

Sex: Female

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=65) Patients n (%)	 Events n	Placebo (N=171) Patients n (%)	 Events n	Overall (N=360) Patients n (%)	 Events n
Renal and urinary disorders	4 (3.2)	5	11 (16.9)	14	8 (4.7)	9	23 (6.4)	28
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68		4.15					
95% CI of the odds ratio	(0.20, 2.31)		(1.59, 10.85)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69		3.62					
95% CI of the risk ratio	(0.21, 2.24)		(1.52, 8.59)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.45		12.24					
95% CI of the absolute risk difference	(-5.89, 2.98)		(2.60, 21.89)					
p-value	0.5330		0.0020					
p-value of Breslow-Day Test for Homogeneity [2]	0.1675		0.0048					
Injury, poisoning and procedural complications								
Contusion	1 (0.8)	1	0	0	8 (4.7)	12	9 (2.5)	13
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.17		NE					
95% CI of the odds ratio	(0.02, 1.34)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.17		NE					
95% CI of the risk ratio	(0.02, 1.36)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.87		-4.68					
95% CI of the absolute risk difference	(-7.41, -0.34)		(-7.84, -1.51)					
p-value	0.0563		0.0760					
p-value of Breslow-Day Test for Homogeneity [2]	0.1314		NE					

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Events n:				
Total TEAEs	716	810	1492	3018
Total Serious TEAEs	11	26	70	107
Total TEAEs Leading to Discontinuation of Study Drug	8	16	17	41
Total TEAEs Related to Study Drug	85	90	108	283
Total TEAEs >= Grade 3 Severity	13	33	81	127
Patients n (%):				
Any TEAE	89 (94.7)	108 (90.8)	187 (94.4)	384 (93.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.05	0.58		
95% CI of the odds ratio	(0.35, 3.10)	(0.24, 1.38)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.96		
95% CI of the risk ratio	(0.95, 1.06)	(0.90, 1.03)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.24	-3.69		
95% CI of the absolute risk difference	(-5.31, 5.78)	(-9.79, 2.42)		
p-value	0.9339	0.2109		
p-value of Breslow-Day Test for Homogeneity [2]	0.6009	0.3284		
Any Serious TEAE	7 (7.4)	16 (13.4)	28 (14.1)	51 (12.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.49	0.94		
95% CI of the odds ratio	(0.21, 1.16)	(0.49, 1.83)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53	0.95		
95% CI of the risk ratio	(0.24, 1.16)	(0.54, 1.68)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.69	-0.70		
95% CI of the absolute risk difference	(-13.89, 0.50)	(-8.51, 7.12)		
p-value	0.0999	0.8622		
p-value of Breslow-Day Test for Homogeneity [2]	0.3858	0.8022		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Any TEAEs >= Grade 3 Severity	9 (9.6)	18 (15.1)	36 (18.2)	63 (15.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48	0.80		
95% CI of the odds ratio	(0.22, 1.04)	(0.43, 1.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53	0.83		
95% CI of the risk ratio	(0.26, 1.05)	(0.50, 1.40)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.61	-3.06		
95% CI of the absolute risk difference	(-16.62, -0.59)	(-11.44, 5.33)		
p-value	0.0570	0.4834		
p-value of Breslow-Day Test for Homogeneity [2]	0.1957	0.2693		
Any TEAEs <= Grade 2 Severity	89 (94.7)	107 (89.9)	187 (94.4)	383 (93.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.05	0.52		
95% CI of the odds ratio	(0.35, 3.10)	(0.22, 1.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.95		
95% CI of the risk ratio	(0.95, 1.06)	(0.89, 1.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.24	-4.53		
95% CI of the absolute risk difference	(-5.31, 5.78)	(-10.81, 1.75)		
p-value	0.9339	0.1323		
p-value of Breslow-Day Test for Homogeneity [2]	0.9998	0.5051		
Any TEAEs leading to Study-Drug Discontinuation	6 (6.4)	14 (11.8)	13 (6.6)	33 (8.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	1.90		
95% CI of the odds ratio	(0.36, 2.64)	(0.86, 4.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	1.79		
95% CI of the risk ratio	(0.38, 2.48)	(0.87, 3.68)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.18	5.20		
95% CI of the absolute risk difference	(-6.21, 5.84)	(-1.54, 11.94)		
p-value	0.9528	0.1083		
p-value of Breslow-Day Test for Homogeneity [2]	0.8823	0.9050		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Any TEAEs leading to Study Discontinuation	1 (1.1)	8 (6.7)	8 (4.0)	17 (4.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.26	1.71		
95% CI of the odds ratio	(0.03, 2.07)	(0.62, 4.69)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.26	1.66		
95% CI of the risk ratio	(0.03, 2.07)	(0.64, 4.32)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.98	2.68		
95% CI of the absolute risk difference	(-6.42, 0.46)	(-2.59, 7.95)		
p-value	0.1691	0.2908		
p-value of Breslow-Day Test for Homogeneity [2]	0.3327	0.4616		
Any Fatal TEAEs	0	1 (0.8)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.67		
95% CI of the odds ratio	NE	(0.10, 26.94)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.66		
95% CI of the risk ratio	NE	(0.11, 26.35)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.51	0.34		
95% CI of the absolute risk difference	(-1.49, 0.48)	(-1.58, 2.25)		
p-value	0.4901	0.7151		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
Any Treatment-related TEAE	40 (42.6)	41 (34.5)	57 (28.8)	138 (33.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.83	1.30		
95% CI of the odds ratio	(1.10, 3.06)	(0.80, 2.12)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.48	1.20		
95% CI of the risk ratio	(1.07, 2.04)	(0.86, 1.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.77	5.67		
95% CI of the absolute risk difference	(1.95, 25.58)	(-4.95, 16.28)		
p-value	0.0196	0.2905		
p-value of Breslow-Day Test for Homogeneity [2]	0.7979	0.4063		

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.51	-0.51		
95% CI of the absolute risk difference	(-1.49, 0.48)	(-1.49, 0.48)		
p-value	0.4901	0.4375		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (1.1)	0	2 (1.0)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.05	NE		
95% CI of the odds ratio	(0.09, 11.77)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.05	NE		
95% CI of the risk ratio	(0.10, 11.47)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.05	-1.01		
95% CI of the absolute risk difference	(-2.44, 2.55)	(-2.40, 0.38)		
p-value	0.9661	0.2714		
p-value of Breslow-Day Test for Homogeneity [2]	0.3162	0.0077		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	1 (1.1)	7 (5.9)	6 (3.0)	14 (3.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.34	2.00		
95% CI of the odds ratio	(0.04, 2.90)	(0.66, 6.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.35	1.94		
95% CI of the risk ratio	(0.04, 2.87)	(0.67, 5.64)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.97	2.85		
95% CI of the absolute risk difference	(-5.13, 1.20)	(-2.00, 7.71)		
p-value	0.3047	0.2150		
p-value of Breslow-Day Test for Homogeneity [2]	0.4646	0.5766		

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	5 (4.2)	4 (2.0)	9 (2.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.13		
95% CI of the odds ratio	NE	(0.56, 8.08)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.08		
95% CI of the risk ratio	NE	(0.57, 7.59)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.02	2.18		
95% CI of the absolute risk difference	(-3.98, -0.06)	(-1.92, 6.28)		
p-value	0.1653	0.2575		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3919		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	15 (16.0)	20 (16.8)	43 (21.7)	78 (19.0)
Grade 2	65 (69.1)	70 (58.8)	108 (54.5)	243 (59.1)
Grade 3	9 (9.6)	17 (14.3)	31 (15.7)	57 (13.9)
Grade 4	0	0	4 (2.0)	4 (1.0)
Grade 5	0	1 (0.8)	1 (0.5)	2 (0.5)

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	23 (24.5)	24 (20.2)	32 (16.2)	79 (19.2)
Grade 2	16 (17.0)	17 (14.3)	23 (11.6)	56 (13.6)
Grade 3	1 (1.1)	0	1 (0.5)	2 (0.5)
Grade 4	0	0	1 (0.5)	1 (0.2)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (0.8)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.67		
95% CI of the odds ratio	NE	(0.10, 26.94)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.66		
95% CI of the risk ratio	NE	(0.11, 26.35)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.51	0.34		
95% CI of the absolute risk difference	(-1.49, 0.48)	(-1.58, 2.25)		
p-value	0.4901	0.7151		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.8)	0	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	0.84		
95% CI of the absolute risk difference	NE	(-0.80, 2.48)		
p-value	NE	0.1964		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.51	-0.51		
95% CI of the absolute risk difference	(-1.49, 0.48)	(-1.49, 0.48)		
p-value	0.4901	0.4375		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	1 (0.8)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.67		
95% CI of the odds ratio	NE	(0.10, 26.94)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.66		
95% CI of the risk ratio	NE	(0.11, 26.35)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.51	0.34		
95% CI of the absolute risk difference	(-1.49, 0.48)	(-1.58, 2.25)		
p-value	0.4901	0.7151		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
Other MACE AE – Adjudicated Event	0	1 (0.8)	4 (2.0)	5 (1.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.41		
95% CI of the odds ratio	NE	(0.05, 3.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.42		
95% CI of the risk ratio	NE	(0.05, 3.68)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.02	-1.18		
95% CI of the absolute risk difference	(-3.98, -0.06)	(-3.74, 1.38)		
p-value	0.1653	0.4143		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.8)	3 (1.5)	4 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.55		
95% CI of the odds ratio	NE	(0.06, 5.36)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.55		
95% CI of the risk ratio	NE	(0.06, 5.27)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.52	-0.67		
95% CI of the absolute risk difference	(-3.22, 0.19)	(-3.04, 1.69)		
p-value	0.2303	0.6022		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.51	-0.51		
95% CI of the absolute risk difference	(-1.49, 0.48)	(-1.49, 0.48)		
p-value	0.4901	0.4375		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (0.8)	3 (1.5)	4 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.55		
95% CI of the odds ratio	NE	(0.06, 5.36)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.55		
95% CI of the risk ratio	NE	(0.06, 5.27)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.52	-0.67		
95% CI of the absolute risk difference	(-3.22, 0.19)	(-3.04, 1.69)		
p-value	0.2303	0.6022		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Events n:				
Total TEAEs	483	212	665	1360
Total Serious TEAEs	18	6	26	50
Total TEAEs Leading to Discontinuation of Study Drug	10	4	8	22
Total TEAEs Related to Study Drug	70	36	51	157
Total TEAEs >= Grade 3 Severity	21	12	25	58
Patients n (%):				
Any TEAE	69 (94.5)	30 (93.8)	96 (91.4)	195 (92.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.62	1.41		
95% CI of the odds ratio	(0.48, 5.47)	(0.29, 6.87)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03	1.03		
95% CI of the risk ratio	(0.95, 1.12)	(0.92, 1.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.09	2.32		
95% CI of the absolute risk difference	(-4.39, 10.57)	(-7.63, 12.27)		
p-value	0.4355	0.6723		
p-value of Breslow-Day Test for Homogeneity [2]	0.6009	0.3284		
Any Serious TEAE	9 (12.3)	5 (15.6)	15 (14.3)	29 (13.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.84	1.11		
95% CI of the odds ratio	(0.35, 2.05)	(0.37, 3.34)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.86	1.09		
95% CI of the risk ratio	(0.40, 1.86)	(0.43, 2.78)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.96	1.34		
95% CI of the absolute risk difference	(-12.04, 8.13)	(-12.91, 15.59)		
p-value	0.7069	0.8510		
p-value of Breslow-Day Test for Homogeneity [2]	0.3858	0.8022		

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Any TEAEs >= Grade 3 Severity	13 (17.8)	8 (25.0)	19 (18.1)	40 (19.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	1.51		
95% CI of the odds ratio	(0.45, 2.14)	(0.59, 3.87)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	1.38		
95% CI of the risk ratio	(0.52, 1.86)	(0.67, 2.85)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.29	6.90		
95% CI of the absolute risk difference	(-11.74, 11.17)	(-9.81, 23.62)		
p-value	0.9609	0.3900		
p-value of Breslow-Day Test for Homogeneity [2]	0.1957	0.2693		
Any TEAEs <= Grade 2 Severity	67 (91.8)	29 (90.6)	96 (91.4)	192 (91.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.05	0.91		
95% CI of the odds ratio	(0.36, 3.08)	(0.23, 3.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.99		
95% CI of the risk ratio	(0.92, 1.10)	(0.87, 1.12)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.35	-0.80		
95% CI of the absolute risk difference	(-7.92, 8.62)	(-12.23, 10.63)		
p-value	0.9337	0.8881		
p-value of Breslow-Day Test for Homogeneity [2]	0.9998	0.5051		
Any TEAEs leading to Study-Drug Discontinuation	6 (8.2)	4 (12.5)	8 (7.6)	18 (8.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.09	1.73		
95% CI of the odds ratio	(0.36, 3.27)	(0.49, 6.18)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08	1.64		
95% CI of the risk ratio	(0.39, 2.98)	(0.53, 5.09)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.60	4.88		
95% CI of the absolute risk difference	(-7.49, 8.69)	(-7.65, 17.41)		
p-value	0.8837	0.3925		
p-value of Breslow-Day Test for Homogeneity [2]	0.8823	0.9050		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Any TEAEs leading to Study Discontinuation	2 (2.7)	3 (9.4)	3 (2.9)	8 (3.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96	3.52		
95% CI of the odds ratio	(0.16, 5.88)	(0.67, 18.36)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96	3.28		
95% CI of the risk ratio	(0.16, 5.60)	(0.70, 15.47)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.12	6.52		
95% CI of the absolute risk difference	(-5.03, 4.80)	(-4.07, 17.11)		
p-value	0.9628	0.1147		
p-value of Breslow-Day Test for Homogeneity [2]	0.3327	0.4616		
Any Fatal TEAEs	1 (1.4)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.37	NE		
95% CI of the absolute risk difference	(-1.30, 4.04)	NE		
p-value	0.2291	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
Any Treatment-related TEAE	29 (39.7)	14 (43.8)	30 (28.6)	73 (34.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.65	1.94		
95% CI of the odds ratio	(0.88, 3.10)	(0.86, 4.40)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.39	1.53		
95% CI of the risk ratio	(0.92, 2.10)	(0.93, 2.51)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.15	15.18		
95% CI of the absolute risk difference	(-3.01, 25.32)	(-4.06, 34.42)		
p-value	0.1200	0.1074		
p-value of Breslow-Day Test for Homogeneity [2]	0.7979	0.4063		

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (1.4)	3 (9.4)	0	4 (1.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	25.03		
95% CI of the odds ratio	NE	(1.26, 498.40)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	22.48		
95% CI of the risk ratio	NE	(1.19, 424.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.37	10.13		
95% CI of the absolute risk difference	(-1.30, 4.04)	(-0.45, 20.72)		
p-value	0.2291	0.0024		
p-value of Breslow-Day Test for Homogeneity [2]	0.3162	0.0077		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (2.7)	3 (9.4)	3 (2.9)	8 (3.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96	3.52		
95% CI of the odds ratio	(0.16, 5.88)	(0.67, 18.36)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96	3.28		
95% CI of the risk ratio	(0.16, 5.60)	(0.70, 15.47)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.12	6.52		
95% CI of the absolute risk difference	(-5.03, 4.80)	(-4.07, 17.11)		
p-value	0.9628	0.1147		
p-value of Breslow-Day Test for Homogeneity [2]	0.4646	0.5766		

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	2 (6.3)	1 (1.0)	3 (1.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	6.93		
95% CI of the odds ratio	NE	(0.61, 79.12)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	6.56		
95% CI of the risk ratio	NE	(0.61, 70.03)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.95	5.30		
95% CI of the absolute risk difference	(-2.81, 0.91)	(-3.29, 13.89)		
p-value	0.4031	0.0730		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3919		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	24 (32.9)	6 (18.8)	26 (24.8)	56 (26.7)
Grade 2	32 (43.8)	16 (50.0)	51 (48.6)	99 (47.1)
Grade 3	12 (16.4)	8 (25.0)	16 (15.2)	36 (17.1)
Grade 4	0	0	3 (2.9)	3 (1.4)
Grade 5	1 (1.4)	0	0	1 (0.5)

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	18 (24.7)	5 (15.6)	21 (20.0)	44 (21.0)
Grade 2	10 (13.7)	6 (18.8)	9 (8.6)	25 (11.9)
Grade 3	1 (1.4)	3 (9.4)	0	4 (1.9)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (1.4)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	1.37	NE		
95% CI of the absolute risk difference	(-1.30, 4.04)	NE		
p-value	0.2291	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	1 (1.4)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.37	NE		
95% CI of the absolute risk difference	(-1.30, 4.04)	NE		
p-value	0.2291	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
Serious 3-PT MACE AE - Adjudicated Event	1 (1.4)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.37	NE		
95% CI of the absolute risk difference	(-1.30, 4.04)	NE		
p-value	0.2291	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
Other MACE AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Events n:				
Total TEAEs	710	802	1475	2987
Total Serious TEAEs	11	26	70	107
Total TEAEs Leading to Discontinuation of Study Drug	6	14	14	34
Total TEAEs Related to Study Drug	85	90	107	282
Total TEAEs >= Grade 3 Severity	12	32	78	122
Patients n (%):				
Any TEAE	89 (94.7)	108 (90.8)	187 (94.4)	384 (93.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.05	0.58		
95% CI of the odds ratio	(0.35, 3.10)	(0.24, 1.38)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.96		
95% CI of the risk ratio	(0.95, 1.06)	(0.90, 1.03)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.24	-3.69		
95% CI of the absolute risk difference	(-5.31, 5.78)	(-9.79, 2.42)		
p-value	0.9339	0.2109		
p-value of Breslow-Day Test for Homogeneity [2]	0.5954	0.2133		
Any Serious TEAE	7 (7.4)	16 (13.4)	28 (14.1)	51 (12.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.49	0.94		
95% CI of the odds ratio	(0.21, 1.16)	(0.49, 1.83)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53	0.95		
95% CI of the risk ratio	(0.24, 1.16)	(0.54, 1.68)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.69	-0.70		
95% CI of the absolute risk difference	(-13.89, 0.50)	(-8.51, 7.12)		
p-value	0.0999	0.8622		
p-value of Breslow-Day Test for Homogeneity [2]	0.3858	0.8022		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Any TEAEs >= Grade 3 Severity	8 (8.5)	17 (14.3)	33 (16.7)	58 (14.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47	0.83		
95% CI of the odds ratio	(0.21, 1.05)	(0.44, 1.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	0.86		
95% CI of the risk ratio	(0.25, 1.06)	(0.50, 1.47)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.16	-2.38		
95% CI of the absolute risk difference	(-15.82, -0.49)	(-10.53, 5.77)		
p-value	0.0609	0.5733		
p-value of Breslow-Day Test for Homogeneity [2]	0.3500	0.3038		
Any TEAEs <= Grade 2 Severity	89 (94.7)	107 (89.9)	187 (94.4)	383 (93.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.05	0.52		
95% CI of the odds ratio	(0.35, 3.10)	(0.22, 1.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.95		
95% CI of the risk ratio	(0.95, 1.06)	(0.89, 1.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.24	-4.53		
95% CI of the absolute risk difference	(-5.31, 5.78)	(-10.81, 1.75)		
p-value	0.9339	0.1323		
p-value of Breslow-Day Test for Homogeneity [2]	0.9446	0.3399		
Any TEAEs leading to Study-Drug Discontinuation	4 (4.3)	12 (10.1)	10 (5.1)	26 (6.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.84	2.11		
95% CI of the odds ratio	(0.26, 2.74)	(0.88, 5.04)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.84	2.00		
95% CI of the risk ratio	(0.27, 2.62)	(0.89, 4.48)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.80	5.03		
95% CI of the absolute risk difference	(-5.89, 4.30)	(-1.18, 11.24)		
p-value	0.7664	0.0877		
p-value of Breslow-Day Test for Homogeneity [2]	0.6679	0.8907		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Any TEAEs leading to Study Discontinuation	1 (1.1)	8 (6.7)	8 (4.0)	17 (4.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.26	1.71		
95% CI of the odds ratio	(0.03, 2.07)	(0.62, 4.69)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.26	1.66		
95% CI of the risk ratio	(0.03, 2.07)	(0.64, 4.32)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.98	2.68		
95% CI of the absolute risk difference	(-6.42, 0.46)	(-2.59, 7.95)		
p-value	0.1691	0.2908		
p-value of Breslow-Day Test for Homogeneity [2]	0.3327	0.4616		
Any Fatal TEAEs	0	1 (0.8)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.67		
95% CI of the odds ratio	NE	(0.10, 26.94)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.66		
95% CI of the risk ratio	NE	(0.11, 26.35)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.51	0.34		
95% CI of the absolute risk difference	(-1.49, 0.48)	(-1.58, 2.25)		
p-value	0.4901	0.7151		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
Any Treatment-related TEAE	40 (42.6)	41 (34.5)	56 (28.3)	137 (33.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.88	1.33		
95% CI of the odds ratio	(1.12, 3.14)	(0.82, 2.17)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	1.22		
95% CI of the risk ratio	(1.09, 2.08)	(0.87, 1.70)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.27	6.17		
95% CI of the absolute risk difference	(2.47, 26.07)	(-4.42, 16.77)		
p-value	0.0153	0.2483		
p-value of Breslow-Day Test for Homogeneity [2]	0.7523	0.4361		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.51	-0.51		
95% CI of the absolute risk difference	(-1.49, 0.48)	(-1.49, 0.48)		
p-value	0.4901	0.4375		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (1.1)	0	2 (1.0)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.05	NE		
95% CI of the odds ratio	(0.09, 11.77)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.05	NE		
95% CI of the risk ratio	(0.10, 11.47)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.05	-1.01		
95% CI of the absolute risk difference	(-2.44, 2.55)	(-2.40, 0.38)		
p-value	0.9661	0.2714		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0077		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	1 (1.1)	7 (5.9)	6 (3.0)	14 (3.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.34	2.00		
95% CI of the odds ratio	(0.04, 2.90)	(0.66, 6.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.35	1.94		
95% CI of the risk ratio	(0.04, 2.87)	(0.67, 5.64)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.97	2.85		
95% CI of the absolute risk difference	(-5.13, 1.20)	(-2.00, 7.71)		
p-value	0.3047	0.2150		
p-value of Breslow-Day Test for Homogeneity [2]	0.4646	0.5766		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	5 (4.2)	4 (2.0)	9 (2.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.13		
95% CI of the odds ratio	NE	(0.56, 8.08)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.08		
95% CI of the risk ratio	NE	(0.57, 7.59)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.02	2.18		
95% CI of the absolute risk difference	(-3.98, -0.06)	(-1.92, 6.28)		
p-value	0.1653	0.2575		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3919		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	15 (16.0)	21 (17.6)	44 (22.2)	80 (19.5)
Grade 2	66 (70.2)	70 (58.8)	110 (55.6)	246 (59.9)
Grade 3	8 (8.5)	16 (13.4)	28 (14.1)	52 (12.7)
Grade 4	0	0	4 (2.0)	4 (1.0)
Grade 5	0	1 (0.8)	1 (0.5)	2 (0.5)

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	23 (24.5)	24 (20.2)	31 (15.7)	78 (19.0)
Grade 2	16 (17.0)	17 (14.3)	23 (11.6)	56 (13.6)
Grade 3	1 (1.1)	0	1 (0.5)	2 (0.5)
Grade 4	0	0	1 (0.5)	1 (0.2)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (0.8)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.67		
95% CI of the odds ratio	NE	(0.10, 26.94)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.66		
95% CI of the risk ratio	NE	(0.11, 26.35)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.51	0.34		
95% CI of the absolute risk difference	(-1.49, 0.48)	(-1.58, 2.25)		
p-value	0.4901	0.7151		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.8)	0	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	0.84		
95% CI of the absolute risk difference	NE	(-0.80, 2.48)		
p-value	NE	0.1964		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.51	-0.51		
95% CI of the absolute risk difference	(-1.49, 0.48)	(-1.49, 0.48)		
p-value	0.4901	0.4375		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
Serious 3-PT MACE AE - Adjudicated Event	0	1 (0.8)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.67		
95% CI of the odds ratio	NE	(0.10, 26.94)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.66		
95% CI of the risk ratio	NE	(0.11, 26.35)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.51	0.34		
95% CI of the absolute risk difference	(-1.49, 0.48)	(-1.58, 2.25)		
p-value	0.4901	0.7151		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
Other MACE AE - Adjudicated Event	0	1 (0.8)	4 (2.0)	5 (1.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.41		
95% CI of the odds ratio	NE	(0.05, 3.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.42		
95% CI of the risk ratio	NE	(0.05, 3.68)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.02	-1.18		
95% CI of the absolute risk difference	(-3.98, -0.06)	(-3.74, 1.38)		
p-value	0.1653	0.4143		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.8)	3 (1.5)	4 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.55		
95% CI of the odds ratio	NE	(0.06, 5.36)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.55		
95% CI of the risk ratio	NE	(0.06, 5.27)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.52	-0.67		
95% CI of the absolute risk difference	(-3.22, 0.19)	(-3.04, 1.69)		
p-value	0.2303	0.6022		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.51	-0.51		
95% CI of the absolute risk difference	(-1.49, 0.48)	(-1.49, 0.48)		
p-value	0.4901	0.4375		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (0.8)	3 (1.5)	4 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.55		
95% CI of the odds ratio	NE	(0.06, 5.36)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.55		
95% CI of the risk ratio	NE	(0.06, 5.27)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.52	-0.67		
95% CI of the absolute risk difference	(-3.22, 0.19)	(-3.04, 1.69)		
p-value	0.2303	0.6022		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: US

	MGL-3196 80 mg (N=94) n (%)	MGL-3196 100 mg (N=119) n (%)	Placebo (N=198) n (%)	Overall (N=411) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Events n:				
Total TEAEs	476	212	658	1346
Total Serious TEAEs	18	6	26	50
Total TEAEs Leading to Discontinuation of Study Drug	9	4	6	19
Total TEAEs Related to Study Drug	69	36	51	156
Total TEAEs >= Grade 3 Severity	19	12	25	56
Patients n (%):				
Any TEAE	68 (93.2)	30 (93.8)	94 (89.5)	192 (91.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.59	1.76		
95% CI of the odds ratio	(0.53, 4.79)	(0.37, 8.37)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04	1.05		
95% CI of the risk ratio	(0.95, 1.14)	(0.94, 1.17)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.63	4.23		
95% CI of the absolute risk difference	(-4.61, 11.87)	(-6.00, 14.46)		
p-value	0.4053	0.4751		
p-value of Breslow-Day Test for Homogeneity [2]	0.5954	0.2133		
Any Serious TEAE	9 (12.3)	5 (15.6)	15 (14.3)	29 (13.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.84	1.11		
95% CI of the odds ratio	(0.35, 2.05)	(0.37, 3.34)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.86	1.09		
95% CI of the risk ratio	(0.40, 1.86)	(0.43, 2.78)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.96	1.34		
95% CI of the absolute risk difference	(-12.04, 8.13)	(-12.91, 15.59)		
p-value	0.7069	0.8510		
p-value of Breslow-Day Test for Homogeneity [2]	0.3858	0.8022		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Any TEAEs >= Grade 3 Severity	11 (15.1)	8 (25.0)	19 (18.1)	38 (18.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	1.51		
95% CI of the odds ratio	(0.36, 1.81)	(0.59, 3.87)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83	1.38		
95% CI of the risk ratio	(0.42, 1.64)	(0.67, 2.85)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.03	6.90		
95% CI of the absolute risk difference	(-14.05, 8.00)	(-9.81, 23.62)		
p-value	0.5957	0.3900		
p-value of Breslow-Day Test for Homogeneity [2]	0.3500	0.3038		
Any TEAEs <= Grade 2 Severity	66 (90.4)	29 (90.6)	94 (89.5)	189 (90.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.10	1.13		
95% CI of the odds ratio	(0.41, 2.99)	(0.30, 4.33)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	1.01		
95% CI of the risk ratio	(0.91, 1.12)	(0.89, 1.15)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.89	1.10		
95% CI of the absolute risk difference	(-8.05, 9.83)	(-10.57, 12.78)		
p-value	0.8469	0.8571		
p-value of Breslow-Day Test for Homogeneity [2]	0.9446	0.3399		
Any TEAEs leading to Study-Drug Discontinuation	5 (6.8)	4 (12.5)	6 (5.7)	15 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21	2.36		
95% CI of the odds ratio	(0.36, 4.14)	(0.62, 8.94)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.20	2.19		
95% CI of the risk ratio	(0.38, 3.78)	(0.66, 7.27)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.14	6.79		
95% CI of the absolute risk difference	(-6.16, 8.43)	(-5.50, 19.07)		
p-value	0.7571	0.1964		
p-value of Breslow-Day Test for Homogeneity [2]	0.6679	0.8907		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Any TEAEs leading to Study Discontinuation	2 (2.7)	3 (9.4)	3 (2.9)	8 (3.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96	3.52		
95% CI of the odds ratio	(0.16, 5.88)	(0.67, 18.36)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96	3.28		
95% CI of the risk ratio	(0.16, 5.60)	(0.70, 15.47)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.12	6.52		
95% CI of the absolute risk difference	(-5.03, 4.80)	(-4.07, 17.11)		
p-value	0.9628	0.1147		
p-value of Breslow-Day Test for Homogeneity [2]	0.3327	0.4616		
Any Fatal TEAEs	1 (1.4)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.37	NE		
95% CI of the absolute risk difference	(-1.30, 4.04)	NE		
p-value	0.2291	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
Any Treatment-related TEAE	29 (39.7)	14 (43.8)	30 (28.6)	73 (34.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.65	1.94		
95% CI of the odds ratio	(0.88, 3.10)	(0.86, 4.40)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.39	1.53		
95% CI of the risk ratio	(0.92, 2.10)	(0.93, 2.51)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.15	15.18		
95% CI of the absolute risk difference	(-3.01, 25.32)	(-4.06, 34.42)		
p-value	0.1200	0.1074		
p-value of Breslow-Day Test for Homogeneity [2]	0.7523	0.4361		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	3 (9.4)	0	3 (1.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	25.03		
95% CI of the odds ratio	NE	(1.26, 498.40)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	22.48		
95% CI of the risk ratio	NE	(1.19, 424.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	10.13		
95% CI of the absolute risk difference	NE	(-0.45, 20.72)		
p-value	NE	0.0024		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0077		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (2.7)	3 (9.4)	3 (2.9)	8 (3.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96	3.52		
95% CI of the odds ratio	(0.16, 5.88)	(0.67, 18.36)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96	3.28		
95% CI of the risk ratio	(0.16, 5.60)	(0.70, 15.47)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.12	6.52		
95% CI of the absolute risk difference	(-5.03, 4.80)	(-4.07, 17.11)		
p-value	0.9628	0.1147		
p-value of Breslow-Day Test for Homogeneity [2]	0.4646	0.5766		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	2 (6.3)	1 (1.0)	3 (1.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	6.93		
95% CI of the odds ratio	NE	(0.61, 79.12)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	6.56		
95% CI of the risk ratio	NE	(0.61, 70.03)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.95	5.30		
95% CI of the absolute risk difference	(-2.81, 0.91)	(-3.29, 13.89)		
p-value	0.4031	0.0730		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3919		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	23 (31.5)	6 (18.8)	26 (24.8)	55 (26.2)
Grade 2	34 (46.6)	16 (50.0)	49 (46.7)	99 (47.1)
Grade 3	10 (13.7)	8 (25.0)	16 (15.2)	34 (16.2)
Grade 4	0	0	3 (2.9)	3 (1.4)
Grade 5	1 (1.4)	0	0	1 (0.5)

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	18 (24.7)	5 (15.6)	21 (20.0)	44 (21.0)
Grade 2	11 (15.1)	6 (18.8)	9 (8.6)	26 (12.4)
Grade 3	0	3 (9.4)	0	3 (1.4)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (1.4)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	1.37	NE		
95% CI of the absolute risk difference	(-1.30, 4.04)	NE		
p-value	0.2291	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	1 (1.4)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.37	NE		
95% CI of the absolute risk difference	(-1.30, 4.04)	NE		
p-value	0.2291	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
Serious 3-PT MACE AE - Adjudicated Event	1 (1.4)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.37	NE		
95% CI of the absolute risk difference	(-1.30, 4.04)	NE		
p-value	0.2291	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1971	NE		
Other MACE AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Region
(Label Population)

Region: Ex-US

	MGL-3196 80 mg (N=73) n (%)	MGL-3196 100 mg (N=32) n (%)	Placebo (N=105) n (%)	Overall (N=210) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.4.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.

AMNOG Table S1.4.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Region: US

System Organ Class Preferred Term	MGL-3196 80 mg (N=94) Patients n (%)	 Events n	MGL-3196 100 mg (N=119) Patients n (%)	 Events n	Placebo (N=198) Patients n (%)	 Events n	Overall (N=411) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	24 (25.5)	39	37 (31.1)	54	35 (17.7)	43	96 (23.4)	136
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.60		2.10					
95% CI of the odds ratio	(0.88, 2.88)		(1.23, 3.58)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44		1.76					
95% CI of the risk ratio	(0.91, 2.28)		(1.18, 2.63)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.86		13.42					
95% CI of the absolute risk difference	(-2.44, 18.15)		(3.55, 23.28)					
p-value	0.1183		0.0058					
p-value of Breslow-Day Test for Homogeneity [2]	0.5634		0.0967					
Nausea	28 (29.8)	34	17 (14.3)	22	30 (15.2)	36	75 (18.2)	92
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.38		0.93					
95% CI of the odds ratio	(1.32, 4.28)		(0.49, 1.78)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.97		0.94					
95% CI of the risk ratio	(1.25, 3.09)		(0.54, 1.63)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.64		-0.87					
95% CI of the absolute risk difference	(4.13, 25.14)		(-8.90, 7.16)					
p-value	0.0034		0.8336					
p-value of Breslow-Day Test for Homogeneity [2]	0.7833		0.4926					

AMNOG Table S1.4.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Region: US

System Organ Class Preferred Term	MGL-3196 80 mg (N=94) Patients n (%)	 Events n	MGL-3196 100 mg (N=119) Patients n (%)	 Events n	Placebo (N=198) Patients n (%)	 Events n	Overall (N=411) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	14 (14.9)	15	8 (6.7)	8	13 (6.6)	14	35 (8.5)	37
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.49		1.03					
95% CI of the odds ratio	(1.12, 5.54)		(0.41, 2.55)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.27		1.02					
95% CI of the risk ratio	(1.11, 4.63)		(0.44, 2.40)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.33		0.16					
95% CI of the absolute risk difference	(0.35, 16.31)		(-5.51, 5.83)					
p-value	0.0217		0.9566					
p-value of Breslow-Day Test for Homogeneity [2]	0.9014		0.8509					
Abdominal discomfort	1 (1.1)	1	2 (1.7)	3	7 (3.5)	7	10 (2.4)	11
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		0.47					
95% CI of the odds ratio	(0.04, 2.42)		(0.10, 2.28)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.30		0.48					
95% CI of the risk ratio	(0.04, 2.41)		(0.10, 2.25)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.47		-1.85					
95% CI of the absolute risk difference	(-5.78, 0.83)		(-5.31, 1.60)					
p-value	0.2267		0.3357					
p-value of Breslow-Day Test for Homogeneity [2]	0.2908		0.9230					

AMNOG Table S1.4.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Region: US

System Organ Class Preferred Term	MGL-3196 80 mg (N=94) Patients n (%)	 Events n	MGL-3196 100 mg (N=119) Patients n (%)	 Events n	Placebo (N=198) Patients n (%)	 Events n	Overall (N=411) Patients n (%)	 Events n
General disorders and administration site conditions	18 (19.1)	28	22 (18.5)	30	55 (27.8)	68	95 (23.1)	126
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.62		0.59					
95% CI of the odds ratio	(0.34, 1.12)		(0.34, 1.03)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69		0.67					
95% CI of the risk ratio	(0.43, 1.11)		(0.43, 1.03)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.63		-9.29					
95% CI of the absolute risk difference	(-18.74, 1.48)		(-18.65, 0.07)					
p-value	0.1116		0.0618					
p-value of Breslow-Day Test for Homogeneity [2]	0.6537		0.7582					
Skin and subcutaneous tissue disorders								
Pruritus	12 (12.8)	14	8 (6.7)	10	13 (6.6)	14	33 (8.0)	38
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.08		1.03					
95% CI of the odds ratio	(0.91, 4.76)		(0.41, 2.55)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.94		1.02					
95% CI of the risk ratio	(0.92, 4.10)		(0.44, 2.40)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.20		0.16					
95% CI of the absolute risk difference	(-1.38, 13.78)		(-5.51, 5.83)					
p-value	0.0769		0.9566					
p-value of Breslow-Day Test for Homogeneity [2]	0.6112		0.0805					

AMNOG Table S1.4.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Region: US

System Organ Class Preferred Term	MGL-3196 80 mg (N=94) Patients n (%)	 Events n	MGL-3196 100 mg (N=119) Patients n (%)	 Events n	Placebo (N=198) Patients n (%)	 Events n	Overall (N=411) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	6 (6.4)	6	12 (10.1)	15	11 (5.6)	13	29 (7.1)	34
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.16		1.91					
95% CI of the odds ratio	(0.42, 3.24)		(0.81, 4.47)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.15		1.82					
95% CI of the risk ratio	(0.44, 3.01)		(0.83, 3.98)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.83		4.53					
95% CI of the absolute risk difference	(-5.05, 6.71)		(-1.75, 10.81)					
p-value	0.7779		0.1323					
p-value of Breslow-Day Test for Homogeneity [2]	0.4804		0.0640					
Renal and urinary disorders	5 (5.3)	6	17 (14.3)	21	19 (9.6)	24	41 (10.0)	51
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53		1.57					
95% CI of the odds ratio	(0.19, 1.46)		(0.78, 3.16)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.55		1.49					
95% CI of the risk ratio	(0.21, 1.44)		(0.81, 2.75)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.28		4.69					
95% CI of the absolute risk difference	(-10.39, 1.84)		(-2.82, 12.20)					
p-value	0.2138		0.2025					
p-value of Breslow-Day Test for Homogeneity [2]	0.0956		0.7770					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Region: US

System Organ Class Preferred Term	MGL-3196 80 mg (N=94) Patients n (%)	 Events n	MGL-3196 100 mg (N=119) Patients n (%)	 Events n	Placebo (N=198) Patients n (%)	 Events n	Overall (N=411) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	5 (5.3)	6	4 (3.4)	4	18 (9.1)	20	27 (6.6)	30
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56		0.35					
95% CI of the odds ratio	(0.20, 1.56)		(0.11, 1.05)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59		0.37					
95% CI of the risk ratio	(0.22, 1.53)		(0.13, 1.07)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.77		-5.73					
95% CI of the absolute risk difference	(-9.82, 2.28)		(-10.88, -0.58)					
p-value	0.2636		0.0519					
p-value of Breslow-Day Test for Homogeneity [2]	0.8468		0.4120					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Region: US

System Organ Class Preferred Term	MGL-3196 80 mg (N=94) Patients n (%)	 Events n	MGL-3196 100 mg (N=119) Patients n (%)	 Events n	Placebo (N=198) Patients n (%)	 Events n	Overall (N=411) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	1 (1.1)	1	0	0	7 (3.5)	11	8 (1.9)	12
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		NE					
95% CI of the odds ratio	(0.04, 2.42)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.30		NE					
95% CI of the risk ratio	(0.04, 2.41)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.47		-3.54					
95% CI of the absolute risk difference	(-5.78, 0.83)		(-6.11, -0.96)					
p-value	0.2267		0.0381					
p-value of Breslow-Day Test for Homogeneity [2]	0.7623		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Region: Ex-US

System Organ Class Preferred Term	MGL-3196 80 mg (N=73) Patients n (%)	 Events n	MGL-3196 100 mg (N=32) Patients n (%)	 Events n	Placebo (N=105) Patients n (%)	 Events n	Overall (N=210) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	18 (24.7)	34	14 (43.8)	26	14 (13.3)	18	46 (21.9)	78
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.13		5.06					
95% CI of the odds ratio	(0.98, 4.62)		(2.06, 12.40)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.85		3.28					
95% CI of the risk ratio	(0.98, 3.48)		(1.75, 6.14)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.32		30.42					
95% CI of the absolute risk difference	(-0.51, 23.16)		(12.04, 48.79)					
p-value	0.0530		0.0002					
p-value of Breslow-Day Test for Homogeneity [2]	0.5634		0.0967					
Nausea	15 (20.5)	17	4 (12.5)	4	9 (8.6)	10	28 (13.3)	31
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.76		1.52					
95% CI of the odds ratio	(1.13, 6.71)		(0.44, 5.32)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.40		1.46					
95% CI of the risk ratio	(1.11, 5.18)		(0.48, 4.42)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.98		3.93					
95% CI of the absolute risk difference	(1.27, 22.68)		(-8.72, 16.58)					
p-value	0.0214		0.5068					
p-value of Breslow-Day Test for Homogeneity [2]	0.7833		0.4926					

AMNOG Table S1.4.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Region: Ex-US

System Organ Class Preferred Term	MGL-3196 80 mg (N=73) Patients n (%)	 Events n	MGL-3196 100 mg (N=32) Patients n (%)	 Events n	Placebo (N=105) Patients n (%)	 Events n	Overall (N=210) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	6 (8.2)	7	1 (3.1)	1	4 (3.8)	4	11 (5.2)	12
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.26		0.81					
95% CI of the odds ratio	(0.61, 8.32)		(0.09, 7.56)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.16		0.82					
95% CI of the risk ratio	(0.63, 7.38)		(0.10, 7.08)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.41		-0.68					
95% CI of the absolute risk difference	(-2.88, 11.70)		(-7.74, 6.37)					
p-value	0.2089		0.8565					
p-value of Breslow-Day Test for Homogeneity [2]	0.9014		0.8509					
Abdominal discomfort	0	0	1 (3.1)	1	6 (5.7)	7	7 (3.3)	8
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.10		0.53					
95% CI of the odds ratio	(0.01, 1.88)		(0.06, 4.59)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11		0.55					
95% CI of the risk ratio	(0.01, 1.93)		(0.07, 4.38)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.46		-2.59					
95% CI of the absolute risk difference	(-10.39, -0.52)		(-10.08, 4.90)					
p-value	0.0624		0.5603					
p-value of Breslow-Day Test for Homogeneity [2]	0.2908		0.9230					

AMNOG Table S1.4.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Region: Ex-US

System Organ Class Preferred Term	MGL-3196 80 mg (N=73) Patients n (%)	 Events n	MGL-3196 100 mg (N=32) Patients n (%)	 Events n	Placebo (N=105) Patients n (%)	 Events n	Overall (N=210) Patients n (%)	 Events n
General disorders and administration site conditions	17 (23.3)	24	7 (21.9)	9	30 (28.6)	36	54 (25.7)	69
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76		0.70					
95% CI of the odds ratio	(0.38, 1.51)		(0.27, 1.79)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82		0.77					
95% CI of the risk ratio	(0.49, 1.36)		(0.37, 1.57)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.28		-6.70					
95% CI of the absolute risk difference	(-18.27, 7.70)		(-23.42, 10.03)					
p-value	0.4315		0.4551					
p-value of Breslow-Day Test for Homogeneity [2]	0.6537		0.7582					
Skin and subcutaneous tissue disorders								
Pruritus	10 (13.7)	14	0	0	10 (9.5)	12	20 (9.5)	26
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.51		0.14					
95% CI of the odds ratio	(0.59, 3.83)		(0.01, 2.46)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44		0.15					
95% CI of the risk ratio	(0.63, 3.28)		(0.01, 2.54)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.17		-8.39					
95% CI of the absolute risk difference	(-5.51, 13.86)		(-15.44, -1.34)					
p-value	0.3857		0.1189					
p-value of Breslow-Day Test for Homogeneity [2]	0.6112		0.0805					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Region: Ex-US

System Organ Class Preferred Term	MGL-3196 80 mg (N=73) Patients n (%)	 Events n	MGL-3196 100 mg (N=32) Patients n (%)	 Events n	Placebo (N=105) Patients n (%)	 Events n	Overall (N=210) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	2 (2.7)	2	4 (12.5)	5	1 (1.0)	1	7 (3.3)	8
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.93		14.86					
95% CI of the odds ratio	(0.26, 32.92)		(1.60, 138.26)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.88		13.13					
95% CI of the risk ratio	(0.27, 31.14)		(1.52, 113.27)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.79		11.55					
95% CI of the absolute risk difference	(-2.39, 5.97)		(-0.06, 23.16)					
p-value	0.3622		0.0023					
p-value of Breslow-Day Test for Homogeneity [2]	0.4804		0.0640					
Renal and urinary disorders	0	0	3 (9.4)	3	8 (7.6)	9	11 (5.2)	12
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.08		1.25					
95% CI of the odds ratio	(0.00, 1.37)		(0.31, 5.04)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.08		1.23					
95% CI of the risk ratio	(0.00, 1.44)		(0.35, 4.37)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.34		1.76					
95% CI of the absolute risk difference	(-12.84, -1.85)		(-9.55, 13.06)					
p-value	0.0261		0.7490					
p-value of Breslow-Day Test for Homogeneity [2]	0.0956		0.7770					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.4.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Region: Ex-US

System Organ Class Preferred Term	MGL-3196 80 mg (N=73) Patients n (%)	 Events n	MGL-3196 100 mg (N=32) Patients n (%)	 Events n	Placebo (N=105) Patients n (%)	 Events n	Overall (N=210) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	2 (2.7)	2	0	0	6 (5.7)	8	8 (3.8)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.46		0.24					
95% CI of the odds ratio	(0.09, 2.37)		(0.01, 4.30)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48		0.25					
95% CI of the risk ratio	(0.10, 2.31)		(0.01, 4.27)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.97		-4.62					
95% CI of the absolute risk difference	(-8.78, 2.83)		(-10.80, 1.57)					
p-value	0.3461		0.2896					
p-value of Breslow-Day Test for Homogeneity [2]	0.8468		0.4120					

AMNOG Table S1.4.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Region: Ex-US

System Organ Class Preferred Term	MGL-3196 80 mg (N=73) Patients n (%)	 Events n	MGL-3196 100 mg (N=32) Patients n (%)	 Events n	Placebo (N=105) Patients n (%)	 Events n	Overall (N=210) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	1 (1.4)	1	0	0	3 (2.9)	3	4 (1.9)	4
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47		NE					
95% CI of the odds ratio	(0.05, 4.63)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48		NE					
95% CI of the risk ratio	(0.05, 4.52)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.49		-2.86					
95% CI of the absolute risk difference	(-5.64, 2.67)		(-6.04, 0.33)					
p-value	0.5102		0.3336					
p-value of Breslow-Day Test for Homogeneity [2]	0.7623		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Events n:				
Total TEAEs	366	1022	1330	2718
Total Serious TEAEs	6	32	50	88
Total TEAEs Leading to Discontinuation of Study Drug	1	20	13	34
Total TEAEs Related to Study Drug	37	126	91	254
Total TEAEs >= Grade 3 Severity	11	45	58	114
Patients n (%):				
Any TEAE	47 (90.4)	138 (91.4)	172 (92.5)	357 (91.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.77	0.86		
95% CI of the odds ratio	(0.26, 2.23)	(0.39, 1.90)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	0.99		
95% CI of the risk ratio	(0.89, 1.08)	(0.93, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.09	-1.08		
95% CI of the absolute risk difference	(-10.95, 6.78)	(-6.95, 4.78)		
p-value	0.6233	0.7159		
p-value of Breslow-Day Test for Homogeneity [2]	0.4294	NE		
Any Serious TEAE	4 (7.7)	21 (13.9)	29 (15.6)	54 (13.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45	0.87		
95% CI of the odds ratio	(0.15, 1.35)	(0.48, 1.61)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.49	0.89		
95% CI of the risk ratio	(0.18, 1.34)	(0.53, 1.50)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.90	-1.68		
95% CI of the absolute risk difference	(-16.82, 1.02)	(-9.28, 5.91)		
p-value	0.1451	0.6654		
p-value of Breslow-Day Test for Homogeneity [2]	0.3530	NE		

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Any TEAEs >= Grade 3 Severity	8 (15.4)	26 (17.2)	37 (19.9)	71 (18.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.84		
95% CI of the odds ratio	(0.32, 1.69)	(0.48, 1.46)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.77	0.87		
95% CI of the risk ratio	(0.38, 1.56)	(0.55, 1.36)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.51	-2.67		
95% CI of the absolute risk difference	(-15.87, 6.85)	(-10.99, 5.64)		
p-value	0.4630	0.5312		
p-value of Breslow-Day Test for Homogeneity [2]	0.9438	NE		
Any TEAEs <= Grade 2 Severity	46 (88.5)	136 (90.1)	172 (92.5)	354 (91.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.62	0.74		
95% CI of the odds ratio	(0.23, 1.71)	(0.34, 1.58)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96	0.97		
95% CI of the risk ratio	(0.86, 1.06)	(0.91, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.01	-2.41		
95% CI of the absolute risk difference	(-13.49, 5.46)	(-8.50, 3.69)		
p-value	0.3567	0.4333		
p-value of Breslow-Day Test for Homogeneity [2]	0.4216	NE		
Any TEAEs leading to Study-Drug Discontinuation	1 (1.9)	18 (11.9)	12 (6.5)	31 (8.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.28	1.96		
95% CI of the odds ratio	(0.04, 2.24)	(0.91, 4.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.30	1.85		
95% CI of the risk ratio	(0.04, 2.24)	(0.92, 3.71)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.53	5.47		
95% CI of the absolute risk difference	(-9.67, 0.61)	(-0.79, 11.73)		
p-value	0.2039	0.0796		
p-value of Breslow-Day Test for Homogeneity [2]	0.1704	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Any TEAEs leading to Study Discontinuation	0	11 (7.3)	5 (2.7)	16 (4.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.84		
95% CI of the odds ratio	NE	(0.97, 8.37)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.71		
95% CI of the risk ratio	NE	(0.96, 7.63)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.69	4.60		
95% CI of the absolute risk difference	(-5.01, -0.36)	(-0.16, 9.35)		
p-value	0.2321	0.0485		
p-value of Breslow-Day Test for Homogeneity [2]	0.3976	NE		
Any Fatal TEAEs	0	1 (0.7)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the odds ratio	NE	(0.08, 19.88)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the risk ratio	NE	(0.08, 19.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.54	0.12		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.54, 1.79)		
p-value	0.5962	0.8823		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
Any Treatment-related TEAE	20 (38.5)	55 (36.4)	47 (25.3)	122 (31.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.85	1.69		
95% CI of the odds ratio	(0.97, 3.54)	(1.06, 2.71)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.52	1.44		
95% CI of the risk ratio	(1.00, 2.32)	(1.04, 1.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.19	11.16		
95% CI of the absolute risk difference	(-1.43, 27.82)	(1.26, 21.05)		
p-value	0.0615	0.0266		
p-value of Breslow-Day Test for Homogeneity [2]	0.5476	NE		

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.5)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.54	-0.54		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.59, 0.51)		
p-value	0.5962	0.3669		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	3 (2.0)	1 (0.5)	4 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.75		
95% CI of the odds ratio	NE	(0.39, 36.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.70		
95% CI of the risk ratio	NE	(0.39, 35.16)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.54	1.45		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.01, 3.91)		
p-value	0.5962	0.2219		
p-value of Breslow-Day Test for Homogeneity [2]	0.4843	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	10 (6.6)	6 (3.2)	16 (4.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.13		
95% CI of the odds ratio	NE	(0.76, 5.99)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.05		
95% CI of the risk ratio	NE	(0.76, 5.52)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.23	3.40		
95% CI of the absolute risk difference	(-5.76, -0.69)	(-1.31, 8.11)		
p-value	0.1896	0.1448		
p-value of Breslow-Day Test for Homogeneity [2]	0.2131	NE		

Madrigal Pharmaceuticals, Inc. Page 6 of 21
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	7 (4.6)	3 (1.6)	10 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.97		
95% CI of the odds ratio	NE	(0.75, 11.67)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.87		
95% CI of the risk ratio	NE	(0.76, 10.93)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.61	3.02		
95% CI of the absolute risk difference	(-3.42, 0.20)	(-0.79, 6.83)		
p-value	0.3567	0.1039		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	12 (23.1)	26 (17.2)	34 (18.3)	72 (18.5)
Grade 2	27 (51.9)	86 (57.0)	101 (54.3)	214 (55.0)
Grade 3	8 (15.4)	25 (16.6)	33 (17.7)	66 (17.0)
Grade 4	0	0	3 (1.6)	3 (0.8)
Grade 5	0	1 (0.7)	1 (0.5)	2 (0.5)

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	14 (26.9)	29 (19.2)	28 (15.1)	71 (18.3)
Grade 2	6 (11.5)	23 (15.2)	18 (9.7)	47 (12.1)
Grade 3	0	3 (2.0)	0	3 (0.8)
Grade 4	0	0	1 (0.5)	1 (0.3)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (0.7)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the odds ratio	NE	(0.08, 19.88)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the risk ratio	NE	(0.08, 19.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.54	0.12		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.54, 1.79)		
p-value	0.5962	0.8823		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.7)	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	0.66		
95% CI of the absolute risk difference	NE	(-0.63, 1.96)		
p-value	NE	0.2663		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.54	-0.54		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.59, 0.51)		
p-value	0.5962	0.3669		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
Serious 3-PT MACE AE - Adjudicated Event	0	1 (0.7)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the odds ratio	NE	(0.08, 19.88)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the risk ratio	NE	(0.08, 19.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.54	0.12		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.54, 1.79)		
p-value	0.5962	0.8823		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
Other MACE AE - Adjudicated Event	0	1 (0.7)	2 (1.1)	3 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.61		
95% CI of the odds ratio	NE	(0.06, 6.83)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.62		
95% CI of the risk ratio	NE	(0.06, 6.73)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.08	-0.41		
95% CI of the absolute risk difference	(-2.56, 0.41)	(-2.38, 1.55)		
p-value	0.4527	0.6881		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.7)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the odds ratio	NE	(0.08, 19.88)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the risk ratio	NE	(0.08, 19.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.54	0.12		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.54, 1.79)		
p-value	0.5962	0.8823		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.54	-0.54		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.59, 0.51)		
p-value	0.5962	0.3669		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (0.7)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the odds ratio	NE	(0.08, 19.88)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the risk ratio	NE	(0.08, 19.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.54	0.12		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.54, 1.79)		
p-value	0.5962	0.8823		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
DILI AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE - Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE - Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Events n:				
Total TEAEs	833	0	827	1660
Total Serious TEAEs	23	0	46	69
Total TEAEs Leading to Discontinuation of Study Drug	17	0	12	29
Total TEAEs Related to Study Drug	118	0	68	186
Total TEAEs >= Grade 3 Severity	23	0	48	71
Patients n (%):				
Any TEAE	111 (96.5)	0	111 (94.9)	222 (95.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	NE		
95% CI of the odds ratio	(0.41, 5.46)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	NE		
95% CI of the risk ratio	(0.96, 1.07)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.65	NE		
95% CI of the absolute risk difference	(-3.56, 6.86)	NE		
p-value	0.5361	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.4294	NE		
Any Serious TEAE	12 (10.4)	0	14 (12.0)	26 (11.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.86	NE		
95% CI of the odds ratio	(0.38, 1.94)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87	NE		
95% CI of the risk ratio	(0.42, 1.80)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.53	NE		
95% CI of the absolute risk difference	(-9.64, 6.58)	NE		
p-value	0.7117	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.3530	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Any TEAEs >= Grade 3 Severity	14 (12.2)	0	18 (15.4)	32 (13.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76	NE		
95% CI of the odds ratio	(0.36, 1.62)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.79	NE		
95% CI of the risk ratio	(0.41, 1.51)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.21	NE		
95% CI of the absolute risk difference	(-12.07, 5.65)	NE		
p-value	0.4783	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.9438	NE		
Any TEAEs <= Grade 2 Severity	110 (95.7)	0	111 (94.9)	221 (95.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.19	NE		
95% CI of the odds ratio	(0.35, 4.01)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	NE		
95% CI of the risk ratio	(0.95, 1.07)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.78	NE		
95% CI of the absolute risk difference	(-4.68, 6.25)	NE		
p-value	0.7798	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.4216	NE		
Any TEAEs leading to Study-Drug Discontinuation	11 (9.6)	0	9 (7.7)	20 (8.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.27	NE		
95% CI of the odds ratio	(0.51, 3.19)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.24	NE		
95% CI of the risk ratio	(0.54, 2.89)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.87	NE		
95% CI of the absolute risk difference	(-5.35, 9.10)	NE		
p-value	0.6113	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1704	NE		

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Any TEAEs leading to Study Discontinuation	3 (2.6)	0	6 (5.1)	9 (3.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50	NE		
95% CI of the odds ratio	(0.12, 2.03)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	NE		
95% CI of the risk ratio	(0.13, 1.99)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.52	NE		
95% CI of the absolute risk difference	(-7.47, 2.43)	NE		
p-value	0.3204	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.3976	NE		
Any Fatal TEAEs	1 (0.9)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.87	NE		
95% CI of the absolute risk difference	(-0.83, 2.57)	NE		
p-value	0.3121	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
Any Treatment-related TEAE	49 (42.6)	0	40 (34.2)	89 (38.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43	NE		
95% CI of the odds ratio	(0.84, 2.43)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25	NE		
95% CI of the risk ratio	(0.90, 1.73)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.42	NE		
95% CI of the absolute risk difference	(-4.05, 20.89)	NE		
p-value	0.1872	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.5476	NE		

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	2 (1.7)	0	1 (0.9)	3 (1.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.05	NE		
95% CI of the odds ratio	(0.18, 22.96)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.03	NE		
95% CI of the risk ratio	(0.19, 22.13)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.88	NE		
95% CI of the absolute risk difference	(-2.03, 3.80)	NE		
p-value	0.5511	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.4843	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	3 (2.6)	0	3 (2.6)	6 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	NE		
95% CI of the odds ratio	(0.20, 5.15)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	NE		
95% CI of the risk ratio	(0.21, 4.94)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.04	NE		
95% CI of the absolute risk difference	(-4.04, 4.13)	NE		
p-value	0.9829	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2131	NE		

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	2 (1.7)	2 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.71	NE		
95% CI of the absolute risk difference	(-4.06, 0.64)	NE		
p-value	0.1591	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	27 (23.5)	0	35 (29.9)	62 (26.7)
Grade 2	70 (60.9)	0	58 (49.6)	128 (55.2)
Grade 3	13 (11.3)	0	14 (12.0)	27 (11.6)
Grade 4	0	0	4 (3.4)	4 (1.7)
Grade 5	1 (0.9)	0	0	1 (0.4)

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	27 (23.5)	0	25 (21.4)	52 (22.4)
Grade 2	20 (17.4)	0	14 (12.0)	34 (14.7)
Grade 3	2 (1.7)	0	1 (0.9)	3 (1.3)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (0.9)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.87	NE		
95% CI of the absolute risk difference	(-0.83, 2.57)	NE		
p-value	0.3121	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	1 (0.9)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.87	NE		
95% CI of the absolute risk difference	(-0.83, 2.57)	NE		
p-value	0.3121	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
Serious 3-PT MACE AE - Adjudicated Event	1 (0.9)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.87	NE		
95% CI of the absolute risk difference	(-0.83, 2.57)	NE		
p-value	0.3121	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
Other MACE AE - Adjudicated Event	0	0	2 (1.7)	2 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.71	NE		
95% CI of the absolute risk difference	(-4.06, 0.64)	NE		
p-value	0.1591	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (1.7)	2 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.71	NE		
95% CI of the absolute risk difference	(-4.06, 0.64)	NE		
p-value	0.1591	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (1.7)	2 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.71	NE		
95% CI of the absolute risk difference	(-4.06, 0.64)	NE		
p-value	0.1591	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Events n:				
Total TEAEs	364	1014	1317	2695
Total Serious TEAEs	6	32	50	88
Total TEAEs Leading to Discontinuation of Study Drug	1	18	10	29
Total TEAEs Related to Study Drug	37	126	91	254
Total TEAEs >= Grade 3 Severity	10	44	57	111
Patients n (%):				
Any TEAE	47 (90.4)	138 (91.4)	171 (91.9)	356 (91.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82	0.93		
95% CI of the odds ratio	(0.29, 2.39)	(0.43, 2.02)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	0.99		
95% CI of the risk ratio	(0.89, 1.08)	(0.93, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.55	-0.54		
95% CI of the absolute risk difference	(-10.47, 7.37)	(-6.49, 5.40)		
p-value	0.7216	0.8570		
p-value of Breslow-Day Test for Homogeneity [2]	0.5118	NE		
Any Serious TEAE	4 (7.7)	21 (13.9)	29 (15.6)	54 (13.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45	0.87		
95% CI of the odds ratio	(0.15, 1.35)	(0.48, 1.61)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.49	0.89		
95% CI of the risk ratio	(0.18, 1.34)	(0.53, 1.50)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.90	-1.68		
95% CI of the absolute risk difference	(-16.82, 1.02)	(-9.28, 5.91)		
p-value	0.1451	0.6654		
p-value of Breslow-Day Test for Homogeneity [2]	0.3530	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Any TEAEs >= Grade 3 Severity	7 (13.5)	25 (16.6)	36 (19.4)	68 (17.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.65	0.83		
95% CI of the odds ratio	(0.27, 1.56)	(0.47, 1.45)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.70	0.86		
95% CI of the risk ratio	(0.33, 1.47)	(0.54, 1.36)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.89	-2.80		
95% CI of the absolute risk difference	(-16.77, 4.98)	(-11.01, 5.41)		
p-value	0.3288	0.5070		
p-value of Breslow-Day Test for Homogeneity [2]	0.8342	NE		
Any TEAEs <= Grade 2 Severity	46 (88.5)	136 (90.1)	171 (91.9)	353 (90.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67	0.80		
95% CI of the odds ratio	(0.25, 1.83)	(0.38, 1.68)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96	0.98		
95% CI of the risk ratio	(0.86, 1.07)	(0.92, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.47	-1.87		
95% CI of the absolute risk difference	(-13.00, 6.05)	(-8.04, 4.30)		
p-value	0.4349	0.5490		
p-value of Breslow-Day Test for Homogeneity [2]	0.4786	NE		
Any TEAEs leading to Study-Drug Discontinuation	1 (1.9)	16 (10.6)	9 (4.8)	26 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	2.33		
95% CI of the odds ratio	(0.05, 3.12)	(1.00, 5.44)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40	2.19		
95% CI of the risk ratio	(0.05, 3.07)	(1.00, 4.82)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.92	5.76		
95% CI of the absolute risk difference	(-7.76, 1.93)	(-0.04, 11.55)		
p-value	0.3542	0.0449		
p-value of Breslow-Day Test for Homogeneity [2]	0.3360	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Any TEAEs leading to Study Discontinuation	0	11 (7.3)	5 (2.7)	16 (4.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.84		
95% CI of the odds ratio	NE	(0.97, 8.37)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.71		
95% CI of the risk ratio	NE	(0.96, 7.63)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.69	4.60		
95% CI of the absolute risk difference	(-5.01, -0.36)	(-0.16, 9.35)		
p-value	0.2321	0.0485		
p-value of Breslow-Day Test for Homogeneity [2]	0.3976	NE		
Any Fatal TEAEs	0	1 (0.7)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the odds ratio	NE	(0.08, 19.88)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the risk ratio	NE	(0.08, 19.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.54	0.12		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.54, 1.79)		
p-value	0.5962	0.8823		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
Any Treatment-related TEAE	20 (38.5)	55 (36.4)	47 (25.3)	122 (31.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.85	1.69		
95% CI of the odds ratio	(0.97, 3.54)	(1.06, 2.71)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.52	1.44		
95% CI of the risk ratio	(1.00, 2.32)	(1.04, 1.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.19	11.16		
95% CI of the absolute risk difference	(-1.43, 27.82)	(1.26, 21.05)		
p-value	0.0615	0.0266		
p-value of Breslow-Day Test for Homogeneity [2]	0.6092	NE		

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.5)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.54	-0.54		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.59, 0.51)		
p-value	0.5962	0.3669		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	3 (2.0)	1 (0.5)	4 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.75		
95% CI of the odds ratio	NE	(0.39, 36.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.70		
95% CI of the risk ratio	NE	(0.39, 35.16)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.54	1.45		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.01, 3.91)		
p-value	0.5962	0.2219		
p-value of Breslow-Day Test for Homogeneity [2]	0.6063	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	10 (6.6)	6 (3.2)	16 (4.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.13		
95% CI of the odds ratio	NE	(0.76, 5.99)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.05		
95% CI of the risk ratio	NE	(0.76, 5.52)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.23	3.40		
95% CI of the absolute risk difference	(-5.76, -0.69)	(-1.31, 8.11)		
p-value	0.1896	0.1448		
p-value of Breslow-Day Test for Homogeneity [2]	0.2131	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	7 (4.6)	3 (1.6)	10 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.97		
95% CI of the odds ratio	NE	(0.75, 11.67)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.87		
95% CI of the risk ratio	NE	(0.76, 10.93)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.61	3.02		
95% CI of the absolute risk difference	(-3.42, 0.20)	(-0.79, 6.83)		
p-value	0.3567	0.1039		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	12 (23.1)	27 (17.9)	34 (18.3)	73 (18.8)
Grade 2	28 (53.8)	86 (57.0)	101 (54.3)	215 (55.3)
Grade 3	7 (13.5)	24 (15.9)	32 (17.2)	63 (16.2)
Grade 4	0	0	3 (1.6)	3 (0.8)
Grade 5	0	1 (0.7)	1 (0.5)	2 (0.5)

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	14 (26.9)	29 (19.2)	28 (15.1)	71 (18.3)
Grade 2	6 (11.5)	23 (15.2)	18 (9.7)	47 (12.1)
Grade 3	0	3 (2.0)	0	3 (0.8)
Grade 4	0	0	1 (0.5)	1 (0.3)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (0.7)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the odds ratio	NE	(0.08, 19.88)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the risk ratio	NE	(0.08, 19.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.54	0.12		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.54, 1.79)		
p-value	0.5962	0.8823		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.7)	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	0.66		
95% CI of the absolute risk difference	NE	(-0.63, 1.96)		
p-value	NE	0.2663		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.54	-0.54		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.59, 0.51)		
p-value	0.5962	0.3669		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
Serious 3-PT MACE AE - Adjudicated Event	0	1 (0.7)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the odds ratio	NE	(0.08, 19.88)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the risk ratio	NE	(0.08, 19.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.54	0.12		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.54, 1.79)		
p-value	0.5962	0.8823		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
Other MACE AE - Adjudicated Event	0	1 (0.7)	2 (1.1)	3 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.61		
95% CI of the odds ratio	NE	(0.06, 6.83)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.62		
95% CI of the risk ratio	NE	(0.06, 6.73)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.08	-0.41		
95% CI of the absolute risk difference	(-2.56, 0.41)	(-2.38, 1.55)		
p-value	0.4527	0.6881		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Other MACE AE - Adjudicated Event >= Grade 3 Severity	0	1 (0.7)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the odds ratio	NE	(0.08, 19.88)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the risk ratio	NE	(0.08, 19.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.54	0.12		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.54, 1.79)		
p-value	0.5962	0.8823		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE - Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.54	-0.54		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.59, 0.51)		
p-value	0.5962	0.3669		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE - Adjudicated Event	0	1 (0.7)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the odds ratio	NE	(0.08, 19.88)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.23		
95% CI of the risk ratio	NE	(0.08, 19.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.54	0.12		
95% CI of the absolute risk difference	(-1.59, 0.51)	(-1.54, 1.79)		
p-value	0.5962	0.8823		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: > 200 lbs

	MGL-3196 80 mg (N=52) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=186) n (%)	Overall (N=389) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Events n:				
Total TEAEs	822	0	816	1638
Total Serious TEAEs	23	0	46	69
Total TEAEs Leading to Discontinuation of Study Drug	14	0	10	24
Total TEAEs Related to Study Drug	117	0	67	184
Total TEAEs >= Grade 3 Severity	21	0	46	67
Patients n (%):				
Any TEAE	110 (95.7)	0	110 (94.0)	220 (94.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.40	NE		
95% CI of the odds ratio	(0.43, 4.55)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	NE		
95% CI of the risk ratio	(0.96, 1.08)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.64	NE		
95% CI of the absolute risk difference	(-4.05, 7.32)	NE		
p-value	0.5740	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.5118	NE		
Any Serious TEAE	12 (10.4)	0	14 (12.0)	26 (11.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.86	NE		
95% CI of the odds ratio	(0.38, 1.94)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87	NE		
95% CI of the risk ratio	(0.42, 1.80)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.53	NE		
95% CI of the absolute risk difference	(-9.64, 6.58)	NE		
p-value	0.7117	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.3530	NE		

Madrigal Pharmaceuticals, Inc. Page 13 of 21
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Any TEAEs >= Grade 3 Severity	12 (10.4)	0	16 (13.7)	28 (12.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.74	NE		
95% CI of the odds ratio	(0.33, 1.63)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76	NE		
95% CI of the risk ratio	(0.38, 1.54)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.24	NE		
95% CI of the absolute risk difference	(-11.61, 5.12)	NE		
p-value	0.4487	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.8342	NE		
Any TEAEs <= Grade 2 Severity	109 (94.8)	0	110 (94.0)	219 (94.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.16	NE		
95% CI of the odds ratio	(0.38, 3.55)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	NE		
95% CI of the risk ratio	(0.95, 1.07)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.77	NE		
95% CI of the absolute risk difference	(-5.15, 6.68)	NE		
p-value	0.7999	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.4786	NE		
Any TEAEs leading to Study-Drug Discontinuation	8 (7.0)	0	7 (6.0)	15 (6.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE		
95% CI of the odds ratio	(0.41, 3.35)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.16	NE		
95% CI of the risk ratio	(0.44, 3.10)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.97	NE		
95% CI of the absolute risk difference	(-5.36, 7.31)	NE		
p-value	0.7630	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.3360	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Any TEAEs leading to Study Discontinuation	3 (2.6)	0	6 (5.1)	9 (3.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50	NE		
95% CI of the odds ratio	(0.12, 2.03)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	NE		
95% CI of the risk ratio	(0.13, 1.99)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.52	NE		
95% CI of the absolute risk difference	(-7.47, 2.43)	NE		
p-value	0.3204	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.3976	NE		
Any Fatal TEAEs	1 (0.9)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.87	NE		
95% CI of the absolute risk difference	(-0.83, 2.57)	NE		
p-value	0.3121	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
Any Treatment-related TEAE	49 (42.6)	0	39 (33.3)	88 (37.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.48	NE		
95% CI of the odds ratio	(0.87, 2.53)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.28	NE		
95% CI of the risk ratio	(0.92, 1.78)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.28	NE		
95% CI of the absolute risk difference	(-3.16, 21.71)	NE		
p-value	0.1455	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.6092	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (0.9)	0	1 (0.9)	2 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	NE		
95% CI of the odds ratio	(0.06, 16.46)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	NE		
95% CI of the risk ratio	(0.06, 16.07)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.01	NE		
95% CI of the absolute risk difference	(-2.36, 2.39)	NE		
p-value	0.9902	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.6063	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	3 (2.6)	0	3 (2.6)	6 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	NE		
95% CI of the odds ratio	(0.20, 5.15)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	NE		
95% CI of the risk ratio	(0.21, 4.94)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.04	NE		
95% CI of the absolute risk difference	(-4.04, 4.13)	NE		
p-value	0.9829	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2131	NE		

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	2 (1.7)	2 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.71	NE		
95% CI of the absolute risk difference	(-4.06, 0.64)	NE		
p-value	0.1591	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	26 (22.6)	0	36 (30.8)	62 (26.7)
Grade 2	72 (62.6)	0	58 (49.6)	130 (56.0)
Grade 3	11 (9.6)	0	12 (10.3)	23 (9.9)
Grade 4	0	0	4 (3.4)	4 (1.7)
Grade 5	1 (0.9)	0	0	1 (0.4)

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	27 (23.5)	0	24 (20.5)	51 (22.0)
Grade 2	21 (18.3)	0	14 (12.0)	35 (15.1)
Grade 3	1 (0.9)	0	1 (0.9)	2 (0.9)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (0.9)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.87	NE		
95% CI of the absolute risk difference	(-0.83, 2.57)	NE		
p-value	0.3121	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	1 (0.9)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.87	NE		
95% CI of the absolute risk difference	(-0.83, 2.57)	NE		
p-value	0.3121	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
Serious 3-PT MACE AE - Adjudicated Event	1 (0.9)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.87	NE		
95% CI of the absolute risk difference	(-0.83, 2.57)	NE		
p-value	0.3121	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2964	NE		
Other MACE AE - Adjudicated Event	0	0	2 (1.7)	2 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.71	NE		
95% CI of the absolute risk difference	(-4.06, 0.64)	NE		
p-value	0.1591	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (1.7)	2 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.71	NE		
95% CI of the absolute risk difference	(-4.06, 0.64)	NE		
p-value	0.1591	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (1.7)	2 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.71	NE		
95% CI of the absolute risk difference	(-4.06, 0.64)	NE		
p-value	0.1591	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight
(Label Population)

Weight: <= 200 lbs

	MGL-3196 80 mg (N=115) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=117) n (%)	Overall (N=232) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.5.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.
Note: PT 'Contusion' has statistically significant results in table S1.1.3, but is not included in this table due to patient counts being less than 10 in all subgroup categories.

AMNOG Table S1.5.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight
(Label Population)

Weight: > 200 lbs

System Organ Class Preferred Term	MGL-3196 80 mg (N=52) Patients n (%)	 Events n	MGL-3196 100 mg (N=151) Patients n (%)	 Events n	Placebo (N=186) Patients n (%)	 Events n	Overall (N=389) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	14 (26.9)	28	51 (33.8)	80	28 (15.1)	36	93 (23.9)	144
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.08		2.88					
95% CI of the odds ratio	(1.00, 4.33)		(1.70, 4.86)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.79		2.24					
95% CI of the risk ratio	(1.02, 3.14)		(1.49, 3.37)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.87		18.72					
95% CI of the absolute risk difference	(-1.24, 24.97)		(9.59, 27.85)					
p-value	0.0472		<0.0001					
p-value of Breslow-Day Test for Homogeneity [2]	0.4839		NE					
Nausea	12 (23.1)	15	21 (13.9)	26	21 (11.3)	24	54 (13.9)	65
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.36		1.27					
95% CI of the odds ratio	(1.07, 5.19)		(0.66, 2.42)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.04		1.23					
95% CI of the risk ratio	(1.08, 3.87)		(0.70, 2.17)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.79		2.62					
95% CI of the absolute risk difference	(-0.54, 24.11)		(-4.53, 9.77)					
p-value	0.0297		0.4695					
p-value of Breslow-Day Test for Homogeneity [2]	0.7737		NE					

AMNOG Table S1.5.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight
(Label Population)

Weight: > 200 lbs

System Organ Class Preferred Term	MGL-3196 80 mg (N=52) Patients n (%)	 Events n	MGL-3196 100 mg (N=151) Patients n (%)	 Events n	Placebo (N=186) Patients n (%)	 Events n	Overall (N=389) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	3 (5.8)	3	9 (6.0)	9	6 (3.2)	7	18 (4.6)	19
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.84		1.90					
95% CI of the odds ratio	(0.44, 7.61)		(0.66, 5.47)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.79		1.85					
95% CI of the risk ratio	(0.46, 6.91)		(0.67, 5.08)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.54		2.73					
95% CI of the absolute risk difference	(-4.28, 9.37)		(-1.82, 7.28)					
p-value	0.3953		0.2261					
p-value of Breslow-Day Test for Homogeneity [2]	0.9099		NE					
Abdominal discomfort	1 (1.9)	1	3 (2.0)	4	7 (3.8)	7	11 (2.8)	12
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		0.52					
95% CI of the odds ratio	(0.06, 4.17)		(0.13, 2.04)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51		0.53					
95% CI of the risk ratio	(0.06, 4.06)		(0.14, 2.01)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.84		-1.78					
95% CI of the absolute risk difference	(-6.47, 2.79)		(-5.30, 1.75)					
p-value	0.5151		0.3391					
p-value of Breslow-Day Test for Homogeneity [2]	0.1408		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.5.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight
(Label Population)

Weight: > 200 lbs

System Organ Class Preferred Term	MGL-3196 80 mg (N=52) Patients n (%)	 Events n	MGL-3196 100 mg (N=151) Patients n (%)	 Events n	Placebo (N=186) Patients n (%)	 Events n	Overall (N=389) Patients n (%)	 Events n
General disorders and administration site conditions	10 (19.2)	15	29 (19.2)	39	54 (29.0)	70	93 (23.9)	124
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58		0.58					
95% CI of the odds ratio	(0.27, 1.24)		(0.35, 0.97)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.66		0.66					
95% CI of the risk ratio	(0.36, 1.21)		(0.44, 0.98)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.80		-9.83					
95% CI of the absolute risk difference	(-22.34, 2.74)		(-18.88, -0.77)					
p-value	0.1588		0.0373					
p-value of Breslow-Day Test for Homogeneity [2]	0.5700		NE					
Skin and subcutaneous tissue disorders								
Rash	3 (5.8)	3	16 (10.6)	20	7 (3.8)	8	26 (6.7)	31
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.57		3.03					
95% CI of the odds ratio	(0.39, 6.28)		(1.21, 7.57)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.53		2.82					
95% CI of the risk ratio	(0.41, 5.72)		(1.19, 6.67)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.01		6.83					
95% CI of the absolute risk difference	(-4.90, 8.91)		(1.21, 12.45)					
p-value	0.5239		0.0134					
p-value of Breslow-Day Test for Homogeneity [2]	0.6528		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.5.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight
(Label Population)

Weight: > 200 lbs

System Organ Class Preferred Term	MGL-3196 80 mg (N=52) Patients n (%)	 Events n	MGL-3196 100 mg (N=151) Patients n (%)	 Events n	Placebo (N=186) Patients n (%)	 Events n	Overall (N=389) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Pruritus	4 (7.7)	4	8 (5.3)	10	12 (6.5)	14	24 (6.2)	28
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21		0.81					
95% CI of the odds ratio	(0.37, 3.92)		(0.32, 2.04)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.19		0.82					
95% CI of the risk ratio	(0.40, 3.54)		(0.34, 1.96)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.24		-1.15					
95% CI of the absolute risk difference	(-6.82, 9.30)		(-6.18, 3.87)					
p-value	0.7521		0.6558					
p-value of Breslow-Day Test for Homogeneity [2]	0.5880		NE					
Renal and urinary disorders	2 (3.8)	2	20 (13.2)	24	20 (10.8)	25	42 (10.8)	51
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		1.27					
95% CI of the odds ratio	(0.08, 1.47)		(0.65, 2.45)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		1.23					
95% CI of the risk ratio	(0.09, 1.48)		(0.69, 2.20)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.91		2.49					
95% CI of the absolute risk difference	(-13.77, -0.04)		(-4.51, 9.50)					
p-value	0.1285		0.4817					
p-value of Breslow-Day Test for Homogeneity [2]	0.8171		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.5.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight
(Label Population)

Weight: > 200 lbs

System Organ Class Preferred Term	MGL-3196 80 mg (N=52) Patients n (%)	 Events n	MGL-3196 100 mg (N=151) Patients n (%)	 Events n	Placebo (N=186) Patients n (%)	 Events n	Overall (N=389) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	3 (5.8)	4	4 (2.6)	4	11 (5.9)	14	18 (4.6)	22
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97		0.43					
95% CI of the odds ratio	(0.26, 3.63)		(0.14, 1.39)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98		0.45					
95% CI of the risk ratio	(0.28, 3.37)		(0.15, 1.38)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.14		-3.26					
95% CI of the absolute risk difference	(-7.33, 7.04)		(-7.51, 0.98)					
p-value	0.9687		0.1484					
p-value of Breslow-Day Test for Homogeneity [2]	0.1648		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.5.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight
(Label Population)

Weight: <= 200 lbs

System Organ Class Preferred Term	MGL-3196 80 mg (N=115) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=117) Patients n (%)	 Events n	Overall (N=232) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	28 (24.3)	45	0	0	21 (17.9)	25	49 (21.1)	70
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.47		NE					
95% CI of the odds ratio	(0.78, 2.78)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.36		NE					
95% CI of the risk ratio	(0.82, 2.25)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.40		NE					
95% CI of the absolute risk difference	(-4.08, 16.88)		NE					
p-value	0.2325		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.4839		NE					
Nausea	31 (27.0)	36	0	0	18 (15.4)	22	49 (21.1)	58
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.03		NE					
95% CI of the odds ratio	(1.06, 3.89)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.75		NE					
95% CI of the risk ratio	(1.04, 2.95)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.57		NE					
95% CI of the absolute risk difference	(1.15, 21.99)		NE					
p-value	0.0308		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.7737		NE					

AMNOG Table S1.5.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight
(Label Population)

Weight: <= 200 lbs

System Organ Class Preferred Term	MGL-3196 80 mg (N=115) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=117) Patients n (%)	 Events n	Overall (N=232) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	17 (14.8)	19	0	0	11 (9.4)	11	28 (12.1)	30
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67		NE					
95% CI of the odds ratio	(0.75, 3.74)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.57		NE					
95% CI of the risk ratio	(0.77, 3.21)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.38		NE					
95% CI of the absolute risk difference	(-2.99, 13.75)		NE					
p-value	0.2084		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.9099		NE					
Abdominal discomfort	0	0	0	0	6 (5.1)	7	6 (2.6)	7
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.07		NE					
95% CI of the odds ratio	(0.00, 1.33)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.08		NE					
95% CI of the risk ratio	(0.00, 1.37)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.08		NE					
95% CI of the absolute risk difference	(-9.36, -0.79)		NE					
p-value	0.0226		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.1408		NE					

AMNOG Table S1.5.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight
(Label Population)

Weight: <= 200 lbs

System Organ Class Preferred Term	MGL-3196 80 mg (N=115) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=117) Patients n (%)	 Events n	Overall (N=232) Patients n (%)	 Events n
General disorders and administration site conditions	25 (21.7)	37	0	0	31 (26.5)	34	56 (24.1)	71
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.77		NE					
95% CI of the odds ratio	(0.42, 1.41)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82		NE					
95% CI of the risk ratio	(0.52, 1.30)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76		NE					
95% CI of the absolute risk difference	(-15.75, 6.23)		NE					
p-value	0.3973		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.5700		NE					
Skin and subcutaneous tissue disorders								
Pruritus	18 (15.7)	24	0	0	11 (9.4)	12	29 (12.5)	36
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.79		NE					
95% CI of the odds ratio	(0.80, 3.98)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.66		NE					
95% CI of the risk ratio	(0.82, 3.37)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.25		NE					
95% CI of the absolute risk difference	(-2.24, 14.74)		NE					
p-value	0.1501		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.5880		NE					

Madrigal Pharmaceuticals, Inc. Page 10 of 11
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.5.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight
(Label Population)

Weight: <= 200 lbs

System Organ Class Preferred Term	MGL-3196 80 mg (N=115) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=117) Patients n (%)	 Events n	Overall (N=232) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	5 (4.3)	5	0	0	5 (4.3)	6	10 (4.3)	11
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02		NE					
95% CI of the odds ratio	(0.29, 3.62)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02		NE					
95% CI of the risk ratio	(0.30, 3.42)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.07		NE					
95% CI of the absolute risk difference	(-5.15, 5.30)		NE					
p-value	0.9778		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.6528		NE					
Musculoskeletal and connective tissue disorders								
Pain in extremity	4 (3.5)	4	0	0	13 (11.1)	14	17 (7.3)	18
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		NE					
95% CI of the odds ratio	(0.09, 0.91)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.31		NE					
95% CI of the risk ratio	(0.11, 0.93)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.63		NE					
95% CI of the absolute risk difference	(-14.24, -1.03)		NE					
p-value	0.0257		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.1648		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.5.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight
(Label Population)

Weight: <= 200 lbs

System Organ Class Preferred Term	MGL-3196 80 mg (N=115) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=117) Patients n (%)	 Events n	Overall (N=232) Patients n (%)	 Events n
Renal and urinary disorders	3 (2.6)	4	0	0	7 (6.0)	8	10 (4.3)	12
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42		NE					
95% CI of the odds ratio	(0.11, 1.67)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44		NE					
95% CI of the risk ratio	(0.12, 1.64)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.37		NE					
95% CI of the absolute risk difference	(-8.57, 1.82)		NE					
p-value	0.2058		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.8171		NE					

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Events n:				
Total TEAEs	72	0	53	125
Total Serious TEAEs	11	0	5	16
Total TEAEs Leading to Discontinuation of Study Drug	4	0	1	5
Total TEAEs Related to Study Drug	4	0	6	10
Total TEAEs >= Grade 3 Severity	9	0	5	14
Patients n (%):				
Any TEAE	7 (100)	0	8 (100)	15 (100)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.5070	NE		
Any Serious TEAE	2 (28.6)	0	2 (25.0)	4 (26.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.20	NE		
95% CI of the odds ratio	(0.12, 11.87)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14	NE		
95% CI of the risk ratio	(0.21, 6.11)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.57	NE		
95% CI of the absolute risk difference	(-41.38, 48.52)	NE		
p-value	0.8760	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.8346	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Any TEAEs >= Grade 3 Severity	3 (42.9)	0	2 (25.0)	5 (33.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.25	NE		
95% CI of the odds ratio	(0.25, 20.13)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.71	NE		
95% CI of the risk ratio	(0.39, 7.48)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	17.86	NE		
95% CI of the absolute risk difference	(-29.52, 65.23)	NE		
p-value	0.4642	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2802	NE		
Any TEAEs <= Grade 2 Severity	7 (100)	0	8 (100)	15 (100)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.3801	NE		
Any TEAEs leading to Study-Drug Discontinuation	1 (14.3)	0	1 (12.5)	2 (13.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE		
95% CI of the odds ratio	(0.06, 22.94)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14	NE		
95% CI of the risk ratio	(0.09, 15.08)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.79	NE		
95% CI of the absolute risk difference	(-32.81, 36.39)	NE		
p-value	0.9192	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2888	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Any TEAEs leading to Study Discontinuation	1 (14.3)	0	1 (12.5)	2 (13.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE		
95% CI of the odds ratio	(0.06, 22.94)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14	NE		
95% CI of the risk ratio	(0.09, 15.08)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.79	NE		
95% CI of the absolute risk difference	(-32.81, 36.39)	NE		
p-value	0.9192	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.4535	NE		
Any Fatal TEAEs	1 (14.3)	0	0	1 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.92	NE		
95% CI of the odds ratio	(0.14, 112.90)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.38	NE		
95% CI of the risk ratio	(0.16, 71.67)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.19	NE		
95% CI of the absolute risk difference	(-17.72, 44.11)	NE		
p-value	0.3993	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Any Treatment-related TEAE	2 (28.6)	0	3 (37.5)	5 (33.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67	NE		
95% CI of the odds ratio	(0.08, 5.88)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76	NE		
95% CI of the risk ratio	(0.17, 3.33)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.93	NE		
95% CI of the absolute risk difference	(-56.31, 38.46)	NE		
p-value	0.7144	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1734	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.0713	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.9385	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	3 (42.9)	0	3 (37.5)	6 (40.0)
Grade 2	1 (14.3)	0	3 (37.5)	4 (26.7)
Grade 3	2 (28.6)	0	2 (25.0)	4 (26.7)
Grade 4	0	0	0	0
Grade 5	1 (14.3)	0	0	1 (6.7)

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	2 (28.6)	0	2 (25.0)	4 (26.7)
Grade 2	0	0	1 (12.5)	1 (6.7)
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (14.3)	0	0	1 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.92	NE		
95% CI of the odds ratio	(0.14, 112.90)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.38	NE		
95% CI of the risk ratio	(0.16, 71.67)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	13.19	NE		
95% CI of the absolute risk difference	(-17.72, 44.11)	NE		
p-value	0.3993	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (14.3)	0	0	1 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.92	NE		
95% CI of the odds ratio	(0.14, 112.90)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.38	NE		
95% CI of the risk ratio	(0.16, 71.67)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	13.19	NE		
95% CI of the absolute risk difference	(-17.72, 44.11)	NE		
p-value	0.3993	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (14.3)	0	0	1 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.92	NE		
95% CI of the odds ratio	(0.14, 112.90)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.38	NE		
95% CI of the risk ratio	(0.16, 71.67)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	13.19	NE		
95% CI of the absolute risk difference	(-17.72, 44.11)	NE		
p-value	0.3993	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Other MACE AE – Adjudicated Event	0	0	1 (12.5)	1 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33	NE		
95% CI of the odds ratio	(0.01, 9.57)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38	NE		
95% CI of the risk ratio	(0.02, 7.96)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-10.42	NE		
95% CI of the absolute risk difference	(-39.98, 19.15)	NE		
p-value	0.5058	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	1 (12.5)	1 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33	NE		
95% CI of the odds ratio	(0.01, 9.57)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38	NE		
95% CI of the risk ratio	(0.02, 7.96)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-10.42	NE		
95% CI of the absolute risk difference	(-39.98, 19.15)	NE		
p-value	0.5058	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	1 (12.5)	1 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33	NE		
95% CI of the odds ratio	(0.01, 9.57)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38	NE		
95% CI of the risk ratio	(0.02, 7.96)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-10.42	NE		
95% CI of the absolute risk difference	(-39.98, 19.15)	NE		
p-value	0.5058	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Madrigal Pharmaceuticals, Inc. Page 12 of 31
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Events n:				
Total TEAEs	363	0	374	737
Total Serious TEAEs	2	0	7	9
Total TEAEs Leading to Discontinuation of Study Drug	3	0	8	11
Total TEAEs Related to Study Drug	60	0	22	82
Total TEAEs >= Grade 3 Severity	8	0	9	17
Patients n (%):				
Any TEAE	46 (97.9)	0	59 (95.2)	105 (96.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.34	NE		
95% CI of the odds ratio	(0.24, 23.23)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03	NE		
95% CI of the risk ratio	(0.96, 1.10)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.71	NE		
95% CI of the absolute risk difference	(-4.04, 9.46)	NE		
p-value	0.4559	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.5070	NE		
Any Serious TEAE	2 (4.3)	0	5 (8.1)	7 (6.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	NE		
95% CI of the odds ratio	(0.09, 2.73)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53	NE		
95% CI of the risk ratio	(0.11, 2.60)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.81	NE		
95% CI of the absolute risk difference	(-12.71, 5.09)	NE		
p-value	0.4217	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.8346	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Any TEAEs >= Grade 3 Severity	6 (12.8)	0	7 (11.3)	13 (11.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.15	NE		
95% CI of the odds ratio	(0.36, 3.68)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13	NE		
95% CI of the risk ratio	(0.41, 3.14)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.48	NE		
95% CI of the absolute risk difference	(-10.90, 13.85)	NE		
p-value	0.8139	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2802	NE		
Any TEAEs <= Grade 2 Severity	46 (97.9)	0	59 (95.2)	105 (96.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.34	NE		
95% CI of the odds ratio	(0.24, 23.23)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03	NE		
95% CI of the risk ratio	(0.96, 1.10)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.71	NE		
95% CI of the absolute risk difference	(-4.04, 9.46)	NE		
p-value	0.4559	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.3801	NE		
Any TEAEs leading to Study-Drug Discontinuation	2 (4.3)	0	7 (11.3)	9 (8.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.35	NE		
95% CI of the odds ratio	(0.07, 1.76)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38	NE		
95% CI of the risk ratio	(0.08, 1.73)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.04	NE		
95% CI of the absolute risk difference	(-16.80, 2.73)	NE		
p-value	0.1863	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2888	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Any TEAEs leading to Study Discontinuation	0	0	3 (4.8)	3 (2.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.84	NE		
95% CI of the absolute risk difference	(-10.18, 0.50)	NE		
p-value	0.1262	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.4535	NE		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Any Treatment-related TEAE	23 (48.9)	0	14 (22.6)	37 (33.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.29	NE		
95% CI of the odds ratio	(1.44, 7.50)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.17	NE		
95% CI of the risk ratio	(1.26, 3.74)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	26.36	NE		
95% CI of the absolute risk difference	(8.68, 44.03)	NE		
p-value	0.0040	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1734	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	2 (4.3)	0	0	2 (1.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.26	NE		
95% CI of the absolute risk difference	(-1.52, 10.03)	NE		
p-value	0.1011	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.0713	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	1 (2.1)	0	2 (3.2)	3 (2.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.65	NE		
95% CI of the odds ratio	(0.06, 7.42)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.66	NE		
95% CI of the risk ratio	(0.06, 7.06)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.10	NE		
95% CI of the absolute risk difference	(-7.13, 4.93)	NE		
p-value	0.7285	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.9385	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.61	NE		
95% CI of the absolute risk difference	(-4.75, 1.52)	NE		
p-value	0.3817	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	9 (19.1)	0	17 (27.4)	26 (23.9)
Grade 2	31 (66.0)	0	35 (56.5)	66 (60.6)
Grade 3	6 (12.8)	0	6 (9.7)	12 (11.0)
Grade 4	0	0	1 (1.6)	1 (0.9)
Grade 5	0	0	0	0

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	14 (29.8)	0	6 (9.7)	20 (18.3)
Grade 2	7 (14.9)	0	8 (12.9)	15 (13.8)
Grade 3	2 (4.3)	0	0	2 (1.8)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Serious 3-PT MACE AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Other MACE AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Events n:				
Total TEAEs	764	1022	1730	3516
Total Serious TEAEs	16	32	84	132
Total TEAEs Leading to Discontinuation of Study Drug	11	20	16	47
Total TEAEs Related to Study Drug	91	126	131	348
Total TEAEs >= Grade 3 Severity	17	45	92	154
Patients n (%):				
Any TEAE	105 (92.9)	138 (91.4)	216 (92.7)	459 (92.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03	0.84		
95% CI of the odds ratio	(0.43, 2.47)	(0.39, 1.77)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.99		
95% CI of the risk ratio	(0.94, 1.07)	(0.93, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.22	-1.31		
95% CI of the absolute risk difference	(-5.57, 6.01)	(-6.90, 4.27)		
p-value	0.9419	0.6395		
p-value of Breslow-Day Test for Homogeneity [2]	0.5070	NE		
Any Serious TEAE	12 (10.6)	21 (13.9)	36 (15.5)	69 (13.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.65	0.88		
95% CI of the odds ratio	(0.32, 1.30)	(0.49, 1.58)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	0.90		
95% CI of the risk ratio	(0.37, 1.27)	(0.55, 1.48)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.83	-1.54		
95% CI of the absolute risk difference	(-12.17, 2.50)	(-8.75, 5.67)		
p-value	0.2228	0.6778		
p-value of Breslow-Day Test for Homogeneity [2]	0.8346	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Any TEAEs >= Grade 3 Severity	13 (11.5)	26 (17.2)	46 (19.7)	85 (17.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53	0.85		
95% CI of the odds ratio	(0.27, 1.02)	(0.50, 1.44)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58	0.87		
95% CI of the risk ratio	(0.33, 1.03)	(0.56, 1.35)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.24	-2.52		
95% CI of the absolute risk difference	(-16.03, -0.44)	(-10.42, 5.37)		
p-value	0.0560	0.5359		
p-value of Breslow-Day Test for Homogeneity [2]	0.2802	NE		
Any TEAEs <= Grade 2 Severity	103 (91.2)	136 (90.1)	216 (92.7)	455 (91.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81	0.71		
95% CI of the odds ratio	(0.36, 1.83)	(0.35, 1.48)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	0.97		
95% CI of the risk ratio	(0.92, 1.05)	(0.91, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.55	-2.64		
95% CI of the absolute risk difference	(-7.76, 4.66)	(-8.46, 3.19)		
p-value	0.6134	0.3610		
p-value of Breslow-Day Test for Homogeneity [2]	0.3801	NE		
Any TEAEs leading to Study-Drug Discontinuation	9 (8.0)	18 (11.9)	13 (5.6)	40 (8.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.46	2.29		
95% CI of the odds ratio	(0.61, 3.54)	(1.09, 4.83)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43	2.14		
95% CI of the risk ratio	(0.63, 3.24)	(1.08, 4.23)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.39	6.34		
95% CI of the absolute risk difference	(-3.41, 8.18)	(0.39, 12.29)		
p-value	0.3938	0.0259		
p-value of Breslow-Day Test for Homogeneity [2]	0.2888	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Any TEAEs leading to Study Discontinuation	2 (1.8)	11 (7.3)	7 (3.0)	20 (4.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58	2.54		
95% CI of the odds ratio	(0.12, 2.85)	(0.96, 6.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	2.42		
95% CI of the risk ratio	(0.12, 2.79)	(0.96, 6.12)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.23	4.28		
95% CI of the absolute risk difference	(-4.51, 2.04)	(-0.41, 8.97)		
p-value	0.4987	0.0526		
p-value of Breslow-Day Test for Homogeneity [2]	0.4535	NE		
Any Fatal TEAEs	0	1 (0.7)	1 (0.4)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.55		
95% CI of the odds ratio	NE	(0.10, 24.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the risk ratio	NE	(0.10, 24.48)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.43	0.23		
95% CI of the absolute risk difference	(-1.27, 0.41)	(-1.31, 1.78)		
p-value	0.4855	0.7566		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Any Treatment-related TEAE	44 (38.9)	55 (36.4)	70 (30.0)	169 (34.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.48	1.33		
95% CI of the odds ratio	(0.93, 2.38)	(0.86, 2.06)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.30	1.21		
95% CI of the risk ratio	(0.96, 1.75)	(0.91, 1.62)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.90	6.38		
95% CI of the absolute risk difference	(-1.85, 19.64)	(-3.29, 16.05)		
p-value	0.0988	0.1924		
p-value of Breslow-Day Test for Homogeneity [2]	0.1734	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.43	-0.43		
95% CI of the absolute risk difference	(-1.27, 0.41)	(-1.27, 0.41)		
p-value	0.4855	0.4202		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	3 (2.0)	2 (0.9)	5 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.34		
95% CI of the odds ratio	NE	(0.39, 14.18)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.31		
95% CI of the risk ratio	NE	(0.39, 13.69)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.86	1.13		
95% CI of the absolute risk difference	(-2.04, 0.33)	(-1.39, 3.65)		
p-value	0.3233	0.3407		
p-value of Breslow-Day Test for Homogeneity [2]	0.0713	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (1.8)	10 (6.6)	7 (3.0)	19 (3.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58	2.29		
95% CI of the odds ratio	(0.12, 2.85)	(0.85, 6.15)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	2.20		
95% CI of the risk ratio	(0.12, 2.79)	(0.86, 5.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.23	3.62		
95% CI of the absolute risk difference	(-4.51, 2.04)	(-0.91, 8.15)		
p-value	0.4987	0.0922		
p-value of Breslow-Day Test for Homogeneity [2]	0.9385	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	7 (4.6)	4 (1.7)	11 (2.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.78		
95% CI of the odds ratio	NE	(0.80, 9.68)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.70		
95% CI of the risk ratio	NE	(0.80, 9.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.72	2.92		
95% CI of the absolute risk difference	(-3.38, -0.05)	(-0.83, 6.66)		
p-value	0.1612	0.0939		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	27 (23.9)	26 (17.2)	49 (21.0)	102 (20.5)
Grade 2	65 (57.5)	86 (57.0)	121 (51.9)	272 (54.7)
Grade 3	13 (11.5)	25 (16.6)	39 (16.7)	77 (15.5)
Grade 4	0	0	6 (2.6)	6 (1.2)
Grade 5	0	1 (0.7)	1 (0.4)	2 (0.4)

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	25 (22.1)	29 (19.2)	45 (19.3)	99 (19.9)
Grade 2	19 (16.8)	23 (15.2)	23 (9.9)	65 (13.1)
Grade 3	0	3 (2.0)	1 (0.4)	4 (0.8)
Grade 4	0	0	1 (0.4)	1 (0.2)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (0.7)	1 (0.4)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.55		
95% CI of the odds ratio	NE	(0.10, 24.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the risk ratio	NE	(0.10, 24.48)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.43	0.23		
95% CI of the absolute risk difference	(-1.27, 0.41)	(-1.31, 1.78)		
p-value	0.4855	0.7566		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.7)	0	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	0.66		
95% CI of the absolute risk difference	NE	(-0.63, 1.96)		
p-value	NE	0.2136		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.43	-0.43		
95% CI of the absolute risk difference	(-1.27, 0.41)	(-1.27, 0.41)		
p-value	0.4855	0.4202		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	1 (0.7)	1 (0.4)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.55		
95% CI of the odds ratio	NE	(0.10, 24.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the risk ratio	NE	(0.10, 24.48)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.43	0.23		
95% CI of the absolute risk difference	(-1.27, 0.41)	(-1.31, 1.78)		
p-value	0.4855	0.7566		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Other MACE AE – Adjudicated Event	0	1 (0.7)	3 (1.3)	4 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.51		
95% CI of the odds ratio	NE	(0.05, 4.96)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.51		
95% CI of the risk ratio	NE	(0.05, 4.90)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.29	-0.63		
95% CI of the absolute risk difference	(-2.74, 0.16)	(-2.57, 1.32)		
p-value	0.2257	0.5555		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.7)	2 (0.9)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.77		
95% CI of the odds ratio	NE	(0.07, 8.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.77		
95% CI of the risk ratio	NE	(0.07, 8.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.86	-0.20		
95% CI of the absolute risk difference	(-2.04, 0.33)	(-1.95, 1.56)		
p-value	0.3233	0.8312		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.43	-0.43		
95% CI of the absolute risk difference	(-1.27, 0.41)	(-1.27, 0.41)		
p-value	0.4855	0.4202		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (0.7)	2 (0.9)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.77		
95% CI of the odds ratio	NE	(0.07, 8.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.77		
95% CI of the risk ratio	NE	(0.07, 8.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.86	-0.20		
95% CI of the absolute risk difference	(-2.04, 0.33)	(-1.95, 1.56)		
p-value	0.3233	0.8312		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Events n:				
Total TEAEs	72	0	53	125
Total Serious TEAEs	11	0	5	16
Total TEAEs Leading to Discontinuation of Study Drug	4	0	1	5
Total TEAEs Related to Study Drug	4	0	6	10
Total TEAEs >= Grade 3 Severity	9	0	5	14
Patients n (%):				
Any TEAE	7 (100)	0	8 (100)	15 (100)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.5004	NE		
Any Serious TEAE	2 (28.6)	0	2 (25.0)	4 (26.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.20	NE		
95% CI of the odds ratio	(0.12, 11.87)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14	NE		
95% CI of the risk ratio	(0.21, 6.11)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.57	NE		
95% CI of the absolute risk difference	(-41.38, 48.52)	NE		
p-value	0.8760	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.8346	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Any TEAEs >= Grade 3 Severity	3 (42.9)	0	2 (25.0)	5 (33.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.25	NE		
95% CI of the odds ratio	(0.25, 20.13)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.71	NE		
95% CI of the risk ratio	(0.39, 7.48)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	17.86	NE		
95% CI of the absolute risk difference	(-29.52, 65.23)	NE		
p-value	0.4642	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.3768	NE		
Any TEAEs <= Grade 2 Severity	7 (100)	0	8 (100)	15 (100)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.3847	NE		
Any TEAEs leading to Study-Drug Discontinuation	1 (14.3)	0	1 (12.5)	2 (13.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE		
95% CI of the odds ratio	(0.06, 22.94)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14	NE		
95% CI of the risk ratio	(0.09, 15.08)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.79	NE		
95% CI of the absolute risk difference	(-32.81, 36.39)	NE		
p-value	0.9192	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2988	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Any TEAEs leading to Study Discontinuation	1 (14.3)	0	1 (12.5)	2 (13.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE		
95% CI of the odds ratio	(0.06, 22.94)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14	NE		
95% CI of the risk ratio	(0.09, 15.08)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.79	NE		
95% CI of the absolute risk difference	(-32.81, 36.39)	NE		
p-value	0.9192	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.4535	NE		
Any Fatal TEAEs	1 (14.3)	0	0	1 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.92	NE		
95% CI of the odds ratio	(0.14, 112.90)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.38	NE		
95% CI of the risk ratio	(0.16, 71.67)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.19	NE		
95% CI of the absolute risk difference	(-17.72, 44.11)	NE		
p-value	0.3993	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Any Treatment-related TEAE	2 (28.6)	0	3 (37.5)	5 (33.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67	NE		
95% CI of the odds ratio	(0.08, 5.88)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76	NE		
95% CI of the risk ratio	(0.17, 3.33)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.93	NE		
95% CI of the absolute risk difference	(-56.31, 38.46)	NE		
p-value	0.7144	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1252	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1232	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.9385	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	3 (42.9)	0	3 (37.5)	6 (40.0)
Grade 2	1 (14.3)	0	3 (37.5)	4 (26.7)
Grade 3	2 (28.6)	0	2 (25.0)	4 (26.7)
Grade 4	0	0	0	0
Grade 5	1 (14.3)	0	0	1 (6.7)

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	2 (28.6)	0	2 (25.0)	4 (26.7)
Grade 2	0	0	1 (12.5)	1 (6.7)
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (14.3)	0	0	1 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.92	NE		
95% CI of the odds ratio	(0.14, 112.90)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.38	NE		
95% CI of the risk ratio	(0.16, 71.67)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	13.19	NE		
95% CI of the absolute risk difference	(-17.72, 44.11)	NE		
p-value	0.3993	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	1 (14.3)	0	0	1 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.92	NE		
95% CI of the odds ratio	(0.14, 112.90)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.38	NE		
95% CI of the risk ratio	(0.16, 71.67)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.19	NE		
95% CI of the absolute risk difference	(-17.72, 44.11)	NE		
p-value	0.3993	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Serious 3-PT MACE AE - Adjudicated Event	1 (14.3)	0	0	1 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.92	NE		
95% CI of the odds ratio	(0.14, 112.90)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.38	NE		
95% CI of the risk ratio	(0.16, 71.67)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.19	NE		
95% CI of the absolute risk difference	(-17.72, 44.11)	NE		
p-value	0.3993	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Other MACE AE - Adjudicated Event	0	0	1 (12.5)	1 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33	NE		
95% CI of the odds ratio	(0.01, 9.57)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38	NE		
95% CI of the risk ratio	(0.02, 7.96)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.42	NE		
95% CI of the absolute risk difference	(-39.98, 19.15)	NE		
p-value	0.5058	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	1 (12.5)	1 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33	NE		
95% CI of the odds ratio	(0.01, 9.57)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38	NE		
95% CI of the risk ratio	(0.02, 7.96)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-10.42	NE		
95% CI of the absolute risk difference	(-39.98, 19.15)	NE		
p-value	0.5058	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	1 (12.5)	1 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33	NE		
95% CI of the odds ratio	(0.01, 9.57)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38	NE		
95% CI of the risk ratio	(0.02, 7.96)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-10.42	NE		
95% CI of the absolute risk difference	(-39.98, 19.15)	NE		
p-value	0.5058	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=8) n (%)	Overall (N=15) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Events n:				
Total TEAEs	357	0	369	726
Total Serious TEAEs	2	0	7	9
Total TEAEs Leading to Discontinuation of Study Drug	2	0	6	8
Total TEAEs Related to Study Drug	59	0	21	80
Total TEAEs >= Grade 3 Severity	6	0	8	14
Patients n (%):				
Any TEAE	46 (97.9)	0	59 (95.2)	105 (96.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.34	NE		
95% CI of the odds ratio	(0.24, 23.23)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03	NE		
95% CI of the risk ratio	(0.96, 1.10)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.71	NE		
95% CI of the absolute risk difference	(-4.04, 9.46)	NE		
p-value	0.4559	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.5004	NE		
Any Serious TEAE	2 (4.3)	0	5 (8.1)	7 (6.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	NE		
95% CI of the odds ratio	(0.09, 2.73)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53	NE		
95% CI of the risk ratio	(0.11, 2.60)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.81	NE		
95% CI of the absolute risk difference	(-12.71, 5.09)	NE		
p-value	0.4217	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.8346	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Any TEAEs >= Grade 3 Severity	4 (8.5)	0	6 (9.7)	10 (9.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87	NE		
95% CI of the odds ratio	(0.23, 3.27)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.88	NE		
95% CI of the risk ratio	(0.26, 2.94)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.17	NE		
95% CI of the absolute risk difference	(-12.02, 9.69)	NE		
p-value	0.8345	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.3768	NE		
Any TEAEs <= Grade 2 Severity	46 (97.9)	0	59 (95.2)	105 (96.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.34	NE		
95% CI of the odds ratio	(0.24, 23.23)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03	NE		
95% CI of the risk ratio	(0.96, 1.10)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.71	NE		
95% CI of the absolute risk difference	(-4.04, 9.46)	NE		
p-value	0.4559	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.3847	NE		
Any TEAEs leading to Study-Drug Discontinuation	1 (2.1)	0	5 (8.1)	6 (5.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.25	NE		
95% CI of the odds ratio	(0.03, 2.20)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.26	NE		
95% CI of the risk ratio	(0.03, 2.18)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.94	NE		
95% CI of the absolute risk difference	(-13.87, 2.00)	NE		
p-value	0.1783	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2988	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Any TEAEs leading to Study Discontinuation	0	0	3 (4.8)	3 (2.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.84	NE		
95% CI of the absolute risk difference	(-10.18, 0.50)	NE		
p-value	0.1262	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.4535	NE		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Any Treatment-related TEAE	23 (48.9)	0	13 (21.0)	36 (33.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.61	NE		
95% CI of the odds ratio	(1.56, 8.34)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.33	NE		
95% CI of the risk ratio	(1.33, 4.10)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	27.97	NE		
95% CI of the absolute risk difference	(10.45, 45.49)	NE		
p-value	0.0021	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1252	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (2.1)	0	0	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.13	NE		
95% CI of the absolute risk difference	(-2.00, 6.25)	NE		
p-value	0.2486	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1232	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	1 (2.1)	0	2 (3.2)	3 (2.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.65	NE		
95% CI of the odds ratio	(0.06, 7.42)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.66	NE		
95% CI of the risk ratio	(0.06, 7.06)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.10	NE		
95% CI of the absolute risk difference	(-7.13, 4.93)	NE		
p-value	0.7285	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.9385	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.61	NE		
95% CI of the absolute risk difference	(-4.75, 1.52)	NE		
p-value	0.3817	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	9 (19.1)	0	18 (29.0)	27 (24.8)
Grade 2	33 (70.2)	0	35 (56.5)	68 (62.4)
Grade 3	4 (8.5)	0	5 (8.1)	9 (8.3)
Grade 4	0	0	1 (1.6)	1 (0.9)
Grade 5	0	0	0	0

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	14 (29.8)	0	5 (8.1)	19 (17.4)
Grade 2	8 (17.0)	0	8 (12.9)	16 (14.7)
Grade 3	1 (2.1)	0	0	1 (0.9)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Serious 3-PT MACE AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Other MACE AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
DILI AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE - Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE - Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47) n (%)	MGL-3196 100 mg (N=0) n (%)	Placebo (N=62) n (%)	Overall (N=109) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Events n:				
Total TEAEs	757	1014	1711	3482
Total Serious TEAEs	16	32	84	132
Total TEAEs Leading to Discontinuation of Study Drug	9	18	13	40
Total TEAEs Related to Study Drug	91	126	131	348
Total TEAEs >= Grade 3 Severity	16	44	90	150
Patients n (%):				
Any TEAE	104 (92.0)	138 (91.4)	214 (91.8)	456 (91.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03	0.94		
95% CI of the odds ratio	(0.45, 2.35)	(0.45, 1.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.00		
95% CI of the risk ratio	(0.94, 1.07)	(0.94, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.19	-0.45		
95% CI of the absolute risk difference	(-5.91, 6.29)	(-6.14, 5.23)		
p-value	0.9516	0.8749		
p-value of Breslow-Day Test for Homogeneity [2]	0.5004	NE		
Any Serious TEAE	12 (10.6)	21 (13.9)	36 (15.5)	69 (13.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.65	0.88		
95% CI of the odds ratio	(0.32, 1.30)	(0.49, 1.58)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	0.90		
95% CI of the risk ratio	(0.37, 1.27)	(0.55, 1.48)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.83	-1.54		
95% CI of the absolute risk difference	(-12.17, 2.50)	(-8.75, 5.67)		
p-value	0.2228	0.6778		
p-value of Breslow-Day Test for Homogeneity [2]	0.8346	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Any TEAEs >= Grade 3 Severity	12 (10.6)	25 (16.6)	44 (18.9)	81 (16.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	0.85		
95% CI of the odds ratio	(0.26, 1.01)	(0.50, 1.46)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56	0.88		
95% CI of the risk ratio	(0.31, 1.02)	(0.56, 1.37)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.26	-2.33		
95% CI of the absolute risk difference	(-15.85, -0.68)	(-10.10, 5.44)		
p-value	0.0503	0.5617		
p-value of Breslow-Day Test for Homogeneity [2]	0.3768	NE		
Any TEAEs <= Grade 2 Severity	102 (90.3)	136 (90.1)	214 (91.8)	452 (90.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82	0.80		
95% CI of the odds ratio	(0.38, 1.79)	(0.40, 1.64)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	0.98		
95% CI of the risk ratio	(0.91, 1.06)	(0.92, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.58	-1.78		
95% CI of the absolute risk difference	(-8.08, 4.92)	(-7.70, 4.15)		
p-value	0.6243	0.5488		
p-value of Breslow-Day Test for Homogeneity [2]	0.3847	NE		
Any TEAEs leading to Study-Drug Discontinuation	7 (6.2)	16 (10.6)	10 (4.3)	33 (6.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.47	2.64		
95% CI of the odds ratio	(0.55, 3.98)	(1.17, 5.99)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44	2.47		
95% CI of the risk ratio	(0.56, 3.69)	(1.15, 5.30)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.90	6.30		
95% CI of the absolute risk difference	(-3.25, 7.05)	(0.75, 11.86)		
p-value	0.4425	0.0163		
p-value of Breslow-Day Test for Homogeneity [2]	0.2988	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Any TEAEs leading to Study Discontinuation	2 (1.8)	11 (7.3)	7 (3.0)	20 (4.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58	2.54		
95% CI of the odds ratio	(0.12, 2.85)	(0.96, 6.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	2.42		
95% CI of the risk ratio	(0.12, 2.79)	(0.96, 6.12)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.23	4.28		
95% CI of the absolute risk difference	(-4.51, 2.04)	(-0.41, 8.97)		
p-value	0.4987	0.0526		
p-value of Breslow-Day Test for Homogeneity [2]	0.4535	NE		
Any Fatal TEAEs	0	1 (0.7)	1 (0.4)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.55		
95% CI of the odds ratio	NE	(0.10, 24.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the risk ratio	NE	(0.10, 24.48)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.43	0.23		
95% CI of the absolute risk difference	(-1.27, 0.41)	(-1.31, 1.78)		
p-value	0.4855	0.7566		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Any Treatment-related TEAE	44 (38.9)	55 (36.4)	70 (30.0)	169 (34.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.48	1.33		
95% CI of the odds ratio	(0.93, 2.38)	(0.86, 2.06)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.30	1.21		
95% CI of the risk ratio	(0.96, 1.75)	(0.91, 1.62)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.90	6.38		
95% CI of the absolute risk difference	(-1.85, 19.64)	(-3.29, 16.05)		
p-value	0.0988	0.1924		
p-value of Breslow-Day Test for Homogeneity [2]	0.1252	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.43	-0.43		
95% CI of the absolute risk difference	(-1.27, 0.41)	(-1.27, 0.41)		
p-value	0.4855	0.4202		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	3 (2.0)	2 (0.9)	5 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.34		
95% CI of the odds ratio	NE	(0.39, 14.18)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.31		
95% CI of the risk ratio	NE	(0.39, 13.69)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.86	1.13		
95% CI of the absolute risk difference	(-2.04, 0.33)	(-1.39, 3.65)		
p-value	0.3233	0.3407		
p-value of Breslow-Day Test for Homogeneity [2]	0.1232	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (1.8)	10 (6.6)	7 (3.0)	19 (3.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58	2.29		
95% CI of the odds ratio	(0.12, 2.85)	(0.85, 6.15)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	2.20		
95% CI of the risk ratio	(0.12, 2.79)	(0.86, 5.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.23	3.62		
95% CI of the absolute risk difference	(-4.51, 2.04)	(-0.91, 8.15)		
p-value	0.4987	0.0922		
p-value of Breslow-Day Test for Homogeneity [2]	0.9385	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	7 (4.6)	4 (1.7)	11 (2.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.78		
95% CI of the odds ratio	NE	(0.80, 9.68)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.70		
95% CI of the risk ratio	NE	(0.80, 9.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.72	2.92		
95% CI of the absolute risk difference	(-3.38, -0.05)	(-0.83, 6.66)		
p-value	0.1612	0.0939		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	26 (23.0)	27 (17.9)	49 (21.0)	102 (20.5)
Grade 2	66 (58.4)	86 (57.0)	121 (51.9)	273 (54.9)
Grade 3	12 (10.6)	24 (15.9)	37 (15.9)	73 (14.7)
Grade 4	0	0	6 (2.6)	6 (1.2)
Grade 5	0	1 (0.7)	1 (0.4)	2 (0.4)

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	25 (22.1)	29 (19.2)	45 (19.3)	99 (19.9)
Grade 2	19 (16.8)	23 (15.2)	23 (9.9)	65 (13.1)
Grade 3	0	3 (2.0)	1 (0.4)	4 (0.8)
Grade 4	0	0	1 (0.4)	1 (0.2)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (0.7)	1 (0.4)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.55		
95% CI of the odds ratio	NE	(0.10, 24.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the risk ratio	NE	(0.10, 24.48)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.43	0.23		
95% CI of the absolute risk difference	(-1.27, 0.41)	(-1.31, 1.78)		
p-value	0.4855	0.7566		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.7)	0	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	0.66		
95% CI of the absolute risk difference	NE	(-0.63, 1.96)		
p-value	NE	0.2136		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.43	-0.43		
95% CI of the absolute risk difference	(-1.27, 0.41)	(-1.27, 0.41)		
p-value	0.4855	0.4202		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Serious 3-PT MACE AE - Adjudicated Event	0	1 (0.7)	1 (0.4)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.55		
95% CI of the odds ratio	NE	(0.10, 24.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the risk ratio	NE	(0.10, 24.48)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.43	0.23		
95% CI of the absolute risk difference	(-1.27, 0.41)	(-1.31, 1.78)		
p-value	0.4855	0.7566		
p-value of Breslow-Day Test for Homogeneity [2]	0.2106	NE		
Other MACE AE - Adjudicated Event	0	1 (0.7)	3 (1.3)	4 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.51		
95% CI of the odds ratio	NE	(0.05, 4.96)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.51		
95% CI of the risk ratio	NE	(0.05, 4.90)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.29	-0.63		
95% CI of the absolute risk difference	(-2.74, 0.16)	(-2.57, 1.32)		
p-value	0.2257	0.5555		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.7)	2 (0.9)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.77		
95% CI of the odds ratio	NE	(0.07, 8.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.77		
95% CI of the risk ratio	NE	(0.07, 8.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.86	-0.20		
95% CI of the absolute risk difference	(-2.04, 0.33)	(-1.95, 1.56)		
p-value	0.3233	0.8312		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.43	-0.43		
95% CI of the absolute risk difference	(-1.27, 0.41)	(-1.27, 0.41)		
p-value	0.4855	0.4202		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (0.7)	2 (0.9)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.77		
95% CI of the odds ratio	NE	(0.07, 8.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.77		
95% CI of the risk ratio	NE	(0.07, 8.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.86	-0.20		
95% CI of the absolute risk difference	(-2.04, 0.33)	(-1.95, 1.56)		
p-value	0.3233	0.8312		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113) n (%)	MGL-3196 100 mg (N=151) n (%)	Placebo (N=233) n (%)	Overall (N=497) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.
Note: PT 'Contusion' has statistically significant results in table S1.1.3, but is not included in this table due to patient counts being less than 10 in all subgroup categories.

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: <25 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=7) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=8) Patients n (%)	 Events n	Overall (N=15) Patients n (%)	 Events n
General disorders and administration site conditions	3 (42.9)	6	0	0	3 (37.5)	3	6 (40.0)	9
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25		NE					
95% CI of the odds ratio	(0.16, 9.92)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14		NE					
95% CI of the risk ratio	(0.33, 3.94)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.36		NE					
95% CI of the absolute risk difference	(-44.34, 55.05)		NE					
p-value	0.8327		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.2868		NE					
Gastrointestinal disorders								
Diarrhoea	2 (28.6)	2	0	0	1 (12.5)	1	3 (20.0)	3
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.80		NE					
95% CI of the odds ratio	(0.20, 40.06)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.29		NE					
95% CI of the risk ratio	(0.26, 20.13)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	16.07		NE					
95% CI of the absolute risk difference	(-24.49, 56.63)		NE					
p-value	0.4376		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.2745		NE					

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: <25 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=7) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=8) Patients n (%)	 Events n	Overall (N=15) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Nausea	1 (14.3)	1	0	0	0	0	1 (6.7)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.92		NE					
95% CI of the odds ratio	(0.14, 112.90)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.38		NE					
95% CI of the risk ratio	(0.16, 71.67)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.19		NE					
95% CI of the absolute risk difference	(-17.72, 44.11)		NE					
p-value	0.3993		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.0910		NE					
Vomiting	1 (14.3)	1	0	0	0	0	1 (6.7)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.92		NE					
95% CI of the odds ratio	(0.14, 112.90)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.38		NE					
95% CI of the risk ratio	(0.16, 71.67)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.19		NE					
95% CI of the absolute risk difference	(-17.72, 44.11)		NE					
p-value	0.3993		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.6349		NE					

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: <25 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=7) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=8) Patients n (%)	 Events n	Overall (N=15) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Abdominal discomfort	0	0	0	0	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.3439		NE					
Skin and subcutaneous tissue disorders								
Pruritus	1 (14.3)	2	0	0	1 (12.5)	1	2 (13.3)	3
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17		NE					
95% CI of the odds ratio	(0.06, 22.94)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14		NE					
95% CI of the risk ratio	(0.09, 15.08)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.79		NE					
95% CI of the absolute risk difference	(-32.81, 36.39)		NE					
p-value	0.9192		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.6306		NE					

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: <25 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=7) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=8) Patients n (%)	 Events n	Overall (N=15) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	0	0	0	0	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.2744		NE					
Musculoskeletal and connective tissue disorders								
Pain in extremity	0	0	0	0	1 (12.5)	1	1 (6.7)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		NE					
95% CI of the odds ratio	(0.01, 9.57)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		NE					
95% CI of the risk ratio	(0.02, 7.96)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.42		NE					
95% CI of the absolute risk difference	(-39.98, 19.15)		NE					
p-value	0.5058		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.2540		NE					

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: <25 kg/m2

	MGL-3196 80 mg (N=7)		MGL-3196 100 mg (N=0)		Placebo (N=8)		Overall (N=15)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Renal and urinary disorders	0	0	0	0	1 (12.5)	2	1 (6.7)	2
Odds ratio, Chi-square,								
MGL-3196 treatment group / Placebo [1]	0.33		NE					
95% CI of the odds ratio	(0.01, 9.57)		NE					
Risk ratio, Chi-square,								
MGL-3196 treatment group / Placebo [1]	0.38		NE					
95% CI of the risk ratio	(0.02, 7.96)		NE					
Absolute risk difference, Chi-square,								
MGL-3196 treatment group - Placebo [1]	-10.42		NE					
95% CI of the absolute risk difference	(-39.98, 19.15)		NE					
p-value	0.5058		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.8295		NE					

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=47) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=62) Patients n (%)	 Events n	Overall (N=109) Patients n (%)	 Events n
Gastrointestinal disorders								
Nausea	15 (31.9)	20	0	0	4 (6.5)	5	19 (17.4)	25
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	6.80		NE					
95% CI of the odds ratio	(2.08, 22.22)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.95		NE					
95% CI of the risk ratio	(1.76, 13.94)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	25.46		NE					
95% CI of the absolute risk difference	(10.80, 40.13)		NE					
p-value	0.0005		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.0910		NE					
Diarrhoea	12 (25.5)	26	0	0	5 (8.1)	5	17 (15.6)	31
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.91		NE					
95% CI of the odds ratio	(1.27, 12.04)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.17		NE					
95% CI of the risk ratio	(1.20, 8.37)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	17.47		NE					
95% CI of the absolute risk difference	(3.28, 31.66)		NE					
p-value	0.0128		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.2745		NE					

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=47) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=62) Patients n (%)	 Events n	Overall (N=109) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	5 (10.6)	7	0	0	2 (3.2)	2	7 (6.4)	9
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.57		NE					
95% CI of the odds ratio	(0.66, 19.29)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.30		NE					
95% CI of the risk ratio	(0.67, 16.26)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.41		NE					
95% CI of the absolute risk difference	(-2.44, 17.26)		NE					
p-value	0.1180		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.6349		NE					
Abdominal discomfort	0	0	0	0	5 (8.1)	6	5 (4.6)	6
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11		NE					
95% CI of the odds ratio	(0.01, 2.04)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.12		NE					
95% CI of the risk ratio	(0.01, 2.11)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.69		NE					
95% CI of the absolute risk difference	(-15.23, -0.15)		NE					
p-value	0.0759		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.3439		NE					

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=47) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=62) Patients n (%)	 Events n	Overall (N=109) Patients n (%)	 Events n
General disorders and administration site conditions	10 (21.3)	14	0	0	11 (17.7)	12	21 (19.3)	26
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25		NE					
95% CI of the odds ratio	(0.48, 3.26)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.20		NE					
95% CI of the risk ratio	(0.56, 2.58)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.53		NE					
95% CI of the absolute risk difference	(-11.54, 18.61)		NE					
p-value	0.6431		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.2868		NE					
Skin and subcutaneous tissue disorders								
Pruritus	7 (14.9)	8	0	0	8 (12.9)	8	15 (13.8)	16
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.18		NE					
95% CI of the odds ratio	(0.40, 3.53)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.15		NE					
95% CI of the risk ratio	(0.45, 2.96)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.99		NE					
95% CI of the absolute risk difference	(-11.17, 15.15)		NE					
p-value	0.7651		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.6306		NE					

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=47) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=62) Patients n (%)	 Events n	Overall (N=109) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	1 (2.1)	1	0	0	3 (4.8)	3	4 (3.7)	4
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43		NE					
95% CI of the odds ratio	(0.04, 4.25)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44		NE					
95% CI of the risk ratio	(0.05, 4.09)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.71		NE					
95% CI of the absolute risk difference	(-9.46, 4.04)		NE					
p-value	0.4559		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.2744		NE					
Musculoskeletal and connective tissue disorders								
Pain in extremity	0	0	0	0	4 (6.5)	4	4 (3.7)	4
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.14		NE					
95% CI of the odds ratio	(0.01, 2.61)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.15		NE					
95% CI of the risk ratio	(0.01, 2.64)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.10		NE					
95% CI of the absolute risk difference	(-13.08, 0.88)		NE					
p-value	0.1247		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.2540		NE					

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=47) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=62) Patients n (%)	 Events n	Overall (N=109) Patients n (%)	 Events n
Renal and urinary disorders	1 (2.1)	2	0	0	3 (4.8)	3	4 (3.7)	5
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43		NE					
95% CI of the odds ratio	(0.04, 4.25)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44		NE					
95% CI of the risk ratio	(0.05, 4.09)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.71		NE					
95% CI of the absolute risk difference	(-9.46, 4.04)		NE					
p-value	0.4559		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.8295		NE					

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: >= 30 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=113) Patients n (%)	 Events n	MGL-3196 100 mg (N=151) Patients n (%)	 Events n	Placebo (N=233) Patients n (%)	 Events n	Overall (N=497) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	28 (24.8)	45	51 (33.8)	80	43 (18.5)	55	122 (24.5)	180
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.46		2.25					
95% CI of the odds ratio	(0.85, 2.50)		(1.40, 3.61)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.34		1.83					
95% CI of the risk ratio	(0.88, 2.04)		(1.29, 2.60)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.32		15.32					
95% CI of the absolute risk difference	(-3.07, 15.71)		(6.28, 24.36)					
p-value	0.1719		0.0006					
p-value of Breslow-Day Test for Homogeneity [2]	0.2745		NE					
Nausea	27 (23.9)	30	21 (13.9)	26	35 (15.0)	41	83 (16.7)	97
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.78		0.91					
95% CI of the odds ratio	(1.01, 3.12)		(0.51, 1.64)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.59		0.93					
95% CI of the risk ratio	(1.02, 2.49)		(0.56, 1.53)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.87		-1.11					
95% CI of the absolute risk difference	(-0.23, 17.98)		(-8.29, 6.06)					
p-value	0.0436		0.7625					
p-value of Breslow-Day Test for Homogeneity [2]	0.0910		NE					

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: >= 30 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=113) Patients n (%)	 Events n	MGL-3196 100 mg (N=151) Patients n (%)	 Events n	Placebo (N=233) Patients n (%)	 Events n	Overall (N=497) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	14 (12.4)	14	9 (6.0)	9	15 (6.4)	16	38 (7.6)	39
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.06		0.92					
95% CI of the odds ratio	(0.96, 4.42)		(0.39, 2.16)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.92		0.93					
95% CI of the risk ratio	(0.96, 3.85)		(0.42, 2.06)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.95		-0.48					
95% CI of the absolute risk difference	(-0.89, 12.79)		(-5.40, 4.44)					
p-value	0.0610		0.8502					
p-value of Breslow-Day Test for Homogeneity [2]	0.6349		NE					
Abdominal discomfort	1 (0.9)	1	3 (2.0)	4	8 (3.4)	8	12 (2.4)	13
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.25		0.57					
95% CI of the odds ratio	(0.03, 2.03)		(0.15, 2.18)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.26		0.58					
95% CI of the risk ratio	(0.03, 2.04)		(0.16, 2.15)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.55		-1.45					
95% CI of the absolute risk difference	(-5.46, 0.36)		(-4.67, 1.78)					
p-value	0.1625		0.4064					
p-value of Breslow-Day Test for Homogeneity [2]	0.3439		NE					

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: >= 30 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=113) Patients n (%)	 Events n	MGL-3196 100 mg (N=151) Patients n (%)	 Events n	Placebo (N=233) Patients n (%)	 Events n	Overall (N=497) Patients n (%)	 Events n
General disorders and administration site conditions	22 (19.5)	32	29 (19.2)	39	71 (30.5)	89	122 (24.5)	160
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.55		0.54					
95% CI of the odds ratio	(0.32, 0.95)		(0.33, 0.89)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.64		0.63					
95% CI of the risk ratio	(0.42, 0.97)		(0.43, 0.92)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-11.00		-11.27					
95% CI of the absolute risk difference	(-20.40, -1.61)		(-19.89, -2.64)					
p-value	0.0304		0.0140					
p-value of Breslow-Day Test for Homogeneity [2]	0.2868		NE					
Skin and subcutaneous tissue disorders								
Pruritus	14 (12.4)	18	8 (5.3)	10	14 (6.0)	17	36 (7.2)	45
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.21		0.88					
95% CI of the odds ratio	(1.02, 4.82)		(0.36, 2.14)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.06		0.88					
95% CI of the risk ratio	(1.02, 4.18)		(0.38, 2.05)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.38		-0.71					
95% CI of the absolute risk difference	(-0.42, 13.18)		(-5.41, 3.99)					
p-value	0.0413		0.7698					
p-value of Breslow-Day Test for Homogeneity [2]	0.6306		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113)		MGL-3196 100 mg (N=151)		Placebo (N=233)		Overall (N=497)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	7 (6.2)	7	16 (10.6)	20	9 (3.9)	11	32 (6.4)	38
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.64		2.95					
95% CI of the odds ratio	(0.60, 4.53)		(1.27, 6.86)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.60		2.74					
95% CI of the risk ratio	(0.61, 4.20)		(1.24, 6.05)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.33		6.73					
95% CI of the absolute risk difference	(-2.75, 7.42)		(1.24, 12.23)					
p-value	0.3327		0.0090					
p-value of Breslow-Day Test for Homogeneity [2]	0.2744		NE					
Renal and urinary disorders	4 (3.5)	4	20 (13.2)	24	23 (9.9)	28	47 (9.5)	56
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.34		1.39					
95% CI of the odds ratio	(0.11, 0.99)		(0.74, 2.64)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		1.34					
95% CI of the risk ratio	(0.13, 1.01)		(0.76, 2.36)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.33		3.37					
95% CI of the absolute risk difference	(-11.46, -1.21)		(-3.25, 10.00)					
p-value	0.0395		0.3058					
p-value of Breslow-Day Test for Homogeneity [2]	0.8295		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.6.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: >= 30 kg/m2

	MGL-3196 80 mg (N=113)		MGL-3196 100 mg (N=151)		Placebo (N=233)		Overall (N=497)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	7 (6.2)	8	4 (2.6)	4	19 (8.2)	23	30 (6.0)	35
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.74		0.31					
95% CI of the odds ratio	(0.30, 1.82)		(0.10, 0.92)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76		0.32					
95% CI of the risk ratio	(0.33, 1.75)		(0.11, 0.94)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.96		-5.51					
95% CI of the absolute risk difference	(-7.63, 3.71)		(-9.85, -1.16)					
p-value	0.5167		0.0264					
p-value of Breslow-Day Test for Homogeneity [2]	0.2540		NE					

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Events n:				
Total TEAEs	823	655	1448	2926
Total Serious TEAEs	13	24	77	114
Total TEAEs Leading to Discontinuation of Study Drug	11	15	14	40
Total TEAEs Related to Study Drug	109	85	86	280
Total TEAEs >= Grade 3 Severity	15	32	84	131
Patients n (%):				
Any TEAE	112 (94.9)	90 (90.0)	184 (91.5)	386 (92.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.72	0.83		
95% CI of the odds ratio	(0.66, 4.50)	(0.37, 1.89)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04	0.98		
95% CI of the risk ratio	(0.98, 1.10)	(0.91, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.37	-1.54		
95% CI of the absolute risk difference	(-2.15, 8.90)	(-8.57, 5.48)		
p-value	0.2608	0.6592		
p-value of Breslow-Day Test for Homogeneity [2]	0.1625	0.5615		
Any Serious TEAE	11 (9.3)	14 (14.0)	33 (16.4)	58 (13.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.52	0.83		
95% CI of the odds ratio	(0.25, 1.08)	(0.42, 1.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57	0.85		
95% CI of the risk ratio	(0.30, 1.08)	(0.48, 1.52)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.10	-2.42		
95% CI of the absolute risk difference	(-14.43, 0.24)	(-10.93, 6.10)		
p-value	0.0760	0.5862		
p-value of Breslow-Day Test for Homogeneity [2]	0.3094	0.3640		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Any TEAEs >= Grade 3 Severity	11 (9.3)	18 (18.0)	39 (19.4)	68 (16.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43	0.91		
95% CI of the odds ratio	(0.21, 0.87)	(0.49, 1.69)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48	0.93		
95% CI of the risk ratio	(0.26, 0.90)	(0.56, 1.54)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.08	-1.40		
95% CI of the absolute risk difference	(-17.66, -2.50)	(-10.71, 7.90)		
p-value	0.0168	0.7698		
p-value of Breslow-Day Test for Homogeneity [2]	0.0209	0.8707		
Any TEAEs <= Grade 2 Severity	112 (94.9)	88 (88.0)	184 (91.5)	384 (91.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.72	0.68		
95% CI of the odds ratio	(0.66, 4.50)	(0.31, 1.48)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04	0.96		
95% CI of the risk ratio	(0.98, 1.10)	(0.88, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.37	-3.54		
95% CI of the absolute risk difference	(-2.15, 8.90)	(-10.98, 3.90)		
p-value	0.2608	0.3266		
p-value of Breslow-Day Test for Homogeneity [2]	0.0291	0.7171		
Any TEAEs leading to Study-Drug Discontinuation	9 (7.6)	13 (13.0)	12 (6.0)	34 (8.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.30	2.35		
95% CI of the odds ratio	(0.53, 3.19)	(1.03, 5.37)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.28	2.18		
95% CI of the risk ratio	(0.55, 2.94)	(1.03, 4.60)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.66	7.03		
95% CI of the absolute risk difference	(-4.15, 7.46)	(-0.33, 14.39)		
p-value	0.5645	0.0374		
p-value of Breslow-Day Test for Homogeneity [2]	0.4245	0.3026		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Any TEAEs leading to Study Discontinuation	2 (1.7)	6 (6.0)	7 (3.5)	15 (3.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48	1.77		
95% CI of the odds ratio	(0.10, 2.34)	(0.58, 5.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.49	1.72		
95% CI of the risk ratio	(0.10, 2.30)	(0.59, 4.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.79	2.52		
95% CI of the absolute risk difference	(-5.23, 1.65)	(-2.78, 7.82)		
p-value	0.3519	0.3116		
p-value of Breslow-Day Test for Homogeneity [2]	0.9622	0.6484		
Any Fatal TEAEs	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.02		
95% CI of the odds ratio	NE	(0.13, 32.64)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.01		
95% CI of the risk ratio	NE	(0.13, 31.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.50	0.50		
95% CI of the absolute risk difference	(-1.47, 0.48)	(-1.68, 2.68)		
p-value	0.4428	0.6133		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
Any Treatment-related TEAE	49 (41.5)	34 (34.0)	50 (24.9)	133 (31.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.14	1.56		
95% CI of the odds ratio	(1.32, 3.49)	(0.92, 2.62)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	1.37		
95% CI of the risk ratio	(1.21, 2.30)	(0.95, 1.97)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	16.65	9.12		
95% CI of the absolute risk difference	(5.94, 27.36)	(-1.92, 20.17)		
p-value	0.0019	0.0964		
p-value of Breslow-Day Test for Homogeneity [2]	0.1876	0.5938		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (0.8)	3 (3.0)	1 (0.5)	5 (1.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.71	6.19		
95% CI of the odds ratio	(0.11, 27.59)	(0.64, 60.24)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.70	6.03		
95% CI of the risk ratio	(0.11, 26.98)	(0.64, 57.24)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.35	2.50		
95% CI of the absolute risk difference	(-1.57, 2.27)	(-0.98, 5.98)		
p-value	0.7022	0.0741		
p-value of Breslow-Day Test for Homogeneity [2]	0.9177	0.1671		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (1.7)	7 (7.0)	5 (2.5)	14 (3.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	2.95		
95% CI of the odds ratio	(0.13, 3.54)	(0.91, 9.54)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	2.81		
95% CI of the risk ratio	(0.13, 3.46)	(0.92, 8.64)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.79	4.51		
95% CI of the absolute risk difference	(-3.96, 2.38)	(-0.93, 9.96)		
p-value	0.6408	0.0595		
p-value of Breslow-Day Test for Homogeneity [2]	0.8421	0.5041		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	4 (4.0)	1 (0.5)	5 (1.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.33		
95% CI of the odds ratio	NE	(0.92, 75.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.04		
95% CI of the risk ratio	NE	(0.91, 70.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.50	3.50		
95% CI of the absolute risk difference	(-1.47, 0.48)	(-0.46, 7.46)		
p-value	0.4428	0.0251		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1995		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	29 (24.6)	15 (15.0)	44 (21.9)	88 (21.0)
Grade 2	72 (61.0)	57 (57.0)	101 (50.2)	230 (54.9)
Grade 3	11 (9.3)	17 (17.0)	33 (16.4)	61 (14.6)
Grade 4	0	0	5 (2.5)	5 (1.2)
Grade 5	0	1 (1.0)	1 (0.5)	2 (0.5)

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	29 (24.6)	16 (16.0)	33 (16.4)	78 (18.6)
Grade 2	19 (16.1)	15 (15.0)	16 (8.0)	50 (11.9)
Grade 3	1 (0.8)	3 (3.0)	1 (0.5)	5 (1.2)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.02		
95% CI of the odds ratio	NE	(0.13, 32.64)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.01		
95% CI of the risk ratio	NE	(0.13, 31.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.50	0.50		
95% CI of the absolute risk difference	(-1.47, 0.48)	(-1.68, 2.68)		
p-value	0.4428	0.6133		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.0)	0	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.00		
95% CI of the absolute risk difference	NE	(-0.95, 2.95)		
p-value	NE	0.1556		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.50	-0.50		
95% CI of the absolute risk difference	(-1.47, 0.48)	(-1.47, 0.48)		
p-value	0.4428	0.4799		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.02		
95% CI of the odds ratio	NE	(0.13, 32.64)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.01		
95% CI of the risk ratio	NE	(0.13, 31.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.50	0.50		
95% CI of the absolute risk difference	(-1.47, 0.48)	(-1.68, 2.68)		
p-value	0.4428	0.6133		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
Other MACE AE – Adjudicated Event	0	1 (1.0)	2 (1.0)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.01		
95% CI of the odds ratio	NE	(0.09, 11.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.01		
95% CI of the risk ratio	NE	(0.09, 10.95)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.00	0.00		
95% CI of the absolute risk difference	(-2.37, 0.38)	(-2.38, 2.39)		
p-value	0.2770	0.9967		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3582		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.0)	2 (1.0)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.01		
95% CI of the odds ratio	NE	(0.09, 11.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.01		
95% CI of the risk ratio	NE	(0.09, 10.95)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.00	0.00		
95% CI of the absolute risk difference	(-2.37, 0.38)	(-2.38, 2.39)		
p-value	0.2770	0.9967		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5030		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (1.0)	2 (1.0)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.01		
95% CI of the odds ratio	NE	(0.09, 11.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.01		
95% CI of the risk ratio	NE	(0.09, 10.95)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.00	0.00		
95% CI of the absolute risk difference	(-2.37, 0.38)	(-2.38, 2.39)		
p-value	0.2770	0.9967		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5030		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Events n:				
Total TEAEs	376	367	709	1452
Total Serious TEAEs	16	8	19	43
Total TEAEs Leading to Discontinuation of Study Drug	7	5	11	23
Total TEAEs Related to Study Drug	46	41	73	160
Total TEAEs >= Grade 3 Severity	19	13	22	54
Patients n (%):				
Any TEAE	46 (93.9)	48 (94.1)	99 (97.1)	193 (95.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.46	0.48		
95% CI of the odds ratio	(0.09, 2.39)	(0.09, 2.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	0.97		
95% CI of the risk ratio	(0.89, 1.05)	(0.90, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.18	-2.94		
95% CI of the absolute risk difference	(-10.65, 4.29)	(-10.18, 4.30)		
p-value	0.3488	0.3770		
p-value of Breslow-Day Test for Homogeneity [2]	0.1625	0.5615		
Any Serious TEAE	5 (10.2)	7 (13.7)	10 (9.8)	22 (10.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.05	1.46		
95% CI of the odds ratio	(0.34, 3.24)	(0.52, 4.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04	1.40		
95% CI of the risk ratio	(0.38, 2.88)	(0.57, 3.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.40	3.92		
95% CI of the absolute risk difference	(-9.85, 10.65)	(-7.15, 14.99)		
p-value	0.9386	0.4669		
p-value of Breslow-Day Test for Homogeneity [2]	0.3094	0.3640		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Any TEAEs >= Grade 3 Severity	11 (22.4)	8 (15.7)	16 (15.7)	35 (17.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.56	1.00		
95% CI of the odds ratio	(0.66, 3.67)	(0.40, 2.52)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43	1.00		
95% CI of the risk ratio	(0.72, 2.85)	(0.46, 2.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.76	0.00		
95% CI of the absolute risk difference	(-6.89, 20.41)	(-12.22, 12.22)		
p-value	0.3099	>0.9999		
p-value of Breslow-Day Test for Homogeneity [2]	0.0209	0.8707		
Any TEAEs <= Grade 2 Severity	44 (89.8)	48 (94.1)	99 (97.1)	191 (94.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.27	0.48		
95% CI of the odds ratio	(0.06, 1.17)	(0.09, 2.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.93	0.97		
95% CI of the risk ratio	(0.84, 1.02)	(0.90, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.26	-2.94		
95% CI of the absolute risk difference	(-16.35, 1.82)	(-10.18, 4.30)		
p-value	0.0621	0.3770		
p-value of Breslow-Day Test for Homogeneity [2]	0.0291	0.7171		
Any TEAEs leading to Study-Drug Discontinuation	3 (6.1)	5 (9.8)	9 (8.8)	17 (8.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67	1.12		
95% CI of the odds ratio	(0.17, 2.61)	(0.36, 3.54)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	1.11		
95% CI of the risk ratio	(0.20, 2.45)	(0.39, 3.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.70	0.98		
95% CI of the absolute risk difference	(-11.38, 5.98)	(-8.86, 10.82)		
p-value	0.5656	0.8428		
p-value of Breslow-Day Test for Homogeneity [2]	0.4245	0.3026		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Any TEAEs leading to Study Discontinuation	1 (2.0)	5 (9.8)	4 (3.9)	10 (5.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	2.66		
95% CI of the odds ratio	(0.06, 4.69)	(0.68, 10.38)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.52	2.50		
95% CI of the risk ratio	(0.06, 4.53)	(0.70, 8.91)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.88	5.88		
95% CI of the absolute risk difference	(-7.35, 3.58)	(-3.11, 14.87)		
p-value	0.5454	0.1449		
p-value of Breslow-Day Test for Homogeneity [2]	0.9622	0.6484		
Any Fatal TEAEs	1 (2.0)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.04	NE		
95% CI of the absolute risk difference	(-1.92, 6.00)	NE		
p-value	0.1477	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
Any Treatment-related TEAE	20 (40.8)	21 (41.2)	37 (36.3)	78 (38.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21	1.23		
95% CI of the odds ratio	(0.60, 2.44)	(0.62, 2.45)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13	1.14		
95% CI of the risk ratio	(0.74, 1.72)	(0.75, 1.72)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.54	4.90		
95% CI of the absolute risk difference	(-12.08, 21.17)	(-11.51, 21.32)		
p-value	0.5899	0.5558		
p-value of Breslow-Day Test for Homogeneity [2]	0.1876	0.5938		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Any Treatment-related Serious TEAE	0	0	1 (1.0)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.98	-0.98		
95% CI of the absolute risk difference	(-2.89, 0.93)	(-2.89, 0.93)		
p-value	0.4868	0.4781		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (2.0)	0	1 (1.0)	2 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.10	NE		
95% CI of the odds ratio	(0.13, 34.36)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.08	NE		
95% CI of the risk ratio	(0.13, 32.59)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.06	-0.98		
95% CI of the absolute risk difference	(-3.34, 5.46)	(-2.89, 0.93)		
p-value	0.5936	0.4781		
p-value of Breslow-Day Test for Homogeneity [2]	0.9177	0.1671		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	1 (2.0)	3 (5.9)	4 (3.9)	8 (4.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	1.53		
95% CI of the odds ratio	(0.06, 4.69)	(0.33, 7.12)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.52	1.50		
95% CI of the risk ratio	(0.06, 4.53)	(0.35, 6.45)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.88	1.96		
95% CI of the absolute risk difference	(-7.35, 3.58)	(-5.52, 9.44)		
p-value	0.5454	0.5843		
p-value of Breslow-Day Test for Homogeneity [2]	0.8421	0.5041		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	3 (5.9)	4 (3.9)	7 (3.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.53		
95% CI of the odds ratio	NE	(0.33, 7.12)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.50		
95% CI of the risk ratio	NE	(0.35, 6.45)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.92	1.96		
95% CI of the absolute risk difference	(-7.69, -0.15)	(-5.52, 9.44)		
p-value	0.1600	0.5843		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1995		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	10 (20.4)	11 (21.6)	25 (24.5)	46 (22.8)
Grade 2	25 (51.0)	29 (56.9)	58 (56.9)	112 (55.4)
Grade 3	10 (20.4)	8 (15.7)	14 (13.7)	32 (15.8)
Grade 4	0	0	2 (2.0)	2 (1.0)
Grade 5	1 (2.0)	0	0	1 (0.5)

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	12 (24.5)	13 (25.5)	20 (19.6)	45 (22.3)
Grade 2	7 (14.3)	8 (15.7)	16 (15.7)	31 (15.3)
Grade 3	1 (2.0)	0	0	1 (0.5)
Grade 4	0	0	1 (1.0)	1 (0.5)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (2.0)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	2.04	NE		
95% CI of the absolute risk difference	(-1.92, 6.00)	NE		
p-value	0.1477	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (2.0)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	2.04	NE		
95% CI of the absolute risk difference	(-1.92, 6.00)	NE		
p-value	0.1477	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (2.0)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	2.04	NE		
95% CI of the absolute risk difference	(-1.92, 6.00)	NE		
p-value	0.1477	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
Other MACE AE – Adjudicated Event	0	0	2 (2.0)	2 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.96	-1.96		
95% CI of the absolute risk difference	(-4.65, 0.73)	(-4.65, 0.73)		
p-value	0.3238	0.3141		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3582		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	1 (1.0)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.98	-0.98		
95% CI of the absolute risk difference	(-2.89, 0.93)	(-2.89, 0.93)		
p-value	0.4868	0.4781		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5030		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (1.0)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.98	-0.98		
95% CI of the absolute risk difference	(-2.89, 0.93)	(-2.89, 0.93)		
p-value	0.4868	0.4781		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	1 (1.0)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.98	-0.98		
95% CI of the absolute risk difference	(-2.89, 0.93)	(-2.89, 0.93)		
p-value	0.4868	0.4781		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5030		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.7.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Events n:				
Total TEAEs	812	651	1433	2896
Total Serious TEAEs	13	24	77	114
Total TEAEs Leading to Discontinuation of Study Drug	8	13	13	34
Total TEAEs Related to Study Drug	109	85	85	279
Total TEAEs >= Grade 3 Severity	13	32	82	127
Patients n (%):				
Any TEAE	111 (94.1)	90 (90.0)	184 (91.5)	385 (91.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.47	0.83		
95% CI of the odds ratio	(0.59, 3.64)	(0.37, 1.89)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03	0.98		
95% CI of the risk ratio	(0.97, 1.09)	(0.91, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.53	-1.54		
95% CI of the absolute risk difference	(-3.22, 8.27)	(-8.57, 5.48)		
p-value	0.4090	0.6592		
p-value of Breslow-Day Test for Homogeneity [2]	0.4823	0.9924		
Any Serious TEAE	11 (9.3)	14 (14.0)	33 (16.4)	58 (13.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.52	0.83		
95% CI of the odds ratio	(0.25, 1.08)	(0.42, 1.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57	0.85		
95% CI of the risk ratio	(0.30, 1.08)	(0.48, 1.52)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.10	-2.42		
95% CI of the absolute risk difference	(-14.43, 0.24)	(-10.93, 6.10)		
p-value	0.0760	0.5862		
p-value of Breslow-Day Test for Homogeneity [2]	0.3094	0.3640		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Any TEAEs >= Grade 3 Severity	9 (7.6)	18 (18.0)	37 (18.4)	64 (15.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.37	0.97		
95% CI of the odds ratio	(0.17, 0.79)	(0.52, 1.81)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.41	0.98		
95% CI of the risk ratio	(0.21, 0.83)	(0.59, 1.63)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.78	-0.41		
95% CI of the absolute risk difference	(-17.97, -3.59)	(-9.65, 8.83)		
p-value	0.0081	0.9313		
p-value of Breslow-Day Test for Homogeneity [2]	0.0167	0.9280		
Any TEAEs <= Grade 2 Severity	111 (94.1)	88 (88.0)	184 (91.5)	383 (91.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.47	0.68		
95% CI of the odds ratio	(0.59, 3.64)	(0.31, 1.48)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03	0.96		
95% CI of the risk ratio	(0.97, 1.09)	(0.88, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.53	-3.54		
95% CI of the absolute risk difference	(-3.22, 8.27)	(-10.98, 3.90)		
p-value	0.4090	0.3266		
p-value of Breslow-Day Test for Homogeneity [2]	0.1385	0.8171		
Any TEAEs leading to Study-Drug Discontinuation	6 (5.1)	11 (11.0)	11 (5.5)	28 (6.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.93	2.13		
95% CI of the odds ratio	(0.33, 2.57)	(0.89, 5.11)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.93	2.01		
95% CI of the risk ratio	(0.35, 2.45)	(0.90, 4.48)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.39	5.53		
95% CI of the absolute risk difference	(-5.45, 4.67)	(-1.36, 12.42)		
p-value	0.8816	0.0827		
p-value of Breslow-Day Test for Homogeneity [2]	0.7320	0.9876		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Any TEAEs leading to Study Discontinuation	2 (1.7)	6 (6.0)	7 (3.5)	15 (3.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48	1.77		
95% CI of the odds ratio	(0.10, 2.34)	(0.58, 5.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.49	1.72		
95% CI of the risk ratio	(0.10, 2.30)	(0.59, 4.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.79	2.52		
95% CI of the absolute risk difference	(-5.23, 1.65)	(-2.78, 7.82)		
p-value	0.3519	0.3116		
p-value of Breslow-Day Test for Homogeneity [2]	0.9622	0.6484		
Any Fatal TEAEs	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.02		
95% CI of the odds ratio	NE	(0.13, 32.64)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.01		
95% CI of the risk ratio	NE	(0.13, 31.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.50	0.50		
95% CI of the absolute risk difference	(-1.47, 0.48)	(-1.68, 2.68)		
p-value	0.4428	0.6133		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
Any Treatment-related TEAE	49 (41.5)	34 (34.0)	49 (24.4)	132 (31.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.20	1.60		
95% CI of the odds ratio	(1.35, 3.59)	(0.95, 2.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.70	1.39		
95% CI of the risk ratio	(1.23, 2.36)	(0.97, 2.01)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	17.15	9.62		
95% CI of the absolute risk difference	(6.46, 27.84)	(-1.40, 20.64)		
p-value	0.0014	0.0785		
p-value of Breslow-Day Test for Homogeneity [2]	0.1681	0.5528		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (0.8)	3 (3.0)	1 (0.5)	5 (1.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.71	6.19		
95% CI of the odds ratio	(0.11, 27.59)	(0.64, 60.24)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.70	6.03		
95% CI of the risk ratio	(0.11, 26.98)	(0.64, 57.24)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.35	2.50		
95% CI of the absolute risk difference	(-1.57, 2.27)	(-0.98, 5.98)		
p-value	0.7022	0.0741		
p-value of Breslow-Day Test for Homogeneity [2]	0.4219	0.1671		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (1.7)	7 (7.0)	5 (2.5)	14 (3.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	2.95		
95% CI of the odds ratio	(0.13, 3.54)	(0.91, 9.54)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	2.81		
95% CI of the risk ratio	(0.13, 3.46)	(0.92, 8.64)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.79	4.51		
95% CI of the absolute risk difference	(-3.96, 2.38)	(-0.93, 9.96)		
p-value	0.6408	0.0595		
p-value of Breslow-Day Test for Homogeneity [2]	0.8421	0.5041		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	4 (4.0)	1 (0.5)	5 (1.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.33		
95% CI of the odds ratio	NE	(0.92, 75.57)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.04		
95% CI of the risk ratio	NE	(0.91, 70.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.50	3.50		
95% CI of the absolute risk difference	(-1.47, 0.48)	(-0.46, 7.46)		
p-value	0.4428	0.0251		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1995		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	28 (23.7)	15 (15.0)	46 (22.9)	89 (21.2)
Grade 2	74 (62.7)	57 (57.0)	101 (50.2)	232 (55.4)
Grade 3	9 (7.6)	17 (17.0)	31 (15.4)	57 (13.6)
Grade 4	0	0	5 (2.5)	5 (1.2)
Grade 5	0	1 (1.0)	1 (0.5)	2 (0.5)

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	29 (24.6)	16 (16.0)	32 (15.9)	77 (18.4)
Grade 2	19 (16.1)	15 (15.0)	16 (8.0)	50 (11.9)
Grade 3	1 (0.8)	3 (3.0)	1 (0.5)	5 (1.2)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.02		
95% CI of the odds ratio	NE	(0.13, 32.64)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.01		
95% CI of the risk ratio	NE	(0.13, 31.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.50	0.50		
95% CI of the absolute risk difference	(-1.47, 0.48)	(-1.68, 2.68)		
p-value	0.4428	0.6133		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.0)	0	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.00		
95% CI of the absolute risk difference	NE	(-0.95, 2.95)		
p-value	NE	0.1556		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.50	-0.50		
95% CI of the absolute risk difference	(-1.47, 0.48)	(-1.47, 0.48)		
p-value	0.4428	0.4799		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
Serious 3-PT MACE AE - Adjudicated Event	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.02		
95% CI of the odds ratio	NE	(0.13, 32.64)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.01		
95% CI of the risk ratio	NE	(0.13, 31.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.50	0.50		
95% CI of the absolute risk difference	(-1.47, 0.48)	(-1.68, 2.68)		
p-value	0.4428	0.6133		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
Other MACE AE - Adjudicated Event	0	1 (1.0)	2 (1.0)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.01		
95% CI of the odds ratio	NE	(0.09, 11.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.01		
95% CI of the risk ratio	NE	(0.09, 10.95)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.00	0.00		
95% CI of the absolute risk difference	(-2.37, 0.38)	(-2.38, 2.39)		
p-value	0.2770	0.9967		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3582		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.0)	2 (1.0)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.01		
95% CI of the odds ratio	NE	(0.09, 11.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.01		
95% CI of the risk ratio	NE	(0.09, 10.95)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.00	0.00		
95% CI of the absolute risk difference	(-2.37, 0.38)	(-2.38, 2.39)		
p-value	0.2770	0.9967		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5030		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (1.0)	2 (1.0)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.01		
95% CI of the odds ratio	NE	(0.09, 11.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.01		
95% CI of the risk ratio	NE	(0.09, 10.95)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.00	0.00		
95% CI of the absolute risk difference	(-2.37, 0.38)	(-2.38, 2.39)		
p-value	0.2770	0.9967		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5030		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118) n (%)	MGL-3196 100 mg (N=100) n (%)	Placebo (N=201) n (%)	Overall (N=419) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Events n:				
Total TEAEs	374	363	700	1437
Total Serious TEAEs	16	8	19	43
Total TEAEs Leading to Discontinuation of Study Drug	7	5	7	19
Total TEAEs Related to Study Drug	45	41	73	159
Total TEAEs >= Grade 3 Severity	18	12	21	51
Patients n (%):				
Any TEAE	46 (93.9)	48 (94.1)	97 (95.1)	191 (94.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.79	0.82		
95% CI of the odds ratio	(0.18, 3.45)	(0.19, 3.60)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	0.99		
95% CI of the risk ratio	(0.91, 1.07)	(0.91, 1.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.22	-0.98		
95% CI of the absolute risk difference	(-9.13, 6.69)	(-8.68, 6.72)		
p-value	0.7539	0.7973		
p-value of Breslow-Day Test for Homogeneity [2]	0.4823	0.9924		
Any Serious TEAE	5 (10.2)	7 (13.7)	10 (9.8)	22 (10.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.05	1.46		
95% CI of the odds ratio	(0.34, 3.24)	(0.52, 4.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04	1.40		
95% CI of the risk ratio	(0.38, 2.88)	(0.57, 3.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.40	3.92		
95% CI of the absolute risk difference	(-9.85, 10.65)	(-7.15, 14.99)		
p-value	0.9386	0.4669		
p-value of Breslow-Day Test for Homogeneity [2]	0.3094	0.3640		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Any TEAEs >= Grade 3 Severity	10 (20.4)	7 (13.7)	15 (14.7)	32 (15.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.49	0.92		
95% CI of the odds ratio	(0.61, 3.60)	(0.35, 2.43)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.39	0.93		
95% CI of the risk ratio	(0.67, 2.86)	(0.41, 2.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.70	-0.98		
95% CI of the absolute risk difference	(-7.51, 18.92)	(-12.66, 10.70)		
p-value	0.3774	0.8706		
p-value of Breslow-Day Test for Homogeneity [2]	0.0167	0.9280		
Any TEAEs <= Grade 2 Severity	44 (89.8)	48 (94.1)	97 (95.1)	189 (93.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45	0.82		
95% CI of the odds ratio	(0.12, 1.65)	(0.19, 3.60)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.94	0.99		
95% CI of the risk ratio	(0.85, 1.05)	(0.91, 1.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.30	-0.98		
95% CI of the absolute risk difference	(-14.76, 4.15)	(-8.68, 6.72)		
p-value	0.2199	0.7973		
p-value of Breslow-Day Test for Homogeneity [2]	0.1385	0.8171		
Any TEAEs leading to Study-Drug Discontinuation	3 (6.1)	5 (9.8)	5 (4.9)	13 (6.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.27	2.11		
95% CI of the odds ratio	(0.29, 5.52)	(0.58, 7.65)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25	2.00		
95% CI of the risk ratio	(0.31, 5.02)	(0.61, 6.59)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.22	4.90		
95% CI of the absolute risk difference	(-6.69, 9.13)	(-4.27, 14.08)		
p-value	0.7539	0.2475		
p-value of Breslow-Day Test for Homogeneity [2]	0.7320	0.9876		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Any TEAEs leading to Study Discontinuation	1 (2.0)	5 (9.8)	4 (3.9)	10 (5.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	2.66		
95% CI of the odds ratio	(0.06, 4.69)	(0.68, 10.38)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.52	2.50		
95% CI of the risk ratio	(0.06, 4.53)	(0.70, 8.91)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.88	5.88		
95% CI of the absolute risk difference	(-7.35, 3.58)	(-3.11, 14.87)		
p-value	0.5454	0.1449		
p-value of Breslow-Day Test for Homogeneity [2]	0.9622	0.6484		
Any Fatal TEAEs	1 (2.0)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.04	NE		
95% CI of the absolute risk difference	(-1.92, 6.00)	NE		
p-value	0.1477	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
Any Treatment-related TEAE	20 (40.8)	21 (41.2)	37 (36.3)	78 (38.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21	1.23		
95% CI of the odds ratio	(0.60, 2.44)	(0.62, 2.45)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13	1.14		
95% CI of the risk ratio	(0.74, 1.72)	(0.75, 1.72)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.54	4.90		
95% CI of the absolute risk difference	(-12.08, 21.17)	(-11.51, 21.32)		
p-value	0.5899	0.5558		
p-value of Breslow-Day Test for Homogeneity [2]	0.1681	0.5528		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Any Treatment-related Serious TEAE	0	0	1 (1.0)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.98	-0.98		
95% CI of the absolute risk difference	(-2.89, 0.93)	(-2.89, 0.93)		
p-value	0.4868	0.4781		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	1 (1.0)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.98	-0.98		
95% CI of the absolute risk difference	(-2.89, 0.93)	(-2.89, 0.93)		
p-value	0.4868	0.4781		
p-value of Breslow-Day Test for Homogeneity [2]	0.4219	0.1671		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	1 (2.0)	3 (5.9)	4 (3.9)	8 (4.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	1.53		
95% CI of the odds ratio	(0.06, 4.69)	(0.33, 7.12)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.52	1.50		
95% CI of the risk ratio	(0.06, 4.53)	(0.35, 6.45)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.88	1.96		
95% CI of the absolute risk difference	(-7.35, 3.58)	(-5.52, 9.44)		
p-value	0.5454	0.5843		
p-value of Breslow-Day Test for Homogeneity [2]	0.8421	0.5041		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	3 (5.9)	4 (3.9)	7 (3.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.53		
95% CI of the odds ratio	NE	(0.33, 7.12)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.50		
95% CI of the risk ratio	NE	(0.35, 6.45)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.92	1.96		
95% CI of the absolute risk difference	(-7.69, -0.15)	(-5.52, 9.44)		
p-value	0.1600	0.5843		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1995		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	10 (20.4)	12 (23.5)	24 (23.5)	46 (22.8)
Grade 2	26 (53.1)	29 (56.9)	58 (56.9)	113 (55.9)
Grade 3	9 (18.4)	7 (13.7)	13 (12.7)	29 (14.4)
Grade 4	0	0	2 (2.0)	2 (1.0)
Grade 5	1 (2.0)	0	0	1 (0.5)

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	12 (24.5)	13 (25.5)	20 (19.6)	45 (22.3)
Grade 2	8 (16.3)	8 (15.7)	16 (15.7)	32 (15.8)
Grade 3	0	0	0	0
Grade 4	0	0	1 (1.0)	1 (0.5)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (2.0)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	2.04	NE		
95% CI of the absolute risk difference	(-1.92, 6.00)	NE		
p-value	0.1477	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (2.0)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	2.04	NE		
95% CI of the absolute risk difference	(-1.92, 6.00)	NE		
p-value	0.1477	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (2.0)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	2.04	NE		
95% CI of the absolute risk difference	(-1.92, 6.00)	NE		
p-value	0.1477	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1356	NE		
Other MACE AE – Adjudicated Event	0	0	2 (2.0)	2 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.96	-1.96		
95% CI of the absolute risk difference	(-4.65, 0.73)	(-4.65, 0.73)		
p-value	0.3238	0.3141		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3582		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	1 (1.0)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.98	-0.98		
95% CI of the absolute risk difference	(-2.89, 0.93)	(-2.89, 0.93)		
p-value	0.4868	0.4781		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5030		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (1.0)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.98	-0.98		
95% CI of the absolute risk difference	(-2.89, 0.93)	(-2.89, 0.93)		
p-value	0.4868	0.4781		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	1 (1.0)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.98	-0.98		
95% CI of the absolute risk difference	(-2.89, 0.93)	(-2.89, 0.93)		
p-value	0.4868	0.4781		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5030		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.7.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49) n (%)	MGL-3196 100 mg (N=51) n (%)	Placebo (N=102) n (%)	Overall (N=202) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.7.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Diabetes Status at Baseline
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.

AMNOG Table S1.7.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Diabetes Status at Baseline (Label Population)

Diabetes status at baseline: Yes

System Organ Class Preferred Term	MGL-3196 80 mg (N=118) Patients n (%)	 Events n	MGL-3196 100 mg (N=100) Patients n (%)	 Events n	Placebo (N=201) Patients n (%)	 Events n	Overall (N=419) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	28 (23.7)	49	32 (32.0)	57	30 (14.9)	41	90 (21.5)	147
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.77		2.68					
95% CI of the odds ratio	(1.00, 3.15)		(1.51, 4.75)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.59		2.14					
95% CI of the risk ratio	(1.00, 2.52)		(1.39, 3.32)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.80		17.07					
95% CI of the absolute risk difference	(-0.32, 17.92)		(6.69, 27.46)					
p-value	0.0491		0.0006					
p-value of Breslow-Day Test for Homogeneity [2]	0.9765		0.9446					
Nausea	28 (23.7)	34	15 (15.0)	19	26 (12.9)	31	69 (16.5)	84
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.09		1.19					
95% CI of the odds ratio	(1.16, 3.78)		(0.60, 2.36)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.83		1.16					
95% CI of the risk ratio	(1.13, 2.97)		(0.64, 2.09)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	10.79		2.06					
95% CI of the absolute risk difference	(1.82, 19.76)		(-6.33, 10.46)					
p-value	0.0131		0.6228					
p-value of Breslow-Day Test for Homogeneity [2]	0.4846		0.6768					

AMNOG Table S1.7.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Diabetes Status at Baseline (Label Population)

Diabetes status at baseline: Yes

System Organ Class Preferred Term	MGL-3196 80 mg (N=118) Patients n (%)	 Events n	MGL-3196 100 mg (N=100) Patients n (%)	 Events n	Placebo (N=201) Patients n (%)	 Events n	Overall (N=419) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	17 (14.4)	19	7 (7.0)	7	11 (5.5)	12	35 (8.4)	38
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.91		1.30					
95% CI of the odds ratio	(1.31, 6.44)		(0.49, 3.46)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.63		1.28					
95% CI of the risk ratio	(1.28, 5.43)		(0.51, 3.20)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.93		1.53					
95% CI of the absolute risk difference	(1.86, 16.01)		(-4.38, 7.43)					
p-value	0.0065		0.5986					
p-value of Breslow-Day Test for Homogeneity [2]	0.2123		0.4758					
Abdominal discomfort	1 (0.8)	1	1 (1.0)	1	7 (3.5)	7	9 (2.1)	9
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.24		0.28					
95% CI of the odds ratio	(0.03, 1.95)		(0.03, 2.31)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.24		0.29					
95% CI of the risk ratio	(0.03, 1.95)		(0.04, 2.30)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.64		-2.48					
95% CI of the absolute risk difference	(-5.66, 0.39)		(-5.68, 0.72)					
p-value	0.1462		0.2072					
p-value of Breslow-Day Test for Homogeneity [2]	0.4045		0.5275					

AMNOG Table S1.7.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Diabetes Status at Baseline (Label Population)

Diabetes status at baseline: Yes

System Organ Class Preferred Term	MGL-3196 80 mg (N=118) Patients n (%)	 Events n	MGL-3196 100 mg (N=100) Patients n (%)	 Events n	Placebo (N=201) Patients n (%)	 Events n	Overall (N=419) Patients n (%)	 Events n
General disorders and administration site conditions	21 (17.8)	32	19 (19.0)	27	60 (29.9)	74	100 (23.9)	133
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51		0.55					
95% CI of the odds ratio	(0.29, 0.89)		(0.31, 0.99)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60		0.64					
95% CI of the risk ratio	(0.38, 0.93)		(0.40, 1.01)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-12.05		-10.85					
95% CI of the absolute risk difference	(-21.42, -2.69)		(-20.81, -0.89)					
p-value	0.0169		0.0439					
p-value of Breslow-Day Test for Homogeneity [2]	0.0662		0.5481					
Skin and subcutaneous tissue disorders								
Pruritus	15 (12.7)	20	5 (5.0)	7	18 (9.0)	20	38 (9.1)	47
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.48		0.54					
95% CI of the odds ratio	(0.72, 3.06)		(0.19, 1.49)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.42		0.56					
95% CI of the risk ratio	(0.74, 2.71)		(0.21, 1.46)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.76		-3.96					
95% CI of the absolute risk difference	(-3.43, 10.95)		(-9.77, 1.86)					
p-value	0.2875		0.2237					
p-value of Breslow-Day Test for Homogeneity [2]	0.2723		0.3656					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.7.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Diabetes Status at Baseline (Label Population)

Diabetes status at baseline: Yes

System Organ Class Preferred Term	MGL-3196 80 mg (N=118) Patients n (%)	 Events n	MGL-3196 100 mg (N=100) Patients n (%)	 Events n	Placebo (N=201) Patients n (%)	 Events n	Overall (N=419) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	6 (5.1)	6	8 (8.0)	12	6 (3.0)	7	20 (4.8)	25
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.74		2.83					
95% CI of the odds ratio	(0.55, 5.53)		(0.95, 8.38)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.70		2.68					
95% CI of the risk ratio	(0.56, 5.16)		(0.96, 7.51)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.10		5.01					
95% CI of the absolute risk difference	(-2.51, 6.71)		(-0.80, 10.83)					
p-value	0.3413		0.0517					
p-value of Breslow-Day Test for Homogeneity [2]	0.3531		0.9480					
Renal and urinary disorders	5 (4.2)	6	11 (11.0)	12	18 (9.0)	23	34 (8.1)	41
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45		1.26					
95% CI of the odds ratio	(0.16, 1.25)		(0.57, 2.77)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47		1.23					
95% CI of the risk ratio	(0.18, 1.24)		(0.60, 2.50)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.72		2.04					
95% CI of the absolute risk difference	(-10.08, 0.65)		(-5.25, 9.34)					
p-value	0.1158		0.5712					
p-value of Breslow-Day Test for Homogeneity [2]	0.1586		0.3807					

AMNOG Table S1.7.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Diabetes Status at Baseline (Label Population)

Diabetes status at baseline: Yes

System Organ Class Preferred Term	MGL-3196 80 mg (N=118) Patients n (%)	 Events n	MGL-3196 100 mg (N=100) Patients n (%)	 Events n	Placebo (N=201) Patients n (%)	 Events n	Overall (N=419) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	5 (4.2)	6	3 (3.0)	3	18 (9.0)	22	26 (6.2)	31
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45		0.31					
95% CI of the odds ratio	(0.16, 1.25)		(0.09, 1.09)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47		0.34					
95% CI of the risk ratio	(0.18, 1.24)		(0.10, 1.11)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.72		-5.96					
95% CI of the absolute risk difference	(-10.08, 0.65)		(-11.13, -0.78)					
p-value	0.1158		0.0561					
p-value of Breslow-Day Test for Homogeneity [2]	0.6727		0.9889					

AMNOG Table S1.7.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Diabetes Status at Baseline (Label Population)

Diabetes status at baseline: Yes

System Organ Class Preferred Term	MGL-3196 80 mg (N=118) Patients n (%)	 Events n	MGL-3196 100 mg (N=100) Patients n (%)	 Events n	Placebo (N=201) Patients n (%)	 Events n	Overall (N=419) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	1 (0.8)	1	0	0	6 (3.0)	10	7 (1.7)	11
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.28		NE					
95% CI of the odds ratio	(0.03, 2.34)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.28		NE					
95% CI of the risk ratio	(0.03, 2.33)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.14		-2.99					
95% CI of the absolute risk difference	(-5.01, 0.74)		(-5.34, -0.63)					
p-value	0.2083		0.0809					
p-value of Breslow-Day Test for Homogeneity [2]	0.6961		NE					

AMNOG Table S1.7.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Diabetes Status at Baseline (Label Population)

Diabetes status at baseline: No

System Organ Class Preferred Term	MGL-3196 80 mg (N=49) Patients n (%)	 Events n	MGL-3196 100 mg (N=51) Patients n (%)	 Events n	Placebo (N=102) Patients n (%)	 Events n	Overall (N=202) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	14 (28.6)	24	19 (37.3)	23	19 (18.6)	20	52 (25.7)	67
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.75		2.59					
95% CI of the odds ratio	(0.79, 3.87)		(1.22, 5.52)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.53		2.00					
95% CI of the risk ratio	(0.84, 2.80)		(1.17, 3.43)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.94		18.63					
95% CI of the absolute risk difference	(-4.79, 24.68)		(3.36, 33.90)					
p-value	0.1662		0.0119					
p-value of Breslow-Day Test for Homogeneity [2]	0.9765		0.9446					
Nausea	15 (30.6)	17	6 (11.8)	7	13 (12.7)	15	34 (16.8)	39
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.02		0.91					
95% CI of the odds ratio	(1.30, 7.01)		(0.33, 2.56)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.40		0.92					
95% CI of the risk ratio	(1.24, 4.65)		(0.37, 2.29)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	17.87		-0.98					
95% CI of the absolute risk difference	(3.43, 32.30)		(-11.94, 9.98)					
p-value	0.0082		0.8624					
p-value of Breslow-Day Test for Homogeneity [2]	0.4846		0.6768					

AMNOG Table S1.7.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Diabetes Status at Baseline (Label Population)

Diabetes status at baseline: No

System Organ Class Preferred Term	MGL-3196 80 mg (N=49) Patients n (%)	 Events n	MGL-3196 100 mg (N=51) Patients n (%)	 Events n	Placebo (N=102) Patients n (%)	 Events n	Overall (N=202) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	3 (6.1)	3	2 (3.9)	2	6 (5.9)	6	11 (5.4)	11
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04		0.65					
95% CI of the odds ratio	(0.25, 4.36)		(0.13, 3.36)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04		0.67					
95% CI of the risk ratio	(0.27, 3.99)		(0.14, 3.19)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.24		-1.96					
95% CI of the absolute risk difference	(-7.88, 8.36)		(-8.98, 5.06)					
p-value	0.9535		0.6075					
p-value of Breslow-Day Test for Homogeneity [2]	0.2123		0.4758					
Abdominal discomfort	0	0	2 (3.9)	3	6 (5.9)	7	8 (4.0)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.15		0.65					
95% CI of the odds ratio	(0.01, 2.72)		(0.13, 3.36)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.16		0.67					
95% CI of the risk ratio	(0.01, 2.76)		(0.14, 3.19)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.31		-1.96					
95% CI of the absolute risk difference	(-10.76, 0.14)		(-8.98, 5.06)					
p-value	0.1403		0.6075					
p-value of Breslow-Day Test for Homogeneity [2]	0.4045		0.5275					

AMNOG Table S1.7.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Diabetes Status at Baseline (Label Population)

Diabetes status at baseline: No

System Organ Class Preferred Term	MGL-3196 80 mg (N=49) Patients n (%)	 Events n	MGL-3196 100 mg (N=51) Patients n (%)	 Events n	Placebo (N=102) Patients n (%)	 Events n	Overall (N=202) Patients n (%)	 Events n
General disorders and administration site conditions	14 (28.6)	20	10 (19.6)	12	25 (24.5)	30	49 (24.3)	62
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.23		0.75					
95% CI of the odds ratio	(0.57, 2.65)		(0.33, 1.71)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17		0.80					
95% CI of the risk ratio	(0.67, 2.04)		(0.42, 1.54)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.06		-4.90					
95% CI of the absolute risk difference	(-11.09, 19.22)		(-18.63, 8.82)					
p-value	0.5934		0.4962					
p-value of Breslow-Day Test for Homogeneity [2]	0.0662		0.5481					
Skin and subcutaneous tissue disorders								
Rash	2 (4.1)	2	8 (15.7)	8	6 (5.9)	7	16 (7.9)	17
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68		2.98					
95% CI of the odds ratio	(0.13, 3.50)		(0.97, 9.10)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69		2.67					
95% CI of the risk ratio	(0.15, 3.31)		(0.98, 7.28)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.80		9.80					
95% CI of the absolute risk difference	(-8.98, 5.38)		(-1.17, 20.78)					
p-value	0.6437		0.0474					
p-value of Breslow-Day Test for Homogeneity [2]	0.3531		0.9480					

AMNOG Table S1.7.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Diabetes Status at Baseline (Label Population)

Diabetes status at baseline: No

System Organ Class Preferred Term	MGL-3196 80 mg (N=49) Patients n (%)	 Events n	MGL-3196 100 mg (N=51) Patients n (%)	 Events n	Placebo (N=102) Patients n (%)	 Events n	Overall (N=202) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Pruritus	7 (14.3)	8	3 (5.9)	3	5 (4.9)	6	15 (7.4)	17
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.23		1.21					
95% CI of the odds ratio	(0.97, 10.77)		(0.28, 5.29)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.91		1.20					
95% CI of the risk ratio	(0.97, 8.72)		(0.30, 4.82)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.38		0.98					
95% CI of the absolute risk difference	(-1.27, 20.04)		(-6.72, 8.68)					
p-value	0.0459		0.7973					
p-value of Breslow-Day Test for Homogeneity [2]	0.2723		0.3656					
Renal and urinary disorders	0	0	9 (17.6)	12	9 (8.8)	10	18 (8.9)	22
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.10		2.21					
95% CI of the odds ratio	(0.01, 1.74)		(0.82, 5.98)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11		2.00					
95% CI of the risk ratio	(0.01, 1.83)		(0.85, 4.73)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.22		8.82					
95% CI of the absolute risk difference	(-14.45, -1.99)		(-3.00, 20.65)					
p-value	0.0536		0.1103					
p-value of Breslow-Day Test for Homogeneity [2]	0.1586		0.3807					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.7.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Diabetes Status at Baseline (Label Population)

Diabetes status at baseline: No

System Organ Class Preferred Term	MGL-3196 80 mg (N=49) Patients n (%)	 Events n	MGL-3196 100 mg (N=51) Patients n (%)	 Events n	Placebo (N=102) Patients n (%)	 Events n	Overall (N=202) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	2 (4.1)	2	1 (2.0)	1	6 (5.9)	6	9 (4.5)	9
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68		0.32					
95% CI of the odds ratio	(0.13, 3.50)		(0.04, 2.73)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69		0.33					
95% CI of the risk ratio	(0.15, 3.31)		(0.04, 2.70)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.80		-3.92					
95% CI of the absolute risk difference	(-8.98, 5.38)		(-9.87, 2.02)					
p-value	0.6437		0.2738					
p-value of Breslow-Day Test for Homogeneity [2]	0.6727		0.9889					

AMNOG Table S1.7.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Diabetes Status at Baseline (Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49)		MGL-3196 100 mg (N=51)		Placebo (N=102)		Overall (N=202)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Injury, poisoning and procedural complications								
Contusion	1 (2.0)	1	0	0	4 (3.9)	4	5 (2.5)	5
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51		NE					
95% CI of the odds ratio	(0.06, 4.69)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.52		NE					
95% CI of the risk ratio	(0.06, 4.53)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.88		-3.92					
95% CI of the absolute risk difference	(-7.35, 3.58)		(-7.69, -0.15)					
p-value	0.5454		0.1518					
p-value of Breslow-Day Test for Homogeneity [2]	0.6961		NE					

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Events n:				
Total TEAEs	460	399	804	1663
Total Serious TEAEs	18	15	48	81
Total TEAEs Leading to Discontinuation of Study Drug	9	6	12	27
Total TEAEs Related to Study Drug	42	53	61	156
Total TEAEs >= Grade 3 Severity	18	20	52	90
Patients n (%):				
Any TEAE	60 (93.8)	47 (88.7)	103 (92.8)	210 (92.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	0.61		
95% CI of the odds ratio	(0.34, 4.03)	(0.20, 1.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	0.96		
95% CI of the risk ratio	(0.93, 1.10)	(0.86, 1.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.96	-4.11		
95% CI of the absolute risk difference	(-6.68, 8.59)	(-13.91, 5.68)		
p-value	0.8093	0.3779		
p-value of Breslow-Day Test for Homogeneity [2]	0.8910	0.6376		
Any Serious TEAE	7 (10.9)	11 (20.8)	20 (18.0)	38 (16.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56	1.19		
95% CI of the odds ratio	(0.22, 1.41)	(0.52, 2.71)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.61	1.15		
95% CI of the risk ratio	(0.27, 1.36)	(0.60, 2.23)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.08	2.74		
95% CI of the absolute risk difference	(-17.55, 3.39)	(-10.31, 15.79)		
p-value	0.2117	0.6755		
p-value of Breslow-Day Test for Homogeneity [2]	0.7130	0.5393		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Any TEAEs >= Grade 3 Severity	9 (14.1)	10 (18.9)	22 (19.8)	41 (18.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.66	0.94		
95% CI of the odds ratio	(0.28, 1.54)	(0.41, 2.16)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	0.95		
95% CI of the risk ratio	(0.35, 1.45)	(0.49, 1.86)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.76	-0.95		
95% CI of the absolute risk difference	(-17.05, 5.54)	(-13.83, 11.93)		
p-value	0.3367	0.8856		
p-value of Breslow-Day Test for Homogeneity [2]	0.9284	0.9989		
Any TEAEs <= Grade 2 Severity	59 (92.2)	46 (86.8)	103 (92.8)	208 (91.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.92	0.51		
95% CI of the odds ratio	(0.29, 2.93)	(0.17, 1.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	0.94		
95% CI of the risk ratio	(0.91, 1.09)	(0.83, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.61	-6.00		
95% CI of the absolute risk difference	(-8.75, 7.54)	(-16.31, 4.31)		
p-value	0.8831	0.2125		
p-value of Breslow-Day Test for Homogeneity [2]	0.8365	0.5946		
Any TEAEs leading to Study-Drug Discontinuation	6 (9.4)	6 (11.3)	8 (7.2)	20 (8.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	1.64		
95% CI of the odds ratio	(0.44, 4.03)	(0.54, 5.00)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.30	1.57		
95% CI of the risk ratio	(0.47, 3.58)	(0.57, 4.30)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.17	4.11		
95% CI of the absolute risk difference	(-6.44, 10.78)	(-5.68, 13.91)		
p-value	0.6107	0.3779		
p-value of Breslow-Day Test for Homogeneity [2]	0.5557	0.8253		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Any TEAEs leading to Study Discontinuation	3 (4.7)	4 (7.5)	6 (5.4)	13 (5.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.86	1.43		
95% CI of the odds ratio	(0.21, 3.57)	(0.39, 5.29)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87	1.40		
95% CI of the risk ratio	(0.22, 3.35)	(0.41, 4.74)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.72	2.14		
95% CI of the absolute risk difference	(-7.39, 5.95)	(-6.12, 10.40)		
p-value	0.8359	0.5919		
p-value of Breslow-Day Test for Homogeneity [2]	0.1565	0.4335		
Any Fatal TEAEs	1 (1.6)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.56	NE		
95% CI of the absolute risk difference	(-1.48, 4.60)	NE		
p-value	0.1866	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
Any Treatment-related TEAE	23 (35.9)	20 (37.7)	33 (29.7)	76 (33.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	1.43		
95% CI of the odds ratio	(0.69, 2.55)	(0.72, 2.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21	1.27		
95% CI of the risk ratio	(0.78, 1.87)	(0.81, 1.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.21	8.01		
95% CI of the absolute risk difference	(-8.30, 20.72)	(-7.57, 23.58)		
p-value	0.3965	0.3052		
p-value of Breslow-Day Test for Homogeneity [2]	0.2920	0.9838		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (1.6)	0	1 (0.9)	2 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.75	NE		
95% CI of the odds ratio	(0.11, 28.40)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.73	NE		
95% CI of the risk ratio	(0.11, 27.26)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.66	-0.90		
95% CI of the absolute risk difference	(-2.85, 4.17)	(-2.66, 0.86)		
p-value	0.6917	0.4882		
p-value of Breslow-Day Test for Homogeneity [2]	0.9722	0.1783		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	1 (1.9)	5 (4.5)	6 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.41		
95% CI of the odds ratio	NE	(0.05, 3.58)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.42		
95% CI of the risk ratio	NE	(0.05, 3.50)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.50	-2.62		
95% CI of the absolute risk difference	(-8.36, -0.65)	(-7.94, 2.70)		
p-value	0.0849	0.4037		
p-value of Breslow-Day Test for Homogeneity [2]	0.0790	0.0340		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	1 (1.9)	4 (3.6)	5 (2.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.51		
95% CI of the odds ratio	NE	(0.06, 4.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.52		
95% CI of the risk ratio	NE	(0.06, 4.57)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.60	-1.72		
95% CI of the absolute risk difference	(-7.07, -0.14)	(-6.76, 3.33)		
p-value	0.1245	0.5498		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0247		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	13 (20.3)	8 (15.1)	26 (23.4)	47 (20.6)
Grade 2	38 (59.4)	29 (54.7)	55 (49.5)	122 (53.5)
Grade 3	8 (12.5)	10 (18.9)	20 (18.0)	38 (16.7)
Grade 4	0	0	2 (1.8)	2 (0.9)
Grade 5	1 (1.6)	0	0	1 (0.4)

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	16 (25.0)	12 (22.6)	19 (17.1)	47 (20.6)
Grade 2	6 (9.4)	8 (15.1)	13 (11.7)	27 (11.8)
Grade 3	1 (1.6)	0	1 (0.9)	2 (0.9)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (1.6)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	1.56	NE		
95% CI of the absolute risk difference	(-1.48, 4.60)	NE		
p-value	0.1866	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (1.6)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	1.56	NE		
95% CI of the absolute risk difference	(-1.48, 4.60)	NE		
p-value	0.1866	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (1.6)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	1.56	NE		
95% CI of the absolute risk difference	(-1.48, 4.60)	NE		
p-value	0.1866	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
Other MACE AE – Adjudicated Event	0	0	3 (2.7)	3 (1.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.70	-2.70		
95% CI of the absolute risk difference	(-5.72, 0.31)	(-5.72, 0.31)		
p-value	0.1846	0.2271		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1788		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (1.8)	2 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.80	-1.80		
95% CI of the absolute risk difference	(-4.28, 0.67)	(-4.28, 0.67)		
p-value	0.2801	0.3255		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2576		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.9)	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.90	-0.90		
95% CI of the absolute risk difference	(-2.66, 0.86)	(-2.66, 0.86)		
p-value	0.4464	0.4882		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (1.8)	2 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.80	-1.80		
95% CI of the absolute risk difference	(-4.28, 0.67)	(-4.28, 0.67)		
p-value	0.2801	0.3255		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2576		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Events n:				
Total TEAEs	739	623	1353	2715
Total Serious TEAEs	11	17	48	76
Total TEAEs Leading to Discontinuation of Study Drug	9	14	13	36
Total TEAEs Related to Study Drug	113	73	98	284
Total TEAEs >= Grade 3 Severity	16	25	54	95
Patients n (%):				
Any TEAE	98 (95.1)	91 (92.9)	180 (93.8)	369 (93.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.31	0.87		
95% CI of the odds ratio	(0.45, 3.82)	(0.33, 2.28)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	0.99		
95% CI of the risk ratio	(0.96, 1.07)	(0.93, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.40	-0.89		
95% CI of the absolute risk difference	(-3.98, 6.78)	(-7.03, 5.25)		
p-value	0.6239	0.7713		
p-value of Breslow-Day Test for Homogeneity [2]	0.8910	0.6376		
Any Serious TEAE	9 (8.7)	10 (10.2)	23 (12.0)	42 (10.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.70	0.83		
95% CI of the odds ratio	(0.31, 1.58)	(0.38, 1.83)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.85		
95% CI of the risk ratio	(0.35, 1.52)	(0.42, 1.72)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.24	-1.78		
95% CI of the absolute risk difference	(-10.37, 3.89)	(-9.33, 5.78)		
p-value	0.3934	0.6525		
p-value of Breslow-Day Test for Homogeneity [2]	0.7130	0.5393		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Any TEAEs >= Grade 3 Severity	13 (12.6)	16 (16.3)	33 (17.2)	62 (15.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.70	0.94		
95% CI of the odds ratio	(0.35, 1.39)	(0.49, 1.81)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.95		
95% CI of the risk ratio	(0.40, 1.33)	(0.55, 1.64)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.57	-0.86		
95% CI of the absolute risk difference	(-12.91, 3.78)	(-9.92, 8.20)		
p-value	0.3028	0.8532		
p-value of Breslow-Day Test for Homogeneity [2]	0.9284	0.9989		
Any TEAEs <= Grade 2 Severity	97 (94.2)	90 (91.8)	180 (93.8)	367 (93.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08	0.75		
95% CI of the odds ratio	(0.39, 2.96)	(0.30, 1.90)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.98		
95% CI of the risk ratio	(0.95, 1.07)	(0.91, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.42	-1.91		
95% CI of the absolute risk difference	(-5.25, 6.10)	(-8.32, 4.50)		
p-value	0.8845	0.5431		
p-value of Breslow-Day Test for Homogeneity [2]	0.8365	0.5946		
Any TEAEs leading to Study-Drug Discontinuation	6 (5.8)	12 (12.2)	13 (6.8)	31 (7.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.85	1.92		
95% CI of the odds ratio	(0.31, 2.31)	(0.84, 4.39)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.86	1.81		
95% CI of the risk ratio	(0.34, 2.20)	(0.86, 3.81)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.95	5.47		
95% CI of the absolute risk difference	(-6.70, 4.81)	(-1.93, 12.87)		
p-value	0.7525	0.1162		
p-value of Breslow-Day Test for Homogeneity [2]	0.5557	0.8253		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Any TEAEs leading to Study Discontinuation	0	7 (7.1)	5 (2.6)	12 (3.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.88		
95% CI of the odds ratio	NE	(0.89, 9.31)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.74		
95% CI of the risk ratio	NE	(0.89, 8.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.60	4.54		
95% CI of the absolute risk difference	(-4.86, -0.35)	(-1.04, 10.11)		
p-value	0.0986	0.0664		
p-value of Breslow-Day Test for Homogeneity [2]	0.1565	0.4335		
Any Fatal TEAEs	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.97		
95% CI of the odds ratio	NE	(0.12, 31.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.96		
95% CI of the risk ratio	NE	(0.12, 30.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.52	0.50		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.74, 2.73)		
p-value	0.4631	0.6268		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
Any Treatment-related TEAE	46 (44.7)	35 (35.7)	54 (28.1)	135 (34.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.06	1.42		
95% CI of the odds ratio	(1.25, 3.40)	(0.84, 2.39)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.59	1.27		
95% CI of the risk ratio	(1.16, 2.17)	(0.90, 1.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	16.54	7.59		
95% CI of the absolute risk difference	(5.02, 28.05)	(-3.83, 19.01)		
p-value	0.0042	0.1850		
p-value of Breslow-Day Test for Homogeneity [2]	0.2920	0.9838		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.5)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.52	-0.52		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.54, 0.50)		
p-value	0.4631	0.4742		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (1.0)	3 (3.1)	1 (0.5)	5 (1.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.87	6.03		
95% CI of the odds ratio	(0.12, 30.25)	(0.62, 58.76)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.86	5.88		
95% CI of the risk ratio	(0.12, 29.49)	(0.62, 55.77)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.45	2.54		
95% CI of the absolute risk difference	(-1.70, 2.60)	(-1.02, 6.10)		
p-value	0.6534	0.0793		
p-value of Breslow-Day Test for Homogeneity [2]	0.9722	0.1783		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	3 (2.9)	9 (9.2)	4 (2.1)	16 (4.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.41	4.75		
95% CI of the odds ratio	(0.31, 6.42)	(1.43, 15.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.40	4.41		
95% CI of the risk ratio	(0.32, 6.13)	(1.39, 13.96)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.83	7.10		
95% CI of the absolute risk difference	(-3.00, 4.65)	(1.04, 13.16)		
p-value	0.6555	0.0057		
p-value of Breslow-Day Test for Homogeneity [2]	0.0790	0.0340		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	6 (6.1)	1 (0.5)	7 (1.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	12.46		
95% CI of the odds ratio	NE	(1.48, 104.98)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	11.76		
95% CI of the risk ratio	NE	(1.44, 96.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.52	5.60		
95% CI of the absolute risk difference	(-1.54, 0.50)	(0.75, 10.46)		
p-value	0.4631	0.0033		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0247		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	26 (25.2)	18 (18.4)	43 (22.4)	87 (22.1)
Grade 2	59 (57.3)	57 (58.2)	104 (54.2)	220 (56.0)
Grade 3	13 (12.6)	15 (15.3)	27 (14.1)	55 (14.0)
Grade 4	0	0	5 (2.6)	5 (1.3)
Grade 5	0	1 (1.0)	1 (0.5)	2 (0.5)

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	25 (24.3)	17 (17.3)	34 (17.7)	76 (19.3)
Grade 2	20 (19.4)	15 (15.3)	19 (9.9)	54 (13.7)
Grade 3	1 (1.0)	3 (3.1)	0	4 (1.0)
Grade 4	0	0	1 (0.5)	1 (0.3)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.97		
95% CI of the odds ratio	NE	(0.12, 31.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.96		
95% CI of the risk ratio	NE	(0.12, 30.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.52	0.50		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.74, 2.73)		
p-value	0.4631	0.6268		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.0)	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.02		
95% CI of the absolute risk difference	NE	(-0.97, 3.01)		
p-value	NE	0.1609		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.52	-0.52		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.54, 0.50)		
p-value	0.4631	0.4742		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.97		
95% CI of the odds ratio	NE	(0.12, 31.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.96		
95% CI of the risk ratio	NE	(0.12, 30.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.52	0.50		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.74, 2.73)		
p-value	0.4631	0.6268		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
Other MACE AE – Adjudicated Event	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.97		
95% CI of the odds ratio	NE	(0.12, 31.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.96		
95% CI of the risk ratio	NE	(0.12, 30.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.52	0.50		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.74, 2.73)		
p-value	0.4631	0.6268		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1788		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.97		
95% CI of the odds ratio	NE	(0.12, 31.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.96		
95% CI of the risk ratio	NE	(0.12, 30.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.52	0.50		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.74, 2.73)		
p-value	0.4631	0.6268		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2576		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.97		
95% CI of the odds ratio	NE	(0.12, 31.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.96		
95% CI of the risk ratio	NE	(0.12, 30.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.52	0.50		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.74, 2.73)		
p-value	0.4631	0.6268		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2576		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.8.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Events n:				
Total TEAEs	459	399	802	1660
Total Serious TEAEs	18	15	48	81
Total TEAEs Leading to Discontinuation of Study Drug	9	6	12	27
Total TEAEs Related to Study Drug	41	53	61	155
Total TEAEs >= Grade 3 Severity	17	20	51	88
Patients n (%):				
Any TEAE	60 (93.8)	47 (88.7)	103 (92.8)	210 (92.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	0.61		
95% CI of the odds ratio	(0.34, 4.03)	(0.20, 1.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	0.96		
95% CI of the risk ratio	(0.93, 1.10)	(0.86, 1.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.96	-4.11		
95% CI of the absolute risk difference	(-6.68, 8.59)	(-13.91, 5.68)		
p-value	0.8093	0.3779		
p-value of Breslow-Day Test for Homogeneity [2]	0.9140	0.4841		
Any Serious TEAE	7 (10.9)	11 (20.8)	20 (18.0)	38 (16.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56	1.19		
95% CI of the odds ratio	(0.22, 1.41)	(0.52, 2.71)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.61	1.15		
95% CI of the risk ratio	(0.27, 1.36)	(0.60, 2.23)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.08	2.74		
95% CI of the absolute risk difference	(-17.55, 3.39)	(-10.31, 15.79)		
p-value	0.2117	0.6755		
p-value of Breslow-Day Test for Homogeneity [2]	0.7130	0.5393		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Any TEAEs >= Grade 3 Severity	8 (12.5)	10 (18.9)	21 (18.9)	39 (17.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.61	1.00		
95% CI of the odds ratio	(0.25, 1.48)	(0.43, 2.30)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.66	1.00		
95% CI of the risk ratio	(0.31, 1.40)	(0.51, 1.97)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.42	-0.05		
95% CI of the absolute risk difference	(-17.32, 4.48)	(-12.86, 12.76)		
p-value	0.2714	0.9938		
p-value of Breslow-Day Test for Homogeneity [2]	0.9807	0.9126		
Any TEAEs <= Grade 2 Severity	59 (92.2)	46 (86.8)	103 (92.8)	208 (91.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.92	0.51		
95% CI of the odds ratio	(0.29, 2.93)	(0.17, 1.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	0.94		
95% CI of the risk ratio	(0.91, 1.09)	(0.83, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.61	-6.00		
95% CI of the absolute risk difference	(-8.75, 7.54)	(-16.31, 4.31)		
p-value	0.8831	0.2125		
p-value of Breslow-Day Test for Homogeneity [2]	0.8309	0.4408		
Any TEAEs leading to Study-Drug Discontinuation	6 (9.4)	6 (11.3)	8 (7.2)	20 (8.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	1.64		
95% CI of the odds ratio	(0.44, 4.03)	(0.54, 5.00)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.30	1.57		
95% CI of the risk ratio	(0.47, 3.58)	(0.57, 4.30)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.17	4.11		
95% CI of the absolute risk difference	(-6.44, 10.78)	(-5.68, 13.91)		
p-value	0.6107	0.3779		
p-value of Breslow-Day Test for Homogeneity [2]	0.4577	0.5362		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Any TEAEs leading to Study Discontinuation	3 (4.7)	4 (7.5)	6 (5.4)	13 (5.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.86	1.43		
95% CI of the odds ratio	(0.21, 3.57)	(0.39, 5.29)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87	1.40		
95% CI of the risk ratio	(0.22, 3.35)	(0.41, 4.74)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.72	2.14		
95% CI of the absolute risk difference	(-7.39, 5.95)	(-6.12, 10.40)		
p-value	0.8359	0.5919		
p-value of Breslow-Day Test for Homogeneity [2]	0.1565	0.4335		
Any Fatal TEAEs	1 (1.6)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.56	NE		
95% CI of the absolute risk difference	(-1.48, 4.60)	NE		
p-value	0.1866	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
Any Treatment-related TEAE	23 (35.9)	20 (37.7)	33 (29.7)	76 (33.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	1.43		
95% CI of the odds ratio	(0.69, 2.55)	(0.72, 2.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21	1.27		
95% CI of the risk ratio	(0.78, 1.87)	(0.81, 1.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.21	8.01		
95% CI of the absolute risk difference	(-8.30, 20.72)	(-7.57, 23.58)		
p-value	0.3965	0.3052		
p-value of Breslow-Day Test for Homogeneity [2]	0.2650	0.9693		

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	1 (0.9)	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.90	-0.90		
95% CI of the absolute risk difference	(-2.66, 0.86)	(-2.66, 0.86)		
p-value	0.4464	0.4882		
p-value of Breslow-Day Test for Homogeneity [2]	0.3718	0.1783		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	1 (1.9)	5 (4.5)	6 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.41		
95% CI of the odds ratio	NE	(0.05, 3.58)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.42		
95% CI of the risk ratio	NE	(0.05, 3.50)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.50	-2.62		
95% CI of the absolute risk difference	(-8.36, -0.65)	(-7.94, 2.70)		
p-value	0.0849	0.4037		
p-value of Breslow-Day Test for Homogeneity [2]	0.0790	0.0340		

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	1 (1.9)	4 (3.6)	5 (2.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.51		
95% CI of the odds ratio	NE	(0.06, 4.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.52		
95% CI of the risk ratio	NE	(0.06, 4.57)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.60	-1.72		
95% CI of the absolute risk difference	(-7.07, -0.14)	(-6.76, 3.33)		
p-value	0.1245	0.5498		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0247		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	13 (20.3)	8 (15.1)	26 (23.4)	47 (20.6)
Grade 2	39 (60.9)	29 (54.7)	56 (50.5)	124 (54.4)
Grade 3	7 (10.9)	10 (18.9)	19 (17.1)	36 (15.8)
Grade 4	0	0	2 (1.8)	2 (0.9)
Grade 5	1 (1.6)	0	0	1 (0.4)

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	16 (25.0)	12 (22.6)	19 (17.1)	47 (20.6)
Grade 2	7 (10.9)	8 (15.1)	13 (11.7)	28 (12.3)
Grade 3	0	0	1 (0.9)	1 (0.4)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (1.6)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	1.56	NE		
95% CI of the absolute risk difference	(-1.48, 4.60)	NE		
p-value	0.1866	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (1.6)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	1.56	NE		
95% CI of the absolute risk difference	(-1.48, 4.60)	NE		
p-value	0.1866	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (1.6)	0	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	1.56	NE		
95% CI of the absolute risk difference	(-1.48, 4.60)	NE		
p-value	0.1866	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
Other MACE AE – Adjudicated Event	0	0	3 (2.7)	3 (1.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.70	-2.70		
95% CI of the absolute risk difference	(-5.72, 0.31)	(-5.72, 0.31)		
p-value	0.1846	0.2271		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1788		

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (1.8)	2 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.80	-1.80		
95% CI of the absolute risk difference	(-4.28, 0.67)	(-4.28, 0.67)		
p-value	0.2801	0.3255		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2576		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.9)	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.90	-0.90		
95% CI of the absolute risk difference	(-2.66, 0.86)	(-2.66, 0.86)		
p-value	0.4464	0.4882		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (1.8)	2 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.80	-1.80		
95% CI of the absolute risk difference	(-4.28, 0.67)	(-4.28, 0.67)		
p-value	0.2801	0.3255		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2576		

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64) n (%)	MGL-3196 100 mg (N=53) n (%)	Placebo (N=111) n (%)	Overall (N=228) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Events n:				
Total TEAEs	727	615	1331	2673
Total Serious TEAEs	11	17	48	76
Total TEAEs Leading to Discontinuation of Study Drug	6	12	8	26
Total TEAEs Related to Study Drug	113	73	97	283
Total TEAEs >= Grade 3 Severity	14	24	52	90
Patients n (%):				
Any TEAE	97 (94.2)	91 (92.9)	178 (92.7)	366 (93.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.27	1.02		
95% CI of the odds ratio	(0.47, 3.41)	(0.40, 2.62)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	1.00		
95% CI of the risk ratio	(0.95, 1.08)	(0.94, 1.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.47	0.15		
95% CI of the absolute risk difference	(-4.36, 7.30)	(-6.14, 6.44)		
p-value	0.6329	0.9631		
p-value of Breslow-Day Test for Homogeneity [2]	0.9140	0.4841		
Any Serious TEAE	9 (8.7)	10 (10.2)	23 (12.0)	42 (10.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.70	0.83		
95% CI of the odds ratio	(0.31, 1.58)	(0.38, 1.83)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.85		
95% CI of the risk ratio	(0.35, 1.52)	(0.42, 1.72)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.24	-1.78		
95% CI of the absolute risk difference	(-10.37, 3.89)	(-9.33, 5.78)		
p-value	0.3934	0.6525		
p-value of Breslow-Day Test for Homogeneity [2]	0.7130	0.5393		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Any TEAEs >= Grade 3 Severity	11 (10.7)	15 (15.3)	31 (16.1)	57 (14.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.62	0.94		
95% CI of the odds ratio	(0.30, 1.29)	(0.48, 1.84)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.66	0.95		
95% CI of the risk ratio	(0.35, 1.26)	(0.54, 1.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.47	-0.84		
95% CI of the absolute risk difference	(-13.38, 2.45)	(-9.67, 7.99)		
p-value	0.2003	0.8531		
p-value of Breslow-Day Test for Homogeneity [2]	0.9807	0.9126		
Any TEAEs <= Grade 2 Severity	96 (93.2)	90 (91.8)	178 (92.7)	364 (92.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08	0.88		
95% CI of the odds ratio	(0.42, 2.76)	(0.36, 2.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	0.99		
95% CI of the risk ratio	(0.94, 1.07)	(0.92, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.50	-0.87		
95% CI of the absolute risk difference	(-5.60, 6.59)	(-7.42, 5.68)		
p-value	0.8746	0.7909		
p-value of Breslow-Day Test for Homogeneity [2]	0.8309	0.4408		
Any TEAEs leading to Study-Drug Discontinuation	3 (2.9)	10 (10.2)	8 (4.2)	21 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	2.61		
95% CI of the odds ratio	(0.18, 2.66)	(1.00, 6.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.70	2.45		
95% CI of the risk ratio	(0.19, 2.58)	(1.00, 6.01)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.25	6.04		
95% CI of the absolute risk difference	(-5.56, 3.05)	(-0.59, 12.66)		
p-value	0.5879	0.0438		
p-value of Breslow-Day Test for Homogeneity [2]	0.4577	0.5362		

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Any TEAEs leading to Study Discontinuation	0	7 (7.1)	5 (2.6)	12 (3.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.88		
95% CI of the odds ratio	NE	(0.89, 9.31)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.74		
95% CI of the risk ratio	NE	(0.89, 8.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.60	4.54		
95% CI of the absolute risk difference	(-4.86, -0.35)	(-1.04, 10.11)		
p-value	0.0986	0.0664		
p-value of Breslow-Day Test for Homogeneity [2]	0.1565	0.4335		
Any Fatal TEAEs	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.97		
95% CI of the odds ratio	NE	(0.12, 31.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.96		
95% CI of the risk ratio	NE	(0.12, 30.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.52	0.50		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.74, 2.73)		
p-value	0.4631	0.6268		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
Any Treatment-related TEAE	46 (44.7)	35 (35.7)	53 (27.6)	134 (34.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.12	1.46		
95% CI of the odds ratio	(1.28, 3.49)	(0.87, 2.45)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.62	1.29		
95% CI of the risk ratio	(1.18, 2.22)	(0.91, 1.84)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	17.06	8.11		
95% CI of the absolute risk difference	(5.56, 28.55)	(-3.29, 19.51)		
p-value	0.0031	0.1553		
p-value of Breslow-Day Test for Homogeneity [2]	0.2650	0.9693		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.5)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.52	-0.52		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.54, 0.50)		
p-value	0.4631	0.4742		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (1.0)	3 (3.1)	1 (0.5)	5 (1.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.87	6.03		
95% CI of the odds ratio	(0.12, 30.25)	(0.62, 58.76)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.86	5.88		
95% CI of the risk ratio	(0.12, 29.49)	(0.62, 55.77)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.45	2.54		
95% CI of the absolute risk difference	(-1.70, 2.60)	(-1.02, 6.10)		
p-value	0.6534	0.0793		
p-value of Breslow-Day Test for Homogeneity [2]	0.3718	0.1783		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	3 (2.9)	9 (9.2)	4 (2.1)	16 (4.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.41	4.75		
95% CI of the odds ratio	(0.31, 6.42)	(1.43, 15.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.40	4.41		
95% CI of the risk ratio	(0.32, 6.13)	(1.39, 13.96)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.83	7.10		
95% CI of the absolute risk difference	(-3.00, 4.65)	(1.04, 13.16)		
p-value	0.6555	0.0057		
p-value of Breslow-Day Test for Homogeneity [2]	0.0790	0.0340		

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	6 (6.1)	1 (0.5)	7 (1.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	12.46		
95% CI of the odds ratio	NE	(1.48, 104.98)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	11.76		
95% CI of the risk ratio	NE	(1.44, 96.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.52	5.60		
95% CI of the absolute risk difference	(-1.54, 0.50)	(0.75, 10.46)		
p-value	0.4631	0.0033		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0247		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	25 (24.3)	19 (19.4)	44 (22.9)	88 (22.4)
Grade 2	61 (59.2)	57 (58.2)	103 (53.6)	221 (56.2)
Grade 3	11 (10.7)	14 (14.3)	25 (13.0)	50 (12.7)
Grade 4	0	0	5 (2.6)	5 (1.3)
Grade 5	0	1 (1.0)	1 (0.5)	2 (0.5)

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	25 (24.3)	17 (17.3)	33 (17.2)	75 (19.1)
Grade 2	20 (19.4)	15 (15.3)	19 (9.9)	54 (13.7)
Grade 3	1 (1.0)	3 (3.1)	0	4 (1.0)
Grade 4	0	0	1 (0.5)	1 (0.3)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.97		
95% CI of the odds ratio	NE	(0.12, 31.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.96		
95% CI of the risk ratio	NE	(0.12, 30.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.52	0.50		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.74, 2.73)		
p-value	0.4631	0.6268		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.0)	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.02		
95% CI of the absolute risk difference	NE	(-0.97, 3.01)		
p-value	NE	0.1609		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.52	-0.52		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.54, 0.50)		
p-value	0.4631	0.4742		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.97		
95% CI of the odds ratio	NE	(0.12, 31.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.96		
95% CI of the risk ratio	NE	(0.12, 30.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.52	0.50		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.74, 2.73)		
p-value	0.4631	0.6268		
p-value of Breslow-Day Test for Homogeneity [2]	0.1636	NE		
Other MACE AE – Adjudicated Event	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.97		
95% CI of the odds ratio	NE	(0.12, 31.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.96		
95% CI of the risk ratio	NE	(0.12, 30.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.52	0.50		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.74, 2.73)		
p-value	0.4631	0.6268		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1788		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.97		
95% CI of the odds ratio	NE	(0.12, 31.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.96		
95% CI of the risk ratio	NE	(0.12, 30.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.52	0.50		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.74, 2.73)		
p-value	0.4631	0.6268		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2576		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (1.0)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.97		
95% CI of the odds ratio	NE	(0.12, 31.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.96		
95% CI of the risk ratio	NE	(0.12, 30.99)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.52	0.50		
95% CI of the absolute risk difference	(-1.54, 0.50)	(-1.74, 2.73)		
p-value	0.4631	0.6268		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2576		

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.8.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103) n (%)	MGL-3196 100 mg (N=98) n (%)	Placebo (N=192) n (%)	Overall (N=393) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.8.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.

AMNOG Table S1.8.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Fibrosis Stage at Baseline (Label Population)

Fibrosis Stage at Baseline: F2 only

System Organ Class Preferred Term	MGL-3196 80 mg (N=64) Patients n (%)	 Events n	MGL-3196 100 mg (N=53) Patients n (%)	 Events n	Placebo (N=111) Patients n (%)	 Events n	Overall (N=228) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	21 (32.8)	34	18 (34.0)	29	18 (16.2)	25	57 (25.0)	88
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.52		2.66					
95% CI of the odds ratio	(1.22, 5.21)		(1.24, 5.68)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.02		2.09					
95% CI of the risk ratio	(1.17, 3.50)		(1.19, 3.69)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	16.60		17.75					
95% CI of the absolute risk difference	(3.20, 29.99)		(3.27, 32.22)					
p-value	0.0111		0.0102					
p-value of Breslow-Day Test for Homogeneity [2]	0.1860		0.9873					
Nausea	15 (23.4)	17	8 (15.1)	12	18 (16.2)	22	41 (18.0)	51
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.58		0.92					
95% CI of the odds ratio	(0.73, 3.41)		(0.37, 2.27)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.45		0.93					
95% CI of the risk ratio	(0.78, 2.67)		(0.43, 2.00)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.22		-1.12					
95% CI of the absolute risk difference	(-5.22, 19.66)		(-12.95, 10.71)					
p-value	0.2395		0.8540					
p-value of Breslow-Day Test for Homogeneity [2]	0.1953		0.6094					

AMNOG Table S1.8.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Fibrosis Stage at Baseline (Label Population)

Fibrosis Stage at Baseline: F2 only

System Organ Class Preferred Term	MGL-3196 80 mg (N=64) Patients n (%)	 Events n	MGL-3196 100 mg (N=53) Patients n (%)	 Events n	Placebo (N=111) Patients n (%)	 Events n	Overall (N=228) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	7 (10.9)	7	4 (7.5)	4	7 (6.3)	8	18 (7.9)	19
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.82		1.21					
95% CI of the odds ratio	(0.61, 5.46)		(0.34, 4.34)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.73		1.20					
95% CI of the risk ratio	(0.64, 4.72)		(0.37, 3.91)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.63		1.24					
95% CI of the absolute risk difference	(-4.25, 13.51)		(-7.19, 9.67)					
p-value	0.2768		0.7664					
p-value of Breslow-Day Test for Homogeneity [2]	0.6073		0.8027					
Abdominal discomfort	0	0	2 (3.8)	2	3 (2.7)	3	5 (2.2)	5
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		1.41					
95% CI of the odds ratio	NE		(0.23, 8.71)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		1.40					
95% CI of the risk ratio	NE		(0.24, 8.11)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.70		1.07					
95% CI of the absolute risk difference	(-5.72, 0.31)		(-4.88, 7.02)					
p-value	0.1846		0.7091					
p-value of Breslow-Day Test for Homogeneity [2]	0.5782		0.1220					

AMNOG Table S1.8.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Fibrosis Stage at Baseline (Label Population)

Fibrosis Stage at Baseline: F2 only

System Organ Class Preferred Term	MGL-3196 80 mg (N=64) Patients n (%)	 Events n	MGL-3196 100 mg (N=53) Patients n (%)	 Events n	Placebo (N=111) Patients n (%)	 Events n	Overall (N=228) Patients n (%)	 Events n
General disorders and administration site conditions	11 (17.2)	18	9 (17.0)	12	30 (27.0)	36	50 (21.9)	66
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56		0.55					
95% CI of the odds ratio	(0.26, 1.21)		(0.24, 1.27)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.64		0.63					
95% CI of the risk ratio	(0.34, 1.18)		(0.32, 1.23)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.84		-10.05					
95% CI of the absolute risk difference	(-22.24, 2.56)		(-23.10, 3.01)					
p-value	0.1388		0.1576					
p-value of Breslow-Day Test for Homogeneity [2]	0.5354		0.7787					
Skin and subcutaneous tissue disorders								
Pruritus	6 (9.4)	9	2 (3.8)	2	6 (5.4)	6	14 (6.1)	17
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81		0.69					
95% CI of the odds ratio	(0.56, 5.87)		(0.13, 3.52)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.73		0.70					
95% CI of the risk ratio	(0.58, 5.15)		(0.15, 3.34)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.97		-1.63					
95% CI of the absolute risk difference	(-4.32, 12.26)		(-8.27, 5.00)					
p-value	0.3169		0.6500					
p-value of Breslow-Day Test for Homogeneity [2]	0.9495		0.9819					

AMNOG Table S1.8.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Fibrosis Stage at Baseline (Label Population)

Fibrosis Stage at Baseline: F2 only

System Organ Class Preferred Term	MGL-3196 80 mg (N=64) Patients n (%)	 Events n	MGL-3196 100 mg (N=53) Patients n (%)	 Events n	Placebo (N=111) Patients n (%)	 Events n	Overall (N=228) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	2 (3.1)	2	6 (11.3)	6	2 (1.8)	2	10 (4.4)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.76		6.96					
95% CI of the odds ratio	(0.24, 12.79)		(1.35, 35.74)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.73		6.28					
95% CI of the risk ratio	(0.25, 12.02)		(1.31, 30.09)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.32		9.52					
95% CI of the absolute risk difference	(-3.61, 6.25)		(0.64, 18.40)					
p-value	0.5727		0.0081					
p-value of Breslow-Day Test for Homogeneity [2]	0.6956		0.1940					
Renal and urinary disorders	1 (1.6)	1	6 (11.3)	7	11 (9.9)	15	18 (7.9)	23
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.14		1.16					
95% CI of the odds ratio	(0.02, 1.14)		(0.40, 3.33)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.16		1.14					
95% CI of the risk ratio	(0.02, 1.19)		(0.45, 2.92)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.35		1.41					
95% CI of the absolute risk difference	(-14.68, -2.01)		(-8.77, 11.59)					
p-value	0.0353		0.7816					
p-value of Breslow-Day Test for Homogeneity [2]	0.3340		0.4899					

AMNOG Table S1.8.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Fibrosis Stage at Baseline (Label Population)

Fibrosis Stage at Baseline: F2 only

System Organ Class Preferred Term	MGL-3196 80 mg (N=64) Patients n (%)	 Events n	MGL-3196 100 mg (N=53) Patients n (%)	 Events n	Placebo (N=111) Patients n (%)	 Events n	Overall (N=228) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	3 (4.7)	3	2 (3.8)	2	9 (8.1)	11	14 (6.1)	16
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56		0.44					
95% CI of the odds ratio	(0.15, 2.14)		(0.09, 2.13)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58		0.47					
95% CI of the risk ratio	(0.16, 2.06)		(0.10, 2.08)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.42		-4.33					
95% CI of the absolute risk difference	(-10.67, 3.83)		(-11.55, 2.88)					
p-value	0.3885		0.2994					
p-value of Breslow-Day Test for Homogeneity [2]	0.8615		0.5895					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.8.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Fibrosis Stage at Baseline (Label Population)

Fibrosis Stage at Baseline: F2 only

System Organ Class Preferred Term	MGL-3196 80 mg (N=64) Patients n (%)	 Events n	MGL-3196 100 mg (N=53) Patients n (%)	 Events n	Placebo (N=111) Patients n (%)	 Events n	Overall (N=228) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	1 (1.6)	1	0	0	6 (5.4)	9	7 (3.1)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.28		0.15					
95% CI of the odds ratio	(0.03, 2.36)		(0.01, 2.74)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		0.16					
95% CI of the risk ratio	(0.04, 2.35)		(0.01, 2.78)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.84		-4.88					
95% CI of the absolute risk difference	(-9.03, 1.35)		(-9.91, 0.15)					
p-value	0.2115		0.1429					
p-value of Breslow-Day Test for Homogeneity [2]	0.7456		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.8.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Fibrosis Stage at Baseline (Label Population)

Fibrosis Stage at Baseline: F3 only

System Organ Class Preferred Term	MGL-3196 80 mg (N=103) Patients n (%)	 Events n	MGL-3196 100 mg (N=98) Patients n (%)	 Events n	Placebo (N=192) Patients n (%)	 Events n	Overall (N=393) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	21 (20.4)	39	33 (33.7)	51	31 (16.1)	36	85 (21.6)	126
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33		2.64					
95% CI of the odds ratio	(0.72, 2.46)		(1.49, 4.66)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.26		2.09					
95% CI of the risk ratio	(0.77, 2.08)		(1.36, 3.19)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.24		17.53					
95% CI of the absolute risk difference	(-5.12, 13.60)		(6.82, 28.23)					
p-value	0.3620		0.0007					
p-value of Breslow-Day Test for Homogeneity [2]	0.1860		0.9873					
Nausea	28 (27.2)	34	13 (13.3)	14	21 (10.9)	24	62 (15.8)	72
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.04		1.25					
95% CI of the odds ratio	(1.62, 5.69)		(0.59, 2.61)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.49		1.21					
95% CI of the risk ratio	(1.49, 4.15)		(0.63, 2.32)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	16.25		2.33					
95% CI of the absolute risk difference	(6.59, 25.91)		(-5.71, 10.36)					
p-value	0.0004		0.5600					
p-value of Breslow-Day Test for Homogeneity [2]	0.1953		0.6094					

AMNOG Table S1.8.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Fibrosis Stage at Baseline (Label Population)

Fibrosis Stage at Baseline: F3 only

System Organ Class Preferred Term	MGL-3196 80 mg (N=103) Patients n (%)	 Events n	MGL-3196 100 mg (N=98) Patients n (%)	 Events n	Placebo (N=192) Patients n (%)	 Events n	Overall (N=393) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	13 (12.6)	15	5 (5.1)	5	10 (5.2)	10	28 (7.1)	30
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.63		0.98					
95% CI of the odds ratio	(1.11, 6.23)		(0.32, 2.95)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.42		0.98					
95% CI of the risk ratio	(1.10, 5.33)		(0.34, 2.79)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.41		-0.11					
95% CI of the absolute risk difference	(0.27, 14.56)		(-5.48, 5.27)					
p-value	0.0236		0.9692					
p-value of Breslow-Day Test for Homogeneity [2]	0.6073		0.8027					
Abdominal discomfort	1 (1.0)	1	1 (1.0)	2	10 (5.2)	11	12 (3.1)	14
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.18		0.19					
95% CI of the odds ratio	(0.02, 1.41)		(0.02, 1.49)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.19		0.20					
95% CI of the risk ratio	(0.02, 1.44)		(0.03, 1.51)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.24		-4.19					
95% CI of the absolute risk difference	(-7.91, -0.57)		(-7.91, -0.47)					
p-value	0.0671		0.0774					
p-value of Breslow-Day Test for Homogeneity [2]	0.5782		0.1220					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.8.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Fibrosis Stage at Baseline (Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103)		MGL-3196 100 mg (N=98)		Placebo (N=192)		Overall (N=393)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
General disorders and administration site conditions	24 (23.3)	34	20 (20.4)	27	55 (28.6)	68	99 (25.2)	129
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76		0.64					
95% CI of the odds ratio	(0.43, 1.32)		(0.36, 1.14)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81		0.71					
95% CI of the risk ratio	(0.54, 1.23)		(0.45, 1.12)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.34		-8.24					
95% CI of the absolute risk difference	(-15.72, 5.03)		(-18.46, 1.99)					
p-value	0.3230		0.1297					
p-value of Breslow-Day Test for Homogeneity [2]	0.5354		0.7787					
Skin and subcutaneous tissue disorders								
Pruritus	16 (15.5)	19	6 (6.1)	8	17 (8.9)	20	39 (9.9)	47
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89		0.67					
95% CI of the odds ratio	(0.91, 3.93)		(0.26, 1.76)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.75		0.69					
95% CI of the risk ratio	(0.93, 3.33)		(0.28, 1.70)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.68		-2.73					
95% CI of the absolute risk difference	(-1.39, 14.75)		(-8.95, 3.49)					
p-value	0.0827		0.4155					
p-value of Breslow-Day Test for Homogeneity [2]	0.9495		0.9819					

AMNOG Table S1.8.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Fibrosis Stage at Baseline (Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103)		MGL-3196 100 mg (N=98)		Placebo (N=192)		Overall (N=393)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	6 (5.8)	6	10 (10.2)	14	10 (5.2)	12	26 (6.6)	32
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13		2.07					
95% CI of the odds ratio	(0.40, 3.19)		(0.83, 5.15)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.12		1.96					
95% CI of the risk ratio	(0.42, 2.99)		(0.84, 4.55)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.62		5.00					
95% CI of the absolute risk difference	(-4.89, 6.12)		(-1.77, 11.76)					
p-value	0.8235		0.1123					
p-value of Breslow-Day Test for Homogeneity [2]	0.6956		0.1940					
Renal and urinary disorders	4 (3.9)	5	14 (14.3)	17	16 (8.3)	18	34 (8.7)	40
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44		1.83					
95% CI of the odds ratio	(0.14, 1.37)		(0.85, 3.93)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47		1.71					
95% CI of the risk ratio	(0.16, 1.36)		(0.87, 3.37)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.45		5.95					
95% CI of the absolute risk difference	(-9.85, 0.95)		(-2.00, 13.91)					
p-value	0.1473		0.1154					
p-value of Breslow-Day Test for Homogeneity [2]	0.3340		0.4899					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.8.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Fibrosis Stage at Baseline (Label Population)

Fibrosis Stage at Baseline: F3 only

System Organ Class Preferred Term	MGL-3196 80 mg (N=103) Patients n (%)	 Events n	MGL-3196 100 mg (N=98) Patients n (%)	 Events n	Placebo (N=192) Patients n (%)	 Events n	Overall (N=393) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	4 (3.9)	5	2 (2.0)	2	15 (7.8)	17	21 (5.3)	24
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48		0.25					
95% CI of the odds ratio	(0.15, 1.48)		(0.06, 1.10)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		0.26					
95% CI of the risk ratio	(0.17, 1.46)		(0.06, 1.12)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.93		-5.77					
95% CI of the absolute risk difference	(-9.25, 1.39)		(-10.49, -1.06)					
p-value	0.1900		0.0478					
p-value of Breslow-Day Test for Homogeneity [2]	0.8615		0.5895					

AMNOG Table S1.8.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Fibrosis Stage at Baseline (Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103)		MGL-3196 100 mg (N=98)		Placebo (N=192)		Overall (N=393)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Injury, poisoning and procedural complications								
Contusion	1 (1.0)	1	0	0	4 (2.1)	5	5 (1.3)	6
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.46		NE					
95% CI of the odds ratio	(0.05, 4.18)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47		NE					
95% CI of the risk ratio	(0.05, 4.12)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.11		-2.08					
95% CI of the absolute risk difference	(-3.88, 1.66)		(-4.10, -0.06)					
p-value	0.4804		0.1502					
p-value of Breslow-Day Test for Homogeneity [2]	0.7456		NE					

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Events n:				
Total TEAEs	215	166	332	713
Total Serious TEAEs	4	2	19	25
Total TEAEs Leading to Discontinuation of Study Drug	1	2	1	4
Total TEAEs Related to Study Drug	30	33	17	80
Total TEAEs >= Grade 3 Severity	4	1	19	24
Patients n (%):				
Any TEAE	26 (96.3)	21 (95.5)	38 (97.4)	85 (96.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	0.55		
95% CI of the odds ratio	(0.04, 11.44)	(0.03, 9.30)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	0.98		
95% CI of the risk ratio	(0.90, 1.08)	(0.88, 1.09)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.14	-1.98		
95% CI of the absolute risk difference	(-9.82, 7.54)	(-12.00, 8.04)		
p-value	0.7906	0.6765		
p-value of Breslow-Day Test for Homogeneity [2]	0.6731	0.8329		
Any Serious TEAE	3 (11.1)	1 (4.5)	9 (23.1)	13 (14.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42	0.16		
95% CI of the odds ratio	(0.10, 1.71)	(0.02, 1.35)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48	0.20		
95% CI of the risk ratio	(0.14, 1.62)	(0.03, 1.45)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-11.97	-18.53		
95% CI of the absolute risk difference	(-29.72, 5.79)	(-34.36, -2.70)		
p-value	0.2153	0.0605		
p-value of Breslow-Day Test for Homogeneity [2]	0.5232	0.0444		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Any TEAEs >= Grade 3 Severity	3 (11.1)	1 (4.5)	11 (28.2)	15 (17.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.32	0.12		
95% CI of the odds ratio	(0.08, 1.28)	(0.01, 1.01)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	0.16		
95% CI of the risk ratio	(0.12, 1.28)	(0.02, 1.17)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-17.09	-23.66		
95% CI of the absolute risk difference	(-35.53, 1.34)	(-40.25, -7.07)		
p-value	0.0949	0.0256		
p-value of Breslow-Day Test for Homogeneity [2]	0.2333	0.0199		
Any TEAEs <= Grade 2 Severity	26 (96.3)	21 (95.5)	38 (97.4)	85 (96.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	0.55		
95% CI of the odds ratio	(0.04, 11.44)	(0.03, 9.30)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	0.98		
95% CI of the risk ratio	(0.90, 1.08)	(0.88, 1.09)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.14	-1.98		
95% CI of the absolute risk difference	(-9.82, 7.54)	(-12.00, 8.04)		
p-value	0.7906	0.6765		
p-value of Breslow-Day Test for Homogeneity [2]	0.7942	0.9238		
Any TEAEs leading to Study-Drug Discontinuation	1 (3.7)	2 (9.1)	1 (2.6)	4 (4.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.46	3.80		
95% CI of the odds ratio	(0.09, 24.43)	(0.32, 44.51)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44	3.55		
95% CI of the risk ratio	(0.09, 22.10)	(0.34, 36.91)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.14	6.53		
95% CI of the absolute risk difference	(-7.54, 9.82)	(-6.47, 19.52)		
p-value	0.7906	0.2576		
p-value of Breslow-Day Test for Homogeneity [2]	0.8188	0.5386		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Any TEAEs leading to Study Discontinuation	0	2 (9.1)	0	2 (2.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	9.63		
95% CI of the odds ratio	NE	(0.44, 210.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.70		
95% CI of the risk ratio	NE	(0.44, 173.39)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	9.62		
95% CI of the absolute risk difference	NE	(-3.56, 22.80)		
p-value	NE	0.0843		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1596		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	10 (37.0)	10 (45.5)	9 (23.1)	29 (33.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.96	2.78		
95% CI of the odds ratio	(0.67, 5.77)	(0.90, 8.53)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.60	1.97		
95% CI of the risk ratio	(0.75, 3.42)	(0.95, 4.10)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.96	22.38		
95% CI of the absolute risk difference	(-8.55, 36.47)	(-2.28, 47.03)		
p-value	0.2181	0.0699		
p-value of Breslow-Day Test for Homogeneity [2]	0.8378	0.2052		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	1 (4.5)	0	1 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	4.55		
95% CI of the absolute risk difference	NE	(-4.16, 13.25)		
p-value	NE	0.1794		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3847		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	2 (9.1)	1 (2.6)	3 (3.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.80		
95% CI of the odds ratio	NE	(0.32, 44.51)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.55		
95% CI of the risk ratio	NE	(0.34, 36.91)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.56	6.53		
95% CI of the absolute risk difference	(-7.52, 2.40)	(-6.47, 19.52)		
p-value	0.4018	0.2576		
p-value of Breslow-Day Test for Homogeneity [2]	0.4919	0.6633		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	2 (9.1)	0	2 (2.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	9.63		
95% CI of the odds ratio	NE	(0.44, 210.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.70		
95% CI of the risk ratio	NE	(0.44, 173.39)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	9.62		
95% CI of the absolute risk difference	NE	(-3.56, 22.80)		
p-value	NE	0.0843		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2092		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	7 (25.9)	5 (22.7)	5 (12.8)	17 (19.3)
Grade 2	16 (59.3)	15 (68.2)	22 (56.4)	53 (60.2)
Grade 3	3 (11.1)	1 (4.5)	8 (20.5)	12 (13.6)
Grade 4	0	0	3 (7.7)	3 (3.4)
Grade 5	0	0	0	0

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	7 (25.9)	6 (27.3)	6 (15.4)	19 (21.6)
Grade 2	3 (11.1)	3 (13.6)	3 (7.7)	9 (10.2)
Grade 3	0	1 (4.5)	0	1 (1.1)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Events n:				
Total TEAEs	984	856	1825	3665
Total Serious TEAEs	25	30	77	132
Total TEAEs Leading to Discontinuation of Study Drug	17	18	24	59
Total TEAEs Related to Study Drug	125	93	142	360
Total TEAEs >= Grade 3 Severity	30	44	87	161
Patients n (%):				
Any TEAE	132 (94.3)	117 (90.7)	245 (92.8)	494 (92.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.28	0.76		
95% CI of the odds ratio	(0.55, 3.00)	(0.36, 1.61)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	0.98		
95% CI of the risk ratio	(0.96, 1.07)	(0.92, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.48	-2.11		
95% CI of the absolute risk difference	(-3.47, 6.43)	(-8.01, 3.80)		
p-value	0.5701	0.4672		
p-value of Breslow-Day Test for Homogeneity [2]	0.6731	0.8329		
Any Serious TEAE	13 (9.3)	20 (15.5)	34 (12.9)	67 (12.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	1.24		
95% CI of the odds ratio	(0.35, 1.36)	(0.68, 2.26)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.72	1.20		
95% CI of the risk ratio	(0.39, 1.32)	(0.72, 2.01)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.59	2.63		
95% CI of the absolute risk difference	(-9.87, 2.69)	(-4.81, 10.06)		
p-value	0.2838	0.4778		
p-value of Breslow-Day Test for Homogeneity [2]	0.5232	0.0444		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Any TEAEs >= Grade 3 Severity	19 (13.6)	25 (19.4)	44 (16.7)	88 (16.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.79	1.20		
95% CI of the odds ratio	(0.44, 1.41)	(0.70, 2.07)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81	1.16		
95% CI of the risk ratio	(0.50, 1.34)	(0.75, 1.81)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.10	2.71		
95% CI of the absolute risk difference	(-10.33, 4.14)	(-5.46, 10.88)		
p-value	0.4145	0.5068		
p-value of Breslow-Day Test for Homogeneity [2]	0.2333	0.0199		
Any TEAEs <= Grade 2 Severity	130 (92.9)	115 (89.1)	245 (92.8)	490 (91.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	0.64		
95% CI of the odds ratio	(0.46, 2.23)	(0.31, 1.32)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.96		
95% CI of the risk ratio	(0.95, 1.06)	(0.90, 1.03)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.05	-3.66		
95% CI of the absolute risk difference	(-5.23, 5.34)	(-9.86, 2.55)		
p-value	0.9840	0.2198		
p-value of Breslow-Day Test for Homogeneity [2]	0.7942	0.9238		
Any TEAEs leading to Study-Drug Discontinuation	11 (7.9)	16 (12.4)	20 (7.6)	47 (8.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04	1.73		
95% CI of the odds ratio	(0.48, 2.24)	(0.86, 3.46)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04	1.64		
95% CI of the risk ratio	(0.51, 2.10)	(0.88, 3.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.28	4.83		
95% CI of the absolute risk difference	(-5.20, 5.76)	(-1.70, 11.35)		
p-value	0.9195	0.1193		
p-value of Breslow-Day Test for Homogeneity [2]	0.8188	0.5386		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Any TEAEs leading to Study Discontinuation	3 (2.1)	9 (7.0)	11 (4.2)	23 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50	1.73		
95% CI of the odds ratio	(0.14, 1.84)	(0.70, 4.27)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	1.67		
95% CI of the risk ratio	(0.15, 1.81)	(0.71, 3.94)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.02	2.81		
95% CI of the absolute risk difference	(-5.42, 1.38)	(-2.20, 7.82)		
p-value	0.2899	0.2339		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1596		
Any Fatal TEAEs	1 (0.7)	1 (0.8)	1 (0.4)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	2.05		
95% CI of the odds ratio	(0.12, 30.48)	(0.13, 33.11)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	2.05		
95% CI of the risk ratio	(0.12, 29.92)	(0.13, 32.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.34	0.40		
95% CI of the absolute risk difference	(-1.24, 1.92)	(-1.29, 2.08)		
p-value	0.6475	0.6040		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	59 (42.1)	45 (34.9)	78 (29.5)	182 (34.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.74	1.28		
95% CI of the odds ratio	(1.13, 2.66)	(0.82, 2.00)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43	1.18		
95% CI of the risk ratio	(1.09, 1.87)	(0.87, 1.59)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	12.60	5.34		
95% CI of the absolute risk difference	(2.74, 22.46)	(-4.56, 15.23)		
p-value	0.0109	0.2839		
p-value of Breslow-Day Test for Homogeneity [2]	0.8378	0.2052		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.12, 0.36)	(-1.12, 0.36)		
p-value	0.4659	0.4840		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	2 (1.4)	2 (1.6)	2 (0.8)	6 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.90	2.06		
95% CI of the odds ratio	(0.26, 13.62)	(0.29, 14.81)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	2.05		
95% CI of the risk ratio	(0.27, 13.24)	(0.29, 14.36)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.67	0.79		
95% CI of the absolute risk difference	(-1.56, 2.90)	(-1.58, 3.17)		
p-value	0.5168	0.4622		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3847		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	3 (2.1)	8 (6.2)	8 (3.0)	19 (3.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.70	2.12		
95% CI of the odds ratio	(0.18, 2.68)	(0.78, 5.77)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	2.05		
95% CI of the risk ratio	(0.19, 2.62)	(0.79, 5.33)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.89	3.17		
95% CI of the absolute risk difference	(-4.05, 2.28)	(-1.48, 7.82)		
p-value	0.6020	0.1352		
p-value of Breslow-Day Test for Homogeneity [2]	0.4919	0.6633		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	5 (3.9)	5 (1.9)	10 (1.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.09		
95% CI of the odds ratio	NE	(0.59, 7.35)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.05		
95% CI of the risk ratio	NE	(0.60, 6.94)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.89	1.98		
95% CI of the absolute risk difference	(-3.54, -0.25)	(-1.73, 5.70)		
p-value	0.1013	0.2413		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2092		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	32 (22.9)	21 (16.3)	64 (24.2)	117 (22.0)
Grade 2	81 (57.9)	71 (55.0)	137 (51.9)	289 (54.2)
Grade 3	18 (12.9)	24 (18.6)	39 (14.8)	81 (15.2)
Grade 4	0	0	4 (1.5)	4 (0.8)
Grade 5	1 (0.7)	1 (0.8)	1 (0.4)	3 (0.6)

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	34 (24.3)	23 (17.8)	47 (17.8)	104 (19.5)
Grade 2	23 (16.4)	20 (15.5)	29 (11.0)	72 (13.5)
Grade 3	2 (1.4)	2 (1.6)	1 (0.4)	5 (0.9)
Grade 4	0	0	1 (0.4)	1 (0.2)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (0.7)	1 (0.8)	1 (0.4)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	2.05		
95% CI of the odds ratio	(0.12, 30.48)	(0.13, 33.11)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	2.05		
95% CI of the risk ratio	(0.12, 29.92)	(0.13, 32.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.34	0.40		
95% CI of the absolute risk difference	(-1.24, 1.92)	(-1.29, 2.08)		
p-value	0.6475	0.6040		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.8)	0	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	0.78		
95% CI of the absolute risk difference	NE	(-0.74, 2.29)		
p-value	NE	0.1520		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (0.7)	0	1 (0.4)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	NE		
95% CI of the odds ratio	(0.12, 30.48)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	NE		
95% CI of the risk ratio	(0.12, 29.92)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.34	-0.38		
95% CI of the absolute risk difference	(-1.24, 1.92)	(-1.12, 0.36)		
p-value	0.6475	0.4840		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (0.7)	1 (0.8)	1 (0.4)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	2.05		
95% CI of the odds ratio	(0.12, 30.48)	(0.13, 33.11)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	2.05		
95% CI of the risk ratio	(0.12, 29.92)	(0.13, 32.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.34	0.40		
95% CI of the absolute risk difference	(-1.24, 1.92)	(-1.29, 2.08)		
p-value	0.6475	0.6040		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	1 (0.8)	4 (1.5)	5 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.51		
95% CI of the odds ratio	NE	(0.06, 4.59)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.51		
95% CI of the risk ratio	NE	(0.06, 4.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.52	-0.74		
95% CI of the absolute risk difference	(-2.99, -0.04)	(-2.85, 1.37)		
p-value	0.1433	0.5388		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.8)	3 (1.1)	4 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.68		
95% CI of the odds ratio	NE	(0.07, 6.60)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.68		
95% CI of the risk ratio	NE	(0.07, 6.49)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.14	-0.36		
95% CI of the absolute risk difference	(-2.41, 0.14)	(-2.34, 1.62)		
p-value	0.2055	0.7377		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.12, 0.36)	(-1.12, 0.36)		
p-value	0.4659	0.4840		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (0.8)	3 (1.1)	4 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.68		
95% CI of the odds ratio	NE	(0.07, 6.60)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.68		
95% CI of the risk ratio	NE	(0.07, 6.49)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.14	-0.36		
95% CI of the absolute risk difference	(-2.41, 0.14)	(-2.34, 1.62)		
p-value	0.2055	0.7377		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Events n:				
Total TEAEs	212	164	326	702
Total Serious TEAEs	4	2	19	25
Total TEAEs Leading to Discontinuation of Study Drug	0	2	1	3
Total TEAEs Related to Study Drug	30	33	17	80
Total TEAEs >= Grade 3 Severity	4	1	18	23
Patients n (%):				
Any TEAE	26 (96.3)	21 (95.5)	38 (97.4)	85 (96.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	0.55		
95% CI of the odds ratio	(0.04, 11.44)	(0.03, 9.30)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	0.98		
95% CI of the risk ratio	(0.90, 1.08)	(0.88, 1.09)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.14	-1.98		
95% CI of the absolute risk difference	(-9.82, 7.54)	(-12.00, 8.04)		
p-value	0.7906	0.6765		
p-value of Breslow-Day Test for Homogeneity [2]	0.6804	0.7758		
Any Serious TEAE	3 (11.1)	1 (4.5)	9 (23.1)	13 (14.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42	0.16		
95% CI of the odds ratio	(0.10, 1.71)	(0.02, 1.35)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48	0.20		
95% CI of the risk ratio	(0.14, 1.62)	(0.03, 1.45)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-11.97	-18.53		
95% CI of the absolute risk difference	(-29.72, 5.79)	(-34.36, -2.70)		
p-value	0.2153	0.0605		
p-value of Breslow-Day Test for Homogeneity [2]	0.5232	0.0444		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Any TEAEs >= Grade 3 Severity	3 (11.1)	1 (4.5)	10 (25.6)	14 (15.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36	0.14		
95% CI of the odds ratio	(0.09, 1.47)	(0.02, 1.16)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43	0.18		
95% CI of the risk ratio	(0.13, 1.43)	(0.02, 1.29)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-14.53	-21.10		
95% CI of the absolute risk difference	(-32.65, 3.59)	(-37.33, -4.86)		
p-value	0.1445	0.0396		
p-value of Breslow-Day Test for Homogeneity [2]	0.4147	0.0302		
Any TEAEs <= Grade 2 Severity	26 (96.3)	21 (95.5)	38 (97.4)	85 (96.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	0.55		
95% CI of the odds ratio	(0.04, 11.44)	(0.03, 9.30)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	0.98		
95% CI of the risk ratio	(0.90, 1.08)	(0.88, 1.09)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.14	-1.98		
95% CI of the absolute risk difference	(-9.82, 7.54)	(-12.00, 8.04)		
p-value	0.7906	0.6765		
p-value of Breslow-Day Test for Homogeneity [2]	0.7908	0.8659		
Any TEAEs leading to Study-Drug Discontinuation	0	2 (9.1)	1 (2.6)	3 (3.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.80		
95% CI of the odds ratio	NE	(0.32, 44.51)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.55		
95% CI of the risk ratio	NE	(0.34, 36.91)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.56	6.53		
95% CI of the absolute risk difference	(-7.52, 2.40)	(-6.47, 19.52)		
p-value	0.4018	0.2576		
p-value of Breslow-Day Test for Homogeneity [2]	0.3791	0.6272		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Any TEAEs leading to Study Discontinuation	0	2 (9.1)	0	2 (2.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	9.63		
95% CI of the odds ratio	NE	(0.44, 210.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.70		
95% CI of the risk ratio	NE	(0.44, 173.39)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	9.62		
95% CI of the absolute risk difference	NE	(-3.56, 22.80)		
p-value	NE	0.0843		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1596		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	10 (37.0)	10 (45.5)	9 (23.1)	29 (33.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.96	2.78		
95% CI of the odds ratio	(0.67, 5.77)	(0.90, 8.53)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.60	1.97		
95% CI of the risk ratio	(0.75, 3.42)	(0.95, 4.10)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.96	22.38		
95% CI of the absolute risk difference	(-8.55, 36.47)	(-2.28, 47.03)		
p-value	0.2181	0.0699		
p-value of Breslow-Day Test for Homogeneity [2]	0.8620	0.2163		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	1 (4.5)	0	1 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	4.55		
95% CI of the absolute risk difference	NE	(-4.16, 13.25)		
p-value	NE	0.1794		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3847		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	2 (9.1)	1 (2.6)	3 (3.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.80		
95% CI of the odds ratio	NE	(0.32, 44.51)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.55		
95% CI of the risk ratio	NE	(0.34, 36.91)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.56	6.53		
95% CI of the absolute risk difference	(-7.52, 2.40)	(-6.47, 19.52)		
p-value	0.4018	0.2576		
p-value of Breslow-Day Test for Homogeneity [2]	0.4919	0.6633		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	2 (9.1)	0	2 (2.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	9.63		
95% CI of the odds ratio	NE	(0.44, 210.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.70		
95% CI of the risk ratio	NE	(0.44, 173.39)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	9.62		
95% CI of the absolute risk difference	NE	(-3.56, 22.80)		
p-value	NE	0.0843		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2092		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	7 (25.9)	5 (22.7)	7 (17.9)	19 (21.6)
Grade 2	16 (59.3)	15 (68.2)	21 (53.8)	52 (59.1)
Grade 3	3 (11.1)	1 (4.5)	7 (17.9)	11 (12.5)
Grade 4	0	0	3 (7.7)	3 (3.4)
Grade 5	0	0	0	0

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	7 (25.9)	6 (27.3)	6 (15.4)	19 (21.6)
Grade 2	3 (11.1)	3 (13.6)	3 (7.7)	9 (10.2)
Grade 3	0	1 (4.5)	0	1 (1.1)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=39) n (%)	Overall (N=88) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Events n:				
Total TEAEs	974	850	1807	3631
Total Serious TEAEs	25	30	77	132
Total TEAEs Leading to Discontinuation of Study Drug	15	16	19	50
Total TEAEs Related to Study Drug	124	93	141	358
Total TEAEs >= Grade 3 Severity	27	43	85	155
Patients n (%):				
Any TEAE	131 (93.6)	117 (90.7)	243 (92.0)	491 (92.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.26	0.84		
95% CI of the odds ratio	(0.56, 2.83)	(0.40, 1.77)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	0.99		
95% CI of the risk ratio	(0.96, 1.08)	(0.92, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.53	-1.35		
95% CI of the absolute risk difference	(-3.69, 6.74)	(-7.33, 4.63)		
p-value	0.5777	0.6510		
p-value of Breslow-Day Test for Homogeneity [2]	0.6804	0.7758		
Any Serious TEAE	13 (9.3)	20 (15.5)	34 (12.9)	67 (12.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	1.24		
95% CI of the odds ratio	(0.35, 1.36)	(0.68, 2.26)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.72	1.20		
95% CI of the risk ratio	(0.39, 1.32)	(0.72, 2.01)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.59	2.63		
95% CI of the absolute risk difference	(-9.87, 2.69)	(-4.81, 10.06)		
p-value	0.2838	0.4778		
p-value of Breslow-Day Test for Homogeneity [2]	0.5232	0.0444		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Any TEAEs >= Grade 3 Severity	16 (11.4)	24 (18.6)	42 (15.9)	82 (15.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	1.21		
95% CI of the odds ratio	(0.37, 1.26)	(0.70, 2.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.72	1.17		
95% CI of the risk ratio	(0.42, 1.23)	(0.74, 1.84)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.48	2.70		
95% CI of the absolute risk difference	(-11.35, 2.39)	(-5.34, 10.73)		
p-value	0.2216	0.5020		
p-value of Breslow-Day Test for Homogeneity [2]	0.4147	0.0302		
Any TEAEs <= Grade 2 Severity	129 (92.1)	115 (89.1)	243 (92.0)	487 (91.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	0.71		
95% CI of the odds ratio	(0.47, 2.17)	(0.35, 1.45)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.97		
95% CI of the risk ratio	(0.94, 1.06)	(0.90, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.10	-2.90		
95% CI of the absolute risk difference	(-5.43, 5.62)	(-9.18, 3.38)		
p-value	0.9725	0.3435		
p-value of Breslow-Day Test for Homogeneity [2]	0.7908	0.8659		
Any TEAEs leading to Study-Drug Discontinuation	9 (6.4)	14 (10.9)	15 (5.7)	38 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14	2.02		
95% CI of the odds ratio	(0.49, 2.68)	(0.94, 4.33)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13	1.91		
95% CI of the risk ratio	(0.51, 2.52)	(0.95, 3.84)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.75	5.17		
95% CI of the absolute risk difference	(-4.18, 5.68)	(-0.88, 11.22)		
p-value	0.7625	0.0656		
p-value of Breslow-Day Test for Homogeneity [2]	0.3791	0.6272		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Any TEAEs leading to Study Discontinuation	3 (2.1)	9 (7.0)	11 (4.2)	23 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50	1.73		
95% CI of the odds ratio	(0.14, 1.84)	(0.70, 4.27)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	1.67		
95% CI of the risk ratio	(0.15, 1.81)	(0.71, 3.94)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.02	2.81		
95% CI of the absolute risk difference	(-5.42, 1.38)	(-2.20, 7.82)		
p-value	0.2899	0.2339		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1596		
Any Fatal TEAEs	1 (0.7)	1 (0.8)	1 (0.4)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	2.05		
95% CI of the odds ratio	(0.12, 30.48)	(0.13, 33.11)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	2.05		
95% CI of the risk ratio	(0.12, 29.92)	(0.13, 32.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.34	0.40		
95% CI of the absolute risk difference	(-1.24, 1.92)	(-1.29, 2.08)		
p-value	0.6475	0.6040		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	59 (42.1)	45 (34.9)	77 (29.2)	181 (34.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.77	1.30		
95% CI of the odds ratio	(1.15, 2.71)	(0.83, 2.04)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44	1.20		
95% CI of the risk ratio	(1.10, 1.89)	(0.88, 1.62)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	12.98	5.72		
95% CI of the absolute risk difference	(3.13, 22.82)	(-4.17, 15.60)		
p-value	0.0086	0.2500		
p-value of Breslow-Day Test for Homogeneity [2]	0.8620	0.2163		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.12, 0.36)	(-1.12, 0.36)		
p-value	0.4659	0.4840		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (0.7)	2 (1.6)	2 (0.8)	5 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.94	2.06		
95% CI of the odds ratio	(0.08, 10.49)	(0.29, 14.81)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.94	2.05		
95% CI of the risk ratio	(0.09, 10.31)	(0.29, 14.36)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.04	0.79		
95% CI of the absolute risk difference	(-1.79, 1.70)	(-1.58, 3.17)		
p-value	0.9615	0.4622		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3847		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	3 (2.1)	8 (6.2)	8 (3.0)	19 (3.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.70	2.12		
95% CI of the odds ratio	(0.18, 2.68)	(0.78, 5.77)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	2.05		
95% CI of the risk ratio	(0.19, 2.62)	(0.79, 5.33)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.89	3.17		
95% CI of the absolute risk difference	(-4.05, 2.28)	(-1.48, 7.82)		
p-value	0.6020	0.1352		
p-value of Breslow-Day Test for Homogeneity [2]	0.4919	0.6633		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	5 (3.9)	5 (1.9)	10 (1.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.09		
95% CI of the odds ratio	NE	(0.59, 7.35)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.05		
95% CI of the risk ratio	NE	(0.60, 6.94)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.89	1.98		
95% CI of the absolute risk difference	(-3.54, -0.25)	(-1.73, 5.70)		
p-value	0.1013	0.2413		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2092		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	31 (22.1)	22 (17.1)	63 (23.9)	116 (21.8)
Grade 2	84 (60.0)	71 (55.0)	138 (52.3)	293 (55.0)
Grade 3	15 (10.7)	23 (17.8)	37 (14.0)	75 (14.1)
Grade 4	0	0	4 (1.5)	4 (0.8)
Grade 5	1 (0.7)	1 (0.8)	1 (0.4)	3 (0.6)

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	34 (24.3)	23 (17.8)	46 (17.4)	103 (19.3)
Grade 2	24 (17.1)	20 (15.5)	29 (11.0)	73 (13.7)
Grade 3	1 (0.7)	2 (1.6)	1 (0.4)	4 (0.8)
Grade 4	0	0	1 (0.4)	1 (0.2)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (0.7)	1 (0.8)	1 (0.4)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	2.05		
95% CI of the odds ratio	(0.12, 30.48)	(0.13, 33.11)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	2.05		
95% CI of the risk ratio	(0.12, 29.92)	(0.13, 32.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.34	0.40		
95% CI of the absolute risk difference	(-1.24, 1.92)	(-1.29, 2.08)		
p-value	0.6475	0.6040		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.8)	0	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	0.78		
95% CI of the absolute risk difference	NE	(-0.74, 2.29)		
p-value	NE	0.1520		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (0.7)	0	1 (0.4)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	NE		
95% CI of the odds ratio	(0.12, 30.48)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	NE		
95% CI of the risk ratio	(0.12, 29.92)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.34	-0.38		
95% CI of the absolute risk difference	(-1.24, 1.92)	(-1.12, 0.36)		
p-value	0.6475	0.4840		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (0.7)	1 (0.8)	1 (0.4)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	2.05		
95% CI of the odds ratio	(0.12, 30.48)	(0.13, 33.11)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	2.05		
95% CI of the risk ratio	(0.12, 29.92)	(0.13, 32.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.34	0.40		
95% CI of the absolute risk difference	(-1.24, 1.92)	(-1.29, 2.08)		
p-value	0.6475	0.6040		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	1 (0.8)	4 (1.5)	5 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.51		
95% CI of the odds ratio	NE	(0.06, 4.59)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.51		
95% CI of the risk ratio	NE	(0.06, 4.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.52	-0.74		
95% CI of the absolute risk difference	(-2.99, -0.04)	(-2.85, 1.37)		
p-value	0.1433	0.5388		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.8)	3 (1.1)	4 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.68		
95% CI of the odds ratio	NE	(0.07, 6.60)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.68		
95% CI of the risk ratio	NE	(0.07, 6.49)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.14	-0.36		
95% CI of the absolute risk difference	(-2.41, 0.14)	(-2.34, 1.62)		
p-value	0.2055	0.7377		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.12, 0.36)	(-1.12, 0.36)		
p-value	0.4659	0.4840		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (0.8)	3 (1.1)	4 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.68		
95% CI of the odds ratio	NE	(0.07, 6.60)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.68		
95% CI of the risk ratio	NE	(0.07, 6.49)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.14	-0.36		
95% CI of the absolute risk difference	(-2.41, 0.14)	(-2.34, 1.62)		
p-value	0.2055	0.7377		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140) n (%)	MGL-3196 100 mg (N=129) n (%)	Placebo (N=264) n (%)	Overall (N=533) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.9.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.2 are presented in this table.

AMNOG Table S1.9.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

System Organ Class Preferred Term	MGL-3196 80 mg (N=27) Patients n (%)	 Events n	MGL-3196 100 mg (N=22) Patients n (%)	 Events n	Placebo (N=39) Patients n (%)	 Events n	Overall (N=88) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	6 (22.2)	13	12 (54.5)	25	5 (12.8)	7	23 (26.1)	45
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.94		8.16					
95% CI of the odds ratio	(0.53, 7.17)		(2.32, 28.74)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.73		4.25					
95% CI of the risk ratio	(0.59, 5.11)		(1.72, 10.50)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.40		41.72					
95% CI of the absolute risk difference	(-9.47, 28.27)		(18.42, 65.03)					
p-value	0.3136		0.0005					
p-value of Breslow-Day Test for Homogeneity [2]	0.8712		0.0509					
Nausea	7 (25.9)	8	7 (31.8)	10	5 (12.8)	5	19 (21.6)	23
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.38		3.17					
95% CI of the odds ratio	(0.67, 8.51)		(0.87, 11.63)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.02		2.48					
95% CI of the risk ratio	(0.72, 5.71)		(0.89, 6.89)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.11		19.00					
95% CI of the absolute risk difference	(-6.47, 32.68)		(-3.11, 41.11)					
p-value	0.1747		0.0731					
p-value of Breslow-Day Test for Homogeneity [2]	0.9815		0.0642					

AMNOG Table S1.9.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

System Organ Class Preferred Term	MGL-3196 80 mg (N=27) Patients n (%)	 Events n	MGL-3196 100 mg (N=22) Patients n (%)	 Events n	Placebo (N=39) Patients n (%)	 Events n	Overall (N=88) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	3 (11.1)	4	3 (13.6)	3	4 (10.3)	4	10 (11.4)	11
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.09		1.38					
95% CI of the odds ratio	(0.22, 5.33)		(0.28, 6.83)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08		1.33					
95% CI of the risk ratio	(0.26, 4.46)		(0.33, 5.41)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.85		3.38					
95% CI of the absolute risk difference	(-14.35, 16.06)		(-13.83, 20.59)					
p-value	0.9117		0.6908					
p-value of Breslow-Day Test for Homogeneity [2]	0.3130		0.6890					
General disorders and administration site conditions	6 (22.2)	7	4 (18.2)	4	9 (23.1)	11	19 (21.6)	22
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95		0.74					
95% CI of the odds ratio	(0.29, 3.08)		(0.20, 2.76)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96		0.79					
95% CI of the risk ratio	(0.39, 2.39)		(0.27, 2.26)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.85		-4.90					
95% CI of the absolute risk difference	(-21.37, 19.66)		(-25.74, 15.95)					
p-value	0.9351		0.6539					
p-value of Breslow-Day Test for Homogeneity [2]	0.5491		0.7600					

AMNOG Table S1.9.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

System Organ Class Preferred Term	MGL-3196 80 mg (N=27) Patients n (%)	 Events n	MGL-3196 100 mg (N=22) Patients n (%)	 Events n	Placebo (N=39) Patients n (%)	 Events n	Overall (N=88) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders								
Pruritus	6 (22.2)	7	1 (4.5)	1	6 (15.4)	6	13 (14.8)	14
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.57		0.26					
95% CI of the odds ratio	(0.45, 5.52)		(0.03, 2.33)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44		0.30					
95% CI of the risk ratio	(0.52, 4.00)		(0.04, 2.30)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.84		-10.84					
95% CI of the absolute risk difference	(-12.50, 26.18)		(-25.12, 3.44)					
p-value	0.4789		0.2022					
p-value of Breslow-Day Test for Homogeneity [2]	0.8109		0.3230					
Rash	1 (3.7)	1	1 (4.5)	2	3 (7.7)	3	5 (5.7)	6
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.46		0.57					
95% CI of the odds ratio	(0.05, 4.69)		(0.06, 5.85)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48		0.59					
95% CI of the risk ratio	(0.05, 4.39)		(0.07, 5.34)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.99		-3.15					
95% CI of the absolute risk difference	(-14.97, 7.00)		(-15.22, 8.92)					
p-value	0.5043		0.6335					
p-value of Breslow-Day Test for Homogeneity [2]	0.3497		0.1096					

AMNOG Table S1.9.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

System Organ Class Preferred Term	MGL-3196 80 mg (N=27) Patients n (%)	 Events n	MGL-3196 100 mg (N=22) Patients n (%)	 Events n	Placebo (N=39) Patients n (%)	 Events n	Overall (N=88) Patients n (%)	 Events n
Renal and urinary disorders	1 (3.7)	2	6 (27.3)	6	5 (12.8)	6	12 (13.6)	14
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.26		2.55					
95% CI of the odds ratio	(0.03, 2.38)		(0.68, 9.62)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		2.13					
95% CI of the risk ratio	(0.04, 2.34)		(0.73, 6.17)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.12		14.45					
95% CI of the absolute risk difference	(-21.80, 3.57)		(-6.91, 35.82)					
p-value	0.2053		0.1586					
p-value of Breslow-Day Test for Homogeneity [2]	0.8653		0.3990					

AMNOG Table S1.9.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140)		MGL-3196 100 mg (N=129)		Placebo (N=264)		Overall (N=533)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders								
Diarrhoea	36 (25.7)	60	39 (30.2)	55	44 (16.7)	54	119 (22.3)	169
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.73		2.17					
95% CI of the odds ratio	(1.05, 2.85)		(1.32, 3.56)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.54		1.81					
95% CI of the risk ratio	(1.04, 2.28)		(1.25, 2.64)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.05		13.57					
95% CI of the absolute risk difference	(0.53, 17.57)		(4.45, 22.68)					
p-value	0.0299		0.0020					
p-value of Breslow-Day Test for Homogeneity [2]	0.8712		0.0509					
Nausea	36 (25.7)	43	14 (10.9)	16	34 (12.9)	41	84 (15.8)	100
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.34		0.82					
95% CI of the odds ratio	(1.39, 3.95)		(0.43, 1.60)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.00		0.84					
95% CI of the risk ratio	(1.31, 3.04)		(0.47, 1.51)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	12.84		-2.03					
95% CI of the absolute risk difference	(4.54, 21.13)		(-8.74, 4.69)					
p-value	0.0012		0.5646					
p-value of Breslow-Day Test for Homogeneity [2]	0.9815		0.0642					

AMNOG Table S1.9.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

System Organ Class Preferred Term	MGL-3196 80 mg (N=140) Patients n (%)	 Events n	MGL-3196 100 mg (N=129) Patients n (%)	 Events n	Placebo (N=264) Patients n (%)	 Events n	Overall (N=533) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	17 (12.1)	18	6 (4.7)	6	13 (4.9)	14	36 (6.8)	38
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.67		0.94					
95% CI of the odds ratio	(1.26, 5.67)		(0.35, 2.54)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.47		0.94					
95% CI of the risk ratio	(1.23, 4.93)		(0.37, 2.43)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.22		-0.27					
95% CI of the absolute risk difference	(1.21, 13.23)		(-4.75, 4.20)					
p-value	0.0085		0.9057					
p-value of Breslow-Day Test for Homogeneity [2]	0.3130		0.6890					
General disorders and administration site conditions	29 (20.7)	45	25 (19.4)	35	76 (28.8)	93	130 (24.4)	173
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.65		0.59					
95% CI of the odds ratio	(0.40, 1.05)		(0.36, 0.99)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.72		0.67					
95% CI of the risk ratio	(0.49, 1.05)		(0.45, 1.00)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.07		-9.41					
95% CI of the absolute risk difference	(-16.73, 0.58)		(-18.15, -0.67)					
p-value	0.0783		0.0450					
p-value of Breslow-Day Test for Homogeneity [2]	0.5491		0.7600					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.9.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140)		MGL-3196 100 mg (N=129)		Placebo (N=264)		Overall (N=533)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Skin and subcutaneous tissue disorders								
Pruritus	16 (11.4)	21	7 (5.4)	9	17 (6.4)	20	40 (7.5)	50
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.87		0.83					
95% CI of the odds ratio	(0.92, 3.84)		(0.34, 2.06)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.77		0.84					
95% CI of the risk ratio	(0.93, 3.40)		(0.36, 1.98)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.99		-1.01					
95% CI of the absolute risk difference	(-1.06, 11.03)		(-5.92, 3.89)					
p-value	0.0814		0.6937					
p-value of Breslow-Day Test for Homogeneity [2]	0.8109		0.3230					
Rash	7 (5.0)	7	15 (11.6)	18	9 (3.4)	11	31 (5.8)	36
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.49		3.73					
95% CI of the odds ratio	(0.54, 4.09)		(1.58, 8.77)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.47		3.41					
95% CI of the risk ratio	(0.56, 3.85)		(1.53, 7.58)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.59		8.22					
95% CI of the absolute risk difference	(-2.63, 5.81)		(2.27, 14.17)					
p-value	0.4353		0.0014					
p-value of Breslow-Day Test for Homogeneity [2]	0.3497		0.1096					

AMNOG Table S1.9.2

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140)		MGL-3196 100 mg (N=129)		Placebo (N=264)		Overall (N=533)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Renal and urinary disorders	4 (2.9)	4	14 (10.9)	18	22 (8.3)	27	40 (7.5)	49
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.32		1.34					
95% CI of the odds ratio	(0.11, 0.96)		(0.66, 2.71)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.34		1.30					
95% CI of the risk ratio	(0.12, 0.98)		(0.69, 2.46)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.48		2.52					
95% CI of the absolute risk difference	(-9.80, -1.15)		(-3.80, 8.84)					
p-value	0.0328		0.4162					
p-value of Breslow-Day Test for Homogeneity [2]	0.8653		0.3990					

AMNOG Table S1.9.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.

AMNOG Table S1.9.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Baseline GLP-1 Analogues (Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

System Organ Class Preferred Term	MGL-3196 80 mg (N=27) Patients n (%)	 Events n	MGL-3196 100 mg (N=22) Patients n (%)	 Events n	Placebo (N=39) Patients n (%)	 Events n	Overall (N=88) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	6 (22.2)	13	12 (54.5)	25	5 (12.8)	7	23 (26.1)	45
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.94		8.16					
95% CI of the odds ratio	(0.53, 7.17)		(2.32, 28.74)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.73		4.25					
95% CI of the risk ratio	(0.59, 5.11)		(1.72, 10.50)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.40		41.72					
95% CI of the absolute risk difference	(-9.47, 28.27)		(18.42, 65.03)					
p-value	0.3136		0.0005					
p-value of Breslow-Day Test for Homogeneity [2]	0.8712		0.0509					
Nausea	7 (25.9)	8	7 (31.8)	10	5 (12.8)	5	19 (21.6)	23
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.38		3.17					
95% CI of the odds ratio	(0.67, 8.51)		(0.87, 11.63)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.02		2.48					
95% CI of the risk ratio	(0.72, 5.71)		(0.89, 6.89)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.11		19.00					
95% CI of the absolute risk difference	(-6.47, 32.68)		(-3.11, 41.11)					
p-value	0.1747		0.0731					
p-value of Breslow-Day Test for Homogeneity [2]	0.9815		0.0642					

AMNOG Table S1.9.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Baseline GLP-1 Analogues (Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

System Organ Class Preferred Term	MGL-3196 80 mg (N=27) Patients n (%)	 Events n	MGL-3196 100 mg (N=22) Patients n (%)	 Events n	Placebo (N=39) Patients n (%)	 Events n	Overall (N=88) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	3 (11.1)	4	3 (13.6)	3	4 (10.3)	4	10 (11.4)	11
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.09		1.38					
95% CI of the odds ratio	(0.22, 5.33)		(0.28, 6.83)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08		1.33					
95% CI of the risk ratio	(0.26, 4.46)		(0.33, 5.41)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.85		3.38					
95% CI of the absolute risk difference	(-14.35, 16.06)		(-13.83, 20.59)					
p-value	0.9117		0.6908					
p-value of Breslow-Day Test for Homogeneity [2]	0.3130		0.6890					
Abdominal discomfort	0	0	0	0	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					

AMNOG Table S1.9.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Baseline GLP-1 Analogues (Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27)		MGL-3196 100 mg (N=22)		Placebo (N=39)		Overall (N=88)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
General disorders and administration site conditions	6 (22.2)	7	4 (18.2)	4	9 (23.1)	11	19 (21.6)	22
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95		0.74					
95% CI of the odds ratio	(0.29, 3.08)		(0.20, 2.76)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.96		0.79					
95% CI of the risk ratio	(0.39, 2.39)		(0.27, 2.26)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.85		-4.90					
95% CI of the absolute risk difference	(-21.37, 19.66)		(-25.74, 15.95)					
p-value	0.9351		0.6539					
p-value of Breslow-Day Test for Homogeneity [2]	0.5491		0.7600					
Skin and subcutaneous tissue disorders								
Pruritus	6 (22.2)	7	1 (4.5)	1	6 (15.4)	6	13 (14.8)	14
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.57		0.26					
95% CI of the odds ratio	(0.45, 5.52)		(0.03, 2.33)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.44		0.30					
95% CI of the risk ratio	(0.52, 4.00)		(0.04, 2.30)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.84		-10.84					
95% CI of the absolute risk difference	(-12.50, 26.18)		(-25.12, 3.44)					
p-value	0.4789		0.2022					
p-value of Breslow-Day Test for Homogeneity [2]	0.8109		0.3230					

AMNOG Table S1.9.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

System Organ Class Preferred Term	MGL-3196 80 mg (N=27) Patients n (%)	 Events n	MGL-3196 100 mg (N=22) Patients n (%)	 Events n	Placebo (N=39) Patients n (%)	 Events n	Overall (N=88) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	1 (3.7)	1	1 (4.5)	2	3 (7.7)	3	5 (5.7)	6
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.46		0.57					
95% CI of the odds ratio	(0.05, 4.69)		(0.06, 5.85)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48		0.59					
95% CI of the risk ratio	(0.05, 4.39)		(0.07, 5.34)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.99		-3.15					
95% CI of the absolute risk difference	(-14.97, 7.00)		(-15.22, 8.92)					
p-value	0.5043		0.6335					
p-value of Breslow-Day Test for Homogeneity [2]	0.3497		0.1096					
Renal and urinary disorders	1 (3.7)	2	6 (27.3)	6	5 (12.8)	6	12 (13.6)	14
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.26		2.55					
95% CI of the odds ratio	(0.03, 2.38)		(0.68, 9.62)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		2.13					
95% CI of the risk ratio	(0.04, 2.34)		(0.73, 6.17)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.12		14.45					
95% CI of the absolute risk difference	(-21.80, 3.57)		(-6.91, 35.82)					
p-value	0.2053		0.1586					
p-value of Breslow-Day Test for Homogeneity [2]	0.8653		0.3990					

AMNOG Table S1.9.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Baseline GLP-1 Analogues (Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27)		MGL-3196 100 mg (N=22)		Placebo (N=39)		Overall (N=88)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	0	0	0	0	4 (10.3)	4	4 (4.5)	4
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.14		0.18					
95% CI of the odds ratio	(0.01, 2.78)		(0.01, 3.41)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.16		0.19					
95% CI of the risk ratio	(0.01, 2.83)		(0.01, 3.43)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.46		-9.08					
95% CI of the absolute risk difference	(-20.42, 1.49)		(-20.54, 2.39)					
p-value	0.1411		0.1995					
p-value of Breslow-Day Test for Homogeneity [2]	0.1801		0.3354					

AMNOG Table S1.9.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Baseline GLP-1 Analogues (Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27)		MGL-3196 100 mg (N=22)		Placebo (N=39)		Overall (N=88)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Injury, poisoning and procedural complications								
Contusion	1 (3.7)	1	0	0	0	0	1 (1.1)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.70		NE					
95% CI of the absolute risk difference	(-3.42, 10.83)		NE					
p-value	0.2259		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.0345		NE					

AMNOG Table S1.9.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Baseline GLP-1 Analogues (Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140)		MGL-3196 100 mg (N=129)		Placebo (N=264)		Overall (N=533)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders								
Diarrhoea	36 (25.7)	60	39 (30.2)	55	44 (16.7)	54	119 (22.3)	169
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.73		2.17					
95% CI of the odds ratio	(1.05, 2.85)		(1.32, 3.56)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.54		1.81					
95% CI of the risk ratio	(1.04, 2.28)		(1.25, 2.64)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.05		13.57					
95% CI of the absolute risk difference	(0.53, 17.57)		(4.45, 22.68)					
p-value	0.0299		0.0020					
p-value of Breslow-Day Test for Homogeneity [2]	0.8712		0.0509					
Nausea	36 (25.7)	43	14 (10.9)	16	34 (12.9)	41	84 (15.8)	100
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.34		0.82					
95% CI of the odds ratio	(1.39, 3.95)		(0.43, 1.60)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.00		0.84					
95% CI of the risk ratio	(1.31, 3.04)		(0.47, 1.51)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	12.84		-2.03					
95% CI of the absolute risk difference	(4.54, 21.13)		(-8.74, 4.69)					
p-value	0.0012		0.5646					
p-value of Breslow-Day Test for Homogeneity [2]	0.9815		0.0642					

AMNOG Table S1.9.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Baseline GLP-1 Analogues (Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140)		MGL-3196 100 mg (N=129)		Placebo (N=264)		Overall (N=533)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders (cont.)								
Vomiting	17 (12.1)	18	6 (4.7)	6	13 (4.9)	14	36 (6.8)	38
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.67		0.94					
95% CI of the odds ratio	(1.26, 5.67)		(0.35, 2.54)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.47		0.94					
95% CI of the risk ratio	(1.23, 4.93)		(0.37, 2.43)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.22		-0.27					
95% CI of the absolute risk difference	(1.21, 13.23)		(-4.75, 4.20)					
p-value	0.0085		0.9057					
p-value of Breslow-Day Test for Homogeneity [2]	0.3130		0.6890					
Abdominal discomfort	1 (0.7)	1	3 (2.3)	4	13 (4.9)	14	17 (3.2)	19
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.14		0.46					
95% CI of the odds ratio	(0.02, 1.07)		(0.13, 1.64)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.15		0.47					
95% CI of the risk ratio	(0.02, 1.10)		(0.14, 1.63)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.21		-2.60					
95% CI of the absolute risk difference	(-7.17, -1.25)		(-6.28, 1.09)					
p-value	0.0277		0.2209					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.9.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Baseline GLP-1 Analogues (Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

System Organ Class Preferred Term	MGL-3196 80 mg (N=140) Patients n (%)	 Events n	MGL-3196 100 mg (N=129) Patients n (%)	 Events n	Placebo (N=264) Patients n (%)	 Events n	Overall (N=533) Patients n (%)	 Events n
General disorders and administration site conditions	29 (20.7)	45	25 (19.4)	35	76 (28.8)	93	130 (24.4)	173
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.65		0.59					
95% CI of the odds ratio	(0.40, 1.05)		(0.36, 0.99)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.72		0.67					
95% CI of the risk ratio	(0.49, 1.05)		(0.45, 1.00)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.07		-9.41					
95% CI of the absolute risk difference	(-16.73, 0.58)		(-18.15, -0.67)					
p-value	0.0783		0.0450					
p-value of Breslow-Day Test for Homogeneity [2]	0.5491		0.7600					
Skin and subcutaneous tissue disorders								
Pruritus	16 (11.4)	21	7 (5.4)	9	17 (6.4)	20	40 (7.5)	50
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.87		0.83					
95% CI of the odds ratio	(0.92, 3.84)		(0.34, 2.06)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.77		0.84					
95% CI of the risk ratio	(0.93, 3.40)		(0.36, 1.98)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.99		-1.01					
95% CI of the absolute risk difference	(-1.06, 11.03)		(-5.92, 3.89)					
p-value	0.0814		0.6937					
p-value of Breslow-Day Test for Homogeneity [2]	0.8109		0.3230					

AMNOG Table S1.9.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Baseline GLP-1 Analogues (Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140)		MGL-3196 100 mg (N=129)		Placebo (N=264)		Overall (N=533)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	7 (5.0)	7	15 (11.6)	18	9 (3.4)	11	31 (5.8)	36
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.49		3.73					
95% CI of the odds ratio	(0.54, 4.09)		(1.58, 8.77)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.47		3.41					
95% CI of the risk ratio	(0.56, 3.85)		(1.53, 7.58)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.59		8.22					
95% CI of the absolute risk difference	(-2.63, 5.81)		(2.27, 14.17)					
p-value	0.4353		0.0014					
p-value of Breslow-Day Test for Homogeneity [2]	0.3497		0.1096					
Renal and urinary disorders	4 (2.9)	4	14 (10.9)	18	22 (8.3)	27	40 (7.5)	49
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.32		1.34					
95% CI of the odds ratio	(0.11, 0.96)		(0.66, 2.71)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.34		1.30					
95% CI of the risk ratio	(0.12, 0.98)		(0.69, 2.46)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.48		2.52					
95% CI of the absolute risk difference	(-9.80, -1.15)		(-3.80, 8.84)					
p-value	0.0328		0.4162					
p-value of Breslow-Day Test for Homogeneity [2]	0.8653		0.3990					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.9.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Baseline GLP-1 Analogues (Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140)		MGL-3196 100 mg (N=129)		Placebo (N=264)		Overall (N=533)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	7 (5.0)	8	4 (3.1)	4	20 (7.6)	24	31 (5.8)	36
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.64		0.39					
95% CI of the odds ratio	(0.26, 1.56)		(0.13, 1.17)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.66		0.41					
95% CI of the risk ratio	(0.29, 1.52)		(0.14, 1.17)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.58		-4.47					
95% CI of the absolute risk difference	(-7.39, 2.24)		(-8.85, -0.10)					
p-value	0.3239		0.0819					
p-value of Breslow-Day Test for Homogeneity [2]	0.1801		0.3354					

AMNOG Table S1.9.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Baseline GLP-1 Analogues (Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140)		MGL-3196 100 mg (N=129)		Placebo (N=264)		Overall (N=533)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Injury, poisoning and procedural complications								
Contusion	1 (0.7)	1	0	0	10 (3.8)	14	11 (2.1)	15
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.18		0.09					
95% CI of the odds ratio	(0.02, 1.44)		(0.01, 1.61)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.19		0.10					
95% CI of the risk ratio	(0.02, 1.46)		(0.01, 1.64)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.07		-3.58					
95% CI of the absolute risk difference	(-5.77, -0.38)		(-6.16, -1.00)					
p-value	0.0709		0.0423					
p-value of Breslow-Day Test for Homogeneity [2]	0.0345		NE					

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Events n:				
Total TEAEs	175	171	308	654
Total Serious TEAEs	13	9	15	37
Total TEAEs Leading to Discontinuation of Study Drug	5	4	5	14
Total TEAEs Related to Study Drug	21	19	39	79
Total TEAEs >= Grade 3 Severity	12	12	13	37
Patients n (%):				
Any TEAE	19 (100)	14 (87.5)	40 (93.0)	73 (93.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.53		
95% CI of the odds ratio	NE	(0.08, 3.47)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08	0.94		
95% CI of the risk ratio	(0.99, 1.17)	(0.77, 1.15)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.98	-5.52		
95% CI of the absolute risk difference	(-0.64, 14.59)	(-23.43, 12.38)		
p-value	0.2379	0.4983		
p-value of Breslow-Day Test for Homogeneity [2]	0.2656	0.6959		
Any Serious TEAE	4 (21.1)	4 (25.0)	7 (16.3)	15 (19.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.37	1.71		
95% CI of the odds ratio	(0.35, 5.39)	(0.43, 6.89)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.29	1.54		
95% CI of the risk ratio	(0.43, 3.90)	(0.52, 4.55)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.77	8.72		
95% CI of the absolute risk difference	(-16.62, 26.17)	(-15.19, 32.64)		
p-value	0.6501	0.4445		
p-value of Breslow-Day Test for Homogeneity [2]	0.2350	0.4009		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Any TEAEs >= Grade 3 Severity	5 (26.3)	4 (25.0)	6 (14.0)	15 (19.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.20	2.06		
95% CI of the odds ratio	(0.58, 8.38)	(0.50, 8.53)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.89	1.79		
95% CI of the risk ratio	(0.66, 5.43)	(0.58, 5.53)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	12.36	11.05		
95% CI of the absolute risk difference	(-9.98, 34.71)	(-12.56, 34.66)		
p-value	0.2401	0.3147		
p-value of Breslow-Day Test for Homogeneity [2]	0.0584	0.2428		
Any TEAEs <= Grade 2 Severity	19 (100)	14 (87.5)	40 (93.0)	73 (93.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.53		
95% CI of the odds ratio	NE	(0.08, 3.47)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08	0.94		
95% CI of the risk ratio	(0.99, 1.17)	(0.77, 1.15)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.98	-5.52		
95% CI of the absolute risk difference	(-0.64, 14.59)	(-23.43, 12.38)		
p-value	0.2379	0.4983		
p-value of Breslow-Day Test for Homogeneity [2]	0.2182	0.8293		
Any TEAEs leading to Study-Drug Discontinuation	2 (10.5)	3 (18.8)	4 (9.3)	9 (11.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.15	2.25		
95% CI of the odds ratio	(0.19, 6.87)	(0.44, 11.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13	2.02		
95% CI of the risk ratio	(0.23, 5.66)	(0.51, 8.03)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.22	9.45		
95% CI of the absolute risk difference	(-15.08, 17.53)	(-11.56, 30.45)		
p-value	0.8805	0.3184		
p-value of Breslow-Day Test for Homogeneity [2]	0.9189	0.7993		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Any TEAEs leading to Study Discontinuation	1 (5.3)	3 (18.8)	3 (7.0)	7 (9.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.74	3.08		
95% CI of the odds ratio	(0.07, 7.62)	(0.55, 17.15)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	2.69		
95% CI of the risk ratio	(0.08, 6.79)	(0.60, 11.97)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.71	11.77		
95% CI of the absolute risk difference	(-14.31, 10.89)	(-8.81, 32.36)		
p-value	0.8001	0.1835		
p-value of Breslow-Day Test for Homogeneity [2]	0.7042	0.6648		
Any Fatal TEAEs	1 (5.3)	1 (6.3)	0	2 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.05	8.42		
95% CI of the odds ratio	(0.27, 181.29)	(0.33, 217.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	6.60	7.76		
95% CI of the risk ratio	(0.28, 155.05)	(0.33, 181.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.36	7.69		
95% CI of the absolute risk difference	(-5.60, 18.32)	(-6.15, 21.53)		
p-value	0.1750	0.1306		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	0.1202		
Any Treatment-related TEAE	10 (52.6)	5 (31.3)	17 (39.5)	32 (41.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.70	0.70		
95% CI of the odds ratio	(0.57, 5.05)	(0.21, 2.36)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	0.79		
95% CI of the risk ratio	(0.76, 2.34)	(0.35, 1.79)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.10	-8.28		
95% CI of the absolute risk difference	(-13.69, 39.88)	(-35.29, 18.72)		
p-value	0.3376	0.5585		
p-value of Breslow-Day Test for Homogeneity [2]	0.9237	0.2057		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Any Treatment-related Serious TEAE	0	0	1 (2.3)	1 (1.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.33	-2.33		
95% CI of the absolute risk difference	(-6.83, 2.18)	(-6.83, 2.18)		
p-value	0.5028	0.5384		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (5.3)	0	1 (2.3)	2 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.33	NE		
95% CI of the odds ratio	(0.14, 39.39)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.26	NE		
95% CI of the risk ratio	(0.15, 34.31)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.94	-2.33		
95% CI of the absolute risk difference	(-8.07, 13.94)	(-6.83, 2.18)		
p-value	0.5462	0.5384		
p-value of Breslow-Day Test for Homogeneity [2]	0.8894	0.2243		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	1 (6.3)	2 (4.7)	3 (3.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.37		
95% CI of the odds ratio	NE	(0.12, 16.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.34		
95% CI of the risk ratio	NE	(0.13, 13.82)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.65	1.60		
95% CI of the absolute risk difference	(-10.95, 1.64)	(-11.83, 15.03)		
p-value	0.3393	0.8037		
p-value of Breslow-Day Test for Homogeneity [2]	0.4194	0.6377		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	1 (6.3)	2 (4.7)	3 (3.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.37		
95% CI of the odds ratio	NE	(0.12, 16.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.34		
95% CI of the risk ratio	NE	(0.13, 13.82)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.65	1.60		
95% CI of the absolute risk difference	(-10.95, 1.64)	(-11.83, 15.03)		
p-value	0.3393	0.8037		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4523		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	2 (10.5)	3 (18.8)	5 (11.6)	10 (12.8)
Grade 2	12 (63.2)	7 (43.8)	29 (67.4)	48 (61.5)
Grade 3	4 (21.1)	3 (18.8)	5 (11.6)	12 (15.4)
Grade 4	0	0	1 (2.3)	1 (1.3)
Grade 5	1 (5.3)	1 (6.3)	0	2 (2.6)

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	4 (21.1)	3 (18.8)	10 (23.3)	17 (21.8)
Grade 2	5 (26.3)	2 (12.5)	6 (14.0)	13 (16.7)
Grade 3	1 (5.3)	0	0	1 (1.3)
Grade 4	0	0	1 (2.3)	1 (1.3)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (5.3)	1 (6.3)	0	2 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.05	8.42		
95% CI of the odds ratio	(0.27, 181.29)	(0.33, 217.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	6.60	7.76		
95% CI of the risk ratio	(0.28, 155.05)	(0.33, 181.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	6.36	7.69		
95% CI of the absolute risk difference	(-5.60, 18.32)	(-6.15, 21.53)		
p-value	0.1750	0.1306		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	0.1202		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (6.3)	0	1 (1.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.42		
95% CI of the odds ratio	NE	(0.33, 217.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	7.76		
95% CI of the risk ratio	NE	(0.33, 181.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	7.69		
95% CI of the absolute risk difference	NE	(-6.15, 21.53)		
p-value	NE	0.1306		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (5.3)	0	0	1 (1.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.05	NE		
95% CI of the odds ratio	(0.27, 181.29)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	6.60	NE		
95% CI of the risk ratio	(0.28, 155.05)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	6.36	NE		
95% CI of the absolute risk difference	(-5.60, 18.32)	NE		
p-value	0.1750	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (5.3)	1 (6.3)	0	2 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.05	8.42		
95% CI of the odds ratio	(0.27, 181.29)	(0.33, 217.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	6.60	7.76		
95% CI of the risk ratio	(0.28, 155.05)	(0.33, 181.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	6.36	7.69		
95% CI of the absolute risk difference	(-5.60, 18.32)	(-6.15, 21.53)		
p-value	0.1750	0.1306		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	0.1202		
Other MACE AE – Adjudicated Event	0	1 (6.3)	1 (2.3)	2 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.80		
95% CI of the odds ratio	NE	(0.16, 47.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.69		
95% CI of the risk ratio	NE	(0.18, 40.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.33	3.92		
95% CI of the absolute risk difference	(-6.83, 2.18)	(-8.76, 16.61)		
p-value	0.5028	0.4590		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1219		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (6.3)	1 (2.3)	2 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.80		
95% CI of the odds ratio	NE	(0.16, 47.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.69		
95% CI of the risk ratio	NE	(0.18, 40.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.33	3.92		
95% CI of the absolute risk difference	(-6.83, 2.18)	(-8.76, 16.61)		
p-value	0.5028	0.4590		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1900		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (6.3)	1 (2.3)	2 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.80		
95% CI of the odds ratio	NE	(0.16, 47.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.69		
95% CI of the risk ratio	NE	(0.18, 40.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.33	3.92		
95% CI of the absolute risk difference	(-6.83, 2.18)	(-8.76, 16.61)		
p-value	0.5028	0.4590		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1900		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Events n:				
Total TEAEs	1024	851	1849	3724
Total Serious TEAEs	16	23	81	120
Total TEAEs Leading to Discontinuation of Study Drug	13	16	20	49
Total TEAEs Related to Study Drug	134	107	120	361
Total TEAEs >= Grade 3 Severity	22	33	93	148
Patients n (%):				
Any TEAE	139 (93.9)	124 (91.9)	243 (93.5)	506 (93.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08	0.79		
95% CI of the odds ratio	(0.47, 2.49)	(0.36, 1.74)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.98		
95% CI of the risk ratio	(0.95, 1.06)	(0.93, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.46	-1.61		
95% CI of the absolute risk difference	(-4.43, 5.34)	(-7.12, 3.90)		
p-value	0.8557	0.5543		
p-value of Breslow-Day Test for Homogeneity [2]	0.2656	0.6959		
Any Serious TEAE	12 (8.1)	17 (12.6)	36 (13.8)	65 (12.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.55	0.90		
95% CI of the odds ratio	(0.28, 1.09)	(0.48, 1.66)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	0.91		
95% CI of the risk ratio	(0.31, 1.09)	(0.53, 1.56)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.74	-1.25		
95% CI of the absolute risk difference	(-11.82, 0.34)	(-8.25, 5.74)		
p-value	0.0837	0.7288		
p-value of Breslow-Day Test for Homogeneity [2]	0.2350	0.4009		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Any TEAEs >= Grade 3 Severity	17 (11.5)	22 (16.3)	49 (18.8)	88 (16.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56	0.84		
95% CI of the odds ratio	(0.31, 1.01)	(0.48, 1.46)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.61	0.86		
95% CI of the risk ratio	(0.36, 1.02)	(0.55, 1.37)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.36	-2.55		
95% CI of the absolute risk difference	(-14.36, -0.36)	(-10.39, 5.29)		
p-value	0.0523	0.5313		
p-value of Breslow-Day Test for Homogeneity [2]	0.0584	0.2428		
Any TEAEs <= Grade 2 Severity	137 (92.6)	122 (90.4)	243 (93.5)	502 (92.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87	0.66		
95% CI of the odds ratio	(0.40, 1.91)	(0.31, 1.40)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	0.97		
95% CI of the risk ratio	(0.94, 1.05)	(0.91, 1.03)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.89	-3.09		
95% CI of the absolute risk difference	(-6.08, 4.29)	(-8.90, 2.72)		
p-value	0.7313	0.2714		
p-value of Breslow-Day Test for Homogeneity [2]	0.2182	0.8293		
Any TEAEs leading to Study-Drug Discontinuation	10 (6.8)	15 (11.1)	17 (6.5)	42 (7.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04	1.79		
95% CI of the odds ratio	(0.46, 2.33)	(0.86, 3.70)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03	1.70		
95% CI of the risk ratio	(0.49, 2.20)	(0.88, 3.30)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.22	4.57		
95% CI of the absolute risk difference	(-4.82, 5.26)	(-1.52, 10.67)		
p-value	0.9320	0.1142		
p-value of Breslow-Day Test for Homogeneity [2]	0.9189	0.7993		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Any TEAEs leading to Study Discontinuation	2 (1.4)	8 (5.9)	8 (3.1)	18 (3.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43	1.98		
95% CI of the odds ratio	(0.09, 2.06)	(0.73, 5.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	1.93		
95% CI of the risk ratio	(0.09, 2.04)	(0.74, 5.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.73	2.85		
95% CI of the absolute risk difference	(-4.53, 1.08)	(-1.65, 7.35)		
p-value	0.2785	0.1731		
p-value of Breslow-Day Test for Homogeneity [2]	0.7042	0.6648		
Any Fatal TEAEs	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.14, 0.37)	(-1.14, 0.37)		
p-value	0.4500	0.4706		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	0.1202		
Any Treatment-related TEAE	59 (39.9)	50 (37.0)	70 (26.9)	179 (33.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	1.60		
95% CI of the odds ratio	(1.17, 2.76)	(1.02, 2.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.48	1.38		
95% CI of the risk ratio	(1.12, 1.96)	(1.02, 1.85)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	12.94	10.11		
95% CI of the absolute risk difference	(3.39, 22.50)	(0.35, 19.88)		
p-value	0.0069	0.0382		
p-value of Breslow-Day Test for Homogeneity [2]	0.9237	0.2057		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (0.7)	3 (2.2)	1 (0.4)	5 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.76	5.89		
95% CI of the odds ratio	(0.11, 28.38)	(0.61, 57.14)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.76	5.78		
95% CI of the risk ratio	(0.11, 27.88)	(0.61, 55.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.29	1.84		
95% CI of the absolute risk difference	(-1.23, 1.81)	(-0.76, 4.44)		
p-value	0.6857	0.0836		
p-value of Breslow-Day Test for Homogeneity [2]	0.8894	0.2243		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	3 (2.0)	9 (6.7)	7 (2.7)	19 (3.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	2.58		
95% CI of the odds ratio	(0.19, 2.94)	(0.94, 7.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	2.48		
95% CI of the risk ratio	(0.20, 2.87)	(0.94, 6.50)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.67	3.97		
95% CI of the absolute risk difference	(-3.67, 2.34)	(-0.67, 8.62)		
p-value	0.6761	0.0574		
p-value of Breslow-Day Test for Homogeneity [2]	0.4194	0.6377		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	6 (4.4)	3 (1.2)	9 (1.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.98		
95% CI of the odds ratio	NE	(0.98, 16.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.85		
95% CI of the risk ratio	NE	(0.98, 15.16)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.15	3.29		
95% CI of the absolute risk difference	(-2.45, 0.14)	(-0.42, 7.00)		
p-value	0.1896	0.0376		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4523		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	37 (25.0)	23 (17.0)	64 (24.6)	124 (22.8)
Grade 2	85 (57.4)	79 (58.5)	130 (50.0)	294 (54.1)
Grade 3	17 (11.5)	22 (16.3)	42 (16.2)	81 (14.9)
Grade 4	0	0	6 (2.3)	6 (1.1)
Grade 5	0	0	1 (0.4)	1 (0.2)

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	37 (25.0)	26 (19.3)	43 (16.5)	106 (19.5)
Grade 2	21 (14.2)	21 (15.6)	26 (10.0)	68 (12.5)
Grade 3	1 (0.7)	3 (2.2)	1 (0.4)	5 (0.9)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.14, 0.37)	(-1.14, 0.37)		
p-value	0.4500	0.4706		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	0.1202		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.14, 0.37)	(-1.14, 0.37)		
p-value	0.4500	0.4706		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.14, 0.37)	(-1.14, 0.37)		
p-value	0.4500	0.4706		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	0.1202		
Other MACE AE – Adjudicated Event	0	0	3 (1.2)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.15	-1.15		
95% CI of the absolute risk difference	(-2.45, 0.14)	(-2.45, 0.14)		
p-value	0.1896	0.2103		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1219		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (0.8)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.77	-0.77		
95% CI of the absolute risk difference	(-1.83, 0.29)	(-1.83, 0.29)		
p-value	0.2848	0.3070		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1900		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.14, 0.37)	(-1.14, 0.37)		
p-value	0.4500	0.4706		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (0.8)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.77	-0.77		
95% CI of the absolute risk difference	(-1.83, 0.29)	(-1.83, 0.29)		
p-value	0.2848	0.3070		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1900		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.10.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Events n:				
Total TEAEs	173	171	305	649
Total Serious TEAEs	13	9	15	37
Total TEAEs Leading to Discontinuation of Study Drug	5	4	4	13
Total TEAEs Related to Study Drug	21	19	39	79
Total TEAEs >= Grade 3 Severity	11	12	12	35
Patients n (%):				
Any TEAE	19 (100)	14 (87.5)	40 (93.0)	73 (93.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.53		
95% CI of the odds ratio	NE	(0.08, 3.47)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08	0.94		
95% CI of the risk ratio	(0.99, 1.17)	(0.77, 1.15)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.98	-5.52		
95% CI of the absolute risk difference	(-0.64, 14.59)	(-23.43, 12.38)		
p-value	0.2379	0.4983		
p-value of Breslow-Day Test for Homogeneity [2]	0.2663	0.6113		
Any Serious TEAE	4 (21.1)	4 (25.0)	7 (16.3)	15 (19.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.37	1.71		
95% CI of the odds ratio	(0.35, 5.39)	(0.43, 6.89)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.29	1.54		
95% CI of the risk ratio	(0.43, 3.90)	(0.52, 4.55)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.77	8.72		
95% CI of the absolute risk difference	(-16.62, 26.17)	(-15.19, 32.64)		
p-value	0.6501	0.4445		
p-value of Breslow-Day Test for Homogeneity [2]	0.2350	0.4009		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Any TEAEs >= Grade 3 Severity	4 (21.1)	4 (25.0)	5 (11.6)	13 (16.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.03	2.53		
95% CI of the odds ratio	(0.48, 8.59)	(0.58, 10.98)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81	2.15		
95% CI of the risk ratio	(0.55, 6.00)	(0.66, 7.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.42	13.37		
95% CI of the absolute risk difference	(-11.26, 30.11)	(-9.91, 36.65)		
p-value	0.3314	0.2041		
p-value of Breslow-Day Test for Homogeneity [2]	0.0754	0.1567		
Any TEAEs <= Grade 2 Severity	19 (100)	14 (87.5)	40 (93.0)	73 (93.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.53		
95% CI of the odds ratio	NE	(0.08, 3.47)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08	0.94		
95% CI of the risk ratio	(0.99, 1.17)	(0.77, 1.15)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.98	-5.52		
95% CI of the absolute risk difference	(-0.64, 14.59)	(-23.43, 12.38)		
p-value	0.2379	0.4983		
p-value of Breslow-Day Test for Homogeneity [2]	0.2227	0.7397		
Any TEAEs leading to Study-Drug Discontinuation	2 (10.5)	3 (18.8)	3 (7.0)	8 (10.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.57	3.08		
95% CI of the odds ratio	(0.24, 10.25)	(0.55, 17.15)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.51	2.69		
95% CI of the risk ratio	(0.27, 8.31)	(0.60, 11.97)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.55	11.77		
95% CI of the absolute risk difference	(-12.21, 19.31)	(-8.81, 32.36)		
p-value	0.6361	0.1835		
p-value of Breslow-Day Test for Homogeneity [2]	0.6334	0.6641		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Any TEAEs leading to Study Discontinuation	1 (5.3)	3 (18.8)	3 (7.0)	7 (9.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.74	3.08		
95% CI of the odds ratio	(0.07, 7.62)	(0.55, 17.15)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	2.69		
95% CI of the risk ratio	(0.08, 6.79)	(0.60, 11.97)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.71	11.77		
95% CI of the absolute risk difference	(-14.31, 10.89)	(-8.81, 32.36)		
p-value	0.8001	0.1835		
p-value of Breslow-Day Test for Homogeneity [2]	0.7042	0.6648		
Any Fatal TEAEs	1 (5.3)	1 (6.3)	0	2 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.05	8.42		
95% CI of the odds ratio	(0.27, 181.29)	(0.33, 217.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	6.60	7.76		
95% CI of the risk ratio	(0.28, 155.05)	(0.33, 181.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.36	7.69		
95% CI of the absolute risk difference	(-5.60, 18.32)	(-6.15, 21.53)		
p-value	0.1750	0.1306		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	0.1202		
Any Treatment-related TEAE	10 (52.6)	5 (31.3)	17 (39.5)	32 (41.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.70	0.70		
95% CI of the odds ratio	(0.57, 5.05)	(0.21, 2.36)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33	0.79		
95% CI of the risk ratio	(0.76, 2.34)	(0.35, 1.79)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.10	-8.28		
95% CI of the absolute risk difference	(-13.69, 39.88)	(-35.29, 18.72)		
p-value	0.3376	0.5585		
p-value of Breslow-Day Test for Homogeneity [2]	0.8976	0.1952		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Any Treatment-related Serious TEAE	0	0	1 (2.3)	1 (1.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.33	-2.33		
95% CI of the absolute risk difference	(-6.83, 2.18)	(-6.83, 2.18)		
p-value	0.5028	0.5384		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (5.3)	0	1 (2.3)	2 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.33	NE		
95% CI of the odds ratio	(0.14, 39.39)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.26	NE		
95% CI of the risk ratio	(0.15, 34.31)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.94	-2.33		
95% CI of the absolute risk difference	(-8.07, 13.94)	(-6.83, 2.18)		
p-value	0.5462	0.5384		
p-value of Breslow-Day Test for Homogeneity [2]	0.3365	0.2243		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	1 (6.3)	2 (4.7)	3 (3.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.37		
95% CI of the odds ratio	NE	(0.12, 16.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.34		
95% CI of the risk ratio	NE	(0.13, 13.82)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.65	1.60		
95% CI of the absolute risk difference	(-10.95, 1.64)	(-11.83, 15.03)		
p-value	0.3393	0.8037		
p-value of Breslow-Day Test for Homogeneity [2]	0.4194	0.6377		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	1 (6.3)	2 (4.7)	3 (3.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.37		
95% CI of the odds ratio	NE	(0.12, 16.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.34		
95% CI of the risk ratio	NE	(0.13, 13.82)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.65	1.60		
95% CI of the absolute risk difference	(-10.95, 1.64)	(-11.83, 15.03)		
p-value	0.3393	0.8037		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4523		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	2 (10.5)	3 (18.8)	5 (11.6)	10 (12.8)
Grade 2	13 (68.4)	7 (43.8)	30 (69.8)	50 (64.1)
Grade 3	3 (15.8)	3 (18.8)	4 (9.3)	10 (12.8)
Grade 4	0	0	1 (2.3)	1 (1.3)
Grade 5	1 (5.3)	1 (6.3)	0	2 (2.6)

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	4 (21.1)	3 (18.8)	10 (23.3)	17 (21.8)
Grade 2	5 (26.3)	2 (12.5)	6 (14.0)	13 (16.7)
Grade 3	1 (5.3)	0	0	1 (1.3)
Grade 4	0	0	1 (2.3)	1 (1.3)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (5.3)	1 (6.3)	0	2 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.05	8.42		
95% CI of the odds ratio	(0.27, 181.29)	(0.33, 217.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	6.60	7.76		
95% CI of the risk ratio	(0.28, 155.05)	(0.33, 181.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	6.36	7.69		
95% CI of the absolute risk difference	(-5.60, 18.32)	(-6.15, 21.53)		
p-value	0.1750	0.1306		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	0.1202		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (6.3)	0	1 (1.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.42		
95% CI of the odds ratio	NE	(0.33, 217.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	7.76		
95% CI of the risk ratio	NE	(0.33, 181.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	7.69		
95% CI of the absolute risk difference	NE	(-6.15, 21.53)		
p-value	NE	0.1306		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	1 (5.3)	0	0	1 (1.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.05	NE		
95% CI of the odds ratio	(0.27, 181.29)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	6.60	NE		
95% CI of the risk ratio	(0.28, 155.05)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.36	NE		
95% CI of the absolute risk difference	(-5.60, 18.32)	NE		
p-value	0.1750	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	NE		
Serious 3-PT MACE AE - Adjudicated Event	1 (5.3)	1 (6.3)	0	2 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	7.05	8.42		
95% CI of the odds ratio	(0.27, 181.29)	(0.33, 217.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	6.60	7.76		
95% CI of the risk ratio	(0.28, 155.05)	(0.33, 181.43)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.36	7.69		
95% CI of the absolute risk difference	(-5.60, 18.32)	(-6.15, 21.53)		
p-value	0.1750	0.1306		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	0.1202		
Other MACE AE - Adjudicated Event	0	1 (6.3)	1 (2.3)	2 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.80		
95% CI of the odds ratio	NE	(0.16, 47.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.69		
95% CI of the risk ratio	NE	(0.18, 40.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.33	3.92		
95% CI of the absolute risk difference	(-6.83, 2.18)	(-8.76, 16.61)		
p-value	0.5028	0.4590		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1219		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (6.3)	1 (2.3)	2 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.80		
95% CI of the odds ratio	NE	(0.16, 47.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.69		
95% CI of the risk ratio	NE	(0.18, 40.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.33	3.92		
95% CI of the absolute risk difference	(-6.83, 2.18)	(-8.76, 16.61)		
p-value	0.5028	0.4590		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1900		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (6.3)	1 (2.3)	2 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.80		
95% CI of the odds ratio	NE	(0.16, 47.63)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.69		
95% CI of the risk ratio	NE	(0.18, 40.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.33	3.92		
95% CI of the absolute risk difference	(-6.83, 2.18)	(-8.76, 16.61)		
p-value	0.5028	0.4590		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1900		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19) n (%)	MGL-3196 100 mg (N=16) n (%)	Placebo (N=43) n (%)	Overall (N=78) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Events n:				
Total TEAEs	1013	843	1828	3684
Total Serious TEAEs	16	23	81	120
Total TEAEs Leading to Discontinuation of Study Drug	10	14	16	40
Total TEAEs Related to Study Drug	133	107	119	359
Total TEAEs >= Grade 3 Severity	20	32	91	143
Patients n (%):				
Any TEAE	138 (93.2)	124 (91.9)	241 (92.7)	503 (92.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.09	0.89		
95% CI of the odds ratio	(0.49, 2.41)	(0.41, 1.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	0.99		
95% CI of the risk ratio	(0.95, 1.06)	(0.93, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.55	-0.84		
95% CI of the absolute risk difference	(-4.58, 5.69)	(-6.44, 4.75)		
p-value	0.8351	0.7649		
p-value of Breslow-Day Test for Homogeneity [2]	0.2663	0.6113		
Any Serious TEAE	12 (8.1)	17 (12.6)	36 (13.8)	65 (12.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.55	0.90		
95% CI of the odds ratio	(0.28, 1.09)	(0.48, 1.66)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	0.91		
95% CI of the risk ratio	(0.31, 1.09)	(0.53, 1.56)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.74	-1.25		
95% CI of the absolute risk difference	(-11.82, 0.34)	(-8.25, 5.74)		
p-value	0.0837	0.7288		
p-value of Breslow-Day Test for Homogeneity [2]	0.2350	0.4009		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Any TEAEs >= Grade 3 Severity	15 (10.1)	21 (15.6)	47 (18.1)	83 (15.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	0.83		
95% CI of the odds ratio	(0.27, 0.95)	(0.48, 1.47)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56	0.86		
95% CI of the risk ratio	(0.33, 0.97)	(0.54, 1.38)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.94	-2.52		
95% CI of the absolute risk difference	(-14.69, -1.19)	(-10.22, 5.18)		
p-value	0.0317	0.5290		
p-value of Breslow-Day Test for Homogeneity [2]	0.0754	0.1567		
Any TEAEs <= Grade 2 Severity	136 (91.9)	122 (90.4)	241 (92.7)	499 (91.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89	0.74		
95% CI of the odds ratio	(0.42, 1.90)	(0.35, 1.55)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	0.97		
95% CI of the risk ratio	(0.93, 1.05)	(0.91, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.80	-2.32		
95% CI of the absolute risk difference	(-6.22, 4.62)	(-8.22, 3.57)		
p-value	0.7692	0.4224		
p-value of Breslow-Day Test for Homogeneity [2]	0.2227	0.7397		
Any TEAEs leading to Study-Drug Discontinuation	7 (4.7)	13 (9.6)	13 (5.0)	33 (6.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.94	2.02		
95% CI of the odds ratio	(0.37, 2.42)	(0.91, 4.50)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	1.93		
95% CI of the risk ratio	(0.39, 2.32)	(0.92, 4.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.27	4.63		
95% CI of the absolute risk difference	(-4.60, 4.06)	(-1.01, 10.27)		
p-value	0.9032	0.0784		
p-value of Breslow-Day Test for Homogeneity [2]	0.6334	0.6641		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Any TEAEs leading to Study Discontinuation	2 (1.4)	8 (5.9)	8 (3.1)	18 (3.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.43	1.98		
95% CI of the odds ratio	(0.09, 2.06)	(0.73, 5.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	1.93		
95% CI of the risk ratio	(0.09, 2.04)	(0.74, 5.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.73	2.85		
95% CI of the absolute risk difference	(-4.53, 1.08)	(-1.65, 7.35)		
p-value	0.2785	0.1731		
p-value of Breslow-Day Test for Homogeneity [2]	0.7042	0.6648		
Any Fatal TEAEs	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.14, 0.37)	(-1.14, 0.37)		
p-value	0.4500	0.4706		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	0.1202		
Any Treatment-related TEAE	59 (39.9)	50 (37.0)	69 (26.5)	178 (32.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.84	1.63		
95% CI of the odds ratio	(1.19, 2.82)	(1.04, 2.54)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	1.40		
95% CI of the risk ratio	(1.13, 1.99)	(1.04, 1.88)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.33	10.50		
95% CI of the absolute risk difference	(3.79, 22.87)	(0.74, 20.25)		
p-value	0.0053	0.0310		
p-value of Breslow-Day Test for Homogeneity [2]	0.8976	0.1952		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	3 (2.2)	1 (0.4)	4 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.89		
95% CI of the odds ratio	NE	(0.61, 57.14)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	5.78		
95% CI of the risk ratio	NE	(0.61, 55.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.38	1.84		
95% CI of the absolute risk difference	(-1.14, 0.37)	(-0.76, 4.44)		
p-value	0.4500	0.0836		
p-value of Breslow-Day Test for Homogeneity [2]	0.3365	0.2243		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	3 (2.0)	9 (6.7)	7 (2.7)	19 (3.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	2.58		
95% CI of the odds ratio	(0.19, 2.94)	(0.94, 7.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	2.48		
95% CI of the risk ratio	(0.20, 2.87)	(0.94, 6.50)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.67	3.97		
95% CI of the absolute risk difference	(-3.67, 2.34)	(-0.67, 8.62)		
p-value	0.6761	0.0574		
p-value of Breslow-Day Test for Homogeneity [2]	0.4194	0.6377		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	6 (4.4)	3 (1.2)	9 (1.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.98		
95% CI of the odds ratio	NE	(0.98, 16.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.85		
95% CI of the risk ratio	NE	(0.98, 15.16)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.15	3.29		
95% CI of the absolute risk difference	(-2.45, 0.14)	(-0.42, 7.00)		
p-value	0.1896	0.0376		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4523		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	36 (24.3)	24 (17.8)	65 (25.0)	125 (23.0)
Grade 2	87 (58.8)	79 (58.5)	129 (49.6)	295 (54.3)
Grade 3	15 (10.1)	21 (15.6)	40 (15.4)	76 (14.0)
Grade 4	0	0	6 (2.3)	6 (1.1)
Grade 5	0	0	1 (0.4)	1 (0.2)

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	37 (25.0)	26 (19.3)	42 (16.2)	105 (19.3)
Grade 2	22 (14.9)	21 (15.6)	26 (10.0)	69 (12.7)
Grade 3	0	3 (2.2)	1 (0.4)	4 (0.7)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.14, 0.37)	(-1.14, 0.37)		
p-value	0.4500	0.4706		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	0.1202		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.14, 0.37)	(-1.14, 0.37)		
p-value	0.4500	0.4706		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.14, 0.37)	(-1.14, 0.37)		
p-value	0.4500	0.4706		
p-value of Breslow-Day Test for Homogeneity [2]	0.1286	0.1202		
Other MACE AE – Adjudicated Event	0	0	3 (1.2)	3 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.15	-1.15		
95% CI of the absolute risk difference	(-2.45, 0.14)	(-2.45, 0.14)		
p-value	0.1896	0.2103		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1219		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (0.8)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.77	-0.77		
95% CI of the absolute risk difference	(-1.83, 0.29)	(-1.83, 0.29)		
p-value	0.2848	0.3070		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1900		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.14, 0.37)	(-1.14, 0.37)		
p-value	0.4500	0.4706		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (0.8)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.77	-0.77		
95% CI of the absolute risk difference	(-1.83, 0.29)	(-1.83, 0.29)		
p-value	0.2848	0.3070		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1900		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.10.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148) n (%)	MGL-3196 100 mg (N=135) n (%)	Placebo (N=260) n (%)	Overall (N=543) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.10.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Thyroxine at Baseline
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.

AMNOG Table S1.10.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Thyroxine at Baseline (Label Population)

Thyroxine at Baseline: Yes

System Organ Class Preferred Term	MGL-3196 80 mg (N=19) Patients n (%)	 Events n	MGL-3196 100 mg (N=16) Patients n (%)	 Events n	Placebo (N=43) Patients n (%)	 Events n	Overall (N=78) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	9 (47.4)	14	7 (43.8)	14	6 (14.0)	6	22 (28.2)	34
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	5.55		4.80					
95% CI of the odds ratio	(1.59, 19.31)		(1.29, 17.80)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.39		3.14					
95% CI of the risk ratio	(1.41, 8.19)		(1.24, 7.92)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	33.41		29.80					
95% CI of the absolute risk difference	(8.69, 58.14)		(3.37, 56.22)					
p-value	0.0046		0.0141					
p-value of Breslow-Day Test for Homogeneity [2]	0.0463		0.3410					
Nausea	4 (21.1)	4	6 (37.5)	8	5 (11.6)	6	15 (19.2)	18
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.03		4.56					
95% CI of the odds ratio	(0.48, 8.59)		(1.15, 18.06)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.81		3.23					
95% CI of the risk ratio	(0.55, 6.00)		(1.14, 9.11)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.42		25.87					
95% CI of the absolute risk difference	(-11.26, 30.11)		(0.29, 51.46)					
p-value	0.3314		0.0233					
p-value of Breslow-Day Test for Homogeneity [2]	0.8378		0.0230					

AMNOG Table S1.10.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

System Organ Class Preferred Term	MGL-3196 80 mg (N=19) Patients n (%)	 Events n	MGL-3196 100 mg (N=16) Patients n (%)	 Events n	Placebo (N=43) Patients n (%)	 Events n	Overall (N=78) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	2 (10.5)	3	3 (18.8)	3	4 (9.3)	5	9 (11.5)	11
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.15		2.25					
95% CI of the odds ratio	(0.19, 6.87)		(0.44, 11.41)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13		2.02					
95% CI of the risk ratio	(0.23, 5.66)		(0.51, 8.03)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.22		9.45					
95% CI of the absolute risk difference	(-15.08, 17.53)		(-11.56, 30.45)					
p-value	0.8805		0.3184					
p-value of Breslow-Day Test for Homogeneity [2]	0.3954		0.3296					
Abdominal discomfort	0	0	0	0	1 (2.3)	1	1 (1.3)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.33		-2.33					
95% CI of the absolute risk difference	(-6.83, 2.18)		(-6.83, 2.18)					
p-value	0.5028		0.5384					
p-value of Breslow-Day Test for Homogeneity [2]	0.8008		0.6737					

AMNOG Table S1.10.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Thyroxine at Baseline (Label Population)

Thyroxine at Baseline: Yes

System Organ Class Preferred Term	MGL-3196 80 mg (N=19) Patients n (%)	 Events n	MGL-3196 100 mg (N=16) Patients n (%)	 Events n	Placebo (N=43) Patients n (%)	 Events n	Overall (N=78) Patients n (%)	 Events n
General disorders and administration site conditions	4 (21.1)	7	4 (25.0)	6	17 (39.5)	20	25 (32.1)	33
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.41		0.51					
95% CI of the odds ratio	(0.12, 1.44)		(0.14, 1.84)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53		0.63					
95% CI of the risk ratio	(0.21, 1.37)		(0.25, 1.60)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-18.48		-14.53					
95% CI of the absolute risk difference	(-41.93, 4.96)		(-40.30, 11.23)					
p-value	0.1563		0.2999					
p-value of Breslow-Day Test for Homogeneity [2]	0.3759		0.7446					
Skin and subcutaneous tissue disorders								
Pruritus	3 (15.8)	3	2 (12.5)	4	3 (7.0)	3	8 (10.3)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.50		1.90					
95% CI of the odds ratio	(0.46, 13.71)		(0.29, 12.61)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.26		1.79					
95% CI of the risk ratio	(0.50, 10.21)		(0.33, 9.76)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.81		5.52					
95% CI of the absolute risk difference	(-9.27, 26.89)		(-12.38, 23.43)					
p-value	0.2792		0.4983					
p-value of Breslow-Day Test for Homogeneity [2]	0.7092		0.2394					

AMNOG Table S1.10.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19)		MGL-3196 100 mg (N=16)		Placebo (N=43)		Overall (N=78)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	0	0	3 (18.8)	4	1 (2.3)	1	4 (5.1)	5
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		9.69					
95% CI of the odds ratio	NE		(0.93, 101.34)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		8.06					
95% CI of the risk ratio	NE		(0.90, 71.98)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.33		16.42					
95% CI of the absolute risk difference	(-6.83, 2.18)		(-3.22, 36.07)					
p-value	0.5028		0.0257					
p-value of Breslow-Day Test for Homogeneity [2]	0.4530		0.2532					
Renal and urinary disorders	0	0	3 (18.8)	4	4 (9.3)	4	7 (9.0)	8
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.23		2.25					
95% CI of the odds ratio	(0.01, 4.39)		(0.44, 11.41)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.24		2.02					
95% CI of the risk ratio	(0.01, 4.33)		(0.51, 8.03)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.73		9.45					
95% CI of the absolute risk difference	(-19.00, 3.54)		(-11.56, 30.45)					
p-value	0.2857		0.3184					
p-value of Breslow-Day Test for Homogeneity [2]	0.4079		0.6411					

AMNOG Table S1.10.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Thyroxine at Baseline (Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19)		MGL-3196 100 mg (N=16)		Placebo (N=43)		Overall (N=78)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	1 (5.3)	1	0	0	3 (7.0)	3	4 (5.1)	4
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.74		0.35					
95% CI of the odds ratio	(0.07, 7.62)		(0.02, 7.17)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75		0.37					
95% CI of the risk ratio	(0.08, 6.79)		(0.02, 6.79)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.71		-5.01					
95% CI of the absolute risk difference	(-14.31, 10.89)		(-16.35, 6.32)					
p-value	0.8001		0.4782					
p-value of Breslow-Day Test for Homogeneity [2]	0.7345		0.5211					

AMNOG Table S1.10.3
TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19)		MGL-3196 100 mg (N=16)		Placebo (N=43)		Overall (N=78)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Injury, poisoning and procedural complications								
Contusion	0	0	0	0	1 (2.3)	1	1 (1.3)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.33		-2.33					
95% CI of the absolute risk difference	(-6.83, 2.18)		(-6.83, 2.18)					
p-value	0.5028		0.5384					
p-value of Breslow-Day Test for Homogeneity [2]	0.6793		NE					

AMNOG Table S1.10.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

System Organ Class Preferred Term	MGL-3196 80 mg (N=148) Patients n (%)	 Events n	MGL-3196 100 mg (N=135) Patients n (%)	 Events n	Placebo (N=260) Patients n (%)	 Events n	Overall (N=543) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	33 (22.3)	59	44 (32.6)	66	43 (16.5)	55	120 (22.1)	180
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.45		2.44					
95% CI of the odds ratio	(0.87, 2.40)		(1.50, 3.97)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.35		1.97					
95% CI of the risk ratio	(0.90, 2.02)		(1.37, 2.84)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.76		16.05					
95% CI of the absolute risk difference	(-2.33, 13.84)		(6.95, 25.16)					
p-value	0.1509		0.0003					
p-value of Breslow-Day Test for Homogeneity [2]	0.0463		0.3410					
Nausea	39 (26.4)	47	15 (11.1)	18	34 (13.1)	40	88 (16.2)	105
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.38		0.83					
95% CI of the odds ratio	(1.42, 3.97)		(0.44, 1.59)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.02		0.85					
95% CI of the risk ratio	(1.33, 3.05)		(0.48, 1.50)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.27		-1.97					
95% CI of the absolute risk difference	(5.08, 21.47)		(-8.67, 4.73)					
p-value	0.0008		0.5740					
p-value of Breslow-Day Test for Homogeneity [2]	0.8378		0.0230					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.10.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Thyroxine at Baseline (Label Population)

Thyroxine at Baseline: No

System Organ Class Preferred Term	MGL-3196 80 mg (N=148) Patients n (%)	 Events n	MGL-3196 100 mg (N=135) Patients n (%)	 Events n	Placebo (N=260) Patients n (%)	 Events n	Overall (N=543) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	18 (12.2)	19	6 (4.4)	6	13 (5.0)	13	37 (6.8)	38
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.63		0.88					
95% CI of the odds ratio	(1.25, 5.54)		(0.33, 2.38)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.43		0.89					
95% CI of the risk ratio	(1.23, 4.82)		(0.35, 2.29)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.16		-0.56					
95% CI of the absolute risk difference	(1.27, 13.06)		(-4.93, 3.82)					
p-value	0.0087		0.8067					
p-value of Breslow-Day Test for Homogeneity [2]	0.3954		0.3296					
Abdominal discomfort	1 (0.7)	1	3 (2.2)	4	12 (4.6)	13	16 (2.9)	18
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.14		0.47					
95% CI of the odds ratio	(0.02, 1.09)		(0.13, 1.69)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.15		0.48					
95% CI of the risk ratio	(0.02, 1.11)		(0.14, 1.68)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.94		-2.39					
95% CI of the absolute risk difference	(-6.81, -1.07)		(-5.96, 1.17)					
p-value	0.0294		0.2379					
p-value of Breslow-Day Test for Homogeneity [2]	0.8008		0.6737					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.10.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Thyroxine at Baseline (Label Population)

Thyroxine at Baseline: No

System Organ Class Preferred Term	MGL-3196 80 mg (N=148) Patients n (%)	 Events n	MGL-3196 100 mg (N=135) Patients n (%)	 Events n	Placebo (N=260) Patients n (%)	 Events n	Overall (N=543) Patients n (%)	 Events n
General disorders and administration site conditions	31 (20.9)	45	25 (18.5)	33	68 (26.2)	84	124 (22.8)	162
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75		0.64					
95% CI of the odds ratio	(0.46, 1.21)		(0.38, 1.07)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80		0.71					
95% CI of the risk ratio	(0.55, 1.16)		(0.47, 1.07)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.21		-7.64					
95% CI of the absolute risk difference	(-13.66, 3.25)		(-16.09, 0.82)					
p-value	0.2381		0.0898					
p-value of Breslow-Day Test for Homogeneity [2]	0.3759		0.7446					
Skin and subcutaneous tissue disorders								
Pruritus	19 (12.8)	25	6 (4.4)	6	20 (7.7)	23	45 (8.3)	54
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.77		0.56					
95% CI of the odds ratio	(0.91, 3.43)		(0.22, 1.42)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67		0.58					
95% CI of the risk ratio	(0.92, 3.02)		(0.24, 1.40)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.15		-3.25					
95% CI of the absolute risk difference	(-1.14, 11.43)		(-8.00, 1.50)					
p-value	0.0892		0.2170					
p-value of Breslow-Day Test for Homogeneity [2]	0.7092		0.2394					

AMNOG Table S1.10.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Thyroxine at Baseline (Label Population)

Thyroxine at Baseline: No

System Organ Class Preferred Term	MGL-3196 80 mg (N=148) Patients n (%)	 Events n	MGL-3196 100 mg (N=135) Patients n (%)	 Events n	Placebo (N=260) Patients n (%)	 Events n	Overall (N=543) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	8 (5.4)	8	13 (9.6)	16	11 (4.2)	13	32 (5.9)	37
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.29		2.41					
95% CI of the odds ratio	(0.51, 3.29)		(1.05, 5.54)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.28		2.28					
95% CI of the risk ratio	(0.53, 3.11)		(1.05, 4.94)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.17		5.40					
95% CI of the absolute risk difference	(-3.21, 5.56)		(-0.15, 10.94)					
p-value	0.5882		0.0331					
p-value of Breslow-Day Test for Homogeneity [2]	0.4530		0.2532					
Renal and urinary disorders	5 (3.4)	6	17 (12.6)	20	23 (8.8)	29	45 (8.3)	55
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		1.48					
95% CI of the odds ratio	(0.13, 0.97)		(0.76, 2.89)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		1.42					
95% CI of the risk ratio	(0.15, 0.98)		(0.79, 2.57)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.47		3.75					
95% CI of the absolute risk difference	(-9.98, -0.95)		(-2.83, 10.32)					
p-value	0.0357		0.2417					
p-value of Breslow-Day Test for Homogeneity [2]	0.4079		0.6411					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.10.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Thyroxine at Baseline (Label Population)

Thyroxine at Baseline: No

System Organ Class Preferred Term	MGL-3196 80 mg (N=148) Patients n (%)	 Events n	MGL-3196 100 mg (N=135) Patients n (%)	 Events n	Placebo (N=260) Patients n (%)	 Events n	Overall (N=543) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	6 (4.1)	7	4 (3.0)	4	21 (8.1)	25	31 (5.7)	36
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48		0.35					
95% CI of the odds ratio	(0.19, 1.22)		(0.12, 1.03)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		0.37					
95% CI of the risk ratio	(0.21, 1.22)		(0.13, 1.05)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.02		-5.11					
95% CI of the absolute risk difference	(-8.61, 0.57)		(-9.49, -0.74)					
p-value	0.1160		0.0477					
p-value of Breslow-Day Test for Homogeneity [2]	0.7345		0.5211					

AMNOG Table S1.10.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Thyroxine at Baseline (Label Population)

Thyroxine at Baseline: No

System Organ Class Preferred Term	MGL-3196 80 mg (N=148) Patients n (%)	 Events n	MGL-3196 100 mg (N=135) Patients n (%)	 Events n	Placebo (N=260) Patients n (%)	 Events n	Overall (N=543) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	2 (1.4)	2	0	0	9 (3.5)	13	11 (2.0)	15
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		NE					
95% CI of the odds ratio	(0.08, 1.79)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		NE					
95% CI of the risk ratio	(0.09, 1.78)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.11		-3.46					
95% CI of the absolute risk difference	(-5.01, 0.79)		(-5.68, -1.24)					
p-value	0.2058		0.0288					
p-value of Breslow-Day Test for Homogeneity [2]	0.6793		NE					

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Events n:				
Total TEAEs	255	279	261	795
Total Serious TEAEs	12	6	10	28
Total TEAEs Leading to Discontinuation of Study Drug	6	1	1	8
Total TEAEs Related to Study Drug	28	27	12	67
Total TEAEs >= Grade 3 Severity	9	9	16	34
Patients n (%):				
Any TEAE	30 (100)	30 (96.8)	33 (94.3)	93 (96.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.82		
95% CI of the odds ratio	NE	(0.16, 21.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.06	1.03		
95% CI of the risk ratio	(0.98, 1.15)	(0.93, 1.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.71	2.49		
95% CI of the absolute risk difference	(-1.98, 13.40)	(-7.40, 12.38)		
p-value	0.1835	0.6281		
p-value of Breslow-Day Test for Homogeneity [2]	0.2001	0.4770		
Any Serious TEAE	3 (10.0)	4 (12.9)	4 (11.4)	11 (11.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.86	1.15		
95% CI of the odds ratio	(0.18, 4.19)	(0.26, 5.04)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.88	1.13		
95% CI of the risk ratio	(0.21, 3.60)	(0.31, 4.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.43	1.47		
95% CI of the absolute risk difference	(-16.47, 13.62)	(-14.35, 17.30)		
p-value	0.8531	0.8546		
p-value of Breslow-Day Test for Homogeneity [2]	0.6346	0.7827		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Any TEAEs >= Grade 3 Severity	3 (10.0)	5 (16.1)	7 (20.0)	15 (15.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	0.77		
95% CI of the odds ratio	(0.10, 1.90)	(0.22, 2.73)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50	0.81		
95% CI of the risk ratio	(0.14, 1.77)	(0.28, 2.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.00	-3.87		
95% CI of the absolute risk difference	(-27.05, 7.05)	(-22.40, 14.66)		
p-value	0.2653	0.6841		
p-value of Breslow-Day Test for Homogeneity [2]	0.7638	0.6812		
Any TEAEs <= Grade 2 Severity	30 (100)	30 (96.8)	33 (94.3)	93 (96.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.82		
95% CI of the odds ratio	NE	(0.16, 21.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.06	1.03		
95% CI of the risk ratio	(0.98, 1.15)	(0.93, 1.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.71	2.49		
95% CI of the absolute risk difference	(-1.98, 13.40)	(-7.40, 12.38)		
p-value	0.1835	0.6281		
p-value of Breslow-Day Test for Homogeneity [2]	0.1607	0.4770		
Any TEAEs leading to Study-Drug Discontinuation	2 (6.7)	1 (3.2)	1 (2.9)	4 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.43	1.13		
95% CI of the odds ratio	(0.21, 28.20)	(0.07, 18.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.33	1.13		
95% CI of the risk ratio	(0.22, 24.48)	(0.07, 17.30)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.81	0.37		
95% CI of the absolute risk difference	(-6.69, 14.30)	(-7.95, 8.68)		
p-value	0.4656	0.9305		
p-value of Breslow-Day Test for Homogeneity [2]	0.7110	0.9861		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Any TEAEs leading to Study Discontinuation	1 (3.3)	0	1 (2.9)	2 (2.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE		
95% CI of the odds ratio	(0.07, 19.59)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE		
95% CI of the risk ratio	(0.08, 17.86)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.48	-2.86		
95% CI of the absolute risk difference	(-7.99, 8.95)	(-8.38, 2.66)		
p-value	0.9118	0.3430		
p-value of Breslow-Day Test for Homogeneity [2]	0.9310	0.2017		
Any Fatal TEAEs	1 (3.3)	0	0	1 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.33	NE		
95% CI of the absolute risk difference	(-3.09, 9.76)	NE		
p-value	0.2764	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	10 (33.3)	14 (45.2)	8 (22.9)	32 (33.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.69	2.78		
95% CI of the odds ratio	(0.56, 5.04)	(0.96, 8.02)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.46	1.98		
95% CI of the risk ratio	(0.66, 3.22)	(0.96, 4.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	10.48	22.30		
95% CI of the absolute risk difference	(-11.39, 32.34)	(-0.07, 44.67)		
p-value	0.3467	0.0551		
p-value of Breslow-Day Test for Homogeneity [2]	0.5879	0.1644		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Any Treatment-related Serious TEAE	0	0	1 (2.9)	1 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	-2.86		
95% CI of the absolute risk difference	(-8.38, 2.66)	(-8.38, 2.66)		
p-value	0.3508	0.3430		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	2 (5.7)	2 (2.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.22	0.21		
95% CI of the odds ratio	(0.01, 4.76)	(0.01, 4.61)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.23	0.23		
95% CI of the risk ratio	(0.01, 4.66)	(0.01, 4.51)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.33	-5.38		
95% CI of the absolute risk difference	(-14.75, 4.08)	(-14.73, 3.97)		
p-value	0.2927	0.2807		
p-value of Breslow-Day Test for Homogeneity [2]	0.0212	0.0134		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	1 (3.3)	0	1 (2.9)	2 (2.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE		
95% CI of the odds ratio	(0.07, 19.59)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE		
95% CI of the risk ratio	(0.08, 17.86)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.48	-2.86		
95% CI of the absolute risk difference	(-7.99, 8.95)	(-8.38, 2.66)		
p-value	0.9118	0.3430		
p-value of Breslow-Day Test for Homogeneity [2]	0.9224	0.3241		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (2.9)	1 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	-2.86		
95% CI of the absolute risk difference	(-8.38, 2.66)	(-8.38, 2.66)		
p-value	0.3508	0.3430		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2400		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	8 (26.7)	6 (19.4)	10 (28.6)	24 (25.0)
Grade 2	19 (63.3)	19 (61.3)	16 (45.7)	54 (56.3)
Grade 3	2 (6.7)	5 (16.1)	6 (17.1)	13 (13.5)
Grade 4	0	0	1 (2.9)	1 (1.0)
Grade 5	1 (3.3)	0	0	1 (1.0)

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	7 (23.3)	11 (35.5)	5 (14.3)	23 (24.0)
Grade 2	3 (10.0)	3 (9.7)	1 (2.9)	7 (7.3)
Grade 3	0	0	1 (2.9)	1 (1.0)
Grade 4	0	0	1 (2.9)	1 (1.0)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (3.3)	0	0	1 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	3.33	NE		
95% CI of the absolute risk difference	(-3.09, 9.76)	NE		
p-value	0.2764	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	1 (3.3)	0	0	1 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.33	NE		
95% CI of the absolute risk difference	(-3.09, 9.76)	NE		
p-value	0.2764	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
Serious 3-PT MACE AE - Adjudicated Event	1 (3.3)	0	0	1 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.33	NE		
95% CI of the absolute risk difference	(-3.09, 9.76)	NE		
p-value	0.2764	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
Other MACE AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Madrigal Pharmaceuticals, Inc. Page 12 of 31
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Events n:				
Total TEAEs	85	36	91	212
Total Serious TEAEs	0	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0	0
Total TEAEs Related to Study Drug	8	2	7	17
Total TEAEs >= Grade 3 Severity	1	0	1	2
Patients n (%):				
Any TEAE	12 (100)	6 (75.0)	12 (92.3)	30 (90.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.25		
95% CI of the odds ratio	NE	(0.02, 3.34)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08	0.81		
95% CI of the risk ratio	(0.93, 1.27)	(0.53, 1.25)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.69	-17.31		
95% CI of the absolute risk difference	(-6.79, 22.18)	(-50.63, 16.01)		
p-value	0.3268	0.2710		
p-value of Breslow-Day Test for Homogeneity [2]	0.2001	0.4770		
Any Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.6346	0.7827		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Any TEAEs >= Grade 3 Severity	1 (8.3)	0	1 (7.7)	2 (6.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.09	0.49		
95% CI of the odds ratio	(0.06, 19.63)	(0.02, 13.52)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08	0.52		
95% CI of the risk ratio	(0.08, 15.46)	(0.02, 11.39)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.64	-5.16		
95% CI of the absolute risk difference	(-20.67, 21.96)	(-27.21, 16.90)		
p-value	0.9529	0.6683		
p-value of Breslow-Day Test for Homogeneity [2]	0.7638	0.6812		
Any TEAEs <= Grade 2 Severity	12 (100)	6 (75.0)	12 (92.3)	30 (90.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.25		
95% CI of the odds ratio	NE	(0.02, 3.34)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08	0.81		
95% CI of the risk ratio	(0.93, 1.27)	(0.53, 1.25)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.69	-17.31		
95% CI of the absolute risk difference	(-6.79, 22.18)	(-50.63, 16.01)		
p-value	0.3268	0.2710		
p-value of Breslow-Day Test for Homogeneity [2]	0.1607	0.4770		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.7110	0.9861		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Any TEAEs leading to Study Discontinuation	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.9310	0.2017		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	4 (33.3)	2 (25.0)	5 (38.5)	11 (33.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	0.53		
95% CI of the odds ratio	(0.16, 4.12)	(0.08, 3.76)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87	0.65		
95% CI of the risk ratio	(0.30, 2.49)	(0.16, 2.59)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.13	-13.46		
95% CI of the absolute risk difference	(-42.69, 32.43)	(-53.46, 26.54)		
p-value	0.7896	0.5251		
p-value of Breslow-Day Test for Homogeneity [2]	0.5879	0.1644		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.0212	0.0134		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.9224	0.3241		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2400		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	4 (33.3)	0	3 (23.1)	7 (21.2)
Grade 2	7 (58.3)	6 (75.0)	8 (61.5)	21 (63.6)
Grade 3	1 (8.3)	0	1 (7.7)	2 (6.1)
Grade 4	0	0	0	0
Grade 5	0	0	0	0

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	2 (16.7)	1 (12.5)	1 (7.7)	4 (12.1)
Grade 2	2 (16.7)	1 (12.5)	4 (30.8)	7 (21.2)
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
DILI AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE - Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE - Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Events n:				
Total TEAEs	823	599	1688	3110
Total Serious TEAEs	14	16	70	100
Total TEAEs Leading to Discontinuation of Study Drug	10	5	11	26
Total TEAEs Related to Study Drug	108	57	121	286
Total TEAEs >= Grade 3 Severity	22	26	74	122
Patients n (%):				
Any TEAE	104 (93.7)	79 (90.8)	211 (95.5)	394 (94.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.70	0.47		
95% CI of the odds ratio	(0.26, 1.90)	(0.18, 1.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	0.95		
95% CI of the risk ratio	(0.93, 1.04)	(0.88, 1.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.78	-4.67		
95% CI of the absolute risk difference	(-7.07, 3.51)	(-11.33, 1.99)		
p-value	0.4872	0.1157		
p-value of Breslow-Day Test for Homogeneity [2]	0.2001	0.4770		
Any Serious TEAE	10 (9.0)	12 (13.8)	33 (14.9)	55 (13.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56	0.91		
95% CI of the odds ratio	(0.27, 1.19)	(0.45, 1.86)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	0.92		
95% CI of the risk ratio	(0.31, 1.18)	(0.50, 1.70)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.92	-1.14		
95% CI of the absolute risk difference	(-13.03, 1.18)	(-9.78, 7.50)		
p-value	0.1294	0.7989		
p-value of Breslow-Day Test for Homogeneity [2]	0.6346	0.7827		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Any TEAEs >= Grade 3 Severity	16 (14.4)	16 (18.4)	40 (18.1)	72 (17.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76	1.02		
95% CI of the odds ratio	(0.41, 1.43)	(0.54, 1.94)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	1.02		
95% CI of the risk ratio	(0.47, 1.36)	(0.60, 1.72)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.69	0.29		
95% CI of the absolute risk difference	(-11.96, 4.59)	(-9.30, 9.88)		
p-value	0.3976	0.9524		
p-value of Breslow-Day Test for Homogeneity [2]	0.7638	0.6812		
Any TEAEs <= Grade 2 Severity	103 (92.8)	79 (90.8)	211 (95.5)	393 (93.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.61	0.47		
95% CI of the odds ratio	(0.23, 1.59)	(0.18, 1.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	0.95		
95% CI of the risk ratio	(0.92, 1.03)	(0.88, 1.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.68	-4.67		
95% CI of the absolute risk difference	(-8.22, 2.85)	(-11.33, 1.99)		
p-value	0.3086	0.1157		
p-value of Breslow-Day Test for Homogeneity [2]	0.1607	0.4770		
Any TEAEs leading to Study-Drug Discontinuation	8 (7.2)	5 (5.7)	11 (5.0)	24 (5.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.48	1.16		
95% CI of the odds ratio	(0.58, 3.80)	(0.39, 3.45)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.45	1.15		
95% CI of the risk ratio	(0.60, 3.50)	(0.41, 3.23)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.23	0.77		
95% CI of the absolute risk difference	(-3.37, 7.83)	(-4.90, 6.44)		
p-value	0.4093	0.7840		
p-value of Breslow-Day Test for Homogeneity [2]	0.7110	0.9861		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Any TEAEs leading to Study Discontinuation	1 (0.9)	2 (2.3)	2 (0.9)	5 (1.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	2.58		
95% CI of the odds ratio	(0.09, 11.10)	(0.36, 18.58)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	2.54		
95% CI of the risk ratio	(0.09, 10.86)	(0.36, 17.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	1.39		
95% CI of the absolute risk difference	(-2.16, 2.15)	(-1.99, 4.78)		
p-value	0.9970	0.3307		
p-value of Breslow-Day Test for Homogeneity [2]	0.9310	0.2017		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	49 (44.1)	25 (28.7)	64 (29.0)	138 (32.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.94	0.99		
95% CI of the odds ratio	(1.21, 3.11)	(0.57, 1.71)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.52	0.99		
95% CI of the risk ratio	(1.14, 2.05)	(0.67, 1.47)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	15.18	-0.22		
95% CI of the absolute risk difference	(4.18, 26.19)	(-11.46, 11.01)		
p-value	0.0059	0.9689		
p-value of Breslow-Day Test for Homogeneity [2]	0.5879	0.1644		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	2 (1.8)	2 (2.3)	0	4 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.80	2.30		
95% CI of the absolute risk difference	(-0.67, 4.28)	(-0.85, 5.45)		
p-value	0.0453	0.0237		
p-value of Breslow-Day Test for Homogeneity [2]	0.0212	0.0134		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (1.8)	2 (2.3)	4 (1.8)	8 (1.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.28		
95% CI of the odds ratio	(0.18, 5.52)	(0.23, 7.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.27		
95% CI of the risk ratio	(0.19, 5.35)	(0.24, 6.81)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.01	0.49		
95% CI of the absolute risk difference	(-3.04, 3.03)	(-3.12, 4.10)		
p-value	0.9958	0.7799		
p-value of Breslow-Day Test for Homogeneity [2]	0.9224	0.3241		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	1 (1.1)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.56		
95% CI of the odds ratio	NE	(0.16, 41.36)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.54		
95% CI of the risk ratio	NE	(0.16, 40.16)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.45	0.70		
95% CI of the absolute risk difference	(-1.34, 0.43)	(-1.71, 3.11)		
p-value	0.4778	0.4930		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2400		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	22 (19.8)	14 (16.1)	45 (20.4)	81 (19.3)
Grade 2	66 (59.5)	49 (56.3)	126 (57.0)	241 (57.5)
Grade 3	16 (14.4)	16 (18.4)	34 (15.4)	66 (15.8)
Grade 4	0	0	6 (2.7)	6 (1.4)
Grade 5	0	0	0	0

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	28 (25.2)	12 (13.8)	41 (18.6)	81 (19.3)
Grade 2	19 (17.1)	11 (12.6)	23 (10.4)	53 (12.6)
Grade 3	2 (1.8)	2 (2.3)	0	4 (1.0)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.45	-0.45		
95% CI of the absolute risk difference	(-1.34, 0.43)	(-1.34, 0.43)		
p-value	0.4778	0.5297		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.45	-0.45		
95% CI of the absolute risk difference	(-1.34, 0.43)	(-1.34, 0.43)		
p-value	0.4778	0.5297		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.45	-0.45		
95% CI of the absolute risk difference	(-1.34, 0.43)	(-1.34, 0.43)		
p-value	0.4778	0.5297		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
Other MACE AE – Adjudicated Event	0	0	3 (1.4)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.36	-1.36		
95% CI of the absolute risk difference	(-2.88, 0.17)	(-2.88, 0.17)		
p-value	0.2175	0.2748		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (0.9)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.90	-0.90		
95% CI of the absolute risk difference	(-2.15, 0.34)	(-2.15, 0.34)		
p-value	0.3148	0.3734		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.45	-0.45		
95% CI of the absolute risk difference	(-1.34, 0.43)	(-1.34, 0.43)		
p-value	0.4778	0.5297		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (0.9)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.90	-0.90		
95% CI of the absolute risk difference	(-2.15, 0.34)	(-2.15, 0.34)		
p-value	0.3148	0.3734		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Madrigal Pharmaceuticals, Inc. Page 2 of 31
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Events n:				
Total TEAEs	253	278	261	792
Total Serious TEAEs	12	6	10	28
Total TEAEs Leading to Discontinuation of Study Drug	6	1	1	8
Total TEAEs Related to Study Drug	28	27	12	67
Total TEAEs >= Grade 3 Severity	9	8	16	33
Patients n (%):				
Any TEAE	30 (100)	30 (96.8)	33 (94.3)	93 (96.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.82		
95% CI of the odds ratio	NE	(0.16, 21.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.06	1.03		
95% CI of the risk ratio	(0.98, 1.15)	(0.93, 1.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.71	2.49		
95% CI of the absolute risk difference	(-1.98, 13.40)	(-7.40, 12.38)		
p-value	0.1835	0.6281		
p-value of Breslow-Day Test for Homogeneity [2]	0.1072	0.6194		
Any Serious TEAE	3 (10.0)	4 (12.9)	4 (11.4)	11 (11.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.86	1.15		
95% CI of the odds ratio	(0.18, 4.19)	(0.26, 5.04)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.88	1.13		
95% CI of the risk ratio	(0.21, 3.60)	(0.31, 4.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.43	1.47		
95% CI of the absolute risk difference	(-16.47, 13.62)	(-14.35, 17.30)		
p-value	0.8531	0.8546		
p-value of Breslow-Day Test for Homogeneity [2]	0.6346	0.7827		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Any TEAEs >= Grade 3 Severity	3 (10.0)	4 (12.9)	7 (20.0)	14 (14.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	0.59		
95% CI of the odds ratio	(0.10, 1.90)	(0.16, 2.26)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50	0.65		
95% CI of the risk ratio	(0.14, 1.77)	(0.21, 2.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-10.00	-7.10		
95% CI of the absolute risk difference	(-27.05, 7.05)	(-24.84, 10.65)		
p-value	0.2653	0.4401		
p-value of Breslow-Day Test for Homogeneity [2]	0.8260	0.5098		
Any TEAEs <= Grade 2 Severity	30 (100)	30 (96.8)	33 (94.3)	93 (96.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.82		
95% CI of the odds ratio	NE	(0.16, 21.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.06	1.03		
95% CI of the risk ratio	(0.98, 1.15)	(0.93, 1.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.71	2.49		
95% CI of the absolute risk difference	(-1.98, 13.40)	(-7.40, 12.38)		
p-value	0.1835	0.6281		
p-value of Breslow-Day Test for Homogeneity [2]	0.0827	0.6194		
Any TEAEs leading to Study-Drug Discontinuation	2 (6.7)	1 (3.2)	1 (2.9)	4 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.43	1.13		
95% CI of the odds ratio	(0.21, 28.20)	(0.07, 18.92)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.33	1.13		
95% CI of the risk ratio	(0.22, 24.48)	(0.07, 17.30)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.81	0.37		
95% CI of the absolute risk difference	(-6.69, 14.30)	(-7.95, 8.68)		
p-value	0.4656	0.9305		
p-value of Breslow-Day Test for Homogeneity [2]	0.7943	0.9397		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Any TEAEs leading to Study Discontinuation	1 (3.3)	0	1 (2.9)	2 (2.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE		
95% CI of the odds ratio	(0.07, 19.59)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE		
95% CI of the risk ratio	(0.08, 17.86)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.48	-2.86		
95% CI of the absolute risk difference	(-7.99, 8.95)	(-8.38, 2.66)		
p-value	0.9118	0.3430		
p-value of Breslow-Day Test for Homogeneity [2]	0.9310	0.2017		
Any Fatal TEAEs	1 (3.3)	0	0	1 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.33	NE		
95% CI of the absolute risk difference	(-3.09, 9.76)	NE		
p-value	0.2764	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	10 (33.3)	14 (45.2)	8 (22.9)	32 (33.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.69	2.78		
95% CI of the odds ratio	(0.56, 5.04)	(0.96, 8.02)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.46	1.98		
95% CI of the risk ratio	(0.66, 3.22)	(0.96, 4.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	10.48	22.30		
95% CI of the absolute risk difference	(-11.39, 32.34)	(-0.07, 44.67)		
p-value	0.3467	0.0551		
p-value of Breslow-Day Test for Homogeneity [2]	0.5700	0.1726		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Any Treatment-related Serious TEAE	0	0	1 (2.9)	1 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	-2.86		
95% CI of the absolute risk difference	(-8.38, 2.66)	(-8.38, 2.66)		
p-value	0.3508	0.3430		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	2 (5.7)	2 (2.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.22	0.21		
95% CI of the odds ratio	(0.01, 4.76)	(0.01, 4.61)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.23	0.23		
95% CI of the risk ratio	(0.01, 4.66)	(0.01, 4.51)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.33	-5.38		
95% CI of the absolute risk difference	(-14.75, 4.08)	(-14.73, 3.97)		
p-value	0.2927	0.2807		
p-value of Breslow-Day Test for Homogeneity [2]	0.0441	0.0134		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	1 (3.3)	0	1 (2.9)	2 (2.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE		
95% CI of the odds ratio	(0.07, 19.59)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.17	NE		
95% CI of the risk ratio	(0.08, 17.86)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.48	-2.86		
95% CI of the absolute risk difference	(-7.99, 8.95)	(-8.38, 2.66)		
p-value	0.9118	0.3430		
p-value of Breslow-Day Test for Homogeneity [2]	0.9224	0.3241		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (2.9)	1 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	-2.86		
95% CI of the absolute risk difference	(-8.38, 2.66)	(-8.38, 2.66)		
p-value	0.3508	0.3430		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2400		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	8 (26.7)	7 (22.6)	10 (28.6)	25 (26.0)
Grade 2	19 (63.3)	19 (61.3)	16 (45.7)	54 (56.3)
Grade 3	2 (6.7)	4 (12.9)	6 (17.1)	12 (12.5)
Grade 4	0	0	1 (2.9)	1 (1.0)
Grade 5	1 (3.3)	0	0	1 (1.0)

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	7 (23.3)	11 (35.5)	5 (14.3)	23 (24.0)
Grade 2	3 (10.0)	3 (9.7)	1 (2.9)	7 (7.3)
Grade 3	0	0	1 (2.9)	1 (1.0)
Grade 4	0	0	1 (2.9)	1 (1.0)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (3.3)	0	0	1 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	3.33	NE		
95% CI of the absolute risk difference	(-3.09, 9.76)	NE		
p-value	0.2764	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	1 (3.3)	0	0	1 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.33	NE		
95% CI of the absolute risk difference	(-3.09, 9.76)	NE		
p-value	0.2764	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
Serious 3-PT MACE AE - Adjudicated Event	1 (3.3)	0	0	1 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.33	NE		
95% CI of the absolute risk difference	(-3.09, 9.76)	NE		
p-value	0.2764	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
Other MACE AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
DILI AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE - Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE - Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=31) n (%)	Placebo (N=35) n (%)	Overall (N=96) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Events n:				
Total TEAEs	85	35	89	209
Total Serious TEAEs	0	0	0	0
Total TEAEs Leading to Discontinuation of Study Drug	0	0	0	0
Total TEAEs Related to Study Drug	8	2	7	17
Total TEAEs >= Grade 3 Severity	1	0	1	2
Patients n (%):				
Any TEAE	12 (100)	6 (75.0)	11 (84.6)	29 (87.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.55		
95% CI of the odds ratio	NE	(0.06, 4.91)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.18	0.89		
95% CI of the risk ratio	(0.94, 1.49)	(0.56, 1.41)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	15.38	-9.62		
95% CI of the absolute risk difference	(-4.23, 35.00)	(-45.46, 26.23)		
p-value	0.1566	0.5858		
p-value of Breslow-Day Test for Homogeneity [2]	0.1072	0.6194		
Any Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.6346	0.7827		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Any TEAEs >= Grade 3 Severity	1 (8.3)	0	1 (7.7)	2 (6.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.09	0.49		
95% CI of the odds ratio	(0.06, 19.63)	(0.02, 13.52)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08	0.52		
95% CI of the risk ratio	(0.08, 15.46)	(0.02, 11.39)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.64	-5.16		
95% CI of the absolute risk difference	(-20.67, 21.96)	(-27.21, 16.90)		
p-value	0.9529	0.6683		
p-value of Breslow-Day Test for Homogeneity [2]	0.8260	0.5098		
Any TEAEs <= Grade 2 Severity	12 (100)	6 (75.0)	11 (84.6)	29 (87.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.55		
95% CI of the odds ratio	NE	(0.06, 4.91)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.18	0.89		
95% CI of the risk ratio	(0.94, 1.49)	(0.56, 1.41)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	15.38	-9.62		
95% CI of the absolute risk difference	(-4.23, 35.00)	(-45.46, 26.23)		
p-value	0.1566	0.5858		
p-value of Breslow-Day Test for Homogeneity [2]	0.0827	0.6194		
Any TEAEs leading to Study-Drug Discontinuation	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.7943	0.9397		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Any TEAEs leading to Study Discontinuation	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.9310	0.2017		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	4 (33.3)	2 (25.0)	5 (38.5)	11 (33.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	0.53		
95% CI of the odds ratio	(0.16, 4.12)	(0.08, 3.76)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87	0.65		
95% CI of the risk ratio	(0.30, 2.49)	(0.16, 2.59)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.13	-13.46		
95% CI of the absolute risk difference	(-42.69, 32.43)	(-53.46, 26.54)		
p-value	0.7896	0.5251		
p-value of Breslow-Day Test for Homogeneity [2]	0.5700	0.1726		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.0441	0.0134		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.9224	0.3241		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2400		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	4 (33.3)	0	3 (23.1)	7 (21.2)
Grade 2	7 (58.3)	6 (75.0)	7 (53.8)	20 (60.6)
Grade 3	1 (8.3)	0	1 (7.7)	2 (6.1)
Grade 4	0	0	0	0
Grade 5	0	0	0	0

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	2 (16.7)	1 (12.5)	1 (7.7)	4 (12.1)
Grade 2	2 (16.7)	1 (12.5)	4 (30.8)	7 (21.2)
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12) n (%)	MGL-3196 100 mg (N=8) n (%)	Placebo (N=13) n (%)	Overall (N=33) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Events n:				
Total TEAEs	812	593	1666	3071
Total Serious TEAEs	14	16	70	100
Total TEAEs Leading to Discontinuation of Study Drug	7	3	6	16
Total TEAEs Related to Study Drug	107	57	120	284
Total TEAEs >= Grade 3 Severity	19	26	71	116
Patients n (%):				
Any TEAE	103 (92.8)	79 (90.8)	210 (95.0)	392 (93.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67	0.52		
95% CI of the odds ratio	(0.26, 1.73)	(0.20, 1.33)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	0.96		
95% CI of the risk ratio	(0.92, 1.04)	(0.89, 1.03)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.23	-4.22		
95% CI of the absolute risk difference	(-7.83, 3.37)	(-10.93, 2.50)		
p-value	0.4093	0.1660		
p-value of Breslow-Day Test for Homogeneity [2]	0.1072	0.6194		
Any Serious TEAE	10 (9.0)	12 (13.8)	33 (14.9)	55 (13.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56	0.91		
95% CI of the odds ratio	(0.27, 1.19)	(0.45, 1.86)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	0.92		
95% CI of the risk ratio	(0.31, 1.18)	(0.50, 1.70)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.92	-1.14		
95% CI of the absolute risk difference	(-13.03, 1.18)	(-9.78, 7.50)		
p-value	0.1294	0.7989		
p-value of Breslow-Day Test for Homogeneity [2]	0.6346	0.7827		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Any TEAEs >= Grade 3 Severity	13 (11.7)	16 (18.4)	37 (16.7)	66 (15.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.66	1.12		
95% CI of the odds ratio	(0.33, 1.30)	(0.59, 2.14)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.70	1.10		
95% CI of the risk ratio	(0.39, 1.26)	(0.65, 1.87)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.03	1.65		
95% CI of the absolute risk difference	(-12.78, 2.72)	(-7.86, 11.16)		
p-value	0.2267	0.7300		
p-value of Breslow-Day Test for Homogeneity [2]	0.8260	0.5098		
Any TEAEs <= Grade 2 Severity	102 (91.9)	79 (90.8)	210 (95.0)	391 (93.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	0.52		
95% CI of the odds ratio	(0.24, 1.48)	(0.20, 1.33)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	0.96		
95% CI of the risk ratio	(0.91, 1.03)	(0.89, 1.03)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.13	-4.22		
95% CI of the absolute risk difference	(-8.96, 2.70)	(-10.93, 2.50)		
p-value	0.2580	0.1660		
p-value of Breslow-Day Test for Homogeneity [2]	0.0827	0.6194		
Any TEAEs leading to Study-Drug Discontinuation	5 (4.5)	3 (3.4)	6 (2.7)	14 (3.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.69	1.28		
95% CI of the odds ratio	(0.50, 5.66)	(0.31, 5.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.66	1.27		
95% CI of the risk ratio	(0.52, 5.32)	(0.32, 4.97)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.79	0.73		
95% CI of the absolute risk difference	(-2.62, 6.20)	(-3.66, 5.13)		
p-value	0.3901	0.7308		
p-value of Breslow-Day Test for Homogeneity [2]	0.7943	0.9397		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Any TEAEs leading to Study Discontinuation	1 (0.9)	2 (2.3)	2 (0.9)	5 (1.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	2.58		
95% CI of the odds ratio	(0.09, 11.10)	(0.36, 18.58)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	2.54		
95% CI of the risk ratio	(0.09, 10.86)	(0.36, 17.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00	1.39		
95% CI of the absolute risk difference	(-2.16, 2.15)	(-1.99, 4.78)		
p-value	0.9970	0.3307		
p-value of Breslow-Day Test for Homogeneity [2]	0.9310	0.2017		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	49 (44.1)	25 (28.7)	63 (28.5)	137 (32.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.98	1.01		
95% CI of the odds ratio	(1.23, 3.19)	(0.58, 1.75)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.55	1.01		
95% CI of the risk ratio	(1.15, 2.08)	(0.68, 1.49)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	15.64	0.23		
95% CI of the absolute risk difference	(4.65, 26.63)	(-10.99, 11.45)		
p-value	0.0045	0.9681		
p-value of Breslow-Day Test for Homogeneity [2]	0.5700	0.1726		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (0.9)	2 (2.3)	0	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.90	2.30		
95% CI of the absolute risk difference	(-0.86, 2.66)	(-0.85, 5.45)		
p-value	0.1576	0.0237		
p-value of Breslow-Day Test for Homogeneity [2]	0.0441	0.0134		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (1.8)	2 (2.3)	4 (1.8)	8 (1.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.28		
95% CI of the odds ratio	(0.18, 5.52)	(0.23, 7.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.27		
95% CI of the risk ratio	(0.19, 5.35)	(0.24, 6.81)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.01	0.49		
95% CI of the absolute risk difference	(-3.04, 3.03)	(-3.12, 4.10)		
p-value	0.9958	0.7799		
p-value of Breslow-Day Test for Homogeneity [2]	0.9224	0.3241		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	1 (1.1)	1 (0.5)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.56		
95% CI of the odds ratio	NE	(0.16, 41.36)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.54		
95% CI of the risk ratio	NE	(0.16, 40.16)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.45	0.70		
95% CI of the absolute risk difference	(-1.34, 0.43)	(-1.71, 3.11)		
p-value	0.4778	0.4930		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.2400		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	21 (18.9)	14 (16.1)	46 (20.8)	81 (19.3)
Grade 2	69 (62.2)	49 (56.3)	127 (57.5)	245 (58.5)
Grade 3	13 (11.7)	16 (18.4)	31 (14.0)	60 (14.3)
Grade 4	0	0	6 (2.7)	6 (1.4)
Grade 5	0	0	0	0

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	28 (25.2)	12 (13.8)	40 (18.1)	80 (19.1)
Grade 2	20 (18.0)	11 (12.6)	23 (10.4)	54 (12.9)
Grade 3	1 (0.9)	2 (2.3)	0	3 (0.7)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.45	-0.45		
95% CI of the absolute risk difference	(-1.34, 0.43)	(-1.34, 0.43)		
p-value	0.4778	0.5297		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.45	-0.45		
95% CI of the absolute risk difference	(-1.34, 0.43)	(-1.34, 0.43)		
p-value	0.4778	0.5297		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.45	-0.45		
95% CI of the absolute risk difference	(-1.34, 0.43)	(-1.34, 0.43)		
p-value	0.4778	0.5297		
p-value of Breslow-Day Test for Homogeneity [2]	0.2129	NE		
Other MACE AE – Adjudicated Event	0	0	3 (1.4)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.36	-1.36		
95% CI of the absolute risk difference	(-2.88, 0.17)	(-2.88, 0.17)		
p-value	0.2175	0.2748		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (0.9)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.90	-0.90		
95% CI of the absolute risk difference	(-2.15, 0.34)	(-2.15, 0.34)		
p-value	0.3148	0.3734		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.5)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.45	-0.45		
95% CI of the absolute risk difference	(-1.34, 0.43)	(-1.34, 0.43)		
p-value	0.4778	0.5297		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (0.9)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.90	-0.90		
95% CI of the absolute risk difference	(-2.15, 0.34)	(-2.15, 0.34)		
p-value	0.3148	0.3734		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=221) n (%)	Overall (N=419) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

System Organ Class Preferred Term	MGL-3196 80 mg (N=30) Patients n (%)	 Events n	MGL-3196 100 mg (N=31) Patients n (%)	 Events n	Placebo (N=35) Patients n (%)	 Events n	Overall (N=96) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	7 (23.3)	20	14 (45.2)	22	4 (11.4)	6	25 (26.0)	48
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.36		6.38					
95% CI of the odds ratio	(0.62, 9.02)		(1.81, 22.47)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.04		3.95					
95% CI of the risk ratio	(0.66, 6.30)		(1.45, 10.75)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.90		33.73					
95% CI of the absolute risk difference	(-6.54, 30.35)		(13.29, 54.18)					
p-value	0.2019		0.0021					
p-value of Breslow-Day Test for Homogeneity [2]	0.8375		0.2319					
Nausea	8 (26.7)	11	7 (22.6)	8	3 (8.6)	4	18 (18.8)	23
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.88		3.11					
95% CI of the odds ratio	(0.92, 16.27)		(0.73, 13.29)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.11		2.63					
95% CI of the risk ratio	(0.91, 10.69)		(0.74, 9.32)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	18.10		14.01					
95% CI of the absolute risk difference	(-0.25, 36.44)		(-3.39, 31.41)					
p-value	0.0524		0.1132					
p-value of Breslow-Day Test for Homogeneity [2]	0.6000		0.0998					

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Weight Change at Week 52 (Label Population)

Weight Change at Week 52: >= 5% weight Loss

System Organ Class Preferred Term	MGL-3196 80 mg (N=30) Patients n (%)	 Events n	MGL-3196 100 mg (N=31) Patients n (%)	 Events n	Placebo (N=35) Patients n (%)	 Events n	Overall (N=96) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	2 (6.7)	2	2 (6.5)	2	1 (2.9)	1	5 (5.2)	5
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.43		2.34					
95% CI of the odds ratio	(0.21, 28.20)		(0.20, 27.20)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.33		2.26					
95% CI of the risk ratio	(0.22, 24.48)		(0.22, 23.71)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.81		3.59					
95% CI of the absolute risk difference	(-6.69, 14.30)		(-6.66, 13.85)					
p-value	0.4656		0.4841					
p-value of Breslow-Day Test for Homogeneity [2]	0.3459		0.3813					
Abdominal discomfort	0	0	1 (3.2)	1	0	0	1 (1.0)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		3.23					
95% CI of the absolute risk difference	NE		(-2.99, 9.45)					
p-value	NE		0.2843					
p-value of Breslow-Day Test for Homogeneity [2]	0.6959		0.1431					

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

System Organ Class Preferred Term	MGL-3196 80 mg (N=30) Patients n (%)	 Events n	MGL-3196 100 mg (N=31) Patients n (%)	 Events n	Placebo (N=35) Patients n (%)	 Events n	Overall (N=96) Patients n (%)	 Events n
General disorders and administration site conditions	3 (10.0)	9	8 (25.8)	12	12 (34.3)	18	23 (24.0)	39
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.21		0.67					
95% CI of the odds ratio	(0.05, 0.85)		(0.23, 1.93)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		0.75					
95% CI of the risk ratio	(0.09, 0.94)		(0.35, 1.60)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-24.29		-8.48					
95% CI of the absolute risk difference	(-43.33, -5.25)		(-30.49, 13.53)					
p-value	0.0205		0.4544					
p-value of Breslow-Day Test for Homogeneity [2]	0.2023		0.9609					
Skin and subcutaneous tissue disorders								
Rash	3 (10.0)	3	4 (12.9)	5	1 (2.9)	2	8 (8.3)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.78		5.04					
95% CI of the odds ratio	(0.37, 38.40)		(0.53, 47.73)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.50		4.52					
95% CI of the risk ratio	(0.38, 31.91)		(0.53, 38.28)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.14		10.05					
95% CI of the absolute risk difference	(-4.93, 19.21)		(-2.98, 23.07)					
p-value	0.2322		0.1237					
p-value of Breslow-Day Test for Homogeneity [2]	0.2065		0.6568					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

System Organ Class Preferred Term	MGL-3196 80 mg (N=30) Patients n (%)	 Events n	MGL-3196 100 mg (N=31) Patients n (%)	 Events n	Placebo (N=35) Patients n (%)	 Events n	Overall (N=96) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Pruritus	4 (13.3)	5	1 (3.2)	1	2 (5.7)	2	7 (7.3)	8
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.54		0.55					
95% CI of the odds ratio	(0.43, 14.95)		(0.05, 6.38)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.33		0.56					
95% CI of the risk ratio	(0.46, 11.86)		(0.05, 5.93)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.62		-2.49					
95% CI of the absolute risk difference	(-6.77, 22.01)		(-12.38, 7.40)					
p-value	0.2901		0.6281					
p-value of Breslow-Day Test for Homogeneity [2]	0.2612		0.4699					
Renal and urinary disorders	1 (3.3)	1	5 (16.1)	5	4 (11.4)	4	10 (10.4)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.27		1.49					
95% CI of the odds ratio	(0.03, 2.53)		(0.36, 6.13)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		1.41					
95% CI of the risk ratio	(0.03, 2.47)		(0.42, 4.79)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.10		4.70					
95% CI of the absolute risk difference	(-20.44, 4.25)		(-11.99, 21.40)					
p-value	0.2221		0.5787					
p-value of Breslow-Day Test for Homogeneity [2]	0.8218		0.1537					

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30)		MGL-3196 100 mg (N=31)		Placebo (N=35)		Overall (N=96)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	0	0	2 (6.5)	2	5 (14.3)	6	7 (7.3)	8
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.09		0.41					
95% CI of the odds ratio	(0.00, 1.72)		(0.07, 2.30)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11		0.45					
95% CI of the risk ratio	(0.01, 1.83)		(0.09, 2.16)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-13.66		-7.83					
95% CI of the absolute risk difference	(-26.23, -1.10)		(-22.30, 6.63)					
p-value	0.0508		0.3023					
p-value of Breslow-Day Test for Homogeneity [2]	0.1031		0.7480					

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

System Organ Class Preferred Term	MGL-3196 80 mg (N=30) Patients n (%)	 Events n	MGL-3196 100 mg (N=31) Patients n (%)	 Events n	Placebo (N=35) Patients n (%)	 Events n	Overall (N=96) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	0	0	0	0	1 (2.9)	2	1 (1.0)	2
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86		-2.86					
95% CI of the absolute risk difference	(-8.38, 2.66)		(-8.38, 2.66)					
p-value	0.3508		0.3430					
p-value of Breslow-Day Test for Homogeneity [2]	0.5701		NE					

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

System Organ Class Preferred Term	MGL-3196 80 mg (N=12) Patients n (%)	 Events n	MGL-3196 100 mg (N=8) Patients n (%)	 Events n	Placebo (N=13) Patients n (%)	 Events n	Overall (N=33) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	2 (16.7)	3	1 (12.5)	1	2 (15.4)	2	5 (15.2)	6
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.10		0.79					
95% CI of the odds ratio	(0.13, 9.34)		(0.06, 10.38)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08		0.81					
95% CI of the risk ratio	(0.18, 6.53)		(0.09, 7.58)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.28		-2.88					
95% CI of the absolute risk difference	(-27.52, 30.08)		(-33.05, 27.28)					
p-value	0.9304		0.8544					
p-value of Breslow-Day Test for Homogeneity [2]	0.8375		0.2319					
Nausea	2 (16.7)	3	0	0	2 (15.4)	2	4 (12.1)	5
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.10		0.27					
95% CI of the odds ratio	(0.13, 9.34)		(0.01, 6.40)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08		0.31					
95% CI of the risk ratio	(0.18, 6.53)		(0.02, 5.76)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.28		-12.30					
95% CI of the absolute risk difference	(-27.52, 30.08)		(-37.33, 12.73)					
p-value	0.9304		0.3926					
p-value of Breslow-Day Test for Homogeneity [2]	0.6000		0.0998					

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

System Organ Class Preferred Term	MGL-3196 80 mg (N=12) Patients n (%)	 Events n	MGL-3196 100 mg (N=8) Patients n (%)	 Events n	Placebo (N=13) Patients n (%)	 Events n	Overall (N=33) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	1 (8.3)	1	0	0	2 (15.4)	2	3 (9.1)	3
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		0.27					
95% CI of the odds ratio	(0.04, 6.35)		(0.01, 6.40)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.54		0.31					
95% CI of the risk ratio	(0.06, 5.24)		(0.02, 5.76)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.05		-12.30					
95% CI of the absolute risk difference	(-32.14, 18.03)		(-37.33, 12.73)					
p-value	0.5878		0.3926					
p-value of Breslow-Day Test for Homogeneity [2]	0.3459		0.3813					
Abdominal discomfort	0	0	0	0	1 (7.7)	1	1 (3.0)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		0.49					
95% CI of the odds ratio	(0.01, 8.99)		(0.02, 13.52)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		0.52					
95% CI of the risk ratio	(0.02, 8.05)		(0.02, 11.39)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.87		-5.16					
95% CI of the absolute risk difference	(-26.15, 12.41)		(-27.21, 16.90)					
p-value	0.4959		0.6683					
p-value of Breslow-Day Test for Homogeneity [2]	0.6959		0.1431					

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

System Organ Class Preferred Term	MGL-3196 80 mg (N=12) Patients n (%)	 Events n	MGL-3196 100 mg (N=8) Patients n (%)	 Events n	Placebo (N=13) Patients n (%)	 Events n	Overall (N=33) Patients n (%)	 Events n
General disorders and administration site conditions	3 (25.0)	4	1 (12.5)	1	3 (23.1)	3	7 (21.2)	8
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.11		0.48					
95% CI of the odds ratio	(0.18, 6.97)		(0.04, 5.58)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08		0.54					
95% CI of the risk ratio	(0.27, 4.37)		(0.07, 4.36)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.92		-10.58					
95% CI of the absolute risk difference	(-31.61, 35.46)		(-42.98, 21.82)					
p-value	0.9104		0.5489					
p-value of Breslow-Day Test for Homogeneity [2]	0.2023		0.9609					
Skin and subcutaneous tissue disorders								
Pruritus	1 (8.3)	2	0	0	3 (23.1)	3	4 (12.1)	5
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.30		0.18					
95% CI of the odds ratio	(0.03, 3.41)		(0.01, 3.91)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		0.22					
95% CI of the risk ratio	(0.04, 3.02)		(0.01, 3.81)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-14.74		-19.44					
95% CI of the absolute risk difference	(-42.48, 12.99)		(-46.62, 7.73)					
p-value	0.3151		0.2299					
p-value of Breslow-Day Test for Homogeneity [2]	0.2612		0.4699					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

System Organ Class Preferred Term	MGL-3196 80 mg (N=12) Patients n (%)	 Events n	MGL-3196 100 mg (N=8) Patients n (%)	 Events n	Placebo (N=13) Patients n (%)	 Events n	Overall (N=33) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	1 (8.3)	1	1 (12.5)	1	0	0	2 (6.1)	2
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.52		5.40					
95% CI of the odds ratio	(0.13, 95.09)		(0.19, 149.78)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.23		4.67					
95% CI of the risk ratio	(0.14, 72.46)		(0.21, 102.47)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.97		13.10					
95% CI of the absolute risk difference	(-11.94, 27.87)		(-13.12, 39.31)					
p-value	0.4296		0.2767					
p-value of Breslow-Day Test for Homogeneity [2]	0.2065		0.6568					
Renal and urinary disorders	0	0	3 (37.5)	4	0	0	3 (9.1)	4
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		17.18					
95% CI of the odds ratio	NE		(0.76, 390.92)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		10.89					
95% CI of the risk ratio	NE		(0.63, 186.82)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		35.32					
95% CI of the absolute risk difference	NE		(2.02, 68.62)					
p-value	NE		0.0292					
p-value of Breslow-Day Test for Homogeneity [2]	0.8218		0.1537					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Weight Change at Week 52 (Label Population)

Weight Change at Week 52: >= 5% weight Gain

System Organ Class Preferred Term	MGL-3196 80 mg (N=12) Patients n (%)	 Events n	MGL-3196 100 mg (N=8) Patients n (%)	 Events n	Placebo (N=13) Patients n (%)	 Events n	Overall (N=33) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	1 (8.3)	1	0	0	1 (7.7)	1	2 (6.1)	2
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.09		0.49					
95% CI of the odds ratio	(0.06, 19.63)		(0.02, 13.52)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.08		0.52					
95% CI of the risk ratio	(0.08, 15.46)		(0.02, 11.39)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.64		-5.16					
95% CI of the absolute risk difference	(-20.67, 21.96)		(-27.21, 16.90)					
p-value	0.9529		0.6683					
p-value of Breslow-Day Test for Homogeneity [2]	0.5701		NE					

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Weight Change at Week 52 (Label Population)

Weight Change at Week 52: >= 5% weight Gain

System Organ Class Preferred Term	MGL-3196 80 mg (N=12) Patients n (%)	 Events n	MGL-3196 100 mg (N=8) Patients n (%)	 Events n	Placebo (N=13) Patients n (%)	 Events n	Overall (N=33) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	0	0	0	0	2 (15.4)	2	2 (6.1)	2
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.18		0.27					
95% CI of the odds ratio	(0.01, 4.25)		(0.01, 6.40)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.22		0.31					
95% CI of the risk ratio	(0.01, 4.08)		(0.02, 5.76)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-14.01		-12.30					
95% CI of the absolute risk difference	(-36.63, 8.61)		(-37.33, 12.73)					
p-value	0.2471		0.3926					
p-value of Breslow-Day Test for Homogeneity [2]	0.1031		0.7480					

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

System Organ Class Preferred Term	MGL-3196 80 mg (N=111) Patients n (%)	 Events n	MGL-3196 100 mg (N=87) Patients n (%)	 Events n	Placebo (N=221) Patients n (%)	 Events n	Overall (N=419) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	30 (27.0)	47	28 (32.2)	39	36 (16.3)	44	94 (22.4)	130
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.90		2.44					
95% CI of the odds ratio	(1.10, 3.30)		(1.37, 4.33)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.66		1.98					
95% CI of the risk ratio	(1.08, 2.54)		(1.29, 3.03)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	10.74		15.89					
95% CI of the absolute risk difference	(1.15, 20.33)		(4.94, 26.85)					
p-value	0.0207		0.0020					
p-value of Breslow-Day Test for Homogeneity [2]	0.8375		0.2319					
Nausea	29 (26.1)	32	9 (10.3)	10	31 (14.0)	37	69 (16.5)	79
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.17		0.71					
95% CI of the odds ratio	(1.23, 3.83)		(0.32, 1.55)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.86		0.74					
95% CI of the risk ratio	(1.19, 2.93)		(0.37, 1.48)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	12.10		-3.68					
95% CI of the absolute risk difference	(2.73, 21.47)		(-11.55, 4.19)					
p-value	0.0069		0.3868					
p-value of Breslow-Day Test for Homogeneity [2]	0.6000		0.0998					

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

System Organ Class Preferred Term	MGL-3196 80 mg (N=111) Patients n (%)	 Events n	MGL-3196 100 mg (N=87) Patients n (%)	 Events n	Placebo (N=221) Patients n (%)	 Events n	Overall (N=419) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	17 (15.3)	19	6 (6.9)	6	12 (5.4)	13	35 (8.4)	38
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.15		1.29					
95% CI of the odds ratio	(1.45, 6.86)		(0.47, 3.55)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.82		1.27					
95% CI of the risk ratio	(1.40, 5.70)		(0.49, 3.28)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.89		1.47					
95% CI of the absolute risk difference	(2.55, 17.22)		(-4.64, 7.57)					
p-value	0.0026		0.6213					
p-value of Breslow-Day Test for Homogeneity [2]	0.3459		0.3813					
Abdominal discomfort	1 (0.9)	1	1 (1.1)	1	12 (5.4)	13	14 (3.3)	15
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.16		0.20					
95% CI of the odds ratio	(0.02, 1.23)		(0.03, 1.58)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.17		0.21					
95% CI of the risk ratio	(0.02, 1.26)		(0.03, 1.60)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.53		-4.28					
95% CI of the absolute risk difference	(-8.00, -1.06)		(-8.01, -0.55)					
p-value	0.0447		0.0926					
p-value of Breslow-Day Test for Homogeneity [2]	0.6959		0.1431					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111)		MGL-3196 100 mg (N=87)		Placebo (N=221)		Overall (N=419)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
General disorders and administration site conditions	26 (23.4)	36	17 (19.5)	20	65 (29.4)	77	108 (25.8)	133
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73		0.58					
95% CI of the odds ratio	(0.43, 1.24)		(0.32, 1.07)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80		0.66					
95% CI of the risk ratio	(0.54, 1.18)		(0.41, 1.07)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.99		-9.87					
95% CI of the absolute risk difference	(-15.90, 3.92)		(-20.14, 0.40)					
p-value	0.2485		0.0776					
p-value of Breslow-Day Test for Homogeneity [2]	0.2023		0.9609					
Skin and subcutaneous tissue disorders								
Pruritus	16 (14.4)	20	5 (5.7)	7	17 (7.7)	20	38 (9.1)	47
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.02		0.73					
95% CI of the odds ratio	(0.98, 4.17)		(0.26, 2.05)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.87		0.75					
95% CI of the risk ratio	(0.98, 3.57)		(0.28, 1.96)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.72		-1.95					
95% CI of the absolute risk difference	(-0.70, 14.14)		(-7.97, 4.08)					
p-value	0.0535		0.5507					
p-value of Breslow-Day Test for Homogeneity [2]	0.2612		0.4699					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

System Organ Class Preferred Term	MGL-3196 80 mg (N=111) Patients n (%)	 Events n	MGL-3196 100 mg (N=87) Patients n (%)	 Events n	Placebo (N=221) Patients n (%)	 Events n	Overall (N=419) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	3 (2.7)	3	10 (11.5)	12	10 (4.5)	11	23 (5.5)	26
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59		2.74					
95% CI of the odds ratio	(0.16, 2.17)		(1.10, 6.84)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60		2.54					
95% CI of the risk ratio	(0.17, 2.13)		(1.10, 5.89)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.82		6.97					
95% CI of the absolute risk difference	(-5.90, 2.25)		(-0.27, 14.21)					
p-value	0.4194		0.0254					
p-value of Breslow-Day Test for Homogeneity [2]	0.2065		0.6568					
Renal and urinary disorders	4 (3.6)	5	12 (13.8)	15	21 (9.5)	27	37 (8.8)	47
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		1.52					
95% CI of the odds ratio	(0.12, 1.06)		(0.71, 3.25)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		1.45					
95% CI of the risk ratio	(0.13, 1.08)		(0.75, 2.82)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.90		4.29					
95% CI of the absolute risk difference	(-11.09, -0.71)		(-3.92, 12.50)					
p-value	0.0547		0.2730					
p-value of Breslow-Day Test for Homogeneity [2]	0.8218		0.1537					

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

System Organ Class Preferred Term	MGL-3196 80 mg (N=111) Patients n (%)	 Events n	MGL-3196 100 mg (N=87) Patients n (%)	 Events n	Placebo (N=221) Patients n (%)	 Events n	Overall (N=419) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	7 (6.3)	8	2 (2.3)	2	17 (7.7)	20	26 (6.2)	30
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81		0.28					
95% CI of the odds ratio	(0.32, 2.01)		(0.06, 1.25)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.82		0.30					
95% CI of the risk ratio	(0.35, 1.92)		(0.07, 1.27)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.39		-5.39					
95% CI of the absolute risk difference	(-7.11, 4.34)		(-10.11, -0.68)					
p-value	0.6455		0.0765					
p-value of Breslow-Day Test for Homogeneity [2]	0.1031		0.7480					

AMNOG Table S1.11.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

System Organ Class Preferred Term	MGL-3196 80 mg (N=111) Patients n (%)	 Events n	MGL-3196 100 mg (N=87) Patients n (%)	 Events n	Placebo (N=221) Patients n (%)	 Events n	Overall (N=419) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	1 (0.9)	1	0	0	8 (3.6)	11	9 (2.1)	12
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.24		NE					
95% CI of the odds ratio	(0.03, 1.96)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.25		NE					
95% CI of the risk ratio	(0.03, 1.97)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.72		-3.62					
95% CI of the absolute risk difference	(-5.74, 0.31)		(-6.08, -1.16)					
p-value	0.1501		0.0722					
p-value of Breslow-Day Test for Homogeneity [2]	0.5701		NE					

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CFB = Change from Baseline; DILI = drug-induced liver injury; NE = Not estimable.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Events n:				
Total TEAEs	714	488	0	1202
Total Serious TEAEs	21	14	0	35
Total TEAEs Leading to Discontinuation of Study Drug	7	2	0	9
Total TEAEs Related to Study Drug	85	49	0	134
Total TEAEs >= Grade 3 Severity	24	23	0	47
Patients n (%):				
Any TEAE	88 (96.7)	62 (92.5)	0	150 (94.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Serious TEAE	10 (11.0)	10 (14.9)	0	20 (12.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Any TEAEs >= Grade 3 Severity	13 (14.3)	13 (19.4)	0	26 (16.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any TEAEs <= Grade 2 Severity	88 (96.7)	62 (92.5)	0	150 (94.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any TEAEs leading to Study-Drug Discontinuation	4 (4.4)	2 (3.0)	0	6 (3.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Any TEAEs leading to Study Discontinuation	2 (2.2)	1 (1.5)	0	3 (1.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Fatal TEAEs	1 (1.1)	0	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	38 (41.8)	25 (37.3)	0	63 (39.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	2 (2.2)	2 (3.0)	0	4 (2.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	1 (1.5)	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	1 (1.5)	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	20 (22.0)	11 (16.4)	0	31 (19.6)
Grade 2	55 (60.4)	38 (56.7)	0	93 (58.9)
Grade 3	12 (13.2)	13 (19.4)	0	25 (15.8)
Grade 4	0	0	0	0
Grade 5	1 (1.1)	0	0	1 (0.6)

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	24 (26.4)	14 (20.9)	0	38 (24.1)
Grade 2	12 (13.2)	9 (13.4)	0	21 (13.3)
Grade 3	2 (2.2)	2 (3.0)	0	4 (2.5)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (1.1)	0	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (1.1)	0	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (1.1)	0	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
DILI AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE - Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE - Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Events n:				
Total TEAEs	434	412	2017	2863
Total Serious TEAEs	5	8	80	93
Total TEAEs Leading to Discontinuation of Study Drug	9	3	12	24
Total TEAEs Related to Study Drug	59	34	134	227
Total TEAEs >= Grade 3 Severity	8	12	91	111
Patients n (%):				
Any TEAE	57 (93.4)	51 (89.5)	253 (95.1)	361 (94.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.44		
95% CI of the odds ratio	(0.23, 2.33)	(0.16, 1.20)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	0.94		
95% CI of the risk ratio	(0.91, 1.06)	(0.86, 1.03)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.67	-5.64		
95% CI of the absolute risk difference	(-8.40, 5.06)	(-14.02, 2.74)		
p-value	0.5961	0.1006		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Serious TEAE	3 (4.9)	6 (10.5)	37 (13.9)	46 (12.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.32	0.73		
95% CI of the odds ratio	(0.10, 1.07)	(0.29, 1.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.35	0.76		
95% CI of the risk ratio	(0.11, 1.11)	(0.34, 1.71)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.99	-3.38		
95% CI of the absolute risk difference	(-15.83, -2.15)	(-12.37, 5.60)		
p-value	0.0532	0.4950		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Any TEAEs >= Grade 3 Severity	7 (11.5)	8 (14.0)	48 (18.0)	63 (16.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	0.74		
95% CI of the odds ratio	(0.25, 1.37)	(0.33, 1.67)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.64	0.78		
95% CI of the risk ratio	(0.30, 1.34)	(0.39, 1.55)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.57	-4.01		
95% CI of the absolute risk difference	(-15.81, 2.67)	(-14.14, 6.12)		
p-value	0.2160	0.4680		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any TEAEs <= Grade 2 Severity	56 (91.8)	51 (89.5)	253 (95.1)	360 (93.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58	0.44		
95% CI of the odds ratio	(0.20, 1.68)	(0.16, 1.20)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	0.94		
95% CI of the risk ratio	(0.89, 1.05)	(0.86, 1.03)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.31	-5.64		
95% CI of the absolute risk difference	(-10.66, 4.05)	(-14.02, 2.74)		
p-value	0.3067	0.1006		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any TEAEs leading to Study-Drug Discontinuation	6 (9.8)	3 (5.3)	12 (4.5)	21 (5.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.31	1.18		
95% CI of the odds ratio	(0.83, 6.42)	(0.32, 4.31)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.18	1.17		
95% CI of the risk ratio	(0.85, 5.58)	(0.34, 4.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.32	0.75		
95% CI of the absolute risk difference	(-2.55, 13.20)	(-5.56, 7.06)		
p-value	0.1000	0.8066		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Any TEAEs leading to Study Discontinuation	0	1 (1.8)	3 (1.1)	4 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.57		
95% CI of the odds ratio	NE	(0.16, 15.33)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.56		
95% CI of the risk ratio	NE	(0.16, 14.69)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.13	0.63		
95% CI of the absolute risk difference	(-2.40, 0.14)	(-3.01, 4.26)		
p-value	0.4047	0.6979		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	25 (41.0)	15 (26.3)	75 (28.2)	115 (29.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.77	0.91		
95% CI of the odds ratio	(0.99, 3.15)	(0.48, 1.74)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.45	0.93		
95% CI of the risk ratio	(1.02, 2.08)	(0.58, 1.50)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	12.79	-1.88		
95% CI of the absolute risk difference	(-0.69, 26.26)	(-14.53, 10.77)		
p-value	0.0506	0.7739		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.4)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.11, 0.36)	(-1.11, 0.36)		
p-value	0.6315	0.6429		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	2 (0.8)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.75	-0.75		
95% CI of the absolute risk difference	(-1.79, 0.29)	(-1.79, 0.29)		
p-value	0.4969	0.5114		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	3 (4.9)	0	5 (1.9)	8 (2.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.70	NE		
95% CI of the odds ratio	(0.63, 11.62)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.62	NE		
95% CI of the risk ratio	(0.64, 10.65)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.04	-1.88		
95% CI of the absolute risk difference	(-2.63, 8.71)	(-3.51, -0.25)		
p-value	0.1659	0.2969		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	2 (0.8)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.75	-0.75		
95% CI of the absolute risk difference	(-1.79, 0.29)	(-1.79, 0.29)		
p-value	0.4969	0.5114		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	14 (23.0)	9 (15.8)	57 (21.4)	80 (20.8)
Grade 2	36 (59.0)	34 (59.6)	148 (55.6)	218 (56.8)
Grade 3	7 (11.5)	8 (14.0)	41 (15.4)	56 (14.6)
Grade 4	0	0	7 (2.6)	7 (1.8)
Grade 5	0	0	0	0

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	13 (21.3)	10 (17.5)	46 (17.3)	69 (18.0)
Grade 2	12 (19.7)	5 (8.8)	27 (10.2)	44 (11.5)
Grade 3	0	0	1 (0.4)	1 (0.3)
Grade 4	0	0	1 (0.4)	1 (0.3)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	1 (0.4)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.11, 0.36)	(-1.11, 0.36)		
p-value	0.6315	0.6429		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.11, 0.36)	(-1.11, 0.36)		
p-value	0.6315	0.6429		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	1 (0.4)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.11, 0.36)	(-1.11, 0.36)		
p-value	0.6315	0.6429		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	3 (1.1)	3 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.13	-1.13		
95% CI of the absolute risk difference	(-2.40, 0.14)	(-2.40, 0.14)		
p-value	0.4047	0.4205		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (0.8)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.75	-0.75		
95% CI of the absolute risk difference	(-1.79, 0.29)	(-1.79, 0.29)		
p-value	0.4969	0.5114		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.11, 0.36)	(-1.11, 0.36)		
p-value	0.6315	0.6429		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (0.8)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.75	-0.75		
95% CI of the absolute risk difference	(-1.79, 0.29)	(-1.79, 0.29)		
p-value	0.4969	0.5114		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; CFB = Change from Baseline; NE = Not estimable.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Events n:				
Total TEAEs	705	484	0	1189
Total Serious TEAEs	21	14	0	35
Total TEAEs Leading to Discontinuation of Study Drug	5	2	0	7
Total TEAEs Related to Study Drug	84	49	0	133
Total TEAEs >= Grade 3 Severity	22	22	0	44
Patients n (%):				
Any TEAE	87 (95.6)	62 (92.5)	0	149 (94.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Serious TEAE	10 (11.0)	10 (14.9)	0	20 (12.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Any TEAEs >= Grade 3 Severity	11 (12.1)	12 (17.9)	0	23 (14.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any TEAEs <= Grade 2 Severity	87 (95.6)	62 (92.5)	0	149 (94.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any TEAEs leading to Study-Drug Discontinuation	2 (2.2)	2 (3.0)	0	4 (2.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Any TEAEs leading to Study Discontinuation	2 (2.2)	1 (1.5)	0	3 (1.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Fatal TEAEs	1 (1.1)	0	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	38 (41.8)	25 (37.3)	0	63 (39.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (1.1)	2 (3.0)	0	3 (1.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	1 (1.5)	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	1 (1.5)	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	19 (20.9)	12 (17.9)	0	31 (19.6)
Grade 2	57 (62.6)	38 (56.7)	0	95 (60.1)
Grade 3	10 (11.0)	12 (17.9)	0	22 (13.9)
Grade 4	0	0	0	0
Grade 5	1 (1.1)	0	0	1 (0.6)

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	24 (26.4)	14 (20.9)	0	38 (24.1)
Grade 2	13 (14.3)	9 (13.4)	0	22 (13.9)
Grade 3	1 (1.1)	2 (3.0)	0	3 (1.9)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (1.1)	0	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	1 (1.1)	0	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE - Adjudicated Event	1 (1.1)	0	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91) n (%)	MGL-3196 100 mg (N=67) n (%)	Placebo (N=0) n (%)	Overall (N=158) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Events n:				
Total TEAEs	430	408	1994	2832
Total Serious TEAEs	5	8	80	93
Total TEAEs Leading to Discontinuation of Study Drug	8	1	7	16
Total TEAEs Related to Study Drug	59	34	133	226
Total TEAEs >= Grade 3 Severity	7	12	88	107
Patients n (%):				
Any TEAE	57 (93.4)	51 (89.5)	251 (94.4)	359 (93.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.85	0.51		
95% CI of the odds ratio	(0.27, 2.66)	(0.19, 1.37)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	0.95		
95% CI of the risk ratio	(0.92, 1.06)	(0.86, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.92	-4.89		
95% CI of the absolute risk difference	(-7.72, 5.88)	(-13.32, 3.55)		
p-value	0.7822	0.1744		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Serious TEAE	3 (4.9)	6 (10.5)	37 (13.9)	46 (12.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.32	0.73		
95% CI of the odds ratio	(0.10, 1.07)	(0.29, 1.82)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.35	0.76		
95% CI of the risk ratio	(0.11, 1.11)	(0.34, 1.71)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.99	-3.38		
95% CI of the absolute risk difference	(-15.83, -2.15)	(-12.37, 5.60)		
p-value	0.0532	0.4950		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Any TEAEs >= Grade 3 Severity	6 (9.8)	8 (14.0)	45 (16.9)	59 (15.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.54	0.80		
95% CI of the odds ratio	(0.22, 1.32)	(0.36, 1.81)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58	0.83		
95% CI of the risk ratio	(0.26, 1.30)	(0.41, 1.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.08	-2.88		
95% CI of the absolute risk difference	(-15.81, 1.65)	(-12.96, 7.20)		
p-value	0.1692	0.5939		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any TEAEs <= Grade 2 Severity	56 (91.8)	51 (89.5)	251 (94.4)	358 (93.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67	0.51		
95% CI of the odds ratio	(0.23, 1.92)	(0.19, 1.37)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	0.95		
95% CI of the risk ratio	(0.90, 1.05)	(0.86, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.56	-4.89		
95% CI of the absolute risk difference	(-9.98, 4.86)	(-13.32, 3.55)		
p-value	0.4521	0.1744		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any TEAEs leading to Study-Drug Discontinuation	5 (8.2)	1 (1.8)	7 (2.6)	13 (3.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.30	0.66		
95% CI of the odds ratio	(1.01, 10.79)	(0.08, 5.48)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.11	0.67		
95% CI of the risk ratio	(1.02, 9.48)	(0.08, 5.31)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.57	-0.88		
95% CI of the absolute risk difference	(-1.58, 12.71)	(-4.79, 3.04)		
p-value	0.0371	0.6990		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Any TEAEs leading to Study Discontinuation	0	1 (1.8)	3 (1.1)	4 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.57		
95% CI of the odds ratio	NE	(0.16, 15.33)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.56		
95% CI of the risk ratio	NE	(0.16, 14.69)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.13	0.63		
95% CI of the absolute risk difference	(-2.40, 0.14)	(-3.01, 4.26)		
p-value	0.4047	0.6979		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	25 (41.0)	15 (26.3)	74 (27.8)	114 (29.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	0.93		
95% CI of the odds ratio	(1.01, 3.21)	(0.48, 1.77)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.47	0.95		
95% CI of the risk ratio	(1.03, 2.11)	(0.59, 1.52)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.16	-1.50		
95% CI of the absolute risk difference	(-0.30, 26.63)	(-14.14, 11.13)		
p-value	0.0436	0.8176		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.4)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.11, 0.36)	(-1.11, 0.36)		
p-value	0.6315	0.6429		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	2 (0.8)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.75	-0.75		
95% CI of the absolute risk difference	(-1.79, 0.29)	(-1.79, 0.29)		
p-value	0.4969	0.5114		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	3 (4.9)	0	5 (1.9)	8 (2.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.70	NE		
95% CI of the odds ratio	(0.63, 11.62)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.62	NE		
95% CI of the risk ratio	(0.64, 10.65)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.04	-1.88		
95% CI of the absolute risk difference	(-2.63, 8.71)	(-3.51, -0.25)		
p-value	0.1659	0.2969		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	2 (0.8)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.75	-0.75		
95% CI of the absolute risk difference	(-1.79, 0.29)	(-1.79, 0.29)		
p-value	0.4969	0.5114		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	14 (23.0)	9 (15.8)	58 (21.8)	81 (21.1)
Grade 2	37 (60.7)	34 (59.6)	148 (55.6)	219 (57.0)
Grade 3	6 (9.8)	8 (14.0)	38 (14.3)	52 (13.5)
Grade 4	0	0	7 (2.6)	7 (1.8)
Grade 5	0	0	0	0

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	13 (21.3)	10 (17.5)	45 (16.9)	68 (17.7)
Grade 2	12 (19.7)	5 (8.8)	27 (10.2)	44 (11.5)
Grade 3	0	0	1 (0.4)	1 (0.3)
Grade 4	0	0	1 (0.4)	1 (0.3)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	1 (0.4)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.11, 0.36)	(-1.11, 0.36)		
p-value	0.6315	0.6429		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.11, 0.36)	(-1.11, 0.36)		
p-value	0.6315	0.6429		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	1 (0.4)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.11, 0.36)	(-1.11, 0.36)		
p-value	0.6315	0.6429		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	3 (1.1)	3 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.13	-1.13		
95% CI of the absolute risk difference	(-2.40, 0.14)	(-2.40, 0.14)		
p-value	0.4047	0.4205		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (0.8)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.75	-0.75		
95% CI of the absolute risk difference	(-1.79, 0.29)	(-1.79, 0.29)		
p-value	0.4969	0.5114		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.4)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.38	-0.38		
95% CI of the absolute risk difference	(-1.11, 0.36)	(-1.11, 0.36)		
p-value	0.6315	0.6429		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (0.8)	2 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.75	-0.75		
95% CI of the absolute risk difference	(-1.79, 0.29)	(-1.79, 0.29)		
p-value	0.4969	0.5114		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61) n (%)	MGL-3196 100 mg (N=57) n (%)	Placebo (N=266) n (%)	Overall (N=384) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.12.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; CFB = Change from Baseline; NE = Not estimable.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.

AMNOG Table S1.12.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=91) Patients n (%)	 Events n	MGL-3196 100 mg (N=67) Patients n (%)	 Events n	Placebo (N=0) Patients n (%)	 Events n	Overall (N=158) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	20 (22.0)	37	26 (38.8)	33	0	0	46 (29.1)	70
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					
Nausea	24 (26.4)	29	9 (13.4)	10	0	0	33 (20.9)	39
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					

AMNOG Table S1.12.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=91) Patients n (%)	 Events n	MGL-3196 100 mg (N=67) Patients n (%)	 Events n	Placebo (N=0) Patients n (%)	 Events n	Overall (N=158) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	13 (14.3)	15	6 (9.0)	6	0	0	19 (12.0)	21
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					
Abdominal discomfort	1 (1.1)	1	0	0	0	0	1 (0.6)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					

AMNOG Table S1.12.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=91) Patients n (%)	 Events n	MGL-3196 100 mg (N=67) Patients n (%)	 Events n	Placebo (N=0) Patients n (%)	 Events n	Overall (N=158) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders								
Pruritus	18 (19.8)	24	5 (7.5)	7	0	0	23 (14.6)	31
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					
Rash	5 (5.5)	5	5 (7.5)	7	0	0	10 (6.3)	12
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					

AMNOG Table S1.12.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=91) Patients n (%)	 Events n	MGL-3196 100 mg (N=67) Patients n (%)	 Events n	Placebo (N=0) Patients n (%)	 Events n	Overall (N=158) Patients n (%)	 Events n
General disorders and administration site conditions	14 (15.4)	23	11 (16.4)	17	0	0	25 (15.8)	40
Odds ratio, Chi-square,								
MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square,								
MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square,								
MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					
Renal and urinary disorders	3 (3.3)	4	8 (11.9)	10	0	0	11 (7.0)	14
Odds ratio, Chi-square,								
MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square,								
MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square,								
MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.12.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=91) Patients n (%)	 Events n	MGL-3196 100 mg (N=67) Patients n (%)	 Events n	Placebo (N=0) Patients n (%)	 Events n	Overall (N=158) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	2 (2.2)	2	3 (4.5)	3	0	0	5 (3.2)	5
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					

AMNOG Table S1.12.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=91) Patients n (%)	 Events n	MGL-3196 100 mg (N=67) Patients n (%)	 Events n	Placebo (N=0) Patients n (%)	 Events n	Overall (N=158) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	1 (1.1)	1	0	0	0	0	1 (0.6)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					

AMNOG Table S1.12.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=61) Patients n (%)	 Events n	MGL-3196 100 mg (N=57) Patients n (%)	 Events n	Placebo (N=266) Patients n (%)	 Events n	Overall (N=384) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	19 (31.1)	33	16 (28.1)	26	42 (15.8)	52	77 (20.1)	111
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.41		2.08					
95% CI of the odds ratio	(1.28, 4.55)		(1.07, 4.05)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.97		1.78					
95% CI of the risk ratio	(1.24, 3.14)		(1.08, 2.93)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	15.36		12.28					
95% CI of the absolute risk difference	(2.94, 27.78)		(-0.18, 24.74)					
p-value	0.0055		0.0284					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					
Nausea	15 (24.6)	17	7 (12.3)	8	35 (13.2)	42	57 (14.8)	67
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.15		0.92					
95% CI of the odds ratio	(1.09, 4.26)		(0.39, 2.20)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.87		0.93					
95% CI of the risk ratio	(1.09, 3.20)		(0.44, 1.99)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.43		-0.88					
95% CI of the absolute risk difference	(-0.11, 22.98)		(-10.32, 8.56)					
p-value	0.0252		0.8582					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.12.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=61) Patients n (%)	 Events n	MGL-3196 100 mg (N=57) Patients n (%)	 Events n	Placebo (N=266) Patients n (%)	 Events n	Overall (N=384) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	7 (11.5)	7	2 (3.5)	2	14 (5.3)	14	23 (6.0)	23
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.33		0.65					
95% CI of the odds ratio	(0.90, 6.06)		(0.14, 2.96)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.18		0.67					
95% CI of the risk ratio	(0.92, 5.17)		(0.16, 2.85)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.21		-1.75					
95% CI of the absolute risk difference	(-2.22, 14.65)		(-7.23, 3.72)					
p-value	0.0742		0.5796					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					
Abdominal discomfort	0	0	2 (3.5)	2	13 (4.9)	14	15 (3.9)	16
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.15		0.71					
95% CI of the odds ratio	(0.01, 2.60)		(0.16, 3.23)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.16		0.72					
95% CI of the risk ratio	(0.01, 2.65)		(0.17, 3.09)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.25		-1.38					
95% CI of the absolute risk difference	(-7.69, -0.81)		(-6.81, 4.06)					
p-value	0.1353		0.6536					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					

AMNOG Table S1.12.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=61) Patients n (%)	 Events n	MGL-3196 100 mg (N=57) Patients n (%)	 Events n	Placebo (N=266) Patients n (%)	 Events n	Overall (N=384) Patients n (%)	 Events n
General disorders and administration site conditions	18 (29.5)	26	14 (24.6)	15	79 (29.7)	97	111 (28.9)	138
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99		0.77					
95% CI of the odds ratio	(0.54, 1.82)		(0.40, 1.49)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99		0.83					
95% CI of the risk ratio	(0.65, 1.53)		(0.51, 1.35)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.19		-5.14					
95% CI of the absolute risk difference	(-12.89, 12.50)		(-17.59, 7.31)					
p-value	0.9765		0.4369					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					
Skin and subcutaneous tissue disorders								
Pruritus	3 (4.9)	3	1 (1.8)	1	21 (7.9)	24	25 (6.5)	28
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60		0.21					
95% CI of the odds ratio	(0.17, 2.09)		(0.03, 1.58)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.62		0.22					
95% CI of the risk ratio	(0.19, 2.02)		(0.03, 1.62)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.98		-6.14					
95% CI of the absolute risk difference	(-9.30, 3.34)		(-10.84, -1.44)					
p-value	0.4214		0.0949					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					

Madrigal Pharmaceuticals, Inc. Page 11 of 13
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.12.3
TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61)		MGL-3196 100 mg (N=57)		Placebo (N=266)		Overall (N=384)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	2 (3.3)	2	9 (15.8)	9	11 (4.1)	13	22 (5.7)	24
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.79		4.35					
95% CI of the odds ratio	(0.17, 3.64)		(1.71, 11.05)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.79		3.82					
95% CI of the risk ratio	(0.18, 3.49)		(1.66, 8.78)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.86		11.65					
95% CI of the absolute risk difference	(-5.93, 4.21)		(1.89, 21.42)					
p-value	0.7574		0.0009					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					
Renal and urinary disorders	2 (3.3)	2	12 (21.1)	14	25 (9.4)	31	39 (10.2)	47
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33		2.57					
95% CI of the odds ratio	(0.08, 1.42)		(1.20, 5.49)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.35		2.24					
95% CI of the risk ratio	(0.08, 1.43)		(1.20, 4.19)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.12		11.65					
95% CI of the absolute risk difference	(-11.80, -0.44)		(0.50, 22.80)					
p-value	0.1173		0.0122					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.12.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=61) Patients n (%)	 Events n	MGL-3196 100 mg (N=57) Patients n (%)	 Events n	Placebo (N=266) Patients n (%)	 Events n	Overall (N=384) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	5 (8.2)	6	1 (1.8)	1	24 (9.0)	28	30 (7.8)	35
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90		0.18					
95% CI of the odds ratio	(0.33, 2.46)		(0.02, 1.36)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.91		0.19					
95% CI of the risk ratio	(0.36, 2.29)		(0.03, 1.41)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.83		-7.27					
95% CI of the absolute risk difference	(-8.52, 6.87)		(-12.11, -2.42)					
p-value	0.8379		0.0624					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.12.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=61) Patients n (%)	 Events n	MGL-3196 100 mg (N=57) Patients n (%)	 Events n	Placebo (N=266) Patients n (%)	 Events n	Overall (N=384) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	1 (1.6)	1	0	0	9 (3.4)	13	10 (2.6)	14
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48		NE					
95% CI of the odds ratio	(0.06, 3.83)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48		NE					
95% CI of the risk ratio	(0.06, 3.75)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.74		-3.38					
95% CI of the absolute risk difference	(-5.60, 2.11)		(-5.56, -1.21)					
p-value	0.4755		0.1590					
p-value of Breslow-Day Test for Homogeneity [2]	NE		NE					

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CFB = Change from Baseline; DILI = drug-induced liver injury; NE = Not estimable.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Events n:				
Total TEAEs	610	569	205	1384
Total Serious TEAEs	22	14	6	42
Total TEAEs Leading to Discontinuation of Study Drug	11	3	0	14
Total TEAEs Related to Study Drug	87	57	10	154
Total TEAEs >= Grade 3 Severity	21	19	8	48
Patients n (%):				
Any TEAE	74 (97.4)	68 (90.7)	28 (93.3)	170 (93.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.64	0.69		
95% CI of the odds ratio	(0.35, 19.68)	(0.14, 3.55)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04	0.97		
95% CI of the risk ratio	(0.94, 1.16)	(0.86, 1.10)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.04	-2.67		
95% CI of the absolute risk difference	(-5.59, 13.66)	(-13.76, 8.42)		
p-value	0.3261	0.6592		
p-value of Breslow-Day Test for Homogeneity [2]	0.1230	0.8262		
Any Serious TEAE	10 (13.2)	11 (14.7)	3 (10.0)	24 (13.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.36	1.55		
95% CI of the odds ratio	(0.35, 5.34)	(0.40, 5.99)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.32	1.47		
95% CI of the risk ratio	(0.39, 4.45)	(0.44, 4.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.16	4.67		
95% CI of the absolute risk difference	(-10.00, 16.31)	(-8.73, 18.06)		
p-value	0.6552	0.5251		
p-value of Breslow-Day Test for Homogeneity [2]	0.2569	0.5190		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Any TEAEs >= Grade 3 Severity	11 (14.5)	10 (13.3)	5 (16.7)	26 (14.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.85	0.77		
95% CI of the odds ratio	(0.27, 2.68)	(0.24, 2.47)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87	0.80		
95% CI of the risk ratio	(0.33, 2.29)	(0.30, 2.15)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.19	-3.33		
95% CI of the absolute risk difference	(-17.70, 13.31)	(-18.73, 12.06)		
p-value	0.7763	0.6592		
p-value of Breslow-Day Test for Homogeneity [2]	0.7283	0.5837		
Any TEAEs <= Grade 2 Severity	74 (97.4)	67 (89.3)	28 (93.3)	169 (93.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.64	0.60		
95% CI of the odds ratio	(0.35, 19.68)	(0.12, 3.00)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04	0.96		
95% CI of the risk ratio	(0.94, 1.16)	(0.85, 1.08)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.04	-4.00		
95% CI of the absolute risk difference	(-5.59, 13.66)	(-15.33, 7.33)		
p-value	0.3261	0.5282		
p-value of Breslow-Day Test for Homogeneity [2]	0.1230	0.9265		
Any TEAEs leading to Study-Drug Discontinuation	5 (6.6)	3 (4.0)	0	8 (4.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.69	NE		
95% CI of the odds ratio	(0.25, 87.52)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.43	NE		
95% CI of the risk ratio	(0.25, 77.71)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.53	4.00		
95% CI of the absolute risk difference	(-1.73, 12.79)	(-0.43, 8.43)		
p-value	0.2564	0.2664		
p-value of Breslow-Day Test for Homogeneity [2]	0.1087	0.4964		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Any TEAEs leading to Study Discontinuation	2 (2.6)	2 (2.7)	0	4 (2.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.63	2.67		
95% CI of the absolute risk difference	(-0.97, 6.23)	(-0.98, 6.31)		
p-value	0.3697	0.3665		
p-value of Breslow-Day Test for Homogeneity [2]	0.1514	0.6458		
Any Fatal TEAEs	1 (1.3)	0	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.32	NE		
95% CI of the absolute risk difference	(-1.25, 3.88)	NE		
p-value	0.5279	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.4315	NE		
Any Treatment-related TEAE	33 (43.4)	30 (40.0)	9 (30.0)	72 (39.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.79	1.56		
95% CI of the odds ratio	(0.73, 4.42)	(0.63, 3.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.45	1.33		
95% CI of the risk ratio	(0.79, 2.65)	(0.72, 2.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.42	10.00		
95% CI of the absolute risk difference	(-6.41, 33.25)	(-9.79, 29.79)		
p-value	0.2032	0.3380		
p-value of Breslow-Day Test for Homogeneity [2]	0.7287	0.2812		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	1 (1.3)	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	1.33		
95% CI of the absolute risk difference	NE	(-1.26, 3.93)		
p-value	NE	0.5251		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4794		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	3 (3.9)	1 (1.3)	0	4 (2.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.95	1.33		
95% CI of the absolute risk difference	(-0.43, 8.33)	(-1.26, 3.93)		
p-value	0.2696	0.5251		
p-value of Breslow-Day Test for Homogeneity [2]	0.1417	0.7279		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	1 (1.3)	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	1.33		
95% CI of the absolute risk difference	NE	(-1.26, 3.93)		
p-value	NE	0.5251		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.8467		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	17 (22.4)	11 (14.7)	10 (33.3)	38 (21.0)
Grade 2	46 (60.5)	47 (62.7)	13 (43.3)	106 (58.6)
Grade 3	10 (13.2)	10 (13.3)	5 (16.7)	25 (13.8)
Grade 4	0	0	0	0
Grade 5	1 (1.3)	0	0	1 (0.6)

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	21 (27.6)	21 (28.0)	7 (23.3)	49 (27.1)
Grade 2	12 (15.8)	8 (10.7)	2 (6.7)	22 (12.2)
Grade 3	0	1 (1.3)	0	1 (0.6)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (1.3)	0	1 (3.3)	2 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	NE		
95% CI of the odds ratio	(0.02, 6.39)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	NE		
95% CI of the risk ratio	(0.03, 6.11)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.02	-3.33		
95% CI of the absolute risk difference	(-8.93, 4.90)	(-9.76, 3.09)		
p-value	0.4916	0.1121		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0028		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	1 (1.3)	0	1 (3.3)	2 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	NE		
95% CI of the odds ratio	(0.02, 6.39)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	NE		
95% CI of the risk ratio	(0.03, 6.11)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.02	-3.33		
95% CI of the absolute risk difference	(-8.93, 4.90)	(-9.76, 3.09)		
p-value	0.4916	0.1121		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE - Adjudicated Event	1 (1.3)	0	1 (3.3)	2 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	NE		
95% CI of the odds ratio	(0.02, 6.39)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	NE		
95% CI of the risk ratio	(0.03, 6.11)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.02	-3.33		
95% CI of the absolute risk difference	(-8.93, 4.90)	(-9.76, 3.09)		
p-value	0.4916	0.1121		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0028		
Other MACE AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Other MACE AE - Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE - Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
DILI AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE - Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE - Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Serious DILI AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Madrigal Pharmaceuticals, Inc. Page 12 of 21
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Events n:				
Total TEAEs	269	194	1361	1824
Total Serious TEAEs	4	10	62	76
Total TEAEs Leading to Discontinuation of Study Drug	2	6	14	22
Total TEAEs Related to Study Drug	29	24	110	163
Total TEAEs >= Grade 3 Severity	7	13	68	88
Patients n (%):				
Any TEAE	38 (90.5)	23 (92.0)	171 (95.5)	232 (94.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	0.54		
95% CI of the odds ratio	(0.13, 1.55)	(0.11, 2.69)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.96		
95% CI of the risk ratio	(0.85, 1.05)	(0.85, 1.09)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.05	-3.53		
95% CI of the absolute risk difference	(-14.43, 4.32)	(-14.59, 7.53)		
p-value	0.1933	0.4437		
p-value of Breslow-Day Test for Homogeneity [2]	0.1230	0.8262		
Any Serious TEAE	3 (7.1)	3 (12.0)	25 (14.0)	31 (12.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47	0.84		
95% CI of the odds ratio	(0.14, 1.65)	(0.23, 3.02)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	0.86		
95% CI of the risk ratio	(0.16, 1.61)	(0.28, 2.64)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.82	-1.97		
95% CI of the absolute risk difference	(-16.12, 2.47)	(-15.68, 11.75)		
p-value	0.2315	0.7890		
p-value of Breslow-Day Test for Homogeneity [2]	0.2569	0.5190		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Any TEAEs >= Grade 3 Severity	5 (11.9)	5 (20.0)	31 (17.3)	41 (16.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.65	1.19		
95% CI of the odds ratio	(0.23, 1.77)	(0.42, 3.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	1.15		
95% CI of the risk ratio	(0.28, 1.66)	(0.50, 2.69)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.41	2.68		
95% CI of the absolute risk difference	(-16.67, 5.84)	(-13.95, 19.31)		
p-value	0.3925	0.7418		
p-value of Breslow-Day Test for Homogeneity [2]	0.7283	0.5837		
Any TEAEs <= Grade 2 Severity	38 (90.5)	23 (92.0)	171 (95.5)	232 (94.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	0.54		
95% CI of the odds ratio	(0.13, 1.55)	(0.11, 2.69)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.96		
95% CI of the risk ratio	(0.85, 1.05)	(0.85, 1.09)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.05	-3.53		
95% CI of the absolute risk difference	(-14.43, 4.32)	(-14.59, 7.53)		
p-value	0.1933	0.4437		
p-value of Breslow-Day Test for Homogeneity [2]	0.1230	0.9265		
Any TEAEs leading to Study-Drug Discontinuation	2 (4.8)	5 (20.0)	14 (7.8)	21 (8.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	2.95		
95% CI of the odds ratio	(0.13, 2.70)	(0.96, 9.05)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.61	2.56		
95% CI of the risk ratio	(0.14, 2.58)	(1.01, 6.49)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.06	12.18		
95% CI of the absolute risk difference	(-10.61, 4.49)	(-3.99, 28.34)		
p-value	0.4911	0.0497		
p-value of Breslow-Day Test for Homogeneity [2]	0.1087	0.4964		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Any TEAEs leading to Study Discontinuation	0	3 (12.0)	5 (2.8)	8 (3.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.75		
95% CI of the odds ratio	NE	(1.06, 21.24)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.30		
95% CI of the risk ratio	NE	(1.09, 16.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.79	9.21		
95% CI of the absolute risk difference	(-5.21, -0.38)	(-3.76, 22.17)		
p-value	0.2733	0.0263		
p-value of Breslow-Day Test for Homogeneity [2]	0.1514	0.6458		
Any Fatal TEAEs	0	1 (4.0)	1 (0.6)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	7.42		
95% CI of the odds ratio	NE	(0.45, 122.50)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	7.16		
95% CI of the risk ratio	NE	(0.46, 110.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.56	3.44		
95% CI of the absolute risk difference	(-1.65, 0.53)	(-4.32, 11.20)		
p-value	0.6273	0.1019		
p-value of Breslow-Day Test for Homogeneity [2]	0.4315	NE		
Any Treatment-related TEAE	16 (38.1)	6 (24.0)	53 (29.6)	75 (30.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.46	0.75		
95% CI of the odds ratio	(0.73, 2.95)	(0.28, 1.99)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.29	0.81		
95% CI of the risk ratio	(0.82, 2.01)	(0.39, 1.69)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.49	-5.61		
95% CI of the absolute risk difference	(-7.65, 24.62)	(-23.64, 12.42)		
p-value	0.2855	0.5623		
p-value of Breslow-Day Test for Homogeneity [2]	0.7287	0.2812		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.6)	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.56	-0.56		
95% CI of the absolute risk difference	(-1.65, 0.53)	(-1.65, 0.53)		
p-value	0.6273	0.7079		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (2.4)	0	1 (0.6)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.34	NE		
95% CI of the odds ratio	(0.27, 70.86)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.26	NE		
95% CI of the risk ratio	(0.27, 66.76)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.82	-0.56		
95% CI of the absolute risk difference	(-2.92, 6.56)	(-1.65, 0.53)		
p-value	0.2617	0.7079		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4794		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	2 (8.0)	4 (2.2)	6 (2.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.80		
95% CI of the odds ratio	NE	(0.66, 21.94)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.58		
95% CI of the risk ratio	NE	(0.69, 18.55)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.23	5.77		
95% CI of the absolute risk difference	(-4.40, -0.07)	(-5.09, 16.62)		
p-value	0.3282	0.1100		
p-value of Breslow-Day Test for Homogeneity [2]	0.1417	0.7279		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	2 (8.0)	1 (0.6)	3 (1.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	15.48		
95% CI of the odds ratio	NE	(1.35, 177.48)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	14.32		
95% CI of the risk ratio	NE	(1.35, 152.22)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.56	7.44		
95% CI of the absolute risk difference	(-1.65, 0.53)	(-3.25, 18.13)		
p-value	0.6273	0.0038		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.8467		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	12 (28.6)	2 (8.0)	34 (19.0)	48 (19.5)
Grade 2	21 (50.0)	16 (64.0)	106 (59.2)	143 (58.1)
Grade 3	5 (11.9)	4 (16.0)	27 (15.1)	36 (14.6)
Grade 4	0	0	3 (1.7)	3 (1.2)
Grade 5	0	1 (4.0)	1 (0.6)	2 (0.8)

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	10 (23.8)	3 (12.0)	32 (17.9)	45 (18.3)
Grade 2	5 (11.9)	3 (12.0)	20 (11.2)	28 (11.4)
Grade 3	1 (2.4)	0	0	1 (0.4)
Grade 4	0	0	1 (0.6)	1 (0.4)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (4.0)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	4.00		
95% CI of the absolute risk difference	NE	(-3.68, 11.68)		
p-value	NE	0.0073		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0028		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (4.0)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	4.00		
95% CI of the absolute risk difference	NE	(-3.68, 11.68)		
p-value	NE	0.0073		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	1 (4.0)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	4.00		
95% CI of the absolute risk difference	NE	(-3.68, 11.68)		
p-value	NE	0.0073		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0028		
Other MACE AE – Adjudicated Event	0	1 (4.0)	2 (1.1)	3 (1.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.69		
95% CI of the odds ratio	NE	(0.32, 42.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.58		
95% CI of the risk ratio	NE	(0.34, 38.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.12	2.88		
95% CI of the absolute risk difference	(-2.66, 0.42)	(-4.95, 10.72)		
p-value	0.4914	0.2620		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (4.0)	1 (0.6)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	7.42		
95% CI of the odds ratio	NE	(0.45, 122.50)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	7.16		
95% CI of the risk ratio	NE	(0.46, 110.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.56	3.44		
95% CI of the absolute risk difference	(-1.65, 0.53)	(-4.32, 11.20)		
p-value	0.6273	0.1019		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.6)	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.56	-0.56		
95% CI of the absolute risk difference	(-1.65, 0.53)	(-1.65, 0.53)		
p-value	0.6273	0.7079		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (4.0)	1 (0.6)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	7.42		
95% CI of the odds ratio	NE	(0.45, 122.50)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	7.16		
95% CI of the risk ratio	NE	(0.46, 110.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.56	3.44		
95% CI of the absolute risk difference	(-1.65, 0.53)	(-4.32, 11.20)		
p-value	0.6273	0.1019		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; CFB = Change from Baseline; DILI = drug-induced liver injury; NE = Not estimable.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Events n:				
Total TEAEs	608	566	203	1377
Total Serious TEAEs	22	14	6	42
Total TEAEs Leading to Discontinuation of Study Drug	11	3	0	14
Total TEAEs Related to Study Drug	87	57	10	154
Total TEAEs >= Grade 3 Severity	21	19	8	48
Patients n (%):				
Any TEAE	74 (97.4)	68 (90.7)	28 (93.3)	170 (93.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.64	0.69		
95% CI of the odds ratio	(0.35, 19.68)	(0.14, 3.55)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04	0.97		
95% CI of the risk ratio	(0.94, 1.16)	(0.86, 1.10)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.04	-2.67		
95% CI of the absolute risk difference	(-5.59, 13.66)	(-13.76, 8.42)		
p-value	0.3261	0.6592		
p-value of Breslow-Day Test for Homogeneity [2]	0.1510	0.9099		
Any Serious TEAE	10 (13.2)	11 (14.7)	3 (10.0)	24 (13.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.36	1.55		
95% CI of the odds ratio	(0.35, 5.34)	(0.40, 5.99)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.32	1.47		
95% CI of the risk ratio	(0.39, 4.45)	(0.44, 4.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.16	4.67		
95% CI of the absolute risk difference	(-10.00, 16.31)	(-8.73, 18.06)		
p-value	0.6552	0.5251		
p-value of Breslow-Day Test for Homogeneity [2]	0.2569	0.5190		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Any TEAEs >= Grade 3 Severity	11 (14.5)	10 (13.3)	5 (16.7)	26 (14.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.85	0.77		
95% CI of the odds ratio	(0.27, 2.68)	(0.24, 2.47)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87	0.80		
95% CI of the risk ratio	(0.33, 2.29)	(0.30, 2.15)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.19	-3.33		
95% CI of the absolute risk difference	(-17.70, 13.31)	(-18.73, 12.06)		
p-value	0.7763	0.6592		
p-value of Breslow-Day Test for Homogeneity [2]	0.3758	0.5174		
Any TEAEs <= Grade 2 Severity	74 (97.4)	67 (89.3)	28 (93.3)	169 (93.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.64	0.60		
95% CI of the odds ratio	(0.35, 19.68)	(0.12, 3.00)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04	0.96		
95% CI of the risk ratio	(0.94, 1.16)	(0.85, 1.08)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.04	-4.00		
95% CI of the absolute risk difference	(-5.59, 13.66)	(-15.33, 7.33)		
p-value	0.3261	0.5282		
p-value of Breslow-Day Test for Homogeneity [2]	0.1510	0.9878		
Any TEAEs leading to Study-Drug Discontinuation	5 (6.6)	3 (4.0)	0	8 (4.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.69	NE		
95% CI of the odds ratio	(0.25, 87.52)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.43	NE		
95% CI of the risk ratio	(0.25, 77.71)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.53	4.00		
95% CI of the absolute risk difference	(-1.73, 12.79)	(-0.43, 8.43)		
p-value	0.2564	0.2664		
p-value of Breslow-Day Test for Homogeneity [2]	0.0378	0.5257		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Any TEAEs leading to Study Discontinuation	2 (2.6)	2 (2.7)	0	4 (2.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.63	2.67		
95% CI of the absolute risk difference	(-0.97, 6.23)	(-0.98, 6.31)		
p-value	0.3697	0.3665		
p-value of Breslow-Day Test for Homogeneity [2]	0.1514	0.6458		
Any Fatal TEAEs	1 (1.3)	0	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.32	NE		
95% CI of the absolute risk difference	(-1.25, 3.88)	NE		
p-value	0.5279	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.4315	NE		
Any Treatment-related TEAE	33 (43.4)	30 (40.0)	9 (30.0)	72 (39.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.79	1.56		
95% CI of the odds ratio	(0.73, 4.42)	(0.63, 3.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.45	1.33		
95% CI of the risk ratio	(0.79, 2.65)	(0.72, 2.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	13.42	10.00		
95% CI of the absolute risk difference	(-6.41, 33.25)	(-9.79, 29.79)		
p-value	0.2032	0.3380		
p-value of Breslow-Day Test for Homogeneity [2]	0.7638	0.2997		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	1 (1.3)	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	1.33		
95% CI of the absolute risk difference	NE	(-1.26, 3.93)		
p-value	NE	0.5251		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4794		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	3 (3.9)	1 (1.3)	0	4 (2.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.95	1.33		
95% CI of the absolute risk difference	(-0.43, 8.33)	(-1.26, 3.93)		
p-value	0.2696	0.5251		
p-value of Breslow-Day Test for Homogeneity [2]	0.1417	0.7279		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	1 (1.3)	0	1 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	1.33		
95% CI of the absolute risk difference	NE	(-1.26, 3.93)		
p-value	NE	0.5251		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.8467		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	17 (22.4)	11 (14.7)	10 (33.3)	38 (21.0)
Grade 2	46 (60.5)	47 (62.7)	13 (43.3)	106 (58.6)
Grade 3	10 (13.2)	10 (13.3)	5 (16.7)	25 (13.8)
Grade 4	0	0	0	0
Grade 5	1 (1.3)	0	0	1 (0.6)

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	21 (27.6)	21 (28.0)	7 (23.3)	49 (27.1)
Grade 2	12 (15.8)	8 (10.7)	2 (6.7)	22 (12.2)
Grade 3	0	1 (1.3)	0	1 (0.6)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (1.3)	0	1 (3.3)	2 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	NE		
95% CI of the odds ratio	(0.02, 6.39)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	NE		
95% CI of the risk ratio	(0.03, 6.11)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.02	-3.33		
95% CI of the absolute risk difference	(-8.93, 4.90)	(-9.76, 3.09)		
p-value	0.4916	0.1121		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0028		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	1 (1.3)	0	1 (3.3)	2 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	NE		
95% CI of the odds ratio	(0.02, 6.39)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	NE		
95% CI of the risk ratio	(0.03, 6.11)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.02	-3.33		
95% CI of the absolute risk difference	(-8.93, 4.90)	(-9.76, 3.09)		
p-value	0.4916	0.1121		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE - Adjudicated Event	1 (1.3)	0	1 (3.3)	2 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	NE		
95% CI of the odds ratio	(0.02, 6.39)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	NE		
95% CI of the risk ratio	(0.03, 6.11)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.02	-3.33		
95% CI of the absolute risk difference	(-8.93, 4.90)	(-9.76, 3.09)		
p-value	0.4916	0.1121		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0028		
Other MACE AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
DILI AE - Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE - Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE - Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76) n (%)	MGL-3196 100 mg (N=75) n (%)	Placebo (N=30) n (%)	Overall (N=181) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Events n:				
Total TEAEs	263	192	1342	1797
Total Serious TEAEs	4	10	62	76
Total TEAEs Leading to Discontinuation of Study Drug	0	5	9	14
Total TEAEs Related to Study Drug	29	24	109	162
Total TEAEs >= Grade 3 Severity	5	13	66	84
Patients n (%):				
Any TEAE	38 (90.5)	23 (92.0)	170 (95.0)	231 (93.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50	0.61		
95% CI of the odds ratio	(0.15, 1.72)	(0.12, 2.99)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.97		
95% CI of the risk ratio	(0.86, 1.06)	(0.86, 1.09)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.50	-2.97		
95% CI of the absolute risk difference	(-13.93, 4.94)	(-14.08, 8.13)		
p-value	0.2651	0.5377		
p-value of Breslow-Day Test for Homogeneity [2]	0.1510	0.9099		
Any Serious TEAE	3 (7.1)	3 (12.0)	25 (14.0)	31 (12.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.47	0.84		
95% CI of the odds ratio	(0.14, 1.65)	(0.23, 3.02)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51	0.86		
95% CI of the risk ratio	(0.16, 1.61)	(0.28, 2.64)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.82	-1.97		
95% CI of the absolute risk difference	(-16.12, 2.47)	(-15.68, 11.75)		
p-value	0.2315	0.7890		
p-value of Breslow-Day Test for Homogeneity [2]	0.2569	0.5190		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Any TEAEs >= Grade 3 Severity	3 (7.1)	5 (20.0)	29 (16.2)	37 (15.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40	1.29		
95% CI of the odds ratio	(0.12, 1.37)	(0.45, 3.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	1.23		
95% CI of the risk ratio	(0.14, 1.38)	(0.53, 2.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.06	3.80		
95% CI of the absolute risk difference	(-18.53, 0.42)	(-12.78, 20.38)		
p-value	0.1333	0.6331		
p-value of Breslow-Day Test for Homogeneity [2]	0.3758	0.5174		
Any TEAEs <= Grade 2 Severity	38 (90.5)	23 (92.0)	170 (95.0)	231 (93.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50	0.61		
95% CI of the odds ratio	(0.15, 1.72)	(0.12, 2.99)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.97		
95% CI of the risk ratio	(0.86, 1.06)	(0.86, 1.09)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.50	-2.97		
95% CI of the absolute risk difference	(-13.93, 4.94)	(-14.08, 8.13)		
p-value	0.2651	0.5377		
p-value of Breslow-Day Test for Homogeneity [2]	0.1510	0.9878		
Any TEAEs leading to Study-Drug Discontinuation	0	4 (16.0)	9 (5.0)	13 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.21	3.60		
95% CI of the odds ratio	(0.01, 3.70)	(1.02, 12.71)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.22	3.18		
95% CI of the risk ratio	(0.01, 3.71)	(1.06, 9.57)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.11	10.97		
95% CI of the absolute risk difference	(-8.69, 0.46)	(-3.75, 25.69)		
p-value	0.2414	0.0354		
p-value of Breslow-Day Test for Homogeneity [2]	0.0378	0.5257		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Any TEAEs leading to Study Discontinuation	0	3 (12.0)	5 (2.8)	8 (3.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.75		
95% CI of the odds ratio	NE	(1.06, 21.24)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	4.30		
95% CI of the risk ratio	NE	(1.09, 16.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.79	9.21		
95% CI of the absolute risk difference	(-5.21, -0.38)	(-3.76, 22.17)		
p-value	0.2733	0.0263		
p-value of Breslow-Day Test for Homogeneity [2]	0.1514	0.6458		
Any Fatal TEAEs	0	1 (4.0)	1 (0.6)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	7.42		
95% CI of the odds ratio	NE	(0.45, 122.50)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	7.16		
95% CI of the risk ratio	NE	(0.46, 110.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.56	3.44		
95% CI of the absolute risk difference	(-1.65, 0.53)	(-4.32, 11.20)		
p-value	0.6273	0.1019		
p-value of Breslow-Day Test for Homogeneity [2]	0.4315	NE		
Any Treatment-related TEAE	16 (38.1)	6 (24.0)	52 (29.1)	74 (30.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	0.77		
95% CI of the odds ratio	(0.75, 3.03)	(0.29, 2.04)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.31	0.83		
95% CI of the risk ratio	(0.84, 2.05)	(0.40, 1.72)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.04	-5.05		
95% CI of the absolute risk difference	(-7.08, 25.17)	(-23.06, 12.96)		
p-value	0.2530	0.6000		
p-value of Breslow-Day Test for Homogeneity [2]	0.7638	0.2997		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.6)	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.56	-0.56		
95% CI of the absolute risk difference	(-1.65, 0.53)	(-1.65, 0.53)		
p-value	0.6273	0.7079		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (2.4)	0	1 (0.6)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.34	NE		
95% CI of the odds ratio	(0.27, 70.86)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.26	NE		
95% CI of the risk ratio	(0.27, 66.76)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.82	-0.56		
95% CI of the absolute risk difference	(-2.92, 6.56)	(-1.65, 0.53)		
p-value	0.2617	0.7079		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4794		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	2 (8.0)	4 (2.2)	6 (2.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.80		
95% CI of the odds ratio	NE	(0.66, 21.94)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.58		
95% CI of the risk ratio	NE	(0.69, 18.55)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.23	5.77		
95% CI of the absolute risk difference	(-4.40, -0.07)	(-5.09, 16.62)		
p-value	0.3282	0.1100		
p-value of Breslow-Day Test for Homogeneity [2]	0.1417	0.7279		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	2 (8.0)	1 (0.6)	3 (1.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	15.48		
95% CI of the odds ratio	NE	(1.35, 177.48)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	14.32		
95% CI of the risk ratio	NE	(1.35, 152.22)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.56	7.44		
95% CI of the absolute risk difference	(-1.65, 0.53)	(-3.25, 18.13)		
p-value	0.6273	0.0038		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.8467		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	12 (28.6)	2 (8.0)	35 (19.6)	49 (19.9)
Grade 2	23 (54.8)	16 (64.0)	106 (59.2)	145 (58.9)
Grade 3	3 (7.1)	4 (16.0)	25 (14.0)	32 (13.0)
Grade 4	0	0	3 (1.7)	3 (1.2)
Grade 5	0	1 (4.0)	1 (0.6)	2 (0.8)

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	10 (23.8)	3 (12.0)	31 (17.3)	44 (17.9)
Grade 2	5 (11.9)	3 (12.0)	20 (11.2)	28 (11.4)
Grade 3	1 (2.4)	0	0	1 (0.4)
Grade 4	0	0	1 (0.6)	1 (0.4)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (4.0)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	4.00		
95% CI of the absolute risk difference	NE	(-3.68, 11.68)		
p-value	NE	0.0073		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0028		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (4.0)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	4.00		
95% CI of the absolute risk difference	NE	(-3.68, 11.68)		
p-value	NE	0.0073		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	1 (4.0)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	4.00		
95% CI of the absolute risk difference	NE	(-3.68, 11.68)		
p-value	NE	0.0073		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0028		
Other MACE AE – Adjudicated Event	0	1 (4.0)	2 (1.1)	3 (1.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.69		
95% CI of the odds ratio	NE	(0.32, 42.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.58		
95% CI of the risk ratio	NE	(0.34, 38.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.12	2.88		
95% CI of the absolute risk difference	(-2.66, 0.42)	(-4.95, 10.72)		
p-value	0.4914	0.2620		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (4.0)	1 (0.6)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	7.42		
95% CI of the odds ratio	NE	(0.45, 122.50)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	7.16		
95% CI of the risk ratio	NE	(0.46, 110.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.56	3.44		
95% CI of the absolute risk difference	(-1.65, 0.53)	(-4.32, 11.20)		
p-value	0.6273	0.1019		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.6)	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.56	-0.56		
95% CI of the absolute risk difference	(-1.65, 0.53)	(-1.65, 0.53)		
p-value	0.6273	0.7079		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (4.0)	1 (0.6)	2 (0.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	7.42		
95% CI of the odds ratio	NE	(0.45, 122.50)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	7.16		
95% CI of the risk ratio	NE	(0.46, 110.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.56	3.44		
95% CI of the absolute risk difference	(-1.65, 0.53)	(-4.32, 11.20)		
p-value	0.6273	0.1019		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

	MGL-3196 80 mg (N=42) n (%)	MGL-3196 100 mg (N=25) n (%)	Placebo (N=179) n (%)	Overall (N=246) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.13.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; CFB = Change from Baseline; NE = Not estimable.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.
Note: PT 'Contusion' has statistically significant results in table S1.1.3, but is not included in this table due to patient counts being less than 10 in all subgroup categories.

AMNOG Table S1.13.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=76) Patients n (%)	 Events n	MGL-3196 100 mg (N=75) Patients n (%)	 Events n	Placebo (N=30) Patients n (%)	 Events n	Overall (N=181) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	19 (25.0)	35	28 (37.3)	34	6 (20.0)	7	53 (29.3)	76
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.33		2.38					
95% CI of the odds ratio	(0.47, 3.75)		(0.87, 6.54)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.25		1.87					
95% CI of the risk ratio	(0.55, 2.82)		(0.86, 4.05)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.00		17.33					
95% CI of the absolute risk difference	(-12.31, 22.31)		(-0.69, 35.35)					
p-value	0.5849		0.0864					
p-value of Breslow-Day Test for Homogeneity [2]	0.9567		0.8455					
Nausea	22 (28.9)	27	11 (14.7)	12	2 (6.7)	2	35 (19.3)	41
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	5.70		2.41					
95% CI of the odds ratio	(1.25, 26.02)		(0.50, 11.57)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.34		2.20					
95% CI of the risk ratio	(1.09, 17.34)		(0.52, 9.34)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	22.28		8.00					
95% CI of the absolute risk difference	(8.73, 35.83)		(-3.99, 19.99)					
p-value	0.0135		0.2609					
p-value of Breslow-Day Test for Homogeneity [2]	0.0802		0.3191					

AMNOG Table S1.13.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=76) Patients n (%)	 Events n	MGL-3196 100 mg (N=75) Patients n (%)	 Events n	Placebo (N=30) Patients n (%)	 Events n	Overall (N=181) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	10 (13.2)	11	4 (5.3)	4	0	0	14 (7.7)	15
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	9.63		3.84					
95% CI of the odds ratio	(0.55, 169.74)		(0.20, 73.52)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	8.45		3.67					
95% CI of the risk ratio	(0.51, 139.90)		(0.20, 66.17)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	12.02		4.31					
95% CI of the absolute risk difference	(3.17, 20.88)		(-2.61, 11.22)					
p-value	0.0616		0.3382					
p-value of Breslow-Day Test for Homogeneity [2]	0.0686		0.2938					
Abdominal discomfort	0	0	1 (1.3)	1	0	0	1 (0.6)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		1.33					
95% CI of the absolute risk difference	NE		(-1.26, 3.93)					
p-value	NE		0.5251					
p-value of Breslow-Day Test for Homogeneity [2]	NE		0.1702					

AMNOG Table S1.13.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=76) Patients n (%)	 Events n	MGL-3196 100 mg (N=75) Patients n (%)	 Events n	Placebo (N=30) Patients n (%)	 Events n	Overall (N=181) Patients n (%)	 Events n
General disorders and administration site conditions	18 (23.7)	33	13 (17.3)	18	9 (30.0)	11	40 (22.1)	62
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.72		0.49					
95% CI of the odds ratio	(0.28, 1.86)		(0.18, 1.31)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.79		0.58					
95% CI of the risk ratio	(0.40, 1.56)		(0.28, 1.21)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.32		-12.67					
95% CI of the absolute risk difference	(-25.30, 12.66)		(-31.17, 5.83)					
p-value	0.5014		0.1496					
p-value of Breslow-Day Test for Homogeneity [2]	0.3886		0.3353					
Skin and subcutaneous tissue disorders								
Pruritus	11 (14.5)	14	5 (6.7)	7	2 (6.7)	4	18 (9.9)	25
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.37		1.00					
95% CI of the odds ratio	(0.49, 11.39)		(0.18, 5.46)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.17		1.00					
95% CI of the risk ratio	(0.51, 9.22)		(0.21, 4.88)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.81		0.00					
95% CI of the absolute risk difference	(-4.12, 19.73)		(-10.56, 10.56)					
p-value	0.2697		>0.9999					
p-value of Breslow-Day Test for Homogeneity [2]	0.2784		0.1433					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.13.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=76) Patients n (%)	 Events n	MGL-3196 100 mg (N=75) Patients n (%)	 Events n	Placebo (N=30) Patients n (%)	 Events n	Overall (N=181) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	3 (3.9)	3	9 (12.0)	10	3 (10.0)	4	15 (8.3)	17
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.37		1.23					
95% CI of the odds ratio	(0.07, 1.95)		(0.31, 4.88)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		1.20					
95% CI of the risk ratio	(0.08, 1.85)		(0.35, 4.13)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.05		2.00					
95% CI of the absolute risk difference	(-17.65, 5.54)		(-11.01, 15.01)					
p-value	0.2245		0.7711					
p-value of Breslow-Day Test for Homogeneity [2]	0.0588		0.6070					
Renal and urinary disorders	4 (5.3)	5	14 (18.7)	17	5 (16.7)	6	23 (12.7)	28
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.28		1.15					
95% CI of the odds ratio	(0.07, 1.12)		(0.37, 3.52)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.32		1.12					
95% CI of the risk ratio	(0.09, 1.10)		(0.44, 2.84)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-11.40		2.00					
95% CI of the absolute risk difference	(-25.65, 2.85)		(-13.99, 17.99)					
p-value	0.0578		0.8100					
p-value of Breslow-Day Test for Homogeneity [2]	0.9260		0.9731					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.13.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=76) Patients n (%)	 Events n	MGL-3196 100 mg (N=75) Patients n (%)	 Events n	Placebo (N=30) Patients n (%)	 Events n	Overall (N=181) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	4 (5.3)	5	1 (1.3)	1	1 (3.3)	1	6 (3.3)	7
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.61		0.39					
95% CI of the odds ratio	(0.17, 15.03)		(0.02, 6.48)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.58		0.40					
95% CI of the risk ratio	(0.18, 13.56)		(0.03, 6.19)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.93		-2.00					
95% CI of the absolute risk difference	(-6.22, 10.08)		(-8.93, 4.93)					
p-value	0.6729		0.4982					
p-value of Breslow-Day Test for Homogeneity [2]	0.1839		0.9940					

AMNOG Table S1.13.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=42) Patients n (%)	 Events n	MGL-3196 100 mg (N=25) Patients n (%)	 Events n	Placebo (N=179) Patients n (%)	 Events n	Overall (N=246) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	10 (23.8)	14	8 (32.0)	20	33 (18.4)	41	51 (20.7)	75
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.38		2.08					
95% CI of the odds ratio	(0.62, 3.09)		(0.83, 5.23)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.29		1.74					
95% CI of the risk ratio	(0.69, 2.41)		(0.91, 3.32)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.37		13.56					
95% CI of the absolute risk difference	(-8.70, 19.45)		(-5.58, 32.71)					
p-value	0.4285		0.1129					
p-value of Breslow-Day Test for Homogeneity [2]	0.9567		0.8455					
Nausea	9 (21.4)	12	4 (16.0)	8	31 (17.3)	37	44 (17.9)	57
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.30		0.91					
95% CI of the odds ratio	(0.57, 2.99)		(0.29, 2.84)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.24		0.92					
95% CI of the risk ratio	(0.64, 2.40)		(0.36, 2.40)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.11		-1.32					
95% CI of the absolute risk difference	(-9.48, 17.70)		(-16.72, 14.08)					
p-value	0.5335		0.8699					
p-value of Breslow-Day Test for Homogeneity [2]	0.0802		0.3191					

AMNOG Table S1.13.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=42) Patients n (%)	 Events n	MGL-3196 100 mg (N=25) Patients n (%)	 Events n	Placebo (N=179) Patients n (%)	 Events n	Overall (N=246) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	4 (9.5)	5	3 (12.0)	3	15 (8.4)	16	22 (8.9)	24
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.15		1.49					
95% CI of the odds ratio	(0.36, 3.66)		(0.40, 5.56)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14		1.43					
95% CI of the risk ratio	(0.40, 3.25)		(0.45, 4.60)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.14		3.62					
95% CI of the absolute risk difference	(-8.62, 10.91)		(-9.75, 16.99)					
p-value	0.8119		0.5500					
p-value of Breslow-Day Test for Homogeneity [2]	0.0686		0.2938					
Abdominal discomfort	0	0	0	0	9 (5.0)	10	9 (3.7)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.21		0.35					
95% CI of the odds ratio	(0.01, 3.70)		(0.02, 6.23)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.22		0.36					
95% CI of the risk ratio	(0.01, 3.71)		(0.02, 6.08)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.11		-3.35					
95% CI of the absolute risk difference	(-8.69, 0.46)		(-9.56, 2.85)					
p-value	0.2414		0.4569					
p-value of Breslow-Day Test for Homogeneity [2]	NE		0.1702					

AMNOG Table S1.13.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=42) Patients n (%)	 Events n	MGL-3196 100 mg (N=25) Patients n (%)	 Events n	Placebo (N=179) Patients n (%)	 Events n	Overall (N=246) Patients n (%)	 Events n
General disorders and administration site conditions	6 (14.3)	6	7 (28.0)	10	52 (29.1)	63	65 (26.4)	79
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.41		0.95					
95% CI of the odds ratio	(0.16, 1.02)		(0.37, 2.41)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.49		0.96					
95% CI of the risk ratio	(0.23, 1.07)		(0.49, 1.88)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-14.76		-1.05					
95% CI of the absolute risk difference	(-27.26, -2.27)		(-19.87, 17.76)					
p-value	0.0503		0.9136					
p-value of Breslow-Day Test for Homogeneity [2]	0.3886		0.3353					
Skin and subcutaneous tissue disorders								
Pruritus	3 (7.1)	5	0	0	16 (8.9)	17	19 (7.7)	22
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78		0.19					
95% CI of the odds ratio	(0.22, 2.82)		(0.01, 3.34)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80		0.21					
95% CI of the risk ratio	(0.24, 2.62)		(0.01, 3.39)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.80		-7.24					
95% CI of the absolute risk difference	(-10.63, 7.04)		(-14.00, -0.49)					
p-value	0.7087		0.2096					
p-value of Breslow-Day Test for Homogeneity [2]	0.2784		0.1433					

AMNOG Table S1.13.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=42) Patients n (%)	 Events n	MGL-3196 100 mg (N=25) Patients n (%)	 Events n	Placebo (N=179) Patients n (%)	 Events n	Overall (N=246) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	4 (9.5)	4	2 (8.0)	4	7 (3.9)	8	13 (5.3)	16
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.59		2.14					
95% CI of the odds ratio	(0.72, 9.28)		(0.42, 10.91)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.44		2.05					
95% CI of the risk ratio	(0.75, 7.94)		(0.45, 9.30)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.61		4.09					
95% CI of the absolute risk difference	(-3.71, 14.93)		(-6.92, 15.10)					
p-value	0.1322		0.3510					
p-value of Breslow-Day Test for Homogeneity [2]	0.0588		0.6070					
Musculoskeletal and connective tissue disorders								
Pain in extremity	1 (2.4)	1	1 (4.0)	1	17 (9.5)	19	19 (7.7)	21
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.23		0.40					
95% CI of the odds ratio	(0.03, 1.80)		(0.05, 3.12)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.25		0.42					
95% CI of the risk ratio	(0.03, 1.83)		(0.06, 3.03)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.12		-5.50					
95% CI of the absolute risk difference	(-13.42, -0.82)		(-14.30, 3.30)					
p-value	0.1292		0.3640					
p-value of Breslow-Day Test for Homogeneity [2]	0.1839		0.9940					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.13.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=42) Patients n (%)	 Events n	MGL-3196 100 mg (N=25) Patients n (%)	 Events n	Placebo (N=179) Patients n (%)	 Events n	Overall (N=246) Patients n (%)	 Events n
Renal and urinary disorders	1 (2.4)	1	2 (8.0)	2	13 (7.3)	18	16 (6.5)	21
Odds ratio, Chi-square,								
MGL-3196 treatment group / Placebo [1]	0.31		1.11					
95% CI of the odds ratio	(0.04, 2.45)		(0.24, 5.24)					
Risk ratio, Chi-square,								
MGL-3196 treatment group / Placebo [1]	0.33		1.10					
95% CI of the risk ratio	(0.04, 2.44)		(0.26, 4.60)					
Absolute risk difference, Chi-square,								
MGL-3196 treatment group - Placebo [1]	-4.88		0.74					
95% CI of the absolute risk difference	(-10.86, 1.09)		(-10.56, 12.03)					
p-value	0.2425		0.8947					
p-value of Breslow-Day Test for Homogeneity [2]	0.9260		0.9731					

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable; SNP = Single Nucleotide Polymorphism.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Events n:				
Total TEAEs	336	255	653	1244
Total Serious TEAEs	6	6	25	37
Total TEAEs Leading to Discontinuation of Study Drug	6	7	7	20
Total TEAEs Related to Study Drug	57	33	32	122
Total TEAEs >= Grade 3 Severity	7	8	26	41
Patients n (%):				
Any TEAE	42 (87.5)	36 (81.8)	86 (90.5)	164 (87.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.47		
95% CI of the odds ratio	(0.24, 2.19)	(0.17, 1.32)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	0.90		
95% CI of the risk ratio	(0.85, 1.10)	(0.78, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.03	-8.71		
95% CI of the absolute risk difference	(-14.08, 8.03)	(-21.54, 4.12)		
p-value	0.5770	0.1450		
p-value of Breslow-Day Test for Homogeneity [2]	0.2841	0.2608		
Any Serious TEAE	5 (10.4)	5 (11.4)	13 (13.7)	23 (12.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.81		
95% CI of the odds ratio	(0.25, 2.19)	(0.27, 2.43)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76	0.83		
95% CI of the risk ratio	(0.29, 2.01)	(0.32, 2.19)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.27	-2.32		
95% CI of the absolute risk difference	(-14.33, 7.80)	(-13.97, 9.33)		
p-value	0.5780	0.7047		
p-value of Breslow-Day Test for Homogeneity [2]	0.7036	0.8108		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Any TEAEs >= Grade 3 Severity	5 (10.4)	6 (13.6)	14 (14.7)	25 (13.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.67	0.91		
95% CI of the odds ratio	(0.23, 1.99)	(0.33, 2.56)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	0.93		
95% CI of the risk ratio	(0.27, 1.85)	(0.38, 2.25)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.32	-1.10		
95% CI of the absolute risk difference	(-15.52, 6.88)	(-13.50, 11.29)		
p-value	0.4723	0.8635		
p-value of Breslow-Day Test for Homogeneity [2]	0.3899	0.7690		
Any TEAEs <= Grade 2 Severity	42 (87.5)	36 (81.8)	86 (90.5)	164 (87.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.47		
95% CI of the odds ratio	(0.24, 2.19)	(0.17, 1.32)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	0.90		
95% CI of the risk ratio	(0.85, 1.10)	(0.78, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.03	-8.71		
95% CI of the absolute risk difference	(-14.08, 8.03)	(-21.54, 4.12)		
p-value	0.5770	0.1450		
p-value of Breslow-Day Test for Homogeneity [2]	0.3058	0.2638		
Any TEAEs leading to Study-Drug Discontinuation	4 (8.3)	6 (13.6)	6 (6.3)	16 (8.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.35	2.34		
95% CI of the odds ratio	(0.36, 5.03)	(0.71, 7.73)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.32	2.16		
95% CI of the risk ratio	(0.39, 4.45)	(0.74, 6.32)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.02	7.32		
95% CI of the absolute risk difference	(-7.21, 11.24)	(-3.94, 18.58)		
p-value	0.6551	0.1529		
p-value of Breslow-Day Test for Homogeneity [2]	0.8013	0.2364		

Madrigal Pharmaceuticals, Inc. Page 4 of 31
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Any TEAEs leading to Study Discontinuation	1 (2.1)	2 (4.5)	4 (4.2)	7 (3.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48	1.08		
95% CI of the odds ratio	(0.05, 4.45)	(0.19, 6.15)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.49	1.08		
95% CI of the risk ratio	(0.06, 4.31)	(0.21, 5.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.13	0.33		
95% CI of the absolute risk difference	(-7.84, 3.59)	(-7.03, 7.70)		
p-value	0.5132	0.9280		
p-value of Breslow-Day Test for Homogeneity [2]	0.2944	0.1033		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1807	0.2070		
Any Treatment-related TEAE	21 (43.8)	19 (43.2)	18 (18.9)	58 (31.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.33	3.25		
95% CI of the odds ratio	(1.54, 7.17)	(1.48, 7.14)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.31	2.28		
95% CI of the risk ratio	(1.37, 3.90)	(1.33, 3.90)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	24.80	24.23		
95% CI of the absolute risk difference	(8.71, 40.90)	(7.61, 40.86)		
p-value	0.0017	0.0026		
p-value of Breslow-Day Test for Homogeneity [2]	0.1536	0.1052		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (2.1)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.08	NE		
95% CI of the absolute risk difference	(-1.96, 6.12)	NE		
p-value	0.1580	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1524	0.0734		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (4.2)	4 (9.1)	2 (2.1)	8 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.02	4.65		
95% CI of the odds ratio	(0.28, 14.81)	(0.82, 26.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.98	4.32		
95% CI of the risk ratio	(0.29, 13.62)	(0.82, 22.70)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.06	6.99		
95% CI of the absolute risk difference	(-4.29, 8.41)	(-1.99, 15.96)		
p-value	0.4802	0.0594		
p-value of Breslow-Day Test for Homogeneity [2]	0.1375	0.5334		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	1 (2.3)	2 (2.1)	3 (1.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.08		
95% CI of the odds ratio	NE	(0.10, 12.25)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.08		
95% CI of the risk ratio	NE	(0.10, 11.59)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.11	0.17		
95% CI of the absolute risk difference	(-4.99, 0.78)	(-5.10, 5.43)		
p-value	0.3114	0.9496		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3159		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	10 (20.8)	9 (20.5)	25 (26.3)	44 (23.5)
Grade 2	27 (56.3)	21 (47.7)	47 (49.5)	95 (50.8)
Grade 3	5 (10.4)	6 (13.6)	13 (13.7)	24 (12.8)
Grade 4	0	0	1 (1.1)	1 (0.5)
Grade 5	0	0	0	0

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	14 (29.2)	13 (29.5)	8 (8.4)	35 (18.7)
Grade 2	6 (12.5)	6 (13.6)	10 (10.5)	22 (11.8)
Grade 3	1 (2.1)	0	0	1 (0.5)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	2 (2.1)	2 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.11	-2.11		
95% CI of the absolute risk difference	(-4.99, 0.78)	(-4.99, 0.78)		
p-value	0.3114	0.3323		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4614		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	1 (1.1)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.05	-1.05		
95% CI of the absolute risk difference	(-3.10, 1.00)	(-3.10, 1.00)		
p-value	0.4756	0.4946		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5900		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (1.1)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.05	-1.05		
95% CI of the absolute risk difference	(-3.10, 1.00)	(-3.10, 1.00)		
p-value	0.4756	0.4946		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	1 (1.1)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.05	-1.05		
95% CI of the absolute risk difference	(-3.10, 1.00)	(-3.10, 1.00)		
p-value	0.4756	0.4946		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5900		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Events n:				
Total TEAEs	591	505	962	2058
Total Serious TEAEs	20	18	44	82
Total TEAEs Leading to Discontinuation of Study Drug	8	12	9	29
Total TEAEs Related to Study Drug	62	69	74	205
Total TEAEs >= Grade 3 Severity	22	26	55	103
Patients n (%):				
Any TEAE	74 (96.1)	67 (93.1)	121 (94.5)	262 (94.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43	0.78		
95% CI of the odds ratio	(0.36, 5.69)	(0.24, 2.54)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	0.98		
95% CI of the risk ratio	(0.96, 1.08)	(0.91, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.57	-1.48		
95% CI of the absolute risk difference	(-4.27, 7.42)	(-8.55, 5.59)		
p-value	0.6127	0.6732		
p-value of Breslow-Day Test for Homogeneity [2]	0.2841	0.2608		
Any Serious TEAE	8 (10.4)	11 (15.3)	16 (12.5)	35 (12.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81	1.26		
95% CI of the odds ratio	(0.33, 2.00)	(0.55, 2.89)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83	1.22		
95% CI of the risk ratio	(0.37, 1.85)	(0.60, 2.49)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.11	2.78		
95% CI of the absolute risk difference	(-11.01, 6.79)	(-7.32, 12.87)		
p-value	0.6490	0.5811		
p-value of Breslow-Day Test for Homogeneity [2]	0.7036	0.8108		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Any TEAEs >= Grade 3 Severity	13 (16.9)	14 (19.4)	23 (18.0)	50 (18.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.93	1.10		
95% CI of the odds ratio	(0.44, 1.96)	(0.53, 2.30)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.94	1.08		
95% CI of the risk ratio	(0.51, 1.74)	(0.59, 1.97)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.09	1.48		
95% CI of the absolute risk difference	(-11.77, 9.60)	(-9.83, 12.78)		
p-value	0.8432	0.7964		
p-value of Breslow-Day Test for Homogeneity [2]	0.3899	0.7690		
Any TEAEs <= Grade 2 Severity	72 (93.5)	65 (90.3)	121 (94.5)	258 (93.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83	0.54		
95% CI of the odds ratio	(0.25, 2.72)	(0.18, 1.60)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	0.96		
95% CI of the risk ratio	(0.92, 1.06)	(0.88, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.02	-4.25		
95% CI of the absolute risk difference	(-7.79, 5.74)	(-12.15, 3.64)		
p-value	0.7621	0.2578		
p-value of Breslow-Day Test for Homogeneity [2]	0.3058	0.2638		
Any TEAEs leading to Study-Drug Discontinuation	5 (6.5)	11 (15.3)	7 (5.5)	23 (8.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.20	3.12		
95% CI of the odds ratio	(0.37, 3.92)	(1.15, 8.44)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.19	2.79		
95% CI of the risk ratio	(0.39, 3.61)	(1.13, 6.89)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.02	9.81		
95% CI of the absolute risk difference	(-5.74, 7.79)	(0.61, 19.01)		
p-value	0.7621	0.0200		
p-value of Breslow-Day Test for Homogeneity [2]	0.8013	0.2364		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Any TEAEs leading to Study Discontinuation	2 (2.6)	8 (11.1)	2 (1.6)	12 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.68	7.88		
95% CI of the odds ratio	(0.23, 12.18)	(1.62, 38.17)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.66	7.11		
95% CI of the risk ratio	(0.24, 11.56)	(1.55, 32.59)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.03	9.55		
95% CI of the absolute risk difference	(-3.12, 5.19)	(1.98, 17.12)		
p-value	0.6039	0.0029		
p-value of Breslow-Day Test for Homogeneity [2]	0.2944	0.1033		
Any Fatal TEAEs	1 (1.3)	1 (1.4)	0	2 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.30	1.39		
95% CI of the absolute risk difference	(-1.23, 3.83)	(-1.31, 4.09)		
p-value	0.1962	0.1813		
p-value of Breslow-Day Test for Homogeneity [2]	0.1807	0.2070		
Any Treatment-related TEAE	27 (35.1)	24 (33.3)	38 (29.7)	89 (32.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.28	1.18		
95% CI of the odds ratio	(0.70, 2.34)	(0.64, 2.20)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.18	1.12		
95% CI of the risk ratio	(0.79, 1.77)	(0.74, 1.71)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.38	3.65		
95% CI of the absolute risk difference	(-7.90, 18.65)	(-9.82, 17.11)		
p-value	0.4230	0.5926		
p-value of Breslow-Day Test for Homogeneity [2]	0.1536	0.1052		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (1.3)	2 (2.8)	0	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.30	2.78		
95% CI of the absolute risk difference	(-1.23, 3.83)	(-1.02, 6.57)		
p-value	0.1962	0.0581		
p-value of Breslow-Day Test for Homogeneity [2]	0.1524	0.0734		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	5 (6.9)	3 (2.3)	8 (2.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.11		
95% CI of the odds ratio	NE	(0.72, 13.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.96		
95% CI of the risk ratio	NE	(0.73, 12.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.34	4.60		
95% CI of the absolute risk difference	(-4.96, 0.28)	(-1.83, 11.03)		
p-value	0.1760	0.1110		
p-value of Breslow-Day Test for Homogeneity [2]	0.1375	0.5334		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	5 (6.9)	1 (0.8)	6 (2.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	9.48		
95% CI of the odds ratio	NE	(1.09, 82.79)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.89		
95% CI of the risk ratio	NE	(1.06, 74.61)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.78	6.16		
95% CI of the absolute risk difference	(-2.31, 0.74)	(0.10, 12.23)		
p-value	0.4369	0.0142		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3159		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	15 (19.5)	9 (12.5)	23 (18.0)	47 (17.0)
Grade 2	46 (59.7)	44 (61.1)	75 (58.6)	165 (59.6)
Grade 3	12 (15.6)	13 (18.1)	20 (15.6)	45 (16.2)
Grade 4	0	0	3 (2.3)	3 (1.1)
Grade 5	1 (1.3)	1 (1.4)	0	2 (0.7)

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	13 (16.9)	11 (15.3)	27 (21.1)	51 (18.4)
Grade 2	13 (16.9)	11 (15.3)	11 (8.6)	35 (12.6)
Grade 3	1 (1.3)	2 (2.8)	0	3 (1.1)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (1.3)	1 (1.4)	1 (0.8)	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	1.79		
95% CI of the odds ratio	(0.10, 27.11)	(0.11, 29.03)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.66	1.78		
95% CI of the risk ratio	(0.11, 26.20)	(0.11, 28.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.52	0.61		
95% CI of the absolute risk difference	(-2.44, 3.47)	(-2.50, 3.71)		
p-value	0.7151	0.6785		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.4)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.39		
95% CI of the absolute risk difference	NE	(-1.31, 4.09)		
p-value	NE	0.1813		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (1.3)	0	1 (0.8)	2 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	NE		
95% CI of the odds ratio	(0.10, 27.11)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.66	NE		
95% CI of the risk ratio	(0.11, 26.20)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.52	-0.78		
95% CI of the absolute risk difference	(-2.44, 3.47)	(-2.31, 0.74)		
p-value	0.7151	0.4521		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (1.3)	1 (1.4)	1 (0.8)	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	1.79		
95% CI of the odds ratio	(0.10, 27.11)	(0.11, 29.03)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.66	1.78		
95% CI of the risk ratio	(0.11, 26.20)	(0.11, 28.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.52	0.61		
95% CI of the absolute risk difference	(-2.44, 3.47)	(-2.50, 3.71)		
p-value	0.7151	0.6785		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	1 (1.4)	1 (0.8)	2 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.79		
95% CI of the odds ratio	NE	(0.11, 29.03)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.78		
95% CI of the risk ratio	NE	(0.11, 28.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.78	0.61		
95% CI of the absolute risk difference	(-2.31, 0.74)	(-2.50, 3.71)		
p-value	0.4369	0.6785		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4614		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.4)	1 (0.8)	2 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.79		
95% CI of the odds ratio	NE	(0.11, 29.03)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.78		
95% CI of the risk ratio	NE	(0.11, 28.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.78	0.61		
95% CI of the absolute risk difference	(-2.31, 0.74)	(-2.50, 3.71)		
p-value	0.4369	0.6785		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5900		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (1.4)	1 (0.8)	2 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.79		
95% CI of the odds ratio	NE	(0.11, 29.03)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.78		
95% CI of the risk ratio	NE	(0.11, 28.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.78	0.61		
95% CI of the absolute risk difference	(-2.31, 0.74)	(-2.50, 3.71)		
p-value	0.4369	0.6785		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5900		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Events n:				
Total TEAEs	221	197	442	860
Total Serious TEAEs	2	7	22	31
Total TEAEs Leading to Discontinuation of Study Drug	2	1	7	10
Total TEAEs Related to Study Drug	24	14	39	77
Total TEAEs >= Grade 3 Severity	4	9	23	36
Patients n (%):				
Any TEAE	30 (100)	22 (100)	59 (93.7)	111 (96.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.07	1.07		
95% CI of the risk ratio	(1.00, 1.14)	(1.00, 1.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.35	6.35		
95% CI of the absolute risk difference	(0.33, 12.37)	(0.33, 12.37)		
p-value	0.1583	0.2260		
p-value of Breslow-Day Test for Homogeneity [2]	0.2841	0.2608		
Any Serious TEAE	2 (6.7)	4 (18.2)	10 (15.9)	16 (13.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38	1.18		
95% CI of the odds ratio	(0.08, 1.85)	(0.33, 4.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42	1.15		
95% CI of the risk ratio	(0.10, 1.80)	(0.40, 3.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.21	2.31		
95% CI of the absolute risk difference	(-21.90, 3.49)	(-16.16, 20.78)		
p-value	0.2157	0.8015		
p-value of Breslow-Day Test for Homogeneity [2]	0.7036	0.8108		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Any TEAEs >= Grade 3 Severity	3 (10.0)	4 (18.2)	16 (25.4)	23 (20.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33	0.65		
95% CI of the odds ratio	(0.09, 1.22)	(0.19, 2.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39	0.72		
95% CI of the risk ratio	(0.12, 1.25)	(0.27, 1.91)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-15.40	-7.22		
95% CI of the absolute risk difference	(-30.59, -0.21)	(-26.59, 12.16)		
p-value	0.0852	0.4922		
p-value of Breslow-Day Test for Homogeneity [2]	0.3899	0.7690		
Any TEAEs <= Grade 2 Severity	30 (100)	22 (100)	59 (93.7)	111 (96.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.07	1.07		
95% CI of the risk ratio	(1.00, 1.14)	(1.00, 1.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.35	6.35		
95% CI of the absolute risk difference	(0.33, 12.37)	(0.33, 12.37)		
p-value	0.1583	0.2260		
p-value of Breslow-Day Test for Homogeneity [2]	0.3058	0.2638		
Any TEAEs leading to Study-Drug Discontinuation	2 (6.7)	1 (4.5)	6 (9.5)	9 (7.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	0.45		
95% CI of the odds ratio	(0.13, 3.58)	(0.05, 3.98)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.70	0.48		
95% CI of the risk ratio	(0.15, 3.27)	(0.06, 3.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.86	-4.98		
95% CI of the absolute risk difference	(-14.36, 8.64)	(-16.31, 6.35)		
p-value	0.6460	0.4646		
p-value of Breslow-Day Test for Homogeneity [2]	0.8013	0.2364		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Any TEAEs leading to Study Discontinuation	0	1 (4.5)	4 (6.3)	5 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.22	0.70		
95% CI of the odds ratio	(0.01, 4.16)	(0.07, 6.65)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.23	0.72		
95% CI of the risk ratio	(0.01, 4.13)	(0.08, 6.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.42	-1.80		
95% CI of the absolute risk difference	(-13.09, 2.26)	(-12.39, 8.78)		
p-value	0.2675	0.7569		
p-value of Breslow-Day Test for Homogeneity [2]	0.2944	0.1033		
Any Fatal TEAEs	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.59	-1.59		
95% CI of the absolute risk difference	(-4.67, 1.50)	(-4.67, 1.50)		
p-value	0.4878	0.5522		
p-value of Breslow-Day Test for Homogeneity [2]	0.1807	0.2070		
Any Treatment-related TEAE	15 (50.0)	8 (36.4)	21 (33.3)	44 (38.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.00	1.14		
95% CI of the odds ratio	(0.82, 4.86)	(0.41, 3.15)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50	1.09		
95% CI of the risk ratio	(0.91, 2.47)	(0.57, 2.10)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	16.67	3.03		
95% CI of the absolute risk difference	(-4.68, 38.01)	(-20.20, 26.26)		
p-value	0.1229	0.7963		
p-value of Breslow-Day Test for Homogeneity [2]	0.1536	0.1052		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Any Treatment-related Serious TEAE	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.59	-1.59		
95% CI of the absolute risk difference	(-4.67, 1.50)	(-4.67, 1.50)		
p-value	0.4878	0.5522		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	2 (3.2)	2 (1.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.17	-3.17		
95% CI of the absolute risk difference	(-7.50, 1.15)	(-7.50, 1.15)		
p-value	0.3239	0.3977		
p-value of Breslow-Day Test for Homogeneity [2]	0.1524	0.0734		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	1 (4.5)	3 (4.8)	4 (3.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.95		
95% CI of the odds ratio	NE	(0.09, 9.66)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.95		
95% CI of the risk ratio	NE	(0.10, 8.71)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	-0.22		
95% CI of the absolute risk difference	(-10.02, 0.50)	(-10.39, 9.95)		
p-value	0.2244	0.9671		
p-value of Breslow-Day Test for Homogeneity [2]	0.1375	0.5334		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	1 (4.5)	2 (3.2)	3 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.45		
95% CI of the odds ratio	NE	(0.13, 16.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.43		
95% CI of the risk ratio	NE	(0.14, 15.03)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.17	1.37		
95% CI of the absolute risk difference	(-7.50, 1.15)	(-8.35, 11.09)		
p-value	0.3239	0.7642		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3159		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	6 (20.0)	4 (18.2)	16 (25.4)	26 (22.6)
Grade 2	21 (70.0)	14 (63.6)	27 (42.9)	62 (53.9)
Grade 3	3 (10.0)	4 (18.2)	12 (19.0)	19 (16.5)
Grade 4	0	0	3 (4.8)	3 (2.6)
Grade 5	0	0	1 (1.6)	1 (0.9)

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	10 (33.3)	4 (18.2)	12 (19.0)	26 (22.6)
Grade 2	5 (16.7)	4 (18.2)	7 (11.1)	16 (13.9)
Grade 3	0	0	1 (1.6)	1 (0.9)
Grade 4	0	0	1 (1.6)	1 (0.9)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.59	-1.59		
95% CI of the absolute risk difference	(-4.67, 1.50)	(-4.67, 1.50)		
p-value	0.4878	0.5522		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4614		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.59	-1.59		
95% CI of the absolute risk difference	(-4.67, 1.50)	(-4.67, 1.50)		
p-value	0.4878	0.5522		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5900		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.59	-1.59		
95% CI of the absolute risk difference	(-4.67, 1.50)	(-4.67, 1.50)		
p-value	0.4878	0.5522		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5900		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable; SNP = Single Nucleotide Polymorphism.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Events n:				
Total TEAEs	334	252	647	1233
Total Serious TEAEs	6	6	25	37
Total TEAEs Leading to Discontinuation of Study Drug	5	6	6	17
Total TEAEs Related to Study Drug	56	33	32	121
Total TEAEs >= Grade 3 Severity	6	7	26	39
Patients n (%):				
Any TEAE	42 (87.5)	36 (81.8)	86 (90.5)	164 (87.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.47		
95% CI of the odds ratio	(0.24, 2.19)	(0.17, 1.32)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	0.90		
95% CI of the risk ratio	(0.85, 1.10)	(0.78, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.03	-8.71		
95% CI of the absolute risk difference	(-14.08, 8.03)	(-21.54, 4.12)		
p-value	0.5770	0.1450		
p-value of Breslow-Day Test for Homogeneity [2]	0.2316	0.2199		
Any Serious TEAE	5 (10.4)	5 (11.4)	13 (13.7)	23 (12.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.81		
95% CI of the odds ratio	(0.25, 2.19)	(0.27, 2.43)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76	0.83		
95% CI of the risk ratio	(0.29, 2.01)	(0.32, 2.19)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.27	-2.32		
95% CI of the absolute risk difference	(-14.33, 7.80)	(-13.97, 9.33)		
p-value	0.5780	0.7047		
p-value of Breslow-Day Test for Homogeneity [2]	0.7036	0.8108		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Any TEAEs >= Grade 3 Severity	4 (8.3)	5 (11.4)	14 (14.7)	23 (12.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53	0.74		
95% CI of the odds ratio	(0.16, 1.70)	(0.25, 2.21)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57	0.77		
95% CI of the risk ratio	(0.20, 1.63)	(0.30, 2.01)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.40	-3.37		
95% CI of the absolute risk difference	(-16.98, 4.18)	(-15.15, 8.41)		
p-value	0.2757	0.5902		
p-value of Breslow-Day Test for Homogeneity [2]	0.2331	0.6476		
Any TEAEs <= Grade 2 Severity	42 (87.5)	36 (81.8)	86 (90.5)	164 (87.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.47		
95% CI of the odds ratio	(0.24, 2.19)	(0.17, 1.32)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	0.90		
95% CI of the risk ratio	(0.85, 1.10)	(0.78, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.03	-8.71		
95% CI of the absolute risk difference	(-14.08, 8.03)	(-21.54, 4.12)		
p-value	0.5770	0.1450		
p-value of Breslow-Day Test for Homogeneity [2]	0.3105	0.2677		
Any TEAEs leading to Study-Drug Discontinuation	3 (6.3)	5 (11.4)	5 (5.3)	13 (7.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.20	2.31		
95% CI of the odds ratio	(0.27, 5.25)	(0.63, 8.43)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.19	2.16		
95% CI of the risk ratio	(0.30, 4.76)	(0.66, 7.08)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.99	6.10		
95% CI of the absolute risk difference	(-7.20, 9.18)	(-4.30, 16.50)		
p-value	0.8084	0.1954		
p-value of Breslow-Day Test for Homogeneity [2]	0.5312	0.1789		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Any TEAEs leading to Study Discontinuation	1 (2.1)	2 (4.5)	4 (4.2)	7 (3.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48	1.08		
95% CI of the odds ratio	(0.05, 4.45)	(0.19, 6.15)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.49	1.08		
95% CI of the risk ratio	(0.06, 4.31)	(0.21, 5.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.13	0.33		
95% CI of the absolute risk difference	(-7.84, 3.59)	(-7.03, 7.70)		
p-value	0.5132	0.9280		
p-value of Breslow-Day Test for Homogeneity [2]	0.2944	0.1033		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1807	0.2070		
Any Treatment-related TEAE	21 (43.8)	19 (43.2)	18 (18.9)	58 (31.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.33	3.25		
95% CI of the odds ratio	(1.54, 7.17)	(1.48, 7.14)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.31	2.28		
95% CI of the risk ratio	(1.37, 3.90)	(1.33, 3.90)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	24.80	24.23		
95% CI of the absolute risk difference	(8.71, 40.90)	(7.61, 40.86)		
p-value	0.0017	0.0026		
p-value of Breslow-Day Test for Homogeneity [2]	0.1489	0.1149		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1024	0.0734		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (4.2)	4 (9.1)	2 (2.1)	8 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.02	4.65		
95% CI of the odds ratio	(0.28, 14.81)	(0.82, 26.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.98	4.32		
95% CI of the risk ratio	(0.29, 13.62)	(0.82, 22.70)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.06	6.99		
95% CI of the absolute risk difference	(-4.29, 8.41)	(-1.99, 15.96)		
p-value	0.4802	0.0594		
p-value of Breslow-Day Test for Homogeneity [2]	0.1375	0.5334		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	1 (2.3)	2 (2.1)	3 (1.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.08		
95% CI of the odds ratio	NE	(0.10, 12.25)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.08		
95% CI of the risk ratio	NE	(0.10, 11.59)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.11	0.17		
95% CI of the absolute risk difference	(-4.99, 0.78)	(-5.10, 5.43)		
p-value	0.3114	0.9496		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3159		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	10 (20.8)	10 (22.7)	26 (27.4)	46 (24.6)
Grade 2	28 (58.3)	21 (47.7)	46 (48.4)	95 (50.8)
Grade 3	4 (8.3)	5 (11.4)	13 (13.7)	22 (11.8)
Grade 4	0	0	1 (1.1)	1 (0.5)
Grade 5	0	0	0	0

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	14 (29.2)	13 (29.5)	8 (8.4)	35 (18.7)
Grade 2	7 (14.6)	6 (13.6)	10 (10.5)	23 (12.3)
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	2 (2.1)	2 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.11	-2.11		
95% CI of the absolute risk difference	(-4.99, 0.78)	(-4.99, 0.78)		
p-value	0.3114	0.3323		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4614		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	1 (1.1)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.05	-1.05		
95% CI of the absolute risk difference	(-3.10, 1.00)	(-3.10, 1.00)		
p-value	0.4756	0.4946		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5900		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (1.1)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.05	-1.05		
95% CI of the absolute risk difference	(-3.10, 1.00)	(-3.10, 1.00)		
p-value	0.4756	0.4946		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	1 (1.1)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.05	-1.05		
95% CI of the absolute risk difference	(-3.10, 1.00)	(-3.10, 1.00)		
p-value	0.4756	0.4946		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5900		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48) n (%)	MGL-3196 100 mg (N=44) n (%)	Placebo (N=95) n (%)	Overall (N=187) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Events n:				
Total TEAEs	586	501	951	2038
Total Serious TEAEs	20	18	44	82
Total TEAEs Leading to Discontinuation of Study Drug	7	11	6	24
Total TEAEs Related to Study Drug	62	69	74	205
Total TEAEs >= Grade 3 Severity	21	26	53	100
Patients n (%):				
Any TEAE	74 (96.1)	67 (93.1)	119 (93.0)	260 (93.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.87	1.01		
95% CI of the odds ratio	(0.49, 7.11)	(0.33, 3.15)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03	1.00		
95% CI of the risk ratio	(0.97, 1.10)	(0.92, 1.08)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.14	0.09		
95% CI of the absolute risk difference	(-3.05, 9.32)	(-7.27, 7.44)		
p-value	0.3544	0.9816		
p-value of Breslow-Day Test for Homogeneity [2]	0.2316	0.2199		
Any Serious TEAE	8 (10.4)	11 (15.3)	16 (12.5)	35 (12.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81	1.26		
95% CI of the odds ratio	(0.33, 2.00)	(0.55, 2.89)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83	1.22		
95% CI of the risk ratio	(0.37, 1.85)	(0.60, 2.49)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.11	2.78		
95% CI of the absolute risk difference	(-11.01, 6.79)	(-7.32, 12.87)		
p-value	0.6490	0.5811		
p-value of Breslow-Day Test for Homogeneity [2]	0.7036	0.8108		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Any TEAEs >= Grade 3 Severity	12 (15.6)	14 (19.4)	21 (16.4)	47 (17.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.94	1.23		
95% CI of the odds ratio	(0.43, 2.04)	(0.58, 2.60)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	1.19		
95% CI of the risk ratio	(0.50, 1.82)	(0.64, 2.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.82	3.04		
95% CI of the absolute risk difference	(-11.16, 9.51)	(-8.13, 14.21)		
p-value	0.8768	0.5873		
p-value of Breslow-Day Test for Homogeneity [2]	0.2331	0.6476		
Any TEAEs <= Grade 2 Severity	72 (93.5)	65 (90.3)	119 (93.0)	256 (92.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.09	0.70		
95% CI of the odds ratio	(0.35, 3.38)	(0.25, 1.97)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	0.97		
95% CI of the risk ratio	(0.93, 1.08)	(0.89, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.54	-2.69		
95% CI of the absolute risk difference	(-6.53, 7.60)	(-10.84, 5.46)		
p-value	0.8825	0.5007		
p-value of Breslow-Day Test for Homogeneity [2]	0.3105	0.2677		
Any TEAEs leading to Study-Drug Discontinuation	4 (5.2)	10 (13.9)	4 (3.1)	18 (6.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.70	5.00		
95% CI of the odds ratio	(0.41, 7.00)	(1.51, 16.58)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.66	4.44		
95% CI of the risk ratio	(0.43, 6.46)	(1.45, 13.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.07	10.76		
95% CI of the absolute risk difference	(-3.73, 7.87)	(2.23, 19.30)		
p-value	0.4586	0.0042		
p-value of Breslow-Day Test for Homogeneity [2]	0.5312	0.1789		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Any TEAEs leading to Study Discontinuation	2 (2.6)	8 (11.1)	2 (1.6)	12 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.68	7.88		
95% CI of the odds ratio	(0.23, 12.18)	(1.62, 38.17)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.66	7.11		
95% CI of the risk ratio	(0.24, 11.56)	(1.55, 32.59)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.03	9.55		
95% CI of the absolute risk difference	(-3.12, 5.19)	(1.98, 17.12)		
p-value	0.6039	0.0029		
p-value of Breslow-Day Test for Homogeneity [2]	0.2944	0.1033		
Any Fatal TEAEs	1 (1.3)	1 (1.4)	0	2 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.30	1.39		
95% CI of the absolute risk difference	(-1.23, 3.83)	(-1.31, 4.09)		
p-value	0.1962	0.1813		
p-value of Breslow-Day Test for Homogeneity [2]	0.1807	0.2070		
Any Treatment-related TEAE	27 (35.1)	24 (33.3)	38 (29.7)	89 (32.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.28	1.18		
95% CI of the odds ratio	(0.70, 2.34)	(0.64, 2.20)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.18	1.12		
95% CI of the risk ratio	(0.79, 1.77)	(0.74, 1.71)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.38	3.65		
95% CI of the absolute risk difference	(-7.90, 18.65)	(-9.82, 17.11)		
p-value	0.4230	0.5926		
p-value of Breslow-Day Test for Homogeneity [2]	0.1489	0.1149		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (1.3)	2 (2.8)	0	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.30	2.78		
95% CI of the absolute risk difference	(-1.23, 3.83)	(-1.02, 6.57)		
p-value	0.1962	0.0581		
p-value of Breslow-Day Test for Homogeneity [2]	0.1024	0.0734		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	5 (6.9)	3 (2.3)	8 (2.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.11		
95% CI of the odds ratio	NE	(0.72, 13.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.96		
95% CI of the risk ratio	NE	(0.73, 12.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.34	4.60		
95% CI of the absolute risk difference	(-4.96, 0.28)	(-1.83, 11.03)		
p-value	0.1760	0.1110		
p-value of Breslow-Day Test for Homogeneity [2]	0.1375	0.5334		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	5 (6.9)	1 (0.8)	6 (2.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	9.48		
95% CI of the odds ratio	NE	(1.09, 82.79)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.89		
95% CI of the risk ratio	NE	(1.06, 74.61)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.78	6.16		
95% CI of the absolute risk difference	(-2.31, 0.74)	(0.10, 12.23)		
p-value	0.4369	0.0142		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3159		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	15 (19.5)	9 (12.5)	22 (17.2)	46 (16.6)
Grade 2	47 (61.0)	44 (61.1)	76 (59.4)	167 (60.3)
Grade 3	11 (14.3)	13 (18.1)	18 (14.1)	42 (15.2)
Grade 4	0	0	3 (2.3)	3 (1.1)
Grade 5	1 (1.3)	1 (1.4)	0	2 (0.7)

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	13 (16.9)	11 (15.3)	27 (21.1)	51 (18.4)
Grade 2	13 (16.9)	11 (15.3)	11 (8.6)	35 (12.6)
Grade 3	1 (1.3)	2 (2.8)	0	3 (1.1)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (1.3)	1 (1.4)	1 (0.8)	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	1.79		
95% CI of the odds ratio	(0.10, 27.11)	(0.11, 29.03)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.66	1.78		
95% CI of the risk ratio	(0.11, 26.20)	(0.11, 28.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.52	0.61		
95% CI of the absolute risk difference	(-2.44, 3.47)	(-2.50, 3.71)		
p-value	0.7151	0.6785		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.4)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.39		
95% CI of the absolute risk difference	NE	(-1.31, 4.09)		
p-value	NE	0.1813		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (1.3)	0	1 (0.8)	2 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	NE		
95% CI of the odds ratio	(0.10, 27.11)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.66	NE		
95% CI of the risk ratio	(0.11, 26.20)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.52	-0.78		
95% CI of the absolute risk difference	(-2.44, 3.47)	(-2.31, 0.74)		
p-value	0.7151	0.4521		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (1.3)	1 (1.4)	1 (0.8)	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.67	1.79		
95% CI of the odds ratio	(0.10, 27.11)	(0.11, 29.03)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.66	1.78		
95% CI of the risk ratio	(0.11, 26.20)	(0.11, 28.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.52	0.61		
95% CI of the absolute risk difference	(-2.44, 3.47)	(-2.50, 3.71)		
p-value	0.7151	0.6785		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	1 (1.4)	1 (0.8)	2 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.79		
95% CI of the odds ratio	NE	(0.11, 29.03)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.78		
95% CI of the risk ratio	NE	(0.11, 28.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.78	0.61		
95% CI of the absolute risk difference	(-2.31, 0.74)	(-2.50, 3.71)		
p-value	0.4369	0.6785		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4614		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.4)	1 (0.8)	2 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.79		
95% CI of the odds ratio	NE	(0.11, 29.03)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.78		
95% CI of the risk ratio	NE	(0.11, 28.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.78	0.61		
95% CI of the absolute risk difference	(-2.31, 0.74)	(-2.50, 3.71)		
p-value	0.4369	0.6785		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5900		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (1.4)	1 (0.8)	2 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.79		
95% CI of the odds ratio	NE	(0.11, 29.03)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.78		
95% CI of the risk ratio	NE	(0.11, 28.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.78	0.61		
95% CI of the absolute risk difference	(-2.31, 0.74)	(-2.50, 3.71)		
p-value	0.4369	0.6785		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5900		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77) n (%)	MGL-3196 100 mg (N=72) n (%)	Placebo (N=128) n (%)	Overall (N=277) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Events n:				
Total TEAEs	218	196	435	849
Total Serious TEAEs	2	7	22	31
Total TEAEs Leading to Discontinuation of Study Drug	1	1	6	8
Total TEAEs Related to Study Drug	24	14	38	76
Total TEAEs >= Grade 3 Severity	3	9	22	34
Patients n (%):				
Any TEAE	30 (100)	22 (100)	59 (93.7)	111 (96.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.07	1.07		
95% CI of the risk ratio	(1.00, 1.14)	(1.00, 1.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.35	6.35		
95% CI of the absolute risk difference	(0.33, 12.37)	(0.33, 12.37)		
p-value	0.1583	0.2260		
p-value of Breslow-Day Test for Homogeneity [2]	0.2316	0.2199		
Any Serious TEAE	2 (6.7)	4 (18.2)	10 (15.9)	16 (13.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38	1.18		
95% CI of the odds ratio	(0.08, 1.85)	(0.33, 4.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42	1.15		
95% CI of the risk ratio	(0.10, 1.80)	(0.40, 3.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.21	2.31		
95% CI of the absolute risk difference	(-21.90, 3.49)	(-16.16, 20.78)		
p-value	0.2157	0.8015		
p-value of Breslow-Day Test for Homogeneity [2]	0.7036	0.8108		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Any TEAEs >= Grade 3 Severity	2 (6.7)	4 (18.2)	15 (23.8)	21 (18.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.23	0.71		
95% CI of the odds ratio	(0.05, 1.07)	(0.21, 2.43)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.28	0.76		
95% CI of the risk ratio	(0.07, 1.15)	(0.28, 2.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-17.14	-5.63		
95% CI of the absolute risk difference	(-30.94, -3.35)	(-24.87, 13.62)		
p-value	0.0456	0.5854		
p-value of Breslow-Day Test for Homogeneity [2]	0.2331	0.6476		
Any TEAEs <= Grade 2 Severity	30 (100)	22 (100)	59 (93.7)	111 (96.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.07	1.07		
95% CI of the risk ratio	(1.00, 1.14)	(1.00, 1.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.35	6.35		
95% CI of the absolute risk difference	(0.33, 12.37)	(0.33, 12.37)		
p-value	0.1583	0.2260		
p-value of Breslow-Day Test for Homogeneity [2]	0.3105	0.2677		
Any TEAEs leading to Study-Drug Discontinuation	1 (3.3)	1 (4.5)	5 (7.9)	7 (6.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40	0.55		
95% CI of the odds ratio	(0.04, 3.58)	(0.06, 5.01)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.42	0.57		
95% CI of the risk ratio	(0.05, 3.44)	(0.07, 4.64)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.60	-3.39		
95% CI of the absolute risk difference	(-13.87, 4.66)	(-14.36, 7.58)		
p-value	0.3983	0.5929		
p-value of Breslow-Day Test for Homogeneity [2]	0.5312	0.1789		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Any TEAEs leading to Study Discontinuation	0	1 (4.5)	4 (6.3)	5 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.22	0.70		
95% CI of the odds ratio	(0.01, 4.16)	(0.07, 6.65)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.23	0.72		
95% CI of the risk ratio	(0.01, 4.13)	(0.08, 6.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.42	-1.80		
95% CI of the absolute risk difference	(-13.09, 2.26)	(-12.39, 8.78)		
p-value	0.2675	0.7569		
p-value of Breslow-Day Test for Homogeneity [2]	0.2944	0.1033		
Any Fatal TEAEs	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.59	-1.59		
95% CI of the absolute risk difference	(-4.67, 1.50)	(-4.67, 1.50)		
p-value	0.4878	0.5522		
p-value of Breslow-Day Test for Homogeneity [2]	0.1807	0.2070		
Any Treatment-related TEAE	15 (50.0)	8 (36.4)	20 (31.7)	43 (37.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.15	1.23		
95% CI of the odds ratio	(0.88, 5.24)	(0.44, 3.40)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.58	1.15		
95% CI of the risk ratio	(0.95, 2.62)	(0.59, 2.22)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	18.25	4.62		
95% CI of the absolute risk difference	(-3.01, 39.52)	(-18.54, 27.77)		
p-value	0.0894	0.6916		
p-value of Breslow-Day Test for Homogeneity [2]	0.1489	0.1149		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Any Treatment-related Serious TEAE	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.59	-1.59		
95% CI of the absolute risk difference	(-4.67, 1.50)	(-4.67, 1.50)		
p-value	0.4878	0.5522		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	2 (3.2)	2 (1.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.17	-3.17		
95% CI of the absolute risk difference	(-7.50, 1.15)	(-7.50, 1.15)		
p-value	0.3239	0.3977		
p-value of Breslow-Day Test for Homogeneity [2]	0.1024	0.0734		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	1 (4.5)	3 (4.8)	4 (3.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.95		
95% CI of the odds ratio	NE	(0.09, 9.66)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.95		
95% CI of the risk ratio	NE	(0.10, 8.71)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76	-0.22		
95% CI of the absolute risk difference	(-10.02, 0.50)	(-10.39, 9.95)		
p-value	0.2244	0.9671		
p-value of Breslow-Day Test for Homogeneity [2]	0.1375	0.5334		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	1 (4.5)	2 (3.2)	3 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.45		
95% CI of the odds ratio	NE	(0.13, 16.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.43		
95% CI of the risk ratio	NE	(0.14, 15.03)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.17	1.37		
95% CI of the absolute risk difference	(-7.50, 1.15)	(-8.35, 11.09)		
p-value	0.3239	0.7642		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3159		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	6 (20.0)	4 (18.2)	17 (27.0)	27 (23.5)
Grade 2	22 (73.3)	14 (63.6)	27 (42.9)	63 (54.8)
Grade 3	2 (6.7)	4 (18.2)	11 (17.5)	17 (14.8)
Grade 4	0	0	3 (4.8)	3 (2.6)
Grade 5	0	0	1 (1.6)	1 (0.9)

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	10 (33.3)	4 (18.2)	11 (17.5)	25 (21.7)
Grade 2	5 (16.7)	4 (18.2)	7 (11.1)	16 (13.9)
Grade 3	0	0	1 (1.6)	1 (0.9)
Grade 4	0	0	1 (1.6)	1 (0.9)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.59	-1.59		
95% CI of the absolute risk difference	(-4.67, 1.50)	(-4.67, 1.50)		
p-value	0.4878	0.5522		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4614		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.59	-1.59		
95% CI of the absolute risk difference	(-4.67, 1.50)	(-4.67, 1.50)		
p-value	0.4878	0.5522		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5900		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.59	-1.59		
95% CI of the absolute risk difference	(-4.67, 1.50)	(-4.67, 1.50)		
p-value	0.4878	0.5522		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.5900		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=22) n (%)	Placebo (N=63) n (%)	Overall (N=115) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.
Note: PT 'Contusion' has statistically significant results in table S1.1.3, but is not included in this table due to patient counts being less than 10 in all subgroup categories.

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

System Organ Class Preferred Term	MGL-3196 80 mg (N=48) Patients n (%)	 Events n	MGL-3196 100 mg (N=44) Patients n (%)	 Events n	Placebo (N=95) Patients n (%)	 Events n	Overall (N=187) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	11 (22.9)	20	11 (25.0)	13	15 (15.8)	20	37 (19.8)	53
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.59		1.78					
95% CI of the odds ratio	(0.66, 3.79)		(0.74, 4.27)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.45		1.58					
95% CI of the risk ratio	(0.72, 2.91)		(0.79, 3.16)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.13		9.21					
95% CI of the absolute risk difference	(-6.84, 21.10)		(-5.54, 23.96)					
p-value	0.2967		0.1952					
p-value of Breslow-Day Test for Homogeneity [2]	0.8044		0.1904					
Nausea	17 (35.4)	19	8 (18.2)	8	12 (12.6)	13	37 (19.8)	40
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.79		1.54					
95% CI of the odds ratio	(1.63, 8.84)		(0.58, 4.08)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.80		1.44					
95% CI of the risk ratio	(1.46, 5.38)		(0.63, 3.27)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	22.79		5.55					
95% CI of the absolute risk difference	(7.70, 37.87)		(-7.66, 18.76)					
p-value	0.0014		0.3858					
p-value of Breslow-Day Test for Homogeneity [2]	0.4909		0.6099					

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

System Organ Class Preferred Term	MGL-3196 80 mg (N=48) Patients n (%)	 Events n	MGL-3196 100 mg (N=44) Patients n (%)	 Events n	Placebo (N=95) Patients n (%)	 Events n	Overall (N=187) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	4 (8.3)	4	2 (4.5)	2	6 (6.3)	6	12 (6.4)	12
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.35		0.71					
95% CI of the odds ratio	(0.36, 5.03)		(0.14, 3.65)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.32		0.72					
95% CI of the risk ratio	(0.39, 4.45)		(0.15, 3.42)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.02		-1.77					
95% CI of the absolute risk difference	(-7.21, 11.24)		(-9.63, 6.09)					
p-value	0.6551		0.6768					
p-value of Breslow-Day Test for Homogeneity [2]	0.6067		0.2122					
Abdominal discomfort	0	0	1 (2.3)	2	4 (4.2)	4	5 (2.7)	6
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		0.53					
95% CI of the odds ratio	NE		(0.06, 4.88)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		0.54					
95% CI of the risk ratio	NE		(0.06, 4.69)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.21		-1.94					
95% CI of the absolute risk difference	(-8.25, -0.17)		(-7.91, 4.04)					
p-value	0.1493		0.5682					
p-value of Breslow-Day Test for Homogeneity [2]	0.6317		0.7398					

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48)		MGL-3196 100 mg (N=44)		Placebo (N=95)		Overall (N=187)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
General disorders and administration site conditions	12 (25.0)	14	3 (6.8)	4	23 (24.2)	29	38 (20.3)	47
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04		0.23					
95% CI of the odds ratio	(0.47, 2.33)		(0.06, 0.81)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03		0.28					
95% CI of the risk ratio	(0.56, 1.89)		(0.09, 0.89)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.79		-17.39					
95% CI of the absolute risk difference	(-14.19, 15.76)		(-28.78, -6.01)					
p-value	0.9174		0.0145					
p-value of Breslow-Day Test for Homogeneity [2]	0.4554		0.0229					
Skin and subcutaneous tissue disorders								
Pruritus	5 (10.4)	7	4 (9.1)	4	7 (7.4)	9	16 (8.6)	20
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.46		1.26					
95% CI of the odds ratio	(0.44, 4.87)		(0.35, 4.54)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.41		1.23					
95% CI of the risk ratio	(0.47, 4.22)		(0.38, 4.00)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.05		1.72					
95% CI of the absolute risk difference	(-7.07, 13.16)		(-8.27, 11.71)					
p-value	0.5347		0.7264					
p-value of Breslow-Day Test for Homogeneity [2]	0.9770		0.3232					

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

System Organ Class Preferred Term	MGL-3196 80 mg (N=48) Patients n (%)	 Events n	MGL-3196 100 mg (N=44) Patients n (%)	 Events n	Placebo (N=95) Patients n (%)	 Events n	Overall (N=187) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	4 (8.3)	4	5 (11.4)	7	2 (2.1)	2	11 (5.9)	13
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.23		5.96					
95% CI of the odds ratio	(0.75, 23.96)		(1.11, 32.05)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.96		5.40					
95% CI of the risk ratio	(0.75, 20.85)		(1.09, 26.75)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.23		9.26					
95% CI of the absolute risk difference	(-2.11, 14.56)		(-0.55, 19.07)					
p-value	0.0794		0.0203					
p-value of Breslow-Day Test for Homogeneity [2]	0.2956		0.7185					
Renal and urinary disorders	2 (4.2)	2	4 (9.1)	4	10 (10.5)	15	16 (8.6)	21
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.37		0.85					
95% CI of the odds ratio	(0.08, 1.76)		(0.25, 2.88)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40		0.86					
95% CI of the risk ratio	(0.09, 1.74)		(0.29, 2.60)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.36		-1.44					
95% CI of the absolute risk difference	(-14.73, 2.01)		(-11.93, 9.06)					
p-value	0.1952		0.7937					
p-value of Breslow-Day Test for Homogeneity [2]	0.7647		0.1100					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48)		MGL-3196 100 mg (N=44)		Placebo (N=95)		Overall (N=187)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	4 (8.3)	4	0	0	11 (11.6)	13	15 (8.0)	17
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69		0.08					
95% CI of the odds ratio	(0.21, 2.31)		(0.00, 1.43)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.72		0.09					
95% CI of the risk ratio	(0.24, 2.14)		(0.01, 1.54)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.25		-10.87					
95% CI of the absolute risk difference	(-13.37, 6.88)		(-18.05, -3.69)					
p-value	0.5498		0.0311					
p-value of Breslow-Day Test for Homogeneity [2]	0.6141		0.0039					

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77)		MGL-3196 100 mg (N=72)		Placebo (N=128)		Overall (N=277)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders								
Diarrhoea	23 (29.9)	41	27 (37.5)	46	20 (15.6)	25	70 (25.3)	112
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.30		3.24					
95% CI of the odds ratio	(1.16, 4.55)		(1.65, 6.36)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.91		2.40					
95% CI of the risk ratio	(1.13, 3.24)		(1.45, 3.96)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.25		21.88					
95% CI of the absolute risk difference	(2.24, 26.25)		(9.04, 34.71)					
p-value	0.0153		0.0005					
p-value of Breslow-Day Test for Homogeneity [2]	0.8044		0.1904					
Nausea	18 (23.4)	24	11 (15.3)	16	16 (12.5)	19	45 (16.2)	59
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.14		1.26					
95% CI of the odds ratio	(1.02, 4.49)		(0.55, 2.89)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.87		1.22					
95% CI of the risk ratio	(1.01, 3.45)		(0.60, 2.49)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	10.88		2.78					
95% CI of the absolute risk difference	(-0.18, 21.93)		(-7.32, 12.87)					
p-value	0.0426		0.5811					
p-value of Breslow-Day Test for Homogeneity [2]	0.4909		0.6099					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77)		MGL-3196 100 mg (N=72)		Placebo (N=128)		Overall (N=277)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders (cont.)								
Vomiting	13 (16.9)	14	4 (5.6)	4	8 (6.3)	9	25 (9.0)	27
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.05		0.88					
95% CI of the odds ratio	(1.20, 7.73)		(0.26, 3.04)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.70		0.89					
95% CI of the risk ratio	(1.17, 6.22)		(0.28, 2.85)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	10.63		-0.69					
95% CI of the absolute risk difference	(1.27, 19.99)		(-7.45, 6.06)					
p-value	0.0150		0.8427					
p-value of Breslow-Day Test for Homogeneity [2]	0.6067		0.2122					
Abdominal discomfort	1 (1.3)	1	2 (2.8)	2	6 (4.7)	7	9 (3.2)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.27		0.58					
95% CI of the odds ratio	(0.03, 2.27)		(0.11, 2.96)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.28		0.59					
95% CI of the risk ratio	(0.03, 2.26)		(0.12, 2.86)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.39		-1.91					
95% CI of the absolute risk difference	(-7.84, 1.06)		(-7.18, 3.36)					
p-value	0.1957		0.5083					
p-value of Breslow-Day Test for Homogeneity [2]	0.6317		0.7398					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77)		MGL-3196 100 mg (N=72)		Placebo (N=128)		Overall (N=277)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
General disorders and administration site conditions	16 (20.8)	28	15 (20.8)	20	42 (32.8)	54	73 (26.4)	102
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.54		0.54					
95% CI of the odds ratio	(0.28, 1.04)		(0.27, 1.06)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.63		0.63					
95% CI of the risk ratio	(0.38, 1.05)		(0.38, 1.06)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-12.03		-11.98					
95% CI of the absolute risk difference	(-24.21, 0.14)		(-24.40, 0.44)					
p-value	0.0640		0.0716					
p-value of Breslow-Day Test for Homogeneity [2]	0.4554		0.0229					
Skin and subcutaneous tissue disorders								
Pruritus	8 (10.4)	9	1 (1.4)	1	8 (6.3)	8	17 (6.1)	18
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.74		0.21					
95% CI of the odds ratio	(0.62, 4.84)		(0.03, 1.72)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.66		0.22					
95% CI of the risk ratio	(0.65, 4.25)		(0.03, 1.74)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.14		-4.86					
95% CI of the absolute risk difference	(-3.86, 12.14)		(-9.85, 0.13)					
p-value	0.2846		0.1114					
p-value of Breslow-Day Test for Homogeneity [2]	0.9770		0.3232					

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77)		MGL-3196 100 mg (N=72)		Placebo (N=128)		Overall (N=277)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	2 (2.6)	2	6 (8.3)	6	4 (3.1)	5	12 (4.3)	13
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83		2.82					
95% CI of the odds ratio	(0.15, 4.62)		(0.77, 10.34)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83		2.67					
95% CI of the risk ratio	(0.16, 4.43)		(0.78, 9.14)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.53		5.21					
95% CI of the absolute risk difference	(-5.19, 4.13)		(-1.85, 12.27)					
p-value	0.8282		0.1048					
p-value of Breslow-Day Test for Homogeneity [2]	0.2956		0.7185					
Renal and urinary disorders	3 (3.9)	4	9 (12.5)	11	13 (10.2)	14	25 (9.0)	29
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.36		1.26					
95% CI of the odds ratio	(0.10, 1.30)		(0.51, 3.12)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		1.23					
95% CI of the risk ratio	(0.11, 1.30)		(0.55, 2.74)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.26		2.34					
95% CI of the absolute risk difference	(-13.05, 0.53)		(-6.92, 11.60)					
p-value	0.1056		0.6111					
p-value of Breslow-Day Test for Homogeneity [2]	0.7647		0.1100					

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77)		MGL-3196 100 mg (N=72)		Placebo (N=128)		Overall (N=277)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	3 (3.9)	4	1 (1.4)	1	9 (7.0)	10	13 (4.7)	15
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.54		0.19					
95% CI of the odds ratio	(0.14, 2.04)		(0.02, 1.50)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.55		0.20					
95% CI of the risk ratio	(0.15, 1.98)		(0.03, 1.53)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.14		-5.64					
95% CI of the absolute risk difference	(-9.32, 3.05)		(-10.83, -0.45)					
p-value	0.3544		0.0788					
p-value of Breslow-Day Test for Homogeneity [2]	0.6141		0.0039					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30)		MGL-3196 100 mg (N=22)		Placebo (N=63)		Overall (N=115)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders								
Diarrhoea	6 (20.0)	10	10 (45.5)	15	7 (11.1)	7	23 (20.0)	32
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.00		6.67					
95% CI of the odds ratio	(0.61, 6.58)		(2.11, 21.05)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80		4.09					
95% CI of the risk ratio	(0.66, 4.89)		(1.77, 9.43)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.89		34.34					
95% CI of the absolute risk difference	(-7.39, 25.17)		(12.14, 56.55)					
p-value	0.2478		0.0005					
p-value of Breslow-Day Test for Homogeneity [2]	0.8044		0.1904					
Nausea	7 (23.3)	7	2 (9.1)	2	9 (14.3)	11	18 (15.7)	20
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.83		0.60					
95% CI of the odds ratio	(0.61, 5.50)		(0.12, 3.02)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.63		0.64					
95% CI of the risk ratio	(0.67, 3.97)		(0.15, 2.72)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.05		-5.19					
95% CI of the absolute risk difference	(-8.38, 26.48)		(-19.99, 9.60)					
p-value	0.2798		0.5320					
p-value of Breslow-Day Test for Homogeneity [2]	0.4909		0.6099					

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

System Organ Class Preferred Term	MGL-3196 80 mg (N=30) Patients n (%)	 Events n	MGL-3196 100 mg (N=22) Patients n (%)	 Events n	Placebo (N=63) Patients n (%)	 Events n	Overall (N=115) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	2 (6.7)	3	3 (13.6)	3	2 (3.2)	2	7 (6.1)	8
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.18		4.82					
95% CI of the odds ratio	(0.29, 16.27)		(0.75, 30.99)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.10		4.30					
95% CI of the risk ratio	(0.31, 14.20)		(0.77, 24.04)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.49		10.46					
95% CI of the absolute risk difference	(-6.43, 13.41)		(-4.52, 25.44)					
p-value	0.4378		0.0726					
p-value of Breslow-Day Test for Homogeneity [2]	0.6067		0.2122					
Abdominal discomfort	0	0	0	0	3 (4.8)	3	3 (2.6)	3
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76		-4.76					
95% CI of the absolute risk difference	(-10.02, 0.50)		(-10.02, 0.50)					
p-value	0.2244		0.2974					
p-value of Breslow-Day Test for Homogeneity [2]	0.6317		0.7398					

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30)		MGL-3196 100 mg (N=22)		Placebo (N=63)		Overall (N=115)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
General disorders and administration site conditions	6 (20.0)	9	9 (40.9)	13	17 (27.0)	18	32 (27.8)	40
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68		1.87					
95% CI of the odds ratio	(0.24, 1.94)		(0.68, 5.17)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.74		1.52					
95% CI of the risk ratio	(0.33, 1.69)		(0.79, 2.89)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.98		13.92					
95% CI of the absolute risk difference	(-25.01, 11.04)		(-9.36, 37.21)					
p-value	0.4655		0.2223					
p-value of Breslow-Day Test for Homogeneity [2]	0.4554		0.0229					
Skin and subcutaneous tissue disorders								
Pruritus	5 (16.7)	6	2 (9.1)	4	7 (11.1)	8	14 (12.2)	18
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.60		0.80					
95% CI of the odds ratio	(0.46, 5.53)		(0.15, 4.18)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50		0.82					
95% CI of the risk ratio	(0.52, 4.34)		(0.18, 3.65)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.56		-2.02					
95% CI of the absolute risk difference	(-9.87, 20.99)		(-16.32, 12.28)					
p-value	0.4550		0.7909					
p-value of Breslow-Day Test for Homogeneity [2]	0.9770		0.3232					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30)		MGL-3196 100 mg (N=22)		Placebo (N=63)		Overall (N=115)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	2 (6.7)	2	4 (18.2)	6	5 (7.9)	6	11 (9.6)	14
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83		2.58					
95% CI of the odds ratio	(0.15, 4.54)		(0.62, 10.63)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.84		2.29					
95% CI of the risk ratio	(0.17, 4.08)		(0.68, 7.77)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.27		10.25					
95% CI of the absolute risk difference	(-12.42, 9.88)		(-7.20, 27.69)					
p-value	0.8282		0.1788					
p-value of Breslow-Day Test for Homogeneity [2]	0.2956		0.7185					
Renal and urinary disorders	0	0	5 (22.7)	7	3 (4.8)	3	8 (7.0)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		5.88					
95% CI of the odds ratio	NE		(1.27, 27.15)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		4.77					
95% CI of the risk ratio	NE		(1.24, 18.35)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76		17.97					
95% CI of the absolute risk difference	(-10.02, 0.50)		(-0.32, 36.25)					
p-value	0.2244		0.0130					
p-value of Breslow-Day Test for Homogeneity [2]	0.7647		0.1100					

AMNOG Table S1.14a.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30)		MGL-3196 100 mg (N=22)		Placebo (N=63)		Overall (N=115)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	0	0	3 (13.6)	3	3 (4.8)	4	6 (5.2)	7
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		3.16					
95% CI of the odds ratio	NE		(0.59, 16.97)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		2.86					
95% CI of the risk ratio	NE		(0.62, 13.16)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.76		8.87					
95% CI of the absolute risk difference	(-10.02, 0.50)		(-6.40, 24.15)					
p-value	0.2244		0.1618					
p-value of Breslow-Day Test for Homogeneity [2]	0.6141		0.0039					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable; SNP = Single Nucleotide Polymorphism.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Events n:				
Total TEAEs	915	799	1625	3339
Total Serious TEAEs	24	29	72	125
Total TEAEs Leading to Discontinuation of Study Drug	13	13	19	45
Total TEAEs Related to Study Drug	118	92	115	325
Total TEAEs >= Grade 3 Severity	28	38	79	145
Patients n (%):				
Any TEAE	117 (94.4)	102 (91.1)	205 (91.9)	424 (92.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.47	0.90		
95% CI of the odds ratio	(0.60, 3.62)	(0.40, 2.01)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03	0.99		
95% CI of the risk ratio	(0.97, 1.09)	(0.92, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.43	-0.86		
95% CI of the absolute risk difference	(-2.98, 7.84)	(-7.23, 5.52)		
p-value	0.4022	0.7892		
p-value of Breslow-Day Test for Homogeneity [2]	0.7781	0.1769		
Any Serious TEAE	12 (9.7)	18 (16.1)	28 (12.6)	58 (12.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	1.33		
95% CI of the odds ratio	(0.36, 1.53)	(0.70, 2.53)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.77	1.28		
95% CI of the risk ratio	(0.41, 1.46)	(0.74, 2.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.88	3.52		
95% CI of the absolute risk difference	(-9.66, 3.90)	(-4.56, 11.59)		
p-value	0.4210	0.3778		
p-value of Breslow-Day Test for Homogeneity [2]	0.7894	0.1287		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Any TEAEs >= Grade 3 Severity	17 (13.7)	21 (18.8)	40 (17.9)	78 (17.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	1.06		
95% CI of the odds ratio	(0.39, 1.35)	(0.59, 1.90)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76	1.05		
95% CI of the risk ratio	(0.45, 1.29)	(0.65, 1.68)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.23	0.81		
95% CI of the absolute risk difference	(-12.10, 3.65)	(-8.00, 9.62)		
p-value	0.3084	0.8557		
p-value of Breslow-Day Test for Homogeneity [2]	0.9331	0.2684		
Any TEAEs <= Grade 2 Severity	116 (93.5)	102 (91.1)	205 (91.9)	423 (92.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.27	0.90		
95% CI of the odds ratio	(0.54, 3.02)	(0.40, 2.01)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	0.99		
95% CI of the risk ratio	(0.96, 1.08)	(0.92, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.62	-0.86		
95% CI of the absolute risk difference	(-3.99, 7.23)	(-7.23, 5.52)		
p-value	0.5828	0.7892		
p-value of Breslow-Day Test for Homogeneity [2]	0.5007	0.1588		
Any TEAEs leading to Study-Drug Discontinuation	8 (6.5)	12 (10.7)	16 (7.2)	36 (7.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.89	1.55		
95% CI of the odds ratio	(0.37, 2.15)	(0.71, 3.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90	1.49		
95% CI of the risk ratio	(0.40, 2.04)	(0.73, 3.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.72	3.54		
95% CI of the absolute risk difference	(-6.22, 4.77)	(-3.12, 10.19)		
p-value	0.7991	0.2695		
p-value of Breslow-Day Test for Homogeneity [2]	0.0146	0.1101		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Any TEAEs leading to Study Discontinuation	2 (1.6)	7 (6.3)	8 (3.6)	17 (3.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	1.79		
95% CI of the odds ratio	(0.09, 2.11)	(0.63, 5.07)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45	1.74		
95% CI of the risk ratio	(0.10, 2.08)	(0.65, 4.68)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.97	2.66		
95% CI of the absolute risk difference	(-5.27, 1.32)	(-2.44, 7.77)		
p-value	0.2921	0.2663		
p-value of Breslow-Day Test for Homogeneity [2]	0.0728	0.0224		
Any Fatal TEAEs	1 (0.8)	1 (0.9)	1 (0.4)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	2.00		
95% CI of the odds ratio	(0.11, 29.11)	(0.12, 32.28)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	1.99		
95% CI of the risk ratio	(0.11, 28.50)	(0.13, 31.54)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.36	0.44		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.51, 2.39)		
p-value	0.6729	0.6184		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	51 (41.1)	40 (35.7)	60 (26.9)	151 (32.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.90	1.51		
95% CI of the odds ratio	(1.19, 3.02)	(0.93, 2.46)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.53	1.33		
95% CI of the risk ratio	(1.13, 2.07)	(0.95, 1.85)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.22	8.81		
95% CI of the absolute risk difference	(3.79, 24.66)	(-1.80, 19.42)		
p-value	0.0065	0.0965		
p-value of Breslow-Day Test for Homogeneity [2]	0.1369	0.0968		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.45	-0.45		
95% CI of the absolute risk difference	(-1.33, 0.43)	(-1.33, 0.43)		
p-value	0.4552	0.4779		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (0.8)	1 (0.9)	2 (0.9)	4 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90	1.00		
95% CI of the odds ratio	(0.08, 10.01)	(0.09, 11.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90	1.00		
95% CI of the risk ratio	(0.08, 9.82)	(0.09, 10.86)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.09	0.00		
95% CI of the absolute risk difference	(-2.09, 1.91)	(-2.14, 2.13)		
p-value	0.9305	0.9971		
p-value of Breslow-Day Test for Homogeneity [2]	0.1961	0.1994		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (1.6)	5 (4.5)	6 (2.7)	13 (2.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	1.69		
95% CI of the odds ratio	(0.12, 2.98)	(0.50, 5.66)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	1.66		
95% CI of the risk ratio	(0.12, 2.93)	(0.52, 5.32)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.08	1.77		
95% CI of the absolute risk difference	(-4.15, 1.99)	(-2.60, 6.15)		
p-value	0.5215	0.3901		
p-value of Breslow-Day Test for Homogeneity [2]	0.1638	0.0115		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	3 (2.7)	4 (1.8)	7 (1.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.51		
95% CI of the odds ratio	NE	(0.33, 6.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.49		
95% CI of the risk ratio	NE	(0.34, 6.56)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.79	0.88		
95% CI of the absolute risk difference	(-3.54, -0.05)	(-2.58, 4.35)		
p-value	0.1336	0.5932		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0062		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	23 (18.5)	16 (14.3)	49 (22.0)	88 (19.2)
Grade 2	77 (62.1)	65 (58.0)	116 (52.0)	258 (56.2)
Grade 3	16 (12.9)	20 (17.9)	34 (15.2)	70 (15.3)
Grade 4	0	0	5 (2.2)	5 (1.1)
Grade 5	1 (0.8)	1 (0.9)	1 (0.4)	3 (0.7)

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	29 (23.4)	23 (20.5)	35 (15.7)	87 (19.0)
Grade 2	21 (16.9)	16 (14.3)	23 (10.3)	60 (13.1)
Grade 3	1 (0.8)	1 (0.9)	1 (0.4)	3 (0.7)
Grade 4	0	0	1 (0.4)	1 (0.2)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (0.8)	1 (0.9)	1 (0.4)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	2.00		
95% CI of the odds ratio	(0.11, 29.11)	(0.12, 32.28)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	1.99		
95% CI of the risk ratio	(0.11, 28.50)	(0.13, 31.54)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.36	0.44		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.51, 2.39)		
p-value	0.6729	0.6184		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.9)	0	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	0.89		
95% CI of the absolute risk difference	NE	(-0.85, 2.63)		
p-value	NE	0.1576		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (0.8)	0	1 (0.4)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	NE		
95% CI of the odds ratio	(0.11, 29.11)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	NE		
95% CI of the risk ratio	(0.11, 28.50)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.36	-0.45		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.33, 0.43)		
p-value	0.6729	0.4779		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (0.8)	1 (0.9)	1 (0.4)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	2.00		
95% CI of the odds ratio	(0.11, 29.11)	(0.12, 32.28)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	1.99		
95% CI of the risk ratio	(0.11, 28.50)	(0.13, 31.54)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.36	0.44		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.51, 2.39)		
p-value	0.6729	0.6184		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	1 (0.9)	3 (1.3)	4 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.66		
95% CI of the odds ratio	NE	(0.07, 6.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.66		
95% CI of the risk ratio	NE	(0.07, 6.31)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.35	-0.45		
95% CI of the absolute risk difference	(-2.86, 0.17)	(-2.76, 1.85)		
p-value	0.1946	0.7191		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6183		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.9)	3 (1.3)	4 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.66		
95% CI of the odds ratio	NE	(0.07, 6.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.66		
95% CI of the risk ratio	NE	(0.07, 6.31)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.35	-0.45		
95% CI of the absolute risk difference	(-2.86, 0.17)	(-2.76, 1.85)		
p-value	0.1946	0.7191		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (0.9)	3 (1.3)	4 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.66		
95% CI of the odds ratio	NE	(0.07, 6.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.66		
95% CI of the risk ratio	NE	(0.07, 6.31)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.35	-0.45		
95% CI of the absolute risk difference	(-2.86, 0.17)	(-2.76, 1.85)		
p-value	0.1946	0.7191		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Events n:				
Total TEAEs	191	136	429	756
Total Serious TEAEs	4	1	19	24
Total TEAEs Leading to Discontinuation of Study Drug	3	6	2	11
Total TEAEs Related to Study Drug	24	24	28	76
Total TEAEs >= Grade 3 Severity	5	3	25	33
Patients n (%):				
Any TEAE	25 (96.2)	21 (87.5)	60 (96.8)	106 (94.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83	0.23		
95% CI of the odds ratio	(0.07, 9.61)	(0.04, 1.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	0.90		
95% CI of the risk ratio	(0.91, 1.09)	(0.77, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.62	-9.27		
95% CI of the absolute risk difference	(-9.22, 7.98)	(-23.22, 4.67)		
p-value	0.8837	0.0992		
p-value of Breslow-Day Test for Homogeneity [2]	0.7781	0.1769		
Any Serious TEAE	3 (11.5)	1 (4.2)	11 (17.7)	15 (13.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	0.20		
95% CI of the odds ratio	(0.15, 2.38)	(0.02, 1.66)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.65	0.23		
95% CI of the risk ratio	(0.20, 2.14)	(0.03, 1.72)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.20	-13.58		
95% CI of the absolute risk difference	(-21.74, 9.33)	(-26.00, -1.15)		
p-value	0.4679	0.1032		
p-value of Breslow-Day Test for Homogeneity [2]	0.7894	0.1287		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Any TEAEs >= Grade 3 Severity	4 (15.4)	2 (8.3)	13 (21.0)	19 (17.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	0.34		
95% CI of the odds ratio	(0.20, 2.34)	(0.07, 1.65)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	0.40		
95% CI of the risk ratio	(0.26, 2.04)	(0.10, 1.63)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.58	-12.63		
95% CI of the absolute risk difference	(-22.76, 11.59)	(-27.63, 2.36)		
p-value	0.5450	0.1661		
p-value of Breslow-Day Test for Homogeneity [2]	0.9331	0.2684		
Any TEAEs <= Grade 2 Severity	24 (92.3)	20 (83.3)	60 (96.8)	104 (92.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40	0.17		
95% CI of the odds ratio	(0.05, 3.00)	(0.03, 0.98)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.86		
95% CI of the risk ratio	(0.85, 1.08)	(0.72, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.47	-13.44		
95% CI of the absolute risk difference	(-15.61, 6.68)	(-28.99, 2.10)		
p-value	0.3588	0.0282		
p-value of Breslow-Day Test for Homogeneity [2]	0.5007	0.1588		
Any TEAEs leading to Study-Drug Discontinuation	3 (11.5)	5 (20.8)	2 (3.2)	10 (8.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.91	7.89		
95% CI of the odds ratio	(0.61, 24.95)	(1.41, 44.05)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.58	6.46		
95% CI of the risk ratio	(0.63, 20.17)	(1.34, 31.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.31	17.61		
95% CI of the absolute risk difference	(-4.73, 21.36)	(0.78, 34.44)		
p-value	0.1243	0.0074		
p-value of Breslow-Day Test for Homogeneity [2]	0.0146	0.1101		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Any TEAEs leading to Study Discontinuation	1 (3.8)	4 (16.7)	1 (1.6)	6 (5.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.44	12.20		
95% CI of the odds ratio	(0.15, 40.55)	(1.29, 115.61)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.38	10.33		
95% CI of the risk ratio	(0.15, 36.70)	(1.22, 87.83)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.23	15.05		
95% CI of the absolute risk difference	(-5.80, 10.26)	(-0.18, 30.29)		
p-value	0.5213	0.0075		
p-value of Breslow-Day Test for Homogeneity [2]	0.0728	0.0224		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	11 (42.3)	11 (45.8)	16 (25.8)	38 (33.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.11	2.43		
95% CI of the odds ratio	(0.80, 5.53)	(0.91, 6.51)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.64	1.78		
95% CI of the risk ratio	(0.89, 3.04)	(0.97, 3.26)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	16.50	20.03		
95% CI of the absolute risk difference	(-5.39, 38.39)	(-2.69, 42.74)		
p-value	0.1257	0.0727		
p-value of Breslow-Day Test for Homogeneity [2]	0.1369	0.0968		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (3.8)	1 (4.2)	0	2 (1.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.85	4.17		
95% CI of the absolute risk difference	(-3.55, 11.24)	(-3.83, 12.16)		
p-value	0.1204	0.1059		
p-value of Breslow-Day Test for Homogeneity [2]	0.1961	0.1994		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	5 (20.8)	1 (1.6)	6 (5.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	16.05		
95% CI of the odds ratio	NE	(1.76, 146.03)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	12.92		
95% CI of the risk ratio	NE	(1.59, 104.92)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.61	19.22		
95% CI of the absolute risk difference	(-4.75, 1.52)	(2.67, 35.77)		
p-value	0.5149	0.0017		
p-value of Breslow-Day Test for Homogeneity [2]	0.1638	0.0115		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	4 (16.7)	0	4 (3.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	27.44		
95% CI of the odds ratio	NE	(1.42, 531.65)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	22.68		
95% CI of the risk ratio	NE	(1.27, 405.96)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	17.21		
95% CI of the absolute risk difference	NE	(1.99, 32.42)		
p-value	NE	0.0017		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0062		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	7 (26.9)	6 (25.0)	15 (24.2)	28 (25.0)
Grade 2	14 (53.8)	13 (54.2)	32 (51.6)	59 (52.7)
Grade 3	4 (15.4)	2 (8.3)	11 (17.7)	17 (15.2)
Grade 4	0	0	2 (3.2)	2 (1.8)
Grade 5	0	0	0	0

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	7 (26.9)	5 (20.8)	12 (19.4)	24 (21.4)
Grade 2	3 (11.5)	5 (20.8)	4 (6.5)	12 (10.7)
Grade 3	1 (3.8)	1 (4.2)	0	2 (1.8)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.61	-1.61		
95% CI of the absolute risk difference	(-4.75, 1.52)	(-4.75, 1.52)		
p-value	0.5149	0.5314		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6183		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.61	-1.61		
95% CI of the absolute risk difference	(-4.75, 1.52)	(-4.75, 1.52)		
p-value	0.5149	0.5314		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Events n:				
Total TEAEs	42	22	3	67
Total Serious TEAEs	0	1	0	1
Total TEAEs Leading to Discontinuation of Study Drug	0	1	2	3
Total TEAEs Related to Study Drug	1	0	2	3
Total TEAEs >= Grade 3 Severity	0	2	0	2
Patients n (%):				
Any TEAE	4 (80.0)	2 (100)	1 (100)	7 (87.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	NE		
95% CI of the risk ratio	(0.52, 1.24)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-20.00	NE		
95% CI of the absolute risk difference	(-55.06, 15.06)	NE		
p-value	0.6242	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.7781	0.1769		
Any Serious TEAE	0	1 (50.0)	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.00		
95% CI of the odds ratio	NE	(0.06, 151.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.00		
95% CI of the risk ratio	NE	(0.14, 28.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	25.00		
95% CI of the absolute risk difference	NE	(-57.48, 100.00)		
p-value	NE	0.5762		
p-value of Breslow-Day Test for Homogeneity [2]	0.7894	0.1287		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Any TEAEs >= Grade 3 Severity	0	1 (50.0)	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.00		
95% CI of the odds ratio	NE	(0.06, 151.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.00		
95% CI of the risk ratio	NE	(0.14, 28.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	25.00		
95% CI of the absolute risk difference	NE	(-57.48, 100.00)		
p-value	NE	0.5762		
p-value of Breslow-Day Test for Homogeneity [2]	0.9331	0.2684		
Any TEAEs <= Grade 2 Severity	4 (80.0)	1 (50.0)	1 (100)	6 (75.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	0.50		
95% CI of the risk ratio	(0.52, 1.24)	(0.13, 2.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-20.00	-50.00		
95% CI of the absolute risk difference	(-55.06, 15.06)	(-100.00, 19.30)		
p-value	0.6242	0.3865		
p-value of Breslow-Day Test for Homogeneity [2]	0.5007	0.1588		
Any TEAEs leading to Study-Drug Discontinuation	0	1 (50.0)	1 (100)	2 (25.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.03	NE		
95% CI of the odds ratio	(0.00, 2.27)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11	0.50		
95% CI of the risk ratio	(0.01, 1.78)	(0.13, 2.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-66.67	-50.00		
95% CI of the absolute risk difference	(-100.00, -2.71)	(-100.00, 19.30)		
p-value	0.0593	0.3865		
p-value of Breslow-Day Test for Homogeneity [2]	0.0146	0.1101		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Any TEAEs leading to Study Discontinuation	0	0	1 (100)	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.03	0.07		
95% CI of the odds ratio	(0.00, 2.27)	(0.00, 5.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11	0.22		
95% CI of the risk ratio	(0.01, 1.78)	(0.02, 3.16)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-66.67	-58.33		
95% CI of the absolute risk difference	(-100.00, -2.71)	(-100.00, 15.01)		
p-value	0.0593	0.1921		
p-value of Breslow-Day Test for Homogeneity [2]	0.0728	0.0224		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	1 (20.0)	0	1 (100)	2 (25.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.07		
95% CI of the odds ratio	NE	(0.00, 5.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.20	0.22		
95% CI of the risk ratio	(0.03, 1.15)	(0.02, 3.16)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-80.00	-58.33		
95% CI of the absolute risk difference	(-100.00, -44.94)	(-100.00, 15.01)		
p-value	0.1213	0.1921		
p-value of Breslow-Day Test for Homogeneity [2]	0.1369	0.0968		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1961	0.1994		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (100)	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.03	0.07		
95% CI of the odds ratio	(0.00, 2.27)	(0.00, 5.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11	0.22		
95% CI of the risk ratio	(0.01, 1.78)	(0.02, 3.16)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-66.67	-58.33		
95% CI of the absolute risk difference	(-100.00, -2.71)	(-100.00, 15.01)		
p-value	0.0593	0.1921		
p-value of Breslow-Day Test for Homogeneity [2]	0.1638	0.0115		

Madrigal Pharmaceuticals, Inc. Page 26 of 31
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (100)	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.03	0.07		
95% CI of the odds ratio	(0.00, 2.27)	(0.00, 5.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11	0.22		
95% CI of the risk ratio	(0.01, 1.78)	(0.02, 3.16)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-66.67	-58.33		
95% CI of the absolute risk difference	(-100.00, -2.71)	(-100.00, 15.01)		
p-value	0.0593	0.1921		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0062		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	1 (20.0)	0	0	1 (12.5)
Grade 2	3 (60.0)	1 (50.0)	1 (100)	5 (62.5)
Grade 3	0	1 (50.0)	0	1 (12.5)
Grade 4	0	0	0	0
Grade 5	0	0	0	0

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	1 (20.0)	0	0	1 (12.5)
Grade 2	0	0	1 (100)	1 (12.5)
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6183		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable; SNP = Single Nucleotide Polymorphism.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Events n:				
Total TEAEs	908	792	1605	3305
Total Serious TEAEs	24	29	72	125
Total TEAEs Leading to Discontinuation of Study Drug	11	11	14	36
Total TEAEs Related to Study Drug	118	92	114	324
Total TEAEs >= Grade 3 Severity	26	37	76	139
Patients n (%):				
Any TEAE	117 (94.4)	102 (91.1)	203 (91.0)	422 (91.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.65	1.00		
95% CI of the odds ratio	(0.68, 4.01)	(0.45, 2.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.04	1.00		
95% CI of the risk ratio	(0.98, 1.10)	(0.93, 1.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.32	0.04		
95% CI of the absolute risk difference	(-2.21, 8.85)	(-6.44, 6.52)		
p-value	0.2681	0.9903		
p-value of Breslow-Day Test for Homogeneity [2]	0.7341	0.1386		
Any Serious TEAE	12 (9.7)	18 (16.1)	28 (12.6)	58 (12.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	1.33		
95% CI of the odds ratio	(0.36, 1.53)	(0.70, 2.53)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.77	1.28		
95% CI of the risk ratio	(0.41, 1.46)	(0.74, 2.21)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.88	3.52		
95% CI of the absolute risk difference	(-9.66, 3.90)	(-4.56, 11.59)		
p-value	0.4210	0.3778		
p-value of Breslow-Day Test for Homogeneity [2]	0.7894	0.1287		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Any TEAEs >= Grade 3 Severity	15 (12.1)	20 (17.9)	37 (16.6)	72 (15.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	1.09		
95% CI of the odds ratio	(0.36, 1.32)	(0.60, 1.99)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	1.08		
95% CI of the risk ratio	(0.42, 1.27)	(0.66, 1.76)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.50	1.27		
95% CI of the absolute risk difference	(-12.03, 3.04)	(-7.35, 9.88)		
p-value	0.2609	0.7713		
p-value of Breslow-Day Test for Homogeneity [2]	0.6537	0.2562		
Any TEAEs <= Grade 2 Severity	116 (93.5)	102 (91.1)	203 (91.0)	421 (91.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43	1.00		
95% CI of the odds ratio	(0.61, 3.35)	(0.45, 2.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.03	1.00		
95% CI of the risk ratio	(0.97, 1.09)	(0.93, 1.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.52	0.04		
95% CI of the absolute risk difference	(-3.21, 8.24)	(-6.44, 6.52)		
p-value	0.4094	0.9903		
p-value of Breslow-Day Test for Homogeneity [2]	0.4339	0.1194		
Any TEAEs leading to Study-Drug Discontinuation	6 (4.8)	10 (8.9)	11 (4.9)	27 (5.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	1.89		
95% CI of the odds ratio	(0.35, 2.72)	(0.78, 4.59)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	1.81		
95% CI of the risk ratio	(0.37, 2.59)	(0.79, 4.13)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.09	4.00		
95% CI of the absolute risk difference	(-4.82, 4.63)	(-2.00, 9.99)		
p-value	0.9690	0.1546		
p-value of Breslow-Day Test for Homogeneity [2]	0.0334	0.1556		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Any TEAEs leading to Study Discontinuation	2 (1.6)	7 (6.3)	8 (3.6)	17 (3.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	1.79		
95% CI of the odds ratio	(0.09, 2.11)	(0.63, 5.07)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.45	1.74		
95% CI of the risk ratio	(0.10, 2.08)	(0.65, 4.68)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.97	2.66		
95% CI of the absolute risk difference	(-5.27, 1.32)	(-2.44, 7.77)		
p-value	0.2921	0.2663		
p-value of Breslow-Day Test for Homogeneity [2]	0.0728	0.0224		
Any Fatal TEAEs	1 (0.8)	1 (0.9)	1 (0.4)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	2.00		
95% CI of the odds ratio	(0.11, 29.11)	(0.12, 32.28)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	1.99		
95% CI of the risk ratio	(0.11, 28.50)	(0.13, 31.54)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.36	0.44		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.51, 2.39)		
p-value	0.6729	0.6184		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	51 (41.1)	40 (35.7)	59 (26.5)	150 (32.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.94	1.54		
95% CI of the odds ratio	(1.22, 3.09)	(0.95, 2.52)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.55	1.35		
95% CI of the risk ratio	(1.15, 2.11)	(0.97, 1.88)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.67	9.26		
95% CI of the absolute risk difference	(4.25, 25.09)	(-1.34, 19.85)		
p-value	0.0049	0.0798		
p-value of Breslow-Day Test for Homogeneity [2]	0.1339	0.0982		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.4)	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.45	-0.45		
95% CI of the absolute risk difference	(-1.33, 0.43)	(-1.33, 0.43)		
p-value	0.4552	0.4779		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (0.8)	1 (0.9)	2 (0.9)	4 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90	1.00		
95% CI of the odds ratio	(0.08, 10.01)	(0.09, 11.10)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.90	1.00		
95% CI of the risk ratio	(0.08, 9.82)	(0.09, 10.86)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.09	0.00		
95% CI of the absolute risk difference	(-2.09, 1.91)	(-2.14, 2.13)		
p-value	0.9305	0.9971		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1994		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (1.6)	5 (4.5)	6 (2.7)	13 (2.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	1.69		
95% CI of the odds ratio	(0.12, 2.98)	(0.50, 5.66)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	1.66		
95% CI of the risk ratio	(0.12, 2.93)	(0.52, 5.32)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.08	1.77		
95% CI of the absolute risk difference	(-4.15, 1.99)	(-2.60, 6.15)		
p-value	0.5215	0.3901		
p-value of Breslow-Day Test for Homogeneity [2]	0.1638	0.0115		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	3 (2.7)	4 (1.8)	7 (1.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.51		
95% CI of the odds ratio	NE	(0.33, 6.85)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.49		
95% CI of the risk ratio	NE	(0.34, 6.56)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.79	0.88		
95% CI of the absolute risk difference	(-3.54, -0.05)	(-2.58, 4.35)		
p-value	0.1336	0.5932		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0062		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	23 (18.5)	17 (15.2)	50 (22.4)	90 (19.6)
Grade 2	79 (63.7)	65 (58.0)	116 (52.0)	260 (56.6)
Grade 3	14 (11.3)	19 (17.0)	31 (13.9)	64 (13.9)
Grade 4	0	0	5 (2.2)	5 (1.1)
Grade 5	1 (0.8)	1 (0.9)	1 (0.4)	3 (0.7)

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	29 (23.4)	23 (20.5)	34 (15.2)	86 (18.7)
Grade 2	21 (16.9)	16 (14.3)	23 (10.3)	60 (13.1)
Grade 3	1 (0.8)	1 (0.9)	1 (0.4)	3 (0.7)
Grade 4	0	0	1 (0.4)	1 (0.2)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (0.8)	1 (0.9)	1 (0.4)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	2.00		
95% CI of the odds ratio	(0.11, 29.11)	(0.12, 32.28)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	1.99		
95% CI of the risk ratio	(0.11, 28.50)	(0.13, 31.54)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.36	0.44		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.51, 2.39)		
p-value	0.6729	0.6184		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.9)	0	1 (0.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	0.89		
95% CI of the absolute risk difference	NE	(-0.85, 2.63)		
p-value	NE	0.1576		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (0.8)	0	1 (0.4)	2 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	NE		
95% CI of the odds ratio	(0.11, 29.11)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	NE		
95% CI of the risk ratio	(0.11, 28.50)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.36	-0.45		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.33, 0.43)		
p-value	0.6729	0.4779		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (0.8)	1 (0.9)	1 (0.4)	3 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	2.00		
95% CI of the odds ratio	(0.11, 29.11)	(0.12, 32.28)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80	1.99		
95% CI of the risk ratio	(0.11, 28.50)	(0.13, 31.54)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.36	0.44		
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.51, 2.39)		
p-value	0.6729	0.6184		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	1 (0.9)	3 (1.3)	4 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.66		
95% CI of the odds ratio	NE	(0.07, 6.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.66		
95% CI of the risk ratio	NE	(0.07, 6.31)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.35	-0.45		
95% CI of the absolute risk difference	(-2.86, 0.17)	(-2.76, 1.85)		
p-value	0.1946	0.7191		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6183		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (0.9)	3 (1.3)	4 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.66		
95% CI of the odds ratio	NE	(0.07, 6.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.66		
95% CI of the risk ratio	NE	(0.07, 6.31)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.35	-0.45		
95% CI of the absolute risk difference	(-2.86, 0.17)	(-2.76, 1.85)		
p-value	0.1946	0.7191		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (0.9)	3 (1.3)	4 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.66		
95% CI of the odds ratio	NE	(0.07, 6.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.66		
95% CI of the risk ratio	NE	(0.07, 6.31)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.35	-0.45		
95% CI of the absolute risk difference	(-2.86, 0.17)	(-2.76, 1.85)		
p-value	0.1946	0.7191		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124) n (%)	MGL-3196 100 mg (N=112) n (%)	Placebo (N=223) n (%)	Overall (N=459) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Events n:				
Total TEAEs	188	135	425	748
Total Serious TEAEs	4	1	19	24
Total TEAEs Leading to Discontinuation of Study Drug	2	6	2	10
Total TEAEs Related to Study Drug	23	24	28	75
Total TEAEs >= Grade 3 Severity	4	3	25	32
Patients n (%):				
Any TEAE	25 (96.2)	21 (87.5)	60 (96.8)	106 (94.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.83	0.23		
95% CI of the odds ratio	(0.07, 9.61)	(0.04, 1.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	0.90		
95% CI of the risk ratio	(0.91, 1.09)	(0.77, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.62	-9.27		
95% CI of the absolute risk difference	(-9.22, 7.98)	(-23.22, 4.67)		
p-value	0.8837	0.0992		
p-value of Breslow-Day Test for Homogeneity [2]	0.7341	0.1386		
Any Serious TEAE	3 (11.5)	1 (4.2)	11 (17.7)	15 (13.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	0.20		
95% CI of the odds ratio	(0.15, 2.38)	(0.02, 1.66)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.65	0.23		
95% CI of the risk ratio	(0.20, 2.14)	(0.03, 1.72)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.20	-13.58		
95% CI of the absolute risk difference	(-21.74, 9.33)	(-26.00, -1.15)		
p-value	0.4679	0.1032		
p-value of Breslow-Day Test for Homogeneity [2]	0.7894	0.1287		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Any TEAEs >= Grade 3 Severity	3 (11.5)	2 (8.3)	13 (21.0)	18 (16.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.49	0.34		
95% CI of the odds ratio	(0.13, 1.90)	(0.07, 1.65)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.55	0.40		
95% CI of the risk ratio	(0.17, 1.77)	(0.10, 1.63)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.43	-12.63		
95% CI of the absolute risk difference	(-25.35, 6.49)	(-27.63, 2.36)		
p-value	0.2954	0.1661		
p-value of Breslow-Day Test for Homogeneity [2]	0.6537	0.2562		
Any TEAEs <= Grade 2 Severity	24 (92.3)	20 (83.3)	60 (96.8)	104 (92.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.40	0.17		
95% CI of the odds ratio	(0.05, 3.00)	(0.03, 0.98)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.86		
95% CI of the risk ratio	(0.85, 1.08)	(0.72, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.47	-13.44		
95% CI of the absolute risk difference	(-15.61, 6.68)	(-28.99, 2.10)		
p-value	0.3588	0.0282		
p-value of Breslow-Day Test for Homogeneity [2]	0.4339	0.1194		
Any TEAEs leading to Study-Drug Discontinuation	2 (7.7)	5 (20.8)	2 (3.2)	9 (8.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.50	7.89		
95% CI of the odds ratio	(0.33, 18.78)	(1.41, 44.05)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.38	6.46		
95% CI of the risk ratio	(0.35, 16.03)	(1.34, 31.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.47	17.61		
95% CI of the absolute risk difference	(-6.68, 15.61)	(0.78, 34.44)		
p-value	0.3588	0.0074		
p-value of Breslow-Day Test for Homogeneity [2]	0.0334	0.1556		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Any TEAEs leading to Study Discontinuation	1 (3.8)	4 (16.7)	1 (1.6)	6 (5.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.44	12.20		
95% CI of the odds ratio	(0.15, 40.55)	(1.29, 115.61)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.38	10.33		
95% CI of the risk ratio	(0.15, 36.70)	(1.22, 87.83)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.23	15.05		
95% CI of the absolute risk difference	(-5.80, 10.26)	(-0.18, 30.29)		
p-value	0.5213	0.0075		
p-value of Breslow-Day Test for Homogeneity [2]	0.0728	0.0224		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	11 (42.3)	11 (45.8)	16 (25.8)	38 (33.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.11	2.43		
95% CI of the odds ratio	(0.80, 5.53)	(0.91, 6.51)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.64	1.78		
95% CI of the risk ratio	(0.89, 3.04)	(0.97, 3.26)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	16.50	20.03		
95% CI of the absolute risk difference	(-5.39, 38.39)	(-2.69, 42.74)		
p-value	0.1257	0.0727		
p-value of Breslow-Day Test for Homogeneity [2]	0.1339	0.0982		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	1 (4.2)	0	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	4.17		
95% CI of the absolute risk difference	NE	(-3.83, 12.16)		
p-value	NE	0.1059		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1994		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	5 (20.8)	1 (1.6)	6 (5.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	16.05		
95% CI of the odds ratio	NE	(1.76, 146.03)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	12.92		
95% CI of the risk ratio	NE	(1.59, 104.92)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.61	19.22		
95% CI of the absolute risk difference	(-4.75, 1.52)	(2.67, 35.77)		
p-value	0.5149	0.0017		
p-value of Breslow-Day Test for Homogeneity [2]	0.1638	0.0115		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)
Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	4 (16.7)	0	4 (3.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	27.44		
95% CI of the odds ratio	NE	(1.42, 531.65)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	22.68		
95% CI of the risk ratio	NE	(1.27, 405.96)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	17.21		
95% CI of the absolute risk difference	NE	(1.99, 32.42)		
p-value	NE	0.0017		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0062		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	7 (26.9)	6 (25.0)	15 (24.2)	28 (25.0)
Grade 2	15 (57.7)	13 (54.2)	32 (51.6)	60 (53.6)
Grade 3	3 (11.5)	2 (8.3)	11 (17.7)	16 (14.3)
Grade 4	0	0	2 (3.2)	2 (1.8)
Grade 5	0	0	0	0

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	7 (26.9)	5 (20.8)	12 (19.4)	24 (21.4)
Grade 2	4 (15.4)	5 (20.8)	4 (6.5)	13 (11.6)
Grade 3	0	1 (4.2)	0	1 (0.9)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.61	-1.61		
95% CI of the absolute risk difference	(-4.75, 1.52)	(-4.75, 1.52)		
p-value	0.5149	0.5314		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6183		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (1.6)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.61	-1.61		
95% CI of the absolute risk difference	(-4.75, 1.52)	(-4.75, 1.52)		
p-value	0.5149	0.5314		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26) n (%)	MGL-3196 100 mg (N=24) n (%)	Placebo (N=62) n (%)	Overall (N=112) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Events n:				
Total TEAEs	42	22	3	67
Total Serious TEAEs	0	1	0	1
Total TEAEs Leading to Discontinuation of Study Drug	0	1	2	3
Total TEAEs Related to Study Drug	1	0	2	3
Total TEAEs >= Grade 3 Severity	0	2	0	2
Patients n (%):				
Any TEAE	4 (80.0)	2 (100)	1 (100)	7 (87.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	NE		
95% CI of the risk ratio	(0.52, 1.24)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-20.00	NE		
95% CI of the absolute risk difference	(-55.06, 15.06)	NE		
p-value	0.6242	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.7341	0.1386		
Any Serious TEAE	0	1 (50.0)	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.00		
95% CI of the odds ratio	NE	(0.06, 151.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.00		
95% CI of the risk ratio	NE	(0.14, 28.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	25.00		
95% CI of the absolute risk difference	NE	(-57.48, 100.00)		
p-value	NE	0.5762		
p-value of Breslow-Day Test for Homogeneity [2]	0.7894	0.1287		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Any TEAEs >= Grade 3 Severity	0	1 (50.0)	0	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.00		
95% CI of the odds ratio	NE	(0.06, 151.19)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.00		
95% CI of the risk ratio	NE	(0.14, 28.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	25.00		
95% CI of the absolute risk difference	NE	(-57.48, 100.00)		
p-value	NE	0.5762		
p-value of Breslow-Day Test for Homogeneity [2]	0.6537	0.2562		
Any TEAEs <= Grade 2 Severity	4 (80.0)	1 (50.0)	1 (100)	6 (75.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.80	0.50		
95% CI of the risk ratio	(0.52, 1.24)	(0.13, 2.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-20.00	-50.00		
95% CI of the absolute risk difference	(-55.06, 15.06)	(-100.00, 19.30)		
p-value	0.6242	0.3865		
p-value of Breslow-Day Test for Homogeneity [2]	0.4339	0.1194		
Any TEAEs leading to Study-Drug Discontinuation	0	1 (50.0)	1 (100)	2 (25.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.03	NE		
95% CI of the odds ratio	(0.00, 2.27)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11	0.50		
95% CI of the risk ratio	(0.01, 1.78)	(0.13, 2.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-66.67	-50.00		
95% CI of the absolute risk difference	(-100.00, -2.71)	(-100.00, 19.30)		
p-value	0.0593	0.3865		
p-value of Breslow-Day Test for Homogeneity [2]	0.0334	0.1556		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Any TEAEs leading to Study Discontinuation	0	0	1 (100)	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.03	0.07		
95% CI of the odds ratio	(0.00, 2.27)	(0.00, 5.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11	0.22		
95% CI of the risk ratio	(0.01, 1.78)	(0.02, 3.16)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-66.67	-58.33		
95% CI of the absolute risk difference	(-100.00, -2.71)	(-100.00, 15.01)		
p-value	0.0593	0.1921		
p-value of Breslow-Day Test for Homogeneity [2]	0.0728	0.0224		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	1 (20.0)	0	1 (100)	2 (25.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.07		
95% CI of the odds ratio	NE	(0.00, 5.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.20	0.22		
95% CI of the risk ratio	(0.03, 1.15)	(0.02, 3.16)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-80.00	-58.33		
95% CI of the absolute risk difference	(-100.00, -44.94)	(-100.00, 15.01)		
p-value	0.1213	0.1921		
p-value of Breslow-Day Test for Homogeneity [2]	0.1339	0.0982		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1994		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	0	1 (100)	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.03	0.07		
95% CI of the odds ratio	(0.00, 2.27)	(0.00, 5.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11	0.22		
95% CI of the risk ratio	(0.01, 1.78)	(0.02, 3.16)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-66.67	-58.33		
95% CI of the absolute risk difference	(-100.00, -2.71)	(-100.00, 15.01)		
p-value	0.0593	0.1921		
p-value of Breslow-Day Test for Homogeneity [2]	0.1638	0.0115		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	1 (100)	1 (12.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.03	0.07		
95% CI of the odds ratio	(0.00, 2.27)	(0.00, 5.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11	0.22		
95% CI of the risk ratio	(0.01, 1.78)	(0.02, 3.16)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-66.67	-58.33		
95% CI of the absolute risk difference	(-100.00, -2.71)	(-100.00, 15.01)		
p-value	0.0593	0.1921		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0062		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	1 (20.0)	0	0	1 (12.5)
Grade 2	3 (60.0)	1 (50.0)	1 (100)	5 (62.5)
Grade 3	0	1 (50.0)	0	1 (12.5)
Grade 4	0	0	0	0
Grade 5	0	0	0	0

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	1 (20.0)	0	0	1 (12.5)
Grade 2	0	0	1 (100)	1 (12.5)
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.6183		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5) n (%)	MGL-3196 100 mg (N=2) n (%)	Placebo (N=1) n (%)	Overall (N=8) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124)		MGL-3196 100 mg (N=112)		Placebo (N=223)		Overall (N=459)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders								
Diarrhoea	33 (26.6)	59	37 (33.0)	62	35 (15.7)	44	105 (22.9)	165
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.95		2.65					
95% CI of the odds ratio	(1.14, 3.33)		(1.55, 4.52)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.70		2.10					
95% CI of the risk ratio	(1.11, 2.59)		(1.41, 3.15)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	10.92		17.34					
95% CI of the absolute risk difference	(1.79, 20.04)		(7.41, 27.27)					
p-value	0.0141		0.0003					
p-value of Breslow-Day Test for Homogeneity [2]	0.9036		0.1442					
Nausea	33 (26.6)	40	14 (12.5)	18	24 (10.8)	29	71 (15.5)	87
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.01		1.18					
95% CI of the odds ratio	(1.68, 5.38)		(0.59, 2.39)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.47		1.16					
95% CI of the risk ratio	(1.53, 3.99)		(0.63, 2.16)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	15.85		1.74					
95% CI of the absolute risk difference	(7.07, 24.63)		(-5.61, 9.09)					
p-value	0.0001		0.6361					
p-value of Breslow-Day Test for Homogeneity [2]	0.5958		0.6791					

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124)		MGL-3196 100 mg (N=112)		Placebo (N=223)		Overall (N=459)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders (cont.)								
Vomiting	15 (12.1)	17	6 (5.4)	6	13 (5.8)	14	34 (7.4)	37
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.22		0.91					
95% CI of the odds ratio	(1.02, 4.84)		(0.34, 2.47)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.08		0.92					
95% CI of the risk ratio	(1.02, 4.22)		(0.36, 2.35)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.27		-0.47					
95% CI of the absolute risk difference	(-0.24, 12.78)		(-5.65, 4.71)					
p-value	0.0400		0.8600					
p-value of Breslow-Day Test for Homogeneity [2]	0.9363		0.2497					
Abdominal discomfort	0	0	3 (2.7)	4	9 (4.0)	10	12 (2.6)	14
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		0.65					
95% CI of the odds ratio	NE		(0.17, 2.47)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		0.66					
95% CI of the risk ratio	NE		(0.18, 2.40)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.04		-1.36					
95% CI of the absolute risk difference	(-6.62, -1.45)		(-5.31, 2.59)					
p-value	0.0234		0.5283					
p-value of Breslow-Day Test for Homogeneity [2]	0.1229		0.3152					

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124)		MGL-3196 100 mg (N=112)		Placebo (N=223)		Overall (N=459)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
General disorders and administration site conditions	27 (21.8)	40	24 (21.4)	34	65 (29.1)	80	116 (25.3)	154
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68		0.66					
95% CI of the odds ratio	(0.40, 1.13)		(0.39, 1.13)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75		0.74					
95% CI of the risk ratio	(0.51, 1.10)		(0.49, 1.11)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.37		-7.72					
95% CI of the absolute risk difference	(-16.77, 2.03)		(-17.38, 1.94)					
p-value	0.1359		0.1313					
p-value of Breslow-Day Test for Homogeneity [2]	0.5333		0.4404					
Skin and subcutaneous tissue disorders								
Pruritus	15 (12.1)	19	4 (3.6)	6	18 (8.1)	21	37 (8.1)	46
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.57		0.42					
95% CI of the odds ratio	(0.76, 3.23)		(0.14, 1.28)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.50		0.44					
95% CI of the risk ratio	(0.78, 2.87)		(0.15, 1.28)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.03		-4.50					
95% CI of the absolute risk difference	(-2.74, 10.79)		(-9.46, 0.46)					
p-value	0.2206		0.1167					
p-value of Breslow-Day Test for Homogeneity [2]	0.0141		0.0407					

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=112) Patients n (%)	 Events n	Placebo (N=223) Patients n (%)	 Events n	Overall (N=459) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	8 (6.5)	8	14 (12.5)	17	8 (3.6)	9	30 (6.5)	34
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.85		3.84					
95% CI of the odds ratio	(0.68, 5.07)		(1.56, 9.45)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.80		3.48					
95% CI of the risk ratio	(0.69, 4.67)		(1.51, 8.06)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.86		8.91					
95% CI of the absolute risk difference	(-2.10, 7.83)		(2.32, 15.51)					
p-value	0.2228		0.0019					
p-value of Breslow-Day Test for Homogeneity [2]	0.0133		0.0422					
Renal and urinary disorders	4 (3.2)	5	13 (11.6)	16	21 (9.4)	23	38 (8.3)	44
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.32		1.26					
95% CI of the odds ratio	(0.11, 0.96)		(0.61, 2.63)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.34		1.23					
95% CI of the risk ratio	(0.12, 0.98)		(0.64, 2.37)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.19		2.19					
95% CI of the absolute risk difference	(-11.13, -1.26)		(-4.87, 9.25)					
p-value	0.0326		0.5312					
p-value of Breslow-Day Test for Homogeneity [2]	0.7779		0.5789					

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Genetic NASH SNP - TM6SF2 (Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124)		MGL-3196 100 mg (N=112)		Placebo (N=223)		Overall (N=459)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	7 (5.6)	8	2 (1.8)	2	17 (7.6)	21	26 (5.7)	31
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.72		0.22					
95% CI of the odds ratio	(0.29, 1.80)		(0.05, 0.97)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.74		0.23					
95% CI of the risk ratio	(0.32, 1.74)		(0.06, 1.00)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.98		-5.84					
95% CI of the absolute risk difference	(-7.33, 3.37)		(-10.10, -1.58)					
p-value	0.4865		0.0293					
p-value of Breslow-Day Test for Homogeneity [2]	0.1725		0.2204					

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124)		MGL-3196 100 mg (N=112)		Placebo (N=223)		Overall (N=459)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Injury, poisoning and procedural complications								
Contusion	1 (0.8)	1	0	0	8 (3.6)	12	9 (2.0)	13
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.22		NE					
95% CI of the odds ratio	(0.03, 1.77)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.22		NE					
95% CI of the risk ratio	(0.03, 1.78)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.78		-3.59					
95% CI of the absolute risk difference	(-5.69, 0.12)		(-6.03, -1.15)					
p-value	0.1183		0.0425					
p-value of Breslow-Day Test for Homogeneity [2]	0.6236		NE					

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26)		MGL-3196 100 mg (N=24)		Placebo (N=62)		Overall (N=112)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders								
Nausea	8 (30.8)	9	7 (29.2)	8	13 (21.0)	14	28 (25.0)	31
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.68		1.55					
95% CI of the odds ratio	(0.60, 4.71)		(0.53, 4.53)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.47		1.39					
95% CI of the risk ratio	(0.69, 3.11)		(0.63, 3.06)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.80		8.20					
95% CI of the absolute risk difference	(-10.63, 30.23)		(-12.62, 29.02)					
p-value	0.3250		0.4195					
p-value of Breslow-Day Test for Homogeneity [2]	0.5958		0.6791					
Diarrhoea	6 (23.1)	10	11 (45.8)	12	7 (11.3)	8	24 (21.4)	30
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.36		6.65					
95% CI of the odds ratio	(0.71, 7.86)		(2.16, 20.46)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.04		4.06					
95% CI of the risk ratio	(0.76, 5.50)		(1.78, 9.24)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.79		34.54					
95% CI of the absolute risk difference	(-6.22, 29.80)		(13.11, 55.98)					
p-value	0.1551		0.0004					
p-value of Breslow-Day Test for Homogeneity [2]	0.9036		0.1442					

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

System Organ Class Preferred Term	MGL-3196 80 mg (N=26) Patients n (%)	 Events n	MGL-3196 100 mg (N=24) Patients n (%)	 Events n	Placebo (N=62) Patients n (%)	 Events n	Overall (N=112) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	3 (11.5)	3	3 (12.5)	3	3 (4.8)	3	9 (8.0)	9
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.57		2.81					
95% CI of the odds ratio	(0.48, 13.64)		(0.53, 15.01)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.38		2.58					
95% CI of the risk ratio	(0.51, 11.05)		(0.56, 11.92)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.70		7.66					
95% CI of the absolute risk difference	(-6.69, 20.09)		(-6.61, 21.93)					
p-value	0.2553		0.2110					
p-value of Breslow-Day Test for Homogeneity [2]	0.9363		0.2497					
Abdominal discomfort	1 (3.8)	1	0	0	4 (6.5)	4	5 (4.5)	5
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.58		0.27					
95% CI of the odds ratio	(0.06, 5.45)		(0.01, 5.12)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60		0.28					
95% CI of the risk ratio	(0.07, 5.08)		(0.02, 5.01)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.61		-5.14					
95% CI of the absolute risk difference	(-12.20, 6.99)		(-13.54, 3.26)					
p-value	0.6300		0.3473					
p-value of Breslow-Day Test for Homogeneity [2]	0.1229		0.3152					

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26)		MGL-3196 100 mg (N=24)		Placebo (N=62)		Overall (N=112)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
General disorders and administration site conditions	7 (26.9)	11	3 (12.5)	3	17 (27.4)	21	27 (24.1)	35
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98		0.38					
95% CI of the odds ratio	(0.35, 2.73)		(0.10, 1.43)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98		0.46					
95% CI of the risk ratio	(0.46, 2.08)		(0.15, 1.42)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.50		-14.92					
95% CI of the absolute risk difference	(-20.84, 19.85)		(-32.19, 2.35)					
p-value	0.9620		0.1418					
p-value of Breslow-Day Test for Homogeneity [2]	0.5333		0.4404					
Skin and subcutaneous tissue disorders								
Pruritus	3 (11.5)	3	3 (12.5)	3	3 (4.8)	3	9 (8.0)	9
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.57		2.81					
95% CI of the odds ratio	(0.48, 13.64)		(0.53, 15.01)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.38		2.58					
95% CI of the risk ratio	(0.51, 11.05)		(0.56, 11.92)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.70		7.66					
95% CI of the absolute risk difference	(-6.69, 20.09)		(-6.61, 21.93)					
p-value	0.2553		0.2110					
p-value of Breslow-Day Test for Homogeneity [2]	0.0141		0.0407					

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26)		MGL-3196 100 mg (N=24)		Placebo (N=62)		Overall (N=112)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	0	0	1 (4.2)	2	2 (3.2)	3	3 (2.7)	5
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		1.30					
95% CI of the odds ratio	NE		(0.11, 15.09)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		1.29					
95% CI of the risk ratio	NE		(0.12, 13.59)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.23		0.94					
95% CI of the absolute risk difference	(-7.62, 1.17)		(-8.18, 10.07)					
p-value	0.3542		0.8311					
p-value of Breslow-Day Test for Homogeneity [2]	0.0133		0.0422					
Renal and urinary disorders	1 (3.8)	1	4 (16.7)	5	5 (8.1)	9	10 (8.9)	15
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.46		2.28					
95% CI of the odds ratio	(0.05, 4.11)		(0.56, 9.34)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.48		2.07					
95% CI of the risk ratio	(0.06, 3.89)		(0.61, 7.05)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.22		8.60					
95% CI of the absolute risk difference	(-14.25, 5.81)		(-7.78, 24.98)					
p-value	0.4738		0.2424					
p-value of Breslow-Day Test for Homogeneity [2]	0.7779		0.5789					

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26)		MGL-3196 100 mg (N=24)		Placebo (N=62)		Overall (N=112)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	0	0	2 (8.3)	2	6 (9.7)	6	8 (7.1)	8
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.16		0.85					
95% CI of the odds ratio	(0.01, 3.02)		(0.16, 4.53)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.18		0.86					
95% CI of the risk ratio	(0.01, 3.07)		(0.19, 3.97)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.47		-1.34					
95% CI of the absolute risk difference	(-17.54, 0.61)		(-14.63, 11.94)					
p-value	0.1694		0.8474					
p-value of Breslow-Day Test for Homogeneity [2]	0.1725		0.2204					

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26)		MGL-3196 100 mg (N=24)		Placebo (N=62)		Overall (N=112)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Injury, poisoning and procedural complications								
Contusion	0	0	0	0	1 (1.6)	1	1 (0.9)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.61		-1.61					
95% CI of the absolute risk difference	(-4.75, 1.52)		(-4.75, 1.52)					
p-value	0.5149		0.5314					
p-value of Breslow-Day Test for Homogeneity [2]	0.6236		NE					

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5)		MGL-3196 100 mg (N=2)		Placebo (N=1)		Overall (N=8)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders								
Diarrhoea	1 (20.0)	2	0	0	0	0	1 (12.5)	2
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		NE					
95% CI of the odds ratio	(0.02, 40.28)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		NE					
95% CI of the risk ratio	(0.06, 15.99)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		NE					
95% CI of the absolute risk difference	(-69.30, 69.30)		NE					
p-value	>0.9999		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.9036		0.1442					
Nausea	1 (20.0)	1	0	0	0	0	1 (12.5)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		NE					
95% CI of the odds ratio	(0.02, 40.28)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		NE					
95% CI of the risk ratio	(0.06, 15.99)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		NE					
95% CI of the absolute risk difference	(-69.30, 69.30)		NE					
p-value	>0.9999		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.5958		0.6791					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5)		MGL-3196 100 mg (N=2)		Placebo (N=1)		Overall (N=8)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders (cont.)								
Vomiting	1 (20.0)	1	0	0	0	0	1 (12.5)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		NE					
95% CI of the odds ratio	(0.02, 40.28)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		NE					
95% CI of the risk ratio	(0.06, 15.99)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		NE					
95% CI of the absolute risk difference	(-69.30, 69.30)		NE					
p-value	>0.9999		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.9363		0.2497					
Abdominal discomfort	0	0	0	0	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.1229		0.3152					

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5)		MGL-3196 100 mg (N=2)		Placebo (N=1)		Overall (N=8)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Skin and subcutaneous tissue disorders								
Pruritus	0	0	0	0	1 (100)	1	1 (12.5)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.03		0.07					
95% CI of the odds ratio	(0.00, 2.27)		(0.00, 5.49)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11		0.22					
95% CI of the risk ratio	(0.01, 1.78)		(0.02, 3.16)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-66.67		-58.33					
95% CI of the absolute risk difference	(-100.00, -2.71)		(-100.00, 15.01)					
p-value	0.0593		0.1921					
p-value of Breslow-Day Test for Homogeneity [2]	0.0141		0.0407					
Rash	0	0	0	0	1 (100)	1	1 (12.5)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.03		0.07					
95% CI of the odds ratio	(0.00, 2.27)		(0.00, 5.49)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.11		0.22					
95% CI of the risk ratio	(0.01, 1.78)		(0.02, 3.16)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-66.67		-58.33					
95% CI of the absolute risk difference	(-100.00, -2.71)		(-100.00, 15.01)					
p-value	0.0593		0.1921					
p-value of Breslow-Day Test for Homogeneity [2]	0.0133		0.0422					

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5)		MGL-3196 100 mg (N=2)		Placebo (N=1)		Overall (N=8)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Injury, poisoning and procedural complications								
Contusion	1 (20.0)	1	0	0	0	0	1 (12.5)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		NE					
95% CI of the odds ratio	(0.02, 40.28)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00		NE					
95% CI of the risk ratio	(0.06, 15.99)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.00		NE					
95% CI of the absolute risk difference	(-69.30, 69.30)		NE					
p-value	>0.9999		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.6236		NE					
Renal and urinary disorders	0	0	1 (50.0)	1	0	0	1 (12.5)	1
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		3.00					
95% CI of the odds ratio	NE		(0.06, 151.19)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		2.00					
95% CI of the risk ratio	NE		(0.14, 28.42)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		25.00					
95% CI of the absolute risk difference	NE		(-57.48, 100.00)					
p-value	NE		0.5762					
p-value of Breslow-Day Test for Homogeneity [2]	0.7779		0.5789					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14b.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5)		MGL-3196 100 mg (N=2)		Placebo (N=1)		Overall (N=8)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
General disorders and administration site conditions	0	0	0	0	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.5333		0.4404					
Musculoskeletal and connective tissue disorders								
Pain in extremity	0	0	0	0	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE		NE					
95% CI of the absolute risk difference	NE		NE					
p-value	NE		NE					
p-value of Breslow-Day Test for Homogeneity [2]	0.1725		0.2204					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable; SNP = Single Nucleotide Polymorphism.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Events n:				
Total TEAEs	374	291	619	1284
Total Serious TEAEs	6	11	22	39
Total TEAEs Leading to Discontinuation of Study Drug	3	6	11	20
Total TEAEs Related to Study Drug	37	52	54	143
Total TEAEs >= Grade 3 Severity	13	15	24	52
Patients n (%):				
Any TEAE	48 (90.6)	38 (84.4)	84 (93.3)	170 (90.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	0.39		
95% CI of the odds ratio	(0.20, 2.37)	(0.12, 1.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	0.90		
95% CI of the risk ratio	(0.88, 1.08)	(0.79, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.77	-8.89		
95% CI of the absolute risk difference	(-12.17, 6.64)	(-20.67, 2.89)		
p-value	0.5486	0.0989		
p-value of Breslow-Day Test for Homogeneity [2]	0.1481	0.1373		
Any Serious TEAE	5 (9.4)	7 (15.6)	9 (10.0)	21 (11.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.94	1.66		
95% CI of the odds ratio	(0.30, 2.96)	(0.57, 4.79)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.94	1.56		
95% CI of the risk ratio	(0.33, 2.67)	(0.62, 3.91)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.57	5.56		
95% CI of the absolute risk difference	(-10.58, 9.45)	(-6.71, 17.83)		
p-value	0.9124	0.3465		
p-value of Breslow-Day Test for Homogeneity [2]	0.7462	0.3890		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Any TEAEs >= Grade 3 Severity	10 (18.9)	9 (20.0)	14 (15.6)	33 (17.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.26	1.36		
95% CI of the odds ratio	(0.52, 3.09)	(0.54, 3.43)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21	1.29		
95% CI of the risk ratio	(0.58, 2.53)	(0.60, 2.74)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.31	4.44		
95% CI of the absolute risk difference	(-9.61, 16.24)	(-9.44, 18.32)		
p-value	0.6087	0.5173		
p-value of Breslow-Day Test for Homogeneity [2]	0.2070	0.4485		
Any TEAEs <= Grade 2 Severity	47 (88.7)	38 (84.4)	84 (93.3)	169 (89.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56	0.39		
95% CI of the odds ratio	(0.17, 1.83)	(0.12, 1.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.90		
95% CI of the risk ratio	(0.85, 1.06)	(0.79, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.65	-8.89		
95% CI of the absolute risk difference	(-14.62, 5.31)	(-20.67, 2.89)		
p-value	0.3323	0.0989		
p-value of Breslow-Day Test for Homogeneity [2]	0.2351	0.1382		
Any TEAEs leading to Study-Drug Discontinuation	3 (5.7)	6 (13.3)	7 (7.8)	16 (8.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.71	1.82		
95% CI of the odds ratio	(0.18, 2.88)	(0.57, 5.79)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.73	1.71		
95% CI of the risk ratio	(0.20, 2.70)	(0.61, 4.80)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.12	5.56		
95% CI of the absolute risk difference	(-10.44, 6.21)	(-5.81, 16.92)		
p-value	0.6316	0.3023		
p-value of Breslow-Day Test for Homogeneity [2]	0.0302	0.6450		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Any TEAEs leading to Study Discontinuation	0	5 (11.1)	5 (5.6)	10 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.15	2.13		
95% CI of the odds ratio	(0.01, 2.68)	(0.58, 7.76)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.15	2.00		
95% CI of the risk ratio	(0.01, 2.72)	(0.61, 6.55)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.12	5.56		
95% CI of the absolute risk difference	(-10.64, 0.40)	(-4.77, 15.89)		
p-value	0.1347	0.2453		
p-value of Breslow-Day Test for Homogeneity [2]	0.0829	0.6354		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	17 (32.1)	18 (40.0)	29 (32.2)	64 (34.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	1.40		
95% CI of the odds ratio	(0.48, 2.05)	(0.67, 2.95)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.24		
95% CI of the risk ratio	(0.61, 1.63)	(0.78, 1.98)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.15	7.78		
95% CI of the absolute risk difference	(-15.99, 15.70)	(-9.49, 25.04)		
p-value	0.9855	0.3712		
p-value of Breslow-Day Test for Homogeneity [2]	0.0748	0.9089		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	2 (3.8)	0	0	2 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.77	NE		
95% CI of the absolute risk difference	(-1.36, 8.90)	NE		
p-value	0.0635	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.0511	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	4 (8.9)	4 (4.4)	8 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.10		
95% CI of the odds ratio	NE	(0.50, 8.81)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.00		
95% CI of the risk ratio	NE	(0.52, 7.63)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.44	4.44		
95% CI of the absolute risk difference	(-8.70, -0.19)	(-4.90, 13.79)		
p-value	0.1195	0.3025		
p-value of Breslow-Day Test for Homogeneity [2]	0.0444	0.1534		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	3 (6.7)	4 (4.4)	7 (3.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the odds ratio	NE	(0.33, 7.18)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.50		
95% CI of the risk ratio	NE	(0.35, 6.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.44	2.22		
95% CI of the absolute risk difference	(-8.70, -0.19)	(-6.22, 10.66)		
p-value	0.1195	0.5830		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1798		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	10 (18.9)	7 (15.6)	18 (20.0)	35 (18.6)
Grade 2	28 (52.8)	22 (48.9)	52 (57.8)	102 (54.3)
Grade 3	10 (18.9)	9 (20.0)	12 (13.3)	31 (16.5)
Grade 4	0	0	2 (2.2)	2 (1.1)
Grade 5	0	0	0	0

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	9 (17.0)	9 (20.0)	18 (20.0)	36 (19.1)
Grade 2	6 (11.3)	9 (20.0)	11 (12.2)	26 (13.8)
Grade 3	2 (3.8)	0	0	2 (1.1)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	3 (3.3)	3 (1.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-3.33	-3.33		
95% CI of the absolute risk difference	(-7.04, 0.38)	(-7.04, 0.38)		
p-value	0.1792	0.2155		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0734		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (2.2)	2 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.22	-2.22		
95% CI of the absolute risk difference	(-5.27, 0.82)	(-5.27, 0.82)		
p-value	0.2744	0.3137		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1242		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (1.1)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.11	-1.11		
95% CI of the absolute risk difference	(-3.28, 1.05)	(-3.28, 1.05)		
p-value	0.4412	0.4779		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (2.2)	2 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.22	-2.22		
95% CI of the absolute risk difference	(-5.27, 0.82)	(-5.27, 0.82)		
p-value	0.2744	0.3137		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1242		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Events n:				
Total TEAEs	518	397	1015	1930
Total Serious TEAEs	19	14	52	85
Total TEAEs Leading to Discontinuation of Study Drug	13	10	6	29
Total TEAEs Related to Study Drug	67	41	52	160
Total TEAEs >= Grade 3 Severity	17	18	63	98
Patients n (%):				
Any TEAE	71 (98.6)	59 (90.8)	129 (92.8)	259 (93.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	5.50	0.76		
95% CI of the odds ratio	(0.69, 43.88)	(0.26, 2.20)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.06	0.98		
95% CI of the risk ratio	(1.01, 1.12)	(0.89, 1.07)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.81	-2.04		
95% CI of the absolute risk difference	(0.73, 10.88)	(-10.28, 6.21)		
p-value	0.0721	0.6142		
p-value of Breslow-Day Test for Homogeneity [2]	0.1481	0.1373		
Any Serious TEAE	7 (9.7)	8 (12.3)	23 (16.5)	38 (13.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.54	0.71		
95% CI of the odds ratio	(0.22, 1.33)	(0.30, 1.68)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	0.74		
95% CI of the risk ratio	(0.26, 1.30)	(0.35, 1.57)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.82	-4.24		
95% CI of the absolute risk difference	(-16.04, 2.39)	(-14.34, 5.86)		
p-value	0.1784	0.4319		
p-value of Breslow-Day Test for Homogeneity [2]	0.7462	0.3890		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Any TEAEs >= Grade 3 Severity	9 (12.5)	9 (13.8)	28 (20.1)	46 (16.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57	0.64		
95% CI of the odds ratio	(0.25, 1.28)	(0.28, 1.44)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.62	0.69		
95% CI of the risk ratio	(0.31, 1.24)	(0.34, 1.37)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.64	-6.30		
95% CI of the absolute risk difference	(-17.78, 2.50)	(-17.02, 4.42)		
p-value	0.1662	0.2767		
p-value of Breslow-Day Test for Homogeneity [2]	0.2070	0.4485		
Any TEAEs <= Grade 2 Severity	70 (97.2)	57 (87.7)	129 (92.8)	256 (92.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.71	0.55		
95% CI of the odds ratio	(0.58, 12.73)	(0.21, 1.47)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.05	0.94		
95% CI of the risk ratio	(0.99, 1.11)	(0.85, 1.05)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.42	-5.11		
95% CI of the absolute risk difference	(-1.32, 10.15)	(-14.18, 3.96)		
p-value	0.1891	0.2302		
p-value of Breslow-Day Test for Homogeneity [2]	0.2351	0.1382		
Any TEAEs leading to Study-Drug Discontinuation	8 (11.1)	8 (12.3)	6 (4.3)	22 (8.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.77	3.11		
95% CI of the odds ratio	(0.92, 8.32)	(1.03, 9.37)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.57	2.85		
95% CI of the risk ratio	(0.93, 7.14)	(1.03, 7.88)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.79	7.99		
95% CI of the absolute risk difference	(-1.21, 14.80)	(-0.68, 16.66)		
p-value	0.0601	0.0354		
p-value of Breslow-Day Test for Homogeneity [2]	0.0302	0.6450		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Any TEAEs leading to Study Discontinuation	3 (4.2)	5 (7.7)	3 (2.2)	11 (4.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.97	3.78		
95% CI of the odds ratio	(0.39, 10.02)	(0.87, 16.32)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.93	3.56		
95% CI of the risk ratio	(0.40, 9.32)	(0.88, 14.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.01	5.53		
95% CI of the absolute risk difference	(-3.20, 7.22)	(-1.38, 12.45)		
p-value	0.4053	0.0578		
p-value of Breslow-Day Test for Homogeneity [2]	0.0829	0.6354		
Any Fatal TEAEs	1 (1.4)	1 (1.5)	1 (0.7)	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.94	2.16		
95% CI of the odds ratio	(0.12, 31.54)	(0.13, 35.02)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.93	2.14		
95% CI of the risk ratio	(0.12, 30.42)	(0.14, 33.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.67	0.82		
95% CI of the absolute risk difference	(-2.38, 3.72)	(-2.49, 4.12)		
p-value	0.6342	0.5801		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	29 (40.3)	22 (33.8)	33 (23.7)	84 (30.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.17	1.64		
95% CI of the odds ratio	(1.17, 3.99)	(0.86, 3.13)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.70	1.43		
95% CI of the risk ratio	(1.13, 2.56)	(0.91, 2.24)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	16.54	10.11		
95% CI of the absolute risk difference	(3.18, 29.89)	(-3.40, 23.61)		
p-value	0.0124	0.1297		
p-value of Breslow-Day Test for Homogeneity [2]	0.0748	0.9089		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.7)	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.72	-0.72		
95% CI of the absolute risk difference	(-2.12, 0.69)	(-2.12, 0.69)		
p-value	0.4706	0.4930		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	2 (3.1)	2 (1.4)	4 (1.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.17		
95% CI of the odds ratio	NE	(0.30, 15.79)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.14		
95% CI of the risk ratio	NE	(0.31, 14.85)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.44	1.64		
95% CI of the absolute risk difference	(-3.42, 0.54)	(-3.00, 6.28)		
p-value	0.3065	0.4317		
p-value of Breslow-Day Test for Homogeneity [2]	0.0511	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (2.8)	5 (7.7)	1 (0.7)	8 (2.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.94	11.50		
95% CI of the odds ratio	(0.35, 44.24)	(1.32, 100.55)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.86	10.69		
95% CI of the risk ratio	(0.36, 41.87)	(1.27, 89.68)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.06	6.97		
95% CI of the absolute risk difference	(-1.99, 6.11)	(0.34, 13.60)		
p-value	0.2311	0.0060		
p-value of Breslow-Day Test for Homogeneity [2]	0.0444	0.1534		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	4 (6.2)	1 (0.7)	5 (1.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	9.05		
95% CI of the odds ratio	NE	(0.99, 82.65)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.55		
95% CI of the risk ratio	NE	(0.98, 75.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.72	5.43		
95% CI of the absolute risk difference	(-2.12, 0.69)	(-0.57, 11.44)		
p-value	0.4706	0.0193		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1798		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	17 (23.6)	13 (20.0)	35 (25.2)	65 (23.6)
Grade 2	45 (62.5)	37 (56.9)	66 (47.5)	148 (53.6)
Grade 3	8 (11.1)	8 (12.3)	24 (17.3)	40 (14.5)
Grade 4	0	0	3 (2.2)	3 (1.1)
Grade 5	1 (1.4)	1 (1.5)	1 (0.7)	3 (1.1)

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	17 (23.6)	11 (16.9)	21 (15.1)	49 (17.8)
Grade 2	12 (16.7)	9 (13.8)	10 (7.2)	31 (11.2)
Grade 3	0	2 (3.1)	1 (0.7)	3 (1.1)
Grade 4	0	0	1 (0.7)	1 (0.4)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (1.4)	1 (1.5)	1 (0.7)	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.94	2.16		
95% CI of the odds ratio	(0.12, 31.54)	(0.13, 35.02)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.93	2.14		
95% CI of the risk ratio	(0.12, 30.42)	(0.14, 33.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.67	0.82		
95% CI of the absolute risk difference	(-2.38, 3.72)	(-2.49, 4.12)		
p-value	0.6342	0.5801		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.5)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.54		
95% CI of the absolute risk difference	NE	(-1.45, 4.53)		
p-value	NE	0.1427		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (1.4)	0	1 (0.7)	2 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.94	NE		
95% CI of the odds ratio	(0.12, 31.54)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.93	NE		
95% CI of the risk ratio	(0.12, 30.42)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.67	-0.72		
95% CI of the absolute risk difference	(-2.38, 3.72)	(-2.12, 0.69)		
p-value	0.6342	0.4930		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (1.4)	1 (1.5)	1 (0.7)	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.94	2.16		
95% CI of the odds ratio	(0.12, 31.54)	(0.13, 35.02)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.93	2.14		
95% CI of the risk ratio	(0.12, 30.42)	(0.14, 33.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.67	0.82		
95% CI of the absolute risk difference	(-2.38, 3.72)	(-2.49, 4.12)		
p-value	0.6342	0.5801		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	1 (1.5)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.54		
95% CI of the absolute risk difference	NE	(-1.45, 4.53)		
p-value	NE	0.1427		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0734		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.5)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.54		
95% CI of the absolute risk difference	NE	(-1.45, 4.53)		
p-value	NE	0.1427		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1242		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (1.5)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.54		
95% CI of the absolute risk difference	NE	(-1.45, 4.53)		
p-value	NE	0.1427		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1242		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Events n:				
Total TEAEs	256	269	423	948
Total Serious TEAEs	3	6	17	26
Total TEAEs Leading to Discontinuation of Study Drug	0	4	6	10
Total TEAEs Related to Study Drug	39	23	39	101
Total TEAEs >= Grade 3 Severity	3	10	17	30
Patients n (%):				
Any TEAE	27 (90.0)	28 (100)	53 (93.0)	108 (93.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	NE		
95% CI of the odds ratio	(0.14, 3.26)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	1.08		
95% CI of the risk ratio	(0.84, 1.11)	(1.00, 1.15)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.98	7.02		
95% CI of the absolute risk difference	(-15.60, 9.64)	(0.39, 13.65)		
p-value	0.6269	0.1510		
p-value of Breslow-Day Test for Homogeneity [2]	0.1481	0.1373		
Any Serious TEAE	3 (10.0)	5 (17.9)	7 (12.3)	15 (13.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.79	1.55		
95% CI of the odds ratio	(0.19, 3.32)	(0.45, 5.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81	1.45		
95% CI of the risk ratio	(0.23, 2.92)	(0.51, 4.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.28	5.58		
95% CI of the absolute risk difference	(-15.99, 11.42)	(-10.97, 22.12)		
p-value	0.7512	0.4877		
p-value of Breslow-Day Test for Homogeneity [2]	0.7462	0.3890		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Any TEAEs >= Grade 3 Severity	2 (6.7)	6 (21.4)	11 (19.3)	19 (16.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.30	1.14		
95% CI of the odds ratio	(0.06, 1.45)	(0.37, 3.48)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.35	1.11		
95% CI of the risk ratio	(0.08, 1.46)	(0.46, 2.69)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-12.63	2.13		
95% CI of the absolute risk difference	(-26.22, 0.96)	(-16.20, 20.46)		
p-value	0.1162	0.8175		
p-value of Breslow-Day Test for Homogeneity [2]	0.2070	0.4485		
Any TEAEs <= Grade 2 Severity	27 (90.0)	28 (100)	53 (93.0)	108 (93.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.68	NE		
95% CI of the odds ratio	(0.14, 3.26)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	1.08		
95% CI of the risk ratio	(0.84, 1.11)	(1.00, 1.15)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.98	7.02		
95% CI of the absolute risk difference	(-15.60, 9.64)	(0.39, 13.65)		
p-value	0.6269	0.1510		
p-value of Breslow-Day Test for Homogeneity [2]	0.2351	0.1382		
Any TEAEs leading to Study-Drug Discontinuation	0	4 (14.3)	6 (10.5)	10 (8.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.13	1.42		
95% CI of the odds ratio	(0.01, 2.39)	(0.37, 5.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.14	1.36		
95% CI of the risk ratio	(0.01, 2.47)	(0.42, 4.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.59	3.76		
95% CI of the absolute risk difference	(-18.84, -0.34)	(-11.45, 18.97)		
p-value	0.1092	0.6131		
p-value of Breslow-Day Test for Homogeneity [2]	0.0302	0.6450		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Any TEAEs leading to Study Discontinuation	0	1 (3.6)	2 (3.5)	3 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.02		
95% CI of the odds ratio	NE	(0.09, 11.74)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.02		
95% CI of the risk ratio	NE	(0.10, 10.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.51	0.06		
95% CI of the absolute risk difference	(-8.29, 1.27)	(-8.31, 8.43)		
p-value	0.2993	0.9883		
p-value of Breslow-Day Test for Homogeneity [2]	0.0829	0.6354		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	17 (56.7)	11 (39.3)	15 (26.3)	43 (37.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.66	1.81		
95% CI of the odds ratio	(1.44, 9.30)	(0.69, 4.73)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.15	1.49		
95% CI of the risk ratio	(1.26, 3.68)	(0.79, 2.81)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	30.35	12.97		
95% CI of the absolute risk difference	(9.25, 51.45)	(-8.43, 34.37)		
p-value	0.0053	0.2226		
p-value of Breslow-Day Test for Homogeneity [2]	0.0748	0.9089		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.0511	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	1 (3.6)	3 (5.3)	4 (3.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.26	0.67		
95% CI of the odds ratio	(0.01, 5.11)	(0.07, 6.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.27	0.68		
95% CI of the risk ratio	(0.01, 5.01)	(0.07, 6.23)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.42	-1.69		
95% CI of the absolute risk difference	(-11.99, 3.14)	(-10.68, 7.30)		
p-value	0.3374	0.7292		
p-value of Breslow-Day Test for Homogeneity [2]	0.0444	0.1534		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1798		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	4 (13.3)	2 (7.1)	11 (19.3)	17 (14.8)
Grade 2	21 (70.0)	20 (71.4)	31 (54.4)	72 (62.6)
Grade 3	2 (6.7)	6 (21.4)	9 (15.8)	17 (14.8)
Grade 4	0	0	2 (3.5)	2 (1.7)
Grade 5	0	0	0	0

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	11 (36.7)	8 (28.6)	8 (14.0)	27 (23.5)
Grade 2	6 (20.0)	3 (10.7)	7 (12.3)	16 (13.9)
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	1 (1.8)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.75	-1.75		
95% CI of the absolute risk difference	(-5.16, 1.65)	(-5.16, 1.65)		
p-value	0.4656	0.4808		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0734		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	1 (1.8)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.75	-1.75		
95% CI of the absolute risk difference	(-5.16, 1.65)	(-5.16, 1.65)		
p-value	0.4656	0.4808		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1242		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	1 (1.8)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.75	-1.75		
95% CI of the absolute risk difference	(-5.16, 1.65)	(-5.16, 1.65)		
p-value	0.4656	0.4808		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1242		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable; SNP = Single Nucleotide Polymorphism.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Events n:				
Total TEAEs	368	291	609	1268
Total Serious TEAEs	6	11	22	39
Total TEAEs Leading to Discontinuation of Study Drug	1	6	9	16
Total TEAEs Related to Study Drug	36	52	54	142
Total TEAEs >= Grade 3 Severity	11	15	21	47
Patients n (%):				
Any TEAE	48 (90.6)	38 (84.4)	84 (93.3)	170 (90.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.69	0.39		
95% CI of the odds ratio	(0.20, 2.37)	(0.12, 1.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.97	0.90		
95% CI of the risk ratio	(0.88, 1.08)	(0.79, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.77	-8.89		
95% CI of the absolute risk difference	(-12.17, 6.64)	(-20.67, 2.89)		
p-value	0.5486	0.0989		
p-value of Breslow-Day Test for Homogeneity [2]	0.1371	0.0907		
Any Serious TEAE	5 (9.4)	7 (15.6)	9 (10.0)	21 (11.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.94	1.66		
95% CI of the odds ratio	(0.30, 2.96)	(0.57, 4.79)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.94	1.56		
95% CI of the risk ratio	(0.33, 2.67)	(0.62, 3.91)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.57	5.56		
95% CI of the absolute risk difference	(-10.58, 9.45)	(-6.71, 17.83)		
p-value	0.9124	0.3465		
p-value of Breslow-Day Test for Homogeneity [2]	0.7462	0.3890		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Any TEAEs >= Grade 3 Severity	8 (15.1)	9 (20.0)	11 (12.2)	28 (14.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.28	1.80		
95% CI of the odds ratio	(0.48, 3.41)	(0.68, 4.71)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.23	1.64		
95% CI of the risk ratio	(0.53, 2.88)	(0.73, 3.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.87	7.78		
95% CI of the absolute risk difference	(-8.90, 14.65)	(-5.73, 21.28)		
p-value	0.6251	0.2305		
p-value of Breslow-Day Test for Homogeneity [2]	0.1961	0.1858		
Any TEAEs <= Grade 2 Severity	47 (88.7)	38 (84.4)	84 (93.3)	169 (89.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56	0.39		
95% CI of the odds ratio	(0.17, 1.83)	(0.12, 1.23)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95	0.90		
95% CI of the risk ratio	(0.85, 1.06)	(0.79, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.65	-8.89		
95% CI of the absolute risk difference	(-14.62, 5.31)	(-20.67, 2.89)		
p-value	0.3323	0.0989		
p-value of Breslow-Day Test for Homogeneity [2]	0.2060	0.0933		
Any TEAEs leading to Study-Drug Discontinuation	1 (1.9)	6 (13.3)	5 (5.6)	12 (6.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.33	2.62		
95% CI of the odds ratio	(0.04, 2.88)	(0.75, 9.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.34	2.40		
95% CI of the risk ratio	(0.04, 2.83)	(0.77, 7.44)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.67	7.78		
95% CI of the absolute risk difference	(-9.65, 2.32)	(-3.22, 18.78)		
p-value	0.2906	0.1194		
p-value of Breslow-Day Test for Homogeneity [2]	0.0161	0.4909		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Any TEAEs leading to Study Discontinuation	0	5 (11.1)	5 (5.6)	10 (5.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.15	2.13		
95% CI of the odds ratio	(0.01, 2.68)	(0.58, 7.76)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.15	2.00		
95% CI of the risk ratio	(0.01, 2.72)	(0.61, 6.55)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.12	5.56		
95% CI of the absolute risk difference	(-10.64, 0.40)	(-4.77, 15.89)		
p-value	0.1347	0.2453		
p-value of Breslow-Day Test for Homogeneity [2]	0.0829	0.6354		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	17 (32.1)	18 (40.0)	29 (32.2)	64 (34.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	1.40		
95% CI of the odds ratio	(0.48, 2.05)	(0.67, 2.95)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.24		
95% CI of the risk ratio	(0.61, 1.63)	(0.78, 1.98)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.15	7.78		
95% CI of the absolute risk difference	(-15.99, 15.70)	(-9.49, 25.04)		
p-value	0.9855	0.3712		
p-value of Breslow-Day Test for Homogeneity [2]	0.0699	0.8938		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (1.9)	0	0	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.89	NE		
95% CI of the absolute risk difference	(-1.78, 5.55)	NE		
p-value	0.1910	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.0932	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	4 (8.9)	4 (4.4)	8 (4.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.10		
95% CI of the odds ratio	NE	(0.50, 8.81)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.00		
95% CI of the risk ratio	NE	(0.52, 7.63)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.44	4.44		
95% CI of the absolute risk difference	(-8.70, -0.19)	(-4.90, 13.79)		
p-value	0.1195	0.3025		
p-value of Breslow-Day Test for Homogeneity [2]	0.0444	0.1534		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	3 (6.7)	4 (4.4)	7 (3.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.54		
95% CI of the odds ratio	NE	(0.33, 7.18)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.50		
95% CI of the risk ratio	NE	(0.35, 6.42)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.44	2.22		
95% CI of the absolute risk difference	(-8.70, -0.19)	(-6.22, 10.66)		
p-value	0.1195	0.5830		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1798		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	10 (18.9)	7 (15.6)	20 (22.2)	37 (19.7)
Grade 2	30 (56.6)	22 (48.9)	53 (58.9)	105 (55.9)
Grade 3	8 (15.1)	9 (20.0)	9 (10.0)	26 (13.8)
Grade 4	0	0	2 (2.2)	2 (1.1)
Grade 5	0	0	0	0

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	9 (17.0)	9 (20.0)	18 (20.0)	36 (19.1)
Grade 2	7 (13.2)	9 (20.0)	11 (12.2)	27 (14.4)
Grade 3	1 (1.9)	0	0	1 (0.5)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	3 (3.3)	3 (1.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-3.33	-3.33		
95% CI of the absolute risk difference	(-7.04, 0.38)	(-7.04, 0.38)		
p-value	0.1792	0.2155		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0734		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (2.2)	2 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.22	-2.22		
95% CI of the absolute risk difference	(-5.27, 0.82)	(-5.27, 0.82)		
p-value	0.2744	0.3137		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1242		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (1.1)	1 (0.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.11	-1.11		
95% CI of the absolute risk difference	(-3.28, 1.05)	(-3.28, 1.05)		
p-value	0.4412	0.4779		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (2.2)	2 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-2.22	-2.22		
95% CI of the absolute risk difference	(-5.27, 0.82)	(-5.27, 0.82)		
p-value	0.2744	0.3137		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1242		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53) n (%)	MGL-3196 100 mg (N=45) n (%)	Placebo (N=90) n (%)	Overall (N=188) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Events n:				
Total TEAEs	515	392	1005	1912
Total Serious TEAEs	19	14	52	85
Total TEAEs Leading to Discontinuation of Study Drug	12	9	4	25
Total TEAEs Related to Study Drug	67	41	51	159
Total TEAEs >= Grade 3 Severity	16	17	63	96
Patients n (%):				
Any TEAE	71 (98.6)	59 (90.8)	128 (92.1)	258 (93.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	6.10	0.85		
95% CI of the odds ratio	(0.77, 48.24)	(0.30, 2.39)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.07	0.99		
95% CI of the risk ratio	(1.01, 1.13)	(0.90, 1.08)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.52	-1.32		
95% CI of the absolute risk difference	(1.29, 11.76)	(-9.66, 7.03)		
p-value	0.0523	0.7511		
p-value of Breslow-Day Test for Homogeneity [2]	0.1371	0.0907		
Any Serious TEAE	7 (9.7)	8 (12.3)	23 (16.5)	38 (13.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.54	0.71		
95% CI of the odds ratio	(0.22, 1.33)	(0.30, 1.68)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.59	0.74		
95% CI of the risk ratio	(0.26, 1.30)	(0.35, 1.57)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-6.82	-4.24		
95% CI of the absolute risk difference	(-16.04, 2.39)	(-14.34, 5.86)		
p-value	0.1784	0.4319		
p-value of Breslow-Day Test for Homogeneity [2]	0.7462	0.3890		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Any TEAEs >= Grade 3 Severity	8 (11.1)	8 (12.3)	28 (20.1)	44 (15.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50	0.56		
95% CI of the odds ratio	(0.21, 1.15)	(0.24, 1.30)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.55	0.61		
95% CI of the risk ratio	(0.27, 1.15)	(0.29, 1.27)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.03	-7.84		
95% CI of the absolute risk difference	(-18.89, 0.82)	(-18.24, 2.57)		
p-value	0.0982	0.1713		
p-value of Breslow-Day Test for Homogeneity [2]	0.1961	0.1858		
Any TEAEs <= Grade 2 Severity	70 (97.2)	57 (87.7)	128 (92.1)	255 (92.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.01	0.61		
95% CI of the odds ratio	(0.65, 13.95)	(0.23, 1.60)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.06	0.95		
95% CI of the risk ratio	(0.99, 1.12)	(0.86, 1.06)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	5.14	-4.39		
95% CI of the absolute risk difference	(-0.74, 11.01)	(-13.56, 4.77)		
p-value	0.1413	0.3143		
p-value of Breslow-Day Test for Homogeneity [2]	0.2060	0.0933		
Any TEAEs leading to Study-Drug Discontinuation	7 (9.7)	7 (10.8)	4 (2.9)	18 (6.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.63	4.07		
95% CI of the odds ratio	(1.03, 12.86)	(1.15, 14.45)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.38	3.74		
95% CI of the risk ratio	(1.02, 11.16)	(1.14, 12.33)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.84	7.89		
95% CI of the absolute risk difference	(-0.54, 14.23)	(-0.14, 15.92)		
p-value	0.0340	0.0201		
p-value of Breslow-Day Test for Homogeneity [2]	0.0161	0.4909		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Any TEAEs leading to Study Discontinuation	3 (4.2)	5 (7.7)	3 (2.2)	11 (4.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.97	3.78		
95% CI of the odds ratio	(0.39, 10.02)	(0.87, 16.32)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.93	3.56		
95% CI of the risk ratio	(0.40, 9.32)	(0.88, 14.46)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.01	5.53		
95% CI of the absolute risk difference	(-3.20, 7.22)	(-1.38, 12.45)		
p-value	0.4053	0.0578		
p-value of Breslow-Day Test for Homogeneity [2]	0.0829	0.6354		
Any Fatal TEAEs	1 (1.4)	1 (1.5)	1 (0.7)	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.94	2.16		
95% CI of the odds ratio	(0.12, 31.54)	(0.13, 35.02)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.93	2.14		
95% CI of the risk ratio	(0.12, 30.42)	(0.14, 33.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.67	0.82		
95% CI of the absolute risk difference	(-2.38, 3.72)	(-2.49, 4.12)		
p-value	0.6342	0.5801		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	29 (40.3)	22 (33.8)	32 (23.0)	83 (30.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.26	1.71		
95% CI of the odds ratio	(1.22, 4.17)	(0.89, 3.27)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.75	1.47		
95% CI of the risk ratio	(1.16, 2.65)	(0.93, 2.32)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	17.26	10.82		
95% CI of the absolute risk difference	(3.94, 30.57)	(-2.64, 24.29)		
p-value	0.0088	0.1025		
p-value of Breslow-Day Test for Homogeneity [2]	0.0699	0.8938		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.7)	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.72	-0.72		
95% CI of the absolute risk difference	(-2.12, 0.69)	(-2.12, 0.69)		
p-value	0.4706	0.4930		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	2 (3.1)	2 (1.4)	4 (1.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.17		
95% CI of the odds ratio	NE	(0.30, 15.79)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	2.14		
95% CI of the risk ratio	NE	(0.31, 14.85)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.44	1.64		
95% CI of the absolute risk difference	(-3.42, 0.54)	(-3.00, 6.28)		
p-value	0.3065	0.4317		
p-value of Breslow-Day Test for Homogeneity [2]	0.0932	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (2.8)	5 (7.7)	1 (0.7)	8 (2.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.94	11.50		
95% CI of the odds ratio	(0.35, 44.24)	(1.32, 100.55)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.86	10.69		
95% CI of the risk ratio	(0.36, 41.87)	(1.27, 89.68)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.06	6.97		
95% CI of the absolute risk difference	(-1.99, 6.11)	(0.34, 13.60)		
p-value	0.2311	0.0060		
p-value of Breslow-Day Test for Homogeneity [2]	0.0444	0.1534		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	4 (6.2)	1 (0.7)	5 (1.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	9.05		
95% CI of the odds ratio	NE	(0.99, 82.65)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	8.55		
95% CI of the risk ratio	NE	(0.98, 75.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.72	5.43		
95% CI of the absolute risk difference	(-2.12, 0.69)	(-0.57, 11.44)		
p-value	0.4706	0.0193		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1798		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	17 (23.6)	14 (21.5)	34 (24.5)	65 (23.6)
Grade 2	46 (63.9)	37 (56.9)	66 (47.5)	149 (54.0)
Grade 3	7 (9.7)	7 (10.8)	24 (17.3)	38 (13.8)
Grade 4	0	0	3 (2.2)	3 (1.1)
Grade 5	1 (1.4)	1 (1.5)	1 (0.7)	3 (1.1)

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	17 (23.6)	11 (16.9)	20 (14.4)	48 (17.4)
Grade 2	12 (16.7)	9 (13.8)	10 (7.2)	31 (11.2)
Grade 3	0	2 (3.1)	1 (0.7)	3 (1.1)
Grade 4	0	0	1 (0.7)	1 (0.4)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (1.4)	1 (1.5)	1 (0.7)	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.94	2.16		
95% CI of the odds ratio	(0.12, 31.54)	(0.13, 35.02)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.93	2.14		
95% CI of the risk ratio	(0.12, 30.42)	(0.14, 33.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.67	0.82		
95% CI of the absolute risk difference	(-2.38, 3.72)	(-2.49, 4.12)		
p-value	0.6342	0.5801		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.5)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.54		
95% CI of the absolute risk difference	NE	(-1.45, 4.53)		
p-value	NE	0.1427		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	1 (1.4)	0	1 (0.7)	2 (0.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.94	NE		
95% CI of the odds ratio	(0.12, 31.54)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.93	NE		
95% CI of the risk ratio	(0.12, 30.42)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.67	-0.72		
95% CI of the absolute risk difference	(-2.38, 3.72)	(-2.12, 0.69)		
p-value	0.6342	0.4930		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	1 (1.4)	1 (1.5)	1 (0.7)	3 (1.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.94	2.16		
95% CI of the odds ratio	(0.12, 31.54)	(0.13, 35.02)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.93	2.14		
95% CI of the risk ratio	(0.12, 30.42)	(0.14, 33.66)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	0.67	0.82		
95% CI of the absolute risk difference	(-2.38, 3.72)	(-2.49, 4.12)		
p-value	0.6342	0.5801		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	1 (1.5)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.54		
95% CI of the absolute risk difference	NE	(-1.45, 4.53)		
p-value	NE	0.1427		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0734		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.5)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.54		
95% CI of the absolute risk difference	NE	(-1.45, 4.53)		
p-value	NE	0.1427		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1242		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (1.5)	0	1 (0.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.54		
95% CI of the absolute risk difference	NE	(-1.45, 4.53)		
p-value	NE	0.1427		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1242		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72) n (%)	MGL-3196 100 mg (N=65) n (%)	Placebo (N=139) n (%)	Overall (N=276) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Events n:				
Total TEAEs	255	266	419	940
Total Serious TEAEs	3	6	17	26
Total TEAEs Leading to Discontinuation of Study Drug	0	3	5	8
Total TEAEs Related to Study Drug	39	23	39	101
Total TEAEs >= Grade 3 Severity	3	10	17	30
Patients n (%):				
Any TEAE	27 (90.0)	28 (100)	52 (91.2)	107 (93.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87	NE		
95% CI of the odds ratio	(0.19, 3.90)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	1.10		
95% CI of the risk ratio	(0.85, 1.14)	(1.01, 1.19)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.23	8.77		
95% CI of the absolute risk difference	(-14.23, 11.78)	(1.43, 16.12)		
p-value	0.8505	0.1062		
p-value of Breslow-Day Test for Homogeneity [2]	0.1371	0.0907		
Any Serious TEAE	3 (10.0)	5 (17.9)	7 (12.3)	15 (13.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.79	1.55		
95% CI of the odds ratio	(0.19, 3.32)	(0.45, 5.42)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81	1.45		
95% CI of the risk ratio	(0.23, 2.92)	(0.51, 4.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.28	5.58		
95% CI of the absolute risk difference	(-15.99, 11.42)	(-10.97, 22.12)		
p-value	0.7512	0.4877		
p-value of Breslow-Day Test for Homogeneity [2]	0.7462	0.3890		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Any TEAEs >= Grade 3 Severity	2 (6.7)	6 (21.4)	11 (19.3)	19 (16.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.30	1.14		
95% CI of the odds ratio	(0.06, 1.45)	(0.37, 3.48)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.35	1.11		
95% CI of the risk ratio	(0.08, 1.46)	(0.46, 2.69)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-12.63	2.13		
95% CI of the absolute risk difference	(-26.22, 0.96)	(-16.20, 20.46)		
p-value	0.1162	0.8175		
p-value of Breslow-Day Test for Homogeneity [2]	0.1961	0.1858		
Any TEAEs <= Grade 2 Severity	27 (90.0)	28 (100)	52 (91.2)	107 (93.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.87	NE		
95% CI of the odds ratio	(0.19, 3.90)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	1.10		
95% CI of the risk ratio	(0.85, 1.14)	(1.01, 1.19)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.23	8.77		
95% CI of the absolute risk difference	(-14.23, 11.78)	(1.43, 16.12)		
p-value	0.8505	0.1062		
p-value of Breslow-Day Test for Homogeneity [2]	0.2060	0.0933		
Any TEAEs leading to Study-Drug Discontinuation	0	3 (10.7)	5 (8.8)	8 (7.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.16	1.25		
95% CI of the odds ratio	(0.01, 2.93)	(0.28, 5.64)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.17	1.22		
95% CI of the risk ratio	(0.01, 2.98)	(0.31, 4.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.87	1.94		
95% CI of the absolute risk difference	(-16.62, 0.88)	(-11.67, 15.55)		
p-value	0.1583	0.7732		
p-value of Breslow-Day Test for Homogeneity [2]	0.0161	0.4909		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Any TEAEs leading to Study Discontinuation	0	1 (3.6)	2 (3.5)	3 (2.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.02		
95% CI of the odds ratio	NE	(0.09, 11.74)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.02		
95% CI of the risk ratio	NE	(0.10, 10.75)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.51	0.06		
95% CI of the absolute risk difference	(-8.29, 1.27)	(-8.31, 8.43)		
p-value	0.2993	0.9883		
p-value of Breslow-Day Test for Homogeneity [2]	0.0829	0.6354		
Any Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAE	17 (56.7)	11 (39.3)	15 (26.3)	43 (37.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.66	1.81		
95% CI of the odds ratio	(1.44, 9.30)	(0.69, 4.73)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.15	1.49		
95% CI of the risk ratio	(1.26, 3.68)	(0.79, 2.81)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	30.35	12.97		
95% CI of the absolute risk difference	(9.25, 51.45)	(-8.43, 34.37)		
p-value	0.0053	0.2226		
p-value of Breslow-Day Test for Homogeneity [2]	0.0699	0.8938		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.0932	NE		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	0	1 (3.6)	3 (5.3)	4 (3.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.26	0.67		
95% CI of the odds ratio	(0.01, 5.11)	(0.07, 6.72)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.27	0.68		
95% CI of the risk ratio	(0.01, 5.01)	(0.07, 6.23)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.42	-1.69		
95% CI of the absolute risk difference	(-11.99, 3.14)	(-10.68, 7.30)		
p-value	0.3374	0.7292		
p-value of Breslow-Day Test for Homogeneity [2]	0.0444	0.1534		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1798		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	4 (13.3)	2 (7.1)	11 (19.3)	17 (14.8)
Grade 2	21 (70.0)	20 (71.4)	30 (52.6)	71 (61.7)
Grade 3	2 (6.7)	6 (21.4)	9 (15.8)	17 (14.8)
Grade 4	0	0	2 (3.5)	2 (1.7)
Grade 5	0	0	0	0

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	11 (36.7)	8 (28.6)	8 (14.0)	27 (23.5)
Grade 2	6 (20.0)	3 (10.7)	7 (12.3)	16 (13.9)
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Other MACE AE – Adjudicated Event	0	0	1 (1.8)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.75	-1.75		
95% CI of the absolute risk difference	(-5.16, 1.65)	(-5.16, 1.65)		
p-value	0.4656	0.4808		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.0734		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	1 (1.8)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.75	-1.75		
95% CI of the absolute risk difference	(-5.16, 1.65)	(-5.16, 1.65)		
p-value	0.4656	0.4808		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1242		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	1 (1.8)	1 (0.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.75	-1.75		
95% CI of the absolute risk difference	(-5.16, 1.65)	(-5.16, 1.65)		
p-value	0.4656	0.4808		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.1242		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30) n (%)	MGL-3196 100 mg (N=28) n (%)	Placebo (N=57) n (%)	Overall (N=115) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Genetic NASH SNP - TMC4 (Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

System Organ Class Preferred Term	MGL-3196 80 mg (N=53) Patients n (%)	 Events n	MGL-3196 100 mg (N=45) Patients n (%)	 Events n	Placebo (N=90) Patients n (%)	 Events n	Overall (N=188) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	12 (22.6)	23	18 (40.0)	33	14 (15.6)	18	44 (23.4)	74
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.59		3.62					
95% CI of the odds ratio	(0.67, 3.75)		(1.59, 8.26)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.46		2.57					
95% CI of the risk ratio	(0.73, 2.91)		(1.41, 4.68)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.09		24.44					
95% CI of the absolute risk difference	(-6.44, 20.61)		(8.29, 40.60)					
p-value	0.2887		0.0016					
p-value of Breslow-Day Test for Homogeneity [2]	0.1176		0.0567					
Nausea	13 (24.5)	15	6 (13.3)	10	12 (13.3)	15	31 (16.5)	40
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.11		1.00					
95% CI of the odds ratio	(0.88, 5.05)		(0.35, 2.87)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.84		1.00					
95% CI of the risk ratio	(0.91, 3.73)		(0.40, 2.49)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	11.19		0.00					
95% CI of the absolute risk difference	(-2.35, 24.74)		(-12.16, 12.16)					
p-value	0.0887		>0.9999					
p-value of Breslow-Day Test for Homogeneity [2]	0.8655		0.3311					

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Genetic NASH SNP - TMC4 (Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

System Organ Class Preferred Term	MGL-3196 80 mg (N=53) Patients n (%)	 Events n	MGL-3196 100 mg (N=45) Patients n (%)	 Events n	Placebo (N=90) Patients n (%)	 Events n	Overall (N=188) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	5 (9.4)	6	4 (8.9)	4	7 (7.8)	7	16 (8.5)	17
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.24		1.16					
95% CI of the odds ratio	(0.37, 4.11)		(0.32, 4.18)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.21		1.14					
95% CI of the risk ratio	(0.41, 3.63)		(0.35, 3.70)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.66		1.11					
95% CI of the absolute risk difference	(-7.96, 11.28)		(-8.88, 11.10)					
p-value	0.7301		0.8240					
p-value of Breslow-Day Test for Homogeneity [2]	0.3700		0.9769					
Abdominal discomfort	0	0	1 (2.2)	1	3 (3.3)	3	4 (2.1)	4
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		0.66					
95% CI of the odds ratio	NE		(0.07, 6.52)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		0.67					
95% CI of the risk ratio	NE		(0.07, 6.23)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.33		-1.11					
95% CI of the absolute risk difference	(-7.04, 0.38)		(-6.79, 4.57)					
p-value	0.1792		0.7197					
p-value of Breslow-Day Test for Homogeneity [2]	0.2556		0.6377					

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

System Organ Class Preferred Term	MGL-3196 80 mg (N=53) Patients n (%)	 Events n	MGL-3196 100 mg (N=45) Patients n (%)	 Events n	Placebo (N=90) Patients n (%)	 Events n	Overall (N=188) Patients n (%)	 Events n
General disorders and administration site conditions	9 (17.0)	10	8 (17.8)	10	24 (26.7)	29	41 (21.8)	49
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.56		0.59					
95% CI of the odds ratio	(0.24, 1.32)		(0.24, 1.46)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.64		0.67					
95% CI of the risk ratio	(0.32, 1.27)		(0.33, 1.36)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.69		-8.89					
95% CI of the absolute risk difference	(-23.31, 3.94)		(-23.32, 5.54)					
p-value	0.1843		0.2523					
p-value of Breslow-Day Test for Homogeneity [2]	0.8295		0.6365					
Skin and subcutaneous tissue disorders								
Rash	4 (7.5)	4	6 (13.3)	8	6 (6.7)	7	16 (8.5)	19
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14		2.15					
95% CI of the odds ratio	(0.31, 4.25)		(0.65, 7.11)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13		2.00					
95% CI of the risk ratio	(0.33, 3.83)		(0.68, 5.85)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.88		6.67					
95% CI of the absolute risk difference	(-7.90, 9.66)		(-4.52, 17.86)					
p-value	0.8419		0.1995					
p-value of Breslow-Day Test for Homogeneity [2]	0.8381		0.7172					

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Genetic NASH SNP - TMC4 (Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

System Organ Class Preferred Term	MGL-3196 80 mg (N=53) Patients n (%)	 Events n	MGL-3196 100 mg (N=45) Patients n (%)	 Events n	Placebo (N=90) Patients n (%)	 Events n	Overall (N=188) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Pruritus	5 (9.4)	5	2 (4.4)	4	6 (6.7)	6	13 (6.9)	15
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.46		0.65					
95% CI of the odds ratio	(0.42, 5.03)		(0.13, 3.36)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.42		0.67					
95% CI of the risk ratio	(0.45, 4.41)		(0.14, 3.17)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.77		-2.22					
95% CI of the absolute risk difference	(-6.64, 12.17)		(-10.15, 5.70)					
p-value	0.5486		0.6062					
p-value of Breslow-Day Test for Homogeneity [2]	0.5382		0.4344					
Renal and urinary disorders	1 (1.9)	1	4 (8.9)	6	9 (10.0)	10	14 (7.4)	17
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.17		0.88					
95% CI of the odds ratio	(0.02, 1.41)		(0.26, 3.02)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.19		0.89					
95% CI of the risk ratio	(0.02, 1.45)		(0.29, 2.73)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-8.11		-1.11					
95% CI of the absolute risk difference	(-15.31, -0.91)		(-11.48, 9.26)					
p-value	0.0662		0.8366					
p-value of Breslow-Day Test for Homogeneity [2]	0.6720		0.5916					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Genetic NASH SNP - TMC4 (Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

System Organ Class Preferred Term	MGL-3196 80 mg (N=53) Patients n (%)	 Events n	MGL-3196 100 mg (N=45) Patients n (%)	 Events n	Placebo (N=90) Patients n (%)	 Events n	Overall (N=188) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	0	0	1 (2.2)	1	5 (5.6)	7	6 (3.2)	8
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.15		0.39					
95% CI of the odds ratio	(0.01, 2.68)		(0.04, 3.41)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.15		0.40					
95% CI of the risk ratio	(0.01, 2.72)		(0.05, 3.32)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.12		-3.33					
95% CI of the absolute risk difference	(-10.64, 0.40)		(-9.73, 3.07)					
p-value	0.1347		0.3757					
p-value of Breslow-Day Test for Homogeneity [2]	0.1903		0.3013					

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

System Organ Class Preferred Term	MGL-3196 80 mg (N=53) Patients n (%)	 Events n	MGL-3196 100 mg (N=45) Patients n (%)	 Events n	Placebo (N=90) Patients n (%)	 Events n	Overall (N=188) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	1 (1.9)	1	0	0	2 (2.2)	2	3 (1.6)	3
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.85		NE					
95% CI of the odds ratio	(0.07, 9.56)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.85		NE					
95% CI of the risk ratio	(0.08, 9.14)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.34		-2.22					
95% CI of the absolute risk difference	(-5.10, 4.43)		(-5.27, 0.82)					
p-value	0.8925		0.3137					
p-value of Breslow-Day Test for Homogeneity [2]	0.6647		NE					

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

System Organ Class Preferred Term	MGL-3196 80 mg (N=72) Patients n (%)	 Events n	MGL-3196 100 mg (N=65) Patients n (%)	 Events n	Placebo (N=139) Patients n (%)	 Events n	Overall (N=276) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	17 (23.6)	28	17 (26.2)	24	23 (16.5)	29	57 (20.7)	81
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.56		1.79					
95% CI of the odds ratio	(0.77, 3.15)		(0.88, 3.64)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43		1.58					
95% CI of the risk ratio	(0.82, 2.49)		(0.91, 2.75)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	7.06		9.61					
95% CI of the absolute risk difference	(-4.53, 18.66)		(-2.73, 21.95)					
p-value	0.2145		0.1073					
p-value of Breslow-Day Test for Homogeneity [2]	0.1176		0.0567					
Nausea	19 (26.4)	22	7 (10.8)	7	17 (12.2)	18	43 (15.6)	47
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.57		0.87					
95% CI of the odds ratio	(1.24, 5.34)		(0.34, 2.20)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.16		0.88					
95% CI of the risk ratio	(1.20, 3.89)		(0.38, 2.02)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.16		-1.46					
95% CI of the absolute risk difference	(2.61, 25.70)		(-10.76, 7.84)					
p-value	0.0095		0.7628					
p-value of Breslow-Day Test for Homogeneity [2]	0.8655		0.3311					

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

System Organ Class Preferred Term	MGL-3196 80 mg (N=72) Patients n (%)	 Events n	MGL-3196 100 mg (N=65) Patients n (%)	 Events n	Placebo (N=139) Patients n (%)	 Events n	Overall (N=276) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	8 (11.1)	8	3 (4.6)	3	6 (4.3)	6	17 (6.2)	17
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.77		1.07					
95% CI of the odds ratio	(0.92, 8.32)		(0.26, 4.43)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.57		1.07					
95% CI of the risk ratio	(0.93, 7.14)		(0.28, 4.14)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.79		0.30					
95% CI of the absolute risk difference	(-1.21, 14.80)		(-5.82, 6.42)					
p-value	0.0601		0.9228					
p-value of Breslow-Day Test for Homogeneity [2]	0.3700		0.9769					
Abdominal discomfort	0	0	2 (3.1)	3	7 (5.0)	7	9 (3.3)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.12		0.60					
95% CI of the odds ratio	(0.01, 2.16)		(0.12, 2.96)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.13		0.61					
95% CI of the risk ratio	(0.01, 2.21)		(0.13, 2.86)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.67		-1.96					
95% CI of the absolute risk difference	(-8.85, -0.49)		(-7.51, 3.59)					
p-value	0.0887		0.5255					
p-value of Breslow-Day Test for Homogeneity [2]	0.2556		0.6377					

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72)		MGL-3196 100 mg (N=65)		Placebo (N=139)		Overall (N=276)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
General disorders and administration site conditions	16 (22.2)	27	10 (15.4)	15	38 (27.3)	47	64 (23.2)	89
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.76		0.48					
95% CI of the odds ratio	(0.39, 1.48)		(0.22, 1.04)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81		0.56					
95% CI of the risk ratio	(0.49, 1.35)		(0.30, 1.06)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.12		-11.95					
95% CI of the absolute risk difference	(-17.24, 7.01)		(-23.44, -0.47)					
p-value	0.4194		0.0607					
p-value of Breslow-Day Test for Homogeneity [2]	0.8295		0.6365					
Skin and subcutaneous tissue disorders								
Pruritus	9 (12.5)	11	4 (6.2)	4	8 (5.8)	10	21 (7.6)	25
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.34		1.07					
95% CI of the odds ratio	(0.86, 6.35)		(0.31, 3.70)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.17		1.07					
95% CI of the risk ratio	(0.88, 5.39)		(0.33, 3.42)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.74		0.40					
95% CI of the absolute risk difference	(-1.82, 15.31)		(-6.61, 7.41)					
p-value	0.0879		0.9103					
p-value of Breslow-Day Test for Homogeneity [2]	0.5382		0.4344					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

System Organ Class Preferred Term	MGL-3196 80 mg (N=72) Patients n (%)	 Events n	MGL-3196 100 mg (N=65) Patients n (%)	 Events n	Placebo (N=139) Patients n (%)	 Events n	Overall (N=276) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	3 (4.2)	3	6 (9.2)	8	3 (2.2)	3	12 (4.3)	14
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.97		4.61					
95% CI of the odds ratio	(0.39, 10.02)		(1.12, 19.06)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.93		4.28					
95% CI of the risk ratio	(0.40, 9.32)		(1.10, 16.57)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.01		7.07					
95% CI of the absolute risk difference	(-3.20, 7.22)		(-0.37, 14.51)					
p-value	0.4053		0.0219					
p-value of Breslow-Day Test for Homogeneity [2]	0.8381		0.7172					
Renal and urinary disorders	3 (4.2)	3	9 (13.8)	11	11 (7.9)	16	23 (8.3)	30
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.51		1.87					
95% CI of the odds ratio	(0.14, 1.87)		(0.73, 4.76)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53		1.75					
95% CI of the risk ratio	(0.15, 1.83)		(0.76, 4.01)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.75		5.93					
95% CI of the absolute risk difference	(-10.18, 2.69)		(-3.59, 15.45)					
p-value	0.2998		0.1843					
p-value of Breslow-Day Test for Homogeneity [2]	0.6720		0.5916					

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72)		MGL-3196 100 mg (N=65)		Placebo (N=139)		Overall (N=276)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	4 (5.6)	4	1 (1.5)	1	14 (10.1)	16	19 (6.9)	21
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.53		0.14					
95% CI of the odds ratio	(0.17, 1.66)		(0.02, 1.08)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.55		0.15					
95% CI of the risk ratio	(0.19, 1.61)		(0.02, 1.14)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.52		-8.53					
95% CI of the absolute risk difference	(-11.80, 2.77)		(-14.36, -2.70)					
p-value	0.2655		0.0296					
p-value of Breslow-Day Test for Homogeneity [2]	0.1903		0.3013					

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72)		MGL-3196 100 mg (N=65)		Placebo (N=139)		Overall (N=276)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Injury, poisoning and procedural complications								
Contusion	1 (1.4)	1	0	0	5 (3.6)	9	6 (2.2)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		NE					
95% CI of the odds ratio	(0.04, 3.29)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		NE					
95% CI of the risk ratio	(0.05, 3.24)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.21		-3.60					
95% CI of the absolute risk difference	(-6.32, 1.90)		(-6.69, -0.50)					
p-value	0.3602		0.1216					
p-value of Breslow-Day Test for Homogeneity [2]	0.6647		NE					

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30)		MGL-3196 100 mg (N=28)		Placebo (N=57)		Overall (N=115)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Gastrointestinal disorders								
Diarrhoea	11 (36.7)	20	13 (46.4)	17	5 (8.8)	5	29 (25.2)	42
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	6.02		9.01					
95% CI of the odds ratio	(1.85, 19.60)		(2.77, 29.35)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.18		5.29					
95% CI of the risk ratio	(1.60, 10.92)		(2.09, 13.37)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	27.89		37.66					
95% CI of the absolute risk difference	(9.15, 46.64)		(17.78, 57.54)					
p-value	0.0014		<0.0001					
p-value of Breslow-Day Test for Homogeneity [2]	0.1176		0.0567					
Nausea	10 (33.3)	13	8 (28.6)	9	8 (14.0)	10	26 (22.6)	32
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.06		2.45					
95% CI of the odds ratio	(1.06, 8.89)		(0.81, 7.43)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.38		2.04					
95% CI of the risk ratio	(1.05, 5.38)		(0.85, 4.86)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	19.30		14.54					
95% CI of the absolute risk difference	(0.17, 38.43)		(-4.47, 33.54)					
p-value	0.0347		0.1071					
p-value of Breslow-Day Test for Homogeneity [2]	0.8655		0.3311					

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

System Organ Class Preferred Term	MGL-3196 80 mg (N=30) Patients n (%)	 Events n	MGL-3196 100 mg (N=28) Patients n (%)	 Events n	Placebo (N=57) Patients n (%)	 Events n	Overall (N=115) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	6 (20.0)	7	2 (7.1)	2	3 (5.3)	4	11 (9.6)	13
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.50		1.38					
95% CI of the odds ratio	(1.04, 19.51)		(0.22, 8.80)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.80		1.36					
95% CI of the risk ratio	(1.02, 14.13)		(0.24, 7.66)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	14.74		1.88					
95% CI of the absolute risk difference	(-0.71, 30.18)		(-9.28, 13.04)					
p-value	0.0319		0.7292					
p-value of Breslow-Day Test for Homogeneity [2]	0.3700		0.9769					
Abdominal discomfort	1 (3.3)	1	0	0	3 (5.3)	4	4 (3.5)	5
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.62		0.27					
95% CI of the odds ratio	(0.06, 6.24)		(0.01, 5.47)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.63		0.29					
95% CI of the risk ratio	(0.07, 5.83)		(0.02, 5.35)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.93		-4.31					
95% CI of the absolute risk difference	(-10.58, 6.72)		(-12.06, 3.44)					
p-value	0.6829		0.3655					
p-value of Breslow-Day Test for Homogeneity [2]	0.2556		0.6377					

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30)		MGL-3196 100 mg (N=28)		Placebo (N=57)		Overall (N=115)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
General disorders and administration site conditions	9 (30.0)	14	9 (32.1)	12	20 (35.1)	25	38 (33.0)	51
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.79		0.88					
95% CI of the odds ratio	(0.31, 2.05)		(0.33, 2.29)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.86		0.92					
95% CI of the risk ratio	(0.45, 1.64)		(0.48, 1.74)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.09		-2.94					
95% CI of the absolute risk difference	(-25.64, 15.46)		(-24.22, 18.33)					
p-value	0.6323		0.7878					
p-value of Breslow-Day Test for Homogeneity [2]	0.8295		0.6365					
Skin and subcutaneous tissue disorders								
Pruritus	4 (13.3)	6	1 (3.6)	1	8 (14.0)	9	13 (11.3)	16
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.94		0.23					
95% CI of the odds ratio	(0.26, 3.43)		(0.03, 1.91)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95		0.25					
95% CI of the risk ratio	(0.31, 2.90)		(0.03, 1.94)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.70		-10.46					
95% CI of the absolute risk difference	(-15.84, 14.44)		(-21.80, 0.87)					
p-value	0.9281		0.1406					
p-value of Breslow-Day Test for Homogeneity [2]	0.5382		0.4344					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

System Organ Class Preferred Term	MGL-3196 80 mg (N=30) Patients n (%)	 Events n	MGL-3196 100 mg (N=28) Patients n (%)	 Events n	Placebo (N=57) Patients n (%)	 Events n	Overall (N=115) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	1 (3.3)	1	3 (10.7)	3	2 (3.5)	3	6 (5.2)	7
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95		3.30					
95% CI of the odds ratio	(0.08, 10.90)		(0.52, 21.00)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.95		3.05					
95% CI of the risk ratio	(0.09, 10.06)		(0.54, 17.24)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.18		7.21					
95% CI of the absolute risk difference	(-8.18, 7.83)		(-5.21, 19.62)					
p-value	0.9660		0.1845					
p-value of Breslow-Day Test for Homogeneity [2]	0.8381		0.7172					
Renal and urinary disorders	1 (3.3)	2	5 (17.9)	5	6 (10.5)	6	12 (10.4)	13
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29		1.85					
95% CI of the odds ratio	(0.03, 2.56)		(0.51, 6.68)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.32		1.70					
95% CI of the risk ratio	(0.04, 2.51)		(0.57, 5.08)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.19		7.33					
95% CI of the absolute risk difference	(-17.43, 3.04)		(-8.94, 23.60)					
p-value	0.2410		0.3440					
p-value of Breslow-Day Test for Homogeneity [2]	0.6720		0.5916					

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

System Organ Class Preferred Term	MGL-3196 80 mg (N=30) Patients n (%)	 Events n	MGL-3196 100 mg (N=28) Patients n (%)	 Events n	Placebo (N=57) Patients n (%)	 Events n	Overall (N=115) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	3 (10.0)	4	2 (7.1)	2	4 (7.0)	4	9 (7.8)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.47		1.02					
95% CI of the odds ratio	(0.31, 7.06)		(0.18, 5.93)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.43		1.02					
95% CI of the risk ratio	(0.34, 5.96)		(0.20, 5.23)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.98		0.13					
95% CI of the absolute risk difference	(-9.64, 15.60)		(-11.49, 11.74)					
p-value	0.6269		0.9831					
p-value of Breslow-Day Test for Homogeneity [2]	0.1903		0.3013					

AMNOG Table S1.14c.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term; by Genetic NASH SNP - TMC4 (Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

System Organ Class Preferred Term	MGL-3196 80 mg (N=30) Patients n (%)	 Events n	MGL-3196 100 mg (N=28) Patients n (%)	 Events n	Placebo (N=57) Patients n (%)	 Events n	Overall (N=115) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	0	0	0	0	2 (3.5)	2	2 (1.7)	2
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.51		-3.51					
95% CI of the absolute risk difference	(-8.29, 1.27)		(-8.29, 1.27)					
p-value	0.2993		0.3158					
p-value of Breslow-Day Test for Homogeneity [2]	0.6647		NE					

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Events n:				
Total TEAEs	497	493	1097	2087
Total Serious TEAEs	11	18	55	84
Total TEAEs Leading to Discontinuation of Study Drug	11	10	6	27
Total TEAEs Related to Study Drug	75	56	60	191
Total TEAEs >= Grade 3 Severity	15	23	54	92
Patients n (%):				
Any TEAE	71 (94.7)	77 (88.5)	137 (93.2)	285 (92.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.30	0.56		
95% CI of the odds ratio	(0.39, 4.28)	(0.22, 1.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	0.95		
95% CI of the risk ratio	(0.95, 1.09)	(0.87, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.47	-4.69		
95% CI of the absolute risk difference	(-5.04, 7.98)	(-12.53, 3.15)		
p-value	0.6701	0.2148		
p-value of Breslow-Day Test for Homogeneity [2]	0.9199	0.2650		
Any Serious TEAE	10 (13.3)	12 (13.8)	26 (17.7)	48 (15.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.72	0.74		
95% CI of the odds ratio	(0.33, 1.58)	(0.35, 1.56)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	0.78		
95% CI of the risk ratio	(0.38, 1.48)	(0.42, 1.47)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.35	-3.89		
95% CI of the absolute risk difference	(-14.21, 5.51)	(-13.41, 5.62)		
p-value	0.4052	0.4351		
p-value of Breslow-Day Test for Homogeneity [2]	0.7214	0.3123		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Any TEAEs >= Grade 3 Severity	12 (16.0)	15 (17.2)	29 (19.7)	56 (18.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	0.85		
95% CI of the odds ratio	(0.37, 1.62)	(0.43, 1.69)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81	0.87		
95% CI of the risk ratio	(0.44, 1.50)	(0.50, 1.54)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.73	-2.49		
95% CI of the absolute risk difference	(-14.23, 6.77)	(-12.70, 7.73)		
p-value	0.4984	0.6380		
p-value of Breslow-Day Test for Homogeneity [2]	0.6615	0.7019		
Any TEAEs <= Grade 2 Severity	70 (93.3)	75 (86.2)	137 (93.2)	282 (91.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	0.46		
95% CI of the odds ratio	(0.34, 3.11)	(0.19, 1.11)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.92		
95% CI of the risk ratio	(0.93, 1.08)	(0.84, 1.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.14	-6.99		
95% CI of the absolute risk difference	(-6.82, 7.10)	(-15.30, 1.32)		
p-value	0.9695	0.0766		
p-value of Breslow-Day Test for Homogeneity [2]	0.9589	0.1630		
Any TEAEs leading to Study-Drug Discontinuation	9 (12.0)	8 (9.2)	5 (3.4)	22 (7.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.87	2.88		
95% CI of the odds ratio	(1.25, 12.01)	(0.91, 9.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.53	2.70		
95% CI of the risk ratio	(1.23, 10.16)	(0.91, 8.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.60	5.79		
95% CI of the absolute risk difference	(0.68, 16.52)	(-0.95, 12.54)		
p-value	0.0127	0.0615		
p-value of Breslow-Day Test for Homogeneity [2]	0.0015	0.4302		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Any TEAEs leading to Study Discontinuation	2 (2.7)	5 (5.7)	5 (3.4)	12 (3.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	1.73		
95% CI of the odds ratio	(0.15, 4.11)	(0.49, 6.16)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	1.69		
95% CI of the risk ratio	(0.16, 3.95)	(0.50, 5.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.73	2.35		
95% CI of the absolute risk difference	(-5.41, 3.94)	(-3.36, 8.05)		
p-value	0.7670	0.3912		
p-value of Breslow-Day Test for Homogeneity [2]	0.4416	0.6484		
Any Fatal TEAEs	0	1 (1.1)	1 (0.7)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.70		
95% CI of the odds ratio	NE	(0.10, 27.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.69		
95% CI of the risk ratio	NE	(0.11, 26.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.68	0.47		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-2.14, 3.07)		
p-value	0.4741	0.7063		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
Any Treatment-related TEAE	31 (41.3)	27 (31.0)	38 (25.9)	96 (31.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.02	1.29		
95% CI of the odds ratio	(1.12, 3.64)	(0.72, 2.32)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.60	1.20		
95% CI of the risk ratio	(1.09, 2.35)	(0.79, 1.82)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	15.48	5.18		
95% CI of the absolute risk difference	(2.28, 28.68)	(-6.84, 17.21)		
p-value	0.0184	0.3922		
p-value of Breslow-Day Test for Homogeneity [2]	0.5000	0.5204		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (1.3)	3 (3.4)	1 (0.7)	5 (1.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.97	5.21		
95% CI of the odds ratio	(0.12, 31.99)	(0.53, 50.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.96	5.07		
95% CI of the risk ratio	(0.12, 30.90)	(0.54, 47.98)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.65	2.77		
95% CI of the absolute risk difference	(-2.26, 3.57)	(-1.29, 6.83)		
p-value	0.6262	0.1144		
p-value of Breslow-Day Test for Homogeneity [2]	0.9417	0.2286		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (2.7)	3 (3.4)	1 (0.7)	6 (1.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.00	5.21		
95% CI of the odds ratio	(0.36, 44.84)	(0.53, 50.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.92	5.07		
95% CI of the risk ratio	(0.36, 42.54)	(0.54, 47.98)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.99	2.77		
95% CI of the absolute risk difference	(-1.89, 5.87)	(-1.29, 6.83)		
p-value	0.2254	0.1144		
p-value of Breslow-Day Test for Homogeneity [2]	0.0380	0.5100		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	2 (2.3)	1 (0.7)	3 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.44		
95% CI of the odds ratio	NE	(0.31, 38.45)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.38		
95% CI of the risk ratio	NE	(0.31, 36.72)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.68	1.62		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-1.80, 5.04)		
p-value	0.4741	0.2875		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.9634		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	17 (22.7)	18 (20.7)	29 (19.7)	64 (20.7)
Grade 2	42 (56.0)	44 (50.6)	79 (53.7)	165 (53.4)
Grade 3	12 (16.0)	14 (16.1)	25 (17.0)	51 (16.5)
Grade 4	0	0	3 (2.0)	3 (1.0)
Grade 5	0	1 (1.1)	1 (0.7)	2 (0.6)

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	19 (25.3)	12 (13.8)	25 (17.0)	56 (18.1)
Grade 2	11 (14.7)	12 (13.8)	12 (8.2)	35 (11.3)
Grade 3	1 (1.3)	3 (3.4)	1 (0.7)	5 (1.6)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (1.1)	1 (0.7)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.70		
95% CI of the odds ratio	NE	(0.10, 27.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.69		
95% CI of the risk ratio	NE	(0.11, 26.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.68	0.47		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-2.14, 3.07)		
p-value	0.4741	0.7063		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.1)	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.15		
95% CI of the absolute risk difference	NE	(-1.09, 3.39)		
p-value	NE	0.1927		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
3-PT MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.7)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.68	-0.68		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-2.01, 0.65)		
p-value	0.4741	0.4407		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
Serious 3-PT MACE AE – Adjudicated Event	0	1 (1.1)	1 (0.7)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.70		
95% CI of the odds ratio	NE	(0.10, 27.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.69		
95% CI of the risk ratio	NE	(0.11, 26.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.68	0.47		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-2.14, 3.07)		
p-value	0.4741	0.7063		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
Other MACE AE – Adjudicated Event	0	1 (1.1)	2 (1.4)	3 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.84		
95% CI of the odds ratio	NE	(0.08, 9.44)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.84		
95% CI of the risk ratio	NE	(0.08, 9.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.36	-0.21		
95% CI of the absolute risk difference	(-3.23, 0.51)	(-3.13, 2.71)		
p-value	0.3102	0.8897		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4308		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.1)	1 (0.7)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.70		
95% CI of the odds ratio	NE	(0.10, 27.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.69		
95% CI of the risk ratio	NE	(0.11, 26.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.68	0.47		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-2.14, 3.07)		
p-value	0.4741	0.7063		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3113		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.7)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.68	-0.68		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-2.01, 0.65)		
p-value	0.4741	0.4407		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (1.1)	1 (0.7)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.70		
95% CI of the odds ratio	NE	(0.10, 27.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.69		
95% CI of the risk ratio	NE	(0.11, 26.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.68	0.47		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-2.14, 3.07)		
p-value	0.4741	0.7063		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3113		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Events n:				
Total TEAEs	702	529	1060	2291
Total Serious TEAEs	18	14	41	73
Total TEAEs Leading to Discontinuation of Study Drug	7	10	19	36
Total TEAEs Related to Study Drug	80	70	99	249
Total TEAEs >= Grade 3 Severity	19	22	52	93
Patients n (%):				
Any TEAE	87 (94.6)	61 (95.3)	146 (93.6)	294 (94.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.19	1.39		
95% CI of the odds ratio	(0.39, 3.60)	(0.37, 5.24)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	1.02		
95% CI of the risk ratio	(0.95, 1.08)	(0.95, 1.09)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.98	1.72		
95% CI of the absolute risk difference	(-5.04, 6.99)	(-4.73, 8.17)		
p-value	0.7556	0.6226		
p-value of Breslow-Day Test for Homogeneity [2]	0.9199	0.2650		
Any Serious TEAE	6 (6.5)	9 (14.1)	17 (10.9)	32 (10.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57	1.34		
95% CI of the odds ratio	(0.22, 1.50)	(0.56, 3.18)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	1.29		
95% CI of the risk ratio	(0.24, 1.46)	(0.61, 2.74)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.38	3.17		
95% CI of the absolute risk difference	(-11.40, 2.65)	(-6.66, 12.99)		
p-value	0.2512	0.5089		
p-value of Breslow-Day Test for Homogeneity [2]	0.7214	0.3123		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Any TEAEs >= Grade 3 Severity	10 (10.9)	11 (17.2)	26 (16.7)	47 (15.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.61	1.04		
95% CI of the odds ratio	(0.28, 1.33)	(0.48, 2.25)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.65	1.03		
95% CI of the risk ratio	(0.33, 1.29)	(0.54, 1.96)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.80	0.52		
95% CI of the absolute risk difference	(-14.44, 2.84)	(-10.42, 11.46)		
p-value	0.2106	0.9253		
p-value of Breslow-Day Test for Homogeneity [2]	0.6615	0.7019		
Any TEAEs <= Grade 2 Severity	86 (93.5)	61 (95.3)	146 (93.6)	293 (93.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.98	1.39		
95% CI of the odds ratio	(0.34, 2.80)	(0.37, 5.24)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	1.02		
95% CI of the risk ratio	(0.93, 1.07)	(0.95, 1.09)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.11	1.72		
95% CI of the absolute risk difference	(-6.45, 6.23)	(-4.73, 8.17)		
p-value	0.9725	0.6226		
p-value of Breslow-Day Test for Homogeneity [2]	0.9589	0.1630		
Any TEAEs leading to Study-Drug Discontinuation	3 (3.3)	10 (15.6)	16 (10.3)	29 (9.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.29	1.62		
95% CI of the odds ratio	(0.08, 1.04)	(0.69, 3.79)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.32	1.52		
95% CI of the risk ratio	(0.10, 1.06)	(0.73, 3.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.00	5.37		
95% CI of the absolute risk difference	(-12.98, -1.01)	(-4.72, 15.46)		
p-value	0.0454	0.2626		
p-value of Breslow-Day Test for Homogeneity [2]	0.0015	0.4302		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Any TEAEs leading to Study Discontinuation	1 (1.1)	6 (9.4)	6 (3.8)	13 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.27	2.59		
95% CI of the odds ratio	(0.03, 2.32)	(0.80, 8.34)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.28	2.44		
95% CI of the risk ratio	(0.03, 2.31)	(0.82, 7.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.76	5.53		
95% CI of the absolute risk difference	(-6.45, 0.93)	(-2.22, 13.28)		
p-value	0.2050	0.1010		
p-value of Breslow-Day Test for Homogeneity [2]	0.4416	0.6484		
Any Fatal TEAEs	1 (1.1)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.09	NE		
95% CI of the absolute risk difference	(-1.03, 3.21)	NE		
p-value	0.1920	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
Any Treatment-related TEAE	38 (41.3)	28 (43.8)	49 (31.4)	115 (36.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.54	1.70		
95% CI of the odds ratio	(0.90, 2.62)	(0.93, 3.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.31	1.39		
95% CI of the risk ratio	(0.94, 1.84)	(0.97, 2.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.89	12.34		
95% CI of the absolute risk difference	(-2.53, 22.32)	(-1.83, 26.51)		
p-value	0.1148	0.0814		
p-value of Breslow-Day Test for Homogeneity [2]	0.5000	0.5204		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.6)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.64	-0.64		
95% CI of the absolute risk difference	(-1.89, 0.61)	(-1.89, 0.61)		
p-value	0.4416	0.5209		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (1.1)	0	1 (0.6)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.70	NE		
95% CI of the odds ratio	(0.11, 27.56)	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.70	NE		
95% CI of the risk ratio	(0.11, 26.79)	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.45	-0.64		
95% CI of the absolute risk difference	(-2.02, 2.91)	(-1.89, 0.61)		
p-value	0.7045	0.5209		
p-value of Breslow-Day Test for Homogeneity [2]	0.9417	0.2286		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	1 (1.1)	7 (10.9)	8 (5.1)	16 (5.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.20	2.27		
95% CI of the odds ratio	(0.03, 1.65)	(0.79, 6.55)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.21	2.13		
95% CI of the risk ratio	(0.03, 1.67)	(0.81, 5.64)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.04	5.81		
95% CI of the absolute risk difference	(-8.10, 0.02)	(-2.58, 14.20)		
p-value	0.1002	0.1205		
p-value of Breslow-Day Test for Homogeneity [2]	0.0380	0.5100		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	5 (7.8)	4 (2.6)	9 (2.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.22		
95% CI of the odds ratio	NE	(0.84, 12.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.05		
95% CI of the risk ratio	NE	(0.85, 10.98)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.56	5.25		
95% CI of the absolute risk difference	(-5.04, -0.08)	(-1.78, 12.28)		
p-value	0.1215	0.0743		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.9634		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	22 (23.9)	8 (12.5)	40 (25.6)	70 (22.4)
Grade 2	55 (59.8)	42 (65.6)	80 (51.3)	177 (56.7)
Grade 3	9 (9.8)	11 (17.2)	22 (14.1)	42 (13.5)
Grade 4	0	0	4 (2.6)	4 (1.3)
Grade 5	1 (1.1)	0	0	1 (0.3)

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	22 (23.9)	17 (26.6)	28 (17.9)	67 (21.5)
Grade 2	15 (16.3)	11 (17.2)	20 (12.8)	46 (14.7)
Grade 3	1 (1.1)	0	0	1 (0.3)
Grade 4	0	0	1 (0.6)	1 (0.3)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (1.1)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	1.09	NE		
95% CI of the absolute risk difference	(-1.03, 3.21)	NE		
p-value	0.1920	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	1 (1.1)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.09	NE		
95% CI of the absolute risk difference	(-1.03, 3.21)	NE		
p-value	0.1920	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
Serious 3-PT MACE AE - Adjudicated Event	1 (1.1)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.09	NE		
95% CI of the absolute risk difference	(-1.03, 3.21)	NE		
p-value	0.1920	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
Other MACE AE - Adjudicated Event	0	0	2 (1.3)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.28	-1.28		
95% CI of the absolute risk difference	(-3.05, 0.48)	(-3.05, 0.48)		
p-value	0.2755	0.3628		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4308		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (1.3)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.28	-1.28		
95% CI of the absolute risk difference	(-3.05, 0.48)	(-3.05, 0.48)		
p-value	0.2755	0.3628		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3113		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (1.3)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.28	-1.28		
95% CI of the absolute risk difference	(-3.05, 0.48)	(-3.05, 0.48)		
p-value	0.2755	0.3628		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3113		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.15.1.1
TEAE (S1): Treatment-Emergent Adverse Events - Overall Summary;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Abbreviations: AE = adverse event; TEAE = treatment-emergent adverse event; MACE = major adverse cardiac events; DILI = drug-induced liver injury; NE = Not estimable.
Note: disease related events include the following preferred terms: Hepatic cirrhosis; Ascites; Varices oesophageal; Oesophageal varices haemorrhage; Hepatic encephalopathy.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment).
Note: A patient with multiple TEAEs is counted only once by maximum severity under the patients heading, but for all events under the events heading. If severity is missing, the TEAE will be classified as 'Grade 3'. Severity is assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03.
Note: If the relationship is missing for an AE, the event is assumed to be related.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
[3] 3-pt MACE AE includes nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Events n:				
Total TEAEs	486	488	1086	2060
Total Serious TEAEs	11	18	55	84
Total TEAEs Leading to Discontinuation of Study Drug	8	9	6	23
Total TEAEs Related to Study Drug	75	56	59	190
Total TEAEs >= Grade 3 Severity	13	22	53	88
Patients n (%):				
Any TEAE	70 (93.3)	77 (88.5)	137 (93.2)	284 (91.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	0.56		
95% CI of the odds ratio	(0.34, 3.11)	(0.22, 1.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.00	0.95		
95% CI of the risk ratio	(0.93, 1.08)	(0.87, 1.04)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.14	-4.69		
95% CI of the absolute risk difference	(-6.82, 7.10)	(-12.53, 3.15)		
p-value	0.9695	0.2148		
p-value of Breslow-Day Test for Homogeneity [2]	0.6572	0.1678		
Any Serious TEAE	10 (13.3)	12 (13.8)	26 (17.7)	48 (15.5)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.72	0.74		
95% CI of the odds ratio	(0.33, 1.58)	(0.35, 1.56)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75	0.78		
95% CI of the risk ratio	(0.38, 1.48)	(0.42, 1.47)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.35	-3.89		
95% CI of the absolute risk difference	(-14.21, 5.51)	(-13.41, 5.62)		
p-value	0.4052	0.4351		
p-value of Breslow-Day Test for Homogeneity [2]	0.7214	0.3123		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Any TEAEs >= Grade 3 Severity	10 (13.3)	14 (16.1)	28 (19.0)	52 (16.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.65	0.82		
95% CI of the odds ratio	(0.30, 1.43)	(0.40, 1.65)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.70	0.84		
95% CI of the risk ratio	(0.36, 1.36)	(0.47, 1.52)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.71	-2.96		
95% CI of the absolute risk difference	(-15.69, 4.26)	(-12.95, 7.04)		
p-value	0.2850	0.5691		
p-value of Breslow-Day Test for Homogeneity [2]	0.8731	0.5300		
Any TEAEs <= Grade 2 Severity	69 (92.0)	75 (86.2)	137 (93.2)	281 (90.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.84	0.46		
95% CI of the odds ratio	(0.29, 2.41)	(0.19, 1.11)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.99	0.92		
95% CI of the risk ratio	(0.91, 1.07)	(0.84, 1.02)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.20	-6.99		
95% CI of the absolute risk difference	(-8.56, 6.17)	(-15.30, 1.32)		
p-value	0.7442	0.0766		
p-value of Breslow-Day Test for Homogeneity [2]	0.6361	0.0948		
Any TEAEs leading to Study-Drug Discontinuation	6 (8.0)	7 (8.0)	5 (3.4)	18 (5.8)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.47	2.49		
95% CI of the odds ratio	(0.73, 8.37)	(0.76, 8.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.35	2.37		
95% CI of the risk ratio	(0.74, 7.46)	(0.77, 7.23)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.60	4.64		
95% CI of the absolute risk difference	(-2.20, 11.40)	(-1.78, 11.07)		
p-value	0.1353	0.1195		
p-value of Breslow-Day Test for Homogeneity [2]	0.0521	0.8536		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Any TEAEs leading to Study Discontinuation	2 (2.7)	5 (5.7)	5 (3.4)	12 (3.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	1.73		
95% CI of the odds ratio	(0.15, 4.11)	(0.49, 6.16)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.78	1.69		
95% CI of the risk ratio	(0.16, 3.95)	(0.50, 5.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.73	2.35		
95% CI of the absolute risk difference	(-5.41, 3.94)	(-3.36, 8.05)		
p-value	0.7670	0.3912		
p-value of Breslow-Day Test for Homogeneity [2]	0.4416	0.6484		
Any Fatal TEAEs	0	1 (1.1)	1 (0.7)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.70		
95% CI of the odds ratio	NE	(0.10, 27.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.69		
95% CI of the risk ratio	NE	(0.11, 26.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.68	0.47		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-2.14, 3.07)		
p-value	0.4741	0.7063		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
Any Treatment-related TEAE	31 (41.3)	27 (31.0)	37 (25.2)	95 (30.7)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.09	1.34		
95% CI of the odds ratio	(1.16, 3.78)	(0.74, 2.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.64	1.23		
95% CI of the risk ratio	(1.11, 2.42)	(0.81, 1.88)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	16.16	5.86		
95% CI of the absolute risk difference	(2.99, 29.33)	(-6.12, 17.85)		
p-value	0.0135	0.3307		
p-value of Breslow-Day Test for Homogeneity [2]	0.4465	0.5769		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Any Treatment-related Serious TEAE	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	1 (1.3)	3 (3.4)	1 (0.7)	5 (1.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.97	5.21		
95% CI of the odds ratio	(0.12, 31.99)	(0.53, 50.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.96	5.07		
95% CI of the risk ratio	(0.12, 30.90)	(0.54, 47.98)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.65	2.77		
95% CI of the absolute risk difference	(-2.26, 3.57)	(-1.29, 6.83)		
p-value	0.6262	0.1144		
p-value of Breslow-Day Test for Homogeneity [2]	0.3586	0.2286		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	2 (2.7)	3 (3.4)	1 (0.7)	6 (1.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	4.00	5.21		
95% CI of the odds ratio	(0.36, 44.84)	(0.53, 50.93)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.92	5.07		
95% CI of the risk ratio	(0.36, 42.54)	(0.54, 47.98)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.99	2.77		
95% CI of the absolute risk difference	(-1.89, 5.87)	(-1.29, 6.83)		
p-value	0.2254	0.1144		
p-value of Breslow-Day Test for Homogeneity [2]	0.0380	0.5100		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	2 (2.3)	1 (0.7)	3 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.44		
95% CI of the odds ratio	NE	(0.31, 38.45)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.38		
95% CI of the risk ratio	NE	(0.31, 36.72)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.68	1.62		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-1.80, 5.04)		
p-value	0.4741	0.2875		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.9634		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	16 (21.3)	19 (21.8)	31 (21.1)	66 (21.4)
Grade 2	44 (58.7)	44 (50.6)	78 (53.1)	166 (53.7)
Grade 3	10 (13.3)	13 (14.9)	24 (16.3)	47 (15.2)
Grade 4	0	0	3 (2.0)	3 (1.0)
Grade 5	0	1 (1.1)	1 (0.7)	2 (0.6)

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	19 (25.3)	12 (13.8)	24 (16.3)	55 (17.8)
Grade 2	11 (14.7)	12 (13.8)	12 (8.2)	35 (11.3)
Grade 3	1 (1.3)	3 (3.4)	1 (0.7)	5 (1.6)
Grade 4	0	0	0	0
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	0	1 (1.1)	1 (0.7)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.70		
95% CI of the odds ratio	NE	(0.10, 27.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.69		
95% CI of the risk ratio	NE	(0.11, 26.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.68	0.47		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-2.14, 3.07)		
p-value	0.4741	0.7063		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.1)	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	1.15		
95% CI of the absolute risk difference	NE	(-1.09, 3.39)		
p-value	NE	0.1927		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	0	0	1 (0.7)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.68	-0.68		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-2.01, 0.65)		
p-value	0.4741	0.4407		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
Serious 3-PT MACE AE - Adjudicated Event	0	1 (1.1)	1 (0.7)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.70		
95% CI of the odds ratio	NE	(0.10, 27.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.69		
95% CI of the risk ratio	NE	(0.11, 26.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.68	0.47		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-2.14, 3.07)		
p-value	0.4741	0.7063		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
Other MACE AE - Adjudicated Event	0	1 (1.1)	2 (1.4)	3 (1.0)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.84		
95% CI of the odds ratio	NE	(0.08, 9.44)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	0.84		
95% CI of the risk ratio	NE	(0.08, 9.18)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.36	-0.21		
95% CI of the absolute risk difference	(-3.23, 0.51)	(-3.13, 2.71)		
p-value	0.3102	0.8897		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4308		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	1 (1.1)	1 (0.7)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.70		
95% CI of the odds ratio	NE	(0.10, 27.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.69		
95% CI of the risk ratio	NE	(0.11, 26.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.68	0.47		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-2.14, 3.07)		
p-value	0.4741	0.7063		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3113		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	1 (0.7)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.68	-0.68		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-2.01, 0.65)		
p-value	0.4741	0.4407		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	1 (1.1)	1 (0.7)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.70		
95% CI of the odds ratio	NE	(0.10, 27.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	1.69		
95% CI of the risk ratio	NE	(0.11, 26.67)		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-0.68	0.47		
95% CI of the absolute risk difference	(-2.01, 0.65)	(-2.14, 3.07)		
p-value	0.4741	0.7063		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3113		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75) n (%)	MGL-3196 100 mg (N=87) n (%)	Placebo (N=147) n (%)	Overall (N=309) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Events n:				
Total TEAEs	700	526	1047	2273
Total Serious TEAEs	18	14	41	73
Total TEAEs Leading to Discontinuation of Study Drug	7	9	14	30
Total TEAEs Related to Study Drug	79	70	99	248
Total TEAEs >= Grade 3 Severity	18	22	50	90
Patients n (%):				
Any TEAE	87 (94.6)	61 (95.3)	144 (92.3)	292 (93.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.45	1.69		
95% CI of the odds ratio	(0.49, 4.26)	(0.46, 6.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.02	1.03		
95% CI of the risk ratio	(0.96, 1.10)	(0.96, 1.11)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	2.26	3.00		
95% CI of the absolute risk difference	(-3.98, 8.50)	(-3.65, 9.66)		
p-value	0.4967	0.4219		
p-value of Breslow-Day Test for Homogeneity [2]	0.6572	0.1678		
Any Serious TEAE	6 (6.5)	9 (14.1)	17 (10.9)	32 (10.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57	1.34		
95% CI of the odds ratio	(0.22, 1.50)	(0.56, 3.18)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	1.29		
95% CI of the risk ratio	(0.24, 1.46)	(0.61, 2.74)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.38	3.17		
95% CI of the absolute risk difference	(-11.40, 2.65)	(-6.66, 12.99)		
p-value	0.2512	0.5089		
p-value of Breslow-Day Test for Homogeneity [2]	0.7214	0.3123		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Any TEAEs >= Grade 3 Severity	9 (9.8)	11 (17.2)	24 (15.4)	44 (14.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.60	1.14		
95% CI of the odds ratio	(0.26, 1.35)	(0.52, 2.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.64	1.12		
95% CI of the risk ratio	(0.31, 1.31)	(0.58, 2.14)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-5.60	1.80		
95% CI of the absolute risk difference	(-13.90, 2.70)	(-9.04, 12.64)		
p-value	0.2096	0.7398		
p-value of Breslow-Day Test for Homogeneity [2]	0.8731	0.5300		
Any TEAEs <= Grade 2 Severity	86 (93.5)	61 (95.3)	144 (92.3)	291 (93.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.19	1.69		
95% CI of the odds ratio	(0.43, 3.30)	(0.46, 6.22)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.01	1.03		
95% CI of the risk ratio	(0.94, 1.09)	(0.96, 1.11)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.17	3.00		
95% CI of the absolute risk difference	(-5.38, 7.72)	(-3.65, 9.66)		
p-value	0.7314	0.4219		
p-value of Breslow-Day Test for Homogeneity [2]	0.6361	0.0948		
Any TEAEs leading to Study-Drug Discontinuation	3 (3.3)	9 (14.1)	11 (7.1)	23 (7.4)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.44	2.16		
95% CI of the odds ratio	(0.12, 1.64)	(0.85, 5.49)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.46	1.99		
95% CI of the risk ratio	(0.13, 1.61)	(0.87, 4.58)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-3.79	7.01		
95% CI of the absolute risk difference	(-9.20, 1.62)	(-2.41, 16.43)		
p-value	0.2115	0.1004		
p-value of Breslow-Day Test for Homogeneity [2]	0.0521	0.8536		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Any TEAEs leading to Study Discontinuation	1 (1.1)	6 (9.4)	6 (3.8)	13 (4.2)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.27	2.59		
95% CI of the odds ratio	(0.03, 2.32)	(0.80, 8.34)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.28	2.44		
95% CI of the risk ratio	(0.03, 2.31)	(0.82, 7.28)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.76	5.53		
95% CI of the absolute risk difference	(-6.45, 0.93)	(-2.22, 13.28)		
p-value	0.2050	0.1010		
p-value of Breslow-Day Test for Homogeneity [2]	0.4416	0.6484		
Any Fatal TEAEs	1 (1.1)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.09	NE		
95% CI of the absolute risk difference	(-1.03, 3.21)	NE		
p-value	0.1920	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
Any Treatment-related TEAE	38 (41.3)	28 (43.8)	49 (31.4)	115 (36.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.54	1.70		
95% CI of the odds ratio	(0.90, 2.62)	(0.93, 3.09)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.31	1.39		
95% CI of the risk ratio	(0.94, 1.84)	(0.97, 2.00)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.89	12.34		
95% CI of the absolute risk difference	(-2.53, 22.32)	(-1.83, 26.51)		
p-value	0.1148	0.0814		
p-value of Breslow-Day Test for Homogeneity [2]	0.4465	0.5769		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Any Treatment-related Serious TEAE	0	0	1 (0.6)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.64	-0.64		
95% CI of the absolute risk difference	(-1.89, 0.61)	(-1.89, 0.61)		
p-value	0.4416	0.5209		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Any Treatment-related TEAEs >= Grade 3 Severity	0	0	1 (0.6)	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.64	-0.64		
95% CI of the absolute risk difference	(-1.89, 0.61)	(-1.89, 0.61)		
p-value	0.4416	0.5209		
p-value of Breslow-Day Test for Homogeneity [2]	0.3586	0.2286		
Any Treatment-related TEAEs leading to Study-Drug Discontinuation	1 (1.1)	7 (10.9)	8 (5.1)	16 (5.1)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.20	2.27		
95% CI of the odds ratio	(0.03, 1.65)	(0.79, 6.55)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.21	2.13		
95% CI of the risk ratio	(0.03, 1.67)	(0.81, 5.64)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.04	5.81		
95% CI of the absolute risk difference	(-8.10, 0.02)	(-2.58, 14.20)		
p-value	0.1002	0.1205		
p-value of Breslow-Day Test for Homogeneity [2]	0.0380	0.5100		

Program: t-s01-02-01-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Any Treatment-related TEAEs leading to Study Discontinuation	0	5 (7.8)	4 (2.6)	9 (2.9)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.22		
95% CI of the odds ratio	NE	(0.84, 12.41)		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	3.05		
95% CI of the risk ratio	NE	(0.85, 10.98)		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.56	5.25		
95% CI of the absolute risk difference	(-5.04, -0.08)	(-1.78, 12.28)		
p-value	0.1215	0.0743		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.9634		
Any Treatment-related Fatal TEAEs	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Maximum Severity of TEAEs				
Grade 1	22 (23.9)	8 (12.5)	39 (25.0)	69 (22.1)
Grade 2	56 (60.9)	42 (65.6)	81 (51.9)	179 (57.4)
Grade 3	8 (8.7)	11 (17.2)	20 (12.8)	39 (12.5)
Grade 4	0	0	4 (2.6)	4 (1.3)
Grade 5	1 (1.1)	0	0	1 (0.3)

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Maximum Severity of Treatment-related TEAEs				
Grade 1	22 (23.9)	17 (26.6)	28 (17.9)	67 (21.5)
Grade 2	16 (17.4)	11 (17.2)	20 (12.8)	47 (15.1)
Grade 3	0	0	0	0
Grade 4	0	0	1 (0.6)	1 (0.3)
Grade 5	0	0	0	0
3-PT MACE AE – Adjudicated Event [3]	1 (1.1)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	1.09	NE		
95% CI of the absolute risk difference	(-1.03, 3.21)	NE		
p-value	0.1920	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
3-PT MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
3-PT MACE AE - Adjudicated Event <= Grade 2 Severity	1 (1.1)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.09	NE		
95% CI of the absolute risk difference	(-1.03, 3.21)	NE		
p-value	0.1920	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
Serious 3-PT MACE AE - Adjudicated Event	1 (1.1)	0	0	1 (0.3)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.09	NE		
95% CI of the absolute risk difference	(-1.03, 3.21)	NE		
p-value	0.1920	NE		
p-value of Breslow-Day Test for Homogeneity [2]	0.1716	NE		
Other MACE AE - Adjudicated Event	0	0	2 (1.3)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-1.28	-1.28		
95% CI of the absolute risk difference	(-3.05, 0.48)	(-3.05, 0.48)		
p-value	0.2755	0.3628		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.4308		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Other MACE AE – Adjudicated Event >= Grade 3 Severity	0	0	2 (1.3)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.28	-1.28		
95% CI of the absolute risk difference	(-3.05, 0.48)	(-3.05, 0.48)		
p-value	0.2755	0.3628		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3113		
Other MACE AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
Serious Other MACE AE – Adjudicated Event	0	0	2 (1.3)	2 (0.6)
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	-1.28	-1.28		
95% CI of the absolute risk difference	(-3.05, 0.48)	(-3.05, 0.48)		
p-value	0.2755	0.3628		
p-value of Breslow-Day Test for Homogeneity [2]	NE	0.3113		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event >= Grade 3 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		
DILI AE – Adjudicated Event <= Grade 2 Severity	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.14c.1.2
TEAE (S1): Treatment-Emergent Adverse Events Excluding Disease Related Events - Overall Summary
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92) n (%)	MGL-3196 100 mg (N=64) n (%)	Placebo (N=156) n (%)	Overall (N=312) n (%)
Serious DILI AE – Adjudicated Event	0	0	0	0
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the odds ratio	NE	NE		
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE	NE		
95% CI of the risk ratio	NE	NE		
Absolute risk difference, Chi-square, MGL-3196 treatment group – Placebo [1]	NE	NE		
95% CI of the absolute risk difference	NE	NE		
p-value	NE	NE		
p-value of Breslow-Day Test for Homogeneity [2]	NE	NE		

AMNOG Table S1.15.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Abbreviation: TEAE = Treatment-emergent adverse event; NE = Not estimable.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Walds asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only SOCs and PTs that have statistically significant results in table S1.1.3 are presented in this table.

AMNOG Table S1.15.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

System Organ Class Preferred Term	MGL-3196 80 mg (N=75) Patients n (%)	 Events n	MGL-3196 100 mg (N=87) Patients n (%)	 Events n	Placebo (N=147) Patients n (%)	 Events n	Overall (N=309) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	14 (18.7)	26	23 (26.4)	36	18 (12.2)	25	55 (17.8)	87
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.64		2.58					
95% CI of the odds ratio	(0.77, 3.52)		(1.30, 5.11)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.52		2.16					
95% CI of the risk ratio	(0.80, 2.89)		(1.24, 3.77)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	6.42		14.19					
95% CI of the absolute risk difference	(-3.87, 16.71)		(3.52, 24.87)					
p-value	0.1976		0.0058					
p-value of Breslow-Day Test for Homogeneity [2]	0.8870		0.6786					
Nausea	15 (20.0)	16	8 (9.2)	9	16 (10.9)	19	39 (12.6)	44
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.05		0.83					
95% CI of the odds ratio	(0.95, 4.41)		(0.34, 2.03)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.84		0.84					
95% CI of the risk ratio	(0.96, 3.51)		(0.38, 1.89)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	9.12		-1.69					
95% CI of the absolute risk difference	(-1.24, 19.47)		(-9.58, 6.20)					
p-value	0.0638		0.6807					
p-value of Breslow-Day Test for Homogeneity [2]	0.6752		0.3329					

AMNOG Table S1.15.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

System Organ Class Preferred Term	MGL-3196 80 mg (N=75) Patients n (%)	 Events n	MGL-3196 100 mg (N=87) Patients n (%)	 Events n	Placebo (N=147) Patients n (%)	 Events n	Overall (N=309) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	11 (14.7)	13	4 (4.6)	4	9 (6.1)	10	24 (7.8)	27
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.64		0.74					
95% CI of the odds ratio	(1.04, 6.68)		(0.22, 2.48)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.40		0.75					
95% CI of the risk ratio	(1.04, 5.53)		(0.24, 2.37)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.54		-1.52					
95% CI of the absolute risk difference	(-0.35, 17.44)		(-7.39, 4.34)					
p-value	0.0355		0.6226					
p-value of Breslow-Day Test for Homogeneity [2]	0.6934		0.3753					
Abdominal discomfort	1 (1.3)	1	2 (2.3)	3	5 (3.4)	5	8 (2.6)	9
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		0.67					
95% CI of the odds ratio	(0.04, 3.35)		(0.13, 3.52)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.39		0.68					
95% CI of the risk ratio	(0.05, 3.30)		(0.13, 3.41)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.07		-1.10					
95% CI of the absolute risk difference	(-5.98, 1.85)		(-5.40, 3.20)					
p-value	0.3688		0.6323					
p-value of Breslow-Day Test for Homogeneity [2]	0.2033		0.5403					

AMNOG Table S1.15.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

System Organ Class Preferred Term	MGL-3196 80 mg (N=75) Patients n (%)	 Events n	MGL-3196 100 mg (N=87) Patients n (%)	 Events n	Placebo (N=147) Patients n (%)	 Events n	Overall (N=309) Patients n (%)	 Events n
General disorders and administration site conditions	16 (21.3)	23	15 (17.2)	20	45 (30.6)	56	76 (24.6)	99
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.61		0.47					
95% CI of the odds ratio	(0.32, 1.18)		(0.24, 0.91)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.70		0.56					
95% CI of the risk ratio	(0.42, 1.15)		(0.33, 0.95)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-9.28		-13.37					
95% CI of the absolute risk difference	(-21.17, 2.62)		(-24.26, -2.48)					
p-value	0.1430		0.0236					
p-value of Breslow-Day Test for Homogeneity [2]	0.6551		0.2652					
Skin and subcutaneous tissue disorders								
Pruritus	11 (14.7)	15	7 (8.0)	9	17 (11.6)	18	35 (11.3)	42
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.31		0.67					
95% CI of the odds ratio	(0.58, 2.97)		(0.27, 1.68)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.27		0.70					
95% CI of the risk ratio	(0.63, 2.57)		(0.30, 1.61)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	3.10		-3.52					
95% CI of the absolute risk difference	(-6.43, 12.63)		(-11.23, 4.19)					
p-value	0.5102		0.3912					
p-value of Breslow-Day Test for Homogeneity [2]	0.1536		0.6572					

AMNOG Table S1.15.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

System Organ Class Preferred Term	MGL-3196 80 mg (N=75) Patients n (%)	 Events n	MGL-3196 100 mg (N=87) Patients n (%)	 Events n	Placebo (N=147) Patients n (%)	 Events n	Overall (N=309) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	4 (5.3)	4	8 (9.2)	10	6 (4.1)	6	18 (5.8)	20
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.32		2.38					
95% CI of the odds ratio	(0.36, 4.84)		(0.80, 7.10)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.31		2.25					
95% CI of the risk ratio	(0.38, 4.49)		(0.81, 6.28)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	1.25		5.11					
95% CI of the absolute risk difference	(-4.76, 7.26)		(-1.75, 11.98)					
p-value	0.6706		0.1109					
p-value of Breslow-Day Test for Homogeneity [2]	0.8700		0.6077					
Renal and urinary disorders	4 (5.3)	5	12 (13.8)	14	19 (12.9)	25	35 (11.3)	44
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.38		1.08					
95% CI of the odds ratio	(0.12, 1.16)		(0.50, 2.34)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.41		1.07					
95% CI of the risk ratio	(0.15, 1.17)		(0.54, 2.09)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-7.59		0.87					
95% CI of the absolute risk difference	(-15.03, -0.16)		(-8.18, 9.92)					
p-value	0.0792		0.8499					
p-value of Breslow-Day Test for Homogeneity [2]	0.6022		0.1684					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.15.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

System Organ Class Preferred Term	MGL-3196 80 mg (N=75) Patients n (%)	 Events n	MGL-3196 100 mg (N=87) Patients n (%)	 Events n	Placebo (N=147) Patients n (%)	 Events n	Overall (N=309) Patients n (%)	 Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	4 (5.3)	5	0	0	15 (10.2)	16	19 (6.1)	21
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.50		0.05					
95% CI of the odds ratio	(0.16, 1.55)		(0.00, 0.83)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.52		0.05					
95% CI of the risk ratio	(0.18, 1.52)		(0.00, 0.90)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.87		-9.90					
95% CI of the absolute risk difference	(-11.93, 2.19)		(-15.08, -4.73)					
p-value	0.2198		0.0034					
p-value of Breslow-Day Test for Homogeneity [2]	0.9067		0.0068					

AMNOG Table S1.15.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

System Organ Class Preferred Term	MGL-3196 80 mg (N=75) Patients n (%)	 Events n	MGL-3196 100 mg (N=87) Patients n (%)	 Events n	Placebo (N=147) Patients n (%)	 Events n	Overall (N=309) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	0	0	0	0	6 (4.1)	10	6 (1.9)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the odds ratio	NE		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	NE		NE					
95% CI of the risk ratio	NE		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.08		-4.08					
95% CI of the absolute risk difference	(-7.28, -0.88)		(-7.28, -0.88)					
p-value	0.0761		0.0563					
p-value of Breslow-Day Test for Homogeneity [2]	0.1400		NE					

AMNOG Table S1.15.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

System Organ Class Preferred Term	MGL-3196 80 mg (N=92) Patients n (%)	 Events n	MGL-3196 100 mg (N=64) Patients n (%)	 Events n	Placebo (N=156) Patients n (%)	 Events n	Overall (N=312) Patients n (%)	 Events n
Gastrointestinal disorders								
Diarrhoea	28 (30.4)	47	28 (43.8)	44	31 (19.9)	36	87 (27.9)	127
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.76		3.14					
95% CI of the odds ratio	(0.97, 3.19)		(1.67, 5.90)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.53		2.20					
95% CI of the risk ratio	(0.99, 2.38)		(1.45, 3.35)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	10.56		23.88					
95% CI of the absolute risk difference	(-0.73, 21.86)		(10.21, 37.55)					
p-value	0.0591		0.0003					
p-value of Breslow-Day Test for Homogeneity [2]	0.8870		0.6786					
Nausea	28 (30.4)	35	13 (20.3)	17	23 (14.7)	27	64 (20.5)	79
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.53		1.47					
95% CI of the odds ratio	(1.35, 4.74)		(0.69, 3.13)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.06		1.38					
95% CI of the risk ratio	(1.27, 3.36)		(0.75, 2.55)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	15.69		5.57					
95% CI of the absolute risk difference	(4.77, 26.62)		(-5.75, 16.89)					
p-value	0.0031		0.3105					
p-value of Breslow-Day Test for Homogeneity [2]	0.6752		0.3329					

AMNOG Table S1.15.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

System Organ Class Preferred Term	MGL-3196 80 mg (N=92) Patients n (%)	 Events n	MGL-3196 100 mg (N=64) Patients n (%)	 Events n	Placebo (N=156) Patients n (%)	 Events n	Overall (N=312) Patients n (%)	 Events n
Gastrointestinal disorders (cont.)								
Vomiting	9 (9.8)	9	5 (7.8)	5	8 (5.1)	8	22 (7.1)	22
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	2.01		1.57					
95% CI of the odds ratio	(0.75, 5.40)		(0.49, 4.99)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.91		1.52					
95% CI of the risk ratio	(0.76, 4.77)		(0.52, 4.48)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	4.65		2.68					
95% CI of the absolute risk difference	(-2.33, 11.64)		(-4.75, 10.11)					
p-value	0.1611		0.4431					
p-value of Breslow-Day Test for Homogeneity [2]	0.6934		0.3753					
Abdominal discomfort	0	0	1 (1.6)	1	8 (5.1)	9	9 (2.9)	10
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.09		0.29					
95% CI of the odds ratio	(0.01, 1.66)		(0.04, 2.40)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.10		0.30					
95% CI of the risk ratio	(0.01, 1.70)		(0.04, 2.39)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.88		-3.57					
95% CI of the absolute risk difference	(-8.72, -1.04)		(-8.17, 1.04)					
p-value	0.0455		0.2253					
p-value of Breslow-Day Test for Homogeneity [2]	0.2033		0.5403					

AMNOG Table S1.15.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

System Organ Class Preferred Term	MGL-3196 80 mg (N=92) Patients n (%)	 Events n	MGL-3196 100 mg (N=64) Patients n (%)	 Events n	Placebo (N=156) Patients n (%)	 Events n	Overall (N=312) Patients n (%)	 Events n
General disorders and administration site conditions	19 (20.7)	29	14 (21.9)	19	40 (25.6)	48	73 (23.4)	96
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.75		0.81					
95% CI of the odds ratio	(0.41, 1.40)		(0.41, 1.62)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.81		0.85					
95% CI of the risk ratio	(0.50, 1.30)		(0.50, 1.46)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.99		-3.77					
95% CI of the absolute risk difference	(-15.73, 5.75)		(-15.99, 8.46)					
p-value	0.3728		0.5555					
p-value of Breslow-Day Test for Homogeneity [2]	0.6551		0.2652					
Skin and subcutaneous tissue disorders								
Pruritus	11 (12.0)	13	1 (1.6)	1	6 (3.8)	8	18 (5.8)	22
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.40		0.40					
95% CI of the odds ratio	(1.21, 9.52)		(0.05, 3.36)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	3.11		0.41					
95% CI of the risk ratio	(1.19, 8.13)		(0.05, 3.31)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	8.11		-2.28					
95% CI of the absolute risk difference	(0.83, 15.39)		(-6.57, 2.00)					
p-value	0.0146		0.3808					
p-value of Breslow-Day Test for Homogeneity [2]	0.1536		0.6572					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.15.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

System Organ Class Preferred Term	MGL-3196 80 mg (N=92) Patients n (%)	 Events n	MGL-3196 100 mg (N=64) Patients n (%)	 Events n	Placebo (N=156) Patients n (%)	 Events n	Overall (N=312) Patients n (%)	 Events n
Skin and subcutaneous tissue disorders (cont.)								
Rash	4 (4.3)	4	8 (12.5)	10	6 (3.8)	8	18 (5.8)	22
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.14		3.57					
95% CI of the odds ratio	(0.31, 4.14)		(1.19, 10.75)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	1.13		3.25					
95% CI of the risk ratio	(0.33, 3.90)		(1.17, 8.99)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	0.50		8.65					
95% CI of the absolute risk difference	(-4.64, 5.65)		(0.01, 17.30)					
p-value	0.8462		0.0169					
p-value of Breslow-Day Test for Homogeneity [2]	0.8700		0.6077					
Renal and urinary disorders	1 (1.1)	1	8 (12.5)	10	8 (5.1)	8	17 (5.4)	19
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.20		2.64					
95% CI of the odds ratio	(0.03, 1.65)		(0.95, 7.38)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.21		2.44					
95% CI of the risk ratio	(0.03, 1.67)		(0.96, 6.21)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-4.04		7.37					
95% CI of the absolute risk difference	(-8.10, 0.02)		(-1.44, 16.18)					
p-value	0.1002		0.0558					
p-value of Breslow-Day Test for Homogeneity [2]	0.6022		0.1684					

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S1.15.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92)		MGL-3196 100 mg (N=64)		Placebo (N=156)		Overall (N=312)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n
Musculoskeletal and connective tissue disorders								
Pain in extremity	3 (3.3)	3	4 (6.3)	4	9 (5.8)	12	16 (5.1)	19
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.55		1.09					
95% CI of the odds ratio	(0.15, 2.09)		(0.32, 3.67)					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.57		1.08					
95% CI of the risk ratio	(0.16, 2.03)		(0.35, 3.39)					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-2.51		0.48					
95% CI of the absolute risk difference	(-7.66, 2.65)		(-6.49, 7.45)					
p-value	0.3739		0.8908					
p-value of Breslow-Day Test for Homogeneity [2]	0.9067		0.0068					

AMNOG Table S1.15.3

TEAE (S1): Treatment-Emergent Adverse Events Occurring in at Least 10 Patients and at Least 1% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

System Organ Class Preferred Term	MGL-3196 80 mg (N=92) Patients n (%)	 Events n	MGL-3196 100 mg (N=64) Patients n (%)	 Events n	Placebo (N=156) Patients n (%)	 Events n	Overall (N=312) Patients n (%)	 Events n
Injury, poisoning and procedural complications								
Contusion	2 (2.2)	2	0	0	4 (2.6)	4	6 (1.9)	6
Odds ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.84		NE					
95% CI of the odds ratio	(0.15, 4.70)		NE					
Risk ratio, Chi-square, MGL-3196 treatment group / Placebo [1]	0.85		NE					
95% CI of the risk ratio	(0.16, 4.54)		NE					
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [1]	-0.39		-2.56					
95% CI of the absolute risk difference	(-4.27, 3.49)		(-5.04, -0.08)					
p-value	0.8468		0.1961					
p-value of Breslow-Day Test for Homogeneity [2]	0.1400		NE					

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.2.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Age
(Label Population)

Age: < 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=126) Patients n (%)	 Events n	Placebo (N=224) Patients n (%)	 Events n	Overall (N=474) Patients n (%)	 Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.2.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Age
(Label Population)

Age: >= 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=43) Patients n (%)	 Events n	MGL-3196 100 mg (N=25) Patients n (%)	 Events n	Placebo (N=79) Patients n (%)	 Events n	Overall (N=147) Patients n (%)	 Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.3.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Sex
(Label Population)

Sex: Male

System Organ Class Preferred Term	MGL-3196 80 mg (N=43) Patients n (%)	 Events n	MGL-3196 100 mg (N=86) Patients n (%)	 Events n	Placebo (N=132) Patients n (%)	 Events n	Overall (N=261) Patients n (%)	 Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.3.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Sex
(Label Population)

Sex: Female

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=65) Patients n (%)	 Events n	Placebo (N=171) Patients n (%)	 Events n	Overall (N=360) Patients n (%)	 Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.4.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Region
(Label Population)

Region: US

System Organ Class Preferred Term	MGL-3196 80 mg (N=94)		MGL-3196 100 mg (N=119)		Placebo (N=198)		Overall (N=411)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.4.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Region
(Label Population)

Region: Ex-US

System Organ Class Preferred Term	MGL-3196 80 mg (N=73) Patients n (%)	 Events n	MGL-3196 100 mg (N=32) Patients n (%)	 Events n	Placebo (N=105) Patients n (%)	 Events n	Overall (N=210) Patients n (%)	 Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.5.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Weight
(Label Population)

Weight: > 200 lbs

System Organ Class Preferred Term	MGL-3196 80 mg (N=52) Patients n (%)	 Events n	MGL-3196 100 mg (N=151) Patients n (%)	 Events n	Placebo (N=186) Patients n (%)	 Events n	Overall (N=389) Patients n (%)	 Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.5.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Weight
(Label Population)

Weight: <= 200 lbs

System Organ Class Preferred Term	MGL-3196 80 mg (N=115) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=117) Patients n (%)	 Events n	Overall (N=232) Patients n (%)	 Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.6.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by BMI
(Label Population)

BMI: <25 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=7) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=8) Patients n (%)	 Events n	Overall (N=15) Patients n (%)	 Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.6.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=47) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=62) Patients n (%)	 Events n	Overall (N=109) Patients n (%)	 Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.6.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by BMI
(Label Population)

BMI: >= 30 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=113)		MGL-3196 100 mg (N=151)		Placebo (N=233)		Overall (N=497)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.7.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118)		MGL-3196 100 mg (N=100)		Placebo (N=201)		Overall (N=419)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.7.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49)		MGL-3196 100 mg (N=51)		Placebo (N=102)		Overall (N=202)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.8.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

	MGL-3196 80 mg (N=64)		MGL-3196 100 mg (N=53)		Placebo (N=111)		Overall (N=228)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test.Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.8.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

	MGL-3196 80 mg (N=103)		MGL-3196 100 mg (N=98)		Placebo (N=192)		Overall (N=393)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test.Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.9.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27)		MGL-3196 100 mg (N=22)		Placebo (N=39)		Overall (N=88)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.9.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140)		MGL-3196 100 mg (N=129)		Placebo (N=264)		Overall (N=533)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.10.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19)		MGL-3196 100 mg (N=16)		Placebo (N=43)		Overall (N=78)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.10.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

	MGL-3196 80 mg (N=148)		MGL-3196 100 mg (N=135)		Placebo (N=260)		Overall (N=543)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.11.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30)		MGL-3196 100 mg (N=31)		Placebo (N=35)		Overall (N=96)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.11.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

System Organ Class Preferred Term	MGL-3196 80 mg (N=12) Patients n (%)	 Events n	MGL-3196 100 mg (N=8) Patients n (%)	 Events n	Placebo (N=13) Patients n (%)	 Events n	Overall (N=33) Patients n (%)	 Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.11.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

System Organ Class Preferred Term	MGL-3196 80 mg (N=111) Patients n (%)	 Events n	MGL-3196 100 mg (N=87) Patients n (%)	 Events n	Placebo (N=221) Patients n (%)	 Events n	Overall (N=419) Patients n (%)	 Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.12.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91)		MGL-3196 100 mg (N=67)		Placebo (N=0)		Overall (N=158)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CFB = Change from Baseline; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.12.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61)		MGL-3196 100 mg (N=57)		Placebo (N=266)		Overall (N=384)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CFB = Change from Baseline; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 1 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.13.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76)		MGL-3196 100 mg (N=75)		Placebo (N=30)		Overall (N=181)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CFB = Change from Baseline; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.13.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=42) Patients n (%)	 Events n	MGL-3196 100 mg (N=25) Patients n (%)	 Events n	Placebo (N=179) Patients n (%)	 Events n	Overall (N=246) Patients n (%)	 Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CFB = Change from Baseline; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.14a.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48)		MGL-3196 100 mg (N=44)		Placebo (N=95)		Overall (N=187)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.14a.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77)		MGL-3196 100 mg (N=72)		Placebo (N=128)		Overall (N=277)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events; SNP = Single Nucleotide Polymorphism.

Note: Adverse events are coded using MedDRA version 25.0.

Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).

Note: Percentages are based on the number of patients in the label population.

[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.14a.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30)		MGL-3196 100 mg (N=22)		Placebo (N=63)		Overall (N=115)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.14b.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124)		MGL-3196 100 mg (N=112)		Placebo (N=223)		Overall (N=459)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events; SNP = Single Nucleotide Polymorphism.

Note: Adverse events are coded using MedDRA version 25.0.

Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).

Note: Percentages are based on the number of patients in the label population.

[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.14b.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26)		MGL-3196 100 mg (N=24)		Placebo (N=62)		Overall (N=112)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events; SNP = Single Nucleotide Polymorphism.

Note: Adverse events are coded using MedDRA version 25.0.

Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).

Note: Percentages are based on the number of patients in the label population.

[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.14b.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5)		MGL-3196 100 mg (N=2)		Placebo (N=1)		Overall (N=8)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events; SNP = Single Nucleotide Polymorphism.

Note: Adverse events are coded using MedDRA version 25.0.

Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).

Note: Percentages are based on the number of patients in the label population.

[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.14c.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53)		MGL-3196 100 mg (N=45)		Placebo (N=90)		Overall (N=188)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.14c.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72)		MGL-3196 100 mg (N=65)		Placebo (N=139)		Overall (N=276)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.14c.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30)		MGL-3196 100 mg (N=28)		Placebo (N=57)		Overall (N=115)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events; SNP = Single Nucleotide Polymorphism.

Note: Adverse events are coded using MedDRA version 25.0.

Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).

Note: Percentages are based on the number of patients in the label population.

[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.

[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.

Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.15.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

System Organ Class Preferred Term	MGL-3196 80 mg (N=75) Patients n (%)	 Events n	MGL-3196 100 mg (N=87) Patients n (%)	 Events n	Placebo (N=147) Patients n (%)	 Events n	Overall (N=309) Patients n (%)	 Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S2.15.1

TEAE (S2): Treatment-Emergent Adverse Events of CTCAE Grade >= 3 Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class, Preferred Term and Maximum CTCAE Grade;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

System Organ Class Preferred Term	MGL-3196 80 mg (N=92) Patients n (%)	 Events n	MGL-3196 100 mg (N=64) Patients n (%)	 Events n	Placebo (N=156) Patients n (%)	 Events n	Overall (N=312) Patients n (%)	 Events n

Not enough data to perform this subgroup analysis.

Abbreviation: TEAE = Treatment-emergent adverse event; CTCAE = Common Terminology Criteria for Adverse Events.
Note: Adverse events are coded using MedDRA version 25.0.
Note: A TEAE is defined as any AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT) at the maximum CTCAE grade. TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency. If the CTCAE grade is missing for an AE, the event is assumed to have the maximum CTCAE grade (i.e., Grade 5).
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio (MGL-3196 treatment group / Placebo), risk ratio (MGL-3196 treatment group / Placebo), absolute risk difference (MGL-3196 treatment group - Placebo), 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.2.1
SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Age
(Label Population)

Age: < 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=124) Patients n (%)	 Events n	MGL-3196 100 mg (N=126) Patients n (%)	 Events n	Placebo (N=224) Patients n (%)	 Events n	Overall (N=474) Patients n (%)	 Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.2.1
SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Age
(Label Population)

Age: >= 65 years

System Organ Class Preferred Term	MGL-3196 80 mg (N=43) Patients n (%)	 Events n	MGL-3196 100 mg (N=25) Patients n (%)	 Events n	Placebo (N=79) Patients n (%)	 Events n	Overall (N=147) Patients n (%)	 Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.3.1
SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Sex
(Label Population)

Sex: Male

	MGL-3196 80 mg (N=43)		MGL-3196 100 mg (N=86)		Placebo (N=132)		Overall (N=261)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.3.1
SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Sex
(Label Population)

Sex: Female

System Organ Class Preferred Term	MGL-3196 80 mg (N=124)		MGL-3196 100 mg (N=65)		Placebo (N=171)		Overall (N=360)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.4.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Region: US

System Organ Class Preferred Term	MGL-3196 80 mg (N=94)		MGL-3196 100 mg (N=119)		Placebo (N=198)		Overall (N=411)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.4.1
SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Region
(Label Population)

Region: Ex-US

System Organ Class Preferred Term	MGL-3196 80 mg (N=73) Patients n (%)	 Events n	MGL-3196 100 mg (N=32) Patients n (%)	 Events n	Placebo (N=105) Patients n (%)	 Events n	Overall (N=210) Patients n (%)	 Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.5.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight
(Label Population)

Weight: > 200 lbs

System Organ Class Preferred Term	MGL-3196 80 mg (N=52) Patients n (%)	 Events n	MGL-3196 100 mg (N=151) Patients n (%)	 Events n	Placebo (N=186) Patients n (%)	 Events n	Overall (N=389) Patients n (%)	 Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.5.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight
(Label Population)

Weight: <= 200 lbs

System Organ Class Preferred Term	MGL-3196 80 mg (N=115) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=117) Patients n (%)	 Events n	Overall (N=232) Patients n (%)	 Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.6.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: <25 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=7) Patients n (%)	 Events n	MGL-3196 100 mg (N=0) Patients n (%)	 Events n	Placebo (N=8) Patients n (%)	 Events n	Overall (N=15) Patients n (%)	 Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S4.6.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

	MGL-3196 80 mg (N=47)		MGL-3196 100 mg (N=0)		Placebo (N=62)		Overall (N=109)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.6.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by BMI
(Label Population)

BMI: >= 30 kg/m2

System Organ Class Preferred Term	MGL-3196 80 mg (N=113) Patients n (%)	 Events n	MGL-3196 100 mg (N=151) Patients n (%)	 Events n	Placebo (N=233) Patients n (%)	 Events n	Overall (N=497) Patients n (%)	 Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.7.1
SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

	MGL-3196 80 mg (N=118)		MGL-3196 100 mg (N=100)		Placebo (N=201)		Overall (N=419)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.7.1
SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

	MGL-3196 80 mg (N=49)		MGL-3196 100 mg (N=51)		Placebo (N=102)		Overall (N=202)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.8.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

System Organ Class Preferred Term	MGL-3196 80 mg (N=64)		MGL-3196 100 mg (N=53)		Placebo (N=111)		Overall (N=228)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S4.8.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

System Organ Class Preferred Term	MGL-3196 80 mg (N=103)		MGL-3196 100 mg (N=98)		Placebo (N=192)		Overall (N=393)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.9.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

	MGL-3196 80 mg (N=27)		MGL-3196 100 mg (N=22)		Placebo (N=39)		Overall (N=88)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S4.9.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

	MGL-3196 80 mg (N=140)		MGL-3196 100 mg (N=129)		Placebo (N=264)		Overall (N=533)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.10.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

	MGL-3196 80 mg (N=19)		MGL-3196 100 mg (N=16)		Placebo (N=43)		Overall (N=78)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.10.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

System Organ Class Preferred Term	MGL-3196 80 mg (N=148)		MGL-3196 100 mg (N=135)		Placebo (N=260)		Overall (N=543)	
	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.11.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

	MGL-3196 80 mg (N=30)		MGL-3196 100 mg (N=31)		Placebo (N=35)		Overall (N=96)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S4.11.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

	MGL-3196 80 mg (N=12)		MGL-3196 100 mg (N=8)		Placebo (N=13)		Overall (N=33)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.11.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

	MGL-3196 80 mg (N=111)		MGL-3196 100 mg (N=87)		Placebo (N=221)		Overall (N=419)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.12.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

	MGL-3196 80 mg (N=91)		MGL-3196 100 mg (N=67)		Placebo (N=0)		Overall (N=158)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; CFB = Change from Baseline.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S4.12.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

	MGL-3196 80 mg (N=61)		MGL-3196 100 mg (N=57)		Placebo (N=266)		Overall (N=384)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; CFB = Change from Baseline.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.13.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

	MGL-3196 80 mg (N=76)		MGL-3196 100 mg (N=75)		Placebo (N=30)		Overall (N=181)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; CFB = Change from Baseline.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S4.13.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

System Organ Class Preferred Term	MGL-3196 80 mg (N=42) Patients n (%)	 Events n	MGL-3196 100 mg (N=25) Patients n (%)	 Events n	Placebo (N=179) Patients n (%)	 Events n	Overall (N=246) Patients n (%)	 Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; CFB = Change from Baseline.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.14a.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

	MGL-3196 80 mg (N=48)		MGL-3196 100 mg (N=44)		Placebo (N=95)		Overall (N=187)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S4.14a.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

	MGL-3196 80 mg (N=77)		MGL-3196 100 mg (N=72)		Placebo (N=128)		Overall (N=277)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.14a.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

	MGL-3196 80 mg (N=30)		MGL-3196 100 mg (N=22)		Placebo (N=63)		Overall (N=115)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.14b.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

	MGL-3196 80 mg (N=124)		MGL-3196 100 mg (N=112)		Placebo (N=223)		Overall (N=459)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S4.14b.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

	MGL-3196 80 mg (N=26)		MGL-3196 100 mg (N=24)		Placebo (N=62)		Overall (N=112)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S4.14b.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

	MGL-3196 80 mg (N=5)		MGL-3196 100 mg (N=2)		Placebo (N=1)		Overall (N=8)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.14c.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

	MGL-3196 80 mg (N=53)		MGL-3196 100 mg (N=45)		Placebo (N=90)		Overall (N=188)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table S4.14c.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

	MGL-3196 80 mg (N=72)		MGL-3196 100 mg (N=65)		Placebo (N=139)		Overall (N=276)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.14c.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

	MGL-3196 80 mg (N=30)		MGL-3196 100 mg (N=28)		Placebo (N=57)		Overall (N=115)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event; SNP = Single Nucleotide Polymorphism.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.15.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

	MGL-3196 80 mg (N=75)		MGL-3196 100 mg (N=87)		Placebo (N=147)		Overall (N=309)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table S4.15.1

SE-TEAE (S4): Serious Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any Study Arm - by System Organ Class and Preferred Term;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

	MGL-3196 80 mg (N=92)		MGL-3196 100 mg (N=64)		Placebo (N=156)		Overall (N=312)	
System Organ Class Preferred Term	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n	Patients n (%)	Events n

Results for the overall population are not statistically significant.

Abbreviation: SE-TEAE = Serious treatment-emergent adverse event.
Note: Adverse events are coded using MedDRA version 25.0.
Note: An SE-TEAE is defined as any serious AE with onset on or after the first dose of study medication and within 30 days of the last dose of study medication (and, if applicable, prior to the first dose of open label treatment). Patients are counted only once within each system organ class (SOC) and preferred term (PT). SE-TEAEs are presented by decreasing frequency of SOC and, within SOC, PTs are sorted by decreasing frequency.
Note: Percentages are based on the number of patients in the label population.
[1] The odds ratio, risk ratio, absolute risk difference, 95% CIs, and p-values were obtained from chi-square test. Wald's asymptotic 95% CIs are reported. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[2] The Breslow-Day Test for homogeneity of treatment effect was performed based on the risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-s01-02-02-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Total LDQOL						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	76.09 (15.35)	75.93 (14.89)	77.10 (14.58)			
Median	78.30	79.75	81.00			
IQR: Q1, Q3	68.10, 88.05	66.05, 86.85	68.55, 88.10			
Min, Max	28.3, 96.7	23.6, 96.3	34.8, 97.8			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	76.86 (15.99)	76.66 (12.99)	78.23 (14.24)	0.97 (0.92)	0.54 (0.79)	0.55 (0.69)
Median	80.00	78.10	82.10	0.95	0.10	0.40
IQR: Q1, Q3	68.90, 89.70	69.40, 86.30	69.20, 89.00	-5.00, 6.90	-5.55, 5.25	-3.30, 5.00
Min, Max	22.9, 97.8	32.4, 96.9	22.4, 98.3	-23.4, 35.6	-15.4, 27.0	-46.4, 29.7
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	78.58 (13.96)	77.51 (14.58)	77.94 (15.27)	1.70 (0.97)	0.60 (0.99)	0.15 (0.76)
Median	82.95	79.80	81.70	1.30	0.45	0.50
IQR: Q1, Q3	69.40, 89.00	68.40, 89.80	70.40, 89.20	-3.60, 6.70	-4.80, 5.90	-4.30, 5.20
Min, Max	34.0, 97.5	33.8, 97.4	20.3, 100.0	-19.5, 36.0	-23.3, 33.9	-46.3, 24.9

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Symptoms of Liver Disease						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	76.69 (20.43)	75.23 (18.77)	75.76 (18.44)			
Median	83.30	80.00	80.00			
IQR: Q1, Q3	68.35, 93.30	63.30, 90.00	63.30, 90.00			
Min, Max	13.3, 100.0	10.0, 100.0	20.0, 100.0			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	75.88 (21.65)	73.87 (18.30)	76.58 (20.26)	-1.03 (1.40)	-1.49 (1.20)	0.11 (1.01)
Median	83.30	76.70	83.30	0	0	0
IQR: Q1, Q3	66.70, 90.00	63.30, 86.70	63.30, 93.30	-6.70, 6.60	-10.00, 5.70	-6.70, 6.70
Min, Max	0.0, 100.0	26.7, 100.0	16.7, 100.0	-46.7, 36.7	-36.6, 30.0	-53.3, 43.3
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	76.87 (20.34)	76.29 (18.83)	77.07 (19.90)	-1.93 (1.37)	0.40 (1.43)	0.46 (1.04)
Median	83.30	80.00	83.30	0	0	0
IQR: Q1, Q3	66.70, 93.30	66.70, 93.30	66.70, 93.30	-6.70, 6.60	-6.70, 6.70	-6.70, 6.70
Min, Max	6.7, 100.0	26.7, 100.0	16.7, 100.0	-43.4, 43.4	-36.7, 36.7	-60.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Effects of Liver Disease						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	76.79 (15.54)	77.82 (15.12)	76.89 (15.38)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	76.65, 80.00	76.65, 86.70	73.30, 80.00			
Min, Max	6.7, 100.0	13.3, 100.0	6.7, 100.0			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	74.84 (16.28)	78.53 (10.40)	77.42 (14.54)	-2.18 (1.18)	0.40 (1.44)	-0.11 (1.03)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	73.30, 80.00	73.30, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 6.60
Min, Max	0.0, 100.0	40.0, 100.0	6.7, 100.0	-40.0, 33.3	-33.3, 76.7	-46.7, 53.4
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	76.12 (14.38)	78.08 (12.13)	76.84 (14.70)	-1.08 (1.52)	0.00 (1.38)	-0.69 (1.49)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	73.30, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 6.60
Min, Max	6.7, 100.0	20.0, 100.0	13.3, 100.0	-40.0, 80.0	-33.3, 53.4	-80.0, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Concentration/Memory						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	78.79 (25.00)	78.14 (21.17)	77.76 (21.88)			
Median	84.40	81.30	87.50			
IQR: Q1, Q3	68.80, 100.00	62.50, 100.00	62.50, 93.80			
Min, Max	6.3, 100.0	18.8, 100.0	6.3, 100.0			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	76.86 (24.57)	79.26 (19.74)	79.42 (22.23)	-1.65 (1.49)	0.29 (1.44)	0.60 (1.14)
Median	87.50	81.30	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	68.80, 100.00	68.80, 100.00	-6.30, 6.20	-6.30, 6.30	-6.20, 6.30
Min, Max	0.0, 100.0	25.0, 100.0	6.3, 100.0	-43.8, 31.2	-37.5, 56.2	-81.2, 62.5
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	78.34 (21.85)	78.95 (20.75)	78.62 (23.18)	0.07 (1.58)	-1.39 (1.59)	-0.34 (1.10)
Median	81.30	81.30	87.50	0	0	0
IQR: Q1, Q3	68.80, 100.00	62.50, 100.00	68.80, 100.00	-6.20, 6.20	-6.30, 6.30	-6.30, 6.30
Min, Max	0.0, 100.0	18.8, 100.0	0.0, 100.0	-43.7, 50.0	-43.8, 50.0	-43.8, 43.8

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Health Distress						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	76.08 (27.51)	78.88 (26.40)	79.93 (25.38)			
Median	87.50	87.50	87.50			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	80.98 (24.85)	85.54 (21.11)	84.92 (23.58)	5.45 (2.06)	6.71 (1.79)	4.55 (1.43)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 18.75	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 75.0	-37.5, 50.0	-62.5, 75.0
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	80.61 (25.83)	85.70 (21.72)	85.31 (22.49)	4.57 (2.59)	5.32 (2.18)	3.48 (1.69)
Median	93.75	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-75.0, 75.0	-50.0, 75.0	-87.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Sexual Function						
Baseline						
m	124	126	224			
n	55	68	99			
Mean (SD)	79.60 (25.94)	79.14 (23.26)	79.12 (25.07)			
Median	93.30	85.00	86.70			
IQR: Q1, Q3	68.30, 100.00	63.30, 100.00	68.30, 100.00			
Min, Max	-1.7, 100.0	-1.7, 100.0	-1.7, 100.0			
Week 24						
m	119	119	214			
n	55	72	101	45	55	78
Mean (SD/SE)	78.40 (24.78)	73.65 (28.11)	78.14 (24.34)	-1.24 (3.62)	-4.97 (2.90)	-0.23 (2.20)
Median	85.00	82.50	85.00	0	0	0
IQR: Q1, Q3	61.70, 100.00	55.00, 100.00	63.30, 100.00	-8.30, 6.70	-16.60, 1.70	-8.30, 6.70
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-85.0, 63.3	-55.0, 46.7	-48.4, 50.0
Week 52						
m	108	107	201			
n	41	53	84	37	44	66
Mean (SD/SE)	86.27 (17.93)	76.39 (29.20)	76.45 (27.26)	3.84 (3.22)	-3.23 (3.22)	-0.82 (2.70)
Median	93.30	91.70	89.20	0	0	0
IQR: Q1, Q3	78.30, 100.00	55.00, 100.00	58.35, 100.00	-1.70, 6.70	-14.15, 4.15	-8.40, 6.70
Min, Max	28.3, 100.0	-1.7, 100.0	-1.7, 100.0	-45.0, 61.7	-50.0, 61.7	-53.3, 65.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Sleep						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	61.72 (22.09)	58.62 (20.61)	60.86 (20.49)			
Median	65.00	60.00	60.00			
IQR: Q1, Q3	45.00, 80.00	45.00, 75.00	45.00, 75.00			
Min, Max	0.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	63.26 (21.84)	57.57 (20.97)	61.66 (20.31)	1.68 (1.59)	-0.79 (1.40)	0.38 (1.17)
Median	65.00	60.00	60.00	0	0	0
IQR: Q1, Q3	50.00, 80.00	40.00, 75.00	50.00, 75.00	-5.00, 10.00	-10.00, 7.50	-10.00, 10.00
Min, Max	5.0, 100.0	0.0, 100.0	15.0, 100.0	-30.0, 90.0	-35.0, 45.0	-40.0, 45.0
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	64.76 (20.13)	59.07 (22.22)	62.20 (21.00)	1.63 (1.81)	-0.27 (1.82)	1.40 (1.33)
Median	65.00	65.00	60.00	0	0	0
IQR: Q1, Q3	50.00, 80.00	40.00, 75.00	45.00, 80.00	-10.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	10.0, 100.0	0.0, 95.0	5.0, 100.0	-40.0, 75.0	-60.0, 45.0	-40.0, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Loneliness						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	82.89 (18.69)	82.46 (20.46)	83.40 (19.17)			
Median	90.00	90.00	90.00			
IQR: Q1, Q3	72.50, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	10.0, 100.0			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	81.63 (19.65)	83.87 (19.44)	82.69 (20.47)	-0.93 (1.70)	0.56 (1.35)	-1.59 (1.21)
Median	90.00	90.00	90.00	0	0	0
IQR: Q1, Q3	70.00, 100.00	75.00, 100.00	75.00, 100.00	-10.00, 10.00	-5.00, 5.00	-10.00, 5.00
Min, Max	15.0, 100.0	0.0, 100.0	20.0, 100.0	-50.0, 45.0	-35.0, 65.0	-80.0, 45.0
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	84.85 (18.25)	82.73 (21.40)	83.19 (20.10)	1.77 (1.77)	0.05 (1.59)	-0.98 (1.23)
Median	95.00	90.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	-5.00, 5.00	-10.00, 10.00	-5.00, 5.00
Min, Max	25.0, 100.0	0.0, 100.0	5.0, 100.0	-60.0, 50.0	-40.0, 35.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Hopelessness						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	74.14 (22.99)	76.15 (22.90)	79.73 (21.46)			
Median	75.00	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	66.70, 100.00			
Min, Max	8.3, 100.0	8.3, 100.0	16.7, 100.0			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	76.09 (23.69)	77.39 (22.48)	79.55 (21.27)	2.80 (1.85)	1.39 (1.69)	-1.09 (1.35)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	66.70, 100.00	-8.30, 16.70	-8.30, 12.50	-8.30, 8.30
Min, Max	8.3, 100.0	8.3, 100.0	16.7, 100.0	-58.3, 50.0	-41.7, 50.0	-66.6, 50.0
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	78.06 (21.18)	77.50 (22.73)	78.44 (22.68)	2.51 (2.03)	0.81 (2.27)	-2.73 (1.48)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	66.70, 100.00	58.30, 100.00	-8.30, 16.60	-16.60, 16.70	-8.30, 8.30
Min, Max	16.7, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 41.7	-58.3, 50.0	-100.0, 33.4

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Stigma of Liver Disease						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	80.35 (23.09)	79.65 (20.57)	82.77 (19.25)			
Median	87.50	81.30	87.50			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	84.80 (19.95)	79.53 (20.33)	84.59 (18.39)	4.21 (1.71)	0.41 (1.46)	1.64 (1.24)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	68.80, 100.00	81.30, 100.00	-6.20, 12.50	-6.30, 6.20	-6.20, 6.30
Min, Max	6.3, 100.0	12.5, 100.0	6.3, 100.0	-43.8, 56.2	-31.3, 56.3	-62.5, 75.0
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	86.50 (17.59)	83.25 (19.70)	84.27 (18.98)	4.51 (1.40)	2.71 (1.76)	2.09 (1.26)
Median	93.80	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	68.80, 100.00	75.00, 100.00	0.00, 6.30	-6.20, 12.50	-6.20, 12.50
Min, Max	31.3, 100.0	12.5, 100.0	25.0, 100.0	-31.3, 56.2	-56.2, 56.3	-56.3, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Total LDQOL						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	81.28 (10.45)	81.94 (11.45)	80.16 (11.71)			
Median	84.10	84.60	82.40			
IQR: Q1, Q3	74.00, 88.90	77.30, 89.30	76.00, 88.70			
Min, Max	54.8, 94.4	45.3, 95.4	43.1, 97.8			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	81.52 (10.34)	82.68 (9.20)	79.76 (13.90)	0.31 (0.94)	0.96 (1.59)	1.05 (1.31)
Median	85.50	83.90	82.90	0.50	0.35	0.25
IQR: Q1, Q3	74.60, 90.10	77.90, 88.50	73.10, 90.15	-4.10, 4.00	-2.10, 4.70	-3.70, 4.20
Min, Max	53.0, 96.1	60.3, 95.2	42.2, 98.8	-10.5, 15.0	-13.9, 15.0	-27.7, 42.3
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	80.62 (11.77)	82.24 (9.52)	81.46 (10.57)	-0.47 (1.19)	0.90 (1.74)	1.59 (1.19)
Median	83.90	84.80	82.30	0.50	-1.20	0.60
IQR: Q1, Q3	72.40, 90.00	80.50, 89.50	74.80, 89.80	-3.80, 5.20	-3.90, 6.10	-2.40, 5.30
Min, Max	50.0, 97.5	59.8, 92.4	60.5, 97.8	-18.9, 12.6	-8.6, 14.5	-14.3, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Symptoms of Liver Disease						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	80.16 (16.20)	73.49 (19.12)	78.83 (16.02)			
Median	83.30	73.30	83.30			
IQR: Q1, Q3	73.30, 93.30	56.70, 90.00	66.70, 93.30			
Min, Max	30.0, 100.0	30.0, 100.0	40.0, 100.0			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	77.62 (15.95)	75.40 (17.04)	79.61 (15.71)	-2.28 (1.78)	2.96 (2.35)	0.33 (1.63)
Median	81.65	73.30	81.65	0	1.65	0
IQR: Q1, Q3	66.70, 90.00	66.70, 93.30	71.65, 93.30	-10.00, 3.40	-3.30, 10.00	-6.60, 6.70
Min, Max	36.7, 100.0	43.3, 100.0	33.3, 100.0	-23.3, 30.0	-16.7, 26.7	-30.0, 36.7
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	78.42 (16.48)	78.04 (15.55)	80.21 (16.16)	-1.98 (1.86)	3.99 (3.04)	1.04 (1.49)
Median	83.30	80.00	83.30	0	3.30	0
IQR: Q1, Q3	66.70, 90.00	66.70, 90.00	66.70, 93.30	-10.00, 3.40	-3.40, 13.40	-6.60, 6.60
Min, Max	40.0, 100.0	43.3, 96.7	43.3, 100.0	-33.3, 20.0	-20.0, 20.0	-26.7, 26.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Effects of Liver Disease						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	79.85 (8.13)	82.42 (15.05)	78.62 (13.89)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	73.30, 93.30	80.00, 86.70			
Min, Max	60.0, 100.0	40.0, 100.0	26.7, 100.0			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	79.05 (8.66)	83.18 (10.68)	77.26 (16.22)	-0.98 (1.64)	1.12 (4.39)	-0.11 (2.07)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 86.70	80.00, 86.70	-6.70, 6.60	-6.70, 0.00	-6.70, 6.70
Min, Max	46.7, 100.0	53.3, 100.0	6.7, 100.0	-40.0, 20.0	-20.0, 60.0	-46.7, 46.7
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	77.81 (10.17)	76.67 (14.43)	80.27 (9.09)	-1.89 (1.73)	-3.77 (3.57)	1.09 (1.52)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	80.00, 86.70	-6.60, 0.00	-13.30, 0.00	-6.60, 6.60
Min, Max	40.0, 100.0	26.7, 100.0	53.3, 100.0	-33.3, 20.0	-33.3, 30.0	-40.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Concentration/Memory						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	84.39 (16.58)	82.98 (17.48)	81.01 (17.28)			
Median	87.50	87.50	87.50			
IQR: Q1, Q3	75.00, 93.80	75.00, 93.80	68.80, 93.80			
Min, Max	37.5, 100.0	37.5, 100.0	31.3, 100.0			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	83.35 (14.85)	85.43 (18.15)	80.90 (20.05)	-1.07 (2.16)	1.38 (3.45)	0.81 (2.18)
Median	87.50	93.80	87.50	0	0	0
IQR: Q1, Q3	75.00, 93.80	75.00, 100.00	71.90, 100.00	-6.30, 6.30	0.00, 6.20	-6.20, 6.20
Min, Max	50.0, 100.0	25.0, 100.0	12.5, 100.0	-43.8, 25.0	-25.0, 37.5	-50.0, 62.5
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	80.94 (15.31)	83.11 (17.92)	80.26 (17.31)	-2.87 (1.65)	-0.84 (2.51)	-1.07 (1.93)
Median	81.30	87.50	81.30	0	0	0
IQR: Q1, Q3	68.80, 93.80	81.30, 93.80	68.80, 93.80	-6.30, 0.00	-6.30, 0.00	-6.30, 6.30
Min, Max	37.5, 100.0	37.5, 100.0	37.5, 100.0	-25.0, 18.8	-12.5, 18.8	-43.7, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Health Distress						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	83.93 (21.44)	92.05 (16.16)	84.38 (19.65)			
Median	100.00	100.00	87.50			
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	50.0, 100.0	25.0, 100.0			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	88.69 (17.64)	94.05 (15.11)	88.24 (15.85)	5.18 (2.83)	2.78 (3.72)	7.06 (2.40)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	100.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 0.00	0.00, 12.50
Min, Max	37.5, 100.0	50.0, 100.0	37.5, 100.0	-37.5, 50.0	-37.5, 37.5	-25.0, 62.5
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	89.47 (16.83)	94.85 (15.35)	89.31 (15.66)	5.74 (3.38)	5.83 (3.63)	6.47 (2.98)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	100.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	50.0, 100.0	37.5, 100.0	37.5, 100.0	-25.0, 75.0	-12.5, 37.5	-62.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Sexual Function						
Baseline						
m	43	25	79			
n	16	4	22			
Mean (SD)	79.30 (28.94)	84.58 (26.57)	81.75 (21.79)			
Median	93.30	96.65	85.85			
IQR: Q1, Q3	76.70, 96.65	69.15, 100.00	76.70, 100.00			
Min, Max	8.9, 100.0	45.0, 100.0	6.7, 100.0			
Week 24						
m	42	22	75			
n	17	5	24	12	4	16
Mean (SD/SE)	86.08 (20.68)	86.66 (22.59)	82.84 (19.35)	12.73 (7.52)	0.43 (0.43)	1.44 (3.23)
Median	93.30	93.30	92.50	6.65	0	0
IQR: Q1, Q3	86.70, 100.00	93.30, 100.00	74.20, 96.65	0.00, 12.45	0.00, 0.85	-3.35, 8.30
Min, Max	23.3, 100.0	46.7, 100.0	30.0, 100.0	-8.3, 91.1	0.0, 1.7	-23.4, 31.7
Week 52						
m	41	18	69			
n	12	4	17	9	3	14
Mean (SD/SE)	80.97 (30.76)	86.65 (22.46)	82.45 (16.86)	5.87 (11.30)	5.00 (2.54)	-3.58 (4.10)
Median	93.30	96.65	85.00	0	6.70	0
IQR: Q1, Q3	77.50, 100.00	73.30, 100.00	70.00, 100.00	-8.30, 6.70	0.00, 8.30	-8.40, 0.00
Min, Max	6.7, 100.0	53.3, 100.0	46.7, 100.0	-23.3, 91.1	0.0, 8.3	-33.4, 25.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Sleep						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	66.07 (16.47)	68.41 (11.69)	68.19 (17.57)			
Median	65.00	70.00	70.00			
IQR: Q1, Q3	55.00, 80.00	65.00, 75.00	55.00, 80.00			
Min, Max	25.0, 90.0	40.0, 85.0	25.0, 100.0			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	64.64 (18.02)	61.19 (16.19)	64.85 (20.44)	-0.85 (2.12)	-6.94 (2.43)	-2.42 (1.89)
Median	70.00	65.00	65.00	0	-10.00	0
IQR: Q1, Q3	50.00, 75.00	50.00, 70.00	50.00, 80.00	-10.00, 5.00	-10.00, 0.00	-10.00, 5.00
Min, Max	25.0, 95.0	25.0, 90.0	20.0, 100.0	-25.0, 55.0	-30.0, 10.0	-30.0, 50.0
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	64.47 (17.93)	62.94 (14.26)	68.15 (19.27)	-2.57 (2.32)	-5.00 (2.29)	-0.69 (1.78)
Median	70.00	65.00	70.00	-5.00	-5.00	0
IQR: Q1, Q3	55.00, 75.00	55.00, 75.00	55.00, 80.00	-10.00, 5.00	-10.00, 0.00	-5.00, 5.00
Min, Max	15.0, 100.0	30.0, 80.0	20.0, 100.0	-30.0, 40.0	-20.0, 10.0	-35.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Loneliness						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	89.29 (14.30)	86.14 (16.69)	85.07 (20.97)			
Median	95.00	95.00	95.00			
IQR: Q1, Q3	80.00, 100.00	75.00, 100.00	80.00, 100.00			
Min, Max	50.0, 100.0	50.0, 100.0	5.0, 100.0			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	88.81 (15.29)	90.95 (17.07)	83.31 (20.85)	-0.73 (1.70)	2.50 (2.15)	-0.81 (2.12)
Median	95.00	100.00	90.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	90.00, 100.00	77.50, 100.00	-5.00, 5.00	0.00, 5.00	-10.00, 5.00
Min, Max	40.0, 100.0	35.0, 100.0	10.0, 100.0	-25.0, 25.0	-20.0, 20.0	-40.0, 70.0
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	85.66 (15.12)	87.35 (17.78)	86.61 (15.60)	-3.24 (1.85)	1.33 (3.86)	2.76 (2.17)
Median	85.00	100.00	92.50	0	0	0
IQR: Q1, Q3	80.00, 100.00	80.00, 100.00	80.00, 100.00	-10.00, 0.00	-15.00, 10.00	-5.00, 10.00
Min, Max	45.0, 100.0	40.0, 100.0	35.0, 100.0	-25.0, 35.0	-20.0, 30.0	-30.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Hopelessness						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	80.36 (21.29)	79.55 (23.26)	77.89 (21.27)			
Median	91.70	91.70	83.30			
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	58.30, 100.00			
Min, Max	41.7, 100.0	33.3, 100.0	25.0, 100.0			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	81.95 (19.73)	80.16 (21.17)	76.96 (22.82)	1.42 (2.71)	3.70 (6.65)	1.89 (2.29)
Median	87.50	83.30	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	66.70, 100.00	58.30, 100.00	-8.30, 8.30	-16.70, 25.00	-8.30, 16.60
Min, Max	33.3, 100.0	33.3, 100.0	33.3, 100.0	-33.4, 33.3	-33.4, 58.4	-33.3, 41.7
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	79.82 (21.97)	82.84 (15.16)	79.04 (21.38)	-0.46 (2.89)	3.89 (5.39)	3.16 (2.27)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	75.00, 91.70	66.70, 100.00	-8.30, 8.30	-8.40, 25.00	-8.30, 16.60
Min, Max	33.3, 100.0	50.0, 100.0	25.0, 100.0	-41.7, 41.6	-25.0, 41.6	-41.7, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Stigma of Liver Disease						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	87.96 (15.82)	90.07 (11.35)	87.17 (18.28)			
Median	93.80	93.80	96.90			
IQR: Q1, Q3	75.00, 100.00	81.30, 100.00	81.30, 100.00			
Min, Max	37.5, 100.0	62.5, 100.0	31.3, 100.0			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	87.36 (17.91)	90.80 (9.18)	87.15 (18.72)	-0.61 (2.68)	0.71 (2.76)	1.41 (1.94)
Median	100.00	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	81.30, 100.00	81.30, 100.00	-6.20, 0.00	-6.20, 0.00	-6.20, 6.20
Min, Max	50.0, 100.0	75.0, 100.0	25.0, 100.0	-43.7, 50.0	-18.7, 25.0	-37.5, 50.0
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	88.66 (17.84)	91.20 (9.11)	87.92 (17.08)	1.68 (2.34)	1.68 (2.06)	0.65 (2.33)
Median	100.00	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	81.30, 100.00	81.30, 100.00	0.00, 6.20	0.00, 0.00	-6.20, 0.00
Min, Max	37.5, 100.0	75.0, 100.0	18.8, 100.0	-25.0, 37.5	-6.2, 25.0	-62.5, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Age
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.2.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Total LDQOL			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	76.25 (15.12)	75.86 (15.03)	77.84 (14.24)
Analysis Visit Mean (SD)	77.23 (15.89)	76.39 (13.13)	78.39 (14.35)
LS Mean of Change from Baseline (SE)	0.95 (0.85)	0.19 (0.84)	0.76 (0.64)
95% CI	(-0.72, 2.62)	(-1.47, 1.85)	(-0.50, 2.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.19 (1.04)	-0.57 (1.04)	
95% CI	(-1.85, 2.23)	(-2.62, 1.47)	
p-value	0.8542	0.5826	
Corrected Hedge's g Statistics	0.022	-0.065	
95% CI	(-0.21, 0.26)	(-0.30, 0.17)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	77.12 (14.84)	76.49 (15.38)	77.67 (14.66)
Analysis Visit Mean (SD)	78.82 (13.74)	77.08 (14.58)	77.82 (15.55)
LS Mean of Change from Baseline (SE)	1.71 (0.96)	0.48 (0.95)	0.10 (0.72)
95% CI	(-0.17, 3.59)	(-1.38, 2.34)	(-1.30, 1.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.61 (1.17)	0.37 (1.17)	
95% CI	(-0.70, 3.91)	(-1.92, 2.67)	
p-value	0.1722	0.7492	
Corrected Hedge's g Statistics	0.174	0.041	
95% CI	(-0.08, 0.43)	(-0.21, 0.29)	
Subgroup*Treatment Interaction p-value	0.3563	0.8850	

AMNOG Table SE21.2.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Total LDQOL			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	81.11 (10.51)	81.66 (12.46)	79.90 (12.12)
Analysis Visit Mean (SD)	81.42 (10.45)	82.61 (9.72)	80.95 (13.16)
LS Mean of Change from Baseline (SE)	0.59 (1.31)	1.41 (1.96)	0.98 (1.13)
95% CI	(-2.00, 3.19)	(-2.47, 5.29)	(-1.27, 3.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.39 (1.65)	0.43 (2.18)	
95% CI	(-3.64, 2.87)	(-3.88, 4.74)	
p-value	0.8154	0.8435	
Corrected Hedge's g Statistics	-0.044	0.048	
95% CI	(-0.44, 0.35)	(-0.48, 0.57)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	80.64 (10.96)	81.12 (13.65)	80.39 (10.63)
Analysis Visit Mean (SD)	80.16 (11.59)	82.02 (9.98)	81.99 (10.59)
LS Mean of Change from Baseline (SE)	-0.26 (1.30)	1.11 (1.99)	1.62 (1.10)
95% CI	(-2.82, 2.31)	(-2.83, 5.06)	(-0.56, 3.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.88 (1.61)	-0.51 (2.19)	
95% CI	(-5.07, 1.32)	(-4.84, 3.82)	
p-value	0.2470	0.8169	
Corrected Hedge's g Statistics	-0.227	-0.061	
95% CI	(-0.64, 0.19)	(-0.63, 0.51)	
Subgroup*Treatment Interaction p-value	0.3563	0.8850	

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Symptoms of Liver Disease			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	76.91 (20.30)	75.34 (18.69)	76.86 (18.51)
Analysis Visit Mean (SD)	75.88 (21.82)	73.84 (17.86)	76.96 (20.18)
LS Mean of Change from Baseline (SE)	-0.62 (1.29)	-1.52 (1.29)	0.13 (0.98)
95% CI	(-3.16, 1.92)	(-4.05, 1.01)	(-1.79, 2.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.75 (1.58)	-1.66 (1.59)	
95% CI	(-3.87, 2.36)	(-4.78, 1.47)	
p-value	0.6344	0.2978	
Corrected Hedge's g Statistics	-0.056	-0.123	
95% CI	(-0.29, 0.18)	(-0.36, 0.11)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	78.49 (19.64)	75.81 (17.88)	76.60 (18.39)
Analysis Visit Mean (SD)	76.56 (20.37)	76.21 (18.47)	77.06 (19.82)
LS Mean of Change from Baseline (SE)	-1.47 (1.35)	-0.07 (1.34)	0.62 (1.01)
95% CI	(-4.12, 1.19)	(-2.70, 2.55)	(-1.37, 2.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.08 (1.65)	-0.69 (1.65)	
95% CI	(-5.33, 1.17)	(-3.93, 2.55)	
p-value	0.2090	0.6750	
Corrected Hedge's g Statistics	-0.160	-0.053	
95% CI	(-0.41, 0.09)	(-0.31, 0.20)	
Subgroup*Treatment Interaction p-value	0.6450	0.4648	

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Effects of Liver Disease			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	77.40 (14.81)	77.84 (15.49)	77.44 (14.60)
Analysis Visit Mean (SD)	75.21 (15.95)	78.24 (10.41)	77.32 (14.61)
LS Mean of Change from Baseline (SE)	-2.19 (1.16)	0.54 (1.16)	-0.13 (0.88)
95% CI	(-4.48, 0.09)	(-1.74, 2.82)	(-1.87, 1.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.06 (1.43)	0.67 (1.43)	
95% CI	(-4.86, 0.74)	(-2.14, 3.48)	
p-value	0.1491	0.6379	
Corrected Hedge's g Statistics	-0.170	0.056	
95% CI	(-0.41, 0.07)	(-0.18, 0.29)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	77.57 (14.54)	78.02 (15.91)	77.38 (14.29)
Analysis Visit Mean (SD)	76.49 (14.46)	78.02 (12.32)	76.69 (14.90)
LS Mean of Change from Baseline (SE)	-1.27 (1.39)	0.12 (1.38)	-1.00 (1.04)
95% CI	(-4.00, 1.47)	(-2.59, 2.82)	(-3.05, 1.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.26 (1.71)	1.12 (1.70)	
95% CI	(-3.63, 3.10)	(-2.23, 4.47)	
p-value	0.8775	0.5111	
Corrected Hedge's g Statistics	-0.020	0.084	
95% CI	(-0.27, 0.23)	(-0.17, 0.34)	
Subgroup*Treatment Interaction p-value	0.9327	0.7313	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Concentration/Memory			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	79.11 (24.69)	78.61 (21.12)	78.66 (21.74)
Analysis Visit Mean (SD)	77.46 (24.46)	78.89 (19.98)	79.26 (22.50)
LS Mean of Change from Baseline (SE)	-1.43 (1.42)	0.02 (1.42)	0.51 (1.08)
95% CI	(-4.23, 1.37)	(-2.77, 2.81)	(-1.61, 2.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.95 (1.75)	-0.49 (1.75)	
95% CI	(-5.39, 1.49)	(-3.94, 2.96)	
p-value	0.2662	0.7797	
Corrected Hedge's g Statistics	-0.131	-0.033	
95% CI	(-0.37, 0.10)	(-0.27, 0.20)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	78.45 (24.49)	79.81 (20.06)	78.43 (21.80)
Analysis Visit Mean (SD)	78.51 (21.83)	78.41 (20.83)	78.09 (23.59)
LS Mean of Change from Baseline (SE)	-0.83 (1.47)	-0.79 (1.45)	-0.29 (1.10)
95% CI	(-3.73, 2.06)	(-3.65, 2.07)	(-2.45, 1.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.54 (1.80)	-0.50 (1.79)	
95% CI	(-4.09, 3.00)	(-4.03, 3.03)	
p-value	0.7625	0.7811	
Corrected Hedge's g Statistics	-0.038	-0.035	
95% CI	(-0.29, 0.22)	(-0.29, 0.22)	
Subgroup*Treatment Interaction p-value	0.9656	0.7030	

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Health Distress			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	76.25 (27.72)	78.13 (26.81)	80.21 (25.16)
Analysis Visit Mean (SD)	81.70 (23.87)	84.84 (21.48)	84.76 (23.97)
LS Mean of Change from Baseline (SE)	4.73 (1.67)	6.38 (1.66)	5.17 (1.26)
95% CI	(1.46, 8.01)	(3.12, 9.64)	(2.69, 7.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.43 (2.05)	1.21 (2.05)	
95% CI	(-4.46, 3.59)	(-2.81, 5.24)	
p-value	0.8322	0.5535	
Corrected Hedge's g Statistics	-0.025	0.070	
95% CI	(-0.26, 0.21)	(-0.17, 0.31)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	76.34 (26.99)	80.05 (27.02)	81.36 (24.79)
Analysis Visit Mean (SD)	80.91 (24.90)	85.37 (21.97)	84.85 (22.97)
LS Mean of Change from Baseline (SE)	2.80 (1.97)	5.90 (1.95)	4.44 (1.47)
95% CI	(-1.08, 6.67)	(2.07, 9.72)	(1.55, 7.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.65 (2.43)	1.45 (2.41)	
95% CI	(-6.42, 3.12)	(-3.28, 6.18)	
p-value	0.4969	0.5470	
Corrected Hedge's g Statistics	-0.087	0.077	
95% CI	(-0.34, 0.17)	(-0.18, 0.33)	
Subgroup*Treatment Interaction p-value	0.8814	0.8558	

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Sexual Function			
Week 24			
m	119	119	214
n	45	55	78
Baseline Mean (SD)	78.47 (27.05)	81.39 (21.65)	80.98 (23.32)
Analysis Visit Mean (SD)	77.23 (26.08)	76.42 (25.44)	80.75 (22.58)
LS Mean of Change from Baseline (SE)	-1.22 (2.88)	-4.99 (2.63)	-0.41 (2.19)
95% CI	(-6.91, 4.46)	(-10.18, 0.19)	(-4.73, 3.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.81 (3.57)	-4.58 (3.37)	
95% CI	(-7.86, 6.24)	(-11.22, 2.06)	
p-value	0.8215	0.1753	
Corrected Hedge's g Statistics	-0.041	-0.235	
95% CI	(-0.41, 0.33)	(-0.58, 0.11)	
Week 52			
m	108	107	201
n	37	44	66
Baseline Mean (SD)	82.83 (25.53)	81.88 (21.64)	78.88 (25.50)
Analysis Visit Mean (SD)	86.66 (18.36)	78.66 (28.30)	78.06 (26.44)
LS Mean of Change from Baseline (SE)	3.92 (3.09)	-2.22 (2.84)	-2.06 (2.33)
95% CI	(-2.18, 10.03)	(-7.81, 3.38)	(-6.65, 2.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.98 (3.83)	-0.16 (3.62)	
95% CI	(-1.57, 13.53)	(-7.30, 6.98)	
p-value	0.1198	0.9647	
Corrected Hedge's g Statistics	0.314	-0.008	
95% CI	(-0.09, 0.72)	(-0.39, 0.37)	
Subgroup*Treatment Interaction p-value	0.4145	0.7346	

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Sleep			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	61.77 (21.95)	58.29 (20.78)	61.89 (20.55)
Analysis Visit Mean (SD)	63.45 (21.12)	57.50 (21.12)	62.27 (20.05)
LS Mean of Change from Baseline (SE)	1.88 (1.42)	-1.95 (1.42)	0.49 (1.08)
95% CI	(-0.92, 4.68)	(-4.75, 0.84)	(-1.64, 2.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.39 (1.75)	-2.44 (1.75)	
95% CI	(-2.04, 4.83)	(-5.89, 1.01)	
p-value	0.4261	0.1648	
Corrected Hedge's g Statistics	0.094	-0.165	
95% CI	(-0.14, 0.33)	(-0.40, 0.07)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	63.33 (21.77)	58.67 (21.47)	61.14 (20.71)
Analysis Visit Mean (SD)	64.96 (19.48)	58.40 (22.22)	62.55 (21.20)
LS Mean of Change from Baseline (SE)	2.72 (1.64)	-1.25 (1.62)	0.98 (1.22)
95% CI	(-0.50, 5.93)	(-4.43, 1.93)	(-1.43, 3.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.74 (2.01)	-2.23 (2.00)	
95% CI	(-2.21, 5.69)	(-6.16, 1.70)	
p-value	0.3865	0.2660	
Corrected Hedge's g Statistics	0.110	-0.141	
95% CI	(-0.14, 0.36)	(-0.39, 0.11)	
Subgroup*Treatment Interaction p-value	0.5422	0.5272	

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Loneliness			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	82.77 (18.92)	83.19 (20.34)	84.08 (18.66)
Analysis Visit Mean (SD)	81.84 (19.55)	83.75 (19.60)	82.49 (20.75)
LS Mean of Change from Baseline (SE)	-1.77 (1.48)	-0.01 (1.48)	-1.76 (1.13)
95% CI	(-4.69, 1.14)	(-2.92, 2.89)	(-3.97, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (1.82)	1.75 (1.83)	
95% CI	(-3.60, 3.57)	(-1.84, 5.34)	
p-value	0.9948	0.3395	
Corrected Hedge's g Statistics	-0.001	0.113	
95% CI	(-0.24, 0.23)	(-0.12, 0.35)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	83.12 (19.59)	82.23 (21.08)	83.89 (19.34)
Analysis Visit Mean (SD)	84.89 (18.19)	82.29 (21.57)	82.91 (20.58)
LS Mean of Change from Baseline (SE)	0.83 (1.56)	-0.84 (1.55)	-1.55 (1.17)
95% CI	(-2.25, 3.91)	(-3.88, 2.20)	(-3.85, 0.75)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.38 (1.92)	0.71 (1.91)	
95% CI	(-1.39, 6.15)	(-3.04, 4.46)	
p-value	0.2158	0.7110	
Corrected Hedge's g Statistics	0.157	0.047	
95% CI	(-0.10, 0.41)	(-0.21, 0.30)	
Subgroup*Treatment Interaction p-value	0.4122	0.8982	

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Hopelessness			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	74.09 (22.84)	75.54 (22.74)	80.88 (20.71)
Analysis Visit Mean (SD)	76.89 (23.49)	76.93 (22.69)	79.79 (21.24)
LS Mean of Change from Baseline (SE)	1.35 (1.67)	0.09 (1.66)	-0.16 (1.27)
95% CI	(-1.94, 4.63)	(-3.18, 3.35)	(-2.65, 2.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.50 (2.06)	0.24 (2.06)	
95% CI	(-2.55, 5.55)	(-3.80, 4.29)	
p-value	0.4660	0.9056	
Corrected Hedge's g Statistics	0.086	0.014	
95% CI	(-0.15, 0.32)	(-0.22, 0.25)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	76.17 (22.17)	76.06 (23.83)	81.11 (20.83)
Analysis Visit Mean (SD)	78.68 (20.97)	76.87 (22.80)	78.39 (22.93)
LS Mean of Change from Baseline (SE)	2.73 (1.90)	-0.10 (1.88)	-1.70 (1.43)
95% CI	(-1.01, 6.48)	(-3.80, 3.60)	(-4.51, 1.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.44 (2.34)	1.60 (2.33)	
95% CI	(-0.17, 9.04)	(-2.98, 6.19)	
p-value	0.0592	0.4919	
Corrected Hedge's g Statistics	0.241	0.087	
95% CI	(-0.01, 0.50)	(-0.17, 0.34)	
Subgroup*Treatment Interaction p-value	0.3003	0.7665	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Stigma of Liver Disease			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	80.70 (22.61)	79.01 (20.87)	83.33 (19.04)
Analysis Visit Mean (SD)	84.90 (19.95)	79.42 (20.86)	84.97 (18.54)
LS Mean of Change from Baseline (SE)	3.95 (1.45)	-0.42 (1.45)	2.33 (1.10)
95% CI	(1.10, 6.81)	(-3.28, 2.43)	(0.16, 4.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.62 (1.79)	-2.75 (1.80)	
95% CI	(-1.89, 5.14)	(-6.28, 0.78)	
p-value	0.3649	0.1269	
Corrected Hedge's g Statistics	0.107	-0.182	
95% CI	(-0.13, 0.34)	(-0.42, 0.06)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	82.47 (22.06)	80.01 (21.01)	82.36 (19.42)
Analysis Visit Mean (SD)	86.98 (17.32)	82.71 (19.79)	84.45 (19.20)
LS Mean of Change from Baseline (SE)	4.82 (1.46)	1.88 (1.45)	2.28 (1.09)
95% CI	(1.94, 7.69)	(-0.96, 4.73)	(0.13, 4.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.54 (1.79)	-0.40 (1.78)	
95% CI	(-0.98, 6.05)	(-3.90, 3.11)	
p-value	0.1573	0.8241	
Corrected Hedge's g Statistics	0.180	-0.028	
95% CI	(-0.07, 0.43)	(-0.28, 0.23)	
Subgroup*Treatment Interaction p-value	0.4603	0.3917	

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Symptoms of Liver Disease			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	79.84 (16.26)	72.04 (19.68)	79.77 (15.25)
Analysis Visit Mean (SD)	77.56 (16.14)	75.01 (17.83)	80.11 (15.71)
LS Mean of Change from Baseline (SE)	-1.94 (1.80)	1.10 (2.71)	0.42 (1.55)
95% CI	(-5.50, 1.62)	(-4.27, 6.47)	(-2.65, 3.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.35 (2.27)	0.68 (3.04)	
95% CI	(-6.85, 2.14)	(-5.34, 6.71)	
p-value	0.3023	0.8231	
Corrected Hedge's g Statistics	-0.196	0.056	
95% CI	(-0.59, 0.20)	(-0.47, 0.58)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	79.82 (15.77)	73.12 (20.34)	79.64 (14.31)
Analysis Visit Mean (SD)	77.84 (16.30)	77.11 (16.28)	80.68 (15.88)
LS Mean of Change from Baseline (SE)	-1.71 (1.84)	2.50 (2.88)	1.30 (1.54)
95% CI	(-5.35, 1.93)	(-3.20, 8.20)	(-1.76, 4.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.00 (2.30)	1.20 (3.18)	
95% CI	(-7.56, 1.55)	(-5.09, 7.50)	
p-value	0.1946	0.7062	
Corrected Hedge's g Statistics	-0.258	0.102	
95% CI	(-0.67, 0.16)	(-0.47, 0.67)	
Subgroup*Treatment Interaction p-value	0.6450	0.4648	

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Effects of Liver Disease			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	79.84 (8.23)	82.22 (15.34)	78.82 (13.69)
Analysis Visit Mean (SD)	78.87 (8.68)	83.33 (11.50)	78.71 (14.87)
LS Mean of Change from Baseline (SE)	-0.73 (1.93)	2.95 (2.90)	-0.69 (1.64)
95% CI	(-4.55, 3.08)	(-2.79, 8.70)	(-3.94, 2.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (2.45)	3.65 (3.26)	
95% CI	(-4.90, 4.82)	(-2.81, 10.11)	
p-value	0.9870	0.2654	
Corrected Hedge's g Statistics	-0.003	0.283	
95% CI	(-0.40, 0.39)	(-0.24, 0.81)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	79.64 (8.60)	79.99 (15.33)	79.78 (10.52)
Analysis Visit Mean (SD)	77.75 (10.31)	76.23 (15.36)	80.87 (8.53)
LS Mean of Change from Baseline (SE)	-1.74 (1.62)	-3.73 (2.52)	1.16 (1.36)
95% CI	(-4.94, 1.46)	(-8.73, 1.26)	(-1.53, 3.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.90 (2.03)	-4.89 (2.77)	
95% CI	(-6.91, 1.11)	(-10.38, 0.59)	
p-value	0.1549	0.0799	
Corrected Hedge's g Statistics	-0.283	-0.473	
95% CI	(-0.70, 0.13)	(-1.05, 0.10)	
Subgroup*Treatment Interaction p-value	0.9327	0.7313	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Concentration/Memory			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	84.32 (16.78)	83.02 (17.26)	81.07 (18.11)
Analysis Visit Mean (SD)	83.25 (15.02)	84.39 (18.85)	81.87 (19.81)
LS Mean of Change from Baseline (SE)	-0.17 (2.35)	1.89 (3.51)	0.85 (2.02)
95% CI	(-4.82, 4.48)	(-5.05, 8.84)	(-3.14, 4.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.02 (2.97)	1.04 (3.92)	
95% CI	(-6.89, 4.86)	(-6.71, 8.79)	
p-value	0.7324	0.7908	
Corrected Hedge's g Statistics	-0.065	0.066	
95% CI	(-0.46, 0.33)	(-0.46, 0.59)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	83.29 (17.31)	82.11 (18.43)	81.70 (16.55)
Analysis Visit Mean (SD)	80.43 (15.18)	81.27 (18.29)	80.63 (17.74)
LS Mean of Change from Baseline (SE)	-2.41 (2.08)	-0.38 (3.19)	-1.27 (1.78)
95% CI	(-6.53, 1.71)	(-6.70, 5.94)	(-4.79, 2.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.14 (2.59)	0.89 (3.50)	
95% CI	(-6.27, 3.99)	(-6.04, 7.82)	
p-value	0.6617	0.7992	
Corrected Hedge's g Statistics	-0.085	0.066	
95% CI	(-0.50, 0.33)	(-0.50, 0.63)	
Subgroup*Treatment Interaction p-value	0.9656	0.7030	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Health Distress			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	83.54 (21.55)	90.97 (17.58)	82.46 (20.43)
Analysis Visit Mean (SD)	88.72 (17.85)	93.75 (16.18)	89.52 (14.88)
LS Mean of Change from Baseline (SE)	4.32 (2.25)	6.35 (3.39)	5.44 (1.96)
95% CI	(-0.13, 8.77)	(-0.36, 13.07)	(1.55, 9.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.11 (2.83)	0.92 (3.76)	
95% CI	(-6.71, 4.48)	(-6.54, 8.37)	
p-value	0.6946	0.8078	
Corrected Hedge's g Statistics	-0.073	0.060	
95% CI	(-0.47, 0.32)	(-0.47, 0.58)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	83.45 (21.66)	89.17 (18.82)	83.19 (19.53)
Analysis Visit Mean (SD)	89.19 (16.97)	95.00 (16.23)	89.66 (15.56)
LS Mean of Change from Baseline (SE)	4.96 (2.52)	9.45 (3.92)	5.35 (2.13)
95% CI	(-0.04, 9.96)	(1.69, 17.22)	(1.13, 9.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.39 (3.16)	4.10 (4.32)	
95% CI	(-6.65, 5.88)	(-4.45, 12.66)	
p-value	0.9030	0.3441	
Corrected Hedge's g Statistics	-0.024	0.254	
95% CI	(-0.44, 0.39)	(-0.32, 0.82)	
Subgroup*Treatment Interaction p-value	0.8814	0.8558	

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Sexual Function			
Week 24			
m	42	22	75
n	12	4	16
Baseline Mean (SD)	75.46 (32.41)	84.58 (26.57)	85.01 (14.98)
Analysis Visit Mean (SD)	88.18 (21.65)	85.00 (25.73)	86.45 (15.07)
LS Mean of Change from Baseline (SE)	10.32 (4.31)	2.08 (7.48)	3.49 (4.78)
95% CI	(1.54, 19.10)	(-13.18, 17.35)	(-6.26, 13.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.83 (6.32)	-1.41 (8.48)	
95% CI	(-6.05, 19.71)	(-18.71, 15.89)	
p-value	0.2879	0.8691	
Corrected Hedge's g Statistics	0.380	-0.073	
95% CI	(-0.38, 1.13)	(-1.17, 1.02)	
Week 52			
m	41	18	69
n	9	3	14
Baseline Mean (SD)	76.53 (36.96)	79.43 (30.01)	85.12 (13.33)
Analysis Visit Mean (SD)	82.40 (29.72)	84.43 (26.96)	81.54 (17.97)
LS Mean of Change from Baseline (SE)	4.18 (5.48)	6.67 (9.57)	-0.96 (5.53)
95% CI	(-6.99, 15.35)	(-12.85, 26.19)	(-12.23, 10.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.14 (7.62)	7.63 (10.74)	
95% CI	(-10.40, 20.67)	(-14.27, 29.52)	
p-value	0.5052	0.4827	
Corrected Hedge's g Statistics	0.258	0.359	
95% CI	(-0.58, 1.10)	(-0.89, 1.61)	
Subgroup*Treatment Interaction p-value	0.4145	0.7346	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Sleep			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	66.22 (16.65)	67.78 (12.51)	68.31 (17.44)
Analysis Visit Mean (SD)	65.37 (17.62)	60.83 (17.51)	65.89 (20.77)
LS Mean of Change from Baseline (SE)	-1.04 (2.21)	-6.90 (3.30)	-2.62 (1.91)
95% CI	(-5.42, 3.34)	(-13.44, -0.36)	(-6.40, 1.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.57 (2.79)	-4.29 (3.68)	
95% CI	(-3.95, 7.09)	(-11.57, 3.00)	
p-value	0.5736	0.2462	
Corrected Hedge's g Statistics	0.106	-0.286	
95% CI	(-0.29, 0.50)	(-0.81, 0.24)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	66.08 (16.96)	70.00 (12.25)	69.66 (17.19)
Analysis Visit Mean (SD)	63.51 (17.15)	65.00 (13.63)	68.97 (19.46)
LS Mean of Change from Baseline (SE)	-2.90 (2.17)	-4.99 (3.34)	-0.13 (1.85)
95% CI	(-7.19, 1.39)	(-11.59, 1.61)	(-3.79, 3.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.77 (2.71)	-4.86 (3.66)	
95% CI	(-8.14, 2.60)	(-12.11, 2.39)	
p-value	0.3093	0.1869	
Corrected Hedge's g Statistics	-0.200	-0.347	
95% CI	(-0.61, 0.21)	(-0.92, 0.22)	
Subgroup*Treatment Interaction p-value	0.5422	0.5272	

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Loneliness			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	89.27 (14.47)	87.50 (17.34)	84.92 (22.17)
Analysis Visit Mean (SD)	88.54 (15.38)	90.00 (18.23)	84.11 (20.79)
LS Mean of Change from Baseline (SE)	0.46 (2.09)	3.24 (3.10)	-0.67 (1.79)
95% CI	(-3.67, 4.59)	(-2.90, 9.38)	(-4.21, 2.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.13 (2.63)	3.91 (3.46)	
95% CI	(-4.07, 6.33)	(-2.94, 10.76)	
p-value	0.6682	0.2605	
Corrected Hedge's g Statistics	0.081	0.279	
95% CI	(-0.31, 0.48)	(-0.25, 0.81)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	88.51 (14.99)	85.33 (18.27)	84.66 (21.19)
Analysis Visit Mean (SD)	85.27 (15.14)	86.67 (18.68)	87.41 (15.20)
LS Mean of Change from Baseline (SE)	-1.76 (2.05)	1.31 (3.15)	2.29 (1.72)
95% CI	(-5.82, 2.30)	(-4.93, 7.55)	(-1.12, 5.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.05 (2.56)	-0.98 (3.47)	
95% CI	(-9.11, 1.01)	(-7.84, 5.88)	
p-value	0.1157	0.7777	
Corrected Hedge's g Statistics	-0.312	-0.075	
95% CI	(-0.73, 0.10)	(-0.64, 0.49)	
Subgroup*Treatment Interaction p-value	0.4122	0.8982	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Hopelessness			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	80.09 (21.48)	78.24 (23.60)	77.15 (21.02)
Analysis Visit Mean (SD)	81.50 (19.77)	81.94 (22.20)	79.04 (21.80)
LS Mean of Change from Baseline (SE)	3.12 (2.76)	4.78 (4.11)	2.85 (2.38)
95% CI	(-2.34, 8.57)	(-3.35, 12.92)	(-1.86, 7.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.27 (3.47)	1.93 (4.58)	
95% CI	(-6.61, 7.14)	(-7.14, 11.01)	
p-value	0.9388	0.6743	
Corrected Hedge's g Statistics	0.014	0.104	
95% CI	(-0.38, 0.41)	(-0.42, 0.63)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	79.74 (21.12)	77.78 (25.14)	76.87 (21.47)
Analysis Visit Mean (SD)	79.28 (22.01)	81.67 (15.50)	80.03 (21.23)
LS Mean of Change from Baseline (SE)	0.97 (2.74)	5.24 (4.23)	3.38 (2.32)
95% CI	(-4.46, 6.40)	(-3.14, 13.62)	(-1.21, 7.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.41 (3.43)	1.86 (4.66)	
95% CI	(-9.20, 4.38)	(-7.37, 11.08)	
p-value	0.4833	0.6911	
Corrected Hedge's g Statistics	-0.138	0.105	
95% CI	(-0.55, 0.27)	(-0.46, 0.67)	
Subgroup*Treatment Interaction p-value	0.3003	0.7665	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Stigma of Liver Disease			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	87.67 (15.90)	90.98 (11.58)	86.61 (19.22)
Analysis Visit Mean (SD)	87.05 (18.02)	91.69 (8.56)	88.02 (18.01)
LS Mean of Change from Baseline (SE)	0.12 (2.20)	2.98 (3.30)	1.98 (1.91)
95% CI	(-4.24, 4.47)	(-3.55, 9.51)	(-1.80, 5.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.87 (2.77)	1.00 (3.67)	
95% CI	(-7.34, 3.61)	(-6.26, 8.26)	
p-value	0.5017	0.7860	
Corrected Hedge's g Statistics	-0.126	0.067	
95% CI	(-0.52, 0.27)	(-0.46, 0.59)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	86.67 (16.35)	90.84 (12.24)	87.08 (17.55)
Analysis Visit Mean (SD)	88.35 (17.99)	92.52 (8.89)	87.73 (17.56)
LS Mean of Change from Baseline (SE)	2.31 (2.35)	3.51 (3.65)	1.36 (1.99)
95% CI	(-2.35, 6.96)	(-3.70, 10.73)	(-2.57, 5.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.94 (2.94)	2.15 (4.01)	
95% CI	(-4.88, 6.77)	(-5.79, 10.09)	
p-value	0.7487	0.5924	
Corrected Hedge's g Statistics	0.063	0.143	
95% CI	(-0.35, 0.48)	(-0.43, 0.71)	
Subgroup*Treatment Interaction p-value	0.4603	0.3917	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (4.8)	4 (3.2)	9 (4.0)
No	118 (95.2)	122 (96.8)	215 (96.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.28	
95% CI of the inverse odds ratio	(0.29, 2.37)	(0.39, 4.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	1.27	
95% CI of the inverse risk ratio	(0.30, 2.28)	(0.40, 4.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.82	-0.84	
95% CI of the absolute risk difference	(-3.75, 5.39)	(-4.84, 3.15)	
p-value	0.7180	0.6888	
p-value of Breslow-Day Test for Homogeneity [3]	0.4243	0.6190	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (22.6)	28 (22.2)	43 (19.2)
No	96 (77.4)	98 (77.8)	181 (80.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.83	
95% CI of the inverse odds ratio	(0.48, 1.39)	(0.49, 1.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.86	
95% CI of the inverse risk ratio	(0.56, 1.30)	(0.57, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.38	3.03	
95% CI of the absolute risk difference	(-5.60, 12.37)	(-5.88, 11.93)	
p-value	0.4531	0.4992	
p-value of Breslow-Day Test for Homogeneity [3]	0.9231	0.5600	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.0)	13 (10.3)	20 (8.9)
No	119 (96.0)	113 (89.7)	204 (91.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	0.85	
95% CI of the inverse odds ratio	(0.85, 6.38)	(0.41, 1.78)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.21	0.87	
95% CI of the inverse risk ratio	(0.85, 5.75)	(0.45, 1.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.90	1.39	
95% CI of the absolute risk difference	(-9.99, 0.20)	(-5.10, 7.88)	
p-value	0.0903	0.6695	
p-value of Breslow-Day Test for Homogeneity [3]	0.7454	0.6781	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (21.8)	32 (25.4)	59 (26.3)
No	97 (78.2)	94 (74.6)	165 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	1.05	
95% CI of the inverse odds ratio	(0.76, 2.16)	(0.64, 1.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.04	
95% CI of the inverse risk ratio	(0.81, 1.80)	(0.72, 1.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.57	-0.94	
95% CI of the absolute risk difference	(-13.84, 4.71)	(-10.48, 8.60)	
p-value	0.3444	0.8470	
p-value of Breslow-Day Test for Homogeneity [3]	0.7897	0.5738	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.2)	9 (7.1)	22 (9.8)
No	120 (96.8)	117 (92.9)	202 (90.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.27	1.42	
95% CI of the inverse odds ratio	(1.10, 9.71)	(0.63, 3.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.04	1.38	
95% CI of the inverse risk ratio	(1.07, 8.64)	(0.65, 2.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.60	-2.68	
95% CI of the absolute risk difference	(-11.58, -1.61)	(-8.63, 3.27)	
p-value	0.0250	0.3972	
p-value of Breslow-Day Test for Homogeneity [3]	0.7642	0.9338	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (16.1)	26 (20.6)	44 (19.6)
No	104 (83.9)	100 (79.4)	180 (80.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	0.94	
95% CI of the inverse odds ratio	(0.71, 2.27)	(0.55, 1.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	0.95	
95% CI of the inverse risk ratio	(0.75, 1.97)	(0.62, 1.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.51	0.99	
95% CI of the absolute risk difference	(-11.82, 4.79)	(-7.78, 9.77)	
p-value	0.4178	0.8238	
p-value of Breslow-Day Test for Homogeneity [3]	0.9275	0.1966	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (10.5)	7 (5.6)	16 (7.1)
No	111 (89.5)	119 (94.4)	208 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	1.31	
95% CI of the inverse odds ratio	(0.30, 1.41)	(0.52, 3.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	1.29	
95% CI of the inverse risk ratio	(0.34, 1.37)	(0.54, 3.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.34	-1.59	
95% CI of the absolute risk difference	(-3.02, 9.70)	(-6.82, 3.64)	
p-value	0.2802	0.5651	
p-value of Breslow-Day Test for Homogeneity [3]	0.5973	0.4491	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (22.6)	33 (26.2)	49 (21.9)
No	96 (77.4)	93 (73.8)	175 (78.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.79	
95% CI of the inverse odds ratio	(0.57, 1.63)	(0.47, 1.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.84	
95% CI of the inverse risk ratio	(0.64, 1.46)	(0.57, 1.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.71	4.32	
95% CI of the absolute risk difference	(-8.43, 9.84)	(-5.08, 13.71)	
p-value	0.8793	0.3602	
p-value of Breslow-Day Test for Homogeneity [3]	0.7794	0.1525	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	20 (16.1)	24 (19.0)	31 (13.8)
No	104 (83.9)	102 (81.0)	193 (86.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.68	
95% CI of the inverse odds ratio	(0.45, 1.54)	(0.38, 1.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.73	
95% CI of the inverse risk ratio	(0.51, 1.44)	(0.45, 1.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.29	5.21	
95% CI of the absolute risk difference	(-5.61, 10.19)	(-3.01, 13.42)	
p-value	0.5630	0.1987	
p-value of Breslow-Day Test for Homogeneity [3]	0.8355	0.1150	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (24.2)	32 (25.4)	51 (22.8)
No	94 (75.8)	94 (74.6)	173 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.87	
95% CI of the inverse odds ratio	(0.55, 1.55)	(0.52, 1.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.90	
95% CI of the inverse risk ratio	(0.63, 1.40)	(0.61, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.43	2.63	
95% CI of the absolute risk difference	(-7.90, 10.75)	(-6.75, 12.01)	
p-value	0.7631	0.5789	
p-value of Breslow-Day Test for Homogeneity [3]	0.7107	0.2686	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.0)	6 (4.8)	11 (4.9)
No	119 (96.0)	120 (95.2)	213 (95.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	1.03	
95% CI of the inverse odds ratio	(0.42, 3.62)	(0.37, 2.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	1.03	
95% CI of the inverse risk ratio	(0.43, 3.43)	(0.39, 2.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.88	-0.15	
95% CI of the absolute risk difference	(-5.35, 3.59)	(-4.82, 4.52)	
p-value	0.7079	0.9504	
p-value of Breslow-Day Test for Homogeneity [3]	0.9299	0.4355	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (8.1)	11 (8.7)	23 (10.3)
No	114 (91.9)	115 (91.3)	201 (89.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	1.20	
95% CI of the inverse odds ratio	(0.60, 2.84)	(0.56, 2.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	1.18	
95% CI of the inverse risk ratio	(0.63, 2.59)	(0.59, 2.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.20	-1.54	
95% CI of the absolute risk difference	(-8.43, 4.02)	(-7.87, 4.79)	
p-value	0.5017	0.6410	
p-value of Breslow-Day Test for Homogeneity [3]	0.1737	0.1836	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	22 (17.7)	20 (15.9)	38 (17.0)
No	102 (82.3)	106 (84.1)	186 (83.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	1.08	
95% CI of the inverse odds ratio	(0.53, 1.69)	(0.60, 1.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.07	
95% CI of the inverse risk ratio	(0.59, 1.54)	(0.65, 1.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.78	-1.09	
95% CI of the absolute risk difference	(-7.55, 9.11)	(-9.15, 6.96)	
p-value	0.8541	0.7921	
p-value of Breslow-Day Test for Homogeneity [3]	0.3356	0.0783	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	37 (29.8)	43 (34.1)	79 (35.3)
No	87 (70.2)	83 (65.9)	145 (64.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	1.05	
95% CI of the inverse odds ratio	(0.80, 2.05)	(0.66, 1.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.03	
95% CI of the inverse risk ratio	(0.86, 1.63)	(0.77, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.43	-1.14	
95% CI of the absolute risk difference	(-15.63, 4.77)	(-11.52, 9.24)	
p-value	0.3035	0.8298	
p-value of Breslow-Day Test for Homogeneity [3]	0.2936	0.1379	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	19 (15.3)	21 (16.7)	23 (10.3)
No	105 (84.7)	105 (83.3)	201 (89.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.57	
95% CI of the inverse odds ratio	(0.33, 1.21)	(0.30, 1.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.62	
95% CI of the inverse risk ratio	(0.38, 1.18)	(0.36, 1.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.05	6.40	
95% CI of the absolute risk difference	(-2.43, 12.54)	(-1.23, 14.02)	
p-value	0.1657	0.0831	
p-value of Breslow-Day Test for Homogeneity [3]	0.0213	0.4205	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (25.8)	34 (27.0)	59 (26.3)
No	92 (74.2)	92 (73.0)	165 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.97	
95% CI of the inverse odds ratio	(0.62, 1.70)	(0.59, 1.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.98	
95% CI of the inverse risk ratio	(0.70, 1.48)	(0.68, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.53	0.64	
95% CI of the absolute risk difference	(-10.16, 9.09)	(-9.02, 10.31)	
p-value	0.9137	0.8957	
p-value of Breslow-Day Test for Homogeneity [3]	0.3584	0.3314	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	25 (20.2)	29 (23.0)	26 (11.6)
No	99 (79.8)	97 (77.0)	198 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	0.44	
95% CI of the inverse odds ratio	(0.29, 0.95)	(0.25, 0.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.50	
95% CI of the inverse risk ratio	(0.35, 0.95)	(0.31, 0.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.55	11.41	
95% CI of the absolute risk difference	(0.34, 16.77)	(2.95, 19.87)	
p-value	0.0307	0.0049	
p-value of Breslow-Day Test for Homogeneity [3]	0.0889	0.2391	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	38 (30.6)	39 (31.0)	47 (21.0)
No	86 (69.4)	87 (69.0)	177 (79.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.59	
95% CI of the inverse odds ratio	(0.36, 0.99)	(0.36, 0.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.68	
95% CI of the inverse risk ratio	(0.47, 0.99)	(0.47, 0.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.66	9.97	
95% CI of the absolute risk difference	(-0.05, 19.37)	(0.30, 19.64)	
p-value	0.0445	0.0376	
p-value of Breslow-Day Test for Homogeneity [3]	0.1063	0.0911	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (12.9)	17 (13.5)	26 (11.6)
No	108 (87.1)	109 (86.5)	198 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.84	
95% CI of the inverse odds ratio	(0.46, 1.72)	(0.44, 1.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	0.86	
95% CI of the inverse risk ratio	(0.50, 1.61)	(0.49, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.30	1.88	
95% CI of the absolute risk difference	(-5.94, 8.54)	(-5.41, 9.18)	
p-value	0.7223	0.6061	
p-value of Breslow-Day Test for Homogeneity [3]	0.9277	0.3586	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	39 (31.5)	40 (31.7)	67 (29.9)
No	85 (68.5)	86 (68.3)	157 (70.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.92	
95% CI of the inverse odds ratio	(0.58, 1.50)	(0.57, 1.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.94	
95% CI of the inverse risk ratio	(0.68, 1.32)	(0.68, 1.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.54	1.84	
95% CI of the absolute risk difference	(-8.60, 11.68)	(-8.26, 11.94)	
p-value	0.7649	0.7205	
p-value of Breslow-Day Test for Homogeneity [3]	0.2136	0.4498	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (1.3)
No	43 (100)	25 (100)	78 (98.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.27	-1.27	
95% CI of the absolute risk difference	(-3.73, 1.20)	(-3.73, 1.20)	
p-value	0.4588	0.5719	
p-value of Breslow-Day Test for Homogeneity [3]	0.4243	0.6190	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (23.3)	4 (16.0)	15 (19.0)
No	33 (76.7)	21 (84.0)	64 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.23	
95% CI of the inverse odds ratio	(0.31, 1.91)	(0.37, 4.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.19	
95% CI of the inverse risk ratio	(0.40, 1.66)	(0.43, 3.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.27	-2.99	
95% CI of the absolute risk difference	(-11.04, 19.57)	(-19.76, 13.79)	
p-value	0.5768	0.7362	
p-value of Breslow-Day Test for Homogeneity [3]	0.9231	0.5600	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	3 (12.0)	6 (7.6)
No	42 (97.7)	22 (88.0)	73 (92.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.45	0.60	
95% CI of the inverse odds ratio	(0.40, 29.66)	(0.14, 2.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.27	0.63	
95% CI of the inverse risk ratio	(0.41, 26.25)	(0.17, 2.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.27	4.41	
95% CI of the absolute risk difference	(-12.65, 2.11)	(-9.61, 18.42)	
p-value	0.2319	0.4948	
p-value of Breslow-Day Test for Homogeneity [3]	0.7454	0.6781	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (20.9)	7 (28.0)	18 (22.8)
No	34 (79.1)	18 (72.0)	61 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.76	
95% CI of the inverse odds ratio	(0.45, 2.75)	(0.27, 2.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.81	
95% CI of the inverse risk ratio	(0.54, 2.21)	(0.39, 1.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.85	5.22	
95% CI of the absolute risk difference	(-17.13, 13.42)	(-14.67, 25.10)	
p-value	0.8136	0.5948	
p-value of Breslow-Day Test for Homogeneity [3]	0.7897	0.5738	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	1 (4.0)	4 (5.1)
No	42 (97.7)	24 (96.0)	75 (94.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.24	1.28	
95% CI of the inverse odds ratio	(0.24, 20.70)	(0.14, 12.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.18	1.27	
95% CI of the inverse risk ratio	(0.25, 18.87)	(0.15, 10.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.74	-1.06	
95% CI of the absolute risk difference	(-9.35, 3.87)	(-10.14, 8.01)	
p-value	0.4662	0.8285	
p-value of Breslow-Day Test for Homogeneity [3]	0.7642	0.9338	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (16.3)	2 (8.0)	15 (19.0)
No	36 (83.7)	23 (92.0)	64 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	2.70	
95% CI of the inverse odds ratio	(0.45, 3.23)	(0.57, 12.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	2.37	
95% CI of the inverse risk ratio	(0.52, 2.64)	(0.58, 9.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.71	-10.99	
95% CI of the absolute risk difference	(-16.73, 11.31)	(-24.69, 2.72)	
p-value	0.7101	0.1954	
p-value of Breslow-Day Test for Homogeneity [3]	0.9275	0.1966	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.7)	2 (8.0)	4 (5.1)
No	41 (95.3)	23 (92.0)	75 (94.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.61	
95% CI of the inverse odds ratio	(0.19, 6.23)	(0.11, 3.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.63	
95% CI of the inverse risk ratio	(0.21, 5.70)	(0.12, 3.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.41	2.94	
95% CI of the absolute risk difference	(-8.35, 7.52)	(-8.75, 14.62)	
p-value	0.9199	0.5831	
p-value of Breslow-Day Test for Homogeneity [3]	0.5973	0.4491	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (20.9)	3 (12.0)	18 (22.8)
No	34 (79.1)	22 (88.0)	61 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	2.16	
95% CI of the inverse odds ratio	(0.45, 2.75)	(0.58, 8.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.90	
95% CI of the inverse risk ratio	(0.54, 2.21)	(0.61, 5.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.85	-10.78	
95% CI of the absolute risk difference	(-17.13, 13.42)	(-26.53, 4.96)	
p-value	0.8136	0.2417	
p-value of Breslow-Day Test for Homogeneity [3]	0.7794	0.1525	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (18.6)	2 (8.0)	14 (17.7)
No	35 (81.4)	23 (92.0)	65 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	2.48	
95% CI of the inverse odds ratio	(0.36, 2.46)	(0.52, 11.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	2.22	
95% CI of the inverse risk ratio	(0.43, 2.09)	(0.54, 9.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.88	-9.72	
95% CI of the absolute risk difference	(-13.48, 15.24)	(-23.29, 3.84)	
p-value	0.9035	0.2403	
p-value of Breslow-Day Test for Homogeneity [3]	0.8355	0.1150	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (23.3)	4 (16.0)	20 (25.3)
No	33 (76.7)	21 (84.0)	59 (74.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	1.78	
95% CI of the inverse odds ratio	(0.47, 2.67)	(0.54, 5.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.58	
95% CI of the inverse risk ratio	(0.56, 2.11)	(0.60, 4.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.06	-9.32	
95% CI of the absolute risk difference	(-17.92, 13.79)	(-26.59, 7.96)	
p-value	0.8006	0.3352	
p-value of Breslow-Day Test for Homogeneity [3]	0.7107	0.2686	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	0	2 (2.5)
No	42 (97.7)	25 (100)	77 (97.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	NE	
95% CI of the inverse odds ratio	(0.10, 12.39)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	NE	
95% CI of the inverse risk ratio	(0.10, 11.66)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.21	-2.53	
95% CI of the absolute risk difference	(-5.89, 5.48)	(-6.00, 0.93)	
p-value	0.9440	0.4218	
p-value of Breslow-Day Test for Homogeneity [3]	0.9299	0.4355	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (7.0)	2 (8.0)	2 (2.5)
No	40 (93.0)	23 (92.0)	77 (97.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.35	0.30	
95% CI of the inverse odds ratio	(0.06, 2.16)	(0.04, 2.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	0.32	
95% CI of the inverse risk ratio	(0.06, 2.09)	(0.05, 2.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.45	5.47	
95% CI of the absolute risk difference	(-3.92, 12.81)	(-5.72, 16.65)	
p-value	0.2368	0.2153	
p-value of Breslow-Day Test for Homogeneity [3]	0.1737	0.1836	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (7.0)	0	10 (12.7)
No	40 (93.0)	25 (100)	69 (87.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.93	7.71	
95% CI of the inverse odds ratio	(0.50, 7.44)	(0.44, 136.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.81	6.83	
95% CI of the inverse risk ratio	(0.53, 6.24)	(0.41, 112.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.68	-11.20	
95% CI of the absolute risk difference	(-16.25, 4.89)	(-20.29, -2.11)	
p-value	0.3312	0.1037	
p-value of Breslow-Day Test for Homogeneity [3]	0.3356	0.0783	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (27.9)	2 (8.0)	18 (22.8)
No	31 (72.1)	23 (92.0)	61 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	3.39	
95% CI of the inverse odds ratio	(0.33, 1.78)	(0.73, 15.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	2.85	
95% CI of the inverse risk ratio	(0.44, 1.53)	(0.71, 11.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.12	-14.78	
95% CI of the absolute risk difference	(-11.17, 21.41)	(-28.88, -0.69)	
p-value	0.5302	0.1021	
p-value of Breslow-Day Test for Homogeneity [3]	0.2936	0.1379	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	3 (12.0)	10 (12.7)
No	42 (97.7)	22 (88.0)	69 (87.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.09	1.06	
95% CI of the inverse odds ratio	(0.75, 49.27)	(0.27, 4.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.44	1.05	
95% CI of the inverse risk ratio	(0.72, 41.10)	(0.31, 3.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.33	-0.66	
95% CI of the absolute risk difference	(-18.94, -1.73)	(-15.36, 14.04)	
p-value	0.0570	0.9309	
p-value of Breslow-Day Test for Homogeneity [3]	0.0213	0.4205	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (20.9)	5 (20.0)	24 (30.4)
No	34 (79.1)	20 (80.0)	55 (69.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	1.75	
95% CI of the inverse odds ratio	(0.69, 3.96)	(0.59, 5.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	1.52	
95% CI of the inverse risk ratio	(0.74, 2.84)	(0.65, 3.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.45	-10.38	
95% CI of the absolute risk difference	(-25.28, 6.38)	(-29.05, 8.29)	
p-value	0.2617	0.3131	
p-value of Breslow-Day Test for Homogeneity [3]	0.3584	0.3314	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (14.0)	5 (20.0)	15 (19.0)
No	37 (86.0)	20 (80.0)	64 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	0.94	
95% CI of the inverse odds ratio	(0.52, 4.05)	(0.30, 2.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.95	
95% CI of the inverse risk ratio	(0.57, 3.25)	(0.38, 2.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.03	1.01	
95% CI of the absolute risk difference	(-18.53, 8.46)	(-16.89, 18.92)	
p-value	0.4816	0.9108	
p-value of Breslow-Day Test for Homogeneity [3]	0.0889	0.2391	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (23.3)	5 (20.0)	23 (29.1)
No	33 (76.7)	20 (80.0)	56 (70.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	1.64	
95% CI of the inverse odds ratio	(0.57, 3.20)	(0.55, 4.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.46	
95% CI of the inverse risk ratio	(0.66, 2.38)	(0.62, 3.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.86	-9.11	
95% CI of the absolute risk difference	(-21.98, 10.26)	(-27.72, 9.49)	
p-value	0.4865	0.3706	
p-value of Breslow-Day Test for Homogeneity [3]	0.1063	0.0911	

AMNOG Table SE21.2.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (9.3)	1 (4.0)	7 (8.9)
No	39 (90.7)	24 (96.0)	72 (91.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	2.33	
95% CI of the inverse odds ratio	(0.26, 3.44)	(0.27, 19.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	2.22	
95% CI of the inverse risk ratio	(0.30, 3.07)	(0.29, 17.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.44	-4.86	
95% CI of the absolute risk difference	(-10.27, 11.15)	(-14.77, 5.05)	
p-value	0.9352	0.4267	
p-value of Breslow-Day Test for Homogeneity [3]	0.9277	0.3586	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (30.2)	3 (12.0)	14 (17.7)
No	30 (69.8)	22 (88.0)	65 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	1.58	
95% CI of the inverse odds ratio	(0.21, 1.19)	(0.41, 6.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	1.48	
95% CI of the inverse risk ratio	(0.30, 1.13)	(0.46, 4.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.51	-5.72	
95% CI of the absolute risk difference	(-3.59, 28.61)	(-20.99, 9.55)	
p-value	0.1118	0.5001	
p-value of Breslow-Day Test for Homogeneity [3]	0.2136	0.4498	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Total LDQOL						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	81.26 (10.54)	78.85 (14.44)	79.35 (14.00)			
Median	83.15	84.20	84.00			
IQR: Q1, Q3	72.75, 89.65	73.10, 88.30	74.70, 89.50			
Min, Max	57.5, 96.7	27.3, 96.3	38.5, 97.8			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	82.69 (9.78)	78.45 (13.62)	81.02 (13.19)	2.20 (1.10)	-0.52 (0.74)	1.44 (1.00)
Median	85.00	80.70	84.50	2.30	-0.90	0.50
IQR: Q1, Q3	76.30, 90.40	71.50, 88.90	73.50, 90.30	-2.00, 6.20	-5.00, 3.60	-3.00, 5.10
Min, Max	54.0, 96.9	32.4, 96.9	22.4, 98.8	-18.3, 15.9	-13.9, 14.3	-46.4, 42.3
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	84.30 (8.95)	78.74 (14.82)	81.79 (12.58)	3.03 (1.10)	-0.45 (0.94)	1.57 (1.00)
Median	86.60	82.20	84.70	2.35	-0.40	0.40
IQR: Q1, Q3	77.85, 90.80	71.10, 89.90	75.60, 90.20	-1.00, 8.10	-4.60, 4.10	-3.30, 5.80
Min, Max	64.8, 96.9	33.8, 96.3	35.7, 100.0	-10.2, 18.1	-19.2, 22.4	-36.2, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Symptoms of Liver Disease						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	85.25 (11.94)	78.14 (19.02)	80.70 (16.15)			
Median	90.00	83.30	86.70			
IQR: Q1, Q3	75.00, 95.00	66.70, 93.30	70.00, 93.30			
Min, Max	53.3, 100.0	10.0, 100.0	40.0, 100.0			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	82.48 (14.88)	77.19 (18.02)	83.33 (15.69)	-2.07 (1.95)	-1.21 (1.41)	1.75 (1.20)
Median	83.30	80.00	86.70	0	0	0
IQR: Q1, Q3	73.30, 96.70	68.00, 93.30	76.70, 93.30	-3.40, 6.60	-10.00, 3.40	-3.30, 6.70
Min, Max	46.7, 100.0	26.7, 100.0	16.7, 100.0	-46.6, 13.4	-36.6, 30.0	-43.3, 43.3
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	84.26 (12.86)	78.26 (18.23)	83.08 (14.44)	-0.78 (1.82)	-0.30 (1.66)	1.16 (1.11)
Median	86.70	80.00	86.70	1.65	0	0
IQR: Q1, Q3	70.00, 95.00	66.70, 93.30	70.00, 93.30	-3.40, 6.70	-6.70, 6.60	-6.60, 6.70
Min, Max	60.0, 100.0	26.7, 100.0	36.7, 100.0	-33.4, 20.0	-36.7, 36.7	-30.0, 26.6

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Effects of Liver Disease						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	80.34 (3.99)	79.07 (14.62)	78.80 (12.92)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	80.00, 86.70	80.00, 86.70			
Min, Max	66.7, 86.7	26.7, 100.0	33.3, 100.0			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	81.20 (7.79)	78.82 (11.64)	80.39 (13.17)	1.26 (1.39)	-0.55 (1.57)	1.71 (1.38)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 86.70	80.00, 80.00	80.00, 86.70	0.00, 6.70	-6.70, 0.00	0.00, 6.70
Min, Max	60.0, 100.0	40.0, 100.0	6.7, 100.0	-20.0, 20.0	-33.3, 53.3	-40.0, 46.7
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	82.13 (7.18)	78.71 (12.35)	79.19 (11.20)	1.86 (1.24)	0.20 (1.42)	-0.07 (1.51)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 86.70	80.00, 80.00	80.00, 80.00	0.00, 6.60	-6.70, 6.70	-6.70, 6.70
Min, Max	66.7, 100.0	20.0, 100.0	26.7, 100.0	-6.7, 20.0	-20.0, 40.0	-40.0, 46.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Concentration/Memory						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	84.24 (19.66)	80.56 (19.25)	79.89 (21.34)			
Median	93.80	87.50	87.50			
IQR: Q1, Q3	75.00, 100.00	68.80, 100.00	68.80, 100.00			
Min, Max	31.3, 100.0	31.3, 100.0	12.5, 100.0			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	83.03 (18.07)	80.55 (20.06)	81.94 (21.88)	0.00 (1.98)	-0.26 (1.33)	1.32 (1.58)
Median	87.50	81.30	87.50	0	0	0
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	75.00, 100.00	-6.20, 6.20	-6.20, 6.20	-6.20, 6.30
Min, Max	43.8, 100.0	25.0, 100.0	6.3, 100.0	-31.3, 25.0	-31.2, 25.0	-43.8, 62.5
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	82.83 (18.50)	79.40 (20.95)	82.55 (20.65)	-1.66 (2.24)	-1.73 (1.62)	1.61 (1.45)
Median	87.50	81.30	87.50	0	0	0
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	68.80, 100.00	-12.50, 6.20	-12.50, 6.30	-6.20, 6.30
Min, Max	37.5, 100.0	18.8, 100.0	0.0, 100.0	-25.0, 25.0	-43.8, 25.0	-43.8, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Health Distress						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	85.00 (23.20)	84.18 (23.99)	83.71 (24.58)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	91.03 (15.95)	88.13 (20.11)	88.53 (19.80)	7.43 (3.19)	3.77 (1.96)	4.65 (1.70)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	75.00, 100.00	87.50, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	37.5, 100.0	0.0, 100.0	0.0, 100.0	-37.5, 62.5	-37.5, 50.0	-50.0, 75.0
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	92.01 (14.99)	87.69 (23.08)	89.60 (19.54)	7.72 (3.46)	2.88 (2.08)	5.07 (2.02)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	87.50, 100.00	75.00, 100.00	0.00, 0.00	0.00, 0.00	0.00, 12.50
Min, Max	37.5, 100.0	0.0, 100.0	0.0, 100.0	-25.0, 75.0	-37.5, 50.0	-87.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Sexual Function						
Baseline						
m	43	86	132			
n	28	45	69			
Mean (SD)	78.88 (31.07)	80.00 (25.04)	80.58 (23.60)			
Median	93.30	93.30	86.70			
IQR: Q1, Q3	72.50, 100.00	63.30, 100.00	75.00, 100.00			
Min, Max	-1.7, 100.0	-1.7, 100.0	-1.7, 100.0			
Week 24						
m	40	82	129			
n	23	46	66	22	37	54
Mean (SD/SE)	82.17 (26.51)	72.78 (29.32)	78.38 (24.32)	6.19 (4.41)	-5.81 (3.41)	-1.21 (2.64)
Median	93.30	80.85	85.00	0	0	0
IQR: Q1, Q3	76.70, 100.00	55.00, 100.00	68.30, 100.00	0.00, 6.70	-15.00, 0.00	-8.30, 6.70
Min, Max	23.3, 100.0	-1.7, 100.0	-1.7, 100.0	-15.0, 91.1	-55.0, 46.7	-48.4, 50.0
Week 52						
m	39	74	116			
n	21	37	57	20	31	50
Mean (SD/SE)	83.81 (26.51)	76.31 (29.69)	79.01 (24.70)	8.91 (6.28)	-2.97 (3.20)	0.54 (3.13)
Median	100.00	93.30	93.30	0	0	0
IQR: Q1, Q3	76.70, 100.00	55.00, 100.00	68.30, 100.00	0.00, 6.70	-8.30, 0.00	-6.70, 8.30
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-23.3, 91.1	-48.4, 61.7	-53.3, 65.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Sleep						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	64.63 (18.62)	63.86 (18.43)	63.31 (20.52)			
Median	65.00	65.00	65.00			
IQR: Q1, Q3	55.00, 80.00	50.00, 80.00	50.00, 80.00			
Min, Max	15.0, 100.0	5.0, 100.0	5.0, 100.0			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	68.33 (17.71)	60.51 (20.92)	64.75 (20.03)	3.78 (2.37)	-2.67 (1.35)	0.94 (1.55)
Median	75.00	60.00	65.00	0	-5.00	0
IQR: Q1, Q3	60.00, 75.00	50.00, 80.00	50.00, 80.00	0.00, 10.00	-10.00, 5.00	-10.00, 10.00
Min, Max	15.0, 95.0	0.0, 100.0	20.0, 100.0	-30.0, 55.0	-35.0, 25.0	-40.0, 50.0
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	68.65 (20.07)	61.49 (20.87)	66.45 (20.60)	3.27 (2.24)	-2.69 (1.96)	1.35 (1.76)
Median	75.00	65.00	70.00	0	-5.00	0
IQR: Q1, Q3	62.50, 80.00	50.00, 75.00	50.00, 85.00	-5.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	15.0, 95.0	0.0, 95.0	20.0, 100.0	-15.0, 40.0	-55.0, 40.0	-40.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Loneliness						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	84.38 (19.05)	85.70 (17.39)	84.02 (18.77)			
Median	95.00	95.00	90.00			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	15.0, 100.0	25.0, 100.0			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	86.03 (16.98)	87.15 (17.74)	83.39 (20.44)	1.49 (2.62)	0.27 (1.35)	-0.71 (1.73)
Median	90.00	95.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	80.00, 100.00	80.00, 100.00	-5.00, 10.00	-5.00, 5.00	-10.00, 5.00
Min, Max	35.0, 100.0	0.0, 100.0	10.0, 100.0	-45.0, 40.0	-35.0, 20.0	-80.0, 70.0
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	87.36 (14.81)	84.03 (19.93)	86.12 (17.12)	2.65 (3.08)	-1.69 (1.84)	1.68 (1.75)
Median	95.00	90.00	95.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	75.00, 100.00	75.00, 100.00	-5.00, 10.00	-10.00, 5.00	-5.00, 5.00
Min, Max	40.0, 100.0	0.0, 100.0	5.0, 100.0	-55.0, 50.0	-40.0, 30.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Hopelessness						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	80.42 (20.55)	76.37 (22.83)	79.85 (21.32)			
Median	91.70	83.30	83.30			
IQR: Q1, Q3	62.50, 100.00	58.30, 100.00	58.30, 100.00			
Min, Max	33.3, 100.0	8.3, 100.0	16.7, 100.0			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	78.63 (19.10)	76.06 (22.15)	78.93 (22.02)	-0.23 (3.11)	-0.11 (1.93)	-1.25 (1.91)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	58.30, 100.00	66.70, 100.00	-8.40, 0.00	-8.30, 8.40	-8.30, 8.30
Min, Max	33.3, 100.0	8.3, 100.0	16.7, 100.0	-33.4, 33.4	-41.7, 41.7	-66.6, 50.0
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	85.42 (16.10)	76.12 (23.16)	80.23 (22.27)	4.42 (3.09)	-0.63 (2.64)	-1.15 (2.08)
Median	91.70	75.00	91.70	0	0	0
IQR: Q1, Q3	75.00, 100.00	58.30, 100.00	66.70, 100.00	0.00, 8.40	-16.60, 16.70	-8.30, 8.40
Min, Max	50.0, 100.0	0.0, 100.0	0.0, 100.0	-41.7, 41.7	-58.3, 50.0	-100.0, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Stigma of Liver Disease						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	88.92 (15.98)	82.45 (20.28)	84.79 (19.21)			
Median	100.00	87.50	93.80			
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00			
Min, Max	50.0, 100.0	31.3, 100.0	12.5, 100.0			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	90.72 (14.47)	82.06 (19.25)	89.26 (15.60)	2.20 (2.22)	0.18 (1.49)	4.54 (1.65)
Median	100.00	81.30	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	0.00, 6.20	-6.20, 6.30	0.00, 12.50
Min, Max	50.0, 100.0	25.0, 100.0	25.0, 100.0	-31.3, 37.5	-25.0, 31.2	-62.5, 75.0
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	92.02 (13.82)	85.56 (18.34)	89.68 (15.06)	3.12 (2.10)	3.08 (1.82)	5.47 (1.42)
Median	100.00	93.80	93.80	0	0	0
IQR: Q1, Q3	84.40, 100.00	81.30, 100.00	87.50, 100.00	0.00, 6.20	-6.20, 12.50	0.00, 12.50
Min, Max	50.0, 100.0	12.5, 100.0	31.3, 100.0	-25.0, 37.5	-37.5, 50.0	-18.8, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Total LDQOL						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	76.19 (15.27)	74.27 (14.35)	76.75 (13.84)			
Median	79.35	76.10	80.15			
IQR: Q1, Q3	68.60, 87.80	64.20, 85.60	70.60, 86.20			
Min, Max	28.3, 96.4	23.6, 95.4	34.8, 97.8			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	76.59 (15.88)	76.39 (11.14)	76.63 (14.63)	0.34 (0.87)	2.13 (1.32)	0.04 (0.75)
Median	79.95	77.60	80.65	0.30	1.60	0.30
IQR: Q1, Q3	69.10, 89.50	68.60, 84.70	67.30, 88.10	-5.70, 5.20	-4.50, 8.60	-4.10, 4.15
Min, Max	22.9, 97.8	49.6, 95.2	33.3, 96.7	-23.4, 35.6	-15.4, 27.0	-27.7, 23.9
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	77.30 (14.23)	77.48 (12.89)	76.47 (15.12)	0.40 (0.96)	2.25 (1.68)	-0.33 (0.82)
Median	81.45	80.20	79.10	0.55	1.80	0.60
IQR: Q1, Q3	67.50, 88.15	65.30, 88.50	68.95, 88.05	-4.95, 5.45	-3.50, 9.95	-4.60, 4.60
Min, Max	34.0, 97.5	38.2, 97.4	20.3, 97.8	-19.5, 36.0	-23.3, 33.9	-46.3, 23.8

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Symptoms of Liver Disease						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	75.03 (20.76)	70.67 (17.69)	73.35 (18.52)			
Median	80.00	70.00	76.70			
IQR: Q1, Q3	63.30, 90.00	60.00, 83.30	60.00, 90.00			
Min, Max	13.3, 100.0	30.0, 100.0	20.0, 100.0			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	74.32 (21.41)	69.83 (17.37)	72.39 (20.47)	-1.14 (1.36)	-0.37 (1.72)	-1.15 (1.21)
Median	80.00	70.00	76.70	0	0	0
IQR: Q1, Q3	63.30, 90.00	60.00, 80.00	56.70, 90.00	-10.00, 6.70	-6.70, 6.70	-10.00, 6.70
Min, Max	0.0, 100.0	26.7, 100.0	20.0, 100.0	-46.7, 36.7	-33.3, 30.0	-53.3, 36.7
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	74.80 (20.62)	74.11 (18.38)	73.67 (21.17)	-2.36 (1.36)	2.65 (2.09)	0.15 (1.28)
Median	80.00	73.30	80.00	0	3.35	0
IQR: Q1, Q3	60.00, 91.65	60.00, 90.00	60.00, 90.00	-10.00, 6.60	-6.70, 13.40	-6.70, 6.70
Min, Max	6.7, 100.0	36.7, 100.0	16.7, 100.0	-43.4, 43.4	-23.4, 30.0	-60.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Effects of Liver Disease						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	76.67 (15.95)	77.86 (15.92)	76.21 (16.39)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	73.30, 80.00	73.30, 86.70	73.30, 80.00			
Min, Max	6.7, 100.0	13.3, 100.0	6.7, 100.0			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	74.24 (16.05)	79.83 (8.88)	74.88 (15.89)	-2.87 (1.19)	1.95 (2.47)	-1.62 (1.25)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	66.70, 80.00	73.30, 86.70	73.30, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 6.60
Min, Max	0.0, 100.0	60.0, 100.0	6.7, 100.0	-40.0, 33.3	-26.7, 76.7	-46.7, 53.4
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	74.60 (14.45)	76.67 (12.60)	76.54 (15.11)	-2.43 (1.54)	-1.59 (2.41)	-0.36 (1.75)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	73.30, 80.00	73.30, 80.00	-6.70, 0.00	-10.00, 0.00	-6.70, 6.60
Min, Max	6.7, 100.0	26.7, 100.0	13.3, 100.0	-40.0, 80.0	-33.3, 53.4	-80.0, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Concentration/Memory						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	78.94 (24.15)	76.72 (22.37)	77.59 (20.41)			
Median	84.40	81.30	81.30			
IQR: Q1, Q3	68.80, 100.00	62.50, 93.80	62.50, 93.80			
Min, Max	6.3, 100.0	18.8, 100.0	6.3, 100.0			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	77.13 (23.70)	79.73 (19.02)	78.02 (21.40)	-1.98 (1.50)	1.41 (2.58)	0.09 (1.31)
Median	84.40	81.30	81.30	0	0	0
IQR: Q1, Q3	68.80, 100.00	75.00, 93.80	62.50, 93.80	-12.50, 6.20	-6.30, 6.30	-6.20, 6.30
Min, Max	0.0, 100.0	25.0, 100.0	18.8, 100.0	-43.8, 31.2	-37.5, 56.2	-81.2, 56.2
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	77.71 (20.72)	79.81 (19.64)	76.20 (22.34)	-0.45 (1.46)	-0.71 (2.56)	-2.31 (1.24)
Median	81.30	87.50	81.30	0	0	0
IQR: Q1, Q3	68.80, 93.80	62.50, 100.00	62.50, 93.80	-6.30, 6.20	-6.30, 6.25	-6.30, 6.20
Min, Max	0.0, 100.0	37.5, 100.0	12.5, 100.0	-43.7, 50.0	-37.5, 50.0	-43.7, 31.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Health Distress						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	75.85 (26.84)	76.69 (26.92)	79.03 (23.58)			
Median	87.50	75.00	87.50			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	80.40 (24.81)	85.09 (21.05)	83.48 (23.30)	4.71 (1.98)	9.43 (2.71)	5.61 (1.75)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	25.0, 100.0	0.0, 100.0	-50.0, 75.0	-37.5, 50.0	-62.5, 62.5
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	79.88 (25.74)	86.17 (18.10)	83.71 (21.78)	3.91 (2.54)	9.09 (3.64)	3.59 (2.11)
Median	87.50	87.50	93.75	0	0	0
IQR: Q1, Q3	68.75, 100.00	75.00, 100.00	75.00, 100.00	-12.50, 12.50	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	25.0, 100.0	0.0, 100.0	-75.0, 75.0	-50.0, 75.0	-62.5, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Sexual Function						
Baseline						
m	124	65	171			
n	43	27	52			
Mean (SD)	79.96 (23.30)	78.51 (20.43)	78.30 (25.68)			
Median	85.00	83.30	85.85			
IQR: Q1, Q3	68.30, 100.00	68.30, 100.00	67.50, 100.00			
Min, Max	30.0, 100.0	38.3, 100.0	6.7, 100.0			
Week 24						
m	121	59	160			
n	49	31	59	35	22	40
Mean (SD/SE)	79.29 (22.90)	77.05 (25.77)	79.77 (22.66)	-1.13 (4.63)	-2.56 (4.52)	1.75 (2.72)
Median	85.00	85.00	86.70	0	0	0
IQR: Q1, Q3	70.00, 100.00	51.70, 100.00	61.70, 100.00	-8.30, 16.70	-16.60, 8.30	-6.65, 8.30
Min, Max	6.7, 100.0	13.3, 100.0	13.3, 100.0	-85.0, 63.3	-48.3, 40.0	-46.7, 38.4
Week 52						
m	110	51	154			
n	32	20	44	26	16	30
Mean (SD/SE)	85.90 (17.42)	78.58 (27.56)	75.45 (27.40)	0.64 (3.35)	-2.18 (6.54)	-4.37 (3.40)
Median	93.30	89.20	83.30	0	0	-3.30
IQR: Q1, Q3	78.30, 100.00	60.80, 100.00	60.00, 100.00	-6.70, 0.00	-19.15, 11.65	-15.00, 0.00
Min, Max	28.3, 100.0	5.0, 100.0	-1.7, 100.0	-45.0, 48.3	-50.0, 48.3	-46.6, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Sleep						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	62.29 (21.51)	55.25 (20.54)	62.31 (19.65)			
Median	65.00	60.00	65.00			
IQR: Q1, Q3	45.00, 80.00	40.00, 70.00	50.00, 75.00			
Min, Max	0.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	62.08 (21.62)	54.82 (19.09)	60.58 (20.50)	0.09 (1.52)	-0.28 (2.37)	-1.36 (1.30)
Median	65.00	55.00	60.00	0	0	0
IQR: Q1, Q3	45.00, 80.00	40.00, 70.00	45.00, 75.00	-10.00, 5.00	-10.00, 10.00	-10.00, 10.00
Min, Max	5.0, 100.0	10.0, 90.0	15.0, 100.0	-30.0, 90.0	-35.0, 45.0	-35.0, 35.0
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	63.25 (19.15)	57.02 (21.66)	61.55 (20.58)	-0.57 (1.80)	1.70 (2.71)	0.45 (1.36)
Median	65.00	65.00	60.00	-5.00	2.50	0
IQR: Q1, Q3	50.00, 80.00	40.00, 75.00	45.00, 77.50	-10.00, 7.50	-10.00, 12.50	-10.00, 10.00
Min, Max	10.0, 100.0	10.0, 90.0	5.0, 100.0	-40.0, 75.0	-60.0, 45.0	-40.0, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Loneliness						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	84.66 (17.45)	79.49 (22.49)	83.69 (20.32)			
Median	90.00	80.00	90.00			
IQR: Q1, Q3	75.00, 100.00	65.00, 100.00	75.00, 100.00			
Min, Max	35.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	82.73 (19.37)	81.93 (20.87)	82.40 (20.67)	-1.64 (1.53)	1.60 (2.17)	-1.97 (1.28)
Median	90.00	90.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	65.00, 100.00	75.00, 100.00	-10.00, 5.00	-5.00, 10.00	-10.00, 5.00
Min, Max	15.0, 100.0	25.0, 100.0	15.0, 100.0	-50.0, 45.0	-25.0, 65.0	-40.0, 45.0
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	84.25 (18.22)	82.55 (22.38)	82.42 (20.42)	-0.47 (1.52)	3.07 (2.35)	-1.41 (1.33)
Median	90.00	95.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	-5.00, 5.00	-5.00, 15.00	-10.00, 5.00
Min, Max	25.0, 100.0	15.0, 100.0	10.0, 100.0	-60.0, 40.0	-35.0, 35.0	-40.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Hopelessness						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	74.23 (23.19)	77.12 (23.19)	78.80 (21.50)			
Median	75.00	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	58.30, 100.00			
Min, Max	8.3, 100.0	33.3, 100.0	25.0, 100.0			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	77.33 (23.95)	80.26 (22.31)	78.85 (21.43)	3.29 (1.76)	4.24 (3.11)	0.40 (1.42)
Median	83.30	91.70	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	58.30, 100.00	-8.30, 16.70	-8.30, 16.70	-8.30, 8.30
Min, Max	8.3, 100.0	8.3, 100.0	25.0, 100.0	-58.3, 50.0	-41.7, 58.4	-50.0, 50.0
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	76.08 (22.49)	81.39 (19.52)	77.27 (22.33)	0.69 (1.97)	3.98 (3.39)	-1.23 (1.52)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	58.30, 100.00	-8.30, 12.50	-8.30, 16.70	-8.30, 8.30
Min, Max	16.7, 100.0	41.7, 100.0	8.3, 100.0	-50.0, 41.7	-50.0, 50.0	-58.4, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 20 of 20
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.3.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Stigma of Liver Disease						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	80.15 (22.85)	79.79 (19.05)	83.21 (19.00)			
Median	87.50	81.30	87.50			
IQR: Q1, Q3	68.80, 100.00	68.80, 93.80	75.00, 100.00			
Min, Max	12.5, 100.0	12.5, 100.0	31.3, 100.0			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	83.76 (20.54)	80.17 (19.84)	81.91 (20.00)	3.13 (1.79)	0.82 (2.35)	-0.88 (1.31)
Median	87.50	81.30	87.50	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 93.80	75.00, 100.00	-6.20, 12.50	-6.30, 6.20	-6.30, 6.20
Min, Max	6.3, 100.0	12.5, 100.0	6.3, 100.0	-43.8, 56.2	-31.3, 56.3	-43.8, 50.0
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	85.33 (18.55)	82.83 (19.29)	81.60 (20.29)	3.91 (1.46)	1.80 (2.72)	-1.39 (1.60)
Median	93.80	87.50	87.50	0	0	0
IQR: Q1, Q3	78.15, 100.00	68.80, 100.00	75.00, 100.00	0.00, 6.30	-3.10, 12.50	-6.30, 6.20
Min, Max	31.3, 100.0	12.5, 100.0	18.8, 100.0	-31.3, 56.2	-56.2, 56.3	-62.5, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Sex
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.3.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Total LDQOL			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	80.58 (10.67)	78.72 (14.69)	79.96 (13.49)
Analysis Visit Mean (SD)	82.78 (9.32)	78.21 (13.99)	81.41 (13.43)
LS Mean of Change from Baseline (SE)	2.51 (1.36)	-0.89 (0.98)	1.61 (0.80)
95% CI	(-0.18, 5.20)	(-2.81, 1.04)	(0.03, 3.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.90 (1.55)	-2.49 (1.22)	
95% CI	(-2.15, 3.96)	(-4.91, -0.08)	
p-value	0.5607	0.0427	
Corrected Hedge's g Statistics	0.106	-0.295	
95% CI	(-0.27, 0.48)	(-0.59, 0.00)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	80.71 (10.70)	79.02 (14.70)	80.37 (13.27)
Analysis Visit Mean (SD)	83.74 (8.86)	78.58 (15.00)	81.94 (12.83)
LS Mean of Change from Baseline (SE)	3.49 (1.46)	-0.57 (1.06)	1.59 (0.86)
95% CI	(0.60, 6.37)	(-2.65, 1.51)	(-0.11, 3.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.89 (1.67)	-2.16 (1.33)	
95% CI	(-1.40, 5.18)	(-4.77, 0.46)	
p-value	0.2576	0.1056	
Corrected Hedge's g Statistics	0.218	-0.249	
95% CI	(-0.17, 0.61)	(-0.56, 0.06)	
Subgroup*Treatment Interaction p-value	0.6858	0.0198	

AMNOG Table SE21.3.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Total LDQOL			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	76.60 (15.02)	73.88 (14.60)	77.01 (13.86)
Analysis Visit Mean (SD)	76.94 (15.83)	76.01 (11.10)	77.06 (14.34)
LS Mean of Change from Baseline (SE)	0.44 (0.85)	1.60 (1.21)	0.11 (0.76)
95% CI	(-1.22, 2.11)	(-0.78, 3.98)	(-1.39, 1.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.34 (1.10)	1.49 (1.40)	
95% CI	(-1.83, 2.51)	(-1.27, 4.25)	
p-value	0.7598	0.2888	
Corrected Hedge's g Statistics	0.038	0.168	
95% CI	(-0.21, 0.29)	(-0.15, 0.49)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	77.20 (14.81)	74.31 (15.60)	76.73 (13.98)
Analysis Visit Mean (SD)	77.60 (14.03)	76.56 (12.74)	76.40 (15.38)
LS Mean of Change from Baseline (SE)	0.52 (0.95)	1.66 (1.37)	-0.45 (0.83)
95% CI	(-1.34, 2.38)	(-1.03, 4.35)	(-2.09, 1.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.97 (1.23)	2.12 (1.58)	
95% CI	(-1.44, 3.39)	(-0.99, 5.22)	
p-value	0.4285	0.1808	
Corrected Hedge's g Statistics	0.105	0.230	
95% CI	(-0.16, 0.37)	(-0.12, 0.58)	
Subgroup*Treatment Interaction p-value	0.6858	0.0198	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Symptoms of Liver Disease			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	84.68 (12.25)	77.95 (19.09)	81.64 (15.48)
Analysis Visit Mean (SD)	82.61 (14.53)	76.74 (18.43)	83.39 (16.12)
LS Mean of Change from Baseline (SE)	-0.75 (1.94)	-1.71 (1.39)	2.10 (1.13)
95% CI	(-4.57, 3.07)	(-4.45, 1.02)	(-0.13, 4.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.84 (2.20)	-3.81 (1.75)	
95% CI	(-7.19, 1.50)	(-7.26, -0.36)	
p-value	0.1980	0.0305	
Corrected Hedge's g Statistics	-0.237	-0.318	
95% CI	(-0.61, 0.14)	(-0.61, -0.02)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	84.31 (12.39)	78.36 (17.23)	81.71 (14.36)
Analysis Visit Mean (SD)	83.53 (12.84)	78.06 (18.45)	82.87 (14.36)
LS Mean of Change from Baseline (SE)	0.53 (1.93)	-0.93 (1.40)	1.99 (1.14)
95% CI	(-3.28, 4.34)	(-3.70, 1.83)	(-0.27, 4.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.46 (2.20)	-2.92 (1.77)	
95% CI	(-5.80, 2.88)	(-6.40, 0.56)	
p-value	0.5091	0.0997	
Corrected Hedge's g Statistics	-0.127	-0.254	
95% CI	(-0.52, 0.26)	(-0.57, 0.06)	
Subgroup*Treatment Interaction p-value	0.5114	0.0890	

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Effects of Liver Disease			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	80.36 (4.15)	78.91 (14.82)	78.88 (12.63)
Analysis Visit Mean (SD)	81.62 (7.61)	78.36 (11.80)	80.59 (12.99)
LS Mean of Change from Baseline (SE)	2.10 (1.83)	-0.62 (1.31)	1.54 (1.07)
95% CI	(-1.50, 5.70)	(-3.19, 1.95)	(-0.56, 3.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.56 (2.08)	-2.16 (1.64)	
95% CI	(-3.53, 4.66)	(-5.40, 1.08)	
p-value	0.7869	0.1905	
Corrected Hedge's g Statistics	0.050	-0.191	
95% CI	(-0.32, 0.42)	(-0.49, 0.10)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	80.40 (4.34)	78.46 (14.61)	79.21 (12.23)
Analysis Visit Mean (SD)	82.25 (7.37)	78.67 (12.54)	79.15 (11.45)
LS Mean of Change from Baseline (SE)	2.49 (1.81)	-0.10 (1.31)	0.06 (1.08)
95% CI	(-1.08, 6.06)	(-2.69, 2.50)	(-2.06, 2.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.43 (2.07)	-0.15 (1.65)	
95% CI	(-1.65, 6.51)	(-3.41, 3.11)	
p-value	0.2412	0.9265	
Corrected Hedge's g Statistics	0.225	-0.014	
95% CI	(-0.16, 0.61)	(-0.33, 0.30)	
Subgroup*Treatment Interaction p-value	0.2855	0.1272	

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Concentration/Memory			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	83.46 (20.21)	80.41 (19.88)	80.38 (21.40)
Analysis Visit Mean (SD)	83.46 (17.50)	80.15 (20.39)	81.71 (22.48)
LS Mean of Change from Baseline (SE)	0.77 (2.30)	-0.57 (1.64)	1.53 (1.35)
95% CI	(-3.77, 5.31)	(-3.81, 2.67)	(-1.12, 4.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.76 (2.62)	-2.10 (2.07)	
95% CI	(-5.92, 4.40)	(-6.17, 1.97)	
p-value	0.7723	0.3100	
Corrected Hedge's g Statistics	-0.053	-0.147	
95% CI	(-0.42, 0.32)	(-0.44, 0.15)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	83.66 (20.35)	80.60 (19.17)	80.77 (20.36)
Analysis Visit Mean (SD)	82.00 (18.70)	78.87 (21.03)	82.38 (21.01)
LS Mean of Change from Baseline (SE)	-0.89 (2.34)	-1.45 (1.69)	1.67 (1.38)
95% CI	(-5.50, 3.73)	(-4.78, 1.88)	(-1.06, 4.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.55 (2.67)	-3.11 (2.12)	
95% CI	(-7.82, 2.71)	(-7.30, 1.07)	
p-value	0.3405	0.1440	
Corrected Hedge's g Statistics	-0.183	-0.225	
95% CI	(-0.57, 0.21)	(-0.54, 0.09)	
Subgroup*Treatment Interaction p-value	0.6113	0.1152	

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Health Distress			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	84.46 (23.83)	83.56 (24.28)	84.07 (24.34)
Analysis Visit Mean (SD)	91.89 (14.79)	87.33 (20.68)	88.72 (20.25)
LS Mean of Change from Baseline (SE)	7.95 (2.38)	3.80 (1.70)	5.07 (1.39)
95% CI	(3.27, 12.63)	(0.45, 7.15)	(2.33, 7.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.88 (2.70)	-1.27 (2.13)	
95% CI	(-2.45, 8.20)	(-5.48, 2.94)	
p-value	0.2880	0.5526	
Corrected Hedge's g Statistics	0.194	-0.086	
95% CI	(-0.18, 0.57)	(-0.38, 0.21)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	83.82 (24.53)	84.62 (24.88)	84.16 (23.97)
Analysis Visit Mean (SD)	91.54 (15.30)	87.50 (23.39)	89.23 (19.92)
LS Mean of Change from Baseline (SE)	7.72 (2.69)	3.62 (1.95)	4.98 (1.59)
95% CI	(2.41, 13.03)	(-0.22, 7.46)	(1.85, 8.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.74 (3.08)	-1.36 (2.45)	
95% CI	(-3.33, 8.80)	(-6.20, 3.47)	
p-value	0.3753	0.5791	
Corrected Hedge's g Statistics	0.171	-0.085	
95% CI	(-0.22, 0.56)	(-0.40, 0.23)	
Subgroup*Treatment Interaction p-value	0.1974	0.1781	

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Sexual Function			
Week 24			
m	40	82	129
n	22	37	54
Baseline Mean (SD)	77.59 (33.14)	84.32 (22.87)	82.78 (21.63)
Analysis Visit Mean (SD)	83.78 (25.95)	78.51 (25.41)	81.57 (22.31)
LS Mean of Change from Baseline (SE)	6.85 (3.78)	-4.72 (2.93)	0.35 (2.47)
95% CI	(-0.64, 14.34)	(-10.53, 1.08)	(-4.54, 5.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.50 (4.45)	-5.07 (3.76)	
95% CI	(-2.31, 15.31)	(-12.52, 2.37)	
p-value	0.1466	0.1798	
Corrected Hedge's g Statistics	0.357	-0.279	
95% CI	(-0.14, 0.86)	(-0.70, 0.14)	
Week 52			
m	39	74	116
n	20	31	50
Baseline Mean (SD)	77.60 (34.22)	82.52 (23.13)	79.87 (24.43)
Analysis Visit Mean (SD)	86.50 (24.08)	79.55 (28.36)	80.40 (24.61)
LS Mean of Change from Baseline (SE)	7.81 (4.18)	-2.26 (3.30)	1.40 (2.71)
95% CI	(-0.47, 16.08)	(-8.79, 4.27)	(-3.96, 6.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.41 (4.89)	-3.66 (4.19)	
95% CI	(-3.28, 16.10)	(-11.96, 4.64)	
p-value	0.1928	0.3843	
Corrected Hedge's g Statistics	0.333	-0.192	
95% CI	(-0.19, 0.85)	(-0.64, 0.26)	
Subgroup*Treatment Interaction p-value	0.3750	0.4917	

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Sleep			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	63.78 (18.87)	63.42 (18.71)	64.64 (20.19)
Analysis Visit Mean (SD)	67.57 (17.62)	60.75 (21.34)	65.58 (19.91)
LS Mean of Change from Baseline (SE)	3.86 (2.32)	-2.93 (1.66)	1.28 (1.36)
95% CI	(-0.70, 8.43)	(-6.20, 0.34)	(-1.39, 3.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.58 (2.63)	-4.21 (2.08)	
95% CI	(-2.61, 7.77)	(-8.32, -0.11)	
p-value	0.3292	0.0442	
Corrected Hedge's g Statistics	0.178	-0.292	
95% CI	(-0.19, 0.55)	(-0.59, 0.00)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	64.26 (19.58)	64.62 (19.00)	65.58 (19.56)
Analysis Visit Mean (SD)	67.54 (20.02)	61.92 (21.00)	66.93 (20.71)
LS Mean of Change from Baseline (SE)	3.85 (2.66)	-2.76 (1.93)	2.08 (1.57)
95% CI	(-1.40, 9.10)	(-6.55, 1.04)	(-1.02, 5.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.77 (3.05)	-4.84 (2.43)	
95% CI	(-4.23, 7.77)	(-9.62, -0.06)	
p-value	0.5619	0.0474	
Corrected Hedge's g Statistics	0.112	-0.307	
95% CI	(-0.28, 0.50)	(-0.62, 0.01)	
Subgroup*Treatment Interaction p-value	0.8011	0.1801	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Loneliness			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	84.46 (19.21)	86.64 (16.63)	84.47 (18.14)
Analysis Visit Mean (SD)	85.95 (17.19)	86.92 (17.85)	83.76 (20.61)
LS Mean of Change from Baseline (SE)	0.89 (2.49)	0.29 (1.79)	-1.30 (1.46)
95% CI	(-4.01, 5.80)	(-3.23, 3.81)	(-4.17, 1.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.19 (2.84)	1.58 (2.25)	
95% CI	(-3.40, 7.78)	(-2.85, 6.02)	
p-value	0.4412	0.4823	
Corrected Hedge's g Statistics	0.141	0.102	
95% CI	(-0.23, 0.51)	(-0.19, 0.40)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	84.12 (19.79)	85.46 (17.43)	84.90 (18.33)
Analysis Visit Mean (SD)	86.76 (15.02)	83.77 (20.14)	86.58 (17.22)
LS Mean of Change from Baseline (SE)	2.01 (2.57)	-1.94 (1.87)	0.76 (1.53)
95% CI	(-3.05, 7.07)	(-5.62, 1.74)	(-2.24, 3.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.24 (2.94)	-2.70 (2.35)	
95% CI	(-4.55, 7.03)	(-7.34, 1.93)	
p-value	0.6724	0.2513	
Corrected Hedge's g Statistics	0.081	-0.177	
95% CI	(-0.31, 0.47)	(-0.49, 0.14)	
Subgroup*Treatment Interaction p-value	0.7568	0.2550	

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Hopelessness			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	79.06 (20.76)	75.80 (22.88)	80.97 (19.88)
Analysis Visit Mean (SD)	78.83 (18.70)	75.68 (22.73)	79.73 (21.96)
LS Mean of Change from Baseline (SE)	-0.11 (2.88)	-1.82 (2.07)	-0.27 (1.69)
95% CI	(-5.78, 5.55)	(-5.90, 2.25)	(-3.60, 3.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.16 (3.27)	-1.55 (2.60)	
95% CI	(-6.29, 6.61)	(-6.68, 3.58)	
p-value	0.9613	0.5526	
Corrected Hedge's g Statistics	0.009	-0.086	
95% CI	(-0.36, 0.38)	(-0.38, 0.21)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	80.64 (19.87)	76.28 (24.22)	82.26 (18.70)
Analysis Visit Mean (SD)	85.06 (16.38)	75.65 (23.30)	81.11 (21.95)
LS Mean of Change from Baseline (SE)	5.64 (3.20)	-1.98 (2.32)	0.05 (1.90)
95% CI	(-0.65, 11.94)	(-6.55, 2.60)	(-3.69, 3.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.60 (3.65)	-2.02 (2.94)	
95% CI	(-1.60, 12.80)	(-7.81, 3.77)	
p-value	0.1270	0.4920	
Corrected Hedge's g Statistics	0.294	-0.106	
95% CI	(-0.10, 0.68)	(-0.42, 0.21)	
Subgroup*Treatment Interaction p-value	0.7320	0.1390	

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Stigma of Liver Disease			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	88.02 (16.29)	81.78 (20.56)	84.90 (19.27)
Analysis Visit Mean (SD)	90.22 (14.70)	81.96 (19.91)	89.44 (15.90)
LS Mean of Change from Baseline (SE)	3.60 (2.20)	-0.95 (1.57)	4.51 (1.28)
95% CI	(-0.73, 7.93)	(-4.05, 2.15)	(1.99, 7.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.91 (2.50)	-5.46 (1.98)	
95% CI	(-5.84, 4.01)	(-9.37, -1.56)	
p-value	0.7150	0.0063	
Corrected Hedge's g Statistics	-0.067	-0.402	
95% CI	(-0.44, 0.30)	(-0.70, -0.11)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	88.43 (15.39)	82.61 (20.11)	84.47 (19.37)
Analysis Visit Mean (SD)	91.55 (14.09)	85.70 (18.60)	89.93 (14.89)
LS Mean of Change from Baseline (SE)	4.79 (2.04)	2.19 (1.48)	5.00 (1.21)
95% CI	(0.76, 8.82)	(-0.73, 5.11)	(2.61, 7.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.21 (2.33)	-2.81 (1.86)	
95% CI	(-4.81, 4.38)	(-6.48, 0.85)	
p-value	0.9276	0.1319	
Corrected Hedge's g Statistics	-0.017	-0.232	
95% CI	(-0.41, 0.37)	(-0.54, 0.08)	
Subgroup*Treatment Interaction p-value	0.1013	0.0706	

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Symptoms of Liver Disease			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	75.44 (20.60)	70.62 (17.67)	74.21 (18.86)
Analysis Visit Mean (SD)	74.30 (21.63)	70.25 (16.29)	73.06 (20.29)
LS Mean of Change from Baseline (SE)	-0.70 (1.31)	-1.07 (1.87)	-1.37 (1.18)
95% CI	(-3.27, 1.87)	(-4.75, 2.61)	(-3.68, 0.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.67 (1.70)	0.30 (2.17)	
95% CI	(-2.68, 4.02)	(-3.96, 4.57)	
p-value	0.6943	0.8890	
Corrected Hedge's g Statistics	0.048	0.022	
95% CI	(-0.20, 0.30)	(-0.30, 0.34)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	76.94 (20.02)	71.13 (18.82)	73.82 (18.96)
Analysis Visit Mean (SD)	74.58 (20.61)	73.79 (17.52)	73.97 (21.20)
LS Mean of Change from Baseline (SE)	-1.94 (1.39)	1.36 (2.01)	-0.06 (1.22)
95% CI	(-4.68, 0.80)	(-2.59, 5.31)	(-2.46, 2.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.88 (1.80)	1.42 (2.31)	
95% CI	(-5.43, 1.67)	(-3.12, 5.97)	
p-value	0.2974	0.5384	
Corrected Hedge's g Statistics	-0.138	0.105	
95% CI	(-0.41, 0.13)	(-0.24, 0.45)	
Subgroup*Treatment Interaction p-value	0.5114	0.0890	

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Effects of Liver Disease			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	77.31 (15.15)	77.87 (16.48)	76.87 (15.65)
Analysis Visit Mean (SD)	74.45 (15.64)	79.81 (8.93)	75.24 (15.54)
LS Mean of Change from Baseline (SE)	-2.93 (1.21)	2.08 (1.72)	-1.86 (1.09)
95% CI	(-5.31, -0.56)	(-1.31, 5.47)	(-4.00, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.07 (1.58)	3.94 (2.00)	
95% CI	(-4.18, 2.03)	(0.00, 7.88)	
p-value	0.4958	0.0502	
Corrected Hedge's g Statistics	-0.084	0.310	
95% CI	(-0.33, 0.17)	(-0.01, 0.63)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	77.36 (15.00)	78.03 (17.53)	77.00 (14.32)
Analysis Visit Mean (SD)	74.93 (14.50)	76.44 (13.00)	76.64 (15.17)
LS Mean of Change from Baseline (SE)	-2.55 (1.44)	-1.58 (2.09)	-0.81 (1.27)
95% CI	(-5.39, 0.28)	(-5.69, 2.53)	(-3.30, 1.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.75 (1.88)	-0.77 (2.41)	
95% CI	(-5.44, 1.95)	(-5.52, 3.98)	
p-value	0.3535	0.7490	
Corrected Hedge's g Statistics	-0.124	-0.055	
95% CI	(-0.39, 0.14)	(-0.40, 0.29)	
Subgroup*Treatment Interaction p-value	0.2855	0.1272	

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Concentration/Memory			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	79.57 (23.69)	77.62 (21.66)	78.33 (20.47)
Analysis Visit Mean (SD)	77.59 (23.66)	79.03 (19.23)	78.42 (21.28)
LS Mean of Change from Baseline (SE)	-1.68 (1.47)	1.10 (2.10)	-0.18 (1.32)
95% CI	(-4.57, 1.21)	(-3.03, 5.23)	(-2.78, 2.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.50 (1.92)	1.28 (2.44)	
95% CI	(-5.29, 2.28)	(-3.53, 6.08)	
p-value	0.4345	0.6014	
Corrected Hedge's g Statistics	-0.096	0.083	
95% CI	(-0.35, 0.15)	(-0.23, 0.40)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	78.47 (23.45)	79.42 (20.85)	78.04 (20.76)
Analysis Visit Mean (SD)	78.02 (20.59)	78.71 (19.77)	75.74 (22.80)
LS Mean of Change from Baseline (SE)	-1.24 (1.43)	-0.07 (2.06)	-2.46 (1.26)
95% CI	(-4.06, 1.58)	(-4.13, 3.99)	(-4.94, 0.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.22 (1.85)	2.40 (2.38)	
95% CI	(-2.42, 4.87)	(-2.28, 7.07)	
p-value	0.5096	0.3141	
Corrected Hedge's g Statistics	0.087	0.172	
95% CI	(-0.18, 0.35)	(-0.17, 0.52)	
Subgroup*Treatment Interaction p-value	0.6113	0.1152	

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Health Distress			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	76.21 (26.86)	75.00 (27.74)	78.03 (23.55)
Analysis Visit Mean (SD)	80.92 (24.00)	84.43 (21.50)	83.64 (23.40)
LS Mean of Change from Baseline (SE)	4.05 (1.74)	8.08 (2.48)	5.42 (1.57)
95% CI	(0.63, 7.47)	(3.20, 12.96)	(2.34, 8.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.38 (2.27)	2.66 (2.88)	
95% CI	(-5.83, 3.08)	(-3.01, 8.32)	
p-value	0.5441	0.3567	
Corrected Hedge's g Statistics	-0.075	0.145	
95% CI	(-0.32, 0.17)	(-0.17, 0.46)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	76.43 (25.96)	76.42 (27.52)	79.92 (23.04)
Analysis Visit Mean (SD)	80.34 (24.78)	85.51 (18.47)	83.50 (22.23)
LS Mean of Change from Baseline (SE)	2.58 (2.06)	8.04 (2.98)	4.58 (1.81)
95% CI	(-1.47, 6.62)	(2.19, 13.90)	(1.02, 8.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.00 (2.68)	3.46 (3.44)	
95% CI	(-7.28, 3.27)	(-3.31, 10.23)	
p-value	0.4554	0.3152	
Corrected Hedge's g Statistics	-0.100	0.173	
95% CI	(-0.37, 0.17)	(-0.17, 0.52)	
Subgroup*Treatment Interaction p-value	0.1974	0.1781	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Sexual Function			
Week 24			
m	121	59	160
n	35	22	40
Baseline Mean (SD)	77.99 (24.72)	77.04 (19.38)	80.17 (22.92)
Analysis Visit Mean (SD)	76.87 (25.11)	74.47 (25.57)	81.92 (20.71)
LS Mean of Change from Baseline (SE)	-2.22 (3.37)	-4.60 (4.34)	-0.02 (3.17)
95% CI	(-8.91, 4.47)	(-13.22, 4.01)	(-6.30, 6.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.20 (4.56)	-4.59 (5.26)	
95% CI	(-11.25, 6.84)	(-15.02, 5.84)	
p-value	0.6300	0.3850	
Corrected Hedge's g Statistics	-0.109	-0.225	
95% CI	(-0.56, 0.35)	(-0.75, 0.30)	
Week 52			
m	110	51	154
n	26	16	30
Baseline Mean (SD)	84.67 (21.79)	80.20 (19.73)	80.15 (23.32)
Analysis Visit Mean (SD)	85.32 (18.21)	78.02 (28.10)	75.78 (26.05)
LS Mean of Change from Baseline (SE)	1.36 (3.49)	-0.89 (4.47)	-6.96 (3.25)
95% CI	(-5.56, 8.28)	(-9.76, 7.98)	(-13.40, -0.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.32 (4.71)	6.07 (5.43)	
95% CI	(-1.02, 17.65)	(-4.70, 16.83)	
p-value	0.0802	0.2662	
Corrected Hedge's g Statistics	0.461	0.335	
95% CI	(-0.07, 0.99)	(-0.28, 0.95)	
Subgroup*Treatment Interaction p-value	0.3750	0.4917	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Sleep			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	62.72 (21.32)	54.43 (20.84)	62.54 (19.83)
Analysis Visit Mean (SD)	62.81 (20.90)	54.15 (19.11)	61.18 (20.39)
LS Mean of Change from Baseline (SE)	0.42 (1.42)	-2.75 (2.05)	-1.50 (1.28)
95% CI	(-2.38, 3.22)	(-6.78, 1.28)	(-4.03, 1.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.92 (1.86)	-1.24 (2.38)	
95% CI	(-1.73, 5.57)	(-5.93, 3.44)	
p-value	0.3012	0.6022	
Corrected Hedge's g Statistics	0.127	-0.083	
95% CI	(-0.12, 0.38)	(-0.40, 0.23)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	64.06 (20.90)	53.75 (21.78)	61.52 (20.56)
Analysis Visit Mean (SD)	63.49 (18.33)	55.45 (21.43)	61.97 (20.88)
LS Mean of Change from Baseline (SE)	0.50 (1.53)	-1.15 (2.23)	-0.23 (1.34)
95% CI	(-2.52, 3.52)	(-5.54, 3.24)	(-2.87, 2.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.73 (1.99)	-0.93 (2.57)	
95% CI	(-3.18, 4.64)	(-5.98, 4.13)	
p-value	0.7140	0.7185	
Corrected Hedge's g Statistics	0.049	-0.062	
95% CI	(-0.22, 0.32)	(-0.41, 0.28)	
Subgroup*Treatment Interaction p-value	0.8011	0.1801	

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Loneliness			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	84.56 (17.69)	79.91 (23.36)	84.14 (20.71)
Analysis Visit Mean (SD)	82.92 (19.18)	81.51 (21.27)	82.17 (20.88)
LS Mean of Change from Baseline (SE)	-1.82 (1.41)	0.29 (2.02)	-2.04 (1.27)
95% CI	(-4.60, 0.96)	(-3.69, 4.27)	(-4.54, 0.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.22 (1.85)	2.33 (2.35)	
95% CI	(-3.41, 3.85)	(-2.30, 6.95)	
p-value	0.9066	0.3230	
Corrected Hedge's g Statistics	0.014	0.157	
95% CI	(-0.23, 0.26)	(-0.16, 0.47)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	84.84 (18.13)	78.52 (24.32)	83.42 (20.98)
Analysis Visit Mean (SD)	84.38 (18.10)	81.59 (22.79)	82.01 (20.87)
LS Mean of Change from Baseline (SE)	-0.77 (1.44)	1.30 (2.09)	-1.90 (1.27)
95% CI	(-3.61, 2.07)	(-2.81, 5.41)	(-4.39, 0.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.13 (1.87)	3.20 (2.40)	
95% CI	(-2.55, 4.80)	(-1.53, 7.93)	
p-value	0.5474	0.1841	
Corrected Hedge's g Statistics	0.080	0.228	
95% CI	(-0.19, 0.35)	(-0.12, 0.57)	
Subgroup*Treatment Interaction p-value	0.7568	0.2550	

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Hopelessness			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	74.64 (23.11)	76.10 (22.88)	79.11 (21.59)
Analysis Visit Mean (SD)	77.92 (23.76)	80.35 (22.36)	79.51 (20.89)
LS Mean of Change from Baseline (SE)	2.27 (1.65)	3.74 (2.35)	1.16 (1.49)
95% CI	(-0.97, 5.51)	(-0.88, 8.36)	(-1.77, 4.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.11 (2.16)	2.59 (2.73)	
95% CI	(-3.13, 5.36)	(-2.79, 7.96)	
p-value	0.6057	0.3448	
Corrected Hedge's g Statistics	0.064	0.149	
95% CI	(-0.19, 0.31)	(-0.17, 0.47)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	75.96 (22.49)	76.33 (23.70)	78.14 (22.69)
Analysis Visit Mean (SD)	76.65 (22.31)	80.31 (19.69)	76.91 (22.80)
LS Mean of Change from Baseline (SE)	0.81 (1.77)	3.76 (2.55)	-1.01 (1.55)
95% CI	(-2.67, 4.29)	(-1.25, 8.78)	(-4.06, 2.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.82 (2.29)	4.77 (2.94)	
95% CI	(-2.69, 6.34)	(-1.02, 10.56)	
p-value	0.4281	0.1060	
Corrected Hedge's g Statistics	0.105	0.278	
95% CI	(-0.16, 0.37)	(-0.07, 0.62)	
Subgroup*Treatment Interaction p-value	0.7320	0.1390	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Stigma of Liver Disease			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	80.83 (22.32)	79.27 (19.83)	83.52 (19.01)
Analysis Visit Mean (SD)	83.95 (20.53)	80.09 (20.33)	82.65 (19.81)
LS Mean of Change from Baseline (SE)	3.27 (1.50)	0.34 (2.14)	0.12 (1.35)
95% CI	(0.33, 6.22)	(-3.87, 4.56)	(-2.53, 2.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.15 (1.96)	0.22 (2.49)	
95% CI	(-0.70, 7.01)	(-4.68, 5.13)	
p-value	0.1088	0.9293	
Corrected Hedge's g Statistics	0.198	0.014	
95% CI	(-0.05, 0.45)	(-0.30, 0.33)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	81.98 (22.00)	79.85 (20.79)	82.86 (18.78)
Analysis Visit Mean (SD)	85.89 (18.34)	81.65 (19.39)	81.47 (20.81)
LS Mean of Change from Baseline (SE)	4.47 (1.56)	0.82 (2.26)	-0.61 (1.37)
95% CI	(1.39, 7.55)	(-3.63, 5.26)	(-3.31, 2.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.08 (2.03)	1.43 (2.60)	
95% CI	(1.09, 9.07)	(-3.69, 6.55)	
p-value	0.0127	0.5835	
Corrected Hedge's g Statistics	0.332	0.094	
95% CI	(0.06, 0.60)	(-0.25, 0.44)	
Subgroup*Treatment Interaction p-value	0.1013	0.0706	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	1 (1.2)	6 (4.5)
No	42 (97.7)	85 (98.8)	126 (95.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	4.05	
95% CI of the inverse odds ratio	(0.23, 17.09)	(0.48, 34.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.95	3.91	
95% CI of the inverse risk ratio	(0.24, 15.78)	(0.48, 31.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.22	-3.38	
95% CI of the absolute risk difference	(-7.96, 3.52)	(-7.60, 0.83)	
p-value	0.5188	0.1662	
p-value of Breslow-Day Test for Homogeneity [3]	0.3181	0.0935	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (30.2)	15 (17.4)	30 (22.7)
No	30 (69.8)	71 (82.6)	102 (77.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	1.39	
95% CI of the inverse odds ratio	(0.32, 1.46)	(0.70, 2.78)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.30	
95% CI of the inverse risk ratio	(0.43, 1.31)	(0.75, 2.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.51	-5.29	
95% CI of the absolute risk difference	(-7.97, 22.98)	(-16.03, 5.46)	
p-value	0.3208	0.3460	
p-value of Breslow-Day Test for Homogeneity [3]	0.7884	0.0612	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	7 (8.1)	12 (9.1)
No	42 (97.7)	79 (91.9)	120 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.20	1.13	
95% CI of the inverse odds ratio	(0.53, 33.29)	(0.43, 2.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.91	1.12	
95% CI of the inverse risk ratio	(0.52, 29.20)	(0.46, 2.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.77	-0.95	
95% CI of the absolute risk difference	(-13.42, -0.11)	(-8.53, 6.63)	
p-value	0.1418	0.8077	
p-value of Breslow-Day Test for Homogeneity [3]	0.5567	0.2895	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (23.3)	19 (22.1)	32 (24.2)
No	33 (76.7)	67 (77.9)	100 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.13	
95% CI of the inverse odds ratio	(0.47, 2.38)	(0.59, 2.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.10	
95% CI of the inverse risk ratio	(0.56, 1.94)	(0.67, 1.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.99	-2.15	
95% CI of the absolute risk difference	(-15.58, 13.60)	(-13.57, 9.27)	
p-value	0.8953	0.7141	
p-value of Breslow-Day Test for Homogeneity [3]	0.6274	0.4597	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.7)	4 (4.7)	14 (10.6)
No	41 (95.3)	82 (95.3)	118 (89.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.43	2.43	
95% CI of the inverse odds ratio	(0.53, 11.16)	(0.77, 7.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.28	2.28	
95% CI of the inverse risk ratio	(0.54, 9.63)	(0.78, 6.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.95	-5.95	
95% CI of the absolute risk difference	(-14.15, 2.24)	(-12.84, 0.93)	
p-value	0.2393	0.1185	
p-value of Breslow-Day Test for Homogeneity [3]	0.8254	0.1238	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (20.9)	18 (20.9)	27 (20.5)
No	34 (79.1)	68 (79.1)	105 (79.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.97	
95% CI of the inverse odds ratio	(0.42, 2.27)	(0.50, 1.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.98	
95% CI of the inverse risk ratio	(0.50, 1.91)	(0.57, 1.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.48	0.48	
95% CI of the absolute risk difference	(-13.50, 14.45)	(-10.54, 11.49)	
p-value	0.9466	0.9324	
p-value of Breslow-Day Test for Homogeneity [3]	0.5359	0.6121	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (7.0)	4 (4.7)	12 (9.1)
No	40 (93.0)	82 (95.3)	120 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	2.05	
95% CI of the inverse odds ratio	(0.36, 4.97)	(0.64, 6.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	1.95	
95% CI of the inverse risk ratio	(0.39, 4.40)	(0.65, 5.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.11	-4.44	
95% CI of the absolute risk difference	(-11.17, 6.94)	(-11.06, 2.18)	
p-value	0.6671	0.2192	
p-value of Breslow-Day Test for Homogeneity [3]	0.1872	0.1293	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (27.9)	21 (24.4)	34 (25.8)
No	31 (72.1)	65 (75.6)	98 (74.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.07	
95% CI of the inverse odds ratio	(0.41, 1.94)	(0.57, 2.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.05	
95% CI of the inverse risk ratio	(0.53, 1.62)	(0.66, 1.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.15	-1.34	
95% CI of the absolute risk difference	(-13.19, 17.49)	(-13.09, 10.41)	
p-value	0.7809	0.8240	
p-value of Breslow-Day Test for Homogeneity [3]	0.9111	0.5312	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (14.0)	12 (14.0)	17 (12.9)
No	37 (86.0)	74 (86.0)	115 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.91	
95% CI of the inverse odds ratio	(0.33, 2.48)	(0.41, 2.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.92	
95% CI of the inverse risk ratio	(0.39, 2.19)	(0.46, 1.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.07	1.07	
95% CI of the absolute risk difference	(-10.75, 12.90)	(-8.21, 10.36)	
p-value	0.8562	0.8194	
p-value of Breslow-Day Test for Homogeneity [3]	0.9945	0.6530	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (18.6)	16 (18.6)	30 (22.7)
No	35 (81.4)	70 (81.4)	102 (77.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.29	
95% CI of the inverse odds ratio	(0.54, 3.07)	(0.65, 2.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	1.22	
95% CI of the inverse risk ratio	(0.61, 2.46)	(0.71, 2.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.12	-4.12	
95% CI of the absolute risk difference	(-17.78, 9.53)	(-15.02, 6.77)	
p-value	0.5690	0.4659	
p-value of Breslow-Day Test for Homogeneity [3]	0.5006	0.2078	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (7.0)	2 (2.3)	9 (6.8)
No	40 (93.0)	84 (97.7)	123 (93.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	3.07	
95% CI of the inverse odds ratio	(0.25, 3.78)	(0.65, 14.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	2.93	
95% CI of the inverse risk ratio	(0.28, 3.45)	(0.65, 13.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.16	-4.49	
95% CI of the absolute risk difference	(-8.59, 8.90)	(-9.84, 0.86)	
p-value	0.9715	0.1386	
p-value of Breslow-Day Test for Homogeneity [3]	0.9924	0.0359	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (16.3)	6 (7.0)	18 (13.6)
No	36 (83.7)	80 (93.0)	114 (86.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	2.11	
95% CI of the inverse odds ratio	(0.31, 2.10)	(0.80, 5.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.95	
95% CI of the inverse risk ratio	(0.38, 1.87)	(0.81, 4.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.64	-6.66	
95% CI of the absolute risk difference	(-9.85, 15.13)	(-14.61, 1.29)	
p-value	0.6671	0.1247	
p-value of Breslow-Day Test for Homogeneity [3]	0.9646	0.0129	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (16.3)	9 (10.5)	20 (15.2)
No	36 (83.7)	77 (89.5)	112 (84.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.53	
95% CI of the inverse odds ratio	(0.36, 2.35)	(0.66, 3.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.45	
95% CI of the inverse risk ratio	(0.42, 2.05)	(0.69, 3.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.13	-4.69	
95% CI of the absolute risk difference	(-11.49, 13.74)	(-13.59, 4.22)	
p-value	0.8589	0.3193	
p-value of Breslow-Day Test for Homogeneity [3]	0.6950	0.4226	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (34.9)	23 (26.7)	46 (34.8)
No	28 (65.1)	63 (73.3)	86 (65.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.47	
95% CI of the inverse odds ratio	(0.48, 2.06)	(0.81, 2.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.30	
95% CI of the inverse risk ratio	(0.62, 1.60)	(0.86, 1.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.04	-8.10	
95% CI of the absolute risk difference	(-16.37, 16.44)	(-20.50, 4.29)	
p-value	0.9966	0.2086	
p-value of Breslow-Day Test for Homogeneity [3]	0.7917	0.1915	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (18.6)	11 (12.8)	18 (13.6)
No	35 (81.4)	75 (87.2)	114 (86.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.08	
95% CI of the inverse odds ratio	(0.28, 1.72)	(0.48, 2.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	1.07	
95% CI of the inverse risk ratio	(0.34, 1.56)	(0.53, 2.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.97	-0.85	
95% CI of the absolute risk difference	(-8.05, 17.99)	(-10.02, 8.32)	
p-value	0.4263	0.8574	
p-value of Breslow-Day Test for Homogeneity [3]	0.6722	0.0740	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (25.6)	21 (24.4)	41 (31.1)
No	32 (74.4)	65 (75.6)	91 (68.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.39	
95% CI of the inverse odds ratio	(0.60, 2.85)	(0.75, 2.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.27	
95% CI of the inverse risk ratio	(0.69, 2.15)	(0.81, 2.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.48	-6.64	
95% CI of the absolute risk difference	(-20.72, 9.77)	(-18.67, 5.39)	
p-value	0.4947	0.2880	
p-value of Breslow-Day Test for Homogeneity [3]	0.6035	0.2757	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (16.3)	18 (20.9)	22 (16.7)
No	36 (83.7)	68 (79.1)	110 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.76	
95% CI of the inverse odds ratio	(0.41, 2.61)	(0.38, 1.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.80	
95% CI of the inverse risk ratio	(0.47, 2.23)	(0.45, 1.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.39	4.26	
95% CI of the absolute risk difference	(-13.12, 12.35)	(-6.43, 14.96)	
p-value	0.9527	0.4267	
p-value of Breslow-Day Test for Homogeneity [3]	0.2385	0.1866	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (34.9)	23 (26.7)	31 (23.5)
No	28 (65.1)	63 (73.3)	101 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	0.84	
95% CI of the inverse odds ratio	(0.27, 1.21)	(0.45, 1.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.88	
95% CI of the inverse risk ratio	(0.40, 1.12)	(0.55, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.40	3.26	
95% CI of the absolute risk difference	(-4.58, 27.37)	(-8.56, 15.08)	
p-value	0.1403	0.5859	
p-value of Breslow-Day Test for Homogeneity [3]	0.4514	0.4988	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (9.3)	10 (11.6)	19 (14.4)
No	39 (90.7)	76 (88.4)	113 (85.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.64	1.28	
95% CI of the inverse odds ratio	(0.53, 5.12)	(0.56, 2.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	1.24	
95% CI of the inverse risk ratio	(0.56, 4.30)	(0.60, 2.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.09	-2.77	
95% CI of the absolute risk difference	(-15.64, 5.46)	(-11.81, 6.28)	
p-value	0.3908	0.5567	
p-value of Breslow-Day Test for Homogeneity [3]	0.1459	0.2638	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (25.6)	25 (29.1)	44 (33.3)
No	32 (74.4)	61 (70.9)	88 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	1.22	
95% CI of the inverse odds ratio	(0.67, 3.16)	(0.68, 2.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	1.15	
95% CI of the inverse risk ratio	(0.74, 2.29)	(0.76, 1.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.75	-4.26	
95% CI of the absolute risk difference	(-23.07, 7.57)	(-16.78, 8.26)	
p-value	0.3416	0.5083	
p-value of Breslow-Day Test for Homogeneity [3]	0.0433	0.2408	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.0)	3 (4.6)	4 (2.3)
No	119 (96.0)	62 (95.4)	167 (97.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	0.50	
95% CI of the inverse odds ratio	(0.15, 2.17)	(0.11, 2.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.51	
95% CI of the inverse risk ratio	(0.16, 2.12)	(0.12, 2.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.69	2.28	
95% CI of the absolute risk difference	(-2.44, 5.83)	(-3.30, 7.86)	
p-value	0.4039	0.3572	
p-value of Breslow-Day Test for Homogeneity [3]	0.3181	0.0935	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (20.2)	17 (26.2)	28 (16.4)
No	99 (79.8)	48 (73.8)	143 (83.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.55	
95% CI of the inverse odds ratio	(0.43, 1.41)	(0.28, 1.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.63	
95% CI of the inverse risk ratio	(0.50, 1.32)	(0.37, 1.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.79	9.78	
95% CI of the absolute risk difference	(-5.19, 12.77)	(-2.26, 21.82)	
p-value	0.4030	0.0875	
p-value of Breslow-Day Test for Homogeneity [3]	0.7884	0.0612	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.0)	9 (13.8)	14 (8.2)
No	119 (96.0)	56 (86.2)	157 (91.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.12	0.55	
95% CI of the inverse odds ratio	(0.74, 6.06)	(0.23, 1.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.03	0.59	
95% CI of the inverse risk ratio	(0.75, 5.49)	(0.27, 1.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.15	5.66	
95% CI of the absolute risk difference	(-9.53, 1.22)	(-3.69, 15.01)	
p-value	0.1513	0.1904	
p-value of Breslow-Day Test for Homogeneity [3]	0.5567	0.2895	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (21.0)	20 (30.8)	45 (26.3)
No	98 (79.0)	45 (69.2)	126 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	0.80	
95% CI of the inverse odds ratio	(0.78, 2.33)	(0.43, 1.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	0.86	
95% CI of the inverse risk ratio	(0.82, 1.92)	(0.55, 1.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.35	4.45	
95% CI of the absolute risk difference	(-15.09, 4.39)	(-8.56, 17.47)	
p-value	0.2889	0.4939	
p-value of Breslow-Day Test for Homogeneity [3]	0.6274	0.4597	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (2.4)	6 (9.2)	12 (7.0)
No	121 (97.6)	59 (90.8)	159 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.04	0.74	
95% CI of the inverse odds ratio	(0.84, 11.03)	(0.27, 2.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.90	0.76	
95% CI of the inverse risk ratio	(0.84, 10.06)	(0.30, 1.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.60	2.21	
95% CI of the absolute risk difference	(-9.29, 0.09)	(-5.80, 10.22)	
p-value	0.0760	0.5672	
p-value of Breslow-Day Test for Homogeneity [3]	0.8254	0.1238	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (14.5)	10 (15.4)	32 (18.7)
No	106 (85.5)	55 (84.6)	139 (81.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	1.27	
95% CI of the inverse odds ratio	(0.72, 2.55)	(0.58, 2.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.22	
95% CI of the inverse risk ratio	(0.76, 2.19)	(0.63, 2.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.20	-3.33	
95% CI of the absolute risk difference	(-12.72, 4.32)	(-13.87, 7.21)	
p-value	0.3429	0.5503	
p-value of Breslow-Day Test for Homogeneity [3]	0.5359	0.6121	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (9.7)	5 (7.7)	8 (4.7)
No	112 (90.3)	60 (92.3)	163 (95.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.46	0.59	
95% CI of the inverse odds ratio	(0.18, 1.16)	(0.19, 1.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	0.61	
95% CI of the inverse risk ratio	(0.20, 1.15)	(0.21, 1.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.00	3.01	
95% CI of the absolute risk difference	(-1.09, 11.09)	(-4.20, 10.22)	
p-value	0.0918	0.3646	
p-value of Breslow-Day Test for Homogeneity [3]	0.1872	0.1293	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (20.2)	15 (23.1)	33 (19.3)
No	99 (79.8)	50 (76.9)	138 (80.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.80	
95% CI of the inverse odds ratio	(0.53, 1.69)	(0.40, 1.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.84	
95% CI of the inverse risk ratio	(0.60, 1.52)	(0.49, 1.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.86	3.78	
95% CI of the absolute risk difference	(-8.35, 10.07)	(-8.05, 15.61)	
p-value	0.8539	0.5194	
p-value of Breslow-Day Test for Homogeneity [3]	0.9111	0.5312	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	22 (17.7)	14 (21.5)	28 (16.4)
No	102 (82.3)	51 (78.5)	143 (83.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.71	
95% CI of the inverse odds ratio	(0.49, 1.68)	(0.35, 1.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.76	
95% CI of the inverse risk ratio	(0.56, 1.53)	(0.43, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.37	5.16	
95% CI of the absolute risk difference	(-7.35, 10.08)	(-6.27, 16.59)	
p-value	0.7573	0.3541	
p-value of Breslow-Day Test for Homogeneity [3]	0.9945	0.6530	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (25.8)	20 (30.8)	41 (24.0)
No	92 (74.2)	45 (69.2)	130 (76.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.71	
95% CI of the inverse odds ratio	(0.53, 1.55)	(0.38, 1.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.78	
95% CI of the inverse risk ratio	(0.62, 1.39)	(0.50, 1.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.83	6.79	
95% CI of the absolute risk difference	(-8.18, 11.84)	(-6.12, 19.71)	
p-value	0.7192	0.2870	
p-value of Breslow-Day Test for Homogeneity [3]	0.5006	0.2078	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (2.4)	4 (6.2)	4 (2.3)
No	121 (97.6)	61 (93.8)	167 (97.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.37	
95% CI of the inverse odds ratio	(0.21, 4.40)	(0.09, 1.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.38	
95% CI of the inverse risk ratio	(0.22, 4.24)	(0.10, 1.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.08	3.81	
95% CI of the absolute risk difference	(-3.45, 3.61)	(-2.45, 10.08)	
p-value	0.9644	0.1480	
p-value of Breslow-Day Test for Homogeneity [3]	0.9924	0.0359	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (4.8)	7 (10.8)	7 (4.1)
No	118 (95.2)	58 (89.2)	164 (95.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.35	
95% CI of the inverse odds ratio	(0.28, 2.56)	(0.12, 1.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.38	
95% CI of the inverse risk ratio	(0.29, 2.46)	(0.14, 1.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.75	6.68	
95% CI of the absolute risk difference	(-4.06, 5.55)	(-1.42, 14.78)	
p-value	0.7582	0.0525	
p-value of Breslow-Day Test for Homogeneity [3]	0.9646	0.0129	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (14.5)	11 (16.9)	28 (16.4)
No	106 (85.5)	54 (83.1)	143 (83.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.96	
95% CI of the inverse odds ratio	(0.61, 2.19)	(0.45, 2.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	0.97	
95% CI of the inverse risk ratio	(0.65, 1.95)	(0.51, 1.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.86	0.55	
95% CI of the absolute risk difference	(-10.18, 6.46)	(-10.12, 11.22)	
p-value	0.6641	0.9192	
p-value of Breslow-Day Test for Homogeneity [3]	0.6950	0.4226	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	34 (27.4)	22 (33.8)	51 (29.8)
No	90 (72.6)	43 (66.2)	120 (70.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	0.83	
95% CI of the inverse odds ratio	(0.67, 1.88)	(0.45, 1.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.88	
95% CI of the inverse risk ratio	(0.75, 1.57)	(0.58, 1.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.41	4.02	
95% CI of the absolute risk difference	(-12.83, 8.02)	(-9.37, 17.41)	
p-value	0.6525	0.5504	
p-value of Breslow-Day Test for Homogeneity [3]	0.7917	0.1915	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (9.7)	13 (20.0)	15 (8.8)
No	112 (90.3)	52 (80.0)	156 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	0.38	
95% CI of the inverse odds ratio	(0.40, 1.99)	(0.17, 0.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.44	
95% CI of the inverse risk ratio	(0.44, 1.87)	(0.22, 0.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.91	11.23	
95% CI of the absolute risk difference	(-5.81, 7.62)	(0.62, 21.84)	
p-value	0.7901	0.0172	
p-value of Breslow-Day Test for Homogeneity [3]	0.6722	0.0740	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (24.2)	18 (27.7)	42 (24.6)
No	94 (75.8)	47 (72.3)	129 (75.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.85	
95% CI of the inverse odds ratio	(0.60, 1.75)	(0.45, 1.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.89	
95% CI of the inverse risk ratio	(0.68, 1.53)	(0.55, 1.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.37	3.13	
95% CI of the absolute risk difference	(-10.29, 9.55)	(-9.52, 15.78)	
p-value	0.9421	0.6217	
p-value of Breslow-Day Test for Homogeneity [3]	0.6035	0.2757	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	24 (19.4)	16 (24.6)	19 (11.1)
No	100 (80.6)	49 (75.4)	152 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	0.38	
95% CI of the inverse odds ratio	(0.27, 1.00)	(0.18, 0.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	0.45	
95% CI of the inverse risk ratio	(0.33, 1.00)	(0.25, 0.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.24	13.50	
95% CI of the absolute risk difference	(-0.16, 16.64)	(2.02, 24.99)	
p-value	0.0476	0.0091	
p-value of Breslow-Day Test for Homogeneity [3]	0.2385	0.1866	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (26.6)	21 (32.3)	39 (22.8)
No	91 (73.4)	44 (67.7)	132 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.62	
95% CI of the inverse odds ratio	(0.48, 1.39)	(0.33, 1.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.71	
95% CI of the inverse risk ratio	(0.57, 1.28)	(0.45, 1.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.81	9.50	
95% CI of the absolute risk difference	(-6.20, 13.81)	(-3.49, 22.49)	
p-value	0.4525	0.1343	
p-value of Breslow-Day Test for Homogeneity [3]	0.4514	0.4988	

AMNOG Table SE21.3.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (12.9)	8 (12.3)	14 (8.2)
No	108 (87.1)	57 (87.7)	157 (91.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.64	
95% CI of the inverse odds ratio	(0.28, 1.28)	(0.25, 1.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.67	
95% CI of the inverse risk ratio	(0.32, 1.25)	(0.29, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.72	4.12	
95% CI of the absolute risk difference	(-2.47, 11.91)	(-4.86, 13.10)	
p-value	0.1859	0.3307	
p-value of Breslow-Day Test for Homogeneity [3]	0.1459	0.2638	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	41 (33.1)	18 (27.7)	37 (21.6)
No	83 (66.9)	47 (72.3)	134 (78.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.72	
95% CI of the inverse odds ratio	(0.33, 0.94)	(0.37, 1.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	0.78	
95% CI of the inverse risk ratio	(0.45, 0.96)	(0.48, 1.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.43	6.05	
95% CI of the absolute risk difference	(1.10, 21.75)	(-6.45, 18.56)	
p-value	0.0280	0.3257	
p-value of Breslow-Day Test for Homogeneity [3]	0.0433	0.2408	

Madrigal Pharmaceuticals, Inc. Page 1 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE21.3.5
Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component;
by Sex;
(Label Population)

Sex: Male
Total LDQOL



Patients with result at given visit			
MGL-3196 80 mg	40	39	36
MGL-3196 100 mg	79	79	67
Placebo	122	121	107

Abbreviations: Abbreviations: LDLOQ = Liver Disease Quality of Life; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE21.3.5
Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component;
by Sex;
(Label Population)

Sex: Female
Total LDQOL



Patients with result at given visit			
MGL-3196 80 mg	118	118	100
MGL-3196 100 mg	59	57	47
Placebo	158	146	132

Abbreviations: Abbreviations: LDLOQ = Liver Disease Quality of Life; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Total LDQOL						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	78.31 (13.56)	76.99 (13.90)	77.80 (13.73)			
Median	82.45	79.65	81.80			
IQR: Q1, Q3	69.70, 89.30	67.60, 87.85	71.80, 87.90			
Min, Max	38.5, 96.5	23.6, 96.3	34.8, 97.1			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	79.05 (12.86)	78.05 (12.29)	78.89 (13.98)	0.20 (0.96)	0.53 (0.80)	0.30 (0.78)
Median	81.90	79.80	82.80	0.15	-0.40	0.40
IQR: Q1, Q3	71.40, 89.90	70.80, 86.70	71.30, 89.30	-5.80, 5.05	-5.00, 5.70	-4.40, 4.80
Min, Max	36.6, 96.3	32.4, 96.9	22.4, 98.8	-23.4, 24.2	-15.4, 26.0	-46.4, 42.3
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	79.62 (12.59)	78.66 (13.52)	79.15 (14.24)	0.26 (1.01)	0.51 (0.94)	0.38 (0.79)
Median	82.40	82.20	83.05	-0.05	0.75	0.60
IQR: Q1, Q3	72.40, 88.50	70.30, 89.80	71.20, 89.90	-4.15, 5.55	-4.00, 5.40	-4.30, 5.30
Min, Max	34.0, 97.5	34.2, 97.4	34.3, 100.0	-19.3, 25.3	-23.3, 24.3	-36.2, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Symptoms of Liver Disease						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	77.17 (17.51)	74.72 (18.56)	75.16 (17.61)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	66.70, 90.00	63.30, 86.70	63.30, 90.00			
Min, Max	30.0, 100.0	10.0, 100.0	20.0, 100.0			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	75.76 (18.56)	74.52 (17.09)	76.21 (18.78)	-1.78 (1.51)	-0.54 (1.22)	-0.17 (1.03)
Median	80.00	76.70	80.00	0	0	0
IQR: Q1, Q3	66.70, 90.00	63.30, 86.70	63.30, 90.00	-10.00, 3.40	-6.70, 6.70	-6.70, 6.70
Min, Max	20.0, 100.0	30.0, 100.0	20.0, 100.0	-46.6, 36.7	-33.3, 30.0	-53.3, 36.7
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	77.53 (16.78)	77.01 (17.91)	76.82 (19.39)	-1.31 (1.46)	0.43 (1.48)	0.57 (1.05)
Median	80.00	80.00	83.30	0	0	0
IQR: Q1, Q3	66.70, 90.00	66.70, 93.30	66.70, 93.30	-8.35, 6.70	-6.70, 6.70	-6.70, 6.70
Min, Max	26.7, 100.0	26.7, 100.0	16.7, 100.0	-33.4, 43.4	-36.7, 36.7	-36.7, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Effects of Liver Disease						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	78.27 (12.57)	78.77 (13.52)	76.63 (15.05)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	76.65, 86.70	80.00, 80.00			
Min, Max	20.0, 100.0	26.7, 100.0	6.7, 100.0			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	76.33 (10.87)	79.44 (10.25)	77.03 (14.87)	-2.88 (1.07)	0.00 (1.33)	-0.04 (1.06)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 6.60
Min, Max	40.0, 100.0	40.0, 100.0	6.7, 100.0	-40.0, 33.3	-26.7, 53.3	-46.7, 53.4
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	78.14 (9.28)	78.20 (12.00)	78.20 (12.57)	-1.36 (1.29)	-1.01 (1.39)	0.63 (1.41)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 0.00	-6.70, 0.00	0.00, 6.60
Min, Max	40.0, 100.0	26.7, 100.0	20.0, 100.0	-40.0, 46.7	-33.3, 40.0	-80.0, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Concentration/Memory						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	81.00 (22.09)	79.30 (19.86)	79.09 (20.83)			
Median	87.50	87.50	87.50			
IQR: Q1, Q3	68.80, 100.00	68.80, 93.80	68.80, 93.80			
Min, Max	12.5, 100.0	18.8, 100.0	6.3, 100.0			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	79.65 (20.33)	80.63 (18.73)	81.84 (20.45)	-1.85 (1.69)	-0.19 (1.46)	1.55 (1.28)
Median	81.30	81.30	87.50	0	0	0
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	75.00, 100.00	-12.50, 6.20	-6.30, 6.30	-6.20, 6.30
Min, Max	0.0, 100.0	25.0, 100.0	6.3, 100.0	-43.8, 31.2	-37.5, 56.2	-81.2, 62.5
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	79.08 (19.26)	80.92 (18.98)	79.68 (22.61)	-2.22 (1.40)	-1.23 (1.49)	-1.10 (1.19)
Median	81.30	87.50	87.50	0	0	0
IQR: Q1, Q3	68.80, 93.80	68.80, 100.00	68.80, 100.00	-6.30, 0.00	-6.30, 6.20	-6.30, 6.20
Min, Max	0.0, 100.0	18.8, 100.0	0.0, 100.0	-43.7, 31.3	-37.5, 43.7	-43.8, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Health Distress						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	78.80 (26.77)	81.48 (25.38)	80.78 (24.63)			
Median	87.50	100.00	87.50			
IQR: Q1, Q3	68.75, 100.00	68.75, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	85.53 (20.46)	88.32 (19.37)	85.07 (23.55)	5.97 (2.30)	6.57 (1.83)	4.09 (1.45)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	25.0, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 75.0	-37.5, 50.0	-62.5, 50.0
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	85.39 (23.33)	87.64 (20.16)	85.83 (22.37)	5.10 (2.74)	4.94 (2.14)	2.90 (1.91)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-75.0, 75.0	-50.0, 75.0	-87.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Sexual Function						
Baseline						
m	94	119	198			
n	35	57	68			
Mean (SD)	76.25 (30.46)	80.58 (23.39)	75.00 (26.76)			
Median	93.30	93.30	85.00			
IQR: Q1, Q3	55.00, 100.00	68.30, 100.00	61.70, 100.00			
Min, Max	-1.7, 100.0	-1.7, 100.0	-1.7, 100.0			
Week 24						
m	91	110	187			
n	39	62	76	30	47	54
Mean (SD/SE)	78.60 (24.50)	74.33 (27.96)	77.17 (24.06)	3.77 (5.34)	-3.64 (2.68)	1.21 (2.38)
Median	85.00	85.00	85.00	0	0	0
IQR: Q1, Q3	61.70, 100.00	55.00, 100.00	61.70, 100.00	-6.60, 8.40	-15.00, 0.00	-6.70, 8.30
Min, Max	15.0, 100.0	-1.7, 100.0	6.7, 100.0	-85.0, 91.1	-48.3, 41.7	-46.7, 38.4
Week 52						
m	85	97	175			
n	27	43	59	24	36	42
Mean (SD/SE)	80.31 (27.05)	79.17 (28.30)	75.59 (26.60)	4.15 (5.26)	-3.62 (3.09)	-0.63 (2.91)
Median	93.30	93.30	83.30	0	0	0
IQR: Q1, Q3	61.70, 100.00	63.30, 100.00	56.70, 100.00	-4.20, 0.00	-10.80, 0.00	-8.30, 8.30
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-45.0, 91.1	-50.0, 48.3	-53.3, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Sleep						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	63.80 (19.92)	59.07 (20.04)	62.18 (19.63)			
Median	65.00	60.00	65.00			
IQR: Q1, Q3	50.00, 80.00	47.50, 75.00	50.00, 75.00			
Min, Max	15.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	65.34 (19.70)	57.38 (20.38)	61.57 (20.16)	0.51 (1.60)	-1.77 (1.42)	-1.58 (1.27)
Median	65.00	60.00	60.00	0	-5.00	0
IQR: Q1, Q3	50.00, 80.00	45.00, 70.00	50.00, 75.00	-5.00, 5.00	-10.00, 5.00	-10.00, 10.00
Min, Max	15.0, 100.0	0.0, 100.0	15.0, 100.0	-30.0, 55.0	-35.0, 45.0	-40.0, 50.0
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	63.20 (19.74)	58.60 (21.62)	64.07 (21.02)	-1.89 (1.84)	-1.34 (1.86)	1.23 (1.34)
Median	65.00	60.00	65.00	-5.00	0	0
IQR: Q1, Q3	50.00, 80.00	45.00, 75.00	50.00, 80.00	-10.00, 5.00	-10.00, 10.00	-10.00, 10.00
Min, Max	15.0, 100.0	0.0, 95.0	5.0, 100.0	-40.0, 45.0	-60.0, 45.0	-40.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Loneliness						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	87.88 (16.43)	82.69 (20.66)	85.69 (17.69)			
Median	95.00	90.00	95.00			
IQR: Q1, Q3	82.50, 100.00	70.00, 100.00	75.00, 100.00			
Min, Max	35.0, 100.0	0.0, 100.0	25.0, 100.0			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	85.22 (16.75)	85.47 (20.02)	84.77 (19.30)	-2.44 (1.72)	1.57 (1.40)	-1.98 (1.36)
Median	90.00	95.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	80.00, 100.00	-10.00, 5.00	-5.00, 10.00	-10.00, 5.00
Min, Max	35.0, 100.0	0.0, 100.0	20.0, 100.0	-45.0, 45.0	-35.0, 65.0	-80.0, 70.0
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	86.30 (17.23)	83.99 (21.95)	86.23 (17.11)	-1.38 (1.76)	1.22 (1.61)	-0.40 (1.35)
Median	95.00	95.00	95.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	75.00, 100.00	80.00, 100.00	-5.00, 2.50	-5.00, 10.00	-10.00, 5.00
Min, Max	25.0, 100.0	0.0, 100.0	30.0, 100.0	-60.0, 40.0	-40.0, 35.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Hopelessness						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	78.90 (21.45)	77.47 (22.28)	80.51 (21.82)			
Median	83.30	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	66.70, 100.00			
Min, Max	25.0, 100.0	25.0, 100.0	16.7, 100.0			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	81.28 (19.76)	79.36 (20.49)	81.15 (20.89)	2.18 (2.08)	2.11 (1.99)	-0.55 (1.46)
Median	91.70	83.30	91.70	0	0	0
IQR: Q1, Q3	66.70, 100.00	66.70, 100.00	66.70, 100.00	-8.30, 16.65	-8.30, 16.60	-8.30, 8.30
Min, Max	33.3, 100.0	8.3, 100.0	16.7, 100.0	-41.7, 50.0	-41.7, 58.4	-66.6, 50.0
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	81.71 (20.42)	79.97 (20.16)	80.89 (21.28)	1.53 (2.22)	1.95 (2.39)	-1.06 (1.44)
Median	83.30	83.30	91.70	0	0	0
IQR: Q1, Q3	66.70, 100.00	66.70, 100.00	66.70, 100.00	-8.30, 8.35	-8.40, 16.70	-8.30, 8.30
Min, Max	33.3, 100.0	16.7, 100.0	0.0, 100.0	-41.7, 41.7	-58.3, 50.0	-100.0, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Stigma of Liver Disease						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	81.94 (22.36)	81.79 (18.16)	84.03 (18.56)			
Median	93.80	81.30	87.50			
IQR: Q1, Q3	68.80, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	18.8, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	84.64 (20.64)	81.39 (19.55)	84.52 (18.85)	1.63 (1.88)	-0.63 (1.36)	-0.11 (1.26)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	-6.20, 12.50	-6.30, 6.20	-6.20, 6.30
Min, Max	6.3, 100.0	12.5, 100.0	6.3, 100.0	-43.7, 56.2	-31.3, 50.0	-62.5, 75.0
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	86.46 (19.19)	84.13 (18.31)	83.81 (18.95)	3.04 (1.66)	2.23 (1.61)	0.05 (1.31)
Median	100.00	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	75.00, 100.00	0.00, 6.30	-6.20, 12.50	-6.20, 6.20
Min, Max	31.3, 100.0	12.5, 100.0	18.8, 100.0	-31.3, 56.2	-56.2, 50.0	-62.5, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Total LDQOL						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	76.30 (15.44)	76.53 (16.85)	78.05 (14.43)			
Median	79.35	83.90	81.40			
IQR: Q1, Q3	66.70, 87.80	69.70, 86.90	72.60, 88.80			
Min, Max	28.3, 96.7	34.5, 94.1	39.5, 97.8			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	76.88 (17.05)	75.86 (13.93)	78.12 (14.51)	1.63 (1.06)	0.85 (1.52)	1.41 (0.99)
Median	81.90	78.10	81.40	1.60	1.00	0.35
IQR: Q1, Q3	69.65, 89.30	63.70, 87.70	69.75, 89.20	-2.50, 6.60	-4.00, 4.40	-2.85, 4.60
Min, Max	22.9, 97.8	41.4, 95.2	38.2, 98.3	-18.3, 35.6	-12.5, 27.0	-27.7, 29.7
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	78.55 (14.42)	76.64 (15.83)	78.35 (14.36)	2.24 (1.19)	1.13 (2.32)	0.79 (1.10)
Median	84.40	79.80	80.70	2.35	0.20	-0.10
IQR: Q1, Q3	65.70, 90.20	68.40, 89.50	71.20, 88.40	-2.30, 6.40	-5.60, 6.80	-4.10, 4.90
Min, Max	44.4, 97.5	33.8, 95.6	20.3, 97.8	-19.5, 36.0	-19.2, 33.9	-46.3, 24.9

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Symptoms of Liver Disease						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	78.23 (21.90)	75.78 (19.80)	79.32 (18.16)			
Median	86.70	75.00	83.30			
IQR: Q1, Q3	70.00, 93.30	63.30, 93.30	66.70, 93.30			
Min, Max	13.3, 100.0	30.0, 100.0	23.3, 100.0			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	77.11 (22.39)	72.58 (21.52)	79.51 (19.94)	-0.79 (1.71)	-2.04 (2.44)	0.83 (1.55)
Median	83.30	73.30	85.00	0	0	0
IQR: Q1, Q3	68.35, 93.30	66.70, 86.70	71.65, 93.30	-6.70, 6.70	-10.00, 4.70	-6.60, 6.70
Min, Max	0.0, 100.0	26.7, 100.0	16.7, 100.0	-46.7, 30.0	-36.6, 26.7	-33.3, 43.3
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	77.00 (22.30)	74.94 (20.05)	79.68 (18.33)	-2.84 (1.72)	2.61 (2.80)	0.68 (1.51)
Median	83.30	80.00	83.30	0	0	0
IQR: Q1, Q3	66.70, 93.30	66.70, 86.70	70.00, 93.30	-10.00, 6.60	-6.60, 13.30	-6.60, 6.70
Min, Max	6.7, 100.0	30.0, 100.0	23.3, 100.0	-43.4, 26.7	-26.6, 30.0	-60.0, 30.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Effects of Liver Disease						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	76.67 (15.83)	77.78 (20.22)	78.73 (14.90)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	73.30, 86.70	80.00, 86.70			
Min, Max	6.7, 100.0	13.3, 100.0	33.3, 100.0			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	75.49 (18.70)	78.51 (11.74)	78.04 (15.17)	-0.42 (1.77)	2.35 (4.25)	-0.25 (1.80)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	70.00, 86.70	73.30, 80.00	73.30, 86.70	-6.70, 6.70	-6.70, 6.70	-6.70, 6.70
Min, Max	0.0, 100.0	46.7, 100.0	26.7, 100.0	-40.0, 26.6	-33.3, 76.7	-46.7, 46.7
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	74.58 (17.12)	76.67 (14.08)	76.93 (15.08)	-1.24 (2.24)	1.31 (3.19)	-1.73 (2.08)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	66.70, 80.00	80.00, 80.00	73.30, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 0.00
Min, Max	6.7, 100.0	20.0, 93.3	13.3, 100.0	-40.0, 80.0	-20.0, 53.4	-73.4, 46.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Concentration/Memory						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	79.28 (24.68)	77.52 (23.58)	77.61 (20.86)			
Median	87.50	81.30	81.30			
IQR: Q1, Q3	75.00, 100.00	56.30, 100.00	68.80, 93.80			
Min, Max	6.3, 100.0	31.3, 100.0	31.3, 100.0			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	77.22 (25.20)	78.68 (22.69)	75.90 (23.43)	-0.99 (1.77)	2.77 (3.15)	-1.12 (1.61)
Median	87.50	81.30	81.30	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	62.50, 100.00	-6.20, 6.20	-6.20, 12.50	-6.30, 6.30
Min, Max	18.8, 100.0	25.0, 100.0	12.5, 100.0	-37.5, 31.2	-31.2, 56.2	-50.0, 31.2
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	79.05 (21.58)	74.78 (24.37)	77.97 (20.40)	1.28 (2.18)	-1.63 (3.77)	0.46 (1.58)
Median	81.30	87.50	81.30	0	0	0
IQR: Q1, Q3	68.80, 93.80	56.30, 93.80	68.80, 100.00	-6.20, 6.30	-12.50, 6.30	-6.30, 6.30
Min, Max	18.8, 100.0	18.8, 100.0	18.8, 100.0	-25.0, 50.0	-43.8, 50.0	-43.7, 37.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Health Distress						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	77.27 (25.56)	79.17 (26.12)	81.65 (23.09)			
Median	81.25	87.50	87.50			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	12.5, 100.0	25.0, 100.0			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	79.78 (26.45)	81.47 (23.77)	87.09 (18.39)	4.56 (2.45)	4.63 (3.54)	7.29 (2.27)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	25.0, 100.0	25.0, 100.0	-37.5, 62.5	-37.5, 37.5	-50.0, 75.0
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	80.08 (24.58)	85.00 (24.47)	87.22 (18.46)	4.63 (3.23)	7.07 (4.57)	6.64 (2.26)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	87.50, 100.00	75.00, 100.00	0.00, 12.50	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	25.0, 100.0	-50.0, 75.0	-25.0, 50.0	-50.0, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Sexual Function						
Baseline						
m	73	32	105			
n	36	15	53			
Mean (SD)	82.72 (21.77)	75.14 (23.11)	85.50 (19.81)			
Median	93.30	85.00	93.30			
IQR: Q1, Q3	72.50, 100.00	53.30, 93.30	76.70, 100.00			
Min, Max	30.0, 100.0	30.0, 100.0	5.0, 100.0			
Week 24						
m	70	31	102			
n	33	15	49	27	12	40
Mean (SD/SE)	82.12 (23.53)	75.21 (28.32)	81.93 (22.44)	-0.61 (3.81)	-8.34 (8.43)	-1.51 (3.13)
Median	93.30	85.00	93.30	0	0	0
IQR: Q1, Q3	76.70, 100.00	70.00, 93.30	70.00, 100.00	-5.00, 6.70	-32.50, 6.65	-7.55, 6.70
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-65.0, 36.7	-55.0, 46.7	-48.4, 50.0
Week 52						
m	64	28	95			
n	26	14	42	22	11	38
Mean (SD/SE)	90.02 (11.40)	70.78 (30.19)	80.09 (24.81)	4.33 (4.09)	0.30 (8.32)	-2.05 (3.75)
Median	93.30	80.80	93.30	0	1.70	0
IQR: Q1, Q3	80.00, 100.00	53.30, 93.30	68.30, 100.00	-5.00, 6.70	-21.70, 6.70	-13.30, 6.70
Min, Max	61.7, 100.0	-1.7, 100.0	-1.7, 100.0	-23.3, 61.7	-48.4, 61.7	-48.4, 65.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Sleep						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	61.59 (22.02)	64.17 (18.48)	63.87 (20.79)			
Median	65.00	70.00	65.00			
IQR: Q1, Q3	50.00, 80.00	55.00, 75.00	45.00, 80.00			
Min, Max	0.0, 100.0	15.0, 90.0	5.0, 100.0			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	61.40 (22.19)	60.86 (20.09)	64.18 (20.73)	1.67 (2.15)	-1.30 (2.86)	2.16 (1.58)
Median	65.00	60.00	65.00	0	0	0
IQR: Q1, Q3	47.50, 75.00	40.00, 80.00	50.00, 80.00	-10.00, 10.00	-10.00, 10.00	-6.90, 10.00
Min, Max	5.0, 100.0	20.0, 90.0	20.0, 100.0	-25.0, 90.0	-35.0, 25.0	-25.0, 45.0
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	66.61 (19.11)	63.40 (19.67)	63.20 (20.24)	3.70 (2.31)	0.65 (3.12)	0.20 (1.87)
Median	70.00	65.00	60.00	0	0	0
IQR: Q1, Q3	55.00, 80.00	45.00, 80.00	50.00, 75.00	-5.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	10.0, 100.0	30.0, 95.0	20.0, 100.0	-30.0, 75.0	-25.0, 40.0	-40.0, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Loneliness						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	80.00 (18.75)	84.33 (17.11)	80.16 (22.63)			
Median	80.00	90.00	90.00			
IQR: Q1, Q3	70.00, 95.00	80.00, 100.00	65.00, 100.00			
Min, Max	25.0, 100.0	35.0, 100.0	5.0, 100.0			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	81.36 (21.13)	83.10 (16.06)	79.18 (22.34)	1.31 (2.06)	-1.85 (2.19)	-0.24 (1.61)
Median	90.00	85.00	80.00	0	0	0
IQR: Q1, Q3	72.50, 100.00	80.00, 95.00	70.00, 100.00	-5.00, 10.00	-10.00, 5.00	-10.00, 10.00
Min, Max	15.0, 100.0	40.0, 100.0	10.0, 100.0	-50.0, 40.0	-20.0, 20.0	-35.0, 35.0
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	83.47 (17.60)	81.40 (16.80)	80.45 (21.59)	2.78 (2.20)	-3.48 (3.35)	0.68 (1.79)
Median	85.00	85.00	85.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 95.00	70.00, 100.00	-5.00, 5.00	-15.00, 10.00	-5.00, 10.00
Min, Max	35.0, 100.0	45.0, 100.0	5.0, 100.0	-35.0, 50.0	-40.0, 25.0	-40.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Hopelessness						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	71.47 (23.71)	73.89 (25.22)	76.77 (20.41)			
Median	75.00	79.15	75.00			
IQR: Q1, Q3	50.00, 91.70	50.00, 91.70	58.30, 100.00			
Min, Max	8.3, 100.0	8.3, 100.0	25.0, 100.0			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	72.91 (25.62)	72.12 (27.40)	74.59 (22.55)	2.77 (2.27)	0.31 (3.40)	0.05 (1.94)
Median	75.00	75.00	75.00	0	8.30	0
IQR: Q1, Q3	54.15, 100.00	58.30, 100.00	58.30, 100.00	-8.30, 16.70	-8.30, 8.40	-8.30, 8.30
Min, Max	8.3, 100.0	8.3, 100.0	16.7, 100.0	-58.3, 50.0	-41.7, 25.0	-50.0, 41.6
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	74.44 (21.98)	72.34 (26.44)	74.72 (23.56)	1.85 (2.53)	-1.44 (4.31)	-1.44 (2.38)
Median	75.00	75.00	75.00	0	0	0
IQR: Q1, Q3	58.30, 100.00	50.00, 100.00	58.30, 100.00	0.00, 8.40	-16.70, 16.70	-16.60, 8.40
Min, Max	16.7, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 41.7	-41.7, 33.4	-58.4, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Stigma of Liver Disease						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	82.97 (20.70)	79.60 (24.88)	83.64 (20.16)			
Median	93.80	93.80	93.80			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	86.60 (17.75)	80.84 (19.40)	86.61 (17.75)	4.66 (2.28)	4.40 (3.43)	4.91 (1.84)
Median	93.80	87.50	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 93.80	81.30, 100.00	0.00, 6.30	-6.20, 18.80	0.00, 6.30
Min, Max	12.5, 100.0	31.3, 100.0	37.5, 100.0	-43.8, 50.0	-25.0, 56.3	-37.5, 75.0
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	87.94 (15.47)	85.52 (20.39)	87.59 (17.69)	4.63 (1.73)	3.81 (4.19)	4.65 (1.98)
Median	93.80	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	81.30, 100.00	81.30, 100.00	0.00, 6.30	-6.20, 12.50	0.00, 12.50
Min, Max	43.8, 100.0	12.5, 100.0	25.0, 100.0	-25.0, 37.5	-37.5, 56.3	-56.3, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Region
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.4.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Total LDQOL			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	78.93 (13.00)	77.01 (14.06)	78.64 (13.25)
Analysis Visit Mean (SD)	79.13 (12.91)	77.54 (12.51)	78.94 (14.04)
LS Mean of Change from Baseline (SE)	0.43 (0.95)	0.16 (0.89)	0.28 (0.69)
95% CI	(-1.45, 2.30)	(-1.59, 1.90)	(-1.07, 1.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.15 (1.14)	-0.12 (1.10)	
95% CI	(-2.10, 2.39)	(-2.28, 2.03)	
p-value	0.8984	0.9093	
Corrected Hedge's g Statistics	0.016	-0.014	
95% CI	(-0.24, 0.28)	(-0.26, 0.24)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	79.51 (12.42)	77.67 (14.27)	78.68 (13.49)
Analysis Visit Mean (SD)	79.77 (12.61)	78.18 (13.49)	79.06 (14.32)
LS Mean of Change from Baseline (SE)	0.29 (1.02)	0.29 (0.95)	0.30 (0.74)
95% CI	(-1.73, 2.30)	(-1.59, 2.16)	(-1.15, 1.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (1.23)	-0.02 (1.18)	
95% CI	(-2.44, 2.41)	(-2.34, 2.31)	
p-value	0.9917	0.9896	
Corrected Hedge's g Statistics	-0.001	-0.002	
95% CI	(-0.28, 0.28)	(-0.27, 0.27)	
Subgroup*Treatment Interaction p-value	0.7578	0.6230	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Total LDQOL			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	75.67 (15.53)	75.48 (17.47)	77.79 (14.74)
Analysis Visit Mean (SD)	77.30 (16.94)	76.33 (14.25)	79.20 (14.24)
LS Mean of Change from Baseline (SE)	1.55 (1.07)	0.31 (1.60)	1.78 (0.95)
95% CI	(-0.56, 3.65)	(-2.84, 3.45)	(-0.10, 3.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.23 (1.38)	-1.47 (1.82)	
95% CI	(-2.95, 2.49)	(-5.05, 2.11)	
p-value	0.8683	0.4194	
Corrected Hedge's g Statistics	-0.026	-0.169	
95% CI	(-0.35, 0.30)	(-0.60, 0.26)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	76.17 (15.66)	75.09 (18.42)	77.84 (14.29)
Analysis Visit Mean (SD)	78.41 (13.92)	76.22 (16.44)	78.63 (14.94)
LS Mean of Change from Baseline (SE)	2.41 (1.25)	0.70 (1.88)	0.85 (1.06)
95% CI	(-0.05, 4.87)	(-3.01, 4.41)	(-1.24, 2.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.56 (1.59)	-0.15 (2.12)	
95% CI	(-1.58, 4.71)	(-4.33, 4.04)	
p-value	0.3278	0.9452	
Corrected Hedge's g Statistics	0.166	-0.015	
95% CI	(-0.18, 0.51)	(-0.48, 0.45)	
Subgroup*Treatment Interaction p-value	0.7578	0.6230	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Symptoms of Liver Disease			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	77.80 (17.02)	74.48 (18.65)	76.44 (17.29)
Analysis Visit Mean (SD)	76.02 (18.51)	73.94 (17.13)	76.26 (18.66)
LS Mean of Change from Baseline (SE)	-1.12 (1.37)	-0.92 (1.28)	-0.36 (0.99)
95% CI	(-3.82, 1.58)	(-3.44, 1.59)	(-2.31, 1.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.76 (1.65)	-0.56 (1.58)	
95% CI	(-4.00, 2.48)	(-3.67, 2.54)	
p-value	0.6457	0.7212	
Corrected Hedge's g Statistics	-0.059	-0.044	
95% CI	(-0.32, 0.20)	(-0.29, 0.20)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	79.21 (15.62)	75.93 (17.93)	76.15 (17.30)
Analysis Visit Mean (SD)	77.89 (16.58)	76.36 (17.85)	76.71 (19.23)
LS Mean of Change from Baseline (SE)	-0.87 (1.45)	-0.02 (1.34)	0.61 (1.05)
95% CI	(-3.72, 1.98)	(-2.66, 2.62)	(-1.45, 2.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.48 (1.75)	-0.63 (1.67)	
95% CI	(-4.92, 1.95)	(-3.92, 2.65)	
p-value	0.3960	0.7049	
Corrected Hedge's g Statistics	-0.118	-0.051	
95% CI	(-0.40, 0.16)	(-0.32, 0.22)	
Subgroup*Treatment Interaction p-value	0.4971	0.5790	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Effects of Liver Disease			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	79.17 (10.87)	78.99 (13.78)	77.01 (14.43)
Analysis Visit Mean (SD)	76.29 (10.93)	78.99 (10.36)	76.97 (14.93)
LS Mean of Change from Baseline (SE)	-2.37 (1.20)	0.31 (1.12)	-0.64 (0.87)
95% CI	(-4.72, -0.01)	(-1.89, 2.50)	(-2.35, 1.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.72 (1.45)	0.95 (1.39)	
95% CI	(-4.57, 1.12)	(-1.78, 3.68)	
p-value	0.2343	0.4950	
Corrected Hedge's g Statistics	-0.154	0.085	
95% CI	(-0.41, 0.11)	(-0.16, 0.33)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	79.57 (9.06)	79.15 (13.75)	77.52 (13.01)
Analysis Visit Mean (SD)	78.20 (9.33)	78.14 (12.21)	78.15 (12.61)
LS Mean of Change from Baseline (SE)	-0.46 (1.33)	-0.56 (1.23)	0.02 (0.96)
95% CI	(-3.07, 2.15)	(-2.99, 1.86)	(-1.88, 1.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.47 (1.61)	-0.58 (1.54)	
95% CI	(-3.64, 2.69)	(-3.61, 2.45)	
p-value	0.7684	0.7079	
Corrected Hedge's g Statistics	-0.041	-0.050	
95% CI	(-0.32, 0.24)	(-0.32, 0.22)	
Subgroup*Treatment Interaction p-value	0.9989	0.8728	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Concentration/Memory			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	81.70 (21.16)	80.01 (19.49)	80.06 (20.63)
Analysis Visit Mean (SD)	79.85 (20.36)	79.82 (18.87)	81.61 (20.73)
LS Mean of Change from Baseline (SE)	-1.74 (1.59)	-0.67 (1.48)	1.05 (1.15)
95% CI	(-4.88, 1.39)	(-3.58, 2.25)	(-1.21, 3.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.80 (1.92)	-1.72 (1.84)	
95% CI	(-6.57, 0.97)	(-5.33, 1.89)	
p-value	0.1452	0.3498	
Corrected Hedge's g Statistics	-0.188	-0.116	
95% CI	(-0.45, 0.07)	(-0.37, 0.13)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	81.43 (20.38)	81.49 (18.22)	80.39 (20.18)
Analysis Visit Mean (SD)	79.21 (19.35)	80.25 (18.97)	79.29 (22.79)
LS Mean of Change from Baseline (SE)	-3.27 (1.57)	-1.10 (1.45)	-1.11 (1.13)
95% CI	(-6.35, -0.19)	(-3.96, 1.76)	(-3.34, 1.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.15 (1.88)	0.02 (1.80)	
95% CI	(-5.86, 1.55)	(-3.53, 3.56)	
p-value	0.2535	0.9927	
Corrected Hedge's g Statistics	-0.158	0.001	
95% CI	(-0.44, 0.12)	(-0.27, 0.27)	
Subgroup*Treatment Interaction p-value	0.2451	0.5926	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Health Distress			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	79.40 (26.74)	80.81 (25.96)	80.83 (24.44)
Analysis Visit Mean (SD)	85.37 (20.52)	87.37 (19.84)	84.92 (23.89)
LS Mean of Change from Baseline (SE)	5.75 (1.79)	6.72 (1.66)	4.14 (1.29)
95% CI	(2.23, 9.27)	(3.45, 9.98)	(1.60, 6.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.61 (2.14)	2.58 (2.05)	
95% CI	(-2.60, 5.83)	(-1.46, 6.62)	
p-value	0.4517	0.2099	
Corrected Hedge's g Statistics	0.097	0.155	
95% CI	(-0.16, 0.36)	(-0.09, 0.40)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	80.10 (25.83)	82.27 (25.69)	82.66 (23.48)
Analysis Visit Mean (SD)	85.20 (23.43)	87.21 (20.38)	85.56 (22.74)
LS Mean of Change from Baseline (SE)	4.39 (2.18)	5.74 (2.03)	3.82 (1.58)
95% CI	(0.11, 8.68)	(1.75, 9.73)	(0.71, 6.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.57 (2.64)	1.92 (2.53)	
95% CI	(-4.62, 5.77)	(-3.05, 6.90)	
p-value	0.8277	0.4478	
Corrected Hedge's g Statistics	0.030	0.102	
95% CI	(-0.25, 0.31)	(-0.17, 0.37)	
Subgroup*Treatment Interaction p-value	0.0936	0.1428	

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Sexual Function			
Week 24			
m	91	110	187
n	30	47	54
Baseline Mean (SD)	74.29 (32.22)	82.12 (22.29)	78.39 (24.31)
Analysis Visit Mean (SD)	78.06 (26.29)	78.47 (24.06)	79.60 (21.80)
LS Mean of Change from Baseline (SE)	2.45 (3.37)	-3.25 (2.69)	0.77 (2.46)
95% CI	(-4.22, 9.11)	(-8.58, 2.08)	(-4.10, 5.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.67 (4.08)	-4.02 (3.57)	
95% CI	(-6.39, 9.74)	(-11.09, 3.04)	
p-value	0.6822	0.2618	
Corrected Hedge's g Statistics	0.091	-0.219	
95% CI	(-0.36, 0.54)	(-0.61, 0.17)	
Week 52			
m	85	97	175
n	24	36	42
Baseline Mean (SD)	76.89 (33.23)	85.36 (19.92)	76.97 (25.01)
Analysis Visit Mean (SD)	81.04 (26.31)	81.74 (26.06)	76.35 (25.74)
LS Mean of Change from Baseline (SE)	4.69 (3.75)	-1.01 (3.06)	-2.48 (2.78)
95% CI	(-2.73, 12.11)	(-7.06, 5.03)	(-7.97, 3.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.17 (4.58)	1.46 (4.06)	
95% CI	(-1.88, 16.22)	(-6.58, 9.50)	
p-value	0.1195	0.7195	
Corrected Hedge's g Statistics	0.390	0.080	
95% CI	(-0.12, 0.90)	(-0.37, 0.53)	
Subgroup*Treatment Interaction p-value	0.9321	0.3300	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Sleep			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	64.55 (19.65)	58.79 (20.42)	63.45 (19.21)
Analysis Visit Mean (SD)	65.06 (19.63)	57.02 (20.66)	61.88 (19.99)
LS Mean of Change from Baseline (SE)	1.07 (1.59)	-2.96 (1.48)	-1.43 (1.14)
95% CI	(-2.06, 4.19)	(-5.87, -0.05)	(-3.68, 0.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.50 (1.90)	-1.53 (1.83)	
95% CI	(-1.24, 6.24)	(-5.13, 2.07)	
p-value	0.1891	0.4036	
Corrected Hedge's g Statistics	0.169	-0.104	
95% CI	(-0.09, 0.43)	(-0.35, 0.15)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	65.00 (19.85)	59.53 (20.87)	63.06 (19.77)
Analysis Visit Mean (SD)	63.11 (19.86)	58.20 (21.77)	64.30 (21.01)
LS Mean of Change from Baseline (SE)	-1.11 (1.79)	-2.69 (1.66)	1.13 (1.29)
95% CI	(-4.62, 2.40)	(-5.96, 0.58)	(-1.40, 3.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.24 (2.15)	-3.82 (2.07)	
95% CI	(-6.47, 1.99)	(-7.89, 0.24)	
p-value	0.2976	0.0653	
Corrected Hedge's g Statistics	-0.145	-0.248	
95% CI	(-0.42, 0.13)	(-0.52, 0.02)	
Subgroup*Treatment Interaction p-value	0.8427	0.8800	

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Loneliness			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	88.13 (16.48)	83.64 (20.61)	86.47 (17.39)
Analysis Visit Mean (SD)	85.68 (16.28)	85.20 (20.23)	84.48 (19.56)
LS Mean of Change from Baseline (SE)	-2.32 (1.64)	0.28 (1.53)	-2.35 (1.18)
95% CI	(-5.54, 0.91)	(-2.73, 3.28)	(-4.67, -0.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (1.97)	2.62 (1.89)	
95% CI	(-3.84, 3.91)	(-1.10, 6.35)	
p-value	0.9875	0.1670	
Corrected Hedge's g Statistics	0.002	0.172	
95% CI	(-0.26, 0.26)	(-0.08, 0.42)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	88.16 (17.01)	82.33 (21.51)	86.29 (17.68)
Analysis Visit Mean (SD)	86.78 (16.83)	83.55 (22.19)	85.88 (17.40)
LS Mean of Change from Baseline (SE)	-1.62 (1.67)	-0.60 (1.56)	-1.17 (1.21)
95% CI	(-4.90, 1.67)	(-3.67, 2.46)	(-3.55, 1.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.44 (2.01)	0.57 (1.93)	
95% CI	(-4.39, 3.51)	(-3.23, 4.37)	
p-value	0.8260	0.7679	
Corrected Hedge's g Statistics	-0.030	0.039	
95% CI	(-0.31, 0.25)	(-0.23, 0.31)	
Subgroup*Treatment Interaction p-value	0.4743	0.2582	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Hopelessness			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	79.45 (20.99)	76.68 (22.08)	81.82 (20.73)
Analysis Visit Mean (SD)	81.63 (19.58)	78.79 (20.94)	81.27 (20.83)
LS Mean of Change from Baseline (SE)	1.88 (1.86)	0.53 (1.73)	0.14 (1.34)
95% CI	(-1.78, 5.53)	(-2.88, 3.94)	(-2.49, 2.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.73 (2.23)	0.38 (2.15)	
95% CI	(-2.66, 6.12)	(-3.84, 4.61)	
p-value	0.4380	0.8581	
Corrected Hedge's g Statistics	0.100	0.022	
95% CI	(-0.16, 0.36)	(-0.23, 0.27)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	80.49 (20.17)	77.32 (22.89)	81.93 (21.40)
Analysis Visit Mean (SD)	82.02 (20.37)	79.27 (20.16)	80.87 (21.49)
LS Mean of Change from Baseline (SE)	2.04 (1.99)	0.95 (1.86)	-0.48 (1.44)
95% CI	(-1.88, 5.96)	(-2.70, 4.60)	(-3.32, 2.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.52 (2.40)	1.43 (2.31)	
95% CI	(-2.20, 7.25)	(-3.11, 5.98)	
p-value	0.2942	0.5363	
Corrected Hedge's g Statistics	0.146	0.083	
95% CI	(-0.13, 0.42)	(-0.19, 0.35)	
Subgroup*Treatment Interaction p-value	0.8421	0.4484	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Stigma of Liver Disease			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	82.90 (21.53)	81.65 (18.66)	84.87 (18.15)
Analysis Visit Mean (SD)	84.53 (20.73)	81.02 (20.20)	84.76 (19.08)
LS Mean of Change from Baseline (SE)	1.87 (1.62)	-0.79 (1.51)	0.56 (1.17)
95% CI	(-1.31, 5.06)	(-3.76, 2.18)	(-1.74, 2.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.31 (1.95)	-1.35 (1.88)	
95% CI	(-2.52, 5.15)	(-5.04, 2.34)	
p-value	0.5010	0.4715	
Corrected Hedge's g Statistics	0.087	-0.090	
95% CI	(-0.17, 0.35)	(-0.34, 0.16)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	83.57 (21.10)	81.56 (19.14)	83.78 (18.14)
Analysis Visit Mean (SD)	86.61 (19.27)	83.79 (18.47)	83.82 (19.26)
LS Mean of Change from Baseline (SE)	3.45 (1.63)	1.55 (1.52)	0.34 (1.18)
95% CI	(0.24, 6.66)	(-1.44, 4.54)	(-1.98, 2.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.10 (1.96)	1.21 (1.89)	
95% CI	(-0.76, 6.97)	(-2.50, 4.92)	
p-value	0.1151	0.5211	
Corrected Hedge's g Statistics	0.219	0.086	
95% CI	(-0.06, 0.50)	(-0.18, 0.35)	
Subgroup*Treatment Interaction p-value	0.4258	0.6410	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Symptoms of Liver Disease			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	77.57 (22.20)	76.30 (19.57)	79.83 (18.57)
Analysis Visit Mean (SD)	76.78 (22.92)	74.26 (20.37)	80.66 (19.96)
LS Mean of Change from Baseline (SE)	-0.68 (1.71)	-2.03 (2.58)	1.47 (1.52)
95% CI	(-4.06, 2.70)	(-7.12, 3.06)	(-1.54, 4.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.15 (2.23)	-3.50 (2.94)	
95% CI	(-6.54, 2.24)	(-9.29, 2.30)	
p-value	0.3357	0.2356	
Corrected Hedge's g Statistics	-0.155	-0.251	
95% CI	(-0.48, 0.17)	(-0.69, 0.18)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	78.39 (22.23)	73.62 (19.30)	79.59 (17.59)
Analysis Visit Mean (SD)	75.55 (22.57)	76.23 (19.50)	80.27 (18.22)
LS Mean of Change from Baseline (SE)	-2.40 (1.74)	1.40 (2.64)	1.52 (1.48)
95% CI	(-5.83, 1.03)	(-3.80, 6.61)	(-1.39, 4.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.92 (2.21)	-0.12 (2.97)	
95% CI	(-8.29, 0.45)	(-5.98, 5.73)	
p-value	0.0781	0.9673	
Corrected Hedge's g Statistics	-0.298	-0.009	
95% CI	(-0.64, 0.05)	(-0.47, 0.45)	
Subgroup*Treatment Interaction p-value	0.4971	0.5790	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Effects of Liver Disease			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	76.51 (16.19)	76.54 (20.79)	79.29 (14.19)
Analysis Visit Mean (SD)	76.09 (18.30)	78.89 (11.95)	79.05 (14.08)
LS Mean of Change from Baseline (SE)	-1.07 (1.79)	1.69 (2.69)	0.70 (1.60)
95% CI	(-4.61, 2.46)	(-3.63, 7.00)	(-2.46, 3.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.77 (2.33)	0.99 (3.07)	
95% CI	(-6.37, 2.83)	(-5.07, 7.05)	
p-value	0.4493	0.7472	
Corrected Hedge's g Statistics	-0.121	0.068	
95% CI	(-0.45, 0.21)	(-0.37, 0.50)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	76.18 (17.21)	75.07 (21.86)	78.85 (14.18)
Analysis Visit Mean (SD)	74.94 (17.51)	76.38 (14.67)	77.12 (15.35)
LS Mean of Change from Baseline (SE)	-2.39 (2.00)	-0.39 (3.02)	-1.24 (1.69)
95% CI	(-6.33, 1.55)	(-6.35, 5.58)	(-4.57, 2.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.14 (2.55)	0.86 (3.41)	
95% CI	(-6.17, 3.88)	(-5.86, 7.58)	
p-value	0.6538	0.8019	
Corrected Hedge's g Statistics	-0.076	0.057	
95% CI	(-0.42, 0.27)	(-0.41, 0.52)	
Subgroup*Treatment Interaction p-value	0.9989	0.8728	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Concentration/Memory			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	78.89 (25.18)	76.41 (24.46)	77.70 (21.41)
Analysis Visit Mean (SD)	77.89 (25.09)	79.18 (23.45)	76.58 (23.68)
LS Mean of Change from Baseline (SE)	-0.34 (1.84)	2.38 (2.76)	-0.53 (1.64)
95% CI	(-3.97, 3.29)	(-3.07, 7.82)	(-3.76, 2.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.19 (2.39)	2.90 (3.14)	
95% CI	(-4.52, 4.90)	(-3.30, 9.11)	
p-value	0.9357	0.3568	
Corrected Hedge's g Statistics	0.013	0.194	
95% CI	(-0.31, 0.34)	(-0.24, 0.63)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	77.56 (25.68)	75.03 (24.56)	77.33 (21.24)
Analysis Visit Mean (SD)	78.84 (21.35)	73.40 (24.94)	77.80 (21.25)
LS Mean of Change from Baseline (SE)	1.37 (1.91)	-1.09 (2.88)	0.13 (1.62)
95% CI	(-2.40, 5.14)	(-6.78, 4.60)	(-3.08, 3.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.24 (2.43)	-1.22 (3.24)	
95% CI	(-3.56, 6.04)	(-7.62, 5.18)	
p-value	0.6108	0.7071	
Corrected Hedge's g Statistics	0.086	-0.084	
95% CI	(-0.26, 0.43)	(-0.55, 0.38)	
Subgroup*Treatment Interaction p-value	0.2451	0.5926	

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Health Distress			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	76.59 (25.84)	76.85 (26.56)	80.65 (23.40)
Analysis Visit Mean (SD)	81.15 (25.09)	81.48 (24.61)	87.95 (18.15)
LS Mean of Change from Baseline (SE)	3.40 (2.16)	3.16 (3.25)	7.79 (1.93)
95% CI	(-0.86, 7.67)	(-3.25, 9.57)	(3.99, 11.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.39 (2.81)	-4.64 (3.70)	
95% CI	(-9.93, 1.15)	(-11.94, 2.67)	
p-value	0.1198	0.2119	
Corrected Hedge's g Statistics	-0.250	-0.263	
95% CI	(-0.58, 0.08)	(-0.70, 0.17)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	75.93 (25.57)	77.72 (28.19)	80.40 (23.63)
Analysis Visit Mean (SD)	80.56 (22.74)	84.78 (25.55)	87.04 (18.80)
LS Mean of Change from Baseline (SE)	2.49 (2.40)	6.42 (3.62)	6.74 (2.03)
95% CI	(-2.24, 7.22)	(-0.72, 13.57)	(2.74, 10.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.25 (3.06)	-0.32 (4.08)	
95% CI	(-10.29, 1.79)	(-8.36, 7.73)	
p-value	0.1667	0.9377	
Corrected Hedge's g Statistics	-0.235	-0.018	
95% CI	(-0.58, 0.11)	(-0.48, 0.45)	
Subgroup*Treatment Interaction p-value	0.0936	0.1428	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Sexual Function			
Week 24			
m	70	31	102
n	27	12	40
Baseline Mean (SD)	81.78 (22.30)	79.58 (20.31)	86.09 (18.09)
Analysis Visit Mean (SD)	81.17 (24.84)	71.23 (30.26)	84.58 (21.09)
LS Mean of Change from Baseline (SE)	-0.44 (3.66)	-12.03 (5.54)	0.19 (3.18)
95% CI	(-7.72, 6.84)	(-23.05, -1.01)	(-6.12, 6.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.63 (4.84)	-12.22 (6.39)	
95% CI	(-10.24, 8.98)	(-24.92, 0.47)	
p-value	0.8964	0.0590	
Corrected Hedge's g Statistics	-0.032	-0.605	
95% CI	(-0.52, 0.46)	(-1.26, 0.05)	
Week 52			
m	64	28	95
n	22	11	38
Baseline Mean (SD)	86.73 (19.73)	69.84 (24.56)	83.29 (22.40)
Analysis Visit Mean (SD)	91.05 (10.36)	70.14 (33.32)	81.24 (24.46)
LS Mean of Change from Baseline (SE)	4.08 (3.95)	-8.54 (5.80)	-0.41 (3.23)
95% CI	(-3.78, 11.94)	(-20.07, 2.99)	(-6.83, 6.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.49 (5.05)	-8.13 (6.64)	
95% CI	(-5.54, 14.53)	(-21.32, 5.06)	
p-value	0.3760	0.2238	
Corrected Hedge's g Statistics	0.228	-0.405	
95% CI	(-0.30, 0.76)	(-1.08, 0.27)	
Subgroup*Treatment Interaction p-value	0.9321	0.3300	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Sleep			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	60.79 (22.04)	62.78 (18.67)	63.56 (21.54)
Analysis Visit Mean (SD)	62.46 (21.02)	61.48 (20.42)	65.71 (20.64)
LS Mean of Change from Baseline (SE)	1.06 (1.84)	-2.09 (2.76)	1.85 (1.63)
95% CI	(-2.56, 4.69)	(-7.53, 3.35)	(-1.37, 5.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.79 (2.38)	-3.94 (3.14)	
95% CI	(-5.49, 3.91)	(-10.14, 2.25)	
p-value	0.7409	0.2105	
Corrected Hedge's g Statistics	-0.053	-0.264	
95% CI	(-0.38, 0.27)	(-0.70, 0.17)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	62.87 (21.49)	62.83 (20.66)	63.87 (20.97)
Analysis Visit Mean (SD)	66.57 (17.15)	63.48 (19.39)	64.07 (20.86)
LS Mean of Change from Baseline (SE)	4.11 (1.96)	1.29 (2.96)	0.06 (1.66)
95% CI	(0.25, 7.97)	(-4.55, 7.13)	(-3.20, 3.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.05 (2.49)	1.23 (3.33)	
95% CI	(-0.88, 8.97)	(-5.35, 7.80)	
p-value	0.1065	0.7132	
Corrected Hedge's g Statistics	0.274	0.083	
95% CI	(-0.07, 0.62)	(-0.38, 0.55)	
Subgroup*Treatment Interaction p-value	0.8427	0.8800	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Loneliness			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	79.52 (18.98)	84.44 (17.56)	80.00 (22.73)
Analysis Visit Mean (SD)	80.83 (21.45)	82.59 (16.55)	79.76 (22.65)
LS Mean of Change from Baseline (SE)	0.83 (1.83)	-1.41 (2.76)	-0.31 (1.63)
95% CI	(-2.78, 4.43)	(-6.86, 4.04)	(-3.52, 2.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.14 (2.37)	-1.10 (3.14)	
95% CI	(-3.55, 5.82)	(-7.30, 5.10)	
p-value	0.6332	0.7269	
Corrected Hedge's g Statistics	0.077	-0.074	
95% CI	(-0.25, 0.40)	(-0.51, 0.36)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	79.72 (19.53)	83.91 (17.51)	80.25 (22.64)
Analysis Visit Mean (SD)	82.50 (17.85)	80.43 (17.05)	80.93 (22.24)
LS Mean of Change from Baseline (SE)	2.48 (2.01)	-2.63 (3.05)	0.36 (1.69)
95% CI	(-1.48, 6.43)	(-8.65, 3.39)	(-2.98, 3.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.12 (2.56)	-2.98 (3.43)	
95% CI	(-2.92, 7.17)	(-9.75, 3.78)	
p-value	0.4076	0.3855	
Corrected Hedge's g Statistics	0.141	-0.196	
95% CI	(-0.20, 0.49)	(-0.66, 0.27)	
Subgroup*Treatment Interaction p-value	0.4743	0.2582	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Hopelessness			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	70.51 (23.80)	73.14 (25.47)	76.29 (20.60)
Analysis Visit Mean (SD)	73.28 (25.55)	73.45 (27.94)	76.34 (22.07)
LS Mean of Change from Baseline (SE)	1.97 (2.21)	-0.81 (3.32)	0.72 (1.98)
95% CI	(-2.39, 6.32)	(-7.36, 5.74)	(-3.18, 4.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.24 (2.88)	-1.53 (3.78)	
95% CI	(-4.45, 6.93)	(-9.00, 5.93)	
p-value	0.6672	0.6858	
Corrected Hedge's g Statistics	0.069	-0.085	
95% CI	(-0.26, 0.40)	(-0.52, 0.35)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	72.54 (23.44)	72.46 (27.59)	76.65 (20.05)
Analysis Visit Mean (SD)	74.39 (21.70)	71.02 (27.17)	75.21 (23.79)
LS Mean of Change from Baseline (SE)	2.45 (2.58)	-2.47 (3.92)	-0.98 (2.18)
95% CI	(-2.65, 7.54)	(-10.21, 5.26)	(-5.29, 3.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.43 (3.31)	-1.49 (4.42)	
95% CI	(-3.10, 9.96)	(-10.20, 7.22)	
p-value	0.3008	0.7361	
Corrected Hedge's g Statistics	0.176	-0.076	
95% CI	(-0.17, 0.52)	(-0.54, 0.39)	
Subgroup*Treatment Interaction p-value	0.8421	0.4484	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Stigma of Liver Disease			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	82.16 (20.84)	77.33 (25.24)	82.73 (20.88)
Analysis Visit Mean (SD)	86.82 (17.46)	81.73 (19.75)	87.64 (17.01)
LS Mean of Change from Baseline (SE)	4.63 (1.78)	2.12 (2.69)	5.20 (1.58)
95% CI	(1.12, 8.13)	(-3.18, 7.42)	(2.08, 8.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.57 (2.31)	-3.08 (3.06)	
95% CI	(-5.13, 3.99)	(-9.12, 2.96)	
p-value	0.8043	0.3159	
Corrected Hedge's g Statistics	-0.040	-0.213	
95% CI	(-0.37, 0.29)	(-0.65, 0.22)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	83.81 (20.12)	81.26 (24.78)	83.25 (20.60)
Analysis Visit Mean (SD)	88.44 (14.63)	85.07 (21.04)	87.90 (17.80)
LS Mean of Change from Baseline (SE)	5.43 (1.85)	3.25 (2.80)	5.06 (1.56)
95% CI	(1.79, 9.08)	(-2.27, 8.77)	(1.98, 8.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.37 (2.35)	-1.81 (3.15)	
95% CI	(-4.27, 5.02)	(-8.02, 4.40)	
p-value	0.8745	0.5661	
Corrected Hedge's g Statistics	0.027	-0.129	
95% CI	(-0.32, 0.37)	(-0.59, 0.33)	
Subgroup*Treatment Interaction p-value	0.4258	0.6410	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (3.2)	3 (2.5)	4 (2.0)
No	91 (96.8)	116 (97.5)	194 (98.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.80	
95% CI of the inverse odds ratio	(0.14, 2.85)	(0.18, 3.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.80	
95% CI of the inverse risk ratio	(0.14, 2.77)	(0.18, 3.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.17	0.50	
95% CI of the absolute risk difference	(-2.89, 5.23)	(-2.93, 3.93)	
p-value	0.5410	0.7689	
p-value of Breslow-Day Test for Homogeneity [3]	0.4380	0.5181	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (21.3)	24 (20.2)	38 (19.2)
No	74 (78.7)	95 (79.8)	160 (80.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.94	
95% CI of the inverse odds ratio	(0.48, 1.61)	(0.53, 1.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	0.95	
95% CI of the inverse risk ratio	(0.56, 1.46)	(0.60, 1.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.08	0.98	
95% CI of the absolute risk difference	(-7.84, 12.01)	(-8.08, 10.04)	
p-value	0.6766	0.8320	
p-value of Breslow-Day Test for Homogeneity [3]	0.6766	0.6083	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (3.2)	12 (10.1)	15 (7.6)
No	91 (96.8)	107 (89.9)	183 (92.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.49	0.73	
95% CI of the inverse odds ratio	(0.70, 8.81)	(0.33, 1.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	0.75	
95% CI of the inverse risk ratio	(0.70, 8.00)	(0.36, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.38	2.51	
95% CI of the absolute risk difference	(-9.50, 0.74)	(-4.04, 9.05)	
p-value	0.1456	0.4385	
p-value of Breslow-Day Test for Homogeneity [3]	0.9198	0.8780	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (23.4)	31 (26.1)	50 (25.3)
No	72 (76.6)	88 (73.9)	148 (74.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.96	
95% CI of the inverse odds ratio	(0.62, 1.97)	(0.57, 1.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.97	
95% CI of the inverse risk ratio	(0.70, 1.67)	(0.66, 1.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.85	0.80	
95% CI of the absolute risk difference	(-12.33, 8.63)	(-9.14, 10.74)	
p-value	0.7321	0.8747	
p-value of Breslow-Day Test for Homogeneity [3]	0.5582	0.8819	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.1)	8 (6.7)	14 (7.1)
No	92 (97.9)	111 (93.3)	184 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	1.06	
95% CI of the inverse odds ratio	(0.78, 15.73)	(0.43, 2.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.32	1.05	
95% CI of the inverse risk ratio	(0.77, 14.33)	(0.45, 2.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.94	-0.35	
95% CI of the absolute risk difference	(-9.55, -0.33)	(-6.09, 5.40)	
p-value	0.0829	0.9060	
p-value of Breslow-Day Test for Homogeneity [3]	0.8817	0.5046	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (16.0)	21 (17.6)	39 (19.7)
No	79 (84.0)	98 (82.4)	159 (80.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.14	
95% CI of the inverse odds ratio	(0.67, 2.48)	(0.64, 2.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	1.12	
95% CI of the inverse risk ratio	(0.72, 2.12)	(0.69, 1.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.74	-2.05	
95% CI of the absolute risk difference	(-12.99, 5.51)	(-10.86, 6.76)	
p-value	0.4419	0.6519	
p-value of Breslow-Day Test for Homogeneity [3]	0.8828	0.5926	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (6.4)	6 (5.0)	10 (5.1)
No	88 (93.6)	113 (95.0)	188 (94.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.00	
95% CI of the inverse odds ratio	(0.27, 2.21)	(0.35, 2.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	1.00	
95% CI of the inverse risk ratio	(0.30, 2.11)	(0.37, 2.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.33	-0.01	
95% CI of the absolute risk difference	(-4.47, 7.14)	(-4.98, 4.97)	
p-value	0.6402	0.9973	
p-value of Breslow-Day Test for Homogeneity [3]	0.9543	0.9857	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (19.1)	28 (23.5)	41 (20.7)
No	76 (80.9)	91 (76.5)	157 (79.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	0.85	
95% CI of the inverse odds ratio	(0.59, 2.05)	(0.49, 1.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.88	
95% CI of the inverse risk ratio	(0.66, 1.78)	(0.58, 1.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.56	2.82	
95% CI of the absolute risk difference	(-11.31, 8.20)	(-6.66, 12.31)	
p-value	0.7567	0.5554	
p-value of Breslow-Day Test for Homogeneity [3]	0.7268	0.7806	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (16.0)	19 (16.0)	28 (14.1)
No	79 (84.0)	100 (84.0)	170 (85.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.87	
95% CI of the inverse odds ratio	(0.44, 1.71)	(0.46, 1.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.89	
95% CI of the inverse risk ratio	(0.50, 1.58)	(0.52, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.82	1.82	
95% CI of the absolute risk difference	(-7.04, 10.67)	(-6.35, 10.00)	
p-value	0.6824	0.6579	
p-value of Breslow-Day Test for Homogeneity [3]	0.9589	0.7023	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (24.5)	26 (21.8)	46 (23.2)
No	71 (75.5)	93 (78.2)	152 (76.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.08	
95% CI of the inverse odds ratio	(0.53, 1.66)	(0.63, 1.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	1.06	
95% CI of the inverse risk ratio	(0.61, 1.47)	(0.70, 1.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.24	-1.38	
95% CI of the absolute risk difference	(-9.26, 11.73)	(-10.86, 8.09)	
p-value	0.8163	0.7759	
p-value of Breslow-Day Test for Homogeneity [3]	0.8342	0.3861	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (3.2)	4 (3.4)	7 (3.5)
No	91 (96.8)	115 (96.6)	191 (96.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.05	
95% CI of the inverse odds ratio	(0.28, 4.40)	(0.30, 3.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.05	
95% CI of the inverse risk ratio	(0.29, 4.19)	(0.31, 3.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.34	-0.17	
95% CI of the absolute risk difference	(-4.73, 4.04)	(-4.31, 3.96)	
p-value	0.8800	0.9347	
p-value of Breslow-Day Test for Homogeneity [3]	0.8113	0.8889	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (5.3)	8 (6.7)	13 (6.6)
No	89 (94.7)	111 (93.3)	185 (93.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.98	
95% CI of the inverse odds ratio	(0.43, 3.62)	(0.39, 2.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	0.98	
95% CI of the inverse risk ratio	(0.45, 3.36)	(0.42, 2.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.25	0.16	
95% CI of the absolute risk difference	(-6.95, 4.45)	(-5.51, 5.83)	
p-value	0.6790	0.9566	
p-value of Breslow-Day Test for Homogeneity [3]	0.8080	0.6493	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (13.8)	17 (14.3)	33 (16.7)
No	81 (86.2)	102 (85.7)	165 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.20	
95% CI of the inverse odds ratio	(0.62, 2.50)	(0.64, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.17	
95% CI of the inverse risk ratio	(0.67, 2.18)	(0.68, 2.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.84	-2.38	
95% CI of the absolute risk difference	(-11.53, 5.86)	(-10.53, 5.77)	
p-value	0.5341	0.5733	
p-value of Breslow-Day Test for Homogeneity [3]	0.4829	0.6907	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (24.5)	35 (29.4)	64 (32.3)
No	71 (75.5)	84 (70.6)	134 (67.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	1.15	
95% CI of the inverse odds ratio	(0.85, 2.57)	(0.70, 1.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	1.10	
95% CI of the inverse risk ratio	(0.88, 1.99)	(0.78, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.86	-2.91	
95% CI of the absolute risk difference	(-18.72, 3.01)	(-13.37, 7.55)	
p-value	0.1703	0.5881	
p-value of Breslow-Day Test for Homogeneity [3]	0.1791	0.7988	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (10.6)	20 (16.8)	18 (9.1)
No	84 (89.4)	99 (83.2)	180 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.50	
95% CI of the inverse odds ratio	(0.37, 1.90)	(0.25, 0.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.54	
95% CI of the inverse risk ratio	(0.41, 1.78)	(0.30, 0.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.55	7.72	
95% CI of the absolute risk difference	(-5.86, 8.96)	(-0.11, 15.54)	
p-value	0.6748	0.0406	
p-value of Breslow-Day Test for Homogeneity [3]	0.7124	0.2138	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (20.2)	29 (24.4)	49 (24.7)
No	75 (79.8)	90 (75.6)	149 (75.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	1.02	
95% CI of the inverse odds ratio	(0.71, 2.36)	(0.60, 1.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	1.02	
95% CI of the inverse risk ratio	(0.77, 1.96)	(0.68, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.53	-0.38	
95% CI of the absolute risk difference	(-14.64, 5.57)	(-10.16, 9.40)	
p-value	0.3917	0.9397	
p-value of Breslow-Day Test for Homogeneity [3]	0.7275	0.9505	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (19.1)	27 (22.7)	23 (11.6)
No	76 (80.9)	92 (77.3)	175 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	0.45	
95% CI of the inverse odds ratio	(0.28, 1.09)	(0.24, 0.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	0.51	
95% CI of the inverse risk ratio	(0.34, 1.07)	(0.31, 0.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.53	11.07	
95% CI of the absolute risk difference	(-1.59, 16.65)	(2.32, 19.82)	
p-value	0.0834	0.0088	
p-value of Breslow-Day Test for Homogeneity [3]	0.3027	0.3941	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (25.5)	34 (28.6)	42 (21.2)
No	70 (74.5)	85 (71.4)	156 (78.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.67	
95% CI of the inverse odds ratio	(0.44, 1.40)	(0.40, 1.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.74	
95% CI of the inverse risk ratio	(0.54, 1.29)	(0.50, 1.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.32	7.36	
95% CI of the absolute risk difference	(-6.17, 14.81)	(-2.56, 17.27)	
p-value	0.4096	0.1372	
p-value of Breslow-Day Test for Homogeneity [3]	0.8994	0.7374	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (11.7)	13 (10.9)	18 (9.1)
No	83 (88.3)	106 (89.1)	180 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.82	
95% CI of the inverse odds ratio	(0.34, 1.67)	(0.38, 1.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.83	
95% CI of the inverse risk ratio	(0.38, 1.58)	(0.42, 1.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.61	1.83	
95% CI of the absolute risk difference	(-5.02, 10.24)	(-5.05, 8.72)	
p-value	0.4858	0.5946	
p-value of Breslow-Day Test for Homogeneity [3]	0.4562	0.8845	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (31.9)	36 (30.3)	45 (22.7)
No	64 (68.1)	83 (69.7)	153 (77.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.68	
95% CI of the inverse odds ratio	(0.36, 1.08)	(0.41, 1.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.75	
95% CI of the inverse risk ratio	(0.48, 1.05)	(0.52, 1.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.19	7.52	
95% CI of the absolute risk difference	(-1.90, 20.27)	(-2.58, 17.63)	
p-value	0.0932	0.1369	
p-value of Breslow-Day Test for Homogeneity [3]	0.1263	0.0592	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.1)	1 (3.1)	6 (5.7)
No	70 (95.9)	31 (96.9)	99 (94.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	1.88	
95% CI of the inverse odds ratio	(0.34, 5.85)	(0.22, 16.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	1.83	
95% CI of the inverse risk ratio	(0.36, 5.38)	(0.23, 14.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.60	-2.59	
95% CI of the absolute risk difference	(-7.96, 4.76)	(-10.08, 4.90)	
p-value	0.6308	0.5603	
p-value of Breslow-Day Test for Homogeneity [3]	0.4380	0.5181	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (24.7)	8 (25.0)	20 (19.0)
No	55 (75.3)	24 (75.0)	85 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.71	
95% CI of the inverse odds ratio	(0.35, 1.48)	(0.28, 1.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.76	
95% CI of the inverse risk ratio	(0.44, 1.36)	(0.37, 1.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.61	5.95	
95% CI of the absolute risk difference	(-6.81, 18.03)	(-10.83, 22.73)	
p-value	0.3690	0.4648	
p-value of Breslow-Day Test for Homogeneity [3]	0.6766	0.6083	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.1)	4 (12.5)	11 (10.5)
No	70 (95.9)	28 (87.5)	94 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.73	0.82	
95% CI of the inverse odds ratio	(0.73, 10.16)	(0.24, 2.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.55	0.84	
95% CI of the inverse risk ratio	(0.74, 8.82)	(0.29, 2.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.37	2.02	
95% CI of the absolute risk difference	(-13.79, 1.05)	(-10.85, 14.89)	
p-value	0.1207	0.7482	
p-value of Breslow-Day Test for Homogeneity [3]	0.9198	0.8780	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (19.2)	8 (25.0)	27 (25.7)
No	59 (80.8)	24 (75.0)	78 (74.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.46	1.04	
95% CI of the inverse odds ratio	(0.70, 3.02)	(0.42, 2.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.34	1.03	
95% CI of the inverse risk ratio	(0.76, 2.38)	(0.52, 2.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.54	-0.71	
95% CI of the absolute risk difference	(-18.84, 5.77)	(-17.89, 16.46)	
p-value	0.3084	0.9354	
p-value of Breslow-Day Test for Homogeneity [3]	0.5582	0.8819	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.1)	2 (6.3)	12 (11.4)
No	70 (95.9)	30 (93.8)	93 (88.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.01	1.94	
95% CI of the inverse odds ratio	(0.82, 11.08)	(0.41, 9.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.78	1.83	
95% CI of the inverse risk ratio	(0.81, 9.51)	(0.43, 7.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.32	-5.18	
95% CI of the absolute risk difference	(-14.92, 0.28)	(-15.54, 5.18)	
p-value	0.0838	0.3972	
p-value of Breslow-Day Test for Homogeneity [3]	0.8817	0.5046	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (16.4)	7 (21.9)	20 (19.0)
No	61 (83.6)	25 (78.1)	85 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	0.84	
95% CI of the inverse odds ratio	(0.54, 2.63)	(0.32, 2.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	0.87	
95% CI of the inverse risk ratio	(0.60, 2.22)	(0.41, 1.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.61	2.83	
95% CI of the absolute risk difference	(-13.95, 8.74)	(-13.35, 19.00)	
p-value	0.6557	0.7248	
p-value of Breslow-Day Test for Homogeneity [3]	0.8828	0.5926	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (12.3)	3 (9.4)	10 (9.5)
No	64 (87.7)	29 (90.6)	95 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.02	
95% CI of the inverse odds ratio	(0.29, 1.94)	(0.26, 3.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.02	
95% CI of the inverse risk ratio	(0.33, 1.81)	(0.30, 3.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.80	-0.15	
95% CI of the absolute risk difference	(-6.60, 12.21)	(-11.70, 11.41)	
p-value	0.5511	0.9799	
p-value of Breslow-Day Test for Homogeneity [3]	0.9543	0.9857	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (26.0)	8 (25.0)	26 (24.8)
No	54 (74.0)	24 (75.0)	79 (75.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.99	
95% CI of the inverse odds ratio	(0.47, 1.86)	(0.40, 2.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.99	
95% CI of the inverse risk ratio	(0.57, 1.59)	(0.50, 1.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.27	0.24	
95% CI of the absolute risk difference	(-11.75, 14.28)	(-16.89, 17.36)	
p-value	0.8485	0.9782	
p-value of Breslow-Day Test for Homogeneity [3]	0.7268	0.7806	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (17.8)	7 (21.9)	17 (16.2)
No	60 (82.2)	25 (78.1)	88 (83.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.69	
95% CI of the inverse odds ratio	(0.40, 1.97)	(0.26, 1.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.74	
95% CI of the inverse risk ratio	(0.47, 1.75)	(0.34, 1.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.62	5.68	
95% CI of the absolute risk difference	(-9.64, 12.87)	(-10.28, 21.65)	
p-value	0.7767	0.4589	
p-value of Breslow-Day Test for Homogeneity [3]	0.9589	0.7023	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (23.3)	10 (31.3)	25 (23.8)
No	56 (76.7)	22 (68.8)	80 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.69	
95% CI of the inverse odds ratio	(0.51, 2.08)	(0.29, 1.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.76	
95% CI of the inverse risk ratio	(0.60, 1.75)	(0.41, 1.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.52	7.44	
95% CI of the absolute risk difference	(-13.19, 12.14)	(-10.57, 25.45)	
p-value	0.9357	0.3982	
p-value of Breslow-Day Test for Homogeneity [3]	0.8342	0.3861	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.1)	2 (6.3)	6 (5.7)
No	70 (95.9)	30 (93.8)	99 (94.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	0.91	
95% CI of the inverse odds ratio	(0.34, 5.85)	(0.17, 4.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	0.91	
95% CI of the inverse risk ratio	(0.36, 5.38)	(0.19, 4.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.60	0.54	
95% CI of the absolute risk difference	(-7.96, 4.76)	(-8.95, 10.03)	
p-value	0.6308	0.9099	
p-value of Breslow-Day Test for Homogeneity [3]	0.8113	0.8889	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (11.0)	5 (15.6)	12 (11.4)
No	65 (89.0)	27 (84.4)	93 (88.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.70	
95% CI of the inverse odds ratio	(0.41, 2.71)	(0.23, 2.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.73	
95% CI of the inverse risk ratio	(0.45, 2.42)	(0.28, 1.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.47	4.20	
95% CI of the absolute risk difference	(-9.87, 8.93)	(-9.78, 18.17)	
p-value	0.9223	0.5285	
p-value of Breslow-Day Test for Homogeneity [3]	0.8080	0.6493	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (16.4)	3 (9.4)	15 (14.3)
No	61 (83.6)	29 (90.6)	90 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.61	
95% CI of the inverse odds ratio	(0.37, 1.93)	(0.44, 5.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.52	
95% CI of the inverse risk ratio	(0.43, 1.75)	(0.47, 4.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.15	-4.91	
95% CI of the absolute risk difference	(-8.67, 12.97)	(-17.03, 7.20)	
p-value	0.6937	0.4716	
p-value of Breslow-Day Test for Homogeneity [3]	0.4829	0.6907	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (35.6)	10 (31.3)	33 (31.4)
No	47 (64.4)	22 (68.8)	72 (68.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	1.01	
95% CI of the inverse odds ratio	(0.44, 1.56)	(0.43, 2.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	1.01	
95% CI of the inverse risk ratio	(0.58, 1.34)	(0.56, 1.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.19	-0.18	
95% CI of the absolute risk difference	(-9.94, 18.31)	(-18.53, 18.17)	
p-value	0.5594	0.9848	
p-value of Breslow-Day Test for Homogeneity [3]	0.1791	0.7988	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (13.7)	4 (12.5)	15 (14.3)
No	63 (86.3)	28 (87.5)	90 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.17	
95% CI of the inverse odds ratio	(0.44, 2.49)	(0.36, 3.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.14	
95% CI of the inverse risk ratio	(0.50, 2.19)	(0.41, 3.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.59	-1.79	
95% CI of the absolute risk difference	(-10.93, 9.76)	(-15.06, 11.48)	
p-value	0.9117	0.7980	
p-value of Breslow-Day Test for Homogeneity [3]	0.7124	0.2138	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (30.1)	10 (31.3)	34 (32.4)
No	51 (69.9)	22 (68.8)	71 (67.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.05	
95% CI of the inverse odds ratio	(0.58, 2.12)	(0.45, 2.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.04	
95% CI of the inverse risk ratio	(0.69, 1.68)	(0.58, 1.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.24	-1.13	
95% CI of the absolute risk difference	(-16.06, 11.57)	(-19.52, 17.25)	
p-value	0.7512	0.9045	
p-value of Breslow-Day Test for Homogeneity [3]	0.7275	0.9505	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (17.8)	7 (21.9)	18 (17.1)
No	60 (82.2)	25 (78.1)	87 (82.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.74	
95% CI of the inverse odds ratio	(0.44, 2.09)	(0.28, 1.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.78	
95% CI of the inverse risk ratio	(0.50, 1.84)	(0.36, 1.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.67	4.73	
95% CI of the absolute risk difference	(-10.69, 12.02)	(-11.30, 20.77)	
p-value	0.9083	0.5440	
p-value of Breslow-Day Test for Homogeneity [3]	0.3027	0.3941	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (32.9)	10 (31.3)	28 (26.7)
No	49 (67.1)	22 (68.8)	77 (73.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.80	
95% CI of the inverse odds ratio	(0.39, 1.43)	(0.34, 1.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.85	
95% CI of the inverse risk ratio	(0.51, 1.28)	(0.47, 1.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.21	4.58	
95% CI of the absolute risk difference	(-7.49, 19.91)	(-13.57, 22.73)	
p-value	0.3702	0.6122	
p-value of Breslow-Day Test for Homogeneity [3]	0.8994	0.7374	

AMNOG Table SE21.4.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (12.3)	5 (15.6)	15 (14.3)
No	64 (87.7)	27 (84.4)	90 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	0.90	
95% CI of the inverse odds ratio	(0.49, 2.88)	(0.30, 2.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	0.91	
95% CI of the inverse risk ratio	(0.54, 2.50)	(0.36, 2.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.96	1.34	
95% CI of the absolute risk difference	(-12.04, 8.13)	(-12.91, 15.59)	
p-value	0.7069	0.8510	
p-value of Breslow-Day Test for Homogeneity [3]	0.4562	0.8845	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (30.1)	7 (21.9)	36 (34.3)
No	51 (69.9)	25 (78.1)	69 (65.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.86	
95% CI of the inverse odds ratio	(0.64, 2.30)	(0.74, 4.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	1.57	
95% CI of the inverse risk ratio	(0.73, 1.76)	(0.77, 3.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.15	-12.41	
95% CI of the absolute risk difference	(-18.05, 9.75)	(-29.37, 4.55)	
p-value	0.5613	0.1854	
p-value of Breslow-Day Test for Homogeneity [3]	0.1263	0.0592	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Total LDQOL						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	75.98 (14.22)	76.89 (14.53)	77.32 (14.49)			
Median	78.20	80.70	80.90			
IQR: Q1, Q3	70.20, 84.50	67.60, 87.00	68.80, 87.70			
Min, Max	38.5, 96.5	23.6, 96.3	34.8, 97.8			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	77.79 (15.26)	77.59 (12.64)	78.30 (14.12)	1.54 (1.35)	0.60 (0.71)	0.61 (0.78)
Median	81.85	78.85	81.85	1.40	0.10	0.25
IQR: Q1, Q3	71.40, 89.50	70.65, 86.85	70.10, 89.00	-3.95, 7.70	-5.00, 5.10	-3.30, 4.60
Min, Max	28.2, 96.9	32.4, 96.9	22.4, 98.3	-18.3, 24.2	-15.4, 27.0	-46.4, 29.7
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	80.52 (12.49)	78.22 (14.01)	78.68 (15.01)	1.31 (1.17)	0.64 (0.88)	0.13 (0.83)
Median	85.55	81.05	82.60	1.30	0.30	0.20
IQR: Q1, Q3	71.00, 90.60	69.90, 89.80	70.70, 89.40	-2.90, 6.30	-4.40, 5.90	-4.35, 4.90
Min, Max	48.8, 96.9	33.8, 97.4	20.3, 100.0	-14.4, 17.3	-23.3, 33.9	-46.3, 24.9

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Symptoms of Liver Disease						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	75.84 (19.67)	74.95 (18.77)	74.74 (17.80)			
Median	80.00	80.00	76.70			
IQR: Q1, Q3	66.70, 93.30	63.30, 90.00	63.30, 90.00			
Min, Max	26.7, 96.7	10.0, 100.0	26.7, 100.0			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	75.46 (21.71)	74.11 (18.06)	76.07 (19.37)	-0.42 (2.11)	-0.86 (1.09)	-0.06 (1.17)
Median	80.00	76.70	80.00	0	0	0
IQR: Q1, Q3	66.70, 93.30	65.00, 86.70	63.30, 90.00	-10.00, 6.70	-10.00, 6.70	-6.70, 6.70
Min, Max	16.7, 100.0	26.7, 100.0	16.7, 100.0	-46.6, 33.4	-36.6, 30.0	-53.3, 43.3
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	78.81 (18.58)	76.55 (18.33)	76.55 (19.41)	-1.37 (1.94)	0.89 (1.30)	-0.14 (1.15)
Median	83.30	80.00	83.30	0	0	0
IQR: Q1, Q3	66.70, 93.30	66.70, 93.30	66.70, 90.00	-6.70, 6.70	-6.70, 10.00	-6.70, 6.70
Min, Max	26.7, 100.0	26.7, 100.0	16.7, 100.0	-43.4, 33.4	-36.7, 36.7	-60.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Effects of Liver Disease						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	78.20 (12.12)	78.55 (15.15)	76.65 (15.71)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	73.30, 86.70	80.00, 80.00			
Min, Max	26.7, 100.0	13.3, 100.0	6.7, 100.0			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	77.20 (13.54)	79.24 (10.54)	77.90 (14.74)	-1.11 (1.84)	0.50 (1.38)	0.65 (1.14)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	76.65, 80.00	80.00, 80.00	-6.70, 6.70	-6.70, 6.70	-6.70, 6.70
Min, Max	40.0, 100.0	40.0, 100.0	6.7, 100.0	-40.0, 33.3	-33.3, 76.7	-40.0, 53.4
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	79.20 (10.74)	77.87 (12.44)	78.06 (13.25)	0.34 (1.96)	-0.52 (1.28)	-0.46 (1.58)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 0.00	-6.70, 6.60	-6.70, 6.70
Min, Max	40.0, 100.0	20.0, 100.0	13.3, 100.0	-40.0, 46.7	-33.3, 53.4	-80.0, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Concentration/Memory						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	77.49 (25.25)	78.91 (20.65)	79.14 (21.27)			
Median	81.30	84.40	87.50			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	68.80, 100.00			
Min, Max	12.5, 100.0	18.8, 100.0	6.3, 100.0			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	77.89 (24.87)	80.21 (19.56)	80.42 (21.63)	0.26 (2.27)	0.44 (1.33)	0.41 (1.07)
Median	84.40	81.30	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	68.80, 100.00	68.80, 100.00	-6.30, 9.40	-6.30, 6.30	-6.20, 6.25
Min, Max	0.0, 100.0	25.0, 100.0	12.5, 100.0	-43.8, 25.0	-37.5, 56.2	-43.8, 62.5
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	82.31 (16.09)	79.57 (20.33)	80.18 (21.49)	2.88 (2.72)	-1.32 (1.41)	-0.27 (1.03)
Median	84.40	87.50	87.50	0	0	0
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	68.80, 100.00	-6.30, 6.30	-6.30, 6.30	-6.30, 6.25
Min, Max	37.5, 100.0	18.8, 100.0	12.5, 100.0	-25.0, 50.0	-43.8, 50.0	-43.8, 31.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Health Distress						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	75.00 (28.60)	80.98 (25.46)	81.72 (24.39)			
Median	87.50	100.00	100.00			
IQR: Q1, Q3	50.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	82.50 (22.30)	86.86 (20.49)	85.49 (22.33)	6.77 (3.05)	6.15 (1.62)	3.78 (1.60)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	12.5, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 75.0	-37.5, 50.0	-62.5, 75.0
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	81.85 (26.65)	87.06 (21.10)	87.58 (20.98)	1.92 (3.39)	5.39 (1.94)	3.66 (1.89)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-75.0, 50.0	-50.0, 75.0	-87.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Sexual Function						
Baseline						
m	52	151	186			
n	24	72	80			
Mean (SD)	76.89 (29.79)	79.44 (23.28)	78.94 (25.42)			
Median	93.30	85.85	85.00			
IQR: Q1, Q3	60.80, 100.00	63.30, 100.00	68.30, 100.00			
Min, Max	8.9, 100.0	-1.7, 100.0	-1.7, 100.0			
Week 24						
m	51	141	178			
n	26	77	76	21	59	59
Mean (SD/SE)	84.62 (19.71)	74.50 (27.85)	79.93 (22.29)	8.16 (5.51)	-4.60 (2.71)	-1.98 (2.51)
Median	92.50	85.00	85.00	0	0	0
IQR: Q1, Q3	76.70, 100.00	55.00, 100.00	68.30, 100.00	0.00, 8.30	-16.60, 1.70	-8.30, 6.70
Min, Max	23.3, 100.0	-1.7, 100.0	-1.7, 100.0	-23.3, 91.1	-55.0, 46.7	-48.4, 50.0
Week 52						
m	46	125	165			
n	19	57	66	18	47	56
Mean (SD/SE)	87.98 (24.07)	77.11 (28.74)	77.23 (25.24)	5.99 (6.34)	-2.70 (3.03)	-2.55 (2.72)
Median	100.00	93.30	86.70	0	0	0
IQR: Q1, Q3	85.00, 100.00	55.00, 100.00	60.00, 100.00	-6.70, 0.00	-13.30, 6.70	-8.40, 6.70
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-16.6, 91.1	-50.0, 61.7	-53.3, 65.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Sleep						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	60.42 (21.06)	60.18 (19.76)	61.50 (20.11)			
Median	60.00	65.00	60.00			
IQR: Q1, Q3	45.00, 77.50	50.00, 75.00	50.00, 75.00			
Min, Max	15.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	63.40 (21.20)	58.13 (20.29)	61.88 (20.66)	1.77 (2.45)	-1.67 (1.26)	-0.12 (1.23)
Median	65.00	60.00	60.00	0	-2.50	0
IQR: Q1, Q3	50.00, 80.00	45.00, 75.00	50.00, 75.00	-10.00, 10.00	-10.00, 5.00	-10.00, 10.00
Min, Max	5.0, 100.0	0.0, 100.0	15.0, 100.0	-30.0, 55.0	-35.0, 45.0	-40.0, 45.0
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	65.71 (18.46)	59.65 (21.22)	62.95 (20.78)	0.90 (2.46)	-0.92 (1.61)	0.58 (1.32)
Median	70.00	65.00	65.00	0	0	0
IQR: Q1, Q3	55.00, 80.00	45.00, 75.00	50.00, 80.00	-10.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	15.0, 100.0	0.0, 95.0	5.0, 100.0	-30.0, 40.0	-60.0, 45.0	-40.0, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Loneliness						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	84.27 (17.56)	83.04 (19.89)	84.10 (19.45)			
Median	90.00	90.00	90.00			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	40.0, 100.0	0.0, 100.0	10.0, 100.0			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	83.00 (19.19)	84.96 (19.21)	82.01 (20.86)	-0.83 (2.59)	0.83 (1.20)	-1.81 (1.36)
Median	90.00	95.00	90.00	0	0	0
IQR: Q1, Q3	70.00, 100.00	80.00, 100.00	75.00, 100.00	-10.00, 7.50	-5.00, 5.00	-10.00, 5.00
Min, Max	30.0, 100.0	0.0, 100.0	10.0, 100.0	-45.0, 45.0	-35.0, 65.0	-80.0, 45.0
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	87.50 (16.79)	83.42 (20.89)	83.42 (20.33)	2.56 (2.34)	0.23 (1.46)	-1.25 (1.26)
Median	95.00	90.00	90.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 5.00	-10.00, 10.00	-10.00, 5.00
Min, Max	35.0, 100.0	0.0, 100.0	5.0, 100.0	-25.0, 50.0	-40.0, 35.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Hopelessness						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	77.96 (23.35)	76.69 (22.90)	79.19 (21.52)			
Median	91.70	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	58.30, 100.00			
Min, Max	25.0, 100.0	8.3, 100.0	16.7, 100.0			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	79.00 (21.25)	77.82 (22.23)	78.71 (21.78)	1.21 (2.67)	1.72 (1.72)	-0.60 (1.58)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	58.30, 100.00	66.70, 100.00	-8.40, 8.35	-8.30, 16.60	-8.30, 8.30
Min, Max	33.3, 100.0	8.3, 100.0	16.7, 100.0	-33.4, 50.0	-41.7, 58.4	-66.6, 50.0
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	81.55 (20.04)	78.29 (21.80)	78.58 (23.32)	-2.35 (2.45)	1.23 (2.09)	-2.02 (1.71)
Median	91.70	83.30	91.70	0	0	0
IQR: Q1, Q3	66.70, 100.00	66.70, 100.00	58.30, 100.00	-8.30, 0.00	-8.40, 16.70	-8.30, 8.30
Min, Max	33.3, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 33.3	-58.3, 50.0	-100.0, 33.4

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Stigma of Liver Disease						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	79.83 (21.07)	81.31 (19.74)	81.91 (19.48)			
Median	81.30	84.40	87.50			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	81.89 (23.15)	81.27 (19.45)	84.50 (17.79)	1.43 (3.04)	0.45 (1.30)	2.79 (1.34)
Median	90.65	81.30	92.75	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	81.30, 100.00	-9.35, 12.50	-6.30, 6.20	-6.20, 12.50
Min, Max	12.5, 100.0	12.5, 100.0	25.0, 100.0	-43.8, 43.8	-31.3, 56.3	-62.5, 75.0
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	85.28 (19.21)	84.44 (18.70)	84.50 (17.86)	2.24 (2.26)	2.57 (1.54)	2.96 (1.36)
Median	96.90	93.80	93.80	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 6.30	-6.20, 12.50	-6.20, 12.50
Min, Max	37.5, 100.0	12.5, 100.0	25.0, 100.0	-31.3, 37.5	-56.2, 56.3	-56.3, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Total LDQOL						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	78.13 (14.44)	N/A	78.80 (13.04)			
Median	82.90	N/A	82.20			
IQR: Q1, Q3	68.90, 89.20	N/A	72.80, 88.60			
Min, Max	28.3, 96.7	N/A	38.5, 97.8			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	78.26 (14.66)	N/A	79.12 (14.23)	0.45 (0.84)	N/A	0.79 (0.99)
Median	82.00	N/A	83.50	0.30	N/A	0.40
IQR: Q1, Q3	70.30, 89.90	N/A	71.30, 89.90	-5.10, 5.20	N/A	-3.80, 5.00
Min, Max	22.9, 97.8	N/A	38.2, 98.8	-23.4, 35.6	N/A	-27.7, 42.3
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	78.54 (13.77)	N/A	79.14 (13.01)	0.99 (0.99)	N/A	1.20 (1.01)
Median	82.25	N/A	81.05	0.90	N/A	1.00
IQR: Q1, Q3	69.70, 88.50	N/A	72.50, 89.30	-4.80, 6.30	N/A	-2.80, 5.90
Min, Max	34.0, 97.5	N/A	35.7, 97.8	-19.5, 36.0	N/A	-22.1, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Symptoms of Liver Disease						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	78.39 (19.32)	N/A	79.49 (17.68)			
Median	83.30	N/A	83.30			
IQR: Q1, Q3	70.00, 93.30	N/A	66.70, 93.30			
Min, Max	13.3, 100.0	N/A	20.0, 100.0			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	76.76 (19.62)	N/A	79.32 (18.91)	-1.81 (1.34)	N/A	0.51 (1.23)
Median	83.30	N/A	83.30	0	N/A	0
IQR: Q1, Q3	66.70, 90.00	N/A	70.00, 93.30	-10.00, 3.40	N/A	-3.40, 6.70
Min, Max	0.0, 100.0	N/A	20.0, 100.0	-46.7, 36.7	N/A	-30.0, 33.4
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	76.63 (19.66)	N/A	80.09 (18.23)	-2.20 (1.36)	N/A	1.87 (1.26)
Median	80.00	N/A	83.30	0	N/A	3.30
IQR: Q1, Q3	66.70, 93.30	N/A	72.00, 93.30	-10.00, 6.60	N/A	-3.40, 6.70
Min, Max	6.7, 100.0	N/A	23.3, 100.0	-36.7, 43.4	N/A	-30.0, 26.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Effects of Liver Disease						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	77.34 (14.79)	N/A	78.45 (13.79)			
Median	80.00	N/A	80.00			
IQR: Q1, Q3	80.00, 80.00	N/A	80.00, 86.70			
Min, Max	6.7, 100.0	N/A	33.3, 100.0			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	75.39 (15.28)	N/A	76.57 (15.31)	-2.20 (1.13)	N/A	-1.31 (1.58)
Median	80.00	N/A	80.00	0	N/A	0
IQR: Q1, Q3	73.30, 80.00	N/A	80.00, 86.70	-6.70, 0.00	N/A	-6.70, 6.60
Min, Max	0.0, 100.0	N/A	6.7, 100.0	-40.0, 26.6	N/A	-46.7, 46.7
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	75.43 (14.23)	N/A	77.18 (14.06)	-2.02 (1.48)	N/A	0.16 (1.68)
Median	80.00	N/A	80.00	0	N/A	0
IQR: Q1, Q3	73.30, 80.00	N/A	73.30, 80.00	-6.70, 0.00	N/A	-6.60, 0.00
Min, Max	6.7, 100.0	N/A	20.0, 100.0	-40.0, 80.0	N/A	-53.3, 46.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Concentration/Memory						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	81.50 (22.18)	N/A	77.71 (20.13)			
Median	87.50	N/A	81.30			
IQR: Q1, Q3	75.00, 100.00	N/A	68.80, 93.80			
Min, Max	6.3, 100.0	N/A	12.5, 100.0			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	78.93 (21.45)	N/A	78.83 (21.79)	-2.31 (1.46)	N/A	1.03 (1.98)
Median	87.50	N/A	81.30	0	N/A	0
IQR: Q1, Q3	68.80, 100.00	N/A	68.80, 100.00	-6.30, 6.20	N/A	-6.20, 12.50
Min, Max	18.8, 100.0	N/A	6.3, 100.0	-43.8, 31.2	N/A	-81.2, 62.5
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	77.61 (21.73)	N/A	77.17 (22.25)	-2.33 (1.28)	N/A	-0.98 (1.88)
Median	81.30	N/A	81.30	0	N/A	0
IQR: Q1, Q3	68.80, 93.80	N/A	62.50, 93.80	-6.30, 6.20	N/A	-6.30, 6.30
Min, Max	0.0, 100.0	N/A	0.0, 100.0	-43.7, 25.0	N/A	-43.7, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Health Distress						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	79.55 (25.10)	N/A	80.02 (23.66)			
Median	87.50	N/A	87.50			
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 100.00			
Min, Max	0.0, 100.0	N/A	0.0, 100.0			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	83.29 (23.91)	N/A	86.19 (21.30)	4.73 (2.03)	N/A	7.35 (1.91)
Median	100.00	N/A	100.00	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 100.00	0.00, 12.50	N/A	0.00, 12.50
Min, Max	0.0, 100.0	N/A	0.0, 100.0	-37.5, 62.5	N/A	-50.0, 62.5
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	83.64 (22.75)	N/A	84.31 (20.91)	6.18 (2.59)	N/A	5.27 (2.36)
Median	100.00	N/A	87.50	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 100.00	0.00, 12.50	N/A	0.00, 12.50
Min, Max	0.0, 100.0	N/A	0.0, 100.0	-50.0, 75.0	N/A	-62.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Sexual Function						
Baseline						
m	115	0	117			
n	47	0	41			
Mean (SD)	80.88 (24.77)	N/A	80.89 (22.64)			
Median	93.30	N/A	91.70			
IQR: Q1, Q3	68.30, 100.00	N/A	70.00, 100.00			
Min, Max	-1.7, 100.0	N/A	6.7, 100.0			
Week 24						
m	110	0	111			
n	46	0	49	36	0	35
Mean (SD/SE)	77.72 (25.93)	N/A	77.65 (25.35)	-2.08 (4.09)	N/A	3.47 (2.81)
Median	86.70	N/A	91.70	0	N/A	0
IQR: Q1, Q3	61.70, 100.00	N/A	61.70, 100.00	-8.30, 8.35	N/A	-6.60, 8.30
Min, Max	6.7, 100.0	N/A	6.7, 100.0	-85.0, 36.7	N/A	-45.0, 38.4
Week 52						
m	103	0	105			
n	34	0	35	28	0	24
Mean (SD/SE)	83.44 (19.73)	N/A	77.89 (27.29)	3.10 (3.75)	N/A	1.60 (4.52)
Median	92.50	N/A	85.00	0	N/A	0
IQR: Q1, Q3	76.70, 100.00	N/A	60.00, 100.00	-3.35, 7.50	N/A	-9.15, 6.70
Min, Max	28.3, 100.0	N/A	-1.7, 100.0	-45.0, 55.0	N/A	-38.3, 63.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Sleep						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	63.95 (20.67)	N/A	64.77 (19.77)			
Median	65.00	N/A	70.00			
IQR: Q1, Q3	50.00, 80.00	N/A	50.00, 80.00			
Min, Max	0.0, 100.0	N/A	5.0, 100.0			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	63.74 (20.76)	N/A	63.38 (19.95)	0.63 (1.52)	N/A	-0.62 (1.70)
Median	65.00	N/A	65.00	0	N/A	0
IQR: Q1, Q3	50.00, 80.00	N/A	50.00, 80.00	-5.00, 5.00	N/A	-15.00, 10.00
Min, Max	10.0, 100.0	N/A	20.0, 100.0	-30.0, 90.0	N/A	-35.0, 50.0
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	64.22 (19.98)	N/A	65.06 (20.60)	0.23 (1.80)	N/A	1.33 (1.91)
Median	65.00	N/A	65.00	0	N/A	0
IQR: Q1, Q3	50.00, 80.00	N/A	50.00, 85.00	-10.00, 10.00	N/A	-10.00, 10.00
Min, Max	10.0, 100.0	N/A	25.0, 100.0	-40.0, 75.0	N/A	-40.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Loneliness						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	84.73 (17.99)	N/A	83.39 (19.99)			
Median	92.50	N/A	90.00			
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 100.00			
Min, Max	25.0, 100.0	N/A	5.0, 100.0			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	83.81 (18.71)	N/A	84.14 (20.04)	-0.90 (1.52)	N/A	-0.75 (1.65)
Median	90.00	N/A	90.00	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	80.00, 100.00	-7.50, 5.00	N/A	-10.00, 5.00
Min, Max	15.0, 100.0	N/A	15.0, 100.0	-50.0, 40.0	N/A	-40.0, 70.0
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	83.99 (17.62)	N/A	85.17 (16.82)	-0.60 (1.70)	N/A	2.08 (1.94)
Median	87.50	N/A	90.00	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	80.00, 100.00	-5.00, 5.00	N/A	-5.00, 10.00
Min, Max	25.0, 100.0	N/A	35.0, 100.0	-60.0, 40.0	N/A	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 19 of 20
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Hopelessness						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	74.85 (22.38)	N/A	79.36 (21.28)			
Median	75.00	N/A	83.30			
IQR: Q1, Q3	58.30, 100.00	N/A	66.70, 100.00			
Min, Max	8.3, 100.0	N/A	16.7, 100.0			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	77.02 (23.54)	N/A	79.17 (21.58)	2.99 (1.88)	N/A	0.05 (1.69)
Median	83.30	N/A	83.30	0	N/A	0
IQR: Q1, Q3	58.30, 100.00	N/A	58.30, 100.00	-8.30, 16.70	N/A	-8.30, 8.30
Min, Max	8.3, 100.0	N/A	25.0, 100.0	-58.3, 50.0	N/A	-41.7, 41.7
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	77.22 (21.86)	N/A	78.61 (20.64)	3.38 (2.12)	N/A	0.20 (1.76)
Median	83.30	N/A	83.30	0	N/A	0
IQR: Q1, Q3	58.30, 100.00	N/A	66.70, 100.00	-8.30, 16.70	N/A	-8.30, 8.40
Min, Max	16.7, 100.0	N/A	25.0, 100.0	-41.7, 41.7	N/A	-41.7, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.5.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Stigma of Liver Disease						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	83.48 (21.85)	N/A	87.11 (18.03)			
Median	93.80	N/A	93.80			
IQR: Q1, Q3	75.00, 100.00	N/A	81.30, 100.00			
Min, Max	12.5, 100.0	N/A	12.5, 100.0			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	87.16 (17.25)	N/A	86.38 (19.50)	3.58 (1.59)	N/A	-0.32 (1.67)
Median	93.80	N/A	93.80	0	N/A	0
IQR: Q1, Q3	81.30, 100.00	N/A	81.30, 100.00	-6.20, 6.30	N/A	-6.20, 0.00
Min, Max	6.3, 100.0	N/A	6.3, 100.0	-31.3, 56.2	N/A	-43.8, 75.0
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	87.91 (16.91)	N/A	86.41 (19.66)	4.33 (1.43)	N/A	-0.37 (1.89)
Median	96.90	N/A	93.80	0	N/A	0
IQR: Q1, Q3	81.30, 100.00	N/A	81.30, 100.00	0.00, 6.30	N/A	-6.20, 6.20
Min, Max	31.3, 100.0	N/A	18.8, 100.0	-25.0, 56.2	N/A	-62.5, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Weight
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.5.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Total LDQOL			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	75.98 (14.22)	76.68 (14.79)	77.94 (14.39)
Analysis Visit Mean (SD)	77.51 (15.30)	77.28 (12.85)	78.55 (14.41)
LS Mean of Change from Baseline (SE)	1.35 (1.22)	0.37 (0.76)	0.78 (0.69)
95% CI	(-1.05, 3.75)	(-1.12, 1.87)	(-0.58, 2.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.57 (1.38)	-0.41 (0.99)	
95% CI	(-2.14, 3.28)	(-2.36, 1.55)	
p-value	0.6799	0.6834	
Corrected Hedge's g Statistics	0.067	-0.047	
95% CI	(-0.26, 0.39)	(-0.28, 0.19)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	78.85 (12.25)	77.12 (15.18)	78.42 (14.08)
Analysis Visit Mean (SD)	80.16 (12.43)	77.76 (14.10)	78.55 (15.39)
LS Mean of Change from Baseline (SE)	0.94 (1.44)	0.60 (0.88)	-0.08 (0.78)
95% CI	(-1.89, 3.77)	(-1.13, 2.33)	(-1.62, 1.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.02 (1.62)	0.68 (1.15)	
95% CI	(-2.16, 4.20)	(-1.58, 2.94)	
p-value	0.5283	0.5544	
Corrected Hedge's g Statistics	0.111	0.073	
95% CI	(-0.24, 0.47)	(-0.18, 0.32)	
Subgroup*Treatment Interaction p-value	0.4971	NE	

AMNOG Table SE21.5.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Total LDQOL			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	78.32 (14.13)	N/A	79.00 (12.71)
Analysis Visit Mean (SD)	78.77 (14.47)	N/A	79.78 (13.58)
LS Mean of Change from Baseline (SE)	0.33 (0.92)	NE	0.72 (0.93)
95% CI	(-1.48, 2.14)	NE	(-1.12, 2.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.39 (1.25)	NE	
95% CI	(-2.86, 2.08)	NE	
p-value	0.7557	NE	
Corrected Hedge's g Statistics	-0.042	NE	
95% CI	(-0.32, 0.24)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	77.81 (14.60)	N/A	78.31 (13.27)
Analysis Visit Mean (SD)	78.80 (13.47)	N/A	79.51 (12.98)
LS Mean of Change from Baseline (SE)	0.79 (0.93)	NE	1.05 (0.95)
95% CI	(-1.05, 2.62)	NE	(-0.83, 2.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.26 (1.28)	NE	
95% CI	(-2.78, 2.26)	NE	
p-value	0.8375	NE	
Corrected Hedge's g Statistics	-0.030	NE	
95% CI	(-0.33, 0.27)	NE	
Subgroup*Treatment Interaction p-value	0.4971	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Symptoms of Liver Disease			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	75.84 (19.67)	74.87 (18.79)	76.05 (17.70)
Analysis Visit Mean (SD)	75.41 (21.63)	74.01 (17.79)	75.99 (19.77)
LS Mean of Change from Baseline (SE)	0.07 (1.90)	-0.52 (1.19)	0.17 (1.08)
95% CI	(-3.67, 3.82)	(-2.86, 1.81)	(-1.95, 2.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (2.15)	-0.70 (1.56)	
95% CI	(-4.34, 4.14)	(-3.77, 2.37)	
p-value	0.9632	0.6551	
Corrected Hedge's g Statistics	-0.007	-0.052	
95% CI	(-0.33, 0.32)	(-0.29, 0.18)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	80.00 (17.05)	75.44 (18.16)	76.40 (16.88)
Analysis Visit Mean (SD)	78.63 (18.25)	76.33 (18.12)	76.26 (19.73)
LS Mean of Change from Baseline (SE)	-0.53 (2.07)	0.88 (1.26)	0.32 (1.12)
95% CI	(-4.61, 3.55)	(-1.61, 3.36)	(-1.88, 2.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.85 (2.33)	0.56 (1.64)	
95% CI	(-5.43, 3.72)	(-2.68, 3.79)	
p-value	0.7139	0.7358	
Corrected Hedge's g Statistics	-0.064	0.042	
95% CI	(-0.42, 0.29)	(-0.21, 0.29)	
Subgroup*Treatment Interaction p-value	0.2184	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Effects of Liver Disease			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	78.20 (12.12)	78.47 (15.48)	77.20 (14.93)
Analysis Visit Mean (SD)	77.09 (13.81)	78.97 (10.67)	77.85 (14.75)
LS Mean of Change from Baseline (SE)	-1.05 (1.70)	0.71 (1.06)	0.19 (0.97)
95% CI	(-4.39, 2.30)	(-1.38, 2.81)	(-1.72, 2.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.23 (1.93)	0.53 (1.40)	
95% CI	(-5.03, 2.56)	(-2.23, 3.28)	
p-value	0.5233	0.7075	
Corrected Hedge's g Statistics	-0.103	0.044	
95% CI	(-0.43, 0.22)	(-0.19, 0.28)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	78.98 (9.12)	78.29 (15.78)	78.20 (13.35)
Analysis Visit Mean (SD)	79.32 (11.11)	77.77 (12.72)	77.74 (13.47)
LS Mean of Change from Baseline (SE)	0.27 (1.99)	-0.55 (1.21)	-0.49 (1.07)
95% CI	(-3.65, 4.18)	(-2.93, 1.83)	(-2.60, 1.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.76 (2.24)	-0.05 (1.58)	
95% CI	(-3.64, 5.16)	(-3.16, 3.06)	
p-value	0.7335	0.9736	
Corrected Hedge's g Statistics	0.060	-0.004	
95% CI	(-0.29, 0.42)	(-0.25, 0.25)	
Subgroup*Treatment Interaction p-value	0.6974	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Concentration/Memory			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	77.49 (25.25)	79.24 (20.61)	80.20 (21.12)
Analysis Visit Mean (SD)	77.75 (25.09)	79.68 (19.84)	80.61 (22.06)
LS Mean of Change from Baseline (SE)	0.25 (1.99)	0.53 (1.24)	0.84 (1.13)
95% CI	(-3.66, 4.15)	(-1.91, 2.97)	(-1.38, 3.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.59 (2.25)	-0.31 (1.63)	
95% CI	(-5.02, 3.83)	(-3.51, 2.89)	
p-value	0.7922	0.8498	
Corrected Hedge's g Statistics	-0.043	-0.022	
95% CI	(-0.37, 0.28)	(-0.26, 0.21)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	79.02 (24.01)	80.12 (19.78)	80.24 (20.50)
Analysis Visit Mean (SD)	81.91 (16.21)	78.80 (20.44)	79.97 (22.02)
LS Mean of Change from Baseline (SE)	1.55 (2.11)	-0.44 (1.29)	-0.09 (1.15)
95% CI	(-2.61, 5.71)	(-2.98, 2.10)	(-2.35, 2.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.64 (2.37)	-0.35 (1.68)	
95% CI	(-3.02, 6.31)	(-3.66, 2.95)	
p-value	0.4889	0.8341	
Corrected Hedge's g Statistics	0.121	-0.026	
95% CI	(-0.23, 0.48)	(-0.28, 0.22)	
Subgroup*Treatment Interaction p-value	0.3691	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Health Distress			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	75.00 (28.60)	79.96 (26.03)	81.66 (24.45)
Analysis Visit Mean (SD)	81.77 (22.47)	86.11 (20.99)	85.44 (22.86)
LS Mean of Change from Baseline (SE)	4.33 (2.38)	5.65 (1.48)	3.97 (1.35)
95% CI	(-0.35, 9.02)	(2.73, 8.57)	(1.32, 6.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.36 (2.70)	1.67 (1.95)	
95% CI	(-4.95, 5.66)	(-2.16, 5.51)	
p-value	0.8950	0.3915	
Corrected Hedge's g Statistics	0.021	0.100	
95% CI	(-0.30, 0.35)	(-0.14, 0.34)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	78.53 (25.64)	81.31 (26.17)	83.39 (23.01)
Analysis Visit Mean (SD)	80.45 (27.17)	86.70 (21.47)	87.05 (21.44)
LS Mean of Change from Baseline (SE)	-1.11 (2.91)	5.51 (1.76)	4.24 (1.57)
95% CI	(-6.82, 4.61)	(2.05, 8.98)	(1.16, 7.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.34 (3.27)	1.28 (2.31)	
95% CI	(-11.77, 1.08)	(-3.26, 5.82)	
p-value	0.1028	0.5796	
Corrected Hedge's g Statistics	-0.289	0.069	
95% CI	(-0.64, 0.07)	(-0.18, 0.32)	
Subgroup*Treatment Interaction p-value	0.9243	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Sexual Function			
Week 24			
m	51	141	178
n	21	59	59
Baseline Mean (SD)	77.64 (30.31)	81.60 (21.76)	83.08 (20.98)
Analysis Visit Mean (SD)	85.80 (20.63)	77.00 (25.33)	81.10 (22.21)
LS Mean of Change from Baseline (SE)	8.35 (4.13)	-4.68 (2.47)	-1.33 (2.43)
95% CI	(0.19, 16.51)	(-9.56, 0.19)	(-6.12, 3.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.68 (4.74)	-3.35 (3.37)	
95% CI	(0.31, 19.05)	(-10.01, 3.30)	
p-value	0.0430	0.3207	
Corrected Hedge's g Statistics	0.512	-0.177	
95% CI	(0.01, 1.02)	(-0.54, 0.18)	
Week 52			
m	46	125	165
n	18	47	56
Baseline Mean (SD)	81.32 (29.79)	81.73 (21.85)	79.76 (24.60)
Analysis Visit Mean (SD)	87.31 (24.58)	79.03 (27.97)	77.21 (25.59)
LS Mean of Change from Baseline (SE)	6.35 (4.60)	-1.75 (2.79)	-3.03 (2.64)
95% CI	(-2.74, 15.43)	(-7.26, 3.77)	(-8.25, 2.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.38 (5.24)	1.29 (3.75)	
95% CI	(-0.98, 19.74)	(-6.13, 8.71)	
p-value	0.0758	0.7321	
Corrected Hedge's g Statistics	0.471	0.066	
95% CI	(-0.07, 1.01)	(-0.32, 0.45)	
Subgroup*Treatment Interaction p-value	0.0555	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Sleep			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	60.42 (21.06)	59.64 (20.05)	62.76 (20.16)
Analysis Visit Mean (SD)	62.19 (20.75)	57.98 (20.61)	62.63 (20.57)
LS Mean of Change from Baseline (SE)	1.87 (2.06)	-2.19 (1.29)	0.32 (1.17)
95% CI	(-2.19, 5.93)	(-4.73, 0.35)	(-1.99, 2.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.55 (2.34)	-2.51 (1.70)	
95% CI	(-3.05, 6.15)	(-5.85, 0.82)	
p-value	0.5076	0.1395	
Corrected Hedge's g Statistics	0.107	-0.173	
95% CI	(-0.22, 0.43)	(-0.41, 0.06)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	63.59 (20.26)	60.23 (20.78)	62.63 (20.02)
Analysis Visit Mean (SD)	64.49 (18.38)	59.31 (21.32)	63.21 (21.11)
LS Mean of Change from Baseline (SE)	1.98 (2.34)	-1.27 (1.43)	0.65 (1.27)
95% CI	(-2.63, 6.59)	(-4.07, 1.54)	(-1.84, 3.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.33 (2.63)	-1.92 (1.86)	
95% CI	(-3.84, 6.50)	(-5.58, 1.75)	
p-value	0.6136	0.3045	
Corrected Hedge's g Statistics	0.089	-0.128	
95% CI	(-0.27, 0.44)	(-0.38, 0.12)	
Subgroup*Treatment Interaction p-value	0.7652	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Loneliness			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	84.27 (17.56)	83.81 (19.93)	84.05 (20.00)
Analysis Visit Mean (SD)	83.44 (18.63)	84.64 (19.46)	82.24 (21.16)
LS Mean of Change from Baseline (SE)	-1.29 (2.14)	0.33 (1.33)	-2.20 (1.22)
95% CI	(-5.49, 2.91)	(-2.29, 2.96)	(-4.59, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.92 (2.42)	2.53 (1.76)	
95% CI	(-3.85, 5.68)	(-0.93, 5.99)	
p-value	0.7061	0.1509	
Corrected Hedge's g Statistics	0.061	0.169	
95% CI	(-0.26, 0.39)	(-0.07, 0.41)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	85.38 (17.71)	82.66 (20.67)	84.57 (19.96)
Analysis Visit Mean (SD)	87.95 (16.17)	82.89 (21.17)	83.32 (20.65)
LS Mean of Change from Baseline (SE)	1.59 (2.27)	-0.60 (1.38)	-1.83 (1.22)
95% CI	(-2.87, 6.06)	(-3.32, 2.12)	(-4.24, 0.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.42 (2.55)	1.23 (1.80)	
95% CI	(-1.58, 8.43)	(-2.31, 4.78)	
p-value	0.1795	0.4939	
Corrected Hedge's g Statistics	0.237	0.085	
95% CI	(-0.12, 0.59)	(-0.17, 0.34)	
Subgroup*Treatment Interaction p-value	0.2302	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Hopelessness			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	77.96 (23.35)	75.92 (22.79)	80.05 (20.95)
Analysis Visit Mean (SD)	79.17 (21.06)	77.65 (22.60)	79.45 (21.74)
LS Mean of Change from Baseline (SE)	1.08 (2.54)	0.31 (1.59)	-0.01 (1.44)
95% CI	(-3.91, 6.06)	(-2.82, 3.43)	(-2.85, 2.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.08 (2.87)	0.31 (2.09)	
95% CI	(-4.56, 6.73)	(-3.79, 4.42)	
p-value	0.7059	0.8804	
Corrected Hedge's g Statistics	0.061	0.018	
95% CI	(-0.26, 0.39)	(-0.22, 0.25)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	83.98 (20.09)	76.30 (23.90)	80.84 (20.82)
Analysis Visit Mean (SD)	81.63 (20.25)	77.53 (21.94)	78.81 (23.41)
LS Mean of Change from Baseline (SE)	0.74 (2.93)	0.36 (1.79)	-1.98 (1.58)
95% CI	(-5.03, 6.51)	(-3.16, 3.87)	(-5.10, 1.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.73 (3.29)	2.34 (2.33)	
95% CI	(-3.74, 9.19)	(-2.25, 6.93)	
p-value	0.4075	0.3165	
Corrected Hedge's g Statistics	0.146	0.125	
95% CI	(-0.21, 0.50)	(-0.13, 0.38)	
Subgroup*Treatment Interaction p-value	0.9260	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Stigma of Liver Disease			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	79.83 (21.07)	80.72 (20.21)	82.16 (19.51)
Analysis Visit Mean (SD)	81.27 (23.41)	81.17 (20.03)	84.96 (17.88)
LS Mean of Change from Baseline (SE)	0.98 (2.17)	0.35 (1.36)	3.07 (1.23)
95% CI	(-3.29, 5.26)	(-2.32, 3.02)	(0.64, 5.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.09 (2.46)	-2.72 (1.78)	
95% CI	(-6.93, 2.76)	(-6.23, 0.79)	
p-value	0.3975	0.1281	
Corrected Hedge's g Statistics	-0.137	-0.178	
95% CI	(-0.46, 0.19)	(-0.42, 0.06)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	82.55 (20.33)	81.50 (20.34)	81.88 (19.15)
Analysis Visit Mean (SD)	84.79 (19.59)	84.06 (18.94)	84.84 (17.98)
LS Mean of Change from Baseline (SE)	2.12 (2.25)	2.29 (1.37)	2.85 (1.22)
95% CI	(-2.31, 6.55)	(-0.42, 4.99)	(0.45, 5.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.74 (2.53)	-0.57 (1.79)	
95% CI	(-5.71, 4.23)	(-4.08, 2.95)	
p-value	0.7704	0.7513	
Corrected Hedge's g Statistics	-0.051	-0.039	
95% CI	(-0.41, 0.30)	(-0.29, 0.21)	
Subgroup*Treatment Interaction p-value	0.0807	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Symptoms of Liver Disease			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	78.57 (19.13)	N/A	79.99 (17.70)
Analysis Visit Mean (SD)	76.76 (19.89)	N/A	80.50 (17.98)
LS Mean of Change from Baseline (SE)	-2.38 (1.26)	NE	0.01 (1.28)
95% CI	(-4.87, 0.11)	NE	(-2.51, 2.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.40 (1.73)	NE	
95% CI	(-5.81, 1.01)	NE	
p-value	0.1672	NE	
Corrected Hedge's g Statistics	-0.188	NE	
95% CI	(-0.47, 0.09)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	78.38 (19.26)	N/A	79.07 (18.34)
Analysis Visit Mean (SD)	76.19 (19.71)	N/A	80.94 (17.15)
LS Mean of Change from Baseline (SE)	-2.90 (1.24)	NE	1.48 (1.27)
95% CI	(-5.34, -0.46)	NE	(-1.02, 3.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.38 (1.70)	NE	
95% CI	(-7.73, -1.03)	NE	
p-value	0.0107	NE	
Corrected Hedge's g Statistics	-0.373	NE	
95% CI	(-0.67, -0.07)	NE	
Subgroup*Treatment Interaction p-value	0.2184	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Effects of Liver Disease			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	78.00 (13.97)	N/A	78.70 (13.46)
Analysis Visit Mean (SD)	75.80 (14.73)	N/A	77.39 (14.58)
LS Mean of Change from Baseline (SE)	-2.19 (1.29)	NE	-1.14 (1.30)
95% CI	(-4.73, 0.34)	NE	(-3.71, 1.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.06 (1.76)	NE	
95% CI	(-4.53, 2.42)	NE	
p-value	0.5497	NE	
Corrected Hedge's g Statistics	-0.081	NE	
95% CI	(-0.36, 0.20)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	77.81 (14.54)	N/A	77.67 (13.63)
Analysis Visit Mean (SD)	75.79 (14.17)	N/A	77.83 (14.01)
LS Mean of Change from Baseline (SE)	-2.12 (1.36)	NE	-0.29 (1.41)
95% CI	(-4.81, 0.57)	NE	(-3.06, 2.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.83 (1.89)	NE	
95% CI	(-5.57, 1.90)	NE	
p-value	0.3333	NE	
Corrected Hedge's g Statistics	-0.141	NE	
95% CI	(-0.44, 0.16)	NE	
Subgroup*Treatment Interaction p-value	0.6974	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Concentration/Memory			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	81.94 (21.68)	N/A	77.79 (20.53)
Analysis Visit Mean (SD)	79.63 (21.13)	N/A	78.82 (21.58)
LS Mean of Change from Baseline (SE)	-2.08 (1.65)	NE	-0.13 (1.67)
95% CI	(-5.33, 1.17)	NE	(-3.42, 3.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.95 (2.26)	NE	
95% CI	(-6.41, 2.51)	NE	
p-value	0.3896	NE	
Corrected Hedge's g Statistics	-0.117	NE	
95% CI	(-0.39, 0.16)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	80.17 (22.27)	N/A	77.66 (20.73)
Analysis Visit Mean (SD)	77.84 (21.55)	N/A	76.68 (22.49)
LS Mean of Change from Baseline (SE)	-3.03 (1.55)	NE	-1.64 (1.59)
95% CI	(-6.08, 0.03)	NE	(-4.78, 1.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.38 (2.12)	NE	
95% CI	(-5.57, 2.80)	NE	
p-value	0.5156	NE	
Corrected Hedge's g Statistics	-0.094	NE	
95% CI	(-0.39, 0.20)	NE	
Subgroup*Treatment Interaction p-value	0.3691	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Health Distress			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	79.73 (25.19)	N/A	79.38 (23.46)
Analysis Visit Mean (SD)	84.47 (22.65)	N/A	86.73 (21.03)
LS Mean of Change from Baseline (SE)	5.15 (1.76)	NE	7.53 (1.78)
95% CI	(1.67, 8.62)	NE	(4.01, 11.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.38 (2.39)	NE	
95% CI	(-7.09, 2.33)	NE	
p-value	0.3209	NE	
Corrected Hedge's g Statistics	-0.134	NE	
95% CI	(-0.41, 0.14)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	78.30 (25.88)	N/A	79.22 (24.25)
Analysis Visit Mean (SD)	84.48 (21.27)	N/A	84.49 (21.26)
LS Mean of Change from Baseline (SE)	5.82 (1.97)	NE	5.51 (2.03)
95% CI	(1.93, 9.72)	NE	(1.51, 9.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.32 (2.73)	NE	
95% CI	(-5.06, 5.69)	NE	
p-value	0.9075	NE	
Corrected Hedge's g Statistics	0.017	NE	
95% CI	(-0.28, 0.31)	NE	
Subgroup*Treatment Interaction p-value	0.9243	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Sexual Function			
Week 24			
m	110	0	111
n	36	0	35
Baseline Mean (SD)	77.96 (26.97)	N/A	79.29 (24.01)
Analysis Visit Mean (SD)	75.88 (27.47)	N/A	82.76 (20.60)
LS Mean of Change from Baseline (SE)	-2.40 (3.15)	NE	3.18 (3.32)
95% CI	(-8.68, 3.87)	NE	(-3.43, 9.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.58 (4.47)	NE	
95% CI	(-14.50, 3.33)	NE	
p-value	0.2157	NE	
Corrected Hedge's g Statistics	-0.287	NE	
95% CI	(-0.75, 0.18)	NE	
Week 52			
m	103	0	105
n	28	0	24
Baseline Mean (SD)	81.78 (26.94)	N/A	80.48 (22.56)
Analysis Visit Mean (SD)	84.88 (18.25)	N/A	82.08 (24.10)
LS Mean of Change from Baseline (SE)	4.04 (3.23)	NE	0.96 (3.51)
95% CI	(-2.39, 10.47)	NE	(-6.04, 7.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.08 (4.65)	NE	
95% CI	(-6.18, 12.35)	NE	
p-value	0.5089	NE	
Corrected Hedge's g Statistics	0.177	NE	
95% CI	(-0.37, 0.72)	NE	
Subgroup*Treatment Interaction p-value	0.0555	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Sleep			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	64.17 (20.51)	N/A	64.64 (19.75)
Analysis Visit Mean (SD)	64.81 (19.97)	N/A	64.02 (19.81)
LS Mean of Change from Baseline (SE)	-0.13 (1.54)	NE	-1.31 (1.56)
95% CI	(-3.16, 2.91)	NE	(-4.38, 1.75)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.19 (2.09)	NE	
95% CI	(-2.93, 5.31)	NE	
p-value	0.5698	NE	
Corrected Hedge's g Statistics	0.077	NE	
95% CI	(-0.20, 0.35)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	64.34 (20.70)	N/A	64.58 (20.49)
Analysis Visit Mean (SD)	64.57 (19.06)	N/A	65.90 (20.57)
LS Mean of Change from Baseline (SE)	-0.18 (1.67)	NE	0.78 (1.71)
95% CI	(-3.47, 3.11)	NE	(-2.60, 4.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.95 (2.30)	NE	
95% CI	(-5.49, 3.58)	NE	
p-value	0.6788	NE	
Corrected Hedge's g Statistics	-0.060	NE	
95% CI	(-0.36, 0.24)	NE	
Subgroup*Treatment Interaction p-value	0.7652	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Loneliness			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	84.66 (18.30)	N/A	84.66 (18.93)
Analysis Visit Mean (SD)	83.76 (18.83)	N/A	83.92 (20.11)
LS Mean of Change from Baseline (SE)	-0.95 (1.53)	NE	-0.85 (1.55)
95% CI	(-3.97, 2.07)	NE	(-3.91, 2.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (2.09)	NE	
95% CI	(-4.22, 4.02)	NE	
p-value	0.9614	NE	
Corrected Hedge's g Statistics	-0.007	NE	
95% CI	(-0.28, 0.27)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	84.34 (18.92)	N/A	83.28 (19.60)
Analysis Visit Mean (SD)	83.74 (17.73)	N/A	85.36 (17.10)
LS Mean of Change from Baseline (SE)	-0.53 (1.55)	NE	1.12 (1.60)
95% CI	(-3.60, 2.53)	NE	(-2.03, 4.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.65 (2.14)	NE	
95% CI	(-5.86, 2.57)	NE	
p-value	0.4417	NE	
Corrected Hedge's g Statistics	-0.112	NE	
95% CI	(-0.41, 0.19)	NE	
Subgroup*Treatment Interaction p-value	0.2302	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Hopelessness			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	74.68 (22.23)	N/A	79.81 (20.69)
Analysis Visit Mean (SD)	77.67 (23.32)	N/A	79.85 (20.81)
LS Mean of Change from Baseline (SE)	2.19 (1.73)	NE	1.10 (1.76)
95% CI	(-1.21, 5.60)	NE	(-2.36, 4.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.09 (2.37)	NE	
95% CI	(-3.59, 5.77)	NE	
p-value	0.6472	NE	
Corrected Hedge's g Statistics	0.062	NE	
95% CI	(-0.22, 0.34)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	74.27 (22.04)	N/A	78.61 (21.44)
Analysis Visit Mean (SD)	77.65 (21.58)	N/A	78.81 (20.92)
LS Mean of Change from Baseline (SE)	2.74 (1.81)	NE	1.19 (1.86)
95% CI	(-0.82, 6.31)	NE	(-2.48, 4.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.55 (2.51)	NE	
95% CI	(-3.39, 6.49)	NE	
p-value	0.5374	NE	
Corrected Hedge's g Statistics	0.090	NE	
95% CI	(-0.21, 0.39)	NE	
Subgroup*Treatment Interaction p-value	0.9260	NE	

AMNOG Table SE21.5.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Stigma of Liver Disease			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	83.87 (21.21)	N/A	87.26 (18.10)
Analysis Visit Mean (SD)	87.45 (17.00)	N/A	86.94 (19.28)
LS Mean of Change from Baseline (SE)	3.08 (1.46)	NE	0.65 (1.48)
95% CI	(0.20, 5.96)	NE	(-2.28, 3.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.44 (2.01)	NE	
95% CI	(-1.52, 6.39)	NE	
p-value	0.2258	NE	
Corrected Hedge's g Statistics	0.165	NE	
95% CI	(-0.11, 0.44)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	84.15 (20.84)	N/A	86.46 (18.56)
Analysis Visit Mean (SD)	88.48 (16.45)	N/A	86.09 (20.22)
LS Mean of Change from Baseline (SE)	4.24 (1.49)	NE	0.35 (1.53)
95% CI	(1.31, 7.17)	NE	(-2.67, 3.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.89 (2.05)	NE	
95% CI	(-0.16, 7.94)	NE	
p-value	0.0597	NE	
Corrected Hedge's g Statistics	0.275	NE	
95% CI	(-0.02, 0.57)	NE	
Subgroup*Treatment Interaction p-value	0.0807	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.9)	4 (2.6)	6 (3.2)
No	51 (98.1)	147 (97.4)	180 (96.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.70	1.23	
95% CI of the inverse odds ratio	(0.20, 14.44)	(0.34, 4.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.68	1.22	
95% CI of the inverse risk ratio	(0.21, 13.62)	(0.35, 4.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.30	-0.58	
95% CI of the absolute risk difference	(-5.82, 3.21)	(-4.18, 3.03)	
p-value	0.6231	0.7563	
p-value of Breslow-Day Test for Homogeneity [3]	0.5401	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (23.1)	32 (21.2)	34 (18.3)
No	40 (76.9)	119 (78.8)	152 (81.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.83	
95% CI of the inverse odds ratio	(0.35, 1.57)	(0.49, 1.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.86	
95% CI of the inverse risk ratio	(0.44, 1.42)	(0.56, 1.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.80	2.91	
95% CI of the absolute risk difference	(-7.93, 17.52)	(-5.65, 11.48)	
p-value	0.4386	0.5029	
p-value of Breslow-Day Test for Homogeneity [3]	0.7326	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.9)	16 (10.6)	16 (8.6)
No	51 (98.1)	135 (89.4)	170 (91.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.80	0.79	
95% CI of the inverse odds ratio	(0.62, 37.08)	(0.38, 1.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.47	0.81	
95% CI of the inverse risk ratio	(0.61, 32.94)	(0.42, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.68	1.99	
95% CI of the absolute risk difference	(-12.17, -1.19)	(-4.36, 8.35)	
p-value	0.0983	0.5347	
p-value of Breslow-Day Test for Homogeneity [3]	0.4591	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (21.2)	39 (25.8)	44 (23.7)
No	41 (78.8)	112 (74.2)	142 (76.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.89	
95% CI of the inverse odds ratio	(0.55, 2.44)	(0.54, 1.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.92	
95% CI of the inverse risk ratio	(0.62, 2.01)	(0.63, 1.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.50	2.17	
95% CI of the absolute risk difference	(-15.17, 10.17)	(-7.10, 11.45)	
p-value	0.7051	0.6454	
p-value of Breslow-Day Test for Homogeneity [3]	0.6781	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.8)	10 (6.6)	18 (9.7)
No	50 (96.2)	141 (93.4)	168 (90.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.68	1.51	
95% CI of the inverse odds ratio	(0.60, 11.94)	(0.68, 3.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.52	1.46	
95% CI of the inverse risk ratio	(0.60, 10.49)	(0.70, 3.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.83	-3.05	
95% CI of the absolute risk difference	(-12.57, 0.90)	(-8.87, 2.76)	
p-value	0.1803	0.3123	
p-value of Breslow-Day Test for Homogeneity [3]	0.9823	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (17.3)	28 (18.5)	39 (21.0)
No	43 (82.7)	123 (81.5)	147 (79.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	1.17	
95% CI of the inverse odds ratio	(0.57, 2.82)	(0.68, 2.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.13	
95% CI of the inverse risk ratio	(0.63, 2.34)	(0.73, 1.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.66	-2.42	
95% CI of the absolute risk difference	(-15.49, 8.17)	(-10.95, 6.10)	
p-value	0.5609	0.5792	
p-value of Breslow-Day Test for Homogeneity [3]	0.8076	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (13.5)	9 (6.0)	13 (7.0)
No	45 (86.5)	142 (94.0)	173 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	1.19	
95% CI of the inverse odds ratio	(0.18, 1.28)	(0.49, 2.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	1.17	
95% CI of the inverse risk ratio	(0.22, 1.23)	(0.52, 2.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.47	-1.03	
95% CI of the absolute risk difference	(-3.50, 16.45)	(-6.29, 4.23)	
p-value	0.1370	0.7037	
p-value of Breslow-Day Test for Homogeneity [3]	0.4361	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (26.9)	36 (23.8)	42 (22.6)
No	38 (73.1)	115 (76.2)	144 (77.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.93	
95% CI of the inverse odds ratio	(0.39, 1.60)	(0.56, 1.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.95	
95% CI of the inverse risk ratio	(0.50, 1.41)	(0.64, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.34	1.26	
95% CI of the absolute risk difference	(-9.13, 17.81)	(-7.81, 10.33)	
p-value	0.5140	0.7850	
p-value of Breslow-Day Test for Homogeneity [3]	0.5117	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (15.4)	26 (17.2)	27 (14.5)
No	44 (84.6)	125 (82.8)	159 (85.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.82	
95% CI of the inverse odds ratio	(0.40, 2.20)	(0.45, 1.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.84	
95% CI of the inverse risk ratio	(0.46, 1.95)	(0.51, 1.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.87	2.70	
95% CI of the absolute risk difference	(-10.17, 11.90)	(-5.16, 10.57)	
p-value	0.8758	0.4980	
p-value of Breslow-Day Test for Homogeneity [3]	0.8895	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (19.2)	36 (23.8)	43 (23.1)
No	42 (80.8)	115 (76.2)	143 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	0.96	
95% CI of the inverse odds ratio	(0.59, 2.73)	(0.58, 1.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	0.97	
95% CI of the inverse risk ratio	(0.65, 2.22)	(0.66, 1.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.89	0.72	
95% CI of the absolute risk difference	(-16.19, 8.42)	(-8.38, 9.83)	
p-value	0.5514	0.8762	
p-value of Breslow-Day Test for Homogeneity [3]	0.4820	NE	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.8)	6 (4.0)	8 (4.3)
No	50 (96.2)	145 (96.0)	178 (95.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	1.09	
95% CI of the inverse odds ratio	(0.23, 5.46)	(0.37, 3.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	1.08	
95% CI of the inverse risk ratio	(0.24, 5.11)	(0.38, 3.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.45	-0.33	
95% CI of the absolute risk difference	(-6.44, 5.53)	(-4.59, 3.94)	
p-value	0.8851	0.8809	
p-value of Breslow-Day Test for Homogeneity [3]	0.9264	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (7.7)	13 (8.6)	17 (9.1)
No	48 (92.3)	138 (91.4)	169 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.07	
95% CI of the inverse odds ratio	(0.39, 3.76)	(0.50, 2.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	1.06	
95% CI of the inverse risk ratio	(0.42, 3.38)	(0.53, 2.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.45	-0.53	
95% CI of the absolute risk difference	(-9.79, 6.90)	(-6.63, 5.57)	
p-value	0.7449	0.8650	
p-value of Breslow-Day Test for Homogeneity [3]	0.6635	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (17.3)	20 (13.2)	28 (15.1)
No	43 (82.7)	131 (86.8)	158 (84.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.16	
95% CI of the inverse odds ratio	(0.37, 1.93)	(0.63, 2.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.14	
95% CI of the inverse risk ratio	(0.44, 1.73)	(0.67, 1.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.25	-1.81	
95% CI of the absolute risk difference	(-9.24, 13.75)	(-9.27, 5.65)	
p-value	0.6917	0.6366	
p-value of Breslow-Day Test for Homogeneity [3]	0.4604	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (32.7)	45 (29.8)	61 (32.8)
No	35 (67.3)	106 (70.2)	125 (67.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.15	
95% CI of the inverse odds ratio	(0.52, 1.93)	(0.72, 1.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.10	
95% CI of the inverse risk ratio	(0.65, 1.56)	(0.80, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.10	-2.99	
95% CI of the absolute risk difference	(-14.53, 14.32)	(-12.93, 6.94)	
p-value	0.9888	0.5561	
p-value of Breslow-Day Test for Homogeneity [3]	0.7557	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (11.5)	24 (15.9)	18 (9.7)
No	46 (88.5)	127 (84.1)	168 (90.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.57	
95% CI of the inverse odds ratio	(0.31, 2.19)	(0.30, 1.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.61	
95% CI of the inverse risk ratio	(0.35, 2.00)	(0.34, 1.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.86	6.22	
95% CI of the absolute risk difference	(-7.81, 11.53)	(-1.00, 13.43)	
p-value	0.6936	0.0858	
p-value of Breslow-Day Test for Homogeneity [3]	0.6884	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (19.2)	39 (25.8)	47 (25.3)
No	42 (80.8)	112 (74.2)	139 (74.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	0.97	
95% CI of the inverse odds ratio	(0.66, 3.05)	(0.59, 1.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	0.98	
95% CI of the inverse risk ratio	(0.71, 2.42)	(0.68, 1.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.04	0.56	
95% CI of the absolute risk difference	(-18.44, 6.36)	(-8.81, 9.93)	
p-value	0.3671	0.9068	
p-value of Breslow-Day Test for Homogeneity [3]	0.7345	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (5.8)	34 (22.5)	24 (12.9)
No	49 (94.2)	117 (77.5)	162 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.42	0.51	
95% CI of the inverse odds ratio	(0.70, 8.38)	(0.29, 0.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.24	0.57	
95% CI of the inverse risk ratio	(0.70, 7.14)	(0.36, 0.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.13	9.61	
95% CI of the absolute risk difference	(-15.09, 0.83)	(1.39, 17.83)	
p-value	0.1516	0.0201	
p-value of Breslow-Day Test for Homogeneity [3]	0.0281	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (17.3)	44 (29.1)	43 (23.1)
No	43 (82.7)	107 (70.9)	143 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	0.73	
95% CI of the inverse odds ratio	(0.65, 3.18)	(0.45, 1.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.34	0.79	
95% CI of the inverse risk ratio	(0.70, 2.56)	(0.55, 1.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.81	6.02	
95% CI of the absolute risk difference	(-17.75, 6.12)	(-3.43, 15.47)	
p-value	0.3700	0.2091	
p-value of Breslow-Day Test for Homogeneity [3]	0.0711	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (9.6)	18 (11.9)	23 (12.4)
No	47 (90.4)	133 (88.1)	163 (87.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	1.04	
95% CI of the inverse odds ratio	(0.48, 3.68)	(0.54, 2.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.04	
95% CI of the inverse risk ratio	(0.51, 3.22)	(0.58, 1.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.75	-0.45	
95% CI of the absolute risk difference	(-12.06, 6.55)	(-7.45, 6.56)	
p-value	0.5863	0.9011	
p-value of Breslow-Day Test for Homogeneity [3]	0.2611	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (26.9)	43 (28.5)	59 (31.7)
No	38 (73.1)	108 (71.5)	127 (68.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	1.17	
95% CI of the inverse odds ratio	(0.63, 2.50)	(0.73, 1.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.11	
95% CI of the inverse risk ratio	(0.72, 1.93)	(0.80, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.80	-3.24	
95% CI of the absolute risk difference	(-18.58, 8.99)	(-13.07, 6.58)	
p-value	0.5072	0.5192	
p-value of Breslow-Day Test for Homogeneity [3]	0.0332	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.3)	0	4 (3.4)
No	110 (95.7)	0	113 (96.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	NE	
95% CI of the inverse odds ratio	(0.20, 2.98)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	NE	
95% CI of the inverse risk ratio	(0.22, 2.85)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.93	NE	
95% CI of the absolute risk difference	(-4.04, 5.90)	NE	
p-value	0.7141	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5401	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (22.6)	0	24 (20.5)
No	89 (77.4)	0	93 (79.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse odds ratio	(0.47, 1.65)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	NE	
95% CI of the inverse risk ratio	(0.56, 1.48)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.10	NE	
95% CI of the absolute risk difference	(-8.49, 12.68)	NE	
p-value	0.6979	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7326	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.3)	0	10 (8.5)
No	110 (95.7)	0	107 (91.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.06	NE	
95% CI of the inverse odds ratio	(0.68, 6.21)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.97	NE	
95% CI of the inverse risk ratio	(0.69, 5.57)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.20	NE	
95% CI of the absolute risk difference	(-10.49, 2.09)	NE	
p-value	0.1935	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4591	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (21.7)	0	33 (28.2)
No	90 (78.3)	0	84 (71.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	NE	
95% CI of the inverse odds ratio	(0.78, 2.57)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	NE	
95% CI of the inverse risk ratio	(0.83, 2.04)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.47	NE	
95% CI of the absolute risk difference	(-17.57, 4.64)	NE	
p-value	0.2555	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6781	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (2.6)	0	8 (6.8)
No	112 (97.4)	0	109 (93.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.74	NE	
95% CI of the inverse odds ratio	(0.71, 10.60)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.62	NE	
95% CI of the inverse risk ratio	(0.71, 9.63)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.23	NE	
95% CI of the absolute risk difference	(-9.65, 1.19)	NE	
p-value	0.1297	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9823	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (15.7)	0	20 (17.1)
No	97 (84.3)	0	97 (82.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	NE	
95% CI of the inverse odds ratio	(0.55, 2.23)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	NE	
95% CI of the inverse risk ratio	(0.61, 1.96)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.44	NE	
95% CI of the absolute risk difference	(-10.96, 8.08)	NE	
p-value	0.7667	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8076	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (7.0)	0	7 (6.0)
No	107 (93.0)	0	110 (94.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	NE	
95% CI of the inverse odds ratio	(0.30, 2.43)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	NE	
95% CI of the inverse risk ratio	(0.32, 2.29)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.97	NE	
95% CI of the absolute risk difference	(-5.36, 7.31)	NE	
p-value	0.7630	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4361	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (20.0)	0	25 (21.4)
No	92 (80.0)	0	92 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	NE	
95% CI of the inverse odds ratio	(0.58, 2.05)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	NE	
95% CI of the inverse risk ratio	(0.65, 1.77)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.37	NE	
95% CI of the absolute risk difference	(-11.79, 9.05)	NE	
p-value	0.7971	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5117	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	20 (17.4)	0	18 (15.4)
No	95 (82.6)	0	99 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	NE	
95% CI of the inverse odds ratio	(0.43, 1.73)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.49, 1.58)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.01	NE	
95% CI of the absolute risk difference	(-7.52, 11.53)	NE	
p-value	0.6797	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8895	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (26.1)	0	28 (23.9)
No	85 (73.9)	0	89 (76.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	NE	
95% CI of the inverse odds ratio	(0.49, 1.62)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	NE	
95% CI of the inverse risk ratio	(0.59, 1.43)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.16	NE	
95% CI of the absolute risk difference	(-8.99, 13.30)	NE	
p-value	0.7046	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4820	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.5)	0	5 (4.3)
No	111 (96.5)	0	112 (95.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	NE	
95% CI of the inverse odds ratio	(0.32, 4.73)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	NE	
95% CI of the inverse risk ratio	(0.34, 4.46)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.80	NE	
95% CI of the absolute risk difference	(-5.76, 4.17)	NE	
p-value	0.7538	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9264	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (7.8)	0	8 (6.8)
No	106 (92.2)	0	109 (93.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	NE	
95% CI of the inverse odds ratio	(0.32, 2.32)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	NE	
95% CI of the inverse risk ratio	(0.35, 2.19)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.99	NE	
95% CI of the absolute risk difference	(-5.72, 7.70)	NE	
p-value	0.7727	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6635	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (13.9)	0	20 (17.1)
No	99 (86.1)	0	97 (82.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	NE	
95% CI of the inverse odds ratio	(0.62, 2.61)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	NE	
95% CI of the inverse risk ratio	(0.67, 2.25)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.18	NE	
95% CI of the absolute risk difference	(-12.48, 6.12)	NE	
p-value	0.5035	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4604	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (27.8)	0	36 (30.8)
No	83 (72.2)	0	81 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	NE	
95% CI of the inverse odds ratio	(0.65, 2.03)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	NE	
95% CI of the inverse risk ratio	(0.74, 1.65)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.94	NE	
95% CI of the absolute risk difference	(-14.65, 8.76)	NE	
p-value	0.6224	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7557	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component; by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (12.2)	0	15 (12.8)
No	101 (87.8)	0	102 (87.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	NE	
95% CI of the inverse odds ratio	(0.49, 2.31)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	NE	
95% CI of the inverse risk ratio	(0.53, 2.08)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.65	NE	
95% CI of the absolute risk difference	(-9.16, 7.86)	NE	
p-value	0.8816	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6884	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	31 (27.0)	0	36 (30.8)
No	84 (73.0)	0	81 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	NE	
95% CI of the inverse odds ratio	(0.68, 2.13)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	NE	
95% CI of the inverse risk ratio	(0.76, 1.71)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.81	NE	
95% CI of the absolute risk difference	(-15.46, 7.84)	NE	
p-value	0.5217	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7345	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	28 (24.3)	0	17 (14.5)
No	87 (75.7)	0	100 (85.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	NE	
95% CI of the inverse odds ratio	(0.27, 1.03)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	NE	
95% CI of the inverse risk ratio	(0.35, 1.03)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.82	NE	
95% CI of the absolute risk difference	(-0.30, 19.93)	NE	
p-value	0.0586	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0281	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	39 (33.9)	0	27 (23.1)
No	76 (66.1)	0	90 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	NE	
95% CI of the inverse odds ratio	(0.33, 1.04)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	NE	
95% CI of the inverse risk ratio	(0.45, 1.03)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.84	NE	
95% CI of the absolute risk difference	(-0.70, 22.38)	NE	
p-value	0.0674	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0711	NE	

AMNOG Table SE21.5.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (13.0)	0	10 (8.5)
No	100 (87.0)	0	107 (91.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	NE	
95% CI of the inverse odds ratio	(0.27, 1.45)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	NE	
95% CI of the inverse risk ratio	(0.31, 1.40)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.50	NE	
95% CI of the absolute risk difference	(-3.48, 12.47)	NE	
p-value	0.2694	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2611	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	38 (33.0)	0	22 (18.8)
No	77 (67.0)	0	95 (81.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse odds ratio	(0.26, 0.86)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	NE	
95% CI of the inverse risk ratio	(0.36, 0.90)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.24	NE	
95% CI of the absolute risk difference	(3.10, 25.38)	NE	
p-value	0.0133	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0332	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Total LDQOL						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	81.74 (19.33)	N/A	79.71 (13.20)			
Median	91.30	N/A	82.70			
IQR: Q1, Q3	80.10, 92.50	N/A	76.20, 87.90			
Min, Max	39.3, 93.1	N/A	52.3, 91.9			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	76.15 (26.74)	N/A	81.00 (12.09)	-3.97 (2.86)	N/A	1.00 (1.08)
Median	83.70	N/A	83.50	-3.20	N/A	1.60
IQR: Q1, Q3	80.00, 90.50	N/A	79.60, 88.10	-5.90, 1.90	N/A	0.20, 3.00
Min, Max	22.9, 96.1	N/A	55.3, 92.8	-16.4, 3.0	N/A	-3.8, 3.4
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	81.28 (16.81)	N/A	79.46 (8.70)	1.17 (1.86)	N/A	1.53 (1.84)
Median	86.85	N/A	82.30	1.25	N/A	1.20
IQR: Q1, Q3	81.40, 90.20	N/A	80.30, 82.30	-2.30, 2.50	N/A	-1.30, 4.35
Min, Max	48.1, 94.3	N/A	64.7, 87.7	-4.5, 8.8	N/A	-2.4, 6.1

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Symptoms of Liver Disease						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	89.04 (10.49)	N/A	74.76 (16.65)			
Median	90.00	N/A	73.30			
IQR: Q1, Q3	83.30, 100.00	N/A	63.30, 86.70			
Min, Max	70.0, 100.0	N/A	50.0, 100.0			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	78.88 (26.63)	N/A	80.47 (17.57)	-10.00 (6.82)	N/A	6.67 (6.27)
Median	83.30	N/A	90.00	-3.35	N/A	6.60
IQR: Q1, Q3	83.30, 96.70	N/A	66.70, 93.30	-10.00, 0.00	N/A	-6.60, 10.00
Min, Max	26.7, 100.0	N/A	50.0, 96.7	-43.3, 0.0	N/A	-10.0, 33.4
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	80.55 (24.37)	N/A	82.66 (16.55)	-8.33 (6.13)	N/A	9.98 (5.78)
Median	86.65	N/A	83.30	-1.65	N/A	13.30
IQR: Q1, Q3	80.00, 96.70	N/A	80.00, 93.30	-13.30, 0.00	N/A	3.30, 16.65
Min, Max	33.3, 100.0	N/A	56.7, 100.0	-36.7, 3.3	N/A	-6.7, 20.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Effects of Liver Disease						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	83.81 (10.78)	N/A	74.29 (18.24)			
Median	80.00	N/A	80.00			
IQR: Q1, Q3	80.00, 93.30	N/A	80.00, 80.00			
Min, Max	66.7, 100.0	N/A	33.3, 86.7			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	74.43 (20.84)	N/A	73.33 (11.56)	-10.02 (5.10)	N/A	-4.45 (3.30)
Median	80.00	N/A	80.00	-6.70	N/A	0
IQR: Q1, Q3	80.00, 80.00	N/A	60.00, 80.00	-13.30, 0.00	N/A	-6.70, 0.00
Min, Max	33.3, 93.3	N/A	53.3, 80.0	-33.4, 0.0	N/A	-20.0, 0.0
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	78.90 (18.09)	N/A	73.32 (11.56)	-5.55 (4.01)	N/A	-1.68 (1.68)
Median	83.35	N/A	80.00	-3.35	N/A	0
IQR: Q1, Q3	73.30, 86.70	N/A	73.30, 80.00	-13.30, 0.00	N/A	-3.35, 0.00
Min, Max	46.7, 100.0	N/A	53.3, 80.0	-20.0, 6.7	N/A	-6.7, 0.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Concentration/Memory						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	87.51 (21.33)	N/A	77.70 (13.89)			
Median	100.00	N/A	75.00			
IQR: Q1, Q3	75.00, 100.00	N/A	68.80, 87.50			
Min, Max	43.8, 100.0	N/A	56.3, 100.0			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	81.27 (23.06)	N/A	78.60 (11.89)	-5.20 (1.92)	N/A	0.02 (1.61)
Median	90.65	N/A	81.30	-6.20	N/A	0
IQR: Q1, Q3	75.00, 93.80	N/A	68.80, 81.30	-6.30, 0.00	N/A	0.00, 0.00
Min, Max	37.5, 100.0	N/A	62.5, 100.0	-12.5, 0.0	N/A	-6.2, 6.3
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	86.47 (21.78)	N/A	72.54 (5.58)	0.00 (3.23)	N/A	-3.10 (1.79)
Median	93.75	N/A	68.80	0	N/A	-3.10
IQR: Q1, Q3	87.50, 100.00	N/A	68.80, 75.00	0.00, 0.00	N/A	-6.20, 0.00
Min, Max	43.8, 100.0	N/A	68.8, 81.3	-12.5, 12.5	N/A	-6.2, 0.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Health Distress						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	76.79 (35.67)	N/A	83.93 (22.49)			
Median	87.50	N/A	87.50			
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 100.00			
Min, Max	0.0, 100.0	N/A	37.5, 100.0			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	77.08 (39.06)	N/A	92.86 (9.83)	0.00 (6.45)	N/A	4.17 (2.64)
Median	93.75	N/A	100.00	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	87.50, 100.00	0.00, 0.00	N/A	0.00, 12.50
Min, Max	0.0, 100.0	N/A	75.0, 100.0	-25.0, 25.0	N/A	0.0, 12.5
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	93.75 (10.46)	N/A	82.50 (16.77)	16.67 (12.36)	N/A	-3.13 (10.67)
Median	100.00	N/A	75.00	0	N/A	-6.25
IQR: Q1, Q3	87.50, 100.00	N/A	75.00, 100.00	0.00, 25.00	N/A	-18.75, 12.50
Min, Max	75.0, 100.0	N/A	62.5, 100.0	0.0, 75.0	N/A	-25.0, 25.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Sexual Function						
Baseline						
m	7	0	8			
n	4	0	3			
Mean (SD)	75.00 (29.83)	N/A	74.47 (11.81)			
Median	84.15	N/A	76.70			
IQR: Q1, Q3	57.50, 92.50	N/A	61.70, 85.00			
Min, Max	31.7, 100.0	N/A	61.7, 85.0			
Week 24						
m	6	0	7			
n	2	0	2	2	0	2
Mean (SD/SE)	45.85 (55.37)	N/A	84.15 (1.20)	-12.50 (12.50)	N/A	14.95 (6.65)
Median	45.85	N/A	84.15	-12.50	N/A	14.95
IQR: Q1, Q3	6.70, 85.00	N/A	83.30, 85.00	-25.00, 0.00	N/A	8.30, 21.60
Min, Max	6.7, 85.0	N/A	83.3, 85.0	-25.0, 0.0	N/A	8.3, 21.6
Week 52						
m	6	0	6			
n	1	0	1	1	0	1
Mean (SD/SE)	80.00 (N/A)	N/A	93.30 (N/A)	-5.00 (N/A)	N/A	16.60 (N/A)
Median	80.00	N/A	93.30	-5.00	N/A	16.60
IQR: Q1, Q3	80.00, 80.00	N/A	93.30, 93.30	-5.00, -5.00	N/A	16.60, 16.60
Min, Max	80.0, 80.0	N/A	93.3, 93.3	-5.0, -5.0	N/A	16.6, 16.6

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Sleep						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	70.00 (29.01)	N/A	72.14 (12.86)			
Median	80.00	N/A	75.00			
IQR: Q1, Q3	55.00, 90.00	N/A	60.00, 75.00			
Min, Max	10.0, 90.0	N/A	55.0, 95.0			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	73.33 (31.89)	N/A	68.57 (15.20)	5.83 (5.97)	N/A	-3.33 (7.15)
Median	85.00	N/A	75.00	0	N/A	-5.00
IQR: Q1, Q3	75.00, 90.00	N/A	55.00, 80.00	0.00, 5.00	N/A	-15.00, 5.00
Min, Max	10.0, 95.0	N/A	45.0, 85.0	-5.0, 35.0	N/A	-25.0, 25.0
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	65.00 (24.29)	N/A	68.00 (10.37)	-2.50 (9.29)	N/A	2.50 (4.33)
Median	65.00	N/A	70.00	-2.50	N/A	0
IQR: Q1, Q3	50.00, 80.00	N/A	70.00, 75.00	-10.00, 20.00	N/A	-2.50, 7.50
Min, Max	30.0, 100.0	N/A	50.0, 75.0	-40.0, 20.0	N/A	-5.0, 15.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Loneliness						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	85.00 (21.41)	N/A	81.43 (27.80)			
Median	95.00	N/A	95.00			
IQR: Q1, Q3	65.00, 100.00	N/A	55.00, 100.00			
Min, Max	45.0, 100.0	N/A	30.0, 100.0			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	71.25 (36.87)	N/A	84.29 (23.70)	-11.25 (8.65)	N/A	-0.83 (3.00)
Median	87.50	N/A	95.00	-3.75	N/A	-2.50
IQR: Q1, Q3	37.50, 100.00	N/A	55.00, 100.00	-20.00, 5.00	N/A	-5.00, 5.00
Min, Max	15.0, 100.0	N/A	45.0, 100.0	-50.0, 5.0	N/A	-10.0, 10.0
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	79.17 (30.56)	N/A	83.00 (21.10)	-3.33 (5.43)	N/A	3.75 (2.39)
Median	97.50	N/A	95.00	0	N/A	2.50
IQR: Q1, Q3	45.00, 100.00	N/A	60.00, 100.00	0.00, 5.00	N/A	0.00, 7.50
Min, Max	35.0, 100.0	N/A	60.0, 100.0	-30.0, 5.0	N/A	0.0, 10.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Hopelessness						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	73.83 (23.77)	N/A	80.96 (19.67)			
Median	66.70	N/A	75.00			
IQR: Q1, Q3	50.00, 100.00	N/A	66.70, 100.00			
Min, Max	41.7, 100.0	N/A	50.0, 100.0			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	66.67 (34.98)	N/A	85.71 (21.89)	-2.80 (7.67)	N/A	6.93 (3.98)
Median	75.00	N/A	100.00	0	N/A	4.15
IQR: Q1, Q3	50.00, 91.70	N/A	75.00, 100.00	-8.40, 0.00	N/A	0.00, 8.30
Min, Max	8.3, 100.0	N/A	41.7, 100.0	-33.4, 25.0	N/A	0.0, 25.0
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	79.17 (15.60)	N/A	76.68 (10.86)	9.70 (7.58)	N/A	0.00 (5.87)
Median	79.15	N/A	75.00	8.30	N/A	-4.15
IQR: Q1, Q3	66.70, 91.70	N/A	66.70, 83.30	0.00, 25.00	N/A	-8.30, 8.30
Min, Max	58.3, 100.0	N/A	66.7, 91.7	-16.7, 33.3	N/A	-8.3, 16.6

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Stigma of Liver Disease						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	88.40 (28.05)	N/A	91.99 (11.23)			
Median	100.00	N/A	93.80			
IQR: Q1, Q3	93.80, 100.00	N/A	87.50, 100.00			
Min, Max	25.0, 100.0	N/A	68.8, 100.0			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	88.57 (12.11)	N/A	84.84 (18.00)	2.10 (8.65)	N/A	-5.20 (2.51)
Median	90.65	N/A	93.80	-3.10	N/A	-3.10
IQR: Q1, Q3	81.30, 100.00	N/A	75.00, 100.00	-12.50, 0.00	N/A	-12.50, 0.00
Min, Max	68.8, 100.0	N/A	50.0, 100.0	-12.5, 43.8	N/A	-12.5, 0.0
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	87.52 (15.30)	N/A	95.04 (2.77)	1.05 (7.97)	N/A	1.58 (3.92)
Median	90.65	N/A	93.80	0	N/A	0
IQR: Q1, Q3	81.30, 100.00	N/A	93.80, 93.80	-12.50, 0.00	N/A	-3.10, 6.25
Min, Max	62.5, 100.0	N/A	93.8, 100.0	-18.7, 37.5	N/A	-6.2, 12.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Total LDQOL						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	79.80 (13.43)	N/A	80.04 (14.30)			
Median	83.10	N/A	83.70			
IQR: Q1, Q3	75.40, 89.20	N/A	72.90, 90.00			
Min, Max	28.3, 94.2	N/A	38.5, 97.8			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	79.48 (13.84)	N/A	82.39 (11.09)	0.16 (1.06)	N/A	1.94 (1.32)
Median	85.30	N/A	86.40	0.10	N/A	0.30
IQR: Q1, Q3	72.20, 90.10	N/A	74.20, 91.10	-3.00, 4.35	N/A	-3.40, 4.90
Min, Max	40.6, 95.8	N/A	56.1, 98.3	-18.3, 15.9	N/A	-14.2, 42.3
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	80.34 (13.05)	N/A	80.55 (12.99)	1.66 (1.26)	N/A	0.74 (1.50)
Median	83.80	N/A	82.50	0.90	N/A	-0.75
IQR: Q1, Q3	73.50, 90.50	N/A	72.70, 90.30	-2.70, 8.10	N/A	-3.85, 3.30
Min, Max	44.4, 97.5	N/A	35.7, 97.8	-19.3, 18.1	N/A	-11.9, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Symptoms of Liver Disease						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	82.07 (17.27)	N/A	82.45 (15.83)			
Median	83.30	N/A	86.70			
IQR: Q1, Q3	76.70, 96.70	N/A	76.70, 93.30			
Min, Max	13.3, 100.0	N/A	36.7, 100.0			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	78.78 (17.04)	N/A	83.25 (16.54)	-3.02 (1.55)	N/A	0.05 (1.81)
Median	78.35	N/A	86.70	0	N/A	0
IQR: Q1, Q3	66.70, 93.30	N/A	76.70, 96.70	-8.35, 3.35	N/A	-8.30, 6.70
Min, Max	16.7, 100.0	N/A	16.7, 100.0	-26.6, 16.7	N/A	-33.3, 33.3
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	77.89 (18.28)	N/A	82.19 (14.87)	-3.16 (1.81)	N/A	-0.09 (1.61)
Median	80.00	N/A	83.30	0	N/A	0
IQR: Q1, Q3	70.00, 90.00	N/A	73.30, 93.30	-6.70, 3.40	N/A	-6.70, 6.60
Min, Max	6.7, 100.0	N/A	40.0, 100.0	-33.4, 20.0	N/A	-30.0, 20.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Effects of Liver Disease						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	76.45 (14.32)	N/A	78.36 (14.87)			
Median	80.00	N/A	80.00			
IQR: Q1, Q3	80.00, 80.00	N/A	73.30, 86.70			
Min, Max	6.7, 93.3	N/A	33.3, 100.0			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	76.09 (15.11)	N/A	78.67 (12.86)	-0.61 (1.56)	N/A	1.15 (2.19)
Median	80.00	N/A	80.00	0	N/A	0
IQR: Q1, Q3	73.30, 80.00	N/A	80.00, 86.70	-6.70, 0.00	N/A	-3.30, 6.70
Min, Max	0.0, 100.0	N/A	40.0, 100.0	-33.3, 26.6	N/A	-40.0, 46.7
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	75.04 (14.74)	N/A	76.45 (13.32)	-0.43 (1.16)	N/A	-0.76 (2.54)
Median	80.00	N/A	80.00	0	N/A	0
IQR: Q1, Q3	73.30, 80.00	N/A	73.30, 80.00	-6.60, 0.00	N/A	-6.70, 0.00
Min, Max	6.7, 93.3	N/A	26.7, 100.0	-26.6, 13.4	N/A	-40.0, 46.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Concentration/Memory						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	83.35 (20.81)	N/A	76.22 (22.58)			
Median	87.50	N/A	87.50			
IQR: Q1, Q3	75.00, 100.00	N/A	62.50, 93.80			
Min, Max	6.3, 100.0	N/A	12.5, 100.0			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	79.64 (20.12)	N/A	80.81 (20.71)	-3.41 (2.28)	N/A	3.85 (2.51)
Median	84.40	N/A	87.50	0	N/A	0
IQR: Q1, Q3	68.80, 100.00	N/A	68.80, 100.00	-6.30, 6.20	N/A	0.00, 12.50
Min, Max	18.8, 100.0	N/A	6.3, 100.0	-43.8, 25.0	N/A	-37.5, 56.2
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	79.90 (20.61)	N/A	76.09 (23.86)	-1.92 (2.06)	N/A	0.15 (2.71)
Median	81.30	N/A	81.30	0	N/A	0
IQR: Q1, Q3	75.00, 93.80	N/A	62.50, 93.80	-6.20, 6.30	N/A	-6.30, 12.50
Min, Max	18.8, 100.0	N/A	0.0, 100.0	-37.5, 25.0	N/A	-43.7, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Health Distress						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	80.56 (25.08)	N/A	79.82 (24.64)			
Median	100.00	N/A	87.50			
IQR: Q1, Q3	62.50, 100.00	N/A	75.00, 100.00			
Min, Max	12.5, 100.0	N/A	0.0, 100.0			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	83.42 (23.73)	N/A	88.18 (18.23)	3.41 (3.31)	N/A	8.65 (2.44)
Median	100.00	N/A	100.00	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 100.00	0.00, 12.50	N/A	0.00, 25.00
Min, Max	12.5, 100.0	N/A	25.0, 100.0	-37.5, 62.5	N/A	-37.5, 50.0
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	85.37 (21.08)	N/A	85.64 (18.79)	6.41 (3.87)	N/A	4.83 (2.82)
Median	100.00	N/A	87.50	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 100.00	0.00, 25.00	N/A	0.00, 12.50
Min, Max	12.5, 100.0	N/A	12.5, 100.0	-50.0, 75.0	N/A	-25.0, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Sexual Function						
Baseline						
m	47	0	62			
n	24	0	23			
Mean (SD)	85.62 (21.50)	N/A	84.77 (20.82)			
Median	93.30	N/A	93.30			
IQR: Q1, Q3	85.85, 100.00	N/A	78.30, 100.00			
Min, Max	30.0, 100.0	N/A	30.0, 100.0			
Week 24						
m	46	0	59			
n	22	0	27	20	0	21
Mean (SD/SE)	83.41 (20.62)	N/A	82.34 (24.85)	-0.16 (4.17)	N/A	1.35 (3.61)
Median	93.30	N/A	93.30	0	N/A	0
IQR: Q1, Q3	76.70, 100.00	N/A	70.00, 100.00	-0.80, 7.50	N/A	-6.70, 6.70
Min, Max	30.0, 100.0	N/A	6.7, 100.0	-65.0, 25.0	N/A	-30.0, 38.3
Week 52						
m	44	0	56			
n	16	0	21	14	0	18
Mean (SD/SE)	93.74 (10.26)	N/A	82.45 (23.56)	5.60 (3.42)	N/A	-1.94 (5.40)
Median	96.65	N/A	93.30	0	N/A	0
IQR: Q1, Q3	93.30, 100.00	N/A	76.70, 100.00	0.00, 6.70	N/A	-8.30, 6.70
Min, Max	61.7, 100.0	N/A	28.3, 100.0	0.0, 48.3	N/A	-40.0, 63.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Sleep						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	64.11 (18.13)	N/A	68.07 (19.38)			
Median	65.00	N/A	70.00			
IQR: Q1, Q3	55.00, 75.00	N/A	55.00, 80.00			
Min, Max	10.0, 100.0	N/A	15.0, 100.0			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	63.91 (20.22)	N/A	67.09 (18.80)	1.59 (1.88)	N/A	-1.06 (2.32)
Median	65.00	N/A	65.00	0	N/A	0
IQR: Q1, Q3	50.00, 75.00	N/A	55.00, 80.00	-5.00, 10.00	N/A	-12.50, 5.00
Min, Max	25.0, 100.0	N/A	25.0, 100.0	-25.0, 35.0	N/A	-35.0, 50.0
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	67.10 (16.71)	N/A	66.38 (19.66)	3.37 (2.76)	N/A	-0.80 (2.53)
Median	65.00	N/A	65.00	0	N/A	0
IQR: Q1, Q3	55.00, 80.00	N/A	50.00, 85.00	-5.00, 10.00	N/A	-12.50, 10.00
Min, Max	30.0, 100.0	N/A	30.0, 100.0	-20.0, 75.0	N/A	-40.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Loneliness						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	81.33 (21.06)	N/A	84.39 (18.03)			
Median	95.00	N/A	90.00			
IQR: Q1, Q3	65.00, 100.00	N/A	80.00, 95.00			
Min, Max	25.0, 100.0	N/A	25.0, 100.0			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	84.57 (19.29)	N/A	87.36 (16.86)	2.84 (1.89)	N/A	0.67 (2.36)
Median	92.50	N/A	95.00	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	80.00, 100.00	-5.00, 5.00	N/A	-7.50, 5.00
Min, Max	35.0, 100.0	N/A	30.0, 100.0	-20.0, 40.0	N/A	-40.0, 70.0
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	84.15 (16.16)	N/A	87.34 (15.25)	3.08 (2.39)	N/A	2.84 (2.44)
Median	85.00	N/A	95.00	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	80.00, 100.00	-5.00, 5.00	N/A	-5.00, 5.00
Min, Max	45.0, 100.0	N/A	45.0, 100.0	-20.0, 50.0	N/A	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Hopelessness						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	80.19 (22.50)	N/A	80.41 (20.92)			
Median	91.70	N/A	83.30			
IQR: Q1, Q3	66.70, 100.00	N/A	66.70, 100.00			
Min, Max	8.3, 100.0	N/A	16.7, 100.0			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	79.16 (22.90)	N/A	83.11 (17.94)	-0.20 (2.40)	N/A	1.21 (2.22)
Median	83.30	N/A	91.70	0	N/A	0
IQR: Q1, Q3	66.70, 100.00	N/A	66.70, 100.00	-8.40, 0.00	N/A	-8.30, 12.50
Min, Max	8.3, 100.0	N/A	33.3, 100.0	-33.4, 33.4	N/A	-33.3, 41.7
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	79.88 (21.96)	N/A	81.21 (20.07)	0.43 (3.44)	N/A	1.15 (2.62)
Median	83.30	N/A	91.70	0	N/A	0
IQR: Q1, Q3	66.70, 100.00	N/A	66.70, 100.00	-16.70, 16.70	N/A	-8.30, 12.50
Min, Max	16.7, 100.0	N/A	25.0, 100.0	-41.7, 41.7	N/A	-33.3, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Stigma of Liver Disease						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	88.07 (18.41)	N/A	89.82 (19.50)			
Median	100.00	N/A	100.00			
IQR: Q1, Q3	81.30, 100.00	N/A	87.50, 100.00			
Min, Max	12.5, 100.0	N/A	12.5, 100.0			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	88.46 (17.77)	N/A	92.06 (13.89)	1.28 (1.77)	N/A	1.32 (2.86)
Median	100.00	N/A	100.00	0	N/A	0
IQR: Q1, Q3	81.30, 100.00	N/A	87.50, 100.00	-3.10, 6.20	N/A	-3.10, 3.10
Min, Max	31.3, 100.0	N/A	43.8, 100.0	-37.5, 37.5	N/A	-50.0, 75.0
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	89.34 (17.74)	N/A	89.51 (20.10)	3.53 (2.20)	N/A	-0.28 (2.59)
Median	100.00	N/A	100.00	0	N/A	0
IQR: Q1, Q3	81.30, 100.00	N/A	93.80, 100.00	0.00, 6.30	N/A	0.00, 6.20
Min, Max	37.5, 100.0	N/A	18.8, 100.0	-31.3, 37.5	N/A	-62.5, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Total LDQOL						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	76.20 (14.37)	76.89 (14.53)	77.26 (13.87)			
Median	78.20	80.70	80.75			
IQR: Q1, Q3	67.80, 86.90	67.60, 87.00	70.80, 87.30			
Min, Max	29.0, 96.7	23.6, 96.3	34.8, 97.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	77.62 (14.51)	77.59 (12.64)	77.53 (14.79)	1.36 (0.94)	0.60 (0.71)	0.32 (0.71)
Median	79.90	78.85	81.80	1.20	0.10	0.40
IQR: Q1, Q3	69.80, 89.50	70.65, 86.85	69.20, 88.40	-5.60, 7.00	-5.00, 5.10	-3.90, 4.90
Min, Max	28.2, 97.8	32.4, 96.9	22.4, 98.8	-23.4, 35.6	-15.4, 27.0	-46.4, 29.7
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	78.46 (13.40)	78.22 (14.01)	78.41 (14.69)	0.82 (1.03)	0.64 (0.88)	0.45 (0.72)
Median	82.10	81.05	81.70	0.60	0.30	0.90
IQR: Q1, Q3	69.40, 88.80	69.90, 89.80	70.70, 89.40	-5.10, 5.90	-4.40, 5.90	-4.30, 5.80
Min, Max	34.0, 96.9	33.8, 97.4	20.3, 100.0	-19.5, 36.0	-23.3, 33.9	-46.3, 24.9

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Symptoms of Liver Disease						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	74.97 (20.18)	74.95 (18.77)	75.06 (18.17)			
Median	80.00	80.00	76.70			
IQR: Q1, Q3	66.70, 90.00	63.30, 90.00	63.30, 90.00			
Min, Max	23.3, 100.0	10.0, 100.0	20.0, 100.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	75.14 (21.23)	74.11 (18.06)	75.66 (19.68)	-0.13 (1.48)	-0.86 (1.09)	-0.01 (0.99)
Median	83.30	76.70	80.00	0	0	0
IQR: Q1, Q3	63.30, 90.00	65.00, 86.70	63.30, 90.00	-10.00, 6.70	-10.00, 6.70	-6.70, 6.70
Min, Max	0.0, 100.0	26.7, 100.0	20.0, 100.0	-46.7, 36.7	-36.6, 30.0	-53.3, 43.3
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	76.81 (19.60)	76.55 (18.33)	76.68 (19.88)	-0.94 (1.41)	0.89 (1.30)	0.57 (1.01)
Median	83.30	80.00	83.30	0	0	0
IQR: Q1, Q3	63.30, 93.30	66.70, 93.30	66.70, 93.30	-10.00, 6.70	-6.70, 10.00	-6.70, 6.70
Min, Max	23.3, 100.0	26.7, 100.0	16.7, 100.0	-43.4, 43.4	-36.7, 36.7	-60.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Effects of Liver Disease						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	77.68 (14.05)	78.55 (15.15)	77.17 (14.99)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	73.30, 86.70	80.00, 80.00			
Min, Max	13.3, 100.0	13.3, 100.0	6.7, 100.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	76.00 (14.34)	79.24 (10.54)	77.17 (15.58)	-1.91 (1.23)	0.50 (1.38)	-0.32 (1.05)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	76.65, 80.00	80.00, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 6.60
Min, Max	20.0, 100.0	40.0, 100.0	6.7, 100.0	-40.0, 33.3	-33.3, 76.7	-46.7, 53.4
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	77.15 (12.38)	77.87 (12.44)	78.17 (13.66)	-1.42 (1.72)	-0.52 (1.28)	-0.06 (1.35)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 0.00	-6.70, 6.60	-6.70, 6.70
Min, Max	40.0, 100.0	20.0, 100.0	13.3, 100.0	-40.0, 80.0	-33.3, 53.4	-80.0, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Concentration/Memory						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	78.50 (24.15)	78.91 (20.65)	79.24 (20.55)			
Median	81.30	84.40	87.50			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	68.80, 100.00			
Min, Max	12.5, 100.0	18.8, 100.0	6.3, 100.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	77.99 (23.64)	80.21 (19.56)	79.56 (22.23)	-0.44 (1.54)	0.44 (1.33)	-0.20 (1.12)
Median	87.50	81.30	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	68.80, 100.00	68.80, 100.00	-6.30, 6.30	-6.30, 6.30	-6.20, 6.20
Min, Max	0.0, 100.0	25.0, 100.0	12.5, 100.0	-43.8, 31.2	-37.5, 56.2	-81.2, 62.5
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	78.18 (20.06)	79.57 (20.33)	79.96 (21.48)	-0.29 (1.61)	-1.32 (1.41)	-0.64 (1.01)
Median	81.30	87.50	87.50	0	0	0
IQR: Q1, Q3	68.80, 93.80	62.50, 100.00	68.80, 100.00	-6.30, 6.20	-6.30, 6.30	-6.30, 6.30
Min, Max	0.0, 100.0	18.8, 100.0	12.5, 100.0	-43.7, 50.0	-43.8, 50.0	-43.8, 43.8

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Health Distress						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	77.24 (26.21)	80.98 (25.46)	81.31 (24.08)			
Median	87.50	100.00	87.50			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	83.21 (22.32)	86.86 (20.49)	84.88 (23.02)	6.56 (2.03)	6.15 (1.62)	4.25 (1.45)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 75.0	-37.5, 50.0	-62.5, 75.0
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	81.32 (25.64)	87.06 (21.10)	86.63 (21.65)	3.38 (2.51)	5.39 (1.94)	4.29 (1.72)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-75.0, 75.0	-50.0, 75.0	-87.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Sexual Function						
Baseline						
m	113	151	233			
n	43	72	95			
Mean (SD)	76.56 (28.55)	79.44 (23.28)	78.51 (25.48)			
Median	85.00	85.85	85.00			
IQR: Q1, Q3	63.30, 100.00	63.30, 100.00	68.30, 100.00			
Min, Max	-1.7, 100.0	-1.7, 100.0	-1.7, 100.0			
Week 24						
m	109	141	223			
n	48	77	96	35	59	71
Mean (SD/SE)	80.18 (23.60)	74.50 (27.85)	78.00 (23.34)	3.57 (4.83)	-4.60 (2.71)	-0.75 (2.27)
Median	86.70	85.00	85.00	0	0	0
IQR: Q1, Q3	66.65, 100.00	55.00, 100.00	61.70, 100.00	-8.30, 16.70	-16.60, 1.70	-8.30, 6.70
Min, Max	15.0, 100.0	-1.7, 100.0	-1.7, 100.0	-85.0, 91.1	-55.0, 46.7	-48.4, 50.0
Week 52						
m	99	125	208			
n	36	57	79	31	47	61
Mean (SD/SE)	81.36 (24.04)	77.11 (28.74)	75.93 (26.48)	3.92 (4.73)	-2.70 (3.03)	-1.41 (2.62)
Median	89.20	93.30	85.00	0	0	0
IQR: Q1, Q3	72.50, 100.00	55.00, 100.00	60.00, 100.00	-8.30, 6.70	-13.30, 6.70	-8.40, 6.70
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-45.0, 91.1	-50.0, 61.7	-53.3, 65.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Sleep						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	61.89 (21.33)	60.18 (19.76)	61.04 (20.09)			
Median	65.00	65.00	60.00			
IQR: Q1, Q3	45.00, 80.00	50.00, 75.00	47.50, 75.00			
Min, Max	0.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	62.95 (20.48)	58.13 (20.29)	61.02 (20.76)	0.45 (1.72)	-1.67 (1.26)	-0.02 (1.13)
Median	65.00	60.00	60.00	0	-2.50	0
IQR: Q1, Q3	50.00, 75.00	45.00, 75.00	50.00, 75.00	-10.00, 5.00	-10.00, 5.00	-10.00, 10.00
Min, Max	5.0, 100.0	0.0, 100.0	15.0, 100.0	-30.0, 90.0	-35.0, 45.0	-40.0, 45.0
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	63.54 (20.42)	59.65 (21.22)	62.97 (21.15)	-0.71 (1.72)	-0.92 (1.61)	1.24 (1.23)
Median	70.00	65.00	65.00	0	0	0
IQR: Q1, Q3	50.00, 80.00	45.00, 75.00	50.00, 80.00	-10.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	10.0, 100.0	0.0, 95.0	5.0, 100.0	-30.0, 45.0	-60.0, 45.0	-40.0, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Loneliness						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	85.94 (15.99)	83.04 (19.89)	83.76 (19.83)			
Median	90.00	90.00	90.00			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	40.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	83.81 (17.17)	84.96 (19.21)	81.59 (21.23)	-1.88 (1.70)	0.83 (1.20)	-1.98 (1.20)
Median	90.00	95.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	80.00, 100.00	75.00, 100.00	-10.00, 5.00	-5.00, 5.00	-10.00, 5.00
Min, Max	30.0, 100.0	0.0, 100.0	10.0, 100.0	-45.0, 45.0	-35.0, 65.0	-80.0, 45.0
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	85.90 (16.98)	83.42 (20.89)	83.29 (19.87)	-0.65 (1.77)	0.23 (1.46)	-0.81 (1.22)
Median	95.00	90.00	90.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	75.00, 100.00	75.00, 100.00	-5.00, 5.00	-10.00, 10.00	-10.00, 5.00
Min, Max	25.0, 100.0	0.0, 100.0	5.0, 100.0	-60.0, 40.0	-40.0, 35.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Hopelessness						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	74.06 (22.61)	76.69 (22.90)	78.90 (21.64)			
Median	75.00	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	58.30, 100.00			
Min, Max	25.0, 100.0	8.3, 100.0	16.7, 100.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	77.62 (22.03)	77.82 (22.23)	77.52 (22.46)	3.88 (1.99)	1.72 (1.72)	-1.00 (1.39)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	58.30, 100.00	-8.30, 16.70	-8.30, 16.60	-8.30, 8.30
Min, Max	16.7, 100.0	8.3, 100.0	16.7, 100.0	-58.3, 50.0	-41.7, 58.4	-66.6, 50.0
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	77.90 (21.54)	78.29 (21.80)	77.99 (23.07)	1.66 (1.94)	1.23 (2.09)	-1.81 (1.45)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	58.30, 100.00	-8.30, 8.30	-8.40, 16.70	-8.30, 8.30
Min, Max	33.3, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 41.7	-58.3, 50.0	-100.0, 33.4

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Stigma of Liver Disease						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	79.56 (22.08)	81.31 (19.74)	82.07 (18.83)			
Median	84.40	84.40	87.50			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	75.00, 100.00			
Min, Max	18.8, 100.0	12.5, 100.0	31.3, 100.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	84.01 (20.36)	81.27 (19.45)	83.43 (19.20)	3.65 (1.97)	0.45 (1.30)	1.86 (1.12)
Median	93.80	81.30	87.50	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	75.00, 100.00	-6.20, 12.50	-6.30, 6.20	-6.20, 12.50
Min, Max	6.3, 100.0	12.5, 100.0	6.3, 100.0	-43.8, 56.2	-31.3, 56.3	-62.5, 50.0
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	86.04 (17.80)	84.44 (18.70)	83.88 (18.19)	3.97 (1.46)	2.57 (1.54)	2.22 (1.25)
Median	93.80	93.80	87.50	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 6.30	-6.20, 12.50	-6.20, 12.50
Min, Max	31.3, 100.0	12.5, 100.0	25.0, 100.0	-25.0, 56.2	-56.2, 56.3	-56.3, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by BMI
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.6.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Total LDQOL			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	80.12 (20.65)	N/A	84.28 (5.81)
Analysis Visit Mean (SD)	76.15 (26.74)	N/A	85.28 (4.62)
LS Mean of Change from Baseline (SE)	-4.24 (1.52)	NE	0.42 (1.48)
95% CI	(-7.73, -0.74)	NE	(-3.00, 3.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.65 (2.13)	NE	
95% CI	(-9.57, 0.27)	NE	
p-value	0.0608	NE	
Corrected Hedge's g Statistics	-1.170	NE	
95% CI	(-2.39, 0.05)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	80.12 (20.65)	N/A	81.63 (4.96)
Analysis Visit Mean (SD)	81.28 (16.81)	N/A	83.15 (3.18)
LS Mean of Change from Baseline (SE)	0.26 (1.29)	NE	0.83 (1.45)
95% CI	(-2.71, 3.23)	NE	(-2.52, 4.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.57 (1.95)	NE	
95% CI	(-5.05, 3.92)	NE	
p-value	0.7779	NE	
Corrected Hedge's g Statistics	-0.167	NE	
95% CI	(-1.43, 1.10)	NE	
Subgroup*Treatment Interaction p-value	0.5275	NE	

AMNOG Table SE21.6.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Total LDQOL			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	79.59 (13.51)	N/A	80.65 (13.97)
Analysis Visit Mean (SD)	79.75 (13.86)	N/A	82.59 (11.20)
LS Mean of Change from Baseline (SE)	0.37 (1.16)	NE	2.54 (1.10)
95% CI	(-1.94, 2.68)	NE	(0.35, 4.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.17 (1.55)	NE	
95% CI	(-5.24, 0.90)	NE	
p-value	0.1643	NE	
Corrected Hedge's g Statistics	-0.275	NE	
95% CI	(-0.68, 0.13)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	78.70 (14.07)	N/A	79.93 (14.75)
Analysis Visit Mean (SD)	80.35 (12.78)	N/A	80.67 (13.42)
LS Mean of Change from Baseline (SE)	1.93 (1.31)	NE	1.48 (1.25)
95% CI	(-0.68, 4.54)	NE	(-1.01, 3.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.44 (1.77)	NE	
95% CI	(-3.07, 3.95)	NE	
p-value	0.8019	NE	
Corrected Hedge's g Statistics	0.053	NE	
95% CI	(-0.38, 0.48)	NE	
Subgroup*Treatment Interaction p-value	0.5275	NE	

AMNOG Table SE21.6.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Total LDQOL			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	76.54 (14.05)	76.68 (14.79)	77.54 (13.79)
Analysis Visit Mean (SD)	77.90 (14.30)	77.28 (12.85)	77.86 (14.78)
LS Mean of Change from Baseline (SE)	1.37 (0.90)	0.35 (0.79)	0.38 (0.65)
95% CI	(-0.39, 3.14)	(-1.20, 1.90)	(-0.89, 1.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.00 (1.07)	-0.03 (0.99)	
95% CI	(-1.10, 3.10)	(-1.97, 1.92)	
p-value	0.3515	0.9785	
Corrected Hedge's g Statistics	0.111	-0.003	
95% CI	(-0.13, 0.35)	(-0.23, 0.22)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	77.71 (13.46)	77.12 (15.18)	77.91 (13.64)
Analysis Visit Mean (SD)	78.53 (13.14)	77.76 (14.10)	78.37 (14.92)
LS Mean of Change from Baseline (SE)	0.77 (1.01)	0.54 (0.88)	0.27 (0.71)
95% CI	(-1.21, 2.75)	(-1.19, 2.27)	(-1.12, 1.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.50 (1.20)	0.27 (1.10)	
95% CI	(-1.85, 2.86)	(-1.90, 2.44)	
p-value	0.6758	0.8072	
Corrected Hedge's g Statistics	0.054	0.029	
95% CI	(-0.21, 0.31)	(-0.21, 0.27)	
Subgroup*Treatment Interaction p-value	0.5275	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Symptoms of Liver Disease			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	88.88 (11.48)	N/A	78.88 (13.78)
Analysis Visit Mean (SD)	78.88 (26.63)	N/A	85.55 (12.41)
LS Mean of Change from Baseline (SE)	-7.26 (8.68)	NE	4.61 (8.84)
95% CI	(-27.27, 12.76)	NE	(-15.77, 24.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	-11.87 (12.88)	NE	
95% CI	(-41.58, 17.83)	NE	
p-value	0.3837	NE	
Corrected Hedge's g Statistics	-0.511	NE	
95% CI	(-1.66, 0.64)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	88.88 (11.48)	N/A	79.18 (17.30)
Analysis Visit Mean (SD)	80.55 (24.37)	N/A	89.15 (9.18)
LS Mean of Change from Baseline (SE)	-5.74 (6.21)	NE	6.39 (6.37)
95% CI	(-20.05, 8.58)	NE	(-8.29, 21.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-12.13 (9.24)	NE	
95% CI	(-33.43, 9.16)	NE	
p-value	0.2253	NE	
Corrected Hedge's g Statistics	-0.765	NE	
95% CI	(-2.07, 0.54)	NE	
Subgroup*Treatment Interaction p-value	0.0548	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Effects of Liver Disease			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	84.45 (11.66)	N/A	81.12 (2.74)
Analysis Visit Mean (SD)	74.43 (20.84)	N/A	76.67 (8.16)
LS Mean of Change from Baseline (SE)	-11.70 (4.54)	NE	-3.98 (4.46)
95% CI	(-22.18, -1.22)	NE	(-14.27, 6.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.72 (6.44)	NE	
95% CI	(-22.57, 7.13)	NE	
p-value	0.2649	NE	
Corrected Hedge's g Statistics	-0.646	NE	
95% CI	(-1.81, 0.51)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	84.45 (11.66)	N/A	80.00 (0.00)
Analysis Visit Mean (SD)	78.90 (18.09)	N/A	78.33 (3.35)
LS Mean of Change from Baseline (SE)	-7.02 (2.73)	NE	-1.15 (3.04)
95% CI	(-13.32, -0.72)	NE	(-8.16, 5.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.87 (4.15)	NE	
95% CI	(-15.45, 3.71)	NE	
p-value	0.1952	NE	
Corrected Hedge's g Statistics	-0.820	NE	
95% CI	(-2.14, 0.50)	NE	
Subgroup*Treatment Interaction p-value	0.9336	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Concentration/Memory			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	86.47 (23.17)	N/A	81.27 (11.17)
Analysis Visit Mean (SD)	81.27 (23.06)	N/A	81.28 (10.45)
LS Mean of Change from Baseline (SE)	-5.44 (1.89)	NE	-0.11 (1.81)
95% CI	(-9.80, -1.09)	NE	(-4.29, 4.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.34 (2.63)	NE	
95% CI	(-11.41, 0.74)	NE	
p-value	0.0774	NE	
Corrected Hedge's g Statistics	-1.086	NE	
95% CI	(-2.30, 0.13)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	86.47 (23.17)	N/A	75.03 (5.10)
Analysis Visit Mean (SD)	86.47 (21.78)	N/A	71.93 (6.25)
LS Mean of Change from Baseline (SE)	-0.01 (2.93)	NE	-4.13 (3.66)
95% CI	(-6.77, 6.75)	NE	(-12.56, 4.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.12 (4.80)	NE	
95% CI	(-6.95, 15.19)	NE	
p-value	0.4160	NE	
Corrected Hedge's g Statistics	0.514	NE	
95% CI	(-0.77, 1.80)	NE	
Subgroup*Treatment Interaction p-value	0.6377	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Health Distress			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	77.08 (39.06)	N/A	91.67 (10.21)
Analysis Visit Mean (SD)	77.08 (39.06)	N/A	95.83 (6.45)
LS Mean of Change from Baseline (SE)	-0.54 (5.67)	NE	5.76 (5.61)
95% CI	(-13.62, 12.53)	NE	(-7.19, 18.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.30 (8.14)	NE	
95% CI	(-25.06, 12.47)	NE	
p-value	0.4612	NE	
Corrected Hedge's g Statistics	-0.421	NE	
95% CI	(-1.56, 0.72)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	77.08 (39.06)	N/A	90.63 (11.97)
Analysis Visit Mean (SD)	93.75 (10.46)	N/A	87.50 (14.43)
LS Mean of Change from Baseline (SE)	11.67 (3.69)	NE	3.42 (4.24)
95% CI	(3.16, 20.17)	NE	(-6.36, 13.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.25 (5.71)	NE	
95% CI	(-4.92, 21.41)	NE	
p-value	0.1866	NE	
Corrected Hedge's g Statistics	0.843	NE	
95% CI	(-0.47, 2.16)	NE	
Subgroup*Treatment Interaction p-value	0.8038	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Sexual Function			
Week 24			
m	6	0	7
n	2	0	2
Baseline Mean (SD)	58.35 (37.69)	N/A	69.20 (10.61)
Analysis Visit Mean (SD)	45.85 (55.37)	N/A	84.15 (1.20)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	6	0	6
n	1	0	1
Baseline Mean (SD)	85.00 (N/A)	N/A	76.70 (N/A)
Analysis Visit Mean (SD)	80.00 (N/A)	N/A	93.30 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.1320	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Sleep			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	67.50 (30.94)	N/A	74.17 (12.81)
Analysis Visit Mean (SD)	73.33 (31.89)	N/A	70.83 (15.30)
LS Mean of Change from Baseline (SE)	1.70 (5.84)	NE	-2.36 (5.80)
95% CI	(-11.77, 15.18)	NE	(-15.74, 11.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.06 (8.28)	NE	
95% CI	(-15.03, 23.16)	NE	
p-value	0.6369	NE	
Corrected Hedge's g Statistics	0.263	NE	
95% CI	(-0.87, 1.40)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	67.50 (30.94)	N/A	70.00 (10.00)
Analysis Visit Mean (SD)	65.00 (24.29)	N/A	72.50 (2.89)
LS Mean of Change from Baseline (SE)	-7.18 (4.95)	NE	4.44 (5.80)
95% CI	(-18.59, 4.23)	NE	(-8.94, 17.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	-11.62 (7.63)	NE	
95% CI	(-29.22, 5.98)	NE	
p-value	0.1663	NE	
Corrected Hedge's g Statistics	-0.880	NE	
95% CI	(-2.20, 0.44)	NE	
Subgroup*Treatment Interaction p-value	0.8738	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Loneliness			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	82.50 (22.30)	N/A	90.00 (17.61)
Analysis Visit Mean (SD)	71.25 (36.87)	N/A	89.17 (21.78)
LS Mean of Change from Baseline (SE)	-10.42 (6.20)	NE	-2.49 (6.16)
95% CI	(-24.71, 3.87)	NE	(-16.69, 11.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.93 (8.80)	NE	
95% CI	(-28.21, 12.36)	NE	
p-value	0.3939	NE	
Corrected Hedge's g Statistics	-0.484	NE	
95% CI	(-1.63, 0.66)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	82.50 (22.30)	N/A	85.00 (20.41)
Analysis Visit Mean (SD)	79.17 (30.56)	N/A	88.75 (19.31)
LS Mean of Change from Baseline (SE)	-3.00 (4.28)	NE	2.32 (4.40)
95% CI	(-12.86, 6.86)	NE	(-7.83, 12.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.32 (6.16)	NE	
95% CI	(-19.52, 8.89)	NE	
p-value	0.4132	NE	
Corrected Hedge's g Statistics	-0.486	NE	
95% CI	(-1.77, 0.80)	NE	
Subgroup*Treatment Interaction p-value	0.3561	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Hopelessness			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	69.47 (22.77)	N/A	86.12 (15.51)
Analysis Visit Mean (SD)	66.67 (34.98)	N/A	93.05 (11.08)
LS Mean of Change from Baseline (SE)	-1.43 (7.34)	NE	5.97 (7.60)
95% CI	(-18.36, 15.51)	NE	(-11.55, 23.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.40 (11.06)	NE	
95% CI	(-32.91, 18.12)	NE	
p-value	0.5226	NE	
Corrected Hedge's g Statistics	-0.373	NE	
95% CI	(-1.51, 0.77)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	69.47 (22.77)	N/A	79.18 (14.42)
Analysis Visit Mean (SD)	79.17 (15.60)	N/A	79.18 (10.75)
LS Mean of Change from Baseline (SE)	6.54 (5.73)	NE	0.69 (6.42)
95% CI	(-6.68, 19.76)	NE	(-14.11, 15.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.85 (8.81)	NE	
95% CI	(-14.47, 26.17)	NE	
p-value	0.5254	NE	
Corrected Hedge's g Statistics	0.388	NE	
95% CI	(-0.89, 1.67)	NE	
Subgroup*Treatment Interaction p-value	0.2574	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Stigma of Liver Disease			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	86.47 (30.21)	N/A	95.85 (5.09)
Analysis Visit Mean (SD)	88.57 (12.11)	N/A	90.65 (10.27)
LS Mean of Change from Baseline (SE)	-0.57 (3.47)	NE	-1.37 (3.37)
95% CI	(-8.58, 7.44)	NE	(-9.15, 6.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.80 (4.95)	NE	
95% CI	(-10.62, 12.23)	NE	
p-value	0.8753	NE	
Corrected Hedge's g Statistics	0.088	NE	
95% CI	(-1.04, 1.22)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	86.47 (30.21)	N/A	93.78 (5.10)
Analysis Visit Mean (SD)	87.52 (15.30)	N/A	95.35 (3.10)
LS Mean of Change from Baseline (SE)	-1.49 (3.92)	NE	4.87 (4.52)
95% CI	(-10.53, 7.55)	NE	(-5.56, 15.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.35 (6.06)	NE	
95% CI	(-20.33, 7.62)	NE	
p-value	0.3252	NE	
Corrected Hedge's g Statistics	-0.611	NE	
95% CI	(-1.90, 0.68)	NE	
Subgroup*Treatment Interaction p-value	0.9660	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Symptoms of Liver Disease			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	81.81 (17.38)	N/A	83.26 (15.67)
Analysis Visit Mean (SD)	78.80 (17.43)	N/A	83.31 (17.02)
LS Mean of Change from Baseline (SE)	-3.32 (1.75)	NE	-0.09 (1.65)
95% CI	(-6.80, 0.16)	NE	(-3.36, 3.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.23 (2.35)	NE	
95% CI	(-7.89, 1.43)	NE	
p-value	0.1721	NE	
Corrected Hedge's g Statistics	-0.272	NE	
95% CI	(-0.68, 0.13)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	80.59 (17.92)	N/A	82.58 (16.26)
Analysis Visit Mean (SD)	77.44 (18.39)	N/A	82.49 (14.47)
LS Mean of Change from Baseline (SE)	-3.88 (1.66)	NE	0.10 (1.60)
95% CI	(-7.18, -0.57)	NE	(-3.08, 3.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.97 (2.25)	NE	
95% CI	(-8.44, 0.50)	NE	
p-value	0.0808	NE	
Corrected Hedge's g Statistics	-0.374	NE	
95% CI	(-0.81, 0.06)	NE	
Subgroup*Treatment Interaction p-value	0.0548	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Effects of Liver Disease			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	76.37 (14.48)	N/A	78.21 (15.18)
Analysis Visit Mean (SD)	75.76 (15.36)	N/A	79.36 (12.05)
LS Mean of Change from Baseline (SE)	-0.56 (1.76)	NE	2.25 (1.66)
95% CI	(-4.05, 2.93)	NE	(-1.04, 5.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.81 (2.35)	NE	
95% CI	(-7.47, 1.86)	NE	
p-value	0.2348	NE	
Corrected Hedge's g Statistics	-0.236	NE	
95% CI	(-0.64, 0.17)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	75.90 (15.26)	N/A	77.58 (15.76)
Analysis Visit Mean (SD)	75.47 (14.67)	N/A	76.82 (13.52)
LS Mean of Change from Baseline (SE)	-0.24 (1.82)	NE	-0.03 (1.74)
95% CI	(-3.84, 3.37)	NE	(-3.49, 3.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.20 (2.45)	NE	
95% CI	(-5.07, 4.66)	NE	
p-value	0.9344	NE	
Corrected Hedge's g Statistics	-0.018	NE	
95% CI	(-0.45, 0.41)	NE	
Subgroup*Treatment Interaction p-value	0.9336	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Concentration/Memory			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	82.97 (20.89)	N/A	76.34 (22.90)
Analysis Visit Mean (SD)	79.56 (20.54)	N/A	80.19 (21.09)
LS Mean of Change from Baseline (SE)	-2.10 (2.36)	NE	2.77 (2.21)
95% CI	(-6.78, 2.58)	NE	(-1.61, 7.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.87 (3.15)	NE	
95% CI	(-11.13, 1.38)	NE	
p-value	0.1250	NE	
Corrected Hedge's g Statistics	-0.306	NE	
95% CI	(-0.71, 0.10)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	81.43 (21.67)	N/A	75.59 (24.33)
Analysis Visit Mean (SD)	79.51 (20.87)	N/A	75.73 (24.31)
LS Mean of Change from Baseline (SE)	-1.13 (2.41)	NE	-0.09 (2.30)
95% CI	(-5.91, 3.64)	NE	(-4.66, 4.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.04 (3.24)	NE	
95% CI	(-7.48, 5.40)	NE	
p-value	0.7491	NE	
Corrected Hedge's g Statistics	-0.068	NE	
95% CI	(-0.50, 0.36)	NE	
Subgroup*Treatment Interaction p-value	0.6377	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Health Distress			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	80.11 (25.19)	N/A	79.33 (24.62)
Analysis Visit Mean (SD)	83.52 (24.23)	N/A	87.98 (18.52)
LS Mean of Change from Baseline (SE)	4.42 (2.47)	NE	9.68 (2.33)
95% CI	(-0.49, 9.33)	NE	(5.05, 14.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.25 (3.29)	NE	
95% CI	(-11.79, 1.28)	NE	
p-value	0.1139	NE	
Corrected Hedge's g Statistics	-0.314	NE	
95% CI	(-0.72, 0.09)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	78.85 (25.51)	N/A	80.40 (25.20)
Analysis Visit Mean (SD)	85.26 (21.44)	N/A	85.23 (19.11)
LS Mean of Change from Baseline (SE)	7.03 (2.68)	NE	6.95 (2.56)
95% CI	(1.71, 12.35)	NE	(1.87, 12.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (3.61)	NE	
95% CI	(-7.08, 7.24)	NE	
p-value	0.9820	NE	
Corrected Hedge's g Statistics	0.005	NE	
95% CI	(-0.43, 0.44)	NE	
Subgroup*Treatment Interaction p-value	0.8038	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Sexual Function			
Week 24			
m	46	0	59
n	20	0	21
Baseline Mean (SD)	83.41 (22.84)	N/A	84.68 (21.70)
Analysis Visit Mean (SD)	83.25 (21.50)	N/A	86.02 (18.21)
LS Mean of Change from Baseline (SE)	-0.59 (3.16)	NE	3.56 (3.23)
95% CI	(-7.00, 5.81)	NE	(-2.98, 10.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.16 (4.52)	NE	
95% CI	(-13.30, 4.99)	NE	
p-value	0.3632	NE	
Corrected Hedge's g Statistics	-0.281	NE	
95% CI	(-0.90, 0.33)	NE	
Week 52			
m	44	0	56
n	14	0	18
Baseline Mean (SD)	88.20 (20.72)	N/A	83.88 (23.09)
Analysis Visit Mean (SD)	93.80 (11.02)	N/A	81.94 (25.15)
LS Mean of Change from Baseline (SE)	8.32 (4.36)	NE	-0.42 (4.02)
95% CI	(-0.50, 17.14)	NE	(-8.55, 7.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.73 (5.91)	NE	
95% CI	(-3.24, 20.71)	NE	
p-value	0.1481	NE	
Corrected Hedge's g Statistics	0.509	NE	
95% CI	(-0.20, 1.22)	NE	
Subgroup*Treatment Interaction p-value	0.1320	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Sleep			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	63.75 (18.18)	N/A	68.94 (18.93)
Analysis Visit Mean (SD)	65.34 (19.48)	N/A	67.88 (18.61)
LS Mean of Change from Baseline (SE)	0.68 (2.18)	NE	-0.67 (2.06)
95% CI	(-3.65, 5.02)	NE	(-4.76, 3.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.36 (2.92)	NE	
95% CI	(-4.44, 7.16)	NE	
p-value	0.6433	NE	
Corrected Hedge's g Statistics	0.092	NE	
95% CI	(-0.31, 0.49)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	63.33 (18.72)	N/A	68.52 (19.69)
Analysis Visit Mean (SD)	66.70 (16.05)	N/A	67.73 (19.48)
LS Mean of Change from Baseline (SE)	2.40 (2.38)	NE	0.25 (2.27)
95% CI	(-2.33, 7.12)	NE	(-4.26, 4.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.15 (3.22)	NE	
95% CI	(-4.25, 8.54)	NE	
p-value	0.5068	NE	
Corrected Hedge's g Statistics	0.142	NE	
95% CI	(-0.29, 0.57)	NE	
Subgroup*Treatment Interaction p-value	0.8738	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Loneliness			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	81.82 (21.05)	N/A	85.96 (16.33)
Analysis Visit Mean (SD)	84.66 (19.36)	N/A	86.63 (17.06)
LS Mean of Change from Baseline (SE)	2.09 (2.12)	NE	1.35 (2.00)
95% CI	(-2.12, 6.29)	NE	(-2.62, 5.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.74 (2.85)	NE	
95% CI	(-4.92, 6.39)	NE	
p-value	0.7969	NE	
Corrected Hedge's g Statistics	0.051	NE	
95% CI	(-0.35, 0.45)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	80.90 (21.55)	N/A	84.55 (17.75)
Analysis Visit Mean (SD)	83.97 (16.31)	N/A	87.39 (15.57)
LS Mean of Change from Baseline (SE)	1.76 (2.03)	NE	2.91 (1.96)
95% CI	(-2.27, 5.80)	NE	(-0.98, 6.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.14 (2.75)	NE	
95% CI	(-6.61, 4.32)	NE	
p-value	0.6791	NE	
Corrected Hedge's g Statistics	-0.088	NE	
95% CI	(-0.52, 0.34)	NE	
Subgroup*Treatment Interaction p-value	0.3561	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Hopelessness			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	79.74 (22.55)	N/A	81.89 (19.44)
Analysis Visit Mean (SD)	79.54 (22.49)	N/A	83.10 (17.94)
LS Mean of Change from Baseline (SE)	0.21 (2.22)	NE	2.66 (2.10)
95% CI	(-4.20, 4.62)	NE	(-1.51, 6.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.45 (2.96)	NE	
95% CI	(-8.32, 3.42)	NE	
p-value	0.4094	NE	
Corrected Hedge's g Statistics	-0.162	NE	
95% CI	(-0.56, 0.24)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	79.70 (22.53)	N/A	80.30 (20.27)
Analysis Visit Mean (SD)	80.13 (21.76)	N/A	81.44 (20.08)
LS Mean of Change from Baseline (SE)	1.44 (2.78)	NE	2.70 (2.65)
95% CI	(-4.08, 6.96)	NE	(-2.57, 7.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.26 (3.76)	NE	
95% CI	(-8.73, 6.21)	NE	
p-value	0.7383	NE	
Corrected Hedge's g Statistics	-0.071	NE	
95% CI	(-0.50, 0.36)	NE	
Subgroup*Treatment Interaction p-value	0.2574	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Stigma of Liver Disease			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	87.80 (18.53)	N/A	90.40 (19.23)
Analysis Visit Mean (SD)	89.07 (17.11)	N/A	91.72 (14.19)
LS Mean of Change from Baseline (SE)	1.14 (2.05)	NE	2.86 (1.94)
95% CI	(-2.94, 5.22)	NE	(-0.99, 6.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.72 (2.75)	NE	
95% CI	(-7.18, 3.73)	NE	
p-value	0.5316	NE	
Corrected Hedge's g Statistics	-0.124	NE	
95% CI	(-0.53, 0.28)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	86.55 (19.27)	N/A	89.22 (20.54)
Analysis Visit Mean (SD)	90.08 (16.94)	N/A	88.94 (20.65)
LS Mean of Change from Baseline (SE)	3.35 (2.28)	NE	0.60 (2.18)
95% CI	(-1.18, 7.87)	NE	(-3.74, 4.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.75 (3.08)	NE	
95% CI	(-3.37, 8.88)	NE	
p-value	0.3741	NE	
Corrected Hedge's g Statistics	0.190	NE	
95% CI	(-0.24, 0.62)	NE	
Subgroup*Treatment Interaction p-value	0.9660	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Symptoms of Liver Disease			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	75.25 (20.00)	74.87 (18.79)	76.00 (18.16)
Analysis Visit Mean (SD)	75.11 (21.30)	74.01 (17.79)	75.99 (19.62)
LS Mean of Change from Baseline (SE)	0.27 (1.33)	-0.75 (1.17)	0.07 (0.96)
95% CI	(-2.35, 2.89)	(-3.06, 1.56)	(-1.82, 1.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.20 (1.59)	-0.82 (1.48)	
95% CI	(-2.94, 3.33)	(-3.73, 2.08)	
p-value	0.9020	0.5786	
Corrected Hedge's g Statistics	0.015	-0.062	
95% CI	(-0.23, 0.26)	(-0.29, 0.16)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	77.37 (19.12)	75.44 (18.16)	76.05 (17.58)
Analysis Visit Mean (SD)	76.43 (19.48)	76.33 (18.12)	76.62 (19.82)
LS Mean of Change from Baseline (SE)	-0.29 (1.42)	0.66 (1.24)	0.75 (0.99)
95% CI	(-3.08, 2.50)	(-1.78, 3.10)	(-1.20, 2.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.04 (1.68)	-0.09 (1.55)	
95% CI	(-4.35, 2.27)	(-3.14, 2.96)	
p-value	0.5367	0.9540	
Corrected Hedge's g Statistics	-0.079	-0.007	
95% CI	(-0.34, 0.18)	(-0.25, 0.23)	
Subgroup*Treatment Interaction p-value	0.0548	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Effects of Liver Disease			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	78.42 (12.93)	78.47 (15.48)	77.56 (14.38)
Analysis Visit Mean (SD)	76.50 (13.71)	78.97 (10.67)	77.24 (15.45)
LS Mean of Change from Baseline (SE)	-1.81 (1.24)	0.52 (1.09)	-0.73 (0.90)
95% CI	(-4.25, 0.63)	(-1.63, 2.67)	(-2.50, 1.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.08 (1.49)	1.25 (1.38)	
95% CI	(-4.00, 1.85)	(-1.46, 3.97)	
p-value	0.4697	0.3647	
Corrected Hedge's g Statistics	-0.086	0.101	
95% CI	(-0.33, 0.15)	(-0.12, 0.33)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	78.75 (12.07)	78.29 (15.78)	78.06 (12.99)
Analysis Visit Mean (SD)	77.33 (12.52)	77.77 (12.72)	78.00 (13.85)
LS Mean of Change from Baseline (SE)	-1.39 (1.41)	-0.72 (1.23)	-0.38 (0.98)
95% CI	(-4.16, 1.38)	(-3.15, 1.70)	(-2.32, 1.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.00 (1.68)	-0.34 (1.55)	
95% CI	(-4.31, 2.30)	(-3.38, 2.70)	
p-value	0.5502	0.8272	
Corrected Hedge's g Statistics	-0.077	-0.026	
95% CI	(-0.34, 0.18)	(-0.27, 0.21)	
Subgroup*Treatment Interaction p-value	0.9336	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Concentration/Memory			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	79.10 (23.75)	79.24 (20.61)	79.99 (20.55)
Analysis Visit Mean (SD)	78.67 (23.32)	79.68 (19.84)	79.80 (22.38)
LS Mean of Change from Baseline (SE)	-0.20 (1.50)	0.25 (1.32)	-0.01 (1.08)
95% CI	(-3.15, 2.74)	(-2.34, 2.85)	(-2.14, 2.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.19 (1.79)	0.27 (1.67)	
95% CI	(-3.71, 3.34)	(-3.00, 3.54)	
p-value	0.9174	0.8723	
Corrected Hedge's g Statistics	-0.012	0.018	
95% CI	(-0.25, 0.23)	(-0.21, 0.24)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	78.62 (23.29)	80.12 (19.78)	80.30 (19.71)
Analysis Visit Mean (SD)	78.33 (19.80)	78.80 (20.44)	79.66 (21.87)
LS Mean of Change from Baseline (SE)	-1.29 (1.50)	-0.79 (1.31)	-0.54 (1.05)
95% CI	(-4.24, 1.66)	(-3.37, 1.79)	(-2.60, 1.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.75 (1.78)	-0.25 (1.64)	
95% CI	(-4.24, 2.75)	(-3.46, 2.97)	
p-value	0.6751	0.8792	
Corrected Hedge's g Statistics	-0.054	-0.018	
95% CI	(-0.31, 0.21)	(-0.26, 0.22)	
Subgroup*Treatment Interaction p-value	0.6377	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Health Distress			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	77.48 (26.22)	79.96 (26.03)	80.82 (24.19)
Analysis Visit Mean (SD)	84.03 (20.78)	86.11 (20.99)	85.08 (23.26)
LS Mean of Change from Baseline (SE)	5.22 (1.71)	5.67 (1.50)	4.19 (1.23)
95% CI	(1.87, 8.58)	(2.72, 8.62)	(1.77, 6.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.04 (2.04)	1.48 (1.89)	
95% CI	(-2.97, 5.04)	(-2.22, 5.19)	
p-value	0.6114	0.4315	
Corrected Hedge's g Statistics	0.061	0.088	
95% CI	(-0.18, 0.30)	(-0.14, 0.31)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	78.24 (25.09)	81.31 (26.17)	82.00 (23.31)
Analysis Visit Mean (SD)	81.62 (24.44)	86.70 (21.47)	86.29 (22.09)
LS Mean of Change from Baseline (SE)	1.09 (2.06)	5.57 (1.80)	4.37 (1.44)
95% CI	(-2.95, 5.14)	(2.03, 9.11)	(1.54, 7.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.28 (2.46)	1.20 (2.26)	
95% CI	(-8.11, 1.55)	(-3.24, 5.64)	
p-value	0.1831	0.5957	
Corrected Hedge's g Statistics	-0.172	0.063	
95% CI	(-0.43, 0.09)	(-0.18, 0.30)	
Subgroup*Treatment Interaction p-value	0.8038	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Sexual Function			
Week 24			
m	109	141	223
n	35	59	71
Baseline Mean (SD)	75.77 (30.18)	81.60 (21.76)	81.13 (22.48)
Analysis Visit Mean (SD)	79.34 (25.34)	77.00 (25.33)	80.38 (22.66)
LS Mean of Change from Baseline (SE)	3.16 (3.36)	-4.42 (2.57)	-0.85 (2.32)
95% CI	(-3.47, 9.80)	(-9.49, 0.66)	(-5.43, 3.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.01 (3.99)	-3.57 (3.38)	
95% CI	(-3.87, 11.89)	(-10.24, 3.10)	
p-value	0.3166	0.2924	
Corrected Hedge's g Statistics	0.202	-0.181	
95% CI	(-0.20, 0.61)	(-0.53, 0.17)	
Week 52			
m	99	125	208
n	31	47	61
Baseline Mean (SD)	78.50 (30.65)	81.73 (21.85)	78.88 (24.36)
Analysis Visit Mean (SD)	82.42 (23.43)	79.03 (27.97)	77.47 (25.34)
LS Mean of Change from Baseline (SE)	2.57 (3.54)	-1.48 (2.79)	-2.47 (2.48)
95% CI	(-4.43, 9.56)	(-7.00, 4.03)	(-7.36, 2.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.04 (4.23)	0.98 (3.66)	
95% CI	(-3.31, 13.38)	(-6.23, 8.20)	
p-value	0.2352	0.7881	
Corrected Hedge's g Statistics	0.256	0.051	
95% CI	(-0.18, 0.69)	(-0.33, 0.43)	
Subgroup*Treatment Interaction p-value	0.1320	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Sleep			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	62.38 (21.22)	59.64 (20.05)	61.67 (20.14)
Analysis Visit Mean (SD)	62.82 (19.75)	57.98 (20.61)	61.65 (20.64)
LS Mean of Change from Baseline (SE)	0.90 (1.49)	-2.46 (1.31)	-0.09 (1.07)
95% CI	(-2.03, 3.83)	(-5.05, 0.12)	(-2.21, 2.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.00 (1.78)	-2.37 (1.65)	
95% CI	(-2.50, 4.50)	(-5.61, 0.88)	
p-value	0.5758	0.1525	
Corrected Hedge's g Statistics	0.067	-0.159	
95% CI	(-0.17, 0.31)	(-0.38, 0.07)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	64.24 (20.69)	60.23 (20.78)	61.91 (20.29)
Analysis Visit Mean (SD)	63.53 (19.68)	59.31 (21.32)	63.14 (21.40)
LS Mean of Change from Baseline (SE)	0.50 (1.67)	-1.52 (1.46)	0.99 (1.17)
95% CI	(-2.78, 3.79)	(-4.39, 1.35)	(-1.30, 3.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.49 (1.98)	-2.51 (1.83)	
95% CI	(-4.39, 3.41)	(-6.10, 1.08)	
p-value	0.8063	0.1705	
Corrected Hedge's g Statistics	-0.031	-0.163	
95% CI	(-0.29, 0.23)	(-0.40, 0.08)	
Subgroup*Treatment Interaction p-value	0.8738	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Loneliness			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	85.84 (16.31)	83.81 (19.93)	83.65 (20.42)
Analysis Visit Mean (SD)	83.96 (16.90)	84.64 (19.46)	81.68 (21.54)
LS Mean of Change from Baseline (SE)	-1.91 (1.51)	0.31 (1.33)	-2.49 (1.09)
95% CI	(-4.88, 1.07)	(-2.31, 2.93)	(-4.63, -0.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.58 (1.81)	2.80 (1.68)	
95% CI	(-2.98, 4.14)	(-0.51, 6.10)	
p-value	0.7498	0.0970	
Corrected Hedge's g Statistics	0.038	0.185	
95% CI	(-0.20, 0.28)	(-0.04, 0.41)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	86.53 (16.60)	82.66 (20.67)	83.96 (20.37)
Analysis Visit Mean (SD)	85.88 (16.76)	82.89 (21.17)	83.14 (20.23)
LS Mean of Change from Baseline (SE)	-0.75 (1.63)	-0.68 (1.43)	-1.56 (1.14)
95% CI	(-3.95, 2.46)	(-3.48, 2.13)	(-3.79, 0.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.81 (1.94)	0.88 (1.78)	
95% CI	(-3.00, 4.62)	(-2.62, 4.38)	
p-value	0.6764	0.6217	
Corrected Hedge's g Statistics	0.054	0.059	
95% CI	(-0.21, 0.31)	(-0.18, 0.30)	
Subgroup*Treatment Interaction p-value	0.3561	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Hopelessness			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	74.34 (22.54)	75.92 (22.79)	79.23 (21.32)
Analysis Visit Mean (SD)	78.22 (21.83)	77.65 (22.60)	78.23 (22.22)
LS Mean of Change from Baseline (SE)	2.81 (1.81)	0.72 (1.59)	-0.28 (1.30)
95% CI	(-0.75, 6.37)	(-2.41, 3.86)	(-2.84, 2.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.09 (2.17)	1.00 (2.01)	
95% CI	(-1.17, 7.35)	(-2.94, 4.95)	
p-value	0.1552	0.6177	
Corrected Hedge's g Statistics	0.170	0.056	
95% CI	(-0.07, 0.41)	(-0.17, 0.28)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	76.57 (21.58)	76.30 (23.90)	79.95 (21.43)
Analysis Visit Mean (SD)	78.24 (21.44)	77.53 (21.94)	78.14 (23.24)
LS Mean of Change from Baseline (SE)	2.06 (1.98)	0.77 (1.73)	-1.44 (1.39)
95% CI	(-1.83, 5.96)	(-2.63, 4.18)	(-4.16, 1.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.50 (2.36)	2.21 (2.17)	
95% CI	(-1.13, 8.13)	(-2.06, 6.48)	
p-value	0.1385	0.3095	
Corrected Hedge's g Statistics	0.191	0.121	
95% CI	(-0.07, 0.45)	(-0.12, 0.36)	
Subgroup*Treatment Interaction p-value	0.2574	NE	

AMNOG Table SE21.6.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Stigma of Liver Disease			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	80.09 (21.46)	80.72 (20.21)	82.08 (18.89)
Analysis Visit Mean (SD)	83.74 (20.55)	81.17 (20.03)	83.94 (19.30)
LS Mean of Change from Baseline (SE)	3.39 (1.53)	0.35 (1.35)	2.13 (1.10)
95% CI	(0.38, 6.40)	(-2.31, 3.00)	(-0.04, 4.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.26 (1.83)	-1.78 (1.70)	
95% CI	(-2.34, 4.86)	(-5.12, 1.56)	
p-value	0.4919	0.2958	
Corrected Hedge's g Statistics	0.082	-0.117	
95% CI	(-0.16, 0.32)	(-0.34, 0.11)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	82.15 (20.59)	81.50 (20.34)	81.94 (18.54)
Analysis Visit Mean (SD)	86.12 (17.86)	84.06 (18.94)	84.16 (18.41)
LS Mean of Change from Baseline (SE)	4.40 (1.56)	2.31 (1.36)	2.29 (1.09)
95% CI	(1.34, 7.46)	(-0.37, 4.98)	(0.16, 4.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.11 (1.84)	0.01 (1.70)	
95% CI	(-1.51, 5.73)	(-3.32, 3.35)	
p-value	0.2532	0.9930	
Corrected Hedge's g Statistics	0.146	0.001	
95% CI	(-0.11, 0.41)	(-0.24, 0.24)	
Subgroup*Treatment Interaction p-value	0.9660	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7877	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	1 (12.5)
No	6 (85.7)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	NE	
95% CI of the inverse odds ratio	(0.04, 16.85)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.07, 11.54)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.79	NE	
95% CI of the absolute risk difference	(-32.81, 36.39)	NE	
p-value	0.9192	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7071	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (12.5)
No	7 (100)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	NE	
95% CI of the inverse odds ratio	(0.10, 86.09)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	NE	
95% CI of the inverse risk ratio	(0.13, 56.63)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.42	NE	
95% CI of the absolute risk difference	(-39.98, 19.15)	NE	
p-value	0.5058	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7044	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	3 (37.5)
No	7 (100)	0	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	9.55	NE	
95% CI of the inverse odds ratio	(0.40, 225.19)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.22	NE	
95% CI of the inverse risk ratio	(0.38, 102.93)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-32.64	NE	
95% CI of the absolute risk difference	(-68.64, 3.36)	NE	
p-value	0.1133	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2188	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1862	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	NE	
95% CI of the inverse odds ratio	(0.01, 7.34)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	NE	
95% CI of the inverse risk ratio	(0.01, 6.29)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.19	NE	
95% CI of the absolute risk difference	(-17.72, 44.11)	NE	
p-value	0.3993	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3774	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3479	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	NE	
95% CI of the inverse odds ratio	(0.01, 7.34)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	NE	
95% CI of the inverse risk ratio	(0.01, 6.29)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.19	NE	
95% CI of the absolute risk difference	(-17.72, 44.11)	NE	
p-value	0.3993	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5217	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (28.6)	0	1 (12.5)
No	5 (71.4)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	NE	
95% CI of the inverse odds ratio	(0.02, 5.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	NE	
95% CI of the inverse risk ratio	(0.05, 3.85)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.07	NE	
95% CI of the absolute risk difference	(-24.49, 56.63)	NE	
p-value	0.4376	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1834	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	1 (12.5)
No	5 (71.4)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	NE	
95% CI of the inverse odds ratio	(0.02, 5.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	NE	
95% CI of the inverse risk ratio	(0.05, 3.85)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.07	NE	
95% CI of the absolute risk difference	(-24.49, 56.63)	NE	
p-value	0.4376	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6135	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (12.5)
No	7 (100)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	NE	
95% CI of the inverse odds ratio	(0.10, 86.09)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	NE	
95% CI of the inverse risk ratio	(0.13, 56.63)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.42	NE	
95% CI of the absolute risk difference	(-39.98, 19.15)	NE	
p-value	0.5058	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6154	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (12.5)
No	7 (100)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	NE	
95% CI of the inverse odds ratio	(0.10, 86.09)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	NE	
95% CI of the inverse risk ratio	(0.13, 56.63)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.42	NE	
95% CI of the absolute risk difference	(-39.98, 19.15)	NE	
p-value	0.5058	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5389	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (28.6)	0	1 (12.5)
No	5 (71.4)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	NE	
95% CI of the inverse odds ratio	(0.02, 5.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	NE	
95% CI of the inverse risk ratio	(0.05, 3.85)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.07	NE	
95% CI of the absolute risk difference	(-24.49, 56.63)	NE	
p-value	0.4376	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2320	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (42.9)	0	1 (12.5)
No	4 (57.1)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.19	NE	
95% CI of the inverse odds ratio	(0.01, 2.50)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	NE	
95% CI of the inverse risk ratio	(0.04, 2.21)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	30.36	NE	
95% CI of the absolute risk difference	(-12.88, 73.59)	NE	
p-value	0.1847	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1393	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6748	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	2 (25.0)
No	5 (71.4)	0	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	NE	
95% CI of the inverse odds ratio	(0.08, 8.24)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.16, 4.68)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.57	NE	
95% CI of the absolute risk difference	(-41.38, 48.52)	NE	
p-value	0.8760	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9503	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (42.9)	0	1 (12.5)
No	4 (57.1)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.19	NE	
95% CI of the inverse odds ratio	(0.01, 2.50)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	NE	
95% CI of the inverse risk ratio	(0.04, 2.21)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	30.36	NE	
95% CI of the absolute risk difference	(-12.88, 73.59)	NE	
p-value	0.1847	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5476	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (42.9)	0	1 (12.5)
No	4 (57.1)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.19	NE	
95% CI of the inverse odds ratio	(0.01, 2.50)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	NE	
95% CI of the inverse risk ratio	(0.04, 2.21)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	30.36	NE	
95% CI of the absolute risk difference	(-12.88, 73.59)	NE	
p-value	0.1847	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5014	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	NE	
95% CI of the inverse odds ratio	(0.01, 7.34)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	NE	
95% CI of the inverse risk ratio	(0.01, 6.29)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.19	NE	
95% CI of the absolute risk difference	(-17.72, 44.11)	NE	
p-value	0.3993	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4279	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	1 (12.5)
No	6 (85.7)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	NE	
95% CI of the inverse odds ratio	(0.04, 16.85)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.07, 11.54)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.79	NE	
95% CI of the absolute risk difference	(-32.81, 36.39)	NE	
p-value	0.9192	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4072	NE	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.3)	0	3 (4.8)
No	45 (95.7)	0	59 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	NE	
95% CI of the inverse odds ratio	(0.18, 7.14)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	NE	
95% CI of the inverse risk ratio	(0.20, 6.53)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.58	NE	
95% CI of the absolute risk difference	(-8.45, 7.28)	NE	
p-value	0.8854	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7877	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (25.5)	0	10 (16.1)
No	35 (74.5)	0	52 (83.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	NE	
95% CI of the inverse odds ratio	(0.22, 1.44)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	NE	
95% CI of the inverse risk ratio	(0.30, 1.34)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.40	NE	
95% CI of the absolute risk difference	(-6.06, 24.87)	NE	
p-value	0.2258	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7071	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.3)	0	4 (6.5)
No	45 (95.7)	0	58 (93.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	NE	
95% CI of the inverse odds ratio	(0.27, 8.85)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	NE	
95% CI of the inverse risk ratio	(0.29, 7.93)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.20	NE	
95% CI of the absolute risk difference	(-10.60, 6.21)	NE	
p-value	0.6185	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7044	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (19.1)	0	15 (24.2)
No	38 (80.9)	0	47 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	NE	
95% CI of the inverse odds ratio	(0.53, 3.42)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	NE	
95% CI of the inverse risk ratio	(0.61, 2.63)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.04	NE	
95% CI of the absolute risk difference	(-20.54, 10.45)	NE	
p-value	0.5290	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2188	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	5 (8.1)
No	47 (100)	0	57 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	9.09	NE	
95% CI of the inverse odds ratio	(0.49, 168.56)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	8.38	NE	
95% CI of the inverse risk ratio	(0.47, 147.90)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.69	NE	
95% CI of the absolute risk difference	(-15.23, -0.15)	NE	
p-value	0.0759	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1862	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (17.0)	0	10 (16.1)
No	39 (83.0)	0	52 (83.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	NE	
95% CI of the inverse odds ratio	(0.34, 2.60)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	NE	
95% CI of the inverse risk ratio	(0.41, 2.21)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.89	NE	
95% CI of the absolute risk difference	(-13.22, 15.01)	NE	
p-value	0.9011	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3774	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (6.4)	0	5 (8.1)
No	44 (93.6)	0	57 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	NE	
95% CI of the inverse odds ratio	(0.29, 5.68)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	NE	
95% CI of the inverse risk ratio	(0.32, 5.02)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.68	NE	
95% CI of the absolute risk difference	(-11.42, 8.05)	NE	
p-value	0.7388	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3479	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (25.5)	0	15 (24.2)
No	35 (74.5)	0	47 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	NE	
95% CI of the inverse odds ratio	(0.39, 2.24)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	NE	
95% CI of the inverse risk ratio	(0.49, 1.83)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.34	NE	
95% CI of the absolute risk difference	(-15.06, 17.74)	NE	
p-value	0.8726	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5217	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (21.3)	0	6 (9.7)
No	37 (78.7)	0	56 (90.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	NE	
95% CI of the inverse odds ratio	(0.13, 1.18)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.45	NE	
95% CI of the inverse risk ratio	(0.18, 1.16)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.60	NE	
95% CI of the absolute risk difference	(-2.22, 25.42)	NE	
p-value	0.0901	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1834	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (25.5)	0	13 (21.0)
No	35 (74.5)	0	49 (79.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	NE	
95% CI of the inverse odds ratio	(0.32, 1.90)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	NE	
95% CI of the inverse risk ratio	(0.41, 1.63)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.56	NE	
95% CI of the absolute risk difference	(-11.50, 20.63)	NE	
p-value	0.5746	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6135	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.1)	0	2 (3.2)
No	46 (97.9)	0	60 (96.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	NE	
95% CI of the inverse odds ratio	(0.13, 17.43)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	NE	
95% CI of the inverse risk ratio	(0.14, 16.22)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.10	NE	
95% CI of the absolute risk difference	(-7.13, 4.93)	NE	
p-value	0.7285	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6154	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (10.6)	0	5 (8.1)
No	42 (89.4)	0	57 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	NE	
95% CI of the inverse odds ratio	(0.20, 2.71)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	NE	
95% CI of the inverse risk ratio	(0.23, 2.47)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.57	NE	
95% CI of the absolute risk difference	(-8.55, 13.69)	NE	
p-value	0.6448	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5389	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (17.0)	0	6 (9.7)
No	39 (83.0)	0	56 (90.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	NE	
95% CI of the inverse odds ratio	(0.17, 1.62)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	NE	
95% CI of the inverse risk ratio	(0.21, 1.53)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.34	NE	
95% CI of the absolute risk difference	(-5.68, 20.37)	NE	
p-value	0.2564	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2320	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (34.0)	0	17 (27.4)
No	31 (66.0)	0	45 (72.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	NE	
95% CI of the inverse odds ratio	(0.32, 1.66)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	NE	
95% CI of the inverse risk ratio	(0.46, 1.42)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.62	NE	
95% CI of the absolute risk difference	(-10.89, 24.14)	NE	
p-value	0.4561	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1393	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (14.9)	0	7 (11.3)
No	40 (85.1)	0	55 (88.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	NE	
95% CI of the inverse odds ratio	(0.24, 2.24)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	NE	
95% CI of the inverse risk ratio	(0.29, 2.01)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.60	NE	
95% CI of the absolute risk difference	(-9.27, 16.47)	NE	
p-value	0.5776	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6748	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (27.7)	0	19 (30.6)
No	34 (72.3)	0	43 (69.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	NE	
95% CI of the inverse odds ratio	(0.50, 2.67)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	NE	
95% CI of the inverse risk ratio	(0.61, 2.01)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.99	NE	
95% CI of the absolute risk difference	(-20.17, 14.20)	NE	
p-value	0.7346	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9503	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (23.4)	0	11 (17.7)
No	36 (76.6)	0	51 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	NE	
95% CI of the inverse odds ratio	(0.28, 1.80)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	NE	
95% CI of the inverse risk ratio	(0.36, 1.60)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.66	NE	
95% CI of the absolute risk difference	(-9.73, 21.06)	NE	
p-value	0.4657	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5476	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (31.9)	0	15 (24.2)
No	32 (68.1)	0	47 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	NE	
95% CI of the inverse odds ratio	(0.29, 1.58)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	NE	
95% CI of the inverse risk ratio	(0.41, 1.39)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.72	NE	
95% CI of the absolute risk difference	(-9.34, 24.79)	NE	
p-value	0.3714	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5014	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (12.8)	0	5 (8.1)
No	41 (87.2)	0	57 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	NE	
95% CI of the inverse odds ratio	(0.17, 2.10)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	NE	
95% CI of the inverse risk ratio	(0.21, 1.95)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.70	NE	
95% CI of the absolute risk difference	(-7.00, 16.40)	NE	
p-value	0.4197	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4279	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (34.0)	0	12 (19.4)
No	31 (66.0)	0	50 (80.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse odds ratio	(0.19, 1.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	NE	
95% CI of the inverse risk ratio	(0.30, 1.08)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.69	NE	
95% CI of the absolute risk difference	(-2.05, 31.43)	NE	
p-value	0.0822	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4072	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.5)	4 (2.6)	7 (3.0)
No	109 (96.5)	147 (97.4)	226 (97.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.14	
95% CI of the inverse odds ratio	(0.24, 2.94)	(0.33, 3.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.13	
95% CI of the inverse risk ratio	(0.25, 2.84)	(0.34, 3.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.54	-0.36	
95% CI of the absolute risk difference	(-3.52, 4.59)	(-3.73, 3.02)	
p-value	0.7900	0.8385	
p-value of Breslow-Day Test for Homogeneity [3]	0.7877	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (22.1)	32 (21.2)	47 (20.2)
No	88 (77.9)	119 (78.8)	186 (79.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.94	
95% CI of the inverse odds ratio	(0.51, 1.54)	(0.57, 1.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.95	
95% CI of the inverse risk ratio	(0.59, 1.40)	(0.64, 1.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.95	1.02	
95% CI of the absolute risk difference	(-7.27, 11.18)	(-7.29, 9.33)	
p-value	0.6748	0.8091	
p-value of Breslow-Day Test for Homogeneity [3]	0.7071	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.5)	16 (10.6)	21 (9.0)
No	109 (96.5)	135 (89.4)	212 (91.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.70	0.84	
95% CI of the inverse odds ratio	(0.90, 8.06)	(0.42, 1.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.55	0.85	
95% CI of the inverse risk ratio	(0.90, 7.24)	(0.46, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.47	1.58	
95% CI of the absolute risk difference	(-10.49, -0.46)	(-4.55, 7.72)	
p-value	0.0652	0.6076	
p-value of Breslow-Day Test for Homogeneity [3]	0.7044	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (23.9)	39 (25.8)	59 (25.3)
No	86 (76.1)	112 (74.2)	174 (74.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.97	
95% CI of the inverse odds ratio	(0.64, 1.82)	(0.61, 1.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.98	
95% CI of the inverse risk ratio	(0.71, 1.57)	(0.69, 1.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.43	0.51	
95% CI of the absolute risk difference	(-11.07, 8.22)	(-8.43, 9.45)	
p-value	0.7732	0.9116	
p-value of Breslow-Day Test for Homogeneity [3]	0.2188	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.4)	10 (6.6)	21 (9.0)
No	108 (95.6)	141 (93.4)	212 (91.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.14	1.40	
95% CI of the inverse odds ratio	(0.79, 5.83)	(0.64, 3.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.04	1.36	
95% CI of the inverse risk ratio	(0.79, 5.26)	(0.66, 2.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.59	-2.39	
95% CI of the absolute risk difference	(-9.87, 0.69)	(-7.80, 3.02)	
p-value	0.1290	0.4010	
p-value of Breslow-Day Test for Homogeneity [3]	0.1862	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (15.9)	28 (18.5)	49 (21.0)
No	95 (84.1)	123 (81.5)	184 (79.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	1.17	
95% CI of the inverse odds ratio	(0.78, 2.55)	(0.70, 1.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	1.13	
95% CI of the inverse risk ratio	(0.81, 2.16)	(0.75, 1.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.10	-2.49	
95% CI of the absolute risk difference	(-13.64, 3.44)	(-10.60, 5.63)	
p-value	0.2601	0.5521	
p-value of Breslow-Day Test for Homogeneity [3]	0.3774	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (10.6)	9 (6.0)	15 (6.4)
No	101 (89.4)	142 (94.0)	218 (93.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	1.09	
95% CI of the inverse odds ratio	(0.26, 1.28)	(0.46, 2.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	1.08	
95% CI of the inverse risk ratio	(0.29, 1.25)	(0.49, 2.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.18	-0.48	
95% CI of the absolute risk difference	(-2.31, 10.68)	(-5.40, 4.44)	
p-value	0.1738	0.8502	
p-value of Breslow-Day Test for Homogeneity [3]	0.3479	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (21.2)	36 (23.8)	52 (22.3)
No	89 (78.8)	115 (76.2)	181 (77.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.92	
95% CI of the inverse odds ratio	(0.62, 1.84)	(0.57, 1.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.94	
95% CI of the inverse risk ratio	(0.68, 1.61)	(0.65, 1.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.08	1.52	
95% CI of the absolute risk difference	(-10.32, 8.17)	(-7.12, 10.17)	
p-value	0.8202	0.7286	
p-value of Breslow-Day Test for Homogeneity [3]	0.5217	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (14.2)	26 (17.2)	38 (16.3)
No	97 (85.8)	125 (82.8)	195 (83.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.94	
95% CI of the inverse odds ratio	(0.63, 2.22)	(0.54, 1.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.95	
95% CI of the inverse risk ratio	(0.67, 1.97)	(0.60, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.15	0.91	
95% CI of the absolute risk difference	(-10.14, 5.84)	(-6.76, 8.58)	
p-value	0.6054	0.8153	
p-value of Breslow-Day Test for Homogeneity [3]	0.1834	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (23.0)	36 (23.8)	57 (24.5)
No	87 (77.0)	115 (76.2)	176 (75.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	1.03	
95% CI of the inverse odds ratio	(0.64, 1.84)	(0.64, 1.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.03	
95% CI of the inverse risk ratio	(0.71, 1.60)	(0.71, 1.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.45	-0.62	
95% CI of the absolute risk difference	(-10.98, 8.07)	(-9.38, 8.13)	
p-value	0.7663	0.8894	
p-value of Breslow-Day Test for Homogeneity [3]	0.6135	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.4)	6 (4.0)	10 (4.3)
No	108 (95.6)	145 (96.0)	223 (95.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	1.08	
95% CI of the inverse odds ratio	(0.32, 2.90)	(0.39, 3.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	1.08	
95% CI of the inverse risk ratio	(0.34, 2.77)	(0.40, 2.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.13	-0.32	
95% CI of the absolute risk difference	(-4.47, 4.73)	(-4.38, 3.74)	
p-value	0.9546	0.8788	
p-value of Breslow-Day Test for Homogeneity [3]	0.6154	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (7.1)	13 (8.6)	19 (8.2)
No	105 (92.9)	138 (91.4)	214 (91.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.94	
95% CI of the inverse odds ratio	(0.49, 2.75)	(0.45, 1.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.95	
95% CI of the inverse risk ratio	(0.52, 2.55)	(0.48, 1.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.07	0.45	
95% CI of the absolute risk difference	(-6.97, 4.82)	(-5.23, 6.14)	
p-value	0.7267	0.8749	
p-value of Breslow-Day Test for Homogeneity [3]	0.5389	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (13.3)	20 (13.2)	41 (17.6)
No	98 (86.7)	131 (86.8)	192 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.40	
95% CI of the inverse odds ratio	(0.74, 2.64)	(0.78, 2.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	1.33	
95% CI of the inverse risk ratio	(0.77, 2.29)	(0.81, 2.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.32	-4.35	
95% CI of the absolute risk difference	(-12.26, 3.62)	(-11.64, 2.94)	
p-value	0.3060	0.2545	
p-value of Breslow-Day Test for Homogeneity [3]	0.2320	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (26.5)	45 (29.8)	79 (33.9)
No	83 (73.5)	106 (70.2)	154 (66.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	1.21	
95% CI of the inverse odds ratio	(0.86, 2.34)	(0.78, 1.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	1.14	
95% CI of the inverse risk ratio	(0.90, 1.82)	(0.84, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.36	-4.10	
95% CI of the absolute risk difference	(-17.52, 2.80)	(-13.60, 5.39)	
p-value	0.1671	0.4008	
p-value of Breslow-Day Test for Homogeneity [3]	0.1393	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (11.5)	24 (15.9)	26 (11.2)
No	100 (88.5)	127 (84.1)	207 (88.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.66	
95% CI of the inverse odds ratio	(0.48, 1.96)	(0.37, 1.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.70	
95% CI of the inverse risk ratio	(0.52, 1.82)	(0.42, 1.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.35	4.74	
95% CI of the absolute risk difference	(-6.79, 7.48)	(-2.36, 11.83)	
p-value	0.9240	0.1780	
p-value of Breslow-Day Test for Homogeneity [3]	0.6748	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (23.0)	39 (25.8)	62 (26.6)
No	87 (77.0)	112 (74.2)	171 (73.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.04	
95% CI of the inverse odds ratio	(0.72, 2.05)	(0.65, 1.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.03	
95% CI of the inverse risk ratio	(0.78, 1.72)	(0.73, 1.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.60	-0.78	
95% CI of the absolute risk difference	(-13.21, 6.01)	(-9.78, 8.21)	
p-value	0.4708	0.8651	
p-value of Breslow-Day Test for Homogeneity [3]	0.9503	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	17 (15.0)	34 (22.5)	29 (12.4)
No	96 (85.0)	117 (77.5)	204 (87.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.49	
95% CI of the inverse odds ratio	(0.42, 1.53)	(0.28, 0.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.55	
95% CI of the inverse risk ratio	(0.47, 1.44)	(0.35, 0.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.60	10.07	
95% CI of the absolute risk difference	(-5.24, 10.43)	(2.17, 17.97)	
p-value	0.5045	0.0092	
p-value of Breslow-Day Test for Homogeneity [3]	0.5476	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (26.5)	44 (29.1)	54 (23.2)
No	83 (73.5)	107 (70.9)	179 (76.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.73	
95% CI of the inverse odds ratio	(0.50, 1.40)	(0.46, 1.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.80	
95% CI of the inverse risk ratio	(0.59, 1.28)	(0.57, 1.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.37	5.96	
95% CI of the absolute risk difference	(-6.41, 13.15)	(-3.09, 15.01)	
p-value	0.4926	0.1905	
p-value of Breslow-Day Test for Homogeneity [3]	0.5014	NE	

AMNOG Table SE21.6.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (11.5)	18 (11.9)	28 (12.0)
No	100 (88.5)	133 (88.1)	205 (88.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.01	
95% CI of the inverse odds ratio	(0.52, 2.12)	(0.54, 1.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.01	
95% CI of the inverse risk ratio	(0.56, 1.94)	(0.58, 1.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.51	-0.10	
95% CI of the absolute risk difference	(-7.73, 6.70)	(-6.74, 6.55)	
p-value	0.8899	0.9773	
p-value of Breslow-Day Test for Homogeneity [3]	0.4279	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	35 (31.0)	43 (28.5)	68 (29.2)
No	78 (69.0)	108 (71.5)	165 (70.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.04	
95% CI of the inverse odds ratio	(0.56, 1.50)	(0.66, 1.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.02	
95% CI of the inverse risk ratio	(0.67, 1.32)	(0.74, 1.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.79	-0.71	
95% CI of the absolute risk difference	(-8.54, 12.12)	(-9.98, 8.56)	
p-value	0.7329	0.8812	
p-value of Breslow-Day Test for Homogeneity [3]	0.4072	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Total LDQOL						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	77.77 (13.43)	77.92 (14.12)	77.59 (14.02)			
Median	79.40	82.80	81.50			
IQR: Q1, Q3	70.60, 88.00	72.70, 87.00	70.60, 88.50			
Min, Max	29.0, 96.7	23.6, 95.6	38.2, 97.8			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	78.18 (13.84)	78.07 (12.22)	77.54 (14.75)	0.74 (0.90)	-0.17 (0.90)	0.35 (0.79)
Median	81.85	80.80	81.80	0.55	-0.90	0.20
IQR: Q1, Q3	70.35, 89.30	70.70, 86.85	69.70, 88.90	-5.65, 6.20	-5.90, 3.60	-3.80, 4.70
Min, Max	33.6, 97.8	41.4, 96.6	22.4, 96.7	-23.4, 35.6	-15.4, 26.0	-46.4, 42.3
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	79.25 (13.00)	77.62 (14.08)	78.63 (14.92)	0.98 (0.97)	-0.72 (1.06)	0.48 (0.86)
Median	83.50	79.35	82.00	0.90	-0.40	0.50
IQR: Q1, Q3	70.00, 88.80	70.30, 89.80	71.20, 89.60	-3.80, 6.30	-5.60, 5.40	-4.60, 5.30
Min, Max	34.0, 97.5	33.8, 97.4	20.3, 100.0	-19.5, 36.0	-23.3, 24.3	-46.3, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Symptoms of Liver Disease						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	77.25 (18.18)	74.69 (18.97)	76.61 (17.02)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	70.00, 93.30	63.30, 90.00	63.30, 90.00			
Min, Max	23.3, 100.0	30.0, 100.0	30.0, 100.0			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	75.83 (20.04)	73.24 (17.80)	75.69 (20.03)	-0.95 (1.38)	-1.50 (1.43)	-1.35 (1.03)
Median	80.00	75.00	80.00	0	-3.30	0
IQR: Q1, Q3	66.70, 90.00	63.30, 86.70	63.30, 90.00	-8.35, 6.65	-10.00, 4.70	-6.70, 6.60
Min, Max	0.0, 100.0	26.7, 100.0	16.7, 100.0	-46.7, 36.7	-36.6, 30.0	-53.3, 36.7
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	77.28 (18.46)	74.91 (19.48)	77.82 (19.40)	-1.29 (1.23)	0.89 (1.67)	-0.09 (1.06)
Median	83.30	78.35	83.30	0	0	0
IQR: Q1, Q3	66.70, 93.30	63.30, 93.30	66.70, 93.30	-6.70, 6.70	-6.70, 6.70	-6.70, 6.70
Min, Max	23.3, 100.0	26.7, 100.0	23.3, 100.0	-33.3, 43.4	-36.7, 30.0	-60.0, 30.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Effects of Liver Disease						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	77.65 (13.39)	79.64 (14.65)	77.31 (14.28)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	80.00, 86.70	76.65, 83.35			
Min, Max	13.3, 100.0	26.7, 100.0	26.7, 100.0			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	76.43 (13.18)	79.93 (11.05)	76.99 (15.16)	-1.42 (1.19)	0.24 (1.50)	-0.25 (1.15)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	76.65, 86.70	80.00, 80.00	-6.70, 3.30	-6.70, 6.70	-6.70, 6.60
Min, Max	20.0, 100.0	40.0, 100.0	6.7, 100.0	-40.0, 33.3	-26.7, 60.0	-46.7, 46.6
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	76.60 (12.06)	77.98 (13.48)	76.92 (14.44)	-1.12 (1.53)	-1.08 (1.42)	-1.24 (1.49)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	73.30, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 0.00
Min, Max	40.0, 100.0	20.0, 100.0	13.3, 100.0	-40.0, 80.0	-33.3, 30.0	-80.0, 46.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Concentration/Memory						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	80.72 (21.70)	79.82 (20.11)	77.68 (20.61)			
Median	87.50	81.30	81.30			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	65.65, 93.80			
Min, Max	18.8, 100.0	25.0, 100.0	6.3, 100.0			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	79.04 (22.08)	79.70 (19.47)	78.45 (22.52)	-1.10 (1.52)	-1.23 (1.57)	1.03 (1.25)
Median	87.50	81.30	81.30	0	0	0
IQR: Q1, Q3	68.80, 100.00	68.80, 96.90	62.50, 100.00	-9.40, 6.20	-6.30, 6.30	-6.20, 6.30
Min, Max	0.0, 100.0	25.0, 100.0	6.3, 100.0	-43.8, 31.2	-37.5, 25.0	-50.0, 62.5
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	78.37 (20.47)	78.23 (20.53)	78.91 (21.55)	-1.48 (1.42)	-2.82 (1.90)	0.09 (1.27)
Median	81.30	81.30	81.30	0	0	0
IQR: Q1, Q3	68.80, 93.80	68.80, 93.80	68.80, 100.00	-6.30, 6.20	-12.50, 6.30	-6.30, 6.30
Min, Max	0.0, 100.0	18.8, 100.0	0.0, 100.0	-43.7, 50.0	-43.8, 43.7	-43.8, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Health Distress						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	80.09 (25.59)	83.24 (25.70)	80.72 (24.57)			
Median	87.50	100.00	87.50			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	84.38 (21.19)	87.78 (19.78)	84.75 (23.46)	4.40 (2.06)	5.25 (1.91)	4.75 (1.61)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	12.5, 100.0	25.0, 100.0	0.0, 100.0	-50.0, 75.0	-37.5, 50.0	-62.5, 75.0
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	84.28 (22.91)	87.16 (21.60)	86.30 (22.58)	4.17 (2.35)	2.64 (2.36)	4.97 (1.88)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 75.0	-50.0, 75.0	-87.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Sexual Function						
Baseline						
m	118	100	201			
n	47	45	82			
Mean (SD)	78.09 (28.37)	79.49 (22.27)	80.57 (24.85)			
Median	93.30	86.70	86.70			
IQR: Q1, Q3	63.30, 100.00	63.30, 100.00	76.70, 100.00			
Min, Max	-1.7, 100.0	30.0, 100.0	-1.7, 100.0			
Week 24						
m	115	92	189			
n	48	45	79	36	36	60
Mean (SD/SE)	81.11 (23.53)	75.33 (26.38)	78.25 (24.16)	3.28 (5.07)	-6.16 (3.84)	-1.31 (2.03)
Median	92.50	85.00	85.00	0	0	0
IQR: Q1, Q3	76.70, 100.00	60.00, 100.00	63.30, 100.00	-2.50, 19.20	-16.70, 0.00	-7.50, 6.70
Min, Max	15.0, 100.0	-1.7, 100.0	6.7, 100.0	-85.0, 91.1	-55.0, 46.7	-45.0, 38.3
Week 52						
m	107	81	176			
n	37	33	65	32	29	51
Mean (SD/SE)	83.61 (23.78)	75.38 (29.78)	78.25 (26.21)	4.52 (4.52)	-4.73 (4.64)	-1.54 (2.70)
Median	93.30	86.70	93.30	0	0	0
IQR: Q1, Q3	78.30, 100.00	53.30, 100.00	68.30, 100.00	-4.20, 3.35	-21.70, 6.70	-8.40, 6.70
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-45.0, 91.1	-50.0, 61.7	-53.3, 63.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Sleep						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	63.72 (19.51)	60.27 (20.03)	62.74 (19.86)			
Median	65.00	65.00	65.00			
IQR: Q1, Q3	50.00, 80.00	50.00, 75.00	50.00, 77.50			
Min, Max	0.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	63.75 (19.20)	57.67 (18.88)	61.04 (20.74)	0.42 (1.61)	-2.22 (1.56)	-1.13 (1.20)
Median	65.00	60.00	60.00	0	-5.00	0
IQR: Q1, Q3	50.00, 75.00	42.50, 70.00	45.00, 75.00	-10.00, 5.00	-10.00, 5.00	-10.00, 5.00
Min, Max	25.0, 100.0	10.0, 95.0	15.0, 100.0	-30.0, 90.0	-35.0, 40.0	-35.0, 50.0
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	65.48 (18.51)	58.51 (20.52)	62.98 (20.23)	-0.20 (1.76)	-1.55 (1.97)	0.00 (1.30)
Median	70.00	60.00	65.00	0	-5.00	0
IQR: Q1, Q3	55.00, 80.00	45.00, 75.00	47.50, 80.00	-10.00, 5.00	-10.00, 10.00	-10.00, 10.00
Min, Max	15.0, 100.0	10.0, 95.0	20.0, 100.0	-40.0, 75.0	-55.0, 45.0	-40.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Loneliness						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	84.87 (17.04)	84.56 (20.16)	83.11 (20.20)			
Median	90.00	95.00	90.00			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	35.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	83.71 (17.37)	87.90 (16.08)	81.97 (21.17)	-0.69 (1.63)	1.11 (1.66)	-1.26 (1.36)
Median	90.00	95.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	80.00, 100.00	75.00, 100.00	-10.00, 5.00	-5.00, 10.00	-10.00, 5.00
Min, Max	35.0, 100.0	25.0, 100.0	10.0, 100.0	-45.0, 45.0	-35.0, 65.0	-80.0, 70.0
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	85.67 (16.92)	85.07 (18.16)	84.36 (19.84)	0.97 (1.69)	0.14 (1.61)	0.75 (1.35)
Median	95.00	90.00	90.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	80.00, 100.00	80.00, 100.00	-5.00, 5.00	-10.00, 10.00	-5.00, 10.00
Min, Max	25.0, 100.0	15.0, 100.0	5.0, 100.0	-60.0, 50.0	-35.0, 30.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Hopelessness						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	75.52 (21.92)	78.30 (22.88)	78.68 (20.47)			
Median	75.00	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	58.30, 100.00			
Min, Max	8.3, 100.0	8.3, 100.0	16.7, 100.0			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	77.31 (22.90)	78.60 (21.44)	77.87 (22.10)	2.85 (1.97)	0.82 (2.16)	0.08 (1.44)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	62.50, 100.00	58.30, 100.00	-8.35, 16.70	-8.30, 16.60	-8.30, 8.40
Min, Max	8.3, 100.0	25.0, 100.0	16.7, 100.0	-58.3, 50.0	-41.7, 50.0	-66.6, 50.0
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	77.83 (22.08)	77.14 (22.37)	78.10 (23.35)	1.97 (2.02)	-2.22 (2.65)	-1.19 (1.60)
Median	83.30	79.15	91.70	0	0	0
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	58.30, 100.00	-8.30, 8.40	-16.70, 16.70	-8.30, 8.30
Min, Max	16.7, 100.0	0.0, 100.0	0.0, 100.0	-41.7, 41.7	-58.3, 50.0	-100.0, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Stigma of Liver Disease						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	83.26 (20.39)	82.02 (19.06)	83.52 (19.91)			
Median	93.80	87.50	90.65			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	18.8, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	85.51 (19.53)	81.56 (19.16)	84.33 (19.29)	2.08 (1.71)	0.08 (1.52)	1.46 (1.45)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	-6.20, 6.30	-6.20, 6.20	-6.20, 6.20
Min, Max	6.3, 100.0	12.5, 100.0	25.0, 100.0	-43.7, 56.2	-31.3, 37.5	-62.5, 75.0
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	87.71 (16.86)	83.05 (19.67)	85.20 (18.25)	3.23 (1.49)	0.62 (2.02)	2.11 (1.45)
Median	93.80	90.65	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	68.80, 100.00	75.00, 100.00	0.00, 6.30	-6.20, 6.30	-6.20, 12.50
Min, Max	37.5, 100.0	12.5, 100.0	25.0, 100.0	-31.3, 56.2	-56.2, 50.0	-56.3, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Total LDQOL						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	76.72 (16.62)	74.89 (15.24)	78.50 (13.85)			
Median	83.20	76.30	81.90			
IQR: Q1, Q3	64.80, 89.40	64.50, 88.00	72.85, 88.10			
Min, Max	28.3, 96.4	27.3, 96.3	34.8, 97.8			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	77.93 (17.16)	76.70 (13.45)	80.61 (12.79)	0.93 (1.09)	1.98 (1.12)	1.29 (0.96)
Median	82.00	78.20	83.95	1.20	2.60	0.70
IQR: Q1, Q3	71.40, 90.10	70.30, 86.75	74.80, 89.90	-3.50, 5.20	-4.50, 7.10	-3.00, 5.20
Min, Max	22.9, 96.9	32.4, 96.9	33.3, 98.8	-16.4, 15.9	-12.7, 27.0	-27.6, 22.3
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	78.92 (14.44)	79.32 (14.00)	79.26 (13.01)	1.34 (1.19)	3.18 (1.52)	0.63 (0.90)
Median	84.00	82.95	82.30	0.90	2.25	0.60
IQR: Q1, Q3	69.40, 90.00	69.15, 90.20	72.50, 89.30	-2.30, 5.70	-3.00, 6.90	-4.10, 4.90
Min, Max	44.6, 96.9	34.2, 96.3	34.3, 97.0	-12.0, 18.1	-13.7, 33.9	-20.5, 23.8

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Symptoms of Liver Disease						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	78.51 (22.39)	75.46 (18.57)	76.45 (19.60)			
Median	83.30	76.70	80.00			
IQR: Q1, Q3	70.00, 93.30	63.30, 86.70	63.30, 93.30			
Min, Max	13.3, 100.0	10.0, 100.0	20.0, 100.0			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	77.63 (20.95)	75.70 (18.61)	80.40 (17.32)	-2.40 (1.95)	0.31 (1.63)	3.03 (1.51)
Median	83.30	76.70	83.30	0	0	3.30
IQR: Q1, Q3	66.70, 93.30	66.70, 88.35	70.00, 93.30	-10.00, 6.60	-6.60, 6.70	-3.30, 10.00
Min, Max	16.7, 100.0	30.0, 100.0	30.0, 100.0	-43.3, 33.4	-23.3, 30.0	-30.0, 43.3
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	77.34 (21.49)	79.59 (15.75)	78.02 (18.39)	-3.61 (2.37)	0.89 (2.09)	1.93 (1.49)
Median	83.30	80.00	83.30	0	0	3.30
IQR: Q1, Q3	63.30, 93.30	70.00, 91.65	72.00, 90.00	-10.00, 6.60	-6.70, 10.00	-6.70, 10.00
Min, Max	6.7, 100.0	36.7, 100.0	16.7, 100.0	-43.4, 26.7	-20.0, 36.7	-30.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Effects of Liver Disease						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	77.48 (15.59)	76.45 (16.02)	77.39 (16.48)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	73.30, 80.00	80.00, 86.70			
Min, Max	6.7, 100.0	13.3, 100.0	6.7, 100.0			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	74.82 (18.14)	77.99 (9.52)	78.09 (14.62)	-2.95 (1.62)	0.97 (2.80)	0.15 (1.58)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	76.65, 80.00	80.00, 86.70	-6.70, 0.00	-6.70, 6.70	-6.70, 6.70
Min, Max	0.0, 100.0	40.0, 100.0	26.7, 100.0	-33.4, 20.0	-33.3, 76.7	-46.7, 53.4
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	76.58 (16.24)	77.67 (10.40)	79.24 (11.60)	-1.81 (1.69)	0.53 (2.57)	1.68 (1.86)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 0.00	-6.70, 0.00	0.00, 6.70
Min, Max	6.7, 100.0	26.7, 93.3	40.0, 100.0	-40.0, 13.4	-33.3, 53.4	-46.7, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Concentration/Memory						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	79.18 (26.68)	77.15 (21.77)	80.45 (21.23)			
Median	87.50	87.50	87.50			
IQR: Q1, Q3	75.00, 100.00	56.30, 93.80	68.80, 100.00			
Min, Max	6.3, 100.0	18.8, 100.0	25.0, 100.0			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	77.51 (23.81)	81.14 (19.91)	82.27 (19.87)	-2.48 (2.01)	3.46 (2.37)	-0.07 (1.71)
Median	87.50	87.50	93.80	0	0	0
IQR: Q1, Q3	75.00, 100.00	68.80, 100.00	75.00, 100.00	-6.30, 6.20	0.00, 6.30	-6.20, 6.20
Min, Max	18.8, 100.0	37.5, 100.0	18.8, 100.0	-43.8, 18.8	-25.0, 56.2	-81.2, 62.5
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	80.79 (19.73)	82.05 (19.97)	79.31 (22.36)	1.02 (2.39)	1.48 (1.86)	-1.71 (1.35)
Median	87.50	90.65	87.50	0	0	0
IQR: Q1, Q3	75.00, 93.80	59.40, 100.00	68.80, 100.00	-6.20, 6.30	0.00, 6.20	-6.30, 6.20
Min, Max	18.8, 100.0	43.8, 100.0	12.5, 100.0	-25.0, 50.0	-25.0, 50.0	-31.2, 25.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Health Distress						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	73.33 (27.39)	76.60 (24.67)	81.79 (23.18)			
Median	75.00	75.00	87.50			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	79.72 (27.99)	85.16 (21.83)	87.63 (18.65)	7.85 (2.85)	7.78 (2.98)	5.96 (1.82)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 25.00	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-37.5, 62.5	-37.5, 50.0	-50.0, 62.5
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	80.13 (26.39)	86.88 (20.40)	86.45 (17.70)	6.76 (4.35)	10.53 (3.25)	2.92 (2.34)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 25.00	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	25.0, 100.0	-75.0, 75.0	-25.0, 62.5	-62.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Sexual Function						
Baseline						
m	49	51	102			
n	24	27	39			
Mean (SD)	82.35 (22.43)	79.37 (25.31)	77.56 (23.74)			
Median	93.30	85.00	85.00			
IQR: Q1, Q3	75.85, 100.00	63.30, 100.00	61.70, 100.00			
Min, Max	30.0, 100.0	-1.7, 100.0	23.3, 100.0			
Week 24						
m	46	49	100			
n	24	32	46	21	23	34
Mean (SD/SE)	78.41 (25.21)	73.33 (30.18)	80.40 (22.42)	-1.02 (2.47)	-2.17 (3.53)	2.45 (3.86)
Median	85.85	82.50	86.70	0	0	0
IQR: Q1, Q3	58.35, 100.00	49.20, 100.00	68.30, 100.00	-6.60, 1.70	0.00, 1.70	-6.70, 16.70
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-25.0, 25.0	-40.0, 41.7	-48.4, 50.0
Week 52						
m	42	44	94			
n	16	24	36	14	18	29
Mean (SD/SE)	88.44 (13.91)	79.48 (27.68)	76.04 (25.46)	3.58 (3.92)	0.56 (2.56)	-0.89 (4.42)
Median	96.65	93.30	80.80	0	0	0
IQR: Q1, Q3	77.50, 100.00	59.15, 100.00	60.00, 100.00	-5.00, 6.70	0.00, 1.70	-8.40, 6.70
Min, Max	61.7, 100.0	-1.7, 100.0	-1.7, 100.0	-11.7, 48.3	-30.0, 23.4	-48.4, 65.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Sleep						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	60.78 (23.79)	60.00 (19.42)	62.76 (20.41)			
Median	65.00	60.00	65.00			
IQR: Q1, Q3	45.00, 80.00	50.00, 70.00	50.00, 80.00			
Min, Max	10.0, 95.0	5.0, 100.0	5.0, 100.0			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	63.33 (24.68)	58.96 (22.85)	65.11 (19.45)	2.44 (2.09)	-0.67 (2.16)	1.23 (1.81)
Median	65.00	60.00	65.00	0	0	0
IQR: Q1, Q3	50.00, 80.00	45.00, 80.00	50.00, 80.00	-5.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	5.0, 95.0	0.0, 100.0	20.0, 100.0	-25.0, 45.0	-35.0, 45.0	-40.0, 45.0
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	62.69 (21.82)	61.75 (22.58)	65.18 (21.59)	2.03 (2.60)	0.26 (2.78)	2.48 (1.97)
Median	65.00	65.00	65.00	0	0	5.00
IQR: Q1, Q3	50.00, 80.00	42.50, 80.00	50.00, 80.00	-10.00, 10.00	-10.00, 10.00	-5.00, 15.00
Min, Max	10.0, 100.0	0.0, 90.0	5.0, 100.0	-25.0, 45.0	-60.0, 40.0	-40.0, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Loneliness						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	83.89 (19.80)	80.11 (19.24)	85.30 (18.41)			
Median	90.00	80.00	95.00			
IQR: Q1, Q3	75.00, 100.00	70.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	15.0, 100.0	25.0, 100.0			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	83.17 (22.20)	79.58 (23.15)	84.47 (19.31)	-1.34 (2.23)	0.33 (1.56)	-1.66 (1.63)
Median	95.00	85.00	90.00	0	0	0
IQR: Q1, Q3	70.00, 100.00	65.00, 100.00	80.00, 100.00	-7.50, 5.00	-5.00, 5.00	-7.50, 5.00
Min, Max	15.0, 100.0	0.0, 100.0	20.0, 100.0	-50.0, 25.0	-25.0, 20.0	-60.0, 45.0
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	83.59 (18.64)	80.38 (25.15)	83.55 (17.61)	-1.22 (2.38)	0.39 (2.95)	-1.46 (1.78)
Median	85.00	90.00	85.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	72.50, 100.00	70.00, 100.00	-5.00, 0.00	-10.00, 15.00	-10.00, 5.00
Min, Max	35.0, 100.0	0.0, 100.0	40.0, 100.0	-30.0, 35.0	-40.0, 35.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Hopelessness						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	76.48 (24.64)	73.58 (22.87)	80.44 (23.23)			
Median	91.70	75.00	91.70			
IQR: Q1, Q3	58.30, 100.00	50.00, 100.00	66.70, 100.00			
Min, Max	25.0, 100.0	25.0, 100.0	25.0, 100.0			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	78.52 (22.73)	76.39 (23.79)	80.77 (20.81)	1.35 (2.13)	3.34 (2.88)	-1.16 (1.99)
Median	83.30	83.30	91.70	0	0	0
IQR: Q1, Q3	66.70, 100.00	58.30, 100.00	66.70, 100.00	-8.30, 8.30	-8.30, 16.60	-8.30, 0.00
Min, Max	8.3, 100.0	8.3, 100.0	25.0, 100.0	-33.4, 33.4	-41.7, 58.4	-50.0, 50.0
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	80.35 (19.54)	80.42 (20.80)	79.52 (20.31)	0.91 (2.92)	7.68 (3.15)	-1.20 (2.01)
Median	83.30	87.50	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	66.70, 100.00	66.70, 100.00	-8.30, 8.40	-8.30, 16.70	-8.40, 8.30
Min, Max	41.7, 100.0	16.7, 100.0	25.0, 100.0	-50.0, 33.4	-16.7, 50.0	-50.0, 33.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Stigma of Liver Disease						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	80.15 (24.54)	79.94 (21.13)	84.67 (17.31)			
Median	93.80	81.30	87.50			
IQR: Q1, Q3	68.80, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	25.0, 100.0	31.3, 100.0			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	85.44 (19.31)	80.75 (20.17)	86.92 (16.84)	4.95 (2.75)	1.11 (2.44)	1.82 (1.30)
Median	93.80	84.40	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	71.90, 100.00	81.30, 100.00	-6.20, 12.50	-6.30, 6.20	0.00, 6.30
Min, Max	12.5, 100.0	25.0, 100.0	6.3, 100.0	-43.8, 43.8	-25.0, 56.3	-37.5, 37.5
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	85.59 (19.55)	87.00 (16.70)	85.27 (19.19)	4.90 (2.00)	6.20 (2.22)	0.98 (1.68)
Median	100.00	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	78.15, 100.00	81.30, 100.00	0.00, 6.30	0.00, 12.50	-6.20, 6.30
Min, Max	31.3, 100.0	37.5, 100.0	18.8, 100.0	-18.7, 37.5	-12.5, 56.3	-62.5, 37.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.7.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Total LDQOL			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	77.70 (13.42)	77.91 (14.39)	77.83 (13.90)
Analysis Visit Mean (SD)	78.44 (13.91)	77.74 (12.43)	78.18 (14.56)
LS Mean of Change from Baseline (SE)	0.50 (0.86)	-0.53 (0.99)	0.20 (0.70)
95% CI	(-1.19, 2.19)	(-2.48, 1.42)	(-1.19, 1.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.30 (1.09)	-0.73 (1.20)	
95% CI	(-1.84, 2.45)	(-3.08, 1.62)	
p-value	0.7805	0.5428	
Corrected Hedge's g Statistics	0.034	-0.081	
95% CI	(-0.21, 0.28)	(-0.35, 0.19)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	78.24 (13.14)	78.07 (14.91)	78.35 (13.62)
Analysis Visit Mean (SD)	79.22 (12.92)	77.36 (14.29)	78.82 (15.15)
LS Mean of Change from Baseline (SE)	0.82 (0.98)	-1.01 (1.12)	0.11 (0.79)
95% CI	(-1.11, 2.74)	(-3.22, 1.20)	(-1.44, 1.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.70 (1.24)	-1.12 (1.35)	
95% CI	(-1.74, 3.14)	(-3.78, 1.54)	
p-value	0.5724	0.4074	
Corrected Hedge's g Statistics	0.074	-0.118	
95% CI	(-0.19, 0.33)	(-0.40, 0.17)	
Subgroup*Treatment Interaction p-value	0.7806	0.4326	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Total LDQOL			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	77.26 (16.01)	74.48 (15.39)	79.35 (13.47)
Analysis Visit Mean (SD)	78.19 (16.69)	76.46 (13.68)	80.64 (13.05)
LS Mean of Change from Baseline (SE)	0.87 (1.18)	1.38 (1.17)	1.40 (0.84)
95% CI	(-1.47, 3.20)	(-0.92, 3.68)	(-0.26, 3.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.53 (1.45)	-0.02 (1.43)	
95% CI	(-3.39, 2.33)	(-2.85, 2.81)	
p-value	0.7129	0.9871	
Corrected Hedge's g Statistics	-0.068	-0.003	
95% CI	(-0.43, 0.30)	(-0.36, 0.36)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	77.81 (15.84)	75.35 (15.72)	78.43 (14.09)
Analysis Visit Mean (SD)	79.15 (13.83)	78.52 (13.91)	79.06 (13.34)
LS Mean of Change from Baseline (SE)	1.22 (1.21)	2.68 (1.20)	0.68 (0.85)
95% CI	(-1.17, 3.60)	(0.32, 5.04)	(-0.99, 2.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.54 (1.47)	2.00 (1.46)	
95% CI	(-2.37, 3.45)	(-0.88, 4.88)	
p-value	0.7152	0.1718	
Corrected Hedge's g Statistics	0.072	0.268	
95% CI	(-0.32, 0.46)	(-0.12, 0.66)	
Subgroup*Treatment Interaction p-value	0.7806	0.4326	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Symptoms of Liver Disease			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	77.10 (18.30)	74.65 (19.07)	77.82 (16.72)
Analysis Visit Mean (SD)	76.14 (20.23)	73.15 (17.40)	76.47 (19.73)
LS Mean of Change from Baseline (SE)	-1.13 (1.27)	-2.13 (1.47)	-1.51 (1.04)
95% CI	(-3.62, 1.37)	(-5.02, 0.76)	(-3.56, 0.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.39 (1.62)	-0.61 (1.77)	
95% CI	(-2.79, 3.57)	(-4.10, 2.87)	
p-value	0.8096	0.7287	
Corrected Hedge's g Statistics	0.029	-0.046	
95% CI	(-0.21, 0.27)	(-0.31, 0.22)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	78.49 (17.43)	74.23 (19.75)	78.31 (15.87)
Analysis Visit Mean (SD)	77.20 (18.41)	75.12 (19.36)	78.22 (19.12)
LS Mean of Change from Baseline (SE)	-1.25 (1.30)	-0.39 (1.49)	-0.06 (1.04)
95% CI	(-3.80, 1.29)	(-3.32, 2.54)	(-2.10, 1.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.20 (1.64)	-0.34 (1.79)	
95% CI	(-4.42, 2.02)	(-3.86, 3.19)	
p-value	0.4641	0.8518	
Corrected Hedge's g Statistics	-0.095	-0.027	
95% CI	(-0.36, 0.16)	(-0.31, 0.26)	
Subgroup*Treatment Interaction p-value	0.0768	0.5969	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Effects of Liver Disease			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	77.78 (13.49)	79.68 (14.97)	77.67 (13.53)
Analysis Visit Mean (SD)	76.36 (13.35)	79.92 (11.38)	77.42 (14.75)
LS Mean of Change from Baseline (SE)	-1.83 (1.15)	0.74 (1.32)	-0.70 (0.94)
95% CI	(-4.09, 0.42)	(-1.87, 3.34)	(-2.55, 1.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.13 (1.46)	1.44 (1.60)	
95% CI	(-4.00, 1.74)	(-1.71, 4.59)	
p-value	0.4385	0.3693	
Corrected Hedge's g Statistics	-0.094	0.120	
95% CI	(-0.34, 0.15)	(-0.15, 0.39)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	77.93 (12.78)	78.97 (15.06)	78.13 (12.86)
Analysis Visit Mean (SD)	76.81 (12.06)	77.89 (13.76)	76.90 (14.48)
LS Mean of Change from Baseline (SE)	-1.68 (1.35)	-0.96 (1.55)	-1.70 (1.08)
95% CI	(-4.34, 0.98)	(-4.01, 2.09)	(-3.83, 0.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (1.71)	0.73 (1.87)	
95% CI	(-3.35, 3.38)	(-2.94, 4.41)	
p-value	0.9938	0.6956	
Corrected Hedge's g Statistics	0.001	0.056	
95% CI	(-0.26, 0.26)	(-0.23, 0.34)	
Subgroup*Treatment Interaction p-value	0.3855	0.3502	

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Concentration/Memory			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	80.52 (22.01)	80.42 (19.97)	77.97 (20.90)
Analysis Visit Mean (SD)	79.42 (22.23)	79.18 (19.81)	79.01 (22.56)
LS Mean of Change from Baseline (SE)	-0.98 (1.44)	-1.54 (1.66)	0.61 (1.18)
95% CI	(-3.81, 1.85)	(-4.80, 1.72)	(-1.71, 2.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.59 (1.83)	-2.15 (2.00)	
95% CI	(-5.19, 2.01)	(-6.08, 1.79)	
p-value	0.3861	0.2847	
Corrected Hedge's g Statistics	-0.106	-0.143	
95% CI	(-0.35, 0.14)	(-0.41, 0.12)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	79.59 (21.59)	80.39 (20.05)	78.70 (20.04)
Analysis Visit Mean (SD)	78.11 (20.70)	77.57 (20.68)	78.79 (21.96)
LS Mean of Change from Baseline (SE)	-2.68 (1.50)	-2.51 (1.72)	-0.57 (1.21)
95% CI	(-5.63, 0.27)	(-5.90, 0.87)	(-2.95, 1.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.11 (1.90)	-1.94 (2.07)	
95% CI	(-5.84, 1.62)	(-6.01, 2.12)	
p-value	0.2667	0.3482	
Corrected Hedge's g Statistics	-0.145	-0.133	
95% CI	(-0.40, 0.12)	(-0.42, 0.15)	
Subgroup*Treatment Interaction p-value	0.5141	0.0923	

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Health Distress			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	80.21 (25.70)	81.94 (26.44)	80.29 (24.53)
Analysis Visit Mean (SD)	84.61 (21.25)	87.19 (20.35)	85.05 (23.56)
LS Mean of Change from Baseline (SE)	3.81 (1.64)	5.31 (1.89)	4.36 (1.34)
95% CI	(0.59, 7.04)	(1.59, 9.03)	(1.71, 7.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.54 (2.08)	0.95 (2.28)	
95% CI	(-4.64, 3.56)	(-3.53, 5.44)	
p-value	0.7948	0.6759	
Corrected Hedge's g Statistics	-0.032	0.056	
95% CI	(-0.27, 0.21)	(-0.21, 0.32)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	79.70 (25.53)	84.33 (25.85)	81.16 (24.79)
Analysis Visit Mean (SD)	83.87 (23.21)	86.97 (22.00)	86.13 (22.98)
LS Mean of Change from Baseline (SE)	2.66 (1.93)	3.52 (2.21)	4.45 (1.55)
95% CI	(-1.13, 6.44)	(-0.82, 7.87)	(1.41, 7.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.80 (2.44)	-0.93 (2.66)	
95% CI	(-6.59, 3.00)	(-6.17, 4.30)	
p-value	0.4614	0.7266	
Corrected Hedge's g Statistics	-0.096	-0.050	
95% CI	(-0.36, 0.16)	(-0.33, 0.23)	
Subgroup*Treatment Interaction p-value	0.9850	0.6614	

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Sexual Function			
Week 24			
m	115	92	189
n	36	36	60
Baseline Mean (SD)	75.66 (30.42)	81.94 (19.67)	82.67 (22.70)
Analysis Visit Mean (SD)	78.94 (25.61)	75.78 (25.91)	81.36 (21.55)
LS Mean of Change from Baseline (SE)	2.08 (3.21)	-5.86 (3.28)	-0.28 (2.55)
95% CI	(-4.27, 8.43)	(-12.34, 0.63)	(-5.32, 4.75)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.36 (4.04)	-5.57 (4.04)	
95% CI	(-5.63, 10.36)	(-13.55, 2.41)	
p-value	0.5597	0.1697	
Corrected Hedge's g Statistics	0.120	-0.280	
95% CI	(-0.29, 0.53)	(-0.70, 0.13)	
Week 52			
m	107	81	176
n	32	29	51
Baseline Mean (SD)	79.69 (30.79)	80.74 (23.36)	81.40 (24.27)
Analysis Visit Mean (SD)	84.22 (23.43)	76.01 (30.80)	79.86 (23.86)
LS Mean of Change from Baseline (SE)	4.27 (3.43)	-4.60 (3.62)	-1.67 (2.74)
95% CI	(-2.52, 11.06)	(-11.75, 2.54)	(-7.08, 3.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.94 (4.34)	-2.93 (4.44)	
95% CI	(-2.63, 14.51)	(-11.70, 5.83)	
p-value	0.1729	0.5096	
Corrected Hedge's g Statistics	0.302	-0.149	
95% CI	(-0.14, 0.75)	(-0.61, 0.31)	
Subgroup*Treatment Interaction p-value	0.6910	0.5284	

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Sleep			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	63.61 (19.30)	59.69 (20.41)	63.28 (20.09)
Analysis Visit Mean (SD)	64.03 (18.90)	57.47 (19.51)	62.15 (20.58)
LS Mean of Change from Baseline (SE)	0.21 (1.39)	-3.74 (1.61)	-1.44 (1.14)
95% CI	(-2.52, 2.94)	(-6.89, -0.58)	(-3.68, 0.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.65 (1.77)	-2.29 (1.94)	
95% CI	(-1.82, 5.12)	(-6.10, 1.51)	
p-value	0.3497	0.2371	
Corrected Hedge's g Statistics	0.114	-0.158	
95% CI	(-0.13, 0.36)	(-0.42, 0.11)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	65.27 (18.93)	60.00 (21.33)	63.80 (19.99)
Analysis Visit Mean (SD)	65.07 (18.42)	58.45 (20.59)	63.80 (20.34)
LS Mean of Change from Baseline (SE)	0.59 (1.53)	-3.21 (1.76)	-0.20 (1.23)
95% CI	(-2.43, 3.61)	(-6.67, 0.26)	(-2.62, 2.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.79 (1.94)	-3.01 (2.12)	
95% CI	(-3.02, 4.60)	(-7.18, 1.16)	
p-value	0.6842	0.1568	
Corrected Hedge's g Statistics	0.053	-0.202	
95% CI	(-0.21, 0.31)	(-0.49, 0.08)	
Subgroup*Treatment Interaction p-value	0.7607	0.9212	

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Loneliness			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	84.86 (17.14)	86.05 (19.98)	83.28 (20.28)
Analysis Visit Mean (SD)	84.17 (17.10)	87.16 (16.51)	82.02 (21.34)
LS Mean of Change from Baseline (SE)	-0.87 (1.45)	1.22 (1.67)	-1.95 (1.19)
95% CI	(-3.71, 1.98)	(-2.07, 4.50)	(-4.29, 0.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.09 (1.85)	3.17 (2.02)	
95% CI	(-2.55, 4.72)	(-0.81, 7.15)	
p-value	0.5569	0.1184	
Corrected Hedge's g Statistics	0.072	0.209	
95% CI	(-0.17, 0.31)	(-0.06, 0.48)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	84.95 (17.75)	84.51 (20.81)	83.66 (20.13)
Analysis Visit Mean (SD)	85.91 (16.75)	84.65 (18.37)	84.42 (20.16)
LS Mean of Change from Baseline (SE)	0.69 (1.45)	-0.20 (1.67)	0.09 (1.17)
95% CI	(-2.17, 3.55)	(-3.48, 3.08)	(-2.21, 2.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.60 (1.84)	-0.28 (2.00)	
95% CI	(-3.01, 4.21)	(-4.23, 3.66)	
p-value	0.7437	0.8872	
Corrected Hedge's g Statistics	0.043	-0.020	
95% CI	(-0.22, 0.30)	(-0.30, 0.26)	
Subgroup*Treatment Interaction p-value	0.8498	0.7579	

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Hopelessness			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	75.08 (22.14)	77.88 (22.76)	78.73 (19.80)
Analysis Visit Mean (SD)	77.93 (22.66)	78.70 (21.77)	78.81 (21.55)
LS Mean of Change from Baseline (SE)	1.84 (1.71)	0.51 (1.97)	0.69 (1.40)
95% CI	(-1.52, 5.21)	(-3.36, 4.38)	(-2.07, 3.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.16 (2.18)	-0.18 (2.38)	
95% CI	(-3.13, 5.44)	(-4.85, 4.50)	
p-value	0.5955	0.9406	
Corrected Hedge's g Statistics	0.065	-0.010	
95% CI	(-0.18, 0.31)	(-0.28, 0.26)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	76.08 (21.92)	78.75 (23.74)	79.74 (19.30)
Analysis Visit Mean (SD)	78.05 (22.14)	76.53 (22.59)	78.54 (23.51)
LS Mean of Change from Baseline (SE)	2.03 (1.94)	-1.58 (2.22)	-0.79 (1.56)
95% CI	(-1.79, 5.85)	(-5.95, 2.80)	(-3.86, 2.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.82 (2.46)	-0.79 (2.68)	
95% CI	(-2.02, 7.66)	(-6.05, 4.48)	
p-value	0.2531	0.7696	
Corrected Hedge's g Statistics	0.149	-0.042	
95% CI	(-0.11, 0.41)	(-0.33, 0.24)	
Subgroup*Treatment Interaction p-value	0.9345	0.3641	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Stigma of Liver Disease			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	83.41 (19.87)	81.42 (19.64)	83.56 (20.17)
Analysis Visit Mean (SD)	85.49 (19.47)	81.50 (19.70)	85.01 (18.95)
LS Mean of Change from Baseline (SE)	2.15 (1.48)	-0.50 (1.71)	1.62 (1.21)
95% CI	(-0.75, 5.06)	(-3.86, 2.86)	(-0.77, 4.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.54 (1.88)	-2.11 (2.06)	
95% CI	(-3.16, 4.24)	(-6.17, 1.94)	
p-value	0.7749	0.3060	
Corrected Hedge's g Statistics	0.035	-0.137	
95% CI	(-0.21, 0.28)	(-0.40, 0.13)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	84.76 (18.66)	82.24 (19.58)	83.23 (20.24)
Analysis Visit Mean (SD)	87.98 (16.61)	82.86 (19.98)	85.34 (18.57)
LS Mean of Change from Baseline (SE)	4.21 (1.50)	0.01 (1.72)	1.99 (1.20)
95% CI	(1.27, 7.16)	(-3.37, 3.38)	(-0.37, 4.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.22 (1.89)	-1.99 (2.06)	
95% CI	(-1.50, 5.94)	(-6.05, 2.07)	
p-value	0.2417	0.3358	
Corrected Hedge's g Statistics	0.153	-0.137	
95% CI	(-0.11, 0.41)	(-0.42, 0.15)	
Subgroup*Treatment Interaction p-value	0.9101	0.5269	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Symptoms of Liver Disease			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	79.22 (21.69)	75.26 (18.47)	77.13 (19.70)
Analysis Visit Mean (SD)	76.82 (21.06)	75.56 (18.56)	80.16 (17.97)
LS Mean of Change from Baseline (SE)	-1.83 (1.83)	-0.01 (1.79)	2.75 (1.30)
95% CI	(-5.44, 1.78)	(-3.54, 3.53)	(0.20, 5.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.59 (2.24)	-2.76 (2.20)	
95% CI	(-9.00, -0.17)	(-7.10, 1.57)	
p-value	0.0418	0.2105	
Corrected Hedge's g Statistics	-0.380	-0.228	
95% CI	(-0.75, -0.01)	(-0.59, 0.13)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	79.82 (21.41)	77.72 (14.71)	75.67 (20.09)
Analysis Visit Mean (SD)	76.21 (21.48)	78.61 (15.53)	77.60 (18.62)
LS Mean of Change from Baseline (SE)	-3.42 (2.01)	0.92 (1.98)	1.83 (1.41)
95% CI	(-7.39, 0.56)	(-2.99, 4.83)	(-0.95, 4.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.25 (2.46)	-0.91 (2.42)	
95% CI	(-10.10, -0.40)	(-5.69, 3.86)	
p-value	0.0341	0.7068	
Corrected Hedge's g Statistics	-0.423	-0.074	
95% CI	(-0.82, -0.03)	(-0.46, 0.32)	
Subgroup*Treatment Interaction p-value	0.0768	0.5969	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Effects of Liver Disease			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	78.76 (13.19)	76.29 (16.30)	77.99 (15.91)
Analysis Visit Mean (SD)	75.81 (16.97)	77.26 (9.14)	78.14 (14.56)
LS Mean of Change from Baseline (SE)	-2.38 (1.89)	0.17 (1.85)	0.24 (1.34)
95% CI	(-6.11, 1.35)	(-3.49, 3.82)	(-2.40, 2.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.62 (2.31)	-0.08 (2.27)	
95% CI	(-7.18, 1.94)	(-4.56, 4.41)	
p-value	0.2584	0.9732	
Corrected Hedge's g Statistics	-0.210	-0.006	
95% CI	(-0.58, 0.16)	(-0.37, 0.35)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	78.74 (14.12)	77.01 (17.17)	77.75 (14.53)
Analysis Visit Mean (SD)	76.94 (16.44)	77.54 (10.67)	79.44 (11.79)
LS Mean of Change from Baseline (SE)	-1.38 (1.88)	-0.16 (1.85)	1.79 (1.31)
95% CI	(-5.09, 2.32)	(-3.82, 3.49)	(-0.80, 4.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.18 (2.29)	-1.96 (2.26)	
95% CI	(-7.70, 1.34)	(-6.41, 2.50)	
p-value	0.1670	0.3869	
Corrected Hedge's g Statistics	-0.275	-0.169	
95% CI	(-0.67, 0.12)	(-0.56, 0.22)	
Subgroup*Treatment Interaction p-value	0.3855	0.3502	

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Concentration/Memory			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	80.54 (25.23)	77.11 (21.77)	81.70 (20.75)
Analysis Visit Mean (SD)	78.06 (23.04)	80.57 (20.09)	81.64 (20.45)
LS Mean of Change from Baseline (SE)	-2.38 (2.13)	2.65 (2.09)	0.12 (1.51)
95% CI	(-6.58, 1.83)	(-1.48, 6.78)	(-2.87, 3.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.50 (2.61)	2.54 (2.57)	
95% CI	(-7.64, 2.65)	(-2.54, 7.61)	
p-value	0.3400	0.3258	
Corrected Hedge's g Statistics	-0.177	0.180	
95% CI	(-0.54, 0.19)	(-0.18, 0.54)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	80.42 (25.65)	79.63 (19.53)	80.38 (21.66)
Analysis Visit Mean (SD)	81.44 (18.66)	81.11 (20.05)	78.67 (22.81)
LS Mean of Change from Baseline (SE)	0.94 (1.92)	1.64 (1.89)	-1.40 (1.35)
95% CI	(-2.85, 4.72)	(-2.09, 5.38)	(-4.05, 1.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.33 (2.34)	3.04 (2.31)	
95% CI	(-2.29, 6.96)	(-1.52, 7.60)	
p-value	0.3205	0.1898	
Corrected Hedge's g Statistics	0.197	0.257	
95% CI	(-0.20, 0.59)	(-0.13, 0.65)	
Subgroup*Treatment Interaction p-value	0.5141	0.0923	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Health Distress			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	73.26 (27.49)	76.39 (25.17)	81.69 (23.22)
Analysis Visit Mean (SD)	81.10 (25.64)	84.17 (22.20)	87.65 (19.13)
LS Mean of Change from Baseline (SE)	5.76 (2.39)	6.84 (2.34)	6.79 (1.69)
95% CI	(1.04, 10.48)	(2.23, 11.45)	(3.45, 10.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.03 (2.94)	0.05 (2.87)	
95% CI	(-6.83, 4.77)	(-5.62, 5.72)	
p-value	0.7261	0.9859	
Corrected Hedge's g Statistics	-0.065	0.003	
95% CI	(-0.43, 0.30)	(-0.36, 0.36)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	75.00 (26.19)	75.66 (26.15)	83.12 (20.95)
Analysis Visit Mean (SD)	81.76 (23.31)	86.18 (20.71)	86.04 (18.02)
LS Mean of Change from Baseline (SE)	4.23 (2.86)	9.21 (2.82)	5.34 (2.00)
95% CI	(-1.40, 9.87)	(3.65, 14.77)	(1.39, 9.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.11 (3.50)	3.87 (3.46)	
95% CI	(-8.03, 5.81)	(-2.95, 10.69)	
p-value	0.7517	0.2648	
Corrected Hedge's g Statistics	-0.063	0.219	
95% CI	(-0.46, 0.33)	(-0.17, 0.61)	
Subgroup*Treatment Interaction p-value	0.9850	0.6614	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Sexual Function			
Week 24			
m	46	49	100
n	21	23	34
Baseline Mean (SD)	81.58 (23.43)	81.08 (25.14)	79.90 (21.24)
Analysis Visit Mean (SD)	80.56 (25.72)	78.91 (24.83)	82.35 (21.80)
LS Mean of Change from Baseline (SE)	-0.81 (3.87)	-2.44 (3.66)	0.87 (3.01)
95% CI	(-8.52, 6.91)	(-9.72, 4.85)	(-5.13, 6.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.68 (4.92)	-3.31 (4.73)	
95% CI	(-11.48, 8.12)	(-12.73, 6.11)	
p-value	0.7340	0.4863	
Corrected Hedge's g Statistics	-0.094	-0.186	
95% CI	(-0.64, 0.45)	(-0.72, 0.34)	
Week 52			
m	42	44	94
n	14	18	29
Baseline Mean (SD)	85.94 (19.44)	83.32 (19.70)	77.46 (23.35)
Analysis Visit Mean (SD)	89.52 (12.52)	83.88 (22.68)	76.58 (27.45)
LS Mean of Change from Baseline (SE)	3.23 (4.47)	2.95 (4.01)	-2.66 (3.25)
95% CI	(-5.66, 12.12)	(-5.05, 10.94)	(-9.12, 3.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.89 (5.57)	5.61 (5.16)	
95% CI	(-5.19, 16.98)	(-4.67, 15.88)	
p-value	0.2932	0.2806	
Corrected Hedge's g Statistics	0.336	0.319	
95% CI	(-0.31, 0.98)	(-0.27, 0.91)	
Subgroup*Treatment Interaction p-value	0.6910	0.5284	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Sleep			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	61.40 (24.01)	59.56 (19.62)	63.88 (19.90)
Analysis Visit Mean (SD)	63.84 (23.37)	58.89 (22.66)	65.12 (19.58)
LS Mean of Change from Baseline (SE)	2.18 (2.22)	-1.79 (2.18)	1.16 (1.58)
95% CI	(-2.21, 6.56)	(-6.09, 2.52)	(-1.95, 4.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.01 (2.72)	-2.95 (2.68)	
95% CI	(-4.36, 6.38)	(-8.24, 2.34)	
p-value	0.7106	0.2724	
Corrected Hedge's g Statistics	0.069	-0.200	
95% CI	(-0.30, 0.43)	(-0.56, 0.16)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	61.22 (24.02)	60.66 (19.97)	62.52 (20.60)
Analysis Visit Mean (SD)	63.24 (19.90)	60.92 (22.81)	65.00 (22.05)
LS Mean of Change from Baseline (SE)	1.66 (2.55)	-0.37 (2.51)	1.79 (1.78)
95% CI	(-3.37, 6.68)	(-5.33, 4.58)	(-1.72, 5.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (3.11)	-2.16 (3.06)	
95% CI	(-6.26, 6.00)	(-8.21, 3.88)	
p-value	0.9659	0.4810	
Corrected Hedge's g Statistics	-0.008	-0.138	
95% CI	(-0.40, 0.38)	(-0.53, 0.25)	
Subgroup*Treatment Interaction p-value	0.7607	0.9212	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Loneliness			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	83.72 (20.24)	79.78 (19.42)	86.19 (18.06)
Analysis Visit Mean (SD)	82.38 (22.41)	80.11 (23.42)	84.53 (19.53)
LS Mean of Change from Baseline (SE)	-1.31 (2.10)	0.04 (2.07)	-1.29 (1.50)
95% CI	(-5.45, 2.84)	(-4.05, 4.12)	(-4.24, 1.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (2.57)	1.33 (2.55)	
95% CI	(-5.09, 5.06)	(-3.70, 6.36)	
p-value	0.9953	0.6034	
Corrected Hedge's g Statistics	-0.001	0.095	
95% CI	(-0.37, 0.36)	(-0.27, 0.46)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	83.92 (20.52)	79.21 (20.22)	84.90 (19.24)
Analysis Visit Mean (SD)	82.70 (18.73)	79.61 (25.56)	83.44 (17.96)
LS Mean of Change from Baseline (SE)	-1.27 (2.47)	-0.93 (2.45)	-1.73 (1.73)
95% CI	(-6.14, 3.60)	(-5.76, 3.90)	(-5.14, 1.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.46 (3.01)	0.81 (2.99)	
95% CI	(-5.47, 6.40)	(-5.09, 6.71)	
p-value	0.8774	0.7873	
Corrected Hedge's g Statistics	0.031	0.053	
95% CI	(-0.36, 0.42)	(-0.34, 0.44)	
Subgroup*Treatment Interaction p-value	0.8498	0.7579	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Hopelessness			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	77.33 (23.81)	72.40 (22.67)	82.27 (22.54)
Analysis Visit Mean (SD)	78.68 (22.60)	75.74 (24.16)	81.11 (20.98)
LS Mean of Change from Baseline (SE)	0.94 (2.46)	1.03 (2.43)	-0.39 (1.76)
95% CI	(-3.92, 5.80)	(-3.77, 5.83)	(-3.86, 3.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.33 (3.02)	1.42 (3.00)	
95% CI	(-4.64, 7.30)	(-4.51, 7.35)	
p-value	0.6602	0.6372	
Corrected Hedge's g Statistics	0.081	0.087	
95% CI	(-0.28, 0.45)	(-0.27, 0.45)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	79.96 (21.74)	71.71 (23.85)	80.52 (24.09)
Analysis Visit Mean (SD)	80.86 (18.72)	79.39 (20.84)	79.32 (20.49)
LS Mean of Change from Baseline (SE)	2.27 (2.47)	4.41 (2.45)	-0.64 (1.73)
95% CI	(-2.60, 7.14)	(-0.43, 9.25)	(-4.05, 2.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.91 (3.01)	5.05 (3.00)	
95% CI	(-3.03, 8.85)	(-0.87, 10.97)	
p-value	0.3350	0.0940	
Corrected Hedge's g Statistics	0.191	0.331	
95% CI	(-0.20, 0.58)	(-0.06, 0.72)	
Subgroup*Treatment Interaction p-value	0.9345	0.3641	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Stigma of Liver Disease			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	80.54 (24.29)	79.46 (21.38)	85.27 (16.95)
Analysis Visit Mean (SD)	85.48 (19.47)	80.57 (20.82)	87.08 (17.40)
LS Mean of Change from Baseline (SE)	4.29 (2.03)	0.09 (2.00)	2.67 (1.45)
95% CI	(0.27, 8.30)	(-3.85, 4.03)	(-0.18, 5.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.62 (2.50)	-2.58 (2.46)	
95% CI	(-3.31, 6.54)	(-7.44, 2.28)	
p-value	0.5181	0.2957	
Corrected Hedge's g Statistics	0.120	-0.191	
95% CI	(-0.25, 0.49)	(-0.55, 0.17)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	80.93 (24.96)	80.12 (21.88)	84.27 (16.58)
Analysis Visit Mean (SD)	85.83 (19.57)	86.32 (16.87)	85.25 (19.36)
LS Mean of Change from Baseline (SE)	3.76 (2.06)	5.03 (2.03)	1.36 (1.44)
95% CI	(-0.29, 7.82)	(1.02, 9.04)	(-1.48, 4.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.40 (2.51)	3.67 (2.48)	
95% CI	(-2.56, 7.36)	(-1.23, 8.57)	
p-value	0.3402	0.1412	
Corrected Hedge's g Statistics	0.189	0.289	
95% CI	(-0.20, 0.58)	(-0.10, 0.68)	
Subgroup*Treatment Interaction p-value	0.9101	0.5269	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.4)	1 (1.0)	8 (4.0)
No	114 (96.6)	99 (99.0)	193 (96.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	4.10	
95% CI of the inverse odds ratio	(0.35, 4.01)	(0.51, 33.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	3.98	
95% CI of the inverse risk ratio	(0.36, 3.82)	(0.50, 31.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.59	-2.98	
95% CI of the absolute risk difference	(-4.83, 3.65)	(-6.31, 0.35)	
p-value	0.7891	0.1528	
p-value of Breslow-Day Test for Homogeneity [3]	0.4327	0.0496	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (23.7)	19 (19.0)	39 (19.4)
No	90 (76.3)	81 (81.0)	162 (80.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.03	
95% CI of the inverse odds ratio	(0.45, 1.34)	(0.56, 1.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.02	
95% CI of the inverse risk ratio	(0.53, 1.26)	(0.62, 1.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.33	-0.40	
95% CI of the absolute risk difference	(-5.10, 13.75)	(-9.84, 9.03)	
p-value	0.3598	0.9335	
p-value of Breslow-Day Test for Homogeneity [3]	0.7827	0.4051	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.4)	11 (11.0)	13 (6.5)
No	114 (96.6)	89 (89.0)	188 (93.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.97	0.56	
95% CI of the inverse odds ratio	(0.63, 6.19)	(0.24, 1.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.91	0.59	
95% CI of the inverse risk ratio	(0.64, 5.72)	(0.27, 1.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.08	4.53	
95% CI of the absolute risk difference	(-7.79, 1.64)	(-2.48, 11.54)	
p-value	0.2374	0.1715	
p-value of Breslow-Day Test for Homogeneity [3]	0.5667	0.2091	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (22.0)	27 (27.0)	47 (23.4)
No	92 (78.0)	73 (73.0)	154 (76.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.83	
95% CI of the inverse odds ratio	(0.63, 1.86)	(0.48, 1.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.87	
95% CI of the inverse risk ratio	(0.70, 1.62)	(0.58, 1.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.35	3.62	
95% CI of the absolute risk difference	(-10.84, 8.15)	(-6.87, 14.10)	
p-value	0.7818	0.4924	
p-value of Breslow-Day Test for Homogeneity [3]	0.4130	0.3057	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.2)	7 (7.0)	17 (8.5)
No	113 (95.8)	93 (93.0)	184 (91.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.09	1.23	
95% CI of the inverse odds ratio	(0.75, 5.82)	(0.49, 3.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	1.21	
95% CI of the inverse risk ratio	(0.76, 5.27)	(0.52, 2.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.22	-1.46	
95% CI of the absolute risk difference	(-9.51, 1.07)	(-7.77, 4.85)	
p-value	0.1510	0.6601	
p-value of Breslow-Day Test for Homogeneity [3]	0.1473	0.7802	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (16.1)	19 (19.0)	36 (17.9)
No	99 (83.9)	81 (81.0)	165 (82.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	0.93	
95% CI of the inverse odds ratio	(0.62, 2.09)	(0.50, 1.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.94	
95% CI of the inverse risk ratio	(0.67, 1.85)	(0.57, 1.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.81	1.09	
95% CI of the absolute risk difference	(-10.30, 6.68)	(-8.25, 10.43)	
p-value	0.6797	0.8178	
p-value of Breslow-Day Test for Homogeneity [3]	0.6205	0.4810	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (9.3)	8 (8.0)	16 (8.0)
No	107 (90.7)	92 (92.0)	185 (92.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.99	
95% CI of the inverse odds ratio	(0.38, 1.88)	(0.41, 2.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.00	
95% CI of the inverse risk ratio	(0.41, 1.78)	(0.44, 2.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.36	0.04	
95% CI of the absolute risk difference	(-5.08, 7.81)	(-6.46, 6.54)	
p-value	0.6731	0.9904	
p-value of Breslow-Day Test for Homogeneity [3]	0.4667	0.5497	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (22.0)	22 (22.0)	46 (22.9)
No	92 (78.0)	78 (78.0)	155 (77.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.05	
95% CI of the inverse odds ratio	(0.61, 1.81)	(0.59, 1.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.04	
95% CI of the inverse risk ratio	(0.68, 1.59)	(0.66, 1.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.85	-0.89	
95% CI of the absolute risk difference	(-10.32, 8.62)	(-10.87, 9.10)	
p-value	0.8606	0.8626	
p-value of Breslow-Day Test for Homogeneity [3]	0.7525	0.3854	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (15.3)	14 (14.0)	32 (15.9)
No	100 (84.7)	86 (86.0)	169 (84.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.16	
95% CI of the inverse odds ratio	(0.56, 1.97)	(0.59, 2.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.14	
95% CI of the inverse risk ratio	(0.61, 1.77)	(0.64, 2.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.67	-1.92	
95% CI of the absolute risk difference	(-8.89, 7.56)	(-10.40, 6.56)	
p-value	0.8745	0.6627	
p-value of Breslow-Day Test for Homogeneity [3]	0.2739	0.1093	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (22.9)	19 (19.0)	48 (23.9)
No	91 (77.1)	81 (81.0)	153 (76.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.34	
95% CI of the inverse odds ratio	(0.62, 1.81)	(0.74, 2.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.26	
95% CI of the inverse risk ratio	(0.69, 1.58)	(0.78, 2.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.00	-4.88	
95% CI of the absolute risk difference	(-10.60, 8.60)	(-14.57, 4.81)	
p-value	0.8390	0.3377	
p-value of Breslow-Day Test for Homogeneity [3]	0.5767	0.0860	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.2)	4 (4.0)	8 (4.0)
No	113 (95.8)	96 (96.0)	193 (96.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.99	
95% CI of the inverse odds ratio	(0.30, 2.93)	(0.29, 3.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.00	
95% CI of the inverse risk ratio	(0.31, 2.80)	(0.31, 3.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.26	0.02	
95% CI of the absolute risk difference	(-4.27, 4.79)	(-4.68, 4.72)	
p-value	0.9107	0.9934	
p-value of Breslow-Day Test for Homogeneity [3]	0.4289	0.8216	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (6.8)	9 (9.0)	16 (8.0)
No	110 (93.2)	91 (91.0)	185 (92.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	0.87	
95% CI of the inverse odds ratio	(0.49, 2.87)	(0.37, 2.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.88	
95% CI of the inverse risk ratio	(0.52, 2.66)	(0.41, 1.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.18	1.04	
95% CI of the absolute risk difference	(-7.06, 4.70)	(-5.70, 7.78)	
p-value	0.6996	0.7582	
p-value of Breslow-Day Test for Homogeneity [3]	0.6511	0.7307	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (13.6)	13 (13.0)	27 (13.4)
No	102 (86.4)	87 (87.0)	174 (86.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.04	
95% CI of the inverse odds ratio	(0.51, 1.92)	(0.51, 2.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.03	
95% CI of the inverse risk ratio	(0.56, 1.76)	(0.56, 1.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.13	-0.43	
95% CI of the absolute risk difference	(-7.64, 7.90)	(-8.54, 7.67)	
p-value	0.9745	0.9170	
p-value of Breslow-Day Test for Homogeneity [3]	0.7844	0.4496	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (27.1)	28 (28.0)	57 (28.4)
No	86 (72.9)	72 (72.0)	144 (71.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.02	
95% CI of the inverse odds ratio	(0.64, 1.77)	(0.60, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.01	
95% CI of the inverse risk ratio	(0.72, 1.51)	(0.69, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.24	-0.36	
95% CI of the absolute risk difference	(-11.40, 8.92)	(-11.14, 10.42)	
p-value	0.8116	0.9482	
p-value of Breslow-Day Test for Homogeneity [3]	0.7663	0.5989	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (12.7)	14 (14.0)	24 (11.9)
No	103 (87.3)	86 (86.0)	177 (88.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.83	
95% CI of the inverse odds ratio	(0.47, 1.86)	(0.41, 1.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.85	
95% CI of the inverse risk ratio	(0.51, 1.72)	(0.46, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.77	2.06	
95% CI of the absolute risk difference	(-6.73, 8.27)	(-6.09, 10.21)	
p-value	0.8391	0.6123	
p-value of Breslow-Day Test for Homogeneity [3]	0.8963	0.2246	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (28.0)	26 (26.0)	58 (28.9)
No	85 (72.0)	74 (74.0)	143 (71.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.15	
95% CI of the inverse odds ratio	(0.63, 1.73)	(0.67, 1.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.11	
95% CI of the inverse risk ratio	(0.72, 1.48)	(0.75, 1.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.89	-2.86	
95% CI of the absolute risk difference	(-11.13, 9.35)	(-13.49, 7.78)	
p-value	0.8651	0.6029	
p-value of Breslow-Day Test for Homogeneity [3]	0.3679	0.6845	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	22 (18.6)	20 (20.0)	25 (12.4)
No	96 (81.4)	80 (80.0)	176 (87.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.57	
95% CI of the inverse odds ratio	(0.33, 1.16)	(0.30, 1.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.62	
95% CI of the inverse risk ratio	(0.39, 1.13)	(0.36, 1.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.21	7.56	
95% CI of the absolute risk difference	(-2.17, 14.58)	(-1.51, 16.63)	
p-value	0.1311	0.0831	
p-value of Breslow-Day Test for Homogeneity [3]	0.6055	0.7849	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	36 (30.5)	26 (26.0)	48 (23.9)
No	82 (69.5)	74 (74.0)	153 (76.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.89	
95% CI of the inverse odds ratio	(0.43, 1.19)	(0.51, 1.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.92	
95% CI of the inverse risk ratio	(0.54, 1.13)	(0.61, 1.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.63	2.12	
95% CI of the absolute risk difference	(-3.56, 16.81)	(-8.30, 12.54)	
p-value	0.1944	0.6875	
p-value of Breslow-Day Test for Homogeneity [3]	0.7245	0.2254	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (11.9)	10 (10.0)	23 (11.4)
No	104 (88.1)	90 (90.0)	178 (88.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.16	
95% CI of the inverse odds ratio	(0.47, 1.95)	(0.53, 2.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.14	
95% CI of the inverse risk ratio	(0.52, 1.80)	(0.57, 2.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.42	-1.44	
95% CI of the absolute risk difference	(-6.89, 7.73)	(-8.79, 5.90)	
p-value	0.9096	0.7059	
p-value of Breslow-Day Test for Homogeneity [3]	0.7503	0.2855	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	37 (31.4)	26 (26.0)	54 (26.9)
No	81 (68.6)	74 (74.0)	147 (73.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.05	
95% CI of the inverse odds ratio	(0.49, 1.32)	(0.61, 1.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.03	
95% CI of the inverse risk ratio	(0.60, 1.22)	(0.69, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.49	-0.87	
95% CI of the absolute risk difference	(-5.88, 14.86)	(-11.42, 9.69)	
p-value	0.3912	0.8728	
p-value of Breslow-Day Test for Homogeneity [3]	0.9747	0.4217	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.1)	3 (5.9)	2 (2.0)
No	47 (95.9)	48 (94.1)	100 (98.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	0.32	
95% CI of the inverse odds ratio	(0.06, 3.44)	(0.05, 1.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	0.33	
95% CI of the inverse risk ratio	(0.07, 3.31)	(0.06, 1.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.12	3.92	
95% CI of the absolute risk difference	(-4.04, 8.28)	(-3.07, 10.92)	
p-value	0.4474	0.1984	
p-value of Breslow-Day Test for Homogeneity [3]	0.4327	0.0496	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (20.4)	13 (25.5)	19 (18.6)
No	39 (79.6)	38 (74.5)	83 (81.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.67	
95% CI of the inverse odds ratio	(0.38, 2.10)	(0.30, 1.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.73	
95% CI of the inverse risk ratio	(0.46, 1.81)	(0.39, 1.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.78	6.86	
95% CI of the absolute risk difference	(-11.80, 15.36)	(-7.28, 21.01)	
p-value	0.7948	0.3252	
p-value of Breslow-Day Test for Homogeneity [3]	0.7827	0.4051	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.1)	5 (9.8)	13 (12.7)
No	47 (95.9)	46 (90.2)	89 (87.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.43	1.34	
95% CI of the inverse odds ratio	(0.74, 15.85)	(0.45, 4.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.12	1.30	
95% CI of the inverse risk ratio	(0.73, 13.30)	(0.49, 3.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.66	-2.94	
95% CI of the absolute risk difference	(-17.18, -0.14)	(-13.36, 7.47)	
p-value	0.0956	0.5945	
p-value of Breslow-Day Test for Homogeneity [3]	0.5667	0.2091	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (20.4)	12 (23.5)	30 (29.4)
No	39 (79.6)	39 (76.5)	72 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.63	1.35	
95% CI of the inverse odds ratio	(0.72, 3.67)	(0.62, 2.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.25	
95% CI of the inverse risk ratio	(0.77, 2.70)	(0.70, 2.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.00	-5.88	
95% CI of the absolute risk difference	(-23.34, 5.33)	(-20.50, 8.74)	
p-value	0.2405	0.4421	
p-value of Breslow-Day Test for Homogeneity [3]	0.4130	0.3057	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	3 (5.9)	9 (8.8)
No	49 (100)	48 (94.1)	93 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	10.06	1.55	
95% CI of the inverse odds ratio	(0.57, 176.45)	(0.40, 5.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	9.22	1.50	
95% CI of the inverse risk ratio	(0.55, 155.31)	(0.42, 5.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.22	-2.94	
95% CI of the absolute risk difference	(-14.45, -1.99)	(-11.43, 5.54)	
p-value	0.0536	0.5235	
p-value of Breslow-Day Test for Homogeneity [3]	0.1473	0.7802	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (16.3)	9 (17.6)	23 (22.5)
No	41 (83.7)	42 (82.4)	79 (77.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.49	1.36	
95% CI of the inverse odds ratio	(0.61, 3.63)	(0.58, 3.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	1.28	
95% CI of the inverse risk ratio	(0.67, 2.86)	(0.64, 2.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.22	-4.90	
95% CI of the absolute risk difference	(-19.37, 6.93)	(-18.14, 8.34)	
p-value	0.3755	0.4822	
p-value of Breslow-Day Test for Homogeneity [3]	0.6205	0.4810	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (8.2)	1 (2.0)	4 (3.9)
No	45 (91.8)	50 (98.0)	98 (96.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.46	2.04	
95% CI of the inverse odds ratio	(0.11, 1.92)	(0.22, 18.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	2.00	
95% CI of the inverse risk ratio	(0.13, 1.84)	(0.23, 17.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.24	-1.96	
95% CI of the absolute risk difference	(-4.30, 12.78)	(-7.32, 3.39)	
p-value	0.2759	0.5202	
p-value of Breslow-Day Test for Homogeneity [3]	0.4667	0.5497	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (22.4)	14 (27.5)	21 (20.6)
No	38 (77.6)	37 (72.5)	81 (79.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	0.69	
95% CI of the inverse odds ratio	(0.39, 2.04)	(0.31, 1.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.75	
95% CI of the inverse risk ratio	(0.48, 1.75)	(0.42, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.86	6.86	
95% CI of the absolute risk difference	(-12.21, 15.93)	(-7.68, 21.41)	
p-value	0.7934	0.3407	
p-value of Breslow-Day Test for Homogeneity [3]	0.7525	0.3854	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (20.4)	12 (23.5)	13 (12.7)
No	39 (79.6)	39 (76.5)	89 (87.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	0.47	
95% CI of the inverse odds ratio	(0.23, 1.41)	(0.20, 1.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.54	
95% CI of the inverse risk ratio	(0.29, 1.32)	(0.27, 1.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.66	10.78	
95% CI of the absolute risk difference	(-5.35, 20.67)	(-2.54, 24.10)	
p-value	0.2198	0.0890	
p-value of Breslow-Day Test for Homogeneity [3]	0.2739	0.1093	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (26.5)	17 (33.3)	23 (22.5)
No	36 (73.5)	34 (66.7)	79 (77.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.58	
95% CI of the inverse odds ratio	(0.37, 1.77)	(0.28, 1.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.68	
95% CI of the inverse risk ratio	(0.47, 1.53)	(0.40, 1.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.98	10.78	
95% CI of the absolute risk difference	(-10.80, 18.77)	(-4.49, 26.05)	
p-value	0.5909	0.1524	
p-value of Breslow-Day Test for Homogeneity [3]	0.5767	0.0860	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.0)	2 (3.9)	5 (4.9)
No	48 (98.0)	49 (96.1)	97 (95.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.47	1.26	
95% CI of the inverse odds ratio	(0.28, 21.77)	(0.24, 6.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.40	1.25	
95% CI of the inverse risk ratio	(0.29, 20.01)	(0.25, 6.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.86	-0.98	
95% CI of the absolute risk difference	(-8.63, 2.90)	(-7.76, 5.80)	
p-value	0.3994	0.7844	
p-value of Breslow-Day Test for Homogeneity [3]	0.4289	0.8216	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (10.2)	4 (7.8)	9 (8.8)
No	44 (89.8)	47 (92.2)	93 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.14	
95% CI of the inverse odds ratio	(0.27, 2.69)	(0.33, 3.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.13	
95% CI of the inverse risk ratio	(0.31, 2.44)	(0.36, 3.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.38	-0.98	
95% CI of the absolute risk difference	(-8.73, 11.49)	(-10.19, 8.23)	
p-value	0.7842	0.8376	
p-value of Breslow-Day Test for Homogeneity [3]	0.6511	0.7307	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (18.4)	7 (13.7)	21 (20.6)
No	40 (81.6)	44 (86.3)	81 (79.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.63	
95% CI of the inverse odds ratio	(0.48, 2.74)	(0.64, 4.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	1.50	
95% CI of the inverse risk ratio	(0.56, 2.26)	(0.68, 3.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.22	-6.86	
95% CI of the absolute risk difference	(-15.60, 11.16)	(-19.14, 5.42)	
p-value	0.7488	0.3007	
p-value of Breslow-Day Test for Homogeneity [3]	0.7844	0.4496	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (34.7)	17 (33.3)	40 (39.2)
No	32 (65.3)	34 (66.7)	62 (60.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.29	
95% CI of the inverse odds ratio	(0.60, 2.47)	(0.64, 2.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	1.18	
95% CI of the inverse risk ratio	(0.72, 1.78)	(0.74, 1.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.52	-5.88	
95% CI of the absolute risk difference	(-20.87, 11.83)	(-21.92, 10.15)	
p-value	0.5915	0.4781	
p-value of Breslow-Day Test for Homogeneity [3]	0.7663	0.5989	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (10.2)	10 (19.6)	9 (8.8)
No	44 (89.8)	41 (80.4)	93 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.40	
95% CI of the inverse odds ratio	(0.27, 2.69)	(0.15, 1.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.45	
95% CI of the inverse risk ratio	(0.31, 2.44)	(0.20, 1.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.38	10.78	
95% CI of the absolute risk difference	(-8.73, 11.49)	(-1.42, 22.99)	
p-value	0.7842	0.0566	
p-value of Breslow-Day Test for Homogeneity [3]	0.8963	0.2246	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (16.3)	13 (25.5)	25 (24.5)
No	41 (83.7)	38 (74.5)	77 (75.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.66	0.95	
95% CI of the inverse odds ratio	(0.69, 4.02)	(0.44, 2.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	0.96	
95% CI of the inverse risk ratio	(0.73, 3.08)	(0.54, 1.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.18	0.98	
95% CI of the absolute risk difference	(-21.48, 5.11)	(-13.61, 15.57)	
p-value	0.2546	0.8947	
p-value of Breslow-Day Test for Homogeneity [3]	0.3679	0.6845	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (18.4)	14 (27.5)	16 (15.7)
No	40 (81.6)	37 (72.5)	86 (84.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.49	
95% CI of the inverse odds ratio	(0.34, 2.03)	(0.22, 1.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.57	
95% CI of the inverse risk ratio	(0.41, 1.79)	(0.30, 1.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.68	11.76	
95% CI of the absolute risk difference	(-10.26, 15.62)	(-2.37, 25.90)	
p-value	0.6781	0.0840	
p-value of Breslow-Day Test for Homogeneity [3]	0.6055	0.7849	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (24.5)	18 (35.3)	22 (21.6)
No	37 (75.5)	33 (64.7)	80 (78.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.50	
95% CI of the inverse odds ratio	(0.38, 1.89)	(0.24, 1.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.61	
95% CI of the inverse risk ratio	(0.48, 1.63)	(0.36, 1.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.92	13.73	
95% CI of the absolute risk difference	(-11.52, 17.37)	(-1.63, 29.08)	
p-value	0.6874	0.0686	
p-value of Breslow-Day Test for Homogeneity [3]	0.7245	0.2254	

AMNOG Table SE21.7.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (12.2)	8 (15.7)	10 (9.8)
No	43 (87.8)	43 (84.3)	92 (90.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.58	
95% CI of the inverse odds ratio	(0.27, 2.28)	(0.22, 1.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.63	
95% CI of the inverse risk ratio	(0.31, 2.08)	(0.26, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.44	5.88	
95% CI of the absolute risk difference	(-8.40, 13.28)	(-5.65, 17.41)	
p-value	0.6482	0.2871	
p-value of Breslow-Day Test for Homogeneity [3]	0.7503	0.2855	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (30.6)	17 (33.3)	27 (26.5)
No	34 (69.4)	34 (66.7)	75 (73.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.72	
95% CI of the inverse odds ratio	(0.39, 1.73)	(0.35, 1.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.79	
95% CI of the inverse risk ratio	(0.51, 1.47)	(0.48, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.14	6.86	
95% CI of the absolute risk difference	(-11.34, 19.63)	(-8.65, 22.38)	
p-value	0.5949	0.3767	
p-value of Breslow-Day Test for Homogeneity [3]	0.9747	0.4217	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Total LDQOL						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	76.50 (16.06)	75.09 (16.95)	77.45 (14.53)			
Median	82.90	80.40	82.50			
IQR: Q1, Q3	68.45, 87.80	66.00, 85.80	68.80, 87.70			
Min, Max	29.0, 96.5	23.6, 96.3	38.2, 96.1			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	77.97 (16.80)	75.49 (13.53)	78.66 (15.45)	1.04 (1.22)	0.02 (1.46)	0.47 (1.06)
Median	83.20	76.15	83.40	1.20	-1.20	0.35
IQR: Q1, Q3	71.40, 90.40	68.30, 86.00	72.80, 89.25	-5.70, 6.60	-6.90, 5.60	-3.75, 4.60
Min, Max	22.9, 96.9	32.4, 96.9	22.4, 98.8	-18.3, 35.6	-14.5, 27.0	-46.4, 29.4
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	77.46 (14.50)	77.29 (16.13)	77.93 (15.24)	-0.45 (1.22)	0.73 (1.87)	-0.29 (0.95)
Median	81.50	82.40	81.40	-0.50	0.15	-0.10
IQR: Q1, Q3	69.40, 89.00	68.40, 90.90	71.50, 88.60	-4.50, 3.00	-6.10, 6.85	-5.20, 4.20
Min, Max	34.0, 96.9	34.2, 95.7	34.3, 100.0	-19.5, 36.0	-19.2, 33.9	-23.2, 23.8

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Symptoms of Liver Disease						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	75.44 (19.67)	74.83 (18.91)	75.65 (18.47)			
Median	81.65	73.30	80.00			
IQR: Q1, Q3	60.00, 91.65	63.30, 90.00	63.30, 93.30			
Min, Max	23.3, 100.0	30.0, 100.0	23.3, 100.0			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	74.37 (21.54)	74.30 (19.00)	77.95 (19.47)	-1.32 (2.11)	-1.17 (1.89)	0.91 (1.38)
Median	83.30	76.70	83.30	0	0	0
IQR: Q1, Q3	63.30, 90.00	60.00, 88.35	65.00, 93.30	-10.00, 10.00	-10.00, 6.70	-6.65, 6.70
Min, Max	0.0, 100.0	30.0, 100.0	30.0, 100.0	-46.7, 33.4	-33.3, 30.0	-30.0, 43.3
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	73.66 (20.49)	76.67 (20.01)	76.94 (19.14)	-3.67 (1.78)	-0.74 (2.79)	0.38 (1.53)
Median	80.00	80.00	83.30	-3.30	0	0
IQR: Q1, Q3	60.00, 90.00	66.70, 93.30	66.70, 93.30	-10.00, 6.60	-16.60, 8.35	-6.70, 6.70
Min, Max	23.3, 100.0	26.7, 100.0	23.3, 100.0	-36.7, 16.7	-36.7, 36.7	-30.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Effects of Liver Disease						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	77.12 (14.28)	78.87 (18.62)	77.39 (17.30)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 83.35	80.00, 86.70	80.00, 86.70			
Min, Max	13.3, 100.0	13.3, 100.0	6.7, 100.0			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	75.74 (14.96)	80.49 (9.83)	76.18 (18.55)	-1.73 (1.89)	0.85 (2.91)	-1.67 (1.53)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 86.70	80.00, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 0.00
Min, Max	20.0, 100.0	40.0, 100.0	6.7, 100.0	-40.0, 33.3	-26.7, 76.7	-46.6, 40.0
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	75.36 (12.94)	77.95 (11.36)	77.41 (15.71)	-3.07 (2.33)	-0.37 (2.59)	-0.94 (2.19)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 0.00	-6.70, 0.00	-6.70, 6.60
Min, Max	40.0, 93.3	33.3, 100.0	20.0, 100.0	-40.0, 80.0	-33.3, 53.4	-80.0, 53.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Concentration/Memory						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	79.81 (24.95)	77.94 (21.95)	77.22 (21.37)			
Median	87.50	81.30	81.30			
IQR: Q1, Q3	71.90, 100.00	68.80, 93.80	62.50, 93.80			
Min, Max	12.5, 100.0	18.8, 100.0	6.3, 100.0			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	78.40 (23.65)	79.45 (20.01)	80.29 (22.10)	-1.18 (2.06)	0.00 (2.84)	1.99 (1.70)
Median	87.50	81.30	87.50	0	0	0
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	68.80, 100.00	-6.30, 6.30	-6.30, 6.30	-6.20, 9.40
Min, Max	18.8, 100.0	25.0, 100.0	6.3, 100.0	-43.8, 25.0	-37.5, 56.2	-43.8, 62.5
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	77.23 (23.11)	77.58 (22.83)	77.37 (23.40)	-2.54 (1.84)	-4.51 (2.88)	-1.19 (1.45)
Median	87.50	87.50	81.30	0	0	0
IQR: Q1, Q3	62.50, 93.80	62.50, 100.00	62.50, 100.00	-6.30, 0.00	-15.60, 3.10	-6.30, 6.20
Min, Max	0.0, 100.0	18.8, 100.0	0.0, 100.0	-43.7, 31.3	-43.8, 50.0	-43.7, 43.8

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Health Distress						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	74.38 (29.60)	79.26 (26.87)	80.27 (25.15)			
Median	87.50	87.50	87.50			
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	81.35 (25.68)	85.68 (21.57)	85.68 (24.06)	6.25 (2.84)	6.40 (2.83)	5.26 (2.00)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-37.5, 75.0	-37.5, 50.0	-62.5, 62.5
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	78.92 (27.10)	85.90 (22.61)	86.32 (21.87)	3.57 (3.59)	6.94 (3.13)	3.96 (2.47)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	12.5, 100.0	-75.0, 75.0	-37.5, 50.0	-62.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Sexual Function						
Baseline						
m	64	53	111			
n	31	25	41			
Mean (SD)	85.96 (19.55)	83.94 (18.58)	79.83 (26.19)			
Median	93.30	93.30	91.70			
IQR: Q1, Q3	76.70, 100.00	68.30, 100.00	68.30, 100.00			
Min, Max	30.0, 100.0	38.3, 100.0	6.7, 100.0			
Week 24						
m	63	51	103			
n	34	31	44	26	22	33
Mean (SD/SE)	83.19 (23.36)	72.47 (30.27)	82.01 (20.75)	-2.94 (4.27)	-4.69 (4.61)	2.03 (4.07)
Median	93.30	85.00	91.70	0	0	0
IQR: Q1, Q3	76.70, 100.00	46.70, 100.00	69.15, 100.00	-8.30, 1.70	-16.60, 0.00	-6.70, 16.70
Min, Max	6.7, 100.0	13.3, 100.0	30.0, 100.0	-85.0, 31.7	-40.0, 46.7	-46.7, 50.0
Week 52						
m	56	44	94			
n	24	21	36	21	17	27
Mean (SD/SE)	84.78 (21.69)	79.12 (27.56)	80.97 (22.95)	-3.57 (2.69)	-3.42 (6.02)	1.56 (3.98)
Median	93.30	91.70	90.00	0	0	0
IQR: Q1, Q3	76.70, 100.00	68.30, 100.00	73.35, 100.00	-6.70, 0.00	-21.70, 6.70	-6.60, 6.70
Min, Max	28.3, 100.0	5.0, 100.0	21.7, 100.0	-45.0, 13.4	-48.3, 61.7	-46.6, 65.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Sleep						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	61.17 (22.97)	58.62 (18.47)	62.06 (20.51)			
Median	60.00	60.00	60.00			
IQR: Q1, Q3	50.00, 80.00	50.00, 75.00	50.00, 75.00			
Min, Max	0.0, 100.0	5.0, 90.0	5.0, 100.0			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	64.02 (22.54)	56.04 (18.30)	62.08 (20.43)	0.95 (2.63)	-2.09 (2.29)	-1.36 (1.69)
Median	65.00	60.00	60.00	0	-5.00	0
IQR: Q1, Q3	50.00, 80.00	40.00, 70.00	50.00, 75.00	-10.00, 5.00	-10.00, 10.00	-10.00, 5.00
Min, Max	5.0, 100.0	0.0, 95.0	15.0, 100.0	-30.0, 90.0	-35.0, 30.0	-35.0, 45.0
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	61.27 (17.80)	56.92 (21.60)	60.53 (21.24)	-3.57 (2.32)	-2.22 (3.31)	-2.03 (1.84)
Median	65.00	60.00	60.00	-5.00	0	0
IQR: Q1, Q3	50.00, 75.00	40.00, 70.00	45.00, 80.00	-15.00, 0.00	-12.50, 7.50	-10.00, 10.00
Min, Max	15.0, 95.0	0.0, 90.0	5.0, 100.0	-40.0, 40.0	-60.0, 40.0	-40.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Loneliness						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	85.92 (16.17)	79.15 (24.48)	83.85 (19.92)			
Median	95.00	90.00	90.00			
IQR: Q1, Q3	75.00, 100.00	65.00, 100.00	75.00, 100.00			
Min, Max	40.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	83.85 (19.54)	81.15 (22.06)	82.55 (20.71)	-1.29 (2.16)	1.40 (2.51)	-2.64 (1.68)
Median	90.00	90.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	65.00, 100.00	75.00, 100.00	-10.00, 5.00	-5.00, 5.00	-10.00, 5.00
Min, Max	15.0, 100.0	0.0, 100.0	15.0, 100.0	-50.0, 40.0	-35.0, 65.0	-80.0, 35.0
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	84.41 (18.96)	82.05 (25.33)	81.94 (20.21)	-2.86 (2.37)	2.08 (2.34)	-2.94 (1.62)
Median	90.00	90.00	90.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	75.00, 100.00	70.00, 100.00	-10.00, 0.00	-7.50, 15.00	-15.00, 5.00
Min, Max	25.0, 100.0	0.0, 100.0	30.0, 100.0	-60.0, 40.0	-25.0, 30.0	-40.0, 35.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Hopelessness						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	75.70 (24.99)	74.46 (22.89)	79.33 (21.20)			
Median	79.15	75.00	83.30			
IQR: Q1, Q3	58.30, 100.00	50.00, 100.00	66.70, 100.00			
Min, Max	8.3, 100.0	25.0, 100.0	16.7, 100.0			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	77.87 (25.41)	74.83 (25.30)	79.52 (21.15)	2.58 (2.11)	-0.19 (3.02)	-0.56 (2.21)
Median	91.70	79.15	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	66.70, 100.00	0.00, 8.30	-8.30, 8.40	-8.30, 8.30
Min, Max	8.3, 100.0	8.3, 100.0	16.7, 100.0	-33.4, 50.0	-41.7, 41.7	-66.6, 50.0
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	80.39 (21.72)	78.43 (22.83)	79.32 (21.85)	3.23 (2.39)	1.64 (3.81)	-1.58 (1.93)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	66.70, 100.00	58.30, 100.00	-8.30, 8.40	-12.45, 16.70	-8.40, 8.30
Min, Max	16.7, 100.0	16.7, 100.0	25.0, 100.0	-41.7, 41.7	-58.3, 50.0	-50.0, 33.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Stigma of Liver Disease						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	79.19 (23.74)	75.55 (21.84)	83.72 (18.96)			
Median	87.50	75.00	87.50			
IQR: Q1, Q3	75.00, 100.00	62.50, 93.80	75.00, 100.00			
Min, Max	18.8, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	86.08 (21.29)	76.20 (22.05)	84.98 (18.86)	5.28 (2.61)	0.87 (2.30)	0.92 (1.81)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	65.65, 93.80	78.15, 100.00	0.00, 12.50	-6.30, 6.30	-6.20, 9.40
Min, Max	6.3, 100.0	12.5, 100.0	25.0, 100.0	-43.8, 50.0	-31.2, 56.3	-62.5, 75.0
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	86.29 (18.87)	84.00 (19.90)	84.29 (18.18)	5.74 (1.75)	6.78 (2.75)	1.50 (1.59)
Median	93.80	93.80	93.80	6.20	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	-3.10, 12.50	-6.20, 6.30
Min, Max	31.3, 100.0	12.5, 100.0	31.3, 100.0	-25.0, 37.5	-18.7, 56.3	-43.8, 43.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Total LDQOL						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	78.07 (13.27)	77.82 (13.11)	78.14 (13.63)			
Median	79.20	81.30	81.00			
IQR: Q1, Q3	70.20, 88.80	69.10, 88.30	71.90, 88.50			
Min, Max	28.3, 96.7	36.0, 95.6	34.8, 97.8			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	78.19 (13.49)	78.73 (12.05)	78.60 (13.40)	0.64 (0.88)	0.90 (0.77)	0.79 (0.75)
Median	81.85	80.70	81.50	0	0.60	0.40
IQR: Q1, Q3	69.80, 89.50	71.45, 87.10	69.80, 89.30	-4.50, 5.50	-3.70, 5.00	-3.30, 4.90
Min, Max	40.6, 97.8	41.4, 96.6	32.4, 98.3	-23.4, 24.2	-15.4, 17.7	-27.7, 42.3
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	80.17 (12.63)	78.70 (12.86)	79.36 (13.72)	2.01 (0.99)	0.60 (0.95)	0.98 (0.84)
Median	84.00	80.50	82.45	1.70	0.30	0.85
IQR: Q1, Q3	71.70, 90.20	69.90, 89.60	71.20, 89.80	-2.70, 6.40	-4.00, 5.40	-3.55, 5.85
Min, Max	44.6, 97.5	33.8, 97.4	20.3, 97.8	-19.3, 25.3	-23.3, 24.3	-46.3, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Symptoms of Liver Disease						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	78.94 (19.21)	75.02 (18.80)	77.07 (17.56)			
Median	83.30	80.00	80.00			
IQR: Q1, Q3	70.00, 93.30	63.30, 90.00	63.30, 90.00			
Min, Max	13.3, 100.0	10.0, 100.0	20.0, 100.0			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	77.61 (19.39)	74.00 (17.64)	77.01 (19.13)	-1.39 (1.29)	-0.70 (1.33)	-0.25 (1.10)
Median	83.30	76.70	83.30	0	0	0
IQR: Q1, Q3	68.35, 91.65	66.70, 86.70	66.70, 92.00	-6.70, 3.40	-6.70, 6.70	-6.60, 6.70
Min, Max	16.7, 100.0	26.7, 100.0	16.7, 100.0	-33.4, 36.7	-36.6, 30.0	-53.3, 36.7
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	79.49 (18.31)	76.49 (17.53)	78.41 (18.99)	-0.91 (1.41)	1.70 (1.38)	0.73 (1.04)
Median	83.30	80.00	83.30	0	0	3.30
IQR: Q1, Q3	70.00, 93.30	66.70, 93.30	70.00, 93.30	-6.70, 6.70	-6.60, 10.00	-5.00, 6.70
Min, Max	6.7, 100.0	30.0, 100.0	16.7, 100.0	-43.4, 43.4	-26.6, 30.0	-60.0, 26.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Effects of Liver Disease						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	77.89 (13.89)	78.39 (13.12)	77.31 (13.57)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	73.30, 86.70	73.30, 80.00			
Min, Max	6.7, 100.0	26.7, 100.0	26.7, 100.0			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	76.11 (14.66)	78.56 (10.91)	78.05 (12.50)	-1.94 (1.05)	0.32 (1.47)	0.74 (1.17)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	73.30, 80.00	73.30, 86.70	-6.70, 0.00	-6.70, 6.70	-6.70, 6.70
Min, Max	0.0, 100.0	40.0, 100.0	40.0, 100.0	-33.3, 20.0	-33.3, 60.0	-46.7, 53.4
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	77.33 (13.57)	77.82 (13.04)	77.90 (12.23)	-0.25 (1.29)	-0.59 (1.44)	0.16 (1.36)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	80.00, 80.00	-6.60, 0.00	-6.70, 6.70	-6.60, 6.60
Min, Max	6.7, 100.0	20.0, 100.0	13.3, 100.0	-40.0, 46.7	-33.3, 40.0	-73.4, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Concentration/Memory						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	80.57 (22.10)	79.42 (20.05)	79.38 (20.51)			
Median	87.50	87.50	87.50			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	68.80, 93.80			
Min, Max	6.3, 100.0	25.0, 100.0	25.0, 100.0			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	78.73 (21.90)	80.63 (19.42)	79.52 (21.48)	-1.68 (1.53)	0.67 (1.39)	-0.08 (1.26)
Median	84.40	84.40	87.50	0	0	0
IQR: Q1, Q3	65.65, 100.00	68.80, 100.00	68.80, 100.00	-6.30, 6.20	-6.30, 6.30	-6.20, 6.30
Min, Max	0.0, 100.0	25.0, 100.0	12.5, 100.0	-43.8, 31.2	-25.0, 37.5	-81.2, 56.2
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	80.17 (18.32)	80.60 (18.98)	79.97 (20.86)	0.31 (1.62)	0.26 (1.53)	-0.17 (1.24)
Median	81.30	87.50	84.40	0	0	0
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	68.80, 100.00	-6.20, 6.20	-6.30, 6.30	-6.30, 6.30
Min, Max	18.8, 100.0	37.5, 100.0	18.8, 100.0	-37.5, 50.0	-37.5, 43.7	-43.8, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Health Distress						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	80.48 (23.75)	81.87 (24.81)	81.53 (23.52)			
Median	87.50	100.00	87.50			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	84.11 (21.80)	87.50 (19.97)	85.82 (20.65)	4.84 (2.09)	6.02 (1.99)	5.12 (1.56)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	25.0, 100.0	0.0, 100.0	-50.0, 62.5	-37.5, 50.0	-50.0, 75.0
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	85.59 (21.61)	87.67 (20.39)	86.36 (20.53)	5.71 (2.55)	4.62 (2.46)	4.43 (1.84)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 75.0	-50.0, 75.0	-87.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Sexual Function						
Baseline						
m	103	98	192			
n	40	47	80			
Mean (SD)	74.55 (30.02)	77.05 (25.29)	79.48 (23.66)			
Median	90.00	85.00	85.00			
IQR: Q1, Q3	54.15, 100.00	61.70, 100.00	69.15, 100.00			
Min, Max	-1.7, 100.0	-1.7, 100.0	-1.7, 100.0			
Week 24						
m	98	90	186			
n	38	46	81	31	37	61
Mean (SD/SE)	77.55 (24.48)	75.86 (26.35)	77.42 (24.79)	5.58 (4.90)	-4.55 (3.39)	-1.02 (1.96)
Median	85.00	85.00	85.00	0	0	0
IQR: Q1, Q3	61.70, 100.00	60.00, 100.00	68.30, 100.00	-5.00, 16.70	-10.00, 1.70	-6.70, 6.70
Min, Max	23.3, 100.0	-1.7, 100.0	-1.7, 100.0	-65.0, 91.1	-55.0, 41.7	-48.4, 38.3
Week 52						
m	93	81	176			
n	29	36	65	25	30	53
Mean (SD/SE)	85.31 (21.30)	75.93 (29.72)	75.52 (27.28)	10.79 (5.42)	-2.30 (3.38)	-2.76 (2.88)
Median	93.30	93.30	85.00	0	0	0
IQR: Q1, Q3	78.30, 100.00	53.30, 100.00	60.00, 100.00	0.00, 8.40	0.00, 1.70	-8.40, 6.70
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-23.3, 91.1	-50.0, 48.3	-53.3, 63.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Sleep						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	63.93 (19.37)	60.99 (20.44)	63.14 (19.76)			
Median	67.50	65.00	65.00			
IQR: Q1, Q3	50.00, 80.00	50.00, 75.00	50.00, 80.00			
Min, Max	10.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	63.39 (19.79)	59.26 (21.32)	62.69 (20.37)	1.02 (1.32)	-1.45 (1.52)	0.26 (1.24)
Median	65.00	60.00	65.00	0	0	0
IQR: Q1, Q3	50.00, 75.00	45.00, 75.00	50.00, 80.00	-5.00, 10.00	-10.00, 5.00	-10.00, 10.00
Min, Max	10.0, 100.0	10.0, 100.0	20.0, 100.0	-30.0, 45.0	-30.0, 45.0	-40.0, 50.0
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	66.72 (20.24)	61.07 (21.03)	65.52 (20.24)	2.86 (1.83)	-0.27 (1.77)	2.44 (1.34)
Median	70.00	65.00	65.00	0	0	0
IQR: Q1, Q3	55.00, 80.00	45.00, 80.00	50.00, 80.00	-10.00, 10.00	-10.00, 10.00	-5.00, 10.00
Min, Max	10.0, 100.0	10.0, 95.0	20.0, 100.0	-25.0, 75.0	-30.0, 45.0	-40.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Loneliness						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	83.78 (18.78)	85.05 (16.86)	83.82 (19.51)			
Median	90.00	90.00	90.00			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	35.0, 100.0	10.0, 100.0			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	83.36 (18.42)	87.05 (17.25)	83.01 (20.49)	-0.62 (1.68)	0.54 (1.28)	-0.71 (1.34)
Median	90.00	95.00	90.00	0	0	0
IQR: Q1, Q3	72.50, 100.00	80.00, 100.00	75.00, 100.00	-7.50, 5.00	-5.00, 10.00	-10.00, 5.00
Min, Max	35.0, 100.0	25.0, 100.0	10.0, 100.0	-45.0, 45.0	-25.0, 30.0	-60.0, 70.0
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	85.47 (16.47)	84.13 (18.31)	85.26 (18.36)	2.28 (1.67)	-0.68 (1.85)	1.60 (1.40)
Median	90.00	90.00	92.50	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	80.00, 100.00	-5.00, 5.00	-10.00, 10.00	-5.00, 5.00
Min, Max	40.0, 100.0	35.0, 100.0	5.0, 100.0	-55.0, 50.0	-40.0, 35.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Hopelessness						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	75.85 (21.22)	77.84 (22.95)	79.21 (21.56)			
Median	79.15	83.30	83.30			
IQR: Q1, Q3	58.30, 91.70	58.30, 100.00	58.30, 100.00			
Min, Max	25.0, 100.0	8.3, 100.0	16.7, 100.0			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	77.52 (21.09)	79.45 (20.34)	78.54 (22.00)	2.32 (2.12)	2.71 (2.10)	-0.23 (1.34)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	58.30, 100.00	-8.40, 16.70	-8.30, 16.70	-8.30, 8.30
Min, Max	16.7, 100.0	25.0, 100.0	16.7, 100.0	-58.3, 50.0	-41.7, 58.4	-58.3, 50.0
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	77.45 (21.16)	78.23 (21.40)	78.20 (22.61)	0.72 (2.25)	1.03 (2.51)	-0.98 (1.64)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	58.30, 100.00	-8.30, 8.40	-8.40, 16.70	-8.30, 8.30
Min, Max	33.3, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 41.7	-50.0, 50.0	-100.0, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Stigma of Liver Disease						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	84.32 (20.08)	84.29 (17.97)	84.00 (19.19)			
Median	93.80	87.50	87.50			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	31.3, 100.0	12.5, 100.0			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	85.11 (18.21)	84.04 (17.39)	85.39 (18.31)	1.41 (1.70)	0.23 (1.59)	1.94 (1.29)
Median	93.80	87.50	93.80	0	0	0
IQR: Q1, Q3	78.15, 100.00	78.15, 100.00	81.30, 100.00	-6.20, 6.20	-6.20, 6.20	-6.20, 6.30
Min, Max	31.3, 100.0	25.0, 100.0	6.3, 100.0	-37.5, 56.2	-31.3, 50.0	-50.0, 75.0
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	87.59 (16.93)	84.66 (18.18)	85.73 (18.78)	2.47 (1.61)	0.49 (1.82)	1.84 (1.48)
Median	100.00	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	0.00, 6.20	-6.20, 6.30	-6.20, 6.30
Min, Max	37.5, 100.0	12.5, 100.0	18.8, 100.0	-31.3, 56.2	-56.2, 43.8	-62.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.8.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Total LDQOL			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	76.93 (16.10)	74.81 (17.25)	78.62 (14.06)
Analysis Visit Mean (SD)	77.97 (16.95)	74.83 (13.89)	79.09 (15.45)
LS Mean of Change from Baseline (SE)	1.25 (1.22)	-0.50 (1.41)	0.93 (0.99)
95% CI	(-1.17, 3.66)	(-3.28, 2.27)	(-1.01, 2.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.31 (1.56)	-1.44 (1.71)	
95% CI	(-2.76, 3.38)	(-4.82, 1.94)	
p-value	0.8415	0.4024	
Corrected Hedge's g Statistics	0.033	-0.154	
95% CI	(-0.30, 0.36)	(-0.52, 0.21)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	77.71 (15.33)	75.56 (18.54)	77.93 (14.60)
Analysis Visit Mean (SD)	77.25 (14.47)	76.29 (16.26)	77.65 (15.69)
LS Mean of Change from Baseline (SE)	0.01 (1.27)	0.62 (1.47)	-0.05 (1.01)
95% CI	(-2.50, 2.52)	(-2.28, 3.52)	(-2.04, 1.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.06 (1.61)	0.67 (1.78)	
95% CI	(-3.11, 3.23)	(-2.83, 4.17)	
p-value	0.9714	0.7056	
Corrected Hedge's g Statistics	0.006	0.075	
95% CI	(-0.35, 0.36)	(-0.32, 0.47)	
Subgroup*Treatment Interaction p-value	0.9179	0.7126	

AMNOG Table SE21.8.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Total LDQOL			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	77.97 (12.87)	77.66 (13.35)	78.20 (13.61)
Analysis Visit Mean (SD)	78.61 (13.20)	78.55 (12.17)	79.00 (13.32)
LS Mean of Change from Baseline (SE)	0.74 (0.87)	0.84 (0.90)	0.85 (0.65)
95% CI	(-0.97, 2.44)	(-0.93, 2.60)	(-0.43, 2.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.12 (1.05)	-0.02 (1.09)	
95% CI	(-2.19, 1.95)	(-2.15, 2.12)	
p-value	0.9107	0.9883	
Corrected Hedge's g Statistics	-0.014	-0.002	
95% CI	(-0.27, 0.24)	(-0.27, 0.26)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	78.37 (13.05)	77.89 (13.29)	78.62 (13.32)
Analysis Visit Mean (SD)	80.39 (12.19)	78.49 (12.97)	79.60 (13.84)
LS Mean of Change from Baseline (SE)	1.93 (0.99)	0.52 (1.02)	0.91 (0.74)
95% CI	(-0.01, 3.88)	(-1.49, 2.54)	(-0.53, 2.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.02 (1.20)	-0.39 (1.24)	
95% CI	(-1.34, 3.39)	(-2.83, 2.05)	
p-value	0.3956	0.7533	
Corrected Hedge's g Statistics	0.115	-0.044	
95% CI	(-0.16, 0.39)	(-0.33, 0.24)	
Subgroup*Treatment Interaction p-value	0.9179	0.7126	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Symptoms of Liver Disease			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	75.86 (19.84)	75.20 (18.83)	77.39 (18.48)
Analysis Visit Mean (SD)	74.53 (21.58)	74.03 (19.41)	78.30 (19.88)
LS Mean of Change from Baseline (SE)	-1.03 (1.77)	-1.25 (2.03)	1.21 (1.43)
95% CI	(-4.52, 2.47)	(-5.26, 2.76)	(-1.60, 4.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.24 (2.25)	-2.46 (2.47)	
95% CI	(-6.67, 2.20)	(-7.33, 2.41)	
p-value	0.3212	0.3201	
Corrected Hedge's g Statistics	-0.166	-0.183	
95% CI	(-0.50, 0.17)	(-0.55, 0.18)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	77.27 (19.06)	76.12 (19.35)	76.67 (18.36)
Analysis Visit Mean (SD)	73.60 (20.28)	75.37 (20.14)	77.05 (19.09)
LS Mean of Change from Baseline (SE)	-2.82 (1.89)	-0.57 (2.18)	0.84 (1.49)
95% CI	(-6.54, 0.90)	(-4.86, 3.72)	(-2.11, 3.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.65 (2.38)	-1.41 (2.63)	
95% CI	(-8.35, 1.05)	(-6.59, 3.77)	
p-value	0.1268	0.5918	
Corrected Hedge's g Statistics	-0.274	-0.106	
95% CI	(-0.63, 0.08)	(-0.50, 0.29)	
Subgroup*Treatment Interaction p-value	0.4224	0.5545	

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Effects of Liver Disease			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	77.48 (14.18)	78.92 (19.35)	78.26 (16.15)
Analysis Visit Mean (SD)	75.75 (15.28)	79.77 (9.83)	76.59 (18.25)
LS Mean of Change from Baseline (SE)	-1.76 (1.78)	1.47 (2.05)	-1.33 (1.44)
95% CI	(-5.27, 1.75)	(-2.57, 5.51)	(-4.16, 1.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.43 (2.27)	2.80 (2.49)	
95% CI	(-4.90, 4.03)	(-2.11, 7.71)	
p-value	0.8480	0.2628	
Corrected Hedge's g Statistics	-0.032	0.206	
95% CI	(-0.36, 0.30)	(-0.16, 0.57)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	78.37 (13.17)	78.15 (20.13)	77.89 (15.27)
Analysis Visit Mean (SD)	75.31 (13.19)	77.78 (11.82)	76.96 (16.04)
LS Mean of Change from Baseline (SE)	-2.53 (1.95)	-0.10 (2.26)	-0.90 (1.54)
95% CI	(-6.37, 1.31)	(-4.55, 4.36)	(-3.94, 2.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.63 (2.47)	0.80 (2.73)	
95% CI	(-6.50, 3.23)	(-4.58, 6.18)	
p-value	0.5085	0.7698	
Corrected Hedge's g Statistics	-0.119	0.058	
95% CI	(-0.48, 0.24)	(-0.34, 0.45)	
Subgroup*Treatment Interaction p-value	0.7803	0.3189	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Concentration/Memory			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	79.97 (25.26)	78.65 (21.18)	78.14 (21.79)
Analysis Visit Mean (SD)	78.79 (23.70)	78.65 (20.56)	80.13 (22.15)
LS Mean of Change from Baseline (SE)	-0.34 (2.04)	-0.25 (2.34)	2.19 (1.64)
95% CI	(-4.36, 3.68)	(-4.86, 4.36)	(-1.04, 5.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.53 (2.59)	-2.44 (2.84)	
95% CI	(-7.64, 2.58)	(-8.04, 3.16)	
p-value	0.3296	0.3908	
Corrected Hedge's g Statistics	-0.163	-0.158	
95% CI	(-0.50, 0.17)	(-0.52, 0.21)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	79.48 (24.57)	80.40 (19.77)	77.79 (21.54)
Analysis Visit Mean (SD)	76.93 (23.32)	75.89 (22.96)	76.60 (23.88)
LS Mean of Change from Baseline (SE)	-2.80 (1.99)	-3.42 (2.29)	-0.50 (1.57)
95% CI	(-6.72, 1.12)	(-7.94, 1.09)	(-3.61, 2.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.30 (2.51)	-2.92 (2.77)	
95% CI	(-7.25, 2.65)	(-8.38, 2.53)	
p-value	0.3603	0.2919	
Corrected Hedge's g Statistics	-0.164	-0.209	
95% CI	(-0.52, 0.19)	(-0.60, 0.19)	
Subgroup*Treatment Interaction p-value	0.4984	0.2514	

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Health Distress			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	75.00 (29.71)	77.91 (27.53)	80.97 (24.93)
Analysis Visit Mean (SD)	81.25 (25.78)	84.30 (22.34)	86.22 (24.35)
LS Mean of Change from Baseline (SE)	5.33 (2.28)	6.18 (2.61)	6.35 (1.84)
95% CI	(0.84, 9.83)	(1.03, 11.34)	(2.73, 9.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.02 (2.90)	-0.17 (3.18)	
95% CI	(-6.75, 4.71)	(-6.44, 6.10)	
p-value	0.7260	0.9577	
Corrected Hedge's g Statistics	-0.059	-0.010	
95% CI	(-0.39, 0.27)	(-0.37, 0.35)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	74.49 (27.83)	78.13 (29.03)	81.80 (24.17)
Analysis Visit Mean (SD)	78.06 (27.31)	85.07 (23.30)	85.76 (22.44)
LS Mean of Change from Baseline (SE)	1.69 (2.75)	7.50 (3.18)	5.38 (2.17)
95% CI	(-3.74, 7.11)	(1.23, 13.77)	(1.10, 9.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.70 (3.49)	2.12 (3.84)	
95% CI	(-10.59, 3.19)	(-5.46, 9.69)	
p-value	0.2913	0.5818	
Corrected Hedge's g Statistics	-0.190	0.109	
95% CI	(-0.55, 0.17)	(-0.29, 0.50)	
Subgroup*Treatment Interaction p-value	0.4651	0.9507	

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Sexual Function			
Week 24			
m	63	51	103
n	26	22	33
Baseline Mean (SD)	85.63 (20.74)	82.26 (19.13)	82.82 (23.39)
Analysis Visit Mean (SD)	82.70 (25.38)	77.57 (26.73)	84.85 (18.76)
LS Mean of Change from Baseline (SE)	-2.33 (3.94)	-5.62 (4.32)	1.36 (3.48)
95% CI	(-10.18, 5.52)	(-14.21, 2.98)	(-5.56, 8.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.69 (5.25)	-6.98 (5.54)	
95% CI	(-14.14, 6.75)	(-17.99, 4.04)	
p-value	0.4841	0.2115	
Corrected Hedge's g Statistics	-0.182	-0.342	
95% CI	(-0.70, 0.33)	(-0.89, 0.20)	
Week 52			
m	56	44	94
n	21	17	27
Baseline Mean (SD)	89.51 (17.60)	82.14 (20.23)	83.81 (19.57)
Analysis Visit Mean (SD)	85.94 (19.14)	78.72 (28.07)	85.37 (20.06)
LS Mean of Change from Baseline (SE)	-2.94 (3.96)	-1.54 (4.36)	-0.70 (3.48)
95% CI	(-10.82, 4.95)	(-10.22, 7.14)	(-7.62, 6.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.24 (5.26)	-0.84 (5.58)	
95% CI	(-12.69, 8.22)	(-11.93, 10.25)	
p-value	0.6716	0.8806	
Corrected Hedge's g Statistics	-0.121	-0.046	
95% CI	(-0.69, 0.45)	(-0.65, 0.56)	
Subgroup*Treatment Interaction p-value	0.0801	0.6624	

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Sleep			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	61.98 (22.92)	57.56 (17.84)	63.75 (20.36)
Analysis Visit Mean (SD)	62.93 (22.46)	55.47 (18.02)	62.39 (20.50)
LS Mean of Change from Baseline (SE)	1.07 (2.06)	-3.56 (2.38)	-0.68 (1.67)
95% CI	(-3.00, 5.14)	(-8.25, 1.13)	(-3.97, 2.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.75 (2.62)	-2.88 (2.89)	
95% CI	(-3.43, 6.92)	(-8.58, 2.83)	
p-value	0.5058	0.3214	
Corrected Hedge's g Statistics	0.111	-0.183	
95% CI	(-0.22, 0.44)	(-0.55, 0.18)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	63.98 (22.01)	58.47 (20.10)	62.34 (20.72)
Analysis Visit Mean (SD)	60.41 (17.44)	56.25 (21.69)	60.32 (21.77)
LS Mean of Change from Baseline (SE)	-1.96 (2.25)	-3.85 (2.60)	-1.72 (1.78)
95% CI	(-6.39, 2.48)	(-8.99, 1.28)	(-5.23, 1.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.24 (2.84)	-2.13 (3.14)	
95% CI	(-5.84, 5.37)	(-8.33, 4.06)	
p-value	0.9336	0.4979	
Corrected Hedge's g Statistics	-0.015	-0.134	
95% CI	(-0.37, 0.34)	(-0.53, 0.26)	
Subgroup*Treatment Interaction p-value	0.9925	0.8894	

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Loneliness			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	85.69 (16.34)	79.77 (25.42)	85.48 (18.79)
Analysis Visit Mean (SD)	84.40 (19.22)	81.16 (22.52)	82.84 (20.84)
LS Mean of Change from Baseline (SE)	-0.69 (2.02)	0.18 (2.33)	-2.12 (1.63)
95% CI	(-4.67, 3.29)	(-4.42, 4.79)	(-5.34, 1.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.43 (2.57)	2.30 (2.84)	
95% CI	(-3.64, 6.49)	(-3.29, 7.90)	
p-value	0.5785	0.4178	
Corrected Hedge's g Statistics	0.093	0.150	
95% CI	(-0.24, 0.42)	(-0.22, 0.51)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	87.65 (15.72)	79.17 (26.34)	84.46 (19.38)
Analysis Visit Mean (SD)	84.80 (18.57)	81.25 (26.17)	81.52 (20.57)
LS Mean of Change from Baseline (SE)	-1.65 (2.08)	0.94 (2.41)	-3.00 (1.64)
95% CI	(-5.75, 2.44)	(-3.82, 5.70)	(-6.23, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.34 (2.62)	3.94 (2.91)	
95% CI	(-3.83, 6.52)	(-1.80, 9.67)	
p-value	0.6088	0.1775	
Corrected Hedge's g Statistics	0.092	0.269	
95% CI	(-0.26, 0.45)	(-0.13, 0.66)	
Subgroup*Treatment Interaction p-value	0.5283	0.3449	

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Hopelessness			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	75.87 (25.40)	74.03 (22.44)	80.97 (20.17)
Analysis Visit Mean (SD)	78.45 (25.37)	73.83 (25.89)	80.40 (21.07)
LS Mean of Change from Baseline (SE)	1.58 (2.39)	-2.19 (2.75)	-0.05 (1.93)
95% CI	(-3.14, 6.30)	(-7.61, 3.23)	(-3.85, 3.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.63 (3.05)	-2.14 (3.35)	
95% CI	(-4.38, 7.64)	(-8.74, 4.47)	
p-value	0.5939	0.5239	
Corrected Hedge's g Statistics	0.089	-0.118	
95% CI	(-0.24, 0.42)	(-0.48, 0.25)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	77.22 (24.58)	75.46 (23.74)	80.70 (20.44)
Analysis Visit Mean (SD)	80.44 (21.75)	77.09 (23.17)	79.12 (22.12)
LS Mean of Change from Baseline (SE)	3.43 (2.44)	0.34 (2.81)	-0.71 (1.94)
95% CI	(-1.38, 8.24)	(-5.21, 5.89)	(-4.53, 3.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.14 (3.09)	1.05 (3.41)	
95% CI	(-1.95, 10.22)	(-5.67, 7.77)	
p-value	0.1817	0.7575	
Corrected Hedge's g Statistics	0.240	0.061	
95% CI	(-0.12, 0.60)	(-0.33, 0.46)	
Subgroup*Treatment Interaction p-value	0.7270	0.4276	

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Stigma of Liver Disease			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	80.19 (23.03)	74.44 (22.19)	84.47 (18.80)
Analysis Visit Mean (SD)	85.47 (21.66)	75.31 (23.06)	85.39 (19.02)
LS Mean of Change from Baseline (SE)	5.12 (2.10)	-1.32 (2.45)	2.31 (1.71)
95% CI	(0.97, 9.27)	(-6.14, 3.51)	(-1.07, 5.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.81 (2.69)	-3.63 (3.00)	
95% CI	(-2.50, 8.12)	(-9.54, 2.28)	
p-value	0.2977	0.2278	
Corrected Hedge's g Statistics	0.174	-0.225	
95% CI	(-0.16, 0.51)	(-0.59, 0.14)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	80.50 (23.44)	76.41 (22.91)	82.78 (19.07)
Analysis Visit Mean (SD)	86.24 (19.09)	83.18 (20.36)	84.28 (18.25)
LS Mean of Change from Baseline (SE)	5.71 (1.79)	5.22 (2.08)	1.88 (1.42)
95% CI	(2.18, 9.24)	(1.12, 9.32)	(-0.93, 4.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.83 (2.26)	3.34 (2.52)	
95% CI	(-0.63, 8.30)	(-1.62, 8.31)	
p-value	0.0920	0.1857	
Corrected Hedge's g Statistics	0.302	0.264	
95% CI	(-0.06, 0.66)	(-0.13, 0.66)	
Subgroup*Treatment Interaction p-value	0.2863	0.7639	

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Symptoms of Liver Disease			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	78.85 (18.93)	74.70 (18.88)	77.69 (17.43)
Analysis Visit Mean (SD)	77.46 (19.66)	74.00 (17.01)	77.45 (18.85)
LS Mean of Change from Baseline (SE)	-0.91 (1.33)	-1.11 (1.38)	-0.31 (1.00)
95% CI	(-3.52, 1.70)	(-3.83, 1.61)	(-2.28, 1.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.60 (1.62)	-0.80 (1.68)	
95% CI	(-3.78, 2.58)	(-4.11, 2.50)	
p-value	0.7109	0.6323	
Corrected Hedge's g Statistics	-0.047	-0.063	
95% CI	(-0.30, 0.21)	(-0.33, 0.20)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	79.83 (18.32)	75.11 (17.67)	77.80 (16.97)
Analysis Visit Mean (SD)	78.93 (18.44)	76.81 (17.16)	78.53 (18.85)
LS Mean of Change from Baseline (SE)	-0.65 (1.36)	0.81 (1.41)	0.92 (1.01)
95% CI	(-3.32, 2.03)	(-1.96, 3.58)	(-1.06, 2.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.57 (1.65)	-0.11 (1.70)	
95% CI	(-4.82, 1.67)	(-3.46, 3.24)	
p-value	0.3416	0.9480	
Corrected Hedge's g Statistics	-0.129	-0.009	
95% CI	(-0.40, 0.14)	(-0.29, 0.27)	
Subgroup*Treatment Interaction p-value	0.4224	0.5545	

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Effects of Liver Disease			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	78.43 (12.90)	78.23 (13.17)	77.52 (13.33)
Analysis Visit Mean (SD)	76.49 (13.92)	78.56 (11.12)	78.26 (12.29)
LS Mean of Change from Baseline (SE)	-1.73 (1.18)	0.39 (1.23)	0.43 (0.89)
95% CI	(-4.06, 0.59)	(-2.02, 2.81)	(-1.33, 2.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.16 (1.44)	-0.04 (1.49)	
95% CI	(-5.00, 0.67)	(-2.98, 2.90)	
p-value	0.1345	0.9798	
Corrected Hedge's g Statistics	-0.190	-0.003	
95% CI	(-0.45, 0.07)	(-0.27, 0.26)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	78.03 (13.18)	78.36 (13.28)	78.06 (12.37)
Analysis Visit Mean (SD)	77.78 (13.50)	77.76 (13.22)	78.22 (12.16)
LS Mean of Change from Baseline (SE)	-0.64 (1.35)	-0.75 (1.40)	0.00 (1.00)
95% CI	(-3.29, 2.01)	(-3.50, 2.00)	(-1.97, 1.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.64 (1.64)	-0.75 (1.70)	
95% CI	(-3.87, 2.59)	(-4.09, 2.58)	
p-value	0.6967	0.6570	
Corrected Hedge's g Statistics	-0.053	-0.063	
95% CI	(-0.33, 0.22)	(-0.34, 0.22)	
Subgroup*Treatment Interaction p-value	0.7803	0.3189	

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Concentration/Memory			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	80.87 (21.40)	79.54 (20.43)	79.87 (20.41)
Analysis Visit Mean (SD)	79.18 (21.67)	80.21 (19.56)	79.80 (21.75)
LS Mean of Change from Baseline (SE)	-1.48 (1.51)	0.55 (1.56)	-0.17 (1.13)
95% CI	(-4.44, 1.48)	(-2.52, 3.63)	(-2.40, 2.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.31 (1.84)	0.72 (1.90)	
95% CI	(-4.92, 2.30)	(-3.01, 4.46)	
p-value	0.4765	0.7038	
Corrected Hedge's g Statistics	-0.090	0.050	
95% CI	(-0.35, 0.17)	(-0.21, 0.32)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	80.03 (21.68)	79.99 (19.92)	80.10 (20.06)
Analysis Visit Mean (SD)	80.34 (17.95)	80.24 (19.08)	79.92 (21.23)
LS Mean of Change from Baseline (SE)	-0.31 (1.51)	0.51 (1.56)	-0.43 (1.12)
95% CI	(-3.29, 2.66)	(-2.56, 3.59)	(-2.63, 1.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.11 (1.83)	0.94 (1.89)	
95% CI	(-3.49, 3.72)	(-2.78, 4.66)	
p-value	0.9501	0.6195	
Corrected Hedge's g Statistics	0.008	0.070	
95% CI	(-0.26, 0.28)	(-0.21, 0.35)	
Subgroup*Treatment Interaction p-value	0.4984	0.2514	

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Health Distress			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	80.24 (23.91)	81.02 (25.33)	80.67 (23.63)
Analysis Visit Mean (SD)	85.08 (20.29)	87.05 (20.33)	85.79 (20.89)
LS Mean of Change from Baseline (SE)	4.45 (1.72)	6.02 (1.78)	4.86 (1.29)
95% CI	(1.07, 7.83)	(2.52, 9.52)	(2.31, 7.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.41 (2.09)	1.16 (2.16)	
95% CI	(-4.52, 3.69)	(-3.08, 5.41)	
p-value	0.8436	0.5906	
Corrected Hedge's g Statistics	-0.025	0.071	
95% CI	(-0.28, 0.23)	(-0.19, 0.34)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	80.71 (24.21)	82.88 (24.69)	81.86 (23.23)
Analysis Visit Mean (SD)	86.42 (19.78)	87.50 (20.62)	86.28 (20.82)
LS Mean of Change from Baseline (SE)	4.78 (1.98)	5.02 (2.06)	4.64 (1.47)
95% CI	(0.88, 8.68)	(0.98, 9.07)	(1.74, 7.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.15 (2.41)	0.39 (2.49)	
95% CI	(-4.60, 4.90)	(-4.52, 5.29)	
p-value	0.9512	0.8772	
Corrected Hedge's g Statistics	0.008	0.022	
95% CI	(-0.26, 0.28)	(-0.26, 0.30)	
Subgroup*Treatment Interaction p-value	0.4651	0.9507	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Sexual Function			
Week 24			
m	98	90	186
n	31	37	61
Baseline Mean (SD)	71.30 (31.72)	81.21 (23.43)	81.04 (21.55)
Analysis Visit Mean (SD)	76.88 (25.59)	76.66 (24.83)	80.02 (22.85)
LS Mean of Change from Baseline (SE)	4.42 (3.27)	-3.91 (2.97)	-0.46 (2.34)
95% CI	(-2.05, 10.88)	(-9.77, 1.95)	(-5.09, 4.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.88 (3.92)	-3.45 (3.67)	
95% CI	(-2.86, 12.62)	(-10.71, 3.82)	
p-value	0.2147	0.3499	
Corrected Hedge's g Statistics	0.265	-0.188	
95% CI	(-0.17, 0.70)	(-0.60, 0.22)	
Week 52			
m	93	81	176
n	25	30	53
Baseline Mean (SD)	74.94 (32.96)	81.50 (23.04)	78.02 (25.74)
Analysis Visit Mean (SD)	85.74 (22.36)	79.20 (28.40)	75.26 (26.85)
LS Mean of Change from Baseline (SE)	9.49 (3.77)	-1.79 (3.42)	-2.24 (2.62)
95% CI	(2.04, 16.95)	(-8.55, 4.97)	(-7.42, 2.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	11.73 (4.49)	0.44 (4.23)	
95% CI	(2.86, 20.60)	(-7.91, 8.80)	
p-value	0.0099	0.9165	
Corrected Hedge's g Statistics	0.611	0.023	
95% CI	(0.13, 1.10)	(-0.42, 0.47)	
Subgroup*Treatment Interaction p-value	0.0801	0.6624	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Sleep			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	63.60 (19.27)	60.72 (21.13)	63.35 (19.84)
Analysis Visit Mean (SD)	64.62 (18.74)	59.28 (21.82)	63.60 (20.17)
LS Mean of Change from Baseline (SE)	1.77 (1.46)	-1.69 (1.51)	0.67 (1.10)
95% CI	(-1.10, 4.64)	(-4.66, 1.29)	(-1.49, 2.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.10 (1.77)	-2.36 (1.84)	
95% CI	(-2.39, 4.59)	(-5.97, 1.25)	
p-value	0.5358	0.2000	
Corrected Hedge's g Statistics	0.078	-0.169	
95% CI	(-0.18, 0.33)	(-0.43, 0.10)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	64.20 (19.66)	61.10 (21.18)	63.92 (19.91)
Analysis Visit Mean (SD)	67.05 (19.24)	60.82 (21.11)	66.35 (20.18)
LS Mean of Change from Baseline (SE)	3.77 (1.65)	-0.27 (1.71)	2.78 (1.22)
95% CI	(0.53, 7.01)	(-3.62, 3.09)	(0.37, 5.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.99 (2.00)	-3.04 (2.07)	
95% CI	(-2.95, 4.93)	(-7.11, 1.03)	
p-value	0.6208	0.1422	
Corrected Hedge's g Statistics	0.067	-0.207	
95% CI	(-0.21, 0.34)	(-0.49, 0.08)	
Subgroup*Treatment Interaction p-value	0.9925	0.8894	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Loneliness			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	83.82 (19.03)	85.90 (16.18)	83.63 (19.98)
Analysis Visit Mean (SD)	83.20 (18.46)	86.45 (17.56)	82.92 (20.73)
LS Mean of Change from Baseline (SE)	-1.37 (1.54)	0.77 (1.60)	-1.21 (1.16)
95% CI	(-4.40, 1.66)	(-2.39, 3.92)	(-3.50, 1.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.16 (1.88)	1.98 (1.95)	
95% CI	(-3.85, 3.54)	(-1.85, 5.81)	
p-value	0.9332	0.3110	
Corrected Hedge's g Statistics	-0.011	0.134	
95% CI	(-0.27, 0.24)	(-0.13, 0.40)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	82.84 (19.87)	84.38 (17.16)	83.89 (20.08)
Analysis Visit Mean (SD)	85.12 (16.64)	83.70 (18.37)	85.49 (18.64)
LS Mean of Change from Baseline (SE)	0.71 (1.59)	-0.88 (1.65)	0.85 (1.18)
95% CI	(-2.43, 3.84)	(-4.12, 2.37)	(-1.47, 3.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (1.93)	-1.73 (2.00)	
95% CI	(-3.95, 3.66)	(-5.65, 2.20)	
p-value	0.9401	0.3873	
Corrected Hedge's g Statistics	-0.010	-0.122	
95% CI	(-0.28, 0.26)	(-0.40, 0.16)	
Subgroup*Treatment Interaction p-value	0.5283	0.3449	

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Hopelessness			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	75.63 (20.76)	76.91 (23.04)	79.40 (21.19)
Analysis Visit Mean (SD)	77.95 (20.77)	79.62 (20.59)	79.17 (21.54)
LS Mean of Change from Baseline (SE)	1.87 (1.77)	2.37 (1.84)	0.79 (1.34)
95% CI	(-1.62, 5.36)	(-1.24, 5.99)	(-1.84, 3.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.08 (2.16)	1.58 (2.23)	
95% CI	(-3.17, 5.33)	(-2.81, 5.98)	
p-value	0.6185	0.4795	
Corrected Hedge's g Statistics	0.063	0.093	
95% CI	(-0.19, 0.32)	(-0.17, 0.36)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	77.16 (20.19)	76.71 (24.14)	79.63 (21.41)
Analysis Visit Mean (SD)	77.88 (20.92)	77.74 (21.47)	78.65 (22.73)
LS Mean of Change from Baseline (SE)	1.48 (2.04)	1.05 (2.11)	-0.40 (1.52)
95% CI	(-2.52, 5.49)	(-3.11, 5.20)	(-3.38, 2.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.88 (2.49)	1.45 (2.57)	
95% CI	(-3.01, 6.77)	(-3.60, 6.49)	
p-value	0.4498	0.5735	
Corrected Hedge's g Statistics	0.103	0.079	
95% CI	(-0.17, 0.38)	(-0.20, 0.36)	
Subgroup*Treatment Interaction p-value	0.7270	0.4276	

AMNOG Table SE21.8.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Stigma of Liver Disease			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	84.08 (19.92)	83.98 (18.42)	83.98 (19.32)
Analysis Visit Mean (SD)	85.50 (17.98)	84.21 (17.66)	85.92 (18.15)
LS Mean of Change from Baseline (SE)	1.56 (1.48)	0.35 (1.54)	1.95 (1.12)
95% CI	(-1.36, 4.47)	(-2.67, 3.37)	(-0.25, 4.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.39 (1.80)	-1.60 (1.86)	
95% CI	(-3.94, 3.15)	(-5.27, 2.07)	
p-value	0.8287	0.3917	
Corrected Hedge's g Statistics	-0.027	-0.113	
95% CI	(-0.28, 0.23)	(-0.38, 0.15)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	85.58 (18.60)	84.01 (18.60)	84.03 (19.05)
Analysis Visit Mean (SD)	88.06 (16.47)	84.50 (18.33)	85.87 (19.14)
LS Mean of Change from Baseline (SE)	3.22 (1.64)	0.19 (1.70)	1.97 (1.22)
95% CI	(0.00, 6.45)	(-3.15, 3.53)	(-0.43, 4.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.25 (2.00)	-1.78 (2.06)	
95% CI	(-2.68, 5.18)	(-5.83, 2.27)	
p-value	0.5316	0.3872	
Corrected Hedge's g Statistics	0.085	-0.122	
95% CI	(-0.19, 0.36)	(-0.40, 0.16)	
Subgroup*Treatment Interaction p-value	0.2863	0.7639	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.6)	2 (3.8)	2 (1.8)
No	63 (98.4)	51 (96.2)	109 (98.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	0.47	
95% CI of the inverse odds ratio	(0.10, 13.01)	(0.06, 3.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.48	
95% CI of the inverse risk ratio	(0.11, 12.47)	(0.07, 3.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.24	1.97	
95% CI of the absolute risk difference	(-4.16, 3.68)	(-3.72, 7.67)	
p-value	0.9065	0.4439	
p-value of Breslow-Day Test for Homogeneity [3]	0.8230	0.2312	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (17.2)	12 (22.6)	16 (14.4)
No	53 (82.8)	41 (77.4)	95 (85.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.58	
95% CI of the inverse odds ratio	(0.35, 1.88)	(0.25, 1.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.64	
95% CI of the inverse risk ratio	(0.42, 1.69)	(0.32, 1.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.77	8.23	
95% CI of the absolute risk difference	(-8.55, 14.09)	(-4.80, 21.25)	
p-value	0.6248	0.1904	
p-value of Breslow-Day Test for Homogeneity [3]	0.9547	0.2194	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.1)	7 (13.2)	11 (9.9)
No	62 (96.9)	46 (86.8)	100 (90.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.41	0.72	
95% CI of the inverse odds ratio	(0.73, 15.90)	(0.26, 1.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.17	0.75	
95% CI of the inverse risk ratio	(0.73, 13.86)	(0.31, 1.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.78	3.30	
95% CI of the absolute risk difference	(-13.79, 0.22)	(-7.38, 13.97)	
p-value	0.0993	0.5275	
p-value of Breslow-Day Test for Homogeneity [3]	0.6164	0.8274	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (20.3)	14 (26.4)	26 (23.4)
No	51 (79.7)	39 (73.6)	85 (76.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	0.85	
95% CI of the inverse odds ratio	(0.57, 2.54)	(0.40, 1.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.89	
95% CI of the inverse risk ratio	(0.64, 2.08)	(0.51, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.11	2.99	
95% CI of the absolute risk difference	(-15.73, 9.51)	(-11.25, 17.24)	
p-value	0.6339	0.6765	
p-value of Breslow-Day Test for Homogeneity [3]	0.9214	0.6526	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.1)	3 (5.7)	12 (10.8)
No	62 (96.9)	50 (94.3)	99 (89.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.76	2.02	
95% CI of the inverse odds ratio	(0.81, 17.36)	(0.55, 7.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.46	1.91	
95% CI of the inverse risk ratio	(0.80, 14.97)	(0.56, 6.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.69	-5.15	
95% CI of the absolute risk difference	(-14.86, -0.51)	(-13.64, 3.34)	
p-value	0.0711	0.2846	
p-value of Breslow-Day Test for Homogeneity [3]	0.7223	0.4048	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (10.9)	8 (15.1)	21 (18.9)
No	57 (89.1)	45 (84.9)	90 (81.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.90	1.31	
95% CI of the inverse odds ratio	(0.76, 4.76)	(0.54, 3.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.73	1.25	
95% CI of the inverse risk ratio	(0.78, 3.84)	(0.59, 2.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.98	-3.82	
95% CI of the absolute risk difference	(-18.54, 2.58)	(-15.91, 8.26)	
p-value	0.1654	0.5482	
p-value of Breslow-Day Test for Homogeneity [3]	0.2678	0.5716	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (7.8)	2 (3.8)	5 (4.5)
No	59 (92.2)	51 (96.2)	106 (95.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	1.20	
95% CI of the inverse odds ratio	(0.15, 2.00)	(0.23, 6.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	1.19	
95% CI of the inverse risk ratio	(0.17, 1.92)	(0.24, 5.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.31	-0.73	
95% CI of the absolute risk difference	(-4.32, 10.93)	(-7.15, 5.69)	
p-value	0.3639	0.8285	
p-value of Breslow-Day Test for Homogeneity [3]	0.6554	0.9284	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (18.8)	9 (17.0)	22 (19.8)
No	52 (81.3)	44 (83.0)	89 (80.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.21	
95% CI of the inverse odds ratio	(0.49, 2.34)	(0.51, 2.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.17	
95% CI of the inverse risk ratio	(0.56, 1.99)	(0.58, 2.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.07	-2.84	
95% CI of the absolute risk difference	(-13.17, 11.03)	(-15.38, 9.70)	
p-value	0.8632	0.6641	
p-value of Breslow-Day Test for Homogeneity [3]	0.8153	0.4341	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (15.6)	10 (18.9)	16 (14.4)
No	54 (84.4)	43 (81.1)	95 (85.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.72	
95% CI of the inverse odds ratio	(0.39, 2.14)	(0.30, 1.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.76	
95% CI of the inverse risk ratio	(0.45, 1.91)	(0.37, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.21	4.45	
95% CI of the absolute risk difference	(-9.83, 12.25)	(-7.94, 16.85)	
p-value	0.8283	0.4652	
p-value of Breslow-Day Test for Homogeneity [3]	0.8848	0.6797	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (21.9)	14 (26.4)	22 (19.8)
No	50 (78.1)	39 (73.6)	89 (80.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.69	
95% CI of the inverse odds ratio	(0.42, 1.88)	(0.32, 1.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.75	
95% CI of the inverse risk ratio	(0.50, 1.64)	(0.42, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.06	6.60	
95% CI of the absolute risk difference	(-10.50, 14.61)	(-7.40, 20.59)	
p-value	0.7460	0.3399	
p-value of Breslow-Day Test for Homogeneity [3]	0.7699	0.2675	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	3 (5.7)	4 (3.6)
No	64 (100)	50 (94.3)	107 (96.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.62	
95% CI of the inverse odds ratio	NE	(0.13, 2.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.64	
95% CI of the inverse risk ratio	NE	(0.15, 2.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.60	2.06	
95% CI of the absolute risk difference	(-7.07, -0.14)	(-5.07, 9.18)	
p-value	0.1245	0.5423	
p-value of Breslow-Day Test for Homogeneity [3]	0.1104	0.3712	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (6.3)	6 (11.3)	10 (9.0)
No	60 (93.8)	47 (88.7)	101 (91.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.49	0.78	
95% CI of the inverse odds ratio	(0.45, 4.94)	(0.27, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	0.80	
95% CI of the inverse risk ratio	(0.47, 4.41)	(0.31, 2.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.76	2.31	
95% CI of the absolute risk difference	(-10.73, 5.21)	(-7.74, 12.37)	
p-value	0.5170	0.6408	
p-value of Breslow-Day Test for Homogeneity [3]	0.4918	0.6273	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (12.5)	8 (15.1)	14 (12.6)
No	56 (87.5)	45 (84.9)	97 (87.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.81	
95% CI of the inverse odds ratio	(0.40, 2.56)	(0.32, 2.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.84	
95% CI of the inverse risk ratio	(0.45, 2.27)	(0.37, 1.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.11	2.48	
95% CI of the absolute risk difference	(-10.30, 10.08)	(-8.97, 13.93)	
p-value	0.9827	0.6627	
p-value of Breslow-Day Test for Homogeneity [3]	0.8967	0.2825	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (18.8)	14 (26.4)	31 (27.9)
No	52 (81.3)	39 (73.6)	80 (72.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.68	1.08	
95% CI of the inverse odds ratio	(0.79, 3.56)	(0.52, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.49	1.06	
95% CI of the inverse risk ratio	(0.82, 2.69)	(0.62, 1.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.18	-1.51	
95% CI of the absolute risk difference	(-21.87, 3.51)	(-16.02, 13.00)	
p-value	0.1744	0.8391	
p-value of Breslow-Day Test for Homogeneity [3]	0.2023	0.9177	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (7.8)	10 (18.9)	7 (6.3)
No	59 (92.2)	43 (81.1)	104 (93.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.29	
95% CI of the inverse odds ratio	(0.24, 2.61)	(0.10, 0.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.33	
95% CI of the inverse risk ratio	(0.27, 2.44)	(0.13, 0.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.51	12.56	
95% CI of the absolute risk difference	(-6.47, 9.49)	(1.10, 24.02)	
p-value	0.7042	0.0136	
p-value of Breslow-Day Test for Homogeneity [3]	0.8353	0.0600	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (17.2)	14 (26.4)	26 (23.4)
No	53 (82.8)	39 (73.6)	85 (76.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	0.85	
95% CI of the inverse odds ratio	(0.67, 3.23)	(0.40, 1.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.89	
95% CI of the inverse risk ratio	(0.72, 2.57)	(0.51, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.24	2.99	
95% CI of the absolute risk difference	(-18.38, 5.91)	(-11.25, 17.24)	
p-value	0.3305	0.6765	
p-value of Breslow-Day Test for Homogeneity [3]	0.4532	0.4366	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (18.8)	11 (20.8)	13 (11.7)
No	52 (81.3)	42 (79.2)	98 (88.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	0.51	
95% CI of the inverse odds ratio	(0.24, 1.35)	(0.21, 1.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.56	
95% CI of the inverse risk ratio	(0.30, 1.29)	(0.27, 1.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.04	9.04	
95% CI of the absolute risk difference	(-4.24, 18.32)	(-3.41, 21.49)	
p-value	0.2000	0.1254	
p-value of Breslow-Day Test for Homogeneity [3]	0.6164	0.8630	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (28.1)	14 (26.4)	27 (24.3)
No	46 (71.9)	39 (73.6)	84 (75.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.90	
95% CI of the inverse odds ratio	(0.41, 1.65)	(0.42, 1.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.92	
95% CI of the inverse risk ratio	(0.52, 1.44)	(0.53, 1.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.80	2.09	
95% CI of the absolute risk difference	(-9.80, 17.40)	(-12.21, 16.39)	
p-value	0.5795	0.7724	
p-value of Breslow-Day Test for Homogeneity [3]	0.7280	0.5068	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (14.1)	7 (13.2)	12 (10.8)
No	55 (85.9)	46 (86.8)	99 (89.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.80	
95% CI of the inverse odds ratio	(0.29, 1.87)	(0.29, 2.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.82	
95% CI of the inverse risk ratio	(0.34, 1.72)	(0.34, 1.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.25	2.40	
95% CI of the absolute risk difference	(-7.04, 13.54)	(-8.39, 13.19)	
p-value	0.5238	0.6538	
p-value of Breslow-Day Test for Homogeneity [3]	0.5946	0.7577	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (42.2)	16 (30.2)	29 (26.1)
No	37 (57.8)	37 (69.8)	82 (73.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	0.82	
95% CI of the inverse odds ratio	(0.25, 0.93)	(0.40, 1.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.87	
95% CI of the inverse risk ratio	(0.41, 0.95)	(0.52, 1.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.06	4.06	
95% CI of the absolute risk difference	(1.46, 30.66)	(-10.75, 18.88)	
p-value	0.0283	0.5855	
p-value of Breslow-Day Test for Homogeneity [3]	0.0447	0.7009	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.9)	2 (2.0)	8 (4.2)
No	98 (95.1)	96 (98.0)	184 (95.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	2.09	
95% CI of the inverse odds ratio	(0.27, 2.68)	(0.43, 10.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	2.04	
95% CI of the inverse risk ratio	(0.29, 2.56)	(0.44, 9.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.69	-2.13	
95% CI of the absolute risk difference	(-4.33, 5.71)	(-6.10, 1.85)	
p-value	0.7838	0.3480	
p-value of Breslow-Day Test for Homogeneity [3]	0.8230	0.2312	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (26.2)	20 (20.4)	42 (21.9)
No	76 (73.8)	78 (79.6)	150 (78.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	1.09	
95% CI of the inverse odds ratio	(0.45, 1.38)	(0.60, 1.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	1.07	
95% CI of the inverse risk ratio	(0.55, 1.27)	(0.67, 1.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.34	-1.47	
95% CI of the absolute risk difference	(-5.97, 14.65)	(-11.36, 8.43)	
p-value	0.4014	0.7732	
p-value of Breslow-Day Test for Homogeneity [3]	0.9547	0.2194	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.9)	9 (9.2)	15 (7.8)
No	99 (96.1)	89 (90.8)	177 (92.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.10	0.84	
95% CI of the inverse odds ratio	(0.68, 6.49)	(0.35, 1.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.01	0.85	
95% CI of the inverse risk ratio	(0.69, 5.90)	(0.39, 1.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.93	1.37	
95% CI of the absolute risk difference	(-9.25, 1.39)	(-5.49, 8.23)	
p-value	0.1900	0.6885	
p-value of Breslow-Day Test for Homogeneity [3]	0.6164	0.8274	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (22.3)	25 (25.5)	51 (26.6)
No	80 (77.7)	73 (74.5)	141 (73.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	1.06	
95% CI of the inverse odds ratio	(0.72, 2.21)	(0.61, 1.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	1.04	
95% CI of the inverse risk ratio	(0.77, 1.83)	(0.69, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.23	-1.05	
95% CI of the absolute risk difference	(-14.42, 5.95)	(-11.71, 9.60)	
p-value	0.4241	0.8472	
p-value of Breslow-Day Test for Homogeneity [3]	0.9214	0.6526	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (2.9)	7 (7.1)	14 (7.3)
No	100 (97.1)	91 (92.9)	178 (92.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.62	1.02	
95% CI of the inverse odds ratio	(0.74, 9.34)	(0.40, 2.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	1.02	
95% CI of the inverse risk ratio	(0.74, 8.51)	(0.43, 2.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.38	-0.15	
95% CI of the absolute risk difference	(-9.29, 0.53)	(-6.44, 6.14)	
p-value	0.1239	0.9631	
p-value of Breslow-Day Test for Homogeneity [3]	0.7223	0.4048	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (19.4)	20 (20.4)	38 (19.8)
No	83 (80.6)	78 (79.6)	154 (80.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.96	
95% CI of the inverse odds ratio	(0.56, 1.87)	(0.52, 1.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.97	
95% CI of the inverse risk ratio	(0.63, 1.66)	(0.60, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.37	0.62	
95% CI of the absolute risk difference	(-9.87, 9.12)	(-9.15, 10.39)	
p-value	0.9386	0.9012	
p-value of Breslow-Day Test for Homogeneity [3]	0.2678	0.5716	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (9.7)	7 (7.1)	15 (7.8)
No	93 (90.3)	91 (92.9)	177 (92.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	1.10	
95% CI of the inverse odds ratio	(0.34, 1.82)	(0.43, 2.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.09	
95% CI of the inverse risk ratio	(0.38, 1.73)	(0.46, 2.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.90	-0.67	
95% CI of the absolute risk difference	(-4.97, 8.76)	(-7.03, 5.69)	
p-value	0.5772	0.8386	
p-value of Breslow-Day Test for Homogeneity [3]	0.6554	0.9284	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (24.3)	27 (27.6)	45 (23.4)
No	78 (75.7)	71 (72.4)	147 (76.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.80	
95% CI of the inverse odds ratio	(0.55, 1.67)	(0.46, 1.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.85	
95% CI of the inverse risk ratio	(0.63, 1.48)	(0.56, 1.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.83	4.11	
95% CI of the absolute risk difference	(-9.39, 11.05)	(-6.57, 14.80)	
p-value	0.8724	0.4431	
p-value of Breslow-Day Test for Homogeneity [3]	0.8153	0.4341	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (17.5)	16 (16.3)	29 (15.1)
No	85 (82.5)	82 (83.7)	163 (84.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.91	
95% CI of the inverse odds ratio	(0.44, 1.60)	(0.47, 1.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.93	
95% CI of the inverse risk ratio	(0.51, 1.48)	(0.53, 1.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.37	1.22	
95% CI of the absolute risk difference	(-6.54, 11.28)	(-7.68, 10.12)	
p-value	0.5957	0.7857	
p-value of Breslow-Day Test for Homogeneity [3]	0.8848	0.6797	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (25.2)	22 (22.4)	49 (25.5)
No	77 (74.8)	76 (77.6)	143 (74.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.18	
95% CI of the inverse odds ratio	(0.59, 1.76)	(0.67, 2.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.14	
95% CI of the inverse risk ratio	(0.67, 1.52)	(0.73, 1.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.28	-3.07	
95% CI of the absolute risk difference	(-10.69, 10.13)	(-13.38, 7.24)	
p-value	0.9583	0.5650	
p-value of Breslow-Day Test for Homogeneity [3]	0.7699	0.2675	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (5.8)	3 (3.1)	9 (4.7)
No	97 (94.2)	95 (96.9)	183 (95.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.56	
95% CI of the inverse odds ratio	(0.27, 2.30)	(0.41, 5.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.53	
95% CI of the inverse risk ratio	(0.29, 2.20)	(0.42, 5.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.14	-1.63	
95% CI of the absolute risk difference	(-4.28, 6.56)	(-6.16, 2.91)	
p-value	0.6715	0.5107	
p-value of Breslow-Day Test for Homogeneity [3]	0.1104	0.3712	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (8.7)	7 (7.1)	15 (7.8)
No	94 (91.3)	91 (92.9)	177 (92.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.10	
95% CI of the inverse odds ratio	(0.37, 2.10)	(0.43, 2.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.09	
95% CI of the inverse risk ratio	(0.41, 1.97)	(0.46, 2.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.93	-0.67	
95% CI of the absolute risk difference	(-5.72, 7.57)	(-7.03, 5.69)	
p-value	0.7817	0.8386	
p-value of Breslow-Day Test for Homogeneity [3]	0.4918	0.6273	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	17 (16.5)	12 (12.2)	34 (17.7)
No	86 (83.5)	86 (87.8)	158 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.54	
95% CI of the inverse odds ratio	(0.57, 2.06)	(0.76, 3.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.45	
95% CI of the inverse risk ratio	(0.63, 1.82)	(0.78, 2.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.20	-5.46	
95% CI of the absolute risk difference	(-10.18, 7.77)	(-13.91, 2.98)	
p-value	0.7944	0.2283	
p-value of Breslow-Day Test for Homogeneity [3]	0.8967	0.2825	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	37 (35.9)	31 (31.6)	66 (34.4)
No	66 (64.1)	67 (68.4)	126 (65.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.13	
95% CI of the inverse odds ratio	(0.57, 1.54)	(0.67, 1.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.09	
95% CI of the inverse risk ratio	(0.69, 1.32)	(0.77, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.55	-2.74	
95% CI of the absolute risk difference	(-9.90, 12.99)	(-14.14, 8.66)	
p-value	0.7904	0.6396	
p-value of Breslow-Day Test for Homogeneity [3]	0.2023	0.9177	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (14.6)	14 (14.3)	26 (13.5)
No	88 (85.4)	84 (85.7)	166 (86.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.94	
95% CI of the inverse odds ratio	(0.46, 1.82)	(0.47, 1.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.95	
95% CI of the inverse risk ratio	(0.52, 1.68)	(0.52, 1.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.02	0.74	
95% CI of the absolute risk difference	(-7.33, 9.38)	(-7.71, 9.20)	
p-value	0.8090	0.8620	
p-value of Breslow-Day Test for Homogeneity [3]	0.8353	0.0600	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (29.1)	25 (25.5)	57 (29.7)
No	73 (70.9)	73 (74.5)	135 (70.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.23	
95% CI of the inverse odds ratio	(0.61, 1.74)	(0.71, 2.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.16	
95% CI of the inverse risk ratio	(0.70, 1.48)	(0.78, 1.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.56	-4.18	
95% CI of the absolute risk difference	(-11.46, 10.34)	(-14.96, 6.60)	
p-value	0.9197	0.4550	
p-value of Breslow-Day Test for Homogeneity [3]	0.4532	0.4366	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	19 (18.4)	23 (23.5)	28 (14.6)
No	84 (81.6)	75 (76.5)	164 (85.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.56	
95% CI of the inverse odds ratio	(0.40, 1.43)	(0.30, 1.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.62	
95% CI of the inverse risk ratio	(0.46, 1.34)	(0.38, 1.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.86	8.89	
95% CI of the absolute risk difference	(-5.14, 12.86)	(-0.88, 18.65)	
p-value	0.3874	0.0601	
p-value of Breslow-Day Test for Homogeneity [3]	0.6164	0.8630	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (29.1)	30 (30.6)	43 (22.4)
No	73 (70.9)	68 (69.4)	149 (77.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	0.65	
95% CI of the inverse odds ratio	(0.41, 1.21)	(0.38, 1.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.73	
95% CI of the inverse risk ratio	(0.52, 1.15)	(0.49, 1.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.73	8.22	
95% CI of the absolute risk difference	(-3.84, 17.30)	(-2.65, 19.08)	
p-value	0.2016	0.1273	
p-value of Breslow-Day Test for Homogeneity [3]	0.7280	0.5068	

AMNOG Table SE21.8.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (10.7)	11 (11.2)	21 (10.9)
No	92 (89.3)	87 (88.8)	171 (89.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.97	
95% CI of the inverse odds ratio	(0.47, 2.22)	(0.45, 2.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.97	
95% CI of the inverse risk ratio	(0.51, 2.04)	(0.49, 1.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.26	0.29	
95% CI of the absolute risk difference	(-7.68, 7.16)	(-7.36, 7.94)	
p-value	0.9459	0.9412	
p-value of Breslow-Day Test for Homogeneity [3]	0.5946	0.7577	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (24.3)	27 (27.6)	52 (27.1)
No	78 (75.7)	71 (72.4)	140 (72.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	0.98	
95% CI of the inverse odds ratio	(0.67, 2.01)	(0.57, 1.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.98	
95% CI of the inverse risk ratio	(0.74, 1.69)	(0.66, 1.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.81	0.47	
95% CI of the absolute risk difference	(-13.21, 7.58)	(-10.38, 11.32)	
p-value	0.6002	0.9326	
p-value of Breslow-Day Test for Homogeneity [3]	0.0447	0.7009	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Total LDQOL						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	75.86 (16.71)	75.16 (16.02)	78.38 (15.53)			
Median	79.40	79.40	84.40			
IQR: Q1, Q3	69.70, 88.30	64.40, 87.25	66.75, 89.75			
Min, Max	29.0, 96.5	36.0, 94.0	41.5, 97.8			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	76.15 (16.64)	76.50 (13.46)	79.32 (15.28)	0.64 (1.41)	1.48 (1.72)	2.17 (1.63)
Median	82.00	80.30	86.20	0.50	1.10	1.35
IQR: Q1, Q3	72.20, 89.10	69.30, 85.20	65.90, 91.50	-2.40, 5.00	-1.40, 3.70	-2.10, 6.55
Min, Max	33.6, 93.8	41.4, 95.6	42.8, 96.7	-18.3, 16.4	-12.0, 17.7	-14.6, 28.2
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	77.36 (13.50)	74.75 (15.79)	80.38 (14.92)	3.00 (2.23)	-0.24 (2.68)	2.05 (1.58)
Median	83.50	78.00	85.75	1.30	2.15	1.00
IQR: Q1, Q3	66.20, 87.60	66.60, 84.00	69.70, 91.25	-2.70, 9.60	-8.60, 5.40	-4.30, 5.50
Min, Max	44.4, 92.5	33.8, 97.4	37.2, 97.8	-17.8, 36.0	-23.3, 24.3	-11.3, 24.9

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Symptoms of Liver Disease						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	74.81 (17.79)	72.18 (22.05)	77.29 (20.24)			
Median	80.00	78.35	83.30			
IQR: Q1, Q3	66.70, 90.00	53.35, 91.70	61.65, 91.65			
Min, Max	23.3, 96.7	30.0, 100.0	30.0, 100.0			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	71.74 (24.17)	69.92 (20.57)	76.77 (22.89)	-3.06 (3.63)	0.07 (2.62)	2.11 (1.84)
Median	76.70	70.00	83.30	0	0	1.65
IQR: Q1, Q3	56.70, 86.70	60.00, 76.70	56.70, 96.70	-10.00, 10.00	-10.00, 5.70	-4.95, 6.70
Min, Max	0.0, 100.0	26.7, 100.0	20.0, 100.0	-46.7, 26.7	-13.4, 30.0	-26.6, 26.7
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	71.59 (18.57)	68.25 (21.78)	76.56 (21.92)	-2.75 (2.66)	-2.04 (3.42)	0.81 (1.56)
Median	73.30	66.70	83.30	-3.40	-1.65	0
IQR: Q1, Q3	60.00, 83.30	50.00, 90.00	68.35, 93.30	-6.70, 6.70	-13.40, 6.60	-6.60, 6.70
Min, Max	26.7, 100.0	30.0, 100.0	26.7, 100.0	-33.3, 16.7	-26.6, 30.0	-16.6, 20.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Effects of Liver Disease						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	77.04 (17.09)	77.67 (16.92)	77.97 (11.47)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	76.65, 86.70	73.30, 80.00			
Min, Max	13.3, 100.0	26.7, 100.0	40.0, 100.0			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	77.07 (17.01)	78.49 (13.32)	77.71 (12.42)	0.27 (2.26)	1.00 (2.83)	1.45 (2.00)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	73.30, 86.70	80.00, 80.00	-6.60, 0.00	-6.70, 6.70	0.00, 6.65
Min, Max	20.0, 100.0	46.7, 100.0	40.0, 100.0	-20.0, 26.6	-26.7, 20.0	-26.7, 40.0
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	81.02 (12.03)	74.03 (16.76)	77.92 (13.17)	4.79 (4.59)	-2.97 (3.50)	1.38 (2.74)
Median	80.00	80.00	80.00	0	-6.70	0
IQR: Q1, Q3	80.00, 86.70	66.70, 80.00	80.00, 80.00	0.00, 6.70	-6.70, 0.00	0.00, 6.70
Min, Max	46.7, 100.0	20.0, 100.0	33.3, 100.0	-33.3, 80.0	-33.3, 26.6	-40.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Concentration/Memory						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	78.49 (25.55)	76.90 (22.03)	78.32 (22.42)			
Median	87.50	84.40	81.30			
IQR: Q1, Q3	68.80, 100.00	68.80, 93.80	62.55, 100.00			
Min, Max	18.8, 100.0	31.3, 100.0	25.0, 100.0			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	76.27 (24.60)	77.57 (18.86)	80.91 (22.92)	-1.75 (2.87)	-0.01 (3.36)	2.34 (2.28)
Median	81.30	81.30	93.80	0	0	0
IQR: Q1, Q3	62.50, 100.00	68.80, 87.50	62.50, 100.00	-6.20, 6.20	-12.50, 6.25	0.00, 9.40
Min, Max	18.8, 100.0	31.3, 100.0	25.0, 100.0	-31.2, 25.0	-31.2, 25.0	-31.2, 37.5
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	75.84 (22.87)	73.70 (18.92)	80.09 (22.25)	0.27 (2.50)	-2.44 (4.52)	0.21 (3.03)
Median	81.30	75.00	87.50	0	0	0
IQR: Q1, Q3	62.50, 93.80	56.30, 87.50	68.80, 100.00	-6.20, 6.30	-12.50, 6.20	-6.30, 12.50
Min, Max	18.8, 100.0	43.8, 100.0	25.0, 100.0	-25.0, 25.0	-37.5, 43.7	-37.5, 31.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Health Distress						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	80.56 (26.48)	81.25 (27.36)	83.68 (24.97)			
Median	87.50	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	12.5, 100.0	0.0, 100.0			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	86.50 (26.00)	84.66 (22.47)	87.14 (22.38)	6.50 (2.61)	3.13 (3.94)	5.08 (3.41)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 6.25	0.00, 12.50
Min, Max	12.5, 100.0	25.0, 100.0	0.0, 100.0	-12.5, 37.5	-37.5, 50.0	-25.0, 75.0
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	85.33 (22.50)	85.53 (26.44)	90.23 (22.84)	7.07 (4.22)	3.47 (5.42)	7.33 (3.37)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	93.75, 100.00	0.00, 12.50	0.00, 0.00	0.00, 12.50
Min, Max	12.5, 100.0	0.0, 100.0	0.0, 100.0	-25.0, 50.0	-25.0, 75.0	-25.0, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Sexual Function						
Baseline						
m	27	22	39			
n	8	9	18			
Mean (SD)	85.83 (22.12)	68.89 (28.90)	78.24 (30.64)			
Median	96.65	76.70	90.00			
IQR: Q1, Q3	77.50, 100.00	45.00, 100.00	75.00, 100.00			
Min, Max	38.3, 100.0	30.0, 100.0	5.0, 100.0			
Week 24						
m	27	22	37			
n	7	8	19	6	7	16
Mean (SD/SE)	90.47 (9.87)	79.79 (34.04)	78.24 (26.23)	-1.38 (4.64)	7.86 (11.92)	-0.01 (3.65)
Median	93.30	89.15	93.30	0	0	0
IQR: Q1, Q3	76.70, 100.00	80.85, 100.00	63.30, 100.00	0.00, 6.60	0.00, 40.00	-8.35, 3.35
Min, Max	76.7, 100.0	-1.7, 100.0	13.3, 100.0	-23.3, 8.4	-48.4, 46.7	-23.3, 25.0
Week 52						
m	25	19	36			
n	9	9	15	6	8	13
Mean (SD/SE)	88.76 (15.29)	73.32 (39.83)	71.99 (32.76)	3.90 (11.92)	10.61 (12.04)	-4.50 (6.28)
Median	93.30	100.00	86.70	-3.35	0	0
IQR: Q1, Q3	85.00, 100.00	38.30, 100.00	46.70, 100.00	-15.00, 0.00	0.00, 35.80	-16.70, 8.30
Min, Max	51.7, 100.0	-1.7, 100.0	-1.7, 100.0	-16.6, 61.7	-48.4, 61.7	-53.3, 25.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Sleep						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	62.04 (20.06)	53.50 (24.93)	63.19 (22.59)			
Median	60.00	57.50	60.00			
IQR: Q1, Q3	45.00, 80.00	35.00, 67.50	45.00, 82.50			
Min, Max	25.0, 100.0	0.0, 100.0	25.0, 100.0			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	61.20 (18.67)	51.82 (21.85)	63.43 (20.82)	-0.60 (3.03)	-1.75 (3.67)	1.09 (2.26)
Median	60.00	50.00	60.00	0	-5.00	0
IQR: Q1, Q3	50.00, 75.00	40.00, 70.00	50.00, 80.00	-5.00, 0.00	-12.50, 5.00	-7.50, 10.00
Min, Max	25.0, 95.0	10.0, 85.0	25.0, 100.0	-30.0, 50.0	-25.0, 40.0	-25.0, 25.0
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	63.26 (18.13)	54.21 (22.93)	66.72 (21.87)	0.43 (2.01)	0.00 (4.20)	2.59 (2.19)
Median	65.00	55.00	67.50	0	0	0
IQR: Q1, Q3	50.00, 80.00	35.00, 75.00	50.00, 85.00	-5.00, 5.00	-10.00, 10.00	-5.00, 10.00
Min, Max	25.0, 95.0	10.0, 90.0	30.0, 100.0	-20.0, 20.0	-30.0, 45.0	-25.0, 25.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Loneliness						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	78.33 (22.14)	82.25 (19.90)	81.94 (21.29)			
Median	85.00	90.00	87.50			
IQR: Q1, Q3	60.00, 95.00	72.50, 100.00	75.00, 100.00			
Min, Max	35.0, 100.0	35.0, 100.0	10.0, 100.0			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	80.60 (21.62)	86.14 (15.58)	86.43 (19.69)	2.60 (3.80)	3.00 (2.89)	3.75 (2.95)
Median	85.00	90.00	95.00	0	2.50	0
IQR: Q1, Q3	70.00, 100.00	80.00, 100.00	80.00, 100.00	-5.00, 10.00	-5.00, 12.50	-7.50, 12.50
Min, Max	35.0, 100.0	40.0, 100.0	30.0, 100.0	-40.0, 45.0	-25.0, 30.0	-25.0, 40.0
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	84.57 (17.31)	82.37 (18.21)	87.19 (17.96)	8.70 (3.71)	0.83 (4.17)	3.79 (2.92)
Median	95.00	90.00	95.00	5.00	0	0
IQR: Q1, Q3	75.00, 100.00	70.00, 100.00	80.00, 100.00	0.00, 15.00	-5.00, 15.00	0.00, 5.00
Min, Max	45.0, 100.0	50.0, 100.0	30.0, 100.0	-20.0, 50.0	-35.0, 30.0	-30.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Hopelessness						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	70.68 (26.50)	75.00 (23.26)	81.48 (21.47)			
Median	75.00	83.30	91.70			
IQR: Q1, Q3	58.30, 91.70	50.00, 95.85	62.50, 100.00			
Min, Max	8.3, 100.0	33.3, 100.0	25.0, 100.0			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	69.66 (28.25)	79.17 (22.82)	80.72 (23.11)	-0.34 (2.61)	5.84 (4.84)	1.83 (2.69)
Median	75.00	87.50	91.70	0	0	0
IQR: Q1, Q3	50.00, 100.00	58.30, 100.00	66.70, 100.00	-8.30, 8.30	-8.35, 20.85	-8.30, 12.50
Min, Max	8.3, 100.0	33.3, 100.0	16.7, 100.0	-25.0, 25.0	-25.0, 50.0	-33.3, 33.3
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	71.02 (23.55)	78.51 (21.75)	83.08 (21.63)	2.90 (3.46)	2.32 (4.61)	0.87 (2.12)
Median	66.70	83.30	91.70	0	0	0
IQR: Q1, Q3	58.30, 91.70	66.70, 100.00	62.50, 100.00	0.00, 8.40	-8.40, 16.70	0.00, 8.30
Min, Max	16.7, 100.0	33.3, 100.0	41.7, 100.0	-33.4, 41.7	-33.3, 33.3	-25.0, 33.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Stigma of Liver Disease						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	84.04 (19.01)	82.52 (21.03)	84.57 (17.83)			
Median	93.80	93.80	93.80			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	31.3, 100.0	31.3, 100.0	37.5, 100.0			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	83.27 (20.22)	82.12 (13.95)	83.41 (19.99)	-0.50 (2.16)	-0.31 (3.72)	-0.78 (3.85)
Median	87.50	81.30	93.80	0	0	0
IQR: Q1, Q3	75.00, 100.00	68.80, 93.80	75.00, 100.00	0.00, 0.00	-9.40, 3.10	-9.35, 6.20
Min, Max	31.3, 100.0	62.5, 100.0	43.8, 100.0	-25.0, 25.0	-25.0, 37.5	-50.0, 50.0
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	83.71 (16.81)	81.94 (16.90)	87.13 (16.86)	1.09 (2.24)	-0.68 (4.82)	1.51 (3.64)
Median	87.50	81.30	93.80	0	0	0
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	78.15, 100.00	-6.20, 6.20	-6.20, 6.30	0.00, 6.30
Min, Max	43.8, 100.0	43.8, 100.0	43.8, 100.0	-18.7, 31.2	-56.2, 43.8	-50.0, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Total LDQOL						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	77.81 (13.88)	77.18 (14.31)	77.81 (13.73)			
Median	81.90	82.70	81.40			
IQR: Q1, Q3	68.90, 88.90	68.70, 87.00	71.80, 87.80			
Min, Max	28.3, 96.7	23.6, 96.3	34.8, 97.8			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	78.48 (14.48)	77.79 (12.52)	78.52 (13.99)	0.83 (0.81)	0.43 (0.78)	0.46 (0.66)
Median	81.85	78.85	82.30	0.95	-0.15	0.30
IQR: Q1, Q3	70.05, 89.95	70.80, 87.70	70.85, 88.85	-4.90, 6.60	-5.20, 5.40	-3.80, 4.50
Min, Max	22.9, 97.8	32.4, 96.9	22.4, 98.8	-23.4, 35.6	-15.4, 27.0	-46.4, 42.3
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	79.52 (13.38)	78.91 (13.61)	78.62 (14.18)	0.67 (0.81)	0.81 (0.92)	0.30 (0.70)
Median	83.50	82.40	81.20	0.90	0.20	0.50
IQR: Q1, Q3	70.40, 90.20	70.50, 90.00	71.20, 89.10	-3.80, 6.00	-4.30, 6.10	-4.10, 4.90
Min, Max	34.0, 97.5	34.2, 96.3	20.3, 100.0	-19.5, 25.3	-19.2, 33.9	-46.3, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Symptoms of Liver Disease						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	78.19 (19.73)	75.42 (18.22)	76.45 (17.54)			
Median	83.30	80.00	80.00			
IQR: Q1, Q3	70.00, 93.30	63.30, 90.00	63.30, 93.30			
Min, Max	13.3, 100.0	10.0, 100.0	20.0, 100.0			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	77.22 (19.40)	74.91 (17.52)	77.44 (18.66)	-1.03 (1.15)	-1.03 (1.20)	-0.12 (0.95)
Median	83.30	76.70	83.30	0	0	0
IQR: Q1, Q3	66.70, 93.30	66.70, 86.70	66.70, 91.00	-6.70, 3.40	-6.70, 6.70	-6.70, 6.70
Min, Max	16.7, 100.0	30.0, 100.0	16.7, 100.0	-43.3, 36.7	-36.6, 30.0	-53.3, 43.3
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	78.46 (19.31)	78.21 (17.21)	78.09 (18.58)	-1.78 (1.23)	1.47 (1.41)	0.58 (0.97)
Median	83.30	80.00	83.30	0	0	0
IQR: Q1, Q3	70.00, 93.30	66.70, 93.30	66.70, 93.30	-10.00, 6.60	-6.70, 10.00	-6.70, 6.70
Min, Max	6.7, 100.0	26.7, 100.0	16.7, 100.0	-43.4, 43.4	-36.7, 36.7	-60.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Effects of Liver Disease						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	77.71 (13.35)	78.70 (14.90)	77.24 (15.48)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	73.30, 86.70	80.00, 86.70			
Min, Max	6.7, 100.0	13.3, 100.0	6.7, 100.0			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	75.76 (14.32)	79.39 (9.98)	77.33 (15.32)	-2.28 (1.07)	0.41 (1.56)	-0.34 (1.03)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	76.65, 86.70	-6.70, 0.00	-6.70, 0.00	-6.70, 6.60
Min, Max	0.0, 100.0	40.0, 100.0	6.7, 100.0	-40.0, 33.3	-33.3, 76.7	-46.7, 53.4
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	75.69 (13.45)	78.63 (11.34)	77.70 (13.63)	-2.62 (1.03)	-0.04 (1.38)	-0.47 (1.28)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	73.30, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 6.60
Min, Max	6.7, 100.0	26.7, 100.0	13.3, 100.0	-40.0, 20.0	-33.3, 53.4	-80.0, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Concentration/Memory						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	80.65 (22.71)	79.26 (20.49)	78.63 (20.62)			
Median	87.50	84.40	87.50			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	68.80, 93.80			
Min, Max	6.3, 100.0	18.8, 100.0	6.3, 100.0			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	79.04 (22.18)	80.72 (19.74)	79.63 (21.52)	-1.44 (1.36)	0.53 (1.45)	0.40 (1.11)
Median	87.50	81.30	87.50	0	0	0
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	68.80, 100.00	-6.30, 6.20	-6.20, 6.30	-6.20, 6.30
Min, Max	0.0, 100.0	25.0, 100.0	6.3, 100.0	-43.8, 31.2	-37.5, 56.2	-81.2, 62.5
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	79.72 (19.68)	80.74 (20.49)	78.88 (21.76)	-0.99 (1.39)	-1.10 (1.44)	-0.64 (1.00)
Median	81.30	87.50	81.30	0	0	0
IQR: Q1, Q3	68.80, 93.80	68.80, 100.00	68.80, 100.00	-6.30, 6.20	-6.30, 6.30	-6.30, 6.30
Min, Max	0.0, 100.0	18.8, 100.0	0.0, 100.0	-43.7, 50.0	-43.8, 50.0	-43.8, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Health Distress						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	77.67 (26.22)	80.93 (25.25)	80.69 (23.98)			
Median	87.50	93.75	87.50			
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	82.39 (22.85)	87.28 (20.16)	85.56 (21.86)	5.16 (1.95)	6.72 (1.78)	5.18 (1.32)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 75.0	-37.5, 50.0	-62.5, 62.5
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	82.63 (24.29)	87.37 (20.01)	85.75 (20.66)	4.44 (2.37)	5.77 (2.07)	3.80 (1.62)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-75.0, 75.0	-50.0, 62.5	-87.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Sexual Function						
Baseline						
m	140	129	264			
n	63	63	103			
Mean (SD)	78.73 (26.97)	80.95 (22.23)	79.84 (23.36)			
Median	93.30	88.90	86.70			
IQR: Q1, Q3	68.30, 100.00	68.30, 100.00	68.30, 100.00			
Min, Max	-1.7, 100.0	-1.7, 100.0	-1.7, 100.0			
Week 24						
m	134	119	252			
n	65	69	106	51	52	78
Mean (SD/SE)	79.11 (24.80)	73.88 (27.27)	79.18 (23.07)	2.06 (3.68)	-6.28 (2.60)	0.06 (2.18)
Median	86.70	80.00	85.00	0	0	0
IQR: Q1, Q3	63.30, 100.00	55.00, 100.00	68.30, 100.00	-6.60, 8.40	-16.60, 0.00	-6.70, 8.30
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-85.0, 91.1	-55.0, 41.7	-48.4, 50.0
Week 52						
m	124	106	234			
n	44	48	86	40	39	67
Mean (SD/SE)	84.32 (22.36)	77.82 (26.66)	78.42 (24.54)	4.29 (3.47)	-5.43 (2.59)	-0.68 (2.52)
Median	93.30	89.20	85.85	0	0	0
IQR: Q1, Q3	76.70, 100.00	59.15, 100.00	60.00, 100.00	-0.85, 6.70	-15.00, 6.60	-8.30, 6.70
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-45.0, 91.1	-50.0, 23.4	-48.4, 65.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Sleep						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	63.05 (21.00)	61.31 (18.63)	62.68 (19.65)			
Median	65.00	65.00	65.00			
IQR: Q1, Q3	50.00, 80.00	50.00, 75.00	50.00, 75.00			
Min, Max	0.0, 100.0	5.0, 100.0	5.0, 100.0			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	64.09 (21.26)	59.34 (19.85)	62.33 (20.33)	1.31 (1.43)	-1.65 (1.34)	-0.52 (1.10)
Median	65.00	60.00	62.50	0	0	0
IQR: Q1, Q3	50.00, 80.00	50.00, 75.00	50.00, 75.00	-5.00, 10.00	-10.00, 5.00	-10.00, 10.00
Min, Max	5.0, 100.0	0.0, 100.0	15.0, 100.0	-25.0, 90.0	-35.0, 45.0	-40.0, 50.0
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	64.97 (19.80)	60.74 (20.82)	63.29 (20.52)	0.43 (1.72)	-1.10 (1.75)	0.60 (1.21)
Median	70.00	65.00	65.00	-5.00	0	0
IQR: Q1, Q3	55.00, 80.00	45.00, 75.00	50.00, 80.00	-10.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	10.0, 100.0	0.0, 95.0	5.0, 100.0	-40.0, 75.0	-60.0, 40.0	-40.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Loneliness						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	85.88 (16.59)	83.18 (19.98)	84.11 (19.40)			
Median	95.00	90.00	90.00			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	84.11 (18.26)	84.74 (19.89)	82.31 (20.64)	-1.57 (1.39)	0.42 (1.32)	-2.15 (1.12)
Median	90.00	95.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	80.00, 100.00	75.00, 100.00	-10.00, 5.00	-5.00, 5.00	-10.00, 5.00
Min, Max	15.0, 100.0	0.0, 100.0	10.0, 100.0	-50.0, 40.0	-35.0, 65.0	-80.0, 70.0
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	85.18 (17.47)	83.63 (21.47)	83.60 (19.23)	-1.45 (1.43)	0.11 (1.55)	-0.58 (1.15)
Median	90.00	90.00	90.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	80.00, 100.00	75.00, 100.00	-5.00, 5.00	-10.00, 10.00	-10.00, 5.00
Min, Max	25.0, 100.0	0.0, 100.0	5.0, 100.0	-60.0, 35.0	-40.0, 35.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Hopelessness						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	76.85 (21.74)	76.98 (22.93)	78.93 (21.40)			
Median	83.30	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	58.30, 100.00			
Min, Max	25.0, 100.0	8.3, 100.0	16.7, 100.0			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	79.17 (21.39)	77.56 (22.21)	78.61 (21.47)	2.97 (1.76)	0.94 (1.83)	-0.67 (1.28)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	62.50, 100.00	58.30, 100.00	66.70, 100.00	-8.30, 16.70	-8.30, 8.40	-8.30, 8.30
Min, Max	8.3, 100.0	8.3, 100.0	16.7, 100.0	-58.3, 50.0	-41.7, 58.4	-66.6, 50.0
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	80.09 (20.64)	78.25 (21.92)	77.90 (22.38)	1.40 (1.89)	1.02 (2.34)	-1.50 (1.41)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	66.70, 100.00	58.30, 100.00	-8.30, 16.60	-16.60, 16.70	-8.30, 8.30
Min, Max	33.3, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 41.7	-58.3, 50.0	-100.0, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Stigma of Liver Disease						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	82.03 (22.17)	81.11 (19.60)	83.80 (19.28)			
Median	93.80	81.30	87.50			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	85.90 (19.30)	81.11 (20.39)	85.52 (18.26)	3.57 (1.68)	0.59 (1.39)	1.93 (1.06)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	-6.20, 12.50	-6.30, 6.20	-6.20, 6.30
Min, Max	6.3, 100.0	12.5, 100.0	6.3, 100.0	-43.8, 56.2	-31.3, 56.3	-62.5, 75.0
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	87.79 (17.78)	84.93 (19.08)	84.92 (18.81)	4.26 (1.38)	3.21 (1.59)	1.75 (1.16)
Median	100.00	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	0.00, 6.30	-6.20, 12.50	-6.20, 6.30
Min, Max	31.3, 100.0	12.5, 100.0	18.8, 100.0	-31.3, 56.2	-37.5, 56.3	-62.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.9.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Total LDQOL			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	75.51 (17.18)	75.16 (16.02)	78.41 (16.10)
Analysis Visit Mean (SD)	76.15 (16.64)	76.64 (13.64)	80.58 (14.62)
LS Mean of Change from Baseline (SE)	0.27 (1.49)	0.86 (1.77)	2.18 (1.47)
95% CI	(-2.70, 3.23)	(-2.67, 4.38)	(-0.76, 5.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.91 (2.04)	-1.32 (2.13)	
95% CI	(-5.96, 2.14)	(-5.56, 2.93)	
p-value	0.3512	0.5387	
Corrected Hedge's g Statistics	-0.237	-0.159	
95% CI	(-0.76, 0.29)	(-0.72, 0.40)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	74.37 (17.60)	74.47 (16.79)	79.17 (16.30)
Analysis Visit Mean (SD)	77.36 (13.50)	74.23 (16.09)	81.21 (14.54)
LS Mean of Change from Baseline (SE)	2.84 (1.81)	-1.03 (2.14)	2.31 (1.74)
95% CI	(-0.77, 6.45)	(-5.29, 3.23)	(-1.16, 5.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.53 (2.47)	-3.34 (2.62)	
95% CI	(-4.39, 5.45)	(-8.55, 1.88)	
p-value	0.8310	0.2064	
Corrected Hedge's g Statistics	0.057	-0.354	
95% CI	(-0.49, 0.60)	(-0.95, 0.24)	
Subgroup*Treatment Interaction p-value	0.5805	0.4561	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Total LDQOL			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	77.98 (13.52)	76.97 (14.61)	78.34 (13.41)
Analysis Visit Mean (SD)	78.81 (14.31)	77.40 (12.76)	78.80 (14.02)
LS Mean of Change from Baseline (SE)	0.92 (0.79)	0.07 (0.85)	0.53 (0.60)
95% CI	(-0.63, 2.46)	(-1.60, 1.73)	(-0.64, 1.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.38 (0.97)	-0.47 (1.02)	
95% CI	(-1.52, 2.29)	(-2.48, 1.55)	
p-value	0.6924	0.6496	
Corrected Hedge's g Statistics	0.044	-0.053	
95% CI	(-0.18, 0.26)	(-0.29, 0.18)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	78.93 (12.93)	77.65 (14.89)	78.26 (13.38)
Analysis Visit Mean (SD)	79.60 (13.08)	78.46 (13.67)	78.56 (14.52)
LS Mean of Change from Baseline (SE)	0.73 (0.86)	0.66 (0.92)	0.17 (0.64)
95% CI	(-0.95, 2.42)	(-1.15, 2.47)	(-1.08, 1.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.56 (1.05)	0.49 (1.11)	
95% CI	(-1.51, 2.63)	(-1.69, 2.67)	
p-value	0.5963	0.6599	
Corrected Hedge's g Statistics	0.063	0.055	
95% CI	(-0.17, 0.30)	(-0.19, 0.30)	
Subgroup*Treatment Interaction p-value	0.5805	0.4561	

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Symptoms of Liver Disease			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	74.80 (17.74)	72.18 (22.05)	77.99 (20.43)
Analysis Visit Mean (SD)	71.74 (24.17)	72.25 (19.06)	80.11 (20.42)
LS Mean of Change from Baseline (SE)	-3.36 (2.61)	-1.78 (3.07)	1.13 (2.51)
95% CI	(-8.56, 1.84)	(-7.90, 4.33)	(-3.86, 6.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.49 (3.55)	-2.91 (3.76)	
95% CI	(-11.56, 2.57)	(-10.39, 4.57)	
p-value	0.2094	0.4406	
Corrected Hedge's g Statistics	-0.323	-0.205	
95% CI	(-0.85, 0.20)	(-0.76, 0.36)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	74.34 (18.86)	71.86 (23.22)	78.62 (20.14)
Analysis Visit Mean (SD)	71.59 (18.57)	69.82 (21.28)	79.42 (19.88)
LS Mean of Change from Baseline (SE)	-2.97 (2.24)	-4.50 (2.70)	0.44 (2.20)
95% CI	(-7.42, 1.49)	(-9.87, 0.87)	(-3.94, 4.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.40 (3.05)	-4.94 (3.23)	
95% CI	(-9.48, 2.67)	(-11.37, 1.50)	
p-value	0.2681	0.1308	
Corrected Hedge's g Statistics	-0.295	-0.415	
95% CI	(-0.85, 0.26)	(-1.01, 0.18)	
Subgroup*Treatment Interaction p-value	0.2656	0.2908	

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Effects of Liver Disease			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	76.80 (17.76)	77.67 (16.92)	77.50 (11.94)
Analysis Visit Mean (SD)	77.07 (17.01)	78.67 (13.61)	78.96 (10.99)
LS Mean of Change from Baseline (SE)	0.07 (2.06)	0.73 (2.40)	1.07 (2.00)
95% CI	(-4.02, 4.16)	(-4.05, 5.51)	(-2.91, 5.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.00 (2.79)	-0.34 (2.91)	
95% CI	(-6.55, 4.56)	(-6.14, 5.46)	
p-value	0.7218	0.9085	
Corrected Hedge's g Statistics	-0.091	-0.030	
95% CI	(-0.61, 0.43)	(-0.59, 0.53)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	76.23 (18.41)	76.67 (17.45)	77.24 (12.54)
Analysis Visit Mean (SD)	81.02 (12.03)	73.70 (17.18)	78.62 (13.02)
LS Mean of Change from Baseline (SE)	4.00 (2.76)	-3.94 (3.22)	0.91 (2.59)
95% CI	(-1.50, 9.50)	(-10.35, 2.46)	(-4.25, 6.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.10 (3.73)	-4.85 (3.96)	
95% CI	(-4.33, 10.52)	(-12.73, 3.04)	
p-value	0.4088	0.2248	
Corrected Hedge's g Statistics	0.224	-0.345	
95% CI	(-0.33, 0.77)	(-0.94, 0.25)	
Subgroup*Treatment Interaction p-value	0.4156	0.3140	

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Concentration/Memory			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	78.02 (26.51)	76.90 (22.03)	79.51 (23.12)
Analysis Visit Mean (SD)	76.27 (24.60)	76.89 (19.02)	81.85 (23.23)
LS Mean of Change from Baseline (SE)	-1.93 (2.54)	-1.62 (3.02)	1.19 (2.51)
95% CI	(-6.99, 3.13)	(-7.64, 4.40)	(-3.81, 6.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.12 (3.47)	-2.81 (3.64)	
95% CI	(-10.03, 3.79)	(-10.05, 4.43)	
p-value	0.3711	0.4416	
Corrected Hedge's g Statistics	-0.227	-0.199	
95% CI	(-0.75, 0.30)	(-0.76, 0.36)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	75.57 (26.57)	75.37 (22.72)	80.84 (21.83)
Analysis Visit Mean (SD)	75.84 (22.87)	72.93 (19.16)	81.05 (22.31)
LS Mean of Change from Baseline (SE)	-1.18 (2.88)	-4.14 (3.42)	-0.73 (2.79)
95% CI	(-6.92, 4.55)	(-10.95, 2.67)	(-6.29, 4.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.45 (3.93)	-3.41 (4.15)	
95% CI	(-8.27, 7.36)	(-11.68, 4.86)	
p-value	0.9088	0.4145	
Corrected Hedge's g Statistics	-0.031	-0.226	
95% CI	(-0.58, 0.52)	(-0.82, 0.36)	
Subgroup*Treatment Interaction p-value	0.6637	0.4102	

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Health Distress			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	80.00 (27.24)	81.25 (27.36)	83.20 (25.32)
Analysis Visit Mean (SD)	86.50 (26.00)	84.38 (23.25)	88.28 (22.21)
LS Mean of Change from Baseline (SE)	5.82 (3.01)	2.75 (3.56)	5.24 (2.96)
95% CI	(-0.17, 11.81)	(-4.34, 9.85)	(-0.65, 11.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.58 (4.11)	-2.49 (4.29)	
95% CI	(-7.60, 8.75)	(-11.04, 6.06)	
p-value	0.8885	0.5638	
Corrected Hedge's g Statistics	0.036	-0.149	
95% CI	(-0.49, 0.56)	(-0.71, 0.41)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	78.26 (28.01)	81.94 (27.53)	83.19 (26.57)
Analysis Visit Mean (SD)	85.33 (22.50)	85.42 (27.20)	90.52 (23.30)
LS Mean of Change from Baseline (SE)	5.85 (3.56)	3.42 (4.19)	7.05 (3.41)
95% CI	(-1.23, 12.92)	(-4.92, 11.76)	(0.27, 13.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.20 (4.83)	-3.63 (5.10)	
95% CI	(-10.81, 8.41)	(-13.79, 6.53)	
p-value	0.8036	0.4788	
Corrected Hedge's g Statistics	-0.067	-0.197	
95% CI	(-0.61, 0.48)	(-0.79, 0.39)	
Subgroup*Treatment Interaction p-value	0.8918	0.3073	

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Sexual Function			
Week 24			
m	27	22	37
n	6	7	16
Baseline Mean (SD)	91.38 (12.50)	70.00 (26.44)	81.46 (25.76)
Analysis Visit Mean (SD)	90.00 (10.73)	77.86 (36.29)	81.46 (22.76)
LS Mean of Change from Baseline (SE)	7.31 (7.47)	8.67 (7.81)	6.15 (6.00)
95% CI	(-7.93, 22.54)	(-7.26, 24.60)	(-6.09, 18.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.16 (8.91)	2.52 (8.02)	
95% CI	(-17.02, 19.33)	(-13.84, 18.88)	
p-value	0.8977	0.7558	
Corrected Hedge's g Statistics	0.049	0.105	
95% CI	(-0.89, 0.99)	(-0.78, 0.99)	
Week 52			
m	25	19	36
n	6	8	13
Baseline Mean (SD)	83.32 (25.25)	67.09 (30.35)	80.52 (28.91)
Analysis Visit Mean (SD)	87.22 (18.26)	77.70 (40.19)	76.02 (27.28)
LS Mean of Change from Baseline (SE)	8.93 (10.01)	12.53 (9.57)	-0.30 (7.53)
95% CI	(-11.48, 29.35)	(-6.99, 32.05)	(-15.66, 15.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.24 (11.82)	12.83 (10.86)	
95% CI	(-14.87, 33.35)	(-9.32, 34.98)	
p-value	0.4404	0.2464	
Corrected Hedge's g Statistics	0.334	0.454	
95% CI	(-0.64, 1.31)	(-0.44, 1.35)	
Subgroup*Treatment Interaction p-value	0.4925	0.2062	

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Sleep			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	61.80 (19.57)	53.50 (24.93)	63.59 (22.76)
Analysis Visit Mean (SD)	61.20 (18.67)	51.75 (22.61)	64.69 (21.10)
LS Mean of Change from Baseline (SE)	-0.56 (2.63)	-3.42 (3.10)	2.42 (2.52)
95% CI	(-5.80, 4.67)	(-9.60, 2.76)	(-2.60, 7.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.98 (3.57)	-5.84 (3.81)	
95% CI	(-10.08, 4.11)	(-13.42, 1.74)	
p-value	0.4051	0.1290	
Corrected Hedge's g Statistics	-0.213	-0.407	
95% CI	(-0.74, 0.31)	(-0.97, 0.16)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	62.83 (21.04)	52.50 (26.02)	65.69 (23.63)
Analysis Visit Mean (SD)	63.26 (18.13)	52.50 (22.31)	68.28 (21.76)
LS Mean of Change from Baseline (SE)	1.63 (2.44)	-1.67 (2.95)	4.18 (2.38)
95% CI	(-3.24, 6.49)	(-7.54, 4.20)	(-0.55, 8.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.56 (3.32)	-5.85 (3.58)	
95% CI	(-9.16, 4.05)	(-12.99, 1.28)	
p-value	0.4436	0.1065	
Corrected Hedge's g Statistics	-0.204	-0.453	
95% CI	(-0.75, 0.34)	(-1.05, 0.14)	
Subgroup*Treatment Interaction p-value	0.3877	0.3446	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Loneliness			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	78.00 (23.00)	82.25 (19.90)	81.88 (22.39)
Analysis Visit Mean (SD)	80.60 (21.62)	85.25 (16.02)	85.63 (20.31)
LS Mean of Change from Baseline (SE)	1.28 (2.86)	2.79 (3.36)	3.20 (2.78)
95% CI	(-4.42, 6.97)	(-3.91, 9.48)	(-2.33, 8.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.92 (3.90)	-0.41 (4.07)	
95% CI	(-9.69, 5.85)	(-8.52, 7.69)	
p-value	0.6236	0.9192	
Corrected Hedge's g Statistics	-0.125	-0.026	
95% CI	(-0.65, 0.40)	(-0.59, 0.53)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	75.87 (23.04)	80.56 (20.28)	82.93 (22.06)
Analysis Visit Mean (SD)	84.57 (17.31)	81.39 (18.21)	86.72 (18.63)
LS Mean of Change from Baseline (SE)	6.98 (2.87)	-0.05 (3.40)	4.02 (2.78)
95% CI	(1.27, 12.69)	(-6.81, 6.71)	(-1.52, 9.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.96 (3.92)	-4.07 (4.10)	
95% CI	(-4.85, 10.77)	(-12.22, 4.09)	
p-value	0.4532	0.3238	
Corrected Hedge's g Statistics	0.201	-0.271	
95% CI	(-0.35, 0.75)	(-0.86, 0.32)	
Subgroup*Treatment Interaction p-value	0.9533	0.3363	

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Hopelessness			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	70.00 (27.44)	75.00 (23.26)	80.21 (22.28)
Analysis Visit Mean (SD)	69.66 (28.25)	80.84 (22.96)	82.03 (22.21)
LS Mean of Change from Baseline (SE)	-1.67 (3.16)	6.17 (3.68)	3.77 (3.05)
95% CI	(-7.96, 4.62)	(-1.15, 13.50)	(-2.31, 9.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.43 (4.32)	2.41 (4.49)	
95% CI	(-14.04, 3.18)	(-6.53, 11.35)	
p-value	0.2127	0.5935	
Corrected Hedge's g Statistics	-0.322	0.140	
95% CI	(-0.85, 0.20)	(-0.42, 0.70)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	68.11 (27.60)	75.46 (24.51)	81.61 (20.34)
Analysis Visit Mean (SD)	71.02 (23.55)	77.78 (22.14)	82.48 (22.09)
LS Mean of Change from Baseline (SE)	2.32 (3.03)	3.99 (3.56)	2.17 (2.94)
95% CI	(-3.72, 8.35)	(-3.10, 11.08)	(-3.68, 8.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.15 (4.16)	1.82 (4.31)	
95% CI	(-8.14, 8.43)	(-6.76, 10.39)	
p-value	0.9722	0.6745	
Corrected Hedge's g Statistics	0.009	0.115	
95% CI	(-0.54, 0.56)	(-0.47, 0.70)	
Subgroup*Treatment Interaction p-value	0.0930	0.8089	

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Stigma of Liver Disease			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	83.77 (19.43)	82.52 (21.03)	84.98 (18.43)
Analysis Visit Mean (SD)	83.27 (20.22)	82.21 (13.34)	84.20 (19.76)
LS Mean of Change from Baseline (SE)	-0.42 (3.05)	-1.10 (3.59)	-0.94 (2.96)
95% CI	(-6.49, 5.65)	(-8.24, 6.05)	(-6.83, 4.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.52 (4.15)	-0.15 (4.36)	
95% CI	(-7.74, 8.79)	(-8.84, 8.53)	
p-value	0.8997	0.9719	
Corrected Hedge's g Statistics	0.032	-0.009	
95% CI	(-0.49, 0.56)	(-0.57, 0.55)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	82.63 (19.85)	81.62 (22.01)	85.79 (18.14)
Analysis Visit Mean (SD)	83.71 (16.81)	80.93 (16.80)	87.31 (17.23)
LS Mean of Change from Baseline (SE)	1.27 (2.96)	-2.36 (3.53)	2.96 (2.88)
95% CI	(-4.62, 7.16)	(-9.39, 4.67)	(-2.77, 8.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.69 (4.03)	-5.33 (4.26)	
95% CI	(-9.71, 6.33)	(-13.80, 3.15)	
p-value	0.6758	0.2144	
Corrected Hedge's g Statistics	-0.111	-0.342	
95% CI	(-0.66, 0.44)	(-0.93, 0.25)	
Subgroup*Treatment Interaction p-value	0.4759	0.8171	

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Symptoms of Liver Disease			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	78.28 (19.58)	75.38 (18.18)	77.52 (17.39)
Analysis Visit Mean (SD)	77.25 (19.55)	74.34 (17.61)	77.40 (19.02)
LS Mean of Change from Baseline (SE)	-0.60 (1.15)	-1.32 (1.24)	-0.18 (0.87)
95% CI	(-2.86, 1.65)	(-3.75, 1.11)	(-1.89, 1.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.42 (1.42)	-1.14 (1.49)	
95% CI	(-3.21, 2.36)	(-4.08, 1.79)	
p-value	0.7650	0.4443	
Corrected Hedge's g Statistics	-0.033	-0.089	
95% CI	(-0.25, 0.19)	(-0.32, 0.14)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	79.84 (18.45)	76.15 (17.05)	77.21 (17.06)
Analysis Visit Mean (SD)	78.07 (19.28)	77.62 (17.27)	77.79 (18.80)
LS Mean of Change from Baseline (SE)	-1.36 (1.24)	0.93 (1.33)	0.69 (0.92)
95% CI	(-3.79, 1.08)	(-1.69, 3.54)	(-1.12, 2.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.04 (1.52)	0.24 (1.60)	
95% CI	(-5.04, 0.95)	(-2.91, 3.39)	
p-value	0.1802	0.8807	
Corrected Hedge's g Statistics	-0.159	0.019	
95% CI	(-0.40, 0.08)	(-0.23, 0.27)	
Subgroup*Treatment Interaction p-value	0.2656	0.2908	

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Effects of Liver Disease			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	78.31 (12.39)	78.62 (15.28)	77.82 (14.71)
Analysis Visit Mean (SD)	76.03 (13.91)	79.03 (10.10)	77.48 (15.13)
LS Mean of Change from Baseline (SE)	-2.20 (1.11)	0.61 (1.19)	-0.51 (0.84)
95% CI	(-4.37, -0.02)	(-1.74, 2.95)	(-2.16, 1.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.69 (1.37)	1.11 (1.45)	
95% CI	(-4.38, 1.00)	(-1.73, 3.95)	
p-value	0.2177	0.4420	
Corrected Hedge's g Statistics	-0.136	0.090	
95% CI	(-0.36, 0.08)	(-0.14, 0.32)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	78.57 (11.76)	78.61 (15.51)	78.11 (13.59)
Analysis Visit Mean (SD)	75.95 (13.54)	78.57 (11.59)	77.65 (13.76)
LS Mean of Change from Baseline (SE)	-2.54 (1.20)	0.04 (1.29)	-0.65 (0.89)
95% CI	(-4.89, -0.18)	(-2.50, 2.58)	(-2.41, 1.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.88 (1.47)	0.69 (1.55)	
95% CI	(-4.78, 1.01)	(-2.36, 3.75)	
p-value	0.2023	0.6552	
Corrected Hedge's g Statistics	-0.151	0.056	
95% CI	(-0.39, 0.09)	(-0.19, 0.30)	
Subgroup*Treatment Interaction p-value	0.4156	0.3140	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Concentration/Memory			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	81.02 (22.18)	79.68 (20.41)	79.22 (20.59)
Analysis Visit Mean (SD)	79.58 (22.00)	80.21 (20.04)	79.63 (21.68)
LS Mean of Change from Baseline (SE)	-1.03 (1.34)	0.30 (1.45)	0.26 (1.02)
95% CI	(-3.68, 1.61)	(-2.54, 3.14)	(-1.74, 2.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.29 (1.66)	0.04 (1.75)	
95% CI	(-4.56, 1.97)	(-3.40, 3.48)	
p-value	0.4362	0.9815	
Corrected Hedge's g Statistics	-0.086	0.003	
95% CI	(-0.31, 0.13)	(-0.23, 0.23)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	80.74 (21.83)	81.06 (19.14)	79.05 (20.43)
Analysis Visit Mean (SD)	79.75 (19.53)	79.97 (20.59)	78.40 (22.23)
LS Mean of Change from Baseline (SE)	-1.42 (1.32)	-0.48 (1.41)	-0.74 (0.98)
95% CI	(-4.01, 1.17)	(-3.26, 2.30)	(-2.67, 1.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.67 (1.62)	0.26 (1.70)	
95% CI	(-3.85, 2.50)	(-3.09, 3.60)	
p-value	0.6768	0.8793	
Corrected Hedge's g Statistics	-0.049	0.019	
95% CI	(-0.29, 0.19)	(-0.23, 0.27)	
Subgroup*Treatment Interaction p-value	0.6637	0.4102	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Health Distress			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	77.88 (26.23)	79.72 (25.90)	80.41 (23.89)
Analysis Visit Mean (SD)	83.04 (21.88)	86.44 (20.64)	85.60 (22.15)
LS Mean of Change from Baseline (SE)	4.27 (1.51)	6.46 (1.63)	5.31 (1.15)
95% CI	(1.29, 7.24)	(3.27, 9.66)	(3.05, 7.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.04 (1.87)	1.16 (1.97)	
95% CI	(-4.71, 2.62)	(-2.71, 5.02)	
p-value	0.5768	0.5566	
Corrected Hedge's g Statistics	-0.061	0.069	
95% CI	(-0.28, 0.16)	(-0.16, 0.30)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	78.39 (25.33)	81.18 (26.05)	81.64 (23.09)
Analysis Visit Mean (SD)	82.83 (23.39)	86.95 (20.32)	85.44 (21.04)
LS Mean of Change from Baseline (SE)	2.89 (1.78)	6.27 (1.91)	4.44 (1.32)
95% CI	(-0.61, 6.39)	(2.51, 10.03)	(1.83, 7.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.55 (2.19)	1.83 (2.31)	
95% CI	(-5.86, 2.76)	(-2.70, 6.36)	
p-value	0.4804	0.4274	
Corrected Hedge's g Statistics	-0.084	0.099	
95% CI	(-0.32, 0.15)	(-0.15, 0.35)	
Subgroup*Treatment Interaction p-value	0.8918	0.3073	

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Sexual Function			
Week 24			
m	134	119	252
n	51	52	78
Baseline Mean (SD)	76.25 (28.92)	83.16 (20.86)	81.71 (21.47)
Analysis Visit Mean (SD)	78.30 (26.43)	76.89 (23.97)	81.77 (21.42)
LS Mean of Change from Baseline (SE)	0.51 (2.65)	-5.69 (2.64)	-0.19 (2.13)
95% CI	(-4.71, 5.73)	(-10.89, -0.49)	(-4.38, 4.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.69 (3.38)	-5.50 (3.36)	
95% CI	(-5.97, 7.35)	(-12.12, 1.11)	
p-value	0.8376	0.1026	
Corrected Hedge's g Statistics	0.037	-0.290	
95% CI	(-0.32, 0.39)	(-0.64, 0.06)	
Week 52			
m	124	106	234
n	40	39	67
Baseline Mean (SD)	81.34 (28.41)	84.73 (18.80)	79.87 (23.02)
Analysis Visit Mean (SD)	85.62 (21.27)	79.30 (25.48)	79.19 (24.84)
LS Mean of Change from Baseline (SE)	3.95 (2.75)	-3.63 (2.78)	-1.38 (2.16)
95% CI	(-1.47, 9.37)	(-9.10, 1.85)	(-5.63, 2.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.33 (3.47)	-2.25 (3.49)	
95% CI	(-1.51, 12.17)	(-9.13, 4.63)	
p-value	0.1260	0.5204	
Corrected Hedge's g Statistics	0.302	-0.127	
95% CI	(-0.09, 0.70)	(-0.52, 0.27)	
Subgroup*Treatment Interaction p-value	0.4925	0.2062	

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Sleep			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	63.21 (20.97)	60.80 (18.91)	63.47 (19.60)
Analysis Visit Mean (SD)	64.52 (20.51)	59.15 (20.11)	62.95 (20.16)
LS Mean of Change from Baseline (SE)	1.35 (1.32)	-2.66 (1.42)	-0.65 (1.00)
95% CI	(-1.25, 3.94)	(-5.45, 0.13)	(-2.62, 1.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.00 (1.63)	-2.01 (1.72)	
95% CI	(-1.20, 5.19)	(-5.38, 1.37)	
p-value	0.2193	0.2429	
Corrected Hedge's g Statistics	0.135	-0.136	
95% CI	(-0.08, 0.36)	(-0.37, 0.10)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	64.39 (20.46)	61.76 (19.38)	63.01 (19.65)
Analysis Visit Mean (SD)	64.83 (19.00)	60.66 (20.98)	63.61 (20.77)
LS Mean of Change from Baseline (SE)	0.95 (1.51)	-1.89 (1.62)	0.21 (1.12)
95% CI	(-2.02, 3.91)	(-5.07, 1.29)	(-2.00, 2.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.74 (1.85)	-2.10 (1.95)	
95% CI	(-2.90, 4.38)	(-5.93, 1.74)	
p-value	0.6897	0.2830	
Corrected Hedge's g Statistics	0.047	-0.134	
95% CI	(-0.19, 0.28)	(-0.38, 0.11)	
Subgroup*Treatment Interaction p-value	0.3877	0.3446	

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Loneliness			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	85.83 (16.66)	84.10 (20.02)	84.64 (19.13)
Analysis Visit Mean (SD)	84.27 (18.10)	84.53 (20.11)	82.49 (20.81)
LS Mean of Change from Baseline (SE)	-1.49 (1.33)	0.09 (1.44)	-2.29 (1.01)
95% CI	(-4.11, 1.13)	(-2.74, 2.91)	(-4.28, -0.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.80 (1.65)	2.38 (1.74)	
95% CI	(-2.44, 4.04)	(-1.04, 5.80)	
p-value	0.6273	0.1717	
Corrected Hedge's g Statistics	0.054	0.160	
95% CI	(-0.17, 0.27)	(-0.07, 0.39)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	86.54 (16.91)	83.08 (20.83)	84.27 (19.49)
Analysis Visit Mean (SD)	85.09 (17.40)	83.19 (21.79)	83.69 (19.52)
LS Mean of Change from Baseline (SE)	-1.32 (1.40)	-0.55 (1.51)	-1.22 (1.04)
95% CI	(-4.07, 1.44)	(-3.51, 2.41)	(-3.26, 0.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (1.72)	0.66 (1.81)	
95% CI	(-3.48, 3.28)	(-2.90, 4.23)	
p-value	0.9536	0.7148	
Corrected Hedge's g Statistics	-0.007	0.046	
95% CI	(-0.24, 0.23)	(-0.20, 0.29)	
Subgroup*Treatment Interaction p-value	0.9533	0.3363	

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Hopelessness			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	76.86 (21.42)	76.10 (22.81)	79.91 (20.64)
Analysis Visit Mean (SD)	79.83 (20.99)	77.04 (22.60)	79.25 (21.24)
LS Mean of Change from Baseline (SE)	2.49 (1.56)	-0.28 (1.68)	-0.01 (1.18)
95% CI	(-0.58, 5.55)	(-3.59, 3.02)	(-2.34, 2.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.50 (1.93)	-0.27 (2.04)	
95% CI	(-1.29, 6.29)	(-4.27, 3.73)	
p-value	0.1957	0.8932	
Corrected Hedge's g Statistics	0.143	-0.016	
95% CI	(-0.08, 0.36)	(-0.25, 0.22)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	79.13 (20.04)	76.46 (23.92)	79.77 (21.17)
Analysis Visit Mean (SD)	80.53 (20.38)	77.48 (22.03)	78.27 (22.53)
LS Mean of Change from Baseline (SE)	2.34 (1.76)	0.07 (1.89)	-1.07 (1.31)
95% CI	(-1.12, 5.80)	(-3.65, 3.80)	(-3.64, 1.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.41 (2.16)	1.14 (2.28)	
95% CI	(-0.85, 7.66)	(-3.34, 5.63)	
p-value	0.1160	0.6162	
Corrected Hedge's g Statistics	0.186	0.063	
95% CI	(-0.05, 0.42)	(-0.19, 0.31)	
Subgroup*Treatment Interaction p-value	0.0930	0.8089	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.9.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Stigma of Liver Disease			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	82.36 (21.57)	80.38 (20.14)	84.03 (19.23)
Analysis Visit Mean (SD)	85.93 (19.29)	80.98 (21.10)	85.95 (18.26)
LS Mean of Change from Baseline (SE)	3.46 (1.31)	-0.19 (1.42)	2.46 (1.00)
95% CI	(0.88, 6.05)	(-2.98, 2.60)	(0.50, 4.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.01 (1.63)	-2.64 (1.72)	
95% CI	(-2.19, 4.20)	(-6.02, 0.73)	
p-value	0.5359	0.1248	
Corrected Hedge's g Statistics	0.068	-0.180	
95% CI	(-0.15, 0.29)	(-0.41, 0.05)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	83.89 (20.87)	81.47 (20.12)	83.26 (19.17)
Analysis Visit Mean (SD)	88.16 (17.57)	84.68 (19.36)	85.01 (19.05)
LS Mean of Change from Baseline (SE)	4.59 (1.34)	2.48 (1.44)	1.73 (1.00)
95% CI	(1.95, 7.22)	(-0.36, 5.31)	(-0.23, 3.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.86 (1.65)	0.74 (1.74)	
95% CI	(-0.38, 6.09)	(-2.67, 4.15)	
p-value	0.0833	0.6682	
Corrected Hedge's g Statistics	0.205	0.054	
95% CI	(-0.03, 0.44)	(-0.20, 0.30)	
Subgroup*Treatment Interaction p-value	0.4759	0.8171	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.4)	1 (4.5)	3 (7.7)
No	25 (92.6)	21 (95.5)	36 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.75	
95% CI of the inverse odds ratio	(0.16, 6.69)	(0.17, 17.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.69	
95% CI of the inverse risk ratio	(0.19, 5.80)	(0.19, 15.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.28	-3.15	
95% CI of the absolute risk difference	(-13.23, 12.66)	(-15.22, 8.92)	
p-value	0.9657	0.6335	
p-value of Breslow-Day Test for Homogeneity [3]	0.9180	0.7568	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (25.9)	5 (22.7)	10 (25.6)
No	20 (74.1)	17 (77.3)	29 (74.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.17	
95% CI of the inverse odds ratio	(0.32, 3.02)	(0.34, 4.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.13	
95% CI of the inverse risk ratio	(0.43, 2.27)	(0.44, 2.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.28	-2.91	
95% CI of the absolute risk difference	(-21.19, 21.76)	(-25.15, 19.32)	
p-value	0.9792	0.7997	
p-value of Breslow-Day Test for Homogeneity [3]	0.7118	0.6240	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.4)	2 (9.1)	1 (2.6)
No	25 (92.6)	20 (90.9)	38 (97.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	0.26	
95% CI of the inverse odds ratio	(0.03, 3.82)	(0.02, 3.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.35	0.28	
95% CI of the inverse risk ratio	(0.03, 3.63)	(0.03, 2.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.84	6.53	
95% CI of the absolute risk difference	(-6.21, 15.90)	(-6.47, 19.52)	
p-value	0.3530	0.2576	
p-value of Breslow-Day Test for Homogeneity [3]	0.0473	0.3456	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (25.9)	5 (22.7)	9 (23.1)
No	20 (74.1)	17 (77.3)	30 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.02	
95% CI of the inverse odds ratio	(0.27, 2.68)	(0.29, 3.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.02	
95% CI of the inverse risk ratio	(0.38, 2.10)	(0.39, 2.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.85	-0.35	
95% CI of the absolute risk difference	(-18.32, 24.02)	(-22.29, 21.59)	
p-value	0.7906	0.9751	
p-value of Breslow-Day Test for Homogeneity [3]	0.4881	0.9404	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (11.1)	3 (13.6)	3 (7.7)
No	24 (88.9)	19 (86.4)	36 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.53	
95% CI of the inverse odds ratio	(0.12, 3.58)	(0.10, 2.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.56	
95% CI of the inverse risk ratio	(0.15, 3.18)	(0.12, 2.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.42	5.94	
95% CI of the absolute risk difference	(-11.09, 17.93)	(-10.66, 22.54)	
p-value	0.6348	0.4541	
p-value of Breslow-Day Test for Homogeneity [3]	0.0273	0.2272	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (25.9)	4 (18.2)	8 (20.5)
No	20 (74.1)	18 (81.8)	31 (79.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.16	
95% CI of the inverse odds ratio	(0.23, 2.35)	(0.31, 4.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	1.13	
95% CI of the inverse risk ratio	(0.33, 1.92)	(0.38, 3.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.41	-2.33	
95% CI of the absolute risk difference	(-15.42, 26.24)	(-22.83, 18.17)	
p-value	0.6059	0.8259	
p-value of Breslow-Day Test for Homogeneity [3]	0.3081	0.8882	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (11.1)	2 (9.1)	4 (10.3)
No	24 (88.9)	20 (90.9)	35 (89.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.14	
95% CI of the inverse odds ratio	(0.19, 4.46)	(0.19, 6.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.13	
95% CI of the inverse risk ratio	(0.22, 3.80)	(0.22, 5.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.85	-1.17	
95% CI of the absolute risk difference	(-14.35, 16.06)	(-16.49, 14.16)	
p-value	0.9117	0.8833	
p-value of Breslow-Day Test for Homogeneity [3]	0.7521	0.9873	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (29.6)	6 (27.3)	9 (23.1)
No	19 (70.4)	16 (72.7)	30 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.80	
95% CI of the inverse odds ratio	(0.23, 2.17)	(0.24, 2.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.85	
95% CI of the inverse risk ratio	(0.34, 1.76)	(0.35, 2.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.55	4.20	
95% CI of the absolute risk difference	(-15.16, 28.27)	(-18.63, 27.03)	
p-value	0.5495	0.7148	
p-value of Breslow-Day Test for Homogeneity [3]	0.5056	0.8213	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (18.5)	3 (13.6)	6 (15.4)
No	22 (81.5)	19 (86.4)	33 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.15	
95% CI of the inverse odds ratio	(0.22, 2.95)	(0.26, 5.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	1.13	
95% CI of the inverse risk ratio	(0.28, 2.45)	(0.31, 4.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.13	-1.75	
95% CI of the absolute risk difference	(-15.38, 21.65)	(-20.02, 16.52)	
p-value	0.7370	0.8533	
p-value of Breslow-Day Test for Homogeneity [3]	0.8931	0.6533	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (25.9)	3 (13.6)	8 (20.5)
No	20 (74.1)	19 (86.4)	31 (79.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.63	
95% CI of the inverse odds ratio	(0.23, 2.35)	(0.39, 6.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	1.50	
95% CI of the inverse risk ratio	(0.33, 1.92)	(0.44, 5.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.41	-6.88	
95% CI of the absolute risk difference	(-15.42, 26.24)	(-26.01, 12.26)	
p-value	0.6059	0.5023	
p-value of Breslow-Day Test for Homogeneity [3]	0.6161	0.4500	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.7)	3 (13.6)	3 (7.7)
No	26 (96.3)	19 (86.4)	36 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.17	0.53	
95% CI of the inverse odds ratio	(0.21, 22.02)	(0.10, 2.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	0.56	
95% CI of the inverse risk ratio	(0.23, 18.92)	(0.12, 2.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.99	5.94	
95% CI of the absolute risk difference	(-14.97, 7.00)	(-10.66, 22.54)	
p-value	0.5043	0.4541	
p-value of Breslow-Day Test for Homogeneity [3]	0.5822	0.2882	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (3.7)	3 (13.6)	5 (12.8)
No	26 (96.3)	19 (86.4)	34 (87.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.82	0.93	
95% CI of the inverse odds ratio	(0.42, 34.75)	(0.20, 4.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.46	0.94	
95% CI of the inverse risk ratio	(0.43, 27.99)	(0.25, 3.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.12	0.82	
95% CI of the absolute risk difference	(-21.80, 3.57)	(-16.95, 18.58)	
p-value	0.2053	0.9278	
p-value of Breslow-Day Test for Homogeneity [3]	0.1907	0.9582	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (11.1)	4 (18.2)	4 (10.3)
No	24 (88.9)	18 (81.8)	35 (89.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.51	
95% CI of the inverse odds ratio	(0.19, 4.46)	(0.11, 2.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.56	
95% CI of the inverse risk ratio	(0.22, 3.80)	(0.16, 2.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.85	7.93	
95% CI of the absolute risk difference	(-14.35, 16.06)	(-10.79, 26.64)	
p-value	0.9117	0.3786	
p-value of Breslow-Day Test for Homogeneity [3]	0.8520	0.2130	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (25.9)	7 (31.8)	14 (35.9)
No	20 (74.1)	15 (68.2)	25 (64.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.60	1.20	
95% CI of the inverse odds ratio	(0.54, 4.72)	(0.40, 3.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	1.13	
95% CI of the inverse risk ratio	(0.65, 2.97)	(0.54, 2.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.97	-4.08	
95% CI of the absolute risk difference	(-32.33, 12.39)	(-28.69, 20.53)	
p-value	0.3925	0.7475	
p-value of Breslow-Day Test for Homogeneity [3]	0.4993	0.8849	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (29.6)	5 (22.7)	6 (15.4)
No	19 (70.4)	17 (77.3)	33 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	0.62	
95% CI of the inverse odds ratio	(0.13, 1.43)	(0.16, 2.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	0.68	
95% CI of the inverse risk ratio	(0.20, 1.33)	(0.23, 1.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.25	7.34	
95% CI of the absolute risk difference	(-6.37, 34.86)	(-13.51, 28.20)	
p-value	0.1640	0.4738	
p-value of Breslow-Day Test for Homogeneity [3]	0.1424	0.9309	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (48.1)	8 (36.4)	14 (35.9)
No	14 (51.9)	14 (63.6)	25 (64.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.98	
95% CI of the inverse odds ratio	(0.22, 1.64)	(0.33, 2.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.99	
95% CI of the inverse risk ratio	(0.42, 1.32)	(0.49, 1.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.25	0.47	
95% CI of the absolute risk difference	(-11.87, 36.37)	(-24.65, 25.58)	
p-value	0.3196	0.9710	
p-value of Breslow-Day Test for Homogeneity [3]	0.1321	0.8278	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (14.8)	6 (27.3)	3 (7.7)
No	23 (85.2)	16 (72.7)	36 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	0.22	
95% CI of the inverse odds ratio	(0.10, 2.34)	(0.05, 1.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	0.28	
95% CI of the inverse risk ratio	(0.13, 2.14)	(0.08, 1.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.12	19.58	
95% CI of the absolute risk difference	(-8.67, 22.92)	(-0.82, 39.98)	
p-value	0.3555	0.0384	
p-value of Breslow-Day Test for Homogeneity [3]	0.6521	0.2109	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (33.3)	8 (36.4)	9 (23.1)
No	18 (66.7)	14 (63.6)	30 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.53	
95% CI of the inverse odds ratio	(0.20, 1.79)	(0.17, 1.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.63	
95% CI of the inverse risk ratio	(0.32, 1.51)	(0.29, 1.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.26	13.29	
95% CI of the absolute risk difference	(-11.90, 32.42)	(-10.77, 37.35)	
p-value	0.3576	0.2664	
p-value of Breslow-Day Test for Homogeneity [3]	0.6679	0.5361	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.4)	2 (9.1)	3 (7.7)
No	25 (92.6)	20 (90.9)	36 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.83	
95% CI of the inverse odds ratio	(0.16, 6.69)	(0.13, 5.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.85	
95% CI of the inverse risk ratio	(0.19, 5.80)	(0.15, 4.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.28	1.40	
95% CI of the absolute risk difference	(-13.23, 12.66)	(-13.24, 16.04)	
p-value	0.9657	0.8484	
p-value of Breslow-Day Test for Homogeneity [3]	0.8562	0.9345	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (29.6)	8 (36.4)	9 (23.1)
No	19 (70.4)	14 (63.6)	30 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.53	
95% CI of the inverse odds ratio	(0.23, 2.17)	(0.17, 1.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.63	
95% CI of the inverse risk ratio	(0.34, 1.76)	(0.29, 1.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.55	13.29	
95% CI of the absolute risk difference	(-15.16, 28.27)	(-10.77, 37.35)	
p-value	0.5495	0.2664	
p-value of Breslow-Day Test for Homogeneity [3]	0.8211	0.3003	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (2.9)	3 (2.3)	7 (2.7)
No	136 (97.1)	126 (97.7)	257 (97.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.14	
95% CI of the inverse odds ratio	(0.27, 3.22)	(0.29, 4.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.14	
95% CI of the inverse risk ratio	(0.28, 3.12)	(0.30, 4.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.21	-0.33	
95% CI of the absolute risk difference	(-3.17, 3.58)	(-3.57, 2.92)	
p-value	0.9038	0.8472	
p-value of Breslow-Day Test for Homogeneity [3]	0.9180	0.7568	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	31 (22.1)	27 (20.9)	48 (18.2)
No	109 (77.9)	102 (79.1)	216 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.84	
95% CI of the inverse odds ratio	(0.47, 1.30)	(0.50, 1.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.87	
95% CI of the inverse risk ratio	(0.55, 1.23)	(0.57, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.96	2.75	
95% CI of the absolute risk difference	(-4.34, 12.26)	(-5.67, 11.17)	
p-value	0.3395	0.5150	
p-value of Breslow-Day Test for Homogeneity [3]	0.7118	0.6240	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (2.9)	14 (10.9)	25 (9.5)
No	136 (97.1)	115 (89.1)	239 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.56	0.86	
95% CI of the inverse odds ratio	(1.21, 10.43)	(0.43, 1.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.31	0.87	
95% CI of the inverse risk ratio	(1.18, 9.33)	(0.47, 1.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.61	1.38	
95% CI of the absolute risk difference	(-11.09, -2.13)	(-5.04, 7.81)	
p-value	0.0143	0.6668	
p-value of Breslow-Day Test for Homogeneity [3]	0.0473	0.3456	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (20.7)	34 (26.4)	68 (25.8)
No	111 (79.3)	95 (73.6)	196 (74.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	0.97	
95% CI of the inverse odds ratio	(0.81, 2.17)	(0.60, 1.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	0.98	
95% CI of the inverse risk ratio	(0.85, 1.82)	(0.69, 1.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.04	0.60	
95% CI of the absolute risk difference	(-13.58, 3.49)	(-8.65, 9.85)	
p-value	0.2588	0.8988	
p-value of Breslow-Day Test for Homogeneity [3]	0.4881	0.9404	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (1.4)	7 (5.4)	23 (8.7)
No	138 (98.6)	122 (94.6)	241 (91.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.59	1.66	
95% CI of the inverse odds ratio	(1.53, 28.35)	(0.69, 3.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.10	1.61	
95% CI of the inverse risk ratio	(1.46, 25.49)	(0.71, 3.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.28	-3.29	
95% CI of the absolute risk difference	(-11.21, -3.35)	(-8.47, 1.90)	
p-value	0.0038	0.2494	
p-value of Breslow-Day Test for Homogeneity [3]	0.0273	0.2272	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (14.3)	24 (18.6)	51 (19.3)
No	120 (85.7)	105 (81.4)	213 (80.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.05	
95% CI of the inverse odds ratio	(0.82, 2.52)	(0.61, 1.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	1.04	
95% CI of the inverse risk ratio	(0.84, 2.17)	(0.67, 1.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.03	-0.71	
95% CI of the absolute risk difference	(-12.53, 2.47)	(-8.95, 7.52)	
p-value	0.2060	0.8658	
p-value of Breslow-Day Test for Homogeneity [3]	0.3081	0.8882	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (8.6)	7 (5.4)	16 (6.1)
No	128 (91.4)	122 (94.6)	248 (93.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.12	
95% CI of the inverse odds ratio	(0.32, 1.50)	(0.45, 2.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.12	
95% CI of the inverse risk ratio	(0.34, 1.45)	(0.47, 2.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.51	-0.63	
95% CI of the absolute risk difference	(-2.95, 7.97)	(-5.49, 4.22)	
p-value	0.3444	0.8014	
p-value of Breslow-Day Test for Homogeneity [3]	0.7521	0.9873	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (20.7)	30 (23.3)	58 (22.0)
No	111 (79.3)	99 (76.7)	206 (78.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.93	
95% CI of the inverse odds ratio	(0.65, 1.78)	(0.56, 1.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.94	
95% CI of the inverse risk ratio	(0.71, 1.58)	(0.64, 1.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.26	1.29	
95% CI of the absolute risk difference	(-9.62, 7.11)	(-7.55, 10.12)	
p-value	0.7702	0.7740	
p-value of Breslow-Day Test for Homogeneity [3]	0.5056	0.8213	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	23 (16.4)	23 (17.8)	39 (14.8)
No	117 (83.6)	106 (82.2)	225 (85.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.80	
95% CI of the inverse odds ratio	(0.50, 1.55)	(0.45, 1.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	0.83	
95% CI of the inverse risk ratio	(0.56, 1.44)	(0.52, 1.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.66	3.06	
95% CI of the absolute risk difference	(-5.83, 9.14)	(-4.81, 10.93)	
p-value	0.6604	0.4350	
p-value of Breslow-Day Test for Homogeneity [3]	0.8931	0.6533	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (23.6)	33 (25.6)	63 (23.9)
No	107 (76.4)	96 (74.4)	201 (76.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.91	
95% CI of the inverse odds ratio	(0.63, 1.65)	(0.56, 1.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.93	
95% CI of the inverse risk ratio	(0.70, 1.46)	(0.65, 1.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.29	1.72	
95% CI of the absolute risk difference	(-9.00, 8.42)	(-7.40, 10.84)	
p-value	0.9476	0.7098	
p-value of Breslow-Day Test for Homogeneity [3]	0.6161	0.4500	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (3.6)	3 (2.3)	10 (3.8)
No	135 (96.4)	126 (97.7)	254 (96.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.65	
95% CI of the inverse odds ratio	(0.36, 3.17)	(0.45, 6.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.63	
95% CI of the inverse risk ratio	(0.37, 3.04)	(0.46, 5.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.22	-1.46	
95% CI of the absolute risk difference	(-4.06, 3.62)	(-4.94, 2.01)	
p-value	0.9128	0.4466	
p-value of Breslow-Day Test for Homogeneity [3]	0.5822	0.2882	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (8.6)	10 (7.8)	20 (7.6)
No	128 (91.4)	119 (92.2)	244 (92.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.98	
95% CI of the inverse odds ratio	(0.41, 1.85)	(0.44, 2.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.98	
95% CI of the inverse risk ratio	(0.45, 1.75)	(0.47, 2.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.00	0.18	
95% CI of the absolute risk difference	(-4.63, 6.63)	(-5.43, 5.79)	
p-value	0.7244	0.9508	
p-value of Breslow-Day Test for Homogeneity [3]	0.1907	0.9582	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	22 (15.7)	16 (12.4)	44 (16.7)
No	118 (84.3)	113 (87.6)	220 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.41	
95% CI of the inverse odds ratio	(0.61, 1.88)	(0.76, 2.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.34	
95% CI of the inverse risk ratio	(0.66, 1.70)	(0.79, 2.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.95	-4.26	
95% CI of the absolute risk difference	(-8.47, 6.57)	(-11.51, 2.99)	
p-value	0.8054	0.2698	
p-value of Breslow-Day Test for Homogeneity [3]	0.8520	0.2130	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	42 (30.0)	38 (29.5)	83 (31.4)
No	98 (70.0)	91 (70.5)	181 (68.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.10	
95% CI of the inverse odds ratio	(0.69, 1.67)	(0.69, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.07	
95% CI of the inverse risk ratio	(0.77, 1.43)	(0.77, 1.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.44	-1.98	
95% CI of the absolute risk difference	(-10.87, 7.99)	(-11.64, 7.67)	
p-value	0.7658	0.6894	
p-value of Breslow-Day Test for Homogeneity [3]	0.4993	0.8849	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (8.6)	19 (14.7)	27 (10.2)
No	128 (91.4)	110 (85.3)	237 (89.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	0.66	
95% CI of the inverse odds ratio	(0.60, 2.48)	(0.35, 1.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	0.69	
95% CI of the inverse risk ratio	(0.62, 2.28)	(0.40, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.66	4.50	
95% CI of the absolute risk difference	(-7.56, 4.25)	(-2.62, 11.63)	
p-value	0.5918	0.1924	
p-value of Breslow-Day Test for Homogeneity [3]	0.1424	0.9309	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (20.0)	31 (24.0)	69 (26.1)
No	112 (80.0)	98 (76.0)	195 (73.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	1.12	
95% CI of the inverse odds ratio	(0.86, 2.33)	(0.69, 1.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.09	
95% CI of the inverse risk ratio	(0.89, 1.93)	(0.75, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.14	-2.11	
95% CI of the absolute risk difference	(-14.62, 2.35)	(-11.19, 6.98)	
p-value	0.1694	0.6527	
p-value of Breslow-Day Test for Homogeneity [3]	0.1321	0.8278	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	27 (19.3)	28 (21.7)	38 (14.4)
No	113 (80.7)	101 (78.3)	226 (85.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	0.61	
95% CI of the inverse odds ratio	(0.41, 1.21)	(0.35, 1.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.66	
95% CI of the inverse risk ratio	(0.48, 1.17)	(0.43, 1.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.89	7.31	
95% CI of the absolute risk difference	(-2.90, 12.68)	(-0.97, 15.59)	
p-value	0.2029	0.0686	
p-value of Breslow-Day Test for Homogeneity [3]	0.6521	0.2109	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	39 (27.9)	36 (27.9)	61 (23.1)
No	101 (72.1)	93 (72.1)	203 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.78	
95% CI of the inverse odds ratio	(0.49, 1.24)	(0.48, 1.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.83	
95% CI of the inverse risk ratio	(0.59, 1.17)	(0.58, 1.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.75	4.80	
95% CI of the absolute risk difference	(-4.25, 13.75)	(-4.46, 14.06)	
p-value	0.2924	0.3000	
p-value of Breslow-Day Test for Homogeneity [3]	0.6679	0.5361	

AMNOG Table SE21.9.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (12.9)	16 (12.4)	30 (11.4)
No	122 (87.1)	113 (87.6)	234 (88.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.91	
95% CI of the inverse odds ratio	(0.47, 1.62)	(0.47, 1.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.92	
95% CI of the inverse risk ratio	(0.51, 1.53)	(0.52, 1.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.49	1.04	
95% CI of the absolute risk difference	(-5.24, 8.23)	(-5.82, 7.90)	
p-value	0.6589	0.7634	
p-value of Breslow-Day Test for Homogeneity [3]	0.8562	0.9345	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	44 (31.4)	35 (27.1)	72 (27.3)
No	96 (68.6)	94 (72.9)	192 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.01	
95% CI of the inverse odds ratio	(0.52, 1.28)	(0.63, 1.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.01	
95% CI of the inverse risk ratio	(0.63, 1.19)	(0.71, 1.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.16	-0.14	
95% CI of the absolute risk difference	(-5.22, 13.54)	(-9.51, 9.23)	
p-value	0.3796	0.9765	
p-value of Breslow-Day Test for Homogeneity [3]	0.8211	0.3003	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Total LDQOL						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	74.53 (13.98)	78.09 (12.65)	79.37 (11.32)			
Median	78.20	79.55	82.90			
IQR: Q1, Q3	64.90, 82.70	70.50, 87.35	74.20, 87.30			
Min, Max	39.3, 93.1	50.8, 95.4	43.1, 97.8			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	73.77 (17.24)	81.00 (9.66)	77.72 (13.70)	-0.08 (1.90)	1.46 (1.97)	-0.56 (1.39)
Median	79.20	82.45	80.50	0	0.80	-0.45
IQR: Q1, Q3	65.40, 85.40	74.40, 89.20	69.80, 89.20	-5.10, 4.20	-1.20, 7.90	-5.40, 3.90
Min, Max	22.9, 96.1	65.1, 95.2	46.0, 96.9	-16.4, 14.7	-15.4, 14.3	-20.6, 20.7
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	72.73 (13.81)	83.59 (7.72)	79.61 (15.07)	0.04 (2.41)	2.28 (1.67)	-0.42 (1.96)
Median	72.40	85.55	82.80	1.00	2.40	0.85
IQR: Q1, Q3	62.70, 84.00	77.50, 90.30	75.10, 88.40	-4.80, 7.00	-0.20, 4.65	-4.10, 4.60
Min, Max	48.1, 94.3	70.3, 92.4	20.3, 97.8	-18.9, 14.4	-9.7, 11.9	-46.3, 15.8

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Symptoms of Liver Disease						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	76.29 (17.00)	71.05 (21.35)	76.85 (13.90)			
Median	75.00	80.00	80.00			
IQR: Q1, Q3	66.70, 93.30	60.00, 86.70	66.70, 86.70			
Min, Max	40.0, 100.0	10.0, 90.0	46.7, 100.0			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	74.39 (20.99)	73.34 (16.22)	73.76 (19.52)	-2.03 (3.39)	0.71 (2.76)	-1.18 (2.94)
Median	76.70	76.70	76.70	-3.30	0	0
IQR: Q1, Q3	63.30, 96.70	70.00, 83.30	60.00, 86.70	-6.70, 6.60	-6.70, 6.70	-6.70, 6.70
Min, Max	26.7, 100.0	30.0, 93.3	20.0, 100.0	-43.3, 30.0	-13.4, 20.0	-53.3, 33.4
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	69.80 (19.71)	80.28 (10.96)	76.85 (18.61)	-7.09 (3.47)	3.61 (3.54)	1.21 (3.00)
Median	73.30	78.35	83.30	-5.05	5.00	3.30
IQR: Q1, Q3	60.00, 86.70	71.65, 90.00	70.00, 90.00	-14.95, 3.30	-3.35, 13.35	-3.30, 10.00
Min, Max	33.3, 100.0	66.7, 96.7	23.3, 100.0	-36.7, 10.0	-20.0, 20.0	-60.0, 26.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Effects of Liver Disease						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	78.89 (14.14)	81.67 (11.29)	78.56 (16.19)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	66.70, 86.70	76.65, 86.70	80.00, 86.70			
Min, Max	53.3, 100.0	60.0, 100.0	26.7, 100.0			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	76.14 (14.29)	80.94 (8.63)	76.24 (13.41)	-2.96 (2.86)	-1.91 (2.75)	-1.97 (2.10)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	66.70, 80.00	73.30, 80.00	73.30, 80.00	-6.70, 0.00	-6.70, 0.00	-6.70, 0.00
Min, Max	33.3, 100.0	73.3, 100.0	40.0, 100.0	-33.4, 20.0	-26.7, 20.0	-33.4, 26.6
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	70.98 (12.68)	82.23 (8.20)	77.90 (15.07)	-6.24 (3.67)	-2.78 (3.52)	-3.78 (3.35)
Median	73.30	80.00	80.00	-6.65	0	0
IQR: Q1, Q3	66.70, 80.00	80.00, 83.35	80.00, 80.00	-16.65, 6.65	-3.35, 6.65	-6.70, 0.00
Min, Max	46.7, 86.7	66.7, 100.0	13.3, 100.0	-33.3, 13.4	-33.3, 6.7	-73.4, 33.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Concentration/Memory						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	80.92 (17.47)	78.14 (22.93)	81.44 (16.63)			
Median	84.40	84.40	81.30			
IQR: Q1, Q3	68.80, 100.00	71.90, 96.90	75.00, 93.80			
Min, Max	43.8, 100.0	25.0, 100.0	43.8, 100.0			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	76.66 (18.96)	78.60 (21.33)	77.43 (18.73)	-4.16 (3.43)	-3.56 (2.60)	-2.57 (2.11)
Median	75.00	81.30	81.30	0	0	0
IQR: Q1, Q3	68.80, 93.80	75.00, 93.80	62.50, 93.80	-12.50, 6.20	-6.30, 6.20	-6.20, 0.00
Min, Max	37.5, 100.0	31.3, 100.0	25.0, 100.0	-31.2, 25.0	-25.0, 6.3	-31.2, 18.8
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	75.76 (16.06)	81.78 (18.55)	80.73 (18.40)	-2.72 (2.85)	-2.09 (2.22)	-2.30 (2.62)
Median	75.00	87.50	81.30	-6.20	0	0
IQR: Q1, Q3	68.80, 87.50	75.00, 96.90	75.00, 100.00	-6.25, 3.15	-6.25, 3.10	-12.50, 6.20
Min, Max	43.8, 100.0	43.8, 100.0	37.5, 100.0	-25.0, 18.7	-18.8, 6.3	-37.5, 43.8

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Health Distress						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	71.53 (30.56)	89.84 (14.59)	79.39 (24.69)			
Median	75.00	100.00	87.50			
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	62.50, 100.00			
Min, Max	0.0, 100.0	62.5, 100.0	0.0, 100.0			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	74.34 (29.60)	94.64 (9.45)	83.01 (25.24)	2.78 (4.90)	6.25 (2.54)	4.78 (2.94)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	50.00, 100.00	87.50, 100.00	75.00, 100.00	-12.50, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	75.0, 100.0	0.0, 100.0	-37.5, 37.5	0.0, 25.0	-50.0, 50.0
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	80.15 (22.56)	96.88 (5.65)	85.71 (23.71)	12.50 (7.91)	7.29 (4.20)	4.58 (4.62)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	93.75, 100.00	75.00, 100.00	-6.25, 31.25	0.00, 18.75	0.00, 25.00
Min, Max	37.5, 100.0	87.5, 100.0	0.0, 100.0	-25.0, 75.0	-12.5, 37.5	-50.0, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Sexual Function						
Baseline						
m	19	16	43			
n	5	8	8			
Mean (SD)	70.98 (27.40)	75.63 (36.61)	80.84 (30.92)			
Median	83.30	92.50	92.50			
IQR: Q1, Q3	53.30, 93.30	60.85, 100.00	80.85, 96.65			
Min, Max	31.7, 93.3	-1.7, 100.0	6.7, 100.0			
Week 24						
m	19	15	41			
n	6	7	14	4	7	6
Mean (SD/SE)	75.83 (34.49)	79.53 (26.13)	81.43 (24.01)	-0.40 (9.88)	7.39 (5.83)	-10.27 (7.14)
Median	92.50	93.30	88.35	0	0	-4.15
IQR: Q1, Q3	76.70, 93.30	46.70, 100.00	76.70, 93.30	-12.50, 11.70	0.00, 8.30	-8.30, 0.00
Min, Max	6.7, 93.3	40.0, 100.0	13.3, 100.0	-25.0, 23.4	0.0, 41.7	-45.0, 0.0
Week 52						
m	17	12	39			
n	3	6	8	2	5	4
Mean (SD/SE)	89.60 (6.41)	81.93 (28.39)	75.00 (35.75)	0.00 (0.00)	9.32 (4.49)	-13.73 (11.13)
Median	93.30	100.00	88.35	0	8.30	-4.15
IQR: Q1, Q3	82.20, 93.30	53.30, 100.00	62.50, 100.00	0.00, 0.00	0.00, 15.00	-27.45, 0.00
Min, Max	82.2, 93.3	38.3, 100.0	-1.7, 100.0	0.0, 0.0	0.0, 23.3	-46.6, 0.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Sleep						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	59.72 (23.73)	52.19 (21.68)	67.30 (17.14)			
Median	60.00	52.50	70.00			
IQR: Q1, Q3	45.00, 80.00	35.00, 75.00	55.00, 80.00			
Min, Max	10.0, 90.0	20.0, 80.0	35.0, 100.0			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	58.16 (22.56)	56.43 (21.43)	62.18 (18.02)	0.00 (3.41)	4.64 (4.49)	-4.12 (2.37)
Median	60.00	65.00	60.00	0	-2.50	-5.00
IQR: Q1, Q3	45.00, 75.00	45.00, 70.00	45.00, 75.00	-5.00, 5.00	-5.00, 15.00	-10.00, 0.00
Min, Max	10.0, 95.0	15.0, 80.0	35.0, 95.0	-25.0, 45.0	-10.0, 45.0	-25.0, 30.0
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	57.65 (17.15)	57.50 (21.16)	65.29 (20.14)	-1.56 (4.67)	3.33 (2.91)	-1.17 (2.91)
Median	55.00	60.00	65.00	-5.00	2.50	0
IQR: Q1, Q3	50.00, 70.00	42.50, 75.00	50.00, 80.00	-10.00, 5.00	-5.00, 12.50	-10.00, 5.00
Min, Max	25.0, 85.0	10.0, 85.0	20.0, 100.0	-40.0, 45.0	-10.0, 20.0	-40.0, 30.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Loneliness						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	76.39 (18.69)	85.94 (16.55)	85.95 (22.26)			
Median	75.00	92.50	100.00			
IQR: Q1, Q3	65.00, 95.00	72.50, 100.00	80.00, 100.00			
Min, Max	40.0, 100.0	50.0, 100.0	5.0, 100.0			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	76.05 (21.83)	89.64 (9.09)	86.79 (20.95)	0.28 (4.49)	1.07 (3.89)	0.88 (2.24)
Median	80.00	90.00	95.00	2.50	0	0
IQR: Q1, Q3	70.00, 90.00	85.00, 100.00	80.00, 100.00	-10.00, 10.00	-10.00, 15.00	-5.00, 5.00
Min, Max	15.0, 100.0	75.0, 100.0	15.0, 100.0	-50.0, 40.0	-25.0, 30.0	-25.0, 40.0
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	77.35 (19.77)	91.67 (10.73)	85.57 (20.79)	1.88 (4.21)	2.50 (3.40)	-0.33 (2.56)
Median	75.00	95.00	95.00	0	0	0
IQR: Q1, Q3	70.00, 95.00	87.50, 100.00	80.00, 100.00	0.00, 5.00	0.00, 5.00	0.00, 5.00
Min, Max	35.0, 100.0	65.0, 100.0	10.0, 100.0	-30.0, 50.0	-20.0, 30.0	-30.0, 30.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Hopelessness						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	71.29 (19.21)	81.24 (24.26)	79.28 (20.47)			
Median	70.85	91.70	83.30			
IQR: Q1, Q3	58.30, 83.30	66.65, 100.00	66.70, 100.00			
Min, Max	41.7, 100.0	33.3, 100.0	25.0, 100.0			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	68.86 (28.71)	89.89 (12.74)	78.85 (21.36)	-0.93 (5.04)	5.96 (6.85)	0.98 (2.48)
Median	75.00	91.70	83.30	0	0	0
IQR: Q1, Q3	50.00, 91.70	83.30, 100.00	66.70, 100.00	-8.40, 8.40	0.00, 16.70	-8.30, 8.30
Min, Max	8.3, 100.0	58.3, 100.0	33.3, 100.0	-58.3, 33.3	-41.7, 58.4	-33.3, 41.6
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	69.12 (22.40)	90.28 (13.68)	80.72 (24.98)	1.04 (4.62)	6.27 (6.25)	0.55 (3.22)
Median	66.70	100.00	91.70	0	0	0
IQR: Q1, Q3	50.00, 91.70	79.15, 100.00	66.70, 100.00	-12.45, 12.50	0.00, 25.00	0.00, 8.30
Min, Max	33.3, 100.0	66.7, 100.0	8.3, 100.0	-25.0, 33.3	-33.3, 33.4	-58.4, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Stigma of Liver Disease						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	81.62 (17.88)	86.34 (16.50)	86.17 (17.43)			
Median	81.30	93.80	93.80			
IQR: Q1, Q3	75.00, 93.80	75.00, 100.00	81.30, 100.00			
Min, Max	25.0, 100.0	50.0, 100.0	31.3, 100.0			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	83.91 (12.72)	85.73 (16.88)	82.71 (18.93)	4.17 (3.24)	-2.24 (2.58)	-2.21 (3.46)
Median	87.50	90.65	81.30	0	0	0
IQR: Q1, Q3	75.00, 93.80	81.30, 100.00	75.00, 100.00	-6.20, 6.30	-6.30, 0.00	-12.50, 6.20
Min, Max	50.0, 100.0	50.0, 100.0	37.5, 100.0	-12.5, 43.8	-18.7, 18.7	-43.8, 43.7
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	79.80 (18.82)	90.13 (12.04)	85.38 (20.55)	0.79 (3.42)	4.18 (3.29)	-1.67 (4.34)
Median	81.30	93.80	93.80	0	3.10	0
IQR: Q1, Q3	68.80, 100.00	81.30, 100.00	75.00, 100.00	-6.20, 6.25	0.00, 6.30	-6.20, 12.50
Min, Max	37.5, 100.0	68.8, 100.0	18.8, 100.0	-25.0, 37.5	-18.7, 31.3	-62.5, 43.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Total LDQOL						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	77.85 (14.42)	76.73 (14.79)	77.66 (14.31)			
Median	82.40	81.15	81.50			
IQR: Q1, Q3	70.00, 88.75	67.60, 86.90	71.70, 88.60			
Min, Max	28.3, 96.7	23.6, 96.3	34.8, 97.8			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	78.70 (14.41)	77.19 (12.91)	78.78 (14.24)	0.91 (0.77)	0.49 (0.76)	0.87 (0.67)
Median	82.00	78.70	82.90	1.00	0.10	0.40
IQR: Q1, Q3	71.40, 90.00	70.60, 86.70	70.55, 89.30	-4.50, 5.60	-5.10, 5.05	-3.10, 5.10
Min, Max	28.2, 97.8	32.4, 96.9	22.4, 98.8	-23.4, 35.6	-14.5, 27.0	-46.4, 42.3
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	80.07 (13.12)	77.59 (14.47)	78.72 (14.15)	1.23 (0.82)	0.44 (0.97)	0.68 (0.68)
Median	84.40	80.25	81.25	0.90	0	0.50
IQR: Q1, Q3	71.00, 90.50	67.40, 89.60	71.20, 89.65	-3.30, 6.30	-4.80, 5.90	-4.30, 5.30
Min, Max	34.0, 97.5	33.8, 97.4	34.3, 100.0	-19.5, 36.0	-23.3, 33.9	-36.2, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Symptoms of Liver Disease						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	77.78 (19.74)	75.46 (18.44)	76.51 (18.43)			
Median	83.30	78.35	80.00			
IQR: Q1, Q3	70.00, 93.30	63.30, 90.00	63.30, 93.30			
Min, Max	13.3, 100.0	30.0, 100.0	20.0, 100.0			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	76.62 (20.21)	74.20 (18.32)	77.96 (19.14)	-1.28 (1.20)	-1.05 (1.17)	0.38 (0.88)
Median	83.30	76.70	83.30	0	0	0
IQR: Q1, Q3	66.70, 90.00	63.30, 86.70	66.70, 93.30	-10.00, 6.60	-10.00, 5.70	-6.60, 6.70
Min, Max	0.0, 100.0	26.7, 100.0	16.7, 100.0	-46.7, 36.7	-36.6, 30.0	-43.3, 43.3
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	78.37 (19.08)	76.11 (18.99)	78.06 (19.12)	-1.23 (1.16)	0.55 (1.40)	0.51 (0.88)
Median	83.30	80.00	83.30	0	0	0
IQR: Q1, Q3	66.70, 93.30	63.30, 93.30	66.70, 93.30	-6.70, 6.70	-6.70, 6.70	-6.70, 6.70
Min, Max	6.7, 100.0	26.7, 100.0	16.7, 100.0	-43.4, 43.4	-36.7, 36.7	-36.7, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Effects of Liver Disease						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	77.43 (14.02)	78.15 (15.57)	77.15 (14.84)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	73.30, 86.70	80.00, 80.00			
Min, Max	6.7, 100.0	13.3, 100.0	6.7, 100.0			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	75.94 (14.84)	79.05 (10.75)	77.57 (15.22)	-1.71 (1.03)	0.80 (1.52)	0.18 (1.02)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	80.00, 86.70	-6.70, 0.00	-6.70, 6.70	-6.70, 6.70
Min, Max	0.0, 100.0	40.0, 100.0	6.7, 100.0	-40.0, 33.3	-33.3, 76.7	-46.7, 53.4
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	77.39 (13.27)	77.35 (12.78)	77.70 (13.30)	-0.62 (1.25)	-0.24 (1.38)	0.32 (1.25)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 0.00	-6.70, 0.00	-6.70, 6.60
Min, Max	6.7, 100.0	20.0, 100.0	20.0, 100.0	-40.0, 80.0	-33.3, 53.4	-80.0, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Concentration/Memory						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	80.20 (23.83)	79.02 (20.43)	78.16 (21.38)			
Median	87.50	84.40	87.50			
IQR: Q1, Q3	75.00, 100.00	68.80, 100.00	68.80, 93.80			
Min, Max	6.3, 100.0	18.8, 100.0	6.3, 100.0			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	78.87 (23.02)	80.39 (19.44)	80.20 (22.14)	-1.13 (1.32)	0.94 (1.45)	1.16 (1.12)
Median	87.50	81.30	87.50	0	0	0
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	68.80, 100.00	-6.30, 6.20	-6.25, 6.30	-6.20, 6.30
Min, Max	0.0, 100.0	25.0, 100.0	6.3, 100.0	-43.8, 31.2	-37.5, 56.2	-81.2, 62.5
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	79.54 (20.76)	79.31 (20.60)	78.76 (22.34)	-0.49 (1.34)	-1.22 (1.56)	-0.26 (1.02)
Median	81.30	87.50	81.30	0	0	0
IQR: Q1, Q3	68.80, 100.00	62.50, 100.00	68.80, 100.00	-6.30, 6.20	-6.30, 6.30	-6.30, 6.30
Min, Max	0.0, 100.0	18.8, 100.0	0.0, 100.0	-43.7, 50.0	-43.8, 50.0	-43.8, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Health Distress						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	79.02 (25.59)	79.82 (26.38)	81.33 (24.04)			
Median	87.50	93.75	87.50			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	84.24 (22.21)	85.96 (21.23)	86.24 (21.29)	5.73 (1.80)	6.14 (1.80)	5.23 (1.35)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 75.0	-37.5, 50.0	-62.5, 75.0
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	83.51 (24.19)	85.91 (21.95)	86.46 (20.53)	3.84 (2.10)	5.15 (2.12)	4.21 (1.55)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-75.0, 75.0	-50.0, 75.0	-87.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Sexual Function						
Baseline						
m	148	135	260			
n	66	64	113			
Mean (SD)	80.18 (26.45)	79.92 (21.44)	79.51 (24.08)			
Median	93.30	85.85	86.70			
IQR: Q1, Q3	68.30, 100.00	63.30, 100.00	68.30, 100.00			
Min, Max	-1.7, 100.0	30.0, 100.0	-1.7, 100.0			
Week 24						
m	142	126	248			
n	66	70	111	53	52	88
Mean (SD/SE)	80.61 (23.10)	73.99 (28.14)	78.74 (23.49)	1.85 (3.51)	-6.21 (2.91)	0.75 (1.96)
Median	86.70	85.00	85.00	0	0	0
IQR: Q1, Q3	70.00, 100.00	55.00, 100.00	63.30, 100.00	-5.00, 8.30	-16.65, 0.00	-6.70, 8.30
Min, Max	15.0, 100.0	-1.7, 100.0	-1.7, 100.0	-85.0, 91.1	-55.0, 46.7	-48.4, 50.0
Week 52						
m	132	113	231			
n	50	51	93	44	42	76
Mean (SD/SE)	84.80 (21.84)	76.54 (29.00)	77.67 (25.06)	4.43 (3.49)	-4.13 (3.29)	-0.65 (2.38)
Median	93.30	91.70	86.70	0	0	0
IQR: Q1, Q3	76.70, 100.00	55.00, 100.00	60.00, 100.00	-5.85, 6.70	-15.00, 1.70	-8.40, 6.70
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-45.0, 91.1	-50.0, 61.7	-53.3, 65.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Sleep						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	63.29 (20.43)	61.23 (19.34)	62.05 (20.35)			
Median	65.00	65.00	60.00			
IQR: Q1, Q3	50.00, 80.00	50.00, 75.00	50.00, 80.00			
Min, Max	0.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	64.38 (20.56)	58.32 (20.24)	62.52 (20.76)	1.13 (1.40)	-2.46 (1.30)	0.28 (1.09)
Median	65.00	60.00	60.00	0	-2.50	0
IQR: Q1, Q3	50.00, 80.00	45.00, 75.00	50.00, 80.00	-5.00, 10.00	-10.00, 5.00	-10.00, 10.00
Min, Max	5.0, 100.0	0.0, 100.0	15.0, 100.0	-30.0, 90.0	-35.0, 40.0	-40.0, 50.0
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	65.68 (19.64)	59.90 (21.32)	63.48 (20.82)	0.71 (1.53)	-1.44 (1.76)	1.17 (1.18)
Median	70.00	65.00	65.00	0	0	0
IQR: Q1, Q3	55.00, 80.00	45.00, 75.00	50.00, 80.00	-10.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	10.0, 100.0	0.0, 95.0	5.0, 100.0	-30.0, 75.0	-60.0, 45.0	-40.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Loneliness						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	85.64 (17.48)	82.66 (20.32)	83.51 (19.22)			
Median	95.00	90.00	90.00			
IQR: Q1, Q3	77.50, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	10.0, 100.0			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	84.58 (18.20)	84.43 (20.00)	82.17 (20.43)	-1.03 (1.38)	0.80 (1.26)	-1.76 (1.16)
Median	92.50	95.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	-10.00, 5.00	-5.00, 5.00	-10.00, 5.00
Min, Max	30.0, 100.0	0.0, 100.0	10.0, 100.0	-45.0, 45.0	-35.0, 65.0	-80.0, 70.0
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	86.18 (16.82)	82.45 (21.60)	83.82 (18.80)	0.13 (1.47)	-0.05 (1.59)	0.04 (1.18)
Median	95.00	90.00	90.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	75.00, 100.00	75.00, 100.00	-5.00, 5.00	-10.00, 10.00	-5.00, 5.00
Min, Max	25.0, 100.0	0.0, 100.0	5.0, 100.0	-60.0, 40.0	-40.0, 35.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Hopelessness						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	76.37 (23.05)	76.09 (22.76)	79.25 (21.57)			
Median	83.30	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	58.30, 100.00			
Min, Max	8.3, 100.0	8.3, 100.0	16.7, 100.0			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	78.87 (21.70)	76.43 (22.70)	78.90 (21.76)	2.88 (1.61)	1.19 (1.75)	-0.56 (1.29)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	66.70, 100.00	-8.30, 16.70	-8.30, 12.50	-8.30, 8.30
Min, Max	8.3, 100.0	8.3, 100.0	16.7, 100.0	-41.7, 50.0	-41.7, 58.3	-66.6, 50.0
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	79.90 (20.93)	76.88 (22.18)	78.23 (21.86)	1.75 (1.79)	0.61 (2.22)	-1.47 (1.36)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	58.30, 100.00	58.30, 100.00	-8.30, 8.40	-16.60, 16.70	-8.30, 8.30
Min, Max	16.7, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 41.7	-58.3, 50.0	-100.0, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Stigma of Liver Disease						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	82.47 (22.11)	80.65 (20.09)	83.55 (19.32)			
Median	93.80	81.30	87.50			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	85.70 (20.18)	80.76 (19.72)	85.67 (18.40)	2.73 (1.59)	0.78 (1.43)	2.18 (1.08)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	-6.20, 12.50	-6.30, 6.30	-6.20, 6.30
Min, Max	6.3, 100.0	12.5, 100.0	6.3, 100.0	-43.8, 56.2	-31.3, 56.3	-62.5, 75.0
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	88.14 (17.28)	83.76 (19.27)	85.19 (18.23)	4.11 (1.29)	2.37 (1.68)	2.25 (1.09)
Median	100.00	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	0.00, 6.30	-6.20, 12.50	-6.20, 6.30
Min, Max	31.3, 100.0	12.5, 100.0	25.0, 100.0	-31.3, 56.2	-56.2, 56.3	-43.8, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Thyroxine at Baseline
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.10.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Total LDQOL			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	74.53 (13.98)	79.54 (12.15)	79.51 (11.45)
Analysis Visit Mean (SD)	74.44 (17.49)	81.00 (9.66)	78.94 (12.75)
LS Mean of Change from Baseline (SE)	0.36 (2.03)	1.94 (2.21)	-0.13 (1.38)
95% CI	(-3.69, 4.40)	(-2.48, 6.37)	(-2.89, 2.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.49 (2.39)	2.08 (2.55)	
95% CI	(-4.28, 5.26)	(-3.03, 7.18)	
p-value	0.8382	0.4190	
Corrected Hedge's g Statistics	0.059	0.252	
95% CI	(-0.51, 0.63)	(-0.37, 0.88)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	73.31 (14.29)	81.31 (9.54)	81.28 (9.06)
Analysis Visit Mean (SD)	73.36 (14.01)	83.59 (7.72)	80.85 (14.99)
LS Mean of Change from Baseline (SE)	-0.14 (2.55)	3.63 (2.82)	0.35 (1.76)
95% CI	(-5.23, 4.95)	(-2.00, 9.26)	(-3.18, 3.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.48 (3.10)	3.28 (3.26)	
95% CI	(-6.68, 5.71)	(-3.23, 9.80)	
p-value	0.8764	0.3179	
Corrected Hedge's g Statistics	-0.048	0.332	
95% CI	(-0.66, 0.56)	(-0.34, 1.01)	
Subgroup*Treatment Interaction p-value	0.6399	0.2538	

AMNOG Table SE21.10.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Total LDQOL			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	77.98 (14.18)	76.33 (15.10)	78.17 (14.09)
Analysis Visit Mean (SD)	78.90 (14.27)	76.82 (13.16)	79.04 (14.30)
LS Mean of Change from Baseline (SE)	1.00 (0.76)	0.02 (0.82)	0.90 (0.60)
95% CI	(-0.49, 2.50)	(-1.59, 1.64)	(-0.29, 2.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.11 (0.94)	-0.87 (1.00)	
95% CI	(-1.75, 1.96)	(-2.83, 1.08)	
p-value	0.9108	0.3806	
Corrected Hedge's g Statistics	0.012	-0.099	
95% CI	(-0.20, 0.23)	(-0.33, 0.13)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	78.79 (13.77)	76.61 (15.69)	77.93 (14.31)
Analysis Visit Mean (SD)	80.03 (12.86)	77.04 (14.57)	78.60 (14.46)
LS Mean of Change from Baseline (SE)	1.38 (0.83)	0.05 (0.89)	0.47 (0.64)
95% CI	(-0.25, 3.00)	(-1.69, 1.80)	(-0.80, 1.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.91 (1.02)	-0.42 (1.07)	
95% CI	(-1.10, 2.92)	(-2.53, 1.70)	
p-value	0.3740	0.6994	
Corrected Hedge's g Statistics	0.102	-0.047	
95% CI	(-0.13, 0.33)	(-0.29, 0.20)	
Subgroup*Treatment Interaction p-value	0.6399	0.2538	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Symptoms of Liver Disease			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	76.29 (17.00)	72.63 (21.85)	78.14 (12.96)
Analysis Visit Mean (SD)	74.27 (21.59)	73.34 (16.22)	76.96 (17.11)
LS Mean of Change from Baseline (SE)	-1.01 (3.67)	0.14 (4.08)	-0.35 (2.53)
95% CI	(-8.34, 6.33)	(-8.01, 8.29)	(-5.41, 4.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.65 (4.33)	0.49 (4.73)	
95% CI	(-9.31, 8.01)	(-8.96, 9.94)	
p-value	0.8809	0.9178	
Corrected Hedge's g Statistics	-0.043	0.032	
95% CI	(-0.61, 0.53)	(-0.59, 0.65)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	76.67 (17.68)	76.68 (13.11)	78.67 (12.79)
Analysis Visit Mean (SD)	69.58 (20.33)	80.28 (10.96)	79.88 (15.94)
LS Mean of Change from Baseline (SE)	-5.83 (3.76)	4.00 (4.20)	1.58 (2.59)
95% CI	(-13.34, 1.67)	(-4.40, 12.40)	(-3.60, 6.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.41 (4.47)	2.42 (4.87)	
95% CI	(-16.34, 1.51)	(-7.31, 12.16)	
p-value	0.1018	0.6208	
Corrected Hedge's g Statistics	-0.503	0.166	
95% CI	(-1.12, 0.11)	(-0.50, 0.84)	
Subgroup*Treatment Interaction p-value	0.3812	0.4135	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Effects of Liver Disease			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	78.89 (14.14)	82.86 (11.32)	79.22 (14.65)
Analysis Visit Mean (SD)	75.93 (14.67)	80.94 (8.63)	77.25 (11.86)
LS Mean of Change from Baseline (SE)	-3.43 (2.53)	-0.86 (2.79)	-2.41 (1.74)
95% CI	(-8.49, 1.63)	(-6.42, 4.71)	(-5.88, 1.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.02 (2.96)	1.55 (3.23)	
95% CI	(-6.94, 4.90)	(-4.91, 8.01)	
p-value	0.7316	0.6332	
Corrected Hedge's g Statistics	-0.097	0.149	
95% CI	(-0.67, 0.47)	(-0.47, 0.77)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	78.33 (14.91)	85.00 (9.91)	82.23 (10.26)
Analysis Visit Mean (SD)	72.09 (12.22)	82.23 (8.20)	78.44 (14.31)
LS Mean of Change from Baseline (SE)	-7.30 (3.33)	1.53 (3.78)	-2.44 (2.33)
95% CI	(-13.96, -0.64)	(-6.02, 9.08)	(-7.10, 2.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.86 (4.02)	3.97 (4.38)	
95% CI	(-12.90, 3.17)	(-4.79, 12.72)	
p-value	0.2309	0.3685	
Corrected Hedge's g Statistics	-0.368	0.303	
95% CI	(-0.98, 0.24)	(-0.37, 0.98)	
Subgroup*Treatment Interaction p-value	0.6185	0.5072	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Concentration/Memory			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	80.92 (17.47)	82.16 (19.27)	81.09 (17.03)
Analysis Visit Mean (SD)	76.76 (19.51)	78.60 (21.33)	78.52 (18.67)
LS Mean of Change from Baseline (SE)	-4.01 (3.14)	-3.23 (3.46)	-2.50 (2.16)
95% CI	(-10.28, 2.26)	(-10.16, 3.69)	(-6.82, 1.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.51 (3.70)	-0.73 (4.01)	
95% CI	(-8.90, 5.88)	(-8.75, 7.28)	
p-value	0.6848	0.8552	
Corrected Hedge's g Statistics	-0.116	-0.057	
95% CI	(-0.69, 0.46)	(-0.68, 0.57)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	78.53 (17.06)	83.88 (16.52)	83.77 (15.10)
Analysis Visit Mean (SD)	75.81 (16.59)	81.78 (18.55)	81.47 (18.46)
LS Mean of Change from Baseline (SE)	-3.66 (3.25)	-1.55 (3.62)	-1.55 (2.24)
95% CI	(-10.15, 2.83)	(-8.79, 5.69)	(-6.03, 2.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.10 (3.87)	0.01 (4.19)	
95% CI	(-9.83, 5.62)	(-8.36, 8.37)	
p-value	0.5883	0.9990	
Corrected Hedge's g Statistics	-0.165	0.000	
95% CI	(-0.77, 0.44)	(-0.67, 0.67)	
Subgroup*Treatment Interaction p-value	0.8350	0.9740	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Health Distress			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	71.53 (30.56)	88.39 (15.08)	77.94 (25.20)
Analysis Visit Mean (SD)	74.31 (30.46)	94.64 (9.45)	82.72 (25.93)
LS Mean of Change from Baseline (SE)	2.21 (4.12)	9.13 (4.62)	5.08 (2.81)
95% CI	(-6.02, 10.45)	(-0.11, 18.37)	(-0.55, 10.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.86 (4.84)	4.06 (5.32)	
95% CI	(-12.53, 6.80)	(-6.58, 14.69)	
p-value	0.5558	0.4490	
Corrected Hedge's g Statistics	-0.168	0.239	
95% CI	(-0.74, 0.40)	(-0.38, 0.86)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	67.97 (30.61)	89.58 (15.84)	81.67 (23.84)
Analysis Visit Mean (SD)	80.47 (23.26)	96.88 (5.65)	86.25 (24.64)
LS Mean of Change from Baseline (SE)	5.70 (5.37)	16.13 (6.07)	7.10 (3.70)
95% CI	(-5.04, 16.43)	(3.99, 28.27)	(-0.30, 14.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.40 (6.48)	9.03 (7.00)	
95% CI	(-14.34, 11.54)	(-4.96, 23.03)	
p-value	0.8293	0.2018	
Corrected Hedge's g Statistics	-0.067	0.432	
95% CI	(-0.67, 0.54)	(-0.24, 1.11)	
Subgroup*Treatment Interaction p-value	0.6819	0.2158	

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Sexual Function			
Week 24			
m	19	15	41
n	4	7	6
Baseline Mean (SD)	67.90 (30.63)	72.14 (38.09)	93.88 (5.64)
Analysis Visit Mean (SD)	67.50 (41.28)	79.53 (26.13)	83.62 (18.94)
LS Mean of Change from Baseline (SE)	-8.10 (8.20)	0.22 (6.33)	-9.52 (6.49)
95% CI	(-25.82, 9.61)	(-13.45, 13.88)	(-23.55, 4.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.42 (10.69)	9.74 (9.30)	
95% CI	(-21.69, 24.52)	(-10.35, 29.83)	
p-value	0.8966	0.3140	
Corrected Hedge's g Statistics	0.080	0.554	
95% CI	(-1.19, 1.35)	(-0.56, 1.66)	
Week 52			
m	17	12	39
n	2	5	4
Baseline Mean (SD)	93.30 (0.00)	81.34 (22.65)	96.65 (3.87)
Analysis Visit Mean (SD)	93.30 (0.00)	90.66 (20.88)	82.93 (25.16)
LS Mean of Change from Baseline (SE)	-5.60 (8.54)	2.84 (5.81)	-11.38 (6.41)
95% CI	(-24.04, 12.84)	(-9.71, 15.39)	(-25.24, 2.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.78 (9.96)	14.22 (8.78)	
95% CI	(-15.72, 27.29)	(-4.74, 33.19)	
p-value	0.5712	0.1291	
Corrected Hedge's g Statistics	0.366	0.979	
95% CI	(-1.34, 2.08)	(-0.41, 2.37)	
Subgroup*Treatment Interaction p-value	0.9904	0.0434	

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Sleep			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	59.72 (23.73)	51.79 (21.89)	68.09 (17.50)
Analysis Visit Mean (SD)	59.72 (22.13)	56.43 (21.43)	63.97 (18.00)
LS Mean of Change from Baseline (SE)	-1.26 (3.42)	0.61 (3.87)	-2.68 (2.39)
95% CI	(-8.10, 5.57)	(-7.13, 8.35)	(-7.46, 2.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.42 (4.09)	3.29 (4.56)	
95% CI	(-6.75, 9.59)	(-5.83, 12.41)	
p-value	0.7298	0.4732	
Corrected Hedge's g Statistics	0.099	0.230	
95% CI	(-0.47, 0.67)	(-0.39, 0.85)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	59.69 (25.26)	54.17 (22.24)	69.33 (17.16)
Analysis Visit Mean (SD)	58.13 (17.59)	57.50 (21.16)	68.17 (19.93)
LS Mean of Change from Baseline (SE)	-3.54 (3.66)	-1.29 (4.17)	0.51 (2.58)
95% CI	(-10.85, 3.76)	(-9.62, 7.04)	(-4.65, 5.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.05 (4.43)	-1.80 (4.94)	
95% CI	(-12.90, 4.80)	(-11.66, 8.07)	
p-value	0.3643	0.7168	
Corrected Hedge's g Statistics	-0.278	-0.124	
95% CI	(-0.89, 0.33)	(-0.79, 0.55)	
Subgroup*Treatment Interaction p-value	0.6602	0.2215	

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Loneliness			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	76.39 (18.69)	88.57 (15.74)	86.03 (22.96)
Analysis Visit Mean (SD)	76.67 (22.29)	89.64 (9.09)	86.91 (21.32)
LS Mean of Change from Baseline (SE)	-1.66 (3.54)	2.93 (3.93)	1.71 (2.44)
95% CI	(-8.73, 5.42)	(-4.92, 10.78)	(-3.17, 6.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.36 (4.21)	1.22 (4.52)	
95% CI	(-11.78, 5.05)	(-7.81, 10.25)	
p-value	0.4271	0.7881	
Corrected Hedge's g Statistics	-0.229	0.083	
95% CI	(-0.80, 0.34)	(-0.54, 0.71)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	75.63 (19.57)	89.17 (15.79)	86.17 (23.29)
Analysis Visit Mean (SD)	77.50 (20.41)	91.67 (10.73)	85.83 (21.62)
LS Mean of Change from Baseline (SE)	0.43 (3.51)	5.01 (3.94)	0.83 (2.41)
95% CI	(-6.60, 7.45)	(-2.87, 12.89)	(-3.98, 5.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.41 (4.20)	4.18 (4.52)	
95% CI	(-8.80, 7.98)	(-4.87, 13.22)	
p-value	0.9228	0.3596	
Corrected Hedge's g Statistics	-0.030	0.307	
95% CI	(-0.64, 0.58)	(-0.37, 0.98)	
Subgroup*Treatment Interaction p-value	0.2918	0.8876	

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Hopelessness			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	71.29 (19.21)	83.92 (22.05)	79.66 (20.43)
Analysis Visit Mean (SD)	70.37 (28.76)	89.89 (12.74)	80.64 (19.43)
LS Mean of Change from Baseline (SE)	-1.71 (4.44)	10.39 (4.93)	2.18 (3.07)
95% CI	(-10.59, 7.16)	(0.54, 20.24)	(-3.95, 8.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.90 (5.30)	8.20 (5.70)	
95% CI	(-14.48, 6.69)	(-3.19, 19.59)	
p-value	0.4645	0.1550	
Corrected Hedge's g Statistics	-0.211	0.447	
95% CI	(-0.78, 0.36)	(-0.18, 1.08)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	69.27 (18.92)	84.02 (23.70)	80.84 (20.55)
Analysis Visit Mean (SD)	70.31 (22.56)	90.28 (13.68)	81.39 (26.14)
LS Mean of Change from Baseline (SE)	1.11 (4.70)	9.61 (5.25)	1.34 (3.22)
95% CI	(-8.28, 10.50)	(-0.87, 20.09)	(-5.10, 7.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.23 (5.67)	8.27 (6.06)	
95% CI	(-11.55, 11.09)	(-3.84, 20.38)	
p-value	0.9674	0.1771	
Corrected Hedge's g Statistics	-0.013	0.456	
95% CI	(-0.62, 0.59)	(-0.22, 1.13)	
Subgroup*Treatment Interaction p-value	0.1469	0.1960	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Stigma of Liver Disease			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	81.62 (17.88)	87.96 (17.07)	85.87 (17.88)
Analysis Visit Mean (SD)	85.79 (10.00)	85.73 (16.88)	83.66 (18.39)
LS Mean of Change from Baseline (SE)	4.23 (3.62)	1.03 (3.97)	-1.21 (2.47)
95% CI	(-3.02, 11.47)	(-6.89, 8.95)	(-6.15, 3.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.44 (4.26)	2.24 (4.58)	
95% CI	(-3.06, 13.95)	(-6.91, 11.40)	
p-value	0.2057	0.6259	
Corrected Hedge's g Statistics	0.364	0.152	
95% CI	(-0.21, 0.94)	(-0.47, 0.78)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	80.88 (18.75)	85.96 (17.71)	87.52 (15.82)
Analysis Visit Mean (SD)	81.66 (17.74)	90.13 (12.04)	85.85 (21.58)
LS Mean of Change from Baseline (SE)	0.69 (4.43)	6.29 (4.93)	-0.39 (3.07)
95% CI	(-8.16, 9.54)	(-3.55, 16.14)	(-6.52, 5.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.08 (5.32)	6.69 (5.74)	
95% CI	(-9.56, 11.72)	(-4.78, 18.16)	
p-value	0.8395	0.2485	
Corrected Hedge's g Statistics	0.062	0.389	
95% CI	(-0.54, 0.67)	(-0.29, 1.06)	
Subgroup*Treatment Interaction p-value	0.7740	0.2966	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Symptoms of Liver Disease			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	77.89 (19.62)	75.15 (18.46)	77.49 (18.44)
Analysis Visit Mean (SD)	76.61 (20.30)	74.09 (18.04)	77.87 (19.52)
LS Mean of Change from Baseline (SE)	-0.98 (1.11)	-1.35 (1.20)	0.28 (0.88)
95% CI	(-3.16, 1.21)	(-3.71, 1.01)	(-1.46, 2.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.26 (1.38)	-1.62 (1.46)	
95% CI	(-3.97, 1.46)	(-4.49, 1.24)	
p-value	0.3635	0.2658	
Corrected Hedge's g Statistics	-0.097	-0.126	
95% CI	(-0.31, 0.12)	(-0.35, 0.10)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	79.18 (18.75)	75.29 (18.74)	77.20 (18.08)
Analysis Visit Mean (SD)	77.95 (18.96)	75.84 (18.80)	77.71 (19.35)
LS Mean of Change from Baseline (SE)	-0.90 (1.15)	-0.16 (1.24)	0.73 (0.90)
95% CI	(-3.16, 1.36)	(-2.60, 2.27)	(-1.04, 2.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.63 (1.42)	-0.89 (1.50)	
95% CI	(-4.42, 1.17)	(-3.83, 2.05)	
p-value	0.2532	0.5526	
Corrected Hedge's g Statistics	-0.131	-0.072	
95% CI	(-0.36, 0.10)	(-0.32, 0.17)	
Subgroup*Treatment Interaction p-value	0.3812	0.4135	

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Effects of Liver Disease			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	77.95 (13.31)	77.92 (15.88)	77.55 (14.34)
Analysis Visit Mean (SD)	76.24 (14.43)	78.72 (10.91)	77.74 (15.07)
LS Mean of Change from Baseline (SE)	-1.58 (1.09)	0.86 (1.17)	0.06 (0.86)
95% CI	(-3.71, 0.56)	(-1.44, 3.16)	(-1.64, 1.75)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.63 (1.35)	0.80 (1.43)	
95% CI	(-4.29, 1.02)	(-2.00, 3.61)	
p-value	0.2275	0.5733	
Corrected Hedge's g Statistics	-0.129	0.064	
95% CI	(-0.35, 0.09)	(-0.16, 0.29)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	78.13 (12.93)	77.46 (16.20)	77.34 (13.76)
Analysis Visit Mean (SD)	77.51 (13.45)	77.22 (13.09)	77.67 (13.57)
LS Mean of Change from Baseline (SE)	-0.57 (1.18)	-0.66 (1.27)	-0.08 (0.92)
95% CI	(-2.89, 1.75)	(-3.16, 1.84)	(-1.89, 1.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.49 (1.46)	-0.58 (1.54)	
95% CI	(-3.36, 2.39)	(-3.61, 2.45)	
p-value	0.7399	0.7071	
Corrected Hedge's g Statistics	-0.038	-0.046	
95% CI	(-0.27, 0.19)	(-0.29, 0.20)	
Subgroup*Treatment Interaction p-value	0.6185	0.5072	

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Concentration/Memory			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	80.47 (23.57)	78.87 (20.82)	78.97 (21.45)
Analysis Visit Mean (SD)	79.34 (22.81)	79.81 (19.75)	80.13 (22.34)
LS Mean of Change from Baseline (SE)	-0.72 (1.31)	0.62 (1.42)	1.01 (1.04)
95% CI	(-3.30, 1.87)	(-2.16, 3.41)	(-1.03, 3.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.73 (1.63)	-0.39 (1.72)	
95% CI	(-4.94, 1.48)	(-3.77, 2.99)	
p-value	0.2905	0.8210	
Corrected Hedge's g Statistics	-0.113	-0.026	
95% CI	(-0.33, 0.10)	(-0.25, 0.20)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	80.01 (23.46)	79.66 (20.17)	78.58 (21.25)
Analysis Visit Mean (SD)	79.51 (20.59)	78.44 (20.72)	78.32 (22.75)
LS Mean of Change from Baseline (SE)	-0.95 (1.31)	-0.76 (1.41)	-0.48 (1.02)
95% CI	(-3.52, 1.63)	(-3.53, 2.01)	(-2.49, 1.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.47 (1.62)	-0.29 (1.70)	
95% CI	(-3.65, 2.71)	(-3.63, 3.06)	
p-value	0.7715	0.8665	
Corrected Hedge's g Statistics	-0.033	-0.020	
95% CI	(-0.26, 0.20)	(-0.26, 0.22)	
Subgroup*Treatment Interaction p-value	0.8350	0.9740	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Health Distress			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	79.14 (25.69)	78.91 (26.95)	81.22 (23.89)
Analysis Visit Mean (SD)	84.87 (21.10)	85.04 (21.80)	86.45 (21.49)
LS Mean of Change from Baseline (SE)	5.08 (1.46)	5.25 (1.57)	5.39 (1.16)
95% CI	(2.21, 7.94)	(2.16, 8.33)	(3.11, 7.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.31 (1.81)	-0.14 (1.91)	
95% CI	(-3.86, 3.24)	(-3.88, 3.60)	
p-value	0.8645	0.9413	
Corrected Hedge's g Statistics	-0.018	-0.008	
95% CI	(-0.23, 0.20)	(-0.24, 0.22)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	79.82 (24.75)	80.28 (27.05)	81.87 (23.52)
Analysis Visit Mean (SD)	83.66 (23.23)	85.44 (22.37)	86.08 (20.88)
LS Mean of Change from Baseline (SE)	2.74 (1.69)	4.82 (1.82)	4.47 (1.32)
95% CI	(-0.58, 6.07)	(1.25, 8.40)	(1.88, 7.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.72 (2.09)	0.36 (2.20)	
95% CI	(-5.84, 2.39)	(-3.97, 4.69)	
p-value	0.4114	0.8717	
Corrected Hedge's g Statistics	-0.094	0.020	
95% CI	(-0.33, 0.14)	(-0.22, 0.26)	
Subgroup*Treatment Interaction p-value	0.6819	0.2158	

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Sexual Function			
Week 24			
m	142	126	248
n	53	52	88
Baseline Mean (SD)	78.59 (27.94)	82.88 (18.81)	80.83 (22.57)
Analysis Visit Mean (SD)	80.44 (24.22)	76.66 (25.46)	81.59 (21.78)
LS Mean of Change from Baseline (SE)	2.00 (2.59)	-5.27 (2.63)	0.88 (2.04)
95% CI	(-3.10, 7.11)	(-10.45, -0.08)	(-3.15, 4.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.13 (3.25)	-6.14 (3.26)	
95% CI	(-5.27, 7.52)	(-12.58, 0.29)	
p-value	0.7289	0.0610	
Corrected Hedge's g Statistics	0.059	-0.320	
95% CI	(-0.28, 0.40)	(-0.66, 0.03)	
Week 52			
m	132	113	231
n	44	42	76
Baseline Mean (SD)	81.06 (28.28)	81.77 (22.03)	79.10 (24.16)
Analysis Visit Mean (SD)	85.49 (21.14)	77.64 (28.58)	78.45 (25.24)
LS Mean of Change from Baseline (SE)	4.70 (2.79)	-2.90 (2.85)	-0.97 (2.17)
95% CI	(-0.80, 10.21)	(-8.53, 2.72)	(-5.26, 3.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.67 (3.48)	-1.93 (3.52)	
95% CI	(-1.19, 12.54)	(-8.87, 5.01)	
p-value	0.1048	0.5839	
Corrected Hedge's g Statistics	0.300	-0.102	
95% CI	(-0.07, 0.67)	(-0.48, 0.27)	
Subgroup*Treatment Interaction p-value	0.9904	0.0434	

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Sleep			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	63.42 (20.30)	60.63 (19.70)	62.76 (20.29)
Analysis Visit Mean (SD)	64.55 (19.94)	58.17 (20.60)	63.05 (20.62)
LS Mean of Change from Baseline (SE)	1.45 (1.29)	-3.19 (1.39)	0.17 (1.02)
95% CI	(-1.08, 3.97)	(-5.91, -0.47)	(-1.83, 2.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.27 (1.59)	-3.36 (1.68)	
95% CI	(-1.86, 4.41)	(-6.66, -0.06)	
p-value	0.4240	0.0457	
Corrected Hedge's g Statistics	0.085	-0.226	
95% CI	(-0.13, 0.30)	(-0.45, 0.00)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	64.74 (19.79)	60.98 (20.59)	62.43 (20.48)
Analysis Visit Mean (SD)	65.45 (18.85)	59.54 (21.43)	63.60 (21.04)
LS Mean of Change from Baseline (SE)	1.86 (1.44)	-1.99 (1.55)	0.86 (1.12)
95% CI	(-0.97, 4.69)	(-5.04, 1.05)	(-1.34, 3.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.00 (1.78)	-2.85 (1.87)	
95% CI	(-2.50, 4.51)	(-6.53, 0.83)	
p-value	0.5735	0.1287	
Corrected Hedge's g Statistics	0.065	-0.184	
95% CI	(-0.17, 0.30)	(-0.43, 0.06)	
Subgroup*Treatment Interaction p-value	0.6602	0.2215	

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Loneliness			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	85.64 (17.70)	83.21 (20.38)	84.01 (19.01)
Analysis Visit Mean (SD)	84.61 (18.05)	84.02 (20.33)	82.26 (20.61)
LS Mean of Change from Baseline (SE)	-1.11 (1.31)	0.05 (1.42)	-2.30 (1.04)
95% CI	(-3.69, 1.47)	(-2.73, 2.83)	(-4.35, -0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.19 (1.63)	2.35 (1.72)	
95% CI	(-2.02, 4.40)	(-1.03, 5.74)	
p-value	0.4673	0.1721	
Corrected Hedge's g Statistics	0.078	0.155	
95% CI	(-0.14, 0.29)	(-0.07, 0.38)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	85.92 (18.08)	81.86 (21.12)	83.77 (19.24)
Analysis Visit Mean (SD)	86.05 (16.68)	81.80 (21.92)	83.81 (19.07)
LS Mean of Change from Baseline (SE)	0.02 (1.38)	-1.40 (1.48)	-0.99 (1.07)
95% CI	(-2.68, 2.73)	(-4.31, 1.52)	(-3.09, 1.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.01 (1.70)	-0.41 (1.79)	
95% CI	(-2.34, 4.36)	(-3.93, 3.11)	
p-value	0.5537	0.8191	
Corrected Hedge's g Statistics	0.068	-0.028	
95% CI	(-0.16, 0.30)	(-0.27, 0.22)	
Subgroup*Treatment Interaction p-value	0.2918	0.8876	

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Hopelessness			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	76.32 (22.98)	74.93 (22.78)	80.00 (20.92)
Analysis Visit Mean (SD)	79.20 (21.51)	76.12 (23.13)	79.44 (21.66)
LS Mean of Change from Baseline (SE)	2.19 (1.51)	-0.38 (1.63)	0.10 (1.20)
95% CI	(-0.77, 5.15)	(-3.57, 2.81)	(-2.25, 2.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.09 (1.87)	-0.48 (1.98)	
95% CI	(-1.59, 5.77)	(-4.36, 3.40)	
p-value	0.2645	0.8079	
Corrected Hedge's g Statistics	0.119	-0.028	
95% CI	(-0.10, 0.34)	(-0.26, 0.20)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	78.29 (22.08)	75.34 (23.88)	79.88 (21.15)
Analysis Visit Mean (SD)	80.05 (20.82)	75.95 (22.30)	78.41 (21.89)
LS Mean of Change from Baseline (SE)	2.56 (1.67)	-0.49 (1.80)	-1.02 (1.30)
95% CI	(-0.72, 5.83)	(-4.02, 3.03)	(-3.57, 1.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.58 (2.06)	0.53 (2.18)	
95% CI	(-0.48, 7.63)	(-3.75, 4.80)	
p-value	0.0836	0.8090	
Corrected Hedge's g Statistics	0.199	0.029	
95% CI	(-0.03, 0.43)	(-0.21, 0.27)	
Subgroup*Treatment Interaction p-value	0.1469	0.1960	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.10.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Stigma of Liver Disease			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	82.72 (21.64)	79.82 (20.46)	83.88 (19.31)
Analysis Visit Mean (SD)	85.45 (20.37)	80.60 (20.38)	86.06 (18.45)
LS Mean of Change from Baseline (SE)	2.72 (1.30)	-0.21 (1.40)	2.52 (1.03)
95% CI	(0.17, 5.27)	(-2.97, 2.55)	(0.50, 4.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.20 (1.62)	-2.73 (1.71)	
95% CI	(-2.98, 3.37)	(-6.09, 0.63)	
p-value	0.9036	0.1107	
Corrected Hedge's g Statistics	0.013	-0.181	
95% CI	(-0.20, 0.23)	(-0.41, 0.05)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	84.06 (20.92)	80.95 (20.65)	82.98 (19.44)
Analysis Visit Mean (SD)	88.17 (17.34)	83.31 (19.54)	85.22 (18.40)
LS Mean of Change from Baseline (SE)	4.62 (1.26)	1.38 (1.36)	2.19 (0.98)
95% CI	(2.14, 7.10)	(-1.29, 4.05)	(0.26, 4.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.42 (1.56)	-0.81 (1.64)	
95% CI	(-0.64, 5.48)	(-4.04, 2.41)	
p-value	0.1206	0.6205	
Corrected Hedge's g Statistics	0.178	-0.060	
95% CI	(-0.05, 0.41)	(-0.30, 0.18)	
Subgroup*Treatment Interaction p-value	0.7740	0.2966	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (2.3)
No	19 (100)	16 (100)	42 (97.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.33	-2.33	
95% CI of the absolute risk difference	(-6.83, 2.18)	(-6.83, 2.18)	
p-value	0.5028	0.5384	
p-value of Breslow-Day Test for Homogeneity [3]	0.4743	0.5738	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (26.3)	3 (18.8)	7 (16.3)
No	14 (73.7)	13 (81.3)	36 (83.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	0.84	
95% CI of the inverse odds ratio	(0.15, 2.00)	(0.19, 3.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.87	
95% CI of the inverse risk ratio	(0.22, 1.70)	(0.26, 2.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.04	2.47	
95% CI of the absolute risk difference	(-12.63, 32.70)	(-19.61, 24.55)	
p-value	0.3564	0.8221	
p-value of Breslow-Day Test for Homogeneity [3]	0.5293	0.9437	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (12.5)	5 (11.6)
No	19 (100)	14 (87.5)	38 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.57	0.92	
95% CI of the inverse odds ratio	(0.29, 106.01)	(0.16, 5.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.00	0.93	
95% CI of the inverse risk ratio	(0.29, 86.13)	(0.20, 4.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.00	0.87	
95% CI of the absolute risk difference	(-21.93, 1.93)	(-17.95, 19.70)	
p-value	0.2033	0.9266	
p-value of Breslow-Day Test for Homogeneity [3]	0.2847	0.8412	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (21.1)	6 (37.5)	9 (20.9)
No	15 (78.9)	10 (62.5)	34 (79.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.44	
95% CI of the inverse odds ratio	(0.26, 3.74)	(0.13, 1.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.56	
95% CI of the inverse risk ratio	(0.35, 2.83)	(0.24, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.12	16.57	
95% CI of the absolute risk difference	(-21.87, 22.12)	(-10.09, 43.23)	
p-value	0.9913	0.1938	
p-value of Breslow-Day Test for Homogeneity [3]	0.7202	0.1788	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (4.7)
No	19 (100)	16 (100)	41 (95.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.65	-4.65	
95% CI of the absolute risk difference	(-10.95, 1.64)	(-10.95, 1.64)	
p-value	0.3393	0.3801	
p-value of Breslow-Day Test for Homogeneity [3]	0.5741	0.4389	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (26.3)	4 (25.0)	6 (14.0)
No	14 (73.7)	12 (75.0)	37 (86.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.45	0.49	
95% CI of the inverse odds ratio	(0.12, 1.73)	(0.12, 2.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	0.56	
95% CI of the inverse risk ratio	(0.18, 1.53)	(0.18, 1.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.36	11.05	
95% CI of the absolute risk difference	(-9.98, 34.71)	(-12.56, 34.66)	
p-value	0.2401	0.3147	
p-value of Breslow-Day Test for Homogeneity [3]	0.1036	0.2446	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (5.3)	0	2 (4.7)
No	18 (94.7)	16 (100)	41 (95.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse odds ratio	(0.07, 10.31)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.09, 9.16)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.61	-4.65	
95% CI of the absolute risk difference	(-11.24, 12.46)	(-10.95, 1.64)	
p-value	0.9175	0.3801	
p-value of Breslow-Day Test for Homogeneity [3]	0.8727	0.3952	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (21.1)	3 (18.8)	8 (18.6)
No	15 (78.9)	13 (81.3)	35 (81.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.99	
95% CI of the inverse odds ratio	(0.22, 3.29)	(0.23, 4.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.99	
95% CI of the inverse risk ratio	(0.30, 2.58)	(0.30, 3.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.45	0.15	
95% CI of the absolute risk difference	(-19.26, 24.16)	(-22.24, 22.53)	
p-value	0.8220	0.9898	
p-value of Breslow-Day Test for Homogeneity [3]	0.8082	0.9117	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (31.6)	3 (18.8)	8 (18.6)
No	13 (68.4)	13 (81.3)	35 (81.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	0.99	
95% CI of the inverse odds ratio	(0.14, 1.70)	(0.23, 4.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.99	
95% CI of the inverse risk ratio	(0.24, 1.46)	(0.30, 3.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.97	0.15	
95% CI of the absolute risk difference	(-10.94, 36.89)	(-22.24, 22.53)	
p-value	0.2600	0.9898	
p-value of Breslow-Day Test for Homogeneity [3]	0.3455	0.8001	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (36.8)	4 (25.0)	10 (23.3)
No	12 (63.2)	12 (75.0)	33 (76.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	0.91	
95% CI of the inverse odds ratio	(0.16, 1.67)	(0.24, 3.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.93	
95% CI of the inverse risk ratio	(0.28, 1.41)	(0.34, 2.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.59	1.74	
95% CI of the absolute risk difference	(-11.51, 38.68)	(-22.95, 26.43)	
p-value	0.2689	0.8887	
p-value of Breslow-Day Test for Homogeneity [3]	0.2613	0.9101	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (12.5)	0
No	19 (100)	14 (87.5)	43 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 1.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.08	
95% CI of the inverse risk ratio	NE	(0.00, 1.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	13.57	
95% CI of the absolute risk difference	NE	(-3.55, 30.69)	
p-value	NE	0.0280	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0098	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	3 (18.8)	0
No	19 (100)	13 (81.3)	43 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.04	
95% CI of the inverse odds ratio	NE	(0.00, 0.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.06	
95% CI of the inverse risk ratio	NE	(0.00, 1.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	19.45	
95% CI of the absolute risk difference	NE	(-0.02, 38.93)	
p-value	NE	0.0059	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0028	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (15.8)	3 (18.8)	6 (14.0)
No	16 (84.2)	13 (81.3)	37 (86.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.70	
95% CI of the inverse odds ratio	(0.19, 3.89)	(0.15, 3.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.74	
95% CI of the inverse risk ratio	(0.25, 3.17)	(0.21, 2.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.84	4.80	
95% CI of the absolute risk difference	(-17.56, 21.23)	(-16.95, 26.55)	
p-value	0.8499	0.6487	
p-value of Breslow-Day Test for Homogeneity [3]	0.7660	0.4380	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (26.3)	6 (37.5)	11 (25.6)
No	14 (73.7)	10 (62.5)	32 (74.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.57	
95% CI of the inverse odds ratio	(0.28, 3.29)	(0.17, 1.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.68	
95% CI of the inverse risk ratio	(0.39, 2.41)	(0.30, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.73	11.92	
95% CI of the absolute risk difference	(-22.97, 24.44)	(-15.15, 38.99)	
p-value	0.9514	0.3688	
p-value of Breslow-Day Test for Homogeneity [3]	0.7710	0.2537	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (10.5)	2 (12.5)	4 (9.3)
No	17 (89.5)	14 (87.5)	39 (90.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.72	
95% CI of the inverse odds ratio	(0.15, 5.22)	(0.12, 4.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.74	
95% CI of the inverse risk ratio	(0.18, 4.42)	(0.15, 3.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.22	3.20	
95% CI of the absolute risk difference	(-15.08, 17.53)	(-15.19, 21.58)	
p-value	0.8805	0.7179	
p-value of Breslow-Day Test for Homogeneity [3]	0.9677	0.9118	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (31.6)	4 (25.0)	10 (23.3)
No	13 (68.4)	12 (75.0)	33 (76.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.91	
95% CI of the inverse odds ratio	(0.20, 2.18)	(0.24, 3.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.93	
95% CI of the inverse risk ratio	(0.31, 1.73)	(0.34, 2.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.32	1.74	
95% CI of the absolute risk difference	(-16.10, 32.74)	(-22.95, 26.43)	
p-value	0.4899	0.8887	
p-value of Breslow-Day Test for Homogeneity [3]	0.3174	0.7768	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (21.1)	5 (31.3)	4 (9.3)
No	15 (78.9)	11 (68.8)	39 (90.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	0.23	
95% CI of the inverse odds ratio	(0.09, 1.74)	(0.05, 0.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	0.30	
95% CI of the inverse risk ratio	(0.12, 1.58)	(0.09, 0.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.75	21.95	
95% CI of the absolute risk difference	(-8.53, 32.03)	(-2.37, 46.26)	
p-value	0.2032	0.0371	
p-value of Breslow-Day Test for Homogeneity [3]	0.4165	0.2101	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (26.3)	5 (31.3)	11 (25.6)
No	14 (73.7)	11 (68.8)	32 (74.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.76	
95% CI of the inverse odds ratio	(0.28, 3.29)	(0.21, 2.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.82	
95% CI of the inverse risk ratio	(0.39, 2.41)	(0.34, 1.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.73	5.67	
95% CI of the absolute risk difference	(-22.97, 24.44)	(-20.52, 31.86)	
p-value	0.9514	0.6633	
p-value of Breslow-Day Test for Homogeneity [3]	0.6594	0.9470	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (5.3)	1 (6.3)	6 (14.0)
No	18 (94.7)	15 (93.8)	37 (86.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	2.43	
95% CI of the inverse odds ratio	(0.33, 26.10)	(0.27, 21.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.65	2.23	
95% CI of the inverse risk ratio	(0.34, 20.53)	(0.29, 17.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.69	-7.70	
95% CI of the absolute risk difference	(-23.12, 5.73)	(-23.45, 8.04)	
p-value	0.3189	0.4159	
p-value of Breslow-Day Test for Homogeneity [3]	0.2377	0.3284	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (36.8)	6 (37.5)	10 (23.3)
No	12 (63.2)	10 (62.5)	33 (76.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	0.51	
95% CI of the inverse odds ratio	(0.16, 1.67)	(0.15, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.62	
95% CI of the inverse risk ratio	(0.28, 1.41)	(0.27, 1.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.59	14.24	
95% CI of the absolute risk difference	(-11.51, 38.68)	(-12.63, 41.12)	
p-value	0.2689	0.2739	
p-value of Breslow-Day Test for Homogeneity [3]	0.4286	0.3110	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (4.1)	4 (3.0)	9 (3.5)
No	142 (95.9)	131 (97.0)	251 (96.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.17	
95% CI of the inverse odds ratio	(0.30, 2.43)	(0.35, 3.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.17	
95% CI of the inverse risk ratio	(0.31, 2.35)	(0.37, 3.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.59	-0.50	
95% CI of the absolute risk difference	(-3.28, 4.47)	(-4.12, 3.12)	
p-value	0.7598	0.7922	
p-value of Breslow-Day Test for Homogeneity [3]	0.4743	0.5738	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (22.3)	29 (21.5)	51 (19.6)
No	115 (77.7)	106 (78.5)	209 (80.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.89	
95% CI of the inverse odds ratio	(0.52, 1.39)	(0.53, 1.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.91	
95% CI of the inverse risk ratio	(0.60, 1.30)	(0.61, 1.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.68	1.87	
95% CI of the absolute risk difference	(-5.58, 10.94)	(-6.58, 10.31)	
p-value	0.5195	0.6616	
p-value of Breslow-Day Test for Homogeneity [3]	0.5293	0.9437	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (4.1)	14 (10.4)	21 (8.1)
No	142 (95.9)	121 (89.6)	239 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	0.76	
95% CI of the inverse odds ratio	(0.82, 5.27)	(0.37, 1.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.99	0.78	
95% CI of the inverse risk ratio	(0.82, 4.83)	(0.41, 1.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.02	2.29	
95% CI of the absolute risk difference	(-8.61, 0.57)	(-3.82, 8.41)	
p-value	0.1160	0.4468	
p-value of Breslow-Day Test for Homogeneity [3]	0.2847	0.8412	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (21.6)	33 (24.4)	68 (26.2)
No	116 (78.4)	102 (75.6)	192 (73.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	1.09	
95% CI of the inverse odds ratio	(0.80, 2.07)	(0.68, 1.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.07	
95% CI of the inverse risk ratio	(0.84, 1.75)	(0.75, 1.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.53	-1.71	
95% CI of the absolute risk difference	(-13.05, 3.98)	(-10.71, 7.30)	
p-value	0.3062	0.7119	
p-value of Breslow-Day Test for Homogeneity [3]	0.7202	0.1788	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (3.4)	10 (7.4)	24 (9.2)
No	143 (96.6)	125 (92.6)	236 (90.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.91	1.27	
95% CI of the inverse odds ratio	(1.09, 7.79)	(0.59, 2.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.73	1.25	
95% CI of the inverse risk ratio	(1.07, 7.01)	(0.61, 2.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.85	-1.82	
95% CI of the absolute risk difference	(-10.42, -1.29)	(-7.47, 3.82)	
p-value	0.0270	0.5400	
p-value of Breslow-Day Test for Homogeneity [3]	0.5741	0.4389	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (14.9)	24 (17.8)	53 (20.4)
No	126 (85.1)	111 (82.2)	207 (79.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	1.18	
95% CI of the inverse odds ratio	(0.85, 2.53)	(0.69, 2.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.37	1.15	
95% CI of the inverse risk ratio	(0.87, 2.16)	(0.74, 1.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.52	-2.61	
95% CI of the absolute risk difference	(-13.06, 2.02)	(-10.70, 5.49)	
p-value	0.1664	0.5351	
p-value of Breslow-Day Test for Homogeneity [3]	0.1036	0.2446	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (9.5)	9 (6.7)	18 (6.9)
No	134 (90.5)	126 (93.3)	242 (93.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.04	
95% CI of the inverse odds ratio	(0.34, 1.48)	(0.45, 2.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	1.04	
95% CI of the inverse risk ratio	(0.38, 1.43)	(0.48, 2.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.54	-0.26	
95% CI of the absolute risk difference	(-3.10, 8.17)	(-5.47, 4.96)	
p-value	0.3596	0.9237	
p-value of Breslow-Day Test for Homogeneity [3]	0.8727	0.3952	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (22.3)	33 (24.4)	59 (22.7)
No	115 (77.7)	102 (75.6)	201 (77.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.91	
95% CI of the inverse odds ratio	(0.63, 1.66)	(0.56, 1.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.93	
95% CI of the inverse risk ratio	(0.70, 1.48)	(0.64, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.40	1.75	
95% CI of the absolute risk difference	(-8.81, 8.02)	(-7.11, 10.61)	
p-value	0.9269	0.6960	
p-value of Breslow-Day Test for Homogeneity [3]	0.8082	0.9117	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	22 (14.9)	23 (17.0)	37 (14.2)
No	126 (85.1)	112 (83.0)	223 (85.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.81	
95% CI of the inverse odds ratio	(0.54, 1.68)	(0.46, 1.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.84	
95% CI of the inverse risk ratio	(0.59, 1.56)	(0.52, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.63	2.81	
95% CI of the absolute risk difference	(-6.50, 7.77)	(-4.83, 10.44)	
p-value	0.8610	0.4611	
p-value of Breslow-Day Test for Homogeneity [3]	0.3455	0.8001	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (22.3)	32 (23.7)	61 (23.5)
No	115 (77.7)	103 (76.3)	199 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.99	
95% CI of the inverse odds ratio	(0.66, 1.73)	(0.60, 1.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.99	
95% CI of the inverse risk ratio	(0.73, 1.53)	(0.68, 1.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.16	0.24	
95% CI of the absolute risk difference	(-9.62, 7.29)	(-8.59, 9.07)	
p-value	0.7883	0.9571	
p-value of Breslow-Day Test for Homogeneity [3]	0.2613	0.9101	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (4.1)	4 (3.0)	13 (5.0)
No	142 (95.9)	131 (97.0)	247 (95.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.72	
95% CI of the inverse odds ratio	(0.46, 3.35)	(0.55, 5.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	1.69	
95% CI of the inverse risk ratio	(0.48, 3.18)	(0.56, 5.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.95	-2.04	
95% CI of the absolute risk difference	(-5.08, 3.19)	(-5.94, 1.86)	
p-value	0.6629	0.3440	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0098	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (8.8)	10 (7.4)	25 (9.6)
No	135 (91.2)	125 (92.6)	235 (90.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	1.33	
95% CI of the inverse odds ratio	(0.55, 2.23)	(0.62, 2.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.30	
95% CI of the inverse risk ratio	(0.58, 2.07)	(0.64, 2.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.83	-2.21	
95% CI of the absolute risk difference	(-6.63, 4.97)	(-7.90, 3.48)	
p-value	0.7811	0.4639	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0028	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	22 (14.9)	17 (12.6)	42 (16.2)
No	126 (85.1)	118 (87.4)	218 (83.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	1.34	
95% CI of the inverse odds ratio	(0.63, 1.93)	(0.73, 2.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.28	
95% CI of the inverse risk ratio	(0.68, 1.75)	(0.76, 2.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.29	-3.56	
95% CI of the absolute risk difference	(-8.56, 5.98)	(-10.73, 3.60)	
p-value	0.7307	0.3463	
p-value of Breslow-Day Test for Homogeneity [3]	0.7660	0.4380	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	44 (29.7)	39 (28.9)	86 (33.1)
No	104 (70.3)	96 (71.1)	174 (66.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	1.22	
95% CI of the inverse odds ratio	(0.75, 1.81)	(0.77, 1.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.14	
95% CI of the inverse risk ratio	(0.82, 1.50)	(0.83, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.35	-4.19	
95% CI of the absolute risk difference	(-12.67, 5.98)	(-13.74, 5.36)	
p-value	0.4854	0.3960	
p-value of Breslow-Day Test for Homogeneity [3]	0.7710	0.2537	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (12.2)	22 (16.3)	29 (11.2)
No	130 (87.8)	113 (83.7)	231 (88.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.64	
95% CI of the inverse odds ratio	(0.48, 1.70)	(0.35, 1.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.68	
95% CI of the inverse risk ratio	(0.53, 1.59)	(0.41, 1.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.01	5.14	
95% CI of the absolute risk difference	(-5.50, 7.52)	(-2.17, 12.45)	
p-value	0.7591	0.1483	
p-value of Breslow-Day Test for Homogeneity [3]	0.9677	0.9118	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	35 (23.6)	35 (25.9)	73 (28.1)
No	113 (76.4)	100 (74.1)	187 (71.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	1.12	
95% CI of the inverse odds ratio	(0.79, 2.01)	(0.70, 1.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	1.08	
95% CI of the inverse risk ratio	(0.84, 1.68)	(0.77, 1.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.43	-2.15	
95% CI of the absolute risk difference	(-13.19, 4.33)	(-11.34, 7.04)	
p-value	0.3297	0.6492	
p-value of Breslow-Day Test for Homogeneity [3]	0.3174	0.7768	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	27 (18.2)	29 (21.5)	37 (14.2)
No	121 (81.8)	106 (78.5)	223 (85.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.61	
95% CI of the inverse odds ratio	(0.43, 1.28)	(0.35, 1.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.66	
95% CI of the inverse risk ratio	(0.50, 1.23)	(0.43, 1.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.01	7.25	
95% CI of the absolute risk difference	(-3.52, 11.55)	(-0.88, 15.38)	
p-value	0.2839	0.0669	
p-value of Breslow-Day Test for Homogeneity [3]	0.4165	0.2101	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	43 (29.1)	39 (28.9)	59 (22.7)
No	105 (70.9)	96 (71.1)	201 (77.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.72	
95% CI of the inverse odds ratio	(0.45, 1.13)	(0.45, 1.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.79	
95% CI of the inverse risk ratio	(0.56, 1.09)	(0.56, 1.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.36	6.20	
95% CI of the absolute risk difference	(-2.55, 15.27)	(-2.99, 15.38)	
p-value	0.1536	0.1762	
p-value of Breslow-Day Test for Homogeneity [3]	0.6594	0.9470	

AMNOG Table SE21.10.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	19 (12.8)	17 (12.6)	27 (10.4)
No	129 (87.2)	118 (87.4)	233 (89.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.80	
95% CI of the inverse odds ratio	(0.42, 1.47)	(0.42, 1.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.82	
95% CI of the inverse risk ratio	(0.47, 1.40)	(0.47, 1.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.45	2.21	
95% CI of the absolute risk difference	(-4.09, 8.99)	(-4.51, 8.92)	
p-value	0.4513	0.5083	
p-value of Breslow-Day Test for Homogeneity [3]	0.2377	0.3284	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	45 (30.4)	37 (27.4)	71 (27.3)
No	103 (69.6)	98 (72.6)	189 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.99	
95% CI of the inverse odds ratio	(0.55, 1.34)	(0.62, 1.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.00	
95% CI of the inverse risk ratio	(0.66, 1.23)	(0.71, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.10	0.10	
95% CI of the absolute risk difference	(-6.08, 12.28)	(-9.17, 9.37)	
p-value	0.5048	0.9832	
p-value of Breslow-Day Test for Homogeneity [3]	0.4286	0.3110	

Madrigal Pharmaceuticals, Inc. Page 1 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE21.10.5
Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes
Sexual Function



Patients with result at given visit			
MGL-3196 80 mg	5	6	3
MGL-3196 100 mg	8	7	6
Placebo	8	14	8

Abbreviations: Abbreviations: LDLOQ = Liver Disease Quality of Life; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE21.10.5
Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No
Sexual Function



Patients with result at given visit			
MGL-3196 80 mg	66	66	50
MGL-3196 100 mg	64	70	51
Placebo	113	111	93

Abbreviations: Abbreviations: LDLOQ = Liver Disease Quality of Life; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Total LDQOL						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	80.00 (15.21)	79.84 (11.70)	78.24 (12.57)			
Median	86.00	79.70	80.50			
IQR: Q1, Q3	77.10, 89.20	72.70, 89.30	71.70, 88.60			
Min, Max	28.3, 93.7	50.8, 96.3	49.8, 95.2			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	79.22 (16.70)	80.85 (9.39)	78.95 (13.00)	0.03 (1.81)	0.46 (1.19)	0.47 (1.85)
Median	84.20	80.70	83.30	1.65	-0.40	0.90
IQR: Q1, Q3	75.80, 90.40	75.60, 88.20	67.30, 88.10	-5.30, 6.05	-2.50, 3.60	-4.70, 3.70
Min, Max	22.9, 96.1	58.4, 95.4	45.1, 95.8	-23.4, 15.9	-12.5, 14.3	-20.6, 23.9
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	81.42 (13.38)	84.22 (9.85)	82.93 (12.14)	1.83 (1.66)	2.50 (1.79)	3.38 (1.62)
Median	85.20	88.50	86.20	1.25	5.90	3.65
IQR: Q1, Q3	81.40, 88.50	74.70, 90.95	78.20, 90.00	-2.40, 5.20	-7.10, 10.10	-0.25, 9.05
Min, Max	44.6, 95.0	61.3, 97.4	40.7, 100.0	-14.4, 25.3	-18.2, 18.3	-22.1, 17.4

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Symptoms of Liver Disease						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	85.28 (18.03)	76.89 (20.26)	80.20 (15.55)			
Median	93.30	83.30	83.30			
IQR: Q1, Q3	83.30, 96.70	70.00, 90.00	70.00, 93.30			
Min, Max	13.3, 100.0	10.0, 100.0	46.7, 100.0			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	78.73 (19.92)	77.10 (16.42)	81.50 (15.49)	-5.59 (2.51)	0.35 (1.99)	1.96 (2.50)
Median	83.30	76.70	83.30	-1.65	0	0
IQR: Q1, Q3	73.30, 93.30	66.70, 90.00	73.30, 93.30	-10.00, 0.00	-6.60, 6.70	-6.70, 10.00
Min, Max	16.7, 100.0	30.0, 100.0	40.0, 100.0	-43.3, 23.3	-23.3, 30.0	-26.6, 36.7
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	80.77 (21.71)	82.38 (14.17)	83.79 (17.18)	-4.36 (2.04)	2.72 (2.39)	2.03 (2.27)
Median	85.00	85.00	86.70	0	0	0
IQR: Q1, Q3	80.00, 93.30	73.30, 93.30	83.30, 96.70	-10.00, 0.00	-6.70, 13.30	-5.00, 8.35
Min, Max	6.7, 100.0	36.7, 96.7	23.3, 100.0	-36.7, 10.0	-20.0, 23.4	-30.0, 26.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Effects of Liver Disease						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	77.48 (16.17)	82.30 (9.13)	75.56 (14.50)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	80.00, 86.70	73.30, 86.70			
Min, Max	6.7, 100.0	60.0, 100.0	40.0, 100.0			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	74.26 (19.58)	80.65 (8.33)	80.43 (12.29)	-2.86 (1.98)	-1.84 (1.95)	3.91 (2.64)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	73.30, 86.70	73.30, 86.70	-6.70, 0.00	-6.70, 0.00	-6.70, 13.30
Min, Max	0.0, 100.0	60.0, 100.0	40.0, 100.0	-33.4, 20.0	-33.3, 20.0	-20.0, 40.0
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	76.16 (17.90)	81.19 (6.80)	80.00 (14.80)	-0.26 (1.31)	-2.23 (1.92)	2.14 (3.07)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 83.35	80.00, 86.70	0.00, 0.00	-6.70, 0.00	0.00, 6.70
Min, Max	6.7, 100.0	66.7, 100.0	20.0, 100.0	-20.0, 13.3	-20.0, 20.0	-53.3, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Concentration/Memory						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	82.56 (23.04)	79.97 (21.34)	82.97 (18.17)			
Median	93.80	87.50	87.50			
IQR: Q1, Q3	75.00, 100.00	68.80, 100.00	75.00, 100.00			
Min, Max	6.3, 100.0	25.0, 100.0	43.8, 100.0			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	79.11 (21.99)	80.86 (21.03)	82.27 (22.71)	-2.45 (3.28)	-0.43 (2.03)	-1.94 (3.64)
Median	87.50	87.50	93.80	0	0	0
IQR: Q1, Q3	68.80, 93.80	68.80, 100.00	68.80, 100.00	-9.40, 6.25	-6.20, 6.30	-6.30, 0.00
Min, Max	25.0, 100.0	31.3, 100.0	12.5, 100.0	-43.8, 31.2	-37.5, 12.5	-37.5, 56.2
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	80.31 (20.96)	85.06 (19.48)	83.21 (17.37)	-0.24 (2.29)	2.32 (2.24)	-2.68 (2.66)
Median	87.50	93.80	87.50	0	0	0
IQR: Q1, Q3	68.80, 93.80	71.90, 100.00	75.00, 100.00	-6.20, 6.30	0.00, 12.50	-6.30, 6.25
Min, Max	18.8, 100.0	43.8, 100.0	37.5, 100.0	-25.0, 25.0	-31.2, 25.0	-37.5, 25.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Health Distress						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	74.57 (33.32)	81.47 (25.14)	75.76 (23.16)			
Median	87.50	100.00	75.00			
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	50.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	25.0, 100.0			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	82.76 (23.48)	89.52 (17.11)	86.69 (17.36)	10.27 (5.02)	7.33 (3.19)	10.78 (4.05)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 25.00	0.00, 25.00	0.00, 25.00
Min, Max	0.0, 100.0	37.5, 100.0	37.5, 100.0	-37.5, 75.0	-25.0, 37.5	-25.0, 62.5
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	85.10 (23.46)	93.75 (11.54)	92.67 (17.84)	12.02 (5.35)	11.57 (4.05)	16.52 (5.02)
Median	100.00	100.00	100.00	0	0	12.50
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	100.00, 100.00	0.00, 25.00	0.00, 25.00	0.00, 43.75
Min, Max	0.0, 100.0	50.0, 100.0	12.5, 100.0	-25.0, 75.0	-25.0, 62.5	-62.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Sexual Function						
Baseline						
m	30	31	35			
n	14	15	13			
Mean (SD)	77.03 (28.36)	77.21 (28.82)	75.13 (26.14)			
Median	89.15	93.30	85.00			
IQR: Q1, Q3	55.00, 100.00	63.30, 100.00	61.70, 93.30			
Min, Max	30.0, 100.0	-1.7, 100.0	6.7, 100.0			
Week 24						
m	30	31	35			
n	13	15	15	10	12	11
Mean (SD/SE)	77.69 (29.73)	77.67 (20.29)	79.89 (23.85)	3.83 (4.53)	-7.76 (6.65)	6.05 (4.94)
Median	93.30	76.70	85.00	0	0	6.70
IQR: Q1, Q3	76.70, 100.00	61.70, 93.30	68.30, 100.00	0.00, 16.60	-19.95, 0.00	-8.30, 21.60
Min, Max	6.7, 100.0	40.0, 100.0	31.7, 100.0	-25.0, 25.0	-48.3, 41.7	-25.0, 31.7
Week 52						
m	29	30	35			
n	9	14	13	8	12	9
Mean (SD/SE)	92.96 (8.54)	82.10 (20.28)	79.62 (26.13)	10.00 (7.20)	-3.04 (6.24)	0.74 (4.00)
Median	93.30	92.50	91.70	0	0.85	0
IQR: Q1, Q3	91.70, 100.00	68.30, 100.00	76.70, 100.00	0.00, 18.35	-12.50, 6.70	-8.30, 6.70
Min, Max	78.3, 100.0	50.0, 100.0	21.7, 100.0	-5.0, 48.3	-50.0, 23.4	-16.7, 25.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Sleep						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	67.93 (21.57)	66.03 (18.58)	67.88 (17.59)			
Median	70.00	65.00	70.00			
IQR: Q1, Q3	60.00, 85.00	55.00, 80.00	55.00, 80.00			
Min, Max	10.0, 100.0	20.0, 100.0	30.0, 100.0			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	66.38 (20.70)	62.26 (19.40)	64.68 (19.66)	-0.89 (2.59)	-4.14 (2.16)	-1.90 (3.06)
Median	70.00	65.00	65.00	0	-5.00	-5.00
IQR: Q1, Q3	55.00, 80.00	50.00, 75.00	50.00, 80.00	-10.00, 7.50	-10.00, 5.00	-10.00, 10.00
Min, Max	10.0, 100.0	15.0, 85.0	25.0, 100.0	-30.0, 35.0	-35.0, 20.0	-40.0, 30.0
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	69.04 (16.61)	65.71 (21.80)	67.41 (19.25)	1.35 (3.73)	-2.41 (3.31)	0.54 (2.73)
Median	75.00	75.00	70.00	-5.00	-5.00	0
IQR: Q1, Q3	60.00, 80.00	57.50, 80.00	50.00, 80.00	-10.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	25.0, 85.0	10.0, 90.0	30.0, 100.0	-20.0, 75.0	-60.0, 25.0	-30.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Loneliness						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	87.93 (11.99)	85.34 (19.50)	82.58 (22.15)			
Median	95.00	95.00	90.00			
IQR: Q1, Q3	80.00, 100.00	80.00, 100.00	75.00, 100.00			
Min, Max	60.0, 100.0	20.0, 100.0	5.0, 100.0			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	83.45 (20.45)	87.74 (17.26)	76.77 (25.41)	-4.46 (3.29)	1.90 (2.20)	-6.72 (2.97)
Median	90.00	95.00	80.00	0	0	-5.00
IQR: Q1, Q3	75.00, 100.00	80.00, 100.00	70.00, 100.00	-10.00, 5.00	0.00, 5.00	-20.00, 0.00
Min, Max	15.0, 100.0	25.0, 100.0	10.0, 100.0	-50.0, 25.0	-25.0, 30.0	-45.0, 30.0
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	81.73 (18.44)	87.32 (17.61)	87.24 (15.96)	-6.73 (2.76)	0.56 (2.75)	2.86 (2.83)
Median	82.50	95.00	95.00	-5.00	0	0
IQR: Q1, Q3	75.00, 95.00	80.00, 100.00	80.00, 100.00	-10.00, 0.00	-5.00, 10.00	-5.00, 10.00
Min, Max	35.0, 100.0	35.0, 100.0	35.0, 100.0	-55.0, 15.0	-40.0, 35.0	-25.0, 35.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Hopelessness						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	78.73 (21.55)	81.03 (17.09)	79.55 (18.30)			
Median	83.30	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	58.30, 100.00			
Min, Max	33.3, 100.0	41.7, 100.0	41.7, 100.0			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	80.74 (23.27)	84.68 (15.83)	75.81 (19.89)	3.26 (3.94)	2.87 (3.05)	-2.59 (3.21)
Median	83.30	91.70	75.00	0	8.30	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	58.30, 91.70	0.00, 25.00	-8.30, 16.70	-8.30, 0.00
Min, Max	8.3, 100.0	50.0, 100.0	33.3, 100.0	-41.7, 33.3	-33.4, 25.0	-41.7, 41.7
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	83.32 (17.95)	87.80 (16.27)	81.61 (22.86)	4.16 (4.39)	5.87 (3.97)	2.08 (3.02)
Median	83.30	95.85	91.70	0	8.30	0
IQR: Q1, Q3	75.00, 100.00	79.15, 100.00	58.30, 100.00	0.00, 16.70	-8.40, 16.70	0.00, 8.30
Min, Max	50.0, 100.0	50.0, 100.0	25.0, 100.0	-41.7, 41.7	-50.0, 33.4	-41.7, 33.4

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Stigma of Liver Disease						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	85.14 (22.43)	87.09 (14.93)	83.35 (20.22)			
Median	93.80	93.80	87.50			
IQR: Q1, Q3	75.00, 100.00	81.30, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	50.0, 100.0	31.3, 100.0			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	86.66 (17.41)	84.90 (12.99)	84.09 (19.62)	1.56 (3.38)	-2.15 (2.29)	0.43 (2.81)
Median	93.80	87.50	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	81.30, 93.80	75.00, 100.00	-9.40, 6.25	-12.50, 0.00	0.00, 6.30
Min, Max	31.3, 100.0	50.0, 100.0	43.8, 100.0	-37.5, 43.8	-25.0, 25.0	-50.0, 25.0
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	90.87 (17.33)	91.54 (10.91)	88.17 (14.59)	5.04 (3.16)	3.24 (2.39)	3.13 (2.42)
Median	100.00	93.80	93.80	0	0	0
IQR: Q1, Q3	87.50, 100.00	84.40, 100.00	75.00, 100.00	0.00, 12.50	-6.20, 12.50	-3.10, 12.50
Min, Max	37.5, 100.0	62.5, 100.0	56.3, 100.0	-31.3, 37.5	-18.7, 31.2	-18.8, 31.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Total LDQOL						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	80.21 (8.44)	86.61 (9.70)	79.01 (11.85)			
Median	82.00	89.95	80.65			
IQR: Q1, Q3	78.10, 85.80	85.90, 91.95	71.45, 88.35			
Min, Max	59.5, 89.9	63.7, 93.6	56.9, 96.7			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	80.41 (12.32)	82.26 (15.69)	77.89 (14.91)	3.15 (1.87)	-3.77 (2.87)	-1.12 (2.63)
Median	83.40	89.60	81.70	3.10	-0.90	-1.10
IQR: Q1, Q3	75.00, 89.95	74.40, 92.30	67.00, 89.00	-2.50, 8.50	-12.70, 3.00	-6.00, 1.75
Min, Max	48.0, 92.4	51.0, 96.6	45.6, 96.5	-7.4, 12.2	-15.4, 4.4	-15.6, 20.7
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	78.54 (16.68)	82.71 (12.35)	77.63 (10.54)	1.52 (2.31)	-3.90 (2.52)	1.49 (1.92)
Median	86.10	89.30	75.95	4.00	-1.00	3.15
IQR: Q1, Q3	60.50, 90.80	71.30, 91.50	71.20, 87.80	-1.00, 6.70	-6.50, 0.90	-4.30, 4.40
Min, Max	48.8, 93.8	63.3, 94.2	61.4, 91.5	-12.0, 8.5	-19.0, 1.0	-9.3, 12.4

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Symptoms of Liver Disease						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	82.12 (18.11)	86.26 (9.16)	75.82 (19.50)			
Median	83.30	88.35	71.65			
IQR: Q1, Q3	76.70, 96.70	81.70, 90.00	61.65, 93.30			
Min, Max	33.3, 96.7	70.0, 100.0	43.3, 100.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	85.00 (12.74)	80.00 (11.06)	72.78 (22.14)	2.43 (4.45)	-4.30 (3.23)	-3.03 (2.89)
Median	90.00	76.70	73.35	3.30	-6.70	-1.65
IQR: Q1, Q3	80.00, 93.30	73.30, 93.30	55.00, 91.65	-6.70, 10.00	-13.30, 3.30	-6.60, 0.00
Min, Max	56.7, 100.0	66.7, 96.7	36.7, 100.0	-20.0, 33.4	-13.4, 6.7	-23.3, 13.4
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	81.51 (21.00)	83.34 (21.22)	76.99 (17.66)	-2.01 (5.03)	-2.93 (5.21)	5.34 (4.19)
Median	86.70	93.30	83.30	3.30	1.65	3.35
IQR: Q1, Q3	60.00, 100.00	75.00, 96.70	73.30, 86.70	0.00, 6.70	-8.35, 6.65	-6.70, 20.00
Min, Max	40.0, 100.0	36.7, 100.0	36.7, 96.7	-43.4, 10.0	-33.3, 10.0	-10.0, 26.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Effects of Liver Disease						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	82.44 (8.04)	83.34 (7.98)	79.45 (8.74)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 86.70	80.00, 86.70	76.65, 80.00			
Min, Max	66.7, 100.0	73.3, 100.0	66.7, 100.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	77.23 (16.68)	81.90 (14.26)	72.22 (12.00)	-0.62 (2.46)	-0.96 (4.23)	-7.23 (3.98)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 83.35	73.30, 100.00	66.65, 80.00	-6.70, 0.00	-13.30, 0.00	-6.70, 0.00
Min, Max	26.7, 93.3	60.0, 100.0	46.7, 80.0	-6.7, 20.0	-13.4, 20.0	-46.7, 0.0
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	78.18 (16.08)	81.66 (11.68)	74.66 (13.98)	-2.01 (4.97)	-1.68 (4.32)	-4.68 (5.62)
Median	80.00	80.00	80.00	0	0	-3.35
IQR: Q1, Q3	80.00, 86.70	80.00, 86.65	73.30, 80.00	-6.70, 0.00	-10.00, 3.30	-13.30, 6.60
Min, Max	40.0, 100.0	60.0, 100.0	40.0, 93.3	-40.0, 20.0	-20.0, 20.0	-40.0, 26.6

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Concentration/Memory						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	84.68 (26.13)	92.20 (15.20)	73.98 (25.11)			
Median	93.80	100.00	78.15			
IQR: Q1, Q3	75.00, 100.00	90.65, 100.00	56.30, 96.90			
Min, Max	12.5, 100.0	56.3, 100.0	25.0, 100.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	81.27 (24.70)	83.94 (22.78)	76.58 (26.39)	1.13 (2.90)	-7.14 (4.19)	2.60 (5.24)
Median	87.50	93.80	81.30	6.20	-6.20	0
IQR: Q1, Q3	78.15, 100.00	75.00, 100.00	56.30, 100.00	-6.30, 6.20	-18.80, 0.00	-3.10, 12.45
Min, Max	31.3, 100.0	37.5, 100.0	25.0, 100.0	-12.5, 18.8	-25.0, 6.2	-25.0, 37.5
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	86.36 (20.50)	85.18 (17.33)	78.77 (25.71)	7.48 (5.80)	-7.03 (4.79)	7.49 (3.93)
Median	100.00	90.65	81.30	6.20	-3.10	6.25
IQR: Q1, Q3	75.00, 100.00	71.90, 100.00	75.00, 100.00	0.00, 6.20	-9.35, 0.00	0.00, 12.50
Min, Max	37.5, 100.0	56.3, 100.0	25.0, 100.0	-12.5, 50.0	-37.5, 6.2	-12.5, 31.2

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Health Distress						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	77.27 (16.60)	87.50 (14.94)	84.38 (17.78)			
Median	75.00	93.75	87.50			
IQR: Q1, Q3	75.00, 87.50	75.00, 100.00	75.00, 100.00			
Min, Max	50.0, 100.0	62.5, 100.0	50.0, 100.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	82.29 (27.93)	91.07 (18.70)	86.46 (18.04)	12.50 (4.46)	1.79 (3.26)	2.08 (3.72)
Median	87.50	100.00	100.00	12.50	0	0
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	75.00, 100.00	0.00, 25.00	0.00, 12.50	0.00, 0.00
Min, Max	0.0, 100.0	50.0, 100.0	50.0, 100.0	-12.5, 37.5	-12.5, 12.5	-25.0, 25.0
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	71.59 (39.96)	93.75 (11.57)	90.00 (11.49)	-1.25 (10.11)	6.25 (3.34)	6.25 (5.67)
Median	87.50	100.00	93.75	6.25	0	0
IQR: Q1, Q3	37.50, 100.00	87.50, 100.00	75.00, 100.00	0.00, 25.00	0.00, 12.50	0.00, 25.00
Min, Max	0.0, 100.0	75.0, 100.0	75.0, 100.0	-75.0, 25.0	0.0, 25.0	-25.0, 25.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Sexual Function						
Baseline						
m	12	8	13			
n	6	5	7			
Mean (SD)	88.87 (11.14)	94.00 (8.22)	81.20 (33.88)			
Median	93.30	100.00	93.30			
IQR: Q1, Q3	85.00, 93.30	85.00, 100.00	76.70, 100.00			
Min, Max	68.3, 100.0	85.0, 100.0	6.7, 100.0			
Week 24						
m	12	8	13			
n	6	4	6	5	3	5
Mean (SD/SE)	83.35 (17.41)	77.08 (41.50)	75.83 (27.55)	1.04 (3.01)	2.77 (2.77)	-12.00 (7.42)
Median	84.20	96.65	90.00	0	0	-6.70
IQR: Q1, Q3	76.70, 100.00	54.15, 100.00	45.00, 93.30	-1.60, 6.70	0.00, 8.30	-13.30, 0.00
Min, Max	55.0, 100.0	15.0, 100.0	36.7, 100.0	-8.3, 8.4	0.0, 8.3	-40.0, 0.0
Week 52						
m	12	8	12			
n	7	4	3	6	3	2
Mean (SD/SE)	84.53 (20.80)	92.50 (8.77)	75.73 (25.65)	-0.53 (3.89)	0.57 (8.17)	-24.75 (3.05)
Median	100.00	93.35	78.30	3.35	0	-24.75
IQR: Q1, Q3	61.70, 100.00	85.00, 100.00	48.90, 100.00	-6.70, 6.70	-13.30, 15.00	-27.80, -21.70
Min, Max	51.7, 100.0	83.3, 100.0	48.9, 100.0	-16.6, 6.7	-13.3, 15.0	-27.8, -21.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Sleep						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	68.64 (21.57)	75.00 (10.00)	63.65 (22.75)			
Median	80.00	77.50	62.50			
IQR: Q1, Q3	60.00, 80.00	70.00, 82.50	45.00, 87.50			
Min, Max	25.0, 90.0	55.0, 85.0	25.0, 95.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	63.33 (27.41)	70.00 (15.81)	61.25 (25.51)	-0.45 (2.82)	-4.29 (3.85)	-2.40 (4.32)
Median	77.50	65.00	57.50	0	-5.00	0
IQR: Q1, Q3	42.50, 80.00	60.00, 85.00	42.50, 85.00	-5.00, 5.00	-10.00, 5.00	-11.90, 5.00
Min, Max	10.0, 90.0	50.0, 95.0	25.0, 100.0	-20.0, 15.0	-20.0, 10.0	-30.0, 25.0
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	68.18 (25.33)	65.00 (24.05)	63.00 (20.98)	7.50 (3.89)	-10.00 (7.26)	5.12 (6.88)
Median	75.00	72.50	57.50	5.00	-7.50	5.00
IQR: Q1, Q3	60.00, 85.00	55.00, 82.50	50.00, 80.00	0.00, 10.00	-15.00, 5.00	-5.00, 15.00
Min, Max	10.0, 100.0	15.0, 85.0	35.0, 95.0	-5.0, 35.0	-55.0, 10.0	-35.0, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Loneliness						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	77.27 (18.22)	88.13 (13.08)	88.75 (11.31)			
Median	80.00	90.00	90.00			
IQR: Q1, Q3	60.00, 95.00	77.50, 100.00	85.00, 97.50			
Min, Max	45.0, 100.0	70.0, 100.0	60.0, 100.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	80.21 (22.92)	88.57 (14.92)	88.33 (15.86)	1.14 (4.76)	-1.43 (6.61)	-0.42 (1.89)
Median	90.00	100.00	92.50	0	0	0
IQR: Q1, Q3	60.00, 100.00	75.00, 100.00	85.00, 100.00	-7.50, 10.00	-20.00, 20.00	0.00, 2.50
Min, Max	37.5, 100.0	65.0, 100.0	45.0, 100.0	-30.0, 30.0	-25.0, 20.0	-15.0, 10.0
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	79.09 (21.66)	91.25 (12.46)	79.00 (18.38)	1.50 (5.73)	3.13 (6.19)	-7.50 (5.01)
Median	80.00	100.00	80.00	0	0	-5.00
IQR: Q1, Q3	75.00, 100.00	80.00, 100.00	70.00, 95.00	-10.00, 15.00	-10.00, 20.00	-15.00, 5.00
Min, Max	35.0, 100.0	70.0, 100.0	50.0, 100.0	-25.0, 35.0	-20.0, 25.0	-40.0, 10.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Hopelessness						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	87.13 (14.61)	88.55 (22.23)	77.09 (25.41)			
Median	91.70	100.00	91.70			
IQR: Q1, Q3	75.00, 100.00	83.35, 100.00	54.15, 100.00			
Min, Max	58.3, 100.0	41.7, 100.0	33.3, 100.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	82.63 (19.93)	84.53 (24.26)	81.24 (17.46)	-1.53 (3.87)	-2.39 (7.44)	4.15 (6.03)
Median	91.65	100.00	83.30	0	0	4.15
IQR: Q1, Q3	62.50, 100.00	58.30, 100.00	66.65, 95.85	-8.40, 8.30	0.00, 0.00	-4.20, 16.65
Min, Max	50.0, 100.0	41.7, 100.0	50.0, 100.0	-33.4, 16.7	-41.7, 25.0	-41.7, 33.4
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	79.55 (24.53)	73.96 (24.97)	77.51 (20.42)	-2.50 (5.83)	-14.59 (7.83)	4.17 (4.85)
Median	100.00	75.00	83.30	0	-8.35	0
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	66.70, 91.70	-8.30, 8.30	-25.00, 0.00	0.00, 16.70
Min, Max	41.7, 100.0	41.7, 100.0	41.7, 100.0	-50.0, 16.7	-58.3, 8.3	-16.7, 33.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Stigma of Liver Disease						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	77.85 (19.44)	86.74 (21.50)	87.52 (22.61)			
Median	81.30	96.90	96.90			
IQR: Q1, Q3	62.50, 93.80	81.30, 100.00	90.65, 100.00			
Min, Max	37.5, 100.0	37.5, 100.0	31.3, 100.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	89.08 (13.35)	85.73 (23.02)	83.35 (20.18)	13.06 (4.17)	0.89 (4.18)	-4.17 (3.29)
Median	93.75	100.00	87.50	12.50	0	-6.25
IQR: Q1, Q3	81.30, 100.00	81.30, 100.00	81.30, 96.90	0.00, 18.70	0.00, 6.20	-12.50, 0.00
Min, Max	62.5, 100.0	37.5, 100.0	25.0, 100.0	0.0, 43.8	-18.7, 18.7	-18.7, 25.0
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	80.13 (19.73)	85.19 (20.01)	81.89 (23.47)	5.00 (2.24)	-1.55 (4.83)	-3.13 (5.37)
Median	81.30	93.80	90.65	0	0	-3.10
IQR: Q1, Q3	62.50, 100.00	75.05, 100.00	75.00, 100.00	0.00, 12.50	-9.35, 9.40	-6.30, 6.20
Min, Max	37.5, 100.0	43.8, 100.0	25.0, 100.0	0.0, 18.7	-25.0, 12.5	-37.5, 25.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Total LDQOL						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	78.01 (13.35)	74.95 (16.03)	78.35 (14.03)			
Median	81.00	80.25	82.50			
IQR: Q1, Q3	69.70, 88.80	65.80, 85.80	71.95, 88.65			
Min, Max	29.0, 96.7	23.6, 95.4	34.8, 97.8			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	78.75 (13.50)	76.12 (13.11)	79.40 (13.36)	0.67 (0.77)	1.27 (0.97)	1.23 (0.65)
Median	81.55	77.20	82.70	0.55	0.90	0.40
IQR: Q1, Q3	70.65, 89.75	69.60, 84.90	71.30, 89.70	-4.45, 5.55	-5.20, 7.10	-3.00, 4.85
Min, Max	33.6, 97.8	32.4, 96.9	32.4, 98.8	-18.3, 24.2	-13.9, 27.0	-27.6, 42.3
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	78.82 (12.99)	75.60 (14.77)	78.28 (14.67)	0.90 (0.95)	0.45 (1.08)	0.04 (0.72)
Median	81.65	78.85	81.20	0.60	0.10	-0.10
IQR: Q1, Q3	69.70, 90.00	66.60, 87.20	70.40, 89.20	-3.80, 6.00	-4.40, 4.60	-4.60, 5.10
Min, Max	34.0, 97.5	33.8, 95.6	20.3, 97.8	-19.5, 36.0	-23.3, 33.9	-46.3, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Symptoms of Liver Disease						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	76.73 (18.12)	73.66 (19.13)	77.35 (17.62)			
Median	80.00	76.70	80.00			
IQR: Q1, Q3	66.70, 90.00	63.30, 86.70	66.70, 90.00			
Min, Max	23.3, 100.0	30.0, 100.0	20.0, 100.0			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	76.14 (19.81)	73.39 (18.93)	77.32 (19.31)	-0.83 (1.33)	-0.61 (1.48)	0.11 (1.02)
Median	80.00	76.70	83.30	0	0	0
IQR: Q1, Q3	66.70, 90.00	60.00, 86.70	66.70, 93.30	-6.70, 6.70	-10.00, 6.70	-6.70, 6.70
Min, Max	0.0, 100.0	26.7, 100.0	16.7, 100.0	-46.7, 36.7	-36.6, 30.0	-53.3, 43.3
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	76.29 (18.18)	73.76 (18.88)	77.04 (19.31)	-1.29 (1.34)	0.64 (1.62)	0.07 (0.96)
Median	80.00	76.70	83.30	0	0	0
IQR: Q1, Q3	66.70, 90.00	63.30, 90.00	66.70, 93.30	-10.00, 6.70	-6.70, 6.70	-6.70, 6.70
Min, Max	23.3, 100.0	26.7, 100.0	16.7, 100.0	-33.4, 43.4	-36.7, 36.7	-60.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Effects of Liver Disease						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	78.80 (11.83)	76.59 (17.63)	78.24 (13.70)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	73.30, 86.70	80.00, 86.70			
Min, Max	13.3, 100.0	13.3, 100.0	26.7, 100.0			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	77.10 (12.44)	78.54 (10.15)	77.73 (14.31)	-1.86 (1.14)	2.24 (2.01)	-0.28 (1.02)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 6.60
Min, Max	20.0, 100.0	40.0, 100.0	6.7, 100.0	-40.0, 26.6	-26.7, 76.7	-46.6, 53.4
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	76.83 (11.33)	76.29 (13.80)	77.50 (13.37)	-1.47 (1.54)	0.23 (1.70)	-0.38 (1.31)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	73.30, 80.00	73.30, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 0.00
Min, Max	40.0, 100.0	20.0, 100.0	13.3, 100.0	-40.0, 80.0	-33.3, 53.4	-80.0, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Concentration/Memory						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	80.55 (21.67)	78.60 (20.43)	78.21 (21.12)			
Median	87.50	84.40	84.40			
IQR: Q1, Q3	68.80, 100.00	68.80, 93.80	68.80, 93.80			
Min, Max	12.5, 100.0	18.8, 100.0	6.3, 100.0			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	79.93 (20.45)	79.48 (18.50)	80.24 (20.45)	-0.60 (1.34)	0.71 (1.82)	1.59 (1.08)
Median	84.40	81.30	87.50	0	0	0
IQR: Q1, Q3	68.80, 100.00	68.80, 93.80	68.80, 100.00	-6.20, 6.20	-6.30, 6.30	-6.20, 6.30
Min, Max	18.8, 100.0	25.0, 100.0	6.3, 100.0	-31.3, 31.2	-31.2, 56.2	-81.2, 62.5
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	78.27 (19.81)	77.02 (20.62)	78.44 (22.24)	-1.61 (1.44)	-2.03 (1.82)	-0.61 (1.05)
Median	81.30	81.30	81.30	0	0	0
IQR: Q1, Q3	68.80, 93.80	62.50, 93.80	68.80, 100.00	-6.30, 0.00	-12.50, 6.30	-6.30, 6.25
Min, Max	0.0, 100.0	18.8, 100.0	0.0, 100.0	-43.7, 50.0	-43.8, 50.0	-43.8, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Health Distress						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	81.19 (23.00)	80.64 (26.36)	82.17 (23.28)			
Median	87.50	100.00	87.50			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	85.19 (21.56)	86.90 (20.16)	86.10 (21.43)	3.73 (1.86)	6.65 (2.25)	4.56 (1.41)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 25.00	0.00, 12.50
Min, Max	12.5, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 50.0	-37.5, 50.0	-62.5, 75.0
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	84.06 (21.67)	83.97 (23.74)	85.18 (21.65)	3.63 (2.24)	3.04 (2.38)	2.31 (1.54)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	12.5, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 75.0	-50.0, 75.0	-87.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Sexual Function						
Baseline						
m	111	87	221			
n	44	44	92			
Mean (SD)	80.00 (28.02)	79.80 (21.69)	79.34 (24.20)			
Median	93.30	85.85	86.70			
IQR: Q1, Q3	65.80, 100.00	62.50, 100.00	69.15, 100.00			
Min, Max	-1.7, 100.0	30.0, 100.0	-1.7, 100.0			
Week 24						
m	111	87	221			
n	49	50	100	38	40	74
Mean (SD/SE)	81.63 (23.49)	74.23 (28.77)	79.18 (23.62)	1.05 (4.75)	-4.88 (3.37)	0.50 (2.11)
Median	91.70	85.00	85.00	0	0	0
IQR: Q1, Q3	76.70, 100.00	55.00, 100.00	68.30, 100.00	-8.30, 8.30	-12.50, 0.00	-6.70, 6.70
Min, Max	15.0, 100.0	-1.7, 100.0	-1.7, 100.0	-85.0, 91.1	-55.0, 46.7	-48.4, 50.0
Week 52						
m	107	87	219			
n	37	39	85	32	32	69
Mean (SD/SE)	83.25 (23.37)	73.74 (32.00)	77.19 (26.09)	3.69 (4.41)	-2.88 (3.79)	-0.89 (2.62)
Median	93.30	93.30	86.70	0	0	0
IQR: Q1, Q3	76.70, 100.00	46.70, 100.00	60.00, 100.00	-7.50, 3.35	-11.65, 0.00	-8.30, 6.70
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-45.0, 91.1	-48.4, 61.7	-53.3, 65.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Sleep						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	62.24 (19.33)	56.83 (20.72)	62.92 (20.18)			
Median	65.00	60.00	65.00			
IQR: Q1, Q3	50.00, 75.00	40.00, 70.00	50.00, 77.50			
Min, Max	15.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	63.80 (19.80)	56.37 (20.57)	63.37 (20.21)	1.39 (1.45)	-0.51 (1.70)	0.63 (1.14)
Median	65.00	55.00	65.00	0	0	0
IQR: Q1, Q3	50.00, 75.00	40.00, 70.00	50.00, 75.00	-5.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	15.0, 100.0	0.0, 100.0	15.0, 100.0	-30.0, 55.0	-35.0, 45.0	-35.0, 50.0
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	63.13 (19.53)	56.92 (20.44)	63.24 (20.98)	-0.47 (1.69)	0.61 (1.87)	0.73 (1.20)
Median	65.00	57.50	65.00	0	0	0
IQR: Q1, Q3	50.00, 75.00	40.00, 70.00	50.00, 80.00	-10.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	15.0, 100.0	0.0, 95.0	5.0, 100.0	-40.0, 45.0	-30.0, 45.0	-40.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Loneliness						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	85.05 (19.07)	80.98 (21.12)	84.20 (19.57)			
Median	95.00	85.00	95.00			
IQR: Q1, Q3	75.00, 100.00	70.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	10.0, 100.0			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	84.91 (17.40)	82.38 (20.78)	84.25 (19.04)	0.14 (1.51)	0.76 (1.62)	-0.35 (1.10)
Median	90.00	90.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	70.00, 100.00	75.00, 100.00	-10.00, 5.00	-5.00, 10.00	-10.00, 5.00
Min, Max	35.0, 100.0	0.0, 100.0	30.0, 100.0	-40.0, 45.0	-35.0, 65.0	-40.0, 70.0
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	86.73 (16.55)	81.22 (22.38)	83.79 (19.53)	2.15 (1.62)	-0.20 (1.80)	-0.04 (1.20)
Median	95.00	90.00	90.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 5.00	-10.00, 10.00	-5.00, 5.00
Min, Max	25.0, 100.0	0.0, 100.0	5.0, 100.0	-60.0, 50.0	-40.0, 30.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Hopelessness						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	75.72 (22.33)	73.37 (24.90)	80.35 (20.97)			
Median	75.00	75.00	83.30			
IQR: Q1, Q3	58.30, 100.00	50.00, 100.00	66.70, 100.00			
Min, Max	8.3, 100.0	8.3, 100.0	25.0, 100.0			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	77.24 (22.58)	73.81 (23.65)	80.89 (20.69)	1.68 (1.70)	1.69 (2.26)	0.72 (1.27)
Median	83.30	75.00	91.70	0	0	0
IQR: Q1, Q3	58.30, 100.00	58.30, 91.70	66.70, 100.00	-8.40, 8.30	-8.30, 8.40	-8.30, 8.30
Min, Max	8.3, 100.0	8.3, 100.0	25.0, 100.0	-33.4, 50.0	-41.7, 58.4	-58.3, 50.0
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	77.38 (21.83)	75.33 (22.45)	78.10 (22.39)	1.61 (1.88)	1.25 (2.52)	-1.99 (1.43)
Median	83.30	75.00	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	58.30, 100.00	-8.30, 8.40	-8.40, 16.70	-8.30, 8.30
Min, Max	16.7, 100.0	0.0, 100.0	0.0, 100.0	-41.6, 41.7	-50.0, 50.0	-100.0, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Stigma of Liver Disease						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	84.24 (20.19)	78.07 (21.00)	83.96 (18.63)			
Median	93.80	81.30	87.50			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	18.8, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	85.84 (19.17)	79.71 (20.13)	86.27 (17.52)	1.51 (1.61)	2.46 (1.77)	2.44 (1.19)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	68.80, 100.00	81.30, 100.00	-6.20, 6.20	-6.20, 6.30	-6.20, 6.30
Min, Max	6.3, 100.0	12.5, 100.0	6.3, 100.0	-43.7, 56.2	-31.2, 56.3	-43.8, 75.0
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	86.88 (17.47)	81.81 (20.24)	84.98 (18.87)	3.16 (1.42)	2.76 (2.04)	1.78 (1.26)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	68.80, 100.00	81.30, 100.00	0.00, 6.30	-6.20, 12.50	-6.20, 6.30
Min, Max	31.3, 100.0	12.5, 100.0	18.8, 100.0	-25.0, 56.2	-56.2, 56.3	-62.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Weight Change at Week 52
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.11.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Total LDQOL			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	79.70 (15.40)	79.84 (11.70)	78.64 (11.64)
Analysis Visit Mean (SD)	79.73 (16.78)	80.31 (9.47)	79.12 (13.32)
LS Mean of Change from Baseline (SE)	0.27 (1.64)	0.46 (1.62)	0.75 (1.63)
95% CI	(-2.99, 3.53)	(-2.76, 3.67)	(-2.48, 3.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.48 (2.23)	-0.29 (2.25)	
95% CI	(-4.91, 3.95)	(-4.76, 4.17)	
p-value	0.8303	0.8968	
Corrected Hedge's g Statistics	-0.054	-0.033	
95% CI	(-0.57, 0.47)	(-0.55, 0.48)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	79.59 (15.90)	81.30 (10.43)	79.72 (10.73)
Analysis Visit Mean (SD)	81.42 (13.38)	83.79 (9.77)	83.10 (12.33)
LS Mean of Change from Baseline (SE)	1.91 (1.64)	2.96 (1.61)	3.69 (1.60)
95% CI	(-1.34, 5.17)	(-0.23, 6.16)	(0.50, 6.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.77 (2.21)	-0.72 (2.23)	
95% CI	(-6.16, 2.62)	(-5.15, 3.71)	
p-value	0.4243	0.7466	
Corrected Hedge's g Statistics	-0.207	-0.085	
95% CI	(-0.74, 0.33)	(-0.61, 0.44)	
Subgroup*Treatment Interaction p-value	0.5613	0.9684	

AMNOG Table SE21.11.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Total LDQOL			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	80.21 (8.44)	86.03 (10.32)	79.01 (11.85)
Analysis Visit Mean (SD)	83.35 (7.23)	82.26 (15.69)	77.89 (14.91)
LS Mean of Change from Baseline (SE)	4.33 (2.20)	-3.79 (2.87)	0.16 (2.20)
95% CI	(-0.19, 8.84)	(-9.69, 2.11)	(-4.36, 4.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.17 (2.99)	-3.94 (3.55)	
95% CI	(-1.96, 10.30)	(-11.22, 3.33)	
p-value	0.1740	0.2758	
Corrected Hedge's g Statistics	0.538	-0.494	
95% CI	(-0.30, 1.37)	(-1.44, 0.45)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	79.65 (8.68)	86.61 (9.70)	76.14 (10.70)
Analysis Visit Mean (SD)	81.17 (14.98)	82.71 (12.35)	77.63 (10.54)
LS Mean of Change from Baseline (SE)	2.57 (2.35)	-4.84 (2.75)	3.64 (2.60)
95% CI	(-2.25, 7.38)	(-10.48, 0.81)	(-1.69, 8.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.08 (3.34)	-8.48 (3.87)	
95% CI	(-7.92, 5.77)	(-16.42, -0.54)	
p-value	0.7493	0.0372	
Corrected Hedge's g Statistics	-0.132	-1.006	
95% CI	(-1.01, 0.75)	(-1.99, -0.02)	
Subgroup*Treatment Interaction p-value	0.5613	0.9684	

AMNOG Table SE21.11.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Total LDQOL			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	78.07 (13.40)	74.70 (16.24)	78.52 (14.08)
Analysis Visit Mean (SD)	78.74 (13.51)	75.97 (13.35)	79.74 (13.32)
LS Mean of Change from Baseline (SE)	1.01 (0.79)	0.49 (0.89)	1.42 (0.58)
95% CI	(-0.55, 2.57)	(-1.26, 2.25)	(0.28, 2.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.41 (0.95)	-0.93 (1.04)	
95% CI	(-2.28, 1.46)	(-2.98, 1.12)	
p-value	0.6659	0.3730	
Corrected Hedge's g Statistics	-0.051	-0.116	
95% CI	(-0.29, 0.19)	(-0.38, 0.15)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	77.69 (13.85)	74.57 (16.44)	78.25 (14.35)
Analysis Visit Mean (SD)	78.58 (12.84)	75.03 (14.90)	78.29 (14.98)
LS Mean of Change from Baseline (SE)	1.06 (0.94)	-0.12 (1.05)	0.22 (0.67)
95% CI	(-0.79, 2.90)	(-2.17, 1.94)	(-1.09, 1.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.83 (1.13)	-0.34 (1.22)	
95% CI	(-1.39, 3.05)	(-2.75, 2.06)	
p-value	0.4613	0.7806	
Corrected Hedge's g Statistics	0.091	-0.037	
95% CI	(-0.16, 0.34)	(-0.31, 0.23)	
Subgroup*Treatment Interaction p-value	0.5613	0.9684	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Symptoms of Liver Disease			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	85.00 (18.30)	76.89 (20.26)	80.22 (15.46)
Analysis Visit Mean (SD)	79.40 (19.95)	77.24 (15.97)	82.18 (15.49)
LS Mean of Change from Baseline (SE)	-4.89 (2.25)	-1.47 (2.23)	1.00 (2.22)
95% CI	(-9.37, -0.42)	(-5.90, 2.96)	(-3.41, 5.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.89 (3.06)	-2.46 (3.07)	
95% CI	(-11.97, 0.19)	(-8.57, 3.65)	
p-value	0.0576	0.4250	
Corrected Hedge's g Statistics	-0.487	-0.203	
95% CI	(-1.01, 0.04)	(-0.72, 0.31)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	85.12 (19.06)	79.13 (16.22)	81.78 (14.71)
Analysis Visit Mean (SD)	80.77 (21.71)	81.85 (14.15)	83.81 (17.50)
LS Mean of Change from Baseline (SE)	-4.19 (2.30)	1.63 (2.25)	2.30 (2.23)
95% CI	(-8.76, 0.38)	(-2.84, 6.10)	(-2.14, 6.75)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.49 (3.10)	-0.67 (3.11)	
95% CI	(-12.65, -0.34)	(-6.85, 5.51)	
p-value	0.0389	0.8296	
Corrected Hedge's g Statistics	-0.544	-0.056	
95% CI	(-1.09, 0.00)	(-0.59, 0.47)	
Subgroup*Treatment Interaction p-value	0.2078	0.9269	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Effects of Liver Disease			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	77.39 (16.46)	82.30 (9.13)	75.63 (13.49)
Analysis Visit Mean (SD)	74.53 (19.88)	80.46 (8.54)	79.54 (12.21)
LS Mean of Change from Baseline (SE)	-3.34 (2.17)	-0.65 (2.16)	2.78 (2.16)
95% CI	(-7.65, 0.97)	(-4.94, 3.65)	(-1.51, 7.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.13 (2.93)	-3.43 (3.03)	
95% CI	(-11.95, -0.30)	(-9.46, 2.59)	
p-value	0.0396	0.2601	
Corrected Hedge's g Statistics	-0.523	-0.291	
95% CI	(-1.05, 0.00)	(-0.81, 0.23)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	76.42 (16.78)	83.46 (8.14)	77.62 (12.07)
Analysis Visit Mean (SD)	76.16 (17.90)	81.23 (6.93)	79.76 (15.02)
LS Mean of Change from Baseline (SE)	-1.52 (2.24)	-0.17 (2.23)	1.27 (2.19)
95% CI	(-5.97, 2.94)	(-4.60, 4.27)	(-3.09, 5.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.78 (3.01)	-1.44 (3.10)	
95% CI	(-8.76, 3.19)	(-7.59, 4.72)	
p-value	0.3569	0.6442	
Corrected Hedge's g Statistics	-0.238	-0.122	
95% CI	(-0.77, 0.30)	(-0.65, 0.41)	
Subgroup*Treatment Interaction p-value	0.0684	0.2498	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Concentration/Memory			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	82.61 (23.46)	79.97 (21.34)	84.93 (16.41)
Analysis Visit Mean (SD)	80.15 (21.66)	79.54 (21.12)	82.99 (22.58)
LS Mean of Change from Baseline (SE)	-2.64 (3.01)	-1.43 (2.97)	-1.13 (2.99)
95% CI	(-8.64, 3.35)	(-7.35, 4.48)	(-7.07, 4.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.51 (4.14)	-0.30 (4.17)	
95% CI	(-9.75, 6.72)	(-8.58, 7.98)	
p-value	0.7158	0.9426	
Corrected Hedge's g Statistics	-0.093	-0.019	
95% CI	(-0.61, 0.43)	(-0.53, 0.50)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	80.55 (23.53)	82.19 (20.34)	85.95 (14.59)
Analysis Visit Mean (SD)	80.31 (20.96)	84.51 (19.63)	83.28 (17.68)
LS Mean of Change from Baseline (SE)	-1.45 (2.45)	1.78 (2.39)	-2.15 (2.41)
95% CI	(-6.31, 3.42)	(-2.96, 6.53)	(-6.94, 2.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.70 (3.32)	3.93 (3.33)	
95% CI	(-5.89, 7.30)	(-2.68, 10.55)	
p-value	0.8328	0.2403	
Corrected Hedge's g Statistics	0.055	0.308	
95% CI	(-0.48, 0.59)	(-0.22, 0.84)	
Subgroup*Treatment Interaction p-value	0.7897	0.3792	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Health Distress			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	73.66 (33.57)	81.47 (25.14)	75.86 (22.89)
Analysis Visit Mean (SD)	83.93 (23.04)	88.79 (17.47)	86.64 (17.66)
LS Mean of Change from Baseline (SE)	8.92 (3.06)	10.22 (3.00)	10.84 (3.02)
95% CI	(2.84, 15.00)	(4.25, 16.19)	(4.82, 16.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.92 (4.17)	-0.61 (4.20)	
95% CI	(-10.20, 6.37)	(-8.96, 7.74)	
p-value	0.6468	0.8841	
Corrected Hedge's g Statistics	-0.116	-0.037	
95% CI	(-0.64, 0.40)	(-0.55, 0.48)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	73.08 (34.40)	81.94 (26.02)	75.89 (24.28)
Analysis Visit Mean (SD)	85.10 (23.46)	93.52 (11.69)	92.41 (18.11)
LS Mean of Change from Baseline (SE)	9.84 (3.26)	15.24 (3.18)	16.08 (3.17)
95% CI	(3.36, 16.32)	(8.93, 21.55)	(9.77, 22.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.24 (4.41)	-0.84 (4.44)	
95% CI	(-15.01, 2.53)	(-9.66, 7.98)	
p-value	0.1609	0.8498	
Corrected Hedge's g Statistics	-0.368	-0.050	
95% CI	(-0.91, 0.17)	(-0.58, 0.48)	
Subgroup*Treatment Interaction p-value	0.7854	0.8296	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Sexual Function			
Week 24			
m	30	31	35
n	10	12	11
Baseline Mean (SD)	70.17 (30.56)	80.40 (28.66)	73.49 (27.39)
Analysis Visit Mean (SD)	74.00 (32.88)	72.64 (19.58)	79.55 (23.24)
LS Mean of Change from Baseline (SE)	1.32 (5.09)	-7.23 (4.55)	5.44 (4.90)
95% CI	(-9.01, 11.66)	(-16.47, 2.01)	(-4.53, 15.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.12 (7.02)	-12.67 (6.61)	
95% CI	(-18.39, 10.16)	(-26.10, 0.76)	
p-value	0.5617	0.0637	
Corrected Hedge's g Statistics	-0.244	-0.763	
95% CI	(-1.10, 0.62)	(-1.61, 0.08)	
Week 52			
m	29	30	35
n	8	12	9
Baseline Mean (SD)	82.91 (26.35)	86.23 (16.46)	81.29 (18.10)
Analysis Visit Mean (SD)	92.91 (9.12)	83.19 (19.20)	82.03 (22.95)
LS Mean of Change from Baseline (SE)	8.20 (5.60)	1.36 (4.80)	4.29 (5.34)
95% CI	(-3.18, 19.57)	(-8.40, 11.12)	(-6.57, 15.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.91 (7.67)	-2.93 (7.09)	
95% CI	(-11.68, 19.49)	(-17.34, 11.47)	
p-value	0.6140	0.6817	
Corrected Hedge's g Statistics	0.233	-0.172	
95% CI	(-0.72, 1.19)	(-1.04, 0.69)	
Subgroup*Treatment Interaction p-value	0.6108	0.1827	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Sleep			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	67.14 (21.54)	66.03 (18.58)	67.41 (17.96)
Analysis Visit Mean (SD)	66.25 (21.07)	61.90 (20.02)	65.52 (19.52)
LS Mean of Change from Baseline (SE)	-0.91 (2.62)	-4.81 (2.59)	-1.45 (2.60)
95% CI	(-6.13, 4.31)	(-9.95, 0.33)	(-6.62, 3.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.54 (3.56)	-3.36 (3.59)	
95% CI	(-6.54, 7.62)	(-10.50, 3.77)	
p-value	0.8801	0.3516	
Corrected Hedge's g Statistics	0.038	-0.237	
95% CI	(-0.48, 0.56)	(-0.75, 0.28)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	67.69 (22.64)	67.41 (17.45)	67.68 (17.40)
Analysis Visit Mean (SD)	69.04 (16.61)	65.00 (21.88)	68.21 (19.11)
LS Mean of Change from Baseline (SE)	0.97 (3.09)	-3.19 (3.02)	1.04 (3.01)
95% CI	(-5.17, 7.10)	(-9.20, 2.82)	(-4.95, 7.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (4.19)	-4.23 (4.20)	
95% CI	(-8.41, 8.26)	(-12.59, 4.12)	
p-value	0.9861	0.3169	
Corrected Hedge's g Statistics	-0.005	-0.263	
95% CI	(-0.54, 0.53)	(-0.79, 0.27)	
Subgroup*Treatment Interaction p-value	0.8105	0.9405	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Loneliness			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	88.21 (12.11)	85.34 (19.50)	83.45 (23.15)
Analysis Visit Mean (SD)	83.75 (20.76)	87.24 (17.76)	76.72 (26.30)
LS Mean of Change from Baseline (SE)	-3.88 (2.91)	1.88 (2.85)	-6.71 (2.88)
95% CI	(-9.65, 1.90)	(-3.79, 7.55)	(-12.43, -0.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.83 (4.00)	8.59 (3.99)	
95% CI	(-5.13, 10.79)	(0.65, 16.52)	
p-value	0.4814	0.0342	
Corrected Hedge's g Statistics	0.181	0.549	
95% CI	(-0.34, 0.70)	(0.02, 1.07)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	88.46 (12.39)	86.30 (19.88)	84.64 (21.64)
Analysis Visit Mean (SD)	81.73 (18.44)	86.85 (17.77)	87.50 (16.19)
LS Mean of Change from Baseline (SE)	-5.32 (2.64)	0.80 (2.57)	2.56 (2.58)
95% CI	(-10.56, -0.08)	(-4.31, 5.91)	(-2.57, 7.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.88 (3.58)	-1.76 (3.58)	
95% CI	(-15.00, -0.77)	(-8.87, 5.35)	
p-value	0.0303	0.6238	
Corrected Hedge's g Statistics	-0.573	-0.129	
95% CI	(-1.12, -0.03)	(-0.66, 0.40)	
Subgroup*Treatment Interaction p-value	0.6431	0.2650	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Hopelessness			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	78.57 (21.93)	81.03 (17.09)	79.31 (18.19)
Analysis Visit Mean (SD)	81.84 (22.92)	83.91 (16.06)	76.72 (20.23)
LS Mean of Change from Baseline (SE)	2.33 (3.22)	3.20 (3.17)	-3.27 (3.19)
95% CI	(-4.07, 8.73)	(-3.10, 9.51)	(-9.61, 3.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.60 (4.38)	6.47 (4.41)	
95% CI	(-3.10, 14.30)	(-2.29, 15.23)	
p-value	0.2041	0.1457	
Corrected Hedge's g Statistics	0.323	0.373	
95% CI	(-0.20, 0.85)	(-0.15, 0.89)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	79.17 (21.64)	81.48 (17.65)	80.36 (17.75)
Analysis Visit Mean (SD)	83.32 (17.95)	87.35 (16.40)	82.44 (22.83)
LS Mean of Change from Baseline (SE)	3.87 (3.49)	6.51 (3.42)	1.59 (3.41)
95% CI	(-3.07, 10.81)	(-0.29, 13.31)	(-5.19, 8.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.27 (4.73)	4.92 (4.75)	
95% CI	(-7.13, 11.68)	(-4.52, 14.36)	
p-value	0.6319	0.3031	
Corrected Hedge's g Statistics	0.125	0.271	
95% CI	(-0.41, 0.66)	(-0.26, 0.80)	
Subgroup*Treatment Interaction p-value	0.5416	0.1665	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Stigma of Liver Disease			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	84.61 (22.66)	87.09 (14.93)	84.50 (18.49)
Analysis Visit Mean (SD)	86.18 (17.54)	84.94 (13.42)	84.93 (19.59)
LS Mean of Change from Baseline (SE)	1.64 (2.50)	-1.17 (2.46)	0.55 (2.47)
95% CI	(-3.33, 6.61)	(-6.06, 3.72)	(-4.35, 5.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.09 (3.40)	-1.72 (3.43)	
95% CI	(-5.67, 7.84)	(-8.53, 5.09)	
p-value	0.7499	0.6171	
Corrected Hedge's g Statistics	0.081	-0.128	
95% CI	(-0.44, 0.60)	(-0.64, 0.39)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	85.83 (23.35)	87.99 (13.41)	85.73 (18.06)
Analysis Visit Mean (SD)	90.87 (17.33)	91.23 (10.99)	88.86 (14.36)
LS Mean of Change from Baseline (SE)	5.63 (2.16)	4.30 (2.12)	3.83 (2.12)
95% CI	(1.33, 9.93)	(0.09, 8.50)	(-0.39, 8.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.80 (2.90)	0.47 (2.93)	
95% CI	(-3.97, 7.57)	(-5.37, 6.30)	
p-value	0.5370	0.8741	
Corrected Hedge's g Statistics	0.159	0.041	
95% CI	(-0.38, 0.69)	(-0.49, 0.57)	
Subgroup*Treatment Interaction p-value	0.2523	0.6902	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Symptoms of Liver Disease			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	82.12 (18.11)	84.30 (7.87)	75.82 (19.50)
Analysis Visit Mean (SD)	84.55 (13.26)	80.00 (11.06)	72.78 (22.14)
LS Mean of Change from Baseline (SE)	3.61 (3.53)	-2.73 (4.53)	-2.93 (3.63)
95% CI	(-3.64, 10.86)	(-12.02, 6.56)	(-10.38, 4.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.54 (4.82)	0.20 (5.60)	
95% CI	(-3.34, 16.43)	(-11.28, 11.68)	
p-value	0.1855	0.9713	
Corrected Hedge's g Statistics	0.518	0.016	
95% CI	(-0.31, 1.35)	(-0.92, 0.95)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	82.00 (19.08)	86.26 (9.16)	71.65 (18.61)
Analysis Visit Mean (SD)	79.99 (21.49)	83.34 (21.22)	76.99 (17.66)
LS Mean of Change from Baseline (SE)	-1.15 (4.93)	-1.76 (5.64)	5.62 (5.40)
95% CI	(-11.27, 8.97)	(-13.34, 9.82)	(-5.46, 16.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.78 (7.18)	-7.38 (7.92)	
95% CI	(-21.52, 7.96)	(-23.63, 8.86)	
p-value	0.3538	0.3593	
Corrected Hedge's g Statistics	-0.397	-0.424	
95% CI	(-1.28, 0.49)	(-1.36, 0.52)	
Subgroup*Treatment Interaction p-value	0.2078	0.9269	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Effects of Liver Disease			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	82.44 (8.04)	82.86 (8.49)	79.45 (8.74)
Analysis Visit Mean (SD)	81.82 (5.25)	81.90 (14.26)	72.22 (12.00)
LS Mean of Change from Baseline (SE)	0.88 (3.24)	-1.01 (4.18)	-7.54 (3.29)
95% CI	(-5.77, 7.53)	(-9.59, 7.56)	(-14.29, -0.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.42 (4.40)	6.53 (5.14)	
95% CI	(-0.62, 17.45)	(-4.01, 17.06)	
p-value	0.0667	0.2146	
Corrected Hedge's g Statistics	0.731	0.553	
95% CI	(-0.11, 1.58)	(-0.40, 1.50)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	82.01 (8.34)	83.34 (7.98)	79.34 (9.66)
Analysis Visit Mean (SD)	80.00 (15.71)	81.66 (11.68)	74.66 (13.98)
LS Mean of Change from Baseline (SE)	-0.91 (4.57)	-0.90 (5.18)	-5.20 (4.80)
95% CI	(-10.28, 8.47)	(-11.53, 9.72)	(-15.06, 4.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.29 (6.48)	4.30 (7.01)	
95% CI	(-8.99, 17.58)	(-10.09, 18.68)	
p-value	0.5130	0.5452	
Corrected Hedge's g Statistics	0.277	0.274	
95% CI	(-0.60, 1.16)	(-0.66, 1.21)	
Subgroup*Treatment Interaction p-value	0.0684	0.2498	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Concentration/Memory			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	84.68 (26.13)	91.09 (16.06)	73.98 (25.11)
Analysis Visit Mean (SD)	85.81 (19.97)	83.94 (22.78)	76.58 (26.39)
LS Mean of Change from Baseline (SE)	3.18 (4.14)	-3.99 (5.20)	2.73 (4.14)
95% CI	(-5.31, 11.67)	(-14.66, 6.69)	(-5.77, 11.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.45 (5.61)	-6.72 (6.48)	
95% CI	(-11.07, 11.97)	(-20.02, 6.59)	
p-value	0.9362	0.3095	
Corrected Hedge's g Statistics	0.031	-0.453	
95% CI	(-0.79, 0.85)	(-1.40, 0.49)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	83.77 (27.36)	92.20 (15.20)	71.28 (26.21)
Analysis Visit Mean (SD)	91.25 (13.24)	85.18 (17.33)	78.77 (25.71)
LS Mean of Change from Baseline (SE)	9.85 (4.34)	-2.63 (4.99)	6.53 (4.61)
95% CI	(0.94, 18.75)	(-12.88, 7.61)	(-2.92, 15.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.31 (6.10)	-9.17 (6.74)	
95% CI	(-9.20, 15.83)	(-22.99, 4.66)	
p-value	0.5915	0.1849	
Corrected Hedge's g Statistics	0.224	-0.607	
95% CI	(-0.66, 1.10)	(-1.56, 0.34)	
Subgroup*Treatment Interaction p-value	0.7897	0.3792	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Health Distress			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	77.27 (16.60)	89.29 (15.19)	84.38 (17.78)
Analysis Visit Mean (SD)	89.77 (10.92)	91.07 (18.70)	86.46 (18.04)
LS Mean of Change from Baseline (SE)	11.63 (3.68)	3.32 (4.66)	3.77 (3.62)
95% CI	(4.07, 19.18)	(-6.25, 12.89)	(-3.66, 11.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.86 (4.91)	-0.45 (5.60)	
95% CI	(-2.21, 17.92)	(-11.95, 11.04)	
p-value	0.1210	0.9362	
Corrected Hedge's g Statistics	0.611	-0.035	
95% CI	(-0.23, 1.45)	(-0.97, 0.90)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	80.00 (14.67)	87.50 (14.94)	83.75 (18.68)
Analysis Visit Mean (SD)	78.75 (33.88)	93.75 (11.57)	90.00 (11.49)
LS Mean of Change from Baseline (SE)	-2.07 (6.85)	7.87 (7.69)	8.10 (6.98)
95% CI	(-16.13, 11.98)	(-7.91, 23.65)	(-6.22, 22.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.17 (9.63)	-0.23 (10.25)	
95% CI	(-29.93, 9.59)	(-21.26, 20.81)	
p-value	0.3005	0.9826	
Corrected Hedge's g Statistics	-0.445	-0.010	
95% CI	(-1.33, 0.44)	(-0.94, 0.92)	
Subgroup*Treatment Interaction p-value	0.7854	0.8296	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Sexual Function			
Week 24			
m	12	8	13
n	5	3	5
Baseline Mean (SD)	87.98 (12.22)	95.00 (8.66)	94.00 (10.10)
Analysis Visit Mean (SD)	89.02 (11.75)	97.77 (3.87)	82.00 (25.76)
LS Mean of Change from Baseline (SE)	1.96 (5.29)	-0.87 (7.38)	-15.89 (5.72)
95% CI	(-9.82, 13.74)	(-17.32, 15.59)	(-28.63, -3.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	17.85 (7.87)	15.03 (8.85)	
95% CI	(0.32, 35.38)	(-4.69, 34.75)	
p-value	0.0466	0.1204	
Corrected Hedge's g Statistics	1.310	1.022	
95% CI	(-0.06, 2.68)	(-0.49, 2.54)	
Week 52			
m	12	8	12
n	6	3	2
Baseline Mean (SD)	88.87 (11.14)	95.00 (8.66)	88.35 (16.48)
Analysis Visit Mean (SD)	88.33 (19.94)	95.57 (7.68)	63.60 (20.79)
LS Mean of Change from Baseline (SE)	-0.87 (4.66)	-2.86 (7.06)	-26.33 (8.22)
95% CI	(-11.25, 9.52)	(-18.59, 12.88)	(-44.65, -8.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	25.46 (9.22)	23.47 (10.75)	
95% CI	(4.92, 46.01)	(-0.47, 47.42)	
p-value	0.0201	0.0538	
Corrected Hedge's g Statistics	1.934	1.419	
95% CI	(0.07, 3.79)	(-0.57, 3.41)	
Subgroup*Treatment Interaction p-value	0.6108	0.1827	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Sleep			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	68.64 (21.57)	74.29 (10.58)	63.65 (22.75)
Analysis Visit Mean (SD)	68.18 (22.72)	70.00 (15.81)	61.25 (25.51)
LS Mean of Change from Baseline (SE)	-1.41 (4.13)	-3.85 (5.36)	-3.63 (4.14)
95% CI	(-9.89, 7.07)	(-14.85, 7.14)	(-12.11, 4.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.21 (5.56)	-0.23 (6.51)	
95% CI	(-9.19, 13.62)	(-13.58, 13.13)	
p-value	0.6937	0.9723	
Corrected Hedge's g Statistics	0.152	-0.015	
95% CI	(-0.67, 0.97)	(-0.95, 0.92)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	66.50 (21.48)	75.00 (10.00)	57.88 (20.23)
Analysis Visit Mean (SD)	74.00 (17.29)	65.00 (24.05)	63.00 (20.98)
LS Mean of Change from Baseline (SE)	6.53 (5.36)	-6.96 (6.20)	1.05 (5.80)
95% CI	(-4.47, 17.54)	(-19.68, 5.76)	(-10.85, 12.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.48 (7.66)	-8.01 (8.58)	
95% CI	(-10.23, 21.19)	(-25.61, 9.58)	
p-value	0.4801	0.3584	
Corrected Hedge's g Statistics	0.297	-0.424	
95% CI	(-0.58, 1.18)	(-1.36, 0.52)	
Subgroup*Treatment Interaction p-value	0.8105	0.9405	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Loneliness			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	77.27 (18.22)	90.00 (12.91)	88.75 (11.31)
Analysis Visit Mean (SD)	78.41 (23.14)	88.57 (14.92)	88.33 (15.86)
LS Mean of Change from Baseline (SE)	2.43 (4.34)	-0.80 (5.28)	2.17 (4.21)
95% CI	(-6.48, 11.34)	(-11.64, 10.04)	(-6.47, 10.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.26 (5.86)	-2.97 (6.38)	
95% CI	(-11.76, 12.27)	(-16.06, 10.13)	
p-value	0.9651	0.6460	
Corrected Hedge's g Statistics	0.017	-0.197	
95% CI	(-0.80, 0.84)	(-1.13, 0.74)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	75.50 (18.17)	88.13 (13.08)	86.50 (11.07)
Analysis Visit Mean (SD)	77.00 (21.63)	91.25 (12.46)	79.00 (18.38)
LS Mean of Change from Baseline (SE)	0.00 (5.45)	4.13 (5.75)	-4.05 (5.30)
95% CI	(-11.18, 11.19)	(-7.66, 15.93)	(-14.92, 6.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.05 (7.41)	8.18 (7.60)	
95% CI	(-11.16, 19.25)	(-7.42, 23.78)	
p-value	0.5892	0.2917	
Corrected Hedge's g Statistics	0.228	0.471	
95% CI	(-0.65, 1.11)	(-0.47, 1.41)	
Subgroup*Treatment Interaction p-value	0.6431	0.2650	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Hopelessness			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	87.13 (14.61)	86.91 (23.48)	77.09 (25.41)
Analysis Visit Mean (SD)	85.60 (17.92)	84.53 (24.26)	81.24 (17.46)
LS Mean of Change from Baseline (SE)	2.44 (4.57)	-1.91 (5.82)	3.25 (4.59)
95% CI	(-6.95, 11.82)	(-13.85, 10.04)	(-6.18, 12.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.81 (6.25)	-5.15 (7.16)	
95% CI	(-13.64, 12.02)	(-19.84, 9.53)	
p-value	0.8978	0.4779	
Corrected Hedge's g Statistics	-0.050	-0.313	
95% CI	(-0.87, 0.77)	(-1.25, 0.62)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	85.84 (14.73)	88.55 (22.23)	73.34 (26.30)
Analysis Visit Mean (SD)	83.34 (22.22)	73.96 (24.97)	77.51 (20.42)
LS Mean of Change from Baseline (SE)	0.01 (5.72)	-13.83 (6.47)	3.09 (6.16)
95% CI	(-11.74, 11.75)	(-27.10, -0.56)	(-9.56, 15.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.08 (8.27)	-16.93 (8.92)	
95% CI	(-20.04, 13.88)	(-35.22, 1.37)	
p-value	0.7120	0.0684	
Corrected Hedge's g Statistics	-0.157	-0.849	
95% CI	(-1.03, 0.72)	(-1.82, 0.12)	
Subgroup*Treatment Interaction p-value	0.5416	0.1665	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Stigma of Liver Disease			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	77.85 (19.44)	84.84 (22.49)	87.52 (22.61)
Analysis Visit Mean (SD)	90.92 (12.29)	85.73 (23.02)	83.35 (20.18)
LS Mean of Change from Baseline (SE)	13.90 (3.26)	2.54 (4.03)	-0.25 (3.20)
95% CI	(7.21, 20.58)	(-5.72, 10.80)	(-6.82, 6.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	14.15 (4.34)	2.80 (4.91)	
95% CI	(5.25, 23.05)	(-7.28, 12.88)	
p-value	0.0030	0.5738	
Corrected Hedge's g Statistics	1.245	0.244	
95% CI	(0.35, 2.14)	(-0.69, 1.18)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	76.89 (20.21)	86.74 (21.50)	85.02 (24.15)
Analysis Visit Mean (SD)	81.89 (19.87)	85.19 (20.01)	81.89 (23.47)
LS Mean of Change from Baseline (SE)	5.93 (4.04)	-0.29 (4.45)	0.22 (4.12)
95% CI	(-2.36, 14.22)	(-9.43, 8.85)	(-8.25, 8.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.71 (5.56)	-0.51 (5.92)	
95% CI	(-5.70, 17.13)	(-12.66, 11.64)	
p-value	0.3132	0.9324	
Corrected Hedge's g Statistics	0.424	-0.038	
95% CI	(-0.46, 1.31)	(-0.97, 0.89)	
Subgroup*Treatment Interaction p-value	0.2523	0.6902	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Symptoms of Liver Disease			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	76.92 (18.10)	73.84 (19.14)	77.58 (17.93)
Analysis Visit Mean (SD)	76.09 (19.92)	73.23 (18.36)	77.68 (19.16)
LS Mean of Change from Baseline (SE)	-0.21 (1.33)	-0.83 (1.50)	0.33 (0.97)
95% CI	(-2.83, 2.40)	(-3.77, 2.11)	(-1.58, 2.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.54 (1.60)	-1.16 (1.75)	
95% CI	(-3.69, 2.60)	(-4.60, 2.29)	
p-value	0.7338	0.5098	
Corrected Hedge's g Statistics	-0.040	-0.086	
95% CI	(-0.28, 0.20)	(-0.35, 0.18)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	77.20 (17.83)	72.93 (19.02)	77.08 (17.75)
Analysis Visit Mean (SD)	75.91 (18.04)	73.56 (18.62)	77.15 (19.16)
LS Mean of Change from Baseline (SE)	-0.78 (1.33)	-0.17 (1.48)	0.41 (0.95)
95% CI	(-3.40, 1.85)	(-3.09, 2.74)	(-1.47, 2.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.18 (1.60)	-0.58 (1.73)	
95% CI	(-4.32, 1.96)	(-3.98, 2.82)	
p-value	0.4598	0.7373	
Corrected Hedge's g Statistics	-0.091	-0.045	
95% CI	(-0.34, 0.16)	(-0.31, 0.22)	
Subgroup*Treatment Interaction p-value	0.2078	0.9269	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Effects of Liver Disease			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	78.78 (11.89)	76.37 (17.92)	78.41 (13.62)
Analysis Visit Mean (SD)	76.93 (12.63)	78.61 (10.37)	78.13 (14.15)
LS Mean of Change from Baseline (SE)	-1.08 (1.17)	1.41 (1.32)	0.03 (0.86)
95% CI	(-3.39, 1.23)	(-1.20, 4.01)	(-1.67, 1.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.10 (1.42)	1.38 (1.55)	
95% CI	(-3.90, 1.69)	(-1.68, 4.43)	
p-value	0.4368	0.3760	
Corrected Hedge's g Statistics	-0.092	0.115	
95% CI	(-0.33, 0.15)	(-0.15, 0.38)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	78.50 (12.20)	75.86 (17.88)	77.98 (13.88)
Analysis Visit Mean (SD)	77.02 (11.35)	76.09 (14.14)	77.59 (13.46)
LS Mean of Change from Baseline (SE)	-0.78 (1.32)	-1.25 (1.47)	-0.38 (0.94)
95% CI	(-3.37, 1.81)	(-4.13, 1.63)	(-2.23, 1.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.40 (1.59)	-0.86 (1.71)	
95% CI	(-3.52, 2.72)	(-4.23, 2.50)	
p-value	0.8009	0.6140	
Corrected Hedge's g Statistics	-0.031	-0.068	
95% CI	(-0.28, 0.22)	(-0.34, 0.20)	
Subgroup*Treatment Interaction p-value	0.0684	0.2498	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Concentration/Memory			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	80.49 (21.76)	78.58 (20.81)	78.50 (21.20)
Analysis Visit Mean (SD)	79.88 (20.66)	79.29 (18.71)	80.10 (20.81)
LS Mean of Change from Baseline (SE)	0.01 (1.39)	0.36 (1.56)	1.38 (1.02)
95% CI	(-2.72, 2.74)	(-2.70, 3.42)	(-0.62, 3.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.36 (1.67)	-1.01 (1.82)	
95% CI	(-4.65, 1.92)	(-4.59, 2.57)	
p-value	0.4154	0.5777	
Corrected Hedge's g Statistics	-0.096	-0.072	
95% CI	(-0.34, 0.14)	(-0.33, 0.19)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	79.38 (22.24)	78.06 (19.68)	78.65 (20.92)
Analysis Visit Mean (SD)	77.78 (19.99)	76.03 (20.69)	78.04 (22.71)
LS Mean of Change from Baseline (SE)	-1.67 (1.46)	-1.83 (1.62)	-0.44 (1.04)
95% CI	(-4.54, 1.19)	(-5.01, 1.34)	(-2.49, 1.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.23 (1.75)	-1.39 (1.88)	
95% CI	(-4.66, 2.20)	(-5.09, 2.31)	
p-value	0.4816	0.4612	
Corrected Hedge's g Statistics	-0.087	-0.099	
95% CI	(-0.34, 0.16)	(-0.37, 0.17)	
Subgroup*Treatment Interaction p-value	0.7897	0.3792	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Health Distress			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	81.25 (23.11)	79.91 (26.59)	81.64 (23.48)
Analysis Visit Mean (SD)	84.98 (21.85)	86.55 (20.59)	86.20 (21.82)
LS Mean of Change from Baseline (SE)	3.83 (1.68)	6.00 (1.89)	4.56 (1.23)
95% CI	(0.52, 7.14)	(2.29, 9.71)	(2.13, 6.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.72 (2.02)	1.45 (2.21)	
95% CI	(-4.70, 3.25)	(-2.89, 5.79)	
p-value	0.7205	0.5127	
Corrected Hedge's g Statistics	-0.042	0.085	
95% CI	(-0.28, 0.20)	(-0.18, 0.35)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	79.84 (23.89)	80.41 (27.30)	82.54 (23.63)
Analysis Visit Mean (SD)	83.47 (21.97)	83.45 (24.23)	84.85 (22.11)
LS Mean of Change from Baseline (SE)	2.75 (1.89)	3.25 (2.10)	2.79 (1.35)
95% CI	(-0.98, 6.47)	(-0.88, 7.38)	(0.14, 5.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (2.27)	0.46 (2.45)	
95% CI	(-4.52, 4.43)	(-4.37, 5.28)	
p-value	0.9842	0.8525	
Corrected Hedge's g Statistics	-0.002	0.025	
95% CI	(-0.25, 0.25)	(-0.24, 0.29)	
Subgroup*Treatment Interaction p-value	0.7854	0.8296	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Sexual Function			
Week 24			
m	111	87	221
n	38	40	74
Baseline Mean (SD)	80.09 (28.95)	82.04 (19.68)	81.78 (21.52)
Analysis Visit Mean (SD)	81.14 (25.06)	77.16 (27.70)	82.27 (21.49)
LS Mean of Change from Baseline (SE)	2.22 (3.26)	-4.55 (3.18)	0.80 (2.38)
95% CI	(-4.21, 8.66)	(-10.83, 1.73)	(-3.90, 5.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.42 (3.94)	-5.35 (3.88)	
95% CI	(-6.36, 9.20)	(-13.01, 2.30)	
p-value	0.7189	0.1691	
Corrected Hedge's g Statistics	0.069	-0.261	
95% CI	(-0.32, 0.46)	(-0.65, 0.12)	
Week 52			
m	107	87	219
n	32	32	69
Baseline Mean (SD)	79.90 (30.47)	78.79 (23.94)	79.56 (24.84)
Analysis Visit Mean (SD)	83.59 (22.83)	75.91 (31.36)	78.67 (25.60)
LS Mean of Change from Baseline (SE)	4.69 (3.50)	-2.70 (3.46)	-1.51 (2.47)
95% CI	(-2.22, 11.60)	(-9.54, 4.14)	(-6.39, 3.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.20 (4.20)	-1.19 (4.16)	
95% CI	(-2.10, 14.49)	(-9.41, 7.03)	
p-value	0.1420	0.7748	
Corrected Hedge's g Statistics	0.303	-0.058	
95% CI	(-0.12, 0.72)	(-0.48, 0.36)	
Subgroup*Treatment Interaction p-value	0.6108	0.1827	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Sleep			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	62.45 (19.30)	56.46 (20.71)	63.39 (20.26)
Analysis Visit Mean (SD)	63.85 (19.29)	55.95 (20.83)	64.01 (20.07)
LS Mean of Change from Baseline (SE)	1.78 (1.44)	-2.26 (1.62)	0.85 (1.05)
95% CI	(-1.05, 4.61)	(-5.46, 0.93)	(-1.22, 2.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.93 (1.73)	-3.12 (1.90)	
95% CI	(-2.47, 4.32)	(-6.85, 0.62)	
p-value	0.5922	0.1020	
Corrected Hedge's g Statistics	0.063	-0.214	
95% CI	(-0.18, 0.30)	(-0.48, 0.05)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	62.74 (19.93)	56.01 (21.44)	62.93 (20.57)
Analysis Visit Mean (SD)	62.27 (19.24)	56.62 (20.58)	63.67 (21.26)
LS Mean of Change from Baseline (SE)	0.43 (1.57)	-1.06 (1.75)	0.98 (1.12)
95% CI	(-2.65, 3.51)	(-4.50, 2.38)	(-1.22, 3.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.55 (1.88)	-2.04 (2.04)	
95% CI	(-4.24, 3.14)	(-6.05, 1.98)	
p-value	0.7712	0.3191	
Corrected Hedge's g Statistics	-0.036	-0.134	
95% CI	(-0.29, 0.21)	(-0.40, 0.14)	
Subgroup*Treatment Interaction p-value	0.8105	0.9405	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Loneliness			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	85.05 (19.16)	81.20 (21.02)	84.41 (19.64)
Analysis Visit Mean (SD)	85.19 (17.05)	81.96 (21.11)	84.06 (19.21)
LS Mean of Change from Baseline (SE)	0.11 (1.38)	-0.63 (1.55)	-0.59 (1.01)
95% CI	(-2.59, 2.82)	(-3.67, 2.42)	(-2.58, 1.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.71 (1.66)	-0.03 (1.81)	
95% CI	(-2.55, 3.97)	(-3.60, 3.53)	
p-value	0.6702	0.9847	
Corrected Hedge's g Statistics	0.050	-0.002	
95% CI	(-0.19, 0.29)	(-0.26, 0.26)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	84.73 (19.76)	80.74 (21.51)	83.79 (19.96)
Analysis Visit Mean (SD)	86.88 (16.37)	80.54 (22.73)	83.75 (19.91)
LS Mean of Change from Baseline (SE)	1.88 (1.51)	-1.84 (1.68)	-0.57 (1.08)
95% CI	(-1.09, 4.85)	(-5.14, 1.46)	(-2.69, 1.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.45 (1.81)	-1.27 (1.96)	
95% CI	(-1.11, 6.02)	(-5.12, 2.59)	
p-value	0.1766	0.5183	
Corrected Hedge's g Statistics	0.168	-0.087	
95% CI	(-0.08, 0.42)	(-0.36, 0.18)	
Subgroup*Treatment Interaction p-value	0.6431	0.2650	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Hopelessness			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	75.73 (22.43)	72.46 (24.91)	80.86 (20.77)
Analysis Visit Mean (SD)	77.41 (22.36)	74.16 (24.08)	81.58 (20.13)
LS Mean of Change from Baseline (SE)	1.28 (1.66)	-0.44 (1.87)	2.08 (1.22)
95% CI	(-1.97, 4.54)	(-4.11, 3.24)	(-0.32, 4.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.79 (2.00)	-2.51 (2.19)	
95% CI	(-4.73, 3.14)	(-6.83, 1.80)	
p-value	0.6916	0.2529	
Corrected Hedge's g Statistics	-0.047	-0.149	
95% CI	(-0.29, 0.19)	(-0.41, 0.11)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	75.72 (22.58)	73.08 (25.50)	80.21 (21.25)
Analysis Visit Mean (SD)	77.33 (21.89)	74.33 (22.57)	78.22 (22.58)
LS Mean of Change from Baseline (SE)	1.55 (1.86)	-0.36 (2.06)	-0.61 (1.33)
95% CI	(-2.10, 5.19)	(-4.42, 3.70)	(-3.22, 1.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.16 (2.23)	0.25 (2.42)	
95% CI	(-2.23, 6.55)	(-4.50, 5.01)	
p-value	0.3345	0.9163	
Corrected Hedge's g Statistics	0.120	0.014	
95% CI	(-0.13, 0.37)	(-0.26, 0.28)	
Subgroup*Treatment Interaction p-value	0.5416	0.1665	

AMNOG Table SE21.11.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Stigma of Liver Disease			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	84.33 (20.27)	77.47 (21.09)	84.09 (18.64)
Analysis Visit Mean (SD)	85.83 (19.10)	79.93 (20.67)	86.53 (17.59)
LS Mean of Change from Baseline (SE)	2.38 (1.45)	0.65 (1.65)	3.05 (1.07)
95% CI	(-0.48, 5.24)	(-2.59, 3.89)	(0.95, 5.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.67 (1.75)	-2.40 (1.93)	
95% CI	(-4.12, 2.78)	(-6.19, 1.40)	
p-value	0.7032	0.2150	
Corrected Hedge's g Statistics	-0.045	-0.162	
95% CI	(-0.28, 0.19)	(-0.42, 0.10)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	83.82 (20.04)	78.56 (21.82)	83.20 (19.00)
Analysis Visit Mean (SD)	86.98 (17.32)	81.33 (20.56)	84.97 (19.20)
LS Mean of Change from Baseline (SE)	3.94 (1.54)	1.36 (1.71)	2.08 (1.10)
95% CI	(0.92, 6.97)	(-2.01, 4.73)	(-0.08, 4.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.87 (1.84)	-0.72 (2.00)	
95% CI	(-1.76, 5.50)	(-4.65, 3.21)	
p-value	0.3114	0.7198	
Corrected Hedge's g Statistics	0.126	-0.048	
95% CI	(-0.12, 0.38)	(-0.32, 0.22)	
Subgroup*Treatment Interaction p-value	0.2523	0.6902	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	1 (3.2)	3 (8.6)
No	27 (90.0)	30 (96.8)	32 (91.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	2.81	
95% CI of the inverse odds ratio	(0.16, 4.53)	(0.28, 28.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	2.66	
95% CI of the inverse risk ratio	(0.19, 3.94)	(0.29, 24.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.43	-5.35	
95% CI of the absolute risk difference	(-12.76, 15.62)	(-16.51, 5.82)	
p-value	0.8428	0.3637	
p-value of Breslow-Day Test for Homogeneity [3]	0.7630	0.4054	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	14 (45.2)	10 (28.6)
No	23 (76.7)	17 (54.8)	25 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	0.49	
95% CI of the inverse odds ratio	(0.43, 4.03)	(0.18, 1.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	0.63	
95% CI of the inverse risk ratio	(0.53, 2.82)	(0.33, 1.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.24	16.59	
95% CI of the absolute risk difference	(-26.52, 16.05)	(-6.45, 39.63)	
p-value	0.6319	0.1620	
p-value of Breslow-Day Test for Homogeneity [3]	0.2653	0.3135	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	5 (16.1)	5 (14.3)
No	30 (100)	26 (83.9)	30 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	11.00	0.87	
95% CI of the inverse odds ratio	(0.58, 207.71)	(0.23, 3.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	9.47	0.89	
95% CI of the inverse risk ratio	(0.55, 164.57)	(0.28, 2.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.66	1.84	
95% CI of the absolute risk difference	(-26.23, -1.10)	(-15.54, 19.22)	
p-value	0.0508	0.8349	
p-value of Breslow-Day Test for Homogeneity [3]	0.1149	0.2158	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (10.0)	11 (35.5)	8 (22.9)
No	27 (90.0)	20 (64.5)	27 (77.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	0.54	
95% CI of the inverse odds ratio	(0.64, 11.14)	(0.18, 1.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.29	0.64	
95% CI of the inverse risk ratio	(0.67, 7.85)	(0.30, 1.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.86	12.63	
95% CI of the absolute risk difference	(-30.43, 4.71)	(-9.22, 34.47)	
p-value	0.1682	0.2582	
p-value of Breslow-Day Test for Homogeneity [3]	0.5054	0.5826	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (6.5)	3 (8.6)
No	30 (100)	29 (93.5)	32 (91.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.57	1.36	
95% CI of the inverse odds ratio	(0.33, 132.49)	(0.21, 8.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.03	1.33	
95% CI of the inverse risk ratio	(0.32, 112.21)	(0.24, 7.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.11	-2.12	
95% CI of the absolute risk difference	(-18.75, 2.54)	(-14.80, 10.56)	
p-value	0.1625	0.7453	
p-value of Breslow-Day Test for Homogeneity [3]	0.4363	0.8731	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (16.7)	4 (12.9)	10 (28.6)
No	25 (83.3)	27 (87.1)	25 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	2.70	
95% CI of the inverse odds ratio	(0.60, 6.69)	(0.75, 9.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	2.21	
95% CI of the inverse risk ratio	(0.66, 4.46)	(0.77, 6.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.90	-15.67	
95% CI of the absolute risk difference	(-31.95, 8.14)	(-34.73, 3.39)	
p-value	0.2561	0.1202	
p-value of Breslow-Day Test for Homogeneity [3]	0.7222	0.1940	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	4 (12.9)	1 (2.9)
No	28 (93.3)	27 (87.1)	34 (97.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.41	0.20	
95% CI of the inverse odds ratio	(0.04, 4.78)	(0.02, 1.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	0.22	
95% CI of the inverse risk ratio	(0.04, 4.50)	(0.03, 1.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.81	10.05	
95% CI of the absolute risk difference	(-6.69, 14.30)	(-2.98, 23.07)	
p-value	0.4656	0.1237	
p-value of Breslow-Day Test for Homogeneity [3]	0.8766	0.1288	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (30.0)	10 (32.3)	8 (22.9)
No	21 (70.0)	21 (67.7)	27 (77.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.62	
95% CI of the inverse odds ratio	(0.23, 2.10)	(0.21, 1.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	0.71	
95% CI of the inverse risk ratio	(0.34, 1.73)	(0.32, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.14	9.40	
95% CI of the absolute risk difference	(-14.36, 28.65)	(-12.15, 30.95)	
p-value	0.5136	0.3921	
p-value of Breslow-Day Test for Homogeneity [3]	0.4643	0.3004	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (23.3)	10 (32.3)	11 (31.4)
No	23 (76.7)	21 (67.7)	24 (68.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	0.96	
95% CI of the inverse odds ratio	(0.50, 4.56)	(0.34, 2.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	0.97	
95% CI of the inverse risk ratio	(0.60, 3.04)	(0.48, 1.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.10	0.83	
95% CI of the absolute risk difference	(-29.67, 13.48)	(-21.69, 23.35)	
p-value	0.4672	0.9424	
p-value of Breslow-Day Test for Homogeneity [3]	0.5944	0.5032	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (36.7)	12 (38.7)	15 (42.9)
No	19 (63.3)	19 (61.3)	20 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	1.19	
95% CI of the inverse odds ratio	(0.48, 3.52)	(0.44, 3.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	1.11	
95% CI of the inverse risk ratio	(0.64, 2.14)	(0.62, 1.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.19	-4.15	
95% CI of the absolute risk difference	(-29.98, 17.60)	(-27.87, 19.58)	
p-value	0.6115	0.7323	
p-value of Breslow-Day Test for Homogeneity [3]	0.7519	0.8911	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	2 (6.5)	1 (2.9)
No	28 (93.3)	29 (93.5)	34 (97.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.41	0.43	
95% CI of the inverse odds ratio	(0.04, 4.78)	(0.04, 4.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	0.44	
95% CI of the inverse risk ratio	(0.04, 4.50)	(0.04, 4.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.81	3.59	
95% CI of the absolute risk difference	(-6.69, 14.30)	(-6.66, 13.85)	
p-value	0.4656	0.4841	
p-value of Breslow-Day Test for Homogeneity [3]	0.3245	0.2555	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (6.7)	5 (16.1)	3 (8.6)
No	28 (93.3)	26 (83.9)	32 (91.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	0.49	
95% CI of the inverse odds ratio	(0.20, 8.43)	(0.11, 2.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.53	
95% CI of the inverse risk ratio	(0.23, 7.19)	(0.14, 2.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.90	7.56	
95% CI of the absolute risk difference	(-14.78, 10.97)	(-8.37, 23.48)	
p-value	0.7739	0.3478	
p-value of Breslow-Day Test for Homogeneity [3]	0.1102	0.2529	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (16.7)	5 (16.1)	6 (17.1)
No	25 (83.3)	26 (83.9)	29 (82.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.08	
95% CI of the inverse odds ratio	(0.28, 3.80)	(0.29, 3.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.06	
95% CI of the inverse risk ratio	(0.35, 3.03)	(0.36, 3.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.48	-1.01	
95% CI of the absolute risk difference	(-18.74, 17.79)	(-19.00, 16.97)	
p-value	0.9593	0.9122	
p-value of Breslow-Day Test for Homogeneity [3]	0.9519	0.3646	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (36.7)	9 (29.0)	12 (34.3)
No	19 (63.3)	22 (71.0)	23 (65.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.28	
95% CI of the inverse odds ratio	(0.33, 2.50)	(0.45, 3.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.18	
95% CI of the inverse risk ratio	(0.48, 1.80)	(0.58, 2.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.38	-5.25	
95% CI of the absolute risk difference	(-20.96, 25.72)	(-27.67, 17.17)	
p-value	0.8414	0.6474	
p-value of Breslow-Day Test for Homogeneity [3]	0.5150	0.8650	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.3)	5 (16.1)	5 (14.3)
No	29 (96.7)	26 (83.9)	30 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.83	0.87	
95% CI of the inverse odds ratio	(0.53, 43.92)	(0.23, 3.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.29	0.89	
95% CI of the inverse risk ratio	(0.53, 34.68)	(0.28, 2.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.95	1.84	
95% CI of the absolute risk difference	(-24.21, 2.30)	(-15.54, 19.22)	
p-value	0.1283	0.8349	
p-value of Breslow-Day Test for Homogeneity [3]	0.0480	0.1318	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (13.3)	8 (25.8)	12 (34.3)
No	26 (86.7)	23 (74.2)	23 (65.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.39	1.50	
95% CI of the inverse odds ratio	(0.96, 11.99)	(0.52, 4.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.57	1.33	
95% CI of the inverse risk ratio	(0.93, 7.14)	(0.63, 2.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-20.95	-8.48	
95% CI of the absolute risk difference	(-40.83, -1.07)	(-30.49, 13.53)	
p-value	0.0506	0.4544	
p-value of Breslow-Day Test for Homogeneity [3]	0.2128	0.6832	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (36.7)	12 (38.7)	5 (14.3)
No	19 (63.3)	19 (61.3)	30 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.26	
95% CI of the inverse odds ratio	(0.09, 0.96)	(0.08, 0.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.39	0.37	
95% CI of the inverse risk ratio	(0.15, 1.00)	(0.15, 0.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.38	24.42	
95% CI of the absolute risk difference	(1.60, 43.16)	(3.73, 45.12)	
p-value	0.0368	0.0235	
p-value of Breslow-Day Test for Homogeneity [3]	0.1172	0.0795	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (36.7)	16 (51.6)	10 (28.6)
No	19 (63.3)	15 (48.4)	25 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.38	
95% CI of the inverse odds ratio	(0.24, 1.96)	(0.14, 1.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.55	
95% CI of the inverse risk ratio	(0.39, 1.58)	(0.30, 1.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.10	23.04	
95% CI of the absolute risk difference	(-14.74, 30.93)	(-0.06, 46.14)	
p-value	0.4866	0.0559	
p-value of Breslow-Day Test for Homogeneity [3]	0.9582	0.2053	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (16.7)	5 (16.1)	5 (14.3)
No	25 (83.3)	26 (83.9)	30 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.87	
95% CI of the inverse odds ratio	(0.22, 3.21)	(0.23, 3.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.89	
95% CI of the inverse risk ratio	(0.27, 2.68)	(0.28, 2.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.38	1.84	
95% CI of the absolute risk difference	(-15.29, 20.05)	(-15.54, 19.22)	
p-value	0.7908	0.8349	
p-value of Breslow-Day Test for Homogeneity [3]	0.9822	0.6729	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (36.7)	10 (32.3)	11 (31.4)
No	19 (63.3)	21 (67.7)	24 (68.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.96	
95% CI of the inverse odds ratio	(0.28, 2.22)	(0.34, 2.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.97	
95% CI of the inverse risk ratio	(0.43, 1.69)	(0.48, 1.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.24	0.83	
95% CI of the absolute risk difference	(-17.87, 28.34)	(-21.69, 23.35)	
p-value	0.6564	0.9424	
p-value of Breslow-Day Test for Homogeneity [3]	0.8915	0.8410	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	12 (100)	8 (100)	13 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7630	0.4054	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (33.3)	0	1 (7.7)
No	8 (66.7)	8 (100)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.17	2.04	
95% CI of the inverse odds ratio	(0.02, 1.78)	(0.07, 56.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.23	1.93	
95% CI of the inverse risk ratio	(0.03, 1.79)	(0.09, 42.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	25.64	-5.16	
95% CI of the absolute risk difference	(-4.71, 55.99)	(-27.21, 16.90)	
p-value	0.1093	0.6683	
p-value of Breslow-Day Test for Homogeneity [3]	0.2653	0.3135	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (23.1)
No	12 (100)	8 (100)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	8.33	5.67	
95% CI of the inverse odds ratio	(0.39, 180.36)	(0.26, 125.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.50	4.50	
95% CI of the inverse risk ratio	(0.37, 114.12)	(0.26, 77.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-21.15	-19.44	
95% CI of the absolute risk difference	(-46.13, 3.82)	(-46.62, 7.73)	
p-value	0.1221	0.2299	
p-value of Breslow-Day Test for Homogeneity [3]	0.1149	0.2158	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (33.3)	3 (37.5)	4 (30.8)
No	8 (66.7)	5 (62.5)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.74	
95% CI of the inverse odds ratio	(0.17, 4.78)	(0.12, 4.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.82	
95% CI of the inverse risk ratio	(0.29, 2.89)	(0.24, 2.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.56	6.73	
95% CI of the absolute risk difference	(-34.05, 39.18)	(-35.16, 48.62)	
p-value	0.8908	0.7507	
p-value of Breslow-Day Test for Homogeneity [3]	0.5054	0.5826	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (8.3)	1 (12.5)	1 (7.7)
No	11 (91.7)	7 (87.5)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.58	
95% CI of the inverse odds ratio	(0.05, 16.49)	(0.03, 10.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.62	
95% CI of the inverse risk ratio	(0.06, 13.18)	(0.04, 8.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.64	4.81	
95% CI of the absolute risk difference	(-20.67, 21.96)	(-22.30, 31.92)	
p-value	0.9529	0.7155	
p-value of Breslow-Day Test for Homogeneity [3]	0.4363	0.8731	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (16.7)	2 (25.0)	3 (23.1)
No	10 (83.3)	6 (75.0)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	0.90	
95% CI of the inverse odds ratio	(0.20, 11.00)	(0.12, 7.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	0.92	
95% CI of the inverse risk ratio	(0.28, 6.91)	(0.19, 4.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.41	1.92	
95% CI of the absolute risk difference	(-37.54, 24.72)	(-35.82, 39.67)	
p-value	0.6889	0.9200	
p-value of Breslow-Day Test for Homogeneity [3]	0.7222	0.1940	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (16.7)	0	2 (15.4)
No	10 (83.3)	8 (100)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	3.70	
95% CI of the inverse odds ratio	(0.11, 7.72)	(0.16, 87.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	3.21	
95% CI of the inverse risk ratio	(0.15, 5.56)	(0.17, 59.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.28	-12.30	
95% CI of the absolute risk difference	(-27.52, 30.08)	(-37.33, 12.73)	
p-value	0.9304	0.3926	
p-value of Breslow-Day Test for Homogeneity [3]	0.8766	0.1288	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (50.0)	1 (12.5)	5 (38.5)
No	6 (50.0)	7 (87.5)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	4.38	
95% CI of the inverse odds ratio	(0.13, 3.07)	(0.41, 47.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	3.08	
95% CI of the inverse risk ratio	(0.32, 1.87)	(0.43, 21.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.54	-25.96	
95% CI of the absolute risk difference	(-27.19, 50.26)	(-60.96, 9.03)	
p-value	0.5615	0.2009	
p-value of Breslow-Day Test for Homogeneity [3]	0.4643	0.3004	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (25.0)	1 (12.5)	4 (30.8)
No	9 (75.0)	7 (87.5)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	3.11	
95% CI of the inverse odds ratio	(0.23, 7.74)	(0.28, 34.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	2.46	
95% CI of the inverse risk ratio	(0.34, 4.40)	(0.33, 18.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.77	-18.27	
95% CI of the absolute risk difference	(-40.84, 29.30)	(-52.25, 15.71)	
p-value	0.7482	0.3398	
p-value of Breslow-Day Test for Homogeneity [3]	0.5944	0.5032	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (41.7)	3 (37.5)	4 (30.8)
No	7 (58.3)	5 (62.5)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.74	
95% CI of the inverse odds ratio	(0.12, 3.22)	(0.12, 4.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.82	
95% CI of the inverse risk ratio	(0.26, 2.12)	(0.24, 2.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.90	6.73	
95% CI of the absolute risk difference	(-26.62, 48.41)	(-35.16, 48.62)	
p-value	0.5706	0.7507	
p-value of Breslow-Day Test for Homogeneity [3]	0.7519	0.8911	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (12.5)	0
No	12 (100)	7 (87.5)	13 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.19	
95% CI of the inverse odds ratio	NE	(0.01, 5.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.21	
95% CI of the inverse risk ratio	NE	(0.01, 4.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	13.10	
95% CI of the absolute risk difference	NE	(-13.12, 39.31)	
p-value	NE	0.2767	
p-value of Breslow-Day Test for Homogeneity [3]	0.3245	0.2555	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (25.0)	1 (12.5)	0
No	9 (75.0)	7 (87.5)	13 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.10	0.19	
95% CI of the inverse odds ratio	(0.00, 2.18)	(0.01, 5.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	0.21	
95% CI of the inverse risk ratio	(0.01, 2.33)	(0.01, 4.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	23.35	13.10	
95% CI of the absolute risk difference	(-2.65, 49.35)	(-13.12, 39.31)	
p-value	0.0879	0.2767	
p-value of Breslow-Day Test for Homogeneity [3]	0.1102	0.2529	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (16.7)	0	3 (23.1)
No	10 (83.3)	8 (100)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	5.67	
95% CI of the inverse odds ratio	(0.20, 11.00)	(0.26, 125.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	4.50	
95% CI of the inverse risk ratio	(0.28, 6.91)	(0.26, 77.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.41	-19.44	
95% CI of the absolute risk difference	(-37.54, 24.72)	(-46.62, 7.73)	
p-value	0.6889	0.2299	
p-value of Breslow-Day Test for Homogeneity [3]	0.9519	0.3646	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (50.0)	3 (37.5)	5 (38.5)
No	6 (50.0)	5 (62.5)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	1.04	
95% CI of the inverse odds ratio	(0.13, 3.07)	(0.17, 6.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.03	
95% CI of the inverse risk ratio	(0.32, 1.87)	(0.33, 3.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.54	-0.96	
95% CI of the absolute risk difference	(-27.19, 50.26)	(-43.68, 41.76)	
p-value	0.5615	0.9649	
p-value of Breslow-Day Test for Homogeneity [3]	0.5150	0.8650	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (25.0)	3 (37.5)	0
No	9 (75.0)	5 (62.5)	13 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.10	0.06	
95% CI of the inverse odds ratio	(0.00, 2.18)	(0.00, 1.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	0.09	
95% CI of the inverse risk ratio	(0.01, 2.33)	(0.01, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	23.35	35.32	
95% CI of the absolute risk difference	(-2.65, 49.35)	(2.02, 68.62)	
p-value	0.0879	0.0292	
p-value of Breslow-Day Test for Homogeneity [3]	0.0480	0.1318	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (25.0)	3 (37.5)	4 (30.8)
No	9 (75.0)	5 (62.5)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	0.74	
95% CI of the inverse odds ratio	(0.23, 7.74)	(0.12, 4.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	0.82	
95% CI of the inverse risk ratio	(0.34, 4.40)	(0.24, 2.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.77	6.73	
95% CI of the absolute risk difference	(-40.84, 29.30)	(-35.16, 48.62)	
p-value	0.7482	0.7507	
p-value of Breslow-Day Test for Homogeneity [3]	0.2128	0.6832	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (8.3)	0	3 (23.1)
No	11 (91.7)	8 (100)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.30	5.67	
95% CI of the inverse odds ratio	(0.29, 37.10)	(0.26, 125.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.77	4.50	
95% CI of the inverse risk ratio	(0.33, 23.14)	(0.26, 77.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.74	-19.44	
95% CI of the absolute risk difference	(-42.48, 12.99)	(-46.62, 7.73)	
p-value	0.3151	0.2299	
p-value of Breslow-Day Test for Homogeneity [3]	0.1172	0.0795	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (33.3)	1 (12.5)	4 (30.8)
No	8 (66.7)	7 (87.5)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	3.11	
95% CI of the inverse odds ratio	(0.17, 4.78)	(0.28, 34.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	2.46	
95% CI of the inverse risk ratio	(0.29, 2.89)	(0.33, 18.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.56	-18.27	
95% CI of the absolute risk difference	(-34.05, 39.18)	(-52.25, 15.71)	
p-value	0.8908	0.3398	
p-value of Breslow-Day Test for Homogeneity [3]	0.9582	0.2053	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (8.3)	0	1 (7.7)
No	11 (91.7)	8 (100)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	2.04	
95% CI of the inverse odds ratio	(0.05, 16.49)	(0.07, 56.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.93	
95% CI of the inverse risk ratio	(0.06, 13.18)	(0.09, 42.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.64	-5.16	
95% CI of the absolute risk difference	(-20.67, 21.96)	(-27.21, 16.90)	
p-value	0.9529	0.6683	
p-value of Breslow-Day Test for Homogeneity [3]	0.9822	0.6729	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (33.3)	3 (37.5)	3 (23.1)
No	8 (66.7)	5 (62.5)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.50	
95% CI of the inverse odds ratio	(0.10, 3.49)	(0.07, 3.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.62	
95% CI of the inverse risk ratio	(0.19, 2.48)	(0.16, 2.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.26	14.42	
95% CI of the absolute risk difference	(-24.90, 45.41)	(-26.20, 55.04)	
p-value	0.5683	0.4774	
p-value of Breslow-Day Test for Homogeneity [3]	0.8915	0.8410	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (2.7)	3 (3.4)	7 (3.2)
No	108 (97.3)	84 (96.6)	214 (96.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.92	
95% CI of the inverse odds ratio	(0.30, 4.64)	(0.23, 3.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.92	
95% CI of the inverse risk ratio	(0.31, 4.45)	(0.24, 3.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.46	0.28	
95% CI of the absolute risk difference	(-4.26, 3.33)	(-4.19, 4.76)	
p-value	0.8152	0.9004	
p-value of Breslow-Day Test for Homogeneity [3]	0.7630	0.4054	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (24.3)	18 (20.7)	47 (21.3)
No	84 (75.7)	69 (79.3)	174 (78.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.04	
95% CI of the inverse odds ratio	(0.49, 1.44)	(0.56, 1.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.03	
95% CI of the inverse risk ratio	(0.58, 1.32)	(0.63, 1.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.06	-0.58	
95% CI of the absolute risk difference	(-6.58, 12.69)	(-10.65, 9.50)	
p-value	0.5277	0.9110	
p-value of Breslow-Day Test for Homogeneity [3]	0.2653	0.3135	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (5.4)	11 (12.6)	18 (8.1)
No	105 (94.6)	76 (87.4)	203 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	0.61	
95% CI of the inverse odds ratio	(0.60, 4.03)	(0.28, 1.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	0.64	
95% CI of the inverse risk ratio	(0.62, 3.69)	(0.32, 1.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.74	4.50	
95% CI of the absolute risk difference	(-8.28, 2.80)	(-3.36, 12.36)	
p-value	0.3632	0.2236	
p-value of Breslow-Day Test for Homogeneity [3]	0.1149	0.2158	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (26.1)	25 (28.7)	64 (29.0)
No	82 (73.9)	62 (71.3)	157 (71.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.01	
95% CI of the inverse odds ratio	(0.69, 1.93)	(0.58, 1.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.01	
95% CI of the inverse risk ratio	(0.76, 1.61)	(0.68, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.83	-0.22	
95% CI of the absolute risk difference	(-12.96, 7.29)	(-11.46, 11.01)	
p-value	0.5876	0.9689	
p-value of Breslow-Day Test for Homogeneity [3]	0.5054	0.5826	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.6)	7 (8.0)	22 (10.0)
No	107 (96.4)	80 (92.0)	199 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.96	1.26	
95% CI of the inverse odds ratio	(0.99, 8.80)	(0.52, 3.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.76	1.24	
95% CI of the inverse risk ratio	(0.98, 7.82)	(0.55, 2.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.35	-1.91	
95% CI of the absolute risk difference	(-11.60, -1.10)	(-8.85, 5.04)	
p-value	0.0421	0.6056	
p-value of Breslow-Day Test for Homogeneity [3]	0.4363	0.8731	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (18.0)	22 (25.3)	45 (20.4)
No	91 (82.0)	65 (74.7)	176 (79.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	0.76	
95% CI of the inverse odds ratio	(0.65, 2.09)	(0.42, 1.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	0.81	
95% CI of the inverse risk ratio	(0.70, 1.82)	(0.52, 1.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.34	4.93	
95% CI of the absolute risk difference	(-11.25, 6.56)	(-5.64, 15.49)	
p-value	0.6116	0.3456	
p-value of Breslow-Day Test for Homogeneity [3]	0.7222	0.1940	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (9.9)	5 (5.7)	17 (7.7)
No	100 (90.1)	82 (94.3)	204 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	1.37	
95% CI of the inverse odds ratio	(0.34, 1.68)	(0.49, 3.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.34	
95% CI of the inverse risk ratio	(0.38, 1.60)	(0.51, 3.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.22	-1.95	
95% CI of the absolute risk difference	(-4.36, 8.79)	(-7.97, 4.08)	
p-value	0.4927	0.5507	
p-value of Breslow-Day Test for Homogeneity [3]	0.8766	0.1288	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (19.8)	25 (28.7)	54 (24.4)
No	89 (80.2)	62 (71.3)	167 (75.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	0.80	
95% CI of the inverse odds ratio	(0.75, 2.29)	(0.46, 1.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	0.85	
95% CI of the inverse risk ratio	(0.79, 1.91)	(0.57, 1.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.61	4.30	
95% CI of the absolute risk difference	(-13.95, 4.72)	(-6.77, 15.37)	
p-value	0.3451	0.4364	
p-value of Breslow-Day Test for Homogeneity [3]	0.4643	0.3004	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (16.2)	15 (17.2)	30 (13.6)
No	93 (83.8)	72 (82.8)	191 (86.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.75	
95% CI of the inverse odds ratio	(0.43, 1.53)	(0.38, 1.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.79	
95% CI of the inverse risk ratio	(0.49, 1.43)	(0.45, 1.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.64	3.67	
95% CI of the absolute risk difference	(-5.57, 10.85)	(-5.47, 12.80)	
p-value	0.5185	0.4121	
p-value of Breslow-Day Test for Homogeneity [3]	0.5944	0.5032	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (21.6)	21 (24.1)	52 (23.5)
No	87 (78.4)	66 (75.9)	169 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.97	
95% CI of the inverse odds ratio	(0.64, 1.93)	(0.54, 1.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.97	
95% CI of the inverse risk ratio	(0.71, 1.67)	(0.63, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.91	0.61	
95% CI of the absolute risk difference	(-11.39, 7.58)	(-9.98, 11.20)	
p-value	0.6963	0.9100	
p-value of Breslow-Day Test for Homogeneity [3]	0.7519	0.8911	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.6)	3 (3.4)	12 (5.4)
No	107 (96.4)	84 (96.6)	209 (94.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.54	1.61	
95% CI of the inverse odds ratio	(0.48, 4.88)	(0.44, 5.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	1.57	
95% CI of the inverse risk ratio	(0.50, 4.56)	(0.46, 5.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.83	-1.98	
95% CI of the absolute risk difference	(-6.40, 2.75)	(-6.84, 2.88)	
p-value	0.4636	0.4670	
p-value of Breslow-Day Test for Homogeneity [3]	0.3245	0.2555	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (7.2)	7 (8.0)	22 (10.0)
No	103 (92.8)	80 (92.0)	199 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	1.26	
95% CI of the inverse odds ratio	(0.61, 3.31)	(0.52, 3.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	1.24	
95% CI of the inverse risk ratio	(0.64, 3.00)	(0.55, 2.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.75	-1.91	
95% CI of the absolute risk difference	(-8.97, 3.48)	(-8.85, 5.04)	
p-value	0.4101	0.6056	
p-value of Breslow-Day Test for Homogeneity [3]	0.1102	0.2529	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (16.2)	15 (17.2)	39 (17.6)
No	93 (83.8)	72 (82.8)	182 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.03	
95% CI of the inverse odds ratio	(0.60, 2.04)	(0.53, 1.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.02	
95% CI of the inverse risk ratio	(0.65, 1.81)	(0.60, 1.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.43	-0.41	
95% CI of the absolute risk difference	(-9.93, 7.07)	(-9.80, 8.99)	
p-value	0.7443	0.9328	
p-value of Breslow-Day Test for Homogeneity [3]	0.9519	0.3646	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (28.8)	33 (37.9)	80 (36.2)
No	79 (71.2)	54 (62.1)	141 (63.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	0.93	
95% CI of the inverse odds ratio	(0.85, 2.30)	(0.56, 1.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	0.95	
95% CI of the inverse risk ratio	(0.89, 1.77)	(0.69, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.37	1.73	
95% CI of the absolute risk difference	(-17.91, 3.17)	(-10.27, 13.74)	
p-value	0.1803	0.7765	
p-value of Breslow-Day Test for Homogeneity [3]	0.5150	0.8650	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (14.4)	16 (18.4)	28 (12.7)
No	95 (85.6)	71 (81.6)	193 (87.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.64	
95% CI of the inverse odds ratio	(0.44, 1.67)	(0.33, 1.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.69	
95% CI of the inverse risk ratio	(0.50, 1.55)	(0.39, 1.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.74	5.72	
95% CI of the absolute risk difference	(-6.12, 9.61)	(-3.53, 14.97)	
p-value	0.6583	0.1964	
p-value of Breslow-Day Test for Homogeneity [3]	0.0480	0.1318	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (29.7)	28 (32.2)	67 (30.3)
No	78 (70.3)	59 (67.8)	154 (69.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.92	
95% CI of the inverse odds ratio	(0.63, 1.69)	(0.54, 1.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.94	
95% CI of the inverse risk ratio	(0.72, 1.45)	(0.65, 1.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.59	1.87	
95% CI of the absolute risk difference	(-11.03, 9.85)	(-9.67, 13.40)	
p-value	0.9124	0.7494	
p-value of Breslow-Day Test for Homogeneity [3]	0.2128	0.6832	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	19 (17.1)	22 (25.3)	33 (14.9)
No	92 (82.9)	65 (74.7)	188 (85.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.52	
95% CI of the inverse odds ratio	(0.46, 1.58)	(0.28, 0.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.59	
95% CI of the inverse risk ratio	(0.52, 1.46)	(0.37, 0.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.18	10.36	
95% CI of the absolute risk difference	(-6.25, 10.62)	(0.08, 20.63)	
p-value	0.6053	0.0327	
p-value of Breslow-Day Test for Homogeneity [3]	0.1172	0.0795	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (29.7)	27 (31.0)	56 (25.3)
No	78 (70.3)	60 (69.0)	165 (74.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.75	
95% CI of the inverse odds ratio	(0.48, 1.33)	(0.44, 1.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.82	
95% CI of the inverse risk ratio	(0.59, 1.23)	(0.55, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.39	5.70	
95% CI of the absolute risk difference	(-5.87, 14.65)	(-5.59, 16.98)	
p-value	0.3942	0.3105	
p-value of Breslow-Day Test for Homogeneity [3]	0.9582	0.2053	

AMNOG Table SE21.11.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (12.6)	13 (14.9)	27 (12.2)
No	97 (87.4)	74 (85.1)	194 (87.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.79	
95% CI of the inverse odds ratio	(0.48, 1.92)	(0.39, 1.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.82	
95% CI of the inverse risk ratio	(0.53, 1.77)	(0.44, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.40	2.73	
95% CI of the absolute risk difference	(-7.14, 7.93)	(-5.92, 11.37)	
p-value	0.9177	0.5218	
p-value of Breslow-Day Test for Homogeneity [3]	0.9822	0.6729	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	36 (32.4)	30 (34.5)	67 (30.3)
No	75 (67.6)	57 (65.5)	154 (69.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.83	
95% CI of the inverse odds ratio	(0.56, 1.48)	(0.49, 1.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.88	
95% CI of the inverse risk ratio	(0.67, 1.31)	(0.62, 1.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.12	4.17	
95% CI of the absolute risk difference	(-8.49, 12.73)	(-7.52, 15.85)	
p-value	0.6942	0.4785	
p-value of Breslow-Day Test for Homogeneity [3]	0.8915	0.8410	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 1 of 20
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Total LDQOL						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	79.38 (13.77)	76.97 (13.75)	N/A			
Median	83.35	81.85	N/A			
IQR: Q1, Q3	75.30, 88.90	67.05, 86.60	N/A			
Min, Max	29.0, 96.5	23.6, 95.6	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	78.65 (15.02)	77.21 (11.34)	N/A	-0.27 (0.89)	0.41 (1.12)	N/A
Median	82.90	76.75	N/A	0.50	-1.00	N/A
IQR: Q1, Q3	71.90, 89.70	71.20, 86.45	N/A	-5.60, 4.60	-6.10, 5.00	N/A
Min, Max	22.9, 97.2	48.5, 95.6	N/A	-23.4, 24.2	-15.4, 26.0	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	78.94 (13.86)	77.79 (12.50)	N/A	-0.07 (0.99)	0.73 (1.20)	N/A
Median	83.65	78.90	N/A	0	0.90	N/A
IQR: Q1, Q3	69.75, 88.65	69.90, 88.80	N/A	-4.80, 5.70	-5.60, 6.20	N/A
Min, Max	34.0, 97.5	38.2, 97.4	N/A	-19.5, 36.0	-23.3, 22.4	N/A

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Symptoms of Liver Disease						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	79.61 (17.52)	74.22 (19.42)	N/A			
Median	83.30	76.70	N/A			
IQR: Q1, Q3	70.00, 93.30	56.70, 90.00	N/A			
Min, Max	23.3, 100.0	30.0, 100.0	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	76.74 (19.91)	73.60 (18.27)	N/A	-2.27 (1.63)	-1.47 (1.49)	N/A
Median	83.30	76.70	N/A	0	-3.30	N/A
IQR: Q1, Q3	66.70, 90.00	60.00, 86.70	N/A	-10.00, 3.40	-6.70, 3.40	N/A
Min, Max	0.0, 100.0	26.7, 100.0	N/A	-46.7, 33.4	-33.3, 30.0	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	76.83 (19.70)	74.87 (17.52)	N/A	-3.59 (1.40)	0.63 (1.85)	N/A
Median	83.30	76.70	N/A	-3.30	0	N/A
IQR: Q1, Q3	66.70, 93.30	66.70, 86.70	N/A	-10.00, 3.40	-10.00, 13.30	N/A
Min, Max	23.3, 100.0	30.0, 100.0	N/A	-36.7, 33.4	-36.7, 30.0	N/A

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Effects of Liver Disease						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	79.54 (13.09)	79.07 (14.15)	N/A			
Median	80.00	80.00	N/A			
IQR: Q1, Q3	80.00, 86.70	80.00, 86.70	N/A			
Min, Max	13.3, 100.0	26.7, 100.0	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	77.01 (13.67)	80.21 (9.05)	N/A	-2.59 (1.26)	1.42 (1.89)	N/A
Median	80.00	80.00	N/A	0	0	N/A
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	N/A	-6.70, 0.00	-6.70, 6.70	N/A
Min, Max	20.0, 100.0	53.3, 100.0	N/A	-40.0, 26.6	-26.7, 60.0	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	76.46 (12.81)	78.64 (9.46)	N/A	-2.47 (1.82)	-0.06 (1.66)	N/A
Median	80.00	80.00	N/A	0	0	N/A
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	N/A	-6.70, 0.00	-6.70, 6.70	N/A
Min, Max	40.0, 100.0	46.7, 100.0	N/A	-40.0, 80.0	-33.3, 40.0	N/A

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Concentration/Memory						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	82.94 (20.83)	79.80 (19.78)	N/A			
Median	87.50	87.50	N/A			
IQR: Q1, Q3	75.00, 100.00	68.80, 96.90	N/A			
Min, Max	18.8, 100.0	25.0, 100.0	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	78.95 (20.67)	77.95 (20.29)	N/A	-3.53 (1.58)	-2.15 (1.70)	N/A
Median	81.30	78.15	N/A	0	0	N/A
IQR: Q1, Q3	68.80, 93.80	68.80, 96.90	N/A	-12.50, 0.00	-6.30, 6.20	N/A
Min, Max	18.8, 100.0	25.0, 100.0	N/A	-43.8, 25.0	-37.5, 25.0	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	80.33 (19.84)	78.10 (21.27)	N/A	-1.46 (1.48)	-1.27 (1.69)	N/A
Median	87.50	87.50	N/A	0	0	N/A
IQR: Q1, Q3	75.00, 93.80	62.50, 93.80	N/A	-6.30, 0.00	-6.30, 6.30	N/A
Min, Max	0.0, 100.0	18.8, 100.0	N/A	-25.0, 50.0	-43.8, 25.0	N/A

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Health Distress						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	79.80 (24.11)	79.69 (24.95)	N/A			
Median	87.50	87.50	N/A			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	N/A			
Min, Max	0.0, 100.0	0.0, 100.0	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	84.13 (22.98)	87.30 (18.57)	N/A	4.85 (2.32)	7.79 (2.45)	N/A
Median	100.00	100.00	N/A	0	0	N/A
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	N/A	0.00, 12.50	0.00, 25.00	N/A
Min, Max	0.0, 100.0	25.0, 100.0	N/A	-50.0, 75.0	-37.5, 50.0	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	81.88 (24.99)	88.11 (18.18)	N/A	2.92 (2.58)	8.47 (2.89)	N/A
Median	100.00	100.00	N/A	0	0	N/A
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	N/A	0.00, 12.50	0.00, 25.00	N/A
Min, Max	0.0, 100.0	25.0, 100.0	N/A	-75.0, 75.0	-37.5, 75.0	N/A

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Sexual Function						
Baseline						
m	91	67	0			
n	33	34	0			
Mean (SD)	86.56 (19.94)	83.03 (20.08)	N/A			
Median	100.00	93.30	N/A			
IQR: Q1, Q3	83.30, 100.00	68.30, 100.00	N/A			
Min, Max	30.0, 100.0	30.0, 100.0	N/A			
Week 24						
m	91	67	0			
n	35	34	0	27	28	0
Mean (SD/SE)	82.05 (24.50)	76.03 (26.97)	N/A	-6.78 (4.95)	-5.76 (4.06)	N/A
Median	93.30	88.35	N/A	0	0	N/A
IQR: Q1, Q3	76.70, 100.00	60.00, 100.00	N/A	-15.00, 0.00	-16.65, 0.85	N/A
Min, Max	6.7, 100.0	-1.7, 100.0	N/A	-85.0, 36.7	-48.3, 46.7	N/A
Week 52						
m	88	67	0			
n	31	30	0	26	24	0
Mean (SD/SE)	88.40 (16.67)	73.75 (30.50)	N/A	-2.43 (2.32)	-4.92 (4.82)	N/A
Median	93.30	85.00	N/A	0	0	N/A
IQR: Q1, Q3	80.00, 100.00	51.10, 100.00	N/A	-5.00, 0.00	-23.35, 6.70	N/A
Min, Max	28.3, 100.0	-1.7, 100.0	N/A	-45.0, 23.4	-50.0, 61.7	N/A

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Sleep						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	66.28 (20.32)	62.19 (18.21)	N/A			
Median	70.00	65.00	N/A			
IQR: Q1, Q3	55.00, 80.00	50.00, 75.00	N/A			
Min, Max	10.0, 100.0	20.0, 100.0	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	64.83 (20.25)	57.97 (19.06)	N/A	-0.76 (1.64)	-3.69 (1.83)	N/A
Median	70.00	60.00	N/A	0	-5.00	N/A
IQR: Q1, Q3	50.00, 80.00	45.00, 70.00	N/A	-10.00, 5.00	-15.00, 5.00	N/A
Min, Max	10.0, 100.0	10.0, 100.0	N/A	-30.0, 55.0	-35.0, 30.0	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	66.31 (15.95)	58.52 (20.74)	N/A	-0.45 (1.99)	-3.05 (2.22)	N/A
Median	70.00	65.00	N/A	0	-5.00	N/A
IQR: Q1, Q3	55.00, 80.00	40.00, 75.00	N/A	-10.00, 5.00	-15.00, 10.00	N/A
Min, Max	25.0, 100.0	10.0, 90.0	N/A	-40.0, 75.0	-60.0, 30.0	N/A

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Loneliness						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	84.24 (18.38)	82.27 (21.23)	N/A			
Median	90.00	90.00	N/A			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	N/A			
Min, Max	25.0, 100.0	0.0, 100.0	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	82.98 (19.67)	83.91 (18.93)	N/A	-0.76 (1.69)	1.23 (2.01)	N/A
Median	90.00	90.00	N/A	0	0	N/A
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	N/A	-10.00, 5.00	-5.00, 5.00	N/A
Min, Max	15.0, 100.0	25.0, 100.0	N/A	-50.0, 45.0	-35.0, 65.0	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	83.44 (18.87)	82.46 (20.93)	N/A	-0.26 (1.85)	-0.34 (2.00)	N/A
Median	90.00	90.00	N/A	0	0	N/A
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	N/A	-5.00, 5.00	-10.00, 10.00	N/A
Min, Max	25.0, 100.0	15.0, 100.0	N/A	-60.0, 50.0	-40.0, 35.0	N/A

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Hopelessness						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	76.07 (22.93)	74.48 (22.52)	N/A			
Median	83.30	79.15	N/A			
IQR: Q1, Q3	58.30, 100.00	50.00, 100.00	N/A			
Min, Max	8.3, 100.0	33.3, 100.0	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	77.62 (24.03)	76.17 (19.70)	N/A	2.45 (1.95)	2.87 (2.67)	N/A
Median	83.30	75.00	N/A	0	0	N/A
IQR: Q1, Q3	58.30, 100.00	58.30, 91.70	N/A	-8.30, 8.30	-8.30, 16.70	N/A
Min, Max	8.3, 100.0	33.3, 100.0	N/A	-41.7, 50.0	-41.7, 58.4	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	76.04 (21.52)	78.69 (18.79)	N/A	0.65 (2.14)	3.82 (3.21)	N/A
Median	83.30	83.30	N/A	0	8.30	N/A
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	N/A	-8.30, 8.30	-16.60, 25.00	N/A
Min, Max	16.7, 100.0	41.7, 100.0	N/A	-41.7, 41.7	-50.0, 50.0	N/A

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Stigma of Liver Disease						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	84.61 (20.44)	82.25 (20.74)	N/A			
Median	93.80	93.80	N/A			
IQR: Q1, Q3	75.00, 100.00	71.90, 100.00	N/A			
Min, Max	18.8, 100.0	12.5, 100.0	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	86.74 (18.62)	81.76 (19.17)	N/A	2.36 (1.72)	0.51 (1.73)	N/A
Median	93.80	87.50	N/A	0	0	N/A
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	N/A	-6.20, 6.20	-6.20, 6.20	N/A
Min, Max	6.3, 100.0	12.5, 100.0	N/A	-37.5, 50.0	-31.2, 37.5	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	87.67 (18.47)	85.06 (18.68)	N/A	3.41 (1.49)	2.12 (1.89)	N/A
Median	100.00	93.80	N/A	0	0	N/A
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	N/A	0.00, 6.30	-6.20, 6.30	N/A
Min, Max	37.5, 100.0	12.5, 100.0	N/A	-31.3, 37.5	-56.2, 31.3	N/A

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Total LDQOL						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	77.59 (12.87)	77.05 (16.48)	78.48 (13.58)			
Median	78.30	81.30	81.90			
IQR: Q1, Q3	68.80, 88.80	72.30, 90.00	71.90, 88.60			
Min, Max	28.3, 96.7	27.3, 96.3	34.8, 97.8			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	79.41 (12.54)	78.57 (13.80)	79.31 (13.37)	1.96 (0.99)	1.37 (1.01)	0.93 (0.59)
Median	79.90	81.20	82.70	1.40	1.00	0.40
IQR: Q1, Q3	69.30, 90.10	71.45, 89.20	71.00, 89.70	-2.50, 6.20	-4.40, 5.50	-3.30, 4.70
Min, Max	40.6, 97.8	32.4, 96.9	32.4, 98.8	-17.9, 22.3	-12.0, 27.0	-27.6, 42.3
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	79.74 (12.71)	79.13 (15.46)	78.81 (14.31)	2.62 (1.22)	0.72 (1.36)	0.43 (0.64)
Median	82.25	83.30	81.70	1.80	0.25	0.50
IQR: Q1, Q3	70.40, 90.80	70.60, 91.00	71.20, 89.50	-1.40, 8.20	-3.65, 3.50	-4.30, 5.25
Min, Max	44.6, 97.5	33.8, 96.3	20.3, 100.0	-19.3, 25.3	-19.0, 33.9	-46.3, 49.5

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Symptoms of Liver Disease						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	77.47 (19.57)	76.48 (19.10)	77.86 (17.22)			
Median	83.30	83.30	80.00			
IQR: Q1, Q3	70.00, 93.30	66.70, 90.00	66.70, 93.30			
Min, Max	13.3, 100.0	10.0, 100.0	20.0, 100.0			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	78.13 (18.92)	76.22 (17.91)	77.75 (19.04)	-0.29 (1.54)	0.79 (1.82)	0.09 (0.91)
Median	83.30	76.70	83.30	0	0	0
IQR: Q1, Q3	66.70, 93.30	70.00, 90.00	66.70, 93.30	-6.70, 6.70	-10.00, 6.70	-6.70, 6.70
Min, Max	16.7, 100.0	26.7, 100.0	16.7, 100.0	-26.7, 36.7	-36.6, 30.0	-53.3, 43.3
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	78.64 (18.47)	78.56 (19.47)	77.99 (18.98)	0.72 (1.82)	1.32 (1.90)	0.48 (0.87)
Median	83.30	86.70	83.30	3.30	0	0
IQR: Q1, Q3	70.00, 93.30	66.70, 93.30	66.70, 93.30	-6.60, 6.70	-5.00, 8.35	-6.70, 6.70
Min, Max	6.7, 100.0	26.7, 100.0	16.7, 100.0	-43.4, 43.4	-33.3, 36.7	-60.0, 40.0

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Effects of Liver Disease						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	77.71 (11.88)	77.36 (17.36)	78.01 (13.64)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	73.30, 86.70	80.00, 86.70			
Min, Max	6.7, 100.0	13.3, 100.0	26.7, 100.0			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	75.71 (15.50)	78.16 (11.04)	77.81 (14.06)	-1.17 (1.39)	0.83 (2.42)	-0.18 (0.94)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	73.30, 80.00	80.00, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 6.60
Min, Max	0.0, 100.0	40.0, 100.0	6.7, 100.0	-40.0, 20.0	-33.3, 76.7	-46.7, 53.4
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	77.16 (13.74)	76.86 (15.51)	77.57 (13.56)	0.39 (1.27)	-0.83 (2.05)	-0.35 (1.19)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	73.30, 80.00	80.00, 80.00	0.00, 0.00	-6.70, 0.00	-6.70, 6.60
Min, Max	6.7, 100.0	20.0, 100.0	13.3, 100.0	-40.0, 20.0	-33.3, 53.4	-80.0, 66.7

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Concentration/Memory						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	78.90 (24.15)	79.50 (21.69)	78.74 (20.92)			
Median	87.50	87.50	87.50			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	68.80, 93.80			
Min, Max	6.3, 100.0	18.8, 100.0	6.3, 100.0			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	81.26 (21.67)	82.72 (18.23)	80.41 (21.01)	3.06 (1.69)	3.00 (2.21)	1.19 (1.04)
Median	87.50	87.50	87.50	0	0	0
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	68.80, 100.00	0.00, 6.30	-6.20, 6.30	-6.20, 6.30
Min, Max	25.0, 100.0	25.0, 100.0	6.3, 100.0	-31.2, 31.2	-25.0, 56.2	-81.2, 62.5
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	77.80 (20.66)	81.51 (19.56)	78.96 (21.88)	0.49 (2.15)	-0.78 (2.41)	-0.65 (0.96)
Median	81.30	87.50	81.30	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	68.80, 100.00	-6.20, 6.20	-12.50, 6.25	-6.30, 6.30
Min, Max	18.8, 100.0	18.8, 100.0	0.0, 100.0	-43.7, 50.0	-37.5, 50.0	-43.8, 56.3

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Health Distress						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	80.39 (25.12)	84.43 (25.11)	81.53 (23.12)			
Median	87.50	100.00	87.50			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	85.17 (21.71)	88.84 (20.18)	86.23 (20.76)	5.92 (2.39)	4.33 (2.52)	5.14 (1.29)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-37.5, 62.5	-37.5, 50.0	-62.5, 75.0
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	85.19 (22.66)	86.52 (24.09)	86.22 (21.11)	6.62 (3.33)	1.04 (2.46)	4.09 (1.49)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 0.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-37.5, 75.0	-50.0, 50.0	-87.5, 62.5

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Sexual Function						
Baseline						
m	61	57	266			
n	30	29	112			
Mean (SD)	74.84 (31.07)	77.18 (26.31)	78.97 (24.86)			
Median	93.30	86.70	86.70			
IQR: Q1, Q3	55.00, 100.00	55.00, 100.00	68.30, 100.00			
Min, Max	-1.7, 100.0	-1.7, 100.0	-1.7, 100.0			
Week 24						
m	61	57	266			
n	32	34	121	25	26	90
Mean (SD/SE)	81.52 (22.53)	74.40 (28.90)	79.10 (23.64)	10.66 (4.59)	-4.23 (4.19)	0.48 (1.90)
Median	89.20	85.00	85.00	1.70	0	0
IQR: Q1, Q3	76.70, 100.00	55.00, 100.00	68.30, 100.00	0.00, 16.60	-10.00, 0.00	-6.70, 8.30
Min, Max	23.3, 100.0	-1.7, 100.0	-1.7, 100.0	-13.3, 91.1	-55.0, 41.7	-48.4, 50.0
Week 52						
m	59	56	263			
n	22	26	101	20	22	80
Mean (SD/SE)	80.38 (26.15)	81.90 (26.66)	77.46 (25.84)	12.91 (6.67)	0.73 (3.63)	-1.30 (2.33)
Median	92.50	93.30	86.70	0	0	0
IQR: Q1, Q3	63.30, 100.00	76.70, 100.00	60.00, 100.00	-4.15, 25.05	0.00, 6.60	-8.40, 6.70
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-23.3, 91.1	-48.4, 48.3	-53.3, 65.0

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Sleep						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	60.26 (19.27)	58.30 (22.68)	63.62 (19.96)			
Median	62.50	60.00	65.00			
IQR: Q1, Q3	45.00, 75.00	45.00, 75.00	50.00, 80.00			
Min, Max	15.0, 100.0	0.0, 90.0	5.0, 100.0			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	63.22 (21.21)	59.82 (21.87)	63.40 (20.36)	2.98 (1.67)	0.87 (1.78)	0.11 (1.04)
Median	65.00	60.00	65.00	0	0	0
IQR: Q1, Q3	50.00, 80.00	45.00, 77.50	50.00, 80.00	0.00, 10.00	-7.50, 10.00	-10.00, 10.00
Min, Max	10.0, 100.0	0.0, 95.0	15.0, 100.0	-25.0, 45.0	-20.0, 45.0	-40.0, 50.0
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	62.06 (23.95)	60.88 (22.04)	63.77 (20.76)	1.79 (2.19)	1.25 (2.38)	0.91 (1.10)
Median	65.00	65.00	65.00	0	0	0
IQR: Q1, Q3	50.00, 80.00	45.00, 75.00	50.00, 80.00	-10.00, 10.00	-7.50, 10.00	-10.00, 10.00
Min, Max	10.0, 100.0	0.0, 95.0	5.0, 100.0	-30.0, 45.0	-55.0, 45.0	-40.0, 55.0

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Loneliness						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	86.21 (17.38)	83.02 (19.69)	84.44 (19.06)			
Median	95.00	90.00	95.00			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	45.0, 100.0	15.0, 100.0	5.0, 100.0			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	85.89 (16.38)	84.64 (20.60)	83.62 (19.76)	-0.83 (2.16)	0.67 (1.57)	-1.29 (0.99)
Median	95.00	95.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	77.50, 100.00	75.00, 100.00	-7.50, 5.00	-5.00, 10.00	-10.00, 5.00
Min, Max	37.5, 100.0	0.0, 100.0	10.0, 100.0	-45.0, 40.0	-25.0, 20.0	-45.0, 70.0
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	87.78 (15.01)	84.41 (21.35)	84.21 (18.83)	1.27 (2.16)	0.52 (2.22)	0.01 (1.08)
Median	95.00	95.00	90.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	80.00, 100.00	75.00, 100.00	-5.00, 5.00	-5.00, 10.00	-5.00, 5.00
Min, Max	40.0, 100.0	0.0, 100.0	5.0, 100.0	-55.0, 35.0	-40.0, 30.0	-40.0, 70.0

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Hopelessness						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	78.74 (20.24)	79.24 (22.63)	80.16 (20.77)			
Median	83.30	83.30	83.30			
IQR: Q1, Q3	66.70, 100.00	58.30, 100.00	66.70, 100.00			
Min, Max	33.3, 100.0	25.0, 100.0	25.0, 100.0			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	79.52 (20.20)	79.32 (24.52)	80.32 (20.51)	0.87 (2.32)	0.64 (2.33)	0.45 (1.17)
Median	83.30	91.70	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	62.50, 100.00	66.70, 100.00	-8.40, 8.40	-8.30, 8.35	-8.30, 8.30
Min, Max	33.3, 100.0	8.3, 100.0	25.0, 100.0	-33.4, 33.3	-41.7, 58.3	-58.3, 50.0
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	82.26 (20.73)	79.42 (22.93)	78.48 (22.38)	3.27 (2.72)	-1.21 (2.54)	-1.25 (1.27)
Median	91.70	91.70	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	66.70, 100.00	58.30, 100.00	-8.30, 16.70	-8.30, 12.50	-8.30, 8.30
Min, Max	33.3, 100.0	16.7, 100.0	0.0, 100.0	-50.0, 41.7	-58.3, 41.6	-100.0, 41.7

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Stigma of Liver Disease						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	83.20 (20.91)	79.38 (18.89)	84.20 (18.82)			
Median	90.65	81.30	87.50			
IQR: Q1, Q3	75.00, 100.00	68.80, 93.80	75.00, 100.00			
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	85.71 (18.20)	81.61 (17.49)	85.82 (17.91)	2.41 (2.42)	2.53 (2.23)	1.65 (1.05)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	75.00, 100.00	71.90, 100.00	81.30, 100.00	0.00, 6.30	-6.25, 12.50	-6.20, 6.30
Min, Max	37.5, 100.0	25.0, 100.0	6.3, 100.0	-43.7, 56.2	-25.0, 56.3	-50.0, 75.0
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	86.36 (16.77)	84.79 (16.20)	85.15 (18.66)	3.93 (2.11)	4.00 (2.49)	1.46 (1.10)
Median	93.80	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	75.00, 100.00	0.00, 6.30	-6.20, 12.50	-6.20, 6.30
Min, Max	31.3, 100.0	37.5, 100.0	18.8, 100.0	-25.0, 56.2	-25.0, 56.3	-62.5, 62.5

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by SHBG at Week 52
(Label Population)

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.12.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Total LDQOL			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	79.27 (13.82)	76.47 (13.88)	N/A
Analysis Visit Mean (SD)	79.00 (15.15)	76.88 (11.44)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	79.12 (14.37)	76.85 (13.99)	N/A
Analysis Visit Mean (SD)	79.05 (13.79)	77.58 (12.63)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Total LDQOL			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	77.69 (12.96)	77.13 (16.63)	78.69 (13.51)
Analysis Visit Mean (SD)	79.66 (11.82)	78.50 (14.09)	79.62 (13.38)
LS Mean of Change from Baseline (SE)	1.94 (1.05)	1.20 (1.10)	1.19 (0.54)
95% CI	(-0.12, 4.01)	(-0.96, 3.35)	(0.13, 2.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.75 (1.16)	0.00 (1.20)	
95% CI	(-1.53, 3.03)	(-2.36, 2.37)	
p-value	0.5181	0.9967	
Corrected Hedge's g Statistics	0.092	0.001	
95% CI	(-0.20, 0.38)	(-0.30, 0.30)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	77.11 (13.24)	77.67 (16.58)	78.47 (13.64)
Analysis Visit Mean (SD)	79.73 (12.15)	78.38 (15.59)	78.90 (14.55)
LS Mean of Change from Baseline (SE)	2.43 (1.26)	0.64 (1.30)	0.67 (0.63)
95% CI	(-0.04, 4.91)	(-1.91, 3.19)	(-0.56, 1.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.77 (1.39)	-0.03 (1.43)	
95% CI	(-0.96, 4.49)	(-2.83, 2.78)	
p-value	0.2036	0.9839	
Corrected Hedge's g Statistics	0.191	-0.003	
95% CI	(-0.11, 0.50)	(-0.32, 0.31)	
Subgroup*Treatment Interaction p-value	NE	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Symptoms of Liver Disease			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	79.45 (17.56)	74.37 (19.32)	N/A
Analysis Visit Mean (SD)	77.18 (20.13)	72.90 (18.29)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	80.52 (17.47)	73.90 (19.31)	N/A
Analysis Visit Mean (SD)	76.92 (19.66)	74.52 (17.69)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Effects of Liver Disease			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	79.53 (13.17)	78.80 (14.43)	N/A
Analysis Visit Mean (SD)	76.94 (13.90)	80.22 (9.27)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	79.22 (13.59)	78.65 (14.16)	N/A
Analysis Visit Mean (SD)	76.75 (12.77)	78.59 (9.61)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Concentration/Memory			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	82.96 (20.95)	79.42 (20.09)	N/A
Analysis Visit Mean (SD)	79.43 (20.81)	77.27 (20.38)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	81.75 (21.42)	78.73 (20.06)	N/A
Analysis Visit Mean (SD)	80.29 (20.05)	77.46 (21.33)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Health Distress			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	79.56 (24.16)	79.10 (25.28)	N/A
Analysis Visit Mean (SD)	84.41 (23.14)	86.89 (18.88)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	78.57 (24.91)	79.45 (25.51)	N/A
Analysis Visit Mean (SD)	81.49 (25.30)	87.92 (18.42)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Sexual Function			
Week 24			
m	91	67	0
n	27	28	0
Baseline Mean (SD)	86.23 (21.24)	83.80 (18.41)	N/A
Analysis Visit Mean (SD)	79.45 (27.14)	78.04 (24.33)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	26	24	0
Baseline Mean (SD)	89.80 (17.62)	84.08 (22.50)	N/A
Analysis Visit Mean (SD)	87.37 (17.84)	79.16 (28.19)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Sleep			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	66.00 (20.28)	61.39 (18.15)	N/A
Analysis Visit Mean (SD)	65.24 (19.91)	57.70 (19.48)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	66.49 (21.06)	61.95 (18.66)	N/A
Analysis Visit Mean (SD)	66.04 (15.67)	58.90 (20.95)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Loneliness			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	84.29 (18.49)	82.13 (21.61)	N/A
Analysis Visit Mean (SD)	83.53 (19.48)	83.36 (19.21)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	84.03 (19.23)	82.46 (21.46)	N/A
Analysis Visit Mean (SD)	83.77 (18.73)	82.12 (21.16)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Hopelessness			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	75.98 (23.06)	73.36 (22.46)	N/A
Analysis Visit Mean (SD)	78.43 (23.76)	76.23 (19.95)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	75.65 (23.33)	74.43 (22.48)	N/A
Analysis Visit Mean (SD)	76.30 (21.46)	78.25 (18.89)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Stigma of Liver Disease			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	84.43 (20.49)	81.37 (20.86)	N/A
Analysis Visit Mean (SD)	86.78 (18.50)	81.89 (19.62)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	84.75 (20.46)	83.07 (21.24)	N/A
Analysis Visit Mean (SD)	88.16 (18.20)	85.19 (18.99)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Symptoms of Liver Disease			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	77.83 (19.55)	76.16 (19.14)	78.04 (17.47)
Analysis Visit Mean (SD)	77.54 (18.95)	76.95 (16.54)	78.13 (18.93)
LS Mean of Change from Baseline (SE)	0.01 (1.68)	0.68 (1.75)	0.38 (0.86)
95% CI	(-3.30, 3.32)	(-2.77, 4.13)	(-1.32, 2.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.37 (1.86)	0.30 (1.93)	
95% CI	(-4.03, 3.28)	(-3.50, 4.10)	
p-value	0.8407	0.8758	
Corrected Hedge's g Statistics	-0.029	0.023	
95% CI	(-0.32, 0.26)	(-0.28, 0.32)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	76.86 (19.58)	77.23 (17.02)	77.66 (17.26)
Analysis Visit Mean (SD)	77.58 (18.45)	78.54 (18.84)	78.14 (18.82)
LS Mean of Change from Baseline (SE)	0.36 (1.76)	1.15 (1.82)	1.00 (0.88)
95% CI	(-3.11, 3.82)	(-2.42, 4.72)	(-0.73, 2.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.64 (1.94)	0.15 (1.99)	
95% CI	(-4.45, 3.17)	(-3.77, 4.07)	
p-value	0.7407	0.9408	
Corrected Hedge's g Statistics	-0.049	0.011	
95% CI	(-0.35, 0.26)	(-0.30, 0.32)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Effects of Liver Disease			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	77.66 (11.98)	77.31 (17.53)	78.19 (13.42)
Analysis Visit Mean (SD)	76.49 (14.32)	78.14 (11.29)	78.01 (13.90)
LS Mean of Change from Baseline (SE)	-1.28 (1.62)	0.54 (1.68)	0.11 (0.83)
95% CI	(-4.46, 1.89)	(-2.78, 3.85)	(-1.52, 1.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.39 (1.79)	0.43 (1.85)	
95% CI	(-4.91, 2.12)	(-3.22, 4.07)	
p-value	0.4356	0.8184	
Corrected Hedge's g Statistics	-0.111	0.034	
95% CI	(-0.40, 0.18)	(-0.27, 0.33)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	77.00 (12.17)	77.50 (17.70)	78.07 (13.50)
Analysis Visit Mean (SD)	77.38 (13.92)	76.67 (15.97)	77.71 (13.72)
LS Mean of Change from Baseline (SE)	-0.20 (1.85)	-1.02 (1.91)	-0.20 (0.92)
95% CI	(-3.85, 3.44)	(-4.77, 2.73)	(-2.01, 1.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (2.04)	-0.82 (2.10)	
95% CI	(-4.02, 4.01)	(-4.94, 3.31)	
p-value	0.9989	0.6968	
Corrected Hedge's g Statistics	0.000	-0.060	
95% CI	(-0.30, 0.30)	(-0.37, 0.25)	
Subgroup*Treatment Interaction p-value	NE	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Concentration/Memory			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	78.75 (24.34)	79.59 (21.89)	79.19 (20.89)
Analysis Visit Mean (SD)	81.81 (20.87)	82.59 (18.41)	80.38 (21.31)
LS Mean of Change from Baseline (SE)	3.13 (1.88)	3.06 (1.96)	1.27 (0.96)
95% CI	(-0.56, 6.83)	(-0.79, 6.92)	(-0.63, 3.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.87 (2.08)	1.80 (2.16)	
95% CI	(-2.22, 5.95)	(-2.44, 6.04)	
p-value	0.3694	0.4053	
Corrected Hedge's g Statistics	0.128	0.123	
95% CI	(-0.16, 0.42)	(-0.18, 0.42)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	77.35 (24.81)	81.40 (19.74)	79.37 (20.56)
Analysis Visit Mean (SD)	77.84 (20.12)	80.62 (19.77)	78.71 (22.28)
LS Mean of Change from Baseline (SE)	-0.31 (1.99)	0.09 (2.05)	-0.27 (0.99)
95% CI	(-4.22, 3.60)	(-3.94, 4.12)	(-2.23, 1.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (2.19)	0.37 (2.25)	
95% CI	(-4.34, 4.27)	(-4.06, 4.79)	
p-value	0.9874	0.8705	
Corrected Hedge's g Statistics	-0.002	0.025	
95% CI	(-0.31, 0.30)	(-0.29, 0.34)	
Subgroup*Treatment Interaction p-value	NE	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Health Distress			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	80.48 (25.33)	84.13 (25.26)	81.17 (23.22)
Analysis Visit Mean (SD)	86.40 (18.79)	88.46 (20.69)	86.31 (21.11)
LS Mean of Change from Baseline (SE)	5.48 (2.13)	5.59 (2.22)	5.06 (1.10)
95% CI	(1.28, 9.68)	(1.22, 9.97)	(2.90, 7.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.42 (2.36)	0.53 (2.45)	
95% CI	(-4.21, 5.05)	(-4.28, 5.35)	
p-value	0.8581	0.8278	
Corrected Hedge's g Statistics	0.025	0.032	
95% CI	(-0.26, 0.32)	(-0.27, 0.33)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	79.66 (25.86)	84.90 (26.16)	81.88 (23.60)
Analysis Visit Mean (SD)	86.27 (19.73)	85.94 (24.68)	85.97 (21.46)
LS Mean of Change from Baseline (SE)	5.36 (2.51)	2.98 (2.59)	4.20 (1.25)
95% CI	(0.43, 10.29)	(-2.11, 8.07)	(1.75, 6.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.15 (2.76)	-1.22 (2.84)	
95% CI	(-4.28, 6.59)	(-6.81, 4.37)	
p-value	0.6762	0.6670	
Corrected Hedge's g Statistics	0.063	-0.066	
95% CI	(-0.24, 0.37)	(-0.38, 0.25)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Sexual Function			
Week 24			
m	61	57	266
n	25	26	90
Baseline Mean (SD)	73.08 (32.16)	81.02 (24.93)	81.44 (22.03)
Analysis Visit Mean (SD)	83.74 (22.67)	76.78 (28.03)	81.93 (21.68)
LS Mean of Change from Baseline (SE)	9.89 (3.46)	-3.89 (3.38)	1.47 (1.90)
95% CI	(3.05, 16.73)	(-10.56, 2.78)	(-2.29, 5.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.42 (3.89)	-5.36 (3.81)	
95% CI	(0.74, 16.10)	(-12.89, 2.18)	
p-value	0.0318	0.1622	
Corrected Hedge's g Statistics	0.468	-0.298	
95% CI	(0.02, 0.92)	(-0.74, 0.14)	
Week 52			
m	59	56	263
n	20	22	80
Baseline Mean (SD)	70.93 (34.72)	79.31 (21.87)	79.97 (23.87)
Analysis Visit Mean (SD)	83.84 (24.32)	80.05 (28.47)	78.67 (25.10)
LS Mean of Change from Baseline (SE)	11.70 (4.20)	0.42 (4.02)	-0.79 (2.20)
95% CI	(3.40, 20.00)	(-7.53, 8.38)	(-5.13, 3.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.49 (4.68)	1.21 (4.54)	
95% CI	(3.25, 21.73)	(-7.75, 10.17)	
p-value	0.0084	0.7894	
Corrected Hedge's g Statistics	0.636	0.062	
95% CI	(0.14, 1.13)	(-0.41, 0.53)	
Subgroup*Treatment Interaction p-value	NE	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Sleep			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	60.61 (19.25)	58.56 (22.82)	63.91 (20.06)
Analysis Visit Mean (SD)	63.60 (19.93)	59.42 (22.20)	64.03 (20.24)
LS Mean of Change from Baseline (SE)	2.15 (1.86)	-0.30 (1.95)	0.32 (0.96)
95% CI	(-1.52, 5.82)	(-4.12, 3.53)	(-1.57, 2.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.83 (2.06)	-0.62 (2.14)	
95% CI	(-2.22, 5.88)	(-4.83, 3.60)	
p-value	0.3748	0.7741	
Corrected Hedge's g Statistics	0.126	-0.042	
95% CI	(-0.16, 0.42)	(-0.34, 0.26)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	60.29 (19.58)	58.44 (23.23)	63.31 (20.18)
Analysis Visit Mean (SD)	62.08 (22.93)	59.69 (22.11)	64.23 (20.94)
LS Mean of Change from Baseline (SE)	1.59 (2.11)	-0.34 (2.18)	1.11 (1.05)
95% CI	(-2.56, 5.75)	(-4.63, 3.95)	(-0.96, 3.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.48 (2.33)	-1.45 (2.40)	
95% CI	(-4.09, 5.06)	(-6.17, 3.27)	
p-value	0.8355	0.5464	
Corrected Hedge's g Statistics	0.031	-0.093	
95% CI	(-0.27, 0.34)	(-0.41, 0.22)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Loneliness			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	86.23 (17.53)	83.75 (19.15)	84.77 (19.17)
Analysis Visit Mean (SD)	85.39 (16.45)	84.42 (21.04)	83.48 (20.01)
LS Mean of Change from Baseline (SE)	-0.48 (1.86)	0.41 (1.93)	-1.36 (0.95)
95% CI	(-4.13, 3.18)	(-3.40, 4.21)	(-3.23, 0.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.88 (2.05)	1.77 (2.13)	
95% CI	(-3.15, 4.92)	(-2.42, 5.95)	
p-value	0.6666	0.4073	
Corrected Hedge's g Statistics	0.061	0.123	
95% CI	(-0.23, 0.35)	(-0.18, 0.42)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	85.88 (17.74)	83.13 (20.28)	84.28 (19.23)
Analysis Visit Mean (SD)	87.16 (15.21)	83.65 (21.75)	84.30 (19.14)
LS Mean of Change from Baseline (SE)	1.63 (2.01)	-0.24 (2.07)	-0.41 (1.00)
95% CI	(-2.33, 5.58)	(-4.32, 3.83)	(-2.38, 1.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.04 (2.21)	0.16 (2.28)	
95% CI	(-2.32, 6.39)	(-4.31, 4.64)	
p-value	0.3586	0.9426	
Corrected Hedge's g Statistics	0.137	0.011	
95% CI	(-0.17, 0.44)	(-0.30, 0.32)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Hopelessness			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	78.81 (20.42)	78.84 (22.66)	80.56 (20.63)
Analysis Visit Mean (SD)	79.68 (19.99)	79.49 (24.84)	81.01 (20.07)
LS Mean of Change from Baseline (SE)	0.36 (2.13)	0.12 (2.22)	0.66 (1.10)
95% CI	(-3.83, 4.56)	(-4.25, 4.49)	(-1.50, 2.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.30 (2.36)	-0.54 (2.45)	
95% CI	(-4.93, 4.34)	(-5.35, 4.27)	
p-value	0.9002	0.8255	
Corrected Hedge's g Statistics	-0.018	-0.033	
95% CI	(-0.31, 0.27)	(-0.33, 0.27)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	79.42 (19.89)	79.51 (23.76)	80.00 (21.02)
Analysis Visit Mean (SD)	82.68 (20.40)	78.31 (23.17)	78.75 (22.52)
LS Mean of Change from Baseline (SE)	3.44 (2.43)	-1.11 (2.51)	-1.12 (1.21)
95% CI	(-1.35, 8.22)	(-6.04, 3.82)	(-3.50, 1.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.56 (2.68)	0.01 (2.76)	
95% CI	(-0.72, 9.83)	(-5.41, 5.43)	
p-value	0.0903	0.9967	
Corrected Hedge's g Statistics	0.255	0.001	
95% CI	(-0.05, 0.56)	(-0.31, 0.31)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Stigma of Liver Disease			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	83.35 (21.07)	79.35 (19.07)	84.48 (18.58)
Analysis Visit Mean (SD)	85.76 (18.29)	81.87 (17.94)	86.13 (17.97)
LS Mean of Change from Baseline (SE)	2.59 (1.90)	1.09 (1.99)	2.36 (0.98)
95% CI	(-1.16, 6.33)	(-2.82, 5.01)	(0.44, 4.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.23 (2.10)	-1.26 (2.19)	
95% CI	(-3.91, 4.37)	(-5.58, 3.05)	
p-value	0.9127	0.5652	
Corrected Hedge's g Statistics	0.016	-0.085	
95% CI	(-0.27, 0.31)	(-0.39, 0.22)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	82.37 (21.27)	79.84 (18.96)	83.76 (18.88)
Analysis Visit Mean (SD)	86.29 (16.71)	83.84 (16.24)	85.22 (18.90)
LS Mean of Change from Baseline (SE)	3.73 (1.99)	2.54 (2.05)	1.90 (0.99)
95% CI	(-0.18, 7.64)	(-1.50, 6.58)	(-0.05, 3.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.83 (2.19)	0.64 (2.26)	
95% CI	(-2.48, 6.14)	(-3.80, 5.08)	
p-value	0.4044	0.7767	
Corrected Hedge's g Statistics	0.125	0.044	
95% CI	(-0.18, 0.43)	(-0.27, 0.36)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

Abbreviations: CFB = Change from Baseline; LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.2)	2 (3.0)	0
No	89 (97.8)	65 (97.0)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (23.1)	21 (31.3)	0
No	70 (76.9)	46 (68.7)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (3.3)	12 (17.9)	0
No	88 (96.7)	55 (82.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (20.9)	21 (31.3)	0
No	72 (79.1)	46 (68.7)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.2)	6 (9.0)	0
No	89 (97.8)	61 (91.0)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (17.6)	18 (26.9)	0
No	75 (82.4)	49 (73.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (9.9)	4 (6.0)	0
No	82 (90.1)	63 (94.0)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (20.9)	18 (26.9)	0
No	72 (79.1)	49 (73.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (16.5)	18 (26.9)	0
No	76 (83.5)	49 (73.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (26.4)	24 (35.8)	0
No	67 (73.6)	43 (64.2)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.1)	3 (4.5)	0
No	90 (98.9)	64 (95.5)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (4.4)	7 (10.4)	0
No	87 (95.6)	60 (89.6)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (14.3)	12 (17.9)	0
No	78 (85.7)	55 (82.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (28.6)	20 (29.9)	0
No	65 (71.4)	47 (70.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (11.0)	12 (17.9)	0
No	81 (89.0)	55 (82.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (25.3)	20 (29.9)	0
No	68 (74.7)	47 (70.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (17.6)	22 (32.8)	0
No	75 (82.4)	45 (67.2)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (29.7)	30 (44.8)	0
No	64 (70.3)	37 (55.2)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (13.2)	10 (14.9)	0
No	79 (86.8)	57 (85.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (33.0)	21 (31.3)	0
No	61 (67.0)	46 (68.7)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.9)	2 (3.5)	9 (3.4)
No	58 (95.1)	55 (96.5)	257 (96.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.96	
95% CI of the inverse odds ratio	(0.18, 2.58)	(0.20, 4.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.96	
95% CI of the inverse risk ratio	(0.19, 2.47)	(0.21, 4.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.53	0.13	
95% CI of the absolute risk difference	(-4.31, 7.38)	(-5.12, 5.37)	
p-value	0.5653	0.9622	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (26.2)	11 (19.3)	57 (21.4)
No	45 (73.8)	46 (80.7)	209 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.14	
95% CI of the inverse odds ratio	(0.40, 1.46)	(0.56, 2.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.11	
95% CI of the inverse risk ratio	(0.51, 1.32)	(0.62, 1.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.80	-2.13	
95% CI of the absolute risk difference	(-7.29, 16.89)	(-13.50, 9.24)	
p-value	0.4167	0.7203	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.9)	4 (7.0)	26 (9.8)
No	58 (95.1)	53 (93.0)	240 (90.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.09	1.44	
95% CI of the inverse odds ratio	(0.61, 7.16)	(0.48, 4.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.99	1.39	
95% CI of the inverse risk ratio	(0.62, 6.35)	(0.51, 3.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.86	-2.76	
95% CI of the absolute risk difference	(-11.35, 1.64)	(-10.29, 4.77)	
p-value	0.2288	0.5152	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (27.9)	18 (31.6)	74 (27.8)
No	44 (72.1)	39 (68.4)	192 (72.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.84	
95% CI of the inverse odds ratio	(0.54, 1.86)	(0.45, 1.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.88	
95% CI of the inverse risk ratio	(0.64, 1.56)	(0.57, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.05	3.76	
95% CI of the absolute risk difference	(-12.42, 12.52)	(-9.45, 16.97)	
p-value	0.9938	0.5682	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.9)	4 (7.0)	26 (9.8)
No	58 (95.1)	53 (93.0)	240 (90.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.09	1.44	
95% CI of the inverse odds ratio	(0.61, 7.16)	(0.48, 4.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.99	1.39	
95% CI of the inverse risk ratio	(0.62, 6.35)	(0.51, 3.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.86	-2.76	
95% CI of the absolute risk difference	(-11.35, 1.64)	(-10.29, 4.77)	
p-value	0.2288	0.5152	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (16.4)	9 (15.8)	56 (21.1)
No	51 (83.6)	48 (84.2)	210 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	1.42	
95% CI of the inverse odds ratio	(0.65, 2.85)	(0.66, 3.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	1.33	
95% CI of the inverse risk ratio	(0.70, 2.37)	(0.70, 2.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.66	-5.26	
95% CI of the absolute risk difference	(-15.16, 5.84)	(-15.92, 5.40)	
p-value	0.4135	0.3684	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (9.8)	5 (8.8)	19 (7.1)
No	55 (90.2)	52 (91.2)	247 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.80	
95% CI of the inverse odds ratio	(0.27, 1.85)	(0.29, 2.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.81	
95% CI of the inverse risk ratio	(0.30, 1.74)	(0.32, 2.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.69	1.63	
95% CI of the absolute risk difference	(-5.40, 10.78)	(-6.34, 9.60)	
p-value	0.4752	0.6704	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (27.9)	18 (31.6)	65 (24.4)
No	44 (72.1)	39 (68.4)	201 (75.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.70	
95% CI of the inverse odds ratio	(0.45, 1.56)	(0.38, 1.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.77	
95% CI of the inverse risk ratio	(0.56, 1.38)	(0.50, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.43	7.14	
95% CI of the absolute risk difference	(-8.95, 15.81)	(-5.98, 20.27)	
p-value	0.5769	0.2627	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (19.7)	7 (12.3)	43 (16.2)
No	49 (80.3)	50 (87.7)	223 (83.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	1.38	
95% CI of the inverse odds ratio	(0.39, 1.60)	(0.59, 3.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.32	
95% CI of the inverse risk ratio	(0.46, 1.46)	(0.62, 2.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.51	-3.88	
95% CI of the absolute risk difference	(-7.41, 14.42)	(-13.49, 5.72)	
p-value	0.5090	0.4618	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (24.6)	10 (17.5)	69 (25.9)
No	46 (75.4)	47 (82.5)	197 (74.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.65	
95% CI of the inverse odds ratio	(0.56, 2.05)	(0.79, 3.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.48	
95% CI of the inverse risk ratio	(0.65, 1.71)	(0.81, 2.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.35	-8.40	
95% CI of the absolute risk difference	(-13.37, 10.67)	(-19.59, 2.79)	
p-value	0.8277	0.1808	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (8.2)	3 (5.3)	13 (4.9)
No	56 (91.8)	54 (94.7)	253 (95.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.92	
95% CI of the inverse odds ratio	(0.20, 1.68)	(0.25, 3.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.93	
95% CI of the inverse risk ratio	(0.22, 1.61)	(0.27, 3.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.31	0.38	
95% CI of the absolute risk difference	(-4.05, 10.66)	(-5.97, 6.73)	
p-value	0.3067	0.9055	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (14.8)	6 (10.5)	25 (9.4)
No	52 (85.2)	51 (89.5)	241 (90.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.88	
95% CI of the inverse odds ratio	(0.26, 1.36)	(0.34, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.89	
95% CI of the inverse risk ratio	(0.31, 1.29)	(0.38, 2.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.36	1.13	
95% CI of the absolute risk difference	(-4.21, 14.92)	(-7.58, 9.83)	
p-value	0.2165	0.7931	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (19.7)	8 (14.0)	48 (18.0)
No	49 (80.3)	49 (86.0)	218 (82.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.35	
95% CI of the inverse odds ratio	(0.44, 1.82)	(0.60, 3.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.29	
95% CI of the inverse risk ratio	(0.52, 1.62)	(0.64, 2.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.63	-4.01	
95% CI of the absolute risk difference	(-9.37, 12.62)	(-14.14, 6.12)	
p-value	0.7672	0.4680	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (36.1)	23 (40.4)	97 (36.5)
No	39 (63.9)	34 (59.6)	169 (63.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.85	
95% CI of the inverse odds ratio	(0.57, 1.82)	(0.47, 1.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.90	
95% CI of the inverse risk ratio	(0.70, 1.46)	(0.63, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.40	3.88	
95% CI of the absolute risk difference	(-13.77, 12.97)	(-10.10, 17.87)	
p-value	0.9532	0.5818	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (16.4)	11 (19.3)	32 (12.0)
No	51 (83.6)	46 (80.7)	234 (88.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	0.57	
95% CI of the inverse odds ratio	(0.32, 1.51)	(0.27, 1.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.62	
95% CI of the inverse risk ratio	(0.38, 1.41)	(0.33, 1.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.36	7.27	
95% CI of the absolute risk difference	(-5.72, 14.44)	(-3.70, 18.23)	
p-value	0.3583	0.1427	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (27.9)	17 (29.8)	82 (30.8)
No	44 (72.1)	40 (70.2)	184 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.05	
95% CI of the inverse odds ratio	(0.62, 2.14)	(0.56, 1.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.03	
95% CI of the inverse risk ratio	(0.71, 1.72)	(0.67, 1.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.96	-1.00	
95% CI of the absolute risk difference	(-15.50, 9.59)	(-14.11, 12.11)	
p-value	0.6502	0.8816	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (23.0)	12 (21.1)	41 (15.4)
No	47 (77.0)	45 (78.9)	225 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	0.68	
95% CI of the inverse odds ratio	(0.31, 1.21)	(0.33, 1.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.73	
95% CI of the inverse risk ratio	(0.39, 1.15)	(0.41, 1.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.54	5.64	
95% CI of the absolute risk difference	(-3.87, 18.95)	(-5.80, 17.08)	
p-value	0.1558	0.2969	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (32.8)	14 (24.6)	69 (25.9)
No	41 (67.2)	43 (75.4)	197 (74.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	1.08	
95% CI of the inverse odds ratio	(0.39, 1.31)	(0.55, 2.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	1.06	
95% CI of the inverse risk ratio	(0.52, 1.20)	(0.64, 1.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.85	-1.38	
95% CI of the absolute risk difference	(-6.06, 19.75)	(-13.73, 10.98)	
p-value	0.2785	0.8289	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE21.12.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (13.1)	8 (14.0)	32 (12.0)
No	53 (86.9)	49 (86.0)	234 (88.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.84	
95% CI of the inverse odds ratio	(0.39, 2.08)	(0.36, 1.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.86	
95% CI of the inverse risk ratio	(0.45, 1.89)	(0.42, 1.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.08	2.01	
95% CI of the absolute risk difference	(-8.24, 10.41)	(-7.82, 11.83)	
p-value	0.8156	0.6767	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (32.8)	22 (38.6)	79 (29.7)
No	41 (67.2)	35 (61.4)	187 (70.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.67	
95% CI of the inverse odds ratio	(0.48, 1.57)	(0.37, 1.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.77	
95% CI of the inverse risk ratio	(0.60, 1.36)	(0.53, 1.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.09	8.90	
95% CI of the absolute risk difference	(-9.91, 16.08)	(-4.88, 22.68)	
p-value	0.6359	0.1885	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Total LDQOL						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	76.71 (14.95)	75.60 (15.93)	77.50 (14.89)			
Median	78.40	79.00	82.40			
IQR: Q1, Q3	69.75, 88.35	66.30, 87.30	75.40, 87.70			
Min, Max	28.3, 96.4	23.6, 95.4	38.7, 93.8			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	77.92 (16.23)	76.53 (13.46)	78.32 (13.08)	1.34 (0.95)	0.53 (1.04)	-0.52 (1.34)
Median	82.30	78.70	83.15	1.30	-0.30	0.40
IQR: Q1, Q3	69.30, 90.40	69.50, 86.50	67.80, 87.25	-4.45, 6.60	-5.55, 5.35	-2.10, 1.60
Min, Max	22.9, 97.8	32.4, 96.9	32.4, 91.8	-17.9, 24.2	-15.4, 26.0	-20.6, 15.5
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	78.69 (14.34)	76.73 (14.50)	77.82 (15.77)	1.55 (1.16)	0.09 (1.15)	1.34 (1.47)
Median	83.90	79.80	84.60	0.50	0.75	0.60
IQR: Q1, Q3	69.80, 89.70	66.20, 88.50	68.50, 89.30	-4.50, 6.40	-4.95, 5.40	-4.60, 7.60
Min, Max	34.0, 96.9	34.2, 97.4	34.3, 97.2	-18.9, 36.0	-23.3, 18.3	-11.3, 14.4

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Symptoms of Liver Disease						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	75.83 (20.66)	73.38 (20.47)	74.94 (19.85)			
Median	80.00	80.00	76.70			
IQR: Q1, Q3	66.70, 93.30	60.00, 88.35	63.30, 93.30			
Min, Max	13.3, 100.0	10.0, 100.0	33.3, 100.0			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	75.42 (22.89)	74.14 (18.70)	77.26 (19.18)	-0.55 (1.87)	0.94 (1.48)	0.62 (2.34)
Median	83.30	76.70	83.30	0	0	0
IQR: Q1, Q3	66.70, 93.30	66.70, 90.00	68.35, 91.65	-10.00, 6.70	-6.70, 6.70	-6.70, 6.70
Min, Max	0.0, 100.0	26.7, 100.0	26.7, 100.0	-46.7, 36.7	-23.3, 30.0	-26.6, 33.3
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	75.24 (21.42)	75.35 (18.99)	75.21 (17.60)	-1.99 (1.77)	1.89 (1.74)	0.73 (2.43)
Median	83.30	80.00	83.30	0	0	3.30
IQR: Q1, Q3	66.70, 93.30	63.30, 90.00	63.30, 90.00	-10.00, 6.70	-6.70, 10.00	-6.70, 6.70
Min, Max	6.7, 100.0	26.7, 100.0	40.0, 96.7	-43.4, 43.4	-33.3, 36.7	-30.0, 26.6

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Effects of Liver Disease						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	77.69 (14.89)	78.34 (16.26)	78.40 (12.43)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	73.30, 86.70	73.30, 86.70			
Min, Max	6.7, 100.0	26.7, 100.0	46.7, 100.0			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	74.85 (16.72)	80.10 (11.36)	78.09 (12.94)	-2.87 (1.21)	1.56 (2.14)	-2.23 (2.80)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	73.30, 86.70	73.30, 86.70	-6.70, 0.00	-6.70, 6.70	-6.70, 6.70
Min, Max	0.0, 100.0	40.0, 100.0	40.0, 100.0	-40.0, 20.0	-33.3, 60.0	-46.7, 20.0
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	76.38 (14.78)	78.04 (11.29)	78.83 (12.66)	-0.70 (1.91)	-0.95 (1.83)	0.28 (3.12)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	73.30, 80.00	73.30, 80.00	-6.70, 0.00	-6.70, 0.00	-6.70, 6.70
Min, Max	6.7, 100.0	33.3, 100.0	40.0, 100.0	-40.0, 80.0	-33.3, 40.0	-46.7, 26.7

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Concentration/Memory						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	80.84 (22.67)	75.94 (21.84)	79.76 (22.50)			
Median	87.50	81.30	87.50			
IQR: Q1, Q3	75.00, 100.00	62.50, 93.80	62.50, 100.00			
Min, Max	6.3, 100.0	18.8, 100.0	31.3, 100.0			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	79.60 (21.04)	74.84 (21.78)	79.48 (22.29)	-1.04 (1.76)	-1.86 (1.87)	-1.86 (1.73)
Median	87.50	75.00	87.50	0	0	0
IQR: Q1, Q3	68.80, 100.00	62.50, 93.80	65.65, 100.00	-6.20, 6.20	-12.50, 6.25	-6.20, 0.00
Min, Max	25.0, 100.0	25.0, 100.0	31.3, 100.0	-43.8, 31.2	-37.5, 56.2	-25.0, 12.5
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	79.22 (20.18)	76.61 (21.41)	76.10 (28.49)	-1.87 (1.61)	-1.98 (1.65)	-2.45 (1.70)
Median	81.30	81.30	87.50	0	0	0
IQR: Q1, Q3	68.80, 93.80	62.50, 93.80	56.30, 100.00	-6.30, 0.00	-6.30, 6.30	-6.30, 0.00
Min, Max	0.0, 100.0	18.8, 100.0	12.5, 100.0	-25.0, 50.0	-37.5, 18.8	-18.8, 12.5

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Health Distress						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	75.69 (27.10)	79.78 (26.63)	79.74 (19.60)			
Median	75.00	100.00	75.00			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	25.0, 100.0			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	83.83 (22.11)	87.85 (20.81)	85.71 (20.89)	8.51 (2.39)	7.42 (2.44)	4.63 (2.42)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 18.75	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	12.5, 100.0	-37.5, 75.0	-37.5, 50.0	-12.5, 25.0
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	81.07 (24.52)	86.90 (20.87)	84.78 (19.93)	4.85 (3.07)	6.88 (2.66)	4.89 (3.02)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	25.0, 100.0	-75.0, 75.0	-37.5, 75.0	-37.5, 25.0

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Sexual Function						
Baseline						
m	76	75	30			
n	30	34	12			
Mean (SD)	75.10 (27.88)	78.28 (26.99)	80.55 (29.96)			
Median	85.00	89.15	92.50			
IQR: Q1, Q3	55.00, 93.30	55.00, 100.00	72.50, 100.00			
Min, Max	-1.7, 100.0	-1.7, 100.0	-1.7, 100.0			
Week 24						
m	76	74	29			
n	36	38	12	27	27	10
Mean (SD/SE)	79.31 (26.00)	73.02 (30.08)	80.43 (28.27)	1.93 (4.97)	-4.93 (3.23)	3.02 (5.23)
Median	90.00	89.15	91.70	0	0	0
IQR: Q1, Q3	76.70, 100.00	51.70, 100.00	68.35, 100.00	-6.60, 16.60	-16.60, 0.00	-8.30, 8.40
Min, Max	6.7, 100.0	-1.7, 100.0	6.7, 100.0	-85.0, 63.3	-48.3, 41.7	-23.4, 38.4
Week 52						
m	74	68	27			
n	26	27	10	21	24	10
Mean (SD/SE)	82.58 (22.19)	73.33 (32.12)	79.33 (26.28)	5.24 (5.50)	-4.99 (3.69)	1.84 (5.23)
Median	93.30	91.70	88.30	0	0	0
IQR: Q1, Q3	76.70, 100.00	46.70, 100.00	70.00, 100.00	-6.70, 6.70	-14.15, 0.85	0.00, 1.70
Min, Max	28.3, 100.0	-1.7, 100.0	23.3, 100.0	-45.0, 61.7	-50.0, 23.4	-30.0, 30.0

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Sleep						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	63.9 (21.1)	60.0 (18.8)	59.3 (20.3)			
Median	65.0	65.0	65.0			
IQR: Q1, Q3	47.5, 80.0	50.0, 75.0	40.0, 75.0			
Min, Max	10, 100	5, 100	10, 95			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	64.4 (20.6)	56.0 (20.4)	56.6 (18.5)	0.5 (1.5)	-3.8 (1.7)	-4.3 (2.9)
Median	70.0	60.0	55.0	0	-5.0	-5.0
IQR: Q1, Q3	50.0, 80.0	45.0, 70.0	47.5, 70.0	-5.0, 10.0	-12.5, 5.0	-10.0, 10.0
Min, Max	10, 100	0, 95	15, 95	-30, 30	-35, 30	-40, 15
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	65.4 (17.5)	56.5 (23.1)	61.5 (21.5)	0.7 (2.2)	-3.9 (2.2)	3.5 (2.9)
Median	70.0	55.0	65.0	0	-5.0	5.0
IQR: Q1, Q3	50.0, 80.0	40.0, 75.0	50.0, 75.0	-10.0, 10.0	-15.0, 10.0	-5.0, 15.0
Min, Max	20, 100	0, 95	5, 95	-40, 75	-60, 30	-25, 30

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Loneliness						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	84.65 (18.14)	80.07 (20.62)	82.41 (19.30)			
Median	92.50	80.00	90.00			
IQR: Q1, Q3	75.00, 100.00	70.00, 100.00	75.00, 100.00			
Min, Max	35.0, 100.0	0.0, 100.0	35.0, 100.0			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	83.40 (19.30)	83.17 (19.79)	81.43 (17.84)	-1.11 (1.97)	1.33 (1.89)	-1.11 (3.06)
Median	90.00	90.00	82.50	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	70.00, 100.00	-7.50, 5.00	-5.00, 10.00	-5.00, 5.00
Min, Max	15.0, 100.0	0.0, 100.0	45.0, 100.0	-50.0, 45.0	-25.0, 65.0	-35.0, 35.0
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	85.00 (18.57)	81.03 (22.42)	81.30 (19.67)	0.45 (1.98)	0.08 (2.17)	0.65 (2.69)
Median	92.50	90.00	90.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	70.00, 100.00	60.00, 100.00	-5.00, 5.00	-10.00, 12.50	0.00, 10.00
Min, Max	25.0, 100.0	0.0, 100.0	45.0, 100.0	-60.0, 50.0	-40.0, 35.0	-35.0, 25.0

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Hopelessness						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	75.82 (22.21)	75.49 (23.75)	80.17 (22.43)			
Median	75.00	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	54.15, 100.00	66.70, 100.00			
Min, Max	25.0, 100.0	25.0, 100.0	25.0, 100.0			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	79.22 (23.98)	76.88 (22.42)	77.68 (20.55)	4.05 (1.91)	2.09 (2.27)	-3.09 (3.78)
Median	91.70	83.30	79.15	0	0	0
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	62.50, 100.00	-8.30, 12.55	-8.30, 8.40	-16.70, 8.30
Min, Max	8.3, 100.0	8.3, 100.0	25.0, 100.0	-33.4, 50.0	-41.7, 58.4	-41.7, 50.0
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	79.76 (21.17)	77.78 (21.11)	79.34 (20.24)	3.73 (2.29)	1.67 (2.98)	0.72 (4.47)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	58.30, 100.00	66.70, 100.00	0.00, 16.60	-8.40, 16.70	-16.60, 16.70
Min, Max	33.3, 100.0	16.7, 100.0	25.0, 100.0	-50.0, 41.7	-58.3, 50.0	-50.0, 33.3

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Stigma of Liver Disease						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	79.44 (23.11)	82.56 (20.53)	85.79 (17.82)			
Median	87.50	90.65	87.50			
IQR: Q1, Q3	62.50, 100.00	68.80, 100.00	81.30, 100.00			
Min, Max	12.5, 100.0	12.5, 100.0	37.5, 100.0			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	82.85 (21.74)	82.15 (19.60)	89.75 (14.55)	3.39 (2.43)	-0.30 (1.90)	2.09 (1.70)
Median	93.80	87.50	93.80	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	84.40, 100.00	-6.20, 12.50	-6.30, 0.00	0.00, 6.30
Min, Max	6.3, 100.0	12.5, 100.0	37.5, 100.0	-43.7, 56.2	-31.2, 50.0	-12.5, 25.0
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	85.99 (20.25)	84.71 (19.23)	87.80 (15.47)	5.87 (1.91)	1.01 (1.75)	3.54 (1.75)
Median	100.00	93.80	93.80	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	81.30, 100.00	0.00, 12.50	-6.20, 6.30	0.00, 6.30
Min, Max	31.3, 100.0	12.5, 100.0	43.8, 100.0	-31.3, 56.2	-56.2, 25.0	-12.5, 25.0

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Total LDQOL						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	81.38 (11.96)	81.45 (10.03)	79.03 (12.81)			
Median	83.50	83.90	82.10			
IQR: Q1, Q3	74.80, 90.10	76.10, 88.50	73.90, 88.40			
Min, Max	42.5, 96.7	61.0, 93.4	34.8, 97.8			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	79.08 (14.15)	81.34 (11.80)	79.24 (13.69)	-1.49 (1.46)	-0.54 (1.54)	0.27 (0.77)
Median	82.20	85.70	82.85	0	-0.10	0.35
IQR: Q1, Q3	70.90, 89.80	74.40, 91.70	72.20, 89.90	-7.40, 2.70	-6.50, 4.70	-4.40, 4.55
Min, Max	28.2, 96.7	55.5, 95.4	33.3, 98.8	-23.4, 16.4	-12.7, 13.0	-27.7, 42.3
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	81.05 (11.88)	82.17 (11.95)	80.10 (13.83)	-0.92 (1.43)	-0.73 (1.65)	0.23 (0.85)
Median	85.30	87.70	83.05	0.80	-1.70	0.55
IQR: Q1, Q3	71.70, 91.00	73.00, 90.95	74.80, 89.90	-5.10, 4.80	-4.60, 5.90	-4.30, 5.25
Min, Max	52.2, 97.5	54.9, 96.3	20.3, 97.8	-19.5, 12.5	-13.9, 9.2	-46.3, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Symptoms of Liver Disease						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	83.08 (16.58)	76.38 (15.89)	77.83 (16.48)			
Median	90.00	83.30	80.00			
IQR: Q1, Q3	73.30, 93.30	63.30, 86.70	70.00, 90.00			
Min, Max	26.7, 100.0	46.7, 100.0	20.0, 100.0			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	79.99 (18.17)	71.86 (17.00)	76.89 (18.67)	-3.52 (2.00)	-4.93 (2.39)	-1.01 (1.11)
Median	83.30	76.70	81.65	0	-6.60	0
IQR: Q1, Q3	73.30, 93.30	60.00, 83.30	66.70, 90.00	-6.70, 3.30	-10.00, 0.00	-6.70, 6.70
Min, Max	16.7, 100.0	40.0, 100.0	20.0, 100.0	-46.6, 16.6	-30.0, 20.0	-53.3, 36.7
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	83.42 (14.97)	76.51 (19.54)	78.31 (19.05)	-2.67 (1.76)	-2.22 (3.85)	0.33 (1.08)
Median	83.30	78.35	83.30	0	0	0
IQR: Q1, Q3	76.70, 93.30	60.00, 93.30	66.70, 93.30	-6.70, 3.40	-16.60, 10.00	-6.70, 6.70
Min, Max	40.0, 100.0	36.7, 100.0	16.7, 100.0	-33.3, 13.3	-36.7, 20.0	-60.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Effects of Liver Disease						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	79.67 (9.31)	81.17 (11.31)	76.99 (14.82)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 83.35	80.00, 86.70	80.00, 80.00			
Min, Max	53.3, 100.0	46.7, 100.0	6.7, 100.0			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	76.24 (12.40)	78.14 (9.72)	77.54 (13.70)	-2.35 (1.58)	-3.47 (1.82)	0.70 (1.17)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 0.00	-6.70, 0.00	-6.70, 6.65
Min, Max	26.7, 100.0	40.0, 86.7	6.7, 100.0	-26.6, 20.0	-20.0, 20.0	-46.7, 53.4
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	77.12 (11.17)	79.34 (7.46)	78.47 (12.49)	-2.10 (2.15)	-2.97 (2.17)	0.59 (1.51)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 6.60	-6.70, 0.00	-6.60, 6.60
Min, Max	46.7, 100.0	60.0, 100.0	13.3, 100.0	-40.0, 20.0	-20.0, 13.3	-80.0, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Concentration/Memory						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	83.61 (21.02)	87.79 (13.52)	79.73 (18.94)			
Median	93.80	93.80	87.50			
IQR: Q1, Q3	68.80, 100.00	75.00, 100.00	68.80, 93.80			
Min, Max	18.8, 100.0	50.0, 100.0	25.0, 100.0			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	81.26 (23.11)	87.02 (13.96)	81.23 (20.41)	-0.68 (2.28)	-1.90 (2.53)	0.87 (1.39)
Median	87.50	93.80	87.50	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	68.80, 100.00	-6.20, 6.20	0.00, 6.20	-6.20, 6.30
Min, Max	18.8, 100.0	50.0, 100.0	12.5, 100.0	-31.2, 25.0	-25.0, 25.0	-81.2, 62.5
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	80.42 (20.47)	83.46 (17.12)	80.64 (20.33)	-1.78 (2.63)	-6.59 (3.33)	-0.76 (1.27)
Median	87.50	84.40	87.50	0	-6.25	0
IQR: Q1, Q3	68.80, 100.00	75.00, 100.00	68.80, 100.00	-12.50, 6.20	-18.70, 0.00	-6.30, 6.20
Min, Max	37.5, 100.0	50.0, 100.0	18.8, 100.0	-43.7, 25.0	-25.0, 25.0	-43.8, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Health Distress						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	82.19 (23.32)	85.33 (20.17)	82.08 (23.49)			
Median	87.50	87.50	100.00			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	25.0, 100.0	0.0, 100.0			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	80.77 (26.26)	91.00 (12.25)	86.25 (21.82)	1.35 (2.60)	4.89 (3.02)	4.36 (1.70)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	62.5, 100.0	0.0, 100.0	-37.5, 37.5	-12.5, 50.0	-62.5, 62.5
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	84.46 (24.01)	91.25 (15.76)	87.67 (20.17)	3.93 (3.62)	5.56 (3.81)	3.30 (1.97)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	50.0, 100.0	0.0, 100.0	-37.5, 75.0	-37.5, 37.5	-87.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Sexual Function						
Baseline						
m	42	25	179			
n	18	14	73			
Mean (SD)	84.00 (25.16)	86.41 (14.84)	79.49 (23.30)			
Median	96.65	93.30	85.00			
IQR: Q1, Q3	68.30, 100.00	68.30, 100.00	68.30, 100.00			
Min, Max	8.9, 100.0	61.7, 100.0	6.7, 100.0			
Week 24						
m	41	25	177			
n	18	14	72	15	12	53
Mean (SD/SE)	86.02 (16.90)	80.59 (22.38)	79.03 (23.57)	4.43 (6.74)	-6.66 (5.19)	0.31 (2.41)
Median	92.50	93.30	85.85	0	0	0
IQR: Q1, Q3	76.70, 100.00	65.00, 100.00	65.80, 100.00	-8.30, 0.00	-14.15, 0.00	-6.70, 8.30
Min, Max	55.0, 100.0	30.0, 100.0	6.7, 100.0	-23.3, 91.1	-38.3, 16.7	-46.7, 38.3
Week 52						
m	39	22	167			
n	18	11	64	16	8	49
Mean (SD/SE)	89.82 (14.29)	88.02 (20.69)	79.48 (23.74)	5.50 (6.10)	-5.20 (5.00)	-1.25 (2.92)
Median	100.00	100.00	88.35	0	0	0
IQR: Q1, Q3	76.70, 100.00	68.30, 100.00	68.30, 100.00	0.00, 6.70	-12.50, 3.35	-8.30, 6.70
Min, Max	61.7, 100.0	38.3, 100.0	-1.7, 100.0	-23.3, 91.1	-30.0, 6.7	-53.3, 63.3

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Sleep						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	68.1 (19.5)	61.7 (22.0)	64.5 (18.6)			
Median	72.5	65.0	65.0			
IQR: Q1, Q3	60.0, 80.0	45.0, 80.0	50.0, 80.0			
Min, Max	15, 100	10, 100	5, 100			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	62.8 (22.8)	61.2 (22.0)	63.8 (19.9)	-3.0 (2.4)	-2.0 (3.1)	0.0 (1.3)
Median	65.0	65.0	65.0	0	0	0
IQR: Q1, Q3	50.0, 80.0	40.0, 80.0	50.0, 80.0	-10.0, 5.0	-10.0, 5.0	-10.0, 10.0
Min, Max	5, 100	20, 100	20, 100	-30, 50	-30, 45	-35, 50
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	65.9 (22.6)	63.5 (18.0)	64.9 (20.3)	-3.4 (2.1)	-1.1 (3.7)	0.9 (1.3)
Median	70.0	65.0	65.0	-5.0	-2.5	0
IQR: Q1, Q3	55.0, 80.0	57.5, 77.5	50.0, 80.0	-15.0, 5.0	-10.0, 5.0	-10.0, 10.0
Min, Max	10, 100	20, 90	20, 100	-30, 30	-25, 30	-40, 55

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Loneliness						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	86.38 (15.69)	90.00 (20.28)	85.17 (19.15)			
Median	95.00	100.00	95.00			
IQR: Q1, Q3	77.50, 100.00	95.00, 100.00	80.00, 100.00			
Min, Max	45.0, 100.0	20.0, 100.0	5.0, 100.0			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	84.62 (17.30)	91.00 (17.32)	83.38 (21.72)	-3.51 (2.50)	1.96 (2.53)	-2.22 (1.31)
Median	90.00	100.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	95.00, 100.00	80.00, 100.00	-10.00, 5.00	0.00, 5.00	-10.00, 5.00
Min, Max	30.0, 100.0	40.0, 100.0	10.0, 100.0	-45.0, 20.0	-35.0, 30.0	-60.0, 70.0
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	87.30 (13.87)	88.50 (19.41)	86.60 (18.76)	-2.14 (2.87)	-1.11 (2.38)	0.55 (1.38)
Median	95.00	95.00	95.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	87.50, 100.00	80.00, 100.00	-10.00, 0.00	-5.00, 0.00	-5.00, 5.00
Min, Max	40.0, 100.0	35.0, 100.0	5.0, 100.0	-55.0, 35.0	-20.0, 20.0	-35.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Hopelessness						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	81.25 (18.18)	82.24 (17.11)	81.63 (19.80)			
Median	83.30	83.30	87.50			
IQR: Q1, Q3	70.85, 100.00	66.70, 100.00	66.70, 100.00			
Min, Max	25.0, 100.0	50.0, 100.0	25.0, 100.0			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	76.92 (20.90)	85.67 (14.54)	81.38 (21.53)	-3.84 (3.44)	3.63 (3.95)	-0.19 (1.39)
Median	83.30	91.70	91.70	0	0	0
IQR: Q1, Q3	58.30, 100.00	75.00, 100.00	66.70, 100.00	-16.60, 8.30	-8.30, 16.70	-8.30, 8.30
Min, Max	16.7, 100.0	50.0, 100.0	25.0, 100.0	-58.3, 50.0	-25.0, 41.7	-58.3, 50.0
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	79.96 (19.97)	84.60 (17.57)	80.89 (22.78)	-2.38 (3.03)	0.02 (5.00)	-1.55 (1.51)
Median	83.30	91.70	91.70	0	0	0
IQR: Q1, Q3	66.70, 100.00	70.85, 100.00	66.70, 100.00	-16.60, 8.30	-16.60, 16.70	-8.30, 8.30
Min, Max	41.7, 100.0	41.7, 100.0	0.0, 100.0	-41.7, 33.3	-33.3, 33.4	-100.0, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Stigma of Liver Disease						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	86.27 (16.81)	83.71 (17.03)	84.61 (17.93)			
Median	93.80	87.50	93.80			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	81.30, 100.00			
Min, Max	25.0, 100.0	43.8, 100.0	31.3, 100.0			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	87.03 (19.84)	84.03 (17.21)	84.19 (18.80)	1.34 (2.23)	0.28 (2.20)	-0.54 (1.19)
Median	100.00	87.50	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	81.30, 100.00	81.30, 100.00	0.00, 12.50	-6.20, 6.30	-6.20, 6.20
Min, Max	12.5, 100.0	43.8, 100.0	6.3, 100.0	-43.8, 25.0	-25.0, 18.8	-50.0, 43.8
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	87.35 (14.31)	87.83 (16.65)	84.85 (18.49)	0.18 (2.10)	4.52 (3.49)	-0.57 (1.39)
Median	93.80	100.00	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	81.30, 100.00	75.00, 100.00	-6.20, 6.20	0.00, 12.50	-6.20, 6.20
Min, Max	50.0, 100.0	50.0, 100.0	18.8, 100.0	-25.0, 31.3	-18.8, 31.3	-62.5, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; CFB = Change from Baseline; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; CFB = Change from Baseline; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.13.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Total LDQOL			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	76.71 (14.95)	75.41 (16.14)	78.66 (13.31)
Analysis Visit Mean (SD)	78.06 (16.23)	75.94 (13.76)	78.14 (13.29)
LS Mean of Change from Baseline (SE)	1.12 (0.93)	0.05 (0.98)	-0.71 (1.49)
95% CI	(-0.71, 2.95)	(-1.88, 1.99)	(-3.64, 2.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.83 (1.74)	0.76 (1.77)	
95% CI	(-1.61, 5.26)	(-2.73, 4.25)	
p-value	0.2946	0.6671	
Corrected Hedge's g Statistics	0.232	0.097	
95% CI	(-0.21, 0.68)	(-0.35, 0.55)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	76.93 (15.31)	76.28 (16.32)	76.47 (16.12)
Analysis Visit Mean (SD)	78.48 (14.28)	76.37 (14.74)	77.82 (15.77)
LS Mean of Change from Baseline (SE)	1.20 (1.01)	-0.22 (1.06)	0.77 (1.68)
95% CI	(-0.79, 3.19)	(-2.32, 1.88)	(-2.54, 4.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.43 (1.95)	-0.99 (1.98)	
95% CI	(-3.43, 4.29)	(-4.90, 2.92)	
p-value	0.8268	0.6167	
Corrected Hedge's g Statistics	0.052	-0.120	
95% CI	(-0.42, 0.53)	(-0.60, 0.36)	
Subgroup*Treatment Interaction p-value	0.3004	0.8322	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Total LDQOL			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	81.23 (12.21)	81.45 (10.03)	79.11 (12.92)
Analysis Visit Mean (SD)	79.75 (13.52)	80.90 (12.21)	79.38 (13.67)
LS Mean of Change from Baseline (SE)	-1.08 (1.51)	-0.25 (1.89)	0.11 (0.77)
95% CI	(-4.06, 1.89)	(-3.98, 3.47)	(-1.40, 1.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.19 (1.64)	-0.36 (1.99)	
95% CI	(-4.42, 2.03)	(-4.29, 3.56)	
p-value	0.4666	0.8554	
Corrected Hedge's g Statistics	-0.126	-0.038	
95% CI	(-0.49, 0.23)	(-0.48, 0.40)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	82.33 (10.73)	81.53 (9.96)	79.91 (12.19)
Analysis Visit Mean (SD)	81.41 (10.81)	80.80 (11.81)	80.15 (14.00)
LS Mean of Change from Baseline (SE)	-0.69 (1.65)	-0.42 (2.19)	-0.04 (0.84)
95% CI	(-3.94, 2.56)	(-4.72, 3.89)	(-1.69, 1.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.65 (1.79)	-0.38 (2.30)	
95% CI	(-4.17, 2.88)	(-4.90, 4.15)	
p-value	0.7174	0.8695	
Corrected Hedge's g Statistics	-0.065	-0.038	
95% CI	(-0.44, 0.31)	(-0.53, 0.45)	
Subgroup*Treatment Interaction p-value	0.3004	0.8322	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; CFB = Change from Baseline; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Symptoms of Liver Disease			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	75.83 (20.66)	73.18 (20.60)	76.41 (19.78)
Analysis Visit Mean (SD)	75.28 (23.11)	74.12 (18.31)	77.04 (19.51)
LS Mean of Change from Baseline (SE)	-0.93 (1.59)	0.18 (1.68)	0.15 (2.55)
95% CI	(-4.08, 2.22)	(-3.13, 3.50)	(-4.88, 5.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.08 (2.98)	0.03 (3.03)	
95% CI	(-6.97, 4.81)	(-5.94, 6.01)	
p-value	0.7177	0.9909	
Corrected Hedge's g Statistics	-0.080	0.003	
95% CI	(-0.52, 0.36)	(-0.45, 0.45)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	76.61 (20.53)	73.72 (19.80)	74.49 (18.30)
Analysis Visit Mean (SD)	74.63 (21.56)	75.62 (18.81)	75.21 (17.60)
LS Mean of Change from Baseline (SE)	-2.48 (1.59)	1.09 (1.67)	-0.27 (2.62)
95% CI	(-5.61, 0.65)	(-2.21, 4.38)	(-5.44, 4.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.21 (3.05)	1.36 (3.09)	
95% CI	(-8.24, 3.82)	(-4.75, 7.46)	
p-value	0.4695	0.6614	
Corrected Hedge's g Statistics	-0.170	0.105	
95% CI	(-0.64, 0.30)	(-0.38, 0.59)	
Subgroup*Treatment Interaction p-value	0.9716	0.1895	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Effects of Liver Disease			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	77.69 (14.89)	78.55 (16.48)	79.76 (11.17)
Analysis Visit Mean (SD)	74.82 (17.02)	80.10 (11.79)	77.53 (12.83)
LS Mean of Change from Baseline (SE)	-3.85 (1.45)	1.00 (1.53)	-1.88 (2.33)
95% CI	(-6.72, -0.98)	(-2.02, 4.03)	(-6.48, 2.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.97 (2.73)	2.88 (2.76)	
95% CI	(-7.35, 3.41)	(-2.58, 8.34)	
p-value	0.4712	0.2985	
Corrected Hedge's g Statistics	-0.159	0.234	
95% CI	(-0.60, 0.28)	(-0.22, 0.69)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	77.32 (15.09)	78.89 (16.56)	78.56 (13.63)
Analysis Visit Mean (SD)	76.62 (14.83)	77.95 (11.57)	78.83 (12.66)
LS Mean of Change from Baseline (SE)	-2.14 (1.45)	-1.12 (1.53)	0.79 (2.41)
95% CI	(-5.01, 0.72)	(-4.14, 1.89)	(-3.96, 5.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.94 (2.80)	-1.92 (2.84)	
95% CI	(-8.47, 2.60)	(-7.52, 3.69)	
p-value	0.2964	0.5003	
Corrected Hedge's g Statistics	-0.247	-0.162	
95% CI	(-0.72, 0.23)	(-0.64, 0.32)	
Subgroup*Treatment Interaction p-value	0.8907	0.4676	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Concentration/Memory			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	80.84 (22.67)	75.51 (22.30)	80.81 (20.93)
Analysis Visit Mean (SD)	79.79 (21.04)	73.65 (22.18)	78.95 (22.53)
LS Mean of Change from Baseline (SE)	-0.57 (1.61)	-2.44 (1.71)	-2.04 (2.58)
95% CI	(-3.75, 2.61)	(-5.81, 0.92)	(-7.14, 3.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.47 (3.02)	-0.40 (3.08)	
95% CI	(-4.49, 7.44)	(-6.47, 5.67)	
p-value	0.6263	0.8965	
Corrected Hedge's g Statistics	0.108	-0.029	
95% CI	(-0.34, 0.55)	(-0.48, 0.42)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	80.62 (22.97)	77.73 (21.03)	78.55 (24.04)
Analysis Visit Mean (SD)	78.75 (20.38)	75.75 (21.55)	76.10 (28.49)
LS Mean of Change from Baseline (SE)	-1.82 (1.49)	-1.96 (1.58)	-2.85 (2.48)
95% CI	(-4.77, 1.13)	(-5.08, 1.15)	(-7.74, 2.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.03 (2.89)	0.88 (2.92)	
95% CI	(-4.67, 6.72)	(-4.89, 6.66)	
p-value	0.7229	0.7625	
Corrected Hedge's g Statistics	0.084	0.072	
95% CI	(-0.39, 0.56)	(-0.41, 0.55)	
Subgroup*Treatment Interaction p-value	0.5733	0.5406	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Health Distress			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	75.69 (27.10)	79.69 (26.96)	81.48 (18.47)
Analysis Visit Mean (SD)	84.20 (22.10)	87.11 (21.59)	86.11 (21.18)
LS Mean of Change from Baseline (SE)	7.27 (1.91)	7.79 (2.01)	5.48 (3.06)
95% CI	(3.49, 11.04)	(3.82, 11.76)	(-0.56, 11.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.79 (3.59)	2.31 (3.63)	
95% CI	(-5.29, 8.87)	(-4.85, 9.48)	
p-value	0.6189	0.5249	
Corrected Hedge's g Statistics	0.110	0.143	
95% CI	(-0.33, 0.55)	(-0.31, 0.59)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	75.75 (27.51)	79.79 (27.82)	79.89 (21.23)
Analysis Visit Mean (SD)	80.60 (24.84)	86.67 (21.33)	84.78 (19.93)
LS Mean of Change from Baseline (SE)	3.29 (2.23)	7.42 (2.36)	5.00 (3.74)
95% CI	(-1.13, 7.70)	(2.77, 12.07)	(-2.39, 12.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.72 (4.36)	2.41 (4.41)	
95% CI	(-10.32, 6.89)	(-6.29, 11.12)	
p-value	0.6944	0.5847	
Corrected Hedge's g Statistics	-0.093	0.132	
95% CI	(-0.57, 0.38)	(-0.35, 0.61)	
Subgroup*Treatment Interaction p-value	0.5132	0.8909	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Sexual Function			
Week 24			
m	76	74	29
n	27	27	10
Baseline Mean (SD)	76.10 (28.48)	82.34 (24.69)	77.49 (32.10)
Analysis Visit Mean (SD)	78.03 (27.77)	77.41 (26.51)	80.51 (29.80)
LS Mean of Change from Baseline (SE)	2.40 (3.84)	-4.22 (3.87)	2.41 (6.46)
95% CI	(-5.27, 10.07)	(-11.95, 3.51)	(-10.49, 15.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (7.50)	-6.62 (7.38)	
95% CI	(-14.98, 14.97)	(-21.36, 8.12)	
p-value	0.9996	0.3729	
Corrected Hedge's g Statistics	0.000	-0.321	
95% CI	(-0.73, 0.73)	(-1.05, 0.41)	
Week 52			
m	74	68	27
n	21	24	10
Baseline Mean (SD)	77.69 (29.85)	82.08 (22.83)	77.49 (32.10)
Analysis Visit Mean (SD)	82.93 (21.00)	77.08 (28.92)	79.33 (26.28)
LS Mean of Change from Baseline (SE)	4.84 (3.93)	-2.95 (3.85)	1.07 (6.22)
95% CI	(-3.00, 12.69)	(-10.65, 4.74)	(-11.35, 13.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.77 (7.33)	-4.03 (7.15)	
95% CI	(-10.88, 18.42)	(-18.30, 10.25)	
p-value	0.6090	0.5751	
Corrected Hedge's g Statistics	0.198	-0.206	
95% CI	(-0.56, 0.95)	(-0.95, 0.53)	
Subgroup*Treatment Interaction p-value	0.4936	0.8254	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Sleep			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	63.9 (21.1)	59.3 (19.1)	60.4 (18.2)
Analysis Visit Mean (SD)	64.4 (20.3)	55.5 (21.3)	56.1 (18.6)
LS Mean of Change from Baseline (SE)	0.68 (1.57)	-4.62 (1.65)	-5.23 (2.50)
95% CI	(-2.42, 3.79)	(-7.89, -1.35)	(-10.17, -0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.91 (2.93)	0.61 (2.97)	
95% CI	(0.12, 11.71)	(-5.25, 6.48)	
p-value	0.0454	0.8372	
Corrected Hedge's g Statistics	0.443	0.046	
95% CI	(0.00, 0.89)	(-0.40, 0.50)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	64.2 (21.3)	60.3 (19.3)	58.0 (21.3)
Analysis Visit Mean (SD)	64.9 (17.3)	56.3 (23.3)	61.5 (21.5)
LS Mean of Change from Baseline (SE)	1.45 (1.94)	-5.00 (2.04)	0.99 (3.23)
95% CI	(-2.37, 5.28)	(-9.03, -0.97)	(-5.40, 7.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.47 (3.77)	-5.99 (3.80)	
95% CI	(-6.98, 7.91)	(-13.50, 1.53)	
p-value	0.9014	0.1175	
Corrected Hedge's g Statistics	0.029	-0.377	
95% CI	(-0.44, 0.50)	(-0.86, 0.11)	
Subgroup*Treatment Interaction p-value	0.1090	0.9021	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Loneliness			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	84.65 (18.14)	80.39 (20.75)	82.59 (19.23)
Analysis Visit Mean (SD)	83.54 (19.45)	81.72 (20.28)	81.48 (18.18)
LS Mean of Change from Baseline (SE)	-0.97 (1.78)	0.29 (1.87)	-1.52 (2.84)
95% CI	(-4.49, 2.55)	(-3.41, 3.99)	(-7.12, 4.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.55 (3.33)	1.81 (3.37)	
95% CI	(-6.01, 7.12)	(-4.85, 8.47)	
p-value	0.8681	0.5924	
Corrected Hedge's g Statistics	0.037	0.120	
95% CI	(-0.41, 0.48)	(-0.33, 0.57)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	84.33 (18.65)	80.25 (21.16)	80.65 (20.85)
Analysis Visit Mean (SD)	84.78 (18.82)	80.33 (22.70)	81.30 (19.67)
LS Mean of Change from Baseline (SE)	0.27 (1.85)	-1.22 (1.95)	-0.10 (3.06)
95% CI	(-3.39, 3.93)	(-5.08, 2.63)	(-6.15, 5.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.37 (3.58)	-1.12 (3.61)	
95% CI	(-6.69, 7.43)	(-8.26, 6.01)	
p-value	0.9176	0.7565	
Corrected Hedge's g Statistics	0.024	-0.074	
95% CI	(-0.45, 0.50)	(-0.55, 0.41)	
Subgroup*Treatment Interaction p-value	0.6064	0.6219	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Hopelessness			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	75.82 (22.21)	74.74 (23.90)	81.17 (21.01)
Analysis Visit Mean (SD)	79.86 (23.69)	76.83 (22.93)	78.09 (20.82)
LS Mean of Change from Baseline (SE)	3.65 (1.99)	1.14 (2.09)	-2.38 (3.19)
95% CI	(-0.28, 7.58)	(-3.00, 5.27)	(-8.67, 3.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.02 (3.73)	3.51 (3.79)	
95% CI	(-1.34, 13.38)	(-3.96, 10.99)	
p-value	0.1083	0.3549	
Corrected Hedge's g Statistics	0.356	0.209	
95% CI	(-0.09, 0.80)	(-0.24, 0.66)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	76.12 (22.28)	75.42 (25.00)	78.62 (23.68)
Analysis Visit Mean (SD)	79.85 (21.18)	77.09 (21.35)	79.34 (20.24)
LS Mean of Change from Baseline (SE)	3.26 (2.18)	1.11 (2.29)	1.36 (3.61)
95% CI	(-1.05, 7.56)	(-3.42, 5.64)	(-5.78, 8.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.90 (4.21)	-0.24 (4.26)	
95% CI	(-6.41, 10.21)	(-8.66, 8.18)	
p-value	0.6519	0.9543	
Corrected Hedge's g Statistics	0.106	-0.014	
95% CI	(-0.37, 0.58)	(-0.49, 0.47)	
Subgroup*Treatment Interaction p-value	0.1061	0.7861	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Stigma of Liver Disease			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	79.44 (23.11)	82.44 (20.77)	87.75 (15.74)
Analysis Visit Mean (SD)	82.83 (21.66)	82.15 (20.32)	89.83 (14.82)
LS Mean of Change from Baseline (SE)	2.74 (1.83)	0.11 (1.92)	3.84 (2.95)
95% CI	(-0.88, 6.36)	(-3.69, 3.91)	(-1.98, 9.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.10 (3.47)	-3.73 (3.50)	
95% CI	(-7.95, 5.75)	(-10.64, 3.18)	
p-value	0.7514	0.2884	
Corrected Hedge's g Statistics	-0.070	-0.240	
95% CI	(-0.51, 0.37)	(-0.69, 0.21)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	80.24 (23.01)	83.56 (20.77)	84.26 (19.48)
Analysis Visit Mean (SD)	86.11 (20.08)	84.57 (19.60)	87.80 (15.47)
LS Mean of Change from Baseline (SE)	5.43 (1.53)	1.64 (1.61)	4.26 (2.53)
95% CI	(2.41, 8.45)	(-1.54, 4.82)	(-0.74, 9.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.18 (2.96)	-2.62 (2.99)	
95% CI	(-4.66, 7.01)	(-8.51, 3.28)	
p-value	0.6913	0.3818	
Corrected Hedge's g Statistics	0.094	-0.209	
95% CI	(-0.38, 0.57)	(-0.69, 0.27)	
Subgroup*Treatment Interaction p-value	0.5862	0.1701	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Symptoms of Liver Disease			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	83.24 (16.51)	76.38 (15.89)	78.33 (16.62)
Analysis Visit Mean (SD)	79.72 (18.59)	71.45 (16.23)	77.32 (18.30)
LS Mean of Change from Baseline (SE)	-1.59 (2.18)	-4.90 (2.72)	-1.03 (1.10)
95% CI	(-5.88, 2.70)	(-10.26, 0.47)	(-3.20, 1.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.55 (2.37)	-3.86 (2.87)	
95% CI	(-5.22, 4.11)	(-9.51, 1.78)	
p-value	0.8149	0.1789	
Corrected Hedge's g Statistics	-0.041	-0.285	
95% CI	(-0.40, 0.32)	(-0.72, 0.15)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	85.23 (13.89)	76.29 (15.46)	78.43 (16.56)
Analysis Visit Mean (SD)	82.57 (14.95)	74.08 (19.08)	78.76 (18.68)
LS Mean of Change from Baseline (SE)	-0.64 (2.21)	-2.05 (2.93)	0.65 (1.13)
95% CI	(-5.00, 3.72)	(-7.84, 3.73)	(-1.57, 2.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.29 (2.40)	-2.70 (3.07)	
95% CI	(-6.02, 3.44)	(-8.76, 3.36)	
p-value	0.5916	0.3806	
Corrected Hedge's g Statistics	-0.097	-0.203	
95% CI	(-0.47, 0.27)	(-0.69, 0.29)	
Subgroup*Treatment Interaction p-value	0.9716	0.1895	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Effects of Liver Disease			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	79.64 (9.69)	81.17 (11.31)	77.11 (14.79)
Analysis Visit Mean (SD)	77.30 (9.49)	77.69 (9.97)	77.81 (13.29)
LS Mean of Change from Baseline (SE)	-1.24 (1.85)	-1.67 (2.30)	0.31 (0.93)
95% CI	(-4.88, 2.40)	(-6.21, 2.87)	(-1.53, 2.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.55 (2.01)	-1.98 (2.44)	
95% CI	(-5.51, 2.41)	(-6.79, 2.83)	
p-value	0.4405	0.4175	
Corrected Hedge's g Statistics	-0.135	-0.172	
95% CI	(-0.49, 0.22)	(-0.61, 0.27)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	79.62 (9.83)	82.23 (11.66)	77.96 (12.97)
Analysis Visit Mean (SD)	77.53 (11.09)	79.26 (7.88)	78.55 (12.49)
LS Mean of Change from Baseline (SE)	-0.77 (2.08)	0.41 (2.83)	0.16 (1.06)
95% CI	(-4.86, 3.32)	(-5.16, 5.98)	(-1.93, 2.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.93 (2.26)	0.25 (2.97)	
95% CI	(-5.39, 3.52)	(-5.61, 6.11)	
p-value	0.6799	0.9331	
Corrected Hedge's g Statistics	-0.075	0.020	
95% CI	(-0.45, 0.30)	(-0.47, 0.51)	
Subgroup*Treatment Interaction p-value	0.8907	0.4676	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Concentration/Memory			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	83.12 (21.68)	87.79 (13.52)	80.28 (19.04)
Analysis Visit Mean (SD)	82.45 (22.18)	85.89 (14.00)	81.15 (20.52)
LS Mean of Change from Baseline (SE)	-0.56 (2.58)	-0.57 (3.25)	0.19 (1.30)
95% CI	(-5.65, 4.53)	(-6.96, 5.83)	(-2.38, 2.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.75 (2.80)	-0.76 (3.43)	
95% CI	(-6.28, 4.77)	(-7.52, 6.00)	
p-value	0.7882	0.8245	
Corrected Hedge's g Statistics	-0.047	-0.047	
95% CI	(-0.41, 0.31)	(-0.49, 0.39)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	82.87 (20.68)	88.21 (11.52)	81.27 (17.94)
Analysis Visit Mean (SD)	81.09 (19.43)	81.62 (17.08)	80.51 (20.56)
LS Mean of Change from Baseline (SE)	-2.71 (2.58)	-4.99 (3.47)	-1.23 (1.32)
95% CI	(-7.81, 2.38)	(-11.82, 1.84)	(-3.84, 1.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.48 (2.80)	-3.76 (3.64)	
95% CI	(-6.99, 4.03)	(-10.92, 3.41)	
p-value	0.5972	0.3027	
Corrected Hedge's g Statistics	-0.095	-0.240	
95% CI	(-0.47, 0.28)	(-0.73, 0.25)	
Subgroup*Treatment Interaction p-value	0.5733	0.5406	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Health Distress			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	81.42 (23.87)	85.33 (20.17)	81.66 (23.77)
Analysis Visit Mean (SD)	82.77 (23.26)	90.22 (12.48)	86.02 (22.00)
LS Mean of Change from Baseline (SE)	0.70 (2.88)	6.04 (3.60)	3.96 (1.46)
95% CI	(-4.98, 6.37)	(-1.05, 13.13)	(1.08, 6.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.26 (3.12)	2.09 (3.79)	
95% CI	(-9.40, 2.88)	(-5.39, 9.56)	
p-value	0.2969	0.5830	
Corrected Hedge's g Statistics	-0.181	0.116	
95% CI	(-0.54, 0.18)	(-0.32, 0.55)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	82.50 (21.27)	84.72 (20.36)	84.02 (21.94)
Analysis Visit Mean (SD)	86.43 (19.73)	90.28 (16.36)	87.32 (20.56)
LS Mean of Change from Baseline (SE)	2.52 (3.17)	6.43 (4.24)	3.78 (1.62)
95% CI	(-3.74, 8.77)	(-1.92, 14.79)	(0.58, 6.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.26 (3.45)	2.65 (4.45)	
95% CI	(-8.05, 5.53)	(-6.12, 11.43)	
p-value	0.7154	0.5516	
Corrected Hedge's g Statistics	-0.066	0.139	
95% CI	(-0.44, 0.30)	(-0.35, 0.63)	
Subgroup*Treatment Interaction p-value	0.5132	0.8909	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Sexual Function			
Week 24			
m	41	25	177
n	15	12	53
Baseline Mean (SD)	83.36 (26.95)	87.34 (13.68)	81.42 (21.83)
Analysis Visit Mean (SD)	87.79 (16.44)	80.68 (22.79)	81.73 (19.43)
LS Mean of Change from Baseline (SE)	3.80 (4.09)	-5.84 (4.63)	-1.89 (2.20)
95% CI	(-4.33, 11.93)	(-15.03, 3.35)	(-6.26, 2.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.69 (4.50)	-3.95 (5.10)	
95% CI	(-3.26, 14.64)	(-14.08, 6.17)	
p-value	0.2098	0.4398	
Corrected Hedge's g Statistics	0.352	-0.244	
95% CI	(-0.22, 0.93)	(-0.87, 0.38)	
Week 52			
m	39	22	167
n	16	8	49
Baseline Mean (SD)	85.86 (25.52)	92.69 (10.40)	80.94 (20.96)
Analysis Visit Mean (SD)	91.36 (13.25)	87.49 (22.69)	79.69 (22.84)
LS Mean of Change from Baseline (SE)	5.21 (4.66)	-0.72 (6.08)	-4.19 (2.62)
95% CI	(-4.05, 14.47)	(-12.80, 11.35)	(-9.38, 1.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.40 (5.20)	3.46 (6.62)	
95% CI	(-0.93, 19.73)	(-9.68, 16.61)	
p-value	0.0741	0.6019	
Corrected Hedge's g Statistics	0.505	0.188	
95% CI	(-0.07, 1.08)	(-0.56, 0.94)	
Subgroup*Treatment Interaction p-value	0.4936	0.8254	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Sleep			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	68.0 (19.3)	61.7 (22.0)	64.5 (19.0)
Analysis Visit Mean (SD)	65.0 (21.1)	59.8 (22.3)	64.4 (19.5)
LS Mean of Change from Baseline (SE)	-2.26 (2.45)	-3.20 (3.06)	-0.70 (1.24)
95% CI	(-7.09, 2.57)	(-9.24, 2.84)	(-3.13, 1.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.56 (2.66)	-2.51 (3.23)	
95% CI	(-6.81, 3.68)	(-8.87, 3.86)	
p-value	0.5571	0.4387	
Corrected Hedge's g Statistics	-0.103	-0.164	
95% CI	(-0.46, 0.26)	(-0.60, 0.27)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	70.0 (17.8)	63.1 (23.3)	64.8 (18.8)
Analysis Visit Mean (SD)	66.6 (20.4)	61.9 (18.2)	65.7 (20.3)
LS Mean of Change from Baseline (SE)	-1.83 (2.51)	-2.25 (3.35)	0.33 (1.28)
95% CI	(-6.78, 3.13)	(-8.85, 4.35)	(-2.19, 2.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.16 (2.72)	-2.58 (3.51)	
95% CI	(-7.53, 3.21)	(-9.50, 4.34)	
p-value	0.4284	0.4627	
Corrected Hedge's g Statistics	-0.142	-0.171	
95% CI	(-0.51, 0.23)	(-0.66, 0.32)	
Subgroup*Treatment Interaction p-value	0.1090	0.9021	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Loneliness			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	87.30 (15.66)	90.00 (20.28)	84.95 (19.72)
Analysis Visit Mean (SD)	83.78 (17.38)	91.96 (17.17)	82.73 (22.01)
LS Mean of Change from Baseline (SE)	-3.83 (2.52)	2.12 (3.16)	-3.00 (1.28)
95% CI	(-8.80, 1.15)	(-4.11, 8.34)	(-5.52, -0.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.83 (2.75)	5.11 (3.34)	
95% CI	(-6.24, 4.59)	(-1.47, 11.70)	
p-value	0.7637	0.1275	
Corrected Hedge's g Statistics	-0.053	0.325	
95% CI	(-0.41, 0.31)	(-0.11, 0.76)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	88.71 (14.21)	88.89 (22.59)	85.77 (19.13)
Analysis Visit Mean (SD)	86.57 (13.92)	87.78 (20.31)	86.32 (19.23)
LS Mean of Change from Baseline (SE)	-1.99 (2.54)	-0.65 (3.40)	-0.69 (1.30)
95% CI	(-6.99, 3.01)	(-7.36, 6.06)	(-3.25, 1.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.30 (2.75)	0.04 (3.57)	
95% CI	(-6.72, 4.12)	(-7.00, 7.08)	
p-value	0.6368	0.9908	
Corrected Hedge's g Statistics	-0.085	0.003	
95% CI	(-0.46, 0.29)	(-0.49, 0.49)	
Subgroup*Treatment Interaction p-value	0.6064	0.6219	

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Hopelessness			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	80.86 (18.62)	82.24 (17.11)	81.63 (19.81)
Analysis Visit Mean (SD)	77.02 (20.64)	85.87 (14.32)	81.45 (21.35)
LS Mean of Change from Baseline (SE)	-3.83 (2.82)	4.52 (3.52)	0.47 (1.42)
95% CI	(-9.38, 1.73)	(-2.41, 11.45)	(-2.33, 3.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.30 (3.06)	4.05 (3.71)	
95% CI	(-10.33, 1.73)	(-3.26, 11.37)	
p-value	0.1615	0.2760	
Corrected Hedge's g Statistics	-0.245	0.231	
95% CI	(-0.61, 0.12)	(-0.21, 0.67)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	82.86 (16.42)	82.86 (17.74)	82.32 (20.06)
Analysis Visit Mean (SD)	80.48 (19.17)	82.88 (17.73)	80.78 (23.14)
LS Mean of Change from Baseline (SE)	-1.01 (3.02)	1.10 (4.07)	-1.09 (1.54)
95% CI	(-6.97, 4.95)	(-6.93, 9.12)	(-4.14, 1.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (3.28)	2.19 (4.28)	
95% CI	(-6.39, 6.56)	(-6.24, 10.62)	
p-value	0.9795	0.6096	
Corrected Hedge's g Statistics	0.005	0.120	
95% CI	(-0.37, 0.38)	(-0.37, 0.61)	
Subgroup*Treatment Interaction p-value	0.1061	0.7861	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Stigma of Liver Disease			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	85.83 (17.09)	83.71 (17.03)	84.80 (17.82)
Analysis Visit Mean (SD)	87.17 (20.03)	84.00 (17.95)	84.26 (19.02)
LS Mean of Change from Baseline (SE)	1.36 (2.31)	-0.16 (2.88)	-0.57 (1.17)
95% CI	(-3.18, 5.91)	(-5.84, 5.53)	(-2.87, 1.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.93 (2.50)	0.41 (3.04)	
95% CI	(-3.00, 6.87)	(-5.57, 6.40)	
p-value	0.4408	0.8920	
Corrected Hedge's g Statistics	0.134	0.029	
95% CI	(-0.23, 0.49)	(-0.41, 0.47)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	87.51 (16.81)	81.96 (18.66)	85.32 (16.62)
Analysis Visit Mean (SD)	87.70 (13.92)	86.48 (17.04)	84.75 (18.77)
LS Mean of Change from Baseline (SE)	0.17 (2.53)	2.88 (3.41)	-0.79 (1.29)
95% CI	(-4.82, 5.17)	(-3.84, 9.61)	(-3.34, 1.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.96 (2.75)	3.68 (3.58)	
95% CI	(-4.46, 6.39)	(-3.38, 10.74)	
p-value	0.7266	0.3059	
Corrected Hedge's g Statistics	0.063	0.240	
95% CI	(-0.31, 0.43)	(-0.25, 0.73)	
Subgroup*Treatment Interaction p-value	0.5862	0.1701	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; CFB = Change from Baseline; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (6.6)	1 (1.3)	0
No	71 (93.4)	74 (98.7)	30 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	NE	
95% CI of the inverse odds ratio	(0.01, 3.97)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.23	NE	
95% CI of the inverse risk ratio	(0.01, 3.96)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.53	1.33	
95% CI of the absolute risk difference	(-1.73, 12.79)	(-1.26, 3.93)	
p-value	0.2564	0.5251	
p-value of Breslow-Day Test for Homogeneity [3]	0.0625	0.2422	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (27.6)	16 (21.3)	7 (23.3)
No	55 (72.4)	59 (78.7)	23 (76.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.12	
95% CI of the inverse odds ratio	(0.30, 2.13)	(0.41, 3.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.09	
95% CI of the inverse risk ratio	(0.40, 1.78)	(0.50, 2.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.30	-2.00	
95% CI of the absolute risk difference	(-13.87, 22.47)	(-19.75, 15.75)	
p-value	0.6512	0.8229	
p-value of Breslow-Day Test for Homogeneity [3]	0.6201	0.6692	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (6.6)	10 (13.3)	2 (6.7)
No	71 (93.4)	65 (86.7)	28 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.46	
95% CI of the inverse odds ratio	(0.19, 5.54)	(0.10, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.50	
95% CI of the inverse risk ratio	(0.21, 4.94)	(0.12, 2.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.09	6.67	
95% CI of the absolute risk difference	(-10.61, 10.44)	(-5.12, 18.45)	
p-value	0.9869	0.3321	
p-value of Breslow-Day Test for Homogeneity [3]	0.0885	0.7782	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (23.7)	23 (30.7)	8 (26.7)
No	58 (76.3)	52 (69.3)	22 (73.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.82	
95% CI of the inverse odds ratio	(0.45, 3.08)	(0.32, 2.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	0.87	
95% CI of the inverse risk ratio	(0.55, 2.31)	(0.44, 1.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.98	4.00	
95% CI of the absolute risk difference	(-21.47, 15.50)	(-14.96, 22.96)	
p-value	0.7478	0.6848	
p-value of Breslow-Day Test for Homogeneity [3]	0.6625	0.8407	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (3.9)	8 (10.7)	2 (6.7)
No	73 (96.1)	67 (89.3)	28 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.74	0.60	
95% CI of the inverse odds ratio	(0.28, 10.96)	(0.12, 3.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.69	0.63	
95% CI of the inverse risk ratio	(0.30, 9.61)	(0.14, 2.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.72	4.00	
95% CI of the absolute risk difference	(-12.66, 7.22)	(-7.33, 15.33)	
p-value	0.5519	0.5282	
p-value of Breslow-Day Test for Homogeneity [3]	0.9194	0.0851	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (17.1)	14 (18.7)	7 (23.3)
No	63 (82.9)	61 (81.3)	23 (76.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	1.33	
95% CI of the inverse odds ratio	(0.52, 4.15)	(0.48, 3.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	1.25	
95% CI of the inverse risk ratio	(0.60, 3.08)	(0.56, 2.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.23	-4.67	
95% CI of the absolute risk difference	(-23.57, 11.11)	(-22.18, 12.85)	
p-value	0.4604	0.5892	
p-value of Breslow-Day Test for Homogeneity [3]	0.4866	0.6882	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (7.9)	2 (2.7)	0
No	70 (92.1)	73 (97.3)	30 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.18	NE	
95% CI of the inverse odds ratio	(0.01, 3.26)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.19	NE	
95% CI of the inverse risk ratio	(0.01, 3.29)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.83	2.67	
95% CI of the absolute risk difference	(-0.80, 14.46)	(-0.98, 6.31)	
p-value	0.1922	0.3665	
p-value of Breslow-Day Test for Homogeneity [3]	0.2249	0.4058	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (19.7)	20 (26.7)	5 (16.7)
No	61 (80.3)	55 (73.3)	25 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.55	
95% CI of the inverse odds ratio	(0.27, 2.48)	(0.19, 1.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.63	
95% CI of the inverse risk ratio	(0.34, 2.12)	(0.26, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.07	10.00	
95% CI of the absolute risk difference	(-12.99, 19.13)	(-6.67, 26.67)	
p-value	0.7159	0.2771	
p-value of Breslow-Day Test for Homogeneity [3]	0.9212	0.1262	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (21.1)	16 (21.3)	4 (13.3)
No	60 (78.9)	59 (78.7)	26 (86.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.57	
95% CI of the inverse odds ratio	(0.18, 1.89)	(0.17, 1.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.63	
95% CI of the inverse risk ratio	(0.23, 1.74)	(0.23, 1.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.72	8.00	
95% CI of the absolute risk difference	(-7.51, 22.95)	(-7.29, 23.29)	
p-value	0.3602	0.3456	
p-value of Breslow-Day Test for Homogeneity [3]	0.4633	0.3739	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (25.0)	19 (25.3)	10 (33.3)
No	57 (75.0)	56 (74.7)	20 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	1.47	
95% CI of the inverse odds ratio	(0.60, 3.76)	(0.59, 3.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	1.32	
95% CI of the inverse risk ratio	(0.70, 2.52)	(0.70, 2.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.33	-8.00	
95% CI of the absolute risk difference	(-27.81, 11.14)	(-27.53, 11.53)	
p-value	0.3860	0.4075	
p-value of Breslow-Day Test for Homogeneity [3]	0.2250	0.1808	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (5.3)	3 (4.0)	2 (6.7)
No	72 (94.7)	72 (96.0)	28 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.71	
95% CI of the inverse odds ratio	(0.22, 7.42)	(0.27, 10.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	1.67	
95% CI of the inverse risk ratio	(0.24, 6.56)	(0.29, 9.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.40	-2.67	
95% CI of the absolute risk difference	(-11.64, 8.84)	(-12.63, 7.30)	
p-value	0.7782	0.5621	
p-value of Breslow-Day Test for Homogeneity [3]	0.8519	0.4250	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (7.9)	5 (6.7)	2 (6.7)
No	70 (92.1)	70 (93.3)	28 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	1.00	
95% CI of the inverse odds ratio	(0.16, 4.38)	(0.18, 5.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.00	
95% CI of the inverse risk ratio	(0.18, 3.95)	(0.21, 4.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.23	0.00	
95% CI of the absolute risk difference	(-9.56, 12.02)	(-10.56, 10.56)	
p-value	0.8293	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.8912	0.9173	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (19.7)	10 (13.3)	6 (20.0)
No	61 (80.3)	65 (86.7)	24 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.63	
95% CI of the inverse odds ratio	(0.35, 2.93)	(0.53, 4.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.50	
95% CI of the inverse risk ratio	(0.43, 2.36)	(0.60, 3.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.26	-6.67	
95% CI of the absolute risk difference	(-17.14, 16.62)	(-22.92, 9.58)	
p-value	0.9756	0.3905	
p-value of Breslow-Day Test for Homogeneity [3]	0.5712	0.9477	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (34.2)	22 (29.3)	12 (40.0)
No	50 (65.8)	53 (70.7)	18 (60.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	1.61	
95% CI of the inverse odds ratio	(0.54, 3.06)	(0.66, 3.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	1.36	
95% CI of the inverse risk ratio	(0.68, 2.00)	(0.78, 2.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.79	-10.67	
95% CI of the absolute risk difference	(-26.31, 14.73)	(-31.00, 9.67)	
p-value	0.5755	0.2913	
p-value of Breslow-Day Test for Homogeneity [3]	0.7305	0.7140	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (11.8)	15 (20.0)	2 (6.7)
No	67 (88.2)	60 (80.0)	28 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	0.29	
95% CI of the inverse odds ratio	(0.11, 2.62)	(0.06, 1.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.33	
95% CI of the inverse risk ratio	(0.13, 2.46)	(0.08, 1.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.18	13.33	
95% CI of the absolute risk difference	(-6.33, 16.68)	(0.62, 26.05)	
p-value	0.4312	0.0938	
p-value of Breslow-Day Test for Homogeneity [3]	0.4547	0.1831	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (30.3)	24 (32.0)	10 (33.3)
No	53 (69.7)	51 (68.0)	20 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.06	
95% CI of the inverse odds ratio	(0.47, 2.84)	(0.43, 2.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	1.04	
95% CI of the inverse risk ratio	(0.60, 2.03)	(0.57, 1.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.07	-1.33	
95% CI of the absolute risk difference	(-22.85, 16.71)	(-21.23, 18.57)	
p-value	0.7585	0.8951	
p-value of Breslow-Day Test for Homogeneity [3]	0.6643	0.2461	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (23.7)	19 (25.3)	6 (20.0)
No	58 (76.3)	56 (74.7)	24 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.74	
95% CI of the inverse odds ratio	(0.28, 2.28)	(0.26, 2.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.79	
95% CI of the inverse risk ratio	(0.37, 1.92)	(0.35, 1.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.68	5.33	
95% CI of the absolute risk difference	(-13.53, 20.90)	(-12.04, 22.70)	
p-value	0.6831	0.5621	
p-value of Breslow-Day Test for Homogeneity [3]	0.9287	0.4040	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (34.2)	25 (33.3)	11 (36.7)
No	50 (65.8)	50 (66.7)	19 (63.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.16	
95% CI of the inverse odds ratio	(0.46, 2.69)	(0.48, 2.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.10	
95% CI of the inverse risk ratio	(0.61, 1.88)	(0.62, 1.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.46	-3.33	
95% CI of the absolute risk difference	(-22.73, 17.82)	(-23.61, 16.94)	
p-value	0.8111	0.7451	
p-value of Breslow-Day Test for Homogeneity [3]	0.4869	0.4062	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (19.7)	8 (10.7)	2 (6.7)
No	61 (80.3)	67 (89.3)	28 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.60	
95% CI of the inverse odds ratio	(0.06, 1.36)	(0.12, 3.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.34	0.63	
95% CI of the inverse risk ratio	(0.08, 1.39)	(0.14, 2.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.07	4.00	
95% CI of the absolute risk difference	(0.43, 25.71)	(-7.33, 15.33)	
p-value	0.0986	0.5282	
p-value of Breslow-Day Test for Homogeneity [3]	0.1201	0.9350	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (39.5)	24 (32.0)	9 (30.0)
No	46 (60.5)	51 (68.0)	21 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.91	
95% CI of the inverse odds ratio	(0.27, 1.63)	(0.36, 2.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	0.94	
95% CI of the inverse risk ratio	(0.41, 1.40)	(0.50, 1.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.47	2.00	
95% CI of the absolute risk difference	(-10.27, 29.21)	(-17.50, 21.50)	
p-value	0.3622	0.8419	
p-value of Breslow-Day Test for Homogeneity [3]	0.6897	0.9622	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	6 (3.4)
No	42 (100)	25 (100)	173 (96.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.35	-3.35	
95% CI of the absolute risk difference	(-5.99, -0.72)	(-5.99, -0.72)	
p-value	0.2290	0.3528	
p-value of Breslow-Day Test for Homogeneity [3]	0.0625	0.2422	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (19.0)	6 (24.0)	37 (20.7)
No	34 (81.0)	19 (76.0)	142 (79.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.83	
95% CI of the inverse odds ratio	(0.47, 2.59)	(0.31, 2.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.86	
95% CI of the inverse risk ratio	(0.55, 2.16)	(0.41, 1.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.62	3.33	
95% CI of the absolute risk difference	(-14.90, 11.65)	(-14.43, 21.09)	
p-value	0.8142	0.7022	
p-value of Breslow-Day Test for Homogeneity [3]	0.6201	0.6692	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	3 (12.0)	14 (7.8)
No	42 (100)	22 (88.0)	165 (92.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.45	0.62	
95% CI of the inverse odds ratio	(0.44, 127.37)	(0.17, 2.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.93	0.65	
95% CI of the inverse risk ratio	(0.42, 113.87)	(0.20, 2.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.89	4.18	
95% CI of the absolute risk difference	(-12.00, -1.79)	(-9.15, 17.51)	
p-value	0.1050	0.4789	
p-value of Breslow-Day Test for Homogeneity [3]	0.0885	0.7782	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (19.0)	7 (28.0)	48 (26.8)
No	34 (81.0)	18 (72.0)	131 (73.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	0.94	
95% CI of the inverse odds ratio	(0.67, 3.60)	(0.37, 2.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	0.96	
95% CI of the inverse risk ratio	(0.72, 2.75)	(0.49, 1.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.77	1.18	
95% CI of the absolute risk difference	(-21.30, 5.77)	(-17.57, 19.94)	
p-value	0.2976	0.9005	
p-value of Breslow-Day Test for Homogeneity [3]	0.6625	0.8407	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.8)	0	16 (8.9)
No	40 (95.2)	25 (100)	163 (91.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.96	5.15	
95% CI of the inverse odds ratio	(0.43, 8.89)	(0.30, 88.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.88	4.77	
95% CI of the inverse risk ratio	(0.45, 7.85)	(0.29, 77.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.18	-7.24	
95% CI of the absolute risk difference	(-11.85, 3.50)	(-14.00, -0.49)	
p-value	0.3731	0.2096	
p-value of Breslow-Day Test for Homogeneity [3]	0.9194	0.0851	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (21.4)	3 (12.0)	36 (20.1)
No	33 (78.6)	22 (88.0)	143 (79.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.85	
95% CI of the inverse odds ratio	(0.41, 2.10)	(0.52, 6.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.68	
95% CI of the inverse risk ratio	(0.49, 1.80)	(0.56, 5.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.32	-8.11	
95% CI of the absolute risk difference	(-12.41, 15.05)	(-22.14, 5.91)	
p-value	0.8487	0.3340	
p-value of Breslow-Day Test for Homogeneity [3]	0.4866	0.6882	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (11.9)	2 (8.0)	13 (7.3)
No	37 (88.1)	23 (92.0)	166 (92.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.90	
95% CI of the inverse odds ratio	(0.19, 1.73)	(0.19, 4.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	0.91	
95% CI of the inverse risk ratio	(0.23, 1.62)	(0.22, 3.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.64	0.74	
95% CI of the absolute risk difference	(-5.86, 15.15)	(-10.56, 12.03)	
p-value	0.3222	0.8947	
p-value of Breslow-Day Test for Homogeneity [3]	0.2249	0.4058	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (26.2)	3 (12.0)	38 (21.2)
No	31 (73.8)	22 (88.0)	141 (78.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	1.98	
95% CI of the inverse odds ratio	(0.35, 1.65)	(0.56, 6.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	1.77	
95% CI of the inverse risk ratio	(0.45, 1.45)	(0.59, 5.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.96	-9.23	
95% CI of the absolute risk difference	(-9.62, 19.55)	(-23.31, 4.85)	
p-value	0.4860	0.2807	
p-value of Breslow-Day Test for Homogeneity [3]	0.9212	0.1262	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (14.3)	3 (12.0)	26 (14.5)
No	36 (85.7)	22 (88.0)	153 (85.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.25	
95% CI of the inverse odds ratio	(0.39, 2.66)	(0.35, 4.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.21	
95% CI of the inverse risk ratio	(0.45, 2.31)	(0.40, 3.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.24	-2.53	
95% CI of the absolute risk difference	(-12.01, 11.54)	(-16.27, 11.22)	
p-value	0.9683	0.7349	
p-value of Breslow-Day Test for Homogeneity [3]	0.4633	0.3739	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (28.6)	8 (32.0)	40 (22.3)
No	30 (71.4)	17 (68.0)	139 (77.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.61	
95% CI of the inverse odds ratio	(0.34, 1.53)	(0.25, 1.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.70	
95% CI of the inverse risk ratio	(0.45, 1.36)	(0.37, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.23	9.65	
95% CI of the absolute risk difference	(-8.74, 21.19)	(-9.62, 28.93)	
p-value	0.3920	0.2865	
p-value of Breslow-Day Test for Homogeneity [3]	0.2250	0.1808	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.4)	0	7 (3.9)
No	41 (97.6)	25 (100)	172 (96.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	NE	
95% CI of the inverse odds ratio	(0.20, 13.94)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.64	NE	
95% CI of the inverse risk ratio	(0.21, 12.99)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.53	-3.91	
95% CI of the absolute risk difference	(-6.94, 3.89)	(-6.75, -1.07)	
p-value	0.6329	0.3143	
p-value of Breslow-Day Test for Homogeneity [3]	0.8519	0.4250	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (11.9)	2 (8.0)	16 (8.9)
No	37 (88.1)	23 (92.0)	163 (91.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	1.13	
95% CI of the inverse odds ratio	(0.25, 2.11)	(0.24, 5.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.12	
95% CI of the inverse risk ratio	(0.29, 1.93)	(0.27, 4.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.97	-0.94	
95% CI of the absolute risk difference	(-7.68, 13.61)	(-12.36, 10.49)	
p-value	0.5552	0.8768	
p-value of Breslow-Day Test for Homogeneity [3]	0.8912	0.9173	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (11.9)	3 (12.0)	31 (17.3)
No	37 (88.1)	22 (88.0)	148 (82.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	1.54	
95% CI of the inverse odds ratio	(0.56, 4.26)	(0.43, 5.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	1.44	
95% CI of the inverse risk ratio	(0.60, 3.52)	(0.48, 4.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.41	-5.32	
95% CI of the absolute risk difference	(-16.67, 5.84)	(-19.21, 8.57)	
p-value	0.3925	0.5039	
p-value of Breslow-Day Test for Homogeneity [3]	0.5712	0.9477	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (23.8)	7 (28.0)	59 (33.0)
No	32 (76.2)	18 (72.0)	120 (67.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.57	1.26	
95% CI of the inverse odds ratio	(0.72, 3.42)	(0.50, 3.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	1.18	
95% CI of the inverse risk ratio	(0.78, 2.47)	(0.61, 2.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.15	-4.96	
95% CI of the absolute risk difference	(-23.76, 5.45)	(-23.86, 13.94)	
p-value	0.2494	0.6194	
p-value of Breslow-Day Test for Homogeneity [3]	0.7305	0.7140	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (11.9)	3 (12.0)	23 (12.8)
No	37 (88.1)	22 (88.0)	156 (87.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.08	
95% CI of the inverse odds ratio	(0.39, 3.06)	(0.30, 3.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	1.07	
95% CI of the inverse risk ratio	(0.44, 2.67)	(0.35, 3.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.94	-0.85	
95% CI of the absolute risk difference	(-11.90, 10.01)	(-14.50, 12.80)	
p-value	0.8685	0.9051	
p-value of Breslow-Day Test for Homogeneity [3]	0.4547	0.1831	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (19.0)	3 (12.0)	47 (26.3)
No	34 (81.0)	22 (88.0)	132 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	2.61	
95% CI of the inverse odds ratio	(0.65, 3.50)	(0.75, 9.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	2.19	
95% CI of the inverse risk ratio	(0.71, 2.69)	(0.74, 6.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.21	-14.26	
95% CI of the absolute risk difference	(-20.72, 6.30)	(-28.53, 0.02)	
p-value	0.3308	0.1206	
p-value of Breslow-Day Test for Homogeneity [3]	0.6643	0.2461	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (14.3)	6 (24.0)	20 (11.2)
No	36 (85.7)	19 (76.0)	159 (88.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.40	
95% CI of the inverse odds ratio	(0.28, 2.01)	(0.14, 1.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.47	
95% CI of the inverse risk ratio	(0.33, 1.83)	(0.21, 1.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.11	12.83	
95% CI of the absolute risk difference	(-8.43, 14.66)	(-4.54, 30.19)	
p-value	0.5731	0.0716	
p-value of Breslow-Day Test for Homogeneity [3]	0.9287	0.4040	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (26.2)	7 (28.0)	37 (20.7)
No	31 (73.8)	18 (72.0)	142 (79.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.67	
95% CI of the inverse odds ratio	(0.34, 1.60)	(0.26, 1.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.74	
95% CI of the inverse risk ratio	(0.44, 1.41)	(0.37, 1.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.52	7.33	
95% CI of the absolute risk difference	(-9.04, 20.08)	(-11.24, 25.90)	
p-value	0.4349	0.4039	
p-value of Breslow-Day Test for Homogeneity [3]	0.4869	0.4062	

AMNOG Table SE21.13.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (7.1)	4 (16.0)	17 (9.5)
No	39 (92.9)	21 (84.0)	162 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.55	
95% CI of the inverse odds ratio	(0.38, 4.89)	(0.17, 1.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	0.59	
95% CI of the inverse risk ratio	(0.41, 4.33)	(0.22, 1.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.35	6.50	
95% CI of the absolute risk difference	(-11.25, 6.54)	(-8.50, 21.50)	
p-value	0.6322	0.3162	
p-value of Breslow-Day Test for Homogeneity [3]	0.1201	0.9350	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (26.2)	6 (24.0)	41 (22.9)
No	31 (73.8)	19 (76.0)	138 (77.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.94	
95% CI of the inverse odds ratio	(0.39, 1.81)	(0.35, 2.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.95	
95% CI of the inverse risk ratio	(0.49, 1.55)	(0.45, 2.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.29	1.09	
95% CI of the absolute risk difference	(-11.37, 17.94)	(-16.74, 18.93)	
p-value	0.6515	0.9031	
p-value of Breslow-Day Test for Homogeneity [3]	0.6897	0.9622	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Total LDQOL						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	76.70 (13.74)	79.75 (11.07)	76.06 (14.68)			
Median	77.10	83.80	79.75			
IQR: Q1, Q3	68.40, 88.70	73.10, 88.70	66.60, 87.10			
Min, Max	38.5, 96.7	55.5, 93.0	34.8, 94.9			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	77.52 (13.05)	77.99 (10.89)	79.02 (13.31)	1.88 (1.56)	-1.48 (1.10)	3.00 (1.32)
Median	79.20	78.40	82.10	0.30	-1.55	2.30
IQR: Q1, Q3	68.30, 89.50	69.50, 87.20	70.20, 88.40	-5.80, 5.90	-6.20, 1.90	-1.60, 7.30
Min, Max	42.6, 96.7	56.3, 95.6	22.4, 96.9	-15.6, 35.6	-12.5, 17.7	-46.4, 42.3
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	77.72 (13.85)	78.14 (11.11)	78.89 (12.65)	1.59 (1.52)	-2.85 (1.78)	2.50 (1.26)
Median	80.25	78.85	80.30	1.50	-4.00	0.60
IQR: Q1, Q3	66.90, 88.80	70.55, 86.80	71.20, 88.40	-3.05, 5.00	-8.90, 3.30	-3.90, 7.35
Min, Max	48.8, 96.7	50.7, 96.3	40.7, 97.6	-18.9, 24.7	-23.3, 24.3	-22.1, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Symptoms of Liver Disease						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	74.07 (21.46)	79.14 (17.04)	74.55 (18.91)			
Median	80.00	83.30	76.70			
IQR: Q1, Q3	56.70, 93.30	66.70, 93.30	60.00, 90.00			
Min, Max	23.3, 100.0	30.0, 100.0	26.7, 100.0			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	72.84 (19.37)	76.32 (17.56)	78.31 (18.30)	-0.15 (2.31)	-2.54 (2.04)	2.68 (1.44)
Median	76.70	76.70	83.30	0	-3.30	0
IQR: Q1, Q3	60.00, 86.70	66.70, 90.00	70.00, 93.30	-10.00, 6.70	-10.00, 3.40	-3.40, 10.00
Min, Max	20.0, 100.0	26.7, 100.0	30.0, 100.0	-26.7, 36.7	-36.6, 30.0	-43.3, 43.3
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	74.47 (21.91)	78.64 (15.81)	75.15 (19.95)	-0.28 (2.12)	0.11 (2.80)	0.88 (1.50)
Median	81.65	80.00	76.70	0	0	1.65
IQR: Q1, Q3	53.30, 93.30	68.35, 93.30	60.00, 93.30	-8.35, 5.00	-13.40, 10.00	-6.70, 10.00
Min, Max	23.3, 100.0	40.0, 100.0	23.3, 100.0	-26.7, 43.4	-20.0, 30.0	-36.7, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Effects of Liver Disease						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	76.15 (12.18)	83.76 (9.16)	75.48 (15.80)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	80.00, 86.70	73.30, 80.00			
Min, Max	26.7, 93.3	66.7, 100.0	26.7, 100.0			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	75.89 (13.08)	80.18 (9.62)	76.31 (16.02)	-0.15 (1.93)	-4.12 (1.80)	1.40 (1.49)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	73.30, 80.00	-3.30, 6.70	-6.70, 0.00	0.00, 6.60
Min, Max	40.0, 100.0	53.3, 100.0	6.7, 100.0	-40.0, 33.3	-33.3, 13.3	-40.0, 46.7
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	76.32 (12.08)	80.83 (7.89)	77.69 (13.08)	-0.74 (2.07)	-3.91 (2.11)	2.22 (2.05)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	73.30, 80.00	-3.30, 0.00	-6.70, 0.00	-6.60, 6.70
Min, Max	46.7, 100.0	66.7, 100.0	20.0, 100.0	-33.4, 46.7	-33.3, 20.0	-53.3, 53.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Concentration/Memory						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	79.33 (21.72)	77.10 (20.73)	77.80 (22.15)			
Median	81.30	81.30	81.30			
IQR: Q1, Q3	68.80, 100.00	62.50, 100.00	68.80, 93.80			
Min, Max	18.8, 100.0	25.0, 100.0	6.3, 100.0			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	77.28 (20.50)	77.81 (18.98)	82.67 (21.04)	-0.57 (2.17)	-0.74 (2.39)	5.09 (1.80)
Median	81.30	75.00	93.80	0	0	0
IQR: Q1, Q3	62.50, 100.00	68.80, 93.80	68.80, 100.00	-6.20, 6.20	-6.30, 6.30	0.00, 12.50
Min, Max	25.0, 100.0	25.0, 100.0	12.5, 100.0	-43.8, 25.0	-37.5, 25.0	-43.8, 62.5
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	78.80 (17.53)	77.17 (20.05)	81.27 (20.21)	0.86 (2.35)	-3.45 (3.08)	3.65 (1.69)
Median	81.30	84.40	87.50	0	0	0
IQR: Q1, Q3	68.80, 93.80	62.50, 93.80	68.80, 100.00	-6.30, 6.25	-12.50, 6.20	-6.20, 12.50
Min, Max	37.5, 100.0	18.8, 100.0	18.8, 100.0	-25.0, 50.0	-37.5, 43.7	-31.3, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Health Distress						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	81.67 (23.93)	86.86 (22.39)	80.14 (25.27)			
Median	87.50	100.00	87.50			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	12.5, 100.0	0.0, 100.0			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	87.50 (19.68)	88.16 (19.70)	86.18 (22.16)	7.10 (2.71)	2.57 (2.83)	7.10 (2.31)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	75.00, 100.00	0.00, 12.50	0.00, 0.00	0.00, 12.50
Min, Max	37.5, 100.0	25.0, 100.0	0.0, 100.0	-37.5, 62.5	-25.0, 50.0	-62.5, 75.0
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	85.20 (23.94)	87.50 (18.51)	85.67 (20.31)	3.82 (3.98)	-2.16 (3.17)	5.21 (2.88)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	81.25, 100.00	75.00, 100.00	0.00, 6.25	-12.50, 0.00	0.00, 18.75
Min, Max	0.0, 100.0	37.5, 100.0	0.0, 100.0	-75.0, 75.0	-50.0, 25.0	-62.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Sexual Function						
Baseline						
m	48	44	95			
n	20	22	37			
Mean (SD)	72.33 (30.84)	77.86 (24.35)	69.82 (31.06)			
Median	80.85	93.30	80.00			
IQR: Q1, Q3	58.30, 100.00	53.30, 100.00	53.30, 93.30			
Min, Max	-1.7, 100.0	38.3, 100.0	5.0, 100.0			
Week 24						
m	47	39	87			
n	20	22	37	17	18	28
Mean (SD/SE)	75.00 (26.67)	75.98 (28.36)	77.66 (25.33)	0.88 (4.14)	-5.63 (5.71)	1.43 (4.03)
Median	81.65	85.00	86.70	0	0	0
IQR: Q1, Q3	62.50, 96.65	65.00, 100.00	61.70, 100.00	0.00, 8.30	-16.60, 0.00	-7.50, 7.50
Min, Max	23.3, 100.0	13.3, 100.0	-1.7, 100.0	-38.4, 25.0	-55.0, 46.7	-48.4, 45.0
Week 52						
m	45	35	81			
n	13	20	31	12	16	23
Mean (SD/SE)	81.54 (28.35)	73.77 (29.23)	70.11 (29.41)	9.33 (7.01)	-1.90 (6.67)	-2.32 (4.90)
Median	93.30	85.00	76.70	0	0	0
IQR: Q1, Q3	76.70, 100.00	52.20, 100.00	46.70, 93.30	-4.15, 10.85	-18.35, 4.20	-16.60, 16.60
Min, Max	6.7, 100.0	5.0, 100.0	-1.7, 100.0	-16.6, 61.7	-48.3, 61.7	-53.3, 30.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Sleep						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	60.00 (22.34)	60.00 (19.87)	61.11 (21.09)			
Median	65.00	65.00	62.50			
IQR: Q1, Q3	45.00, 80.00	45.00, 75.00	45.00, 80.00			
Min, Max	0.0, 90.0	0.0, 90.0	15.0, 100.0			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	61.70 (21.19)	57.37 (19.20)	62.35 (19.27)	2.05 (3.06)	-2.50 (2.79)	0.80 (1.97)
Median	65.00	60.00	60.00	0	0	0
IQR: Q1, Q3	45.00, 75.00	45.00, 70.00	50.00, 75.00	-10.00, 7.50	-15.00, 5.00	-10.00, 15.00
Min, Max	15.0, 95.0	15.0, 85.0	15.0, 100.0	-25.0, 90.0	-35.0, 40.0	-40.0, 50.0
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	63.03 (21.98)	55.63 (21.24)	63.40 (19.56)	2.36 (2.84)	-5.00 (3.42)	1.88 (1.97)
Median	65.00	55.00	65.00	0	-5.00	0
IQR: Q1, Q3	55.00, 75.00	42.50, 72.50	50.00, 80.00	-10.00, 10.00	-15.00, 5.00	-7.50, 10.00
Min, Max	15.0, 100.0	10.0, 90.0	25.0, 100.0	-30.0, 45.0	-60.0, 45.0	-40.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Loneliness						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	83.44 (17.28)	87.44 (15.43)	82.83 (20.76)			
Median	90.00	95.00	90.00			
IQR: Q1, Q3	70.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	40.0, 100.0	45.0, 100.0	25.0, 100.0			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	84.68 (16.53)	87.11 (13.69)	83.82 (19.16)	2.27 (2.47)	-0.59 (2.00)	0.99 (2.23)
Median	90.00	90.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	80.00, 100.00	75.00, 100.00	-7.50, 12.50	-5.00, 5.00	-10.00, 10.00
Min, Max	45.0, 100.0	55.0, 100.0	20.0, 100.0	-45.0, 45.0	-25.0, 30.0	-80.0, 70.0
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	82.37 (18.37)	85.31 (14.75)	86.07 (17.33)	0.14 (2.86)	-1.90 (2.96)	2.22 (2.32)
Median	82.50	87.50	95.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	80.00, 100.00	-10.00, 7.50	-10.00, 5.00	-10.00, 5.00
Min, Max	35.0, 100.0	45.0, 100.0	45.0, 100.0	-55.0, 40.0	-40.0, 30.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Hopelessness						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	79.82 (21.73)	80.34 (21.42)	76.48 (22.54)			
Median	91.70	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	58.30, 100.00			
Min, Max	25.0, 100.0	8.3, 100.0	16.7, 100.0			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	75.71 (23.18)	78.73 (22.07)	79.61 (20.02)	-1.71 (3.03)	0.74 (2.60)	2.27 (2.27)
Median	83.30	87.50	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	66.70, 100.00	-8.40, 8.30	-8.30, 8.40	-8.30, 16.60
Min, Max	16.7, 100.0	25.0, 100.0	16.7, 100.0	-58.3, 50.0	-33.4, 41.7	-66.6, 50.0
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	76.75 (23.35)	78.91 (23.47)	79.56 (19.68)	-1.39 (2.58)	-2.01 (2.70)	0.24 (1.97)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	66.70, 100.00	-4.15, 8.30	-16.60, 8.30	-8.30, 8.40
Min, Max	33.3, 100.0	0.0, 100.0	33.3, 100.0	-41.7, 25.0	-25.0, 33.3	-50.0, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Stigma of Liver Disease						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	82.52 (21.25)	84.47 (15.16)	82.66 (16.93)			
Median	93.80	87.50	87.50			
IQR: Q1, Q3	68.80, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	31.3, 100.0	50.0, 100.0	31.3, 100.0			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	86.72 (19.44)	79.79 (20.10)	84.80 (17.40)	4.97 (3.12)	-4.04 (1.84)	2.55 (1.98)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	75.00, 100.00	0.00, 9.40	-6.30, 0.00	-6.20, 12.50
Min, Max	31.3, 100.0	25.0, 100.0	25.0, 100.0	-43.7, 56.2	-31.3, 12.5	-62.5, 43.8
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	85.21 (20.05)	83.62 (20.12)	85.94 (17.07)	3.12 (2.78)	-3.01 (3.35)	4.43 (2.13)
Median	96.90	93.80	93.80	0	0	0
IQR: Q1, Q3	75.00, 100.00	78.15, 100.00	75.00, 100.00	0.00, 6.25	-12.50, 6.30	-6.20, 12.50
Min, Max	37.5, 100.0	12.5, 100.0	25.0, 100.0	-31.3, 56.2	-56.2, 31.2	-43.8, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=77)	Visit Result MGL-3196 100 mg (N=72)	Visit Result Placebo (N=128)	Change from Baseline MGL-3196 80 mg (N=77)	Change from Baseline MGL-3196 100 mg (N=72)	Change from Baseline Placebo (N=128)
Total LDQOL						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	77.64 (14.15)	75.25 (16.36)	78.02 (14.77)			
Median	82.00	79.40	82.40			
IQR: Q1, Q3	69.70, 88.80	65.80, 86.00	71.00, 88.70			
Min, Max	39.3, 96.5	23.6, 96.3	38.5, 97.8			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	76.16 (16.24)	77.64 (13.83)	77.55 (14.90)	-1.31 (0.94)	2.17 (1.16)	-0.81 (0.69)
Median	77.80	80.80	80.85	-0.90	1.80	-0.70
IQR: Q1, Q3	69.20, 89.70	71.30, 86.85	68.40, 89.70	-5.70, 3.10	-3.80, 7.90	-4.60, 2.60
Min, Max	22.9, 97.2	32.4, 96.9	32.4, 98.8	-23.4, 15.0	-15.4, 27.0	-20.6, 23.9
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	79.26 (13.78)	78.21 (15.78)	77.06 (16.92)	0.74 (0.87)	2.63 (1.34)	-1.80 (1.00)
Median	84.85	84.10	81.10	0.60	2.45	-0.20
IQR: Q1, Q3	71.00, 89.00	68.40, 90.70	66.40, 89.90	-3.60, 6.30	-2.80, 7.50	-5.50, 3.60
Min, Max	34.0, 97.5	34.2, 97.4	20.3, 100.0	-19.3, 12.6	-19.2, 33.9	-46.3, 18.6

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=77)	Visit Result MGL-3196 100 mg (N=72)	Visit Result Placebo (N=128)	Change from Baseline MGL-3196 80 mg (N=77)	Change from Baseline MGL-3196 100 mg (N=72)	Change from Baseline Placebo (N=128)
Symptoms of Liver Disease						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	77.85 (17.91)	70.91 (19.54)	77.70 (17.19)			
Median	80.00	73.30	80.00			
IQR: Q1, Q3	70.00, 93.30	56.70, 86.70	66.70, 93.30			
Min, Max	26.7, 100.0	10.0, 100.0	30.0, 100.0			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	74.57 (21.89)	72.61 (19.10)	75.87 (20.35)	-3.94 (1.66)	1.29 (1.61)	-2.21 (1.38)
Median	80.00	75.00	81.65	0	0	0
IQR: Q1, Q3	66.70, 90.00	65.00, 86.70	63.30, 90.00	-10.00, 6.60	-6.70, 10.00	-10.00, 6.60
Min, Max	0.0, 100.0	26.7, 100.0	16.7, 100.0	-46.7, 16.7	-33.3, 30.0	-53.3, 36.7
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	77.82 (17.54)	75.69 (19.61)	78.41 (19.15)	-2.28 (1.53)	3.20 (1.84)	-0.28 (1.41)
Median	83.30	76.70	83.30	0	0	0
IQR: Q1, Q3	66.70, 93.30	63.30, 93.30	66.70, 93.30	-10.00, 6.70	-3.30, 13.30	-6.70, 6.70
Min, Max	33.3, 100.0	26.7, 100.0	23.3, 100.0	-36.7, 20.0	-33.3, 36.7	-60.0, 26.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=77)	Visit Result MGL-3196 100 mg (N=72)	Visit Result Placebo (N=128)	Change from Baseline MGL-3196 80 mg (N=77)	Change from Baseline MGL-3196 100 mg (N=72)	Change from Baseline Placebo (N=128)
Effects of Liver Disease						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	79.18 (9.62)	75.46 (16.83)	78.32 (14.93)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	73.30, 80.00	80.00, 86.70			
Min, Max	46.7, 100.0	13.3, 100.0	6.7, 100.0			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	74.88 (13.59)	79.33 (11.57)	78.53 (13.14)	-3.66 (1.43)	3.90 (2.37)	-0.63 (1.31)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	76.65, 86.70	80.00, 86.70	-6.70, 0.00	-6.70, 6.70	-6.70, 6.60
Min, Max	26.7, 100.0	40.0, 100.0	40.0, 100.0	-33.4, 26.6	-20.0, 76.7	-40.0, 40.0
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	77.12 (11.63)	77.06 (13.24)	76.35 (15.97)	-1.43 (1.16)	2.20 (1.93)	-4.05 (1.89)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	73.30, 80.00	73.30, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 0.00
Min, Max	40.0, 100.0	33.3, 100.0	13.3, 100.0	-26.6, 20.0	-20.0, 53.4	-80.0, 46.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=77)	Visit Result MGL-3196 100 mg (N=72)	Visit Result Placebo (N=128)	Change from Baseline MGL-3196 80 mg (N=77)	Change from Baseline MGL-3196 100 mg (N=72)	Change from Baseline Placebo (N=128)
Concentration/Memory						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	81.61 (22.98)	79.57 (20.72)	76.54 (21.62)			
Median	87.50	87.50	81.30			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	62.50, 93.80			
Min, Max	12.5, 100.0	18.8, 100.0	12.5, 100.0			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	76.90 (24.69)	81.07 (21.13)	76.03 (22.48)	-4.22 (1.68)	0.84 (2.16)	-1.52 (1.42)
Median	87.50	87.50	81.30	0	0	0
IQR: Q1, Q3	62.50, 93.80	68.80, 100.00	62.50, 93.80	-12.50, 6.20	-6.30, 6.30	-6.30, 6.20
Min, Max	0.0, 100.0	25.0, 100.0	6.3, 100.0	-43.8, 25.0	-31.3, 56.2	-37.5, 62.5
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	77.77 (22.31)	81.39 (21.30)	74.59 (23.81)	-4.16 (1.74)	-0.37 (2.12)	-4.04 (1.48)
Median	81.30	93.80	81.30	-6.20	0	0
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	62.50, 93.80	-12.50, 0.00	-6.20, 6.30	-12.50, 0.00
Min, Max	0.0, 100.0	18.8, 100.0	0.0, 100.0	-43.7, 31.3	-43.8, 50.0	-43.8, 37.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=77)	Visit Result MGL-3196 100 mg (N=72)	Visit Result Placebo (N=128)	Change from Baseline MGL-3196 80 mg (N=77)	Change from Baseline MGL-3196 100 mg (N=72)	Change from Baseline Placebo (N=128)
Health Distress						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	76.20 (28.12)	79.55 (25.44)	79.89 (25.20)			
Median	87.50	87.50	87.50			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	62.50, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	78.25 (27.09)	87.11 (21.70)	84.32 (23.30)	3.17 (2.64)	7.42 (2.24)	3.74 (1.81)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 75.0	-37.5, 50.0	-50.0, 62.5
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	82.95 (25.06)	87.01 (21.79)	84.34 (24.36)	6.55 (2.99)	8.00 (2.69)	2.28 (2.33)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 75.0	-25.0, 50.0	-87.5, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=77)	Visit Result MGL-3196 100 mg (N=72)	Visit Result Placebo (N=128)	Change from Baseline MGL-3196 80 mg (N=77)	Change from Baseline MGL-3196 100 mg (N=72)	Change from Baseline Placebo (N=128)
Sexual Function						
Baseline						
m	77	72	128			
n	34	34	47			
Mean (SD)	83.84 (25.87)	77.84 (24.86)	83.83 (21.82)			
Median	93.30	84.15	86.70			
IQR: Q1, Q3	85.00, 100.00	63.30, 100.00	78.30, 100.00			
Min, Max	8.9, 100.0	-1.7, 100.0	-1.7, 100.0			
Week 24						
m	76	68	125			
n	37	38	52	28	26	38
Mean (SD/SE)	79.61 (25.10)	76.18 (24.34)	77.85 (25.02)	-1.79 (6.00)	1.16 (3.01)	-1.45 (3.08)
Median	86.70	78.35	85.00	0	0	0
IQR: Q1, Q3	61.70, 100.00	60.00, 100.00	68.30, 100.00	-8.30, 0.85	0.00, 6.70	-8.30, 6.60
Min, Max	6.7, 100.0	15.0, 100.0	6.7, 100.0	-85.0, 91.1	-40.0, 41.7	-46.7, 50.0
Week 52						
m	70	57	120			
n	29	22	38	24	18	32
Mean (SD/SE)	85.11 (21.00)	85.45 (21.54)	80.22 (25.91)	-1.41 (4.65)	3.99 (2.38)	1.37 (4.02)
Median	93.30	100.00	93.30	0	0	0
IQR: Q1, Q3	76.70, 100.00	70.00, 100.00	68.30, 100.00	-7.50, 0.00	0.00, 6.70	-8.30, 6.65
Min, Max	28.3, 100.0	30.0, 100.0	-1.7, 100.0	-45.0, 91.1	-16.6, 23.4	-40.0, 65.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=77)	Visit Result MGL-3196 100 mg (N=72)	Visit Result Placebo (N=128)	Change from Baseline MGL-3196 80 mg (N=77)	Change from Baseline MGL-3196 100 mg (N=72)	Change from Baseline Placebo (N=128)
Sleep						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	63.49 (20.99)	58.48 (20.44)	64.29 (20.13)			
Median	65.00	60.00	65.00			
IQR: Q1, Q3	50.00, 80.00	45.00, 75.00	50.00, 80.00			
Min, Max	10.0, 100.0	5.0, 100.0	5.0, 100.0			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	63.15 (22.26)	57.73 (21.17)	62.08 (21.84)	-0.42 (1.50)	0.34 (1.85)	-1.53 (1.45)
Median	65.00	60.00	60.00	0	0	0
IQR: Q1, Q3	50.00, 80.00	40.00, 75.00	45.00, 80.00	-5.00, 5.00	-10.00, 10.00	-10.00, 5.00
Min, Max	5.0, 100.0	0.0, 95.0	20.0, 100.0	-30.0, 35.0	-30.0, 45.0	-30.0, 40.0
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	65.32 (19.76)	59.71 (22.24)	63.83 (22.53)	0.26 (2.10)	1.10 (2.46)	0.07 (1.52)
Median	70.00	65.00	60.00	0	0	0
IQR: Q1, Q3	50.00, 80.00	40.00, 75.00	45.00, 85.00	-10.00, 5.00	-10.00, 15.00	-5.00, 5.00
Min, Max	10.0, 100.0	0.0, 95.0	5.0, 100.0	-40.0, 75.0	-55.0, 40.0	-40.0, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=77)	Visit Result MGL-3196 100 mg (N=72)	Visit Result Placebo (N=128)	Change from Baseline MGL-3196 80 mg (N=77)	Change from Baseline MGL-3196 100 mg (N=72)	Change from Baseline Placebo (N=128)
Loneliness						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	83.90 (19.67)	81.89 (22.30)	83.37 (21.16)			
Median	95.00	90.00	95.00			
IQR: Q1, Q3	75.00, 100.00	70.00, 100.00	70.00, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	81.95 (21.31)	86.72 (18.90)	81.57 (22.11)	-2.36 (2.08)	2.88 (1.79)	-2.69 (1.30)
Median	90.00	95.00	90.00	0	0	0
IQR: Q1, Q3	70.00, 100.00	80.00, 100.00	75.00, 100.00	-10.00, 5.00	-5.00, 5.00	-10.00, 5.00
Min, Max	15.0, 100.0	0.0, 100.0	10.0, 100.0	-50.0, 40.0	-25.0, 65.0	-40.0, 35.0
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	85.91 (18.42)	82.35 (24.36)	80.97 (21.97)	1.11 (2.05)	0.40 (2.19)	-2.82 (1.52)
Median	95.00	95.00	90.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	75.00, 100.00	70.00, 100.00	-5.00, 5.00	-5.00, 10.00	-10.00, 5.00
Min, Max	25.0, 100.0	0.0, 100.0	5.0, 100.0	-60.0, 50.0	-40.0, 30.0	-40.0, 35.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=77)	Visit Result: MGL-3196 100 mg (N=72)	Visit Result: Placebo (N=128)	Change from Baseline: MGL-3196 80 mg (N=77)	Change from Baseline: MGL-3196 100 mg (N=72)	Change from Baseline: Placebo (N=128)
Hopelessness						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	74.66 (23.01)	76.26 (23.90)	79.49 (21.36)			
Median	75.00	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	50.00, 100.00	58.30, 100.00			
Min, Max	8.3, 100.0	25.0, 100.0	25.0, 100.0			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	76.03 (23.32)	77.08 (24.04)	77.23 (22.85)	1.64 (2.22)	0.85 (2.52)	-2.06 (1.69)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	58.30, 100.00	-8.40, 16.70	-8.40, 16.70	-8.30, 8.30
Min, Max	8.3, 100.0	8.3, 100.0	16.7, 100.0	-41.7, 41.7	-41.7, 41.7	-58.3, 50.0
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	79.30 (21.54)	77.29 (22.85)	75.41 (25.31)	3.31 (2.36)	0.84 (3.37)	-4.12 (2.19)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	58.30, 100.00	58.30, 100.00	-8.30, 16.60	-8.30, 16.70	-8.30, 8.30
Min, Max	16.7, 100.0	16.7, 100.0	0.0, 100.0	-41.6, 41.7	-58.3, 50.0	-100.0, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=77)	Visit Result: MGL-3196 100 mg (N=72)	Visit Result: Placebo (N=128)	Change from Baseline: MGL-3196 80 mg (N=77)	Change from Baseline: MGL-3196 100 mg (N=72)	Change from Baseline: Placebo (N=128)
Stigma of Liver Disease						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	81.95 (22.01)	79.94 (21.88)	83.45 (21.68)			
Median	93.80	81.30	93.80			
IQR: Q1, Q3	75.00, 100.00	68.80, 100.00	81.30, 100.00			
Min, Max	18.8, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	82.64 (20.78)	81.56 (19.75)	85.24 (19.39)	0.79 (2.10)	2.23 (1.96)	1.16 (1.57)
Median	87.50	84.40	93.80	0	0	0
IQR: Q1, Q3	75.00, 100.00	68.80, 100.00	81.30, 100.00	-6.30, 6.30	-6.30, 6.30	-6.20, 6.20
Min, Max	6.3, 100.0	12.5, 100.0	25.0, 100.0	-43.8, 50.0	-18.8, 56.3	-43.8, 75.0
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	86.10 (17.83)	83.84 (20.73)	83.58 (19.97)	3.47 (1.62)	5.75 (2.20)	-0.41 (1.60)
Median	93.80	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	68.80, 100.00	75.00, 100.00	0.00, 6.30	0.00, 12.50	-6.30, 6.20
Min, Max	31.3, 100.0	12.5, 100.0	25.0, 100.0	-25.0, 37.5	-18.8, 56.3	-56.3, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=63)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=63)
Total LDQOL						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	78.26 (15.27)	76.70 (10.99)	79.26 (10.89)			
Median	82.95	79.70	80.45			
IQR: Q1, Q3	74.80, 88.90	66.10, 84.80	73.10, 87.30			
Min, Max	29.0, 93.9	56.8, 93.2	43.1, 95.7			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	83.32 (12.39)	75.38 (9.95)	80.19 (13.15)	3.27 (1.51)	-1.92 (1.53)	0.28 (1.43)
Median	86.50	77.10	84.10	2.50	-2.10	0.90
IQR: Q1, Q3	80.00, 90.50	69.30, 80.10	74.00, 89.30	-2.00, 8.50	-6.90, 2.90	-3.90, 5.90
Min, Max	33.6, 97.8	55.5, 92.3	44.3, 96.3	-13.6, 24.2	-12.7, 9.7	-27.7, 29.7
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	81.00 (10.12)	77.92 (11.84)	81.86 (9.90)	0.63 (2.34)	0.14 (1.65)	2.19 (1.06)
Median	83.80	80.50	84.10	-0.90	-1.00	3.40
IQR: Q1, Q3	72.60, 90.20	67.40, 86.70	75.10, 89.40	-7.10, 4.10	-3.85, 3.85	-3.30, 6.25
Min, Max	60.5, 92.5	54.9, 95.7	59.3, 97.8	-17.8, 36.0	-13.9, 18.3	-11.7, 22.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Symptoms of Liver Disease						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	81.00 (17.48)	78.41 (17.82)	75.99 (17.26)			
Median	86.70	83.30	80.00			
IQR: Q1, Q3	73.30, 93.30	70.00, 90.00	63.30, 90.00			
Min, Max	23.3, 96.7	43.3, 100.0	20.0, 100.0			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	85.55 (12.30)	70.91 (17.07)	78.49 (17.91)	2.84 (2.30)	-6.66 (2.62)	1.65 (1.78)
Median	90.00	73.30	83.30	0	-3.30	3.30
IQR: Q1, Q3	76.70, 93.30	60.00, 80.00	66.70, 93.30	-3.40, 6.70	-13.40, 0.00	-3.40, 6.70
Min, Max	50.0, 100.0	36.7, 100.0	33.3, 100.0	-20.0, 30.0	-30.0, 30.0	-30.0, 36.7
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	80.66 (15.69)	77.15 (17.49)	80.21 (17.73)	-2.80 (2.99)	-1.16 (3.12)	2.72 (1.64)
Median	86.70	83.30	83.30	0	-1.65	3.30
IQR: Q1, Q3	70.00, 93.30	66.70, 90.00	76.70, 93.30	-6.70, 3.30	-6.70, 8.30	-3.35, 6.70
Min, Max	40.0, 100.0	36.7, 96.7	16.7, 100.0	-43.4, 33.4	-36.7, 23.4	-30.0, 23.4

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=30)	Visit Result: MGL-3196 100 mg (N=22)	Visit Result: Placebo (N=63)	Change from Baseline: MGL-3196 80 mg (N=30)	Change from Baseline: MGL-3196 100 mg (N=22)	Change from Baseline: Placebo (N=63)
Effects of Liver Disease						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	76.68 (20.03)	82.86 (10.45)	78.56 (13.67)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	66.70, 86.70	80.00, 86.70	80.00, 86.70			
Min, Max	13.3, 100.0	60.0, 100.0	26.7, 100.0			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	79.27 (13.88)	77.27 (7.33)	76.85 (16.28)	-0.25 (1.80)	-6.03 (2.39)	-1.39 (2.60)
Median	80.00	80.00	80.00	0	-6.70	0
IQR: Q1, Q3	80.00, 86.70	73.30, 80.00	80.00, 86.70	-6.70, 6.70	-13.30, 0.00	-6.70, 6.70
Min, Max	20.0, 100.0	60.0, 86.7	6.7, 100.0	-20.0, 20.0	-20.0, 20.0	-46.7, 53.4
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	78.14 (13.26)	77.15 (12.21)	80.72 (7.73)	-0.81 (4.59)	-5.66 (2.70)	3.17 (2.41)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 6.60	-13.30, 0.00	-3.35, 6.70
Min, Max	40.0, 100.0	26.7, 86.7	53.3, 100.0	-40.0, 80.0	-33.3, 20.0	-26.7, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Concentration/Memory						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	78.56 (24.93)	79.49 (19.79)	82.83 (17.09)			
Median	84.40	87.50	87.50			
IQR: Q1, Q3	68.80, 100.00	75.00, 93.80	68.80, 100.00			
Min, Max	12.5, 100.0	25.0, 100.0	31.3, 100.0			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	84.27 (18.78)	79.29 (16.41)	83.66 (19.37)	2.77 (3.24)	-1.19 (3.30)	-0.94 (2.40)
Median	87.50	81.30	87.50	0	0	0
IQR: Q1, Q3	75.00, 100.00	68.80, 93.80	75.00, 100.00	-12.50, 18.70	-12.50, 6.30	-6.20, 6.20
Min, Max	31.3, 100.0	37.5, 100.0	18.8, 100.0	-25.0, 31.2	-25.0, 37.5	-81.2, 37.5
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	83.28 (15.17)	77.40 (19.80)	84.26 (17.91)	4.00 (2.55)	-2.51 (3.16)	-0.28 (1.88)
Median	81.30	81.30	90.65	0	0	0
IQR: Q1, Q3	75.00, 93.80	56.30, 93.80	68.80, 100.00	0.00, 6.30	-12.50, 6.25	-6.30, 6.30
Min, Max	37.5, 100.0	43.8, 100.0	25.0, 100.0	-12.5, 50.0	-25.0, 25.0	-25.0, 31.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Health Distress						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	76.67 (27.02)	78.57 (26.26)	82.08 (20.76)			
Median	81.25	87.50	87.50			
IQR: Q1, Q3	50.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	25.0, 100.0			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	86.57 (18.65)	84.09 (17.75)	88.18 (17.75)	8.33 (4.22)	4.76 (4.99)	6.13 (2.66)
Median	87.50	87.50	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 25.00	0.00, 12.50
Min, Max	25.0, 100.0	37.5, 100.0	25.0, 100.0	-37.5, 62.5	-37.5, 37.5	-50.0, 62.5
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	79.50 (22.50)	86.90 (18.74)	89.40 (14.18)	1.50 (4.96)	6.88 (4.84)	7.67 (2.88)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00	-12.50, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	37.5, 100.0	50.0, 100.0	50.0, 100.0	-37.5, 75.0	-37.5, 62.5	-25.0, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Sexual Function						
Baseline						
m	30	22	63			
n	11	9	28			
Mean (SD)	84.99 (18.18)	84.62 (18.57)	82.38 (17.81)			
Median	93.30	93.30	85.85			
IQR: Q1, Q3	70.00, 100.00	76.70, 100.00	68.30, 100.00			
Min, Max	53.3, 100.0	45.0, 100.0	38.3, 100.0			
Week 24						
m	28	22	60			
n	10	10	31	8	9	24
Mean (SD/SE)	93.33 (9.28)	72.34 (26.21)	83.75 (18.94)	9.39 (3.48)	-15.36 (7.23)	2.36 (2.57)
Median	96.65	73.35	93.30	6.70	0	0
IQR: Q1, Q3	93.30, 100.00	51.70, 100.00	68.30, 100.00	0.00, 19.15	-38.30, 0.00	-6.70, 11.65
Min, Max	76.7, 100.0	30.0, 100.0	31.7, 100.0	0.0, 23.4	-48.3, 8.3	-23.3, 26.7
Week 52						
m	27	22	54			
n	7	9	24	6	8	19
Mean (SD/SE)	95.31 (6.79)	75.54 (24.23)	80.63 (22.37)	8.35 (5.83)	-12.09 (7.23)	-2.78 (4.03)
Median	100.00	76.70	85.85	3.35	0	0
IQR: Q1, Q3	91.70, 100.00	53.30, 100.00	73.35, 100.00	0.00, 6.70	-27.50, 0.00	-8.30, 6.70
Min, Max	82.2, 100.0	38.3, 100.0	28.3, 100.0	0.0, 36.7	-50.0, 8.3	-46.6, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=63)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=63)
Sleep						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	66.33 (18.89)	62.14 (14.10)	62.42 (19.23)			
Median	70.00	65.00	62.50			
IQR: Q1, Q3	55.00, 80.00	55.00, 70.00	50.00, 75.00			
Min, Max	30.0, 100.0	25.0, 85.0	5.0, 100.0			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	67.04 (17.66)	58.41 (14.17)	64.27 (18.54)	-0.74 (2.28)	-4.29 (2.54)	-0.09 (2.04)
Median	70.00	57.50	65.00	0	-5.00	0
IQR: Q1, Q3	50.00, 80.00	50.00, 70.00	50.00, 80.00	-5.00, 5.00	-10.00, 5.00	-10.00, 10.00
Min, Max	25.0, 100.0	35.0, 90.0	20.0, 100.0	-25.0, 30.0	-30.0, 20.0	-25.0, 40.0
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	64.40 (15.50)	62.62 (15.13)	65.54 (17.77)	-4.00 (2.66)	-0.75 (2.93)	1.25 (2.51)
Median	65.00	65.00	67.50	-5.00	0	0
IQR: Q1, Q3	55.00, 75.00	60.00, 70.00	50.00, 80.00	-10.00, 5.00	-10.00, 10.00	-10.00, 12.50
Min, Max	40.0, 95.0	20.0, 85.0	30.0, 100.0	-25.0, 25.0	-25.0, 20.0	-30.0, 45.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Loneliness						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	86.17 (15.96)	77.86 (18.07)	85.83 (15.87)			
Median	90.00	80.00	90.00			
IQR: Q1, Q3	75.00, 100.00	65.00, 95.00	77.50, 97.50			
Min, Max	40.0, 100.0	40.0, 100.0	35.0, 100.0			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	85.93 (16.99)	76.59 (26.47)	83.64 (19.89)	0.00 (2.46)	-2.14 (3.55)	-3.21 (2.35)
Median	90.00	92.50	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	55.00, 95.00	80.00, 100.00	-10.00, 5.00	-20.00, 15.00	-10.00, 5.00
Min, Max	35.0, 100.0	25.0, 100.0	30.0, 100.0	-30.0, 25.0	-35.0, 20.0	-60.0, 40.0
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	85.80 (13.90)	83.10 (23.16)	86.74 (15.61)	-0.80 (2.54)	3.75 (2.90)	1.02 (1.93)
Median	80.00	95.00	95.00	0	0	2.50
IQR: Q1, Q3	80.00, 100.00	80.00, 100.00	80.00, 100.00	-5.00, 5.00	-5.00, 15.00	0.00, 7.50
Min, Max	45.0, 100.0	35.0, 100.0	45.0, 100.0	-20.0, 40.0	-20.0, 30.0	-40.0, 30.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=63)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=63)
Hopelessness						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	75.83 (22.57)	71.82 (23.04)	81.25 (19.33)			
Median	75.00	75.00	83.30			
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	66.70, 100.00			
Min, Max	25.0, 100.0	33.3, 100.0	25.0, 100.0			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	85.80 (19.18)	76.51 (18.31)	80.61 (21.10)	8.02 (3.31)	3.57 (5.19)	-0.94 (2.49)
Median	91.70	79.15	91.70	0	0	0
IQR: Q1, Q3	83.30, 100.00	66.70, 91.70	58.30, 100.00	0.00, 16.70	-8.30, 16.60	-16.60, 8.40
Min, Max	25.0, 100.0	33.3, 100.0	25.0, 100.0	-16.7, 50.0	-25.0, 58.4	-41.7, 33.4
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	80.00 (18.63)	76.60 (17.41)	83.15 (18.88)	0.66 (4.69)	2.93 (5.65)	2.65 (2.76)
Median	83.30	75.00	91.70	0	0	0
IQR: Q1, Q3	66.70, 100.00	66.70, 91.70	66.70, 100.00	-8.30, 0.00	-16.60, 25.00	-8.30, 12.50
Min, Max	41.7, 100.0	50.0, 100.0	25.0, 100.0	-50.0, 41.7	-50.0, 41.6	-50.0, 33.4

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=63)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=63)
Stigma of Liver Disease						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	81.89 (18.73)	79.19 (17.71)	84.78 (17.91)			
Median	84.40	81.30	90.65			
IQR: Q1, Q3	75.00, 100.00	62.50, 93.80	75.00, 100.00			
Min, Max	25.0, 100.0	43.8, 100.0	31.3, 100.0			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	88.90 (16.19)	80.99 (17.83)	85.21 (19.09)	4.17 (2.36)	1.49 (3.73)	0.83 (2.09)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 93.80	81.30, 100.00	0.00, 12.50	-6.30, 6.30	-6.20, 6.30
Min, Max	31.3, 100.0	37.5, 100.0	6.3, 100.0	-25.0, 37.5	-25.0, 50.0	-37.5, 50.0
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	92.27 (11.00)	83.26 (13.99)	86.30 (18.66)	5.76 (2.16)	2.09 (2.50)	1.75 (2.64)
Median	100.00	81.30	93.80	0	0	0
IQR: Q1, Q3	87.50, 100.00	75.00, 100.00	81.30, 100.00	0.00, 12.50	-6.20, 9.40	-3.10, 6.30
Min, Max	68.8, 100.0	56.3, 100.0	18.8, 100.0	-12.5, 31.3	-12.5, 25.0	-62.5, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
byGenetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.14a.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
byGenetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Total LDQOL			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	76.41 (13.76)	80.05 (10.79)	76.72 (14.31)
Analysis Visit Mean (SD)	78.29 (13.10)	78.58 (11.05)	79.72 (12.85)
LS Mean of Change from Baseline (SE)	1.90 (1.45)	-0.07 (1.64)	2.95 (1.05)
95% CI	(-0.97, 4.76)	(-3.32, 3.17)	(0.88, 5.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.06 (1.73)	-3.03 (1.90)	
95% CI	(-4.48, 2.37)	(-6.77, 0.72)	
p-value	0.5439	0.1127	
Corrected Hedge's g Statistics	-0.110	-0.316	
95% CI	(-0.48, 0.26)	(-0.72, 0.09)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	76.81 (12.80)	80.24 (10.59)	76.28 (14.68)
Analysis Visit Mean (SD)	78.40 (13.90)	77.39 (11.26)	78.78 (12.88)
LS Mean of Change from Baseline (SE)	2.28 (1.63)	-1.86 (1.82)	2.03 (1.16)
95% CI	(-0.94, 5.49)	(-5.45, 1.74)	(-0.26, 4.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.25 (1.94)	-3.89 (2.11)	
95% CI	(-3.59, 4.08)	(-8.05, 0.28)	
p-value	0.8994	0.0672	
Corrected Hedge's g Statistics	0.025	-0.392	
95% CI	(-0.38, 0.42)	(-0.83, 0.04)	
Subgroup*Treatment Interaction p-value	0.6699	0.0041	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
byGenetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Total LDQOL			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	77.57 (14.27)	74.69 (16.88)	78.69 (14.23)
Analysis Visit Mean (SD)	76.26 (15.94)	76.87 (14.11)	77.88 (15.05)
LS Mean of Change from Baseline (SE)	-1.07 (0.93)	1.75 (1.01)	-0.51 (0.77)
95% CI	(-2.91, 0.76)	(-0.24, 3.75)	(-2.03, 1.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.56 (1.17)	2.27 (1.25)	
95% CI	(-2.87, 1.75)	(-0.19, 4.72)	
p-value	0.6336	0.0705	
Corrected Hedge's g Statistics	-0.070	0.285	
95% CI	(-0.37, 0.23)	(-0.03, 0.60)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	78.49 (13.70)	75.37 (17.57)	78.95 (14.52)
Analysis Visit Mean (SD)	79.23 (13.42)	78.00 (15.87)	77.15 (17.41)
LS Mean of Change from Baseline (SE)	0.76 (1.11)	2.65 (1.23)	-1.34 (0.92)
95% CI	(-1.43, 2.95)	(0.23, 5.08)	(-3.16, 0.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.10 (1.41)	4.00 (1.52)	
95% CI	(-0.68, 4.89)	(1.01, 6.98)	
p-value	0.1381	0.0089	
Corrected Hedge's g Statistics	0.236	0.451	
95% CI	(-0.08, 0.56)	(0.10, 0.80)	
Subgroup*Treatment Interaction p-value	0.6699	0.0041	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
byGenetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Total LDQOL			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	80.05 (13.51)	76.70 (10.99)	79.69 (11.13)
Analysis Visit Mean (SD)	83.32 (12.39)	74.78 (9.77)	79.97 (13.28)
LS Mean of Change from Baseline (SE)	2.95 (1.73)	-2.78 (1.93)	-0.14 (1.24)
95% CI	(-0.49, 6.38)	(-6.60, 1.05)	(-2.61, 2.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.09 (2.09)	-2.64 (2.26)	
95% CI	(-1.07, 7.24)	(-7.12, 1.84)	
p-value	0.1435	0.2457	
Corrected Hedge's g Statistics	0.339	-0.290	
95% CI	(-0.13, 0.81)	(-0.80, 0.22)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	80.37 (14.06)	76.89 (11.24)	79.53 (9.98)
Analysis Visit Mean (SD)	81.00 (10.12)	77.03 (11.40)	81.71 (10.01)
LS Mean of Change from Baseline (SE)	0.39 (1.56)	-1.06 (1.72)	1.62 (1.16)
95% CI	(-2.71, 3.50)	(-4.48, 2.35)	(-0.68, 3.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.22 (1.91)	-2.68 (2.04)	
95% CI	(-5.01, 2.56)	(-6.72, 1.36)	
p-value	0.5230	0.1912	
Corrected Hedge's g Statistics	-0.157	-0.345	
95% CI	(-0.65, 0.33)	(-0.88, 0.19)	
Subgroup*Treatment Interaction p-value	0.6699	0.0041	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Symptoms of Liver Disease			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	73.63 (21.51)	79.60 (16.66)	76.09 (18.39)
Analysis Visit Mean (SD)	73.48 (19.70)	77.06 (15.91)	78.76 (18.48)
LS Mean of Change from Baseline (SE)	-0.57 (1.94)	-1.23 (2.20)	2.68 (1.41)
95% CI	(-4.41, 3.27)	(-5.58, 3.12)	(-0.11, 5.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.25 (2.33)	-3.91 (2.55)	
95% CI	(-7.86, 1.36)	(-8.94, 1.13)	
p-value	0.1664	0.1272	
Corrected Hedge's g Statistics	-0.253	-0.305	
95% CI	(-0.62, 0.12)	(-0.71, 0.10)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	75.46 (21.99)	79.08 (16.97)	74.67 (18.33)
Analysis Visit Mean (SD)	75.18 (22.13)	79.19 (14.38)	75.55 (20.17)
LS Mean of Change from Baseline (SE)	0.01 (2.14)	0.32 (2.38)	0.95 (1.52)
95% CI	(-4.21, 4.23)	(-4.38, 5.02)	(-2.04, 3.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.94 (2.55)	-0.63 (2.75)	
95% CI	(-5.97, 4.09)	(-6.07, 4.81)	
p-value	0.7129	0.8198	
Corrected Hedge's g Statistics	-0.073	-0.049	
95% CI	(-0.47, 0.33)	(-0.48, 0.38)	
Subgroup*Treatment Interaction p-value	0.8728	0.0641	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Effects of Liver Disease			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	76.07 (12.31)	84.12 (9.44)	75.89 (14.70)
Analysis Visit Mean (SD)	75.92 (13.43)	80.00 (9.29)	77.29 (15.12)
LS Mean of Change from Baseline (SE)	-0.97 (1.78)	-1.54 (2.06)	0.60 (1.30)
95% CI	(-4.48, 2.54)	(-5.60, 2.53)	(-1.96, 3.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.57 (2.14)	-2.14 (2.40)	
95% CI	(-5.79, 2.65)	(-6.89, 2.60)	
p-value	0.4635	0.3738	
Corrected Hedge's g Statistics	-0.133	-0.181	
95% CI	(-0.50, 0.23)	(-0.58, 0.22)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	77.78 (10.08)	84.83 (8.90)	75.47 (14.84)
Analysis Visit Mean (SD)	77.04 (11.76)	80.92 (8.30)	77.69 (13.34)
LS Mean of Change from Baseline (SE)	-0.62 (1.99)	1.08 (2.28)	0.41 (1.42)
95% CI	(-4.57, 3.32)	(-3.42, 5.58)	(-2.40, 3.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.04 (2.39)	0.67 (2.67)	
95% CI	(-5.75, 3.68)	(-4.60, 5.93)	
p-value	0.6648	0.8020	
Corrected Hedge's g Statistics	-0.086	0.055	
95% CI	(-0.49, 0.31)	(-0.38, 0.49)	
Subgroup*Treatment Interaction p-value	0.7617	0.2608	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Concentration/Memory			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	78.86 (21.74)	78.51 (19.52)	78.41 (22.42)
Analysis Visit Mean (SD)	78.29 (20.64)	77.77 (19.59)	83.51 (20.64)
LS Mean of Change from Baseline (SE)	-0.20 (2.17)	-0.65 (2.45)	5.14 (1.58)
95% CI	(-4.48, 4.08)	(-5.49, 4.19)	(2.03, 8.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.34 (2.60)	-5.79 (2.84)	
95% CI	(-10.48, -0.19)	(-11.39, -0.18)	
p-value	0.0420	0.0432	
Corrected Hedge's g Statistics	-0.372	-0.404	
95% CI	(-0.74, 0.00)	(-0.81, 0.00)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	78.32 (20.67)	78.90 (18.91)	77.88 (22.05)
Analysis Visit Mean (SD)	79.18 (17.93)	75.45 (20.24)	81.53 (20.51)
LS Mean of Change from Baseline (SE)	1.40 (2.30)	-2.19 (2.55)	3.64 (1.63)
95% CI	(-3.14, 5.94)	(-7.23, 2.85)	(0.42, 6.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.24 (2.74)	-5.84 (2.95)	
95% CI	(-7.65, 3.16)	(-11.66, -0.01)	
p-value	0.4142	0.0495	
Corrected Hedge's g Statistics	-0.161	-0.419	
95% CI	(-0.56, 0.24)	(-0.85, 0.02)	
Subgroup*Treatment Interaction p-value	0.1776	0.0159	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Health Distress			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	81.25 (24.04)	85.29 (23.53)	79.78 (24.89)
Analysis Visit Mean (SD)	88.35 (19.33)	87.87 (20.52)	86.88 (21.91)
LS Mean of Change from Baseline (SE)	7.39 (2.50)	4.77 (2.84)	6.54 (1.82)
95% CI	(2.44, 12.34)	(-0.84, 10.38)	(2.94, 10.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.85 (3.00)	-1.77 (3.29)	
95% CI	(-5.08, 6.78)	(-8.27, 4.72)	
p-value	0.7776	0.5909	
Corrected Hedge's g Statistics	0.051	-0.107	
95% CI	(-0.32, 0.42)	(-0.51, 0.29)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	81.25 (22.06)	89.22 (19.69)	79.86 (25.31)
Analysis Visit Mean (SD)	85.07 (24.43)	87.07 (19.33)	85.07 (20.52)
LS Mean of Change from Baseline (SE)	4.31 (3.21)	0.93 (3.60)	4.31 (2.28)
95% CI	(-2.04, 10.65)	(-6.18, 8.05)	(-0.19, 8.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (3.85)	-3.38 (4.20)	
95% CI	(-7.62, 7.61)	(-11.67, 4.90)	
p-value	0.9987	0.4214	
Corrected Hedge's g Statistics	0.000	-0.173	
95% CI	(-0.40, 0.40)	(-0.61, 0.26)	
Subgroup*Treatment Interaction p-value	0.8227	0.1824	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Sexual Function			
Week 24			
m	47	39	87
n	17	18	28
Baseline Mean (SD)	72.84 (32.06)	81.46 (23.71)	77.62 (23.97)
Analysis Visit Mean (SD)	73.72 (28.80)	75.83 (26.02)	79.05 (24.74)
LS Mean of Change from Baseline (SE)	2.94 (4.72)	-3.73 (4.66)	1.76 (3.66)
95% CI	(-6.48, 12.37)	(-13.02, 5.57)	(-5.55, 9.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.18 (5.87)	-5.49 (5.79)	
95% CI	(-10.55, 12.90)	(-17.04, 6.07)	
p-value	0.8414	0.3464	
Corrected Hedge's g Statistics	0.060	-0.276	
95% CI	(-0.54, 0.66)	(-0.87, 0.32)	
Week 52			
m	45	35	81
n	12	16	23
Baseline Mean (SD)	71.23 (35.82)	77.06 (25.05)	71.88 (26.76)
Analysis Visit Mean (SD)	80.56 (29.38)	75.16 (30.17)	69.56 (30.48)
LS Mean of Change from Baseline (SE)	6.22 (6.01)	-4.92 (5.55)	-3.55 (4.49)
95% CI	(-5.78, 18.22)	(-16.00, 6.16)	(-12.51, 5.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.77 (7.38)	-1.37 (7.03)	
95% CI	(-4.97, 24.51)	(-15.41, 12.68)	
p-value	0.1904	0.8466	
Corrected Hedge's g Statistics	0.448	-0.061	
95% CI	(-0.26, 1.15)	(-0.70, 0.58)	
Subgroup*Treatment Interaction p-value	0.4584	0.0699	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Sleep			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	59.55 (22.38)	60.29 (20.37)	62.47 (20.83)
Analysis Visit Mean (SD)	61.59 (20.90)	57.79 (18.63)	63.27 (18.88)
LS Mean of Change from Baseline (SE)	1.67 (2.45)	-2.42 (2.77)	1.51 (1.78)
95% CI	(-3.18, 6.51)	(-7.89, 3.04)	(-2.00, 5.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.16 (2.94)	-3.94 (3.20)	
95% CI	(-5.65, 5.96)	(-10.25, 2.38)	
p-value	0.9578	0.2206	
Corrected Hedge's g Statistics	0.010	-0.244	
95% CI	(-0.36, 0.38)	(-0.65, 0.16)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	60.83 (22.09)	59.66 (20.79)	61.94 (20.36)
Analysis Visit Mean (SD)	63.19 (22.46)	54.66 (21.25)	63.82 (19.69)
LS Mean of Change from Baseline (SE)	3.65 (2.67)	-4.90 (2.97)	2.30 (1.90)
95% CI	(-1.63, 8.92)	(-10.77, 0.96)	(-1.45, 6.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.34 (3.18)	-7.21 (3.43)	
95% CI	(-4.94, 7.63)	(-13.99, -0.42)	
p-value	0.6733	0.0375	
Corrected Hedge's g Statistics	0.083	-0.445	
95% CI	(-0.32, 0.48)	(-0.88, -0.01)	
Subgroup*Treatment Interaction p-value	0.9070	0.3746	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Loneliness			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	83.98 (17.10)	89.12 (13.40)	82.78 (20.55)
Analysis Visit Mean (SD)	86.25 (15.56)	88.53 (12.70)	83.77 (19.20)
LS Mean of Change from Baseline (SE)	2.31 (2.31)	2.24 (2.63)	0.36 (1.68)
95% CI	(-2.25, 6.87)	(-2.96, 7.43)	(-2.95, 3.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.94 (2.77)	1.87 (3.05)	
95% CI	(-3.54, 7.42)	(-4.15, 7.89)	
p-value	0.4848	0.5402	
Corrected Hedge's g Statistics	0.127	0.122	
95% CI	(-0.24, 0.49)	(-0.28, 0.52)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	83.33 (18.01)	86.55 (15.87)	83.33 (21.44)
Analysis Visit Mean (SD)	83.47 (18.00)	84.66 (15.23)	85.56 (17.49)
LS Mean of Change from Baseline (SE)	-0.21 (2.55)	-0.60 (2.84)	1.23 (1.81)
95% CI	(-5.25, 4.83)	(-6.21, 5.01)	(-2.34, 4.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.45 (3.04)	-1.84 (3.29)	
95% CI	(-7.46, 4.57)	(-8.33, 4.66)	
p-value	0.6353	0.5771	
Corrected Hedge's g Statistics	-0.094	-0.119	
95% CI	(-0.49, 0.31)	(-0.55, 0.31)	
Subgroup*Treatment Interaction p-value	0.7342	0.1827	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Hopelessness			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	79.36 (21.76)	79.41 (20.34)	77.98 (21.26)
Analysis Visit Mean (SD)	77.65 (22.65)	80.15 (22.29)	80.25 (19.74)
LS Mean of Change from Baseline (SE)	-1.14 (2.69)	1.12 (3.05)	2.04 (1.96)
95% CI	(-6.46, 4.17)	(-4.90, 7.13)	(-1.83, 5.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.18 (3.25)	-0.92 (3.54)	
95% CI	(-9.60, 3.24)	(-7.92, 6.08)	
p-value	0.3292	0.7956	
Corrected Hedge's g Statistics	-0.179	-0.052	
95% CI	(-0.55, 0.19)	(-0.45, 0.35)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	79.40 (20.66)	79.60 (21.78)	78.82 (21.30)
Analysis Visit Mean (SD)	78.01 (23.33)	77.59 (24.20)	79.06 (19.88)
LS Mean of Change from Baseline (SE)	-0.48 (2.61)	-1.26 (2.89)	0.02 (1.84)
95% CI	(-5.63, 4.67)	(-6.96, 4.44)	(-3.62, 3.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.51 (3.09)	-1.29 (3.33)	
95% CI	(-6.62, 5.60)	(-7.86, 5.29)	
p-value	0.8703	0.6998	
Corrected Hedge's g Statistics	-0.032	-0.082	
95% CI	(-0.43, 0.37)	(-0.51, 0.35)	
Subgroup*Treatment Interaction p-value	0.2330	0.7121	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Stigma of Liver Disease			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	82.12 (21.33)	84.39 (15.93)	83.20 (16.96)
Analysis Visit Mean (SD)	87.09 (19.17)	80.35 (21.04)	85.75 (16.69)
LS Mean of Change from Baseline (SE)	4.88 (2.43)	-2.89 (2.75)	2.92 (1.77)
95% CI	(0.08, 9.68)	(-8.33, 2.54)	(-0.57, 6.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.96 (2.92)	-5.81 (3.18)	
95% CI	(-3.80, 7.73)	(-12.10, 0.47)	
p-value	0.5026	0.0697	
Corrected Hedge's g Statistics	0.122	-0.362	
95% CI	(-0.25, 0.49)	(-0.77, 0.04)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	83.35 (20.04)	85.58 (14.38)	81.62 (17.51)
Analysis Visit Mean (SD)	86.47 (19.62)	82.57 (20.68)	86.05 (17.12)
LS Mean of Change from Baseline (SE)	4.68 (2.72)	-1.72 (3.03)	3.57 (1.93)
95% CI	(-0.70, 10.06)	(-7.70, 4.27)	(-0.24, 7.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.11 (3.25)	-5.29 (3.51)	
95% CI	(-5.31, 7.53)	(-12.22, 1.65)	
p-value	0.7327	0.1340	
Corrected Hedge's g Statistics	0.067	-0.321	
95% CI	(-0.33, 0.47)	(-0.75, 0.11)	
Subgroup*Treatment Interaction p-value	0.6067	0.1038	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Symptoms of Liver Disease			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	77.93 (17.89)	70.34 (19.62)	78.68 (16.93)
Analysis Visit Mean (SD)	73.99 (21.91)	71.64 (19.33)	76.47 (20.08)
LS Mean of Change from Baseline (SE)	-3.37 (1.63)	0.81 (1.80)	-1.79 (1.35)
95% CI	(-6.59, -0.16)	(-2.72, 4.35)	(-4.45, 0.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.58 (2.06)	2.61 (2.22)	
95% CI	(-5.64, 2.49)	(-1.76, 6.98)	
p-value	0.4450	0.2408	
Corrected Hedge's g Statistics	-0.113	0.187	
95% CI	(-0.41, 0.19)	(-0.13, 0.51)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	79.20 (15.97)	72.21 (18.83)	79.06 (16.26)
Analysis Visit Mean (SD)	76.93 (17.44)	75.40 (19.70)	78.78 (18.62)
LS Mean of Change from Baseline (SE)	-1.79 (1.63)	1.89 (1.81)	0.70 (1.35)
95% CI	(-5.00, 1.42)	(-1.67, 5.46)	(-1.96, 3.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.49 (2.06)	1.20 (2.23)	
95% CI	(-6.54, 1.57)	(-3.20, 5.59)	
p-value	0.2285	0.5922	
Corrected Hedge's g Statistics	-0.190	0.092	
95% CI	(-0.51, 0.13)	(-0.25, 0.44)	
Subgroup*Treatment Interaction p-value	0.8728	0.0641	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Effects of Liver Disease			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	79.15 (9.75)	75.14 (17.19)	79.26 (13.96)
Analysis Visit Mean (SD)	75.49 (12.49)	79.04 (11.97)	78.63 (12.85)
LS Mean of Change from Baseline (SE)	-2.94 (1.40)	2.04 (1.53)	0.24 (1.16)
95% CI	(-5.69, -0.18)	(-0.97, 5.05)	(-2.04, 2.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.18 (1.77)	1.80 (1.88)	
95% CI	(-6.66, 0.31)	(-1.91, 5.51)	
p-value	0.0736	0.3405	
Corrected Hedge's g Statistics	-0.265	0.150	
95% CI	(-0.57, 0.04)	(-0.17, 0.47)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	78.73 (9.41)	74.80 (17.42)	80.51 (11.73)
Analysis Visit Mean (SD)	77.30 (11.70)	77.00 (13.37)	76.45 (16.11)
LS Mean of Change from Baseline (SE)	-1.53 (1.66)	0.05 (1.85)	-2.95 (1.38)
95% CI	(-4.79, 1.74)	(-3.59, 3.70)	(-5.67, -0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.43 (2.11)	3.00 (2.29)	
95% CI	(-2.73, 5.59)	(-1.51, 7.51)	
p-value	0.5002	0.1911	
Corrected Hedge's g Statistics	0.107	0.226	
95% CI	(-0.21, 0.43)	(-0.12, 0.57)	
Subgroup*Treatment Interaction p-value	0.7617	0.2608	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Concentration/Memory			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	81.44 (23.28)	79.36 (21.37)	77.18 (21.46)
Analysis Visit Mean (SD)	77.22 (24.28)	80.21 (21.50)	75.66 (23.01)
LS Mean of Change from Baseline (SE)	-3.19 (1.77)	1.05 (1.91)	-1.57 (1.47)
95% CI	(-6.68, 0.30)	(-2.72, 4.82)	(-4.46, 1.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.62 (2.24)	2.62 (2.37)	
95% CI	(-6.04, 2.81)	(-2.03, 7.28)	
p-value	0.4723	0.2683	
Corrected Hedge's g Statistics	-0.107	0.174	
95% CI	(-0.41, 0.19)	(-0.14, 0.49)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	81.96 (23.19)	81.39 (19.70)	77.78 (21.11)
Analysis Visit Mean (SD)	77.80 (21.99)	81.02 (21.35)	73.74 (24.40)
LS Mean of Change from Baseline (SE)	-4.38 (1.82)	0.71 (2.00)	-3.49 (1.51)
95% CI	(-7.97, -0.79)	(-3.24, 4.65)	(-6.46, -0.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.89 (2.32)	4.19 (2.47)	
95% CI	(-5.45, 3.67)	(-0.66, 9.05)	
p-value	0.7002	0.0903	
Corrected Hedge's g Statistics	-0.061	0.289	
95% CI	(-0.38, 0.26)	(-0.06, 0.63)	
Subgroup*Treatment Interaction p-value	0.1776	0.0159	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Health Distress			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	75.88 (28.37)	78.60 (26.06)	80.26 (25.00)
Analysis Visit Mean (SD)	79.05 (25.68)	86.02 (22.27)	84.00 (23.90)
LS Mean of Change from Baseline (SE)	2.07 (2.10)	7.07 (2.26)	3.87 (1.73)
95% CI	(-2.06, 6.20)	(2.61, 11.53)	(0.46, 7.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.80 (2.65)	3.21 (2.79)	
95% CI	(-7.01, 3.42)	(-2.30, 8.71)	
p-value	0.4981	0.2522	
Corrected Hedge's g Statistics	-0.100	0.180	
95% CI	(-0.40, 0.20)	(-0.14, 0.50)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	77.18 (27.73)	78.75 (27.11)	81.85 (24.56)
Analysis Visit Mean (SD)	83.73 (23.18)	86.75 (21.93)	84.14 (25.14)
LS Mean of Change from Baseline (SE)	4.84 (2.39)	8.47 (2.64)	3.31 (1.98)
95% CI	(0.12, 9.56)	(3.27, 13.67)	(-0.59, 7.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.53 (3.05)	5.16 (3.25)	
95% CI	(-4.48, 7.53)	(-1.25, 11.57)	
p-value	0.6166	0.1141	
Corrected Hedge's g Statistics	0.080	0.271	
95% CI	(-0.24, 0.40)	(-0.07, 0.62)	
Subgroup*Treatment Interaction p-value	0.8227	0.1824	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Sexual Function			
Week 24			
m	76	68	125
n	28	26	38
Baseline Mean (SD)	81.68 (27.94)	79.87 (22.54)	83.12 (23.74)
Analysis Visit Mean (SD)	79.89 (26.52)	81.02 (21.36)	81.67 (21.63)
LS Mean of Change from Baseline (SE)	-2.47 (3.74)	-1.18 (3.84)	-2.49 (3.29)
95% CI	(-9.90, 4.95)	(-8.80, 6.44)	(-9.02, 4.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (4.87)	1.31 (4.96)	
95% CI	(-9.66, 9.70)	(-8.54, 11.17)	
p-value	0.9968	0.7922	
Corrected Hedge's g Statistics	0.001	0.065	
95% CI	(-0.49, 0.49)	(-0.43, 0.56)	
Week 52			
m	70	57	120
n	24	18	32
Baseline Mean (SD)	88.21 (24.01)	83.23 (20.40)	81.87 (24.88)
Analysis Visit Mean (SD)	86.80 (18.86)	87.23 (22.80)	83.24 (21.80)
LS Mean of Change from Baseline (SE)	0.09 (3.57)	5.43 (3.88)	0.48 (3.09)
95% CI	(-6.99, 7.17)	(-2.27, 13.13)	(-5.66, 6.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.39 (4.59)	4.95 (4.83)	
95% CI	(-9.50, 8.71)	(-4.65, 14.54)	
p-value	0.9319	0.3088	
Corrected Hedge's g Statistics	-0.022	0.284	
95% CI	(-0.55, 0.51)	(-0.30, 0.86)	
Subgroup*Treatment Interaction p-value	0.4584	0.0699	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Sleep			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	63.87 (21.10)	56.95 (20.70)	64.57 (19.81)
Analysis Visit Mean (SD)	63.45 (21.32)	57.29 (22.00)	63.04 (22.15)
LS Mean of Change from Baseline (SE)	-0.43 (1.67)	-1.03 (1.83)	-1.61 (1.38)
95% CI	(-3.72, 2.86)	(-4.64, 2.57)	(-4.33, 1.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.18 (2.11)	0.57 (2.26)	
95% CI	(-2.98, 5.34)	(-3.88, 5.02)	
p-value	0.5781	0.8002	
Corrected Hedge's g Statistics	0.082	0.040	
95% CI	(-0.22, 0.38)	(-0.28, 0.36)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	65.24 (20.33)	58.70 (21.99)	64.83 (21.04)
Analysis Visit Mean (SD)	65.50 (18.50)	59.80 (22.45)	64.89 (22.89)
LS Mean of Change from Baseline (SE)	0.93 (1.89)	-0.38 (2.10)	0.17 (1.57)
95% CI	(-2.79, 4.66)	(-4.53, 3.76)	(-2.92, 3.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.76 (2.40)	-0.55 (2.59)	
95% CI	(-3.97, 5.50)	(-5.66, 4.55)	
p-value	0.7507	0.8314	
Corrected Hedge's g Statistics	0.050	-0.037	
95% CI	(-0.27, 0.37)	(-0.38, 0.31)	
Subgroup*Treatment Interaction p-value	0.9070	0.3746	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Loneliness			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	83.80 (19.94)	82.80 (22.96)	84.28 (20.93)
Analysis Visit Mean (SD)	81.44 (21.39)	85.68 (19.33)	81.59 (22.54)
LS Mean of Change from Baseline (SE)	-2.69 (1.70)	2.30 (1.85)	-3.11 (1.41)
95% CI	(-6.04, 0.66)	(-1.34, 5.93)	(-5.88, -0.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.42 (2.15)	5.41 (2.28)	
95% CI	(-3.82, 4.66)	(0.92, 9.90)	
p-value	0.8446	0.0184	
Corrected Hedge's g Statistics	0.029	0.373	
95% CI	(-0.27, 0.33)	(0.05, 0.69)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	84.21 (20.02)	81.60 (23.81)	83.84 (21.06)
Analysis Visit Mean (SD)	85.32 (18.64)	82.00 (24.47)	81.02 (22.75)
LS Mean of Change from Baseline (SE)	0.54 (1.86)	-0.18 (2.07)	-3.36 (1.54)
95% CI	(-3.13, 4.21)	(-4.25, 3.89)	(-6.40, -0.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.90 (2.37)	3.18 (2.54)	
95% CI	(-0.77, 8.57)	(-1.83, 8.18)	
p-value	0.1016	0.2126	
Corrected Hedge's g Statistics	0.261	0.214	
95% CI	(-0.06, 0.58)	(-0.13, 0.56)	
Subgroup*Treatment Interaction p-value	0.7342	0.1827	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Hopelessness			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	74.42 (23.25)	75.42 (24.30)	80.14 (20.79)
Analysis Visit Mean (SD)	76.06 (23.27)	76.27 (24.71)	78.08 (22.43)
LS Mean of Change from Baseline (SE)	0.92 (2.09)	-0.09 (2.26)	-0.88 (1.73)
95% CI	(-3.19, 5.04)	(-4.54, 4.36)	(-4.29, 2.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.81 (2.65)	0.79 (2.79)	
95% CI	(-3.40, 7.02)	(-4.71, 6.29)	
p-value	0.4954	0.7771	
Corrected Hedge's g Statistics	0.101	0.045	
95% CI	(-0.20, 0.40)	(-0.27, 0.36)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	76.20 (22.50)	76.00 (25.46)	79.84 (21.40)
Analysis Visit Mean (SD)	79.50 (21.36)	76.84 (22.85)	75.72 (25.77)
LS Mean of Change from Baseline (SE)	3.96 (2.46)	1.48 (2.72)	-2.66 (2.04)
95% CI	(-0.89, 8.81)	(-3.88, 6.84)	(-6.68, 1.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.62 (3.14)	4.14 (3.35)	
95% CI	(0.44, 12.80)	(-2.47, 10.75)	
p-value	0.0358	0.2184	
Corrected Hedge's g Statistics	0.336	0.211	
95% CI	(0.01, 0.66)	(-0.13, 0.56)	
Subgroup*Treatment Interaction p-value	0.2330	0.7121	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Stigma of Liver Disease			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	81.79 (22.20)	78.83 (22.38)	84.43 (21.19)
Analysis Visit Mean (SD)	82.59 (20.91)	81.06 (20.37)	85.59 (19.58)
LS Mean of Change from Baseline (SE)	1.26 (1.75)	1.59 (1.91)	2.42 (1.45)
95% CI	(-2.20, 4.71)	(-2.17, 5.35)	(-0.43, 5.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.16 (2.23)	-0.83 (2.36)	
95% CI	(-5.54, 3.22)	(-5.48, 3.83)	
p-value	0.6023	0.7259	
Corrected Hedge's g Statistics	-0.078	-0.056	
95% CI	(-0.38, 0.22)	(-0.37, 0.26)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	82.56 (21.77)	78.14 (23.96)	83.62 (21.72)
Analysis Visit Mean (SD)	86.03 (17.84)	83.89 (20.94)	83.22 (20.68)
LS Mean of Change from Baseline (SE)	3.71 (1.65)	4.73 (1.83)	0.83 (1.37)
95% CI	(0.46, 6.96)	(1.12, 8.34)	(-1.86, 3.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.88 (2.09)	3.90 (2.25)	
95% CI	(-1.24, 7.00)	(-0.53, 8.33)	
p-value	0.1698	0.0839	
Corrected Hedge's g Statistics	0.218	0.296	
95% CI	(-0.10, 0.54)	(-0.05, 0.64)	
Subgroup*Treatment Interaction p-value	0.6067	0.1038	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Symptoms of Liver Disease			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	82.71 (15.48)	78.41 (17.82)	76.47 (17.25)
Analysis Visit Mean (SD)	85.55 (12.30)	71.75 (17.02)	78.12 (18.14)
LS Mean of Change from Baseline (SE)	4.03 (2.35)	-6.81 (2.58)	0.66 (1.68)
95% CI	(-0.62, 8.69)	(-11.93, -1.69)	(-2.67, 3.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.38 (2.84)	-7.47 (3.02)	
95% CI	(-2.26, 9.01)	(-13.45, -1.48)	
p-value	0.2374	0.0149	
Corrected Hedge's g Statistics	0.274	-0.610	
95% CI	(-0.19, 0.74)	(-1.12, -0.09)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	83.46 (15.66)	77.33 (17.57)	76.97 (17.56)
Analysis Visit Mean (SD)	80.66 (15.69)	76.17 (17.34)	79.69 (17.95)
LS Mean of Change from Baseline (SE)	-1.91 (2.51)	-1.33 (2.74)	1.94 (1.84)
95% CI	(-6.88, 3.06)	(-6.76, 4.11)	(-1.72, 5.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.84 (3.07)	-3.26 (3.25)	
95% CI	(-9.94, 2.25)	(-9.71, 3.18)	
p-value	0.2141	0.3174	
Corrected Hedge's g Statistics	-0.308	-0.263	
95% CI	(-0.80, 0.19)	(-0.79, 0.27)	
Subgroup*Treatment Interaction p-value	0.8728	0.0641	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Effects of Liver Disease			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	79.52 (17.15)	82.86 (10.45)	77.99 (14.30)
Analysis Visit Mean (SD)	79.27 (13.88)	76.82 (7.19)	76.60 (16.52)
LS Mean of Change from Baseline (SE)	-0.89 (2.60)	-3.98 (2.92)	-2.52 (1.87)
95% CI	(-6.05, 4.27)	(-9.77, 1.81)	(-6.24, 1.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.63 (3.17)	-1.45 (3.43)	
95% CI	(-4.65, 7.91)	(-8.26, 5.35)	
p-value	0.6075	0.6724	
Corrected Hedge's g Statistics	0.119	-0.106	
95% CI	(-0.34, 0.58)	(-0.61, 0.40)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	78.94 (17.72)	82.67 (10.68)	77.58 (12.79)
Analysis Visit Mean (SD)	78.14 (13.26)	77.01 (12.51)	80.75 (7.91)
LS Mean of Change from Baseline (SE)	-1.93 (2.22)	-2.33 (2.46)	1.17 (1.65)
95% CI	(-6.33, 2.47)	(-7.20, 2.55)	(-2.11, 4.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.10 (2.72)	-3.50 (2.93)	
95% CI	(-8.51, 2.30)	(-9.30, 2.31)	
p-value	0.2570	0.2349	
Corrected Hedge's g Statistics	-0.279	-0.315	
95% CI	(-0.77, 0.21)	(-0.85, 0.22)	
Subgroup*Treatment Interaction p-value	0.7617	0.2608	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Concentration/Memory			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	81.50 (22.50)	79.49 (19.79)	83.98 (16.60)
Analysis Visit Mean (SD)	84.27 (18.78)	78.30 (16.14)	83.04 (19.47)
LS Mean of Change from Baseline (SE)	1.89 (2.96)	-2.35 (3.30)	-0.45 (2.13)
95% CI	(-3.98, 7.77)	(-8.90, 4.20)	(-4.68, 3.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.34 (3.60)	-1.90 (3.88)	
95% CI	(-4.80, 9.48)	(-9.60, 5.80)	
p-value	0.5172	0.6251	
Corrected Hedge's g Statistics	0.150	-0.122	
95% CI	(-0.31, 0.61)	(-0.63, 0.38)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	79.27 (22.37)	78.78 (20.02)	83.97 (16.85)
Analysis Visit Mean (SD)	83.28 (15.17)	76.27 (19.61)	83.68 (18.09)
LS Mean of Change from Baseline (SE)	2.35 (2.44)	-3.51 (2.68)	-0.21 (1.81)
95% CI	(-2.50, 7.19)	(-8.83, 1.81)	(-3.79, 3.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.56 (2.99)	-3.30 (3.18)	
95% CI	(-3.38, 8.49)	(-9.61, 3.00)	
p-value	0.3948	0.3012	
Corrected Hedge's g Statistics	0.209	-0.272	
95% CI	(-0.28, 0.70)	(-0.80, 0.26)	
Subgroup*Treatment Interaction p-value	0.1776	0.0159	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Health Distress			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	78.24 (26.54)	78.57 (26.26)	82.08 (20.58)
Analysis Visit Mean (SD)	86.57 (18.65)	83.33 (17.82)	88.21 (17.92)
LS Mean of Change from Baseline (SE)	6.46 (3.13)	3.79 (3.46)	6.99 (2.25)
95% CI	(0.25, 12.68)	(-3.08, 10.66)	(2.53, 11.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.52 (3.79)	-3.20 (4.05)	
95% CI	(-8.04, 7.00)	(-11.22, 4.83)	
p-value	0.8904	0.4310	
Corrected Hedge's g Statistics	-0.032	-0.195	
95% CI	(-0.50, 0.43)	(-0.70, 0.31)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	78.00 (27.07)	79.38 (26.68)	81.82 (18.57)
Analysis Visit Mean (SD)	79.50 (22.50)	86.25 (18.98)	89.49 (14.25)
LS Mean of Change from Baseline (SE)	-1.21 (3.28)	6.73 (3.61)	8.24 (2.43)
95% CI	(-7.72, 5.30)	(-0.43, 13.88)	(3.42, 13.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.45 (4.02)	-1.51 (4.28)	
95% CI	(-17.43, -1.47)	(-10.00, 6.98)	
p-value	0.0208	0.7250	
Corrected Hedge's g Statistics	-0.576	-0.093	
95% CI	(-1.08, -0.08)	(-0.62, 0.44)	
Subgroup*Treatment Interaction p-value	0.8227	0.1824	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Sexual Function			
Week 24			
m	28	22	60
n	8	9	24
Baseline Mean (SD)	83.11 (19.28)	84.62 (18.57)	83.60 (18.47)
Analysis Visit Mean (SD)	92.50 (10.18)	69.27 (25.82)	85.96 (17.73)
LS Mean of Change from Baseline (SE)	10.51 (4.72)	-15.86 (4.39)	2.40 (2.75)
95% CI	(0.96, 20.06)	(-24.74, -6.98)	(-3.18, 7.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.11 (5.53)	-18.26 (5.15)	
95% CI	(-3.09, 19.32)	(-28.68, -7.84)	
p-value	0.1508	0.0011	
Corrected Hedge's g Statistics	0.588	-1.328	
95% CI	(-0.23, 1.40)	(-2.16, -0.50)	
Week 52			
m	27	22	54
n	6	8	19
Baseline Mean (SD)	89.15 (17.05)	84.58 (19.85)	83.41 (19.34)
Analysis Visit Mean (SD)	97.50 (3.91)	72.49 (23.98)	80.62 (24.01)
LS Mean of Change from Baseline (SE)	12.68 (6.64)	-13.48 (5.84)	-4.28 (3.76)
95% CI	(-0.76, 26.11)	(-25.29, -1.66)	(-11.89, 3.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	16.96 (7.68)	-9.20 (6.92)	
95% CI	(1.41, 32.51)	(-23.21, 4.82)	
p-value	0.0334	0.1921	
Corrected Hedge's g Statistics	1.003	-0.543	
95% CI	(0.04, 1.96)	(-1.38, 0.30)	
Subgroup*Treatment Interaction p-value	0.4584	0.0699	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Sleep			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	67.78 (17.28)	62.14 (14.10)	63.68 (19.66)
Analysis Visit Mean (SD)	67.04 (17.66)	57.86 (14.28)	63.58 (18.49)
LS Mean of Change from Baseline (SE)	0.36 (2.49)	-5.46 (2.75)	-0.64 (1.78)
95% CI	(-4.58, 5.29)	(-10.91, -0.01)	(-4.18, 2.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.00 (3.00)	-4.82 (3.20)	
95% CI	(-4.96, 6.96)	(-11.17, 1.53)	
p-value	0.7404	0.1353	
Corrected Hedge's g Statistics	0.076	-0.371	
95% CI	(-0.39, 0.54)	(-0.88, 0.14)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	68.40 (18.30)	62.25 (14.46)	63.64 (19.86)
Analysis Visit Mean (SD)	64.40 (15.50)	61.50 (14.61)	64.89 (17.90)
LS Mean of Change from Baseline (SE)	-2.68 (2.67)	-1.88 (2.94)	0.01 (1.97)
95% CI	(-7.99, 2.62)	(-7.72, 3.95)	(-3.90, 3.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.70 (3.28)	-1.90 (3.48)	
95% CI	(-9.20, 3.80)	(-8.80, 5.00)	
p-value	0.4120	0.5863	
Corrected Hedge's g Statistics	-0.202	-0.143	
95% CI	(-0.69, 0.29)	(-0.67, 0.39)	
Subgroup*Treatment Interaction p-value	0.9070	0.3746	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Loneliness			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	85.93 (16.59)	77.86 (18.07)	86.51 (15.74)
Analysis Visit Mean (SD)	85.93 (16.99)	75.71 (26.80)	83.30 (20.14)
LS Mean of Change from Baseline (SE)	-1.14 (3.11)	-3.66 (3.52)	-4.03 (2.24)
95% CI	(-7.31, 5.03)	(-10.64, 3.31)	(-8.47, 0.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.89 (3.77)	0.37 (4.14)	
95% CI	(-4.59, 10.37)	(-7.85, 8.59)	
p-value	0.4449	0.9286	
Corrected Hedge's g Statistics	0.176	0.023	
95% CI	(-0.29, 0.64)	(-0.48, 0.53)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	86.60 (17.00)	78.50 (18.29)	85.57 (15.67)
Analysis Visit Mean (SD)	85.80 (13.90)	82.25 (23.42)	86.59 (15.80)
LS Mean of Change from Baseline (SE)	-1.31 (2.51)	1.30 (2.79)	0.36 (1.86)
95% CI	(-6.30, 3.68)	(-4.24, 6.83)	(-3.33, 4.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.67 (3.07)	0.93 (3.31)	
95% CI	(-7.76, 4.41)	(-5.63, 7.49)	
p-value	0.5863	0.7790	
Corrected Hedge's g Statistics	-0.133	0.074	
95% CI	(-0.62, 0.36)	(-0.45, 0.60)	
Subgroup*Treatment Interaction p-value	0.7342	0.1827	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Hopelessness			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	77.78 (21.43)	71.82 (23.04)	81.60 (19.64)
Analysis Visit Mean (SD)	85.80 (19.18)	75.39 (17.97)	80.66 (21.11)
LS Mean of Change from Baseline (SE)	7.15 (3.36)	0.04 (3.74)	-0.82 (2.43)
95% CI	(0.48, 13.82)	(-7.38, 7.47)	(-5.65, 4.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.97 (4.07)	0.86 (4.40)	
95% CI	(-0.10, 16.05)	(-7.86, 9.59)	
p-value	0.0528	0.8448	
Corrected Hedge's g Statistics	0.448	0.049	
95% CI	(-0.02, 0.92)	(-0.46, 0.55)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	79.33 (21.53)	72.50 (23.43)	80.68 (19.75)
Analysis Visit Mean (SD)	80.00 (18.63)	75.43 (16.99)	83.33 (19.11)
LS Mean of Change from Baseline (SE)	0.59 (3.53)	-2.26 (3.92)	2.22 (2.62)
95% CI	(-6.42, 7.60)	(-10.04, 5.52)	(-2.97, 7.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.63 (4.32)	-4.48 (4.65)	
95% CI	(-10.19, 6.94)	(-13.71, 4.75)	
p-value	0.7069	0.3381	
Corrected Hedge's g Statistics	-0.092	-0.254	
95% CI	(-0.58, 0.40)	(-0.78, 0.28)	
Subgroup*Treatment Interaction p-value	0.2330	0.7121	

AMNOG Table SE21.14a.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Stigma of Liver Disease			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	84.74 (13.79)	79.19 (17.71)	84.41 (18.44)
Analysis Visit Mean (SD)	88.90 (16.19)	80.68 (18.21)	85.24 (19.44)
LS Mean of Change from Baseline (SE)	3.12 (2.80)	0.21 (3.12)	0.61 (2.01)
95% CI	(-2.44, 8.67)	(-5.98, 6.41)	(-3.38, 4.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.51 (3.39)	-0.39 (3.66)	
95% CI	(-4.21, 9.23)	(-7.65, 6.86)	
p-value	0.4609	0.9142	
Corrected Hedge's g Statistics	0.170	-0.027	
95% CI	(-0.29, 0.63)	(-0.53, 0.48)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	86.51 (14.05)	80.34 (17.36)	84.49 (16.53)
Analysis Visit Mean (SD)	92.27 (11.00)	82.43 (13.80)	86.24 (19.04)
LS Mean of Change from Baseline (SE)	5.56 (2.69)	0.34 (2.96)	1.51 (1.99)
95% CI	(0.23, 10.90)	(-5.54, 6.21)	(-2.43, 5.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.05 (3.28)	-1.18 (3.51)	
95% CI	(-2.47, 10.57)	(-8.14, 5.79)	
p-value	0.2204	0.7382	
Corrected Hedge's g Statistics	0.301	-0.088	
95% CI	(-0.19, 0.79)	(-0.62, 0.44)	
Subgroup*Treatment Interaction p-value	0.6067	0.1038	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (6.3)	1 (2.3)	6 (6.3)
No	45 (93.8)	43 (97.7)	89 (93.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	2.90	
95% CI of the inverse odds ratio	(0.24, 4.23)	(0.34, 24.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	2.78	
95% CI of the inverse risk ratio	(0.26, 3.87)	(0.34, 22.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.07	-4.04	
95% CI of the absolute risk difference	(-8.48, 8.35)	(-10.62, 2.54)	
p-value	0.9878	0.3107	
p-value of Breslow-Day Test for Homogeneity [3]	0.4014	0.4776	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (18.8)	5 (11.4)	26 (27.4)
No	39 (81.3)	39 (88.6)	69 (72.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.63	2.94	
95% CI of the inverse odds ratio	(0.70, 3.83)	(1.04, 8.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.46	2.41	
95% CI of the inverse risk ratio	(0.74, 2.86)	(0.99, 5.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.62	-16.00	
95% CI of the absolute risk difference	(-22.84, 5.60)	(-28.98, -3.03)	
p-value	0.2576	0.0350	
p-value of Breslow-Day Test for Homogeneity [3]	0.0402	0.0035	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.2)	4 (9.1)	8 (8.4)
No	46 (95.8)	40 (90.9)	87 (91.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.11	0.92	
95% CI of the inverse odds ratio	(0.43, 10.37)	(0.26, 3.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.02	0.93	
95% CI of the inverse risk ratio	(0.45, 9.15)	(0.29, 2.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.25	0.67	
95% CI of the absolute risk difference	(-12.20, 3.69)	(-9.50, 10.84)	
p-value	0.3462	0.8959	
p-value of Breslow-Day Test for Homogeneity [3]	0.8518	0.5857	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (18.8)	11 (25.0)	29 (30.5)
No	39 (81.3)	33 (75.0)	66 (69.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.90	1.32	
95% CI of the inverse odds ratio	(0.82, 4.44)	(0.59, 2.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.63	1.22	
95% CI of the inverse risk ratio	(0.84, 3.16)	(0.67, 2.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.78	-5.53	
95% CI of the absolute risk difference	(-26.19, 2.63)	(-21.32, 10.27)	
p-value	0.1322	0.5032	
p-value of Breslow-Day Test for Homogeneity [3]	0.1965	0.3886	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.2)	1 (2.3)	13 (13.7)
No	46 (95.8)	43 (97.7)	82 (86.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.65	6.82	
95% CI of the inverse odds ratio	(0.79, 16.87)	(0.86, 53.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.28	6.02	
95% CI of the inverse risk ratio	(0.77, 13.97)	(0.81, 44.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.52	-11.41	
95% CI of the absolute risk difference	(-18.45, -0.59)	(-19.61, -3.22)	
p-value	0.0794	0.0376	
p-value of Breslow-Day Test for Homogeneity [3]	0.5282	0.0884	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (12.5)	6 (13.6)	19 (20.0)
No	42 (87.5)	38 (86.4)	76 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	1.58	
95% CI of the inverse odds ratio	(0.65, 4.72)	(0.58, 4.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.60	1.47	
95% CI of the inverse risk ratio	(0.68, 3.74)	(0.63, 3.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.50	-6.36	
95% CI of the absolute risk difference	(-19.84, 4.84)	(-19.31, 6.58)	
p-value	0.2648	0.3636	
p-value of Breslow-Day Test for Homogeneity [3]	0.6343	0.4065	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (10.4)	2 (4.5)	11 (11.6)
No	43 (89.6)	42 (95.5)	84 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	2.75	
95% CI of the inverse odds ratio	(0.37, 3.45)	(0.58, 12.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	2.55	
95% CI of the inverse risk ratio	(0.41, 3.02)	(0.59, 11.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.16	-7.03	
95% CI of the absolute risk difference	(-11.94, 9.61)	(-15.94, 1.87)	
p-value	0.8351	0.1853	
p-value of Breslow-Day Test for Homogeneity [3]	0.3840	0.1846	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (25.0)	8 (18.2)	26 (27.4)
No	36 (75.0)	36 (81.8)	69 (72.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	1.70	
95% CI of the inverse odds ratio	(0.51, 2.50)	(0.70, 4.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.51	
95% CI of the inverse risk ratio	(0.61, 1.97)	(0.74, 3.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.37	-9.19	
95% CI of the absolute risk difference	(-17.55, 12.81)	(-23.69, 5.31)	
p-value	0.7621	0.2412	
p-value of Breslow-Day Test for Homogeneity [3]	0.7464	0.2300	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (14.6)	4 (9.1)	18 (18.9)
No	41 (85.4)	40 (90.9)	77 (81.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.37	2.34	
95% CI of the inverse odds ratio	(0.53, 3.55)	(0.74, 7.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	2.08	
95% CI of the inverse risk ratio	(0.58, 2.89)	(0.75, 5.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.36	-9.86	
95% CI of the absolute risk difference	(-17.08, 8.36)	(-21.44, 1.73)	
p-value	0.5165	0.1386	
p-value of Breslow-Day Test for Homogeneity [3]	0.4353	0.1257	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (18.8)	6 (13.6)	21 (22.1)
No	39 (81.3)	38 (86.4)	74 (77.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	1.80	
95% CI of the inverse odds ratio	(0.51, 2.94)	(0.67, 4.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.62	
95% CI of the inverse risk ratio	(0.59, 2.37)	(0.70, 3.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.36	-8.47	
95% CI of the absolute risk difference	(-17.20, 10.48)	(-21.60, 4.66)	
p-value	0.6417	0.2404	
p-value of Breslow-Day Test for Homogeneity [3]	0.7788	0.3640	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.2)	2 (4.5)	6 (6.3)
No	46 (95.8)	42 (95.5)	89 (93.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	1.42	
95% CI of the inverse odds ratio	(0.30, 7.99)	(0.27, 7.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	1.39	
95% CI of the inverse risk ratio	(0.32, 7.23)	(0.29, 6.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.15	-1.77	
95% CI of the absolute risk difference	(-9.62, 5.33)	(-9.63, 6.09)	
p-value	0.5974	0.6768	
p-value of Breslow-Day Test for Homogeneity [3]	0.4695	0.7461	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (10.4)	4 (9.1)	9 (9.5)
No	43 (89.6)	40 (90.9)	86 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.05	
95% CI of the inverse odds ratio	(0.28, 2.85)	(0.30, 3.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.04	
95% CI of the inverse risk ratio	(0.32, 2.56)	(0.34, 3.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.94	-0.38	
95% CI of the absolute risk difference	(-9.51, 11.40)	(-10.72, 9.95)	
p-value	0.8578	0.9425	
p-value of Breslow-Day Test for Homogeneity [3]	0.5955	0.6847	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (16.7)	3 (6.8)	17 (17.9)
No	40 (83.3)	41 (93.2)	78 (82.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	2.98	
95% CI of the inverse odds ratio	(0.43, 2.74)	(0.82, 10.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	2.62	
95% CI of the inverse risk ratio	(0.50, 2.31)	(0.81, 8.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.23	-11.08	
95% CI of the absolute risk difference	(-14.29, 11.83)	(-21.79, -0.36)	
p-value	0.8551	0.0835	
p-value of Breslow-Day Test for Homogeneity [3]	0.6621	0.1433	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (33.3)	9 (20.5)	33 (34.7)
No	32 (66.7)	35 (79.5)	62 (65.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	2.07	
95% CI of the inverse odds ratio	(0.51, 2.22)	(0.89, 4.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.70	
95% CI of the inverse risk ratio	(0.64, 1.69)	(0.89, 3.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.40	-14.28	
95% CI of the absolute risk difference	(-17.82, 15.01)	(-29.57, 1.01)	
p-value	0.8674	0.0881	
p-value of Breslow-Day Test for Homogeneity [3]	0.8276	0.2511	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (14.6)	6 (13.6)	14 (14.7)
No	41 (85.4)	38 (86.4)	81 (85.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.09	
95% CI of the inverse odds ratio	(0.38, 2.70)	(0.39, 3.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.08	
95% CI of the inverse risk ratio	(0.44, 2.34)	(0.45, 2.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.15	-1.10	
95% CI of the absolute risk difference	(-12.42, 12.11)	(-13.50, 11.29)	
p-value	0.9805	0.8635	
p-value of Breslow-Day Test for Homogeneity [3]	0.3412	0.2250	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (25.0)	8 (18.2)	27 (28.4)
No	36 (75.0)	36 (81.8)	68 (71.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	1.79	
95% CI of the inverse odds ratio	(0.54, 2.63)	(0.74, 4.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	1.56	
95% CI of the inverse risk ratio	(0.63, 2.04)	(0.77, 3.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.42	-10.24	
95% CI of the absolute risk difference	(-18.66, 11.82)	(-24.80, 4.33)	
p-value	0.6645	0.1958	
p-value of Breslow-Day Test for Homogeneity [3]	0.5119	0.2985	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (10.4)	5 (11.4)	14 (14.7)
No	43 (89.6)	39 (88.6)	81 (85.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.49	1.35	
95% CI of the inverse odds ratio	(0.50, 4.40)	(0.45, 4.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	1.30	
95% CI of the inverse risk ratio	(0.54, 3.70)	(0.50, 3.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.32	-3.37	
95% CI of the absolute risk difference	(-15.52, 6.88)	(-15.15, 8.41)	
p-value	0.4723	0.5902	
p-value of Breslow-Day Test for Homogeneity [3]	0.1680	0.1626	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (22.9)	10 (22.7)	24 (25.3)
No	37 (77.1)	34 (77.3)	71 (74.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	1.15	
95% CI of the inverse odds ratio	(0.50, 2.57)	(0.49, 2.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	1.11	
95% CI of the inverse risk ratio	(0.59, 2.06)	(0.58, 2.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.35	-2.54	
95% CI of the absolute risk difference	(-17.10, 12.41)	(-17.69, 12.62)	
p-value	0.7579	0.7463	
p-value of Breslow-Day Test for Homogeneity [3]	0.1031	0.4346	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (8.3)	2 (4.5)	15 (15.8)
No	44 (91.7)	42 (95.5)	80 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.06	3.94	
95% CI of the inverse odds ratio	(0.64, 6.60)	(0.86, 18.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.89	3.47	
95% CI of the inverse risk ratio	(0.67, 5.40)	(0.83, 14.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.46	-11.24	
95% CI of the absolute risk difference	(-18.18, 3.26)	(-20.82, -1.67)	
p-value	0.2148	0.0598	
p-value of Breslow-Day Test for Homogeneity [3]	0.1122	0.0492	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (29.2)	11 (25.0)	33 (34.7)
No	34 (70.8)	33 (75.0)	62 (65.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.60	
95% CI of the inverse odds ratio	(0.61, 2.74)	(0.72, 3.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	1.39	
95% CI of the inverse risk ratio	(0.71, 2.00)	(0.78, 2.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.57	-9.74	
95% CI of the absolute risk difference	(-21.60, 10.46)	(-25.72, 6.24)	
p-value	0.5031	0.2510	
p-value of Breslow-Day Test for Homogeneity [3]	0.2113	0.2318	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (2.8)	2 (1.6)
No	77 (100)	70 (97.2)	126 (98.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.56	
95% CI of the inverse odds ratio	NE	(0.08, 4.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.56	
95% CI of the inverse risk ratio	NE	(0.08, 3.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.56	1.22	
95% CI of the absolute risk difference	(-3.71, 0.59)	(-3.15, 5.58)	
p-value	0.2703	0.5557	
p-value of Breslow-Day Test for Homogeneity [3]	0.4014	0.4776	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (24.7)	19 (26.4)	15 (11.7)
No	58 (75.3)	53 (73.6)	113 (88.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.41	0.37	
95% CI of the inverse odds ratio	(0.19, 0.86)	(0.17, 0.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	0.44	
95% CI of the inverse risk ratio	(0.26, 0.88)	(0.24, 0.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.96	14.67	
95% CI of the absolute risk difference	(1.83, 24.08)	(3.06, 26.28)	
p-value	0.0157	0.0080	
p-value of Breslow-Day Test for Homogeneity [3]	0.0402	0.0035	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.6)	10 (13.9)	9 (7.0)
No	75 (97.4)	62 (86.1)	119 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.84	0.47	
95% CI of the inverse odds ratio	(0.60, 13.49)	(0.18, 1.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.71	0.51	
95% CI of the inverse risk ratio	(0.60, 12.20)	(0.22, 1.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.43	6.86	
95% CI of the absolute risk difference	(-10.11, 1.24)	(-2.28, 15.99)	
p-value	0.1725	0.1124	
p-value of Breslow-Day Test for Homogeneity [3]	0.8518	0.5857	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (26.0)	21 (29.2)	27 (21.1)
No	57 (74.0)	51 (70.8)	101 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	0.65	
95% CI of the inverse odds ratio	(0.39, 1.48)	(0.33, 1.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.72	
95% CI of the inverse risk ratio	(0.49, 1.34)	(0.44, 1.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.88	8.07	
95% CI of the absolute risk difference	(-7.20, 16.96)	(-4.58, 20.73)	
p-value	0.4208	0.1994	
p-value of Breslow-Day Test for Homogeneity [3]	0.1965	0.3886	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.3)	6 (8.3)	7 (5.5)
No	76 (98.7)	66 (91.7)	121 (94.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.40	0.64	
95% CI of the inverse odds ratio	(0.53, 36.44)	(0.21, 1.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.21	0.66	
95% CI of the inverse risk ratio	(0.53, 33.58)	(0.23, 1.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.17	2.86	
95% CI of the absolute risk difference	(-8.85, 0.51)	(-4.64, 10.37)	
p-value	0.1354	0.4302	
p-value of Breslow-Day Test for Homogeneity [3]	0.5282	0.0884	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (18.2)	15 (20.8)	23 (18.0)
No	63 (81.8)	57 (79.2)	105 (82.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.83	
95% CI of the inverse odds ratio	(0.47, 2.05)	(0.40, 1.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.86	
95% CI of the inverse risk ratio	(0.54, 1.80)	(0.48, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.21	2.86	
95% CI of the absolute risk difference	(-10.67, 11.10)	(-8.63, 14.36)	
p-value	0.9694	0.6201	
p-value of Breslow-Day Test for Homogeneity [3]	0.6343	0.4065	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (7.8)	4 (5.6)	5 (3.9)
No	71 (92.2)	68 (94.4)	123 (96.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	0.69	
95% CI of the inverse odds ratio	(0.14, 1.63)	(0.18, 2.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	0.70	
95% CI of the inverse risk ratio	(0.16, 1.59)	(0.19, 2.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.89	1.65	
95% CI of the absolute risk difference	(-2.98, 10.75)	(-4.62, 7.92)	
p-value	0.2318	0.5891	
p-value of Breslow-Day Test for Homogeneity [3]	0.3840	0.1846	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (15.6)	17 (23.6)	22 (17.2)
No	65 (84.4)	55 (76.4)	106 (82.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.67	
95% CI of the inverse odds ratio	(0.52, 2.42)	(0.33, 1.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	0.73	
95% CI of the inverse risk ratio	(0.58, 2.10)	(0.41, 1.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.60	6.42	
95% CI of the absolute risk difference	(-12.01, 8.81)	(-5.36, 18.21)	
p-value	0.7651	0.2711	
p-value of Breslow-Day Test for Homogeneity [3]	0.7464	0.2300	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (19.5)	15 (20.8)	17 (13.3)
No	62 (80.5)	57 (79.2)	111 (86.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.58	
95% CI of the inverse odds ratio	(0.30, 1.35)	(0.27, 1.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.64	
95% CI of the inverse risk ratio	(0.36, 1.29)	(0.34, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.20	7.55	
95% CI of the absolute risk difference	(-4.42, 16.82)	(-3.52, 18.62)	
p-value	0.2363	0.1620	
p-value of Breslow-Day Test for Homogeneity [3]	0.4353	0.1257	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (27.3)	20 (27.8)	31 (24.2)
No	56 (72.7)	52 (72.2)	97 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.83	
95% CI of the inverse odds ratio	(0.45, 1.62)	(0.43, 1.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.87	
95% CI of the inverse risk ratio	(0.55, 1.43)	(0.54, 1.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.05	3.56	
95% CI of the absolute risk difference	(-9.36, 15.47)	(-9.17, 16.29)	
p-value	0.6265	0.5794	
p-value of Breslow-Day Test for Homogeneity [3]	0.7788	0.3640	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.3)	4 (5.6)	6 (4.7)
No	76 (98.7)	68 (94.4)	122 (95.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.74	0.84	
95% CI of the inverse odds ratio	(0.44, 31.65)	(0.23, 3.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.61	0.84	
95% CI of the inverse risk ratio	(0.44, 29.42)	(0.25, 2.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.39	0.87	
95% CI of the absolute risk difference	(-7.84, 1.06)	(-5.57, 7.30)	
p-value	0.1957	0.7869	
p-value of Breslow-Day Test for Homogeneity [3]	0.4695	0.7461	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (3.9)	7 (9.7)	10 (7.8)
No	74 (96.1)	65 (90.3)	118 (92.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.09	0.79	
95% CI of the inverse odds ratio	(0.56, 7.85)	(0.29, 2.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.01	0.80	
95% CI of the inverse risk ratio	(0.57, 7.06)	(0.32, 2.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.92	1.91	
95% CI of the absolute risk difference	(-10.26, 2.43)	(-6.36, 10.18)	
p-value	0.2652	0.6420	
p-value of Breslow-Day Test for Homogeneity [3]	0.5955	0.6847	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (14.3)	13 (18.1)	17 (13.3)
No	66 (85.7)	59 (81.9)	111 (86.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.70	
95% CI of the inverse odds ratio	(0.41, 2.08)	(0.32, 1.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.74	
95% CI of the inverse risk ratio	(0.46, 1.88)	(0.38, 1.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.00	4.77	
95% CI of the absolute risk difference	(-8.78, 10.78)	(-5.88, 15.43)	
p-value	0.8393	0.3641	
p-value of Breslow-Day Test for Homogeneity [3]	0.6621	0.1433	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (28.6)	23 (31.9)	39 (30.5)
No	55 (71.4)	49 (68.1)	89 (69.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	0.93	
95% CI of the inverse odds ratio	(0.59, 2.04)	(0.50, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.95	
95% CI of the inverse risk ratio	(0.69, 1.66)	(0.62, 1.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.90	1.48	
95% CI of the absolute risk difference	(-14.76, 10.96)	(-11.92, 14.88)	
p-value	0.7735	0.8285	
p-value of Breslow-Day Test for Homogeneity [3]	0.8276	0.2511	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (14.3)	10 (13.9)	9 (7.0)
No	66 (85.7)	62 (86.1)	119 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.45	0.47	
95% CI of the inverse odds ratio	(0.18, 1.15)	(0.18, 1.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.49	0.51	
95% CI of the inverse risk ratio	(0.21, 1.13)	(0.22, 1.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.25	6.86	
95% CI of the absolute risk difference	(-1.73, 16.24)	(-2.28, 15.99)	
p-value	0.0900	0.1124	
p-value of Breslow-Day Test for Homogeneity [3]	0.3412	0.2250	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (23.4)	19 (26.4)	27 (21.1)
No	59 (76.6)	53 (73.6)	101 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.75	
95% CI of the inverse odds ratio	(0.45, 1.73)	(0.38, 1.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	0.80	
95% CI of the inverse risk ratio	(0.53, 1.53)	(0.48, 1.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.28	5.30	
95% CI of the absolute risk difference	(-9.52, 14.09)	(-7.10, 17.69)	
p-value	0.7021	0.3930	
p-value of Breslow-Day Test for Homogeneity [3]	0.5119	0.2985	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (23.4)	17 (23.6)	15 (11.7)
No	59 (76.6)	55 (76.4)	113 (88.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	0.43	
95% CI of the inverse odds ratio	(0.20, 0.92)	(0.20, 0.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	0.50	
95% CI of the inverse risk ratio	(0.27, 0.94)	(0.26, 0.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.66	11.89	
95% CI of the absolute risk difference	(0.68, 22.63)	(0.61, 23.17)	
p-value	0.0278	0.0277	
p-value of Breslow-Day Test for Homogeneity [3]	0.1680	0.1626	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (33.8)	20 (27.8)	25 (19.5)
No	51 (66.2)	52 (72.2)	103 (80.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	0.63	
95% CI of the inverse odds ratio	(0.25, 0.91)	(0.32, 1.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.70	
95% CI of the inverse risk ratio	(0.36, 0.93)	(0.42, 1.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.23	8.25	
95% CI of the absolute risk difference	(1.64, 26.83)	(-4.17, 20.66)	
p-value	0.0224	0.1801	
p-value of Breslow-Day Test for Homogeneity [3]	0.1031	0.4346	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (15.6)	10 (13.9)	10 (7.8)
No	65 (84.4)	62 (86.1)	118 (92.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.46	0.53	
95% CI of the inverse odds ratio	(0.19, 1.12)	(0.21, 1.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	0.56	
95% CI of the inverse risk ratio	(0.23, 1.10)	(0.25, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.77	6.08	
95% CI of the absolute risk difference	(-1.57, 17.11)	(-3.17, 15.32)	
p-value	0.0817	0.1692	
p-value of Breslow-Day Test for Homogeneity [3]	0.1122	0.0492	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (32.5)	21 (29.2)	27 (21.1)
No	52 (67.5)	51 (70.8)	101 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.65	
95% CI of the inverse odds ratio	(0.29, 1.05)	(0.33, 1.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	0.72	
95% CI of the inverse risk ratio	(0.41, 1.03)	(0.44, 1.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.37	8.07	
95% CI of the absolute risk difference	(-1.25, 24.00)	(-4.58, 20.73)	
p-value	0.0699	0.1994	
p-value of Breslow-Day Test for Homogeneity [3]	0.2113	0.2318	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	1 (4.5)	2 (3.2)
No	28 (93.3)	21 (95.5)	61 (96.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.46	0.69	
95% CI of the inverse odds ratio	(0.06, 3.43)	(0.06, 7.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	0.70	
95% CI of the inverse risk ratio	(0.07, 3.22)	(0.07, 7.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.49	1.37	
95% CI of the absolute risk difference	(-6.43, 13.41)	(-8.35, 11.09)	
p-value	0.4378	0.7642	
p-value of Breslow-Day Test for Homogeneity [3]	0.4014	0.4776	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (20.0)	4 (18.2)	14 (22.2)
No	24 (80.0)	18 (81.8)	49 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	1.29	
95% CI of the inverse odds ratio	(0.39, 3.34)	(0.37, 4.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.22	
95% CI of the inverse risk ratio	(0.47, 2.60)	(0.45, 3.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.22	-4.04	
95% CI of the absolute risk difference	(-19.84, 15.39)	(-23.15, 15.07)	
p-value	0.8074	0.6896	
p-value of Breslow-Day Test for Homogeneity [3]	0.0402	0.0035	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	2 (9.1)	6 (9.5)
No	28 (93.3)	20 (90.9)	57 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	1.05	
95% CI of the inverse odds ratio	(0.28, 7.77)	(0.20, 5.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.05	
95% CI of the inverse risk ratio	(0.31, 6.66)	(0.23, 4.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.86	-0.43	
95% CI of the absolute risk difference	(-14.36, 8.64)	(-14.46, 13.60)	
p-value	0.6460	0.9523	
p-value of Breslow-Day Test for Homogeneity [3]	0.8518	0.5857	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (20.0)	6 (27.3)	18 (28.6)
No	24 (80.0)	16 (72.7)	45 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.60	1.07	
95% CI of the inverse odds ratio	(0.56, 4.56)	(0.36, 3.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.05	
95% CI of the inverse risk ratio	(0.63, 3.23)	(0.48, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.57	-1.30	
95% CI of the absolute risk difference	(-26.72, 9.58)	(-23.00, 20.40)	
p-value	0.3772	0.9073	
p-value of Breslow-Day Test for Homogeneity [3]	0.1965	0.3886	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	1 (4.5)	5 (7.9)
No	28 (93.3)	21 (95.5)	58 (92.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.81	
95% CI of the inverse odds ratio	(0.22, 6.61)	(0.20, 16.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	1.75	
95% CI of the inverse risk ratio	(0.24, 5.79)	(0.22, 14.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.27	-3.39	
95% CI of the absolute risk difference	(-12.42, 9.88)	(-14.36, 7.58)	
p-value	0.8282	0.5929	
p-value of Breslow-Day Test for Homogeneity [3]	0.5282	0.0884	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	3 (13.6)	15 (23.8)
No	23 (76.7)	19 (86.4)	48 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.98	
95% CI of the inverse odds ratio	(0.37, 2.86)	(0.51, 7.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.75	
95% CI of the inverse risk ratio	(0.47, 2.24)	(0.56, 5.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.48	-10.17	
95% CI of the absolute risk difference	(-18.91, 17.95)	(-27.96, 7.61)	
p-value	0.9597	0.3147	
p-value of Breslow-Day Test for Homogeneity [3]	0.6343	0.4065	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	2 (9.1)	2 (3.2)
No	27 (90.0)	20 (90.9)	61 (96.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	0.33	
95% CI of the inverse odds ratio	(0.05, 1.87)	(0.04, 2.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.32	0.35	
95% CI of the inverse risk ratio	(0.06, 1.80)	(0.05, 2.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.83	5.92	
95% CI of the absolute risk difference	(-4.75, 18.40)	(-6.85, 18.69)	
p-value	0.1725	0.2593	
p-value of Breslow-Day Test for Homogeneity [3]	0.3840	0.1846	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (30.0)	7 (31.8)	15 (23.8)
No	21 (70.0)	15 (68.2)	48 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.67	
95% CI of the inverse odds ratio	(0.28, 1.93)	(0.23, 1.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.75	
95% CI of the inverse risk ratio	(0.39, 1.60)	(0.35, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.19	8.01	
95% CI of the absolute risk difference	(-13.29, 25.67)	(-14.11, 30.13)	
p-value	0.5236	0.4603	
p-value of Breslow-Day Test for Homogeneity [3]	0.7464	0.2300	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (13.3)	4 (18.2)	9 (14.3)
No	26 (86.7)	18 (81.8)	54 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.75	
95% CI of the inverse odds ratio	(0.31, 3.85)	(0.21, 2.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.79	
95% CI of the inverse risk ratio	(0.36, 3.20)	(0.27, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.95	3.90	
95% CI of the absolute risk difference	(-15.87, 13.97)	(-14.39, 22.18)	
p-value	0.9015	0.6620	
p-value of Breslow-Day Test for Homogeneity [3]	0.4353	0.1257	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	7 (31.8)	16 (25.4)
No	23 (76.7)	15 (68.2)	47 (74.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.73	
95% CI of the inverse odds ratio	(0.40, 3.10)	(0.25, 2.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.80	
95% CI of the inverse risk ratio	(0.50, 2.36)	(0.38, 1.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.06	6.42	
95% CI of the absolute risk difference	(-20.63, 16.50)	(-15.81, 28.66)	
p-value	0.8293	0.5595	
p-value of Breslow-Day Test for Homogeneity [3]	0.7788	0.3640	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.3)	0	1 (1.6)
No	29 (96.7)	22 (100)	62 (98.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse odds ratio	(0.03, 7.74)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse risk ratio	(0.03, 7.36)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.75	-1.59	
95% CI of the absolute risk difference	(-5.38, 8.87)	(-4.67, 1.50)	
p-value	0.5874	0.5522	
p-value of Breslow-Day Test for Homogeneity [3]	0.4695	0.7461	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (10.0)	1 (4.5)	6 (9.5)
No	27 (90.0)	21 (95.5)	57 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	2.21	
95% CI of the inverse odds ratio	(0.22, 4.08)	(0.25, 19.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	2.10	
95% CI of the inverse risk ratio	(0.26, 3.55)	(0.27, 16.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.48	-4.98	
95% CI of the absolute risk difference	(-12.48, 13.43)	(-16.31, 6.35)	
p-value	0.9421	0.4646	
p-value of Breslow-Day Test for Homogeneity [3]	0.5955	0.6847	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	3 (13.6)	11 (17.5)
No	27 (90.0)	19 (86.4)	52 (82.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.90	1.34	
95% CI of the inverse odds ratio	(0.49, 7.41)	(0.34, 5.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	1.28	
95% CI of the inverse risk ratio	(0.53, 5.80)	(0.39, 4.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.46	-3.82	
95% CI of the absolute risk difference	(-21.71, 6.79)	(-20.96, 13.31)	
p-value	0.3470	0.6772	
p-value of Breslow-Day Test for Homogeneity [3]	0.6621	0.1433	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	8 (36.4)	20 (31.7)
No	23 (76.7)	14 (63.6)	43 (68.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	0.81	
95% CI of the inverse odds ratio	(0.56, 4.15)	(0.29, 2.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.87	
95% CI of the inverse risk ratio	(0.65, 2.86)	(0.45, 1.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.41	4.62	
95% CI of the absolute risk difference	(-27.42, 10.59)	(-18.54, 27.77)	
p-value	0.4034	0.6916	
p-value of Breslow-Day Test for Homogeneity [3]	0.8276	0.2511	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	6 (27.3)	6 (9.5)
No	28 (93.3)	16 (72.7)	57 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	0.28	
95% CI of the inverse odds ratio	(0.28, 7.77)	(0.08, 0.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	0.35	
95% CI of the inverse risk ratio	(0.31, 6.66)	(0.13, 0.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.86	17.75	
95% CI of the absolute risk difference	(-14.36, 8.64)	(-2.22, 37.72)	
p-value	0.6460	0.0396	
p-value of Breslow-Day Test for Homogeneity [3]	0.3412	0.2250	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	8 (36.4)	22 (34.9)
No	23 (76.7)	14 (63.6)	41 (65.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.76	0.94	
95% CI of the inverse odds ratio	(0.65, 4.75)	(0.34, 2.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	0.96	
95% CI of the inverse risk ratio	(0.72, 3.11)	(0.50, 1.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.59	1.44	
95% CI of the absolute risk difference	(-30.76, 7.59)	(-21.85, 24.74)	
p-value	0.2595	0.9030	
p-value of Breslow-Day Test for Homogeneity [3]	0.5119	0.2985	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (20.0)	8 (36.4)	11 (17.5)
No	24 (80.0)	14 (63.6)	52 (82.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.37	
95% CI of the inverse odds ratio	(0.28, 2.56)	(0.13, 1.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.48	
95% CI of the inverse risk ratio	(0.36, 2.14)	(0.22, 1.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.54	18.90	
95% CI of the absolute risk difference	(-14.57, 19.65)	(-3.28, 41.08)	
p-value	0.7671	0.0669	
p-value of Breslow-Day Test for Homogeneity [3]	0.1680	0.1626	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (20.0)	9 (40.9)	17 (27.0)
No	24 (80.0)	13 (59.1)	46 (73.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.48	0.53	
95% CI of the inverse odds ratio	(0.52, 4.24)	(0.19, 1.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	0.66	
95% CI of the inverse risk ratio	(0.59, 3.07)	(0.35, 1.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.98	13.92	
95% CI of the absolute risk difference	(-25.01, 11.04)	(-9.36, 37.21)	
p-value	0.4655	0.2223	
p-value of Breslow-Day Test for Homogeneity [3]	0.1031	0.4346	

AMNOG Table SE21.14a.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	4 (18.2)	7 (11.1)
No	27 (90.0)	18 (81.8)	56 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	0.56	
95% CI of the inverse odds ratio	(0.27, 4.69)	(0.15, 2.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.61	
95% CI of the inverse risk ratio	(0.31, 4.00)	(0.20, 1.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.11	7.07	
95% CI of the absolute risk difference	(-14.36, 12.14)	(-10.82, 24.96)	
p-value	0.8715	0.3950	
p-value of Breslow-Day Test for Homogeneity [3]	0.1122	0.0492	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (40.0)	7 (31.8)	18 (28.6)
No	18 (60.0)	15 (68.2)	45 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.86	
95% CI of the inverse odds ratio	(0.24, 1.49)	(0.30, 2.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.90	
95% CI of the inverse risk ratio	(0.40, 1.28)	(0.43, 1.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.43	3.25	
95% CI of the absolute risk difference	(-9.35, 32.21)	(-19.19, 25.68)	
p-value	0.2704	0.7735	
p-value of Breslow-Day Test for Homogeneity [3]	0.2113	0.2318	

Madrigal Pharmaceuticals, Inc. Page 1 of 6
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE21.14a.5
Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation
Total LDQOL



Patients with result at given visit			
MGL-3196 80 mg	45	47	38
MGL-3196 100 mg	39	38	32
Placebo	90	85	75

Abbreviations: Abbreviations: LDLOQ = Liver Disease Quality of Life; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 6
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE21.14a.5
Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation
Concentration/Memory



Patients with result at given visit			
MGL-3196 80 mg	45	47	38
MGL-3196 100 mg	39	38	32
Placebo	90	85	75

Abbreviations: Abbreviations: LDLOQ = Liver Disease Quality of Life; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 6
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE21.14a.5
Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous
Total LDQOL



Patients with result at given visit			
MGL-3196 80 mg	73	73	66
MGL-3196 100 mg	66	64	51
Placebo	115	118	103

Abbreviations: Abbreviations: LDLOQ = Liver Disease Quality of Life; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 4 of 6
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE21.14a.5
Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous
Concentration/Memory



Patients with result at given visit			
MGL-3196 80 mg	73	73	66
MGL-3196 100 mg	66	64	51
Placebo	115	118	103

Abbreviations: Abbreviations: LDLOQ = Liver Disease Quality of Life; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 5 of 6
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE21.14a.5
Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous
Total LDQOL



Patients with result at given visit			
MGL-3196 80 mg	30	27	25
MGL-3196 100 mg	21	22	21
Placebo	60	55	46

Abbreviations: Abbreviations: LDLOQ = Liver Disease Quality of Life; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 6 of 6
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE21.14a.5
Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous
Concentration/Memory



Patients with result at given visit			
MGL-3196 80 mg	30	27	25
MGL-3196 100 mg	21	22	21
Placebo	60	55	46

Abbreviations: Abbreviations: LDLOQ = Liver Disease Quality of Life; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Total LDQOL						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	77.27 (14.47)	76.53 (14.74)	78.07 (13.62)			
Median	80.00	80.55	81.30			
IQR: Q1, Q3	68.70, 89.20	67.60, 86.80	71.70, 88.10			
Min, Max	29.0, 96.7	23.6, 96.3	38.2, 97.8			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	78.11 (14.97)	76.98 (12.50)	78.44 (13.91)	0.60 (0.86)	0.18 (0.85)	0.33 (0.71)
Median	81.20	78.45	81.85	-0.10	-0.90	0.20
IQR: Q1, Q3	70.40, 89.80	70.60, 86.00	70.10, 88.95	-5.00, 5.20	-5.20, 5.10	-4.00, 4.60
Min, Max	22.9, 97.8	32.4, 96.9	22.4, 98.8	-23.4, 35.6	-15.4, 27.0	-46.4, 29.7
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	79.68 (12.71)	78.22 (14.24)	78.59 (14.51)	1.21 (0.92)	0.89 (1.01)	0.32 (0.71)
Median	83.30	81.60	82.30	0.80	0.75	0.60
IQR: Q1, Q3	70.10, 90.60	68.40, 90.20	70.40, 89.20	-3.70, 6.30	-4.30, 6.20	-4.40, 5.30
Min, Max	48.1, 97.5	34.2, 97.4	20.3, 100.0	-19.3, 36.0	-19.2, 33.9	-46.3, 24.9

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Symptoms of Liver Disease						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	77.03 (19.71)	73.14 (19.30)	76.56 (17.85)			
Median	83.30	75.00	80.00			
IQR: Q1, Q3	68.35, 93.30	61.65, 86.70	63.30, 93.30			
Min, Max	23.3, 100.0	10.0, 100.0	20.0, 100.0			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	76.69 (20.64)	73.50 (17.96)	76.81 (19.40)	-0.99 (1.34)	-0.17 (1.28)	-0.48 (1.02)
Median	83.30	75.00	83.30	0	0	0
IQR: Q1, Q3	66.70, 93.30	63.30, 86.70	63.30, 93.30	-10.00, 6.60	-10.00, 6.70	-6.70, 6.70
Min, Max	0.0, 100.0	26.7, 100.0	16.7, 100.0	-46.7, 36.7	-36.6, 30.0	-53.3, 43.3
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	78.33 (19.07)	76.86 (18.42)	77.54 (19.05)	-1.28 (1.22)	2.48 (1.51)	0.34 (0.94)
Median	83.30	80.00	83.30	0	3.30	0
IQR: Q1, Q3	66.70, 93.30	66.70, 93.30	66.70, 93.30	-6.70, 6.60	-6.70, 13.30	-6.70, 6.70
Min, Max	23.3, 100.0	26.7, 100.0	16.7, 100.0	-36.7, 43.4	-36.7, 36.7	-60.0, 26.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Effects of Liver Disease						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	77.78 (13.78)	78.53 (14.45)	77.93 (14.21)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	73.30, 86.70	73.30, 86.70	80.00, 86.70			
Min, Max	13.3, 100.0	13.3, 100.0	26.7, 100.0			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	75.67 (14.01)	79.64 (9.82)	77.06 (14.64)	-2.38 (1.12)	0.39 (1.61)	-1.11 (1.07)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	73.30, 80.00	-6.70, 0.00	-6.70, 0.00	-6.70, 6.60
Min, Max	20.0, 100.0	40.0, 100.0	6.7, 100.0	-40.0, 33.3	-20.0, 76.7	-46.7, 53.4
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	78.20 (11.02)	77.94 (11.93)	77.52 (14.21)	-0.58 (1.46)	-1.05 (1.42)	-0.89 (1.40)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	73.30, 80.00	-6.70, 3.30	-6.70, 0.00	-6.70, 6.60
Min, Max	40.0, 100.0	26.7, 100.0	13.3, 100.0	-40.0, 80.0	-33.3, 53.4	-80.0, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Concentration/Memory						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	81.11 (22.06)	78.57 (20.69)	78.16 (21.55)			
Median	87.50	84.40	87.50			
IQR: Q1, Q3	68.80, 100.00	62.50, 93.80	68.80, 100.00			
Min, Max	12.5, 100.0	18.8, 100.0	6.3, 100.0			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	79.77 (22.09)	79.61 (20.15)	79.09 (22.01)	-1.63 (1.43)	-0.20 (1.64)	0.48 (1.15)
Median	87.50	81.30	87.50	0	0	0
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	68.80, 100.00	-6.30, 6.20	-6.30, 6.30	-6.20, 6.30
Min, Max	0.0, 100.0	25.0, 100.0	6.3, 100.0	-43.8, 31.2	-37.5, 56.2	-81.2, 62.5
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	80.60 (17.14)	79.51 (20.85)	78.34 (22.56)	-0.94 (1.43)	-1.53 (1.64)	-0.83 (1.06)
Median	81.30	87.50	81.30	0	0	0
IQR: Q1, Q3	68.80, 93.80	62.50, 100.00	62.50, 100.00	-6.30, 6.20	-6.30, 6.20	-6.30, 6.30
Min, Max	37.5, 100.0	18.8, 100.0	0.0, 100.0	-43.7, 50.0	-43.8, 50.0	-43.7, 43.8

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Health Distress						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	77.40 (27.03)	81.97 (23.03)	80.08 (24.27)			
Median	87.50	87.50	87.50			
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	82.69 (23.09)	87.38 (20.09)	85.66 (21.94)	5.65 (1.96)	5.26 (1.89)	6.06 (1.45)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-37.5, 75.0	-37.5, 50.0	-62.5, 75.0
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	83.46 (23.61)	87.36 (20.43)	85.36 (21.83)	5.43 (2.56)	5.38 (2.03)	5.12 (1.71)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-75.0, 75.0	-50.0, 62.5	-62.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Sexual Function						
Baseline						
m	124	112	223			
n	48	52	89			
Mean (SD)	83.79 (23.57)	79.60 (23.87)	78.48 (25.01)			
Median	93.30	89.15	86.70			
IQR: Q1, Q3	76.70, 100.00	68.30, 100.00	68.30, 100.00			
Min, Max	8.9, 100.0	-1.7, 100.0	-1.7, 100.0			
Week 24						
m	121	106	214			
n	49	56	91	38	43	72
Mean (SD/SE)	81.19 (24.56)	74.58 (26.42)	79.69 (24.06)	-0.18 (4.66)	-4.49 (3.04)	1.20 (2.12)
Median	93.30	82.50	86.70	0	0	0
IQR: Q1, Q3	76.70, 100.00	55.00, 100.00	68.30, 100.00	-6.60, 6.60	-15.00, 0.00	-6.70, 7.50
Min, Max	6.7, 100.0	13.3, 100.0	-1.7, 100.0	-85.0, 91.1	-55.0, 46.7	-48.4, 50.0
Week 52						
m	112	96	200			
n	34	41	74	27	35	60
Mean (SD/SE)	90.01 (16.31)	82.91 (24.16)	77.30 (25.60)	0.60 (4.32)	0.01 (3.45)	-0.16 (2.86)
Median	100.00	93.30	85.85	0	0	0
IQR: Q1, Q3	85.00, 100.00	70.00, 100.00	55.00, 100.00	-6.70, 0.00	-13.30, 6.70	-8.30, 6.70
Min, Max	30.0, 100.0	5.0, 100.0	-1.7, 100.0	-45.0, 91.1	-48.3, 61.7	-48.4, 65.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Sleep						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	63.21 (20.86)	59.09 (19.51)	63.32 (20.60)			
Median	65.00	62.50	65.00			
IQR: Q1, Q3	50.00, 80.00	50.00, 75.00	50.00, 80.00			
Min, Max	0.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	63.76 (20.56)	56.67 (19.36)	62.25 (20.06)	0.43 (1.40)	-2.16 (1.50)	-1.13 (1.14)
Median	65.00	57.50	60.00	0	-5.00	0
IQR: Q1, Q3	50.00, 75.00	40.00, 70.00	50.00, 75.00	-5.00, 5.00	-10.00, 5.00	-10.00, 10.00
Min, Max	5.0, 100.0	0.0, 95.0	15.0, 100.0	-30.0, 90.0	-35.0, 45.0	-40.0, 45.0
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	64.96 (19.46)	58.09 (21.21)	63.49 (20.84)	0.22 (1.76)	-1.80 (1.83)	0.28 (1.24)
Median	70.00	60.00	65.00	0	-2.50	0
IQR: Q1, Q3	50.00, 80.00	40.00, 75.00	45.00, 80.00	-10.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	10.0, 100.0	0.0, 90.0	5.0, 100.0	-40.0, 75.0	-60.0, 45.0	-40.0, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Loneliness						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	83.50 (18.77)	82.64 (20.40)	85.25 (18.86)			
Median	90.00	90.00	95.00			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	83.70 (19.52)	83.58 (19.71)	82.89 (19.93)	-0.15 (1.56)	0.37 (1.44)	-2.51 (1.20)
Median	90.00	90.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	-10.00, 10.00	-5.00, 5.00	-10.00, 5.00
Min, Max	15.0, 100.0	0.0, 100.0	15.0, 100.0	-50.0, 45.0	-35.0, 65.0	-80.0, 40.0
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	84.02 (17.58)	83.09 (22.20)	83.80 (19.07)	0.00 (1.53)	0.47 (1.59)	-1.22 (1.17)
Median	85.00	90.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	-5.00, 5.00	-5.00, 10.00	-10.00, 5.00
Min, Max	35.0, 100.0	0.0, 100.0	10.0, 100.0	-55.0, 50.0	-40.0, 30.0	-40.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Hopelessness						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	75.28 (22.22)	77.40 (23.05)	79.58 (20.74)			
Median	75.00	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	66.70, 100.00			
Min, Max	25.0, 100.0	8.3, 100.0	16.7, 100.0			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	77.63 (21.77)	76.96 (23.02)	79.31 (21.52)	2.17 (1.76)	-0.17 (1.86)	0.07 (1.30)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	66.70, 100.00	-8.40, 16.60	-8.30, 8.40	-8.30, 8.30
Min, Max	8.3, 100.0	8.3, 100.0	16.7, 100.0	-41.7, 50.0	-41.7, 58.3	-66.6, 50.0
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	78.43 (21.15)	77.81 (22.50)	79.39 (21.72)	2.02 (1.96)	0.78 (2.39)	-0.80 (1.37)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	58.30, 100.00	58.30, 100.00	-8.30, 16.60	-8.40, 16.70	-8.30, 8.30
Min, Max	33.3, 100.0	0.0, 100.0	8.3, 100.0	-41.7, 41.7	-58.3, 50.0	-58.4, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Stigma of Liver Disease						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	80.95 (21.57)	80.49 (19.89)	84.49 (18.88)			
Median	87.50	81.30	87.50			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	81.30, 100.00			
Min, Max	25.0, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	84.20 (19.63)	80.72 (19.80)	85.27 (18.92)	2.72 (1.77)	0.46 (1.53)	0.71 (1.22)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	81.30, 100.00	-6.20, 12.50	-6.30, 6.20	-6.20, 6.20
Min, Max	12.5, 100.0	12.5, 100.0	6.3, 100.0	-43.8, 56.2	-31.3, 56.3	-62.5, 75.0
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	87.21 (17.76)	83.92 (19.46)	85.20 (18.74)	4.36 (1.48)	2.74 (1.59)	1.40 (1.26)
Median	96.90	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	-6.20, 6.30	-6.20, 6.30
Min, Max	31.3, 100.0	12.5, 100.0	18.8, 100.0	-31.3, 56.2	-37.5, 56.3	-62.5, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=26)	Visit Result MGL-3196 100 mg (N=24)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=26)	Change from Baseline MGL-3196 100 mg (N=24)	Change from Baseline Placebo (N=62)
Total LDQOL						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	77.30 (13.08)	77.88 (11.21)	75.90 (15.30)			
Median	82.00	79.75	80.70			
IQR: Q1, Q3	72.30, 88.30	71.10, 87.30	67.10, 87.70			
Min, Max	42.3, 90.8	56.8, 93.6	34.8, 93.7			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	76.27 (14.89)	78.22 (11.51)	79.19 (14.50)	0.85 (1.50)	0.98 (1.59)	2.29 (1.38)
Median	78.80	79.60	84.35	2.45	0.50	1.80
IQR: Q1, Q3	69.80, 87.50	70.10, 86.75	73.50, 89.70	-5.70, 5.60	-4.40, 3.30	-2.40, 6.00
Min, Max	36.6, 93.5	56.6, 96.6	33.3, 95.0	-11.7, 16.4	-7.8, 15.6	-19.0, 42.3
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	75.54 (15.49)	77.94 (9.68)	78.90 (14.11)	-0.21 (1.39)	-0.95 (2.66)	1.29 (1.84)
Median	80.95	77.15	81.10	-1.50	-0.05	-0.50
IQR: Q1, Q3	68.20, 88.30	72.80, 87.20	72.00, 88.60	-3.95, 3.35	-5.15, 5.60	-4.10, 5.00
Min, Max	34.0, 91.7	61.3, 92.0	40.4, 97.6	-12.0, 13.5	-23.3, 10.1	-36.2, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Symptoms of Liver Disease						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	76.80 (16.62)	81.50 (14.92)	75.15 (17.82)			
Median	80.00	83.30	76.70			
IQR: Q1, Q3	63.30, 93.30	75.00, 91.65	60.00, 90.00			
Min, Max	40.0, 100.0	46.7, 100.0	26.7, 100.0			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	72.80 (18.01)	72.34 (20.52)	78.83 (18.30)	-1.96 (2.19)	-7.06 (2.42)	3.41 (1.64)
Median	76.70	76.70	83.30	0	-3.30	3.30
IQR: Q1, Q3	60.00, 83.30	65.00, 85.00	66.70, 93.30	-10.00, 6.70	-13.30, 0.00	-3.30, 10.00
Min, Max	30.0, 100.0	26.7, 100.0	20.0, 100.0	-23.3, 16.6	-33.3, 3.3	-16.7, 36.7
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	71.20 (16.64)	76.43 (15.93)	78.23 (19.71)	-4.33 (3.50)	-5.56 (3.29)	2.32 (2.32)
Median	71.65	76.65	83.30	-3.30	-5.00	3.30
IQR: Q1, Q3	60.00, 83.30	66.70, 90.00	66.70, 93.30	-11.65, 8.35	-16.65, 0.00	-6.70, 13.30
Min, Max	40.0, 100.0	40.0, 96.7	23.3, 100.0	-43.4, 20.0	-20.0, 16.6	-36.7, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=26)	Visit Result: MGL-3196 100 mg (N=24)	Visit Result: Placebo (N=62)	Change from Baseline: MGL-3196 80 mg (N=26)	Change from Baseline: MGL-3196 100 mg (N=24)	Change from Baseline: Placebo (N=62)
Effects of Liver Disease						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	77.39 (10.20)	81.01 (13.20)	75.15 (17.52)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	80.00, 86.70	73.30, 80.00			
Min, Max	46.7, 93.3	46.7, 100.0	6.7, 100.0			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	77.34 (12.32)	76.67 (11.75)	78.89 (15.47)	0.30 (2.54)	-2.36 (3.28)	3.97 (2.02)
Median	80.00	80.00	80.00	0	-6.70	0
IQR: Q1, Q3	73.30, 80.00	73.30, 80.00	80.00, 86.70	-6.70, 6.70	-6.70, 6.70	0.00, 13.30
Min, Max	40.0, 100.0	40.0, 100.0	26.7, 100.0	-20.0, 26.6	-26.7, 20.0	-26.7, 33.3
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	71.51 (15.96)	79.06 (9.73)	78.30 (11.91)	-4.00 (2.58)	-1.67 (3.86)	1.63 (2.52)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	66.70, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 0.00	-6.70, 3.35	-6.60, 6.70
Min, Max	40.0, 100.0	60.0, 100.0	40.0, 100.0	-40.0, 20.0	-33.3, 20.0	-40.0, 53.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=26)	Visit Result MGL-3196 100 mg (N=24)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=26)	Change from Baseline MGL-3196 100 mg (N=24)	Change from Baseline Placebo (N=62)
Concentration/Memory						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	75.02 (27.44)	80.64 (20.47)	79.11 (18.80)			
Median	87.50	87.50	81.30			
IQR: Q1, Q3	62.50, 93.80	71.90, 100.00	68.80, 93.80			
Min, Max	12.5, 100.0	25.0, 100.0	25.0, 100.0			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	71.76 (24.34)	79.39 (17.69)	82.66 (19.83)	-1.42 (2.97)	-1.10 (2.80)	2.26 (2.37)
Median	75.00	78.15	90.65	0	0	0
IQR: Q1, Q3	56.30, 87.50	71.90, 96.90	75.00, 100.00	-6.30, 6.20	-6.30, 0.00	0.00, 6.30
Min, Max	18.8, 100.0	37.5, 100.0	12.5, 100.0	-25.0, 25.0	-25.0, 25.0	-37.5, 50.0
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	71.90 (28.59)	79.49 (18.89)	80.51 (19.03)	-0.94 (3.34)	-2.08 (4.64)	0.30 (2.53)
Median	78.15	84.40	81.30	0	-3.10	0
IQR: Q1, Q3	50.00, 93.80	62.50, 93.80	75.00, 93.80	-9.35, 3.10	-12.50, 9.35	-6.20, 6.30
Min, Max	0.0, 100.0	43.8, 100.0	18.8, 100.0	-18.8, 50.0	-31.2, 25.0	-43.8, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=26)	Visit Result MGL-3196 100 mg (N=24)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=26)	Change from Baseline MGL-3196 100 mg (N=24)	Change from Baseline Placebo (N=62)
Health Distress						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	80.98 (25.53)	78.13 (33.17)	81.59 (24.28)			
Median	100.00	100.00	87.50			
IQR: Q1, Q3	62.50, 100.00	56.25, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	80.00 (28.41)	83.75 (22.62)	86.11 (21.54)	0.57 (4.07)	8.09 (4.28)	2.66 (2.49)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	50.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	12.5, 100.0	25.0, 100.0	0.0, 100.0	-50.0, 37.5	-12.5, 50.0	-50.0, 50.0
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	78.41 (28.40)	86.61 (18.65)	87.50 (19.26)	-1.25 (2.85)	3.13 (6.55)	1.74 (3.71)
Median	93.75	93.75	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	87.50, 100.00	75.00, 100.00	0.00, 0.00	-6.25, 6.25	0.00, 12.50
Min, Max	12.5, 100.0	50.0, 100.0	12.5, 100.0	-37.5, 25.0	-37.5, 50.0	-87.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Sexual Function						
Baseline						
m	26	24	62			
n	14	12	23			
Mean (SD)	68.67 (35.22)	77.36 (23.73)	80.21 (25.76)			
Median	89.15	83.30	85.00			
IQR: Q1, Q3	38.30, 93.30	58.35, 100.00	68.30, 100.00			
Min, Max	-1.7, 100.0	38.3, 100.0	23.3, 100.0			
Week 24						
m	25	21	58			
n	15	14	29	12	10	18
Mean (SD/SE)	77.89 (25.55)	79.52 (22.25)	78.16 (22.73)	5.30 (4.29)	-1.66 (7.26)	-2.51 (4.50)
Median	85.00	92.50	85.00	7.50	0.85	0
IQR: Q1, Q3	61.70, 100.00	60.00, 100.00	61.70, 100.00	-0.80, 8.40	-16.70, 16.70	-8.30, 8.30
Min, Max	23.3, 100.0	38.3, 100.0	13.3, 100.0	-23.3, 31.7	-48.3, 30.0	-46.7, 31.7
Week 52						
m	25	17	55			
n	12	9	19	12	6	14
Mean (SD/SE)	74.58 (33.19)	64.56 (26.97)	75.62 (30.35)	10.02 (6.86)	-9.53 (8.45)	-3.80 (5.15)
Median	96.65	53.30	86.70	3.35	-3.60	0
IQR: Q1, Q3	52.50, 100.00	46.70, 93.30	60.00, 100.00	-0.85, 8.35	-8.30, 0.00	-13.30, 6.70
Min, Max	6.7, 100.0	31.1, 100.0	-1.7, 100.0	-16.6, 61.7	-50.0, 8.3	-53.3, 30.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=26)	Visit Result MGL-3196 100 mg (N=24)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=26)	Change from Baseline MGL-3196 100 mg (N=24)	Change from Baseline Placebo (N=62)
Sleep						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	60.65 (19.67)	61.00 (17.89)	61.18 (18.83)			
Median	60.00	62.50	60.00			
IQR: Q1, Q3	40.00, 75.00	42.50, 77.50	50.00, 75.00			
Min, Max	25.0, 90.0	35.0, 85.0	5.0, 90.0			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	62.20 (23.23)	61.75 (19.28)	64.07 (21.24)	1.36 (3.47)	2.65 (3.35)	2.45 (2.32)
Median	70.00	60.00	70.00	0	0	0
IQR: Q1, Q3	45.00, 80.00	52.50, 72.50	45.00, 80.00	-5.00, 10.00	-5.00, 10.00	-5.00, 10.00
Min, Max	25.0, 100.0	20.0, 95.0	20.0, 100.0	-25.0, 50.0	-20.0, 30.0	-30.0, 50.0
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	61.82 (18.74)	63.21 (16.13)	66.02 (19.68)	-0.25 (2.28)	4.58 (5.02)	3.49 (2.27)
Median	65.00	62.50	70.00	-2.50	10.00	5.00
IQR: Q1, Q3	50.00, 75.00	55.00, 70.00	50.00, 80.00	-5.00, 2.50	-10.00, 17.50	-5.00, 15.00
Min, Max	15.0, 90.0	35.0, 95.0	25.0, 100.0	-20.0, 25.0	-30.0, 30.0	-30.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=26)	Visit Result: MGL-3196 100 mg (N=24)	Visit Result: Placebo (N=62)	Change from Baseline: MGL-3196 80 mg (N=26)	Change from Baseline: MGL-3196 100 mg (N=24)	Change from Baseline: Placebo (N=62)
Loneliness						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	87.17 (13.38)	83.50 (18.00)	77.91 (22.85)			
Median	90.00	92.50	85.00			
IQR: Q1, Q3	75.00, 100.00	72.50, 100.00	65.00, 95.00			
Min, Max	60.0, 100.0	45.0, 100.0	25.0, 100.0			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	82.40 (17.98)	92.00 (16.89)	82.22 (23.43)	-1.82 (3.33)	4.41 (3.00)	2.34 (2.46)
Median	85.00	97.50	92.50	0	0	0
IQR: Q1, Q3	70.00, 100.00	92.50, 100.00	75.00, 100.00	-10.00, 5.00	0.00, 15.00	-5.00, 10.00
Min, Max	45.0, 100.0	25.0, 100.0	10.0, 100.0	-30.0, 30.0	-25.0, 25.0	-30.0, 70.0
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	86.59 (18.86)	88.21 (12.80)	84.08 (20.78)	1.25 (4.23)	3.33 (4.10)	3.37 (3.09)
Median	95.00	92.50	95.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	80.00, 100.00	80.00, 100.00	-2.50, 7.50	-5.00, 10.00	-5.00, 10.00
Min, Max	25.0, 100.0	60.0, 100.0	5.0, 100.0	-60.0, 35.0	-20.0, 30.0	-35.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=26)	Visit Result MGL-3196 100 mg (N=24)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=26)	Change from Baseline MGL-3196 100 mg (N=24)	Change from Baseline Placebo (N=62)
Hopelessness						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	79.72 (24.34)	73.34 (23.97)	76.06 (23.63)			
Median	91.70	75.00	83.30			
IQR: Q1, Q3	66.70, 100.00	50.00, 100.00	58.30, 100.00			
Min, Max	8.3, 100.0	33.3, 100.0	16.7, 100.0			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	76.68 (28.16)	77.91 (19.17)	76.55 (21.73)	1.52 (4.57)	7.34 (5.39)	-2.12 (3.09)
Median	91.70	83.30	75.00	0	0	0
IQR: Q1, Q3	50.00, 100.00	58.30, 95.85	58.30, 100.00	-8.30, 16.70	-8.30, 16.60	-8.30, 8.40
Min, Max	8.3, 100.0	41.7, 100.0	25.0, 100.0	-58.3, 41.7	-25.0, 58.4	-58.3, 50.0
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	78.04 (24.47)	76.80 (19.10)	74.83 (24.68)	-0.42 (3.85)	-0.68 (5.66)	-2.72 (3.76)
Median	87.50	75.00	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	58.30, 91.70	-4.15, 8.30	-20.80, 16.70	-8.30, 8.30
Min, Max	16.7, 100.0	41.7, 100.0	0.0, 100.0	-50.0, 33.3	-25.0, 33.4	-100.0, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=26)	Visit Result: MGL-3196 100 mg (N=24)	Visit Result: Placebo (N=62)	Change from Baseline: MGL-3196 80 mg (N=26)	Change from Baseline: MGL-3196 100 mg (N=24)	Change from Baseline: Placebo (N=62)
Stigma of Liver Disease						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	86.70 (18.19)	83.14 (16.48)	79.45 (20.53)			
Median	93.80	84.40	81.30			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	68.80, 100.00			
Min, Max	18.8, 100.0	43.8, 100.0	31.3, 100.0			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	88.51 (21.24)	81.27 (18.13)	84.40 (17.58)	3.40 (2.08)	0.37 (2.81)	5.05 (2.03)
Median	100.00	84.40	87.50	0	0	0
IQR: Q1, Q3	81.30, 100.00	65.65, 100.00	81.30, 100.00	0.00, 6.30	0.00, 6.20	0.00, 12.50
Min, Max	6.3, 100.0	43.8, 100.0	25.0, 100.0	-12.5, 25.0	-18.8, 25.0	-18.7, 43.8
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	86.09 (17.98)	81.71 (18.74)	83.96 (18.88)	2.49 (1.46)	1.56 (6.71)	2.91 (2.98)
Median	93.75	84.40	93.80	0	3.10	0
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	81.30, 100.00	0.00, 6.20	-6.25, 15.60	-6.20, 12.50
Min, Max	37.5, 100.0	43.8, 100.0	25.0, 100.0	-12.5, 18.7	-56.2, 31.3	-37.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Total LDQOL						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	83.22 (12.85)	85.65 (1.77)	82.20 (N/A)			
Median	81.00	85.65	82.20			
IQR: Q1, Q3	79.40, 94.40	84.40, 86.90	82.20, 82.20			
Min, Max	64.8, 96.5	84.4, 86.9	82.2, 82.2			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	81.32 (9.86)	87.45 (9.55)	N/A	-1.90 (4.79)	1.80 (8.00)	N/A
Median	82.90	87.45	N/A	1.20	1.80	N/A
IQR: Q1, Q3	78.20, 89.50	80.70, 94.20	N/A	-4.90, 1.90	-6.20, 9.80	N/A
Min, Max	66.0, 90.0	80.7, 94.2	N/A	-18.3, 10.6	-6.2, 9.8	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	83.96 (8.39)	73.20 (N/A)	N/A	0.74 (3.26)	-13.70 (N/A)	N/A
Median	86.30	73.20	N/A	4.60	-13.70	N/A
IQR: Q1, Q3	86.10, 86.90	73.20, 73.20	N/A	-3.30, 5.90	-13.70, -13.70	N/A
Min, Max	69.4, 91.1	73.2, 73.2	N/A	-10.2, 6.7	-13.7, -13.7	N/A

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Symptoms of Liver Disease						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	87.34 (8.62)	88.30 (7.07)	70.00 (N/A)			
Median	90.00	88.30	70.00			
IQR: Q1, Q3	80.00, 93.30	83.30, 93.30	70.00, 70.00			
Min, Max	76.7, 96.7	83.3, 93.3	70.0, 70.0			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	76.66 (17.77)	81.65 (16.48)	N/A	-10.68 (10.28)	-6.65 (16.65)	N/A
Median	83.30	81.65	N/A	-6.70	-6.65	N/A
IQR: Q1, Q3	76.70, 83.30	70.00, 93.30	N/A	-13.40, -3.30	-23.30, 10.00	N/A
Min, Max	46.7, 93.3	70.0, 93.3	N/A	-46.6, 16.6	-23.3, 10.0	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	85.34 (10.93)	86.70 (N/A)	N/A	-2.00 (7.33)	-6.60 (N/A)	N/A
Median	86.70	86.70	N/A	3.30	-6.60	N/A
IQR: Q1, Q3	86.70, 93.30	86.70, 86.70	N/A	-10.00, 10.00	-6.60, -6.60	N/A
Min, Max	66.7, 93.3	86.7, 86.7	N/A	-26.6, 13.3	-6.6, -6.6	N/A

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Effects of Liver Disease						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	78.68 (7.30)	100.00 (0.00)	93.30 (N/A)			
Median	80.00	100.00	93.30			
IQR: Q1, Q3	80.00, 80.00	100.00, 100.00	93.30, 93.30			
Min, Max	66.7, 86.7	100.0, 100.0	93.3, 93.3			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	77.32 (3.67)	83.35 (23.55)	N/A	-1.36 (3.27)	-16.65 (16.65)	N/A
Median	80.00	83.35	N/A	0	-16.65	N/A
IQR: Q1, Q3	73.30, 80.00	66.70, 100.00	N/A	0.00, 0.00	-33.30, 0.00	N/A
Min, Max	73.3, 80.0	66.7, 100.0	N/A	-13.4, 6.6	-33.3, 0.0	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	78.66 (3.00)	93.30 (N/A)	N/A	-0.02 (2.10)	-6.70 (N/A)	N/A
Median	80.00	93.30	N/A	0	-6.70	N/A
IQR: Q1, Q3	80.00, 80.00	93.30, 93.30	N/A	0.00, 0.00	-6.70, -6.70	N/A
Min, Max	73.3, 80.0	93.3, 93.3	N/A	-6.7, 6.6	-6.7, -6.7	N/A

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Concentration/Memory						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	85.02 (21.01)	71.90 (4.38)	87.50 (N/A)			
Median	93.80	71.90	87.50			
IQR: Q1, Q3	81.30, 100.00	68.80, 75.00	87.50, 87.50			
Min, Max	50.0, 100.0	68.8, 75.0	87.5, 87.5			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	78.76 (18.54)	90.65 (13.22)	N/A	-6.26 (3.41)	18.75 (6.25)	N/A
Median	81.30	90.65	N/A	-6.30	18.75	N/A
IQR: Q1, Q3	75.00, 87.50	81.30, 100.00	N/A	-6.30, 0.00	12.50, 25.00	N/A
Min, Max	50.0, 100.0	81.3, 100.0	N/A	-18.7, 0.0	12.5, 25.0	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	81.26 (19.77)	56.30 (N/A)	N/A	-3.76 (1.54)	-12.50 (N/A)	N/A
Median	87.50	56.30	N/A	-6.20	-12.50	N/A
IQR: Q1, Q3	75.00, 93.80	56.30, 56.30	N/A	-6.30, 0.00	-12.50, -12.50	N/A
Min, Max	50.0, 100.0	56.3, 56.3	N/A	-6.3, 0.0	-12.5, -12.5	N/A

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Health Distress						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	77.50 (25.62)	100.00 (0.00)	100.00 (N/A)			
Median	87.50	100.00	100.00			
IQR: Q1, Q3	50.00, 100.00	100.00, 100.00	100.00, 100.00			
Min, Max	50.0, 100.0	100.0, 100.0	100.0, 100.0			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	97.50 (5.59)	93.75 (8.84)	N/A	20.00 (10.16)	-6.25 (6.25)	N/A
Median	100.00	93.75	N/A	12.50	-6.25	N/A
IQR: Q1, Q3	100.00, 100.00	87.50, 100.00	N/A	0.00, 37.50	-12.50, 0.00	N/A
Min, Max	87.5, 100.0	87.5, 100.0	N/A	0.0, 50.0	-12.5, 0.0	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	92.50 (11.18)	75.00 (N/A)	N/A	15.00 (10.00)	-25.00 (N/A)	N/A
Median	100.00	75.00	N/A	0	-25.00	N/A
IQR: Q1, Q3	87.50, 100.00	75.00, 75.00	N/A	0.00, 25.00	-25.00, -25.00	N/A
Min, Max	75.0, 100.0	75.0, 75.0	N/A	0.0, 50.0	-25.0, -25.0	N/A

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Sexual Function						
Baseline						
m	5	2	1			
n	3	1	0			
Mean (SD)	82.77 (18.45)	53.30 (N/A)	N/A			
Median	85.00	53.30	N/A			
IQR: Q1, Q3	63.30, 100.00	53.30, 53.30	N/A			
Min, Max	63.3, 100.0	53.3, 53.3	N/A			
Week 24						
m	5	2	0			
n	3	0	0	3	0	0
Mean (SD/SE)	77.23 (22.50)	N/A	N/A	-5.53 (2.77)	N/A	N/A
Median	76.70	N/A	N/A	-8.30	N/A	N/A
IQR: Q1, Q3	55.00, 100.00	N/A	N/A	-8.30, 0.00	N/A	N/A
Min, Max	55.0, 100.0	N/A	N/A	-8.3, 0.0	N/A	N/A
Week 52						
m	5	1	0			
n	3	1	0	3	1	0
Mean (SD/SE)	80.00 (4.40)	55.00 (N/A)	N/A	-2.77 (8.43)	1.70 (N/A)	N/A
Median	78.30	55.00	N/A	-6.70	1.70	N/A
IQR: Q1, Q3	76.70, 85.00	55.00, 55.00	N/A	-15.00, 13.40	1.70, 1.70	N/A
Min, Max	76.7, 85.0	55.0, 55.0	N/A	-15.0, 13.4	1.7, 1.7	N/A

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Sleep						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	69.00 (32.29)	70.00 (28.28)	40.00 (N/A)			
Median	75.00	70.00	40.00			
IQR: Q1, Q3	70.00, 85.00	50.00, 90.00	40.00, 40.00			
Min, Max	15.0, 100.0	50.0, 90.0	40.0, 40.0			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	61.00 (26.79)	72.50 (17.68)	N/A	-8.00 (7.35)	2.50 (7.50)	N/A
Median	70.00	72.50	N/A	0	2.50	N/A
IQR: Q1, Q3	65.00, 70.00	60.00, 85.00	N/A	-20.00, 0.00	-5.00, 10.00	N/A
Min, Max	15.0, 85.0	60.0, 85.0	N/A	-30.0, 10.0	-5.0, 10.0	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	66.00 (28.81)	85.00 (N/A)	N/A	-3.00 (4.06)	-5.00 (N/A)	N/A
Median	75.00	85.00	N/A	0	-5.00	N/A
IQR: Q1, Q3	75.00, 80.00	85.00, 85.00	N/A	-10.00, 5.00	-5.00, -5.00	N/A
Min, Max	15.0, 85.0	85.0, 85.0	N/A	-15.0, 5.0	-5.0, -5.0	N/A

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Loneliness						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	88.00 (24.14)	92.50 (10.61)	90.00 (N/A)			
Median	100.00	92.50	90.00			
IQR: Q1, Q3	95.00, 100.00	85.00, 100.00	90.00, 90.00			
Min, Max	45.0, 100.0	85.0, 100.0	90.0, 90.0			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	86.00 (17.10)	90.00 (14.14)	N/A	-2.00 (7.18)	-2.50 (2.50)	N/A
Median	95.00	90.00	N/A	0	-2.50	N/A
IQR: Q1, Q3	70.00, 100.00	80.00, 100.00	N/A	-5.00, 0.00	-5.00, 0.00	N/A
Min, Max	65.0, 100.0	80.0, 100.0	N/A	-25.0, 20.0	-5.0, 0.0	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	94.00 (8.22)	45.00 (N/A)	N/A	6.00 (7.31)	-40.00 (N/A)	N/A
Median	95.00	45.00	N/A	0	-40.00	N/A
IQR: Q1, Q3	95.00, 100.00	45.00, 45.00	N/A	0.00, 0.00	-40.00, -40.00	N/A
Min, Max	80.0, 100.0	45.0, 45.0	N/A	-5.0, 35.0	-40.0, -40.0	N/A

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Hopelessness						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	90.00 (18.08)	79.20 (17.68)	83.30 (N/A)			
Median	100.00	79.20	83.30			
IQR: Q1, Q3	91.70, 100.00	66.70, 91.70	83.30, 83.30			
Min, Max	58.3, 100.0	66.7, 91.7	83.3, 83.3			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	85.00 (18.08)	100.00 (0.00)	N/A	-5.00 (5.65)	20.80 (12.50)	N/A
Median	91.70	100.00	N/A	0	20.80	N/A
IQR: Q1, Q3	75.00, 100.00	100.00, 100.00	N/A	-8.30, 0.00	8.30, 33.30	N/A
Min, Max	58.3, 100.0	100.0, 100.0	N/A	-25.0, 8.3	8.3, 33.3	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	86.66 (13.94)	75.00 (N/A)	N/A	-3.34 (5.66)	-16.70 (N/A)	N/A
Median	83.30	75.00	N/A	0	-16.70	N/A
IQR: Q1, Q3	83.30, 100.00	75.00, 75.00	N/A	-16.70, 8.30	-16.70, -16.70	N/A
Min, Max	66.7, 100.0	75.0, 75.0	N/A	-16.7, 8.4	-16.7, -16.7	N/A

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Stigma of Liver Disease						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	88.76 (18.94)	100.00 (0.00)	93.80 (N/A)			
Median	100.00	100.00	93.80			
IQR: Q1, Q3	87.50, 100.00	100.00, 100.00	93.80, 93.80			
Min, Max	56.3, 100.0	100.0, 100.0	93.8, 93.8			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	88.78 (8.13)	87.50 (17.68)	N/A	0.02 (9.25)	-12.50 (12.50)	N/A
Median	87.50	87.50	N/A	0	-12.50	N/A
IQR: Q1, Q3	81.30, 93.80	75.00, 100.00	N/A	-18.70, 6.30	-25.00, 0.00	N/A
Min, Max	81.3, 100.0	75.0, 100.0	N/A	-18.7, 31.2	-25.0, 0.0	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	87.50 (12.50)	87.50 (N/A)	N/A	-1.26 (5.72)	-12.50 (N/A)	N/A
Median	87.50	87.50	N/A	0	-12.50	N/A
IQR: Q1, Q3	75.00, 100.00	87.50, 87.50	N/A	-12.50, 0.00	-12.50, -12.50	N/A
Min, Max	75.0, 100.0	87.5, 87.5	N/A	-12.5, 18.7	-12.5, -12.5	N/A

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.14b.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Total LDQOL			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	77.61 (14.18)	76.42 (14.98)	78.47 (13.24)
Analysis Visit Mean (SD)	78.21 (14.73)	76.61 (12.73)	78.80 (13.84)
LS Mean of Change from Baseline (SE)	0.72 (0.84)	-0.22 (0.91)	0.59 (0.65)
95% CI	(-0.93, 2.36)	(-2.00, 1.56)	(-0.68, 1.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.12 (1.03)	-0.81 (1.10)	
95% CI	(-1.90, 2.15)	(-2.97, 1.34)	
p-value	0.9050	0.4589	
Corrected Hedge's g Statistics	0.014	-0.090	
95% CI	(-0.22, 0.24)	(-0.34, 0.16)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	78.46 (13.49)	76.94 (15.27)	78.29 (13.61)
Analysis Visit Mean (SD)	79.68 (12.43)	77.83 (14.27)	78.61 (14.82)
LS Mean of Change from Baseline (SE)	1.36 (0.90)	0.58 (0.95)	0.36 (0.70)
95% CI	(-0.40, 3.13)	(-1.30, 2.45)	(-1.01, 1.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.01 (1.11)	0.22 (1.16)	
95% CI	(-1.17, 3.18)	(-2.07, 2.50)	
p-value	0.3634	0.8509	
Corrected Hedge's g Statistics	0.112	0.024	
95% CI	(-0.14, 0.36)	(-0.24, 0.28)	
Subgroup*Treatment Interaction p-value	0.5010	0.8905	

AMNOG Table SE21.14b.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Total LDQOL			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	76.80 (13.16)	76.93 (11.53)	77.32 (15.26)
Analysis Visit Mean (SD)	77.64 (15.31)	77.91 (11.47)	79.61 (14.48)
LS Mean of Change from Baseline (SE)	0.69 (1.83)	0.79 (2.08)	1.86 (1.27)
95% CI	(-2.95, 4.33)	(-3.34, 4.93)	(-0.67, 4.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.17 (2.15)	-1.07 (2.31)	
95% CI	(-5.44, 3.09)	(-5.67, 3.53)	
p-value	0.5859	0.6450	
Corrected Hedge's g Statistics	-0.134	-0.122	
95% CI	(-0.64, 0.37)	(-0.68, 0.43)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	76.76 (13.83)	77.48 (10.36)	77.61 (14.50)
Analysis Visit Mean (SD)	76.55 (15.89)	76.53 (9.73)	78.90 (14.13)
LS Mean of Change from Baseline (SE)	-0.15 (2.28)	-0.23 (2.79)	0.92 (1.56)
95% CI	(-4.67, 4.37)	(-5.79, 5.33)	(-2.19, 4.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.07 (2.70)	-1.15 (3.11)	
95% CI	(-6.43, 4.29)	(-7.32, 5.03)	
p-value	0.6927	0.7124	
Corrected Hedge's g Statistics	-0.103	-0.112	
95% CI	(-0.63, 0.43)	(-0.75, 0.53)	
Subgroup*Treatment Interaction p-value	0.5010	0.8905	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Total LDQOL			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	83.22 (12.85)	85.65 (1.77)	N/A
Analysis Visit Mean (SD)	81.32 (9.86)	87.45 (9.55)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	83.22 (12.85)	86.90 (N/A)	N/A
Analysis Visit Mean (SD)	83.96 (8.39)	73.20 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.5010	0.8905	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Symptoms of Liver Disease			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	77.36 (19.49)	73.44 (19.42)	77.33 (17.51)
Analysis Visit Mean (SD)	76.38 (20.67)	73.27 (18.22)	76.85 (19.63)
LS Mean of Change from Baseline (SE)	-0.42 (1.26)	-0.68 (1.37)	-0.09 (0.98)
95% CI	(-2.89, 2.05)	(-3.37, 2.01)	(-2.00, 1.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.33 (1.55)	-0.59 (1.66)	
95% CI	(-3.38, 2.72)	(-3.85, 2.66)	
p-value	0.8303	0.7199	
Corrected Hedge's g Statistics	-0.025	-0.044	
95% CI	(-0.26, 0.21)	(-0.29, 0.20)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	79.06 (18.38)	73.84 (18.57)	77.18 (17.40)
Analysis Visit Mean (SD)	77.78 (19.08)	76.32 (18.44)	77.53 (19.24)
LS Mean of Change from Baseline (SE)	-0.81 (1.23)	1.73 (1.31)	0.74 (0.96)
95% CI	(-3.24, 1.61)	(-0.84, 4.31)	(-1.14, 2.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.55 (1.52)	1.00 (1.60)	
95% CI	(-4.53, 1.43)	(-2.14, 4.13)	
p-value	0.3081	0.5326	
Corrected Hedge's g Statistics	-0.126	0.081	
95% CI	(-0.37, 0.12)	(-0.18, 0.34)	
Subgroup*Treatment Interaction p-value	0.1896	0.0258	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Effects of Liver Disease			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	78.44 (12.78)	78.81 (14.84)	78.53 (13.35)
Analysis Visit Mean (SD)	76.06 (13.36)	79.19 (9.87)	77.42 (14.25)
LS Mean of Change from Baseline (SE)	-2.24 (1.14)	0.59 (1.23)	-0.97 (0.88)
95% CI	(-4.47, -0.01)	(-1.84, 3.01)	(-2.70, 0.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.27 (1.40)	1.55 (1.49)	
95% CI	(-4.03, 1.48)	(-1.38, 4.48)	
p-value	0.3634	0.2979	
Corrected Hedge's g Statistics	-0.104	0.127	
95% CI	(-0.33, 0.13)	(-0.12, 0.37)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	78.93 (12.07)	78.92 (15.03)	78.44 (13.09)
Analysis Visit Mean (SD)	78.35 (11.03)	77.87 (12.13)	77.55 (14.28)
LS Mean of Change from Baseline (SE)	-0.27 (1.27)	-0.90 (1.35)	-1.05 (0.99)
95% CI	(-2.77, 2.23)	(-3.55, 1.76)	(-2.98, 0.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.78 (1.58)	0.15 (1.65)	
95% CI	(-2.32, 3.88)	(-3.10, 3.39)	
p-value	0.6209	0.9282	
Corrected Hedge's g Statistics	0.061	0.012	
95% CI	(-0.19, 0.31)	(-0.25, 0.27)	
Subgroup*Treatment Interaction p-value	0.2459	0.2568	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Concentration/Memory			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	81.65 (21.44)	79.36 (20.54)	78.66 (21.34)
Analysis Visit Mean (SD)	80.02 (21.73)	79.16 (20.48)	79.14 (22.10)
LS Mean of Change from Baseline (SE)	-1.01 (1.43)	-0.45 (1.54)	0.21 (1.11)
95% CI	(-3.82, 1.80)	(-3.48, 2.59)	(-1.96, 2.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.22 (1.76)	-0.66 (1.87)	
95% CI	(-4.69, 2.24)	(-4.33, 3.02)	
p-value	0.4887	0.7249	
Corrected Hedge's g Statistics	-0.079	-0.043	
95% CI	(-0.31, 0.15)	(-0.29, 0.20)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	81.65 (20.66)	80.40 (19.46)	78.86 (21.25)
Analysis Visit Mean (SD)	80.70 (16.68)	78.87 (20.91)	78.03 (22.97)
LS Mean of Change from Baseline (SE)	-1.13 (1.39)	-1.21 (1.47)	-0.90 (1.08)
95% CI	(-3.86, 1.60)	(-4.11, 1.68)	(-3.02, 1.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.23 (1.71)	-0.31 (1.79)	
95% CI	(-3.59, 3.14)	(-3.84, 3.21)	
p-value	0.8942	0.8611	
Corrected Hedge's g Statistics	-0.016	-0.023	
95% CI	(-0.27, 0.23)	(-0.28, 0.24)	
Subgroup*Treatment Interaction p-value	0.4139	0.6803	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Health Distress			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	77.61 (27.08)	81.32 (23.48)	79.96 (24.12)
Analysis Visit Mean (SD)	83.26 (21.90)	86.58 (20.57)	86.02 (22.08)
LS Mean of Change from Baseline (SE)	4.78 (1.60)	5.83 (1.73)	6.18 (1.24)
95% CI	(1.63, 7.93)	(2.42, 9.23)	(3.75, 8.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.40 (1.97)	-0.36 (2.09)	
95% CI	(-5.28, 2.47)	(-4.48, 3.76)	
p-value	0.4770	0.8643	
Corrected Hedge's g Statistics	-0.081	-0.021	
95% CI	(-0.31, 0.15)	(-0.27, 0.22)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	78.54 (26.06)	81.69 (24.15)	80.20 (24.20)
Analysis Visit Mean (SD)	83.96 (22.31)	87.06 (20.69)	85.32 (22.19)
LS Mean of Change from Baseline (SE)	4.40 (1.87)	6.40 (1.98)	5.24 (1.44)
95% CI	(0.73, 8.07)	(2.50, 10.29)	(2.40, 8.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.84 (2.31)	1.16 (2.42)	
95% CI	(-5.38, 3.70)	(-3.60, 5.92)	
p-value	0.7164	0.6332	
Corrected Hedge's g Statistics	-0.045	0.062	
95% CI	(-0.29, 0.20)	(-0.20, 0.32)	
Subgroup*Treatment Interaction p-value	0.5770	0.6520	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Sexual Function			
Week 24			
m	121	106	214
n	38	43	72
Baseline Mean (SD)	81.90 (25.64)	81.73 (22.35)	80.39 (23.00)
Analysis Visit Mean (SD)	81.71 (26.05)	77.24 (23.80)	81.60 (22.82)
LS Mean of Change from Baseline (SE)	0.09 (3.13)	-4.76 (2.95)	0.26 (2.35)
95% CI	(-6.10, 6.28)	(-10.59, 1.08)	(-4.39, 4.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.17 (3.87)	-5.01 (3.72)	
95% CI	(-7.82, 7.47)	(-12.35, 2.32)	
p-value	0.9646	0.1790	
Corrected Hedge's g Statistics	-0.009	-0.252	
95% CI	(-0.40, 0.38)	(-0.63, 0.13)	
Week 52			
m	112	96	200
n	27	35	60
Baseline Mean (SD)	91.99 (19.33)	83.32 (20.18)	78.36 (24.23)
Analysis Visit Mean (SD)	92.59 (12.28)	83.33 (25.07)	78.20 (25.73)
LS Mean of Change from Baseline (SE)	3.97 (3.52)	-0.56 (3.13)	-1.77 (2.47)
95% CI	(-2.97, 10.92)	(-6.74, 5.61)	(-6.66, 3.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.74 (4.27)	1.20 (3.93)	
95% CI	(-2.69, 14.17)	(-6.57, 8.98)	
p-value	0.1805	0.7599	
Corrected Hedge's g Statistics	0.301	0.063	
95% CI	(-0.16, 0.76)	(-0.35, 0.48)	
Subgroup*Treatment Interaction p-value	0.6045	0.5807	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Sleep			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	63.52 (20.66)	58.42 (19.71)	63.96 (20.27)
Analysis Visit Mean (SD)	63.96 (19.91)	56.26 (19.47)	62.84 (20.01)
LS Mean of Change from Baseline (SE)	0.84 (1.34)	-3.68 (1.46)	-0.67 (1.04)
95% CI	(-1.79, 3.47)	(-6.55, -0.82)	(-2.72, 1.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.51 (1.65)	-3.01 (1.76)	
95% CI	(-1.72, 4.75)	(-6.47, 0.45)	
p-value	0.3586	0.0882	
Corrected Hedge's g Statistics	0.105	-0.209	
95% CI	(-0.13, 0.34)	(-0.45, 0.04)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	64.85 (20.03)	59.65 (20.36)	63.70 (20.68)
Analysis Visit Mean (SD)	65.06 (18.65)	57.85 (21.25)	63.98 (21.07)
LS Mean of Change from Baseline (SE)	1.25 (1.53)	-3.09 (1.64)	0.58 (1.19)
95% CI	(-1.77, 4.26)	(-6.30, 0.13)	(-1.76, 2.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.67 (1.90)	-3.66 (2.00)	
95% CI	(-3.05, 4.40)	(-7.59, 0.26)	
p-value	0.7229	0.0670	
Corrected Hedge's g Statistics	0.044	-0.239	
95% CI	(-0.21, 0.29)	(-0.50, 0.02)	
Subgroup*Treatment Interaction p-value	0.5212	0.3682	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Loneliness			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	83.57 (18.98)	83.00 (20.65)	85.45 (19.18)
Analysis Visit Mean (SD)	83.41 (19.57)	83.37 (19.86)	82.94 (20.02)
LS Mean of Change from Baseline (SE)	-0.89 (1.42)	-0.41 (1.54)	-2.60 (1.10)
95% CI	(-3.67, 1.90)	(-3.43, 2.62)	(-4.76, -0.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.71 (1.75)	2.20 (1.86)	
95% CI	(-1.73, 5.16)	(-1.47, 5.86)	
p-value	0.3282	0.2393	
Corrected Hedge's g Statistics	0.112	0.144	
95% CI	(-0.12, 0.34)	(-0.10, 0.39)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	83.59 (19.39)	82.33 (21.11)	85.02 (19.73)
Analysis Visit Mean (SD)	83.59 (17.66)	82.79 (22.50)	83.80 (19.26)
LS Mean of Change from Baseline (SE)	-0.81 (1.41)	-0.55 (1.50)	-1.62 (1.09)
95% CI	(-3.58, 1.97)	(-3.49, 2.40)	(-3.77, 0.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.81 (1.74)	1.07 (1.83)	
95% CI	(-2.61, 4.24)	(-2.52, 4.67)	
p-value	0.6403	0.5567	
Corrected Hedge's g Statistics	0.058	0.076	
95% CI	(-0.19, 0.31)	(-0.18, 0.34)	
Subgroup*Treatment Interaction p-value	0.6555	0.7656	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Hopelessness			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	75.51 (22.06)	76.66 (22.99)	79.94 (20.23)
Analysis Visit Mean (SD)	77.68 (21.71)	76.49 (23.42)	80.01 (21.20)
LS Mean of Change from Baseline (SE)	1.46 (1.61)	-0.82 (1.74)	0.91 (1.25)
95% CI	(-1.70, 4.62)	(-4.24, 2.60)	(-1.54, 3.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.55 (1.98)	-1.73 (2.11)	
95% CI	(-3.35, 4.45)	(-5.87, 2.41)	
p-value	0.7834	0.4114	
Corrected Hedge's g Statistics	0.031	-0.100	
95% CI	(-0.20, 0.26)	(-0.35, 0.15)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	76.52 (21.04)	76.45 (23.89)	80.37 (20.17)
Analysis Visit Mean (SD)	78.54 (21.03)	77.23 (22.63)	79.57 (21.82)
LS Mean of Change from Baseline (SE)	2.03 (1.79)	0.31 (1.90)	0.06 (1.39)
95% CI	(-1.48, 5.54)	(-3.42, 4.04)	(-2.67, 2.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.97 (2.21)	0.25 (2.32)	
95% CI	(-2.39, 6.32)	(-4.31, 4.81)	
p-value	0.3750	0.9138	
Corrected Hedge's g Statistics	0.110	0.014	
95% CI	(-0.14, 0.36)	(-0.25, 0.27)	
Subgroup*Treatment Interaction p-value	0.4419	0.1664	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Stigma of Liver Disease			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	81.48 (20.95)	79.89 (20.30)	84.90 (18.66)
Analysis Visit Mean (SD)	84.20 (19.70)	80.35 (20.36)	85.61 (18.72)
LS Mean of Change from Baseline (SE)	2.60 (1.46)	-0.33 (1.58)	1.80 (1.13)
95% CI	(-0.26, 5.47)	(-3.44, 2.78)	(-0.42, 4.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.80 (1.80)	-2.13 (1.92)	
95% CI	(-2.74, 4.34)	(-5.90, 1.64)	
p-value	0.6565	0.2676	
Corrected Hedge's g Statistics	0.051	-0.136	
95% CI	(-0.18, 0.28)	(-0.38, 0.11)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	82.84 (20.19)	80.83 (20.67)	83.71 (19.21)
Analysis Visit Mean (SD)	87.20 (17.77)	83.58 (19.64)	85.11 (19.06)
LS Mean of Change from Baseline (SE)	4.71 (1.41)	1.91 (1.50)	1.91 (1.10)
95% CI	(1.93, 7.49)	(-1.05, 4.86)	(-0.24, 4.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.79 (1.74)	-0.01 (1.83)	
95% CI	(-0.63, 6.22)	(-3.60, 3.59)	
p-value	0.1095	0.9966	
Corrected Hedge's g Statistics	0.198	-0.001	
95% CI	(-0.05, 0.45)	(-0.26, 0.26)	
Subgroup*Treatment Interaction p-value	0.8773	0.6509	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Symptoms of Liver Disease			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	76.05 (16.60)	79.41 (15.10)	77.31 (17.51)
Analysis Visit Mean (SD)	74.09 (18.50)	72.35 (17.47)	80.71 (16.46)
LS Mean of Change from Baseline (SE)	-2.58 (2.43)	-7.03 (2.76)	2.00 (1.69)
95% CI	(-7.42, 2.26)	(-12.52, -1.53)	(-1.37, 5.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.58 (2.85)	-9.03 (3.08)	
95% CI	(-10.25, 1.08)	(-15.15, -2.91)	
p-value	0.1115	0.0043	
Corrected Hedge's g Statistics	-0.392	-0.772	
95% CI	(-0.90, 0.12)	(-1.34, -0.20)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	76.49 (17.32)	83.89 (11.96)	76.82 (17.07)
Analysis Visit Mean (SD)	72.16 (16.77)	78.33 (12.59)	79.14 (18.33)
LS Mean of Change from Baseline (SE)	-4.32 (3.20)	-5.27 (3.99)	1.97 (2.20)
95% CI	(-10.68, 2.03)	(-13.20, 2.66)	(-2.39, 6.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.30 (3.79)	-7.24 (4.44)	
95% CI	(-13.84, 1.24)	(-16.07, 1.59)	
p-value	0.1006	0.1069	
Corrected Hedge's g Statistics	-0.433	-0.500	
95% CI	(-0.97, 0.10)	(-1.15, 0.15)	
Subgroup*Treatment Interaction p-value	0.1896	0.0258	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Effects of Liver Disease			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	77.27 (10.42)	79.22 (13.10)	75.04 (17.61)
Analysis Visit Mean (SD)	77.58 (12.94)	76.86 (12.50)	79.01 (15.35)
LS Mean of Change from Baseline (SE)	-0.08 (2.56)	-2.05 (2.92)	2.47 (1.80)
95% CI	(-5.16, 5.01)	(-7.86, 3.77)	(-1.10, 6.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.55 (3.03)	-4.52 (3.31)	
95% CI	(-8.58, 3.48)	(-11.09, 2.05)	
p-value	0.4026	0.1750	
Corrected Hedge's g Statistics	-0.206	-0.365	
95% CI	(-0.71, 0.30)	(-0.92, 0.19)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	76.34 (10.25)	80.57 (12.54)	77.06 (13.82)
Analysis Visit Mean (SD)	72.34 (16.22)	78.90 (10.57)	78.68 (12.02)
LS Mean of Change from Baseline (SE)	-5.00 (2.87)	-0.61 (3.73)	1.45 (1.99)
95% CI	(-10.70, 0.69)	(-8.03, 6.81)	(-2.50, 5.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.46 (3.41)	-2.06 (4.12)	
95% CI	(-13.23, 0.32)	(-10.25, 6.12)	
p-value	0.0616	0.6174	
Corrected Hedge's g Statistics	-0.492	-0.156	
95% CI	(-1.03, 0.05)	(-0.80, 0.48)	
Subgroup*Treatment Interaction p-value	0.2459	0.2568	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Concentration/Memory			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	74.45 (27.95)	78.69 (21.09)	80.87 (19.21)
Analysis Visit Mean (SD)	73.03 (25.46)	77.59 (17.55)	83.13 (20.06)
LS Mean of Change from Baseline (SE)	-1.56 (3.10)	-0.47 (3.52)	2.93 (2.16)
95% CI	(-7.71, 4.60)	(-7.46, 6.52)	(-1.35, 7.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.49 (3.66)	-3.40 (3.93)	
95% CI	(-11.76, 2.78)	(-11.20, 4.41)	
p-value	0.2229	0.3890	
Corrected Hedge's g Statistics	-0.302	-0.228	
95% CI	(-0.81, 0.21)	(-0.78, 0.33)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	72.83 (28.70)	79.18 (20.18)	80.11 (18.56)
Analysis Visit Mean (SD)	71.90 (30.04)	77.11 (19.27)	80.40 (19.17)
LS Mean of Change from Baseline (SE)	-1.44 (3.52)	0.95 (4.37)	0.40 (2.42)
95% CI	(-8.43, 5.56)	(-7.73, 9.63)	(-4.42, 5.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.83 (4.18)	0.55 (4.83)	
95% CI	(-10.14, 6.47)	(-9.05, 10.15)	
p-value	0.6621	0.9092	
Corrected Hedge's g Statistics	-0.114	0.035	
95% CI	(-0.65, 0.42)	(-0.61, 0.67)	
Subgroup*Treatment Interaction p-value	0.4139	0.6803	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Health Distress			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	80.11 (25.78)	74.26 (34.65)	82.71 (23.54)
Analysis Visit Mean (SD)	80.68 (29.31)	82.35 (23.82)	85.37 (22.01)
LS Mean of Change from Baseline (SE)	0.49 (3.64)	6.38 (4.18)	2.39 (2.53)
95% CI	(-6.75, 7.73)	(-1.94, 14.70)	(-2.63, 7.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.90 (4.27)	3.99 (4.64)	
95% CI	(-10.40, 6.59)	(-5.25, 13.22)	
p-value	0.6572	0.3930	
Corrected Hedge's g Statistics	-0.109	0.228	
95% CI	(-0.62, 0.40)	(-0.33, 0.78)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	78.75 (26.62)	82.29 (33.90)	84.88 (21.05)
Analysis Visit Mean (SD)	77.50 (29.41)	85.42 (19.82)	86.63 (19.74)
LS Mean of Change from Baseline (SE)	-3.18 (4.32)	4.14 (5.34)	2.51 (2.97)
95% CI	(-11.76, 5.40)	(-6.47, 14.75)	(-3.40, 8.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.69 (5.12)	1.64 (5.91)	
95% CI	(-15.86, 4.49)	(-10.12, 13.39)	
p-value	0.2698	0.7828	
Corrected Hedge's g Statistics	-0.289	0.084	
95% CI	(-0.82, 0.24)	(-0.56, 0.72)	
Subgroup*Treatment Interaction p-value	0.5770	0.6520	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Sexual Function			
Week 24			
m	25	21	58
n	12	10	18
Baseline Mean (SD)	69.15 (36.42)	79.00 (21.43)	86.11 (20.00)
Analysis Visit Mean (SD)	74.45 (27.45)	77.34 (24.59)	83.61 (16.55)
LS Mean of Change from Baseline (SE)	4.44 (5.07)	-0.12 (5.68)	0.95 (4.02)
95% CI	(-5.82, 14.69)	(-11.59, 11.35)	(-7.18, 9.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.48 (6.46)	-1.07 (6.73)	
95% CI	(-9.57, 16.54)	(-14.68, 12.53)	
p-value	0.5927	0.8743	
Corrected Hedge's g Statistics	0.196	-0.060	
95% CI	(-0.54, 0.93)	(-0.83, 0.71)	
Week 52			
m	25	17	55
n	12	6	14
Baseline Mean (SD)	64.57 (36.57)	73.05 (30.00)	82.61 (25.77)
Analysis Visit Mean (SD)	74.58 (33.19)	63.52 (29.27)	78.81 (26.47)
LS Mean of Change from Baseline (SE)	7.77 (6.22)	-4.50 (8.44)	-2.95 (5.40)
95% CI	(-4.81, 20.34)	(-21.56, 12.57)	(-13.86, 7.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.72 (8.28)	-1.55 (9.89)	
95% CI	(-6.01, 27.45)	(-21.53, 18.44)	
p-value	0.2026	0.8766	
Corrected Hedge's g Statistics	0.498	-0.073	
95% CI	(-0.28, 1.28)	(-1.03, 0.88)	
Subgroup*Treatment Interaction p-value	0.6045	0.5807	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Sleep			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	60.68 (20.14)	60.29 (18.41)	62.45 (19.36)
Analysis Visit Mean (SD)	62.05 (22.97)	62.94 (20.24)	64.89 (21.30)
LS Mean of Change from Baseline (SE)	1.14 (3.36)	2.67 (3.83)	2.71 (2.33)
95% CI	(-5.54, 7.83)	(-4.94, 10.29)	(-1.93, 7.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.56 (3.98)	-0.04 (4.32)	
95% CI	(-9.48, 6.35)	(-8.62, 8.55)	
p-value	0.6958	0.9932	
Corrected Hedge's g Statistics	-0.097	-0.002	
95% CI	(-0.60, 0.41)	(-0.56, 0.55)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	62.25 (20.42)	57.50 (18.40)	63.14 (20.03)
Analysis Visit Mean (SD)	62.00 (19.43)	62.08 (16.02)	66.63 (19.57)
LS Mean of Change from Baseline (SE)	0.71 (3.10)	3.56 (3.94)	3.66 (2.16)
95% CI	(-5.45, 6.87)	(-4.28, 11.40)	(-0.63, 7.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.95 (3.65)	-0.10 (4.33)	
95% CI	(-10.21, 4.32)	(-8.71, 8.51)	
p-value	0.4224	0.9823	
Corrected Hedge's g Statistics	-0.207	-0.007	
95% CI	(-0.74, 0.32)	(-0.65, 0.63)	
Subgroup*Treatment Interaction p-value	0.5212	0.3682	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Loneliness			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	87.05 (13.69)	87.06 (16.21)	79.36 (21.43)
Analysis Visit Mean (SD)	85.23 (16.65)	91.47 (18.27)	81.70 (24.35)
LS Mean of Change from Baseline (SE)	-1.44 (3.45)	4.63 (3.93)	0.92 (2.41)
95% CI	(-8.30, 5.42)	(-3.18, 12.43)	(-3.87, 5.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.36 (4.10)	3.71 (4.42)	
95% CI	(-10.50, 5.78)	(-5.07, 12.49)	
p-value	0.5662	0.4037	
Corrected Hedge's g Statistics	-0.142	0.223	
95% CI	(-0.65, 0.36)	(-0.33, 0.78)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	87.75 (14.09)	82.92 (19.36)	80.23 (21.35)
Analysis Visit Mean (SD)	89.00 (17.59)	86.25 (12.81)	83.60 (21.91)
LS Mean of Change from Baseline (SE)	2.75 (3.93)	2.81 (4.90)	1.14 (2.71)
95% CI	(-5.06, 10.56)	(-6.93, 12.55)	(-4.25, 6.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.61 (4.68)	1.67 (5.43)	
95% CI	(-7.69, 10.91)	(-9.11, 12.46)	
p-value	0.7316	0.7588	
Corrected Hedge's g Statistics	0.090	0.094	
95% CI	(-0.44, 0.62)	(-0.55, 0.73)	
Subgroup*Treatment Interaction p-value	0.6555	0.7656	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Hopelessness			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	79.17 (24.77)	71.57 (23.58)	78.90 (22.58)
Analysis Visit Mean (SD)	80.69 (27.63)	78.91 (19.35)	76.78 (21.28)
LS Mean of Change from Baseline (SE)	2.19 (4.18)	3.59 (4.80)	-2.47 (2.91)
95% CI	(-6.12, 10.50)	(-5.95, 13.12)	(-8.25, 3.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.66 (4.93)	6.06 (5.36)	
95% CI	(-5.13, 14.46)	(-4.60, 16.72)	
p-value	0.3465	0.2618	
Corrected Hedge's g Statistics	0.232	0.301	
95% CI	(-0.28, 0.74)	(-0.26, 0.86)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	80.84 (25.09)	74.30 (25.74)	76.94 (23.77)
Analysis Visit Mean (SD)	80.43 (24.37)	73.63 (18.74)	74.22 (25.39)
LS Mean of Change from Baseline (SE)	2.01 (4.59)	-0.98 (5.80)	-4.22 (3.18)
95% CI	(-7.13, 11.14)	(-12.51, 10.55)	(-10.54, 2.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.23 (5.44)	3.24 (6.39)	
95% CI	(-4.59, 17.05)	(-9.47, 15.95)	
p-value	0.2554	0.6134	
Corrected Hedge's g Statistics	0.297	0.155	
95% CI	(-0.24, 0.83)	(-0.49, 0.80)	
Subgroup*Treatment Interaction p-value	0.4419	0.1664	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Stigma of Liver Disease			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	86.10 (18.38)	82.00 (17.38)	80.34 (21.04)
Analysis Visit Mean (SD)	89.50 (20.89)	82.37 (19.16)	85.39 (18.02)
LS Mean of Change from Baseline (SE)	3.32 (2.61)	-0.50 (2.96)	4.19 (1.82)
95% CI	(-1.87, 8.51)	(-6.39, 5.38)	(0.57, 7.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.87 (3.09)	-4.70 (3.31)	
95% CI	(-7.01, 5.27)	(-11.28, 1.89)	
p-value	0.7785	0.1597	
Corrected Hedge's g Statistics	-0.069	-0.374	
95% CI	(-0.58, 0.44)	(-0.93, 0.18)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	85.96 (18.89)	78.67 (18.93)	80.83 (19.54)
Analysis Visit Mean (SD)	88.45 (16.63)	80.23 (19.55)	83.75 (19.63)
LS Mean of Change from Baseline (SE)	3.45 (3.63)	-1.60 (4.61)	2.16 (2.49)
95% CI	(-3.76, 10.66)	(-10.77, 7.58)	(-2.79, 7.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.29 (4.34)	-3.76 (5.13)	
95% CI	(-7.34, 9.92)	(-13.95, 6.44)	
p-value	0.7671	0.4659	
Corrected Hedge's g Statistics	0.078	-0.228	
95% CI	(-0.45, 0.61)	(-0.87, 0.41)	
Subgroup*Treatment Interaction p-value	0.8773	0.6509	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Symptoms of Liver Disease			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	87.34 (8.62)	88.30 (7.07)	N/A
Analysis Visit Mean (SD)	76.66 (17.77)	81.65 (16.48)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	87.34 (8.62)	93.30 (N/A)	N/A
Analysis Visit Mean (SD)	85.34 (10.93)	86.70 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.1896	0.0258	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Effects of Liver Disease			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	78.68 (7.30)	100.00 (0.00)	N/A
Analysis Visit Mean (SD)	77.32 (3.67)	83.35 (23.55)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	78.68 (7.30)	100.00 (N/A)	N/A
Analysis Visit Mean (SD)	78.66 (3.00)	93.30 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.2459	0.2568	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Concentration/Memory			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	85.02 (21.01)	71.90 (4.38)	N/A
Analysis Visit Mean (SD)	78.76 (18.54)	90.65 (13.22)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	85.02 (21.01)	68.80 (N/A)	N/A
Analysis Visit Mean (SD)	81.26 (19.77)	56.30 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.4139	0.6803	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Health Distress			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	77.50 (25.62)	100.00 (0.00)	N/A
Analysis Visit Mean (SD)	97.50 (5.59)	93.75 (8.84)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	77.50 (25.62)	100.00 (N/A)	N/A
Analysis Visit Mean (SD)	92.50 (11.18)	75.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.5770	0.6520	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Sexual Function			
Week 24			
m	5	2	0
n	3	0	0
Baseline Mean (SD)	82.77 (18.45)	N/A	N/A
Analysis Visit Mean (SD)	77.23 (22.50)	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	3	1	0
Baseline Mean (SD)	82.77 (18.45)	53.30 (N/A)	N/A
Analysis Visit Mean (SD)	80.00 (4.40)	55.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.6045	0.5807	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Sleep			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	69.00 (32.29)	70.00 (28.28)	N/A
Analysis Visit Mean (SD)	61.00 (26.79)	72.50 (17.68)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	69.00 (32.29)	90.00 (N/A)	N/A
Analysis Visit Mean (SD)	66.00 (28.81)	85.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.5212	0.3682	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Loneliness			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	88.00 (24.14)	92.50 (10.61)	N/A
Analysis Visit Mean (SD)	86.00 (17.10)	90.00 (14.14)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	88.00 (24.14)	85.00 (N/A)	N/A
Analysis Visit Mean (SD)	94.00 (8.22)	45.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.6555	0.7656	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Hopelessness			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	90.00 (18.08)	79.20 (17.68)	N/A
Analysis Visit Mean (SD)	85.00 (18.08)	100.00 (0.00)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	90.00 (18.08)	91.70 (N/A)	N/A
Analysis Visit Mean (SD)	86.66 (13.94)	75.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.4419	0.1664	

AMNOG Table SE21.14b.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Stigma of Liver Disease			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	88.76 (18.94)	100.00 (0.00)	N/A
Analysis Visit Mean (SD)	88.78 (8.13)	87.50 (17.68)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	88.76 (18.94)	100.00 (N/A)	N/A
Analysis Visit Mean (SD)	87.50 (12.50)	87.50 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.8773	0.6509	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.0)	4 (3.6)	7 (3.1)
No	119 (96.0)	108 (96.4)	216 (96.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.88	
95% CI of the inverse odds ratio	(0.24, 2.48)	(0.25, 3.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.88	
95% CI of the inverse risk ratio	(0.25, 2.40)	(0.26, 2.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.89	0.43	
95% CI of the absolute risk difference	(-3.26, 5.04)	(-3.70, 4.56)	
p-value	0.6625	0.8340	
p-value of Breslow-Day Test for Homogeneity [3]	0.2185	0.2630	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (22.6)	24 (21.4)	44 (19.7)
No	96 (77.4)	88 (78.6)	179 (80.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.90	
95% CI of the inverse odds ratio	(0.49, 1.44)	(0.52, 1.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.92	
95% CI of the inverse risk ratio	(0.57, 1.33)	(0.59, 1.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.85	1.70	
95% CI of the absolute risk difference	(-6.17, 11.87)	(-7.52, 10.92)	
p-value	0.5304	0.7155	
p-value of Breslow-Day Test for Homogeneity [3]	0.6768	0.7980	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.2)	15 (13.4)	17 (7.6)
No	120 (96.8)	97 (86.6)	206 (92.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.48	0.53	
95% CI of the inverse odds ratio	(0.81, 7.53)	(0.26, 1.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.36	0.57	
95% CI of the inverse risk ratio	(0.81, 6.87)	(0.30, 1.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.40	5.77	
95% CI of the absolute risk difference	(-9.07, 0.27)	(-1.44, 12.97)	
p-value	0.0997	0.0901	
p-value of Breslow-Day Test for Homogeneity [3]	0.5189	0.1660	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (21.8)	36 (32.1)	54 (24.2)
No	97 (78.2)	76 (67.9)	169 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.67	
95% CI of the inverse odds ratio	(0.68, 1.94)	(0.41, 1.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.75	
95% CI of the inverse risk ratio	(0.74, 1.67)	(0.53, 1.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.44	7.93	
95% CI of the absolute risk difference	(-11.63, 6.74)	(-2.39, 18.24)	
p-value	0.6065	0.1225	
p-value of Breslow-Day Test for Homogeneity [3]	0.6058	0.0070	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.2)	7 (6.3)	20 (9.0)
No	120 (96.8)	105 (93.8)	203 (91.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.96	1.48	
95% CI of the inverse odds ratio	(0.99, 8.85)	(0.61, 3.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.78	1.43	
95% CI of the inverse risk ratio	(0.97, 7.95)	(0.63, 3.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.74	-2.72	
95% CI of the absolute risk difference	(-10.61, -0.87)	(-8.56, 3.13)	
p-value	0.0433	0.3885	
p-value of Breslow-Day Test for Homogeneity [3]	0.8114	0.7967	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (19.4)	21 (18.8)	43 (19.3)
No	100 (80.6)	91 (81.3)	180 (80.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.04	
95% CI of the inverse odds ratio	(0.57, 1.74)	(0.58, 1.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.03	
95% CI of the inverse risk ratio	(0.64, 1.56)	(0.64, 1.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.07	-0.53	
95% CI of the absolute risk difference	(-8.60, 8.74)	(-9.42, 8.36)	
p-value	0.9869	0.9069	
p-value of Breslow-Day Test for Homogeneity [3]	0.2655	0.3601	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (10.5)	6 (5.4)	14 (6.3)
No	111 (89.5)	106 (94.6)	209 (93.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	1.18	
95% CI of the inverse odds ratio	(0.26, 1.26)	(0.44, 3.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	1.17	
95% CI of the inverse risk ratio	(0.29, 1.23)	(0.46, 2.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.21	-0.92	
95% CI of the absolute risk difference	(-2.06, 10.47)	(-6.17, 4.33)	
p-value	0.1610	0.7372	
p-value of Breslow-Day Test for Homogeneity [3]	0.3480	0.6654	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (22.6)	28 (25.0)	49 (22.0)
No	96 (77.4)	84 (75.0)	174 (78.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.84	
95% CI of the inverse odds ratio	(0.57, 1.64)	(0.50, 1.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.88	
95% CI of the inverse risk ratio	(0.65, 1.46)	(0.59, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.61	3.03	
95% CI of the absolute risk difference	(-8.54, 9.76)	(-6.66, 12.71)	
p-value	0.8962	0.5345	
p-value of Breslow-Day Test for Homogeneity [3]	0.7106	0.4216	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	23 (18.5)	21 (18.8)	37 (16.6)
No	101 (81.5)	91 (81.3)	186 (83.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.86	
95% CI of the inverse odds ratio	(0.49, 1.55)	(0.48, 1.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.88	
95% CI of the inverse risk ratio	(0.56, 1.43)	(0.54, 1.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.96	2.16	
95% CI of the absolute risk difference	(-6.45, 10.36)	(-6.56, 10.88)	
p-value	0.6442	0.6224	
p-value of Breslow-Day Test for Homogeneity [3]	0.3665	0.5850	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (25.8)	30 (26.8)	54 (24.2)
No	92 (74.2)	82 (73.2)	169 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.87	
95% CI of the inverse odds ratio	(0.55, 1.52)	(0.52, 1.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.90	
95% CI of the inverse risk ratio	(0.64, 1.37)	(0.62, 1.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.59	2.57	
95% CI of the absolute risk difference	(-7.94, 11.13)	(-7.37, 12.51)	
p-value	0.7422	0.6086	
p-value of Breslow-Day Test for Homogeneity [3]	0.3435	0.2426	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (1.6)	6 (5.4)	12 (5.4)
No	122 (98.4)	106 (94.6)	211 (94.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.47	1.00	
95% CI of the inverse odds ratio	(0.76, 15.76)	(0.37, 2.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.34	1.00	
95% CI of the inverse risk ratio	(0.76, 14.67)	(0.39, 2.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.77	-0.02	
95% CI of the absolute risk difference	(-7.47, -0.07)	(-5.14, 5.09)	
p-value	0.0873	0.9927	
p-value of Breslow-Day Test for Homogeneity [3]	0.0238	0.5364	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (3.2)	11 (9.8)	21 (9.4)
No	120 (96.8)	101 (90.2)	202 (90.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.12	0.95	
95% CI of the inverse odds ratio	(1.05, 9.30)	(0.44, 2.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.92	0.96	
95% CI of the inverse risk ratio	(1.03, 8.31)	(0.48, 1.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.19	0.40	
95% CI of the absolute risk difference	(-11.13, -1.26)	(-6.31, 7.12)	
p-value	0.0326	0.9054	
p-value of Breslow-Day Test for Homogeneity [3]	0.0063	0.6724	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	19 (15.3)	15 (13.4)	33 (14.8)
No	105 (84.7)	97 (86.6)	190 (85.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.12	
95% CI of the inverse odds ratio	(0.52, 1.77)	(0.58, 2.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	1.10	
95% CI of the inverse risk ratio	(0.57, 1.62)	(0.63, 1.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.52	-1.41	
95% CI of the absolute risk difference	(-7.34, 8.39)	(-9.25, 6.44)	
p-value	0.8957	0.7291	
p-value of Breslow-Day Test for Homogeneity [3]	0.3883	0.9266	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	38 (30.6)	32 (28.6)	67 (30.0)
No	86 (69.4)	80 (71.4)	156 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	1.07	
95% CI of the inverse odds ratio	(0.60, 1.57)	(0.65, 1.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.05	
95% CI of the inverse risk ratio	(0.70, 1.37)	(0.74, 1.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.60	-1.47	
95% CI of the absolute risk difference	(-9.50, 10.70)	(-11.78, 8.83)	
p-value	0.9071	0.7804	
p-value of Breslow-Day Test for Homogeneity [3]	0.1460	0.6840	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (12.1)	20 (17.9)	21 (9.4)
No	109 (87.9)	92 (82.1)	202 (90.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	0.48	
95% CI of the inverse odds ratio	(0.37, 1.52)	(0.25, 0.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.53	
95% CI of the inverse risk ratio	(0.42, 1.45)	(0.30, 0.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.68	8.44	
95% CI of the absolute risk difference	(-4.22, 9.58)	(0.38, 16.50)	
p-value	0.4328	0.0262	
p-value of Breslow-Day Test for Homogeneity [3]	0.9064	0.1588	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (23.4)	30 (26.8)	58 (26.0)
No	95 (76.6)	82 (73.2)	165 (74.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.96	
95% CI of the inverse odds ratio	(0.69, 1.92)	(0.57, 1.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.97	
95% CI of the inverse risk ratio	(0.75, 1.64)	(0.67, 1.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.62	0.78	
95% CI of the absolute risk difference	(-12.04, 6.79)	(-9.24, 10.80)	
p-value	0.5892	0.8789	
p-value of Breslow-Day Test for Homogeneity [3]	0.8714	0.4451	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	27 (21.8)	26 (23.2)	30 (13.5)
No	97 (78.2)	86 (76.8)	193 (86.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.51	
95% CI of the inverse odds ratio	(0.31, 0.99)	(0.29, 0.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.58	
95% CI of the inverse risk ratio	(0.39, 0.99)	(0.36, 0.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.32	9.76	
95% CI of the absolute risk difference	(-0.21, 16.85)	(0.75, 18.77)	
p-value	0.0450	0.0239	
p-value of Breslow-Day Test for Homogeneity [3]	0.0868	0.3770	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	34 (27.4)	34 (30.4)	55 (24.7)
No	90 (72.6)	78 (69.6)	168 (75.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.75	
95% CI of the inverse odds ratio	(0.53, 1.43)	(0.45, 1.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	0.81	
95% CI of the inverse risk ratio	(0.62, 1.30)	(0.57, 1.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.76	5.69	
95% CI of the absolute risk difference	(-6.92, 12.43)	(-4.53, 15.92)	
p-value	0.5732	0.2657	
p-value of Breslow-Day Test for Homogeneity [3]	0.6344	0.8940	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	17 (13.7)	13 (11.6)	24 (10.8)
No	107 (86.3)	99 (88.4)	199 (89.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	0.92	
95% CI of the inverse odds ratio	(0.39, 1.47)	(0.45, 1.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.93	
95% CI of the inverse risk ratio	(0.44, 1.40)	(0.49, 1.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.95	0.84	
95% CI of the absolute risk difference	(-4.35, 10.24)	(-6.35, 8.04)	
p-value	0.4150	0.8160	
p-value of Breslow-Day Test for Homogeneity [3]	0.2977	0.8810	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	42 (33.9)	33 (29.5)	60 (26.9)
No	82 (66.1)	79 (70.5)	163 (73.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.88	
95% CI of the inverse odds ratio	(0.45, 1.16)	(0.53, 1.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.91	
95% CI of the inverse risk ratio	(0.57, 1.10)	(0.64, 1.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.97	2.56	
95% CI of the absolute risk difference	(-3.20, 17.13)	(-7.70, 12.81)	
p-value	0.1723	0.6218	
p-value of Breslow-Day Test for Homogeneity [3]	0.8287	0.5836	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (4.8)
No	26 (100)	24 (100)	59 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.84	-4.84	
95% CI of the absolute risk difference	(-10.18, 0.50)	(-10.18, 0.50)	
p-value	0.2538	0.2727	
p-value of Breslow-Day Test for Homogeneity [3]	0.2185	0.2630	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (15.4)	4 (16.7)	11 (17.7)
No	22 (84.6)	20 (83.3)	51 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	1.08	
95% CI of the inverse odds ratio	(0.34, 4.14)	(0.31, 3.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.06	
95% CI of the inverse risk ratio	(0.40, 3.29)	(0.38, 3.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.36	-1.08	
95% CI of the absolute risk difference	(-19.17, 14.46)	(-18.76, 16.61)	
p-value	0.7885	0.9062	
p-value of Breslow-Day Test for Homogeneity [3]	0.6768	0.7980	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.7)	1 (4.2)	6 (9.7)
No	24 (92.3)	23 (95.8)	56 (90.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	2.46	
95% CI of the inverse odds ratio	(0.24, 6.83)	(0.28, 21.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	2.32	
95% CI of the inverse risk ratio	(0.27, 5.83)	(0.29, 18.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.99	-5.51	
95% CI of the absolute risk difference	(-14.60, 10.63)	(-16.38, 5.36)	
p-value	0.7676	0.4019	
p-value of Breslow-Day Test for Homogeneity [3]	0.5189	0.1660	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (23.1)	2 (8.3)	20 (32.3)
No	20 (76.9)	22 (91.7)	42 (67.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	5.24	
95% CI of the inverse odds ratio	(0.55, 4.56)	(1.12, 24.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	3.87	
95% CI of the inverse risk ratio	(0.64, 3.08)	(0.98, 15.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.18	-23.92	
95% CI of the absolute risk difference	(-29.12, 10.76)	(-39.98, -7.87)	
p-value	0.3891	0.0226	
p-value of Breslow-Day Test for Homogeneity [3]	0.6058	0.0070	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.8)	1 (4.2)	5 (8.1)
No	25 (96.2)	23 (95.8)	57 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.19	2.02	
95% CI of the inverse odds ratio	(0.24, 19.75)	(0.22, 18.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.10	1.94	
95% CI of the inverse risk ratio	(0.26, 17.08)	(0.24, 15.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.22	-3.90	
95% CI of the absolute risk difference	(-14.25, 5.81)	(-14.38, 6.58)	
p-value	0.4738	0.5245	
p-value of Breslow-Day Test for Homogeneity [3]	0.8114	0.7967	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (7.7)	3 (12.5)	14 (22.6)
No	24 (92.3)	21 (87.5)	48 (77.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	2.04	
95% CI of the inverse odds ratio	(0.74, 16.66)	(0.53, 7.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.94	1.81	
95% CI of the inverse risk ratio	(0.72, 12.01)	(0.57, 5.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.89	-10.08	
95% CI of the absolute risk difference	(-29.49, -0.29)	(-26.91, 6.75)	
p-value	0.0985	0.2924	
p-value of Breslow-Day Test for Homogeneity [3]	0.2655	0.3601	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.8)	2 (8.3)	4 (6.5)
No	25 (96.2)	22 (91.7)	58 (93.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.72	0.76	
95% CI of the inverse odds ratio	(0.18, 16.21)	(0.13, 4.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.68	0.77	
95% CI of the inverse risk ratio	(0.20, 14.30)	(0.15, 3.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.61	1.88	
95% CI of the absolute risk difference	(-12.20, 6.99)	(-10.75, 14.52)	
p-value	0.6300	0.7587	
p-value of Breslow-Day Test for Homogeneity [3]	0.3480	0.6654	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (19.2)	4 (16.7)	14 (22.6)
No	21 (80.8)	20 (83.3)	48 (77.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	1.46	
95% CI of the inverse odds ratio	(0.39, 3.84)	(0.43, 4.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	1.35	
95% CI of the inverse risk ratio	(0.47, 2.92)	(0.50, 3.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.35	-5.91	
95% CI of the absolute risk difference	(-21.73, 15.03)	(-24.10, 12.27)	
p-value	0.7275	0.5454	
p-value of Breslow-Day Test for Homogeneity [3]	0.7106	0.4216	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.8)	2 (8.3)	7 (11.3)
No	25 (96.2)	22 (91.7)	55 (88.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	1.40	
95% CI of the inverse odds ratio	(0.37, 27.26)	(0.27, 7.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.94	1.35	
95% CI of the inverse risk ratio	(0.38, 22.68)	(0.30, 6.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.44	-2.96	
95% CI of the absolute risk difference	(-18.25, 3.36)	(-16.53, 10.62)	
p-value	0.2677	0.6878	
p-value of Breslow-Day Test for Homogeneity [3]	0.3665	0.5850	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (11.5)	3 (12.5)	14 (22.6)
No	23 (88.5)	21 (87.5)	48 (77.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.24	2.04	
95% CI of the inverse odds ratio	(0.58, 8.56)	(0.53, 7.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.96	1.81	
95% CI of the inverse risk ratio	(0.61, 6.24)	(0.57, 5.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.04	-10.08	
95% CI of the absolute risk difference	(-27.14, 5.06)	(-26.91, 6.75)	
p-value	0.2313	0.2924	
p-value of Breslow-Day Test for Homogeneity [3]	0.3435	0.2426	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.7)	0	1 (1.6)
No	24 (92.3)	24 (100)	61 (98.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	NE	
95% CI of the inverse odds ratio	(0.02, 2.27)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	NE	
95% CI of the inverse risk ratio	(0.02, 2.21)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.08	-1.61	
95% CI of the absolute risk difference	(-4.63, 16.79)	(-4.75, 1.52)	
p-value	0.1516	0.5314	
p-value of Breslow-Day Test for Homogeneity [3]	0.0238	0.5364	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (23.1)	1 (4.2)	4 (6.5)
No	20 (76.9)	23 (95.8)	58 (93.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.23	1.59	
95% CI of the inverse odds ratio	(0.06, 0.90)	(0.17, 14.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	1.55	
95% CI of the inverse risk ratio	(0.09, 0.91)	(0.18, 13.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.63	-2.28	
95% CI of the absolute risk difference	(-0.69, 33.94)	(-12.35, 7.78)	
p-value	0.0250	0.6846	
p-value of Breslow-Day Test for Homogeneity [3]	0.0063	0.6724	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (11.5)	4 (16.7)	12 (19.4)
No	23 (88.5)	20 (83.3)	50 (80.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.84	1.20	
95% CI of the inverse odds ratio	(0.47, 7.16)	(0.35, 4.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.68	1.16	
95% CI of the inverse risk ratio	(0.52, 5.46)	(0.42, 3.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.82	-2.69	
95% CI of the absolute risk difference	(-23.55, 7.92)	(-20.55, 15.17)	
p-value	0.3737	0.7739	
p-value of Breslow-Day Test for Homogeneity [3]	0.3883	0.9266	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (19.2)	8 (33.3)	25 (40.3)
No	21 (80.8)	16 (66.7)	37 (59.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.84	1.35	
95% CI of the inverse odds ratio	(0.95, 8.52)	(0.50, 3.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.10	1.21	
95% CI of the inverse risk ratio	(0.90, 4.88)	(0.64, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-21.09	-6.99	
95% CI of the absolute risk difference	(-40.55, -1.63)	(-29.46, 15.48)	
p-value	0.0569	0.5499	
p-value of Breslow-Day Test for Homogeneity [3]	0.1460	0.6840	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (15.4)	2 (8.3)	8 (12.9)
No	22 (84.6)	22 (91.7)	54 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	1.63	
95% CI of the inverse odds ratio	(0.22, 2.99)	(0.32, 8.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.55	
95% CI of the inverse risk ratio	(0.28, 2.54)	(0.35, 6.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.48	-4.57	
95% CI of the absolute risk difference	(-13.70, 18.67)	(-18.42, 9.28)	
p-value	0.7570	0.5532	
p-value of Breslow-Day Test for Homogeneity [3]	0.9064	0.1588	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (26.9)	5 (20.8)	18 (29.0)
No	19 (73.1)	19 (79.2)	44 (71.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.55	
95% CI of the inverse odds ratio	(0.40, 3.10)	(0.50, 4.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	1.39	
95% CI of the inverse risk ratio	(0.51, 2.27)	(0.58, 3.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.11	-8.20	
95% CI of the absolute risk difference	(-22.56, 18.34)	(-27.99, 11.59)	
p-value	0.8413	0.4410	
p-value of Breslow-Day Test for Homogeneity [3]	0.8714	0.4451	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.7)	4 (16.7)	10 (16.1)
No	24 (92.3)	20 (83.3)	52 (83.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.31	0.96	
95% CI of the inverse odds ratio	(0.47, 11.35)	(0.27, 3.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.10	0.97	
95% CI of the inverse risk ratio	(0.49, 8.92)	(0.34, 2.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.44	0.54	
95% CI of the absolute risk difference	(-22.17, 5.30)	(-16.96, 18.03)	
p-value	0.2927	0.9517	
p-value of Breslow-Day Test for Homogeneity [3]	0.0868	0.3770	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (26.9)	5 (20.8)	11 (17.7)
No	19 (73.1)	19 (79.2)	51 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.82	
95% CI of the inverse odds ratio	(0.20, 1.73)	(0.25, 2.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.85	
95% CI of the inverse risk ratio	(0.29, 1.51)	(0.33, 2.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.18	3.09	
95% CI of the absolute risk difference	(-10.34, 28.70)	(-15.73, 21.92)	
p-value	0.3300	0.7411	
p-value of Breslow-Day Test for Homogeneity [3]	0.6344	0.8940	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.8)	3 (12.5)	8 (12.9)
No	25 (96.2)	21 (87.5)	54 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.70	1.04	
95% CI of the inverse odds ratio	(0.44, 31.24)	(0.25, 4.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.35	1.03	
95% CI of the inverse risk ratio	(0.44, 25.49)	(0.30, 3.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.06	-0.40	
95% CI of the absolute risk difference	(-20.20, 2.09)	(-16.05, 15.24)	
p-value	0.2008	0.9599	
p-value of Breslow-Day Test for Homogeneity [3]	0.2977	0.8810	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (30.8)	6 (25.0)	18 (29.0)
No	18 (69.2)	18 (75.0)	44 (71.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.23	
95% CI of the inverse odds ratio	(0.34, 2.49)	(0.42, 3.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.16	
95% CI of the inverse risk ratio	(0.47, 1.89)	(0.52, 2.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.74	-4.03	
95% CI of the absolute risk difference	(-19.30, 22.77)	(-24.71, 16.65)	
p-value	0.8706	0.7085	
p-value of Breslow-Day Test for Homogeneity [3]	0.8287	0.5836	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2185	0.2630	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	0	0
No	3 (60.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse odds ratio	(0.01, 16.89)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	NE	
95% CI of the inverse risk ratio	(0.05, 7.92)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	NE	
95% CI of the absolute risk difference	(-55.15, 88.48)	NE	
p-value	0.6733	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6768	0.7980	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5189	0.1660	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	0	0
No	3 (60.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse odds ratio	(0.01, 16.89)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	NE	
95% CI of the inverse risk ratio	(0.05, 7.92)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	NE	
95% CI of the absolute risk difference	(-55.15, 88.48)	NE	
p-value	0.6733	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6058	0.0070	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8114	0.7967	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	0	0
No	4 (80.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse odds ratio	(0.02, 40.28)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse risk ratio	(0.06, 15.99)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	NE	
95% CI of the absolute risk difference	(-69.30, 69.30)	NE	
p-value	>0.9999	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2655	0.3601	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3480	0.6654	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7106	0.4216	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (40.0)	0	0
No	3 (60.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse odds ratio	(0.01, 16.89)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	NE	
95% CI of the inverse risk ratio	(0.05, 7.92)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	NE	
95% CI of the absolute risk difference	(-55.15, 88.48)	NE	
p-value	0.6733	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3665	0.5850	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	0	0
No	3 (60.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse odds ratio	(0.01, 16.89)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	NE	
95% CI of the inverse risk ratio	(0.05, 7.92)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	NE	
95% CI of the absolute risk difference	(-55.15, 88.48)	NE	
p-value	0.6733	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3435	0.2426	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0238	0.5364	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	0	0
No	4 (80.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse odds ratio	(0.02, 40.28)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse risk ratio	(0.06, 15.99)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	NE	
95% CI of the absolute risk difference	(-69.30, 69.30)	NE	
p-value	>0.9999	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0063	0.6724	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3883	0.9266	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	0	0
No	3 (60.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse odds ratio	(0.01, 16.89)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	NE	
95% CI of the inverse risk ratio	(0.05, 7.92)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	NE	
95% CI of the absolute risk difference	(-55.15, 88.48)	NE	
p-value	0.6733	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1460	0.6840	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (20.0)	0	0
No	4 (80.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse odds ratio	(0.02, 40.28)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse risk ratio	(0.06, 15.99)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	NE	
95% CI of the absolute risk difference	(-69.30, 69.30)	NE	
p-value	>0.9999	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9064	0.1588	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	0	0
No	4 (80.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse odds ratio	(0.02, 40.28)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse risk ratio	(0.06, 15.99)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	NE	
95% CI of the absolute risk difference	(-69.30, 69.30)	NE	
p-value	>0.9999	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8714	0.4451	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0868	0.3770	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	0	0
No	3 (60.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse odds ratio	(0.01, 16.89)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	NE	
95% CI of the inverse risk ratio	(0.05, 7.92)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	NE	
95% CI of the absolute risk difference	(-55.15, 88.48)	NE	
p-value	0.6733	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6344	0.8940	

AMNOG Table SE21.14b.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (20.0)	0	0
No	4 (80.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse odds ratio	(0.02, 40.28)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse risk ratio	(0.06, 15.99)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	NE	
95% CI of the absolute risk difference	(-69.30, 69.30)	NE	
p-value	>0.9999	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2977	0.8810	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	0	0
No	4 (80.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse odds ratio	(0.02, 40.28)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse risk ratio	(0.06, 15.99)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	NE	
95% CI of the absolute risk difference	(-69.30, 69.30)	NE	
p-value	>0.9999	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8287	0.5836	

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE21.14b.5
Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation
Symptoms of Liver Disease



Patients with result at given visit			
MGL-3196 80 mg	120	117	102
MGL-3196 100 mg	104	102	89
Placebo	209	204	175

Abbreviations: Abbreviations: LDLOQ = Liver Disease Quality of Life; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE21.14b.5
Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous
Symptoms of Liver Disease



Patients with result at given visit			
MGL-3196 80 mg	23	25	22
MGL-3196 100 mg	20	20	14
Placebo	55	54	49

Abbreviations: Abbreviations: LDLOQ = Liver Disease Quality of Life; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE21.14b.5
Liver Disease Quality of Life (SE21): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous
Symptoms of Liver Disease



Patients with result at given visit			
MGL-3196 80 mg	5	5	5
MGL-3196 100 mg	2	2	1
Placebo	1	0	0

Abbreviations: Abbreviations: LDLOQ = Liver Disease Quality of Life; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Total LDQOL						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	77.24 (14.48)	76.78 (15.43)	78.93 (13.51)			
Median	82.00	81.30	83.00			
IQR: Q1, Q3	69.75, 88.15	67.60, 87.70	72.60, 88.60			
Min, Max	38.5, 96.5	23.6, 93.9	38.5, 97.0			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	79.52 (15.22)	76.76 (13.47)	78.83 (14.61)	1.44 (1.21)	0.64 (1.33)	0.05 (1.18)
Median	83.70	75.60	83.15	2.50	0.95	-0.05
IQR: Q1, Q3	72.75, 90.95	69.30, 87.90	72.40, 89.05	-5.10, 7.00	-5.00, 5.60	-3.80, 3.90
Min, Max	28.2, 97.8	45.3, 96.9	22.4, 96.5	-18.3, 24.2	-15.4, 26.0	-46.4, 29.4
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	79.20 (12.60)	77.74 (14.46)	78.77 (14.23)	0.04 (1.29)	0.70 (1.35)	-0.81 (1.13)
Median	81.90	79.80	83.90	0.25	-0.05	-0.55
IQR: Q1, Q3	70.40, 88.80	70.30, 88.50	71.20, 88.80	-4.80, 4.80	-3.85, 4.35	-6.00, 4.85
Min, Max	44.4, 97.5	38.2, 95.6	35.7, 97.8	-18.9, 17.3	-13.9, 22.4	-36.2, 23.8

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Symptoms of Liver Disease						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	79.22 (17.26)	74.88 (20.20)	76.25 (17.45)			
Median	83.30	76.70	80.00			
IQR: Q1, Q3	73.30, 93.30	66.70, 90.00	63.30, 90.00			
Min, Max	26.7, 100.0	30.0, 100.0	26.7, 100.0			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	77.22 (20.15)	75.61 (18.48)	80.06 (16.58)	-2.76 (1.94)	-0.09 (1.91)	1.90 (1.55)
Median	83.30	76.70	83.30	0	0	3.30
IQR: Q1, Q3	66.70, 91.65	63.30, 90.00	66.70, 93.30	-10.00, 3.40	-6.70, 6.70	-6.60, 6.70
Min, Max	16.7, 100.0	33.3, 100.0	23.3, 100.0	-46.6, 30.0	-30.0, 26.7	-30.0, 43.3
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	77.90 (17.93)	78.20 (19.20)	78.51 (16.92)	-3.33 (1.83)	2.87 (2.11)	0.31 (1.60)
Median	83.30	83.30	80.00	-3.40	1.65	0
IQR: Q1, Q3	66.70, 93.30	66.70, 93.30	70.00, 90.00	-6.70, 3.30	-3.30, 11.65	-6.70, 6.70
Min, Max	26.7, 100.0	26.7, 100.0	23.3, 100.0	-33.3, 33.4	-36.7, 26.7	-36.7, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Effects of Liver Disease						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	76.93 (13.50)	77.89 (15.73)	78.24 (14.18)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	80.00, 86.70	80.00, 86.70			
Min, Max	20.0, 100.0	26.7, 100.0	26.7, 100.0			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	78.61 (11.75)	78.21 (12.65)	78.25 (14.73)	0.14 (1.74)	0.17 (2.65)	-0.35 (1.47)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 80.00	73.30, 80.00	80.00, 83.35	-6.70, 6.70	-6.70, 0.00	0.00, 6.60
Min, Max	40.0, 100.0	40.0, 100.0	6.7, 100.0	-26.6, 26.6	-26.7, 60.0	-46.7, 40.0
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	77.75 (11.87)	76.67 (12.47)	78.26 (11.68)	-0.56 (2.24)	-1.95 (2.09)	-2.09 (1.52)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 6.70	-6.70, 3.30	-6.70, 0.00
Min, Max	46.7, 100.0	33.3, 100.0	26.7, 100.0	-40.0, 46.7	-33.3, 30.0	-33.3, 53.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Concentration/Memory						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	77.42 (24.63)	81.88 (19.10)	80.77 (19.74)			
Median	81.30	87.50	87.50			
IQR: Q1, Q3	68.80, 100.00	75.00, 93.80	68.80, 100.00			
Min, Max	12.5, 100.0	37.5, 100.0	12.5, 100.0			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	78.40 (23.90)	79.74 (21.64)	78.85 (24.90)	-0.40 (2.13)	-2.47 (1.77)	-2.09 (2.18)
Median	87.50	81.30	87.50	0	0	0
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	68.80, 100.00	-12.50, 6.20	-6.30, 0.00	-6.20, 6.20
Min, Max	18.8, 100.0	25.0, 100.0	6.3, 100.0	-31.2, 31.2	-25.0, 25.0	-81.2, 62.5
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	79.23 (19.60)	79.75 (21.97)	78.00 (23.17)	0.75 (2.33)	-3.30 (1.80)	-4.89 (1.68)
Median	75.00	87.50	81.30	0	0	-6.20
IQR: Q1, Q3	68.80, 100.00	68.80, 93.80	68.80, 100.00	-6.20, 6.20	-9.40, 3.10	-12.50, 0.00
Min, Max	18.8, 100.0	18.8, 100.0	0.0, 100.0	-43.7, 50.0	-25.0, 18.8	-43.8, 31.2

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Health Distress						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	75.72 (27.94)	79.27 (24.46)	79.45 (24.85)			
Median	87.50	87.50	87.50			
IQR: Q1, Q3	50.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	12.5, 100.0	0.0, 100.0			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	82.29 (24.44)	85.98 (19.20)	85.31 (23.85)	6.38 (2.84)	6.58 (2.90)	7.53 (2.32)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 25.00
Min, Max	12.5, 100.0	25.0, 100.0	0.0, 100.0	-25.0, 75.0	-37.5, 50.0	-50.0, 62.5
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	79.07 (25.55)	88.85 (18.82)	84.62 (23.05)	-0.30 (2.84)	9.38 (2.79)	5.27 (2.85)
Median	75.00	100.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	87.50, 100.00	75.00, 100.00	-12.50, 0.00	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	25.0, 100.0	0.0, 100.0	-37.5, 50.0	-25.0, 50.0	-87.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Sexual Function						
Baseline						
m	53	45	90			
n	21	19	35			
Mean (SD)	84.36 (18.02)	86.75 (16.94)	84.86 (18.70)			
Median	93.30	93.30	91.70			
IQR: Q1, Q3	76.70, 100.00	76.70, 100.00	83.30, 100.00			
Min, Max	38.3, 100.0	38.3, 100.0	23.3, 100.0			
Week 24						
m	49	43	83			
n	19	21	32	16	16	25
Mean (SD/SE)	87.11 (13.19)	74.28 (25.96)	86.25 (15.50)	0.12 (3.05)	-7.29 (4.42)	2.72 (2.63)
Median	93.30	76.70	91.70	0	0	0
IQR: Q1, Q3	76.70, 100.00	55.00, 100.00	74.20, 100.00	-4.15, 7.50	-17.50, 5.00	-1.70, 6.70
Min, Max	61.7, 100.0	13.3, 100.0	36.7, 100.0	-23.3, 23.4	-40.0, 8.4	-18.4, 45.0
Week 52						
m	47	38	75			
n	14	17	22	13	12	19
Mean (SD/SE)	89.99 (13.47)	83.22 (21.33)	84.25 (19.55)	3.85 (5.21)	-1.53 (3.88)	-4.03 (5.34)
Median	93.30	93.30	96.65	0	0	0
IQR: Q1, Q3	85.00, 100.00	68.30, 100.00	76.70, 100.00	0.00, 6.70	0.00, 3.35	-8.30, 6.70
Min, Max	61.7, 100.0	38.3, 100.0	46.7, 100.0	-15.0, 61.7	-30.0, 15.0	-53.3, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Sleep						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	67.31 (19.67)	54.88 (18.86)	63.05 (20.91)			
Median	70.00	55.00	65.00			
IQR: Q1, Q3	55.00, 80.00	40.00, 70.00	50.00, 80.00			
Min, Max	15.0, 100.0	20.0, 85.0	5.0, 100.0			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	67.60 (22.55)	55.49 (23.21)	62.56 (20.08)	-1.06 (1.83)	1.84 (2.65)	-1.15 (1.86)
Median	72.50	55.00	60.00	0	0	0
IQR: Q1, Q3	52.50, 85.00	35.00, 80.00	50.00, 75.00	-5.00, 5.00	-10.00, 15.00	-10.00, 10.00
Min, Max	5.0, 100.0	15.0, 95.0	20.0, 100.0	-30.0, 30.0	-35.0, 45.0	-35.0, 45.0
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	66.08 (18.71)	55.14 (22.53)	63.85 (19.94)	-3.90 (1.88)	-0.83 (3.10)	0.08 (2.11)
Median	65.00	60.00	65.00	-5.00	-2.50	0
IQR: Q1, Q3	55.00, 80.00	40.00, 70.00	50.00, 75.00	-13.70, 5.00	-10.00, 12.50	-10.00, 15.00
Min, Max	25.0, 100.0	10.0, 90.0	25.0, 100.0	-25.0, 25.0	-60.0, 40.0	-40.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Loneliness						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	85.29 (16.84)	84.39 (21.48)	84.40 (19.42)			
Median	92.50	95.00	90.00			
IQR: Q1, Q3	75.00, 100.00	80.00, 100.00	75.00, 100.00			
Min, Max	40.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	86.35 (17.28)	85.37 (17.80)	80.38 (22.71)	0.53 (2.39)	2.63 (2.62)	-2.79 (1.98)
Median	90.00	95.00	85.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	75.00, 100.00	70.00, 100.00	-10.00, 5.00	-5.00, 10.00	-10.00, 5.00
Min, Max	30.0, 100.0	40.0, 100.0	10.0, 100.0	-45.0, 45.0	-35.0, 65.0	-80.0, 40.0
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	85.47 (15.15)	82.97 (23.14)	82.69 (21.62)	-1.07 (2.58)	0.28 (2.49)	-0.74 (2.14)
Median	85.00	90.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	80.00, 100.00	75.00, 100.00	-10.00, 0.00	-7.50, 10.00	-10.00, 5.00
Min, Max	40.0, 100.0	15.0, 100.0	5.0, 100.0	-55.0, 50.0	-40.0, 30.0	-35.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Hopelessness						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	73.08 (24.57)	76.82 (22.64)	81.90 (20.77)			
Median	75.00	83.30	91.70			
IQR: Q1, Q3	54.15, 100.00	58.30, 100.00	66.70, 100.00			
Min, Max	8.3, 100.0	33.3, 100.0	16.7, 100.0			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	78.12 (24.59)	77.65 (19.94)	78.49 (22.89)	4.60 (3.09)	2.21 (2.61)	-2.29 (2.22)
Median	83.30	83.30	85.40	0	0	0
IQR: Q1, Q3	58.30, 100.00	58.30, 91.70	62.50, 100.00	-8.30, 25.00	-8.30, 16.70	-8.30, 8.30
Min, Max	8.3, 100.0	33.3, 100.0	16.7, 100.0	-58.3, 50.0	-41.7, 33.3	-66.6, 50.0
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	78.69 (23.24)	77.49 (19.92)	77.31 (24.50)	3.38 (2.84)	1.18 (4.10)	-4.95 (2.81)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	66.70, 91.70	58.30, 100.00	0.00, 16.70	-16.60, 16.70	-8.40, 8.30
Min, Max	16.7, 100.0	41.7, 100.0	0.0, 100.0	-41.7, 41.7	-50.0, 50.0	-100.0, 33.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Stigma of Liver Disease						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	81.38 (21.80)	81.57 (20.01)	86.30 (17.15)			
Median	90.65	87.50	93.80			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	81.30, 100.00			
Min, Max	25.0, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	85.69 (19.89)	78.38 (20.45)	85.73 (20.04)	3.19 (2.34)	-1.97 (2.02)	-0.32 (1.88)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	68.80, 93.80	81.30, 100.00	-6.20, 12.50	-12.50, 6.20	-6.20, 6.20
Min, Max	12.5, 100.0	12.5, 100.0	6.3, 100.0	-43.8, 37.5	-31.3, 25.0	-62.5, 75.0
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	87.95 (16.72)	81.95 (19.24)	87.81 (16.83)	3.72 (2.04)	0.70 (2.12)	2.83 (1.77)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	0.00, 6.30	-6.20, 6.25	0.00, 12.50
Min, Max	37.5, 100.0	12.5, 100.0	31.3, 100.0	-25.0, 37.5	-25.0, 31.3	-50.0, 31.2

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Total LDQOL						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	77.31 (14.65)	78.37 (13.07)	77.01 (14.04)			
Median	81.00	82.70	79.70			
IQR: Q1, Q3	67.20, 89.40	72.80, 87.00	70.60, 87.70			
Min, Max	29.0, 96.7	27.3, 96.3	34.8, 97.1			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	77.59 (15.89)	78.63 (12.00)	78.94 (13.14)	0.72 (1.17)	-0.82 (1.00)	1.37 (0.82)
Median	82.05	80.70	81.70	0.40	-1.20	0.95
IQR: Q1, Q3	71.60, 89.90	73.10, 87.00	70.85, 88.90	-4.70, 5.70	-6.20, 4.10	-2.70, 5.50
Min, Max	22.9, 97.2	32.4, 95.6	32.4, 98.8	-23.4, 35.6	-13.9, 17.5	-24.5, 29.7
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	78.87 (14.15)	79.19 (13.43)	78.69 (13.08)	1.37 (1.21)	0.23 (1.28)	0.97 (0.85)
Median	84.00	81.05	81.00	0.90	0.25	2.00
IQR: Q1, Q3	70.85, 89.95	73.10, 90.90	70.20, 89.20	-3.70, 5.90	-3.40, 6.20	-3.70, 5.20
Min, Max	34.0, 96.7	34.2, 97.4	40.7, 100.0	-19.3, 36.0	-19.0, 18.3	-23.2, 24.9

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Symptoms of Liver Disease						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	76.18 (20.49)	76.84 (17.48)	76.16 (17.84)			
Median	83.30	83.30	80.00			
IQR: Q1, Q3	66.70, 93.30	63.30, 90.00	63.30, 93.30			
Min, Max	23.3, 100.0	36.7, 100.0	30.0, 100.0			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	75.95 (19.80)	74.56 (18.11)	76.15 (18.80)	-0.39 (1.85)	-1.53 (1.75)	-0.49 (1.14)
Median	83.30	76.70	80.00	0	0	0
IQR: Q1, Q3	63.30, 93.30	66.70, 86.70	63.30, 90.00	-6.70, 8.35	-10.00, 3.40	-6.60, 6.60
Min, Max	23.3, 100.0	26.7, 100.0	26.7, 100.0	-43.3, 36.7	-36.6, 30.0	-43.3, 36.7
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	77.55 (18.47)	78.48 (17.12)	77.31 (18.53)	-1.31 (1.83)	1.04 (2.21)	0.90 (1.14)
Median	83.30	80.00	83.30	0	0	3.30
IQR: Q1, Q3	65.00, 93.30	66.70, 93.30	63.30, 93.30	-10.00, 6.70	-6.70, 6.70	-6.60, 6.70
Min, Max	33.3, 100.0	30.0, 100.0	23.3, 100.0	-43.4, 43.4	-33.3, 36.7	-30.0, 26.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Effects of Liver Disease						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	78.07 (13.09)	82.22 (12.49)	76.85 (15.62)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	73.30, 80.00	80.00, 86.70	73.30, 86.70			
Min, Max	13.3, 100.0	26.7, 100.0	6.7, 100.0			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	74.95 (15.12)	80.24 (10.00)	77.55 (15.13)	-2.46 (1.25)	-2.53 (1.93)	0.45 (1.35)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 86.70	76.65, 86.70	-6.70, 0.00	-13.30, 6.70	-6.70, 6.70
Min, Max	20.0, 100.0	53.3, 100.0	6.7, 100.0	-33.4, 20.0	-33.3, 53.3	-46.6, 46.7
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	76.46 (12.17)	80.29 (10.03)	77.22 (13.47)	-1.43 (1.80)	-0.80 (1.83)	0.15 (1.79)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	73.30, 80.00	-6.70, 0.00	-6.70, 0.00	-6.70, 6.70
Min, Max	40.0, 100.0	53.3, 100.0	20.0, 100.0	-40.0, 80.0	-20.0, 40.0	-80.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Concentration/Memory						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	83.71 (20.48)	79.29 (20.22)	77.68 (21.16)			
Median	87.50	87.50	81.30			
IQR: Q1, Q3	75.00, 100.00	68.80, 93.80	62.50, 93.80			
Min, Max	12.5, 100.0	25.0, 100.0	6.3, 100.0			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	78.59 (22.18)	81.05 (18.37)	81.17 (19.30)	-4.14 (1.81)	-0.25 (2.09)	2.60 (1.23)
Median	87.50	87.50	87.50	0	0	0
IQR: Q1, Q3	68.80, 93.80	68.80, 100.00	68.80, 96.90	-9.40, 3.10	-6.30, 6.30	-6.20, 6.30
Min, Max	0.0, 100.0	25.0, 100.0	18.8, 100.0	-43.8, 31.2	-37.5, 25.0	-31.2, 62.5
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	79.51 (19.69)	79.91 (19.79)	79.30 (20.69)	-3.28 (1.62)	-0.75 (2.31)	0.78 (1.34)
Median	81.30	84.40	81.30	-6.20	0	0
IQR: Q1, Q3	75.00, 93.80	62.50, 100.00	68.80, 100.00	-12.50, 0.00	-12.50, 12.50	-6.20, 6.30
Min, Max	0.0, 100.0	18.8, 100.0	18.8, 100.0	-37.5, 50.0	-37.5, 25.0	-43.7, 43.8

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Health Distress						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	77.17 (26.43)	81.80 (26.10)	82.48 (22.40)			
Median	87.50	100.00	87.50			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	82.86 (24.92)	87.50 (22.29)	86.52 (19.82)	6.62 (2.64)	5.75 (2.65)	3.50 (1.68)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-37.5, 62.5	-37.5, 50.0	-62.5, 75.0
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	82.23 (25.28)	85.87 (22.46)	87.39 (18.48)	6.76 (3.44)	2.98 (3.04)	3.57 (2.14)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	12.5, 100.0	-75.0, 75.0	-37.5, 62.5	-62.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Sexual Function						
Baseline						
m	72	65	139			
n	32	35	58			
Mean (SD)	74.75 (31.32)	77.18 (24.35)	75.14 (28.01)			
Median	93.30	85.00	85.00			
IQR: Q1, Q3	54.15, 100.00	53.30, 100.00	61.70, 100.00			
Min, Max	-1.7, 100.0	30.0, 100.0	-1.7, 100.0			
Week 24						
m	72	58	135			
n	37	34	65	27	26	50
Mean (SD/SE)	78.97 (25.80)	77.25 (27.41)	78.33 (22.60)	7.83 (4.92)	-6.46 (4.04)	1.47 (2.66)
Median	91.70	93.30	85.00	0	0	0
IQR: Q1, Q3	61.70, 100.00	55.00, 100.00	61.70, 100.00	0.00, 21.70	-16.60, 0.00	-6.70, 8.40
Min, Max	6.7, 100.0	13.3, 100.0	6.7, 100.0	-38.4, 91.1	-55.0, 46.7	-46.7, 50.0
Week 52						
m	69	51	128			
n	25	26	53	21	24	41
Mean (SD/SE)	84.42 (22.45)	76.83 (28.80)	73.58 (26.45)	7.04 (5.50)	-3.07 (4.42)	0.94 (3.02)
Median	100.00	92.50	83.30	0	0	0
IQR: Q1, Q3	78.30, 100.00	53.30, 100.00	55.00, 93.30	0.00, 0.00	-10.80, 4.20	-8.40, 8.30
Min, Max	28.3, 100.0	5.0, 100.0	6.7, 100.0	-21.7, 91.1	-50.0, 61.7	-38.3, 65.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Sleep						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	59.35 (22.94)	65.00 (16.53)	63.07 (19.61)			
Median	65.00	65.00	65.00			
IQR: Q1, Q3	45.00, 80.00	60.00, 75.00	50.00, 80.00			
Min, Max	0.0, 90.0	5.0, 100.0	15.0, 100.0			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	62.00 (21.51)	61.05 (16.22)	63.36 (20.51)	2.72 (2.15)	-4.90 (1.75)	-0.17 (1.43)
Median	65.00	60.00	65.00	0	-5.00	0
IQR: Q1, Q3	50.00, 80.00	55.00, 70.00	50.00, 80.00	-5.00, 10.00	-10.00, 5.00	-10.00, 10.00
Min, Max	10.0, 95.0	0.0, 90.0	15.0, 100.0	-30.0, 90.0	-35.0, 20.0	-40.0, 40.0
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	63.44 (19.43)	62.07 (20.73)	63.42 (19.50)	2.95 (2.44)	-3.93 (2.25)	-0.14 (1.50)
Median	70.00	65.00	60.00	0	-5.00	0
IQR: Q1, Q3	50.00, 80.00	55.00, 75.00	50.00, 80.00	-10.00, 10.00	-10.00, 5.00	-10.00, 10.00
Min, Max	10.0, 100.0	0.0, 95.0	25.0, 100.0	-40.0, 75.0	-55.0, 30.0	-40.0, 45.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Loneliness						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	85.58 (18.34)	82.98 (18.70)	83.46 (20.75)			
Median	95.00	90.00	90.00			
IQR: Q1, Q3	80.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	15.0, 100.0	10.0, 100.0			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	83.04 (20.50)	87.19 (19.62)	83.95 (18.38)	-2.24 (1.97)	0.70 (1.70)	-0.59 (1.40)
Median	95.00	95.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	80.00, 100.00	80.00, 100.00	-8.75, 5.00	-5.00, 5.00	-10.00, 5.00
Min, Max	15.0, 100.0	0.0, 100.0	20.0, 100.0	-50.0, 30.0	-25.0, 20.0	-40.0, 45.0
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	83.98 (19.92)	84.57 (19.94)	84.65 (17.92)	-0.90 (1.89)	1.07 (2.58)	0.14 (1.49)
Median	95.00	90.00	90.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	75.00, 100.00	75.00, 100.00	-5.00, 5.00	-10.00, 15.00	-5.00, 5.00
Min, Max	25.0, 100.0	0.0, 100.0	30.0, 100.0	-60.0, 40.0	-40.0, 30.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Hopelessness						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	78.87 (21.23)	77.78 (23.38)	75.98 (22.24)			
Median	83.30	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	58.30, 100.00			
Min, Max	25.0, 100.0	25.0, 100.0	16.7, 100.0			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	80.36 (21.76)	76.75 (23.51)	78.71 (20.46)	2.33 (2.12)	-1.51 (2.80)	1.98 (1.65)
Median	91.70	75.00	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	58.30, 100.00	58.30, 100.00	-8.30, 8.40	-16.70, 8.30	-8.30, 8.40
Min, Max	8.3, 100.0	8.3, 100.0	16.7, 100.0	-41.7, 50.0	-33.4, 58.4	-50.0, 50.0
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	78.91 (19.86)	77.90 (21.17)	79.46 (20.36)	0.55 (2.53)	-1.39 (2.99)	2.23 (1.52)
Median	83.30	79.15	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	66.70, 100.00	66.70, 100.00	-8.30, 8.40	-16.60, 8.30	0.00, 8.40
Min, Max	33.3, 100.0	16.7, 100.0	25.0, 100.0	-50.0, 41.7	-58.3, 33.4	-41.7, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Stigma of Liver Disease						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	80.36 (22.12)	81.71 (19.50)	81.70 (20.02)			
Median	87.50	81.30	87.50			
IQR: Q1, Q3	68.80, 100.00	75.00, 100.00	68.80, 100.00			
Min, Max	18.8, 100.0	31.3, 100.0	31.3, 100.0			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	82.70 (20.63)	82.37 (19.48)	84.82 (18.16)	2.30 (2.50)	0.62 (2.18)	2.86 (1.45)
Median	87.50	81.30	93.80	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	78.15, 100.00	-6.30, 6.30	-6.20, 0.00	-6.20, 12.50
Min, Max	6.3, 100.0	25.0, 100.0	25.0, 100.0	-43.7, 56.2	-31.2, 50.0	-43.8, 50.0
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	86.63 (18.52)	85.71 (16.80)	83.79 (19.56)	5.02 (1.86)	4.57 (2.10)	1.39 (1.82)
Median	100.00	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	81.30, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	-6.20, 12.50
Min, Max	31.3, 100.0	37.5, 100.0	18.8, 100.0	-31.3, 56.2	-18.8, 50.0	-62.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Total LDQOL						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	78.37 (12.71)	74.02 (14.29)	76.99 (14.59)			
Median	79.00	77.05	79.80			
IQR: Q1, Q3	71.70, 89.90	62.80, 85.95	66.60, 88.50			
Min, Max	39.2, 94.6	34.5, 93.2	38.7, 97.8			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	76.01 (10.88)	75.48 (11.14)	77.38 (15.37)	-1.43 (1.51)	2.10 (1.86)	0.14 (1.63)
Median	76.50	76.85	82.55	-1.30	-0.25	-0.70
IQR: Q1, Q3	67.90, 85.50	65.10, 85.20	67.30, 90.00	-6.90, 2.50	-3.80, 7.50	-3.70, 4.70
Min, Max	56.3, 93.7	57.1, 95.4	42.8, 96.9	-18.3, 23.6	-14.5, 27.0	-27.7, 42.3
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	79.80 (11.48)	76.50 (12.91)	78.42 (17.76)	1.64 (1.51)	0.80 (2.89)	1.47 (2.04)
Median	83.35	77.60	85.90	1.30	1.00	0.50
IQR: Q1, Q3	68.10, 90.00	65.30, 89.80	72.50, 90.10	-2.80, 6.30	-7.50, 6.30	-2.45, 6.45
Min, Max	62.7, 96.3	50.7, 96.3	20.3, 97.8	-11.2, 12.6	-23.3, 33.9	-46.3, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Symptoms of Liver Disease						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	76.67 (18.70)	70.12 (19.18)	76.46 (18.58)			
Median	80.00	75.00	80.00			
IQR: Q1, Q3	63.30, 93.30	63.30, 83.30	63.30, 90.00			
Min, Max	30.0, 100.0	10.0, 96.7	20.0, 100.0			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	74.26 (21.12)	67.57 (17.70)	75.47 (23.36)	-1.98 (2.56)	-2.69 (2.69)	-0.50 (2.51)
Median	76.70	70.00	83.30	0	-6.65	0
IQR: Q1, Q3	70.00, 83.30	60.00, 80.00	60.00, 93.30	-10.00, 6.70	-10.00, 6.70	-10.00, 10.00
Min, Max	0.0, 100.0	30.0, 100.0	16.7, 100.0	-46.7, 20.0	-33.3, 30.0	-53.3, 26.7
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	75.91 (20.97)	71.11 (17.20)	77.48 (23.66)	-0.16 (2.24)	-0.32 (3.32)	1.08 (2.43)
Median	81.65	70.00	83.30	3.30	-6.60	3.30
IQR: Q1, Q3	70.00, 86.70	60.00, 83.30	73.30, 96.70	-6.70, 6.70	-10.00, 10.00	-3.40, 11.65
Min, Max	23.3, 100.0	36.7, 96.7	16.7, 100.0	-23.4, 13.4	-23.4, 30.0	-60.0, 23.4

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Effects of Liver Disease						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	78.52 (12.58)	75.24 (15.06)	77.39 (14.85)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	73.30, 80.00	80.00, 86.70			
Min, Max	26.7, 93.3	13.3, 100.0	33.3, 100.0			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	74.26 (11.64)	78.59 (6.27)	75.86 (14.25)	-4.19 (2.89)	3.20 (3.46)	-1.19 (2.71)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	66.70, 80.00	73.30, 80.00	73.30, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 0.00
Min, Max	46.7, 93.3	60.0, 90.0	40.0, 100.0	-40.0, 33.3	-20.0, 76.7	-46.7, 53.4
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	77.58 (12.28)	76.51 (13.26)	78.08 (16.98)	-1.27 (2.63)	-0.63 (3.56)	1.00 (3.63)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 86.70	73.30, 80.00	80.00, 86.70	0.00, 0.00	-6.70, 0.00	-6.70, 6.70
Min, Max	53.3, 100.0	26.7, 93.3	13.3, 100.0	-33.4, 20.0	-33.3, 53.4	-73.4, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Concentration/Memory						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	77.10 (24.87)	73.24 (22.35)	76.12 (22.38)			
Median	87.50	75.00	87.50			
IQR: Q1, Q3	62.50, 100.00	56.30, 90.65	56.30, 93.80			
Min, Max	18.8, 100.0	18.8, 100.0	31.3, 100.0			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	77.82 (21.29)	76.94 (19.43)	78.02 (21.65)	1.85 (2.87)	4.08 (4.16)	1.25 (2.44)
Median	81.30	78.15	81.30	0	0	0
IQR: Q1, Q3	62.50, 100.00	68.80, 93.80	62.50, 100.00	-6.30, 12.50	-6.30, 12.50	-6.20, 12.50
Min, Max	25.0, 100.0	25.0, 100.0	25.0, 100.0	-25.0, 25.0	-31.3, 56.2	-50.0, 50.0
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	77.86 (20.92)	77.10 (20.37)	78.77 (23.02)	1.79 (3.26)	-0.90 (4.69)	2.66 (2.51)
Median	78.15	75.00	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	68.80, 100.00	-6.20, 18.70	-6.30, 0.00	-6.20, 12.50
Min, Max	37.5, 100.0	37.5, 100.0	12.5, 100.0	-25.0, 25.0	-43.8, 50.0	-31.2, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Health Distress						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	84.26 (24.41)	84.82 (22.66)	77.21 (27.35)			
Median	100.00	100.00	87.50			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	50.00, 100.00			
Min, Max	0.0, 100.0	12.5, 100.0	0.0, 100.0			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	83.19 (20.40)	87.02 (18.19)	84.50 (23.63)	0.46 (4.08)	3.37 (3.51)	6.67 (3.17)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	0.00, 12.50	0.00, 12.50
Min, Max	25.0, 100.0	37.5, 100.0	12.5, 100.0	-50.0, 50.0	-37.5, 37.5	-50.0, 62.5
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	92.61 (14.26)	86.90 (16.99)	83.61 (25.12)	8.93 (5.19)	0.60 (4.84)	5.31 (3.79)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	-12.50, 12.50	0.00, 12.50
Min, Max	50.0, 100.0	50.0, 100.0	0.0, 100.0	-50.0, 75.0	-50.0, 50.0	-50.0, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Sexual Function						
Baseline						
m	30	28	57			
n	12	11	19			
Mean (SD)	89.03 (23.87)	70.14 (29.20)	79.04 (24.77)			
Median	96.65	76.70	85.00			
IQR: Q1, Q3	90.00, 100.00	61.70, 93.30	76.70, 100.00			
Min, Max	15.0, 100.0	-1.7, 100.0	13.3, 100.0			
Week 24						
m	30	28	54			
n	11	15	23	10	11	15
Mean (SD/SE)	72.88 (32.57)	73.55 (21.80)	72.46 (32.88)	-17.33 (10.28)	6.83 (6.46)	-6.67 (5.79)
Median	86.70	76.70	93.30	-0.80	0	0
IQR: Q1, Q3	35.00, 100.00	63.30, 93.30	60.00, 100.00	-30.00, 0.00	0.00, 30.00	-23.30, 0.00
Min, Max	15.0, 100.0	30.0, 100.0	-1.7, 100.0	-85.0, 8.3	-28.3, 41.7	-48.4, 38.3
Week 52						
m	26	25	52			
n	10	8	18	8	6	14
Mean (SD/SE)	82.50 (30.37)	77.84 (23.29)	77.98 (32.80)	-8.74 (6.21)	6.12 (10.95)	-1.76 (7.03)
Median	96.65	89.15	93.30	-3.35	3.35	0
IQR: Q1, Q3	76.70, 100.00	52.20, 96.65	68.30, 100.00	-15.80, 3.35	-16.60, 23.30	0.00, 6.60
Min, Max	6.7, 100.0	46.7, 100.0	-1.7, 100.0	-45.0, 6.7	-25.0, 48.3	-48.4, 63.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Sleep						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	64.07 (16.82)	55.36 (22.56)	61.64 (20.96)			
Median	60.00	57.50	60.00			
IQR: Q1, Q3	50.00, 80.00	47.50, 70.00	50.00, 75.00			
Min, Max	25.0, 100.0	0.0, 90.0	5.0, 100.0			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	59.83 (16.66)	54.04 (18.60)	60.90 (20.35)	-3.52 (2.29)	0.77 (2.78)	0.14 (2.44)
Median	60.00	55.00	60.00	-5.00	0	-5.00
IQR: Q1, Q3	45.00, 70.00	40.00, 70.00	50.00, 80.00	-10.00, 0.00	-5.00, 5.00	-10.00, 10.00
Min, Max	30.0, 95.0	15.0, 85.0	20.0, 95.0	-20.0, 35.0	-20.0, 40.0	-25.0, 50.0
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	64.32 (22.32)	59.29 (16.38)	65.89 (24.22)	-0.71 (2.79)	4.29 (3.95)	5.16 (2.33)
Median	60.00	65.00	70.00	-5.00	5.00	5.00
IQR: Q1, Q3	50.00, 85.00	45.00, 70.00	45.00, 85.00	-10.00, 5.00	-5.00, 15.00	-5.00, 10.00
Min, Max	15.0, 100.0	35.0, 90.0	5.0, 100.0	-20.0, 30.0	-30.0, 45.0	-20.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Loneliness						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	78.70 (19.79)	80.71 (20.22)	83.33 (18.91)			
Median	80.00	82.50	90.00			
IQR: Q1, Q3	60.00, 100.00	70.00, 100.00	70.00, 100.00			
Min, Max	35.0, 100.0	20.0, 100.0	30.0, 100.0			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	80.17 (18.35)	79.81 (20.86)	83.50 (22.77)	2.22 (3.24)	-1.15 (2.58)	-2.00 (2.88)
Median	80.00	85.00	92.50	0	0	0
IQR: Q1, Q3	70.00, 100.00	70.00, 100.00	75.00, 100.00	-10.00, 15.00	-10.00, 0.00	-10.00, 5.00
Min, Max	35.0, 100.0	30.0, 100.0	30.0, 100.0	-40.0, 40.0	-25.0, 30.0	-60.0, 70.0
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	86.14 (15.03)	81.67 (22.38)	83.56 (20.05)	7.38 (3.43)	-0.71 (2.72)	-0.63 (2.87)
Median	90.00	95.00	90.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 15.00	-5.00, 0.00	-10.00, 5.00
Min, Max	50.0, 100.0	35.0, 100.0	10.0, 100.0	-20.0, 35.0	-20.0, 30.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Hopelessness						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	76.87 (21.48)	74.71 (23.52)	80.88 (19.32)			
Median	91.70	83.30	83.30			
IQR: Q1, Q3	58.30, 91.70	50.00, 91.70	66.70, 100.00			
Min, Max	25.0, 100.0	8.3, 100.0	25.0, 100.0			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	70.69 (21.20)	78.84 (24.18)	79.17 (22.48)	-4.33 (3.49)	5.44 (4.13)	-3.14 (2.76)
Median	75.00	83.30	83.30	-8.30	0	0
IQR: Q1, Q3	50.00, 91.70	75.00, 100.00	66.70, 100.00	-16.70, 0.00	-8.30, 16.70	-16.70, 8.30
Min, Max	33.3, 100.0	8.3, 100.0	25.0, 100.0	-33.4, 41.7	-41.7, 58.3	-33.3, 50.0
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	78.04 (23.22)	77.39 (27.27)	77.23 (24.58)	-0.01 (3.86)	2.78 (4.72)	-4.16 (3.32)
Median	87.50	83.30	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	58.30, 100.00	-8.30, 8.30	-8.30, 16.70	-16.60, 8.30
Min, Max	41.7, 100.0	0.0, 100.0	8.3, 100.0	-41.6, 33.3	-41.7, 41.6	-58.4, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Stigma of Liver Disease						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	87.98 (15.49)	79.70 (18.60)	83.11 (20.62)			
Median	93.80	81.30	87.50			
IQR: Q1, Q3	81.30, 100.00	71.90, 100.00	75.00, 100.00			
Min, Max	50.0, 100.0	25.0, 100.0	12.5, 100.0			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	89.88 (16.06)	81.75 (17.75)	84.77 (17.77)	3.00 (2.52)	2.65 (3.05)	1.39 (2.76)
Median	100.00	84.40	90.65	0	0	0
IQR: Q1, Q3	87.50, 100.00	75.00, 93.80	75.00, 100.00	0.00, 6.20	-6.20, 6.30	-6.30, 6.20
Min, Max	50.0, 100.0	31.3, 100.0	37.5, 100.0	-25.0, 43.7	-18.8, 56.3	-50.0, 75.0
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	86.38 (16.77)	82.16 (24.06)	83.63 (19.13)	0.60 (2.55)	1.20 (5.15)	0.78 (2.59)
Median	93.80	93.80	87.50	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	-6.20, 12.50	-6.20, 6.20
Min, Max	50.0, 100.0	12.5, 100.0	25.0, 100.0	-25.0, 25.0	-56.2, 56.3	-56.3, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.14c.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Total LDQOL			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	77.71 (13.66)	75.81 (15.60)	79.35 (13.30)
Analysis Visit Mean (SD)	79.15 (15.17)	76.44 (13.72)	79.40 (14.15)
LS Mean of Change from Baseline (SE)	1.51 (1.35)	0.13 (1.47)	0.37 (1.05)
95% CI	(-1.15, 4.18)	(-2.77, 3.02)	(-1.71, 2.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.14 (1.66)	-0.24 (1.78)	
95% CI	(-2.14, 4.42)	(-3.77, 3.28)	
p-value	0.4931	0.8915	
Corrected Hedge's g Statistics	0.122	-0.026	
95% CI	(-0.24, 0.48)	(-0.41, 0.36)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	78.75 (13.03)	76.61 (15.69)	79.71 (13.36)
Analysis Visit Mean (SD)	78.78 (12.44)	77.30 (14.42)	78.90 (14.31)
LS Mean of Change from Baseline (SE)	0.19 (1.33)	0.30 (1.39)	-0.61 (1.06)
95% CI	(-2.43, 2.81)	(-2.45, 3.05)	(-2.70, 1.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.80 (1.64)	0.91 (1.73)	
95% CI	(-2.44, 4.04)	(-2.50, 4.33)	
p-value	0.6262	0.5982	
Corrected Hedge's g Statistics	0.093	0.107	
95% CI	(-0.30, 0.48)	(-0.30, 0.52)	
Subgroup*Treatment Interaction p-value	0.8526	0.6893	

AMNOG Table SE21.14c.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Total LDQOL			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	77.39 (14.75)	79.02 (13.14)	77.69 (13.73)
Analysis Visit Mean (SD)	78.11 (15.69)	78.20 (12.34)	79.05 (13.34)
LS Mean of Change from Baseline (SE)	0.63 (1.04)	-0.73 (1.20)	1.18 (0.78)
95% CI	(-1.41, 2.67)	(-3.09, 1.63)	(-0.37, 2.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.55 (1.27)	-1.91 (1.41)	
95% CI	(-3.05, 1.96)	(-4.68, 0.87)	
p-value	0.6680	0.1774	
Corrected Hedge's g Statistics	-0.064	-0.223	
95% CI	(-0.36, 0.23)	(-0.55, 0.11)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	77.92 (14.67)	78.23 (13.98)	77.58 (13.30)
Analysis Visit Mean (SD)	79.29 (13.93)	78.46 (13.71)	78.55 (13.44)
LS Mean of Change from Baseline (SE)	1.24 (1.08)	0.30 (1.29)	0.93 (0.83)
95% CI	(-0.89, 3.38)	(-2.24, 2.84)	(-0.70, 2.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.31 (1.34)	-0.64 (1.51)	
95% CI	(-2.33, 2.95)	(-3.61, 2.34)	
p-value	0.8167	0.6741	
Corrected Hedge's g Statistics	0.036	-0.075	
95% CI	(-0.28, 0.35)	(-0.43, 0.28)	
Subgroup*Treatment Interaction p-value	0.8526	0.6893	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Total LDQOL			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	78.37 (12.71)	73.38 (14.62)	77.81 (14.13)
Analysis Visit Mean (SD)	76.94 (10.68)	75.48 (11.14)	77.95 (15.31)
LS Mean of Change from Baseline (SE)	-0.47 (1.80)	1.12 (1.82)	0.86 (1.47)
95% CI	(-4.05, 3.11)	(-2.48, 4.72)	(-2.05, 3.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.33 (2.19)	0.25 (2.20)	
95% CI	(-5.68, 3.01)	(-4.11, 4.62)	
p-value	0.5437	0.9081	
Corrected Hedge's g Statistics	-0.137	0.026	
95% CI	(-0.61, 0.34)	(-0.46, 0.51)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	78.98 (10.97)	75.70 (14.80)	77.17 (15.64)
Analysis Visit Mean (SD)	80.62 (11.09)	76.50 (12.91)	78.64 (18.20)
LS Mean of Change from Baseline (SE)	3.47 (2.48)	0.74 (2.47)	0.44 (1.89)
95% CI	(-1.45, 8.38)	(-4.16, 5.65)	(-3.30, 4.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.03 (3.02)	0.30 (3.01)	
95% CI	(-2.96, 9.02)	(-5.68, 6.29)	
p-value	0.3183	0.9198	
Corrected Hedge's g Statistics	0.255	0.026	
95% CI	(-0.28, 0.78)	(-0.50, 0.55)	
Subgroup*Treatment Interaction p-value	0.8526	0.6893	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Symptoms of Liver Disease			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	79.50 (16.41)	74.39 (19.94)	78.25 (16.38)
Analysis Visit Mean (SD)	76.74 (20.08)	74.30 (18.41)	80.15 (16.57)
LS Mean of Change from Baseline (SE)	-2.06 (1.90)	-0.50 (2.06)	1.92 (1.48)
95% CI	(-5.81, 1.69)	(-4.57, 3.58)	(-1.00, 4.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.98 (2.33)	-2.42 (2.50)	
95% CI	(-8.59, 0.62)	(-7.37, 2.52)	
p-value	0.0895	0.3353	
Corrected Hedge's g Statistics	-0.304	-0.186	
95% CI	(-0.67, 0.06)	(-0.57, 0.20)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	80.71 (15.33)	74.73 (20.36)	78.02 (16.22)
Analysis Visit Mean (SD)	77.38 (17.81)	77.60 (19.11)	78.33 (17.00)
LS Mean of Change from Baseline (SE)	-2.91 (1.89)	2.08 (1.99)	1.11 (1.50)
95% CI	(-6.64, 0.83)	(-1.84, 6.00)	(-1.86, 4.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.01 (2.34)	0.97 (2.46)	
95% CI	(-8.62, 0.60)	(-3.88, 5.82)	
p-value	0.0878	0.6926	
Corrected Hedge's g Statistics	-0.329	0.081	
95% CI	(-0.72, 0.06)	(-0.33, 0.49)	
Subgroup*Treatment Interaction p-value	0.4394	0.7715	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Effects of Liver Disease			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	78.44 (10.79)	77.37 (16.22)	79.07 (12.93)
Analysis Visit Mean (SD)	78.59 (11.87)	77.54 (12.63)	78.72 (13.97)
LS Mean of Change from Baseline (SE)	-0.36 (1.73)	-0.85 (1.90)	-0.52 (1.35)
95% CI	(-3.78, 3.06)	(-4.59, 2.90)	(-3.18, 2.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.16 (2.15)	-0.32 (2.30)	
95% CI	(-4.08, 4.40)	(-4.87, 4.22)	
p-value	0.9406	0.8881	
Corrected Hedge's g Statistics	0.013	-0.027	
95% CI	(-0.35, 0.38)	(-0.42, 0.36)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	78.26 (11.22)	78.53 (16.41)	80.21 (12.40)
Analysis Visit Mean (SD)	77.70 (12.01)	76.58 (12.63)	78.13 (11.72)
LS Mean of Change from Baseline (SE)	-1.25 (1.69)	-2.37 (1.77)	-1.78 (1.36)
95% CI	(-4.60, 2.09)	(-5.87, 1.13)	(-4.46, 0.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.52 (2.12)	-0.60 (2.21)	
95% CI	(-3.66, 4.70)	(-4.96, 3.77)	
p-value	0.8054	0.7878	
Corrected Hedge's g Statistics	0.048	-0.055	
95% CI	(-0.34, 0.44)	(-0.46, 0.35)	
Subgroup*Treatment Interaction p-value	0.7189	0.7679	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Concentration/Memory			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	78.34 (23.70)	81.44 (19.63)	81.59 (19.60)
Analysis Visit Mean (SD)	77.94 (23.95)	78.97 (21.91)	79.51 (24.62)
LS Mean of Change from Baseline (SE)	-0.63 (2.41)	-2.01 (2.62)	-1.79 (1.88)
95% CI	(-5.39, 4.14)	(-7.18, 3.16)	(-5.49, 1.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.16 (2.98)	-0.23 (3.18)	
95% CI	(-4.72, 7.04)	(-6.51, 6.06)	
p-value	0.6977	0.9434	
Corrected Hedge's g Statistics	0.070	-0.014	
95% CI	(-0.29, 0.43)	(-0.40, 0.37)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	78.00 (23.56)	82.49 (19.06)	82.84 (18.12)
Analysis Visit Mean (SD)	78.74 (19.57)	79.19 (22.01)	77.95 (23.35)
LS Mean of Change from Baseline (SE)	0.22 (2.14)	-2.81 (2.23)	-4.20 (1.71)
95% CI	(-4.02, 4.45)	(-7.22, 1.61)	(-7.57, -0.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.41 (2.65)	1.39 (2.77)	
95% CI	(-0.82, 9.64)	(-4.07, 6.85)	
p-value	0.0975	0.6160	
Corrected Hedge's g Statistics	0.319	0.102	
95% CI	(-0.07, 0.71)	(-0.31, 0.51)	
Subgroup*Treatment Interaction p-value	0.0632	0.8443	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Health Distress			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	75.53 (27.95)	78.29 (24.95)	78.53 (24.83)
Analysis Visit Mean (SD)	81.91 (24.56)	84.87 (19.53)	86.06 (23.49)
LS Mean of Change from Baseline (SE)	5.59 (2.55)	6.53 (2.75)	7.75 (1.98)
95% CI	(0.56, 10.62)	(1.10, 11.96)	(3.84, 11.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.16 (3.12)	-1.22 (3.34)	
95% CI	(-8.32, 4.00)	(-7.81, 5.37)	
p-value	0.4899	0.7155	
Corrected Hedge's g Statistics	-0.123	-0.070	
95% CI	(-0.49, 0.24)	(-0.46, 0.32)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	78.87 (26.69)	79.17 (24.46)	79.49 (25.04)
Analysis Visit Mean (SD)	78.57 (25.64)	88.54 (18.99)	84.77 (23.20)
LS Mean of Change from Baseline (SE)	-0.04 (2.79)	9.24 (2.93)	5.59 (2.23)
95% CI	(-5.54, 5.46)	(3.46, 15.02)	(1.19, 9.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.63 (3.46)	3.66 (3.63)	
95% CI	(-12.46, 1.21)	(-3.52, 10.83)	
p-value	0.1061	0.3158	
Corrected Hedge's g Statistics	-0.312	0.205	
95% CI	(-0.70, 0.08)	(-0.20, 0.61)	
Subgroup*Treatment Interaction p-value	0.5495	0.9571	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Sexual Function			
Week 24			
m	49	43	83
n	16	16	25
Baseline Mean (SD)	87.08 (15.63)	84.68 (17.71)	85.47 (16.95)
Analysis Visit Mean (SD)	87.19 (13.76)	77.39 (23.10)	88.20 (13.03)
LS Mean of Change from Baseline (SE)	1.50 (3.33)	-8.62 (3.39)	2.24 (2.66)
95% CI	(-5.17, 8.17)	(-15.41, -1.84)	(-3.09, 7.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.74 (4.28)	-10.86 (4.29)	
95% CI	(-9.32, 7.84)	(-19.46, -2.27)	
p-value	0.8638	0.0141	
Corrected Hedge's g Statistics	-0.054	-0.795	
95% CI	(-0.68, 0.57)	(-1.45, -0.14)	
Week 52			
m	47	38	75
n	13	12	19
Baseline Mean (SD)	85.88 (19.59)	89.99 (11.10)	86.93 (17.02)
Analysis Visit Mean (SD)	89.74 (13.99)	88.47 (19.14)	82.90 (20.63)
LS Mean of Change from Baseline (SE)	4.08 (4.71)	-0.10 (4.90)	-4.35 (3.85)
95% CI	(-5.35, 13.51)	(-9.93, 9.72)	(-12.06, 3.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.43 (6.07)	4.24 (6.23)	
95% CI	(-3.73, 20.59)	(-8.23, 16.72)	
p-value	0.1704	0.4985	
Corrected Hedge's g Statistics	0.487	0.245	
95% CI	(-0.23, 1.20)	(-0.48, 0.97)	
Subgroup*Treatment Interaction p-value	0.3309	0.1674	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Sleep			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	68.09 (19.15)	53.42 (18.75)	64.36 (20.34)
Analysis Visit Mean (SD)	67.02 (22.43)	55.26 (23.04)	63.21 (19.92)
LS Mean of Change from Baseline (SE)	0.06 (2.26)	-0.62 (2.48)	-0.92 (1.75)
95% CI	(-4.41, 4.53)	(-5.52, 4.28)	(-4.37, 2.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.98 (2.76)	0.29 (3.01)	
95% CI	(-4.46, 6.42)	(-5.64, 6.23)	
p-value	0.7233	0.9220	
Corrected Hedge's g Statistics	0.063	0.019	
95% CI	(-0.30, 0.42)	(-0.37, 0.41)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	69.29 (18.27)	55.56 (18.89)	63.98 (21.07)
Analysis Visit Mean (SD)	65.39 (18.38)	54.72 (22.71)	64.06 (20.02)
LS Mean of Change from Baseline (SE)	-1.97 (2.39)	-3.38 (2.53)	0.50 (1.88)
95% CI	(-6.70, 2.75)	(-8.38, 1.63)	(-3.22, 4.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.47 (2.94)	-3.88 (3.13)	
95% CI	(-8.28, 3.33)	(-10.05, 2.30)	
p-value	0.4014	0.2170	
Corrected Hedge's g Statistics	-0.161	-0.254	
95% CI	(-0.55, 0.23)	(-0.66, 0.16)	
Subgroup*Treatment Interaction p-value	0.3180	0.8954	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Loneliness			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	85.53 (17.17)	83.82 (21.98)	83.75 (20.12)
Analysis Visit Mean (SD)	86.06 (17.35)	86.45 (17.39)	80.96 (22.69)
LS Mean of Change from Baseline (SE)	0.64 (2.33)	2.57 (2.52)	-3.09 (1.81)
95% CI	(-3.96, 5.24)	(-2.40, 7.54)	(-6.68, 0.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.73 (2.86)	5.67 (3.06)	
95% CI	(-1.92, 9.38)	(-0.37, 11.71)	
p-value	0.1938	0.0657	
Corrected Hedge's g Statistics	0.232	0.355	
95% CI	(-0.13, 0.59)	(-0.04, 0.75)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	86.19 (16.67)	82.50 (22.28)	83.79 (20.58)
Analysis Visit Mean (SD)	85.12 (15.16)	82.78 (23.44)	83.05 (21.60)
LS Mean of Change from Baseline (SE)	-0.81 (2.46)	-0.48 (2.59)	-1.74 (1.96)
95% CI	(-5.68, 4.05)	(-5.59, 4.62)	(-5.62, 2.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.93 (3.05)	1.26 (3.21)	
95% CI	(-5.10, 6.96)	(-5.07, 7.58)	
p-value	0.7619	0.6957	
Corrected Hedge's g Statistics	0.058	0.080	
95% CI	(-0.33, 0.45)	(-0.33, 0.49)	
Subgroup*Treatment Interaction p-value	0.1742	0.6105	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Hopelessness			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	73.05 (24.34)	74.99 (22.52)	81.84 (19.77)
Analysis Visit Mean (SD)	77.66 (24.65)	77.19 (20.39)	79.54 (22.19)
LS Mean of Change from Baseline (SE)	3.58 (2.70)	0.95 (2.90)	-0.13 (2.11)
95% CI	(-1.75, 8.91)	(-4.77, 6.68)	(-4.30, 4.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.71 (3.33)	1.09 (3.54)	
95% CI	(-2.87, 10.29)	(-5.91, 8.08)	
p-value	0.2671	0.7596	
Corrected Hedge's g Statistics	0.198	0.059	
95% CI	(-0.16, 0.56)	(-0.33, 0.45)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	74.80 (23.10)	75.68 (23.19)	82.81 (19.41)
Analysis Visit Mean (SD)	78.18 (23.28)	76.86 (19.83)	77.86 (24.27)
LS Mean of Change from Baseline (SE)	3.50 (3.10)	0.89 (3.27)	-2.71 (2.50)
95% CI	(-2.62, 9.63)	(-5.56, 7.35)	(-7.65, 2.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.21 (3.90)	3.60 (4.08)	
95% CI	(-1.48, 13.91)	(-4.46, 11.66)	
p-value	0.1127	0.3788	
Corrected Hedge's g Statistics	0.308	0.180	
95% CI	(-0.08, 0.70)	(-0.23, 0.59)	
Subgroup*Treatment Interaction p-value	0.4006	0.1268	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Stigma of Liver Disease			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	82.20 (20.10)	80.12 (20.08)	86.40 (17.58)
Analysis Visit Mean (SD)	85.39 (19.99)	78.15 (21.24)	86.08 (19.66)
LS Mean of Change from Baseline (SE)	2.84 (2.21)	-2.80 (2.40)	0.51 (1.72)
95% CI	(-1.52, 7.19)	(-7.55, 1.95)	(-2.89, 3.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.32 (2.73)	-3.31 (2.94)	
95% CI	(-3.07, 7.72)	(-9.11, 2.49)	
p-value	0.3964	0.2609	
Corrected Hedge's g Statistics	0.152	-0.218	
95% CI	(-0.21, 0.51)	(-0.61, 0.17)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	83.94 (20.05)	80.75 (20.34)	85.08 (18.38)
Analysis Visit Mean (SD)	87.66 (16.81)	81.45 (19.27)	87.91 (16.95)
LS Mean of Change from Baseline (SE)	3.60 (1.96)	-0.79 (2.05)	2.80 (1.56)
95% CI	(-0.27, 7.47)	(-4.84, 3.25)	(-0.28, 5.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.80 (2.42)	-3.59 (2.54)	
95% CI	(-3.97, 5.57)	(-8.61, 1.43)	
p-value	0.7408	0.1596	
Corrected Hedge's g Statistics	0.063	-0.287	
95% CI	(-0.33, 0.45)	(-0.70, 0.12)	
Subgroup*Treatment Interaction p-value	0.8563	0.5353	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Symptoms of Liver Disease			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	76.47 (20.50)	77.00 (17.32)	76.77 (17.71)
Analysis Visit Mean (SD)	76.08 (19.83)	75.47 (17.50)	76.27 (19.04)
LS Mean of Change from Baseline (SE)	-0.32 (1.56)	-1.38 (1.81)	-0.64 (1.18)
95% CI	(-3.39, 2.75)	(-4.94, 2.17)	(-2.96, 1.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.32 (1.92)	-0.75 (2.12)	
95% CI	(-3.46, 4.10)	(-4.93, 3.43)	
p-value	0.8688	0.7248	
Corrected Hedge's g Statistics	0.025	-0.058	
95% CI	(-0.27, 0.32)	(-0.39, 0.27)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	78.74 (19.11)	77.61 (17.07)	76.50 (16.99)
Analysis Visit Mean (SD)	77.43 (18.31)	78.65 (16.56)	77.40 (18.52)
LS Mean of Change from Baseline (SE)	-0.94 (1.59)	0.61 (1.90)	1.01 (1.22)
95% CI	(-4.08, 2.20)	(-3.13, 4.35)	(-1.39, 3.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.95 (1.97)	-0.40 (2.22)	
95% CI	(-5.83, 1.93)	(-4.78, 3.97)	
p-value	0.3242	0.8567	
Corrected Hedge's g Statistics	-0.155	-0.032	
95% CI	(-0.47, 0.16)	(-0.39, 0.33)	
Subgroup*Treatment Interaction p-value	0.4394	0.7715	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Effects of Liver Disease			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	78.05 (13.19)	82.67 (12.34)	77.12 (15.18)
Analysis Visit Mean (SD)	75.59 (14.14)	80.14 (10.39)	77.57 (15.01)
LS Mean of Change from Baseline (SE)	-2.65 (1.45)	-0.63 (1.70)	-0.23 (1.10)
95% CI	(-5.51, 0.21)	(-3.97, 2.72)	(-2.40, 1.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.42 (1.79)	-0.40 (2.00)	
95% CI	(-5.94, 1.10)	(-4.34, 3.54)	
p-value	0.1769	0.8417	
Corrected Hedge's g Statistics	-0.201	-0.033	
95% CI	(-0.50, 0.10)	(-0.36, 0.30)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	78.15 (13.06)	81.11 (12.40)	77.34 (13.03)
Analysis Visit Mean (SD)	76.72 (12.27)	80.32 (10.51)	77.49 (13.69)
LS Mean of Change from Baseline (SE)	-1.89 (1.60)	0.96 (1.93)	-0.63 (1.23)
95% CI	(-5.05, 1.26)	(-2.84, 4.77)	(-3.05, 1.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.26 (1.99)	1.60 (2.26)	
95% CI	(-5.17, 2.65)	(-2.86, 6.06)	
p-value	0.5268	0.4807	
Corrected Hedge's g Statistics	-0.100	0.127	
95% CI	(-0.42, 0.22)	(-0.23, 0.48)	
Subgroup*Treatment Interaction p-value	0.7189	0.7679	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Concentration/Memory			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	83.66 (20.62)	80.64 (19.12)	78.30 (21.47)
Analysis Visit Mean (SD)	79.52 (21.65)	80.39 (18.86)	80.90 (19.56)
LS Mean of Change from Baseline (SE)	-2.92 (1.63)	-0.18 (1.88)	2.10 (1.23)
95% CI	(-6.13, 0.29)	(-3.88, 3.52)	(-0.32, 4.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.02 (2.01)	-2.28 (2.21)	
95% CI	(-8.98, -1.07)	(-6.63, 2.07)	
p-value	0.0131	0.3033	
Corrected Hedge's g Statistics	-0.373	-0.170	
95% CI	(-0.67, -0.07)	(-0.50, 0.16)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	83.42 (20.62)	79.19 (19.35)	78.05 (21.08)
Analysis Visit Mean (SD)	80.14 (19.28)	78.44 (20.05)	78.83 (21.23)
LS Mean of Change from Baseline (SE)	-3.04 (1.69)	-0.09 (2.00)	0.55 (1.29)
95% CI	(-6.36, 0.28)	(-4.04, 3.85)	(-1.99, 3.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.59 (2.09)	-0.64 (2.34)	
95% CI	(-7.70, 0.53)	(-5.25, 3.97)	
p-value	0.0870	0.7852	
Corrected Hedge's g Statistics	-0.271	-0.048	
95% CI	(-0.59, 0.05)	(-0.41, 0.31)	
Subgroup*Treatment Interaction p-value	0.0632	0.8443	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Health Distress			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	77.21 (26.62)	80.75 (26.99)	82.84 (21.97)
Analysis Visit Mean (SD)	83.82 (23.06)	86.50 (23.40)	86.33 (20.35)
LS Mean of Change from Baseline (SE)	4.79 (2.07)	5.42 (2.39)	3.89 (1.57)
95% CI	(0.71, 8.87)	(0.71, 10.13)	(0.81, 6.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.90 (2.55)	1.53 (2.81)	
95% CI	(-4.12, 5.92)	(-4.00, 7.06)	
p-value	0.7241	0.5871	
Corrected Hedge's g Statistics	0.053	0.090	
95% CI	(-0.25, 0.35)	(-0.24, 0.42)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	76.23 (27.45)	82.14 (26.36)	83.57 (20.61)
Analysis Visit Mean (SD)	82.99 (23.39)	85.12 (23.30)	87.14 (18.79)
LS Mean of Change from Baseline (SE)	3.60 (2.40)	3.69 (2.86)	4.72 (1.83)
95% CI	(-1.13, 8.33)	(-1.94, 9.31)	(1.11, 8.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.12 (2.98)	-1.03 (3.34)	
95% CI	(-6.99, 4.76)	(-7.62, 5.56)	
p-value	0.7087	0.7587	
Corrected Hedge's g Statistics	-0.059	-0.055	
95% CI	(-0.37, 0.26)	(-0.41, 0.30)	
Subgroup*Treatment Interaction p-value	0.5495	0.9571	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Sexual Function			
Week 24			
m	72	58	135
n	27	26	50
Baseline Mean (SD)	70.69 (32.42)	83.77 (20.23)	78.70 (25.10)
Analysis Visit Mean (SD)	78.52 (27.78)	77.31 (26.88)	80.17 (22.12)
LS Mean of Change from Baseline (SE)	5.77 (3.66)	-4.88 (3.67)	1.01 (2.69)
95% CI	(-1.48, 13.03)	(-12.15, 2.39)	(-4.32, 6.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.76 (4.45)	-5.89 (4.44)	
95% CI	(-4.06, 13.58)	(-14.69, 2.92)	
p-value	0.2871	0.1878	
Corrected Hedge's g Statistics	0.248	-0.308	
95% CI	(-0.22, 0.72)	(-0.78, 0.17)	
Week 52			
m	69	51	128
n	21	24	41
Baseline Mean (SD)	80.41 (31.80)	78.25 (25.74)	73.98 (27.09)
Analysis Visit Mean (SD)	87.46 (20.22)	75.18 (29.39)	74.91 (26.56)
LS Mean of Change from Baseline (SE)	6.72 (4.08)	-3.01 (3.92)	-0.73 (2.96)
95% CI	(-1.38, 14.81)	(-10.78, 4.75)	(-6.59, 5.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.44 (4.96)	-2.28 (4.82)	
95% CI	(-2.38, 17.27)	(-11.85, 7.28)	
p-value	0.1361	0.6367	
Corrected Hedge's g Statistics	0.390	-0.119	
95% CI	(-0.14, 0.92)	(-0.62, 0.39)	
Subgroup*Treatment Interaction p-value	0.3309	0.1674	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Sleep			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	59.63 (22.99)	66.00 (16.60)	63.47 (19.81)
Analysis Visit Mean (SD)	62.35 (20.60)	61.10 (17.00)	63.31 (20.88)
LS Mean of Change from Baseline (SE)	1.64 (1.79)	-4.23 (2.07)	-0.10 (1.35)
95% CI	(-1.90, 5.17)	(-8.31, -0.15)	(-2.77, 2.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.74 (2.20)	-4.13 (2.43)	
95% CI	(-2.60, 6.07)	(-8.92, 0.66)	
p-value	0.4309	0.0907	
Corrected Hedge's g Statistics	0.117	-0.280	
95% CI	(-0.18, 0.42)	(-0.61, 0.05)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	60.98 (22.11)	65.60 (17.64)	63.52 (19.54)
Analysis Visit Mean (SD)	63.93 (18.53)	61.67 (20.80)	63.38 (19.85)
LS Mean of Change from Baseline (SE)	2.63 (1.92)	-2.62 (2.29)	-0.30 (1.46)
95% CI	(-1.16, 6.42)	(-7.13, 1.89)	(-3.18, 2.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.93 (2.37)	-2.33 (2.68)	
95% CI	(-1.75, 7.60)	(-7.60, 2.95)	
p-value	0.2191	0.3856	
Corrected Hedge's g Statistics	0.194	-0.155	
95% CI	(-0.12, 0.51)	(-0.51, 0.20)	
Subgroup*Treatment Interaction p-value	0.3180	0.8954	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Loneliness			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	85.59 (18.48)	85.20 (17.84)	84.70 (19.73)
Analysis Visit Mean (SD)	83.35 (20.17)	85.90 (20.57)	84.11 (18.55)
LS Mean of Change from Baseline (SE)	-2.27 (1.73)	0.41 (2.01)	-1.00 (1.31)
95% CI	(-5.68, 1.14)	(-3.54, 4.37)	(-3.59, 1.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.27 (2.13)	1.41 (2.36)	
95% CI	(-5.48, 2.93)	(-3.25, 6.07)	
p-value	0.5512	0.5511	
Corrected Hedge's g Statistics	-0.089	0.099	
95% CI	(-0.39, 0.21)	(-0.23, 0.43)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	85.00 (19.13)	82.38 (19.07)	84.67 (20.17)
Analysis Visit Mean (SD)	84.10 (19.78)	83.45 (20.44)	84.81 (18.37)
LS Mean of Change from Baseline (SE)	-1.37 (1.80)	-0.18 (2.16)	-0.01 (1.38)
95% CI	(-4.92, 2.19)	(-4.44, 4.08)	(-2.73, 2.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.36 (2.23)	-0.17 (2.53)	
95% CI	(-5.76, 3.04)	(-5.15, 4.81)	
p-value	0.5424	0.9458	
Corrected Hedge's g Statistics	-0.096	-0.012	
95% CI	(-0.41, 0.22)	(-0.37, 0.35)	
Subgroup*Treatment Interaction p-value	0.1742	0.6105	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Hopelessness			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	78.92 (21.38)	78.00 (22.95)	77.33 (21.82)
Analysis Visit Mean (SD)	81.25 (21.43)	76.50 (24.15)	79.31 (20.38)
LS Mean of Change from Baseline (SE)	2.15 (2.04)	-2.12 (2.36)	1.35 (1.54)
95% CI	(-1.86, 6.16)	(-6.77, 2.52)	(-1.69, 4.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.81 (2.51)	-3.47 (2.78)	
95% CI	(-4.13, 5.75)	(-8.94, 2.00)	
p-value	0.7482	0.2125	
Corrected Hedge's g Statistics	0.048	-0.206	
95% CI	(-0.25, 0.35)	(-0.54, 0.13)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	79.24 (21.50)	77.78 (24.12)	77.14 (21.90)
Analysis Visit Mean (SD)	79.78 (19.57)	76.39 (21.45)	79.37 (20.64)
LS Mean of Change from Baseline (SE)	0.74 (2.01)	-1.79 (2.40)	1.48 (1.54)
95% CI	(-3.23, 4.70)	(-6.52, 2.94)	(-1.55, 4.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.74 (2.49)	-3.26 (2.81)	
95% CI	(-5.64, 4.15)	(-8.79, 2.26)	
p-value	0.7655	0.2458	
Corrected Hedge's g Statistics	-0.047	-0.207	
95% CI	(-0.36, 0.27)	(-0.57, 0.15)	
Subgroup*Treatment Interaction p-value	0.4006	0.1268	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Stigma of Liver Disease			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	80.44 (22.28)	81.65 (20.45)	82.47 (19.72)
Analysis Visit Mean (SD)	82.74 (20.82)	82.27 (20.37)	85.33 (18.30)
LS Mean of Change from Baseline (SE)	1.80 (1.88)	0.60 (2.17)	3.01 (1.42)
95% CI	(-1.90, 5.49)	(-3.68, 4.88)	(0.21, 5.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.21 (2.31)	-2.41 (2.56)	
95% CI	(-5.77, 3.34)	(-7.45, 2.63)	
p-value	0.5998	0.3469	
Corrected Hedge's g Statistics	-0.078	-0.156	
95% CI	(-0.38, 0.22)	(-0.49, 0.18)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	81.98 (21.16)	80.68 (21.28)	81.85 (18.93)
Analysis Visit Mean (SD)	87.00 (18.58)	85.24 (17.28)	83.23 (20.11)
LS Mean of Change from Baseline (SE)	5.11 (1.89)	4.13 (2.26)	1.72 (1.45)
95% CI	(1.38, 8.84)	(-0.33, 8.59)	(-1.13, 4.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.39 (2.34)	2.40 (2.65)	
95% CI	(-1.22, 8.00)	(-2.81, 7.62)	
p-value	0.1488	0.3646	
Corrected Hedge's g Statistics	0.228	0.162	
95% CI	(-0.09, 0.54)	(-0.20, 0.52)	
Subgroup*Treatment Interaction p-value	0.8563	0.5353	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Symptoms of Liver Disease			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	76.67 (18.70)	70.26 (19.87)	77.17 (18.94)
Analysis Visit Mean (SD)	74.69 (21.72)	67.57 (17.70)	76.67 (22.92)
LS Mean of Change from Baseline (SE)	-1.24 (2.91)	-3.90 (2.96)	-0.76 (2.35)
95% CI	(-7.01, 4.52)	(-9.77, 1.96)	(-5.43, 3.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.48 (3.57)	-3.14 (3.62)	
95% CI	(-7.57, 6.61)	(-10.33, 4.05)	
p-value	0.8932	0.3884	
Corrected Hedge's g Statistics	-0.031	-0.200	
95% CI	(-0.51, 0.45)	(-0.68, 0.28)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	76.20 (19.67)	71.43 (16.26)	77.25 (19.96)
Analysis Visit Mean (SD)	76.04 (21.48)	71.11 (17.20)	78.33 (23.40)
LS Mean of Change from Baseline (SE)	0.42 (3.12)	-1.38 (3.15)	-0.01 (2.37)
95% CI	(-5.77, 6.62)	(-7.62, 4.87)	(-4.71, 4.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.43 (3.77)	-1.37 (3.79)	
95% CI	(-7.04, 7.91)	(-8.89, 6.16)	
p-value	0.9084	0.7194	
Corrected Hedge's g Statistics	0.029	-0.091	
95% CI	(-0.50, 0.56)	(-0.62, 0.44)	
Subgroup*Treatment Interaction p-value	0.4394	0.7715	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Effects of Liver Disease			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	78.52 (12.58)	75.38 (15.53)	77.63 (14.37)
Analysis Visit Mean (SD)	74.33 (11.94)	78.59 (6.27)	76.44 (13.97)
LS Mean of Change from Baseline (SE)	-2.06 (2.33)	2.38 (2.35)	0.12 (1.91)
95% CI	(-6.69, 2.56)	(-2.29, 7.05)	(-3.67, 3.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.18 (2.85)	2.26 (2.85)	
95% CI	(-7.83, 3.46)	(-3.40, 7.92)	
p-value	0.4445	0.4296	
Corrected Hedge's g Statistics	-0.172	0.179	
95% CI	(-0.65, 0.31)	(-0.31, 0.66)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	80.00 (7.60)	77.14 (16.42)	77.01 (14.87)
Analysis Visit Mean (SD)	78.73 (11.29)	76.51 (13.26)	78.01 (17.23)
LS Mean of Change from Baseline (SE)	3.17 (3.28)	-0.23 (3.27)	0.83 (2.47)
95% CI	(-3.34, 9.67)	(-6.71, 6.26)	(-4.07, 5.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.34 (3.99)	-1.05 (3.97)	
95% CI	(-5.58, 10.25)	(-8.93, 6.83)	
p-value	0.5589	0.7917	
Corrected Hedge's g Statistics	0.150	-0.067	
95% CI	(-0.38, 0.68)	(-0.60, 0.46)	
Subgroup*Treatment Interaction p-value	0.7189	0.7679	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Concentration/Memory			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	77.10 (24.87)	72.86 (23.16)	76.82 (21.71)
Analysis Visit Mean (SD)	78.96 (21.38)	76.94 (19.43)	78.08 (22.20)
LS Mean of Change from Baseline (SE)	2.69 (3.14)	2.35 (3.16)	1.50 (2.55)
95% CI	(-3.55, 8.93)	(-3.92, 8.62)	(-3.56, 6.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.20 (3.84)	0.86 (3.85)	
95% CI	(-6.43, 8.82)	(-6.79, 8.50)	
p-value	0.7560	0.8249	
Corrected Hedge's g Statistics	0.070	0.051	
95% CI	(-0.41, 0.55)	(-0.43, 0.53)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	76.21 (23.68)	78.00 (20.49)	75.95 (23.06)
Analysis Visit Mean (SD)	78.00 (21.43)	77.10 (20.37)	78.61 (23.42)
LS Mean of Change from Baseline (SE)	1.14 (3.56)	-0.62 (3.56)	1.89 (2.72)
95% CI	(-5.92, 8.19)	(-7.68, 6.44)	(-3.51, 7.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.75 (4.30)	-2.51 (4.29)	
95% CI	(-9.28, 7.78)	(-11.03, 6.02)	
p-value	0.8619	0.5608	
Corrected Hedge's g Statistics	-0.044	-0.147	
95% CI	(-0.57, 0.48)	(-0.68, 0.38)	
Subgroup*Treatment Interaction p-value	0.0632	0.8443	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Health Distress			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	84.26 (24.41)	83.65 (23.12)	77.78 (27.29)
Analysis Visit Mean (SD)	84.72 (20.02)	87.02 (18.19)	84.44 (24.01)
LS Mean of Change from Baseline (SE)	2.80 (3.41)	4.84 (3.42)	5.93 (2.78)
95% CI	(-3.96, 9.57)	(-1.95, 11.62)	(0.41, 11.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.13 (4.19)	-1.09 (4.19)	
95% CI	(-11.44, 5.19)	(-9.41, 7.22)	
p-value	0.4571	0.7946	
Corrected Hedge's g Statistics	-0.169	-0.059	
95% CI	(-0.65, 0.31)	(-0.54, 0.42)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	84.52 (18.92)	86.31 (24.97)	77.50 (28.19)
Analysis Visit Mean (SD)	93.45 (14.04)	86.90 (16.99)	82.81 (26.05)
LS Mean of Change from Baseline (SE)	9.70 (4.04)	5.28 (4.04)	3.15 (3.09)
95% CI	(1.68, 17.72)	(-2.75, 13.30)	(-2.97, 9.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.55 (4.92)	2.13 (4.92)	
95% CI	(-3.20, 16.31)	(-7.64, 11.89)	
p-value	0.1857	0.6664	
Corrected Hedge's g Statistics	0.337	0.109	
95% CI	(-0.19, 0.87)	(-0.42, 0.64)	
Subgroup*Treatment Interaction p-value	0.5495	0.9571	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Sexual Function			
Week 24			
m	30	28	54
n	10	11	15
Baseline Mean (SD)	88.83 (26.34)	70.14 (29.20)	84.45 (20.98)
Analysis Visit Mean (SD)	71.50 (34.00)	76.96 (17.79)	77.77 (29.59)
LS Mean of Change from Baseline (SE)	-13.67 (7.93)	2.25 (7.96)	-5.49 (7.73)
95% CI	(-29.80, 2.45)	(-13.92, 18.43)	(-21.20, 10.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.19 (10.11)	7.74 (10.16)	
95% CI	(-28.74, 12.37)	(-12.91, 28.38)	
p-value	0.4239	0.4515	
Corrected Hedge's g Statistics	-0.281	0.263	
95% CI	(-1.09, 0.52)	(-0.52, 1.04)	
Week 52			
m	26	25	52
n	8	6	14
Baseline Mean (SD)	87.70 (29.53)	74.98 (18.55)	83.81 (22.11)
Analysis Visit Mean (SD)	78.96 (33.33)	81.10 (24.37)	82.05 (29.39)
LS Mean of Change from Baseline (SE)	-5.09 (8.29)	3.82 (9.23)	-1.85 (7.67)
95% CI	(-21.93, 11.76)	(-14.94, 22.58)	(-17.44, 13.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.23 (10.30)	5.67 (10.92)	
95% CI	(-24.17, 17.71)	(-16.52, 27.87)	
p-value	0.7556	0.6068	
Corrected Hedge's g Statistics	-0.115	0.200	
95% CI	(-0.98, 0.75)	(-0.76, 1.16)	
Subgroup*Treatment Interaction p-value	0.3309	0.1674	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Sleep			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	64.07 (16.82)	53.27 (21.95)	62.97 (20.65)
Analysis Visit Mean (SD)	60.56 (16.13)	54.04 (18.60)	63.11 (19.49)
LS Mean of Change from Baseline (SE)	-2.35 (2.62)	-2.31 (2.67)	0.12 (2.13)
95% CI	(-7.54, 2.85)	(-7.61, 2.99)	(-4.10, 4.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.47 (3.20)	-2.43 (3.28)	
95% CI	(-8.83, 3.89)	(-8.93, 4.07)	
p-value	0.4429	0.4592	
Corrected Hedge's g Statistics	-0.174	-0.171	
95% CI	(-0.65, 0.30)	(-0.66, 0.31)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	65.71 (18.53)	55.00 (24.65)	63.10 (22.51)
Analysis Visit Mean (SD)	65.00 (22.64)	59.29 (16.38)	68.25 (24.09)
LS Mean of Change from Baseline (SE)	0.87 (3.14)	1.99 (3.17)	4.31 (2.36)
95% CI	(-5.37, 7.10)	(-4.29, 8.27)	(-0.37, 8.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.44 (3.79)	-2.32 (3.83)	
95% CI	(-10.96, 4.08)	(-9.92, 5.27)	
p-value	0.3656	0.5451	
Corrected Hedge's g Statistics	-0.231	-0.155	
95% CI	(-0.76, 0.30)	(-0.68, 0.37)	
Subgroup*Treatment Interaction p-value	0.3180	0.8954	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Loneliness			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	78.70 (19.79)	80.96 (20.98)	84.00 (19.53)
Analysis Visit Mean (SD)	80.93 (18.76)	79.81 (20.86)	82.00 (23.46)
LS Mean of Change from Baseline (SE)	0.11 (3.26)	-2.65 (3.28)	-2.34 (2.63)
95% CI	(-6.37, 6.59)	(-9.15, 3.86)	(-7.56, 2.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.45 (4.03)	-0.30 (4.03)	
95% CI	(-5.55, 10.46)	(-8.31, 7.70)	
p-value	0.5443	0.9401	
Corrected Hedge's g Statistics	0.140	-0.017	
95% CI	(-0.34, 0.62)	(-0.50, 0.47)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	79.29 (21.52)	82.38 (22.06)	82.75 (19.64)
Analysis Visit Mean (SD)	86.67 (15.19)	81.67 (22.38)	82.13 (20.66)
LS Mean of Change from Baseline (SE)	5.83 (3.23)	-1.01 (3.23)	-2.03 (2.45)
95% CI	(-0.58, 12.24)	(-7.42, 5.40)	(-6.89, 2.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.87 (3.89)	1.03 (3.88)	
95% CI	(0.15, 15.58)	(-6.67, 8.72)	
p-value	0.0458	0.7917	
Corrected Hedge's g Statistics	0.509	0.066	
95% CI	(-0.03, 1.04)	(-0.46, 0.59)	
Subgroup*Treatment Interaction p-value	0.1742	0.6105	

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Hopelessness			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	76.87 (21.48)	73.40 (23.92)	82.41 (18.66)
Analysis Visit Mean (SD)	72.53 (20.78)	78.84 (24.18)	79.26 (22.09)
LS Mean of Change from Baseline (SE)	-4.41 (3.57)	3.68 (3.63)	-1.13 (2.93)
95% CI	(-11.50, 2.68)	(-3.52, 10.88)	(-6.94, 4.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.28 (4.42)	4.81 (4.48)	
95% CI	(-12.04, 5.49)	(-4.07, 13.70)	
p-value	0.4600	0.2852	
Corrected Hedge's g Statistics	-0.168	0.247	
95% CI	(-0.65, 0.31)	(-0.24, 0.73)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	79.38 (19.48)	74.60 (25.75)	81.25 (20.40)
Analysis Visit Mean (SD)	79.37 (22.91)	77.39 (27.27)	77.09 (25.30)
LS Mean of Change from Baseline (SE)	2.39 (4.36)	2.82 (4.38)	-3.23 (3.27)
95% CI	(-6.25, 11.04)	(-5.88, 11.52)	(-9.72, 3.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.62 (5.28)	6.05 (5.31)	
95% CI	(-4.85, 16.09)	(-4.49, 16.60)	
p-value	0.2895	0.2575	
Corrected Hedge's g Statistics	0.271	0.291	
95% CI	(-0.26, 0.80)	(-0.24, 0.82)	
Subgroup*Treatment Interaction p-value	0.4006	0.1268	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.14c.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Stigma of Liver Disease			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	87.98 (15.49)	79.10 (18.87)	83.91 (20.40)
Analysis Visit Mean (SD)	90.98 (14.53)	81.75 (17.75)	85.30 (17.58)
LS Mean of Change from Baseline (SE)	6.49 (2.73)	2.38 (2.77)	3.92 (2.22)
95% CI	(1.06, 11.91)	(-3.12, 7.89)	(-0.49, 8.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.56 (3.36)	-1.54 (3.37)	
95% CI	(-4.11, 9.23)	(-8.22, 5.14)	
p-value	0.4476	0.6478	
Corrected Hedge's g Statistics	0.173	-0.104	
95% CI	(-0.31, 0.65)	(-0.59, 0.38)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	87.51 (15.18)	80.97 (19.51)	83.30 (21.62)
Analysis Visit Mean (SD)	88.11 (15.03)	82.16 (24.06)	84.08 (19.71)
LS Mean of Change from Baseline (SE)	4.20 (3.38)	1.09 (3.39)	2.12 (2.54)
95% CI	(-2.52, 10.91)	(-5.64, 7.83)	(-2.93, 7.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.08 (4.10)	-1.03 (4.09)	
95% CI	(-6.06, 10.22)	(-9.13, 7.08)	
p-value	0.6135	0.8025	
Corrected Hedge's g Statistics	0.129	-0.064	
95% CI	(-0.40, 0.66)	(-0.59, 0.46)	
Subgroup*Treatment Interaction p-value	0.8563	0.5353	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.9)	1 (2.2)	1 (1.1)
No	52 (98.1)	44 (97.8)	89 (98.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.49	
95% CI of the inverse odds ratio	(0.04, 9.54)	(0.03, 8.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.50	
95% CI of the inverse risk ratio	(0.04, 9.22)	(0.03, 7.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.78	1.11	
95% CI of the absolute risk difference	(-3.48, 5.03)	(-3.71, 5.93)	
p-value	0.7028	0.6144	
p-value of Breslow-Day Test for Homogeneity [3]	0.3744	0.4967	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (18.9)	8 (17.8)	14 (15.6)
No	43 (81.1)	37 (82.2)	76 (84.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.85	
95% CI of the inverse odds ratio	(0.32, 1.94)	(0.33, 2.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.88	
95% CI of the inverse risk ratio	(0.39, 1.72)	(0.40, 1.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.31	2.22	
95% CI of the absolute risk difference	(-9.61, 16.24)	(-11.23, 15.67)	
p-value	0.6087	0.7417	
p-value of Breslow-Day Test for Homogeneity [3]	0.9528	0.9572	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.8)	7 (15.6)	6 (6.7)
No	51 (96.2)	38 (84.4)	84 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.82	0.39	
95% CI of the inverse odds ratio	(0.35, 9.37)	(0.12, 1.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	0.43	
95% CI of the inverse risk ratio	(0.37, 8.44)	(0.15, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.89	8.89	
95% CI of the absolute risk difference	(-10.16, 4.38)	(-2.89, 20.67)	
p-value	0.4672	0.0989	
p-value of Breslow-Day Test for Homogeneity [3]	0.3544	0.5148	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (15.1)	14 (31.1)	21 (23.3)
No	45 (84.9)	31 (68.9)	69 (76.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	0.67	
95% CI of the inverse odds ratio	(0.70, 4.20)	(0.30, 1.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	0.75	
95% CI of the inverse risk ratio	(0.74, 3.24)	(0.42, 1.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.24	7.78	
95% CI of the absolute risk difference	(-21.25, 4.77)	(-8.33, 23.88)	
p-value	0.2366	0.3310	
p-value of Breslow-Day Test for Homogeneity [3]	0.6312	0.5439	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.8)	3 (6.7)	2 (2.2)
No	51 (96.2)	42 (93.3)	88 (97.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.32	
95% CI of the inverse odds ratio	(0.08, 4.24)	(0.05, 1.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.33	
95% CI of the inverse risk ratio	(0.09, 4.06)	(0.06, 1.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.55	4.44	
95% CI of the absolute risk difference	(-4.41, 7.52)	(-3.45, 12.34)	
p-value	0.5869	0.1974	
p-value of Breslow-Day Test for Homogeneity [3]	0.1785	0.1204	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (22.6)	9 (20.0)	11 (12.2)
No	41 (77.4)	36 (80.0)	79 (87.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	0.56	
95% CI of the inverse odds ratio	(0.19, 1.17)	(0.21, 1.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	0.61	
95% CI of the inverse risk ratio	(0.26, 1.14)	(0.27, 1.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.42	7.78	
95% CI of the absolute risk difference	(-2.72, 23.56)	(-5.73, 21.28)	
p-value	0.1014	0.2305	
p-value of Breslow-Day Test for Homogeneity [3]	0.0556	0.1888	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (9.4)	1 (2.2)	2 (2.2)
No	48 (90.6)	44 (97.8)	88 (97.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	1.00	
95% CI of the inverse odds ratio	(0.04, 1.17)	(0.09, 11.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.24	1.00	
95% CI of the inverse risk ratio	(0.05, 1.17)	(0.09, 10.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.21	0.00	
95% CI of the absolute risk difference	(-1.23, 15.65)	(-5.27, 5.27)	
p-value	0.0536	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.0654	0.8789	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (22.6)	9 (20.0)	14 (15.6)
No	41 (77.4)	36 (80.0)	76 (84.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.74	
95% CI of the inverse odds ratio	(0.27, 1.49)	(0.29, 1.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.78	
95% CI of the inverse risk ratio	(0.34, 1.37)	(0.36, 1.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.09	4.44	
95% CI of the absolute risk difference	(-6.44, 20.61)	(-9.44, 18.32)	
p-value	0.2887	0.5173	
p-value of Breslow-Day Test for Homogeneity [3]	0.3614	0.4201	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (11.3)	11 (24.4)	14 (15.6)
No	47 (88.7)	34 (75.6)	76 (84.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	0.57	
95% CI of the inverse odds ratio	(0.52, 4.01)	(0.23, 1.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.37	0.64	
95% CI of the inverse risk ratio	(0.56, 3.36)	(0.31, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.23	8.89	
95% CI of the absolute risk difference	(-15.59, 7.12)	(-5.73, 23.51)	
p-value	0.4807	0.2101	
p-value of Breslow-Day Test for Homogeneity [3]	0.5384	0.3936	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (17.0)	16 (35.6)	23 (25.6)
No	44 (83.0)	29 (64.4)	67 (74.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.68	0.62	
95% CI of the inverse odds ratio	(0.71, 3.96)	(0.29, 1.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	0.72	
95% CI of the inverse risk ratio	(0.75, 3.01)	(0.42, 1.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.57	10.00	
95% CI of the absolute risk difference	(-22.12, 4.97)	(-6.64, 26.64)	
p-value	0.2347	0.2269	
p-value of Breslow-Day Test for Homogeneity [3]	0.2501	0.2259	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.9)	2 (4.4)	3 (3.3)
No	52 (98.1)	43 (95.6)	87 (96.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.79	0.74	
95% CI of the inverse odds ratio	(0.18, 17.69)	(0.12, 4.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	0.75	
95% CI of the inverse risk ratio	(0.19, 16.55)	(0.13, 4.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.45	1.11	
95% CI of the absolute risk difference	(-6.66, 3.77)	(-5.96, 8.18)	
p-value	0.6124	0.7473	
p-value of Breslow-Day Test for Homogeneity [3]	0.6954	0.5092	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (7.5)	3 (6.7)	6 (6.7)
No	49 (92.5)	42 (93.3)	84 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	1.00	
95% CI of the inverse odds ratio	(0.24, 3.25)	(0.24, 4.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	1.00	
95% CI of the inverse risk ratio	(0.26, 2.99)	(0.26, 3.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.88	0.00	
95% CI of the absolute risk difference	(-7.90, 9.66)	(-8.93, 8.93)	
p-value	0.8419	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.7578	0.7960	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (11.3)	9 (20.0)	17 (18.9)
No	47 (88.7)	36 (80.0)	73 (81.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.82	0.93	
95% CI of the inverse odds ratio	(0.67, 4.96)	(0.38, 2.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	0.94	
95% CI of the inverse risk ratio	(0.70, 3.97)	(0.46, 1.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.57	1.11	
95% CI of the absolute risk difference	(-19.32, 4.19)	(-13.10, 15.32)	
p-value	0.2341	0.8773	
p-value of Breslow-Day Test for Homogeneity [3]	0.4337	0.0312	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (20.8)	16 (35.6)	27 (30.0)
No	42 (79.2)	29 (64.4)	63 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.64	0.78	
95% CI of the inverse odds ratio	(0.73, 3.65)	(0.36, 1.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	0.84	
95% CI of the inverse risk ratio	(0.78, 2.67)	(0.51, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.25	5.56	
95% CI of the absolute risk difference	(-23.70, 5.21)	(-11.33, 22.44)	
p-value	0.2267	0.5137	
p-value of Breslow-Day Test for Homogeneity [3]	0.2330	0.2605	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (9.4)	8 (17.8)	10 (11.1)
No	48 (90.6)	37 (82.2)	80 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	0.58	
95% CI of the inverse odds ratio	(0.39, 3.72)	(0.21, 1.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.63	
95% CI of the inverse risk ratio	(0.43, 3.26)	(0.26, 1.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.68	6.67	
95% CI of the absolute risk difference	(-11.88, 8.52)	(-6.25, 19.59)	
p-value	0.7519	0.2827	
p-value of Breslow-Day Test for Homogeneity [3]	0.2549	0.9110	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (18.9)	13 (28.9)	23 (25.6)
No	43 (81.1)	32 (71.1)	67 (74.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.48	0.85	
95% CI of the inverse odds ratio	(0.64, 3.40)	(0.38, 1.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	0.88	
95% CI of the inverse risk ratio	(0.70, 2.62)	(0.50, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.69	3.33	
95% CI of the absolute risk difference	(-20.55, 7.17)	(-12.68, 19.35)	
p-value	0.3593	0.6797	
p-value of Breslow-Day Test for Homogeneity [3]	0.4984	0.7646	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (20.8)	12 (26.7)	11 (12.2)
No	42 (79.2)	33 (73.3)	79 (87.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	0.38	
95% CI of the inverse odds ratio	(0.21, 1.33)	(0.15, 0.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.46	
95% CI of the inverse risk ratio	(0.27, 1.26)	(0.22, 0.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.53	14.44	
95% CI of the absolute risk difference	(-4.31, 21.38)	(-0.14, 29.03)	
p-value	0.1720	0.0353	
p-value of Breslow-Day Test for Homogeneity [3]	0.7633	0.0585	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (30.2)	14 (31.1)	17 (18.9)
No	37 (69.8)	31 (68.9)	73 (81.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	0.52	
95% CI of the inverse odds ratio	(0.24, 1.19)	(0.23, 1.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.61	
95% CI of the inverse risk ratio	(0.35, 1.13)	(0.33, 1.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.30	12.22	
95% CI of the absolute risk difference	(-3.47, 26.07)	(-3.54, 27.98)	
p-value	0.1214	0.1115	
p-value of Breslow-Day Test for Homogeneity [3]	0.4118	0.1261	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (11.3)	4 (8.9)	13 (14.4)
No	47 (88.7)	41 (91.1)	77 (85.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	1.73	
95% CI of the inverse odds ratio	(0.47, 3.72)	(0.53, 5.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	1.63	
95% CI of the inverse risk ratio	(0.52, 3.16)	(0.56, 4.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.12	-5.56	
95% CI of the absolute risk difference	(-14.33, 8.08)	(-16.60, 5.48)	
p-value	0.5951	0.3590	
p-value of Breslow-Day Test for Homogeneity [3]	0.6579	0.3551	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (30.2)	11 (24.4)	27 (30.0)
No	37 (69.8)	34 (75.6)	63 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.32	
95% CI of the inverse odds ratio	(0.47, 2.08)	(0.59, 2.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.23	
95% CI of the inverse risk ratio	(0.59, 1.67)	(0.67, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.19	-5.56	
95% CI of the absolute risk difference	(-15.38, 15.76)	(-21.28, 10.17)	
p-value	0.9810	0.4986	
p-value of Breslow-Day Test for Homogeneity [3]	0.1949	0.5133	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (5.6)	1 (1.5)	6 (4.3)
No	68 (94.4)	64 (98.5)	133 (95.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	2.89	
95% CI of the inverse odds ratio	(0.21, 2.81)	(0.34, 24.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	2.81	
95% CI of the inverse risk ratio	(0.23, 2.67)	(0.34, 22.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.24	-2.78	
95% CI of the absolute risk difference	(-5.04, 7.52)	(-7.29, 1.73)	
p-value	0.6880	0.3098	
p-value of Breslow-Day Test for Homogeneity [3]	0.3744	0.4967	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (23.6)	13 (20.0)	28 (20.1)
No	55 (76.4)	52 (80.0)	111 (79.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.01	
95% CI of the inverse odds ratio	(0.41, 1.62)	(0.48, 2.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.01	
95% CI of the inverse risk ratio	(0.50, 1.45)	(0.56, 1.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.47	-0.14	
95% CI of the absolute risk difference	(-8.39, 15.33)	(-11.93, 11.65)	
p-value	0.5599	0.9809	
p-value of Breslow-Day Test for Homogeneity [3]	0.9528	0.9572	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (5.6)	6 (9.2)	11 (7.9)
No	68 (94.4)	59 (90.8)	128 (92.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.46	0.85	
95% CI of the inverse odds ratio	(0.45, 4.76)	(0.30, 2.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	0.86	
95% CI of the inverse risk ratio	(0.47, 4.32)	(0.33, 2.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.36	1.32	
95% CI of the absolute risk difference	(-9.30, 4.58)	(-7.03, 9.66)	
p-value	0.5274	0.7511	
p-value of Breslow-Day Test for Homogeneity [3]	0.3544	0.5148	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (27.8)	16 (24.6)	39 (28.1)
No	52 (72.2)	49 (75.4)	100 (71.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.19	
95% CI of the inverse odds ratio	(0.54, 1.91)	(0.61, 2.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.14	
95% CI of the inverse risk ratio	(0.64, 1.60)	(0.69, 1.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.28	-3.44	
95% CI of the absolute risk difference	(-13.04, 12.48)	(-16.30, 9.42)	
p-value	0.9658	0.6057	
p-value of Breslow-Day Test for Homogeneity [3]	0.6312	0.5439	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.8)	3 (4.6)	16 (11.5)
No	70 (97.2)	62 (95.4)	123 (88.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.55	2.69	
95% CI of the inverse odds ratio	(1.02, 20.38)	(0.75, 9.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.14	2.49	
95% CI of the inverse risk ratio	(0.98, 17.53)	(0.75, 8.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.73	-6.90	
95% CI of the absolute risk difference	(-15.26, -2.21)	(-14.26, 0.46)	
p-value	0.0313	0.1143	
p-value of Breslow-Day Test for Homogeneity [3]	0.1785	0.1204	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (13.9)	10 (15.4)	33 (23.7)
No	62 (86.1)	55 (84.6)	106 (76.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.93	1.71	
95% CI of the inverse odds ratio	(0.89, 4.18)	(0.79, 3.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	1.54	
95% CI of the inverse risk ratio	(0.89, 3.27)	(0.81, 2.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.85	-8.36	
95% CI of the absolute risk difference	(-20.52, 0.82)	(-19.62, 2.91)	
p-value	0.0921	0.1727	
p-value of Breslow-Day Test for Homogeneity [3]	0.0556	0.1888	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.2)	4 (6.2)	11 (7.9)
No	69 (95.8)	61 (93.8)	128 (92.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.98	1.31	
95% CI of the inverse odds ratio	(0.53, 7.32)	(0.40, 4.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.90	1.29	
95% CI of the inverse risk ratio	(0.55, 6.59)	(0.43, 3.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.75	-1.76	
95% CI of the absolute risk difference	(-10.18, 2.69)	(-9.13, 5.61)	
p-value	0.2998	0.6536	
p-value of Breslow-Day Test for Homogeneity [3]	0.0654	0.8789	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (18.1)	18 (27.7)	33 (23.7)
No	59 (81.9)	47 (72.3)	106 (76.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	0.81	
95% CI of the inverse odds ratio	(0.69, 2.89)	(0.42, 1.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	0.86	
95% CI of the inverse risk ratio	(0.74, 2.34)	(0.52, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.69	3.95	
95% CI of the absolute risk difference	(-17.04, 5.67)	(-9.02, 16.93)	
p-value	0.3430	0.5437	
p-value of Breslow-Day Test for Homogeneity [3]	0.3614	0.4201	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (20.8)	8 (12.3)	22 (15.8)
No	57 (79.2)	57 (87.7)	117 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.34	
95% CI of the inverse odds ratio	(0.34, 1.48)	(0.56, 3.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	1.29	
95% CI of the inverse risk ratio	(0.42, 1.37)	(0.61, 2.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.01	-3.52	
95% CI of the absolute risk difference	(-6.17, 16.18)	(-13.55, 6.51)	
p-value	0.3646	0.5084	
p-value of Breslow-Day Test for Homogeneity [3]	0.5384	0.3936	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (26.4)	11 (16.9)	34 (24.5)
No	53 (73.6)	54 (83.1)	105 (75.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.59	
95% CI of the inverse odds ratio	(0.47, 1.73)	(0.75, 3.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.45	
95% CI of the inverse risk ratio	(0.57, 1.50)	(0.78, 2.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.93	-7.54	
95% CI of the absolute risk difference	(-10.51, 14.37)	(-19.12, 4.05)	
p-value	0.7594	0.2264	
p-value of Breslow-Day Test for Homogeneity [3]	0.2501	0.2259	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.2)	2 (3.1)	8 (5.8)
No	69 (95.8)	63 (96.9)	131 (94.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.92	
95% CI of the inverse odds ratio	(0.36, 5.46)	(0.40, 9.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	1.87	
95% CI of the inverse risk ratio	(0.38, 5.05)	(0.41, 8.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-2.68	
95% CI of the absolute risk difference	(-7.61, 4.44)	(-8.39, 3.03)	
p-value	0.6226	0.4090	
p-value of Breslow-Day Test for Homogeneity [3]	0.6954	0.5092	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (6.9)	6 (9.2)	15 (10.8)
No	67 (93.1)	59 (90.8)	124 (89.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	1.19	
95% CI of the inverse odds ratio	(0.56, 4.65)	(0.44, 3.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	1.17	
95% CI of the inverse risk ratio	(0.59, 4.10)	(0.48, 2.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.85	-1.56	
95% CI of the absolute risk difference	(-11.66, 3.97)	(-10.29, 7.16)	
p-value	0.3657	0.7325	
p-value of Breslow-Day Test for Homogeneity [3]	0.7578	0.7960	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (18.1)	3 (4.6)	21 (15.1)
No	59 (81.9)	62 (95.4)	118 (84.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	3.68	
95% CI of the inverse odds ratio	(0.38, 1.73)	(1.06, 12.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	3.27	
95% CI of the inverse risk ratio	(0.45, 1.57)	(1.01, 10.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.95	-10.49	
95% CI of the absolute risk difference	(-7.75, 13.64)	(-18.33, -2.65)	
p-value	0.5808	0.0302	
p-value of Breslow-Day Test for Homogeneity [3]	0.4337	0.0312	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (36.1)	13 (20.0)	43 (30.9)
No	46 (63.9)	52 (80.0)	96 (69.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	1.79	
95% CI of the inverse odds ratio	(0.43, 1.44)	(0.88, 3.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.55	
95% CI of the inverse risk ratio	(0.58, 1.27)	(0.90, 2.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.18	-10.94	
95% CI of the absolute risk difference	(-8.32, 18.67)	(-23.33, 1.46)	
p-value	0.4473	0.1029	
p-value of Breslow-Day Test for Homogeneity [3]	0.2330	0.2605	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (11.1)	11 (16.9)	14 (10.1)
No	64 (88.9)	54 (83.1)	125 (89.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	0.55	
95% CI of the inverse odds ratio	(0.36, 2.25)	(0.23, 1.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.60	
95% CI of the inverse risk ratio	(0.40, 2.06)	(0.29, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.04	6.85	
95% CI of the absolute risk difference	(-7.78, 9.86)	(-3.55, 17.25)	
p-value	0.8148	0.1644	
p-value of Breslow-Day Test for Homogeneity [3]	0.2549	0.9110	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (25.0)	17 (26.2)	40 (28.8)
No	54 (75.0)	48 (73.8)	99 (71.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.14	
95% CI of the inverse odds ratio	(0.63, 2.32)	(0.59, 2.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.10	
95% CI of the inverse risk ratio	(0.71, 1.86)	(0.68, 1.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.78	-2.62	
95% CI of the absolute risk difference	(-16.29, 8.74)	(-15.69, 10.45)	
p-value	0.5601	0.6972	
p-value of Breslow-Day Test for Homogeneity [3]	0.4984	0.7646	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (20.8)	10 (15.4)	24 (17.3)
No	57 (79.2)	55 (84.6)	115 (82.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	1.15	
95% CI of the inverse odds ratio	(0.39, 1.63)	(0.51, 2.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	1.12	
95% CI of the inverse risk ratio	(0.46, 1.48)	(0.57, 2.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.57	-1.88	
95% CI of the absolute risk difference	(-7.72, 14.86)	(-12.67, 8.91)	
p-value	0.5268	0.7369	
p-value of Breslow-Day Test for Homogeneity [3]	0.7633	0.0585	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (26.4)	15 (23.1)	38 (27.3)
No	53 (73.6)	50 (76.9)	101 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.25	
95% CI of the inverse odds ratio	(0.55, 2.00)	(0.63, 2.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.18	
95% CI of the inverse risk ratio	(0.65, 1.66)	(0.70, 1.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.95	-4.26	
95% CI of the absolute risk difference	(-13.54, 11.64)	(-16.90, 8.38)	
p-value	0.8830	0.5178	
p-value of Breslow-Day Test for Homogeneity [3]	0.4118	0.1261	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (13.9)	8 (12.3)	15 (10.8)
No	62 (86.1)	57 (87.7)	124 (89.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.86	
95% CI of the inverse odds ratio	(0.32, 1.77)	(0.35, 2.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.88	
95% CI of the inverse risk ratio	(0.37, 1.64)	(0.39, 1.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.10	1.52	
95% CI of the absolute risk difference	(-6.41, 12.61)	(-7.99, 11.02)	
p-value	0.5092	0.7497	
p-value of Breslow-Day Test for Homogeneity [3]	0.6579	0.3551	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (41.7)	19 (29.2)	38 (27.3)
No	42 (58.3)	46 (70.8)	101 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	0.91	
95% CI of the inverse odds ratio	(0.29, 0.96)	(0.47, 1.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.94	
95% CI of the inverse risk ratio	(0.45, 0.96)	(0.59, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.33	1.89	
95% CI of the absolute risk difference	(0.74, 27.91)	(-11.42, 15.20)	
p-value	0.0347	0.7789	
p-value of Breslow-Day Test for Homogeneity [3]	0.1949	0.5133	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (7.1)	3 (5.3)
No	30 (100)	26 (92.9)	54 (94.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.92	0.72	
95% CI of the inverse odds ratio	(0.20, 78.38)	(0.11, 4.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.74	0.74	
95% CI of the inverse risk ratio	(0.20, 70.13)	(0.13, 4.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.42	1.88	
95% CI of the absolute risk difference	(-11.99, 3.14)	(-9.28, 13.04)	
p-value	0.3374	0.7292	
p-value of Breslow-Day Test for Homogeneity [3]	0.3744	0.4967	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	7 (25.0)	13 (22.8)
No	23 (76.7)	21 (75.0)	44 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.89	
95% CI of the inverse odds ratio	(0.34, 2.77)	(0.31, 2.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.91	
95% CI of the inverse risk ratio	(0.44, 2.19)	(0.41, 2.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.53	2.19	
95% CI of the absolute risk difference	(-18.12, 19.17)	(-17.19, 21.58)	
p-value	0.9558	0.8227	
p-value of Breslow-Day Test for Homogeneity [3]	0.9528	0.9572	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	3 (10.7)	6 (10.5)
No	30 (100)	25 (89.3)	51 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.70	0.98	
95% CI of the inverse odds ratio	(0.42, 141.48)	(0.23, 4.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	6.95	0.98	
95% CI of the inverse risk ratio	(0.40, 119.31)	(0.27, 3.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.59	0.19	
95% CI of the absolute risk difference	(-18.84, -0.34)	(-13.77, 14.14)	
p-value	0.1092	0.9789	
p-value of Breslow-Day Test for Homogeneity [3]	0.3544	0.5148	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	8 (28.6)	14 (24.6)
No	23 (76.7)	20 (71.4)	43 (75.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.81	
95% CI of the inverse odds ratio	(0.38, 3.02)	(0.29, 2.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.86	
95% CI of the inverse risk ratio	(0.48, 2.32)	(0.41, 1.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.23	4.01	
95% CI of the absolute risk difference	(-20.04, 17.59)	(-16.11, 24.13)	
p-value	0.8988	0.6916	
p-value of Breslow-Day Test for Homogeneity [3]	0.6312	0.5439	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.3)	2 (7.1)	7 (12.3)
No	29 (96.7)	26 (92.9)	50 (87.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.06	1.82	
95% CI of the inverse odds ratio	(0.48, 34.67)	(0.35, 9.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.68	1.72	
95% CI of the inverse risk ratio	(0.48, 28.56)	(0.38, 7.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.95	-5.14	
95% CI of the absolute risk difference	(-19.62, 1.72)	(-17.93, 7.65)	
p-value	0.1698	0.4693	
p-value of Breslow-Day Test for Homogeneity [3]	0.1785	0.1204	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (16.7)	5 (17.9)	13 (22.8)
No	25 (83.3)	23 (82.1)	44 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.48	1.36	
95% CI of the inverse odds ratio	(0.47, 4.63)	(0.43, 4.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.37	1.28	
95% CI of the inverse risk ratio	(0.54, 3.47)	(0.51, 3.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.14	-4.95	
95% CI of the absolute risk difference	(-23.36, 11.08)	(-22.84, 12.94)	
p-value	0.5016	0.5996	
p-value of Breslow-Day Test for Homogeneity [3]	0.0556	0.1888	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (20.0)	3 (10.7)	5 (8.8)
No	24 (80.0)	25 (89.3)	52 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	0.80	
95% CI of the inverse odds ratio	(0.11, 1.39)	(0.18, 3.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	0.82	
95% CI of the inverse risk ratio	(0.15, 1.32)	(0.21, 3.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.23	1.94	
95% CI of the absolute risk difference	(-4.86, 27.32)	(-11.67, 15.55)	
p-value	0.1342	0.7732	
p-value of Breslow-Day Test for Homogeneity [3]	0.0654	0.8789	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (26.7)	5 (17.9)	16 (28.1)
No	22 (73.3)	23 (82.1)	41 (71.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.80	
95% CI of the inverse odds ratio	(0.40, 2.90)	(0.58, 5.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.57	
95% CI of the inverse risk ratio	(0.51, 2.17)	(0.64, 3.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.40	-10.21	
95% CI of the absolute risk difference	(-21.06, 18.26)	(-28.58, 8.15)	
p-value	0.8893	0.3049	
p-value of Breslow-Day Test for Homogeneity [3]	0.3614	0.4201	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (16.7)	4 (14.3)	8 (14.0)
No	25 (83.3)	24 (85.7)	49 (86.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.98	
95% CI of the inverse odds ratio	(0.24, 2.76)	(0.27, 3.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.98	
95% CI of the inverse risk ratio	(0.30, 2.35)	(0.32, 2.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.63	0.25	
95% CI of the absolute risk difference	(-13.47, 18.73)	(-15.54, 16.04)	
p-value	0.7435	0.9751	
p-value of Breslow-Day Test for Homogeneity [3]	0.5384	0.3936	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (30.0)	6 (21.4)	11 (19.3)
No	21 (70.0)	22 (78.6)	46 (80.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.88	
95% CI of the inverse odds ratio	(0.20, 1.55)	(0.29, 2.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.90	
95% CI of the inverse risk ratio	(0.30, 1.38)	(0.37, 2.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.70	2.13	
95% CI of the absolute risk difference	(-8.63, 30.04)	(-16.20, 20.46)	
p-value	0.2595	0.8175	
p-value of Breslow-Day Test for Homogeneity [3]	0.2501	0.2259	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (7.1)	2 (3.5)
No	30 (100)	26 (92.9)	55 (96.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.47	
95% CI of the inverse odds ratio	NE	(0.06, 3.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.49	
95% CI of the inverse risk ratio	NE	(0.07, 3.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.51	3.63	
95% CI of the absolute risk difference	(-8.29, 1.27)	(-7.03, 14.30)	
p-value	0.2993	0.4571	
p-value of Breslow-Day Test for Homogeneity [3]	0.6954	0.5092	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (6.7)	3 (10.7)	4 (7.0)
No	28 (93.3)	25 (89.3)	53 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.63	
95% CI of the inverse odds ratio	(0.18, 6.13)	(0.13, 3.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.65	
95% CI of the inverse risk ratio	(0.20, 5.42)	(0.16, 2.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.35	3.70	
95% CI of the absolute risk difference	(-11.47, 10.77)	(-9.54, 16.93)	
p-value	0.9510	0.5601	
p-value of Breslow-Day Test for Homogeneity [3]	0.7578	0.7960	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	7 (25.0)	7 (12.3)
No	27 (90.0)	21 (75.0)	50 (87.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	0.42	
95% CI of the inverse odds ratio	(0.30, 5.27)	(0.13, 1.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	0.49	
95% CI of the inverse risk ratio	(0.34, 4.41)	(0.19, 1.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.28	12.72	
95% CI of the absolute risk difference	(-15.99, 11.42)	(-5.44, 30.88)	
p-value	0.7512	0.1373	
p-value of Breslow-Day Test for Homogeneity [3]	0.4337	0.0312	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (26.7)	11 (39.3)	22 (38.6)
No	22 (73.3)	17 (60.7)	35 (61.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.73	0.97	
95% CI of the inverse odds ratio	(0.66, 4.56)	(0.38, 2.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	0.98	
95% CI of the inverse risk ratio	(0.73, 2.85)	(0.56, 1.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.93	0.69	
95% CI of the absolute risk difference	(-32.18, 8.32)	(-21.38, 22.76)	
p-value	0.2658	0.9511	
p-value of Breslow-Day Test for Homogeneity [3]	0.2330	0.2605	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (23.3)	3 (10.7)	5 (8.8)
No	23 (76.7)	25 (89.3)	52 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.32	0.80	
95% CI of the inverse odds ratio	(0.09, 1.10)	(0.18, 3.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	0.82	
95% CI of the inverse risk ratio	(0.13, 1.08)	(0.21, 3.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.56	1.94	
95% CI of the absolute risk difference	(-2.26, 31.38)	(-11.67, 15.55)	
p-value	0.0612	0.7732	
p-value of Breslow-Day Test for Homogeneity [3]	0.2549	0.9110	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (30.0)	5 (17.9)	13 (22.8)
No	21 (70.0)	23 (82.1)	44 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.36	
95% CI of the inverse odds ratio	(0.25, 1.87)	(0.43, 4.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	1.28	
95% CI of the inverse risk ratio	(0.37, 1.57)	(0.51, 3.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.19	-4.95	
95% CI of the absolute risk difference	(-12.49, 26.88)	(-22.84, 12.94)	
p-value	0.4632	0.5996	
p-value of Breslow-Day Test for Homogeneity [3]	0.4984	0.7646	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	8 (28.6)	5 (8.8)
No	27 (90.0)	20 (71.4)	52 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.24	
95% CI of the inverse odds ratio	(0.19, 3.90)	(0.07, 0.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.31	
95% CI of the inverse risk ratio	(0.22, 3.42)	(0.11, 0.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.23	19.80	
95% CI of the absolute risk difference	(-11.78, 14.23)	(1.53, 38.07)	
p-value	0.8505	0.0171	
p-value of Breslow-Day Test for Homogeneity [3]	0.7633	0.0585	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (26.7)	10 (35.7)	11 (19.3)
No	22 (73.3)	18 (64.3)	46 (80.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.43	
95% CI of the inverse odds ratio	(0.23, 1.87)	(0.16, 1.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.54	
95% CI of the inverse risk ratio	(0.33, 1.60)	(0.26, 1.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.37	16.42	
95% CI of the absolute risk difference	(-11.48, 26.22)	(-4.08, 36.91)	
p-value	0.4291	0.0991	
p-value of Breslow-Day Test for Homogeneity [3]	0.4118	0.1261	

AMNOG Table SE21.14c.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	4 (14.3)	4 (7.0)
No	27 (90.0)	24 (85.7)	53 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.45	
95% CI of the inverse odds ratio	(0.14, 3.26)	(0.10, 1.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	0.49	
95% CI of the inverse risk ratio	(0.17, 2.93)	(0.13, 1.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.98	7.27	
95% CI of the absolute risk difference	(-9.64, 15.60)	(-7.29, 21.83)	
p-value	0.6269	0.2808	
p-value of Breslow-Day Test for Homogeneity [3]	0.6579	0.3551	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (16.7)	9 (32.1)	13 (22.8)
No	25 (83.3)	19 (67.9)	44 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.48	0.62	
95% CI of the inverse odds ratio	(0.47, 4.63)	(0.23, 1.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.37	0.71	
95% CI of the inverse risk ratio	(0.54, 3.47)	(0.35, 1.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.14	9.34	
95% CI of the absolute risk difference	(-23.36, 11.08)	(-11.11, 29.78)	
p-value	0.5016	0.3557	
p-value of Breslow-Day Test for Homogeneity [3]	0.1949	0.5133	

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Total LDQOL						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	77.97 (14.51)	78.16 (13.67)	77.23 (14.21)			
Median	82.70	83.00	80.95			
IQR: Q1, Q3	70.80, 88.30	69.10, 88.30	66.90, 88.60			
Min, Max	29.0, 96.7	36.0, 96.3	38.5, 97.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	79.31 (14.10)	79.98 (12.51)	77.45 (13.79)	1.41 (0.97)	1.00 (0.84)	1.14 (0.87)
Median	82.20	81.90	79.70	0.90	0.75	0.40
IQR: Q1, Q3	71.80, 89.70	73.10, 89.20	68.30, 89.30	-4.90, 5.50	-2.50, 5.60	-3.50, 5.10
Min, Max	33.6, 97.8	41.4, 96.9	32.4, 98.8	-11.7, 35.6	-15.4, 17.7	-27.7, 42.3
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	79.53 (13.56)	79.08 (13.55)	78.91 (14.37)	0.82 (1.12)	0.85 (1.06)	1.34 (0.97)
Median	83.75	82.20	82.00	1.05	0.75	0.90
IQR: Q1, Q3	70.70, 90.30	70.60, 89.90	70.70, 89.80	-4.50, 5.70	-3.40, 3.90	-2.80, 5.90
Min, Max	34.0, 96.7	33.8, 95.6	20.3, 100.0	-17.8, 36.0	-23.3, 24.3	-46.3, 49.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Symptoms of Liver Disease						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	79.40 (19.45)	74.81 (19.20)	75.99 (18.20)			
Median	83.30	80.00	80.00			
IQR: Q1, Q3	70.00, 93.30	60.00, 90.00	63.30, 93.30			
Min, Max	23.3, 100.0	30.0, 100.0	20.0, 100.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	78.00 (18.63)	77.23 (17.17)	76.66 (19.11)	-1.16 (1.47)	1.64 (1.39)	0.99 (1.14)
Median	83.30	76.70	83.30	0	0	0
IQR: Q1, Q3	70.00, 93.30	66.70, 93.30	63.30, 93.30	-10.00, 3.40	-6.60, 6.70	-3.40, 6.70
Min, Max	26.7, 100.0	26.7, 100.0	16.7, 100.0	-26.7, 33.4	-36.6, 30.0	-43.3, 36.7
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	78.55 (18.30)	76.05 (19.25)	77.46 (19.76)	-2.24 (1.39)	1.30 (1.62)	0.95 (1.30)
Median	83.30	80.00	83.30	0	0	0
IQR: Q1, Q3	70.00, 93.30	66.70, 93.30	63.30, 93.30	-10.00, 6.60	-6.65, 6.70	-6.70, 6.70
Min, Max	23.3, 100.0	26.7, 100.0	23.3, 100.0	-33.3, 26.7	-33.3, 30.0	-60.0, 40.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Effects of Liver Disease						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	77.45 (14.73)	79.33 (13.31)	77.82 (14.35)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 86.70	73.30, 86.70	80.00, 86.70			
Min, Max	13.3, 100.0	26.7, 100.0	26.7, 100.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	77.62 (13.72)	80.71 (11.53)	78.15 (13.59)	-0.10 (1.43)	1.14 (1.42)	0.10 (1.37)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	80.00, 86.70	80.00, 86.70	80.00, 86.70	-6.70, 6.70	0.00, 6.70	-6.70, 6.70
Min, Max	20.0, 100.0	40.0, 100.0	26.7, 100.0	-40.0, 33.3	-20.0, 60.0	-46.7, 40.0
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	77.17 (11.72)	77.69 (14.80)	78.47 (13.90)	-1.44 (2.04)	-0.68 (1.44)	-0.12 (1.64)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	80.00, 80.00	80.00, 80.00	-6.70, 0.00	-6.70, 6.70	-6.70, 6.60
Min, Max	40.0, 100.0	20.0, 100.0	13.3, 100.0	-40.0, 80.0	-33.3, 30.0	-73.4, 53.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Concentration/Memory						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	80.92 (22.67)	79.61 (20.23)	77.63 (20.58)			
Median	87.50	87.50	81.30			
IQR: Q1, Q3	75.00, 100.00	68.80, 100.00	68.80, 93.80			
Min, Max	18.8, 100.0	25.0, 100.0	12.5, 100.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	81.62 (22.82)	82.77 (18.91)	77.90 (21.72)	1.27 (1.82)	1.52 (1.58)	1.19 (1.44)
Median	90.65	87.50	81.30	0	0	0
IQR: Q1, Q3	68.80, 100.00	75.00, 100.00	62.50, 100.00	-6.20, 6.30	-6.20, 6.30	-6.20, 6.30
Min, Max	0.0, 100.0	25.0, 100.0	6.3, 100.0	-43.8, 31.2	-31.2, 37.5	-50.0, 62.5
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	78.98 (21.25)	80.31 (19.45)	79.63 (21.09)	-1.72 (1.52)	0.00 (1.72)	1.33 (1.33)
Median	84.40	87.50	84.40	0	0	0
IQR: Q1, Q3	71.90, 93.80	68.80, 100.00	68.80, 100.00	-6.30, 6.20	-6.25, 6.30	-6.30, 6.30
Min, Max	0.0, 100.0	18.8, 100.0	0.0, 100.0	-25.0, 25.0	-37.5, 43.7	-31.3, 56.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Health Distress						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	78.60 (26.14)	84.49 (23.10)	81.34 (25.59)			
Median	87.50	100.00	100.00			
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	12.5, 100.0	0.0, 100.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	82.86 (22.64)	89.83 (18.91)	86.15 (22.46)	3.62 (2.13)	5.54 (2.04)	6.30 (1.82)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	12.5, 100.0	25.0, 100.0	0.0, 100.0	-50.0, 62.5	-37.5, 50.0	-62.5, 75.0
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	82.92 (25.00)	89.81 (19.87)	87.70 (21.50)	3.66 (3.01)	4.69 (2.39)	6.08 (2.01)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-75.0, 75.0	-37.5, 75.0	-62.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Sexual Function						
Baseline						
m	75	87	147			
n	30	40	59			
Mean (SD)	77.29 (28.55)	79.59 (23.68)	77.74 (27.02)			
Median	90.00	86.95	86.70			
IQR: Q1, Q3	63.30, 100.00	58.35, 100.00	68.30, 100.00			
Min, Max	8.9, 100.0	30.0, 100.0	-1.7, 100.0			
Week 24						
m	72	78	142			
n	29	38	55	24	32	40
Mean (SD/SE)	81.44 (22.07)	75.91 (28.82)	76.42 (25.97)	4.99 (5.31)	-6.15 (3.85)	-2.67 (2.80)
Median	85.00	89.15	85.00	0	0	0
IQR: Q1, Q3	76.70, 100.00	60.00, 100.00	63.30, 100.00	-8.30, 20.05	-15.85, 0.00	-8.30, 6.65
Min, Max	23.3, 100.0	-1.7, 100.0	-1.7, 100.0	-38.4, 91.1	-55.0, 46.7	-48.4, 38.3
Week 52						
m	64	70	135			
n	20	31	47	18	28	38
Mean (SD/SE)	86.00 (25.08)	78.95 (30.57)	75.03 (29.69)	3.68 (5.55)	0.16 (4.14)	-1.45 (3.46)
Median	96.65	100.00	93.30	0	0	0
IQR: Q1, Q3	82.50, 100.00	63.30, 100.00	53.30, 100.00	-5.00, 0.00	-3.60, 6.70	-8.30, 8.30
Min, Max	6.7, 100.0	-1.7, 100.0	-1.7, 100.0	-23.3, 91.1	-48.4, 61.7	-53.3, 63.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Sleep						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	63.77 (20.93)	62.85 (19.01)	61.90 (20.00)			
Median	65.00	65.00	60.00			
IQR: Q1, Q3	55.00, 80.00	50.00, 75.00	50.00, 75.00			
Min, Max	0.0, 100.0	0.0, 100.0	5.0, 100.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	66.93 (17.82)	61.53 (19.38)	60.50 (20.16)	2.61 (2.07)	-1.71 (1.54)	-0.29 (1.36)
Median	70.00	60.00	60.00	0	-5.00	0
IQR: Q1, Q3	50.00, 80.00	50.00, 75.00	45.00, 75.00	-5.00, 10.00	-10.00, 5.00	-10.00, 10.00
Min, Max	25.0, 100.0	10.0, 100.0	20.0, 100.0	-30.0, 90.0	-30.0, 40.0	-35.0, 50.0
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	66.50 (17.57)	60.92 (19.96)	63.11 (20.42)	1.29 (2.46)	-1.64 (1.99)	0.97 (1.58)
Median	67.50	65.00	60.00	0	-5.00	0
IQR: Q1, Q3	55.00, 80.00	45.00, 75.00	50.00, 80.00	-10.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	15.0, 100.0	10.0, 95.0	20.0, 100.0	-40.0, 75.0	-55.0, 45.0	-40.0, 55.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Loneliness						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	86.16 (15.98)	83.67 (17.84)	81.90 (21.22)			
Median	95.00	90.00	90.00			
IQR: Q1, Q3	80.00, 100.00	70.00, 100.00	75.00, 100.00			
Min, Max	35.0, 100.0	35.0, 100.0	5.0, 100.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	84.64 (17.82)	87.60 (17.03)	79.08 (22.46)	-0.94 (1.80)	1.57 (1.44)	-1.65 (1.69)
Median	90.00	95.00	85.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	80.00, 100.00	70.00, 100.00	-5.00, 5.00	-5.00, 10.00	-10.00, 5.00
Min, Max	35.0, 100.0	30.0, 100.0	10.0, 100.0	-45.0, 40.0	-25.0, 30.0	-60.0, 70.0
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	86.67 (17.19)	85.15 (17.87)	82.38 (20.79)	0.26 (2.02)	1.25 (2.00)	0.62 (1.64)
Median	95.00	90.00	90.00	0	0	0
IQR: Q1, Q3	80.00, 100.00	75.00, 100.00	70.00, 100.00	-5.00, 5.00	-7.50, 10.00	-5.00, 5.00
Min, Max	25.0, 100.0	35.0, 100.0	5.0, 100.0	-60.0, 50.0	-40.0, 35.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Hopelessness						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	74.44 (22.32)	77.32 (22.77)	78.61 (21.33)			
Median	75.00	83.30	83.30			
IQR: Q1, Q3	58.30, 91.70	58.30, 100.00	58.30, 100.00			
Min, Max	8.3, 100.0	33.3, 100.0	25.0, 100.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	76.19 (23.80)	79.56 (21.24)	76.51 (22.21)	2.77 (2.43)	2.15 (2.50)	-0.38 (1.67)
Median	83.30	91.70	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	58.30, 100.00	-8.40, 16.70	-8.30, 8.40	-8.30, 8.30
Min, Max	8.3, 100.0	33.3, 100.0	16.7, 100.0	-58.3, 50.0	-41.7, 58.4	-50.0, 50.0
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	77.09 (22.32)	77.70 (19.77)	78.76 (22.73)	2.44 (2.43)	0.27 (2.83)	-0.51 (1.72)
Median	83.30	75.00	87.50	0	0	0
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	58.30, 100.00	-8.30, 8.40	-16.60, 16.70	-8.30, 8.30
Min, Max	16.7, 100.0	33.3, 100.0	0.0, 100.0	-41.7, 41.7	-58.3, 50.0	-58.4, 41.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Stigma of Liver Disease						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	84.09 (20.85)	82.29 (19.39)	82.90 (20.43)			
Median	93.80	87.50	87.50			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	81.30, 100.00			
Min, Max	18.8, 100.0	31.3, 100.0	12.5, 100.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	86.36 (19.50)	83.77 (17.82)	85.07 (17.80)	1.63 (1.98)	1.34 (1.62)	2.89 (1.67)
Median	93.80	87.50	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	-6.20, 6.20	-6.20, 6.20	-6.20, 6.30
Min, Max	6.3, 100.0	31.3, 100.0	25.0, 100.0	-43.7, 43.8	-31.2, 37.5	-50.0, 75.0
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	87.52 (16.31)	85.03 (15.80)	86.24 (17.89)	1.62 (1.68)	2.65 (2.04)	3.04 (1.64)
Median	93.80	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	81.30, 100.00	-6.20, 6.20	-6.20, 12.50	0.00, 12.50
Min, Max	37.5, 100.0	43.8, 100.0	25.0, 100.0	-25.0, 37.5	-56.2, 50.0	-56.3, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Total LDQOL						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	77.05 (14.31)	75.18 (15.56)	78.49 (13.72)			
Median	78.30	80.40	82.55			
IQR: Q1, Q3	68.80, 88.70	64.20, 86.10	72.90, 87.90			
Min, Max	28.3, 96.5	23.6, 94.1	34.8, 97.8			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	77.14 (15.36)	74.65 (12.27)	79.74 (14.43)	0.28 (1.03)	0.09 (1.20)	0.24 (0.87)
Median	78.80	76.10	84.30	0.95	-1.20	0.35
IQR: Q1, Q3	69.10, 90.00	68.30, 83.90	74.90, 89.30	-5.00, 7.00	-6.70, 4.55	-3.50, 3.75
Min, Max	22.9, 97.2	32.4, 95.4	22.4, 98.3	-23.4, 24.2	-14.5, 27.0	-46.4, 29.7
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	78.85 (13.31)	77.08 (14.67)	78.79 (14.20)	1.30 (1.07)	0.34 (1.53)	-0.31 (0.83)
Median	81.50	79.80	82.30	0.90	0	-0.20
IQR: Q1, Q3	69.90, 89.10	67.40, 88.50	72.80, 89.20	-2.35, 6.80	-7.10, 6.80	-4.30, 4.70
Min, Max	44.6, 97.5	34.2, 97.4	34.3, 97.8	-19.5, 25.3	-19.2, 33.9	-36.2, 22.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Symptoms of Liver Disease						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	76.08 (19.34)	75.14 (18.33)	77.07 (17.62)			
Median	80.00	76.70	80.00			
IQR: Q1, Q3	66.70, 90.00	66.70, 90.00	66.70, 90.00			
Min, Max	13.3, 100.0	10.0, 100.0	23.3, 100.0			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	75.02 (21.48)	70.27 (18.52)	78.01 (19.36)	-1.55 (1.68)	-3.99 (1.63)	-0.61 (1.27)
Median	80.00	73.30	83.30	0	-3.30	0
IQR: Q1, Q3	63.30, 90.00	60.00, 80.00	66.70, 93.30	-10.00, 6.70	-11.65, 3.30	-8.35, 6.70
Min, Max	0.0, 100.0	26.7, 100.0	23.3, 100.0	-46.7, 36.7	-33.3, 30.0	-53.3, 43.3
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	76.31 (20.10)	77.21 (17.19)	78.33 (18.28)	-1.71 (1.67)	0.30 (2.17)	0.26 (1.14)
Median	83.30	80.00	83.30	0	0	0
IQR: Q1, Q3	65.00, 93.30	66.70, 90.00	70.00, 93.30	-8.35, 6.70	-6.70, 10.00	-6.60, 6.70
Min, Max	6.7, 100.0	36.7, 100.0	16.7, 100.0	-43.4, 43.4	-36.7, 36.7	-33.3, 23.3

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Effects of Liver Disease						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	77.73 (13.43)	77.52 (17.37)	76.90 (15.62)			
Median	80.00	80.00	80.00			
IQR: Q1, Q3	80.00, 80.00	73.30, 86.70	80.00, 80.00			
Min, Max	6.7, 100.0	13.3, 100.0	6.7, 100.0			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	74.64 (15.45)	77.43 (8.95)	76.64 (16.15)	-3.34 (1.29)	-0.30 (2.56)	-0.32 (1.27)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	73.30, 80.00	80.00, 80.00	-6.70, 0.00	-13.30, 0.00	-6.70, 6.60
Min, Max	0.0, 100.0	40.0, 100.0	6.7, 100.0	-40.0, 20.0	-33.3, 76.7	-46.6, 53.4
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	76.14 (14.53)	78.10 (8.50)	76.95 (13.17)	-1.21 (1.40)	-0.30 (2.36)	-0.34 (1.68)
Median	80.00	80.00	80.00	0	0	0
IQR: Q1, Q3	73.30, 80.00	73.30, 80.00	73.30, 80.00	-6.70, 0.00	-6.70, 0.00	-6.70, 6.60
Min, Max	6.7, 100.0	46.7, 100.0	20.0, 100.0	-40.0, 46.7	-33.3, 53.4	-80.0, 66.7

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Concentration/Memory						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	79.73 (23.67)	77.99 (21.34)	79.47 (21.06)			
Median	87.50	81.30	87.50			
IQR: Q1, Q3	68.80, 100.00	62.50, 93.80	68.80, 100.00			
Min, Max	6.3, 100.0	18.8, 100.0	6.3, 100.0			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	76.17 (22.11)	77.07 (20.05)	81.59 (21.54)	-3.81 (1.63)	-0.90 (2.25)	0.15 (1.42)
Median	81.30	75.00	87.50	0	0	0
IQR: Q1, Q3	62.50, 93.80	68.80, 93.80	75.00, 100.00	-12.50, 6.20	-6.30, 6.25	-6.20, 6.20
Min, Max	18.8, 100.0	25.0, 100.0	12.5, 100.0	-43.8, 31.2	-37.5, 56.2	-81.2, 62.5
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	79.13 (19.51)	78.59 (21.61)	78.44 (22.57)	0.00 (1.85)	-3.20 (2.38)	-2.44 (1.35)
Median	81.30	87.50	81.30	0	0	0
IQR: Q1, Q3	65.65, 100.00	62.50, 100.00	68.80, 100.00	-6.30, 6.20	-12.50, 6.20	-6.30, 6.20
Min, Max	18.8, 100.0	18.8, 100.0	12.5, 100.0	-43.7, 50.0	-43.8, 50.0	-43.8, 31.2

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Health Distress						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	77.79 (26.40)	76.27 (27.82)	80.82 (22.70)			
Median	87.50	75.00	87.50			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	83.19 (24.02)	83.20 (21.88)	85.40 (21.41)	6.86 (2.53)	6.92 (2.63)	4.10 (1.66)
Median	100.00	87.50	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 25.00	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-37.5, 75.0	-37.5, 50.0	-50.0, 62.5
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	83.22 (23.23)	83.42 (22.30)	84.94 (20.40)	5.90 (2.88)	6.39 (3.27)	2.39 (2.15)
Median	100.00	87.50	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 25.00	0.00, 25.00	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	12.5, 100.0	-50.0, 75.0	-50.0, 62.5	-87.5, 62.5

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Sexual Function						
Baseline						
m	92	64	156			
n	41	32	62			
Mean (SD)	81.17 (24.99)	79.26 (23.15)	81.37 (21.78)			
Median	93.30	85.00	86.70			
IQR: Q1, Q3	68.30, 100.00	68.30, 96.65	76.70, 100.00			
Min, Max	-1.7, 100.0	-1.7, 100.0	6.7, 100.0			
Week 24						
m	89	63	147			
n	43	39	70	33	27	54
Mean (SD/SE)	79.38 (25.38)	73.12 (27.17)	81.09 (21.26)	-0.70 (4.26)	-2.77 (3.81)	2.06 (2.57)
Median	91.70	76.70	89.20	0	0	0
IQR: Q1, Q3	61.70, 100.00	55.00, 100.00	68.30, 100.00	-1.60, 6.70	-16.60, 8.30	-6.70, 8.30
Min, Max	6.7, 100.0	-1.7, 100.0	6.7, 100.0	-85.0, 63.3	-48.3, 41.7	-46.7, 50.0
Week 52						
m	85	55	135			
n	33	26	54	28	19	42
Mean (SD/SE)	84.51 (19.00)	74.90 (26.82)	79.58 (22.01)	4.59 (4.24)	-6.93 (4.29)	-1.17 (3.19)
Median	93.30	81.65	85.00	0	0	0
IQR: Q1, Q3	76.70, 100.00	53.30, 100.00	68.30, 100.00	-3.35, 7.50	-25.00, 1.70	-10.00, 6.70
Min, Max	30.0, 100.0	-1.7, 100.0	6.7, 100.0	-45.0, 61.7	-50.0, 23.4	-46.6, 65.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Sleep						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	62.12 (20.75)	56.61 (20.33)	63.52 (20.05)			
Median	65.00	60.00	65.00			
IQR: Q1, Q3	50.00, 80.00	40.00, 70.00	50.00, 80.00			
Min, Max	10.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	60.98 (22.73)	53.93 (20.76)	64.34 (20.43)	-0.37 (1.61)	-1.61 (2.12)	-0.34 (1.47)
Median	65.00	55.00	65.00	0	0	0
IQR: Q1, Q3	45.00, 75.00	40.00, 70.00	50.00, 80.00	-10.00, 5.00	-10.00, 7.50	-10.00, 10.00
Min, Max	5.0, 100.0	0.0, 90.0	15.0, 100.0	-30.0, 50.0	-35.0, 45.0	-40.0, 45.0
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	63.24 (20.85)	57.96 (22.89)	64.40 (21.04)	-0.26 (1.74)	0.11 (2.69)	0.74 (1.51)
Median	67.50	60.00	65.00	0	0	0
IQR: Q1, Q3	50.00, 80.00	40.00, 75.00	50.00, 80.00	-10.00, 5.00	-10.00, 10.00	-10.00, 10.00
Min, Max	10.0, 100.0	0.0, 95.0	5.0, 100.0	-30.0, 45.0	-60.0, 30.0	-40.0, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Loneliness						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	83.24 (19.24)	82.20 (22.48)	85.60 (17.93)			
Median	90.00	90.00	95.00			
IQR: Q1, Q3	70.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	25.0, 100.0			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	82.67 (19.62)	81.72 (21.29)	86.42 (17.87)	-0.82 (1.92)	-0.09 (2.01)	-1.15 (1.28)
Median	90.00	90.00	95.00	0	0	0
IQR: Q1, Q3	70.00, 100.00	70.00, 100.00	80.00, 100.00	-10.00, 10.00	-5.00, 2.50	-5.00, 5.00
Min, Max	15.0, 100.0	0.0, 100.0	20.0, 100.0	-50.0, 45.0	-35.0, 65.0	-80.0, 45.0
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	83.82 (17.55)	81.12 (24.33)	85.85 (16.98)	0.42 (1.91)	-1.22 (2.11)	-0.66 (1.39)
Median	85.00	90.00	95.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	80.00, 100.00	-5.00, 5.00	-10.00, 5.00	-5.00, 5.00
Min, Max	35.0, 100.0	0.0, 100.0	30.0, 100.0	-55.0, 40.0	-40.0, 25.0	-40.0, 70.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Hopelessness						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	76.96 (22.99)	75.85 (23.25)	79.85 (21.50)			
Median	83.30	83.30	83.30			
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	66.70, 100.00			
Min, Max	25.0, 100.0	8.3, 100.0	16.7, 100.0			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	78.83 (22.01)	75.68 (23.39)	81.15 (20.96)	2.13 (1.96)	1.19 (2.32)	-0.32 (1.63)
Median	83.30	83.30	91.70	0	0	0
IQR: Q1, Q3	58.30, 100.00	58.30, 100.00	66.70, 100.00	-8.30, 8.40	-8.30, 16.65	-8.30, 8.30
Min, Max	8.3, 100.0	8.3, 100.0	16.7, 100.0	-41.7, 50.0	-41.7, 41.6	-66.6, 50.0
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	79.71 (20.61)	79.09 (24.42)	78.42 (21.95)	1.04 (2.30)	2.60 (3.09)	-1.89 (1.84)
Median	83.30	91.70	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	66.70, 100.00	58.30, 100.00	-8.30, 8.40	-8.30, 16.70	-8.30, 8.30
Min, Max	33.3, 100.0	0.0, 100.0	0.0, 100.0	-50.0, 41.7	-41.7, 50.0	-100.0, 33.4

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.1
Liver Disease Quality of Life (SE21): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Stigma of Liver Disease						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	80.90 (22.27)	80.00 (20.29)	84.81 (17.76)			
Median	87.50	81.30	93.80			
IQR: Q1, Q3	68.80, 100.00	68.80, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	12.5, 100.0	31.3, 100.0			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	84.79 (19.41)	78.20 (21.03)	85.41 (19.15)	3.97 (2.10)	-0.67 (2.13)	0.34 (1.29)
Median	93.80	81.30	93.80	0	0	0
IQR: Q1, Q3	75.00, 100.00	68.80, 93.80	81.30, 100.00	-6.20, 12.50	-12.50, 6.25	-6.20, 6.30
Min, Max	12.5, 100.0	12.5, 100.0	6.3, 100.0	-43.8, 56.2	-31.3, 56.3	-62.5, 50.0
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	86.77 (18.70)	83.65 (22.12)	84.16 (19.22)	5.38 (1.69)	2.45 (2.37)	0.36 (1.49)
Median	100.00	93.80	93.80	0	0	0
IQR: Q1, Q3	81.30, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	-6.20, 12.50	-6.20, 6.30
Min, Max	31.3, 100.0	12.5, 100.0	18.8, 100.0	-31.3, 56.2	-37.5, 56.3	-62.5, 50.0

Abbreviations: LDQOL = Liver Disease Quality of Life; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Statin Status
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.15.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Total LDQOL			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	78.01 (14.52)	78.49 (13.95)	76.90 (14.44)
Analysis Visit Mean (SD)	79.42 (14.18)	79.49 (12.79)	78.05 (13.68)
LS Mean of Change from Baseline (SE)	1.87 (1.01)	1.43 (0.99)	1.42 (0.81)
95% CI	(-0.11, 3.84)	(-0.51, 3.38)	(-0.18, 3.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.44 (1.19)	0.01 (1.18)	
95% CI	(-1.89, 2.78)	(-2.31, 2.34)	
p-value	0.7088	0.9910	
Corrected Hedge's g Statistics	0.051	0.002	
95% CI	(-0.25, 0.35)	(-0.29, 0.30)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	78.72 (13.86)	78.08 (14.25)	77.91 (14.16)
Analysis Visit Mean (SD)	79.54 (13.63)	78.93 (13.60)	79.25 (14.55)
LS Mean of Change from Baseline (SE)	1.70 (1.21)	1.10 (1.16)	1.66 (0.93)
95% CI	(-0.68, 4.08)	(-1.18, 3.39)	(-0.17, 3.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (1.43)	-0.56 (1.40)	
95% CI	(-2.79, 2.86)	(-3.32, 2.20)	
p-value	0.9797	0.6906	
Corrected Hedge's g Statistics	0.004	-0.058	
95% CI	(-0.31, 0.32)	(-0.36, 0.25)	
Subgroup*Treatment Interaction p-value	0.9273	0.7548	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.2
Liver Disease Quality of Life (SE21): Summary of Total LDQOL - MMRM Model;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Total LDQOL			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	77.20 (13.92)	74.43 (15.60)	79.72 (12.97)
Analysis Visit Mean (SD)	77.48 (15.15)	74.52 (12.50)	79.96 (14.44)
LS Mean of Change from Baseline (SE)	0.21 (1.02)	-0.82 (1.22)	0.46 (0.80)
95% CI	(-1.79, 2.21)	(-3.22, 1.58)	(-1.12, 2.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.25 (1.29)	-1.27 (1.46)	
95% CI	(-2.79, 2.29)	(-4.15, 1.60)	
p-value	0.8482	0.3832	
Corrected Hedge's g Statistics	-0.027	-0.140	
95% CI	(-0.30, 0.25)	(-0.45, 0.17)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	77.64 (14.00)	75.76 (16.47)	78.86 (13.37)
Analysis Visit Mean (SD)	78.94 (12.80)	76.11 (14.79)	78.55 (14.54)
LS Mean of Change from Baseline (SE)	0.99 (1.04)	0.02 (1.28)	-0.44 (0.82)
95% CI	(-1.05, 3.03)	(-2.50, 2.55)	(-2.06, 1.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.43 (1.32)	0.46 (1.52)	
95% CI	(-1.17, 4.03)	(-2.54, 3.46)	
p-value	0.2810	0.7631	
Corrected Hedge's g Statistics	0.163	0.053	
95% CI	(-0.13, 0.46)	(-0.29, 0.40)	
Subgroup*Treatment Interaction p-value	0.9273	0.7548	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Symptoms of Liver Disease			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	79.51 (19.68)	75.10 (19.31)	76.74 (18.30)
Analysis Visit Mean (SD)	78.36 (18.53)	76.74 (17.43)	77.73 (18.51)
LS Mean of Change from Baseline (SE)	-0.04 (1.45)	1.67 (1.42)	1.39 (1.16)
95% CI	(-2.89, 2.81)	(-1.14, 4.47)	(-0.90, 3.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.43 (1.72)	0.28 (1.71)	
95% CI	(-4.82, 1.96)	(-3.09, 3.65)	
p-value	0.4063	0.8699	
Corrected Hedge's g Statistics	-0.114	0.022	
95% CI	(-0.41, 0.18)	(-0.27, 0.32)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	81.03 (18.97)	74.53 (19.46)	76.99 (18.02)
Analysis Visit Mean (SD)	78.79 (18.13)	75.84 (19.32)	77.93 (19.46)
LS Mean of Change from Baseline (SE)	-0.59 (1.66)	0.93 (1.59)	1.69 (1.27)
95% CI	(-3.85, 2.68)	(-2.20, 4.05)	(-0.80, 4.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.28 (1.97)	-0.76 (1.91)	
95% CI	(-6.15, 1.60)	(-4.53, 3.00)	
p-value	0.2482	0.6900	
Corrected Hedge's g Statistics	-0.172	-0.058	
95% CI	(-0.49, 0.15)	(-0.36, 0.25)	
Subgroup*Treatment Interaction p-value	0.8616	0.3531	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Effects of Liver Disease			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	77.69 (14.86)	79.43 (13.42)	78.41 (13.47)
Analysis Visit Mean (SD)	77.59 (13.82)	80.57 (11.89)	78.51 (13.35)
LS Mean of Change from Baseline (SE)	-0.51 (1.44)	1.63 (1.42)	0.10 (1.16)
95% CI	(-3.35, 2.33)	(-1.17, 4.43)	(-2.18, 2.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.61 (1.72)	1.52 (1.71)	
95% CI	(-4.00, 2.77)	(-1.85, 4.90)	
p-value	0.7212	0.3745	
Corrected Hedge's g Statistics	-0.049	0.122	
95% CI	(-0.34, 0.25)	(-0.17, 0.42)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	78.62 (14.01)	78.33 (13.23)	78.65 (12.73)
Analysis Visit Mean (SD)	77.18 (11.90)	77.66 (14.91)	78.53 (13.82)
LS Mean of Change from Baseline (SE)	-1.35 (1.75)	-0.78 (1.67)	-0.17 (1.32)
95% CI	(-4.80, 2.09)	(-4.07, 2.51)	(-2.77, 2.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.18 (2.08)	-0.61 (2.03)	
95% CI	(-5.29, 2.92)	(-4.60, 3.38)	
p-value	0.5705	0.7634	
Corrected Hedge's g Statistics	-0.085	-0.044	
95% CI	(-0.40, 0.23)	(-0.35, 0.26)	
Subgroup*Treatment Interaction p-value	0.6742	0.8610	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Concentration/Memory			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	80.63 (23.04)	80.64 (19.73)	77.24 (21.00)
Analysis Visit Mean (SD)	81.90 (22.87)	82.16 (19.16)	78.43 (22.11)
LS Mean of Change from Baseline (SE)	1.88 (1.79)	1.96 (1.77)	0.95 (1.44)
95% CI	(-1.65, 5.41)	(-1.52, 5.44)	(-1.88, 3.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.93 (2.14)	1.01 (2.13)	
95% CI	(-3.29, 5.15)	(-3.18, 5.21)	
p-value	0.6636	0.6357	
Corrected Hedge's g Statistics	0.060	0.065	
95% CI	(-0.24, 0.36)	(-0.23, 0.36)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	80.62 (22.47)	80.00 (19.48)	78.34 (20.27)
Analysis Visit Mean (SD)	78.90 (21.48)	80.00 (19.45)	79.66 (21.58)
LS Mean of Change from Baseline (SE)	-1.98 (1.78)	0.53 (1.71)	1.05 (1.38)
95% CI	(-5.49, 1.52)	(-2.83, 3.89)	(-1.67, 3.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.03 (2.09)	-0.52 (2.04)	
95% CI	(-7.16, 1.09)	(-4.55, 3.50)	
p-value	0.1484	0.7984	
Corrected Hedge's g Statistics	-0.211	-0.036	
95% CI	(-0.53, 0.11)	(-0.34, 0.27)	
Subgroup*Treatment Interaction p-value	0.9505	0.5880	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Health Distress			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	78.99 (26.30)	83.57 (23.75)	80.17 (26.25)
Analysis Visit Mean (SD)	82.61 (22.71)	89.11 (19.38)	86.47 (22.86)
LS Mean of Change from Baseline (SE)	3.52 (1.98)	7.00 (1.95)	6.70 (1.60)
95% CI	(-0.38, 7.42)	(3.16, 10.84)	(3.56, 9.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.18 (2.35)	0.30 (2.34)	
95% CI	(-7.81, 1.45)	(-4.32, 4.91)	
p-value	0.1771	0.8989	
Corrected Hedge's g Statistics	-0.185	0.017	
95% CI	(-0.48, 0.11)	(-0.28, 0.31)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	78.66 (25.22)	84.96 (22.62)	81.64 (25.56)
Analysis Visit Mean (SD)	82.33 (25.22)	89.65 (19.99)	87.72 (21.91)
LS Mean of Change from Baseline (SE)	2.84 (2.40)	6.87 (2.30)	7.06 (1.83)
95% CI	(-1.89, 7.57)	(2.34, 11.40)	(3.46, 10.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.22 (2.86)	-0.19 (2.78)	
95% CI	(-9.85, 1.40)	(-5.67, 5.29)	
p-value	0.1406	0.9454	
Corrected Hedge's g Statistics	-0.221	-0.010	
95% CI	(-0.54, 0.10)	(-0.32, 0.30)	
Subgroup*Treatment Interaction p-value	0.1168	0.8579	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Sexual Function			
Week 24			
m	72	78	142
n	24	32	40
Baseline Mean (SD)	74.11 (30.91)	83.28 (21.20)	82.04 (23.04)
Analysis Visit Mean (SD)	79.10 (23.45)	77.13 (28.46)	79.38 (24.81)
LS Mean of Change from Baseline (SE)	3.17 (4.23)	-5.64 (3.50)	-2.00 (3.51)
95% CI	(-5.23, 11.56)	(-12.58, 1.30)	(-8.96, 4.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.16 (4.96)	-3.65 (4.62)	
95% CI	(-4.67, 14.99)	(-12.81, 5.52)	
p-value	0.3002	0.4320	
Corrected Hedge's g Statistics	0.235	-0.170	
95% CI	(-0.27, 0.74)	(-0.64, 0.30)	
Week 52			
m	64	70	135
n	18	28	38
Baseline Mean (SD)	81.13 (30.67)	78.68 (25.40)	77.89 (26.70)
Analysis Visit Mean (SD)	84.82 (26.20)	78.85 (31.95)	76.44 (27.83)
LS Mean of Change from Baseline (SE)	1.51 (4.88)	-1.08 (3.93)	-3.48 (3.79)
95% CI	(-8.17, 11.18)	(-8.88, 6.72)	(-11.00, 4.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.99 (5.68)	2.40 (5.14)	
95% CI	(-6.28, 16.26)	(-7.80, 12.61)	
p-value	0.3817	0.6411	
Corrected Hedge's g Statistics	0.218	0.106	
95% CI	(-0.34, 0.78)	(-0.38, 0.59)	
Subgroup*Treatment Interaction p-value	0.5611	0.9689	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Sleep			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	63.99 (20.80)	63.14 (19.58)	61.65 (20.42)
Analysis Visit Mean (SD)	66.59 (17.73)	61.43 (20.06)	61.36 (20.33)
LS Mean of Change from Baseline (SE)	3.80 (1.75)	-1.10 (1.72)	0.27 (1.41)
95% CI	(0.35, 7.25)	(-4.49, 2.29)	(-2.52, 3.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.54 (2.08)	-1.37 (2.07)	
95% CI	(-0.55, 7.63)	(-5.44, 2.70)	
p-value	0.0899	0.5080	
Corrected Hedge's g Statistics	0.232	-0.090	
95% CI	(-0.06, 0.53)	(-0.38, 0.20)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	64.91 (20.27)	62.66 (20.24)	62.83 (20.72)
Analysis Visit Mean (SD)	66.21 (17.78)	61.02 (20.10)	63.81 (20.77)
LS Mean of Change from Baseline (SE)	3.44 (2.06)	-1.17 (1.97)	2.00 (1.57)
95% CI	(-0.61, 7.49)	(-5.05, 2.70)	(-1.10, 5.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.44 (2.44)	-3.18 (2.38)	
95% CI	(-3.36, 6.24)	(-7.86, 1.51)	
p-value	0.5556	0.1828	
Corrected Hedge's g Statistics	0.088	-0.193	
95% CI	(-0.23, 0.40)	(-0.50, 0.11)	
Subgroup*Treatment Interaction p-value	0.2325	0.6773	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Loneliness			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	86.16 (15.95)	85.21 (17.20)	80.70 (21.68)
Analysis Visit Mean (SD)	85.22 (17.29)	86.79 (17.34)	79.05 (22.81)
LS Mean of Change from Baseline (SE)	-0.54 (1.91)	1.71 (1.88)	-2.90 (1.53)
95% CI	(-4.30, 3.22)	(-1.98, 5.41)	(-5.91, 0.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.36 (2.28)	4.61 (2.27)	
95% CI	(-2.14, 6.85)	(0.14, 9.07)	
p-value	0.3030	0.0431	
Corrected Hedge's g Statistics	0.142	0.279	
95% CI	(-0.15, 0.44)	(-0.02, 0.57)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	86.90 (16.43)	83.67 (17.85)	81.95 (21.46)
Analysis Visit Mean (SD)	87.16 (16.76)	84.92 (17.92)	82.57 (21.17)
LS Mean of Change from Baseline (SE)	1.19 (2.05)	0.88 (1.96)	-0.80 (1.57)
95% CI	(-2.85, 5.24)	(-2.98, 4.73)	(-3.90, 2.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.00 (2.43)	1.68 (2.36)	
95% CI	(-2.78, 6.78)	(-2.97, 6.33)	
p-value	0.4114	0.4771	
Corrected Hedge's g Statistics	0.122	0.102	
95% CI	(-0.20, 0.44)	(-0.20, 0.41)	
Subgroup*Treatment Interaction p-value	0.2186	0.1147	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Hopelessness			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	73.80 (22.52)	76.90 (22.49)	78.03 (21.58)
Analysis Visit Mean (SD)	76.57 (23.76)	79.05 (21.74)	77.65 (21.66)
LS Mean of Change from Baseline (SE)	2.57 (2.24)	2.71 (2.20)	1.42 (1.79)
95% CI	(-1.83, 6.98)	(-1.61, 7.04)	(-2.10, 4.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.15 (2.68)	1.29 (2.65)	
95% CI	(-4.12, 6.42)	(-3.93, 6.52)	
p-value	0.6668	0.6266	
Corrected Hedge's g Statistics	0.060	0.067	
95% CI	(-0.24, 0.36)	(-0.23, 0.36)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	74.86 (21.72)	77.08 (23.48)	79.94 (21.33)
Analysis Visit Mean (SD)	77.31 (22.55)	77.35 (19.72)	79.43 (22.77)
LS Mean of Change from Baseline (SE)	3.70 (2.38)	0.79 (2.27)	1.50 (1.82)
95% CI	(-0.99, 8.38)	(-3.68, 5.26)	(-2.09, 5.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.19 (2.82)	-0.71 (2.74)	
95% CI	(-3.36, 7.75)	(-6.11, 4.68)	
p-value	0.4378	0.7949	
Corrected Hedge's g Statistics	0.115	-0.037	
95% CI	(-0.20, 0.43)	(-0.34, 0.27)	
Subgroup*Treatment Interaction p-value	0.9534	0.9709	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Stigma of Liver Disease			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	84.62 (20.00)	82.16 (20.19)	82.77 (20.56)
Analysis Visit Mean (SD)	86.25 (19.63)	83.50 (18.30)	85.66 (17.50)
LS Mean of Change from Baseline (SE)	2.96 (1.79)	1.52 (1.76)	3.59 (1.43)
95% CI	(-0.56, 6.48)	(-1.94, 4.99)	(0.78, 6.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.63 (2.14)	-2.06 (2.13)	
95% CI	(-4.84, 3.58)	(-6.25, 2.13)	
p-value	0.7697	0.3331	
Corrected Hedge's g Statistics	-0.041	-0.134	
95% CI	(-0.34, 0.26)	(-0.43, 0.16)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	85.90 (17.96)	82.44 (19.66)	83.70 (19.82)
Analysis Visit Mean (SD)	87.52 (16.43)	85.09 (15.92)	86.75 (18.05)
LS Mean of Change from Baseline (SE)	4.02 (1.83)	2.98 (1.75)	4.01 (1.40)
95% CI	(0.42, 7.61)	(-0.46, 6.42)	(1.25, 6.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (2.16)	-1.03 (2.10)	
95% CI	(-4.24, 4.25)	(-5.17, 3.10)	
p-value	0.9991	0.6231	
Corrected Hedge's g Statistics	0.000	-0.071	
95% CI	(-0.32, 0.32)	(-0.38, 0.24)	
Subgroup*Treatment Interaction p-value	0.1809	0.9105	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Symptoms of Liver Disease			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	76.18 (18.92)	74.58 (18.29)	78.38 (17.28)
Analysis Visit Mean (SD)	74.63 (21.82)	70.60 (17.79)	77.76 (19.87)
LS Mean of Change from Baseline (SE)	-1.48 (1.55)	-4.51 (1.85)	-0.78 (1.22)
95% CI	(-4.53, 1.57)	(-8.16, -0.86)	(-3.18, 1.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.70 (1.96)	-3.73 (2.21)	
95% CI	(-4.57, 3.17)	(-8.09, 0.62)	
p-value	0.7212	0.0929	
Corrected Hedge's g Statistics	-0.050	-0.269	
95% CI	(-0.33, 0.23)	(-0.58, 0.05)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	77.13 (18.19)	76.74 (16.25)	77.82 (16.91)
Analysis Visit Mean (SD)	75.41 (20.11)	77.04 (16.44)	78.08 (18.41)
LS Mean of Change from Baseline (SE)	-2.02 (1.51)	-0.14 (1.86)	0.27 (1.20)
95% CI	(-4.99, 0.96)	(-3.81, 3.53)	(-2.10, 2.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.28 (1.92)	-0.40 (2.21)	
95% CI	(-6.07, 1.50)	(-4.76, 3.95)	
p-value	0.2363	0.8559	
Corrected Hedge's g Statistics	-0.179	-0.032	
95% CI	(-0.48, 0.12)	(-0.38, 0.32)	
Subgroup*Treatment Interaction p-value	0.8616	0.3531	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Effects of Liver Disease			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	78.38 (12.06)	77.27 (17.79)	77.19 (15.19)
Analysis Visit Mean (SD)	75.04 (14.88)	76.97 (8.61)	76.87 (15.80)
LS Mean of Change from Baseline (SE)	-2.79 (1.40)	-0.50 (1.67)	-0.56 (1.11)
95% CI	(-5.55, -0.04)	(-3.79, 2.79)	(-2.74, 1.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.23 (1.78)	0.06 (2.00)	
95% CI	(-5.73, 1.26)	(-3.87, 3.99)	
p-value	0.2092	0.9754	
Corrected Hedge's g Statistics	-0.177	0.005	
95% CI	(-0.45, 0.10)	(-0.31, 0.32)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	77.78 (12.46)	78.23 (18.98)	77.34 (14.14)
Analysis Visit Mean (SD)	76.57 (14.54)	77.93 (8.85)	77.00 (13.47)
LS Mean of Change from Baseline (SE)	-1.28 (1.44)	-0.20 (1.79)	-0.64 (1.15)
95% CI	(-4.12, 1.56)	(-3.72, 3.33)	(-2.91, 1.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.63 (1.84)	0.45 (2.12)	
95% CI	(-4.25, 2.98)	(-3.74, 4.63)	
p-value	0.7302	0.8340	
Corrected Hedge's g Statistics	-0.052	0.037	
95% CI	(-0.35, 0.25)	(-0.31, 0.38)	
Subgroup*Treatment Interaction p-value	0.6742	0.8610	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Concentration/Memory			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	80.43 (22.89)	77.48 (21.70)	81.17 (20.67)
Analysis Visit Mean (SD)	76.62 (21.84)	76.58 (20.41)	81.32 (21.60)
LS Mean of Change from Baseline (SE)	-3.50 (1.66)	-1.91 (1.99)	0.33 (1.31)
95% CI	(-6.77, -0.23)	(-5.81, 2.00)	(-2.25, 2.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.83 (2.11)	-2.23 (2.37)	
95% CI	(-7.97, 0.32)	(-6.90, 2.43)	
p-value	0.0701	0.3469	
Corrected Hedge's g Statistics	-0.256	-0.150	
95% CI	(-0.53, 0.02)	(-0.46, 0.16)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	79.19 (23.05)	80.30 (20.42)	80.25 (20.94)
Analysis Visit Mean (SD)	79.19 (19.11)	77.10 (21.89)	77.80 (22.89)
LS Mean of Change from Baseline (SE)	-0.67 (1.68)	-2.46 (2.07)	-2.17 (1.33)
95% CI	(-3.97, 2.63)	(-6.53, 1.61)	(-4.79, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.50 (2.13)	-0.29 (2.45)	
95% CI	(-2.70, 5.69)	(-5.12, 4.54)	
p-value	0.4829	0.9057	
Corrected Hedge's g Statistics	0.106	-0.021	
95% CI	(-0.19, 0.40)	(-0.37, 0.33)	
Subgroup*Treatment Interaction p-value	0.9505	0.5880	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Health Distress			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	77.59 (26.48)	75.45 (28.20)	81.35 (21.85)
Analysis Visit Mean (SD)	84.45 (22.53)	82.37 (22.46)	85.45 (21.50)
LS Mean of Change from Baseline (SE)	6.06 (1.94)	4.98 (2.31)	4.89 (1.53)
95% CI	(2.25, 9.88)	(0.43, 9.54)	(1.88, 7.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.18 (2.46)	0.10 (2.77)	
95% CI	(-3.66, 6.01)	(-5.35, 5.54)	
p-value	0.6326	0.9721	
Corrected Hedge's g Statistics	0.067	0.006	
95% CI	(-0.21, 0.34)	(-0.31, 0.32)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	78.13 (26.27)	76.11 (30.01)	82.05 (21.32)
Analysis Visit Mean (SD)	84.03 (21.52)	82.50 (22.99)	84.43 (20.75)
LS Mean of Change from Baseline (SE)	4.49 (2.20)	4.82 (2.73)	3.46 (1.76)
95% CI	(0.16, 8.83)	(-0.56, 10.20)	(-0.01, 6.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.04 (2.81)	1.36 (3.25)	
95% CI	(-4.50, 6.57)	(-5.04, 7.76)	
p-value	0.7127	0.6758	
Corrected Hedge's g Statistics	0.056	0.073	
95% CI	(-0.24, 0.35)	(-0.27, 0.42)	
Subgroup*Treatment Interaction p-value	0.1168	0.8579	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Sexual Function			
Week 24			
m	89	63	147
n	33	27	54
Baseline Mean (SD)	80.55 (25.79)	79.62 (22.65)	81.39 (21.60)
Analysis Visit Mean (SD)	79.85 (27.14)	76.85 (21.57)	83.45 (18.79)
LS Mean of Change from Baseline (SE)	-0.36 (3.15)	-3.53 (3.54)	0.86 (2.50)
95% CI	(-6.60, 5.88)	(-10.54, 3.48)	(-4.08, 5.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.23 (4.03)	-4.40 (4.30)	
95% CI	(-9.21, 6.75)	(-12.92, 4.13)	
p-value	0.7613	0.3092	
Corrected Hedge's g Statistics	-0.067	-0.237	
95% CI	(-0.50, 0.37)	(-0.70, 0.23)	
Week 52			
m	85	55	135
n	28	19	42
Baseline Mean (SD)	81.89 (26.31)	86.22 (14.69)	81.86 (21.14)
Analysis Visit Mean (SD)	86.48 (16.81)	79.29 (21.64)	80.69 (22.50)
LS Mean of Change from Baseline (SE)	5.30 (3.20)	-3.07 (3.82)	-1.73 (2.61)
95% CI	(-1.04, 11.65)	(-10.64, 4.50)	(-6.89, 3.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.03 (4.15)	-1.34 (4.60)	
95% CI	(-1.19, 15.26)	(-10.44, 7.77)	
p-value	0.0928	0.7717	
Corrected Hedge's g Statistics	0.411	-0.078	
95% CI	(-0.07, 0.89)	(-0.62, 0.46)	
Subgroup*Treatment Interaction p-value	0.5611	0.9689	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Sleep			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	62.13 (20.68)	55.27 (19.94)	65.23 (19.49)
Analysis Visit Mean (SD)	61.77 (21.92)	53.66 (20.66)	64.88 (20.10)
LS Mean of Change from Baseline (SE)	-0.68 (1.66)	-4.00 (2.00)	-0.03 (1.31)
95% CI	(-3.95, 2.59)	(-7.95, -0.06)	(-2.61, 2.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.65 (2.11)	-3.98 (2.40)	
95% CI	(-4.80, 3.50)	(-8.71, 0.75)	
p-value	0.7580	0.0990	
Corrected Hedge's g Statistics	-0.043	-0.266	
95% CI	(-0.32, 0.23)	(-0.58, 0.05)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	63.47 (20.79)	56.78 (21.27)	63.90 (19.67)
Analysis Visit Mean (SD)	63.21 (19.59)	56.89 (22.94)	64.64 (21.13)
LS Mean of Change from Baseline (SE)	-0.18 (1.76)	-1.66 (2.19)	0.20 (1.40)
95% CI	(-3.64, 3.28)	(-5.96, 2.65)	(-2.55, 2.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.38 (2.24)	-1.86 (2.60)	
95% CI	(-4.78, 4.02)	(-6.97, 3.26)	
p-value	0.8653	0.4749	
Corrected Hedge's g Statistics	-0.026	-0.126	
95% CI	(-0.32, 0.27)	(-0.47, 0.22)	
Subgroup*Treatment Interaction p-value	0.2325	0.6773	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Loneliness			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	83.17 (19.57)	82.05 (22.94)	87.68 (16.69)
Analysis Visit Mean (SD)	82.35 (19.82)	81.96 (21.69)	86.52 (17.90)
LS Mean of Change from Baseline (SE)	-1.87 (1.60)	-1.26 (1.92)	-0.40 (1.27)
95% CI	(-5.03, 1.29)	(-5.04, 2.52)	(-2.90, 2.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.47 (2.04)	-0.86 (2.30)	
95% CI	(-5.49, 2.55)	(-5.39, 3.67)	
p-value	0.4712	0.7078	
Corrected Hedge's g Statistics	-0.102	-0.060	
95% CI	(-0.38, 0.18)	(-0.37, 0.25)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	82.85 (19.94)	81.22 (24.27)	86.30 (17.75)
Analysis Visit Mean (SD)	83.26 (17.69)	80.00 (25.02)	85.64 (17.34)
LS Mean of Change from Baseline (SE)	-0.92 (1.63)	-2.45 (2.02)	-0.65 (1.30)
95% CI	(-4.12, 2.28)	(-6.43, 1.53)	(-3.20, 1.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.28 (2.08)	-1.80 (2.40)	
95% CI	(-4.36, 3.81)	(-6.53, 2.92)	
p-value	0.8940	0.4534	
Corrected Hedge's g Statistics	-0.020	-0.132	
95% CI	(-0.32, 0.28)	(-0.48, 0.22)	
Subgroup*Treatment Interaction p-value	0.2186	0.1147	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Hopelessness			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	77.34 (22.62)	74.70 (23.30)	81.77 (19.97)
Analysis Visit Mean (SD)	79.47 (21.57)	75.89 (23.72)	81.45 (20.95)
LS Mean of Change from Baseline (SE)	1.26 (1.85)	-0.84 (2.21)	0.44 (1.46)
95% CI	(-2.38, 4.91)	(-5.19, 3.51)	(-2.43, 3.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.83 (2.34)	-1.28 (2.64)	
95% CI	(-3.79, 5.44)	(-6.48, 3.93)	
p-value	0.7245	0.6292	
Corrected Hedge's g Statistics	0.050	-0.077	
95% CI	(-0.23, 0.33)	(-0.39, 0.24)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	79.05 (21.94)	75.18 (24.72)	80.07 (20.82)
Analysis Visit Mean (SD)	80.09 (20.10)	77.78 (25.00)	78.18 (22.24)
LS Mean of Change from Baseline (SE)	0.99 (2.13)	1.95 (2.63)	-1.67 (1.69)
95% CI	(-3.20, 5.18)	(-3.23, 7.13)	(-5.00, 1.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.66 (2.71)	3.62 (3.12)	
95% CI	(-2.67, 7.99)	(-2.53, 9.77)	
p-value	0.3265	0.2480	
Corrected Hedge's g Statistics	0.148	0.203	
95% CI	(-0.15, 0.45)	(-0.14, 0.55)	
Subgroup*Treatment Interaction p-value	0.9534	0.9709	

AMNOG Table SE21.15.3
Liver Disease Quality of Life (SE21): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Stigma of Liver Disease			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	80.88 (22.10)	78.93 (20.28)	85.45 (17.59)
Analysis Visit Mean (SD)	84.85 (19.32)	78.26 (21.81)	85.79 (19.32)
LS Mean of Change from Baseline (SE)	3.50 (1.68)	-1.74 (2.01)	1.25 (1.33)
95% CI	(0.19, 6.81)	(-5.69, 2.22)	(-1.37, 3.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.25 (2.14)	-2.99 (2.41)	
95% CI	(-1.95, 6.46)	(-7.73, 1.76)	
p-value	0.2924	0.2163	
Corrected Hedge's g Statistics	0.149	-0.198	
95% CI	(-0.13, 0.43)	(-0.51, 0.12)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	81.87 (22.50)	80.16 (21.41)	83.47 (18.26)
Analysis Visit Mean (SD)	87.25 (18.35)	82.61 (22.68)	83.83 (19.53)
LS Mean of Change from Baseline (SE)	4.88 (1.68)	0.87 (2.08)	0.49 (1.34)
95% CI	(1.56, 8.19)	(-3.23, 4.97)	(-2.15, 3.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.39 (2.14)	0.39 (2.47)	
95% CI	(0.17, 8.61)	(-4.48, 5.25)	
p-value	0.0414	0.8754	
Corrected Hedge's g Statistics	0.309	0.028	
95% CI	(0.01, 0.61)	(-0.32, 0.37)	
Subgroup*Treatment Interaction p-value	0.1809	0.9105	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Abbreviations: LDQOL = Liver Disease Quality of Life; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size.
[2] The (inverse) odds ratio, (inverse) risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
[3] The Breslow-Day Test for homogeneity of treatment effect was performed based on inverse risk ratio with respective subgroup as the only stratification factor.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.7)	2 (2.3)	7 (4.8)
No	73 (97.3)	85 (97.7)	140 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.83	2.13	
95% CI of the inverse odds ratio	(0.37, 9.01)	(0.43, 10.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.79	2.07	
95% CI of the inverse risk ratio	(0.38, 8.39)	(0.44, 9.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.10	-2.46	
95% CI of the absolute risk difference	(-7.11, 2.92)	(-7.13, 2.20)	
p-value	0.4541	0.3437	
p-value of Breslow-Day Test for Homogeneity [3]	0.1896	0.2985	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (21.3)	15 (17.2)	33 (22.4)
No	59 (78.7)	72 (82.8)	114 (77.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.39	
95% CI of the inverse odds ratio	(0.54, 2.10)	(0.71, 2.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.30	
95% CI of the inverse risk ratio	(0.62, 1.78)	(0.75, 2.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.12	-5.21	
95% CI of the absolute risk difference	(-12.58, 10.35)	(-15.62, 5.21)	
p-value	0.8496	0.3404	
p-value of Breslow-Day Test for Homogeneity [3]	0.2344	0.0500	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.0)	10 (11.5)	16 (10.9)
No	72 (96.0)	77 (88.5)	131 (89.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.93	0.94	
95% CI of the inverse odds ratio	(0.83, 10.40)	(0.41, 2.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.72	0.95	
95% CI of the inverse risk ratio	(0.82, 9.05)	(0.45, 1.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.88	0.61	
95% CI of the absolute risk difference	(-13.59, -0.17)	(-7.77, 8.99)	
p-value	0.0829	0.8859	
p-value of Breslow-Day Test for Homogeneity [3]	0.6934	0.6096	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (20.0)	24 (27.6)	36 (24.5)
No	60 (80.0)	63 (72.4)	111 (75.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	0.85	
95% CI of the inverse odds ratio	(0.66, 2.56)	(0.47, 1.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	0.89	
95% CI of the inverse risk ratio	(0.72, 2.09)	(0.57, 1.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.49	3.10	
95% CI of the absolute risk difference	(-15.90, 6.92)	(-8.59, 14.78)	
p-value	0.4520	0.6001	
p-value of Breslow-Day Test for Homogeneity [3]	0.8740	0.4984	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.7)	5 (5.7)	13 (8.8)
No	73 (97.3)	82 (94.3)	134 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.54	1.59	
95% CI of the inverse odds ratio	(0.78, 16.12)	(0.55, 4.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.32	1.54	
95% CI of the inverse risk ratio	(0.77, 14.32)	(0.57, 4.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.18	-3.10	
95% CI of the absolute risk difference	(-12.04, -0.32)	(-9.80, 3.61)	
p-value	0.0829	0.3903	
p-value of Breslow-Day Test for Homogeneity [3]	0.7877	0.6094	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (14.7)	18 (20.7)	30 (20.4)
No	64 (85.3)	69 (79.3)	117 (79.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.49	0.98	
95% CI of the inverse odds ratio	(0.70, 3.17)	(0.51, 1.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	0.99	
95% CI of the inverse risk ratio	(0.74, 2.62)	(0.59, 1.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.74	0.28	
95% CI of the absolute risk difference	(-16.06, 4.58)	(-10.44, 11.00)	
p-value	0.2971	0.9589	
p-value of Breslow-Day Test for Homogeneity [3]	0.5365	0.6640	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (8.0)	6 (6.9)	14 (9.5)
No	69 (92.0)	81 (93.1)	133 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.42	
95% CI of the inverse odds ratio	(0.45, 3.29)	(0.53, 3.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	1.38	
95% CI of the inverse risk ratio	(0.48, 2.97)	(0.55, 3.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.52	-2.63	
95% CI of the absolute risk difference	(-9.28, 6.24)	(-9.76, 4.51)	
p-value	0.7076	0.4872	
p-value of Breslow-Day Test for Homogeneity [3]	0.1068	0.5258	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (21.3)	23 (26.4)	38 (25.9)
No	59 (78.7)	64 (73.6)	109 (74.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.97	
95% CI of the inverse odds ratio	(0.66, 2.50)	(0.53, 1.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	0.98	
95% CI of the inverse risk ratio	(0.72, 2.03)	(0.63, 1.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.52	0.59	
95% CI of the absolute risk difference	(-16.18, 7.15)	(-11.07, 12.25)	
p-value	0.4581	0.9213	
p-value of Breslow-Day Test for Homogeneity [3]	0.2751	0.8691	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (12.0)	14 (16.1)	26 (17.7)
No	66 (88.0)	73 (83.9)	121 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.58	1.12	
95% CI of the inverse odds ratio	(0.70, 3.56)	(0.55, 2.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	1.10	
95% CI of the inverse risk ratio	(0.73, 2.98)	(0.61, 1.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.69	-1.60	
95% CI of the absolute risk difference	(-15.29, 3.91)	(-11.48, 8.29)	
p-value	0.2714	0.7541	
p-value of Breslow-Day Test for Homogeneity [3]	0.0454	0.2493	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (21.3)	19 (21.8)	37 (25.2)
No	59 (78.7)	68 (78.2)	110 (74.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	1.20	
95% CI of the inverse odds ratio	(0.64, 2.41)	(0.64, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.15	
95% CI of the inverse risk ratio	(0.70, 1.98)	(0.71, 1.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.84	-3.33	
95% CI of the absolute risk difference	(-15.46, 7.79)	(-14.49, 7.83)	
p-value	0.5259	0.5638	
p-value of Breslow-Day Test for Homogeneity [3]	0.3233	0.3421	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.7)	4 (4.6)	6 (4.1)
No	73 (97.3)	83 (95.4)	141 (95.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	0.88	
95% CI of the inverse odds ratio	(0.31, 7.89)	(0.24, 3.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	0.89	
95% CI of the inverse risk ratio	(0.32, 7.40)	(0.26, 3.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.41	0.52	
95% CI of the absolute risk difference	(-6.27, 3.44)	(-4.92, 5.96)	
p-value	0.5926	0.8504	
p-value of Breslow-Day Test for Homogeneity [3]	0.6968	0.6322	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (4.0)	9 (10.3)	12 (8.2)
No	72 (96.0)	78 (89.7)	135 (91.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.13	0.77	
95% CI of the inverse odds ratio	(0.58, 7.81)	(0.31, 1.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.04	0.79	
95% CI of the inverse risk ratio	(0.59, 7.01)	(0.35, 1.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.16	2.18	
95% CI of the absolute risk difference	(-10.43, 2.10)	(-5.60, 9.96)	
p-value	0.2425	0.5726	
p-value of Breslow-Day Test for Homogeneity [3]	0.1796	0.4457	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (17.3)	9 (10.3)	27 (18.4)
No	62 (82.7)	78 (89.7)	120 (81.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.95	
95% CI of the inverse odds ratio	(0.52, 2.22)	(0.87, 4.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.78	
95% CI of the inverse risk ratio	(0.58, 1.93)	(0.88, 3.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.03	-8.02	
95% CI of the absolute risk difference	(-11.64, 9.58)	(-16.97, 0.93)	
p-value	0.8496	0.1002	
p-value of Breslow-Day Test for Homogeneity [3]	0.9494	0.0952	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (32.0)	23 (26.4)	49 (33.3)
No	51 (68.0)	64 (73.6)	98 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.39	
95% CI of the inverse odds ratio	(0.59, 1.92)	(0.77, 2.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.26	
95% CI of the inverse risk ratio	(0.70, 1.56)	(0.83, 1.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.33	-6.90	
95% CI of the absolute risk difference	(-14.35, 11.69)	(-18.89, 5.10)	
p-value	0.8415	0.2693	
p-value of Breslow-Day Test for Homogeneity [3]	0.7859	0.2548	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (10.7)	15 (17.2)	21 (14.3)
No	67 (89.3)	72 (82.8)	126 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	0.80	
95% CI of the inverse odds ratio	(0.59, 3.32)	(0.39, 1.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.34	0.83	
95% CI of the inverse risk ratio	(0.62, 2.88)	(0.45, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.62	2.96	
95% CI of the absolute risk difference	(-12.61, 5.37)	(-6.79, 12.70)	
p-value	0.4492	0.5448	
p-value of Breslow-Day Test for Homogeneity [3]	0.1331	0.4478	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (24.0)	25 (28.7)	43 (29.3)
No	57 (76.0)	62 (71.3)	104 (70.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.03	
95% CI of the inverse odds ratio	(0.69, 2.48)	(0.57, 1.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	1.02	
95% CI of the inverse risk ratio	(0.76, 1.96)	(0.67, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.25	-0.52	
95% CI of the absolute risk difference	(-17.40, 6.89)	(-12.54, 11.50)	
p-value	0.4071	0.9330	
p-value of Breslow-Day Test for Homogeneity [3]	0.5960	0.6921	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (18.7)	21 (24.1)	21 (14.3)
No	61 (81.3)	66 (75.9)	126 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.52	
95% CI of the inverse odds ratio	(0.35, 1.53)	(0.27, 1.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.59	
95% CI of the inverse risk ratio	(0.41, 1.42)	(0.34, 1.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.38	9.85	
95% CI of the absolute risk difference	(-6.10, 14.86)	(-0.77, 20.48)	
p-value	0.3969	0.0577	
p-value of Breslow-Day Test for Homogeneity [3]	0.8292	0.8531	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (29.3)	26 (29.9)	37 (25.2)
No	53 (70.7)	61 (70.1)	110 (74.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.79	
95% CI of the inverse odds ratio	(0.44, 1.51)	(0.44, 1.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.84	
95% CI of the inverse risk ratio	(0.55, 1.34)	(0.55, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.16	4.71	
95% CI of the absolute risk difference	(-8.30, 16.63)	(-7.19, 16.62)	
p-value	0.5066	0.4320	
p-value of Breslow-Day Test for Homogeneity [3]	0.6919	0.7571	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (9.3)	9 (10.3)	20 (13.6)
No	68 (90.7)	78 (89.7)	127 (86.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	1.36	
95% CI of the inverse odds ratio	(0.62, 3.80)	(0.59, 3.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.46	1.32	
95% CI of the inverse risk ratio	(0.65, 3.29)	(0.63, 2.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.27	-3.26	
95% CI of the absolute risk difference	(-12.88, 4.33)	(-11.73, 5.21)	
p-value	0.3570	0.4644	
p-value of Breslow-Day Test for Homogeneity [3]	0.0993	0.1495	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (28.0)	26 (29.9)	45 (30.6)
No	54 (72.0)	61 (70.1)	102 (69.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	1.04	
95% CI of the inverse odds ratio	(0.61, 2.10)	(0.58, 1.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.02	
95% CI of the inverse risk ratio	(0.71, 1.69)	(0.68, 1.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.61	-0.73	
95% CI of the absolute risk difference	(-15.21, 9.99)	(-12.89, 11.44)	
p-value	0.6871	0.9069	
p-value of Breslow-Day Test for Homogeneity [3]	0.1259	0.6230	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Total LDQOL			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (4.3)	2 (3.1)	3 (1.9)
No	88 (95.7)	62 (96.9)	153 (98.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	0.61	
95% CI of the inverse odds ratio	(0.09, 1.97)	(0.10, 3.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	0.62	
95% CI of the inverse risk ratio	(0.10, 1.93)	(0.11, 3.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.42	1.20	
95% CI of the absolute risk difference	(-2.27, 7.12)	(-3.57, 5.98)	
p-value	0.2654	0.5869	
p-value of Breslow-Day Test for Homogeneity [3]	0.1896	0.2985	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (23.9)	17 (26.6)	25 (16.0)
No	70 (76.1)	47 (73.4)	131 (84.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	0.53	
95% CI of the inverse odds ratio	(0.32, 1.15)	(0.26, 1.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.60	
95% CI of the inverse risk ratio	(0.40, 1.12)	(0.35, 1.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.89	10.54	
95% CI of the absolute risk difference	(-2.56, 18.33)	(-1.72, 22.79)	
p-value	0.1258	0.0709	
p-value of Breslow-Day Test for Homogeneity [3]	0.2344	0.0500	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Symptoms of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (3.3)	6 (9.4)	10 (6.4)
No	89 (96.7)	58 (90.6)	146 (93.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.03	0.66	
95% CI of the inverse odds ratio	(0.54, 7.58)	(0.23, 1.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.97	0.68	
95% CI of the inverse risk ratio	(0.56, 6.96)	(0.26, 1.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.15	2.96	
95% CI of the absolute risk difference	(-8.44, 2.14)	(-5.15, 11.07)	
p-value	0.2824	0.4418	
p-value of Breslow-Day Test for Homogeneity [3]	0.6934	0.6096	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (22.8)	15 (23.4)	41 (26.3)
No	71 (77.2)	49 (76.6)	115 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.16	
95% CI of the inverse odds ratio	(0.66, 2.20)	(0.59, 2.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.12	
95% CI of the inverse risk ratio	(0.73, 1.82)	(0.67, 1.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.46	-2.84	
95% CI of the absolute risk difference	(-14.47, 7.56)	(-15.31, 9.62)	
p-value	0.5437	0.6600	
p-value of Breslow-Day Test for Homogeneity [3]	0.8740	0.4984	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Effects of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (3.3)	5 (7.8)	13 (8.3)
No	89 (96.7)	59 (92.2)	143 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.70	1.07	
95% CI of the inverse odds ratio	(0.75, 9.73)	(0.37, 3.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.56	1.07	
95% CI of the inverse risk ratio	(0.75, 8.73)	(0.40, 2.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.07	-0.52	
95% CI of the absolute risk difference	(-10.73, 0.58)	(-8.40, 7.36)	
p-value	0.1162	0.8981	
p-value of Breslow-Day Test for Homogeneity [3]	0.7877	0.6094	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (17.4)	10 (15.6)	29 (18.6)
No	76 (82.6)	54 (84.4)	127 (81.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	1.23	
95% CI of the inverse odds ratio	(0.55, 2.13)	(0.56, 2.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.19	
95% CI of the inverse risk ratio	(0.61, 1.86)	(0.62, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.20	-2.96	
95% CI of the absolute risk difference	(-11.06, 8.66)	(-13.75, 7.82)	
p-value	0.8130	0.6010	
p-value of Breslow-Day Test for Homogeneity [3]	0.5365	0.6640	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Concentration/Memory			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (9.8)	3 (4.7)	6 (3.8)
No	83 (90.2)	61 (95.3)	150 (96.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.37	0.81	
95% CI of the inverse odds ratio	(0.13, 1.07)	(0.20, 3.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.39	0.82	
95% CI of the inverse risk ratio	(0.14, 1.07)	(0.21, 3.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.94	0.84	
95% CI of the absolute risk difference	(-0.84, 12.72)	(-5.15, 6.83)	
p-value	0.0582	0.7748	
p-value of Breslow-Day Test for Homogeneity [3]	0.1068	0.5258	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (22.8)	13 (20.3)	29 (18.6)
No	71 (77.2)	51 (79.7)	127 (81.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.90	
95% CI of the inverse odds ratio	(0.41, 1.45)	(0.43, 1.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.92	
95% CI of the inverse risk ratio	(0.49, 1.34)	(0.51, 1.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.24	1.72	
95% CI of the absolute risk difference	(-6.29, 14.76)	(-9.87, 13.32)	
p-value	0.4218	0.7678	
p-value of Breslow-Day Test for Homogeneity [3]	0.2751	0.8691	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Health Distress			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	19 (20.7)	12 (18.8)	19 (12.2)
No	73 (79.3)	52 (81.3)	137 (87.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	0.60	
95% CI of the inverse odds ratio	(0.27, 1.07)	(0.27, 1.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.65	
95% CI of the inverse risk ratio	(0.33, 1.05)	(0.34, 1.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.47	6.57	
95% CI of the absolute risk difference	(-1.26, 18.21)	(-4.28, 17.42)	
p-value	0.0736	0.2033	
p-value of Breslow-Day Test for Homogeneity [3]	0.0454	0.2493	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (26.1)	17 (26.6)	34 (21.8)
No	68 (73.9)	47 (73.4)	122 (78.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.77	
95% CI of the inverse odds ratio	(0.43, 1.44)	(0.39, 1.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.82	
95% CI of the inverse risk ratio	(0.53, 1.32)	(0.50, 1.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.29	4.77	
95% CI of the absolute risk difference	(-6.78, 15.36)	(-7.84, 17.38)	
p-value	0.4405	0.4466	
p-value of Breslow-Day Test for Homogeneity [3]	0.3233	0.3421	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Sexual Function			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (4.3)	2 (3.1)	7 (4.5)
No	88 (95.7)	62 (96.9)	149 (95.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.46	
95% CI of the inverse odds ratio	(0.29, 3.63)	(0.29, 7.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.44	
95% CI of the inverse risk ratio	(0.31, 3.43)	(0.31, 6.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.14	-1.36	
95% CI of the absolute risk difference	(-5.42, 5.14)	(-6.72, 4.00)	
p-value	0.9589	0.6432	
p-value of Breslow-Day Test for Homogeneity [3]	0.6968	0.6322	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (10.9)	4 (6.3)	13 (8.3)
No	82 (89.1)	60 (93.8)	143 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.36	
95% CI of the inverse odds ratio	(0.31, 1.78)	(0.43, 4.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.33	
95% CI of the inverse risk ratio	(0.35, 1.68)	(0.45, 3.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.54	-2.08	
95% CI of the absolute risk difference	(-5.16, 10.23)	(-9.43, 5.26)	
p-value	0.5060	0.5992	
p-value of Breslow-Day Test for Homogeneity [3]	0.1796	0.4457	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Sleep			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (13.0)	11 (17.2)	21 (13.5)
No	80 (87.0)	53 (82.8)	135 (86.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.75	
95% CI of the inverse odds ratio	(0.48, 2.22)	(0.34, 1.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.78	
95% CI of the inverse risk ratio	(0.53, 2.00)	(0.40, 1.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.42	3.73	
95% CI of the absolute risk difference	(-9.14, 8.30)	(-6.96, 14.41)	
p-value	0.9254	0.4765	
p-value of Breslow-Day Test for Homogeneity [3]	0.9494	0.0952	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (27.2)	22 (34.4)	48 (30.8)
No	67 (72.8)	42 (65.6)	108 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	0.85	
95% CI of the inverse odds ratio	(0.67, 2.11)	(0.46, 1.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	0.90	
95% CI of the inverse risk ratio	(0.75, 1.70)	(0.59, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.60	3.61	
95% CI of the absolute risk difference	(-15.22, 8.03)	(-10.10, 17.31)	
p-value	0.5484	0.6020	
p-value of Breslow-Day Test for Homogeneity [3]	0.7859	0.2548	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Loneliness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (13.0)	9 (14.1)	12 (7.7)
No	80 (87.0)	55 (85.9)	144 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.51	
95% CI of the inverse odds ratio	(0.24, 1.29)	(0.20, 1.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.55	
95% CI of the inverse risk ratio	(0.28, 1.26)	(0.24, 1.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.35	6.37	
95% CI of the absolute risk difference	(-2.70, 13.40)	(-3.12, 15.86)	
p-value	0.1685	0.1442	
p-value of Breslow-Day Test for Homogeneity [3]	0.1331	0.4478	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (25.0)	14 (21.9)	40 (25.6)
No	69 (75.0)	50 (78.1)	116 (74.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.23	
95% CI of the inverse odds ratio	(0.57, 1.87)	(0.62, 2.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.17	
95% CI of the inverse risk ratio	(0.66, 1.60)	(0.69, 2.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.64	-3.77	
95% CI of the absolute risk difference	(-11.83, 10.55)	(-15.99, 8.46)	
p-value	0.9108	0.5555	
p-value of Breslow-Day Test for Homogeneity [3]	0.5960	0.6921	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Hopelessness			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	17 (18.5)	13 (20.3)	20 (12.8)
No	75 (81.5)	51 (79.7)	136 (87.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	0.58	
95% CI of the inverse odds ratio	(0.32, 1.31)	(0.27, 1.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.63	
95% CI of the inverse risk ratio	(0.38, 1.26)	(0.33, 1.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.66	7.49	
95% CI of the absolute risk difference	(-3.85, 15.17)	(-3.67, 18.66)	
p-value	0.2270	0.1575	
p-value of Breslow-Day Test for Homogeneity [3]	0.8292	0.8531	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (28.3)	18 (28.1)	33 (21.2)
No	66 (71.7)	46 (71.9)	123 (78.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.69	
95% CI of the inverse odds ratio	(0.38, 1.23)	(0.35, 1.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.75	
95% CI of the inverse risk ratio	(0.48, 1.17)	(0.46, 1.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.11	6.97	
95% CI of the absolute risk difference	(-4.11, 18.32)	(-5.77, 19.72)	
p-value	0.2042	0.2658	
p-value of Breslow-Day Test for Homogeneity [3]	0.6919	0.7571	

AMNOG Table SE21.15.4
Liver Disease Quality of Life (SE21): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Stigma of Liver Disease			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (14.1)	9 (14.1)	13 (8.3)
No	79 (85.9)	55 (85.9)	143 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	0.56	
95% CI of the inverse odds ratio	(0.24, 1.25)	(0.22, 1.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.59	
95% CI of the inverse risk ratio	(0.29, 1.22)	(0.27, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.80	5.73	
95% CI of the absolute risk difference	(-2.54, 14.13)	(-3.83, 15.29)	
p-value	0.1500	0.1983	
p-value of Breslow-Day Test for Homogeneity [3]	0.0993	0.1495	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	31 (33.7)	17 (26.6)	36 (23.1)
No	61 (66.3)	47 (73.4)	120 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.83	
95% CI of the inverse odds ratio	(0.33, 1.04)	(0.43, 1.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.87	
95% CI of the inverse risk ratio	(0.46, 1.03)	(0.53, 1.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.62	3.49	
95% CI of the absolute risk difference	(-1.09, 22.32)	(-9.20, 16.17)	
p-value	0.0689	0.5829	
p-value of Breslow-Day Test for Homogeneity [3]	0.1259	0.6230	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Physical Functioning						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	74.61 (25.28)	71.47 (25.84)	76.63 (25.74)			
Median	80.00	80.00	85.00			
IQR: Q1, Q3	62.50, 95.00	55.00, 90.00	65.00, 100.00			
Min, Max	0.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	76.13 (25.76)	73.01 (24.00)	76.67 (27.01)	1.64 (1.61)	1.58 (1.85)	-0.61 (1.23)
Median	85.00	80.00	90.00	0	0	0
IQR: Q1, Q3	60.00, 100.00	60.00, 95.00	65.00, 100.00	-5.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	5.0, 100.0	5.0, 100.0	0.0, 100.0	-50.0, 60.0	-65.0, 70.0	-70.0, 65.0
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	76.43 (28.29)	71.87 (26.23)	77.80 (24.95)	0.65 (1.64)	0.65 (1.85)	0.21 (1.18)
Median	90.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 100.00	60.00, 95.00	65.00, 100.00	-5.00, 10.00	-5.00, 5.00	-5.00, 5.00
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-65.0, 45.0	-85.0, 40.0	-60.0, 70.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Role Physical						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	73.78 (28.13)	73.51 (27.40)	76.40 (26.59)			
Median	81.30	75.00	81.30			
IQR: Q1, Q3	50.00, 100.00	56.30, 100.00	56.30, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	73.55 (28.52)	74.25 (24.39)	78.06 (26.84)	-0.06 (1.71)	0.52 (2.02)	0.23 (1.38)
Median	81.30	75.00	87.50	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 100.00	62.50, 100.00	-12.50, 12.50	-12.50, 6.30	-6.30, 6.20
Min, Max	0.0, 100.0	0.0, 100.0	6.3, 100.0	-43.8, 50.0	-56.2, 68.7	-56.2, 87.5
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	75.07 (30.13)	73.79 (26.89)	77.56 (25.60)	0.53 (1.97)	0.33 (2.18)	0.22 (1.44)
Median	87.50	75.00	87.50	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 100.00	62.50, 100.00	-6.20, 6.20	-6.30, 6.30	-6.30, 6.30
Min, Max	0.0, 100.0	6.3, 100.0	0.0, 100.0	-43.8, 81.2	-75.0, 81.3	-62.5, 68.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Bodily Pain						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	65.5 (25.2)	62.8 (26.2)	66.1 (26.0)			
Median	72.0	62.0	72.0			
IQR: Q1, Q3	46.0, 84.0	41.0, 84.0	41.0, 84.0			
Min, Max	0, 100	0, 100	0, 100			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	64.6 (26.1)	64.2 (24.3)	67.2 (25.6)	-1.1 (2.0)	0.1 (1.8)	0.3 (1.5)
Median	72.0	62.0	72.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	51.0, 84.0	-12.0, 10.0	-10.0, 10.0	-12.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-59, 68	-62, 52	-78, 78
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	68.5 (27.1)	66.8 (25.6)	68.9 (25.6)	1.8 (2.2)	4.0 (2.2)	1.9 (1.8)
Median	74.0	72.0	72.0	0	0	0
IQR: Q1, Q3	51.0, 100.0	51.0, 84.0	51.0, 84.0	-10.0, 10.0	-10.0, 12.0	-12.0, 16.0
Min, Max	0, 100	10, 100	0, 100	-80, 68	-53, 69	-78, 78

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
General Health						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	57.39 (20.60)	52.53 (19.16)	57.69 (21.34)			
Median	57.00	52.00	57.00			
IQR: Q1, Q3	42.00, 72.00	38.50, 67.00	41.00, 77.00			
Min, Max	10.0, 100.0	10.0, 100.0	15.0, 100.0			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	58.20 (21.30)	53.99 (19.37)	58.34 (22.30)	1.48 (1.41)	2.02 (1.51)	0.24 (1.07)
Median	57.00	52.00	57.00	0	0	0
IQR: Q1, Q3	42.00, 77.00	40.00, 67.00	42.00, 77.00	-5.00, 10.00	-10.00, 10.00	-10.00, 8.00
Min, Max	10.0, 100.0	10.0, 100.0	0.0, 100.0	-60.0, 32.0	-35.0, 40.0	-40.0, 48.0
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	60.95 (21.50)	55.60 (19.39)	59.33 (21.58)	2.92 (1.67)	3.52 (1.76)	1.30 (1.09)
Median	63.50	55.00	62.00	0	4.00	0
IQR: Q1, Q3	42.00, 77.00	42.00, 67.00	45.00, 77.00	-5.00, 12.00	-5.00, 15.00	-5.00, 10.00
Min, Max	20.0, 100.0	10.0, 92.0	10.0, 100.0	-70.0, 47.0	-52.0, 47.0	-42.0, 37.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Vitality						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	55.73 (23.19)	52.56 (22.75)	55.61 (22.67)			
Median	56.30	56.30	56.30			
IQR: Q1, Q3	37.50, 75.00	37.50, 68.80	37.50, 75.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	55.19 (24.32)	53.01 (20.64)	56.24 (22.54)	-0.45 (1.33)	0.35 (1.50)	0.20 (1.15)
Median	56.30	56.30	56.30	0	0	0
IQR: Q1, Q3	37.50, 75.00	37.50, 62.50	37.50, 75.00	-6.30, 6.30	-12.50, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.8, 37.5	-31.3, 43.8	-37.5, 56.2
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	57.23 (24.02)	53.57 (20.86)	56.70 (23.33)	-0.06 (1.60)	0.46 (1.58)	0.46 (1.45)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	37.50, 75.00	37.50, 68.80	43.80, 75.00	-6.30, 12.50	-6.30, 6.30	-6.30, 12.50
Min, Max	6.3, 100.0	6.3, 100.0	0.0, 100.0	-43.7, 50.0	-43.8, 43.8	-56.3, 43.8

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Social Functioning						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	80.17 (24.89)	78.56 (26.37)	83.29 (22.43)			
Median	87.50	87.50	100.00			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	12.5, 100.0			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	77.83 (25.65)	80.11 (21.39)	81.03 (24.65)	-2.27 (1.97)	1.16 (2.06)	-3.01 (1.31)
Median	87.50	87.50	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	62.50, 100.00	-12.50, 0.00	-12.50, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	12.5, 100.0	0.0, 100.0	-50.0, 62.5	-62.5, 87.5	-62.5, 50.0
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	78.57 (25.00)	80.28 (22.95)	82.84 (22.52)	-2.69 (1.90)	1.73 (2.42)	-1.21 (1.43)
Median	87.50	87.50	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	62.50, 100.00	-12.50, 0.00	0.00, 12.50	0.00, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-50.0, 50.0	-62.5, 62.5	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Role Emotional						
Baseline						
m	124	126	224			
n	116	116	207			
Mean (SD)	79.67 (26.25)	81.25 (23.95)	83.57 (23.14)			
Median	91.70	91.70	100.00			
IQR: Q1, Q3	62.50, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	119	119	214			
n	115	115	199	110	108	186
Mean (SD/SE)	79.42 (24.34)	84.42 (20.96)	83.08 (24.13)	0.38 (1.69)	2.55 (1.58)	-0.94 (1.32)
Median	91.70	100.00	100.00	0	0	0
IQR: Q1, Q3	58.30, 100.00	75.00, 100.00	75.00, 100.00	-8.30, 0.00	0.00, 8.30	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-66.7, 50.0	-50.0, 50.0	-50.0, 50.0
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	80.65 (22.87)	84.02 (22.65)	83.28 (23.21)	0.58 (1.91)	2.84 (2.17)	-1.16 (1.33)
Median	89.60	100.00	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	0.00, 16.70	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-50.0, 100.0	-75.0, 50.0	-58.3, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Mental Health						
Baseline						
m	124	126	224			
n	116	116	208			
Mean (SD)	71.7 (21.4)	74.3 (19.3)	74.8 (18.1)			
Median	75.0	80.0	80.0			
IQR: Q1, Q3	57.5, 90.0	65.0, 90.0	65.0, 90.0			
Min, Max	5, 100	15, 100	5, 100			
Week 24						
m	119	119	214			
n	115	115	199	110	108	187
Mean (SD/SE)	71.3 (21.0)	74.3 (19.2)	73.9 (19.1)	0.0 (1.4)	-0.6 (1.3)	-1.0 (0.9)
Median	75.0	80.0	80.0	0	0	0
IQR: Q1, Q3	55.0, 90.0	65.0, 90.0	65.0, 90.0	-5.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	15, 100	5, 100	5, 100	-40, 35	-40, 50	-45, 30
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	73.3 (19.0)	74.5 (18.6)	74.8 (20.5)	0.8 (1.4)	-0.1 (1.4)	-0.6 (1.1)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	60.0, 90.0	65.0, 90.0	70.0, 90.0	-5.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	25, 100	20, 100	0, 100	-35, 40	-30, 50	-60, 40

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Mental Component Score						
Baseline						
m	124	126	224			
n	116	116	207			
Mean (SD)	49.29 (11.64)	50.14 (10.86)	50.79 (9.57)			
Median	52.55	53.10	53.70			
IQR: Q1, Q3	42.55, 57.80	44.85, 58.15	46.00, 57.70			
Min, Max	12.0, 69.0	17.0, 72.3	15.6, 66.5			
Week 24						
m	119	119	214			
n	115	115	199	110	108	186
Mean (SD/SE)	48.74 (11.26)	50.68 (9.89)	50.17 (10.52)	-0.33 (0.73)	0.28 (0.67)	-0.70 (0.52)
Median	51.50	53.00	52.90	-0.20	-0.10	0
IQR: Q1, Q3	41.70, 57.90	46.10, 58.40	44.10, 57.80	-4.30, 3.60	-3.00, 3.45	-4.00, 3.10
Min, Max	18.7, 69.1	9.4, 71.2	14.2, 69.0	-20.0, 19.0	-24.5, 26.1	-24.6, 21.4
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	49.50 (10.07)	50.76 (9.74)	50.52 (10.64)	-0.17 (0.76)	0.48 (0.83)	-0.57 (0.57)
Median	52.35	52.90	53.60	-0.20	-0.05	0.30
IQR: Q1, Q3	42.40, 57.50	44.20, 58.00	46.10, 58.00	-4.00, 3.60	-3.90, 2.90	-3.80, 3.60
Min, Max	23.1, 62.4	17.8, 70.7	8.9, 64.6	-21.7, 26.2	-21.4, 25.2	-25.1, 20.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Physical Component Score						
Baseline						
m	124	126	224			
n	116	116	207			
Mean (SD)	47.35 (9.53)	45.42 (9.79)	47.49 (9.78)			
Median	47.95	46.30	49.80			
IQR: Q1, Q3	42.80, 55.25	39.60, 53.40	40.70, 55.50			
Min, Max	15.3, 60.8	21.2, 60.4	20.7, 65.2			
Week 24						
m	119	119	214			
n	115	115	199	110	108	186
Mean (SD/SE)	47.62 (10.01)	45.87 (8.74)	48.04 (10.14)	0.28 (0.61)	0.45 (0.68)	0.16 (0.48)
Median	50.00	46.80	50.70	0.60	0.10	-0.05
IQR: Q1, Q3	41.80, 54.90	39.60, 52.80	42.30, 56.00	-3.30, 4.40	-2.80, 3.65	-3.40, 2.90
Min, Max	12.5, 63.9	20.2, 60.2	19.0, 63.0	-17.2, 18.3	-22.1, 21.7	-21.7, 23.8
Week 52						
m	108	107	201			
n	98	97	177	93	94	165
Mean (SD/SE)	48.39 (11.13)	46.16 (9.64)	48.37 (9.64)	0.63 (0.75)	0.86 (0.78)	0.64 (0.46)
Median	52.40	47.80	50.50	0.80	1.70	0.60
IQR: Q1, Q3	41.90, 57.50	40.90, 53.10	42.70, 56.00	-1.60, 4.20	-3.10, 5.20	-1.80, 3.40
Min, Max	15.8, 62.8	24.4, 61.2	21.5, 63.9	-24.7, 22.5	-23.5, 18.6	-23.9, 20.5

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Physical Functioning						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	74.47 (19.92)	62.05 (24.58)	68.13 (22.93)			
Median	76.40	60.00	70.00			
IQR: Q1, Q3	60.00, 90.00	40.00, 80.00	55.00, 87.50			
Min, Max	35.0, 100.0	15.0, 100.0	10.0, 100.0			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	74.52 (20.51)	63.65 (26.83)	69.71 (28.35)	0.79 (2.27)	-2.13 (5.80)	2.90 (2.48)
Median	80.00	70.00	80.00	0	-5.00	5.00
IQR: Q1, Q3	60.00, 90.00	55.00, 85.00	55.00, 90.00	-10.00, 10.00	-15.00, 5.00	-5.00, 10.00
Min, Max	20.0, 100.0	10.0, 100.0	0.0, 100.0	-25.0, 40.0	-45.0, 60.0	-50.0, 75.0
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	76.97 (21.95)	66.76 (25.25)	72.80 (22.90)	3.03 (2.25)	-0.33 (4.10)	2.05 (2.36)
Median	87.50	75.00	77.50	5.00	0	0
IQR: Q1, Q3	60.00, 95.00	55.00, 85.00	65.00, 90.00	-5.00, 10.00	-5.00, 5.00	-10.00, 15.00
Min, Max	30.0, 100.0	10.0, 100.0	10.0, 100.0	-42.8, 35.0	-40.0, 30.0	-30.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Role Physical						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	81.26 (18.77)	71.05 (25.34)	74.67 (24.57)			
Median	87.50	78.15	81.30			
IQR: Q1, Q3	75.00, 100.00	50.00, 93.80	56.25, 100.00			
Min, Max	37.5, 100.0	25.0, 100.0	0.0, 100.0			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	76.80 (21.87)	70.85 (22.47)	69.96 (27.72)	-4.26 (2.95)	-4.87 (5.07)	-1.91 (3.03)
Median	81.30	75.00	75.00	0	-6.25	0
IQR: Q1, Q3	62.50, 100.00	56.30, 81.30	50.00, 93.80	-12.50, 6.20	-18.70, 0.00	-12.50, 12.50
Min, Max	31.3, 100.0	18.8, 100.0	0.0, 100.0	-43.7, 43.7	-37.5, 62.5	-68.7, 68.7
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	78.63 (20.89)	74.66 (23.84)	69.78 (22.21)	-3.04 (2.58)	2.91 (5.72)	-4.74 (3.14)
Median	78.15	81.30	68.80	0	0	-6.25
IQR: Q1, Q3	62.50, 100.00	62.50, 93.80	50.00, 93.80	-12.50, 0.00	-12.50, 12.50	-18.70, 0.00
Min, Max	37.5, 100.0	6.3, 100.0	18.8, 100.0	-37.5, 43.8	-37.5, 50.0	-56.2, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Bodily Pain						
Baseline						
m	43	25	79			
n	41	22	72			
Mean (SD)	70.4 (21.5)	58.0 (26.9)	63.5 (22.4)			
Median	72.0	61.5	62.0			
IQR: Q1, Q3	51.0, 84.0	41.0, 74.0	41.0, 84.0			
Min, Max	22, 100	10, 100	12, 100			
Week 24						
m	42	22	75			
n	42	21	68	40	18	62
Mean (SD/SE)	62.7 (23.7)	66.0 (23.8)	62.6 (25.5)	-5.9 (2.6)	5.3 (6.2)	0.4 (2.5)
Median	62.0	72.0	62.0	0	0	0
IQR: Q1, Q3	51.0, 84.0	51.0, 84.0	41.0, 84.0	-20.0, 0.0	0.0, 3.0	-11.0, 12.0
Min, Max	10, 100	22, 100	0, 100	-39, 28	-29, 72	-43, 59
Week 52						
m	41	18	69			
n	38	17	62	36	15	58
Mean (SD/SE)	65.8 (22.2)	69.1 (25.9)	63.8 (22.3)	-4.2 (2.8)	11.1 (5.5)	-0.2 (2.6)
Median	62.0	74.0	62.0	0	0	0
IQR: Q1, Q3	44.0, 84.0	41.0, 84.0	51.0, 84.0	-13.0, 10.0	0.0, 19.0	-10.0, 10.0
Min, Max	22, 100	10, 100	10, 100	-49, 26	-12, 62	-48, 62

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
General Health						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	69.02 (14.87)	62.45 (17.37)	62.04 (16.80)			
Median	69.50	62.00	62.00			
IQR: Q1, Q3	62.00, 77.00	50.00, 72.00	51.00, 72.00			
Min, Max	30.0, 97.0	30.0, 92.0	15.0, 100.0			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	68.07 (18.22)	61.19 (18.91)	62.00 (18.78)	-0.36 (2.04)	-2.72 (3.67)	1.97 (1.88)
Median	72.00	57.00	62.00	0	0	0
IQR: Q1, Q3	52.00, 82.00	45.00, 82.00	51.00, 72.00	-5.00, 10.00	-15.00, 5.00	-8.00, 10.00
Min, Max	25.0, 97.0	30.0, 92.0	25.0, 100.0	-47.0, 18.0	-35.0, 25.0	-37.0, 37.0
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	67.47 (13.97)	57.88 (18.56)	64.05 (17.90)	-2.08 (1.87)	-6.27 (4.26)	1.95 (1.73)
Median	67.00	57.00	64.50	-5.00	-10.00	0
IQR: Q1, Q3	57.00, 77.00	45.00, 72.00	52.00, 77.00	-10.00, 5.00	-20.00, 10.00	-5.00, 10.00
Min, Max	30.0, 100.0	20.0, 87.0	20.0, 100.0	-22.0, 30.0	-35.0, 20.0	-30.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Vitality						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	62.13 (19.66)	59.68 (20.02)	59.28 (17.85)			
Median	62.50	59.40	62.50			
IQR: Q1, Q3	56.30, 75.00	43.80, 75.00	46.90, 71.90			
Min, Max	18.8, 100.0	18.8, 93.8	18.8, 93.8			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	60.30 (21.86)	57.77 (17.78)	59.04 (21.11)	-1.11 (2.63)	-5.20 (3.55)	-0.06 (1.90)
Median	65.65	56.30	56.30	0	-6.25	0
IQR: Q1, Q3	56.30, 75.00	43.80, 75.00	43.80, 75.00	-6.30, 6.30	-18.70, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	25.0, 81.3	6.3, 100.0	-43.8, 43.8	-31.2, 25.0	-31.2, 43.7
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	62.36 (19.35)	62.16 (20.31)	59.60 (19.79)	-0.17 (2.59)	-0.41 (3.93)	0.79 (1.87)
Median	62.50	62.50	62.50	0	0	0
IQR: Q1, Q3	50.00, 75.00	56.30, 81.30	50.00, 68.80	-12.50, 12.50	-12.50, 12.50	-6.30, 6.30
Min, Max	18.8, 93.8	25.0, 87.5	6.3, 100.0	-31.2, 37.5	-31.2, 25.0	-31.3, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Social Functioning						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	86.31 (19.68)	85.23 (22.04)	81.94 (22.68)			
Median	100.00	100.00	87.50			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	25.0, 100.0	12.5, 100.0			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	89.88 (18.77)	90.48 (16.25)	81.62 (24.86)	3.66 (3.42)	4.86 (3.05)	2.62 (2.98)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	87.50, 100.00	62.50, 100.00	0.00, 12.50	0.00, 12.50	-12.50, 12.50
Min, Max	25.0, 100.0	50.0, 100.0	12.5, 100.0	-62.5, 75.0	-12.5, 50.0	-62.5, 75.0
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	89.47 (16.06)	90.44 (16.85)	83.27 (20.24)	1.01 (2.29)	2.50 (4.60)	1.51 (2.93)
Median	100.00	100.00	87.50	0	0	0
IQR: Q1, Q3	75.00, 100.00	87.50, 100.00	75.00, 100.00	0.00, 0.00	0.00, 12.50	-12.50, 12.50
Min, Max	50.0, 100.0	50.0, 100.0	12.5, 100.0	-37.5, 37.5	-37.5, 37.5	-37.5, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Role Emotional						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	88.69 (18.21)	85.99 (22.48)	85.18 (20.04)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	83.30, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	25.0, 100.0	25.0, 100.0			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	87.30 (18.43)	90.09 (18.56)	82.23 (23.87)	-1.42 (2.74)	5.09 (3.03)	-0.94 (2.58)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	91.70, 100.00	66.70, 100.00	-8.30, 0.00	0.00, 8.30	-8.30, 0.00
Min, Max	25.0, 100.0	41.7, 100.0	16.7, 100.0	-33.3, 66.7	-16.7, 41.7	-50.0, 58.3
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	90.35 (15.45)	89.71 (16.28)	81.98 (21.30)	1.35 (2.36)	6.11 (6.11)	-3.45 (2.92)
Median	100.00	100.00	83.30	0	0	0
IQR: Q1, Q3	83.30, 100.00	83.30, 100.00	66.70, 100.00	0.00, 0.00	-8.30, 25.00	-16.70, 0.00
Min, Max	50.0, 100.0	50.0, 100.0	16.7, 100.0	-25.0, 50.0	-33.3, 58.3	-50.0, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Mental Health						
Baseline						
m	43	25	79			
n	42	22	72			
Mean (SD)	79.3 (13.8)	77.7 (19.6)	76.3 (16.9)			
Median	85.0	82.5	80.0			
IQR: Q1, Q3	70.0, 90.0	70.0, 90.0	65.0, 90.0			
Min, Max	35, 100	30, 100	20, 100			
Week 24						
m	42	22	75			
n	42	21	68	41	18	62
Mean (SD/SE)	76.9 (16.3)	79.5 (16.9)	76.6 (18.4)	-2.6 (1.7)	-0.6 (1.8)	2.3 (2.3)
Median	77.5	80.0	85.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	75.0, 90.0	67.5, 90.0	-10.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	25, 100	25, 100	20, 100	-25, 30	-20, 10	-30, 55
Week 52						
m	41	18	69			
n	38	17	62	37	15	58
Mean (SD/SE)	80.3 (14.6)	81.2 (15.1)	78.2 (15.9)	0.0 (1.7)	1.7 (2.0)	3.7 (2.3)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	75.0, 90.0	75.0, 95.0	70.0, 90.0	-5.0, 10.0	0.0, 5.0	-5.0, 15.0
Min, Max	45, 100	40, 100	20, 100	-25, 20	-15, 15	-40, 55

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Mental Component Score						
Baseline						
m	43	25	79			
n	41	22	72			
Mean (SD)	53.93 (7.16)	54.44 (11.35)	52.60 (8.48)			
Median	56.50	56.65	56.00			
IQR: Q1, Q3	49.60, 59.10	50.30, 63.60	47.05, 58.85			
Min, Max	27.6, 62.7	26.0, 70.0	30.0, 65.8			
Week 24						
m	42	22	75			
n	42	21	68	40	18	62
Mean (SD/SE)	53.45 (7.85)	55.56 (8.22)	52.21 (9.63)	-0.61 (0.99)	0.95 (1.38)	0.49 (1.16)
Median	55.10	58.20	55.70	-0.85	0.45	-1.25
IQR: Q1, Q3	47.90, 59.40	52.10, 61.10	47.10, 59.35	-2.90, 3.30	-1.70, 3.40	-6.00, 3.50
Min, Max	31.9, 64.6	34.0, 68.3	23.1, 64.5	-16.5, 11.8	-12.0, 12.4	-18.4, 24.8
Week 52						
m	41	18	69			
n	38	17	62	36	15	58
Mean (SD/SE)	54.63 (6.94)	55.85 (8.47)	52.49 (8.69)	0.17 (0.97)	1.27 (2.33)	0.61 (1.13)
Median	56.80	59.00	54.90	0.95	-1.00	-0.45
IQR: Q1, Q3	52.40, 60.50	50.30, 62.00	47.30, 58.70	-1.90, 3.40	-2.40, 4.80	-4.20, 3.60
Min, Max	38.3, 63.2	33.8, 68.1	20.4, 68.0	-17.3, 12.4	-14.0, 25.1	-20.7, 26.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Physical Component Score						
Baseline						
m	43	25	79			
n	41	22	72			
Mean (SD)	48.80 (6.79)	43.43 (10.44)	45.78 (8.33)			
Median	48.90	45.20	47.45			
IQR: Q1, Q3	43.30, 53.80	34.80, 50.90	40.55, 52.70			
Min, Max	32.7, 59.3	23.4, 61.3	25.9, 59.8			
Week 24						
m	42	22	75			
n	42	21	68	40	18	62
Mean (SD/SE)	47.45 (8.38)	43.98 (10.04)	45.52 (9.64)	-0.80 (0.89)	-1.03 (2.44)	0.32 (0.98)
Median	48.70	44.30	47.10	-1.05	-2.45	0.20
IQR: Q1, Q3	41.70, 52.70	38.00, 51.80	41.00, 53.40	-4.50, 3.05	-5.10, 0.70	-3.10, 4.80
Min, Max	23.1, 61.4	24.6, 61.0	23.1, 59.9	-15.7, 10.9	-22.0, 32.4	-28.8, 22.9
Week 52						
m	41	18	69			
n	38	17	62	36	15	58
Mean (SD/SE)	47.81 (8.36)	44.88 (11.24)	46.24 (7.71)	-0.63 (0.75)	0.30 (2.08)	-0.20 (0.88)
Median	49.00	47.80	46.60	-0.30	0.60	0.05
IQR: Q1, Q3	42.10, 54.20	40.60, 52.70	42.20, 52.10	-2.80, 2.15	-2.60, 2.30	-4.80, 3.80
Min, Max	26.7, 62.5	16.0, 60.9	24.6, 59.9	-14.1, 9.9	-17.5, 17.2	-12.2, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Physical Functioning			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	74.59 (25.18)	71.53 (25.92)	77.41 (25.88)
Analysis Visit Mean (SD)	76.23 (26.01)	73.11 (23.66)	76.80 (27.06)
LS Mean of Change from Baseline (SE)	1.66 (1.62)	0.58 (1.62)	-0.32 (1.23)
95% CI	(-1.52, 4.85)	(-2.60, 3.76)	(-2.74, 2.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.98 (1.99)	0.90 (2.01)	
95% CI	(-1.94, 5.90)	(-3.04, 4.84)	
p-value	0.3211	0.6547	
Corrected Hedge's g Statistics	0.117	0.053	
95% CI	(-0.12, 0.35)	(-0.18, 0.29)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	76.08 (23.89)	70.85 (26.38)	77.58 (25.86)
Analysis Visit Mean (SD)	76.72 (28.35)	71.50 (26.32)	77.79 (24.95)
LS Mean of Change from Baseline (SE)	1.00 (1.63)	0.06 (1.61)	0.45 (1.22)
95% CI	(-2.20, 4.20)	(-3.11, 3.22)	(-1.94, 2.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.55 (1.99)	-0.39 (1.99)	
95% CI	(-3.36, 4.46)	(-4.31, 3.52)	
p-value	0.7832	0.8428	
Corrected Hedge's g Statistics	0.035	-0.025	
95% CI	(-0.22, 0.29)	(-0.28, 0.23)	
Subgroup*Treatment Interaction p-value	0.8464	0.4140	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Role Physical			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	73.88 (28.04)	73.68 (27.82)	77.36 (26.75)
Analysis Visit Mean (SD)	73.82 (28.60)	74.20 (24.60)	77.59 (27.11)
LS Mean of Change from Baseline (SE)	0.04 (1.75)	-0.10 (1.74)	0.85 (1.33)
95% CI	(-3.39, 3.48)	(-3.52, 3.33)	(-1.76, 3.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.81 (2.15)	-0.95 (2.16)	
95% CI	(-5.04, 3.42)	(-5.19, 3.29)	
p-value	0.7081	0.6607	
Corrected Hedge's g Statistics	-0.044	-0.052	
95% CI	(-0.28, 0.19)	(-0.29, 0.18)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	74.74 (29.37)	72.89 (28.48)	77.18 (26.51)
Analysis Visit Mean (SD)	75.28 (30.52)	73.22 (27.04)	77.40 (25.80)
LS Mean of Change from Baseline (SE)	0.70 (1.87)	0.07 (1.85)	0.98 (1.40)
95% CI	(-2.97, 4.37)	(-3.56, 3.69)	(-1.77, 3.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.28 (2.29)	-0.91 (2.28)	
95% CI	(-4.78, 4.22)	(-5.39, 3.57)	
p-value	0.9024	0.6891	
Corrected Hedge's g Statistics	-0.016	-0.051	
95% CI	(-0.27, 0.24)	(-0.30, 0.20)	
Subgroup*Treatment Interaction p-value	0.5222	0.4646	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Bodily Pain			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	65.6 (25.1)	63.6 (26.0)	67.1 (25.9)
Analysis Visit Mean (SD)	64.5 (26.3)	63.7 (24.5)	67.4 (25.9)
LS Mean of Change from Baseline (SE)	-1.06 (1.83)	-0.67 (1.82)	0.57 (1.39)
95% CI	(-4.66, 2.54)	(-4.25, 2.92)	(-2.16, 3.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.63 (2.24)	-1.23 (2.25)	
95% CI	(-6.04, 2.78)	(-5.66, 3.19)	
p-value	0.4685	0.5842	
Corrected Hedge's g Statistics	-0.085	-0.065	
95% CI	(-0.32, 0.15)	(-0.30, 0.17)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	66.6 (25.9)	62.3 (26.1)	67.1 (25.8)
Analysis Visit Mean (SD)	68.4 (27.4)	66.4 (25.7)	69.0 (25.4)
LS Mean of Change from Baseline (SE)	1.81 (2.08)	2.46 (2.06)	2.07 (1.56)
95% CI	(-2.28, 5.89)	(-1.59, 6.50)	(-0.98, 5.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.26 (2.55)	0.38 (2.54)	
95% CI	(-5.27, 4.74)	(-4.61, 5.38)	
p-value	0.9172	0.8805	
Corrected Hedge's g Statistics	-0.013	0.019	
95% CI	(-0.27, 0.24)	(-0.23, 0.27)	
Subgroup*Treatment Interaction p-value	0.5372	0.2877	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
General Health			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	57.22 (19.97)	51.49 (18.68)	58.34 (21.47)
Analysis Visit Mean (SD)	58.70 (20.69)	53.51 (19.48)	58.58 (22.48)
LS Mean of Change from Baseline (SE)	1.62 (1.41)	0.32 (1.41)	0.54 (1.07)
95% CI	(-1.15, 4.39)	(-2.45, 3.10)	(-1.57, 2.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.08 (1.73)	-0.22 (1.75)	
95% CI	(-2.32, 4.48)	(-3.65, 3.22)	
p-value	0.5315	0.9018	
Corrected Hedge's g Statistics	0.074	-0.015	
95% CI	(-0.16, 0.31)	(-0.25, 0.22)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	58.46 (20.62)	51.63 (19.65)	58.47 (21.49)
Analysis Visit Mean (SD)	61.38 (21.45)	55.15 (19.32)	59.77 (21.83)
LS Mean of Change from Baseline (SE)	3.01 (1.51)	1.60 (1.49)	1.85 (1.13)
95% CI	(0.05, 5.97)	(-1.33, 4.54)	(-0.36, 4.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.16 (1.84)	-0.25 (1.85)	
95% CI	(-2.46, 4.77)	(-3.88, 3.38)	
p-value	0.5303	0.8918	
Corrected Hedge's g Statistics	0.080	-0.017	
95% CI	(-0.17, 0.33)	(-0.27, 0.24)	
Subgroup*Treatment Interaction p-value	0.4217	0.1444	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Vitality			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	56.10 (23.42)	52.22 (22.82)	56.24 (22.90)
Analysis Visit Mean (SD)	55.65 (23.79)	52.57 (20.20)	56.44 (22.84)
LS Mean of Change from Baseline (SE)	-0.35 (1.40)	-0.95 (1.39)	0.04 (1.06)
95% CI	(-3.09, 2.40)	(-3.69, 1.79)	(-2.04, 2.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.39 (1.71)	-1.00 (1.72)	
95% CI	(-3.76, 2.97)	(-4.37, 2.38)	
p-value	0.8192	0.5629	
Corrected Hedge's g Statistics	-0.027	-0.069	
95% CI	(-0.26, 0.21)	(-0.31, 0.17)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	57.48 (23.95)	52.82 (22.95)	56.31 (23.02)
Analysis Visit Mean (SD)	57.42 (23.49)	53.28 (20.95)	56.77 (23.73)
LS Mean of Change from Baseline (SE)	0.39 (1.62)	-0.93 (1.61)	0.39 (1.21)
95% CI	(-2.80, 3.58)	(-4.09, 2.22)	(-2.00, 2.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (1.99)	-1.32 (1.98)	
95% CI	(-3.91, 3.91)	(-5.22, 2.58)	
p-value	0.9996	0.5055	
Corrected Hedge's g Statistics	0.000	-0.085	
95% CI	(-0.25, 0.25)	(-0.34, 0.17)	
Subgroup*Treatment Interaction p-value	0.9419	0.6589	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Social Functioning			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	80.80 (24.34)	78.70 (26.54)	83.62 (22.30)
Analysis Visit Mean (SD)	78.52 (25.69)	79.86 (21.67)	80.61 (24.67)
LS Mean of Change from Baseline (SE)	-2.56 (1.76)	-0.34 (1.76)	-2.63 (1.34)
95% CI	(-6.02, 0.90)	(-3.80, 3.12)	(-5.26, 0.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.07 (2.17)	2.29 (2.18)	
95% CI	(-4.19, 4.33)	(-1.99, 6.57)	
p-value	0.9737	0.2931	
Corrected Hedge's g Statistics	0.004	0.125	
95% CI	(-0.23, 0.24)	(-0.11, 0.36)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	81.72 (24.49)	78.32 (27.63)	84.02 (21.98)
Analysis Visit Mean (SD)	79.03 (25.08)	80.05 (23.21)	82.80 (22.95)
LS Mean of Change from Baseline (SE)	-2.72 (1.86)	0.59 (1.84)	-1.00 (1.39)
95% CI	(-6.37, 0.93)	(-3.03, 4.20)	(-3.73, 1.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.72 (2.27)	1.59 (2.27)	
95% CI	(-6.19, 2.75)	(-2.88, 6.05)	
p-value	0.4499	0.4847	
Corrected Hedge's g Statistics	-0.096	0.089	
95% CI	(-0.35, 0.16)	(-0.16, 0.34)	
Subgroup*Treatment Interaction p-value	0.2420	0.5571	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Role Emotional			
Week 24			
m	119	119	214
n	110	108	186
Baseline Mean (SD)	80.07 (25.99)	81.40 (24.29)	83.78 (23.28)
Analysis Visit Mean (SD)	80.45 (23.82)	83.95 (21.22)	82.84 (24.51)
LS Mean of Change from Baseline (SE)	-0.08 (1.58)	2.12 (1.57)	-0.63 (1.20)
95% CI	(-3.18, 3.03)	(-0.96, 5.21)	(-2.98, 1.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.55 (1.94)	2.75 (1.94)	
95% CI	(-3.26, 4.36)	(-1.06, 6.56)	
p-value	0.7759	0.1566	
Corrected Hedge's g Statistics	0.034	0.168	
95% CI	(-0.20, 0.27)	(-0.07, 0.41)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	80.91 (25.14)	80.76 (25.28)	84.09 (23.21)
Analysis Visit Mean (SD)	81.50 (22.57)	83.60 (22.88)	82.93 (23.62)
LS Mean of Change from Baseline (SE)	0.46 (1.74)	2.84 (1.72)	-1.04 (1.30)
95% CI	(-2.95, 3.88)	(-0.54, 6.21)	(-3.60, 1.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.51 (2.13)	3.88 (2.12)	
95% CI	(-2.68, 5.69)	(-0.29, 8.05)	
p-value	0.4797	0.0680	
Corrected Hedge's g Statistics	0.090	0.232	
95% CI	(-0.16, 0.34)	(-0.02, 0.49)	
Subgroup*Treatment Interaction p-value	0.5616	0.4034	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Mental Health			
Week 24			
m	119	119	214
n	110	108	187
Baseline Mean (SD)	72.2 (20.9)	74.7 (19.2)	74.8 (18.1)
Analysis Visit Mean (SD)	72.2 (20.3)	74.0 (19.3)	73.8 (19.3)
LS Mean of Change from Baseline (SE)	-0.43 (1.27)	-0.84 (1.26)	-1.14 (0.96)
95% CI	(-2.93, 2.06)	(-3.32, 1.64)	(-3.02, 0.75)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.71 (1.55)	0.30 (1.55)	
95% CI	(-2.35, 3.76)	(-2.75, 3.35)	
p-value	0.6493	0.8477	
Corrected Hedge's g Statistics	0.054	0.023	
95% CI	(-0.18, 0.29)	(-0.21, 0.26)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	73.1 (20.0)	74.5 (19.8)	75.0 (18.2)
Analysis Visit Mean (SD)	73.8 (18.5)	74.4 (18.8)	74.4 (20.9)
LS Mean of Change from Baseline (SE)	0.67 (1.40)	-0.28 (1.38)	-1.10 (1.05)
95% CI	(-2.08, 3.43)	(-3.00, 2.44)	(-3.16, 0.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.78 (1.72)	0.82 (1.71)	
95% CI	(-1.60, 5.15)	(-2.53, 4.18)	
p-value	0.3013	0.6299	
Corrected Hedge's g Statistics	0.131	0.061	
95% CI	(-0.12, 0.39)	(-0.19, 0.31)	
Subgroup*Treatment Interaction p-value	0.1591	0.6915	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Mental Component Score			
Week 24			
m	119	119	214
n	110	108	186
Baseline Mean (SD)	49.59 (11.47)	50.20 (11.02)	50.79 (9.63)
Analysis Visit Mean (SD)	49.25 (10.81)	50.48 (10.02)	50.09 (10.57)
LS Mean of Change from Baseline (SE)	-0.53 (0.67)	0.03 (0.66)	-0.76 (0.51)
95% CI	(-1.84, 0.79)	(-1.28, 1.33)	(-1.75, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.23 (0.82)	0.79 (0.82)	
95% CI	(-1.38, 1.84)	(-0.83, 2.40)	
p-value	0.7791	0.3389	
Corrected Hedge's g Statistics	0.033	0.113	
95% CI	(-0.20, 0.27)	(-0.12, 0.35)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	50.00 (11.08)	50.20 (11.52)	50.93 (9.61)
Analysis Visit Mean (SD)	49.83 (9.78)	50.68 (9.84)	50.36 (10.78)
LS Mean of Change from Baseline (SE)	-0.19 (0.73)	0.35 (0.72)	-0.77 (0.54)
95% CI	(-1.62, 1.24)	(-1.06, 1.77)	(-1.84, 0.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.58 (0.89)	1.13 (0.89)	
95% CI	(-1.17, 2.33)	(-0.61, 2.87)	
p-value	0.5149	0.2036	
Corrected Hedge's g Statistics	0.083	0.161	
95% CI	(-0.17, 0.34)	(-0.09, 0.41)	
Subgroup*Treatment Interaction p-value	0.7861	0.8315	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Physical Component Score			
Week 24			
m	119	119	214
n	110	108	186
Baseline Mean (SD)	47.26 (9.41)	45.37 (9.80)	47.94 (9.84)
Analysis Visit Mean (SD)	47.54 (10.08)	45.82 (8.71)	48.09 (10.13)
LS Mean of Change from Baseline (SE)	0.39 (0.62)	-0.03 (0.62)	0.34 (0.47)
95% CI	(-0.83, 1.60)	(-1.25, 1.18)	(-0.59, 1.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.76)	-0.37 (0.76)	
95% CI	(-1.45, 1.54)	(-1.88, 1.13)	
p-value	0.9517	0.6268	
Corrected Hedge's g Statistics	0.007	-0.058	
95% CI	(-0.23, 0.24)	(-0.29, 0.18)	
Week 52			
m	108	107	201
n	93	94	165
Baseline Mean (SD)	47.74 (9.66)	45.10 (9.99)	47.86 (9.63)
Analysis Visit Mean (SD)	48.37 (11.27)	45.96 (9.63)	48.50 (9.44)
LS Mean of Change from Baseline (SE)	0.71 (0.66)	0.39 (0.66)	0.87 (0.50)
95% CI	(-0.59, 2.01)	(-0.90, 1.68)	(-0.11, 1.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.16 (0.81)	-0.47 (0.81)	
95% CI	(-1.75, 1.44)	(-2.07, 1.12)	
p-value	0.8465	0.5602	
Corrected Hedge's g Statistics	-0.025	-0.074	
95% CI	(-0.28, 0.23)	(-0.33, 0.18)	
Subgroup*Treatment Interaction p-value	0.9359	0.9013	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Physical Functioning			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	73.85 (19.75)	61.67 (25.55)	68.39 (23.22)
Analysis Visit Mean (SD)	74.63 (20.75)	59.54 (26.78)	71.29 (27.85)
LS Mean of Change from Baseline (SE)	1.94 (2.98)	-3.62 (4.43)	2.39 (2.54)
95% CI	(-3.96, 7.84)	(-12.39, 5.15)	(-2.64, 7.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.45 (3.72)	-6.01 (4.94)	
95% CI	(-7.82, 6.92)	(-15.79, 3.77)	
p-value	0.9032	0.2260	
Corrected Hedge's g Statistics	-0.023	-0.301	
95% CI	(-0.42, 0.37)	(-0.83, 0.23)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	73.32 (20.09)	65.33 (25.46)	71.38 (19.48)
Analysis Visit Mean (SD)	76.35 (21.91)	65.00 (26.39)	73.43 (21.92)
LS Mean of Change from Baseline (SE)	3.85 (2.71)	0.67 (4.12)	2.31 (2.31)
95% CI	(-1.53, 9.22)	(-7.48, 8.82)	(-2.27, 6.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.54 (3.34)	-1.64 (4.54)	
95% CI	(-5.07, 8.16)	(-10.62, 7.35)	
p-value	0.6455	0.7191	
Corrected Hedge's g Statistics	0.089	-0.094	
95% CI	(-0.32, 0.50)	(-0.66, 0.47)	
Subgroup*Treatment Interaction p-value	0.8464	0.4140	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Role Physical			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	80.80 (18.77)	73.29 (24.61)	73.90 (25.01)
Analysis Visit Mean (SD)	76.54 (22.08)	68.42 (23.03)	72.00 (27.64)
LS Mean of Change from Baseline (SE)	-1.81 (3.32)	-5.13 (4.92)	-2.51 (2.84)
95% CI	(-8.39, 4.77)	(-14.87, 4.61)	(-8.14, 3.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.69 (4.17)	-2.62 (5.48)	
95% CI	(-7.56, 8.95)	(-13.48, 8.23)	
p-value	0.8680	0.6330	
Corrected Hedge's g Statistics	0.031	-0.118	
95% CI	(-0.36, 0.43)	(-0.64, 0.41)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	81.09 (18.77)	72.53 (25.31)	76.31 (22.11)
Analysis Visit Mean (SD)	78.05 (20.86)	75.44 (24.93)	71.57 (21.43)
LS Mean of Change from Baseline (SE)	-0.04 (3.18)	2.88 (4.86)	-4.25 (2.68)
95% CI	(-6.35, 6.26)	(-6.73, 12.50)	(-9.57, 1.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.21 (3.94)	7.14 (5.34)	
95% CI	(-3.59, 12.01)	(-3.43, 17.70)	
p-value	0.2876	0.1835	
Corrected Hedge's g Statistics	0.208	0.351	
95% CI	(-0.20, 0.62)	(-0.22, 0.92)	
Subgroup*Treatment Interaction p-value	0.5222	0.4646	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Bodily Pain			
Week 24			
m	42	22	75
n	40	18	62
Baseline Mean (SD)	69.6 (21.2)	57.4 (28.2)	63.6 (22.1)
Analysis Visit Mean (SD)	63.8 (23.8)	62.8 (23.8)	63.9 (25.4)
LS Mean of Change from Baseline (SE)	-3.60 (3.03)	4.05 (4.47)	0.56 (2.57)
95% CI	(-9.61, 2.40)	(-4.80, 12.91)	(-4.54, 5.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.16 (3.81)	3.50 (4.98)	
95% CI	(-11.70, 3.37)	(-6.37, 13.36)	
p-value	0.2766	0.4839	
Corrected Hedge's g Statistics	-0.208	0.173	
95% CI	(-0.61, 0.19)	(-0.35, 0.70)	
Week 52			
m	41	18	69
n	36	15	58
Baseline Mean (SD)	69.7 (21.5)	55.0 (30.3)	64.8 (21.1)
Analysis Visit Mean (SD)	65.5 (21.8)	66.1 (26.0)	64.6 (21.6)
LS Mean of Change from Baseline (SE)	-1.76 (2.93)	7.65 (4.48)	0.99 (2.45)
95% CI	(-7.56, 4.05)	(-1.23, 16.52)	(-3.86, 5.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.74 (3.64)	6.66 (4.92)	
95% CI	(-9.95, 4.47)	(-3.08, 16.41)	
p-value	0.4529	0.1785	
Corrected Hedge's g Statistics	-0.149	0.359	
95% CI	(-0.57, 0.27)	(-0.21, 0.93)	
Subgroup*Treatment Interaction p-value	0.5372	0.2877	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
General Health			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	68.70 (14.92)	62.39 (16.43)	61.23 (16.69)
Analysis Visit Mean (SD)	68.34 (18.36)	59.67 (19.62)	63.19 (18.85)
LS Mean of Change from Baseline (SE)	0.04 (2.31)	-3.57 (3.39)	0.53 (1.96)
95% CI	(-4.53, 4.61)	(-10.28, 3.14)	(-3.34, 4.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.50 (2.90)	-4.10 (3.77)	
95% CI	(-6.24, 5.24)	(-11.57, 3.37)	
p-value	0.8642	0.2789	
Corrected Hedge's g Statistics	-0.033	-0.267	
95% CI	(-0.43, 0.36)	(-0.79, 0.26)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	69.02 (15.63)	63.93 (16.59)	62.97 (17.42)
Analysis Visit Mean (SD)	66.95 (13.78)	57.67 (19.63)	64.91 (17.94)
LS Mean of Change from Baseline (SE)	-1.04 (2.10)	-6.34 (3.15)	1.10 (1.77)
95% CI	(-5.20, 3.11)	(-12.59, -0.10)	(-2.40, 4.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.15 (2.59)	-7.45 (3.46)	
95% CI	(-7.28, 2.99)	(-14.29, -0.60)	
p-value	0.4096	0.0332	
Corrected Hedge's g Statistics	-0.161	-0.557	
95% CI	(-0.57, 0.25)	(-1.13, 0.02)	
Subgroup*Treatment Interaction p-value	0.4217	0.1444	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Vitality			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	61.51 (19.48)	61.13 (20.51)	59.66 (18.04)
Analysis Visit Mean (SD)	60.39 (22.12)	55.93 (18.12)	59.61 (21.82)
LS Mean of Change from Baseline (SE)	-0.78 (2.46)	-5.07 (3.68)	-0.64 (2.13)
95% CI	(-5.65, 4.10)	(-12.35, 2.21)	(-4.85, 3.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (3.10)	-4.43 (4.09)	
95% CI	(-6.27, 6.00)	(-12.53, 3.68)	
p-value	0.9655	0.2816	
Corrected Hedge's g Statistics	-0.008	-0.266	
95% CI	(-0.40, 0.39)	(-0.79, 0.26)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	61.85 (19.86)	62.94 (21.83)	59.58 (16.34)
Analysis Visit Mean (SD)	61.68 (19.15)	62.53 (20.87)	60.37 (19.40)
LS Mean of Change from Baseline (SE)	0.17 (2.40)	-0.26 (3.69)	0.28 (2.04)
95% CI	(-4.58, 4.92)	(-7.56, 7.04)	(-3.75, 4.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (2.99)	-0.54 (4.05)	
95% CI	(-6.03, 5.81)	(-8.56, 7.48)	
p-value	0.9700	0.8940	
Corrected Hedge's g Statistics	-0.007	-0.035	
95% CI	(-0.42, 0.41)	(-0.60, 0.53)	
Subgroup*Treatment Interaction p-value	0.9419	0.6589	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Social Functioning			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	85.98 (19.80)	87.50 (23.09)	80.85 (23.38)
Analysis Visit Mean (SD)	89.63 (18.94)	92.36 (14.31)	83.47 (23.39)
LS Mean of Change from Baseline (SE)	4.80 (2.96)	6.58 (4.43)	0.27 (2.54)
95% CI	(-1.05, 10.66)	(-2.19, 15.35)	(-4.76, 5.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.53 (3.73)	6.31 (4.94)	
95% CI	(-2.85, 11.91)	(-3.46, 16.08)	
p-value	0.2268	0.2037	
Corrected Hedge's g Statistics	0.229	0.316	
95% CI	(-0.17, 0.63)	(-0.21, 0.84)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	88.18 (17.66)	87.50 (24.09)	82.97 (22.05)
Analysis Visit Mean (SD)	89.19 (16.18)	90.00 (17.80)	84.48 (19.49)
LS Mean of Change from Baseline (SE)	3.76 (2.71)	3.85 (4.15)	0.06 (2.30)
95% CI	(-1.60, 9.12)	(-4.36, 12.06)	(-4.48, 4.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.69 (3.36)	3.79 (4.54)	
95% CI	(-2.95, 10.34)	(-5.20, 12.77)	
p-value	0.2733	0.4055	
Corrected Hedge's g Statistics	0.214	0.218	
95% CI	(-0.20, 0.63)	(-0.35, 0.79)	
Subgroup*Treatment Interaction p-value	0.2420	0.5571	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Role Emotional			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	88.41 (18.34)	84.26 (24.07)	84.68 (20.65)
Analysis Visit Mean (SD)	86.99 (18.54)	89.36 (19.96)	83.74 (23.00)
LS Mean of Change from Baseline (SE)	-0.84 (2.77)	4.19 (4.11)	-1.80 (2.39)
95% CI	(-6.32, 4.64)	(-3.95, 12.33)	(-6.53, 2.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.96 (3.47)	5.99 (4.58)	
95% CI	(-5.91, 7.84)	(-3.07, 15.05)	
p-value	0.7823	0.1932	
Corrected Hedge's g Statistics	0.052	0.320	
95% CI	(-0.34, 0.45)	(-0.21, 0.85)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	88.74 (19.07)	85.00 (24.44)	86.49 (18.39)
Analysis Visit Mean (SD)	90.09 (15.58)	91.11 (14.93)	83.04 (21.00)
LS Mean of Change from Baseline (SE)	2.40 (2.86)	4.84 (4.39)	-3.57 (2.41)
95% CI	(-3.26, 8.07)	(-3.86, 13.53)	(-8.35, 1.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.97 (3.56)	8.41 (4.84)	
95% CI	(-1.09, 13.02)	(-1.17, 17.98)	
p-value	0.0965	0.0847	
Corrected Hedge's g Statistics	0.329	0.459	
95% CI	(-0.09, 0.74)	(-0.11, 1.03)	
Subgroup*Treatment Interaction p-value	0.5616	0.4034	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Mental Health			
Week 24			
m	42	22	75
n	41	18	62
Baseline Mean (SD)	79.1 (14.0)	78.9 (18.6)	75.4 (17.5)
Analysis Visit Mean (SD)	76.6 (16.4)	78.3 (17.8)	77.7 (17.7)
LS Mean of Change from Baseline (SE)	-2.74 (2.22)	-0.85 (3.31)	0.50 (1.90)
95% CI	(-7.13, 1.65)	(-7.40, 5.70)	(-3.26, 4.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.24 (2.79)	-1.35 (3.69)	
95% CI	(-8.77, 2.29)	(-8.65, 5.95)	
p-value	0.2478	0.7140	
Corrected Hedge's g Statistics	-0.219	-0.091	
95% CI	(-0.62, 0.18)	(-0.62, 0.43)	
Week 52			
m	41	18	69
n	37	15	58
Baseline Mean (SD)	79.7 (14.4)	79.0 (19.4)	75.6 (17.1)
Analysis Visit Mean (SD)	79.7 (14.4)	80.7 (15.6)	79.3 (15.2)
LS Mean of Change from Baseline (SE)	-0.16 (2.05)	2.18 (3.15)	1.77 (1.74)
95% CI	(-4.23, 3.90)	(-4.05, 8.41)	(-1.67, 5.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.93 (2.55)	0.41 (3.45)	
95% CI	(-6.98, 3.12)	(-6.42, 7.24)	
p-value	0.4505	0.9052	
Corrected Hedge's g Statistics	-0.148	0.031	
95% CI	(-0.56, 0.26)	(-0.54, 0.60)	
Subgroup*Treatment Interaction p-value	0.1591	0.6915	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Mental Component Score			
Week 24			
m	42	22	75
n	40	18	62
Baseline Mean (SD)	53.85 (7.23)	54.78 (11.53)	52.23 (8.80)
Analysis Visit Mean (SD)	53.24 (7.96)	55.73 (8.87)	52.72 (9.31)
LS Mean of Change from Baseline (SE)	-0.66 (1.17)	1.16 (1.74)	-0.39 (1.00)
95% CI	(-2.99, 1.66)	(-2.28, 4.61)	(-2.38, 1.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.27 (1.48)	1.56 (1.94)	
95% CI	(-3.19, 2.65)	(-2.28, 5.40)	
p-value	0.8552	0.4238	
Corrected Hedge's g Statistics	-0.035	0.198	
95% CI	(-0.43, 0.36)	(-0.33, 0.72)	
Week 52			
m	41	18	69
n	36	15	58
Baseline Mean (SD)	54.40 (7.29)	54.94 (11.50)	52.40 (8.50)
Analysis Visit Mean (SD)	54.57 (7.02)	56.21 (8.34)	53.01 (8.50)
LS Mean of Change from Baseline (SE)	0.32 (1.15)	1.52 (1.75)	-0.31 (0.96)
95% CI	(-1.96, 2.60)	(-1.95, 4.99)	(-2.22, 1.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.63 (1.43)	1.83 (1.93)	
95% CI	(-2.21, 3.47)	(-1.98, 5.65)	
p-value	0.6615	0.3434	
Corrected Hedge's g Statistics	0.087	0.250	
95% CI	(-0.33, 0.50)	(-0.32, 0.82)	
Subgroup*Treatment Interaction p-value	0.7861	0.8315	

AMNOG Table SE22.2.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Physical Component Score			
Week 24			
m	42	22	75
n	40	18	62
Baseline Mean (SD)	48.54 (6.67)	43.60 (9.65)	45.78 (8.39)
Analysis Visit Mean (SD)	47.75 (8.48)	42.57 (10.19)	46.10 (9.65)
LS Mean of Change from Baseline (SE)	0.09 (1.19)	-1.57 (1.74)	0.17 (1.00)
95% CI	(-2.26, 2.44)	(-5.02, 1.89)	(-1.80, 2.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (1.49)	-1.74 (1.94)	
95% CI	(-3.03, 2.86)	(-5.59, 2.11)	
p-value	0.9546	0.3721	
Corrected Hedge's g Statistics	-0.011	-0.223	
95% CI	(-0.41, 0.39)	(-0.75, 0.30)	
Week 52			
m	41	18	69
n	36	15	58
Baseline Mean (SD)	48.45 (6.74)	43.92 (10.14)	46.76 (7.57)
Analysis Visit Mean (SD)	47.82 (8.21)	44.22 (11.83)	46.56 (7.38)
LS Mean of Change from Baseline (SE)	0.16 (1.03)	0.23 (1.55)	0.15 (0.87)
95% CI	(-1.88, 2.20)	(-2.84, 3.30)	(-1.56, 1.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (1.27)	0.08 (1.71)	
95% CI	(-2.50, 2.52)	(-3.30, 3.45)	
p-value	0.9931	0.9638	
Corrected Hedge's g Statistics	0.002	0.012	
95% CI	(-0.41, 0.42)	(-0.56, 0.58)	
Subgroup*Treatment Interaction p-value	0.9359	0.9013	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (12.9)	16 (12.7)	22 (9.8)
No	108 (87.1)	110 (87.3)	202 (90.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.75	
95% CI of the inverse odds ratio	(0.37, 1.46)	(0.38, 1.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	0.77	
95% CI of the inverse risk ratio	(0.42, 1.39)	(0.42, 1.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.08	2.88	
95% CI of the absolute risk difference	(-3.99, 10.15)	(-4.12, 9.88)	
p-value	0.3774	0.4063	
p-value of Breslow-Day Test for Homogeneity [3]	0.2817	0.1257	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	36 (29.0)	43 (34.1)	60 (26.8)
No	88 (71.0)	83 (65.9)	164 (73.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.71	
95% CI of the inverse odds ratio	(0.55, 1.46)	(0.44, 1.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.78	
95% CI of the inverse risk ratio	(0.65, 1.31)	(0.57, 1.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.25	7.34	
95% CI of the absolute risk difference	(-7.63, 12.12)	(-2.77, 17.45)	
p-value	0.6534	0.1480	
p-value of Breslow-Day Test for Homogeneity [3]	0.4269	0.0860	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (9.7)	15 (11.9)	30 (13.4)
No	112 (90.3)	111 (88.1)	194 (86.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.14	
95% CI of the inverse odds ratio	(0.71, 2.93)	(0.59, 2.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	1.13	
95% CI of the inverse risk ratio	(0.74, 2.60)	(0.63, 2.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.72	-1.49	
95% CI of the absolute risk difference	(-10.57, 3.14)	(-8.69, 5.71)	
p-value	0.3082	0.6897	
p-value of Breslow-Day Test for Homogeneity [3]	0.9596	0.6815	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (25.8)	34 (27.0)	57 (25.4)
No	92 (74.2)	92 (73.0)	167 (74.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.92	
95% CI of the inverse odds ratio	(0.59, 1.62)	(0.56, 1.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.94	
95% CI of the inverse risk ratio	(0.68, 1.43)	(0.66, 1.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.36	1.54	
95% CI of the absolute risk difference	(-9.22, 9.94)	(-8.09, 11.16)	
p-value	0.9412	0.7529	
p-value of Breslow-Day Test for Homogeneity [3]	0.9416	0.9125	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	19 (15.3)	22 (17.5)	45 (20.1)
No	105 (84.7)	104 (82.5)	179 (79.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	1.19	
95% CI of the inverse odds ratio	(0.77, 2.50)	(0.68, 2.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.15	
95% CI of the inverse risk ratio	(0.80, 2.14)	(0.73, 1.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.77	-2.63	
95% CI of the absolute risk difference	(-13.00, 3.46)	(-11.08, 5.82)	
p-value	0.2717	0.5485	
p-value of Breslow-Day Test for Homogeneity [3]	0.2512	0.3284	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (23.4)	40 (31.7)	62 (27.7)
No	95 (76.6)	86 (68.3)	162 (72.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.82	
95% CI of the inverse odds ratio	(0.75, 2.08)	(0.51, 1.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.87	
95% CI of the inverse risk ratio	(0.81, 1.73)	(0.63, 1.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.29	4.07	
95% CI of the absolute risk difference	(-13.77, 5.19)	(-5.95, 14.09)	
p-value	0.3830	0.4215	
p-value of Breslow-Day Test for Homogeneity [3]	0.6352	0.6506	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	23 (18.5)	26 (20.6)	35 (15.6)
No	101 (81.5)	100 (79.4)	189 (84.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.71	
95% CI of the inverse odds ratio	(0.46, 1.45)	(0.41, 1.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.76	
95% CI of the inverse risk ratio	(0.52, 1.36)	(0.48, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.92	5.01	
95% CI of the absolute risk difference	(-5.41, 11.25)	(-3.51, 13.53)	
p-value	0.4834	0.2356	
p-value of Breslow-Day Test for Homogeneity [3]	0.1139	0.3148	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	39 (31.5)	47 (37.3)	68 (30.4)
No	85 (68.5)	79 (62.7)	156 (69.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.73	
95% CI of the inverse odds ratio	(0.59, 1.53)	(0.46, 1.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.81	
95% CI of the inverse risk ratio	(0.70, 1.34)	(0.60, 1.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.09	6.94	
95% CI of the absolute risk difference	(-9.06, 11.25)	(-3.43, 17.32)	
p-value	0.8322	0.1843	
p-value of Breslow-Day Test for Homogeneity [3]	0.5543	0.2698	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (8.9)	12 (9.5)	31 (13.8)
No	113 (91.1)	114 (90.5)	193 (86.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	1.53	
95% CI of the inverse odds ratio	(0.80, 3.41)	(0.75, 3.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	1.45	
95% CI of the inverse risk ratio	(0.81, 2.99)	(0.77, 2.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.97	-4.32	
95% CI of the absolute risk difference	(-11.71, 1.78)	(-11.15, 2.52)	
p-value	0.1730	0.2378	
p-value of Breslow-Day Test for Homogeneity [3]	0.1162	0.4685	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (26.6)	37 (29.4)	79 (35.3)
No	91 (73.4)	89 (70.6)	145 (64.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	1.31	
95% CI of the inverse odds ratio	(0.93, 2.44)	(0.82, 2.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	1.20	
95% CI of the inverse risk ratio	(0.94, 1.87)	(0.87, 1.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.65	-5.90	
95% CI of the absolute risk difference	(-18.64, 1.33)	(-16.02, 4.22)	
p-value	0.0979	0.2601	
p-value of Breslow-Day Test for Homogeneity [3]	0.0238	0.4721	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (8.1)	21 (16.7)	15 (6.7)
No	114 (91.9)	105 (83.3)	209 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.36	
95% CI of the inverse odds ratio	(0.36, 1.88)	(0.18, 0.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.40	
95% CI of the inverse risk ratio	(0.38, 1.79)	(0.21, 0.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.37	9.97	
95% CI of the absolute risk difference	(-4.44, 7.17)	(2.69, 17.25)	
p-value	0.6360	0.0032	
p-value of Breslow-Day Test for Homogeneity [3]	0.2824	0.0711	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (16.9)	30 (23.8)	37 (16.5)
No	103 (83.1)	96 (76.2)	187 (83.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.63	
95% CI of the inverse odds ratio	(0.54, 1.75)	(0.37, 1.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.69	
95% CI of the inverse risk ratio	(0.60, 1.59)	(0.45, 1.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.42	7.29	
95% CI of the absolute risk difference	(-7.78, 8.62)	(-1.59, 16.18)	
p-value	0.9203	0.0960	
p-value of Breslow-Day Test for Homogeneity [3]	0.8697	0.5382	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (10.5)	25 (19.8)	29 (12.9)
No	111 (89.5)	101 (80.2)	195 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	0.60	
95% CI of the inverse odds ratio	(0.63, 2.54)	(0.33, 1.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	0.65	
95% CI of the inverse risk ratio	(0.67, 2.29)	(0.40, 1.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.46	6.89	
95% CI of the absolute risk difference	(-9.42, 4.49)	(-1.34, 15.13)	
p-value	0.4995	0.0865	
p-value of Breslow-Day Test for Homogeneity [3]	0.4787	0.8195	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (16.9)	35 (27.8)	41 (18.3)
No	103 (83.1)	91 (72.2)	183 (81.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	0.58	
95% CI of the inverse odds ratio	(0.62, 1.96)	(0.35, 0.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.66	
95% CI of the inverse risk ratio	(0.67, 1.74)	(0.44, 0.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.37	9.47	
95% CI of the absolute risk difference	(-9.69, 6.95)	(0.16, 18.79)	
p-value	0.7494	0.0391	
p-value of Breslow-Day Test for Homogeneity [3]	0.3544	0.9942	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (12.1)	13 (10.3)	25 (11.2)
No	109 (87.9)	113 (89.7)	199 (88.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.09	
95% CI of the inverse odds ratio	(0.46, 1.80)	(0.54, 2.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.08	
95% CI of the inverse risk ratio	(0.51, 1.68)	(0.57, 2.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.94	-0.84	
95% CI of the absolute risk difference	(-6.13, 8.00)	(-7.57, 5.88)	
p-value	0.7932	0.8077	
p-value of Breslow-Day Test for Homogeneity [3]	0.1796	0.1152	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	43 (34.7)	34 (27.0)	63 (28.1)
No	81 (65.3)	92 (73.0)	161 (71.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.06	
95% CI of the inverse odds ratio	(0.46, 1.18)	(0.65, 1.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	1.04	
95% CI of the inverse risk ratio	(0.59, 1.12)	(0.73, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.55	-1.14	
95% CI of the absolute risk difference	(-3.69, 16.79)	(-10.87, 8.59)	
p-value	0.2034	0.8190	
p-value of Breslow-Day Test for Homogeneity [3]	0.9195	0.7339	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (4.8)	11 (8.7)	9 (4.0)
No	118 (95.2)	115 (91.3)	215 (96.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.44	
95% CI of the inverse odds ratio	(0.29, 2.37)	(0.18, 1.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.46	
95% CI of the inverse risk ratio	(0.30, 2.28)	(0.20, 1.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.82	4.71	
95% CI of the absolute risk difference	(-3.75, 5.39)	(-0.85, 10.27)	
p-value	0.7180	0.0683	
p-value of Breslow-Day Test for Homogeneity [3]	0.1228	0.2439	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (21.8)	23 (18.3)	44 (19.6)
No	97 (78.2)	103 (81.7)	180 (80.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	1.09	
95% CI of the inverse odds ratio	(0.51, 1.51)	(0.63, 1.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.08	
95% CI of the inverse risk ratio	(0.59, 1.38)	(0.68, 1.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.13	-1.39	
95% CI of the absolute risk difference	(-6.80, 11.07)	(-9.91, 7.13)	
p-value	0.6366	0.7512	
p-value of Breslow-Day Test for Homogeneity [3]	0.8446	0.6043	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (4.8)	10 (7.9)	9 (4.0)
No	118 (95.2)	116 (92.1)	215 (96.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.49	
95% CI of the inverse odds ratio	(0.29, 2.37)	(0.19, 1.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.51	
95% CI of the inverse risk ratio	(0.30, 2.28)	(0.21, 1.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.82	3.92	
95% CI of the absolute risk difference	(-3.75, 5.39)	(-1.46, 9.29)	
p-value	0.7180	0.1204	
p-value of Breslow-Day Test for Homogeneity [3]	0.3011	0.6339	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (23.4)	38 (30.2)	45 (20.1)
No	95 (76.6)	88 (69.8)	179 (79.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.58	
95% CI of the inverse odds ratio	(0.49, 1.40)	(0.35, 0.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.67	
95% CI of the inverse risk ratio	(0.57, 1.30)	(0.46, 0.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.30	10.07	
95% CI of the absolute risk difference	(-5.81, 12.41)	(0.49, 19.65)	
p-value	0.4715	0.0335	
p-value of Breslow-Day Test for Homogeneity [3]	0.3388	0.1269	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (14.0)	2 (8.0)	15 (19.0)
No	37 (86.0)	23 (92.0)	64 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	2.70	
95% CI of the inverse odds ratio	(0.52, 4.05)	(0.57, 12.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	2.37	
95% CI of the inverse risk ratio	(0.57, 3.25)	(0.58, 9.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.03	-10.99	
95% CI of the absolute risk difference	(-18.53, 8.46)	(-24.69, 2.72)	
p-value	0.4816	0.1954	
p-value of Breslow-Day Test for Homogeneity [3]	0.2817	0.1257	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (44.2)	5 (20.0)	26 (32.9)
No	24 (55.8)	20 (80.0)	53 (67.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	1.96	
95% CI of the inverse odds ratio	(0.29, 1.33)	(0.66, 5.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.65	
95% CI of the inverse risk ratio	(0.47, 1.18)	(0.71, 3.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.27	-12.91	
95% CI of the absolute risk difference	(-6.83, 29.38)	(-31.71, 5.88)	
p-value	0.2176	0.2187	
p-value of Breslow-Day Test for Homogeneity [3]	0.4269	0.0860	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (7.0)	3 (12.0)	8 (10.1)
No	40 (93.0)	22 (88.0)	71 (89.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	0.83	
95% CI of the inverse odds ratio	(0.38, 5.99)	(0.20, 3.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	0.84	
95% CI of the inverse risk ratio	(0.41, 5.19)	(0.24, 2.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.15	1.87	
95% CI of the absolute risk difference	(-13.26, 6.96)	(-12.50, 16.24)	
p-value	0.5617	0.7907	
p-value of Breslow-Day Test for Homogeneity [3]	0.9596	0.6815	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (18.6)	5 (20.0)	14 (17.7)
No	35 (81.4)	20 (80.0)	65 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.86	
95% CI of the inverse odds ratio	(0.36, 2.46)	(0.28, 2.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.89	
95% CI of the inverse risk ratio	(0.43, 2.09)	(0.35, 2.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.88	2.28	
95% CI of the absolute risk difference	(-13.48, 15.24)	(-15.52, 20.08)	
p-value	0.9035	0.7972	
p-value of Breslow-Day Test for Homogeneity [3]	0.9416	0.9125	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	4 (16.0)	8 (10.1)
No	42 (97.7)	21 (84.0)	71 (89.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.73	0.59	
95% CI of the inverse odds ratio	(0.57, 39.17)	(0.16, 2.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.35	0.63	
95% CI of the inverse risk ratio	(0.56, 33.67)	(0.21, 1.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.80	5.87	
95% CI of the absolute risk difference	(-15.84, 0.23)	(-9.96, 21.71)	
p-value	0.1153	0.4231	
p-value of Breslow-Day Test for Homogeneity [3]	0.2512	0.3284	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (25.6)	6 (24.0)	20 (25.3)
No	32 (74.4)	19 (76.0)	59 (74.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.07	
95% CI of the inverse odds ratio	(0.42, 2.31)	(0.38, 3.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.05	
95% CI of the inverse risk ratio	(0.52, 1.87)	(0.48, 2.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.26	-1.32	
95% CI of the absolute risk difference	(-15.92, 16.45)	(-20.61, 17.98)	
p-value	0.9744	0.8946	
p-value of Breslow-Day Test for Homogeneity [3]	0.6352	0.6506	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.7)	2 (8.0)	10 (12.7)
No	41 (95.3)	23 (92.0)	69 (87.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.97	1.67	
95% CI of the inverse odds ratio	(0.62, 14.23)	(0.34, 8.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.72	1.58	
95% CI of the inverse risk ratio	(0.62, 11.86)	(0.37, 6.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.01	-4.66	
95% CI of the absolute risk difference	(-17.67, 1.66)	(-17.58, 8.26)	
p-value	0.1560	0.5252	
p-value of Breslow-Day Test for Homogeneity [3]	0.1139	0.3148	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (25.6)	6 (24.0)	24 (30.4)
No	32 (74.4)	19 (76.0)	55 (69.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	1.38	
95% CI of the inverse odds ratio	(0.55, 2.93)	(0.49, 3.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	1.27	
95% CI of the inverse risk ratio	(0.65, 2.18)	(0.58, 2.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.80	-6.38	
95% CI of the absolute risk difference	(-21.32, 11.72)	(-25.95, 13.19)	
p-value	0.5756	0.5394	
p-value of Breslow-Day Test for Homogeneity [3]	0.5543	0.2698	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (11.6)	2 (8.0)	5 (6.3)
No	38 (88.4)	23 (92.0)	74 (93.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.51	0.78	
95% CI of the inverse odds ratio	(0.14, 1.88)	(0.14, 4.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	0.79	
95% CI of the inverse risk ratio	(0.17, 1.78)	(0.16, 3.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.30	1.67	
95% CI of the absolute risk difference	(-5.68, 16.28)	(-10.24, 13.58)	
p-value	0.3081	0.7713	
p-value of Breslow-Day Test for Homogeneity [3]	0.1162	0.4685	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (39.5)	7 (28.0)	20 (25.3)
No	26 (60.5)	18 (72.0)	59 (74.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	0.87	
95% CI of the inverse odds ratio	(0.23, 1.15)	(0.32, 2.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.90	
95% CI of the inverse risk ratio	(0.38, 1.09)	(0.43, 1.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.22	2.68	
95% CI of the absolute risk difference	(-3.26, 31.70)	(-17.36, 22.73)	
p-value	0.1026	0.7897	
p-value of Breslow-Day Test for Homogeneity [3]	0.0238	0.4721	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (7.0)	2 (8.0)	10 (12.7)
No	40 (93.0)	23 (92.0)	69 (87.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.93	1.67	
95% CI of the inverse odds ratio	(0.50, 7.44)	(0.34, 8.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.81	1.58	
95% CI of the inverse risk ratio	(0.53, 6.24)	(0.37, 6.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.68	-4.66	
95% CI of the absolute risk difference	(-16.25, 4.89)	(-17.58, 8.26)	
p-value	0.3312	0.5252	
p-value of Breslow-Day Test for Homogeneity [3]	0.2824	0.0711	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (20.9)	5 (20.0)	15 (19.0)
No	34 (79.1)	20 (80.0)	64 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.94	
95% CI of the inverse odds ratio	(0.35, 2.23)	(0.30, 2.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.95	
95% CI of the inverse risk ratio	(0.43, 1.90)	(0.38, 2.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.94	1.01	
95% CI of the absolute risk difference	(-12.98, 16.86)	(-16.89, 18.92)	
p-value	0.7965	0.9108	
p-value of Breslow-Day Test for Homogeneity [3]	0.8697	0.5382	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (14.0)	5 (20.0)	9 (11.4)
No	37 (86.0)	20 (80.0)	70 (88.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.51	
95% CI of the inverse odds ratio	(0.26, 2.40)	(0.15, 1.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.57	
95% CI of the inverse risk ratio	(0.31, 2.14)	(0.21, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.56	8.61	
95% CI of the absolute risk difference	(-9.94, 15.06)	(-8.57, 25.78)	
p-value	0.6807	0.2718	
p-value of Breslow-Day Test for Homogeneity [3]	0.4787	0.8195	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (18.6)	5 (20.0)	10 (12.7)
No	35 (81.4)	20 (80.0)	69 (87.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.58	
95% CI of the inverse odds ratio	(0.23, 1.75)	(0.18, 1.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.63	
95% CI of the inverse risk ratio	(0.29, 1.60)	(0.24, 1.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.95	7.34	
95% CI of the absolute risk difference	(-7.80, 19.70)	(-9.97, 24.65)	
p-value	0.3763	0.3625	
p-value of Breslow-Day Test for Homogeneity [3]	0.3544	0.9942	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (9.3)	1 (4.0)	15 (19.0)
No	39 (90.7)	24 (96.0)	64 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.29	5.63	
95% CI of the inverse odds ratio	(0.71, 7.38)	(0.70, 44.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.04	4.75	
95% CI of the inverse risk ratio	(0.72, 5.77)	(0.66, 34.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.69	-14.99	
95% CI of the absolute risk difference	(-21.94, 2.57)	(-26.55, -3.42)	
p-value	0.1587	0.0703	
p-value of Breslow-Day Test for Homogeneity [3]	0.1796	0.1152	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (32.6)	7 (28.0)	20 (25.3)
No	29 (67.4)	18 (72.0)	59 (74.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	0.87	
95% CI of the inverse odds ratio	(0.31, 1.59)	(0.32, 2.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.90	
95% CI of the inverse risk ratio	(0.44, 1.38)	(0.43, 1.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.24	2.68	
95% CI of the absolute risk difference	(-9.73, 24.22)	(-17.36, 22.73)	
p-value	0.3941	0.7897	
p-value of Breslow-Day Test for Homogeneity [3]	0.9195	0.7339	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	2 (8.0)	8 (10.1)
No	42 (97.7)	23 (92.0)	71 (89.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.73	1.30	
95% CI of the inverse odds ratio	(0.57, 39.17)	(0.26, 6.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.35	1.27	
95% CI of the inverse risk ratio	(0.56, 33.67)	(0.29, 5.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.80	-2.13	
95% CI of the absolute risk difference	(-15.84, 0.23)	(-14.67, 10.42)	
p-value	0.1153	0.7533	
p-value of Breslow-Day Test for Homogeneity [3]	0.1228	0.2439	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (23.3)	4 (16.0)	18 (22.8)
No	33 (76.7)	21 (84.0)	61 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	1.55	
95% CI of the inverse odds ratio	(0.40, 2.35)	(0.47, 5.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.42	
95% CI of the inverse risk ratio	(0.50, 1.93)	(0.53, 3.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.47	-6.78	
95% CI of the absolute risk difference	(-15.18, 16.12)	(-23.87, 10.31)	
p-value	0.9529	0.4691	
p-value of Breslow-Day Test for Homogeneity [3]	0.8446	0.6043	

AMNOG Table SE22.2.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	2 (8.0)	5 (6.3)
No	42 (97.7)	23 (92.0)	74 (93.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.84	0.78	
95% CI of the inverse odds ratio	(0.32, 25.11)	(0.14, 4.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.72	0.79	
95% CI of the inverse risk ratio	(0.33, 22.55)	(0.16, 3.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.00	1.67	
95% CI of the absolute risk difference	(-11.01, 3.01)	(-10.24, 13.58)	
p-value	0.3286	0.7713	
p-value of Breslow-Day Test for Homogeneity [3]	0.3011	0.6339	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (14.0)	3 (12.0)	15 (19.0)
No	37 (86.0)	22 (88.0)	64 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	1.72	
95% CI of the inverse odds ratio	(0.52, 4.05)	(0.45, 6.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	1.58	
95% CI of the inverse risk ratio	(0.57, 3.25)	(0.50, 5.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.03	-6.99	
95% CI of the absolute risk difference	(-18.53, 8.46)	(-22.38, 8.41)	
p-value	0.4816	0.4209	
p-value of Breslow-Day Test for Homogeneity [3]	0.3388	0.1269	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Physical Functioning						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	81.88 (21.92)	75.44 (24.55)	80.78 (24.34)			
Median	90.00	80.00	90.00			
IQR: Q1, Q3	75.00, 97.50	65.00, 95.00	70.00, 100.00			
Min, Max	25.0, 100.0	10.0, 100.0	10.0, 100.0			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	82.31 (18.02)	73.99 (24.16)	80.83 (25.69)	2.03 (2.40)	-0.96 (1.94)	0.35 (1.72)
Median	85.00	80.00	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	65.00, 95.00	75.00, 100.00	0.00, 10.00	-10.00, 5.00	-5.00, 5.00
Min, Max	40.0, 100.0	10.0, 100.0	5.0, 100.0	-50.0, 40.0	-40.0, 70.0	-70.0, 75.0
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	83.75 (20.51)	72.14 (25.35)	82.62 (21.04)	2.21 (1.72)	-3.10 (1.94)	0.94 (1.70)
Median	92.50	80.00	90.00	0	0	0
IQR: Q1, Q3	72.50, 100.00	60.00, 90.00	70.00, 100.00	-5.00, 10.00	-5.00, 5.00	-5.00, 5.00
Min, Max	30.0, 100.0	0.0, 100.0	0.0, 100.0	-20.0, 25.0	-85.0, 20.0	-60.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Role Physical						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	82.82 (22.49)	77.47 (25.93)	79.98 (26.82)			
Median	93.80	87.50	93.80			
IQR: Q1, Q3	75.00, 100.00	56.30, 100.00	68.80, 100.00			
Min, Max	18.8, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	79.50 (22.66)	74.78 (23.67)	80.80 (25.20)	-1.52 (3.05)	-2.91 (2.17)	1.27 (1.98)
Median	81.30	75.00	93.80	0	0	0
IQR: Q1, Q3	62.50, 100.00	56.30, 100.00	68.80, 100.00	-6.20, 6.30	-12.50, 0.00	-6.20, 6.20
Min, Max	6.3, 100.0	0.0, 100.0	6.3, 100.0	-43.8, 43.7	-50.0, 50.0	-56.2, 87.5
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	82.13 (21.81)	75.67 (25.44)	79.34 (25.06)	-0.56 (1.98)	-1.06 (2.66)	-1.12 (2.13)
Median	93.75	81.30	87.50	0	0	0
IQR: Q1, Q3	68.80, 100.00	62.50, 100.00	62.50, 100.00	0.00, 6.20	-6.30, 6.20	-12.50, 6.20
Min, Max	31.3, 100.0	6.3, 100.0	0.0, 100.0	-31.3, 25.0	-75.0, 56.3	-62.5, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Bodily Pain						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	76.0 (20.0)	67.5 (24.5)	70.7 (25.4)			
Median	74.0	62.0	74.0			
IQR: Q1, Q3	62.0, 100.0	51.0, 84.0	52.0, 84.0			
Min, Max	31, 100	10, 100	0, 100			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	69.5 (23.1)	66.2 (24.5)	70.4 (24.5)	-5.8 (2.6)	-3.2 (1.8)	-0.1 (1.9)
Median	72.0	62.0	74.0	0	0	0
IQR: Q1, Q3	51.0, 84.0	42.0, 84.0	52.0, 84.0	-16.0, 0.0	-11.0, 0.0	-12.0, 11.0
Min, Max	22, 100	21, 100	0, 100	-50, 28	-59, 38	-49, 59
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	75.8 (20.1)	68.6 (25.5)	71.9 (24.1)	-0.1 (2.3)	1.2 (2.4)	-0.6 (2.1)
Median	74.0	72.0	74.0	0	0	0
IQR: Q1, Q3	62.0, 100.0	51.0, 100.0	51.0, 100.0	0.0, 10.0	-11.0, 10.0	-12.0, 10.0
Min, Max	41, 100	10, 100	10, 100	-38, 26	-53, 69	-49, 58

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
General Health						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	66.30 (17.24)	57.29 (18.38)	61.43 (20.33)			
Median	67.00	57.00	65.00			
IQR: Q1, Q3	54.50, 79.50	47.00, 72.00	47.00, 77.00			
Min, Max	20.0, 97.0	10.0, 92.0	15.0, 100.0			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	65.69 (20.50)	56.20 (19.78)	63.01 (19.90)	1.19 (2.16)	-0.58 (1.84)	1.73 (1.39)
Median	67.00	57.00	62.00	0	0	0
IQR: Q1, Q3	52.00, 77.00	42.00, 72.00	52.00, 77.00	-5.00, 7.00	-10.00, 7.00	-7.00, 10.00
Min, Max	20.0, 100.0	10.0, 92.0	0.0, 100.0	-42.0, 30.0	-35.0, 40.0	-35.0, 40.0
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	65.58 (17.62)	55.42 (19.94)	64.79 (18.59)	-0.08 (2.08)	-1.08 (2.14)	1.96 (1.33)
Median	69.50	52.00	67.00	0	0	0
IQR: Q1, Q3	54.50, 77.00	45.00, 72.00	52.00, 77.00	-5.00, 8.00	-10.00, 10.00	-5.00, 10.00
Min, Max	25.0, 100.0	10.0, 92.0	20.0, 100.0	-37.0, 25.0	-52.0, 37.0	-40.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Vitality						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	66.59 (17.02)	57.62 (21.08)	61.53 (22.26)			
Median	68.80	56.30	62.50			
IQR: Q1, Q3	56.30, 75.00	43.80, 75.00	50.00, 75.00			
Min, Max	25.0, 100.0	0.0, 93.8	0.0, 100.0			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	64.76 (16.93)	55.48 (21.12)	63.04 (20.63)	-1.53 (2.09)	-2.40 (1.59)	1.02 (1.49)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	56.30, 75.00	37.50, 75.00	50.00, 75.00	-6.30, 6.30	-12.50, 6.20	-6.30, 6.30
Min, Max	31.3, 100.0	0.0, 100.0	0.0, 100.0	-43.8, 12.5	-31.2, 43.8	-37.5, 56.2
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	68.60 (17.38)	56.09 (21.67)	62.34 (22.01)	1.65 (1.83)	-2.40 (1.81)	-0.97 (1.91)
Median	71.90	56.30	62.50	0	0	0
IQR: Q1, Q3	59.40, 75.00	43.80, 75.00	50.00, 75.00	-6.20, 12.50	-6.30, 6.20	-12.50, 12.50
Min, Max	25.0, 100.0	6.3, 100.0	0.0, 100.0	-31.2, 18.8	-43.8, 43.8	-56.3, 43.8

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Social Functioning						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	89.38 (18.03)	83.07 (25.32)	85.86 (21.86)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	87.50, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	88.78 (20.64)	82.28 (22.34)	85.12 (23.73)	1.01 (2.76)	-0.68 (2.25)	-0.88 (2.00)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	62.50, 100.00	75.00, 100.00	0.00, 0.00	-12.50, 0.00	0.00, 0.00
Min, Max	25.0, 100.0	12.5, 100.0	0.0, 100.0	-50.0, 50.0	-62.5, 37.5	-62.5, 75.0
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	89.58 (18.54)	81.72 (23.27)	87.50 (19.65)	0.00 (1.90)	-1.15 (2.86)	0.37 (2.02)
Median	100.00	87.50	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	62.50, 100.00	75.00, 100.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	37.5, 100.0	25.0, 100.0	12.5, 100.0	-25.0, 37.5	-62.5, 62.5	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Role Emotional						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	87.91 (18.68)	85.13 (22.07)	88.59 (20.84)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	83.30, 100.00			
Min, Max	33.3, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	86.75 (18.40)	86.50 (18.84)	85.68 (23.50)	0.46 (2.85)	0.80 (1.82)	-2.80 (1.70)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	-8.30, 0.00	0.00, 8.30	0.00, 0.00
Min, Max	41.7, 100.0	8.3, 100.0	0.0, 100.0	-33.3, 66.7	-50.0, 50.0	-50.0, 58.3
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	89.12 (15.66)	85.82 (21.22)	86.91 (20.96)	1.97 (1.80)	1.79 (2.22)	-2.48 (1.84)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	-8.30, 8.30	-8.30, 0.00
Min, Max	50.0, 100.0	8.3, 100.0	0.0, 100.0	-25.0, 25.0	-33.3, 50.0	-58.3, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Mental Health						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	79.5 (12.9)	76.3 (19.5)	77.5 (18.3)			
Median	85.0	80.0	82.5			
IQR: Q1, Q3	72.5, 90.0	70.0, 90.0	70.0, 90.0			
Min, Max	45, 100	15, 100	5, 100			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	77.9 (15.3)	76.0 (19.0)	76.7 (19.4)	-1.4 (1.5)	-1.0 (1.5)	-0.4 (1.3)
Median	80.0	80.0	85.0	-5.0	0	0
IQR: Q1, Q3	70.0, 90.0	65.0, 90.0	70.0, 90.0	-5.0, 5.0	-5.0, 5.0	-5.0, 5.0
Min, Max	40, 100	5, 100	5, 100	-30, 15	-40, 50	-45, 45
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	81.1 (14.9)	76.0 (18.2)	78.5 (18.7)	1.0 (1.6)	-0.3 (1.6)	0.4 (1.4)
Median	80.0	80.0	85.0	2.5	0	0
IQR: Q1, Q3	75.0, 90.0	65.0, 90.0	70.0, 90.0	-5.0, 5.0	-5.0, 5.0	-5.0, 5.0
Min, Max	40, 100	20, 100	0, 100	-20, 25	-25, 50	-40, 50

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Mental Component Score						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	53.46 (7.08)	51.65 (11.03)	52.58 (9.22)			
Median	55.75	55.10	56.30			
IQR: Q1, Q3	49.00, 58.60	46.70, 58.30	49.20, 58.40			
Min, Max	32.0, 62.6	17.0, 72.3	15.6, 64.3			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	52.94 (8.87)	51.82 (10.01)	51.92 (10.15)	-0.22 (0.94)	-0.10 (0.77)	-0.70 (0.70)
Median	55.60	54.10	55.70	0	-0.20	0
IQR: Q1, Q3	49.20, 58.60	46.70, 58.70	48.00, 58.70	-2.70, 2.70	-2.70, 2.70	-3.30, 2.40
Min, Max	28.0, 66.6	9.4, 71.2	14.2, 64.4	-20.0, 11.8	-24.5, 26.1	-23.5, 19.9
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	54.21 (7.72)	51.72 (9.90)	52.59 (9.44)	0.64 (0.61)	0.14 (0.88)	-0.43 (0.73)
Median	55.65	53.40	55.30	-0.10	-0.10	0.30
IQR: Q1, Q3	53.00, 59.20	45.10, 58.40	47.30, 59.00	-2.10, 3.70	-3.10, 2.50	-3.70, 2.60
Min, Max	30.6, 63.2	17.8, 70.7	8.9, 63.3	-5.9, 7.6	-15.2, 25.2	-24.6, 24.1

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Physical Component Score						
Baseline						
m	43	86	132			
n	40	79	122			
Mean (SD)	50.64 (7.92)	47.24 (9.80)	48.96 (9.58)			
Median	52.60	49.40	51.40			
IQR: Q1, Q3	44.65, 57.15	41.90, 55.40	45.30, 56.10			
Min, Max	29.8, 59.3	21.2, 61.3	20.7, 65.2			
Week 24						
m	40	82	129			
n	39	79	121	37	73	113
Mean (SD/SE)	49.64 (7.97)	46.27 (9.51)	49.56 (8.72)	-0.36 (0.76)	-0.98 (0.77)	0.70 (0.67)
Median	50.10	49.00	51.90	-0.40	-1.40	0
IQR: Q1, Q3	43.80, 55.90	40.20, 53.70	45.20, 56.60	-3.00, 3.10	-3.50, 2.10	-2.80, 3.00
Min, Max	30.9, 63.9	20.2, 61.0	24.4, 62.9	-10.4, 10.9	-22.1, 21.5	-17.0, 23.8
Week 52						
m	39	74	116			
n	36	67	107	34	65	101
Mean (SD/SE)	50.49 (7.80)	46.37 (9.67)	49.76 (8.15)	0.01 (0.62)	-0.75 (0.90)	0.30 (0.63)
Median	52.50	47.80	52.40	-0.15	0.20	-0.10
IQR: Q1, Q3	44.55, 56.75	40.90, 53.90	45.10, 56.00	-1.20, 1.60	-2.80, 3.30	-2.70, 3.40
Min, Max	34.0, 61.4	24.4, 61.2	24.6, 61.6	-8.4, 9.9	-23.5, 14.8	-17.9, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Physical Functioning						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	72.10 (24.14)	62.63 (25.79)	69.56 (24.97)			
Median	75.00	65.00	75.00			
IQR: Q1, Q3	55.00, 90.00	45.00, 85.00	55.00, 90.00			
Min, Max	0.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	73.52 (25.88)	68.21 (25.00)	69.98 (28.01)	1.20 (1.57)	3.83 (3.27)	0.20 (1.46)
Median	80.00	70.00	80.00	0	5.00	0
IQR: Q1, Q3	55.00, 95.00	55.00, 90.00	50.00, 95.00	-10.00, 10.00	-10.00, 20.00	-10.00, 10.00
Min, Max	5.0, 100.0	5.0, 100.0	0.0, 100.0	-50.0, 60.0	-65.0, 60.0	-50.0, 50.0
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	74.00 (28.11)	69.63 (27.21)	71.54 (26.00)	1.01 (1.71)	5.86 (2.88)	0.48 (1.35)
Median	85.00	80.00	80.00	0	5.00	0
IQR: Q1, Q3	55.00, 100.00	55.00, 95.00	52.50, 95.00	-5.00, 10.00	0.00, 20.00	-10.00, 10.00
Min, Max	0.0, 100.0	5.0, 100.0	0.0, 100.0	-65.0, 45.0	-52.2, 40.0	-45.0, 35.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Role Physical						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	73.37 (26.92)	67.28 (27.54)	72.84 (25.09)			
Median	81.30	75.00	75.00			
IQR: Q1, Q3	50.00, 100.00	50.00, 93.80	50.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	72.74 (28.01)	72.28 (24.71)	72.02 (28.30)	-1.10 (1.71)	3.42 (3.28)	-1.61 (1.67)
Median	81.30	75.00	75.00	0	0	0
IQR: Q1, Q3	50.00, 100.00	50.00, 93.80	50.00, 100.00	-12.50, 12.50	-6.30, 18.70	-12.50, 6.30
Min, Max	0.0, 100.0	12.5, 100.0	0.0, 100.0	-43.7, 50.0	-56.2, 68.7	-68.7, 43.7
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	73.89 (29.49)	71.43 (27.69)	72.46 (24.53)	-0.46 (2.04)	3.27 (3.13)	-1.03 (1.73)
Median	84.40	75.00	75.00	0	0	0
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	50.00, 100.00	-9.40, 6.20	-6.20, 12.50	-12.50, 6.30
Min, Max	0.0, 100.0	6.3, 100.0	6.3, 100.0	-43.8, 81.2	-43.8, 81.3	-56.3, 68.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Bodily Pain						
Baseline						
m	124	65	171			
n	117	59	158			
Mean (SD)	63.6 (25.0)	54.8 (27.0)	61.4 (24.2)			
Median	62.0	52.0	62.0			
IQR: Q1, Q3	41.0, 84.0	31.0, 74.0	41.0, 84.0			
Min, Max	0, 100	0, 100	12, 100			
Week 24						
m	121	59	160			
n	118	57	146	113	53	136
Mean (SD/SE)	62.3 (26.0)	62.1 (23.6)	62.5 (26.0)	-1.3 (2.0)	6.4 (3.3)	0.6 (1.8)
Median	62.0	62.0	62.0	0	10.0	0
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	41.0, 84.0	-19.0, 10.0	-9.0, 19.0	-10.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-59, 68	-62, 72	-78, 78
Week 52						
m	110	51	154			
n	100	47	132	95	44	122
Mean (SD/SE)	64.9 (27.0)	65.1 (25.9)	64.0 (25.0)	0.3 (2.3)	10.7 (3.6)	3.0 (2.0)
Median	72.0	72.0	62.0	0	9.5	0
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	41.0, 84.0	-11.0, 10.0	0.0, 21.0	-11.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-80, 68	-43, 62	-78, 78

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
General Health						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	58.51 (20.39)	49.85 (19.55)	56.78 (20.17)			
Median	60.00	47.00	57.00			
IQR: Q1, Q3	45.00, 72.00	35.00, 67.00	42.00, 72.00			
Min, Max	10.0, 100.0	10.0, 100.0	15.0, 100.0			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	59.24 (20.90)	53.58 (18.94)	56.18 (22.31)	0.91 (1.38)	3.98 (2.12)	-0.21 (1.25)
Median	57.00	52.00	56.00	0	5.00	0
IQR: Q1, Q3	45.00, 77.00	40.00, 67.00	40.00, 72.00	-8.00, 10.00	-5.00, 15.00	-10.00, 7.50
Min, Max	10.0, 100.0	15.0, 100.0	10.0, 100.0	-60.0, 32.0	-35.0, 32.0	-40.0, 48.0
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	61.77 (20.59)	56.68 (18.31)	57.13 (21.83)	2.06 (1.63)	6.98 (2.46)	1.06 (1.28)
Median	62.00	62.00	60.00	0	5.00	0
IQR: Q1, Q3	47.00, 77.00	42.00, 67.00	40.00, 72.00	-9.75, 10.00	-2.50, 17.00	-5.00, 10.00
Min, Max	20.0, 97.0	20.0, 87.0	10.0, 97.0	-70.0, 47.0	-38.0, 47.0	-42.0, 37.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Vitality						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	54.33 (23.23)	48.43 (23.26)	52.71 (20.25)			
Median	56.30	50.00	56.30			
IQR: Q1, Q3	37.50, 75.00	31.30, 62.50	37.50, 68.80			
Min, Max	0.0, 100.0	0.0, 100.0	6.3, 100.0			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	53.84 (25.06)	51.34 (18.85)	51.91 (22.22)	-0.34 (1.44)	2.24 (2.44)	-0.60 (1.31)
Median	56.30	56.30	53.15	0	0	0
IQR: Q1, Q3	37.50, 75.00	37.50, 62.50	31.30, 68.80	-6.30, 6.30	-12.50, 12.50	-12.50, 6.30
Min, Max	0.0, 100.0	12.5, 93.8	0.0, 100.0	-43.8, 43.8	-31.3, 43.7	-37.5, 43.7
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	55.09 (23.60)	53.08 (19.89)	53.48 (22.11)	-0.71 (1.72)	4.40 (2.34)	1.80 (1.45)
Median	56.30	56.30	56.30	0	3.10	0
IQR: Q1, Q3	37.50, 75.00	37.50, 68.80	37.50, 68.80	-12.50, 12.50	-6.30, 12.50	-6.30, 12.50
Min, Max	6.3, 100.0	6.3, 87.5	0.0, 100.0	-43.7, 50.0	-25.0, 37.5	-43.7, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Social Functioning						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	79.24 (24.90)	75.00 (25.85)	80.70 (22.73)			
Median	87.50	75.00	87.50			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	62.50, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	12.5, 100.0			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	78.50 (25.26)	80.92 (19.06)	77.91 (25.00)	-1.21 (2.10)	4.95 (2.98)	-2.21 (1.55)
Median	87.50	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	62.50, 100.00	-12.50, 12.50	0.00, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	37.5, 100.0	0.0, 100.0	-62.5, 75.0	-50.0, 87.5	-62.5, 50.0
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	78.75 (24.26)	81.91 (21.30)	79.26 (23.00)	-2.21 (1.93)	6.25 (3.26)	-1.23 (1.71)
Median	87.50	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	62.50, 100.00	-12.50, 12.50	0.00, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-50.0, 50.0	-37.5, 62.5	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Role Emotional						
Baseline						
m	124	65	171			
n	118	59	157			
Mean (SD)	80.08 (26.13)	77.82 (25.32)	80.41 (22.90)			
Median	91.70	83.30	83.30			
IQR: Q1, Q3	75.00, 100.00	58.30, 100.00	66.70, 100.00			
Min, Max	0.0, 100.0	8.3, 100.0	8.3, 100.0			
Week 24						
m	121	59	160			
n	118	57	146	114	53	135
Mean (SD/SE)	79.80 (24.30)	83.63 (22.98)	80.53 (24.28)	-0.29 (1.67)	5.82 (2.23)	0.62 (1.62)
Median	91.70	100.00	91.70	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	66.70, 100.00	-8.30, 8.30	0.00, 16.70	-8.30, 8.30
Min, Max	25.0, 100.0	25.0, 100.0	8.3, 100.0	-66.7, 50.0	-33.3, 41.7	-50.0, 50.0
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	81.29 (22.90)	83.51 (22.89)	79.73 (23.60)	0.39 (1.96)	5.49 (3.87)	-1.16 (1.69)
Median	91.70	91.70	83.30	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	62.50, 100.00	0.00, 0.00	0.00, 16.70	-8.40, 8.30
Min, Max	25.0, 100.0	25.0, 100.0	0.0, 100.0	-50.0, 100.0	-75.0, 58.3	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Mental Health						
Baseline						
m	124	65	171			
n	118	59	158			
Mean (SD)	71.8 (21.5)	73.0 (19.1)	73.4 (17.2)			
Median	75.0	80.0	80.0			
IQR: Q1, Q3	60.0, 90.0	60.0, 90.0	60.0, 85.0			
Min, Max	5, 100	25, 100	20, 100			
Week 24						
m	121	59	160			
n	118	57	146	114	53	136
Mean (SD/SE)	71.1 (21.0)	73.8 (18.8)	72.8 (18.4)	-0.5 (1.4)	-0.2 (1.7)	0.0 (1.2)
Median	75.0	80.0	77.5	0	0	0
IQR: Q1, Q3	60.0, 90.0	65.0, 90.0	65.0, 85.0	-10.0, 5.0	-5.0, 5.0	-10.0, 7.5
Min, Max	15, 100	20, 100	20, 100	-40, 35	-35, 35	-35, 55
Week 52						
m	110	51	154			
n	100	47	132	96	44	122
Mean (SD/SE)	73.1 (18.7)	74.9 (18.4)	73.4 (19.8)	0.4 (1.4)	0.9 (2.0)	0.5 (1.5)
Median	77.5	80.0	80.0	0	0	0
IQR: Q1, Q3	60.0, 90.0	65.0, 90.0	65.0, 85.0	-5.0, 10.0	-5.0, 5.0	-10.0, 10.0
Min, Max	25, 100	30, 100	15, 100	-35, 40	-30, 35	-60, 55

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Mental Component Score						
Baseline						
m	124	65	171			
n	117	59	157			
Mean (SD)	49.49 (11.69)	49.72 (10.97)	50.23 (9.30)			
Median	52.90	50.90	52.60			
IQR: Q1, Q3	42.80, 57.90	41.10, 59.10	45.30, 56.90			
Min, Max	12.0, 69.0	20.4, 64.7	25.9, 66.5			
Week 24						
m	121	59	160			
n	118	57	146	113	53	135
Mean (SD/SE)	49.03 (11.03)	50.91 (9.53)	49.67 (10.38)	-0.47 (0.73)	1.02 (0.97)	-0.16 (0.68)
Median	51.05	53.30	52.25	-0.60	0	-1.00
IQR: Q1, Q3	42.80, 58.20	45.80, 58.80	42.60, 57.80	-4.90, 3.40	-3.00, 6.40	-5.00, 3.70
Min, Max	18.7, 69.1	21.2, 63.6	21.2, 69.0	-20.0, 19.0	-13.0, 19.1	-24.6, 24.8
Week 52						
m	110	51	154			
n	100	47	132	95	44	122
Mean (SD/SE)	49.75 (9.91)	51.24 (9.51)	49.77 (10.63)	-0.33 (0.80)	1.25 (1.43)	-0.13 (0.73)
Median	52.30	53.20	53.10	0	0	-0.20
IQR: Q1, Q3	42.70, 58.10	44.00, 59.40	44.90, 57.55	-4.80, 3.30	-3.90, 7.15	-3.90, 4.60
Min, Max	23.1, 62.4	27.0, 64.6	20.4, 68.0	-21.7, 26.2	-21.4, 25.1	-25.1, 26.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Physical Component Score						
Baseline						
m	124	65	171			
n	117	59	157			
Mean (SD)	46.73 (9.03)	42.24 (9.34)	45.56 (9.08)			
Median	47.60	43.30	46.50			
IQR: Q1, Q3	42.30, 53.50	36.20, 49.10	38.40, 53.50			
Min, Max	15.3, 60.8	21.9, 59.7	21.8, 61.2			
Week 24						
m	121	59	160			
n	118	57	146	113	53	135
Mean (SD/SE)	46.90 (9.98)	44.62 (8.07)	45.60 (10.74)	0.10 (0.62)	1.91 (1.17)	-0.23 (0.57)
Median	49.50	43.70	47.70	0.30	0.80	0.10
IQR: Q1, Q3	41.40, 53.50	38.70, 51.50	36.70, 54.10	-4.10, 4.40	-1.40, 5.00	-3.40, 3.90
Min, Max	12.5, 61.4	29.0, 58.1	19.0, 63.0	-17.2, 18.3	-19.3, 32.4	-28.8, 13.5
Week 52						
m	110	51	154			
n	100	47	132	95	44	122
Mean (SD/SE)	47.41 (11.12)	45.40 (10.17)	46.24 (9.74)	0.38 (0.75)	3.05 (1.13)	0.53 (0.54)
Median	50.55	48.40	47.40	0.80	3.35	0.70
IQR: Q1, Q3	41.20, 56.60	39.40, 52.70	40.20, 54.00	-2.20, 4.20	-0.75, 8.20	-2.50, 3.60
Min, Max	15.8, 62.8	16.0, 61.1	21.5, 63.9	-24.7, 22.5	-17.5, 18.6	-23.9, 19.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Physical Functioning			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	80.54 (22.26)	75.14 (24.96)	81.02 (24.33)
Analysis Visit Mean (SD)	82.57 (17.70)	74.18 (23.69)	81.37 (25.44)
LS Mean of Change from Baseline (SE)	2.39 (2.68)	-2.49 (1.92)	0.65 (1.57)
95% CI	(-2.90, 7.68)	(-6.27, 1.29)	(-2.45, 3.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.74 (3.05)	-3.15 (2.43)	
95% CI	(-4.28, 7.75)	(-7.93, 1.63)	
p-value	0.5701	0.1957	
Corrected Hedge's g Statistics	0.104	-0.189	
95% CI	(-0.27, 0.48)	(-0.48, 0.11)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	80.74 (22.43)	75.00 (24.01)	82.23 (22.90)
Analysis Visit Mean (SD)	82.94 (20.82)	71.90 (25.69)	83.17 (19.96)
LS Mean of Change from Baseline (SE)	2.72 (2.50)	-3.83 (1.81)	1.30 (1.49)
95% CI	(-2.20, 7.64)	(-7.39, -0.27)	(-1.65, 4.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.42 (2.84)	-5.13 (2.28)	
95% CI	(-4.17, 7.02)	(-9.62, -0.63)	
p-value	0.6168	0.0256	
Corrected Hedge's g Statistics	0.095	-0.344	
95% CI	(-0.29, 0.48)	(-0.66, -0.03)	
Subgroup*Treatment Interaction p-value	0.9979	0.0253	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Role Physical			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	81.43 (22.84)	77.50 (26.47)	79.94 (27.09)
Analysis Visit Mean (SD)	79.91 (22.24)	74.59 (23.98)	81.21 (25.33)
LS Mean of Change from Baseline (SE)	-0.31 (2.93)	-3.76 (2.10)	1.98 (1.72)
95% CI	(-6.09, 5.47)	(-7.90, 0.38)	(-1.40, 5.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.29 (3.34)	-5.74 (2.64)	
95% CI	(-8.87, 4.29)	(-10.95, -0.53)	
p-value	0.4931	0.0309	
Corrected Hedge's g Statistics	-0.126	-0.315	
95% CI	(-0.50, 0.25)	(-0.61, -0.02)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	82.00 (22.96)	76.94 (26.23)	81.27 (25.83)
Analysis Visit Mean (SD)	81.44 (22.21)	75.88 (25.71)	80.15 (24.62)
LS Mean of Change from Baseline (SE)	0.92 (3.13)	-1.17 (2.27)	-0.36 (1.86)
95% CI	(-5.24, 7.09)	(-5.64, 3.29)	(-4.02, 3.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.29 (3.57)	-0.81 (2.86)	
95% CI	(-5.75, 8.33)	(-6.45, 4.83)	
p-value	0.7192	0.7770	
Corrected Hedge's g Statistics	0.069	-0.044	
95% CI	(-0.32, 0.46)	(-0.36, 0.27)	
Subgroup*Treatment Interaction p-value	0.6176	0.0664	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Bodily Pain			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	74.9 (20.3)	68.6 (24.4)	71.0 (24.8)
Analysis Visit Mean (SD)	69.2 (23.0)	65.4 (25.0)	70.9 (24.7)
LS Mean of Change from Baseline (SE)	-4.34 (2.78)	-3.62 (1.99)	0.30 (1.63)
95% CI	(-9.82, 1.13)	(-7.53, 0.30)	(-2.90, 3.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.64 (3.16)	-3.92 (2.50)	
95% CI	(-10.87, 1.58)	(-8.85, 1.01)	
p-value	0.1432	0.1189	
Corrected Hedge's g Statistics	-0.269	-0.227	
95% CI	(-0.64, 0.10)	(-0.52, 0.07)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	74.9 (20.4)	66.7 (24.8)	72.6 (23.7)
Analysis Visit Mean (SD)	74.8 (20.2)	67.9 (25.5)	72.0 (23.5)
LS Mean of Change from Baseline (SE)	1.57 (3.08)	-0.39 (2.24)	0.41 (1.82)
95% CI	(-4.51, 7.64)	(-4.80, 4.01)	(-3.19, 4.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.16 (3.52)	-0.80 (2.83)	
95% CI	(-5.77, 8.09)	(-6.37, 4.77)	
p-value	0.7415	0.7771	
Corrected Hedge's g Statistics	0.063	-0.044	
95% CI	(-0.33, 0.45)	(-0.36, 0.27)	
Subgroup*Treatment Interaction p-value	0.8460	0.0630	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
General Health			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	64.75 (16.96)	56.29 (18.22)	61.95 (20.40)
Analysis Visit Mean (SD)	65.95 (19.24)	55.71 (19.99)	63.67 (20.04)
LS Mean of Change from Baseline (SE)	2.08 (2.36)	-2.40 (1.69)	1.98 (1.37)
95% CI	(-2.56, 6.72)	(-5.73, 0.92)	(-0.72, 4.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (2.67)	-4.39 (2.13)	
95% CI	(-5.17, 5.36)	(-8.57, -0.20)	
p-value	0.9710	0.0402	
Corrected Hedge's g Statistics	0.007	-0.301	
95% CI	(-0.36, 0.38)	(-0.60, 0.00)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	65.14 (17.56)	56.37 (18.57)	63.26 (19.87)
Analysis Visit Mean (SD)	65.06 (17.99)	55.29 (20.19)	65.22 (18.63)
LS Mean of Change from Baseline (SE)	0.91 (2.33)	-2.57 (1.69)	2.23 (1.38)
95% CI	(-3.68, 5.50)	(-5.90, 0.75)	(-0.49, 4.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.32 (2.65)	-4.80 (2.13)	
95% CI	(-6.53, 3.89)	(-9.00, -0.61)	
p-value	0.6182	0.0251	
Corrected Hedge's g Statistics	-0.095	-0.347	
95% CI	(-0.48, 0.29)	(-0.66, -0.03)	
Subgroup*Treatment Interaction p-value	0.4304	0.0167	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Vitality			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	66.08 (17.22)	57.64 (21.61)	62.39 (22.06)
Analysis Visit Mean (SD)	64.55 (15.73)	55.24 (20.88)	63.41 (20.96)
LS Mean of Change from Baseline (SE)	-0.31 (2.26)	-3.89 (1.62)	1.13 (1.32)
95% CI	(-4.76, 4.14)	(-7.09, -0.69)	(-1.47, 3.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.45 (2.57)	-5.03 (2.03)	
95% CI	(-6.50, 3.61)	(-9.04, -1.02)	
p-value	0.5737	0.0142	
Corrected Hedge's g Statistics	-0.103	-0.358	
95% CI	(-0.47, 0.27)	(-0.65, -0.06)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	65.84 (17.90)	58.39 (21.58)	63.68 (20.92)
Analysis Visit Mean (SD)	67.49 (16.97)	55.99 (21.83)	62.71 (21.98)
LS Mean of Change from Baseline (SE)	2.73 (2.67)	-4.08 (1.94)	-0.83 (1.57)
95% CI	(-2.54, 8.00)	(-7.90, -0.26)	(-3.93, 2.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.56 (3.05)	-3.25 (2.45)	
95% CI	(-2.45, 9.58)	(-8.07, 1.57)	
p-value	0.2444	0.1853	
Corrected Hedge's g Statistics	0.225	-0.206	
95% CI	(-0.16, 0.61)	(-0.52, 0.11)	
Subgroup*Treatment Interaction p-value	0.9569	0.0392	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Social Functioning			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	88.51 (18.49)	83.05 (25.72)	86.17 (21.74)
Analysis Visit Mean (SD)	89.53 (20.09)	82.36 (22.62)	85.29 (23.75)
LS Mean of Change from Baseline (SE)	1.72 (3.02)	-2.48 (2.16)	-0.96 (1.76)
95% CI	(-4.24, 7.67)	(-6.74, 1.78)	(-4.44, 2.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.68 (3.44)	-1.52 (2.72)	
95% CI	(-4.10, 9.46)	(-6.89, 3.85)	
p-value	0.4368	0.5779	
Corrected Hedge's g Statistics	0.143	-0.081	
95% CI	(-0.23, 0.51)	(-0.38, 0.21)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	89.34 (18.75)	82.50 (26.31)	87.50 (20.46)
Analysis Visit Mean (SD)	89.34 (19.00)	81.35 (23.50)	87.87 (19.48)
LS Mean of Change from Baseline (SE)	1.46 (2.97)	-2.86 (2.16)	0.08 (1.76)
95% CI	(-4.39, 7.31)	(-7.11, 1.39)	(-3.40, 3.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.38 (3.39)	-2.93 (2.71)	
95% CI	(-5.29, 8.06)	(-8.28, 2.41)	
p-value	0.6829	0.2808	
Corrected Hedge's g Statistics	0.078	-0.166	
95% CI	(-0.31, 0.47)	(-0.48, 0.15)	
Subgroup*Treatment Interaction p-value	0.7674	0.0177	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Role Emotional			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	86.93 (19.10)	85.62 (22.32)	88.64 (21.13)
Analysis Visit Mean (SD)	87.39 (17.74)	86.42 (19.18)	85.84 (23.88)
LS Mean of Change from Baseline (SE)	0.30 (2.65)	-0.18 (1.90)	-2.50 (1.55)
95% CI	(-4.93, 5.52)	(-3.92, 3.56)	(-5.57, 0.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.80 (3.02)	2.32 (2.39)	
95% CI	(-3.15, 8.75)	(-2.39, 7.02)	
p-value	0.3553	0.3325	
Corrected Hedge's g Statistics	0.169	0.141	
95% CI	(-0.20, 0.54)	(-0.15, 0.44)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	87.25 (19.60)	84.23 (23.25)	89.77 (20.07)
Analysis Visit Mean (SD)	89.22 (15.83)	86.02 (21.20)	87.29 (20.90)
LS Mean of Change from Baseline (SE)	2.00 (2.67)	1.08 (1.94)	-2.70 (1.59)
95% CI	(-3.27, 7.27)	(-2.73, 4.89)	(-5.83, 0.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.70 (3.05)	3.78 (2.44)	
95% CI	(-1.31, 10.71)	(-1.02, 8.58)	
p-value	0.1245	0.1221	
Corrected Hedge's g Statistics	0.295	0.238	
95% CI	(-0.10, 0.69)	(-0.07, 0.55)	
Subgroup*Treatment Interaction p-value	0.3945	0.5874	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Mental Health			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	79.5 (13.0)	76.8 (19.7)	77.4 (18.6)
Analysis Visit Mean (SD)	78.1 (14.5)	75.9 (19.0)	76.9 (19.7)
LS Mean of Change from Baseline (SE)	-1.24 (2.09)	-1.78 (1.50)	-0.89 (1.22)
95% CI	(-5.36, 2.88)	(-4.72, 1.17)	(-3.30, 1.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.35 (2.38)	-0.89 (1.88)	
95% CI	(-5.05, 4.34)	(-4.60, 2.82)	
p-value	0.8831	0.6383	
Corrected Hedge's g Statistics	-0.027	-0.068	
95% CI	(-0.40, 0.34)	(-0.36, 0.23)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	79.6 (13.6)	76.0 (19.9)	78.5 (17.4)
Analysis Visit Mean (SD)	80.6 (15.0)	75.7 (18.4)	78.9 (18.4)
LS Mean of Change from Baseline (SE)	1.07 (2.12)	-1.35 (1.54)	-0.58 (1.26)
95% CI	(-3.11, 5.26)	(-4.38, 1.68)	(-3.06, 1.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.66 (2.42)	-0.77 (1.93)	
95% CI	(-3.11, 6.43)	(-4.58, 3.04)	
p-value	0.4941	0.6919	
Corrected Hedge's g Statistics	0.131	-0.061	
95% CI	(-0.26, 0.52)	(-0.37, 0.25)	
Subgroup*Treatment Interaction p-value	0.7916	0.6089	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Mental Component Score			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	53.35 (7.27)	51.88 (11.24)	52.66 (9.39)
Analysis Visit Mean (SD)	53.13 (8.58)	51.78 (10.23)	51.97 (10.34)
LS Mean of Change from Baseline (SE)	-0.21 (1.10)	-0.59 (0.79)	-0.85 (0.64)
95% CI	(-2.38, 1.95)	(-2.14, 0.96)	(-2.11, 0.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.63 (1.25)	0.26 (0.99)	
95% CI	(-1.83, 3.10)	(-1.69, 2.20)	
p-value	0.6125	0.7954	
Corrected Hedge's g Statistics	0.093	0.038	
95% CI	(-0.28, 0.46)	(-0.26, 0.33)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	53.45 (7.52)	51.54 (11.52)	53.19 (8.88)
Analysis Visit Mean (SD)	54.09 (7.79)	51.68 (9.92)	52.77 (9.46)
LS Mean of Change from Baseline (SE)	0.70 (1.09)	-0.43 (0.79)	-0.89 (0.65)
95% CI	(-1.44, 2.85)	(-1.98, 1.13)	(-2.16, 0.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.59 (1.24)	0.46 (0.99)	
95% CI	(-0.86, 4.03)	(-1.49, 2.41)	
p-value	0.2016	0.6431	
Corrected Hedge's g Statistics	0.245	0.071	
95% CI	(-0.14, 0.63)	(-0.24, 0.38)	
Subgroup*Treatment Interaction p-value	0.4426	0.4828	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Physical Component Score			
Week 24			
m	40	82	129
n	37	73	113
Baseline Mean (SD)	50.00 (7.90)	47.12 (9.77)	49.12 (9.54)
Analysis Visit Mean (SD)	49.64 (7.84)	46.14 (9.60)	49.82 (8.67)
LS Mean of Change from Baseline (SE)	0.19 (1.01)	-1.51 (0.72)	0.97 (0.59)
95% CI	(-1.79, 2.17)	(-2.92, -0.09)	(-0.19, 2.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.78 (1.14)	-2.48 (0.91)	
95% CI	(-3.03, 1.47)	(-4.26, -0.69)	
p-value	0.4933	0.0068	
Corrected Hedge's g Statistics	-0.125	-0.397	
95% CI	(-0.50, 0.25)	(-0.69, -0.10)	
Week 52			
m	39	74	116
n	34	65	101
Baseline Mean (SD)	50.11 (7.95)	47.02 (9.60)	49.64 (9.00)
Analysis Visit Mean (SD)	50.12 (7.87)	46.27 (9.80)	49.94 (7.89)
LS Mean of Change from Baseline (SE)	0.61 (0.99)	-1.11 (0.72)	0.76 (0.59)
95% CI	(-1.34, 2.56)	(-2.52, 0.30)	(-0.40, 1.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (1.13)	-1.87 (0.90)	
95% CI	(-2.37, 2.07)	(-3.65, -0.09)	
p-value	0.8950	0.0399	
Corrected Hedge's g Statistics	-0.025	-0.317	
95% CI	(-0.41, 0.36)	(-0.63, 0.00)	
Subgroup*Treatment Interaction p-value	0.4859	0.0073	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Physical Functioning			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	72.39 (23.99)	63.21 (26.04)	70.29 (25.51)
Analysis Visit Mean (SD)	73.60 (26.19)	67.03 (25.18)	70.49 (27.91)
LS Mean of Change from Baseline (SE)	2.05 (1.71)	2.75 (2.45)	0.12 (1.54)
95% CI	(-1.32, 5.42)	(-2.07, 7.58)	(-2.91, 3.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.93 (2.23)	2.63 (2.85)	
95% CI	(-2.46, 6.33)	(-2.97, 8.24)	
p-value	0.3877	0.3561	
Corrected Hedge's g Statistics	0.107	0.146	
95% CI	(-0.14, 0.36)	(-0.17, 0.46)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	73.36 (22.77)	62.84 (27.88)	70.78 (24.61)
Analysis Visit Mean (SD)	74.38 (28.11)	68.70 (27.38)	71.26 (26.13)
LS Mean of Change from Baseline (SE)	1.82 (1.69)	5.42 (2.44)	0.65 (1.48)
95% CI	(-1.51, 5.15)	(0.62, 10.23)	(-2.26, 3.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.17 (2.18)	4.78 (2.81)	
95% CI	(-3.12, 5.46)	(-0.75, 10.30)	
p-value	0.5927	0.0903	
Corrected Hedge's g Statistics	0.071	0.292	
95% CI	(-0.20, 0.34)	(-0.05, 0.64)	
Subgroup*Treatment Interaction p-value	0.9979	0.0253	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Role Physical			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	73.92 (26.75)	68.29 (27.76)	73.64 (25.42)
Analysis Visit Mean (SD)	72.82 (28.16)	71.72 (25.04)	72.03 (28.25)
LS Mean of Change from Baseline (SE)	-0.12 (1.84)	2.86 (2.63)	-1.59 (1.65)
95% CI	(-3.74, 3.50)	(-2.32, 8.03)	(-4.85, 1.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.47 (2.40)	4.45 (3.05)	
95% CI	(-3.25, 6.19)	(-1.56, 10.46)	
p-value	0.5397	0.1461	
Corrected Hedge's g Statistics	0.075	0.230	
95% CI	(-0.17, 0.32)	(-0.09, 0.55)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	74.62 (27.97)	66.78 (29.58)	73.38 (24.55)
Analysis Visit Mean (SD)	74.16 (29.73)	70.05 (27.93)	72.35 (24.53)
LS Mean of Change from Baseline (SE)	0.59 (1.91)	2.32 (2.75)	-0.29 (1.67)
95% CI	(-3.17, 4.34)	(-3.10, 7.74)	(-3.58, 3.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.88 (2.47)	2.61 (3.17)	
95% CI	(-3.97, 5.73)	(-3.63, 8.85)	
p-value	0.7214	0.4110	
Corrected Hedge's g Statistics	0.047	0.141	
95% CI	(-0.22, 0.31)	(-0.20, 0.49)	
Subgroup*Treatment Interaction p-value	0.6176	0.0664	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Bodily Pain			
Week 24			
m	121	59	160
n	113	53	136
Baseline Mean (SD)	63.9 (24.7)	54.6 (26.9)	62.3 (24.6)
Analysis Visit Mean (SD)	62.7 (26.3)	61.0 (23.3)	62.9 (26.2)
LS Mean of Change from Baseline (SE)	-0.41 (1.96)	4.04 (2.78)	0.36 (1.74)
95% CI	(-4.26, 3.44)	(-1.44, 9.52)	(-3.08, 3.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.77 (2.53)	3.68 (3.22)	
95% CI	(-5.75, 4.22)	(-2.66, 10.02)	
p-value	0.7627	0.2546	
Corrected Hedge's g Statistics	-0.037	0.180	
95% CI	(-0.29, 0.21)	(-0.14, 0.50)	
Week 52			
m	110	51	154
n	95	44	122
Baseline Mean (SD)	64.8 (25.7)	53.3 (27.6)	61.4 (24.3)
Analysis Visit Mean (SD)	65.0 (27.3)	64.0 (26.0)	64.4 (24.8)
LS Mean of Change from Baseline (SE)	0.91 (2.13)	7.38 (3.06)	2.68 (1.86)
95% CI	(-3.27, 5.10)	(1.37, 13.40)	(-0.97, 6.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.77 (2.74)	4.70 (3.52)	
95% CI	(-7.17, 3.63)	(-2.22, 11.63)	
p-value	0.5201	0.1825	
Corrected Hedge's g Statistics	-0.085	0.229	
95% CI	(-0.35, 0.18)	(-0.12, 0.57)	
Subgroup*Treatment Interaction p-value	0.8460	0.0630	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
General Health			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	58.90 (19.95)	48.58 (18.61)	56.66 (20.14)
Analysis Visit Mean (SD)	59.81 (20.73)	52.57 (18.94)	56.46 (22.52)
LS Mean of Change from Baseline (SE)	1.34 (1.41)	2.00 (2.02)	-0.47 (1.26)
95% CI	(-1.44, 4.11)	(-1.98, 5.98)	(-2.95, 2.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.80 (1.83)	2.47 (2.35)	
95% CI	(-1.80, 5.41)	(-2.15, 7.09)	
p-value	0.3253	0.2934	
Corrected Hedge's g Statistics	0.121	0.167	
95% CI	(-0.13, 0.37)	(-0.15, 0.48)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	60.16 (20.53)	48.82 (20.54)	56.65 (20.74)
Analysis Visit Mean (SD)	62.22 (20.29)	55.80 (18.09)	57.70 (22.24)
LS Mean of Change from Baseline (SE)	2.75 (1.50)	3.97 (2.16)	1.39 (1.31)
95% CI	(-0.19, 5.69)	(-0.28, 8.21)	(-1.18, 3.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.36 (1.93)	2.58 (2.49)	
95% CI	(-2.43, 5.15)	(-2.32, 7.47)	
p-value	0.4813	0.3008	
Corrected Hedge's g Statistics	0.093	0.178	
95% CI	(-0.17, 0.36)	(-0.17, 0.52)	
Subgroup*Treatment Interaction p-value	0.4304	0.0167	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Vitality			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	54.81 (23.36)	47.78 (23.00)	52.69 (20.66)
Analysis Visit Mean (SD)	54.47 (24.93)	50.03 (18.19)	52.09 (22.67)
LS Mean of Change from Baseline (SE)	0.15 (1.46)	0.84 (2.09)	-1.31 (1.31)
95% CI	(-2.72, 3.03)	(-3.27, 4.94)	(-3.88, 1.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.46 (1.90)	2.14 (2.42)	
95% CI	(-2.28, 5.20)	(-2.62, 6.90)	
p-value	0.4427	0.3764	
Corrected Hedge's g Statistics	0.094	0.140	
95% CI	(-0.15, 0.34)	(-0.18, 0.46)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	56.20 (23.96)	48.04 (23.80)	51.77 (20.52)
Analysis Visit Mean (SD)	55.49 (23.25)	52.44 (20.00)	53.56 (22.53)
LS Mean of Change from Baseline (SE)	0.10 (1.57)	2.78 (2.25)	1.23 (1.37)
95% CI	(-2.98, 3.18)	(-1.66, 7.21)	(-1.47, 3.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.13 (2.03)	1.55 (2.59)	
95% CI	(-5.12, 2.86)	(-3.56, 6.66)	
p-value	0.5772	0.5508	
Corrected Hedge's g Statistics	-0.074	0.102	
95% CI	(-0.34, 0.19)	(-0.24, 0.45)	
Subgroup*Treatment Interaction p-value	0.9569	0.0392	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Social Functioning			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	80.15 (24.32)	75.71 (26.45)	80.24 (22.95)
Analysis Visit Mean (SD)	78.95 (25.29)	80.66 (19.24)	78.03 (24.41)
LS Mean of Change from Baseline (SE)	-0.91 (1.78)	3.36 (2.55)	-2.65 (1.60)
95% CI	(-4.42, 2.59)	(-1.66, 8.37)	(-5.81, 0.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.74 (2.33)	6.01 (2.96)	
95% CI	(-2.84, 6.31)	(0.18, 11.84)	
p-value	0.4553	0.0434	
Corrected Hedge's g Statistics	0.092	0.321	
95% CI	(-0.16, 0.34)	(0.00, 0.64)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	81.51 (23.92)	75.28 (28.34)	80.64 (22.73)
Analysis Visit Mean (SD)	79.30 (24.19)	81.53 (21.82)	79.41 (23.39)
LS Mean of Change from Baseline (SE)	-1.38 (1.82)	4.89 (2.62)	-1.47 (1.59)
95% CI	(-4.95, 2.20)	(-0.27, 10.05)	(-4.60, 1.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (2.35)	6.36 (3.02)	
95% CI	(-4.53, 4.71)	(0.41, 12.30)	
p-value	0.9690	0.0361	
Corrected Hedge's g Statistics	0.005	0.361	
95% CI	(-0.26, 0.27)	(0.01, 0.71)	
Subgroup*Treatment Interaction p-value	0.7674	0.0177	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Role Emotional			
Week 24			
m	121	59	160
n	114	53	135
Baseline Mean (SD)	80.84 (25.76)	76.57 (25.85)	80.12 (23.15)
Analysis Visit Mean (SD)	80.55 (23.85)	82.39 (23.38)	80.74 (24.13)
LS Mean of Change from Baseline (SE)	-0.16 (1.62)	4.69 (2.31)	0.42 (1.46)
95% CI	(-3.35, 3.03)	(0.14, 9.24)	(-2.46, 3.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.57 (2.11)	4.27 (2.68)	
95% CI	(-4.72, 3.57)	(-1.00, 9.55)	
p-value	0.7854	0.1120	
Corrected Hedge's g Statistics	-0.033	0.251	
95% CI	(-0.28, 0.22)	(-0.07, 0.57)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	81.68 (25.00)	77.08 (27.32)	80.53 (22.79)
Analysis Visit Mean (SD)	82.07 (22.48)	82.58 (23.35)	79.37 (23.96)
LS Mean of Change from Baseline (SE)	1.06 (1.86)	4.47 (2.68)	-0.91 (1.63)
95% CI	(-2.60, 4.71)	(-0.80, 9.74)	(-4.12, 2.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.96 (2.41)	5.38 (3.09)	
95% CI	(-2.78, 6.71)	(-0.71, 11.47)	
p-value	0.4157	0.0831	
Corrected Hedge's g Statistics	0.108	0.298	
95% CI	(-0.16, 0.38)	(-0.05, 0.64)	
Subgroup*Treatment Interaction p-value	0.3945	0.5874	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Mental Health			
Week 24			
m	121	59	160
n	114	53	136
Baseline Mean (SD)	72.3 (20.9)	73.1 (18.2)	72.9 (17.1)
Analysis Visit Mean (SD)	71.8 (20.5)	72.9 (19.1)	73.0 (18.3)
LS Mean of Change from Baseline (SE)	-0.87 (1.32)	-0.40 (1.88)	-0.54 (1.19)
95% CI	(-3.48, 1.73)	(-4.10, 3.31)	(-2.88, 1.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.33 (1.72)	0.14 (2.18)	
95% CI	(-3.72, 3.05)	(-4.15, 4.44)	
p-value	0.8460	0.9481	
Corrected Hedge's g Statistics	-0.024	0.010	
95% CI	(-0.27, 0.23)	(-0.31, 0.33)	
Week 52			
m	110	51	154
n	96	44	122
Baseline Mean (SD)	73.3 (20.1)	73.8 (19.5)	72.4 (17.9)
Analysis Visit Mean (SD)	73.7 (18.1)	74.7 (18.8)	73.0 (20.3)
LS Mean of Change from Baseline (SE)	0.27 (1.46)	1.24 (2.09)	-0.03 (1.28)
95% CI	(-2.60, 3.13)	(-2.87, 5.36)	(-2.54, 2.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.29 (1.88)	1.27 (2.41)	
95% CI	(-3.41, 4.00)	(-3.48, 6.02)	
p-value	0.8758	0.5988	
Corrected Hedge's g Statistics	0.021	0.090	
95% CI	(-0.25, 0.29)	(-0.25, 0.43)	
Subgroup*Treatment Interaction p-value	0.7916	0.6089	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Mental Component Score			
Week 24			
m	121	59	160
n	113	53	135
Baseline Mean (SD)	49.86 (11.44)	49.45 (11.00)	49.88 (9.31)
Analysis Visit Mean (SD)	49.39 (10.62)	50.48 (9.72)	49.72 (10.22)
LS Mean of Change from Baseline (SE)	-0.60 (0.70)	0.70 (1.00)	-0.46 (0.63)
95% CI	(-1.98, 0.78)	(-1.26, 2.66)	(-1.70, 0.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.91)	1.16 (1.16)	
95% CI	(-1.93, 1.65)	(-1.11, 3.44)	
p-value	0.8787	0.3149	
Corrected Hedge's g Statistics	-0.019	0.159	
95% CI	(-0.27, 0.23)	(-0.16, 0.48)	
Week 52			
m	110	51	154
n	95	44	122
Baseline Mean (SD)	50.43 (11.09)	49.84 (11.72)	49.75 (9.46)
Analysis Visit Mean (SD)	50.10 (9.63)	51.09 (9.72)	49.62 (10.75)
LS Mean of Change from Baseline (SE)	-0.21 (0.78)	1.21 (1.11)	-0.39 (0.68)
95% CI	(-1.74, 1.32)	(-0.98, 3.40)	(-1.73, 0.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.18 (1.00)	1.60 (1.28)	
95% CI	(-1.79, 2.16)	(-0.92, 4.13)	
p-value	0.8558	0.2132	
Corrected Hedge's g Statistics	0.024	0.213	
95% CI	(-0.24, 0.29)	(-0.13, 0.56)	
Subgroup*Treatment Interaction p-value	0.4426	0.4828	

AMNOG Table SE22.3.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Physical Component Score			
Week 24			
m	121	59	160
n	113	53	135
Baseline Mean (SD)	46.82 (8.92)	42.36 (9.15)	45.96 (9.31)
Analysis Visit Mean (SD)	46.92 (10.12)	44.28 (7.96)	45.73 (10.72)
LS Mean of Change from Baseline (SE)	0.48 (0.67)	1.34 (0.95)	-0.24 (0.60)
95% CI	(-0.83, 1.79)	(-0.53, 3.21)	(-1.42, 0.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.72 (0.87)	1.58 (1.11)	
95% CI	(-0.98, 2.43)	(-0.59, 3.76)	
p-value	0.4048	0.1536	
Corrected Hedge's g Statistics	0.103	0.227	
95% CI	(-0.15, 0.35)	(-0.09, 0.55)	
Week 52			
m	110	51	154
n	95	44	122
Baseline Mean (SD)	47.16 (9.16)	41.87 (9.82)	45.86 (8.92)
Analysis Visit Mean (SD)	47.53 (11.22)	44.92 (10.16)	46.39 (9.51)
LS Mean of Change from Baseline (SE)	0.63 (0.69)	2.48 (0.99)	0.63 (0.60)
95% CI	(-0.72, 1.98)	(0.53, 4.43)	(-0.54, 1.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.88)	1.84 (1.14)	
95% CI	(-1.74, 1.74)	(-0.40, 4.09)	
p-value	0.9963	0.1068	
Corrected Hedge's g Statistics	-0.001	0.278	
95% CI	(-0.27, 0.27)	(-0.07, 0.62)	
Subgroup*Treatment Interaction p-value	0.4859	0.0073	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (11.6)	5 (5.8)	13 (9.8)
No	38 (88.4)	81 (94.2)	119 (90.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	1.77	
95% CI of the inverse odds ratio	(0.28, 2.48)	(0.61, 5.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.69	
95% CI of the inverse risk ratio	(0.32, 2.24)	(0.63, 4.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.78	-4.03	
95% CI of the absolute risk difference	(-9.07, 12.63)	(-11.13, 3.06)	
p-value	0.7387	0.2901	
p-value of Breslow-Day Test for Homogeneity [3]	0.7443	0.1292	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (34.9)	23 (26.7)	30 (22.7)
No	28 (65.1)	63 (73.3)	102 (77.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	0.81	
95% CI of the inverse odds ratio	(0.26, 1.16)	(0.43, 1.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	0.85	
95% CI of the inverse risk ratio	(0.39, 1.09)	(0.53, 1.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.16	4.02	
95% CI of the absolute risk difference	(-3.78, 28.09)	(-7.76, 15.79)	
p-value	0.1132	0.4992	
p-value of Breslow-Day Test for Homogeneity [3]	0.1722	0.9395	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	10 (11.6)	16 (12.1)
No	42 (97.7)	76 (88.4)	116 (87.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.79	1.05	
95% CI of the inverse odds ratio	(0.75, 45.04)	(0.45, 2.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.21	1.04	
95% CI of the inverse risk ratio	(0.71, 38.16)	(0.50, 2.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.80	-0.49	
95% CI of the absolute risk difference	(-16.96, -2.63)	(-9.26, 8.28)	
p-value	0.0596	0.9125	
p-value of Breslow-Day Test for Homogeneity [3]	0.1170	0.9954	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (25.6)	20 (23.3)	29 (22.0)
No	32 (74.4)	66 (76.7)	103 (78.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.93	
95% CI of the inverse odds ratio	(0.37, 1.82)	(0.49, 1.78)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.94	
95% CI of the inverse risk ratio	(0.47, 1.57)	(0.57, 1.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.61	1.29	
95% CI of the absolute risk difference	(-11.22, 18.44)	(-10.10, 12.67)	
p-value	0.6242	0.8241	
p-value of Breslow-Day Test for Homogeneity [3]	0.5919	0.7230	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (7.0)	12 (14.0)	23 (17.4)
No	40 (93.0)	74 (86.0)	109 (82.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.81	1.30	
95% CI of the inverse odds ratio	(0.80, 9.88)	(0.61, 2.78)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	1.25	
95% CI of the inverse risk ratio	(0.79, 7.91)	(0.66, 2.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.45	-3.47	
95% CI of the absolute risk difference	(-20.44, -0.45)	(-13.24, 6.30)	
p-value	0.0943	0.4951	
p-value of Breslow-Day Test for Homogeneity [3]	0.2965	0.3273	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (23.3)	22 (25.6)	32 (24.2)
No	33 (76.7)	64 (74.4)	100 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.93	
95% CI of the inverse odds ratio	(0.47, 2.38)	(0.50, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.95	
95% CI of the inverse risk ratio	(0.56, 1.94)	(0.59, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.99	1.34	
95% CI of the absolute risk difference	(-15.58, 13.60)	(-10.43, 13.11)	
p-value	0.8953	0.8229	
p-value of Breslow-Day Test for Homogeneity [3]	0.6796	0.5325	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (9.3)	11 (12.8)	20 (15.2)
No	39 (90.7)	75 (87.2)	112 (84.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.74	1.22	
95% CI of the inverse odds ratio	(0.56, 5.41)	(0.55, 2.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.63	1.18	
95% CI of the inverse risk ratio	(0.59, 4.50)	(0.60, 2.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.85	-2.36	
95% CI of the absolute risk difference	(-16.47, 4.77)	(-11.70, 6.98)	
p-value	0.3329	0.6257	
p-value of Breslow-Day Test for Homogeneity [3]	0.2668	0.0841	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (30.2)	26 (30.2)	43 (32.6)
No	30 (69.8)	60 (69.8)	89 (67.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.11	
95% CI of the inverse odds ratio	(0.53, 2.35)	(0.62, 2.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	1.08	
95% CI of the inverse risk ratio	(0.64, 1.81)	(0.72, 1.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.34	-2.34	
95% CI of the absolute risk difference	(-18.23, 13.54)	(-14.92, 10.23)	
p-value	0.7748	0.7162	
p-value of Breslow-Day Test for Homogeneity [3]	0.7183	0.1102	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.7)	4 (4.7)	16 (12.1)
No	41 (95.3)	82 (95.3)	116 (87.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.83	2.83	
95% CI of the inverse odds ratio	(0.62, 12.83)	(0.91, 8.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.61	2.61	
95% CI of the inverse risk ratio	(0.62, 10.88)	(0.90, 7.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.47	-7.47	
95% CI of the absolute risk difference	(-15.87, 0.93)	(-14.60, -0.34)	
p-value	0.1614	0.0618	
p-value of Breslow-Day Test for Homogeneity [3]	0.2317	0.0515	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (34.9)	22 (25.6)	40 (30.3)
No	28 (65.1)	64 (74.4)	92 (69.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	1.26	
95% CI of the inverse odds ratio	(0.39, 1.68)	(0.69, 2.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.18	
95% CI of the inverse risk ratio	(0.54, 1.41)	(0.76, 1.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.58	-4.72	
95% CI of the absolute risk difference	(-11.68, 20.84)	(-16.83, 7.38)	
p-value	0.5741	0.4501	
p-value of Breslow-Day Test for Homogeneity [3]	0.2663	0.6382	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.7)	13 (15.1)	14 (10.6)
No	41 (95.3)	73 (84.9)	118 (89.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.43	0.67	
95% CI of the inverse odds ratio	(0.53, 11.16)	(0.30, 1.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.28	0.70	
95% CI of the inverse risk ratio	(0.54, 9.63)	(0.35, 1.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.95	4.51	
95% CI of the absolute risk difference	(-14.15, 2.24)	(-4.70, 13.72)	
p-value	0.2393	0.3231	
p-value of Breslow-Day Test for Homogeneity [3]	0.1557	0.3602	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (9.3)	16 (18.6)	23 (17.4)
No	39 (90.7)	70 (81.4)	109 (82.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.06	0.92	
95% CI of the inverse odds ratio	(0.67, 6.32)	(0.46, 1.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.87	0.94	
95% CI of the inverse risk ratio	(0.69, 5.11)	(0.53, 1.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.12	1.18	
95% CI of the absolute risk difference	(-18.95, 2.71)	(-9.28, 11.65)	
p-value	0.2004	0.8241	
p-value of Breslow-Day Test for Homogeneity [3]	0.1224	0.2062	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (11.6)	15 (17.4)	13 (9.8)
No	38 (88.4)	71 (82.6)	119 (90.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.52	
95% CI of the inverse odds ratio	(0.28, 2.48)	(0.23, 1.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.56	
95% CI of the inverse risk ratio	(0.32, 2.24)	(0.28, 1.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.78	7.59	
95% CI of the absolute risk difference	(-9.07, 12.63)	(-1.90, 17.09)	
p-value	0.7387	0.1015	
p-value of Breslow-Day Test for Homogeneity [3]	0.4648	0.8567	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (18.6)	20 (23.3)	16 (12.1)
No	35 (81.4)	66 (76.7)	116 (87.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.46	
95% CI of the inverse odds ratio	(0.24, 1.53)	(0.22, 0.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	0.52	
95% CI of the inverse risk ratio	(0.30, 1.42)	(0.29, 0.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.48	11.13	
95% CI of the absolute risk difference	(-6.41, 19.38)	(0.61, 21.66)	
p-value	0.2831	0.0305	
p-value of Breslow-Day Test for Homogeneity [3]	0.1875	0.6262	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (9.3)	8 (9.3)	14 (10.6)
No	39 (90.7)	78 (90.7)	118 (89.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.16	
95% CI of the inverse odds ratio	(0.36, 3.72)	(0.46, 2.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	1.14	
95% CI of the inverse risk ratio	(0.40, 3.28)	(0.50, 2.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.30	-1.30	
95% CI of the absolute risk difference	(-11.45, 8.84)	(-9.38, 6.78)	
p-value	0.8069	0.7548	
p-value of Breslow-Day Test for Homogeneity [3]	0.8631	0.5272	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (39.5)	21 (24.4)	35 (26.5)
No	26 (60.5)	65 (75.6)	97 (73.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	1.12	
95% CI of the inverse odds ratio	(0.27, 1.14)	(0.60, 2.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	1.09	
95% CI of the inverse risk ratio	(0.42, 1.07)	(0.68, 1.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.02	-2.10	
95% CI of the absolute risk difference	(-3.42, 29.46)	(-13.89, 9.70)	
p-value	0.1047	0.7291	
p-value of Breslow-Day Test for Homogeneity [3]	0.3784	0.5933	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	5 (5.8)	6 (4.5)
No	43 (100)	81 (94.2)	126 (95.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.77	
95% CI of the inverse odds ratio	NE	(0.23, 2.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.78	
95% CI of the inverse risk ratio	NE	(0.25, 2.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.55	1.27	
95% CI of the absolute risk difference	(-8.10, -0.99)	(-4.82, 7.36)	
p-value	0.1548	0.6758	
p-value of Breslow-Day Test for Homogeneity [3]	0.1967	0.5651	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (30.2)	13 (15.1)	23 (17.4)
No	30 (69.8)	73 (84.9)	109 (82.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.49	1.18	
95% CI of the inverse odds ratio	(0.22, 1.07)	(0.56, 2.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	1.15	
95% CI of the inverse risk ratio	(0.32, 1.04)	(0.62, 2.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.81	-2.31	
95% CI of the absolute risk difference	(-2.37, 27.98)	(-12.27, 7.65)	
p-value	0.0711	0.6538	
p-value of Breslow-Day Test for Homogeneity [3]	0.0605	0.8526	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	4 (4.7)	6 (4.5)
No	42 (97.7)	82 (95.3)	126 (95.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	0.98	
95% CI of the inverse odds ratio	(0.23, 17.09)	(0.27, 3.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.95	0.98	
95% CI of the inverse risk ratio	(0.24, 15.78)	(0.28, 3.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.22	0.11	
95% CI of the absolute risk difference	(-7.96, 3.52)	(-5.59, 5.80)	
p-value	0.5188	0.9709	
p-value of Breslow-Day Test for Homogeneity [3]	0.5473	0.2179	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (11.6)	17 (19.8)	28 (21.2)
No	38 (88.4)	69 (80.2)	104 (78.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.05	1.09	
95% CI of the inverse odds ratio	(0.74, 5.68)	(0.56, 2.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.82	1.07	
95% CI of the inverse risk ratio	(0.75, 4.43)	(0.63, 1.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.58	-1.44	
95% CI of the absolute risk difference	(-21.43, 2.27)	(-12.38, 9.49)	
p-value	0.1629	0.7967	
p-value of Breslow-Day Test for Homogeneity [3]	0.0750	0.0295	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	17 (13.7)	13 (20.0)	24 (14.0)
No	107 (86.3)	52 (80.0)	147 (86.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.65	
95% CI of the inverse odds ratio	(0.53, 2.01)	(0.31, 1.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.70	
95% CI of the inverse risk ratio	(0.58, 1.82)	(0.38, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.33	5.96	
95% CI of the absolute risk difference	(-8.31, 7.66)	(-5.07, 17.00)	
p-value	0.9364	0.2602	
p-value of Breslow-Day Test for Homogeneity [3]	0.7443	0.1292	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	40 (32.3)	25 (38.5)	56 (32.7)
No	84 (67.7)	40 (61.5)	115 (67.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.78	
95% CI of the inverse odds ratio	(0.62, 1.68)	(0.43, 1.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.85	
95% CI of the inverse risk ratio	(0.73, 1.42)	(0.59, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.49	5.71	
95% CI of the absolute risk difference	(-11.32, 10.33)	(-8.05, 19.47)	
p-value	0.9293	0.4089	
p-value of Breslow-Day Test for Homogeneity [3]	0.1722	0.9395	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (11.3)	8 (12.3)	22 (12.9)
No	110 (88.7)	57 (87.7)	149 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.05	
95% CI of the inverse odds ratio	(0.57, 2.37)	(0.44, 2.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	1.05	
95% CI of the inverse risk ratio	(0.61, 2.14)	(0.49, 2.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.58	-0.56	
95% CI of the absolute risk difference	(-9.07, 5.92)	(-9.99, 8.87)	
p-value	0.6833	0.9085	
p-value of Breslow-Day Test for Homogeneity [3]	0.1170	0.9954	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (23.4)	19 (29.2)	42 (24.6)
No	95 (76.6)	46 (70.8)	129 (75.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.79	
95% CI of the inverse odds ratio	(0.62, 1.83)	(0.42, 1.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.84	
95% CI of the inverse risk ratio	(0.69, 1.59)	(0.53, 1.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.17	4.67	
95% CI of the absolute risk difference	(-11.03, 8.68)	(-8.13, 17.47)	
p-value	0.8158	0.4642	
p-value of Breslow-Day Test for Homogeneity [3]	0.5919	0.7230	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	17 (13.7)	14 (21.5)	30 (17.5)
No	107 (86.3)	51 (78.5)	141 (82.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.34	0.78	
95% CI of the inverse odds ratio	(0.70, 2.55)	(0.38, 1.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	0.81	
95% CI of the inverse risk ratio	(0.74, 2.21)	(0.46, 1.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.83	3.99	
95% CI of the absolute risk difference	(-12.15, 4.48)	(-7.51, 15.50)	
p-value	0.3744	0.4815	
p-value of Breslow-Day Test for Homogeneity [3]	0.2965	0.3273	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (24.2)	24 (36.9)	50 (29.2)
No	94 (75.8)	41 (63.1)	121 (70.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.71	
95% CI of the inverse odds ratio	(0.76, 2.19)	(0.39, 1.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	0.79	
95% CI of the inverse risk ratio	(0.82, 1.78)	(0.53, 1.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.05	7.68	
95% CI of the absolute risk difference	(-15.21, 5.12)	(-5.89, 21.25)	
p-value	0.3359	0.2557	
p-value of Breslow-Day Test for Homogeneity [3]	0.6796	0.5325	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	21 (16.9)	17 (26.2)	25 (14.6)
No	103 (83.1)	48 (73.8)	146 (85.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.48	
95% CI of the inverse odds ratio	(0.45, 1.58)	(0.24, 0.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.56	
95% CI of the inverse risk ratio	(0.51, 1.47)	(0.32, 0.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.32	11.53	
95% CI of the absolute risk difference	(-6.15, 10.78)	(-0.39, 23.46)	
p-value	0.5884	0.0385	
p-value of Breslow-Day Test for Homogeneity [3]	0.2668	0.0841	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	37 (29.8)	27 (41.5)	49 (28.7)
No	87 (70.2)	38 (58.5)	122 (71.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.57	
95% CI of the inverse odds ratio	(0.57, 1.57)	(0.31, 1.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.69	
95% CI of the inverse risk ratio	(0.67, 1.37)	(0.48, 1.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.18	12.88	
95% CI of the absolute risk difference	(-9.34, 11.71)	(-0.88, 26.65)	
p-value	0.8252	0.0585	
p-value of Breslow-Day Test for Homogeneity [3]	0.7183	0.1102	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (11.3)	10 (15.4)	20 (11.7)
No	110 (88.7)	55 (84.6)	151 (88.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.73	
95% CI of the inverse odds ratio	(0.50, 2.15)	(0.32, 1.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.76	
95% CI of the inverse risk ratio	(0.54, 1.97)	(0.38, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.41	3.69	
95% CI of the absolute risk difference	(-7.77, 6.96)	(-6.32, 13.70)	
p-value	0.9142	0.4473	
p-value of Breslow-Day Test for Homogeneity [3]	0.2317	0.0515	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	35 (28.2)	22 (33.8)	59 (34.5)
No	89 (71.8)	43 (66.2)	112 (65.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.34	1.03	
95% CI of the inverse odds ratio	(0.81, 2.21)	(0.56, 1.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	1.02	
95% CI of the inverse risk ratio	(0.86, 1.73)	(0.68, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.28	-0.66	
95% CI of the absolute risk difference	(-16.93, 4.38)	(-14.19, 12.87)	
p-value	0.2534	0.9244	
p-value of Breslow-Day Test for Homogeneity [3]	0.2663	0.6382	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (8.9)	10 (15.4)	11 (6.4)
No	113 (91.1)	55 (84.6)	160 (93.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.38	
95% CI of the inverse odds ratio	(0.30, 1.69)	(0.15, 0.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.42	
95% CI of the inverse risk ratio	(0.32, 1.62)	(0.19, 0.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.44	8.95	
95% CI of the absolute risk difference	(-3.77, 8.65)	(-0.56, 18.46)	
p-value	0.4314	0.0309	
p-value of Breslow-Day Test for Homogeneity [3]	0.1557	0.3602	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (21.0)	19 (29.2)	29 (17.0)
No	98 (79.0)	46 (70.8)	142 (83.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.49	
95% CI of the inverse odds ratio	(0.43, 1.39)	(0.25, 0.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.58	
95% CI of the inverse risk ratio	(0.50, 1.30)	(0.35, 0.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.01	12.27	
95% CI of the absolute risk difference	(-5.10, 13.12)	(-0.13, 24.68)	
p-value	0.3829	0.0364	
p-value of Breslow-Day Test for Homogeneity [3]	0.1224	0.2062	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (11.3)	15 (23.1)	25 (14.6)
No	110 (88.7)	50 (76.9)	146 (85.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	0.57	
95% CI of the inverse odds ratio	(0.67, 2.71)	(0.28, 1.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.63	
95% CI of the inverse risk ratio	(0.70, 2.39)	(0.36, 1.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.33	8.46	
95% CI of the absolute risk difference	(-11.02, 4.36)	(-3.07, 19.99)	
p-value	0.4046	0.1219	
p-value of Breslow-Day Test for Homogeneity [3]	0.4648	0.8567	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (16.9)	20 (30.8)	35 (20.5)
No	103 (83.1)	45 (69.2)	136 (79.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	0.58	
95% CI of the inverse odds ratio	(0.69, 2.30)	(0.30, 1.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	0.67	
95% CI of the inverse risk ratio	(0.74, 1.97)	(0.42, 1.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.53	10.30	
95% CI of the absolute risk difference	(-12.48, 5.42)	(-2.44, 23.05)	
p-value	0.4451	0.0945	
p-value of Breslow-Day Test for Homogeneity [3]	0.1875	0.6262	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (12.1)	6 (9.2)	26 (15.2)
No	109 (87.9)	59 (90.8)	145 (84.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	1.76	
95% CI of the inverse odds ratio	(0.66, 2.58)	(0.69, 4.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	1.65	
95% CI of the inverse risk ratio	(0.70, 2.27)	(0.71, 3.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.11	-5.97	
95% CI of the absolute risk difference	(-10.98, 4.76)	(-14.83, 2.89)	
p-value	0.4462	0.2311	
p-value of Breslow-Day Test for Homogeneity [3]	0.8631	0.5272	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	40 (32.3)	20 (30.8)	48 (28.1)
No	84 (67.7)	45 (69.2)	123 (71.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.88	
95% CI of the inverse odds ratio	(0.50, 1.36)	(0.47, 1.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.91	
95% CI of the inverse risk ratio	(0.61, 1.24)	(0.59, 1.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.19	2.70	
95% CI of the absolute risk difference	(-6.44, 14.82)	(-10.39, 15.79)	
p-value	0.4377	0.6825	
p-value of Breslow-Day Test for Homogeneity [3]	0.3784	0.5933	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (5.6)	8 (12.3)	11 (6.4)
No	117 (94.4)	57 (87.7)	160 (93.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.49	
95% CI of the inverse odds ratio	(0.43, 3.05)	(0.19, 1.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	0.52	
95% CI of the inverse risk ratio	(0.45, 2.86)	(0.22, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.79	5.87	
95% CI of the absolute risk difference	(-6.27, 4.69)	(-2.92, 14.67)	
p-value	0.7803	0.1384	
p-value of Breslow-Day Test for Homogeneity [3]	0.1967	0.5651	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (19.4)	14 (21.5)	39 (22.8)
No	100 (80.6)	51 (78.5)	132 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	1.08	
95% CI of the inverse odds ratio	(0.70, 2.18)	(0.54, 2.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.06	
95% CI of the inverse risk ratio	(0.75, 1.85)	(0.62, 1.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.45	-1.27	
95% CI of the absolute risk difference	(-12.83, 5.92)	(-13.08, 10.54)	
p-value	0.4751	0.8347	
p-value of Breslow-Day Test for Homogeneity [3]	0.0605	0.8526	

AMNOG Table SE22.3.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (4.8)	8 (12.3)	8 (4.7)
No	118 (95.2)	57 (87.7)	163 (95.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.35	
95% CI of the inverse odds ratio	(0.33, 2.86)	(0.13, 0.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.38	
95% CI of the inverse risk ratio	(0.34, 2.72)	(0.15, 0.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.16	7.63	
95% CI of the absolute risk difference	(-4.77, 5.09)	(-0.96, 16.22)	
p-value	0.9490	0.0373	
p-value of Breslow-Day Test for Homogeneity [3]	0.5473	0.2179	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (24.2)	24 (36.9)	32 (18.7)
No	94 (75.8)	41 (63.1)	139 (81.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.39	
95% CI of the inverse odds ratio	(0.41, 1.27)	(0.21, 0.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.51	
95% CI of the inverse risk ratio	(0.50, 1.20)	(0.32, 0.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.48	18.21	
95% CI of the absolute risk difference	(-4.06, 15.02)	(5.10, 31.32)	
p-value	0.2541	0.0033	
p-value of Breslow-Day Test for Homogeneity [3]	0.0750	0.0295	

Madrigal Pharmaceuticals, Inc. Page 1 of 10
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.3.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male
Physical Functioning



Patients with result at given visit			
MGL-3196 80 mg	40	39	36
MGL-3196 100 mg	79	79	67
Placebo	122	121	107

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 10
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.3.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male
General Health



Patients with result at given visit			
MGL-3196 80 mg	40	39	36
MGL-3196 100 mg	79	79	67
Placebo	122	121	107

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 10
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.3.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male
Vitality



Patients with result at given visit			
MGL-3196 80 mg	40	39	36
MGL-3196 100 mg	79	79	67
Placebo	122	121	107

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 4 of 10
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.3.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male
Social Functioning



Patients with result at given visit			
MGL-3196 80 mg	40	39	36
MGL-3196 100 mg	79	79	67
Placebo	122	121	107

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 5 of 10
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.3.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Sex
(Label Population)

Sex: Male
Physical Component Score



Patients with result at given visit			
MGL-3196 80 mg	40	39	36
MGL-3196 100 mg	79	79	67
Placebo	122	121	107

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 6 of 10
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.3.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female
Physical Functioning



Patients with result at given visit

MGL-3196 80 mg	118	118	100
MGL-3196 100 mg	59	57	47
Placebo	158	146	132

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 7 of 10
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.3.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female
General Health



Patients with result at given visit			
MGL-3196 80 mg	118	118	100
MGL-3196 100 mg	59	57	47
Placebo	158	146	132

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 8 of 10
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.3.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female
Vitality



Patients with result at given visit			
MGL-3196 80 mg	118	118	100
MGL-3196 100 mg	59	57	47
Placebo	158	146	132

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 9 of 10
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.3.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female
Social Functioning



Patients with result at given visit			
MGL-3196 80 mg	118	118	100
MGL-3196 100 mg	59	57	47
Placebo	158	146	132

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 10 of 10
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.3.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Sex
(Label Population)

Sex: Female
Physical Component Score



Patients with result at given visit			
MGL-3196 80 mg	117	118	100
MGL-3196 100 mg	59	57	47
Placebo	157	146	132

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Physical Functioning						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	74.22 (22.50)	68.70 (25.10)	74.06 (25.90)			
Median	76.40	75.00	80.00			
IQR: Q1, Q3	60.00, 95.00	55.00, 90.00	60.00, 95.00			
Min, Max	10.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	77.53 (22.02)	72.02 (24.43)	74.54 (27.55)	3.09 (1.63)	2.74 (2.05)	-0.82 (1.43)
Median	85.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 95.00	60.00, 90.00	55.00, 95.00	-5.00, 12.50	-5.00, 10.00	-10.00, 10.00
Min, Max	25.0, 100.0	5.0, 100.0	0.0, 100.0	-40.0, 45.0	-65.0, 70.0	-70.0, 75.0
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	76.04 (26.00)	71.87 (26.18)	75.20 (26.02)	1.81 (1.55)	1.06 (1.92)	-0.53 (1.39)
Median	90.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 100.00	60.00, 95.00	60.00, 95.00	-5.00, 10.00	-5.00, 5.00	-10.00, 5.00
Min, Max	10.0, 100.0	0.0, 100.0	0.0, 100.0	-42.8, 45.0	-85.0, 40.0	-60.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Role Physical						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	79.36 (21.85)	73.86 (26.20)	78.11 (25.48)			
Median	87.50	75.00	87.50			
IQR: Q1, Q3	62.50, 100.00	56.30, 100.00	62.50, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	78.87 (21.05)	74.96 (23.76)	77.37 (27.55)	-1.42 (2.07)	-0.13 (2.06)	-2.31 (1.56)
Median	81.30	81.30	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	56.30, 100.00	62.50, 100.00	-12.50, 12.50	-12.50, 6.30	-6.30, 0.00
Min, Max	31.3, 100.0	12.5, 100.0	0.0, 100.0	-43.8, 50.0	-56.2, 68.7	-68.7, 68.7
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	77.77 (24.82)	75.37 (25.77)	77.60 (25.27)	-2.39 (2.03)	0.15 (2.15)	-2.20 (1.65)
Median	87.50	81.30	87.50	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 100.00	56.30, 100.00	-12.50, 6.20	-6.30, 6.30	-12.50, 6.20
Min, Max	18.8, 100.0	6.3, 100.0	0.0, 100.0	-37.5, 56.2	-68.8, 81.3	-62.5, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Bodily Pain						
Baseline						
m	94	119	198			
n	91	108	186			
Mean (SD)	65.8 (21.9)	61.4 (25.2)	63.8 (24.2)			
Median	72.0	62.0	62.0			
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	41.0, 84.0			
Min, Max	22, 100	0, 100	0, 100			
Week 24						
m	91	110	187			
n	89	107	175	87	99	165
Mean (SD/SE)	63.6 (21.1)	65.7 (22.2)	65.3 (24.8)	-2.5 (2.0)	2.8 (1.9)	-0.3 (1.5)
Median	62.0	62.0	72.0	0	0	0
IQR: Q1, Q3	51.0, 74.0	51.0, 84.0	41.0, 84.0	-16.0, 10.0	-10.0, 11.0	-12.0, 12.0
Min, Max	12, 100	22, 100	10, 100	-50, 52	-42, 72	-49, 59
Week 52						
m	85	97	175			
n	77	89	150	75	86	142
Mean (SD/SE)	66.3 (22.7)	65.2 (24.8)	67.1 (23.9)	-1.0 (2.4)	2.8 (2.2)	1.9 (1.7)
Median	62.0	72.0	72.0	0	0	0
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	51.0, 84.0	-12.0, 10.0	-10.0, 11.0	-11.0, 12.0
Min, Max	20, 100	10, 100	0, 100	-80, 59	-53, 62	-48, 69

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
General Health						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	61.34 (18.73)	54.18 (19.37)	58.86 (20.91)			
Median	62.00	52.00	62.00			
IQR: Q1, Q3	50.00, 77.00	40.00, 72.00	42.00, 75.00			
Min, Max	25.0, 100.0	10.0, 100.0	15.0, 100.0			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	62.87 (18.81)	55.35 (18.75)	59.10 (22.18)	0.97 (1.68)	1.32 (1.53)	-0.12 (1.11)
Median	62.00	55.00	62.00	4.10	0	0
IQR: Q1, Q3	52.00, 77.00	40.00, 67.00	42.00, 77.00	-5.00, 10.00	-10.00, 10.00	-10.00, 8.00
Min, Max	20.0, 100.0	15.0, 100.0	0.0, 100.0	-60.0, 32.0	-35.0, 37.0	-40.0, 48.0
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	62.98 (18.65)	56.85 (18.77)	60.79 (21.99)	0.89 (1.88)	1.70 (1.86)	1.13 (1.14)
Median	67.00	57.00	62.00	0	0	0
IQR: Q1, Q3	52.50, 77.00	45.00, 72.00	45.00, 77.00	-6.00, 9.00	-10.00, 15.00	-5.00, 10.00
Min, Max	20.0, 97.0	10.0, 92.0	10.0, 100.0	-70.0, 47.0	-52.0, 47.0	-42.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Vitality						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	57.11 (20.84)	53.73 (23.17)	55.60 (21.05)			
Median	62.50	56.30	56.30			
IQR: Q1, Q3	40.65, 75.00	37.50, 68.80	43.80, 75.00			
Min, Max	12.5, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	58.17 (22.02)	54.35 (20.52)	56.13 (21.70)	0.55 (1.76)	0.00 (1.65)	-0.41 (1.19)
Median	62.50	56.30	56.30	0	0	0
IQR: Q1, Q3	43.80, 75.00	37.50, 68.80	37.50, 75.00	-6.30, 12.50	-12.50, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.8, 43.8	-31.3, 43.8	-37.5, 43.7
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	58.95 (20.49)	55.08 (20.76)	57.19 (23.39)	0.58 (1.84)	0.36 (1.68)	0.97 (1.45)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	43.80, 75.00	43.80, 68.80	43.80, 75.00	-6.30, 12.50	-6.30, 6.30	-6.30, 12.50
Min, Max	12.5, 100.0	6.3, 100.0	0.0, 100.0	-43.7, 50.0	-43.8, 43.8	-56.3, 43.8

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Social Functioning						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	83.42 (21.86)	79.98 (25.80)	84.14 (22.11)			
Median	100.00	87.50	100.00			
IQR: Q1, Q3	68.75, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	12.5, 100.0			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	83.57 (21.70)	82.24 (21.24)	82.57 (23.93)	-0.99 (2.43)	1.89 (2.06)	-2.88 (1.53)
Median	87.50	87.50	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	-12.50, 12.50	0.00, 12.50	-12.50, 0.00
Min, Max	25.0, 100.0	12.5, 100.0	0.0, 100.0	-62.5, 75.0	-62.5, 87.5	-62.5, 75.0
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	83.93 (20.26)	82.30 (22.04)	84.08 (22.20)	-1.64 (2.03)	1.45 (2.37)	-0.97 (1.64)
Median	100.00	87.50	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00	-12.50, 12.50	0.00, 12.50	0.00, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-50.0, 50.0	-62.5, 62.5	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Role Emotional						
Baseline						
m	94	119	198			
n	92	108	185			
Mean (SD)	85.50 (22.48)	82.87 (23.15)	85.04 (21.98)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0			
Week 24						
m	91	110	187			
n	89	107	175	88	99	164
Mean (SD/SE)	86.14 (19.09)	85.91 (21.25)	85.48 (23.14)	-0.28 (1.72)	2.61 (1.56)	-0.46 (1.35)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	-8.30, 0.00	0.00, 8.30	-4.15, 0.00
Min, Max	33.3, 100.0	8.3, 100.0	0.0, 100.0	-33.3, 66.7	-50.0, 41.7	-50.0, 58.3
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	86.96 (19.23)	85.48 (21.64)	85.55 (22.32)	-0.16 (1.61)	2.61 (2.38)	-0.35 (1.53)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	0.00, 16.60	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-33.3, 41.7	-75.0, 58.3	-58.3, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Mental Health						
Baseline						
m	94	119	198			
n	92	108	186			
Mean (SD)	76.0 (18.7)	75.4 (19.1)	76.6 (17.7)			
Median	85.0	80.0	80.0			
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	70.0, 90.0			
Min, Max	10, 100	15, 100	5, 100			
Week 24						
m	91	110	187			
n	89	107	175	88	99	165
Mean (SD/SE)	76.6 (16.7)	76.4 (17.5)	76.5 (17.8)	-0.2 (1.5)	0.4 (1.3)	-0.3 (1.1)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	70.0, 90.0	70.0, 90.0	-5.0, 7.5	-5.0, 5.0	-5.0, 5.0
Min, Max	30, 100	5, 100	5, 100	-40, 35	-40, 50	-45, 50
Week 52						
m	85	97	175			
n	77	89	150	76	86	142
Mean (SD/SE)	77.8 (15.5)	76.6 (17.3)	77.9 (18.4)	-0.2 (1.5)	0.4 (1.4)	1.1 (1.2)
Median	80.0	80.0	82.5	0	0	0
IQR: Q1, Q3	70.0, 90.0	65.0, 90.0	70.0, 90.0	-5.0, 5.0	-5.0, 5.0	-5.0, 10.0
Min, Max	40, 100	20, 100	15, 100	-35, 35	-30, 50	-40, 50

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Mental Component Score						
Baseline						
m	94	119	198			
n	91	108	185			
Mean (SD)	51.81 (10.07)	51.27 (11.14)	51.85 (9.16)			
Median	55.10	54.90	54.70			
IQR: Q1, Q3	47.40, 59.10	44.85, 59.05	47.90, 58.00			
Min, Max	18.9, 69.0	17.0, 72.3	15.6, 66.5			
Week 24						
m	91	110	187			
n	89	107	175	87	99	164
Mean (SD/SE)	51.89 (9.01)	51.87 (9.84)	51.70 (9.70)	-0.40 (0.83)	0.41 (0.72)	-0.33 (0.59)
Median	54.00	54.10	54.60	-0.40	0	0
IQR: Q1, Q3	47.40, 59.10	47.70, 59.10	47.00, 58.50	-4.90, 3.50	-3.00, 3.40	-3.80, 3.30
Min, Max	24.8, 64.6	9.4, 71.2	14.2, 66.3	-20.0, 19.0	-24.5, 26.1	-24.6, 22.7
Week 52						
m	85	97	175			
n	77	89	150	75	86	142
Mean (SD/SE)	52.54 (8.71)	51.92 (9.63)	52.21 (9.62)	-0.32 (0.77)	0.55 (0.92)	0.29 (0.62)
Median	55.40	53.70	54.85	0	-0.20	0.40
IQR: Q1, Q3	48.60, 59.10	46.60, 59.00	48.20, 59.00	-3.90, 3.50	-3.70, 2.90	-3.20, 4.50
Min, Max	25.1, 63.2	17.8, 70.7	20.4, 68.0	-17.3, 20.4	-21.4, 25.2	-21.6, 24.1

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Physical Component Score						
Baseline						
m	94	119	198			
n	91	108	185			
Mean (SD)	47.57 (7.83)	44.78 (9.59)	46.79 (9.56)			
Median	48.60	45.60	48.80			
IQR: Q1, Q3	43.00, 53.60	39.30, 52.05	40.70, 54.50			
Min, Max	27.6, 59.3	21.2, 60.4	20.7, 65.2			
Week 24						
m	91	110	187			
n	89	107	175	87	99	164
Mean (SD/SE)	47.82 (8.06)	45.80 (8.73)	46.95 (10.24)	0.19 (0.65)	0.69 (0.75)	-0.45 (0.54)
Median	49.20	47.20	50.10	0.40	-0.20	-0.30
IQR: Q1, Q3	43.40, 53.50	39.90, 52.30	40.30, 55.00	-4.00, 4.10	-2.50, 3.70	-4.00, 2.90
Min, Max	23.1, 59.9	20.2, 61.0	19.0, 62.9	-15.7, 17.6	-22.0, 32.4	-28.8, 22.9
Week 52						
m	85	97	175			
n	77	89	150	75	86	142
Mean (SD/SE)	47.61 (10.03)	45.96 (9.98)	47.36 (9.46)	0.10 (0.71)	0.50 (0.81)	-0.06 (0.49)
Median	49.10	47.80	48.65	-0.50	0.65	-0.20
IQR: Q1, Q3	41.80, 54.90	40.60, 53.10	41.30, 55.30	-2.80, 3.50	-3.10, 4.80	-3.30, 2.60
Min, Max	20.3, 62.8	16.0, 61.2	22.5, 61.7	-24.7, 15.9	-23.5, 18.6	-17.9, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Physical Functioning						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	75.08 (25.92)	74.50 (28.11)	75.21 (24.13)			
Median	82.50	90.00	85.00			
IQR: Q1, Q3	60.00, 95.00	60.00, 95.00	60.00, 95.00			
Min, Max	0.0, 100.0	10.0, 100.0	10.0, 100.0			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	73.31 (27.22)	69.89 (25.52)	75.56 (27.45)	-0.95 (2.17)	-5.12 (3.35)	2.40 (1.70)
Median	80.00	75.00	85.00	0	-5.00	0
IQR: Q1, Q3	57.50, 95.00	60.00, 90.00	68.35, 100.00	-10.00, 10.00	-15.00, 5.00	-5.00, 10.00
Min, Max	5.0, 100.0	10.0, 100.0	0.0, 100.0	-50.0, 60.0	-45.0, 40.0	-40.0, 60.0
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	77.29 (27.56)	68.40 (25.89)	78.70 (21.63)	0.65 (2.38)	-1.52 (3.52)	2.83 (1.63)
Median	90.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 100.00	50.00, 90.00	70.00, 100.00	-5.00, 10.00	-10.00, 10.00	-5.00, 10.00
Min, Max	0.0, 100.0	15.0, 100.0	10.0, 100.0	-65.0, 35.0	-50.0, 20.0	-45.0, 55.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Role Physical						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	70.75 (30.60)	70.43 (30.08)	71.69 (26.79)			
Median	75.00	75.00	75.00			
IQR: Q1, Q3	50.00, 100.00	43.80, 100.00	50.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	68.58 (32.22)	69.20 (24.99)	73.38 (26.60)	-0.89 (2.09)	-0.69 (4.57)	3.64 (2.18)
Median	81.30	75.00	75.00	0	0	0
IQR: Q1, Q3	40.65, 100.00	50.00, 87.50	53.15, 100.00	-12.50, 6.30	-18.70, 6.30	-6.25, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.7, 37.5	-50.0, 50.0	-50.0, 87.5
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	73.85 (31.41)	68.77 (28.29)	72.07 (24.15)	2.20 (2.51)	2.72 (5.34)	0.92 (2.32)
Median	87.50	75.00	75.00	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 93.80	50.00, 100.00	0.00, 6.30	-6.30, 12.50	-12.50, 12.50
Min, Max	0.0, 100.0	6.3, 100.0	18.8, 100.0	-43.8, 81.2	-75.0, 56.3	-56.3, 68.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Bodily Pain						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	68.0 (27.5)	64.5 (30.0)	68.8 (26.6)			
Median	73.0	62.0	74.0			
IQR: Q1, Q3	51.0, 100.0	41.0, 100.0	51.0, 100.0			
Min, Max	0, 100	12, 100	12, 100			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	64.8 (30.3)	59.9 (30.3)	67.5 (27.1)	-2.2 (2.8)	-6.4 (4.2)	1.5 (2.4)
Median	72.0	51.0	67.0	0	0	0
IQR: Q1, Q3	41.0, 100.0	41.0, 100.0	46.5, 100.0	-20.0, 10.0	-20.0, 3.0	-11.5, 16.0
Min, Max	0, 100	10, 100	0, 100	-59, 68	-62, 29	-78, 78
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	69.6 (29.4)	74.4 (27.4)	68.3 (26.5)	1.8 (2.7)	13.1 (5.2)	0.4 (2.7)
Median	74.0	84.0	74.0	0	10.0	0
IQR: Q1, Q3	51.0, 100.0	51.0, 100.0	51.0, 100.0	0.0, 10.0	0.0, 26.0	-12.0, 11.0
Min, Max	0, 100	22, 100	10, 100	-60, 68	-38, 69	-78, 78

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
General Health						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	59.27 (21.48)	53.87 (18.79)	58.70 (19.25)			
Median	61.00	57.00	57.00			
IQR: Q1, Q3	45.00, 77.00	47.00, 67.00	45.00, 75.00			
Min, Max	10.0, 97.0	10.0, 87.0	15.0, 97.0			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	58.19 (23.29)	54.21 (21.99)	59.60 (20.21)	1.00 (1.54)	1.41 (3.39)	2.23 (1.68)
Median	57.00	52.00	57.00	0	0	2.00
IQR: Q1, Q3	42.00, 77.00	40.00, 72.00	50.00, 74.50	-7.00, 10.00	-10.00, 15.00	-9.00, 10.00
Min, Max	10.0, 100.0	10.0, 92.0	10.0, 100.0	-25.0, 32.0	-35.0, 40.0	-28.0, 40.0
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	62.51 (21.49)	52.68 (20.76)	60.17 (18.59)	2.35 (1.75)	3.96 (3.70)	2.05 (1.56)
Median	67.00	52.00	57.00	1.00	5.00	0
IQR: Q1, Q3	42.00, 82.00	42.00, 67.00	50.00, 72.00	-10.00, 10.00	0.00, 15.00	-5.00, 10.00
Min, Max	20.0, 100.0	15.0, 90.0	10.0, 100.0	-20.0, 32.0	-47.0, 35.0	-40.0, 37.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Vitality						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	57.88 (24.62)	53.57 (19.88)	58.45 (22.53)			
Median	62.50	56.30	62.50			
IQR: Q1, Q3	37.50, 75.00	43.80, 68.80	37.50, 75.00			
Min, Max	0.0, 100.0	0.0, 87.5	6.3, 100.0			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	54.44 (25.81)	51.53 (19.31)	58.51 (23.12)	-2.28 (1.50)	-2.09 (2.38)	1.21 (1.73)
Median	56.30	56.30	62.50	0	0	0
IQR: Q1, Q3	37.50, 75.00	37.50, 62.50	43.80, 75.00	-6.30, 6.20	-12.50, 6.30	-12.50, 6.25
Min, Max	0.0, 100.0	12.5, 87.5	0.0, 100.0	-31.2, 37.5	-25.0, 25.0	-37.5, 56.2
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	58.29 (25.80)	54.02 (21.87)	57.89 (20.91)	-1.04 (1.99)	0.27 (2.98)	-0.21 (2.01)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	43.80, 75.00	31.30, 68.80	43.80, 75.00	-6.30, 12.50	-6.20, 6.30	-6.30, 8.30
Min, Max	6.3, 100.0	6.3, 87.5	0.0, 100.0	-37.5, 37.5	-43.8, 25.0	-43.7, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Social Functioning						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	79.55 (26.09)	78.33 (26.04)	80.59 (23.09)			
Median	87.50	87.50	87.50			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	62.50, 100.00			
Min, Max	0.0, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	77.76 (27.64)	79.74 (20.16)	78.53 (25.90)	-0.20 (2.36)	0.93 (3.94)	0.89 (2.09)
Median	87.50	87.50	87.50	0	0	0
IQR: Q1, Q3	56.25, 100.00	62.50, 100.00	62.50, 100.00	-12.50, 12.50	-12.50, 12.50	0.00, 12.50
Min, Max	12.5, 100.0	50.0, 100.0	0.0, 100.0	-37.5, 62.5	-50.0, 37.5	-50.0, 50.0
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	78.60 (26.67)	80.00 (23.94)	81.04 (21.41)	-1.62 (2.27)	3.26 (5.34)	0.31 (2.16)
Median	87.50	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	62.50, 100.00	0.00, 0.00	0.00, 25.00	-12.50, 12.50
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-50.0, 37.5	-62.5, 50.0	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Role Emotional						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	77.27 (26.82)	78.89 (25.78)	81.91 (23.05)			
Median	83.30	83.30	95.85			
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	25.0, 100.0			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	75.49 (26.47)	83.04 (18.43)	77.90 (25.00)	0.13 (2.49)	4.01 (3.40)	-1.89 (2.26)
Median	83.30	83.30	83.30	0	0	0
IQR: Q1, Q3	50.00, 100.00	75.00, 100.00	54.15, 100.00	-8.40, 8.30	0.00, 16.70	-8.40, 0.00
Min, Max	25.0, 100.0	50.0, 100.0	16.7, 100.0	-66.7, 50.0	-25.0, 50.0	-50.0, 50.0
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	78.67 (23.38)	82.67 (22.94)	78.55 (22.75)	2.16 (2.87)	5.80 (3.83)	-4.22 (2.10)
Median	83.30	91.70	83.30	0	0	0
IQR: Q1, Q3	58.30, 100.00	66.70, 100.00	58.30, 100.00	0.00, 8.30	0.00, 25.00	-16.70, 0.00
Min, Max	25.0, 100.0	25.0, 100.0	16.7, 100.0	-50.0, 100.0	-33.3, 41.7	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Mental Health						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	70.5 (21.1)	72.8 (20.3)	72.3 (17.6)			
Median	75.0	80.0	75.0			
IQR: Q1, Q3	60.0, 85.0	60.0, 85.0	60.0, 85.0			
Min, Max	5, 100	25, 100	30, 100			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	67.9 (22.7)	70.2 (23.0)	71.0 (20.6)	-1.4 (1.5)	-4.3 (2.2)	0.0 (1.7)
Median	75.0	80.0	75.0	0	-5.0	0
IQR: Q1, Q3	50.0, 85.0	65.0, 85.0	52.5, 85.0	-10.0, 5.0	-10.0, 5.0	-10.0, 7.5
Min, Max	15, 100	20, 100	20, 100	-30, 35	-35, 15	-30, 55
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	71.9 (20.6)	71.8 (21.1)	71.9 (20.6)	1.6 (1.8)	-0.7 (2.6)	-0.6 (1.8)
Median	80.0	75.0	80.0	2.5	0	0
IQR: Q1, Q3	55.0, 90.0	60.0, 85.0	65.0, 85.0	-5.0, 10.0	-5.0, 5.0	-10.0, 5.0
Min, Max	25, 100	25, 95	0, 100	-35, 40	-25, 30	-60, 55

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Mental Component Score						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	48.71 (11.62)	49.22 (10.55)	50.09 (9.58)			
Median	51.10	51.90	51.85			
IQR: Q1, Q3	40.70, 57.10	46.70, 55.50	43.60, 57.80			
Min, Max	12.0, 64.7	23.5, 63.7	26.4, 64.3			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	47.53 (12.09)	49.86 (9.59)	48.76 (11.21)	-0.42 (0.86)	0.23 (1.06)	-0.55 (0.86)
Median	49.15	53.00	51.95	-1.00	-0.80	-0.90
IQR: Q1, Q3	38.80, 57.75	45.90, 57.40	40.20, 57.55	-3.70, 3.20	-3.00, 3.80	-5.20, 2.70
Min, Max	18.7, 69.1	30.6, 62.7	23.1, 69.0	-20.0, 18.5	-11.4, 12.4	-18.4, 24.8
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	48.83 (10.27)	50.11 (10.03)	49.05 (10.85)	0.26 (1.00)	0.74 (1.42)	-1.23 (0.90)
Median	52.40	53.10	51.90	-0.10	0.80	-0.80
IQR: Q1, Q3	40.00, 57.10	41.20, 57.90	44.20, 57.00	-3.80, 3.70	-3.90, 6.40	-4.70, 2.50
Min, Max	23.1, 62.4	28.5, 64.2	8.9, 63.7	-21.7, 26.2	-15.2, 12.3	-25.1, 26.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Physical Component Score						
Baseline						
m	73	32	105			
n	66	30	94			
Mean (SD)	47.95 (10.25)	46.27 (10.97)	47.55 (9.22)			
Median	48.95	48.80	48.80			
IQR: Q1, Q3	43.30, 56.30	39.60, 55.40	41.10, 55.90			
Min, Max	15.3, 60.8	24.8, 61.3	24.3, 60.9			
Week 24						
m	70	31	102			
n	68	29	92	63	27	84
Mean (SD/SE)	47.26 (11.31)	44.76 (9.80)	48.25 (9.69)	-0.29 (0.80)	-1.43 (1.52)	1.47 (0.74)
Median	50.20	44.90	49.30	-0.70	-0.10	0.90
IQR: Q1, Q3	40.85, 56.60	36.60, 53.40	42.60, 56.20	-3.70, 3.70	-5.90, 3.30	-1.70, 3.90
Min, Max	12.5, 63.9	25.8, 60.2	23.1, 63.0	-17.2, 18.3	-22.1, 16.2	-21.7, 23.8
Week 52						
m	64	28	95			
n	59	25	89	54	23	81
Mean (SD/SE)	49.04 (10.91)	46.02 (9.57)	48.59 (8.77)	0.53 (0.98)	1.86 (1.63)	1.28 (0.73)
Median	53.10	48.50	49.00	1.20	2.30	1.50
IQR: Q1, Q3	42.70, 57.50	41.40, 53.00	43.80, 55.00	-1.30, 4.20	-0.70, 9.00	-2.20, 3.80
Min, Max	15.8, 61.4	26.9, 60.0	21.5, 63.9	-24.2, 22.5	-20.4, 12.3	-23.9, 20.5

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Physical Functioning			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	74.75 (22.23)	68.94 (25.21)	75.12 (25.92)
Analysis Visit Mean (SD)	77.84 (21.94)	71.68 (24.19)	74.30 (27.92)
LS Mean of Change from Baseline (SE)	3.56 (1.90)	1.71 (1.77)	-0.80 (1.37)
95% CI	(-0.18, 7.30)	(-1.78, 5.19)	(-3.51, 1.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.36 (2.28)	2.51 (2.20)	
95% CI	(-0.13, 8.86)	(-1.82, 6.84)	
p-value	0.0569	0.2551	
Corrected Hedge's g Statistics	0.246	0.142	
95% CI	(-0.01, 0.51)	(-0.11, 0.39)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	74.91 (21.93)	70.17 (25.29)	75.18 (25.97)
Analysis Visit Mean (SD)	76.71 (25.49)	71.23 (26.34)	74.65 (26.32)
LS Mean of Change from Baseline (SE)	2.15 (1.85)	1.08 (1.72)	-0.26 (1.34)
95% CI	(-1.49, 5.78)	(-2.30, 4.45)	(-2.89, 2.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.41 (2.22)	1.34 (2.13)	
95% CI	(-1.95, 6.77)	(-2.85, 5.53)	
p-value	0.2776	0.5301	
Corrected Hedge's g Statistics	0.150	0.084	
95% CI	(-0.13, 0.43)	(-0.18, 0.35)	
Subgroup*Treatment Interaction p-value	0.0448	0.0221	

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Role Physical			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	80.34 (21.07)	74.57 (26.31)	79.10 (25.48)
Analysis Visit Mean (SD)	78.92 (21.17)	74.45 (24.07)	76.80 (27.85)
LS Mean of Change from Baseline (SE)	-0.03 (2.04)	-0.79 (1.90)	-2.08 (1.47)
95% CI	(-4.04, 3.98)	(-4.52, 2.94)	(-4.97, 0.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.05 (2.45)	1.29 (2.35)	
95% CI	(-2.76, 6.87)	(-3.34, 5.92)	
p-value	0.4023	0.5845	
Corrected Hedge's g Statistics	0.108	0.068	
95% CI	(-0.15, 0.37)	(-0.18, 0.32)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	80.52 (22.02)	74.58 (26.84)	79.37 (24.84)
Analysis Visit Mean (SD)	78.13 (24.78)	74.73 (25.93)	77.17 (25.58)
LS Mean of Change from Baseline (SE)	-1.00 (2.10)	-0.26 (1.95)	-1.21 (1.52)
95% CI	(-5.14, 3.13)	(-4.11, 3.58)	(-4.20, 1.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.21 (2.53)	0.95 (2.43)	
95% CI	(-4.76, 5.18)	(-3.83, 5.73)	
p-value	0.9341	0.6953	
Corrected Hedge's g Statistics	0.011	0.052	
95% CI	(-0.27, 0.29)	(-0.22, 0.32)	
Subgroup*Treatment Interaction p-value	0.3443	0.3446	

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Bodily Pain			
Week 24			
m	91	110	187
n	87	99	165
Baseline Mean (SD)	66.6 (21.6)	61.6 (25.3)	65.4 (23.9)
Analysis Visit Mean (SD)	64.1 (21.1)	64.5 (22.2)	65.1 (25.2)
LS Mean of Change from Baseline (SE)	-1.50 (1.94)	2.00 (1.79)	-0.20 (1.39)
95% CI	(-5.31, 2.31)	(-1.53, 5.52)	(-2.93, 2.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.30 (2.32)	2.20 (2.22)	
95% CI	(-5.85, 3.26)	(-2.16, 6.56)	
p-value	0.5757	0.3223	
Corrected Hedge's g Statistics	-0.072	0.123	
95% CI	(-0.33, 0.19)	(-0.13, 0.37)	
Week 52			
m	85	97	175
n	75	86	142
Baseline Mean (SD)	68.0 (22.0)	61.5 (25.6)	65.1 (24.0)
Analysis Visit Mean (SD)	67.0 (22.7)	64.3 (24.8)	67.0 (23.9)
LS Mean of Change from Baseline (SE)	0.79 (2.15)	1.82 (1.99)	2.24 (1.54)
95% CI	(-3.44, 5.01)	(-2.08, 5.72)	(-0.79, 5.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.46 (2.58)	-0.42 (2.47)	
95% CI	(-6.53, 3.62)	(-5.28, 4.43)	
p-value	0.5736	0.8637	
Corrected Hedge's g Statistics	-0.079	-0.023	
95% CI	(-0.36, 0.20)	(-0.29, 0.24)	
Subgroup*Treatment Interaction p-value	0.7962	0.3832	

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
General Health			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	62.02 (17.98)	53.22 (18.86)	59.41 (20.92)
Analysis Visit Mean (SD)	62.99 (18.88)	54.55 (18.78)	59.28 (22.27)
LS Mean of Change from Baseline (SE)	1.62 (1.57)	-0.39 (1.47)	-0.39 (1.13)
95% CI	(-1.47, 4.72)	(-3.28, 2.49)	(-2.61, 1.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.01 (1.88)	-0.01 (1.81)	
95% CI	(-1.69, 5.71)	(-3.58, 3.56)	
p-value	0.2860	0.9965	
Corrected Hedge's g Statistics	0.137	-0.001	
95% CI	(-0.12, 0.40)	(-0.25, 0.25)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	62.43 (18.39)	54.48 (19.97)	59.96 (21.32)
Analysis Visit Mean (SD)	63.32 (18.53)	56.17 (18.69)	61.10 (22.09)
LS Mean of Change from Baseline (SE)	1.75 (1.68)	0.04 (1.56)	1.60 (1.21)
95% CI	(-1.55, 5.04)	(-3.03, 3.11)	(-0.77, 3.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.14 (2.01)	-1.56 (1.94)	
95% CI	(-3.82, 4.10)	(-5.38, 2.25)	
p-value	0.9440	0.4205	
Corrected Hedge's g Statistics	0.010	-0.108	
95% CI	(-0.27, 0.29)	(-0.38, 0.16)	
Subgroup*Treatment Interaction p-value	0.6122	0.5594	

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Vitality			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	57.72 (20.73)	53.50 (23.29)	56.54 (21.09)
Analysis Visit Mean (SD)	58.26 (22.13)	53.50 (20.05)	56.12 (21.93)
LS Mean of Change from Baseline (SE)	1.01 (1.63)	-1.00 (1.51)	-0.64 (1.17)
95% CI	(-2.18, 4.21)	(-3.98, 1.97)	(-2.94, 1.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.65 (1.95)	-0.36 (1.87)	
95% CI	(-2.18, 5.48)	(-4.04, 3.32)	
p-value	0.3969	0.8461	
Corrected Hedge's g Statistics	0.109	-0.024	
95% CI	(-0.15, 0.37)	(-0.27, 0.23)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	58.66 (21.19)	54.31 (23.31)	56.18 (21.27)
Analysis Visit Mean (SD)	59.23 (20.47)	54.67 (20.78)	57.16 (23.58)
LS Mean of Change from Baseline (SE)	1.28 (1.78)	-0.87 (1.66)	0.80 (1.29)
95% CI	(-2.23, 4.79)	(-4.13, 2.39)	(-1.73, 3.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.48 (2.15)	-1.67 (2.06)	
95% CI	(-3.75, 4.71)	(-5.73, 2.38)	
p-value	0.8236	0.4173	
Corrected Hedge's g Statistics	0.031	-0.108	
95% CI	(-0.25, 0.31)	(-0.38, 0.16)	
Subgroup*Treatment Interaction p-value	0.2725	0.4424	

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Social Functioning			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	84.80 (20.54)	80.43 (26.19)	84.55 (21.95)
Analysis Visit Mean (SD)	83.81 (21.71)	82.32 (21.43)	81.67 (24.29)
LS Mean of Change from Baseline (SE)	-0.65 (2.02)	0.17 (1.89)	-3.05 (1.46)
95% CI	(-4.64, 3.33)	(-3.54, 3.89)	(-5.92, -0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.40 (2.43)	3.22 (2.34)	
95% CI	(-2.39, 7.18)	(-1.38, 7.83)	
p-value	0.3256	0.1698	
Corrected Hedge's g Statistics	0.127	0.171	
95% CI	(-0.13, 0.39)	(-0.08, 0.42)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	85.86 (19.72)	80.52 (27.09)	84.86 (21.82)
Analysis Visit Mean (SD)	84.21 (20.25)	81.98 (22.25)	83.89 (22.46)
LS Mean of Change from Baseline (SE)	-0.98 (2.03)	0.05 (1.89)	-1.23 (1.47)
95% CI	(-4.98, 3.01)	(-3.67, 3.77)	(-4.13, 1.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.25 (2.44)	1.29 (2.35)	
95% CI	(-4.55, 5.06)	(-3.33, 5.91)	
p-value	0.9176	0.5837	
Corrected Hedge's g Statistics	0.014	0.073	
95% CI	(-0.26, 0.29)	(-0.19, 0.34)	
Subgroup*Treatment Interaction p-value	0.4881	0.5202	

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Role Emotional			
Week 24			
m	91	110	187
n	88	99	164
Baseline Mean (SD)	86.74 (21.43)	82.83 (23.44)	85.52 (21.94)
Analysis Visit Mean (SD)	86.46 (18.97)	85.44 (21.67)	85.06 (23.51)
LS Mean of Change from Baseline (SE)	0.25 (1.69)	1.91 (1.58)	-0.66 (1.22)
95% CI	(-3.08, 3.58)	(-1.19, 5.01)	(-3.06, 1.75)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.90 (2.03)	2.56 (1.95)	
95% CI	(-3.09, 4.89)	(-1.27, 6.40)	
p-value	0.6570	0.1892	
Corrected Hedge's g Statistics	0.057	0.163	
95% CI	(-0.20, 0.32)	(-0.09, 0.41)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	87.61 (20.75)	82.37 (24.40)	85.27 (22.34)
Analysis Visit Mean (SD)	87.44 (18.88)	84.98 (21.84)	84.92 (22.70)
LS Mean of Change from Baseline (SE)	0.54 (1.93)	2.00 (1.79)	-0.94 (1.39)
95% CI	(-3.24, 4.33)	(-1.53, 5.53)	(-3.68, 1.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.48 (2.32)	2.94 (2.23)	
95% CI	(-3.09, 6.06)	(-1.45, 7.33)	
p-value	0.5234	0.1881	
Corrected Hedge's g Statistics	0.089	0.176	
95% CI	(-0.19, 0.37)	(-0.09, 0.44)	
Subgroup*Treatment Interaction p-value	0.6976	0.4977	

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Mental Health			
Week 24			
m	91	110	187
n	88	99	165
Baseline Mean (SD)	77.0 (17.6)	75.7 (18.9)	76.4 (17.8)
Analysis Visit Mean (SD)	76.8 (16.6)	76.0 (17.5)	76.1 (18.1)
LS Mean of Change from Baseline (SE)	-0.17 (1.39)	-0.21 (1.29)	-0.70 (1.00)
95% CI	(-2.92, 2.57)	(-2.76, 2.34)	(-2.68, 1.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.53 (1.67)	0.49 (1.60)	
95% CI	(-2.75, 3.81)	(-2.65, 3.64)	
p-value	0.7519	0.7580	
Corrected Hedge's g Statistics	0.041	0.038	
95% CI	(-0.22, 0.30)	(-0.21, 0.29)	
Week 52			
m	85	97	175
n	76	86	142
Baseline Mean (SD)	78.4 (16.2)	75.8 (19.7)	76.3 (18.3)
Analysis Visit Mean (SD)	78.2 (15.3)	76.2 (17.4)	77.4 (18.8)
LS Mean of Change from Baseline (SE)	-0.06 (1.48)	0.00 (1.38)	0.17 (1.07)
95% CI	(-2.98, 2.85)	(-2.71, 2.70)	(-1.94, 2.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.23 (1.78)	-0.17 (1.71)	
95% CI	(-3.73, 3.27)	(-3.53, 3.18)	
p-value	0.8972	0.9199	
Corrected Hedge's g Statistics	-0.018	-0.013	
95% CI	(-0.30, 0.26)	(-0.28, 0.25)	
Subgroup*Treatment Interaction p-value	0.9781	0.3766	

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Mental Component Score			
Week 24			
m	91	110	187
n	87	99	164
Baseline Mean (SD)	52.38 (9.47)	51.29 (11.32)	51.83 (9.14)
Analysis Visit Mean (SD)	51.98 (9.04)	51.70 (10.04)	51.50 (9.87)
LS Mean of Change from Baseline (SE)	-0.34 (0.76)	0.03 (0.71)	-0.57 (0.55)
95% CI	(-1.84, 1.16)	(-1.35, 1.42)	(-1.65, 0.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.23 (0.91)	0.60 (0.87)	
95% CI	(-1.57, 2.02)	(-1.12, 2.32)	
p-value	0.8034	0.4919	
Corrected Hedge's g Statistics	0.032	0.085	
95% CI	(-0.23, 0.29)	(-0.16, 0.33)	
Week 52			
m	85	97	175
n	75	86	142
Baseline Mean (SD)	53.05 (9.10)	51.22 (11.68)	51.73 (9.25)
Analysis Visit Mean (SD)	52.72 (8.72)	51.77 (9.68)	52.02 (9.81)
LS Mean of Change from Baseline (SE)	-0.17 (0.81)	0.18 (0.75)	-0.26 (0.58)
95% CI	(-1.75, 1.42)	(-1.29, 1.65)	(-1.40, 0.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (0.97)	0.44 (0.93)	
95% CI	(-1.81, 2.00)	(-1.38, 2.26)	
p-value	0.9240	0.6328	
Corrected Hedge's g Statistics	0.013	0.064	
95% CI	(-0.27, 0.29)	(-0.20, 0.33)	
Subgroup*Treatment Interaction p-value	0.6709	0.8335	

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Physical Component Score			
Week 24			
m	91	110	187
n	87	99	164
Baseline Mean (SD)	47.75 (7.63)	44.80 (9.53)	47.37 (9.55)
Analysis Visit Mean (SD)	47.94 (8.11)	45.50 (8.73)	46.92 (10.35)
LS Mean of Change from Baseline (SE)	0.56 (0.72)	0.24 (0.66)	-0.41 (0.52)
95% CI	(-0.85, 1.97)	(-1.07, 1.54)	(-1.42, 0.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.96 (0.86)	0.64 (0.83)	
95% CI	(-0.73, 2.65)	(-0.98, 2.27)	
p-value	0.2635	0.4380	
Corrected Hedge's g Statistics	0.144	0.097	
95% CI	(-0.12, 0.40)	(-0.15, 0.35)	
Week 52			
m	85	97	175
n	75	86	142
Baseline Mean (SD)	47.81 (7.93)	45.17 (9.67)	47.41 (9.36)
Analysis Visit Mean (SD)	47.91 (9.98)	45.67 (9.99)	47.35 (9.45)
LS Mean of Change from Baseline (SE)	0.48 (0.72)	0.29 (0.67)	0.26 (0.52)
95% CI	(-0.94, 1.90)	(-1.02, 1.60)	(-0.77, 1.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.22 (0.87)	0.03 (0.83)	
95% CI	(-1.48, 1.92)	(-1.60, 1.67)	
p-value	0.8008	0.9693	
Corrected Hedge's g Statistics	0.035	0.005	
95% CI	(-0.24, 0.31)	(-0.26, 0.27)	
Subgroup*Treatment Interaction p-value	0.1246	0.1250	

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Physical Functioning			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	73.89 (25.94)	74.44 (28.80)	75.24 (24.80)
Analysis Visit Mean (SD)	72.94 (27.91)	69.32 (25.95)	77.64 (26.09)
LS Mean of Change from Baseline (SE)	-0.89 (2.05)	-5.85 (3.08)	2.51 (1.82)
95% CI	(-4.93, 3.16)	(-11.92, 0.23)	(-1.09, 6.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.40 (2.66)	-8.35 (3.50)	
95% CI	(-8.64, 1.85)	(-15.27, -1.44)	
p-value	0.2033	0.0182	
Corrected Hedge's g Statistics	-0.204	-0.502	
95% CI	(-0.53, 0.12)	(-0.94, -0.06)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	75.83 (24.24)	69.78 (30.02)	77.35 (21.70)
Analysis Visit Mean (SD)	76.48 (28.31)	68.26 (26.65)	80.17 (19.70)
LS Mean of Change from Baseline (SE)	1.22 (2.06)	-2.73 (3.11)	2.97 (1.76)
95% CI	(-2.84, 5.28)	(-8.87, 3.41)	(-0.50, 6.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.75 (2.62)	-5.70 (3.51)	
95% CI	(-6.92, 3.42)	(-12.61, 1.22)	
p-value	0.5053	0.1061	
Corrected Hedge's g Statistics	-0.112	-0.362	
95% CI	(-0.46, 0.23)	(-0.83, 0.10)	
Subgroup*Treatment Interaction p-value	0.0448	0.0221	

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Role Physical			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	69.36 (30.63)	70.15 (30.93)	71.37 (27.34)
Analysis Visit Mean (SD)	68.47 (32.59)	69.46 (25.55)	75.01 (26.31)
LS Mean of Change from Baseline (SE)	-0.82 (2.38)	-2.42 (3.57)	4.13 (2.12)
95% CI	(-5.52, 3.89)	(-9.47, 4.63)	(-0.06, 8.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.95 (3.09)	-6.55 (4.07)	
95% CI	(-11.04, 1.15)	(-14.58, 1.48)	
p-value	0.1110	0.1090	
Corrected Hedge's g Statistics	-0.256	-0.338	
95% CI	(-0.58, 0.07)	(-0.77, 0.10)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	70.96 (31.87)	66.32 (31.57)	72.70 (25.94)
Analysis Visit Mean (SD)	73.16 (32.13)	69.04 (29.40)	73.63 (23.42)
LS Mean of Change from Baseline (SE)	2.48 (2.55)	2.43 (3.85)	1.20 (2.17)
95% CI	(-2.55, 7.51)	(-5.17, 10.02)	(-3.08, 5.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.28 (3.25)	1.23 (4.34)	
95% CI	(-5.13, 7.69)	(-7.33, 9.79)	
p-value	0.6937	0.7772	
Corrected Hedge's g Statistics	0.066	0.063	
95% CI	(-0.28, 0.41)	(-0.40, 0.53)	
Subgroup*Treatment Interaction p-value	0.3443	0.3446	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Bodily Pain			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	66.8 (27.5)	66.6 (30.0)	67.8 (27.2)
Analysis Visit Mean (SD)	64.6 (30.9)	60.1 (31.1)	69.3 (26.9)
LS Mean of Change from Baseline (SE)	-2.04 (2.67)	-7.64 (3.98)	1.84 (2.38)
95% CI	(-7.31, 3.22)	(-15.50, 0.22)	(-2.85, 6.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.88 (3.45)	-9.48 (4.53)	
95% CI	(-10.68, 2.92)	(-18.42, -0.54)	
p-value	0.2614	0.0378	
Corrected Hedge's g Statistics	-0.179	-0.437	
95% CI	(-0.51, 0.15)	(-0.87, 0.00)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	66.7 (28.3)	60.7 (31.1)	69.0 (25.7)
Analysis Visit Mean (SD)	68.5 (30.0)	73.8 (27.9)	69.4 (25.6)
LS Mean of Change from Baseline (SE)	0.31 (2.87)	9.07 (4.33)	0.93 (2.46)
95% CI	(-5.36, 5.99)	(0.53, 17.61)	(-3.93, 5.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.61 (3.67)	8.14 (4.88)	
95% CI	(-7.85, 6.63)	(-1.49, 17.78)	
p-value	0.8678	0.0972	
Corrected Hedge's g Statistics	-0.028	0.369	
95% CI	(-0.37, 0.32)	(-0.10, 0.84)	
Subgroup*Treatment Interaction p-value	0.7962	0.3832	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
General Health			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	57.98 (21.09)	52.41 (18.47)	58.38 (19.40)
Analysis Visit Mean (SD)	58.98 (22.48)	53.81 (22.50)	60.61 (20.60)
LS Mean of Change from Baseline (SE)	1.14 (1.86)	-0.62 (2.80)	2.75 (1.66)
95% CI	(-2.54, 4.81)	(-6.15, 4.90)	(-0.53, 6.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.61 (2.41)	-3.37 (3.20)	
95% CI	(-6.37, 3.15)	(-9.68, 2.94)	
p-value	0.5059	0.2934	
Corrected Hedge's g Statistics	-0.107	-0.222	
95% CI	(-0.43, 0.22)	(-0.66, 0.21)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	60.11 (21.85)	49.00 (18.17)	59.07 (19.30)
Analysis Visit Mean (SD)	62.46 (21.37)	52.96 (21.64)	61.12 (18.99)
LS Mean of Change from Baseline (SE)	2.64 (1.83)	0.85 (2.78)	2.31 (1.57)
95% CI	(-0.98, 6.25)	(-4.63, 6.32)	(-0.78, 5.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.33 (2.33)	-1.46 (3.13)	
95% CI	(-4.26, 4.91)	(-7.65, 4.72)	
p-value	0.8889	0.6407	
Corrected Hedge's g Statistics	0.023	-0.104	
95% CI	(-0.32, 0.37)	(-0.57, 0.36)	
Subgroup*Treatment Interaction p-value	0.6122	0.5594	

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Vitality			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	57.36 (24.91)	53.50 (20.54)	58.18 (23.23)
Analysis Visit Mean (SD)	55.08 (25.07)	51.41 (19.56)	59.39 (23.81)
LS Mean of Change from Baseline (SE)	-2.16 (1.76)	-3.68 (2.65)	1.03 (1.57)
95% CI	(-5.63, 1.32)	(-8.91, 1.55)	(-2.07, 4.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.19 (2.28)	-4.72 (3.01)	
95% CI	(-7.69, 1.31)	(-10.66, 1.23)	
p-value	0.1637	0.1194	
Corrected Hedge's g Statistics	-0.223	-0.328	
95% CI	(-0.55, 0.10)	(-0.76, 0.11)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	58.82 (25.25)	53.83 (22.12)	58.87 (21.90)
Analysis Visit Mean (SD)	57.78 (24.94)	54.10 (22.66)	58.66 (21.16)
LS Mean of Change from Baseline (SE)	-0.69 (2.07)	-0.89 (3.13)	-0.21 (1.75)
95% CI	(-4.77, 3.39)	(-7.06, 5.29)	(-3.66, 3.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.48 (2.64)	-0.68 (3.53)	
95% CI	(-5.69, 4.72)	(-7.64, 6.28)	
p-value	0.8547	0.8478	
Corrected Hedge's g Statistics	-0.031	-0.043	
95% CI	(-0.38, 0.31)	(-0.51, 0.42)	
Subgroup*Treatment Interaction p-value	0.2725	0.4424	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Social Functioning			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	78.57 (26.32)	78.24 (26.54)	79.76 (23.52)
Analysis Visit Mean (SD)	78.37 (27.79)	79.17 (20.51)	80.65 (24.58)
LS Mean of Change from Baseline (SE)	-0.58 (2.32)	-0.70 (3.48)	0.57 (2.07)
95% CI	(-5.15, 4.00)	(-7.57, 6.17)	(-3.51, 4.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.15 (3.01)	-1.27 (3.96)	
95% CI	(-7.08, 4.79)	(-9.09, 6.55)	
p-value	0.7037	0.7496	
Corrected Hedge's g Statistics	-0.061	-0.067	
95% CI	(-0.39, 0.27)	(-0.50, 0.37)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	80.32 (26.56)	76.09 (28.18)	81.79 (22.19)
Analysis Visit Mean (SD)	78.70 (26.89)	79.35 (24.89)	82.10 (21.46)
LS Mean of Change from Baseline (SE)	-1.01 (2.41)	1.87 (3.63)	0.24 (2.05)
95% CI	(-5.75, 3.74)	(-5.30, 9.03)	(-3.81, 4.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.25 (3.07)	1.62 (4.09)	
95% CI	(-7.30, 4.80)	(-6.46, 9.70)	
p-value	0.6838	0.6926	
Corrected Hedge's g Statistics	-0.069	0.088	
95% CI	(-0.41, 0.28)	(-0.38, 0.55)	
Subgroup*Treatment Interaction p-value	0.4881	0.5202	

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Role Emotional			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	76.19 (26.98)	78.09 (26.87)	81.05 (23.73)
Analysis Visit Mean (SD)	76.32 (25.98)	82.10 (18.73)	79.16 (24.90)
LS Mean of Change from Baseline (SE)	-0.98 (2.33)	2.62 (3.48)	-1.06 (2.07)
95% CI	(-5.57, 3.62)	(-4.24, 9.48)	(-5.15, 3.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (3.02)	3.69 (3.96)	
95% CI	(-5.87, 6.05)	(-4.13, 11.50)	
p-value	0.9768	0.3533	
Corrected Hedge's g Statistics	0.005	0.195	
95% CI	(-0.32, 0.33)	(-0.24, 0.63)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	76.85 (26.38)	77.53 (27.80)	83.74 (21.61)
Analysis Visit Mean (SD)	79.01 (23.22)	83.34 (23.30)	79.52 (23.05)
LS Mean of Change from Baseline (SE)	1.81 (2.38)	5.08 (3.57)	-2.63 (2.04)
95% CI	(-2.88, 6.49)	(-1.96, 12.12)	(-6.66, 1.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.44 (3.04)	7.71 (4.02)	
95% CI	(-1.57, 10.44)	(-0.23, 15.66)	
p-value	0.1464	0.0569	
Corrected Hedge's g Statistics	0.245	0.423	
95% CI	(-0.10, 0.59)	(-0.04, 0.89)	
Subgroup*Treatment Interaction p-value	0.6976	0.4977	

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Mental Health			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	70.0 (21.3)	73.9 (20.0)	72.1 (18.0)
Analysis Visit Mean (SD)	68.6 (21.9)	69.6 (23.7)	72.1 (20.5)
LS Mean of Change from Baseline (SE)	-2.15 (1.75)	-4.96 (2.63)	-0.86 (1.56)
95% CI	(-5.60, 1.30)	(-10.15, 0.23)	(-3.94, 2.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.29 (2.27)	-4.10 (2.99)	
95% CI	(-5.76, 3.19)	(-9.99, 1.80)	
p-value	0.5717	0.1721	
Corrected Hedge's g Statistics	-0.091	-0.287	
95% CI	(-0.42, 0.24)	(-0.72, 0.15)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	70.2 (21.1)	72.6 (20.1)	73.1 (17.1)
Analysis Visit Mean (SD)	71.8 (19.9)	72.0 (22.0)	72.5 (20.8)
LS Mean of Change from Baseline (SE)	1.02 (1.96)	-1.47 (2.96)	-1.31 (1.66)
95% CI	(-2.85, 4.88)	(-7.31, 4.38)	(-4.59, 1.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.33 (2.50)	-0.16 (3.33)	
95% CI	(-2.61, 7.26)	(-6.73, 6.42)	
p-value	0.3537	0.9629	
Corrected Hedge's g Statistics	0.157	-0.010	
95% CI	(-0.19, 0.50)	(-0.47, 0.45)	
Subgroup*Treatment Interaction p-value	0.9781	0.3766	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Mental Component Score			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	48.44 (11.80)	49.27 (10.63)	49.83 (9.91)
Analysis Visit Mean (SD)	48.02 (11.41)	49.50 (9.86)	49.28 (11.04)
LS Mean of Change from Baseline (SE)	-0.79 (0.90)	-0.34 (1.34)	-0.81 (0.80)
95% CI	(-2.56, 0.98)	(-2.99, 2.31)	(-2.39, 0.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (1.16)	0.47 (1.53)	
95% CI	(-2.28, 2.31)	(-2.54, 3.49)	
p-value	0.9871	0.7578	
Corrected Hedge's g Statistics	0.003	0.065	
95% CI	(-0.32, 0.33)	(-0.37, 0.50)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	48.70 (11.44)	49.49 (11.31)	50.57 (9.50)
Analysis Visit Mean (SD)	48.96 (9.76)	50.23 (10.38)	49.35 (10.92)
LS Mean of Change from Baseline (SE)	0.17 (0.97)	0.44 (1.47)	-1.26 (0.83)
95% CI	(-1.75, 2.09)	(-2.45, 3.34)	(-2.90, 0.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.43 (1.25)	1.70 (1.65)	
95% CI	(-1.03, 3.89)	(-1.56, 4.96)	
p-value	0.2521	0.3045	
Corrected Hedge's g Statistics	0.193	0.229	
95% CI	(-0.15, 0.54)	(-0.24, 0.69)	
Subgroup*Treatment Interaction p-value	0.6709	0.8335	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Physical Component Score			
Week 24			
m	70	31	102
n	63	27	84
Baseline Mean (SD)	47.41 (10.18)	46.26 (10.70)	47.44 (9.53)
Analysis Visit Mean (SD)	47.12 (11.51)	44.83 (9.93)	48.91 (9.28)
LS Mean of Change from Baseline (SE)	-0.08 (0.85)	-2.04 (1.27)	1.71 (0.75)
95% CI	(-1.75, 1.59)	(-4.54, 0.47)	(0.23, 3.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.79 (1.10)	-3.75 (1.44)	
95% CI	(-3.95, 0.37)	(-6.60, -0.90)	
p-value	0.1034	0.0101	
Corrected Hedge's g Statistics	-0.261	-0.546	
95% CI	(-0.59, 0.07)	(-0.99, -0.11)	
Week 52			
m	64	28	95
n	54	23	81
Baseline Mean (SD)	48.11 (10.21)	44.06 (11.24)	47.85 (8.77)
Analysis Visit Mean (SD)	48.64 (11.22)	45.92 (9.89)	49.13 (8.01)
LS Mean of Change from Baseline (SE)	0.62 (0.88)	0.92 (1.32)	1.40 (0.75)
95% CI	(-1.11, 2.34)	(-1.70, 3.53)	(-0.08, 2.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.78 (1.11)	-0.48 (1.49)	
95% CI	(-2.98, 1.42)	(-3.43, 2.46)	
p-value	0.4835	0.7477	
Corrected Hedge's g Statistics	-0.118	-0.072	
95% CI	(-0.46, 0.23)	(-0.53, 0.39)	
Subgroup*Treatment Interaction p-value	0.1246	0.1250	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (13.8)	14 (11.8)	20 (10.1)
No	81 (86.2)	105 (88.2)	178 (89.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	0.84	
95% CI of the inverse odds ratio	(0.33, 1.48)	(0.41, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.86	
95% CI of the inverse risk ratio	(0.38, 1.40)	(0.45, 1.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.73	1.66	
95% CI of the absolute risk difference	(-4.41, 11.87)	(-5.49, 8.81)	
p-value	0.3471	0.6430	
p-value of Breslow-Day Test for Homogeneity [3]	0.2471	0.4990	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (34.0)	37 (31.1)	50 (25.3)
No	62 (66.0)	82 (68.9)	148 (74.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	0.75	
95% CI of the inverse odds ratio	(0.38, 1.12)	(0.45, 1.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.81	
95% CI of the inverse risk ratio	(0.51, 1.07)	(0.57, 1.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.79	5.84	
95% CI of the absolute risk difference	(-2.54, 20.12)	(-4.45, 16.13)	
p-value	0.1184	0.2592	
p-value of Breslow-Day Test for Homogeneity [3]	0.1943	0.5653	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (7.4)	14 (11.8)	20 (10.1)
No	87 (92.6)	105 (88.2)	178 (89.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	0.84	
95% CI of the inverse odds ratio	(0.57, 3.43)	(0.41, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.86	
95% CI of the inverse risk ratio	(0.59, 3.10)	(0.45, 1.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.65	1.66	
95% CI of the absolute risk difference	(-9.42, 4.11)	(-5.49, 8.81)	
p-value	0.4645	0.6430	
p-value of Breslow-Day Test for Homogeneity [3]	0.7740	0.4369	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (22.3)	29 (24.4)	42 (21.2)
No	73 (77.7)	90 (75.6)	156 (78.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.84	
95% CI of the inverse odds ratio	(0.52, 1.69)	(0.49, 1.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.87	
95% CI of the inverse risk ratio	(0.60, 1.51)	(0.57, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.13	3.16	
95% CI of the absolute risk difference	(-9.04, 11.29)	(-6.43, 12.75)	
p-value	0.8267	0.5138	
p-value of Breslow-Day Test for Homogeneity [3]	0.7479	0.9928	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (11.7)	17 (14.3)	33 (16.7)
No	83 (88.3)	102 (85.7)	165 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	1.20	
95% CI of the inverse odds ratio	(0.73, 3.14)	(0.64, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	1.17	
95% CI of the inverse risk ratio	(0.75, 2.69)	(0.68, 2.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.96	-2.38	
95% CI of the absolute risk difference	(-13.28, 3.35)	(-10.53, 5.77)	
p-value	0.2679	0.5733	
p-value of Breslow-Day Test for Homogeneity [3]	0.8569	0.2206	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (24.5)	33 (27.7)	53 (26.8)
No	71 (75.5)	86 (72.3)	145 (73.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	0.95	
95% CI of the inverse odds ratio	(0.64, 1.99)	(0.57, 1.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.97	
95% CI of the inverse risk ratio	(0.72, 1.67)	(0.67, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.30	0.96	
95% CI of the absolute risk difference	(-12.96, 8.36)	(-9.17, 11.10)	
p-value	0.6756	0.8518	
p-value of Breslow-Day Test for Homogeneity [3]	0.8127	0.2781	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (14.9)	22 (18.5)	29 (14.6)
No	80 (85.1)	97 (81.5)	169 (85.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.76	
95% CI of the inverse odds ratio	(0.49, 1.96)	(0.41, 1.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.79	
95% CI of the inverse risk ratio	(0.55, 1.77)	(0.48, 1.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.25	3.84	
95% CI of the absolute risk difference	(-8.47, 8.97)	(-4.70, 12.38)	
p-value	0.9556	0.3675	
p-value of Breslow-Day Test for Homogeneity [3]	0.9526	0.9619	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (27.7)	37 (31.1)	59 (29.8)
No	68 (72.3)	82 (68.9)	139 (70.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.94	
95% CI of the inverse odds ratio	(0.64, 1.91)	(0.57, 1.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.96	
95% CI of the inverse risk ratio	(0.73, 1.59)	(0.68, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.14	1.29	
95% CI of the absolute risk difference	(-13.20, 8.92)	(-9.18, 11.77)	
p-value	0.7070	0.8081	
p-value of Breslow-Day Test for Homogeneity [3]	0.6900	0.1344	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (11.7)	12 (10.1)	23 (11.6)
No	83 (88.3)	107 (89.9)	175 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.17	
95% CI of the inverse odds ratio	(0.46, 2.13)	(0.56, 2.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.15	
95% CI of the inverse risk ratio	(0.51, 1.95)	(0.60, 2.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.09	-1.53	
95% CI of the absolute risk difference	(-7.80, 7.97)	(-8.55, 5.48)	
p-value	0.9829	0.6734	
p-value of Breslow-Day Test for Homogeneity [3]	0.3240	0.4937	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (31.9)	34 (28.6)	67 (33.8)
No	64 (68.1)	85 (71.4)	131 (66.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.28	
95% CI of the inverse odds ratio	(0.65, 1.84)	(0.78, 2.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.18	
95% CI of the inverse risk ratio	(0.74, 1.51)	(0.84, 1.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.92	-5.27	
95% CI of the absolute risk difference	(-13.42, 9.58)	(-15.72, 5.19)	
p-value	0.7444	0.3298	
p-value of Breslow-Day Test for Homogeneity [3]	0.8843	0.5755	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (8.5)	17 (14.3)	14 (7.1)
No	86 (91.5)	102 (85.7)	184 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.46	
95% CI of the inverse odds ratio	(0.33, 2.02)	(0.22, 0.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.49	
95% CI of the inverse risk ratio	(0.36, 1.91)	(0.25, 0.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.44	7.22	
95% CI of the absolute risk difference	(-5.24, 8.12)	(-0.02, 14.45)	
p-value	0.6632	0.0362	
p-value of Breslow-Day Test for Homogeneity [3]	0.3582	0.8758	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (21.3)	25 (21.0)	29 (14.6)
No	74 (78.7)	94 (79.0)	169 (85.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.65	
95% CI of the inverse odds ratio	(0.34, 1.19)	(0.36, 1.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.70	
95% CI of the inverse risk ratio	(0.41, 1.15)	(0.43, 1.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.63	6.36	
95% CI of the absolute risk difference	(-3.00, 16.26)	(-2.46, 15.18)	
p-value	0.1566	0.1446	
p-value of Breslow-Day Test for Homogeneity [3]	0.0492	0.9343	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (11.7)	22 (18.5)	24 (12.1)
No	83 (88.3)	97 (81.5)	174 (87.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.61	
95% CI of the inverse odds ratio	(0.49, 2.23)	(0.32, 1.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.66	
95% CI of the inverse risk ratio	(0.53, 2.02)	(0.39, 1.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.42	6.37	
95% CI of the absolute risk difference	(-8.35, 7.51)	(-1.96, 14.69)	
p-value	0.9180	0.1192	
p-value of Breslow-Day Test for Homogeneity [3]	0.7642	0.6416	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (16.0)	30 (25.2)	34 (17.2)
No	79 (84.0)	89 (74.8)	164 (82.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.62	
95% CI of the inverse odds ratio	(0.56, 2.12)	(0.35, 1.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.68	
95% CI of the inverse risk ratio	(0.62, 1.88)	(0.44, 1.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.21	8.04	
95% CI of the absolute risk difference	(-10.29, 7.86)	(-1.37, 17.44)	
p-value	0.7953	0.0843	
p-value of Breslow-Day Test for Homogeneity [3]	0.5743	0.4960	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (10.6)	11 (9.2)	27 (13.6)
No	84 (89.4)	108 (90.8)	171 (86.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	1.55	
95% CI of the inverse odds ratio	(0.61, 2.87)	(0.74, 3.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	1.48	
95% CI of the inverse risk ratio	(0.65, 2.54)	(0.76, 2.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.00	-4.39	
95% CI of the absolute risk difference	(-10.85, 4.86)	(-11.46, 2.67)	
p-value	0.4718	0.2436	
p-value of Breslow-Day Test for Homogeneity [3]	0.6476	0.8700	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (31.9)	31 (26.1)	57 (28.8)
No	64 (68.1)	88 (73.9)	141 (71.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.15	
95% CI of the inverse odds ratio	(0.51, 1.47)	(0.69, 1.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.11	
95% CI of the inverse risk ratio	(0.62, 1.30)	(0.76, 1.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.13	-2.74	
95% CI of the absolute risk difference	(-8.21, 14.47)	(-12.84, 7.36)	
p-value	0.5852	0.5982	
p-value of Breslow-Day Test for Homogeneity [3]	0.3145	0.3697	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (3.2)	11 (9.2)	12 (6.1)
No	91 (96.8)	108 (90.8)	186 (93.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.96	0.63	
95% CI of the inverse odds ratio	(0.54, 7.11)	(0.27, 1.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.90	0.66	
95% CI of the inverse risk ratio	(0.55, 6.57)	(0.30, 1.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.87	3.18	
95% CI of the absolute risk difference	(-7.73, 2.00)	(-2.99, 9.36)	
p-value	0.2994	0.2901	
p-value of Breslow-Day Test for Homogeneity [3]	0.3853	0.8610	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (21.3)	19 (16.0)	46 (23.2)
No	74 (78.7)	100 (84.0)	152 (76.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	1.59	
95% CI of the inverse odds ratio	(0.62, 2.03)	(0.88, 2.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.46	
95% CI of the inverse risk ratio	(0.69, 1.74)	(0.90, 2.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.96	-7.27	
95% CI of the absolute risk difference	(-12.11, 8.20)	(-16.09, 1.56)	
p-value	0.7089	0.1208	
p-value of Breslow-Day Test for Homogeneity [3]	0.1943	0.0562	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (4.3)	7 (5.9)	8 (4.0)
No	90 (95.7)	112 (94.1)	190 (96.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.67	
95% CI of the inverse odds ratio	(0.28, 3.23)	(0.24, 1.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.69	
95% CI of the inverse risk ratio	(0.29, 3.07)	(0.26, 1.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.21	1.84	
95% CI of the absolute risk difference	(-4.70, 5.13)	(-3.20, 6.88)	
p-value	0.9311	0.4545	
p-value of Breslow-Day Test for Homogeneity [3]	0.6749	0.3836	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (21.3)	31 (26.1)	34 (17.2)
No	74 (78.7)	88 (73.9)	164 (82.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.59	
95% CI of the inverse odds ratio	(0.41, 1.42)	(0.34, 1.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.66	
95% CI of the inverse risk ratio	(0.49, 1.32)	(0.43, 1.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.10	8.88	
95% CI of the absolute risk difference	(-5.70, 13.91)	(-0.60, 18.35)	
p-value	0.3986	0.0580	
p-value of Breslow-Day Test for Homogeneity [3]	0.2946	0.6929	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (12.3)	4 (12.5)	17 (16.2)
No	64 (87.7)	28 (87.5)	88 (83.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.37	1.35	
95% CI of the inverse odds ratio	(0.58, 3.28)	(0.42, 4.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.30	
95% CI of the inverse risk ratio	(0.62, 2.78)	(0.47, 3.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.86	-3.69	
95% CI of the absolute risk difference	(-14.18, 6.46)	(-17.14, 9.76)	
p-value	0.4731	0.6119	
p-value of Breslow-Day Test for Homogeneity [3]	0.2471	0.4990	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (31.5)	11 (34.4)	36 (34.3)
No	50 (68.5)	21 (65.6)	69 (65.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	1.00	
95% CI of the inverse odds ratio	(0.60, 2.15)	(0.43, 2.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.00	
95% CI of the inverse risk ratio	(0.71, 1.67)	(0.58, 1.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.78	0.09	
95% CI of the absolute risk difference	(-16.78, 11.22)	(-18.71, 18.88)	
p-value	0.6985	0.9926	
p-value of Breslow-Day Test for Homogeneity [3]	0.1943	0.5653	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (11.0)	4 (12.5)	18 (17.1)
No	65 (89.0)	28 (87.5)	87 (82.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.68	1.45	
95% CI of the inverse odds ratio	(0.69, 4.10)	(0.45, 4.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	1.37	
95% CI of the inverse risk ratio	(0.72, 3.40)	(0.50, 3.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.18	-4.64	
95% CI of the absolute risk difference	(-16.35, 3.98)	(-18.18, 8.89)	
p-value	0.2506	0.5311	
p-value of Breslow-Day Test for Homogeneity [3]	0.7740	0.4369	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (26.0)	10 (31.3)	29 (27.6)
No	54 (74.0)	22 (68.8)	76 (72.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.84	
95% CI of the inverse odds ratio	(0.55, 2.13)	(0.35, 1.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.88	
95% CI of the inverse risk ratio	(0.65, 1.74)	(0.49, 1.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	3.63	
95% CI of the absolute risk difference	(-14.80, 11.62)	(-14.56, 21.83)	
p-value	0.8139	0.6903	
p-value of Breslow-Day Test for Homogeneity [3]	0.7479	0.9928	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (12.3)	9 (28.1)	20 (19.0)
No	64 (87.7)	23 (71.9)	85 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	0.60	
95% CI of the inverse odds ratio	(0.71, 3.92)	(0.24, 1.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.54	0.68	
95% CI of the inverse risk ratio	(0.75, 3.20)	(0.34, 1.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.72	9.08	
95% CI of the absolute risk difference	(-17.36, 3.92)	(-8.22, 26.37)	
p-value	0.2325	0.2711	
p-value of Breslow-Day Test for Homogeneity [3]	0.8569	0.2206	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (23.3)	13 (40.6)	29 (27.6)
No	56 (76.7)	19 (59.4)	76 (72.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	0.56	
95% CI of the inverse odds ratio	(0.63, 2.51)	(0.24, 1.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	0.68	
95% CI of the inverse risk ratio	(0.71, 1.99)	(0.40, 1.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.33	13.01	
95% CI of the absolute risk difference	(-17.26, 8.60)	(-6.04, 32.05)	
p-value	0.5162	0.1624	
p-value of Breslow-Day Test for Homogeneity [3]	0.8127	0.2781	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (15.1)	6 (18.8)	16 (15.2)
No	62 (84.9)	26 (81.3)	89 (84.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.78	
95% CI of the inverse odds ratio	(0.44, 2.33)	(0.28, 2.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.81	
95% CI of the inverse risk ratio	(0.50, 2.05)	(0.35, 1.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.17	3.51	
95% CI of the absolute risk difference	(-10.87, 10.54)	(-11.66, 18.68)	
p-value	0.9752	0.6357	
p-value of Breslow-Day Test for Homogeneity [3]	0.9526	0.9619	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (32.9)	16 (50.0)	33 (31.4)
No	49 (67.1)	16 (50.0)	72 (68.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.46	
95% CI of the inverse odds ratio	(0.49, 1.77)	(0.20, 1.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.63	
95% CI of the inverse risk ratio	(0.62, 1.47)	(0.40, 0.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.45	18.57	
95% CI of the absolute risk difference	(-12.52, 15.41)	(-0.90, 38.04)	
p-value	0.8386	0.0550	
p-value of Breslow-Day Test for Homogeneity [3]	0.6900	0.1344	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (6.8)	2 (6.3)	13 (12.4)
No	68 (93.2)	30 (93.8)	92 (87.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.92	2.12	
95% CI of the inverse odds ratio	(0.65, 5.65)	(0.45, 9.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.81	1.98	
95% CI of the inverse risk ratio	(0.67, 4.85)	(0.47, 8.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.53	-6.13	
95% CI of the absolute risk difference	(-14.09, 3.03)	(-16.62, 4.36)	
p-value	0.2286	0.3309	
p-value of Breslow-Day Test for Homogeneity [3]	0.3240	0.4937	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (27.4)	10 (31.3)	32 (30.5)
No	53 (72.6)	22 (68.8)	73 (69.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	0.96	
95% CI of the inverse odds ratio	(0.60, 2.25)	(0.41, 2.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.98	
95% CI of the inverse risk ratio	(0.69, 1.78)	(0.54, 1.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.08	0.77	
95% CI of the absolute risk difference	(-16.58, 10.42)	(-17.54, 19.09)	
p-value	0.6568	0.9338	
p-value of Breslow-Day Test for Homogeneity [3]	0.8843	0.5755	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (6.8)	6 (18.8)	11 (10.5)
No	68 (93.2)	26 (81.3)	94 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	0.51	
95% CI of the inverse odds ratio	(0.53, 4.79)	(0.17, 1.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	0.56	
95% CI of the inverse risk ratio	(0.55, 4.22)	(0.22, 1.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.63	8.27	
95% CI of the absolute risk difference	(-11.87, 4.61)	(-6.46, 23.01)	
p-value	0.4053	0.2139	
p-value of Breslow-Day Test for Homogeneity [3]	0.3582	0.8758	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (13.7)	10 (31.3)	23 (21.9)
No	63 (86.3)	22 (68.8)	82 (78.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	0.62	
95% CI of the inverse odds ratio	(0.78, 3.98)	(0.26, 1.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.60	0.70	
95% CI of the inverse risk ratio	(0.81, 3.16)	(0.37, 1.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.21	9.35	
95% CI of the absolute risk difference	(-19.38, 2.97)	(-8.56, 27.25)	
p-value	0.1658	0.2791	
p-value of Breslow-Day Test for Homogeneity [3]	0.0492	0.9343	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (11.0)	8 (25.0)	14 (13.3)
No	65 (89.0)	24 (75.0)	91 (86.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.46	
95% CI of the inverse odds ratio	(0.50, 3.15)	(0.17, 1.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	0.53	
95% CI of the inverse risk ratio	(0.54, 2.75)	(0.25, 1.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.37	11.67	
95% CI of the absolute risk difference	(-12.05, 7.30)	(-4.68, 28.02)	
p-value	0.6359	0.1156	
p-value of Breslow-Day Test for Homogeneity [3]	0.7642	0.6416	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (19.2)	10 (31.3)	17 (16.2)
No	59 (80.8)	22 (68.8)	88 (83.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.43	
95% CI of the inverse odds ratio	(0.37, 1.78)	(0.17, 1.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.52	
95% CI of the inverse risk ratio	(0.44, 1.60)	(0.26, 1.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.99	15.06	
95% CI of the absolute risk difference	(-8.47, 14.44)	(-2.48, 32.60)	
p-value	0.6052	0.0608	
p-value of Breslow-Day Test for Homogeneity [3]	0.5743	0.4960	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (12.3)	3 (9.4)	13 (12.4)
No	64 (87.7)	29 (90.6)	92 (87.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.37	
95% CI of the inverse odds ratio	(0.41, 2.49)	(0.36, 5.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.32	
95% CI of the inverse risk ratio	(0.45, 2.23)	(0.40, 4.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.05	-3.01	
95% CI of the absolute risk difference	(-9.88, 9.77)	(-14.91, 8.90)	
p-value	0.9917	0.6430	
p-value of Breslow-Day Test for Homogeneity [3]	0.6476	0.8700	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (37.0)	10 (31.3)	26 (24.8)
No	46 (63.0)	22 (68.8)	79 (75.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.72	
95% CI of the inverse odds ratio	(0.29, 1.07)	(0.30, 1.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.79	
95% CI of the inverse risk ratio	(0.43, 1.05)	(0.43, 1.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.22	6.49	
95% CI of the absolute risk difference	(-1.59, 26.04)	(-11.57, 24.55)	
p-value	0.0794	0.4654	
p-value of Breslow-Day Test for Homogeneity [3]	0.3145	0.3697	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (5.5)	2 (6.3)	5 (4.8)
No	69 (94.5)	30 (93.8)	100 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.75	
95% CI of the inverse odds ratio	(0.22, 3.33)	(0.14, 4.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.76	
95% CI of the inverse risk ratio	(0.24, 3.13)	(0.16, 3.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.72	1.49	
95% CI of the absolute risk difference	(-5.90, 7.34)	(-7.84, 10.81)	
p-value	0.8298	0.7379	
p-value of Breslow-Day Test for Homogeneity [3]	0.3853	0.8610	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (23.3)	8 (25.0)	16 (15.2)
No	56 (76.7)	24 (75.0)	89 (84.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.54	
95% CI of the inverse odds ratio	(0.28, 1.27)	(0.21, 1.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	0.61	
95% CI of the inverse risk ratio	(0.35, 1.21)	(0.29, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.05	9.76	
95% CI of the absolute risk difference	(-3.84, 19.93)	(-6.74, 26.26)	
p-value	0.1741	0.2034	
p-value of Breslow-Day Test for Homogeneity [3]	0.1943	0.0562	

AMNOG Table SE22.4.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.1)	5 (15.6)	6 (5.7)
No	70 (95.9)	27 (84.4)	99 (94.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	0.33	
95% CI of the inverse odds ratio	(0.34, 5.85)	(0.09, 1.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	0.37	
95% CI of the inverse risk ratio	(0.36, 5.38)	(0.12, 1.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.60	9.91	
95% CI of the absolute risk difference	(-7.96, 4.76)	(-3.43, 23.25)	
p-value	0.6308	0.0709	
p-value of Breslow-Day Test for Homogeneity [3]	0.6749	0.3836	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (20.5)	10 (31.3)	26 (24.8)
No	58 (79.5)	22 (68.8)	79 (75.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	0.72	
95% CI of the inverse odds ratio	(0.62, 2.61)	(0.30, 1.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	0.79	
95% CI of the inverse risk ratio	(0.69, 2.11)	(0.43, 1.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.21	6.49	
95% CI of the absolute risk difference	(-16.63, 8.20)	(-11.57, 24.55)	
p-value	0.5113	0.4654	
p-value of Breslow-Day Test for Homogeneity [3]	0.2946	0.6929	

Madrigal Pharmaceuticals, Inc. Page 1 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.4.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Region
(Label Population)

Region: US
Physical Functioning



Patients with result at given visit			
MGL-3196 80 mg	92	89	77
MGL-3196 100 mg	108	107	89
Placebo	186	175	150

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.4.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Region
(Label Population)

Region: Ex-US
Physical Functioning



Patients with result at given visit			
MGL-3196 80 mg	66	68	59
MGL-3196 100 mg	30	29	25
Placebo	94	92	89

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Physical Functioning						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	73.33 (22.53)	69.96 (25.79)	74.57 (26.09)			
Median	77.50	75.00	85.00			
IQR: Q1, Q3	57.50, 90.00	55.00, 90.00	60.00, 95.00			
Min, Max	10.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	76.30 (24.03)	71.56 (24.59)	74.45 (27.07)	3.02 (2.37)	1.05 (1.78)	-0.91 (1.38)
Median	85.00	80.00	85.00	5.00	0	0
IQR: Q1, Q3	55.00, 95.00	60.00, 90.00	55.00, 95.00	-5.00, 10.00	-10.00, 10.00	-10.00, 5.00
Min, Max	20.0, 100.0	5.0, 100.0	5.0, 100.0	-50.0, 40.0	-65.0, 70.0	-70.0, 65.0
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	77.98 (24.04)	71.11 (26.04)	75.67 (23.88)	1.41 (2.46)	0.51 (1.69)	-0.86 (1.36)
Median	90.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 95.00	55.00, 90.00	60.00, 95.00	-5.00, 10.00	-5.00, 5.00	-10.00, 5.00
Min, Max	15.0, 100.0	0.0, 100.0	0.0, 100.0	-45.0, 45.0	-85.0, 40.0	-60.0, 70.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Role Physical						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	75.28 (25.29)	73.11 (27.01)	75.52 (26.66)			
Median	81.30	75.00	81.30			
IQR: Q1, Q3	53.15, 100.00	50.00, 100.00	56.30, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	6.3, 100.0			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	75.14 (23.96)	73.73 (24.05)	75.67 (27.37)	-0.65 (3.09)	-0.25 (1.88)	-0.99 (1.62)
Median	75.00	75.00	81.30	0	0	0
IQR: Q1, Q3	56.30, 100.00	56.30, 100.00	56.30, 100.00	-12.50, 9.40	-12.50, 6.30	-6.30, 0.00
Min, Max	25.0, 100.0	0.0, 100.0	6.3, 100.0	-43.8, 50.0	-56.2, 68.7	-56.2, 87.5
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	77.84 (25.79)	73.92 (26.36)	74.30 (26.17)	-1.45 (2.98)	0.69 (2.03)	-2.82 (1.66)
Median	87.50	78.15	81.30	0	0	0
IQR: Q1, Q3	62.50, 100.00	56.30, 100.00	50.00, 100.00	-12.50, 0.00	-6.30, 6.30	-12.50, 6.20
Min, Max	0.0, 100.0	6.3, 100.0	6.3, 100.0	-37.5, 56.2	-75.0, 81.3	-62.5, 68.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Bodily Pain						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	64.9 (22.7)	62.1 (26.2)	63.6 (25.8)			
Median	63.0	62.0	62.0			
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	41.0, 84.0			
Min, Max	22, 100	0, 100	0, 100			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	61.6 (24.8)	64.5 (24.1)	63.7 (25.4)	-3.7 (3.3)	0.8 (1.8)	-0.9 (1.8)
Median	62.0	62.0	62.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	41.5, 84.0	41.0, 84.0	-16.0, 10.0	-10.0, 10.0	-12.0, 11.5
Min, Max	10, 100	10, 100	0, 100	-59, 52	-62, 72	-78, 78
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	69.1 (22.5)	67.2 (25.6)	66.1 (24.7)	1.2 (3.0)	5.0 (2.1)	0.9 (1.8)
Median	72.0	72.0	72.0	0	0	0
IQR: Q1, Q3	61.0, 84.0	42.0, 84.0	51.0, 84.0	-10.0, 10.0	-9.0, 12.0	-12.0, 10.5
Min, Max	22, 100	10, 100	0, 100	-38, 59	-53, 69	-78, 78

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
General Health						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	60.52 (17.29)	54.11 (19.18)	56.89 (20.12)			
Median	62.00	52.00	57.00			
IQR: Q1, Q3	48.50, 72.00	40.00, 67.00	42.00, 72.00			
Min, Max	25.0, 92.0	10.0, 100.0	15.0, 100.0			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	61.44 (20.92)	55.10 (19.41)	58.29 (21.13)	0.38 (2.26)	1.34 (1.40)	1.13 (1.20)
Median	61.00	52.00	62.00	3.10	0	0
IQR: Q1, Q3	45.00, 77.00	40.00, 69.50	42.00, 77.00	-6.50, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	20.0, 100.0	10.0, 100.0	0.0, 100.0	-47.0, 32.0	-35.0, 40.0	-37.0, 40.0
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	61.37 (17.27)	55.94 (19.21)	59.23 (21.19)	-2.01 (2.01)	2.17 (1.65)	0.98 (1.15)
Median	64.50	56.00	62.00	0	3.00	0
IQR: Q1, Q3	52.00, 72.00	45.00, 72.00	45.00, 77.00	-10.00, 2.00	-10.00, 15.00	-5.00, 10.00
Min, Max	25.0, 97.0	10.0, 92.0	10.0, 100.0	-37.0, 30.0	-52.0, 47.0	-42.0, 37.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Vitality						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	56.67 (20.84)	53.69 (22.42)	55.62 (21.90)			
Median	59.40	56.30	56.30			
IQR: Q1, Q3	43.80, 75.00	37.50, 68.80	43.80, 68.80			
Min, Max	12.5, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	55.89 (23.22)	53.75 (20.23)	55.73 (22.24)	-1.57 (2.21)	-0.45 (1.39)	-0.33 (1.28)
Median	62.50	56.30	56.30	0	0	0
IQR: Q1, Q3	43.80, 75.00	37.50, 68.80	37.50, 75.00	-6.30, 6.25	-12.50, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.8, 31.2	-31.3, 43.8	-37.5, 56.2
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	60.59 (19.50)	54.85 (20.92)	56.69 (23.22)	0.64 (1.62)	0.34 (1.46)	0.22 (1.51)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	50.00, 75.00	43.80, 68.80	43.80, 75.00	-6.30, 6.30	-6.30, 6.30	-6.30, 12.50
Min, Max	12.5, 100.0	6.3, 100.0	0.0, 100.0	-18.7, 18.8	-43.8, 43.8	-56.3, 43.8

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Social Functioning						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	82.81 (22.86)	79.62 (25.77)	83.53 (21.81)			
Median	93.75	87.50	100.00			
IQR: Q1, Q3	68.75, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	12.5, 100.0			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	80.50 (25.15)	81.71 (20.97)	80.79 (25.77)	-2.34 (3.40)	1.69 (1.82)	-2.55 (1.66)
Median	93.75	87.50	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	62.50, 100.00	-12.50, 6.25	0.00, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	12.5, 100.0	0.0, 100.0	-62.5, 50.0	-62.5, 87.5	-62.5, 50.0
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	85.71 (20.76)	81.80 (22.38)	82.55 (22.12)	-0.64 (2.79)	1.83 (2.17)	-1.61 (1.64)
Median	100.00	87.50	87.50	0	0	0
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	62.50, 100.00	-12.50, 0.00	0.00, 12.50	-6.25, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-37.5, 50.0	-62.5, 62.5	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Role Emotional						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	79.68 (28.71)	82.01 (23.70)	84.68 (22.59)			
Median	100.00	95.85	100.00			
IQR: Q1, Q3	70.85, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	8.3, 100.0			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	80.16 (23.98)	85.30 (20.65)	82.61 (24.19)	0.52 (2.68)	2.91 (1.42)	-2.14 (1.45)
Median	95.85	100.00	100.00	0	0	0
IQR: Q1, Q3	58.30, 100.00	75.00, 100.00	66.70, 100.00	-4.15, 0.00	0.00, 8.30	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-33.3, 66.7	-50.0, 50.0	-50.0, 50.0
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	84.03 (21.11)	84.87 (21.86)	83.39 (23.32)	0.11 (3.35)	3.29 (2.04)	-1.97 (1.51)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	-8.30, 0.00	0.00, 16.70	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-33.3, 100.0	-75.0, 58.3	-58.3, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Mental Health						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	73.8 (20.7)	74.9 (19.3)	75.9 (18.1)			
Median	85.0	80.0	80.0			
IQR: Q1, Q3	67.5, 90.0	65.0, 90.0	65.0, 90.0			
Min, Max	10, 95	15, 100	20, 100			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	71.5 (20.6)	75.1 (18.9)	74.1 (20.1)	-2.5 (1.8)	-0.6 (1.1)	-1.5 (1.1)
Median	77.5	80.0	80.0	0	0	0
IQR: Q1, Q3	60.0, 85.0	65.0, 90.0	65.0, 90.0	-10.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	15, 100	5, 100	5, 100	-35, 20	-40, 50	-45, 55
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	78.0 (14.3)	75.5 (18.2)	74.8 (20.3)	0.3 (1.7)	0.2 (1.2)	-1.0 (1.2)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	70.0, 90.0	65.0, 90.0	65.0, 90.0	-5.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	40, 100	20, 100	0, 100	-20, 25	-30, 50	-40, 55

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Mental Component Score						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	50.25 (11.23)	50.82 (11.01)	51.62 (9.56)			
Median	53.80	53.75	55.10			
IQR: Q1, Q3	47.15, 58.15	45.30, 58.30	46.80, 58.40			
Min, Max	12.9, 62.7	17.0, 72.3	25.9, 66.5			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	49.29 (10.92)	51.44 (9.79)	50.49 (10.77)	-1.06 (1.05)	0.37 (0.61)	-0.93 (0.60)
Median	52.80	53.40	53.10	0	-0.10	-0.05
IQR: Q1, Q3	41.70, 58.40	46.65, 58.75	44.30, 58.50	-5.30, 3.35	-3.00, 3.40	-4.30, 2.50
Min, Max	20.0, 62.6	9.4, 71.2	14.2, 69.0	-20.0, 14.8	-24.5, 26.1	-24.6, 24.8
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	52.17 (8.13)	51.52 (9.70)	50.97 (10.66)	0.00 (1.06)	0.59 (0.78)	-0.59 (0.63)
Median	55.05	53.30	54.20	-0.10	-0.10	-0.45
IQR: Q1, Q3	46.10, 58.30	45.10, 58.40	46.60, 58.40	-2.60, 2.80	-3.70, 2.90	-3.75, 3.00
Min, Max	26.7, 62.4	17.8, 70.7	8.9, 64.6	-13.6, 26.2	-21.4, 25.2	-24.6, 26.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Physical Component Score						
Baseline						
m	52	151	186			
n	48	138	173			
Mean (SD)	47.40 (7.23)	45.11 (9.89)	46.36 (9.84)			
Median	48.35	46.15	48.50			
IQR: Q1, Q3	43.60, 52.55	39.50, 52.90	38.40, 54.50			
Min, Max	29.1, 60.8	21.2, 61.3	20.7, 65.2			
Week 24						
m	51	141	178			
n	50	136	162	48	126	152
Mean (SD/SE)	47.76 (8.50)	45.58 (8.94)	46.94 (9.91)	0.21 (1.01)	0.24 (0.68)	0.09 (0.57)
Median	48.90	46.40	49.50	0.95	-0.15	-0.15
IQR: Q1, Q3	41.80, 54.00	38.90, 52.35	40.30, 54.70	-3.65, 4.25	-3.00, 3.50	-4.00, 3.25
Min, Max	28.9, 62.7	20.2, 61.0	22.8, 63.0	-17.2, 17.6	-22.1, 32.4	-21.7, 23.8
Week 52						
m	46	125	165			
n	42	114	149	39	109	140
Mean (SD/SE)	48.32 (9.02)	45.97 (9.85)	47.24 (9.24)	-0.07 (1.06)	0.79 (0.72)	0.02 (0.54)
Median	50.50	47.80	48.20	-0.60	1.50	0.10
IQR: Q1, Q3	42.60, 55.40	40.60, 53.10	41.30, 55.00	-2.50, 4.20	-2.70, 5.00	-3.50, 3.30
Min, Max	23.2, 61.4	16.0, 61.2	22.5, 63.9	-22.4, 14.9	-23.5, 18.6	-23.9, 20.5

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Physical Functioning						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	75.12 (24.57)	N/A	74.25 (24.04)			
Median	80.00	N/A	80.00			
IQR: Q1, Q3	60.00, 95.00	N/A	60.00, 95.00			
Min, Max	0.0, 100.0	N/A	10.0, 100.0			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	75.42 (24.70)	N/A	75.57 (28.20)	0.65 (1.59)	N/A	2.11 (1.85)
Median	80.00	N/A	85.00	0	N/A	0
IQR: Q1, Q3	60.00, 95.00	N/A	65.00, 95.00	-10.00, 10.00	N/A	-5.00, 10.00
Min, Max	5.0, 100.0	N/A	0.0, 100.0	-50.0, 60.0	N/A	-50.0, 75.0
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	75.96 (27.76)	N/A	77.88 (25.54)	1.29 (1.60)	N/A	3.30 (1.69)
Median	90.00	N/A	85.00	0	N/A	5.00
IQR: Q1, Q3	60.00, 100.00	N/A	70.00, 100.00	-5.00, 10.00	N/A	0.00, 10.00
Min, Max	0.0, 100.0	N/A	0.0, 100.0	-65.0, 35.0	N/A	-35.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Role Physical						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	75.98 (26.60)	N/A	76.65 (25.16)			
Median	81.30	N/A	81.30			
IQR: Q1, Q3	56.30, 100.00	N/A	62.50, 100.00			
Min, Max	0.0, 100.0	N/A	0.0, 100.0			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	74.08 (28.23)	N/A	76.50 (27.17)	-1.46 (1.64)	N/A	0.77 (2.09)
Median	81.30	N/A	87.50	0	N/A	0
IQR: Q1, Q3	56.30, 100.00	N/A	56.30, 100.00	-12.50, 12.50	N/A	-6.30, 6.30
Min, Max	0.0, 100.0	N/A	0.0, 100.0	-43.7, 31.3	N/A	-68.7, 68.7
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	75.28 (28.79)	N/A	77.58 (22.79)	-0.07 (1.88)	N/A	1.88 (2.27)
Median	87.50	N/A	81.30	0	N/A	0
IQR: Q1, Q3	50.00, 100.00	N/A	62.50, 100.00	-6.20, 6.20	N/A	-6.30, 6.30
Min, Max	0.0, 100.0	N/A	0.0, 100.0	-43.8, 81.2	N/A	-56.2, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Bodily Pain						
Baseline						
m	115	0	117			
n	109	0	107			
Mean (SD)	67.6 (25.1)	N/A	68.5 (23.8)			
Median	72.0	N/A	72.0			
IQR: Q1, Q3	51.0, 84.0	N/A	51.0, 84.0			
Min, Max	0, 100	N/A	12, 100			
Week 24						
m	110	0	111			
n	107	0	105	102	0	97
Mean (SD/SE)	65.3 (25.7)	N/A	69.6 (25.5)	-1.8 (1.9)	N/A	2.2 (1.8)
Median	72.0	N/A	74.0	0	N/A	0
IQR: Q1, Q3	51.0, 84.0	N/A	52.0, 100.0	-16.0, 1.0	N/A	-9.0, 12.0
Min, Max	0, 100	N/A	0, 100	-43, 68	N/A	-43, 59
Week 52						
m	103	0	105			
n	94	0	90	90	0	83
Mean (SD/SE)	67.2 (27.2)	N/A	69.9 (25.0)	-0.3 (2.2)	N/A	2.2 (2.4)
Median	74.0	N/A	74.0	0	N/A	0
IQR: Q1, Q3	51.0, 84.0	N/A	51.0, 84.0	-10.0, 10.0	N/A	-11.0, 16.0
Min, Max	0, 100	N/A	10, 100	-80, 68	N/A	-49, 69

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
General Health						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	60.46 (20.99)	N/A	61.91 (20.39)			
Median	62.00	N/A	65.00			
IQR: Q1, Q3	47.00, 77.00	N/A	47.00, 77.00			
Min, Max	10.0, 100.0	N/A	15.0, 100.0			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	60.56 (21.02)	N/A	60.79 (22.04)	1.26 (1.36)	N/A	-0.04 (1.48)
Median	60.00	N/A	60.00	0	N/A	0
IQR: Q1, Q3	47.00, 77.00	N/A	47.00, 80.00	-5.00, 10.00	N/A	-8.00, 5.00
Min, Max	10.0, 100.0	N/A	15.0, 100.0	-60.0, 32.0	N/A	-40.0, 48.0
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	63.40 (20.97)	N/A	62.74 (19.94)	3.00 (1.66)	N/A	2.29 (1.54)
Median	67.00	N/A	62.00	0	N/A	0
IQR: Q1, Q3	47.00, 82.00	N/A	52.00, 77.00	-5.00, 10.00	N/A	-5.00, 10.00
Min, Max	20.0, 100.0	N/A	10.0, 100.0	-70.0, 47.0	N/A	-30.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Vitality						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	57.77 (23.16)	N/A	58.06 (21.02)			
Median	62.50	N/A	62.50			
IQR: Q1, Q3	37.50, 75.00	N/A	43.80, 75.00			
Min, Max	0.0, 100.0	N/A	6.3, 100.0			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	56.86 (24.06)	N/A	58.83 (22.06)	-0.19 (1.43)	N/A	0.86 (1.53)
Median	62.50	N/A	62.50	0	N/A	0
IQR: Q1, Q3	43.80, 75.00	N/A	43.80, 75.00	-6.30, 6.30	N/A	-12.50, 12.50
Min, Max	0.0, 100.0	N/A	6.3, 100.0	-37.5, 43.8	N/A	-37.5, 43.7
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	57.80 (24.26)	N/A	58.71 (21.19)	-0.41 (1.81)	N/A	1.08 (1.89)
Median	62.50	N/A	62.50	0	N/A	0
IQR: Q1, Q3	37.50, 75.00	N/A	43.80, 75.00	-12.50, 12.50	N/A	-6.30, 8.30
Min, Max	6.3, 100.0	N/A	6.3, 100.0	-43.7, 50.0	N/A	-43.7, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Social Functioning						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	81.36 (24.17)	N/A	82.01 (23.55)			
Median	87.50	N/A	87.50			
IQR: Q1, Q3	62.50, 100.00	N/A	75.00, 100.00			
Min, Max	0.0, 100.0	N/A	12.5, 100.0			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	81.31 (24.37)	N/A	81.79 (22.93)	0.12 (1.96)	N/A	-0.13 (1.83)
Median	87.50	N/A	87.50	0	N/A	0
IQR: Q1, Q3	62.50, 100.00	N/A	75.00, 100.00	-12.50, 12.50	N/A	-12.50, 0.00
Min, Max	12.5, 100.0	N/A	0.0, 100.0	-50.0, 75.0	N/A	-37.5, 75.0
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	79.79 (24.26)	N/A	83.61 (21.66)	-2.06 (1.80)	N/A	1.36 (2.16)
Median	87.50	N/A	93.75	0	N/A	0
IQR: Q1, Q3	62.50, 100.00	N/A	75.00, 100.00	0.00, 0.00	N/A	0.00, 12.50
Min, Max	12.5, 100.0	N/A	12.5, 100.0	-50.0, 37.5	N/A	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Role Emotional						
Baseline						
m	115	0	117			
n	110	0	106			
Mean (SD)	83.10 (22.70)	N/A	82.86 (22.03)			
Median	100.00	N/A	91.70			
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 100.00			
Min, Max	0.0, 100.0	N/A	0.0, 100.0			
Week 24						
m	110	0	111			
n	107	0	105	103	0	96
Mean (SD/SE)	82.17 (22.79)	N/A	83.25 (23.87)	-0.40 (1.71)	N/A	0.96 (1.98)
Median	91.70	N/A	100.00	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 100.00	-8.30, 8.30	N/A	-8.30, 8.30
Min, Max	25.0, 100.0	N/A	8.3, 100.0	-66.7, 50.0	N/A	-50.0, 58.3
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	83.07 (21.71)	N/A	82.22 (21.72)	1.10 (1.63)	N/A	-1.41 (2.18)
Median	95.85	N/A	83.30	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 100.00	0.00, 8.30	N/A	-16.70, 8.30
Min, Max	25.0, 100.0	N/A	0.0, 100.0	-50.0, 50.0	N/A	-50.0, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Mental Health						
Baseline						
m	115	0	117			
n	110	0	107			
Mean (SD)	73.7 (19.6)	N/A	74.0 (17.2)			
Median	77.5	N/A	80.0			
IQR: Q1, Q3	60.0, 90.0	N/A	65.0, 85.0			
Min, Max	5, 100	N/A	5, 100			
Week 24						
m	110	0	111			
n	107	0	105	103	0	97
Mean (SD/SE)	73.5 (19.7)	N/A	75.4 (17.1)	0.1 (1.4)	N/A	1.9 (1.6)
Median	75.0	N/A	80.0	0	N/A	0
IQR: Q1, Q3	60.0, 90.0	N/A	70.0, 90.0	-5.0, 5.0	N/A	-5.0, 10.0
Min, Max	20, 100	N/A	30, 100	-40, 35	N/A	-30, 50
Week 52						
m	103	0	105			
n	94	0	90	91	0	83
Mean (SD/SE)	74.0 (19.5)	N/A	77.1 (17.8)	0.7 (1.4)	N/A	3.0 (1.8)
Median	77.5	N/A	80.0	0	N/A	0
IQR: Q1, Q3	60.0, 90.0	N/A	70.0, 90.0	-5.0, 10.0	N/A	-5.0, 10.0
Min, Max	25, 100	N/A	15, 100	-35, 40	N/A	-60, 50

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Mental Component Score						
Baseline						
m	115	0	117			
n	109	0	106			
Mean (SD)	50.62 (10.69)	N/A	50.67 (8.93)			
Median	53.10	N/A	52.95			
IQR: Q1, Q3	46.40, 58.30	N/A	45.30, 57.20			
Min, Max	12.0, 69.0	N/A	15.6, 65.8			
Week 24						
m	110	0	111			
n	107	0	105	102	0	96
Mean (SD/SE)	50.33 (10.54)	N/A	51.00 (9.63)	-0.10 (0.73)	N/A	0.43 (0.82)
Median	52.40	N/A	53.60	-0.60	N/A	-0.20
IQR: Q1, Q3	44.60, 58.20	N/A	46.20, 57.90	-3.30, 3.40	N/A	-4.25, 3.65
Min, Max	18.7, 69.1	N/A	21.9, 66.3	-20.0, 19.0	N/A	-17.6, 22.7
Week 52						
m	103	0	105			
n	94	0	90	90	0	83
Mean (SD/SE)	50.38 (10.13)	N/A	51.15 (9.40)	-0.11 (0.75)	N/A	0.29 (0.90)
Median	53.10	N/A	53.65	0	N/A	1.20
IQR: Q1, Q3	42.40, 58.30	N/A	46.70, 57.60	-3.80, 3.70	N/A	-4.30, 4.60
Min, Max	23.1, 63.2	N/A	21.0, 68.0	-21.7, 20.4	N/A	-25.1, 24.1

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Physical Component Score						
Baseline						
m	115	0	117			
n	109	0	106			
Mean (SD)	47.87 (9.57)	N/A	48.16 (8.68)			
Median	49.00	N/A	48.90			
IQR: Q1, Q3	43.00, 55.90	N/A	42.50, 56.00			
Min, Max	15.3, 59.8	N/A	25.9, 61.2			
Week 24						
m	110	0	111			
n	107	0	105	102	0	96
Mean (SD/SE)	47.49 (10.07)	N/A	48.11 (10.28)	-0.11 (0.57)	N/A	0.36 (0.69)
Median	50.00	N/A	50.40	-0.40	N/A	0.50
IQR: Q1, Q3	41.70, 54.10	N/A	42.70, 56.00	-3.70, 3.60	N/A	-2.15, 3.60
Min, Max	12.5, 63.9	N/A	19.0, 62.0	-14.8, 18.3	N/A	-28.8, 22.9
Week 52						
m	103	0	105			
n	94	0	90	90	0	83
Mean (SD/SE)	48.19 (11.01)	N/A	48.77 (9.12)	0.43 (0.69)	N/A	1.12 (0.61)
Median	52.25	N/A	49.45	0.80	N/A	1.20
IQR: Q1, Q3	41.80, 57.50	N/A	43.90, 56.60	-1.50, 3.70	N/A	-1.90, 3.80
Min, Max	15.8, 62.8	N/A	21.5, 61.7	-24.7, 22.5	N/A	-12.2, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Physical Functioning			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	73.33 (22.53)	70.12 (26.00)	75.39 (26.07)
Analysis Visit Mean (SD)	76.35 (23.98)	71.17 (24.49)	74.48 (27.17)
LS Mean of Change from Baseline (SE)	3.28 (2.50)	0.18 (1.56)	-0.73 (1.42)
95% CI	(-1.63, 8.19)	(-2.89, 3.25)	(-3.52, 2.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.01 (2.83)	0.91 (2.06)	
95% CI	(-1.56, 9.57)	(-3.14, 4.95)	
p-value	0.1575	0.6595	
Corrected Hedge's g Statistics	0.229	0.052	
95% CI	(-0.10, 0.55)	(-0.18, 0.29)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	76.92 (19.22)	70.09 (26.21)	76.50 (24.84)
Analysis Visit Mean (SD)	78.33 (23.01)	70.61 (26.31)	75.64 (23.58)
LS Mean of Change from Baseline (SE)	1.52 (2.49)	0.25 (1.52)	-0.77 (1.35)
95% CI	(-3.37, 6.40)	(-2.74, 3.24)	(-3.43, 1.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.28 (2.78)	1.01 (1.98)	
95% CI	(-3.20, 7.76)	(-2.89, 4.92)	
p-value	0.4132	0.6096	
Corrected Hedge's g Statistics	0.143	0.063	
95% CI	(-0.21, 0.50)	(-0.19, 0.31)	
Subgroup*Treatment Interaction p-value	0.1100	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Role Physical			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	75.28 (25.29)	73.63 (27.29)	76.33 (26.97)
Analysis Visit Mean (SD)	74.62 (24.19)	73.38 (24.38)	75.34 (27.60)
LS Mean of Change from Baseline (SE)	0.01 (2.71)	-0.67 (1.69)	-0.39 (1.54)
95% CI	(-5.32, 5.34)	(-4.00, 2.67)	(-3.43, 2.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.41 (3.07)	-0.27 (2.23)	
95% CI	(-5.64, 6.45)	(-4.66, 4.12)	
p-value	0.8952	0.9031	
Corrected Hedge's g Statistics	0.021	-0.014	
95% CI	(-0.30, 0.35)	(-0.25, 0.22)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	79.18 (25.50)	72.84 (27.95)	77.34 (25.58)
Analysis Visit Mean (SD)	77.73 (26.11)	73.53 (26.66)	74.52 (26.20)
LS Mean of Change from Baseline (SE)	-0.22 (2.95)	0.70 (1.80)	-2.06 (1.59)
95% CI	(-6.02, 5.59)	(-2.84, 4.23)	(-5.20, 1.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.84 (3.31)	2.76 (2.35)	
95% CI	(-4.67, 8.36)	(-1.86, 7.37)	
p-value	0.5778	0.2412	
Corrected Hedge's g Statistics	0.098	0.146	
95% CI	(-0.26, 0.45)	(-0.10, 0.40)	
Subgroup*Treatment Interaction p-value	0.3642	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Bodily Pain			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	64.9 (22.7)	62.7 (26.3)	64.6 (25.4)
Analysis Visit Mean (SD)	61.2 (24.5)	63.5 (24.3)	63.7 (25.7)
LS Mean of Change from Baseline (SE)	-3.04 (2.79)	0.50 (1.74)	-0.64 (1.59)
95% CI	(-8.53, 2.45)	(-2.93, 3.92)	(-3.76, 2.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.40 (3.16)	1.14 (2.29)	
95% CI	(-8.62, 3.82)	(-3.37, 5.64)	
p-value	0.4479	0.6198	
Corrected Hedge's g Statistics	-0.123	0.058	
95% CI	(-0.45, 0.20)	(-0.18, 0.29)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	67.4 (21.8)	61.3 (26.7)	65.2 (25.0)
Analysis Visit Mean (SD)	68.6 (22.2)	66.3 (25.7)	66.1 (24.6)
LS Mean of Change from Baseline (SE)	2.04 (3.02)	3.89 (1.84)	1.19 (1.64)
95% CI	(-3.91, 7.98)	(0.26, 7.51)	(-2.03, 4.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.85 (3.39)	2.70 (2.40)	
95% CI	(-5.82, 7.52)	(-2.03, 7.43)	
p-value	0.8027	0.2627	
Corrected Hedge's g Statistics	0.044	0.139	
95% CI	(-0.31, 0.40)	(-0.11, 0.39)	
Subgroup*Treatment Interaction p-value	0.5060	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
General Health			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	60.52 (17.29)	53.05 (18.71)	57.30 (19.99)
Analysis Visit Mean (SD)	60.90 (20.67)	54.39 (19.54)	58.42 (21.43)
LS Mean of Change from Baseline (SE)	1.36 (2.17)	-0.04 (1.35)	1.13 (1.23)
95% CI	(-2.91, 5.62)	(-2.71, 2.62)	(-1.28, 3.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.23 (2.45)	-1.17 (1.78)	
95% CI	(-4.60, 5.05)	(-4.67, 2.33)	
p-value	0.9269	0.5102	
Corrected Hedge's g Statistics	0.015	-0.077	
95% CI	(-0.31, 0.34)	(-0.31, 0.16)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	63.33 (16.83)	53.32 (19.65)	58.46 (20.22)
Analysis Visit Mean (SD)	61.32 (17.22)	55.50 (19.29)	59.44 (21.54)
LS Mean of Change from Baseline (SE)	-0.48 (2.23)	0.83 (1.36)	1.09 (1.21)
95% CI	(-4.86, 3.90)	(-1.84, 3.50)	(-1.29, 3.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.57 (2.49)	-0.26 (1.77)	
95% CI	(-6.46, 3.33)	(-3.74, 3.22)	
p-value	0.5292	0.8843	
Corrected Hedge's g Statistics	-0.110	-0.018	
95% CI	(-0.47, 0.25)	(-0.27, 0.23)	
Subgroup*Treatment Interaction p-value	0.6700	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Vitality			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	56.67 (20.84)	53.50 (22.65)	56.27 (22.57)
Analysis Visit Mean (SD)	55.10 (22.79)	53.05 (19.89)	55.94 (22.54)
LS Mean of Change from Baseline (SE)	-1.20 (2.11)	-1.32 (1.32)	-0.34 (1.20)
95% CI	(-5.36, 2.95)	(-3.92, 1.28)	(-2.70, 2.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.86 (2.39)	-0.98 (1.74)	
95% CI	(-5.57, 3.85)	(-4.40, 2.44)	
p-value	0.7188	0.5730	
Corrected Hedge's g Statistics	-0.058	-0.066	
95% CI	(-0.38, 0.27)	(-0.30, 0.17)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	59.16 (20.57)	54.21 (22.97)	56.63 (22.29)
Analysis Visit Mean (SD)	59.80 (18.68)	54.55 (21.09)	56.85 (23.48)
LS Mean of Change from Baseline (SE)	1.56 (2.34)	-0.51 (1.43)	-0.08 (1.27)
95% CI	(-3.04, 6.17)	(-3.32, 2.30)	(-2.57, 2.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.64 (2.63)	-0.43 (1.86)	
95% CI	(-3.53, 6.81)	(-4.09, 3.23)	
p-value	0.5330	0.8157	
Corrected Hedge's g Statistics	0.110	-0.029	
95% CI	(-0.25, 0.46)	(-0.28, 0.22)	
Subgroup*Treatment Interaction p-value	0.7088	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Social Functioning			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	82.81 (22.86)	79.96 (26.18)	83.55 (21.88)
Analysis Visit Mean (SD)	80.47 (25.38)	81.65 (21.19)	81.00 (25.81)
LS Mean of Change from Baseline (SE)	-2.08 (2.78)	0.50 (1.74)	-2.31 (1.58)
95% CI	(-7.54, 3.38)	(-2.91, 3.92)	(-5.41, 0.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.23 (3.15)	2.81 (2.29)	
95% CI	(-5.96, 6.43)	(-1.69, 7.31)	
p-value	0.9407	0.2194	
Corrected Hedge's g Statistics	0.012	0.144	
95% CI	(-0.31, 0.34)	(-0.09, 0.38)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	86.54 (20.15)	79.59 (27.25)	84.38 (21.21)
Analysis Visit Mean (SD)	85.90 (21.11)	81.42 (22.73)	82.77 (22.31)
LS Mean of Change from Baseline (SE)	-0.09 (2.85)	0.87 (1.74)	-1.65 (1.54)
95% CI	(-5.70, 5.51)	(-2.56, 4.29)	(-4.68, 1.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.56 (3.19)	2.52 (2.27)	
95% CI	(-4.72, 7.84)	(-1.94, 6.97)	
p-value	0.6258	0.2674	
Corrected Hedge's g Statistics	0.086	0.138	
95% CI	(-0.27, 0.44)	(-0.11, 0.39)	
Subgroup*Treatment Interaction p-value	0.5674	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Role Emotional			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	79.68 (28.71)	81.81 (24.18)	84.87 (22.70)
Analysis Visit Mean (SD)	80.21 (24.11)	84.72 (21.05)	82.73 (24.59)
LS Mean of Change from Baseline (SE)	-0.33 (2.33)	2.41 (1.45)	-1.79 (1.32)
95% CI	(-4.91, 4.25)	(-0.44, 5.27)	(-4.38, 0.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.46 (2.63)	4.20 (1.90)	
95% CI	(-3.72, 6.63)	(0.46, 7.94)	
p-value	0.5807	0.0278	
Corrected Hedge's g Statistics	0.089	0.257	
95% CI	(-0.24, 0.41)	(0.02, 0.49)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	84.61 (25.62)	81.35 (25.10)	85.65 (22.33)
Analysis Visit Mean (SD)	84.72 (21.00)	84.63 (22.06)	83.69 (23.44)
LS Mean of Change from Baseline (SE)	0.74 (2.74)	3.07 (1.67)	-1.88 (1.49)
95% CI	(-4.64, 6.13)	(-0.22, 6.36)	(-4.80, 1.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.62 (3.08)	4.95 (2.18)	
95% CI	(-3.43, 8.67)	(0.65, 9.25)	
p-value	0.3947	0.0241	
Corrected Hedge's g Statistics	0.149	0.281	
95% CI	(-0.21, 0.50)	(0.03, 0.53)	
Subgroup*Treatment Interaction p-value	0.6661	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Mental Health			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	73.8 (20.7)	75.3 (19.1)	75.9 (18.3)
Analysis Visit Mean (SD)	71.3 (20.5)	74.6 (19.0)	74.3 (20.3)
LS Mean of Change from Baseline (SE)	-2.87 (1.85)	-0.96 (1.16)	-1.62 (1.05)
95% CI	(-6.52, 0.78)	(-3.24, 1.31)	(-3.69, 0.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.25 (2.10)	0.66 (1.52)	
95% CI	(-5.37, 2.88)	(-2.32, 3.65)	
p-value	0.5530	0.6615	
Corrected Hedge's g Statistics	-0.096	0.051	
95% CI	(-0.42, 0.23)	(-0.19, 0.29)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	77.8 (16.9)	75.1 (19.7)	76.0 (17.9)
Analysis Visit Mean (SD)	78.1 (13.7)	75.3 (18.4)	75.1 (20.4)
LS Mean of Change from Baseline (SE)	0.80 (2.05)	-0.11 (1.25)	-1.94 (1.11)
95% CI	(-3.24, 4.84)	(-2.57, 2.36)	(-4.13, 0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.74 (2.31)	1.83 (1.63)	
95% CI	(-1.79, 7.28)	(-1.38, 5.05)	
p-value	0.2352	0.2628	
Corrected Hedge's g Statistics	0.208	0.139	
95% CI	(-0.15, 0.56)	(-0.11, 0.39)	
Subgroup*Treatment Interaction p-value	0.4826	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Mental Component Score			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	50.25 (11.23)	50.86 (11.16)	51.57 (9.70)
Analysis Visit Mean (SD)	49.18 (10.94)	51.23 (10.00)	50.64 (10.82)
LS Mean of Change from Baseline (SE)	-1.32 (0.99)	0.12 (0.62)	-0.96 (0.56)
95% CI	(-3.26, 0.63)	(-1.09, 1.34)	(-2.06, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.36 (1.12)	1.08 (0.81)	
95% CI	(-2.56, 1.84)	(-0.51, 2.67)	
p-value	0.7486	0.1818	
Corrected Hedge's g Statistics	-0.052	0.156	
95% CI	(-0.38, 0.27)	(-0.08, 0.39)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	52.25 (9.34)	50.85 (11.58)	51.71 (9.54)
Analysis Visit Mean (SD)	52.24 (8.07)	51.44 (9.80)	51.12 (10.69)
LS Mean of Change from Baseline (SE)	0.26 (1.11)	0.40 (0.68)	-1.02 (0.60)
95% CI	(-1.92, 2.45)	(-0.93, 1.74)	(-2.21, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.28 (1.25)	1.42 (0.88)	
95% CI	(-1.17, 3.74)	(-0.32, 3.16)	
p-value	0.3042	0.1084	
Corrected Hedge's g Statistics	0.180	0.199	
95% CI	(-0.18, 0.54)	(-0.05, 0.45)	
Subgroup*Treatment Interaction p-value	0.6900	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Physical Component Score			
Week 24			
m	51	141	178
n	48	126	152
Baseline Mean (SD)	47.40 (7.23)	45.12 (9.76)	46.78 (9.89)
Analysis Visit Mean (SD)	47.61 (8.48)	45.35 (8.96)	46.87 (9.95)
LS Mean of Change from Baseline (SE)	0.70 (0.97)	-0.13 (0.61)	0.23 (0.55)
95% CI	(-1.21, 2.61)	(-1.33, 1.06)	(-0.86, 1.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.47 (1.10)	-0.36 (0.80)	
95% CI	(-1.70, 2.63)	(-1.94, 1.21)	
p-value	0.6704	0.6493	
Corrected Hedge's g Statistics	0.069	-0.053	
95% CI	(-0.26, 0.39)	(-0.29, 0.18)	
Week 52			
m	46	125	165
n	39	109	140
Baseline Mean (SD)	48.29 (6.84)	44.94 (9.97)	47.22 (9.42)
Analysis Visit Mean (SD)	48.22 (8.93)	45.72 (9.92)	47.23 (9.15)
LS Mean of Change from Baseline (SE)	0.27 (1.02)	0.50 (0.62)	0.26 (0.55)
95% CI	(-1.73, 2.27)	(-0.72, 1.72)	(-0.83, 1.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (1.14)	0.25 (0.81)	
95% CI	(-2.23, 2.26)	(-1.35, 1.84)	
p-value	0.9888	0.7618	
Corrected Hedge's g Statistics	0.002	0.038	
95% CI	(-0.35, 0.36)	(-0.21, 0.29)	
Subgroup*Treatment Interaction p-value	0.4755	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Physical Functioning			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	74.88 (24.41)	N/A	74.79 (24.71)
Analysis Visit Mean (SD)	75.53 (25.05)	N/A	76.91 (27.60)
LS Mean of Change from Baseline (SE)	0.70 (1.73)	NE	1.95 (1.75)
95% CI	(-2.71, 4.10)	NE	(-1.50, 5.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.25 (2.36)	NE	
95% CI	(-5.90, 3.40)	NE	
p-value	0.5957	NE	
Corrected Hedge's g Statistics	-0.072	NE	
95% CI	(-0.35, 0.21)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	74.59 (24.28)	N/A	75.06 (23.96)
Analysis Visit Mean (SD)	75.88 (28.07)	N/A	78.36 (25.34)
LS Mean of Change from Baseline (SE)	1.62 (1.66)	NE	3.62 (1.71)
95% CI	(-1.66, 4.90)	NE	(0.25, 6.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.99 (2.28)	NE	
95% CI	(-6.48, 2.50)	NE	
p-value	0.3827	NE	
Corrected Hedge's g Statistics	-0.126	NE	
95% CI	(-0.42, 0.17)	NE	
Subgroup*Treatment Interaction p-value	0.1100	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Role Physical			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	75.98 (26.41)	N/A	76.76 (25.41)
Analysis Visit Mean (SD)	74.53 (28.24)	N/A	77.53 (26.90)
LS Mean of Change from Baseline (SE)	-1.10 (1.90)	NE	0.68 (1.92)
95% CI	(-4.84, 2.64)	NE	(-3.10, 4.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.78 (2.58)	NE	
95% CI	(-6.86, 3.30)	NE	
p-value	0.4914	NE	
Corrected Hedge's g Statistics	-0.093	NE	
95% CI	(-0.37, 0.18)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	75.42 (27.49)	N/A	76.30 (25.20)
Analysis Visit Mean (SD)	75.35 (28.96)	N/A	78.18 (22.26)
LS Mean of Change from Baseline (SE)	0.23 (1.92)	NE	2.41 (1.96)
95% CI	(-3.55, 4.01)	NE	(-1.45, 6.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.18 (2.62)	NE	
95% CI	(-7.35, 2.99)	NE	
p-value	0.4062	NE	
Corrected Hedge's g Statistics	-0.120	NE	
95% CI	(-0.42, 0.18)	NE	
Subgroup*Treatment Interaction p-value	0.3642	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Bodily Pain			
Week 24			
m	110	0	111
n	102	0	97
Baseline Mean (SD)	67.5 (24.9)	N/A	68.9 (24.3)
Analysis Visit Mean (SD)	65.7 (26.1)	N/A	71.0 (25.3)
LS Mean of Change from Baseline (SE)	-1.63 (1.85)	NE	2.15 (1.86)
95% CI	(-5.28, 2.02)	NE	(-1.52, 5.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.78 (2.50)	NE	
95% CI	(-8.70, 1.14)	NE	
p-value	0.1314	NE	
Corrected Hedge's g Statistics	-0.203	NE	
95% CI	(-0.48, 0.08)	NE	
Week 52			
m	103	0	105
n	90	0	83
Baseline Mean (SD)	67.4 (26.0)	N/A	68.7 (24.0)
Analysis Visit Mean (SD)	67.2 (27.4)	N/A	70.9 (24.1)
LS Mean of Change from Baseline (SE)	-0.42 (2.16)	NE	2.75 (2.21)
95% CI	(-4.68, 3.85)	NE	(-1.61, 7.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.16 (2.98)	NE	
95% CI	(-9.04, 2.71)	NE	
p-value	0.2895	NE	
Corrected Hedge's g Statistics	-0.155	NE	
95% CI	(-0.45, 0.14)	NE	
Subgroup*Treatment Interaction p-value	0.5060	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
General Health			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	60.25 (20.35)	N/A	61.82 (20.81)
Analysis Visit Mean (SD)	61.51 (20.49)	N/A	61.78 (22.04)
LS Mean of Change from Baseline (SE)	0.83 (1.42)	NE	-0.20 (1.43)
95% CI	(-1.96, 3.62)	NE	(-3.02, 2.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.03 (1.92)	NE	
95% CI	(-2.76, 4.82)	NE	
p-value	0.5915	NE	
Corrected Hedge's g Statistics	0.072	NE	
95% CI	(-0.21, 0.35)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	60.67 (21.05)	N/A	61.63 (21.12)
Analysis Visit Mean (SD)	63.67 (20.70)	N/A	63.92 (19.80)
LS Mean of Change from Baseline (SE)	2.41 (1.50)	NE	2.87 (1.54)
95% CI	(-0.55, 5.38)	NE	(-0.17, 5.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.46 (2.07)	NE	
95% CI	(-4.53, 3.61)	NE	
p-value	0.8239	NE	
Corrected Hedge's g Statistics	-0.032	NE	
95% CI	(-0.33, 0.27)	NE	
Subgroup*Treatment Interaction p-value	0.6700	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Vitality			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	57.99 (23.30)	N/A	58.38 (20.60)
Analysis Visit Mean (SD)	57.80 (23.70)	N/A	59.24 (22.63)
LS Mean of Change from Baseline (SE)	-0.25 (1.50)	NE	0.24 (1.52)
95% CI	(-3.21, 2.71)	NE	(-2.75, 3.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.49 (2.03)	NE	
95% CI	(-4.50, 3.52)	NE	
p-value	0.8095	NE	
Corrected Hedge's g Statistics	-0.032	NE	
95% CI	(-0.31, 0.24)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	58.54 (23.89)	N/A	58.06 (20.19)
Analysis Visit Mean (SD)	58.13 (23.83)	N/A	59.14 (21.37)
LS Mean of Change from Baseline (SE)	-0.39 (1.73)	NE	1.19 (1.77)
95% CI	(-3.79, 3.02)	NE	(-2.30, 4.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.58 (2.38)	NE	
95% CI	(-6.28, 3.12)	NE	
p-value	0.5088	NE	
Corrected Hedge's g Statistics	-0.096	NE	
95% CI	(-0.39, 0.20)	NE	
Subgroup*Treatment Interaction p-value	0.7088	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Social Functioning			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	81.92 (23.53)	N/A	81.96 (23.66)
Analysis Visit Mean (SD)	82.04 (24.17)	N/A	81.83 (21.95)
LS Mean of Change from Baseline (SE)	-0.42 (1.77)	NE	-1.19 (1.79)
95% CI	(-3.91, 3.06)	NE	(-4.72, 2.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.77 (2.41)	NE	
95% CI	(-3.97, 5.52)	NE	
p-value	0.7491	NE	
Corrected Hedge's g Statistics	0.043	NE	
95% CI	(-0.23, 0.32)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	82.28 (23.94)	N/A	82.68 (23.25)
Analysis Visit Mean (SD)	80.22 (24.09)	N/A	84.04 (21.77)
LS Mean of Change from Baseline (SE)	-1.74 (1.79)	NE	0.80 (1.84)
95% CI	(-5.28, 1.80)	NE	(-2.82, 4.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.54 (2.46)	NE	
95% CI	(-7.39, 2.31)	NE	
p-value	0.3022	NE	
Corrected Hedge's g Statistics	-0.150	NE	
95% CI	(-0.45, 0.15)	NE	
Subgroup*Treatment Interaction p-value	0.5674	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Role Emotional			
Week 24			
m	110	0	111
n	103	0	96
Baseline Mean (SD)	83.57 (22.12)	N/A	82.64 (22.51)
Analysis Visit Mean (SD)	83.17 (21.98)	N/A	83.59 (23.43)
LS Mean of Change from Baseline (SE)	-0.60 (1.76)	NE	0.41 (1.79)
95% CI	(-4.06, 2.87)	NE	(-3.11, 3.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.01 (2.41)	NE	
95% CI	(-5.76, 3.73)	NE	
p-value	0.6737	NE	
Corrected Hedge's g Statistics	-0.057	NE	
95% CI	(-0.34, 0.22)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	82.51 (23.04)	N/A	83.13 (21.58)
Analysis Visit Mean (SD)	83.61 (21.28)	N/A	81.72 (22.10)
LS Mean of Change from Baseline (SE)	0.65 (1.75)	NE	-1.57 (1.80)
95% CI	(-2.81, 4.10)	NE	(-5.12, 1.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.22 (2.41)	NE	
95% CI	(-2.53, 6.96)	NE	
p-value	0.3583	NE	
Corrected Hedge's g Statistics	0.133	NE	
95% CI	(-0.16, 0.43)	NE	
Subgroup*Treatment Interaction p-value	0.6661	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Mental Health			
Week 24			
m	110	0	111
n	103	0	97
Baseline Mean (SD)	74.2 (18.9)	N/A	73.6 (17.3)
Analysis Visit Mean (SD)	74.4 (18.8)	N/A	75.5 (16.8)
LS Mean of Change from Baseline (SE)	-0.34 (1.41)	NE	0.91 (1.42)
95% CI	(-3.11, 2.44)	NE	(-1.90, 3.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.24 (1.91)	NE	
95% CI	(-5.01, 2.53)	NE	
p-value	0.5162	NE	
Corrected Hedge's g Statistics	-0.088	NE	
95% CI	(-0.36, 0.19)	NE	
Week 52			
m	103	0	105
n	91	0	83
Baseline Mean (SD)	73.7 (19.5)	N/A	73.7 (18.0)
Analysis Visit Mean (SD)	74.4 (18.9)	N/A	76.6 (18.4)
LS Mean of Change from Baseline (SE)	0.07 (1.49)	NE	2.43 (1.53)
95% CI	(-2.87, 3.02)	NE	(-0.59, 5.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.35 (2.05)	NE	
95% CI	(-6.40, 1.69)	NE	
p-value	0.2526	NE	
Corrected Hedge's g Statistics	-0.166	NE	
95% CI	(-0.46, 0.13)	NE	
Subgroup*Treatment Interaction p-value	0.4826	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Mental Component Score			
Week 24			
m	110	0	111
n	102	0	96
Baseline Mean (SD)	50.95 (10.42)	N/A	50.49 (9.00)
Analysis Visit Mean (SD)	50.85 (9.93)	N/A	50.92 (9.51)
LS Mean of Change from Baseline (SE)	-0.35 (0.74)	NE	-0.13 (0.75)
95% CI	(-1.82, 1.11)	NE	(-1.61, 1.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.22 (1.01)	NE	
95% CI	(-2.22, 1.78)	NE	
p-value	0.8253	NE	
Corrected Hedge's g Statistics	-0.030	NE	
95% CI	(-0.31, 0.25)	NE	
Week 52			
m	103	0	105
n	90	0	83
Baseline Mean (SD)	50.79 (10.74)	N/A	50.63 (9.00)
Analysis Visit Mean (SD)	50.68 (9.82)	N/A	50.93 (9.63)
LS Mean of Change from Baseline (SE)	-0.34 (0.76)	NE	-0.04 (0.77)
95% CI	(-1.83, 1.15)	NE	(-1.57, 1.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.30 (1.04)	NE	
95% CI	(-2.34, 1.75)	NE	
p-value	0.7740	NE	
Corrected Hedge's g Statistics	-0.042	NE	
95% CI	(-0.34, 0.26)	NE	
Subgroup*Treatment Interaction p-value	0.6900	NE	

AMNOG Table SE22.5.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Physical Component Score			
Week 24			
m	110	0	111
n	102	0	96
Baseline Mean (SD)	47.70 (9.43)	N/A	48.38 (8.89)
Analysis Visit Mean (SD)	47.59 (10.20)	N/A	48.74 (10.11)
LS Mean of Change from Baseline (SE)	-0.01 (0.65)	NE	0.42 (0.66)
95% CI	(-1.28, 1.27)	NE	(-0.87, 1.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.43 (0.88)	NE	
95% CI	(-2.17, 1.31)	NE	
p-value	0.6256	NE	
Corrected Hedge's g Statistics	-0.066	NE	
95% CI	(-0.35, 0.21)	NE	
Week 52			
m	103	0	105
n	90	0	83
Baseline Mean (SD)	47.78 (9.72)	N/A	48.17 (8.64)
Analysis Visit Mean (SD)	48.21 (11.13)	N/A	49.29 (8.56)
LS Mean of Change from Baseline (SE)	0.58 (0.65)	NE	1.36 (0.66)
95% CI	(-0.70, 1.85)	NE	(0.06, 2.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.78 (0.88)	NE	
95% CI	(-2.53, 0.96)	NE	
p-value	0.3765	NE	
Corrected Hedge's g Statistics	-0.128	NE	
95% CI	(-0.43, 0.17)	NE	
Subgroup*Treatment Interaction p-value	0.4755	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (15.4)	18 (11.9)	19 (10.2)
No	44 (84.6)	133 (88.1)	167 (89.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.84	
95% CI of the inverse odds ratio	(0.26, 1.52)	(0.42, 1.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.86	
95% CI of the inverse risk ratio	(0.31, 1.43)	(0.47, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.17	1.71	
95% CI of the absolute risk difference	(-5.56, 15.90)	(-5.05, 8.46)	
p-value	0.2987	0.6185	
p-value of Breslow-Day Test for Homogeneity [3]	0.2105	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (32.7)	48 (31.8)	44 (23.7)
No	35 (67.3)	103 (68.2)	142 (76.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.66	
95% CI of the inverse odds ratio	(0.33, 1.25)	(0.41, 1.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.74	
95% CI of the inverse risk ratio	(0.45, 1.16)	(0.53, 1.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.04	8.13	
95% CI of the absolute risk difference	(-5.10, 23.17)	(-1.48, 17.75)	
p-value	0.1870	0.0956	
p-value of Breslow-Day Test for Homogeneity [3]	0.1895	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (7.7)	18 (11.9)	21 (11.3)
No	48 (92.3)	133 (88.1)	165 (88.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	0.94	
95% CI of the inverse odds ratio	(0.50, 4.66)	(0.48, 1.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	0.95	
95% CI of the inverse risk ratio	(0.53, 4.09)	(0.52, 1.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.60	0.63	
95% CI of the absolute risk difference	(-12.15, 4.95)	(-6.25, 7.51)	
p-value	0.4544	0.8573	
p-value of Breslow-Day Test for Homogeneity [3]	0.9420	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (17.3)	39 (25.8)	42 (22.6)
No	43 (82.7)	112 (74.2)	144 (77.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	0.84	
95% CI of the inverse odds ratio	(0.63, 3.09)	(0.51, 1.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	0.87	
95% CI of the inverse risk ratio	(0.68, 2.50)	(0.60, 1.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.27	3.25	
95% CI of the absolute risk difference	(-17.18, 6.64)	(-5.96, 12.46)	
p-value	0.4127	0.4878	
p-value of Breslow-Day Test for Homogeneity [3]	0.3773	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (9.6)	26 (17.2)	30 (16.1)
No	47 (90.4)	125 (82.8)	156 (83.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.81	0.92	
95% CI of the inverse odds ratio	(0.66, 4.92)	(0.52, 1.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.68	0.94	
95% CI of the inverse risk ratio	(0.69, 4.11)	(0.58, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.51	1.09	
95% CI of the absolute risk difference	(-16.11, 3.09)	(-6.92, 9.10)	
p-value	0.2410	0.7893	
p-value of Breslow-Day Test for Homogeneity [3]	0.8694	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (25.0)	46 (30.5)	50 (26.9)
No	39 (75.0)	105 (69.5)	136 (73.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	0.84	
95% CI of the inverse odds ratio	(0.54, 2.24)	(0.52, 1.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.88	
95% CI of the inverse risk ratio	(0.63, 1.82)	(0.63, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.88	3.58	
95% CI of the absolute risk difference	(-15.26, 11.50)	(-6.14, 13.30)	
p-value	0.7857	0.4688	
p-value of Breslow-Day Test for Homogeneity [3]	0.8207	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (9.6)	28 (18.5)	27 (14.5)
No	47 (90.4)	123 (81.5)	159 (85.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.60	0.75	
95% CI of the inverse odds ratio	(0.58, 4.37)	(0.42, 1.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	0.78	
95% CI of the inverse risk ratio	(0.61, 3.73)	(0.48, 1.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.90	4.03	
95% CI of the absolute risk difference	(-14.38, 4.58)	(-3.98, 12.03)	
p-value	0.3598	0.3198	
p-value of Breslow-Day Test for Homogeneity [3]	0.3232	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (17.3)	53 (35.1)	59 (31.7)
No	43 (82.7)	98 (64.9)	127 (68.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.22	0.86	
95% CI of the inverse odds ratio	(1.02, 4.85)	(0.54, 1.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.83	0.90	
95% CI of the inverse risk ratio	(0.98, 3.44)	(0.67, 1.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.41	3.38	
95% CI of the absolute risk difference	(-26.68, -2.15)	(-6.75, 13.51)	
p-value	0.0420	0.5126	
p-value of Breslow-Day Test for Homogeneity [3]	0.0182	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (5.8)	14 (9.3)	23 (12.4)
No	49 (94.2)	137 (90.7)	163 (87.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.30	1.38	
95% CI of the inverse odds ratio	(0.66, 8.00)	(0.68, 2.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.14	1.33	
95% CI of the inverse risk ratio	(0.67, 6.86)	(0.71, 2.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.60	-3.09	
95% CI of the absolute risk difference	(-14.50, 1.31)	(-9.71, 3.52)	
p-value	0.1777	0.3663	
p-value of Breslow-Day Test for Homogeneity [3]	0.2538	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (26.9)	44 (29.1)	61 (32.8)
No	38 (73.1)	107 (70.9)	125 (67.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	1.19	
95% CI of the inverse odds ratio	(0.67, 2.63)	(0.74, 1.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	1.13	
95% CI of the inverse risk ratio	(0.74, 1.99)	(0.82, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.87	-3.66	
95% CI of the absolute risk difference	(-19.69, 7.94)	(-13.56, 6.25)	
p-value	0.4203	0.4710	
p-value of Breslow-Day Test for Homogeneity [3]	0.6129	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (7.7)	23 (15.2)	15 (8.1)
No	48 (92.3)	128 (84.8)	171 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.49	
95% CI of the inverse odds ratio	(0.33, 3.32)	(0.24, 0.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.53	
95% CI of the inverse risk ratio	(0.36, 3.02)	(0.29, 0.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.37	7.17	
95% CI of the absolute risk difference	(-8.60, 7.86)	(0.23, 14.11)	
p-value	0.9302	0.0386	
p-value of Breslow-Day Test for Homogeneity [3]	0.9529	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (17.3)	35 (23.2)	31 (16.7)
No	43 (82.7)	116 (76.8)	155 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.66	
95% CI of the inverse odds ratio	(0.42, 2.16)	(0.39, 1.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.72	
95% CI of the inverse risk ratio	(0.49, 1.89)	(0.47, 1.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.64	6.51	
95% CI of the absolute risk difference	(-10.95, 12.23)	(-2.09, 15.11)	
p-value	0.9130	0.1341	
p-value of Breslow-Day Test for Homogeneity [3]	0.9638	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (5.8)	30 (19.9)	20 (10.8)
No	49 (94.2)	121 (80.1)	166 (89.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.97	0.49	
95% CI of the inverse odds ratio	(0.56, 6.90)	(0.26, 0.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.86	0.54	
95% CI of the inverse risk ratio	(0.58, 6.03)	(0.32, 0.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.98	9.11	
95% CI of the absolute risk difference	(-12.73, 2.76)	(1.35, 16.88)	
p-value	0.2823	0.0192	
p-value of Breslow-Day Test for Homogeneity [3]	0.4465	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (9.6)	40 (26.5)	29 (15.6)
No	47 (90.4)	111 (73.5)	157 (84.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.74	0.51	
95% CI of the inverse odds ratio	(0.64, 4.74)	(0.30, 0.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	0.59	
95% CI of the inverse risk ratio	(0.66, 3.98)	(0.38, 0.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.98	10.90	
95% CI of the absolute risk difference	(-15.54, 3.58)	(2.14, 19.66)	
p-value	0.2763	0.0137	
p-value of Breslow-Day Test for Homogeneity [3]	0.2595	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (7.7)	14 (9.3)	22 (11.8)
No	48 (92.3)	137 (90.7)	164 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.61	1.31	
95% CI of the inverse odds ratio	(0.53, 4.90)	(0.65, 2.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.54	1.28	
95% CI of the inverse risk ratio	(0.55, 4.26)	(0.68, 2.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.14	-2.56	
95% CI of the absolute risk difference	(-12.74, 4.47)	(-9.11, 4.00)	
p-value	0.3980	0.4499	
p-value of Breslow-Day Test for Homogeneity [3]	0.6765	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (32.7)	41 (27.2)	43 (23.1)
No	35 (67.3)	110 (72.8)	143 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.81	
95% CI of the inverse odds ratio	(0.32, 1.21)	(0.49, 1.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.85	
95% CI of the inverse risk ratio	(0.44, 1.13)	(0.59, 1.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.57	4.03	
95% CI of the absolute risk difference	(-4.54, 23.69)	(-5.29, 13.36)	
p-value	0.1598	0.3946	
p-value of Breslow-Day Test for Homogeneity [3]	0.3027	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.8)	13 (8.6)	10 (5.4)
No	50 (96.2)	138 (91.4)	176 (94.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	0.60	
95% CI of the inverse odds ratio	(0.30, 6.69)	(0.26, 1.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	0.62	
95% CI of the inverse risk ratio	(0.32, 6.18)	(0.28, 1.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.53	3.23	
95% CI of the absolute risk difference	(-7.68, 4.62)	(-2.29, 8.76)	
p-value	0.6557	0.2418	
p-value of Breslow-Day Test for Homogeneity [3]	0.9883	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (17.3)	27 (17.9)	34 (18.3)
No	43 (82.7)	124 (82.1)	152 (81.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.03	
95% CI of the inverse odds ratio	(0.48, 2.40)	(0.59, 1.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.02	
95% CI of the inverse risk ratio	(0.54, 2.06)	(0.65, 1.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.97	-0.40	
95% CI of the absolute risk difference	(-12.66, 10.71)	(-8.66, 7.86)	
p-value	0.8721	0.9247	
p-value of Breslow-Day Test for Homogeneity [3]	0.8623	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.8)	12 (7.9)	10 (5.4)
No	50 (96.2)	139 (92.1)	176 (94.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	0.66	
95% CI of the inverse odds ratio	(0.30, 6.69)	(0.28, 1.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	0.68	
95% CI of the inverse risk ratio	(0.32, 6.18)	(0.30, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.53	2.57	
95% CI of the absolute risk difference	(-7.68, 4.62)	(-2.83, 7.97)	
p-value	0.6557	0.3421	
p-value of Breslow-Day Test for Homogeneity [3]	0.5637	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (19.2)	41 (27.2)	36 (19.4)
No	42 (80.8)	110 (72.8)	150 (80.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.64	
95% CI of the inverse odds ratio	(0.46, 2.20)	(0.39, 1.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.71	
95% CI of the inverse risk ratio	(0.54, 1.89)	(0.48, 1.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.12	7.80	
95% CI of the absolute risk difference	(-12.25, 12.00)	(-1.29, 16.88)	
p-value	0.9840	0.0900	
p-value of Breslow-Day Test for Homogeneity [3]	0.8733	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (12.2)	0	18 (15.4)
No	101 (87.8)	0	99 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	NE	
95% CI of the inverse odds ratio	(0.62, 2.78)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	NE	
95% CI of the inverse risk ratio	(0.66, 2.42)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.21	NE	
95% CI of the absolute risk difference	(-12.07, 5.65)	NE	
p-value	0.4783	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2105	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	38 (33.0)	0	42 (35.9)
No	77 (67.0)	0	75 (64.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	NE	
95% CI of the inverse odds ratio	(0.66, 1.95)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	NE	
95% CI of the inverse risk ratio	(0.76, 1.55)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.85	NE	
95% CI of the absolute risk difference	(-15.08, 9.37)	NE	
p-value	0.6475	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1895	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (9.6)	0	17 (14.5)
No	104 (90.4)	0	100 (85.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.61	NE	
95% CI of the inverse odds ratio	(0.72, 3.60)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	NE	
95% CI of the inverse risk ratio	(0.74, 3.10)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.96	NE	
95% CI of the absolute risk difference	(-13.31, 3.38)	NE	
p-value	0.2458	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9420	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	31 (27.0)	0	29 (24.8)
No	84 (73.0)	0	88 (75.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	NE	
95% CI of the inverse odds ratio	(0.50, 1.61)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	NE	
95% CI of the inverse risk ratio	(0.59, 1.42)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.17	NE	
95% CI of the absolute risk difference	(-9.10, 13.44)	NE	
p-value	0.7058	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3773	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (13.0)	0	23 (19.7)
No	100 (87.0)	0	94 (80.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.63	NE	
95% CI of the inverse odds ratio	(0.80, 3.31)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	NE	
95% CI of the inverse risk ratio	(0.83, 2.74)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.61	NE	
95% CI of the absolute risk difference	(-16.09, 2.86)	NE	
p-value	0.1735	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8694	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (23.5)	0	32 (27.4)
No	88 (76.5)	0	85 (72.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	NE	
95% CI of the inverse odds ratio	(0.68, 2.22)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	NE	
95% CI of the inverse risk ratio	(0.75, 1.81)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.87	NE	
95% CI of the absolute risk difference	(-15.06, 7.32)	NE	
p-value	0.4983	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8207	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	20 (17.4)	0	18 (15.4)
No	95 (82.6)	0	99 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	NE	
95% CI of the inverse odds ratio	(0.43, 1.73)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.49, 1.58)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.01	NE	
95% CI of the absolute risk difference	(-7.52, 11.53)	NE	
p-value	0.6797	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3232	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	41 (35.7)	0	33 (28.2)
No	74 (64.3)	0	84 (71.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	NE	
95% CI of the inverse odds ratio	(0.41, 1.23)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	NE	
95% CI of the inverse risk ratio	(0.54, 1.16)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.45	NE	
95% CI of the absolute risk difference	(-4.52, 19.41)	NE	
p-value	0.2237	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0182	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (11.3)	0	13 (11.1)
No	102 (88.7)	0	104 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	NE	
95% CI of the inverse odds ratio	(0.43, 2.22)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	NE	
95% CI of the inverse risk ratio	(0.48, 2.03)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.19	NE	
95% CI of the absolute risk difference	(-7.93, 8.31)	NE	
p-value	0.9628	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2538	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	36 (31.3)	0	38 (32.5)
No	79 (68.7)	0	79 (67.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	NE	
95% CI of the inverse odds ratio	(0.61, 1.83)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	NE	
95% CI of the inverse risk ratio	(0.71, 1.51)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.17	NE	
95% CI of the absolute risk difference	(-13.17, 10.82)	NE	
p-value	0.8478	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6129	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (7.8)	0	10 (8.5)
No	106 (92.2)	0	107 (91.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	NE	
95% CI of the inverse odds ratio	(0.43, 2.82)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	NE	
95% CI of the inverse risk ratio	(0.46, 2.59)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.72	NE	
95% CI of the absolute risk difference	(-7.78, 6.33)	NE	
p-value	0.8413	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9529	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (18.3)	0	21 (17.9)
No	94 (81.7)	0	96 (82.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	NE	
95% CI of the inverse odds ratio	(0.50, 1.91)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	NE	
95% CI of the inverse risk ratio	(0.57, 1.70)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.31	NE	
95% CI of the absolute risk difference	(-9.60, 10.22)	NE	
p-value	0.9508	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9638	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (13.9)	0	18 (15.4)
No	99 (86.1)	0	99 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	NE	
95% CI of the inverse odds ratio	(0.54, 2.33)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	NE	
95% CI of the inverse risk ratio	(0.59, 2.06)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.47	NE	
95% CI of the absolute risk difference	(-10.57, 7.63)	NE	
p-value	0.7513	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4465	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (20.9)	0	22 (18.8)
No	91 (79.1)	0	95 (81.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse odds ratio	(0.46, 1.68)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	NE	
95% CI of the inverse risk ratio	(0.54, 1.51)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.07	NE	
95% CI of the absolute risk difference	(-8.20, 12.33)	NE	
p-value	0.6931	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2595	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (13.0)	0	18 (15.4)
No	100 (87.0)	0	99 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	NE	
95% CI of the inverse odds ratio	(0.58, 2.54)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	NE	
95% CI of the inverse risk ratio	(0.63, 2.23)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.34	NE	
95% CI of the absolute risk difference	(-11.32, 6.64)	NE	
p-value	0.6098	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6765	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	40 (34.8)	0	40 (34.2)
No	75 (65.2)	0	77 (65.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	NE	
95% CI of the inverse odds ratio	(0.57, 1.67)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	NE	
95% CI of the inverse risk ratio	(0.69, 1.40)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.59	NE	
95% CI of the absolute risk difference	(-11.64, 12.83)	NE	
p-value	0.9241	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3027	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.3)	0	7 (6.0)
No	110 (95.7)	0	110 (94.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	NE	
95% CI of the inverse odds ratio	(0.43, 4.55)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	NE	
95% CI of the inverse risk ratio	(0.45, 4.21)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.64	NE	
95% CI of the absolute risk difference	(-7.32, 4.05)	NE	
p-value	0.5740	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9883	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (24.3)	0	28 (23.9)
No	87 (75.7)	0	89 (76.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	NE	
95% CI of the inverse odds ratio	(0.54, 1.78)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	NE	
95% CI of the inverse risk ratio	(0.62, 1.55)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.42	NE	
95% CI of the absolute risk difference	(-10.60, 11.43)	NE	
p-value	0.9410	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8623	NE	

AMNOG Table SE22.5.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.3)	0	4 (3.4)
No	110 (95.7)	0	113 (96.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	NE	
95% CI of the inverse odds ratio	(0.20, 2.98)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	NE	
95% CI of the inverse risk ratio	(0.22, 2.85)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.93	NE	
95% CI of the absolute risk difference	(-4.04, 5.90)	NE	
p-value	0.7141	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5637	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (21.7)	0	24 (20.5)
No	90 (78.3)	0	93 (79.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	NE	
95% CI of the inverse odds ratio	(0.49, 1.75)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	NE	
95% CI of the inverse risk ratio	(0.57, 1.55)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.23	NE	
95% CI of the absolute risk difference	(-9.28, 11.73)	NE	
p-value	0.8190	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8733	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Physical Functioning						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	82.14 (23.07)	N/A	68.57 (22.31)			
Median	90.00	N/A	65.00			
IQR: Q1, Q3	60.00, 100.00	N/A	45.00, 85.00			
Min, Max	40.0, 100.0	N/A	40.0, 100.0			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	73.33 (37.90)	N/A	72.86 (23.43)	-5.83 (6.51)	N/A	3.33 (4.41)
Median	90.00	N/A	80.00	-2.50	N/A	2.50
IQR: Q1, Q3	55.00, 100.00	N/A	50.00, 95.00	-10.00, 5.00	N/A	-5.00, 10.00
Min, Max	5.0, 100.0	N/A	35.0, 100.0	-35.0, 10.0	N/A	-10.0, 20.0
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	85.83 (22.23)	N/A	79.00 (9.62)	6.67 (6.67)	N/A	8.75 (3.75)
Median	97.50	N/A	80.00	5.00	N/A	10.00
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 85.00	0.00, 10.00	N/A	2.50, 15.00
Min, Max	45.0, 100.0	N/A	65.0, 90.0	-15.0, 35.0	N/A	0.0, 15.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Role Physical						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	73.23 (44.00)	N/A	70.56 (20.31)			
Median	100.00	N/A	62.50			
IQR: Q1, Q3	18.80, 100.00	N/A	56.30, 93.80			
Min, Max	0.0, 100.0	N/A	43.8, 100.0			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	73.97 (42.64)	N/A	73.21 (19.67)	5.20 (4.09)	N/A	2.07 (6.97)
Median	100.00	N/A	75.00	0	N/A	-3.15
IQR: Q1, Q3	43.80, 100.00	N/A	50.00, 87.50	0.00, 6.20	N/A	-12.50, 12.50
Min, Max	0.0, 100.0	N/A	50.0, 100.0	0.0, 25.0	N/A	-12.5, 31.2
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	83.35 (32.50)	N/A	63.78 (12.04)	14.58 (14.21)	N/A	-6.23 (5.71)
Median	100.00	N/A	62.50	3.10	N/A	-6.25
IQR: Q1, Q3	81.30, 100.00	N/A	56.30, 68.80	0.00, 18.80	N/A	-15.60, 3.15
Min, Max	18.8, 100.0	N/A	50.0, 81.3	-18.7, 81.2	N/A	-18.7, 6.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Bodily Pain						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	71.4 (39.6)	N/A	56.3 (17.5)			
Median	84.0	N/A	51.0			
IQR: Q1, Q3	32.0, 100.0	N/A	41.0, 74.0			
Min, Max	0, 100	N/A	41, 84			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	68.0 (36.8)	N/A	62.0 (24.1)	-1.3 (14.8)	N/A	8.2 (6.2)
Median	73.0	N/A	62.0	-11.0	N/A	13.0
IQR: Q1, Q3	62.0, 100.0	N/A	32.0, 74.0	-26.0, 0.0	N/A	-9.0, 21.0
Min, Max	0, 100	N/A	32, 100	-28, 68	N/A	-12, 23
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	76.3 (38.9)	N/A	60.4 (17.9)	7.0 (12.5)	N/A	8.3 (5.3)
Median	92.0	N/A	52.0	0	N/A	5.5
IQR: Q1, Q3	74.0, 100.0	N/A	51.0, 74.0	-10.0, 0.0	N/A	0.0, 16.5
Min, Max	0, 100	N/A	41, 84	-16, 68	N/A	0, 22

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
General Health						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	69.57 (27.32)	N/A	56.43 (18.82)			
Median	82.00	N/A	57.00			
IQR: Q1, Q3	67.00, 87.00	N/A	37.00, 67.00			
Min, Max	10.0, 87.0	N/A	35.0, 87.0			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	60.83 (29.73)	N/A	62.43 (12.03)	-6.67 (4.94)	N/A	4.50 (2.75)
Median	72.00	N/A	62.00	-5.00	N/A	5.00
IQR: Q1, Q3	42.00, 77.00	N/A	52.00, 72.00	-15.00, 5.00	N/A	0.00, 7.00
Min, Max	10.0, 92.0	N/A	50.0, 82.0	-25.0, 5.0	N/A	-5.0, 15.0
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	72.00 (18.97)	N/A	63.00 (8.94)	4.50 (7.21)	N/A	4.25 (1.49)
Median	77.00	N/A	62.00	2.50	N/A	5.00
IQR: Q1, Q3	67.00, 82.00	N/A	57.00, 72.00	-5.00, 20.00	N/A	2.50, 6.00
Min, Max	37.0, 92.0	N/A	52.0, 72.0	-20.0, 27.0	N/A	0.0, 7.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Vitality						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	57.16 (29.40)	N/A	60.71 (16.81)			
Median	56.30	N/A	62.50			
IQR: Q1, Q3	37.50, 87.50	N/A	50.00, 75.00			
Min, Max	6.3, 87.5	N/A	37.5, 87.5			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	56.27 (34.46)	N/A	62.53 (21.05)	-1.03 (6.74)	N/A	-1.02 (6.73)
Median	56.25	N/A	62.50	-3.10	N/A	-3.10
IQR: Q1, Q3	43.80, 81.30	N/A	56.30, 75.00	-6.30, 6.30	N/A	-6.20, 6.30
Min, Max	0.0, 100.0	N/A	25.0, 93.8	-25.0, 25.0	N/A	-25.0, 25.0
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	46.92 (16.65)	N/A	57.54 (11.19)	-10.38 (8.17)	N/A	-3.08 (7.86)
Median	46.90	N/A	56.30	-12.45	N/A	-6.20
IQR: Q1, Q3	43.80, 56.30	N/A	50.00, 68.80	-31.20, 12.50	N/A	-12.45, 6.30
Min, Max	18.8, 68.8	N/A	43.8, 68.8	-31.2, 12.5	N/A	-18.7, 18.8

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Social Functioning						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	82.14 (37.40)	N/A	76.79 (22.16)			
Median	100.00	N/A	87.50			
IQR: Q1, Q3	75.00, 100.00	N/A	50.00, 100.00			
Min, Max	0.0, 100.0	N/A	50.0, 100.0			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	72.92 (34.84)	N/A	76.79 (31.81)	-6.25 (5.35)	N/A	4.17 (7.68)
Median	87.50	N/A	87.50	-6.25	N/A	0
IQR: Q1, Q3	50.00, 100.00	N/A	37.50, 100.00	-12.50, 0.00	N/A	-12.50, 12.50
Min, Max	12.5, 100.0	N/A	25.0, 100.0	-25.0, 12.5	N/A	-12.5, 37.5
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	79.17 (30.28)	N/A	85.00 (20.54)	0.00 (9.68)	N/A	9.38 (5.98)
Median	93.75	N/A	87.50	0	N/A	6.25
IQR: Q1, Q3	62.50, 100.00	N/A	87.50, 100.00	-12.50, 25.00	N/A	0.00, 18.75
Min, Max	25.0, 100.0	N/A	50.0, 100.0	-37.5, 25.0	N/A	0.0, 25.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Role Emotional						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	91.67 (22.04)	N/A	90.47 (16.97)			
Median	100.00	N/A	100.00			
IQR: Q1, Q3	100.00, 100.00	N/A	75.00, 100.00			
Min, Max	41.7, 100.0	N/A	58.3, 100.0			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	75.00 (35.76)	N/A	82.14 (17.63)	-15.28 (10.64)	N/A	-8.33 (5.69)
Median	95.85	N/A	83.30	-4.15	N/A	-4.15
IQR: Q1, Q3	33.30, 100.00	N/A	75.00, 100.00	-16.70, 0.00	N/A	-25.00, 0.00
Min, Max	25.0, 100.0	N/A	50.0, 100.0	-66.7, 0.0	N/A	-25.0, 8.3
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	83.33 (19.01)	N/A	76.66 (14.92)	-6.95 (5.01)	N/A	-12.50 (7.22)
Median	87.50	N/A	75.00	-4.15	N/A	-12.50
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 75.00	-16.70, 0.00	N/A	-25.00, 0.00
Min, Max	50.0, 100.0	N/A	58.3, 100.0	-25.0, 8.3	N/A	-25.0, 0.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Mental Health						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	76.4 (21.9)	N/A	66.4 (18.6)			
Median	85.0	N/A	60.0			
IQR: Q1, Q3	60.0, 95.0	N/A	55.0, 85.0			
Min, Max	40, 100	N/A	40, 90			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	65.0 (28.8)	N/A	72.1 (18.9)	-13.3 (6.8)	N/A	5.8 (4.4)
Median	65.0	N/A	80.0	-12.5	N/A	2.5
IQR: Q1, Q3	50.0, 90.0	N/A	50.0, 90.0	-20.0, -5.0	N/A	0.0, 10.0
Min, Max	20, 100	N/A	45, 90	-40, 10	N/A	-5, 25
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	74.2 (19.9)	N/A	77.0 (11.5)	-4.2 (10.7)	N/A	7.5 (7.8)
Median	72.5	N/A	80.0	-5.0	N/A	2.5
IQR: Q1, Q3	65.0, 90.0	N/A	65.0, 85.0	-25.0, 5.0	N/A	-2.5, 17.5
Min, Max	45, 100	N/A	65, 90	-35, 40	N/A	-5, 30

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Mental Component Score						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	52.07 (10.86)	N/A	51.13 (8.21)			
Median	54.80	N/A	51.80			
IQR: Q1, Q3	49.20, 60.50	N/A	44.40, 56.50			
Min, Max	29.4, 60.9	N/A	37.6, 61.9			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	45.98 (14.62)	N/A	50.51 (9.14)	-6.57 (3.54)	N/A	-0.42 (2.75)
Median	48.90	N/A	54.80	-4.85	N/A	-2.15
IQR: Q1, Q3	32.30, 58.50	N/A	42.10, 59.10	-12.60, -2.00	N/A	-5.20, 2.70
Min, Max	25.0, 62.3	N/A	35.8, 59.3	-20.0, 4.9	N/A	-7.2, 11.5
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	47.53 (9.11)	N/A	51.02 (6.83)	-5.02 (3.95)	N/A	-0.53 (3.72)
Median	48.05	N/A	52.20	-3.75	N/A	-3.30
IQR: Q1, Q3	40.10, 57.10	N/A	45.90, 54.80	-15.50, 4.80	N/A	-5.10, 4.05
Min, Max	34.8, 57.1	N/A	42.6, 59.6	-17.3, 5.4	N/A	-5.9, 10.4

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Physical Component Score						
Baseline						
m	7	0	8			
n	7	0	7			
Mean (SD)	49.23 (13.73)	N/A	44.51 (7.68)			
Median	57.10	N/A	44.10			
IQR: Q1, Q3	35.00, 58.40	N/A	37.40, 48.30			
Min, Max	24.7, 59.2	N/A	35.1, 58.5			
Week 24						
m	6	0	7			
n	6	0	7	6	0	6
Mean (SD/SE)	49.08 (13.51)	N/A	46.99 (6.41)	1.52 (3.53)	N/A	2.32 (1.07)
Median	52.15	N/A	47.00	-0.50	N/A	2.55
IQR: Q1, Q3	50.40, 58.30	N/A	40.80, 49.20	-2.20, 0.70	N/A	0.30, 4.70
Min, Max	22.5, 59.0	N/A	39.0, 58.8	-6.7, 18.3	N/A	-1.3, 5.1
Week 52						
m	6	0	6			
n	6	0	5	6	0	4
Mean (SD/SE)	52.80 (12.36)	N/A	46.46 (3.05)	5.23 (4.05)	N/A	2.25 (0.79)
Median	56.45	N/A	46.90	4.65	N/A	2.05
IQR: Q1, Q3	48.70, 62.50	N/A	44.00, 49.00	2.80, 5.20	N/A	1.00, 3.50
Min, Max	29.9, 62.8	N/A	42.7, 49.7	-8.4, 22.5	N/A	0.7, 4.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Physical Functioning						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	79.56 (24.02)	N/A	76.75 (25.47)			
Median	90.00	N/A	85.00			
IQR: Q1, Q3	75.00, 95.00	N/A	65.00, 100.00			
Min, Max	15.0, 100.0	N/A	10.0, 100.0			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	80.11 (24.46)	N/A	80.27 (27.00)	0.91 (1.69)	N/A	4.13 (2.66)
Median	90.00	N/A	90.00	0	N/A	0
IQR: Q1, Q3	70.00, 100.00	N/A	75.00, 100.00	-7.50, 5.00	N/A	0.00, 10.00
Min, Max	5.0, 100.0	N/A	0.0, 100.0	-15.0, 30.0	N/A	-50.0, 75.0
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	79.27 (26.99)	N/A	80.26 (27.45)	0.51 (1.67)	N/A	4.60 (2.50)
Median	95.00	N/A	95.00	0	N/A	0
IQR: Q1, Q3	70.00, 100.00	N/A	70.00, 100.00	-5.00, 5.00	N/A	-2.50, 10.00
Min, Max	10.0, 100.0	N/A	0.0, 100.0	-20.0, 30.0	N/A	-35.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Role Physical						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	78.21 (26.70)	N/A	76.44 (26.64)			
Median	87.50	N/A	81.30			
IQR: Q1, Q3	68.80, 100.00	N/A	62.50, 100.00			
Min, Max	0.0, 100.0	N/A	0.0, 100.0			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	77.87 (29.06)	N/A	80.58 (24.60)	-0.29 (2.27)	N/A	4.08 (2.95)
Median	87.50	N/A	93.80	0	N/A	0
IQR: Q1, Q3	68.80, 100.00	N/A	68.80, 100.00	-6.25, 6.25	N/A	-6.20, 18.70
Min, Max	0.0, 100.0	N/A	6.3, 100.0	-31.3, 31.3	N/A	-56.2, 68.7
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	78.36 (27.28)	N/A	78.61 (25.45)	0.47 (2.05)	N/A	4.40 (3.44)
Median	87.50	N/A	81.30	0	N/A	0
IQR: Q1, Q3	68.80, 100.00	N/A	68.80, 100.00	0.00, 6.20	N/A	-6.30, 15.60
Min, Max	0.0, 100.0	N/A	0.0, 100.0	-31.3, 43.8	N/A	-37.5, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Bodily Pain						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	68.8 (24.0)	N/A	73.5 (24.3)			
Median	74.0	N/A	74.0			
IQR: Q1, Q3	51.0, 84.0	N/A	62.0, 100.0			
Min, Max	10, 100	N/A	12, 100			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	65.5 (26.8)	N/A	74.0 (24.0)	-2.6 (2.0)	N/A	-0.3 (2.5)
Median	72.0	N/A	74.0	0	N/A	0
IQR: Q1, Q3	41.0, 84.0	N/A	62.0, 100.0	-10.5, 0.0	N/A	-10.0, 11.5
Min, Max	0, 100	N/A	22, 100	-43, 28	N/A	-38, 59
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	68.0 (25.1)	N/A	69.9 (26.2)	-1.0 (2.4)	N/A	-4.2 (3.5)
Median	74.0	N/A	74.0	0	N/A	0
IQR: Q1, Q3	61.0, 84.0	N/A	51.0, 84.0	-10.0, 10.0	N/A	-19.0, 11.0
Min, Max	0, 100	N/A	10, 100	-40, 33	N/A	-49, 62

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
General Health						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	61.77 (20.55)	N/A	65.47 (20.88)			
Median	67.00	N/A	67.00			
IQR: Q1, Q3	45.00, 77.00	N/A	52.00, 82.00			
Min, Max	15.0, 97.0	N/A	15.0, 100.0			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	61.85 (20.72)	N/A	66.24 (20.76)	1.10 (1.83)	N/A	0.79 (2.37)
Median	58.50	N/A	67.00	1.60	N/A	0
IQR: Q1, Q3	52.00, 77.00	N/A	52.00, 87.00	-5.00, 10.00	N/A	-10.00, 10.00
Min, Max	20.0, 100.0	N/A	22.0, 100.0	-35.0, 25.0	N/A	-38.0, 48.0
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	61.51 (19.94)	N/A	66.49 (19.10)	1.29 (2.07)	N/A	2.05 (2.35)
Median	67.00	N/A	67.00	0	N/A	0
IQR: Q1, Q3	52.00, 77.00	N/A	57.00, 82.00	-10.00, 10.00	N/A	-5.00, 13.50
Min, Max	25.0, 100.0	N/A	20.0, 100.0	-27.0, 32.0	N/A	-28.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Vitality						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	58.77 (22.55)	N/A	64.90 (20.51)			
Median	62.50	N/A	68.80			
IQR: Q1, Q3	43.80, 75.00	N/A	56.30, 81.30			
Min, Max	0.0, 100.0	N/A	6.3, 100.0			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	58.04 (22.97)	N/A	65.13 (19.27)	0.14 (1.84)	N/A	0.40 (2.07)
Median	62.50	N/A	68.80	0	N/A	0
IQR: Q1, Q3	50.00, 68.80	N/A	50.00, 81.30	-6.30, 6.30	N/A	-9.40, 6.30
Min, Max	0.0, 100.0	N/A	25.0, 100.0	-31.2, 25.0	N/A	-37.5, 37.5
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	59.78 (23.76)	N/A	60.53 (23.06)	1.60 (2.44)	N/A	-4.50 (2.47)
Median	68.80	N/A	62.50	0	N/A	0
IQR: Q1, Q3	43.80, 75.00	N/A	50.00, 81.30	-6.30, 12.50	N/A	-6.30, 6.20
Min, Max	6.3, 100.0	N/A	6.3, 100.0	-31.3, 50.0	N/A	-43.7, 43.8

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Social Functioning						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	81.94 (26.32)	N/A	83.33 (23.19)			
Median	100.00	N/A	87.50			
IQR: Q1, Q3	62.50, 100.00	N/A	75.00, 100.00			
Min, Max	12.5, 100.0	N/A	12.5, 100.0			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	83.42 (25.28)	N/A	84.09 (21.71)	2.27 (2.41)	N/A	-0.24 (2.58)
Median	100.00	N/A	100.00	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 100.00	0.00, 0.00	N/A	-12.50, 0.00
Min, Max	12.5, 100.0	N/A	0.0, 100.0	-25.0, 75.0	N/A	-37.5, 75.0
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	80.18 (26.37)	N/A	83.24 (24.35)	-2.56 (1.96)	N/A	0.00 (2.76)
Median	100.00	N/A	100.00	0	N/A	0
IQR: Q1, Q3	62.50, 100.00	N/A	75.00, 100.00	0.00, 0.00	N/A	0.00, 0.00
Min, Max	12.5, 100.0	N/A	12.5, 100.0	-37.5, 12.5	N/A	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Role Emotional						
Baseline						
m	47	0	62			
n	45	0	56			
Mean (SD)	83.70 (23.70)	N/A	83.04 (23.41)			
Median	100.00	N/A	100.00			
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 100.00			
Min, Max	0.0, 100.0	N/A	0.0, 100.0			
Week 24						
m	46	0	59			
n	46	0	55	44	0	51
Mean (SD/SE)	82.79 (21.62)	N/A	85.30 (22.34)	-0.18 (2.23)	N/A	2.78 (2.57)
Median	95.85	N/A	100.00	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 100.00	0.00, 8.30	N/A	0.00, 8.30
Min, Max	25.0, 100.0	N/A	8.3, 100.0	-33.3, 41.7	N/A	-50.0, 58.3
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	84.55 (21.37)	N/A	82.80 (24.72)	1.93 (2.07)	N/A	-0.38 (2.83)
Median	100.00	N/A	100.00	0	N/A	0
IQR: Q1, Q3	75.00, 100.00	N/A	75.00, 100.00	0.00, 8.30	N/A	0.00, 4.15
Min, Max	25.0, 100.0	N/A	0.0, 100.0	-25.0, 41.7	N/A	-50.0, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Mental Health						
Baseline						
m	47	0	62			
n	45	0	57			
Mean (SD)	74.3 (18.9)	N/A	77.3 (16.2)			
Median	80.0	N/A	80.0			
IQR: Q1, Q3	65.0, 90.0	N/A	70.0, 90.0			
Min, Max	5, 100	N/A	5, 100			
Week 24						
m	46	0	59			
n	46	0	55	44	0	52
Mean (SD/SE)	73.8 (16.9)	N/A	77.5 (15.7)	0.2 (1.8)	N/A	0.1 (1.9)
Median	75.0	N/A	80.0	0	N/A	0
IQR: Q1, Q3	65.0, 90.0	N/A	70.0, 90.0	-5.0, 5.0	N/A	-5.0, 5.0
Min, Max	35, 100	N/A	35, 100	-30, 35	N/A	-30, 35
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	73.3 (19.4)	N/A	76.2 (19.6)	-0.6 (1.8)	N/A	-0.6 (2.5)
Median	75.0	N/A	80.0	0	N/A	0
IQR: Q1, Q3	60.0, 90.0	N/A	70.0, 90.0	-5.0, 5.0	N/A	-7.5, 5.0
Min, Max	25, 100	N/A	15, 100	-35, 20	N/A	-60, 50

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Mental Component Score						
Baseline						
m	47	0	62			
n	45	0	56			
Mean (SD)	50.43 (10.40)	N/A	52.05 (8.56)			
Median	52.30	N/A	54.00			
IQR: Q1, Q3	46.80, 57.80	N/A	49.20, 57.80			
Min, Max	12.0, 62.6	N/A	15.6, 65.8			
Week 24						
m	46	0	59			
n	46	0	55	44	0	51
Mean (SD/SE)	50.29 (9.26)	N/A	52.07 (8.78)	0.30 (0.87)	N/A	-0.02 (0.96)
Median	51.65	N/A	54.80	-0.05	N/A	-0.60
IQR: Q1, Q3	45.10, 57.70	N/A	47.40, 58.50	-2.45, 3.50	N/A	-3.10, 3.40
Min, Max	26.2, 64.6	N/A	26.0, 63.3	-12.2, 14.2	N/A	-17.3, 19.9
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	50.29 (10.29)	N/A	50.91 (10.27)	0.05 (0.83)	N/A	-1.16 (1.20)
Median	53.50	N/A	54.40	-0.10	N/A	0.35
IQR: Q1, Q3	43.30, 57.50	N/A	45.20, 58.30	-2.20, 3.50	N/A	-4.45, 2.15
Min, Max	25.1, 63.2	N/A	21.0, 62.9	-16.0, 14.9	N/A	-25.1, 24.1

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Physical Component Score						
Baseline						
m	47	0	62			
n	45	0	56			
Mean (SD)	49.06 (9.18)	N/A	49.39 (8.90)			
Median	51.40	N/A	50.15			
IQR: Q1, Q3	44.50, 56.10	N/A	43.75, 56.90			
Min, Max	21.1, 59.3	N/A	29.6, 61.2			
Week 24						
m	46	0	59			
n	46	0	55	44	0	51
Mean (SD/SE)	48.83 (10.53)	N/A	50.26 (8.98)	-0.09 (0.67)	N/A	0.90 (0.95)
Median	52.15	N/A	52.80	0.35	N/A	0.10
IQR: Q1, Q3	41.90, 57.20	N/A	46.40, 57.00	-3.10, 3.15	N/A	-2.80, 3.70
Min, Max	21.8, 63.9	N/A	25.7, 62.0	-9.6, 9.1	N/A	-15.1, 22.9
Week 52						
m	44	0	56			
n	41	0	47	39	0	44
Mean (SD/SE)	48.98 (10.58)	N/A	49.82 (8.44)	0.12 (0.69)	N/A	1.04 (0.95)
Median	52.40	N/A	51.90	-0.40	N/A	0.30
IQR: Q1, Q3	44.20, 57.20	N/A	45.20, 56.50	-1.40, 2.70	N/A	-3.00, 4.20
Min, Max	23.4, 62.7	N/A	24.6, 61.7	-9.6, 11.8	N/A	-10.4, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Physical Functioning						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	71.96 (23.70)	69.96 (25.79)	74.03 (25.37)			
Median	75.00	75.00	82.50			
IQR: Q1, Q3	55.00, 90.00	55.00, 90.00	60.00, 95.00			
Min, Max	0.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	73.90 (23.53)	71.56 (24.59)	73.52 (27.66)	2.05 (1.79)	1.05 (1.78)	-0.88 (1.24)
Median	80.00	80.00	85.00	0	0	0
IQR: Q1, Q3	55.00, 95.00	60.00, 90.00	55.00, 95.00	-5.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	10.0, 100.0	5.0, 100.0	0.0, 100.0	-50.0, 60.0	-65.0, 70.0	-70.0, 65.0
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	74.72 (26.71)	71.11 (26.04)	75.49 (23.97)	1.32 (1.85)	0.51 (1.69)	-0.48 (1.19)
Median	85.00	80.00	85.00	0	0	0
IQR: Q1, Q3	55.00, 95.00	55.00, 90.00	60.00, 95.00	-5.00, 10.00	-5.00, 5.00	-10.00, 5.00
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-65.0, 45.0	-85.0, 40.0	-60.0, 70.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Role Physical						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	74.89 (24.65)	73.11 (27.01)	76.00 (26.15)			
Median	78.15	75.00	81.30			
IQR: Q1, Q3	56.30, 100.00	50.00, 100.00	56.30, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	72.93 (24.96)	73.73 (24.05)	74.86 (28.09)	-1.98 (1.97)	-0.25 (1.88)	-1.57 (1.44)
Median	75.00	75.00	81.30	0	0	0
IQR: Q1, Q3	56.30, 100.00	56.30, 100.00	56.30, 100.00	-12.50, 12.50	-12.50, 6.30	-6.30, 6.20
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.8, 50.0	-56.2, 68.7	-68.7, 87.5
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	74.52 (27.95)	73.92 (26.36)	75.08 (25.04)	-1.99 (2.00)	0.69 (2.03)	-2.32 (1.46)
Median	81.30	78.15	81.30	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 100.00	50.00, 100.00	-12.50, 6.20	-6.30, 6.30	-12.50, 6.20
Min, Max	0.0, 100.0	6.3, 100.0	6.3, 100.0	-43.8, 56.2	-75.0, 81.3	-62.5, 68.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Bodily Pain						
Baseline						
m	113	151	233			
n	105	138	216			
Mean (SD)	65.6 (23.5)	62.1 (26.2)	63.6 (25.2)			
Median	64.0	62.0	62.0			
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	41.0, 84.0			
Min, Max	22, 100	0, 100	0, 100			
Week 24						
m	109	141	223			
n	105	136	205	100	126	191
Mean (SD/SE)	63.3 (24.3)	64.5 (24.1)	64.1 (25.7)	-2.3 (2.2)	0.8 (1.8)	0.2 (1.5)
Median	62.0	62.0	62.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	41.5, 84.0	41.0, 84.0	-18.0, 10.0	-10.0, 10.0	-12.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-59, 52	-62, 72	-78, 78
Week 52						
m	99	125	208			
n	89	114	187	84	109	175
Mean (SD/SE)	67.1 (25.3)	67.2 (25.6)	67.1 (24.7)	0.2 (2.4)	5.0 (2.1)	2.6 (1.6)
Median	72.0	72.0	72.0	0	0	0
IQR: Q1, Q3	51.0, 84.0	42.0, 84.0	51.0, 84.0	-10.0, 10.0	-9.0, 12.0	-10.0, 16.0
Min, Max	0, 100	10, 100	0, 100	-80, 59	-53, 69	-78, 78

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
General Health						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	59.33 (19.08)	54.11 (19.18)	57.13 (19.96)			
Median	58.50	52.00	57.00			
IQR: Q1, Q3	47.00, 72.00	40.00, 67.00	42.00, 72.00			
Min, Max	10.0, 100.0	10.0, 100.0	15.0, 100.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	60.40 (20.69)	55.10 (19.41)	57.30 (21.59)	1.39 (1.52)	1.34 (1.40)	0.52 (1.03)
Median	60.00	52.00	57.00	0	0	0
IQR: Q1, Q3	45.00, 77.00	40.00, 69.50	42.00, 77.00	-5.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	10.0, 100.0	10.0, 100.0	0.0, 100.0	-60.0, 32.0	-35.0, 40.0	-40.0, 40.0
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	62.74 (19.93)	55.94 (19.21)	59.00 (21.16)	1.38 (1.72)	2.17 (1.65)	1.26 (1.02)
Median	67.00	56.00	62.00	0	3.00	0
IQR: Q1, Q3	47.00, 77.00	45.00, 72.00	45.00, 77.00	-9.50, 10.00	-10.00, 15.00	-5.00, 10.00
Min, Max	20.0, 100.0	10.0, 92.0	10.0, 100.0	-70.0, 47.0	-52.0, 47.0	-42.0, 37.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Vitality						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	56.88 (22.10)	53.69 (22.42)	54.22 (21.48)			
Median	62.50	56.30	56.30			
IQR: Q1, Q3	37.50, 75.00	37.50, 68.80	37.50, 68.80			
Min, Max	12.5, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	55.92 (23.62)	53.75 (20.23)	54.57 (22.48)	-0.95 (1.57)	-0.45 (1.39)	0.10 (1.13)
Median	56.30	56.30	56.30	0	0	0
IQR: Q1, Q3	37.50, 75.00	37.50, 68.80	37.50, 68.80	-6.30, 6.30	-12.50, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.8, 43.8	-31.3, 43.8	-37.5, 56.2
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	58.94 (22.79)	54.85 (20.92)	56.68 (22.54)	-0.14 (1.64)	0.34 (1.46)	1.89 (1.34)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	43.80, 75.00	43.80, 68.80	43.80, 75.00	-6.30, 12.50	-6.30, 6.30	-6.30, 12.50
Min, Max	6.3, 100.0	6.3, 100.0	0.0, 100.0	-43.7, 37.5	-43.8, 43.8	-56.3, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Social Functioning						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	81.72 (21.70)	79.62 (25.77)	83.04 (22.35)			
Median	87.50	87.50	100.00			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	12.5, 100.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	80.48 (23.70)	81.71 (20.97)	80.55 (25.19)	-1.61 (2.32)	1.69 (1.82)	-2.16 (1.44)
Median	87.50	87.50	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	62.50, 100.00	-12.50, 12.50	0.00, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	12.5, 100.0	0.0, 100.0	-62.5, 62.5	-62.5, 87.5	-62.5, 50.0
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	82.44 (21.55)	81.80 (22.38)	82.82 (21.41)	-1.32 (2.04)	1.83 (2.17)	-0.86 (1.51)
Median	87.50	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00	-12.50, 12.50	0.00, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-50.0, 50.0	-62.5, 62.5	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Role Emotional						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	80.74 (25.21)	82.01 (23.70)	84.03 (22.28)			
Median	91.70	95.85	100.00			
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	8.3, 100.0			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	81.35 (23.13)	85.30 (20.65)	82.24 (24.68)	0.83 (1.80)	2.91 (1.42)	-1.70 (1.35)
Median	91.70	100.00	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	66.70, 100.00	-8.30, 0.00	0.00, 8.30	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-33.3, 66.7	-50.0, 50.0	-50.0, 50.0
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	82.82 (21.84)	84.87 (21.86)	83.15 (22.40)	0.83 (2.09)	3.29 (2.04)	-1.86 (1.40)
Median	91.70	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	0.00, 16.70	-8.40, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-50.0, 100.0	-75.0, 58.3	-58.3, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Mental Health						
Baseline						
m	113	151	233			
n	106	138	216			
Mean (SD)	73.3 (20.4)	74.9 (19.3)	74.9 (18.1)			
Median	80.0	80.0	80.0			
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	65.0, 90.0			
Min, Max	10, 100	15, 100	20, 100			
Week 24						
m	109	141	223			
n	105	136	205	101	126	191
Mean (SD/SE)	72.9 (20.7)	75.1 (18.9)	73.9 (19.7)	-0.3 (1.4)	-0.6 (1.1)	-0.4 (1.1)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	60.0, 90.0	65.0, 90.0	65.0, 90.0	-5.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	15, 100	5, 100	5, 100	-35, 35	-40, 50	-45, 55
Week 52						
m	99	125	208			
n	89	114	187	85	109	175
Mean (SD/SE)	76.2 (17.5)	75.5 (18.2)	75.5 (19.6)	1.4 (1.3)	0.2 (1.2)	0.6 (1.1)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	70.0, 90.0	-5.0, 10.0	-5.0, 5.0	-10.0, 10.0
Min, Max	30, 100	20, 100	0, 100	-20, 35	-30, 50	-40, 55

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Mental Component Score						
Baseline						
m	113	151	233			
n	105	138	216			
Mean (SD)	50.43 (11.09)	50.82 (11.01)	51.06 (9.57)			
Median	53.60	53.75	54.00			
IQR: Q1, Q3	45.70, 58.50	45.30, 58.30	45.80, 58.05			
Min, Max	12.9, 69.0	17.0, 72.3	25.9, 66.5			
Week 24						
m	109	141	223			
n	105	136	205	100	126	191
Mean (SD/SE)	50.10 (11.02)	51.44 (9.79)	50.32 (10.74)	-0.35 (0.77)	0.37 (0.61)	-0.51 (0.57)
Median	53.20	53.40	52.90	-0.50	-0.10	0
IQR: Q1, Q3	43.40, 58.50	46.65, 58.75	44.00, 58.20	-4.60, 3.35	-3.00, 3.40	-4.60, 3.20
Min, Max	18.7, 69.1	9.4, 71.2	14.2, 69.0	-20.0, 19.0	-24.5, 26.1	-24.6, 24.8
Week 52						
m	99	125	208			
n	89	114	187	84	109	175
Mean (SD/SE)	51.46 (9.28)	51.52 (9.70)	51.07 (10.28)	0.22 (0.81)	0.59 (0.78)	-0.03 (0.58)
Median	54.40	53.30	53.70	0.30	-0.10	0
IQR: Q1, Q3	44.30, 59.10	45.10, 58.40	46.60, 58.10	-3.70, 3.50	-3.70, 2.90	-3.70, 4.50
Min, Max	23.1, 62.4	17.8, 70.7	8.9, 68.0	-21.7, 26.2	-21.4, 25.2	-24.6, 26.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Physical Component Score						
Baseline						
m	113	151	233			
n	105	138	216			
Mean (SD)	47.06 (8.42)	45.11 (9.89)	46.52 (9.56)			
Median	47.80	46.15	48.35			
IQR: Q1, Q3	42.80, 52.90	39.50, 52.90	40.30, 54.55			
Min, Max	15.3, 60.8	21.2, 61.3	20.7, 65.2			
Week 24						
m	109	141	223			
n	105	136	205	100	126	191
Mean (SD/SE)	46.94 (8.92)	45.58 (8.94)	46.64 (10.32)	-0.07 (0.67)	0.24 (0.68)	-0.06 (0.51)
Median	48.70	46.40	49.50	0.15	-0.15	0
IQR: Q1, Q3	41.70, 53.10	38.90, 52.35	40.30, 54.80	-4.30, 4.45	-3.00, 3.50	-3.60, 3.20
Min, Max	12.5, 62.7	20.2, 61.0	19.0, 63.0	-17.2, 17.6	-22.1, 32.4	-28.8, 23.8
Week 52						
m	99	125	208			
n	89	114	187	84	109	175
Mean (SD/SE)	47.57 (10.22)	45.97 (9.85)	47.35 (9.45)	0.00 (0.77)	0.79 (0.72)	0.23 (0.46)
Median	49.30	47.80	48.20	0.40	1.50	0.20
IQR: Q1, Q3	41.80, 56.20	40.60, 53.10	41.30, 55.10	-2.35, 3.95	-2.70, 5.00	-2.90, 3.20
Min, Max	15.8, 59.9	16.0, 61.2	21.5, 63.9	-24.7, 15.9	-23.5, 18.6	-23.9, 20.5

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Physical Functioning			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	79.17 (23.75)	N/A	73.33 (20.17)
Analysis Visit Mean (SD)	73.33 (37.90)	N/A	76.67 (23.17)
LS Mean of Change from Baseline (SE)	-8.07 (5.41)	NE	4.33 (5.23)
95% CI	(-20.54, 4.40)	NE	(-7.73, 16.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-12.41 (7.54)	NE	
95% CI	(-29.80, 4.99)	NE	
p-value	0.1386	NE	
Corrected Hedge's g Statistics	-0.879	NE	
95% CI	(-2.06, 0.31)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	79.17 (23.75)	N/A	73.75 (13.15)
Analysis Visit Mean (SD)	85.83 (22.23)	N/A	82.50 (6.45)
LS Mean of Change from Baseline (SE)	6.20 (5.63)	NE	4.76 (6.11)
95% CI	(-6.79, 19.19)	NE	(-9.33, 18.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.43 (8.35)	NE	
95% CI	(-17.81, 20.68)	NE	
p-value	0.8678	NE	
Corrected Hedge's g Statistics	0.098	NE	
95% CI	(-1.17, 1.36)	NE	
Subgroup*Treatment Interaction p-value	0.1643	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Role Physical			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	68.77 (46.43)	N/A	75.02 (18.11)
Analysis Visit Mean (SD)	73.97 (42.64)	N/A	77.08 (18.40)
LS Mean of Change from Baseline (SE)	4.44 (6.26)	NE	2.81 (6.05)
95% CI	(-10.00, 18.88)	NE	(-11.15, 16.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.63 (8.73)	NE	
95% CI	(-18.50, 21.76)	NE	
p-value	0.8567	NE	
Corrected Hedge's g Statistics	0.100	NE	
95% CI	(-1.03, 1.23)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	68.77 (46.43)	N/A	73.45 (14.79)
Analysis Visit Mean (SD)	83.35 (32.50)	N/A	67.23 (10.68)
LS Mean of Change from Baseline (SE)	12.69 (10.63)	NE	5.61 (11.21)
95% CI	(-11.82, 37.19)	NE	(-20.24, 31.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.08 (15.48)	NE	
95% CI	(-28.61, 42.76)	NE	
p-value	0.6595	NE	
Corrected Hedge's g Statistics	0.258	NE	
95% CI	(-1.01, 1.53)	NE	
Subgroup*Treatment Interaction p-value	0.4146	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Bodily Pain			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	69.3 (43.0)	N/A	58.8 (17.7)
Analysis Visit Mean (SD)	68.0 (36.8)	N/A	67.0 (22.1)
LS Mean of Change from Baseline (SE)	-3.98 (10.30)	NE	6.00 (9.89)
95% CI	(-27.74, 19.78)	NE	(-16.80, 28.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-9.98 (14.43)	NE	
95% CI	(-43.26, 23.31)	NE	
p-value	0.5090	NE	
Corrected Hedge's g Statistics	-0.372	NE	
95% CI	(-1.51, 0.77)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	69.3 (43.0)	N/A	57.0 (14.2)
Analysis Visit Mean (SD)	76.3 (38.9)	N/A	65.3 (16.4)
LS Mean of Change from Baseline (SE)	3.37 (11.14)	NE	5.20 (11.35)
95% CI	(-22.31, 29.06)	NE	(-20.96, 31.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.83 (16.07)	NE	
95% CI	(-38.89, 35.23)	NE	
p-value	0.9121	NE	
Corrected Hedge's g Statistics	-0.064	NE	
95% CI	(-1.33, 1.20)	NE	
Subgroup*Treatment Interaction p-value	0.9776	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
General Health			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	67.50 (29.32)	N/A	60.00 (17.83)
Analysis Visit Mean (SD)	60.83 (29.73)	N/A	64.50 (11.73)
LS Mean of Change from Baseline (SE)	-6.45 (4.44)	NE	3.96 (4.34)
95% CI	(-16.70, 3.80)	NE	(-6.05, 13.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.41 (6.25)	NE	
95% CI	(-24.82, 4.01)	NE	
p-value	0.1345	NE	
Corrected Hedge's g Statistics	-0.893	NE	
95% CI	(-2.08, 0.29)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	67.50 (29.32)	N/A	59.00 (10.46)
Analysis Visit Mean (SD)	72.00 (18.97)	N/A	63.25 (10.31)
LS Mean of Change from Baseline (SE)	5.83 (4.47)	NE	2.19 (5.22)
95% CI	(-4.47, 16.13)	NE	(-9.86, 14.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.65 (6.94)	NE	
95% CI	(-12.36, 19.66)	NE	
p-value	0.6136	NE	
Corrected Hedge's g Statistics	0.306	NE	
95% CI	(-0.97, 1.58)	NE	
Subgroup*Treatment Interaction p-value	0.5495	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Vitality			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	57.30 (32.20)	N/A	64.58 (14.61)
Analysis Visit Mean (SD)	56.27 (34.46)	N/A	63.57 (22.86)
LS Mean of Change from Baseline (SE)	-4.17 (5.75)	NE	-1.13 (5.62)
95% CI	(-17.43, 9.09)	NE	(-14.09, 11.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.04 (8.08)	NE	
95% CI	(-21.66, 15.58)	NE	
p-value	0.7165	NE	
Corrected Hedge's g Statistics	-0.201	NE	
95% CI	(-1.34, 0.93)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	57.30 (32.20)	N/A	62.50 (10.21)
Analysis Visit Mean (SD)	46.92 (16.65)	N/A	59.43 (11.97)
LS Mean of Change from Baseline (SE)	-14.90 (6.11)	NE	-3.06 (7.23)
95% CI	(-29.00, -0.81)	NE	(-19.74, 13.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	-11.84 (9.49)	NE	
95% CI	(-33.72, 10.03)	NE	
p-value	0.2472	NE	
Corrected Hedge's g Statistics	-0.723	NE	
95% CI	(-2.03, 0.58)	NE	
Subgroup*Treatment Interaction p-value	0.7939	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Social Functioning			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	79.17 (40.05)	N/A	81.25 (20.54)
Analysis Visit Mean (SD)	72.92 (34.84)	N/A	85.42 (24.26)
LS Mean of Change from Baseline (SE)	-7.76 (6.28)	NE	4.33 (6.17)
95% CI	(-22.24, 6.73)	NE	(-9.89, 18.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	-12.08 (8.81)	NE	
95% CI	(-32.39, 8.23)	NE	
p-value	0.2073	NE	
Corrected Hedge's g Statistics	-0.731	NE	
95% CI	(-1.90, 0.44)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	79.17 (40.05)	N/A	84.38 (15.73)
Analysis Visit Mean (SD)	79.17 (30.28)	N/A	93.75 (7.22)
LS Mean of Change from Baseline (SE)	-1.90 (6.57)	NE	13.87 (7.74)
95% CI	(-17.06, 13.26)	NE	(-3.99, 31.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	-15.77 (10.17)	NE	
95% CI	(-39.22, 7.68)	NE	
p-value	0.1596	NE	
Corrected Hedge's g Statistics	-0.897	NE	
95% CI	(-2.22, 0.43)	NE	
Subgroup*Treatment Interaction p-value	0.5384	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Role Emotional			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	90.28 (23.80)	N/A	95.83 (10.21)
Analysis Visit Mean (SD)	75.00 (35.76)	N/A	87.50 (11.49)
LS Mean of Change from Baseline (SE)	-16.36 (9.43)	NE	-7.85 (9.36)
95% CI	(-38.09, 5.38)	NE	(-29.43, 13.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.51 (13.37)	NE	
95% CI	(-39.34, 22.32)	NE	
p-value	0.5421	NE	
Corrected Hedge's g Statistics	-0.342	NE	
95% CI	(-1.48, 0.80)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	90.28 (23.80)	N/A	93.75 (12.50)
Analysis Visit Mean (SD)	83.33 (19.01)	N/A	81.25 (12.50)
LS Mean of Change from Baseline (SE)	-8.59 (5.43)	NE	-11.83 (6.33)
95% CI	(-21.11, 3.92)	NE	(-26.43, 2.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.24 (8.36)	NE	
95% CI	(-16.03, 22.51)	NE	
p-value	0.7085	NE	
Corrected Hedge's g Statistics	0.224	NE	
95% CI	(-1.04, 1.49)	NE	
Subgroup*Treatment Interaction p-value	0.5558	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Mental Health			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	78.3 (23.4)	N/A	70.8 (15.9)
Analysis Visit Mean (SD)	65.0 (28.8)	N/A	76.7 (16.0)
LS Mean of Change from Baseline (SE)	-16.71 (4.46)	NE	5.40 (4.31)
95% CI	(-27.00, -6.43)	NE	(-4.54, 15.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-22.12 (6.33)	NE	
95% CI	(-36.72, -7.51)	NE	
p-value	0.0082	NE	
Corrected Hedge's g Statistics	-1.900	NE	
95% CI	(-3.26, -0.54)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	78.3 (23.4)	N/A	72.5 (17.6)
Analysis Visit Mean (SD)	74.2 (19.9)	N/A	80.0 (10.8)
LS Mean of Change from Baseline (SE)	-5.65 (6.40)	NE	5.72 (7.62)
95% CI	(-20.42, 9.12)	NE	(-11.84, 23.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	-11.37 (10.05)	NE	
95% CI	(-34.54, 11.79)	NE	
p-value	0.2904	NE	
Corrected Hedge's g Statistics	-0.662	NE	
95% CI	(-1.96, 0.64)	NE	
Subgroup*Treatment Interaction p-value	0.1459	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Mental Component Score			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	52.55 (11.81)	N/A	53.38 (6.18)
Analysis Visit Mean (SD)	45.98 (14.62)	N/A	52.97 (7.05)
LS Mean of Change from Baseline (SE)	-7.50 (3.13)	NE	-0.33 (3.08)
95% CI	(-14.73, -0.28)	NE	(-7.43, 6.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.18 (4.39)	NE	
95% CI	(-17.31, 2.96)	NE	
p-value	0.1411	NE	
Corrected Hedge's g Statistics	-0.871	NE	
95% CI	(-2.05, 0.31)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	52.55 (11.81)	N/A	53.65 (7.42)
Analysis Visit Mean (SD)	47.53 (9.11)	N/A	53.13 (5.71)
LS Mean of Change from Baseline (SE)	-6.15 (2.76)	NE	0.21 (3.25)
95% CI	(-12.52, 0.22)	NE	(-7.29, 7.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.37 (4.27)	NE	
95% CI	(-16.20, 3.47)	NE	
p-value	0.1740	NE	
Corrected Hedge's g Statistics	-0.862	NE	
95% CI	(-2.18, 0.46)	NE	
Subgroup*Treatment Interaction p-value	0.2949	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Physical Component Score			
Week 24			
m	6	0	7
n	6	0	6
Baseline Mean (SD)	47.57 (14.25)	N/A	45.70 (7.68)
Analysis Visit Mean (SD)	49.08 (13.51)	N/A	48.02 (6.36)
LS Mean of Change from Baseline (SE)	0.99 (2.79)	NE	2.10 (2.68)
95% CI	(-5.45, 7.42)	NE	(-4.08, 8.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.11 (3.87)	NE	
95% CI	(-10.04, 7.82)	NE	
p-value	0.7815	NE	
Corrected Hedge's g Statistics	-0.153	NE	
95% CI	(-1.29, 0.98)	NE	
Week 52			
m	6	0	6
n	6	0	4
Baseline Mean (SD)	47.57 (14.25)	N/A	45.15 (2.39)
Analysis Visit Mean (SD)	52.80 (12.36)	N/A	47.40 (2.56)
LS Mean of Change from Baseline (SE)	4.81 (3.03)	NE	1.76 (3.05)
95% CI	(-2.19, 11.80)	NE	(-5.28, 8.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.05 (4.31)	NE	
95% CI	(-6.89, 12.99)	NE	
p-value	0.4994	NE	
Corrected Hedge's g Statistics	0.395	NE	
95% CI	(-0.88, 1.67)	NE	
Subgroup*Treatment Interaction p-value	0.5699	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Physical Functioning			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	79.20 (24.18)	N/A	77.31 (26.30)
Analysis Visit Mean (SD)	80.11 (24.93)	N/A	81.44 (26.28)
LS Mean of Change from Baseline (SE)	0.43 (2.37)	NE	3.02 (2.22)
95% CI	(-4.26, 5.13)	NE	(-1.38, 7.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.59 (3.13)	NE	
95% CI	(-8.81, 3.63)	NE	
p-value	0.4102	NE	
Corrected Hedge's g Statistics	-0.162	NE	
95% CI	(-0.56, 0.24)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	78.46 (25.34)	N/A	76.70 (26.74)
Analysis Visit Mean (SD)	78.97 (27.44)	N/A	81.30 (26.09)
LS Mean of Change from Baseline (SE)	0.35 (2.22)	NE	4.69 (2.12)
95% CI	(-4.07, 4.76)	NE	(0.48, 8.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.34 (2.96)	NE	
95% CI	(-10.21, 1.53)	NE	
p-value	0.1455	NE	
Corrected Hedge's g Statistics	-0.307	NE	
95% CI	(-0.74, 0.13)	NE	
Subgroup*Treatment Interaction p-value	0.1643	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Role Physical			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	77.72 (26.80)	N/A	77.78 (27.23)
Analysis Visit Mean (SD)	77.43 (29.65)	N/A	81.87 (23.87)
LS Mean of Change from Baseline (SE)	0.46 (2.70)	NE	5.15 (2.55)
95% CI	(-4.91, 5.83)	NE	(0.10, 10.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.69 (3.59)	NE	
95% CI	(-11.82, 2.44)	NE	
p-value	0.1948	NE	
Corrected Hedge's g Statistics	-0.256	NE	
95% CI	(-0.66, 0.15)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	77.42 (27.78)	N/A	75.16 (29.08)
Analysis Visit Mean (SD)	77.89 (27.76)	N/A	79.56 (24.46)
LS Mean of Change from Baseline (SE)	1.97 (2.73)	NE	4.60 (2.61)
95% CI	(-3.45, 7.39)	NE	(-0.58, 9.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.63 (3.66)	NE	
95% CI	(-9.89, 4.63)	NE	
p-value	0.4743	NE	
Corrected Hedge's g Statistics	-0.151	NE	
95% CI	(-0.58, 0.28)	NE	
Subgroup*Treatment Interaction p-value	0.4146	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Bodily Pain			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	68.4 (24.2)	N/A	74.9 (24.6)
Analysis Visit Mean (SD)	65.9 (27.1)	N/A	74.6 (24.3)
LS Mean of Change from Baseline (SE)	-2.90 (2.43)	NE	0.45 (2.31)
95% CI	(-7.73, 1.93)	NE	(-4.14, 5.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.35 (3.26)	NE	
95% CI	(-9.81, 3.12)	NE	
p-value	0.3065	NE	
Corrected Hedge's g Statistics	-0.202	NE	
95% CI	(-0.60, 0.20)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	68.0 (24.9)	N/A	74.5 (24.5)
Analysis Visit Mean (SD)	67.0 (25.2)	N/A	70.3 (25.0)
LS Mean of Change from Baseline (SE)	-2.35 (3.00)	NE	-1.98 (2.87)
95% CI	(-8.32, 3.62)	NE	(-7.67, 3.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.37 (4.08)	NE	
95% CI	(-8.47, 7.73)	NE	
p-value	0.9277	NE	
Corrected Hedge's g Statistics	-0.019	NE	
95% CI	(-0.45, 0.41)	NE	
Subgroup*Treatment Interaction p-value	0.9776	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
General Health			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	61.09 (20.26)	N/A	65.98 (21.44)
Analysis Visit Mean (SD)	62.18 (21.13)	N/A	66.77 (21.15)
LS Mean of Change from Baseline (SE)	0.35 (2.20)	NE	0.99 (2.11)
95% CI	(-4.01, 4.71)	NE	(-3.19, 5.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.64 (2.95)	NE	
95% CI	(-6.50, 5.21)	NE	
p-value	0.8276	NE	
Corrected Hedge's g Statistics	-0.043	NE	
95% CI	(-0.44, 0.36)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	59.69 (20.92)	N/A	65.59 (22.17)
Analysis Visit Mean (SD)	60.97 (20.02)	N/A	67.64 (18.99)
LS Mean of Change from Baseline (SE)	-0.28 (2.13)	NE	3.40 (2.07)
95% CI	(-4.50, 3.94)	NE	(-0.71, 7.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.68 (2.88)	NE	
95% CI	(-9.39, 2.03)	NE	
p-value	0.2036	NE	
Corrected Hedge's g Statistics	-0.270	NE	
95% CI	(-0.70, 0.16)	NE	
Subgroup*Treatment Interaction p-value	0.5495	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Vitality			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	58.40 (22.68)	N/A	65.61 (19.27)
Analysis Visit Mean (SD)	58.55 (23.28)	N/A	66.01 (19.43)
LS Mean of Change from Baseline (SE)	-0.45 (2.09)	NE	0.90 (1.98)
95% CI	(-4.60, 3.70)	NE	(-3.02, 4.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.35 (2.80)	NE	
95% CI	(-6.90, 4.20)	NE	
p-value	0.6305	NE	
Corrected Hedge's g Statistics	-0.095	NE	
95% CI	(-0.50, 0.31)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	57.72 (23.93)	N/A	66.03 (19.64)
Analysis Visit Mean (SD)	59.32 (23.90)	N/A	61.53 (22.67)
LS Mean of Change from Baseline (SE)	1.26 (2.55)	NE	-2.35 (2.43)
95% CI	(-3.81, 6.32)	NE	(-7.16, 2.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.60 (3.47)	NE	
95% CI	(-3.29, 10.49)	NE	
p-value	0.3019	NE	
Corrected Hedge's g Statistics	0.223	NE	
95% CI	(-0.21, 0.66)	NE	
Subgroup*Treatment Interaction p-value	0.7939	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Social Functioning			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	81.53 (26.48)	N/A	84.13 (23.10)
Analysis Visit Mean (SD)	83.81 (25.23)	N/A	83.89 (21.91)
LS Mean of Change from Baseline (SE)	1.45 (2.45)	NE	-0.55 (2.31)
95% CI	(-3.42, 6.32)	NE	(-5.14, 4.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.00 (3.28)	NE	
95% CI	(-4.51, 8.51)	NE	
p-value	0.5431	NE	
Corrected Hedge's g Statistics	0.120	NE	
95% CI	(-0.28, 0.52)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	82.69 (26.22)	N/A	83.81 (24.79)
Analysis Visit Mean (SD)	80.13 (26.70)	N/A	83.81 (24.05)
LS Mean of Change from Baseline (SE)	-2.03 (2.45)	NE	-0.08 (2.36)
95% CI	(-6.89, 2.84)	NE	(-4.76, 4.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.95 (3.31)	NE	
95% CI	(-8.51, 4.61)	NE	
p-value	0.5565	NE	
Corrected Hedge's g Statistics	-0.125	NE	
95% CI	(-0.56, 0.31)	NE	
Subgroup*Treatment Interaction p-value	0.5384	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Role Emotional			
Week 24			
m	46	0	59
n	44	0	51
Baseline Mean (SD)	83.33 (23.85)	N/A	83.17 (24.01)
Analysis Visit Mean (SD)	83.14 (21.38)	N/A	85.95 (22.15)
LS Mean of Change from Baseline (SE)	-0.35 (2.34)	NE	2.12 (2.22)
95% CI	(-4.99, 4.30)	NE	(-2.30, 6.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.47 (3.12)	NE	
95% CI	(-8.66, 3.73)	NE	
p-value	0.4316	NE	
Corrected Hedge's g Statistics	-0.156	NE	
95% CI	(-0.56, 0.25)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	82.69 (25.03)	N/A	83.71 (23.84)
Analysis Visit Mean (SD)	84.62 (21.59)	N/A	83.33 (24.90)
LS Mean of Change from Baseline (SE)	1.85 (2.41)	NE	0.78 (2.31)
95% CI	(-2.93, 6.63)	NE	(-3.80, 5.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.07 (3.23)	NE	
95% CI	(-5.35, 7.48)	NE	
p-value	0.7419	NE	
Corrected Hedge's g Statistics	0.070	NE	
95% CI	(-0.36, 0.50)	NE	
Subgroup*Treatment Interaction p-value	0.5558	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Mental Health			
Week 24			
m	46	0	59
n	44	0	52
Baseline Mean (SD)	74.0 (19.0)	N/A	76.9 (16.6)
Analysis Visit Mean (SD)	74.2 (16.3)	N/A	77.0 (15.9)
LS Mean of Change from Baseline (SE)	-0.48 (1.84)	NE	-0.30 (1.74)
95% CI	(-4.14, 3.17)	NE	(-3.76, 3.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.18 (2.45)	NE	
95% CI	(-5.05, 4.68)	NE	
p-value	0.9407	NE	
Corrected Hedge's g Statistics	-0.015	NE	
95% CI	(-0.42, 0.39)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	73.7 (19.3)	N/A	76.8 (17.8)
Analysis Visit Mean (SD)	73.1 (19.1)	N/A	76.3 (19.7)
LS Mean of Change from Baseline (SE)	-1.10 (2.19)	NE	0.20 (2.08)
95% CI	(-5.44, 3.24)	NE	(-3.93, 4.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.31 (2.95)	NE	
95% CI	(-7.16, 4.55)	NE	
p-value	0.6582	NE	
Corrected Hedge's g Statistics	-0.094	NE	
95% CI	(-0.53, 0.34)	NE	
Subgroup*Treatment Interaction p-value	0.1459	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Mental Component Score			
Week 24			
m	46	0	59
n	44	0	51
Baseline Mean (SD)	50.26 (10.46)	N/A	51.99 (8.56)
Analysis Visit Mean (SD)	50.56 (8.71)	N/A	51.97 (8.94)
LS Mean of Change from Baseline (SE)	-0.09 (0.93)	NE	-0.23 (0.88)
95% CI	(-1.93, 1.75)	NE	(-1.98, 1.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.14 (1.24)	NE	
95% CI	(-2.32, 2.60)	NE	
p-value	0.9105	NE	
Corrected Hedge's g Statistics	0.022	NE	
95% CI	(-0.38, 0.43)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	50.23 (10.78)	N/A	52.20 (8.89)
Analysis Visit Mean (SD)	50.28 (10.29)	N/A	51.04 (10.45)
LS Mean of Change from Baseline (SE)	-0.03 (1.05)	NE	-0.75 (1.01)
95% CI	(-2.12, 2.06)	NE	(-2.75, 1.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.72 (1.42)	NE	
95% CI	(-2.11, 3.55)	NE	
p-value	0.6142	NE	
Corrected Hedge's g Statistics	0.108	NE	
95% CI	(-0.32, 0.54)	NE	
Subgroup*Treatment Interaction p-value	0.2949	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Physical Component Score			
Week 24			
m	46	0	59
n	44	0	51
Baseline Mean (SD)	48.88 (9.20)	N/A	49.95 (9.03)
Analysis Visit Mean (SD)	48.79 (10.62)	N/A	50.85 (8.74)
LS Mean of Change from Baseline (SE)	-0.18 (0.89)	NE	1.03 (0.85)
95% CI	(-1.94, 1.58)	NE	(-0.66, 2.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.20 (1.19)	NE	
95% CI	(-3.57, 1.16)	NE	
p-value	0.3134	NE	
Corrected Hedge's g Statistics	-0.200	NE	
95% CI	(-0.60, 0.20)	NE	
Week 52			
m	44	0	56
n	39	0	44
Baseline Mean (SD)	48.57 (9.49)	N/A	49.21 (9.33)
Analysis Visit Mean (SD)	48.69 (10.75)	N/A	50.25 (7.77)
LS Mean of Change from Baseline (SE)	0.03 (0.85)	NE	1.15 (0.82)
95% CI	(-1.65, 1.71)	NE	(-0.48, 2.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.12 (1.14)	NE	
95% CI	(-3.38, 1.15)	NE	
p-value	0.3299	NE	
Corrected Hedge's g Statistics	-0.206	NE	
95% CI	(-0.64, 0.23)	NE	
Subgroup*Treatment Interaction p-value	0.5699	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Physical Functioning			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	72.01 (23.46)	70.12 (26.00)	74.63 (25.51)
Analysis Visit Mean (SD)	74.06 (23.66)	71.17 (24.49)	73.75 (27.59)
LS Mean of Change from Baseline (SE)	2.38 (1.77)	0.42 (1.56)	-0.54 (1.28)
95% CI	(-1.10, 5.86)	(-2.65, 3.49)	(-3.05, 1.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.92 (2.12)	0.96 (1.97)	
95% CI	(-1.25, 7.09)	(-2.92, 4.84)	
p-value	0.1693	0.6273	
Corrected Hedge's g Statistics	0.165	0.054	
95% CI	(-0.08, 0.41)	(-0.17, 0.28)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	73.56 (21.62)	70.09 (26.21)	75.83 (24.17)
Analysis Visit Mean (SD)	74.88 (26.54)	70.61 (26.31)	75.35 (23.92)
LS Mean of Change from Baseline (SE)	1.80 (1.76)	0.51 (1.54)	-0.21 (1.24)
95% CI	(-1.67, 5.27)	(-2.52, 3.55)	(-2.64, 2.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.01 (2.09)	0.72 (1.93)	
95% CI	(-2.10, 6.12)	(-3.08, 4.52)	
p-value	0.3373	0.7098	
Corrected Hedge's g Statistics	0.123	0.044	
95% CI	(-0.14, 0.38)	(-0.20, 0.28)	
Subgroup*Treatment Interaction p-value	0.1643	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Role Physical			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	75.32 (24.30)	73.63 (27.29)	76.19 (26.38)
Analysis Visit Mean (SD)	73.34 (24.79)	73.38 (24.38)	74.62 (28.28)
LS Mean of Change from Baseline (SE)	-1.16 (1.93)	-0.89 (1.70)	-1.39 (1.39)
95% CI	(-4.95, 2.64)	(-4.23, 2.46)	(-4.12, 1.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.23 (2.31)	0.50 (2.15)	
95% CI	(-4.31, 4.77)	(-3.72, 4.72)	
p-value	0.9203	0.8157	
Corrected Hedge's g Statistics	0.012	0.026	
95% CI	(-0.23, 0.25)	(-0.20, 0.25)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	76.70 (25.02)	72.84 (27.95)	77.48 (24.67)
Analysis Visit Mean (SD)	74.72 (28.11)	73.53 (26.66)	75.16 (25.11)
LS Mean of Change from Baseline (SE)	-1.21 (2.01)	0.47 (1.76)	-1.64 (1.41)
95% CI	(-5.17, 2.75)	(-3.00, 3.94)	(-4.41, 1.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.43 (2.39)	2.11 (2.21)	
95% CI	(-4.27, 5.13)	(-2.22, 6.45)	
p-value	0.8578	0.3384	
Corrected Hedge's g Statistics	0.023	0.114	
95% CI	(-0.24, 0.28)	(-0.13, 0.35)	
Subgroup*Treatment Interaction p-value	0.4146	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Bodily Pain			
Week 24			
m	109	141	223
n	100	126	191
Baseline Mean (SD)	65.7 (23.0)	62.7 (26.3)	64.1 (24.9)
Analysis Visit Mean (SD)	63.4 (24.4)	63.5 (24.3)	64.3 (25.9)
LS Mean of Change from Baseline (SE)	-1.44 (1.97)	0.27 (1.73)	0.04 (1.41)
95% CI	(-5.31, 2.44)	(-3.12, 3.66)	(-2.74, 2.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.47 (2.35)	0.23 (2.17)	
95% CI	(-6.09, 3.14)	(-4.03, 4.50)	
p-value	0.5306	0.9148	
Corrected Hedge's g Statistics	-0.075	0.012	
95% CI	(-0.32, 0.17)	(-0.21, 0.24)	
Week 52			
m	99	125	208
n	84	109	175
Baseline Mean (SD)	67.0 (23.4)	61.3 (26.7)	64.7 (24.5)
Analysis Visit Mean (SD)	67.3 (25.4)	66.3 (25.7)	67.3 (24.6)
LS Mean of Change from Baseline (SE)	1.22 (2.15)	3.61 (1.87)	2.53 (1.50)
95% CI	(-3.01, 5.45)	(-0.08, 7.29)	(-0.42, 5.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.31 (2.55)	1.08 (2.34)	
95% CI	(-6.32, 3.70)	(-3.52, 5.68)	
p-value	0.6080	0.6452	
Corrected Hedge's g Statistics	-0.066	0.055	
95% CI	(-0.33, 0.19)	(-0.18, 0.29)	
Subgroup*Treatment Interaction p-value	0.9776	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
General Health			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	59.58 (18.43)	53.05 (18.71)	57.15 (19.85)
Analysis Visit Mean (SD)	60.97 (19.82)	54.39 (19.54)	57.66 (21.72)
LS Mean of Change from Baseline (SE)	2.08 (1.49)	-0.02 (1.32)	0.43 (1.07)
95% CI	(-0.85, 5.01)	(-2.61, 2.56)	(-1.68, 2.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.65 (1.78)	-0.45 (1.65)	
95% CI	(-1.84, 5.14)	(-3.70, 2.80)	
p-value	0.3540	0.7867	
Corrected Hedge's g Statistics	0.111	-0.030	
95% CI	(-0.13, 0.35)	(-0.26, 0.19)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	61.86 (18.76)	53.32 (19.65)	58.16 (20.13)
Analysis Visit Mean (SD)	63.24 (19.61)	55.50 (19.29)	59.42 (21.37)
LS Mean of Change from Baseline (SE)	2.43 (1.57)	0.73 (1.37)	1.36 (1.09)
95% CI	(-0.66, 5.52)	(-1.97, 3.42)	(-0.79, 3.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.07 (1.86)	-0.64 (1.72)	
95% CI	(-2.58, 4.72)	(-4.01, 2.74)	
p-value	0.5642	0.7109	
Corrected Hedge's g Statistics	0.074	-0.044	
95% CI	(-0.19, 0.33)	(-0.28, 0.20)	
Subgroup*Treatment Interaction p-value	0.5495	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Vitality			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	57.22 (22.03)	53.50 (22.65)	54.54 (22.07)
Analysis Visit Mean (SD)	56.28 (22.93)	53.05 (19.89)	54.64 (22.84)
LS Mean of Change from Baseline (SE)	-0.21 (1.51)	-1.39 (1.33)	-0.44 (1.09)
95% CI	(-3.18, 2.76)	(-4.00, 1.23)	(-2.58, 1.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.23 (1.81)	-0.95 (1.67)	
95% CI	(-3.32, 3.78)	(-4.23, 2.34)	
p-value	0.8985	0.5720	
Corrected Hedge's g Statistics	0.015	-0.063	
95% CI	(-0.23, 0.26)	(-0.29, 0.16)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	59.28 (21.94)	54.21 (22.97)	54.81 (21.59)
Analysis Visit Mean (SD)	59.14 (21.96)	54.55 (21.09)	56.70 (22.87)
LS Mean of Change from Baseline (SE)	0.78 (1.66)	-0.62 (1.45)	1.27 (1.16)
95% CI	(-2.48, 4.04)	(-3.47, 2.23)	(-1.01, 3.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.48 (1.97)	-1.89 (1.81)	
95% CI	(-4.35, 3.39)	(-5.44, 1.67)	
p-value	0.8066	0.2981	
Corrected Hedge's g Statistics	-0.031	-0.123	
95% CI	(-0.29, 0.23)	(-0.36, 0.12)	
Subgroup*Treatment Interaction p-value	0.7939	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Social Functioning			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	82.67 (20.69)	79.96 (26.18)	82.66 (22.57)
Analysis Visit Mean (SD)	81.06 (23.63)	81.65 (21.19)	80.50 (25.02)
LS Mean of Change from Baseline (SE)	-1.35 (1.94)	0.24 (1.71)	-2.44 (1.40)
95% CI	(-5.16, 2.46)	(-3.12, 3.61)	(-5.19, 0.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.09 (2.32)	2.68 (2.16)	
95% CI	(-3.47, 5.65)	(-1.55, 6.92)	
p-value	0.6382	0.2137	
Corrected Hedge's g Statistics	0.056	0.139	
95% CI	(-0.18, 0.30)	(-0.09, 0.36)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	84.26 (19.87)	79.59 (27.25)	83.71 (21.42)
Analysis Visit Mean (SD)	82.94 (21.29)	81.42 (22.73)	82.86 (21.79)
LS Mean of Change from Baseline (SE)	-0.77 (1.96)	0.64 (1.72)	-1.20 (1.37)
95% CI	(-4.62, 3.09)	(-2.74, 4.01)	(-3.90, 1.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.43 (2.32)	1.84 (2.14)	
95% CI	(-4.13, 5.00)	(-2.38, 6.05)	
p-value	0.8525	0.3920	
Corrected Hedge's g Statistics	0.024	0.101	
95% CI	(-0.24, 0.28)	(-0.14, 0.34)	
Subgroup*Treatment Interaction p-value	0.5384	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Role Emotional			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	81.43 (24.78)	81.81 (24.18)	83.86 (22.49)
Analysis Visit Mean (SD)	82.26 (22.47)	84.72 (21.05)	82.15 (24.88)
LS Mean of Change from Baseline (SE)	0.67 (1.69)	2.47 (1.49)	-1.43 (1.22)
95% CI	(-2.65, 4.00)	(-0.45, 5.40)	(-3.82, 0.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.10 (2.01)	3.90 (1.87)	
95% CI	(-1.86, 6.06)	(0.23, 7.57)	
p-value	0.2972	0.0372	
Corrected Hedge's g Statistics	0.124	0.232	
95% CI	(-0.12, 0.37)	(0.01, 0.46)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	82.84 (23.37)	81.35 (25.10)	84.76 (21.78)
Analysis Visit Mean (SD)	83.68 (21.27)	84.63 (22.06)	82.90 (22.68)
LS Mean of Change from Baseline (SE)	1.00 (1.90)	3.08 (1.66)	-1.86 (1.33)
95% CI	(-2.74, 4.73)	(-0.19, 6.35)	(-4.47, 0.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.86 (2.26)	4.94 (2.08)	
95% CI	(-1.59, 7.30)	(0.84, 9.03)	
p-value	0.2071	0.0183	
Corrected Hedge's g Statistics	0.162	0.281	
95% CI	(-0.10, 0.42)	(0.04, 0.52)	
Subgroup*Treatment Interaction p-value	0.5558	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Mental Health			
Week 24			
m	109	141	223
n	101	126	191
Baseline Mean (SD)	73.9 (19.6)	75.3 (19.1)	74.6 (18.4)
Analysis Visit Mean (SD)	73.5 (20.1)	74.6 (19.0)	74.1 (19.8)
LS Mean of Change from Baseline (SE)	-0.66 (1.37)	-0.92 (1.21)	-0.80 (0.99)
95% CI	(-3.35, 2.04)	(-3.29, 1.45)	(-2.74, 1.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.15 (1.64)	-0.11 (1.52)	
95% CI	(-3.07, 3.36)	(-3.09, 2.87)	
p-value	0.9283	0.9400	
Corrected Hedge's g Statistics	0.011	-0.008	
95% CI	(-0.23, 0.25)	(-0.23, 0.22)	
Week 52			
m	99	125	208
n	85	109	175
Baseline Mean (SD)	75.3 (18.4)	75.1 (19.7)	74.8 (18.0)
Analysis Visit Mean (SD)	76.7 (16.7)	75.3 (18.4)	75.4 (19.8)
LS Mean of Change from Baseline (SE)	1.28 (1.43)	-0.03 (1.25)	-0.39 (1.00)
95% CI	(-1.54, 4.10)	(-2.49, 2.43)	(-2.37, 1.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.67 (1.70)	0.36 (1.57)	
95% CI	(-1.67, 5.02)	(-2.71, 3.44)	
p-value	0.3251	0.8168	
Corrected Hedge's g Statistics	0.126	0.027	
95% CI	(-0.13, 0.39)	(-0.21, 0.27)	
Subgroup*Treatment Interaction p-value	0.1459	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Mental Component Score			
Week 24			
m	109	141	223
n	100	126	191
Baseline Mean (SD)	50.82 (10.77)	50.86 (11.16)	50.85 (9.75)
Analysis Visit Mean (SD)	50.47 (10.65)	51.23 (10.00)	50.35 (10.74)
LS Mean of Change from Baseline (SE)	-0.41 (0.73)	0.11 (0.64)	-0.68 (0.53)
95% CI	(-1.85, 1.04)	(-1.15, 1.37)	(-1.72, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.28 (0.87)	0.79 (0.81)	
95% CI	(-1.44, 2.00)	(-0.79, 2.38)	
p-value	0.7512	0.3262	
Corrected Hedge's g Statistics	0.038	0.109	
95% CI	(-0.20, 0.28)	(-0.12, 0.33)	
Week 52			
m	99	125	208
n	84	109	175
Baseline Mean (SD)	51.60 (10.10)	50.85 (11.58)	51.03 (9.51)
Analysis Visit Mean (SD)	51.81 (8.87)	51.44 (9.80)	51.00 (10.36)
LS Mean of Change from Baseline (SE)	0.32 (0.78)	0.41 (0.68)	-0.53 (0.54)
95% CI	(-1.20, 1.85)	(-0.92, 1.74)	(-1.60, 0.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.85 (0.92)	0.94 (0.84)	
95% CI	(-0.95, 2.66)	(-0.72, 2.60)	
p-value	0.3536	0.2649	
Corrected Hedge's g Statistics	0.119	0.132	
95% CI	(-0.14, 0.38)	(-0.11, 0.37)	
Subgroup*Treatment Interaction p-value	0.2949	NE	

AMNOG Table SE22.6.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Physical Component Score			
Week 24			
m	109	141	223
n	100	126	191
Baseline Mean (SD)	47.04 (8.21)	45.12 (9.76)	46.77 (9.63)
Analysis Visit Mean (SD)	46.98 (9.00)	45.35 (8.96)	46.71 (10.29)
LS Mean of Change from Baseline (SE)	0.33 (0.69)	-0.15 (0.61)	-0.01 (0.50)
95% CI	(-1.03, 1.68)	(-1.34, 1.05)	(-0.98, 0.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.34 (0.83)	-0.14 (0.77)	
95% CI	(-1.29, 1.96)	(-1.64, 1.37)	
p-value	0.6848	0.8577	
Corrected Hedge's g Statistics	0.049	-0.020	
95% CI	(-0.19, 0.29)	(-0.24, 0.20)	
Week 52			
m	99	125	208
n	84	109	175
Baseline Mean (SD)	47.66 (8.31)	44.94 (9.97)	47.22 (9.16)
Analysis Visit Mean (SD)	47.67 (10.26)	45.72 (9.92)	47.44 (9.28)
LS Mean of Change from Baseline (SE)	0.34 (0.71)	0.50 (0.62)	0.44 (0.50)
95% CI	(-1.06, 1.74)	(-0.72, 1.72)	(-0.53, 1.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.84)	0.06 (0.78)	
95% CI	(-1.76, 1.55)	(-1.47, 1.58)	
p-value	0.9034	0.9411	
Corrected Hedge's g Statistics	-0.016	0.009	
95% CI	(-0.28, 0.24)	(-0.23, 0.25)	
Subgroup*Treatment Interaction p-value	0.5699	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	2 (25.0)
No	6 (85.7)	0	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	NE	
95% CI of the inverse odds ratio	(0.14, 28.42)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	NE	
95% CI of the inverse risk ratio	(0.20, 15.41)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.71	NE	
95% CI of the absolute risk difference	(-50.37, 28.94)	NE	
p-value	0.6048	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3430	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (57.1)	0	3 (37.5)
No	3 (42.9)	0	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.45	NE	
95% CI of the inverse odds ratio	(0.06, 3.57)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	NE	
95% CI of the inverse risk ratio	(0.22, 1.97)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	19.64	NE	
95% CI of the absolute risk difference	(-30.05, 69.34)	NE	
p-value	0.4468	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2455	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (28.6)	0	0
No	5 (71.4)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	NE	
95% CI of the inverse odds ratio	(0.01, 3.24)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.18	NE	
95% CI of the inverse risk ratio	(0.01, 3.18)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	25.69	NE	
95% CI of the absolute risk difference	(-9.74, 61.13)	NE	
p-value	0.1654	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0410	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (42.9)	0	1 (12.5)
No	4 (57.1)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.19	NE	
95% CI of the inverse odds ratio	(0.01, 2.50)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	NE	
95% CI of the inverse risk ratio	(0.04, 2.21)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	30.36	NE	
95% CI of the absolute risk difference	(-12.88, 73.59)	NE	
p-value	0.1847	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3994	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	1 (12.5)
No	6 (85.7)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	NE	
95% CI of the inverse odds ratio	(0.04, 16.85)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.07, 11.54)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.79	NE	
95% CI of the absolute risk difference	(-32.81, 36.39)	NE	
p-value	0.9192	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9285	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	2 (25.0)
No	6 (85.7)	0	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	NE	
95% CI of the inverse odds ratio	(0.14, 28.42)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	NE	
95% CI of the inverse risk ratio	(0.20, 15.41)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.71	NE	
95% CI of the absolute risk difference	(-50.37, 28.94)	NE	
p-value	0.6048	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4543	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (28.6)	0	0
No	5 (71.4)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	NE	
95% CI of the inverse odds ratio	(0.01, 3.24)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.18	NE	
95% CI of the inverse risk ratio	(0.01, 3.18)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	25.69	NE	
95% CI of the absolute risk difference	(-9.74, 61.13)	NE	
p-value	0.1654	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2458	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (42.9)	0	3 (37.5)
No	4 (57.1)	0	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	NE	
95% CI of the inverse odds ratio	(0.10, 6.35)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.25, 3.02)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.36	NE	
95% CI of the absolute risk difference	(-44.34, 55.05)	NE	
p-value	0.8327	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4127	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (12.5)
No	7 (100)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	NE	
95% CI of the inverse odds ratio	(0.10, 86.09)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	NE	
95% CI of the inverse risk ratio	(0.13, 56.63)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.42	NE	
95% CI of the absolute risk difference	(-39.98, 19.15)	NE	
p-value	0.5058	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1038	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	1 (12.5)
No	5 (71.4)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	NE	
95% CI of the inverse odds ratio	(0.02, 5.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	NE	
95% CI of the inverse risk ratio	(0.05, 3.85)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.07	NE	
95% CI of the absolute risk difference	(-24.49, 56.63)	NE	
p-value	0.4376	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1999	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (28.6)	0	1 (12.5)
No	5 (71.4)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	NE	
95% CI of the inverse odds ratio	(0.02, 5.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	NE	
95% CI of the inverse risk ratio	(0.05, 3.85)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.07	NE	
95% CI of the absolute risk difference	(-24.49, 56.63)	NE	
p-value	0.4376	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2240	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	2 (25.0)
No	5 (71.4)	0	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	NE	
95% CI of the inverse odds ratio	(0.08, 8.24)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.16, 4.68)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.57	NE	
95% CI of the absolute risk difference	(-41.38, 48.52)	NE	
p-value	0.8760	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9902	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8642	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	NE	
95% CI of the inverse odds ratio	(0.01, 7.34)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	NE	
95% CI of the inverse risk ratio	(0.01, 6.29)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.19	NE	
95% CI of the absolute risk difference	(-17.72, 44.11)	NE	
p-value	0.3993	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3700	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	1 (12.5)
No	6 (85.7)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	NE	
95% CI of the inverse odds ratio	(0.04, 16.85)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.07, 11.54)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.79	NE	
95% CI of the absolute risk difference	(-32.81, 36.39)	NE	
p-value	0.9192	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9685	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	2 (25.0)
No	5 (71.4)	0	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	NE	
95% CI of the inverse odds ratio	(0.08, 8.24)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.16, 4.68)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.57	NE	
95% CI of the absolute risk difference	(-41.38, 48.52)	NE	
p-value	0.8760	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8219	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (12.5)
No	7 (100)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	NE	
95% CI of the inverse odds ratio	(0.10, 86.09)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.67	NE	
95% CI of the inverse risk ratio	(0.13, 56.63)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.42	NE	
95% CI of the absolute risk difference	(-39.98, 19.15)	NE	
p-value	0.5058	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6643	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	1 (12.5)
No	5 (71.4)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	NE	
95% CI of the inverse odds ratio	(0.02, 5.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	NE	
95% CI of the inverse risk ratio	(0.05, 3.85)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.07	NE	
95% CI of the absolute risk difference	(-24.49, 56.63)	NE	
p-value	0.4376	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4093	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	NE	
95% CI of the inverse odds ratio	(0.01, 7.34)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	NE	
95% CI of the inverse risk ratio	(0.01, 6.29)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.19	NE	
95% CI of the absolute risk difference	(-17.72, 44.11)	NE	
p-value	0.3993	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4922	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (57.1)	0	1 (12.5)
No	3 (42.9)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.11	NE	
95% CI of the inverse odds ratio	(0.01, 1.41)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.22	NE	
95% CI of the inverse risk ratio	(0.03, 1.53)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	44.64	NE	
95% CI of the absolute risk difference	(1.41, 87.88)	NE	
p-value	0.0673	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1457	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (8.5)	0	9 (14.5)
No	43 (91.5)	0	53 (85.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.83	NE	
95% CI of the inverse odds ratio	(0.53, 6.34)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	NE	
95% CI of the inverse risk ratio	(0.56, 5.20)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.01	NE	
95% CI of the absolute risk difference	(-17.86, 5.85)	NE	
p-value	0.3380	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3430	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (25.5)	0	21 (33.9)
No	35 (74.5)	0	41 (66.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.49	NE	
95% CI of the inverse odds ratio	(0.64, 3.46)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	NE	
95% CI of the inverse risk ratio	(0.73, 2.42)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.34	NE	
95% CI of the absolute risk difference	(-25.49, 8.81)	NE	
p-value	0.3480	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2455	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.3)	0	11 (17.7)
No	45 (95.7)	0	51 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.85	NE	
95% CI of the inverse odds ratio	(1.02, 23.07)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.17	NE	
95% CI of the inverse risk ratio	(0.97, 17.92)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.49	NE	
95% CI of the absolute risk difference	(-24.61, -2.36)	NE	
p-value	0.0314	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0410	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (27.7)	0	18 (29.0)
No	34 (72.3)	0	44 (71.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	NE	
95% CI of the inverse odds ratio	(0.46, 2.48)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	NE	
95% CI of the inverse risk ratio	(0.57, 1.92)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.37	NE	
95% CI of the absolute risk difference	(-18.44, 15.69)	NE	
p-value	0.8750	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3994	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (8.5)	0	8 (12.9)
No	43 (91.5)	0	54 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	NE	
95% CI of the inverse odds ratio	(0.45, 5.64)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	NE	
95% CI of the inverse risk ratio	(0.49, 4.73)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.39	NE	
95% CI of the absolute risk difference	(-15.94, 7.15)	NE	
p-value	0.4681	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9285	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (25.5)	0	12 (19.4)
No	35 (74.5)	0	50 (80.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	NE	
95% CI of the inverse odds ratio	(0.28, 1.74)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	NE	
95% CI of the inverse risk ratio	(0.37, 1.53)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.18	NE	
95% CI of the absolute risk difference	(-9.70, 22.06)	NE	
p-value	0.4408	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4543	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (14.9)	0	11 (17.7)
No	40 (85.1)	0	51 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	NE	
95% CI of the inverse odds ratio	(0.44, 3.47)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	NE	
95% CI of the inverse risk ratio	(0.50, 2.84)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.85	NE	
95% CI of the absolute risk difference	(-16.78, 11.08)	NE	
p-value	0.6916	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2458	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (31.9)	0	14 (22.6)
No	32 (68.1)	0	48 (77.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	NE	
95% CI of the inverse odds ratio	(0.26, 1.46)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	NE	
95% CI of the inverse risk ratio	(0.38, 1.32)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.33	NE	
95% CI of the absolute risk difference	(-7.57, 26.24)	NE	
p-value	0.2748	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4127	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (10.6)	0	2 (3.2)
No	42 (89.4)	0	60 (96.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	NE	
95% CI of the inverse odds ratio	(0.05, 1.51)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	NE	
95% CI of the inverse risk ratio	(0.06, 1.50)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.41	NE	
95% CI of the absolute risk difference	(-2.44, 17.26)	NE	
p-value	0.1180	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1038	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (31.9)	0	14 (22.6)
No	32 (68.1)	0	48 (77.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	NE	
95% CI of the inverse odds ratio	(0.26, 1.46)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	NE	
95% CI of the inverse risk ratio	(0.38, 1.32)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.33	NE	
95% CI of the absolute risk difference	(-7.57, 26.24)	NE	
p-value	0.2748	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1999	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (4.8)
No	47 (100)	0	59 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.84	NE	
95% CI of the absolute risk difference	(-10.18, 0.50)	NE	
p-value	0.1262	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2240	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (12.8)	0	7 (11.3)
No	41 (87.2)	0	55 (88.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	NE	
95% CI of the inverse odds ratio	(0.27, 2.78)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.32, 2.46)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.48	NE	
95% CI of the absolute risk difference	(-10.90, 13.85)	NE	
p-value	0.8139	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9902	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (12.8)	0	8 (12.9)
No	41 (87.2)	0	54 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	NE	
95% CI of the inverse odds ratio	(0.33, 3.15)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	NE	
95% CI of the inverse risk ratio	(0.38, 2.72)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.14	NE	
95% CI of the absolute risk difference	(-12.81, 12.54)	NE	
p-value	0.9831	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8642	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (23.4)	0	11 (17.7)
No	36 (76.6)	0	51 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	NE	
95% CI of the inverse odds ratio	(0.28, 1.80)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	NE	
95% CI of the inverse risk ratio	(0.36, 1.60)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.66	NE	
95% CI of the absolute risk difference	(-9.73, 21.06)	NE	
p-value	0.4657	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3700	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (6.4)	0	5 (8.1)
No	44 (93.6)	0	57 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	NE	
95% CI of the inverse odds ratio	(0.29, 5.68)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	NE	
95% CI of the inverse risk ratio	(0.32, 5.02)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.68	NE	
95% CI of the absolute risk difference	(-11.42, 8.05)	NE	
p-value	0.7388	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9685	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (34.0)	0	14 (22.6)
No	31 (66.0)	0	48 (77.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	NE	
95% CI of the inverse odds ratio	(0.24, 1.32)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	NE	
95% CI of the inverse risk ratio	(0.36, 1.22)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.46	NE	
95% CI of the absolute risk difference	(-5.62, 28.55)	NE	
p-value	0.1845	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8219	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.1)	0	2 (3.2)
No	46 (97.9)	0	60 (96.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	NE	
95% CI of the inverse odds ratio	(0.13, 17.43)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	NE	
95% CI of the inverse risk ratio	(0.14, 16.22)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.10	NE	
95% CI of the absolute risk difference	(-7.13, 4.93)	NE	
p-value	0.7285	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6643	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (23.4)	0	9 (14.5)
No	36 (76.6)	0	53 (85.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	NE	
95% CI of the inverse odds ratio	(0.21, 1.48)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	NE	
95% CI of the inverse risk ratio	(0.28, 1.37)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.89	NE	
95% CI of the absolute risk difference	(-6.06, 23.83)	NE	
p-value	0.2351	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4093	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.1)	0	2 (3.2)
No	46 (97.9)	0	60 (96.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	NE	
95% CI of the inverse odds ratio	(0.13, 17.43)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	NE	
95% CI of the inverse risk ratio	(0.14, 16.22)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.10	NE	
95% CI of the absolute risk difference	(-7.13, 4.93)	NE	
p-value	0.7285	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4922	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (17.0)	0	14 (22.6)
No	39 (83.0)	0	48 (77.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	NE	
95% CI of the inverse odds ratio	(0.54, 3.74)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	NE	
95% CI of the inverse risk ratio	(0.61, 2.90)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.56	NE	
95% CI of the absolute risk difference	(-20.52, 9.40)	NE	
p-value	0.4739	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1457	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	17 (15.0)	18 (11.9)	26 (11.2)
No	96 (85.0)	133 (88.1)	207 (88.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.93	
95% CI of the inverse odds ratio	(0.37, 1.37)	(0.49, 1.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.94	
95% CI of the inverse risk ratio	(0.42, 1.31)	(0.53, 1.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.89	0.76	
95% CI of the absolute risk difference	(-3.85, 11.62)	(-5.80, 7.32)	
p-value	0.3042	0.8189	
p-value of Breslow-Day Test for Homogeneity [3]	0.3430	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	39 (34.5)	48 (31.8)	62 (26.6)
No	74 (65.5)	103 (68.2)	171 (73.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.78	
95% CI of the inverse odds ratio	(0.42, 1.12)	(0.50, 1.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.84	
95% CI of the inverse risk ratio	(0.55, 1.07)	(0.61, 1.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.90	5.18	
95% CI of the absolute risk difference	(-2.54, 18.35)	(-4.17, 14.53)	
p-value	0.1294	0.2729	
p-value of Breslow-Day Test for Homogeneity [3]	0.2455	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (9.7)	18 (11.9)	27 (11.6)
No	102 (90.3)	133 (88.1)	206 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	0.97	
95% CI of the inverse odds ratio	(0.58, 2.55)	(0.51, 1.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	0.97	
95% CI of the inverse risk ratio	(0.61, 2.31)	(0.56, 1.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.85	0.33	
95% CI of the absolute risk difference	(-8.69, 4.98)	(-6.27, 6.94)	
p-value	0.6051	0.9212	
p-value of Breslow-Day Test for Homogeneity [3]	0.0410	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (21.2)	39 (25.8)	52 (22.3)
No	89 (78.8)	112 (74.2)	181 (77.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.83	
95% CI of the inverse odds ratio	(0.62, 1.84)	(0.51, 1.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.86	
95% CI of the inverse risk ratio	(0.68, 1.61)	(0.60, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.08	3.51	
95% CI of the absolute risk difference	(-10.32, 8.17)	(-5.28, 12.30)	
p-value	0.8202	0.4294	
p-value of Breslow-Day Test for Homogeneity [3]	0.3994	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (13.3)	26 (17.2)	44 (18.9)
No	98 (86.7)	125 (82.8)	189 (81.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	1.12	
95% CI of the inverse odds ratio	(0.81, 2.87)	(0.66, 1.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	1.10	
95% CI of the inverse risk ratio	(0.83, 2.44)	(0.71, 1.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.61	-1.67	
95% CI of the absolute risk difference	(-13.63, 2.41)	(-9.51, 6.18)	
p-value	0.1932	0.6797	
p-value of Breslow-Day Test for Homogeneity [3]	0.9285	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (23.9)	46 (30.5)	68 (29.2)
No	86 (76.1)	105 (69.5)	165 (70.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	0.94	
95% CI of the inverse odds ratio	(0.78, 2.20)	(0.60, 1.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	0.96	
95% CI of the inverse risk ratio	(0.83, 1.80)	(0.70, 1.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.29	1.28	
95% CI of the absolute risk difference	(-15.08, 4.50)	(-8.10, 10.66)	
p-value	0.3011	0.7887	
p-value of Breslow-Day Test for Homogeneity [3]	0.4543	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (14.2)	28 (18.5)	34 (14.6)
No	97 (85.8)	123 (81.5)	199 (85.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.75	
95% CI of the inverse odds ratio	(0.55, 1.97)	(0.43, 1.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.79	
95% CI of the inverse risk ratio	(0.59, 1.79)	(0.50, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.43	3.95	
95% CI of the absolute risk difference	(-8.30, 7.43)	(-3.73, 11.63)	
p-value	0.9145	0.3041	
p-value of Breslow-Day Test for Homogeneity [3]	0.2458	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (28.3)	53 (35.1)	75 (32.2)
No	81 (71.7)	98 (64.9)	158 (67.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	0.88	
95% CI of the inverse odds ratio	(0.73, 1.97)	(0.57, 1.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	0.92	
95% CI of the inverse risk ratio	(0.80, 1.61)	(0.69, 1.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.87	2.91	
95% CI of the absolute risk difference	(-14.12, 6.38)	(-6.78, 12.60)	
p-value	0.4651	0.5545	
p-value of Breslow-Day Test for Homogeneity [3]	0.4127	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (9.7)	14 (9.3)	33 (14.2)
No	102 (90.3)	137 (90.7)	200 (85.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	1.61	
95% CI of the inverse odds ratio	(0.74, 3.15)	(0.83, 3.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	1.53	
95% CI of the inverse risk ratio	(0.76, 2.77)	(0.85, 2.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.43	-4.89	
95% CI of the absolute risk difference	(-11.49, 2.64)	(-11.33, 1.55)	
p-value	0.2462	0.1531	
p-value of Breslow-Day Test for Homogeneity [3]	0.1038	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (29.2)	44 (29.1)	84 (36.1)
No	80 (70.8)	107 (70.9)	149 (63.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.37	1.37	
95% CI of the inverse odds ratio	(0.84, 2.22)	(0.88, 2.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	1.24	
95% CI of the inverse risk ratio	(0.88, 1.72)	(0.91, 1.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.85	-6.91	
95% CI of the absolute risk difference	(-17.25, 3.56)	(-16.43, 2.60)	
p-value	0.2067	0.1604	
p-value of Breslow-Day Test for Homogeneity [3]	0.1999	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (9.7)	23 (15.2)	21 (9.0)
No	102 (90.3)	128 (84.8)	212 (91.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.55	
95% CI of the inverse odds ratio	(0.43, 1.98)	(0.29, 1.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.59	
95% CI of the inverse risk ratio	(0.46, 1.85)	(0.34, 1.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.72	6.22	
95% CI of the absolute risk difference	(-5.87, 7.31)	(-0.59, 13.03)	
p-value	0.8280	0.0616	
p-value of Breslow-Day Test for Homogeneity [3]	0.2240	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (19.5)	35 (23.2)	43 (18.5)
No	91 (80.5)	116 (76.8)	190 (81.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.75	
95% CI of the inverse odds ratio	(0.53, 1.66)	(0.45, 1.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.80	
95% CI of the inverse risk ratio	(0.60, 1.50)	(0.54, 1.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.01	4.72	
95% CI of the absolute risk difference	(-7.82, 9.85)	(-3.65, 13.10)	
p-value	0.8208	0.2611	
p-value of Breslow-Day Test for Homogeneity [3]	0.9902	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (11.5)	30 (19.9)	30 (12.9)
No	100 (88.5)	121 (80.1)	203 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	0.60	
95% CI of the inverse odds ratio	(0.57, 2.27)	(0.34, 1.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.65	
95% CI of the inverse risk ratio	(0.61, 2.06)	(0.41, 1.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.37	6.99	
95% CI of the absolute risk difference	(-8.66, 5.92)	(-0.69, 14.67)	
p-value	0.7169	0.0653	
p-value of Breslow-Day Test for Homogeneity [3]	0.8642	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (15.0)	40 (26.5)	40 (17.2)
No	96 (85.0)	111 (73.5)	193 (82.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.58	
95% CI of the inverse odds ratio	(0.63, 2.17)	(0.35, 0.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	0.65	
95% CI of the inverse risk ratio	(0.68, 1.92)	(0.44, 0.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.12	9.32	
95% CI of the absolute risk difference	(-10.30, 6.06)	(0.78, 17.87)	
p-value	0.6176	0.0280	
p-value of Breslow-Day Test for Homogeneity [3]	0.3700	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (13.3)	14 (9.3)	34 (14.6)
No	98 (86.7)	137 (90.7)	199 (85.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	1.67	
95% CI of the inverse odds ratio	(0.58, 2.15)	(0.86, 3.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	1.57	
95% CI of the inverse risk ratio	(0.63, 1.93)	(0.87, 2.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.32	-5.32	
95% CI of the absolute risk difference	(-9.04, 6.41)	(-11.80, 1.16)	
p-value	0.7416	0.1236	
p-value of Breslow-Day Test for Homogeneity [3]	0.9685	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	39 (34.5)	41 (27.2)	67 (28.8)
No	74 (65.5)	110 (72.8)	166 (71.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.08	
95% CI of the inverse odds ratio	(0.47, 1.24)	(0.69, 1.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	1.06	
95% CI of the inverse risk ratio	(0.60, 1.15)	(0.76, 1.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.76	-1.60	
95% CI of the absolute risk difference	(-4.76, 16.28)	(-10.77, 7.57)	
p-value	0.2759	0.7329	
p-value of Breslow-Day Test for Homogeneity [3]	0.8219	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (5.3)	13 (8.6)	14 (6.0)
No	107 (94.7)	138 (91.4)	219 (94.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	0.68	
95% CI of the inverse odds ratio	(0.43, 3.05)	(0.31, 1.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	0.70	
95% CI of the inverse risk ratio	(0.45, 2.87)	(0.34, 1.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.70	2.60	
95% CI of the absolute risk difference	(-5.84, 4.44)	(-2.81, 8.02)	
p-value	0.7939	0.3302	
p-value of Breslow-Day Test for Homogeneity [3]	0.6643	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (21.2)	27 (17.9)	52 (22.3)
No	89 (78.8)	124 (82.1)	181 (77.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.32	
95% CI of the inverse odds ratio	(0.62, 1.84)	(0.79, 2.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.25	
95% CI of the inverse risk ratio	(0.68, 1.61)	(0.82, 1.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.08	-4.44	
95% CI of the absolute risk difference	(-10.32, 8.17)	(-12.56, 3.68)	
p-value	0.8202	0.2934	
p-value of Breslow-Day Test for Homogeneity [3]	0.4093	NE	

AMNOG Table SE22.6.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.4)	12 (7.9)	12 (5.2)
No	108 (95.6)	139 (92.1)	221 (94.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.63	
95% CI of the inverse odds ratio	(0.40, 3.41)	(0.27, 1.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	0.65	
95% CI of the inverse risk ratio	(0.42, 3.22)	(0.30, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.73	2.80	
95% CI of the absolute risk difference	(-5.46, 4.01)	(-2.37, 7.96)	
p-value	0.7697	0.2687	
p-value of Breslow-Day Test for Homogeneity [3]	0.4922	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (20.4)	41 (27.2)	45 (19.3)
No	90 (79.6)	110 (72.8)	188 (80.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.64	
95% CI of the inverse odds ratio	(0.53, 1.64)	(0.40, 1.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.71	
95% CI of the inverse risk ratio	(0.61, 1.49)	(0.49, 1.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.04	7.84	
95% CI of the absolute risk difference	(-7.95, 10.03)	(-0.88, 16.56)	
p-value	0.8193	0.0719	
p-value of Breslow-Day Test for Homogeneity [3]	0.1457	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Physical Functioning						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	72.86 (25.12)	67.53 (25.39)	73.09 (25.34)			
Median	80.00	70.00	80.00			
IQR: Q1, Q3	55.00, 95.00	55.00, 90.00	55.00, 95.00			
Min, Max	0.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	73.35 (24.63)	68.55 (24.25)	72.09 (29.24)	0.99 (1.69)	0.59 (2.13)	-0.66 (1.44)
Median	80.00	75.00	85.00	0	0	0
IQR: Q1, Q3	55.00, 95.00	55.00, 85.00	50.00, 95.00	-7.50, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	10.0, 100.0	5.0, 100.0	0.0, 100.0	-50.0, 60.0	-65.0, 55.0	-70.0, 75.0
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	73.71 (27.58)	68.78 (23.88)	76.34 (24.59)	0.62 (1.59)	1.27 (1.83)	0.57 (1.31)
Median	85.00	75.00	85.00	0	0	0
IQR: Q1, Q3	55.00, 95.00	55.00, 85.00	65.00, 95.00	-5.00, 10.00	-5.00, 10.00	-5.00, 5.00
Min, Max	0.0, 100.0	5.0, 100.0	0.0, 100.0	-65.0, 35.0	-50.0, 40.0	-45.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=118)	Visit Result: MGL-3196 100 mg (N=100)	Visit Result: Placebo (N=201)	Change from Baseline: MGL-3196 80 mg (N=118)	Change from Baseline: MGL-3196 100 mg (N=100)	Change from Baseline: Placebo (N=201)
Role Physical						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	75.73 (24.48)	73.37 (25.54)	75.71 (25.76)			
Median	81.30	75.00	81.30			
IQR: Q1, Q3	56.30, 100.00	50.00, 100.00	56.30, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	73.56 (25.35)	72.89 (23.26)	73.25 (29.06)	-2.20 (1.89)	-1.69 (2.47)	-2.19 (1.60)
Median	81.30	75.00	81.30	0	0	0
IQR: Q1, Q3	56.30, 100.00	56.30, 96.90	50.00, 100.00	-15.60, 12.50	-18.70, 6.30	-12.50, 6.20
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.8, 50.0	-56.2, 68.7	-68.7, 68.7
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	74.88 (26.97)	72.74 (25.24)	75.49 (25.44)	-2.09 (1.74)	0.27 (2.68)	-2.06 (1.71)
Median	81.30	75.00	81.30	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 93.80	50.00, 100.00	-12.50, 6.20	-6.30, 12.50	-12.50, 6.20
Min, Max	0.0, 100.0	6.3, 100.0	0.0, 100.0	-43.8, 43.8	-75.0, 81.3	-62.5, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Bodily Pain						
Baseline						
m	118	100	201			
n	112	91	188			
Mean (SD)	66.7 (23.4)	60.4 (26.2)	64.9 (25.5)			
Median	72.0	62.0	68.0			
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	41.0, 84.0			
Min, Max	12, 100	0, 100	0, 100			
Week 24						
m	115	92	189			
n	112	88	173	107	81	163
Mean (SD/SE)	62.2 (24.4)	62.8 (23.7)	64.7 (26.7)	-3.8 (2.0)	0.4 (2.2)	0.0 (1.6)
Median	62.0	62.0	72.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	41.0, 84.0	-21.0, 10.0	-11.0, 10.0	-12.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-59, 52	-62, 52	-78, 78
Week 52						
m	107	81	176			
n	97	74	156	92	71	146
Mean (SD/SE)	66.5 (25.5)	64.6 (24.8)	68.6 (25.0)	-1.4 (2.2)	4.8 (2.6)	2.5 (1.8)
Median	72.0	62.0	72.0	0	0	0
IQR: Q1, Q3	42.0, 84.0	41.0, 84.0	51.0, 84.0	-11.5, 10.0	-10.0, 12.0	-12.0, 16.0
Min, Max	0, 100	10, 100	10, 100	-80, 59	-43, 69	-78, 78

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
General Health						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	60.02 (19.45)	55.19 (18.25)	57.73 (20.26)			
Median	62.00	57.00	62.00			
IQR: Q1, Q3	45.00, 77.00	42.00, 67.00	42.00, 72.00			
Min, Max	10.0, 100.0	10.0, 92.0	15.0, 97.0			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	60.23 (20.23)	55.72 (19.73)	58.42 (22.80)	1.05 (1.45)	1.14 (1.76)	1.50 (1.15)
Median	60.00	52.00	57.00	0	0	0
IQR: Q1, Q3	45.00, 77.00	40.00, 69.50	42.00, 77.00	-7.50, 10.00	-10.00, 12.00	-8.00, 10.00
Min, Max	15.0, 100.0	15.0, 100.0	0.0, 100.0	-60.0, 32.0	-35.0, 40.0	-35.0, 48.0
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	61.76 (20.18)	54.26 (19.74)	60.62 (21.95)	0.50 (1.63)	0.41 (1.95)	1.86 (1.17)
Median	65.00	52.00	62.00	0	0	0
IQR: Q1, Q3	45.00, 77.00	42.00, 67.00	47.00, 77.00	-10.00, 10.00	-10.00, 10.00	-5.00, 10.00
Min, Max	20.0, 100.0	10.0, 92.0	10.0, 100.0	-70.0, 47.0	-52.0, 32.0	-42.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Vitality						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	58.34 (21.21)	55.04 (21.81)	56.56 (21.18)			
Median	62.50	56.30	62.50			
IQR: Q1, Q3	43.80, 75.00	43.80, 75.00	43.80, 75.00			
Min, Max	0.0, 100.0	0.0, 93.8	6.3, 100.0			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	56.50 (22.56)	54.92 (19.29)	56.24 (22.50)	-1.64 (1.52)	-1.01 (1.83)	-0.18 (1.20)
Median	62.50	56.30	56.30	0	0	0
IQR: Q1, Q3	43.80, 75.00	40.65, 68.80	37.50, 75.00	-7.30, 6.25	-12.50, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	12.5, 100.0	0.0, 100.0	-43.8, 43.8	-31.3, 43.8	-37.5, 56.2
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	59.17 (22.10)	53.82 (21.29)	57.64 (22.43)	-0.94 (1.67)	-1.76 (1.87)	0.02 (1.42)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	43.80, 75.00	37.50, 68.80	43.80, 75.00	-12.50, 6.30	-12.50, 6.20	-6.30, 12.50
Min, Max	6.3, 100.0	6.3, 100.0	0.0, 100.0	-43.7, 50.0	-43.8, 37.5	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=118)	Visit Result: MGL-3196 100 mg (N=100)	Visit Result: Placebo (N=201)	Change from Baseline: MGL-3196 80 mg (N=118)	Change from Baseline: MGL-3196 100 mg (N=100)	Change from Baseline: Placebo (N=201)
Social Functioning						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	82.74 (21.74)	81.46 (25.09)	82.65 (23.10)			
Median	87.50	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	0.0, 100.0	12.5, 100.0			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	80.92 (24.37)	82.95 (18.78)	79.84 (25.95)	-1.62 (2.12)	0.77 (2.18)	-1.69 (1.57)
Median	87.50	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	62.50, 100.00	-12.50, 12.50	-12.50, 12.50	-12.50, 12.50
Min, Max	12.5, 100.0	37.5, 100.0	0.0, 100.0	-62.5, 62.5	-50.0, 87.5	-62.5, 75.0
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	82.09 (22.60)	80.74 (21.22)	82.77 (21.83)	-1.61 (1.86)	-0.70 (2.75)	-1.28 (1.61)
Median	87.50	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00	0.00, 0.00	-12.50, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-50.0, 50.0	-62.5, 62.5	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Role Emotional						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	83.92 (22.54)	81.87 (23.79)	83.64 (22.53)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	83.04 (21.54)	86.46 (18.32)	81.31 (26.32)	-0.30 (1.59)	3.71 (1.84)	-1.43 (1.48)
Median	95.85	100.00	100.00	0	0	0
IQR: Q1, Q3	70.85, 100.00	75.00, 100.00	66.70, 100.00	-8.30, 0.00	0.00, 16.60	-8.30, 0.00
Min, Max	25.0, 100.0	25.0, 100.0	0.0, 100.0	-33.3, 66.7	-33.3, 50.0	-50.0, 58.3
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	83.68 (20.59)	84.23 (22.94)	83.49 (22.55)	0.09 (1.63)	2.70 (2.71)	-1.89 (1.56)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	0.00, 16.70	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-50.0, 50.0	-75.0, 50.0	-58.3, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Mental Health						
Baseline						
m	118	100	201			
n	113	91	188			
Mean (SD)	74.8 (18.6)	75.7 (18.8)	74.4 (17.5)			
Median	80.0	80.0	80.0			
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	62.5, 90.0			
Min, Max	5, 100	25, 100	5, 100			
Week 24						
m	115	92	189			
n	112	88	173	108	81	163
Mean (SD/SE)	74.0 (18.7)	76.1 (18.9)	73.6 (20.6)	-0.3 (1.4)	-1.4 (1.3)	0.3 (1.2)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	60.0, 90.0	70.0, 90.0	65.0, 90.0	-7.5, 5.0	-5.0, 5.0	-5.0, 5.0
Min, Max	25, 100	20, 100	5, 100	-40, 35	-35, 35	-45, 55
Week 52						
m	107	81	176			
n	97	74	156	93	71	146
Mean (SD/SE)	75.5 (17.8)	76.4 (18.0)	76.0 (19.4)	0.4 (1.3)	-0.4 (1.4)	1.3 (1.3)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	70.0, 90.0	70.0, 90.0	-5.0, 10.0	-5.0, 5.0	-5.0, 10.0
Min, Max	25, 100	25, 100	0, 100	-35, 25	-30, 35	-40, 55

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Mental Component Score						
Baseline						
m	118	100	201			
n	112	91	188			
Mean (SD)	51.50 (9.72)	51.61 (10.38)	51.11 (9.26)			
Median	53.75	55.00	53.70			
IQR: Q1, Q3	46.90, 58.40	45.30, 59.10	45.75, 58.00			
Min, Max	12.0, 69.0	23.5, 70.0	15.6, 66.5			
Week 24						
m	115	92	189			
n	112	88	173	107	81	163
Mean (SD/SE)	50.87 (9.73)	52.53 (9.19)	50.34 (11.22)	-0.45 (0.72)	0.29 (0.64)	-0.23 (0.62)
Median	52.95	55.05	54.50	-0.20	-0.20	0
IQR: Q1, Q3	45.05, 58.45	48.05, 59.45	44.00, 58.20	-4.30, 3.20	-3.20, 3.40	-4.30, 3.80
Min, Max	26.2, 69.1	21.2, 68.3	14.2, 69.0	-20.0, 19.0	-13.5, 19.1	-24.6, 24.8
Week 52						
m	107	81	176			
n	97	74	156	92	71	146
Mean (SD/SE)	51.53 (8.97)	51.78 (9.95)	51.19 (10.33)	-0.16 (0.70)	-0.21 (0.91)	-0.22 (0.64)
Median	53.60	53.75	54.45	0.05	-0.20	0.30
IQR: Q1, Q3	45.10, 58.60	44.30, 58.30	47.10, 58.00	-3.05, 3.65	-3.90, 2.90	-4.30, 3.50
Min, Max	26.7, 63.2	26.9, 68.1	8.9, 64.0	-21.7, 14.9	-21.4, 19.6	-24.6, 26.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Physical Component Score						
Baseline						
m	118	100	201			
n	112	91	188			
Mean (SD)	47.12 (8.79)	44.58 (9.15)	46.69 (9.42)			
Median	47.55	46.10	48.60			
IQR: Q1, Q3	42.75, 53.75	37.80, 52.00	39.95, 54.90			
Min, Max	15.3, 60.8	21.9, 61.3	20.7, 61.1			
Week 24						
m	115	92	189			
n	112	88	173	107	81	163
Mean (SD/SE)	46.52 (9.48)	44.64 (8.88)	46.57 (10.66)	-0.42 (0.63)	-0.08 (0.83)	-0.12 (0.55)
Median	48.65	44.70	50.00	-0.70	-0.20	-0.10
IQR: Q1, Q3	40.85, 53.15	37.60, 51.70	39.00, 55.10	-5.40, 3.80	-3.00, 3.50	-3.20, 3.40
Min, Max	12.5, 63.9	24.6, 59.0	19.0, 63.0	-17.2, 17.6	-22.1, 21.7	-28.8, 23.3
Week 52						
m	107	81	176			
n	97	74	156	92	71	146
Mean (SD/SE)	47.28 (10.46)	44.86 (8.90)	47.85 (9.59)	-0.28 (0.68)	0.72 (0.83)	0.39 (0.52)
Median	49.30	43.60	49.40	-0.35	1.50	0.40
IQR: Q1, Q3	41.80, 55.40	39.40, 51.80	41.50, 55.70	-3.00, 3.20	-2.80, 4.80	-2.90, 3.60
Min, Max	15.8, 62.8	24.8, 59.1	21.5, 63.9	-24.7, 15.9	-23.5, 18.6	-23.9, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Physical Functioning						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	78.89 (20.19)	74.68 (26.18)	77.23 (25.06)			
Median	80.00	80.00	85.00			
IQR: Q1, Q3	70.00, 100.00	60.00, 95.00	65.00, 95.00			
Min, Max	15.0, 100.0	10.0, 100.0	10.0, 100.0			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	81.56 (23.11)	77.08 (24.49)	80.05 (23.15)	2.44 (1.90)	1.89 (3.20)	2.03 (1.70)
Median	90.00	85.00	87.50	0	0	0
IQR: Q1, Q3	75.00, 100.00	70.00, 95.00	70.00, 100.00	-5.00, 10.00	-5.00, 10.00	-5.00, 10.00
Min, Max	5.0, 100.0	10.0, 100.0	5.0, 100.0	-35.0, 30.0	-65.0, 70.0	-40.0, 65.0
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	83.72 (22.76)	75.40 (29.47)	76.81 (24.44)	3.11 (2.49)	-0.89 (3.44)	0.91 (1.84)
Median	95.00	85.00	85.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	65.00, 95.00	70.00, 95.00	-5.00, 10.00	-5.00, 5.00	-5.00, 5.00
Min, Max	10.0, 100.0	0.0, 100.0	0.0, 100.0	-45.0, 45.0	-85.0, 35.0	-60.0, 70.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Role Physical						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	75.84 (30.16)	72.62 (29.93)	76.44 (26.78)			
Median	87.50	75.00	84.40			
IQR: Q1, Q3	62.50, 100.00	56.30, 100.00	59.40, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	6.3, 100.0			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	76.54 (30.53)	75.27 (25.62)	81.06 (22.82)	1.31 (2.16)	2.36 (2.82)	3.27 (2.08)
Median	87.50	84.40	93.80	0	0	0
IQR: Q1, Q3	56.30, 100.00	53.15, 100.00	68.80, 100.00	-6.30, 6.30	-6.20, 6.20	-6.20, 6.30
Min, Max	0.0, 100.0	18.8, 100.0	18.8, 100.0	-31.2, 43.7	-50.0, 62.5	-43.8, 87.5
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	79.01 (30.02)	76.11 (28.50)	75.62 (24.15)	3.54 (3.41)	1.48 (3.01)	0.81 (2.17)
Median	100.00	87.50	81.30	0	0	0
IQR: Q1, Q3	62.50, 100.00	65.65, 100.00	62.50, 100.00	0.00, 6.20	-6.30, 6.20	-6.20, 12.50
Min, Max	0.0, 100.0	6.3, 100.0	6.3, 100.0	-37.5, 81.2	-43.8, 50.0	-56.2, 68.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Bodily Pain						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	67.0 (26.9)	65.3 (26.3)	66.6 (24.5)			
Median	72.0	62.0	62.0			
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	51.0, 84.0			
Min, Max	0, 100	10, 100	12, 100			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	68.9 (27.4)	67.6 (24.9)	68.4 (23.3)	1.2 (2.6)	1.6 (2.9)	0.8 (2.2)
Median	72.0	72.0	72.0	0	0	0
IQR: Q1, Q3	51.0, 100.0	46.5, 84.0	51.0, 84.0	-10.0, 10.0	-10.0, 10.0	-12.0, 16.0
Min, Max	0, 100	12, 100	21, 100	-40, 68	-29, 72	-49, 59
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	70.8 (26.5)	72.0 (26.6)	65.6 (24.6)	3.9 (2.7)	5.3 (3.4)	-0.7 (2.4)
Median	74.0	74.0	74.0	0	1.0	0
IQR: Q1, Q3	52.0, 100.0	51.0, 100.0	51.0, 84.0	0.0, 10.0	0.0, 16.0	-11.0, 10.0
Min, Max	0, 100	10, 100	0, 100	-28, 68	-53, 49	-49, 69

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
General Health						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	61.62 (21.11)	52.02 (20.91)	61.01 (20.40)			
Median	67.00	47.00	59.50			
IQR: Q1, Q3	52.00, 77.00	35.00, 72.00	47.00, 77.00			
Min, Max	10.0, 97.0	10.0, 100.0	15.0, 100.0			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	62.35 (22.74)	53.98 (18.96)	60.84 (18.85)	0.81 (1.88)	1.71 (2.32)	-0.90 (1.58)
Median	67.00	52.00	62.00	0	0	0
IQR: Q1, Q3	47.00, 77.00	41.00, 69.50	50.00, 77.00	-5.00, 10.00	-7.00, 10.00	-10.00, 10.00
Min, Max	10.0, 97.0	10.0, 92.0	15.0, 100.0	-35.0, 27.0	-35.0, 37.0	-40.0, 32.0
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	65.29 (19.05)	59.05 (18.02)	60.43 (18.42)	4.01 (2.14)	5.47 (3.00)	0.71 (1.50)
Median	67.00	62.00	62.00	0	5.00	0
IQR: Q1, Q3	57.00, 77.00	46.00, 72.00	50.00, 72.00	-5.00, 10.00	-5.00, 15.00	-5.00, 10.00
Min, Max	22.0, 100.0	20.0, 92.0	10.0, 100.0	-17.0, 37.0	-38.0, 47.0	-30.0, 32.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Vitality						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	55.15 (25.32)	51.09 (23.58)	56.54 (22.45)			
Median	62.50	56.30	59.40			
IQR: Q1, Q3	37.50, 75.00	37.50, 62.50	43.80, 71.90			
Min, Max	6.3, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	56.69 (26.70)	51.59 (21.90)	58.27 (21.63)	1.90 (1.78)	0.56 (2.10)	0.73 (1.71)
Median	62.50	56.30	56.30	0	0	0
IQR: Q1, Q3	43.80, 75.00	37.50, 68.80	37.50, 75.00	-6.20, 6.30	-12.50, 6.30	-6.30, 6.30
Min, Max	0.0, 100.0	0.0, 87.5	6.3, 100.0	-25.0, 37.5	-18.8, 43.8	-37.5, 43.8
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	57.39 (24.91)	56.74 (20.33)	57.11 (22.64)	2.04 (2.25)	4.28 (2.23)	1.55 (2.10)
Median	68.80	56.30	62.50	0	6.20	0
IQR: Q1, Q3	37.50, 75.00	46.90, 71.90	43.80, 75.00	-6.20, 12.50	-6.20, 12.50	-6.30, 12.50
Min, Max	6.3, 100.0	6.3, 87.5	6.3, 100.0	-31.2, 37.5	-25.0, 43.8	-56.3, 43.8

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Social Functioning						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	79.44 (28.22)	76.06 (26.94)	83.56 (21.20)			
Median	100.00	87.50	93.75			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	12.5, 100.0	25.0, 100.0			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	81.39 (25.23)	79.43 (24.53)	83.64 (22.00)	1.74 (2.84)	3.33 (3.26)	-1.45 (2.01)
Median	100.00	87.50	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	62.50, 100.00	-12.50, 0.00	0.00, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	12.5, 100.0	25.0, 100.0	-37.5, 75.0	-62.5, 50.0	-50.0, 50.0
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	80.45 (25.29)	83.75 (24.55)	83.28 (22.20)	-1.69 (2.57)	6.58 (3.46)	0.97 (2.25)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	68.75, 100.00	75.00, 100.00	-12.50, 0.00	0.00, 25.00	0.00, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-37.5, 25.0	-62.5, 62.5	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Role Emotional						
Baseline						
m	49	51	102			
n	45	47	91			
Mean (SD)	77.40 (29.01)	82.27 (23.80)	84.70 (22.09)			
Median	91.70	91.70	100.00			
IQR: Q1, Q3	58.30, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	16.7, 100.0	16.7, 100.0			
Week 24						
m	46	49	100			
n	45	48	94	43	45	85
Mean (SD/SE)	77.77 (26.53)	83.16 (24.41)	85.73 (18.88)	0.39 (3.13)	1.48 (2.24)	0.00 (1.92)
Median	83.30	100.00	100.00	0	0	0
IQR: Q1, Q3	50.00, 100.00	75.00, 100.00	75.00, 100.00	-8.30, 8.30	0.00, 8.30	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	33.3, 100.0	-66.7, 50.0	-50.0, 33.4	-50.0, 50.0
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	82.58 (23.73)	86.04 (19.92)	81.92 (23.05)	2.59 (3.43)	4.38 (2.99)	-1.52 (2.06)
Median	91.70	91.70	83.30	0	0	0
IQR: Q1, Q3	75.00, 100.00	83.30, 100.00	75.00, 100.00	0.00, 0.00	0.00, 16.70	-16.70, 0.00
Min, Max	25.0, 100.0	25.0, 100.0	0.0, 100.0	-25.0, 100.0	-25.0, 58.3	-50.0, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Mental Health						
Baseline						
m	49	51	102			
n	45	47	92			
Mean (SD)	71.1 (22.9)	73.3 (20.4)	76.8 (18.3)			
Median	75.0	80.0	80.0			
IQR: Q1, Q3	60.0, 90.0	65.0, 90.0	70.0, 90.0			
Min, Max	10, 100	15, 100	20, 100			
Week 24						
m	46	49	100			
n	45	48	94	43	45	86
Mean (SD/SE)	70.0 (22.7)	73.2 (18.8)	76.5 (15.5)	-1.7 (1.8)	0.7 (2.2)	-1.2 (1.4)
Median	70.0	80.0	80.0	0	0	0
IQR: Q1, Q3	60.0, 90.0	65.0, 87.5	70.0, 90.0	-5.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	15, 100	5, 100	40, 100	-25, 30	-40, 50	-30, 30
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	74.5 (18.9)	73.9 (18.8)	75.1 (19.5)	0.8 (2.3)	1.3 (2.3)	-1.0 (1.8)
Median	80.0	77.5	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	60.0, 90.0	65.0, 90.0	-10.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	30, 100	20, 100	15, 100	-25, 40	-25, 50	-60, 40

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Mental Component Score						
Baseline						
m	49	51	102			
n	45	47	91			
Mean (SD)	48.02 (12.97)	49.29 (12.10)	51.56 (9.50)			
Median	52.30	52.80	55.00			
IQR: Q1, Q3	36.90, 57.40	45.30, 58.10	48.00, 57.80			
Min, Max	12.9, 62.7	17.0, 72.3	26.5, 64.1			
Week 24						
m	46	49	100			
n	45	48	94	43	45	85
Mean (SD/SE)	47.84 (12.49)	49.43 (10.60)	51.32 (8.44)	-0.30 (1.09)	0.52 (1.26)	-0.74 (0.77)
Median	49.50	52.00	53.15	-1.00	0	-0.20
IQR: Q1, Q3	39.10, 57.90	45.15, 57.10	46.60, 58.10	-4.00, 4.10	-2.50, 3.40	-3.70, 2.70
Min, Max	18.7, 64.6	9.4, 71.2	32.9, 63.3	-20.0, 19.0	-24.5, 26.1	-23.5, 18.6
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	49.44 (10.89)	51.05 (9.32)	50.74 (9.96)	0.11 (1.24)	2.08 (1.43)	-0.36 (0.87)
Median	53.20	52.00	52.80	-0.60	0.75	-0.30
IQR: Q1, Q3	41.40, 57.10	46.10, 58.70	45.70, 58.40	-4.80, 2.30	-3.60, 5.10	-3.80, 4.60
Min, Max	23.1, 62.4	17.8, 70.7	20.4, 68.0	-17.3, 26.2	-11.2, 25.2	-25.1, 20.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Physical Component Score						
Baseline						
m	49	51	102			
n	45	47	91			
Mean (SD)	49.25 (9.09)	46.11 (11.21)	47.78 (9.48)			
Median	50.80	46.40	50.00			
IQR: Q1, Q3	45.10, 56.40	39.60, 56.00	42.70, 54.70			
Min, Max	21.1, 59.3	21.2, 60.4	21.8, 65.2			
Week 24						
m	46	49	100			
n	45	48	94	43	45	85
Mean (SD/SE)	50.21 (9.38)	47.30 (8.89)	48.92 (8.68)	1.01 (0.77)	0.81 (1.16)	0.80 (0.72)
Median	51.90	49.05	50.05	0.60	0	0.40
IQR: Q1, Q3	44.90, 57.30	41.75, 54.40	45.50, 55.40	-2.20, 3.90	-3.00, 3.50	-3.60, 4.00
Min, Max	21.8, 62.7	20.2, 61.0	22.8, 62.1	-12.7, 18.3	-14.4, 32.4	-11.7, 23.8
Week 52						
m	42	44	94			
n	39	40	83	37	38	77
Mean (SD/SE)	50.58 (10.01)	48.04 (11.23)	47.76 (8.51)	1.67 (1.08)	0.91 (1.40)	0.49 (0.65)
Median	53.90	51.35	48.30	2.20	1.50	0.30
IQR: Q1, Q3	44.20, 57.50	42.35, 56.95	43.80, 54.30	-1.00, 4.10	-2.70, 7.10	-2.30, 2.80
Min, Max	23.2, 62.7	16.0, 61.2	23.6, 59.9	-22.4, 22.5	-22.5, 17.2	-17.9, 16.1

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Physical Functioning			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	72.62 (24.91)	67.41 (25.86)	73.22 (26.32)
Analysis Visit Mean (SD)	73.61 (24.86)	68.00 (24.07)	72.56 (29.20)
LS Mean of Change from Baseline (SE)	0.47 (1.70)	-1.26 (1.97)	-1.11 (1.39)
95% CI	(-2.87, 3.82)	(-5.13, 2.61)	(-3.85, 1.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.58 (2.17)	-0.15 (2.38)	
95% CI	(-2.68, 5.85)	(-4.83, 4.54)	
p-value	0.4652	0.9514	
Corrected Hedge's g Statistics	0.089	-0.008	
95% CI	(-0.15, 0.33)	(-0.27, 0.26)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	73.15 (23.64)	67.39 (26.06)	75.79 (24.29)
Analysis Visit Mean (SD)	73.76 (27.48)	68.66 (24.25)	76.36 (24.59)
LS Mean of Change from Baseline (SE)	0.03 (1.56)	-0.08 (1.79)	0.14 (1.25)
95% CI	(-3.03, 3.09)	(-3.60, 3.45)	(-2.33, 2.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (1.96)	-0.22 (2.16)	
95% CI	(-3.97, 3.75)	(-4.46, 4.03)	
p-value	0.9544	0.9205	
Corrected Hedge's g Statistics	-0.007	-0.014	
95% CI	(-0.27, 0.25)	(-0.30, 0.27)	
Subgroup*Treatment Interaction p-value	0.6037	0.9038	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Role Physical			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	75.77 (24.10)	73.93 (26.19)	75.63 (26.43)
Analysis Visit Mean (SD)	73.57 (25.59)	72.24 (23.44)	73.44 (29.19)
LS Mean of Change from Baseline (SE)	-2.67 (1.90)	-3.19 (2.19)	-2.81 (1.55)
95% CI	(-6.40, 1.06)	(-7.50, 1.11)	(-5.87, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.14 (2.41)	-0.38 (2.64)	
95% CI	(-4.61, 4.89)	(-5.58, 4.82)	
p-value	0.9540	0.8855	
Corrected Hedge's g Statistics	0.007	-0.019	
95% CI	(-0.24, 0.25)	(-0.29, 0.25)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	76.83 (24.70)	72.55 (26.67)	78.10 (24.43)
Analysis Visit Mean (SD)	74.74 (27.27)	72.82 (25.68)	76.04 (25.38)
LS Mean of Change from Baseline (SE)	-2.51 (1.93)	-1.21 (2.22)	-1.93 (1.56)
95% CI	(-6.32, 1.29)	(-5.58, 3.16)	(-4.99, 1.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.58 (2.44)	0.72 (2.67)	
95% CI	(-5.39, 4.22)	(-4.54, 5.97)	
p-value	0.8111	0.7893	
Corrected Hedge's g Statistics	-0.031	0.038	
95% CI	(-0.29, 0.23)	(-0.25, 0.32)	
Subgroup*Treatment Interaction p-value	0.7869	0.9111	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Bodily Pain			
Week 24			
m	115	92	189
n	107	81	163
Baseline Mean (SD)	66.6 (23.1)	61.2 (26.6)	65.4 (25.7)
Analysis Visit Mean (SD)	62.8 (24.7)	61.7 (23.8)	65.4 (26.8)
LS Mean of Change from Baseline (SE)	-3.54 (1.85)	-1.31 (2.13)	-0.07 (1.50)
95% CI	(-7.17, 0.08)	(-5.49, 2.88)	(-3.02, 2.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.48 (2.34)	-1.24 (2.56)	
95% CI	(-8.09, 1.13)	(-6.28, 3.80)	
p-value	0.1383	0.6283	
Corrected Hedge's g Statistics	-0.181	-0.064	
95% CI	(-0.43, 0.06)	(-0.33, 0.20)	
Week 52			
m	107	81	176
n	92	71	146
Baseline Mean (SD)	67.8 (23.4)	59.1 (27.0)	66.6 (24.7)
Analysis Visit Mean (SD)	66.4 (25.6)	63.9 (24.8)	69.1 (24.6)
LS Mean of Change from Baseline (SE)	-0.60 (2.04)	1.84 (2.35)	2.41 (1.63)
95% CI	(-4.62, 3.41)	(-2.77, 6.45)	(-0.81, 5.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.01 (2.58)	-0.57 (2.82)	
95% CI	(-8.08, 2.06)	(-6.12, 4.98)	
p-value	0.2434	0.8398	
Corrected Hedge's g Statistics	-0.153	-0.029	
95% CI	(-0.41, 0.11)	(-0.31, 0.25)	
Subgroup*Treatment Interaction p-value	0.1717	0.3781	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
General Health			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	59.69 (18.88)	53.94 (18.11)	57.48 (20.35)
Analysis Visit Mean (SD)	60.74 (20.28)	55.07 (19.99)	58.98 (22.98)
LS Mean of Change from Baseline (SE)	0.98 (1.43)	-0.43 (1.66)	1.03 (1.17)
95% CI	(-1.84, 3.80)	(-3.68, 2.83)	(-1.27, 3.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (1.82)	-1.46 (2.00)	
95% CI	(-3.64, 3.53)	(-5.39, 2.46)	
p-value	0.9769	0.4642	
Corrected Hedge's g Statistics	-0.004	-0.098	
95% CI	(-0.25, 0.24)	(-0.36, 0.17)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	61.20 (19.35)	53.80 (18.85)	59.45 (20.84)
Analysis Visit Mean (SD)	61.70 (20.25)	54.21 (20.08)	61.31 (22.18)
LS Mean of Change from Baseline (SE)	0.67 (1.49)	-2.01 (1.71)	1.99 (1.20)
95% CI	(-2.26, 3.61)	(-5.38, 1.35)	(-0.37, 4.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.32 (1.88)	-4.00 (2.06)	
95% CI	(-5.01, 2.38)	(-8.05, 0.05)	
p-value	0.4842	0.0528	
Corrected Hedge's g Statistics	-0.091	-0.276	
95% CI	(-0.35, 0.17)	(-0.56, 0.01)	
Subgroup*Treatment Interaction p-value	0.1961	0.1224	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Vitality			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	58.55 (21.45)	55.12 (22.21)	56.99 (21.44)
Analysis Visit Mean (SD)	56.91 (22.81)	54.11 (19.37)	56.81 (22.87)
LS Mean of Change from Baseline (SE)	-1.80 (1.44)	-2.37 (1.66)	-0.68 (1.18)
95% CI	(-4.63, 1.04)	(-5.64, 0.90)	(-3.00, 1.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.12 (1.83)	-1.69 (2.01)	
95% CI	(-4.72, 2.48)	(-5.64, 2.25)	
p-value	0.5415	0.3988	
Corrected Hedge's g Statistics	-0.074	-0.112	
95% CI	(-0.32, 0.17)	(-0.38, 0.15)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	59.97 (21.62)	55.31 (23.02)	58.01 (20.39)
Analysis Visit Mean (SD)	59.03 (22.18)	53.55 (21.54)	58.03 (22.78)
LS Mean of Change from Baseline (SE)	-0.95 (1.60)	-3.44 (1.84)	-0.60 (1.29)
95% CI	(-4.10, 2.21)	(-7.06, 0.17)	(-3.13, 1.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.35 (2.03)	-2.85 (2.21)	
95% CI	(-4.34, 3.64)	(-7.20, 1.50)	
p-value	0.8631	0.1990	
Corrected Hedge's g Statistics	-0.022	-0.183	
95% CI	(-0.28, 0.24)	(-0.47, 0.10)	
Subgroup*Treatment Interaction p-value	0.4370	0.5046	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Social Functioning			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	83.10 (21.16)	82.25 (25.45)	81.98 (23.62)
Analysis Visit Mean (SD)	81.48 (24.32)	83.02 (18.78)	80.29 (25.53)
LS Mean of Change from Baseline (SE)	-2.18 (1.81)	-0.58 (2.09)	-2.64 (1.48)
95% CI	(-5.74, 1.38)	(-4.69, 3.52)	(-5.56, 0.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.47 (2.31)	2.06 (2.52)	
95% CI	(-4.07, 5.00)	(-2.90, 7.02)	
p-value	0.8395	0.4137	
Corrected Hedge's g Statistics	0.025	0.109	
95% CI	(-0.22, 0.27)	(-0.16, 0.38)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	83.87 (21.46)	80.99 (26.71)	84.42 (21.80)
Analysis Visit Mean (SD)	82.26 (22.82)	80.28 (21.51)	83.13 (22.05)
LS Mean of Change from Baseline (SE)	-1.79 (1.81)	-2.14 (2.07)	-1.91 (1.45)
95% CI	(-5.35, 1.76)	(-6.22, 1.93)	(-4.76, 0.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.11 (2.28)	-0.24 (2.49)	
95% CI	(-4.37, 4.60)	(-5.14, 4.67)	
p-value	0.9603	0.9249	
Corrected Hedge's g Statistics	0.006	-0.013	
95% CI	(-0.25, 0.27)	(-0.30, 0.27)	
Subgroup*Treatment Interaction p-value	0.9360	0.5346	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Role Emotional			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	84.02 (22.53)	82.00 (24.42)	82.98 (23.21)
Analysis Visit Mean (SD)	83.72 (21.26)	85.70 (18.83)	81.54 (26.38)
LS Mean of Change from Baseline (SE)	-0.11 (1.59)	3.04 (1.83)	-1.30 (1.30)
95% CI	(-3.23, 3.02)	(-0.57, 6.64)	(-3.86, 1.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.19 (2.02)	4.33 (2.21)	
95% CI	(-2.79, 5.16)	(-0.01, 8.68)	
p-value	0.5569	0.0508	
Corrected Hedge's g Statistics	0.071	0.260	
95% CI	(-0.17, 0.31)	(-0.01, 0.53)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	84.05 (22.78)	81.57 (25.04)	85.45 (21.51)
Analysis Visit Mean (SD)	84.14 (20.57)	84.27 (23.13)	83.56 (22.74)
LS Mean of Change from Baseline (SE)	0.17 (1.77)	2.02 (2.03)	-1.61 (1.42)
95% CI	(-3.31, 3.65)	(-1.98, 6.01)	(-4.41, 1.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.77 (2.24)	3.62 (2.45)	
95% CI	(-2.63, 6.18)	(-1.19, 8.43)	
p-value	0.4287	0.1394	
Corrected Hedge's g Statistics	0.103	0.210	
95% CI	(-0.16, 0.36)	(-0.07, 0.49)	
Subgroup*Treatment Interaction p-value	0.9599	0.7592	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Mental Health			
Week 24			
m	115	92	189
n	108	81	163
Baseline Mean (SD)	74.8 (18.7)	76.8 (18.2)	73.7 (17.8)
Analysis Visit Mean (SD)	74.5 (18.4)	75.4 (19.4)	74.0 (20.5)
LS Mean of Change from Baseline (SE)	-0.43 (1.32)	-1.48 (1.53)	-0.08 (1.08)
95% CI	(-3.04, 2.17)	(-4.48, 1.53)	(-2.21, 2.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.36 (1.68)	-1.40 (1.85)	
95% CI	(-3.67, 2.95)	(-5.03, 2.23)	
p-value	0.8322	0.4482	
Corrected Hedge's g Statistics	-0.026	-0.101	
95% CI	(-0.27, 0.22)	(-0.37, 0.17)	
Week 52			
m	107	81	176
n	93	71	146
Baseline Mean (SD)	75.3 (19.0)	76.8 (18.2)	74.7 (17.4)
Analysis Visit Mean (SD)	75.7 (17.7)	76.3 (18.2)	76.0 (19.6)
LS Mean of Change from Baseline (SE)	0.28 (1.36)	-0.54 (1.56)	0.30 (1.09)
95% CI	(-2.39, 2.95)	(-3.61, 2.53)	(-1.85, 2.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (1.72)	-0.84 (1.88)	
95% CI	(-3.40, 3.35)	(-4.53, 2.85)	
p-value	0.9895	0.6535	
Corrected Hedge's g Statistics	-0.002	-0.064	
95% CI	(-0.26, 0.26)	(-0.35, 0.22)	
Subgroup*Treatment Interaction p-value	0.8996	0.3164	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Mental Component Score			
Week 24			
m	115	92	189
n	107	81	163
Baseline Mean (SD)	51.62 (9.78)	51.98 (10.47)	50.76 (9.49)
Analysis Visit Mean (SD)	51.17 (9.52)	52.27 (9.51)	50.53 (11.14)
LS Mean of Change from Baseline (SE)	-0.46 (0.68)	0.16 (0.78)	-0.39 (0.55)
95% CI	(-1.80, 0.87)	(-1.38, 1.69)	(-1.48, 0.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.86)	0.55 (0.94)	
95% CI	(-1.77, 1.62)	(-1.31, 2.40)	
p-value	0.9319	0.5626	
Corrected Hedge's g Statistics	-0.010	0.077	
95% CI	(-0.25, 0.23)	(-0.19, 0.34)	
Week 52			
m	107	81	176
n	92	71	146
Baseline Mean (SD)	51.85 (10.03)	51.93 (10.64)	51.45 (9.00)
Analysis Visit Mean (SD)	51.69 (9.01)	51.72 (10.05)	51.24 (10.38)
LS Mean of Change from Baseline (SE)	-0.13 (0.73)	-0.33 (0.83)	-0.59 (0.58)
95% CI	(-1.55, 1.30)	(-1.96, 1.30)	(-1.74, 0.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.47 (0.92)	0.26 (1.00)	
95% CI	(-1.34, 2.27)	(-1.70, 2.22)	
p-value	0.6109	0.7916	
Corrected Hedge's g Statistics	0.066	0.037	
95% CI	(-0.19, 0.33)	(-0.25, 0.32)	
Subgroup*Treatment Interaction p-value	0.8979	0.5104	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Physical Component Score			
Week 24			
m	115	92	189
n	107	81	163
Baseline Mean (SD)	47.02 (8.56)	44.46 (9.15)	46.88 (9.70)
Analysis Visit Mean (SD)	46.60 (9.59)	44.38 (8.86)	46.76 (10.61)
LS Mean of Change from Baseline (SE)	-0.54 (0.66)	-0.86 (0.76)	-0.31 (0.54)
95% CI	(-1.84, 0.76)	(-2.36, 0.64)	(-1.37, 0.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.23 (0.84)	-0.55 (0.92)	
95% CI	(-1.87, 1.42)	(-2.35, 1.26)	
p-value	0.7865	0.5519	
Corrected Hedge's g Statistics	-0.033	-0.080	
95% CI	(-0.28, 0.21)	(-0.35, 0.19)	
Week 52			
m	107	81	176
n	92	71	146
Baseline Mean (SD)	47.54 (8.60)	44.03 (9.47)	47.68 (9.03)
Analysis Visit Mean (SD)	47.27 (10.51)	44.75 (9.04)	48.07 (9.33)
LS Mean of Change from Baseline (SE)	-0.36 (0.64)	-0.12 (0.74)	0.39 (0.52)
95% CI	(-1.63, 0.91)	(-1.58, 1.34)	(-0.62, 1.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.75 (0.81)	-0.51 (0.89)	
95% CI	(-2.35, 0.84)	(-2.27, 1.24)	
p-value	0.3546	0.5668	
Corrected Hedge's g Statistics	-0.121	-0.082	
95% CI	(-0.38, 0.14)	(-0.37, 0.20)	
Subgroup*Treatment Interaction p-value	0.2429	0.5916	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Physical Functioning			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	78.84 (20.20)	75.00 (25.81)	78.84 (23.57)
Analysis Visit Mean (SD)	81.28 (23.45)	76.89 (24.46)	80.87 (22.48)
LS Mean of Change from Baseline (SE)	2.73 (2.41)	1.17 (2.37)	1.62 (1.71)
95% CI	(-2.03, 7.49)	(-3.50, 5.84)	(-1.76, 5.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.11 (2.95)	-0.45 (2.90)	
95% CI	(-4.71, 6.93)	(-6.18, 5.28)	
p-value	0.7070	0.8773	
Corrected Hedge's g Statistics	0.070	-0.028	
95% CI	(-0.30, 0.44)	(-0.39, 0.33)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	80.68 (19.94)	75.13 (26.08)	76.30 (24.98)
Analysis Visit Mean (SD)	83.78 (23.02)	74.24 (29.79)	77.21 (23.67)
LS Mean of Change from Baseline (SE)	4.16 (2.69)	-0.51 (2.65)	0.87 (1.88)
95% CI	(-1.16, 9.48)	(-5.74, 4.72)	(-2.84, 4.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.29 (3.28)	-1.38 (3.23)	
95% CI	(-3.19, 9.77)	(-7.76, 4.99)	
p-value	0.3182	0.6689	
Corrected Hedge's g Statistics	0.198	-0.084	
95% CI	(-0.19, 0.59)	(-0.47, 0.31)	
Subgroup*Treatment Interaction p-value	0.6037	0.9038	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Role Physical			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	75.74 (30.50)	73.07 (29.46)	78.14 (26.19)
Analysis Visit Mean (SD)	77.04 (30.23)	75.43 (26.12)	81.41 (22.53)
LS Mean of Change from Baseline (SE)	1.35 (2.49)	1.65 (2.44)	3.41 (1.77)
95% CI	(-3.55, 6.26)	(-3.16, 6.46)	(-0.08, 6.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.06 (3.04)	-1.76 (2.99)	
95% CI	(-8.06, 3.95)	(-7.67, 4.15)	
p-value	0.5001	0.5574	
Corrected Hedge's g Statistics	-0.125	-0.107	
95% CI	(-0.49, 0.24)	(-0.47, 0.25)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	75.85 (32.04)	73.37 (30.57)	74.77 (27.15)
Analysis Visit Mean (SD)	79.40 (30.07)	74.85 (28.70)	75.59 (23.88)
LS Mean of Change from Baseline (SE)	3.95 (2.77)	1.73 (2.73)	0.58 (1.94)
95% CI	(-1.52, 9.43)	(-3.67, 7.12)	(-3.25, 4.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.37 (3.38)	1.15 (3.34)	
95% CI	(-3.30, 10.05)	(-5.44, 7.73)	
p-value	0.3198	0.7314	
Corrected Hedge's g Statistics	0.197	0.067	
95% CI	(-0.20, 0.59)	(-0.32, 0.46)	
Subgroup*Treatment Interaction p-value	0.7869	0.9111	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Bodily Pain			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	66.9 (26.8)	65.3 (25.9)	67.8 (23.8)
Analysis Visit Mean (SD)	68.1 (27.6)	66.9 (25.0)	68.6 (23.8)
LS Mean of Change from Baseline (SE)	1.31 (2.75)	1.28 (2.70)	0.40 (1.95)
95% CI	(-4.13, 6.74)	(-4.05, 6.60)	(-3.45, 4.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.90 (3.37)	0.88 (3.31)	
95% CI	(-5.75, 7.55)	(-5.65, 7.41)	
p-value	0.7890	0.7917	
Corrected Hedge's g Statistics	0.050	0.048	
95% CI	(-0.32, 0.42)	(-0.31, 0.41)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	66.6 (28.2)	65.6 (25.8)	66.3 (24.6)
Analysis Visit Mean (SD)	70.5 (26.6)	70.9 (26.8)	65.6 (24.3)
LS Mean of Change from Baseline (SE)	2.94 (3.00)	4.53 (2.95)	-0.47 (2.10)
95% CI	(-2.97, 8.85)	(-1.29, 10.35)	(-4.61, 3.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.42 (3.65)	5.00 (3.60)	
95% CI	(-3.79, 10.63)	(-2.10, 12.11)	
p-value	0.3510	0.1663	
Corrected Hedge's g Statistics	0.185	0.271	
95% CI	(-0.21, 0.58)	(-0.12, 0.66)	
Subgroup*Treatment Interaction p-value	0.1717	0.3781	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
General Health			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	61.95 (20.70)	51.44 (19.84)	62.06 (20.25)
Analysis Visit Mean (SD)	62.76 (21.16)	53.16 (18.87)	61.16 (19.05)
LS Mean of Change from Baseline (SE)	1.65 (2.04)	-0.75 (2.02)	-0.46 (1.45)
95% CI	(-2.37, 5.67)	(-4.73, 3.24)	(-3.31, 2.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.11 (2.48)	-0.29 (2.49)	
95% CI	(-2.79, 7.01)	(-5.20, 4.63)	
p-value	0.3974	0.9085	
Corrected Hedge's g Statistics	0.156	-0.021	
95% CI	(-0.21, 0.52)	(-0.38, 0.34)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	62.14 (21.33)	52.42 (21.30)	60.01 (20.17)
Analysis Visit Mean (SD)	66.15 (18.07)	57.89 (17.72)	60.73 (18.60)
LS Mean of Change from Baseline (SE)	4.77 (2.06)	3.74 (2.04)	1.03 (1.44)
95% CI	(0.72, 8.83)	(-0.29, 7.78)	(-1.81, 3.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.75 (2.50)	2.72 (2.49)	
95% CI	(-1.19, 8.69)	(-2.21, 7.64)	
p-value	0.1360	0.2776	
Corrected Hedge's g Statistics	0.296	0.214	
95% CI	(-0.10, 0.69)	(-0.18, 0.60)	
Subgroup*Treatment Interaction p-value	0.1961	0.1224	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Vitality			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	55.10 (25.01)	50.58 (23.38)	57.29 (22.61)
Analysis Visit Mean (SD)	57.00 (25.01)	51.14 (20.87)	58.02 (22.15)
LS Mean of Change from Baseline (SE)	1.83 (2.09)	-0.87 (2.06)	0.13 (1.49)
95% CI	(-2.30, 5.95)	(-4.93, 3.19)	(-2.80, 3.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.70 (2.56)	-1.00 (2.53)	
95% CI	(-3.35, 6.75)	(-5.99, 3.99)	
p-value	0.5078	0.6936	
Corrected Hedge's g Statistics	0.123	-0.072	
95% CI	(-0.24, 0.49)	(-0.43, 0.29)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	55.59 (25.80)	52.16 (23.04)	55.54 (23.50)
Analysis Visit Mean (SD)	57.62 (23.06)	56.44 (20.36)	57.09 (22.68)
LS Mean of Change from Baseline (SE)	2.34 (2.36)	3.05 (2.33)	1.35 (1.65)
95% CI	(-2.33, 7.00)	(-1.56, 7.65)	(-1.92, 4.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.99 (2.88)	1.70 (2.85)	
95% CI	(-4.70, 6.68)	(-3.92, 7.32)	
p-value	0.7319	0.5509	
Corrected Hedge's g Statistics	0.068	0.117	
95% CI	(-0.32, 0.46)	(-0.27, 0.51)	
Subgroup*Treatment Interaction p-value	0.4370	0.5046	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Social Functioning			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	79.94 (27.97)	75.83 (27.23)	84.74 (20.42)
Analysis Visit Mean (SD)	81.69 (25.20)	79.17 (25.00)	83.28 (21.91)
LS Mean of Change from Baseline (SE)	1.20 (2.69)	1.14 (2.65)	-1.17 (1.92)
95% CI	(-4.11, 6.51)	(-4.09, 6.37)	(-4.95, 2.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.37 (3.30)	2.31 (3.27)	
95% CI	(-4.15, 8.88)	(-4.14, 8.76)	
p-value	0.4742	0.4805	
Corrected Hedge's g Statistics	0.133	0.129	
95% CI	(-0.23, 0.50)	(-0.23, 0.49)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	82.77 (26.41)	76.97 (28.40)	82.47 (22.33)
Analysis Visit Mean (SD)	81.08 (24.76)	83.55 (25.02)	83.44 (22.25)
LS Mean of Change from Baseline (SE)	-1.12 (2.81)	5.26 (2.78)	0.53 (1.97)
95% CI	(-6.67, 4.42)	(-0.23, 10.75)	(-3.36, 4.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.65 (3.43)	4.73 (3.40)	
95% CI	(-8.41, 5.12)	(-1.97, 11.43)	
p-value	0.6313	0.1654	
Corrected Hedge's g Statistics	-0.095	0.273	
95% CI	(-0.49, 0.30)	(-0.12, 0.66)	
Subgroup*Treatment Interaction p-value	0.9360	0.5346	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Role Emotional			
Week 24			
m	46	49	100
n	43	45	85
Baseline Mean (SD)	78.10 (28.35)	81.48 (24.03)	85.98 (21.41)
Analysis Visit Mean (SD)	78.48 (25.67)	82.96 (24.68)	85.98 (18.78)
LS Mean of Change from Baseline (SE)	-1.10 (2.48)	0.85 (2.42)	-0.12 (1.76)
95% CI	(-5.99, 3.78)	(-3.91, 5.62)	(-3.60, 3.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.98 (3.05)	0.98 (2.97)	
95% CI	(-6.99, 5.03)	(-4.89, 6.84)	
p-value	0.7473	0.7432	
Corrected Hedge's g Statistics	-0.060	0.060	
95% CI	(-0.43, 0.31)	(-0.30, 0.42)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	80.85 (26.27)	80.92 (25.55)	83.33 (23.10)
Analysis Visit Mean (SD)	83.45 (22.75)	85.31 (20.18)	81.81 (23.36)
LS Mean of Change from Baseline (SE)	2.59 (2.64)	4.55 (2.60)	-1.62 (1.85)
95% CI	(-2.63, 7.80)	(-0.57, 9.68)	(-5.27, 2.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.21 (3.23)	6.18 (3.17)	
95% CI	(-2.16, 10.58)	(-0.08, 12.44)	
p-value	0.1938	0.0531	
Corrected Hedge's g Statistics	0.258	0.380	
95% CI	(-0.14, 0.65)	(-0.01, 0.77)	
Subgroup*Treatment Interaction p-value	0.9599	0.7592	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Mental Health			
Week 24			
m	46	49	100
n	43	45	86
Baseline Mean (SD)	72.2 (21.3)	72.6 (20.4)	77.4 (17.9)
Analysis Visit Mean (SD)	70.5 (21.5)	73.2 (18.5)	76.3 (15.6)
LS Mean of Change from Baseline (SE)	-2.50 (1.80)	-0.06 (1.77)	-1.17 (1.28)
95% CI	(-6.06, 1.06)	(-3.55, 3.43)	(-3.70, 1.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.32 (2.21)	1.12 (2.17)	
95% CI	(-5.69, 3.04)	(-3.17, 5.40)	
p-value	0.5503	0.6084	
Corrected Hedge's g Statistics	-0.111	0.093	
95% CI	(-0.48, 0.26)	(-0.27, 0.45)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	74.2 (18.3)	72.0 (22.1)	76.0 (18.9)
Analysis Visit Mean (SD)	75.0 (17.4)	73.3 (18.9)	75.0 (19.7)
LS Mean of Change from Baseline (SE)	0.69 (2.20)	0.67 (2.17)	-0.98 (1.54)
95% CI	(-3.66, 5.04)	(-3.62, 4.96)	(-4.02, 2.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.67 (2.69)	1.65 (2.66)	
95% CI	(-3.63, 6.98)	(-3.59, 6.90)	
p-value	0.5343	0.5344	
Corrected Hedge's g Statistics	0.123	0.122	
95% CI	(-0.27, 0.52)	(-0.27, 0.51)	
Subgroup*Treatment Interaction p-value	0.8996	0.3164	

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Mental Component Score			
Week 24			
m	46	49	100
n	43	45	85
Baseline Mean (SD)	48.48 (12.40)	48.84 (12.17)	51.90 (9.35)
Analysis Visit Mean (SD)	48.19 (11.76)	49.36 (10.68)	51.16 (8.55)
LS Mean of Change from Baseline (SE)	-0.87 (1.04)	-0.07 (1.02)	-0.81 (0.74)
95% CI	(-2.93, 1.19)	(-2.09, 1.94)	(-2.28, 0.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (1.28)	0.74 (1.26)	
95% CI	(-2.59, 2.47)	(-1.75, 3.22)	
p-value	0.9633	0.5590	
Corrected Hedge's g Statistics	-0.009	0.107	
95% CI	(-0.38, 0.36)	(-0.25, 0.47)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	49.69 (11.03)	48.85 (13.07)	51.04 (10.01)
Analysis Visit Mean (SD)	49.80 (10.05)	50.92 (9.43)	50.69 (10.16)
LS Mean of Change from Baseline (SE)	0.07 (1.12)	1.66 (1.10)	-0.42 (0.78)
95% CI	(-2.14, 2.27)	(-0.51, 3.84)	(-1.97, 1.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.49 (1.37)	2.09 (1.35)	
95% CI	(-2.20, 3.19)	(-0.57, 4.75)	
p-value	0.7192	0.1233	
Corrected Hedge's g Statistics	0.071	0.303	
95% CI	(-0.32, 0.46)	(-0.09, 0.69)	
Subgroup*Treatment Interaction p-value	0.8979	0.5104	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.7.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Physical Component Score			
Week 24			
m	46	49	100
n	43	45	85
Baseline Mean (SD)	49.06 (9.17)	46.30 (10.79)	48.39 (9.16)
Analysis Visit Mean (SD)	50.07 (9.48)	47.11 (8.98)	49.19 (8.65)
LS Mean of Change from Baseline (SE)	1.39 (0.92)	0.35 (0.90)	0.85 (0.65)
95% CI	(-0.42, 3.20)	(-1.42, 2.13)	(-0.44, 2.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.54 (1.12)	-0.50 (1.11)	
95% CI	(-1.67, 2.76)	(-2.68, 1.69)	
p-value	0.6295	0.6538	
Corrected Hedge's g Statistics	0.090	-0.082	
95% CI	(-0.28, 0.46)	(-0.44, 0.28)	
Week 52			
m	42	44	94
n	37	38	77
Baseline Mean (SD)	48.91 (9.72)	46.63 (10.78)	47.37 (9.39)
Analysis Visit Mean (SD)	50.58 (10.17)	47.54 (11.30)	47.87 (8.30)
LS Mean of Change from Baseline (SE)	1.84 (1.02)	0.77 (1.01)	0.50 (0.71)
95% CI	(-0.17, 3.86)	(-1.21, 2.76)	(-0.91, 1.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.34 (1.25)	0.27 (1.23)	
95% CI	(-1.12, 3.80)	(-2.15, 2.69)	
p-value	0.2828	0.8251	
Corrected Hedge's g Statistics	0.213	0.043	
95% CI	(-0.18, 0.61)	(-0.35, 0.43)	
Subgroup*Treatment Interaction p-value	0.2429	0.5916	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (12.7)	12 (12.0)	25 (12.4)
No	103 (87.3)	88 (88.0)	176 (87.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.04	
95% CI of the inverse odds ratio	(0.49, 1.93)	(0.50, 2.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.04	
95% CI of the inverse risk ratio	(0.54, 1.78)	(0.54, 1.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.27	-0.44	
95% CI of the absolute risk difference	(-7.27, 7.82)	(-8.27, 7.40)	
p-value	0.9431	0.9132	
p-value of Breslow-Day Test for Homogeneity [3]	0.7487	0.9500	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	38 (32.2)	35 (35.0)	53 (26.4)
No	80 (67.8)	65 (65.0)	148 (73.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.67	
95% CI of the inverse odds ratio	(0.46, 1.24)	(0.40, 1.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.75	
95% CI of the inverse risk ratio	(0.58, 1.16)	(0.53, 1.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.84	8.63	
95% CI of the absolute risk difference	(-4.57, 16.24)	(-2.53, 19.79)	
p-value	0.2651	0.1210	
p-value of Breslow-Day Test for Homogeneity [3]	0.6910	0.1099	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (8.5)	11 (11.0)	22 (10.9)
No	108 (91.5)	89 (89.0)	179 (89.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	0.99	
95% CI of the inverse odds ratio	(0.61, 2.91)	(0.46, 2.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.00	
95% CI of the inverse risk ratio	(0.63, 2.63)	(0.50, 1.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.47	0.05	
95% CI of the absolute risk difference	(-9.09, 4.15)	(-7.44, 7.55)	
p-value	0.4782	0.9886	
p-value of Breslow-Day Test for Homogeneity [3]	0.7562	0.7959	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (23.7)	26 (26.0)	43 (21.4)
No	90 (76.3)	74 (74.0)	158 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.77	
95% CI of the inverse odds ratio	(0.51, 1.50)	(0.44, 1.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	0.82	
95% CI of the inverse risk ratio	(0.59, 1.37)	(0.54, 1.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.34	4.61	
95% CI of the absolute risk difference	(-7.21, 11.88)	(-5.69, 14.90)	
p-value	0.6283	0.3705	
p-value of Breslow-Day Test for Homogeneity [3]	0.5531	0.4611	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (11.9)	16 (16.0)	38 (18.9)
No	104 (88.1)	84 (84.0)	163 (81.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.73	1.22	
95% CI of the inverse odds ratio	(0.89, 3.35)	(0.64, 2.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	1.18	
95% CI of the inverse risk ratio	(0.90, 2.81)	(0.69, 2.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.04	-2.91	
95% CI of the absolute risk difference	(-15.00, 0.92)	(-11.90, 6.09)	
p-value	0.1002	0.5360	
p-value of Breslow-Day Test for Homogeneity [3]	0.5842	0.3223	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (22.0)	29 (29.0)	57 (28.4)
No	92 (78.0)	71 (71.0)	144 (71.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	0.97	
95% CI of the inverse odds ratio	(0.82, 2.39)	(0.57, 1.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.98	
95% CI of the inverse risk ratio	(0.86, 1.93)	(0.67, 1.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.32	0.64	
95% CI of the absolute risk difference	(-16.06, 3.41)	(-10.22, 11.50)	
p-value	0.2139	0.9076	
p-value of Breslow-Day Test for Homogeneity [3]	0.2509	0.3866	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (15.3)	15 (15.0)	30 (14.9)
No	100 (84.7)	85 (85.0)	171 (85.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.99	
95% CI of the inverse odds ratio	(0.52, 1.84)	(0.51, 1.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.00	
95% CI of the inverse risk ratio	(0.57, 1.68)	(0.56, 1.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.33	0.07	
95% CI of the absolute risk difference	(-7.82, 8.47)	(-8.48, 8.63)	
p-value	0.9368	0.9864	
p-value of Breslow-Day Test for Homogeneity [3]	0.9197	0.2126	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	34 (28.8)	33 (33.0)	62 (30.8)
No	84 (71.2)	67 (67.0)	139 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	0.91	
95% CI of the inverse odds ratio	(0.67, 1.81)	(0.54, 1.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.93	
95% CI of the inverse risk ratio	(0.75, 1.52)	(0.66, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.03	2.15	
95% CI of the absolute risk difference	(-12.40, 8.34)	(-9.06, 13.37)	
p-value	0.7024	0.7049	
p-value of Breslow-Day Test for Homogeneity [3]	0.5824	0.4472	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (9.3)	8 (8.0)	20 (10.0)
No	107 (90.7)	92 (92.0)	181 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.27	
95% CI of the inverse odds ratio	(0.50, 2.33)	(0.54, 3.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.24	
95% CI of the inverse risk ratio	(0.53, 2.15)	(0.57, 2.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.63	-1.95	
95% CI of the absolute risk difference	(-7.31, 6.05)	(-8.69, 4.79)	
p-value	0.8549	0.5832	
p-value of Breslow-Day Test for Homogeneity [3]	0.5307	0.8896	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (28.0)	24 (24.0)	63 (31.3)
No	85 (72.0)	76 (76.0)	138 (68.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.45	
95% CI of the inverse odds ratio	(0.71, 1.94)	(0.84, 2.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	1.31	
95% CI of the inverse risk ratio	(0.79, 1.60)	(0.87, 1.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.38	-7.34	
95% CI of the absolute risk difference	(-13.71, 6.95)	(-17.89, 3.20)	
p-value	0.5255	0.1856	
p-value of Breslow-Day Test for Homogeneity [3]	0.7606	0.2332	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (7.6)	12 (12.0)	14 (7.0)
No	109 (92.4)	88 (88.0)	187 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.55	
95% CI of the inverse odds ratio	(0.38, 2.16)	(0.24, 1.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.58	
95% CI of the inverse risk ratio	(0.41, 2.04)	(0.28, 1.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.66	5.03	
95% CI of the absolute risk difference	(-5.28, 6.61)	(-2.24, 12.31)	
p-value	0.8253	0.1430	
p-value of Breslow-Day Test for Homogeneity [3]	0.5910	0.7215	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (18.6)	18 (18.0)	34 (16.9)
No	96 (81.4)	82 (82.0)	167 (83.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.93	
95% CI of the inverse odds ratio	(0.49, 1.61)	(0.49, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.94	
95% CI of the inverse risk ratio	(0.56, 1.47)	(0.56, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.73	1.08	
95% CI of the absolute risk difference	(-7.00, 10.46)	(-8.06, 10.23)	
p-value	0.6952	0.8146	
p-value of Breslow-Day Test for Homogeneity [3]	0.7024	0.1278	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (12.7)	20 (20.0)	22 (10.9)
No	103 (87.3)	80 (80.0)	179 (89.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.49	
95% CI of the inverse odds ratio	(0.42, 1.70)	(0.25, 0.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.55	
95% CI of the inverse risk ratio	(0.47, 1.59)	(0.31, 0.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.77	9.05	
95% CI of the absolute risk difference	(-5.63, 9.17)	(0.11, 18.00)	
p-value	0.6343	0.0327	
p-value of Breslow-Day Test for Homogeneity [3]	0.1817	0.4310	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (16.9)	25 (25.0)	32 (15.9)
No	98 (83.1)	75 (75.0)	169 (84.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.57	
95% CI of the inverse odds ratio	(0.50, 1.71)	(0.32, 1.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.64	
95% CI of the inverse risk ratio	(0.56, 1.56)	(0.40, 1.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.03	9.08	
95% CI of the absolute risk difference	(-7.42, 9.48)	(-0.80, 18.96)	
p-value	0.8102	0.0583	
p-value of Breslow-Day Test for Homogeneity [3]	0.8659	0.9467	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (11.9)	7 (7.0)	27 (13.4)
No	104 (88.1)	93 (93.0)	174 (86.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	2.06	
95% CI of the inverse odds ratio	(0.58, 2.30)	(0.86, 4.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	1.92	
95% CI of the inverse risk ratio	(0.62, 2.07)	(0.87, 4.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.57	-6.43	
95% CI of the absolute risk difference	(-9.07, 5.93)	(-13.31, 0.44)	
p-value	0.6861	0.0968	
p-value of Breslow-Day Test for Homogeneity [3]	0.8687	0.2243	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	42 (35.6)	26 (26.0)	58 (28.9)
No	76 (64.4)	74 (74.0)	143 (71.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	1.15	
95% CI of the inverse odds ratio	(0.45, 1.19)	(0.67, 1.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	1.11	
95% CI of the inverse risk ratio	(0.59, 1.12)	(0.75, 1.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.74	-2.86	
95% CI of the absolute risk difference	(-3.93, 17.41)	(-13.49, 7.78)	
p-value	0.2105	0.6029	
p-value of Breslow-Day Test for Homogeneity [3]	0.9953	0.4054	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.4)	7 (7.0)	12 (6.0)
No	114 (96.6)	93 (93.0)	189 (94.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.81	0.84	
95% CI of the inverse odds ratio	(0.57, 5.74)	(0.32, 2.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.76	0.85	
95% CI of the inverse risk ratio	(0.58, 5.34)	(0.35, 2.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.58	1.03	
95% CI of the absolute risk difference	(-7.21, 2.04)	(-4.95, 7.01)	
p-value	0.3080	0.7293	
p-value of Breslow-Day Test for Homogeneity [3]	0.3812	0.3270	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (24.6)	16 (16.0)	40 (19.9)
No	89 (75.4)	84 (84.0)	161 (80.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	1.30	
95% CI of the inverse odds ratio	(0.44, 1.31)	(0.69, 2.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	1.24	
95% CI of the inverse risk ratio	(0.53, 1.23)	(0.73, 2.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.68	-3.90	
95% CI of the absolute risk difference	(-4.85, 14.21)	(-12.96, 5.16)	
p-value	0.3275	0.4127	
p-value of Breslow-Day Test for Homogeneity [3]	0.2473	0.6150	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.2)	6 (6.0)	8 (4.0)
No	113 (95.8)	94 (94.0)	193 (96.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.65	
95% CI of the inverse odds ratio	(0.30, 2.93)	(0.22, 1.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.66	
95% CI of the inverse risk ratio	(0.31, 2.80)	(0.24, 1.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.26	2.02	
95% CI of the absolute risk difference	(-4.27, 4.79)	(-3.36, 7.40)	
p-value	0.9107	0.4332	
p-value of Breslow-Day Test for Homogeneity [3]	0.6578	0.6909	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (19.5)	29 (29.0)	42 (20.9)
No	95 (80.5)	71 (71.0)	159 (79.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.65	
95% CI of the inverse odds ratio	(0.62, 1.93)	(0.37, 1.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.72	
95% CI of the inverse risk ratio	(0.68, 1.69)	(0.48, 1.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.40	8.10	
95% CI of the absolute risk difference	(-10.50, 7.69)	(-2.42, 18.63)	
p-value	0.7638	0.1188	
p-value of Breslow-Day Test for Homogeneity [3]	0.3260	0.8834	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (14.3)	6 (11.8)	12 (11.8)
No	42 (85.7)	45 (88.2)	90 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.00	
95% CI of the inverse odds ratio	(0.29, 2.18)	(0.35, 2.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.00	
95% CI of the inverse risk ratio	(0.35, 1.96)	(0.40, 2.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.52	0.00	
95% CI of the absolute risk difference	(-9.10, 14.14)	(-10.83, 10.83)	
p-value	0.6619	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.7487	0.9500	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (34.7)	13 (25.5)	33 (32.4)
No	32 (65.3)	38 (74.5)	69 (67.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.40	
95% CI of the inverse odds ratio	(0.44, 1.85)	(0.66, 2.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.27	
95% CI of the inverse risk ratio	(0.58, 1.50)	(0.73, 2.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.34	-6.86	
95% CI of the absolute risk difference	(-13.79, 18.47)	(-21.88, 8.15)	
p-value	0.7747	0.3828	
p-value of Breslow-Day Test for Homogeneity [3]	0.6910	0.1099	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (10.2)	7 (13.7)	16 (15.7)
No	44 (89.8)	44 (86.3)	86 (84.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.64	1.17	
95% CI of the inverse odds ratio	(0.56, 4.76)	(0.45, 3.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.54	1.14	
95% CI of the inverse risk ratio	(0.60, 3.95)	(0.50, 2.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.48	-1.96	
95% CI of the absolute risk difference	(-16.51, 5.55)	(-13.75, 9.83)	
p-value	0.3620	0.7490	
p-value of Breslow-Day Test for Homogeneity [3]	0.7562	0.7959	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (24.5)	13 (25.5)	28 (27.5)
No	37 (75.5)	38 (74.5)	74 (72.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	1.11	
95% CI of the inverse odds ratio	(0.53, 2.55)	(0.51, 2.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	1.08	
95% CI of the inverse risk ratio	(0.62, 2.01)	(0.61, 1.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.96	-1.96	
95% CI of the absolute risk difference	(-17.79, 11.87)	(-16.73, 12.81)	
p-value	0.6994	0.7963	
p-value of Breslow-Day Test for Homogeneity [3]	0.5531	0.4611	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (12.2)	10 (19.6)	15 (14.7)
No	43 (87.8)	41 (80.4)	87 (85.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	0.71	
95% CI of the inverse odds ratio	(0.45, 3.41)	(0.29, 1.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	0.75	
95% CI of the inverse risk ratio	(0.50, 2.91)	(0.36, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.46	4.90	
95% CI of the absolute risk difference	(-13.93, 9.01)	(-7.98, 17.78)	
p-value	0.6824	0.4395	
p-value of Breslow-Day Test for Homogeneity [3]	0.5842	0.3223	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (28.6)	17 (33.3)	25 (24.5)
No	35 (71.4)	34 (66.7)	77 (75.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.65	
95% CI of the inverse odds ratio	(0.38, 1.75)	(0.31, 1.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.74	
95% CI of the inverse risk ratio	(0.49, 1.50)	(0.44, 1.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.06	8.82	
95% CI of the absolute risk difference	(-11.09, 19.22)	(-6.57, 24.22)	
p-value	0.5934	0.2490	
p-value of Breslow-Day Test for Homogeneity [3]	0.2509	0.3866	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (14.3)	13 (25.5)	15 (14.7)
No	42 (85.7)	38 (74.5)	87 (85.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.50	
95% CI of the inverse odds ratio	(0.39, 2.73)	(0.22, 1.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.58	
95% CI of the inverse risk ratio	(0.45, 2.36)	(0.30, 1.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.42	10.78	
95% CI of the absolute risk difference	(-12.39, 11.55)	(-3.01, 24.58)	
p-value	0.9454	0.1039	
p-value of Breslow-Day Test for Homogeneity [3]	0.9197	0.2126	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (32.7)	20 (39.2)	30 (29.4)
No	33 (67.3)	31 (60.8)	72 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.65	
95% CI of the inverse odds ratio	(0.41, 1.79)	(0.32, 1.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	0.75	
95% CI of the inverse risk ratio	(0.55, 1.49)	(0.48, 1.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.24	9.80	
95% CI of the absolute risk difference	(-12.59, 19.07)	(-6.25, 25.86)	
p-value	0.6854	0.2229	
p-value of Breslow-Day Test for Homogeneity [3]	0.5824	0.4472	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (10.2)	6 (11.8)	16 (15.7)
No	44 (89.8)	45 (88.2)	86 (84.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.64	1.40	
95% CI of the inverse odds ratio	(0.56, 4.76)	(0.51, 3.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.54	1.33	
95% CI of the inverse risk ratio	(0.60, 3.95)	(0.56, 3.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.48	-3.92	
95% CI of the absolute risk difference	(-16.51, 5.55)	(-15.24, 7.39)	
p-value	0.3620	0.5146	
p-value of Breslow-Day Test for Homogeneity [3]	0.5307	0.8896	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (34.7)	20 (39.2)	36 (35.3)
No	32 (65.3)	31 (60.8)	66 (64.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.85	
95% CI of the inverse odds ratio	(0.50, 2.10)	(0.42, 1.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.90	
95% CI of the inverse risk ratio	(0.64, 1.62)	(0.58, 1.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.60	3.92	
95% CI of the absolute risk difference	(-16.84, 15.64)	(-12.37, 20.22)	
p-value	0.9423	0.6350	
p-value of Breslow-Day Test for Homogeneity [3]	0.7606	0.2332	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (8.2)	11 (21.6)	11 (10.8)
No	45 (91.8)	40 (78.4)	91 (89.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.44	
95% CI of the inverse odds ratio	(0.41, 4.51)	(0.18, 1.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	0.50	
95% CI of the inverse risk ratio	(0.44, 3.94)	(0.23, 1.07)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.62	10.78	
95% CI of the absolute risk difference	(-12.37, 7.13)	(-2.01, 23.58)	
p-value	0.6142	0.0731	
p-value of Breslow-Day Test for Homogeneity [3]	0.5910	0.7215	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (16.3)	17 (33.3)	18 (17.6)
No	41 (83.7)	34 (66.7)	84 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	0.43	
95% CI of the inverse odds ratio	(0.44, 2.74)	(0.20, 0.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.53	
95% CI of the inverse risk ratio	(0.51, 2.31)	(0.30, 0.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.32	15.69	
95% CI of the absolute risk difference	(-14.04, 11.40)	(0.78, 30.59)	
p-value	0.8405	0.0294	
p-value of Breslow-Day Test for Homogeneity [3]	0.7024	0.1278	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (8.2)	10 (19.6)	16 (15.7)
No	45 (91.8)	41 (80.4)	86 (84.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.09	0.76	
95% CI of the inverse odds ratio	(0.66, 6.63)	(0.32, 1.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.92	0.80	
95% CI of the inverse risk ratio	(0.68, 5.44)	(0.39, 1.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.52	3.92	
95% CI of the absolute risk difference	(-17.94, 2.90)	(-9.06, 16.90)	
p-value	0.2017	0.5426	
p-value of Breslow-Day Test for Homogeneity [3]	0.1817	0.4310	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (18.4)	15 (29.4)	19 (18.6)
No	40 (81.6)	36 (70.6)	83 (81.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.55	
95% CI of the inverse odds ratio	(0.42, 2.45)	(0.25, 1.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.63	
95% CI of the inverse risk ratio	(0.50, 2.08)	(0.35, 1.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.26	10.78	
95% CI of the absolute risk difference	(-13.47, 12.95)	(-3.83, 25.39)	
p-value	0.9693	0.1304	
p-value of Breslow-Day Test for Homogeneity [3]	0.8659	0.9467	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (10.2)	7 (13.7)	13 (12.7)
No	44 (89.8)	44 (86.3)	89 (87.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.92	
95% CI of the inverse odds ratio	(0.43, 3.83)	(0.34, 2.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.93	
95% CI of the inverse risk ratio	(0.47, 3.31)	(0.39, 2.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.54	0.98	
95% CI of the absolute risk difference	(-13.20, 8.12)	(-10.47, 12.43)	
p-value	0.6519	0.8653	
p-value of Breslow-Day Test for Homogeneity [3]	0.8687	0.2243	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (30.6)	15 (29.4)	25 (24.5)
No	34 (69.4)	36 (70.6)	77 (75.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.78	
95% CI of the inverse odds ratio	(0.35, 1.57)	(0.37, 1.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.83	
95% CI of the inverse risk ratio	(0.47, 1.38)	(0.48, 1.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.10	4.90	
95% CI of the absolute risk difference	(-9.27, 21.47)	(-10.13, 19.94)	
p-value	0.4263	0.5154	
p-value of Breslow-Day Test for Homogeneity [3]	0.9953	0.4054	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (6.1)	6 (11.8)	5 (4.9)
No	46 (93.9)	45 (88.2)	97 (95.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.39	
95% CI of the inverse odds ratio	(0.18, 3.45)	(0.11, 1.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.42	
95% CI of the inverse risk ratio	(0.20, 3.22)	(0.13, 1.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.22	6.86	
95% CI of the absolute risk difference	(-6.69, 9.13)	(-2.92, 16.65)	
p-value	0.7539	0.1214	
p-value of Breslow-Day Test for Homogeneity [3]	0.3812	0.3270	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (16.3)	11 (21.6)	22 (21.6)
No	41 (83.7)	40 (78.4)	80 (78.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	1.00	
95% CI of the inverse odds ratio	(0.58, 3.44)	(0.44, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	1.00	
95% CI of the inverse risk ratio	(0.63, 2.75)	(0.53, 1.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.24	0.00	
95% CI of the absolute risk difference	(-18.31, 7.83)	(-13.82, 13.82)	
p-value	0.4497	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.2473	0.6150	

AMNOG Table SE22.7.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.1)	6 (11.8)	6 (5.9)
No	47 (95.9)	45 (88.2)	96 (94.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	0.47	
95% CI of the inverse odds ratio	(0.29, 7.56)	(0.14, 1.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	0.50	
95% CI of the inverse risk ratio	(0.30, 6.88)	(0.17, 1.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.80	5.88	
95% CI of the absolute risk difference	(-8.98, 5.38)	(-4.07, 15.83)	
p-value	0.6437	0.2020	
p-value of Breslow-Day Test for Homogeneity [3]	0.6578	0.6909	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (24.5)	12 (23.5)	18 (17.6)
No	37 (75.5)	39 (76.5)	84 (82.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.70	
95% CI of the inverse odds ratio	(0.29, 1.51)	(0.31, 1.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.75	
95% CI of the inverse risk ratio	(0.38, 1.37)	(0.39, 1.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.84	5.88	
95% CI of the absolute risk difference	(-7.29, 20.97)	(-7.91, 19.68)	
p-value	0.3238	0.3876	
p-value of Breslow-Day Test for Homogeneity [3]	0.3260	0.8834	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Physical Functioning						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	73.67 (25.54)	73.51 (25.51)	76.23 (26.20)			
Median	80.00	80.00	87.50			
IQR: Q1, Q3	60.00, 95.00	55.00, 95.00	60.00, 100.00			
Min, Max	0.0, 100.0	10.0, 100.0	10.0, 100.0			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	76.80 (27.46)	75.94 (20.82)	73.40 (29.79)	2.67 (2.26)	1.63 (2.74)	-3.28 (1.61)
Median	90.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 100.00	65.00, 95.00	50.00, 97.50	0.00, 10.00	-10.00, 10.00	-10.00, 5.00
Min, Max	5.0, 100.0	10.0, 100.0	0.0, 100.0	-50.0, 60.0	-45.0, 55.0	-70.0, 30.0
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	77.06 (29.04)	75.21 (25.56)	72.94 (28.39)	1.43 (2.33)	-2.69 (3.66)	-2.85 (1.60)
Median	90.00	85.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 100.00	60.00, 95.00	50.00, 100.00	-5.00, 10.00	-5.00, 5.00	-10.00, 5.00
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-65.0, 45.0	-85.0, 30.0	-60.0, 35.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Role Physical						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	75.32 (27.84)	75.81 (25.95)	76.06 (27.30)			
Median	84.40	81.30	84.40			
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	56.30, 100.00			
Min, Max	0.0, 100.0	12.5, 100.0	0.0, 100.0			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	75.83 (28.56)	76.71 (22.24)	75.66 (30.75)	-0.64 (2.23)	-0.14 (3.16)	-1.64 (2.25)
Median	87.50	81.30	100.00	0	0	0
IQR: Q1, Q3	56.30, 100.00	65.65, 100.00	50.00, 100.00	-6.30, 12.50	-18.70, 6.20	-6.30, 6.25
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.7, 43.7	-31.3, 68.7	-62.5, 87.5
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	76.85 (30.00)	74.05 (28.69)	72.81 (27.99)	-1.02 (2.67)	-5.04 (3.65)	-3.41 (2.35)
Median	93.80	81.30	81.30	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 100.00	50.00, 100.00	-6.20, 6.20	-9.40, 6.25	-12.50, 6.20
Min, Max	0.0, 100.0	6.3, 100.0	0.0, 100.0	-43.8, 56.2	-75.0, 25.0	-56.3, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Bodily Pain						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	65.2 (25.3)	66.7 (27.2)	64.1 (26.2)			
Median	68.0	74.0	62.0			
IQR: Q1, Q3	51.5, 84.0	52.0, 84.0	41.0, 84.0			
Min, Max	0, 100	0, 100	12, 100			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	62.8 (28.0)	68.3 (22.8)	65.2 (26.8)	-3.5 (2.8)	-0.8 (2.8)	0.4 (2.2)
Median	62.0	62.0	67.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	56.5, 84.0	41.0, 84.0	-20.0, 10.0	-12.0, 10.0	-10.5, 11.5
Min, Max	0, 100	21, 100	10, 100	-59, 52	-42, 52	-49, 78
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	63.8 (28.8)	72.0 (24.1)	66.3 (26.6)	-3.0 (2.9)	2.8 (4.7)	3.4 (2.7)
Median	72.0	74.0	72.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	62.0, 100.0	51.0, 84.0	-10.0, 10.0	-12.0, 16.5	-10.0, 16.0
Min, Max	0, 100	10, 100	0, 100	-80, 42	-53, 69	-49, 78

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
General Health						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	63.55 (20.90)	55.09 (18.35)	60.35 (21.60)			
Median	67.00	52.00	62.00			
IQR: Q1, Q3	52.00, 77.00	40.00, 67.00	45.00, 77.00			
Min, Max	10.0, 100.0	10.0, 100.0	15.0, 100.0			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	62.92 (22.50)	56.17 (17.78)	59.97 (23.35)	-1.41 (2.11)	1.00 (2.00)	0.28 (1.46)
Median	67.00	57.00	58.50	-1.00	0	0
IQR: Q1, Q3	52.00, 77.00	42.00, 72.00	47.00, 82.00	-8.00, 10.00	-10.00, 10.00	-5.00, 6.00
Min, Max	10.0, 100.0	17.0, 87.0	0.0, 100.0	-60.0, 32.0	-20.0, 32.0	-38.0, 40.0
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	64.12 (20.00)	58.10 (20.04)	59.44 (23.14)	-1.08 (2.32)	0.56 (3.25)	0.13 (1.58)
Median	67.00	62.00	62.00	0	5.00	0
IQR: Q1, Q3	55.00, 77.00	42.00, 72.00	45.00, 77.00	-10.00, 10.00	-10.00, 10.00	-5.00, 7.00
Min, Max	20.0, 100.0	10.0, 90.0	10.0, 100.0	-70.0, 30.0	-52.0, 37.0	-42.0, 37.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Vitality						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	58.08 (23.86)	51.76 (21.44)	55.84 (21.60)			
Median	62.50	56.30	56.30			
IQR: Q1, Q3	37.50, 75.00	43.80, 62.50	43.80, 75.00			
Min, Max	0.0, 100.0	0.0, 93.8	6.3, 100.0			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	57.51 (24.60)	50.54 (19.55)	55.88 (23.18)	-1.54 (2.03)	-2.19 (2.08)	-1.42 (1.64)
Median	62.50	50.00	56.30	0	-6.20	-3.10
IQR: Q1, Q3	43.80, 75.00	37.50, 62.50	37.50, 75.00	-6.20, 6.30	-12.50, 6.20	-12.50, 6.30
Min, Max	0.0, 100.0	0.0, 87.5	0.0, 100.0	-43.8, 25.0	-25.0, 43.7	-37.5, 43.8
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	57.62 (22.50)	52.11 (22.46)	54.66 (23.07)	-3.44 (2.23)	-1.92 (3.01)	-2.53 (1.84)
Median	62.50	50.00	56.30	-6.20	0	0
IQR: Q1, Q3	37.50, 75.00	37.50, 68.80	37.50, 68.80	-12.50, 6.30	-12.50, 6.30	-12.50, 6.30
Min, Max	6.3, 100.0	6.3, 87.5	6.3, 100.0	-43.7, 25.0	-43.8, 37.5	-56.3, 31.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Social Functioning						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	82.71 (25.43)	80.32 (25.77)	84.07 (23.28)			
Median	100.00	87.50	100.00			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	12.5, 100.0			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	79.71 (26.04)	82.03 (21.40)	79.82 (27.29)	-4.09 (3.02)	0.58 (3.67)	-4.55 (1.95)
Median	87.50	87.50	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	62.50, 100.00	-12.50, 0.00	-12.50, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	12.5, 100.0	0.0, 100.0	-62.5, 62.5	-62.5, 87.5	-62.5, 50.0
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	81.62 (24.03)	80.45 (23.08)	79.85 (23.23)	-4.59 (2.65)	-0.35 (4.44)	-4.75 (2.08)
Median	100.00	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	62.50, 100.00	-12.50, 0.00	-6.25, 12.50	-12.50, 0.00
Min, Max	25.0, 100.0	25.0, 100.0	12.5, 100.0	-50.0, 50.0	-62.5, 62.5	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Role Emotional						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	81.80 (26.20)	79.08 (22.18)	83.82 (24.62)			
Median	100.00	83.30	100.00			
IQR: Q1, Q3	75.00, 100.00	58.30, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	25.0, 100.0	0.0, 100.0			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	81.70 (23.90)	83.51 (21.65)	81.86 (26.55)	-0.43 (2.13)	4.27 (2.70)	-2.18 (1.65)
Median	100.00	95.85	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	66.70, 100.00	-8.30, 0.00	0.00, 8.30	0.00, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-33.3, 50.0	-50.0, 41.7	-50.0, 41.7
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	82.68 (23.08)	85.89 (21.56)	82.06 (24.11)	-1.36 (2.30)	5.56 (2.99)	-1.79 (2.04)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	66.70, 100.00	0.00, 0.00	0.00, 16.70	-8.40, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-50.0, 41.7	-33.3, 41.7	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Mental Health						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	73.3 (21.4)	73.4 (20.6)	74.2 (18.9)			
Median	82.5	80.0	80.0			
IQR: Q1, Q3	60.0, 90.0	60.0, 90.0	65.0, 90.0			
Min, Max	5, 100	15, 100	5, 100			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	73.1 (19.8)	72.7 (19.6)	72.9 (19.4)	-0.3 (2.0)	-1.3 (2.5)	-1.4 (1.4)
Median	75.0	80.0	80.0	0	0	0
IQR: Q1, Q3	60.0, 90.0	62.5, 85.0	65.0, 90.0	-10.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	15, 100	5, 100	5, 100	-40, 35	-40, 50	-45, 30
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	74.7 (17.5)	74.4 (18.7)	74.0 (18.9)	-0.4 (1.9)	-0.3 (2.4)	-0.2 (1.4)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	65.0, 85.0	-10.0, 10.0	-5.0, 5.0	-10.0, 5.0
Min, Max	25, 100	20, 95	20, 100	-35, 25	-25, 50	-40, 30

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Mental Component Score						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	50.59 (11.99)	49.16 (11.12)	50.90 (10.04)			
Median	55.10	53.00	54.10			
IQR: Q1, Q3	46.80, 59.10	40.70, 57.30	47.80, 57.80			
Min, Max	12.0, 67.0	17.0, 66.8	15.6, 64.3			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	49.94 (10.45)	49.51 (10.47)	49.99 (10.61)	-0.85 (0.98)	0.16 (1.27)	-1.06 (0.67)
Median	52.60	51.45	52.85	-1.15	0	-0.55
IQR: Q1, Q3	43.80, 57.70	42.90, 58.45	43.55, 58.35	-4.30, 2.80	-3.20, 3.50	-4.65, 2.65
Min, Max	20.0, 69.1	9.4, 63.6	14.2, 66.3	-20.0, 18.5	-24.5, 26.1	-20.9, 17.9
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	50.63 (9.50)	50.40 (9.74)	50.29 (9.99)	-1.19 (1.05)	1.04 (1.33)	-0.90 (0.74)
Median	54.40	52.00	53.60	-1.40	0.10	0
IQR: Q1, Q3	42.40, 57.90	44.30, 57.80	44.20, 57.60	-5.00, 2.80	-3.80, 5.05	-4.70, 2.80
Min, Max	26.9, 63.2	17.8, 64.2	21.0, 64.0	-21.7, 14.9	-15.2, 22.2	-17.9, 14.8

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Physical Component Score						
Baseline						
m	64	53	111			
n	60	47	102			
Mean (SD)	47.76 (9.62)	47.10 (9.16)	47.44 (9.80)			
Median	49.40	49.00	49.95			
IQR: Q1, Q3	43.80, 54.90	42.50, 54.20	41.10, 55.60			
Min, Max	15.3, 59.3	25.3, 60.4	24.3, 61.2			
Week 24						
m	63	51	103			
n	61	48	96	58	43	88
Mean (SD/SE)	47.98 (11.15)	47.65 (7.16)	47.35 (11.04)	-0.19 (0.81)	0.04 (0.99)	-0.32 (0.69)
Median	50.90	48.70	50.75	0.75	-0.50	0.30
IQR: Q1, Q3	41.50, 57.20	43.75, 52.25	39.10, 55.30	-2.70, 3.90	-4.00, 3.30	-4.20, 2.90
Min, Max	12.5, 63.9	25.8, 58.9	19.0, 62.9	-17.2, 9.1	-14.4, 21.7	-17.0, 23.8
Week 52						
m	56	44	94			
n	51	39	85	49	36	79
Mean (SD/SE)	48.16 (11.56)	47.55 (9.32)	46.85 (10.83)	-0.27 (1.00)	-1.08 (1.56)	-0.30 (0.68)
Median	53.00	50.40	49.00	0.50	0.35	-0.10
IQR: Q1, Q3	42.10, 57.20	41.40, 54.10	38.80, 55.90	-3.20, 4.20	-3.50, 5.35	-3.30, 2.90
Min, Max	15.8, 62.8	27.5, 61.2	21.5, 61.7	-24.7, 14.7	-23.5, 14.8	-17.9, 16.1

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Physical Functioning						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	75.13 (22.98)	68.13 (25.88)	73.43 (24.75)			
Median	80.00	75.00	80.00			
IQR: Q1, Q3	60.00, 95.00	55.00, 90.00	60.00, 95.00			
Min, Max	15.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	75.00 (22.38)	69.18 (26.22)	75.73 (26.14)	0.62 (1.62)	0.76 (2.31)	2.20 (1.46)
Median	80.00	75.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 95.00	55.00, 90.00	65.00, 95.00	-10.00, 10.00	-10.00, 10.00	-5.00, 10.00
Min, Max	5.0, 100.0	5.0, 100.0	0.0, 100.0	-50.0, 40.0	-65.0, 70.0	-50.0, 75.0
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	76.29 (25.19)	68.97 (26.21)	78.47 (21.90)	1.26 (1.63)	2.09 (1.74)	2.63 (1.37)
Median	85.00	75.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 100.00	55.00, 90.00	65.00, 95.00	-5.00, 5.00	-5.00, 10.00	-5.00, 10.00
Min, Max	10.0, 100.0	5.0, 100.0	10.0, 100.0	-45.0, 35.0	-52.2, 40.0	-45.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Role Physical						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	76.04 (25.17)	71.72 (27.58)	75.89 (25.39)			
Median	81.30	75.00	81.30			
IQR: Q1, Q3	56.30, 100.00	50.00, 100.00	62.50, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	73.52 (25.86)	72.10 (24.96)	76.19 (25.16)	-1.55 (1.98)	-0.30 (2.35)	0.43 (1.55)
Median	81.30	75.00	81.30	0	0	0
IQR: Q1, Q3	53.15, 100.00	50.00, 100.00	62.50, 100.00	-12.50, 6.30	-12.50, 6.30	-6.30, 6.20
Min, Max	0.0, 100.0	12.5, 100.0	0.0, 100.0	-43.8, 50.0	-56.2, 62.5	-68.7, 68.7
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	75.60 (26.61)	73.85 (25.26)	77.04 (23.06)	-0.16 (1.98)	3.51 (2.39)	0.22 (1.64)
Median	81.30	75.00	81.30	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 100.00	56.30, 100.00	-6.20, 6.20	-6.20, 12.50	-12.50, 6.30
Min, Max	0.0, 100.0	6.3, 100.0	6.3, 100.0	-37.5, 81.2	-43.8, 81.3	-62.5, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Bodily Pain						
Baseline						
m	103	98	192			
n	97	91	178			
Mean (SD)	67.8 (23.8)	59.6 (25.5)	66.2 (24.5)			
Median	74.0	52.0	72.0			
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	51.0, 84.0			
Min, Max	10, 100	10, 100	0, 100			
Week 24						
m	98	90	186			
n	96	88	171	92	83	161
Mean (SD/SE)	65.0 (23.7)	62.4 (24.7)	66.5 (24.9)	-1.7 (2.0)	1.7 (2.2)	0.2 (1.6)
Median	68.0	62.0	72.0	0	0	0
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	51.0, 84.0	-16.0, 5.5	-9.0, 10.0	-12.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-43, 68	-62, 72	-78, 59
Week 52						
m	93	81	176			
n	85	75	154	80	73	144
Mean (SD/SE)	70.1 (23.7)	64.7 (26.1)	68.2 (23.9)	2.1 (2.2)	6.1 (2.0)	0.3 (1.7)
Median	74.0	62.0	72.0	0	0	0
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	51.0, 84.0	-10.0, 10.0	0.0, 12.0	-12.0, 11.5
Min, Max	0, 100	10, 100	12, 100	-49, 68	-31, 59	-78, 62

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
General Health						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	58.60 (19.10)	53.60 (19.67)	57.92 (19.58)			
Median	61.00	52.00	61.00			
IQR: Q1, Q3	45.00, 72.00	40.00, 72.00	45.00, 72.00			
Min, Max	10.0, 97.0	10.0, 92.0	15.0, 97.0			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	59.52 (19.87)	54.52 (20.32)	58.88 (20.43)	2.48 (1.35)	1.52 (1.86)	0.88 (1.20)
Median	60.00	52.00	62.00	5.00	0	0
IQR: Q1, Q3	45.00, 72.00	40.00, 67.00	42.00, 77.00	-5.00, 10.00	-10.00, 12.00	-10.00, 10.00
Min, Max	10.0, 100.0	10.0, 100.0	10.0, 100.0	-35.0, 32.0	-35.0, 40.0	-40.0, 48.0
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	61.97 (19.84)	54.81 (18.80)	61.18 (19.37)	3.06 (1.57)	2.97 (1.89)	2.20 (1.13)
Median	65.00	52.00	62.00	0	0	0
IQR: Q1, Q3	45.00, 77.00	45.00, 67.00	50.00, 77.00	-5.00, 10.00	-10.00, 15.00	-5.00, 10.00
Min, Max	22.0, 100.0	15.0, 92.0	10.0, 97.0	-27.0, 47.0	-35.0, 47.0	-40.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Vitality						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	57.04 (21.62)	54.69 (22.97)	56.96 (21.59)			
Median	62.50	56.30	62.50			
IQR: Q1, Q3	37.50, 75.00	37.50, 75.00	43.80, 75.00			
Min, Max	6.3, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	55.95 (23.27)	55.50 (20.50)	57.55 (21.65)	-0.07 (1.49)	0.46 (1.81)	0.99 (1.22)
Median	62.50	56.30	56.30	0	0	0
IQR: Q1, Q3	40.65, 71.90	37.50, 71.90	43.80, 75.00	-6.30, 6.30	-12.50, 12.50	-6.30, 6.30
Min, Max	0.0, 100.0	12.5, 100.0	0.0, 100.0	-31.2, 43.8	-31.3, 43.8	-37.5, 56.2
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	59.29 (23.18)	56.27 (20.08)	58.99 (22.04)	1.93 (1.68)	1.46 (1.60)	2.23 (1.50)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	43.80, 75.00	43.80, 75.00	43.80, 75.00	-6.20, 12.50	-6.30, 6.30	-6.30, 12.50
Min, Max	6.3, 100.0	6.3, 100.0	0.0, 100.0	-31.3, 50.0	-31.2, 43.8	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Social Functioning						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	81.25 (22.72)	79.26 (25.90)	82.30 (22.02)			
Median	87.50	87.50	87.50			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	12.5, 100.0	25.0, 100.0			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	81.90 (23.64)	81.53 (20.85)	81.94 (23.09)	1.48 (2.04)	2.26 (2.01)	0.00 (1.58)
Median	87.50	87.50	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	68.75, 100.00	75.00, 100.00	-12.50, 12.50	0.00, 12.50	-12.50, 12.50
Min, Max	25.0, 100.0	12.5, 100.0	0.0, 100.0	-50.0, 75.0	-50.0, 50.0	-62.5, 75.0
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	81.62 (23.03)	82.50 (22.13)	84.66 (21.03)	0.15 (1.80)	2.91 (2.41)	1.82 (1.64)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-37.5, 37.5	-50.0, 62.5	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Role Emotional						
Baseline						
m	103	98	192			
n	98	91	177			
Mean (SD)	82.22 (23.77)	83.52 (24.44)	84.09 (21.01)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	16.7, 100.0			
Week 24						
m	98	90	186			
n	96	88	171	93	83	160
Mean (SD/SE)	81.42 (22.73)	86.27 (20.14)	83.43 (22.54)	0.09 (1.93)	2.21 (1.65)	-0.26 (1.58)
Median	91.70	100.00	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	75.00, 100.00	-8.30, 0.00	0.00, 8.30	-8.30, 8.30
Min, Max	25.0, 100.0	25.0, 100.0	8.3, 100.0	-66.7, 66.7	-33.3, 50.0	-50.0, 58.3
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	83.77 (20.54)	84.33 (22.13)	83.44 (21.93)	2.11 (1.99)	2.17 (2.68)	-1.74 (1.57)
Median	91.70	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	0.00, 16.70	-8.40, 0.00
Min, Max	25.0, 100.0	25.0, 100.0	16.7, 100.0	-33.3, 100.0	-75.0, 58.3	-58.3, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Mental Health						
Baseline						
m	103	98	192			
n	98	91	178			
Mean (SD)	74.0 (19.0)	75.6 (18.7)	75.7 (17.1)			
Median	80.0	80.0	80.0			
IQR: Q1, Q3	65.0, 90.0	70.0, 90.0	65.0, 90.0			
Min, Max	10, 100	25, 100	20, 100			
Week 24						
m	98	90	186			
n	96	88	171	93	83	161
Mean (SD/SE)	72.7 (20.1)	76.4 (18.4)	75.5 (18.7)	-0.9 (1.3)	-0.3 (1.2)	0.5 (1.2)
Median	75.0	80.0	80.0	0	0	0
IQR: Q1, Q3	60.0, 90.0	70.0, 90.0	70.0, 90.0	-5.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	20, 100	20, 100	20, 100	-35, 35	-35, 35	-35, 55
Week 52						
m	93	81	176			
n	85	75	154	81	73	144
Mean (SD/SE)	75.5 (18.5)	76.1 (18.1)	76.6 (19.7)	1.1 (1.4)	0.4 (1.4)	0.9 (1.4)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	70.0, 90.0	-5.0, 5.0	-5.0, 5.0	-10.0, 10.0
Min, Max	30, 100	25, 100	0, 100	-35, 40	-30, 35	-60, 55

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Mental Component Score						
Baseline						
m	103	98	192			
n	97	91	177			
Mean (SD)	50.45 (10.10)	51.68 (10.91)	51.46 (8.91)			
Median	52.90	55.10	53.90			
IQR: Q1, Q3	46.40, 57.70	47.40, 59.00	46.00, 58.00			
Min, Max	18.9, 69.0	20.4, 72.3	26.4, 66.5			
Week 24						
m	98	90	186			
n	96	88	171	92	83	160
Mean (SD/SE)	50.04 (10.81)	52.49 (9.29)	51.08 (10.17)	-0.13 (0.76)	0.49 (0.65)	-0.04 (0.66)
Median	52.20	54.70	55.10	-0.05	-0.20	0.05
IQR: Q1, Q3	43.40, 58.85	49.25, 59.05	46.20, 58.20	-3.60, 3.65	-2.90, 3.40	-3.80, 3.45
Min, Max	18.7, 66.6	21.2, 71.2	21.9, 69.0	-20.0, 19.0	-13.0, 22.4	-24.6, 24.8
Week 52						
m	93	81	176			
n	85	75	154	80	73	144
Mean (SD/SE)	51.12 (9.65)	52.11 (9.69)	51.44 (10.30)	0.60 (0.74)	0.36 (0.97)	0.09 (0.69)
Median	53.20	53.80	54.45	0.35	-0.10	0.30
IQR: Q1, Q3	45.10, 58.60	45.10, 59.60	47.10, 58.10	-2.30, 3.55	-3.10, 2.90	-3.35, 4.50
Min, Max	23.1, 62.3	27.0, 70.7	8.9, 68.0	-17.3, 26.2	-21.4, 25.2	-25.1, 26.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Physical Component Score						
Baseline						
m	103	98	192			
n	97	91	177			
Mean (SD)	47.71 (8.47)	44.07 (10.13)	46.82 (9.25)			
Median	48.10	45.00	48.40			
IQR: Q1, Q3	43.00, 55.20	37.90, 52.00	40.70, 54.40			
Min, Max	21.1, 60.8	21.2, 61.3	20.7, 65.2			
Week 24						
m	98	90	186			
n	96	88	171	92	83	160
Mean (SD/SE)	47.32 (8.48)	44.45 (9.63)	47.42 (9.49)	0.10 (0.65)	0.34 (0.89)	0.48 (0.56)
Median	49.05	43.75	49.50	-0.75	-0.10	0
IQR: Q1, Q3	41.85, 53.35	37.00, 52.85	42.30, 55.20	-4.10, 3.75	-2.70, 3.70	-2.80, 3.70
Min, Max	21.8, 62.7	20.2, 61.0	22.8, 63.0	-11.0, 18.3	-22.1, 32.4	-28.8, 23.3
Week 52						
m	93	81	176			
n	85	75	154	80	73	144
Mean (SD/SE)	48.26 (9.71)	45.15 (10.08)	48.36 (8.17)	0.62 (0.70)	1.71 (0.75)	0.82 (0.51)
Median	50.80	45.20	48.95	0.15	2.00	0.60
IQR: Q1, Q3	41.80, 56.30	38.80, 52.40	43.00, 55.10	-1.80, 3.30	-1.90, 4.80	-2.50, 3.55
Min, Max	23.2, 62.7	16.0, 61.1	22.5, 63.9	-22.4, 22.5	-17.5, 18.6	-23.9, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Physical Functioning			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	74.57 (25.15)	73.49 (25.81)	78.35 (25.79)
Analysis Visit Mean (SD)	77.24 (27.63)	75.12 (20.74)	75.08 (28.84)
LS Mean of Change from Baseline (SE)	2.69 (2.14)	1.03 (2.46)	-2.89 (1.73)
95% CI	(-1.53, 6.91)	(-3.82, 5.87)	(-6.30, 0.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.58 (2.72)	3.91 (2.99)	
95% CI	(0.20, 10.95)	(-1.98, 9.81)	
p-value	0.0420	0.1921	
Corrected Hedge's g Statistics	0.341	0.240	
95% CI	(0.01, 0.68)	(-0.13, 0.61)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	76.22 (21.88)	76.39 (25.43)	76.90 (26.21)
Analysis Visit Mean (SD)	77.65 (28.47)	73.70 (25.99)	74.05 (27.57)
LS Mean of Change from Baseline (SE)	1.41 (2.37)	-1.80 (2.74)	-2.57 (1.88)
95% CI	(-3.27, 6.09)	(-7.21, 3.61)	(-6.28, 1.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.97 (3.00)	0.77 (3.31)	
95% CI	(-1.94, 9.89)	(-5.76, 7.30)	
p-value	0.1870	0.8172	
Corrected Hedge's g Statistics	0.237	0.046	
95% CI	(-0.12, 0.59)	(-0.35, 0.44)	
Subgroup*Treatment Interaction p-value	0.0601	0.2408	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Role Physical			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	76.63 (27.29)	76.47 (26.12)	78.07 (27.34)
Analysis Visit Mean (SD)	75.98 (28.81)	76.32 (22.80)	76.43 (30.75)
LS Mean of Change from Baseline (SE)	-0.11 (2.54)	-0.53 (2.92)	-1.34 (2.05)
95% CI	(-5.13, 4.91)	(-6.29, 5.23)	(-5.39, 2.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.23 (3.23)	0.81 (3.55)	
95% CI	(-5.14, 7.61)	(-6.18, 7.81)	
p-value	0.7036	0.8186	
Corrected Hedge's g Statistics	0.064	0.042	
95% CI	(-0.27, 0.40)	(-0.32, 0.41)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	77.94 (27.84)	78.14 (26.74)	76.84 (27.46)
Analysis Visit Mean (SD)	76.92 (30.19)	73.10 (29.07)	73.43 (27.59)
LS Mean of Change from Baseline (SE)	-0.96 (2.74)	-3.27 (3.17)	-2.61 (2.17)
95% CI	(-6.37, 4.45)	(-9.52, 2.97)	(-6.90, 1.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.66 (3.47)	-0.66 (3.82)	
95% CI	(-5.18, 8.49)	(-8.20, 6.88)	
p-value	0.6333	0.8638	
Corrected Hedge's g Statistics	0.085	-0.034	
95% CI	(-0.27, 0.44)	(-0.43, 0.36)	
Subgroup*Treatment Interaction p-value	0.5253	0.8909	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Bodily Pain			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	66.1 (25.0)	67.9 (26.7)	65.8 (25.9)
Analysis Visit Mean (SD)	62.7 (28.1)	67.1 (23.2)	66.2 (27.2)
LS Mean of Change from Baseline (SE)	-3.06 (2.54)	-0.20 (2.91)	0.42 (2.04)
95% CI	(-8.06, 1.95)	(-5.93, 5.54)	(-3.61, 4.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.47 (3.22)	-0.61 (3.53)	
95% CI	(-9.82, 2.87)	(-7.57, 6.35)	
p-value	0.2815	0.8623	
Corrected Hedge's g Statistics	-0.180	-0.032	
95% CI	(-0.51, 0.15)	(-0.40, 0.33)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	66.5 (26.2)	67.3 (28.0)	64.5 (26.2)
Analysis Visit Mean (SD)	63.6 (28.7)	70.1 (24.1)	67.8 (25.9)
LS Mean of Change from Baseline (SE)	-2.41 (3.01)	3.30 (3.48)	2.83 (2.39)
95% CI	(-8.36, 3.53)	(-3.56, 10.16)	(-1.87, 7.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.24 (3.81)	0.47 (4.20)	
95% CI	(-12.76, 2.27)	(-7.81, 8.76)	
p-value	0.1703	0.9104	
Corrected Hedge's g Statistics	-0.246	0.022	
95% CI	(-0.60, 0.11)	(-0.37, 0.42)	
Subgroup*Treatment Interaction p-value	0.2628	0.8588	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
General Health			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	64.59 (20.44)	53.84 (17.31)	60.80 (21.93)
Analysis Visit Mean (SD)	63.17 (22.02)	54.84 (17.84)	61.08 (23.65)
LS Mean of Change from Baseline (SE)	-0.64 (1.91)	-1.07 (2.19)	0.25 (1.52)
95% CI	(-4.40, 3.12)	(-5.39, 3.25)	(-2.76, 3.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.89 (2.41)	-1.32 (2.65)	
95% CI	(-5.65, 3.87)	(-6.55, 3.92)	
p-value	0.7127	0.6198	
Corrected Hedge's g Statistics	-0.061	-0.092	
95% CI	(-0.39, 0.27)	(-0.46, 0.27)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	65.49 (21.80)	56.44 (19.49)	60.03 (22.20)
Analysis Visit Mean (SD)	64.41 (19.94)	57.00 (20.07)	60.15 (23.69)
LS Mean of Change from Baseline (SE)	0.50 (2.12)	-0.41 (2.43)	-0.12 (1.66)
95% CI	(-3.68, 4.67)	(-5.21, 4.39)	(-3.41, 3.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.62 (2.67)	-0.29 (2.93)	
95% CI	(-4.64, 5.88)	(-6.07, 5.50)	
p-value	0.8159	0.9223	
Corrected Hedge's g Statistics	0.042	-0.019	
95% CI	(-0.31, 0.40)	(-0.41, 0.37)	
Subgroup*Treatment Interaction p-value	0.6585	0.9152	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Vitality			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	58.78 (23.95)	51.19 (20.65)	57.34 (21.57)
Analysis Visit Mean (SD)	57.25 (24.44)	49.00 (17.94)	55.92 (23.74)
LS Mean of Change from Baseline (SE)	-1.02 (1.93)	-3.60 (2.23)	-1.30 (1.56)
95% CI	(-4.83, 2.79)	(-8.00, 0.79)	(-4.37, 1.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.28 (2.45)	-2.30 (2.70)	
95% CI	(-4.55, 5.12)	(-7.63, 3.03)	
p-value	0.9087	0.3963	
Corrected Hedge's g Statistics	0.019	-0.157	
95% CI	(-0.31, 0.35)	(-0.52, 0.21)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	60.61 (24.25)	53.68 (22.58)	57.38 (21.80)
Analysis Visit Mean (SD)	57.16 (21.94)	51.76 (22.79)	54.85 (23.32)
LS Mean of Change from Baseline (SE)	-1.71 (2.20)	-2.76 (2.55)	-2.50 (1.74)
95% CI	(-6.05, 2.63)	(-7.78, 2.26)	(-5.93, 0.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.79 (2.78)	-0.26 (3.07)	
95% CI	(-4.69, 6.27)	(-6.32, 5.80)	
p-value	0.7766	0.9329	
Corrected Hedge's g Statistics	0.051	-0.017	
95% CI	(-0.31, 0.41)	(-0.41, 0.38)	
Subgroup*Treatment Interaction p-value	0.6993	0.8837	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Social Functioning			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	84.27 (24.40)	80.52 (26.06)	84.52 (22.98)
Analysis Visit Mean (SD)	80.17 (26.18)	81.10 (21.89)	79.97 (27.04)
LS Mean of Change from Baseline (SE)	-3.57 (2.64)	-0.78 (3.04)	-4.37 (2.13)
95% CI	(-8.77, 1.64)	(-6.77, 5.21)	(-8.57, -0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.81 (3.36)	3.59 (3.69)	
95% CI	(-5.81, 7.43)	(-3.69, 10.87)	
p-value	0.8106	0.3318	
Corrected Hedge's g Statistics	0.040	0.179	
95% CI	(-0.29, 0.37)	(-0.19, 0.54)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	86.22 (23.83)	80.21 (27.77)	84.65 (22.99)
Analysis Visit Mean (SD)	81.63 (24.22)	79.86 (23.77)	79.91 (23.38)
LS Mean of Change from Baseline (SE)	-2.95 (2.60)	-0.87 (3.01)	-4.47 (2.06)
95% CI	(-8.09, 2.18)	(-6.81, 5.07)	(-8.54, -0.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.52 (3.29)	3.60 (3.64)	
95% CI	(-4.96, 8.00)	(-3.57, 10.77)	
p-value	0.6447	0.3233	
Corrected Hedge's g Statistics	0.083	0.196	
95% CI	(-0.27, 0.44)	(-0.20, 0.59)	
Subgroup*Treatment Interaction p-value	0.6795	0.4464	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Role Emotional			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	82.76 (26.11)	78.49 (22.51)	84.47 (25.12)
Analysis Visit Mean (SD)	82.33 (23.83)	82.75 (22.08)	82.29 (26.65)
LS Mean of Change from Baseline (SE)	-0.53 (2.07)	2.70 (2.38)	-2.11 (1.67)
95% CI	(-4.61, 3.55)	(-1.99, 7.40)	(-5.40, 1.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.58 (2.63)	4.81 (2.89)	
95% CI	(-3.60, 6.77)	(-0.90, 10.52)	
p-value	0.5480	0.0982	
Corrected Hedge's g Statistics	0.100	0.306	
95% CI	(-0.23, 0.43)	(-0.06, 0.67)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	84.35 (23.85)	80.32 (22.37)	83.65 (25.65)
Analysis Visit Mean (SD)	83.00 (22.95)	85.88 (21.72)	81.85 (24.49)
LS Mean of Change from Baseline (SE)	-0.36 (2.26)	5.59 (2.61)	-1.77 (1.79)
95% CI	(-4.81, 4.10)	(0.44, 10.75)	(-5.30, 1.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.42 (2.86)	7.37 (3.15)	
95% CI	(-4.22, 7.05)	(1.15, 13.59)	
p-value	0.6205	0.0205	
Corrected Hedge's g Statistics	0.089	0.462	
95% CI	(-0.27, 0.45)	(0.06, 0.86)	
Subgroup*Treatment Interaction p-value	0.9865	0.4560	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Mental Health			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	73.7 (21.7)	73.3 (20.7)	74.5 (19.0)
Analysis Visit Mean (SD)	73.4 (19.6)	72.0 (19.5)	73.1 (19.6)
LS Mean of Change from Baseline (SE)	-0.45 (1.76)	-1.87 (2.02)	-1.44 (1.42)
95% CI	(-3.92, 3.02)	(-5.85, 2.11)	(-4.23, 1.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.99 (2.24)	-0.43 (2.45)	
95% CI	(-3.42, 5.40)	(-5.27, 4.41)	
p-value	0.6596	0.8603	
Corrected Hedge's g Statistics	0.074	-0.032	
95% CI	(-0.26, 0.41)	(-0.40, 0.33)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	75.1 (20.0)	74.0 (21.7)	74.2 (19.4)
Analysis Visit Mean (SD)	74.7 (17.1)	73.8 (19.1)	74.1 (19.1)
LS Mean of Change from Baseline (SE)	0.34 (1.74)	-0.72 (2.00)	-0.97 (1.38)
95% CI	(-3.09, 3.77)	(-4.67, 3.24)	(-3.69, 1.75)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.31 (2.20)	0.25 (2.42)	
95% CI	(-3.02, 5.64)	(-4.52, 5.03)	
p-value	0.5517	0.9171	
Corrected Hedge's g Statistics	0.106	0.021	
95% CI	(-0.25, 0.46)	(-0.37, 0.41)	
Subgroup*Treatment Interaction p-value	0.4286	0.9990	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Mental Component Score			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	50.94 (12.03)	48.90 (11.25)	50.97 (10.16)
Analysis Visit Mean (SD)	50.09 (10.40)	49.06 (10.62)	49.91 (10.70)
LS Mean of Change from Baseline (SE)	-0.80 (0.88)	-0.54 (1.02)	-1.08 (0.71)
95% CI	(-2.54, 0.95)	(-2.55, 1.47)	(-2.48, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.28 (1.12)	0.54 (1.24)	
95% CI	(-1.94, 2.50)	(-1.90, 2.98)	
p-value	0.8028	0.6647	
Corrected Hedge's g Statistics	0.042	0.080	
95% CI	(-0.29, 0.37)	(-0.28, 0.44)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	51.77 (11.18)	49.35 (11.60)	51.01 (10.42)
Analysis Visit Mean (SD)	50.58 (9.44)	50.39 (9.95)	50.11 (10.13)
LS Mean of Change from Baseline (SE)	-0.48 (0.90)	0.63 (1.04)	-1.12 (0.71)
95% CI	(-2.26, 1.29)	(-1.42, 2.68)	(-2.53, 0.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.64 (1.14)	1.76 (1.26)	
95% CI	(-1.60, 2.89)	(-0.72, 4.23)	
p-value	0.5718	0.1633	
Corrected Hedge's g Statistics	0.101	0.277	
95% CI	(-0.26, 0.46)	(-0.12, 0.67)	
Subgroup*Treatment Interaction p-value	0.7650	0.8227	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Physical Component Score			
Week 24			
m	63	51	103
n	58	43	88
Baseline Mean (SD)	48.19 (9.39)	47.25 (9.12)	48.23 (9.76)
Analysis Visit Mean (SD)	48.00 (11.26)	47.29 (7.26)	47.92 (10.93)
LS Mean of Change from Baseline (SE)	0.01 (0.84)	-0.16 (0.96)	-0.26 (0.68)
95% CI	(-1.66, 1.67)	(-2.06, 1.74)	(-1.60, 1.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.27 (1.07)	0.10 (1.17)	
95% CI	(-1.84, 2.37)	(-2.21, 2.41)	
p-value	0.8032	0.9326	
Corrected Hedge's g Statistics	0.042	0.016	
95% CI	(-0.29, 0.37)	(-0.35, 0.38)	
Week 52			
m	56	44	94
n	49	36	79
Baseline Mean (SD)	48.51 (9.35)	47.96 (9.51)	47.69 (9.71)
Analysis Visit Mean (SD)	48.24 (11.58)	46.88 (9.35)	47.39 (10.52)
LS Mean of Change from Baseline (SE)	-0.30 (0.98)	-0.69 (1.13)	-0.12 (0.78)
95% CI	(-2.24, 1.63)	(-2.92, 1.53)	(-1.65, 1.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.19 (1.24)	-0.58 (1.36)	
95% CI	(-2.63, 2.25)	(-3.27, 2.11)	
p-value	0.8798	0.6730	
Corrected Hedge's g Statistics	-0.027	-0.084	
95% CI	(-0.38, 0.33)	(-0.48, 0.31)	
Subgroup*Treatment Interaction p-value	0.8803	0.8687	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Physical Functioning			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	74.28 (23.00)	68.37 (26.08)	73.42 (25.25)
Analysis Visit Mean (SD)	74.89 (22.69)	69.13 (26.10)	75.62 (26.53)
LS Mean of Change from Baseline (SE)	1.49 (1.84)	0.07 (1.92)	2.46 (1.38)
95% CI	(-2.13, 5.11)	(-3.70, 3.84)	(-0.26, 5.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.97 (2.24)	-2.39 (2.33)	
95% CI	(-5.38, 3.44)	(-6.98, 2.19)	
p-value	0.6660	0.3055	
Corrected Hedge's g Statistics	-0.055	-0.136	
95% CI	(-0.31, 0.20)	(-0.40, 0.13)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	74.73 (23.50)	66.99 (26.20)	75.45 (23.55)
Analysis Visit Mean (SD)	75.99 (25.55)	69.08 (26.51)	78.08 (22.15)
LS Mean of Change from Baseline (SE)	2.32 (1.69)	1.54 (1.75)	3.20 (1.26)
95% CI	(-1.01, 5.65)	(-1.91, 4.99)	(0.73, 5.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.88 (2.04)	-1.65 (2.12)	
95% CI	(-4.89, 3.14)	(-5.83, 2.52)	
p-value	0.6680	0.4363	
Corrected Hedge's g Statistics	-0.058	-0.110	
95% CI	(-0.33, 0.21)	(-0.39, 0.17)	
Subgroup*Treatment Interaction p-value	0.0601	0.2408	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Role Physical			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	75.22 (25.26)	72.15 (27.92)	75.64 (25.79)
Analysis Visit Mean (SD)	73.67 (25.82)	71.85 (25.15)	76.07 (25.31)
LS Mean of Change from Baseline (SE)	-0.57 (1.93)	-0.67 (2.01)	1.11 (1.45)
95% CI	(-4.36, 3.23)	(-4.61, 3.28)	(-1.75, 3.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.68 (2.35)	-1.78 (2.44)	
95% CI	(-6.31, 2.95)	(-6.58, 3.01)	
p-value	0.4755	0.4655	
Corrected Hedge's g Statistics	-0.090	-0.097	
95% CI	(-0.35, 0.16)	(-0.36, 0.17)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	75.71 (26.40)	70.22 (28.34)	77.01 (24.28)
Analysis Visit Mean (SD)	75.55 (26.87)	73.73 (25.60)	77.23 (23.15)
LS Mean of Change from Baseline (SE)	1.27 (1.98)	2.58 (2.05)	1.27 (1.47)
95% CI	(-2.61, 5.16)	(-1.45, 6.62)	(-1.62, 4.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (2.40)	1.31 (2.48)	
95% CI	(-4.71, 4.72)	(-3.58, 6.20)	
p-value	0.9995	0.5983	
Corrected Hedge's g Statistics	0.000	0.074	
95% CI	(-0.27, 0.27)	(-0.21, 0.36)	
Subgroup*Treatment Interaction p-value	0.5253	0.8909	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Bodily Pain			
Week 24			
m	98	90	186
n	92	83	161
Baseline Mean (SD)	67.0 (23.7)	60.0 (25.9)	66.5 (24.6)
Analysis Visit Mean (SD)	65.3 (23.9)	61.7 (24.7)	66.7 (25.0)
LS Mean of Change from Baseline (SE)	-0.78 (1.98)	0.14 (2.05)	0.62 (1.48)
95% CI	(-4.66, 3.11)	(-3.89, 4.17)	(-2.29, 3.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.39 (2.40)	-0.48 (2.49)	
95% CI	(-6.11, 3.32)	(-5.37, 4.42)	
p-value	0.5617	0.8484	
Corrected Hedge's g Statistics	-0.074	-0.025	
95% CI	(-0.33, 0.18)	(-0.29, 0.24)	
Week 52			
m	93	81	176
n	80	73	144
Baseline Mean (SD)	68.0 (23.9)	58.4 (25.7)	67.6 (23.8)
Analysis Visit Mean (SD)	70.1 (23.9)	64.5 (26.4)	67.9 (23.7)
LS Mean of Change from Baseline (SE)	2.77 (2.06)	3.64 (2.14)	1.14 (1.52)
95% CI	(-1.28, 6.83)	(-0.57, 7.85)	(-1.86, 4.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.63 (2.49)	2.50 (2.59)	
95% CI	(-3.27, 6.54)	(-2.59, 7.59)	
p-value	0.5131	0.3351	
Corrected Hedge's g Statistics	0.089	0.136	
95% CI	(-0.18, 0.36)	(-0.15, 0.42)	
Subgroup*Treatment Interaction p-value	0.2628	0.8588	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
General Health			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	57.68 (18.29)	52.64 (19.48)	58.11 (19.50)
Analysis Visit Mean (SD)	60.16 (19.49)	54.16 (20.47)	58.99 (20.58)
LS Mean of Change from Baseline (SE)	2.65 (1.53)	0.32 (1.59)	1.09 (1.15)
95% CI	(-0.36, 5.66)	(-2.81, 3.46)	(-1.17, 3.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.56 (1.86)	-0.77 (1.94)	
95% CI	(-2.10, 5.22)	(-4.58, 3.04)	
p-value	0.4025	0.6914	
Corrected Hedge's g Statistics	0.106	-0.053	
95% CI	(-0.15, 0.36)	(-0.32, 0.21)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	59.03 (18.29)	51.78 (19.68)	59.43 (19.69)
Analysis Visit Mean (SD)	62.09 (19.60)	54.75 (18.98)	61.63 (19.40)
LS Mean of Change from Baseline (SE)	3.20 (1.53)	1.01 (1.59)	3.04 (1.13)
95% CI	(0.20, 6.20)	(-2.12, 4.13)	(0.81, 5.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.16 (1.85)	-2.03 (1.93)	
95% CI	(-3.47, 3.79)	(-5.82, 1.75)	
p-value	0.9296	0.2918	
Corrected Hedge's g Statistics	0.012	-0.149	
95% CI	(-0.26, 0.28)	(-0.43, 0.13)	
Subgroup*Treatment Interaction p-value	0.6585	0.9152	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Vitality			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	56.81 (21.62)	54.69 (23.65)	56.96 (22.00)
Analysis Visit Mean (SD)	56.74 (22.82)	55.15 (20.61)	57.94 (21.97)
LS Mean of Change from Baseline (SE)	0.61 (1.54)	0.28 (1.60)	1.22 (1.16)
95% CI	(-2.42, 3.65)	(-2.87, 3.43)	(-1.06, 3.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.61 (1.87)	-0.94 (1.94)	
95% CI	(-4.30, 3.08)	(-4.76, 2.88)	
p-value	0.7458	0.6277	
Corrected Hedge's g Statistics	-0.041	-0.064	
95% CI	(-0.30, 0.21)	(-0.33, 0.20)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	57.58 (22.07)	54.48 (23.31)	57.04 (21.40)
Analysis Visit Mean (SD)	59.52 (22.69)	55.93 (20.22)	59.27 (22.27)
LS Mean of Change from Baseline (SE)	2.29 (1.70)	0.80 (1.77)	2.66 (1.27)
95% CI	(-1.06, 5.64)	(-2.67, 4.28)	(0.17, 5.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.38 (2.07)	-1.86 (2.14)	
95% CI	(-4.45, 3.69)	(-6.07, 2.34)	
p-value	0.8551	0.3844	
Corrected Hedge's g Statistics	-0.025	-0.122	
95% CI	(-0.30, 0.25)	(-0.40, 0.16)	
Subgroup*Treatment Interaction p-value	0.6993	0.8837	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Social Functioning			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	80.91 (22.54)	79.67 (26.39)	82.07 (22.35)
Analysis Visit Mean (SD)	82.39 (23.47)	81.93 (20.96)	82.07 (22.78)
LS Mean of Change from Baseline (SE)	1.62 (1.86)	1.80 (1.93)	0.39 (1.40)
95% CI	(-2.03, 5.28)	(-2.00, 5.59)	(-2.36, 3.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.23 (2.26)	1.40 (2.34)	
95% CI	(-3.22, 5.67)	(-3.20, 6.00)	
p-value	0.5870	0.5497	
Corrected Hedge's g Statistics	0.069	0.079	
95% CI	(-0.19, 0.32)	(-0.19, 0.34)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	81.94 (22.27)	79.28 (27.18)	83.25 (21.43)
Analysis Visit Mean (SD)	82.10 (22.87)	82.19 (22.33)	85.07 (21.18)
LS Mean of Change from Baseline (SE)	0.63 (1.92)	2.41 (1.99)	2.13 (1.43)
95% CI	(-3.15, 4.40)	(-1.50, 6.32)	(-0.67, 4.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.51 (2.33)	0.28 (2.41)	
95% CI	(-6.09, 3.07)	(-4.46, 5.01)	
p-value	0.5181	0.9088	
Corrected Hedge's g Statistics	-0.087	0.016	
95% CI	(-0.36, 0.18)	(-0.27, 0.30)	
Subgroup*Treatment Interaction p-value	0.6795	0.4464	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Role Emotional			
Week 24			
m	98	90	186
n	93	83	160
Baseline Mean (SD)	82.07 (23.38)	83.53 (24.96)	83.75 (21.18)
Analysis Visit Mean (SD)	82.17 (22.00)	85.74 (20.56)	83.49 (22.66)
LS Mean of Change from Baseline (SE)	-0.12 (1.78)	2.39 (1.84)	-0.08 (1.34)
95% CI	(-3.62, 3.37)	(-1.22, 6.00)	(-2.71, 2.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (2.16)	2.47 (2.23)	
95% CI	(-4.28, 4.19)	(-1.92, 6.85)	
p-value	0.9832	0.2692	
Corrected Hedge's g Statistics	-0.003	0.146	
95% CI	(-0.26, 0.25)	(-0.12, 0.41)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	82.40 (23.83)	81.85 (26.47)	85.30 (19.86)
Analysis Visit Mean (SD)	84.51 (20.07)	84.02 (22.34)	83.56 (22.08)
LS Mean of Change from Baseline (SE)	1.71 (1.95)	1.78 (2.02)	-1.38 (1.45)
95% CI	(-2.12, 5.55)	(-2.19, 5.75)	(-4.24, 1.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.09 (2.37)	3.16 (2.45)	
95% CI	(-1.57, 7.75)	(-1.65, 7.97)	
p-value	0.1930	0.1970	
Corrected Hedge's g Statistics	0.176	0.181	
95% CI	(-0.10, 0.45)	(-0.10, 0.46)	
Subgroup*Treatment Interaction p-value	0.9865	0.4560	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Mental Health			
Week 24			
m	98	90	186
n	93	83	161
Baseline Mean (SD)	74.3 (18.1)	76.3 (18.2)	75.2 (17.3)
Analysis Visit Mean (SD)	73.4 (19.3)	76.0 (18.8)	75.7 (18.6)
LS Mean of Change from Baseline (SE)	-1.33 (1.40)	-0.32 (1.44)	0.02 (1.05)
95% CI	(-4.07, 1.42)	(-3.16, 2.52)	(-2.04, 2.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.35 (1.69)	-0.34 (1.75)	
95% CI	(-4.68, 1.98)	(-3.78, 3.11)	
p-value	0.4269	0.8468	
Corrected Hedge's g Statistics	-0.100	-0.025	
95% CI	(-0.36, 0.15)	(-0.29, 0.24)	
Week 52			
m	93	81	176
n	81	73	144
Baseline Mean (SD)	74.9 (18.1)	75.6 (18.8)	75.7 (17.1)
Analysis Visit Mean (SD)	76.0 (17.9)	76.0 (18.2)	76.5 (19.9)
LS Mean of Change from Baseline (SE)	0.41 (1.56)	0.47 (1.61)	0.40 (1.16)
95% CI	(-2.66, 3.47)	(-2.70, 3.64)	(-1.88, 2.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (1.89)	0.07 (1.95)	
95% CI	(-3.72, 3.73)	(-3.77, 3.91)	
p-value	0.9965	0.9719	
Corrected Hedge's g Statistics	0.001	0.005	
95% CI	(-0.27, 0.27)	(-0.28, 0.29)	
Subgroup*Treatment Interaction p-value	0.4286	0.9990	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Mental Component Score			
Week 24			
m	98	90	186
n	92	83	160
Baseline Mean (SD)	50.58 (9.75)	51.87 (11.05)	51.25 (9.04)
Analysis Visit Mean (SD)	50.45 (10.22)	52.35 (9.54)	51.20 (10.10)
LS Mean of Change from Baseline (SE)	-0.30 (0.76)	0.60 (0.78)	-0.17 (0.57)
95% CI	(-1.80, 1.20)	(-0.94, 2.14)	(-1.29, 0.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.92)	0.77 (0.95)	
95% CI	(-1.95, 1.68)	(-1.11, 2.64)	
p-value	0.8827	0.4222	
Corrected Hedge's g Statistics	-0.019	0.106	
95% CI	(-0.28, 0.24)	(-0.16, 0.37)	
Week 52			
m	93	81	176
n	80	73	144
Baseline Mean (SD)	50.90 (9.83)	51.59 (11.57)	51.48 (8.73)
Analysis Visit Mean (SD)	51.50 (9.29)	51.96 (9.76)	51.56 (10.37)
LS Mean of Change from Baseline (SE)	0.27 (0.83)	0.45 (0.85)	-0.10 (0.61)
95% CI	(-1.36, 1.91)	(-1.23, 2.13)	(-1.31, 1.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.37 (1.01)	0.55 (1.03)	
95% CI	(-1.61, 2.35)	(-1.49, 2.58)	
p-value	0.7115	0.5969	
Corrected Hedge's g Statistics	0.050	0.074	
95% CI	(-0.22, 0.32)	(-0.21, 0.36)	
Subgroup*Treatment Interaction p-value	0.7650	0.8227	

AMNOG Table SE22.8.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Physical Component Score			
Week 24			
m	98	90	186
n	92	83	160
Baseline Mean (SD)	47.24 (8.37)	44.01 (9.96)	46.94 (9.40)
Analysis Visit Mean (SD)	47.34 (8.55)	44.35 (9.62)	47.42 (9.53)
LS Mean of Change from Baseline (SE)	0.58 (0.71)	-0.20 (0.73)	0.75 (0.53)
95% CI	(-0.81, 1.97)	(-1.65, 1.24)	(-0.29, 1.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.17 (0.86)	-0.95 (0.89)	
95% CI	(-1.86, 1.52)	(-2.71, 0.80)	
p-value	0.8410	0.2864	
Corrected Hedge's g Statistics	-0.026	-0.142	
95% CI	(-0.28, 0.23)	(-0.41, 0.12)	
Week 52			
m	93	81	176
n	80	73	144
Baseline Mean (SD)	47.58 (8.69)	43.45 (9.92)	47.51 (8.83)
Analysis Visit Mean (SD)	48.20 (9.82)	45.15 (10.21)	48.33 (8.02)
LS Mean of Change from Baseline (SE)	1.14 (0.67)	1.10 (0.69)	1.22 (0.49)
95% CI	(-0.18, 2.45)	(-0.26, 2.46)	(0.25, 2.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.80)	-0.12 (0.84)	
95% CI	(-1.66, 1.50)	(-1.77, 1.53)	
p-value	0.9197	0.8890	
Corrected Hedge's g Statistics	-0.014	-0.020	
95% CI	(-0.29, 0.26)	(-0.30, 0.26)	
Subgroup*Treatment Interaction p-value	0.8803	0.8687	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (10.9)	6 (11.3)	9 (8.1)
No	57 (89.1)	47 (88.7)	102 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.69	
95% CI of the inverse odds ratio	(0.25, 2.03)	(0.23, 2.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.72	
95% CI of the inverse risk ratio	(0.29, 1.90)	(0.27, 1.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.83	3.21	
95% CI of the absolute risk difference	(-6.35, 12.01)	(-6.71, 13.14)	
p-value	0.5317	0.5045	
p-value of Breslow-Day Test for Homogeneity [3]	0.5994	0.3902	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (37.5)	17 (32.1)	23 (20.7)
No	40 (62.5)	36 (67.9)	88 (79.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	0.55	
95% CI of the inverse odds ratio	(0.22, 0.86)	(0.26, 1.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	0.65	
95% CI of the inverse risk ratio	(0.34, 0.89)	(0.38, 1.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.78	11.35	
95% CI of the absolute risk difference	(2.72, 30.83)	(-3.30, 26.01)	
p-value	0.0159	0.1133	
p-value of Breslow-Day Test for Homogeneity [3]	0.0279	0.1599	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (10.9)	4 (7.5)	15 (13.5)
No	57 (89.1)	49 (92.5)	96 (86.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	1.91	
95% CI of the inverse odds ratio	(0.49, 3.31)	(0.60, 6.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	1.79	
95% CI of the inverse risk ratio	(0.53, 2.87)	(0.62, 5.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.58	-5.97	
95% CI of the absolute risk difference	(-12.52, 7.37)	(-15.51, 3.57)	
p-value	0.6206	0.2642	
p-value of Breslow-Day Test for Homogeneity [3]	0.7127	0.2141	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (20.3)	12 (22.6)	22 (19.8)
No	51 (79.7)	41 (77.4)	89 (80.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.84	
95% CI of the inverse odds ratio	(0.45, 2.09)	(0.38, 1.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.88	
95% CI of the inverse risk ratio	(0.53, 1.80)	(0.47, 1.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.49	2.82	
95% CI of the absolute risk difference	(-11.84, 12.83)	(-10.67, 16.31)	
p-value	0.9374	0.6768	
p-value of Breslow-Day Test for Homogeneity [3]	0.9910	0.8955	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (7.8)	9 (17.0)	23 (20.7)
No	59 (92.2)	44 (83.0)	88 (79.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.08	1.28	
95% CI of the inverse odds ratio	(1.11, 8.57)	(0.55, 2.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.65	1.22	
95% CI of the inverse risk ratio	(1.06, 6.63)	(0.61, 2.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.91	-3.74	
95% CI of the absolute risk difference	(-22.91, -2.90)	(-16.35, 8.87)	
p-value	0.0249	0.5720	
p-value of Breslow-Day Test for Homogeneity [3]	0.0898	0.4980	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (20.3)	13 (24.5)	29 (26.1)
No	51 (79.7)	40 (75.5)	82 (73.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	1.09	
95% CI of the inverse odds ratio	(0.66, 2.91)	(0.51, 2.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.07	
95% CI of the inverse risk ratio	(0.72, 2.29)	(0.60, 1.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.81	-1.60	
95% CI of the absolute risk difference	(-18.62, 6.99)	(-15.77, 12.58)	
p-value	0.3858	0.8265	
p-value of Breslow-Day Test for Homogeneity [3]	0.5835	0.4291	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (12.5)	8 (15.1)	13 (11.7)
No	56 (87.5)	45 (84.9)	98 (88.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.75	
95% CI of the inverse odds ratio	(0.36, 2.38)	(0.29, 1.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.78	
95% CI of the inverse risk ratio	(0.41, 2.14)	(0.34, 1.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.79	3.38	
95% CI of the absolute risk difference	(-9.28, 10.86)	(-7.96, 14.73)	
p-value	0.8772	0.5443	
p-value of Breslow-Day Test for Homogeneity [3]	0.8826	0.9389	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (28.1)	19 (35.8)	31 (27.9)
No	46 (71.9)	34 (64.2)	80 (72.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.69	
95% CI of the inverse odds ratio	(0.50, 1.96)	(0.35, 1.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.78	
95% CI of the inverse risk ratio	(0.61, 1.63)	(0.49, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.20	7.92	
95% CI of the absolute risk difference	(-13.62, 14.02)	(-7.45, 23.29)	
p-value	0.9777	0.3027	
p-value of Breslow-Day Test for Homogeneity [3]	0.9228	0.5964	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (9.4)	6 (11.3)	9 (8.1)
No	58 (90.6)	47 (88.7)	102 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.69	
95% CI of the inverse odds ratio	(0.29, 2.52)	(0.23, 2.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.72	
95% CI of the inverse risk ratio	(0.32, 2.32)	(0.27, 1.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.27	3.21	
95% CI of the absolute risk difference	(-7.50, 10.03)	(-6.71, 13.14)	
p-value	0.7731	0.5045	
p-value of Breslow-Day Test for Homogeneity [3]	0.3905	0.1557	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (26.6)	12 (22.6)	31 (27.9)
No	47 (73.4)	41 (77.4)	80 (72.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.32	
95% CI of the inverse odds ratio	(0.54, 2.14)	(0.62, 2.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.23	
95% CI of the inverse risk ratio	(0.63, 1.74)	(0.69, 2.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.37	-5.29	
95% CI of the absolute risk difference	(-15.03, 12.30)	(-19.31, 8.74)	
p-value	0.8454	0.4716	
p-value of Breslow-Day Test for Homogeneity [3]	0.8511	0.7379	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.7)	7 (13.2)	5 (4.5)
No	61 (95.3)	46 (86.8)	106 (95.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.31	
95% CI of the inverse odds ratio	(0.22, 4.15)	(0.09, 1.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.34	
95% CI of the inverse risk ratio	(0.24, 3.89)	(0.11, 1.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.18	8.70	
95% CI of the absolute risk difference	(-6.27, 6.64)	(-1.20, 18.60)	
p-value	0.9555	0.0453	
p-value of Breslow-Day Test for Homogeneity [3]	0.8880	0.3547	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (12.5)	13 (24.5)	11 (9.9)
No	56 (87.5)	40 (75.5)	100 (90.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.34	
95% CI of the inverse odds ratio	(0.29, 2.03)	(0.14, 0.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.40	
95% CI of the inverse risk ratio	(0.34, 1.87)	(0.19, 0.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.59	14.62	
95% CI of the absolute risk difference	(-7.24, 12.42)	(1.77, 27.47)	
p-value	0.5958	0.0132	
p-value of Breslow-Day Test for Homogeneity [3]	0.6505	0.0570	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (9.4)	11 (20.8)	15 (13.5)
No	58 (90.6)	42 (79.2)	96 (86.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	0.60	
95% CI of the inverse odds ratio	(0.55, 4.11)	(0.25, 1.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	0.65	
95% CI of the inverse risk ratio	(0.59, 3.53)	(0.32, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.14	7.24	
95% CI of the absolute risk difference	(-13.70, 5.42)	(-5.39, 19.88)	
p-value	0.4171	0.2351	
p-value of Breslow-Day Test for Homogeneity [3]	0.4535	0.9239	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (15.6)	15 (28.3)	19 (17.1)
No	54 (84.4)	38 (71.7)	92 (82.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.52	
95% CI of the inverse odds ratio	(0.48, 2.57)	(0.24, 1.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	0.60	
95% CI of the inverse risk ratio	(0.54, 2.21)	(0.33, 1.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.49	11.18	
95% CI of the absolute risk difference	(-12.82, 9.83)	(-2.82, 25.19)	
p-value	0.7982	0.0984	
p-value of Breslow-Day Test for Homogeneity [3]	0.6630	0.8251	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (14.1)	4 (7.5)	13 (11.7)
No	55 (85.9)	49 (92.5)	98 (88.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	1.63	
95% CI of the inverse odds ratio	(0.33, 2.02)	(0.50, 5.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	1.55	
95% CI of the inverse risk ratio	(0.38, 1.84)	(0.53, 4.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.35	-4.16	
95% CI of the absolute risk difference	(-8.06, 12.76)	(-13.46, 5.13)	
p-value	0.6514	0.4132	
p-value of Breslow-Day Test for Homogeneity [3]	0.2987	0.8658	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (34.4)	12 (22.6)	30 (27.0)
No	42 (65.6)	41 (77.4)	81 (73.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.27	
95% CI of the inverse odds ratio	(0.36, 1.37)	(0.59, 2.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	1.19	
95% CI of the inverse risk ratio	(0.50, 1.24)	(0.67, 2.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.35	-4.39	
95% CI of the absolute risk difference	(-6.92, 21.62)	(-18.36, 9.59)	
p-value	0.3056	0.5473	
p-value of Breslow-Day Test for Homogeneity [3]	0.9136	0.4859	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.1)	5 (9.4)	4 (3.6)
No	62 (96.9)	48 (90.6)	107 (96.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	0.36	
95% CI of the inverse odds ratio	(0.21, 6.51)	(0.09, 1.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.38	
95% CI of the inverse risk ratio	(0.22, 6.12)	(0.11, 1.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.48	5.83	
95% CI of the absolute risk difference	(-5.97, 5.02)	(-2.77, 14.43)	
p-value	0.8669	0.1252	
p-value of Breslow-Day Test for Homogeneity [3]	0.8422	0.3209	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (18.8)	11 (20.8)	18 (16.2)
No	52 (81.3)	42 (79.2)	93 (83.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.74	
95% CI of the inverse odds ratio	(0.37, 1.88)	(0.32, 1.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.78	
95% CI of the inverse risk ratio	(0.45, 1.68)	(0.40, 1.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.53	4.54	
95% CI of the absolute risk difference	(-9.23, 14.30)	(-8.35, 17.43)	
p-value	0.6684	0.4762	
p-value of Breslow-Day Test for Homogeneity [3]	0.8407	0.1734	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.6)	3 (5.7)	4 (3.6)
No	63 (98.4)	50 (94.3)	107 (96.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.36	0.62	
95% CI of the inverse odds ratio	(0.26, 21.54)	(0.13, 2.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.31	0.64	
95% CI of the inverse risk ratio	(0.26, 20.19)	(0.15, 2.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.04	2.06	
95% CI of the absolute risk difference	(-6.65, 2.57)	(-5.07, 9.18)	
p-value	0.4350	0.5423	
p-value of Breslow-Day Test for Homogeneity [3]	0.4247	0.8813	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (23.4)	13 (24.5)	19 (17.1)
No	49 (76.6)	40 (75.5)	92 (82.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.64	
95% CI of the inverse odds ratio	(0.32, 1.44)	(0.29, 1.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.70	
95% CI of the inverse risk ratio	(0.40, 1.33)	(0.37, 1.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.32	7.41	
95% CI of the absolute risk difference	(-6.20, 18.84)	(-6.13, 20.95)	
p-value	0.3088	0.2627	
p-value of Breslow-Day Test for Homogeneity [3]	0.2978	0.8942	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (14.6)	12 (12.2)	28 (14.6)
No	88 (85.4)	86 (87.8)	164 (85.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.22	
95% CI of the inverse odds ratio	(0.51, 1.97)	(0.59, 2.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.19	
95% CI of the inverse risk ratio	(0.56, 1.79)	(0.63, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.02	-2.34	
95% CI of the absolute risk difference	(-8.47, 8.43)	(-10.53, 5.85)	
p-value	0.9963	0.5849	
p-value of Breslow-Day Test for Homogeneity [3]	0.5994	0.3902	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	31 (30.1)	31 (31.6)	63 (32.8)
No	72 (69.9)	67 (68.4)	129 (67.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	1.06	
95% CI of the inverse odds ratio	(0.68, 1.90)	(0.63, 1.78)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.04	
95% CI of the inverse risk ratio	(0.76, 1.56)	(0.73, 1.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.72	-1.18	
95% CI of the absolute risk difference	(-13.79, 8.36)	(-12.53, 10.17)	
p-value	0.6333	0.8391	
p-value of Breslow-Day Test for Homogeneity [3]	0.0279	0.1599	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (7.8)	14 (14.3)	23 (12.0)
No	95 (92.2)	84 (85.7)	169 (88.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	0.82	
95% CI of the inverse odds ratio	(0.70, 3.75)	(0.40, 1.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.54	0.84	
95% CI of the inverse risk ratio	(0.72, 3.32)	(0.45, 1.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.21	2.31	
95% CI of the absolute risk difference	(-11.13, 2.70)	(-6.01, 10.62)	
p-value	0.2608	0.5776	
p-value of Breslow-Day Test for Homogeneity [3]	0.7127	0.2141	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (26.2)	27 (27.6)	49 (25.5)
No	76 (73.8)	71 (72.4)	143 (74.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.90	
95% CI of the inverse odds ratio	(0.56, 1.67)	(0.52, 1.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.93	
95% CI of the inverse risk ratio	(0.65, 1.46)	(0.62, 1.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.69	2.03	
95% CI of the absolute risk difference	(-9.80, 11.19)	(-8.75, 12.81)	
p-value	0.8968	0.7100	
p-value of Breslow-Day Test for Homogeneity [3]	0.9910	0.8955	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (14.6)	17 (17.3)	30 (15.6)
No	88 (85.4)	81 (82.7)	162 (84.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.88	
95% CI of the inverse odds ratio	(0.55, 2.13)	(0.46, 1.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.90	
95% CI of the inverse risk ratio	(0.61, 1.90)	(0.52, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.06	1.72	
95% CI of the absolute risk difference	(-9.59, 7.47)	(-7.37, 10.81)	
p-value	0.8089	0.7066	
p-value of Breslow-Day Test for Homogeneity [3]	0.0898	0.4980	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (26.2)	33 (33.7)	53 (27.6)
No	76 (73.8)	65 (66.3)	139 (72.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.75	
95% CI of the inverse odds ratio	(0.62, 1.84)	(0.44, 1.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.82	
95% CI of the inverse risk ratio	(0.71, 1.57)	(0.57, 1.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.39	6.07	
95% CI of the absolute risk difference	(-11.98, 9.20)	(-5.22, 17.36)	
p-value	0.7979	0.2844	
p-value of Breslow-Day Test for Homogeneity [3]	0.5835	0.4291	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	17 (16.5)	20 (20.4)	32 (16.7)
No	86 (83.5)	78 (79.6)	160 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.78	
95% CI of the inverse odds ratio	(0.53, 1.93)	(0.42, 1.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.82	
95% CI of the inverse risk ratio	(0.59, 1.73)	(0.49, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.16	3.74	
95% CI of the absolute risk difference	(-9.06, 8.74)	(-5.82, 13.30)	
p-value	0.9716	0.4321	
p-value of Breslow-Day Test for Homogeneity [3]	0.8826	0.9389	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (31.1)	34 (34.7)	61 (31.8)
No	71 (68.9)	64 (65.3)	131 (68.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.88	
95% CI of the inverse odds ratio	(0.62, 1.73)	(0.52, 1.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.92	
95% CI of the inverse risk ratio	(0.72, 1.46)	(0.65, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.70	2.92	
95% CI of the absolute risk difference	(-11.80, 10.40)	(-8.57, 14.42)	
p-value	0.9014	0.6159	
p-value of Breslow-Day Test for Homogeneity [3]	0.9228	0.5964	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (9.7)	8 (8.2)	27 (14.1)
No	93 (90.3)	90 (91.8)	165 (85.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	1.84	
95% CI of the inverse odds ratio	(0.71, 3.28)	(0.80, 4.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	1.72	
95% CI of the inverse risk ratio	(0.73, 2.87)	(0.81, 3.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.35	-5.90	
95% CI of the absolute risk difference	(-11.90, 3.19)	(-13.22, 1.42)	
p-value	0.2818	0.1447	
p-value of Breslow-Day Test for Homogeneity [3]	0.3905	0.1557	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (32.0)	32 (32.7)	68 (35.4)
No	70 (68.0)	66 (67.3)	124 (64.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.13	
95% CI of the inverse odds ratio	(0.70, 1.93)	(0.68, 1.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.08	
95% CI of the inverse risk ratio	(0.79, 1.55)	(0.77, 1.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.38	-2.76	
95% CI of the absolute risk difference	(-14.65, 7.89)	(-14.25, 8.72)	
p-value	0.5600	0.6395	
p-value of Breslow-Day Test for Homogeneity [3]	0.8511	0.7379	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (9.7)	16 (16.3)	20 (10.4)
No	93 (90.3)	82 (83.7)	172 (89.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.60	
95% CI of the inverse odds ratio	(0.49, 2.41)	(0.29, 1.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.64	
95% CI of the inverse risk ratio	(0.52, 2.21)	(0.35, 1.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.71	5.91	
95% CI of the absolute risk difference	(-7.87, 6.46)	(-2.59, 14.41)	
p-value	0.8479	0.1488	
p-value of Breslow-Day Test for Homogeneity [3]	0.8880	0.3547	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (21.4)	22 (22.4)	41 (21.4)
No	81 (78.6)	76 (77.6)	151 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.94	
95% CI of the inverse odds ratio	(0.56, 1.79)	(0.52, 1.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.95	
95% CI of the inverse risk ratio	(0.63, 1.58)	(0.60, 1.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.01	1.09	
95% CI of the absolute risk difference	(-9.81, 9.82)	(-9.00, 11.19)	
p-value	0.9992	0.8307	
p-value of Breslow-Day Test for Homogeneity [3]	0.6505	0.0570	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (12.6)	19 (19.4)	23 (12.0)
No	90 (87.4)	79 (80.6)	169 (88.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.57	
95% CI of the inverse odds ratio	(0.46, 1.95)	(0.29, 1.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.62	
95% CI of the inverse risk ratio	(0.50, 1.79)	(0.35, 1.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.64	7.41	
95% CI of the absolute risk difference	(-7.25, 8.53)	(-1.67, 16.48)	
p-value	0.8724	0.0899	
p-value of Breslow-Day Test for Homogeneity [3]	0.4535	0.9239	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (18.4)	25 (25.5)	32 (16.7)
No	84 (81.6)	73 (74.5)	160 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.58	
95% CI of the inverse odds ratio	(0.47, 1.65)	(0.32, 1.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	0.65	
95% CI of the inverse risk ratio	(0.54, 1.51)	(0.41, 1.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.78	8.84	
95% CI of the absolute risk difference	(-7.38, 10.94)	(-1.27, 18.96)	
p-value	0.6999	0.0730	
p-value of Breslow-Day Test for Homogeneity [3]	0.6630	0.8251	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (9.7)	10 (10.2)	27 (14.1)
No	93 (90.3)	88 (89.8)	165 (85.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	1.44	
95% CI of the inverse odds ratio	(0.71, 3.28)	(0.67, 3.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	1.38	
95% CI of the inverse risk ratio	(0.73, 2.87)	(0.70, 2.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.35	-3.86	
95% CI of the absolute risk difference	(-11.90, 3.19)	(-11.61, 3.89)	
p-value	0.2818	0.3516	
p-value of Breslow-Day Test for Homogeneity [3]	0.2987	0.8658	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	35 (34.0)	29 (29.6)	53 (27.6)
No	68 (66.0)	69 (70.4)	139 (72.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.91	
95% CI of the inverse odds ratio	(0.44, 1.24)	(0.53, 1.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.93	
95% CI of the inverse risk ratio	(0.57, 1.16)	(0.64, 1.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.38	1.99	
95% CI of the absolute risk difference	(-4.74, 17.50)	(-9.04, 13.02)	
p-value	0.2538	0.7222	
p-value of Breslow-Day Test for Homogeneity [3]	0.9136	0.4859	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.9)	8 (8.2)	13 (6.8)
No	98 (95.1)	90 (91.8)	179 (93.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	0.82	
95% CI of the inverse odds ratio	(0.49, 4.11)	(0.33, 2.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	0.83	
95% CI of the inverse risk ratio	(0.51, 3.80)	(0.36, 1.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.92	1.39	
95% CI of the absolute risk difference	(-7.38, 3.55)	(-5.09, 7.87)	
p-value	0.5121	0.6652	
p-value of Breslow-Day Test for Homogeneity [3]	0.8422	0.3209	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (24.3)	16 (16.3)	44 (22.9)
No	78 (75.7)	82 (83.7)	148 (77.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.52	
95% CI of the inverse odds ratio	(0.53, 1.63)	(0.81, 2.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.40	
95% CI of the inverse risk ratio	(0.62, 1.45)	(0.84, 2.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.36	-6.59	
95% CI of the absolute risk difference	(-8.84, 11.55)	(-16.02, 2.84)	
p-value	0.7932	0.1900	
p-value of Breslow-Day Test for Homogeneity [3]	0.8407	0.1734	

AMNOG Table SE22.8.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (5.8)	9 (9.2)	10 (5.2)
No	97 (94.2)	89 (90.8)	182 (94.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.54	
95% CI of the inverse odds ratio	(0.31, 2.52)	(0.21, 1.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.57	
95% CI of the inverse risk ratio	(0.33, 2.39)	(0.24, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.62	3.98	
95% CI of the absolute risk difference	(-4.89, 6.12)	(-2.55, 10.50)	
p-value	0.8235	0.1956	
p-value of Breslow-Day Test for Homogeneity [3]	0.4247	0.8813	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (19.4)	28 (28.6)	41 (21.4)
No	83 (80.6)	70 (71.4)	151 (78.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	0.68	
95% CI of the inverse odds ratio	(0.62, 2.05)	(0.39, 1.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	0.75	
95% CI of the inverse risk ratio	(0.68, 1.77)	(0.49, 1.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.94	7.22	
95% CI of the absolute risk difference	(-11.53, 7.65)	(-3.44, 17.88)	
p-value	0.6954	0.1722	
p-value of Breslow-Day Test for Homogeneity [3]	0.2978	0.8942	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Physical Functioning						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	77.41 (21.72)	60.25 (32.42)	77.92 (21.56)			
Median	85.00	62.50	85.00			
IQR: Q1, Q3	70.00, 95.00	35.00, 90.00	65.00, 92.50			
Min, Max	25.0, 100.0	5.0, 100.0	15.0, 100.0			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	73.20 (26.37)	67.50 (27.85)	74.76 (30.03)	-5.40 (2.22)	6.75 (3.83)	-1.04 (3.00)
Median	85.00	77.50	85.00	-5.00	5.00	0
IQR: Q1, Q3	55.00, 95.00	45.00, 90.00	45.00, 100.00	-10.00, 0.00	-7.50, 22.50	-7.50, 10.00
Min, Max	20.0, 100.0	5.0, 100.0	5.0, 100.0	-40.0, 15.0	-20.0, 40.0	-50.0, 35.0
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	70.65 (31.24)	62.89 (31.11)	75.94 (26.83)	-4.57 (3.34)	3.33 (3.70)	-3.62 (1.87)
Median	85.00	65.00	85.00	-5.00	0	0
IQR: Q1, Q3	45.00, 95.00	35.00, 95.00	57.50, 95.00	-10.00, 5.00	-5.00, 5.00	-10.00, 5.00
Min, Max	5.0, 100.0	5.0, 100.0	10.0, 100.0	-65.0, 20.0	-20.0, 40.0	-30.0, 10.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Role Physical						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	72.93 (26.68)	69.39 (30.54)	82.65 (22.90)			
Median	81.30	81.30	96.90			
IQR: Q1, Q3	50.00, 100.00	46.90, 100.00	68.75, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	31.3, 100.0			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	71.77 (26.46)	70.19 (26.64)	75.55 (28.60)	-2.00 (3.88)	1.57 (4.73)	-6.44 (2.78)
Median	81.30	75.00	87.50	0	0	0
IQR: Q1, Q3	50.00, 100.00	50.00, 93.80	50.00, 100.00	-12.50, 12.50	-9.40, 6.30	-12.50, 0.00
Min, Max	25.0, 100.0	12.5, 100.0	18.8, 100.0	-37.5, 31.3	-31.3, 50.0	-56.2, 37.5
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	70.40 (30.28)	69.42 (27.39)	79.11 (26.35)	-2.44 (3.77)	2.08 (5.46)	-4.96 (3.00)
Median	75.00	75.00	93.80	0	0	0
IQR: Q1, Q3	50.00, 100.00	50.00, 100.00	53.15, 100.00	-12.50, 6.20	-12.50, 12.50	-12.50, 0.00
Min, Max	0.0, 100.0	18.8, 100.0	6.3, 100.0	-43.8, 43.8	-37.5, 56.3	-50.0, 37.5

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Bodily Pain						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	60.9 (23.3)	61.5 (30.5)	66.5 (26.8)			
Median	62.0	62.0	72.0			
IQR: Q1, Q3	41.0, 84.0	36.0, 92.0	41.0, 84.0			
Min, Max	12, 100	12, 100	12, 100			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	57.2 (25.3)	63.0 (27.1)	67.7 (28.0)	-3.7 (4.5)	0.8 (3.6)	3.1 (3.2)
Median	62.0	62.0	72.0	0	0	0
IQR: Q1, Q3	41.0, 74.0	41.0, 84.0	51.0, 100.0	-19.0, 10.0	0.0, 10.0	-5.0, 12.0
Min, Max	10, 100	22, 100	0, 100	-50, 43	-38, 33	-31, 59
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	59.4 (26.9)	62.2 (29.1)	66.5 (27.6)	-2.7 (4.0)	1.9 (3.9)	-0.4 (3.4)
Median	62.0	62.0	67.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	51.0, 84.0	-9.0, 10.0	0.0, 11.0	-12.0, 12.0
Min, Max	0, 100	10, 100	10, 100	-60, 38	-38, 33	-33, 33

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
General Health						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	55.84 (20.59)	46.40 (19.18)	56.72 (20.32)			
Median	60.00	46.00	62.00			
IQR: Q1, Q3	40.00, 68.80	30.00, 62.00	45.00, 72.00			
Min, Max	15.0, 95.0	10.0, 92.0	15.0, 92.0			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	56.04 (21.91)	54.14 (21.28)	58.14 (24.11)	0.61 (2.99)	7.95 (2.93)	4.06 (2.31)
Median	57.00	52.00	57.00	3.20	5.00	0
IQR: Q1, Q3	40.00, 72.00	35.00, 67.00	40.00, 77.00	-5.00, 5.00	-4.00, 20.00	-5.00, 10.00
Min, Max	15.0, 92.0	15.0, 92.0	15.0, 100.0	-42.0, 32.0	-15.0, 27.0	-15.0, 37.0
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	55.13 (22.96)	52.63 (21.01)	57.75 (22.61)	-1.34 (2.54)	7.72 (3.92)	2.38 (2.00)
Median	52.00	52.00	62.00	0	9.00	0
IQR: Q1, Q3	35.00, 77.00	35.00, 67.00	38.50, 72.00	-10.00, 5.00	-10.00, 25.00	-5.00, 10.00
Min, Max	20.0, 97.0	20.0, 92.0	10.0, 92.0	-37.0, 17.0	-15.0, 32.0	-27.0, 27.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Vitality						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	56.27 (20.59)	50.96 (25.18)	53.84 (25.49)			
Median	62.50	50.00	50.00			
IQR: Q1, Q3	43.80, 75.00	28.15, 75.00	34.40, 75.00			
Min, Max	0.0, 81.3	6.3, 93.8	6.3, 100.0			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	52.77 (21.43)	50.88 (24.65)	55.55 (27.02)	-4.00 (3.60)	0.32 (3.34)	3.51 (2.75)
Median	62.50	50.05	62.50	0	0	3.10
IQR: Q1, Q3	37.50, 68.80	31.30, 68.80	31.30, 75.00	-12.50, 6.20	-6.25, 9.40	-9.40, 12.50
Min, Max	0.0, 81.3	12.5, 100.0	12.5, 100.0	-43.8, 25.0	-31.3, 31.2	-18.8, 43.7
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	54.91 (26.03)	50.68 (21.73)	57.05 (23.90)	-0.28 (4.00)	0.35 (3.45)	3.23 (3.20)
Median	62.50	50.00	56.30	0	0	6.20
IQR: Q1, Q3	31.30, 75.00	31.30, 62.50	37.50, 75.00	-12.50, 12.50	-12.50, 6.30	-6.30, 12.50
Min, Max	6.3, 87.5	18.8, 100.0	12.5, 100.0	-37.5, 50.0	-25.0, 37.5	-31.3, 37.5

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Social Functioning						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	84.26 (24.66)	75.63 (27.94)	82.99 (22.98)			
Median	100.00	81.25	93.75			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	12.5, 100.0	25.0, 100.0			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	80.00 (28.41)	78.41 (18.97)	83.93 (21.56)	-5.50 (4.33)	2.50 (3.34)	1.56 (2.36)
Median	100.00	75.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00	-12.50, 0.00	0.00, 12.50	0.00, 12.50
Min, Max	12.5, 100.0	37.5, 100.0	37.5, 100.0	-50.0, 37.5	-25.0, 37.5	-25.0, 25.0
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	83.15 (25.45)	72.37 (23.41)	84.38 (20.82)	-1.63 (2.12)	-3.47 (5.52)	0.43 (3.25)
Median	100.00	75.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	68.75, 100.00	0.00, 0.00	-25.00, 0.00	0.00, 12.50
Min, Max	12.5, 100.0	25.0, 100.0	50.0, 100.0	-25.0, 12.5	-37.5, 37.5	-50.0, 25.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Role Emotional						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	81.48 (29.08)	75.00 (28.99)	83.56 (20.56)			
Median	100.00	75.00	95.85			
IQR: Q1, Q3	50.00, 100.00	54.15, 100.00	66.65, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	50.0, 100.0			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	78.66 (27.01)	79.17 (20.85)	82.62 (25.28)	-3.33 (3.33)	2.51 (4.65)	-0.26 (3.40)
Median	83.30	79.15	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	66.70, 100.00	-16.70, 0.00	-8.35, 16.70	-4.15, 0.00
Min, Max	25.0, 100.0	41.7, 100.0	8.3, 100.0	-33.3, 33.3	-33.3, 50.0	-41.7, 50.0
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	80.43 (25.70)	76.32 (28.23)	84.11 (22.93)	2.17 (3.20)	0.46 (6.82)	-2.01 (3.27)
Median	91.70	83.30	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	50.00, 100.00	75.00, 100.00	0.00, 0.00	-8.30, 25.00	0.00, 0.00
Min, Max	25.0, 100.0	25.0, 100.0	25.0, 100.0	-25.0, 41.7	-75.0, 50.0	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Mental Health						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	67.6 (24.7)	70.5 (19.5)	75.0 (17.6)			
Median	75.0	77.5	80.0			
IQR: Q1, Q3	50.0, 90.0	60.0, 80.0	62.5, 90.0			
Min, Max	5, 100	25, 100	30, 100			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	67.4 (21.6)	70.0 (20.6)	74.4 (21.1)	0.6 (2.7)	-1.0 (2.1)	1.3 (2.8)
Median	70.0	75.0	80.0	0	0	0
IQR: Q1, Q3	50.0, 85.0	60.0, 80.0	70.0, 90.0	-5.0, 5.0	-5.0, 5.0	-5.0, 5.0
Min, Max	25, 95	20, 100	20, 100	-30, 35	-20, 15	-25, 55
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	71.3 (21.2)	72.1 (18.3)	77.5 (20.1)	5.9 (2.0)	1.9 (3.4)	-0.2 (3.1)
Median	80.0	75.0	85.0	5.0	0	0
IQR: Q1, Q3	50.0, 90.0	65.0, 85.0	70.0, 90.0	0.0, 15.0	-10.0, 10.0	-10.0, 5.0
Min, Max	25, 100	25, 100	20, 100	-20, 20	-15, 35	-30, 55

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Mental Component Score						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	49.07 (12.90)	48.81 (11.87)	50.20 (10.04)			
Median	53.60	52.05	51.95			
IQR: Q1, Q3	40.70, 57.60	39.95, 57.45	45.60, 58.85			
Min, Max	12.0, 69.0	23.5, 64.5	28.8, 62.4			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	48.22 (11.11)	48.94 (9.68)	50.72 (11.80)	-0.80 (1.51)	-0.25 (1.09)	1.06 (1.47)
Median	51.80	51.55	55.80	1.20	-0.15	0.35
IQR: Q1, Q3	42.90, 57.50	40.50, 56.80	43.30, 59.00	-4.30, 3.20	-3.80, 2.65	-2.40, 4.10
Min, Max	26.2, 61.6	31.5, 62.3	21.9, 62.4	-20.0, 14.2	-10.4, 8.8	-17.6, 24.8
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	50.31 (10.82)	48.76 (10.18)	51.77 (10.49)	2.30 (1.24)	-0.28 (2.31)	0.53 (1.50)
Median	54.40	51.20	54.30	3.00	0.20	0.60
IQR: Q1, Q3	43.00, 57.50	43.10, 56.20	47.80, 59.45	-0.80, 7.10	-5.40, 2.90	-1.60, 4.10
Min, Max	26.7, 63.2	28.5, 64.5	25.6, 63.7	-12.7, 14.9	-21.4, 16.1	-18.8, 26.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Physical Component Score						
Baseline						
m	27	22	39			
n	27	20	36			
Mean (SD)	47.25 (8.11)	43.12 (11.74)	48.33 (8.61)			
Median	47.40	46.75	51.45			
IQR: Q1, Q3	42.70, 53.60	29.85, 52.70	43.00, 55.55			
Min, Max	27.6, 60.8	21.9, 57.4	28.4, 59.3			
Week 24						
m	27	22	37			
n	25	22	35	25	20	32
Mean (SD/SE)	46.18 (8.34)	45.21 (9.83)	47.41 (11.37)	-1.36 (1.21)	2.25 (1.31)	-0.18 (0.97)
Median	49.20	47.85	51.90	-1.90	1.95	-0.05
IQR: Q1, Q3	40.70, 52.20	35.90, 53.30	42.30, 56.60	-5.40, 3.60	-1.95, 5.10	-1.50, 2.15
Min, Max	31.8, 59.1	28.8, 59.0	23.1, 59.6	-14.8, 10.5	-9.2, 13.6	-15.1, 13.4
Week 52						
m	25	19	36			
n	23	19	32	23	18	29
Mean (SD/SE)	45.21 (10.90)	44.09 (11.08)	47.39 (10.84)	-2.40 (1.22)	1.73 (1.24)	-0.75 (0.78)
Median	47.50	42.50	51.65	-2.00	2.35	-1.10
IQR: Q1, Q3	38.20, 54.10	35.90, 53.90	41.70, 55.60	-4.40, 0.50	0.80, 5.50	-3.10, 2.00
Min, Max	20.3, 59.6	24.8, 59.1	21.5, 59.6	-24.2, 5.2	-13.8, 9.6	-9.7, 8.6

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Physical Functioning						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	73.99 (24.38)	71.61 (24.27)	73.93 (25.78)			
Median	80.00	80.00	82.50			
IQR: Q1, Q3	60.00, 95.00	55.00, 90.00	60.00, 95.00			
Min, Max	0.0, 100.0	10.0, 100.0	10.0, 100.0			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	76.17 (24.10)	72.35 (23.96)	74.91 (27.14)	2.76 (1.49)	-0.02 (1.98)	0.46 (1.20)
Median	85.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 95.00	61.10, 90.00	60.00, 95.00	-5.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	5.0, 100.0	10.0, 100.0	0.0, 100.0	-50.0, 60.0	-65.0, 70.0	-70.0, 75.0
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	77.79 (25.54)	72.75 (24.77)	76.59 (24.18)	2.59 (1.44)	-0.04 (1.88)	1.33 (1.19)
Median	90.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 100.00	60.00, 90.00	65.00, 95.00	-5.00, 10.00	-5.00, 5.00	-5.00, 5.00
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-45.0, 45.0	-85.0, 35.0	-60.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Role Physical						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	76.35 (26.08)	73.74 (26.46)	74.96 (26.39)			
Median	81.30	75.00	81.30			
IQR: Q1, Q3	56.30, 100.00	56.30, 100.00	56.30, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	74.92 (27.02)	74.41 (23.59)	76.07 (27.10)	-1.04 (1.61)	-0.59 (2.06)	0.60 (1.40)
Median	81.30	75.00	81.30	0	0	0
IQR: Q1, Q3	56.30, 100.00	56.30, 100.00	56.30, 100.00	-12.50, 6.30	-12.50, 6.20	-6.30, 6.30
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.8, 50.0	-56.2, 68.7	-68.7, 87.5
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	77.22 (27.30)	74.82 (26.20)	74.99 (24.75)	-0.06 (1.76)	0.41 (2.19)	-0.49 (1.48)
Median	87.50	81.30	81.30	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 100.00	56.30, 100.00	-6.20, 6.20	-6.30, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	6.3, 100.0	0.0, 100.0	-37.5, 81.2	-75.0, 81.3	-62.5, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Bodily Pain						
Baseline						
m	140	129	264			
n	130	118	244			
Mean (SD)	68.0 (24.5)	62.1 (25.6)	65.3 (24.9)			
Median	72.0	62.0	62.0			
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	41.0, 84.0			
Min, Max	0, 100	0, 100	0, 100			
Week 24						
m	134	119	252			
n	132	114	232	125	106	217
Mean (SD/SE)	65.4 (25.3)	64.8 (23.7)	65.8 (25.3)	-2.1 (1.8)	0.9 (2.0)	-0.1 (1.4)
Median	68.0	62.0	72.0	0	0	0
IQR: Q1, Q3	46.0, 84.0	42.0, 84.0	41.0, 84.0	-16.0, 10.0	-10.0, 10.0	-12.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-59, 68	-62, 72	-78, 78
Week 52						
m	124	106	234			
n	113	95	207	106	91	194
Mean (SD/SE)	69.5 (25.3)	68.2 (24.8)	67.7 (24.5)	0.8 (2.0)	5.6 (2.4)	1.6 (1.6)
Median	74.0	72.0	74.0	0	0	0
IQR: Q1, Q3	51.0, 100.0	51.0, 84.0	51.0, 84.0	-10.0, 10.0	-10.0, 16.0	-11.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-80, 68	-53, 69	-78, 78

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
General Health						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	61.43 (19.68)	55.42 (18.95)	59.11 (20.36)			
Median	62.00	53.50	62.00			
IQR: Q1, Q3	50.00, 77.00	40.00, 72.00	45.00, 77.00			
Min, Max	10.0, 100.0	10.0, 100.0	15.0, 100.0			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	61.75 (20.69)	55.29 (19.12)	59.44 (21.11)	1.06 (1.27)	0.09 (1.54)	0.17 (1.01)
Median	62.00	52.00	62.00	0	0	0
IQR: Q1, Q3	47.00, 77.00	40.00, 72.00	45.00, 77.00	-5.00, 10.00	-10.00, 10.00	-10.00, 8.00
Min, Max	10.0, 100.0	10.0, 100.0	0.0, 100.0	-60.0, 32.0	-35.0, 40.0	-40.0, 48.0
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	64.33 (18.90)	56.60 (18.88)	60.99 (20.48)	2.11 (1.50)	1.08 (1.81)	1.33 (1.02)
Median	67.00	57.00	62.00	0	3.00	0
IQR: Q1, Q3	55.00, 77.00	45.00, 72.00	47.00, 77.00	-5.00, 10.00	-10.00, 10.00	-5.00, 10.00
Min, Max	20.0, 100.0	10.0, 92.0	10.0, 100.0	-70.0, 47.0	-52.0, 47.0	-42.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Vitality						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	57.67 (22.85)	54.15 (22.01)	56.96 (20.95)			
Median	62.50	56.30	62.50			
IQR: Q1, Q3	37.50, 75.00	43.80, 68.80	43.80, 75.00			
Min, Max	6.3, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	57.27 (24.15)	54.30 (19.35)	57.16 (21.42)	0.04 (1.25)	-0.59 (1.53)	-0.36 (1.05)
Median	62.50	56.30	56.30	0	0	0
IQR: Q1, Q3	43.80, 75.00	37.50, 68.80	43.80, 75.00	-6.30, 6.30	-12.50, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	0.0, 93.8	0.0, 100.0	-43.8, 43.8	-31.2, 43.8	-37.5, 56.2
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	59.43 (22.21)	55.68 (20.77)	57.51 (22.29)	-0.05 (1.42)	0.34 (1.62)	0.14 (1.26)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	43.80, 75.00	43.80, 75.00	43.80, 75.00	-6.30, 12.50	-6.30, 6.30	-6.30, 12.50
Min, Max	6.3, 100.0	6.3, 87.5	0.0, 100.0	-43.7, 37.5	-43.8, 43.8	-56.3, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Social Functioning						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	81.30 (23.58)	80.30 (25.45)	82.94 (22.43)			
Median	87.50	93.75	100.00			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	12.5, 100.0			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	81.25 (23.85)	82.35 (21.35)	80.77 (25.10)	0.30 (1.87)	1.53 (2.07)	-2.07 (1.38)
Median	87.50	87.50	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	62.50, 100.00	-12.50, 12.50	-12.50, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	12.5, 100.0	0.0, 100.0	-62.5, 75.0	-62.5, 87.5	-62.5, 75.0
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	81.31 (22.97)	83.68 (21.81)	82.73 (22.12)	-1.64 (1.78)	2.88 (2.36)	-0.64 (1.42)
Median	87.50	100.00	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00	-12.50, 0.00	0.00, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-50.0, 50.0	-62.5, 62.5	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Role Emotional						
Baseline						
m	140	129	264			
n	131	118	243			
Mean (SD)	82.18 (23.75)	83.19 (22.62)	84.05 (22.65)			
Median	91.70	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	8.3, 100.0	0.0, 100.0			
Week 24						
m	134	119	252			
n	132	114	232	126	106	216
Mean (SD/SE)	82.07 (22.38)	86.48 (20.49)	82.90 (23.89)	0.53 (1.59)	2.99 (1.46)	-1.04 (1.26)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	75.00, 100.00	-8.30, 0.00	0.00, 8.30	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-66.7, 66.7	-50.0, 41.7	-50.0, 58.3
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	83.96 (20.56)	86.58 (20.10)	82.77 (22.70)	0.51 (1.71)	3.85 (2.06)	-1.72 (1.34)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	0.00, 16.70	-8.40, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-50.0, 100.0	-50.0, 58.3	-58.3, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Mental Health						
Baseline						
m	140	129	264			
n	131	118	244			
Mean (SD)	75.0 (18.6)	75.6 (19.3)	75.2 (17.8)			
Median	80.0	80.0	80.0			
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	65.0, 90.0			
Min, Max	10, 100	15, 100	5, 100			
Week 24						
m	134	119	252			
n	132	114	232	126	106	217
Mean (SD/SE)	73.9 (19.5)	76.1 (18.4)	74.6 (18.6)	-1.0 (1.2)	-0.6 (1.3)	-0.4 (1.0)
Median	77.5	80.0	80.0	0	0	0
IQR: Q1, Q3	60.0, 90.0	65.0, 90.0	65.0, 90.0	-5.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	15, 100	5, 100	5, 100	-40, 35	-40, 50	-45, 50
Week 52						
m	124	106	234			
n	113	95	207	107	91	194
Mean (SD/SE)	76.0 (17.4)	76.2 (18.3)	75.4 (19.4)	-0.6 (1.3)	-0.2 (1.3)	0.6 (1.1)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	70.0, 90.0	-10.0, 5.0	-5.0, 5.0	-10.0, 10.0
Min, Max	30, 100	20, 100	0, 100	-35, 40	-30, 50	-60, 50

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Mental Component Score						
Baseline						
m	140	129	264			
n	130	118	243			
Mean (SD)	50.80 (10.37)	51.17 (10.87)	51.41 (9.22)			
Median	53.50	54.05	54.30			
IQR: Q1, Q3	46.80, 58.30	46.40, 58.30	46.70, 57.80			
Min, Max	12.9, 67.0	17.0, 72.3	15.6, 66.5			
Week 24						
m	134	119	252			
n	132	114	232	125	106	216
Mean (SD/SE)	50.34 (10.56)	51.92 (9.78)	50.68 (10.11)	-0.33 (0.65)	0.49 (0.69)	-0.62 (0.51)
Median	52.75	54.40	53.05	-0.80	-0.10	-0.15
IQR: Q1, Q3	43.80, 58.55	46.90, 59.00	44.55, 58.15	-3.90, 3.50	-2.70, 3.50	-4.50, 2.90
Min, Max	18.7, 69.1	9.4, 71.2	14.2, 69.0	-20.0, 19.0	-24.5, 26.1	-24.6, 22.7
Week 52						
m	124	106	234			
n	113	95	207	106	91	194
Mean (SD/SE)	51.06 (9.33)	52.08 (9.56)	50.92 (10.16)	-0.59 (0.69)	0.76 (0.82)	-0.38 (0.55)
Median	53.50	53.70	53.70	-0.15	-0.10	-0.15
IQR: Q1, Q3	44.30, 58.30	46.10, 59.00	46.10, 58.10	-4.00, 2.80	-3.60, 4.10	-4.20, 3.50
Min, Max	23.1, 62.4	17.8, 70.7	8.9, 68.0	-21.7, 26.2	-15.2, 25.2	-25.1, 24.1

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Physical Component Score						
Baseline						
m	140	129	264			
n	130	118	243			
Mean (SD)	47.83 (9.08)	45.44 (9.55)	46.86 (9.56)			
Median	49.00	45.95	48.50			
IQR: Q1, Q3	43.10, 55.30	39.60, 53.00	40.50, 54.70			
Min, Max	15.3, 59.8	21.2, 61.3	20.7, 65.2			
Week 24						
m	134	119	252			
n	132	114	232	125	106	216
Mean (SD/SE)	47.84 (9.80)	45.65 (8.80)	47.40 (9.87)	0.26 (0.55)	-0.14 (0.76)	0.25 (0.48)
Median	49.65	45.95	49.70	0.60	-0.65	0.10
IQR: Q1, Q3	42.75, 54.65	39.20, 52.30	41.50, 55.05	-3.70, 3.80	-3.50, 3.30	-3.50, 3.65
Min, Max	12.5, 63.9	20.2, 61.0	19.0, 63.0	-17.2, 18.3	-22.1, 32.4	-28.8, 23.8
Week 52						
m	124	106	234			
n	113	95	207	106	91	194
Mean (SD/SE)	48.84 (10.24)	46.35 (9.60)	47.89 (8.96)	0.86 (0.64)	0.60 (0.83)	0.60 (0.46)
Median	52.40	48.00	48.70	0.90	0.70	0.60
IQR: Q1, Q3	42.60, 57.20	41.00, 53.00	42.70, 55.10	-1.40, 4.20	-2.80, 5.00	-2.40, 3.70
Min, Max	15.8, 62.8	16.0, 61.2	22.5, 63.9	-24.7, 22.5	-23.5, 18.6	-23.9, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Physical Functioning			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	78.60 (19.34)	60.25 (32.42)	78.28 (22.35)
Analysis Visit Mean (SD)	73.20 (26.37)	67.00 (28.95)	77.24 (29.27)
LS Mean of Change from Baseline (SE)	-5.91 (3.08)	5.14 (3.75)	-2.44 (3.00)
95% CI	(-12.04, 0.22)	(-2.32, 12.59)	(-8.41, 3.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.47 (4.17)	7.57 (4.59)	
95% CI	(-11.78, 4.83)	(-1.55, 16.70)	
p-value	0.4076	0.1026	
Corrected Hedge's g Statistics	-0.210	0.442	
95% CI	(-0.73, 0.31)	(-0.12, 1.01)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	75.22 (22.84)	60.00 (34.26)	81.72 (20.19)
Analysis Visit Mean (SD)	70.65 (31.24)	63.33 (31.95)	78.10 (25.37)
LS Mean of Change from Baseline (SE)	-4.97 (2.79)	2.42 (3.46)	-4.80 (2.78)
95% CI	(-10.52, 0.57)	(-4.48, 9.31)	(-10.34, 0.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.17 (3.81)	7.22 (4.21)	
95% CI	(-7.75, 7.41)	(-1.16, 15.60)	
p-value	0.9647	0.0903	
Corrected Hedge's g Statistics	-0.012	0.478	
95% CI	(-0.56, 0.54)	(-0.12, 1.07)	
Subgroup*Treatment Interaction p-value	0.2614	0.3604	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Role Physical			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	73.77 (25.38)	69.39 (30.54)	83.02 (22.51)
Analysis Visit Mean (SD)	71.77 (26.46)	70.96 (27.59)	76.58 (28.69)
LS Mean of Change from Baseline (SE)	-3.27 (3.63)	-1.47 (4.26)	-7.52 (3.53)
95% CI	(-10.49, 3.95)	(-9.96, 7.01)	(-14.56, -0.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.25 (4.98)	6.05 (5.27)	
95% CI	(-5.66, 14.16)	(-4.45, 16.54)	
p-value	0.3959	0.2549	
Corrected Hedge's g Statistics	0.218	0.303	
95% CI	(-0.31, 0.74)	(-0.26, 0.86)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	72.84 (27.98)	67.03 (31.20)	86.21 (20.68)
Analysis Visit Mean (SD)	70.40 (30.28)	69.11 (28.15)	81.26 (24.77)
LS Mean of Change from Baseline (SE)	-3.27 (3.69)	-1.92 (4.42)	-5.24 (3.61)
95% CI	(-10.62, 4.09)	(-10.73, 6.88)	(-12.43, 1.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.97 (5.10)	3.32 (5.49)	
95% CI	(-8.18, 12.12)	(-7.61, 14.25)	
p-value	0.6999	0.5476	
Corrected Hedge's g Statistics	0.104	0.170	
95% CI	(-0.44, 0.65)	(-0.42, 0.76)	
Subgroup*Treatment Interaction p-value	0.7154	0.5175	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Bodily Pain			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	60.8 (21.5)	61.5 (30.5)	67.3 (27.4)
Analysis Visit Mean (SD)	57.2 (25.3)	62.3 (26.7)	70.4 (27.5)
LS Mean of Change from Baseline (SE)	-5.32 (3.55)	-2.42 (4.17)	0.97 (3.44)
95% CI	(-12.39, 1.76)	(-10.72, 5.88)	(-5.87, 7.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.29 (4.83)	-3.39 (5.06)	
95% CI	(-15.90, 3.33)	(-13.48, 6.69)	
p-value	0.1967	0.5048	
Corrected Hedge's g Statistics	-0.331	-0.175	
95% CI	(-0.86, 0.20)	(-0.73, 0.39)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	62.1 (24.9)	60.2 (32.0)	70.2 (25.7)
Analysis Visit Mean (SD)	59.4 (26.9)	62.2 (30.0)	69.8 (25.4)
LS Mean of Change from Baseline (SE)	-3.12 (3.58)	-1.48 (4.27)	-1.78 (3.47)
95% CI	(-10.25, 4.02)	(-9.98, 7.02)	(-8.68, 5.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.34 (4.88)	0.30 (5.18)	
95% CI	(-11.05, 8.37)	(-10.01, 10.60)	
p-value	0.7843	0.9544	
Corrected Hedge's g Statistics	-0.073	0.016	
95% CI	(-0.62, 0.47)	(-0.57, 0.60)	
Subgroup*Treatment Interaction p-value	0.2787	0.4850	

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
General Health			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	55.43 (18.99)	46.40 (19.18)	56.13 (19.71)
Analysis Visit Mean (SD)	56.04 (21.91)	54.35 (22.30)	60.19 (23.77)
LS Mean of Change from Baseline (SE)	0.18 (2.72)	6.34 (3.27)	2.46 (2.66)
95% CI	(-5.23, 5.59)	(-0.18, 12.86)	(-2.84, 7.75)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.27 (3.70)	3.88 (3.97)	
95% CI	(-9.64, 5.09)	(-4.03, 11.79)	
p-value	0.5406	0.3315	
Corrected Hedge's g Statistics	-0.155	0.257	
95% CI	(-0.68, 0.37)	(-0.30, 0.82)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	56.47 (21.64)	45.22 (19.83)	58.17 (19.64)
Analysis Visit Mean (SD)	55.13 (22.96)	52.94 (21.58)	60.55 (21.59)
LS Mean of Change from Baseline (SE)	0.09 (2.65)	4.65 (3.24)	2.41 (2.61)
95% CI	(-5.18, 5.36)	(-1.79, 11.09)	(-2.78, 7.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.32 (3.60)	2.24 (3.91)	
95% CI	(-9.50, 4.85)	(-5.55, 10.02)	
p-value	0.5211	0.5689	
Corrected Hedge's g Statistics	-0.170	0.158	
95% CI	(-0.72, 0.38)	(-0.43, 0.75)	
Subgroup*Treatment Interaction p-value	0.2357	0.4282	

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Vitality			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	56.78 (21.04)	50.96 (25.18)	53.73 (26.88)
Analysis Visit Mean (SD)	52.77 (21.43)	51.28 (25.70)	57.24 (27.50)
LS Mean of Change from Baseline (SE)	-3.79 (3.13)	-1.93 (3.72)	1.73 (3.07)
95% CI	(-10.01, 2.44)	(-9.34, 5.47)	(-4.39, 7.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.51 (4.26)	-3.66 (4.48)	
95% CI	(-14.00, 2.97)	(-12.57, 5.25)	
p-value	0.1998	0.4158	
Corrected Hedge's g Statistics	-0.327	-0.211	
95% CI	(-0.85, 0.20)	(-0.77, 0.35)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	55.19 (21.96)	49.68 (25.94)	56.06 (25.79)
Analysis Visit Mean (SD)	54.91 (26.03)	50.03 (22.17)	59.29 (23.42)
LS Mean of Change from Baseline (SE)	0.04 (3.24)	-2.61 (3.88)	2.43 (3.17)
95% CI	(-6.41, 6.49)	(-10.34, 5.12)	(-3.88, 8.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.39 (4.42)	-5.03 (4.68)	
95% CI	(-11.18, 6.40)	(-14.35, 4.28)	
p-value	0.5899	0.2852	
Corrected Hedge's g Statistics	-0.143	-0.294	
95% CI	(-0.69, 0.40)	(-0.88, 0.30)	
Subgroup*Treatment Interaction p-value	0.1404	0.4191	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Social Functioning			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	85.50 (23.57)	75.63 (27.94)	81.64 (23.76)
Analysis Visit Mean (SD)	80.00 (28.41)	78.13 (19.82)	83.20 (22.14)
LS Mean of Change from Baseline (SE)	-5.06 (3.06)	-1.04 (3.61)	-0.47 (2.96)
95% CI	(-11.14, 1.03)	(-8.23, 6.15)	(-6.37, 5.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.58 (4.16)	-0.56 (4.36)	
95% CI	(-12.86, 3.69)	(-9.25, 8.12)	
p-value	0.2733	0.8974	
Corrected Hedge's g Statistics	-0.280	-0.034	
95% CI	(-0.81, 0.25)	(-0.59, 0.53)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	84.78 (26.10)	75.00 (28.76)	85.34 (19.50)
Analysis Visit Mean (SD)	83.15 (25.45)	71.53 (23.80)	85.78 (20.79)
LS Mean of Change from Baseline (SE)	-0.20 (3.28)	-7.37 (3.92)	-0.08 (3.16)
95% CI	(-6.73, 6.34)	(-15.17, 0.43)	(-6.36, 6.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (4.45)	-7.29 (4.76)	
95% CI	(-8.97, 8.74)	(-16.77, 2.19)	
p-value	0.9795	0.1299	
Corrected Hedge's g Statistics	-0.007	-0.425	
95% CI	(-0.55, 0.54)	(-1.02, 0.17)	
Subgroup*Treatment Interaction p-value	0.4823	0.1289	

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Role Emotional			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	82.00 (29.34)	75.00 (28.99)	82.03 (21.18)
Analysis Visit Mean (SD)	78.66 (27.01)	77.51 (21.13)	81.77 (26.22)
LS Mean of Change from Baseline (SE)	-2.64 (3.43)	0.87 (4.12)	0.26 (3.39)
95% CI	(-9.47, 4.20)	(-7.32, 9.07)	(-6.49, 7.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.90 (4.69)	0.61 (4.94)	
95% CI	(-12.24, 6.44)	(-9.23, 10.45)	
p-value	0.5383	0.9019	
Corrected Hedge's g Statistics	-0.156	0.032	
95% CI	(-0.68, 0.37)	(-0.53, 0.59)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	78.26 (30.44)	75.00 (29.43)	85.92 (20.67)
Analysis Visit Mean (SD)	80.43 (25.70)	75.46 (28.79)	83.91 (23.88)
LS Mean of Change from Baseline (SE)	1.56 (3.90)	-1.31 (4.66)	-1.44 (3.79)
95% CI	(-6.20, 9.32)	(-10.59, 7.97)	(-8.98, 6.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.00 (5.32)	0.13 (5.67)	
95% CI	(-7.60, 13.59)	(-11.17, 11.42)	
p-value	0.5750	0.9824	
Corrected Hedge's g Statistics	0.150	0.006	
95% CI	(-0.40, 0.70)	(-0.58, 0.59)	
Subgroup*Treatment Interaction p-value	0.6503	0.3688	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Mental Health			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	66.8 (25.0)	70.5 (19.5)	73.4 (18.1)
Analysis Visit Mean (SD)	67.4 (21.6)	69.5 (21.6)	74.7 (22.0)
LS Mean of Change from Baseline (SE)	0.20 (2.61)	-0.73 (3.10)	2.27 (2.58)
95% CI	(-4.99, 5.39)	(-6.90, 5.44)	(-2.85, 7.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.07 (3.58)	-3.00 (3.73)	
95% CI	(-9.19, 5.05)	(-10.42, 4.41)	
p-value	0.5640	0.4225	
Corrected Hedge's g Statistics	-0.147	-0.207	
95% CI	(-0.67, 0.38)	(-0.77, 0.35)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	65.4 (26.1)	70.6 (20.4)	77.1 (16.8)
Analysis Visit Mean (SD)	71.3 (21.2)	72.5 (18.7)	76.9 (21.0)
LS Mean of Change from Baseline (SE)	5.44 (2.81)	3.12 (3.34)	1.69 (2.75)
95% CI	(-0.16, 11.04)	(-3.52, 9.76)	(-3.79, 7.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.75 (3.87)	1.43 (4.04)	
95% CI	(-3.96, 11.47)	(-6.61, 9.48)	
p-value	0.3359	0.7236	
Corrected Hedge's g Statistics	0.259	0.097	
95% CI	(-0.29, 0.81)	(-0.49, 0.69)	
Subgroup*Treatment Interaction p-value	0.8309	0.7029	

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Mental Component Score			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	49.01 (13.27)	48.81 (11.87)	49.29 (10.22)
Analysis Visit Mean (SD)	48.22 (11.11)	48.56 (10.10)	50.35 (12.04)
LS Mean of Change from Baseline (SE)	-0.67 (1.35)	-0.40 (1.61)	1.14 (1.34)
95% CI	(-3.35, 2.01)	(-3.61, 2.81)	(-1.52, 3.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.81 (1.84)	-1.53 (1.93)	
95% CI	(-5.47, 1.86)	(-5.38, 2.31)	
p-value	0.3300	0.4301	
Corrected Hedge's g Statistics	-0.247	-0.203	
95% CI	(-0.77, 0.28)	(-0.76, 0.36)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	48.01 (13.73)	48.80 (12.05)	51.01 (9.60)
Analysis Visit Mean (SD)	50.31 (10.82)	48.52 (10.42)	51.54 (10.90)
LS Mean of Change from Baseline (SE)	2.24 (1.46)	-0.23 (1.75)	0.94 (1.43)
95% CI	(-0.68, 5.15)	(-3.72, 3.26)	(-1.92, 3.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.30 (2.00)	-1.17 (2.11)	
95% CI	(-2.69, 5.28)	(-5.38, 3.04)	
p-value	0.5192	0.5809	
Corrected Hedge's g Statistics	0.172	-0.151	
95% CI	(-0.38, 0.72)	(-0.74, 0.44)	
Subgroup*Treatment Interaction p-value	0.8183	0.2052	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Physical Component Score			
Week 24			
m	27	22	37
n	25	20	32
Baseline Mean (SD)	47.55 (6.99)	43.12 (11.74)	48.78 (8.54)
Analysis Visit Mean (SD)	46.18 (8.34)	45.36 (10.00)	48.60 (10.74)
LS Mean of Change from Baseline (SE)	-1.73 (1.15)	0.81 (1.37)	-1.28 (1.11)
95% CI	(-4.02, 0.55)	(-1.93, 3.54)	(-3.49, 0.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.45 (1.56)	2.09 (1.69)	
95% CI	(-3.56, 2.66)	(-1.29, 5.46)	
p-value	0.7725	0.2216	
Corrected Hedge's g Statistics	-0.074	0.330	
95% CI	(-0.60, 0.45)	(-0.23, 0.89)	
Week 52			
m	25	19	36
n	23	18	29
Baseline Mean (SD)	47.60 (8.57)	42.45 (12.21)	49.63 (8.01)
Analysis Visit Mean (SD)	45.21 (10.90)	44.18 (11.40)	48.88 (9.34)
LS Mean of Change from Baseline (SE)	-2.40 (0.98)	0.29 (1.21)	-1.67 (0.97)
95% CI	(-4.36, -0.44)	(-2.12, 2.71)	(-3.60, 0.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.73 (1.34)	1.96 (1.47)	
95% CI	(-3.40, 1.94)	(-0.97, 4.89)	
p-value	0.5859	0.1864	
Corrected Hedge's g Statistics	-0.144	0.370	
95% CI	(-0.69, 0.40)	(-0.22, 0.96)	
Subgroup*Treatment Interaction p-value	0.3032	0.4220	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Physical Functioning			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	73.55 (24.53)	71.98 (24.34)	74.70 (25.95)
Analysis Visit Mean (SD)	76.31 (24.36)	71.96 (23.63)	75.16 (27.07)
LS Mean of Change from Baseline (SE)	2.76 (1.54)	-0.75 (1.66)	0.30 (1.17)
95% CI	(-0.27, 5.79)	(-4.01, 2.52)	(-2.00, 2.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.46 (1.91)	-1.04 (2.01)	
95% CI	(-1.28, 6.21)	(-5.00, 2.91)	
p-value	0.1971	0.6052	
Corrected Hedge's g Statistics	0.142	-0.060	
95% CI	(-0.08, 0.36)	(-0.29, 0.17)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	75.31 (22.93)	72.09 (24.05)	75.10 (24.98)
Analysis Visit Mean (SD)	77.90 (25.47)	72.05 (25.00)	76.44 (24.11)
LS Mean of Change from Baseline (SE)	2.82 (1.52)	-0.12 (1.63)	1.26 (1.13)
95% CI	(-0.17, 5.81)	(-3.33, 3.10)	(-0.96, 3.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.56 (1.87)	-1.38 (1.97)	
95% CI	(-2.11, 5.23)	(-5.25, 2.49)	
p-value	0.4045	0.4835	
Corrected Hedge's g Statistics	0.098	-0.087	
95% CI	(-0.14, 0.33)	(-0.34, 0.16)	
Subgroup*Treatment Interaction p-value	0.2614	0.3604	

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Role Physical			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	76.15 (26.17)	74.43 (26.72)	75.53 (26.75)
Analysis Visit Mean (SD)	75.11 (27.10)	73.84 (23.84)	76.14 (27.15)
LS Mean of Change from Baseline (SE)	-0.41 (1.69)	-1.17 (1.81)	0.51 (1.28)
95% CI	(-3.72, 2.91)	(-4.74, 2.39)	(-2.00, 3.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.92 (2.08)	-1.69 (2.19)	
95% CI	(-5.01, 3.17)	(-6.00, 2.62)	
p-value	0.6591	0.4425	
Corrected Hedge's g Statistics	-0.049	-0.090	
95% CI	(-0.27, 0.17)	(-0.32, 0.14)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	77.35 (26.69)	73.99 (27.31)	75.56 (25.78)
Analysis Visit Mean (SD)	77.29 (27.56)	74.40 (26.43)	75.08 (24.79)
LS Mean of Change from Baseline (SE)	0.58 (1.77)	0.44 (1.90)	-0.24 (1.31)
95% CI	(-2.89, 4.05)	(-3.28, 4.17)	(-2.82, 2.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.82 (2.17)	0.68 (2.28)	
95% CI	(-3.44, 5.08)	(-3.80, 5.16)	
p-value	0.7061	0.7661	
Corrected Hedge's g Statistics	0.045	0.037	
95% CI	(-0.19, 0.28)	(-0.21, 0.29)	
Subgroup*Treatment Interaction p-value	0.7154	0.5175	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Bodily Pain			
Week 24			
m	134	119	252
n	125	106	217
Baseline Mean (SD)	67.8 (24.6)	62.9 (25.6)	66.1 (24.7)
Analysis Visit Mean (SD)	65.7 (25.5)	63.8 (23.9)	66.0 (25.5)
LS Mean of Change from Baseline (SE)	-1.14 (1.71)	-0.03 (1.83)	-0.06 (1.29)
95% CI	(-4.50, 2.22)	(-3.63, 3.57)	(-2.60, 2.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.08 (2.10)	0.03 (2.21)	
95% CI	(-5.21, 3.06)	(-4.32, 4.38)	
p-value	0.6087	0.9887	
Corrected Hedge's g Statistics	-0.056	0.002	
95% CI	(-0.28, 0.16)	(-0.23, 0.23)	
Week 52			
m	124	106	234
n	106	91	194
Baseline Mean (SD)	68.6 (24.7)	61.5 (25.7)	65.9 (24.5)
Analysis Visit Mean (SD)	69.4 (25.4)	67.1 (24.8)	67.6 (24.4)
LS Mean of Change from Baseline (SE)	1.45 (1.90)	3.62 (2.03)	1.80 (1.41)
95% CI	(-2.28, 5.18)	(-0.37, 7.61)	(-0.96, 4.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.35 (2.33)	1.82 (2.45)	
95% CI	(-4.93, 4.23)	(-2.99, 6.63)	
p-value	0.8801	0.4573	
Corrected Hedge's g Statistics	-0.018	0.093	
95% CI	(-0.25, 0.22)	(-0.16, 0.34)	
Subgroup*Treatment Interaction p-value	0.2787	0.4850	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
General Health			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	61.31 (19.37)	54.30 (18.44)	59.49 (20.50)
Analysis Visit Mean (SD)	62.36 (20.11)	54.40 (19.10)	59.66 (21.42)
LS Mean of Change from Baseline (SE)	1.65 (1.30)	-1.52 (1.40)	0.18 (0.98)
95% CI	(-0.90, 4.20)	(-4.28, 1.23)	(-1.75, 2.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.47 (1.60)	-1.70 (1.69)	
95% CI	(-1.67, 4.61)	(-5.03, 1.62)	
p-value	0.3576	0.3146	
Corrected Hedge's g Statistics	0.101	-0.118	
95% CI	(-0.12, 0.32)	(-0.35, 0.11)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	62.54 (19.39)	54.92 (19.32)	59.86 (20.74)
Analysis Visit Mean (SD)	64.65 (18.60)	56.00 (18.89)	61.19 (20.94)
LS Mean of Change from Baseline (SE)	2.59 (1.37)	-0.49 (1.47)	1.53 (1.01)
95% CI	(-0.09, 5.28)	(-3.37, 2.39)	(-0.46, 3.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.06 (1.67)	-2.02 (1.76)	
95% CI	(-2.22, 4.35)	(-5.49, 1.44)	
p-value	0.5244	0.2520	
Corrected Hedge's g Statistics	0.075	-0.143	
95% CI	(-0.16, 0.31)	(-0.39, 0.11)	
Subgroup*Treatment Interaction p-value	0.2357	0.4282	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Vitality			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	57.73 (22.84)	53.97 (22.24)	57.59 (20.98)
Analysis Visit Mean (SD)	57.76 (23.73)	53.38 (18.72)	57.22 (21.84)
LS Mean of Change from Baseline (SE)	0.18 (1.29)	-1.75 (1.39)	-0.58 (0.98)
95% CI	(-2.36, 2.71)	(-4.49, 0.98)	(-2.51, 1.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.76 (1.59)	-1.17 (1.68)	
95% CI	(-2.37, 3.89)	(-4.48, 2.14)	
p-value	0.6338	0.4871	
Corrected Hedge's g Statistics	0.052	-0.081	
95% CI	(-0.17, 0.27)	(-0.31, 0.15)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	59.48 (23.09)	55.11 (22.38)	57.33 (20.85)
Analysis Visit Mean (SD)	59.43 (21.54)	55.45 (20.88)	57.47 (22.64)
LS Mean of Change from Baseline (SE)	0.40 (1.46)	-0.80 (1.57)	-0.12 (1.09)
95% CI	(-2.48, 3.27)	(-3.90, 2.29)	(-2.25, 2.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.51 (1.80)	-0.69 (1.90)	
95% CI	(-3.03, 4.05)	(-4.41, 3.04)	
p-value	0.7765	0.7172	
Corrected Hedge's g Statistics	0.034	-0.045	
95% CI	(-0.20, 0.27)	(-0.29, 0.20)	
Subgroup*Treatment Interaction p-value	0.1404	0.4191	

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Social Functioning			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	81.55 (23.22)	80.78 (25.89)	83.12 (22.43)
Analysis Visit Mean (SD)	81.85 (23.75)	82.31 (21.47)	81.05 (24.68)
LS Mean of Change from Baseline (SE)	-0.19 (1.70)	0.32 (1.83)	-2.28 (1.29)
95% CI	(-3.53, 3.15)	(-3.28, 3.91)	(-4.81, 0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.09 (2.10)	2.59 (2.21)	
95% CI	(-2.04, 6.21)	(-1.75, 6.94)	
p-value	0.3204	0.2417	
Corrected Hedge's g Statistics	0.110	0.137	
95% CI	(-0.11, 0.33)	(-0.10, 0.37)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	83.29 (22.25)	80.49 (27.02)	83.51 (22.34)
Analysis Visit Mean (SD)	81.66 (22.93)	83.38 (22.13)	82.86 (22.28)
LS Mean of Change from Baseline (SE)	-1.58 (1.71)	2.08 (1.83)	-1.08 (1.27)
95% CI	(-4.94, 1.78)	(-1.52, 5.69)	(-3.58, 1.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.50 (2.10)	3.16 (2.21)	
95% CI	(-4.62, 3.62)	(-1.18, 7.50)	
p-value	0.8109	0.1525	
Corrected Hedge's g Statistics	-0.028	0.179	
95% CI	(-0.26, 0.21)	(-0.07, 0.43)	
Subgroup*Treatment Interaction p-value	0.4823	0.1289	

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Role Emotional			
Week 24			
m	134	119	252
n	126	106	216
Baseline Mean (SD)	82.40 (23.41)	83.10 (23.10)	84.30 (22.85)
Analysis Visit Mean (SD)	82.94 (21.73)	86.09 (20.86)	83.26 (23.83)
LS Mean of Change from Baseline (SE)	0.03 (1.46)	2.45 (1.57)	-1.15 (1.11)
95% CI	(-2.85, 2.90)	(-0.64, 5.55)	(-3.33, 1.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.18 (1.81)	3.60 (1.90)	
95% CI	(-2.38, 4.73)	(-0.14, 7.34)	
p-value	0.5155	0.0591	
Corrected Hedge's g Statistics	0.072	0.221	
95% CI	(-0.15, 0.29)	(-0.01, 0.45)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	84.19 (22.11)	82.60 (24.14)	84.54 (22.28)
Analysis Visit Mean (SD)	84.70 (20.07)	86.45 (20.17)	82.81 (22.83)
LS Mean of Change from Baseline (SE)	0.70 (1.59)	3.69 (1.71)	-1.79 (1.19)
95% CI	(-2.43, 3.83)	(0.33, 7.05)	(-4.12, 0.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.50 (1.96)	5.49 (2.06)	
95% CI	(-1.35, 6.34)	(1.44, 9.53)	
p-value	0.2022	0.0080	
Corrected Hedge's g Statistics	0.151	0.333	
95% CI	(-0.09, 0.39)	(0.08, 0.58)	
Subgroup*Treatment Interaction p-value	0.6503	0.3688	

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Mental Health			
Week 24			
m	134	119	252
n	126	106	217
Baseline Mean (SD)	75.5 (17.9)	76.2 (18.9)	75.2 (17.9)
Analysis Visit Mean (SD)	74.6 (18.8)	75.6 (18.5)	74.8 (18.6)
LS Mean of Change from Baseline (SE)	-1.25 (1.19)	-0.84 (1.28)	-1.01 (0.90)
95% CI	(-3.58, 1.09)	(-3.35, 1.67)	(-2.78, 0.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.24 (1.46)	0.17 (1.54)	
95% CI	(-3.12, 2.64)	(-2.87, 3.20)	
p-value	0.8694	0.9131	
Corrected Hedge's g Statistics	-0.018	0.013	
95% CI	(-0.24, 0.20)	(-0.22, 0.24)	
Week 52			
m	124	106	234
n	107	91	194
Baseline Mean (SD)	77.0 (16.2)	76.0 (19.6)	74.9 (18.1)
Analysis Visit Mean (SD)	76.4 (16.7)	75.8 (18.4)	75.5 (19.5)
LS Mean of Change from Baseline (SE)	-0.61 (1.28)	-0.52 (1.38)	-0.44 (0.96)
95% CI	(-3.13, 1.92)	(-3.22, 2.19)	(-2.32, 1.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.17 (1.58)	-0.08 (1.66)	
95% CI	(-3.27, 2.93)	(-3.34, 3.18)	
p-value	0.9155	0.9618	
Corrected Hedge's g Statistics	-0.013	-0.006	
95% CI	(-0.25, 0.22)	(-0.26, 0.24)	
Subgroup*Treatment Interaction p-value	0.8309	0.7029	

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Mental Component Score			
Week 24			
m	134	119	252
n	125	106	216
Baseline Mean (SD)	51.06 (10.08)	51.24 (11.04)	51.42 (9.31)
Analysis Visit Mean (SD)	50.74 (10.07)	51.73 (9.95)	50.80 (10.07)
LS Mean of Change from Baseline (SE)	-0.56 (0.63)	0.20 (0.68)	-0.85 (0.48)
95% CI	(-1.80, 0.68)	(-1.13, 1.53)	(-1.78, 0.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.29 (0.78)	1.05 (0.82)	
95% CI	(-1.24, 1.82)	(-0.56, 2.65)	
p-value	0.7121	0.2020	
Corrected Hedge's g Statistics	0.041	0.149	
95% CI	(-0.18, 0.26)	(-0.08, 0.38)	
Week 52			
m	124	106	234
n	106	91	194
Baseline Mean (SD)	51.93 (9.37)	51.26 (11.51)	51.35 (9.33)
Analysis Visit Mean (SD)	51.33 (9.01)	52.02 (9.63)	50.97 (10.22)
LS Mean of Change from Baseline (SE)	-0.53 (0.67)	0.54 (0.72)	-0.79 (0.50)
95% CI	(-1.86, 0.79)	(-0.88, 1.95)	(-1.77, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.26 (0.83)	1.33 (0.87)	
95% CI	(-1.36, 1.88)	(-0.37, 3.03)	
p-value	0.7528	0.1259	
Corrected Hedge's g Statistics	0.037	0.191	
95% CI	(-0.20, 0.27)	(-0.06, 0.44)	
Subgroup*Treatment Interaction p-value	0.8183	0.2052	

AMNOG Table SE22.9.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Physical Component Score			
Week 24			
m	134	119	252
n	125	106	216
Baseline Mean (SD)	47.62 (9.10)	45.49 (9.36)	47.19 (9.67)
Analysis Visit Mean (SD)	47.88 (9.90)	45.35 (8.81)	47.45 (9.94)
LS Mean of Change from Baseline (SE)	0.57 (0.60)	-0.58 (0.65)	0.30 (0.46)
95% CI	(-0.61, 1.76)	(-1.85, 0.69)	(-0.60, 1.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.27 (0.74)	-0.87 (0.78)	
95% CI	(-1.19, 1.74)	(-2.41, 0.67)	
p-value	0.7118	0.2657	
Corrected Hedge's g Statistics	0.041	-0.130	
95% CI	(-0.18, 0.26)	(-0.36, 0.10)	
Week 52			
m	124	106	234
n	106	91	194
Baseline Mean (SD)	48.01 (9.03)	45.43 (9.47)	47.26 (9.27)
Analysis Visit Mean (SD)	48.87 (10.32)	46.03 (9.65)	47.87 (8.94)
LS Mean of Change from Baseline (SE)	1.04 (0.62)	0.29 (0.66)	0.76 (0.46)
95% CI	(-0.18, 2.26)	(-1.02, 1.59)	(-0.15, 1.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.28 (0.76)	-0.47 (0.80)	
95% CI	(-1.21, 1.77)	(-2.04, 1.10)	
p-value	0.7126	0.5587	
Corrected Hedge's g Statistics	0.044	-0.073	
95% CI	(-0.19, 0.28)	(-0.32, 0.18)	
Subgroup*Treatment Interaction p-value	0.3032	0.4220	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.7)	3 (13.6)	0
No	26 (96.3)	19 (86.4)	39 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 1.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.08	
95% CI of the inverse risk ratio	NE	(0.00, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.70	13.97	
95% CI of the absolute risk difference	(-3.42, 10.83)	(-1.11, 29.05)	
p-value	0.2259	0.0286	
p-value of Breslow-Day Test for Homogeneity [3]	0.2505	0.0140	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (25.9)	8 (36.4)	8 (20.5)
No	20 (74.1)	14 (63.6)	31 (79.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.45	
95% CI of the inverse odds ratio	(0.23, 2.35)	(0.14, 1.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.56	
95% CI of the inverse risk ratio	(0.33, 1.92)	(0.25, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.41	15.85	
95% CI of the absolute risk difference	(-15.42, 26.24)	(-7.91, 39.61)	
p-value	0.6059	0.1766	
p-value of Breslow-Day Test for Homogeneity [3]	0.8915	0.2532	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (14.8)	3 (13.6)	2 (5.1)
No	23 (85.2)	19 (86.4)	37 (94.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.31	0.34	
95% CI of the inverse odds ratio	(0.05, 1.83)	(0.05, 2.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.35	0.38	
95% CI of the inverse risk ratio	(0.07, 1.76)	(0.07, 2.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.69	8.51	
95% CI of the absolute risk difference	(-5.40, 24.77)	(-7.42, 24.43)	
p-value	0.1783	0.2447	
p-value of Breslow-Day Test for Homogeneity [3]	0.0512	0.1982	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (22.2)	7 (31.8)	5 (12.8)
No	21 (77.8)	15 (68.2)	34 (87.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.51	0.32	
95% CI of the inverse odds ratio	(0.14, 1.90)	(0.09, 1.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.40	
95% CI of the inverse risk ratio	(0.20, 1.70)	(0.15, 1.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.40	19.00	
95% CI of the absolute risk difference	(-9.47, 28.27)	(-3.11, 41.11)	
p-value	0.3136	0.0731	
p-value of Breslow-Day Test for Homogeneity [3]	0.3178	0.0933	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.7)	3 (13.6)	7 (17.9)
No	26 (96.3)	19 (86.4)	32 (82.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.69	1.39	
95% CI of the inverse odds ratio	(0.66, 49.23)	(0.32, 6.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.85	1.32	
95% CI of the inverse risk ratio	(0.63, 37.16)	(0.38, 4.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.25	-4.31	
95% CI of the absolute risk difference	(-28.24, -0.25)	(-23.04, 14.41)	
p-value	0.0813	0.6622	
p-value of Breslow-Day Test for Homogeneity [3]	0.1802	0.6573	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (22.2)	6 (27.3)	10 (25.6)
No	21 (77.8)	16 (72.7)	29 (74.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	0.92	
95% CI of the inverse odds ratio	(0.38, 3.84)	(0.28, 3.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.94	
95% CI of the inverse risk ratio	(0.48, 2.80)	(0.40, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.42	1.63	
95% CI of the absolute risk difference	(-24.24, 17.41)	(-21.48, 24.74)	
p-value	0.7500	0.8894	
p-value of Breslow-Day Test for Homogeneity [3]	0.9602	0.8806	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (14.8)	9 (40.9)	5 (12.8)
No	23 (85.2)	13 (59.1)	34 (87.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.21	
95% CI of the inverse odds ratio	(0.20, 3.49)	(0.06, 0.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.31	
95% CI of the inverse risk ratio	(0.26, 2.93)	(0.12, 0.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.99	28.09	
95% CI of the absolute risk difference	(-15.02, 19.01)	(5.02, 51.16)	
p-value	0.8164	0.0122	
p-value of Breslow-Day Test for Homogeneity [3]	0.8178	0.0229	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (25.9)	9 (40.9)	11 (28.2)
No	20 (74.1)	13 (59.1)	28 (71.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.57	
95% CI of the inverse odds ratio	(0.37, 3.40)	(0.19, 1.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.69	
95% CI of the inverse risk ratio	(0.48, 2.45)	(0.34, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.28	12.70	
95% CI of the absolute risk difference	(-24.02, 19.46)	(-12.23, 37.64)	
p-value	0.8380	0.3101	
p-value of Breslow-Day Test for Homogeneity [3]	0.8476	0.4978	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (11.1)	2 (9.1)	7 (17.9)
No	24 (88.9)	20 (90.9)	32 (82.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	2.19	
95% CI of the inverse odds ratio	(0.41, 7.48)	(0.41, 11.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	1.97	
95% CI of the inverse risk ratio	(0.46, 5.70)	(0.45, 8.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.84	-8.86	
95% CI of the absolute risk difference	(-23.74, 10.06)	(-25.87, 8.15)	
p-value	0.4462	0.3489	
p-value of Breslow-Day Test for Homogeneity [3]	0.6488	0.5150	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (37.0)	8 (36.4)	16 (41.0)
No	17 (63.0)	14 (63.6)	23 (59.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.22	
95% CI of the inverse odds ratio	(0.43, 3.24)	(0.41, 3.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.13	
95% CI of the inverse risk ratio	(0.60, 2.06)	(0.58, 2.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.99	-4.66	
95% CI of the absolute risk difference	(-27.87, 19.89)	(-30.01, 20.68)	
p-value	0.7444	0.7204	
p-value of Breslow-Day Test for Homogeneity [3]	0.9560	0.9637	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	4 (18.2)	3 (7.7)
No	27 (100)	18 (81.8)	36 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.27	0.38	
95% CI of the inverse odds ratio	(0.26, 106.38)	(0.08, 1.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.90	0.42	
95% CI of the inverse risk ratio	(0.26, 91.18)	(0.10, 1.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.96	10.49	
95% CI of the absolute risk difference	(-17.00, 3.07)	(-7.67, 28.65)	
p-value	0.2297	0.2171	
p-value of Breslow-Day Test for Homogeneity [3]	0.1308	0.7002	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (14.8)	4 (18.2)	10 (25.6)
No	23 (85.2)	18 (81.8)	29 (74.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.98	1.55	
95% CI of the inverse odds ratio	(0.55, 7.15)	(0.42, 5.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.73	1.41	
95% CI of the inverse risk ratio	(0.61, 4.95)	(0.50, 3.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.83	-7.46	
95% CI of the absolute risk difference	(-29.99, 8.34)	(-28.61, 13.70)	
p-value	0.2902	0.5059	
p-value of Breslow-Day Test for Homogeneity [3]	0.2144	0.1767	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (14.8)	6 (27.3)	3 (7.7)
No	23 (85.2)	16 (72.7)	36 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	0.22	
95% CI of the inverse odds ratio	(0.10, 2.34)	(0.05, 1.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	0.28	
95% CI of the inverse risk ratio	(0.13, 2.14)	(0.08, 1.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.12	19.58	
95% CI of the absolute risk difference	(-8.67, 22.92)	(-0.82, 39.98)	
p-value	0.3555	0.0384	
p-value of Breslow-Day Test for Homogeneity [3]	0.2542	0.1712	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (18.5)	8 (36.4)	5 (12.8)
No	22 (81.5)	14 (63.6)	34 (87.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	0.26	
95% CI of the inverse odds ratio	(0.17, 2.50)	(0.07, 0.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.35	
95% CI of the inverse risk ratio	(0.22, 2.16)	(0.13, 0.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.70	23.54	
95% CI of the absolute risk difference	(-12.32, 23.72)	(0.87, 46.22)	
p-value	0.5256	0.0311	
p-value of Breslow-Day Test for Homogeneity [3]	0.5387	0.1906	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (22.2)	3 (13.6)	3 (7.7)
No	21 (77.8)	19 (86.4)	36 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.53	
95% CI of the inverse odds ratio	(0.07, 1.29)	(0.10, 2.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.35	0.56	
95% CI of the inverse risk ratio	(0.09, 1.27)	(0.12, 2.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.53	5.94	
95% CI of the absolute risk difference	(-3.24, 32.30)	(-10.66, 22.54)	
p-value	0.0908	0.4541	
p-value of Breslow-Day Test for Homogeneity [3]	0.0329	0.1880	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (55.6)	7 (31.8)	12 (30.8)
No	12 (44.4)	15 (68.2)	27 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	0.95	
95% CI of the inverse odds ratio	(0.13, 0.99)	(0.31, 2.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	0.97	
95% CI of the inverse risk ratio	(0.31, 0.99)	(0.45, 2.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	24.79	1.05	
95% CI of the absolute risk difference	(1.10, 48.47)	(-23.21, 25.31)	
p-value	0.0440	0.9323	
p-value of Breslow-Day Test for Homogeneity [3]	0.1194	0.9026	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.7)	3 (13.6)	2 (5.1)
No	26 (96.3)	19 (86.4)	37 (94.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	0.34	
95% CI of the inverse odds ratio	(0.12, 16.32)	(0.05, 2.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	0.38	
95% CI of the inverse risk ratio	(0.13, 14.52)	(0.07, 2.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.42	8.51	
95% CI of the absolute risk difference	(-11.36, 8.51)	(-7.42, 24.43)	
p-value	0.7847	0.2447	
p-value of Breslow-Day Test for Homogeneity [3]	0.9741	0.4750	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (40.7)	4 (18.2)	10 (25.6)
No	16 (59.3)	18 (81.8)	29 (74.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	1.55	
95% CI of the inverse odds ratio	(0.18, 1.44)	(0.42, 5.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	1.41	
95% CI of the inverse risk ratio	(0.31, 1.27)	(0.50, 3.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.10	-7.46	
95% CI of the absolute risk difference	(-7.95, 38.15)	(-28.61, 13.70)	
p-value	0.1954	0.5059	
p-value of Breslow-Day Test for Homogeneity [3]	0.2010	0.6590	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (4.5)	0
No	27 (100)	21 (95.5)	39 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	4.55	
95% CI of the absolute risk difference	NE	(-4.16, 13.25)	
p-value	NE	0.1794	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.3061	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (14.8)	8 (36.4)	5 (12.8)
No	23 (85.2)	14 (63.6)	34 (87.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.26	
95% CI of the inverse odds ratio	(0.20, 3.49)	(0.07, 0.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.35	
95% CI of the inverse risk ratio	(0.26, 2.93)	(0.13, 0.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.99	23.54	
95% CI of the absolute risk difference	(-15.02, 19.01)	(0.87, 46.22)	
p-value	0.8164	0.0311	
p-value of Breslow-Day Test for Homogeneity [3]	0.9064	0.1138	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	21 (15.0)	15 (11.6)	37 (14.0)
No	119 (85.0)	114 (88.4)	227 (86.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.24	
95% CI of the inverse odds ratio	(0.52, 1.65)	(0.65, 2.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.21	
95% CI of the inverse risk ratio	(0.57, 1.53)	(0.69, 2.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.98	-2.39	
95% CI of the absolute risk difference	(-6.26, 8.23)	(-9.33, 4.55)	
p-value	0.7882	0.5119	
p-value of Breslow-Day Test for Homogeneity [3]	0.2505	0.0140	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	48 (34.3)	40 (31.0)	78 (29.5)
No	92 (65.7)	89 (69.0)	186 (70.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.93	
95% CI of the inverse odds ratio	(0.52, 1.25)	(0.59, 1.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.95	
95% CI of the inverse risk ratio	(0.64, 1.16)	(0.69, 1.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.74	1.46	
95% CI of the absolute risk difference	(-4.86, 14.34)	(-8.23, 11.16)	
p-value	0.3277	0.7665	
p-value of Breslow-Day Test for Homogeneity [3]	0.8915	0.2532	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (7.9)	15 (11.6)	36 (13.6)
No	129 (92.1)	114 (88.4)	228 (86.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.85	1.20	
95% CI of the inverse odds ratio	(0.91, 3.76)	(0.63, 2.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.74	1.17	
95% CI of the inverse risk ratio	(0.91, 3.30)	(0.67, 2.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.78	-2.01	
95% CI of the absolute risk difference	(-11.86, 0.30)	(-8.92, 4.90)	
p-value	0.0847	0.5780	
p-value of Breslow-Day Test for Homogeneity [3]	0.0512	0.1982	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	34 (24.3)	32 (24.8)	66 (25.0)
No	106 (75.7)	97 (75.2)	198 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.01	
95% CI of the inverse odds ratio	(0.65, 1.67)	(0.62, 1.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.01	
95% CI of the inverse risk ratio	(0.72, 1.47)	(0.70, 1.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.71	-0.19	
95% CI of the absolute risk difference	(-9.53, 8.10)	(-9.29, 8.91)	
p-value	0.8742	0.9667	
p-value of Breslow-Day Test for Homogeneity [3]	0.3178	0.0933	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	19 (13.6)	23 (17.8)	46 (17.4)
No	121 (86.4)	106 (82.2)	218 (82.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.34	0.97	
95% CI of the inverse odds ratio	(0.75, 2.40)	(0.56, 1.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	0.98	
95% CI of the inverse risk ratio	(0.78, 2.10)	(0.62, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.85	0.41	
95% CI of the absolute risk difference	(-11.14, 3.44)	(-7.63, 8.44)	
p-value	0.3159	0.9210	
p-value of Breslow-Day Test for Homogeneity [3]	0.1802	0.6573	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	34 (24.3)	40 (31.0)	72 (27.3)
No	106 (75.7)	89 (69.0)	192 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.83	
95% CI of the inverse odds ratio	(0.73, 1.87)	(0.53, 1.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.88	
95% CI of the inverse risk ratio	(0.79, 1.60)	(0.64, 1.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.99	3.74	
95% CI of the absolute risk difference	(-11.89, 5.92)	(-5.89, 13.36)	
p-value	0.5161	0.4412	
p-value of Breslow-Day Test for Homogeneity [3]	0.9602	0.8806	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	21 (15.0)	19 (14.7)	40 (15.2)
No	119 (85.0)	110 (85.3)	224 (84.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.03	
95% CI of the inverse odds ratio	(0.57, 1.79)	(0.57, 1.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.03	
95% CI of the inverse risk ratio	(0.62, 1.64)	(0.62, 1.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.15	-0.42	
95% CI of the absolute risk difference	(-7.48, 7.18)	(-7.91, 7.07)	
p-value	0.9677	0.9123	
p-value of Breslow-Day Test for Homogeneity [3]	0.8178	0.0229	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	43 (30.7)	44 (34.1)	81 (30.7)
No	97 (69.3)	85 (65.9)	183 (69.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.86	
95% CI of the inverse odds ratio	(0.64, 1.56)	(0.55, 1.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.90	
95% CI of the inverse risk ratio	(0.73, 1.36)	(0.67, 1.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.03	3.43	
95% CI of the absolute risk difference	(-9.42, 9.48)	(-6.47, 13.32)	
p-value	0.9946	0.4934	
p-value of Breslow-Day Test for Homogeneity [3]	0.8476	0.4978	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (9.3)	12 (9.3)	29 (11.0)
No	127 (90.7)	117 (90.7)	235 (89.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.20	
95% CI of the inverse odds ratio	(0.61, 2.40)	(0.59, 2.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.18	
95% CI of the inverse risk ratio	(0.64, 2.20)	(0.62, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.70	-1.68	
95% CI of the absolute risk difference	(-7.81, 4.41)	(-7.96, 4.59)	
p-value	0.5944	0.6084	
p-value of Breslow-Day Test for Homogeneity [3]	0.6488	0.5150	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	40 (28.6)	36 (27.9)	83 (31.4)
No	100 (71.4)	93 (72.1)	181 (68.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.18	
95% CI of the inverse odds ratio	(0.73, 1.80)	(0.74, 1.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	1.13	
95% CI of the inverse risk ratio	(0.80, 1.51)	(0.81, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.87	-3.53	
95% CI of the absolute risk difference	(-12.21, 6.48)	(-13.09, 6.02)	
p-value	0.5511	0.4742	
p-value of Breslow-Day Test for Homogeneity [3]	0.9560	0.9637	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (9.3)	19 (14.7)	22 (8.3)
No	127 (90.7)	110 (85.3)	242 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.53	
95% CI of the inverse odds ratio	(0.43, 1.82)	(0.27, 1.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	0.57	
95% CI of the inverse risk ratio	(0.47, 1.73)	(0.32, 1.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.95	6.40	
95% CI of the absolute risk difference	(-4.90, 6.80)	(-0.57, 13.36)	
p-value	0.7461	0.0515	
p-value of Breslow-Day Test for Homogeneity [3]	0.1308	0.7002	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (18.6)	31 (24.0)	42 (15.9)
No	114 (81.4)	98 (76.0)	222 (84.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.60	
95% CI of the inverse odds ratio	(0.48, 1.42)	(0.36, 1.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.66	
95% CI of the inverse risk ratio	(0.55, 1.34)	(0.44, 1.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.66	8.12	
95% CI of the absolute risk difference	(-5.15, 10.47)	(-0.47, 16.71)	
p-value	0.4961	0.0519	
p-value of Breslow-Day Test for Homogeneity [3]	0.2144	0.1767	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (10.7)	24 (18.6)	35 (13.3)
No	125 (89.3)	105 (81.4)	229 (86.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	0.67	
95% CI of the inverse odds ratio	(0.67, 2.42)	(0.38, 1.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	0.71	
95% CI of the inverse risk ratio	(0.70, 2.19)	(0.44, 1.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.54	5.35	
95% CI of the absolute risk difference	(-9.10, 4.01)	(-2.52, 13.21)	
p-value	0.4601	0.1635	
p-value of Breslow-Day Test for Homogeneity [3]	0.2542	0.1712	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (17.1)	32 (24.8)	46 (17.4)
No	116 (82.9)	97 (75.2)	218 (82.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.64	
95% CI of the inverse odds ratio	(0.59, 1.75)	(0.38, 1.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.70	
95% CI of the inverse risk ratio	(0.65, 1.59)	(0.47, 1.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.28	7.38	
95% CI of the absolute risk difference	(-8.02, 7.46)	(-1.36, 16.13)	
p-value	0.9433	0.0849	
p-value of Breslow-Day Test for Homogeneity [3]	0.5387	0.1906	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (9.3)	11 (8.5)	37 (14.0)
No	127 (90.7)	118 (91.5)	227 (86.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	1.75	
95% CI of the inverse odds ratio	(0.82, 3.11)	(0.86, 3.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	1.64	
95% CI of the inverse risk ratio	(0.83, 2.74)	(0.87, 3.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.73	-5.49	
95% CI of the absolute risk difference	(-11.11, 1.65)	(-11.87, 0.90)	
p-value	0.1695	0.1187	
p-value of Breslow-Day Test for Homogeneity [3]	0.0329	0.1880	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	42 (30.0)	34 (26.4)	71 (26.9)
No	98 (70.0)	95 (73.6)	193 (73.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.03	
95% CI of the inverse odds ratio	(0.55, 1.35)	(0.64, 1.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.02	
95% CI of the inverse risk ratio	(0.65, 1.24)	(0.72, 1.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.11	-0.54	
95% CI of the absolute risk difference	(-6.18, 12.39)	(-9.83, 8.76)	
p-value	0.5080	0.9100	
p-value of Breslow-Day Test for Homogeneity [3]	0.1194	0.9026	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (4.3)	10 (7.8)	15 (5.7)
No	134 (95.7)	119 (92.2)	249 (94.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	0.72	
95% CI of the inverse odds ratio	(0.51, 3.55)	(0.31, 1.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	0.73	
95% CI of the inverse risk ratio	(0.53, 3.34)	(0.34, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.40	2.07	
95% CI of the absolute risk difference	(-5.76, 2.97)	(-3.32, 7.46)	
p-value	0.5475	0.4298	
p-value of Breslow-Day Test for Homogeneity [3]	0.9741	0.4750	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (18.6)	23 (17.8)	52 (19.7)
No	114 (81.4)	106 (82.2)	212 (80.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	1.13	
95% CI of the inverse odds ratio	(0.64, 1.81)	(0.66, 1.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.10	
95% CI of the inverse risk ratio	(0.69, 1.62)	(0.71, 1.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.13	-1.87	
95% CI of the absolute risk difference	(-9.16, 6.91)	(-10.03, 6.30)	
p-value	0.7850	0.6582	
p-value of Breslow-Day Test for Homogeneity [3]	0.2010	0.6590	

AMNOG Table SE22.9.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (5.0)	11 (8.5)	14 (5.3)
No	133 (95.0)	118 (91.5)	250 (94.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.60	
95% CI of the inverse odds ratio	(0.42, 2.70)	(0.26, 1.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.62	
95% CI of the inverse risk ratio	(0.44, 2.57)	(0.29, 1.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.30	3.22	
95% CI of the absolute risk difference	(-4.81, 4.21)	(-2.30, 8.75)	
p-value	0.8961	0.2188	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.3061	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	31 (22.1)	33 (25.6)	55 (20.8)
No	109 (77.9)	96 (74.4)	209 (79.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.77	
95% CI of the inverse odds ratio	(0.56, 1.52)	(0.47, 1.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.81	
95% CI of the inverse risk ratio	(0.64, 1.39)	(0.56, 1.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.31	4.75	
95% CI of the absolute risk difference	(-7.13, 9.75)	(-4.23, 13.73)	
p-value	0.7596	0.2890	
p-value of Breslow-Day Test for Homogeneity [3]	0.9064	0.1138	

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Physical Functioning						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	75.16 (21.22)	67.81 (24.49)	69.86 (24.59)			
Median	76.40	72.50	80.00			
IQR: Q1, Q3	70.00, 95.00	50.00, 90.00	60.00, 90.00			
Min, Max	40.0, 100.0	20.0, 95.0	10.0, 100.0			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	69.74 (30.11)	75.36 (22.91)	68.46 (25.86)	-6.54 (4.27)	5.36 (8.92)	0.00 (2.62)
Median	85.00	82.50	80.00	0	0	2.50
IQR: Q1, Q3	40.00, 95.00	70.00, 90.00	50.00, 90.00	-15.00, 5.00	-5.00, 20.00	-10.00, 10.00
Min, Max	5.0, 100.0	25.0, 95.0	15.0, 100.0	-50.0, 25.0	-65.0, 70.0	-45.0, 35.0
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	70.29 (24.20)	74.17 (19.17)	72.43 (23.81)	-2.05 (4.14)	1.67 (4.05)	0.17 (2.91)
Median	70.00	75.00	80.00	5.00	-2.50	2.50
IQR: Q1, Q3	45.00, 90.00	62.50, 87.50	50.00, 95.00	-7.50, 5.00	-5.00, 7.50	-10.00, 10.00
Min, Max	35.0, 100.0	30.0, 100.0	20.0, 100.0	-42.8, 25.0	-25.0, 30.0	-30.0, 35.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Role Physical						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	74.67 (27.15)	71.51 (27.28)	74.00 (24.71)			
Median	81.30	78.15	81.30			
IQR: Q1, Q3	56.30, 100.00	43.80, 96.90	56.30, 100.00			
Min, Max	0.0, 100.0	25.0, 100.0	18.8, 100.0			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	66.46 (30.84)	73.69 (25.38)	71.97 (27.04)	-9.37 (4.41)	-1.34 (7.98)	-0.92 (2.86)
Median	81.30	81.30	75.00	-6.25	-3.15	0
IQR: Q1, Q3	37.50, 100.00	56.30, 93.80	50.00, 100.00	-25.00, 0.00	-18.70, 25.00	-6.30, 6.20
Min, Max	0.0, 100.0	12.5, 100.0	18.8, 100.0	-43.7, 31.3	-56.2, 62.5	-43.8, 37.5
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	68.04 (25.85)	77.10 (23.43)	74.12 (23.00)	-7.03 (5.26)	-0.53 (5.98)	-1.04 (3.57)
Median	68.80	84.40	75.00	-6.20	0	0
IQR: Q1, Q3	50.00, 93.80	62.55, 96.90	50.00, 100.00	-18.80, 3.10	-12.55, 9.40	-12.50, 6.20
Min, Max	18.8, 100.0	25.0, 100.0	25.0, 100.0	-37.5, 43.8	-37.5, 37.5	-43.7, 68.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Bodily Pain						
Baseline						
m	19	16	43			
n	17	16	37			
Mean (SD)	63.6 (29.0)	50.8 (25.2)	61.3 (26.2)			
Median	61.0	51.0	62.0			
IQR: Q1, Q3	41.0, 84.0	27.0, 73.0	41.0, 84.0			
Min, Max	0, 100	12, 100	12, 100			
Week 24						
m	19	15	41			
n	19	14	39	17	14	34
Mean (SD/SE)	51.8 (26.0)	66.1 (21.6)	61.9 (26.2)	-12.5 (5.0)	13.4 (6.3)	1.6 (3.8)
Median	51.0	62.0	72.0	0	10.0	0
IQR: Q1, Q3	41.0, 74.0	51.0, 84.0	32.0, 84.0	-26.0, 0.0	0.0, 26.0	-10.0, 12.0
Min, Max	0, 100	31, 100	21, 100	-59, 21	-23, 72	-38, 59
Week 52						
m	17	12	39			
n	17	12	35	15	12	30
Mean (SD/SE)	57.3 (28.6)	65.2 (22.9)	63.8 (25.6)	-4.3 (5.0)	10.6 (4.8)	3.6 (4.5)
Median	51.0	66.5	74.0	0	8.0	0
IQR: Q1, Q3	41.0, 84.0	46.5, 84.0	41.0, 84.0	-19.0, 10.0	0.0, 15.5	-10.0, 12.0
Min, Max	0, 100	22, 100	10, 100	-49, 33	-12, 49	-33, 69

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
General Health						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	56.33 (22.58)	51.00 (16.90)	60.76 (19.77)			
Median	57.00	47.00	62.00			
IQR: Q1, Q3	42.00, 72.00	39.50, 67.00	47.00, 75.00			
Min, Max	10.0, 92.0	25.0, 82.0	15.0, 100.0			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	58.37 (22.15)	62.43 (16.54)	56.67 (21.12)	2.39 (3.13)	11.79 (4.95)	-2.00 (2.69)
Median	57.00	67.00	52.00	5.00	13.50	0
IQR: Q1, Q3	40.00, 77.00	45.00, 72.00	40.00, 72.00	-10.00, 10.00	0.00, 25.00	-10.00, 5.00
Min, Max	10.0, 92.0	37.0, 92.0	15.0, 100.0	-22.0, 27.0	-27.0, 37.0	-38.0, 33.0
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	59.76 (16.70)	61.67 (13.30)	62.06 (20.92)	5.25 (4.62)	9.83 (2.85)	1.70 (2.49)
Median	57.00	62.00	67.00	-1.50	5.00	0
IQR: Q1, Q3	52.00, 72.00	51.00, 69.50	47.00, 82.00	-10.00, 22.00	4.00, 17.50	-5.00, 10.00
Min, Max	30.0, 87.0	42.0, 87.0	15.0, 100.0	-20.0, 37.0	-5.0, 25.0	-27.0, 32.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Vitality						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	47.93 (22.38)	48.45 (25.57)	56.44 (16.37)			
Median	46.90	50.00	56.30			
IQR: Q1, Q3	25.00, 62.50	21.90, 68.75	43.80, 68.80			
Min, Max	6.3, 87.5	12.5, 87.5	25.0, 93.8			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	51.34 (25.98)	53.59 (22.56)	53.71 (18.85)	4.18 (4.55)	3.58 (4.76)	-2.21 (2.42)
Median	56.30	62.50	50.00	0	6.20	0
IQR: Q1, Q3	31.30, 68.80	25.00, 68.80	37.50, 68.80	-6.20, 12.50	-6.20, 12.50	-12.50, 6.20
Min, Max	0.0, 100.0	18.8, 87.5	25.0, 100.0	-31.2, 43.8	-25.0, 37.5	-37.5, 31.2
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	48.92 (16.56)	54.18 (22.81)	55.21 (20.43)	2.75 (5.00)	1.57 (3.62)	-2.70 (2.54)
Median	50.00	56.30	62.50	3.15	3.10	0
IQR: Q1, Q3	37.50, 62.50	34.40, 68.75	43.80, 68.80	-6.25, 12.50	-6.20, 12.50	-6.30, 6.30
Min, Max	18.8, 75.0	18.8, 87.5	12.5, 100.0	-31.2, 37.5	-25.0, 18.8	-37.5, 25.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Social Functioning						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	73.61 (27.42)	81.25 (19.36)	84.46 (21.73)			
Median	81.25	81.25	100.00			
IQR: Q1, Q3	50.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	50.0, 100.0	12.5, 100.0			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	75.00 (26.02)	82.14 (18.81)	80.45 (23.26)	2.78 (5.40)	-2.68 (4.93)	-2.21 (3.10)
Median	75.00	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	62.50, 100.00	-12.50, 12.50	-12.50, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	50.0, 100.0	25.0, 100.0	-37.5, 37.5	-50.0, 25.0	-37.5, 50.0
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	72.06 (20.02)	78.13 (24.50)	82.14 (21.71)	0.78 (4.03)	-7.29 (6.43)	-2.92 (3.48)
Median	75.00	81.25	87.50	0	0	0
IQR: Q1, Q3	62.50, 87.50	62.50, 100.00	62.50, 100.00	0.00, 12.50	-25.00, 6.25	-12.50, 0.00
Min, Max	25.0, 100.0	25.0, 100.0	25.0, 100.0	-37.5, 25.0	-50.0, 25.0	-37.5, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=19)	Visit Result: MGL-3196 100 mg (N=16)	Visit Result: Placebo (N=43)	Change from Baseline: MGL-3196 80 mg (N=19)	Change from Baseline: MGL-3196 100 mg (N=16)	Change from Baseline: Placebo (N=43)
Role Emotional						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	80.09 (21.42)	84.89 (17.81)	85.58 (19.71)			
Median	87.50	91.70	100.00			
IQR: Q1, Q3	58.30, 100.00	70.85, 100.00	75.00, 100.00			
Min, Max	41.7, 100.0	50.0, 100.0	41.7, 100.0			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	74.56 (25.98)	89.89 (17.65)	82.48 (22.28)	-4.17 (3.70)	4.17 (4.77)	-2.69 (2.74)
Median	83.30	100.00	91.70	0	0	0
IQR: Q1, Q3	50.00, 100.00	83.30, 100.00	66.70, 100.00	-16.70, 8.30	0.00, 16.70	-8.30, 0.00
Min, Max	25.0, 100.0	41.7, 100.0	25.0, 100.0	-33.3, 25.0	-33.3, 41.7	-50.0, 25.0
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	75.00 (21.25)	86.81 (24.74)	81.66 (21.47)	-3.65 (4.43)	2.78 (7.83)	-5.28 (3.43)
Median	75.00	100.00	83.30	0	0	0
IQR: Q1, Q3	58.30, 91.70	83.35, 100.00	66.70, 100.00	-20.85, 4.15	0.00, 12.50	-16.70, 0.00
Min, Max	33.3, 100.0	25.0, 100.0	25.0, 100.0	-25.0, 33.3	-50.0, 50.0	-50.0, 25.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Mental Health						
Baseline						
m	19	16	43			
n	18	16	37			
Mean (SD)	66.9 (19.5)	81.6 (17.1)	77.4 (14.5)			
Median	67.5	82.5	80.0			
IQR: Q1, Q3	50.0, 85.0	72.5, 97.5	70.0, 90.0			
Min, Max	35, 100	45, 100	45, 100			
Week 24						
m	19	15	41			
n	19	14	39	18	14	34
Mean (SD/SE)	62.9 (22.4)	79.3 (17.6)	73.1 (17.5)	-2.8 (4.0)	-5.0 (2.9)	-2.9 (1.8)
Median	65.0	77.5	80.0	0	0	0
IQR: Q1, Q3	50.0, 75.0	70.0, 95.0	55.0, 90.0	-10.0, 10.0	-10.0, 0.0	-10.0, 5.0
Min, Max	20, 100	40, 100	30, 100	-40, 30	-30, 5	-25, 25
Week 52						
m	17	12	39			
n	17	12	35	16	12	30
Mean (SD/SE)	65.3 (15.4)	80.4 (19.9)	76.6 (17.8)	1.3 (4.5)	-2.5 (3.4)	-1.5 (2.7)
Median	65.0	87.5	80.0	5.0	-2.5	0
IQR: Q1, Q3	50.0, 80.0	67.5, 95.0	65.0, 90.0	-10.0, 10.0	-5.0, 5.0	-10.0, 5.0
Min, Max	45, 90	45, 100	15, 100	-35, 35	-30, 15	-40, 30

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Mental Component Score						
Baseline						
m	19	16	43			
n	17	16	37			
Mean (SD)	46.84 (9.72)	53.39 (9.30)	52.91 (7.00)			
Median	47.70	56.65	54.70			
IQR: Q1, Q3	39.70, 54.90	44.70, 61.25	49.10, 58.20			
Min, Max	29.4, 60.9	36.4, 64.5	33.3, 64.3			
Week 24						
m	19	15	41			
n	19	14	39	17	14	34
Mean (SD/SE)	46.36 (11.04)	52.92 (8.23)	50.72 (9.74)	0.09 (1.97)	-1.44 (1.66)	-1.73 (1.05)
Median	50.70	55.85	52.10	1.90	-0.05	-1.85
IQR: Q1, Q3	40.60, 54.10	48.10, 58.80	42.20, 59.30	-4.40, 3.60	-6.80, 3.40	-5.20, 1.40
Min, Max	25.0, 62.3	35.1, 63.6	27.8, 63.3	-12.6, 19.0	-12.0, 8.1	-17.6, 13.1
Week 52						
m	17	12	39			
n	17	12	35	15	12	30
Mean (SD/SE)	46.12 (8.14)	52.28 (11.14)	51.25 (10.11)	0.19 (2.55)	-1.38 (2.51)	-2.07 (1.37)
Median	45.40	55.90	53.70	2.50	-1.60	-0.30
IQR: Q1, Q3	40.20, 50.80	45.45, 60.40	45.20, 59.10	-3.80, 5.40	-6.45, 1.25	-5.90, 1.70
Min, Max	34.6, 59.4	30.3, 63.2	21.3, 64.6	-17.3, 20.4	-15.2, 14.9	-21.4, 12.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Physical Component Score						
Baseline						
m	19	16	43			
n	17	16	37			
Mean (SD)	47.72 (9.34)	41.66 (10.19)	45.32 (9.64)			
Median	50.10	45.60	45.50			
IQR: Q1, Q3	43.20, 54.30	34.20, 49.15	38.60, 52.90			
Min, Max	24.7, 59.2	21.2, 53.7	27.1, 60.7			
Week 24						
m	19	15	41			
n	19	14	39	17	14	34
Mean (SD/SE)	45.39 (11.17)	46.39 (8.17)	45.16 (10.24)	-2.85 (1.52)	4.09 (3.29)	0.39 (1.02)
Median	44.10	48.50	46.70	-2.20	3.55	0.20
IQR: Q1, Q3	37.50, 57.90	41.40, 51.60	36.70, 52.70	-6.70, 0.70	-2.10, 6.50	-3.10, 3.20
Min, Max	22.5, 59.1	32.1, 57.3	25.8, 63.0	-17.2, 7.9	-19.3, 32.4	-11.5, 13.4
Week 52						
m	17	12	39			
n	17	12	35	15	12	30
Mean (SD/SE)	46.21 (10.44)	46.56 (6.38)	46.65 (9.67)	-0.58 (1.47)	2.82 (1.98)	1.13 (1.26)
Median	49.10	45.05	46.90	-1.00	3.10	0.30
IQR: Q1, Q3	38.50, 50.80	42.15, 51.90	41.50, 54.60	-5.00, 4.10	-1.80, 5.50	-3.10, 2.90
Min, Max	24.0, 62.8	35.2, 57.6	21.5, 63.9	-9.4, 11.8	-6.6, 17.2	-10.9, 19.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Physical Functioning						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	74.50 (24.31)	70.25 (26.04)	75.14 (25.36)			
Median	80.00	77.50	85.00			
IQR: Q1, Q3	60.00, 95.00	55.00, 90.00	60.00, 95.00			
Min, Max	0.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	76.52 (23.53)	71.13 (24.82)	75.99 (27.64)	2.48 (1.36)	0.52 (1.68)	0.31 (1.22)
Median	85.00	77.50	85.00	0	0	0
IQR: Q1, Q3	60.00, 95.00	60.00, 90.00	65.00, 100.00	-5.00, 10.00	-10.00, 10.00	-5.00, 10.00
Min, Max	5.0, 100.0	5.0, 100.0	0.0, 100.0	-50.0, 60.0	-65.0, 55.0	-70.0, 75.0
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	77.48 (26.89)	70.75 (26.79)	77.20 (24.59)	1.80 (1.41)	0.37 (1.83)	0.77 (1.15)
Median	90.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 100.00	55.00, 90.00	65.00, 95.00	-5.00, 10.00	-5.00, 5.00	-5.00, 5.00
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-65.0, 45.0	-85.0, 40.0	-60.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=148)	Visit Result: MGL-3196 100 mg (N=135)	Visit Result: Placebo (N=260)	Change from Baseline: MGL-3196 80 mg (N=148)	Change from Baseline: MGL-3196 100 mg (N=135)	Change from Baseline: Placebo (N=260)
Role Physical						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	75.91 (26.09)	73.32 (27.08)	76.25 (26.29)			
Median	81.30	75.00	81.30			
IQR: Q1, Q3	56.30, 100.00	56.30, 100.00	62.50, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	75.51 (26.22)	73.73 (24.01)	76.69 (27.28)	-0.09 (1.56)	-0.11 (1.88)	-0.20 (1.41)
Median	81.30	75.00	87.50	0	0	0
IQR: Q1, Q3	56.30, 100.00	56.30, 100.00	62.50, 100.00	-12.50, 12.50	-9.40, 6.25	-6.30, 6.30
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.8, 50.0	-50.0, 68.7	-68.7, 87.5
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	77.21 (28.01)	73.55 (26.76)	75.78 (25.32)	0.43 (1.65)	0.84 (2.17)	-1.07 (1.46)
Median	87.50	75.00	81.30	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 100.00	56.30, 100.00	-6.20, 6.20	-6.30, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	6.3, 100.0	0.0, 100.0	-43.8, 81.2	-75.0, 81.3	-62.5, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Bodily Pain						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	67.1 (23.8)	63.5 (26.1)	66.1 (24.9)			
Median	72.0	62.0	72.0			
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	41.0, 84.0			
Min, Max	10, 100	0, 100	0, 100			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	65.8 (24.9)	64.3 (24.5)	66.8 (25.5)	-1.1 (1.7)	-0.7 (1.8)	0.1 (1.4)
Median	72.0	62.0	72.0	0	0	0
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	51.0, 84.0	-16.0, 10.0	-10.5, 10.0	-12.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-50, 68	-62, 64	-78, 78
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	69.3 (25.1)	67.4 (26.0)	68.2 (24.7)	0.7 (1.9)	4.3 (2.2)	1.0 (1.5)
Median	74.0	72.0	72.0	0	0	0
IQR: Q1, Q3	51.0, 84.0	42.0, 84.0	51.0, 84.0	-10.0, 10.0	-10.0, 12.0	-12.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-80, 68	-53, 69	-78, 78

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
General Health						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	61.01 (19.54)	54.52 (19.48)	58.51 (20.44)			
Median	62.00	52.00	60.00			
IQR: Q1, Q3	50.00, 77.00	40.00, 67.00	45.00, 75.00			
Min, Max	10.0, 100.0	10.0, 100.0	15.0, 100.0			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	61.18 (20.81)	54.26 (19.59)	59.72 (21.56)	0.79 (1.26)	0.04 (1.41)	1.09 (0.99)
Median	62.00	52.00	62.00	0	0	0
IQR: Q1, Q3	47.00, 77.00	40.00, 67.00	45.00, 77.00	-5.00, 10.00	-10.00, 10.00	-8.00, 10.00
Min, Max	10.0, 100.0	10.0, 100.0	0.0, 100.0	-60.0, 32.0	-35.0, 40.0	-40.0, 48.0
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	63.21 (20.29)	55.26 (19.73)	60.30 (20.77)	0.97 (1.36)	1.23 (1.80)	1.43 (0.99)
Median	67.00	55.00	62.00	0	0	0
IQR: Q1, Q3	47.00, 77.00	40.00, 72.00	47.00, 77.00	-5.00, 10.00	-10.00, 10.00	-5.00, 10.00
Min, Max	20.0, 100.0	10.0, 92.0	10.0, 100.0	-70.0, 47.0	-52.0, 47.0	-42.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Vitality						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	58.65 (22.21)	54.38 (22.01)	56.57 (22.27)			
Median	62.50	56.30	62.50			
IQR: Q1, Q3	43.80, 75.00	43.80, 68.80	43.80, 75.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	57.27 (23.41)	53.76 (20.05)	57.51 (22.69)	-1.28 (1.21)	-0.95 (1.45)	0.51 (1.07)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	43.80, 75.00	37.50, 68.80	40.65, 75.00	-6.30, 6.30	-12.50, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.8, 37.5	-31.3, 43.8	-37.5, 56.2
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	60.05 (23.34)	54.93 (20.80)	57.84 (22.81)	-0.49 (1.38)	0.19 (1.59)	1.05 (1.30)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	43.80, 75.00	43.80, 68.80	43.80, 75.00	-6.30, 12.50	-6.30, 6.30	-6.30, 12.50
Min, Max	6.3, 100.0	6.3, 100.0	0.0, 100.0	-43.7, 50.0	-43.8, 43.8	-56.3, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Social Functioning						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	82.86 (23.10)	79.41 (26.55)	82.72 (22.60)			
Median	100.00	87.50	100.00			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	0.0, 100.0	12.5, 100.0			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	81.88 (24.31)	81.66 (21.27)	81.30 (24.93)	-1.13 (1.81)	2.23 (1.95)	-1.51 (1.35)
Median	100.00	87.50	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	62.50, 100.00	-12.50, 0.00	0.00, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	12.5, 100.0	0.0, 100.0	-62.5, 75.0	-62.5, 87.5	-62.5, 75.0
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	82.98 (23.51)	82.23 (22.21)	83.09 (22.00)	-1.97 (1.63)	2.96 (2.29)	-0.13 (1.41)
Median	100.00	93.75	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00	-12.50, 0.00	0.00, 12.50	0.00, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-50.0, 50.0	-62.5, 62.5	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Role Emotional						
Baseline						
m	148	135	260			
n	140	122	242			
Mean (SD)	82.32 (25.08)	81.63 (24.41)	83.75 (22.76)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	142	126	248			
n	138	122	228	133	112	214
Mean (SD/SE)	82.49 (22.63)	84.77 (20.96)	82.93 (24.35)	0.44 (1.55)	2.75 (1.49)	-0.66 (1.29)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	75.00, 100.00	-8.30, 0.00	0.00, 8.30	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-66.7, 66.7	-50.0, 50.0	-50.0, 58.3
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	84.56 (21.30)	84.64 (21.62)	83.17 (22.94)	1.43 (1.61)	3.35 (2.10)	-1.21 (1.33)
Median	100.00	95.85	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	0.00, 16.70	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-50.0, 100.0	-75.0, 58.3	-58.3, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Mental Health						
Baseline						
m	148	135	260			
n	140	122	243			
Mean (SD)	74.6 (19.9)	74.0 (19.5)	74.8 (18.2)			
Median	80.0	80.0	80.0			
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	65.0, 90.0			
Min, Max	5, 100	15, 100	5, 100			
Week 24						
m	142	126	248			
n	138	122	228	133	112	215
Mean (SD/SE)	74.2 (19.3)	74.6 (19.0)	74.8 (19.2)	-0.4 (1.1)	-0.1 (1.2)	0.3 (1.0)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	60.0, 90.0	65.0, 90.0	65.0, 90.0	-5.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	15, 100	5, 100	5, 100	-35, 35	-40, 50	-45, 55
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	76.6 (18.1)	75.0 (18.1)	75.5 (19.7)	0.4 (1.1)	0.5 (1.3)	0.8 (1.1)
Median	80.0	77.5	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	70.0, 90.0	-5.0, 5.0	-5.0, 5.0	-5.0, 10.0
Min, Max	25, 100	20, 100	0, 100	-35, 40	-25, 50	-60, 55

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Mental Component Score						
Baseline						
m	148	135	260			
n	140	122	242			
Mean (SD)	50.95 (10.90)	50.49 (11.20)	51.01 (9.62)			
Median	53.85	53.65	53.90			
IQR: Q1, Q3	46.90, 58.90	45.30, 58.20	45.60, 57.90			
Min, Max	12.0, 69.0	17.0, 72.3	15.6, 66.5			
Week 24						
m	142	126	248			
n	138	122	228	133	112	214
Mean (SD/SE)	50.50 (10.53)	51.27 (9.97)	50.68 (10.44)	-0.47 (0.63)	0.60 (0.65)	-0.19 (0.54)
Median	53.00	53.30	53.55	-0.60	-0.10	0
IQR: Q1, Q3	43.80, 58.60	46.10, 58.70	45.75, 58.10	-3.90, 3.20	-2.70, 3.45	-4.20, 3.50
Min, Max	18.7, 69.1	9.4, 71.2	14.2, 69.0	-20.0, 19.0	-24.5, 26.1	-24.6, 24.8
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	51.62 (9.58)	51.44 (9.57)	51.00 (10.23)	-0.11 (0.61)	0.83 (0.82)	0.02 (0.56)
Median	54.40	53.00	54.10	0	0	0.30
IQR: Q1, Q3	46.10, 58.90	45.10, 58.30	46.75, 57.95	-3.80, 3.40	-3.60, 4.10	-3.50, 4.00
Min, Max	23.1, 63.2	17.8, 70.7	8.9, 68.0	-21.7, 26.2	-21.4, 25.2	-25.1, 26.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Physical Component Score						
Baseline						
m	148	135	260			
n	140	122	242			
Mean (SD)	47.73 (8.88)	45.56 (9.80)	47.31 (9.40)			
Median	48.65	46.50	48.90			
IQR: Q1, Q3	43.00, 55.10	39.60, 53.70	41.20, 55.10			
Min, Max	15.3, 60.8	21.6, 61.3	20.7, 65.2			
Week 24						
m	142	126	248			
n	138	122	228	133	112	214
Mean (SD/SE)	47.88 (9.34)	45.49 (9.05)	47.78 (10.00)	0.35 (0.53)	-0.24 (0.63)	0.17 (0.48)
Median	50.00	45.95	50.20	0.40	-0.50	0
IQR: Q1, Q3	42.70, 54.00	38.70, 52.40	42.50, 55.50	-3.10, 4.10	-3.05, 3.25	-3.40, 3.50
Min, Max	12.5, 63.9	20.2, 61.0	19.0, 62.9	-15.7, 18.3	-22.1, 21.7	-28.8, 23.8
Week 52						
m	132	113	231			
n	119	102	204	114	97	193
Mean (SD/SE)	48.52 (10.41)	45.90 (10.20)	48.02 (9.14)	0.40 (0.63)	0.54 (0.78)	0.32 (0.43)
Median	52.40	47.90	49.40	0.50	1.40	0.30
IQR: Q1, Q3	42.10, 57.20	39.40, 53.40	42.45, 55.40	-1.60, 3.70	-2.70, 4.80	-2.40, 3.50
Min, Max	15.8, 62.7	16.0, 61.2	22.5, 61.7	-24.7, 22.5	-23.5, 18.6	-23.9, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Physical Functioning			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	75.16 (21.22)	70.00 (25.34)	70.29 (23.77)
Analysis Visit Mean (SD)	68.61 (30.57)	75.36 (22.91)	70.29 (25.25)
LS Mean of Change from Baseline (SE)	-2.57 (4.89)	6.68 (5.41)	0.26 (3.40)
95% CI	(-12.34, 7.21)	(-4.12, 17.49)	(-6.54, 7.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.83 (5.84)	6.42 (6.30)	
95% CI	(-14.51, 8.85)	(-6.18, 19.02)	
p-value	0.6298	0.3126	
Corrected Hedge's g Statistics	-0.138	0.316	
95% CI	(-0.71, 0.43)	(-0.31, 0.94)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	72.36 (20.85)	72.50 (22.11)	73.67 (22.28)
Analysis Visit Mean (SD)	70.31 (25.00)	74.17 (19.17)	73.83 (22.73)
LS Mean of Change from Baseline (SE)	0.41 (4.11)	5.38 (4.56)	0.69 (2.80)
95% CI	(-7.80, 8.63)	(-3.74, 14.49)	(-4.90, 6.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.28 (4.86)	4.68 (5.27)	
95% CI	(-10.00, 9.43)	(-5.85, 15.21)	
p-value	0.9540	0.3775	
Corrected Hedge's g Statistics	-0.018	0.297	
95% CI	(-0.62, 0.59)	(-0.38, 0.97)	
Subgroup*Treatment Interaction p-value	0.2137	0.2631	

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Role Physical			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	74.67 (27.15)	75.02 (27.40)	74.83 (25.06)
Analysis Visit Mean (SD)	65.29 (31.30)	73.69 (25.38)	73.91 (27.32)
LS Mean of Change from Baseline (SE)	-7.33 (4.96)	0.22 (5.49)	-0.60 (3.43)
95% CI	(-17.25, 2.59)	(-10.74, 11.19)	(-7.46, 6.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.73 (5.87)	0.82 (6.37)	
95% CI	(-18.47, 5.01)	(-11.91, 13.55)	
p-value	0.2562	0.8979	
Corrected Hedge's g Statistics	-0.325	0.040	
95% CI	(-0.90, 0.25)	(-0.58, 0.66)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	74.63 (27.43)	77.63 (24.91)	77.51 (22.71)
Analysis Visit Mean (SD)	67.60 (26.64)	77.10 (23.43)	76.47 (21.63)
LS Mean of Change from Baseline (SE)	-5.35 (4.70)	2.61 (5.23)	0.54 (3.22)
95% CI	(-14.73, 4.04)	(-7.84, 13.06)	(-5.89, 6.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.89 (5.56)	2.06 (6.04)	
95% CI	(-17.00, 5.23)	(-10.01, 14.14)	
p-value	0.2938	0.7338	
Corrected Hedge's g Statistics	-0.321	0.114	
95% CI	(-0.93, 0.29)	(-0.56, 0.78)	
Subgroup*Treatment Interaction p-value	0.1086	0.9268	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Bodily Pain			
Week 24			
m	19	15	41
n	17	14	34
Baseline Mean (SD)	63.6 (29.0)	52.7 (25.7)	61.9 (25.4)
Analysis Visit Mean (SD)	51.2 (26.9)	66.1 (21.6)	63.6 (26.1)
LS Mean of Change from Baseline (SE)	-9.63 (5.12)	11.50 (5.55)	2.59 (3.45)
95% CI	(-19.85, 0.60)	(0.40, 22.60)	(-4.31, 9.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	-12.21 (6.00)	8.92 (6.43)	
95% CI	(-24.20, -0.23)	(-3.94, 21.77)	
p-value	0.0459	0.1705	
Corrected Hedge's g Statistics	-0.589	0.432	
95% CI	(-1.18, 0.00)	(-0.20, 1.06)	
Week 52			
m	17	12	39
n	15	12	30
Baseline Mean (SD)	61.4 (29.3)	54.6 (27.2)	63.1 (24.9)
Analysis Visit Mean (SD)	57.1 (30.0)	65.2 (22.9)	66.6 (23.1)
LS Mean of Change from Baseline (SE)	-3.16 (5.38)	8.23 (5.90)	4.92 (3.63)
95% CI	(-13.91, 7.59)	(-3.55, 20.02)	(-2.33, 12.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.08 (6.35)	3.31 (6.84)	
95% CI	(-20.78, 4.62)	(-10.37, 16.99)	
p-value	0.2083	0.6300	
Corrected Hedge's g Statistics	-0.393	0.162	
95% CI	(-1.02, 0.23)	(-0.51, 0.83)	
Subgroup*Treatment Interaction p-value	0.0431	0.2022	

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
General Health			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	56.33 (22.58)	50.64 (16.61)	59.76 (19.90)
Analysis Visit Mean (SD)	58.72 (22.74)	62.43 (16.54)	57.76 (21.20)
LS Mean of Change from Baseline (SE)	3.18 (3.73)	10.78 (4.16)	-0.85 (2.60)
95% CI	(-4.27, 10.63)	(2.47, 19.10)	(-6.05, 4.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.03 (4.43)	11.63 (4.86)	
95% CI	(-4.83, 12.89)	(1.93, 21.34)	
p-value	0.3671	0.0196	
Corrected Hedge's g Statistics	0.258	0.749	
95% CI	(-0.32, 0.83)	(0.11, 1.39)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	54.69 (23.47)	51.83 (15.91)	62.93 (20.30)
Analysis Visit Mean (SD)	59.94 (17.23)	61.67 (13.30)	64.63 (20.19)
LS Mean of Change from Baseline (SE)	5.02 (3.42)	8.56 (3.82)	4.26 (2.38)
95% CI	(-1.81, 11.85)	(0.93, 16.19)	(-0.49, 9.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.76 (4.08)	4.30 (4.47)	
95% CI	(-7.39, 8.91)	(-4.63, 13.23)	
p-value	0.8533	0.3398	
Corrected Hedge's g Statistics	0.056	0.323	
95% CI	(-0.55, 0.66)	(-0.35, 1.00)	
Subgroup*Treatment Interaction p-value	0.6370	0.0140	

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Vitality			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	47.93 (22.38)	50.01 (25.24)	56.83 (16.60)
Analysis Visit Mean (SD)	52.11 (26.51)	53.59 (22.56)	54.62 (19.78)
LS Mean of Change from Baseline (SE)	3.44 (3.95)	2.38 (4.35)	-1.21 (2.75)
95% CI	(-4.46, 11.34)	(-6.32, 11.08)	(-6.70, 4.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.65 (4.73)	3.59 (5.08)	
95% CI	(-4.80, 14.10)	(-6.57, 13.75)	
p-value	0.3292	0.4825	
Corrected Hedge's g Statistics	0.281	0.219	
95% CI	(-0.29, 0.86)	(-0.40, 0.84)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	46.11 (23.15)	52.62 (24.78)	59.82 (16.14)
Analysis Visit Mean (SD)	48.86 (17.11)	54.18 (22.81)	57.11 (20.36)
LS Mean of Change from Baseline (SE)	0.25 (3.84)	0.94 (4.24)	-0.48 (2.67)
95% CI	(-7.43, 7.93)	(-7.54, 9.42)	(-5.83, 4.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.73 (4.66)	1.42 (4.96)	
95% CI	(-8.59, 10.05)	(-8.48, 11.32)	
p-value	0.8760	0.7751	
Corrected Hedge's g Statistics	0.048	0.095	
95% CI	(-0.56, 0.66)	(-0.57, 0.76)	
Subgroup*Treatment Interaction p-value	0.3476	0.2938	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Social Functioning			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	73.61 (27.42)	84.82 (17.80)	83.82 (22.30)
Analysis Visit Mean (SD)	76.39 (26.04)	82.14 (18.81)	81.62 (20.92)
LS Mean of Change from Baseline (SE)	0.78 (4.44)	-0.45 (4.85)	-1.05 (3.04)
95% CI	(-8.10, 9.66)	(-10.13, 9.23)	(-7.12, 5.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.83 (5.27)	0.60 (5.62)	
95% CI	(-8.71, 12.37)	(-10.62, 11.83)	
p-value	0.7300	0.9150	
Corrected Hedge's g Statistics	0.099	0.033	
95% CI	(-0.47, 0.67)	(-0.59, 0.66)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	71.88 (28.69)	85.42 (17.54)	87.50 (20.50)
Analysis Visit Mean (SD)	72.66 (20.52)	78.13 (24.50)	84.58 (21.19)
LS Mean of Change from Baseline (SE)	-2.27 (4.63)	-4.86 (5.06)	-1.15 (3.16)
95% CI	(-11.52, 6.98)	(-14.98, 5.26)	(-7.47, 5.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.12 (5.60)	-3.71 (5.87)	
95% CI	(-12.32, 10.07)	(-15.45, 8.03)	
p-value	0.8418	0.5301	
Corrected Hedge's g Statistics	-0.062	-0.209	
95% CI	(-0.67, 0.54)	(-0.88, 0.46)	
Subgroup*Treatment Interaction p-value	0.8408	0.3469	

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Role Emotional			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	80.09 (21.42)	85.71 (17.12)	85.54 (20.34)
Analysis Visit Mean (SD)	75.93 (26.03)	89.89 (17.65)	82.85 (22.37)
LS Mean of Change from Baseline (SE)	-2.81 (4.04)	6.04 (4.44)	-1.58 (2.76)
95% CI	(-10.89, 5.26)	(-2.84, 14.92)	(-7.10, 3.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.23 (4.74)	7.62 (5.12)	
95% CI	(-10.71, 8.25)	(-2.61, 17.84)	
p-value	0.7958	0.1415	
Corrected Hedge's g Statistics	-0.074	0.461	
95% CI	(-0.65, 0.50)	(-0.17, 1.09)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	79.17 (22.15)	84.03 (17.93)	87.50 (19.17)
Analysis Visit Mean (SD)	75.52 (21.84)	86.81 (24.74)	82.22 (21.52)
LS Mean of Change from Baseline (SE)	-3.29 (4.86)	4.56 (5.43)	-3.29 (3.38)
95% CI	(-13.00, 6.43)	(-6.29, 15.40)	(-10.05, 3.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (5.83)	7.84 (6.31)	
95% CI	(-11.65, 11.66)	(-4.76, 20.45)	
p-value	0.9999	0.2184	
Corrected Hedge's g Statistics	0.000	0.414	
95% CI	(-0.61, 0.61)	(-0.26, 1.09)	
Subgroup*Treatment Interaction p-value	0.3932	0.4730	

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Mental Health			
Week 24			
m	19	15	41
n	18	14	34
Baseline Mean (SD)	66.9 (19.5)	84.3 (15.0)	77.1 (14.8)
Analysis Visit Mean (SD)	64.2 (22.4)	79.3 (17.6)	74.1 (17.2)
LS Mean of Change from Baseline (SE)	-2.55 (3.25)	-2.55 (3.61)	-2.21 (2.18)
95% CI	(-9.04, 3.95)	(-9.77, 4.67)	(-6.56, 2.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.34 (3.83)	-0.34 (4.10)	
95% CI	(-7.99, 7.31)	(-8.54, 7.86)	
p-value	0.9295	0.9342	
Corrected Hedge's g Statistics	-0.026	-0.026	
95% CI	(-0.60, 0.55)	(-0.65, 0.60)	
Week 52			
m	17	12	39
n	16	12	30
Baseline Mean (SD)	64.7 (19.5)	82.9 (15.6)	78.7 (14.6)
Analysis Visit Mean (SD)	65.9 (15.6)	80.4 (19.9)	77.2 (18.4)
LS Mean of Change from Baseline (SE)	-0.24 (3.92)	1.09 (4.32)	-0.73 (2.63)
95% CI	(-8.07, 7.59)	(-7.54, 9.71)	(-5.98, 4.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.49 (4.71)	1.82 (4.93)	
95% CI	(-8.92, 9.91)	(-8.04, 11.67)	
p-value	0.9169	0.7135	
Corrected Hedge's g Statistics	0.033	0.123	
95% CI	(-0.57, 0.64)	(-0.55, 0.79)	
Subgroup*Treatment Interaction p-value	0.6225	0.9763	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Mental Component Score			
Week 24			
m	19	15	41
n	17	14	34
Baseline Mean (SD)	46.84 (9.72)	54.36 (8.70)	52.69 (7.18)
Analysis Visit Mean (SD)	46.94 (10.59)	52.92 (8.23)	50.96 (8.80)
LS Mean of Change from Baseline (SE)	-0.39 (1.76)	-0.38 (1.87)	-1.23 (1.15)
95% CI	(-3.92, 3.14)	(-4.12, 3.37)	(-3.53, 1.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.84 (2.07)	0.85 (2.14)	
95% CI	(-3.30, 4.99)	(-3.42, 5.12)	
p-value	0.6864	0.6921	
Corrected Hedge's g Statistics	0.120	0.123	
95% CI	(-0.46, 0.70)	(-0.50, 0.75)	
Week 52			
m	17	12	39
n	15	12	30
Baseline Mean (SD)	46.03 (10.07)	53.65 (9.21)	53.70 (7.08)
Analysis Visit Mean (SD)	46.22 (8.47)	52.28 (11.14)	51.63 (9.87)
LS Mean of Change from Baseline (SE)	-0.81 (2.21)	-0.40 (2.34)	-1.36 (1.46)
95% CI	(-5.23, 3.62)	(-5.08, 4.28)	(-4.28, 1.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.56 (2.66)	0.96 (2.70)	
95% CI	(-4.77, 5.88)	(-4.43, 6.36)	
p-value	0.8356	0.7226	
Corrected Hedge's g Statistics	0.067	0.118	
95% CI	(-0.55, 0.69)	(-0.55, 0.79)	
Subgroup*Treatment Interaction p-value	0.9824	0.8666	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Physical Component Score			
Week 24			
m	19	15	41
n	17	14	34
Baseline Mean (SD)	47.72 (9.34)	42.30 (10.74)	45.51 (9.51)
Analysis Visit Mean (SD)	44.88 (11.38)	46.39 (8.17)	45.91 (9.54)
LS Mean of Change from Baseline (SE)	-1.50 (1.84)	3.46 (2.00)	0.50 (1.24)
95% CI	(-5.16, 2.17)	(-0.53, 7.45)	(-1.98, 2.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.99 (2.17)	2.96 (2.32)	
95% CI	(-6.33, 2.34)	(-1.67, 7.59)	
p-value	0.3612	0.2058	
Corrected Hedge's g Statistics	-0.267	0.399	
95% CI	(-0.85, 0.32)	(-0.23, 1.03)	
Week 52			
m	17	12	39
n	15	12	30
Baseline Mean (SD)	47.09 (9.80)	43.74 (9.61)	46.61 (9.03)
Analysis Visit Mean (SD)	46.51 (10.81)	46.56 (6.38)	47.74 (7.82)
LS Mean of Change from Baseline (SE)	0.25 (1.60)	2.78 (1.74)	1.62 (1.06)
95% CI	(-2.94, 3.45)	(-0.70, 6.25)	(-0.51, 3.75)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.37 (1.88)	1.16 (2.01)	
95% CI	(-5.11, 2.38)	(-2.86, 5.17)	
p-value	0.4691	0.5674	
Corrected Hedge's g Statistics	-0.226	0.193	
95% CI	(-0.85, 0.40)	(-0.48, 0.86)	
Subgroup*Treatment Interaction p-value	0.1656	0.1589	

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Physical Functioning			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	74.29 (24.16)	70.13 (26.19)	75.93 (25.73)
Analysis Visit Mean (SD)	76.77 (23.69)	70.65 (24.72)	76.24 (27.59)
LS Mean of Change from Baseline (SE)	2.46 (1.46)	-0.60 (1.58)	0.29 (1.16)
95% CI	(-0.41, 5.33)	(-3.70, 2.50)	(-1.99, 2.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.17 (1.81)	-0.88 (1.92)	
95% CI	(-1.39, 5.74)	(-4.65, 2.88)	
p-value	0.2318	0.6450	
Corrected Hedge's g Statistics	0.128	-0.052	
95% CI	(-0.09, 0.34)	(-0.28, 0.18)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	75.70 (23.15)	69.79 (26.76)	76.32 (24.83)
Analysis Visit Mean (SD)	77.50 (26.79)	70.17 (27.11)	77.09 (24.48)
LS Mean of Change from Baseline (SE)	2.14 (1.47)	-0.31 (1.58)	0.87 (1.15)
95% CI	(-0.75, 5.03)	(-3.42, 2.81)	(-1.40, 3.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.27 (1.81)	-1.17 (1.92)	
95% CI	(-2.29, 4.84)	(-4.94, 2.60)	
p-value	0.4826	0.5413	
Corrected Hedge's g Statistics	0.080	-0.074	
95% CI	(-0.15, 0.31)	(-0.32, 0.17)	
Subgroup*Treatment Interaction p-value	0.2137	0.2631	

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Role Physical			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	75.91 (25.91)	73.45 (27.40)	76.76 (26.56)
Analysis Visit Mean (SD)	75.81 (26.18)	73.34 (24.37)	76.56 (27.34)
LS Mean of Change from Baseline (SE)	0.39 (1.62)	-0.91 (1.75)	0.05 (1.29)
95% CI	(-2.80, 3.58)	(-4.35, 2.53)	(-2.49, 2.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.35 (2.02)	-0.96 (2.13)	
95% CI	(-3.62, 4.31)	(-5.14, 3.22)	
p-value	0.8634	0.6526	
Corrected Hedge's g Statistics	0.018	-0.051	
95% CI	(-0.20, 0.23)	(-0.28, 0.18)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	76.82 (26.90)	72.24 (28.37)	76.86 (25.83)
Analysis Visit Mean (SD)	77.26 (28.16)	73.08 (27.11)	75.79 (25.33)
LS Mean of Change from Baseline (SE)	1.10 (1.72)	0.30 (1.85)	-0.59 (1.34)
95% CI	(-2.28, 4.47)	(-3.33, 3.94)	(-3.22, 2.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.69 (2.12)	0.89 (2.24)	
95% CI	(-2.48, 5.86)	(-3.50, 5.29)	
p-value	0.4264	0.6895	
Corrected Hedge's g Statistics	0.091	0.048	
95% CI	(-0.14, 0.32)	(-0.20, 0.29)	
Subgroup*Treatment Interaction p-value	0.1086	0.9268	

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Bodily Pain			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	67.0 (23.6)	63.9 (26.2)	66.9 (25.0)
Analysis Visit Mean (SD)	66.0 (25.0)	63.2 (24.7)	67.0 (25.7)
LS Mean of Change from Baseline (SE)	-0.73 (1.63)	-1.47 (1.75)	0.10 (1.29)
95% CI	(-3.93, 2.47)	(-4.91, 1.97)	(-2.44, 2.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.83 (2.01)	-1.57 (2.12)	
95% CI	(-4.78, 3.13)	(-5.74, 2.60)	
p-value	0.6815	0.4599	
Corrected Hedge's g Statistics	-0.044	-0.083	
95% CI	(-0.26, 0.17)	(-0.31, 0.15)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	68.2 (24.1)	62.2 (26.6)	67.0 (24.6)
Analysis Visit Mean (SD)	69.0 (25.1)	66.5 (26.1)	68.1 (24.7)
LS Mean of Change from Baseline (SE)	1.26 (1.82)	2.61 (1.96)	1.22 (1.41)
95% CI	(-2.31, 4.83)	(-1.24, 6.45)	(-1.56, 4.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (2.24)	1.39 (2.37)	
95% CI	(-4.37, 4.45)	(-3.26, 6.04)	
p-value	0.9857	0.5580	
Corrected Hedge's g Statistics	0.002	0.071	
95% CI	(-0.23, 0.23)	(-0.17, 0.31)	
Subgroup*Treatment Interaction p-value	0.0431	0.2022	

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
General Health			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	60.88 (18.93)	53.35 (19.00)	58.95 (20.51)
Analysis Visit Mean (SD)	61.67 (20.23)	53.38 (19.72)	60.04 (21.80)
LS Mean of Change from Baseline (SE)	1.16 (1.26)	-1.65 (1.36)	0.86 (0.99)
95% CI	(-1.30, 3.63)	(-4.31, 1.01)	(-1.09, 2.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.30 (1.55)	-2.51 (1.64)	
95% CI	(-2.75, 3.35)	(-5.74, 0.72)	
p-value	0.8462	0.1267	
Corrected Hedge's g Statistics	0.021	-0.173	
95% CI	(-0.20, 0.24)	(-0.40, 0.06)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	62.42 (19.22)	53.51 (20.13)	59.13 (20.62)
Analysis Visit Mean (SD)	63.39 (20.04)	54.73 (19.82)	60.56 (21.09)
LS Mean of Change from Baseline (SE)	1.65 (1.33)	-0.67 (1.43)	1.42 (1.03)
95% CI	(-0.96, 4.27)	(-3.49, 2.14)	(-0.61, 3.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.23 (1.64)	-2.10 (1.73)	
95% CI	(-2.99, 3.45)	(-5.50, 1.30)	
p-value	0.8884	0.2264	
Corrected Hedge's g Statistics	0.016	-0.146	
95% CI	(-0.22, 0.25)	(-0.39, 0.10)	
Subgroup*Treatment Interaction p-value	0.6370	0.0140	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Vitality			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	58.87 (22.27)	53.93 (22.39)	57.13 (22.55)
Analysis Visit Mean (SD)	57.59 (22.95)	52.98 (19.64)	57.64 (23.01)
LS Mean of Change from Baseline (SE)	-0.80 (1.27)	-2.06 (1.37)	0.10 (1.01)
95% CI	(-3.30, 1.69)	(-4.75, 0.63)	(-1.88, 2.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.91 (1.57)	-2.16 (1.66)	
95% CI	(-3.99, 2.18)	(-5.42, 1.09)	
p-value	0.5651	0.1923	
Corrected Hedge's g Statistics	-0.061	-0.147	
95% CI	(-0.28, 0.15)	(-0.38, 0.08)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	60.49 (22.36)	54.41 (22.86)	56.75 (22.22)
Analysis Visit Mean (SD)	60.00 (22.72)	54.60 (20.99)	57.80 (23.09)
LS Mean of Change from Baseline (SE)	0.46 (1.45)	-1.11 (1.56)	0.59 (1.13)
95% CI	(-2.40, 3.31)	(-4.18, 1.95)	(-1.62, 2.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (1.80)	-1.71 (1.89)	
95% CI	(-3.67, 3.39)	(-5.42, 2.00)	
p-value	0.9386	0.3657	
Corrected Hedge's g Statistics	-0.009	-0.109	
95% CI	(-0.24, 0.22)	(-0.35, 0.13)	
Subgroup*Treatment Interaction p-value	0.3476	0.2938	

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Social Functioning			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	83.36 (22.49)	79.35 (27.04)	82.79 (22.65)
Analysis Visit Mean (SD)	82.24 (24.29)	81.58 (21.55)	81.28 (24.88)
LS Mean of Change from Baseline (SE)	-0.99 (1.63)	0.44 (1.76)	-2.09 (1.30)
95% CI	(-4.20, 2.22)	(-3.02, 3.91)	(-4.63, 0.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.09 (2.03)	2.53 (2.14)	
95% CI	(-2.89, 5.08)	(-1.68, 6.74)	
p-value	0.5901	0.2385	
Corrected Hedge's g Statistics	0.058	0.134	
95% CI	(-0.16, 0.27)	(-0.10, 0.36)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	85.20 (21.59)	78.87 (28.20)	83.16 (22.17)
Analysis Visit Mean (SD)	83.22 (23.45)	81.83 (22.61)	83.03 (22.25)
LS Mean of Change from Baseline (SE)	-0.83 (1.65)	1.41 (1.78)	-0.84 (1.29)
95% CI	(-4.07, 2.42)	(-2.09, 4.90)	(-3.37, 1.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (2.04)	2.25 (2.15)	
95% CI	(-3.98, 4.02)	(-1.97, 6.46)	
p-value	0.9932	0.2949	
Corrected Hedge's g Statistics	0.001	0.126	
95% CI	(-0.23, 0.23)	(-0.12, 0.37)	
Subgroup*Treatment Interaction p-value	0.8408	0.3469	

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Role Emotional			
Week 24			
m	142	126	248
n	133	112	214
Baseline Mean (SD)	82.64 (24.81)	81.33 (24.94)	83.76 (22.99)
Analysis Visit Mean (SD)	83.08 (22.12)	84.08 (21.42)	83.10 (24.41)
LS Mean of Change from Baseline (SE)	0.16 (1.45)	1.85 (1.56)	-0.81 (1.15)
95% CI	(-2.68, 3.01)	(-1.22, 4.91)	(-3.07, 1.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.97 (1.80)	2.66 (1.89)	
95% CI	(-2.56, 4.50)	(-1.06, 6.38)	
p-value	0.5882	0.1611	
Corrected Hedge's g Statistics	0.058	0.158	
95% CI	(-0.16, 0.27)	(-0.07, 0.39)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	83.70 (24.02)	81.01 (25.90)	84.28 (22.47)
Analysis Visit Mean (SD)	85.12 (20.85)	84.36 (21.83)	83.07 (23.18)
LS Mean of Change from Baseline (SE)	1.55 (1.56)	2.76 (1.68)	-1.34 (1.22)
95% CI	(-1.51, 4.62)	(-0.54, 6.06)	(-3.74, 1.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.90 (1.93)	4.10 (2.03)	
95% CI	(-0.89, 6.68)	(0.11, 8.09)	
p-value	0.1338	0.0440	
Corrected Hedge's g Statistics	0.172	0.244	
95% CI	(-0.06, 0.40)	(0.00, 0.49)	
Subgroup*Treatment Interaction p-value	0.3932	0.4730	

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Mental Health			
Week 24			
m	142	126	248
n	133	112	215
Baseline Mean (SD)	75.0 (19.3)	74.2 (19.3)	74.6 (18.4)
Analysis Visit Mean (SD)	74.6 (18.7)	74.1 (19.2)	74.9 (19.3)
LS Mean of Change from Baseline (SE)	-0.72 (1.17)	-0.85 (1.26)	-0.52 (0.93)
95% CI	(-3.01, 1.57)	(-3.32, 1.62)	(-2.34, 1.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.20 (1.45)	-0.33 (1.52)	
95% CI	(-3.04, 2.64)	(-3.32, 2.66)	
p-value	0.8908	0.8284	
Corrected Hedge's g Statistics	-0.015	-0.024	
95% CI	(-0.23, 0.20)	(-0.25, 0.20)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	76.4 (18.3)	74.1 (20.0)	74.6 (18.3)
Analysis Visit Mean (SD)	76.8 (17.5)	74.6 (18.3)	75.4 (19.9)
LS Mean of Change from Baseline (SE)	0.37 (1.24)	-0.17 (1.33)	-0.25 (0.97)
95% CI	(-2.06, 2.81)	(-2.79, 2.44)	(-2.15, 1.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.63 (1.53)	0.08 (1.61)	
95% CI	(-2.38, 3.63)	(-3.08, 3.24)	
p-value	0.6825	0.9608	
Corrected Hedge's g Statistics	0.047	0.006	
95% CI	(-0.18, 0.28)	(-0.24, 0.25)	
Subgroup*Treatment Interaction p-value	0.6225	0.9763	

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Mental Component Score			
Week 24			
m	142	126	248
n	133	112	214
Baseline Mean (SD)	51.22 (10.70)	50.42 (11.39)	50.90 (9.74)
Analysis Visit Mean (SD)	50.75 (10.17)	51.02 (10.21)	50.71 (10.55)
LS Mean of Change from Baseline (SE)	-0.57 (0.62)	0.13 (0.67)	-0.56 (0.49)
95% CI	(-1.78, 0.65)	(-1.18, 1.44)	(-1.53, 0.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.77)	0.70 (0.81)	
95% CI	(-1.51, 1.50)	(-0.89, 2.28)	
p-value	0.9941	0.3904	
Corrected Hedge's g Statistics	-0.001	0.097	
95% CI	(-0.22, 0.22)	(-0.13, 0.33)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	51.91 (10.21)	50.51 (11.83)	50.94 (9.61)
Analysis Visit Mean (SD)	51.80 (9.26)	51.34 (9.68)	50.96 (10.37)
LS Mean of Change from Baseline (SE)	0.03 (0.64)	0.48 (0.69)	-0.50 (0.50)
95% CI	(-1.23, 1.30)	(-0.88, 1.84)	(-1.48, 0.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.53 (0.80)	0.97 (0.84)	
95% CI	(-1.04, 2.09)	(-0.67, 2.62)	
p-value	0.5082	0.2445	
Corrected Hedge's g Statistics	0.076	0.140	
95% CI	(-0.16, 0.31)	(-0.10, 0.38)	
Subgroup*Treatment Interaction p-value	0.9824	0.8666	

AMNOG Table SE22.10.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Physical Component Score			
Week 24			
m	142	126	248
n	133	112	214
Baseline Mean (SD)	47.59 (8.72)	45.47 (9.63)	47.70 (9.52)
Analysis Visit Mean (SD)	47.94 (9.40)	45.22 (9.08)	47.86 (10.10)
LS Mean of Change from Baseline (SE)	0.54 (0.57)	-0.67 (0.61)	0.25 (0.45)
95% CI	(-0.58, 1.65)	(-1.88, 0.53)	(-0.64, 1.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.28 (0.70)	-0.93 (0.75)	
95% CI	(-1.10, 1.67)	(-2.39, 0.54)	
p-value	0.6871	0.2149	
Corrected Hedge's g Statistics	0.043	-0.141	
95% CI	(-0.17, 0.26)	(-0.37, 0.09)	
Week 52			
m	132	113	231
n	114	97	193
Baseline Mean (SD)	48.04 (8.84)	45.08 (10.06)	47.72 (9.16)
Analysis Visit Mean (SD)	48.44 (10.46)	45.62 (10.30)	48.04 (9.16)
LS Mean of Change from Baseline (SE)	0.62 (0.59)	0.13 (0.64)	0.50 (0.46)
95% CI	(-0.55, 1.78)	(-1.12, 1.39)	(-0.41, 1.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.12 (0.73)	-0.37 (0.77)	
95% CI	(-1.32, 1.56)	(-1.89, 1.16)	
p-value	0.8715	0.6370	
Corrected Hedge's g Statistics	0.018	-0.057	
95% CI	(-0.21, 0.25)	(-0.30, 0.19)	
Subgroup*Treatment Interaction p-value	0.1656	0.1589	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (5.3)	2 (12.5)	7 (16.3)
No	18 (94.7)	14 (87.5)	36 (83.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	1.36	
95% CI of the inverse odds ratio	(0.40, 30.66)	(0.25, 7.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.09	1.30	
95% CI of the inverse risk ratio	(0.41, 23.42)	(0.30, 5.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.02	-3.78	
95% CI of the absolute risk difference	(-25.93, 3.90)	(-23.38, 15.83)	
p-value	0.2329	0.7197	
p-value of Breslow-Day Test for Homogeneity [3]	0.1690	0.7128	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (47.4)	5 (31.3)	15 (34.9)
No	10 (52.6)	11 (68.8)	28 (65.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	1.18	
95% CI of the inverse odds ratio	(0.20, 1.78)	(0.34, 4.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.12	
95% CI of the inverse risk ratio	(0.39, 1.38)	(0.48, 2.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.48	-3.63	
95% CI of the absolute risk difference	(-14.10, 39.07)	(-30.44, 23.18)	
p-value	0.3521	0.7932	
p-value of Breslow-Day Test for Homogeneity [3]	0.5773	0.5661	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (10.5)	2 (12.5)	4 (9.3)
No	17 (89.5)	14 (87.5)	39 (90.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.72	
95% CI of the inverse odds ratio	(0.15, 5.22)	(0.12, 4.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.74	
95% CI of the inverse risk ratio	(0.18, 4.42)	(0.15, 3.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.22	3.20	
95% CI of the absolute risk difference	(-15.08, 17.53)	(-15.19, 21.58)	
p-value	0.8805	0.7179	
p-value of Breslow-Day Test for Homogeneity [3]	0.5468	0.6477	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (21.1)	5 (31.3)	8 (18.6)
No	15 (78.9)	11 (68.8)	35 (81.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.50	
95% CI of the inverse odds ratio	(0.22, 3.29)	(0.14, 1.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.60	
95% CI of the inverse risk ratio	(0.30, 2.58)	(0.23, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.45	12.65	
95% CI of the absolute risk difference	(-19.26, 24.16)	(-12.87, 38.16)	
p-value	0.8220	0.2975	
p-value of Breslow-Day Test for Homogeneity [3]	0.8374	0.3676	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (5.3)	3 (18.8)	5 (11.6)
No	18 (94.7)	13 (81.3)	38 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	0.57	
95% CI of the inverse odds ratio	(0.26, 21.79)	(0.12, 2.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.21	0.62	
95% CI of the inverse risk ratio	(0.28, 17.65)	(0.17, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.36	7.12	
95% CI of the absolute risk difference	(-20.24, 7.51)	(-14.27, 28.51)	
p-value	0.4345	0.4775	
p-value of Breslow-Day Test for Homogeneity [3]	0.7100	0.4311	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (21.1)	7 (43.8)	11 (25.6)
No	15 (78.9)	9 (56.3)	32 (74.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.44	
95% CI of the inverse odds ratio	(0.35, 4.72)	(0.13, 1.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	0.58	
95% CI of the inverse risk ratio	(0.44, 3.33)	(0.28, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.53	18.17	
95% CI of the absolute risk difference	(-27.03, 17.97)	(-9.42, 45.75)	
p-value	0.7011	0.1778	
p-value of Breslow-Day Test for Homogeneity [3]	0.8892	0.2580	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (31.6)	5 (31.3)	6 (14.0)
No	13 (68.4)	11 (68.8)	37 (86.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.35	0.36	
95% CI of the inverse odds ratio	(0.10, 1.28)	(0.09, 1.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	0.45	
95% CI of the inverse risk ratio	(0.16, 1.19)	(0.16, 1.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	17.63	17.30	
95% CI of the absolute risk difference	(-5.70, 40.95)	(-7.67, 42.26)	
p-value	0.1053	0.1294	
p-value of Breslow-Day Test for Homogeneity [3]	0.0851	0.2379	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (36.8)	9 (56.3)	12 (27.9)
No	12 (63.2)	7 (43.8)	31 (72.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.30	
95% CI of the inverse odds ratio	(0.21, 2.09)	(0.09, 0.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	0.50	
95% CI of the inverse risk ratio	(0.35, 1.62)	(0.26, 0.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.94	28.34	
95% CI of the absolute risk difference	(-16.56, 34.43)	(0.58, 56.10)	
p-value	0.4817	0.0432	
p-value of Breslow-Day Test for Homogeneity [3]	0.4311	0.0814	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (15.8)	1 (6.3)	1 (2.3)
No	16 (84.2)	15 (93.8)	42 (97.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	0.36	
95% CI of the inverse odds ratio	(0.01, 1.31)	(0.02, 6.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.15	0.37	
95% CI of the inverse risk ratio	(0.02, 1.33)	(0.02, 5.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.46	3.92	
95% CI of the absolute risk difference	(-3.54, 30.47)	(-8.76, 16.61)	
p-value	0.0467	0.4590	
p-value of Breslow-Day Test for Homogeneity [3]	0.0161	0.3125	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (42.1)	6 (37.5)	12 (27.9)
No	11 (57.9)	10 (62.5)	31 (72.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	0.65	
95% CI of the inverse odds ratio	(0.17, 1.65)	(0.19, 2.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.74	
95% CI of the inverse risk ratio	(0.32, 1.35)	(0.34, 1.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.20	9.59	
95% CI of the absolute risk difference	(-11.74, 40.13)	(-17.65, 36.84)	
p-value	0.2702	0.4768	
p-value of Breslow-Day Test for Homogeneity [3]	0.1562	0.2944	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (10.5)	1 (6.3)	3 (7.0)
No	17 (89.5)	15 (93.8)	40 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	1.13	
95% CI of the inverse odds ratio	(0.10, 4.17)	(0.11, 11.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	1.12	
95% CI of the inverse risk ratio	(0.12, 3.65)	(0.13, 9.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.55	-0.73	
95% CI of the absolute risk difference	(-12.21, 19.31)	(-14.82, 13.37)	
p-value	0.6361	0.9214	
p-value of Breslow-Day Test for Homogeneity [3]	0.5638	0.4765	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (26.3)	3 (18.8)	5 (11.6)
No	14 (73.7)	13 (81.3)	38 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.37	0.57	
95% CI of the inverse odds ratio	(0.09, 1.47)	(0.12, 2.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	0.62	
95% CI of the inverse risk ratio	(0.14, 1.35)	(0.17, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.69	7.12	
95% CI of the absolute risk difference	(-7.31, 36.68)	(-14.27, 28.51)	
p-value	0.1472	0.4775	
p-value of Breslow-Day Test for Homogeneity [3]	0.1452	0.7932	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (10.5)	3 (18.8)	5 (11.6)
No	17 (89.5)	13 (81.3)	38 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.57	
95% CI of the inverse odds ratio	(0.20, 6.35)	(0.12, 2.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	0.62	
95% CI of the inverse risk ratio	(0.23, 5.20)	(0.17, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.10	7.12	
95% CI of the absolute risk difference	(-17.90, 15.70)	(-14.27, 28.51)	
p-value	0.8994	0.4775	
p-value of Breslow-Day Test for Homogeneity [3]	0.9986	0.9815	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (21.1)	4 (25.0)	5 (11.6)
No	15 (78.9)	12 (75.0)	38 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.49	0.39	
95% CI of the inverse odds ratio	(0.12, 2.09)	(0.09, 1.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	0.47	
95% CI of the inverse risk ratio	(0.17, 1.83)	(0.14, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.42	13.37	
95% CI of the absolute risk difference	(-11.26, 30.11)	(-9.91, 36.65)	
p-value	0.3314	0.2041	
p-value of Breslow-Day Test for Homogeneity [3]	0.3268	0.6081	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (15.8)	1 (6.3)	5 (11.6)
No	16 (84.2)	15 (93.8)	38 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	1.97	
95% CI of the inverse odds ratio	(0.15, 3.29)	(0.21, 18.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.86	
95% CI of the inverse risk ratio	(0.20, 2.77)	(0.24, 14.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.16	-5.38	
95% CI of the absolute risk difference	(-14.83, 23.15)	(-20.63, 9.87)	
p-value	0.6523	0.5435	
p-value of Breslow-Day Test for Homogeneity [3]	0.4753	0.7990	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (47.4)	4 (25.0)	9 (20.9)
No	10 (52.6)	12 (75.0)	34 (79.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.29	0.79	
95% CI of the inverse odds ratio	(0.09, 0.94)	(0.21, 3.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	0.84	
95% CI of the inverse risk ratio	(0.21, 0.94)	(0.30, 2.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	26.44	4.07	
95% CI of the absolute risk difference	(0.91, 51.97)	(-20.38, 28.52)	
p-value	0.0345	0.7374	
p-value of Breslow-Day Test for Homogeneity [3]	0.0981	0.6972	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (5.3)	2 (12.5)	2 (4.7)
No	18 (94.7)	14 (87.5)	41 (95.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.34	
95% CI of the inverse odds ratio	(0.07, 10.31)	(0.04, 2.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.37	
95% CI of the inverse risk ratio	(0.09, 9.16)	(0.06, 2.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.61	7.85	
95% CI of the absolute risk difference	(-11.24, 12.46)	(-9.54, 25.23)	
p-value	0.9175	0.2864	
p-value of Breslow-Day Test for Homogeneity [3]	0.7089	0.5271	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (36.8)	2 (12.5)	6 (14.0)
No	12 (63.2)	14 (87.5)	37 (86.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	1.14	
95% CI of the inverse odds ratio	(0.08, 0.99)	(0.20, 6.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	1.12	
95% CI of the inverse risk ratio	(0.15, 0.98)	(0.25, 4.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	22.89	-1.45	
95% CI of the absolute risk difference	(-1.15, 46.92)	(-20.69, 17.78)	
p-value	0.0412	0.8847	
p-value of Breslow-Day Test for Homogeneity [3]	0.0458	0.9459	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (5.3)	2 (12.5)	4 (9.3)
No	18 (94.7)	14 (87.5)	39 (90.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.85	0.72	
95% CI of the inverse odds ratio	(0.19, 17.72)	(0.12, 4.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	0.74	
95% CI of the inverse risk ratio	(0.21, 14.78)	(0.15, 3.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.04	3.20	
95% CI of the absolute risk difference	(-17.31, 9.23)	(-15.19, 21.58)	
p-value	0.5902	0.7179	
p-value of Breslow-Day Test for Homogeneity [3]	0.5949	0.7246	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (26.3)	6 (37.5)	7 (16.3)
No	14 (73.7)	10 (62.5)	36 (83.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	0.32	
95% CI of the inverse odds ratio	(0.15, 2.00)	(0.09, 1.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.43	
95% CI of the inverse risk ratio	(0.22, 1.70)	(0.17, 1.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.04	21.22	
95% CI of the absolute risk difference	(-12.63, 32.70)	(-4.94, 47.38)	
p-value	0.3564	0.0804	
p-value of Breslow-Day Test for Homogeneity [3]	0.3852	0.2452	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	21 (14.2)	16 (11.9)	30 (11.5)
No	127 (85.8)	119 (88.1)	230 (88.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.97	
95% CI of the inverse odds ratio	(0.43, 1.43)	(0.51, 1.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.97	
95% CI of the inverse risk ratio	(0.48, 1.37)	(0.55, 1.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.65	0.31	
95% CI of the absolute risk difference	(-4.18, 9.48)	(-6.38, 7.01)	
p-value	0.4363	0.9266	
p-value of Breslow-Day Test for Homogeneity [3]	0.1690	0.7128	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	46 (31.1)	43 (31.9)	71 (27.3)
No	102 (68.9)	92 (68.1)	189 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.80	
95% CI of the inverse odds ratio	(0.54, 1.30)	(0.51, 1.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.86	
95% CI of the inverse risk ratio	(0.64, 1.20)	(0.62, 1.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.77	4.54	
95% CI of the absolute risk difference	(-5.44, 12.99)	(-5.00, 14.09)	
p-value	0.4178	0.3445	
p-value of Breslow-Day Test for Homogeneity [3]	0.5773	0.5661	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (8.8)	16 (11.9)	34 (13.1)
No	135 (91.2)	119 (88.1)	226 (86.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	1.12	
95% CI of the inverse odds ratio	(0.80, 3.06)	(0.59, 2.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.49	1.10	
95% CI of the inverse risk ratio	(0.81, 2.73)	(0.63, 1.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.29	-1.23	
95% CI of the absolute risk difference	(-10.42, 1.84)	(-8.05, 5.60)	
p-value	0.1916	0.7284	
p-value of Breslow-Day Test for Homogeneity [3]	0.5468	0.6477	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	36 (24.3)	34 (25.2)	63 (24.2)
No	112 (75.7)	101 (74.8)	197 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.95	
95% CI of the inverse odds ratio	(0.62, 1.59)	(0.59, 1.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.96	
95% CI of the inverse risk ratio	(0.70, 1.42)	(0.67, 1.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.09	0.95	
95% CI of the absolute risk difference	(-8.56, 8.75)	(-8.03, 9.94)	
p-value	0.9831	0.8344	
p-value of Breslow-Day Test for Homogeneity [3]	0.8374	0.3676	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	19 (12.8)	23 (17.0)	48 (18.5)
No	129 (87.2)	112 (83.0)	212 (81.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.54	1.10	
95% CI of the inverse odds ratio	(0.87, 2.73)	(0.64, 1.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.08	
95% CI of the inverse risk ratio	(0.88, 2.35)	(0.69, 1.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.62	-1.42	
95% CI of the absolute risk difference	(-12.79, 1.54)	(-9.33, 6.48)	
p-value	0.1404	0.7266	
p-value of Breslow-Day Test for Homogeneity [3]	0.7100	0.4311	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	36 (24.3)	39 (28.9)	71 (27.3)
No	112 (75.7)	96 (71.1)	189 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.92	
95% CI of the inverse odds ratio	(0.73, 1.86)	(0.58, 1.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.95	
95% CI of the inverse risk ratio	(0.79, 1.59)	(0.68, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.98	1.58	
95% CI of the absolute risk difference	(-11.76, 5.80)	(-7.79, 10.95)	
p-value	0.5101	0.7395	
p-value of Breslow-Day Test for Homogeneity [3]	0.8892	0.2580	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	19 (12.8)	23 (17.0)	39 (15.0)
No	129 (87.2)	112 (83.0)	221 (85.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	0.86	
95% CI of the inverse odds ratio	(0.66, 2.16)	(0.49, 1.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.88	
95% CI of the inverse risk ratio	(0.70, 1.95)	(0.55, 1.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.16	2.04	
95% CI of the absolute risk difference	(-9.08, 4.76)	(-5.65, 9.72)	
p-value	0.5476	0.5976	
p-value of Breslow-Day Test for Homogeneity [3]	0.0851	0.2379	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	43 (29.1)	44 (32.6)	80 (30.8)
No	105 (70.9)	91 (67.4)	180 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.92	
95% CI of the inverse odds ratio	(0.70, 1.69)	(0.59, 1.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.94	
95% CI of the inverse risk ratio	(0.78, 1.45)	(0.70, 1.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.72	1.82	
95% CI of the absolute risk difference	(-10.93, 7.50)	(-7.87, 11.52)	
p-value	0.7166	0.7111	
p-value of Breslow-Day Test for Homogeneity [3]	0.4311	0.0814	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (8.8)	13 (9.6)	35 (13.5)
No	135 (91.2)	122 (90.4)	225 (86.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	1.46	
95% CI of the inverse odds ratio	(0.83, 3.16)	(0.74, 2.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	1.40	
95% CI of the inverse risk ratio	(0.84, 2.80)	(0.77, 2.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.68	-3.83	
95% CI of the absolute risk difference	(-10.84, 1.49)	(-10.31, 2.65)	
p-value	0.1585	0.2689	
p-value of Breslow-Day Test for Homogeneity [3]	0.0161	0.3125	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	42 (28.4)	38 (28.1)	87 (33.5)
No	106 (71.6)	97 (71.9)	173 (66.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	1.28	
95% CI of the inverse odds ratio	(0.82, 1.97)	(0.81, 2.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.19	
95% CI of the inverse risk ratio	(0.87, 1.60)	(0.86, 1.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.08	-5.31	
95% CI of the absolute risk difference	(-14.34, 4.17)	(-14.82, 4.20)	
p-value	0.2884	0.2815	
p-value of Breslow-Day Test for Homogeneity [3]	0.1562	0.2944	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (7.4)	22 (16.3)	22 (8.5)
No	137 (92.6)	113 (83.7)	238 (91.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.47	
95% CI of the inverse odds ratio	(0.54, 2.45)	(0.25, 0.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	0.52	
95% CI of the inverse risk ratio	(0.57, 2.28)	(0.30, 0.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.03	7.83	
95% CI of the absolute risk difference	(-6.44, 4.38)	(0.75, 14.92)	
p-value	0.7140	0.0189	
p-value of Breslow-Day Test for Homogeneity [3]	0.5638	0.4765	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (16.9)	32 (23.7)	47 (18.1)
No	123 (83.1)	103 (76.3)	213 (81.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.71	
95% CI of the inverse odds ratio	(0.64, 1.85)	(0.43, 1.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.76	
95% CI of the inverse risk ratio	(0.69, 1.66)	(0.51, 1.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.19	5.63	
95% CI of the absolute risk difference	(-8.82, 6.45)	(-2.94, 14.19)	
p-value	0.7627	0.1848	
p-value of Breslow-Day Test for Homogeneity [3]	0.1452	0.7932	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	17 (11.5)	27 (20.0)	33 (12.7)
No	131 (88.5)	108 (80.0)	227 (87.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.58	
95% CI of the inverse odds ratio	(0.60, 2.09)	(0.33, 1.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	0.63	
95% CI of the inverse risk ratio	(0.64, 1.91)	(0.40, 1.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.21	7.31	
95% CI of the absolute risk difference	(-7.75, 5.33)	(-0.56, 15.18)	
p-value	0.7210	0.0550	
p-value of Breslow-Day Test for Homogeneity [3]	0.9986	0.9815	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (16.9)	36 (26.7)	46 (17.7)
No	123 (83.1)	99 (73.3)	214 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.59	
95% CI of the inverse odds ratio	(0.62, 1.81)	(0.36, 0.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.66	
95% CI of the inverse risk ratio	(0.67, 1.63)	(0.45, 0.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.80	8.97	
95% CI of the absolute risk difference	(-8.41, 6.81)	(0.19, 17.76)	
p-value	0.8375	0.0370	
p-value of Breslow-Day Test for Homogeneity [3]	0.3268	0.6081	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (10.8)	13 (9.6)	35 (13.5)
No	132 (89.2)	122 (90.4)	225 (86.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	1.46	
95% CI of the inverse odds ratio	(0.68, 2.41)	(0.74, 2.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.40	
95% CI of the inverse risk ratio	(0.71, 2.17)	(0.77, 2.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.65	-3.83	
95% CI of the absolute risk difference	(-9.15, 3.85)	(-10.31, 2.65)	
p-value	0.4363	0.2689	
p-value of Breslow-Day Test for Homogeneity [3]	0.4753	0.7990	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	48 (32.4)	37 (27.4)	74 (28.5)
No	100 (67.6)	98 (72.6)	186 (71.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	1.05	
95% CI of the inverse odds ratio	(0.54, 1.28)	(0.66, 1.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	1.04	
95% CI of the inverse risk ratio	(0.65, 1.19)	(0.74, 1.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.97	-1.05	
95% CI of the absolute risk difference	(-5.35, 13.30)	(-10.37, 8.26)	
p-value	0.3996	0.8250	
p-value of Breslow-Day Test for Homogeneity [3]	0.0981	0.6972	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (4.1)	11 (8.1)	15 (5.8)
No	142 (95.9)	124 (91.9)	245 (94.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	0.69	
95% CI of the inverse odds ratio	(0.55, 3.82)	(0.31, 1.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	0.71	
95% CI of the inverse risk ratio	(0.56, 3.59)	(0.33, 1.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.72	2.38	
95% CI of the absolute risk difference	(-5.97, 2.54)	(-3.04, 7.79)	
p-value	0.4509	0.3658	
p-value of Breslow-Day Test for Homogeneity [3]	0.7089	0.5271	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (20.3)	25 (18.5)	56 (21.5)
No	118 (79.7)	110 (81.5)	204 (78.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	1.21	
95% CI of the inverse odds ratio	(0.66, 1.78)	(0.71, 2.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.16	
95% CI of the inverse risk ratio	(0.72, 1.58)	(0.76, 1.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.27	-3.02	
95% CI of the absolute risk difference	(-9.45, 6.91)	(-11.26, 5.22)	
p-value	0.7627	0.4808	
p-value of Breslow-Day Test for Homogeneity [3]	0.0458	0.9459	

AMNOG Table SE22.10.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (4.1)	10 (7.4)	10 (3.8)
No	142 (95.9)	125 (92.6)	250 (96.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.50	
95% CI of the inverse odds ratio	(0.34, 2.66)	(0.20, 1.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.52	
95% CI of the inverse risk ratio	(0.35, 2.56)	(0.22, 1.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.21	3.56	
95% CI of the absolute risk difference	(-3.74, 4.15)	(-1.44, 8.56)	
p-value	0.9172	0.1257	
p-value of Breslow-Day Test for Homogeneity [3]	0.5949	0.7246	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (20.3)	35 (25.9)	53 (20.4)
No	118 (79.7)	100 (74.1)	207 (79.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.73	
95% CI of the inverse odds ratio	(0.61, 1.66)	(0.45, 1.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.79	
95% CI of the inverse risk ratio	(0.67, 1.50)	(0.54, 1.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.11	5.54	
95% CI of the absolute risk difference	(-8.23, 8.01)	(-3.33, 14.41)	
p-value	0.9780	0.2094	
p-value of Breslow-Day Test for Homogeneity [3]	0.3852	0.2452	

Madrigal Pharmaceuticals, Inc. Page 1 of 4
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.10.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes
Bodily Pain



Patients with result at given visit			
MGL-3196 80 mg	17	19	17
MGL-3196 100 mg	16	14	12
Placebo	37	39	35

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 4
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.10.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes
General Health



Patients with result at given visit			
MGL-3196 80 mg	18	19	17
MGL-3196 100 mg	16	14	12
Placebo	37	39	35

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 4
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.10.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No
Bodily Pain



Patients with result at given visit			
MGL-3196 80 mg	140	138	119
MGL-3196 100 mg	122	122	102
Placebo	243	228	204

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 4 of 4
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.10.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No
General Health



Patients with result at given visit			
MGL-3196 80 mg	140	138	119
MGL-3196 100 mg	122	122	102
Placebo	243	228	204

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Physical Functioning						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	80.52 (25.79)	73.79 (24.52)	74.70 (24.27)			
Median	90.00	85.00	85.00			
IQR: Q1, Q3	80.00, 100.00	55.00, 95.00	60.00, 95.00			
Min, Max	15.0, 100.0	20.0, 100.0	25.0, 100.0			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	77.24 (29.54)	76.77 (22.16)	79.03 (29.79)	-1.79 (2.65)	1.55 (4.22)	2.76 (3.21)
Median	90.00	80.00	90.00	0	0	0
IQR: Q1, Q3	65.00, 100.00	65.00, 95.00	65.00, 100.00	-10.00, 5.00	-5.00, 10.00	0.00, 10.00
Min, Max	5.0, 100.0	15.0, 100.0	5.0, 100.0	-40.0, 20.0	-45.0, 70.0	-50.0, 35.0
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	83.85 (28.72)	81.07 (20.79)	77.47 (23.41)	5.38 (1.54)	5.19 (2.74)	0.78 (2.80)
Median	95.00	87.50	85.00	5.00	0	0
IQR: Q1, Q3	95.00, 100.00	72.50, 97.50	60.00, 100.00	0.00, 10.00	-5.00, 15.00	-5.00, 7.50
Min, Max	10.0, 100.0	25.0, 100.0	30.0, 100.0	-5.0, 20.0	-20.0, 35.0	-30.0, 35.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Role Physical						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	83.42 (29.47)	73.50 (27.98)	78.05 (19.89)			
Median	100.00	75.00	75.00			
IQR: Q1, Q3	81.30, 100.00	56.30, 100.00	62.50, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	37.5, 100.0			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	75.44 (28.44)	76.02 (25.11)	80.86 (24.88)	-6.25 (2.96)	1.51 (3.98)	1.51 (3.85)
Median	81.30	81.30	93.80	0	0	0
IQR: Q1, Q3	62.50, 100.00	56.30, 100.00	56.30, 100.00	-18.70, 0.00	-6.30, 6.20	0.00, 18.70
Min, Max	0.0, 100.0	12.5, 100.0	18.8, 100.0	-43.8, 25.0	-37.5, 68.7	-56.2, 31.3
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	83.66 (30.10)	83.71 (22.13)	81.26 (20.46)	2.15 (1.43)	7.87 (4.01)	1.55 (2.97)
Median	100.00	96.90	87.50	0	0	0
IQR: Q1, Q3	87.50, 100.00	75.00, 100.00	62.50, 100.00	0.00, 6.20	0.00, 12.50	-6.30, 9.35
Min, Max	0.0, 100.0	25.0, 100.0	50.0, 100.0	-12.5, 25.0	-18.8, 81.3	-25.0, 43.8

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Bodily Pain						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	66.0 (26.7)	60.0 (29.3)	66.4 (25.3)			
Median	72.0	52.0	72.0			
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	41.0, 84.0			
Min, Max	0, 100	0, 100	22, 100			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	62.9 (25.7)	66.0 (24.1)	68.3 (21.3)	-1.6 (3.6)	4.7 (3.5)	-0.8 (4.1)
Median	62.0	62.0	72.0	0	0	0
IQR: Q1, Q3	52.0, 74.0	42.0, 84.0	52.0, 84.0	-10.0, 5.5	0.0, 10.0	-16.0, 12.0
Min, Max	0, 100	22, 100	10, 100	-43, 52	-29, 52	-49, 43
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	72.4 (28.1)	78.4 (23.7)	70.3 (23.2)	6.3 (2.3)	17.2 (4.5)	4.5 (4.4)
Median	74.0	84.0	72.0	0	2.0	0
IQR: Q1, Q3	61.0, 100.0	62.0, 100.0	51.0, 84.0	0.0, 12.0	0.0, 33.0	-3.0, 16.0
Min, Max	0, 100	22, 100	22, 100	-12, 42	-12, 62	-49, 53

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
General Health						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	61.41 (24.41)	55.59 (20.19)	57.21 (23.11)			
Median	67.00	57.00	55.00			
IQR: Q1, Q3	50.00, 77.00	45.00, 67.00	40.00, 72.00			
Min, Max	10.0, 97.0	10.0, 92.0	15.0, 92.0			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	60.17 (24.45)	60.32 (19.76)	60.65 (25.41)	1.21 (2.14)	3.76 (3.33)	4.17 (2.66)
Median	62.00	57.00	67.00	0	2.00	3.00
IQR: Q1, Q3	45.00, 77.00	52.00, 72.00	35.00, 82.00	-6.50, 10.00	-5.00, 15.00	-5.00, 12.00
Min, Max	10.0, 100.0	10.0, 100.0	15.0, 100.0	-25.0, 22.0	-35.0, 37.0	-22.0, 48.0
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	67.96 (19.98)	64.14 (15.03)	64.00 (23.58)	5.00 (2.54)	6.89 (3.36)	6.29 (2.74)
Median	72.00	67.00	67.00	2.00	10.00	10.00
IQR: Q1, Q3	62.00, 82.00	59.50, 77.00	52.00, 82.00	0.00, 10.00	-5.00, 20.00	-2.50, 16.00
Min, Max	25.0, 100.0	25.0, 85.0	10.0, 97.0	-20.0, 47.0	-35.0, 32.0	-42.0, 30.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Vitality						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	58.87 (22.50)	56.71 (21.84)	57.98 (19.84)			
Median	62.50	56.30	62.50			
IQR: Q1, Q3	56.30, 75.00	50.00, 75.00	43.80, 75.00			
Min, Max	6.3, 93.8	0.0, 81.3	25.0, 87.5			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	55.19 (28.06)	57.49 (20.69)	57.89 (24.15)	-2.91 (2.66)	-0.64 (2.78)	-0.64 (3.00)
Median	56.30	56.30	56.30	-3.10	0	0
IQR: Q1, Q3	43.80, 75.00	43.80, 75.00	37.50, 75.00	-12.50, 6.20	-6.30, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	18.8, 93.8	12.5, 100.0	-25.0, 25.0	-31.2, 43.7	-31.3, 43.7
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	60.60 (21.62)	60.51 (20.34)	62.74 (19.07)	1.20 (3.06)	1.15 (3.09)	6.25 (2.55)
Median	62.50	65.65	62.50	0	0	3.10
IQR: Q1, Q3	43.80, 75.00	50.00, 75.00	43.80, 75.00	-12.50, 12.50	-6.30, 6.30	0.00, 12.50
Min, Max	6.3, 93.8	6.3, 87.5	18.8, 100.0	-31.2, 37.5	-31.2, 37.5	-12.5, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Social Functioning						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	82.33 (26.63)	81.47 (26.22)	81.06 (22.56)			
Median	100.00	100.00	87.50			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	12.5, 100.0			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	79.74 (26.39)	82.66 (21.08)	80.65 (22.56)	-0.89 (4.31)	0.00 (4.47)	0.86 (4.80)
Median	87.50	100.00	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00	-12.50, 6.25	0.00, 0.00	-12.50, 12.50
Min, Max	12.5, 100.0	37.5, 100.0	12.5, 100.0	-50.0, 50.0	-50.0, 87.5	-50.0, 50.0
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	80.77 (27.67)	85.71 (24.23)	87.50 (18.30)	-0.96 (4.33)	2.31 (4.33)	7.14 (4.24)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00	-12.50, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	12.5, 100.0	25.0, 100.0	37.5, 100.0	-37.5, 50.0	-50.0, 62.5	-37.5, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Role Emotional						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	87.35 (18.04)	83.91 (21.13)	81.06 (21.48)			
Median	100.00	91.70	83.30			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	41.7, 100.0	8.3, 100.0	25.0, 100.0			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	83.04 (22.98)	89.52 (18.25)	82.80 (23.26)	-2.68 (2.88)	4.89 (3.00)	1.44 (3.56)
Median	91.70	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	83.30, 100.00	66.70, 100.00	-12.50, 0.00	0.00, 16.70	0.00, 8.40
Min, Max	25.0, 100.0	25.0, 100.0	16.7, 100.0	-25.0, 25.0	-33.3, 41.7	-33.3, 50.0
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	85.25 (19.63)	90.48 (17.38)	83.04 (22.44)	-0.64 (2.69)	6.48 (4.39)	1.79 (3.28)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	83.30, 100.00	58.30, 100.00	-8.30, 8.30	0.00, 25.00	0.00, 8.35
Min, Max	33.3, 100.0	25.0, 100.0	33.3, 100.0	-33.3, 25.0	-50.0, 50.0	-41.7, 33.4

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Mental Health						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	78.3 (17.5)	77.9 (13.5)	76.2 (15.4)			
Median	85.0	80.0	75.0			
IQR: Q1, Q3	70.0, 90.0	75.0, 85.0	65.0, 90.0			
Min, Max	40, 100	35, 100	45, 100			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	75.9 (20.8)	78.4 (15.8)	75.0 (20.0)	-0.9 (3.3)	-0.3 (2.2)	-0.5 (2.7)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	75.0, 90.0	65.0, 90.0	-12.5, 10.0	-5.0, 5.0	-5.0, 5.0
Min, Max	20, 100	20, 100	20, 100	-35, 35	-35, 35	-30, 25
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	76.0 (20.4)	78.6 (15.6)	78.6 (16.7)	-1.3 (2.6)	0.2 (2.2)	2.7 (2.5)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	72.5, 90.0	75.0, 90.0	-10.0, 5.0	-5.0, 5.0	-5.0, 12.5
Min, Max	30, 100	30, 95	35, 100	-35, 25	-25, 35	-30, 30

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Mental Component Score						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	51.94 (8.56)	52.20 (7.35)	50.80 (9.02)			
Median	54.80	52.90	52.60			
IQR: Q1, Q3	46.80, 57.30	48.00, 58.20	45.30, 57.70			
Min, Max	29.4, 69.0	32.3, 63.6	26.5, 62.8			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	50.62 (10.31)	52.91 (8.51)	50.15 (11.91)	-0.66 (1.58)	0.32 (1.24)	-0.16 (1.74)
Median	54.00	54.60	53.50	-1.05	0.20	0.70
IQR: Q1, Q3	45.00, 58.20	48.10, 58.60	41.30, 59.10	-5.85, 4.00	-2.90, 2.70	-4.70, 6.40
Min, Max	25.0, 62.3	21.2, 62.7	23.1, 66.3	-16.4, 19.0	-13.0, 19.1	-19.0, 19.6
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	50.39 (9.50)	52.56 (8.46)	52.41 (9.80)	-1.29 (1.31)	0.07 (1.45)	2.11 (1.35)
Median	53.55	53.60	56.20	-1.25	0	1.90
IQR: Q1, Q3	43.30, 58.10	50.40, 58.80	47.30, 59.00	-4.90, 3.00	-6.10, 2.90	-0.35, 6.70
Min, Max	29.2, 62.3	27.0, 62.5	26.5, 63.2	-17.3, 13.0	-15.2, 19.6	-18.8, 21.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Physical Component Score						
Baseline						
m	30	31	35			
n	29	29	33			
Mean (SD)	48.74 (10.13)	45.22 (10.30)	47.39 (9.17)			
Median	52.20	46.20	49.70			
IQR: Q1, Q3	49.00, 55.50	38.70, 53.70	39.50, 55.60			
Min, Max	21.1, 59.4	21.2, 60.3	26.4, 59.1			
Week 24						
m	30	31	35			
n	29	31	31	28	29	29
Mean (SD/SE)	47.24 (9.99)	46.85 (9.17)	49.11 (10.87)	-0.84 (0.97)	1.13 (1.62)	0.96 (1.13)
Median	48.70	49.10	51.90	-1.35	-0.50	1.80
IQR: Q1, Q3	43.90, 52.60	39.20, 54.50	43.20, 56.70	-3.90, 3.10	-2.50, 3.30	-1.50, 3.70
Min, Max	21.8, 61.4	24.6, 61.0	19.0, 63.0	-10.2, 9.1	-22.0, 21.7	-15.1, 11.1
Week 52						
m	29	30	35			
n	26	28	29	26	27	28
Mean (SD/SE)	51.37 (10.79)	50.50 (8.98)	49.18 (9.48)	2.77 (0.61)	4.33 (1.23)	1.27 (1.04)
Median	55.15	52.30	49.40	2.55	2.70	0.55
IQR: Q1, Q3	53.10, 58.20	48.70, 56.75	44.50, 57.00	-0.10, 5.20	0.60, 9.40	-2.90, 4.30
Min, Max	23.4, 62.5	26.9, 61.1	26.0, 63.9	-1.5, 9.3	-10.6, 18.6	-7.5, 13.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Physical Functioning						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	80.00 (13.60)	83.13 (16.46)	74.58 (16.58)			
Median	75.00	90.00	75.00			
IQR: Q1, Q3	70.00, 95.00	70.00, 95.00	62.50, 87.50			
Min, Max	60.0, 100.0	55.0, 100.0	45.0, 100.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	89.17 (13.62)	77.14 (25.96)	69.58 (27.67)	10.45 (3.53)	-3.57 (11.84)	-5.00 (5.33)
Median	95.00	80.00	75.00	10.00	0	-2.50
IQR: Q1, Q3	82.50, 100.00	65.00, 95.00	45.00, 95.00	0.00, 20.00	-10.00, 5.00	-15.00, 7.50
Min, Max	55.0, 100.0	25.0, 100.0	25.0, 100.0	-5.0, 30.0	-65.0, 40.0	-40.0, 20.0
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	82.27 (23.81)	75.63 (21.95)	67.22 (26.09)	3.50 (7.85)	-7.50 (6.34)	-3.28 (5.66)
Median	95.00	80.00	73.60	2.50	-5.00	2.50
IQR: Q1, Q3	65.00, 100.00	62.50, 92.50	45.00, 85.00	-10.00, 30.00	-15.00, 0.00	-20.00, 10.00
Min, Max	30.0, 100.0	35.0, 100.0	30.0, 100.0	-45.0, 35.0	-40.0, 20.0	-30.0, 20.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Role Physical						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	76.15 (34.55)	85.95 (24.25)	66.68 (27.08)			
Median	87.50	100.00	65.65			
IQR: Q1, Q3	75.00, 100.00	71.90, 100.00	43.75, 93.75			
Min, Max	0.0, 100.0	43.8, 100.0	31.3, 100.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	77.63 (28.11)	77.70 (25.20)	71.89 (26.44)	5.69 (6.27)	-6.24 (12.12)	5.21 (3.52)
Median	93.75	81.30	71.90	12.50	0	0
IQR: Q1, Q3	56.30, 100.00	43.80, 100.00	56.25, 100.00	0.00, 25.00	-25.00, 0.00	0.00, 12.50
Min, Max	31.3, 100.0	43.8, 100.0	25.0, 100.0	-31.2, 31.3	-56.2, 50.0	-12.5, 31.3
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	77.28 (34.71)	75.03 (30.25)	60.02 (28.13)	4.37 (9.90)	-10.93 (10.01)	-1.87 (5.82)
Median	100.00	87.55	53.15	0	-6.20	0
IQR: Q1, Q3	43.80, 100.00	53.15, 96.90	50.00, 81.30	-6.20, 12.50	-18.75, 0.00	-12.50, 12.50
Min, Max	0.0, 100.0	25.0, 100.0	6.3, 100.0	-37.5, 81.2	-68.8, 31.3	-37.5, 18.8

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Bodily Pain						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	72.5 (27.3)	77.9 (17.1)	64.8 (25.6)			
Median	74.0	84.0	57.0			
IQR: Q1, Q3	62.0, 100.0	73.0, 84.0	51.0, 92.0			
Min, Max	22, 100	41, 100	22, 100			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	80.3 (25.5)	64.6 (22.1)	58.4 (27.4)	8.5 (7.4)	-10.1 (7.4)	-6.3 (4.3)
Median	92.0	62.0	51.0	0	0	-5.0
IQR: Q1, Q3	61.5, 100.0	42.0, 84.0	41.0, 79.0	0.0, 22.0	-23.0, 0.0	-16.0, 0.0
Min, Max	32, 100	41, 100	22, 100	-21, 68	-42, 16	-29, 22
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	77.2 (28.2)	69.4 (28.4)	61.6 (26.8)	6.1 (7.9)	-8.5 (7.3)	0.1 (5.8)
Median	100.0	78.0	56.5	0	0	0
IQR: Q1, Q3	52.0, 100.0	46.5, 92.0	51.0, 74.0	0.0, 0.0	-25.5, 5.0	-1.0, 12.0
Min, Max	22, 100	22, 100	12, 100	-23, 68	-43, 16	-43, 23

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
General Health						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	64.55 (9.61)	70.50 (20.93)	65.00 (12.90)			
Median	67.00	74.50	64.50			
IQR: Q1, Q3	57.00, 72.00	54.50, 84.50	54.50, 77.00			
Min, Max	50.0, 77.0	37.0, 100.0	45.0, 82.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	66.50 (22.90)	66.00 (21.99)	60.42 (15.82)	7.09 (4.29)	-0.29 (7.80)	-4.58 (4.41)
Median	74.50	77.00	54.50	10.00	0	0
IQR: Q1, Q3	56.00, 82.00	45.00, 87.00	52.00, 76.00	5.00, 18.00	-15.00, 0.00	-12.50, 5.00
Min, Max	10.0, 90.0	37.0, 87.0	37.0, 82.0	-25.0, 25.0	-27.0, 40.0	-40.0, 20.0
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	66.82 (22.08)	58.63 (24.46)	61.10 (13.10)	7.50 (4.30)	-11.88 (7.61)	-3.00 (3.59)
Median	77.00	64.50	59.50	10.00	-2.50	-5.00
IQR: Q1, Q3	57.00, 82.00	47.00, 77.00	52.00, 70.00	0.00, 20.00	-24.00, 0.00	-15.00, 10.00
Min, Max	22.0, 92.0	10.0, 82.0	45.0, 87.0	-15.0, 25.0	-52.0, 10.0	-15.0, 15.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Vitality						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	56.27 (23.22)	70.35 (16.61)	54.71 (25.43)			
Median	62.50	75.05	53.15			
IQR: Q1, Q3	37.50, 75.00	56.30, 84.40	34.40, 68.75			
Min, Max	18.8, 93.8	43.8, 87.5	18.8, 100.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	53.67 (25.34)	64.31 (20.97)	54.71 (26.53)	2.27 (3.07)	-3.59 (6.23)	0.00 (3.61)
Median	62.50	56.30	50.05	6.20	-6.30	0
IQR: Q1, Q3	37.55, 75.00	50.00, 81.30	37.50, 68.75	0.00, 12.50	-18.80, 6.30	-9.40, 9.40
Min, Max	0.0, 81.3	37.5, 93.8	12.5, 100.0	-18.8, 12.5	-25.0, 25.0	-25.0, 18.8
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	55.70 (28.43)	64.08 (25.17)	53.77 (22.86)	4.99 (2.93)	-6.28 (6.02)	3.75 (4.08)
Median	62.50	68.75	53.15	6.25	0	3.10
IQR: Q1, Q3	37.50, 75.00	53.15, 84.40	37.50, 68.80	-6.30, 12.50	-12.50, 6.20	0.00, 12.50
Min, Max	6.3, 93.8	12.5, 87.5	25.0, 100.0	-6.3, 18.8	-43.8, 6.2	-25.0, 25.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Social Functioning						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	81.82 (24.60)	90.63 (26.52)	84.38 (20.73)			
Median	87.50	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	100.00, 100.00	68.75, 100.00			
Min, Max	25.0, 100.0	25.0, 100.0	50.0, 100.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	88.54 (19.55)	85.71 (19.67)	81.25 (18.84)	10.23 (7.87)	-3.57 (6.52)	-3.13 (6.55)
Median	100.00	100.00	81.25	0	0	0
IQR: Q1, Q3	81.25, 100.00	75.00, 100.00	62.50, 100.00	0.00, 25.00	-25.00, 0.00	-12.50, 6.25
Min, Max	50.0, 100.0	50.0, 100.0	50.0, 100.0	-25.0, 75.0	-25.0, 25.0	-50.0, 37.5
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	80.68 (25.84)	84.38 (19.76)	81.25 (22.24)	-2.50 (4.49)	-6.25 (6.68)	0.00 (6.72)
Median	100.00	93.75	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	68.75, 100.00	62.50, 100.00	-12.50, 0.00	-18.75, 0.00	-12.50, 25.00
Min, Max	37.5, 100.0	50.0, 100.0	37.5, 100.0	-25.0, 25.0	-37.5, 25.0	-37.5, 25.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Role Emotional						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	81.82 (31.36)	87.50 (20.88)	83.33 (18.80)			
Median	100.00	100.00	87.50			
IQR: Q1, Q3	75.00, 100.00	79.15, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	41.7, 100.0	50.0, 100.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	73.61 (28.17)	88.09 (24.95)	79.17 (21.17)	-3.79 (8.66)	2.37 (5.38)	-4.17 (7.91)
Median	79.15	100.00	79.15	0	0	0
IQR: Q1, Q3	50.00, 100.00	83.30, 100.00	58.35, 100.00	-8.40, 0.00	-8.40, 16.70	-12.50, 0.00
Min, Max	25.0, 100.0	33.3, 100.0	50.0, 100.0	-66.7, 50.0	-16.7, 25.0	-50.0, 50.0
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	83.34 (28.63)	88.55 (17.78)	68.33 (26.59)	6.67 (10.67)	1.05 (2.92)	-11.67 (9.48)
Median	100.00	95.85	66.70	0	0	-4.20
IQR: Q1, Q3	66.70, 100.00	83.35, 100.00	50.00, 100.00	0.00, 0.00	-4.15, 4.15	-41.70, 16.70
Min, Max	25.0, 100.0	50.0, 100.0	33.3, 100.0	-25.0, 100.0	-8.3, 16.7	-50.0, 25.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Mental Health						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	71.4 (12.5)	82.5 (22.4)	71.3 (21.5)			
Median	70.0	87.5	77.5			
IQR: Q1, Q3	60.0, 85.0	82.5, 95.0	57.5, 82.5			
Min, Max	50, 90	30, 100	20, 100			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	65.4 (19.2)	82.1 (16.8)	75.4 (14.2)	-1.8 (1.7)	2.1 (6.3)	4.2 (5.2)
Median	67.5	85.0	75.0	-5.0	5.0	-2.5
IQR: Q1, Q3	57.5, 77.5	70.0, 95.0	70.0, 80.0	-5.0, 0.0	-5.0, 15.0	-7.5, 12.5
Min, Max	20, 95	50, 95	50, 100	-10, 10	-30, 20	-15, 50
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	77.7 (21.1)	81.9 (16.7)	75.5 (16.6)	11.0 (4.4)	-0.6 (3.8)	7.5 (5.0)
Median	80.0	85.0	72.5	5.0	-2.5	5.0
IQR: Q1, Q3	65.0, 95.0	72.5, 95.0	70.0, 85.0	0.0, 20.0	-7.5, 5.0	-5.0, 20.0
Min, Max	30, 100	50, 100	50, 100	-5, 40	-15, 20	-10, 30

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Mental Component Score						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	48.91 (9.80)	54.34 (11.08)	50.46 (10.34)			
Median	51.40	58.05	53.15			
IQR: Q1, Q3	44.30, 57.70	54.35, 59.95	43.50, 57.30			
Min, Max	30.1, 61.0	27.8, 62.2	30.0, 64.1			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	45.16 (11.86)	54.63 (9.66)	50.93 (9.00)	-1.35 (2.43)	1.21 (1.66)	0.48 (3.56)
Median	48.30	57.30	50.95	-1.00	2.80	-2.55
IQR: Q1, Q3	37.45, 54.00	55.40, 59.60	43.80, 59.45	-4.30, 4.10	-2.40, 4.50	-5.90, 10.75
Min, Max	18.7, 58.9	33.4, 61.9	35.0, 62.3	-20.0, 10.3	-6.8, 5.6	-17.5, 21.4
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	50.18 (11.97)	54.56 (7.68)	49.49 (9.92)	3.52 (2.83)	0.23 (1.88)	0.62 (3.14)
Median	55.70	56.60	48.25	2.05	-0.75	0.90
IQR: Q1, Q3	41.40, 57.10	50.65, 59.65	43.40, 57.40	-1.70, 4.80	-2.70, 1.50	-5.40, 9.60
Min, Max	23.1, 61.6	39.5, 63.2	33.5, 64.6	-5.9, 26.2	-6.0, 11.7	-14.9, 12.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Physical Component Score						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	50.15 (7.30)	51.70 (6.08)	46.98 (8.23)			
Median	49.00	52.80	45.85			
IQR: Q1, Q3	45.60, 58.00	47.65, 55.65	43.00, 53.55			
Min, Max	35.0, 59.0	41.7, 59.7	28.4, 59.0			
Week 24						
m	12	8	13			
n	12	7	12	11	7	12
Mean (SD/SE)	54.35 (4.54)	47.39 (9.23)	45.33 (11.30)	4.87 (1.94)	-3.17 (4.11)	-1.65 (2.00)
Median	54.70	44.50	46.50	4.50	-1.80	-1.80
IQR: Q1, Q3	50.60, 57.40	42.50, 56.00	35.30, 56.55	-0.70, 8.80	-9.70, -0.20	-8.15, 2.95
Min, Max	47.0, 62.7	32.1, 57.9	25.6, 58.0	-5.5, 18.3	-19.3, 16.2	-11.4, 9.4
Week 52						
m	12	8	12			
n	11	8	10	10	8	10
Mean (SD/SE)	50.68 (11.43)	46.53 (10.35)	44.81 (9.37)	1.08 (3.76)	-5.18 (3.48)	-0.97 (1.17)
Median	57.50	51.25	45.60	0	-3.10	-0.35
IQR: Q1, Q3	44.10, 58.40	38.95, 54.00	42.10, 47.60	-4.50, 8.10	-10.30, -0.40	-1.70, 2.00
Min, Max	23.2, 61.4	27.5, 56.3	26.7, 59.3	-22.4, 22.5	-23.5, 9.7	-8.6, 3.1

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Physical Functioning						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	73.31 (23.40)	67.93 (27.35)	76.03 (25.17)			
Median	75.00	77.50	85.00			
IQR: Q1, Q3	55.00, 90.00	55.00, 90.00	62.50, 95.00			
Min, Max	0.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	75.32 (22.98)	69.44 (26.50)	76.32 (25.32)	1.46 (1.49)	1.30 (2.06)	0.84 (1.25)
Median	80.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 95.00	55.00, 90.00	65.00, 95.00	-5.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	10.0, 100.0	5.0, 100.0	0.0, 100.0	-50.0, 45.0	-65.0, 60.0	-50.0, 75.0
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	74.44 (25.94)	67.07 (27.30)	76.73 (24.62)	0.35 (1.57)	-0.32 (2.14)	0.90 (1.18)
Median	82.50	75.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 95.00	50.00, 90.00	65.00, 95.00	-5.00, 5.00	-5.00, 5.00	-5.00, 5.00
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-65.0, 45.0	-85.0, 40.0	-60.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Role Physical						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	74.95 (24.30)	72.27 (28.11)	77.96 (25.99)			
Median	81.30	81.30	87.50			
IQR: Q1, Q3	56.30, 100.00	50.00, 100.00	62.50, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	75.59 (26.10)	72.19 (24.94)	76.74 (26.43)	-0.30 (1.80)	-0.48 (2.35)	-1.01 (1.48)
Median	81.30	75.00	87.50	0	0	0
IQR: Q1, Q3	56.30, 100.00	50.00, 96.90	56.30, 100.00	-12.50, 9.40	-12.50, 6.30	-9.40, 6.20
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.7, 50.0	-50.0, 62.5	-68.7, 87.5
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	74.31 (26.19)	70.29 (26.76)	75.36 (25.16)	-1.35 (1.88)	-0.67 (2.32)	-1.53 (1.54)
Median	78.15	75.00	81.30	0	0	0
IQR: Q1, Q3	50.00, 100.00	50.00, 93.80	56.30, 100.00	-12.50, 6.20	-6.30, 6.30	-12.50, 6.25
Min, Max	0.0, 100.0	6.3, 100.0	0.0, 100.0	-43.8, 56.2	-75.0, 56.3	-62.5, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Bodily Pain						
Baseline						
m	111	87	221			
n	104	82	204			
Mean (SD)	66.6 (23.4)	61.8 (26.9)	67.1 (24.5)			
Median	72.0	62.0	72.0			
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	51.0, 84.0			
Min, Max	12, 100	10, 100	0, 100			
Week 24						
m	111	87	221			
n	108	84	206	103	79	192
Mean (SD/SE)	63.9 (25.1)	64.1 (24.7)	67.3 (24.8)	-2.9 (1.8)	0.9 (2.3)	1.0 (1.5)
Median	72.0	62.0	72.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	51.0, 84.0	-16.0, 1.0	-10.0, 10.0	-10.0, 12.0
Min, Max	0, 100	10, 100	12, 100	-50, 48	-62, 72	-78, 78
Week 52						
m	107	87	219			
n	98	78	199	92	74	184
Mean (SD/SE)	65.6 (24.8)	62.9 (25.0)	67.4 (25.1)	-2.2 (2.2)	2.0 (2.2)	1.1 (1.6)
Median	72.0	62.0	72.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	51.0, 84.0	-12.0, 10.0	-11.0, 11.0	-12.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-80, 59	-53, 69	-78, 78

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
General Health						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	60.42 (19.29)	50.89 (18.30)	59.31 (20.20)			
Median	62.00	47.00	62.00			
IQR: Q1, Q3	45.00, 77.00	37.00, 67.00	45.00, 76.00			
Min, Max	15.0, 100.0	10.0, 92.0	15.0, 100.0			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	61.51 (20.04)	52.50 (18.97)	59.94 (20.49)	0.66 (1.48)	1.46 (1.64)	0.63 (1.05)
Median	61.00	50.00	61.00	0	0	0
IQR: Q1, Q3	47.00, 77.00	37.00, 67.00	47.00, 77.00	-5.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	15.0, 100.0	15.0, 92.0	10.0, 100.0	-60.0, 32.0	-32.0, 32.0	-38.0, 40.0
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	61.23 (19.39)	52.72 (19.29)	59.94 (20.69)	0.00 (1.61)	1.97 (1.87)	0.98 (1.01)
Median	62.00	51.00	62.00	0	2.50	0
IQR: Q1, Q3	47.00, 77.00	40.00, 67.00	47.00, 77.00	-10.00, 10.00	-10.00, 10.00	-5.00, 10.00
Min, Max	20.0, 100.0	15.0, 92.0	10.0, 100.0	-70.0, 37.0	-47.0, 47.0	-40.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Vitality						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	58.55 (22.38)	51.55 (23.70)	57.61 (21.73)			
Median	62.50	56.30	62.50			
IQR: Q1, Q3	43.80, 75.00	37.50, 62.50	43.80, 75.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	58.48 (22.21)	52.03 (20.15)	58.34 (21.12)	-0.37 (1.52)	-0.16 (1.86)	0.89 (1.11)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	43.80, 75.00	37.50, 65.65	43.80, 75.00	-6.20, 6.30	-12.50, 6.30	-6.30, 6.30
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.8, 43.8	-31.3, 43.8	-37.5, 56.2
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	58.70 (22.73)	51.87 (20.25)	56.81 (22.92)	-1.00 (1.66)	0.76 (1.72)	-0.53 (1.34)
Median	62.50	50.00	62.50	0	0	0
IQR: Q1, Q3	43.80, 75.00	37.50, 68.80	43.80, 75.00	-6.30, 6.30	-6.30, 6.30	-6.30, 12.50
Min, Max	6.3, 100.0	6.3, 100.0	0.0, 100.0	-43.7, 50.0	-43.8, 43.8	-56.3, 43.8

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Social Functioning						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	84.05 (21.12)	78.35 (26.65)	83.88 (22.12)			
Median	87.50	87.50	100.00			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	82.06 (23.39)	79.61 (22.10)	82.89 (23.75)	-2.28 (1.85)	2.06 (2.22)	-1.24 (1.29)
Median	87.50	87.50	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	62.50, 100.00	-12.50, 6.25	-12.50, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	12.5, 100.0	0.0, 100.0	-62.5, 37.5	-62.5, 50.0	-62.5, 75.0
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	82.27 (21.90)	80.13 (22.02)	82.29 (22.41)	-1.75 (1.68)	2.53 (2.70)	-1.70 (1.39)
Median	87.50	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00	0.00, 0.00	0.00, 12.50	0.00, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-50.0, 37.5	-62.5, 62.5	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Role Emotional						
Baseline						
m	111	87	221			
n	105	82	203			
Mean (SD)	83.33 (23.32)	80.49 (26.10)	84.61 (22.73)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	111	87	221			
n	108	84	206	104	79	191
Mean (SD/SE)	83.87 (21.32)	83.43 (21.67)	84.10 (23.06)	0.48 (1.59)	2.11 (1.90)	-0.66 (1.26)
Median	100.00	91.70	100.00	0	0	0
IQR: Q1, Q3	70.85, 100.00	75.00, 100.00	75.00, 100.00	-4.15, 4.15	0.00, 8.30	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	8.3, 100.0	-33.3, 66.7	-50.0, 50.0	-50.0, 58.3
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	83.38 (20.73)	82.48 (23.40)	83.58 (22.42)	0.85 (1.62)	2.36 (2.54)	-1.77 (1.32)
Median	91.70	91.70	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	0.00, 16.60	-8.40, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-50.0, 50.0	-75.0, 58.3	-58.3, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Mental Health						
Baseline						
m	111	87	221			
n	105	82	204			
Mean (SD)	74.9 (19.2)	73.9 (20.5)	75.5 (17.8)			
Median	80.0	80.0	80.0			
IQR: Q1, Q3	65.0, 90.0	60.0, 90.0	65.0, 90.0			
Min, Max	5, 100	15, 100	5, 100			
Week 24						
m	111	87	221			
n	108	84	206	104	79	192
Mean (SD/SE)	74.4 (18.6)	73.4 (20.1)	75.9 (17.9)	-0.5 (1.2)	-1.0 (1.5)	0.3 (1.0)
Median	80.0	75.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	70.0, 90.0	-5.0, 5.0	-5.0, 5.0	-7.5, 5.0
Min, Max	25, 100	5, 100	20, 100	-40, 35	-40, 50	-35, 55
Week 52						
m	107	87	219			
n	98	78	199	93	74	184
Mean (SD/SE)	75.1 (17.1)	73.8 (19.2)	75.2 (20.0)	0.1 (1.3)	0.3 (1.6)	-0.2 (1.1)
Median	80.0	75.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	60.0, 90.0	65.0, 90.0	-5.0, 5.0	-5.0, 5.0	-10.0, 7.5
Min, Max	25, 100	20, 100	0, 100	-35, 35	-30, 50	-60, 55

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Mental Component Score						
Baseline						
m	111	87	221			
n	104	82	203			
Mean (SD)	51.59 (10.42)	50.18 (12.36)	51.37 (9.37)			
Median	54.95	54.15	54.10			
IQR: Q1, Q3	47.70, 59.10	41.50, 58.20	47.00, 57.80			
Min, Max	12.0, 67.0	17.0, 72.3	15.6, 66.5			
Week 24						
m	111	87	221			
n	108	84	206	103	79	191
Mean (SD/SE)	51.13 (9.89)	50.54 (10.46)	51.38 (9.72)	-0.46 (0.66)	0.19 (0.82)	-0.15 (0.49)
Median	53.00	52.25	54.55	-0.20	-0.80	-0.10
IQR: Q1, Q3	44.85, 58.85	46.05, 58.70	47.10, 58.50	-3.70, 3.20	-3.60, 2.90	-3.70, 2.70
Min, Max	26.2, 69.1	9.4, 71.2	21.2, 69.0	-20.0, 19.0	-24.5, 26.1	-24.6, 24.8
Week 52						
m	107	87	219			
n	98	78	199	92	74	184
Mean (SD/SE)	51.33 (9.28)	50.84 (10.29)	50.89 (10.31)	-0.09 (0.71)	0.82 (1.01)	-0.66 (0.56)
Median	53.30	52.30	53.60	0	0	-0.20
IQR: Q1, Q3	44.30, 58.60	43.80, 58.30	46.50, 58.10	-3.60, 3.45	-3.10, 5.10	-4.30, 3.15
Min, Max	25.1, 63.2	17.8, 70.7	8.9, 68.0	-21.7, 20.4	-21.4, 25.2	-25.1, 26.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Physical Component Score						
Baseline						
m	111	87	221			
n	104	82	203			
Mean (SD)	47.17 (8.77)	44.47 (10.18)	47.77 (9.19)			
Median	47.35	46.10	50.10			
IQR: Q1, Q3	42.50, 54.55	37.50, 52.50	42.60, 55.10			
Min, Max	15.3, 60.8	21.6, 60.4	20.7, 65.2			
Week 24						
m	111	87	221			
n	108	84	206	103	79	191
Mean (SD/SE)	47.37 (9.68)	45.01 (9.24)	47.72 (9.39)	-0.05 (0.59)	0.38 (0.81)	0.21 (0.51)
Median	49.90	46.40	49.95	0.30	0.10	-0.10
IQR: Q1, Q3	41.70, 54.05	37.90, 52.15	42.40, 55.00	-4.00, 3.80	-2.70, 4.50	-3.30, 3.50
Min, Max	12.5, 63.9	20.2, 59.4	22.8, 62.0	-15.7, 17.6	-22.1, 32.4	-28.8, 23.8
Week 52						
m	107	87	219			
n	98	78	199	92	74	184
Mean (SD/SE)	47.22 (10.09)	44.29 (9.69)	47.73 (9.17)	-0.42 (0.67)	0.14 (0.84)	0.37 (0.47)
Median	48.90	43.70	49.30	-0.50	1.30	0.40
IQR: Q1, Q3	41.80, 55.20	38.80, 51.70	42.10, 55.10	-3.25, 2.70	-3.10, 4.60	-2.70, 3.60
Min, Max	15.8, 62.8	16.0, 61.2	21.5, 61.7	-24.7, 15.9	-22.5, 17.2	-23.9, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Physical Functioning			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	79.82 (25.98)	73.79 (24.52)	74.83 (25.27)
Analysis Visit Mean (SD)	78.04 (29.76)	75.34 (22.20)	77.59 (30.28)
LS Mean of Change from Baseline (SE)	-0.12 (3.42)	1.35 (3.36)	2.86 (3.36)
95% CI	(-6.92, 6.69)	(-5.34, 8.04)	(-3.81, 9.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.97 (4.68)	-1.51 (4.68)	
95% CI	(-12.28, 6.33)	(-10.82, 7.80)	
p-value	0.5267	0.7479	
Corrected Hedge's g Statistics	-0.162	-0.082	
95% CI	(-0.68, 0.36)	(-0.60, 0.43)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	78.46 (26.49)	75.37 (22.99)	75.89 (23.30)
Analysis Visit Mean (SD)	83.85 (28.72)	80.56 (21.00)	76.67 (23.43)
LS Mean of Change from Baseline (SE)	6.95 (2.55)	6.32 (2.49)	2.27 (2.50)
95% CI	(1.88, 12.02)	(1.37, 11.28)	(-2.70, 7.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.68 (3.42)	4.05 (3.45)	
95% CI	(-2.12, 11.47)	(-2.81, 10.91)	
p-value	0.1747	0.2436	
Corrected Hedge's g Statistics	0.351	0.305	
95% CI	(-0.19, 0.89)	(-0.23, 0.84)	
Subgroup*Treatment Interaction p-value	0.1273	0.5078	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Role Physical			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	82.83 (29.83)	73.50 (27.98)	78.03 (20.29)
Analysis Visit Mean (SD)	76.58 (28.29)	75.01 (25.55)	79.54 (25.20)
LS Mean of Change from Baseline (SE)	-3.85 (3.45)	0.79 (3.40)	2.13 (3.40)
95% CI	(-10.71, 3.02)	(-5.97, 7.55)	(-4.62, 8.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.98 (4.71)	-1.34 (4.73)	
95% CI	(-15.34, 3.39)	(-10.74, 8.06)	
p-value	0.2081	0.7775	
Corrected Hedge's g Statistics	-0.322	-0.072	
95% CI	(-0.85, 0.20)	(-0.59, 0.44)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	81.50 (30.59)	75.24 (27.37)	79.04 (18.72)
Analysis Visit Mean (SD)	83.66 (30.10)	83.11 (22.32)	80.59 (20.51)
LS Mean of Change from Baseline (SE)	3.97 (2.97)	7.89 (2.90)	3.40 (2.91)
95% CI	(-1.93, 9.87)	(2.11, 13.66)	(-2.38, 9.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.57 (4.00)	4.49 (4.03)	
95% CI	(-7.38, 8.51)	(-3.52, 12.49)	
p-value	0.8874	0.2684	
Corrected Hedge's g Statistics	0.037	0.290	
95% CI	(-0.50, 0.57)	(-0.24, 0.82)	
Subgroup*Treatment Interaction p-value	0.5330	0.8431	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Bodily Pain			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	64.8 (26.4)	60.0 (29.3)	68.0 (25.8)
Analysis Visit Mean (SD)	63.3 (26.1)	64.7 (24.5)	67.2 (21.6)
LS Mean of Change from Baseline (SE)	-0.84 (3.41)	3.72 (3.37)	1.37 (3.38)
95% CI	(-7.61, 5.93)	(-2.99, 10.43)	(-5.36, 8.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.21 (4.61)	2.35 (4.71)	
95% CI	(-11.38, 6.96)	(-7.01, 11.70)	
p-value	0.6327	0.6190	
Corrected Hedge's g Statistics	-0.120	0.127	
95% CI	(-0.64, 0.40)	(-0.39, 0.64)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	66.1 (27.9)	61.0 (29.9)	64.8 (25.0)
Analysis Visit Mean (SD)	72.4 (28.1)	78.2 (24.1)	69.3 (22.9)
LS Mean of Change from Baseline (SE)	7.37 (3.61)	15.99 (3.56)	4.85 (3.54)
95% CI	(0.18, 14.55)	(8.92, 23.06)	(-2.19, 11.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.52 (4.87)	11.15 (4.94)	
95% CI	(-7.17, 12.21)	(1.32, 20.97)	
p-value	0.6063	0.0266	
Corrected Hedge's g Statistics	0.134	0.590	
95% CI	(-0.40, 0.67)	(0.05, 1.13)	
Subgroup*Treatment Interaction p-value	0.1025	0.2694	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
General Health			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	60.21 (23.98)	55.59 (20.19)	56.21 (23.12)
Analysis Visit Mean (SD)	61.43 (23.93)	59.34 (20.07)	60.38 (26.27)
LS Mean of Change from Baseline (SE)	1.79 (2.86)	3.52 (2.81)	2.94 (2.82)
95% CI	(-3.89, 7.47)	(-2.07, 9.11)	(-2.66, 8.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.15 (3.88)	0.58 (3.90)	
95% CI	(-8.87, 6.57)	(-7.17, 8.34)	
p-value	0.7673	0.8818	
Corrected Hedge's g Statistics	-0.075	0.038	
95% CI	(-0.59, 0.44)	(-0.48, 0.55)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	62.96 (23.60)	56.48 (20.02)	57.96 (23.78)
Analysis Visit Mean (SD)	67.96 (19.98)	63.37 (14.74)	64.25 (23.97)
LS Mean of Change from Baseline (SE)	6.53 (2.74)	6.78 (2.67)	6.09 (2.67)
95% CI	(1.08, 11.98)	(1.46, 12.09)	(0.79, 11.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.44 (3.68)	0.69 (3.70)	
95% CI	(-6.89, 7.76)	(-6.67, 8.04)	
p-value	0.9060	0.8535	
Corrected Hedge's g Statistics	0.031	0.048	
95% CI	(-0.50, 0.56)	(-0.48, 0.58)	
Subgroup*Treatment Interaction p-value	0.1146	0.7803	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Vitality			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	58.74 (22.91)	56.71 (21.84)	58.43 (20.47)
Analysis Visit Mean (SD)	55.83 (28.36)	56.06 (20.62)	57.79 (24.30)
LS Mean of Change from Baseline (SE)	-1.38 (2.87)	0.55 (2.82)	0.79 (2.84)
95% CI	(-7.08, 4.32)	(-5.07, 6.16)	(-4.86, 6.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.17 (3.91)	-0.24 (3.93)	
95% CI	(-9.95, 5.61)	(-8.06, 7.57)	
p-value	0.5812	0.9509	
Corrected Hedge's g Statistics	-0.140	-0.016	
95% CI	(-0.66, 0.38)	(-0.53, 0.50)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	59.40 (21.96)	58.59 (20.82)	57.17 (19.44)
Analysis Visit Mean (SD)	60.60 (21.62)	59.74 (20.31)	63.41 (19.07)
LS Mean of Change from Baseline (SE)	2.52 (2.78)	2.43 (2.72)	6.94 (2.73)
95% CI	(-3.00, 8.04)	(-2.97, 7.84)	(1.52, 12.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.42 (3.77)	-4.50 (3.78)	
95% CI	(-11.90, 3.07)	(-12.01, 3.01)	
p-value	0.2439	0.2366	
Corrected Hedge's g Statistics	-0.305	-0.311	
95% CI	(-0.84, 0.23)	(-0.84, 0.22)	
Subgroup*Treatment Interaction p-value	0.6303	0.9744	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Social Functioning			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	81.70 (26.89)	81.47 (26.22)	80.60 (23.29)
Analysis Visit Mean (SD)	80.80 (26.24)	81.47 (21.29)	81.47 (21.55)
LS Mean of Change from Baseline (SE)	0.40 (3.84)	1.09 (3.78)	1.03 (3.80)
95% CI	(-7.22, 8.03)	(-6.43, 8.61)	(-6.52, 8.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.63 (5.21)	0.06 (5.25)	
95% CI	(-10.98, 9.73)	(-10.38, 10.49)	
p-value	0.9043	0.9915	
Corrected Hedge's g Statistics	-0.030	0.003	
95% CI	(-0.55, 0.49)	(-0.51, 0.52)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	81.73 (28.11)	82.87 (26.66)	81.25 (23.69)
Analysis Visit Mean (SD)	80.77 (27.67)	85.19 (24.52)	88.39 (17.98)
LS Mean of Change from Baseline (SE)	0.26 (3.90)	3.40 (3.82)	6.69 (3.81)
95% CI	(-7.48, 8.01)	(-4.20, 10.99)	(-0.89, 14.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.43 (5.26)	-3.29 (5.29)	
95% CI	(-16.88, 4.03)	(-13.82, 7.24)	
p-value	0.2249	0.5360	
Corrected Hedge's g Statistics	-0.316	-0.162	
95% CI	(-0.85, 0.22)	(-0.69, 0.37)	
Subgroup*Treatment Interaction p-value	0.3420	0.7460	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Role Emotional			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	86.90 (18.20)	83.91 (21.13)	81.61 (21.41)
Analysis Visit Mean (SD)	84.23 (22.49)	88.80 (18.67)	83.05 (23.41)
LS Mean of Change from Baseline (SE)	-1.40 (3.09)	6.15 (3.03)	1.31 (3.04)
95% CI	(-7.55, 4.75)	(0.11, 12.18)	(-4.74, 7.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.71 (4.18)	4.83 (4.20)	
95% CI	(-11.02, 5.60)	(-3.52, 13.19)	
p-value	0.5185	0.2530	
Corrected Hedge's g Statistics	-0.163	0.292	
95% CI	(-0.68, 0.36)	(-0.23, 0.81)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	85.89 (18.52)	83.64 (21.87)	82.44 (20.58)
Analysis Visit Mean (SD)	85.25 (19.63)	90.12 (17.61)	84.22 (21.92)
LS Mean of Change from Baseline (SE)	0.27 (3.21)	7.53 (3.14)	0.29 (3.13)
95% CI	(-6.10, 6.65)	(1.29, 13.77)	(-5.92, 6.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (4.31)	7.24 (4.34)	
95% CI	(-8.60, 8.55)	(-1.39, 15.86)	
p-value	0.9958	0.0991	
Corrected Hedge's g Statistics	-0.001	0.434	
95% CI	(-0.54, 0.53)	(-0.10, 0.97)	
Subgroup*Treatment Interaction p-value	0.3359	0.5148	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Mental Health			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	77.7 (17.6)	77.9 (13.5)	76.4 (15.7)
Analysis Visit Mean (SD)	76.8 (20.6)	77.6 (16.1)	75.9 (19.9)
LS Mean of Change from Baseline (SE)	-0.72 (2.79)	0.72 (2.75)	-0.58 (2.76)
95% CI	(-6.27, 4.82)	(-4.74, 6.18)	(-6.06, 4.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (3.82)	1.30 (3.83)	
95% CI	(-7.73, 7.44)	(-6.31, 8.92)	
p-value	0.9704	0.7345	
Corrected Hedge's g Statistics	-0.009	0.087	
95% CI	(-0.53, 0.51)	(-0.43, 0.60)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	77.3 (18.0)	77.8 (13.9)	77.0 (15.2)
Analysis Visit Mean (SD)	76.0 (20.4)	78.0 (15.6)	79.6 (16.1)
LS Mean of Change from Baseline (SE)	-1.16 (2.41)	0.89 (2.36)	1.89 (2.37)
95% CI	(-5.96, 3.64)	(-3.80, 5.59)	(-2.82, 6.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.05 (3.25)	-0.99 (3.27)	
95% CI	(-9.52, 3.42)	(-7.50, 5.52)	
p-value	0.3516	0.7629	
Corrected Hedge's g Statistics	-0.242	-0.079	
95% CI	(-0.78, 0.29)	(-0.61, 0.45)	
Subgroup*Treatment Interaction p-value	0.9363	0.9847	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Mental Component Score			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	51.77 (8.66)	52.20 (7.35)	50.88 (9.21)
Analysis Visit Mean (SD)	51.11 (10.15)	52.51 (8.67)	50.72 (11.52)
LS Mean of Change from Baseline (SE)	-0.41 (1.52)	1.10 (1.50)	-0.16 (1.51)
95% CI	(-3.44, 2.62)	(-1.88, 4.09)	(-3.16, 2.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.24 (2.08)	1.27 (2.09)	
95% CI	(-4.38, 3.89)	(-2.89, 5.42)	
p-value	0.9067	0.5466	
Corrected Hedge's g Statistics	-0.030	0.154	
95% CI	(-0.55, 0.49)	(-0.36, 0.67)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	51.68 (8.79)	52.21 (7.52)	51.09 (9.24)
Analysis Visit Mean (SD)	50.39 (9.50)	52.28 (8.49)	53.20 (9.00)
LS Mean of Change from Baseline (SE)	-1.20 (1.33)	0.61 (1.30)	1.46 (1.30)
95% CI	(-3.84, 1.44)	(-1.97, 3.20)	(-1.14, 4.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.65 (1.79)	-0.84 (1.80)	
95% CI	(-6.21, 0.90)	(-4.43, 2.74)	
p-value	0.1417	0.6419	
Corrected Hedge's g Statistics	-0.382	-0.121	
95% CI	(-0.92, 0.16)	(-0.65, 0.41)	
Subgroup*Treatment Interaction p-value	0.5812	0.9071	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Physical Component Score			
Week 24			
m	30	31	35
n	28	29	29
Baseline Mean (SD)	48.36 (10.10)	45.22 (10.30)	47.45 (9.62)
Analysis Visit Mean (SD)	47.52 (10.06)	46.35 (9.27)	48.41 (10.85)
LS Mean of Change from Baseline (SE)	-0.21 (1.25)	0.71 (1.23)	1.11 (1.23)
95% CI	(-2.69, 2.27)	(-1.74, 3.16)	(-1.33, 3.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.32 (1.70)	-0.40 (1.72)	
95% CI	(-4.70, 2.06)	(-3.82, 3.01)	
p-value	0.4395	0.8146	
Corrected Hedge's g Statistics	-0.197	-0.060	
95% CI	(-0.72, 0.32)	(-0.57, 0.45)	
Week 52			
m	29	30	35
n	26	27	28
Baseline Mean (SD)	48.59 (10.70)	45.98 (9.54)	47.38 (9.25)
Analysis Visit Mean (SD)	51.37 (10.79)	50.31 (9.10)	48.65 (9.21)
LS Mean of Change from Baseline (SE)	3.36 (1.01)	4.36 (0.99)	1.91 (0.99)
95% CI	(1.36, 5.37)	(2.39, 6.32)	(-0.06, 3.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.45 (1.35)	2.45 (1.37)	
95% CI	(-1.24, 4.15)	(-0.28, 5.17)	
p-value	0.2859	0.0776	
Corrected Hedge's g Statistics	0.276	0.465	
95% CI	(-0.26, 0.81)	(-0.07, 1.00)	
Subgroup*Treatment Interaction p-value	0.1250	0.2884	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Physical Functioning			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	80.00 (13.60)	80.71 (16.18)	74.58 (16.58)
Analysis Visit Mean (SD)	90.45 (13.50)	77.14 (25.96)	69.58 (27.67)
LS Mean of Change from Baseline (SE)	9.56 (6.50)	-1.80 (8.19)	-7.09 (6.52)
95% CI	(-3.77, 22.89)	(-18.60, 15.01)	(-20.47, 6.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	16.65 (8.82)	5.29 (10.14)	
95% CI	(-1.46, 34.75)	(-15.52, 26.10)	
p-value	0.0700	0.6062	
Corrected Hedge's g Statistics	0.726	0.227	
95% CI	(-0.12, 1.57)	(-0.71, 1.16)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	80.50 (14.23)	83.13 (16.46)	70.50 (14.80)
Analysis Visit Mean (SD)	84.00 (24.36)	75.63 (21.95)	67.22 (26.09)
LS Mean of Change from Baseline (SE)	2.93 (6.79)	-6.26 (7.76)	-4.85 (7.39)
95% CI	(-11.01, 16.86)	(-22.18, 9.66)	(-20.01, 10.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.77 (9.75)	-1.42 (10.69)	
95% CI	(-12.23, 27.78)	(-23.36, 20.52)	
p-value	0.4324	0.8956	
Corrected Hedge's g Statistics	0.332	-0.059	
95% CI	(-0.55, 1.21)	(-0.99, 0.87)	
Subgroup*Treatment Interaction p-value	0.1273	0.5078	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Role Physical			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	76.15 (34.55)	83.94 (25.47)	66.68 (27.08)
Analysis Visit Mean (SD)	81.84 (25.20)	77.70 (25.20)	71.89 (26.44)
LS Mean of Change from Baseline (SE)	5.58 (5.83)	0.07 (7.38)	2.80 (5.89)
95% CI	(-6.38, 17.55)	(-15.08, 15.22)	(-9.28, 14.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.79 (7.84)	-2.73 (9.05)	
95% CI	(-13.31, 18.88)	(-21.30, 15.84)	
p-value	0.7251	0.7654	
Corrected Hedge's g Statistics	0.135	-0.130	
95% CI	(-0.68, 0.95)	(-1.06, 0.80)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	76.26 (36.41)	85.95 (24.25)	61.89 (26.90)
Analysis Visit Mean (SD)	80.63 (34.67)	75.03 (30.25)	60.02 (28.13)
LS Mean of Change from Baseline (SE)	5.35 (8.05)	-5.51 (9.22)	-4.24 (8.48)
95% CI	(-11.17, 21.87)	(-24.44, 13.42)	(-21.64, 13.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.59 (11.42)	-1.27 (12.54)	
95% CI	(-13.85, 33.02)	(-27.01, 24.46)	
p-value	0.4086	0.9198	
Corrected Hedge's g Statistics	0.351	-0.046	
95% CI	(-0.53, 1.23)	(-0.98, 0.88)	
Subgroup*Treatment Interaction p-value	0.5330	0.8431	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Bodily Pain			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	72.5 (27.3)	74.7 (15.8)	64.8 (25.6)
Analysis Visit Mean (SD)	81.1 (26.6)	64.6 (22.1)	58.4 (27.4)
LS Mean of Change from Baseline (SE)	7.47 (6.22)	-7.87 (7.59)	-9.33 (6.30)
95% CI	(-5.29, 20.23)	(-23.44, 7.70)	(-22.27, 3.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	16.80 (8.37)	1.47 (9.48)	
95% CI	(-0.36, 33.97)	(-17.99, 20.92)	
p-value	0.0547	0.8782	
Corrected Hedge's g Statistics	0.762	0.066	
95% CI	(-0.09, 1.61)	(-0.87, 1.00)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	73.6 (28.5)	77.9 (17.1)	61.5 (25.5)
Analysis Visit Mean (SD)	79.7 (28.4)	69.4 (28.4)	61.6 (26.8)
LS Mean of Change from Baseline (SE)	2.75 (7.10)	-6.94 (8.13)	-0.06 (7.37)
95% CI	(-11.82, 17.32)	(-23.61, 9.73)	(-15.18, 15.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.81 (9.84)	-6.88 (10.79)	
95% CI	(-17.39, 23.00)	(-29.02, 15.25)	
p-value	0.7777	0.5289	
Corrected Hedge's g Statistics	0.117	-0.283	
95% CI	(-0.76, 0.99)	(-1.22, 0.65)	
Subgroup*Treatment Interaction p-value	0.1025	0.2694	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
General Health			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	64.55 (9.61)	66.29 (18.58)	65.00 (12.90)
Analysis Visit Mean (SD)	71.64 (15.12)	66.00 (21.99)	60.42 (15.82)
LS Mean of Change from Baseline (SE)	4.95 (4.95)	-3.40 (6.18)	-7.71 (4.95)
95% CI	(-5.21, 15.11)	(-16.09, 9.28)	(-17.86, 2.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.66 (6.65)	4.31 (7.63)	
95% CI	(-0.99, 26.31)	(-11.35, 19.97)	
p-value	0.0677	0.5770	
Corrected Hedge's g Statistics	0.726	0.244	
95% CI	(-0.12, 1.57)	(-0.69, 1.18)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	63.80 (9.78)	70.50 (20.93)	64.10 (13.62)
Analysis Visit Mean (SD)	71.30 (17.20)	58.63 (24.46)	61.10 (13.10)
LS Mean of Change from Baseline (SE)	6.06 (4.86)	-12.30 (5.60)	-4.89 (5.13)
95% CI	(-3.92, 16.04)	(-23.79, -0.80)	(-15.41, 5.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.96 (6.70)	-7.40 (7.37)	
95% CI	(-2.79, 24.71)	(-22.52, 7.71)	
p-value	0.1137	0.3238	
Corrected Hedge's g Statistics	0.664	-0.439	
95% CI	(-0.24, 1.56)	(-1.38, 0.50)	
Subgroup*Treatment Interaction p-value	0.1146	0.7803	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Vitality			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	56.27 (23.22)	67.90 (16.30)	54.71 (25.43)
Analysis Visit Mean (SD)	58.55 (19.80)	64.31 (20.97)	54.71 (26.53)
LS Mean of Change from Baseline (SE)	1.09 (4.02)	-3.69 (5.16)	-2.12 (4.04)
95% CI	(-7.17, 9.34)	(-14.27, 6.89)	(-10.40, 6.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.21 (5.41)	-1.57 (6.37)	
95% CI	(-7.89, 14.30)	(-14.63, 11.49)	
p-value	0.5582	0.8070	
Corrected Hedge's g Statistics	0.226	-0.108	
95% CI	(-0.59, 1.05)	(-1.04, 0.82)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	55.65 (24.38)	70.35 (16.61)	50.02 (24.28)
Analysis Visit Mean (SD)	60.64 (24.49)	64.08 (25.17)	53.77 (22.86)
LS Mean of Change from Baseline (SE)	4.31 (4.25)	-6.39 (4.98)	2.24 (4.56)
95% CI	(-4.41, 13.03)	(-16.62, 3.84)	(-7.11, 11.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.07 (5.92)	-8.63 (6.75)	
95% CI	(-10.08, 14.23)	(-22.48, 5.22)	
p-value	0.7289	0.2121	
Corrected Hedge's g Statistics	0.143	-0.576	
95% CI	(-0.74, 1.02)	(-1.52, 0.37)	
Subgroup*Treatment Interaction p-value	0.6303	0.9744	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Social Functioning			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	81.82 (24.60)	89.29 (28.35)	84.38 (20.73)
Analysis Visit Mean (SD)	92.05 (16.08)	85.71 (19.67)	81.25 (18.84)
LS Mean of Change from Baseline (SE)	6.96 (5.33)	-3.25 (6.79)	-5.56 (5.26)
95% CI	(-3.97, 17.89)	(-17.18, 10.68)	(-16.35, 5.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.52 (7.21)	2.31 (8.30)	
95% CI	(-2.27, 27.32)	(-14.71, 19.34)	
p-value	0.0939	0.7826	
Corrected Hedge's g Statistics	0.672	0.122	
95% CI	(-0.17, 1.51)	(-0.81, 1.05)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	87.50 (16.67)	90.63 (26.52)	81.25 (21.45)
Analysis Visit Mean (SD)	85.00 (22.67)	84.38 (19.76)	81.25 (22.24)
LS Mean of Change from Baseline (SE)	-2.72 (5.37)	-5.78 (6.07)	-3.82 (5.73)
95% CI	(-13.75, 8.30)	(-18.23, 6.66)	(-15.58, 7.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.09 (7.61)	-1.97 (8.19)	
95% CI	(-14.53, 16.72)	(-18.78, 14.85)	
p-value	0.8867	0.8123	
Corrected Hedge's g Statistics	0.060	-0.106	
95% CI	(-0.82, 0.94)	(-1.04, 0.82)	
Subgroup*Treatment Interaction p-value	0.3420	0.7460	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Role Emotional			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	81.82 (31.36)	85.71 (21.89)	83.33 (18.80)
Analysis Visit Mean (SD)	78.03 (24.80)	88.09 (24.95)	79.17 (21.17)
LS Mean of Change from Baseline (SE)	-5.30 (6.90)	2.63 (8.65)	-5.40 (6.91)
95% CI	(-19.46, 8.87)	(-15.13, 20.39)	(-19.58, 8.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (9.27)	8.03 (10.63)	
95% CI	(-18.91, 19.12)	(-13.78, 29.85)	
p-value	0.9911	0.4565	
Corrected Hedge's g Statistics	0.004	0.325	
95% CI	(-0.81, 0.82)	(-0.61, 1.26)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	81.67 (33.06)	87.50 (20.88)	80.00 (18.92)
Analysis Visit Mean (SD)	88.34 (24.59)	88.55 (17.78)	68.33 (26.59)
LS Mean of Change from Baseline (SE)	5.85 (7.34)	3.00 (8.29)	-14.12 (7.76)
95% CI	(-9.22, 20.92)	(-14.00, 20.00)	(-30.04, 1.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	19.98 (10.18)	17.12 (11.04)	
95% CI	(-0.92, 40.87)	(-5.53, 39.78)	
p-value	0.0602	0.1325	
Corrected Hedge's g Statistics	0.801	0.678	
95% CI	(-0.11, 1.71)	(-0.28, 1.63)	
Subgroup*Treatment Interaction p-value	0.3359	0.5148	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Mental Health			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	71.4 (12.5)	80.0 (22.9)	71.3 (21.5)
Analysis Visit Mean (SD)	69.5 (13.5)	82.1 (16.8)	75.4 (14.2)
LS Mean of Change from Baseline (SE)	-3.50 (3.51)	4.30 (4.51)	1.92 (3.49)
95% CI	(-10.71, 3.71)	(-4.95, 13.56)	(-5.25, 9.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.42 (4.74)	2.38 (5.53)	
95% CI	(-15.15, 4.32)	(-8.96, 13.73)	
p-value	0.2637	0.6697	
Corrected Hedge's g Statistics	-0.439	0.189	
95% CI	(-1.27, 0.39)	(-0.75, 1.12)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	71.5 (13.1)	82.5 (22.4)	68.0 (22.0)
Analysis Visit Mean (SD)	82.5 (14.8)	81.9 (16.7)	75.5 (16.6)
LS Mean of Change from Baseline (SE)	9.57 (3.70)	2.43 (4.27)	3.86 (3.95)
95% CI	(1.99, 17.16)	(-6.33, 11.19)	(-4.25, 11.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.71 (5.19)	-1.43 (5.78)	
95% CI	(-4.94, 16.36)	(-13.28, 10.43)	
p-value	0.2807	0.8068	
Corrected Hedge's g Statistics	0.452	-0.110	
95% CI	(-0.44, 1.34)	(-1.04, 0.82)	
Subgroup*Treatment Interaction p-value	0.9363	0.9847	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Mental Component Score			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	48.91 (9.80)	53.41 (11.63)	50.46 (10.34)
Analysis Visit Mean (SD)	47.56 (8.85)	54.63 (9.66)	50.93 (9.00)
LS Mean of Change from Baseline (SE)	-2.74 (2.51)	2.04 (3.15)	-0.42 (2.49)
95% CI	(-7.90, 2.41)	(-4.41, 8.50)	(-5.52, 4.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.32 (3.38)	2.46 (3.89)	
95% CI	(-9.26, 4.61)	(-5.51, 10.44)	
p-value	0.4978	0.5315	
Corrected Hedge's g Statistics	-0.264	0.276	
95% CI	(-1.09, 0.56)	(-0.66, 1.21)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	49.37 (10.21)	54.34 (11.08)	48.87 (10.62)
Analysis Visit Mean (SD)	52.89 (8.35)	54.56 (7.68)	49.49 (9.92)
LS Mean of Change from Baseline (SE)	2.74 (2.27)	1.56 (2.58)	-0.97 (2.42)
95% CI	(-1.91, 7.39)	(-3.73, 6.85)	(-5.94, 4.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.71 (3.13)	2.53 (3.45)	
95% CI	(-2.72, 10.14)	(-4.54, 9.61)	
p-value	0.2471	0.4691	
Corrected Hedge's g Statistics	0.479	0.322	
95% CI	(-0.41, 1.37)	(-0.61, 1.26)	
Subgroup*Treatment Interaction p-value	0.5812	0.9071	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Physical Component Score			
Week 24			
m	12	8	13
n	11	7	12
Baseline Mean (SD)	50.15 (7.30)	50.56 (5.56)	46.98 (8.23)
Analysis Visit Mean (SD)	55.02 (4.09)	47.39 (9.23)	45.33 (11.30)
LS Mean of Change from Baseline (SE)	4.63 (2.43)	-2.25 (3.02)	-2.87 (2.45)
95% CI	(-0.35, 9.61)	(-8.45, 3.95)	(-7.89, 2.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.50 (3.27)	0.62 (3.74)	
95% CI	(0.78, 14.22)	(-7.06, 8.29)	
p-value	0.0300	0.8701	
Corrected Hedge's g Statistics	0.873	0.071	
95% CI	(0.02, 1.73)	(-0.86, 1.00)	
Week 52			
m	12	8	12
n	10	8	10
Baseline Mean (SD)	50.26 (7.69)	51.70 (6.08)	45.78 (8.44)
Analysis Visit Mean (SD)	51.34 (11.83)	46.53 (10.35)	44.81 (9.37)
LS Mean of Change from Baseline (SE)	0.72 (2.97)	-4.47 (3.40)	-1.16 (3.12)
95% CI	(-5.39, 6.82)	(-11.45, 2.51)	(-7.56, 5.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.88 (4.20)	-3.31 (4.59)	
95% CI	(-6.73, 10.49)	(-12.74, 6.12)	
p-value	0.6583	0.4775	
Corrected Hedge's g Statistics	0.186	-0.323	
95% CI	(-0.69, 1.06)	(-1.26, 0.61)	
Subgroup*Treatment Interaction p-value	0.1250	0.2884	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Physical Functioning			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	73.78 (23.02)	67.97 (27.64)	76.07 (25.14)
Analysis Visit Mean (SD)	75.24 (23.11)	69.28 (26.29)	76.91 (25.18)
LS Mean of Change from Baseline (SE)	1.39 (1.62)	-0.36 (1.82)	0.95 (1.19)
95% CI	(-1.80, 4.57)	(-3.95, 3.22)	(-1.39, 3.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.44 (1.95)	-1.31 (2.14)	
95% CI	(-3.40, 4.27)	(-5.53, 2.90)	
p-value	0.8222	0.5412	
Corrected Hedge's g Statistics	0.027	-0.080	
95% CI	(-0.21, 0.27)	(-0.34, 0.18)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	73.90 (22.63)	66.76 (27.60)	76.17 (25.14)
Analysis Visit Mean (SD)	74.25 (25.77)	66.43 (27.63)	77.07 (24.31)
LS Mean of Change from Baseline (SE)	0.27 (1.64)	-1.65 (1.83)	1.22 (1.18)
95% CI	(-2.96, 3.50)	(-5.25, 1.94)	(-1.09, 3.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.95 (1.96)	-2.87 (2.14)	
95% CI	(-4.81, 2.91)	(-7.08, 1.33)	
p-value	0.6294	0.1802	
Corrected Hedge's g Statistics	-0.059	-0.180	
95% CI	(-0.31, 0.19)	(-0.45, 0.09)	
Subgroup*Treatment Interaction p-value	0.1273	0.5078	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Role Physical			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	75.43 (23.91)	72.48 (28.44)	78.04 (25.96)
Analysis Visit Mean (SD)	75.13 (26.44)	72.01 (25.27)	77.03 (26.51)
LS Mean of Change from Baseline (SE)	-0.01 (1.90)	-1.80 (2.13)	-0.59 (1.39)
95% CI	(-3.74, 3.72)	(-6.00, 2.39)	(-3.32, 2.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.58 (2.29)	-1.22 (2.50)	
95% CI	(-3.92, 5.08)	(-6.14, 3.71)	
p-value	0.8006	0.6272	
Corrected Hedge's g Statistics	0.030	-0.063	
95% CI	(-0.21, 0.27)	(-0.33, 0.20)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	75.21 (24.88)	70.54 (28.40)	77.43 (26.10)
Analysis Visit Mean (SD)	73.87 (26.46)	69.87 (27.18)	75.90 (25.02)
LS Mean of Change from Baseline (SE)	-1.08 (1.92)	-1.82 (2.14)	-1.04 (1.37)
95% CI	(-4.86, 2.70)	(-6.02, 2.38)	(-3.73, 1.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (2.30)	-0.78 (2.49)	
95% CI	(-4.57, 4.48)	(-5.68, 4.12)	
p-value	0.9839	0.7544	
Corrected Hedge's g Statistics	-0.002	-0.042	
95% CI	(-0.25, 0.25)	(-0.31, 0.23)	
Subgroup*Treatment Interaction p-value	0.5330	0.8431	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Bodily Pain			
Week 24			
m	111	87	221
n	103	79	192
Baseline Mean (SD)	67.1 (23.1)	62.7 (26.9)	66.9 (24.6)
Analysis Visit Mean (SD)	64.1 (25.1)	63.6 (24.9)	67.9 (24.9)
LS Mean of Change from Baseline (SE)	-2.45 (1.88)	-0.20 (2.11)	1.03 (1.37)
95% CI	(-6.15, 1.26)	(-4.34, 3.95)	(-1.67, 3.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.48 (2.26)	-1.23 (2.46)	
95% CI	(-7.92, 0.97)	(-6.07, 3.62)	
p-value	0.1251	0.6193	
Corrected Hedge's g Statistics	-0.182	-0.065	
95% CI	(-0.42, 0.06)	(-0.33, 0.20)	
Week 52			
m	107	87	219
n	92	74	184
Baseline Mean (SD)	67.3 (23.6)	59.6 (25.9)	66.8 (24.6)
Analysis Visit Mean (SD)	65.1 (24.8)	61.7 (24.8)	67.9 (24.7)
LS Mean of Change from Baseline (SE)	-1.31 (2.03)	-0.30 (2.25)	1.40 (1.44)
95% CI	(-5.30, 2.68)	(-4.73, 4.12)	(-1.43, 4.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.71 (2.43)	-1.71 (2.63)	
95% CI	(-7.49, 2.06)	(-6.87, 3.46)	
p-value	0.2647	0.5163	
Corrected Hedge's g Statistics	-0.138	-0.087	
95% CI	(-0.39, 0.11)	(-0.36, 0.18)	
Subgroup*Treatment Interaction p-value	0.1025	0.2694	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
General Health			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	60.74 (19.10)	50.28 (18.09)	59.65 (20.11)
Analysis Visit Mean (SD)	61.39 (20.08)	51.73 (18.78)	60.28 (20.76)
LS Mean of Change from Baseline (SE)	1.28 (1.42)	-0.88 (1.61)	0.94 (1.04)
95% CI	(-1.51, 4.07)	(-4.04, 2.28)	(-1.10, 2.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.34 (1.70)	-1.82 (1.88)	
95% CI	(-3.00, 3.68)	(-5.52, 1.88)	
p-value	0.8415	0.3347	
Corrected Hedge's g Statistics	0.024	-0.127	
95% CI	(-0.22, 0.26)	(-0.39, 0.14)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	60.97 (19.69)	50.31 (18.48)	59.56 (20.43)
Analysis Visit Mean (SD)	60.97 (19.46)	52.28 (19.52)	60.54 (20.91)
LS Mean of Change from Baseline (SE)	0.71 (1.46)	-0.42 (1.63)	1.39 (1.04)
95% CI	(-2.16, 3.58)	(-3.62, 2.79)	(-0.66, 3.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.68 (1.74)	-1.80 (1.91)	
95% CI	(-4.10, 2.74)	(-5.55, 1.94)	
p-value	0.6963	0.3445	
Corrected Hedge's g Statistics	-0.048	-0.128	
95% CI	(-0.30, 0.20)	(-0.40, 0.14)	
Subgroup*Treatment Interaction p-value	0.1146	0.7803	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Vitality			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	58.75 (22.39)	51.37 (24.05)	57.76 (22.01)
Analysis Visit Mean (SD)	58.38 (22.15)	51.21 (19.94)	58.65 (21.52)
LS Mean of Change from Baseline (SE)	0.27 (1.45)	-2.17 (1.63)	0.61 (1.06)
95% CI	(-2.58, 3.12)	(-5.38, 1.04)	(-1.47, 2.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.34 (1.74)	-2.78 (1.91)	
95% CI	(-3.76, 3.08)	(-6.53, 0.97)	
p-value	0.8458	0.1460	
Corrected Hedge's g Statistics	-0.023	-0.189	
95% CI	(-0.26, 0.22)	(-0.45, 0.07)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	59.09 (23.19)	50.87 (23.51)	57.52 (21.74)
Analysis Visit Mean (SD)	58.09 (22.54)	51.63 (20.53)	56.99 (23.21)
LS Mean of Change from Baseline (SE)	-0.10 (1.63)	-1.62 (1.82)	-0.43 (1.16)
95% CI	(-3.31, 3.11)	(-5.20, 1.96)	(-2.72, 1.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.33 (1.96)	-1.18 (2.12)	
95% CI	(-3.51, 4.18)	(-5.36, 2.99)	
p-value	0.8648	0.5776	
Corrected Hedge's g Statistics	0.021	-0.075	
95% CI	(-0.23, 0.27)	(-0.34, 0.19)	
Subgroup*Treatment Interaction p-value	0.6303	0.9744	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Social Functioning			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	84.50 (20.72)	78.16 (26.74)	84.11 (22.01)
Analysis Visit Mean (SD)	82.21 (23.41)	80.22 (22.25)	82.88 (23.63)
LS Mean of Change from Baseline (SE)	-1.84 (1.72)	-0.09 (1.94)	-1.51 (1.26)
95% CI	(-5.22, 1.54)	(-3.90, 3.72)	(-3.98, 0.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.34 (2.07)	1.42 (2.27)	
95% CI	(-4.40, 3.73)	(-3.04, 5.88)	
p-value	0.8711	0.5324	
Corrected Hedge's g Statistics	-0.019	0.081	
95% CI	(-0.26, 0.22)	(-0.18, 0.34)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	84.01 (21.84)	77.20 (27.48)	84.17 (21.83)
Analysis Visit Mean (SD)	82.26 (22.14)	79.73 (22.45)	82.47 (22.64)
LS Mean of Change from Baseline (SE)	-1.44 (1.79)	0.16 (2.00)	-1.78 (1.28)
95% CI	(-4.96, 2.08)	(-3.76, 4.09)	(-4.29, 0.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.34 (2.15)	1.94 (2.33)	
95% CI	(-3.88, 4.56)	(-2.64, 6.52)	
p-value	0.8757	0.4057	
Corrected Hedge's g Statistics	0.019	0.112	
95% CI	(-0.23, 0.27)	(-0.16, 0.38)	
Subgroup*Treatment Interaction p-value	0.3420	0.7460	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Role Emotional			
Week 24			
m	111	87	221
n	104	79	191
Baseline Mean (SD)	83.65 (23.20)	80.59 (26.27)	84.73 (22.71)
Analysis Visit Mean (SD)	84.14 (21.21)	82.70 (22.08)	84.07 (23.32)
LS Mean of Change from Baseline (SE)	0.60 (1.57)	0.89 (1.76)	-0.69 (1.15)
95% CI	(-2.49, 3.68)	(-2.57, 4.35)	(-2.96, 1.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.29 (1.89)	1.58 (2.06)	
95% CI	(-2.42, 5.00)	(-2.47, 5.64)	
p-value	0.4943	0.4432	
Corrected Hedge's g Statistics	0.081	0.100	
95% CI	(-0.16, 0.32)	(-0.16, 0.36)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	82.79 (24.14)	79.84 (26.67)	85.24 (22.49)
Analysis Visit Mean (SD)	83.65 (20.76)	82.21 (23.67)	83.47 (22.76)
LS Mean of Change from Baseline (SE)	0.72 (1.72)	1.33 (1.91)	-1.38 (1.23)
95% CI	(-2.65, 4.09)	(-2.42, 5.08)	(-3.79, 1.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.10 (2.06)	2.71 (2.23)	
95% CI	(-1.95, 6.15)	(-1.67, 7.09)	
p-value	0.3077	0.2245	
Corrected Hedge's g Statistics	0.126	0.163	
95% CI	(-0.12, 0.38)	(-0.11, 0.43)	
Subgroup*Treatment Interaction p-value	0.3359	0.5148	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Mental Health			
Week 24			
m	111	87	221
n	104	79	192
Baseline Mean (SD)	75.0 (19.2)	73.8 (20.9)	75.6 (17.8)
Analysis Visit Mean (SD)	74.5 (18.3)	72.8 (20.4)	75.9 (18.0)
LS Mean of Change from Baseline (SE)	-0.77 (1.26)	-1.91 (1.42)	-0.20 (0.92)
95% CI	(-3.25, 1.72)	(-4.70, 0.87)	(-2.02, 1.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.56 (1.52)	-1.71 (1.65)	
95% CI	(-3.55, 2.42)	(-4.96, 1.54)	
p-value	0.7101	0.3015	
Corrected Hedge's g Statistics	-0.044	-0.134	
95% CI	(-0.28, 0.19)	(-0.40, 0.13)	
Week 52			
m	107	87	219
n	93	74	184
Baseline Mean (SD)	74.8 (19.6)	73.3 (21.1)	75.2 (18.1)
Analysis Visit Mean (SD)	74.9 (16.8)	73.6 (19.5)	75.0 (20.3)
LS Mean of Change from Baseline (SE)	-0.15 (1.41)	-0.52 (1.57)	-0.56 (1.01)
95% CI	(-2.93, 2.63)	(-3.60, 2.57)	(-2.55, 1.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.41 (1.70)	0.05 (1.83)	
95% CI	(-2.92, 3.74)	(-3.56, 3.65)	
p-value	0.8080	0.9800	
Corrected Hedge's g Statistics	0.030	0.003	
95% CI	(-0.22, 0.28)	(-0.27, 0.27)	
Subgroup*Treatment Interaction p-value	0.9363	0.9847	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Mental Component Score			
Week 24			
m	111	87	221
n	103	79	191
Baseline Mean (SD)	51.67 (10.43)	50.09 (12.56)	51.47 (9.45)
Analysis Visit Mean (SD)	51.21 (9.71)	50.27 (10.73)	51.32 (9.79)
LS Mean of Change from Baseline (SE)	-0.41 (0.65)	-0.42 (0.72)	-0.41 (0.47)
95% CI	(-1.68, 0.86)	(-1.84, 1.00)	(-1.34, 0.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.78)	0.00 (0.84)	
95% CI	(-1.52, 1.53)	(-1.66, 1.66)	
p-value	0.9936	0.9958	
Corrected Hedge's g Statistics	0.001	-0.001	
95% CI	(-0.24, 0.24)	(-0.26, 0.26)	
Week 52			
m	107	87	219
n	92	74	184
Baseline Mean (SD)	51.44 (10.78)	49.98 (12.79)	51.45 (9.34)
Analysis Visit Mean (SD)	51.36 (9.32)	50.80 (10.44)	50.78 (10.52)
LS Mean of Change from Baseline (SE)	-0.07 (0.74)	0.28 (0.81)	-0.82 (0.52)
95% CI	(-1.51, 1.38)	(-1.32, 1.88)	(-1.85, 0.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.76 (0.88)	1.10 (0.95)	
95% CI	(-0.98, 2.49)	(-0.76, 2.97)	
p-value	0.3918	0.2453	
Corrected Hedge's g Statistics	0.106	0.156	
95% CI	(-0.14, 0.36)	(-0.11, 0.43)	
Subgroup*Treatment Interaction p-value	0.5812	0.9071	

AMNOG Table SE22.11.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Physical Component Score			
Week 24			
m	111	87	221
n	103	79	191
Baseline Mean (SD)	47.36 (8.59)	44.55 (10.21)	47.78 (9.24)
Analysis Visit Mean (SD)	47.30 (9.75)	44.93 (9.19)	47.99 (9.37)
LS Mean of Change from Baseline (SE)	0.10 (0.66)	-0.30 (0.74)	0.35 (0.48)
95% CI	(-1.19, 1.39)	(-1.75, 1.14)	(-0.59, 1.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.25 (0.79)	-0.66 (0.86)	
95% CI	(-1.80, 1.29)	(-2.36, 1.04)	
p-value	0.7466	0.4483	
Corrected Hedge's g Statistics	-0.038	-0.099	
95% CI	(-0.28, 0.20)	(-0.36, 0.16)	
Week 52			
m	107	87	219
n	92	74	184
Baseline Mean (SD)	47.51 (8.59)	43.82 (10.22)	47.66 (9.20)
Analysis Visit Mean (SD)	47.09 (10.12)	43.96 (9.74)	48.03 (8.94)
LS Mean of Change from Baseline (SE)	-0.21 (0.65)	-0.57 (0.72)	0.54 (0.46)
95% CI	(-1.49, 1.07)	(-1.99, 0.85)	(-0.37, 1.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.75 (0.78)	-1.11 (0.85)	
95% CI	(-2.28, 0.78)	(-2.77, 0.55)	
p-value	0.3351	0.1901	
Corrected Hedge's g Statistics	-0.119	-0.176	
95% CI	(-0.37, 0.13)	(-0.45, 0.09)	
Subgroup*Treatment Interaction p-value	0.1250	0.2884	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (20.0)	7 (22.6)	5 (14.3)
No	24 (80.0)	24 (77.4)	30 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.57	
95% CI of the inverse odds ratio	(0.18, 2.45)	(0.16, 2.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.63	
95% CI of the inverse risk ratio	(0.24, 2.11)	(0.22, 1.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.71	8.29	
95% CI of the absolute risk difference	(-12.71, 24.13)	(-10.44, 27.03)	
p-value	0.5402	0.3832	
p-value of Breslow-Day Test for Homogeneity [3]	0.6187	0.5965	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (46.7)	13 (41.9)	11 (31.4)
No	16 (53.3)	18 (58.1)	24 (68.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	0.63	
95% CI of the inverse odds ratio	(0.19, 1.44)	(0.23, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.75	
95% CI of the inverse risk ratio	(0.36, 1.25)	(0.39, 1.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.24	10.51	
95% CI of the absolute risk difference	(-8.33, 38.80)	(-12.69, 33.71)	
p-value	0.2081	0.3758	
p-value of Breslow-Day Test for Homogeneity [3]	0.5640	0.2812	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	6 (19.4)	5 (14.3)
No	28 (93.3)	25 (80.6)	30 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.33	0.69	
95% CI of the inverse odds ratio	(0.42, 13.01)	(0.19, 2.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.14	0.74	
95% CI of the inverse risk ratio	(0.45, 10.26)	(0.25, 2.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.62	5.07	
95% CI of the absolute risk difference	(-22.25, 7.01)	(-13.04, 23.17)	
p-value	0.3232	0.5813	
p-value of Breslow-Day Test for Homogeneity [3]	0.7960	0.8257	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (26.7)	10 (32.3)	9 (25.7)
No	22 (73.3)	21 (67.7)	26 (74.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.73	
95% CI of the inverse odds ratio	(0.31, 2.88)	(0.25, 2.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.80	
95% CI of the inverse risk ratio	(0.43, 2.19)	(0.37, 1.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.95	6.54	
95% CI of the absolute risk difference	(-20.50, 22.40)	(-15.38, 28.46)	
p-value	0.9306	0.5579	
p-value of Breslow-Day Test for Homogeneity [3]	0.9810	0.4821	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (16.7)	13 (41.9)	8 (22.9)
No	25 (83.3)	18 (58.1)	27 (77.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.48	0.41	
95% CI of the inverse odds ratio	(0.43, 5.13)	(0.14, 1.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.37	0.55	
95% CI of the inverse risk ratio	(0.50, 3.75)	(0.26, 1.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.19	19.08	
95% CI of the absolute risk difference	(-25.46, 13.08)	(-3.18, 41.33)	
p-value	0.5339	0.0968	
p-value of Breslow-Day Test for Homogeneity [3]	0.8119	0.1254	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (40.0)	13 (41.9)	12 (34.3)
No	18 (60.0)	18 (58.1)	23 (65.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.72	
95% CI of the inverse odds ratio	(0.28, 2.15)	(0.27, 1.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.82	
95% CI of the inverse risk ratio	(0.45, 1.62)	(0.44, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.71	7.65	
95% CI of the absolute risk difference	(-17.84, 29.26)	(-15.78, 31.08)	
p-value	0.6341	0.5226	
p-value of Breslow-Day Test for Homogeneity [3]	0.5789	0.9793	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	12 (38.7)	11 (31.4)
No	27 (90.0)	19 (61.3)	24 (68.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.13	0.73	
95% CI of the inverse odds ratio	(1.03, 16.56)	(0.26, 2.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.14	0.81	
95% CI of the inverse risk ratio	(0.97, 10.23)	(0.42, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-21.43	7.28	
95% CI of the absolute risk difference	(-40.18, -2.67)	(-15.75, 30.31)	
p-value	0.0362	0.5355	
p-value of Breslow-Day Test for Homogeneity [3]	0.0158	0.6574	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (36.7)	18 (58.1)	16 (45.7)
No	19 (63.3)	13 (41.9)	19 (54.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	0.61	
95% CI of the inverse odds ratio	(0.54, 3.94)	(0.23, 1.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.79	
95% CI of the inverse risk ratio	(0.69, 2.26)	(0.49, 1.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.05	12.35	
95% CI of the absolute risk difference	(-32.92, 14.82)	(-11.61, 36.31)	
p-value	0.4606	0.3164	
p-value of Breslow-Day Test for Homogeneity [3]	0.2652	0.6400	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (13.3)	4 (12.9)	5 (14.3)
No	26 (86.7)	27 (87.1)	30 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	1.13	
95% CI of the inverse odds ratio	(0.26, 4.46)	(0.27, 4.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.11	
95% CI of the inverse risk ratio	(0.32, 3.63)	(0.33, 3.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.95	-1.38	
95% CI of the absolute risk difference	(-17.76, 15.85)	(-17.93, 15.16)	
p-value	0.9118	0.8703	
p-value of Breslow-Day Test for Homogeneity [3]	0.9135	0.7608	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (36.7)	12 (38.7)	14 (40.0)
No	19 (63.3)	19 (61.3)	21 (60.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.06	
95% CI of the inverse odds ratio	(0.42, 3.14)	(0.39, 2.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.03	
95% CI of the inverse risk ratio	(0.59, 2.03)	(0.57, 1.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.33	-1.29	
95% CI of the absolute risk difference	(-27.01, 20.35)	(-24.90, 22.32)	
p-value	0.7830	0.9147	
p-value of Breslow-Day Test for Homogeneity [3]	0.6743	0.9941	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (16.7)	5 (16.1)	5 (14.3)
No	25 (83.3)	26 (83.9)	30 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.87	
95% CI of the inverse odds ratio	(0.22, 3.21)	(0.23, 3.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.89	
95% CI of the inverse risk ratio	(0.27, 2.68)	(0.28, 2.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.38	1.84	
95% CI of the absolute risk difference	(-15.29, 20.05)	(-15.54, 19.22)	
p-value	0.7908	0.8349	
p-value of Breslow-Day Test for Homogeneity [3]	0.6077	0.2104	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	9 (29.0)	11 (31.4)
No	23 (76.7)	22 (71.0)	24 (68.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	1.12	
95% CI of the inverse odds ratio	(0.50, 4.56)	(0.39, 3.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	1.08	
95% CI of the inverse risk ratio	(0.60, 3.04)	(0.52, 2.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.10	-2.40	
95% CI of the absolute risk difference	(-29.67, 13.48)	(-24.57, 19.78)	
p-value	0.4672	0.8326	
p-value of Breslow-Day Test for Homogeneity [3]	0.6608	0.2742	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (13.3)	10 (32.3)	6 (17.1)
No	26 (86.7)	21 (67.7)	29 (82.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.34	0.43	
95% CI of the inverse odds ratio	(0.34, 5.30)	(0.14, 1.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.53	
95% CI of the inverse risk ratio	(0.40, 4.13)	(0.22, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.81	15.12	
95% CI of the absolute risk difference	(-21.24, 13.62)	(-5.54, 35.77)	
p-value	0.6713	0.1527	
p-value of Breslow-Day Test for Homogeneity [3]	0.6413	0.4962	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	11 (35.5)	10 (28.6)
No	23 (76.7)	20 (64.5)	25 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	0.73	
95% CI of the inverse odds ratio	(0.43, 4.03)	(0.26, 2.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	0.81	
95% CI of the inverse risk ratio	(0.53, 2.82)	(0.40, 1.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.24	6.91	
95% CI of the absolute risk difference	(-26.52, 16.05)	(-15.62, 29.44)	
p-value	0.6319	0.5474	
p-value of Breslow-Day Test for Homogeneity [3]	0.5027	0.6569	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	2 (6.5)	7 (20.0)
No	28 (93.3)	29 (93.5)	28 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	3.63	
95% CI of the inverse odds ratio	(0.67, 18.34)	(0.69, 18.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	3.10	
95% CI of the inverse risk ratio	(0.67, 13.36)	(0.69, 13.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.33	-13.55	
95% CI of the absolute risk difference	(-29.31, 2.64)	(-29.37, 2.28)	
p-value	0.1208	0.1094	
p-value of Breslow-Day Test for Homogeneity [3]	0.4080	0.3034	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (40.0)	10 (32.3)	13 (37.1)
No	18 (60.0)	21 (67.7)	22 (62.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.24	
95% CI of the inverse odds ratio	(0.33, 2.41)	(0.45, 3.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.15	
95% CI of the inverse risk ratio	(0.50, 1.72)	(0.59, 2.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.86	-4.88	
95% CI of the absolute risk difference	(-20.88, 26.60)	(-27.84, 18.07)	
p-value	0.8134	0.6777	
p-value of Breslow-Day Test for Homogeneity [3]	0.7624	0.8361	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.3)	3 (9.7)	2 (5.7)
No	29 (96.7)	28 (90.3)	33 (94.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.76	0.57	
95% CI of the inverse odds ratio	(0.15, 20.40)	(0.09, 3.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	0.59	
95% CI of the inverse risk ratio	(0.16, 17.98)	(0.11, 3.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.38	3.96	
95% CI of the absolute risk difference	(-12.40, 7.64)	(-8.98, 16.90)	
p-value	0.6483	0.5437	
p-value of Breslow-Day Test for Homogeneity [3]	0.7464	0.5368	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (20.0)	6 (19.4)	11 (31.4)
No	24 (80.0)	25 (80.6)	24 (68.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.83	1.91	
95% CI of the inverse odds ratio	(0.58, 5.76)	(0.61, 5.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.57	1.62	
95% CI of the inverse risk ratio	(0.66, 3.74)	(0.68, 3.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.43	-12.07	
95% CI of the absolute risk difference	(-32.44, 9.58)	(-32.81, 8.66)	
p-value	0.2959	0.2629	
p-value of Breslow-Day Test for Homogeneity [3]	0.4943	0.2400	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	6 (19.4)	4 (11.4)
No	30 (100)	25 (80.6)	31 (88.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	8.71	0.54	
95% CI of the inverse odds ratio	(0.45, 168.82)	(0.14, 2.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.75	0.59	
95% CI of the inverse risk ratio	(0.43, 138.34)	(0.18, 1.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.89	7.93	
95% CI of the absolute risk difference	(-22.57, 0.79)	(-9.52, 25.38)	
p-value	0.0909	0.3701	
p-value of Breslow-Day Test for Homogeneity [3]	0.0509	0.5250	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (33.3)	12 (38.7)	7 (20.0)
No	20 (66.7)	19 (61.3)	28 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	0.40	
95% CI of the inverse odds ratio	(0.16, 1.54)	(0.13, 1.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.52	
95% CI of the inverse risk ratio	(0.26, 1.38)	(0.23, 1.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.33	18.71	
95% CI of the absolute risk difference	(-8.12, 34.78)	(-2.96, 40.38)	
p-value	0.2227	0.0938	
p-value of Breslow-Day Test for Homogeneity [3]	0.0529	0.4218	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (25.0)	1 (12.5)	2 (15.4)
No	9 (75.0)	7 (87.5)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	1.27	
95% CI of the inverse odds ratio	(0.07, 4.01)	(0.10, 16.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	1.23	
95% CI of the inverse risk ratio	(0.12, 3.07)	(0.13, 11.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.62	-2.88	
95% CI of the absolute risk difference	(-21.77, 41.00)	(-33.05, 27.28)	
p-value	0.5482	0.8544	
p-value of Breslow-Day Test for Homogeneity [3]	0.6187	0.5965	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (41.7)	1 (12.5)	5 (38.5)
No	7 (58.3)	7 (87.5)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	4.38	
95% CI of the inverse odds ratio	(0.18, 4.34)	(0.41, 47.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	3.08	
95% CI of the inverse risk ratio	(0.35, 2.41)	(0.43, 21.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.21	-25.96	
95% CI of the absolute risk difference	(-35.23, 41.64)	(-60.96, 9.03)	
p-value	0.8702	0.2009	
p-value of Breslow-Day Test for Homogeneity [3]	0.5640	0.2812	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (8.3)	1 (12.5)	2 (15.4)
No	11 (91.7)	7 (87.5)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	1.27	
95% CI of the inverse odds ratio	(0.16, 25.40)	(0.10, 16.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.85	1.23	
95% CI of the inverse risk ratio	(0.19, 17.84)	(0.13, 11.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.05	-2.88	
95% CI of the absolute risk difference	(-32.14, 18.03)	(-33.05, 27.28)	
p-value	0.5878	0.8544	
p-value of Breslow-Day Test for Homogeneity [3]	0.7960	0.8257	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (33.3)	1 (12.5)	4 (30.8)
No	8 (66.7)	7 (87.5)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	3.11	
95% CI of the inverse odds ratio	(0.17, 4.78)	(0.28, 34.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	2.46	
95% CI of the inverse risk ratio	(0.29, 2.89)	(0.33, 18.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.56	-18.27	
95% CI of the absolute risk difference	(-34.05, 39.18)	(-52.25, 15.71)	
p-value	0.8908	0.3398	
p-value of Breslow-Day Test for Homogeneity [3]	0.9810	0.4821	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (16.7)	1 (12.5)	2 (15.4)
No	10 (83.3)	7 (87.5)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.27	
95% CI of the inverse odds ratio	(0.11, 7.72)	(0.10, 16.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.23	
95% CI of the inverse risk ratio	(0.15, 5.56)	(0.13, 11.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.28	-2.88	
95% CI of the absolute risk difference	(-27.52, 30.08)	(-33.05, 27.28)	
p-value	0.9304	0.8544	
p-value of Breslow-Day Test for Homogeneity [3]	0.8119	0.1254	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (16.7)	2 (25.0)	3 (23.1)
No	10 (83.3)	6 (75.0)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	0.90	
95% CI of the inverse odds ratio	(0.20, 11.00)	(0.12, 7.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	0.92	
95% CI of the inverse risk ratio	(0.28, 6.91)	(0.19, 4.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.41	1.92	
95% CI of the absolute risk difference	(-37.54, 24.72)	(-35.82, 39.67)	
p-value	0.6889	0.9200	
p-value of Breslow-Day Test for Homogeneity [3]	0.5789	0.9793	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (41.7)	0	1 (7.7)
No	7 (58.3)	8 (100)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.12	2.04	
95% CI of the inverse odds ratio	(0.01, 1.21)	(0.07, 56.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.18	1.93	
95% CI of the inverse risk ratio	(0.03, 1.36)	(0.09, 42.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	33.97	-5.16	
95% CI of the absolute risk difference	(2.54, 65.41)	(-27.21, 16.90)	
p-value	0.0469	0.6683	
p-value of Breslow-Day Test for Homogeneity [3]	0.0158	0.6574	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (50.0)	1 (12.5)	3 (23.1)
No	6 (50.0)	7 (87.5)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	2.10	
95% CI of the inverse odds ratio	(0.05, 1.67)	(0.18, 24.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.46	1.85	
95% CI of the inverse risk ratio	(0.15, 1.45)	(0.23, 14.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	26.92	-10.58	
95% CI of the absolute risk difference	(-9.48, 63.32)	(-42.98, 21.82)	
p-value	0.1612	0.5489	
p-value of Breslow-Day Test for Homogeneity [3]	0.2652	0.6400	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (8.3)	0	1 (7.7)
No	11 (91.7)	8 (100)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	2.04	
95% CI of the inverse odds ratio	(0.05, 16.49)	(0.07, 56.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.93	
95% CI of the inverse risk ratio	(0.06, 13.18)	(0.09, 42.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.64	-5.16	
95% CI of the absolute risk difference	(-20.67, 21.96)	(-27.21, 16.90)	
p-value	0.9529	0.6683	
p-value of Breslow-Day Test for Homogeneity [3]	0.9135	0.7608	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (50.0)	3 (37.5)	5 (38.5)
No	6 (50.0)	5 (62.5)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	1.04	
95% CI of the inverse odds ratio	(0.13, 3.07)	(0.17, 6.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.03	
95% CI of the inverse risk ratio	(0.32, 1.87)	(0.33, 3.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.54	-0.96	
95% CI of the absolute risk difference	(-27.19, 50.26)	(-43.68, 41.76)	
p-value	0.5615	0.9649	
p-value of Breslow-Day Test for Homogeneity [3]	0.6743	0.9941	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (8.3)	1 (12.5)	3 (23.1)
No	11 (91.7)	7 (87.5)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.30	2.10	
95% CI of the inverse odds ratio	(0.29, 37.10)	(0.18, 24.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.77	1.85	
95% CI of the inverse risk ratio	(0.33, 23.14)	(0.23, 14.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.74	-10.58	
95% CI of the absolute risk difference	(-42.48, 12.99)	(-42.98, 21.82)	
p-value	0.3151	0.5489	
p-value of Breslow-Day Test for Homogeneity [3]	0.6077	0.2104	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (16.7)	1 (12.5)	3 (23.1)
No	10 (83.3)	7 (87.5)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	2.10	
95% CI of the inverse odds ratio	(0.20, 11.00)	(0.18, 24.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	1.85	
95% CI of the inverse risk ratio	(0.28, 6.91)	(0.23, 14.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.41	-10.58	
95% CI of the absolute risk difference	(-37.54, 24.72)	(-42.98, 21.82)	
p-value	0.6889	0.5489	
p-value of Breslow-Day Test for Homogeneity [3]	0.6608	0.2742	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (8.3)	1 (12.5)	3 (23.1)
No	11 (91.7)	7 (87.5)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.30	2.10	
95% CI of the inverse odds ratio	(0.29, 37.10)	(0.18, 24.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.77	1.85	
95% CI of the inverse risk ratio	(0.33, 23.14)	(0.23, 14.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.74	-10.58	
95% CI of the absolute risk difference	(-42.48, 12.99)	(-42.98, 21.82)	
p-value	0.3151	0.5489	
p-value of Breslow-Day Test for Homogeneity [3]	0.6413	0.4962	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (8.3)	2 (25.0)	3 (23.1)
No	11 (91.7)	6 (75.0)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.30	0.90	
95% CI of the inverse odds ratio	(0.29, 37.10)	(0.12, 7.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.77	0.92	
95% CI of the inverse risk ratio	(0.33, 23.14)	(0.19, 4.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.74	1.92	
95% CI of the absolute risk difference	(-42.48, 12.99)	(-35.82, 39.67)	
p-value	0.3151	0.9200	
p-value of Breslow-Day Test for Homogeneity [3]	0.5027	0.6569	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (33.3)	1 (12.5)	4 (30.8)
No	8 (66.7)	7 (87.5)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	3.11	
95% CI of the inverse odds ratio	(0.17, 4.78)	(0.28, 34.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	2.46	
95% CI of the inverse risk ratio	(0.29, 2.89)	(0.33, 18.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.56	-18.27	
95% CI of the absolute risk difference	(-34.05, 39.18)	(-52.25, 15.71)	
p-value	0.8908	0.3398	
p-value of Breslow-Day Test for Homogeneity [3]	0.4080	0.3034	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (58.3)	3 (37.5)	5 (38.5)
No	5 (41.7)	5 (62.5)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.45	1.04	
95% CI of the inverse odds ratio	(0.09, 2.22)	(0.17, 6.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	1.03	
95% CI of the inverse risk ratio	(0.29, 1.52)	(0.33, 3.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	19.87	-0.96	
95% CI of the absolute risk difference	(-18.57, 58.31)	(-43.68, 41.76)	
p-value	0.3204	0.9649	
p-value of Breslow-Day Test for Homogeneity [3]	0.7624	0.8361	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (8.3)	1 (12.5)	3 (23.1)
No	11 (91.7)	7 (87.5)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.30	2.10	
95% CI of the inverse odds ratio	(0.29, 37.10)	(0.18, 24.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.77	1.85	
95% CI of the inverse risk ratio	(0.33, 23.14)	(0.23, 14.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.74	-10.58	
95% CI of the absolute risk difference	(-42.48, 12.99)	(-42.98, 21.82)	
p-value	0.3151	0.5489	
p-value of Breslow-Day Test for Homogeneity [3]	0.7464	0.5368	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (41.7)	1 (12.5)	5 (38.5)
No	7 (58.3)	7 (87.5)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	4.38	
95% CI of the inverse odds ratio	(0.18, 4.34)	(0.41, 47.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	3.08	
95% CI of the inverse risk ratio	(0.35, 2.41)	(0.43, 21.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.21	-25.96	
95% CI of the absolute risk difference	(-35.23, 41.64)	(-60.96, 9.03)	
p-value	0.8702	0.2009	
p-value of Breslow-Day Test for Homogeneity [3]	0.4943	0.2400	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (16.7)	1 (12.5)	0
No	10 (83.3)	7 (87.5)	13 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.16	0.19	
95% CI of the inverse odds ratio	(0.01, 3.60)	(0.01, 5.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.19	0.21	
95% CI of the inverse risk ratio	(0.01, 3.52)	(0.01, 4.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.66	13.10	
95% CI of the absolute risk difference	(-7.87, 39.19)	(-13.12, 39.31)	
p-value	0.1958	0.2767	
p-value of Breslow-Day Test for Homogeneity [3]	0.0509	0.5250	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (25.0)	1 (12.5)	0
No	9 (75.0)	7 (87.5)	13 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.10	0.19	
95% CI of the inverse odds ratio	(0.00, 2.18)	(0.01, 5.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	0.21	
95% CI of the inverse risk ratio	(0.01, 2.33)	(0.01, 4.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	23.35	13.10	
95% CI of the absolute risk difference	(-2.65, 49.35)	(-13.12, 39.31)	
p-value	0.0879	0.2767	
p-value of Breslow-Day Test for Homogeneity [3]	0.0529	0.4218	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (11.7)	10 (11.5)	30 (13.6)
No	98 (88.3)	77 (88.5)	191 (86.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.21	
95% CI of the inverse odds ratio	(0.59, 2.37)	(0.56, 2.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.18	
95% CI of the inverse risk ratio	(0.63, 2.13)	(0.60, 2.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.86	-2.08	
95% CI of the absolute risk difference	(-9.36, 5.63)	(-10.16, 6.00)	
p-value	0.6334	0.6249	
p-value of Breslow-Day Test for Homogeneity [3]	0.6187	0.5965	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	36 (32.4)	34 (39.1)	70 (31.7)
No	75 (67.6)	53 (60.9)	151 (68.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.72	
95% CI of the inverse odds ratio	(0.59, 1.57)	(0.43, 1.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.81	
95% CI of the inverse risk ratio	(0.70, 1.36)	(0.58, 1.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.76	7.41	
95% CI of the absolute risk difference	(-9.89, 11.41)	(-4.54, 19.35)	
p-value	0.8888	0.2160	
p-value of Breslow-Day Test for Homogeneity [3]	0.5640	0.2812	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (10.8)	11 (12.6)	30 (13.6)
No	99 (89.2)	76 (87.4)	191 (86.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	1.09	
95% CI of the inverse odds ratio	(0.64, 2.64)	(0.52, 2.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	1.07	
95% CI of the inverse risk ratio	(0.67, 2.36)	(0.56, 2.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.76	-0.93	
95% CI of the absolute risk difference	(-10.10, 4.57)	(-9.25, 7.39)	
p-value	0.4748	0.8286	
p-value of Breslow-Day Test for Homogeneity [3]	0.7960	0.8257	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (25.2)	28 (32.2)	57 (25.8)
No	83 (74.8)	59 (67.8)	164 (74.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.73	
95% CI of the inverse odds ratio	(0.61, 1.74)	(0.43, 1.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.80	
95% CI of the inverse risk ratio	(0.69, 1.51)	(0.55, 1.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.57	6.39	
95% CI of the absolute risk difference	(-10.49, 9.36)	(-4.99, 17.78)	
p-value	0.9111	0.2586	
p-value of Breslow-Day Test for Homogeneity [3]	0.9810	0.4821	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (11.7)	12 (13.8)	43 (19.5)
No	98 (88.3)	75 (86.2)	178 (80.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.82	1.51	
95% CI of the inverse odds ratio	(0.93, 3.55)	(0.75, 3.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.66	1.41	
95% CI of the inverse risk ratio	(0.93, 2.96)	(0.78, 2.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.75	-5.66	
95% CI of the absolute risk difference	(-15.68, 0.19)	(-14.59, 3.27)	
p-value	0.0754	0.2426	
p-value of Breslow-Day Test for Homogeneity [3]	0.8119	0.1254	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (23.4)	31 (35.6)	67 (30.3)
No	85 (76.6)	56 (64.4)	154 (69.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	0.79	
95% CI of the inverse odds ratio	(0.84, 2.40)	(0.47, 1.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.85	
95% CI of the inverse risk ratio	(0.88, 1.91)	(0.60, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.89	5.32	
95% CI of the absolute risk difference	(-16.83, 3.05)	(-6.43, 17.06)	
p-value	0.1870	0.3672	
p-value of Breslow-Day Test for Homogeneity [3]	0.5789	0.9793	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	17 (15.3)	16 (18.4)	33 (14.9)
No	94 (84.7)	71 (81.6)	188 (85.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.78	
95% CI of the inverse odds ratio	(0.51, 1.83)	(0.40, 1.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.81	
95% CI of the inverse risk ratio	(0.57, 1.67)	(0.47, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.38	3.46	
95% CI of the absolute risk difference	(-7.80, 8.57)	(-5.94, 12.86)	
p-value	0.9266	0.4550	
p-value of Breslow-Day Test for Homogeneity [3]	0.0158	0.6574	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (29.7)	34 (39.1)	73 (33.0)
No	78 (70.3)	53 (60.9)	148 (67.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.77	
95% CI of the inverse odds ratio	(0.71, 1.91)	(0.46, 1.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.85	
95% CI of the inverse risk ratio	(0.79, 1.56)	(0.61, 1.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.30	6.05	
95% CI of the absolute risk difference	(-13.83, 7.22)	(-5.93, 18.03)	
p-value	0.5426	0.3155	
p-value of Breslow-Day Test for Homogeneity [3]	0.2652	0.6400	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (9.9)	10 (11.5)	30 (13.6)
No	100 (90.1)	77 (88.5)	191 (86.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.21	
95% CI of the inverse odds ratio	(0.69, 2.97)	(0.56, 2.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.37	1.18	
95% CI of the inverse risk ratio	(0.71, 2.63)	(0.60, 2.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.66	-2.08	
95% CI of the absolute risk difference	(-10.83, 3.50)	(-10.16, 6.00)	
p-value	0.3383	0.6249	
p-value of Breslow-Day Test for Homogeneity [3]	0.9135	0.7608	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (29.7)	29 (33.3)	79 (35.7)
No	78 (70.3)	58 (66.7)	142 (64.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.11	
95% CI of the inverse odds ratio	(0.80, 2.15)	(0.66, 1.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	1.07	
95% CI of the inverse risk ratio	(0.86, 1.68)	(0.76, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.02	-2.41	
95% CI of the absolute risk difference	(-16.61, 4.58)	(-14.16, 9.34)	
p-value	0.2740	0.6895	
p-value of Breslow-Day Test for Homogeneity [3]	0.6743	0.9941	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (6.3)	17 (19.5)	17 (7.7)
No	104 (93.7)	70 (80.5)	204 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	0.34	
95% CI of the inverse odds ratio	(0.50, 3.08)	(0.17, 0.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	0.39	
95% CI of the inverse risk ratio	(0.52, 2.85)	(0.21, 0.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.39	11.85	
95% CI of the absolute risk difference	(-7.11, 4.34)	(2.81, 20.89)	
p-value	0.6455	0.0028	
p-value of Breslow-Day Test for Homogeneity [3]	0.6077	0.2104	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (18.9)	25 (28.7)	38 (17.2)
No	90 (81.1)	62 (71.3)	183 (82.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.51	
95% CI of the inverse odds ratio	(0.49, 1.60)	(0.29, 0.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.60	
95% CI of the inverse risk ratio	(0.56, 1.47)	(0.39, 0.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.72	11.54	
95% CI of the absolute risk difference	(-7.10, 10.55)	(0.81, 22.27)	
p-value	0.6982	0.0238	
p-value of Breslow-Day Test for Homogeneity [3]	0.6608	0.2742	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (12.6)	19 (21.8)	29 (13.1)
No	97 (87.4)	68 (78.2)	192 (86.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.54	
95% CI of the inverse odds ratio	(0.53, 2.07)	(0.28, 1.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.60	
95% CI of the inverse risk ratio	(0.57, 1.89)	(0.36, 1.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.51	8.72	
95% CI of the absolute risk difference	(-8.12, 7.10)	(-1.04, 18.47)	
p-value	0.8962	0.0576	
p-value of Breslow-Day Test for Homogeneity [3]	0.6413	0.4962	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (18.9)	27 (31.0)	38 (17.2)
No	90 (81.1)	60 (69.0)	183 (82.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.46	
95% CI of the inverse odds ratio	(0.49, 1.60)	(0.26, 0.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.55	
95% CI of the inverse risk ratio	(0.56, 1.47)	(0.36, 0.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.72	13.84	
95% CI of the absolute risk difference	(-7.10, 10.55)	(2.92, 24.76)	
p-value	0.6982	0.0074	
p-value of Breslow-Day Test for Homogeneity [3]	0.5027	0.6569	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (11.7)	11 (12.6)	29 (13.1)
No	98 (88.3)	76 (87.4)	192 (86.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	1.04	
95% CI of the inverse odds ratio	(0.57, 2.29)	(0.50, 2.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	1.04	
95% CI of the inverse risk ratio	(0.61, 2.07)	(0.54, 1.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.41	-0.48	
95% CI of the absolute risk difference	(-8.87, 6.05)	(-8.76, 7.80)	
p-value	0.7153	0.9105	
p-value of Breslow-Day Test for Homogeneity [3]	0.4080	0.3034	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	38 (34.2)	28 (32.2)	65 (29.4)
No	73 (65.8)	59 (67.8)	156 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.88	
95% CI of the inverse odds ratio	(0.49, 1.30)	(0.51, 1.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.91	
95% CI of the inverse risk ratio	(0.62, 1.19)	(0.63, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.82	2.77	
95% CI of the absolute risk difference	(-5.85, 15.50)	(-8.74, 14.28)	
p-value	0.3702	0.6333	
p-value of Breslow-Day Test for Homogeneity [3]	0.7624	0.8361	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.5)	9 (10.3)	12 (5.4)
No	106 (95.5)	78 (89.7)	209 (94.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	0.50	
95% CI of the inverse odds ratio	(0.42, 3.55)	(0.20, 1.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	0.52	
95% CI of the inverse risk ratio	(0.44, 3.34)	(0.23, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.93	4.91	
95% CI of the absolute risk difference	(-5.81, 3.95)	(-2.15, 11.98)	
p-value	0.7182	0.1234	
p-value of Breslow-Day Test for Homogeneity [3]	0.7464	0.5368	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (23.4)	20 (23.0)	46 (20.8)
No	85 (76.6)	67 (77.0)	175 (79.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.88	
95% CI of the inverse odds ratio	(0.50, 1.48)	(0.49, 1.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.91	
95% CI of the inverse risk ratio	(0.58, 1.36)	(0.57, 1.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.61	2.17	
95% CI of the absolute risk difference	(-6.92, 12.13)	(-8.16, 12.51)	
p-value	0.5863	0.6755	
p-value of Breslow-Day Test for Homogeneity [3]	0.4943	0.2400	

AMNOG Table SE22.11.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.5)	5 (5.7)	10 (4.5)
No	106 (95.5)	82 (94.3)	211 (95.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.78	
95% CI of the inverse odds ratio	(0.33, 3.01)	(0.26, 2.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.79	
95% CI of the inverse risk ratio	(0.35, 2.87)	(0.28, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.02	1.22	
95% CI of the absolute risk difference	(-4.75, 4.71)	(-4.38, 6.83)	
p-value	0.9933	0.6537	
p-value of Breslow-Day Test for Homogeneity [3]	0.0509	0.5250	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (19.8)	28 (32.2)	53 (24.0)
No	89 (80.2)	59 (67.8)	168 (76.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	0.66	
95% CI of the inverse odds ratio	(0.73, 2.23)	(0.39, 1.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	0.75	
95% CI of the inverse risk ratio	(0.78, 1.88)	(0.51, 1.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.16	8.20	
95% CI of the absolute risk difference	(-13.47, 5.15)	(-3.11, 19.52)	
p-value	0.3923	0.1410	
p-value of Breslow-Day Test for Homogeneity [3]	0.0529	0.4218	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Physical Functioning						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	76.78 (23.02)	67.66 (27.20)	N/A			
Median	85.00	72.50	N/A			
IQR: Q1, Q3	70.00, 95.00	50.00, 90.00	N/A			
Min, Max	0.0, 100.0	5.0, 100.0	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	75.90 (25.76)	68.93 (26.75)	N/A	-0.15 (1.48)	0.60 (2.63)	N/A
Median	85.00	72.50	N/A	0	0	N/A
IQR: Q1, Q3	60.00, 100.00	55.00, 90.00	N/A	-5.00, 5.00	-5.00, 10.00	N/A
Min, Max	5.0, 100.0	5.0, 100.0	N/A	-40.0, 45.0	-65.0, 60.0	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	75.50 (27.47)	69.67 (25.99)	N/A	-0.82 (1.64)	2.29 (1.87)	N/A
Median	90.00	75.00	N/A	0	0	N/A
IQR: Q1, Q3	57.50, 100.00	55.00, 90.00	N/A	-5.00, 5.00	-5.00, 5.00	N/A
Min, Max	0.0, 100.0	5.0, 100.0	N/A	-65.0, 30.0	-50.0, 35.0	N/A

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Role Physical						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	77.70 (25.92)	70.72 (26.62)	N/A			
Median	87.50	75.00	N/A			
IQR: Q1, Q3	62.50, 100.00	50.00, 100.00	N/A			
Min, Max	0.0, 100.0	0.0, 100.0	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	76.21 (27.58)	71.20 (25.84)	N/A	-1.10 (1.90)	-0.41 (2.94)	N/A
Median	87.50	75.00	N/A	0	0	N/A
IQR: Q1, Q3	62.50, 100.00	50.00, 100.00	N/A	-12.50, 12.50	-18.70, 6.30	N/A
Min, Max	0.0, 100.0	0.0, 100.0	N/A	-37.5, 50.0	-56.2, 68.7	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	76.73 (28.05)	69.90 (26.18)	N/A	-0.57 (1.92)	0.74 (2.94)	N/A
Median	87.50	75.00	N/A	0	0	N/A
IQR: Q1, Q3	50.00, 100.00	50.00, 93.80	N/A	-6.20, 6.20	-6.30, 12.50	N/A
Min, Max	0.0, 100.0	6.3, 100.0	N/A	-43.8, 43.8	-75.0, 81.3	N/A

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Bodily Pain						
Baseline						
m	91	67	0			
n	85	64	0			
Mean (SD)	67.5 (25.0)	57.0 (27.4)	N/A			
Median	72.0	52.0	N/A			
IQR: Q1, Q3	51.0, 84.0	41.0, 74.0	N/A			
Min, Max	0, 100	0, 100	N/A			
Week 24						
m	91	67	0			
n	89	64	0	84	61	0
Mean (SD/SE)	63.6 (25.9)	62.9 (23.7)	N/A	-2.7 (2.2)	4.9 (2.5)	N/A
Median	72.0	62.0	N/A	0	0	N/A
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	N/A	-19.5, 10.0	0.0, 10.0	N/A
Min, Max	0, 100	21, 100	N/A	-50, 52	-38, 72	N/A
Week 52						
m	88	67	0			
n	80	61	0	76	59	0
Mean (SD/SE)	67.7 (26.5)	64.7 (26.4)	N/A	-0.6 (2.4)	8.4 (3.1)	N/A
Median	74.0	62.0	N/A	0	0	N/A
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	N/A	-10.0, 10.0	0.0, 20.0	N/A
Min, Max	0, 100	10, 100	N/A	-80, 59	-38, 69	N/A

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
General Health						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	61.02 (20.92)	51.94 (19.06)	N/A			
Median	62.00	48.50	N/A			
IQR: Q1, Q3	47.00, 77.00	40.00, 66.00	N/A			
Min, Max	10.0, 100.0	10.0, 100.0	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	60.07 (21.73)	54.03 (20.48)	N/A	0.08 (1.51)	1.92 (1.78)	N/A
Median	62.00	52.00	N/A	0	0	N/A
IQR: Q1, Q3	47.00, 77.00	38.50, 72.00	N/A	-5.00, 10.00	-5.00, 10.00	N/A
Min, Max	10.0, 100.0	10.0, 100.0	N/A	-60.0, 32.0	-35.0, 32.0	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	62.04 (19.71)	55.21 (18.36)	N/A	-0.24 (1.68)	3.24 (2.25)	N/A
Median	67.00	52.00	N/A	0	5.00	N/A
IQR: Q1, Q3	52.00, 77.00	42.00, 67.00	N/A	-10.00, 10.00	-10.00, 15.00	N/A
Min, Max	20.0, 97.0	20.0, 92.0	N/A	-70.0, 32.0	-47.0, 37.0	N/A

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Vitality						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	58.48 (21.81)	53.05 (23.36)	N/A			
Median	62.50	56.30	N/A			
IQR: Q1, Q3	43.80, 75.00	43.80, 68.80	N/A			
Min, Max	0.0, 100.0	0.0, 100.0	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	56.63 (22.41)	53.44 (20.80)	N/A	-1.27 (1.64)	0.10 (2.30)	N/A
Median	62.50	56.30	N/A	0	0	N/A
IQR: Q1, Q3	43.80, 75.00	34.40, 68.80	N/A	-6.30, 6.20	-12.50, 6.30	N/A
Min, Max	0.0, 100.0	12.5, 100.0	N/A	-43.8, 43.8	-31.3, 43.8	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	58.77 (21.45)	53.51 (21.05)	N/A	-0.65 (1.95)	0.74 (2.09)	N/A
Median	62.50	50.00	N/A	0	0	N/A
IQR: Q1, Q3	43.80, 75.00	37.50, 75.00	N/A	-6.30, 12.50	-6.30, 12.50	N/A
Min, Max	6.3, 93.8	6.3, 100.0	N/A	-43.7, 50.0	-43.8, 43.8	N/A

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Social Functioning						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	85.03 (22.83)	78.32 (26.19)	N/A			
Median	100.00	87.50	N/A			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	N/A			
Min, Max	0.0, 100.0	0.0, 100.0	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	80.06 (25.12)	80.27 (22.03)	N/A	-4.12 (2.01)	2.05 (2.71)	N/A
Median	87.50	87.50	N/A	0	0	N/A
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	N/A	-12.50, 0.00	-12.50, 12.50	N/A
Min, Max	12.5, 100.0	12.5, 100.0	N/A	-50.0, 50.0	-62.5, 87.5	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	81.25 (24.36)	82.38 (22.75)	N/A	-3.25 (1.95)	4.45 (2.88)	N/A
Median	87.50	100.00	N/A	0	0	N/A
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	N/A	-12.50, 0.00	0.00, 12.50	N/A
Min, Max	12.5, 100.0	25.0, 100.0	N/A	-50.0, 50.0	-62.5, 62.5	N/A

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Role Emotional						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	85.85 (21.66)	82.94 (22.64)	N/A			
Median	100.00	95.85	N/A			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	N/A			
Min, Max	0.0, 100.0	8.3, 100.0	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	82.86 (22.59)	85.16 (20.55)	N/A	-1.96 (1.45)	2.19 (2.41)	N/A
Median	100.00	100.00	N/A	0	0	N/A
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	N/A	-8.30, 0.00	-8.30, 16.70	N/A
Min, Max	25.0, 100.0	25.0, 100.0	N/A	-33.3, 33.3	-50.0, 41.7	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	83.12 (21.71)	84.56 (20.63)	N/A	-1.08 (1.58)	2.12 (3.09)	N/A
Median	95.85	91.70	N/A	0	0	N/A
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	N/A	0.00, 0.00	-8.30, 16.70	N/A
Min, Max	25.0, 100.0	25.0, 100.0	N/A	-50.0, 41.7	-75.0, 50.0	N/A

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Mental Health						
Baseline						
m	91	67	0			
n	86	64	0			
Mean (SD)	75.2 (19.0)	76.4 (17.7)	N/A			
Median	80.0	80.0	N/A			
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	N/A			
Min, Max	5, 100	30, 100	N/A			
Week 24						
m	91	67	0			
n	89	64	0	85	61	0
Mean (SD/SE)	73.3 (19.0)	73.9 (18.7)	N/A	-0.9 (1.5)	-2.9 (1.8)	N/A
Median	80.0	80.0	N/A	0	0	N/A
IQR: Q1, Q3	60.0, 90.0	65.0, 87.5	N/A	-10.0, 5.0	-5.0, 5.0	N/A
Min, Max	20, 100	20, 100	N/A	-40, 35	-40, 35	N/A
Week 52						
m	88	67	0			
n	80	61	0	77	59	0
Mean (SD/SE)	74.3 (17.9)	75.2 (18.6)	N/A	0.1 (1.4)	-1.4 (1.6)	N/A
Median	80.0	75.0	N/A	0	0	N/A
IQR: Q1, Q3	60.0, 90.0	65.0, 90.0	N/A	-5.0, 10.0	-10.0, 5.0	N/A
Min, Max	25, 100	25, 100	N/A	-35, 25	-30, 35	N/A

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Mental Component Score						
Baseline						
m	91	67	0			
n	85	64	0			
Mean (SD)	51.77 (10.18)	51.70 (10.73)	N/A			
Median	55.00	53.65	N/A			
IQR: Q1, Q3	47.70, 58.10	46.50, 59.05	N/A			
Min, Max	12.0, 69.0	23.6, 72.3	N/A			
Week 24						
m	91	67	0			
n	89	64	0	84	61	0
Mean (SD/SE)	50.20 (9.90)	51.34 (10.11)	N/A	-1.17 (0.72)	-0.34 (0.95)	N/A
Median	52.90	53.25	N/A	-0.95	-0.50	N/A
IQR: Q1, Q3	43.40, 57.70	46.40, 58.50	N/A	-4.35, 2.95	-3.70, 2.70	N/A
Min, Max	25.0, 69.1	21.2, 71.2	N/A	-20.0, 17.7	-24.5, 22.4	N/A
Week 52						
m	88	67	0			
n	80	61	0	76	59	0
Mean (SD/SE)	50.69 (9.40)	51.69 (9.97)	N/A	-0.59 (0.77)	-0.01 (1.08)	N/A
Median	53.50	53.40	N/A	0.30	-0.30	N/A
IQR: Q1, Q3	43.05, 58.30	45.10, 58.60	N/A	-3.85, 3.45	-4.30, 4.10	N/A
Min, Max	26.7, 63.2	27.0, 70.7	N/A	-21.7, 14.9	-21.4, 25.2	N/A

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Physical Component Score						
Baseline						
m	91	67	0			
n	85	64	0			
Mean (SD)	48.03 (9.05)	43.27 (10.36)	N/A			
Median	49.00	44.10	N/A			
IQR: Q1, Q3	44.50, 55.00	36.95, 51.30	N/A			
Min, Max	15.3, 60.8	21.6, 60.3	N/A			
Week 24						
m	91	67	0			
n	89	64	0	84	61	0
Mean (SD/SE)	47.51 (10.39)	44.65 (9.70)	N/A	-0.22 (0.65)	1.05 (1.03)	N/A
Median	50.20	45.55	N/A	-0.55	0.30	N/A
IQR: Q1, Q3	41.50, 54.70	38.00, 52.35	N/A	-4.05, 3.55	-1.70, 3.30	N/A
Min, Max	12.5, 63.9	20.2, 61.0	N/A	-14.8, 17.6	-22.0, 32.4	N/A
Week 52						
m	88	67	0			
n	80	61	0	76	59	0
Mean (SD/SE)	48.17 (10.48)	44.88 (10.05)	N/A	-0.14 (0.72)	1.92 (0.99)	N/A
Median	52.00	43.70	N/A	-0.25	2.10	N/A
IQR: Q1, Q3	41.85, 55.65	38.20, 52.40	N/A	-2.35, 3.60	-3.10, 7.10	N/A
Min, Max	15.8, 62.8	24.4, 61.2	N/A	-24.7, 14.9	-20.4, 18.6	N/A

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Physical Functioning						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	72.59 (23.92)	72.83 (25.22)	75.81 (24.73)			
Median	75.00	80.00	85.00			
IQR: Q1, Q3	60.00, 95.00	60.00, 90.00	60.00, 95.00			
Min, Max	15.0, 100.0	10.0, 100.0	10.0, 100.0			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	77.80 (21.18)	74.66 (24.20)	76.40 (26.04)	4.04 (2.21)	2.14 (2.81)	0.83 (1.15)
Median	85.00	80.00	85.00	0	0	0
IQR: Q1, Q3	65.00, 95.00	63.05, 95.00	65.00, 100.00	-5.00, 15.00	-7.50, 10.00	-10.00, 10.00
Min, Max	5.0, 100.0	10.0, 100.0	0.0, 100.0	-50.0, 40.0	-65.0, 70.0	-50.0, 75.0
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	78.52 (25.06)	72.37 (26.47)	76.34 (24.65)	5.29 (2.14)	-1.23 (3.01)	0.61 (1.08)
Median	90.00	80.00	85.00	5.00	0	0
IQR: Q1, Q3	65.00, 100.00	60.00, 95.00	65.00, 95.00	-5.00, 15.00	-5.00, 7.50	-5.00, 5.00
Min, Max	10.0, 100.0	0.0, 100.0	0.0, 100.0	-45.0, 45.0	-85.0, 40.0	-60.0, 75.0

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Role Physical						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	74.91 (26.94)	76.55 (29.39)	77.55 (25.39)			
Median	81.30	87.50	87.50			
IQR: Q1, Q3	50.00, 100.00	75.00, 100.00	62.50, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	74.59 (25.15)	76.36 (23.99)	77.09 (26.29)	-0.88 (2.58)	0.36 (2.74)	-0.43 (1.33)
Median	75.00	81.30	87.50	0	0	0
IQR: Q1, Q3	50.00, 100.00	59.40, 100.00	56.30, 100.00	-12.50, 6.30	-9.40, 3.10	-6.30, 6.20
Min, Max	0.0, 100.0	18.8, 100.0	0.0, 100.0	-43.8, 43.7	-50.0, 50.0	-68.7, 87.5
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	75.35 (27.56)	78.45 (26.43)	75.55 (25.08)	0.36 (2.76)	0.65 (2.89)	-1.17 (1.36)
Median	78.15	87.50	81.30	0	0	0
IQR: Q1, Q3	50.00, 100.00	75.00, 100.00	56.30, 100.00	-6.20, 6.20	-6.30, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	6.3, 100.0	0.0, 100.0	-37.5, 81.2	-68.8, 56.3	-62.5, 75.0

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Bodily Pain						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	66.3 (23.7)	68.9 (26.1)	66.9 (24.6)			
Median	72.0	74.0	72.0			
IQR: Q1, Q3	51.0, 84.0	51.0, 84.0	42.0, 84.0			
Min, Max	10, 100	10, 100	0, 100			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	67.3 (25.1)	67.8 (24.1)	67.2 (24.4)	-0.4 (2.4)	-1.8 (2.6)	0.6 (1.3)
Median	72.0	72.0	72.0	0	0	0
IQR: Q1, Q3	51.0, 84.0	42.0, 84.0	51.0, 84.0	-11.0, 1.0	-14.0, 10.0	-11.0, 12.0
Min, Max	0, 100	22, 100	10, 100	-39, 68	-59, 64	-78, 78
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	68.1 (25.3)	70.4 (24.8)	67.6 (25.0)	1.0 (2.7)	1.2 (2.6)	1.5 (1.5)
Median	72.0	72.0	72.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	51.0, 84.0	51.0, 84.0	-10.0, 10.0	-9.5, 11.5	-11.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-38, 68	-53, 33	-78, 78

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
General Health						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	60.69 (18.39)	55.40 (20.14)	59.28 (20.37)			
Median	62.00	52.00	62.00			
IQR: Q1, Q3	50.00, 72.00	42.00, 72.00	45.00, 77.00			
Min, Max	15.0, 97.0	15.0, 92.0	15.0, 100.0			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	63.95 (20.23)	57.23 (18.67)	60.13 (20.96)	3.04 (1.99)	2.21 (2.49)	0.92 (0.96)
Median	62.00	57.00	62.00	5.00	0	0
IQR: Q1, Q3	47.00, 77.00	45.00, 72.00	45.00, 77.00	-5.00, 12.00	-10.00, 16.50	-8.00, 10.00
Min, Max	10.0, 100.0	17.0, 92.0	10.0, 100.0	-47.0, 32.0	-35.0, 40.0	-40.0, 48.0
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	64.12 (20.10)	57.69 (19.80)	60.39 (20.83)	4.19 (2.15)	1.42 (2.50)	1.42 (0.93)
Median	67.00	62.00	62.00	0	1.50	0
IQR: Q1, Q3	47.00, 77.00	45.00, 72.00	47.00, 77.00	-5.00, 15.00	-10.00, 10.00	-5.00, 10.00
Min, Max	20.0, 100.0	10.0, 92.0	10.0, 100.0	-27.0, 47.0	-52.0, 47.0	-42.0, 42.0

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Vitality						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	58.21 (23.39)	55.10 (23.26)	57.68 (21.54)			
Median	62.50	56.30	62.50			
IQR: Q1, Q3	37.50, 75.00	37.50, 75.00	43.80, 75.00			
Min, Max	6.3, 100.0	6.3, 93.8	0.0, 100.0			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	58.50 (25.55)	55.15 (20.30)	58.25 (21.69)	0.22 (1.95)	-0.73 (1.91)	0.63 (1.01)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	43.80, 75.00	40.65, 68.80	43.80, 75.00	-6.30, 6.30	-12.50, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	0.0, 93.8	0.0, 100.0	-43.8, 37.5	-31.2, 25.0	-37.5, 56.2
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	58.47 (25.03)	56.40 (20.67)	57.44 (22.56)	0.49 (1.81)	0.00 (2.11)	0.41 (1.19)
Median	62.50	62.50	62.50	0	0	0
IQR: Q1, Q3	37.50, 75.00	43.80, 68.80	43.80, 75.00	-6.30, 12.50	-6.30, 6.30	-6.30, 12.50
Min, Max	6.3, 100.0	6.3, 87.5	0.0, 100.0	-25.0, 37.5	-43.8, 37.5	-56.3, 50.0

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Social Functioning						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	81.03 (21.87)	83.02 (26.75)	83.65 (21.92)			
Median	87.50	100.00	100.00			
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	84.96 (21.25)	81.70 (21.32)	82.64 (23.22)	3.51 (2.96)	-0.48 (2.77)	-1.08 (1.27)
Median	100.00	87.50	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00	-12.50, 12.50	-12.50, 12.50	-12.50, 0.00
Min, Max	25.0, 100.0	12.5, 100.0	0.0, 100.0	-62.5, 75.0	-50.0, 50.0	-62.5, 75.0
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	82.41 (21.79)	81.13 (22.27)	82.87 (21.91)	0.74 (2.46)	-2.60 (3.22)	-0.57 (1.32)
Median	93.75	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00	0.00, 12.50	-12.50, 6.25	0.00, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-37.5, 37.5	-62.5, 37.5	-50.0, 75.0

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Role Emotional						
Baseline						
m	61	57	266			
n	58	53	246			
Mean (SD)	81.46 (24.88)	80.82 (26.63)	84.25 (22.32)			
Median	91.70	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	61	57	266			
n	59	56	247	57	52	230
Mean (SD/SE)	82.63 (22.01)	85.71 (21.54)	83.77 (22.91)	1.32 (2.84)	3.53 (1.91)	-0.69 (1.20)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	75.00, 100.00	-8.30, 8.30	0.00, 8.30	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	8.3, 100.0	-66.7, 66.7	-25.0, 50.0	-50.0, 58.3
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	84.65 (20.51)	85.13 (23.71)	82.83 (22.74)	4.01 (2.96)	4.16 (2.63)	-1.93 (1.25)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 8.30	0.00, 12.50	-8.40, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-33.3, 100.0	-50.0, 58.3	-58.3, 58.3

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Mental Health						
Baseline						
m	61	57	266			
n	58	53	247			
Mean (SD)	75.5 (17.9)	74.8 (20.9)	75.5 (17.6)			
Median	82.5	80.0	80.0			
IQR: Q1, Q3	65.0, 90.0	70.0, 90.0	65.0, 90.0			
Min, Max	35, 100	15, 100	5, 100			
Week 24						
m	61	57	266			
n	59	56	247	57	52	231
Mean (SD/SE)	74.7 (19.5)	77.1 (19.1)	75.9 (17.8)	-0.6 (1.7)	1.9 (1.6)	0.4 (0.9)
Median	75.0	80.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	72.5, 90.0	70.0, 90.0	-5.0, 5.0	-5.0, 5.0	-5.0, 5.0
Min, Max	20, 100	5, 100	20, 100	-35, 35	-30, 50	-35, 55
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	77.1 (18.2)	76.6 (17.3)	75.7 (19.2)	1.5 (1.9)	2.3 (1.9)	0.5 (1.0)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	70.0, 90.0	65.0, 90.0	70.0, 90.0	-5.0, 5.0	-5.0, 5.0	-7.5, 10.0
Min, Max	30, 100	20, 95	0, 100	-35, 40	-25, 50	-60, 55

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Mental Component Score						
Baseline						
m	61	57	266			
n	58	53	246			
Mean (SD)	51.02 (9.85)	50.44 (11.76)	51.34 (9.26)			
Median	53.00	54.90	54.10			
IQR: Q1, Q3	45.70, 59.10	46.40, 58.20	46.70, 57.80			
Min, Max	27.6, 62.6	17.0, 64.5	15.6, 66.5			
Week 24						
m	61	57	266			
n	59	56	247	57	52	230
Mean (SD/SE)	50.96 (10.72)	51.64 (9.60)	51.26 (9.84)	0.16 (1.04)	0.84 (0.88)	-0.15 (0.49)
Median	53.20	54.30	54.40	-0.20	0.35	0
IQR: Q1, Q3	45.20, 59.40	47.80, 58.85	46.60, 58.50	-3.40, 4.10	-2.60, 3.45	-4.00, 3.20
Min, Max	18.7, 66.6	9.4, 63.6	21.2, 69.0	-20.0, 19.0	-11.4, 26.1	-24.6, 24.8
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	51.55 (9.78)	51.49 (9.38)	51.04 (10.09)	0.68 (1.03)	1.08 (1.16)	-0.30 (0.52)
Median	54.00	53.20	53.70	-0.40	0	0.20
IQR: Q1, Q3	47.00, 58.30	47.00, 58.40	46.60, 58.10	-3.00, 3.70	-2.70, 2.50	-4.05, 3.60
Min, Max	23.1, 62.4	17.8, 62.8	8.9, 68.0	-16.0, 26.2	-14.0, 25.1	-25.1, 26.2

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Physical Component Score						
Baseline						
m	61	57	266			
n	58	53	246			
Mean (SD)	47.10 (8.87)	47.14 (9.53)	47.68 (9.13)			
Median	47.55	49.10	50.00			
IQR: Q1, Q3	42.80, 55.00	43.20, 54.40	42.50, 55.10			
Min, Max	21.1, 59.3	21.2, 60.4	20.7, 65.2			
Week 24						
m	61	57	266			
n	59	56	247	57	52	230
Mean (SD/SE)	48.44 (8.36)	46.84 (8.57)	47.81 (9.66)	0.82 (0.80)	-0.08 (1.02)	0.25 (0.45)
Median	48.70	49.05	50.10	0.70	-0.85	0.05
IQR: Q1, Q3	43.20, 54.10	41.15, 54.40	42.40, 55.20	-2.40, 4.70	-4.50, 4.55	-3.30, 3.50
Min, Max	21.8, 60.9	25.5, 59.4	19.0, 63.0	-15.7, 18.3	-22.1, 21.5	-28.8, 23.8
Week 52						
m	59	56	263			
n	54	51	235	51	48	220
Mean (SD/SE)	48.32 (10.42)	47.25 (9.70)	47.78 (9.25)	1.05 (0.98)	-0.38 (1.08)	0.42 (0.41)
Median	51.65	49.20	49.00	1.10	0.60	0.30
IQR: Q1, Q3	42.60, 57.50	41.40, 54.10	42.10, 55.20	-1.30, 3.80	-2.70, 4.10	-2.80, 3.55
Min, Max	20.3, 62.7	16.0, 60.0	21.5, 63.9	-22.4, 22.5	-23.5, 10.6	-23.9, 22.7

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Physical Functioning			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	76.50 (23.01)	67.13 (27.24)	N/A
Analysis Visit Mean (SD)	76.35 (26.05)	67.73 (26.80)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	76.72 (22.24)	67.03 (27.14)	N/A
Analysis Visit Mean (SD)	75.91 (27.25)	69.32 (26.35)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Role Physical			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	77.44 (25.96)	70.51 (26.76)	N/A
Analysis Visit Mean (SD)	76.34 (27.95)	70.10 (25.90)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	77.37 (26.47)	69.19 (26.58)	N/A
Analysis Visit Mean (SD)	76.80 (28.31)	69.93 (26.52)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Bodily Pain			
Week 24			
m	91	67	0
n	84	61	0
Baseline Mean (SD)	67.1 (24.9)	57.1 (27.0)	N/A
Analysis Visit Mean (SD)	64.4 (26.2)	62.1 (23.9)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	76	59	0
Baseline Mean (SD)	68.4 (25.7)	55.3 (26.4)	N/A
Analysis Visit Mean (SD)	67.8 (26.6)	63.8 (26.4)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
General Health			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	60.62 (20.71)	50.98 (18.39)	N/A
Analysis Visit Mean (SD)	60.71 (21.86)	52.90 (20.30)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	62.35 (20.89)	51.83 (19.52)	N/A
Analysis Visit Mean (SD)	62.10 (19.67)	55.07 (18.60)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Vitality			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	58.43 (21.93)	52.18 (23.41)	N/A
Analysis Visit Mean (SD)	57.16 (22.73)	52.28 (20.57)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	59.44 (21.92)	52.57 (23.42)	N/A
Analysis Visit Mean (SD)	58.79 (21.46)	53.31 (21.19)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Social Functioning			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	84.85 (22.91)	78.07 (26.29)	N/A
Analysis Visit Mean (SD)	80.74 (25.12)	80.12 (21.93)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	84.74 (23.79)	77.54 (26.85)	N/A
Analysis Visit Mean (SD)	81.49 (24.55)	81.99 (23.01)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Role Emotional			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	85.68 (21.73)	82.38 (22.98)	N/A
Analysis Visit Mean (SD)	83.72 (22.30)	84.57 (20.85)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	84.63 (22.46)	82.63 (22.92)	N/A
Analysis Visit Mean (SD)	83.55 (21.63)	84.74 (20.60)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Mental Health			
Week 24			
m	91	67	0
n	85	61	0
Baseline Mean (SD)	74.9 (19.0)	76.0 (17.9)	N/A
Analysis Visit Mean (SD)	74.0 (18.7)	73.1 (18.8)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	77	59	0
Baseline Mean (SD)	74.4 (19.6)	76.3 (17.9)	N/A
Analysis Visit Mean (SD)	74.5 (17.7)	74.8 (18.8)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Mental Component Score			
Week 24			
m	91	67	0
n	84	61	0
Baseline Mean (SD)	51.71 (10.23)	51.42 (10.89)	N/A
Analysis Visit Mean (SD)	50.54 (9.67)	51.08 (10.29)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	76	59	0
Baseline Mean (SD)	51.42 (10.55)	51.66 (10.98)	N/A
Analysis Visit Mean (SD)	50.82 (9.43)	51.64 (10.00)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Physical Component Score			
Week 24			
m	91	67	0
n	84	61	0
Baseline Mean (SD)	47.90 (9.01)	43.15 (10.22)	N/A
Analysis Visit Mean (SD)	47.68 (10.55)	44.20 (9.71)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	76	59	0
Baseline Mean (SD)	48.46 (9.00)	42.79 (10.37)	N/A
Analysis Visit Mean (SD)	48.32 (10.51)	44.71 (10.18)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Physical Functioning			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	73.42 (23.26)	72.98 (25.44)	75.87 (24.81)
Analysis Visit Mean (SD)	77.46 (21.34)	75.12 (23.41)	76.70 (25.99)
LS Mean of Change from Baseline (SE)	2.88 (2.23)	1.40 (2.33)	0.47 (1.14)
95% CI	(-1.50, 7.27)	(-3.18, 5.97)	(-1.78, 2.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.42 (2.47)	0.93 (2.56)	
95% CI	(-2.44, 7.27)	(-4.11, 5.97)	
p-value	0.3282	0.7174	
Corrected Hedge's g Statistics	0.139	0.054	
95% CI	(-0.15, 0.43)	(-0.25, 0.35)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	72.75 (23.88)	72.92 (25.07)	75.91 (24.59)
Analysis Visit Mean (SD)	78.04 (25.44)	71.69 (26.67)	76.52 (24.34)
LS Mean of Change from Baseline (SE)	4.68 (2.21)	-1.38 (2.28)	0.63 (1.11)
95% CI	(0.33, 9.03)	(-5.87, 3.10)	(-1.55, 2.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.05 (2.43)	-2.01 (2.50)	
95% CI	(-0.74, 8.84)	(-6.94, 2.91)	
p-value	0.0970	0.4223	
Corrected Hedge's g Statistics	0.247	-0.123	
95% CI	(-0.06, 0.55)	(-0.44, 0.19)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Role Physical			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	75.78 (26.33)	76.58 (29.68)	77.59 (25.46)
Analysis Visit Mean (SD)	74.90 (24.69)	76.94 (24.42)	77.15 (26.38)
LS Mean of Change from Baseline (SE)	-1.42 (2.45)	0.32 (2.55)	-0.21 (1.25)
95% CI	(-6.23, 3.39)	(-4.69, 5.33)	(-2.68, 2.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.21 (2.70)	0.53 (2.80)	
95% CI	(-6.53, 4.10)	(-4.98, 6.05)	
p-value	0.6543	0.8492	
Corrected Hedge's g Statistics	-0.064	0.028	
95% CI	(-0.35, 0.23)	(-0.27, 0.33)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	74.89 (27.96)	76.97 (29.52)	77.06 (25.50)
Analysis Visit Mean (SD)	75.25 (27.75)	77.62 (26.88)	75.90 (24.91)
LS Mean of Change from Baseline (SE)	0.46 (2.53)	0.73 (2.61)	-0.75 (1.27)
95% CI	(-4.52, 5.44)	(-4.40, 5.87)	(-3.24, 1.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.21 (2.79)	1.48 (2.87)	
95% CI	(-4.27, 6.70)	(-4.16, 7.12)	
p-value	0.6645	0.6062	
Corrected Hedge's g Statistics	0.065	0.079	
95% CI	(-0.24, 0.37)	(-0.23, 0.39)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Bodily Pain			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	67.0 (23.1)	69.2 (26.2)	67.0 (24.8)
Analysis Visit Mean (SD)	66.7 (25.2)	67.4 (24.2)	67.6 (24.5)
LS Mean of Change from Baseline (SE)	-0.55 (2.44)	-1.05 (2.54)	0.32 (1.25)
95% CI	(-5.35, 4.25)	(-6.05, 3.95)	(-2.14, 2.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.87 (2.69)	-1.37 (2.80)	
95% CI	(-6.16, 4.43)	(-6.86, 4.13)	
p-value	0.7473	0.6257	
Corrected Hedge's g Statistics	-0.046	-0.072	
95% CI	(-0.34, 0.24)	(-0.37, 0.23)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	66.4 (23.7)	68.4 (26.1)	66.4 (24.7)
Analysis Visit Mean (SD)	67.4 (25.4)	69.6 (25.1)	67.9 (24.6)
LS Mean of Change from Baseline (SE)	0.35 (2.65)	0.95 (2.74)	1.30 (1.33)
95% CI	(-4.87, 5.57)	(-4.44, 6.33)	(-1.31, 3.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.95 (2.92)	-0.36 (3.01)	
95% CI	(-6.70, 4.79)	(-6.27, 5.56)	
p-value	0.7445	0.9059	
Corrected Hedge's g Statistics	-0.049	-0.018	
95% CI	(-0.35, 0.26)	(-0.33, 0.29)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
General Health			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	61.28 (17.98)	54.79 (19.84)	59.46 (20.28)
Analysis Visit Mean (SD)	64.31 (18.77)	57.00 (18.76)	60.38 (21.29)
LS Mean of Change from Baseline (SE)	3.11 (1.93)	0.77 (2.01)	0.62 (0.99)
95% CI	(-0.67, 6.90)	(-3.18, 4.72)	(-1.31, 2.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.49 (2.12)	0.15 (2.21)	
95% CI	(-1.69, 6.67)	(-4.20, 4.50)	
p-value	0.2424	0.9469	
Corrected Hedge's g Statistics	0.167	0.010	
95% CI	(-0.12, 0.46)	(-0.29, 0.31)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	60.35 (18.58)	55.52 (20.09)	59.53 (20.66)
Analysis Visit Mean (SD)	64.54 (19.70)	56.94 (19.75)	60.95 (21.01)
LS Mean of Change from Baseline (SE)	3.87 (1.94)	0.13 (2.00)	1.40 (0.97)
95% CI	(0.06, 7.69)	(-3.81, 4.07)	(-0.52, 3.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.48 (2.13)	-1.26 (2.20)	
95% CI	(-1.71, 6.67)	(-5.59, 3.06)	
p-value	0.2458	0.5660	
Corrected Hedge's g Statistics	0.173	-0.088	
95% CI	(-0.13, 0.48)	(-0.40, 0.22)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Vitality			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	58.58 (23.43)	55.31 (23.43)	57.86 (21.86)
Analysis Visit Mean (SD)	58.79 (24.17)	54.59 (20.23)	58.49 (22.05)
LS Mean of Change from Baseline (SE)	-0.03 (1.90)	-1.44 (1.98)	0.34 (0.98)
95% CI	(-3.76, 3.70)	(-5.33, 2.45)	(-1.58, 2.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.37 (2.09)	-1.78 (2.18)	
95% CI	(-4.49, 3.75)	(-6.06, 2.50)	
p-value	0.8608	0.4139	
Corrected Hedge's g Statistics	-0.025	-0.120	
95% CI	(-0.31, 0.27)	(-0.42, 0.18)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	57.87 (24.62)	56.02 (22.51)	57.31 (21.48)
Analysis Visit Mean (SD)	58.36 (23.87)	56.01 (20.91)	57.72 (22.76)
LS Mean of Change from Baseline (SE)	0.66 (2.16)	-1.10 (2.23)	0.37 (1.08)
95% CI	(-3.59, 4.92)	(-5.49, 3.29)	(-1.75, 2.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.29 (2.38)	-1.47 (2.45)	
95% CI	(-4.39, 4.98)	(-6.29, 3.35)	
p-value	0.9022	0.5492	
Corrected Hedge's g Statistics	0.018	-0.092	
95% CI	(-0.29, 0.32)	(-0.40, 0.22)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Social Functioning			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	81.80 (21.27)	82.69 (26.91)	83.82 (21.90)
Analysis Visit Mean (SD)	85.31 (21.01)	82.21 (21.63)	82.74 (22.97)
LS Mean of Change from Baseline (SE)	2.36 (2.38)	-1.14 (2.48)	-1.39 (1.22)
95% CI	(-2.33, 7.05)	(-6.03, 3.74)	(-3.79, 1.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.75 (2.64)	0.25 (2.73)	
95% CI	(-1.43, 8.94)	(-5.13, 5.63)	
p-value	0.1553	0.9274	
Corrected Hedge's g Statistics	0.203	0.013	
95% CI	(-0.09, 0.49)	(-0.29, 0.31)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	82.11 (21.40)	83.33 (27.57)	83.81 (21.83)
Analysis Visit Mean (SD)	82.84 (21.35)	80.73 (22.77)	83.24 (22.05)
LS Mean of Change from Baseline (SE)	0.10 (2.44)	-3.38 (2.52)	-0.90 (1.22)
95% CI	(-4.70, 4.90)	(-8.32, 1.57)	(-3.30, 1.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.00 (2.69)	-2.48 (2.76)	
95% CI	(-4.29, 6.28)	(-7.91, 2.96)	
p-value	0.7102	0.3705	
Corrected Hedge's g Statistics	0.055	-0.137	
95% CI	(-0.25, 0.36)	(-0.45, 0.18)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Role Emotional			
Week 24			
m	61	57	266
n	57	52	230
Baseline Mean (SD)	82.02 (24.74)	81.41 (26.54)	84.46 (22.28)
Analysis Visit Mean (SD)	83.34 (20.89)	84.94 (22.08)	83.77 (23.13)
LS Mean of Change from Baseline (SE)	0.76 (2.21)	2.70 (2.31)	-0.58 (1.14)
95% CI	(-3.60, 5.11)	(-1.84, 7.24)	(-2.82, 1.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.34 (2.45)	3.28 (2.54)	
95% CI	(-3.47, 6.15)	(-1.71, 8.28)	
p-value	0.5842	0.1968	
Corrected Hedge's g Statistics	0.078	0.191	
95% CI	(-0.21, 0.37)	(-0.11, 0.49)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	81.54 (25.89)	80.21 (27.48)	84.85 (22.03)
Analysis Visit Mean (SD)	85.54 (19.64)	84.38 (24.23)	82.91 (22.96)
LS Mean of Change from Baseline (SE)	3.48 (2.38)	3.03 (2.46)	-1.62 (1.19)
95% CI	(-1.20, 8.16)	(-1.80, 7.86)	(-3.96, 0.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.10 (2.62)	4.65 (2.70)	
95% CI	(-0.05, 10.26)	(-0.66, 9.96)	
p-value	0.0523	0.0858	
Corrected Hedge's g Statistics	0.290	0.264	
95% CI	(-0.02, 0.60)	(-0.05, 0.58)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Mental Health			
Week 24			
m	61	57	266
n	57	52	231
Baseline Mean (SD)	75.8 (17.9)	74.8 (21.1)	75.6 (17.7)
Analysis Visit Mean (SD)	75.2 (18.1)	76.7 (19.6)	76.0 (17.9)
LS Mean of Change from Baseline (SE)	-0.80 (1.68)	1.34 (1.75)	-0.21 (0.86)
95% CI	(-4.11, 2.50)	(-2.10, 4.78)	(-1.91, 1.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.59 (1.85)	1.55 (1.92)	
95% CI	(-4.24, 3.06)	(-2.23, 5.33)	
p-value	0.7504	0.4208	
Corrected Hedge's g Statistics	-0.045	0.119	
95% CI	(-0.34, 0.24)	(-0.18, 0.42)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	76.1 (17.9)	74.2 (21.8)	75.2 (17.9)
Analysis Visit Mean (SD)	77.5 (17.2)	76.5 (17.6)	75.8 (19.3)
LS Mean of Change from Baseline (SE)	1.42 (1.90)	1.40 (1.96)	-0.15 (0.95)
95% CI	(-2.32, 5.17)	(-2.46, 5.26)	(-2.02, 1.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.58 (2.09)	1.55 (2.16)	
95% CI	(-2.54, 5.70)	(-2.69, 5.80)	
p-value	0.4516	0.4716	
Corrected Hedge's g Statistics	0.112	0.111	
95% CI	(-0.19, 0.42)	(-0.20, 0.42)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Mental Component Score			
Week 24			
m	61	57	266
n	57	52	230
Baseline Mean (SD)	51.17 (9.88)	50.51 (11.87)	51.44 (9.35)
Analysis Visit Mean (SD)	51.33 (9.90)	51.35 (9.90)	51.29 (9.83)
LS Mean of Change from Baseline (SE)	0.03 (0.93)	0.45 (0.97)	-0.36 (0.48)
95% CI	(-1.79, 1.85)	(-1.44, 2.35)	(-1.29, 0.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.39 (1.02)	0.81 (1.06)	
95% CI	(-1.62, 2.40)	(-1.28, 2.90)	
p-value	0.7059	0.4459	
Corrected Hedge's g Statistics	0.054	0.113	
95% CI	(-0.24, 0.34)	(-0.19, 0.41)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	51.24 (10.13)	50.29 (12.19)	51.38 (9.27)
Analysis Visit Mean (SD)	51.92 (9.09)	51.37 (9.57)	51.08 (10.17)
LS Mean of Change from Baseline (SE)	0.65 (0.99)	0.48 (1.03)	-0.51 (0.50)
95% CI	(-1.30, 2.61)	(-1.54, 2.50)	(-1.49, 0.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.16 (1.10)	0.99 (1.13)	
95% CI	(-0.99, 3.32)	(-1.23, 3.21)	
p-value	0.2891	0.3796	
Corrected Hedge's g Statistics	0.158	0.135	
95% CI	(-0.15, 0.46)	(-0.18, 0.45)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Physical Component Score			
Week 24			
m	61	57	266
n	57	52	230
Baseline Mean (SD)	47.45 (8.55)	47.09 (9.62)	47.69 (9.23)
Analysis Visit Mean (SD)	48.26 (8.37)	47.02 (8.39)	47.94 (9.64)
LS Mean of Change from Baseline (SE)	0.61 (0.86)	-0.21 (0.89)	0.21 (0.44)
95% CI	(-1.08, 2.29)	(-1.96, 1.55)	(-0.65, 1.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.39 (0.95)	-0.42 (0.98)	
95% CI	(-1.47, 2.25)	(-2.35, 1.51)	
p-value	0.6792	0.6694	
Corrected Hedge's g Statistics	0.059	-0.063	
95% CI	(-0.23, 0.35)	(-0.36, 0.24)	
Week 52			
m	59	56	263
n	51	48	220
Baseline Mean (SD)	47.03 (8.93)	47.30 (9.08)	47.53 (9.17)
Analysis Visit Mean (SD)	48.08 (10.57)	46.92 (9.74)	47.95 (9.00)
LS Mean of Change from Baseline (SE)	0.91 (0.86)	-0.46 (0.88)	0.49 (0.43)
95% CI	(-0.77, 2.59)	(-2.19, 1.28)	(-0.36, 1.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.42 (0.94)	-0.94 (0.97)	
95% CI	(-1.43, 2.27)	(-2.85, 0.96)	
p-value	0.6560	0.3308	
Corrected Hedge's g Statistics	0.066	-0.149	
95% CI	(-0.24, 0.37)	(-0.46, 0.16)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

Abbreviations: CFB = Change from Baseline; SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (9.9)	12 (17.9)	0
No	82 (90.1)	55 (82.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (31.9)	27 (40.3)	0
No	62 (68.1)	40 (59.7)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (11.0)	10 (14.9)	0
No	81 (89.0)	57 (85.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (26.4)	22 (32.8)	0
No	67 (73.6)	45 (67.2)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (13.2)	17 (25.4)	0
No	79 (86.8)	50 (74.6)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (24.2)	28 (41.8)	0
No	69 (75.8)	39 (58.2)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (13.2)	18 (26.9)	0
No	79 (86.8)	49 (73.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (29.7)	30 (44.8)	0
No	64 (70.3)	37 (55.2)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (11.0)	9 (13.4)	0
No	81 (89.0)	58 (86.6)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (31.9)	26 (38.8)	0
No	62 (68.1)	41 (61.2)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (4.4)	12 (17.9)	0
No	87 (95.6)	55 (82.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (17.6)	21 (31.3)	0
No	75 (82.4)	46 (68.7)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (8.8)	17 (25.4)	0
No	83 (91.2)	50 (74.6)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (15.4)	21 (31.3)	0
No	77 (84.6)	46 (68.7)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (11.0)	5 (7.5)	0
No	81 (89.0)	62 (92.5)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	34 (37.4)	22 (32.8)	0
No	57 (62.6)	45 (67.2)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.2)	7 (10.4)	0
No	89 (97.8)	60 (89.6)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (24.2)	15 (22.4)	0
No	69 (75.8)	52 (77.6)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (3.3)	8 (11.9)	0
No	88 (96.7)	59 (88.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (23.1)	25 (37.3)	0
No	70 (76.9)	42 (62.7)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (21.3)	6 (10.5)	37 (13.9)
No	48 (78.7)	51 (89.5)	229 (86.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	1.37	
95% CI of the inverse odds ratio	(0.29, 1.21)	(0.55, 3.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	1.32	
95% CI of the inverse risk ratio	(0.37, 1.15)	(0.59, 2.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.40	-3.38	
95% CI of the absolute risk difference	(-3.68, 18.49)	(-12.37, 5.60)	
p-value	0.1474	0.4950	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (42.6)	20 (35.1)	84 (31.6)
No	35 (57.4)	37 (64.9)	182 (68.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.85	
95% CI of the inverse odds ratio	(0.35, 1.10)	(0.47, 1.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.90	
95% CI of the inverse risk ratio	(0.53, 1.04)	(0.61, 1.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.04	3.51	
95% CI of the absolute risk difference	(-2.57, 24.65)	(-10.08, 17.10)	
p-value	0.0996	0.6069	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (8.2)	8 (14.0)	37 (13.9)
No	56 (91.8)	49 (86.0)	229 (86.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.81	0.99	
95% CI of the inverse odds ratio	(0.68, 4.81)	(0.43, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.70	0.99	
95% CI of the inverse risk ratio	(0.70, 4.14)	(0.49, 2.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.71	0.13	
95% CI of the absolute risk difference	(-13.76, 2.33)	(-9.80, 10.06)	
p-value	0.2290	0.9802	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (26.2)	16 (28.1)	69 (25.9)
No	45 (73.8)	41 (71.9)	197 (74.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.90	
95% CI of the inverse odds ratio	(0.52, 1.86)	(0.47, 1.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.92	
95% CI of the inverse risk ratio	(0.62, 1.58)	(0.58, 1.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.29	2.13	
95% CI of the absolute risk difference	(-11.94, 12.52)	(-10.67, 14.93)	
p-value	0.9629	0.7403	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (13.1)	9 (15.8)	53 (19.9)
No	53 (86.9)	48 (84.2)	213 (80.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	1.33	
95% CI of the inverse odds ratio	(0.74, 3.68)	(0.61, 2.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	1.26	
95% CI of the inverse risk ratio	(0.76, 3.03)	(0.66, 2.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.81	-4.14	
95% CI of the absolute risk difference	(-16.55, 2.93)	(-14.75, 6.48)	
p-value	0.2181	0.4719	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (27.9)	18 (31.6)	82 (30.8)
No	44 (72.1)	39 (68.4)	184 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.97	
95% CI of the inverse odds ratio	(0.62, 2.14)	(0.52, 1.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.98	
95% CI of the inverse risk ratio	(0.71, 1.72)	(0.64, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.96	0.75	
95% CI of the absolute risk difference	(-15.50, 9.59)	(-12.53, 14.03)	
p-value	0.6502	0.9113	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (21.3)	10 (17.5)	44 (16.5)
No	48 (78.7)	47 (82.5)	222 (83.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.93	
95% CI of the inverse odds ratio	(0.37, 1.46)	(0.44, 1.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.94	
95% CI of the inverse risk ratio	(0.45, 1.35)	(0.51, 1.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.77	1.00	
95% CI of the absolute risk difference	(-6.43, 15.97)	(-9.83, 11.84)	
p-value	0.3758	0.8540	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (36.1)	23 (40.4)	91 (34.2)
No	39 (63.9)	34 (59.6)	175 (65.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.77	
95% CI of the inverse odds ratio	(0.52, 1.65)	(0.43, 1.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.85	
95% CI of the inverse risk ratio	(0.65, 1.38)	(0.59, 1.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.86	6.14	
95% CI of the absolute risk difference	(-11.48, 15.19)	(-7.81, 20.09)	
p-value	0.7835	0.3787	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (9.8)	5 (8.8)	36 (13.5)
No	55 (90.2)	52 (91.2)	230 (86.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.63	
95% CI of the inverse odds ratio	(0.58, 3.58)	(0.61, 4.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	1.54	
95% CI of the inverse risk ratio	(0.61, 3.12)	(0.63, 3.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.70	-4.76	
95% CI of the absolute risk difference	(-12.23, 4.83)	(-13.18, 3.65)	
p-value	0.4363	0.3271	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (32.8)	18 (31.6)	96 (36.1)
No	41 (67.2)	39 (68.4)	170 (63.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.22	
95% CI of the inverse odds ratio	(0.64, 2.09)	(0.66, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	1.14	
95% CI of the inverse risk ratio	(0.74, 1.63)	(0.76, 1.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.30	-4.51	
95% CI of the absolute risk difference	(-16.42, 9.81)	(-17.89, 8.87)	
p-value	0.6267	0.5178	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (14.8)	10 (17.5)	25 (9.4)
No	52 (85.2)	47 (82.5)	241 (90.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.49	
95% CI of the inverse odds ratio	(0.26, 1.36)	(0.22, 1.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.54	
95% CI of the inverse risk ratio	(0.31, 1.29)	(0.27, 1.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.36	8.15	
95% CI of the absolute risk difference	(-4.21, 14.92)	(-2.33, 18.62)	
p-value	0.2165	0.0726	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (23.0)	12 (21.1)	51 (19.2)
No	47 (77.0)	45 (78.9)	215 (80.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.89	
95% CI of the inverse odds ratio	(0.41, 1.56)	(0.44, 1.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.91	
95% CI of the inverse risk ratio	(0.50, 1.41)	(0.52, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.78	1.88	
95% CI of the absolute risk difference	(-7.79, 15.34)	(-9.71, 13.47)	
p-value	0.5049	0.7452	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (18.0)	12 (21.1)	37 (13.9)
No	50 (82.0)	45 (78.9)	229 (86.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.61	
95% CI of the inverse odds ratio	(0.35, 1.54)	(0.29, 1.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.66	
95% CI of the inverse risk ratio	(0.42, 1.42)	(0.37, 1.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.12	7.14	
95% CI of the absolute risk difference	(-6.38, 14.63)	(-4.23, 18.51)	
p-value	0.4118	0.1725	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (23.0)	18 (31.6)	49 (18.4)
No	47 (77.0)	39 (68.4)	217 (81.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	0.49	
95% CI of the inverse odds ratio	(0.39, 1.49)	(0.26, 0.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.58	
95% CI of the inverse risk ratio	(0.47, 1.36)	(0.37, 0.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.53	13.16	
95% CI of the absolute risk difference	(-7.01, 16.07)	(0.22, 26.09)	
p-value	0.4185	0.0262	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (14.8)	9 (15.8)	39 (14.7)
No	52 (85.2)	48 (84.2)	227 (85.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.92	
95% CI of the inverse odds ratio	(0.45, 2.18)	(0.42, 2.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.93	
95% CI of the inverse risk ratio	(0.51, 1.94)	(0.48, 1.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.09	1.13	
95% CI of the absolute risk difference	(-9.77, 9.96)	(-9.25, 11.50)	
p-value	0.9853	0.8280	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (36.1)	18 (31.6)	82 (30.8)
No	39 (63.9)	39 (68.4)	184 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.97	
95% CI of the inverse odds ratio	(0.44, 1.42)	(0.52, 1.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.98	
95% CI of the inverse risk ratio	(0.58, 1.25)	(0.64, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.24	0.75	
95% CI of the absolute risk difference	(-8.03, 18.51)	(-12.53, 14.03)	
p-value	0.4282	0.9113	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (8.2)	6 (10.5)	16 (6.0)
No	56 (91.8)	51 (89.5)	250 (94.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.54	
95% CI of the inverse odds ratio	(0.25, 2.04)	(0.20, 1.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.57	
95% CI of the inverse risk ratio	(0.28, 1.93)	(0.23, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.18	4.51	
95% CI of the absolute risk difference	(-5.27, 9.63)	(-3.95, 12.98)	
p-value	0.5307	0.2199	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (23.0)	10 (17.5)	61 (22.9)
No	47 (77.0)	47 (82.5)	205 (77.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.40	
95% CI of the inverse odds ratio	(0.52, 1.94)	(0.67, 2.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.31	
95% CI of the inverse risk ratio	(0.60, 1.66)	(0.71, 2.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.02	-5.39	
95% CI of the absolute risk difference	(-11.68, 11.72)	(-16.48, 5.70)	
p-value	0.9975	0.3727	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE22.12.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (6.6)	4 (7.0)	14 (5.3)
No	57 (93.4)	53 (93.0)	252 (94.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.74	
95% CI of the inverse odds ratio	(0.25, 2.49)	(0.23, 2.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.75	
95% CI of the inverse risk ratio	(0.27, 2.35)	(0.26, 2.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.29	1.75	
95% CI of the absolute risk difference	(-5.47, 8.06)	(-5.40, 8.91)	
p-value	0.6894	0.6003	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (23.0)	16 (28.1)	60 (22.6)
No	47 (77.0)	41 (71.9)	206 (77.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.75	
95% CI of the inverse odds ratio	(0.50, 1.90)	(0.39, 1.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.80	
95% CI of the inverse risk ratio	(0.59, 1.64)	(0.50, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.39	5.51	
95% CI of the absolute risk difference	(-11.29, 12.08)	(-7.19, 18.21)	
p-value	0.9471	0.3732	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Physical Functioning						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	75.66 (23.75)	68.68 (26.27)	71.55 (29.73)			
Median	80.00	75.00	85.00			
IQR: Q1, Q3	65.00, 95.00	55.00, 90.00	55.00, 95.00			
Min, Max	0.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	76.53 (25.20)	71.71 (26.16)	73.04 (28.36)	0.66 (1.58)	2.92 (2.85)	-1.85 (3.28)
Median	85.00	80.00	82.50	0	0	0
IQR: Q1, Q3	65.00, 95.00	60.00, 90.00	45.00, 97.50	-7.50, 7.50	-5.00, 15.00	-5.00, 10.00
Min, Max	5.0, 100.0	5.0, 100.0	15.0, 100.0	-40.0, 40.0	-65.0, 70.0	-50.0, 25.0
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	76.71 (27.65)	69.86 (27.18)	70.00 (30.34)	-0.12 (1.83)	0.52 (2.44)	1.30 (2.31)
Median	90.00	80.00	80.00	0	0	0
IQR: Q1, Q3	60.00, 100.00	55.00, 95.00	45.00, 95.00	-5.00, 10.00	-5.00, 5.00	-5.00, 5.00
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-65.0, 25.0	-85.0, 40.0	-20.0, 30.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Role Physical						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	77.18 (28.36)	70.70 (27.81)	74.79 (25.13)			
Median	87.50	75.00	87.50			
IQR: Q1, Q3	59.40, 100.00	50.00, 100.00	50.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	25.0, 100.0			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	76.18 (26.70)	73.87 (25.07)	73.90 (26.73)	-1.04 (1.88)	2.15 (2.70)	-3.70 (3.85)
Median	81.30	81.30	75.00	0	0	0
IQR: Q1, Q3	56.30, 100.00	50.00, 100.00	53.15, 100.00	-9.40, 6.20	-6.30, 18.70	-12.50, 6.20
Min, Max	0.0, 100.0	0.0, 100.0	18.8, 100.0	-37.5, 50.0	-56.2, 62.5	-68.7, 37.5
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	75.63 (30.77)	71.05 (26.38)	71.76 (27.23)	-2.34 (2.10)	-0.63 (2.82)	0.28 (2.87)
Median	93.80	75.00	81.30	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 93.80	50.00, 93.80	-12.50, 0.00	-9.40, 6.30	-6.20, 6.30
Min, Max	0.0, 100.0	12.5, 100.0	6.3, 100.0	-43.8, 43.8	-68.8, 81.3	-31.2, 25.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Bodily Pain						
Baseline						
m	76	75	30			
n	71	68	29			
Mean (SD)	64.5 (24.9)	61.1 (26.2)	63.9 (26.0)			
Median	72.0	62.0	62.0			
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	51.0, 84.0			
Min, Max	0, 100	10, 100	0, 100			
Week 24						
m	76	74	29			
n	75	71	28	71	64	27
Mean (SD/SE)	63.4 (25.6)	62.6 (22.8)	63.4 (21.8)	-1.3 (2.3)	-0.2 (2.3)	-2.9 (3.7)
Median	72.0	62.0	62.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	51.0, 84.0	-12.0, 10.0	-11.5, 10.0	-10.0, 0.0
Min, Max	0, 100	21, 100	31, 100	-43, 52	-42, 72	-49, 41
Week 52						
m	74	68	27			
n	70	63	23	66	60	23
Mean (SD/SE)	67.7 (25.4)	65.8 (26.6)	60.3 (26.0)	2.2 (2.2)	4.4 (2.9)	0.9 (3.9)
Median	74.0	72.0	62.0	0	0	0
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	41.0, 84.0	0.0, 10.0	-10.5, 14.0	-11.0, 16.0
Min, Max	0, 100	10, 100	0, 100	-60, 59	-53, 69	-28, 51

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
General Health						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	59.43 (20.04)	54.19 (20.40)	57.24 (22.11)			
Median	62.00	52.00	60.00			
IQR: Q1, Q3	46.00, 77.00	40.00, 71.00	45.00, 77.00			
Min, Max	10.0, 97.0	10.0, 100.0	15.0, 87.0			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	61.96 (22.31)	57.83 (19.75)	55.25 (22.71)	2.69 (1.17)	3.91 (1.91)	-3.63 (2.73)
Median	67.00	57.00	57.00	5.00	5.00	0
IQR: Q1, Q3	47.00, 77.00	42.00, 72.00	36.00, 74.50	-5.00, 10.00	-5.00, 15.00	-15.00, 5.00
Min, Max	10.0, 100.0	15.0, 100.0	10.0, 92.0	-15.0, 32.0	-35.0, 37.0	-40.0, 17.0
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	62.98 (18.64)	57.75 (18.99)	57.13 (22.70)	2.41 (1.65)	3.45 (2.36)	0.30 (2.28)
Median	67.00	62.00	62.00	0	3.00	0
IQR: Q1, Q3	52.50, 77.00	45.00, 67.00	42.00, 72.00	-9.50, 10.00	-7.50, 15.00	-5.00, 5.00
Min, Max	20.0, 100.0	10.0, 92.0	10.0, 92.0	-20.0, 47.0	-52.0, 47.0	-30.0, 20.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Vitality						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	57.31 (22.74)	52.14 (22.67)	55.41 (19.95)			
Median	62.50	56.30	56.30			
IQR: Q1, Q3	43.80, 75.00	43.80, 65.65	43.80, 68.80			
Min, Max	6.3, 100.0	0.0, 93.8	12.5, 87.5			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	57.28 (24.16)	52.31 (20.25)	52.48 (21.68)	-0.08 (1.63)	-0.20 (1.95)	-5.33 (2.53)
Median	62.50	50.00	56.30	0	0	-6.20
IQR: Q1, Q3	43.80, 75.00	37.50, 62.50	34.40, 68.80	-6.30, 6.30	-12.50, 6.30	-12.50, 0.00
Min, Max	0.0, 100.0	0.0, 100.0	12.5, 87.5	-25.0, 43.8	-31.3, 43.8	-37.5, 18.8
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	58.95 (23.06)	52.50 (21.01)	54.92 (19.67)	0.28 (1.98)	-0.73 (1.97)	2.72 (2.60)
Median	62.50	56.30	56.30	0	0	0
IQR: Q1, Q3	43.80, 75.00	37.50, 68.80	37.50, 75.00	-12.50, 12.50	-6.30, 6.30	-6.30, 6.30
Min, Max	6.3, 100.0	6.3, 100.0	18.8, 81.3	-37.5, 50.0	-43.8, 43.8	-12.5, 31.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Social Functioning						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	83.68 (21.97)	76.84 (25.21)	80.60 (22.06)			
Median	93.75	87.50	87.50			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	12.5, 100.0	25.0, 100.0			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	82.00 (24.85)	79.93 (22.51)	76.79 (24.47)	-1.04 (2.25)	2.34 (2.06)	-6.48 (3.49)
Median	100.00	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	56.25, 100.00	-12.50, 12.50	0.00, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	12.5, 100.0	37.5, 100.0	-50.0, 50.0	-50.0, 37.5	-62.5, 25.0
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	80.71 (24.61)	80.16 (23.29)	78.80 (27.03)	-3.54 (2.33)	2.71 (2.87)	1.09 (2.35)
Median	87.50	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	50.00, 100.00	-12.50, 0.00	0.00, 12.50	0.00, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	25.0, 100.0	-50.0, 50.0	-62.5, 62.5	-25.0, 25.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Role Emotional						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	83.68 (23.21)	79.66 (24.66)	84.49 (22.46)			
Median	100.00	87.50	100.00			
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	8.3, 100.0	25.0, 100.0			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	83.66 (23.15)	83.45 (22.48)	80.35 (22.37)	0.70 (1.67)	3.26 (1.95)	-6.49 (2.89)
Median	100.00	91.70	87.50	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	54.15, 100.00	0.00, 0.00	0.00, 16.70	-8.40, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	33.3, 100.0	-33.3, 50.0	-33.3, 33.4	-50.0, 16.7
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	84.94 (22.36)	82.27 (23.97)	77.17 (27.08)	0.56 (2.11)	3.19 (2.71)	-3.27 (2.86)
Median	100.00	91.70	83.30	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	66.70, 100.00	0.00, 0.00	0.00, 16.70	-8.40, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-33.3, 100.0	-75.0, 50.0	-25.0, 25.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Mental Health						
Baseline						
m	76	75	30			
n	72	68	29			
Mean (SD)	74.4 (18.5)	73.2 (20.5)	76.4 (19.4)			
Median	77.5	80.0	85.0			
IQR: Q1, Q3	65.0, 90.0	62.5, 90.0	65.0, 90.0			
Min, Max	25, 100	15, 100	25, 95			
Week 24						
m	76	74	29			
n	75	71	28	72	64	27
Mean (SD/SE)	74.4 (20.0)	73.7 (19.4)	72.9 (19.0)	0.4 (1.4)	-0.1 (1.8)	-5.2 (2.9)
Median	80.0	80.0	80.0	0	0	-5.0
IQR: Q1, Q3	65.0, 90.0	65.0, 85.0	57.5, 87.5	-5.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	20, 100	5, 100	30, 100	-40, 35	-35, 50	-35, 30
Week 52						
m	74	68	27			
n	70	63	23	67	60	23
Mean (SD/SE)	75.9 (17.6)	72.5 (19.3)	74.3 (20.0)	0.4 (1.5)	0.3 (1.6)	1.5 (2.4)
Median	80.0	75.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	60.0, 85.0	70.0, 90.0	-5.0, 5.0	-5.0, 5.0	-5.0, 10.0
Min, Max	30, 100	20, 100	30, 100	-35, 25	-30, 50	-20, 25

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Mental Component Score						
Baseline						
m	76	75	30			
n	71	68	29			
Mean (SD)	51.17 (10.03)	49.77 (11.96)	51.64 (9.76)			
Median	53.30	53.05	55.80			
IQR: Q1, Q3	46.80, 59.00	42.40, 57.90	47.40, 58.90			
Min, Max	23.3, 69.0	17.0, 66.8	27.3, 66.5			
Week 24						
m	76	74	29			
n	75	71	28	71	64	27
Mean (SD/SE)	50.84 (10.51)	50.42 (10.19)	49.21 (10.75)	-0.03 (0.70)	0.42 (0.91)	-3.32 (1.70)
Median	53.40	52.70	53.00	-0.20	-0.10	-1.90
IQR: Q1, Q3	45.00, 59.10	46.60, 58.20	39.45, 58.40	-2.70, 3.40	-4.15, 3.85	-6.60, 1.00
Min, Max	24.8, 64.6	9.4, 63.6	30.3, 64.5	-16.4, 19.0	-13.0, 26.1	-24.6, 22.7
Week 52						
m	74	68	27			
n	70	63	23	66	60	23
Mean (SD/SE)	51.34 (9.44)	50.13 (10.49)	49.97 (10.95)	-0.26 (0.86)	0.63 (1.03)	0.06 (1.22)
Median	54.15	52.70	52.60	0.10	0.20	0.20
IQR: Q1, Q3	44.30, 58.60	43.50, 58.20	42.50, 57.40	-4.70, 3.40	-3.80, 2.90	-3.80, 1.70
Min, Max	25.1, 62.4	17.8, 64.6	25.9, 68.0	-17.3, 26.2	-21.4, 25.2	-10.7, 15.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Physical Component Score						
Baseline						
m	76	75	30			
n	71	68	29			
Mean (SD)	47.46 (9.90)	44.84 (10.06)	45.83 (9.97)			
Median	49.20	46.00	47.70			
IQR: Q1, Q3	41.00, 55.60	39.40, 52.20	37.80, 54.20			
Min, Max	15.3, 60.8	21.2, 60.4	20.7, 60.1			
Week 24						
m	76	74	29			
n	75	71	28	71	64	27
Mean (SD/SE)	47.62 (10.42)	46.00 (8.66)	46.36 (9.62)	0.05 (0.70)	0.92 (1.05)	-0.51 (1.49)
Median	50.10	48.10	48.55	0.60	0.25	-0.80
IQR: Q1, Q3	41.70, 56.80	39.90, 52.40	39.40, 53.90	-3.10, 3.90	-2.40, 4.25	-2.70, 3.00
Min, Max	12.5, 63.9	24.6, 59.4	26.3, 62.9	-14.8, 17.6	-22.0, 32.4	-28.8, 14.6
Week 52						
m	74	68	27			
n	70	63	23	66	60	23
Mean (SD/SE)	48.01 (11.03)	45.97 (9.73)	45.54 (10.35)	0.28 (0.78)	0.68 (1.04)	0.52 (1.22)
Median	52.25	47.80	47.50	0.75	1.60	1.10
IQR: Q1, Q3	41.80, 56.30	38.80, 53.60	39.10, 54.80	-2.00, 3.80	-3.25, 5.00	-4.50, 4.00
Min, Max	15.8, 62.8	24.8, 61.1	23.6, 60.3	-24.2, 15.9	-23.5, 18.6	-9.3, 18.4

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Physical Functioning						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	76.50 (23.10)	72.83 (22.35)	76.39 (24.32)			
Median	82.50	80.00	85.00			
IQR: Q1, Q3	62.50, 97.50	60.00, 85.00	65.00, 95.00			
Min, Max	25.0, 100.0	10.0, 100.0	10.0, 100.0			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	77.31 (22.27)	73.40 (21.49)	77.35 (25.98)	0.81 (3.45)	-1.52 (3.86)	1.26 (1.42)
Median	85.00	80.00	90.00	0	0	0
IQR: Q1, Q3	60.00, 100.00	55.00, 85.00	68.35, 100.00	-5.00, 15.00	-10.00, 5.00	-7.50, 10.00
Min, Max	30.0, 100.0	10.0, 100.0	0.0, 100.0	-50.0, 45.0	-45.0, 55.0	-50.0, 75.0
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	77.57 (26.53)	73.00 (22.50)	78.65 (22.53)	2.00 (2.74)	0.28 (3.01)	1.91 (1.38)
Median	90.00	77.50	85.00	0	0	0
IQR: Q1, Q3	65.00, 100.00	57.50, 92.50	70.00, 100.00	-10.00, 10.00	-5.00, 5.00	-5.00, 10.00
Min, Max	10.0, 100.0	15.0, 100.0	10.0, 100.0	-35.0, 45.0	-25.0, 30.0	-30.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Role Physical						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	80.01 (21.65)	77.73 (23.06)	78.29 (26.15)			
Median	84.40	75.00	87.50			
IQR: Q1, Q3	62.50, 100.00	56.30, 100.00	62.50, 100.00			
Min, Max	25.0, 100.0	25.0, 100.0	0.0, 100.0			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	75.17 (23.75)	72.52 (23.17)	77.95 (26.81)	-4.39 (3.56)	-6.25 (4.58)	-0.53 (1.65)
Median	81.30	75.00	87.50	0	0	0
IQR: Q1, Q3	56.30, 100.00	56.30, 100.00	62.50, 100.00	-18.80, 12.50	-18.70, 0.00	-6.30, 6.20
Min, Max	25.0, 100.0	25.0, 100.0	0.0, 100.0	-43.8, 43.7	-43.7, 68.7	-62.5, 68.7
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	78.73 (25.49)	83.77 (19.38)	79.39 (23.36)	-1.79 (3.04)	7.29 (3.86)	0.27 (1.77)
Median	87.50	93.80	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	71.90, 100.00	62.50, 100.00	-12.50, 6.20	0.00, 25.00	-6.30, 6.30
Min, Max	18.8, 100.0	50.0, 100.0	18.8, 100.0	-37.5, 56.2	-25.0, 43.7	-62.5, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Bodily Pain						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	74.3 (22.3)	61.6 (26.5)	67.1 (24.2)			
Median	74.0	72.0	72.0			
IQR: Q1, Q3	61.5, 100.0	41.0, 84.0	51.0, 84.0			
Min, Max	22, 100	0, 100	12, 100			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	68.9 (24.2)	65.4 (25.6)	67.4 (25.3)	-5.2 (3.3)	1.5 (4.8)	0.3 (1.5)
Median	74.0	62.0	73.0	0	0	0
IQR: Q1, Q3	52.0, 84.0	51.0, 84.0	51.0, 84.0	-16.0, 0.0	-10.0, 21.0	-12.0, 12.0
Min, Max	22, 100	10, 100	0, 100	-59, 38	-62, 52	-38, 58
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	73.7 (26.3)	67.7 (20.0)	70.6 (24.1)	-1.1 (3.7)	6.6 (6.1)	3.4 (1.8)
Median	74.0	62.0	74.0	0	3.0	0
IQR: Q1, Q3	52.0, 100.0	61.5, 82.0	51.0, 84.0	0.0, 10.0	-12.0, 21.0	-11.0, 16.0
Min, Max	20, 100	31, 100	10, 100	-80, 38	-33, 62	-43, 69

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
General Health						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	63.02 (19.10)	55.83 (15.88)	60.79 (19.89)			
Median	62.00	57.00	62.00			
IQR: Q1, Q3	46.00, 77.00	40.00, 72.00	47.00, 77.00			
Min, Max	27.0, 100.0	30.0, 77.0	15.0, 100.0			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	59.92 (20.10)	55.72 (15.46)	60.92 (21.05)	-0.99 (3.05)	-1.96 (3.14)	-0.10 (1.20)
Median	60.00	55.00	62.00	0	0	0
IQR: Q1, Q3	45.00, 77.00	45.00, 62.00	47.00, 77.00	-10.00, 12.00	-15.00, 5.00	-10.00, 10.00
Min, Max	10.0, 100.0	27.0, 82.0	10.0, 100.0	-60.0, 32.0	-22.0, 32.0	-38.0, 48.0
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	61.97 (23.78)	56.15 (19.77)	62.09 (20.99)	-0.31 (3.27)	-1.11 (2.58)	1.21 (1.23)
Median	67.00	54.50	62.00	0	0	0
IQR: Q1, Q3	45.00, 82.00	41.00, 72.00	50.00, 77.00	-10.00, 5.00	-10.00, 5.00	-5.00, 10.00
Min, Max	20.0, 100.0	20.0, 87.0	10.0, 100.0	-70.0, 32.0	-22.0, 17.0	-42.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Vitality						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	64.86 (21.87)	60.63 (24.38)	57.65 (20.40)			
Median	68.80	56.30	62.50			
IQR: Q1, Q3	53.15, 78.15	43.80, 81.30	43.80, 75.00			
Min, Max	12.5, 100.0	6.3, 100.0	0.0, 100.0			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	58.99 (23.85)	59.27 (18.14)	58.38 (21.38)	-4.73 (2.50)	-3.27 (4.27)	1.09 (1.24)
Median	62.50	62.50	62.50	0	-6.30	0
IQR: Q1, Q3	43.80, 75.00	50.00, 75.00	43.80, 75.00	-12.50, 6.20	-18.80, 6.20	-9.40, 6.30
Min, Max	0.0, 100.0	18.8, 87.5	0.0, 100.0	-43.8, 25.0	-31.2, 43.8	-37.5, 56.2
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	60.84 (23.46)	62.53 (19.56)	59.48 (22.12)	-4.28 (2.63)	3.12 (3.96)	2.21 (1.44)
Median	62.50	65.65	62.50	0	3.10	0
IQR: Q1, Q3	43.80, 81.30	43.80, 81.30	43.80, 75.00	-12.50, 6.30	-12.50, 12.50	-6.30, 12.50
Min, Max	6.3, 100.0	25.0, 87.5	0.0, 100.0	-43.7, 25.0	-25.0, 37.5	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Social Functioning						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	84.69 (21.83)	80.98 (28.17)	84.56 (22.31)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	12.5, 100.0			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	80.77 (23.97)	86.00 (17.80)	83.59 (22.70)	-4.05 (2.87)	5.43 (5.14)	-0.90 (1.59)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	-12.50, 0.00	-12.50, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	37.5, 100.0	0.0, 100.0	-50.0, 25.0	-25.0, 87.5	-62.5, 75.0
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	83.11 (21.29)	86.88 (17.43)	85.33 (20.72)	-1.43 (2.39)	5.56 (5.65)	0.45 (1.74)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	68.75, 100.00	75.00, 100.00	0.00, 0.00	0.00, 12.50	0.00, 0.00
Min, Max	37.5, 100.0	50.0, 100.0	12.5, 100.0	-37.5, 25.0	-50.0, 62.5	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Role Emotional						
Baseline						
m	42	25	179			
n	40	23	165			
Mean (SD)	83.96 (25.56)	86.23 (19.88)	85.50 (21.34)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	50.0, 100.0	16.7, 100.0			
Week 24						
m	41	25	177			
n	39	25	160	37	23	151
Mean (SD/SE)	81.41 (23.21)	91.34 (15.49)	85.31 (22.38)	-1.57 (3.38)	4.35 (3.81)	-0.11 (1.48)
Median	91.70	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	91.70, 100.00	75.00, 100.00	-8.30, 0.00	0.00, 0.00	-8.30, 0.00
Min, Max	25.0, 100.0	50.0, 100.0	8.3, 100.0	-33.3, 66.7	-25.0, 41.7	-50.0, 58.3
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	82.43 (21.59)	93.75 (13.21)	86.28 (20.53)	-1.90 (3.00)	7.41 (5.55)	-0.42 (1.49)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	95.85, 100.00	75.00, 100.00	0.00, 0.00	0.00, 25.00	0.00, 0.00
Min, Max	33.3, 100.0	50.0, 100.0	16.7, 100.0	-50.0, 41.7	-33.3, 50.0	-58.3, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Mental Health						
Baseline						
m	42	25	179			
n	40	23	166			
Mean (SD)	77.8 (19.3)	82.4 (15.9)	76.5 (15.6)			
Median	85.0	90.0	80.0			
IQR: Q1, Q3	67.5, 90.0	80.0, 90.0	70.0, 90.0			
Min, Max	10, 100	35, 100	20, 100			
Week 24						
m	41	25	177			
n	39	25	160	37	23	152
Mean (SD/SE)	72.3 (21.9)	82.4 (13.6)	76.7 (16.8)	-4.2 (2.2)	-0.7 (2.5)	0.3 (1.0)
Median	80.0	85.0	80.0	0	0	0
IQR: Q1, Q3	60.0, 90.0	70.0, 90.0	70.0, 90.0	-10.0, 5.0	-5.0, 5.0	-5.0, 5.0
Min, Max	15, 100	50, 100	20, 100	-35, 20	-30, 35	-30, 45
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	75.7 (18.9)	85.0 (12.6)	77.8 (18.4)	-2.4 (2.2)	1.9 (3.1)	1.3 (1.3)
Median	80.0	90.0	85.0	-5.0	0	0
IQR: Q1, Q3	65.0, 90.0	72.5, 95.0	70.0, 90.0	-10.0, 5.0	0.0, 10.0	-5.0, 10.0
Min, Max	30, 100	55, 100	0, 100	-35, 25	-25, 35	-40, 50

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Mental Component Score						
Baseline						
m	42	25	179			
n	40	23	165			
Mean (SD)	52.29 (10.82)	53.98 (10.17)	51.82 (8.30)			
Median	56.90	55.70	54.60			
IQR: Q1, Q3	47.65, 59.10	50.10, 60.10	46.80, 57.70			
Min, Max	12.9, 67.0	32.3, 72.3	26.4, 65.8			
Week 24						
m	41	25	177			
n	39	25	160	37	23	151
Mean (SD/SE)	49.74 (12.02)	55.33 (8.83)	51.73 (9.39)	-1.98 (1.21)	1.21 (1.41)	-0.03 (0.56)
Median	52.90	59.00	55.10	-1.20	0.70	0.50
IQR: Q1, Q3	43.60, 59.40	50.00, 60.00	47.65, 58.05	-6.40, 2.30	-1.70, 6.10	-3.50, 3.20
Min, Max	18.7, 66.6	33.3, 71.2	21.9, 63.3	-20.0, 12.0	-13.5, 19.1	-23.5, 21.4
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	50.85 (10.44)	56.33 (8.12)	52.17 (9.79)	-1.66 (1.15)	2.19 (1.95)	0.21 (0.64)
Median	55.50	57.70	54.80	-1.40	-0.45	0.55
IQR: Q1, Q3	43.00, 59.20	51.60, 61.25	48.00, 58.70	-3.90, 3.00	-1.90, 9.60	-3.25, 4.50
Min, Max	23.1, 62.2	38.3, 70.7	8.9, 64.6	-21.7, 11.2	-14.5, 19.6	-24.6, 24.1

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE22.13.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Physical Component Score						
Baseline						
m	42	25	179			
n	40	23	165			
Mean (SD)	49.31 (7.61)	45.18 (9.22)	47.87 (9.07)			
Median	49.65	46.10	50.10			
IQR: Q1, Q3	46.25, 56.00	41.90, 52.00	42.60, 55.10			
Min, Max	27.6, 59.4	21.6, 57.5	21.8, 61.2			
Week 24						
m	41	25	177			
n	39	25	160	37	23	151
Mean (SD/SE)	48.55 (7.83)	44.66 (9.60)	47.98 (9.88)	-0.64 (1.07)	-1.40 (1.50)	0.11 (0.52)
Median	50.20	43.80	50.45	0	-1.70	0
IQR: Q1, Q3	42.70, 54.10	38.90, 52.20	42.65, 55.60	-5.40, 3.20	-5.90, 0.30	-3.20, 3.40
Min, Max	27.4, 62.7	20.2, 57.5	22.8, 63.0	-17.2, 11.1	-16.0, 21.7	-16.1, 23.3
Week 52						
m	39	22	167			
n	37	20	150	35	18	140
Mean (SD/SE)	49.44 (10.67)	45.90 (8.85)	48.73 (8.92)	0.31 (1.18)	0.89 (1.21)	0.85 (0.51)
Median	53.40	44.45	50.20	-0.30	0.20	0.40
IQR: Q1, Q3	44.20, 58.00	40.95, 52.65	43.00, 56.00	-1.60, 3.70	-1.10, 4.00	-2.20, 3.75
Min, Max	20.3, 61.4	24.4, 59.4	21.5, 63.9	-24.7, 14.7	-10.1, 11.6	-12.2, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; CFB = Change from Baseline; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Physical Functioning			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	75.66 (23.75)	68.44 (26.53)	73.89 (28.30)
Analysis Visit Mean (SD)	76.32 (25.40)	71.35 (26.22)	72.04 (28.39)
LS Mean of Change from Baseline (SE)	1.49 (2.10)	2.22 (2.21)	-1.80 (3.34)
95% CI	(-2.66, 5.64)	(-2.13, 6.58)	(-8.40, 4.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.29 (3.92)	4.02 (3.98)	
95% CI	(-4.44, 11.03)	(-3.83, 11.88)	
p-value	0.4018	0.3134	
Corrected Hedge's g Statistics	0.184	0.227	
95% CI	(-0.26, 0.63)	(-0.22, 0.68)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	76.31 (23.43)	69.25 (26.08)	68.70 (31.34)
Analysis Visit Mean (SD)	76.19 (28.02)	69.77 (27.72)	70.00 (30.34)
LS Mean of Change from Baseline (SE)	0.43 (2.03)	0.98 (2.13)	0.17 (3.34)
95% CI	(-3.59, 4.45)	(-3.23, 5.19)	(-6.43, 6.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.26 (3.91)	0.81 (3.94)	
95% CI	(-7.47, 7.98)	(-6.98, 8.59)	
p-value	0.9475	0.8381	
Corrected Hedge's g Statistics	0.016	0.049	
95% CI	(-0.46, 0.49)	(-0.43, 0.53)	
Subgroup*Treatment Interaction p-value	0.5361	0.2758	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Role Physical			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	77.18 (28.36)	71.01 (28.11)	76.63 (24.11)
Analysis Visit Mean (SD)	76.14 (26.81)	73.16 (25.50)	72.93 (26.73)
LS Mean of Change from Baseline (SE)	0.10 (2.11)	1.49 (2.22)	-3.45 (3.36)
95% CI	(-4.07, 4.27)	(-2.89, 5.88)	(-10.10, 3.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.55 (3.94)	4.95 (4.00)	
95% CI	(-4.22, 11.33)	(-2.95, 12.85)	
p-value	0.3685	0.2181	
Corrected Hedge's g Statistics	0.198	0.277	
95% CI	(-0.25, 0.64)	(-0.17, 0.73)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	77.44 (29.03)	71.69 (28.47)	71.48 (26.30)
Analysis Visit Mean (SD)	75.10 (31.28)	71.06 (26.93)	71.76 (27.23)
LS Mean of Change from Baseline (SE)	-1.48 (2.24)	-0.51 (2.36)	0.01 (3.71)
95% CI	(-5.91, 2.96)	(-5.18, 4.15)	(-7.31, 7.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.48 (4.33)	-0.52 (4.37)	
95% CI	(-10.03, 7.06)	(-9.16, 8.11)	
p-value	0.7320	0.9052	
Corrected Hedge's g Statistics	-0.081	-0.028	
95% CI	(-0.55, 0.39)	(-0.51, 0.45)	
Subgroup*Treatment Interaction p-value	0.4460	0.7059	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Bodily Pain			
Week 24			
m	76	74	29
n	71	64	27
Baseline Mean (SD)	64.5 (24.9)	61.4 (26.0)	65.6 (25.7)
Analysis Visit Mean (SD)	63.2 (25.7)	61.2 (22.9)	62.6 (21.8)
LS Mean of Change from Baseline (SE)	-0.95 (2.08)	-0.82 (2.17)	-2.87 (3.29)
95% CI	(-5.06, 3.15)	(-5.11, 3.46)	(-9.37, 3.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.92 (3.86)	2.05 (3.91)	
95% CI	(-5.70, 9.53)	(-5.67, 9.77)	
p-value	0.6198	0.6015	
Corrected Hedge's g Statistics	0.109	0.117	
95% CI	(-0.33, 0.55)	(-0.33, 0.57)	
Week 52			
m	74	68	27
n	66	60	23
Baseline Mean (SD)	65.0 (25.1)	60.6 (27.0)	59.4 (25.8)
Analysis Visit Mean (SD)	67.2 (25.6)	65.0 (26.7)	60.3 (26.0)
LS Mean of Change from Baseline (SE)	2.68 (2.31)	3.45 (2.42)	-0.30 (3.79)
95% CI	(-1.89, 7.24)	(-1.32, 8.22)	(-7.80, 7.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.98 (4.43)	3.75 (4.47)	
95% CI	(-5.77, 11.74)	(-5.08, 12.59)	
p-value	0.5022	0.4031	
Corrected Hedge's g Statistics	0.159	0.200	
95% CI	(-0.32, 0.63)	(-0.28, 0.68)	
Subgroup*Treatment Interaction p-value	0.2120	0.5232	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
General Health			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	59.43 (20.04)	53.34 (20.06)	58.63 (21.33)
Analysis Visit Mean (SD)	62.12 (21.93)	57.25 (20.16)	55.00 (23.11)
LS Mean of Change from Baseline (SE)	2.58 (1.55)	2.73 (1.62)	-3.97 (2.45)
95% CI	(-0.47, 5.63)	(-0.47, 5.94)	(-8.80, 0.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.55 (2.87)	6.70 (2.91)	
95% CI	(0.89, 12.21)	(0.95, 12.46)	
p-value	0.0236	0.0227	
Corrected Hedge's g Statistics	0.500	0.515	
95% CI	(0.05, 0.95)	(0.06, 0.97)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	60.31 (20.20)	54.42 (20.87)	56.83 (24.04)
Analysis Visit Mean (SD)	62.72 (18.93)	57.87 (19.36)	57.13 (22.70)
LS Mean of Change from Baseline (SE)	2.79 (1.72)	2.34 (1.80)	-0.78 (2.81)
95% CI	(-0.60, 6.19)	(-1.21, 5.89)	(-6.33, 4.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.57 (3.28)	3.12 (3.32)	
95% CI	(-2.91, 10.05)	(-3.44, 9.68)	
p-value	0.2783	0.3497	
Corrected Hedge's g Statistics	0.254	0.223	
95% CI	(-0.22, 0.73)	(-0.26, 0.71)	
Subgroup*Treatment Interaction p-value	0.0910	0.0346	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Vitality			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	57.31 (22.74)	51.20 (22.85)	56.74 (19.37)
Analysis Visit Mean (SD)	57.23 (23.91)	51.00 (20.27)	51.41 (21.33)
LS Mean of Change from Baseline (SE)	0.16 (1.66)	-1.34 (1.76)	-5.44 (2.65)
95% CI	(-3.12, 3.44)	(-4.81, 2.12)	(-10.67, -0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.59 (3.10)	4.09 (3.16)	
95% CI	(-0.53, 11.72)	(-2.15, 10.33)	
p-value	0.0732	0.1970	
Corrected Hedge's g Statistics	0.396	0.291	
95% CI	(-0.05, 0.84)	(-0.16, 0.74)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	57.95 (23.12)	52.84 (23.06)	52.20 (20.52)
Analysis Visit Mean (SD)	58.23 (22.90)	52.11 (21.26)	54.92 (19.67)
LS Mean of Change from Baseline (SE)	0.58 (1.75)	-1.76 (1.85)	0.20 (2.90)
95% CI	(-2.88, 4.04)	(-5.41, 1.89)	(-5.53, 5.93)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.38 (3.39)	-1.96 (3.42)	
95% CI	(-6.30, 7.07)	(-8.72, 4.80)	
p-value	0.9100	0.5681	
Corrected Hedge's g Statistics	0.027	-0.137	
95% CI	(-0.45, 0.50)	(-0.62, 0.34)	
Subgroup*Treatment Interaction p-value	0.0430	0.3882	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Social Functioning			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	83.68 (21.97)	77.34 (25.48)	82.41 (19.99)
Analysis Visit Mean (SD)	82.64 (24.69)	79.69 (22.88)	75.93 (24.50)
LS Mean of Change from Baseline (SE)	-0.77 (2.05)	1.08 (2.16)	-6.80 (3.26)
95% CI	(-4.82, 3.28)	(-3.18, 5.35)	(-13.24, -0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.03 (3.82)	7.88 (3.89)	
95% CI	(-1.51, 13.57)	(0.20, 15.55)	
p-value	0.1164	0.0443	
Corrected Hedge's g Statistics	0.346	0.454	
95% CI	(-0.10, 0.79)	(0.00, 0.91)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	84.14 (22.15)	76.88 (26.22)	77.72 (23.52)
Analysis Visit Mean (SD)	80.60 (24.93)	79.58 (23.69)	78.80 (27.03)
LS Mean of Change from Baseline (SE)	-3.37 (2.28)	0.84 (2.40)	-1.56 (3.77)
95% CI	(-7.87, 1.13)	(-3.91, 5.58)	(-9.00, 5.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.81 (4.40)	2.40 (4.44)	
95% CI	(-10.49, 6.88)	(-6.38, 11.17)	
p-value	0.6819	0.5904	
Corrected Hedge's g Statistics	-0.097	0.129	
95% CI	(-0.57, 0.38)	(-0.35, 0.61)	
Subgroup*Treatment Interaction p-value	0.3229	0.9059	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Role Emotional			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	83.68 (23.21)	78.91 (24.98)	86.11 (19.88)
Analysis Visit Mean (SD)	84.37 (22.85)	82.16 (23.24)	79.63 (22.45)
LS Mean of Change from Baseline (SE)	0.83 (1.71)	2.37 (1.80)	-6.35 (2.73)
95% CI	(-2.55, 4.22)	(-1.19, 5.93)	(-11.74, -0.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.19 (3.19)	8.72 (3.25)	
95% CI	(0.89, 13.48)	(2.31, 15.13)	
p-value	0.0255	0.0080	
Corrected Hedge's g Statistics	0.494	0.602	
95% CI	(0.05, 0.94)	(0.14, 1.06)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	84.57 (22.67)	79.03 (25.60)	80.44 (23.65)
Analysis Visit Mean (SD)	85.14 (22.64)	82.22 (24.24)	77.17 (27.08)
LS Mean of Change from Baseline (SE)	0.97 (2.12)	2.40 (2.23)	-5.01 (3.50)
95% CI	(-3.22, 5.16)	(-2.01, 6.81)	(-11.92, 1.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.97 (4.08)	7.41 (4.13)	
95% CI	(-2.09, 14.04)	(-0.76, 15.57)	
p-value	0.1453	0.0750	
Corrected Hedge's g Statistics	0.344	0.428	
95% CI	(-0.13, 0.82)	(-0.06, 0.91)	
Subgroup*Treatment Interaction p-value	0.0505	0.5992	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Mental Health			
Week 24			
m	76	74	29
n	72	64	27
Baseline Mean (SD)	74.4 (18.5)	72.7 (20.8)	77.8 (17.1)
Analysis Visit Mean (SD)	74.9 (19.5)	72.6 (20.0)	72.6 (19.3)
LS Mean of Change from Baseline (SE)	0.26 (1.53)	-0.61 (1.61)	-4.67 (2.45)
95% CI	(-2.75, 3.28)	(-3.78, 2.57)	(-9.51, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.94 (2.86)	4.07 (2.91)	
95% CI	(-0.72, 10.60)	(-1.69, 9.82)	
p-value	0.0867	0.1646	
Corrected Hedge's g Statistics	0.380	0.315	
95% CI	(-0.07, 0.83)	(-0.14, 0.77)	
Week 52			
m	74	68	27
n	67	60	23
Baseline Mean (SD)	75.4 (17.8)	72.0 (21.3)	72.8 (20.0)
Analysis Visit Mean (SD)	75.8 (17.5)	72.3 (19.6)	74.3 (20.0)
LS Mean of Change from Baseline (SE)	0.51 (1.42)	-0.88 (1.50)	0.12 (2.35)
95% CI	(-2.30, 3.32)	(-3.85, 2.08)	(-4.52, 4.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.39 (2.74)	-1.00 (2.77)	
95% CI	(-5.02, 5.80)	(-6.48, 4.47)	
p-value	0.8869	0.7177	
Corrected Hedge's g Statistics	0.033	-0.086	
95% CI	(-0.44, 0.51)	(-0.57, 0.39)	
Subgroup*Treatment Interaction p-value	0.0341	0.7931	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Mental Component Score			
Week 24			
m	76	74	29
n	71	64	27
Baseline Mean (SD)	51.17 (10.03)	49.44 (12.16)	52.28 (8.80)
Analysis Visit Mean (SD)	51.14 (10.23)	49.86 (10.56)	48.96 (10.87)
LS Mean of Change from Baseline (SE)	-0.09 (0.79)	-0.05 (0.83)	-3.19 (1.26)
95% CI	(-1.66, 1.48)	(-1.69, 1.60)	(-5.68, -0.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.11 (1.48)	3.15 (1.50)	
95% CI	(0.18, 6.03)	(0.18, 6.11)	
p-value	0.0374	0.0380	
Corrected Hedge's g Statistics	0.463	0.470	
95% CI	(0.01, 0.91)	(0.02, 0.92)	
Week 52			
m	74	68	27
n	66	60	23
Baseline Mean (SD)	51.63 (9.80)	49.35 (12.38)	49.91 (10.03)
Analysis Visit Mean (SD)	51.37 (9.53)	49.98 (10.61)	49.97 (10.95)
LS Mean of Change from Baseline (SE)	-0.23 (0.83)	-0.14 (0.87)	-0.99 (1.36)
95% CI	(-1.86, 1.41)	(-1.85, 1.57)	(-3.67, 1.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.77 (1.58)	0.85 (1.60)	
95% CI	(-2.36, 3.89)	(-2.31, 4.02)	
p-value	0.6297	0.5953	
Corrected Hedge's g Statistics	0.114	0.127	
95% CI	(-0.36, 0.59)	(-0.35, 0.61)	
Subgroup*Treatment Interaction p-value	0.0395	0.8596	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Physical Component Score			
Week 24			
m	76	74	29
n	71	64	27
Baseline Mean (SD)	47.46 (9.90)	44.89 (10.00)	46.54 (9.81)
Analysis Visit Mean (SD)	47.51 (10.48)	45.81 (8.66)	46.03 (9.63)
LS Mean of Change from Baseline (SE)	0.44 (0.82)	0.54 (0.86)	-0.60 (1.29)
95% CI	(-1.18, 2.06)	(-1.14, 2.23)	(-3.16, 1.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.04 (1.52)	1.15 (1.54)	
95% CI	(-1.96, 4.05)	(-1.89, 4.19)	
p-value	0.4934	0.4567	
Corrected Hedge's g Statistics	0.151	0.167	
95% CI	(-0.29, 0.59)	(-0.28, 0.62)	
Week 52			
m	74	68	27
n	66	60	23
Baseline Mean (SD)	47.59 (10.07)	45.23 (10.05)	45.03 (10.35)
Analysis Visit Mean (SD)	47.87 (11.17)	45.90 (9.93)	45.54 (10.35)
LS Mean of Change from Baseline (SE)	0.55 (0.85)	0.70 (0.88)	0.27 (1.38)
95% CI	(-1.12, 2.22)	(-1.04, 2.44)	(-2.47, 3.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.29 (1.62)	0.43 (1.63)	
95% CI	(-2.92, 3.49)	(-2.79, 3.66)	
p-value	0.8605	0.7903	
Corrected Hedge's g Statistics	0.041	0.063	
95% CI	(-0.43, 0.52)	(-0.42, 0.54)	
Subgroup*Treatment Interaction p-value	0.4674	0.1868	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Physical Functioning			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	76.76 (21.90)	72.83 (22.35)	76.61 (24.88)
Analysis Visit Mean (SD)	77.57 (22.84)	71.30 (21.12)	77.87 (25.49)
LS Mean of Change from Baseline (SE)	1.33 (2.88)	-2.11 (3.61)	1.28 (1.45)
95% CI	(-4.35, 7.01)	(-9.23, 5.01)	(-1.58, 4.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (3.14)	-3.39 (3.82)	
95% CI	(-6.14, 6.23)	(-10.93, 4.14)	
p-value	0.9887	0.3756	
Corrected Hedge's g Statistics	0.002	-0.189	
95% CI	(-0.36, 0.36)	(-0.63, 0.25)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	75.29 (22.88)	70.00 (23.83)	77.36 (23.49)
Analysis Visit Mean (SD)	77.29 (26.94)	70.28 (22.06)	79.27 (21.61)
LS Mean of Change from Baseline (SE)	1.78 (2.61)	-0.10 (3.49)	2.07 (1.34)
95% CI	(-3.37, 6.93)	(-6.99, 6.79)	(-0.58, 4.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.29 (2.82)	-2.17 (3.66)	
95% CI	(-5.84, 5.27)	(-9.39, 5.05)	
p-value	0.9195	0.5547	
Corrected Hedge's g Statistics	-0.018	-0.137	
95% CI	(-0.39, 0.35)	(-0.63, 0.35)	
Subgroup*Treatment Interaction p-value	0.5361	0.2758	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Role Physical			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	80.42 (20.04)	77.73 (23.06)	78.51 (26.53)
Analysis Visit Mean (SD)	76.02 (23.17)	71.49 (23.89)	77.98 (26.74)
LS Mean of Change from Baseline (SE)	-3.63 (3.28)	-6.47 (4.10)	-1.02 (1.65)
95% CI	(-10.09, 2.83)	(-14.56, 1.61)	(-4.27, 2.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.61 (3.56)	-5.45 (4.33)	
95% CI	(-9.63, 4.41)	(-13.99, 3.09)	
p-value	0.4641	0.2094	
Corrected Hedge's g Statistics	-0.128	-0.268	
95% CI	(-0.49, 0.23)	(-0.71, 0.17)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	80.91 (21.16)	74.67 (24.48)	79.79 (24.69)
Analysis Visit Mean (SD)	79.12 (25.27)	81.96 (19.63)	80.06 (22.81)
LS Mean of Change from Baseline (SE)	-0.63 (3.09)	6.96 (4.12)	0.67 (1.58)
95% CI	(-6.72, 5.45)	(-1.17, 15.08)	(-2.45, 3.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.30 (3.33)	6.29 (4.32)	
95% CI	(-7.87, 5.27)	(-2.23, 14.81)	
p-value	0.6963	0.1471	
Corrected Hedge's g Statistics	-0.070	0.336	
95% CI	(-0.44, 0.30)	(-0.16, 0.83)	
Subgroup*Treatment Interaction p-value	0.4460	0.7059	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Bodily Pain			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	74.8 (21.0)	61.6 (26.5)	67.3 (24.5)
Analysis Visit Mean (SD)	69.6 (24.5)	63.1 (25.3)	67.6 (25.4)
LS Mean of Change from Baseline (SE)	-2.85 (3.11)	0.47 (3.87)	0.62 (1.56)
95% CI	(-8.97, 3.28)	(-7.16, 8.10)	(-2.46, 3.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.47 (3.37)	-0.15 (4.08)	
95% CI	(-10.11, 3.17)	(-8.19, 7.89)	
p-value	0.3046	0.9710	
Corrected Hedge's g Statistics	-0.180	-0.008	
95% CI	(-0.54, 0.18)	(-0.45, 0.43)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	74.7 (22.9)	58.3 (26.1)	67.8 (24.0)
Analysis Visit Mean (SD)	73.6 (26.4)	64.9 (19.0)	71.2 (23.1)
LS Mean of Change from Baseline (SE)	1.47 (3.31)	3.15 (4.43)	3.77 (1.68)
95% CI	(-5.05, 8.00)	(-5.58, 11.88)	(0.45, 7.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.29 (3.59)	-0.62 (4.65)	
95% CI	(-9.37, 4.79)	(-9.77, 8.54)	
p-value	0.5239	0.8942	
Corrected Hedge's g Statistics	-0.115	-0.031	
95% CI	(-0.49, 0.26)	(-0.52, 0.46)	
Subgroup*Treatment Interaction p-value	0.2120	0.5232	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
General Health			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	62.35 (17.52)	55.83 (15.88)	61.20 (19.74)
Analysis Visit Mean (SD)	61.35 (18.84)	53.87 (14.61)	61.11 (21.09)
LS Mean of Change from Baseline (SE)	-0.50 (2.51)	-3.53 (3.15)	-0.37 (1.27)
95% CI	(-5.46, 4.45)	(-9.74, 2.69)	(-2.88, 2.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (2.72)	-3.15 (3.33)	
95% CI	(-5.49, 5.23)	(-9.71, 3.40)	
p-value	0.9614	0.3444	
Corrected Hedge's g Statistics	-0.008	-0.201	
95% CI	(-0.37, 0.35)	(-0.64, 0.24)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	62.71 (19.40)	54.50 (16.27)	61.55 (19.42)
Analysis Visit Mean (SD)	62.40 (23.09)	53.39 (18.82)	62.76 (20.99)
LS Mean of Change from Baseline (SE)	0.12 (2.55)	-2.89 (3.40)	0.95 (1.31)
95% CI	(-4.91, 5.15)	(-9.58, 3.80)	(-1.62, 3.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.83 (2.76)	-3.84 (3.56)	
95% CI	(-6.27, 4.61)	(-10.87, 3.18)	
p-value	0.7640	0.2819	
Corrected Hedge's g Statistics	-0.054	-0.249	
95% CI	(-0.42, 0.32)	(-0.74, 0.24)	
Subgroup*Treatment Interaction p-value	0.0910	0.0346	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Vitality			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	65.39 (22.23)	60.63 (24.38)	57.65 (20.88)
Analysis Visit Mean (SD)	60.66 (22.38)	57.36 (17.54)	58.74 (21.68)
LS Mean of Change from Baseline (SE)	-2.85 (2.52)	-3.46 (3.13)	0.00 (1.27)
95% CI	(-7.81, 2.12)	(-9.63, 2.71)	(-2.50, 2.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.85 (2.74)	-3.46 (3.30)	
95% CI	(-8.24, 2.55)	(-9.97, 3.04)	
p-value	0.2992	0.2954	
Corrected Hedge's g Statistics	-0.182	-0.222	
95% CI	(-0.54, 0.18)	(-0.66, 0.22)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	65.91 (21.30)	59.41 (23.99)	57.82 (20.46)
Analysis Visit Mean (SD)	61.63 (21.76)	62.52 (19.66)	60.03 (22.04)
LS Mean of Change from Baseline (SE)	-2.30 (2.71)	1.45 (3.61)	1.24 (1.38)
95% CI	(-7.65, 3.04)	(-5.66, 8.56)	(-1.48, 3.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.54 (2.95)	0.21 (3.79)	
95% CI	(-9.36, 2.27)	(-7.26, 7.68)	
p-value	0.2311	0.9552	
Corrected Hedge's g Statistics	-0.217	0.013	
95% CI	(-0.59, 0.15)	(-0.48, 0.50)	
Subgroup*Treatment Interaction p-value	0.0430	0.3882	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Social Functioning			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	85.14 (21.01)	80.98 (28.17)	84.29 (22.77)
Analysis Visit Mean (SD)	81.08 (23.87)	86.41 (17.64)	83.39 (22.69)
LS Mean of Change from Baseline (SE)	-3.47 (3.00)	3.99 (3.76)	-1.29 (1.52)
95% CI	(-9.38, 2.44)	(-3.42, 11.40)	(-4.27, 1.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.19 (3.26)	5.28 (3.97)	
95% CI	(-8.61, 4.23)	(-2.54, 13.10)	
p-value	0.5028	0.1847	
Corrected Hedge's g Statistics	-0.117	0.283	
95% CI	(-0.48, 0.24)	(-0.16, 0.72)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	85.36 (20.67)	81.25 (28.84)	85.36 (22.03)
Analysis Visit Mean (SD)	83.93 (20.24)	86.81 (17.92)	85.80 (20.57)
LS Mean of Change from Baseline (SE)	-1.37 (2.93)	4.73 (3.90)	0.12 (1.50)
95% CI	(-7.14, 4.40)	(-2.96, 12.41)	(-2.83, 3.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.49 (3.16)	4.60 (4.09)	
95% CI	(-7.73, 4.74)	(-3.46, 12.66)	
p-value	0.6372	0.2618	
Corrected Hedge's g Statistics	-0.084	0.260	
95% CI	(-0.45, 0.29)	(-0.23, 0.75)	
Subgroup*Treatment Interaction p-value	0.3229	0.9059	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Role Emotional			
Week 24			
m	41	25	177
n	37	23	151
Baseline Mean (SD)	84.01 (25.72)	86.23 (19.88)	85.48 (21.59)
Analysis Visit Mean (SD)	82.44 (21.67)	90.58 (15.95)	85.38 (22.49)
LS Mean of Change from Baseline (SE)	-1.51 (2.84)	5.13 (3.56)	0.42 (1.44)
95% CI	(-7.11, 4.09)	(-1.88, 12.14)	(-2.43, 3.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.92 (3.08)	4.72 (3.75)	
95% CI	(-7.99, 4.14)	(-2.67, 12.10)	
p-value	0.5325	0.2098	
Corrected Hedge's g Statistics	-0.109	0.266	
95% CI	(-0.47, 0.25)	(-0.17, 0.71)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	85.24 (22.70)	85.64 (19.97)	86.73 (20.21)
Analysis Visit Mean (SD)	83.33 (20.31)	93.06 (13.78)	86.31 (20.58)
LS Mean of Change from Baseline (SE)	-1.56 (2.84)	7.36 (3.76)	-0.10 (1.45)
95% CI	(-7.15, 4.03)	(-0.05, 14.77)	(-2.97, 2.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.46 (3.07)	7.46 (3.94)	
95% CI	(-7.50, 4.59)	(-0.31, 15.24)	
p-value	0.6352	0.0597	
Corrected Hedge's g Statistics	-0.085	0.435	
95% CI	(-0.46, 0.29)	(-0.06, 0.93)	
Subgroup*Treatment Interaction p-value	0.0505	0.5992	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Mental Health			
Week 24			
m	41	25	177
n	37	23	152
Baseline Mean (SD)	77.4 (19.6)	82.4 (15.9)	76.3 (15.9)
Analysis Visit Mean (SD)	73.2 (20.5)	81.7 (14.0)	76.6 (17.0)
LS Mean of Change from Baseline (SE)	-3.66 (2.05)	0.71 (2.57)	0.06 (1.04)
95% CI	(-7.71, 0.38)	(-4.36, 5.78)	(-2.00, 2.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.72 (2.21)	0.65 (2.71)	
95% CI	(-8.09, 0.64)	(-4.69, 5.99)	
p-value	0.0942	0.8113	
Corrected Hedge's g Statistics	-0.290	0.050	
95% CI	(-0.65, 0.07)	(-0.39, 0.49)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	78.7 (16.4)	83.1 (15.8)	76.4 (15.9)
Analysis Visit Mean (SD)	76.3 (17.3)	85.0 (12.8)	77.7 (18.6)
LS Mean of Change from Baseline (SE)	-1.87 (2.44)	3.70 (3.27)	0.21 (1.24)
95% CI	(-6.69, 2.94)	(-2.75, 10.15)	(-2.24, 2.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.09 (2.67)	3.48 (3.45)	
95% CI	(-7.34, 3.17)	(-3.31, 10.28)	
p-value	0.4343	0.3137	
Corrected Hedge's g Statistics	-0.142	0.237	
95% CI	(-0.51, 0.23)	(-0.25, 0.73)	
Subgroup*Treatment Interaction p-value	0.0341	0.7931	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Mental Component Score			
Week 24			
m	41	25	177
n	37	23	151
Baseline Mean (SD)	52.26 (11.08)	53.98 (10.17)	51.72 (8.45)
Analysis Visit Mean (SD)	50.29 (11.06)	55.19 (9.18)	51.68 (9.35)
LS Mean of Change from Baseline (SE)	-1.71 (1.14)	1.62 (1.43)	-0.14 (0.58)
95% CI	(-3.96, 0.54)	(-1.20, 4.44)	(-1.28, 1.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.57 (1.23)	1.76 (1.51)	
95% CI	(-4.01, 0.86)	(-1.21, 4.73)	
p-value	0.2040	0.2441	
Corrected Hedge's g Statistics	-0.220	0.246	
95% CI	(-0.58, 0.14)	(-0.19, 0.69)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	53.01 (9.21)	54.46 (10.32)	51.93 (8.21)
Analysis Visit Mean (SD)	51.35 (9.46)	56.64 (8.23)	52.15 (9.81)
LS Mean of Change from Baseline (SE)	-1.28 (1.26)	2.38 (1.68)	-0.20 (0.64)
95% CI	(-3.76, 1.21)	(-0.92, 5.69)	(-1.47, 1.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.07 (1.37)	2.58 (1.76)	
95% CI	(-3.77, 1.62)	(-0.89, 6.06)	
p-value	0.4328	0.1440	
Corrected Hedge's g Statistics	-0.141	0.340	
95% CI	(-0.51, 0.23)	(-0.15, 0.83)	
Subgroup*Treatment Interaction p-value	0.0395	0.8596	

AMNOG Table SE22.13.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Physical Component Score			
Week 24			
m	41	25	177
n	37	23	151
Baseline Mean (SD)	49.42 (6.72)	45.18 (9.22)	48.02 (9.21)
Analysis Visit Mean (SD)	48.78 (7.94)	43.78 (9.48)	48.13 (9.66)
LS Mean of Change from Baseline (SE)	-0.28 (1.07)	-1.92 (1.34)	0.03 (0.54)
95% CI	(-2.38, 1.83)	(-4.55, 0.71)	(-1.03, 1.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.31 (1.16)	-1.95 (1.41)	
95% CI	(-2.59, 1.97)	(-4.74, 0.83)	
p-value	0.7891	0.1679	
Corrected Hedge's g Statistics	-0.047	-0.295	
95% CI	(-0.41, 0.31)	(-0.73, 0.14)	
Week 52			
m	39	22	167
n	35	18	140
Baseline Mean (SD)	49.03 (7.99)	43.72 (9.47)	48.25 (8.62)
Analysis Visit Mean (SD)	49.34 (10.84)	44.61 (8.34)	49.09 (8.29)
LS Mean of Change from Baseline (SE)	0.50 (1.02)	0.21 (1.37)	0.94 (0.52)
95% CI	(-1.50, 2.51)	(-2.49, 2.90)	(-0.09, 1.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.44 (1.10)	-0.74 (1.44)	
95% CI	(-2.60, 1.73)	(-3.57, 2.10)	
p-value	0.6910	0.6093	
Corrected Hedge's g Statistics	-0.071	-0.119	
95% CI	(-0.44, 0.30)	(-0.61, 0.37)	
Subgroup*Treatment Interaction p-value	0.4674	0.1868	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; CFB = Change from Baseline; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (13.2)	11 (14.7)	3 (10.0)
No	66 (86.8)	64 (85.3)	27 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.65	
95% CI of the inverse odds ratio	(0.19, 2.87)	(0.17, 2.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	0.68	
95% CI of the inverse risk ratio	(0.22, 2.57)	(0.20, 2.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.16	4.67	
95% CI of the absolute risk difference	(-10.00, 16.31)	(-8.73, 18.06)	
p-value	0.6552	0.5251	
p-value of Breslow-Day Test for Homogeneity [3]	0.6597	0.4582	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (32.9)	24 (32.0)	9 (30.0)
No	51 (67.1)	51 (68.0)	21 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.91	
95% CI of the inverse odds ratio	(0.35, 2.18)	(0.36, 2.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.94	
95% CI of the inverse risk ratio	(0.48, 1.72)	(0.50, 1.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.89	2.00	
95% CI of the absolute risk difference	(-16.61, 22.40)	(-17.50, 21.50)	
p-value	0.7736	0.8419	
p-value of Breslow-Day Test for Homogeneity [3]	0.8780	0.8339	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (9.2)	8 (10.7)	3 (10.0)
No	69 (90.8)	67 (89.3)	27 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	0.93	
95% CI of the inverse odds ratio	(0.26, 4.55)	(0.23, 3.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.94	
95% CI of the inverse risk ratio	(0.30, 3.92)	(0.27, 3.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.79	0.67	
95% CI of the absolute risk difference	(-13.34, 11.76)	(-12.14, 13.47)	
p-value	0.9003	0.9197	
p-value of Breslow-Day Test for Homogeneity [3]	0.7897	0.4308	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (21.1)	20 (26.7)	10 (33.3)
No	60 (78.9)	55 (73.3)	20 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.88	1.38	
95% CI of the inverse odds ratio	(0.73, 4.79)	(0.55, 3.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.58	1.25	
95% CI of the inverse risk ratio	(0.81, 3.09)	(0.67, 2.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.28	-6.67	
95% CI of the absolute risk difference	(-31.48, 6.92)	(-26.28, 12.95)	
p-value	0.1856	0.4945	
p-value of Breslow-Day Test for Homogeneity [3]	0.3099	0.5419	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (13.2)	15 (20.0)	6 (20.0)
No	66 (86.8)	60 (80.0)	24 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	1.00	
95% CI of the inverse odds ratio	(0.54, 5.03)	(0.35, 2.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	1.00	
95% CI of the inverse risk ratio	(0.61, 3.81)	(0.43, 2.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.84	0.00	
95% CI of the absolute risk difference	(-23.05, 9.36)	(-16.94, 16.94)	
p-value	0.3754	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.8152	0.8864	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (28.9)	24 (32.0)	7 (23.3)
No	54 (71.1)	51 (68.0)	23 (76.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.65	
95% CI of the inverse odds ratio	(0.28, 1.99)	(0.24, 1.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.73	
95% CI of the inverse risk ratio	(0.39, 1.69)	(0.35, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.61	8.67	
95% CI of the absolute risk difference	(-12.63, 23.86)	(-9.79, 27.12)	
p-value	0.5592	0.3791	
p-value of Breslow-Day Test for Homogeneity [3]	0.1830	0.6795	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (18.4)	19 (25.3)	3 (10.0)
No	62 (81.6)	56 (74.7)	27 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.49	0.33	
95% CI of the inverse odds ratio	(0.13, 1.85)	(0.09, 1.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	0.39	
95% CI of the inverse risk ratio	(0.17, 1.75)	(0.13, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.42	15.33	
95% CI of the absolute risk difference	(-5.41, 22.25)	(0.77, 29.90)	
p-value	0.2872	0.0811	
p-value of Breslow-Day Test for Homogeneity [3]	0.4306	0.0134	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (34.2)	29 (38.7)	10 (33.3)
No	50 (65.8)	46 (61.3)	20 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.79	
95% CI of the inverse odds ratio	(0.39, 2.35)	(0.33, 1.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.86	
95% CI of the inverse risk ratio	(0.54, 1.77)	(0.48, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.88	5.33	
95% CI of the absolute risk difference	(-19.08, 20.84)	(-14.82, 25.48)	
p-value	0.9315	0.6094	
p-value of Breslow-Day Test for Homogeneity [3]	0.8566	0.5009	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (10.5)	6 (8.0)	3 (10.0)
No	68 (89.5)	69 (92.0)	27 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.28	
95% CI of the inverse odds ratio	(0.23, 3.83)	(0.30, 5.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	1.25	
95% CI of the inverse risk ratio	(0.27, 3.34)	(0.33, 4.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.53	-2.00	
95% CI of the absolute risk difference	(-12.23, 13.29)	(-14.37, 10.37)	
p-value	0.9362	0.7409	
p-value of Breslow-Day Test for Homogeneity [3]	0.3685	0.7037	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (32.9)	22 (29.3)	10 (33.3)
No	51 (67.1)	53 (70.7)	20 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.20	
95% CI of the inverse odds ratio	(0.42, 2.50)	(0.49, 2.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.14	
95% CI of the inverse risk ratio	(0.56, 1.85)	(0.61, 2.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.44	-4.00	
95% CI of the absolute risk difference	(-20.34, 19.46)	(-23.77, 15.77)	
p-value	0.9655	0.6875	
p-value of Breslow-Day Test for Homogeneity [3]	0.3147	0.8170	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (7.9)	14 (18.7)	2 (6.7)
No	70 (92.1)	61 (81.3)	28 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.31	
95% CI of the inverse odds ratio	(0.16, 4.38)	(0.07, 1.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.36	
95% CI of the inverse risk ratio	(0.18, 3.95)	(0.09, 1.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.23	12.00	
95% CI of the absolute risk difference	(-9.56, 12.02)	(-0.55, 24.55)	
p-value	0.8293	0.1222	
p-value of Breslow-Day Test for Homogeneity [3]	0.6435	0.3708	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (19.7)	21 (28.0)	5 (16.7)
No	61 (80.3)	54 (72.0)	25 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.51	
95% CI of the inverse odds ratio	(0.27, 2.48)	(0.17, 1.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.60	
95% CI of the inverse risk ratio	(0.34, 2.12)	(0.25, 1.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.07	11.33	
95% CI of the absolute risk difference	(-12.99, 19.13)	(-5.43, 28.10)	
p-value	0.7159	0.2242	
p-value of Breslow-Day Test for Homogeneity [3]	0.6153	0.6227	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (10.5)	17 (22.7)	3 (10.0)
No	68 (89.5)	58 (77.3)	27 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.38	
95% CI of the inverse odds ratio	(0.23, 3.83)	(0.10, 1.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.44	
95% CI of the inverse risk ratio	(0.27, 3.34)	(0.14, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.53	12.67	
95% CI of the absolute risk difference	(-12.23, 13.29)	(-1.65, 26.99)	
p-value	0.9362	0.1354	
p-value of Breslow-Day Test for Homogeneity [3]	0.9162	0.8501	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (19.7)	24 (32.0)	5 (16.7)
No	61 (80.3)	51 (68.0)	25 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.43	
95% CI of the inverse odds ratio	(0.27, 2.48)	(0.14, 1.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.52	
95% CI of the inverse risk ratio	(0.34, 2.12)	(0.22, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.07	15.33	
95% CI of the absolute risk difference	(-12.99, 19.13)	(-1.68, 32.34)	
p-value	0.7159	0.1124	
p-value of Breslow-Day Test for Homogeneity [3]	0.3990	0.5492	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (11.8)	7 (9.3)	3 (10.0)
No	67 (88.2)	68 (90.7)	27 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	1.08	
95% CI of the inverse odds ratio	(0.21, 3.29)	(0.26, 4.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.07	
95% CI of the inverse risk ratio	(0.25, 2.91)	(0.30, 3.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.84	-0.67	
95% CI of the absolute risk difference	(-11.12, 14.80)	(-13.26, 11.93)	
p-value	0.7874	0.9163	
p-value of Breslow-Day Test for Homogeneity [3]	0.5960	0.5416	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	31 (40.8)	24 (32.0)	11 (36.7)
No	45 (59.2)	51 (68.0)	19 (63.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.23	
95% CI of the inverse odds ratio	(0.35, 2.01)	(0.51, 2.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.15	
95% CI of the inverse risk ratio	(0.52, 1.55)	(0.65, 2.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.12	-4.67	
95% CI of the absolute risk difference	(-16.36, 24.60)	(-24.89, 15.55)	
p-value	0.6958	0.6468	
p-value of Breslow-Day Test for Homogeneity [3]	0.5293	0.8762	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.6)	6 (8.0)	1 (3.3)
No	74 (97.4)	69 (92.0)	29 (96.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	0.40	
95% CI of the inverse odds ratio	(0.11, 14.62)	(0.05, 3.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	0.42	
95% CI of the inverse risk ratio	(0.12, 13.46)	(0.05, 3.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.70	4.67	
95% CI of the absolute risk difference	(-8.06, 6.66)	(-4.22, 13.55)	
p-value	0.8444	0.3865	
p-value of Breslow-Day Test for Homogeneity [3]	0.6414	0.9077	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (25.0)	14 (18.7)	4 (13.3)
No	57 (75.0)	61 (81.3)	26 (86.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.46	0.67	
95% CI of the inverse odds ratio	(0.14, 1.49)	(0.20, 2.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	0.71	
95% CI of the inverse risk ratio	(0.20, 1.44)	(0.26, 2.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.67	5.33	
95% CI of the absolute risk difference	(-3.91, 27.25)	(-9.69, 20.36)	
p-value	0.1893	0.5124	
p-value of Breslow-Day Test for Homogeneity [3]	0.1210	0.5587	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.6)	6 (8.0)	1 (3.3)
No	74 (97.4)	69 (92.0)	29 (96.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	0.40	
95% CI of the inverse odds ratio	(0.11, 14.62)	(0.05, 3.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	0.42	
95% CI of the inverse risk ratio	(0.12, 13.46)	(0.05, 3.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.70	4.67	
95% CI of the absolute risk difference	(-8.06, 6.66)	(-4.22, 13.55)	
p-value	0.8444	0.3865	
p-value of Breslow-Day Test for Homogeneity [3]	0.5498	0.3985	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (26.3)	23 (30.7)	7 (23.3)
No	56 (73.7)	52 (69.3)	23 (76.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.69	
95% CI of the inverse odds ratio	(0.32, 2.29)	(0.26, 1.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.76	
95% CI of the inverse risk ratio	(0.42, 1.88)	(0.37, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.98	7.33	
95% CI of the absolute risk difference	(-15.10, 21.07)	(-11.05, 25.72)	
p-value	0.7509	0.4524	
p-value of Breslow-Day Test for Homogeneity [3]	0.7070	0.4522	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (14.3)	3 (12.0)	27 (15.1)
No	36 (85.7)	22 (88.0)	152 (84.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.30	
95% CI of the inverse odds ratio	(0.41, 2.77)	(0.36, 4.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.26	
95% CI of the inverse risk ratio	(0.47, 2.39)	(0.41, 3.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.80	-3.08	
95% CI of the absolute risk difference	(-12.61, 11.01)	(-16.86, 10.69)	
p-value	0.8961	0.6834	
p-value of Breslow-Day Test for Homogeneity [3]	0.6597	0.4582	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (38.1)	8 (32.0)	59 (33.0)
No	26 (61.9)	17 (68.0)	120 (67.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.04	
95% CI of the inverse odds ratio	(0.40, 1.60)	(0.43, 2.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.03	
95% CI of the inverse risk ratio	(0.56, 1.34)	(0.56, 1.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.13	-0.96	
95% CI of the absolute risk difference	(-11.09, 21.36)	(-20.50, 18.58)	
p-value	0.5271	0.9237	
p-value of Breslow-Day Test for Homogeneity [3]	0.8780	0.8339	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (9.5)	6 (24.0)	23 (12.8)
No	38 (90.5)	19 (76.0)	156 (87.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	0.47	
95% CI of the inverse odds ratio	(0.46, 4.29)	(0.17, 1.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	0.54	
95% CI of the inverse risk ratio	(0.49, 3.69)	(0.24, 1.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.33	11.15	
95% CI of the absolute risk difference	(-13.47, 6.82)	(-6.29, 28.60)	
p-value	0.5537	0.1348	
p-value of Breslow-Day Test for Homogeneity [3]	0.7897	0.4308	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (26.2)	7 (28.0)	47 (26.3)
No	31 (73.8)	18 (72.0)	132 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.92	
95% CI of the inverse odds ratio	(0.47, 2.15)	(0.36, 2.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.94	
95% CI of the inverse risk ratio	(0.57, 1.76)	(0.48, 1.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.07	1.74	
95% CI of the absolute risk difference	(-14.84, 14.71)	(-17.00, 20.49)	
p-value	0.9930	0.8532	
p-value of Breslow-Day Test for Homogeneity [3]	0.3099	0.5419	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (16.7)	5 (20.0)	39 (21.8)
No	35 (83.3)	20 (80.0)	140 (78.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	1.11	
95% CI of the inverse odds ratio	(0.57, 3.38)	(0.39, 3.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.09	
95% CI of the inverse risk ratio	(0.63, 2.72)	(0.47, 2.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.12	-1.79	
95% CI of the absolute risk difference	(-17.91, 7.67)	(-18.59, 15.02)	
p-value	0.4619	0.8387	
p-value of Breslow-Day Test for Homogeneity [3]	0.8152	0.8864	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (21.4)	9 (36.0)	58 (32.4)
No	33 (78.6)	16 (64.0)	121 (67.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.76	0.85	
95% CI of the inverse odds ratio	(0.79, 3.91)	(0.36, 2.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	0.90	
95% CI of the inverse risk ratio	(0.82, 2.80)	(0.51, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.97	3.60	
95% CI of the absolute risk difference	(-25.15, 3.20)	(-16.43, 23.62)	
p-value	0.1638	0.7197	
p-value of Breslow-Day Test for Homogeneity [3]	0.1830	0.6795	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (19.0)	1 (4.0)	32 (17.9)
No	34 (81.0)	24 (96.0)	147 (82.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	5.22	
95% CI of the inverse odds ratio	(0.39, 2.19)	(0.68, 40.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	4.47	
95% CI of the inverse risk ratio	(0.47, 1.89)	(0.64, 31.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.17	-13.88	
95% CI of the absolute risk difference	(-11.96, 14.31)	(-23.39, -4.36)	
p-value	0.8593	0.0776	
p-value of Breslow-Day Test for Homogeneity [3]	0.4306	0.0134	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (31.0)	7 (28.0)	58 (32.4)
No	29 (69.0)	18 (72.0)	121 (67.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.23	
95% CI of the inverse odds ratio	(0.52, 2.21)	(0.49, 3.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.16	
95% CI of the inverse risk ratio	(0.64, 1.72)	(0.60, 2.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.45	-4.40	
95% CI of the absolute risk difference	(-17.02, 14.12)	(-23.29, 14.49)	
p-value	0.8563	0.6581	
p-value of Breslow-Day Test for Homogeneity [3]	0.8566	0.5009	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (7.1)	4 (16.0)	26 (14.5)
No	39 (92.9)	21 (84.0)	153 (85.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.21	0.89	
95% CI of the inverse odds ratio	(0.64, 7.68)	(0.28, 2.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.03	0.91	
95% CI of the inverse risk ratio	(0.65, 6.40)	(0.35, 2.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.38	1.47	
95% CI of the absolute risk difference	(-16.73, 1.96)	(-13.79, 16.74)	
p-value	0.2022	0.8454	
p-value of Breslow-Day Test for Homogeneity [3]	0.3685	0.7037	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (23.8)	9 (36.0)	66 (36.9)
No	32 (76.2)	16 (64.0)	113 (63.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.87	1.04	
95% CI of the inverse odds ratio	(0.86, 4.05)	(0.43, 2.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	1.02	
95% CI of the inverse risk ratio	(0.87, 2.75)	(0.59, 1.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.06	-0.87	
95% CI of the absolute risk difference	(-27.75, 1.63)	(-20.97, 19.23)	
p-value	0.1087	0.9325	
p-value of Breslow-Day Test for Homogeneity [3]	0.3147	0.8170	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (7.1)	3 (12.0)	17 (9.5)
No	39 (92.9)	22 (88.0)	162 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.77	
95% CI of the inverse odds ratio	(0.38, 4.89)	(0.21, 2.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	0.79	
95% CI of the inverse risk ratio	(0.41, 4.33)	(0.25, 2.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.35	2.50	
95% CI of the absolute risk difference	(-11.25, 6.54)	(-10.94, 15.95)	
p-value	0.6322	0.6934	
p-value of Breslow-Day Test for Homogeneity [3]	0.6435	0.3708	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (16.7)	6 (24.0)	34 (19.0)
No	35 (83.3)	19 (76.0)	145 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.74	
95% CI of the inverse odds ratio	(0.48, 2.86)	(0.28, 2.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	0.79	
95% CI of the inverse risk ratio	(0.54, 2.39)	(0.37, 1.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.33	5.01	
95% CI of the absolute risk difference	(-14.98, 10.32)	(-12.69, 22.71)	
p-value	0.7269	0.5549	
p-value of Breslow-Day Test for Homogeneity [3]	0.6153	0.6227	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (11.9)	6 (24.0)	22 (12.3)
No	37 (88.1)	19 (76.0)	157 (87.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.44	
95% CI of the inverse odds ratio	(0.37, 2.92)	(0.16, 1.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.51	
95% CI of the inverse risk ratio	(0.42, 2.57)	(0.23, 1.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.39	11.71	
95% CI of the absolute risk difference	(-11.30, 10.53)	(-5.71, 29.13)	
p-value	0.9452	0.1110	
p-value of Breslow-Day Test for Homogeneity [3]	0.9162	0.8501	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (11.9)	6 (24.0)	31 (17.3)
No	37 (88.1)	19 (76.0)	148 (82.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	0.66	
95% CI of the inverse odds ratio	(0.56, 4.26)	(0.24, 1.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	0.72	
95% CI of the inverse risk ratio	(0.60, 3.52)	(0.33, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.41	6.68	
95% CI of the absolute risk difference	(-16.67, 5.84)	(-10.95, 24.32)	
p-value	0.3925	0.4167	
p-value of Breslow-Day Test for Homogeneity [3]	0.3990	0.5492	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (11.9)	2 (8.0)	27 (15.1)
No	37 (88.1)	23 (92.0)	152 (84.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	2.04	
95% CI of the inverse odds ratio	(0.47, 3.64)	(0.45, 9.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	1.89	
95% CI of the inverse risk ratio	(0.52, 3.10)	(0.48, 7.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.18	-7.08	
95% CI of the absolute risk difference	(-14.29, 7.93)	(-18.94, 4.77)	
p-value	0.5983	0.3421	
p-value of Breslow-Day Test for Homogeneity [3]	0.5960	0.5416	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (26.2)	7 (28.0)	54 (30.2)
No	31 (73.8)	18 (72.0)	125 (69.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	1.11	
95% CI of the inverse odds ratio	(0.57, 2.60)	(0.44, 2.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.08	
95% CI of the inverse risk ratio	(0.66, 2.01)	(0.55, 2.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.98	-2.17	
95% CI of the absolute risk difference	(-18.88, 10.92)	(-21.01, 16.67)	
p-value	0.6107	0.8245	
p-value of Breslow-Day Test for Homogeneity [3]	0.5293	0.8762	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.4)	4 (16.0)	11 (6.1)
No	41 (97.6)	21 (84.0)	168 (93.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.68	0.34	
95% CI of the inverse odds ratio	(0.34, 21.39)	(0.10, 1.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.58	0.38	
95% CI of the inverse risk ratio	(0.34, 19.44)	(0.13, 1.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.76	9.85	
95% CI of the absolute risk difference	(-9.56, 2.04)	(-4.94, 24.65)	
p-value	0.3326	0.0770	
p-value of Breslow-Day Test for Homogeneity [3]	0.6414	0.9077	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (19.0)	6 (24.0)	45 (25.1)
No	34 (81.0)	19 (76.0)	134 (74.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.06	
95% CI of the inverse odds ratio	(0.62, 3.31)	(0.40, 2.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	1.05	
95% CI of the inverse risk ratio	(0.67, 2.59)	(0.50, 2.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.09	-1.14	
95% CI of the absolute risk difference	(-19.56, 7.38)	(-19.05, 16.77)	
p-value	0.4053	0.9019	
p-value of Breslow-Day Test for Homogeneity [3]	0.1210	0.5587	

AMNOG Table SE22.13.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (9.5)	1 (4.0)	10 (5.6)
No	38 (90.5)	24 (96.0)	169 (94.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	1.42	
95% CI of the inverse odds ratio	(0.17, 1.89)	(0.17, 11.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	1.40	
95% CI of the inverse risk ratio	(0.19, 1.78)	(0.19, 10.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.94	-1.59	
95% CI of the absolute risk difference	(-5.56, 13.43)	(-9.97, 6.80)	
p-value	0.3458	0.7422	
p-value of Breslow-Day Test for Homogeneity [3]	0.5498	0.3985	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (21.4)	5 (20.0)	41 (22.9)
No	33 (78.6)	20 (80.0)	138 (77.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.19	
95% CI of the inverse odds ratio	(0.48, 2.46)	(0.42, 3.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.15	
95% CI of the inverse risk ratio	(0.56, 2.02)	(0.50, 2.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.48	-2.91	
95% CI of the absolute risk difference	(-15.33, 12.38)	(-19.75, 13.94)	
p-value	0.8369	0.7447	
p-value of Breslow-Day Test for Homogeneity [3]	0.7070	0.4522	

Madrigal Pharmaceuticals, Inc. Page 1 of 8
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.13.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB
General Health



Patients with result at given visit			
MGL-3196 80 mg	72	75	70
MGL-3196 100 mg	68	71	63
Placebo	29	28	23

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 8
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.13.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB
Vitality



Patients with result at given visit			
MGL-3196 80 mg	72	75	70
MGL-3196 100 mg	68	71	63
Placebo	29	28	23

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 8
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.13.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB
Mental Health



Patients with result at given visit			
MGL-3196 80 mg	72	75	70
MGL-3196 100 mg	68	71	63
Placebo	29	28	23

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 4 of 8
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.13.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB
Mental Component Score



Patients with result at given visit			
MGL-3196 80 mg	71	75	70
MGL-3196 100 mg	68	71	63
Placebo	29	28	23

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 5 of 8
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.13.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB
General Health



Patients with result at given visit			
MGL-3196 80 mg	40	39	37
MGL-3196 100 mg	23	25	20
Placebo	166	160	150

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 6 of 8
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.13.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB
Vitality



Patients with result at given visit			
MGL-3196 80 mg	40	39	37
MGL-3196 100 mg	23	25	20
Placebo	166	160	150

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 7 of 8
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.13.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB
Mental Health



Patients with result at given visit			
MGL-3196 80 mg	40	39	37
MGL-3196 100 mg	23	25	20
Placebo	166	160	150

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 8 of 8
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.13.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB
Mental Component Score



Patients with result at given visit			
MGL-3196 80 mg	40	39	37
MGL-3196 100 mg	23	25	20
Placebo	165	160	150

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Physical Functioning						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	69.95 (29.16)	69.74 (28.88)	70.11 (28.33)			
Median	75.00	75.00	80.00			
IQR: Q1, Q3	55.00, 95.00	50.00, 95.00	55.00, 95.00			
Min, Max	0.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	69.15 (25.86)	72.00 (25.84)	72.76 (29.66)	0.05 (2.84)	0.91 (2.84)	2.78 (2.17)
Median	75.00	75.00	85.00	0	0	0
IQR: Q1, Q3	50.00, 90.00	60.00, 95.00	50.00, 95.00	-10.00, 10.00	-10.00, 10.00	-5.00, 10.00
Min, Max	10.0, 100.0	10.0, 100.0	5.0, 100.0	-50.0, 60.0	-35.0, 40.0	-70.0, 75.0
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	69.08 (29.41)	72.13 (27.51)	73.56 (25.38)	-2.44 (2.22)	2.70 (2.72)	3.92 (2.14)
Median	75.00	81.65	80.00	0	0	0
IQR: Q1, Q3	45.00, 100.00	60.00, 95.00	60.00, 95.00	-7.50, 5.00	-5.00, 10.00	-5.00, 12.50
Min, Max	0.0, 100.0	5.0, 100.0	10.0, 100.0	-42.8, 25.0	-25.0, 40.0	-30.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Role Physical						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	73.90 (26.15)	74.69 (25.65)	72.73 (27.33)			
Median	81.30	75.00	78.15			
IQR: Q1, Q3	50.00, 100.00	62.50, 100.00	50.00, 100.00			
Min, Max	0.0, 100.0	25.0, 100.0	6.3, 100.0			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	69.16 (27.34)	72.38 (25.94)	77.15 (28.12)	-4.12 (3.10)	-3.31 (3.18)	4.63 (2.43)
Median	75.00	78.15	93.80	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 93.80	62.50, 100.00	-18.80, 6.25	-12.50, 6.30	0.00, 12.50
Min, Max	0.0, 100.0	0.0, 100.0	6.3, 100.0	-43.7, 43.7	-50.0, 50.0	-56.2, 87.5
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	69.25 (28.34)	73.06 (26.82)	74.93 (24.60)	-6.08 (2.81)	-1.50 (3.38)	2.86 (2.41)
Median	71.90	75.00	81.30	0	0	0
IQR: Q1, Q3	50.00, 100.00	59.40, 100.00	50.00, 100.00	-18.75, 0.00	-12.50, 12.50	-6.30, 12.50
Min, Max	0.0, 100.0	12.5, 100.0	6.3, 100.0	-37.5, 31.3	-37.5, 31.3	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Bodily Pain						
Baseline						
m	48	44	95			
n	44	39	90			
Mean (SD)	62.6 (24.0)	65.5 (26.3)	62.5 (24.7)			
Median	62.0	62.0	62.0			
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	41.0, 84.0			
Min, Max	22, 100	22, 100	0, 100			
Week 24						
m	47	39	87			
n	47	38	85	43	34	81
Mean (SD/SE)	58.8 (25.5)	65.5 (23.6)	65.3 (24.0)	-2.6 (2.7)	-1.7 (3.2)	2.5 (2.2)
Median	62.0	62.0	62.0	0	0	0
IQR: Q1, Q3	41.0, 74.0	41.0, 84.0	51.0, 84.0	-16.0, 10.0	-10.0, 10.0	-11.0, 16.0
Min, Max	0, 100	21, 100	10, 100	-39, 48	-59, 31	-49, 49
Week 52						
m	45	35	81			
n	38	32	75	35	29	72
Mean (SD/SE)	65.0 (24.2)	71.9 (25.8)	64.6 (23.8)	2.2 (2.6)	5.5 (4.2)	2.4 (2.4)
Median	67.0	72.0	62.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	51.5, 100.0	51.0, 84.0	0.0, 10.0	0.0, 12.0	-10.0, 14.0
Min, Max	22, 100	10, 100	10, 100	-38, 48	-43, 69	-49, 49

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
General Health						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	58.22 (19.28)	58.56 (20.34)	55.83 (20.00)			
Median	62.00	62.00	57.00			
IQR: Q1, Q3	45.00, 77.00	45.00, 72.00	40.00, 72.00			
Min, Max	25.0, 92.0	10.0, 92.0	15.0, 100.0			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	57.00 (20.38)	56.97 (20.58)	58.25 (21.85)	0.50 (2.27)	-2.18 (3.02)	2.35 (1.49)
Median	57.00	53.50	62.00	0	-2.50	0
IQR: Q1, Q3	43.80, 72.00	42.00, 72.00	42.00, 77.00	-7.60, 8.50	-10.00, 10.00	-5.00, 10.00
Min, Max	20.0, 100.0	10.0, 92.0	0.0, 100.0	-47.0, 32.0	-35.0, 40.0	-35.0, 40.0
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	59.00 (20.05)	56.97 (19.44)	59.12 (20.32)	1.58 (2.18)	-1.48 (2.70)	3.67 (1.39)
Median	62.00	56.00	62.00	0	0	2.50
IQR: Q1, Q3	40.00, 72.00	46.00, 69.50	45.00, 77.00	-5.00, 8.50	-12.00, 10.00	-5.00, 10.00
Min, Max	20.0, 100.0	15.0, 92.0	10.0, 100.0	-22.0, 37.0	-25.0, 25.0	-35.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Vitality						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	55.06 (21.79)	54.03 (20.51)	53.36 (22.67)			
Median	56.30	56.30	56.30			
IQR: Q1, Q3	37.50, 75.00	37.50, 68.80	37.50, 68.80			
Min, Max	12.5, 100.0	0.0, 87.5	0.0, 93.8			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	52.02 (23.28)	52.16 (18.62)	55.39 (21.18)	-1.89 (2.51)	-2.57 (2.63)	2.31 (1.83)
Median	56.30	56.30	56.30	0	-6.20	0
IQR: Q1, Q3	31.30, 68.80	37.50, 62.50	37.50, 75.00	-10.40, 6.30	-12.50, 6.20	-6.30, 6.30
Min, Max	0.0, 100.0	12.5, 87.5	0.0, 100.0	-43.8, 43.8	-31.3, 31.2	-31.3, 43.8
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	56.11 (23.36)	53.35 (17.24)	55.61 (21.40)	0.36 (2.41)	-0.22 (2.39)	2.08 (2.02)
Median	59.40	56.30	56.30	0	0	0
IQR: Q1, Q3	37.50, 75.00	43.80, 65.65	37.50, 68.80	-9.40, 9.40	-6.30, 6.20	-6.30, 12.50
Min, Max	12.5, 100.0	6.3, 87.5	12.5, 100.0	-31.2, 37.5	-25.0, 37.5	-43.7, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Social Functioning						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	80.00 (23.29)	84.29 (23.25)	80.14 (23.92)			
Median	87.50	100.00	87.50			
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	62.50, 100.00			
Min, Max	25.0, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	79.26 (27.12)	83.22 (18.67)	79.26 (25.41)	1.42 (3.41)	-1.47 (2.83)	0.00 (2.33)
Median	100.00	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	62.50, 100.00	-12.50, 12.50	-12.50, 0.00	0.00, 12.50
Min, Max	25.0, 100.0	37.5, 100.0	0.0, 100.0	-62.5, 62.5	-37.5, 37.5	-62.5, 75.0
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	76.64 (25.86)	78.52 (22.05)	82.33 (20.76)	-3.47 (2.80)	-7.33 (3.85)	2.95 (2.35)
Median	81.25	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	68.75, 100.00	75.00, 100.00	-12.50, 0.00	-25.00, 0.00	0.00, 12.50
Min, Max	12.5, 100.0	25.0, 100.0	25.0, 100.0	-50.0, 25.0	-50.0, 37.5	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Role Emotional						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	81.85 (21.93)	85.89 (20.61)	82.87 (24.39)			
Median	91.70	100.00	100.00			
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	25.0, 100.0	8.3, 100.0			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	79.79 (23.10)	86.19 (17.57)	82.74 (25.06)	0.19 (2.42)	-0.48 (2.88)	1.23 (2.31)
Median	91.70	91.70	100.00	0	0	0
IQR: Q1, Q3	58.30, 100.00	75.00, 100.00	75.00, 100.00	-8.30, 4.15	-8.30, 0.00	-8.30, 0.00
Min, Max	33.3, 100.0	41.7, 100.0	0.0, 100.0	-33.3, 50.0	-33.3, 41.7	-50.0, 58.3
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	78.50 (22.82)	82.81 (21.27)	82.77 (21.81)	-1.63 (2.22)	-1.44 (4.66)	0.34 (2.34)
Median	83.30	87.50	91.70	0	0	0
IQR: Q1, Q3	58.30, 100.00	75.00, 100.00	75.00, 100.00	-4.15, 0.00	-16.70, 16.70	-8.40, 8.30
Min, Max	25.0, 100.0	25.0, 100.0	16.7, 100.0	-33.3, 33.3	-75.0, 50.0	-50.0, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Mental Health						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	73.9 (18.0)	77.6 (16.5)	73.7 (18.7)			
Median	75.0	80.0	77.5			
IQR: Q1, Q3	65.0, 90.0	70.0, 90.0	60.0, 90.0			
Min, Max	25, 100	25, 100	20, 100			
Week 24						
m	47	39	87			
n	47	38	85	44	34	81
Mean (SD/SE)	72.3 (20.2)	76.7 (15.4)	74.1 (19.1)	0.5 (2.1)	-0.6 (2.1)	1.4 (1.7)
Median	75.0	80.0	80.0	0	-2.5	0
IQR: Q1, Q3	60.0, 90.0	70.0, 90.0	65.0, 85.0	-5.0, 7.5	-5.0, 5.0	-5.0, 10.0
Min, Max	30, 100	40, 100	5, 100	-35, 30	-20, 50	-45, 45
Week 52						
m	45	35	81			
n	38	32	75	36	29	72
Mean (SD/SE)	73.6 (17.3)	76.4 (14.3)	77.2 (15.7)	1.0 (1.7)	-1.2 (2.8)	3.5 (1.8)
Median	75.0	75.0	80.0	2.5	-5.0	0
IQR: Q1, Q3	60.0, 90.0	70.0, 87.5	70.0, 85.0	-5.0, 5.0	-10.0, 5.0	-5.0, 10.0
Min, Max	40, 100	35, 100	30, 100	-25, 35	-20, 50	-30, 50

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Mental Component Score						
Baseline						
m	48	44	95			
n	44	39	90			
Mean (SD)	50.86 (10.05)	52.54 (9.64)	50.67 (10.19)			
Median	52.60	55.60	54.20			
IQR: Q1, Q3	46.75, 58.95	47.40, 59.00	44.40, 57.80			
Min, Max	23.3, 64.7	26.6, 64.5	25.9, 65.8			
Week 24						
m	47	39	87			
n	47	38	85	43	34	81
Mean (SD/SE)	49.91 (11.56)	51.96 (8.00)	50.33 (10.43)	0.10 (1.16)	-0.54 (1.10)	0.28 (0.94)
Median	53.00	53.45	54.50	0.70	-1.60	0
IQR: Q1, Q3	41.70, 59.10	47.70, 58.20	44.10, 57.90	-4.00, 4.30	-3.20, 0.80	-4.30, 3.80
Min, Max	26.2, 69.1	30.6, 63.1	14.2, 66.3	-16.5, 19.0	-10.4, 26.1	-20.9, 21.4
Week 52						
m	45	35	81			
n	38	32	75	35	29	72
Mean (SD/SE)	49.90 (9.70)	50.60 (7.78)	51.53 (8.35)	-0.22 (1.03)	-1.77 (1.72)	0.92 (0.88)
Median	52.65	50.40	53.40	0.50	-2.90	0.25
IQR: Q1, Q3	43.10, 58.30	44.70, 56.60	46.80, 57.80	-2.20, 2.80	-6.10, 2.50	-3.85, 4.30
Min, Max	26.7, 62.2	30.3, 65.3	25.9, 62.9	-17.3, 20.4	-21.4, 22.2	-13.5, 24.1

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Physical Component Score						
Baseline						
m	48	44	95			
n	44	39	90			
Mean (SD)	45.90 (10.37)	45.61 (11.14)	45.40 (10.11)			
Median	46.45	47.40	47.40			
IQR: Q1, Q3	42.00, 54.40	41.30, 56.10	37.20, 54.70			
Min, Max	15.3, 60.8	21.9, 60.4	21.8, 60.1			
Week 24						
m	47	39	87			
n	47	38	85	43	34	81
Mean (SD/SE)	44.86 (10.83)	45.55 (9.70)	47.03 (10.67)	-0.87 (0.96)	-0.66 (1.25)	1.40 (0.79)
Median	45.10	46.40	49.90	-2.10	0.10	0.90
IQR: Q1, Q3	40.10, 52.90	38.70, 53.30	41.60, 55.60	-5.50, 3.90	-4.20, 3.00	-2.50, 4.90
Min, Max	12.5, 60.7	25.5, 61.0	19.0, 62.9	-15.7, 14.3	-22.1, 16.2	-17.0, 23.8
Week 52						
m	45	35	81			
n	38	32	75	35	29	72
Mean (SD/SE)	45.91 (11.14)	46.82 (9.74)	46.54 (9.44)	-0.50 (0.89)	1.06 (1.27)	1.32 (0.68)
Median	47.90	48.25	47.00	-0.50	2.10	1.15
IQR: Q1, Q3	37.90, 56.30	41.60, 52.30	40.90, 55.30	-2.80, 2.50	-2.00, 5.50	-1.75, 4.70
Min, Max	15.8, 62.5	26.7, 60.9	24.6, 60.1	-14.1, 15.9	-13.8, 10.6	-11.0, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Physical Functioning						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	74.66 (22.33)	69.55 (23.43)	73.78 (24.71)			
Median	80.00	75.00	85.00			
IQR: Q1, Q3	55.00, 95.00	55.00, 90.00	55.00, 95.00			
Min, Max	25.0, 100.0	15.0, 100.0	10.0, 100.0			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	76.85 (23.87)	71.04 (23.41)	74.59 (26.65)	1.55 (1.63)	1.55 (2.76)	-0.12 (1.41)
Median	85.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 100.00	57.50, 87.50	55.00, 95.00	-5.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	5.0, 100.0	5.0, 100.0	5.0, 100.0	-40.0, 40.0	-65.0, 70.0	-45.0, 50.0
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	80.00 (22.90)	70.98 (23.83)	75.16 (26.17)	4.05 (1.66)	-0.90 (2.68)	-0.79 (1.39)
Median	90.00	75.00	85.00	0	0	0
IQR: Q1, Q3	70.00, 100.00	55.00, 90.00	55.00, 95.00	-5.00, 10.00	-5.00, 5.00	-10.00, 5.00
Min, Max	10.0, 100.0	0.0, 100.0	0.0, 100.0	-20.0, 45.0	-85.0, 30.0	-45.0, 35.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Role Physical						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	76.04 (26.33)	73.79 (24.39)	76.54 (25.72)			
Median	81.30	75.00	81.30			
IQR: Q1, Q3	56.30, 100.00	50.00, 100.00	56.30, 100.00			
Min, Max	0.0, 100.0	12.5, 100.0	0.0, 100.0			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	74.50 (27.43)	76.38 (22.66)	74.12 (26.89)	-1.67 (2.00)	1.38 (2.54)	-2.92 (1.66)
Median	81.30	81.30	81.30	0	0	0
IQR: Q1, Q3	56.30, 100.00	56.30, 100.00	50.00, 100.00	-12.50, 6.30	-6.30, 6.20	-12.50, 6.20
Min, Max	0.0, 100.0	18.8, 100.0	6.3, 100.0	-43.8, 43.7	-56.2, 68.7	-50.0, 37.5
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	79.18 (25.26)	74.40 (26.61)	72.71 (27.18)	2.67 (2.21)	-0.13 (2.79)	-3.63 (2.10)
Median	90.65	81.30	81.30	0	0	0
IQR: Q1, Q3	62.50, 100.00	56.30, 100.00	50.00, 100.00	0.00, 6.20	-6.20, 6.30	-12.50, 0.00
Min, Max	18.8, 100.0	6.3, 100.0	0.0, 100.0	-31.3, 81.2	-75.0, 50.0	-62.5, 68.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Bodily Pain						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	64.5 (24.4)	61.5 (24.9)	66.3 (25.2)			
Median	62.0	62.0	72.0			
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	41.0, 84.0			
Min, Max	0, 100	0, 100	0, 100			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	64.6 (25.4)	64.7 (23.3)	64.1 (26.4)	-0.5 (2.4)	1.0 (2.2)	-2.6 (2.0)
Median	64.0	62.0	72.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	46.5, 84.0	41.0, 84.0	-12.0, 11.0	-11.0, 11.0	-16.0, 10.0
Min, Max	0, 100	12, 100	0, 100	-50, 68	-29, 52	-78, 59
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	67.7 (25.9)	66.2 (25.5)	66.0 (26.1)	2.2 (2.4)	3.6 (3.1)	-0.8 (2.2)
Median	72.0	72.0	72.0	0	0	0
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	41.0, 84.0	-9.0, 11.0	-11.0, 11.0	-16.0, 10.0
Min, Max	0, 100	10, 100	0, 100	-40, 68	-53, 62	-78, 69

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=77)	Visit Result MGL-3196 100 mg (N=72)	Visit Result Placebo (N=128)	Change from Baseline MGL-3196 80 mg (N=77)	Change from Baseline MGL-3196 100 mg (N=72)	Change from Baseline Placebo (N=128)
General Health						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	60.86 (19.11)	53.24 (18.59)	59.05 (20.45)			
Median	62.00	52.00	62.00			
IQR: Q1, Q3	50.00, 75.00	40.00, 67.00	45.00, 77.00			
Min, Max	10.0, 97.0	10.0, 100.0	15.0, 100.0			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	60.47 (20.82)	55.77 (19.32)	58.72 (22.04)	-0.37 (1.47)	3.80 (1.99)	-0.45 (1.46)
Median	60.00	57.00	57.00	0	2.00	0
IQR: Q1, Q3	45.00, 77.00	40.00, 72.00	42.00, 77.00	-8.00, 10.00	-5.00, 15.00	-12.00, 5.00
Min, Max	10.0, 100.0	17.0, 92.0	10.0, 100.0	-42.0, 25.0	-35.0, 37.0	-37.0, 48.0
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	63.22 (19.84)	56.24 (19.96)	59.61 (22.34)	2.22 (1.63)	3.78 (2.67)	0.57 (1.36)
Median	64.50	57.00	62.00	0	5.00	0
IQR: Q1, Q3	52.00, 77.00	40.00, 72.00	47.00, 77.00	-5.00, 10.00	-5.00, 15.00	-5.00, 10.00
Min, Max	20.0, 97.0	10.0, 92.0	10.0, 97.0	-37.0, 32.0	-52.0, 37.0	-35.0, 32.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Vitality						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	56.96 (23.19)	52.87 (24.42)	57.45 (21.19)			
Median	62.50	56.30	62.50			
IQR: Q1, Q3	37.50, 75.00	37.50, 68.80	37.50, 75.00			
Min, Max	0.0, 100.0	0.0, 100.0	6.3, 100.0			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	56.62 (24.29)	54.13 (21.43)	56.17 (23.20)	0.00 (1.58)	0.95 (2.13)	-2.49 (1.27)
Median	62.50	56.30	56.30	0	0	0
IQR: Q1, Q3	43.80, 75.00	37.50, 71.90	37.50, 75.00	-6.20, 6.30	-12.50, 12.50	-12.50, 6.30
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.8, 31.2	-31.2, 43.8	-37.5, 31.2
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	59.40 (23.29)	54.68 (23.41)	55.91 (24.60)	1.78 (1.77)	0.37 (2.38)	-2.12 (1.69)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	43.80, 75.00	31.30, 75.00	43.80, 75.00	-6.30, 12.50	-6.30, 6.30	-6.30, 6.30
Min, Max	6.3, 100.0	6.3, 100.0	0.0, 100.0	-31.3, 50.0	-43.8, 43.8	-50.0, 31.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=77)	Visit Result MGL-3196 100 mg (N=72)	Visit Result Placebo (N=128)	Change from Baseline MGL-3196 80 mg (N=77)	Change from Baseline MGL-3196 100 mg (N=72)	Change from Baseline Placebo (N=128)
Social Functioning						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	80.65 (25.86)	77.65 (26.45)	82.50 (23.40)			
Median	87.50	87.50	100.00			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	62.50, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	12.5, 100.0			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	78.08 (25.41)	81.45 (20.89)	80.40 (25.24)	-2.82 (2.68)	3.39 (3.05)	-3.50 (1.88)
Median	87.50	87.50	93.75	0	0	0
IQR: Q1, Q3	62.50, 100.00	68.75, 100.00	62.50, 100.00	-12.50, 0.00	0.00, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	12.5, 100.0	0.0, 100.0	-50.0, 75.0	-62.5, 87.5	-62.5, 50.0
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	82.58 (22.77)	82.60 (23.06)	79.73 (24.26)	0.20 (2.32)	4.25 (3.60)	-3.49 (1.98)
Median	87.50	100.00	87.50	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	62.50, 100.00	0.00, 12.50	0.00, 25.00	-12.50, 0.00
Min, Max	25.0, 100.0	25.0, 100.0	12.5, 100.0	-50.0, 50.0	-62.5, 62.5	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Role Emotional						
Baseline						
m	77	72	128			
n	73	66	114			
Mean (SD)	81.39 (26.66)	80.56 (21.94)	82.82 (23.18)			
Median	100.00	83.30	100.00			
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	25.0, 100.0	0.0, 100.0			
Week 24						
m	76	68	125			
n	73	64	118	71	59	106
Mean (SD/SE)	80.48 (24.85)	85.94 (20.63)	81.14 (24.13)	-0.58 (2.37)	5.22 (2.10)	-2.67 (1.70)
Median	91.70	100.00	95.85	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	58.30, 100.00	-8.30, 8.30	0.00, 16.70	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	8.3, 100.0	-66.7, 66.7	-50.0, 41.7	-50.0, 50.0
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	84.66 (20.32)	85.46 (22.48)	79.12 (26.01)	2.06 (1.95)	4.83 (2.80)	-5.11 (1.84)
Median	100.00	100.00	91.70	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	58.30, 100.00	0.00, 0.00	0.00, 16.70	-16.70, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-33.3, 50.0	-50.0, 50.0	-58.3, 33.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Mental Health						
Baseline						
m	77	72	128			
n	73	66	115			
Mean (SD)	73.0 (20.8)	74.3 (21.4)	74.0 (19.0)			
Median	80.0	80.0	80.0			
IQR: Q1, Q3	65.0, 90.0	60.0, 90.0	60.0, 90.0			
Min, Max	5, 100	15, 100	5, 100			
Week 24						
m	76	68	125			
n	73	64	118	71	59	107
Mean (SD/SE)	71.4 (21.0)	75.9 (20.3)	73.6 (20.2)	-1.3 (1.7)	-0.2 (1.7)	-0.8 (1.2)
Median	75.0	80.0	80.0	0	0	0
IQR: Q1, Q3	60.0, 85.0	70.0, 90.0	65.0, 90.0	-10.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	15, 100	5, 100	20, 100	-40, 35	-40, 35	-30, 50
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	75.2 (18.8)	75.5 (20.5)	73.0 (22.8)	0.4 (1.8)	0.5 (1.6)	-1.9 (1.5)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	65.0, 90.0	-5.0, 10.0	-5.0, 5.0	-10.0, 5.0
Min, Max	25, 100	20, 100	0, 100	-35, 40	-25, 35	-40, 30

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=77)	Visit Result MGL-3196 100 mg (N=72)	Visit Result Placebo (N=128)	Change from Baseline MGL-3196 80 mg (N=77)	Change from Baseline MGL-3196 100 mg (N=72)	Change from Baseline Placebo (N=128)
Mental Component Score						
Baseline						
m	77	72	128			
n	73	66	114			
Mean (SD)	50.03 (11.45)	50.16 (11.36)	50.82 (9.77)			
Median	53.30	52.95	53.40			
IQR: Q1, Q3	46.40, 57.90	43.30, 58.30	45.60, 58.20			
Min, Max	12.0, 69.0	17.0, 70.0	15.6, 66.5			
Week 24						
m	76	68	125			
n	73	64	118	71	59	106
Mean (SD/SE)	49.01 (11.07)	51.68 (10.18)	50.14 (10.80)	-0.79 (0.90)	1.11 (0.93)	-1.11 (0.67)
Median	51.80	52.25	52.75	-1.00	1.00	-0.90
IQR: Q1, Q3	43.40, 57.60	47.80, 59.15	42.60, 58.80	-4.40, 4.00	-2.10, 5.60	-4.60, 2.70
Min, Max	18.7, 64.6	9.4, 68.3	23.1, 69.0	-20.0, 14.2	-24.5, 22.4	-18.4, 18.6
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	50.92 (9.84)	51.71 (10.52)	49.45 (12.19)	0.12 (0.81)	1.42 (1.05)	-1.75 (0.79)
Median	53.95	53.80	52.80	0.10	0	-0.50
IQR: Q1, Q3	44.30, 57.60	46.10, 59.00	42.50, 58.40	-3.90, 4.60	-2.00, 4.80	-4.60, 2.80
Min, Max	23.1, 63.2	17.8, 68.1	8.9, 68.0	-16.0, 14.9	-15.2, 25.2	-24.6, 16.9

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Physical Component Score						
Baseline						
m	77	72	128			
n	73	66	114			
Mean (SD)	47.65 (8.43)	45.12 (8.80)	47.42 (9.10)			
Median	48.90	46.15	50.05			
IQR: Q1, Q3	42.70, 54.80	40.30, 51.40	40.60, 54.60			
Min, Max	24.7, 59.3	21.2, 61.3	20.7, 65.2			
Week 24						
m	76	68	125			
n	73	64	118	71	59	106
Mean (SD/SE)	48.06 (8.69)	45.79 (8.25)	47.04 (9.76)	0.14 (0.65)	0.60 (0.94)	-0.57 (0.59)
Median	49.50	46.55	49.45	0.60	0	-0.45
IQR: Q1, Q3	41.90, 54.70	39.05, 51.80	40.80, 55.00	-3.10, 3.50	-2.50, 3.60	-3.90, 2.80
Min, Max	22.5, 62.7	24.6, 59.0	24.4, 63.0	-12.7, 18.3	-22.0, 21.7	-21.7, 14.6
Week 52						
m	70	57	120			
n	66	51	103	63	50	93
Mean (SD/SE)	49.13 (9.43)	45.88 (9.38)	47.54 (9.91)	1.35 (0.66)	0.29 (1.10)	-0.01 (0.63)
Median	51.65	47.80	49.40	1.10	1.70	0.20
IQR: Q1, Q3	44.00, 57.20	38.50, 53.40	42.10, 55.10	-1.40, 4.20	-2.60, 3.90	-3.20, 2.70
Min, Max	20.3, 62.8	24.8, 61.2	21.5, 63.9	-9.6, 22.5	-23.5, 14.8	-23.9, 19.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Physical Functioning						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	80.00 (17.86)	71.90 (23.74)	80.17 (22.25)			
Median	80.00	80.00	90.00			
IQR: Q1, Q3	70.00, 95.00	60.00, 90.00	65.00, 95.00			
Min, Max	40.0, 100.0	10.0, 100.0	10.0, 100.0			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	82.59 (20.21)	73.64 (24.55)	78.45 (26.40)	2.22 (3.79)	0.71 (5.12)	-2.17 (2.70)
Median	90.00	82.50	90.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	55.00, 95.00	70.00, 100.00	-5.00, 10.00	-10.00, 10.00	-10.00, 5.00
Min, Max	30.0, 100.0	15.0, 100.0	0.0, 100.0	-50.0, 45.0	-65.0, 60.0	-50.0, 60.0
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	78.00 (29.08)	71.80 (27.90)	82.07 (20.26)	-0.80 (4.39)	-0.36 (4.76)	-2.05 (2.68)
Median	95.00	85.00	85.00	0	0	0
IQR: Q1, Q3	65.00, 100.00	60.00, 95.00	75.00, 100.00	-5.00, 15.00	-7.50, 5.00	-10.00, 5.00
Min, Max	5.0, 100.0	10.0, 100.0	0.0, 100.0	-65.0, 30.0	-52.2, 35.0	-60.0, 55.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Role Physical						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	77.93 (25.51)	69.96 (33.28)	77.82 (25.43)			
Median	87.50	81.30	87.50			
IQR: Q1, Q3	56.30, 100.00	56.30, 100.00	62.50, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	80.34 (22.57)	67.92 (25.02)	77.06 (27.55)	1.39 (3.64)	-2.68 (5.46)	-2.12 (3.20)
Median	87.50	71.90	87.50	0	-6.20	0
IQR: Q1, Q3	75.00, 100.00	50.00, 87.50	68.80, 100.00	-12.50, 12.50	-18.70, 6.20	-12.50, 6.30
Min, Max	31.3, 100.0	18.8, 100.0	0.0, 100.0	-31.3, 50.0	-43.7, 62.5	-68.7, 56.3
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	78.01 (30.52)	74.72 (29.47)	81.27 (20.62)	-1.25 (4.04)	4.69 (6.03)	-1.42 (2.54)
Median	93.80	81.30	81.30	0	0	0
IQR: Q1, Q3	62.50, 100.00	56.30, 100.00	68.80, 100.00	-12.50, 6.20	-6.25, 9.35	-12.50, 6.30
Min, Max	0.0, 100.0	6.3, 100.0	12.5, 100.0	-43.8, 43.8	-43.8, 81.3	-56.2, 37.5

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Bodily Pain						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	76.5 (21.3)	58.3 (29.3)	64.4 (25.7)			
Median	74.0	62.0	64.0			
IQR: Q1, Q3	60.0, 100.0	31.0, 74.0	41.5, 84.0			
Min, Max	41, 100	10, 100	12, 100			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	73.1 (23.3)	63.3 (26.3)	69.2 (26.4)	-4.8 (4.2)	4.0 (6.7)	3.1 (2.9)
Median	74.0	67.0	74.0	0	0	0
IQR: Q1, Q3	51.0, 100.0	41.0, 84.0	61.0, 84.0	-23.0, 0.0	-16.0, 12.0	-10.0, 12.0
Min, Max	22, 100	10, 100	0, 100	-59, 43	-62, 72	-43, 78
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	73.6 (26.7)	63.1 (24.2)	73.5 (22.9)	-5.0 (5.8)	5.9 (4.8)	6.5 (3.9)
Median	74.0	62.0	79.0	0	1.0	0
IQR: Q1, Q3	62.0, 100.0	41.0, 74.0	52.0, 84.0	-16.0, 10.0	-4.5, 19.5	-9.5, 21.0
Min, Max	0, 100	10, 100	12, 100	-80, 59	-33, 49	-48, 78

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
General Health						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	61.70 (22.12)	53.24 (18.72)	60.00 (20.54)			
Median	64.50	47.00	61.00			
IQR: Q1, Q3	52.00, 72.00	42.00, 67.00	45.00, 73.50			
Min, Max	10.0, 100.0	15.0, 87.0	15.0, 97.0			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	67.52 (21.26)	53.55 (17.55)	60.98 (20.36)	4.96 (3.32)	-0.57 (3.50)	1.42 (2.14)
Median	72.00	51.00	62.00	10.00	0	0
IQR: Q1, Q3	57.00, 82.00	42.00, 62.00	45.00, 77.00	0.00, 13.00	-12.00, 8.00	-10.00, 10.00
Min, Max	15.0, 97.0	30.0, 100.0	22.0, 97.0	-60.0, 32.0	-25.0, 32.0	-40.0, 37.0
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	65.52 (19.35)	56.05 (19.18)	63.00 (19.26)	0.12 (4.45)	0.70 (4.05)	0.77 (2.53)
Median	67.00	57.00	62.00	0	1.00	0
IQR: Q1, Q3	57.00, 77.00	45.00, 67.00	50.00, 77.00	-12.00, 15.00	-13.50, 11.00	-5.00, 10.00
Min, Max	30.0, 100.0	20.0, 87.0	20.0, 100.0	-70.0, 47.0	-22.0, 47.0	-42.0, 30.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=30)	Visit Result: MGL-3196 100 mg (N=22)	Visit Result: Placebo (N=63)	Change from Baseline: MGL-3196 80 mg (N=30)	Change from Baseline: MGL-3196 100 mg (N=22)	Change from Baseline: Placebo (N=63)
Vitality						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	63.56 (21.84)	53.30 (19.82)	57.11 (20.40)			
Median	62.50	56.30	56.30			
IQR: Q1, Q3	50.00, 81.30	43.80, 62.50	43.80, 75.00			
Min, Max	18.8, 100.0	12.5, 87.5	12.5, 87.5			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	62.76 (22.63)	53.71 (17.32)	59.34 (21.35)	-3.24 (2.90)	-0.60 (3.66)	1.53 (2.50)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	56.30, 75.00	37.50, 62.50	43.80, 75.00	-12.50, 6.20	-18.70, 6.30	-12.50, 12.50
Min, Max	0.0, 100.0	25.0, 93.8	6.3, 100.0	-37.5, 25.0	-25.0, 37.5	-37.5, 56.2
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	62.77 (19.64)	54.79 (20.06)	62.26 (18.68)	-4.50 (3.81)	0.31 (3.70)	4.55 (3.14)
Median	68.80	56.30	62.50	-6.30	0	6.25
IQR: Q1, Q3	56.30, 75.00	37.50, 68.80	56.30, 75.00	-12.50, 12.50	-9.40, 12.50	-6.20, 18.80
Min, Max	12.5, 87.5	25.0, 87.5	12.5, 100.0	-43.7, 25.0	-25.0, 37.5	-56.3, 43.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Social Functioning						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	85.42 (18.88)	75.60 (26.36)	86.04 (19.40)			
Median	87.50	87.50	100.00			
IQR: Q1, Q3	75.00, 100.00	50.00, 100.00	75.00, 100.00			
Min, Max	37.5, 100.0	25.0, 100.0	25.0, 100.0			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	88.89 (18.78)	77.27 (21.35)	85.68 (21.97)	0.46 (3.09)	0.60 (4.44)	0.24 (2.55)
Median	100.00	81.25	100.00	0	0	0
IQR: Q1, Q3	87.50, 100.00	62.50, 100.00	75.00, 100.00	0.00, 12.50	-12.50, 12.50	-12.50, 12.50
Min, Max	25.0, 100.0	37.5, 100.0	12.5, 100.0	-37.5, 25.0	-25.0, 50.0	-62.5, 50.0
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	87.00 (17.49)	85.71 (19.88)	89.40 (18.25)	-2.00 (3.20)	10.00 (3.47)	0.57 (3.15)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	87.50, 100.00	0.00, 0.00	0.00, 18.75	-6.25, 12.50
Min, Max	50.0, 100.0	50.0, 100.0	12.5, 100.0	-37.5, 25.0	-12.5, 50.0	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Role Emotional						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	81.94 (26.45)	78.18 (30.10)	86.25 (18.08)			
Median	100.00	91.70	95.85			
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	8.3, 100.0	25.0, 100.0			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	84.56 (18.74)	79.17 (26.70)	86.06 (22.85)	0.31 (3.07)	0.00 (2.23)	-0.78 (2.49)
Median	91.70	91.70	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	0.00, 0.00	0.00, 8.30
Min, Max	41.7, 100.0	25.0, 100.0	8.3, 100.0	-25.0, 50.0	-25.0, 16.7	-50.0, 50.0
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	88.34 (19.98)	86.51 (22.28)	89.85 (14.48)	4.34 (4.77)	8.34 (4.87)	1.33 (2.82)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	83.30, 100.00	75.00, 100.00	83.30, 100.00	0.00, 0.00	0.00, 20.85	-4.15, 8.30
Min, Max	25.0, 100.0	25.0, 100.0	41.7, 100.0	-33.3, 100.0	-33.3, 58.3	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Mental Health						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	75.0 (22.1)	72.1 (17.8)	78.3 (13.4)			
Median	85.0	80.0	80.0			
IQR: Q1, Q3	60.0, 90.0	60.0, 85.0	70.0, 90.0			
Min, Max	10, 100	25, 90	45, 100			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	75.9 (17.5)	71.8 (19.5)	77.3 (15.8)	-1.3 (2.2)	-1.2 (3.0)	-1.1 (2.2)
Median	80.0	80.0	80.0	0	5.0	0
IQR: Q1, Q3	65.0, 90.0	60.0, 85.0	70.0, 90.0	-10.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	30, 100	20, 95	30, 100	-25, 35	-35, 20	-35, 55
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	77.6 (16.3)	71.7 (19.7)	80.2 (13.6)	0.8 (2.5)	-2.0 (3.2)	2.6 (2.4)
Median	80.0	75.0	85.0	0	0	2.5
IQR: Q1, Q3	75.0, 90.0	55.0, 90.0	75.0, 90.0	-5.0, 10.0	-10.0, 5.0	-10.0, 10.0
Min, Max	40, 100	30, 95	35, 100	-20, 25	-30, 25	-40, 55

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=30)	Visit Result: MGL-3196 100 mg (N=22)	Visit Result: Placebo (N=63)	Change from Baseline: MGL-3196 80 mg (N=30)	Change from Baseline: MGL-3196 100 mg (N=22)	Change from Baseline: Placebo (N=63)
Mental Component Score						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	50.86 (11.51)	49.08 (11.99)	52.31 (7.09)			
Median	54.95	52.80	53.80			
IQR: Q1, Q3	46.70, 58.20	38.10, 58.40	49.55, 57.30			
Min, Max	18.9, 67.0	20.4, 63.8	32.6, 63.8			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	51.60 (8.56)	49.16 (11.16)	52.20 (9.23)	-0.70 (1.30)	-0.39 (1.65)	-0.08 (1.12)
Median	53.00	53.80	53.20	-1.10	-0.90	0.80
IQR: Q1, Q3	44.60, 59.10	39.30, 57.50	49.90, 59.10	-3.70, 2.80	-4.30, 2.80	-3.50, 3.10
Min, Max	30.0, 62.7	21.2, 61.9	21.9, 64.5	-12.8, 19.0	-13.5, 17.6	-24.6, 24.8
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	53.02 (7.88)	51.32 (10.60)	53.68 (6.85)	0.59 (1.66)	1.71 (2.09)	1.46 (1.20)
Median	56.20	57.40	54.85	-0.30	0.90	1.85
IQR: Q1, Q3	50.50, 58.30	43.50, 60.00	49.20, 57.90	-3.40, 3.30	-2.70, 5.65	-1.90, 5.35
Min, Max	34.8, 61.5	27.0, 62.8	32.9, 63.7	-13.6, 26.2	-14.5, 25.1	-17.9, 26.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=63)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=63)
Physical Component Score						
Baseline						
m	30	22	63			
n	30	21	60			
Mean (SD)	50.20 (6.00)	45.06 (9.83)	47.64 (9.33)			
Median	50.10	45.00	48.85			
IQR: Q1, Q3	46.70, 55.40	37.80, 52.00	42.85, 54.85			
Min, Max	37.5, 59.4	23.4, 60.3	23.6, 61.1			
Week 24						
m	28	22	60			
n	27	22	55	27	21	53
Mean (SD/SE)	50.84 (8.41)	45.74 (8.85)	48.17 (10.13)	0.60 (1.52)	0.37 (2.17)	0.16 (1.09)
Median	52.10	45.75	51.60	1.20	-0.70	-0.10
IQR: Q1, Q3	44.90, 58.60	38.10, 54.50	42.40, 56.00	-5.00, 5.20	-4.80, 3.50	-2.50, 3.70
Min, Max	32.6, 63.9	28.8, 56.2	23.1, 62.0	-17.2, 17.6	-16.0, 32.4	-28.8, 23.3
Week 52						
m	27	22	54			
n	25	21	46	25	20	44
Mean (SD/SE)	49.14 (11.43)	45.99 (11.13)	49.46 (7.53)	-1.42 (2.04)	0.92 (2.03)	0.07 (0.97)
Median	54.20	46.40	50.00	-0.50	-0.95	-0.60
IQR: Q1, Q3	45.00, 58.00	40.60, 55.60	46.10, 55.10	-3.30, 3.30	-3.35, 8.25	-3.40, 2.75
Min, Max	22.9, 59.2	16.0, 61.1	30.0, 61.7	-24.7, 14.9	-17.5, 18.6	-17.9, 20.5

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Physical Functioning			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	69.38 (29.24)	70.74 (29.60)	71.30 (28.71)
Analysis Visit Mean (SD)	69.43 (26.31)	71.65 (26.12)	74.07 (29.06)
LS Mean of Change from Baseline (SE)	0.02 (2.63)	1.26 (2.98)	3.32 (1.92)
95% CI	(-5.18, 5.23)	(-4.62, 7.14)	(-0.47, 7.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.29 (3.17)	-2.06 (3.45)	
95% CI	(-9.55, 2.96)	(-8.86, 4.75)	
p-value	0.3001	0.5518	
Corrected Hedge's g Statistics	-0.189	-0.118	
95% CI	(-0.56, 0.18)	(-0.52, 0.28)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	72.72 (26.86)	68.62 (30.70)	70.35 (27.98)
Analysis Visit Mean (SD)	70.28 (29.28)	71.32 (28.16)	74.27 (24.63)
LS Mean of Change from Baseline (SE)	-1.83 (2.53)	2.50 (2.81)	3.86 (1.80)
95% CI	(-6.83, 3.18)	(-3.06, 8.05)	(0.29, 7.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.68 (3.00)	-1.36 (3.24)	
95% CI	(-11.61, 0.25)	(-7.75, 5.03)	
p-value	0.0604	0.6755	
Corrected Hedge's g Statistics	-0.369	-0.088	
95% CI	(-0.77, 0.03)	(-0.52, 0.34)	
Subgroup*Treatment Interaction p-value	0.0420	0.8399	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Role Physical			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	73.31 (26.14)	76.30 (25.13)	73.16 (27.93)
Analysis Visit Mean (SD)	69.19 (27.86)	72.99 (26.72)	77.79 (27.50)
LS Mean of Change from Baseline (SE)	-3.56 (2.94)	-1.85 (3.34)	5.00 (2.14)
95% CI	(-9.38, 2.25)	(-8.45, 4.74)	(0.77, 9.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.56 (3.55)	-6.85 (3.87)	
95% CI	(-15.57, -1.55)	(-14.50, 0.80)	
p-value	0.0170	0.0789	
Corrected Hedge's g Statistics	-0.439	-0.352	
95% CI	(-0.81, -0.07)	(-0.76, 0.05)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	75.71 (26.12)	74.15 (26.02)	72.59 (27.44)
Analysis Visit Mean (SD)	69.63 (28.94)	72.64 (27.57)	75.45 (24.02)
LS Mean of Change from Baseline (SE)	-5.57 (2.94)	-1.43 (3.26)	2.90 (2.08)
95% CI	(-11.39, 0.24)	(-7.87, 5.01)	(-1.21, 7.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.48 (3.50)	-4.33 (3.76)	
95% CI	(-15.38, -1.57)	(-11.76, 3.10)	
p-value	0.0165	0.2512	
Corrected Hedge's g Statistics	-0.476	-0.244	
95% CI	(-0.88, -0.07)	(-0.68, 0.19)	
Subgroup*Treatment Interaction p-value	0.0058	0.1207	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Bodily Pain			
Week 24			
m	47	39	87
n	43	34	81
Baseline Mean (SD)	62.1 (24.0)	67.1 (25.9)	63.4 (23.8)
Analysis Visit Mean (SD)	59.5 (26.2)	65.5 (23.7)	66.0 (24.0)
LS Mean of Change from Baseline (SE)	-3.23 (2.78)	-0.80 (3.13)	2.31 (2.01)
95% CI	(-8.73, 2.27)	(-6.99, 5.38)	(-1.66, 6.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.54 (3.34)	-3.11 (3.62)	
95% CI	(-12.13, 1.05)	(-10.26, 4.04)	
p-value	0.0989	0.3913	
Corrected Hedge's g Statistics	-0.304	-0.171	
95% CI	(-0.68, 0.07)	(-0.57, 0.23)	
Week 52			
m	45	35	81
n	35	29	72
Baseline Mean (SD)	63.8 (25.1)	64.8 (25.4)	63.1 (23.7)
Analysis Visit Mean (SD)	66.0 (24.6)	70.3 (26.0)	65.5 (23.3)
LS Mean of Change from Baseline (SE)	1.94 (3.14)	5.21 (3.45)	1.87 (2.20)
95% CI	(-4.26, 8.14)	(-1.61, 12.03)	(-2.49, 6.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.07 (3.74)	3.35 (4.00)	
95% CI	(-7.31, 7.46)	(-4.55, 11.24)	
p-value	0.9842	0.4037	
Corrected Hedge's g Statistics	0.004	0.178	
95% CI	(-0.40, 0.41)	(-0.25, 0.61)	
Subgroup*Treatment Interaction p-value	0.3098	0.7161	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
General Health			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	57.45 (18.80)	58.62 (19.99)	56.36 (20.14)
Analysis Visit Mean (SD)	57.95 (20.46)	56.44 (21.01)	58.70 (21.90)
LS Mean of Change from Baseline (SE)	0.26 (2.24)	-2.48 (2.54)	2.05 (1.63)
95% CI	(-4.17, 4.68)	(-7.49, 2.53)	(-1.16, 5.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.80 (2.70)	-4.53 (2.94)	
95% CI	(-7.13, 3.54)	(-10.35, 1.28)	
p-value	0.5069	0.1255	
Corrected Hedge's g Statistics	-0.121	-0.307	
95% CI	(-0.49, 0.25)	(-0.71, 0.10)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	58.08 (19.41)	58.28 (20.81)	56.01 (20.26)
Analysis Visit Mean (SD)	59.67 (20.26)	56.79 (19.99)	59.68 (20.41)
LS Mean of Change from Baseline (SE)	1.28 (2.09)	-2.63 (2.32)	3.29 (1.48)
95% CI	(-2.86, 5.41)	(-7.22, 1.96)	(0.36, 6.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.01 (2.48)	-5.92 (2.67)	
95% CI	(-6.90, 2.89)	(-11.19, -0.64)	
p-value	0.4192	0.0282	
Corrected Hedge's g Statistics	-0.158	-0.467	
95% CI	(-0.56, 0.24)	(-0.90, -0.03)	
Subgroup*Treatment Interaction p-value	0.4457	0.1379	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Vitality			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	54.61 (21.83)	54.80 (19.83)	53.89 (22.59)
Analysis Visit Mean (SD)	52.73 (23.86)	52.23 (16.99)	56.20 (21.28)
LS Mean of Change from Baseline (SE)	-1.49 (2.31)	-2.09 (2.61)	2.36 (1.68)
95% CI	(-6.05, 3.08)	(-7.25, 3.07)	(-0.96, 5.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.85 (2.78)	-4.45 (3.03)	
95% CI	(-9.33, 1.64)	(-10.42, 1.53)	
p-value	0.1680	0.1436	
Corrected Hedge's g Statistics	-0.252	-0.292	
95% CI	(-0.62, 0.12)	(-0.69, 0.11)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	56.44 (22.64)	53.91 (19.94)	54.19 (22.98)
Analysis Visit Mean (SD)	56.80 (23.78)	53.69 (17.87)	56.27 (21.16)
LS Mean of Change from Baseline (SE)	1.38 (2.43)	-0.59 (2.70)	1.95 (1.72)
95% CI	(-3.42, 6.18)	(-5.92, 4.73)	(-1.45, 5.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.57 (2.89)	-2.55 (3.11)	
95% CI	(-6.28, 5.14)	(-8.69, 3.60)	
p-value	0.8435	0.4146	
Corrected Hedge's g Statistics	-0.039	-0.173	
95% CI	(-0.44, 0.36)	(-0.60, 0.26)	
Subgroup*Treatment Interaction p-value	0.1585	0.2409	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Social Functioning			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	79.55 (23.36)	84.93 (23.59)	79.94 (24.02)
Analysis Visit Mean (SD)	80.97 (27.16)	83.46 (19.15)	79.94 (25.13)
LS Mean of Change from Baseline (SE)	0.49 (2.97)	-0.68 (3.37)	-0.48 (2.16)
95% CI	(-5.37, 6.35)	(-7.34, 5.99)	(-4.75, 3.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.97 (3.58)	-0.20 (3.92)	
95% CI	(-6.10, 8.04)	(-7.94, 7.55)	
p-value	0.7866	0.9599	
Corrected Hedge's g Statistics	0.049	-0.010	
95% CI	(-0.32, 0.42)	(-0.41, 0.39)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	80.90 (22.66)	85.34 (24.79)	80.03 (23.33)
Analysis Visit Mean (SD)	77.43 (26.36)	78.02 (23.06)	82.99 (20.48)
LS Mean of Change from Baseline (SE)	-2.82 (2.98)	-6.35 (3.32)	1.66 (2.11)
95% CI	(-8.72, 3.07)	(-12.90, 0.20)	(-2.51, 5.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.48 (3.54)	-8.01 (3.83)	
95% CI	(-11.48, 2.52)	(-15.57, -0.44)	
p-value	0.2080	0.0383	
Corrected Hedge's g Statistics	-0.249	-0.444	
95% CI	(-0.65, 0.15)	(-0.88, -0.01)	
Subgroup*Treatment Interaction p-value	0.6003	0.0780	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Role Emotional			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	81.44 (22.00)	86.52 (20.21)	82.31 (24.98)
Analysis Visit Mean (SD)	81.63 (22.70)	86.04 (17.61)	83.54 (24.62)
LS Mean of Change from Baseline (SE)	0.26 (2.67)	1.32 (3.02)	1.42 (1.94)
95% CI	(-5.01, 5.53)	(-4.65, 7.29)	(-2.41, 5.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.16 (3.20)	-0.09 (3.50)	
95% CI	(-7.49, 5.17)	(-7.00, 6.82)	
p-value	0.7183	0.9788	
Corrected Hedge's g Statistics	-0.066	-0.005	
95% CI	(-0.43, 0.30)	(-0.41, 0.40)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	81.25 (20.65)	84.20 (22.42)	82.76 (24.60)
Analysis Visit Mean (SD)	79.62 (22.84)	82.76 (21.59)	83.10 (21.80)
LS Mean of Change from Baseline (SE)	-1.30 (2.95)	-0.36 (3.28)	0.35 (2.09)
95% CI	(-7.13, 4.54)	(-6.84, 6.12)	(-3.79, 4.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.64 (3.52)	-0.71 (3.80)	
95% CI	(-8.60, 5.32)	(-8.21, 6.79)	
p-value	0.6415	0.8520	
Corrected Hedge's g Statistics	-0.092	-0.040	
95% CI	(-0.49, 0.31)	(-0.47, 0.39)	
Subgroup*Treatment Interaction p-value	0.2720	0.0963	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Mental Health			
Week 24			
m	47	39	87
n	44	34	81
Baseline Mean (SD)	73.5 (18.1)	77.9 (16.5)	72.9 (19.1)
Analysis Visit Mean (SD)	74.0 (19.8)	77.4 (14.7)	74.3 (19.1)
LS Mean of Change from Baseline (SE)	0.17 (2.08)	0.28 (2.36)	0.93 (1.51)
95% CI	(-3.93, 4.27)	(-4.37, 4.94)	(-2.06, 3.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.76 (2.50)	-0.65 (2.74)	
95% CI	(-5.71, 4.19)	(-6.07, 4.78)	
p-value	0.7624	0.8145	
Corrected Hedge's g Statistics	-0.055	-0.047	
95% CI	(-0.42, 0.31)	(-0.45, 0.35)	
Week 52			
m	45	35	81
n	36	29	72
Baseline Mean (SD)	73.8 (17.9)	78.1 (17.3)	73.8 (19.0)
Analysis Visit Mean (SD)	74.7 (17.0)	76.9 (14.9)	77.4 (15.7)
LS Mean of Change from Baseline (SE)	1.18 (2.03)	0.17 (2.26)	2.61 (1.44)
95% CI	(-2.83, 5.19)	(-4.29, 4.63)	(-0.23, 5.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.43 (2.41)	-2.45 (2.61)	
95% CI	(-6.20, 3.33)	(-7.60, 2.70)	
p-value	0.5532	0.3492	
Corrected Hedge's g Statistics	-0.117	-0.199	
95% CI	(-0.52, 0.28)	(-0.63, 0.23)	
Subgroup*Treatment Interaction p-value	0.8042	0.4246	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Mental Component Score			
Week 24			
m	47	39	87
n	43	34	81
Baseline Mean (SD)	50.69 (10.10)	52.68 (9.72)	50.25 (10.31)
Analysis Visit Mean (SD)	50.79 (11.32)	52.14 (8.04)	50.53 (10.43)
LS Mean of Change from Baseline (SE)	0.01 (1.15)	-0.10 (1.29)	0.05 (0.83)
95% CI	(-2.26, 2.28)	(-2.65, 2.46)	(-1.59, 1.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (1.39)	-0.15 (1.51)	
95% CI	(-2.78, 2.70)	(-3.12, 2.82)	
p-value	0.9772	0.9210	
Corrected Hedge's g Statistics	-0.005	-0.020	
95% CI	(-0.38, 0.36)	(-0.42, 0.38)	
Week 52			
m	45	35	81
n	35	29	72
Baseline Mean (SD)	50.64 (10.12)	52.62 (10.42)	50.73 (10.35)
Analysis Visit Mean (SD)	50.41 (9.85)	50.86 (8.05)	51.65 (8.35)
LS Mean of Change from Baseline (SE)	0.06 (1.09)	-1.17 (1.19)	0.52 (0.76)
95% CI	(-2.09, 2.21)	(-3.53, 1.19)	(-0.99, 2.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.46 (1.29)	-1.69 (1.38)	
95% CI	(-3.00, 2.08)	(-4.41, 1.03)	
p-value	0.7224	0.2219	
Corrected Hedge's g Statistics	-0.070	-0.259	
95% CI	(-0.47, 0.33)	(-0.69, 0.17)	
Subgroup*Treatment Interaction p-value	0.6474	0.1127	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Physical Component Score			
Week 24			
m	47	39	87
n	43	34	81
Baseline Mean (SD)	45.65 (10.35)	46.10 (11.00)	45.98 (10.11)
Analysis Visit Mean (SD)	44.78 (11.11)	45.44 (9.84)	47.38 (10.59)
LS Mean of Change from Baseline (SE)	-0.93 (1.02)	-0.65 (1.15)	1.43 (0.74)
95% CI	(-2.95, 1.09)	(-2.91, 1.62)	(-0.02, 2.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.37 (1.23)	-2.08 (1.33)	
95% CI	(-4.80, 0.07)	(-4.71, 0.55)	
p-value	0.0567	0.1206	
Corrected Hedge's g Statistics	-0.352	-0.310	
95% CI	(-0.72, 0.02)	(-0.71, 0.09)	
Week 52			
m	45	35	81
n	35	29	72
Baseline Mean (SD)	46.83 (10.25)	45.30 (11.30)	45.53 (9.94)
Analysis Visit Mean (SD)	46.32 (11.34)	46.36 (9.87)	46.85 (9.23)
LS Mean of Change from Baseline (SE)	-0.56 (0.93)	0.60 (1.02)	1.27 (0.65)
95% CI	(-2.40, 1.27)	(-1.41, 2.62)	(-0.02, 2.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.83 (1.10)	-0.67 (1.17)	
95% CI	(-4.00, 0.33)	(-2.98, 1.64)	
p-value	0.0966	0.5696	
Corrected Hedge's g Statistics	-0.330	-0.120	
95% CI	(-0.74, 0.08)	(-0.55, 0.31)	
Subgroup*Treatment Interaction p-value	0.0793	0.6912	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Physical Functioning			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	75.00 (21.65)	69.24 (23.41)	75.00 (24.20)
Analysis Visit Mean (SD)	76.55 (24.05)	70.79 (22.97)	74.88 (26.61)
LS Mean of Change from Baseline (SE)	1.91 (1.92)	0.84 (2.09)	0.16 (1.59)
95% CI	(-1.88, 5.69)	(-3.28, 4.96)	(-2.96, 3.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.74 (2.43)	0.67 (2.59)	
95% CI	(-3.05, 6.54)	(-4.42, 5.77)	
p-value	0.4745	0.7947	
Corrected Hedge's g Statistics	0.106	0.041	
95% CI	(-0.19, 0.41)	(-0.28, 0.36)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	75.63 (21.90)	71.80 (22.94)	75.59 (24.26)
Analysis Visit Mean (SD)	79.68 (23.16)	70.90 (24.07)	74.80 (26.29)
LS Mean of Change from Baseline (SE)	4.85 (1.87)	-0.17 (2.07)	-0.32 (1.55)
95% CI	(1.16, 8.54)	(-4.25, 3.91)	(-3.38, 2.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.17 (2.37)	0.15 (2.55)	
95% CI	(0.49, 9.84)	(-4.86, 5.17)	
p-value	0.0305	0.9521	
Corrected Hedge's g Statistics	0.344	0.010	
95% CI	(0.02, 0.67)	(-0.33, 0.35)	
Subgroup*Treatment Interaction p-value	0.0420	0.8399	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Role Physical			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	76.42 (25.83)	74.17 (24.82)	77.18 (25.42)
Analysis Visit Mean (SD)	74.75 (27.16)	75.55 (22.83)	74.26 (27.33)
LS Mean of Change from Baseline (SE)	-1.04 (2.06)	0.97 (2.23)	-2.36 (1.70)
95% CI	(-5.10, 3.01)	(-3.43, 5.37)	(-5.72, 1.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.32 (2.60)	3.33 (2.75)	
95% CI	(-3.81, 6.44)	(-2.10, 8.76)	
p-value	0.6134	0.2279	
Corrected Hedge's g Statistics	0.075	0.190	
95% CI	(-0.23, 0.37)	(-0.13, 0.51)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	76.60 (27.35)	74.39 (25.22)	76.90 (25.82)
Analysis Visit Mean (SD)	79.27 (25.32)	74.26 (26.86)	73.27 (27.42)
LS Mean of Change from Baseline (SE)	3.65 (2.28)	0.68 (2.52)	-2.23 (1.89)
95% CI	(-0.84, 8.15)	(-4.29, 5.64)	(-5.96, 1.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.89 (2.90)	2.91 (3.10)	
95% CI	(0.17, 11.60)	(-3.20, 9.02)	
p-value	0.0434	0.3494	
Corrected Hedge's g Statistics	0.322	0.160	
95% CI	(0.00, 0.64)	(-0.18, 0.50)	
Subgroup*Treatment Interaction p-value	0.0058	0.1207	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Bodily Pain			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	64.6 (23.8)	62.2 (25.0)	67.2 (25.5)
Analysis Visit Mean (SD)	64.0 (25.4)	63.1 (23.4)	64.5 (26.6)
LS Mean of Change from Baseline (SE)	-0.42 (2.24)	0.23 (2.43)	-1.94 (1.85)
95% CI	(-4.84, 3.99)	(-4.55, 5.01)	(-5.59, 1.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.52 (2.83)	2.17 (3.00)	
95% CI	(-4.06, 7.09)	(-3.74, 8.08)	
p-value	0.5930	0.4701	
Corrected Hedge's g Statistics	0.079	0.114	
95% CI	(-0.22, 0.38)	(-0.20, 0.43)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	65.0 (24.9)	62.3 (26.5)	66.7 (25.0)
Analysis Visit Mean (SD)	67.2 (26.0)	65.9 (25.7)	65.8 (25.4)
LS Mean of Change from Baseline (SE)	2.21 (2.41)	2.52 (2.66)	0.45 (2.00)
95% CI	(-2.55, 6.96)	(-2.72, 7.76)	(-3.49, 4.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.76 (3.06)	2.07 (3.28)	
95% CI	(-4.27, 7.79)	(-4.38, 8.53)	
p-value	0.5662	0.5271	
Corrected Hedge's g Statistics	0.091	0.108	
95% CI	(-0.23, 0.41)	(-0.24, 0.45)	
Subgroup*Treatment Interaction p-value	0.3098	0.7161	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
General Health			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	61.04 (18.79)	51.22 (17.68)	59.78 (20.19)
Analysis Visit Mean (SD)	60.66 (19.76)	55.02 (19.46)	59.33 (22.32)
LS Mean of Change from Baseline (SE)	0.28 (1.73)	1.87 (1.88)	-0.29 (1.42)
95% CI	(-3.12, 3.67)	(-1.84, 5.58)	(-3.09, 2.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.56 (2.17)	2.16 (2.33)	
95% CI	(-3.71, 4.84)	(-2.42, 6.74)	
p-value	0.7951	0.3542	
Corrected Hedge's g Statistics	0.038	0.147	
95% CI	(-0.26, 0.34)	(-0.17, 0.47)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	61.30 (19.60)	52.24 (19.10)	59.61 (20.95)
Analysis Visit Mean (SD)	63.52 (19.52)	56.02 (20.10)	60.18 (22.69)
LS Mean of Change from Baseline (SE)	2.96 (1.78)	2.48 (1.97)	1.21 (1.47)
95% CI	(-0.55, 6.48)	(-1.41, 6.36)	(-1.69, 4.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.75 (2.25)	1.27 (2.43)	
95% CI	(-2.68, 6.19)	(-3.51, 6.05)	
p-value	0.4369	0.6022	
Corrected Hedge's g Statistics	0.123	0.089	
95% CI	(-0.20, 0.44)	(-0.25, 0.43)	
Subgroup*Treatment Interaction p-value	0.4457	0.1379	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Vitality			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	56.80 (23.12)	51.93 (25.20)	58.70 (21.05)
Analysis Visit Mean (SD)	56.80 (23.12)	52.88 (21.54)	56.21 (23.97)
LS Mean of Change from Baseline (SE)	0.10 (1.64)	-0.03 (1.79)	-2.23 (1.36)
95% CI	(-3.13, 3.33)	(-3.56, 3.49)	(-4.91, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.33 (2.07)	2.20 (2.21)	
95% CI	(-1.76, 6.42)	(-2.15, 6.55)	
p-value	0.2624	0.3208	
Corrected Hedge's g Statistics	0.166	0.157	
95% CI	(-0.13, 0.47)	(-0.16, 0.48)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	57.56 (23.50)	53.90 (25.47)	58.06 (20.99)
Analysis Visit Mean (SD)	59.35 (22.19)	54.27 (23.46)	55.94 (25.24)
LS Mean of Change from Baseline (SE)	2.02 (1.92)	-0.40 (2.14)	-1.55 (1.59)
95% CI	(-1.77, 5.81)	(-4.61, 3.80)	(-4.69, 1.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.57 (2.45)	1.15 (2.63)	
95% CI	(-1.25, 8.40)	(-4.03, 6.33)	
p-value	0.1458	0.6618	
Corrected Hedge's g Statistics	0.232	0.075	
95% CI	(-0.09, 0.55)	(-0.27, 0.42)	
Subgroup*Treatment Interaction p-value	0.1585	0.2409	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Social Functioning			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	80.99 (25.61)	78.18 (27.03)	83.53 (22.95)
Analysis Visit Mean (SD)	78.17 (25.42)	81.57 (20.94)	80.02 (24.99)
LS Mean of Change from Baseline (SE)	-2.72 (2.32)	1.96 (2.52)	-2.91 (1.91)
95% CI	(-7.29, 1.84)	(-3.00, 6.92)	(-6.68, 0.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.19 (2.93)	4.87 (3.11)	
95% CI	(-5.59, 5.97)	(-1.25, 10.99)	
p-value	0.9493	0.1185	
Corrected Hedge's g Statistics	0.009	0.247	
95% CI	(-0.29, 0.31)	(-0.07, 0.57)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	82.74 (24.94)	78.00 (28.07)	83.20 (23.78)
Analysis Visit Mean (SD)	82.94 (22.48)	82.25 (23.16)	79.70 (24.79)
LS Mean of Change from Baseline (SE)	0.52 (2.28)	3.74 (2.51)	-2.92 (1.89)
95% CI	(-3.97, 5.00)	(-1.21, 8.69)	(-6.64, 0.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.43 (2.88)	6.66 (3.09)	
95% CI	(-2.25, 9.11)	(0.58, 12.74)	
p-value	0.2350	0.0320	
Corrected Hedge's g Statistics	0.188	0.367	
95% CI	(-0.13, 0.51)	(0.02, 0.71)	
Subgroup*Treatment Interaction p-value	0.6003	0.0780	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Role Emotional			
Week 24			
m	76	68	125
n	71	59	106
Baseline Mean (SD)	81.57 (26.69)	79.95 (22.70)	83.65 (22.42)
Analysis Visit Mean (SD)	80.99 (24.20)	85.17 (21.23)	80.97 (24.53)
LS Mean of Change from Baseline (SE)	-0.68 (2.03)	4.12 (2.19)	-2.72 (1.68)
95% CI	(-4.68, 3.32)	(-0.20, 8.44)	(-6.04, 0.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.04 (2.57)	6.84 (2.71)	
95% CI	(-3.02, 7.09)	(1.50, 12.18)	
p-value	0.4284	0.0123	
Corrected Hedge's g Statistics	0.118	0.396	
95% CI	(-0.18, 0.42)	(0.08, 0.72)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	83.33 (25.49)	80.33 (23.19)	83.87 (22.92)
Analysis Visit Mean (SD)	85.39 (19.61)	85.17 (22.61)	78.76 (26.59)
LS Mean of Change from Baseline (SE)	2.56 (2.05)	4.76 (2.25)	-4.36 (1.70)
95% CI	(-1.48, 6.60)	(0.32, 9.19)	(-7.72, -1.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.92 (2.60)	9.12 (2.77)	
95% CI	(1.81, 12.04)	(3.67, 14.58)	
p-value	0.0082	0.0011	
Corrected Hedge's g Statistics	0.421	0.559	
95% CI	(0.10, 0.74)	(0.21, 0.91)	
Subgroup*Treatment Interaction p-value	0.2720	0.0963	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Mental Health			
Week 24			
m	76	68	125
n	71	59	107
Baseline Mean (SD)	73.0 (21.0)	75.2 (20.9)	74.6 (18.5)
Analysis Visit Mean (SD)	71.7 (20.1)	75.0 (20.8)	73.8 (20.5)
LS Mean of Change from Baseline (SE)	-1.61 (1.57)	-0.37 (1.69)	-1.05 (1.29)
95% CI	(-4.69, 1.48)	(-3.70, 2.97)	(-3.60, 1.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.56 (1.98)	0.68 (2.09)	
95% CI	(-4.45, 3.34)	(-3.43, 4.80)	
p-value	0.7783	0.7438	
Corrected Hedge's g Statistics	-0.042	0.051	
95% CI	(-0.34, 0.26)	(-0.27, 0.37)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	75.1 (19.2)	74.6 (21.9)	74.4 (19.2)
Analysis Visit Mean (SD)	75.5 (18.1)	75.1 (20.5)	72.5 (23.3)
LS Mean of Change from Baseline (SE)	0.45 (1.69)	0.65 (1.86)	-1.99 (1.39)
95% CI	(-2.87, 3.77)	(-3.01, 4.31)	(-4.74, 0.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.44 (2.14)	2.64 (2.28)	
95% CI	(-1.77, 6.65)	(-1.86, 7.14)	
p-value	0.2543	0.2489	
Corrected Hedge's g Statistics	0.181	0.197	
95% CI	(-0.14, 0.50)	(-0.15, 0.54)	
Subgroup*Treatment Interaction p-value	0.8042	0.4246	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)
Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Mental Component Score			
Week 24			
m	76	68	125
n	71	59	106
Baseline Mean (SD)	50.04 (11.55)	50.21 (11.58)	51.19 (9.60)
Analysis Visit Mean (SD)	49.25 (10.50)	51.32 (10.50)	50.08 (10.83)
LS Mean of Change from Baseline (SE)	-0.92 (0.82)	0.78 (0.89)	-1.18 (0.68)
95% CI	(-2.54, 0.71)	(-0.96, 2.53)	(-2.53, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.27 (1.04)	1.97 (1.10)	
95% CI	(-1.78, 2.31)	(-0.19, 4.13)	
p-value	0.7975	0.0742	
Corrected Hedge's g Statistics	0.038	0.281	
95% CI	(-0.26, 0.34)	(-0.04, 0.60)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	51.07 (10.68)	50.09 (11.90)	51.04 (9.88)
Analysis Visit Mean (SD)	51.19 (9.32)	51.51 (10.53)	49.28 (12.43)
LS Mean of Change from Baseline (SE)	0.12 (0.88)	1.32 (0.96)	-1.72 (0.73)
95% CI	(-1.61, 1.85)	(-0.58, 3.22)	(-3.16, -0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.84 (1.11)	3.04 (1.19)	
95% CI	(-0.35, 4.03)	(0.70, 5.38)	
p-value	0.0989	0.0110	
Corrected Hedge's g Statistics	0.262	0.435	
95% CI	(-0.06, 0.58)	(0.09, 0.78)	
Subgroup*Treatment Interaction p-value	0.6474	0.1127	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Physical Component Score			
Week 24			
m	76	68	125
n	71	59	106
Baseline Mean (SD)	47.77 (8.09)	44.90 (8.57)	47.79 (9.08)
Analysis Visit Mean (SD)	47.91 (8.71)	45.51 (8.18)	47.23 (9.65)
LS Mean of Change from Baseline (SE)	0.42 (0.73)	0.15 (0.79)	-0.29 (0.60)
95% CI	(-1.01, 1.85)	(-1.41, 1.70)	(-1.48, 0.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.71 (0.92)	0.44 (0.98)	
95% CI	(-1.09, 2.52)	(-1.49, 2.36)	
p-value	0.4382	0.6540	
Corrected Hedge's g Statistics	0.115	0.071	
95% CI	(-0.19, 0.42)	(-0.25, 0.39)	
Week 52			
m	70	57	120
n	63	50	93
Baseline Mean (SD)	47.62 (8.54)	45.55 (8.76)	47.69 (8.98)
Analysis Visit Mean (SD)	48.97 (9.53)	45.84 (9.48)	47.68 (9.54)
LS Mean of Change from Baseline (SE)	1.64 (0.77)	0.31 (0.85)	0.39 (0.64)
95% CI	(0.13, 3.16)	(-1.37, 1.99)	(-0.87, 1.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.25 (0.98)	-0.09 (1.05)	
95% CI	(-0.67, 3.18)	(-2.15, 1.98)	
p-value	0.2019	0.9346	
Corrected Hedge's g Statistics	0.202	-0.014	
95% CI	(-0.12, 0.52)	(-0.36, 0.33)	
Subgroup*Treatment Interaction p-value	0.0793	0.6912	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Physical Functioning			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	80.37 (17.92)	71.90 (23.74)	80.09 (23.15)
Analysis Visit Mean (SD)	82.59 (20.21)	72.62 (24.68)	77.92 (26.75)
LS Mean of Change from Baseline (SE)	2.83 (3.99)	-2.08 (4.44)	-3.36 (2.87)
95% CI	(-5.08, 10.75)	(-10.89, 6.72)	(-9.05, 2.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.19 (4.80)	1.28 (5.20)	
95% CI	(-3.32, 15.71)	(-9.04, 11.60)	
p-value	0.1995	0.8062	
Corrected Hedge's g Statistics	0.294	0.061	
95% CI	(-0.17, 0.76)	(-0.44, 0.57)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	78.80 (17.69)	71.00 (23.98)	83.64 (18.28)
Analysis Visit Mean (SD)	78.00 (29.08)	70.64 (28.10)	81.59 (20.54)
LS Mean of Change from Baseline (SE)	-1.61 (4.04)	-1.83 (4.50)	-2.42 (3.02)
95% CI	(-9.62, 6.41)	(-10.75, 7.10)	(-8.40, 3.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.81 (4.94)	0.60 (5.39)	
95% CI	(-8.98, 10.60)	(-10.09, 11.28)	
p-value	0.8695	0.9122	
Corrected Hedge's g Statistics	0.040	0.029	
95% CI	(-0.45, 0.53)	(-0.50, 0.56)	
Subgroup*Treatment Interaction p-value	0.0420	0.8399	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Role Physical			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	78.94 (25.66)	69.96 (33.28)	78.31 (25.78)
Analysis Visit Mean (SD)	80.34 (22.57)	67.28 (25.45)	76.19 (27.70)
LS Mean of Change from Baseline (SE)	1.97 (4.06)	-5.81 (4.52)	-2.67 (2.91)
95% CI	(-6.08, 10.02)	(-14.78, 3.16)	(-8.45, 3.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.64 (4.89)	-3.14 (5.28)	
95% CI	(-5.07, 14.35)	(-13.62, 7.33)	
p-value	0.3455	0.5531	
Corrected Hedge's g Statistics	0.217	-0.148	
95% CI	(-0.25, 0.68)	(-0.65, 0.36)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	79.26 (25.68)	68.77 (33.68)	81.97 (20.35)
Analysis Visit Mean (SD)	78.01 (30.52)	73.46 (29.65)	80.56 (20.80)
LS Mean of Change from Baseline (SE)	-1.38 (3.94)	2.58 (4.38)	-1.09 (2.92)
95% CI	(-9.21, 6.44)	(-6.11, 11.28)	(-6.88, 4.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.30 (4.81)	3.67 (5.20)	
95% CI	(-9.84, 9.24)	(-6.65, 13.99)	
p-value	0.9507	0.4820	
Corrected Hedge's g Statistics	-0.015	0.187	
95% CI	(-0.51, 0.48)	(-0.34, 0.72)	
Subgroup*Treatment Interaction p-value	0.0058	0.1207	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Bodily Pain			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	77.9 (20.3)	58.3 (29.3)	66.0 (25.7)
Analysis Visit Mean (SD)	73.1 (23.3)	62.3 (26.5)	69.1 (26.8)
LS Mean of Change from Baseline (SE)	0.85 (4.43)	-0.38 (4.82)	2.04 (3.09)
95% CI	(-7.95, 9.64)	(-9.95, 9.18)	(-4.10, 8.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.19 (5.28)	-2.42 (5.60)	
95% CI	(-11.67, 9.29)	(-13.53, 8.69)	
p-value	0.8220	0.6663	
Corrected Hedge's g Statistics	-0.052	-0.107	
95% CI	(-0.52, 0.41)	(-0.61, 0.40)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	78.6 (20.4)	56.2 (28.5)	66.9 (25.5)
Analysis Visit Mean (SD)	73.6 (26.7)	62.1 (24.4)	73.4 (23.5)
LS Mean of Change from Baseline (SE)	-0.08 (4.72)	0.22 (5.14)	4.99 (3.37)
95% CI	(-9.45, 9.28)	(-9.98, 10.42)	(-1.69, 11.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.07 (5.69)	-4.76 (6.04)	
95% CI	(-16.35, 6.21)	(-16.74, 7.21)	
p-value	0.3747	0.4318	
Corrected Hedge's g Statistics	-0.220	-0.209	
95% CI	(-0.71, 0.27)	(-0.74, 0.32)	
Subgroup*Treatment Interaction p-value	0.3098	0.7161	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
General Health			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	62.56 (20.93)	53.24 (18.72)	59.43 (21.11)
Analysis Visit Mean (SD)	67.52 (21.26)	52.67 (17.48)	60.85 (20.73)
LS Mean of Change from Baseline (SE)	5.54 (3.02)	-2.85 (3.36)	0.42 (2.17)
95% CI	(-0.46, 11.54)	(-9.50, 3.81)	(-3.89, 4.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.12 (3.64)	-3.26 (3.91)	
95% CI	(-2.10, 12.34)	(-11.02, 4.50)	
p-value	0.1623	0.4061	
Corrected Hedge's g Statistics	0.321	-0.206	
95% CI	(-0.14, 0.79)	(-0.71, 0.30)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	65.40 (19.75)	53.90 (18.95)	62.50 (20.11)
Analysis Visit Mean (SD)	65.52 (19.35)	54.60 (18.47)	63.27 (19.66)
LS Mean of Change from Baseline (SE)	0.82 (3.37)	-2.01 (3.73)	1.19 (2.48)
95% CI	(-5.87, 7.51)	(-9.40, 5.39)	(-3.73, 6.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.37 (4.10)	-3.20 (4.42)	
95% CI	(-8.50, 7.75)	(-11.97, 5.58)	
p-value	0.9277	0.4714	
Corrected Hedge's g Statistics	-0.022	-0.191	
95% CI	(-0.51, 0.47)	(-0.72, 0.34)	
Subgroup*Treatment Interaction p-value	0.4457	0.1379	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Vitality			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	65.99 (21.04)	53.30 (19.82)	57.33 (21.32)
Analysis Visit Mean (SD)	62.76 (22.63)	52.70 (17.07)	58.87 (21.60)
LS Mean of Change from Baseline (SE)	-0.60 (3.29)	-3.49 (3.61)	-0.70 (2.33)
95% CI	(-7.13, 5.92)	(-10.66, 3.68)	(-5.33, 3.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (3.94)	-2.79 (4.20)	
95% CI	(-7.71, 7.91)	(-11.11, 5.54)	
p-value	0.9799	0.5082	
Corrected Hedge's g Statistics	0.006	-0.164	
95% CI	(-0.46, 0.47)	(-0.67, 0.34)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	67.27 (19.37)	53.15 (20.33)	57.41 (20.09)
Analysis Visit Mean (SD)	62.77 (19.64)	53.46 (19.61)	61.96 (19.05)
LS Mean of Change from Baseline (SE)	-2.07 (3.48)	-2.96 (3.81)	1.61 (2.51)
95% CI	(-8.98, 4.84)	(-10.52, 4.61)	(-3.37, 6.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.68 (4.22)	-4.57 (4.47)	
95% CI	(-12.05, 4.68)	(-13.43, 4.30)	
p-value	0.3847	0.3092	
Corrected Hedge's g Statistics	-0.215	-0.269	
95% CI	(-0.71, 0.28)	(-0.80, 0.26)	
Subgroup*Treatment Interaction p-value	0.1585	0.2409	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Social Functioning			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	88.43 (14.26)	75.60 (26.36)	84.91 (20.12)
Analysis Visit Mean (SD)	88.89 (18.78)	76.19 (21.25)	85.14 (22.21)
LS Mean of Change from Baseline (SE)	2.49 (3.38)	-3.96 (3.79)	-1.39 (2.41)
95% CI	(-4.22, 9.20)	(-11.48, 3.56)	(-6.18, 3.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.88 (4.06)	-2.57 (4.42)	
95% CI	(-4.17, 11.94)	(-11.33, 6.19)	
p-value	0.3411	0.5625	
Corrected Hedge's g Statistics	0.219	-0.145	
95% CI	(-0.25, 0.68)	(-0.65, 0.36)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	89.00 (15.02)	75.00 (26.90)	88.64 (15.68)
Analysis Visit Mean (SD)	87.00 (17.49)	85.00 (20.11)	89.20 (18.60)
LS Mean of Change from Baseline (SE)	-0.39 (3.40)	4.95 (3.81)	0.10 (2.51)
95% CI	(-7.13, 6.36)	(-2.61, 12.52)	(-4.87, 5.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.49 (4.11)	4.85 (4.54)	
95% CI	(-8.65, 7.67)	(-4.15, 13.85)	
p-value	0.9053	0.2875	
Corrected Hedge's g Statistics	-0.029	0.286	
95% CI	(-0.52, 0.46)	(-0.24, 0.82)	
Subgroup*Treatment Interaction p-value	0.6003	0.0780	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Role Emotional			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	84.26 (24.82)	78.18 (30.10)	86.32 (19.07)
Analysis Visit Mean (SD)	84.56 (18.74)	78.18 (26.94)	85.53 (23.12)
LS Mean of Change from Baseline (SE)	0.14 (3.07)	-2.18 (3.41)	-1.35 (2.22)
95% CI	(-5.96, 6.23)	(-8.95, 4.59)	(-5.75, 3.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.49 (3.71)	-0.83 (3.99)	
95% CI	(-5.87, 8.84)	(-8.75, 7.09)	
p-value	0.6891	0.8354	
Corrected Hedge's g Statistics	0.092	-0.051	
95% CI	(-0.37, 0.56)	(-0.56, 0.45)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	84.00 (25.56)	77.50 (30.72)	88.06 (15.82)
Analysis Visit Mean (SD)	88.34 (19.98)	85.84 (22.64)	89.39 (14.64)
LS Mean of Change from Baseline (SE)	3.42 (3.37)	4.14 (3.75)	1.15 (2.51)
95% CI	(-3.28, 10.11)	(-3.29, 11.58)	(-3.82, 6.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.27 (4.13)	2.99 (4.46)	
95% CI	(-5.93, 10.47)	(-5.86, 11.85)	
p-value	0.5841	0.5038	
Corrected Hedge's g Statistics	0.134	0.177	
95% CI	(-0.36, 0.63)	(-0.35, 0.71)	
Subgroup*Treatment Interaction p-value	0.2720	0.0963	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Mental Health			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	77.2 (18.8)	72.1 (17.8)	77.9 (13.7)
Analysis Visit Mean (SD)	75.9 (17.5)	71.0 (19.5)	76.8 (15.9)
LS Mean of Change from Baseline (SE)	-1.22 (2.75)	-3.17 (3.05)	-1.52 (1.97)
95% CI	(-6.67, 4.22)	(-9.23, 2.89)	(-5.42, 2.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.29 (3.30)	-1.65 (3.57)	
95% CI	(-6.24, 6.83)	(-8.72, 5.43)	
p-value	0.9289	0.6452	
Corrected Hedge's g Statistics	0.020	-0.114	
95% CI	(-0.44, 0.48)	(-0.62, 0.39)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	76.8 (19.3)	72.5 (18.2)	77.4 (12.9)
Analysis Visit Mean (SD)	77.6 (16.3)	70.5 (19.5)	80.0 (13.8)
LS Mean of Change from Baseline (SE)	0.11 (2.78)	-3.75 (3.08)	0.73 (2.03)
95% CI	(-5.40, 5.62)	(-9.85, 2.36)	(-3.30, 4.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.62 (3.36)	-4.47 (3.62)	
95% CI	(-7.29, 6.05)	(-11.66, 2.71)	
p-value	0.8547	0.2198	
Corrected Hedge's g Statistics	-0.045	-0.326	
95% CI	(-0.54, 0.45)	(-0.86, 0.21)	
Subgroup*Treatment Interaction p-value	0.8042	0.4246	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Mental Component Score			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	52.30 (9.93)	49.08 (11.99)	52.05 (7.32)
Analysis Visit Mean (SD)	51.60 (8.56)	48.69 (11.22)	51.96 (9.32)
LS Mean of Change from Baseline (SE)	-0.52 (1.44)	-1.57 (1.60)	-0.56 (1.03)
95% CI	(-3.37, 2.33)	(-4.74, 1.60)	(-2.60, 1.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (1.73)	-1.01 (1.86)	
95% CI	(-3.39, 3.47)	(-4.71, 2.69)	
p-value	0.9822	0.5885	
Corrected Hedge's g Statistics	0.005	-0.134	
95% CI	(-0.46, 0.47)	(-0.64, 0.37)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	52.42 (10.15)	49.18 (12.29)	52.11 (6.34)
Analysis Visit Mean (SD)	53.02 (7.88)	50.89 (10.68)	53.56 (6.96)
LS Mean of Change from Baseline (SE)	0.68 (1.49)	0.30 (1.65)	0.38 (1.09)
95% CI	(-2.28, 3.64)	(-2.98, 3.58)	(-1.79, 2.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.30 (1.81)	-0.08 (1.95)	
95% CI	(-3.29, 3.89)	(-3.94, 3.78)	
p-value	0.8680	0.9676	
Corrected Hedge's g Statistics	0.041	-0.011	
95% CI	(-0.45, 0.53)	(-0.54, 0.52)	
Subgroup*Treatment Interaction p-value	0.6474	0.1127	

AMNOG Table SE22.14a.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Physical Component Score			
Week 24			
m	28	22	60
n	27	21	53
Baseline Mean (SD)	50.24 (5.87)	45.06 (9.83)	47.88 (9.61)
Analysis Visit Mean (SD)	50.84 (8.41)	45.43 (8.95)	48.03 (10.30)
LS Mean of Change from Baseline (SE)	1.56 (1.59)	-0.91 (1.76)	-0.27 (1.13)
95% CI	(-1.59, 4.71)	(-4.39, 2.58)	(-2.52, 1.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.83 (1.91)	-0.63 (2.05)	
95% CI	(-1.95, 5.61)	(-4.70, 3.43)	
p-value	0.3383	0.7575	
Corrected Hedge's g Statistics	0.220	-0.077	
95% CI	(-0.24, 0.69)	(-0.58, 0.43)	
Week 52			
m	27	22	54
n	25	20	44
Baseline Mean (SD)	50.56 (6.34)	44.59 (9.84)	49.31 (8.09)
Analysis Visit Mean (SD)	49.14 (11.43)	45.51 (11.20)	49.38 (7.68)
LS Mean of Change from Baseline (SE)	-1.07 (1.65)	-0.02 (1.83)	0.23 (1.21)
95% CI	(-4.35, 2.20)	(-3.65, 3.61)	(-2.17, 2.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.31 (2.00)	-0.25 (2.17)	
95% CI	(-5.27, 2.65)	(-4.56, 4.06)	
p-value	0.5141	0.9079	
Corrected Hedge's g Statistics	-0.159	-0.031	
95% CI	(-0.65, 0.33)	(-0.56, 0.50)	
Subgroup*Treatment Interaction p-value	0.0793	0.6912	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (6.3)	5 (11.4)	18 (18.9)
No	45 (93.8)	39 (88.6)	77 (81.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.51	1.82	
95% CI of the inverse odds ratio	(0.98, 12.57)	(0.63, 5.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.03	1.67	
95% CI of the inverse risk ratio	(0.94, 9.79)	(0.66, 4.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.70	-7.58	
95% CI of the absolute risk difference	(-23.14, -2.26)	(-19.83, 4.67)	
p-value	0.0428	0.2631	
p-value of Breslow-Day Test for Homogeneity [3]	0.0089	0.2027	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (22.9)	13 (29.5)	29 (30.5)
No	37 (77.1)	31 (70.5)	66 (69.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.48	1.05	
95% CI of the inverse odds ratio	(0.66, 3.30)	(0.48, 2.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	1.03	
95% CI of the inverse risk ratio	(0.73, 2.43)	(0.60, 1.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.61	-0.98	
95% CI of the absolute risk difference	(-22.68, 7.46)	(-17.34, 15.37)	
p-value	0.3384	0.9068	
p-value of Breslow-Day Test for Homogeneity [3]	0.1631	0.7442	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.2)	5 (11.4)	15 (15.8)
No	46 (95.8)	39 (88.6)	80 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.31	1.46	
95% CI of the inverse odds ratio	(0.94, 19.70)	(0.50, 4.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.79	1.39	
95% CI of the inverse risk ratio	(0.90, 15.90)	(0.54, 3.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.62	-4.43	
95% CI of the absolute risk difference	(-20.88, -2.36)	(-16.33, 7.48)	
p-value	0.0426	0.4892	
p-value of Breslow-Day Test for Homogeneity [3]	0.1680	0.5455	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (14.6)	11 (25.0)	28 (29.5)
No	41 (85.4)	33 (75.0)	67 (70.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.45	1.25	
95% CI of the inverse odds ratio	(0.98, 6.11)	(0.56, 2.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.02	1.18	
95% CI of the inverse risk ratio	(0.95, 4.29)	(0.65, 2.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.89	-4.47	
95% CI of the absolute risk difference	(-28.45, -1.34)	(-20.21, 11.27)	
p-value	0.0505	0.5850	
p-value of Breslow-Day Test for Homogeneity [3]	0.0311	0.4944	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (6.3)	7 (15.9)	18 (18.9)
No	45 (93.8)	37 (84.1)	77 (81.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.51	1.24	
95% CI of the inverse odds ratio	(0.98, 12.57)	(0.47, 3.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.03	1.19	
95% CI of the inverse risk ratio	(0.94, 9.79)	(0.54, 2.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.70	-3.04	
95% CI of the absolute risk difference	(-23.14, -2.26)	(-16.41, 10.34)	
p-value	0.0428	0.6644	
p-value of Breslow-Day Test for Homogeneity [3]	0.0763	0.8347	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (25.0)	13 (29.5)	32 (33.7)
No	36 (75.0)	31 (70.5)	63 (66.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	1.21	
95% CI of the inverse odds ratio	(0.70, 3.32)	(0.56, 2.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	1.14	
95% CI of the inverse risk ratio	(0.77, 2.37)	(0.67, 1.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.68	-4.14	
95% CI of the absolute risk difference	(-24.19, 6.82)	(-20.63, 12.36)	
p-value	0.2880	0.6276	
p-value of Breslow-Day Test for Homogeneity [3]	0.2937	0.5413	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (14.6)	6 (13.6)	15 (15.8)
No	41 (85.4)	38 (86.4)	80 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	1.19	
95% CI of the inverse odds ratio	(0.42, 2.91)	(0.43, 3.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	1.16	
95% CI of the inverse risk ratio	(0.47, 2.48)	(0.48, 2.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.21	-2.15	
95% CI of the absolute risk difference	(-13.59, 11.18)	(-14.67, 10.36)	
p-value	0.8503	0.7416	
p-value of Breslow-Day Test for Homogeneity [3]	0.3502	0.7316	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (25.0)	10 (22.7)	34 (35.8)
No	36 (75.0)	34 (77.3)	61 (64.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	1.90	
95% CI of the inverse odds ratio	(0.77, 3.63)	(0.83, 4.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.57	
95% CI of the inverse risk ratio	(0.82, 2.50)	(0.86, 2.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.79	-13.06	
95% CI of the absolute risk difference	(-26.38, 4.80)	(-28.75, 2.63)	
p-value	0.1921	0.1236	
p-value of Breslow-Day Test for Homogeneity [3]	0.2305	0.0467	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (6.3)	2 (4.5)	13 (13.7)
No	45 (93.8)	42 (95.5)	82 (86.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.38	3.33	
95% CI of the inverse odds ratio	(0.64, 8.79)	(0.72, 15.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.19	3.01	
95% CI of the inverse risk ratio	(0.66, 7.32)	(0.71, 12.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.43	-9.14	
95% CI of the absolute risk difference	(-17.16, 2.29)	(-18.39, 0.12)	
p-value	0.1829	0.1063	
p-value of Breslow-Day Test for Homogeneity [3]	0.2151	0.1289	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (27.1)	9 (20.5)	29 (30.5)
No	35 (72.9)	35 (79.5)	66 (69.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.71	
95% CI of the inverse odds ratio	(0.55, 2.56)	(0.73, 4.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	1.49	
95% CI of the inverse risk ratio	(0.65, 1.96)	(0.77, 2.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.44	-10.07	
95% CI of the absolute risk difference	(-19.06, 12.17)	(-25.17, 5.02)	
p-value	0.6695	0.2153	
p-value of Breslow-Day Test for Homogeneity [3]	0.2968	0.5886	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.2)	3 (6.8)	11 (11.6)
No	46 (95.8)	41 (93.2)	84 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.01	1.79	
95% CI of the inverse odds ratio	(0.64, 14.18)	(0.47, 6.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.78	1.70	
95% CI of the inverse risk ratio	(0.64, 12.04)	(0.50, 5.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.41	-4.76	
95% CI of the absolute risk difference	(-15.98, 1.15)	(-14.60, 5.08)	
p-value	0.1454	0.3857	
p-value of Breslow-Day Test for Homogeneity [3]	0.1855	0.0471	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (16.7)	5 (11.4)	19 (20.0)
No	40 (83.3)	39 (88.6)	76 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.95	
95% CI of the inverse odds ratio	(0.50, 3.11)	(0.68, 5.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	1.76	
95% CI of the inverse risk ratio	(0.57, 2.54)	(0.70, 4.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.33	-8.64	
95% CI of the absolute risk difference	(-16.59, 9.93)	(-20.99, 3.72)	
p-value	0.6305	0.2102	
p-value of Breslow-Day Test for Homogeneity [3]	0.2503	0.0381	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (6.3)	8 (18.2)	14 (14.7)
No	45 (93.8)	36 (81.8)	81 (85.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.59	0.78	
95% CI of the inverse odds ratio	(0.71, 9.50)	(0.30, 2.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.36	0.81	
95% CI of the inverse risk ratio	(0.71, 7.81)	(0.37, 1.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.49	3.44	
95% CI of the absolute risk difference	(-18.37, 1.40)	(-10.00, 16.89)	
p-value	0.1387	0.6048	
p-value of Breslow-Day Test for Homogeneity [3]	0.1358	0.6177	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (16.7)	10 (22.7)	19 (20.0)
No	40 (83.3)	34 (77.3)	76 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.85	
95% CI of the inverse odds ratio	(0.50, 3.11)	(0.36, 2.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	0.88	
95% CI of the inverse risk ratio	(0.57, 2.54)	(0.45, 1.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.33	2.73	
95% CI of the absolute risk difference	(-16.59, 9.93)	(-12.04, 17.49)	
p-value	0.6305	0.7128	
p-value of Breslow-Day Test for Homogeneity [3]	0.3310	0.3601	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (6.3)	3 (6.8)	17 (17.9)
No	45 (93.8)	41 (93.2)	78 (82.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.27	2.98	
95% CI of the inverse odds ratio	(0.91, 11.77)	(0.82, 10.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.86	2.62	
95% CI of the inverse risk ratio	(0.88, 9.29)	(0.81, 8.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.64	-11.08	
95% CI of the absolute risk difference	(-21.96, -1.33)	(-21.79, -0.36)	
p-value	0.0580	0.0835	
p-value of Breslow-Day Test for Homogeneity [3]	0.1301	0.3180	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (37.5)	9 (20.5)	29 (30.5)
No	30 (62.5)	35 (79.5)	66 (69.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	1.71	
95% CI of the inverse odds ratio	(0.35, 1.52)	(0.73, 4.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	1.49	
95% CI of the inverse risk ratio	(0.51, 1.31)	(0.77, 2.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.97	-10.07	
95% CI of the absolute risk difference	(-9.56, 23.51)	(-25.17, 5.02)	
p-value	0.4018	0.2153	
p-value of Breslow-Day Test for Homogeneity [3]	0.3282	0.5316	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.1)	3 (6.8)	10 (10.5)
No	47 (97.9)	41 (93.2)	85 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.53	1.61	
95% CI of the inverse odds ratio	(0.69, 44.54)	(0.42, 6.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.05	1.54	
95% CI of the inverse risk ratio	(0.67, 38.32)	(0.45, 5.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.44	-3.71	
95% CI of the absolute risk difference	(-15.82, -1.07)	(-13.38, 5.96)	
p-value	0.0736	0.4849	
p-value of Breslow-Day Test for Homogeneity [3]	0.1897	0.1546	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (16.7)	6 (13.6)	21 (22.1)
No	40 (83.3)	38 (86.4)	74 (77.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	1.80	
95% CI of the inverse odds ratio	(0.58, 3.49)	(0.67, 4.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	1.62	
95% CI of the inverse risk ratio	(0.63, 2.77)	(0.70, 3.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.44	-8.47	
95% CI of the absolute risk difference	(-18.88, 8.01)	(-21.60, 4.66)	
p-value	0.4450	0.2404	
p-value of Breslow-Day Test for Homogeneity [3]	0.2331	0.4952	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.1)	2 (4.5)	5 (5.3)
No	47 (97.9)	42 (95.5)	90 (94.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.61	1.17	
95% CI of the inverse odds ratio	(0.30, 23.00)	(0.22, 6.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.53	1.16	
95% CI of the inverse risk ratio	(0.30, 21.02)	(0.23, 5.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.18	-0.72	
95% CI of the absolute risk difference	(-9.22, 2.86)	(-8.34, 6.90)	
p-value	0.3705	0.8572	
p-value of Breslow-Day Test for Homogeneity [3]	0.4232	0.5461	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (12.5)	12 (27.3)	27 (28.4)
No	42 (87.5)	32 (72.7)	68 (71.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.78	1.06	
95% CI of the inverse odds ratio	(1.06, 7.29)	(0.48, 2.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.27	1.04	
95% CI of the inverse risk ratio	(1.01, 5.13)	(0.58, 1.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.92	-1.15	
95% CI of the absolute risk difference	(-28.95, -2.89)	(-17.13, 14.83)	
p-value	0.0329	0.8885	
p-value of Breslow-Day Test for Homogeneity [3]	0.0135	0.2891	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (15.6)	8 (11.1)	12 (9.4)
No	65 (84.4)	64 (88.9)	116 (90.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.83	
95% CI of the inverse odds ratio	(0.24, 1.32)	(0.32, 2.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.84	
95% CI of the inverse risk ratio	(0.28, 1.27)	(0.36, 1.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.21	1.74	
95% CI of the absolute risk difference	(-3.34, 15.76)	(-7.11, 10.58)	
p-value	0.1805	0.6944	
p-value of Breslow-Day Test for Homogeneity [3]	0.0089	0.2027	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (37.7)	22 (30.6)	33 (25.8)
No	48 (62.3)	50 (69.4)	95 (74.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	0.79	
95% CI of the inverse odds ratio	(0.31, 1.06)	(0.42, 1.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.84	
95% CI of the inverse risk ratio	(0.45, 1.03)	(0.53, 1.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.88	4.77	
95% CI of the absolute risk difference	(-1.33, 25.09)	(-8.29, 17.84)	
p-value	0.0729	0.4679	
p-value of Breslow-Day Test for Homogeneity [3]	0.1631	0.7442	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (11.7)	7 (9.7)	13 (10.2)
No	68 (88.3)	65 (90.3)	115 (89.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.05	
95% CI of the inverse odds ratio	(0.35, 2.10)	(0.40, 2.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.04	
95% CI of the inverse risk ratio	(0.39, 1.94)	(0.44, 2.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.53	-0.43	
95% CI of the absolute risk difference	(-7.35, 10.41)	(-9.05, 8.18)	
p-value	0.7314	0.9218	
p-value of Breslow-Day Test for Homogeneity [3]	0.1680	0.5455	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (28.6)	18 (25.0)	23 (18.0)
No	55 (71.4)	54 (75.0)	105 (82.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	0.66	
95% CI of the inverse odds ratio	(0.28, 1.07)	(0.33, 1.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.72	
95% CI of the inverse risk ratio	(0.38, 1.05)	(0.42, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.60	7.03	
95% CI of the absolute risk difference	(-1.48, 22.69)	(-4.98, 19.04)	
p-value	0.0757	0.2371	
p-value of Breslow-Day Test for Homogeneity [3]	0.0311	0.4944	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (16.9)	11 (15.3)	17 (13.3)
No	64 (83.1)	61 (84.7)	111 (86.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.85	
95% CI of the inverse odds ratio	(0.34, 1.65)	(0.37, 1.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.87	
95% CI of the inverse risk ratio	(0.40, 1.53)	(0.43, 1.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.60	2.00	
95% CI of the absolute risk difference	(-6.62, 13.83)	(-8.18, 12.18)	
p-value	0.4798	0.6961	
p-value of Breslow-Day Test for Homogeneity [3]	0.0763	0.8347	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (27.3)	20 (27.8)	28 (21.9)
No	56 (72.7)	52 (72.2)	100 (78.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.73	
95% CI of the inverse odds ratio	(0.39, 1.44)	(0.37, 1.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.79	
95% CI of the inverse risk ratio	(0.49, 1.31)	(0.48, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.40	5.90	
95% CI of the absolute risk difference	(-6.86, 17.66)	(-6.68, 18.49)	
p-value	0.3802	0.3481	
p-value of Breslow-Day Test for Homogeneity [3]	0.2937	0.5413	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (13.0)	14 (19.4)	19 (14.8)
No	67 (87.0)	58 (80.6)	109 (85.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.72	
95% CI of the inverse odds ratio	(0.51, 2.66)	(0.34, 1.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	0.76	
95% CI of the inverse risk ratio	(0.56, 2.33)	(0.41, 1.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.86	4.60	
95% CI of the absolute risk difference	(-11.57, 7.85)	(-6.42, 15.62)	
p-value	0.7118	0.4001	
p-value of Breslow-Day Test for Homogeneity [3]	0.3502	0.7316	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (33.8)	29 (40.3)	34 (26.6)
No	51 (66.2)	43 (59.7)	94 (73.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.54	
95% CI of the inverse odds ratio	(0.38, 1.31)	(0.29, 0.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.66	
95% CI of the inverse risk ratio	(0.51, 1.20)	(0.44, 0.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.20	13.72	
95% CI of the absolute risk difference	(-5.84, 20.25)	(0.04, 27.39)	
p-value	0.2723	0.0450	
p-value of Breslow-Day Test for Homogeneity [3]	0.2305	0.0467	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (10.4)	8 (11.1)	9 (7.0)
No	69 (89.6)	64 (88.9)	119 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	0.61	
95% CI of the inverse odds ratio	(0.24, 1.77)	(0.22, 1.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.63	
95% CI of the inverse risk ratio	(0.27, 1.68)	(0.26, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.36	4.08	
95% CI of the absolute risk difference	(-4.77, 11.49)	(-4.42, 12.58)	
p-value	0.3984	0.3207	
p-value of Breslow-Day Test for Homogeneity [3]	0.2151	0.1289	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (35.1)	21 (29.2)	37 (28.9)
No	50 (64.9)	51 (70.8)	91 (71.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.99	
95% CI of the inverse odds ratio	(0.41, 1.38)	(0.52, 1.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.99	
95% CI of the inverse risk ratio	(0.55, 1.24)	(0.63, 1.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.16	0.26	
95% CI of the absolute risk difference	(-7.08, 19.40)	(-12.85, 13.37)	
p-value	0.3568	0.9689	
p-value of Breslow-Day Test for Homogeneity [3]	0.2968	0.5886	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (10.4)	14 (19.4)	8 (6.3)
No	69 (89.6)	58 (80.6)	120 (93.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.28	
95% CI of the inverse odds ratio	(0.21, 1.60)	(0.11, 0.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.32	
95% CI of the inverse risk ratio	(0.24, 1.54)	(0.14, 0.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.14	13.19	
95% CI of the absolute risk difference	(-3.86, 12.14)	(3.14, 23.25)	
p-value	0.2846	0.0042	
p-value of Breslow-Day Test for Homogeneity [3]	0.1855	0.0471	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (23.4)	19 (26.4)	19 (14.8)
No	59 (76.6)	53 (73.6)	109 (85.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	0.49	
95% CI of the inverse odds ratio	(0.28, 1.17)	(0.24, 0.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.56	
95% CI of the inverse risk ratio	(0.36, 1.13)	(0.32, 0.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.53	11.55	
95% CI of the absolute risk difference	(-2.75, 19.82)	(-0.35, 23.44)	
p-value	0.1240	0.0457	
p-value of Breslow-Day Test for Homogeneity [3]	0.2503	0.0381	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (15.6)	14 (19.4)	12 (9.4)
No	65 (84.4)	58 (80.6)	116 (90.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.43	
95% CI of the inverse odds ratio	(0.24, 1.32)	(0.19, 0.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.48	
95% CI of the inverse risk ratio	(0.28, 1.27)	(0.24, 0.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.21	10.07	
95% CI of the absolute risk difference	(-3.34, 15.76)	(-0.37, 20.51)	
p-value	0.1805	0.0421	
p-value of Breslow-Day Test for Homogeneity [3]	0.1358	0.6177	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (19.5)	19 (26.4)	15 (11.7)
No	62 (80.5)	53 (73.6)	113 (88.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	0.37	
95% CI of the inverse odds ratio	(0.25, 1.20)	(0.17, 0.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.44	
95% CI of the inverse risk ratio	(0.31, 1.16)	(0.24, 0.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.76	14.67	
95% CI of the absolute risk difference	(-2.69, 18.22)	(3.06, 26.28)	
p-value	0.1278	0.0080	
p-value of Breslow-Day Test for Homogeneity [3]	0.3310	0.3601	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (11.7)	5 (6.9)	13 (10.2)
No	68 (88.3)	67 (93.1)	115 (89.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.51	
95% CI of the inverse odds ratio	(0.35, 2.10)	(0.52, 4.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.46	
95% CI of the inverse risk ratio	(0.39, 1.94)	(0.54, 3.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.53	-3.21	
95% CI of the absolute risk difference	(-7.35, 10.41)	(-11.08, 4.65)	
p-value	0.7314	0.4462	
p-value of Breslow-Day Test for Homogeneity [3]	0.1301	0.3180	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (36.4)	18 (25.0)	30 (23.4)
No	49 (63.6)	54 (75.0)	98 (76.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	0.92	
95% CI of the inverse odds ratio	(0.29, 0.99)	(0.47, 1.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.94	
95% CI of the inverse risk ratio	(0.42, 0.99)	(0.56, 1.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.93	1.56	
95% CI of the absolute risk difference	(-0.09, 25.94)	(-10.84, 13.97)	
p-value	0.0466	0.8039	
p-value of Breslow-Day Test for Homogeneity [3]	0.3282	0.5316	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (3.9)	6 (8.3)	3 (2.3)
No	74 (96.1)	66 (91.7)	125 (97.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.26	
95% CI of the inverse odds ratio	(0.12, 3.01)	(0.06, 1.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.28	
95% CI of the inverse risk ratio	(0.12, 2.91)	(0.07, 1.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.55	5.99	
95% CI of the absolute risk difference	(-3.50, 6.61)	(-0.91, 12.89)	
p-value	0.5231	0.0498	
p-value of Breslow-Day Test for Homogeneity [3]	0.1897	0.1546	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (27.3)	13 (18.1)	23 (18.0)
No	56 (72.7)	59 (81.9)	105 (82.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.99	
95% CI of the inverse odds ratio	(0.30, 1.15)	(0.47, 2.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	1.00	
95% CI of the inverse risk ratio	(0.39, 1.11)	(0.54, 1.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.30	0.09	
95% CI of the absolute risk difference	(-2.66, 21.27)	(-11.01, 11.19)	
p-value	0.1161	0.9878	
p-value of Breslow-Day Test for Homogeneity [3]	0.2331	0.4952	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (3.9)	5 (6.9)	5 (3.9)
No	74 (96.1)	67 (93.1)	123 (96.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.54	
95% CI of the inverse odds ratio	(0.23, 4.32)	(0.15, 1.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.56	
95% CI of the inverse risk ratio	(0.25, 4.08)	(0.17, 1.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.01	3.04	
95% CI of the absolute risk difference	(-5.48, 5.46)	(-3.73, 9.80)	
p-value	0.9971	0.3440	
p-value of Breslow-Day Test for Homogeneity [3]	0.4232	0.5461	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (26.0)	19 (26.4)	19 (14.8)
No	57 (74.0)	53 (73.6)	109 (85.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	0.49	
95% CI of the inverse odds ratio	(0.25, 1.01)	(0.24, 0.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	0.56	
95% CI of the inverse risk ratio	(0.33, 1.00)	(0.32, 0.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.13	11.55	
95% CI of the absolute risk difference	(-0.44, 22.70)	(-0.35, 23.44)	
p-value	0.0493	0.0457	
p-value of Breslow-Day Test for Homogeneity [3]	0.0135	0.2891	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (23.3)	4 (18.2)	5 (7.9)
No	23 (76.7)	18 (81.8)	58 (92.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	0.39	
95% CI of the inverse odds ratio	(0.08, 0.98)	(0.09, 1.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.34	0.44	
95% CI of the inverse risk ratio	(0.12, 0.98)	(0.13, 1.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.40	10.25	
95% CI of the absolute risk difference	(-1.14, 31.94)	(-7.20, 27.69)	
p-value	0.0384	0.1788	
p-value of Breslow-Day Test for Homogeneity [3]	0.0089	0.2027	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (36.7)	8 (36.4)	17 (27.0)
No	19 (63.3)	14 (63.6)	46 (73.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.65	
95% CI of the inverse odds ratio	(0.25, 1.61)	(0.23, 1.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.74	
95% CI of the inverse risk ratio	(0.40, 1.37)	(0.37, 1.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.68	9.38	
95% CI of the absolute risk difference	(-10.75, 30.12)	(-13.52, 32.27)	
p-value	0.3413	0.4058	
p-value of Breslow-Day Test for Homogeneity [3]	0.1631	0.7442	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	4 (18.2)	7 (11.1)
No	27 (90.0)	18 (81.8)	56 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	0.56	
95% CI of the inverse odds ratio	(0.27, 4.69)	(0.15, 2.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.61	
95% CI of the inverse risk ratio	(0.31, 4.00)	(0.20, 1.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.11	7.07	
95% CI of the absolute risk difference	(-14.36, 12.14)	(-10.82, 24.96)	
p-value	0.8715	0.3950	
p-value of Breslow-Day Test for Homogeneity [3]	0.1680	0.5455	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (26.7)	6 (27.3)	16 (25.4)
No	22 (73.3)	16 (72.7)	47 (74.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.91	
95% CI of the inverse odds ratio	(0.35, 2.52)	(0.30, 2.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.93	
95% CI of the inverse risk ratio	(0.46, 1.97)	(0.42, 2.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.27	1.88	
95% CI of the absolute risk difference	(-17.86, 20.40)	(-19.62, 23.37)	
p-value	0.8959	0.8627	
p-value of Breslow-Day Test for Homogeneity [3]	0.0311	0.4944	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (13.3)	6 (27.3)	16 (25.4)
No	26 (86.7)	16 (72.7)	47 (74.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.21	0.91	
95% CI of the inverse odds ratio	(0.67, 7.32)	(0.30, 2.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.90	0.93	
95% CI of the inverse risk ratio	(0.70, 5.21)	(0.42, 2.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.06	1.88	
95% CI of the absolute risk difference	(-28.30, 4.17)	(-19.62, 23.37)	
p-value	0.1856	0.8627	
p-value of Breslow-Day Test for Homogeneity [3]	0.0763	0.8347	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	9 (40.9)	20 (31.7)
No	23 (76.7)	13 (59.1)	43 (68.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	0.67	
95% CI of the inverse odds ratio	(0.56, 4.15)	(0.25, 1.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.78	
95% CI of the inverse risk ratio	(0.65, 2.86)	(0.42, 1.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.41	9.16	
95% CI of the absolute risk difference	(-27.42, 10.59)	(-14.38, 32.70)	
p-value	0.4034	0.4351	
p-value of Breslow-Day Test for Homogeneity [3]	0.2937	0.5413	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (26.7)	4 (18.2)	9 (14.3)
No	22 (73.3)	18 (81.8)	54 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.46	0.75	
95% CI of the inverse odds ratio	(0.16, 1.34)	(0.21, 2.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	0.79	
95% CI of the inverse risk ratio	(0.23, 1.25)	(0.27, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.38	3.90	
95% CI of the absolute risk difference	(-5.65, 30.41)	(-14.39, 22.18)	
p-value	0.1487	0.6620	
p-value of Breslow-Day Test for Homogeneity [3]	0.3502	0.7316	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (30.0)	9 (40.9)	20 (31.7)
No	21 (70.0)	13 (59.1)	43 (68.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.67	
95% CI of the inverse odds ratio	(0.42, 2.79)	(0.25, 1.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.78	
95% CI of the inverse risk ratio	(0.55, 2.04)	(0.42, 1.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.75	9.16	
95% CI of the absolute risk difference	(-21.77, 18.28)	(-14.38, 32.70)	
p-value	0.8651	0.4351	
p-value of Breslow-Day Test for Homogeneity [3]	0.2305	0.0467	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (13.3)	3 (13.6)	14 (22.2)
No	26 (86.7)	19 (86.4)	49 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.86	1.81	
95% CI of the inverse odds ratio	(0.55, 6.22)	(0.47, 7.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	1.63	
95% CI of the inverse risk ratio	(0.60, 4.63)	(0.52, 5.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.89	-8.59	
95% CI of the absolute risk difference	(-24.81, 7.03)	(-26.22, 9.05)	
p-value	0.3105	0.3861	
p-value of Breslow-Day Test for Homogeneity [3]	0.2151	0.1289	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (30.0)	9 (40.9)	27 (42.9)
No	21 (70.0)	13 (59.1)	36 (57.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	1.08	
95% CI of the inverse odds ratio	(0.69, 4.42)	(0.40, 2.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.05	
95% CI of the inverse risk ratio	(0.77, 2.65)	(0.59, 1.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.86	-1.95	
95% CI of the absolute risk difference	(-33.31, 7.59)	(-25.85, 21.96)	
p-value	0.2341	0.8735	
p-value of Breslow-Day Test for Homogeneity [3]	0.2968	0.5886	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	5 (22.7)	5 (7.9)
No	27 (90.0)	17 (77.3)	58 (92.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.29	
95% CI of the inverse odds ratio	(0.17, 3.49)	(0.08, 1.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.35	
95% CI of the inverse risk ratio	(0.20, 3.10)	(0.11, 1.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.06	14.79	
95% CI of the absolute risk difference	(-10.58, 14.70)	(-3.95, 33.53)	
p-value	0.7401	0.0638	
p-value of Breslow-Day Test for Homogeneity [3]	0.1855	0.0471	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (13.3)	9 (40.9)	12 (19.0)
No	26 (86.7)	13 (59.1)	51 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	0.34	
95% CI of the inverse odds ratio	(0.45, 5.21)	(0.12, 0.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	0.47	
95% CI of the inverse risk ratio	(0.50, 4.06)	(0.23, 0.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.71	21.86	
95% CI of the absolute risk difference	(-21.27, 9.84)	(-0.86, 44.58)	
p-value	0.4949	0.0407	
p-value of Breslow-Day Test for Homogeneity [3]	0.2503	0.0381	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (13.3)	6 (27.3)	9 (14.3)
No	26 (86.7)	16 (72.7)	54 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.44	
95% CI of the inverse odds ratio	(0.31, 3.85)	(0.14, 1.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.52	
95% CI of the inverse risk ratio	(0.36, 3.20)	(0.21, 1.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.95	12.99	
95% CI of the absolute risk difference	(-15.87, 13.97)	(-7.53, 33.51)	
p-value	0.9015	0.1689	
p-value of Breslow-Day Test for Homogeneity [3]	0.1358	0.6177	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (20.0)	8 (36.4)	14 (22.2)
No	24 (80.0)	14 (63.6)	49 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	0.50	
95% CI of the inverse odds ratio	(0.39, 3.34)	(0.17, 1.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.61	
95% CI of the inverse risk ratio	(0.47, 2.60)	(0.30, 1.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.22	14.14	
95% CI of the absolute risk difference	(-19.84, 15.39)	(-8.43, 36.71)	
p-value	0.8074	0.1923	
p-value of Breslow-Day Test for Homogeneity [3]	0.3310	0.3601	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (20.0)	4 (18.2)	9 (14.3)
No	24 (80.0)	18 (81.8)	54 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.75	
95% CI of the inverse odds ratio	(0.21, 2.08)	(0.21, 2.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.79	
95% CI of the inverse risk ratio	(0.28, 1.82)	(0.27, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.71	3.90	
95% CI of the absolute risk difference	(-11.01, 22.43)	(-14.39, 22.18)	
p-value	0.4837	0.6620	
p-value of Breslow-Day Test for Homogeneity [3]	0.1301	0.3180	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (30.0)	7 (31.8)	22 (34.9)
No	21 (70.0)	15 (68.2)	41 (65.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.15	
95% CI of the inverse odds ratio	(0.49, 3.20)	(0.41, 3.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.10	
95% CI of the inverse risk ratio	(0.61, 2.21)	(0.55, 2.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.92	-3.10	
95% CI of the absolute risk difference	(-25.11, 15.27)	(-25.85, 19.64)	
p-value	0.6380	0.7916	
p-value of Breslow-Day Test for Homogeneity [3]	0.3282	0.5316	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	3 (13.6)	4 (6.3)
No	28 (93.3)	19 (86.4)	59 (93.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.43	
95% CI of the inverse odds ratio	(0.16, 5.49)	(0.09, 2.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.47	
95% CI of the inverse risk ratio	(0.18, 4.91)	(0.11, 1.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.32	7.29	
95% CI of the absolute risk difference	(-10.45, 11.08)	(-8.27, 22.84)	
p-value	0.9535	0.2844	
p-value of Breslow-Day Test for Homogeneity [3]	0.1897	0.1546	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	7 (31.8)	17 (27.0)
No	23 (76.7)	15 (68.2)	46 (73.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	0.79	
95% CI of the inverse odds ratio	(0.44, 3.34)	(0.28, 2.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	0.85	
95% CI of the inverse risk ratio	(0.54, 2.49)	(0.41, 1.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.65	4.83	
95% CI of the absolute risk difference	(-22.34, 15.04)	(-17.50, 27.17)	
p-value	0.7068	0.6645	
p-value of Breslow-Day Test for Homogeneity [3]	0.2331	0.4952	

AMNOG Table SE22.14a.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	3 (13.6)	3 (4.8)
No	27 (90.0)	19 (86.4)	60 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.45	0.32	
95% CI of the inverse odds ratio	(0.09, 2.38)	(0.06, 1.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	0.35	
95% CI of the inverse risk ratio	(0.10, 2.22)	(0.08, 1.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.24	8.87	
95% CI of the absolute risk difference	(-6.72, 17.19)	(-6.40, 24.15)	
p-value	0.3365	0.1618	
p-value of Breslow-Day Test for Homogeneity [3]	0.4232	0.5461	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	7 (31.8)	11 (17.5)
No	23 (76.7)	15 (68.2)	52 (82.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	0.45	
95% CI of the inverse odds ratio	(0.24, 2.02)	(0.15, 1.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.55	
95% CI of the inverse risk ratio	(0.32, 1.74)	(0.24, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.87	14.36	
95% CI of the absolute risk difference	(-11.93, 23.68)	(-7.24, 35.96)	
p-value	0.5028	0.1559	
p-value of Breslow-Day Test for Homogeneity [3]	0.0135	0.2891	

Madrigal Pharmaceuticals, Inc. Page 1 of 6
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.14a.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation
Physical Functioning



Patients with result at given visit			
MGL-3196 80 mg	45	47	38
MGL-3196 100 mg	39	38	32
Placebo	90	85	75

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 6
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.14a.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation
Role Physical



Patients with result at given visit			
MGL-3196 80 mg	45	47	38
MGL-3196 100 mg	39	38	32
Placebo	90	85	75

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 6
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.14a.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous
Physical Functioning



Patients with result at given visit			
MGL-3196 80 mg	73	73	66
MGL-3196 100 mg	66	64	51
Placebo	115	118	103

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 4 of 6
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.14a.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous
Role Physical



Patients with result at given visit			
MGL-3196 80 mg	73	73	66
MGL-3196 100 mg	66	64	51
Placebo	115	118	103

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 5 of 6
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.14a.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous
Physical Functioning



Patients with result at given visit			
MGL-3196 80 mg	30	27	25
MGL-3196 100 mg	21	22	21
Placebo	60	55	46

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 6 of 6
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE22.14a.5
Liver Disease Quality of Life SF-36 (SE22): Mean Profile of Results by Domain/Component;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous
Role Physical



Patients with result at given visit			
MGL-3196 80 mg	30	27	25
MGL-3196 100 mg	21	22	21
Placebo	60	55	46

Abbreviations: Abbreviations: SF-36 = 36-Item Short Form Survey; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Physical Functioning						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	72.98 (24.76)	70.00 (24.80)	74.23 (25.45)			
Median	75.00	75.00	85.00			
IQR: Q1, Q3	55.00, 95.00	55.00, 90.00	60.00, 95.00			
Min, Max	0.0, 100.0	10.0, 100.0	10.0, 100.0			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	74.49 (24.98)	70.86 (25.03)	74.71 (27.76)	1.15 (1.61)	0.24 (2.05)	0.01 (1.17)
Median	80.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 95.00	55.00, 90.00	60.00, 95.00	-10.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	5.0, 100.0	5.0, 100.0	0.0, 100.0	-50.0, 60.0	-65.0, 70.0	-70.0, 60.0
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	77.01 (26.77)	71.19 (25.85)	76.31 (24.98)	2.19 (1.56)	-0.22 (1.99)	0.51 (1.10)
Median	90.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 100.00	55.00, 90.00	65.00, 95.00	-5.00, 10.00	-5.00, 5.00	-5.00, 5.00
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-65.0, 45.0	-85.0, 40.0	-45.0, 55.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Role Physical						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	75.01 (26.12)	73.33 (25.98)	76.54 (25.60)			
Median	81.30	75.00	81.30			
IQR: Q1, Q3	50.00, 100.00	53.15, 100.00	62.50, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	73.41 (27.71)	72.93 (24.81)	76.03 (27.65)	-1.85 (1.66)	-1.58 (2.07)	-0.48 (1.40)
Median	81.30	75.00	87.50	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 100.00	56.30, 100.00	-12.50, 6.30	-12.50, 6.20	-6.30, 6.20
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.7, 50.0	-56.2, 68.7	-68.7, 87.5
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	76.66 (28.03)	73.96 (27.98)	75.69 (25.24)	0.12 (1.88)	0.00 (2.11)	-1.62 (1.40)
Median	90.65	81.30	81.30	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 100.00	56.30, 100.00	-6.20, 6.20	-6.30, 6.30	-12.50, 6.20
Min, Max	0.0, 100.0	6.3, 100.0	0.0, 100.0	-43.8, 81.2	-75.0, 50.0	-56.3, 68.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Bodily Pain						
Baseline						
m	124	112	223			
n	119	104	209			
Mean (SD)	65.3 (24.6)	62.3 (25.4)	65.1 (25.4)			
Median	62.0	62.0	72.0			
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	41.0, 84.0			
Min, Max	0, 100	0, 100	0, 100			
Week 24						
m	121	106	214			
n	117	102	204	114	95	194
Mean (SD/SE)	64.7 (26.2)	63.5 (23.6)	65.3 (25.7)	-1.0 (1.9)	-1.1 (2.0)	-0.5 (1.5)
Median	72.0	62.0	62.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	46.5, 84.0	-16.0, 10.0	-12.0, 10.0	-12.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-59, 68	-62, 64	-78, 78
Week 52						
m	112	96	200			
n	102	89	175	98	86	166
Mean (SD/SE)	68.0 (26.9)	67.4 (25.5)	67.7 (24.5)	1.3 (2.2)	3.9 (2.4)	2.1 (1.8)
Median	74.0	72.0	72.0	0	0	0
IQR: Q1, Q3	42.0, 100.0	51.0, 84.0	51.0, 84.0	-9.0, 11.0	-11.0, 12.0	-11.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-80, 68	-53, 69	-78, 78

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
General Health						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	59.96 (20.09)	53.05 (19.25)	58.03 (21.07)			
Median	62.00	52.00	62.00			
IQR: Q1, Q3	46.00, 73.50	38.50, 67.00	42.00, 72.00			
Min, Max	10.0, 100.0	10.0, 100.0	15.0, 100.0			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	60.27 (21.43)	53.96 (18.97)	58.94 (21.85)	0.27 (1.28)	1.04 (1.64)	1.06 (1.03)
Median	57.00	52.00	58.50	0	0	0
IQR: Q1, Q3	45.00, 77.00	40.00, 67.00	42.00, 77.00	-7.00, 10.00	-10.00, 10.00	-8.00, 10.00
Min, Max	10.0, 100.0	10.0, 92.0	0.0, 100.0	-60.0, 32.0	-35.0, 40.0	-40.0, 48.0
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	63.39 (20.17)	55.93 (20.35)	60.17 (21.63)	2.39 (1.57)	2.17 (1.96)	1.69 (1.07)
Median	67.00	57.00	62.00	0	4.00	0
IQR: Q1, Q3	52.00, 77.00	40.00, 72.00	47.00, 77.00	-5.00, 10.00	-10.00, 15.00	-5.00, 10.00
Min, Max	20.0, 100.0	10.0, 92.0	10.0, 100.0	-70.0, 47.0	-52.0, 47.0	-42.0, 32.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Vitality						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	57.80 (22.91)	52.73 (23.16)	56.50 (21.35)			
Median	62.50	56.30	62.50			
IQR: Q1, Q3	37.50, 75.00	37.50, 68.80	43.80, 75.00			
Min, Max	6.3, 100.0	0.0, 93.8	6.3, 100.0			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	57.02 (24.24)	52.35 (19.43)	56.12 (22.56)	-1.10 (1.40)	-0.60 (1.60)	-0.66 (1.08)
Median	62.50	56.30	56.30	0	0	0
IQR: Q1, Q3	43.80, 75.00	37.50, 62.50	37.50, 75.00	-6.30, 6.30	-12.50, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.8, 43.8	-31.3, 43.8	-37.5, 56.2
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	60.07 (22.78)	54.24 (21.60)	57.27 (21.62)	0.00 (1.68)	0.50 (1.71)	0.62 (1.28)
Median	62.50	56.30	62.50	0	0	0
IQR: Q1, Q3	43.80, 75.00	43.80, 68.80	43.80, 75.00	-12.50, 12.50	-6.30, 6.30	-6.30, 12.50
Min, Max	6.3, 100.0	6.3, 100.0	0.0, 100.0	-43.7, 50.0	-43.8, 43.8	-43.7, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Social Functioning						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	79.48 (24.08)	78.25 (26.19)	82.95 (22.44)			
Median	87.50	87.50	87.50			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	12.5, 100.0			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	79.81 (24.83)	81.00 (20.72)	80.09 (24.77)	-0.33 (2.05)	1.71 (2.20)	-2.58 (1.26)
Median	87.50	87.50	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	62.50, 100.00	-12.50, 12.50	0.00, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	12.5, 100.0	0.0, 100.0	-62.5, 75.0	-62.5, 87.5	-62.5, 50.0
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	81.50 (23.32)	81.74 (22.85)	82.14 (22.20)	-0.51 (1.85)	2.91 (2.56)	-1.73 (1.43)
Median	87.50	100.00	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	62.50, 100.00	0.00, 12.50	0.00, 12.50	0.00, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-50.0, 50.0	-62.5, 62.5	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Role Emotional						
Baseline						
m	124	112	223			
n	120	104	208			
Mean (SD)	81.32 (24.45)	81.33 (22.97)	83.73 (22.73)			
Median	91.70	91.70	100.00			
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	16.7, 100.0	0.0, 100.0			
Week 24						
m	121	106	214			
n	117	102	204	115	95	193
Mean (SD/SE)	80.70 (22.86)	83.58 (21.48)	82.19 (25.00)	-0.94 (1.72)	2.37 (1.62)	-1.17 (1.23)
Median	83.30	91.70	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	66.70, 100.00	-8.30, 0.00	0.00, 8.30	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-66.7, 66.7	-50.0, 41.7	-50.0, 50.0
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	83.78 (21.35)	85.30 (21.62)	82.95 (22.55)	1.05 (1.44)	4.36 (2.17)	-1.21 (1.32)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 8.30	0.00, 16.70	-8.40, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-33.3, 50.0	-50.0, 58.3	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Mental Health						
Baseline						
m	124	112	223			
n	120	104	209			
Mean (SD)	73.3 (20.5)	74.3 (19.8)	75.4 (17.2)			
Median	80.0	80.0	80.0			
IQR: Q1, Q3	60.0, 90.0	65.0, 90.0	65.0, 90.0			
Min, Max	10, 100	15, 100	5, 100			
Week 24						
m	121	106	214			
n	117	102	204	115	95	194
Mean (SD/SE)	72.4 (20.5)	74.5 (18.8)	74.2 (19.3)	-1.1 (1.3)	-0.4 (1.3)	-0.9 (1.0)
Median	75.0	80.0	80.0	0	0	0
IQR: Q1, Q3	60.0, 90.0	65.0, 90.0	65.0, 90.0	-10.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	15, 100	5, 100	5, 100	-40, 35	-40, 50	-45, 55
Week 52						
m	112	96	200			
n	102	89	175	99	86	166
Mean (SD/SE)	75.5 (17.7)	74.7 (18.6)	75.9 (18.3)	0.7 (1.4)	0.1 (1.4)	0.6 (1.0)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	70.0, 85.0	-5.0, 10.0	-5.0, 5.0	-10.0, 10.0
Min, Max	30, 100	20, 100	15, 100	-35, 40	-30, 50	-40, 55

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Mental Component Score						
Baseline						
m	124	112	223			
n	119	104	208			
Mean (SD)	50.28 (10.91)	50.29 (11.19)	51.29 (9.22)			
Median	53.10	53.65	54.10			
IQR: Q1, Q3	44.30, 58.50	45.40, 58.15	46.00, 57.85			
Min, Max	12.9, 69.0	17.0, 70.0	15.6, 66.5			
Week 24						
m	121	106	214			
n	117	102	204	114	95	193
Mean (SD/SE)	49.79 (10.62)	50.90 (9.90)	50.30 (10.49)	-0.70 (0.70)	0.53 (0.74)	-0.76 (0.51)
Median	51.50	52.95	52.95	-0.85	-0.20	-0.10
IQR: Q1, Q3	43.40, 58.20	46.00, 58.70	43.25, 58.25	-4.90, 3.40	-3.00, 3.50	-4.30, 2.70
Min, Max	18.7, 69.1	9.4, 68.3	14.2, 69.0	-20.0, 19.0	-24.5, 26.1	-23.5, 24.8
Week 52						
m	112	96	200			
n	102	89	175	98	86	166
Mean (SD/SE)	51.15 (9.30)	51.29 (9.75)	50.98 (9.53)	-0.04 (0.65)	1.02 (0.91)	-0.25 (0.54)
Median	53.70	52.90	53.60	0.10	-0.05	0.25
IQR: Q1, Q3	44.30, 58.30	45.60, 58.60	46.10, 57.80	-3.80, 3.70	-3.70, 5.00	-4.20, 3.60
Min, Max	23.1, 63.2	17.8, 68.1	21.0, 64.6	-17.3, 20.4	-15.2, 25.2	-21.4, 26.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Physical Component Score						
Baseline						
m	124	112	223			
n	119	104	208			
Mean (SD)	47.26 (9.02)	45.15 (9.43)	46.95 (9.65)			
Median	47.80	46.15	48.85			
IQR: Q1, Q3	42.30, 55.20	39.55, 52.35	40.50, 54.90			
Min, Max	15.3, 59.4	21.2, 60.4	20.7, 61.2			
Week 24						
m	121	106	214			
n	117	102	204	114	95	193
Mean (SD/SE)	47.39 (10.07)	45.29 (8.91)	47.33 (10.02)	0.06 (0.60)	-0.33 (0.73)	0.15 (0.49)
Median	49.50	45.95	49.70	0.60	-0.10	0.10
IQR: Q1, Q3	41.70, 54.60	38.60, 52.10	41.50, 55.20	-3.70, 3.90	-3.50, 3.30	-3.10, 3.00
Min, Max	12.5, 63.9	24.6, 61.0	19.0, 62.9	-17.2, 18.3	-22.1, 21.7	-28.8, 23.8
Week 52						
m	112	96	200			
n	102	89	175	98	86	166
Mean (SD/SE)	48.43 (10.78)	46.07 (9.94)	47.76 (9.16)	0.73 (0.68)	0.37 (0.83)	0.39 (0.46)
Median	53.00	48.00	49.00	0.75	1.55	0.30
IQR: Q1, Q3	41.80, 57.50	39.90, 53.40	42.70, 55.10	-1.60, 3.80	-2.70, 5.00	-3.10, 3.40
Min, Max	15.8, 62.8	16.0, 61.2	22.5, 61.7	-24.7, 22.5	-23.5, 14.8	-23.9, 20.5

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Physical Functioning						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	79.13 (20.92)	71.00 (25.88)	72.91 (26.89)			
Median	85.00	80.00	85.00			
IQR: Q1, Q3	75.00, 90.00	55.00, 90.00	50.00, 95.00			
Min, Max	25.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	78.20 (21.74)	76.75 (20.60)	75.19 (27.21)	1.82 (3.06)	5.59 (4.71)	2.02 (3.22)
Median	85.00	80.00	85.00	0	5.00	0
IQR: Q1, Q3	75.00, 95.00	62.50, 95.00	55.00, 100.00	-5.00, 10.00	0.00, 15.00	-5.00, 10.00
Min, Max	25.0, 100.0	30.0, 100.0	5.0, 100.0	-30.0, 40.0	-30.0, 60.0	-40.0, 75.0
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	72.95 (27.67)	71.79 (24.93)	75.08 (24.83)	-2.25 (3.74)	3.75 (5.00)	0.79 (3.46)
Median	85.00	75.00	85.00	0	2.50	0
IQR: Q1, Q3	45.00, 95.00	60.00, 90.00	55.00, 95.00	-10.00, 10.00	-7.50, 12.50	-10.00, 5.00
Min, Max	20.0, 100.0	5.0, 100.0	20.0, 100.0	-45.0, 20.0	-25.0, 35.0	-60.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Role Physical						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	76.91 (27.40)	74.08 (28.69)	72.18 (28.32)			
Median	81.30	81.25	81.30			
IQR: Q1, Q3	75.00, 100.00	62.55, 100.00	43.80, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	6.3, 100.0			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	75.26 (24.16)	77.20 (21.58)	74.67 (26.52)	0.29 (4.70)	3.31 (5.33)	0.93 (3.52)
Median	75.00	84.40	78.15	0	0	0
IQR: Q1, Q3	68.80, 100.00	53.15, 100.00	50.00, 100.00	-6.30, 12.50	-12.50, 0.00	-6.30, 6.30
Min, Max	25.0, 100.0	37.5, 100.0	6.3, 100.0	-43.8, 43.7	-25.0, 62.5	-50.0, 68.7
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	72.45 (26.84)	73.69 (21.53)	73.48 (25.24)	-2.19 (3.61)	4.18 (8.58)	1.74 (3.89)
Median	75.00	81.30	75.00	0	-3.10	0
IQR: Q1, Q3	50.00, 100.00	68.80, 81.30	50.00, 100.00	-12.50, 6.20	-9.40, 6.30	-6.20, 12.50
Min, Max	0.0, 100.0	18.8, 100.0	25.0, 100.0	-37.5, 25.0	-37.5, 81.3	-62.5, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Bodily Pain						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	70.7 (23.7)	59.9 (30.4)	63.0 (24.2)			
Median	74.0	62.0	62.0			
IQR: Q1, Q3	51.0, 84.0	36.0, 84.0	41.0, 84.0			
Min, Max	12, 100	12, 100	12, 100			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	62.3 (22.2)	70.4 (25.6)	66.8 (25.4)	-6.1 (3.4)	12.4 (5.9)	4.1 (2.9)
Median	62.0	74.0	73.0	-5.0	2.0	0
IQR: Q1, Q3	51.0, 74.0	50.5, 92.0	41.0, 84.0	-20.0, 0.0	0.0, 26.0	-10.0, 19.0
Min, Max	22, 100	22, 100	21, 100	-43, 31	-26, 72	-31, 59
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	67.2 (21.6)	65.0 (24.5)	64.9 (26.2)	-2.5 (3.7)	8.4 (6.6)	0.8 (3.1)
Median	62.0	62.0	72.0	0	3.0	0
IQR: Q1, Q3	51.0, 84.0	52.0, 84.0	41.0, 84.0	-11.0, 10.0	-4.5, 18.5	-16.0, 12.0
Min, Max	22, 100	10, 100	10, 100	-38, 31	-28, 49	-48, 48

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
General Health						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	59.73 (18.30)	62.00 (16.37)	58.73 (17.51)			
Median	62.00	61.00	57.00			
IQR: Q1, Q3	45.00, 72.00	47.00, 77.00	45.00, 72.00			
Min, Max	15.0, 92.0	37.0, 87.0	30.0, 92.0			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	62.84 (18.31)	63.45 (19.16)	59.44 (20.69)	6.83 (2.89)	3.47 (3.97)	0.23 (2.30)
Median	62.00	64.50	62.00	5.00	5.00	0
IQR: Q1, Q3	52.00, 77.00	46.00, 79.50	47.00, 77.00	0.00, 17.00	-5.00, 15.00	-10.00, 10.00
Min, Max	25.0, 92.0	37.0, 100.0	15.0, 100.0	-25.0, 32.0	-35.0, 27.0	-37.0, 37.0
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	59.27 (17.55)	59.14 (13.58)	60.04 (18.94)	1.26 (2.52)	-0.17 (3.19)	1.65 (1.96)
Median	62.00	56.00	57.00	0	1.50	0
IQR: Q1, Q3	45.00, 77.00	47.00, 67.00	50.00, 77.00	-5.00, 10.00	-7.50, 7.50	-5.00, 7.00
Min, Max	25.0, 87.0	42.0, 87.0	15.0, 95.0	-15.0, 32.0	-20.0, 15.0	-30.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Vitality						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	57.09 (22.24)	55.02 (19.19)	54.34 (22.37)			
Median	62.50	50.00	56.30			
IQR: Q1, Q3	43.80, 68.80	40.65, 71.90	37.50, 68.80			
Min, Max	0.0, 93.8	25.0, 100.0	0.0, 100.0			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	53.53 (23.32)	58.47 (22.15)	58.35 (20.49)	-0.56 (2.28)	1.48 (4.78)	2.79 (2.58)
Median	56.30	65.65	62.50	0	0	0
IQR: Q1, Q3	37.50, 68.80	43.75, 75.00	43.80, 75.00	-6.20, 6.20	-12.50, 12.50	-6.30, 12.50
Min, Max	0.0, 93.8	12.5, 81.3	12.5, 100.0	-18.8, 25.0	-25.0, 43.8	-37.5, 43.7
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	54.57 (22.26)	53.59 (16.21)	56.53 (25.61)	0.63 (1.86)	-2.09 (4.10)	1.17 (3.34)
Median	56.30	50.00	56.30	0	-3.10	0
IQR: Q1, Q3	37.50, 75.00	43.80, 62.50	43.80, 75.00	-3.10, 6.25	-9.40, 9.35	-6.30, 12.50
Min, Max	6.3, 93.8	25.0, 81.3	0.0, 100.0	-18.7, 12.5	-25.0, 18.8	-56.3, 43.8

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Social Functioning						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	89.67 (21.86)	83.13 (22.31)	80.68 (24.27)			
Median	100.00	87.50	100.00			
IQR: Q1, Q3	87.50, 100.00	75.00, 100.00	62.50, 100.00			
Min, Max	12.5, 100.0	37.5, 100.0	25.0, 100.0			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	83.50 (26.69)	81.88 (18.79)	85.19 (24.05)	-1.70 (3.88)	1.47 (4.53)	2.93 (3.92)
Median	100.00	81.25	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	-12.50, 12.50	0.00, 12.50
Min, Max	12.5, 100.0	37.5, 100.0	12.5, 100.0	-50.0, 37.5	-25.0, 37.5	-62.5, 75.0
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	81.82 (22.73)	83.93 (17.97)	84.18 (22.36)	-4.38 (3.18)	-2.08 (5.06)	4.65 (3.70)
Median	100.00	87.50	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	-12.50, 12.50	0.00, 12.50
Min, Max	25.0, 100.0	50.0, 100.0	12.5, 100.0	-50.0, 12.5	-37.5, 25.0	-37.5, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Role Emotional						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	81.52 (29.51)	82.92 (24.86)	83.33 (22.16)			
Median	100.00	95.85	100.00			
IQR: Q1, Q3	75.00, 100.00	70.85, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	8.3, 100.0	16.7, 100.0			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	82.33 (25.04)	90.84 (18.12)	84.72 (20.78)	5.69 (3.26)	4.91 (3.65)	0.00 (3.59)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	58.30, 100.00	87.50, 100.00	75.00, 100.00	0.00, 16.70	0.00, 16.60	-16.60, 8.30
Min, Max	25.0, 100.0	25.0, 100.0	16.7, 100.0	-25.0, 50.0	-25.0, 41.7	-50.0, 58.3
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	81.82 (20.99)	83.34 (24.69)	81.12 (24.46)	4.59 (6.21)	1.39 (9.39)	-4.46 (3.77)
Median	87.50	95.85	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	58.30, 100.00	58.30, 100.00	0.00, 0.00	0.00, 16.65	-16.70, 0.00
Min, Max	33.3, 100.0	25.0, 100.0	16.7, 100.0	-33.3, 100.0	-75.0, 50.0	-58.3, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Mental Health						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	74.3 (19.3)	77.3 (17.4)	72.7 (20.2)			
Median	75.0	82.5	80.0			
IQR: Q1, Q3	65.0, 85.0	62.5, 90.0	60.0, 90.0			
Min, Max	5, 100	35, 95	20, 100			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	73.8 (19.6)	79.0 (19.2)	75.9 (17.7)	3.4 (2.9)	-0.9 (3.6)	3.0 (2.5)
Median	80.0	82.5	80.0	5.0	0	0
IQR: Q1, Q3	65.0, 90.0	70.0, 95.0	70.0, 90.0	0.0, 10.0	-5.0, 5.0	-5.0, 10.0
Min, Max	30, 100	20, 100	20, 100	-30, 35	-35, 30	-35, 50
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	73.2 (19.2)	78.2 (18.6)	75.9 (22.1)	1.8 (2.5)	-3.3 (3.5)	2.2 (3.1)
Median	80.0	85.0	80.0	2.5	0	0
IQR: Q1, Q3	60.0, 90.0	65.0, 95.0	70.0, 90.0	-5.0, 7.5	-12.5, 5.0	-5.0, 20.0
Min, Max	25, 95	30, 95	0, 100	-20, 20	-25, 15	-40, 50

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Mental Component Score						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	50.72 (11.61)	52.02 (9.71)	50.42 (10.07)			
Median	55.10	55.95	52.40			
IQR: Q1, Q3	47.30, 57.80	43.60, 60.15	45.60, 58.20			
Min, Max	12.0, 61.9	34.2, 64.5	26.6, 64.3			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	50.11 (11.39)	53.08 (9.05)	51.95 (9.79)	1.65 (1.35)	-0.16 (1.51)	1.00 (1.46)
Median	54.10	55.00	55.65	1.95	-0.20	0
IQR: Q1, Q3	45.10, 59.20	50.60, 58.90	50.30, 58.10	-2.30, 6.00	-2.70, 2.90	-4.10, 7.50
Min, Max	26.2, 64.6	21.2, 61.8	23.1, 63.3	-12.0, 14.2	-13.0, 9.4	-24.6, 21.4
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	50.23 (9.87)	52.02 (9.68)	51.12 (12.27)	1.25 (1.93)	-1.91 (2.40)	0.19 (1.55)
Median	53.20	55.90	54.80	0.05	-1.70	0.20
IQR: Q1, Q3	41.40, 57.50	44.50, 58.20	46.80, 59.10	-2.25, 3.95	-5.60, 1.65	-3.70, 5.20
Min, Max	26.9, 61.7	27.0, 62.0	8.9, 68.0	-15.5, 26.2	-21.4, 11.7	-24.6, 24.1

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Physical Component Score						
Baseline						
m	26	24	62			
n	23	20	55			
Mean (SD)	48.95 (7.81)	45.71 (10.87)	46.28 (9.14)			
Median	49.70	46.45	47.40			
IQR: Q1, Q3	45.30, 54.30	39.55, 54.85	36.70, 52.80			
Min, Max	29.8, 60.8	21.9, 61.3	28.2, 65.2			
Week 24						
m	25	21	58			
n	25	20	54	22	17	47
Mean (SD/SE)	47.87 (7.57)	47.78 (8.19)	47.10 (10.57)	-0.48 (1.16)	3.06 (2.48)	0.68 (1.07)
Median	48.70	48.85	50.05	-1.80	-0.60	0.60
IQR: Q1, Q3	43.40, 54.00	40.65, 55.75	39.20, 55.10	-5.00, 3.50	-3.10, 3.80	-3.30, 4.10
Min, Max	31.8, 58.9	35.5, 60.2	24.4, 63.0	-9.7, 10.9	-7.7, 32.4	-11.7, 22.9
Week 52						
m	25	17	55			
n	22	14	49	20	12	43
Mean (SD/SE)	47.00 (9.73)	45.94 (8.54)	47.03 (9.97)	-1.35 (1.43)	2.45 (2.45)	0.75 (0.99)
Median	49.20	45.15	46.90	-0.55	0.75	0.50
IQR: Q1, Q3	41.90, 54.10	41.40, 51.40	41.20, 55.90	-4.10, 2.50	-3.60, 6.00	-2.00, 3.80
Min, Max	23.2, 61.4	26.7, 58.4	21.5, 63.9	-22.4, 6.6	-6.8, 18.6	-17.9, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Physical Functioning						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	84.00 (12.45)	60.00 (49.50)	80.00 (N/A)			
Median	85.00	60.00	80.00			
IQR: Q1, Q3	80.00, 95.00	25.00, 95.00	80.00, 80.00			
Min, Max	65.0, 95.0	25.0, 95.0	80.0, 80.0			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	84.00 (18.84)	70.00 (7.07)	N/A	0.00 (4.18)	10.00 (30.00)	N/A
Median	95.00	70.00	N/A	0	10.00	N/A
IQR: Q1, Q3	75.00, 95.00	65.00, 75.00	N/A	-5.00, 0.00	-20.00, 40.00	N/A
Min, Max	55.0, 100.0	65.0, 75.0	N/A	-10.0, 15.0	-20.0, 40.0	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	79.00 (11.94)	95.00 (N/A)	N/A	-5.00 (1.58)	0.00 (N/A)	N/A
Median	85.00	95.00	N/A	-5.00	0	N/A
IQR: Q1, Q3	75.00, 85.00	95.00, 95.00	N/A	-5.00, -5.00	0.00, 0.00	N/A
Min, Max	60.0, 90.0	95.0, 95.0	N/A	-10.0, 0.0	0.0, 0.0	N/A

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Role Physical						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	88.76 (11.17)	71.90 (30.97)	50.00 (N/A)			
Median	87.50	71.90	50.00			
IQR: Q1, Q3	81.30, 100.00	50.00, 93.80	50.00, 50.00			
Min, Max	75.0, 100.0	50.0, 93.8	50.0, 50.0			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	77.50 (13.69)	75.00 (17.68)	N/A	-11.26 (6.96)	3.10 (9.40)	N/A
Median	75.00	75.00	N/A	-6.30	3.10	N/A
IQR: Q1, Q3	75.00, 75.00	62.50, 87.50	N/A	-12.50, 0.00	-6.30, 12.50	N/A
Min, Max	62.5, 100.0	62.5, 87.5	N/A	-37.5, 0.0	-6.3, 12.5	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	78.76 (17.47)	87.50 (N/A)	N/A	-10.00 (5.81)	-6.30 (N/A)	N/A
Median	87.50	87.50	N/A	-6.20	-6.30	N/A
IQR: Q1, Q3	75.00, 87.50	87.50, 87.50	N/A	-12.50, 0.00	-6.30, -6.30	N/A
Min, Max	50.0, 93.8	87.5, 87.5	N/A	-31.3, 0.0	-6.3, -6.3	N/A

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Bodily Pain						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	70.8 (9.2)	79.0 (7.1)	41.0 (N/A)			
Median	72.0	79.0	41.0			
IQR: Q1, Q3	62.0, 74.0	74.0, 84.0	41.0, 41.0			
Min, Max	62, 84	74, 84	41, 41			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	65.2 (25.8)	68.0 (8.5)	N/A	-5.6 (13.3)	-11.0 (1.0)	N/A
Median	74.0	68.0	N/A	-10.0	-11.0	N/A
IQR: Q1, Q3	62.0, 84.0	62.0, 74.0	N/A	-12.0, 22.0	-12.0, -10.0	N/A
Min, Max	22, 84	62, 74	N/A	-50, 22	-12, -10	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	72.8 (11.0)	100.0 (N/A)	N/A	2.0 (2.0)	16.0 (N/A)	N/A
Median	72.0	100.0	N/A	0	16.0	N/A
IQR: Q1, Q3	62.0, 84.0	100.0, 100.0	N/A	0.0, 0.0	16.0, 16.0	N/A
Min, Max	62, 84	100, 100	N/A	0, 10	16, 16	N/A

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
General Health						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	69.00 (18.23)	79.50 (10.61)	57.00 (N/A)			
Median	62.00	79.50	57.00			
IQR: Q1, Q3	57.00, 77.00	72.00, 87.00	57.00, 57.00			
Min, Max	52.0, 97.0	72.0, 87.0	57.0, 57.0			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	58.60 (25.16)	69.50 (24.75)	N/A	-10.40 (10.30)	-10.00 (25.00)	N/A
Median	72.00	69.50	N/A	-5.00	-10.00	N/A
IQR: Q1, Q3	47.00, 72.00	52.00, 87.00	N/A	-25.00, 5.00	-35.00, 15.00	N/A
Min, Max	20.0, 82.0	52.0, 87.0	N/A	-42.0, 15.0	-35.0, 15.0	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	56.60 (23.04)	62.00 (N/A)	N/A	-12.40 (6.42)	-25.00 (N/A)	N/A
Median	57.00	62.00	N/A	-10.00	-25.00	N/A
IQR: Q1, Q3	47.00, 67.00	62.00, 62.00	N/A	-10.00, -5.00	-25.00, -25.00	N/A
Min, Max	25.0, 87.0	62.0, 62.0	N/A	-37.0, 0.0	-25.0, -25.0	N/A

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Vitality						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	58.78 (19.06)	65.65 (4.45)	37.50 (N/A)			
Median	56.30	65.65	37.50			
IQR: Q1, Q3	43.80, 75.00	62.50, 68.80	37.50, 37.50			
Min, Max	37.5, 81.3	62.5, 68.8	37.5, 37.5			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	52.54 (17.47)	59.40 (4.38)	N/A	-6.24 (10.28)	-6.25 (0.05)	N/A
Median	56.30	59.40	N/A	-6.20	-6.25	N/A
IQR: Q1, Q3	37.50, 68.80	56.30, 62.50	N/A	-6.20, 12.50	-6.30, -6.20	N/A
Min, Max	31.3, 68.8	56.3, 62.5	N/A	-43.8, 12.5	-6.3, -6.2	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	58.76 (22.35)	68.80 (N/A)	N/A	-0.02 (4.83)	0.00 (N/A)	N/A
Median	75.00	68.80	N/A	-6.20	0	N/A
IQR: Q1, Q3	37.50, 75.00	68.80, 68.80	N/A	-6.30, 0.00	0.00, 0.00	N/A
Min, Max	31.3, 75.0	68.8, 68.8	N/A	-6.3, 18.7	0.0, 0.0	N/A

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Social Functioning						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	90.00 (16.30)	100.00 (0.00)	87.50 (N/A)			
Median	100.00	100.00	87.50			
IQR: Q1, Q3	87.50, 100.00	100.00, 100.00	87.50, 87.50			
Min, Max	62.5, 100.0	100.0, 100.0	87.5, 87.5			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	80.00 (27.39)	87.50 (17.68)	N/A	-10.00 (10.75)	-12.50 (12.50)	N/A
Median	100.00	87.50	N/A	0	-12.50	N/A
IQR: Q1, Q3	50.00, 100.00	75.00, 100.00	N/A	-12.50, 0.00	-25.00, 0.00	N/A
Min, Max	50.0, 100.0	75.0, 100.0	N/A	-50.0, 12.5	-25.0, 0.0	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	85.00 (20.54)	75.00 (N/A)	N/A	-5.00 (3.06)	-25.00 (N/A)	N/A
Median	87.50	75.00	N/A	0	-25.00	N/A
IQR: Q1, Q3	87.50, 100.00	75.00, 75.00	N/A	-12.50, 0.00	-25.00, -25.00	N/A
Min, Max	50.0, 100.0	75.0, 75.0	N/A	-12.5, 0.0	-25.0, -25.0	N/A

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Role Emotional						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	90.00 (22.36)	95.85 (5.87)	75.00 (N/A)			
Median	100.00	95.85	75.00			
IQR: Q1, Q3	100.00, 100.00	91.70, 100.00	75.00, 75.00			
Min, Max	50.0, 100.0	91.7, 100.0	75.0, 75.0			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	81.68 (26.60)	87.50 (17.68)	N/A	-8.32 (6.45)	-8.35 (8.35)	N/A
Median	100.00	87.50	N/A	0	-8.35	N/A
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	N/A	-8.30, 0.00	-16.70, 0.00	N/A
Min, Max	41.7, 100.0	75.0, 100.0	N/A	-33.3, 0.0	-16.7, 0.0	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	86.66 (21.73)	66.70 (N/A)	N/A	-3.34 (3.34)	-25.00 (N/A)	N/A
Median	100.00	66.70	N/A	0	-25.00	N/A
IQR: Q1, Q3	83.30, 100.00	66.70, 66.70	N/A	0.00, 0.00	-25.00, -25.00	N/A
Min, Max	50.0, 100.0	66.7, 66.7	N/A	-16.7, 0.0	-25.0, -25.0	N/A

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Mental Health						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	81.0 (18.2)	85.0 (14.1)	80.0 (N/A)			
Median	90.0	85.0	80.0			
IQR: Q1, Q3	80.0, 90.0	75.0, 95.0	80.0, 80.0			
Min, Max	50, 95	75, 95	80, 80			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	69.0 (17.1)	85.0 (7.1)	N/A	-12.0 (5.6)	0.0 (5.0)	N/A
Median	75.0	85.0	N/A	-5.0	0	N/A
IQR: Q1, Q3	60.0, 75.0	80.0, 90.0	N/A	-20.0, -5.0	-5.0, 5.0	N/A
Min, Max	45, 90	80, 90	N/A	-30, 0	-5, 5	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	77.0 (18.6)	60.0 (N/A)	N/A	-4.0 (1.9)	-15.0 (N/A)	N/A
Median	80.0	60.0	N/A	-5.0	-15.0	N/A
IQR: Q1, Q3	80.0, 90.0	60.0, 60.0	N/A	-5.0, 0.0	-15.0, -15.0	N/A
Min, Max	45, 90	60, 60	N/A	-10, 0	-15, -15	N/A

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Mental Component Score						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	53.14 (12.13)	59.55 (10.25)	50.80 (N/A)			
Median	59.10	59.55	50.80			
IQR: Q1, Q3	53.90, 59.40	52.30, 66.80	50.80, 50.80			
Min, Max	32.0, 61.3	52.3, 66.8	50.8, 50.8			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	47.62 (13.85)	55.45 (7.99)	N/A	-5.52 (3.72)	-4.10 (1.60)	N/A
Median	51.80	55.45	N/A	-2.60	-4.10	N/A
IQR: Q1, Q3	39.40, 56.50	49.80, 61.10	N/A	-4.00, -2.10	-5.70, -2.50	N/A
Min, Max	28.0, 62.4	49.8, 61.1	N/A	-20.0, 1.1	-5.7, -2.5	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	51.88 (12.55)	41.10 (N/A)	N/A	-1.26 (1.09)	-11.20 (N/A)	N/A
Median	54.40	41.10	N/A	-1.40	-11.20	N/A
IQR: Q1, Q3	52.20, 60.40	41.10, 41.10	N/A	-1.70, 0.50	-11.20, -11.20	N/A
Min, Max	30.6, 61.8	41.1, 41.1	N/A	-5.0, 1.3	-11.2, -11.2	N/A

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Physical Component Score						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	50.92 (3.53)	46.30 (16.26)	41.20 (N/A)			
Median	49.00	46.30	41.20			
IQR: Q1, Q3	48.70, 51.90	34.80, 57.80	41.20, 41.20			
Min, Max	48.3, 56.7	34.8, 57.8	41.2, 41.2			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	49.56 (6.53)	46.35 (3.89)	N/A	-1.36 (3.01)	0.05 (8.75)	N/A
Median	49.80	46.35	N/A	-1.70	0.05	N/A
IQR: Q1, Q3	44.70, 55.00	43.60, 49.10	N/A	-4.00, 1.50	-8.70, 8.80	N/A
Min, Max	41.5, 56.8	43.6, 49.1	N/A	-10.4, 7.8	-8.7, 8.8	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	48.38 (2.31)	60.00 (N/A)	N/A	-2.54 (0.76)	2.20 (N/A)	N/A
Median	47.50	60.00	N/A	-2.00	2.20	N/A
IQR: Q1, Q3	47.10, 48.20	60.00, 60.00	N/A	-4.30, -1.20	2.20, 2.20	N/A
Min, Max	46.7, 52.4	60.0, 60.0	N/A	-4.4, -0.8	2.2, 2.2	N/A

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Physical Functioning			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	73.11 (24.65)	70.37 (24.65)	75.10 (25.33)
Analysis Visit Mean (SD)	74.26 (25.08)	70.61 (24.78)	75.11 (27.66)
LS Mean of Change from Baseline (SE)	1.36 (1.60)	-0.53 (1.74)	0.37 (1.24)
95% CI	(-1.79, 4.51)	(-3.95, 2.88)	(-2.07, 2.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.99 (1.98)	-0.91 (2.11)	
95% CI	(-2.90, 4.88)	(-5.05, 3.24)	
p-value	0.6167	0.6679	
Corrected Hedge's g Statistics	0.057	-0.052	
95% CI	(-0.17, 0.29)	(-0.30, 0.19)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	74.52 (23.22)	70.64 (25.11)	75.75 (24.31)
Analysis Visit Mean (SD)	76.72 (26.98)	70.42 (25.93)	76.27 (24.87)
LS Mean of Change from Baseline (SE)	2.62 (1.56)	-0.33 (1.66)	0.92 (1.22)
95% CI	(-0.45, 5.70)	(-3.59, 2.93)	(-1.47, 3.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.70 (1.92)	-1.25 (2.03)	
95% CI	(-2.08, 5.48)	(-5.24, 2.73)	
p-value	0.3780	0.5361	
Corrected Hedge's g Statistics	0.108	-0.080	
95% CI	(-0.14, 0.36)	(-0.34, 0.18)	
Subgroup*Treatment Interaction p-value	0.8800	0.2958	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Role Physical			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	75.39 (25.90)	74.29 (25.89)	76.79 (25.73)
Analysis Visit Mean (SD)	73.55 (27.56)	72.71 (25.32)	76.30 (27.53)
LS Mean of Change from Baseline (SE)	-1.12 (1.74)	-2.00 (1.88)	0.24 (1.35)
95% CI	(-4.54, 2.30)	(-5.71, 1.70)	(-2.41, 2.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.36 (2.14)	-2.25 (2.28)	
95% CI	(-5.57, 2.86)	(-6.73, 2.24)	
p-value	0.5264	0.3254	
Corrected Hedge's g Statistics	-0.072	-0.120	
95% CI	(-0.30, 0.16)	(-0.37, 0.13)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	76.53 (26.56)	73.56 (26.40)	77.61 (24.59)
Analysis Visit Mean (SD)	76.65 (28.14)	73.56 (28.12)	75.99 (25.12)
LS Mean of Change from Baseline (SE)	0.83 (1.79)	0.11 (1.90)	-0.53 (1.39)
95% CI	(-2.68, 4.34)	(-3.62, 3.84)	(-3.25, 2.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.36 (2.20)	0.64 (2.31)	
95% CI	(-2.97, 5.69)	(-3.91, 5.19)	
p-value	0.5372	0.7826	
Corrected Hedge's g Statistics	0.076	0.036	
95% CI	(-0.17, 0.33)	(-0.22, 0.30)	
Subgroup*Treatment Interaction p-value	0.8910	0.3925	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Bodily Pain			
Week 24			
m	121	106	214
n	114	95	194
Baseline Mean (SD)	65.6 (24.4)	63.5 (25.1)	66.3 (25.2)
Analysis Visit Mean (SD)	64.5 (26.2)	62.4 (23.6)	65.7 (25.8)
LS Mean of Change from Baseline (SE)	-0.41 (1.79)	-1.55 (1.93)	0.12 (1.39)
95% CI	(-3.93, 3.11)	(-5.35, 2.24)	(-2.61, 2.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.53 (2.20)	-1.67 (2.33)	
95% CI	(-4.85, 3.79)	(-6.26, 2.92)	
p-value	0.8104	0.4744	
Corrected Hedge's g Statistics	-0.027	-0.087	
95% CI	(-0.26, 0.20)	(-0.33, 0.16)	
Week 52			
m	112	96	200
n	98	86	166
Baseline Mean (SD)	66.7 (25.3)	62.5 (25.8)	65.8 (24.7)
Analysis Visit Mean (SD)	67.9 (27.1)	66.4 (25.4)	67.8 (24.4)
LS Mean of Change from Baseline (SE)	1.50 (2.03)	2.68 (2.16)	2.31 (1.57)
95% CI	(-2.50, 5.50)	(-1.56, 6.92)	(-0.78, 5.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.81 (2.51)	0.37 (2.63)	
95% CI	(-5.74, 4.12)	(-4.79, 5.54)	
p-value	0.7481	0.8869	
Corrected Hedge's g Statistics	-0.040	0.019	
95% CI	(-0.29, 0.21)	(-0.24, 0.28)	
Subgroup*Treatment Interaction p-value	0.4679	0.1831	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
General Health			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	60.12 (19.47)	52.32 (18.94)	58.10 (20.99)
Analysis Visit Mean (SD)	60.39 (20.81)	53.36 (19.14)	59.16 (22.18)
LS Mean of Change from Baseline (SE)	0.95 (1.35)	-0.49 (1.46)	1.09 (1.05)
95% CI	(-1.71, 3.62)	(-3.37, 2.39)	(-0.97, 3.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (1.66)	-1.58 (1.77)	
95% CI	(-3.39, 3.12)	(-5.07, 1.90)	
p-value	0.9347	0.3721	
Corrected Hedge's g Statistics	-0.009	-0.109	
95% CI	(-0.24, 0.22)	(-0.35, 0.14)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	61.19 (19.90)	53.22 (19.58)	58.86 (21.32)
Analysis Visit Mean (SD)	63.58 (19.98)	55.40 (20.33)	60.55 (22.03)
LS Mean of Change from Baseline (SE)	2.96 (1.47)	0.68 (1.56)	2.22 (1.13)
95% CI	(0.08, 5.84)	(-2.38, 3.75)	(-0.01, 4.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.74 (1.80)	-1.53 (1.90)	
95% CI	(-2.80, 4.28)	(-5.27, 2.20)	
p-value	0.6805	0.4201	
Corrected Hedge's g Statistics	0.051	-0.105	
95% CI	(-0.20, 0.30)	(-0.37, 0.16)	
Subgroup*Treatment Interaction p-value	0.3234	0.6994	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Vitality			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	58.24 (22.99)	52.33 (23.34)	56.94 (21.41)
Analysis Visit Mean (SD)	57.14 (23.51)	51.73 (19.00)	56.27 (22.85)
LS Mean of Change from Baseline (SE)	-0.23 (1.36)	-1.72 (1.48)	-0.24 (1.06)
95% CI	(-2.91, 2.45)	(-4.63, 1.19)	(-2.31, 1.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (1.68)	-1.48 (1.79)	
95% CI	(-3.29, 3.30)	(-4.99, 2.03)	
p-value	0.9964	0.4071	
Corrected Hedge's g Statistics	0.001	-0.101	
95% CI	(-0.23, 0.23)	(-0.35, 0.14)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	60.06 (22.95)	53.66 (23.79)	56.83 (21.00)
Analysis Visit Mean (SD)	60.06 (22.06)	54.17 (21.72)	57.44 (21.85)
LS Mean of Change from Baseline (SE)	1.15 (1.51)	-0.38 (1.61)	0.92 (1.17)
95% CI	(-1.82, 4.12)	(-3.54, 2.78)	(-1.38, 3.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.23 (1.87)	-1.30 (1.96)	
95% CI	(-3.44, 3.90)	(-5.15, 2.55)	
p-value	0.9028	0.5069	
Corrected Hedge's g Statistics	0.015	-0.086	
95% CI	(-0.23, 0.26)	(-0.35, 0.17)	
Subgroup*Treatment Interaction p-value	0.8487	0.9765	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Social Functioning			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	80.22 (23.47)	78.95 (26.50)	82.93 (22.46)
Analysis Visit Mean (SD)	79.89 (24.82)	80.66 (21.01)	80.35 (24.50)
LS Mean of Change from Baseline (SE)	-0.82 (1.72)	0.31 (1.87)	-2.37 (1.34)
95% CI	(-4.21, 2.57)	(-3.36, 3.99)	(-4.99, 0.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.54 (2.13)	2.68 (2.26)	
95% CI	(-2.64, 5.72)	(-1.77, 7.13)	
p-value	0.4687	0.2369	
Corrected Hedge's g Statistics	0.083	0.145	
95% CI	(-0.15, 0.31)	(-0.10, 0.39)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	82.20 (22.80)	78.63 (27.51)	84.04 (21.61)
Analysis Visit Mean (SD)	81.69 (23.17)	81.54 (23.15)	82.30 (22.28)
LS Mean of Change from Baseline (SE)	-0.09 (1.78)	1.41 (1.89)	-1.23 (1.38)
95% CI	(-3.60, 3.41)	(-2.31, 5.14)	(-3.95, 1.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.14 (2.20)	2.64 (2.31)	
95% CI	(-3.19, 5.46)	(-1.91, 7.19)	
p-value	0.6057	0.2546	
Corrected Hedge's g Statistics	0.064	0.148	
95% CI	(-0.19, 0.31)	(-0.11, 0.41)	
Subgroup*Treatment Interaction p-value	0.3288	0.5641	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Role Emotional			
Week 24			
m	121	106	214
n	115	95	193
Baseline Mean (SD)	81.95 (24.01)	80.79 (23.48)	83.72 (22.68)
Analysis Visit Mean (SD)	81.01 (22.39)	83.16 (21.88)	82.55 (24.90)
LS Mean of Change from Baseline (SE)	-1.05 (1.54)	1.56 (1.67)	-1.00 (1.20)
95% CI	(-4.07, 1.98)	(-1.71, 4.84)	(-3.35, 1.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (1.90)	2.56 (2.02)	
95% CI	(-3.78, 3.68)	(-1.41, 6.53)	
p-value	0.9802	0.2056	
Corrected Hedge's g Statistics	-0.003	0.155	
95% CI	(-0.23, 0.23)	(-0.09, 0.40)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	83.16 (22.62)	80.91 (24.15)	84.34 (22.09)
Analysis Visit Mean (SD)	84.22 (20.98)	85.27 (21.68)	83.13 (22.68)
LS Mean of Change from Baseline (SE)	1.35 (1.58)	3.77 (1.68)	-0.93 (1.23)
95% CI	(-1.77, 4.46)	(0.46, 7.08)	(-3.35, 1.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.28 (1.95)	4.70 (2.05)	
95% CI	(-1.56, 6.12)	(0.66, 8.73)	
p-value	0.2440	0.0226	
Corrected Hedge's g Statistics	0.144	0.297	
95% CI	(-0.11, 0.39)	(0.04, 0.56)	
Subgroup*Treatment Interaction p-value	0.1517	0.5231	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Mental Health			
Week 24			
m	121	106	214
n	115	95	194
Baseline Mean (SD)	73.7 (19.8)	74.6 (19.8)	75.2 (16.9)
Analysis Visit Mean (SD)	72.6 (19.9)	74.2 (18.9)	74.3 (19.3)
LS Mean of Change from Baseline (SE)	-1.37 (1.22)	-0.75 (1.32)	-0.89 (0.95)
95% CI	(-3.78, 1.03)	(-3.35, 1.85)	(-2.75, 0.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.49 (1.51)	0.14 (1.60)	
95% CI	(-3.45, 2.47)	(-3.01, 3.29)	
p-value	0.7464	0.9311	
Corrected Hedge's g Statistics	-0.037	0.011	
95% CI	(-0.27, 0.19)	(-0.23, 0.26)	
Week 52			
m	112	96	200
n	99	86	166
Baseline Mean (SD)	75.1 (18.6)	74.4 (20.6)	75.3 (17.0)
Analysis Visit Mean (SD)	75.7 (17.1)	74.4 (18.8)	75.9 (18.4)
LS Mean of Change from Baseline (SE)	0.74 (1.26)	-0.10 (1.34)	0.03 (0.98)
95% CI	(-1.74, 3.22)	(-2.73, 2.54)	(-1.89, 1.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.70 (1.55)	-0.13 (1.63)	
95% CI	(-2.35, 3.76)	(-3.34, 3.08)	
p-value	0.6518	0.9349	
Corrected Hedge's g Statistics	0.056	-0.011	
95% CI	(-0.19, 0.30)	(-0.27, 0.25)	
Subgroup*Treatment Interaction p-value	0.7989	0.5964	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Mental Component Score			
Week 24			
m	121	106	214
n	114	95	193
Baseline Mean (SD)	50.61 (10.62)	50.19 (11.41)	51.13 (9.15)
Analysis Visit Mean (SD)	49.91 (10.28)	50.72 (10.07)	50.37 (10.54)
LS Mean of Change from Baseline (SE)	-0.79 (0.65)	0.17 (0.70)	-0.77 (0.51)
95% CI	(-2.07, 0.49)	(-1.22, 1.55)	(-1.77, 0.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.80)	0.94 (0.85)	
95% CI	(-1.60, 1.56)	(-0.73, 2.62)	
p-value	0.9849	0.2704	
Corrected Hedge's g Statistics	-0.002	0.135	
95% CI	(-0.23, 0.23)	(-0.11, 0.38)	
Week 52			
m	112	96	200
n	98	86	166
Baseline Mean (SD)	51.38 (9.93)	50.30 (11.82)	51.30 (9.04)
Analysis Visit Mean (SD)	51.34 (8.97)	51.32 (9.83)	51.05 (9.63)
LS Mean of Change from Baseline (SE)	0.17 (0.66)	0.72 (0.70)	-0.41 (0.51)
95% CI	(-1.14, 1.47)	(-0.66, 2.10)	(-1.42, 0.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.58 (0.82)	1.13 (0.85)	
95% CI	(-1.03, 2.18)	(-0.55, 2.81)	
p-value	0.4804	0.1874	
Corrected Hedge's g Statistics	0.087	0.171	
95% CI	(-0.16, 0.34)	(-0.09, 0.43)	
Subgroup*Treatment Interaction p-value	0.6236	0.5489	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Physical Component Score			
Week 24			
m	121	106	214
n	114	95	193
Baseline Mean (SD)	47.28 (8.91)	45.39 (9.21)	47.32 (9.64)
Analysis Visit Mean (SD)	47.34 (10.12)	45.07 (8.96)	47.47 (10.10)
LS Mean of Change from Baseline (SE)	0.37 (0.62)	-0.66 (0.67)	0.38 (0.48)
95% CI	(-0.85, 1.60)	(-1.98, 0.66)	(-0.57, 1.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.76)	-1.04 (0.81)	
95% CI	(-1.51, 1.50)	(-2.64, 0.56)	
p-value	0.9948	0.2024	
Corrected Hedge's g Statistics	-0.001	-0.156	
95% CI	(-0.23, 0.23)	(-0.40, 0.09)	
Week 52			
m	112	96	200
n	98	86	166
Baseline Mean (SD)	47.69 (9.05)	45.37 (9.36)	47.44 (9.20)
Analysis Visit Mean (SD)	48.42 (10.86)	45.74 (9.93)	47.83 (9.16)
LS Mean of Change from Baseline (SE)	0.92 (0.65)	0.16 (0.68)	0.71 (0.50)
95% CI	(-0.35, 2.18)	(-1.18, 1.51)	(-0.27, 1.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.20 (0.79)	-0.55 (0.83)	
95% CI	(-1.35, 1.76)	(-2.19, 1.09)	
p-value	0.7965	0.5122	
Corrected Hedge's g Statistics	0.032	-0.085	
95% CI	(-0.22, 0.28)	(-0.35, 0.18)	
Subgroup*Treatment Interaction p-value	0.5990	0.2014	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Physical Functioning			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	78.18 (20.90)	70.29 (27.75)	73.94 (27.38)
Analysis Visit Mean (SD)	80.00 (21.60)	75.88 (21.16)	75.96 (26.65)
LS Mean of Change from Baseline (SE)	3.45 (4.08)	4.40 (4.62)	0.34 (2.82)
95% CI	(-4.66, 11.56)	(-4.79, 13.59)	(-5.26, 5.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.11 (4.79)	4.06 (5.16)	
95% CI	(-6.41, 12.63)	(-6.19, 14.32)	
p-value	0.5181	0.4333	
Corrected Hedge's g Statistics	0.160	0.209	
95% CI	(-0.35, 0.67)	(-0.35, 0.76)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	77.75 (21.79)	69.17 (28.75)	74.42 (27.33)
Analysis Visit Mean (SD)	75.50 (26.80)	72.92 (26.58)	75.21 (24.09)
LS Mean of Change from Baseline (SE)	-0.59 (4.27)	1.84 (5.21)	-0.29 (2.94)
95% CI	(-9.07, 7.89)	(-8.53, 12.21)	(-6.13, 5.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.30 (5.02)	2.13 (5.76)	
95% CI	(-10.28, 9.68)	(-9.32, 13.57)	
p-value	0.9522	0.7125	
Corrected Hedge's g Statistics	-0.016	0.110	
95% CI	(-0.55, 0.51)	(-0.53, 0.75)	
Subgroup*Treatment Interaction p-value	0.8800	0.2958	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Role Physical			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	75.86 (27.57)	72.81 (30.85)	73.16 (28.87)
Analysis Visit Mean (SD)	76.15 (24.74)	76.12 (20.99)	74.09 (27.07)
LS Mean of Change from Baseline (SE)	2.13 (4.39)	3.89 (5.00)	-0.06 (3.05)
95% CI	(-6.60, 10.87)	(-6.06, 13.84)	(-6.13, 6.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.19 (5.19)	3.95 (5.62)	
95% CI	(-8.12, 12.50)	(-7.22, 15.12)	
p-value	0.6737	0.4838	
Corrected Hedge's g Statistics	0.104	0.187	
95% CI	(-0.40, 0.61)	(-0.37, 0.74)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	75.64 (28.96)	68.76 (33.39)	72.11 (28.54)
Analysis Visit Mean (SD)	73.45 (27.72)	72.94 (23.28)	73.85 (24.90)
LS Mean of Change from Baseline (SE)	0.00 (4.62)	2.13 (5.87)	1.13 (3.20)
95% CI	(-9.18, 9.18)	(-9.54, 13.79)	(-5.23, 7.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.13 (5.47)	0.99 (6.46)	
95% CI	(-12.00, 9.73)	(-11.86, 13.84)	
p-value	0.8364	0.8784	
Corrected Hedge's g Statistics	-0.054	0.047	
95% CI	(-0.58, 0.48)	(-0.59, 0.69)	
Subgroup*Treatment Interaction p-value	0.8910	0.3925	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)
Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Bodily Pain			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	69.3 (23.3)	58.1 (32.3)	63.1 (23.9)
Analysis Visit Mean (SD)	63.2 (23.0)	70.5 (26.4)	67.2 (25.7)
LS Mean of Change from Baseline (SE)	-4.69 (4.20)	10.80 (4.78)	3.20 (2.89)
95% CI	(-13.04, 3.67)	(1.29, 20.31)	(-2.56, 8.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.88 (4.95)	7.60 (5.34)	
95% CI	(-17.73, 1.97)	(-3.01, 18.22)	
p-value	0.1153	0.1581	
Corrected Hedge's g Statistics	-0.394	0.379	
95% CI	(-0.90, 0.12)	(-0.18, 0.94)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	70.6 (24.1)	55.3 (31.6)	64.4 (24.6)
Analysis Visit Mean (SD)	68.2 (21.8)	63.7 (26.0)	65.2 (24.7)
LS Mean of Change from Baseline (SE)	0.37 (4.06)	3.55 (5.01)	2.68 (2.80)
95% CI	(-7.70, 8.43)	(-6.40, 13.51)	(-2.88, 8.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.31 (4.77)	0.88 (5.49)	
95% CI	(-11.79, 7.17)	(-10.05, 11.80)	
p-value	0.6291	0.8735	
Corrected Hedge's g Statistics	-0.125	0.048	
95% CI	(-0.66, 0.41)	(-0.59, 0.69)	
Subgroup*Treatment Interaction p-value	0.4679	0.1831	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
General Health			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	58.72 (18.06)	59.06 (15.19)	60.40 (17.57)
Analysis Visit Mean (SD)	65.55 (17.21)	62.53 (19.62)	60.64 (20.15)
LS Mean of Change from Baseline (SE)	5.73 (3.26)	1.85 (3.70)	-0.61 (2.25)
95% CI	(-0.75, 12.20)	(-5.52, 9.21)	(-5.09, 3.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.34 (3.87)	2.46 (4.19)	
95% CI	(-1.34, 14.03)	(-5.88, 10.80)	
p-value	0.1046	0.5589	
Corrected Hedge's g Statistics	0.408	0.158	
95% CI	(-0.10, 0.92)	(-0.40, 0.71)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	59.24 (18.71)	59.67 (17.56)	59.44 (17.64)
Analysis Visit Mean (SD)	60.50 (17.67)	59.50 (14.09)	61.09 (18.17)
LS Mean of Change from Baseline (SE)	0.59 (2.71)	-3.12 (3.45)	1.07 (1.89)
95% CI	(-4.79, 5.97)	(-9.98, 3.74)	(-2.68, 4.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.48 (3.18)	-4.18 (3.77)	
95% CI	(-6.81, 5.85)	(-11.69, 3.32)	
p-value	0.8816	0.2706	
Corrected Hedge's g Statistics	-0.038	-0.336	
95% CI	(-0.57, 0.49)	(-0.98, 0.31)	
Subgroup*Treatment Interaction p-value	0.3234	0.6994	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)
Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Vitality			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	55.71 (21.73)	55.54 (19.62)	56.14 (22.85)
Analysis Visit Mean (SD)	55.15 (24.37)	57.01 (22.09)	58.93 (21.16)
LS Mean of Change from Baseline (SE)	-1.87 (3.53)	-0.60 (4.02)	-0.26 (2.45)
95% CI	(-8.90, 5.15)	(-8.58, 7.39)	(-5.14, 4.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.61 (4.15)	-0.34 (4.47)	
95% CI	(-9.86, 6.63)	(-9.22, 8.55)	
p-value	0.6983	0.9403	
Corrected Hedge's g Statistics	-0.095	-0.020	
95% CI	(-0.60, 0.41)	(-0.57, 0.53)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	55.03 (22.64)	53.15 (14.96)	55.69 (23.54)
Analysis Visit Mean (SD)	55.65 (23.02)	51.06 (15.96)	56.86 (26.02)
LS Mean of Change from Baseline (SE)	-0.44 (4.14)	-8.27 (5.09)	-1.21 (2.85)
95% CI	(-8.67, 7.80)	(-18.40, 1.85)	(-6.88, 4.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.77 (4.90)	-7.06 (5.65)	
95% CI	(-8.97, 10.52)	(-18.29, 4.17)	
p-value	0.8749	0.2147	
Corrected Hedge's g Statistics	0.041	-0.376	
95% CI	(-0.49, 0.57)	(-1.02, 0.27)	
Subgroup*Treatment Interaction p-value	0.8487	0.9765	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Social Functioning			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	89.20 (22.26)	81.62 (23.85)	81.38 (24.01)
Analysis Visit Mean (SD)	87.50 (25.88)	83.09 (18.19)	84.31 (24.24)
LS Mean of Change from Baseline (SE)	2.37 (4.69)	1.37 (5.28)	0.71 (3.22)
95% CI	(-6.95, 11.69)	(-9.12, 11.86)	(-5.68, 7.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.65 (5.53)	0.66 (5.91)	
95% CI	(-9.34, 12.65)	(-11.09, 12.40)	
p-value	0.7656	0.9117	
Corrected Hedge's g Statistics	0.074	0.030	
95% CI	(-0.43, 0.58)	(-0.53, 0.58)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	88.13 (23.11)	84.38 (23.31)	80.23 (24.74)
Analysis Visit Mean (SD)	83.75 (22.98)	82.29 (18.81)	84.88 (22.75)
LS Mean of Change from Baseline (SE)	-2.22 (4.42)	3.19 (5.36)	1.35 (3.05)
95% CI	(-11.01, 6.57)	(-7.46, 13.83)	(-4.72, 7.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.57 (5.21)	1.84 (5.89)	
95% CI	(-13.93, 6.79)	(-9.87, 13.55)	
p-value	0.4952	0.7558	
Corrected Hedge's g Statistics	-0.177	0.092	
95% CI	(-0.71, 0.35)	(-0.55, 0.73)	
Subgroup*Treatment Interaction p-value	0.3288	0.5641	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)
Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Role Emotional			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	80.68 (29.92)	84.31 (25.33)	84.04 (22.51)
Analysis Visit Mean (SD)	86.36 (23.93)	89.22 (19.27)	84.04 (21.41)
LS Mean of Change from Baseline (SE)	5.18 (3.95)	6.27 (4.48)	0.82 (2.74)
95% CI	(-2.67, 13.03)	(-2.63, 15.18)	(-4.63, 6.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.36 (4.63)	5.46 (4.98)	
95% CI	(-4.84, 13.57)	(-4.44, 15.36)	
p-value	0.3487	0.2759	
Corrected Hedge's g Statistics	0.231	0.288	
95% CI	(-0.28, 0.74)	(-0.27, 0.85)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	79.58 (31.12)	79.86 (28.98)	84.50 (23.04)
Analysis Visit Mean (SD)	84.17 (20.39)	81.25 (26.15)	80.04 (25.01)
LS Mean of Change from Baseline (SE)	3.49 (5.01)	2.97 (6.14)	-3.70 (3.44)
95% CI	(-6.47, 13.46)	(-9.24, 15.17)	(-10.53, 3.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.20 (5.95)	6.67 (6.84)	
95% CI	(-4.63, 19.03)	(-6.92, 20.26)	
p-value	0.2297	0.3321	
Corrected Hedge's g Statistics	0.316	0.295	
95% CI	(-0.22, 0.85)	(-0.35, 0.94)	
Subgroup*Treatment Interaction p-value	0.1517	0.5231	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Mental Health			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	73.9 (19.6)	78.8 (15.1)	73.1 (21.1)
Analysis Visit Mean (SD)	77.3 (18.1)	77.9 (20.2)	76.1 (18.0)
LS Mean of Change from Baseline (SE)	2.79 (3.21)	0.10 (3.67)	1.54 (2.24)
95% CI	(-3.60, 9.18)	(-7.20, 7.41)	(-2.92, 5.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.25 (3.78)	-1.43 (4.11)	
95% CI	(-6.26, 8.76)	(-9.60, 6.73)	
p-value	0.7416	0.7277	
Corrected Hedge's g Statistics	0.081	-0.093	
95% CI	(-0.43, 0.59)	(-0.65, 0.46)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	73.5 (20.4)	81.3 (14.0)	72.9 (21.5)
Analysis Visit Mean (SD)	75.3 (18.9)	77.9 (19.1)	75.1 (22.8)
LS Mean of Change from Baseline (SE)	0.94 (3.82)	-1.32 (4.80)	1.05 (2.64)
95% CI	(-6.66, 8.55)	(-10.87, 8.23)	(-4.20, 6.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (4.53)	-2.37 (5.34)	
95% CI	(-9.12, 8.91)	(-12.97, 8.24)	
p-value	0.9819	0.6582	
Corrected Hedge's g Statistics	-0.006	-0.136	
95% CI	(-0.54, 0.52)	(-0.78, 0.50)	
Subgroup*Treatment Interaction p-value	0.7989	0.5964	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Mental Component Score			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	50.43 (11.80)	52.78 (9.29)	50.77 (10.44)
Analysis Visit Mean (SD)	52.09 (10.49)	52.61 (9.74)	51.77 (9.61)
LS Mean of Change from Baseline (SE)	1.42 (1.73)	0.36 (1.97)	0.51 (1.20)
95% CI	(-2.02, 4.86)	(-3.55, 4.27)	(-1.88, 2.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.91 (2.03)	-0.15 (2.19)	
95% CI	(-3.12, 4.94)	(-4.50, 4.20)	
p-value	0.6547	0.9450	
Corrected Hedge's g Statistics	0.110	-0.018	
95% CI	(-0.40, 0.62)	(-0.57, 0.54)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	49.94 (12.27)	53.00 (9.78)	50.59 (10.77)
Analysis Visit Mean (SD)	51.19 (9.84)	51.09 (10.03)	50.79 (12.46)
LS Mean of Change from Baseline (SE)	0.64 (2.13)	-0.39 (2.60)	-0.60 (1.46)
95% CI	(-3.59, 4.87)	(-5.55, 4.77)	(-3.50, 2.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.24 (2.52)	0.20 (2.89)	
95% CI	(-3.77, 6.24)	(-5.54, 5.94)	
p-value	0.6239	0.9448	
Corrected Hedge's g Statistics	0.128	0.021	
95% CI	(-0.40, 0.66)	(-0.62, 0.66)	
Subgroup*Treatment Interaction p-value	0.6236	0.5489	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Physical Component Score			
Week 24			
m	25	21	58
n	22	17	47
Baseline Mean (SD)	48.48 (7.66)	44.58 (11.09)	46.71 (9.27)
Analysis Visit Mean (SD)	48.00 (7.50)	47.64 (8.02)	47.39 (10.10)
LS Mean of Change from Baseline (SE)	0.01 (1.56)	2.19 (1.78)	0.12 (1.08)
95% CI	(-3.09, 3.12)	(-1.35, 5.72)	(-2.02, 2.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (1.84)	2.07 (2.00)	
95% CI	(-3.77, 3.56)	(-1.90, 6.04)	
p-value	0.9548	0.3029	
Corrected Hedge's g Statistics	-0.014	0.277	
95% CI	(-0.52, 0.49)	(-0.28, 0.83)	
Week 52			
m	25	17	55
n	20	12	43
Baseline Mean (SD)	48.74 (8.00)	43.62 (11.88)	46.68 (9.36)
Analysis Visit Mean (SD)	47.39 (9.83)	46.07 (9.21)	47.43 (8.82)
LS Mean of Change from Baseline (SE)	-0.71 (1.45)	0.56 (1.82)	0.72 (1.00)
95% CI	(-3.59, 2.18)	(-3.05, 4.17)	(-1.28, 2.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.42 (1.70)	-0.15 (1.99)	
95% CI	(-4.81, 1.97)	(-4.11, 3.81)	
p-value	0.4067	0.9389	
Corrected Hedge's g Statistics	-0.214	-0.023	
95% CI	(-0.75, 0.32)	(-0.66, 0.62)	
Subgroup*Treatment Interaction p-value	0.5990	0.2014	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Physical Functioning			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	84.00 (12.45)	60.00 (49.50)	N/A
Analysis Visit Mean (SD)	84.00 (18.84)	70.00 (7.07)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	84.00 (12.45)	95.00 (N/A)	N/A
Analysis Visit Mean (SD)	79.00 (11.94)	95.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.8800	0.2958	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Role Physical			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	88.76 (11.17)	71.90 (30.97)	N/A
Analysis Visit Mean (SD)	77.50 (13.69)	75.00 (17.68)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	88.76 (11.17)	93.80 (N/A)	N/A
Analysis Visit Mean (SD)	78.76 (17.47)	87.50 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.8910	0.3925	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Bodily Pain			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	70.8 (9.2)	79.0 (7.1)	N/A
Analysis Visit Mean (SD)	65.2 (25.8)	68.0 (8.5)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	70.8 (9.2)	84.0 (N/A)	N/A
Analysis Visit Mean (SD)	72.8 (11.0)	100.0 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.4679	0.1831	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
General Health			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	69.00 (18.23)	79.50 (10.61)	N/A
Analysis Visit Mean (SD)	58.60 (25.16)	69.50 (24.75)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	69.00 (18.23)	87.00 (N/A)	N/A
Analysis Visit Mean (SD)	56.60 (23.04)	62.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.3234	0.6994	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Vitality			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	58.78 (19.06)	65.65 (4.45)	N/A
Analysis Visit Mean (SD)	52.54 (17.47)	59.40 (4.38)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	58.78 (19.06)	68.80 (N/A)	N/A
Analysis Visit Mean (SD)	58.76 (22.35)	68.80 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.8487	0.9765	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Social Functioning			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	90.00 (16.30)	100.00 (0.00)	N/A
Analysis Visit Mean (SD)	80.00 (27.39)	87.50 (17.68)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	90.00 (16.30)	100.00 (N/A)	N/A
Analysis Visit Mean (SD)	85.00 (20.54)	75.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.3288	0.5641	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Role Emotional			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	90.00 (22.36)	95.85 (5.87)	N/A
Analysis Visit Mean (SD)	81.68 (26.60)	87.50 (17.68)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	90.00 (22.36)	91.70 (N/A)	N/A
Analysis Visit Mean (SD)	86.66 (21.73)	66.70 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.1517	0.5231	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Mental Health			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	81.0 (18.2)	85.0 (14.1)	N/A
Analysis Visit Mean (SD)	69.0 (17.1)	85.0 (7.1)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	81.0 (18.2)	75.0 (N/A)	N/A
Analysis Visit Mean (SD)	77.0 (18.6)	60.0 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.7989	0.5964	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Mental Component Score			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	53.14 (12.13)	59.55 (10.25)	N/A
Analysis Visit Mean (SD)	47.62 (13.85)	55.45 (7.99)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	53.14 (12.13)	52.30 (N/A)	N/A
Analysis Visit Mean (SD)	51.88 (12.55)	41.10 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.6236	0.5489	

AMNOG Table SE22.14b.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Physical Component Score			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	50.92 (3.53)	46.30 (16.26)	N/A
Analysis Visit Mean (SD)	49.56 (6.53)	46.35 (3.89)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	50.92 (3.53)	57.80 (N/A)	N/A
Analysis Visit Mean (SD)	48.38 (2.31)	60.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.5990	0.2014	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	19 (15.3)	14 (12.5)	28 (12.6)
No	105 (84.7)	98 (87.5)	195 (87.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	1.01	
95% CI of the inverse odds ratio	(0.42, 1.49)	(0.51, 2.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.00	
95% CI of the inverse risk ratio	(0.48, 1.41)	(0.55, 1.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.77	-0.06	
95% CI of the absolute risk difference	(-4.92, 10.45)	(-7.57, 7.46)	
p-value	0.4705	0.9883	
p-value of Breslow-Day Test for Homogeneity [3]	0.7961	0.8823	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	42 (33.9)	37 (33.0)	63 (28.3)
No	82 (66.1)	75 (67.0)	160 (71.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.80	
95% CI of the inverse odds ratio	(0.48, 1.23)	(0.49, 1.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.86	
95% CI of the inverse risk ratio	(0.60, 1.15)	(0.61, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.62	4.78	
95% CI of the absolute risk difference	(-4.59, 15.83)	(-5.74, 15.31)	
p-value	0.2748	0.3666	
p-value of Breslow-Day Test for Homogeneity [3]	0.7786	0.6587	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (9.7)	14 (12.5)	25 (11.2)
No	112 (90.3)	98 (87.5)	198 (88.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.88	
95% CI of the inverse odds ratio	(0.57, 2.44)	(0.44, 1.78)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	0.90	
95% CI of the inverse risk ratio	(0.60, 2.22)	(0.49, 1.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.53	1.29	
95% CI of the absolute risk difference	(-8.18, 5.12)	(-6.10, 8.68)	
p-value	0.6574	0.7285	
p-value of Breslow-Day Test for Homogeneity [3]	0.4475	0.3189	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (24.2)	31 (27.7)	47 (21.1)
No	94 (75.8)	81 (72.3)	176 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.70	
95% CI of the inverse odds ratio	(0.50, 1.41)	(0.41, 1.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.76	
95% CI of the inverse risk ratio	(0.58, 1.30)	(0.51, 1.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.12	6.60	
95% CI of the absolute risk difference	(-6.13, 12.36)	(-3.26, 16.47)	
p-value	0.5030	0.1774	
p-value of Breslow-Day Test for Homogeneity [3]	0.4551	0.0601	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (14.5)	20 (17.9)	41 (18.4)
No	106 (85.5)	92 (82.1)	182 (81.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	1.04	
95% CI of the inverse odds ratio	(0.73, 2.43)	(0.57, 1.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	1.03	
95% CI of the inverse risk ratio	(0.76, 2.11)	(0.63, 1.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.87	-0.53	
95% CI of the absolute risk difference	(-11.89, 4.15)	(-9.26, 8.20)	
p-value	0.3578	0.9059	
p-value of Breslow-Day Test for Homogeneity [3]	0.5210	0.6362	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (26.6)	35 (31.3)	62 (27.8)
No	91 (73.4)	77 (68.8)	161 (72.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.85	
95% CI of the inverse odds ratio	(0.65, 1.74)	(0.52, 1.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.89	
95% CI of the inverse risk ratio	(0.73, 1.50)	(0.63, 1.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.19	3.45	
95% CI of the absolute risk difference	(-10.94, 8.56)	(-6.96, 13.85)	
p-value	0.8117	0.5116	
p-value of Breslow-Day Test for Homogeneity [3]	0.8030	0.5864	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	23 (18.5)	23 (20.5)	37 (16.6)
No	101 (81.5)	89 (79.5)	186 (83.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.77	
95% CI of the inverse odds ratio	(0.49, 1.55)	(0.43, 1.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.81	
95% CI of the inverse risk ratio	(0.56, 1.43)	(0.51, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.96	3.94	
95% CI of the absolute risk difference	(-6.45, 10.36)	(-4.99, 12.88)	
p-value	0.6442	0.3745	
p-value of Breslow-Day Test for Homogeneity [3]	0.6668	0.2912	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	40 (32.3)	43 (38.4)	71 (31.8)
No	84 (67.7)	69 (61.6)	152 (68.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.75	
95% CI of the inverse odds ratio	(0.61, 1.57)	(0.47, 1.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.83	
95% CI of the inverse risk ratio	(0.72, 1.36)	(0.61, 1.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.42	6.55	
95% CI of the absolute risk difference	(-9.83, 10.67)	(-4.33, 17.44)	
p-value	0.9360	0.2323	
p-value of Breslow-Day Test for Homogeneity [3]	0.9388	0.2964	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (11.3)	12 (10.7)	27 (12.1)
No	110 (88.7)	100 (89.3)	196 (87.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	1.15	
95% CI of the inverse odds ratio	(0.54, 2.15)	(0.56, 2.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.13	
95% CI of the inverse risk ratio	(0.58, 1.97)	(0.60, 2.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.82	-1.39	
95% CI of the absolute risk difference	(-7.84, 6.21)	(-8.54, 5.76)	
p-value	0.8212	0.7076	
p-value of Breslow-Day Test for Homogeneity [3]	0.1413	0.2646	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	39 (31.5)	34 (30.4)	72 (32.3)
No	85 (68.5)	78 (69.6)	151 (67.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.09	
95% CI of the inverse odds ratio	(0.65, 1.67)	(0.67, 1.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.06	
95% CI of the inverse risk ratio	(0.74, 1.42)	(0.76, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.84	-1.93	
95% CI of the absolute risk difference	(-11.06, 9.38)	(-12.43, 8.57)	
p-value	0.8730	0.7201	
p-value of Breslow-Day Test for Homogeneity [3]	0.8771	0.3522	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (10.5)	21 (18.8)	14 (6.3)
No	111 (89.5)	91 (81.3)	209 (93.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	0.29	
95% CI of the inverse odds ratio	(0.26, 1.26)	(0.14, 0.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.33	
95% CI of the inverse risk ratio	(0.29, 1.23)	(0.18, 0.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.21	12.47	
95% CI of the absolute risk difference	(-2.06, 10.47)	(4.57, 20.37)	
p-value	0.1610	0.0004	
p-value of Breslow-Day Test for Homogeneity [3]	0.0103	0.0055	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (22.6)	29 (25.9)	35 (15.7)
No	96 (77.4)	83 (74.1)	188 (84.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.53	
95% CI of the inverse odds ratio	(0.37, 1.11)	(0.31, 0.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	0.61	
95% CI of the inverse risk ratio	(0.45, 1.09)	(0.39, 0.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.89	10.20	
95% CI of the absolute risk difference	(-1.89, 15.66)	(0.78, 19.61)	
p-value	0.1108	0.0251	
p-value of Breslow-Day Test for Homogeneity [3]	0.0232	0.1031	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (12.1)	25 (22.3)	29 (13.0)
No	109 (87.9)	87 (77.7)	194 (87.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.52	
95% CI of the inverse odds ratio	(0.56, 2.11)	(0.29, 0.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.58	
95% CI of the inverse risk ratio	(0.60, 1.93)	(0.36, 0.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.91	9.32	
95% CI of the absolute risk difference	(-8.15, 6.33)	(0.43, 18.20)	
p-value	0.8076	0.0287	
p-value of Breslow-Day Test for Homogeneity [3]	0.4251	0.6508	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (20.2)	33 (29.5)	40 (17.9)
No	99 (79.8)	79 (70.5)	183 (82.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.52	
95% CI of the inverse odds ratio	(0.50, 1.51)	(0.31, 0.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.61	
95% CI of the inverse risk ratio	(0.57, 1.39)	(0.41, 0.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.22	11.53	
95% CI of the absolute risk difference	(-6.45, 10.90)	(1.70, 21.36)	
p-value	0.6109	0.0159	
p-value of Breslow-Day Test for Homogeneity [3]	0.9332	0.6281	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (12.1)	11 (9.8)	26 (11.7)
No	109 (87.9)	101 (90.2)	197 (88.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.21	
95% CI of the inverse odds ratio	(0.49, 1.89)	(0.58, 2.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.19	
95% CI of the inverse risk ratio	(0.53, 1.75)	(0.61, 2.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.44	-1.84	
95% CI of the absolute risk difference	(-6.68, 7.56)	(-8.77, 5.10)	
p-value	0.9037	0.6127	
p-value of Breslow-Day Test for Homogeneity [3]	0.3245	0.1270	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	45 (36.3)	30 (26.8)	65 (29.1)
No	79 (63.7)	82 (73.2)	158 (70.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	1.12	
95% CI of the inverse odds ratio	(0.45, 1.15)	(0.68, 1.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.09	
95% CI of the inverse risk ratio	(0.59, 1.10)	(0.75, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.14	-2.36	
95% CI of the absolute risk difference	(-3.21, 17.50)	(-12.50, 7.78)	
p-value	0.1706	0.6509	
p-value of Breslow-Day Test for Homogeneity [3]	0.6358	0.5149	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.2)	11 (9.8)	10 (4.5)
No	120 (96.8)	101 (90.2)	213 (95.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	0.43	
95% CI of the inverse odds ratio	(0.43, 4.59)	(0.18, 1.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	0.46	
95% CI of the inverse risk ratio	(0.45, 4.34)	(0.20, 1.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.26	5.34	
95% CI of the absolute risk difference	(-5.39, 2.87)	(-0.81, 11.48)	
p-value	0.5680	0.0573	
p-value of Breslow-Day Test for Homogeneity [3]	0.9375	0.0823	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (24.2)	24 (21.4)	45 (20.2)
No	94 (75.8)	88 (78.6)	178 (79.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.93	
95% CI of the inverse odds ratio	(0.47, 1.34)	(0.53, 1.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.94	
95% CI of the inverse risk ratio	(0.56, 1.25)	(0.61, 1.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.01	1.25	
95% CI of the absolute risk difference	(-5.18, 13.21)	(-8.00, 10.50)	
p-value	0.3840	0.7897	
p-value of Breslow-Day Test for Homogeneity [3]	0.5319	0.0788	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (5.6)	8 (7.1)	10 (4.5)
No	117 (94.4)	104 (92.9)	213 (95.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.61	
95% CI of the inverse odds ratio	(0.29, 2.12)	(0.23, 1.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.63	
95% CI of the inverse risk ratio	(0.31, 2.03)	(0.25, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.16	2.66	
95% CI of the absolute risk difference	(-3.73, 6.05)	(-2.83, 8.15)	
p-value	0.6312	0.3087	
p-value of Breslow-Day Test for Homogeneity [3]	0.2165	0.9347	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (23.4)	33 (29.5)	45 (20.2)
No	95 (76.6)	79 (70.5)	178 (79.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.61	
95% CI of the inverse odds ratio	(0.49, 1.41)	(0.36, 1.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.68	
95% CI of the inverse risk ratio	(0.57, 1.30)	(0.46, 1.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.21	9.28	
95% CI of the absolute risk difference	(-5.92, 12.33)	(-0.67, 19.24)	
p-value	0.4845	0.0578	
p-value of Breslow-Day Test for Homogeneity [3]	0.4957	0.5292	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (11.5)	3 (12.5)	7 (11.3)
No	23 (88.5)	21 (87.5)	55 (88.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.89	
95% CI of the inverse odds ratio	(0.23, 4.11)	(0.21, 3.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.90	
95% CI of the inverse risk ratio	(0.27, 3.49)	(0.25, 3.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.25	1.21	
95% CI of the absolute risk difference	(-14.34, 14.84)	(-14.19, 16.61)	
p-value	0.9733	0.8753	
p-value of Breslow-Day Test for Homogeneity [3]	0.7961	0.8823	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (34.6)	6 (25.0)	16 (25.8)
No	17 (65.4)	18 (75.0)	46 (74.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	1.04	
95% CI of the inverse odds ratio	(0.24, 1.76)	(0.35, 3.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.03	
95% CI of the inverse risk ratio	(0.38, 1.47)	(0.46, 2.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.81	-0.81	
95% CI of the absolute risk difference	(-12.48, 30.09)	(-21.27, 19.66)	
p-value	0.4032	0.9387	
p-value of Breslow-Day Test for Homogeneity [3]	0.7786	0.6587	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.7)	2 (8.3)	10 (16.1)
No	24 (92.3)	22 (91.7)	52 (83.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.31	2.12	
95% CI of the inverse odds ratio	(0.47, 11.35)	(0.43, 10.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.10	1.94	
95% CI of the inverse risk ratio	(0.49, 8.92)	(0.46, 8.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.44	-7.80	
95% CI of the absolute risk difference	(-22.17, 5.30)	(-22.15, 6.56)	
p-value	0.2927	0.3494	
p-value of Breslow-Day Test for Homogeneity [3]	0.4475	0.3189	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (26.9)	4 (16.7)	20 (32.3)
No	19 (73.1)	20 (83.3)	42 (67.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	2.38	
95% CI of the inverse odds ratio	(0.47, 3.57)	(0.72, 7.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	1.94	
95% CI of the inverse risk ratio	(0.58, 2.48)	(0.74, 5.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.33	-15.59	
95% CI of the absolute risk difference	(-25.98, 15.31)	(-34.50, 3.32)	
p-value	0.6205	0.1482	
p-value of Breslow-Day Test for Homogeneity [3]	0.4551	0.0601	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.7)	3 (12.5)	10 (16.1)
No	24 (92.3)	21 (87.5)	52 (83.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.31	1.35	
95% CI of the inverse odds ratio	(0.47, 11.35)	(0.34, 5.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.10	1.29	
95% CI of the inverse risk ratio	(0.49, 8.92)	(0.39, 4.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.44	-3.63	
95% CI of the absolute risk difference	(-22.17, 5.30)	(-19.72, 12.46)	
p-value	0.2927	0.6735	
p-value of Breslow-Day Test for Homogeneity [3]	0.5210	0.6362	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (23.1)	6 (25.0)	18 (29.0)
No	20 (76.9)	18 (75.0)	44 (71.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	1.23	
95% CI of the inverse odds ratio	(0.47, 3.95)	(0.42, 3.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	1.16	
95% CI of the inverse risk ratio	(0.56, 2.81)	(0.52, 2.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.96	-4.03	
95% CI of the absolute risk difference	(-25.70, 13.79)	(-24.71, 16.65)	
p-value	0.5671	0.7085	
p-value of Breslow-Day Test for Homogeneity [3]	0.8030	0.5864	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.7)	1 (4.2)	6 (9.7)
No	24 (92.3)	23 (95.8)	56 (90.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	2.46	
95% CI of the inverse odds ratio	(0.24, 6.83)	(0.28, 21.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	2.32	
95% CI of the inverse risk ratio	(0.27, 5.83)	(0.29, 18.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.99	-5.51	
95% CI of the absolute risk difference	(-14.60, 10.63)	(-16.38, 5.36)	
p-value	0.7676	0.4019	
p-value of Breslow-Day Test for Homogeneity [3]	0.6668	0.2912	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (26.9)	5 (20.8)	17 (27.4)
No	19 (73.1)	19 (79.2)	45 (72.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.44	
95% CI of the inverse odds ratio	(0.37, 2.87)	(0.46, 4.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.32	
95% CI of the inverse risk ratio	(0.48, 2.16)	(0.55, 3.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.50	-6.59	
95% CI of the absolute risk difference	(-20.84, 19.85)	(-26.27, 13.09)	
p-value	0.9620	0.5301	
p-value of Breslow-Day Test for Homogeneity [3]	0.9388	0.2964	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (4.2)	9 (14.5)
No	26 (100)	23 (95.8)	53 (85.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	9.41	3.91	
95% CI of the inverse odds ratio	(0.53, 167.93)	(0.47, 32.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	8.14	3.48	
95% CI of the inverse risk ratio	(0.49, 134.96)	(0.47, 26.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.23	-10.35	
95% CI of the absolute risk difference	(-23.42, -3.03)	(-22.22, 1.52)	
p-value	0.0673	0.1793	
p-value of Breslow-Day Test for Homogeneity [3]	0.1413	0.2646	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (34.6)	5 (20.8)	21 (33.9)
No	17 (65.4)	19 (79.2)	41 (66.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	1.95	
95% CI of the inverse odds ratio	(0.37, 2.54)	(0.64, 5.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.63	
95% CI of the inverse risk ratio	(0.52, 1.84)	(0.69, 3.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.74	-13.04	
95% CI of the absolute risk difference	(-21.01, 22.50)	(-33.11, 7.03)	
p-value	0.9464	0.2377	
p-value of Breslow-Day Test for Homogeneity [3]	0.8771	0.3522	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (4.2)	10 (16.1)
No	26 (100)	23 (95.8)	52 (83.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	10.60	4.42	
95% CI of the inverse odds ratio	(0.60, 187.93)	(0.53, 36.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	9.00	3.87	
95% CI of the inverse risk ratio	(0.55, 148.15)	(0.52, 28.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.81	-11.96	
95% CI of the absolute risk difference	(-25.33, -4.30)	(-24.12, 0.19)	
p-value	0.0493	0.1363	
p-value of Breslow-Day Test for Homogeneity [3]	0.0103	0.0055	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (7.7)	4 (16.7)	15 (24.2)
No	24 (92.3)	20 (83.3)	47 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.83	1.60	
95% CI of the inverse odds ratio	(0.81, 18.14)	(0.47, 5.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.15	1.45	
95% CI of the inverse risk ratio	(0.77, 12.79)	(0.54, 3.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-16.50	-7.53	
95% CI of the absolute risk difference	(-31.28, -1.72)	(-25.86, 10.80)	
p-value	0.0736	0.4505	
p-value of Breslow-Day Test for Homogeneity [3]	0.0232	0.1031	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (15.4)	3 (12.5)	6 (9.7)
No	22 (84.6)	21 (87.5)	56 (90.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.75	
95% CI of the inverse odds ratio	(0.15, 2.29)	(0.17, 3.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.77	
95% CI of the inverse risk ratio	(0.19, 2.05)	(0.21, 2.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.71	2.82	
95% CI of the absolute risk difference	(-9.99, 21.41)	(-12.32, 17.96)	
p-value	0.4415	0.7013	
p-value of Breslow-Day Test for Homogeneity [3]	0.4251	0.6508	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (15.4)	4 (16.7)	8 (12.9)
No	22 (84.6)	20 (83.3)	54 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.74	
95% CI of the inverse odds ratio	(0.22, 2.99)	(0.20, 2.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.77	
95% CI of the inverse risk ratio	(0.28, 2.54)	(0.26, 2.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.48	3.76	
95% CI of the absolute risk difference	(-13.70, 18.67)	(-13.32, 20.85)	
p-value	0.7570	0.6514	
p-value of Breslow-Day Test for Homogeneity [3]	0.9332	0.6281	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (11.5)	1 (4.2)	13 (21.0)
No	23 (88.5)	23 (95.8)	49 (79.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.03	6.10	
95% CI of the inverse odds ratio	(0.53, 7.84)	(0.75, 49.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.82	5.03	
95% CI of the inverse risk ratio	(0.56, 5.85)	(0.70, 36.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.43	-16.80	
95% CI of the absolute risk difference	(-25.35, 6.49)	(-29.71, -3.89)	
p-value	0.2954	0.0584	
p-value of Breslow-Day Test for Homogeneity [3]	0.3245	0.1270	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (38.5)	4 (16.7)	16 (25.8)
No	16 (61.5)	20 (83.3)	46 (74.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	1.74	
95% CI of the inverse odds ratio	(0.21, 1.47)	(0.52, 5.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	1.55	
95% CI of the inverse risk ratio	(0.35, 1.28)	(0.58, 4.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.66	-9.14	
95% CI of the absolute risk difference	(-8.99, 34.30)	(-27.60, 9.32)	
p-value	0.2352	0.3682	
p-value of Breslow-Day Test for Homogeneity [3]	0.6358	0.5149	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.7)	1 (4.2)	7 (11.3)
No	24 (92.3)	23 (95.8)	55 (88.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	2.93	
95% CI of the inverse odds ratio	(0.30, 7.90)	(0.34, 25.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	2.71	
95% CI of the inverse risk ratio	(0.33, 6.60)	(0.35, 20.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.60	-7.12	
95% CI of the absolute risk difference	(-16.52, 9.32)	(-18.35, 4.10)	
p-value	0.6113	0.3077	
p-value of Breslow-Day Test for Homogeneity [3]	0.9375	0.0823	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (23.1)	2 (8.3)	16 (25.8)
No	20 (76.9)	22 (91.7)	46 (74.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	3.83	
95% CI of the inverse odds ratio	(0.40, 3.40)	(0.81, 18.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	3.10	
95% CI of the inverse risk ratio	(0.49, 2.54)	(0.77, 12.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.73	-17.47	
95% CI of the absolute risk difference	(-22.25, 16.79)	(-32.99, -1.95)	
p-value	0.7873	0.0740	
p-value of Breslow-Day Test for Homogeneity [3]	0.5319	0.0788	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (8.3)	3 (4.8)
No	26 (100)	22 (91.7)	59 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.56	
95% CI of the inverse odds ratio	NE	(0.09, 3.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.58	
95% CI of the inverse risk ratio	NE	(0.10, 3.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.84	3.49	
95% CI of the absolute risk difference	(-10.18, 0.50)	(-8.79, 15.77)	
p-value	0.2538	0.5345	
p-value of Breslow-Day Test for Homogeneity [3]	0.2165	0.9347	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (15.4)	5 (20.8)	12 (19.4)
No	22 (84.6)	19 (79.2)	50 (80.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	0.91	
95% CI of the inverse odds ratio	(0.38, 4.55)	(0.28, 2.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	0.93	
95% CI of the inverse risk ratio	(0.45, 3.54)	(0.37, 2.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.97	1.48	
95% CI of the absolute risk difference	(-20.97, 13.03)	(-17.51, 20.47)	
p-value	0.6595	0.8773	
p-value of Breslow-Day Test for Homogeneity [3]	0.4957	0.5292	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7961	0.8823	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7786	0.6587	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4475	0.3189	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4551	0.0601	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (50.0)	0
No	5 (100)	1 (50.0)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.33	
95% CI of the inverse odds ratio	NE	(0.01, 16.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.50	
95% CI of the inverse risk ratio	NE	(0.04, 7.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	25.00	
95% CI of the absolute risk difference	NE	(-57.48, 100.00)	
p-value	NE	0.5762	
p-value of Breslow-Day Test for Homogeneity [3]	0.5210	0.6362	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	1 (50.0)	0
No	4 (80.0)	1 (50.0)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.33	
95% CI of the inverse odds ratio	(0.02, 40.28)	(0.01, 16.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.50	
95% CI of the inverse risk ratio	(0.06, 15.99)	(0.04, 7.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	25.00	
95% CI of the absolute risk difference	(-69.30, 69.30)	(-57.48, 100.00)	
p-value	>0.9999	0.5762	
p-value of Breslow-Day Test for Homogeneity [3]	0.8030	0.5864	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6668	0.2912	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9388	0.2964	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (20.0)	0	0
No	4 (80.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse odds ratio	(0.02, 40.28)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse risk ratio	(0.06, 15.99)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	NE	
95% CI of the absolute risk difference	(-69.30, 69.30)	NE	
p-value	>0.9999	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1413	0.2646	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	0	0
No	4 (80.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse odds ratio	(0.02, 40.28)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse risk ratio	(0.06, 15.99)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	NE	
95% CI of the absolute risk difference	(-69.30, 69.30)	NE	
p-value	>0.9999	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8771	0.3522	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0103	0.0055	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0232	0.1031	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4251	0.6508	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9332	0.6281	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3245	0.1270	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6358	0.5149	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9375	0.0823	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5319	0.0788	

AMNOG Table SE22.14b.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2165	0.9347	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4957	0.5292	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Physical Functioning						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	76.40 (22.17)	74.76 (20.37)	74.14 (25.78)			
Median	78.90	80.00	85.00			
IQR: Q1, Q3	60.00, 97.50	60.00, 90.00	60.00, 95.00			
Min, Max	25.0, 100.0	15.0, 100.0	10.0, 100.0			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	77.92 (23.85)	73.33 (22.63)	75.00 (27.96)	1.96 (2.14)	-1.53 (2.81)	0.58 (1.86)
Median	85.00	80.00	85.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	65.00, 95.00	67.50, 95.00	-10.00, 10.00	-10.00, 5.00	-5.00, 10.00
Min, Max	20.0, 100.0	16.7, 100.0	5.0, 100.0	-30.0, 45.0	-65.0, 40.0	-70.0, 50.0
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	76.98 (27.39)	74.05 (23.83)	76.88 (22.98)	-0.66 (2.35)	-0.14 (2.98)	-0.04 (1.49)
Median	90.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 100.00	60.00, 90.00	65.00, 95.00	-5.00, 10.00	-5.00, 5.00	-5.00, 5.00
Min, Max	20.0, 100.0	0.0, 100.0	0.0, 100.0	-42.8, 45.0	-85.0, 35.0	-25.0, 35.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Role Physical						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	77.42 (22.24)	76.54 (22.82)	78.53 (25.38)			
Median	81.30	75.00	87.50			
IQR: Q1, Q3	56.30, 100.00	56.30, 100.00	68.80, 100.00			
Min, Max	25.0, 100.0	18.8, 100.0	0.0, 100.0			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	76.96 (24.36)	74.25 (22.62)	77.36 (28.45)	-0.53 (3.12)	-2.31 (3.45)	-1.04 (2.18)
Median	84.40	75.00	87.50	0	0	0
IQR: Q1, Q3	59.40, 100.00	56.30, 93.80	59.40, 100.00	-12.50, 6.30	-18.70, 6.20	-12.50, 6.20
Min, Max	25.0, 100.0	12.5, 100.0	6.3, 100.0	-43.7, 50.0	-56.2, 50.0	-43.7, 87.5
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	78.07 (23.47)	77.55 (24.80)	76.65 (24.18)	-0.30 (3.03)	1.56 (2.90)	-3.41 (2.11)
Median	81.30	87.50	81.30	0	0	0
IQR: Q1, Q3	62.50, 100.00	56.30, 100.00	56.30, 100.00	-12.50, 6.20	-6.30, 6.30	-12.50, 3.10
Min, Max	31.3, 100.0	12.5, 100.0	0.0, 100.0	-37.5, 56.2	-37.5, 50.0	-62.5, 37.5

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Bodily Pain						
Baseline						
m	53	45	90			
n	51	41	87			
Mean (SD)	69.3 (23.6)	64.4 (25.9)	66.7 (26.0)			
Median	72.0	62.0	72.0			
IQR: Q1, Q3	51.0, 100.0	51.0, 84.0	41.0, 84.0			
Min, Max	12, 100	10, 100	0, 100			
Week 24						
m	49	43	83			
n	48	41	80	46	38	78
Mean (SD/SE)	65.8 (26.0)	68.8 (24.1)	68.6 (25.4)	-3.1 (3.1)	4.0 (2.3)	0.8 (1.8)
Median	67.0	62.0	74.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	62.0, 84.0	51.0, 84.0	-16.0, 0.0	0.0, 11.0	-10.0, 12.0
Min, Max	10, 100	22, 100	12, 100	-50, 52	-23, 38	-39, 42
Week 52						
m	47	38	75			
n	43	37	65	41	36	64
Mean (SD/SE)	69.7 (24.6)	68.9 (25.6)	66.7 (23.7)	-0.2 (3.6)	4.4 (2.9)	-2.3 (2.3)
Median	74.0	74.0	72.0	0	4.0	0
IQR: Q1, Q3	51.0, 100.0	51.0, 84.0	51.0, 84.0	0.0, 10.0	0.0, 12.0	-14.0, 10.0
Min, Max	20, 100	10, 100	12, 100	-80, 59	-53, 38	-49, 33

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
General Health						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	59.98 (21.51)	51.32 (19.04)	59.93 (19.91)			
Median	61.00	52.00	62.00			
IQR: Q1, Q3	43.50, 72.00	35.00, 67.00	45.00, 75.00			
Min, Max	10.0, 100.0	10.0, 100.0	15.0, 100.0			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	60.19 (22.64)	52.90 (17.96)	60.08 (21.54)	0.20 (2.38)	2.24 (2.59)	-0.08 (1.78)
Median	57.00	50.00	61.00	5.00	2.50	0
IQR: Q1, Q3	42.00, 77.00	40.00, 62.00	47.00, 77.00	-8.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	15.0, 100.0	20.0, 92.0	0.0, 100.0	-60.0, 32.0	-27.0, 40.0	-40.0, 48.0
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	61.19 (19.73)	55.62 (16.62)	60.89 (18.80)	-0.38 (2.72)	4.25 (2.67)	-0.98 (1.61)
Median	60.00	55.00	62.00	0	5.00	0
IQR: Q1, Q3	52.00, 77.00	45.00, 67.00	47.00, 72.00	-10.00, 10.00	0.00, 10.00	-7.00, 5.00
Min, Max	25.0, 100.0	20.0, 92.0	10.0, 95.0	-70.0, 32.0	-38.0, 37.0	-35.0, 30.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Vitality						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	58.79 (25.35)	51.86 (23.61)	56.10 (21.72)			
Median	62.50	56.30	62.50			
IQR: Q1, Q3	37.50, 75.00	37.50, 62.50	37.50, 75.00			
Min, Max	0.0, 100.0	0.0, 93.8	6.3, 93.8			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	58.62 (26.38)	52.46 (21.14)	57.37 (22.15)	-1.19 (2.22)	1.64 (2.87)	0.51 (1.78)
Median	62.50	50.00	56.30	0	0	0
IQR: Q1, Q3	40.65, 75.00	37.50, 62.50	37.50, 75.00	-6.30, 6.30	-6.30, 6.30	-12.50, 12.50
Min, Max	0.0, 100.0	12.5, 100.0	0.0, 100.0	-43.8, 43.8	-25.0, 43.8	-31.3, 43.8
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	61.94 (22.36)	52.05 (22.15)	57.43 (23.60)	0.01 (2.33)	0.51 (2.38)	0.62 (2.27)
Median	62.50	50.00	62.50	0	0	6.20
IQR: Q1, Q3	43.80, 75.00	37.50, 68.80	43.80, 75.00	-6.30, 12.50	-6.30, 6.30	-6.30, 12.50
Min, Max	6.3, 100.0	6.3, 100.0	0.0, 100.0	-43.7, 37.5	-25.0, 43.8	-50.0, 37.5

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Social Functioning						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	79.57 (26.55)	78.66 (25.19)	82.33 (23.93)			
Median	93.75	87.50	100.00			
IQR: Q1, Q3	50.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	81.25 (25.79)	80.18 (19.96)	80.00 (27.39)	0.80 (3.14)	1.64 (3.44)	-0.96 (2.23)
Median	87.50	75.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	62.50, 100.00	-12.50, 0.00	-12.50, 12.50	-12.50, 12.50
Min, Max	12.5, 100.0	37.5, 100.0	0.0, 100.0	-50.0, 75.0	-62.5, 37.5	-62.5, 50.0
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	84.59 (22.47)	82.09 (22.92)	83.27 (23.41)	1.19 (2.58)	3.13 (3.67)	-0.39 (2.36)
Median	100.00	87.50	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 12.50	0.00, 12.50	0.00, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-37.5, 50.0	-62.5, 62.5	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Role Emotional						
Baseline						
m	53	45	90			
n	52	41	86			
Mean (SD)	80.28 (27.17)	85.97 (21.44)	84.01 (24.19)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	70.85, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	25.0, 100.0	0.0, 100.0			
Week 24						
m	49	43	83			
n	48	41	80	47	38	77
Mean (SD/SE)	79.86 (24.84)	86.18 (20.30)	81.35 (26.83)	-1.24 (2.25)	1.32 (2.69)	-0.76 (2.16)
Median	87.50	100.00	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	66.70, 100.00	-8.30, 0.00	0.00, 8.30	0.00, 0.00
Min, Max	25.0, 100.0	33.3, 100.0	0.0, 100.0	-33.3, 41.7	-50.0, 41.7	-50.0, 50.0
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	84.11 (20.80)	84.91 (23.15)	83.46 (24.14)	0.40 (1.91)	-1.62 (3.63)	-1.95 (2.09)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	-16.70, 8.35	-8.30, 0.00
Min, Max	33.3, 100.0	8.3, 100.0	0.0, 100.0	-25.0, 41.7	-50.0, 50.0	-58.3, 33.4

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Mental Health						
Baseline						
m	53	45	90			
n	52	41	87			
Mean (SD)	72.5 (24.5)	76.8 (17.5)	75.6 (18.1)			
Median	77.5	80.0	80.0			
IQR: Q1, Q3	62.5, 90.0	65.0, 90.0	70.0, 90.0			
Min, Max	5, 100	30, 100	5, 100			
Week 24						
m	49	43	83			
n	48	41	80	47	38	78
Mean (SD/SE)	72.7 (22.9)	73.9 (17.7)	73.6 (19.8)	-0.9 (1.8)	-2.1 (2.2)	-0.1 (1.7)
Median	80.0	75.0	80.0	0	0	0
IQR: Q1, Q3	62.5, 90.0	65.0, 90.0	67.5, 87.5	-10.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	15, 100	25, 100	5, 100	-30, 35	-40, 35	-45, 45
Week 52						
m	47	38	75			
n	43	37	65	42	36	64
Mean (SD/SE)	76.0 (18.6)	75.1 (17.3)	75.8 (21.4)	0.0 (1.6)	-2.4 (1.9)	1.4 (1.8)
Median	80.0	75.0	85.0	0	0	0
IQR: Q1, Q3	70.0, 90.0	65.0, 90.0	65.0, 90.0	-5.0, 5.0	-5.0, 5.0	-7.5, 10.0
Min, Max	25, 100	35, 100	0, 100	-20, 25	-30, 25	-40, 30

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Mental Component Score						
Baseline						
m	53	45	90			
n	51	41	86			
Mean (SD)	49.55 (12.97)	51.09 (10.12)	51.12 (9.94)			
Median	53.70	53.70	53.90			
IQR: Q1, Q3	44.30, 58.50	46.90, 58.00	48.40, 57.80			
Min, Max	12.0, 67.0	23.6, 63.8	15.6, 65.8			
Week 24						
m	49	43	83			
n	48	41	80	46	38	77
Mean (SD/SE)	49.56 (11.84)	50.66 (8.66)	49.91 (10.80)	-0.79 (0.98)	0.13 (1.21)	-0.26 (0.86)
Median	53.10	52.00	54.15	-0.40	0.75	0
IQR: Q1, Q3	43.60, 58.55	46.10, 58.70	43.00, 57.65	-3.40, 2.90	-2.10, 2.90	-3.80, 3.40
Min, Max	20.0, 62.3	33.3, 62.3	14.2, 63.2	-20.0, 14.2	-24.5, 22.4	-20.9, 18.6
Week 52						
m	47	38	75			
n	43	37	65	41	36	64
Mean (SD/SE)	51.78 (9.65)	50.67 (9.27)	51.13 (11.58)	0.09 (0.79)	-0.75 (1.33)	0.29 (0.99)
Median	54.40	52.00	54.80	0	-1.05	1.70
IQR: Q1, Q3	43.50, 59.40	46.10, 58.00	46.60, 59.40	-2.20, 3.40	-4.50, 2.10	-3.20, 5.30
Min, Max	26.7, 63.2	26.9, 63.2	8.9, 68.0	-12.7, 14.9	-15.2, 25.2	-24.6, 16.9

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Physical Component Score						
Baseline						
m	53	45	90			
n	51	41	86			
Mean (SD)	48.85 (6.94)	45.72 (8.79)	47.63 (9.51)			
Median	49.20	45.10	50.10			
IQR: Q1, Q3	43.00, 54.80	39.60, 53.00	41.20, 54.60			
Min, Max	33.4, 60.8	29.2, 59.7	24.3, 65.2			
Week 24						
m	49	43	83			
n	48	41	80	46	38	77
Mean (SD/SE)	48.56 (8.55)	46.28 (8.39)	48.26 (9.65)	0.10 (0.93)	0.39 (0.99)	0.05 (0.67)
Median	48.65	47.20	50.35	0.60	0.20	0
IQR: Q1, Q3	42.25, 55.55	39.60, 52.10	41.25, 55.80	-4.10, 4.10	-3.10, 5.10	-2.80, 3.00
Min, Max	27.4, 63.9	28.8, 60.2	24.4, 62.9	-12.7, 17.6	-19.3, 16.2	-17.0, 23.8
Week 52						
m	47	38	75			
n	43	37	65	41	36	64
Mean (SD/SE)	48.48 (9.44)	47.10 (8.36)	47.90 (8.15)	-0.10 (1.04)	1.65 (1.12)	-0.84 (0.57)
Median	51.90	47.60	47.60	-0.60	1.90	-0.25
IQR: Q1, Q3	41.80, 56.00	41.40, 53.40	42.10, 55.00	-2.80, 1.50	-1.85, 5.00	-3.95, 2.55
Min, Max	22.9, 59.2	29.4, 61.2	27.3, 59.6	-24.7, 14.9	-22.5, 14.8	-11.0, 10.6

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Physical Functioning						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	74.35 (23.02)	70.88 (25.25)	74.25 (25.77)			
Median	80.00	75.00	85.00			
IQR: Q1, Q3	60.00, 95.00	55.00, 90.00	55.00, 95.00			
Min, Max	20.0, 100.0	10.0, 100.0	10.0, 100.0			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	74.71 (23.31)	71.58 (25.30)	73.98 (27.67)	0.00 (2.10)	-1.10 (2.96)	-0.64 (1.53)
Median	80.00	80.00	85.00	0	0	0
IQR: Q1, Q3	60.00, 95.00	65.00, 90.00	55.00, 100.00	-7.50, 10.00	-10.00, 5.00	-10.00, 5.00
Min, Max	5.0, 100.0	5.0, 100.0	0.0, 100.0	-50.0, 60.0	-65.0, 60.0	-50.0, 65.0
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	75.63 (26.52)	74.59 (24.01)	75.28 (25.78)	0.98 (2.06)	1.22 (2.72)	0.40 (1.67)
Median	85.00	84.15	85.00	0	5.00	0
IQR: Q1, Q3	55.00, 97.50	60.00, 95.00	65.00, 95.00	-5.00, 5.00	-5.00, 10.00	-10.00, 10.00
Min, Max	5.0, 100.0	15.0, 100.0	0.0, 100.0	-65.0, 35.0	-52.2, 40.0	-60.0, 70.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=72)	Visit Result: MGL-3196 100 mg (N=65)	Visit Result: Placebo (N=139)	Change from Baseline: MGL-3196 80 mg (N=72)	Change from Baseline: MGL-3196 100 mg (N=65)	Change from Baseline: Placebo (N=139)
Role Physical						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	76.19 (27.75)	75.78 (27.27)	74.62 (26.39)			
Median	87.50	87.50	81.30			
IQR: Q1, Q3	56.30, 100.00	56.30, 100.00	56.30, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	6.3, 100.0			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	73.85 (25.29)	74.47 (24.72)	74.43 (27.45)	-2.48 (1.99)	-3.63 (2.68)	-0.58 (1.96)
Median	75.00	81.30	81.30	0	0	0
IQR: Q1, Q3	56.30, 100.00	56.30, 100.00	50.00, 100.00	-12.50, 9.40	-12.50, 0.00	-6.30, 6.30
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.8, 31.3	-50.0, 62.5	-68.7, 62.5
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	74.52 (29.06)	76.10 (24.19)	73.53 (25.72)	-1.13 (2.41)	0.30 (3.46)	-0.60 (1.92)
Median	87.50	81.30	81.30	0	0	0
IQR: Q1, Q3	50.00, 100.00	62.50, 100.00	50.00, 100.00	-6.20, 6.20	-6.30, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	12.5, 100.0	6.3, 100.0	-43.8, 81.2	-68.8, 81.3	-56.3, 68.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Bodily Pain						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	64.8 (24.2)	64.5 (25.9)	63.6 (24.5)			
Median	72.0	72.0	62.0			
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	41.0, 84.0			
Min, Max	0, 100	12, 100	0, 100			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	64.1 (23.5)	65.4 (24.5)	62.7 (25.8)	-1.1 (2.4)	-2.3 (3.3)	-0.7 (1.8)
Median	62.0	62.0	62.0	0	0	0
IQR: Q1, Q3	51.0, 84.0	42.0, 84.0	41.0, 84.0	-14.0, 10.0	-12.0, 10.0	-12.0, 12.0
Min, Max	0, 100	10, 100	0, 100	-43, 68	-62, 72	-49, 58
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	67.0 (25.1)	71.7 (24.1)	67.4 (24.7)	1.2 (2.4)	5.9 (4.1)	4.6 (2.0)
Median	67.0	73.0	73.0	0	0	0
IQR: Q1, Q3	51.0, 84.0	52.0, 100.0	51.0, 84.0	-10.0, 10.0	-12.0, 20.0	-10.0, 16.0
Min, Max	0, 100	20, 100	10, 100	-60, 68	-43, 69	-48, 69

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
General Health						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	60.52 (20.05)	59.12 (18.67)	56.36 (20.47)			
Median	62.00	62.00	57.00			
IQR: Q1, Q3	50.00, 77.00	47.00, 72.00	42.00, 72.00			
Min, Max	10.0, 97.0	15.0, 92.0	15.0, 97.0			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	62.23 (20.93)	59.00 (19.39)	57.75 (21.64)	2.13 (1.47)	-0.48 (2.25)	0.90 (1.35)
Median	64.50	57.00	57.00	0	0	0
IQR: Q1, Q3	52.00, 77.00	47.00, 72.00	42.00, 72.00	-5.00, 10.00	-10.00, 10.00	-10.00, 10.00
Min, Max	10.0, 100.0	17.0, 100.0	10.0, 100.0	-25.0, 32.0	-35.0, 35.0	-37.0, 40.0
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	64.26 (20.18)	60.61 (19.89)	58.77 (20.89)	3.90 (1.79)	1.52 (2.89)	3.12 (1.26)
Median	67.00	62.00	61.00	0	3.00	2.00
IQR: Q1, Q3	49.50, 79.50	47.00, 77.00	47.00, 77.00	-5.00, 15.00	-10.00, 15.00	-5.00, 12.00
Min, Max	20.0, 100.0	10.0, 92.0	10.0, 100.0	-27.0, 47.0	-52.0, 47.0	-40.0, 32.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Vitality						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	57.02 (21.55)	56.93 (17.82)	55.14 (21.34)			
Median	62.50	56.30	56.30			
IQR: Q1, Q3	37.50, 75.00	43.80, 68.80	43.80, 68.80			
Min, Max	6.3, 100.0	12.5, 100.0	0.0, 100.0			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	55.47 (23.89)	56.16 (17.14)	55.64 (22.47)	-0.94 (1.63)	-3.37 (1.72)	-0.74 (1.27)
Median	56.30	56.30	56.30	0	-3.10	0
IQR: Q1, Q3	37.50, 75.00	43.80, 68.80	37.50, 68.80	-6.30, 6.30	-12.50, 6.20	-6.30, 6.30
Min, Max	0.0, 100.0	0.0, 93.8	6.3, 100.0	-25.0, 37.5	-31.2, 25.0	-37.5, 56.2
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	57.44 (22.13)	57.77 (18.64)	55.45 (22.36)	-0.10 (1.92)	-0.89 (2.38)	0.18 (1.66)
Median	62.50	59.40	56.30	0	0	0
IQR: Q1, Q3	40.65, 75.00	50.00, 75.00	43.80, 68.80	-6.30, 12.50	-12.50, 6.30	-6.30, 12.50
Min, Max	6.3, 100.0	6.3, 87.5	6.3, 100.0	-37.5, 37.5	-43.8, 37.5	-56.3, 43.8

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Social Functioning						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	82.79 (22.49)	82.46 (23.37)	83.27 (21.02)			
Median	87.50	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	12.5, 100.0	25.0, 100.0			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	81.25 (24.52)	83.11 (21.06)	82.03 (22.77)	-1.47 (2.38)	-0.75 (2.78)	-1.91 (1.52)
Median	100.00	87.50	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	62.50, 100.00	-12.50, 12.50	-12.50, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	12.5, 100.0	12.5, 100.0	-50.0, 62.5	-50.0, 37.5	-50.0, 50.0
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	79.30 (22.85)	84.78 (19.53)	81.58 (21.70)	-3.48 (2.25)	1.19 (3.40)	-1.55 (1.79)
Median	87.50	93.75	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	62.50, 100.00	-12.50, 0.00	0.00, 12.50	-12.50, 0.00
Min, Max	25.0, 100.0	25.0, 100.0	12.5, 100.0	-50.0, 25.0	-50.0, 50.0	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Role Emotional						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	83.57 (22.78)	81.00 (23.08)	84.45 (21.14)			
Median	100.00	91.70	100.00			
IQR: Q1, Q3	75.00, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	8.3, 100.0	8.3, 100.0			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	81.90 (22.61)	86.11 (20.92)	83.53 (21.88)	-0.98 (2.37)	3.00 (2.09)	-1.48 (1.54)
Median	95.85	100.00	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	70.85, 100.00	-8.30, 0.00	0.00, 8.40	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	8.3, 100.0	-66.7, 66.7	-25.0, 41.7	-50.0, 50.0
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	83.66 (21.06)	86.05 (20.64)	80.92 (22.63)	1.57 (2.48)	7.34 (2.74)	-3.34 (1.95)
Median	95.85	100.00	91.70	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	58.30, 100.00	0.00, 8.30	0.00, 16.70	-16.70, 0.00
Min, Max	25.0, 100.0	25.0, 100.0	16.7, 100.0	-33.3, 100.0	-33.3, 50.0	-50.0, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Mental Health						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	75.2 (17.1)	74.7 (21.5)	74.1 (18.2)			
Median	80.0	80.0	80.0			
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	60.0, 90.0			
Min, Max	25, 100	15, 100	20, 100			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	73.0 (18.6)	78.8 (19.0)	75.2 (18.7)	-1.4 (1.8)	1.5 (1.8)	0.7 (1.3)
Median	75.0	80.0	80.0	0	0	0
IQR: Q1, Q3	60.0, 90.0	75.0, 90.0	65.0, 90.0	-7.5, 5.0	-5.0, 5.0	-5.0, 5.0
Min, Max	20, 100	5, 100	20, 100	-40, 35	-35, 50	-30, 55
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	74.6 (17.3)	75.9 (19.0)	74.9 (18.5)	-0.2 (1.9)	0.1 (2.0)	0.4 (1.5)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	62.5, 90.0	70.0, 90.0	65.0, 90.0	-10.0, 5.0	-10.0, 5.0	-10.0, 10.0
Min, Max	30, 100	20, 100	20, 100	-35, 40	-25, 50	-40, 55

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Mental Component Score						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	51.23 (9.26)	50.95 (11.43)	51.11 (9.18)			
Median	53.60	53.80	53.30			
IQR: Q1, Q3	47.00, 57.90	46.70, 59.20	46.00, 57.70			
Min, Max	27.2, 69.0	17.0, 66.8	25.9, 66.5			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	50.11 (10.27)	52.85 (10.16)	51.20 (9.94)	-0.66 (0.97)	0.82 (0.99)	-0.27 (0.67)
Median	52.80	55.30	53.15	-1.10	-0.70	0
IQR: Q1, Q3	42.90, 58.20	51.40, 59.00	45.35, 58.95	-4.90, 3.70	-3.20, 5.60	-4.60, 2.70
Min, Max	18.7, 66.6	9.4, 63.6	21.2, 66.3	-20.0, 19.0	-13.0, 26.1	-19.0, 24.8
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	50.61 (9.04)	51.85 (10.23)	50.32 (9.84)	-0.25 (1.02)	1.02 (1.17)	-0.85 (0.72)
Median	52.95	53.15	52.65	0	-0.05	-0.50
IQR: Q1, Q3	43.65, 57.25	47.80, 59.00	45.20, 57.80	-3.40, 3.50	-3.90, 5.40	-4.30, 2.20
Min, Max	23.1, 62.4	17.8, 65.3	20.4, 64.6	-17.3, 26.2	-14.0, 22.2	-20.7, 26.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Physical Component Score						
Baseline						
m	72	65	139			
n	69	57	127			
Mean (SD)	47.19 (9.05)	46.63 (9.50)	46.36 (10.02)			
Median	48.60	47.30	48.50			
IQR: Q1, Q3	40.50, 55.30	41.60, 54.20	37.40, 54.90			
Min, Max	24.7, 59.3	23.4, 61.3	20.7, 59.8			
Week 24						
m	72	58	135			
n	70	57	128	68	50	118
Mean (SD/SE)	47.45 (9.00)	45.79 (9.29)	46.30 (10.54)	0.04 (0.75)	-1.44 (1.20)	-0.13 (0.66)
Median	49.10	47.20	48.15	0.30	-0.60	0
IQR: Q1, Q3	42.50, 53.30	39.20, 52.20	39.05, 54.75	-4.30, 4.15	-5.10, 1.70	-4.60, 3.40
Min, Max	22.5, 61.4	24.6, 61.0	19.0, 63.0	-14.8, 18.3	-22.1, 32.4	-28.8, 23.3
Week 52						
m	69	51	128			
n	64	46	114	61	42	105
Mean (SD/SE)	47.99 (10.71)	47.85 (9.52)	47.36 (9.77)	0.54 (0.91)	0.56 (1.28)	1.18 (0.59)
Median	50.85	50.10	49.00	1.10	1.85	0.20
IQR: Q1, Q3	41.25, 57.20	41.40, 55.60	42.20, 55.10	-1.60, 4.10	-3.50, 5.00	-1.70, 4.20
Min, Max	20.3, 62.8	24.8, 61.1	21.5, 63.9	-24.2, 22.5	-23.5, 18.6	-17.9, 20.5

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Physical Functioning						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	70.19 (29.50)	61.25 (29.40)	73.04 (25.67)			
Median	75.00	72.50	80.00			
IQR: Q1, Q3	55.00, 95.00	40.00, 87.50	60.00, 95.00			
Min, Max	0.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	73.10 (27.43)	69.85 (24.86)	76.63 (27.27)	2.96 (3.47)	9.66 (4.14)	2.82 (3.22)
Median	85.00	75.00	85.00	5.00	7.50	0
IQR: Q1, Q3	55.00, 95.00	50.00, 90.00	70.00, 100.00	-5.00, 10.00	-10.00, 20.00	-5.00, 15.00
Min, Max	10.0, 100.0	30.0, 100.0	0.0, 100.0	-50.0, 40.0	-15.0, 70.0	-50.0, 75.0
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	77.50 (25.30)	60.24 (29.77)	76.78 (25.74)	5.48 (3.10)	-0.95 (4.47)	2.00 (3.13)
Median	82.50	65.00	85.00	5.00	0	0
IQR: Q1, Q3	65.00, 100.00	40.00, 85.00	60.00, 100.00	-5.00, 10.00	-5.00, 10.00	-7.50, 7.50
Min, Max	0.0, 100.0	5.0, 100.0	0.0, 100.0	-20.0, 35.0	-50.0, 35.0	-45.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Role Physical						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	71.54 (28.39)	64.08 (27.57)	72.69 (27.09)			
Median	81.30	75.00	81.30			
IQR: Q1, Q3	50.00, 100.00	40.65, 84.40	56.30, 100.00			
Min, Max	0.0, 100.0	12.5, 100.0	0.0, 100.0			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	68.77 (33.15)	70.93 (25.85)	76.51 (25.73)	-2.55 (3.52)	6.97 (3.96)	2.21 (3.06)
Median	81.30	71.90	81.30	0	0	0
IQR: Q1, Q3	43.80, 100.00	50.00, 100.00	62.50, 100.00	-12.50, 6.30	-6.30, 18.70	-6.30, 6.30
Min, Max	0.0, 100.0	18.8, 100.0	0.0, 100.0	-43.7, 43.7	-18.7, 68.7	-56.2, 68.7
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	76.42 (30.37)	63.41 (34.35)	77.38 (25.57)	-0.01 (2.90)	-1.19 (5.21)	2.18 (3.77)
Median	93.75	75.00	81.30	0	0	0
IQR: Q1, Q3	62.50, 100.00	31.30, 93.80	62.50, 100.00	0.00, 6.20	-6.20, 12.50	-12.50, 15.60
Min, Max	0.0, 100.0	6.3, 100.0	6.3, 100.0	-31.3, 25.0	-75.0, 25.0	-56.3, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Bodily Pain						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	64.8 (25.1)	54.3 (25.9)	63.3 (25.4)			
Median	62.0	57.0	62.0			
IQR: Q1, Q3	51.0, 84.0	36.5, 72.0	41.0, 84.0			
Min, Max	22, 100	0, 100	22, 100			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	62.4 (29.1)	56.7 (20.3)	68.0 (25.1)	-2.4 (3.7)	1.8 (4.3)	2.5 (4.2)
Median	72.0	51.5	73.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	41.0, 74.0	51.0, 84.0	-16.0, 10.0	-16.0, 10.0	-16.0, 20.0
Min, Max	0, 100	22, 100	0, 100	-59, 38	-22, 64	-78, 78
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	67.9 (29.5)	55.0 (24.6)	66.8 (27.2)	1.0 (4.3)	2.4 (4.4)	1.1 (4.7)
Median	74.0	62.0	72.0	0	0	0
IQR: Q1, Q3	32.0, 100.0	41.0, 72.0	51.0, 84.0	0.0, 10.0	-12.0, 10.0	-19.5, 19.5
Min, Max	22, 100	10, 100	0, 100	-40, 38	-22, 62	-78, 78

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
General Health						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	59.96 (15.43)	51.50 (19.32)	59.69 (20.63)			
Median	62.00	48.50	62.00			
IQR: Q1, Q3	47.00, 72.00	38.50, 66.00	45.00, 77.00			
Min, Max	25.0, 82.0	10.0, 87.0	15.0, 100.0			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	57.62 (18.15)	53.08 (20.74)	60.72 (21.69)	-0.93 (3.01)	2.96 (3.45)	2.60 (1.91)
Median	57.00	53.50	62.00	-5.00	0	2.00
IQR: Q1, Q3	42.00, 72.00	37.00, 67.00	42.00, 82.00	-10.00, 10.00	-10.00, 22.00	-5.00, 10.00
Min, Max	20.0, 90.0	10.0, 87.0	15.0, 100.0	-47.0, 25.0	-22.0, 37.0	-20.0, 37.0
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	59.50 (19.16)	48.67 (21.41)	62.53 (24.39)	-1.05 (2.75)	-2.71 (3.83)	2.15 (2.48)
Median	59.50	50.00	62.00	-5.00	-5.00	0
IQR: Q1, Q3	47.00, 77.00	27.00, 67.00	50.00, 82.00	-10.00, 5.00	-15.00, 12.00	-5.00, 11.50
Min, Max	20.0, 87.0	15.0, 82.0	10.0, 100.0	-22.0, 30.0	-47.0, 25.0	-42.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Vitality						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	57.44 (19.98)	48.02 (27.85)	57.87 (22.00)			
Median	56.30	50.00	62.50			
IQR: Q1, Q3	43.80, 75.00	25.00, 68.80	43.80, 75.00			
Min, Max	18.8, 100.0	0.0, 93.8	6.3, 93.8			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	54.33 (19.13)	49.07 (22.69)	57.76 (21.52)	-1.86 (3.30)	2.40 (3.81)	1.10 (2.93)
Median	56.30	53.15	62.50	0	3.10	0
IQR: Q1, Q3	43.80, 68.80	31.30, 62.50	37.50, 75.00	-12.50, 6.30	-12.50, 18.80	-12.50, 12.50
Min, Max	0.0, 87.5	12.5, 93.8	6.3, 100.0	-43.8, 31.2	-31.3, 43.7	-37.5, 43.7
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	58.26 (24.88)	50.62 (22.79)	60.86 (21.17)	0.89 (3.82)	1.78 (4.00)	2.35 (3.02)
Median	59.40	50.00	62.50	0	0	0
IQR: Q1, Q3	37.50, 81.30	31.30, 68.80	43.80, 75.00	-12.50, 6.30	-6.30, 6.30	-9.40, 12.50
Min, Max	18.8, 93.8	6.3, 87.5	12.5, 100.0	-31.3, 50.0	-43.8, 37.5	-31.3, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Social Functioning						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	81.48 (21.75)	74.11 (29.84)	80.88 (25.17)			
Median	87.50	75.00	87.50			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	0.0, 100.0	25.0, 100.0			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	77.16 (25.89)	78.85 (19.29)	80.75 (25.15)	-2.31 (4.99)	5.29 (4.56)	-1.39 (4.04)
Median	87.50	75.00	100.00	0	0	0
IQR: Q1, Q3	50.00, 100.00	75.00, 100.00	62.50, 100.00	-12.50, 12.50	0.00, 12.50	-12.50, 0.00
Min, Max	25.0, 100.0	37.5, 100.0	12.5, 100.0	-62.5, 50.0	-25.0, 87.5	-62.5, 75.0
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	82.95 (24.56)	75.60 (25.46)	84.17 (22.04)	0.00 (4.05)	1.79 (6.06)	2.50 (3.96)
Median	100.00	75.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00	0.00, 0.00	0.00, 12.50	-6.25, 12.50
Min, Max	25.0, 100.0	25.0, 100.0	25.0, 100.0	-50.0, 37.5	-62.5, 62.5	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Role Emotional						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	79.32 (27.19)	77.38 (25.14)	80.88 (23.23)			
Median	91.70	87.50	83.30			
IQR: Q1, Q3	75.00, 100.00	54.15, 100.00	75.00, 100.00			
Min, Max	25.0, 100.0	25.0, 100.0	25.0, 100.0			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	80.75 (22.50)	79.82 (22.13)	82.83 (25.61)	3.71 (3.48)	3.53 (3.14)	0.18 (3.52)
Median	91.70	87.50	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	75.00, 100.00	0.00, 16.70	0.00, 8.30	-8.30, 16.70
Min, Max	25.0, 100.0	25.0, 100.0	8.3, 100.0	-33.3, 41.7	-25.0, 33.4	-50.0, 58.3
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	82.20 (23.05)	82.14 (23.17)	85.37 (22.06)	3.17 (3.88)	5.55 (6.15)	2.09 (2.99)
Median	95.85	100.00	100.00	0	0	0
IQR: Q1, Q3	66.70, 100.00	75.00, 100.00	75.00, 100.00	0.00, 0.00	0.00, 16.70	-4.15, 12.55
Min, Max	25.0, 100.0	25.0, 100.0	0.0, 100.0	-25.0, 50.0	-75.0, 58.3	-33.3, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Mental Health						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	72.0 (18.6)	72.7 (17.9)	75.6 (16.4)			
Median	85.0	80.0	80.0			
IQR: Q1, Q3	55.0, 85.0	57.5, 85.0	65.0, 90.0			
Min, Max	35, 95	35, 100	25, 100			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	71.0 (19.1)	70.4 (19.0)	74.3 (18.7)	0.9 (2.5)	-1.9 (2.5)	-2.3 (2.4)
Median	70.0	72.5	80.0	0	-5.0	-5.0
IQR: Q1, Q3	60.0, 90.0	55.0, 85.0	65.0, 90.0	-5.0, 5.0	-10.0, 5.0	-10.0, 5.0
Min, Max	40, 100	30, 100	30, 100	-25, 30	-30, 35	-35, 35
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	75.2 (18.6)	72.9 (20.3)	78.4 (17.2)	4.3 (2.3)	1.4 (3.3)	1.5 (2.4)
Median	80.0	75.0	80.0	5.0	0	0
IQR: Q1, Q3	60.0, 90.0	65.0, 90.0	75.0, 85.0	-5.0, 10.0	-5.0, 5.0	-7.5, 7.5
Min, Max	40, 100	35, 100	15, 100	-15, 25	-25, 35	-40, 50

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Mental Component Score						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	50.14 (11.32)	49.69 (11.45)	51.07 (9.06)			
Median	53.10	53.95	55.00			
IQR: Q1, Q3	42.30, 59.10	41.10, 59.05	43.60, 58.60			
Min, Max	26.7, 64.7	27.9, 70.0	27.3, 65.3			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	49.31 (10.56)	49.02 (10.15)	50.39 (10.79)	0.40 (1.36)	-0.26 (1.27)	-1.05 (1.38)
Median	51.00	48.80	52.80	1.10	-1.00	-1.20
IQR: Q1, Q3	43.40, 56.60	40.90, 59.10	47.10, 57.90	-4.30, 4.40	-3.00, 1.70	-5.20, 2.40
Min, Max	28.3, 69.1	30.6, 68.3	21.9, 69.0	-16.5, 14.8	-11.4, 19.1	-24.6, 19.9
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	50.75 (10.51)	51.16 (9.64)	52.60 (8.69)	1.25 (1.26)	1.81 (2.34)	0.96 (1.30)
Median	54.55	53.40	54.80	2.30	0.10	0.30
IQR: Q1, Q3	41.40, 58.30	43.10, 59.70	49.20, 58.10	-3.90, 6.70	-2.90, 5.90	-2.15, 4.70
Min, Max	25.1, 61.9	36.4, 68.1	21.3, 62.3	-9.3, 12.4	-21.4, 25.1	-21.4, 24.1

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Physical Component Score						
Baseline						
m	30	28	57			
n	27	28	51			
Mean (SD)	46.57 (10.79)	41.81 (10.70)	46.43 (8.28)			
Median	47.50	44.90	47.20			
IQR: Q1, Q3	43.10, 56.10	33.90, 48.40	40.70, 54.10			
Min, Max	15.3, 59.0	21.2, 57.5	25.9, 61.1			
Week 24						
m	30	28	54			
n	29	26	50	27	26	45
Mean (SD/SE)	46.09 (12.24)	44.63 (8.31)	48.21 (9.66)	-0.67 (1.23)	2.98 (1.55)	1.63 (1.18)
Median	50.20	43.10	50.25	-1.20	0.10	0.30
IQR: Q1, Q3	39.50, 54.10	38.00, 53.30	43.30, 56.00	-2.80, 3.70	-3.00, 7.40	-1.70, 6.20
Min, Max	12.5, 62.7	28.0, 56.7	23.1, 62.0	-17.2, 10.9	-7.0, 21.7	-21.7, 22.9
Week 52						
m	26	25	52			
n	22	21	45	21	21	40
Mean (SD/SE)	48.14 (11.55)	40.95 (11.21)	47.76 (9.96)	0.16 (1.10)	-0.91 (1.79)	0.68 (1.22)
Median	50.90	41.70	48.10	0.80	-0.50	1.25
IQR: Q1, Q3	42.60, 57.70	34.50, 50.40	42.90, 56.00	-1.00, 3.50	-3.10, 4.80	-4.85, 3.60
Min, Max	15.8, 62.7	16.0, 57.0	23.6, 61.7	-14.1, 9.9	-20.4, 11.6	-23.9, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Physical Functioning			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	75.49 (22.48)	74.21 (19.75)	75.13 (25.97)
Analysis Visit Mean (SD)	77.45 (23.89)	72.68 (22.21)	75.71 (27.47)
LS Mean of Change from Baseline (SE)	2.54 (2.35)	-1.39 (2.55)	0.89 (1.83)
95% CI	(-2.09, 7.18)	(-6.43, 3.64)	(-2.72, 4.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.65 (2.89)	-2.28 (3.10)	
95% CI	(-4.06, 7.36)	(-8.40, 3.83)	
p-value	0.5683	0.4626	
Corrected Hedge's g Statistics	0.102	-0.141	
95% CI	(-0.26, 0.46)	(-0.53, 0.25)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	77.09 (22.74)	73.47 (20.80)	76.72 (23.62)
Analysis Visit Mean (SD)	76.43 (27.48)	73.33 (23.75)	76.68 (23.10)
LS Mean of Change from Baseline (SE)	0.67 (2.31)	-0.12 (2.41)	0.22 (1.84)
95% CI	(-3.89, 5.22)	(-4.88, 4.65)	(-3.42, 3.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.44 (2.85)	-0.34 (3.00)	
95% CI	(-5.19, 6.08)	(-6.26, 5.58)	
p-value	0.8763	0.9106	
Corrected Hedge's g Statistics	0.030	-0.023	
95% CI	(-0.36, 0.42)	(-0.43, 0.39)	
Subgroup*Treatment Interaction p-value	0.9644	0.9483	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Role Physical			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	77.01 (22.11)	76.17 (22.45)	79.34 (25.50)
Analysis Visit Mean (SD)	76.47 (24.38)	73.87 (22.69)	78.30 (28.08)
LS Mean of Change from Baseline (SE)	0.54 (2.88)	-2.40 (3.13)	0.22 (2.25)
95% CI	(-5.14, 6.23)	(-8.59, 3.79)	(-4.21, 4.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.32 (3.56)	-2.62 (3.81)	
95% CI	(-6.70, 7.35)	(-10.15, 4.91)	
p-value	0.9282	0.4927	
Corrected Hedge's g Statistics	0.016	-0.132	
95% CI	(-0.35, 0.38)	(-0.52, 0.26)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	77.84 (22.55)	75.37 (23.66)	80.58 (24.77)
Analysis Visit Mean (SD)	77.54 (23.50)	76.92 (24.86)	77.16 (24.02)
LS Mean of Change from Baseline (SE)	1.57 (2.62)	1.52 (2.74)	-2.11 (2.09)
95% CI	(-3.59, 6.74)	(-3.88, 6.92)	(-6.24, 2.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.68 (3.24)	3.63 (3.40)	
95% CI	(-2.71, 10.07)	(-3.09, 10.34)	
p-value	0.2568	0.2881	
Corrected Hedge's g Statistics	0.217	0.216	
95% CI	(-0.17, 0.61)	(-0.19, 0.63)	
Subgroup*Treatment Interaction p-value	0.6173	0.9236	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Bodily Pain			
Week 24			
m	49	43	83
n	46	38	78
Baseline Mean (SD)	68.6 (23.4)	64.1 (25.1)	68.8 (25.3)
Analysis Visit Mean (SD)	65.6 (25.8)	68.1 (24.2)	69.6 (25.0)
LS Mean of Change from Baseline (SE)	-2.35 (2.44)	3.43 (2.63)	1.34 (1.89)
95% CI	(-7.18, 2.47)	(-1.76, 8.61)	(-2.39, 5.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.70 (2.99)	2.08 (3.19)	
95% CI	(-9.60, 2.21)	(-4.22, 8.39)	
p-value	0.2180	0.5152	
Corrected Hedge's g Statistics	-0.221	0.125	
95% CI	(-0.59, 0.14)	(-0.26, 0.51)	
Week 52			
m	47	38	75
n	41	36	64
Baseline Mean (SD)	69.8 (24.9)	63.7 (26.3)	68.8 (23.9)
Analysis Visit Mean (SD)	69.6 (24.4)	68.1 (25.4)	66.5 (23.7)
LS Mean of Change from Baseline (SE)	0.02 (2.86)	3.33 (2.99)	-1.66 (2.26)
95% CI	(-5.63, 5.66)	(-2.57, 9.23)	(-6.13, 2.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.68 (3.55)	4.99 (3.71)	
95% CI	(-5.34, 8.69)	(-2.35, 12.32)	
p-value	0.6373	0.1811	
Corrected Hedge's g Statistics	0.092	0.274	
95% CI	(-0.30, 0.48)	(-0.14, 0.68)	
Subgroup*Treatment Interaction p-value	0.8569	0.4181	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
General Health			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	59.21 (20.50)	49.47 (17.49)	60.71 (20.00)
Analysis Visit Mean (SD)	59.40 (22.22)	51.71 (17.53)	60.63 (21.42)
LS Mean of Change from Baseline (SE)	1.07 (2.29)	-0.57 (2.52)	0.90 (1.80)
95% CI	(-3.45, 5.60)	(-5.54, 4.40)	(-2.65, 4.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.17 (2.81)	-1.47 (3.08)	
95% CI	(-5.38, 5.73)	(-7.55, 4.62)	
p-value	0.9505	0.6345	
Corrected Hedge's g Statistics	0.011	-0.093	
95% CI	(-0.35, 0.37)	(-0.48, 0.30)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	61.19 (20.04)	50.78 (18.96)	62.09 (19.88)
Analysis Visit Mean (SD)	60.81 (19.81)	55.03 (16.46)	61.11 (18.87)
LS Mean of Change from Baseline (SE)	0.54 (2.17)	1.99 (2.30)	0.94 (1.73)
95% CI	(-3.75, 4.82)	(-2.54, 6.53)	(-2.48, 4.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.41 (2.66)	1.05 (2.87)	
95% CI	(-5.65, 4.84)	(-4.62, 6.71)	
p-value	0.8786	0.7151	
Corrected Hedge's g Statistics	-0.029	0.075	
95% CI	(-0.42, 0.36)	(-0.33, 0.48)	
Subgroup*Treatment Interaction p-value	0.3679	0.4271	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Vitality			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	58.93 (25.57)	50.19 (23.46)	57.12 (22.07)
Analysis Visit Mean (SD)	57.74 (25.94)	51.83 (19.60)	57.64 (22.31)
LS Mean of Change from Baseline (SE)	0.44 (2.25)	0.18 (2.46)	1.22 (1.75)
95% CI	(-4.01, 4.89)	(-4.67, 5.03)	(-2.25, 4.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.78 (2.77)	-1.04 (2.98)	
95% CI	(-6.24, 4.68)	(-6.91, 4.84)	
p-value	0.7792	0.7284	
Corrected Hedge's g Statistics	-0.050	-0.067	
95% CI	(-0.41, 0.31)	(-0.45, 0.32)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	61.03 (25.08)	51.76 (24.40)	56.73 (21.50)
Analysis Visit Mean (SD)	61.04 (21.81)	52.28 (22.41)	57.35 (23.77)
LS Mean of Change from Baseline (SE)	1.89 (2.36)	-0.74 (2.48)	0.86 (1.87)
95% CI	(-2.76, 6.55)	(-5.63, 4.16)	(-2.84, 4.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.03 (2.92)	-1.60 (3.07)	
95% CI	(-4.73, 6.80)	(-7.66, 4.46)	
p-value	0.7244	0.6033	
Corrected Hedge's g Statistics	0.068	-0.106	
95% CI	(-0.32, 0.46)	(-0.51, 0.30)	
Subgroup*Treatment Interaction p-value	0.8296	0.8972	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Social Functioning			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	80.05 (26.02)	78.29 (25.28)	81.89 (24.64)
Analysis Visit Mean (SD)	80.85 (25.91)	79.93 (20.25)	80.93 (26.93)
LS Mean of Change from Baseline (SE)	1.16 (2.82)	1.06 (3.06)	-0.10 (2.20)
95% CI	(-4.40, 6.73)	(-4.98, 7.11)	(-4.44, 4.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.26 (3.47)	1.16 (3.72)	
95% CI	(-5.59, 8.12)	(-6.18, 8.51)	
p-value	0.7162	0.7546	
Corrected Hedge's g Statistics	0.065	0.060	
95% CI	(-0.30, 0.43)	(-0.33, 0.45)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	83.04 (24.04)	79.17 (25.35)	83.59 (24.18)
Analysis Visit Mean (SD)	84.23 (22.61)	82.29 (23.22)	83.20 (23.59)
LS Mean of Change from Baseline (SE)	2.95 (2.71)	3.03 (2.84)	0.43 (2.16)
95% CI	(-2.41, 8.30)	(-2.58, 8.64)	(-3.84, 4.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.51 (3.35)	2.59 (3.53)	
95% CI	(-4.11, 9.13)	(-4.37, 9.55)	
p-value	0.4546	0.4634	
Corrected Hedge's g Statistics	0.143	0.149	
95% CI	(-0.25, 0.53)	(-0.26, 0.56)	
Subgroup*Treatment Interaction p-value	0.8588	0.9701	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Role Emotional			
Week 24			
m	49	43	83
n	47	38	77
Baseline Mean (SD)	80.67 (26.76)	84.87 (21.91)	83.44 (25.02)
Analysis Visit Mean (SD)	79.43 (24.93)	86.18 (20.35)	82.68 (26.24)
LS Mean of Change from Baseline (SE)	-1.03 (2.43)	2.02 (2.61)	0.06 (1.91)
95% CI	(-5.83, 3.78)	(-3.14, 7.17)	(-3.71, 3.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.09 (2.98)	1.96 (3.18)	
95% CI	(-6.97, 4.80)	(-4.33, 8.24)	
p-value	0.7158	0.5393	
Corrected Hedge's g Statistics	-0.065	0.118	
95% CI	(-0.43, 0.30)	(-0.27, 0.51)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	83.33 (23.93)	86.11 (21.82)	85.80 (23.65)
Analysis Visit Mean (SD)	83.73 (20.91)	84.49 (23.33)	83.85 (24.12)
LS Mean of Change from Baseline (SE)	1.92 (2.53)	-0.78 (2.66)	-0.55 (2.02)
95% CI	(-3.08, 6.92)	(-6.04, 4.48)	(-4.53, 3.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.47 (3.12)	-0.23 (3.29)	
95% CI	(-3.70, 8.64)	(-6.73, 6.26)	
p-value	0.4309	0.9439	
Corrected Hedge's g Statistics	0.151	-0.014	
95% CI	(-0.24, 0.54)	(-0.42, 0.39)	
Subgroup*Treatment Interaction p-value	0.7606	0.5754	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Mental Health			
Week 24			
m	49	43	83
n	47	38	78
Baseline Mean (SD)	73.0 (23.6)	76.1 (17.7)	74.5 (18.4)
Analysis Visit Mean (SD)	72.1 (22.8)	73.9 (17.1)	74.4 (19.5)
LS Mean of Change from Baseline (SE)	-0.98 (1.96)	-1.76 (2.11)	0.02 (1.52)
95% CI	(-4.84, 2.89)	(-5.93, 2.41)	(-2.99, 3.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.99 (2.40)	-1.78 (2.57)	
95% CI	(-5.73, 3.75)	(-6.85, 3.29)	
p-value	0.6793	0.4898	
Corrected Hedge's g Statistics	-0.074	-0.133	
95% CI	(-0.44, 0.29)	(-0.52, 0.26)	
Week 52			
m	47	38	75
n	42	36	64
Baseline Mean (SD)	75.5 (21.4)	77.5 (18.2)	74.8 (18.8)
Analysis Visit Mean (SD)	75.5 (18.4)	75.1 (17.5)	76.3 (21.2)
LS Mean of Change from Baseline (SE)	0.55 (1.94)	-1.69 (2.04)	0.72 (1.54)
95% CI	(-3.28, 4.37)	(-5.70, 2.33)	(-2.32, 3.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.17 (2.39)	-2.41 (2.52)	
95% CI	(-4.90, 4.55)	(-7.38, 2.56)	
p-value	0.9422	0.3402	
Corrected Hedge's g Statistics	-0.014	-0.194	
95% CI	(-0.40, 0.38)	(-0.60, 0.21)	
Subgroup*Treatment Interaction p-value	0.5630	0.6702	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Mental Component Score			
Week 24			
m	49	43	83
n	46	38	77
Baseline Mean (SD)	49.96 (12.60)	50.56 (10.31)	50.59 (10.20)
Analysis Visit Mean (SD)	49.17 (11.92)	50.69 (8.62)	50.33 (10.75)
LS Mean of Change from Baseline (SE)	-0.67 (1.02)	0.17 (1.09)	-0.03 (0.80)
95% CI	(-2.69, 1.34)	(-1.98, 2.32)	(-1.60, 1.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.64 (1.25)	0.20 (1.33)	
95% CI	(-3.11, 1.82)	(-2.42, 2.82)	
p-value	0.6065	0.8818	
Corrected Hedge's g Statistics	-0.092	0.028	
95% CI	(-0.46, 0.27)	(-0.36, 0.42)	
Week 52			
m	47	38	75
n	41	36	64
Baseline Mean (SD)	51.46 (11.09)	51.53 (10.46)	51.03 (10.33)
Analysis Visit Mean (SD)	51.55 (9.74)	50.77 (9.38)	51.31 (11.58)
LS Mean of Change from Baseline (SE)	0.69 (1.08)	-0.51 (1.13)	0.26 (0.86)
95% CI	(-1.45, 2.83)	(-2.74, 1.72)	(-1.43, 1.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.43 (1.34)	-0.77 (1.40)	
95% CI	(-2.21, 3.07)	(-3.53, 1.99)	
p-value	0.7470	0.5842	
Corrected Hedge's g Statistics	0.062	-0.111	
95% CI	(-0.33, 0.45)	(-0.52, 0.30)	
Subgroup*Treatment Interaction p-value	0.7604	0.6412	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Physical Component Score			
Week 24			
m	49	43	83
n	46	38	77
Baseline Mean (SD)	48.38 (6.78)	45.48 (8.22)	48.46 (9.28)
Analysis Visit Mean (SD)	48.47 (8.52)	45.87 (8.33)	48.51 (9.63)
LS Mean of Change from Baseline (SE)	0.44 (0.90)	0.02 (0.97)	0.31 (0.70)
95% CI	(-1.33, 2.21)	(-1.89, 1.93)	(-1.07, 1.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.13 (1.10)	-0.29 (1.18)	
95% CI	(-2.05, 2.30)	(-2.63, 2.05)	
p-value	0.9084	0.8059	
Corrected Hedge's g Statistics	0.021	-0.048	
95% CI	(-0.34, 0.39)	(-0.44, 0.34)	
Week 52			
m	47	38	75
n	41	36	64
Baseline Mean (SD)	48.66 (7.35)	45.11 (8.84)	48.68 (8.74)
Analysis Visit Mean (SD)	48.55 (9.40)	46.76 (8.21)	47.84 (8.19)
LS Mean of Change from Baseline (SE)	0.27 (0.89)	1.18 (0.92)	-0.51 (0.70)
95% CI	(-1.48, 2.02)	(-0.65, 3.00)	(-1.90, 0.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.78 (1.09)	1.69 (1.15)	
95% CI	(-1.37, 2.93)	(-0.59, 3.97)	
p-value	0.4747	0.1448	
Corrected Hedge's g Statistics	0.138	0.300	
95% CI	(-0.25, 0.53)	(-0.11, 0.71)	
Subgroup*Treatment Interaction p-value	0.6059	0.4380	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Physical Functioning			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	75.07 (22.39)	72.30 (25.46)	74.87 (25.86)
Analysis Visit Mean (SD)	75.07 (23.46)	71.20 (25.37)	74.24 (27.27)
LS Mean of Change from Baseline (SE)	0.16 (2.12)	-1.47 (2.46)	-0.84 (1.61)
95% CI	(-4.02, 4.35)	(-6.31, 3.37)	(-4.01, 2.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.00 (2.61)	-0.63 (2.89)	
95% CI	(-4.14, 6.14)	(-6.33, 5.06)	
p-value	0.7022	0.8266	
Corrected Hedge's g Statistics	0.057	-0.036	
95% CI	(-0.24, 0.36)	(-0.37, 0.29)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	75.33 (21.91)	73.10 (25.01)	75.10 (25.38)
Analysis Visit Mean (SD)	76.31 (26.22)	74.31 (24.71)	75.49 (25.09)
LS Mean of Change from Baseline (SE)	1.34 (2.09)	1.22 (2.48)	0.63 (1.60)
95% CI	(-2.77, 5.45)	(-3.67, 6.11)	(-2.51, 3.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.71 (2.57)	0.59 (2.90)	
95% CI	(-4.36, 5.78)	(-5.13, 6.30)	
p-value	0.7827	0.8398	
Corrected Hedge's g Statistics	0.043	0.036	
95% CI	(-0.27, 0.36)	(-0.32, 0.39)	
Subgroup*Treatment Interaction p-value	0.9644	0.9483	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Role Physical			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	76.94 (27.23)	77.64 (27.52)	74.70 (26.55)
Analysis Visit Mean (SD)	74.46 (25.12)	74.01 (25.51)	74.12 (27.57)
LS Mean of Change from Baseline (SE)	-1.48 (2.23)	-2.58 (2.58)	-0.71 (1.69)
95% CI	(-5.86, 2.91)	(-7.65, 2.50)	(-4.03, 2.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.76 (2.73)	-1.86 (3.03)	
95% CI	(-6.15, 4.62)	(-7.83, 4.10)	
p-value	0.7802	0.5390	
Corrected Hedge's g Statistics	-0.042	-0.101	
95% CI	(-0.34, 0.26)	(-0.43, 0.23)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	76.34 (28.66)	75.61 (28.62)	74.54 (25.87)
Analysis Visit Mean (SD)	75.21 (29.29)	75.91 (24.86)	73.94 (25.29)
LS Mean of Change from Baseline (SE)	-0.50 (2.35)	0.81 (2.79)	0.21 (1.79)
95% CI	(-5.12, 4.12)	(-4.69, 6.30)	(-3.32, 3.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.71 (2.90)	0.60 (3.26)	
95% CI	(-6.42, 5.00)	(-5.83, 7.03)	
p-value	0.8066	0.8546	
Corrected Hedge's g Statistics	-0.039	0.033	
95% CI	(-0.35, 0.28)	(-0.33, 0.39)	
Subgroup*Treatment Interaction p-value	0.6173	0.9236	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Bodily Pain			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	65.4 (23.8)	66.2 (26.1)	63.3 (24.6)
Analysis Visit Mean (SD)	64.4 (23.7)	64.0 (25.1)	62.6 (26.1)
LS Mean of Change from Baseline (SE)	-0.64 (2.37)	-1.62 (2.75)	-1.40 (1.80)
95% CI	(-5.32, 4.03)	(-7.03, 3.80)	(-4.94, 2.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.76 (2.91)	-0.21 (3.23)	
95% CI	(-4.98, 6.50)	(-6.57, 6.14)	
p-value	0.7948	0.9476	
Corrected Hedge's g Statistics	0.039	-0.011	
95% CI	(-0.26, 0.34)	(-0.34, 0.32)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	66.2 (24.7)	64.8 (26.4)	63.1 (24.3)
Analysis Visit Mean (SD)	67.4 (25.4)	70.7 (24.7)	67.8 (23.9)
LS Mean of Change from Baseline (SE)	2.40 (2.48)	5.59 (2.94)	4.24 (1.89)
95% CI	(-2.49, 7.28)	(-0.21, 11.39)	(0.51, 7.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.84 (3.06)	1.35 (3.44)	
95% CI	(-7.87, 4.19)	(-5.43, 8.13)	
p-value	0.5487	0.6953	
Corrected Hedge's g Statistics	-0.094	0.070	
95% CI	(-0.41, 0.22)	(-0.29, 0.43)	
Subgroup*Treatment Interaction p-value	0.8569	0.4181	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
General Health			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	61.01 (19.77)	59.00 (18.30)	56.95 (20.74)
Analysis Visit Mean (SD)	63.14 (20.20)	58.52 (20.00)	57.85 (22.13)
LS Mean of Change from Baseline (SE)	2.45 (1.71)	-0.60 (1.98)	0.40 (1.30)
95% CI	(-0.92, 5.83)	(-4.49, 3.30)	(-2.15, 2.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.05 (2.11)	-1.00 (2.33)	
95% CI	(-2.10, 6.20)	(-5.58, 3.59)	
p-value	0.3322	0.6686	
Corrected Hedge's g Statistics	0.145	-0.071	
95% CI	(-0.15, 0.44)	(-0.40, 0.26)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	61.37 (20.77)	58.88 (19.51)	55.87 (20.65)
Analysis Visit Mean (SD)	65.27 (19.58)	60.40 (20.30)	58.99 (21.35)
LS Mean of Change from Baseline (SE)	4.45 (1.78)	0.77 (2.11)	2.40 (1.36)
95% CI	(0.95, 7.95)	(-3.40, 4.93)	(-0.28, 5.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.06 (2.20)	-1.63 (2.47)	
95% CI	(-2.28, 6.40)	(-6.50, 3.24)	
p-value	0.3515	0.5108	
Corrected Hedge's g Statistics	0.147	-0.117	
95% CI	(-0.17, 0.46)	(-0.48, 0.24)	
Subgroup*Treatment Interaction p-value	0.3679	0.4271	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Vitality			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	57.31 (21.58)	58.52 (17.11)	56.01 (21.45)
Analysis Visit Mean (SD)	56.37 (23.25)	55.15 (17.21)	55.27 (22.97)
LS Mean of Change from Baseline (SE)	-1.08 (1.64)	-3.49 (1.90)	-1.36 (1.24)
95% CI	(-4.30, 2.15)	(-7.23, 0.24)	(-3.81, 1.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.28 (2.01)	-2.13 (2.23)	
95% CI	(-3.67, 4.24)	(-6.52, 2.25)	
p-value	0.8879	0.3389	
Corrected Hedge's g Statistics	0.021	-0.158	
95% CI	(-0.28, 0.32)	(-0.49, 0.17)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	58.42 (21.68)	57.91 (16.85)	55.20 (21.31)
Analysis Visit Mean (SD)	58.32 (21.40)	57.02 (18.83)	55.38 (22.62)
LS Mean of Change from Baseline (SE)	0.13 (1.95)	-0.65 (2.32)	-0.24 (1.49)
95% CI	(-3.71, 3.97)	(-5.23, 3.92)	(-3.17, 2.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.38 (2.42)	-0.41 (2.72)	
95% CI	(-4.38, 5.13)	(-5.78, 4.95)	
p-value	0.8767	0.8801	
Corrected Hedge's g Statistics	0.025	-0.027	
95% CI	(-0.29, 0.34)	(-0.38, 0.33)	
Subgroup*Treatment Interaction p-value	0.8296	0.8972	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Social Functioning			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	83.46 (21.97)	84.00 (23.56)	83.90 (20.61)
Analysis Visit Mean (SD)	81.99 (24.47)	83.25 (21.37)	81.99 (22.26)
LS Mean of Change from Baseline (SE)	-1.53 (2.10)	-1.10 (2.44)	-2.32 (1.59)
95% CI	(-5.68, 2.61)	(-5.90, 3.70)	(-5.46, 0.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.79 (2.59)	1.22 (2.86)	
95% CI	(-4.31, 5.88)	(-4.41, 6.86)	
p-value	0.7615	0.6697	
Corrected Hedge's g Statistics	0.045	0.070	
95% CI	(-0.25, 0.34)	(-0.26, 0.40)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	83.61 (22.42)	82.74 (24.84)	83.57 (20.31)
Analysis Visit Mean (SD)	80.12 (22.64)	83.93 (20.15)	82.02 (21.71)
LS Mean of Change from Baseline (SE)	-3.56 (2.18)	1.17 (2.60)	-1.99 (1.67)
95% CI	(-7.87, 0.74)	(-3.95, 6.29)	(-5.28, 1.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.57 (2.70)	3.16 (3.04)	
95% CI	(-6.88, 3.74)	(-2.82, 9.15)	
p-value	0.5605	0.2989	
Corrected Hedge's g Statistics	-0.092	0.185	
95% CI	(-0.41, 0.22)	(-0.17, 0.54)	
Subgroup*Treatment Interaction p-value	0.8588	0.9701	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Role Emotional			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	84.07 (22.57)	81.84 (23.61)	85.03 (20.86)
Analysis Visit Mean (SD)	83.09 (21.64)	84.83 (21.94)	83.54 (22.05)
LS Mean of Change from Baseline (SE)	-1.19 (1.97)	1.99 (2.28)	-1.67 (1.49)
95% CI	(-5.07, 2.69)	(-2.51, 6.49)	(-4.62, 1.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.49 (2.42)	3.66 (2.68)	
95% CI	(-4.28, 5.25)	(-1.63, 8.95)	
p-value	0.8414	0.1738	
Corrected Hedge's g Statistics	0.030	0.225	
95% CI	(-0.27, 0.33)	(-0.11, 0.56)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	83.60 (23.07)	78.57 (25.18)	84.37 (21.24)
Analysis Visit Mean (SD)	85.18 (20.02)	85.91 (20.94)	81.03 (22.78)
LS Mean of Change from Baseline (SE)	1.14 (2.18)	5.23 (2.60)	-3.28 (1.66)
95% CI	(-3.16, 5.43)	(0.10, 10.36)	(-6.55, 0.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.41 (2.69)	8.51 (3.05)	
95% CI	(-0.89, 9.72)	(2.50, 14.51)	
p-value	0.1026	0.0057	
Corrected Hedge's g Statistics	0.258	0.498	
95% CI	(-0.06, 0.57)	(0.14, 0.86)	
Subgroup*Treatment Interaction p-value	0.7606	0.5754	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Mental Health			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	75.4 (17.1)	76.6 (20.5)	74.6 (18.5)
Analysis Visit Mean (SD)	74.0 (17.6)	78.1 (19.9)	75.3 (18.8)
LS Mean of Change from Baseline (SE)	-1.53 (1.62)	1.43 (1.88)	0.02 (1.23)
95% CI	(-4.73, 1.66)	(-2.27, 5.12)	(-2.40, 2.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.55 (1.99)	1.41 (2.20)	
95% CI	(-5.48, 2.37)	(-2.94, 5.75)	
p-value	0.4356	0.5244	
Corrected Hedge's g Statistics	-0.116	0.105	
95% CI	(-0.41, 0.18)	(-0.23, 0.44)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	75.8 (17.2)	75.1 (21.3)	74.4 (18.1)
Analysis Visit Mean (SD)	75.7 (16.4)	75.2 (19.4)	74.8 (18.7)
LS Mean of Change from Baseline (SE)	-0.17 (1.73)	0.45 (2.06)	-0.18 (1.32)
95% CI	(-3.58, 3.25)	(-3.61, 4.52)	(-2.79, 2.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (2.14)	0.64 (2.42)	
95% CI	(-4.21, 4.24)	(-4.12, 5.39)	
p-value	0.9945	0.7926	
Corrected Hedge's g Statistics	0.001	0.047	
95% CI	(-0.31, 0.32)	(-0.31, 0.40)	
Subgroup*Treatment Interaction p-value	0.5630	0.6702	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Mental Component Score			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	51.36 (9.27)	51.64 (11.49)	51.45 (9.25)
Analysis Visit Mean (SD)	50.70 (9.61)	52.46 (10.76)	51.18 (9.90)
LS Mean of Change from Baseline (SE)	-0.82 (0.87)	0.57 (1.01)	-0.60 (0.66)
95% CI	(-2.54, 0.89)	(-1.42, 2.55)	(-1.90, 0.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.22 (1.07)	1.17 (1.18)	
95% CI	(-2.32, 1.89)	(-1.16, 3.50)	
p-value	0.8395	0.3240	
Corrected Hedge's g Statistics	-0.030	0.163	
95% CI	(-0.33, 0.27)	(-0.17, 0.49)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	51.48 (9.50)	50.55 (12.00)	51.15 (9.19)
Analysis Visit Mean (SD)	51.23 (8.45)	51.57 (10.45)	50.30 (9.83)
LS Mean of Change from Baseline (SE)	-0.43 (0.88)	0.84 (1.05)	-1.15 (0.67)
95% CI	(-2.17, 1.30)	(-1.23, 2.90)	(-2.48, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.72 (1.09)	1.99 (1.22)	
95% CI	(-1.42, 2.86)	(-0.42, 4.40)	
p-value	0.5081	0.1051	
Corrected Hedge's g Statistics	0.104	0.289	
95% CI	(-0.21, 0.42)	(-0.07, 0.65)	
Subgroup*Treatment Interaction p-value	0.7604	0.6412	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Physical Component Score			
Week 24			
m	72	58	135
n	68	50	118
Baseline Mean (SD)	47.48 (8.79)	47.04 (9.23)	46.42 (10.18)
Analysis Visit Mean (SD)	47.52 (9.12)	45.60 (9.44)	46.29 (10.48)
LS Mean of Change from Baseline (SE)	0.30 (0.84)	-1.27 (0.97)	-0.26 (0.64)
95% CI	(-1.36, 1.96)	(-3.18, 0.65)	(-1.51, 1.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.56 (1.03)	-1.01 (1.14)	
95% CI	(-1.48, 2.60)	(-3.26, 1.25)	
p-value	0.5906	0.3795	
Corrected Hedge's g Statistics	0.080	-0.145	
95% CI	(-0.22, 0.38)	(-0.48, 0.19)	
Week 52			
m	69	51	128
n	61	42	105
Baseline Mean (SD)	47.59 (9.27)	47.14 (9.48)	46.34 (9.82)
Analysis Visit Mean (SD)	48.13 (10.79)	47.70 (9.84)	47.52 (9.37)
LS Mean of Change from Baseline (SE)	0.87 (0.83)	0.50 (0.98)	1.28 (0.63)
95% CI	(-0.76, 2.50)	(-1.44, 2.44)	(0.03, 2.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.41 (1.02)	-0.78 (1.15)	
95% CI	(-2.42, 1.60)	(-3.04, 1.49)	
p-value	0.6886	0.4991	
Corrected Hedge's g Statistics	-0.063	-0.120	
95% CI	(-0.38, 0.25)	(-0.48, 0.24)	
Subgroup*Treatment Interaction p-value	0.6059	0.4380	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Physical Functioning			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	70.19 (29.50)	60.19 (29.98)	74.44 (25.32)
Analysis Visit Mean (SD)	73.15 (28.05)	69.85 (24.86)	77.26 (28.16)
LS Mean of Change from Baseline (SE)	3.39 (3.83)	5.24 (3.89)	2.30 (3.10)
95% CI	(-4.22, 11.00)	(-2.48, 12.96)	(-3.85, 8.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.09 (4.69)	2.94 (4.78)	
95% CI	(-8.22, 10.41)	(-6.54, 12.43)	
p-value	0.8162	0.5393	
Corrected Hedge's g Statistics	0.053	0.142	
95% CI	(-0.42, 0.53)	(-0.34, 0.63)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	72.38 (25.23)	61.19 (31.70)	74.50 (26.11)
Analysis Visit Mean (SD)	77.86 (25.86)	60.24 (29.77)	76.50 (26.49)
LS Mean of Change from Baseline (SE)	4.22 (3.94)	-1.53 (3.98)	0.96 (3.04)
95% CI	(-3.59, 12.03)	(-9.42, 6.36)	(-5.07, 6.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.26 (4.74)	-2.49 (4.81)	
95% CI	(-6.15, 12.67)	(-12.04, 7.06)	
p-value	0.4934	0.6059	
Corrected Hedge's g Statistics	0.171	-0.130	
95% CI	(-0.36, 0.70)	(-0.66, 0.40)	
Subgroup*Treatment Interaction p-value	0.9644	0.9483	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Role Physical			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	71.54 (28.39)	63.95 (28.30)	74.05 (27.30)
Analysis Visit Mean (SD)	69.00 (33.85)	70.93 (25.85)	76.26 (25.95)
LS Mean of Change from Baseline (SE)	-2.27 (3.79)	3.55 (3.85)	1.31 (3.09)
95% CI	(-9.80, 5.26)	(-4.09, 11.18)	(-4.83, 7.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.58 (4.66)	2.24 (4.72)	
95% CI	(-12.82, 5.66)	(-7.12, 11.60)	
p-value	0.4436	0.6364	
Corrected Hedge's g Statistics	-0.174	0.109	
95% CI	(-0.65, 0.30)	(-0.37, 0.59)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	76.50 (28.36)	64.60 (29.21)	75.02 (25.43)
Analysis Visit Mean (SD)	76.49 (31.12)	63.41 (34.35)	77.21 (26.26)
LS Mean of Change from Baseline (SE)	-0.09 (4.54)	-2.31 (4.56)	1.00 (3.43)
95% CI	(-9.10, 8.92)	(-11.37, 6.75)	(-5.80, 7.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.09 (5.48)	-3.31 (5.54)	
95% CI	(-11.96, 9.78)	(-14.30, 7.68)	
p-value	0.8424	0.5515	
Corrected Hedge's g Statistics	-0.050	-0.152	
95% CI	(-0.58, 0.48)	(-0.68, 0.38)	
Subgroup*Treatment Interaction p-value	0.6173	0.9236	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Bodily Pain			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	64.8 (25.1)	54.8 (26.8)	66.1 (25.0)
Analysis Visit Mean (SD)	62.3 (30.0)	56.7 (20.3)	68.6 (25.6)
LS Mean of Change from Baseline (SE)	-0.64 (4.36)	-2.20 (4.40)	3.79 (3.53)
95% CI	(-9.29, 8.02)	(-10.93, 6.52)	(-3.22, 10.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.42 (5.30)	-5.99 (5.36)	
95% CI	(-14.93, 6.09)	(-16.63, 4.65)	
p-value	0.4055	0.2666	
Corrected Hedge's g Statistics	-0.188	-0.255	
95% CI	(-0.67, 0.29)	(-0.74, 0.23)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	66.7 (24.4)	52.6 (26.1)	66.3 (26.5)
Analysis Visit Mean (SD)	67.6 (30.2)	55.0 (24.6)	67.4 (27.3)
LS Mean of Change from Baseline (SE)	1.05 (5.04)	-1.92 (5.09)	1.29 (3.88)
95% CI	(-8.95, 11.06)	(-12.02, 8.18)	(-6.40, 8.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.24 (6.09)	-3.21 (6.18)	
95% CI	(-12.33, 11.85)	(-15.48, 9.05)	
p-value	0.9686	0.6042	
Corrected Hedge's g Statistics	-0.010	-0.131	
95% CI	(-0.54, 0.52)	(-0.66, 0.40)	
Subgroup*Treatment Interaction p-value	0.8569	0.4181	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
General Health			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	59.96 (15.43)	50.12 (19.36)	59.02 (20.03)
Analysis Visit Mean (SD)	59.04 (17.62)	53.08 (20.74)	61.62 (21.54)
LS Mean of Change from Baseline (SE)	-1.15 (2.96)	-0.86 (3.00)	0.14 (2.39)
95% CI	(-7.02, 4.73)	(-6.82, 5.10)	(-4.60, 4.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.29 (3.61)	-1.00 (3.68)	
95% CI	(-8.44, 5.87)	(-8.30, 6.30)	
p-value	0.7218	0.7860	
Corrected Hedge's g Statistics	-0.081	-0.063	
95% CI	(-0.56, 0.40)	(-0.55, 0.42)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	60.67 (15.52)	51.38 (19.74)	62.18 (20.77)
Analysis Visit Mean (SD)	59.62 (19.62)	48.67 (21.41)	64.33 (24.43)
LS Mean of Change from Baseline (SE)	-2.00 (3.22)	-5.30 (3.25)	0.88 (2.49)
95% CI	(-8.40, 4.40)	(-11.75, 1.15)	(-4.06, 5.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.88 (3.88)	-6.18 (3.96)	
95% CI	(-10.58, 4.82)	(-14.04, 1.69)	
p-value	0.4597	0.1224	
Corrected Hedge's g Statistics	-0.185	-0.395	
95% CI	(-0.71, 0.34)	(-0.93, 0.14)	
Subgroup*Treatment Interaction p-value	0.3679	0.4271	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Vitality			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	57.44 (19.98)	46.66 (28.47)	58.22 (21.85)
Analysis Visit Mean (SD)	55.58 (19.25)	49.07 (22.69)	59.32 (21.83)
LS Mean of Change from Baseline (SE)	-0.90 (3.30)	-2.42 (3.36)	1.46 (2.67)
95% CI	(-7.45, 5.65)	(-9.09, 4.25)	(-3.84, 6.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.37 (4.03)	-3.89 (4.11)	
95% CI	(-10.37, 5.64)	(-12.05, 4.28)	
p-value	0.5587	0.3472	
Corrected Hedge's g Statistics	-0.133	-0.218	
95% CI	(-0.61, 0.34)	(-0.70, 0.27)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	57.77 (21.27)	48.84 (29.10)	60.02 (22.10)
Analysis Visit Mean (SD)	58.66 (25.43)	50.62 (22.79)	62.37 (20.87)
LS Mean of Change from Baseline (SE)	1.69 (3.63)	-2.90 (3.66)	2.00 (2.79)
95% CI	(-5.50, 8.89)	(-10.16, 4.37)	(-3.54, 7.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.30 (4.38)	-4.89 (4.44)	
95% CI	(-8.99, 8.38)	(-13.71, 3.93)	
p-value	0.9451	0.2735	
Corrected Hedge's g Statistics	-0.017	-0.279	
95% CI	(-0.55, 0.51)	(-0.81, 0.25)	
Subgroup*Treatment Interaction p-value	0.8296	0.8972	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Social Functioning			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	81.48 (21.75)	73.56 (30.48)	80.56 (24.79)
Analysis Visit Mean (SD)	79.17 (25.71)	78.85 (19.29)	79.17 (25.84)
LS Mean of Change from Baseline (SE)	-1.75 (4.35)	-0.08 (4.39)	-3.26 (3.50)
95% CI	(-10.38, 6.88)	(-8.79, 8.64)	(-10.22, 3.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.51 (5.35)	3.18 (5.40)	
95% CI	(-9.10, 12.12)	(-7.53, 13.90)	
p-value	0.7780	0.5569	
Corrected Hedge's g Statistics	0.065	0.136	
95% CI	(-0.41, 0.54)	(-0.35, 0.62)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	83.93 (21.34)	73.81 (33.28)	81.88 (24.51)
Analysis Visit Mean (SD)	83.93 (24.73)	75.60 (25.46)	84.38 (22.42)
LS Mean of Change from Baseline (SE)	1.52 (4.40)	-2.78 (4.41)	0.52 (3.33)
95% CI	(-7.22, 10.25)	(-11.54, 5.98)	(-6.10, 7.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.00 (5.28)	-3.30 (5.31)	
95% CI	(-9.48, 11.48)	(-13.84, 7.25)	
p-value	0.8500	0.5363	
Corrected Hedge's g Statistics	0.048	-0.156	
95% CI	(-0.48, 0.58)	(-0.69, 0.37)	
Subgroup*Treatment Interaction p-value	0.8588	0.9701	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Role Emotional			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	79.32 (27.19)	76.28 (25.68)	81.11 (22.92)
Analysis Visit Mean (SD)	83.03 (21.61)	79.82 (22.13)	81.29 (26.48)
LS Mean of Change from Baseline (SE)	3.33 (3.75)	1.29 (3.77)	-0.27 (3.04)
95% CI	(-4.12, 10.77)	(-6.20, 8.78)	(-6.29, 5.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.59 (4.60)	1.55 (4.62)	
95% CI	(-5.54, 12.72)	(-7.62, 10.73)	
p-value	0.4369	0.7378	
Corrected Hedge's g Statistics	0.177	0.077	
95% CI	(-0.30, 0.66)	(-0.41, 0.56)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	79.77 (27.71)	76.59 (27.08)	82.08 (22.84)
Analysis Visit Mean (SD)	82.94 (23.35)	82.14 (23.17)	84.17 (22.87)
LS Mean of Change from Baseline (SE)	2.68 (4.10)	5.02 (4.10)	0.57 (3.12)
95% CI	(-5.45, 10.81)	(-3.12, 13.17)	(-5.62, 6.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.11 (4.95)	4.45 (4.95)	
95% CI	(-7.71, 11.92)	(-5.38, 14.28)	
p-value	0.6708	0.3711	
Corrected Hedge's g Statistics	0.107	0.226	
95% CI	(-0.42, 0.64)	(-0.30, 0.76)	
Subgroup*Treatment Interaction p-value	0.7606	0.5754	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Mental Health			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	72.0 (18.6)	72.3 (18.5)	75.7 (14.9)
Analysis Visit Mean (SD)	73.0 (18.3)	70.4 (19.0)	73.3 (19.2)
LS Mean of Change from Baseline (SE)	-0.07 (2.79)	-3.43 (2.79)	-2.60 (2.26)
95% CI	(-5.60, 5.46)	(-8.97, 2.11)	(-7.07, 1.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.52 (3.41)	-0.83 (3.42)	
95% CI	(-4.25, 9.30)	(-7.60, 5.95)	
p-value	0.4612	0.8091	
Corrected Hedge's g Statistics	0.168	-0.055	
95% CI	(-0.31, 0.65)	(-0.54, 0.43)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	71.9 (18.1)	71.4 (19.8)	76.0 (16.5)
Analysis Visit Mean (SD)	76.2 (18.5)	72.9 (20.3)	77.5 (18.0)
LS Mean of Change from Baseline (SE)	3.30 (3.02)	-0.80 (3.02)	-0.01 (2.32)
95% CI	(-2.70, 9.29)	(-6.78, 5.19)	(-4.61, 4.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.31 (3.65)	-0.78 (3.65)	
95% CI	(-3.94, 10.56)	(-8.02, 6.45)	
p-value	0.3670	0.8301	
Corrected Hedge's g Statistics	0.227	-0.054	
95% CI	(-0.30, 0.76)	(-0.58, 0.47)	
Subgroup*Treatment Interaction p-value	0.5630	0.6702	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Mental Component Score			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	50.14 (11.32)	49.27 (11.79)	50.84 (8.44)
Analysis Visit Mean (SD)	50.54 (9.78)	49.02 (10.15)	49.80 (11.01)
LS Mean of Change from Baseline (SE)	0.01 (1.53)	-1.21 (1.53)	-1.41 (1.23)
95% CI	(-3.01, 3.04)	(-4.25, 1.83)	(-3.86, 1.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.43 (1.87)	0.20 (1.88)	
95% CI	(-2.29, 5.14)	(-3.52, 3.93)	
p-value	0.4479	0.9139	
Corrected Hedge's g Statistics	0.173	0.025	
95% CI	(-0.30, 0.65)	(-0.46, 0.51)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	50.00 (11.63)	49.34 (12.67)	51.37 (8.56)
Analysis Visit Mean (SD)	51.25 (10.49)	51.16 (9.64)	52.33 (9.09)
LS Mean of Change from Baseline (SE)	1.07 (1.63)	0.63 (1.63)	0.18 (1.25)
95% CI	(-2.17, 4.31)	(-2.61, 3.88)	(-2.30, 2.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.89 (1.97)	0.46 (1.97)	
95% CI	(-3.02, 4.80)	(-3.46, 4.37)	
p-value	0.6523	0.8169	
Corrected Hedge's g Statistics	0.113	0.058	
95% CI	(-0.42, 0.64)	(-0.47, 0.59)	
Subgroup*Treatment Interaction p-value	0.7604	0.6412	

AMNOG Table SE22.14c.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Physical Component Score			
Week 24			
m	30	28	54
n	27	26	45
Baseline Mean (SD)	46.57 (10.79)	41.65 (11.03)	47.10 (8.20)
Analysis Visit Mean (SD)	45.90 (12.42)	44.63 (8.31)	48.73 (9.60)
LS Mean of Change from Baseline (SE)	-0.29 (1.42)	1.32 (1.45)	1.33 (1.15)
95% CI	(-3.12, 2.53)	(-1.56, 4.20)	(-0.96, 3.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.62 (1.74)	0.00 (1.78)	
95% CI	(-5.06, 1.82)	(-3.53, 3.52)	
p-value	0.3529	0.9979	
Corrected Hedge's g Statistics	-0.211	-0.001	
95% CI	(-0.69, 0.27)	(-0.48, 0.48)	
Week 52			
m	26	25	52
n	21	21	40
Baseline Mean (SD)	47.85 (9.83)	41.86 (10.90)	47.54 (8.19)
Analysis Visit Mean (SD)	48.01 (11.82)	40.95 (11.21)	48.22 (9.81)
LS Mean of Change from Baseline (SE)	-0.20 (1.57)	-1.37 (1.60)	0.48 (1.21)
95% CI	(-3.33, 2.92)	(-4.54, 1.79)	(-1.91, 2.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.68 (1.89)	-1.85 (1.94)	
95% CI	(-4.44, 3.07)	(-5.70, 1.99)	
p-value	0.7182	0.3413	
Corrected Hedge's g Statistics	-0.090	-0.243	
95% CI	(-0.62, 0.44)	(-0.77, 0.29)	
Subgroup*Treatment Interaction p-value	0.6059	0.4380	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (11.3)	5 (11.1)	6 (6.7)
No	47 (88.7)	40 (88.9)	84 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.57	
95% CI of the inverse odds ratio	(0.17, 1.83)	(0.16, 1.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.60	
95% CI of the inverse risk ratio	(0.20, 1.73)	(0.19, 1.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.65	4.44	
95% CI of the absolute risk difference	(-5.31, 14.62)	(-6.09, 14.97)	
p-value	0.3323	0.3736	
p-value of Breslow-Day Test for Homogeneity [3]	0.7599	0.5093	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (24.5)	14 (31.1)	26 (28.9)
No	40 (75.5)	31 (68.9)	64 (71.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.90	
95% CI of the inverse odds ratio	(0.58, 2.71)	(0.41, 1.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.93	
95% CI of the inverse risk ratio	(0.66, 2.09)	(0.54, 1.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.36	2.22	
95% CI of the absolute risk difference	(-19.26, 10.53)	(-14.23, 18.67)	
p-value	0.5717	0.7898	
p-value of Breslow-Day Test for Homogeneity [3]	0.2812	0.9049	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (13.2)	5 (11.1)	7 (7.8)
No	46 (86.8)	40 (88.9)	83 (92.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	0.67	
95% CI of the inverse odds ratio	(0.18, 1.68)	(0.20, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.70	
95% CI of the inverse risk ratio	(0.22, 1.59)	(0.24, 2.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.43	3.33	
95% CI of the absolute risk difference	(-5.23, 16.09)	(-7.39, 14.05)	
p-value	0.2913	0.5212	
p-value of Breslow-Day Test for Homogeneity [3]	0.1235	0.6113	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (24.5)	13 (28.9)	16 (17.8)
No	40 (75.5)	32 (71.1)	74 (82.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.53	
95% CI of the inverse odds ratio	(0.29, 1.52)	(0.23, 1.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.62	
95% CI of the inverse risk ratio	(0.38, 1.39)	(0.33, 1.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.75	11.11	
95% CI of the absolute risk difference	(-7.27, 20.77)	(-4.31, 26.53)	
p-value	0.3322	0.1384	
p-value of Breslow-Day Test for Homogeneity [3]	0.5473	0.2513	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (11.3)	8 (17.8)	12 (13.3)
No	47 (88.7)	37 (82.2)	78 (86.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	0.71	
95% CI of the inverse odds ratio	(0.42, 3.43)	(0.27, 1.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.75	
95% CI of the inverse risk ratio	(0.47, 2.95)	(0.33, 1.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.01	4.44	
95% CI of the absolute risk difference	(-13.06, 9.04)	(-8.75, 17.64)	
p-value	0.7260	0.4932	
p-value of Breslow-Day Test for Homogeneity [3]	0.9015	0.5899	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (20.8)	18 (40.0)	21 (23.3)
No	42 (79.2)	27 (60.0)	69 (76.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	0.46	
95% CI of the inverse odds ratio	(0.51, 2.65)	(0.21, 0.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.58	
95% CI of the inverse risk ratio	(0.59, 2.14)	(0.35, 0.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.58	16.67	
95% CI of the absolute risk difference	(-16.56, 11.41)	(-0.10, 33.44)	
p-value	0.7208	0.0440	
p-value of Breslow-Day Test for Homogeneity [3]	0.9216	0.1172	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (11.3)	8 (17.8)	9 (10.0)
No	47 (88.7)	37 (82.2)	81 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.51	
95% CI of the inverse odds ratio	(0.29, 2.60)	(0.18, 1.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.56	
95% CI of the inverse risk ratio	(0.33, 2.34)	(0.23, 1.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.32	7.78	
95% CI of the absolute risk difference	(-9.22, 11.86)	(-5.00, 20.55)	
p-value	0.8034	0.1991	
p-value of Breslow-Day Test for Homogeneity [3]	0.6047	0.5275	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (24.5)	20 (44.4)	22 (24.4)
No	40 (75.5)	25 (55.6)	68 (75.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.40	
95% CI of the inverse odds ratio	(0.45, 2.19)	(0.19, 0.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.55	
95% CI of the inverse risk ratio	(0.55, 1.81)	(0.34, 0.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.08	20.00	
95% CI of the absolute risk difference	(-14.51, 14.68)	(2.98, 37.02)	
p-value	0.9910	0.0180	
p-value of Breslow-Day Test for Homogeneity [3]	0.7690	0.0636	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (9.4)	5 (11.1)	12 (13.3)
No	48 (90.6)	40 (88.9)	78 (86.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.48	1.23	
95% CI of the inverse odds ratio	(0.49, 4.45)	(0.41, 3.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	1.20	
95% CI of the inverse risk ratio	(0.53, 3.79)	(0.45, 3.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.90	-2.22	
95% CI of the absolute risk difference	(-14.45, 6.65)	(-13.78, 9.34)	
p-value	0.4865	0.7137	
p-value of Breslow-Day Test for Homogeneity [3]	0.9544	0.7020	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (32.1)	16 (35.6)	34 (37.8)
No	36 (67.9)	29 (64.4)	56 (62.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.10	
95% CI of the inverse odds ratio	(0.63, 2.63)	(0.52, 2.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.06	
95% CI of the inverse risk ratio	(0.73, 1.89)	(0.66, 1.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.70	-2.22	
95% CI of the absolute risk difference	(-21.77, 10.37)	(-19.42, 14.98)	
p-value	0.4917	0.8010	
p-value of Breslow-Day Test for Homogeneity [3]	0.6919	0.6110	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (7.5)	8 (17.8)	8 (8.9)
No	49 (92.5)	37 (82.2)	82 (91.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	0.45	
95% CI of the inverse odds ratio	(0.34, 4.18)	(0.16, 1.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.50	
95% CI of the inverse risk ratio	(0.37, 3.72)	(0.20, 1.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.34	8.89	
95% CI of the absolute risk difference	(-10.57, 7.89)	(-3.73, 21.51)	
p-value	0.7799	0.1320	
p-value of Breslow-Day Test for Homogeneity [3]	0.8078	0.8722	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (22.6)	11 (24.4)	15 (16.7)
No	41 (77.4)	34 (75.6)	75 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.62	
95% CI of the inverse odds ratio	(0.29, 1.60)	(0.26, 1.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.68	
95% CI of the inverse risk ratio	(0.37, 1.45)	(0.34, 1.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.97	7.78	
95% CI of the absolute risk difference	(-7.67, 19.62)	(-6.95, 22.51)	
p-value	0.3779	0.2800	
p-value of Breslow-Day Test for Homogeneity [3]	0.5630	0.8461	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (7.5)	8 (17.8)	9 (10.0)
No	49 (92.5)	37 (82.2)	81 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.51	
95% CI of the inverse odds ratio	(0.40, 4.66)	(0.18, 1.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	0.56	
95% CI of the inverse risk ratio	(0.43, 4.09)	(0.23, 1.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.45	7.78	
95% CI of the absolute risk difference	(-11.89, 6.98)	(-5.00, 20.55)	
p-value	0.6222	0.1991	
p-value of Breslow-Day Test for Homogeneity [3]	0.5772	0.9486	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (11.3)	10 (22.2)	13 (14.4)
No	47 (88.7)	35 (77.8)	77 (85.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	0.59	
95% CI of the inverse odds ratio	(0.47, 3.72)	(0.24, 1.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	0.65	
95% CI of the inverse risk ratio	(0.52, 3.16)	(0.31, 1.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.12	7.78	
95% CI of the absolute risk difference	(-14.33, 8.08)	(-6.37, 21.93)	
p-value	0.5951	0.2572	
p-value of Breslow-Day Test for Homogeneity [3]	0.3133	0.9735	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (7.5)	3 (6.7)	15 (16.7)
No	49 (92.5)	42 (93.3)	75 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.45	2.80	
95% CI of the inverse odds ratio	(0.77, 7.82)	(0.77, 10.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.21	2.50	
95% CI of the inverse risk ratio	(0.77, 6.31)	(0.76, 8.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.12	-10.00	
95% CI of the absolute risk difference	(-19.60, 1.36)	(-20.60, 0.60)	
p-value	0.1207	0.1071	
p-value of Breslow-Day Test for Homogeneity [3]	0.3133	0.3239	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (32.1)	10 (22.2)	30 (33.3)
No	36 (67.9)	35 (77.8)	60 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.75	
95% CI of the inverse odds ratio	(0.51, 2.18)	(0.76, 4.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.50	
95% CI of the inverse risk ratio	(0.64, 1.69)	(0.81, 2.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.26	-11.11	
95% CI of the absolute risk difference	(-17.16, 14.64)	(-26.68, 4.46)	
p-value	0.8771	0.1826	
p-value of Breslow-Day Test for Homogeneity [3]	0.4100	0.4311	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.8)	3 (6.7)	4 (4.4)
No	51 (96.2)	42 (93.3)	86 (95.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	0.65	
95% CI of the inverse odds ratio	(0.21, 6.71)	(0.14, 3.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.67	
95% CI of the inverse risk ratio	(0.22, 6.21)	(0.16, 2.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.67	2.22	
95% CI of the absolute risk difference	(-7.34, 6.00)	(-6.22, 10.66)	
p-value	0.8468	0.5830	
p-value of Breslow-Day Test for Homogeneity [3]	0.9111	0.8130	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (20.8)	7 (15.6)	26 (28.9)
No	42 (79.2)	38 (84.4)	64 (71.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	2.21	
95% CI of the inverse odds ratio	(0.69, 3.47)	(0.87, 5.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	1.86	
95% CI of the inverse risk ratio	(0.75, 2.58)	(0.87, 3.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.13	-13.33	
95% CI of the absolute risk difference	(-22.52, 6.25)	(-27.47, 0.80)	
p-value	0.2834	0.0893	
p-value of Breslow-Day Test for Homogeneity [3]	0.2437	0.2269	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (5.7)	4 (8.9)	1 (1.1)
No	50 (94.3)	41 (91.1)	89 (98.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.19	0.12	
95% CI of the inverse odds ratio	(0.02, 1.85)	(0.01, 1.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	0.13	
95% CI of the inverse risk ratio	(0.02, 1.84)	(0.01, 1.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.55	7.78	
95% CI of the absolute risk difference	(-2.04, 11.14)	(-0.81, 16.37)	
p-value	0.1111	0.0241	
p-value of Breslow-Day Test for Homogeneity [3]	0.1954	0.1838	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (17.0)	16 (35.6)	11 (12.2)
No	44 (83.0)	29 (64.4)	79 (87.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.25	
95% CI of the inverse odds ratio	(0.26, 1.77)	(0.10, 0.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.34	
95% CI of the inverse risk ratio	(0.32, 1.62)	(0.17, 0.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.76	23.33	
95% CI of the absolute risk difference	(-7.41, 16.92)	(7.80, 38.87)	
p-value	0.4281	0.0014	
p-value of Breslow-Day Test for Homogeneity [3]	0.7469	0.0349	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (15.3)	7 (10.8)	20 (14.4)
No	61 (84.7)	58 (89.2)	119 (85.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.39	
95% CI of the inverse odds ratio	(0.42, 2.07)	(0.56, 3.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.34	
95% CI of the inverse risk ratio	(0.48, 1.86)	(0.60, 3.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.89	-3.62	
95% CI of the absolute risk difference	(-9.26, 11.04)	(-13.15, 5.91)	
p-value	0.8627	0.4772	
p-value of Breslow-Day Test for Homogeneity [3]	0.7599	0.5093	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (36.1)	22 (33.8)	39 (28.1)
No	46 (63.9)	43 (66.2)	100 (71.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.76	
95% CI of the inverse odds ratio	(0.38, 1.27)	(0.40, 1.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.83	
95% CI of the inverse risk ratio	(0.52, 1.17)	(0.54, 1.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.05	5.79	
95% CI of the absolute risk difference	(-5.32, 21.43)	(-7.93, 19.50)	
p-value	0.2296	0.4001	
p-value of Breslow-Day Test for Homogeneity [3]	0.2812	0.9049	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (6.9)	6 (9.2)	18 (12.9)
No	67 (93.1)	59 (90.8)	121 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.99	1.46	
95% CI of the inverse odds ratio	(0.71, 5.61)	(0.55, 3.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.86	1.40	
95% CI of the inverse risk ratio	(0.72, 4.82)	(0.58, 3.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.01	-3.72	
95% CI of the absolute risk difference	(-14.11, 2.10)	(-12.70, 5.26)	
p-value	0.1845	0.4424	
p-value of Breslow-Day Test for Homogeneity [3]	0.1235	0.6113	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (23.6)	13 (20.0)	35 (25.2)
No	55 (76.4)	52 (80.0)	104 (74.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.35	
95% CI of the inverse odds ratio	(0.56, 2.12)	(0.66, 2.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.26	
95% CI of the inverse risk ratio	(0.64, 1.77)	(0.72, 2.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.57	-5.18	
95% CI of the absolute risk difference	(-13.75, 10.61)	(-17.29, 6.93)	
p-value	0.8020	0.4164	
p-value of Breslow-Day Test for Homogeneity [3]	0.5473	0.2513	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (13.9)	12 (18.5)	27 (19.4)
No	62 (86.1)	53 (81.5)	112 (80.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.49	1.06	
95% CI of the inverse odds ratio	(0.68, 3.29)	(0.50, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.05	
95% CI of the inverse risk ratio	(0.72, 2.73)	(0.57, 1.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.54	-0.96	
95% CI of the absolute risk difference	(-15.88, 4.81)	(-12.46, 10.54)	
p-value	0.3161	0.8705	
p-value of Breslow-Day Test for Homogeneity [3]	0.9015	0.5899	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (30.6)	17 (26.2)	43 (30.9)
No	50 (69.4)	48 (73.8)	96 (69.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.26	
95% CI of the inverse odds ratio	(0.55, 1.89)	(0.65, 2.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.18	
95% CI of the inverse risk ratio	(0.66, 1.55)	(0.73, 1.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.38	-4.78	
95% CI of the absolute risk difference	(-13.50, 12.75)	(-17.94, 8.38)	
p-value	0.9548	0.4850	
p-value of Breslow-Day Test for Homogeneity [3]	0.9216	0.1172	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (22.2)	11 (16.9)	25 (18.0)
No	56 (77.8)	54 (83.1)	114 (82.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.08	
95% CI of the inverse odds ratio	(0.38, 1.55)	(0.49, 2.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	1.06	
95% CI of the inverse risk ratio	(0.46, 1.42)	(0.56, 2.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.24	-1.06	
95% CI of the absolute risk difference	(-7.30, 15.77)	(-12.19, 10.07)	
p-value	0.4609	0.8528	
p-value of Breslow-Day Test for Homogeneity [3]	0.6047	0.5275	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (38.9)	20 (30.8)	51 (36.7)
No	44 (61.1)	45 (69.2)	88 (63.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.30	
95% CI of the inverse odds ratio	(0.51, 1.64)	(0.69, 2.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.19	
95% CI of the inverse risk ratio	(0.66, 1.36)	(0.78, 1.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.20	-5.92	
95% CI of the absolute risk difference	(-11.62, 16.02)	(-19.71, 7.87)	
p-value	0.7544	0.4081	
p-value of Breslow-Day Test for Homogeneity [3]	0.7690	0.0636	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (9.7)	4 (6.2)	16 (11.5)
No	65 (90.3)	61 (93.8)	123 (88.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.98	
95% CI of the inverse odds ratio	(0.47, 3.08)	(0.64, 6.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.87	
95% CI of the inverse risk ratio	(0.51, 2.75)	(0.65, 5.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.79	-5.36	
95% CI of the absolute risk difference	(-10.45, 6.87)	(-13.25, 2.53)	
p-value	0.6927	0.2306	
p-value of Breslow-Day Test for Homogeneity [3]	0.9544	0.7020	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (33.3)	14 (21.5)	42 (30.2)
No	48 (66.7)	51 (78.5)	97 (69.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.58	
95% CI of the inverse odds ratio	(0.47, 1.59)	(0.79, 3.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.40	
95% CI of the inverse risk ratio	(0.60, 1.37)	(0.83, 2.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.12	-8.68	
95% CI of the absolute risk difference	(-10.18, 16.42)	(-21.25, 3.90)	
p-value	0.6433	0.1957	
p-value of Breslow-Day Test for Homogeneity [3]	0.6919	0.6110	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (8.3)	9 (13.8)	9 (6.5)
No	66 (91.7)	56 (86.2)	130 (93.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	0.43	
95% CI of the inverse odds ratio	(0.26, 2.23)	(0.16, 1.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.47	
95% CI of the inverse risk ratio	(0.29, 2.10)	(0.19, 1.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.86	7.37	
95% CI of the absolute risk difference	(-5.72, 9.44)	(-1.97, 16.71)	
p-value	0.6184	0.0837	
p-value of Breslow-Day Test for Homogeneity [3]	0.8078	0.8722	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (18.1)	15 (23.1)	22 (15.8)
No	59 (81.9)	50 (76.9)	117 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.63	
95% CI of the inverse odds ratio	(0.40, 1.81)	(0.30, 1.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.69	
95% CI of the inverse risk ratio	(0.47, 1.64)	(0.38, 1.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.23	7.25	
95% CI of the absolute risk difference	(-8.53, 12.99)	(-4.66, 19.15)	
p-value	0.6799	0.2105	
p-value of Breslow-Day Test for Homogeneity [3]	0.5630	0.8461	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (15.3)	13 (20.0)	16 (11.5)
No	61 (84.7)	52 (80.0)	123 (88.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.52	
95% CI of the inverse odds ratio	(0.32, 1.65)	(0.23, 1.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.58	
95% CI of the inverse risk ratio	(0.37, 1.54)	(0.29, 1.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.77	8.49	
95% CI of the absolute risk difference	(-6.09, 13.63)	(-2.59, 19.57)	
p-value	0.4374	0.1057	
p-value of Breslow-Day Test for Homogeneity [3]	0.5772	0.9486	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (25.0)	18 (27.7)	23 (16.5)
No	54 (75.0)	47 (72.3)	116 (83.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.52	
95% CI of the inverse odds ratio	(0.30, 1.19)	(0.26, 1.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.60	
95% CI of the inverse risk ratio	(0.38, 1.14)	(0.35, 1.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.45	11.15	
95% CI of the absolute risk difference	(-3.30, 20.21)	(-1.36, 23.66)	
p-value	0.1412	0.0642	
p-value of Breslow-Day Test for Homogeneity [3]	0.3133	0.9735	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (13.9)	5 (7.7)	18 (12.9)
No	62 (86.1)	60 (92.3)	121 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.79	
95% CI of the inverse odds ratio	(0.40, 2.12)	(0.63, 5.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.68	
95% CI of the inverse risk ratio	(0.45, 1.91)	(0.65, 4.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.94	-5.26	
95% CI of the absolute risk difference	(-8.81, 10.68)	(-13.81, 3.29)	
p-value	0.8488	0.2686	
p-value of Breslow-Day Test for Homogeneity [3]	0.3133	0.3239	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (37.5)	16 (24.6)	38 (27.3)
No	45 (62.5)	49 (75.4)	101 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	1.15	
95% CI of the inverse odds ratio	(0.34, 1.15)	(0.59, 2.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	1.11	
95% CI of the inverse risk ratio	(0.49, 1.09)	(0.67, 1.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.16	-2.72	
95% CI of the absolute risk difference	(-3.25, 23.58)	(-15.55, 10.11)	
p-value	0.1296	0.6813	
p-value of Breslow-Day Test for Homogeneity [3]	0.4100	0.4311	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.2)	5 (7.7)	9 (6.5)
No	69 (95.8)	60 (92.3)	130 (93.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	0.83	
95% CI of the inverse odds ratio	(0.42, 6.07)	(0.27, 2.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	0.84	
95% CI of the inverse risk ratio	(0.43, 5.56)	(0.29, 2.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.31	1.22	
95% CI of the absolute risk difference	(-8.48, 3.86)	(-6.44, 8.88)	
p-value	0.4925	0.7486	
p-value of Breslow-Day Test for Homogeneity [3]	0.9111	0.8130	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (23.6)	13 (20.0)	23 (16.5)
No	55 (76.4)	52 (80.0)	116 (83.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.79	
95% CI of the inverse odds ratio	(0.32, 1.30)	(0.37, 1.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	0.83	
95% CI of the inverse risk ratio	(0.40, 1.23)	(0.45, 1.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.06	3.45	
95% CI of the absolute risk difference	(-4.53, 18.66)	(-8.07, 14.97)	
p-value	0.2145	0.5466	
p-value of Breslow-Day Test for Homogeneity [3]	0.2437	0.2269	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.2)	4 (6.2)	8 (5.8)
No	69 (95.8)	61 (93.8)	131 (94.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	0.93	
95% CI of the inverse odds ratio	(0.36, 5.46)	(0.27, 3.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	0.94	
95% CI of the inverse risk ratio	(0.38, 5.05)	(0.29, 2.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	0.40	
95% CI of the absolute risk difference	(-7.61, 4.44)	(-6.61, 7.41)	
p-value	0.6226	0.9103	
p-value of Breslow-Day Test for Homogeneity [3]	0.1954	0.1838	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (25.0)	15 (23.1)	33 (23.7)
No	54 (75.0)	50 (76.9)	106 (76.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.04	
95% CI of the inverse odds ratio	(0.48, 1.81)	(0.52, 2.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	1.03	
95% CI of the inverse risk ratio	(0.58, 1.56)	(0.60, 1.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.26	-0.66	
95% CI of the absolute risk difference	(-10.99, 13.51)	(-13.11, 11.78)	
p-value	0.8395	0.9170	
p-value of Breslow-Day Test for Homogeneity [3]	0.7469	0.0349	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (16.7)	5 (17.9)	9 (15.8)
No	25 (83.3)	23 (82.1)	48 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.86	
95% CI of the inverse odds ratio	(0.28, 3.10)	(0.26, 2.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.88	
95% CI of the inverse risk ratio	(0.35, 2.57)	(0.33, 2.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.88	2.07	
95% CI of the absolute risk difference	(-15.48, 17.23)	(-14.99, 19.12)	
p-value	0.9157	0.8091	
p-value of Breslow-Day Test for Homogeneity [3]	0.7599	0.5093	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (40.0)	7 (25.0)	14 (24.6)
No	18 (60.0)	21 (75.0)	43 (75.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.49	0.98	
95% CI of the inverse odds ratio	(0.19, 1.26)	(0.34, 2.78)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	0.98	
95% CI of the inverse risk ratio	(0.33, 1.15)	(0.45, 2.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.44	0.44	
95% CI of the absolute risk difference	(-5.35, 36.23)	(-19.11, 19.99)	
p-value	0.1348	0.9649	
p-value of Breslow-Day Test for Homogeneity [3]	0.2812	0.9049	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	5 (17.9)	10 (17.5)
No	28 (93.3)	23 (82.1)	47 (82.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.98	0.98	
95% CI of the inverse odds ratio	(0.61, 14.59)	(0.30, 3.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.63	0.98	
95% CI of the inverse risk ratio	(0.62, 11.25)	(0.37, 2.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.88	0.31	
95% CI of the absolute risk difference	(-24.19, 2.43)	(-16.97, 17.60)	
p-value	0.1620	0.9716	
p-value of Breslow-Day Test for Homogeneity [3]	0.1235	0.6113	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	9 (32.1)	16 (28.1)
No	23 (76.7)	19 (67.9)	41 (71.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	0.82	
95% CI of the inverse odds ratio	(0.46, 3.57)	(0.31, 2.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	0.87	
95% CI of the inverse risk ratio	(0.56, 2.60)	(0.44, 1.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.74	4.07	
95% CI of the absolute risk difference	(-23.85, 14.37)	(-16.79, 24.94)	
p-value	0.6339	0.6985	
p-value of Breslow-Day Test for Homogeneity [3]	0.5473	0.2513	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (13.3)	4 (14.3)	12 (21.1)
No	26 (86.7)	24 (85.7)	45 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.73	1.60	
95% CI of the inverse odds ratio	(0.51, 5.93)	(0.47, 5.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.58	1.47	
95% CI of the inverse risk ratio	(0.56, 4.47)	(0.52, 4.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.72	-6.77	
95% CI of the absolute risk difference	(-23.84, 8.40)	(-23.50, 9.97)	
p-value	0.3770	0.4532	
p-value of Breslow-Day Test for Homogeneity [3]	0.9015	0.5899	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	7 (25.0)	16 (28.1)
No	23 (76.7)	21 (75.0)	41 (71.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	1.17	
95% CI of the inverse odds ratio	(0.46, 3.57)	(0.42, 3.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	1.12	
95% CI of the inverse risk ratio	(0.56, 2.60)	(0.52, 2.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.74	-3.07	
95% CI of the absolute risk difference	(-23.85, 14.37)	(-22.90, 16.76)	
p-value	0.6339	0.7646	
p-value of Breslow-Day Test for Homogeneity [3]	0.9216	0.1172	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	5 (17.9)	9 (15.8)
No	27 (90.0)	23 (82.1)	48 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.69	0.86	
95% CI of the inverse odds ratio	(0.42, 6.77)	(0.26, 2.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.58	0.88	
95% CI of the inverse risk ratio	(0.46, 5.40)	(0.33, 2.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.79	2.07	
95% CI of the absolute risk difference	(-20.10, 8.52)	(-14.99, 19.12)	
p-value	0.4567	0.8091	
p-value of Breslow-Day Test for Homogeneity [3]	0.6047	0.5275	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (20.0)	8 (28.6)	15 (26.3)
No	24 (80.0)	20 (71.4)	42 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	0.89	
95% CI of the inverse odds ratio	(0.49, 4.17)	(0.33, 2.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	0.92	
95% CI of the inverse risk ratio	(0.57, 3.04)	(0.44, 1.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.32	2.26	
95% CI of the absolute risk difference	(-24.63, 12.00)	(-18.01, 22.52)	
p-value	0.5129	0.8259	
p-value of Breslow-Day Test for Homogeneity [3]	0.7690	0.0636	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	4 (14.3)	8 (14.0)
No	27 (90.0)	24 (85.7)	49 (86.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	0.98	
95% CI of the inverse odds ratio	(0.36, 6.00)	(0.27, 3.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	0.98	
95% CI of the inverse risk ratio	(0.40, 4.90)	(0.32, 2.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.04	0.25	
95% CI of the absolute risk difference	(-18.05, 9.98)	(-15.54, 16.04)	
p-value	0.5904	0.9751	
p-value of Breslow-Day Test for Homogeneity [3]	0.9544	0.7020	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (26.7)	9 (32.1)	17 (29.8)
No	22 (73.3)	19 (67.9)	40 (70.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.90	
95% CI of the inverse odds ratio	(0.44, 3.14)	(0.34, 2.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.93	
95% CI of the inverse risk ratio	(0.55, 2.29)	(0.48, 1.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.16	2.32	
95% CI of the absolute risk difference	(-22.94, 16.63)	(-18.66, 23.30)	
p-value	0.7570	0.8274	
p-value of Breslow-Day Test for Homogeneity [3]	0.6919	0.6110	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	5 (17.9)	7 (12.3)
No	27 (90.0)	23 (82.1)	50 (87.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	0.64	
95% CI of the inverse odds ratio	(0.30, 5.27)	(0.18, 2.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	0.69	
95% CI of the inverse risk ratio	(0.34, 4.41)	(0.24, 1.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.28	5.58	
95% CI of the absolute risk difference	(-15.99, 11.42)	(-10.97, 22.12)	
p-value	0.7512	0.4877	
p-value of Breslow-Day Test for Homogeneity [3]	0.8078	0.8722	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (16.7)	7 (25.0)	13 (22.8)
No	25 (83.3)	21 (75.0)	44 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.48	0.89	
95% CI of the inverse odds ratio	(0.47, 4.63)	(0.31, 2.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.37	0.91	
95% CI of the inverse risk ratio	(0.54, 3.47)	(0.41, 2.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.14	2.19	
95% CI of the absolute risk difference	(-23.36, 11.08)	(-17.19, 21.58)	
p-value	0.5016	0.8227	
p-value of Breslow-Day Test for Homogeneity [3]	0.5630	0.8461	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (13.3)	7 (25.0)	10 (17.5)
No	26 (86.7)	21 (75.0)	47 (82.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	0.64	
95% CI of the inverse odds ratio	(0.39, 4.85)	(0.21, 1.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	0.70	
95% CI of the inverse risk ratio	(0.45, 3.84)	(0.30, 1.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.21	7.46	
95% CI of the absolute risk difference	(-19.88, 11.46)	(-11.38, 26.29)	
p-value	0.6114	0.4193	
p-value of Breslow-Day Test for Homogeneity [3]	0.5772	0.9486	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (16.7)	9 (32.1)	12 (21.1)
No	25 (83.3)	19 (67.9)	45 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	0.56	
95% CI of the inverse odds ratio	(0.42, 4.22)	(0.20, 1.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	0.65	
95% CI of the inverse risk ratio	(0.49, 3.25)	(0.31, 1.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.39	11.09	
95% CI of the absolute risk difference	(-21.41, 12.64)	(-9.19, 31.37)	
p-value	0.6239	0.2652	
p-value of Breslow-Day Test for Homogeneity [3]	0.3133	0.9735	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (13.3)	4 (14.3)	6 (10.5)
No	26 (86.7)	24 (85.7)	51 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	0.71	
95% CI of the inverse odds ratio	(0.20, 2.95)	(0.18, 2.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.74	
95% CI of the inverse risk ratio	(0.24, 2.58)	(0.23, 2.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.81	3.76	
95% CI of the absolute risk difference	(-11.73, 17.35)	(-11.45, 18.97)	
p-value	0.6964	0.6131	
p-value of Breslow-Day Test for Homogeneity [3]	0.3133	0.3239	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (36.7)	8 (28.6)	13 (22.8)
No	19 (63.3)	20 (71.4)	44 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.51	0.74	
95% CI of the inverse odds ratio	(0.19, 1.34)	(0.26, 2.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.80	
95% CI of the inverse risk ratio	(0.32, 1.22)	(0.37, 1.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.86	5.76	
95% CI of the absolute risk difference	(-6.54, 34.26)	(-14.20, 25.73)	
p-value	0.1692	0.5625	
p-value of Breslow-Day Test for Homogeneity [3]	0.4100	0.4311	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.3)	4 (14.3)	4 (7.0)
No	29 (96.7)	24 (85.7)	53 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.19	0.45	
95% CI of the inverse odds ratio	(0.23, 20.51)	(0.10, 1.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.11	0.49	
95% CI of the inverse risk ratio	(0.25, 18.01)	(0.13, 1.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.68	7.27	
95% CI of the absolute risk difference	(-12.92, 5.55)	(-7.29, 21.83)	
p-value	0.4828	0.2808	
p-value of Breslow-Day Test for Homogeneity [3]	0.9111	0.8130	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (26.7)	6 (21.4)	12 (21.1)
No	22 (73.3)	22 (78.6)	45 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.98	
95% CI of the inverse odds ratio	(0.26, 2.05)	(0.32, 2.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.98	
95% CI of the inverse risk ratio	(0.36, 1.72)	(0.41, 2.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.61	0.38	
95% CI of the absolute risk difference	(-13.42, 24.65)	(-18.14, 18.90)	
p-value	0.5542	0.9682	
p-value of Breslow-Day Test for Homogeneity [3]	0.2437	0.2269	

AMNOG Table SE22.14c.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.3)	2 (7.1)	4 (7.0)
No	29 (96.7)	26 (92.9)	53 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.19	0.98	
95% CI of the inverse odds ratio	(0.23, 20.51)	(0.17, 5.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.11	0.98	
95% CI of the inverse risk ratio	(0.25, 18.01)	(0.19, 5.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.68	0.13	
95% CI of the absolute risk difference	(-12.92, 5.55)	(-11.49, 11.74)	
p-value	0.4828	0.9831	
p-value of Breslow-Day Test for Homogeneity [3]	0.1954	0.1838	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (20.0)	7 (25.0)	13 (22.8)
No	24 (80.0)	21 (75.0)	44 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.89	
95% CI of the inverse odds ratio	(0.40, 3.51)	(0.31, 2.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	0.91	
95% CI of the inverse risk ratio	(0.48, 2.70)	(0.41, 2.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.81	2.19	
95% CI of the absolute risk difference	(-20.79, 15.18)	(-17.19, 21.58)	
p-value	0.7633	0.8227	
p-value of Breslow-Day Test for Homogeneity [3]	0.7469	0.0349	

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Physical Functioning						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	71.44 (24.88)	67.22 (27.66)	72.61 (26.08)			
Median	75.00	75.00	80.00			
IQR: Q1, Q3	55.00, 90.00	50.00, 90.00	55.00, 95.00			
Min, Max	0.0, 100.0	5.0, 100.0	10.0, 100.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	73.57 (25.38)	68.76 (26.26)	73.62 (28.54)	2.54 (2.29)	0.10 (2.41)	1.65 (1.55)
Median	82.50	80.00	85.00	5.00	0	0
IQR: Q1, Q3	55.00, 95.00	55.00, 90.00	60.00, 95.00	-5.00, 10.00	-10.00, 10.00	-5.00, 10.00
Min, Max	10.0, 100.0	5.0, 100.0	0.0, 100.0	-50.0, 60.0	-65.0, 60.0	-50.0, 75.0
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	71.42 (28.95)	67.28 (28.12)	77.15 (25.28)	0.34 (2.00)	-0.03 (2.27)	2.36 (1.38)
Median	80.00	75.00	85.00	0	0	0
IQR: Q1, Q3	52.50, 95.00	55.00, 90.00	65.00, 95.00	-5.00, 10.00	-5.00, 5.00	-5.00, 5.00
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-65.0, 30.0	-85.0, 40.0	-35.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Role Physical						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	75.87 (23.46)	72.09 (26.60)	77.11 (25.91)			
Median	81.30	75.00	87.50			
IQR: Q1, Q3	56.30, 100.00	50.00, 100.00	62.50, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	74.66 (25.92)	73.27 (23.75)	74.01 (26.34)	-1.63 (2.32)	-1.43 (2.52)	-2.01 (1.73)
Median	81.30	75.00	81.30	0	0	0
IQR: Q1, Q3	56.30, 100.00	50.00, 100.00	56.30, 100.00	-12.50, 12.50	-12.50, 6.20	-12.50, 6.20
Min, Max	0.0, 100.0	12.5, 100.0	0.0, 100.0	-43.8, 43.7	-56.2, 62.5	-68.7, 68.7
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	74.59 (28.13)	72.23 (26.24)	76.60 (24.94)	-2.49 (2.37)	-0.20 (2.53)	-1.44 (1.99)
Median	84.40	75.00	84.40	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 93.80	56.30, 100.00	-12.50, 6.20	-6.30, 9.40	-12.50, 6.20
Min, Max	0.0, 100.0	6.3, 100.0	0.0, 100.0	-43.8, 43.8	-68.8, 56.3	-56.3, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Bodily Pain						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	67.2 (24.8)	61.9 (26.7)	65.3 (24.9)			
Median	72.0	62.0	72.0			
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	51.0, 84.0			
Min, Max	12, 100	10, 100	0, 100			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	63.9 (24.5)	66.5 (23.7)	65.9 (24.9)	-3.4 (2.4)	1.6 (2.5)	1.5 (1.8)
Median	63.0	62.0	72.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	42.0, 84.0	51.0, 84.0	-19.0, 10.0	0.0, 10.0	-10.0, 12.0
Min, Max	0, 100	22, 100	0, 100	-59, 43	-59, 72	-49, 59
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	65.4 (25.5)	64.0 (27.0)	67.6 (24.3)	-2.6 (2.8)	2.1 (2.5)	1.3 (2.0)
Median	72.0	72.0	72.0	0	0	0
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	51.0, 84.0	-10.0, 10.0	-10.0, 10.5	-12.0, 16.0
Min, Max	0, 100	10, 100	10, 100	-80, 38	-53, 62	-49, 69

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
General Health						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	61.30 (18.66)	56.00 (18.48)	58.24 (20.04)			
Median	62.00	57.00	62.00			
IQR: Q1, Q3	47.00, 72.00	40.00, 72.00	42.00, 72.00			
Min, Max	15.0, 100.0	10.0, 92.0	15.0, 100.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	62.57 (19.43)	56.48 (19.94)	59.18 (21.41)	1.37 (1.69)	0.40 (1.87)	1.56 (1.26)
Median	64.50	52.00	57.00	0	0	0
IQR: Q1, Q3	47.00, 77.00	40.00, 75.00	42.00, 77.00	-5.00, 10.00	-5.00, 10.00	-5.00, 10.00
Min, Max	15.0, 100.0	15.0, 92.0	15.0, 100.0	-60.0, 32.0	-35.0, 40.0	-40.0, 40.0
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	62.63 (20.26)	56.23 (19.07)	62.15 (20.62)	1.27 (1.96)	1.30 (2.07)	3.58 (1.30)
Median	67.00	55.00	62.00	0	0	2.00
IQR: Q1, Q3	52.00, 77.00	45.00, 72.00	50.00, 80.00	-10.00, 10.00	-10.00, 10.00	-5.00, 12.00
Min, Max	20.0, 100.0	10.0, 92.0	15.0, 100.0	-70.0, 32.0	-52.0, 37.0	-35.0, 42.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Vitality						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	59.01 (20.68)	55.08 (20.92)	56.63 (22.27)			
Median	62.50	56.30	56.30			
IQR: Q1, Q3	43.80, 68.80	43.80, 68.80	37.50, 75.00			
Min, Max	0.0, 100.0	6.3, 93.8	6.3, 100.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	58.59 (21.07)	56.86 (19.23)	55.89 (22.55)	-0.72 (1.69)	0.09 (1.67)	0.17 (1.34)
Median	62.50	56.30	56.30	0	0	0
IQR: Q1, Q3	43.80, 75.00	43.80, 75.00	37.50, 75.00	-6.30, 6.20	-6.30, 6.30	-12.50, 6.30
Min, Max	0.0, 100.0	12.5, 100.0	6.3, 100.0	-37.5, 37.5	-31.2, 37.5	-37.5, 43.7
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	60.65 (21.57)	57.24 (21.43)	56.68 (23.01)	-0.10 (2.12)	1.08 (1.65)	-0.54 (1.61)
Median	65.65	56.30	56.30	0	0	0
IQR: Q1, Q3	43.80, 75.00	43.80, 75.00	43.80, 75.00	-6.20, 12.50	-6.25, 6.30	-6.30, 12.50
Min, Max	6.3, 100.0	12.5, 100.0	0.0, 100.0	-43.7, 50.0	-43.8, 37.5	-43.7, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Social Functioning						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	83.05 (22.57)	81.80 (24.00)	82.18 (23.77)			
Median	100.00	87.50	87.50			
IQR: Q1, Q3	62.50, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	12.5, 100.0	12.5, 100.0	12.5, 100.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	84.11 (22.21)	84.17 (20.27)	80.48 (24.56)	0.54 (2.56)	0.89 (2.29)	0.10 (1.76)
Median	100.00	100.00	87.50	0	0	0
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	62.50, 100.00	0.00, 12.50	0.00, 12.50	0.00, 12.50
Min, Max	12.5, 100.0	37.5, 100.0	0.0, 100.0	-50.0, 75.0	-62.5, 50.0	-50.0, 75.0
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	83.33 (22.74)	81.15 (22.55)	82.99 (23.01)	-2.37 (2.10)	-0.98 (2.73)	-0.22 (1.85)
Median	100.00	87.50	100.00	0	0	0
IQR: Q1, Q3	68.75, 100.00	62.50, 100.00	75.00, 100.00	0.00, 0.00	-12.50, 12.50	0.00, 0.00
Min, Max	25.0, 100.0	25.0, 100.0	12.5, 100.0	-50.0, 25.0	-62.5, 37.5	-50.0, 75.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Role Emotional						
Baseline						
m	75	87	147			
n	73	79	133			
Mean (SD)	84.47 (22.45)	83.33 (23.80)	84.15 (22.63)			
Median	100.00	100.00	100.00			
IQR: Q1, Q3	75.00, 100.00	75.00, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	72	78	142			
n	70	75	130	69	70	120
Mean (SD/SE)	86.55 (20.48)	87.22 (20.10)	82.44 (24.16)	2.06 (2.10)	2.98 (2.03)	-0.69 (1.72)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	83.30, 100.00	66.70, 100.00	0.00, 8.30	0.00, 16.60	-8.30, 0.00
Min, Max	25.0, 100.0	25.0, 100.0	8.3, 100.0	-33.3, 66.7	-50.0, 50.0	-50.0, 58.3
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	84.44 (21.29)	84.23 (23.49)	84.76 (22.21)	-0.14 (1.86)	1.43 (2.78)	-0.37 (1.72)
Median	100.00	100.00	100.00	0	0	0
IQR: Q1, Q3	75.00, 100.00	83.30, 100.00	75.00, 100.00	0.00, 0.00	-4.15, 12.45	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-33.3, 41.7	-75.0, 58.3	-50.0, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Mental Health						
Baseline						
m	75	87	147			
n	73	79	134			
Mean (SD)	76.2 (17.9)	75.2 (20.5)	75.7 (18.0)			
Median	85.0	80.0	80.0			
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	65.0, 90.0			
Min, Max	5, 100	25, 100	5, 100			
Week 24						
m	72	78	142			
n	70	75	130	69	70	121
Mean (SD/SE)	76.3 (17.2)	76.3 (18.7)	74.2 (19.2)	0.0 (1.6)	-0.8 (1.5)	0.0 (1.3)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	65.0, 90.0	-5.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	25, 100	20, 100	20, 100	-40, 35	-40, 50	-30, 50
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	75.6 (17.1)	76.8 (17.8)	75.7 (19.4)	-1.1 (1.6)	0.7 (1.6)	-0.1 (1.4)
Median	80.0	80.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	65.0, 90.0	-5.0, 5.0	-5.0, 5.0	-5.0, 10.0
Min, Max	25, 100	25, 100	0, 100	-35, 25	-30, 50	-40, 50

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Mental Component Score						
Baseline						
m	75	87	147			
n	73	79	133			
Mean (SD)	52.06 (9.85)	51.82 (10.97)	51.47 (9.48)			
Median	54.90	55.50	54.60			
IQR: Q1, Q3	47.00, 58.90	46.30, 58.40	46.70, 58.20			
Min, Max	12.0, 69.0	23.5, 72.3	15.6, 65.8			
Week 24						
m	72	78	142			
n	70	75	130	69	70	120
Mean (SD/SE)	52.52 (9.12)	52.90 (9.17)	50.52 (10.55)	0.32 (0.89)	0.43 (0.79)	-0.23 (0.72)
Median	54.40	55.30	53.10	0.50	0.10	-0.30
IQR: Q1, Q3	48.30, 58.50	49.20, 59.40	44.00, 58.30	-2.70, 3.60	-3.20, 3.50	-4.20, 3.65
Min, Max	26.2, 69.1	31.4, 71.2	21.9, 66.3	-16.4, 18.5	-24.5, 26.1	-23.5, 22.7
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	52.24 (8.74)	52.46 (9.75)	51.18 (10.24)	-0.41 (0.79)	0.37 (1.04)	-0.40 (0.70)
Median	55.45	54.00	54.20	0.05	-0.20	0.30
IQR: Q1, Q3	47.25, 58.90	47.80, 59.00	47.10, 58.10	-3.90, 3.40	-2.75, 3.65	-4.30, 3.50
Min, Max	26.9, 63.2	26.9, 70.7	8.9, 68.0	-15.5, 14.9	-21.4, 25.1	-24.6, 24.1

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Physical Component Score						
Baseline						
m	75	87	147			
n	73	79	133			
Mean (SD)	46.92 (9.13)	44.61 (10.19)	46.77 (9.43)			
Median	47.60	46.60	48.50			
IQR: Q1, Q3	42.70, 54.80	38.70, 52.80	40.60, 54.70			
Min, Max	15.3, 60.8	21.6, 61.3	20.7, 60.9			
Week 24						
m	72	78	142			
n	70	75	130	69	70	120
Mean (SD/SE)	46.66 (9.83)	45.22 (9.51)	46.97 (10.03)	-0.23 (0.75)	-0.05 (0.95)	0.39 (0.60)
Median	48.90	45.90	49.60	0.40	-0.35	0.05
IQR: Q1, Q3	41.40, 53.40	38.10, 52.00	41.60, 55.00	-3.70, 3.90	-2.50, 3.70	-2.80, 3.50
Min, Max	12.5, 61.4	20.2, 61.0	19.0, 63.0	-17.2, 11.1	-22.1, 32.4	-28.8, 22.9
Week 52						
m	64	70	135			
n	60	65	122	58	64	113
Mean (SD/SE)	46.77 (11.01)	44.70 (10.71)	48.09 (9.36)	-0.29 (0.88)	0.22 (1.01)	0.84 (0.58)
Median	49.20	46.70	48.95	0.25	1.75	0.60
IQR: Q1, Q3	39.30, 56.10	36.50, 52.40	42.90, 55.70	-2.20, 3.50	-2.75, 4.80	-2.10, 3.80
Min, Max	15.8, 62.8	16.0, 61.2	21.5, 63.9	-24.7, 11.8	-23.5, 17.2	-12.2, 22.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=92)	Visit Result: MGL-3196 100 mg (N=64)	Visit Result: Placebo (N=156)	Change from Baseline: MGL-3196 80 mg (N=92)	Change from Baseline: MGL-3196 100 mg (N=64)	Change from Baseline: Placebo (N=156)
Physical Functioning						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	77.27 (22.85)	73.64 (22.76)	76.13 (24.49)			
Median	85.00	80.00	85.00			
IQR: Q1, Q3	70.00, 95.00	60.00, 90.00	60.00, 95.00			
Min, Max	15.0, 100.0	10.0, 100.0	10.0, 100.0			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	77.41 (23.61)	75.02 (22.09)	76.11 (26.46)	0.45 (1.49)	2.25 (2.65)	-1.04 (1.59)
Median	85.00	80.00	85.00	0	0	0
IQR: Q1, Q3	65.00, 100.00	65.00, 95.00	60.00, 100.00	-10.00, 10.00	-10.00, 10.00	-10.00, 5.00
Min, Max	5.0, 100.0	10.0, 100.0	5.0, 100.0	-40.0, 30.0	-65.0, 70.0	-70.0, 65.0
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	80.66 (23.99)	76.18 (22.28)	75.83 (23.73)	2.11 (1.81)	1.28 (2.53)	-1.03 (1.62)
Median	90.00	85.00	80.00	0	0	0
IQR: Q1, Q3	70.00, 100.00	60.00, 95.00	65.00, 95.00	-5.00, 10.00	-5.00, 5.00	-10.00, 5.00
Min, Max	10.0, 100.0	15.0, 100.0	0.0, 100.0	-45.0, 45.0	-52.2, 35.0	-60.0, 70.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Role Physical						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	75.67 (28.36)	74.48 (27.72)	74.89 (26.24)			
Median	87.50	81.30	81.30			
IQR: Q1, Q3	50.00, 100.00	62.50, 100.00	56.30, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	6.3, 100.0			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	74.22 (27.76)	74.30 (24.60)	77.89 (28.04)	-0.84 (1.92)	1.23 (2.83)	1.31 (1.87)
Median	81.30	81.30	93.80	0	0	0
IQR: Q1, Q3	50.00, 100.00	56.30, 100.00	62.50, 100.00	-12.50, 6.20	-12.50, 15.60	-6.30, 6.30
Min, Max	0.0, 100.0	0.0, 100.0	0.0, 100.0	-43.7, 50.0	-50.0, 68.7	-62.5, 87.5
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	77.23 (27.72)	76.16 (26.62)	74.43 (25.02)	1.13 (2.13)	1.95 (3.37)	-0.69 (1.82)
Median	87.50	81.30	81.30	0	0	0
IQR: Q1, Q3	56.25, 100.00	56.30, 100.00	50.00, 100.00	-6.20, 6.20	-6.20, 6.30	-6.30, 12.50
Min, Max	0.0, 100.0	6.3, 100.0	6.3, 100.0	-37.5, 81.2	-75.0, 81.3	-62.5, 68.7

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Bodily Pain						
Baseline						
m	92	64	156			
n	84	59	146			
Mean (SD)	66.4 (24.1)	62.2 (25.8)	65.6 (25.4)			
Median	72.0	62.0	62.0			
IQR: Q1, Q3	51.0, 84.0	41.0, 84.0	41.0, 84.0			
Min, Max	0, 100	0, 100	0, 100			
Week 24						
m	89	63	147			
n	87	61	137	81	56	128
Mean (SD/SE)	64.3 (26.2)	62.0 (24.6)	66.2 (26.3)	-1.5 (2.3)	-0.2 (2.5)	-0.8 (1.9)
Median	62.0	62.0	72.0	0	0	0
IQR: Q1, Q3	41.0, 84.0	41.0, 84.0	41.0, 84.0	-12.0, 0.0	-11.0, 10.5	-14.0, 12.0
Min, Max	0, 100	10, 100	10, 100	-50, 68	-62, 52	-78, 78
Week 52						
m	85	55	135			
n	76	49	117	71	45	110
Mean (SD/SE)	69.6 (26.0)	71.4 (23.1)	67.5 (25.5)	2.4 (2.3)	9.1 (3.4)	1.4 (2.1)
Median	74.0	72.0	72.0	0	2.0	0
IQR: Q1, Q3	51.0, 100.0	52.0, 100.0	51.0, 84.0	-10.0, 10.0	0.0, 21.0	-11.0, 11.0
Min, Max	0, 100	20, 100	0, 100	-40, 68	-33, 69	-78, 78

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
General Health						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	59.78 (20.96)	51.58 (19.95)	59.33 (20.65)			
Median	62.00	50.00	57.00			
IQR: Q1, Q3	47.00, 77.00	37.00, 67.00	45.00, 77.00			
Min, Max	10.0, 97.0	10.0, 100.0	15.0, 100.0			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	59.45 (22.07)	53.41 (18.75)	59.36 (21.64)	0.66 (1.62)	2.52 (2.11)	-0.17 (1.36)
Median	57.00	52.00	62.00	2.50	3.50	0
IQR: Q1, Q3	45.00, 77.00	40.00, 67.00	47.00, 77.00	-8.00, 10.00	-10.00, 15.00	-10.00, 9.00
Min, Max	10.0, 100.0	10.0, 100.0	0.0, 100.0	-47.0, 32.0	-35.0, 37.0	-38.0, 48.0
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	62.89 (19.66)	55.55 (19.59)	58.90 (20.85)	1.69 (1.79)	3.42 (2.73)	-0.71 (1.28)
Median	67.00	57.00	62.00	0	5.00	0
IQR: Q1, Q3	47.00, 77.00	45.00, 67.00	47.00, 72.00	-7.25, 10.00	-5.00, 15.00	-5.00, 5.00
Min, Max	22.0, 100.0	15.0, 90.0	10.0, 100.0	-37.0, 47.0	-47.0, 47.0	-42.0, 30.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Vitality						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	56.08 (23.86)	51.83 (24.35)	56.48 (20.97)			
Median	62.50	50.00	62.50			
IQR: Q1, Q3	37.50, 75.00	37.50, 68.80	43.80, 75.00			
Min, Max	6.3, 100.0	0.0, 100.0	0.0, 100.0			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	54.91 (25.67)	49.92 (20.94)	57.96 (21.86)	-0.55 (1.70)	-1.12 (2.34)	0.10 (1.43)
Median	56.30	50.00	62.50	0	-6.20	0
IQR: Q1, Q3	37.50, 75.00	37.50, 62.50	43.80, 75.00	-6.30, 6.30	-12.50, 6.25	-12.50, 6.30
Min, Max	0.0, 100.0	0.0, 93.8	0.0, 100.0	-43.8, 43.8	-31.3, 43.8	-37.5, 56.2
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	57.09 (23.85)	51.68 (20.00)	58.25 (21.94)	-0.09 (1.77)	-0.70 (2.67)	1.66 (1.71)
Median	62.50	50.00	62.50	0	0	0
IQR: Q1, Q3	37.50, 75.00	43.80, 68.80	43.80, 75.00	-12.50, 12.50	-12.50, 6.30	-6.30, 12.50
Min, Max	6.3, 100.0	6.3, 87.5	0.0, 100.0	-37.5, 37.5	-43.8, 43.8	-56.3, 43.8

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Social Functioning						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	80.74 (24.74)	76.69 (27.90)	83.65 (21.25)			
Median	87.50	87.50	100.00			
IQR: Q1, Q3	75.00, 100.00	62.50, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	0.0, 100.0	12.5, 100.0			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	78.59 (26.13)	78.69 (21.57)	81.84 (24.81)	-1.68 (2.32)	2.68 (2.93)	-3.22 (1.74)
Median	87.50	75.00	100.00	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	62.50, 100.00	-12.50, 0.00	-12.50, 12.50	-12.50, 0.00
Min, Max	12.5, 100.0	12.5, 100.0	0.0, 100.0	-62.5, 50.0	-50.0, 87.5	-62.5, 50.0
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	80.26 (23.83)	82.65 (22.36)	82.91 (20.80)	-1.04 (2.15)	5.83 (3.50)	-0.80 (1.85)
Median	87.50	100.00	87.50	0	0	0
IQR: Q1, Q3	62.50, 100.00	75.00, 100.00	75.00, 100.00	-12.50, 6.25	0.00, 12.50	0.00, 0.00
Min, Max	12.5, 100.0	25.0, 100.0	12.5, 100.0	-37.5, 50.0	-62.5, 62.5	-50.0, 50.0

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Role Emotional						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	80.00 (26.33)	80.23 (23.67)	83.85 (22.17)			
Median	91.70	91.70	100.00			
IQR: Q1, Q3	66.70, 100.00	66.70, 100.00	75.00, 100.00			
Min, Max	0.0, 100.0	8.3, 100.0	8.3, 100.0			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	77.49 (24.42)	82.92 (21.22)	83.27 (23.97)	-1.93 (1.96)	2.83 (1.97)	-1.17 (1.61)
Median	83.30	91.70	100.00	0	0	0
IQR: Q1, Q3	58.30, 100.00	75.00, 100.00	75.00, 100.00	-8.30, 0.00	0.00, 8.30	-8.30, 0.00
Min, Max	25.0, 100.0	8.3, 100.0	0.0, 100.0	-66.7, 50.0	-33.3, 33.4	-50.0, 50.0
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	82.51 (21.68)	85.72 (19.69)	81.05 (23.12)	1.57 (2.30)	5.93 (2.98)	-3.18 (1.79)
Median	91.70	91.70	83.30	0	0	0
IQR: Q1, Q3	70.85, 100.00	75.00, 100.00	66.70, 100.00	-4.15, 4.15	0.00, 16.70	-16.70, 0.00
Min, Max	25.0, 100.0	25.0, 100.0	0.0, 100.0	-50.0, 100.0	-33.3, 50.0	-58.3, 58.3

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Mental Health						
Baseline						
m	92	64	156			
n	85	59	146			
Mean (SD)	71.6 (21.4)	74.4 (17.7)	74.7 (17.6)			
Median	75.0	80.0	80.0			
IQR: Q1, Q3	60.0, 90.0	65.0, 85.0	65.0, 90.0			
Min, Max	10, 100	15, 100	20, 100			
Week 24						
m	89	63	147			
n	87	61	137	82	56	128
Mean (SD/SE)	70.1 (21.6)	73.5 (19.1)	75.0 (18.7)	-1.3 (1.5)	-0.4 (1.7)	-0.4 (1.2)
Median	75.0	75.0	80.0	0	0	0
IQR: Q1, Q3	55.0, 90.0	65.0, 90.0	65.0, 90.0	-5.0, 5.0	-5.0, 5.0	-10.0, 5.0
Min, Max	15, 100	5, 100	5, 100	-35, 35	-35, 35	-45, 55
Week 52						
m	85	55	135			
n	76	49	117	72	45	110
Mean (SD/SE)	74.9 (18.9)	73.9 (18.9)	75.6 (19.5)	1.9 (1.6)	-0.6 (1.9)	1.1 (1.5)
Median	80.0	75.0	80.0	0	0	0
IQR: Q1, Q3	65.0, 90.0	65.0, 90.0	70.0, 90.0	-5.0, 10.0	-5.0, 5.0	-10.0, 10.0
Min, Max	30, 100	20, 95	15, 100	-35, 40	-25, 35	-60, 55

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=92)	Visit Result: MGL-3196 100 mg (N=64)	Visit Result: Placebo (N=156)	Change from Baseline: MGL-3196 80 mg (N=92)	Change from Baseline: MGL-3196 100 mg (N=64)	Change from Baseline: Placebo (N=156)
Mental Component Score						
Baseline						
m	92	64	156			
n	84	59	146			
Mean (SD)	49.15 (11.49)	49.49 (11.01)	51.07 (9.21)			
Median	52.80	51.50	53.90			
IQR: Q1, Q3	43.35, 57.65	43.30, 58.20	46.00, 57.70			
Min, Max	12.9, 62.6	17.0, 64.7	25.9, 66.5			
Week 24						
m	89	63	147			
n	87	61	137	81	56	128
Mean (SD/SE)	47.97 (11.38)	49.64 (10.28)	50.85 (10.13)	-1.03 (0.80)	0.30 (0.94)	-0.57 (0.66)
Median	49.90	51.20	53.30	-1.30	-0.25	0
IQR: Q1, Q3	39.40, 58.20	45.80, 58.20	45.30, 58.20	-4.30, 2.90	-2.95, 2.75	-4.45, 2.70
Min, Max	18.7, 64.6	9.4, 63.3	14.2, 69.0	-20.0, 19.0	-13.5, 22.4	-24.6, 24.8
Week 52						
m	85	55	135			
n	76	49	117	71	45	110
Mean (SD/SE)	49.90 (10.10)	50.28 (9.59)	50.88 (10.18)	0.19 (0.91)	0.89 (1.19)	-0.12 (0.76)
Median	52.95	52.00	53.60	0	0.40	0.10
IQR: Q1, Q3	43.00, 58.00	44.30, 58.00	45.90, 58.30	-3.00, 3.70	-3.90, 2.90	-3.60, 4.10
Min, Max	23.1, 62.4	17.8, 64.6	20.4, 64.6	-21.7, 26.2	-15.2, 25.2	-25.1, 26.2

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.1
Liver Disease Quality of Life SF-36 (SE22): Summary of Results by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Physical Component Score						
Baseline						
m	92	64	156			
n	84	59	146			
Mean (SD)	48.43 (8.68)	45.77 (9.50)	47.30 (9.48)			
Median	49.40	45.60	48.85			
IQR: Q1, Q3	43.60, 55.55	42.00, 53.70	42.00, 54.70			
Min, Max	21.1, 59.4	21.2, 60.3	21.8, 65.2			
Week 24						
m	89	63	147			
n	87	61	137	81	56	128
Mean (SD/SE)	48.32 (9.35)	46.02 (8.24)	47.80 (10.10)	0.18 (0.68)	0.60 (0.96)	0.02 (0.64)
Median	50.40	47.20	50.20	0	0	0.25
IQR: Q1, Q3	41.90, 55.00	39.90, 52.40	41.90, 55.20	-3.10, 3.60	-3.45, 3.25	-3.80, 3.25
Min, Max	21.8, 63.9	25.8, 57.5	22.8, 62.9	-15.7, 18.3	-16.0, 21.7	-21.7, 23.8
Week 52						
m	85	55	135			
n	76	49	117	71	45	110
Mean (SD/SE)	49.38 (9.82)	47.66 (8.39)	47.54 (9.08)	0.75 (0.77)	1.60 (1.02)	0.00 (0.58)
Median	52.70	48.90	49.00	0.40	1.30	0.05
IQR: Q1, Q3	44.15, 57.50	41.70, 54.10	42.10, 55.00	-1.50, 3.80	-2.70, 6.20	-3.30, 2.70
Min, Max	23.2, 62.7	26.9, 61.1	23.6, 61.7	-22.4, 22.5	-20.4, 18.6	-23.9, 20.5

Abbreviations: SF-36 = 36-Item Short Form Survey; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Physical Functioning			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	71.38 (24.57)	68.29 (28.40)	72.60 (26.58)
Analysis Visit Mean (SD)	73.91 (25.41)	68.38 (26.10)	74.26 (28.77)
LS Mean of Change from Baseline (SE)	2.50 (2.19)	-0.89 (2.16)	1.61 (1.75)
95% CI	(-1.82, 6.82)	(-5.16, 3.37)	(-1.84, 5.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.89 (2.63)	-2.50 (2.62)	
95% CI	(-4.29, 6.07)	(-7.67, 2.66)	
p-value	0.7343	0.3407	
Corrected Hedge's g Statistics	0.047	-0.132	
95% CI	(-0.25, 0.34)	(-0.43, 0.16)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	71.47 (22.77)	67.19 (27.89)	75.22 (24.84)
Analysis Visit Mean (SD)	71.81 (28.63)	67.16 (28.32)	77.59 (25.21)
LS Mean of Change from Baseline (SE)	0.33 (2.06)	-1.13 (1.98)	2.59 (1.61)
95% CI	(-3.73, 4.39)	(-5.02, 2.77)	(-0.59, 5.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.26 (2.42)	-3.72 (2.38)	
95% CI	(-7.03, 2.51)	(-8.41, 0.97)	
p-value	0.3524	0.1199	
Corrected Hedge's g Statistics	-0.135	-0.222	
95% CI	(-0.45, 0.18)	(-0.53, 0.09)	
Subgroup*Treatment Interaction p-value	0.1321	0.0544	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Role Physical			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	76.29 (22.75)	73.77 (26.90)	76.61 (26.44)
Analysis Visit Mean (SD)	74.65 (26.11)	72.34 (23.85)	74.61 (26.61)
LS Mean of Change from Baseline (SE)	-0.81 (2.32)	-1.73 (2.28)	-1.16 (1.87)
95% CI	(-5.38, 3.76)	(-6.22, 2.77)	(-4.84, 2.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.36 (2.76)	-0.56 (2.75)	
95% CI	(-5.08, 5.80)	(-5.98, 4.86)	
p-value	0.8972	0.8387	
Corrected Hedge's g Statistics	0.018	-0.028	
95% CI	(-0.28, 0.31)	(-0.32, 0.27)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	77.28 (23.20)	72.28 (27.04)	79.00 (24.36)
Analysis Visit Mean (SD)	74.79 (28.38)	72.09 (26.42)	77.56 (24.77)
LS Mean of Change from Baseline (SE)	-1.52 (2.55)	-0.82 (2.44)	-0.05 (1.96)
95% CI	(-6.54, 3.50)	(-5.63, 3.99)	(-3.92, 3.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.47 (3.02)	-0.76 (2.96)	
95% CI	(-7.40, 4.47)	(-6.58, 5.06)	
p-value	0.6271	0.7963	
Corrected Hedge's g Statistics	-0.072	-0.037	
95% CI	(-0.39, 0.25)	(-0.34, 0.27)	
Subgroup*Treatment Interaction p-value	0.7552	0.6464	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Bodily Pain			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	67.6 (24.7)	63.7 (27.0)	65.4 (25.4)
Analysis Visit Mean (SD)	64.2 (24.5)	65.3 (23.9)	66.9 (24.9)
LS Mean of Change from Baseline (SE)	-1.66 (2.26)	1.54 (2.22)	2.37 (1.82)
95% CI	(-6.11, 2.78)	(-2.83, 5.92)	(-1.21, 5.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.04 (2.68)	-0.83 (2.66)	
95% CI	(-9.31, 1.23)	(-6.08, 4.41)	
p-value	0.1324	0.7547	
Corrected Hedge's g Statistics	-0.205	-0.042	
95% CI	(-0.50, 0.09)	(-0.34, 0.25)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	68.1 (25.2)	61.6 (27.4)	67.1 (24.1)
Analysis Visit Mean (SD)	65.5 (25.7)	63.7 (27.1)	68.4 (23.8)
LS Mean of Change from Baseline (SE)	-0.48 (2.58)	0.79 (2.48)	2.72 (1.99)
95% CI	(-5.57, 4.60)	(-4.10, 5.68)	(-1.19, 6.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.21 (3.06)	-1.93 (2.99)	
95% CI	(-9.23, 2.81)	(-7.83, 3.96)	
p-value	0.2951	0.5189	
Corrected Hedge's g Statistics	-0.155	-0.093	
95% CI	(-0.47, 0.16)	(-0.40, 0.21)	
Subgroup*Treatment Interaction p-value	0.2803	0.4909	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
General Health			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	61.36 (18.02)	55.50 (18.29)	58.31 (20.07)
Analysis Visit Mean (SD)	62.72 (19.53)	55.90 (20.13)	59.88 (21.68)
LS Mean of Change from Baseline (SE)	2.02 (1.78)	-0.24 (1.75)	1.87 (1.43)
95% CI	(-1.48, 5.52)	(-3.68, 3.19)	(-0.94, 4.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.15 (2.11)	-2.11 (2.10)	
95% CI	(-4.00, 4.30)	(-6.25, 2.02)	
p-value	0.9422	0.3145	
Corrected Hedge's g Statistics	0.010	-0.138	
95% CI	(-0.29, 0.31)	(-0.43, 0.16)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	61.65 (19.09)	54.77 (18.90)	59.67 (20.11)
Analysis Visit Mean (SD)	62.91 (20.29)	56.06 (19.17)	63.26 (20.62)
LS Mean of Change from Baseline (SE)	2.39 (1.90)	-0.10 (1.82)	4.03 (1.46)
95% CI	(-1.34, 6.13)	(-3.68, 3.48)	(1.15, 6.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.64 (2.23)	-4.13 (2.19)	
95% CI	(-6.03, 2.75)	(-8.44, 0.18)	
p-value	0.4632	0.0601	
Corrected Hedge's g Statistics	-0.107	-0.270	
95% CI	(-0.42, 0.21)	(-0.58, 0.04)	
Subgroup*Treatment Interaction p-value	0.3424	0.1741	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Vitality			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	59.44 (20.86)	55.92 (21.20)	56.31 (23.16)
Analysis Visit Mean (SD)	58.72 (21.20)	56.00 (19.31)	56.48 (23.02)
LS Mean of Change from Baseline (SE)	0.02 (1.71)	-0.25 (1.68)	0.24 (1.38)
95% CI	(-3.36, 3.39)	(-3.56, 3.07)	(-2.48, 2.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.22 (2.03)	-0.48 (2.02)	
95% CI	(-4.22, 3.78)	(-4.46, 3.49)	
p-value	0.9148	0.8107	
Corrected Hedge's g Statistics	-0.015	-0.033	
95% CI	(-0.31, 0.28)	(-0.33, 0.26)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	60.90 (21.64)	55.88 (21.96)	57.81 (22.33)
Analysis Visit Mean (SD)	60.80 (21.64)	56.96 (21.48)	57.27 (23.41)
LS Mean of Change from Baseline (SE)	1.50 (2.00)	0.57 (1.91)	-0.17 (1.53)
95% CI	(-2.44, 5.43)	(-3.20, 4.33)	(-3.18, 2.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.67 (2.37)	0.74 (2.31)	
95% CI	(-3.00, 6.33)	(-3.81, 5.28)	
p-value	0.4822	0.7492	
Corrected Hedge's g Statistics	0.104	0.046	
95% CI	(-0.21, 0.42)	(-0.26, 0.35)	
Subgroup*Treatment Interaction p-value	0.6537	0.2326	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Social Functioning			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	83.88 (21.66)	83.57 (24.13)	81.10 (24.43)
Analysis Visit Mean (SD)	84.42 (22.22)	84.46 (20.24)	81.20 (24.00)
LS Mean of Change from Baseline (SE)	1.47 (2.22)	1.30 (2.18)	-0.18 (1.78)
95% CI	(-2.90, 5.83)	(-3.00, 5.59)	(-3.68, 3.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.64 (2.64)	1.47 (2.63)	
95% CI	(-3.56, 6.85)	(-3.71, 6.65)	
p-value	0.5343	0.5760	
Corrected Hedge's g Statistics	0.085	0.077	
95% CI	(-0.21, 0.38)	(-0.22, 0.37)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	85.99 (20.42)	81.84 (25.09)	83.85 (23.07)
Analysis Visit Mean (SD)	83.62 (22.97)	80.86 (22.60)	83.63 (23.33)
LS Mean of Change from Baseline (SE)	-0.29 (2.38)	-1.14 (2.27)	0.20 (1.83)
95% CI	(-4.97, 4.40)	(-5.62, 3.33)	(-3.40, 3.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.49 (2.81)	-1.34 (2.74)	
95% CI	(-6.02, 5.05)	(-6.74, 4.05)	
p-value	0.8628	0.6245	
Corrected Hedge's g Statistics	-0.025	-0.070	
95% CI	(-0.34, 0.29)	(-0.38, 0.24)	
Subgroup*Treatment Interaction p-value	0.9282	0.3356	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Role Emotional			
Week 24			
m	72	78	142
n	69	70	120
Baseline Mean (SD)	84.90 (22.34)	83.69 (24.35)	83.61 (23.12)
Analysis Visit Mean (SD)	86.96 (20.34)	86.67 (20.63)	82.92 (24.44)
LS Mean of Change from Baseline (SE)	2.97 (2.06)	3.53 (2.03)	0.27 (1.67)
95% CI	(-1.09, 7.02)	(-0.46, 7.52)	(-3.02, 3.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.70 (2.44)	3.26 (2.43)	
95% CI	(-2.12, 7.51)	(-1.53, 8.04)	
p-value	0.2711	0.1815	
Corrected Hedge's g Statistics	0.150	0.182	
95% CI	(-0.15, 0.45)	(-0.11, 0.48)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	85.34 (22.64)	82.55 (25.10)	85.69 (21.43)
Analysis Visit Mean (SD)	85.20 (21.12)	83.98 (23.59)	85.32 (22.39)
LS Mean of Change from Baseline (SE)	1.12 (2.28)	1.90 (2.19)	0.37 (1.77)
95% CI	(-3.37, 5.61)	(-2.42, 6.21)	(-3.12, 3.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.75 (2.69)	1.53 (2.64)	
95% CI	(-4.55, 6.06)	(-3.66, 6.72)	
p-value	0.7800	0.5619	
Corrected Hedge's g Statistics	0.041	0.083	
95% CI	(-0.28, 0.36)	(-0.22, 0.39)	
Subgroup*Treatment Interaction p-value	0.8396	0.5189	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Mental Health			
Week 24			
m	72	78	142
n	69	70	121
Baseline Mean (SD)	76.6 (18.1)	76.4 (20.1)	74.9 (18.5)
Analysis Visit Mean (SD)	76.6 (17.1)	75.6 (19.1)	74.9 (19.2)
LS Mean of Change from Baseline (SE)	-0.17 (1.64)	-1.11 (1.61)	-0.78 (1.32)
95% CI	(-3.39, 3.05)	(-4.28, 2.05)	(-3.37, 1.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.60 (1.94)	-0.34 (1.93)	
95% CI	(-3.23, 4.43)	(-4.14, 3.47)	
p-value	0.7573	0.8616	
Corrected Hedge's g Statistics	0.042	-0.024	
95% CI	(-0.25, 0.34)	(-0.32, 0.27)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	77.1 (18.4)	75.8 (20.0)	76.2 (18.1)
Analysis Visit Mean (SD)	75.9 (17.1)	76.5 (17.8)	76.1 (19.6)
LS Mean of Change from Baseline (SE)	-0.95 (1.76)	0.23 (1.69)	-1.05 (1.36)
95% CI	(-4.42, 2.51)	(-3.09, 3.55)	(-3.73, 1.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (2.08)	1.28 (2.03)	
95% CI	(-3.99, 4.19)	(-2.71, 5.27)	
p-value	0.9627	0.5288	
Corrected Hedge's g Statistics	0.007	0.090	
95% CI	(-0.31, 0.32)	(-0.22, 0.40)	
Subgroup*Treatment Interaction p-value	0.6633	0.8039	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Mental Component Score			
Week 24			
m	72	78	142
n	69	70	120
Baseline Mean (SD)	52.36 (9.89)	52.25 (11.05)	51.03 (9.72)
Analysis Visit Mean (SD)	52.68 (9.09)	52.69 (9.43)	50.81 (10.42)
LS Mean of Change from Baseline (SE)	0.51 (0.86)	0.55 (0.85)	-0.38 (0.70)
95% CI	(-1.19, 2.20)	(-1.12, 2.21)	(-1.75, 1.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.89 (1.02)	0.93 (1.02)	
95% CI	(-1.13, 2.90)	(-1.08, 2.93)	
p-value	0.3876	0.3635	
Corrected Hedge's g Statistics	0.118	0.124	
95% CI	(-0.18, 0.41)	(-0.17, 0.42)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	52.88 (10.06)	51.94 (11.25)	51.79 (9.30)
Analysis Visit Mean (SD)	52.47 (8.76)	52.31 (9.75)	51.39 (10.26)
LS Mean of Change from Baseline (SE)	0.13 (0.93)	0.47 (0.89)	-0.64 (0.72)
95% CI	(-1.69, 1.95)	(-1.28, 2.22)	(-2.05, 0.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.77 (1.09)	1.11 (1.07)	
95% CI	(-1.38, 2.92)	(-0.99, 3.21)	
p-value	0.4837	0.2991	
Corrected Hedge's g Statistics	0.103	0.148	
95% CI	(-0.21, 0.42)	(-0.16, 0.46)	
Subgroup*Treatment Interaction p-value	0.3588	0.7753	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Physical Component Score			
Week 24			
m	72	78	142
n	69	70	120
Baseline Mean (SD)	46.94 (8.88)	44.99 (10.09)	46.86 (9.56)
Analysis Visit Mean (SD)	46.71 (9.89)	44.94 (9.53)	47.25 (9.99)
LS Mean of Change from Baseline (SE)	0.11 (0.82)	-0.31 (0.81)	0.68 (0.67)
95% CI	(-1.50, 1.73)	(-1.90, 1.28)	(-0.63, 1.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.56 (0.98)	-0.99 (0.98)	
95% CI	(-2.49, 1.36)	(-2.91, 0.94)	
p-value	0.5648	0.3138	
Corrected Hedge's g Statistics	-0.079	-0.138	
95% CI	(-0.37, 0.22)	(-0.43, 0.16)	
Week 52			
m	64	70	135
n	58	64	113
Baseline Mean (SD)	47.10 (8.68)	44.44 (10.28)	47.60 (8.84)
Analysis Visit Mean (SD)	46.80 (11.03)	44.65 (10.79)	48.43 (8.99)
LS Mean of Change from Baseline (SE)	0.06 (0.88)	-0.24 (0.85)	1.29 (0.69)
95% CI	(-1.68, 1.81)	(-1.91, 1.44)	(-0.06, 2.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.23 (1.04)	-1.53 (1.03)	
95% CI	(-3.28, 0.83)	(-3.55, 0.50)	
p-value	0.2408	0.1388	
Corrected Hedge's g Statistics	-0.172	-0.213	
95% CI	(-0.49, 0.15)	(-0.52, 0.09)	
Subgroup*Treatment Interaction p-value	0.1338	0.1272	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Physical Functioning			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	76.92 (22.91)	72.41 (22.68)	77.58 (24.28)
Analysis Visit Mean (SD)	77.38 (24.01)	74.66 (22.04)	76.54 (25.92)
LS Mean of Change from Baseline (SE)	1.04 (1.85)	1.05 (2.21)	-1.29 (1.45)
95% CI	(-2.60, 4.69)	(-3.30, 5.40)	(-4.16, 1.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.34 (2.34)	2.34 (2.64)	
95% CI	(-2.27, 6.94)	(-2.85, 7.53)	
p-value	0.3187	0.3754	
Corrected Hedge's g Statistics	0.141	0.142	
95% CI	(-0.14, 0.42)	(-0.17, 0.46)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	78.37 (22.56)	74.22 (23.31)	76.73 (24.18)
Analysis Visit Mean (SD)	80.49 (24.34)	75.51 (22.55)	75.70 (23.25)
LS Mean of Change from Baseline (SE)	3.03 (1.84)	1.73 (2.26)	-1.25 (1.46)
95% CI	(-0.59, 6.66)	(-2.73, 6.18)	(-4.12, 1.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.28 (2.34)	2.97 (2.68)	
95% CI	(-0.31, 8.88)	(-2.31, 8.26)	
p-value	0.0678	0.2686	
Corrected Hedge's g Statistics	0.277	0.194	
95% CI	(-0.02, 0.58)	(-0.15, 0.54)	
Subgroup*Treatment Interaction p-value	0.1321	0.0544	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Role Physical			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	75.32 (28.54)	73.45 (28.01)	76.38 (26.31)
Analysis Visit Mean (SD)	74.48 (27.77)	74.68 (25.18)	77.70 (27.95)
LS Mean of Change from Baseline (SE)	-0.42 (2.11)	0.07 (2.52)	1.02 (1.66)
95% CI	(-4.58, 3.73)	(-4.89, 5.02)	(-2.25, 4.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.44 (2.67)	-0.95 (3.01)	
95% CI	(-6.70, 3.82)	(-6.87, 4.97)	
p-value	0.5906	0.7524	
Corrected Hedge's g Statistics	-0.076	-0.050	
95% CI	(-0.35, 0.20)	(-0.36, 0.26)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	75.97 (29.64)	73.62 (29.49)	74.85 (26.35)
Analysis Visit Mean (SD)	77.09 (27.95)	75.57 (27.16)	74.16 (24.88)
LS Mean of Change from Baseline (SE)	1.69 (2.06)	2.12 (2.54)	-0.87 (1.64)
95% CI	(-2.38, 5.75)	(-2.88, 7.13)	(-4.09, 2.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.55 (2.62)	2.99 (3.01)	
95% CI	(-2.61, 7.72)	(-2.95, 8.92)	
p-value	0.3307	0.3222	
Corrected Hedge's g Statistics	0.147	0.174	
95% CI	(-0.15, 0.44)	(-0.17, 0.52)	
Subgroup*Treatment Interaction p-value	0.7552	0.6464	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Bodily Pain			
Week 24			
m	89	63	147
n	81	56	128
Baseline Mean (SD)	65.9 (23.8)	61.5 (25.6)	67.1 (24.8)
Analysis Visit Mean (SD)	64.3 (26.6)	61.3 (24.7)	66.2 (26.7)
LS Mean of Change from Baseline (SE)	-1.38 (2.20)	-1.48 (2.60)	-0.83 (1.71)
95% CI	(-5.70, 2.94)	(-6.61, 3.64)	(-4.20, 2.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.55 (2.77)	-0.66 (3.11)	
95% CI	(-6.00, 4.90)	(-6.78, 5.46)	
p-value	0.8420	0.8327	
Corrected Hedge's g Statistics	-0.028	-0.034	
95% CI	(-0.31, 0.25)	(-0.35, 0.28)	
Week 52			
m	85	55	135
n	71	45	110
Baseline Mean (SD)	66.9 (24.5)	61.0 (26.0)	65.9 (25.3)
Analysis Visit Mean (SD)	69.3 (26.1)	70.1 (23.2)	67.3 (25.2)
LS Mean of Change from Baseline (SE)	2.11 (2.29)	7.27 (2.80)	1.59 (1.80)
95% CI	(-2.39, 6.62)	(1.75, 12.78)	(-1.96, 5.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.52 (2.90)	5.67 (3.32)	
95% CI	(-5.19, 6.23)	(-0.87, 12.22)	
p-value	0.8580	0.0889	
Corrected Hedge's g Statistics	0.027	0.299	
95% CI	(-0.27, 0.33)	(-0.05, 0.65)	
Subgroup*Treatment Interaction p-value	0.2803	0.4909	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
General Health			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	59.48 (20.51)	49.98 (18.93)	59.77 (20.74)
Analysis Visit Mean (SD)	60.13 (21.30)	52.50 (18.80)	59.59 (21.78)
LS Mean of Change from Baseline (SE)	1.10 (1.65)	-0.32 (1.99)	-0.25 (1.30)
95% CI	(-2.15, 4.35)	(-4.23, 3.59)	(-2.80, 2.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.35 (2.08)	-0.07 (2.38)	
95% CI	(-2.75, 5.45)	(-4.75, 4.60)	
p-value	0.5180	0.9753	
Corrected Hedge's g Statistics	0.091	-0.005	
95% CI	(-0.19, 0.37)	(-0.32, 0.31)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	61.32 (20.58)	51.27 (20.72)	59.61 (21.12)
Analysis Visit Mean (SD)	63.01 (19.32)	54.69 (19.64)	58.90 (21.20)
LS Mean of Change from Baseline (SE)	2.09 (1.64)	1.10 (2.03)	-0.13 (1.30)
95% CI	(-1.14, 5.32)	(-2.89, 5.10)	(-2.69, 2.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.22 (2.08)	1.24 (2.41)	
95% CI	(-1.87, 6.31)	(-3.51, 5.98)	
p-value	0.2855	0.6081	
Corrected Hedge's g Statistics	0.161	0.090	
95% CI	(-0.14, 0.46)	(-0.26, 0.44)	
Subgroup*Treatment Interaction p-value	0.3424	0.1741	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Vitality			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	55.99 (23.79)	50.47 (24.19)	57.83 (20.51)
Analysis Visit Mean (SD)	55.44 (25.09)	49.36 (20.15)	57.93 (22.23)
LS Mean of Change from Baseline (SE)	-0.51 (1.74)	-3.06 (2.08)	-0.16 (1.37)
95% CI	(-3.93, 2.91)	(-7.15, 1.04)	(-2.85, 2.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.35 (2.20)	-2.90 (2.49)	
95% CI	(-4.68, 3.97)	(-7.80, 1.99)	
p-value	0.8718	0.2442	
Corrected Hedge's g Statistics	-0.023	-0.187	
95% CI	(-0.30, 0.25)	(-0.50, 0.13)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	56.97 (23.82)	51.83 (24.38)	56.50 (20.68)
Analysis Visit Mean (SD)	56.88 (22.91)	51.13 (20.26)	58.15 (22.04)
LS Mean of Change from Baseline (SE)	-0.29 (1.84)	-2.67 (2.27)	1.34 (1.46)
95% CI	(-3.92, 3.33)	(-7.15, 1.81)	(-1.54, 4.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.63 (2.34)	-4.00 (2.70)	
95% CI	(-6.23, 2.97)	(-9.32, 1.31)	
p-value	0.4867	0.1393	
Corrected Hedge's g Statistics	-0.105	-0.260	
95% CI	(-0.40, 0.19)	(-0.61, 0.09)	
Subgroup*Treatment Interaction p-value	0.6537	0.2326	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Social Functioning			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	80.79 (24.55)	75.45 (28.10)	84.67 (20.59)
Analysis Visit Mean (SD)	79.12 (26.14)	78.13 (22.01)	81.45 (24.75)
LS Mean of Change from Baseline (SE)	-2.18 (2.14)	-0.29 (2.57)	-2.98 (1.69)
95% CI	(-6.40, 2.04)	(-5.35, 4.77)	(-6.31, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.81 (2.72)	2.69 (3.08)	
95% CI	(-4.55, 6.16)	(-3.37, 8.75)	
p-value	0.7673	0.3830	
Corrected Hedge's g Statistics	0.042	0.140	
95% CI	(-0.24, 0.32)	(-0.17, 0.45)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	81.60 (24.64)	76.39 (30.06)	83.64 (20.86)
Analysis Visit Mean (SD)	80.56 (23.63)	82.22 (23.15)	82.84 (20.80)
LS Mean of Change from Baseline (SE)	-1.56 (2.03)	4.06 (2.51)	-0.95 (1.61)
95% CI	(-5.55, 2.44)	(-0.88, 9.00)	(-4.13, 2.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.60 (2.58)	5.01 (2.98)	
95% CI	(-5.68, 4.48)	(-0.86, 10.89)	
p-value	0.8160	0.0938	
Corrected Hedge's g Statistics	-0.035	0.295	
95% CI	(-0.33, 0.26)	(-0.05, 0.64)	
Subgroup*Treatment Interaction p-value	0.9282	0.3356	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Role Emotional			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	80.18 (25.92)	79.47 (23.99)	84.37 (22.21)
Analysis Visit Mean (SD)	78.25 (23.81)	82.29 (21.50)	83.20 (23.87)
LS Mean of Change from Baseline (SE)	-2.63 (1.82)	1.45 (2.16)	-1.28 (1.43)
95% CI	(-6.21, 0.95)	(-2.81, 5.71)	(-4.10, 1.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.34 (2.30)	2.73 (2.59)	
95% CI	(-5.88, 3.19)	(-2.36, 7.82)	
p-value	0.5597	0.2918	
Corrected Hedge's g Statistics	-0.082	0.168	
95% CI	(-0.36, 0.20)	(-0.15, 0.48)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	81.36 (24.65)	79.63 (25.28)	83.71 (22.70)
Analysis Visit Mean (SD)	82.93 (21.22)	85.56 (19.90)	80.53 (23.30)
LS Mean of Change from Baseline (SE)	1.02 (1.98)	5.27 (2.44)	-2.94 (1.57)
95% CI	(-2.87, 4.91)	(0.48, 10.07)	(-6.03, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.97 (2.51)	8.22 (2.89)	
95% CI	(-0.98, 8.92)	(2.52, 13.91)	
p-value	0.1159	0.0049	
Corrected Hedge's g Statistics	0.238	0.497	
95% CI	(-0.06, 0.54)	(0.15, 0.85)	
Subgroup*Treatment Interaction p-value	0.8396	0.5189	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Mental Health			
Week 24			
m	89	63	147
n	82	56	128
Baseline Mean (SD)	72.0 (20.4)	73.8 (17.8)	75.0 (17.4)
Analysis Visit Mean (SD)	70.7 (20.8)	73.4 (19.1)	74.7 (18.9)
LS Mean of Change from Baseline (SE)	-1.86 (1.49)	-0.88 (1.77)	-0.71 (1.17)
95% CI	(-4.79, 1.08)	(-4.36, 2.61)	(-3.01, 1.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.15 (1.89)	-0.17 (2.11)	
95% CI	(-4.86, 2.56)	(-4.33, 3.99)	
p-value	0.5426	0.9366	
Corrected Hedge's g Statistics	-0.086	-0.013	
95% CI	(-0.36, 0.19)	(-0.33, 0.30)	
Week 52			
m	85	55	135
n	72	45	110
Baseline Mean (SD)	73.3 (19.0)	74.1 (19.4)	74.0 (17.7)
Analysis Visit Mean (SD)	75.1 (18.1)	73.6 (19.4)	75.2 (19.8)
LS Mean of Change from Baseline (SE)	1.30 (1.61)	-0.64 (1.98)	0.39 (1.28)
95% CI	(-1.87, 4.48)	(-4.54, 3.27)	(-2.13, 2.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.92 (2.05)	-1.02 (2.35)	
95% CI	(-3.12, 4.95)	(-5.65, 3.61)	
p-value	0.6551	0.6645	
Corrected Hedge's g Statistics	0.068	-0.076	
95% CI	(-0.23, 0.36)	(-0.42, 0.27)	
Subgroup*Treatment Interaction p-value	0.6633	0.8039	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Mental Component Score			
Week 24			
m	89	63	147
n	81	56	128
Baseline Mean (SD)	49.33 (11.14)	49.11 (11.16)	51.26 (9.20)
Analysis Visit Mean (SD)	48.30 (10.81)	49.41 (10.47)	50.69 (10.26)
LS Mean of Change from Baseline (SE)	-1.38 (0.79)	-0.30 (0.93)	-0.71 (0.61)
95% CI	(-2.93, 0.17)	(-2.14, 1.53)	(-1.92, 0.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.67 (1.00)	0.41 (1.11)	
95% CI	(-2.63, 1.29)	(-1.78, 2.60)	
p-value	0.5044	0.7128	
Corrected Hedge's g Statistics	-0.095	0.059	
95% CI	(-0.37, 0.18)	(-0.26, 0.37)	
Week 52			
m	85	55	135
n	71	45	110
Baseline Mean (SD)	49.88 (10.41)	49.31 (11.99)	50.81 (9.40)
Analysis Visit Mean (SD)	50.07 (9.68)	50.21 (9.84)	50.69 (10.34)
LS Mean of Change from Baseline (SE)	-0.18 (0.85)	0.47 (1.04)	-0.37 (0.67)
95% CI	(-1.85, 1.49)	(-1.57, 2.51)	(-1.69, 0.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.20 (1.08)	0.85 (1.23)	
95% CI	(-1.93, 2.32)	(-1.58, 3.27)	
p-value	0.8559	0.4921	
Corrected Hedge's g Statistics	0.028	0.120	
95% CI	(-0.27, 0.33)	(-0.23, 0.47)	
Subgroup*Treatment Interaction p-value	0.3588	0.7753	

AMNOG Table SE22.15.2
Liver Disease Quality of Life SF-36 (SE22): Summary of Results - MMRM Model by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Physical Component Score			
Week 24			
m	89	63	147
n	81	56	128
Baseline Mean (SD)	48.17 (8.67)	45.28 (9.43)	47.90 (9.51)
Analysis Visit Mean (SD)	48.35 (9.44)	45.88 (8.25)	47.92 (10.10)
LS Mean of Change from Baseline (SE)	0.50 (0.74)	-0.16 (0.88)	-0.04 (0.58)
95% CI	(-0.96, 1.96)	(-1.90, 1.58)	(-1.18, 1.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.54 (0.94)	-0.12 (1.05)	
95% CI	(-1.30, 2.39)	(-2.19, 1.96)	
p-value	0.5622	0.9130	
Corrected Hedge's g Statistics	0.082	-0.017	
95% CI	(-0.20, 0.36)	(-0.33, 0.30)	
Week 52			
m	85	55	135
n	71	45	110
Baseline Mean (SD)	48.62 (9.12)	45.64 (9.59)	47.55 (9.47)
Analysis Visit Mean (SD)	49.37 (9.94)	47.24 (8.43)	47.55 (8.97)
LS Mean of Change from Baseline (SE)	1.03 (0.70)	1.29 (0.85)	0.08 (0.55)
95% CI	(-0.34, 2.40)	(-0.39, 2.96)	(-1.00, 1.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.95 (0.88)	1.21 (1.01)	
95% CI	(-0.78, 2.69)	(-0.77, 3.19)	
p-value	0.2783	0.2307	
Corrected Hedge's g Statistics	0.165	0.210	
95% CI	(-0.13, 0.46)	(-0.14, 0.56)	
Subgroup*Treatment Interaction p-value	0.1338	0.1272	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Abbreviations: SF-36 = 36-Item Short Form Survey; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (12.0)	10 (11.5)	23 (15.6)
No	66 (88.0)	77 (88.5)	124 (84.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	1.43	
95% CI of the inverse odds ratio	(0.60, 3.11)	(0.64, 3.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	1.36	
95% CI of the inverse risk ratio	(0.64, 2.68)	(0.68, 2.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.65	-4.15	
95% CI of the absolute risk difference	(-13.06, 5.77)	(-13.06, 4.76)	
p-value	0.4644	0.3778	
p-value of Breslow-Day Test for Homogeneity [3]	0.1609	0.2391	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (30.7)	27 (31.0)	45 (30.6)
No	52 (69.3)	60 (69.0)	102 (69.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.98	
95% CI of the inverse odds ratio	(0.55, 1.82)	(0.55, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.99	
95% CI of the inverse risk ratio	(0.66, 1.52)	(0.66, 1.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.05	0.42	
95% CI of the absolute risk difference	(-12.77, 12.88)	(-11.83, 12.67)	
p-value	0.9934	0.9461	
p-value of Breslow-Day Test for Homogeneity [3]	0.3394	0.4982	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (9.3)	10 (11.5)	17 (11.6)
No	68 (90.7)	77 (88.5)	130 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	1.01	
95% CI of the inverse odds ratio	(0.50, 3.21)	(0.44, 2.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	1.01	
95% CI of the inverse risk ratio	(0.54, 2.86)	(0.48, 2.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.23	-0.07	
95% CI of the absolute risk difference	(-10.60, 6.14)	(-8.53, 8.39)	
p-value	0.6126	0.9870	
p-value of Breslow-Day Test for Homogeneity [3]	0.6966	0.8986	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (24.0)	22 (25.3)	37 (25.2)
No	57 (76.0)	65 (74.7)	110 (74.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.99	
95% CI of the inverse odds ratio	(0.56, 2.04)	(0.54, 1.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.00	
95% CI of the inverse risk ratio	(0.64, 1.71)	(0.63, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.17	0.12	
95% CI of the absolute risk difference	(-13.11, 10.77)	(-11.40, 11.63)	
p-value	0.8485	0.9841	
p-value of Breslow-Day Test for Homogeneity [3]	0.6866	0.5826	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (12.0)	11 (12.6)	29 (19.7)
No	66 (88.0)	76 (87.4)	118 (80.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.80	1.70	
95% CI of the inverse odds ratio	(0.80, 4.04)	(0.80, 3.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.64	1.56	
95% CI of the inverse risk ratio	(0.82, 3.29)	(0.82, 2.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.73	-7.08	
95% CI of the absolute risk difference	(-17.50, 2.04)	(-16.58, 2.41)	
p-value	0.1482	0.1642	
p-value of Breslow-Day Test for Homogeneity [3]	0.5999	0.0465	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (21.3)	24 (27.6)	42 (28.6)
No	59 (78.7)	63 (72.4)	105 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.48	1.05	
95% CI of the inverse odds ratio	(0.76, 2.85)	(0.58, 1.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.34	1.04	
95% CI of the inverse risk ratio	(0.81, 2.22)	(0.68, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.24	-0.99	
95% CI of the absolute risk difference	(-19.04, 4.56)	(-12.88, 10.91)	
p-value	0.2456	0.8714	
p-value of Breslow-Day Test for Homogeneity [3]	0.3598	0.2883	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (14.7)	14 (16.1)	28 (19.0)
No	64 (85.3)	73 (83.9)	119 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.37	1.23	
95% CI of the inverse odds ratio	(0.64, 2.93)	(0.61, 2.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	1.18	
95% CI of the inverse risk ratio	(0.69, 2.46)	(0.66, 2.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.38	-2.96	
95% CI of the absolute risk difference	(-14.60, 5.84)	(-12.95, 7.04)	
p-value	0.4172	0.5691	
p-value of Breslow-Day Test for Homogeneity [3]	0.2017	0.0518	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (34.7)	30 (34.5)	53 (36.1)
No	49 (65.3)	57 (65.5)	94 (63.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.07	
95% CI of the inverse odds ratio	(0.59, 1.90)	(0.61, 1.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.05	
95% CI of the inverse risk ratio	(0.71, 1.52)	(0.73, 1.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.39	-1.57	
95% CI of the absolute risk difference	(-14.66, 11.89)	(-14.22, 11.08)	
p-value	0.8381	0.8081	
p-value of Breslow-Day Test for Homogeneity [3]	0.7805	0.1669	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (9.3)	7 (8.0)	13 (8.8)
No	68 (90.7)	80 (92.0)	134 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.11	
95% CI of the inverse odds ratio	(0.36, 2.47)	(0.42, 2.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	1.10	
95% CI of the inverse risk ratio	(0.39, 2.27)	(0.46, 2.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.49	-0.80	
95% CI of the absolute risk difference	(-7.54, 8.52)	(-8.13, 6.53)	
p-value	0.9040	0.8330	
p-value of Breslow-Day Test for Homogeneity [3]	0.4134	0.7217	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (28.0)	28 (32.2)	45 (30.6)
No	54 (72.0)	59 (67.8)	102 (69.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	0.93	
95% CI of the inverse odds ratio	(0.61, 2.10)	(0.53, 1.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.95	
95% CI of the inverse risk ratio	(0.71, 1.69)	(0.64, 1.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.61	1.57	
95% CI of the absolute risk difference	(-15.21, 9.99)	(-10.75, 13.90)	
p-value	0.6871	0.8020	
p-value of Breslow-Day Test for Homogeneity [3]	0.9740	0.2259	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.0)	12 (13.8)	12 (8.2)
No	72 (96.0)	75 (86.2)	135 (91.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.13	0.56	
95% CI of the inverse odds ratio	(0.58, 7.81)	(0.24, 1.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.04	0.59	
95% CI of the inverse risk ratio	(0.59, 7.01)	(0.28, 1.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.16	5.63	
95% CI of the absolute risk difference	(-10.43, 2.10)	(-2.86, 14.12)	
p-value	0.2425	0.1701	
p-value of Breslow-Day Test for Homogeneity [3]	0.1796	0.7000	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (16.0)	20 (23.0)	26 (17.7)
No	63 (84.0)	67 (77.0)	121 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	0.72	
95% CI of the inverse odds ratio	(0.53, 2.39)	(0.37, 1.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.77	
95% CI of the inverse risk ratio	(0.59, 2.07)	(0.46, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.69	5.30	
95% CI of the absolute risk difference	(-12.03, 8.65)	(-5.48, 16.08)	
p-value	0.7523	0.3240	
p-value of Breslow-Day Test for Homogeneity [3]	0.5357	0.8447	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (10.7)	16 (18.4)	24 (16.3)
No	67 (89.3)	71 (81.6)	123 (83.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.63	0.87	
95% CI of the inverse odds ratio	(0.70, 3.84)	(0.43, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	0.89	
95% CI of the inverse risk ratio	(0.72, 3.24)	(0.50, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.66	2.06	
95% CI of the absolute risk difference	(-14.85, 3.53)	(-8.03, 12.16)	
p-value	0.2561	0.6852	
p-value of Breslow-Day Test for Homogeneity [3]	0.1804	0.0962	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (14.7)	22 (25.3)	27 (18.4)
No	64 (85.3)	65 (74.7)	120 (81.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	0.66	
95% CI of the inverse odds ratio	(0.61, 2.81)	(0.35, 1.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.73	
95% CI of the inverse risk ratio	(0.66, 2.38)	(0.44, 1.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.70	6.92	
95% CI of the absolute risk difference	(-13.86, 6.46)	(-4.15, 17.99)	
p-value	0.4887	0.2086	
p-value of Breslow-Day Test for Homogeneity [3]	0.2798	0.4574	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (9.3)	7 (8.0)	19 (12.9)
No	68 (90.7)	80 (92.0)	128 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.70	
95% CI of the inverse odds ratio	(0.58, 3.60)	(0.68, 4.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	1.61	
95% CI of the inverse risk ratio	(0.61, 3.15)	(0.70, 3.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.59	-4.88	
95% CI of the absolute risk difference	(-12.12, 4.94)	(-12.76, 3.00)	
p-value	0.4312	0.2511	
p-value of Breslow-Day Test for Homogeneity [3]	0.5868	0.6561	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (30.7)	26 (29.9)	39 (26.5)
No	52 (69.3)	61 (70.1)	108 (73.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.85	
95% CI of the inverse odds ratio	(0.44, 1.51)	(0.47, 1.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.89	
95% CI of the inverse risk ratio	(0.56, 1.33)	(0.58, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.14	3.35	
95% CI of the absolute risk difference	(-8.51, 16.78)	(-8.62, 15.33)	
p-value	0.5159	0.5798	
p-value of Breslow-Day Test for Homogeneity [3]	0.6378	0.3626	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.7)	8 (9.2)	9 (6.1)
No	73 (97.3)	79 (90.8)	138 (93.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.38	0.64	
95% CI of the inverse odds ratio	(0.50, 11.31)	(0.24, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.30	0.67	
95% CI of the inverse risk ratio	(0.51, 10.36)	(0.27, 1.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.46	3.07	
95% CI of the absolute risk difference	(-8.78, 1.87)	(-4.13, 10.28)	
p-value	0.2618	0.3814	
p-value of Breslow-Day Test for Homogeneity [3]	0.3404	0.9901	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (21.3)	16 (18.4)	30 (20.4)
No	59 (78.7)	71 (81.6)	117 (79.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	1.14	
95% CI of the inverse odds ratio	(0.48, 1.87)	(0.58, 2.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.11	
95% CI of the inverse risk ratio	(0.56, 1.64)	(0.64, 1.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.93	-2.02	
95% CI of the absolute risk difference	(-10.41, 12.26)	(-12.44, 8.41)	
p-value	0.8722	0.7075	
p-value of Breslow-Day Test for Homogeneity [3]	0.8647	0.8638	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.0)	7 (8.0)	8 (5.4)
No	72 (96.0)	80 (92.0)	139 (94.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	0.66	
95% CI of the inverse odds ratio	(0.36, 5.37)	(0.23, 1.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	0.68	
95% CI of the inverse risk ratio	(0.37, 4.98)	(0.25, 1.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.44	2.60	
95% CI of the absolute risk difference	(-7.20, 4.31)	(-4.19, 9.39)	
p-value	0.6396	0.4319	
p-value of Breslow-Day Test for Homogeneity [3]	0.6364	0.6865	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (21.3)	24 (27.6)	35 (23.8)
No	59 (78.7)	63 (72.4)	112 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.82	
95% CI of the inverse odds ratio	(0.59, 2.25)	(0.45, 1.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.86	
95% CI of the inverse risk ratio	(0.66, 1.88)	(0.55, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.48	3.78	
95% CI of the absolute risk difference	(-14.02, 9.07)	(-7.87, 15.42)	
p-value	0.6783	0.5202	
p-value of Breslow-Day Test for Homogeneity [3]	0.3462	0.3491	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Physical Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (14.1)	8 (12.5)	14 (9.0)
No	79 (85.9)	56 (87.5)	142 (91.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.69	
95% CI of the inverse odds ratio	(0.27, 1.34)	(0.27, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.72	
95% CI of the inverse risk ratio	(0.31, 1.29)	(0.32, 1.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.16	3.53	
95% CI of the absolute risk difference	(-3.26, 13.57)	(-5.74, 12.79)	
p-value	0.2079	0.4285	
p-value of Breslow-Day Test for Homogeneity [3]	0.1609	0.2391	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (34.8)	21 (32.8)	41 (26.3)
No	60 (65.2)	43 (67.2)	115 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.73	
95% CI of the inverse odds ratio	(0.38, 1.17)	(0.39, 1.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	0.80	
95% CI of the inverse risk ratio	(0.51, 1.11)	(0.52, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.50	6.53	
95% CI of the absolute risk difference	(-3.43, 20.43)	(-6.89, 19.95)	
p-value	0.1559	0.3281	
p-value of Breslow-Day Test for Homogeneity [3]	0.3394	0.4982	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Role Physical			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (8.7)	8 (12.5)	21 (13.5)
No	84 (91.3)	56 (87.5)	135 (86.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.63	1.09	
95% CI of the inverse odds ratio	(0.69, 3.85)	(0.46, 2.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	1.08	
95% CI of the inverse risk ratio	(0.72, 3.35)	(0.50, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.77	-0.96	
95% CI of the absolute risk difference	(-12.63, 3.10)	(-10.67, 8.75)	
p-value	0.2592	0.8482	
p-value of Breslow-Day Test for Homogeneity [3]	0.6966	0.8986	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (23.9)	17 (26.6)	34 (21.8)
No	70 (76.1)	47 (73.4)	122 (78.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.77	
95% CI of the inverse odds ratio	(0.48, 1.63)	(0.39, 1.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.82	
95% CI of the inverse risk ratio	(0.57, 1.46)	(0.50, 1.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.12	4.77	
95% CI of the absolute risk difference	(-8.74, 12.98)	(-7.84, 17.38)	
p-value	0.6999	0.4466	
p-value of Breslow-Day Test for Homogeneity [3]	0.6866	0.5826	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Bodily Pain			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (12.0)	15 (23.4)	24 (15.4)
No	81 (88.0)	49 (76.6)	132 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.34	0.59	
95% CI of the inverse odds ratio	(0.62, 2.88)	(0.29, 1.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.66	
95% CI of the inverse risk ratio	(0.66, 2.50)	(0.37, 1.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.43	8.05	
95% CI of the absolute risk difference	(-12.15, 5.29)	(-3.77, 19.88)	
p-value	0.4538	0.1555	
p-value of Breslow-Day Test for Homogeneity [3]	0.5999	0.0465	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (26.1)	22 (34.4)	40 (25.6)
No	68 (73.9)	42 (65.6)	116 (74.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.66	
95% CI of the inverse odds ratio	(0.54, 1.76)	(0.35, 1.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.75	
95% CI of the inverse risk ratio	(0.64, 1.52)	(0.48, 1.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.45	8.73	
95% CI of the absolute risk difference	(-10.84, 11.74)	(-4.77, 22.24)	
p-value	0.9382	0.1909	
p-value of Breslow-Day Test for Homogeneity [3]	0.3598	0.2883	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
General Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (15.2)	14 (21.9)	17 (10.9)
No	78 (84.8)	50 (78.1)	139 (89.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.44	
95% CI of the inverse odds ratio	(0.32, 1.46)	(0.20, 0.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.50	
95% CI of the inverse risk ratio	(0.37, 1.38)	(0.26, 0.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.32	10.98	
95% CI of the absolute risk difference	(-4.50, 13.14)	(-0.27, 22.22)	
p-value	0.3204	0.0335	
p-value of Breslow-Day Test for Homogeneity [3]	0.2017	0.0518	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (26.1)	23 (35.9)	39 (25.0)
No	68 (73.9)	41 (64.1)	117 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.59	
95% CI of the inverse odds ratio	(0.52, 1.70)	(0.32, 1.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.70	
95% CI of the inverse risk ratio	(0.62, 1.49)	(0.45, 1.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.09	10.94	
95% CI of the absolute risk difference	(-10.17, 12.34)	(-2.64, 24.52)	
p-value	0.8493	0.1015	
p-value of Breslow-Day Test for Homogeneity [3]	0.7805	0.1669	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Vitality			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (9.8)	7 (10.9)	23 (14.7)
No	83 (90.2)	57 (89.1)	133 (85.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	1.41	
95% CI of the inverse odds ratio	(0.70, 3.61)	(0.57, 3.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	1.35	
95% CI of the inverse risk ratio	(0.73, 3.12)	(0.61, 2.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.96	-3.81	
95% CI of the absolute risk difference	(-13.20, 3.27)	(-13.26, 5.65)	
p-value	0.2603	0.4550	
p-value of Breslow-Day Test for Homogeneity [3]	0.4134	0.7217	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (31.5)	16 (25.0)	54 (34.6)
No	63 (68.5)	48 (75.0)	102 (65.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.59	
95% CI of the inverse odds ratio	(0.66, 1.99)	(0.83, 3.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	1.38	
95% CI of the inverse risk ratio	(0.76, 1.59)	(0.86, 2.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.09	-9.62	
95% CI of the absolute risk difference	(-15.17, 8.98)	(-22.59, 3.36)	
p-value	0.6180	0.1643	
p-value of Breslow-Day Test for Homogeneity [3]	0.9740	0.2259	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component; by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Social Functioning			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (10.9)	11 (17.2)	13 (8.3)
No	82 (89.1)	53 (82.8)	143 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.44	
95% CI of the inverse odds ratio	(0.31, 1.78)	(0.18, 1.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.48	
95% CI of the inverse risk ratio	(0.35, 1.68)	(0.23, 1.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.54	8.85	
95% CI of the absolute risk difference	(-5.16, 10.23)	(-1.36, 19.06)	
p-value	0.5060	0.0557	
p-value of Breslow-Day Test for Homogeneity [3]	0.1796	0.7000	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (19.6)	15 (23.4)	26 (16.7)
No	74 (80.4)	49 (76.6)	130 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.65	
95% CI of the inverse odds ratio	(0.42, 1.60)	(0.32, 1.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.71	
95% CI of the inverse risk ratio	(0.49, 1.47)	(0.40, 1.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.90	6.77	
95% CI of the absolute risk difference	(-7.10, 12.89)	(-5.14, 18.68)	
p-value	0.5638	0.2415	
p-value of Breslow-Day Test for Homogeneity [3]	0.5357	0.8447	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Role Emotional			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (12.0)	14 (21.9)	14 (9.0)
No	81 (88.0)	50 (78.1)	142 (91.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.35	
95% CI of the inverse odds ratio	(0.31, 1.67)	(0.16, 0.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.41	
95% CI of the inverse risk ratio	(0.36, 1.58)	(0.21, 0.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.98	12.90	
95% CI of the absolute risk difference	(-5.02, 10.99)	(1.82, 23.98)	
p-value	0.4511	0.0091	
p-value of Breslow-Day Test for Homogeneity [3]	0.1804	0.0962	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (19.6)	18 (28.1)	24 (15.4)
No	74 (80.4)	46 (71.9)	132 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.46	
95% CI of the inverse odds ratio	(0.38, 1.47)	(0.23, 0.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.55	
95% CI of the inverse risk ratio	(0.45, 1.37)	(0.32, 0.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.18	12.74	
95% CI of the absolute risk difference	(-5.71, 14.07)	(0.36, 25.13)	
p-value	0.3965	0.0290	
p-value of Breslow-Day Test for Homogeneity [3]	0.2798	0.4574	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Mental Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (13.0)	7 (10.9)	21 (13.5)
No	80 (87.0)	57 (89.1)	135 (86.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.27	
95% CI of the inverse odds ratio	(0.48, 2.22)	(0.51, 3.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.23	
95% CI of the inverse risk ratio	(0.53, 2.00)	(0.55, 2.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.42	-2.52	
95% CI of the absolute risk difference	(-9.14, 8.30)	(-11.86, 6.81)	
p-value	0.9254	0.6099	
p-value of Breslow-Day Test for Homogeneity [3]	0.5868	0.6561	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	34 (37.0)	15 (23.4)	44 (28.2)
No	58 (63.0)	49 (76.6)	112 (71.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	1.28	
95% CI of the inverse odds ratio	(0.39, 1.16)	(0.65, 2.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	1.20	
95% CI of the inverse risk ratio	(0.53, 1.10)	(0.72, 2.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.75	-4.77	
95% CI of the absolute risk difference	(-3.38, 20.88)	(-17.32, 7.79)	
p-value	0.1516	0.4685	
p-value of Breslow-Day Test for Homogeneity [3]	0.6378	0.3626	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Mental Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (5.4)	5 (7.8)	8 (5.1)
No	87 (94.6)	59 (92.2)	148 (94.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.64	
95% CI of the inverse odds ratio	(0.30, 2.97)	(0.20, 2.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.66	
95% CI of the inverse risk ratio	(0.32, 2.80)	(0.22, 1.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.31	2.68	
95% CI of the absolute risk difference	(-5.48, 6.09)	(-4.75, 10.11)	
p-value	0.9167	0.4431	
p-value of Breslow-Day Test for Homogeneity [3]	0.3404	0.9901	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (22.8)	11 (17.2)	32 (20.5)
No	71 (77.2)	53 (82.8)	124 (79.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.24	
95% CI of the inverse odds ratio	(0.47, 1.63)	(0.58, 2.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.19	
95% CI of the inverse risk ratio	(0.55, 1.46)	(0.64, 2.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.31	-3.33	
95% CI of the absolute risk difference	(-8.35, 12.98)	(-14.53, 7.88)	
p-value	0.6677	0.5721	
p-value of Breslow-Day Test for Homogeneity [3]	0.8647	0.8638	

AMNOG Table SE22.15.3
Liver Disease Quality of Life SF-36 (SE22): Summary of Response at Week 52 by Domain/Component;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Physical Component Score			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (4.3)	5 (7.8)	6 (3.8)
No	88 (95.7)	59 (92.2)	150 (96.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.47	
95% CI of the inverse odds ratio	(0.24, 3.20)	(0.14, 1.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.49	
95% CI of the inverse risk ratio	(0.26, 3.05)	(0.16, 1.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.50	3.97	
95% CI of the absolute risk difference	(-4.64, 5.65)	(-3.27, 11.20)	
p-value	0.8462	0.2202	
p-value of Breslow-Day Test for Homogeneity [3]	0.6364	0.6865	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (20.7)	17 (26.6)	25 (16.0)
No	73 (79.3)	47 (73.4)	131 (84.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.53	
95% CI of the inverse odds ratio	(0.38, 1.42)	(0.26, 1.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.60	
95% CI of the inverse risk ratio	(0.45, 1.33)	(0.35, 1.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.63	10.54	
95% CI of the absolute risk difference	(-5.45, 14.70)	(-1.72, 22.79)	
p-value	0.3569	0.0709	
p-value of Breslow-Day Test for Homogeneity [3]	0.3462	0.3491	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE23.2.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
CLDQ-NASH						
Baseline						
m	124	126	224			
n	116	115	205			
Mean (SD)	5.16 (1.28)	5.22 (1.14)	5.16 (1.16)			
Median	5.30	5.60	5.30			
IQR: Q1, Q3	4.30, 6.25	4.50, 6.10	4.40, 6.10			
Min, Max	1.5, 7.0	2.1, 7.0	2.0, 7.0			
Week 24						
m	119	119	214			
n	114	115	199	109	108	184
Mean (SD/SE)	5.23 (1.19)	5.23 (1.04)	5.35 (1.10)	0.08 (0.07)	0.00 (0.06)	0.14 (0.05)
Median	5.35	5.30	5.50	0.10	0	0.10
IQR: Q1, Q3	4.50, 6.30	4.40, 6.10	4.60, 6.20	-0.10, 0.40	-0.40, 0.35	-0.30, 0.50
Min, Max	2.1, 7.0	2.7, 7.0	2.3, 7.0	-2.6, 2.5	-1.4, 1.6	-2.3, 3.0
Week 52						
m	108	107	201			
n	98	96	172	92	92	159
Mean (SD/SE)	5.34 (1.23)	5.29 (1.05)	5.34 (1.16)	0.09 (0.08)	-0.01 (0.07)	0.07 (0.05)
Median	5.60	5.50	5.60	0.10	0	0
IQR: Q1, Q3	4.60, 6.30	4.60, 6.10	4.55, 6.30	-0.20, 0.50	-0.35, 0.30	-0.30, 0.50
Min, Max	1.6, 7.0	2.2, 6.9	1.9, 7.0	-2.7, 2.7	-2.4, 1.8	-2.2, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Abdominal Symptoms						
Baseline						
m	124	126	224			
n	116	115	205			
Mean (SD)	5.19 (1.68)	5.51 (1.39)	5.11 (1.57)			
Median	5.70	6.00	5.30			
IQR: Q1, Q3	4.00, 6.70	4.30, 6.70	4.00, 6.30			
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0			
Week 24						
m	119	119	214			
n	114	115	199	109	108	184
Mean (SD/SE)	5.30 (1.52)	5.35 (1.46)	5.40 (1.52)	0.09 (0.11)	-0.14 (0.11)	0.21 (0.09)
Median	5.30	5.70	5.70	0	0	0
IQR: Q1, Q3	4.30, 6.70	4.30, 6.70	4.30, 7.00	-0.30, 0.70	-0.65, 0.30	-0.40, 1.00
Min, Max	1.0, 7.0	1.3, 7.0	1.0, 7.0	-4.7, 3.0	-4.0, 2.4	-3.0, 4.0
Week 52						
m	108	107	201			
n	98	96	172	92	92	159
Mean (SD/SE)	5.50 (1.50)	5.51 (1.33)	5.45 (1.39)	0.19 (0.14)	-0.14 (0.10)	0.18 (0.10)
Median	5.70	5.70	5.70	0.15	0	0
IQR: Q1, Q3	4.70, 6.70	4.85, 6.70	4.70, 6.70	-0.30, 1.00	-0.65, 0.30	-0.60, 1.00
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0	-3.3, 4.0	-3.0, 2.7	-4.6, 4.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Activity						
Baseline						
m	124	126	224			
n	116	115	205			
Mean (SD)	5.22 (1.47)	5.35 (1.32)	5.44 (1.41)			
Median	5.50	5.60	5.80			
IQR: Q1, Q3	4.20, 6.40	4.60, 6.40	4.60, 6.60			
Min, Max	1.4, 7.0	2.0, 7.0	1.4, 7.0			
Week 24						
m	119	119	214			
n	114	115	199	109	108	184
Mean (SD/SE)	5.24 (1.45)	5.41 (1.24)	5.57 (1.30)	0.02 (0.09)	0.04 (0.08)	0.07 (0.07)
Median	5.60	5.80	6.00	0	0	0
IQR: Q1, Q3	4.40, 6.40	4.60, 6.40	4.80, 6.60	-0.40, 0.60	-0.50, 0.60	-0.40, 0.60
Min, Max	1.2, 7.0	2.4, 7.0	1.2, 7.0	-3.2, 2.8	-2.2, 3.2	-2.8, 2.6
Week 52						
m	108	107	201			
n	98	96	172	92	92	159
Mean (SD/SE)	5.34 (1.59)	5.35 (1.28)	5.43 (1.44)	-0.02 (0.13)	-0.07 (0.09)	-0.16 (0.08)
Median	5.80	5.50	5.80	0	0	0
IQR: Q1, Q3	4.40, 6.80	4.50, 6.40	4.40, 6.60	-0.60, 0.60	-0.50, 0.60	-0.60, 0.40
Min, Max	1.0, 7.0	1.6, 7.0	1.4, 7.0	-4.4, 3.0	-2.8, 2.0	-3.4, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Emotional Health						
Baseline						
m	124	126	224			
n	116	115	205			
Mean (SD)	5.28 (1.30)	5.34 (1.32)	5.32 (1.23)			
Median	5.50	5.70	5.60			
IQR: Q1, Q3	4.60, 6.20	4.70, 6.30	4.60, 6.30			
Min, Max	1.3, 7.0	1.8, 7.0	1.9, 7.0			
Week 24						
m	119	119	214			
n	114	115	199	109	108	184
Mean (SD/SE)	5.31 (1.30)	5.28 (1.25)	5.42 (1.23)	0.07 (0.08)	-0.07 (0.07)	0.06 (0.07)
Median	5.60	5.40	5.70	0.10	-0.05	0.05
IQR: Q1, Q3	4.40, 6.30	4.60, 6.20	4.70, 6.40	-0.30, 0.50	-0.40, 0.20	-0.40, 0.50
Min, Max	2.0, 7.0	1.0, 7.0	1.9, 7.0	-2.8, 2.5	-3.1, 2.4	-2.9, 3.3
Week 52						
m	108	107	201			
n	98	96	172	92	92	159
Mean (SD/SE)	5.37 (1.18)	5.39 (1.23)	5.44 (1.30)	0.04 (0.09)	0.02 (0.08)	0.01 (0.06)
Median	5.60	5.70	5.70	0	0	0
IQR: Q1, Q3	4.60, 6.20	4.70, 6.40	4.60, 6.60	-0.50, 0.60	-0.50, 0.35	-0.40, 0.40
Min, Max	1.9, 7.0	1.0, 7.0	1.3, 7.0	-2.5, 2.9	-1.9, 2.9	-2.0, 2.5

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Fatigue						
Baseline						
m	124	126	224			
n	116	115	205			
Mean (SD)	4.66 (1.60)	4.53 (1.51)	4.50 (1.49)			
Median	4.80	4.80	4.80			
IQR: Q1, Q3	3.40, 6.00	3.50, 5.70	3.30, 5.70			
Min, Max	1.2, 7.0	1.2, 7.0	1.0, 7.0			
Week 24						
m	119	119	214			
n	114	115	199	109	108	184
Mean (SD/SE)	4.70 (1.52)	4.56 (1.41)	4.67 (1.44)	0.04 (0.11)	-0.03 (0.09)	0.14 (0.08)
Median	4.80	4.70	4.80	0	0	0.20
IQR: Q1, Q3	3.50, 6.00	3.70, 5.70	3.30, 5.80	-0.50, 0.50	-0.50, 0.50	-0.50, 0.70
Min, Max	1.3, 7.0	1.5, 7.0	1.2, 7.0	-2.7, 4.1	-4.2, 2.3	-3.3, 3.7
Week 52						
m	108	107	201			
n	98	96	172	92	92	159
Mean (SD/SE)	4.86 (1.57)	4.58 (1.48)	4.65 (1.51)	0.14 (0.11)	-0.05 (0.12)	0.08 (0.09)
Median	5.20	4.75	4.80	0	0	0
IQR: Q1, Q3	3.50, 6.20	3.70, 5.80	3.50, 5.80	-0.30, 0.50	-0.50, 0.50	-0.50, 0.80
Min, Max	1.0, 7.0	1.2, 7.0	1.0, 7.0	-2.0, 4.0	-4.4, 2.5	-3.8, 2.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Systemic Symptoms						
Baseline						
m	124	126	224			
n	116	115	205			
Mean (SD)	5.14 (1.36)	5.10 (1.24)	5.04 (1.25)			
Median	5.50	5.20	5.20			
IQR: Q1, Q3	4.15, 6.30	4.50, 6.00	4.20, 6.00			
Min, Max	1.5, 7.0	1.8, 7.0	1.7, 7.0			
Week 24						
m	119	119	214			
n	114	115	199	109	108	184
Mean (SD/SE)	5.16 (1.28)	4.99 (1.24)	5.16 (1.27)	0.01 (0.08)	-0.15 (0.07)	0.01 (0.07)
Median	5.50	5.00	5.30	0	-0.15	0
IQR: Q1, Q3	4.30, 6.20	4.20, 6.00	4.30, 6.20	-0.50, 0.40	-0.50, 0.20	-0.50, 0.50
Min, Max	1.7, 7.0	1.8, 7.0	1.5, 7.0	-2.0, 3.5	-2.0, 2.2	-2.5, 3.7
Week 52						
m	108	107	201			
n	98	96	172	92	92	159
Mean (SD/SE)	5.18 (1.37)	5.04 (1.24)	5.15 (1.39)	-0.10 (0.09)	-0.11 (0.09)	0.03 (0.07)
Median	5.50	5.20	5.40	-0.10	0	0
IQR: Q1, Q3	4.20, 6.30	4.20, 6.00	4.20, 6.25	-0.50, 0.30	-0.60, 0.30	-0.50, 0.50
Min, Max	1.3, 7.0	1.5, 7.0	1.3, 7.0	-2.7, 2.3	-2.5, 2.0	-2.7, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Worry						
Baseline						
m	124	126	224			
n	116	115	205			
Mean (SD)	5.46 (1.48)	5.49 (1.53)	5.55 (1.43)			
Median	5.70	6.00	6.00			
IQR: Q1, Q3	4.65, 6.70	4.60, 6.70	4.70, 6.70			
Min, Max	1.1, 7.0	1.0, 7.0	1.1, 7.0			
Week 24						
m	119	119	214			
n	114	115	199	109	108	184
Mean (SD/SE)	5.70 (1.48)	5.77 (1.34)	5.85 (1.36)	0.29 (0.10)	0.32 (0.10)	0.31 (0.07)
Median	6.30	6.10	6.30	0.10	0	0.15
IQR: Q1, Q3	5.10, 6.70	5.00, 6.90	5.40, 6.90	-0.20, 0.70	-0.25, 0.75	-0.10, 0.65
Min, Max	1.6, 7.0	1.0, 7.0	1.0, 7.0	-2.4, 3.1	-2.6, 3.6	-2.6, 3.5
Week 52						
m	108	107	201			
n	98	96	172	92	92	159
Mean (SD/SE)	5.80 (1.44)	5.89 (1.38)	5.91 (1.38)	0.30 (0.12)	0.37 (0.12)	0.27 (0.08)
Median	6.35	6.30	6.40	0.10	0	0.10
IQR: Q1, Q3	5.30, 7.00	5.35, 7.00	5.40, 7.00	-0.30, 0.85	-0.25, 0.85	-0.10, 0.70
Min, Max	1.7, 7.0	1.0, 7.0	1.0, 7.0	-4.8, 3.8	-3.3, 3.6	-2.7, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
CLDQ-NASH						
Baseline						
m	43	25	79			
n	40	21	72			
Mean (SD)	5.42 (0.95)	5.50 (0.92)	5.40 (0.96)			
Median	5.60	5.60	5.50			
IQR: Q1, Q3	4.75, 6.20	5.10, 6.00	4.85, 6.15			
Min, Max	3.3, 6.7	3.4, 6.7	2.9, 7.0			
Week 24						
m	42	22	75			
n	41	21	64	38	17	60
Mean (SD/SE)	5.47 (1.00)	5.50 (0.98)	5.38 (1.10)	0.06 (0.11)	-0.11 (0.15)	0.05 (0.09)
Median	5.70	5.70	5.50	0	0	0
IQR: Q1, Q3	4.70, 6.20	5.30, 6.20	4.65, 6.25	-0.30, 0.50	-0.50, 0.30	-0.40, 0.25
Min, Max	2.5, 6.8	3.1, 6.6	2.4, 7.0	-2.0, 1.9	-1.6, 0.8	-1.6, 2.6
Week 52						
m	41	18	69			
n	39	17	62	36	14	58
Mean (SD/SE)	5.41 (0.96)	5.62 (0.85)	5.46 (0.92)	-0.08 (0.08)	0.07 (0.13)	0.04 (0.09)
Median	5.50	5.60	5.45	-0.05	-0.10	0
IQR: Q1, Q3	4.70, 6.40	5.50, 6.10	4.90, 6.20	-0.20, 0.20	-0.10, 0.20	-0.40, 0.40
Min, Max	3.3, 7.0	3.8, 6.6	3.3, 6.9	-1.4, 0.8	-0.6, 1.0	-1.4, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Abdominal Symptoms						
Baseline						
m	43	25	79			
n	40	21	72			
Mean (SD)	5.52 (1.47)	5.92 (1.22)	5.50 (1.36)			
Median	6.00	6.30	5.70			
IQR: Q1, Q3	4.30, 7.00	5.30, 7.00	4.70, 6.70			
Min, Max	2.3, 7.0	3.3, 7.0	2.0, 7.0			
Week 24						
m	42	22	75			
n	41	21	64	38	17	60
Mean (SD/SE)	5.66 (1.26)	5.84 (1.47)	5.69 (1.26)	0.13 (0.17)	0.11 (0.29)	0.19 (0.15)
Median	5.70	6.30	6.00	0	0	0
IQR: Q1, Q3	5.00, 7.00	4.70, 7.00	5.00, 7.00	-0.60, 0.70	-0.60, 0.70	-0.35, 0.70
Min, Max	2.0, 7.0	2.3, 7.0	2.7, 7.0	-1.7, 3.3	-2.7, 2.3	-3.0, 2.7
Week 52						
m	41	18	69			
n	39	17	62	36	14	58
Mean (SD/SE)	5.59 (1.42)	6.09 (0.84)	5.49 (1.40)	-0.04 (0.19)	0.39 (0.24)	-0.11 (0.16)
Median	6.00	6.00	5.85	0	0	0
IQR: Q1, Q3	4.70, 7.00	5.30, 7.00	4.70, 6.70	-0.70, 0.40	0.00, 1.00	-0.70, 0.60
Min, Max	2.0, 7.0	4.7, 7.0	1.0, 7.0	-2.0, 3.3	-1.3, 2.0	-3.7, 3.3

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Activity						
Baseline						
m	43	25	79			
n	40	21	72			
Mean (SD)	5.43 (1.19)	5.24 (1.39)	5.31 (1.29)			
Median	5.60	5.80	5.20			
IQR: Q1, Q3	4.70, 6.40	4.60, 6.40	4.40, 6.50			
Min, Max	2.0, 7.0	1.8, 7.0	2.0, 7.0			
Week 24						
m	42	22	75			
n	41	21	64	38	17	60
Mean (SD/SE)	5.37 (1.42)	5.47 (1.42)	5.24 (1.45)	-0.06 (0.16)	0.06 (0.31)	0.08 (0.15)
Median	5.60	5.80	5.60	-0.10	0	0
IQR: Q1, Q3	4.80, 6.60	4.80, 6.40	4.00, 6.50	-0.80, 0.40	-1.00, 1.20	-0.60, 0.60
Min, Max	1.4, 7.0	2.4, 7.0	2.2, 7.0	-2.4, 2.6	-2.4, 2.4	-3.0, 3.2
Week 52						
m	41	18	69			
n	39	17	62	36	14	58
Mean (SD/SE)	5.35 (1.24)	5.53 (1.11)	5.45 (1.21)	-0.13 (0.13)	0.19 (0.27)	0.05 (0.12)
Median	5.40	6.00	5.80	0.20	0.20	0
IQR: Q1, Q3	4.60, 6.60	4.80, 6.40	4.40, 6.40	-0.50, 0.40	-0.60, 1.20	-0.40, 0.60
Min, Max	2.4, 7.0	3.4, 6.8	2.4, 7.0	-2.2, 1.0	-1.8, 1.6	-1.8, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Emotional Health						
Baseline						
m	43	25	79			
n	40	21	72			
Mean (SD)	5.62 (1.04)	5.61 (1.14)	5.68 (1.10)			
Median	5.90	5.70	5.90			
IQR: Q1, Q3	4.85, 6.30	5.10, 6.60	5.00, 6.60			
Min, Max	3.2, 7.0	2.3, 7.0	1.8, 7.0			
Week 24						
m	42	22	75			
n	41	21	64	38	17	60
Mean (SD/SE)	5.78 (0.96)	5.72 (1.14)	5.58 (1.26)	0.13 (0.12)	-0.09 (0.19)	-0.03 (0.12)
Median	6.10	5.90	6.00	0.10	0	0
IQR: Q1, Q3	5.30, 6.40	5.30, 6.70	4.95, 6.60	-0.40, 0.60	-0.50, 0.30	-0.65, 0.40
Min, Max	3.4, 7.0	2.9, 7.0	2.2, 7.0	-1.4, 2.1	-2.0, 1.1	-2.2, 2.6
Week 52						
m	41	18	69			
n	39	17	62	36	14	58
Mean (SD/SE)	5.63 (0.98)	5.93 (0.91)	5.67 (0.98)	-0.07 (0.11)	0.08 (0.18)	0.02 (0.12)
Median	5.90	6.00	5.90	-0.05	-0.05	-0.05
IQR: Q1, Q3	5.20, 6.30	5.70, 6.60	4.90, 6.40	-0.50, 0.30	-0.60, 0.70	-0.60, 0.40
Min, Max	3.1, 7.0	3.3, 7.0	3.0, 7.0	-1.9, 1.5	-0.8, 1.0	-1.8, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Fatigue						
Baseline						
m	43	25	79			
n	40	21	72			
Mean (SD)	5.02 (1.16)	4.96 (1.01)	4.92 (1.23)			
Median	5.25	5.00	5.20			
IQR: Q1, Q3	4.35, 5.80	4.70, 5.50	3.90, 6.00			
Min, Max	2.0, 6.8	2.8, 6.7	2.2, 7.0			
Week 24						
m	42	22	75			
n	41	21	64	38	17	60
Mean (SD/SE)	4.91 (1.45)	4.58 (1.12)	4.73 (1.50)	-0.10 (0.16)	-0.56 (0.21)	-0.20 (0.13)
Median	5.00	4.80	5.20	-0.05	-0.50	-0.20
IQR: Q1, Q3	4.20, 6.20	4.20, 5.30	3.70, 6.00	-0.80, 0.50	-0.80, 0.00	-0.75, 0.30
Min, Max	2.2, 6.8	2.2, 6.3	1.5, 7.0	-2.5, 2.3	-3.1, 0.6	-3.8, 3.0
Week 52						
m	41	18	69			
n	39	17	62	36	14	58
Mean (SD/SE)	4.77 (1.38)	4.72 (1.33)	4.85 (1.23)	-0.30 (0.15)	-0.36 (0.23)	-0.13 (0.12)
Median	5.20	5.00	5.00	-0.20	-0.15	0
IQR: Q1, Q3	3.80, 5.70	3.70, 6.20	3.80, 5.80	-0.75, 0.40	-0.60, 0.10	-0.70, 0.30
Min, Max	2.0, 7.0	2.7, 6.8	1.8, 7.0	-2.4, 1.0	-2.3, 1.0	-2.4, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Systemic Symptoms						
Baseline						
m	43	25	79			
n	40	21	72			
Mean (SD)	5.24 (1.05)	5.05 (1.10)	5.12 (1.21)			
Median	5.40	5.20	5.30			
IQR: Q1, Q3	4.50, 6.00	4.20, 5.80	4.20, 6.10			
Min, Max	2.7, 6.8	2.8, 6.8	2.0, 7.0			
Week 24						
m	42	22	75			
n	41	21	64	38	17	60
Mean (SD/SE)	5.13 (1.12)	5.00 (1.12)	5.05 (1.18)	-0.07 (0.14)	-0.21 (0.17)	-0.03 (0.10)
Median	5.20	5.30	5.00	-0.15	0	0
IQR: Q1, Q3	4.30, 5.80	4.00, 5.80	4.20, 5.90	-0.50, 0.40	-0.90, 0.20	-0.65, 0.50
Min, Max	2.3, 7.0	3.2, 6.8	2.3, 7.0	-1.9, 2.1	-1.8, 1.0	-1.8, 2.4
Week 52						
m	41	18	69			
n	39	17	62	36	14	58
Mean (SD/SE)	5.03 (1.08)	5.05 (1.12)	5.06 (1.21)	-0.28 (0.12)	-0.13 (0.20)	-0.06 (0.11)
Median	4.80	5.30	5.00	0	-0.10	-0.15
IQR: Q1, Q3	4.30, 6.00	4.80, 5.70	4.20, 6.20	-0.80, 0.30	-0.50, 0.40	-0.50, 0.50
Min, Max	2.7, 7.0	3.0, 6.8	2.5, 7.0	-1.6, 1.0	-2.0, 1.1	-2.4, 2.7

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Worry						
Baseline						
m	43	25	79			
n	40	21	72			
Mean (SD)	5.71 (1.12)	6.22 (1.02)	5.83 (1.20)			
Median	5.90	6.60	6.10			
IQR: Q1, Q3	5.20, 6.40	6.00, 7.00	5.10, 7.00			
Min, Max	2.0, 7.0	4.0, 7.0	2.3, 7.0			
Week 24						
m	42	22	75			
n	41	21	64	38	17	60
Mean (SD/SE)	6.00 (1.00)	6.30 (1.09)	5.97 (1.31)	0.29 (0.18)	0.04 (0.18)	0.29 (0.12)
Median	6.10	6.90	6.40	0.30	0	0
IQR: Q1, Q3	5.40, 6.90	6.10, 7.00	5.60, 7.00	0.00, 0.60	-0.20, 0.30	-0.30, 0.70
Min, Max	3.3, 7.0	3.1, 7.0	1.9, 7.0	-3.1, 3.3	-1.5, 1.8	-1.4, 3.5
Week 52						
m	41	18	69			
n	39	17	62	36	14	58
Mean (SD/SE)	6.12 (0.98)	6.39 (1.10)	6.20 (0.94)	0.37 (0.14)	0.29 (0.23)	0.49 (0.14)
Median	6.40	6.90	6.60	0.15	0	0.05
IQR: Q1, Q3	5.40, 7.00	6.60, 7.00	5.70, 7.00	-0.25, 0.75	0.00, 0.60	0.00, 0.90
Min, Max	3.9, 7.0	3.6, 7.0	3.6, 7.0	-1.0, 2.3	-0.9, 2.4	-1.3, 3.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Age
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.2.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
CLDQ-NASH			
Week 24			
m	119	119	214
n	109	108	184
Baseline Mean (SD)	5.15 (1.25)	5.23 (1.15)	5.21 (1.16)
Analysis Visit Mean (SD)	5.24 (1.20)	5.23 (1.04)	5.35 (1.10)
LS Mean of Change from Baseline (SE)	0.09 (0.06)	0.00 (0.06)	0.15 (0.05)
95% CI	(-0.03, 0.22)	(-0.12, 0.13)	(0.05, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.08)	-0.14 (0.08)	
95% CI	(-0.21, 0.10)	(-0.30, 0.01)	
p-value	0.4904	0.0700	
Corrected Hedge's g Statistics	-0.082	-0.216	
95% CI	(-0.32, 0.16)	(-0.45, 0.02)	
Week 52			
m	108	107	201
n	92	92	159
Baseline Mean (SD)	5.24 (1.25)	5.26 (1.16)	5.26 (1.15)
Analysis Visit Mean (SD)	5.34 (1.24)	5.26 (1.05)	5.33 (1.16)
LS Mean of Change from Baseline (SE)	0.10 (0.07)	0.01 (0.07)	0.09 (0.05)
95% CI	(-0.04, 0.24)	(-0.12, 0.15)	(-0.01, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.09)	-0.08 (0.09)	
95% CI	(-0.16, 0.18)	(-0.25, 0.09)	
p-value	0.9113	0.3648	
Corrected Hedge's g Statistics	0.014	-0.117	
95% CI	(-0.24, 0.27)	(-0.37, 0.14)	
Subgroup*Treatment Interaction p-value	0.7679	0.8652	

AMNOG Table SE23.2.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
CLDQ-NASH			
Week 24			
m	42	22	75
n	38	17	60
Baseline Mean (SD)	5.41 (0.97)	5.51 (0.95)	5.41 (0.96)
Analysis Visit Mean (SD)	5.47 (1.02)	5.41 (1.05)	5.45 (1.07)
LS Mean of Change from Baseline (SE)	0.05 (0.11)	-0.10 (0.17)	0.02 (0.09)
95% CI	(-0.17, 0.27)	(-0.43, 0.22)	(-0.16, 0.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.14)	-0.13 (0.18)	
95% CI	(-0.25, 0.30)	(-0.49, 0.24)	
p-value	0.8473	0.4948	
Corrected Hedge's g Statistics	0.038	-0.174	
95% CI	(-0.37, 0.44)	(-0.71, 0.36)	
Week 52			
m	41	18	69
n	36	14	58
Baseline Mean (SD)	5.41 (0.96)	5.48 (1.05)	5.47 (0.92)
Analysis Visit Mean (SD)	5.33 (0.95)	5.55 (0.90)	5.51 (0.90)
LS Mean of Change from Baseline (SE)	-0.09 (0.10)	0.04 (0.15)	0.06 (0.08)
95% CI	(-0.28, 0.10)	(-0.25, 0.34)	(-0.11, 0.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (0.12)	-0.02 (0.16)	
95% CI	(-0.38, 0.09)	(-0.34, 0.31)	
p-value	0.2262	0.9261	
Corrected Hedge's g Statistics	-0.237	-0.025	
95% CI	(-0.65, 0.18)	(-0.61, 0.56)	
Subgroup*Treatment Interaction p-value	0.7679	0.8652	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.2.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Abdominal Symptoms			
Week 24			
m	119	119	214
n	109	108	184
Baseline Mean (SD)	5.19 (1.67)	5.50 (1.41)	5.20 (1.57)
Analysis Visit Mean (SD)	5.28 (1.53)	5.36 (1.48)	5.41 (1.47)
LS Mean of Change from Baseline (SE)	0.09 (0.11)	-0.04 (0.10)	0.21 (0.08)
95% CI	(-0.11, 0.30)	(-0.25, 0.17)	(0.05, 0.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.13)	-0.25 (0.13)	
95% CI	(-0.37, 0.14)	(-0.51, 0.01)	
p-value	0.3782	0.0571	
Corrected Hedge's g Statistics	-0.104	-0.227	
95% CI	(-0.34, 0.13)	(-0.47, 0.01)	
Week 52			
m	108	107	201
n	92	92	159
Baseline Mean (SD)	5.30 (1.63)	5.63 (1.33)	5.26 (1.52)
Analysis Visit Mean (SD)	5.48 (1.53)	5.49 (1.34)	5.44 (1.37)
LS Mean of Change from Baseline (SE)	0.20 (0.11)	-0.02 (0.11)	0.20 (0.08)
95% CI	(-0.02, 0.41)	(-0.23, 0.20)	(0.03, 0.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.14)	-0.22 (0.14)	
95% CI	(-0.27, 0.26)	(-0.48, 0.05)	
p-value	0.9961	0.1098	
Corrected Hedge's g Statistics	-0.001	-0.206	
95% CI	(-0.26, 0.26)	(-0.46, 0.05)	
Subgroup*Treatment Interaction p-value	0.9336	0.1033	

AMNOG Table SE23.2.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Activity			
Week 24			
m	119	119	214
n	109	108	184
Baseline Mean (SD)	5.23 (1.46)	5.37 (1.32)	5.51 (1.38)
Analysis Visit Mean (SD)	5.24 (1.47)	5.41 (1.21)	5.58 (1.30)
LS Mean of Change from Baseline (SE)	-0.01 (0.08)	0.03 (0.08)	0.10 (0.06)
95% CI	(-0.17, 0.15)	(-0.13, 0.19)	(-0.02, 0.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.10)	-0.08 (0.10)	
95% CI	(-0.31, 0.09)	(-0.27, 0.12)	
p-value	0.2765	0.4531	
Corrected Hedge's g Statistics	-0.129	-0.089	
95% CI	(-0.37, 0.11)	(-0.33, 0.15)	
Week 52			
m	108	107	201
n	92	92	159
Baseline Mean (SD)	5.34 (1.43)	5.38 (1.32)	5.57 (1.33)
Analysis Visit Mean (SD)	5.32 (1.61)	5.31 (1.28)	5.41 (1.46)
LS Mean of Change from Baseline (SE)	-0.02 (0.10)	-0.06 (0.10)	-0.11 (0.08)
95% CI	(-0.22, 0.18)	(-0.25, 0.14)	(-0.26, 0.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.13)	0.05 (0.13)	
95% CI	(-0.17, 0.33)	(-0.20, 0.30)	
p-value	0.5193	0.6902	
Corrected Hedge's g Statistics	0.083	0.051	
95% CI	(-0.17, 0.34)	(-0.21, 0.31)	
Subgroup*Treatment Interaction p-value	0.5727	0.9106	

AMNOG Table SE23.2.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Emotional Health			
Week 24			
m	119	119	214
n	109	108	184
Baseline Mean (SD)	5.26 (1.29)	5.33 (1.33)	5.34 (1.25)
Analysis Visit Mean (SD)	5.33 (1.30)	5.26 (1.25)	5.40 (1.23)
LS Mean of Change from Baseline (SE)	0.06 (0.08)	-0.08 (0.08)	0.06 (0.06)
95% CI	(-0.09, 0.21)	(-0.23, 0.07)	(-0.06, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.10)	-0.14 (0.10)	
95% CI	(-0.18, 0.19)	(-0.32, 0.05)	
p-value	0.9671	0.1543	
Corrected Hedge's g Statistics	0.005	-0.170	
95% CI	(-0.23, 0.24)	(-0.41, 0.07)	
Week 52			
m	108	107	201
n	92	92	159
Baseline Mean (SD)	5.35 (1.27)	5.34 (1.38)	5.39 (1.26)
Analysis Visit Mean (SD)	5.39 (1.16)	5.35 (1.24)	5.40 (1.32)
LS Mean of Change from Baseline (SE)	0.04 (0.08)	0.02 (0.08)	0.00 (0.06)
95% CI	(-0.12, 0.19)	(-0.13, 0.18)	(-0.11, 0.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.10)	0.02 (0.10)	
95% CI	(-0.16, 0.22)	(-0.18, 0.21)	
p-value	0.7570	0.8616	
Corrected Hedge's g Statistics	0.040	0.022	
95% CI	(-0.22, 0.30)	(-0.23, 0.28)	
Subgroup*Treatment Interaction p-value	0.9541	0.7611	

AMNOG Table SE23.2.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Fatigue			
Week 24			
m	119	119	214
n	109	108	184
Baseline Mean (SD)	4.66 (1.57)	4.55 (1.52)	4.54 (1.51)
Analysis Visit Mean (SD)	4.70 (1.51)	4.52 (1.42)	4.68 (1.45)
LS Mean of Change from Baseline (SE)	0.08 (0.10)	-0.05 (0.10)	0.13 (0.07)
95% CI	(-0.11, 0.27)	(-0.24, 0.13)	(-0.02, 0.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.12)	-0.18 (0.12)	
95% CI	(-0.28, 0.18)	(-0.41, 0.05)	
p-value	0.6752	0.1291	
Corrected Hedge's g Statistics	-0.050	-0.180	
95% CI	(-0.29, 0.19)	(-0.42, 0.06)	
Week 52			
m	108	107	201
n	92	92	159
Baseline Mean (SD)	4.72 (1.61)	4.57 (1.53)	4.57 (1.48)
Analysis Visit Mean (SD)	4.87 (1.56)	4.52 (1.47)	4.65 (1.52)
LS Mean of Change from Baseline (SE)	0.16 (0.11)	-0.03 (0.11)	0.07 (0.08)
95% CI	(-0.05, 0.37)	(-0.24, 0.18)	(-0.09, 0.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (0.13)	-0.10 (0.13)	
95% CI	(-0.17, 0.35)	(-0.36, 0.16)	
p-value	0.4927	0.4373	
Corrected Hedge's g Statistics	0.088	-0.100	
95% CI	(-0.17, 0.35)	(-0.36, 0.16)	
Subgroup*Treatment Interaction p-value	0.7708	0.5330	

AMNOG Table SE23.2.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Systemic Symptoms			
Week 24			
m	119	119	214
n	109	108	184
Baseline Mean (SD)	5.14 (1.33)	5.13 (1.25)	5.13 (1.24)
Analysis Visit Mean (SD)	5.14 (1.29)	4.98 (1.23)	5.14 (1.28)
LS Mean of Change from Baseline (SE)	0.04 (0.08)	-0.14 (0.08)	0.03 (0.06)
95% CI	(-0.11, 0.19)	(-0.29, 0.01)	(-0.08, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.10)	-0.17 (0.10)	
95% CI	(-0.18, 0.19)	(-0.35, 0.02)	
p-value	0.9427	0.0793	
Corrected Hedge's g Statistics	0.009	-0.209	
95% CI	(-0.23, 0.25)	(-0.45, 0.03)	
Week 52			
m	108	107	201
n	92	92	159
Baseline Mean (SD)	5.26 (1.30)	5.13 (1.21)	5.11 (1.26)
Analysis Visit Mean (SD)	5.16 (1.38)	5.01 (1.24)	5.14 (1.38)
LS Mean of Change from Baseline (SE)	-0.05 (0.09)	-0.11 (0.09)	0.06 (0.06)
95% CI	(-0.22, 0.12)	(-0.27, 0.06)	(-0.07, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.11)	-0.16 (0.11)	
95% CI	(-0.32, 0.10)	(-0.37, 0.04)	
p-value	0.3071	0.1191	
Corrected Hedge's g Statistics	-0.132	-0.201	
95% CI	(-0.39, 0.13)	(-0.46, 0.06)	
Subgroup*Treatment Interaction p-value	0.6782	0.8953	

AMNOG Table SE23.2.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Worry			
Week 24			
m	119	119	214
n	109	108	184
Baseline Mean (SD)	5.44 (1.48)	5.46 (1.56)	5.55 (1.44)
Analysis Visit Mean (SD)	5.73 (1.45)	5.78 (1.36)	5.87 (1.36)
LS Mean of Change from Baseline (SE)	0.28 (0.09)	0.29 (0.09)	0.33 (0.07)
95% CI	(0.10, 0.45)	(0.12, 0.47)	(0.19, 0.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.11)	-0.03 (0.11)	
95% CI	(-0.27, 0.16)	(-0.25, 0.18)	
p-value	0.6428	0.7615	
Corrected Hedge's g Statistics	-0.055	-0.036	
95% CI	(-0.29, 0.18)	(-0.27, 0.20)	
Week 52			
m	108	107	201
n	92	92	159
Baseline Mean (SD)	5.52 (1.51)	5.51 (1.60)	5.65 (1.41)
Analysis Visit Mean (SD)	5.82 (1.41)	5.88 (1.40)	5.92 (1.36)
LS Mean of Change from Baseline (SE)	0.27 (0.10)	0.37 (0.10)	0.31 (0.08)
95% CI	(0.07, 0.47)	(0.17, 0.56)	(0.15, 0.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.13)	0.06 (0.13)	
95% CI	(-0.29, 0.21)	(-0.19, 0.31)	
p-value	0.7602	0.6320	
Corrected Hedge's g Statistics	-0.039	0.062	
95% CI	(-0.30, 0.22)	(-0.20, 0.32)	
Subgroup*Treatment Interaction p-value	0.8807	0.6338	

AMNOG Table SE23.2.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Abdominal Symptoms			
Week 24			
m	42	22	75
n	38	17	60
Baseline Mean (SD)	5.57 (1.48)	5.84 (1.32)	5.59 (1.29)
Analysis Visit Mean (SD)	5.69 (1.24)	5.95 (1.50)	5.77 (1.21)
LS Mean of Change from Baseline (SE)	0.08 (0.16)	0.17 (0.24)	0.13 (0.14)
95% CI	(-0.24, 0.40)	(-0.31, 0.65)	(-0.15, 0.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.20)	0.04 (0.27)	
95% CI	(-0.45, 0.36)	(-0.49, 0.57)	
p-value	0.8204	0.8801	
Corrected Hedge's g Statistics	-0.044	0.038	
95% CI	(-0.45, 0.36)	(-0.50, 0.58)	
Week 52			
m	41	18	69
n	36	14	58
Baseline Mean (SD)	5.56 (1.49)	5.78 (1.40)	5.63 (1.24)
Analysis Visit Mean (SD)	5.52 (1.45)	6.17 (0.82)	5.52 (1.44)
LS Mean of Change from Baseline (SE)	-0.07 (0.18)	0.33 (0.29)	-0.09 (0.15)
95% CI	(-0.43, 0.29)	(-0.24, 0.90)	(-0.39, 0.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (0.23)	0.42 (0.32)	
95% CI	(-0.43, 0.47)	(-0.21, 1.05)	
p-value	0.9239	0.1877	
Corrected Hedge's g Statistics	0.019	0.363	
95% CI	(-0.40, 0.43)	(-0.22, 0.95)	
Subgroup*Treatment Interaction p-value	0.9336	0.1033	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Activity			
Week 24			
m	42	22	75
n	38	17	60
Baseline Mean (SD)	5.41 (1.19)	5.25 (1.35)	5.28 (1.29)
Analysis Visit Mean (SD)	5.35 (1.43)	5.31 (1.53)	5.37 (1.37)
LS Mean of Change from Baseline (SE)	-0.03 (0.18)	0.04 (0.26)	0.05 (0.15)
95% CI	(-0.38, 0.32)	(-0.48, 0.56)	(-0.25, 0.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.22)	-0.01 (0.29)	
95% CI	(-0.52, 0.36)	(-0.59, 0.57)	
p-value	0.7204	0.9797	
Corrected Hedge's g Statistics	-0.070	-0.007	
95% CI	(-0.48, 0.34)	(-0.55, 0.53)	
Week 52			
m	41	18	69
n	36	14	58
Baseline Mean (SD)	5.40 (1.19)	5.20 (1.49)	5.46 (1.17)
Analysis Visit Mean (SD)	5.27 (1.24)	5.39 (1.16)	5.51 (1.17)
LS Mean of Change from Baseline (SE)	-0.12 (0.14)	0.14 (0.22)	0.09 (0.12)
95% CI	(-0.40, 0.16)	(-0.29, 0.58)	(-0.15, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.21 (0.17)	0.05 (0.24)	
95% CI	(-0.55, 0.14)	(-0.43, 0.53)	
p-value	0.2357	0.8368	
Corrected Hedge's g Statistics	-0.231	0.054	
95% CI	(-0.65, 0.19)	(-0.53, 0.64)	
Subgroup*Treatment Interaction p-value	0.5727	0.9106	

AMNOG Table SE23.2.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Emotional Health			
Week 24			
m	42	22	75
n	38	17	60
Baseline Mean (SD)	5.61 (1.06)	5.68 (1.17)	5.66 (1.11)
Analysis Visit Mean (SD)	5.75 (0.97)	5.59 (1.21)	5.63 (1.23)
LS Mean of Change from Baseline (SE)	0.11 (0.13)	-0.09 (0.20)	-0.03 (0.11)
95% CI	(-0.15, 0.38)	(-0.49, 0.30)	(-0.25, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.14 (0.17)	-0.06 (0.22)	
95% CI	(-0.19, 0.47)	(-0.50, 0.37)	
p-value	0.3945	0.7729	
Corrected Hedge's g Statistics	0.166	-0.074	
95% CI	(-0.24, 0.57)	(-0.61, 0.47)	
Week 52			
m	41	18	69
n	36	14	58
Baseline Mean (SD)	5.63 (1.08)	5.72 (1.22)	5.71 (1.13)
Analysis Visit Mean (SD)	5.56 (0.98)	5.80 (0.94)	5.73 (0.96)
LS Mean of Change from Baseline (SE)	-0.10 (0.12)	0.12 (0.18)	0.03 (0.10)
95% CI	(-0.34, 0.13)	(-0.24, 0.49)	(-0.16, 0.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.15)	0.09 (0.20)	
95% CI	(-0.43, 0.15)	(-0.31, 0.49)	
p-value	0.3496	0.6668	
Corrected Hedge's g Statistics	-0.184	0.115	
95% CI	(-0.60, 0.23)	(-0.47, 0.70)	
Subgroup*Treatment Interaction p-value	0.9541	0.7611	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Fatigue			
Week 24			
m	42	22	75
n	38	17	60
Baseline Mean (SD)	5.01 (1.19)	5.05 (0.97)	4.98 (1.20)
Analysis Visit Mean (SD)	4.91 (1.48)	4.49 (1.16)	4.78 (1.52)
LS Mean of Change from Baseline (SE)	-0.13 (0.16)	-0.60 (0.24)	-0.28 (0.14)
95% CI	(-0.45, 0.19)	(-1.07, -0.12)	(-0.55, -0.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.15 (0.20)	-0.32 (0.27)	
95% CI	(-0.25, 0.55)	(-0.85, 0.21)	
p-value	0.4618	0.2306	
Corrected Hedge's g Statistics	0.143	-0.306	
95% CI	(-0.26, 0.55)	(-0.85, 0.23)	
Week 52			
m	41	18	69
n	36	14	58
Baseline Mean (SD)	4.97 (1.19)	5.08 (1.06)	5.05 (1.16)
Analysis Visit Mean (SD)	4.67 (1.38)	4.72 (1.38)	4.92 (1.22)
LS Mean of Change from Baseline (SE)	-0.36 (0.15)	-0.43 (0.24)	-0.16 (0.13)
95% CI	(-0.66, -0.06)	(-0.90, 0.03)	(-0.41, 0.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.20 (0.19)	-0.27 (0.26)	
95% CI	(-0.57, 0.17)	(-0.78, 0.24)	
p-value	0.2963	0.3018	
Corrected Hedge's g Statistics	-0.207	-0.279	
95% CI	(-0.62, 0.21)	(-0.86, 0.31)	
Subgroup*Treatment Interaction p-value	0.7708	0.5330	

AMNOG Table SE23.2.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Systemic Symptoms			
Week 24			
m	42	22	75
n	38	17	60
Baseline Mean (SD)	5.20 (1.05)	5.03 (1.14)	5.13 (1.15)
Analysis Visit Mean (SD)	5.13 (1.15)	4.82 (1.10)	5.11 (1.18)
LS Mean of Change from Baseline (SE)	-0.05 (0.13)	-0.23 (0.19)	-0.04 (0.11)
95% CI	(-0.30, 0.20)	(-0.60, 0.13)	(-0.25, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.16)	-0.19 (0.21)	
95% CI	(-0.31, 0.31)	(-0.60, 0.22)	
p-value	0.9834	0.3589	
Corrected Hedge's g Statistics	-0.004	-0.232	
95% CI	(-0.41, 0.40)	(-0.77, 0.31)	
Week 52			
m	41	18	69
n	36	14	58
Baseline Mean (SD)	5.21 (1.00)	5.02 (1.27)	5.16 (1.19)
Analysis Visit Mean (SD)	4.93 (1.05)	4.89 (1.13)	5.10 (1.22)
LS Mean of Change from Baseline (SE)	-0.23 (0.13)	-0.22 (0.20)	-0.03 (0.10)
95% CI	(-0.48, 0.01)	(-0.61, 0.17)	(-0.24, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.20 (0.16)	-0.18 (0.22)	
95% CI	(-0.51, 0.11)	(-0.61, 0.24)	
p-value	0.2001	0.3915	
Corrected Hedge's g Statistics	-0.254	-0.232	
95% CI	(-0.67, 0.16)	(-0.82, 0.35)	
Subgroup*Treatment Interaction p-value	0.6782	0.8953	

AMNOG Table SE23.2.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Worry			
Week 24			
m	42	22	75
n	38	17	60
Baseline Mean (SD)	5.68 (1.13)	6.16 (1.10)	5.76 (1.24)
Analysis Visit Mean (SD)	5.97 (1.02)	6.20 (1.18)	6.04 (1.27)
LS Mean of Change from Baseline (SE)	0.27 (0.15)	0.20 (0.23)	0.33 (0.13)
95% CI	(-0.03, 0.57)	(-0.25, 0.65)	(0.08, 0.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.19)	-0.14 (0.25)	
95% CI	(-0.44, 0.31)	(-0.63, 0.36)	
p-value	0.7375	0.5924	
Corrected Hedge's g Statistics	-0.065	-0.137	
95% CI	(-0.47, 0.34)	(-0.68, 0.40)	
Week 52			
m	41	18	69
n	36	14	58
Baseline Mean (SD)	5.69 (1.14)	6.02 (1.17)	5.77 (1.22)
Analysis Visit Mean (SD)	6.05 (1.00)	6.31 (1.21)	6.26 (0.92)
LS Mean of Change from Baseline (SE)	0.34 (0.13)	0.48 (0.21)	0.49 (0.11)
95% CI	(0.07, 0.61)	(0.06, 0.89)	(0.27, 0.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (0.17)	-0.01 (0.23)	
95% CI	(-0.48, 0.18)	(-0.47, 0.44)	
p-value	0.3699	0.9589	
Corrected Hedge's g Statistics	-0.176	-0.014	
95% CI	(-0.59, 0.24)	(-0.60, 0.57)	
Subgroup*Treatment Interaction p-value	0.8807	0.6338	

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (8.9)	9 (7.1)	20 (8.9)
No	113 (91.1)	117 (92.9)	204 (91.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.27	
95% CI of the inverse odds ratio	(0.47, 2.18)	(0.56, 2.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.25	
95% CI of the inverse risk ratio	(0.50, 2.03)	(0.59, 2.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.06	-1.79	
95% CI of the absolute risk difference	(-6.30, 6.19)	(-7.63, 4.06)	
p-value	0.9856	0.5608	
p-value of Breslow-Day Test for Homogeneity [3]	0.0777	0.7520	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (25.8)	28 (22.2)	53 (23.7)
No	92 (74.2)	98 (77.8)	171 (76.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.08	
95% CI of the inverse odds ratio	(0.54, 1.48)	(0.64, 1.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.06	
95% CI of the inverse risk ratio	(0.63, 1.34)	(0.71, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.15	-1.44	
95% CI of the absolute risk difference	(-7.36, 11.65)	(-10.59, 7.71)	
p-value	0.6555	0.7594	
p-value of Breslow-Day Test for Homogeneity [3]	0.2660	0.3901	

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	25 (20.2)	13 (10.3)	46 (20.5)
No	99 (79.8)	113 (89.7)	178 (79.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	2.25	
95% CI of the inverse odds ratio	(0.59, 1.77)	(1.16, 4.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.99	
95% CI of the inverse risk ratio	(0.66, 1.57)	(1.12, 3.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.37	-10.22	
95% CI of the absolute risk difference	(-9.20, 8.45)	(-17.71, -2.72)	
p-value	0.9338	0.0142	
p-value of Breslow-Day Test for Homogeneity [3]	0.5445	0.0625	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	46 (37.1)	24 (19.0)	72 (32.1)
No	78 (62.9)	102 (81.0)	152 (67.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	2.01	
95% CI of the inverse odds ratio	(0.51, 1.27)	(1.19, 3.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.69	
95% CI of the inverse risk ratio	(0.64, 1.17)	(1.12, 2.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.95	-13.10	
95% CI of the absolute risk difference	(-5.52, 15.43)	(-22.28, -3.91)	
p-value	0.3498	0.0084	
p-value of Breslow-Day Test for Homogeneity [3]	0.2369	0.5245	

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (12.9)	12 (9.5)	14 (6.3)
No	108 (87.1)	114 (90.5)	210 (93.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.45	0.63	
95% CI of the inverse odds ratio	(0.21, 0.96)	(0.28, 1.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	0.66	
95% CI of the inverse risk ratio	(0.24, 0.96)	(0.31, 1.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.65	3.27	
95% CI of the absolute risk difference	(-0.04, 13.35)	(-2.75, 9.30)	
p-value	0.0342	0.2623	
p-value of Breslow-Day Test for Homogeneity [3]	0.0368	0.9340	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	34 (27.4)	31 (24.6)	46 (20.5)
No	90 (72.6)	95 (75.4)	178 (79.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.79	
95% CI of the inverse odds ratio	(0.41, 1.14)	(0.47, 1.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.83	
95% CI of the inverse risk ratio	(0.51, 1.10)	(0.56, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.88	4.07	
95% CI of the absolute risk difference	(-2.58, 16.35)	(-5.13, 13.26)	
p-value	0.1438	0.3779	
p-value of Breslow-Day Test for Homogeneity [3]	0.7864	0.6100	

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (12.9)	12 (9.5)	18 (8.0)
No	108 (87.1)	114 (90.5)	206 (92.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.83	
95% CI of the inverse odds ratio	(0.29, 1.20)	(0.39, 1.78)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.84	
95% CI of the inverse risk ratio	(0.33, 1.18)	(0.42, 1.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.87	1.49	
95% CI of the absolute risk difference	(-2.02, 11.76)	(-4.75, 7.73)	
p-value	0.1430	0.6331	
p-value of Breslow-Day Test for Homogeneity [3]	0.2320	0.6246	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (21.0)	29 (23.0)	52 (23.2)
No	98 (79.0)	97 (77.0)	172 (76.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	1.01	
95% CI of the inverse odds ratio	(0.67, 1.94)	(0.60, 1.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.01	
95% CI of the inverse risk ratio	(0.73, 1.68)	(0.68, 1.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.25	-0.20	
95% CI of the absolute risk difference	(-11.30, 6.80)	(-9.40, 9.00)	
p-value	0.6303	0.9663	
p-value of Breslow-Day Test for Homogeneity [3]	0.9716	0.9203	

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (9.7)	20 (15.9)	34 (15.2)
No	112 (90.3)	106 (84.1)	190 (84.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	0.95	
95% CI of the inverse odds ratio	(0.83, 3.36)	(0.52, 1.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.57	0.96	
95% CI of the inverse risk ratio	(0.84, 2.92)	(0.58, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.50	0.69	
95% CI of the absolute risk difference	(-12.51, 1.51)	(-7.23, 8.62)	
p-value	0.1468	0.8629	
p-value of Breslow-Day Test for Homogeneity [3]	0.3158	0.7993	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (26.6)	32 (25.4)	66 (29.5)
No	91 (73.4)	94 (74.6)	158 (70.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	1.23	
95% CI of the inverse odds ratio	(0.70, 1.88)	(0.75, 2.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.16	
95% CI of the inverse risk ratio	(0.78, 1.58)	(0.81, 1.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.85	-4.07	
95% CI of the absolute risk difference	(-12.66, 6.95)	(-13.73, 5.60)	
p-value	0.5723	0.4159	
p-value of Breslow-Day Test for Homogeneity [3]	0.2059	0.6407	

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (5.6)	11 (8.7)	23 (10.3)
No	117 (94.4)	115 (91.3)	201 (89.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.91	1.20	
95% CI of the inverse odds ratio	(0.80, 4.59)	(0.56, 2.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.82	1.18	
95% CI of the inverse risk ratio	(0.80, 4.12)	(0.59, 2.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.62	-1.54	
95% CI of the absolute risk difference	(-10.31, 1.06)	(-7.87, 4.79)	
p-value	0.1412	0.6410	
p-value of Breslow-Day Test for Homogeneity [3]	0.7409	0.7967	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (21.0)	29 (23.0)	59 (26.3)
No	98 (79.0)	97 (77.0)	165 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	1.20	
95% CI of the inverse odds ratio	(0.80, 2.28)	(0.72, 1.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	1.14	
95% CI of the inverse risk ratio	(0.84, 1.89)	(0.78, 1.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.37	-3.32	
95% CI of the absolute risk difference	(-14.57, 3.83)	(-12.67, 6.02)	
p-value	0.2640	0.4915	
p-value of Breslow-Day Test for Homogeneity [3]	0.5341	0.6801	

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	23 (18.5)	23 (18.3)	37 (16.5)
No	101 (81.5)	103 (81.7)	187 (83.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.89	
95% CI of the inverse odds ratio	(0.49, 1.54)	(0.50, 1.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.90	
95% CI of the inverse risk ratio	(0.56, 1.43)	(0.56, 1.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.03	1.74	
95% CI of the absolute risk difference	(-6.36, 10.42)	(-6.58, 10.05)	
p-value	0.6311	0.6791	
p-value of Breslow-Day Test for Homogeneity [3]	0.6624	0.3080	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	41 (33.1)	39 (31.0)	71 (31.7)
No	83 (66.9)	87 (69.0)	153 (68.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.04	
95% CI of the inverse odds ratio	(0.59, 1.50)	(0.65, 1.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.02	
95% CI of the inverse risk ratio	(0.70, 1.31)	(0.74, 1.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.37	-0.74	
95% CI of the absolute risk difference	(-8.91, 11.65)	(-10.86, 9.37)	
p-value	0.7936	0.8856	
p-value of Breslow-Day Test for Homogeneity [3]	0.9759	0.2078	

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (8.0)	6 (7.6)
No	43 (100)	23 (92.0)	73 (92.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.69	0.95	
95% CI of the inverse odds ratio	(0.42, 139.94)	(0.18, 5.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.15	0.95	
95% CI of the inverse risk ratio	(0.41, 123.96)	(0.20, 4.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.99	0.41	
95% CI of the absolute risk difference	(-13.75, -0.23)	(-11.73, 12.54)	
p-value	0.1067	0.9472	
p-value of Breslow-Day Test for Homogeneity [3]	0.0777	0.7520	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (14.0)	3 (12.0)	17 (21.5)
No	37 (86.0)	22 (88.0)	62 (78.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.69	2.01	
95% CI of the inverse odds ratio	(0.61, 4.67)	(0.54, 7.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.54	1.79	
95% CI of the inverse risk ratio	(0.66, 3.62)	(0.57, 5.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.57	-9.52	
95% CI of the absolute risk difference	(-21.33, 6.20)	(-25.15, 6.11)	
p-value	0.3074	0.2926	
p-value of Breslow-Day Test for Homogeneity [3]	0.2660	0.3901	

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (14.0)	4 (16.0)	8 (10.1)
No	37 (86.0)	21 (84.0)	71 (89.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.59	
95% CI of the inverse odds ratio	(0.22, 2.15)	(0.16, 2.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.63	
95% CI of the inverse risk ratio	(0.27, 1.96)	(0.21, 1.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.83	5.87	
95% CI of the absolute risk difference	(-8.48, 16.14)	(-9.96, 21.71)	
p-value	0.5264	0.4231	
p-value of Breslow-Day Test for Homogeneity [3]	0.5445	0.0625	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (23.3)	6 (24.0)	24 (30.4)
No	33 (76.7)	19 (76.0)	55 (69.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.38	
95% CI of the inverse odds ratio	(0.61, 3.38)	(0.49, 3.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.27	
95% CI of the inverse risk ratio	(0.69, 2.47)	(0.58, 2.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.12	-6.38	
95% CI of the absolute risk difference	(-23.32, 9.07)	(-25.95, 13.19)	
p-value	0.4018	0.5394	
p-value of Breslow-Day Test for Homogeneity [3]	0.2369	0.5245	

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.7)	4 (16.0)	9 (11.4)
No	41 (95.3)	21 (84.0)	70 (88.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.64	0.68	
95% CI of the inverse odds ratio	(0.54, 12.80)	(0.19, 2.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.45	0.71	
95% CI of the inverse risk ratio	(0.55, 10.83)	(0.24, 2.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.74	4.61	
95% CI of the absolute risk difference	(-16.16, 2.68)	(-11.38, 20.60)	
p-value	0.2142	0.5438	
p-value of Breslow-Day Test for Homogeneity [3]	0.0368	0.9340	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (30.2)	6 (24.0)	20 (25.3)
No	30 (69.8)	19 (76.0)	59 (74.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.07	
95% CI of the inverse odds ratio	(0.34, 1.79)	(0.38, 3.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.05	
95% CI of the inverse risk ratio	(0.46, 1.51)	(0.48, 2.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.92	-1.32	
95% CI of the absolute risk difference	(-11.83, 21.66)	(-20.61, 17.98)	
p-value	0.5592	0.8946	
p-value of Breslow-Day Test for Homogeneity [3]	0.7864	0.6100	

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (7.0)	2 (8.0)	8 (10.1)
No	40 (93.0)	23 (92.0)	71 (89.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	1.30	
95% CI of the inverse odds ratio	(0.38, 5.99)	(0.26, 6.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	1.27	
95% CI of the inverse risk ratio	(0.41, 5.19)	(0.29, 5.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.15	-2.13	
95% CI of the absolute risk difference	(-13.26, 6.96)	(-14.67, 10.42)	
p-value	0.5617	0.7533	
p-value of Breslow-Day Test for Homogeneity [3]	0.2320	0.6246	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (23.3)	6 (24.0)	20 (25.3)
No	33 (76.7)	19 (76.0)	59 (74.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	1.07	
95% CI of the inverse odds ratio	(0.47, 2.67)	(0.38, 3.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.05	
95% CI of the inverse risk ratio	(0.56, 2.11)	(0.48, 2.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.06	-1.32	
95% CI of the absolute risk difference	(-17.92, 13.79)	(-20.61, 17.98)	
p-value	0.8006	0.8946	
p-value of Breslow-Day Test for Homogeneity [3]	0.9716	0.9203	

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (7.0)	1 (4.0)	4 (5.1)
No	40 (93.0)	24 (96.0)	75 (94.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.28	
95% CI of the inverse odds ratio	(0.15, 3.33)	(0.14, 12.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	1.27	
95% CI of the inverse risk ratio	(0.17, 3.09)	(0.15, 10.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.91	-1.06	
95% CI of the absolute risk difference	(-7.11, 10.93)	(-10.14, 8.01)	
p-value	0.6642	0.8285	
p-value of Breslow-Day Test for Homogeneity [3]	0.3158	0.7993	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (27.9)	3 (12.0)	15 (19.0)
No	31 (72.1)	22 (88.0)	64 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	1.72	
95% CI of the inverse odds ratio	(0.25, 1.45)	(0.45, 6.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	1.58	
95% CI of the inverse risk ratio	(0.35, 1.32)	(0.50, 5.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.92	-6.99	
95% CI of the absolute risk difference	(-7.03, 24.87)	(-22.38, 8.41)	
p-value	0.2569	0.4209	
p-value of Breslow-Day Test for Homogeneity [3]	0.2059	0.6407	

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	1 (4.0)	5 (6.3)
No	42 (97.7)	24 (96.0)	74 (93.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.84	1.62	
95% CI of the inverse odds ratio	(0.32, 25.11)	(0.18, 14.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.72	1.58	
95% CI of the inverse risk ratio	(0.33, 22.55)	(0.19, 12.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.00	-2.33	
95% CI of the absolute risk difference	(-11.01, 3.01)	(-11.70, 7.04)	
p-value	0.3286	0.6633	
p-value of Breslow-Day Test for Homogeneity [3]	0.7409	0.7967	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (23.3)	6 (24.0)	18 (22.8)
No	33 (76.7)	19 (76.0)	61 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.93	
95% CI of the inverse odds ratio	(0.40, 2.35)	(0.32, 2.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.95	
95% CI of the inverse risk ratio	(0.50, 1.93)	(0.42, 2.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.47	1.22	
95% CI of the absolute risk difference	(-15.18, 16.12)	(-17.91, 20.34)	
p-value	0.9529	0.9000	
p-value of Breslow-Day Test for Homogeneity [3]	0.5341	0.6801	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.2.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (18.6)	3 (12.0)	16 (20.3)
No	35 (81.4)	22 (88.0)	63 (79.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.86	
95% CI of the inverse odds ratio	(0.43, 2.86)	(0.49, 7.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.69	
95% CI of the inverse risk ratio	(0.51, 2.33)	(0.54, 5.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.65	-8.25	
95% CI of the absolute risk difference	(-16.27, 12.97)	(-23.77, 7.26)	
p-value	0.8268	0.3520	
p-value of Breslow-Day Test for Homogeneity [3]	0.6624	0.3080	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (37.2)	5 (20.0)	28 (35.4)
No	27 (62.8)	20 (80.0)	51 (64.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	2.20	
95% CI of the inverse odds ratio	(0.43, 2.00)	(0.74, 6.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	1.77	
95% CI of the inverse risk ratio	(0.58, 1.55)	(0.77, 4.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.77	-15.44	
95% CI of the absolute risk difference	(-16.12, 19.65)	(-34.34, 3.45)	
p-value	0.8461	0.1482	
p-value of Breslow-Day Test for Homogeneity [3]	0.9759	0.2078	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
CLDQ-NASH						
Baseline						
m	43	86	132			
n	39	78	120			
Mean (SD)	5.73 (0.88)	5.49 (1.07)	5.51 (1.11)			
Median	6.00	5.85	5.80			
IQR: Q1, Q3	5.10, 6.50	4.70, 6.20	4.95, 6.40			
Min, Max	3.9, 6.9	2.1, 7.0	2.0, 7.0			
Week 24						
m	40	82	129			
n	38	79	119	35	72	111
Mean (SD/SE)	5.80 (0.78)	5.44 (1.04)	5.68 (0.98)	0.07 (0.11)	-0.04 (0.07)	0.15 (0.07)
Median	5.90	5.70	6.00	0	0	0.10
IQR: Q1, Q3	5.40, 6.40	4.70, 6.20	5.10, 6.40	-0.20, 0.40	-0.30, 0.25	-0.20, 0.60
Min, Max	4.0, 6.9	2.7, 7.0	2.6, 7.0	-2.6, 1.7	-1.6, 1.4	-2.3, 3.0
Week 52						
m	39	74	116			
n	36	67	104	32	64	96
Mean (SD/SE)	5.84 (0.80)	5.44 (1.06)	5.68 (1.00)	0.02 (0.09)	-0.07 (0.08)	0.08 (0.07)
Median	6.00	5.70	5.90	0	0	0
IQR: Q1, Q3	5.40, 6.45	4.80, 6.20	5.10, 6.40	-0.15, 0.30	-0.30, 0.20	-0.20, 0.40
Min, Max	4.0, 6.9	2.2, 6.9	2.2, 7.0	-1.9, 0.8	-2.4, 1.4	-2.2, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Abdominal Symptoms						
Baseline						
m	43	86	132			
n	39	78	120			
Mean (SD)	5.99 (1.35)	5.80 (1.28)	5.68 (1.36)			
Median	6.30	6.00	6.00			
IQR: Q1, Q3	5.70, 7.00	5.00, 7.00	5.00, 7.00			
Min, Max	2.0, 7.0	2.0, 7.0	1.7, 7.0			
Week 24						
m	40	82	129			
n	38	79	119	35	72	111
Mean (SD/SE)	5.91 (1.38)	5.58 (1.36)	5.89 (1.33)	-0.16 (0.19)	-0.18 (0.13)	0.18 (0.11)
Median	6.50	6.00	6.30	0	0	0
IQR: Q1, Q3	5.30, 7.00	4.70, 7.00	5.00, 7.00	-0.30, 0.00	-0.65, 0.30	-0.30, 0.70
Min, Max	2.3, 7.0	2.0, 7.0	1.0, 7.0	-4.7, 2.6	-3.3, 2.4	-3.0, 4.0
Week 52						
m	39	74	116			
n	36	67	104	32	64	96
Mean (SD/SE)	6.05 (1.24)	5.74 (1.21)	5.88 (1.16)	-0.11 (0.17)	-0.14 (0.12)	0.17 (0.12)
Median	6.70	6.00	6.00	0	0	0
IQR: Q1, Q3	5.35, 7.00	5.00, 6.70	5.30, 7.00	-0.30, 0.35	-0.70, 0.00	-0.35, 0.70
Min, Max	2.7, 7.0	2.3, 7.0	1.7, 7.0	-3.3, 1.4	-3.0, 2.0	-4.6, 4.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Activity						
Baseline						
m	43	86	132			
n	39	78	120			
Mean (SD)	5.79 (0.97)	5.62 (1.25)	5.72 (1.35)			
Median	5.80	5.80	6.20			
IQR: Q1, Q3	5.20, 6.60	5.00, 6.60	5.00, 6.80			
Min, Max	3.6, 7.0	2.0, 7.0	1.8, 7.0			
Week 24						
m	40	82	129			
n	38	79	119	35	72	111
Mean (SD/SE)	5.92 (1.00)	5.65 (1.24)	5.85 (1.19)	0.14 (0.16)	0.05 (0.11)	0.14 (0.09)
Median	5.90	6.00	6.20	0	0	0
IQR: Q1, Q3	5.20, 7.00	5.00, 6.60	5.20, 6.80	-0.20, 0.80	-0.60, 0.60	-0.40, 0.60
Min, Max	3.6, 7.0	2.4, 7.0	1.2, 7.0	-3.2, 1.8	-2.4, 3.2	-2.0, 3.2
Week 52						
m	39	74	116			
n	36	67	104	32	64	96
Mean (SD/SE)	5.91 (1.10)	5.51 (1.29)	5.73 (1.23)	0.04 (0.13)	-0.12 (0.11)	-0.11 (0.10)
Median	6.10	6.00	6.00	0.10	0	0
IQR: Q1, Q3	5.20, 7.00	4.60, 6.60	4.90, 6.80	-0.10, 0.40	-0.40, 0.40	-0.60, 0.40
Min, Max	3.2, 7.0	1.6, 7.0	1.4, 7.0	-2.2, 1.6	-2.8, 1.2	-3.4, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Emotional Health						
Baseline						
m	43	86	132			
n	39	78	120			
Mean (SD)	5.71 (0.98)	5.57 (1.27)	5.55 (1.23)			
Median	5.90	5.85	5.85			
IQR: Q1, Q3	5.00, 6.40	4.90, 6.60	4.85, 6.65			
Min, Max	3.7, 7.0	1.8, 7.0	1.9, 7.0			
Week 24						
m	40	82	129			
n	38	79	119	35	72	111
Mean (SD/SE)	5.85 (0.92)	5.52 (1.23)	5.66 (1.26)	0.13 (0.13)	-0.06 (0.07)	0.07 (0.10)
Median	6.10	5.70	6.00	0.10	0	0.10
IQR: Q1, Q3	5.30, 6.60	4.90, 6.60	5.10, 6.70	-0.10, 0.60	-0.35, 0.20	-0.40, 0.50
Min, Max	3.6, 7.0	1.0, 7.0	1.9, 7.0	-2.2, 2.1	-1.5, 2.4	-2.9, 3.3
Week 52						
m	39	74	116			
n	36	67	104	32	64	96
Mean (SD/SE)	5.77 (0.93)	5.53 (1.25)	5.71 (1.24)	-0.08 (0.11)	-0.03 (0.09)	0.03 (0.08)
Median	5.90	5.90	6.10	0	0	0
IQR: Q1, Q3	5.20, 6.50	5.00, 6.40	5.00, 6.70	-0.60, 0.20	-0.60, 0.35	-0.35, 0.40
Min, Max	3.7, 7.0	1.0, 7.0	1.3, 7.0	-1.7, 1.0	-1.9, 1.6	-1.9, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Fatigue						
Baseline						
m	43	86	132			
n	39	78	120			
Mean (SD)	5.24 (1.30)	4.87 (1.36)	4.88 (1.41)			
Median	5.30	5.20	5.10			
IQR: Q1, Q3	4.30, 6.30	4.00, 6.00	4.00, 6.00			
Min, Max	2.0, 7.0	1.2, 7.0	1.0, 7.0			
Week 24						
m	40	82	129			
n	38	79	119	35	72	111
Mean (SD/SE)	5.22 (1.15)	4.74 (1.43)	5.11 (1.29)	-0.02 (0.16)	-0.15 (0.10)	0.22 (0.11)
Median	5.30	5.20	5.30	0.10	0	0.30
IQR: Q1, Q3	4.50, 6.20	3.80, 5.70	4.20, 6.20	-0.50, 0.40	-0.50, 0.45	-0.50, 0.70
Min, Max	2.3, 7.0	1.5, 7.0	1.8, 7.0	-2.5, 2.3	-4.2, 1.7	-3.3, 3.7
Week 52						
m	39	74	116			
n	36	67	104	32	64	96
Mean (SD/SE)	5.27 (1.21)	4.73 (1.47)	5.07 (1.31)	-0.02 (0.15)	-0.18 (0.13)	0.06 (0.11)
Median	5.50	5.00	5.30	0	-0.20	0
IQR: Q1, Q3	4.90, 6.00	3.80, 6.00	4.20, 6.00	-0.40, 0.50	-0.50, 0.30	-0.50, 0.50
Min, Max	2.0, 7.0	1.2, 6.8	1.0, 7.0	-2.2, 1.8	-4.4, 1.9	-3.8, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Systemic Symptoms						
Baseline						
m	43	86	132			
n	39	78	120			
Mean (SD)	5.65 (0.97)	5.23 (1.17)	5.32 (1.22)			
Median	5.80	5.30	5.70			
IQR: Q1, Q3	4.80, 6.50	4.70, 6.20	4.50, 6.20			
Min, Max	3.3, 7.0	2.2, 7.0	2.0, 7.0			
Week 24						
m	40	82	129			
n	38	79	119	35	72	111
Mean (SD/SE)	5.62 (0.98)	5.12 (1.22)	5.45 (1.13)	0.04 (0.12)	-0.16 (0.08)	0.09 (0.09)
Median	5.75	5.30	5.70	0	0	0.10
IQR: Q1, Q3	4.80, 6.30	4.20, 6.00	4.80, 6.30	-0.40, 0.40	-0.50, 0.25	-0.30, 0.50
Min, Max	3.0, 7.0	1.8, 7.0	2.3, 7.0	-1.5, 2.1	-2.0, 1.2	-2.5, 3.7
Week 52						
m	39	74	116			
n	36	67	104	32	64	96
Mean (SD/SE)	5.67 (1.01)	5.13 (1.19)	5.48 (1.22)	-0.04 (0.09)	-0.11 (0.10)	0.12 (0.08)
Median	5.75	5.20	5.80	0	-0.10	0.05
IQR: Q1, Q3	4.80, 6.50	4.50, 6.20	4.50, 6.50	-0.30, 0.25	-0.50, 0.30	-0.30, 0.50
Min, Max	2.8, 7.0	1.5, 7.0	2.5, 7.0	-1.5, 1.0	-2.3, 2.0	-2.7, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Worry						
Baseline						
m	43	86	132			
n	39	78	120			
Mean (SD)	5.97 (1.00)	5.82 (1.48)	5.88 (1.24)			
Median	6.10	6.40	6.30			
IQR: Q1, Q3	5.40, 7.00	5.30, 6.90	5.10, 7.00			
Min, Max	3.7, 7.0	1.0, 7.0	2.0, 7.0			
Week 24						
m	40	82	129			
n	38	79	119	35	72	111
Mean (SD/SE)	6.27 (0.66)	6.01 (1.29)	6.10 (1.18)	0.35 (0.14)	0.20 (0.10)	0.23 (0.08)
Median	6.40	6.40	6.60	0	0	0
IQR: Q1, Q3	5.70, 6.90	5.30, 7.00	5.70, 7.00	-0.10, 0.70	-0.20, 0.60	0.00, 0.50
Min, Max	4.3, 7.0	1.0, 7.0	1.9, 7.0	-1.1, 2.3	-2.6, 3.4	-2.6, 3.5
Week 52						
m	39	74	116			
n	36	67	104	32	64	96
Mean (SD/SE)	6.43 (0.69)	6.00 (1.50)	6.21 (1.18)	0.38 (0.13)	0.18 (0.12)	0.24 (0.09)
Median	6.65	6.70	6.80	0.25	0	0
IQR: Q1, Q3	6.05, 7.00	5.40, 7.00	5.80, 7.00	-0.10, 0.85	-0.10, 0.50	0.00, 0.60
Min, Max	4.4, 7.0	1.0, 7.0	1.7, 7.0	-1.1, 2.2	-3.3, 2.9	-2.7, 3.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
CLDQ-NASH						
Baseline						
m	124	65	171			
n	117	58	157			
Mean (SD)	5.06 (1.25)	4.97 (1.11)	5.01 (1.07)			
Median	5.20	5.15	5.10			
IQR: Q1, Q3	4.30, 6.10	4.10, 5.70	4.40, 5.90			
Min, Max	1.5, 7.0	2.2, 6.8	2.2, 7.0			
Week 24						
m	121	59	160			
n	117	57	144	112	53	133
Mean (SD/SE)	5.13 (1.20)	5.04 (0.98)	5.09 (1.12)	0.08 (0.07)	0.02 (0.09)	0.08 (0.06)
Median	5.30	5.10	5.20	0.05	-0.20	0
IQR: Q1, Q3	4.40, 6.20	4.30, 5.80	4.30, 6.00	-0.20, 0.50	-0.40, 0.50	-0.30, 0.50
Min, Max	2.1, 7.0	3.1, 6.8	2.3, 7.0	-2.0, 2.5	-1.4, 1.6	-1.6, 2.4
Week 52						
m	110	51	154			
n	101	46	130	96	42	121
Mean (SD/SE)	5.19 (1.22)	5.19 (0.96)	5.12 (1.12)	0.06 (0.08)	0.12 (0.11)	0.05 (0.06)
Median	5.30	5.35	5.30	0	0.10	0
IQR: Q1, Q3	4.40, 6.20	4.40, 5.90	4.40, 6.00	-0.30, 0.40	-0.40, 0.50	-0.40, 0.50
Min, Max	1.6, 7.0	2.6, 6.9	1.9, 6.9	-2.7, 2.7	-1.5, 1.8	-1.7, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Abdominal Symptoms						
Baseline						
m	124	65	171			
n	117	58	157			
Mean (SD)	5.04 (1.65)	5.26 (1.43)	4.86 (1.56)			
Median	5.30	5.30	5.00			
IQR: Q1, Q3	4.00, 6.30	4.30, 6.70	3.70, 6.00			
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0			
Week 24						
m	121	59	160			
n	117	57	144	112	53	133
Mean (SD/SE)	5.22 (1.45)	5.22 (1.58)	5.13 (1.48)	0.18 (0.11)	0.01 (0.16)	0.22 (0.11)
Median	5.30	5.70	5.30	0	0	0
IQR: Q1, Q3	4.30, 6.30	4.00, 6.70	4.00, 6.30	-0.40, 0.70	-0.60, 0.70	-0.60, 1.00
Min, Max	1.0, 7.0	1.3, 7.0	1.0, 7.0	-3.0, 3.3	-4.0, 2.3	-2.7, 3.7
Week 52						
m	110	51	154			
n	101	46	130	96	42	121
Mean (SD/SE)	5.34 (1.51)	5.38 (1.36)	5.12 (1.47)	0.20 (0.14)	0.05 (0.15)	0.04 (0.11)
Median	5.30	5.50	5.30	0	0	0
IQR: Q1, Q3	4.70, 6.70	5.00, 6.70	4.00, 6.30	-0.60, 1.00	-0.30, 0.70	-0.70, 1.00
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0	-2.7, 4.0	-2.6, 2.7	-3.7, 2.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Activity						
Baseline						
m	124	65	171			
n	117	58	157			
Mean (SD)	5.10 (1.49)	4.96 (1.35)	5.17 (1.36)			
Median	5.20	5.20	5.20			
IQR: Q1, Q3	4.20, 6.40	4.00, 5.80	4.40, 6.40			
Min, Max	1.4, 7.0	1.8, 7.0	1.4, 7.0			
Week 24						
m	121	59	160			
n	117	57	144	112	53	133
Mean (SD/SE)	5.07 (1.50)	5.09 (1.24)	5.19 (1.39)	-0.05 (0.09)	0.03 (0.12)	0.02 (0.09)
Median	5.40	5.00	5.60	0	0	0
IQR: Q1, Q3	4.00, 6.40	4.20, 6.00	4.00, 6.40	-0.60, 0.40	-0.60, 0.60	-0.80, 0.80
Min, Max	1.2, 7.0	2.4, 7.0	2.2, 7.0	-2.4, 2.8	-2.2, 2.4	-3.0, 2.6
Week 52						
m	110	51	154			
n	101	46	130	96	42	121
Mean (SD/SE)	5.14 (1.57)	5.18 (1.18)	5.21 (1.45)	-0.08 (0.12)	0.09 (0.14)	-0.10 (0.08)
Median	5.40	5.40	5.60	0	0.10	0
IQR: Q1, Q3	4.00, 6.60	4.40, 6.00	4.20, 6.40	-0.60, 0.50	-0.60, 0.80	-0.80, 0.60
Min, Max	1.0, 7.0	2.2, 7.0	1.6, 7.0	-4.4, 3.0	-1.6, 2.0	-2.4, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Emotional Health						
Baseline						
m	124	65	171			
n	117	58	157			
Mean (SD)	5.25 (1.31)	5.13 (1.29)	5.31 (1.18)			
Median	5.40	5.40	5.40			
IQR: Q1, Q3	4.60, 6.20	4.20, 6.20	4.70, 6.20			
Min, Max	1.3, 7.0	2.2, 7.0	1.8, 7.0			
Week 24						
m	121	59	160			
n	117	57	144	112	53	133
Mean (SD/SE)	5.30 (1.30)	5.11 (1.23)	5.30 (1.20)	0.07 (0.08)	-0.10 (0.12)	0.01 (0.07)
Median	5.60	5.20	5.60	0.05	-0.10	0
IQR: Q1, Q3	4.30, 6.30	4.30, 6.10	4.60, 6.20	-0.35, 0.60	-0.50, 0.40	-0.60, 0.40
Min, Max	2.0, 7.0	2.3, 7.0	2.0, 7.0	-2.8, 2.5	-3.1, 1.9	-2.0, 2.4
Week 52						
m	110	51	154			
n	101	46	130	96	42	121
Mean (SD/SE)	5.33 (1.17)	5.39 (1.14)	5.33 (1.19)	0.04 (0.09)	0.11 (0.14)	0.00 (0.08)
Median	5.40	5.65	5.60	0	-0.05	0
IQR: Q1, Q3	4.60, 6.20	4.70, 6.40	4.60, 6.30	-0.50, 0.55	-0.50, 0.60	-0.60, 0.40
Min, Max	1.9, 7.0	2.1, 7.0	1.7, 7.0	-2.5, 2.9	-1.3, 2.9	-2.0, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Fatigue						
Baseline						
m	124	65	171			
n	117	58	157			
Mean (SD)	4.59 (1.54)	4.24 (1.50)	4.41 (1.42)			
Median	4.80	4.70	4.50			
IQR: Q1, Q3	3.30, 5.80	2.80, 5.20	3.20, 5.50			
Min, Max	1.2, 7.0	1.5, 7.0	1.3, 7.0			
Week 24						
m	121	59	160			
n	117	57	144	112	53	133
Mean (SD/SE)	4.60 (1.57)	4.31 (1.25)	4.34 (1.49)	0.01 (0.11)	-0.04 (0.14)	-0.07 (0.09)
Median	4.50	4.20	4.30	0	0	0
IQR: Q1, Q3	3.30, 6.00	3.50, 5.20	3.20, 5.70	-0.60, 0.65	-0.70, 0.40	-0.70, 0.50
Min, Max	1.3, 7.0	1.8, 6.7	1.2, 7.0	-2.7, 4.1	-2.4, 2.3	-3.8, 2.7
Week 52						
m	110	51	154			
n	101	46	130	96	42	121
Mean (SD/SE)	4.68 (1.59)	4.42 (1.42)	4.41 (1.48)	0.03 (0.11)	0.05 (0.20)	0.00 (0.09)
Median	5.00	4.25	4.50	0	0.05	0
IQR: Q1, Q3	3.30, 6.20	3.30, 5.70	3.20, 5.50	-0.50, 0.50	-0.50, 1.10	-0.60, 0.70
Min, Max	1.0, 7.0	1.5, 7.0	1.0, 7.0	-2.4, 4.0	-2.8, 2.5	-2.6, 2.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Systemic Symptoms						
Baseline						
m	124	65	171			
n	117	58	157			
Mean (SD)	5.01 (1.34)	4.90 (1.26)	4.86 (1.21)			
Median	5.30	5.00	5.00			
IQR: Q1, Q3	4.00, 6.00	4.00, 5.80	4.20, 5.80			
Min, Max	1.5, 7.0	1.8, 7.0	1.7, 7.0			
Week 24						
m	121	59	160			
n	117	57	144	112	53	133
Mean (SD/SE)	5.01 (1.28)	4.82 (1.20)	4.87 (1.28)	-0.03 (0.08)	-0.16 (0.11)	-0.07 (0.07)
Median	5.30	4.80	5.00	-0.05	-0.20	0
IQR: Q1, Q3	4.20, 6.00	4.00, 5.70	4.00, 5.80	-0.50, 0.45	-0.50, 0.10	-0.70, 0.50
Min, Max	1.7, 7.0	2.3, 7.0	1.5, 7.0	-2.0, 3.5	-1.9, 2.2	-2.5, 2.1
Week 52						
m	110	51	154			
n	101	46	130	96	42	121
Mean (SD/SE)	4.95 (1.34)	4.91 (1.27)	4.84 (1.36)	-0.19 (0.09)	-0.12 (0.12)	-0.09 (0.08)
Median	5.20	5.10	4.80	-0.20	0	-0.10
IQR: Q1, Q3	4.20, 6.00	4.00, 5.80	4.20, 6.00	-0.70, 0.35	-0.60, 0.30	-0.60, 0.50
Min, Max	1.3, 7.0	2.5, 7.0	1.3, 7.0	-2.7, 2.3	-2.5, 1.8	-2.4, 2.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Worry						
Baseline						
m	124	65	171			
n	117	58	157			
Mean (SD)	5.37 (1.48)	5.31 (1.46)	5.43 (1.45)			
Median	5.70	5.65	5.90			
IQR: Q1, Q3	4.70, 6.70	4.40, 6.40	4.70, 6.70			
Min, Max	1.1, 7.0	1.6, 7.0	1.1, 7.0			
Week 24						
m	121	59	160			
n	117	57	144	112	53	133
Mean (SD/SE)	5.62 (1.50)	5.64 (1.33)	5.69 (1.45)	0.27 (0.11)	0.38 (0.17)	0.37 (0.08)
Median	6.10	5.90	6.20	0.20	0	0.10
IQR: Q1, Q3	4.90, 6.70	5.00, 6.70	5.05, 6.90	-0.15, 0.70	-0.30, 0.70	-0.10, 0.80
Min, Max	1.6, 7.0	2.0, 7.0	1.0, 7.0	-3.1, 3.3	-1.7, 3.6	-2.1, 3.5
Week 52						
m	110	51	154			
n	101	46	130	96	42	121
Mean (SD/SE)	5.69 (1.44)	5.91 (1.12)	5.81 (1.34)	0.30 (0.12)	0.65 (0.21)	0.39 (0.10)
Median	6.10	6.00	6.30	0.10	0.40	0.20
IQR: Q1, Q3	5.10, 7.00	5.30, 7.00	5.30, 7.00	-0.30, 0.80	-0.30, 1.60	-0.20, 0.90
Min, Max	1.7, 7.0	2.0, 7.0	1.0, 7.0	-4.8, 3.8	-1.5, 3.6	-2.5, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Sex
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.3.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
CLDQ-NASH			
Week 24			
m	40	82	129
n	35	72	111
Baseline Mean (SD)	5.69 (0.90)	5.47 (1.10)	5.55 (1.10)
Analysis Visit Mean (SD)	5.76 (0.79)	5.43 (1.07)	5.70 (1.00)
LS Mean of Change from Baseline (SE)	0.12 (0.11)	-0.07 (0.08)	0.17 (0.06)
95% CI	(-0.09, 0.34)	(-0.22, 0.08)	(0.05, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.12)	-0.24 (0.10)	
95% CI	(-0.29, 0.19)	(-0.43, -0.06)	
p-value	0.6921	0.0114	
Corrected Hedge's g Statistics	-0.074	-0.373	
95% CI	(-0.45, 0.31)	(-0.67, -0.07)	
Week 52			
m	39	74	116
n	32	64	96
Baseline Mean (SD)	5.74 (0.85)	5.49 (1.09)	5.62 (1.05)
Analysis Visit Mean (SD)	5.77 (0.80)	5.41 (1.08)	5.70 (0.99)
LS Mean of Change from Baseline (SE)	0.10 (0.11)	-0.07 (0.08)	0.11 (0.06)
95% CI	(-0.11, 0.31)	(-0.22, 0.08)	(-0.01, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.12)	-0.19 (0.10)	
95% CI	(-0.26, 0.23)	(-0.38, 0.00)	
p-value	0.9024	0.0543	
Corrected Hedge's g Statistics	-0.024	-0.301	
95% CI	(-0.42, 0.38)	(-0.62, 0.02)	
Subgroup*Treatment Interaction p-value	0.7002	0.1421	

AMNOG Table SE23.3.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
CLDQ-NASH			
Week 24			
m	121	59	160
n	112	53	133
Baseline Mean (SD)	5.07 (1.23)	4.98 (1.12)	5.02 (1.08)
Analysis Visit Mean (SD)	5.15 (1.22)	5.00 (0.95)	5.10 (1.10)
LS Mean of Change from Baseline (SE)	0.10 (0.06)	0.02 (0.09)	0.08 (0.06)
95% CI	(-0.02, 0.23)	(-0.16, 0.20)	(-0.04, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (0.08)	-0.06 (0.11)	
95% CI	(-0.14, 0.19)	(-0.27, 0.15)	
p-value	0.7755	0.5679	
Corrected Hedge's g Statistics	0.035	-0.090	
95% CI	(-0.22, 0.29)	(-0.41, 0.23)	
Week 52			
m	110	51	154
n	96	42	121
Baseline Mean (SD)	5.14 (1.23)	4.99 (1.17)	5.08 (1.07)
Analysis Visit Mean (SD)	5.19 (1.23)	5.11 (0.94)	5.12 (1.12)
LS Mean of Change from Baseline (SE)	0.07 (0.07)	0.10 (0.10)	0.07 (0.06)
95% CI	(-0.07, 0.21)	(-0.10, 0.30)	(-0.05, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.09)	0.03 (0.12)	
95% CI	(-0.17, 0.18)	(-0.20, 0.26)	
p-value	0.9730	0.7896	
Corrected Hedge's g Statistics	0.004	0.046	
95% CI	(-0.26, 0.27)	(-0.30, 0.40)	
Subgroup*Treatment Interaction p-value	0.7002	0.1421	

AMNOG Table SE23.3.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.3.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Abdominal Symptoms			
Week 24			
m	40	82	129
n	35	72	111
Baseline Mean (SD)	6.04 (1.36)	5.78 (1.32)	5.71 (1.35)
Analysis Visit Mean (SD)	5.87 (1.41)	5.60 (1.39)	5.90 (1.30)
LS Mean of Change from Baseline (SE)	-0.04 (0.18)	-0.16 (0.12)	0.20 (0.10)
95% CI	(-0.39, 0.31)	(-0.40, 0.08)	(0.00, 0.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.24 (0.20)	-0.36 (0.15)	
95% CI	(-0.64, 0.15)	(-0.67, -0.06)	
p-value	0.2283	0.0200	
Corrected Hedge's g Statistics	-0.228	-0.343	
95% CI	(-0.61, 0.15)	(-0.64, -0.04)	
Week 52			
m	39	74	116
n	32	64	96
Baseline Mean (SD)	6.11 (1.28)	5.88 (1.24)	5.72 (1.32)
Analysis Visit Mean (SD)	6.00 (1.31)	5.74 (1.22)	5.89 (1.17)
LS Mean of Change from Baseline (SE)	0.08 (0.17)	-0.11 (0.12)	0.20 (0.10)
95% CI	(-0.25, 0.41)	(-0.34, 0.12)	(0.01, 0.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.12 (0.19)	-0.31 (0.15)	
95% CI	(-0.50, 0.25)	(-0.60, -0.01)	
p-value	0.5217	0.0410	
Corrected Hedge's g Statistics	-0.127	-0.320	
95% CI	(-0.53, 0.27)	(-0.64, 0.00)	
Subgroup*Treatment Interaction p-value	0.2373	0.1671	

AMNOG Table SE23.3.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Activity			
Week 24			
m	40	82	129
n	35	72	111
Baseline Mean (SD)	5.75 (0.96)	5.60 (1.27)	5.75 (1.30)
Analysis Visit Mean (SD)	5.89 (1.03)	5.65 (1.26)	5.90 (1.14)
LS Mean of Change from Baseline (SE)	0.18 (0.14)	0.01 (0.10)	0.19 (0.08)
95% CI	(-0.10, 0.46)	(-0.18, 0.21)	(0.03, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.16)	-0.18 (0.13)	
95% CI	(-0.33, 0.31)	(-0.42, 0.07)	
p-value	0.9554	0.1620	
Corrected Hedge's g Statistics	-0.010	-0.205	
95% CI	(-0.39, 0.37)	(-0.50, 0.09)	
Week 52			
m	39	74	116
n	32	64	96
Baseline Mean (SD)	5.79 (0.94)	5.59 (1.25)	5.86 (1.19)
Analysis Visit Mean (SD)	5.83 (1.13)	5.48 (1.31)	5.75 (1.22)
LS Mean of Change from Baseline (SE)	0.11 (0.16)	-0.10 (0.11)	-0.02 (0.09)
95% CI	(-0.20, 0.42)	(-0.32, 0.12)	(-0.20, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.12 (0.18)	-0.08 (0.14)	
95% CI	(-0.23, 0.48)	(-0.36, 0.20)	
p-value	0.4868	0.5665	
Corrected Hedge's g Statistics	0.138	-0.090	
95% CI	(-0.26, 0.54)	(-0.41, 0.23)	
Subgroup*Treatment Interaction p-value	0.6683	0.3943	

AMNOG Table SE23.3.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Emotional Health			
Week 24			
m	40	82	129
n	35	72	111
Baseline Mean (SD)	5.67 (1.01)	5.55 (1.29)	5.58 (1.24)
Analysis Visit Mean (SD)	5.80 (0.91)	5.50 (1.22)	5.66 (1.28)
LS Mean of Change from Baseline (SE)	0.14 (0.14)	-0.09 (0.09)	0.06 (0.08)
95% CI	(-0.13, 0.41)	(-0.28, 0.10)	(-0.09, 0.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.15)	-0.15 (0.12)	
95% CI	(-0.23, 0.38)	(-0.39, 0.08)	
p-value	0.6194	0.1968	
Corrected Hedge's g Statistics	0.094	-0.190	
95% CI	(-0.29, 0.47)	(-0.49, 0.11)	
Week 52			
m	39	74	116
n	32	64	96
Baseline Mean (SD)	5.75 (1.01)	5.51 (1.33)	5.69 (1.18)
Analysis Visit Mean (SD)	5.67 (0.92)	5.48 (1.25)	5.72 (1.25)
LS Mean of Change from Baseline (SE)	-0.05 (0.13)	-0.04 (0.09)	0.01 (0.08)
95% CI	(-0.30, 0.21)	(-0.22, 0.14)	(-0.14, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.15)	-0.05 (0.11)	
95% CI	(-0.35, 0.23)	(-0.27, 0.18)	
p-value	0.6909	0.6742	
Corrected Hedge's g Statistics	-0.079	-0.066	
95% CI	(-0.48, 0.32)	(-0.38, 0.25)	
Subgroup*Treatment Interaction p-value	0.8254	0.6555	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Fatigue			
Week 24			
m	40	82	129
n	35	72	111
Baseline Mean (SD)	5.17 (1.34)	4.88 (1.39)	4.93 (1.40)
Analysis Visit Mean (SD)	5.15 (1.14)	4.73 (1.47)	5.15 (1.31)
LS Mean of Change from Baseline (SE)	0.03 (0.16)	-0.21 (0.11)	0.21 (0.09)
95% CI	(-0.29, 0.36)	(-0.44, 0.01)	(0.02, 0.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.17 (0.19)	-0.42 (0.14)	
95% CI	(-0.54, 0.19)	(-0.70, -0.14)	
p-value	0.3522	0.0039	
Corrected Hedge's g Statistics	-0.175	-0.425	
95% CI	(-0.56, 0.21)	(-0.73, -0.13)	
Week 52			
m	39	74	116
n	32	64	96
Baseline Mean (SD)	5.18 (1.35)	4.91 (1.36)	5.04 (1.32)
Analysis Visit Mean (SD)	5.16 (1.22)	4.73 (1.48)	5.09 (1.32)
LS Mean of Change from Baseline (SE)	0.06 (0.17)	-0.20 (0.12)	0.08 (0.10)
95% CI	(-0.27, 0.39)	(-0.44, 0.03)	(-0.11, 0.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.19)	-0.28 (0.15)	
95% CI	(-0.40, 0.36)	(-0.58, 0.01)	
p-value	0.9121	0.0597	
Corrected Hedge's g Statistics	-0.022	-0.295	
95% CI	(-0.42, 0.38)	(-0.61, 0.02)	
Subgroup*Treatment Interaction p-value	0.2493	0.0455	

AMNOG Table SE23.3.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Systemic Symptoms			
Week 24			
m	40	82	129
n	35	72	111
Baseline Mean (SD)	5.57 (0.97)	5.23 (1.20)	5.37 (1.20)
Analysis Visit Mean (SD)	5.61 (0.96)	5.08 (1.24)	5.46 (1.16)
LS Mean of Change from Baseline (SE)	0.11 (0.13)	-0.19 (0.09)	0.11 (0.08)
95% CI	(-0.15, 0.37)	(-0.37, 0.00)	(-0.04, 0.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.15)	-0.30 (0.12)	
95% CI	(-0.30, 0.29)	(-0.53, -0.07)	
p-value	0.9617	0.0108	
Corrected Hedge's g Statistics	-0.009	-0.377	
95% CI	(-0.39, 0.37)	(-0.68, -0.08)	
Week 52			
m	39	74	116
n	32	64	96
Baseline Mean (SD)	5.62 (0.93)	5.21 (1.17)	5.38 (1.18)
Analysis Visit Mean (SD)	5.58 (1.02)	5.10 (1.20)	5.49 (1.23)
LS Mean of Change from Baseline (SE)	0.06 (0.13)	-0.14 (0.09)	0.16 (0.08)
95% CI	(-0.21, 0.32)	(-0.32, 0.05)	(0.00, 0.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.15)	-0.29 (0.12)	
95% CI	(-0.40, 0.20)	(-0.53, -0.06)	
p-value	0.5162	0.0149	
Corrected Hedge's g Statistics	-0.129	-0.384	
95% CI	(-0.53, 0.27)	(-0.70, -0.06)	
Subgroup*Treatment Interaction p-value	0.6583	0.1515	

AMNOG Table SE23.3.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Worry			
Week 24			
m	40	82	129
n	35	72	111
Baseline Mean (SD)	5.91 (1.02)	5.78 (1.51)	5.92 (1.22)
Analysis Visit Mean (SD)	6.26 (0.65)	5.98 (1.33)	6.15 (1.17)
LS Mean of Change from Baseline (SE)	0.36 (0.13)	0.17 (0.09)	0.27 (0.08)
95% CI	(0.10, 0.62)	(-0.02, 0.35)	(0.12, 0.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (0.15)	-0.10 (0.12)	
95% CI	(-0.20, 0.39)	(-0.33, 0.12)	
p-value	0.5421	0.3701	
Corrected Hedge's g Statistics	0.114	-0.131	
95% CI	(-0.27, 0.49)	(-0.43, 0.17)	
Week 52			
m	39	74	116
n	32	64	96
Baseline Mean (SD)	5.99 (0.99)	5.79 (1.55)	6.01 (1.20)
Analysis Visit Mean (SD)	6.38 (0.71)	5.96 (1.52)	6.25 (1.19)
LS Mean of Change from Baseline (SE)	0.41 (0.15)	0.23 (0.11)	0.28 (0.09)
95% CI	(0.11, 0.71)	(0.02, 0.44)	(0.11, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.13 (0.17)	-0.05 (0.13)	
95% CI	(-0.21, 0.47)	(-0.31, 0.21)	
p-value	0.4496	0.7110	
Corrected Hedge's g Statistics	0.151	-0.058	
95% CI	(-0.25, 0.55)	(-0.37, 0.26)	
Subgroup*Treatment Interaction p-value	0.3066	0.5011	

AMNOG Table SE23.3.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Abdominal Symptoms			
Week 24			
m	121	59	160
n	112	53	133
Baseline Mean (SD)	5.05 (1.64)	5.22 (1.45)	4.95 (1.55)
Analysis Visit Mean (SD)	5.23 (1.46)	5.23 (1.61)	5.17 (1.42)
LS Mean of Change from Baseline (SE)	0.19 (0.11)	0.07 (0.15)	0.19 (0.10)
95% CI	(-0.02, 0.40)	(-0.22, 0.37)	(0.00, 0.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.14)	-0.12 (0.18)	
95% CI	(-0.28, 0.27)	(-0.47, 0.23)	
p-value	0.9718	0.4941	
Corrected Hedge's g Statistics	-0.004	-0.108	
95% CI	(-0.26, 0.25)	(-0.43, 0.21)	
Week 52			
m	110	51	154
n	96	42	121
Baseline Mean (SD)	5.12 (1.61)	5.28 (1.41)	5.08 (1.51)
Analysis Visit Mean (SD)	5.33 (1.54)	5.33 (1.40)	5.13 (1.46)
LS Mean of Change from Baseline (SE)	0.20 (0.12)	0.09 (0.17)	0.08 (0.10)
95% CI	(-0.03, 0.43)	(-0.25, 0.43)	(-0.13, 0.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.13 (0.15)	0.02 (0.20)	
95% CI	(-0.18, 0.43)	(-0.38, 0.41)	
p-value	0.4130	0.9395	
Corrected Hedge's g Statistics	0.109	0.013	
95% CI	(-0.16, 0.38)	(-0.34, 0.36)	
Subgroup*Treatment Interaction p-value	0.2373	0.1671	

AMNOG Table SE23.3.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Activity			
Week 24			
m	121	59	160
n	112	53	133
Baseline Mean (SD)	5.13 (1.48)	5.02 (1.32)	5.20 (1.36)
Analysis Visit Mean (SD)	5.08 (1.52)	5.06 (1.17)	5.22 (1.38)
LS Mean of Change from Baseline (SE)	-0.04 (0.09)	0.00 (0.13)	0.02 (0.08)
95% CI	(-0.22, 0.13)	(-0.25, 0.25)	(-0.14, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.12)	-0.01 (0.15)	
95% CI	(-0.29, 0.17)	(-0.30, 0.27)	
p-value	0.6208	0.9202	
Corrected Hedge's g Statistics	-0.061	-0.016	
95% CI	(-0.31, 0.19)	(-0.33, 0.30)	
Week 52			
m	110	51	154
n	96	42	121
Baseline Mean (SD)	5.21 (1.46)	5.00 (1.39)	5.29 (1.32)
Analysis Visit Mean (SD)	5.13 (1.58)	5.09 (1.16)	5.19 (1.47)
LS Mean of Change from Baseline (SE)	-0.07 (0.10)	0.04 (0.15)	-0.07 (0.09)
95% CI	(-0.27, 0.13)	(-0.26, 0.33)	(-0.25, 0.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.13)	0.11 (0.17)	
95% CI	(-0.26, 0.26)	(-0.23, 0.45)	
p-value	0.9987	0.5163	
Corrected Hedge's g Statistics	0.000	0.113	
95% CI	(-0.27, 0.27)	(-0.24, 0.46)	
Subgroup*Treatment Interaction p-value	0.6683	0.3943	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.3.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Emotional Health			
Week 24			
m	121	59	160
n	112	53	133
Baseline Mean (SD)	5.26 (1.29)	5.15 (1.31)	5.28 (1.20)
Analysis Visit Mean (SD)	5.33 (1.30)	5.05 (1.23)	5.29 (1.17)
LS Mean of Change from Baseline (SE)	0.08 (0.08)	-0.12 (0.11)	0.01 (0.07)
95% CI	(-0.08, 0.23)	(-0.34, 0.09)	(-0.13, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.07 (0.10)	-0.13 (0.13)	
95% CI	(-0.13, 0.26)	(-0.38, 0.12)	
p-value	0.5067	0.2948	
Corrected Hedge's g Statistics	0.083	-0.166	
95% CI	(-0.17, 0.33)	(-0.49, 0.15)	
Week 52			
m	110	51	154
n	96	42	121
Baseline Mean (SD)	5.32 (1.27)	5.20 (1.40)	5.31 (1.24)
Analysis Visit Mean (SD)	5.36 (1.16)	5.31 (1.14)	5.31 (1.20)
LS Mean of Change from Baseline (SE)	0.04 (0.08)	0.08 (0.12)	0.01 (0.07)
95% CI	(-0.12, 0.19)	(-0.15, 0.31)	(-0.13, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.10)	0.07 (0.14)	
95% CI	(-0.18, 0.23)	(-0.19, 0.34)	
p-value	0.7818	0.5905	
Corrected Hedge's g Statistics	0.037	0.094	
95% CI	(-0.23, 0.30)	(-0.26, 0.44)	
Subgroup*Treatment Interaction p-value	0.8254	0.6555	

AMNOG Table SE23.3.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Fatigue			
Week 24			
m	121	59	160
n	112	53	133
Baseline Mean (SD)	4.62 (1.51)	4.27 (1.51)	4.41 (1.45)
Analysis Visit Mean (SD)	4.63 (1.58)	4.23 (1.20)	4.33 (1.49)
LS Mean of Change from Baseline (SE)	0.07 (0.10)	-0.08 (0.14)	-0.10 (0.09)
95% CI	(-0.12, 0.27)	(-0.35, 0.19)	(-0.27, 0.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.18 (0.13)	0.02 (0.16)	
95% CI	(-0.07, 0.43)	(-0.29, 0.34)	
p-value	0.1658	0.8926	
Corrected Hedge's g Statistics	0.173	0.021	
95% CI	(-0.08, 0.42)	(-0.30, 0.34)	
Week 52			
m	110	51	154
n	96	42	121
Baseline Mean (SD)	4.66 (1.54)	4.23 (1.59)	4.43 (1.43)
Analysis Visit Mean (SD)	4.70 (1.58)	4.27 (1.38)	4.43 (1.47)
LS Mean of Change from Baseline (SE)	0.07 (0.11)	0.02 (0.16)	-0.02 (0.09)
95% CI	(-0.14, 0.28)	(-0.29, 0.32)	(-0.20, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.14)	0.03 (0.18)	
95% CI	(-0.19, 0.36)	(-0.32, 0.39)	
p-value	0.5480	0.8591	
Corrected Hedge's g Statistics	0.080	0.031	
95% CI	(-0.19, 0.35)	(-0.32, 0.38)	
Subgroup*Treatment Interaction p-value	0.2493	0.0455	

AMNOG Table SE23.3.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Systemic Symptoms			
Week 24			
m	121	59	160
n	112	53	133
Baseline Mean (SD)	5.02 (1.31)	4.95 (1.26)	4.93 (1.20)
Analysis Visit Mean (SD)	4.99 (1.30)	4.80 (1.15)	4.86 (1.28)
LS Mean of Change from Baseline (SE)	0.02 (0.08)	-0.14 (0.11)	-0.06 (0.07)
95% CI	(-0.13, 0.17)	(-0.35, 0.08)	(-0.20, 0.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.10)	-0.08 (0.13)	
95% CI	(-0.11, 0.28)	(-0.33, 0.17)	
p-value	0.4002	0.5503	
Corrected Hedge's g Statistics	0.105	-0.095	
95% CI	(-0.15, 0.36)	(-0.41, 0.22)	
Week 52			
m	110	51	154
n	96	42	121
Baseline Mean (SD)	5.12 (1.28)	4.95 (1.27)	4.93 (1.25)
Analysis Visit Mean (SD)	4.93 (1.34)	4.84 (1.24)	4.84 (1.36)
LS Mean of Change from Baseline (SE)	-0.12 (0.09)	-0.12 (0.13)	-0.06 (0.08)
95% CI	(-0.29, 0.05)	(-0.37, 0.13)	(-0.20, 0.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.11)	-0.06 (0.14)	
95% CI	(-0.28, 0.15)	(-0.35, 0.22)	
p-value	0.5615	0.6573	
Corrected Hedge's g Statistics	-0.077	-0.077	
95% CI	(-0.35, 0.19)	(-0.43, 0.27)	
Subgroup*Treatment Interaction p-value	0.6583	0.1515	

AMNOG Table SE23.3.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Worry			
Week 24			
m	121	59	160
n	112	53	133
Baseline Mean (SD)	5.37 (1.48)	5.25 (1.50)	5.34 (1.47)
Analysis Visit Mean (SD)	5.64 (1.47)	5.64 (1.35)	5.71 (1.44)
LS Mean of Change from Baseline (SE)	0.28 (0.10)	0.35 (0.14)	0.36 (0.09)
95% CI	(0.09, 0.47)	(0.08, 0.62)	(0.19, 0.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.13)	-0.01 (0.16)	
95% CI	(-0.33, 0.17)	(-0.33, 0.30)	
p-value	0.5218	0.9460	
Corrected Hedge's g Statistics	-0.080	-0.011	
95% CI	(-0.33, 0.17)	(-0.33, 0.31)	
Week 52			
m	110	51	154
n	96	42	121
Baseline Mean (SD)	5.43 (1.51)	5.25 (1.52)	5.43 (1.43)
Analysis Visit Mean (SD)	5.73 (1.42)	5.89 (1.13)	5.82 (1.29)
LS Mean of Change from Baseline (SE)	0.29 (0.10)	0.53 (0.15)	0.39 (0.09)
95% CI	(0.09, 0.50)	(0.23, 0.84)	(0.21, 0.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.14)	0.14 (0.18)	
95% CI	(-0.37, 0.17)	(-0.21, 0.49)	
p-value	0.4669	0.4245	
Corrected Hedge's g Statistics	-0.097	0.139	
95% CI	(-0.36, 0.17)	(-0.21, 0.49)	
Subgroup*Treatment Interaction p-value	0.3066	0.5011	

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	5 (5.8)	11 (8.3)
No	43 (100)	81 (94.2)	121 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	8.23	1.47	
95% CI of the inverse odds ratio	(0.48, 142.72)	(0.49, 4.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	7.61	1.43	
95% CI of the inverse risk ratio	(0.46, 126.49)	(0.52, 3.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.51	-2.52	
95% CI of the absolute risk difference	(-13.22, -1.80)	(-9.35, 4.31)	
p-value	0.0858	0.4857	
p-value of Breslow-Day Test for Homogeneity [3]	0.0604	0.5558	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (23.3)	14 (16.3)	29 (22.0)
No	33 (76.7)	72 (83.7)	103 (78.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.45	
95% CI of the inverse odds ratio	(0.41, 2.11)	(0.72, 2.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.35	
95% CI of the inverse risk ratio	(0.50, 1.78)	(0.76, 2.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.29	-5.69	
95% CI of the absolute risk difference	(-13.18, 15.75)	(-16.22, 4.83)	
p-value	0.8603	0.3021	
p-value of Breslow-Day Test for Homogeneity [3]	0.7628	0.3215	

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.7)	9 (10.5)	23 (17.4)
No	41 (95.3)	77 (89.5)	109 (82.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.33	1.81	
95% CI of the inverse odds ratio	(0.98, 19.17)	(0.79, 4.12)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.75	1.66	
95% CI of the inverse risk ratio	(0.92, 15.24)	(0.81, 3.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.77	-6.96	
95% CI of the absolute risk difference	(-21.80, -3.75)	(-16.11, 2.19)	
p-value	0.0376	0.1559	
p-value of Breslow-Day Test for Homogeneity [3]	0.0182	0.8219	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (23.3)	15 (17.4)	39 (29.5)
No	33 (76.7)	71 (82.6)	93 (70.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	1.98	
95% CI of the inverse odds ratio	(0.62, 3.08)	(1.01, 3.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	1.69	
95% CI of the inverse risk ratio	(0.69, 2.32)	(1.00, 2.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.29	-12.10	
95% CI of the absolute risk difference	(-21.12, 8.54)	(-23.28, -0.93)	
p-value	0.4250	0.0430	
p-value of Breslow-Day Test for Homogeneity [3]	0.3032	0.7156	

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.7)	7 (8.1)	10 (7.6)
No	41 (95.3)	79 (91.9)	122 (92.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.68	0.93	
95% CI of the inverse odds ratio	(0.35, 7.99)	(0.34, 2.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.63	0.93	
95% CI of the inverse risk ratio	(0.37, 7.15)	(0.37, 2.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.92	0.56	
95% CI of the absolute risk difference	(-10.67, 4.82)	(-6.77, 7.90)	
p-value	0.5099	0.8794	
p-value of Breslow-Day Test for Homogeneity [3]	0.2018	0.3894	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (25.6)	20 (23.3)	28 (21.2)
No	32 (74.4)	66 (76.7)	104 (78.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.89	
95% CI of the inverse odds ratio	(0.35, 1.75)	(0.46, 1.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	0.91	
95% CI of the inverse risk ratio	(0.45, 1.52)	(0.55, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.37	2.04	
95% CI of the absolute risk difference	(-10.42, 19.16)	(-9.29, 13.37)	
p-value	0.5499	0.7219	
p-value of Breslow-Day Test for Homogeneity [3]	0.8152	0.8384	

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (9.3)	6 (7.0)	9 (6.8)
No	39 (90.7)	80 (93.0)	123 (93.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.98	
95% CI of the inverse odds ratio	(0.21, 2.44)	(0.33, 2.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.98	
95% CI of the inverse risk ratio	(0.24, 2.26)	(0.36, 2.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.48	0.16	
95% CI of the absolute risk difference	(-7.20, 12.17)	(-6.73, 7.05)	
p-value	0.5895	0.9639	
p-value of Breslow-Day Test for Homogeneity [3]	0.8727	0.7619	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (16.3)	19 (22.1)	32 (24.2)
No	36 (83.7)	67 (77.9)	100 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	1.13	
95% CI of the inverse odds ratio	(0.67, 4.06)	(0.59, 2.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.49	1.10	
95% CI of the inverse risk ratio	(0.71, 3.13)	(0.67, 1.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.96	-2.15	
95% CI of the absolute risk difference	(-21.20, 5.27)	(-13.57, 9.27)	
p-value	0.2758	0.7141	
p-value of Breslow-Day Test for Homogeneity [3]	0.3531	0.6915	

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (11.6)	8 (9.3)	15 (11.4)
No	38 (88.4)	78 (90.7)	117 (88.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	1.25	
95% CI of the inverse odds ratio	(0.33, 2.86)	(0.51, 3.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.22	
95% CI of the inverse risk ratio	(0.38, 2.53)	(0.54, 2.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.26	-2.06	
95% CI of the absolute risk difference	(-10.74, 11.27)	(-10.25, 6.12)	
p-value	0.9623	0.6282	
p-value of Breslow-Day Test for Homogeneity [3]	0.3762	0.2417	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (25.6)	19 (22.1)	34 (25.8)
No	32 (74.4)	67 (77.9)	98 (74.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.22	
95% CI of the inverse odds ratio	(0.46, 2.22)	(0.64, 2.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.17	
95% CI of the inverse risk ratio	(0.56, 1.81)	(0.71, 1.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.18	-3.66	
95% CI of the absolute risk difference	(-15.20, 14.85)	(-15.18, 7.85)	
p-value	0.9817	0.5376	
p-value of Breslow-Day Test for Homogeneity [3]	0.9902	0.9107	

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	9 (10.5)	12 (9.1)
No	42 (97.7)	77 (89.5)	120 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.20	0.86	
95% CI of the inverse odds ratio	(0.53, 33.29)	(0.34, 2.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.91	0.87	
95% CI of the inverse risk ratio	(0.52, 29.20)	(0.38, 1.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.77	1.37	
95% CI of the absolute risk difference	(-13.42, -0.11)	(-6.74, 9.49)	
p-value	0.1418	0.7368	
p-value of Breslow-Day Test for Homogeneity [3]	0.4286	0.2450	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (18.6)	19 (22.1)	38 (28.8)
No	35 (81.4)	67 (77.9)	94 (71.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	1.43	
95% CI of the inverse odds ratio	(0.75, 4.16)	(0.76, 2.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	1.30	
95% CI of the inverse risk ratio	(0.78, 3.06)	(0.81, 2.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-10.18	-6.69	
95% CI of the absolute risk difference	(-24.15, 3.78)	(-18.38, 4.99)	
p-value	0.1877	0.2716	
p-value of Breslow-Day Test for Homogeneity [3]	0.2816	0.3326	

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (18.6)	11 (12.8)	19 (14.4)
No	35 (81.4)	75 (87.2)	113 (85.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.15	
95% CI of the inverse odds ratio	(0.30, 1.83)	(0.52, 2.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.13	
95% CI of the inverse risk ratio	(0.37, 1.64)	(0.56, 2.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.21	-1.60	
95% CI of the absolute risk difference	(-8.87, 17.29)	(-10.86, 7.65)	
p-value	0.5068	0.7370	
p-value of Breslow-Day Test for Homogeneity [3]	0.4759	0.5436	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (37.2)	22 (25.6)	39 (29.5)
No	27 (62.8)	64 (74.4)	93 (70.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.22	
95% CI of the inverse odds ratio	(0.34, 1.46)	(0.66, 2.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	1.15	
95% CI of the inverse risk ratio	(0.50, 1.27)	(0.74, 1.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.66	-3.96	
95% CI of the absolute risk difference	(-8.75, 24.07)	(-16.03, 8.10)	
p-value	0.3471	0.5240	
p-value of Breslow-Day Test for Homogeneity [3]	0.3267	0.7426	

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (8.9)	6 (9.2)	15 (8.8)
No	113 (91.1)	59 (90.8)	156 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.95	
95% CI of the inverse odds ratio	(0.44, 2.23)	(0.35, 2.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.95	
95% CI of the inverse risk ratio	(0.47, 2.08)	(0.39, 2.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.10	0.46	
95% CI of the absolute risk difference	(-6.46, 6.66)	(-7.76, 8.67)	
p-value	0.9764	0.9119	
p-value of Breslow-Day Test for Homogeneity [3]	0.0604	0.5558	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (22.6)	17 (26.2)	41 (24.0)
No	96 (77.4)	48 (73.8)	130 (76.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.89	
95% CI of the inverse odds ratio	(0.63, 1.87)	(0.46, 1.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.92	
95% CI of the inverse risk ratio	(0.70, 1.62)	(0.56, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.40	2.18	
95% CI of the absolute risk difference	(-11.15, 8.36)	(-10.28, 14.63)	
p-value	0.7798	0.7286	
p-value of Breslow-Day Test for Homogeneity [3]	0.7628	0.3215	

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	29 (23.4)	8 (12.3)	31 (18.1)
No	95 (76.6)	57 (87.7)	140 (81.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	1.58	
95% CI of the inverse odds ratio	(0.41, 1.28)	(0.68, 3.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.47	
95% CI of the inverse risk ratio	(0.49, 1.22)	(0.71, 3.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.26	-5.82	
95% CI of the absolute risk difference	(-4.17, 14.68)	(-15.68, 4.03)	
p-value	0.2681	0.2821	
p-value of Breslow-Day Test for Homogeneity [3]	0.0182	0.8219	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	46 (37.1)	15 (23.1)	57 (33.3)
No	78 (62.9)	50 (76.9)	114 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.67	
95% CI of the inverse odds ratio	(0.52, 1.38)	(0.86, 3.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.44	
95% CI of the inverse risk ratio	(0.66, 1.23)	(0.88, 2.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.76	-10.26	
95% CI of the absolute risk difference	(-7.29, 14.82)	(-22.70, 2.19)	
p-value	0.5033	0.1263	
p-value of Breslow-Day Test for Homogeneity [3]	0.3032	0.7156	

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (12.9)	9 (13.8)	13 (7.6)
No	108 (87.1)	56 (86.2)	158 (92.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.51	
95% CI of the inverse odds ratio	(0.26, 1.20)	(0.21, 1.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.55	
95% CI of the inverse risk ratio	(0.29, 1.18)	(0.25, 1.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.30	6.24	
95% CI of the absolute risk difference	(-1.81, 12.41)	(-3.04, 15.53)	
p-value	0.1312	0.1405	
p-value of Breslow-Day Test for Homogeneity [3]	0.2018	0.3894	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	36 (29.0)	17 (26.2)	38 (22.2)
No	88 (71.0)	48 (73.8)	133 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	0.81	
95% CI of the inverse odds ratio	(0.41, 1.19)	(0.42, 1.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.85	
95% CI of the inverse risk ratio	(0.52, 1.13)	(0.52, 1.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.81	3.93	
95% CI of the absolute risk difference	(-3.32, 16.94)	(-8.44, 16.30)	
p-value	0.1829	0.5233	
p-value of Breslow-Day Test for Homogeneity [3]	0.8152	0.8384	

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (12.1)	8 (12.3)	17 (9.9)
No	109 (87.9)	57 (87.7)	154 (90.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.79	
95% CI of the inverse odds ratio	(0.38, 1.68)	(0.32, 1.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.81	
95% CI of the inverse risk ratio	(0.43, 1.58)	(0.37, 1.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.16	2.37	
95% CI of the absolute risk difference	(-5.13, 9.44)	(-6.79, 11.53)	
p-value	0.5568	0.5977	
p-value of Breslow-Day Test for Homogeneity [3]	0.8727	0.7619	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (23.4)	16 (24.6)	40 (23.4)
No	95 (76.6)	49 (75.4)	131 (76.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.94	
95% CI of the inverse odds ratio	(0.58, 1.73)	(0.48, 1.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.95	
95% CI of the inverse risk ratio	(0.66, 1.52)	(0.57, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	1.22	
95% CI of the absolute risk difference	(-9.79, 9.78)	(-11.02, 13.47)	
p-value	0.9992	0.8435	
p-value of Breslow-Day Test for Homogeneity [3]	0.3531	0.6915	

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (8.1)	13 (20.0)	23 (13.5)
No	114 (91.9)	52 (80.0)	148 (86.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	0.62	
95% CI of the inverse odds ratio	(0.81, 3.87)	(0.29, 1.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	0.67	
95% CI of the inverse risk ratio	(0.82, 3.38)	(0.36, 1.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.39	6.55	
95% CI of the absolute risk difference	(-12.39, 1.62)	(-4.44, 17.54)	
p-value	0.1474	0.2112	
p-value of Breslow-Day Test for Homogeneity [3]	0.3762	0.2417	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	34 (27.4)	16 (24.6)	47 (27.5)
No	90 (72.6)	49 (75.4)	124 (72.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.16	
95% CI of the inverse odds ratio	(0.60, 1.68)	(0.60, 2.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.12	
95% CI of the inverse risk ratio	(0.69, 1.46)	(0.68, 1.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.07	-2.87	
95% CI of the absolute risk difference	(-10.38, 10.25)	(-15.30, 9.56)	
p-value	0.9900	0.6561	
p-value of Breslow-Day Test for Homogeneity [3]	0.9902	0.9107	

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (5.6)	3 (4.6)	16 (9.4)
No	117 (94.4)	62 (95.4)	155 (90.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.73	2.13	
95% CI of the inverse odds ratio	(0.69, 4.33)	(0.60, 7.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.66	2.03	
95% CI of the inverse risk ratio	(0.70, 3.91)	(0.61, 6.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.71	-4.74	
95% CI of the absolute risk difference	(-9.67, 2.25)	(-11.45, 1.97)	
p-value	0.2405	0.2317	
p-value of Breslow-Day Test for Homogeneity [3]	0.4286	0.2450	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (22.6)	16 (24.6)	39 (22.8)
No	96 (77.4)	49 (75.4)	132 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.90	
95% CI of the inverse odds ratio	(0.58, 1.76)	(0.46, 1.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.93	
95% CI of the inverse risk ratio	(0.66, 1.55)	(0.56, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.23	1.81	
95% CI of the absolute risk difference	(-9.91, 9.45)	(-10.41, 14.02)	
p-value	0.9635	0.7691	
p-value of Breslow-Day Test for Homogeneity [3]	0.2816	0.3326	

AMNOG Table SE23.3.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	23 (18.5)	15 (23.1)	34 (19.9)
No	101 (81.5)	50 (76.9)	137 (80.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.83	
95% CI of the inverse odds ratio	(0.61, 1.96)	(0.42, 1.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.86	
95% CI of the inverse risk ratio	(0.67, 1.73)	(0.50, 1.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.33	3.19	
95% CI of the absolute risk difference	(-10.42, 7.75)	(-8.67, 15.06)	
p-value	0.7744	0.5889	
p-value of Breslow-Day Test for Homogeneity [3]	0.4759	0.5436	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	41 (33.1)	22 (33.8)	60 (35.1)
No	83 (66.9)	43 (66.2)	111 (64.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.06	
95% CI of the inverse odds ratio	(0.67, 1.78)	(0.58, 1.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.04	
95% CI of the inverse risk ratio	(0.77, 1.47)	(0.70, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.02	-1.24	
95% CI of the absolute risk difference	(-12.97, 8.92)	(-14.79, 12.30)	
p-value	0.7177	0.8580	
p-value of Breslow-Day Test for Homogeneity [3]	0.3267	0.7426	

Madrigal Pharmaceuticals, Inc. Page 1 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE23.3.5
Chronic Liver Disease Questionnaire-NASH (SE23): Mean Profile of Results by Domain;
by Sex
(Label Population)

Sex: Male
Fatigue



Patients with result at given visit			
MGL-3196 80 mg	39	38	36
MGL-3196 100 mg	78	79	67
Placebo	120	119	104

Abbreviations: Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE23.3.5
Chronic Liver Disease Questionnaire-NASH (SE23): Mean Profile of Results by Domain;
by Sex
(Label Population)

Sex: Female
Fatigue



Patients with result at given visit			
MGL-3196 80 mg	117	117	101
MGL-3196 100 mg	58	57	46
Placebo	157	144	130

Abbreviations: Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE23.4.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
CLDQ-NASH						
Baseline						
m	94	119	198			
n	90	107	183			
Mean (SD)	5.23 (1.11)	5.25 (1.10)	5.17 (1.15)			
Median	5.30	5.60	5.30			
IQR: Q1, Q3	4.50, 6.20	4.50, 6.10	4.50, 6.10			
Min, Max	2.2, 7.0	2.1, 7.0	2.0, 7.0			
Week 24						
m	91	110	187			
n	88	107	175	85	99	163
Mean (SD/SE)	5.33 (1.05)	5.27 (1.00)	5.31 (1.11)	0.05 (0.08)	-0.03 (0.06)	0.09 (0.06)
Median	5.45	5.50	5.50	0	-0.10	0
IQR: Q1, Q3	4.50, 6.20	4.50, 6.10	4.60, 6.20	-0.30, 0.50	-0.40, 0.30	-0.30, 0.50
Min, Max	2.1, 7.0	2.7, 6.8	2.3, 7.0	-2.6, 2.4	-1.6, 1.6	-2.3, 3.0
Week 52						
m	85	97	175			
n	78	88	149	75	84	139
Mean (SD/SE)	5.34 (1.02)	5.37 (1.01)	5.33 (1.13)	0.02 (0.08)	0.02 (0.07)	0.04 (0.06)
Median	5.45	5.60	5.60	0	0	-0.10
IQR: Q1, Q3	4.70, 6.20	4.65, 6.10	4.50, 6.20	-0.20, 0.30	-0.30, 0.30	-0.30, 0.40
Min, Max	1.9, 7.0	2.2, 6.9	1.9, 6.9	-2.2, 2.7	-2.4, 1.8	-2.2, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Abdominal Symptoms						
Baseline						
m	94	119	198			
n	90	107	183			
Mean (SD)	5.36 (1.49)	5.55 (1.42)	5.17 (1.57)			
Median	5.70	6.00	5.30			
IQR: Q1, Q3	4.00, 6.70	4.30, 7.00	4.00, 6.70			
Min, Max	1.3, 7.0	1.7, 7.0	1.0, 7.0			
Week 24						
m	91	110	187			
n	88	107	175	85	99	163
Mean (SD/SE)	5.39 (1.43)	5.47 (1.43)	5.42 (1.53)	-0.03 (0.13)	-0.07 (0.11)	0.20 (0.10)
Median	5.30	5.70	6.00	0	0	0
IQR: Q1, Q3	4.70, 6.70	4.70, 6.70	4.30, 7.00	-0.60, 0.60	-0.60, 0.30	-0.40, 1.00
Min, Max	1.0, 7.0	1.3, 7.0	1.0, 7.0	-4.7, 3.3	-4.0, 2.4	-3.0, 3.7
Week 52						
m	85	97	175			
n	78	88	149	75	84	139
Mean (SD/SE)	5.61 (1.29)	5.61 (1.32)	5.43 (1.48)	0.11 (0.15)	-0.04 (0.11)	0.08 (0.10)
Median	5.70	5.70	5.70	0	0	0
IQR: Q1, Q3	5.00, 6.70	5.00, 6.70	4.70, 6.70	-0.70, 1.00	-0.35, 0.30	-0.70, 0.70
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0	-3.3, 3.7	-3.0, 2.7	-4.6, 3.3

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Activity						
Baseline						
m	94	119	198			
n	90	107	183			
Mean (SD)	5.34 (1.29)	5.35 (1.28)	5.39 (1.48)			
Median	5.60	5.60	5.80			
IQR: Q1, Q3	4.40, 6.40	4.60, 6.40	4.40, 6.60			
Min, Max	2.0, 7.0	1.8, 7.0	1.4, 7.0			
Week 24						
m	91	110	187			
n	88	107	175	85	99	163
Mean (SD/SE)	5.38 (1.21)	5.44 (1.23)	5.44 (1.36)	-0.03 (0.11)	0.02 (0.09)	0.00 (0.08)
Median	5.60	5.80	5.80	0	0	0
IQR: Q1, Q3	4.50, 6.40	4.60, 6.40	4.40, 6.60	-0.80, 0.60	-0.60, 0.60	-0.60, 0.60
Min, Max	2.2, 7.0	2.4, 7.0	1.2, 7.0	-3.2, 2.8	-2.4, 3.2	-3.0, 3.2
Week 52						
m	85	97	175			
n	78	88	149	75	84	139
Mean (SD/SE)	5.25 (1.36)	5.44 (1.22)	5.38 (1.46)	-0.20 (0.14)	-0.04 (0.10)	-0.18 (0.08)
Median	5.40	5.60	5.80	0	0.10	0
IQR: Q1, Q3	4.60, 6.20	4.80, 6.40	4.40, 6.60	-0.80, 0.40	-0.60, 0.60	-0.60, 0.40
Min, Max	1.2, 7.0	1.6, 7.0	1.4, 7.0	-4.4, 3.0	-2.8, 2.0	-2.4, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Emotional Health						
Baseline						
m	94	119	198			
n	90	107	183			
Mean (SD)	5.38 (1.19)	5.37 (1.22)	5.40 (1.19)			
Median	5.60	5.60	5.70			
IQR: Q1, Q3	4.70, 6.30	4.70, 6.30	4.70, 6.30			
Min, Max	2.0, 7.0	2.1, 7.0	1.8, 7.0			
Week 24						
m	91	110	187			
n	88	107	175	85	99	163
Mean (SD/SE)	5.46 (1.19)	5.32 (1.21)	5.51 (1.19)	0.05 (0.09)	-0.11 (0.07)	0.05 (0.07)
Median	5.75	5.40	5.80	0	0	0
IQR: Q1, Q3	4.60, 6.50	4.60, 6.20	4.80, 6.40	-0.40, 0.60	-0.40, 0.20	-0.50, 0.50
Min, Max	2.3, 7.0	1.0, 7.0	1.9, 7.0	-2.8, 2.1	-3.1, 1.9	-2.9, 3.3
Week 52						
m	85	97	175			
n	78	88	149	75	84	139
Mean (SD/SE)	5.49 (1.01)	5.51 (1.19)	5.52 (1.18)	0.02 (0.09)	0.05 (0.08)	0.03 (0.07)
Median	5.80	5.80	5.80	-0.10	0	0
IQR: Q1, Q3	4.90, 6.20	4.70, 6.40	4.80, 6.40	-0.50, 0.30	-0.50, 0.40	-0.50, 0.40
Min, Max	2.8, 7.0	1.0, 7.0	1.7, 7.0	-1.9, 2.5	-1.9, 2.9	-2.0, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Fatigue						
Baseline						
m	94	119	198			
n	90	107	183			
Mean (SD)	4.70 (1.45)	4.55 (1.48)	4.52 (1.40)			
Median	5.00	4.80	4.80			
IQR: Q1, Q3	3.70, 6.00	3.50, 5.70	3.50, 5.50			
Min, Max	1.3, 7.0	1.2, 7.0	1.0, 7.0			
Week 24						
m	91	110	187			
n	88	107	175	85	99	163
Mean (SD/SE)	4.81 (1.45)	4.54 (1.36)	4.61 (1.45)	0.02 (0.12)	-0.10 (0.09)	0.02 (0.09)
Median	4.75	4.70	4.70	0	-0.10	0
IQR: Q1, Q3	3.85, 6.10	3.70, 5.50	3.30, 5.80	-0.70, 0.60	-0.60, 0.30	-0.70, 0.60
Min, Max	1.8, 7.0	1.5, 7.0	1.3, 7.0	-2.7, 3.2	-3.1, 2.3	-3.8, 3.7
Week 52						
m	85	97	175			
n	78	88	149	75	84	139
Mean (SD/SE)	4.72 (1.48)	4.59 (1.51)	4.62 (1.48)	-0.05 (0.12)	-0.11 (0.12)	-0.02 (0.09)
Median	5.00	4.80	4.70	0	0	0
IQR: Q1, Q3	3.30, 6.00	3.70, 5.80	3.50, 5.80	-0.50, 0.50	-0.50, 0.45	-0.60, 0.60
Min, Max	1.0, 7.0	1.2, 7.0	1.0, 7.0	-2.3, 4.0	-4.4, 2.5	-3.8, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Systemic Symptoms						
Baseline						
m	94	119	198			
n	90	107	183			
Mean (SD)	5.15 (1.20)	5.06 (1.24)	5.01 (1.27)			
Median	5.30	5.20	5.20			
IQR: Q1, Q3	4.30, 6.00	4.30, 6.00	4.20, 6.00			
Min, Max	1.8, 7.0	1.8, 7.0	1.7, 7.0			
Week 24						
m	91	110	187			
n	88	107	175	85	99	163
Mean (SD/SE)	5.13 (1.14)	5.00 (1.14)	5.10 (1.25)	-0.03 (0.09)	-0.14 (0.07)	-0.03 (0.07)
Median	5.30	5.20	5.30	-0.20	-0.20	0
IQR: Q1, Q3	4.30, 6.00	4.20, 6.00	4.30, 6.20	-0.60, 0.60	-0.50, 0.20	-0.70, 0.50
Min, Max	2.5, 7.0	1.8, 7.0	1.5, 7.0	-1.6, 2.1	-1.9, 2.2	-2.5, 3.7
Week 52						
m	85	97	175			
n	78	88	149	75	84	139
Mean (SD/SE)	5.05 (1.21)	5.05 (1.22)	5.07 (1.34)	-0.21 (0.09)	-0.12 (0.09)	-0.04 (0.08)
Median	5.30	5.20	5.30	-0.10	0	-0.10
IQR: Q1, Q3	4.20, 6.00	4.25, 6.00	4.20, 6.20	-0.70, 0.30	-0.65, 0.40	-0.50, 0.50
Min, Max	1.3, 7.0	1.5, 7.0	1.3, 7.0	-2.0, 2.0	-2.5, 2.0	-2.7, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Worry						
Baseline						
m	94	119	198			
n	90	107	183			
Mean (SD)	5.42 (1.42)	5.58 (1.46)	5.53 (1.46)			
Median	5.70	6.00	6.00			
IQR: Q1, Q3	4.60, 6.60	4.70, 6.90	4.70, 6.70			
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0			
Week 24						
m	91	110	187			
n	88	107	175	85	99	163
Mean (SD/SE)	5.78 (1.35)	5.81 (1.33)	5.81 (1.43)	0.32 (0.11)	0.24 (0.10)	0.31 (0.07)
Median	6.10	6.30	6.30	0.30	0	0.20
IQR: Q1, Q3	5.10, 6.90	5.00, 6.90	5.40, 6.90	-0.10, 0.80	-0.30, 0.60	-0.10, 0.70
Min, Max	1.6, 7.0	1.0, 7.0	1.0, 7.0	-2.3, 3.1	-2.6, 3.6	-2.1, 3.5
Week 52						
m	85	97	175			
n	78	88	149	75	84	139
Mean (SD/SE)	5.94 (1.25)	6.02 (1.30)	5.92 (1.36)	0.42 (0.13)	0.41 (0.13)	0.35 (0.09)
Median	6.40	6.50	6.40	0.20	0	0.20
IQR: Q1, Q3	5.30, 7.00	5.40, 7.00	5.40, 7.00	-0.20, 1.00	-0.10, 0.85	-0.10, 0.90
Min, Max	1.7, 7.0	1.0, 7.0	1.0, 7.0	-2.5, 3.8	-3.3, 3.6	-2.7, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
CLDQ-NASH						
Baseline						
m	73	32	105			
n	66	29	94			
Mean (SD)	5.22 (1.33)	5.33 (1.18)	5.33 (1.04)			
Median	5.45	5.70	5.50			
IQR: Q1, Q3	4.50, 6.40	4.90, 6.10	4.60, 6.10			
Min, Max	1.5, 6.9	2.2, 6.8	3.0, 7.0			
Week 24						
m	70	31	102			
n	67	29	88	62	26	81
Mean (SD/SE)	5.26 (1.27)	5.28 (1.16)	5.43 (1.07)	0.11 (0.09)	0.02 (0.16)	0.16 (0.07)
Median	5.40	5.50	5.70	0.10	0.10	0.10
IQR: Q1, Q3	4.50, 6.30	4.40, 6.30	4.60, 6.25	-0.10, 0.40	-0.60, 0.50	-0.20, 0.50
Min, Max	2.1, 7.0	2.9, 7.0	2.6, 7.0	-2.0, 2.5	-1.4, 1.4	-1.3, 2.2
Week 52						
m	64	28	95			
n	59	25	85	53	22	78
Mean (SD/SE)	5.38 (1.33)	5.22 (1.08)	5.44 (1.05)	0.09 (0.09)	-0.05 (0.16)	0.10 (0.07)
Median	5.70	5.20	5.50	0.10	-0.15	0
IQR: Q1, Q3	4.20, 6.50	4.50, 6.10	4.90, 6.30	-0.20, 0.50	-0.50, 0.60	-0.30, 0.60
Min, Max	1.6, 7.0	3.1, 6.8	2.4, 7.0	-2.7, 1.3	-1.4, 1.5	-1.4, 1.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Abdominal Symptoms						
Baseline						
m	73	32	105			
n	66	29	94			
Mean (SD)	5.16 (1.81)	5.62 (1.16)	5.30 (1.44)			
Median	5.85	6.00	5.70			
IQR: Q1, Q3	4.00, 7.00	4.70, 6.30	4.30, 6.70			
Min, Max	1.0, 7.0	2.7, 7.0	1.7, 7.0			
Week 24						
m	70	31	102			
n	67	29	88	62	26	81
Mean (SD/SE)	5.39 (1.51)	5.25 (1.59)	5.58 (1.30)	0.28 (0.13)	-0.23 (0.28)	0.21 (0.13)
Median	5.30	5.70	5.85	0	-0.15	0
IQR: Q1, Q3	4.30, 7.00	4.00, 6.70	4.70, 7.00	-0.30, 0.70	-1.00, 0.70	-0.30, 0.70
Min, Max	1.3, 7.0	1.7, 7.0	2.7, 7.0	-2.4, 2.7	-3.3, 2.3	-2.0, 4.0
Week 52						
m	64	28	95			
n	59	25	85	53	22	78
Mean (SD/SE)	5.41 (1.69)	5.52 (1.15)	5.50 (1.23)	0.15 (0.16)	-0.15 (0.19)	0.13 (0.14)
Median	6.00	5.70	5.70	0	0	0
IQR: Q1, Q3	4.30, 7.00	5.00, 6.70	4.70, 6.70	-0.30, 0.70	-0.70, 0.40	-0.40, 1.00
Min, Max	1.0, 7.0	2.3, 7.0	2.7, 7.0	-2.7, 4.0	-1.7, 1.7	-3.7, 4.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Activity						
Baseline						
m	73	32	105			
n	66	29	94			
Mean (SD)	5.18 (1.56)	5.28 (1.51)	5.45 (1.16)			
Median	5.40	5.60	5.60			
IQR: Q1, Q3	4.20, 6.60	4.60, 6.40	4.60, 6.40			
Min, Max	1.4, 7.0	2.2, 7.0	2.0, 7.0			
Week 24						
m	70	31	102			
n	67	29	88	62	26	81
Mean (SD/SE)	5.15 (1.69)	5.30 (1.41)	5.58 (1.31)	0.04 (0.11)	0.14 (0.22)	0.23 (0.11)
Median	5.60	5.80	6.00	0	0	0.20
IQR: Q1, Q3	3.80, 6.80	4.60, 6.40	4.80, 6.80	-0.40, 0.60	-0.60, 1.20	-0.40, 0.80
Min, Max	1.2, 7.0	2.4, 7.0	2.2, 7.0	-2.4, 2.6	-2.2, 2.4	-2.8, 2.6
Week 52						
m	64	28	95			
n	59	25	85	53	22	78
Mean (SD/SE)	5.46 (1.67)	5.14 (1.35)	5.54 (1.23)	0.16 (0.13)	-0.04 (0.22)	0.03 (0.11)
Median	6.00	5.20	5.80	0.20	0	0
IQR: Q1, Q3	4.40, 7.00	4.20, 6.20	4.80, 6.60	-0.20, 0.60	-0.40, 0.80	-0.40, 0.60
Min, Max	1.0, 7.0	2.4, 7.0	1.8, 7.0	-3.0, 2.8	-2.8, 1.2	-3.4, 2.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Emotional Health						
Baseline						
m	73	32	105			
n	66	29	94			
Mean (SD)	5.34 (1.33)	5.41 (1.54)	5.44 (1.24)			
Median	5.60	6.00	5.65			
IQR: Q1, Q3	4.60, 6.20	5.10, 6.60	4.80, 6.40			
Min, Max	1.3, 7.0	1.8, 7.0	2.0, 7.0			
Week 24						
m	70	31	102			
n	67	29	88	62	26	81
Mean (SD/SE)	5.39 (1.30)	5.45 (1.39)	5.36 (1.33)	0.14 (0.09)	0.05 (0.16)	0.01 (0.10)
Median	5.80	5.70	5.80	0.10	0.05	0
IQR: Q1, Q3	4.70, 6.30	4.70, 6.60	4.50, 6.30	-0.10, 0.60	-0.50, 0.40	-0.50, 0.50
Min, Max	2.0, 7.0	2.2, 7.0	2.2, 7.0	-2.6, 2.5	-1.5, 2.4	-2.4, 2.2
Week 52						
m	64	28	95			
n	59	25	85	53	22	78
Mean (SD/SE)	5.38 (1.28)	5.34 (1.25)	5.47 (1.30)	0.00 (0.12)	-0.05 (0.17)	-0.02 (0.08)
Median	5.60	5.70	5.70	0	-0.05	0
IQR: Q1, Q3	4.60, 6.40	5.00, 6.20	4.70, 6.60	-0.50, 0.60	-0.60, 0.70	-0.40, 0.40
Min, Max	1.9, 7.0	2.7, 6.9	1.3, 7.0	-2.5, 2.9	-1.4, 1.2	-1.9, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Fatigue						
Baseline						
m	73	32	105			
n	66	29	94			
Mean (SD)	4.82 (1.58)	4.79 (1.35)	4.78 (1.48)			
Median	5.10	5.20	5.20			
IQR: Q1, Q3	3.80, 6.20	4.70, 5.70	3.50, 6.00			
Min, Max	1.2, 7.0	1.7, 6.3	1.2, 7.0			
Week 24						
m	70	31	102			
n	67	29	88	62	26	81
Mean (SD/SE)	4.68 (1.57)	4.61 (1.44)	4.83 (1.44)	-0.03 (0.13)	-0.12 (0.23)	0.14 (0.11)
Median	5.00	5.20	5.00	0	0.20	0
IQR: Q1, Q3	3.50, 6.00	3.80, 5.70	3.70, 6.00	-0.50, 0.40	-0.50, 0.60	-0.30, 0.50
Min, Max	1.3, 7.0	1.8, 7.0	1.2, 7.0	-2.5, 4.1	-4.2, 1.7	-2.5, 3.5
Week 52						
m	64	28	95			
n	59	25	85	53	22	78
Mean (SD/SE)	4.98 (1.57)	4.66 (1.22)	4.84 (1.36)	0.12 (0.13)	-0.04 (0.26)	0.10 (0.12)
Median	5.30	4.20	5.00	0	-0.05	0
IQR: Q1, Q3	3.70, 6.20	3.70, 5.70	3.80, 5.80	-0.30, 0.50	-0.50, 0.70	-0.50, 0.70
Min, Max	1.5, 7.0	2.5, 6.8	1.5, 7.0	-2.4, 3.5	-2.8, 2.5	-2.6, 2.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Systemic Symptoms						
Baseline						
m	73	32	105			
n	66	29	94			
Mean (SD)	5.20 (1.40)	5.21 (1.16)	5.17 (1.16)			
Median	5.50	5.30	5.30			
IQR: Q1, Q3	4.50, 6.30	4.50, 6.00	4.30, 6.00			
Min, Max	1.5, 7.0	2.5, 7.0	2.3, 7.0			
Week 24						
m	70	31	102			
n	67	29	88	62	26	81
Mean (SD/SE)	5.19 (1.36)	4.99 (1.47)	5.20 (1.23)	0.02 (0.10)	-0.21 (0.18)	0.06 (0.09)
Median	5.50	5.20	5.25	0	0	0
IQR: Q1, Q3	4.30, 6.20	4.00, 6.20	4.25, 6.30	-0.30, 0.30	-0.80, 0.20	-0.20, 0.50
Min, Max	1.7, 7.0	2.2, 7.0	2.5, 7.0	-2.0, 3.5	-2.0, 1.7	-2.3, 3.0
Week 52						
m	64	28	95			
n	59	25	85	53	22	78
Mean (SD/SE)	5.26 (1.40)	5.00 (1.26)	5.21 (1.33)	-0.06 (0.11)	-0.10 (0.13)	0.08 (0.08)
Median	5.50	5.20	5.30	0	0	0.20
IQR: Q1, Q3	4.30, 6.50	4.00, 5.80	4.20, 6.50	-0.50, 0.30	-0.50, 0.20	-0.40, 0.50
Min, Max	1.3, 7.0	2.7, 6.8	1.7, 7.0	-2.7, 2.3	-1.6, 1.2	-2.4, 1.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Worry						
Baseline						
m	73	32	105			
n	66	29	94			
Mean (SD)	5.65 (1.38)	5.67 (1.62)	5.81 (1.17)			
Median	6.00	6.40	6.10			
IQR: Q1, Q3	5.00, 6.70	4.40, 7.00	5.00, 6.90			
Min, Max	1.1, 7.0	2.0, 7.0	2.0, 7.0			
Week 24						
m	70	31	102			
n	67	29	88	62	26	81
Mean (SD/SE)	5.79 (1.42)	6.00 (1.27)	6.03 (1.16)	0.24 (0.14)	0.45 (0.22)	0.30 (0.10)
Median	6.30	6.70	6.40	0	0.30	0
IQR: Q1, Q3	5.40, 6.70	5.30, 7.00	5.60, 7.00	-0.20, 0.60	0.00, 1.00	-0.10, 0.70
Min, Max	1.6, 7.0	3.0, 7.0	2.1, 7.0	-3.1, 3.3	-1.6, 3.4	-2.6, 2.8
Week 52						
m	64	28	95			
n	59	25	85	53	22	78
Mean (SD/SE)	5.82 (1.43)	5.76 (1.52)	6.10 (1.15)	0.18 (0.15)	0.16 (0.22)	0.28 (0.11)
Median	6.30	6.30	6.60	0	0	0
IQR: Q1, Q3	5.40, 7.00	5.40, 6.90	5.70, 7.00	-0.30, 0.70	-0.70, 0.70	0.00, 0.60
Min, Max	1.9, 7.0	1.0, 7.0	2.4, 7.0	-4.8, 3.0	-1.2, 2.4	-2.3, 3.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Region
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.4.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
CLDQ-NASH			
Week 24			
m	91	110	187
n	85	99	163
Baseline Mean (SD)	5.26 (1.07)	5.27 (1.11)	5.22 (1.14)
Analysis Visit Mean (SD)	5.31 (1.07)	5.24 (1.01)	5.31 (1.11)
LS Mean of Change from Baseline (SE)	0.07 (0.07)	-0.02 (0.07)	0.08 (0.05)
95% CI	(-0.07, 0.21)	(-0.15, 0.11)	(-0.02, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.09)	-0.10 (0.08)	
95% CI	(-0.18, 0.16)	(-0.26, 0.06)	
p-value	0.9066	0.2287	
Corrected Hedge's g Statistics	-0.015	-0.150	
95% CI	(-0.28, 0.25)	(-0.40, 0.10)	
Week 52			
m	85	97	175
n	75	84	139
Baseline Mean (SD)	5.32 (1.05)	5.31 (1.11)	5.28 (1.14)
Analysis Visit Mean (SD)	5.34 (1.03)	5.33 (1.01)	5.33 (1.12)
LS Mean of Change from Baseline (SE)	0.02 (0.08)	0.02 (0.07)	0.06 (0.05)
95% CI	(-0.13, 0.16)	(-0.12, 0.16)	(-0.05, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.09)	-0.04 (0.09)	
95% CI	(-0.23, 0.13)	(-0.21, 0.13)	
p-value	0.6082	0.6300	
Corrected Hedge's g Statistics	-0.072	-0.065	
95% CI	(-0.35, 0.21)	(-0.34, 0.21)	
Subgroup*Treatment Interaction p-value	0.7927	0.4073	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
CLDQ-NASH			
Week 24			
m	70	31	102
n	62	26	81
Baseline Mean (SD)	5.16 (1.34)	5.27 (1.22)	5.34 (1.07)
Analysis Visit Mean (SD)	5.27 (1.28)	5.29 (1.13)	5.50 (1.05)
LS Mean of Change from Baseline (SE)	0.11 (0.08)	0.00 (0.13)	0.22 (0.08)
95% CI	(-0.06, 0.27)	(-0.25, 0.25)	(0.07, 0.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.11)	-0.22 (0.14)	
95% CI	(-0.33, 0.10)	(-0.51, 0.07)	
p-value	0.3100	0.1315	
Corrected Hedge's g Statistics	-0.165	-0.324	
95% CI	(-0.50, 0.17)	(-0.77, 0.12)	
Week 52			
m	64	28	95
n	53	22	78
Baseline Mean (SD)	5.25 (1.34)	5.20 (1.29)	5.37 (1.02)
Analysis Visit Mean (SD)	5.34 (1.33)	5.16 (1.11)	5.47 (1.06)
LS Mean of Change from Baseline (SE)	0.11 (0.09)	-0.03 (0.14)	0.15 (0.08)
95% CI	(-0.07, 0.29)	(-0.29, 0.24)	(0.00, 0.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.11)	-0.18 (0.15)	
95% CI	(-0.27, 0.18)	(-0.48, 0.13)	
p-value	0.7082	0.2526	
Corrected Hedge's g Statistics	-0.064	-0.262	
95% CI	(-0.41, 0.28)	(-0.74, 0.21)	
Subgroup*Treatment Interaction p-value	0.7927	0.4073	

AMNOG Table SE23.4.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.4.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Abdominal Symptoms			
Week 24			
m	91	110	187
n	85	99	163
Baseline Mean (SD)	5.40 (1.45)	5.54 (1.45)	5.24 (1.54)
Analysis Visit Mean (SD)	5.36 (1.43)	5.48 (1.48)	5.44 (1.48)
LS Mean of Change from Baseline (SE)	0.00 (0.12)	0.00 (0.11)	0.16 (0.09)
95% CI	(-0.23, 0.24)	(-0.22, 0.22)	(-0.01, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.16 (0.14)	-0.16 (0.14)	
95% CI	(-0.44, 0.12)	(-0.43, 0.11)	
p-value	0.2690	0.2388	
Corrected Hedge's g Statistics	-0.144	-0.147	
95% CI	(-0.41, 0.12)	(-0.40, 0.10)	
Week 52			
m	85	97	175
n	75	84	139
Baseline Mean (SD)	5.49 (1.39)	5.65 (1.36)	5.36 (1.50)
Analysis Visit Mean (SD)	5.60 (1.31)	5.61 (1.34)	5.44 (1.46)
LS Mean of Change from Baseline (SE)	0.15 (0.12)	0.05 (0.12)	0.10 (0.09)
95% CI	(-0.09, 0.39)	(-0.18, 0.28)	(-0.08, 0.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.15)	-0.05 (0.14)	
95% CI	(-0.25, 0.34)	(-0.34, 0.23)	
p-value	0.7492	0.7079	
Corrected Hedge's g Statistics	0.045	-0.051	
95% CI	(-0.24, 0.33)	(-0.32, 0.22)	
Subgroup*Treatment Interaction p-value	0.9960	0.2089	

AMNOG Table SE23.4.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Activity			
Week 24			
m	91	110	187
n	85	99	163
Baseline Mean (SD)	5.40 (1.26)	5.39 (1.26)	5.45 (1.45)
Analysis Visit Mean (SD)	5.37 (1.21)	5.41 (1.23)	5.45 (1.36)
LS Mean of Change from Baseline (SE)	-0.02 (0.10)	0.01 (0.09)	0.00 (0.07)
95% CI	(-0.21, 0.17)	(-0.17, 0.18)	(-0.14, 0.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.12)	0.01 (0.11)	
95% CI	(-0.24, 0.21)	(-0.21, 0.23)	
p-value	0.8900	0.9282	
Corrected Hedge's g Statistics	-0.018	0.011	
95% CI	(-0.28, 0.24)	(-0.24, 0.26)	
Week 52			
m	85	97	175
n	75	84	139
Baseline Mean (SD)	5.45 (1.27)	5.44 (1.26)	5.53 (1.41)
Analysis Visit Mean (SD)	5.25 (1.36)	5.40 (1.23)	5.35 (1.47)
LS Mean of Change from Baseline (SE)	-0.18 (0.11)	-0.03 (0.10)	-0.13 (0.08)
95% CI	(-0.40, 0.03)	(-0.23, 0.17)	(-0.28, 0.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.13)	0.10 (0.13)	
95% CI	(-0.31, 0.21)	(-0.15, 0.35)	
p-value	0.6873	0.4353	
Corrected Hedge's g Statistics	-0.056	0.106	
95% CI	(-0.34, 0.22)	(-0.17, 0.38)	
Subgroup*Treatment Interaction p-value	0.4828	0.2112	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Emotional Health			
Week 24			
m	91	110	187
n	85	99	163
Baseline Mean (SD)	5.40 (1.16)	5.39 (1.24)	5.43 (1.19)
Analysis Visit Mean (SD)	5.45 (1.20)	5.28 (1.19)	5.48 (1.19)
LS Mean of Change from Baseline (SE)	0.03 (0.09)	-0.13 (0.08)	0.03 (0.06)
95% CI	(-0.15, 0.20)	(-0.29, 0.03)	(-0.10, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.11)	-0.16 (0.10)	
95% CI	(-0.21, 0.21)	(-0.36, 0.04)	
p-value	0.9890	0.1135	
Corrected Hedge's g Statistics	0.002	-0.197	
95% CI	(-0.26, 0.26)	(-0.45, 0.05)	
Week 52			
m	85	97	175
n	75	84	139
Baseline Mean (SD)	5.47 (1.14)	5.42 (1.27)	5.46 (1.23)
Analysis Visit Mean (SD)	5.49 (1.01)	5.46 (1.19)	5.49 (1.19)
LS Mean of Change from Baseline (SE)	-0.02 (0.09)	0.02 (0.08)	0.01 (0.06)
95% CI	(-0.20, 0.15)	(-0.14, 0.18)	(-0.11, 0.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.11)	0.01 (0.10)	
95% CI	(-0.24, 0.17)	(-0.19, 0.21)	
p-value	0.7419	0.9536	
Corrected Hedge's g Statistics	-0.046	0.008	
95% CI	(-0.33, 0.23)	(-0.26, 0.28)	
Subgroup*Treatment Interaction p-value	0.6875	0.7375	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Fatigue			
Week 24			
m	91	110	187
n	85	99	163
Baseline Mean (SD)	4.76 (1.42)	4.59 (1.49)	4.59 (1.39)
Analysis Visit Mean (SD)	4.78 (1.46)	4.49 (1.37)	4.60 (1.46)
LS Mean of Change from Baseline (SE)	0.06 (0.11)	-0.12 (0.10)	0.00 (0.08)
95% CI	(-0.16, 0.28)	(-0.32, 0.08)	(-0.16, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.07 (0.13)	-0.12 (0.13)	
95% CI	(-0.19, 0.33)	(-0.37, 0.13)	
p-value	0.6142	0.3466	
Corrected Hedge's g Statistics	0.066	-0.117	
95% CI	(-0.20, 0.33)	(-0.37, 0.13)	
Week 52			
m	85	97	175
n	75	84	139
Baseline Mean (SD)	4.76 (1.49)	4.64 (1.49)	4.64 (1.39)
Analysis Visit Mean (SD)	4.71 (1.50)	4.53 (1.51)	4.62 (1.48)
LS Mean of Change from Baseline (SE)	-0.07 (0.12)	-0.13 (0.11)	-0.02 (0.09)
95% CI	(-0.30, 0.17)	(-0.34, 0.09)	(-0.19, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.14)	-0.11 (0.14)	
95% CI	(-0.33, 0.23)	(-0.38, 0.17)	
p-value	0.7324	0.4452	
Corrected Hedge's g Statistics	-0.048	-0.103	
95% CI	(-0.33, 0.23)	(-0.37, 0.17)	
Subgroup*Treatment Interaction p-value	0.7511	0.6618	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Systemic Symptoms			
Week 24			
m	91	110	187
n	85	99	163
Baseline Mean (SD)	5.18 (1.16)	5.09 (1.24)	5.09 (1.23)
Analysis Visit Mean (SD)	5.15 (1.15)	4.95 (1.15)	5.07 (1.26)
LS Mean of Change from Baseline (SE)	0.01 (0.09)	-0.14 (0.08)	-0.03 (0.06)
95% CI	(-0.16, 0.18)	(-0.29, 0.02)	(-0.15, 0.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.10)	-0.11 (0.10)	
95% CI	(-0.16, 0.24)	(-0.30, 0.08)	
p-value	0.6995	0.2705	
Corrected Hedge's g Statistics	0.050	-0.137	
95% CI	(-0.21, 0.31)	(-0.39, 0.11)	
Week 52			
m	85	97	175
n	75	84	139
Baseline Mean (SD)	5.26 (1.10)	5.12 (1.21)	5.10 (1.27)
Analysis Visit Mean (SD)	5.05 (1.21)	5.01 (1.22)	5.06 (1.33)
LS Mean of Change from Baseline (SE)	-0.17 (0.10)	-0.12 (0.09)	0.01 (0.07)
95% CI	(-0.36, 0.02)	(-0.29, 0.06)	(-0.13, 0.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.17 (0.12)	-0.12 (0.11)	
95% CI	(-0.40, 0.06)	(-0.34, 0.10)	
p-value	0.1399	0.2771	
Corrected Hedge's g Statistics	-0.207	-0.147	
95% CI	(-0.49, 0.07)	(-0.42, 0.12)	
Subgroup*Treatment Interaction p-value	0.8284	0.2860	

AMNOG Table SE23.4.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Worry			
Week 24			
m	91	110	187
n	85	99	163
Baseline Mean (SD)	5.43 (1.41)	5.55 (1.49)	5.51 (1.47)
Analysis Visit Mean (SD)	5.75 (1.36)	5.79 (1.37)	5.83 (1.43)
LS Mean of Change from Baseline (SE)	0.32 (0.10)	0.25 (0.09)	0.32 (0.07)
95% CI	(0.12, 0.52)	(0.07, 0.43)	(0.18, 0.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.12)	-0.07 (0.11)	
95% CI	(-0.23, 0.24)	(-0.29, 0.16)	
p-value	0.9763	0.5538	
Corrected Hedge's g Statistics	0.004	-0.074	
95% CI	(-0.26, 0.27)	(-0.32, 0.18)	
Week 52			
m	85	97	175
n	75	84	139
Baseline Mean (SD)	5.50 (1.39)	5.57 (1.53)	5.60 (1.43)
Analysis Visit Mean (SD)	5.92 (1.27)	5.99 (1.32)	5.95 (1.32)
LS Mean of Change from Baseline (SE)	0.37 (0.11)	0.41 (0.10)	0.37 (0.08)
95% CI	(0.15, 0.59)	(0.21, 0.61)	(0.21, 0.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.13)	0.04 (0.13)	
95% CI	(-0.26, 0.27)	(-0.21, 0.29)	
p-value	0.9847	0.7386	
Corrected Hedge's g Statistics	0.003	0.045	
95% CI	(-0.28, 0.28)	(-0.23, 0.32)	
Subgroup*Treatment Interaction p-value	0.4299	0.9085	

AMNOG Table SE23.4.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Abdominal Symptoms			
Week 24			
m	70	31	102
n	62	26	81
Baseline Mean (SD)	5.14 (1.84)	5.54 (1.19)	5.41 (1.44)
Analysis Visit Mean (SD)	5.42 (1.53)	5.31 (1.58)	5.62 (1.27)
LS Mean of Change from Baseline (SE)	0.22 (0.13)	-0.14 (0.20)	0.30 (0.12)
95% CI	(-0.03, 0.48)	(-0.53, 0.25)	(0.07, 0.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.17)	-0.44 (0.23)	
95% CI	(-0.41, 0.26)	(-0.89, 0.01)	
p-value	0.6683	0.0533	
Corrected Hedge's g Statistics	-0.070	-0.418	
95% CI	(-0.40, 0.26)	(-0.86, 0.03)	
Week 52			
m	64	28	95
n	53	22	78
Baseline Mean (SD)	5.20 (1.84)	5.62 (1.26)	5.37 (1.39)
Analysis Visit Mean (SD)	5.35 (1.75)	5.47 (1.20)	5.51 (1.26)
LS Mean of Change from Baseline (SE)	0.10 (0.15)	-0.13 (0.23)	0.22 (0.12)
95% CI	(-0.19, 0.39)	(-0.57, 0.32)	(-0.03, 0.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.12 (0.19)	-0.35 (0.25)	
95% CI	(-0.49, 0.25)	(-0.85, 0.15)	
p-value	0.5328	0.1714	
Corrected Hedge's g Statistics	-0.108	-0.318	
95% CI	(-0.46, 0.24)	(-0.79, 0.16)	
Subgroup*Treatment Interaction p-value	0.9960	0.2089	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Activity			
Week 24			
m	70	31	102
n	62	26	81
Baseline Mean (SD)	5.11 (1.55)	5.20 (1.53)	5.45 (1.16)
Analysis Visit Mean (SD)	5.14 (1.74)	5.34 (1.34)	5.68 (1.22)
LS Mean of Change from Baseline (SE)	0.02 (0.12)	0.09 (0.18)	0.30 (0.11)
95% CI	(-0.21, 0.25)	(-0.26, 0.44)	(0.09, 0.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.28 (0.15)	-0.21 (0.20)	
95% CI	(-0.58, 0.02)	(-0.61, 0.19)	
p-value	0.0699	0.2981	
Corrected Hedge's g Statistics	-0.297	-0.223	
95% CI	(-0.63, 0.04)	(-0.67, 0.22)	
Week 52			
m	64	28	95
n	53	22	78
Baseline Mean (SD)	5.22 (1.49)	5.06 (1.60)	5.56 (1.05)
Analysis Visit Mean (SD)	5.38 (1.71)	5.03 (1.37)	5.59 (1.22)
LS Mean of Change from Baseline (SE)	0.15 (0.13)	-0.04 (0.20)	0.11 (0.11)
95% CI	(-0.11, 0.41)	(-0.44, 0.36)	(-0.12, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.17)	-0.15 (0.23)	
95% CI	(-0.29, 0.38)	(-0.60, 0.30)	
p-value	0.7871	0.5182	
Corrected Hedge's g Statistics	0.047	-0.149	
95% CI	(-0.30, 0.40)	(-0.62, 0.32)	
Subgroup*Treatment Interaction p-value	0.4828	0.2112	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Emotional Health			
Week 24			
m	70	31	102
n	62	26	81
Baseline Mean (SD)	5.29 (1.35)	5.36 (1.58)	5.41 (1.28)
Analysis Visit Mean (SD)	5.43 (1.28)	5.41 (1.43)	5.41 (1.32)
LS Mean of Change from Baseline (SE)	0.14 (0.10)	0.05 (0.15)	0.06 (0.09)
95% CI	(-0.06, 0.33)	(-0.25, 0.35)	(-0.12, 0.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.13)	-0.01 (0.17)	
95% CI	(-0.18, 0.33)	(-0.35, 0.33)	
p-value	0.5520	0.9476	
Corrected Hedge's g Statistics	0.097	-0.014	
95% CI	(-0.23, 0.43)	(-0.46, 0.43)	
Week 52			
m	64	28	95
n	53	22	78
Baseline Mean (SD)	5.36 (1.34)	5.27 (1.69)	5.50 (1.24)
Analysis Visit Mean (SD)	5.36 (1.24)	5.22 (1.28)	5.48 (1.33)
LS Mean of Change from Baseline (SE)	0.02 (0.10)	-0.02 (0.16)	0.03 (0.09)
95% CI	(-0.18, 0.22)	(-0.33, 0.29)	(-0.15, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.13)	-0.05 (0.18)	
95% CI	(-0.27, 0.25)	(-0.40, 0.30)	
p-value	0.9503	0.7873	
Corrected Hedge's g Statistics	-0.011	-0.062	
95% CI	(-0.36, 0.34)	(-0.54, 0.41)	
Subgroup*Treatment Interaction p-value	0.6875	0.7375	

AMNOG Table SE23.4.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Fatigue			
Week 24			
m	70	31	102
n	62	26	81
Baseline Mean (SD)	4.74 (1.59)	4.73 (1.40)	4.77 (1.56)
Analysis Visit Mean (SD)	4.71 (1.55)	4.62 (1.46)	4.91 (1.45)
LS Mean of Change from Baseline (SE)	-0.01 (0.12)	-0.17 (0.19)	0.14 (0.11)
95% CI	(-0.26, 0.23)	(-0.54, 0.20)	(-0.08, 0.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (0.16)	-0.31 (0.22)	
95% CI	(-0.48, 0.17)	(-0.74, 0.12)	
p-value	0.3511	0.1535	
Corrected Hedge's g Statistics	-0.152	-0.308	
95% CI	(-0.48, 0.18)	(-0.75, 0.14)	
Week 52			
m	64	28	95
n	53	22	78
Baseline Mean (SD)	4.84 (1.54)	4.64 (1.51)	4.80 (1.47)
Analysis Visit Mean (SD)	4.95 (1.52)	4.60 (1.23)	4.90 (1.37)
LS Mean of Change from Baseline (SE)	0.16 (0.13)	0.03 (0.20)	0.13 (0.11)
95% CI	(-0.09, 0.42)	(-0.35, 0.42)	(-0.09, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.17)	-0.10 (0.22)	
95% CI	(-0.30, 0.36)	(-0.53, 0.34)	
p-value	0.8500	0.6672	
Corrected Hedge's g Statistics	0.032	-0.098	
95% CI	(-0.32, 0.38)	(-0.57, 0.37)	
Subgroup*Treatment Interaction p-value	0.7511	0.6618	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Systemic Symptoms			
Week 24			
m	70	31	102
n	62	26	81
Baseline Mean (SD)	5.12 (1.40)	5.21 (1.21)	5.21 (1.19)
Analysis Visit Mean (SD)	5.13 (1.39)	5.00 (1.44)	5.27 (1.24)
LS Mean of Change from Baseline (SE)	0.03 (0.10)	-0.22 (0.16)	0.12 (0.09)
95% CI	(-0.18, 0.23)	(-0.53, 0.10)	(-0.07, 0.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.09 (0.14)	-0.33 (0.18)	
95% CI	(-0.36, 0.18)	(-0.69, 0.02)	
p-value	0.5044	0.0663	
Corrected Hedge's g Statistics	-0.109	-0.398	
95% CI	(-0.44, 0.22)	(-0.84, 0.05)	
Week 52			
m	64	28	95
n	53	22	78
Baseline Mean (SD)	5.23 (1.39)	5.06 (1.23)	5.17 (1.19)
Analysis Visit Mean (SD)	5.17 (1.42)	4.96 (1.25)	5.25 (1.36)
LS Mean of Change from Baseline (SE)	-0.01 (0.10)	-0.13 (0.16)	0.11 (0.09)
95% CI	(-0.21, 0.19)	(-0.43, 0.18)	(-0.06, 0.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.12 (0.13)	-0.24 (0.18)	
95% CI	(-0.38, 0.14)	(-0.58, 0.11)	
p-value	0.3517	0.1793	
Corrected Hedge's g Statistics	-0.160	-0.310	
95% CI	(-0.51, 0.19)	(-0.79, 0.16)	
Subgroup*Treatment Interaction p-value	0.8284	0.2860	

AMNOG Table SE23.4.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Worry			
Week 24			
m	70	31	102
n	62	26	81
Baseline Mean (SD)	5.60 (1.39)	5.56 (1.67)	5.78 (1.22)
Analysis Visit Mean (SD)	5.84 (1.35)	6.01 (1.26)	6.08 (1.12)
LS Mean of Change from Baseline (SE)	0.20 (0.12)	0.37 (0.18)	0.34 (0.10)
95% CI	(-0.03, 0.43)	(0.02, 0.72)	(0.14, 0.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.15)	0.03 (0.20)	
95% CI	(-0.44, 0.16)	(-0.37, 0.43)	
p-value	0.3449	0.8809	
Corrected Hedge's g Statistics	-0.154	0.032	
95% CI	(-0.48, 0.18)	(-0.41, 0.47)	
Week 52			
m	64	28	95
n	53	22	78
Baseline Mean (SD)	5.67 (1.46)	5.57 (1.69)	5.83 (1.21)
Analysis Visit Mean (SD)	5.85 (1.37)	5.74 (1.57)	6.11 (1.16)
LS Mean of Change from Baseline (SE)	0.17 (0.13)	0.22 (0.20)	0.32 (0.11)
95% CI	(-0.08, 0.42)	(-0.16, 0.61)	(0.10, 0.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (0.16)	-0.10 (0.22)	
95% CI	(-0.47, 0.18)	(-0.53, 0.34)	
p-value	0.3648	0.6571	
Corrected Hedge's g Statistics	-0.156	-0.102	
95% CI	(-0.51, 0.19)	(-0.58, 0.37)	
Subgroup*Treatment Interaction p-value	0.4299	0.9085	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (4.3)	7 (5.9)	14 (7.1)
No	90 (95.7)	112 (94.1)	184 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	1.22	
95% CI of the inverse odds ratio	(0.55, 5.35)	(0.48, 3.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.66	1.20	
95% CI of the inverse risk ratio	(0.56, 4.91)	(0.50, 2.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.82	-1.19	
95% CI of the absolute risk difference	(-8.24, 2.61)	(-6.72, 4.35)	
p-value	0.3500	0.6804	
p-value of Breslow-Day Test for Homogeneity [3]	0.6559	0.7016	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (21.3)	25 (21.0)	40 (20.2)
No	74 (78.7)	94 (79.0)	158 (79.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.95	
95% CI of the inverse odds ratio	(0.51, 1.71)	(0.54, 1.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.96	
95% CI of the inverse risk ratio	(0.59, 1.53)	(0.62, 1.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.07	0.81	
95% CI of the absolute risk difference	(-8.91, 11.06)	(-8.40, 10.02)	
p-value	0.8319	0.8633	
p-value of Breslow-Day Test for Homogeneity [3]	0.5662	0.2972	

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	21 (22.3)	14 (11.8)	34 (17.2)
No	73 (77.7)	105 (88.2)	164 (82.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	1.55	
95% CI of the inverse odds ratio	(0.39, 1.33)	(0.80, 3.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.46	
95% CI of the inverse risk ratio	(0.47, 1.25)	(0.82, 2.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.17	-5.41	
95% CI of the absolute risk difference	(-4.76, 15.09)	(-13.22, 2.41)	
p-value	0.2912	0.1934	
p-value of Breslow-Day Test for Homogeneity [3]	0.1667	0.6053	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (35.1)	23 (19.3)	65 (32.8)
No	61 (64.9)	96 (80.7)	133 (67.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	2.04	
95% CI of the inverse odds ratio	(0.54, 1.52)	(1.18, 3.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.70	
95% CI of the inverse risk ratio	(0.67, 1.31)	(1.12, 2.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.28	-13.50	
95% CI of the absolute risk difference	(-9.38, 13.94)	(-23.15, -3.85)	
p-value	0.7001	0.0093	
p-value of Breslow-Day Test for Homogeneity [3]	0.9848	0.5744	

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (11.7)	11 (9.2)	13 (6.6)
No	83 (88.3)	108 (90.8)	185 (93.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	0.69	
95% CI of the inverse odds ratio	(0.23, 1.23)	(0.30, 1.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.71	
95% CI of the inverse risk ratio	(0.26, 1.21)	(0.33, 1.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.14	2.68	
95% CI of the absolute risk difference	(-2.22, 12.49)	(-3.57, 8.92)	
p-value	0.1354	0.3828	
p-value of Breslow-Day Test for Homogeneity [3]	0.3503	0.7900	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (26.6)	31 (26.1)	35 (17.7)
No	69 (73.4)	88 (73.9)	163 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.61	
95% CI of the inverse odds ratio	(0.33, 1.06)	(0.35, 1.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.68	
95% CI of the inverse risk ratio	(0.42, 1.04)	(0.44, 1.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.92	8.37	
95% CI of the absolute risk difference	(-1.47, 19.31)	(-1.14, 17.88)	
p-value	0.0780	0.0754	
p-value of Breslow-Day Test for Homogeneity [3]	0.2688	0.0537	

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (11.7)	10 (8.4)	19 (9.6)
No	83 (88.3)	109 (91.6)	179 (90.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.16	
95% CI of the inverse odds ratio	(0.36, 1.76)	(0.52, 2.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.14	
95% CI of the inverse risk ratio	(0.41, 1.65)	(0.55, 2.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.11	-1.19	
95% CI of the absolute risk difference	(-5.58, 9.79)	(-7.65, 5.26)	
p-value	0.5797	0.7214	
p-value of Breslow-Day Test for Homogeneity [3]	0.6325	0.2756	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (20.2)	28 (23.5)	48 (24.2)
No	75 (79.8)	91 (76.5)	150 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	1.04	
95% CI of the inverse odds ratio	(0.69, 2.30)	(0.61, 1.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	1.03	
95% CI of the inverse risk ratio	(0.75, 1.92)	(0.69, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.03	-0.71	
95% CI of the absolute risk difference	(-14.11, 6.05)	(-10.39, 8.97)	
p-value	0.4442	0.8855	
p-value of Breslow-Day Test for Homogeneity [3]	0.5858	0.9752	

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (8.5)	16 (13.4)	22 (11.1)
No	86 (91.5)	103 (86.6)	176 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.34	0.80	
95% CI of the inverse odds ratio	(0.57, 3.14)	(0.40, 1.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	0.83	
95% CI of the inverse risk ratio	(0.60, 2.82)	(0.45, 1.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.60	2.33	
95% CI of the absolute risk difference	(-9.74, 4.54)	(-5.20, 9.87)	
p-value	0.4941	0.5355	
p-value of Breslow-Day Test for Homogeneity [3]	0.7198	0.7757	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (26.6)	27 (22.7)	51 (25.8)
No	69 (73.4)	92 (77.3)	147 (74.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.18	
95% CI of the inverse odds ratio	(0.55, 1.67)	(0.69, 2.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	1.14	
95% CI of the inverse risk ratio	(0.64, 1.46)	(0.76, 1.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.84	-3.07	
95% CI of the absolute risk difference	(-9.97, 11.65)	(-12.75, 6.61)	
p-value	0.8788	0.5391	
p-value of Breslow-Day Test for Homogeneity [3]	0.8186	0.9777	

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (4.3)	10 (8.4)	20 (10.1)
No	90 (95.7)	109 (91.6)	178 (89.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.53	1.22	
95% CI of the inverse odds ratio	(0.84, 7.62)	(0.55, 2.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	1.20	
95% CI of the inverse risk ratio	(0.83, 6.75)	(0.58, 2.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.85	-1.70	
95% CI of the absolute risk difference	(-11.70, 0.01)	(-8.21, 4.82)	
p-value	0.0893	0.6171	
p-value of Breslow-Day Test for Homogeneity [3]	0.4942	0.9912	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (21.3)	30 (25.2)	45 (22.7)
No	74 (78.7)	89 (74.8)	153 (77.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	0.87	
95% CI of the inverse odds ratio	(0.60, 1.97)	(0.51, 1.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.90	
95% CI of the inverse risk ratio	(0.67, 1.70)	(0.60, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.45	2.48	
95% CI of the absolute risk difference	(-11.58, 8.67)	(-7.26, 12.23)	
p-value	0.7807	0.6145	
p-value of Breslow-Day Test for Homogeneity [3]	0.4381	0.0892	

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	20 (21.3)	21 (17.6)	36 (18.2)
No	74 (78.7)	98 (82.4)	162 (81.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.04	
95% CI of the inverse odds ratio	(0.45, 1.52)	(0.57, 1.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.03	
95% CI of the inverse risk ratio	(0.52, 1.39)	(0.63, 1.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.09	-0.53	
95% CI of the absolute risk difference	(-6.77, 12.96)	(-9.24, 8.17)	
p-value	0.5303	0.9044	
p-value of Breslow-Day Test for Homogeneity [3]	0.5918	0.9925	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	37 (39.4)	36 (30.3)	69 (34.8)
No	57 (60.6)	83 (69.7)	129 (65.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.23	
95% CI of the inverse odds ratio	(0.50, 1.37)	(0.76, 2.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.15	
95% CI of the inverse risk ratio	(0.65, 1.21)	(0.83, 1.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.51	-4.60	
95% CI of the absolute risk difference	(-7.39, 16.41)	(-15.19, 5.99)	
p-value	0.4537	0.3998	
p-value of Breslow-Day Test for Homogeneity [3]	0.5552	0.9585	

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (9.6)	4 (12.5)	12 (11.4)
No	66 (90.4)	28 (87.5)	93 (88.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	0.90	
95% CI of the inverse odds ratio	(0.45, 3.25)	(0.27, 3.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	0.91	
95% CI of the inverse risk ratio	(0.49, 2.88)	(0.32, 2.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.84	1.07	
95% CI of the absolute risk difference	(-10.93, 7.25)	(-11.90, 14.05)	
p-value	0.6958	0.8688	
p-value of Breslow-Day Test for Homogeneity [3]	0.6559	0.7016	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (24.7)	6 (18.8)	30 (28.6)
No	55 (75.3)	26 (81.3)	75 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	1.73	
95% CI of the inverse odds ratio	(0.62, 2.41)	(0.65, 4.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.52	
95% CI of the inverse risk ratio	(0.70, 1.91)	(0.70, 3.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.91	-9.82	
95% CI of the absolute risk difference	(-17.04, 9.22)	(-25.87, 6.23)	
p-value	0.5628	0.2691	
p-value of Breslow-Day Test for Homogeneity [3]	0.5662	0.2972	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (13.7)	3 (9.4)	20 (19.0)
No	63 (86.3)	29 (90.6)	85 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.48	2.27	
95% CI of the inverse odds ratio	(0.65, 3.39)	(0.63, 8.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	2.03	
95% CI of the inverse risk ratio	(0.69, 2.79)	(0.65, 6.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.35	-9.67	
95% CI of the absolute risk difference	(-16.24, 5.54)	(-22.26, 2.91)	
p-value	0.3484	0.2000	
p-value of Breslow-Day Test for Homogeneity [3]	0.1667	0.6053	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (31.5)	7 (21.9)	31 (29.5)
No	50 (68.5)	25 (78.1)	74 (70.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.50	
95% CI of the inverse odds ratio	(0.48, 1.74)	(0.59, 3.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.35	
95% CI of the inverse risk ratio	(0.60, 1.47)	(0.66, 2.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.98	-7.65	
95% CI of the absolute risk difference	(-11.79, 15.76)	(-24.42, 9.12)	
p-value	0.7771	0.3975	
p-value of Breslow-Day Test for Homogeneity [3]	0.9848	0.5744	

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (9.6)	5 (15.6)	10 (9.5)
No	66 (90.4)	27 (84.4)	95 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.57	
95% CI of the inverse odds ratio	(0.36, 2.74)	(0.18, 1.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.61	
95% CI of the inverse risk ratio	(0.40, 2.49)	(0.22, 1.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.07	6.10	
95% CI of the absolute risk difference	(-8.72, 8.85)	(-7.68, 19.88)	
p-value	0.9884	0.3332	
p-value of Breslow-Day Test for Homogeneity [3]	0.3503	0.7900	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	22 (30.1)	6 (18.8)	31 (29.5)
No	51 (69.9)	26 (81.3)	74 (70.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	1.82	
95% CI of the inverse odds ratio	(0.51, 1.86)	(0.68, 4.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.57	
95% CI of the inverse risk ratio	(0.62, 1.55)	(0.72, 3.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.61	-10.77	
95% CI of the absolute risk difference	(-13.06, 14.29)	(-26.87, 5.32)	
p-value	0.9299	0.2295	
p-value of Breslow-Day Test for Homogeneity [3]	0.2688	0.0537	

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (11.0)	4 (12.5)	7 (6.7)
No	65 (89.0)	28 (87.5)	98 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.50	
95% CI of the inverse odds ratio	(0.20, 1.68)	(0.14, 1.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	0.53	
95% CI of the inverse risk ratio	(0.23, 1.60)	(0.17, 1.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.29	5.83	
95% CI of the absolute risk difference	(-4.32, 12.90)	(-6.58, 18.25)	
p-value	0.3106	0.2877	
p-value of Breslow-Day Test for Homogeneity [3]	0.6325	0.2756	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (23.3)	7 (21.9)	24 (22.9)
No	56 (76.7)	25 (78.1)	81 (77.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.06	
95% CI of the inverse odds ratio	(0.48, 1.98)	(0.41, 2.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.04	
95% CI of the inverse risk ratio	(0.57, 1.69)	(0.50, 2.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.43	-0.98	
95% CI of the absolute risk difference	(-12.16, 13.02)	(-17.40, 15.44)	
p-value	0.9465	0.9075	
p-value of Breslow-Day Test for Homogeneity [3]	0.5858	0.9752	

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (9.6)	5 (15.6)	16 (15.2)
No	66 (90.4)	27 (84.4)	89 (84.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.70	0.97	
95% CI of the inverse odds ratio	(0.66, 4.35)	(0.33, 2.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	0.98	
95% CI of the inverse risk ratio	(0.69, 3.67)	(0.39, 2.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.65	0.39	
95% CI of the absolute risk difference	(-15.29, 3.99)	(-13.95, 14.72)	
p-value	0.2691	0.9576	
p-value of Breslow-Day Test for Homogeneity [3]	0.7198	0.7757	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (27.4)	8 (25.0)	30 (28.6)
No	53 (72.6)	24 (75.0)	75 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.20	
95% CI of the inverse odds ratio	(0.54, 2.06)	(0.49, 2.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.14	
95% CI of the inverse risk ratio	(0.64, 1.69)	(0.58, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.17	-3.57	
95% CI of the absolute risk difference	(-14.57, 12.22)	(-20.88, 13.74)	
p-value	0.8639	0.6928	
p-value of Breslow-Day Test for Homogeneity [3]	0.8186	0.9777	

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (5.5)	2 (6.3)	8 (7.6)
No	69 (94.5)	30 (93.8)	97 (92.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	1.24	
95% CI of the inverse odds ratio	(0.41, 4.91)	(0.25, 6.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	1.22	
95% CI of the inverse risk ratio	(0.43, 4.45)	(0.27, 5.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.14	-1.37	
95% CI of the absolute risk difference	(-9.42, 5.14)	(-11.17, 8.43)	
p-value	0.5755	0.7944	
p-value of Breslow-Day Test for Homogeneity [3]	0.4942	0.9912	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (21.9)	5 (15.6)	32 (30.5)
No	57 (78.1)	27 (84.4)	73 (69.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	2.37	
95% CI of the inverse odds ratio	(0.78, 3.12)	(0.84, 6.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	1.95	
95% CI of the inverse risk ratio	(0.83, 2.34)	(0.83, 4.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.56	-14.85	
95% CI of the absolute risk difference	(-21.50, 4.39)	(-30.21, 0.50)	
p-value	0.2057	0.0976	
p-value of Breslow-Day Test for Homogeneity [3]	0.4381	0.0892	

AMNOG Table SE23.4.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (15.1)	5 (15.6)	17 (16.2)
No	62 (84.9)	27 (84.4)	88 (83.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.04	
95% CI of the inverse odds ratio	(0.48, 2.48)	(0.35, 3.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.04	
95% CI of the inverse risk ratio	(0.54, 2.16)	(0.41, 2.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.12	-0.57	
95% CI of the absolute risk difference	(-11.94, 9.69)	(-14.98, 13.85)	
p-value	0.8397	0.9392	
p-value of Breslow-Day Test for Homogeneity [3]	0.5918	0.9925	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (27.4)	8 (25.0)	30 (28.6)
No	53 (72.6)	24 (75.0)	75 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.20	
95% CI of the inverse odds ratio	(0.54, 2.06)	(0.49, 2.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.14	
95% CI of the inverse risk ratio	(0.64, 1.69)	(0.58, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.17	-3.57	
95% CI of the absolute risk difference	(-14.57, 12.22)	(-20.88, 13.74)	
p-value	0.8639	0.6928	
p-value of Breslow-Day Test for Homogeneity [3]	0.5552	0.9585	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE23.5.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
CLDQ-NASH						
Baseline						
m	52	151	186			
n	47	136	172			
Mean (SD)	5.17 (1.20)	5.27 (1.11)	5.23 (1.14)			
Median	5.30	5.60	5.40			
IQR: Q1, Q3	4.50, 6.30	4.50, 6.10	4.50, 6.20			
Min, Max	2.7, 6.9	2.1, 7.0	2.2, 7.0			
Week 24						
m	51	141	178			
n	50	136	160	47	125	151
Mean (SD/SE)	5.20 (1.23)	5.27 (1.03)	5.33 (1.09)	-0.04 (0.13)	-0.02 (0.05)	0.08 (0.06)
Median	5.55	5.50	5.45	0	0	0
IQR: Q1, Q3	4.50, 6.30	4.50, 6.10	4.60, 6.20	-0.50, 0.60	-0.40, 0.30	-0.30, 0.40
Min, Max	2.4, 6.8	2.7, 7.0	2.3, 7.0	-2.6, 1.7	-1.6, 1.6	-2.3, 3.0
Week 52						
m	46	125	165			
n	42	113	145	38	106	137
Mean (SD/SE)	5.40 (1.10)	5.34 (1.03)	5.39 (1.06)	-0.09 (0.10)	0.00 (0.06)	0.01 (0.06)
Median	5.45	5.60	5.60	-0.05	0	-0.10
IQR: Q1, Q3	4.80, 6.30	4.60, 6.10	4.70, 6.20	-0.40, 0.20	-0.30, 0.30	-0.40, 0.40
Min, Max	1.9, 6.9	2.2, 6.9	2.4, 7.0	-1.9, 1.4	-2.4, 1.8	-2.2, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Abdominal Symptoms						
Baseline						
m	52	151	186			
n	47	136	172			
Mean (SD)	5.23 (1.67)	5.57 (1.37)	5.22 (1.55)			
Median	6.00	6.00	5.30			
IQR: Q1, Q3	4.00, 7.00	4.70, 7.00	4.15, 6.70			
Min, Max	1.3, 7.0	1.7, 7.0	1.7, 7.0			
Week 24						
m	51	141	178			
n	50	136	160	47	125	151
Mean (SD/SE)	5.35 (1.75)	5.43 (1.47)	5.47 (1.49)	0.01 (0.18)	-0.10 (0.10)	0.17 (0.10)
Median	6.00	5.70	6.00	0	0	0
IQR: Q1, Q3	4.30, 7.00	4.50, 6.70	4.50, 7.00	-0.30, 0.70	-0.60, 0.40	-0.40, 0.70
Min, Max	1.0, 7.0	1.3, 7.0	1.0, 7.0	-4.7, 2.7	-4.0, 2.4	-3.0, 4.0
Week 52						
m	46	125	165			
n	42	113	145	38	106	137
Mean (SD/SE)	5.56 (1.41)	5.59 (1.28)	5.57 (1.25)	-0.07 (0.19)	-0.07 (0.09)	0.14 (0.10)
Median	6.00	5.70	5.70	0	0	0
IQR: Q1, Q3	5.00, 6.70	5.00, 6.70	5.00, 6.70	-0.30, 0.70	-0.40, 0.30	-0.40, 0.70
Min, Max	1.0, 7.0	1.7, 7.0	1.7, 7.0	-3.3, 1.7	-3.0, 2.7	-4.6, 4.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Activity						
Baseline						
m	52	151	186			
n	47	136	172			
Mean (SD)	5.24 (1.39)	5.33 (1.33)	5.47 (1.37)			
Median	5.40	5.60	5.80			
IQR: Q1, Q3	4.20, 6.40	4.60, 6.40	4.60, 6.80			
Min, Max	2.0, 7.0	1.8, 7.0	2.0, 7.0			
Week 24						
m	51	141	178			
n	50	136	160	47	125	151
Mean (SD/SE)	5.19 (1.50)	5.41 (1.26)	5.46 (1.33)	-0.07 (0.14)	0.04 (0.08)	-0.01 (0.07)
Median	5.60	5.80	5.80	0	0	0
IQR: Q1, Q3	4.00, 6.40	4.60, 6.40	4.70, 6.60	-0.60, 0.60	-0.60, 0.60	-0.40, 0.40
Min, Max	1.2, 7.0	2.4, 7.0	1.2, 7.0	-3.2, 1.8	-2.4, 3.2	-2.8, 2.6
Week 52						
m	46	125	165			
n	42	113	145	38	106	137
Mean (SD/SE)	5.48 (1.39)	5.38 (1.25)	5.39 (1.34)	-0.09 (0.14)	-0.04 (0.09)	-0.29 (0.08)
Median	5.80	5.60	5.80	0.10	0	-0.20
IQR: Q1, Q3	4.80, 6.60	4.60, 6.40	4.40, 6.40	-0.40, 0.40	-0.60, 0.60	-1.00, 0.20
Min, Max	2.4, 7.0	1.6, 7.0	1.8, 7.0	-3.0, 1.2	-2.8, 2.0	-3.4, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Emotional Health						
Baseline						
m	52	151	186			
n	47	136	172			
Mean (SD)	5.26 (1.32)	5.38 (1.29)	5.41 (1.25)			
Median	5.60	5.70	5.75			
IQR: Q1, Q3	4.40, 6.20	4.70, 6.35	4.80, 6.30			
Min, Max	1.9, 7.0	1.8, 7.0	1.9, 7.0			
Week 24						
m	51	141	178			
n	50	136	160	47	125	151
Mean (SD/SE)	5.26 (1.34)	5.35 (1.24)	5.43 (1.28)	-0.07 (0.15)	-0.07 (0.06)	0.03 (0.07)
Median	5.65	5.40	5.80	0	0	0.10
IQR: Q1, Q3	4.00, 6.20	4.70, 6.30	4.70, 6.40	-0.70, 0.70	-0.40, 0.20	-0.40, 0.50
Min, Max	2.0, 7.0	1.0, 7.0	1.9, 7.0	-2.8, 2.1	-3.1, 2.4	-2.9, 3.3
Week 52						
m	46	125	165			
n	42	113	145	38	106	137
Mean (SD/SE)	5.53 (1.02)	5.47 (1.20)	5.53 (1.24)	-0.07 (0.12)	0.03 (0.08)	0.01 (0.06)
Median	5.75	5.80	5.80	-0.10	0	0
IQR: Q1, Q3	4.60, 6.30	4.70, 6.40	4.80, 6.60	-0.70, 0.20	-0.50, 0.40	-0.40, 0.40
Min, Max	3.4, 7.0	1.0, 7.0	1.3, 7.0	-1.5, 1.6	-1.9, 2.9	-1.9, 2.5

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Fatigue						
Baseline						
m	52	151	186			
n	47	136	172			
Mean (SD)	4.67 (1.47)	4.60 (1.45)	4.57 (1.42)			
Median	5.00	4.80	4.80			
IQR: Q1, Q3	3.80, 6.00	3.70, 5.70	3.60, 5.60			
Min, Max	1.3, 7.0	1.2, 7.0	1.0, 7.0			
Week 24						
m	51	141	178			
n	50	136	160	47	125	151
Mean (SD/SE)	4.67 (1.50)	4.56 (1.37)	4.64 (1.40)	-0.10 (0.17)	-0.11 (0.08)	0.09 (0.09)
Median	4.50	4.70	4.70	-0.20	0	0.10
IQR: Q1, Q3	4.00, 6.00	3.70, 5.50	3.50, 5.80	-1.00, 0.70	-0.50, 0.40	-0.60, 0.60
Min, Max	1.3, 7.0	1.5, 7.0	1.2, 7.0	-2.5, 2.7	-4.2, 2.3	-3.3, 3.7
Week 52						
m	46	125	165			
n	42	113	145	38	106	137
Mean (SD/SE)	4.83 (1.48)	4.60 (1.45)	4.70 (1.35)	-0.11 (0.13)	-0.09 (0.11)	-0.01 (0.09)
Median	5.10	4.80	4.80	-0.15	0	0
IQR: Q1, Q3	3.80, 6.00	3.70, 5.80	3.80, 5.70	-0.50, 0.50	-0.50, 0.50	-0.70, 0.50
Min, Max	1.0, 7.0	1.2, 7.0	1.2, 7.0	-2.4, 1.8	-4.4, 2.5	-3.8, 2.5

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Systemic Symptoms						
Baseline						
m	52	151	186			
n	47	136	172			
Mean (SD)	5.11 (1.28)	5.09 (1.22)	4.98 (1.27)			
Median	5.50	5.20	5.20			
IQR: Q1, Q3	4.00, 6.20	4.50, 6.00	4.20, 6.00			
Min, Max	1.8, 6.8	1.8, 7.0	1.7, 7.0			
Week 24						
m	51	141	178			
n	50	136	160	47	125	151
Mean (SD/SE)	5.06 (1.27)	5.00 (1.21)	5.04 (1.29)	-0.06 (0.14)	-0.16 (0.06)	-0.01 (0.07)
Median	5.20	5.20	5.20	0	-0.10	0
IQR: Q1, Q3	4.20, 6.20	4.10, 6.00	4.20, 6.00	-0.60, 0.70	-0.50, 0.20	-0.60, 0.50
Min, Max	2.3, 7.0	1.8, 7.0	1.5, 7.0	-1.9, 2.1	-2.0, 2.2	-2.5, 3.7
Week 52						
m	46	125	165			
n	42	113	145	38	106	137
Mean (SD/SE)	5.15 (1.32)	5.04 (1.22)	5.06 (1.36)	-0.27 (0.13)	-0.11 (0.08)	0.01 (0.08)
Median	5.25	5.20	5.30	-0.10	0	0
IQR: Q1, Q3	4.20, 6.20	4.20, 6.00	4.00, 6.20	-0.90, 0.20	-0.50, 0.30	-0.50, 0.50
Min, Max	1.3, 7.0	1.5, 7.0	1.7, 7.0	-1.7, 2.0	-2.5, 2.0	-2.7, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Worry						
Baseline						
m	52	151	186			
n	47	136	172			
Mean (SD)	5.51 (1.48)	5.60 (1.49)	5.73 (1.33)			
Median	5.70	6.05	6.10			
IQR: Q1, Q3	5.00, 6.90	4.65, 6.90	5.00, 6.90			
Min, Max	1.6, 7.0	1.0, 7.0	1.4, 7.0			
Week 24						
m	51	141	178			
n	50	136	160	47	125	151
Mean (SD/SE)	5.66 (1.48)	5.85 (1.31)	5.91 (1.29)	0.07 (0.16)	0.28 (0.09)	0.22 (0.07)
Median	6.05	6.30	6.30	0	0	0
IQR: Q1, Q3	5.10, 6.70	5.10, 7.00	5.50, 7.00	-0.40, 0.60	-0.20, 0.60	-0.10, 0.50
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0	-3.1, 3.1	-2.6, 3.6	-2.0, 3.5
Week 52						
m	46	125	165			
n	42	113	145	38	106	137
Mean (SD/SE)	5.94 (1.30)	5.96 (1.35)	6.09 (1.16)	0.08 (0.13)	0.36 (0.11)	0.23 (0.08)
Median	6.40	6.40	6.60	0	0	0.10
IQR: Q1, Q3	5.40, 7.00	5.40, 7.00	5.40, 7.00	-0.30, 0.60	-0.20, 0.80	-0.10, 0.70
Min, Max	1.7, 7.0	1.0, 7.0	1.4, 7.0	-2.4, 2.5	-3.3, 3.6	-2.7, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=115)	Visit Result: MGL-3196 100 mg (N=0)	Visit Result: Placebo (N=117)	Change from Baseline: MGL-3196 80 mg (N=115)	Change from Baseline: MGL-3196 100 mg (N=0)	Change from Baseline: Placebo (N=117)
CLDQ-NASH						
Baseline						
m	115	0	117			
n	109	0	105			
Mean (SD)	5.25 (1.21)	N/A	5.21 (1.08)			
Median	5.40	N/A	5.40			
IQR: Q1, Q3	4.50, 6.20	N/A	4.50, 6.10			
Min, Max	1.5, 7.0	N/A	2.0, 7.0			
Week 24						
m	110	0	111			
n	105	0	103	100	0	93
Mean (SD/SE)	5.34 (1.11)	N/A	5.40 (1.11)	0.13 (0.06)	N/A	0.17 (0.07)
Median	5.40	N/A	5.60	0.05	N/A	0
IQR: Q1, Q3	4.70, 6.20	N/A	4.50, 6.20	-0.10, 0.40	N/A	-0.30, 0.50
Min, Max	2.1, 7.0	N/A	2.4, 7.0	-1.8, 2.5	N/A	-1.6, 2.6
Week 52						
m	103	0	105			
n	95	0	89	90	0	80
Mean (SD/SE)	5.34 (1.19)	N/A	5.33 (1.18)	0.11 (0.08)	N/A	0.14 (0.07)
Median	5.60	N/A	5.40	0.10	N/A	0.10
IQR: Q1, Q3	4.50, 6.40	N/A	4.60, 6.30	-0.20, 0.40	N/A	-0.25, 0.50
Min, Max	1.6, 7.0	N/A	1.9, 6.9	-2.7, 2.7	N/A	-1.4, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=115)	Visit Result: MGL-3196 100 mg (N=0)	Visit Result: Placebo (N=117)	Change from Baseline: MGL-3196 80 mg (N=115)	Change from Baseline: MGL-3196 100 mg (N=0)	Change from Baseline: Placebo (N=117)
Abdominal Symptoms						
Baseline						
m	115	0	117			
n	109	0	105			
Mean (SD)	5.30 (1.62)	N/A	5.20 (1.49)			
Median	5.70	N/A	5.30			
IQR: Q1, Q3	4.30, 6.70	N/A	4.30, 6.30			
Min, Max	1.0, 7.0	N/A	1.0, 7.0			
Week 24						
m	110	0	111			
n	105	0	103	100	0	93
Mean (SD/SE)	5.41 (1.31)	N/A	5.47 (1.42)	0.14 (0.11)	N/A	0.27 (0.12)
Median	5.30	N/A	5.70	0	N/A	0
IQR: Q1, Q3	4.70, 6.70	N/A	4.30, 6.70	-0.40, 0.70	N/A	-0.40, 1.00
Min, Max	1.3, 7.0	N/A	1.0, 7.0	-2.4, 3.3	N/A	-2.7, 3.0
Week 52						
m	103	0	105			
n	95	0	89	90	0	80
Mean (SD/SE)	5.51 (1.51)	N/A	5.27 (1.58)	0.21 (0.14)	N/A	0.04 (0.14)
Median	5.70	N/A	5.70	0	N/A	0
IQR: Q1, Q3	4.70, 7.00	N/A	4.30, 6.70	-0.40, 1.00	N/A	-0.70, 0.85
Min, Max	1.0, 7.0	N/A	1.0, 7.0	-2.7, 4.0	N/A	-3.7, 3.3

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Activity						
Baseline						
m	115	0	117			
n	109	0	105			
Mean (SD)	5.29 (1.42)	N/A	5.31 (1.40)			
Median	5.60	N/A	5.40			
IQR: Q1, Q3	4.40, 6.40	N/A	4.40, 6.40			
Min, Max	1.4, 7.0	N/A	1.4, 7.0			
Week 24						
m	110	0	111			
n	105	0	103	100	0	93
Mean (SD/SE)	5.32 (1.41)	N/A	5.52 (1.37)	0.03 (0.09)	N/A	0.21 (0.12)
Median	5.60	N/A	6.00	0	N/A	0.20
IQR: Q1, Q3	4.60, 6.40	N/A	4.60, 6.60	-0.60, 0.50	N/A	-0.60, 0.80
Min, Max	1.6, 7.0	N/A	2.4, 7.0	-1.8, 2.8	N/A	-3.0, 3.2
Week 52						
m	103	0	105			
n	95	0	89	90	0	80
Mean (SD/SE)	5.28 (1.54)	N/A	5.51 (1.43)	-0.03 (0.13)	N/A	0.21 (0.09)
Median	5.60	N/A	6.00	0	N/A	0.10
IQR: Q1, Q3	4.40, 6.60	N/A	4.40, 6.60	-0.60, 0.60	N/A	-0.20, 0.60
Min, Max	1.0, 7.0	N/A	1.4, 7.0	-4.4, 3.0	N/A	-1.4, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=115)	Visit Result: MGL-3196 100 mg (N=0)	Visit Result: Placebo (N=117)	Change from Baseline: MGL-3196 80 mg (N=115)	Change from Baseline: MGL-3196 100 mg (N=0)	Change from Baseline: Placebo (N=117)
Emotional Health						
Baseline						
m	115	0	117			
n	109	0	105			
Mean (SD)	5.41 (1.22)	N/A	5.42 (1.13)			
Median	5.60	N/A	5.70			
IQR: Q1, Q3	4.70, 6.30	N/A	4.70, 6.30			
Min, Max	1.3, 7.0	N/A	1.8, 7.0			
Week 24						
m	110	0	111			
n	105	0	103	100	0	93
Mean (SD/SE)	5.51 (1.18)	N/A	5.51 (1.17)	0.16 (0.07)	N/A	0.05 (0.09)
Median	5.80	N/A	5.80	0.10	N/A	0
IQR: Q1, Q3	4.80, 6.40	N/A	4.80, 6.40	-0.20, 0.60	N/A	-0.60, 0.50
Min, Max	2.2, 7.0	N/A	2.4, 7.0	-1.8, 2.5	N/A	-1.9, 2.6
Week 52						
m	103	0	105			
n	95	0	89	90	0	80
Mean (SD/SE)	5.41 (1.18)	N/A	5.45 (1.20)	0.04 (0.09)	N/A	0.02 (0.10)
Median	5.70	N/A	5.70	0	N/A	0
IQR: Q1, Q3	4.70, 6.20	N/A	4.70, 6.40	-0.40, 0.50	N/A	-0.60, 0.45
Min, Max	1.9, 7.0	N/A	1.7, 7.0	-2.5, 2.9	N/A	-2.0, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Fatigue						
Baseline						
m	115	0	117			
n	109	0	105			
Mean (SD)	4.78 (1.52)	N/A	4.68 (1.46)			
Median	5.20	N/A	5.00			
IQR: Q1, Q3	3.50, 6.00	N/A	3.50, 5.80			
Min, Max	1.2, 7.0	N/A	1.2, 7.0			
Week 24						
m	110	0	111			
n	105	0	103	100	0	93
Mean (SD/SE)	4.79 (1.51)	N/A	4.75 (1.53)	0.05 (0.10)	N/A	0.01 (0.11)
Median	4.80	N/A	5.20	0.05	N/A	0
IQR: Q1, Q3	3.70, 6.00	N/A	3.30, 6.00	-0.50, 0.50	N/A	-0.50, 0.50
Min, Max	1.5, 7.0	N/A	1.3, 7.0	-2.7, 4.1	N/A	-3.8, 3.0
Week 52						
m	103	0	105			
n	95	0	89	90	0	80
Mean (SD/SE)	4.84 (1.54)	N/A	4.70 (1.59)	0.07 (0.12)	N/A	0.07 (0.12)
Median	5.20	N/A	5.00	0	N/A	0.10
IQR: Q1, Q3	3.50, 6.20	N/A	3.70, 6.00	-0.40, 0.50	N/A	-0.45, 0.70
Min, Max	1.5, 7.0	N/A	1.0, 7.0	-2.3, 4.0	N/A	-2.6, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Systemic Symptoms						
Baseline						
m	115	0	117			
n	109	0	105			
Mean (SD)	5.19 (1.29)	N/A	5.20 (1.16)			
Median	5.50	N/A	5.30			
IQR: Q1, Q3	4.30, 6.20	N/A	4.30, 6.00			
Min, Max	1.5, 7.0	N/A	2.5, 7.0			
Week 24						
m	110	0	111			
n	105	0	103	100	0	93
Mean (SD/SE)	5.20 (1.22)	N/A	5.27 (1.16)	0.01 (0.07)	N/A	0.02 (0.09)
Median	5.50	N/A	5.50	0	N/A	0
IQR: Q1, Q3	4.30, 6.00	N/A	4.30, 6.30	-0.40, 0.40	N/A	-0.50, 0.60
Min, Max	1.7, 7.0	N/A	2.3, 7.0	-2.0, 3.5	N/A	-2.5, 2.4
Week 52						
m	103	0	105			
n	95	0	89	90	0	80
Mean (SD/SE)	5.14 (1.29)	N/A	5.23 (1.30)	-0.10 (0.08)	N/A	-0.01 (0.09)
Median	5.50	N/A	5.30	0	N/A	0
IQR: Q1, Q3	4.30, 6.20	N/A	4.30, 6.50	-0.50, 0.30	N/A	-0.50, 0.50
Min, Max	1.3, 7.0	N/A	1.3, 7.0	-2.7, 2.3	N/A	-2.4, 2.7

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE23.5.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Worry						
Baseline						
m	115	0	117			
n	109	0	105			
Mean (SD)	5.53 (1.37)	N/A	5.46 (1.44)			
Median	5.70	N/A	5.90			
IQR: Q1, Q3	4.70, 6.70	N/A	4.70, 6.70			
Min, Max	1.1, 7.0	N/A	1.1, 7.0			
Week 24						
m	110	0	111			
n	105	0	103	100	0	93
Mean (SD/SE)	5.84 (1.32)	N/A	5.84 (1.44)	0.39 (0.10)	N/A	0.45 (0.11)
Median	6.30	N/A	6.40	0.30	N/A	0.30
IQR: Q1, Q3	5.30, 6.90	N/A	5.40, 6.90	0.00, 0.75	N/A	-0.10, 0.90
Min, Max	1.6, 7.0	N/A	1.0, 7.0	-2.4, 3.3	N/A	-2.6, 3.5
Week 52						
m	103	0	105			
n	95	0	89	90	0	80
Mean (SD/SE)	5.86 (1.35)	N/A	5.81 (1.45)	0.42 (0.12)	N/A	0.50 (0.13)
Median	6.40	N/A	6.30	0.25	N/A	0.15
IQR: Q1, Q3	5.30, 7.00	N/A	5.30, 7.00	-0.20, 1.00	N/A	-0.05, 1.10
Min, Max	1.9, 7.0	N/A	1.0, 7.0	-4.8, 3.8	N/A	-2.3, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Weight
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.5.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
CLDQ-NASH			
Week 24			
m	51	141	178
n	47	125	151
Baseline Mean (SD)	5.17 (1.20)	5.27 (1.13)	5.27 (1.13)
Analysis Visit Mean (SD)	5.13 (1.23)	5.25 (1.04)	5.35 (1.11)
LS Mean of Change from Baseline (SE)	-0.04 (0.10)	-0.01 (0.06)	0.09 (0.06)
95% CI	(-0.24, 0.15)	(-0.13, 0.11)	(-0.02, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.11)	-0.11 (0.08)	
95% CI	(-0.36, 0.08)	(-0.26, 0.05)	
p-value	0.2195	0.1841	
Corrected Hedge's g Statistics	-0.201	-0.156	
95% CI	(-0.53, 0.13)	(-0.39, 0.08)	
Week 52			
m	46	125	165
n	38	106	137
Baseline Mean (SD)	5.43 (1.12)	5.29 (1.14)	5.38 (1.06)
Analysis Visit Mean (SD)	5.33 (1.09)	5.29 (1.03)	5.40 (1.07)
LS Mean of Change from Baseline (SE)	-0.06 (0.10)	0.01 (0.06)	0.06 (0.05)
95% CI	(-0.26, 0.14)	(-0.11, 0.14)	(-0.05, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.12 (0.11)	-0.04 (0.08)	
95% CI	(-0.34, 0.10)	(-0.20, 0.12)	
p-value	0.2982	0.6106	
Corrected Hedge's g Statistics	-0.184	-0.064	
95% CI	(-0.54, 0.18)	(-0.32, 0.19)	
Subgroup*Treatment Interaction p-value	0.5003	NE	

AMNOG Table SE23.5.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
CLDQ-NASH			
Week 24			
m	110	0	111
n	100	0	93
Baseline Mean (SD)	5.24 (1.18)	N/A	5.24 (1.09)
Analysis Visit Mean (SD)	5.37 (1.12)	N/A	5.41 (1.07)
LS Mean of Change from Baseline (SE)	0.14 (0.07)	NE	0.17 (0.07)
95% CI	(0.01, 0.28)	NE	(0.03, 0.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.09)	NE	
95% CI	(-0.20, 0.16)	NE	
p-value	0.8041	NE	
Corrected Hedge's g Statistics	-0.034	NE	
95% CI	(-0.32, 0.25)	NE	
Week 52			
m	103	0	105
n	90	0	80
Baseline Mean (SD)	5.23 (1.19)	N/A	5.20 (1.15)
Analysis Visit Mean (SD)	5.34 (1.19)	N/A	5.34 (1.16)
LS Mean of Change from Baseline (SE)	0.10 (0.07)	NE	0.15 (0.07)
95% CI	(-0.04, 0.25)	NE	(0.00, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.10)	NE	
95% CI	(-0.24, 0.15)	NE	
p-value	0.6726	NE	
Corrected Hedge's g Statistics	-0.062	NE	
95% CI	(-0.36, 0.24)	NE	
Subgroup*Treatment Interaction p-value	0.5003	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.5.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Abdominal Symptoms			
Week 24			
m	51	141	178
n	47	125	151
Baseline Mean (SD)	5.23 (1.67)	5.54 (1.40)	5.33 (1.52)
Analysis Visit Mean (SD)	5.25 (1.75)	5.44 (1.49)	5.49 (1.46)
LS Mean of Change from Baseline (SE)	-0.03 (0.16)	-0.05 (0.10)	0.16 (0.09)
95% CI	(-0.35, 0.29)	(-0.25, 0.14)	(-0.02, 0.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.19 (0.18)	-0.21 (0.13)	
95% CI	(-0.55, 0.18)	(-0.47, 0.05)	
p-value	0.3108	0.1175	
Corrected Hedge's g Statistics	-0.166	-0.185	
95% CI	(-0.49, 0.16)	(-0.42, 0.05)	
Week 52			
m	46	125	165
n	38	106	137
Baseline Mean (SD)	5.54 (1.54)	5.65 (1.33)	5.45 (1.39)
Analysis Visit Mean (SD)	5.47 (1.45)	5.58 (1.30)	5.59 (1.27)
LS Mean of Change from Baseline (SE)	-0.05 (0.16)	-0.01 (0.10)	0.17 (0.09)
95% CI	(-0.36, 0.27)	(-0.20, 0.18)	(0.00, 0.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.22 (0.18)	-0.18 (0.13)	
95% CI	(-0.57, 0.13)	(-0.42, 0.07)	
p-value	0.2204	0.1574	
Corrected Hedge's g Statistics	-0.218	-0.178	
95% CI	(-0.58, 0.14)	(-0.43, 0.08)	
Subgroup*Treatment Interaction p-value	0.2950	NE	

AMNOG Table SE23.5.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Activity			
Week 24			
m	51	141	178
n	47	125	151
Baseline Mean (SD)	5.24 (1.39)	5.35 (1.32)	5.52 (1.34)
Analysis Visit Mean (SD)	5.17 (1.51)	5.40 (1.25)	5.51 (1.31)
LS Mean of Change from Baseline (SE)	-0.10 (0.13)	0.03 (0.08)	0.02 (0.07)
95% CI	(-0.35, 0.14)	(-0.12, 0.18)	(-0.11, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (0.14)	0.00 (0.10)	
95% CI	(-0.41, 0.15)	(-0.20, 0.21)	
p-value	0.3729	0.9737	
Corrected Hedge's g Statistics	-0.145	0.004	
95% CI	(-0.47, 0.18)	(-0.23, 0.24)	
Week 52			
m	46	125	165
n	38	106	137
Baseline Mean (SD)	5.53 (1.29)	5.36 (1.34)	5.68 (1.21)
Analysis Visit Mean (SD)	5.44 (1.36)	5.32 (1.26)	5.39 (1.35)
LS Mean of Change from Baseline (SE)	-0.06 (0.14)	-0.03 (0.09)	-0.20 (0.08)
95% CI	(-0.35, 0.22)	(-0.20, 0.14)	(-0.36, -0.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.14 (0.16)	0.17 (0.12)	
95% CI	(-0.18, 0.46)	(-0.05, 0.40)	
p-value	0.3884	0.1315	
Corrected Hedge's g Statistics	0.153	0.191	
95% CI	(-0.21, 0.51)	(-0.06, 0.44)	
Subgroup*Treatment Interaction p-value	0.2909	NE	

AMNOG Table SE23.5.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Emotional Health			
Week 24			
m	51	141	178
n	47	125	151
Baseline Mean (SD)	5.26 (1.32)	5.38 (1.31)	5.42 (1.27)
Analysis Visit Mean (SD)	5.19 (1.33)	5.31 (1.24)	5.45 (1.29)
LS Mean of Change from Baseline (SE)	-0.09 (0.12)	-0.08 (0.07)	0.04 (0.07)
95% CI	(-0.33, 0.14)	(-0.22, 0.07)	(-0.09, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (0.14)	-0.12 (0.10)	
95% CI	(-0.40, 0.13)	(-0.31, 0.07)	
p-value	0.3320	0.2310	
Corrected Hedge's g Statistics	-0.159	-0.141	
95% CI	(-0.49, 0.17)	(-0.38, 0.10)	
Week 52			
m	46	125	165
n	38	106	137
Baseline Mean (SD)	5.53 (1.21)	5.39 (1.36)	5.51 (1.24)
Analysis Visit Mean (SD)	5.46 (0.98)	5.41 (1.21)	5.52 (1.26)
LS Mean of Change from Baseline (SE)	-0.05 (0.11)	0.03 (0.07)	0.03 (0.06)
95% CI	(-0.28, 0.17)	(-0.10, 0.17)	(-0.09, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.13)	0.01 (0.09)	
95% CI	(-0.33, 0.17)	(-0.17, 0.18)	
p-value	0.5253	0.9208	
Corrected Hedge's g Statistics	-0.112	0.012	
95% CI	(-0.47, 0.25)	(-0.24, 0.27)	
Subgroup*Treatment Interaction p-value	0.2707	NE	

AMNOG Table SE23.5.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Fatigue			
Week 24			
m	51	141	178
n	47	125	151
Baseline Mean (SD)	4.67 (1.47)	4.62 (1.47)	4.59 (1.44)
Analysis Visit Mean (SD)	4.57 (1.49)	4.52 (1.38)	4.68 (1.42)
LS Mean of Change from Baseline (SE)	-0.07 (0.14)	-0.11 (0.09)	0.09 (0.08)
95% CI	(-0.35, 0.21)	(-0.28, 0.07)	(-0.07, 0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.16 (0.16)	-0.20 (0.12)	
95% CI	(-0.48, 0.15)	(-0.43, 0.03)	
p-value	0.3106	0.0874	
Corrected Hedge's g Statistics	-0.165	-0.201	
95% CI	(-0.49, 0.16)	(-0.44, 0.04)	
Week 52			
m	46	125	165
n	38	106	137
Baseline Mean (SD)	4.83 (1.48)	4.64 (1.49)	4.72 (1.38)
Analysis Visit Mean (SD)	4.72 (1.47)	4.55 (1.45)	4.71 (1.35)
LS Mean of Change from Baseline (SE)	-0.06 (0.15)	-0.06 (0.09)	0.03 (0.08)
95% CI	(-0.36, 0.25)	(-0.25, 0.12)	(-0.13, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.09 (0.17)	-0.10 (0.12)	
95% CI	(-0.43, 0.25)	(-0.34, 0.14)	
p-value	0.6039	0.4203	
Corrected Hedge's g Statistics	-0.092	-0.101	
95% CI	(-0.45, 0.27)	(-0.35, 0.15)	
Subgroup*Treatment Interaction p-value	0.3499	NE	

AMNOG Table SE23.5.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Systemic Symptoms			
Week 24			
m	51	141	178
n	47	125	151
Baseline Mean (SD)	5.11 (1.28)	5.11 (1.23)	5.04 (1.25)
Analysis Visit Mean (SD)	5.05 (1.27)	4.96 (1.21)	5.03 (1.32)
LS Mean of Change from Baseline (SE)	-0.02 (0.12)	-0.13 (0.07)	0.01 (0.07)
95% CI	(-0.25, 0.22)	(-0.28, 0.01)	(-0.12, 0.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.13)	-0.14 (0.10)	
95% CI	(-0.30, 0.23)	(-0.33, 0.05)	
p-value	0.8135	0.1423	
Corrected Hedge's g Statistics	-0.038	-0.173	
95% CI	(-0.37, 0.29)	(-0.41, 0.06)	
Week 52			
m	46	125	165
n	38	106	137
Baseline Mean (SD)	5.36 (1.14)	5.11 (1.21)	5.06 (1.26)
Analysis Visit Mean (SD)	5.08 (1.31)	5.00 (1.22)	5.07 (1.38)
LS Mean of Change from Baseline (SE)	-0.20 (0.13)	-0.10 (0.08)	0.05 (0.07)
95% CI	(-0.46, 0.07)	(-0.26, 0.06)	(-0.09, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.25 (0.15)	-0.15 (0.10)	
95% CI	(-0.54, 0.04)	(-0.36, 0.05)	
p-value	0.0964	0.1479	
Corrected Hedge's g Statistics	-0.297	-0.182	
95% CI	(-0.66, 0.06)	(-0.44, 0.07)	
Subgroup*Treatment Interaction p-value	0.6516	NE	

AMNOG Table SE23.5.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Worry			
Week 24			
m	51	141	178
n	47	125	151
Baseline Mean (SD)	5.51 (1.48)	5.55 (1.52)	5.70 (1.34)
Analysis Visit Mean (SD)	5.58 (1.49)	5.83 (1.34)	5.92 (1.31)
LS Mean of Change from Baseline (SE)	0.03 (0.13)	0.25 (0.08)	0.24 (0.07)
95% CI	(-0.23, 0.29)	(0.09, 0.41)	(0.09, 0.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.21 (0.15)	0.01 (0.11)	
95% CI	(-0.50, 0.08)	(-0.20, 0.22)	
p-value	0.1635	0.9550	
Corrected Hedge's g Statistics	-0.228	0.007	
95% CI	(-0.56, 0.10)	(-0.23, 0.24)	
Week 52			
m	46	125	165
n	38	106	137
Baseline Mean (SD)	5.78 (1.44)	5.57 (1.55)	5.86 (1.21)
Analysis Visit Mean (SD)	5.86 (1.33)	5.94 (1.38)	6.08 (1.18)
LS Mean of Change from Baseline (SE)	0.08 (0.14)	0.34 (0.09)	0.26 (0.08)
95% CI	(-0.20, 0.36)	(0.17, 0.51)	(0.11, 0.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.18 (0.16)	0.08 (0.11)	
95% CI	(-0.49, 0.13)	(-0.14, 0.30)	
p-value	0.2570	0.4854	
Corrected Hedge's g Statistics	-0.201	0.088	
95% CI	(-0.56, 0.16)	(-0.17, 0.34)	
Subgroup*Treatment Interaction p-value	0.4214	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Abdominal Symptoms			
Week 24			
m	110	0	111
n	100	0	93
Baseline Mean (SD)	5.31 (1.62)	N/A	5.25 (1.49)
Analysis Visit Mean (SD)	5.45 (1.32)	N/A	5.51 (1.35)
LS Mean of Change from Baseline (SE)	0.19 (0.10)	NE	0.27 (0.10)
95% CI	(-0.02, 0.39)	NE	(0.07, 0.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.09 (0.14)	NE	
95% CI	(-0.36, 0.19)	NE	
p-value	0.5399	NE	
Corrected Hedge's g Statistics	-0.084	NE	
95% CI	(-0.37, 0.20)	NE	
Week 52			
m	103	0	105
n	90	0	80
Baseline Mean (SD)	5.30 (1.61)	N/A	5.21 (1.56)
Analysis Visit Mean (SD)	5.50 (1.54)	N/A	5.25 (1.55)
LS Mean of Change from Baseline (SE)	0.23 (0.13)	NE	0.07 (0.13)
95% CI	(-0.02, 0.48)	NE	(-0.19, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.16 (0.18)	NE	
95% CI	(-0.19, 0.51)	NE	
p-value	0.3671	NE	
Corrected Hedge's g Statistics	0.134	NE	
95% CI	(-0.17, 0.44)	NE	
Subgroup*Treatment Interaction p-value	0.2950	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Activity			
Week 24			
m	110	0	111
n	100	0	93
Baseline Mean (SD)	5.29 (1.41)	N/A	5.34 (1.38)
Analysis Visit Mean (SD)	5.32 (1.43)	N/A	5.55 (1.34)
LS Mean of Change from Baseline (SE)	0.05 (0.10)	NE	0.20 (0.10)
95% CI	(-0.15, 0.24)	NE	(0.00, 0.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (0.13)	NE	
95% CI	(-0.42, 0.11)	NE	
p-value	0.2519	NE	
Corrected Hedge's g Statistics	-0.158	NE	
95% CI	(-0.44, 0.12)	NE	
Week 52			
m	103	0	105
n	90	0	80
Baseline Mean (SD)	5.28 (1.40)	N/A	5.31 (1.40)
Analysis Visit Mean (SD)	5.25 (1.57)	N/A	5.52 (1.46)
LS Mean of Change from Baseline (SE)	-0.03 (0.11)	NE	0.21 (0.11)
95% CI	(-0.24, 0.18)	NE	(0.00, 0.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.24 (0.15)	NE	
95% CI	(-0.53, 0.05)	NE	
p-value	0.1051	NE	
Corrected Hedge's g Statistics	-0.240	NE	
95% CI	(-0.54, 0.06)	NE	
Subgroup*Treatment Interaction p-value	0.2909	NE	

AMNOG Table SE23.5.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Emotional Health			
Week 24			
m	110	0	111
n	100	0	93
Baseline Mean (SD)	5.40 (1.20)	N/A	5.43 (1.15)
Analysis Visit Mean (SD)	5.56 (1.17)	N/A	5.48 (1.14)
LS Mean of Change from Baseline (SE)	0.14 (0.08)	NE	0.03 (0.08)
95% CI	(-0.02, 0.29)	NE	(-0.13, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.11 (0.11)	NE	
95% CI	(-0.11, 0.32)	NE	
p-value	0.3283	NE	
Corrected Hedge's g Statistics	0.135	NE	
95% CI	(-0.15, 0.42)	NE	
Week 52			
m	103	0	105
n	90	0	80
Baseline Mean (SD)	5.38 (1.23)	N/A	5.42 (1.23)
Analysis Visit Mean (SD)	5.43 (1.16)	N/A	5.44 (1.21)
LS Mean of Change from Baseline (SE)	0.00 (0.09)	NE	-0.01 (0.09)
95% CI	(-0.17, 0.18)	NE	(-0.19, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.12)	NE	
95% CI	(-0.23, 0.26)	NE	
p-value	0.9249	NE	
Corrected Hedge's g Statistics	0.014	NE	
95% CI	(-0.29, 0.32)	NE	
Subgroup*Treatment Interaction p-value	0.2707	NE	

AMNOG Table SE23.5.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Fatigue			
Week 24			
m	110	0	111
n	100	0	93
Baseline Mean (SD)	4.79 (1.50)	N/A	4.73 (1.47)
Analysis Visit Mean (SD)	4.84 (1.50)	N/A	4.74 (1.54)
LS Mean of Change from Baseline (SE)	0.05 (0.11)	NE	-0.05 (0.11)
95% CI	(-0.16, 0.25)	NE	(-0.26, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (0.14)	NE	
95% CI	(-0.19, 0.38)	NE	
p-value	0.5193	NE	
Corrected Hedge's g Statistics	0.089	NE	
95% CI	(-0.19, 0.37)	NE	
Week 52			
m	103	0	105
n	90	0	80
Baseline Mean (SD)	4.78 (1.52)	N/A	4.66 (1.48)
Analysis Visit Mean (SD)	4.85 (1.53)	N/A	4.74 (1.60)
LS Mean of Change from Baseline (SE)	0.03 (0.11)	NE	0.02 (0.12)
95% CI	(-0.19, 0.25)	NE	(-0.21, 0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.16)	NE	
95% CI	(-0.30, 0.32)	NE	
p-value	0.9580	NE	
Corrected Hedge's g Statistics	0.008	NE	
95% CI	(-0.29, 0.31)	NE	
Subgroup*Treatment Interaction p-value	0.3499	NE	

AMNOG Table SE23.5.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Systemic Symptoms			
Week 24			
m	110	0	111
n	100	0	93
Baseline Mean (SD)	5.17 (1.26)	N/A	5.27 (1.15)
Analysis Visit Mean (SD)	5.18 (1.25)	N/A	5.30 (1.14)
LS Mean of Change from Baseline (SE)	0.01 (0.08)	NE	0.02 (0.08)
95% CI	(-0.14, 0.16)	NE	(-0.13, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.11)	NE	
95% CI	(-0.22, 0.19)	NE	
p-value	0.8844	NE	
Corrected Hedge's g Statistics	-0.020	NE	
95% CI	(-0.30, 0.26)	NE	
Week 52			
m	103	0	105
n	90	0	80
Baseline Mean (SD)	5.20 (1.26)	N/A	5.24 (1.20)
Analysis Visit Mean (SD)	5.10 (1.30)	N/A	5.23 (1.27)
LS Mean of Change from Baseline (SE)	-0.08 (0.08)	NE	0.02 (0.09)
95% CI	(-0.25, 0.08)	NE	(-0.15, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.11)	NE	
95% CI	(-0.33, 0.13)	NE	
p-value	0.3863	NE	
Corrected Hedge's g Statistics	-0.128	NE	
95% CI	(-0.43, 0.17)	NE	
Subgroup*Treatment Interaction p-value	0.6516	NE	

AMNOG Table SE23.5.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Worry			
Week 24			
m	110	0	111
n	100	0	93
Baseline Mean (SD)	5.50 (1.37)	N/A	5.44 (1.46)
Analysis Visit Mean (SD)	5.89 (1.27)	N/A	5.89 (1.38)
LS Mean of Change from Baseline (SE)	0.42 (0.10)	NE	0.46 (0.10)
95% CI	(0.23, 0.61)	NE	(0.27, 0.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.13)	NE	
95% CI	(-0.30, 0.22)	NE	
p-value	0.7724	NE	
Corrected Hedge's g Statistics	-0.040	NE	
95% CI	(-0.32, 0.24)	NE	
Week 52			
m	103	0	105
n	90	0	80
Baseline Mean (SD)	5.48 (1.41)	N/A	5.39 (1.54)
Analysis Visit Mean (SD)	5.90 (1.31)	N/A	5.88 (1.39)
LS Mean of Change from Baseline (SE)	0.42 (0.11)	NE	0.49 (0.12)
95% CI	(0.20, 0.64)	NE	(0.26, 0.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.15)	NE	
95% CI	(-0.37, 0.24)	NE	
p-value	0.6894	NE	
Corrected Hedge's g Statistics	-0.059	NE	
95% CI	(-0.36, 0.24)	NE	
Subgroup*Treatment Interaction p-value	0.4214	NE	

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.9)	11 (7.3)	17 (9.1)
No	51 (98.1)	140 (92.7)	169 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.13	1.28	
95% CI of the inverse odds ratio	(0.67, 39.49)	(0.58, 2.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.75	1.25	
95% CI of the inverse risk ratio	(0.65, 34.88)	(0.61, 2.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.22	-1.86	
95% CI of the absolute risk difference	(-12.79, -1.64)	(-7.71, 4.00)	
p-value	0.0819	0.5395	
p-value of Breslow-Day Test for Homogeneity [3]	0.0952	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (17.3)	31 (20.5)	39 (21.0)
No	43 (82.7)	120 (79.5)	147 (79.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	1.03	
95% CI of the inverse odds ratio	(0.57, 2.82)	(0.60, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.02	
95% CI of the inverse risk ratio	(0.63, 2.34)	(0.67, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.66	-0.44	
95% CI of the absolute risk difference	(-15.49, 8.17)	(-9.14, 8.26)	
p-value	0.5609	0.9215	
p-value of Breslow-Day Test for Homogeneity [3]	0.7365	NE	

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (15.4)	17 (11.3)	34 (18.3)
No	44 (84.6)	134 (88.7)	152 (81.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	1.76	
95% CI of the inverse odds ratio	(0.53, 2.85)	(0.94, 3.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	1.62	
95% CI of the inverse risk ratio	(0.59, 2.41)	(0.95, 2.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.89	-7.02	
95% CI of the absolute risk difference	(-14.17, 8.38)	(-14.52, 0.48)	
p-value	0.6283	0.0737	
p-value of Breslow-Day Test for Homogeneity [3]	0.4634	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (28.8)	30 (19.9)	63 (33.9)
No	37 (71.2)	121 (80.1)	123 (66.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	2.07	
95% CI of the inverse odds ratio	(0.64, 2.47)	(1.25, 3.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	1.70	
95% CI of the inverse risk ratio	(0.73, 1.88)	(1.17, 2.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.02	-14.00	
95% CI of the absolute risk difference	(-19.09, 9.04)	(-23.32, -4.69)	
p-value	0.4950	0.0042	
p-value of Breslow-Day Test for Homogeneity [3]	0.1931	NE	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (5.8)	16 (10.6)	12 (6.5)
No	49 (94.2)	135 (89.4)	174 (93.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	0.58	
95% CI of the inverse odds ratio	(0.31, 4.15)	(0.27, 1.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	0.61	
95% CI of the inverse risk ratio	(0.33, 3.82)	(0.30, 1.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.68	4.14	
95% CI of the absolute risk difference	(-7.94, 6.57)	(-1.90, 10.19)	
p-value	0.8579	0.1704	
p-value of Breslow-Day Test for Homogeneity [3]	0.5344	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (23.1)	37 (24.5)	33 (17.7)
No	40 (76.9)	114 (75.5)	153 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.66	
95% CI of the inverse odds ratio	(0.34, 1.52)	(0.39, 1.13)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.72	
95% CI of the inverse risk ratio	(0.43, 1.38)	(0.48, 1.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.33	6.76	
95% CI of the absolute risk difference	(-7.36, 18.03)	(-2.03, 15.55)	
p-value	0.3851	0.1281	
p-value of Breslow-Day Test for Homogeneity [3]	0.6416	NE	

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (11.5)	14 (9.3)	14 (7.5)
No	46 (88.5)	137 (90.7)	172 (92.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.80	
95% CI of the inverse odds ratio	(0.23, 1.71)	(0.37, 1.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	0.81	
95% CI of the inverse risk ratio	(0.26, 1.61)	(0.40, 1.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.01	1.74	
95% CI of the absolute risk difference	(-5.46, 13.49)	(-4.24, 7.73)	
p-value	0.3567	0.5639	
p-value of Breslow-Day Test for Homogeneity [3]	0.5861	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (17.3)	35 (23.2)	45 (24.2)
No	43 (82.7)	116 (76.8)	141 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	1.06	
95% CI of the inverse odds ratio	(0.69, 3.37)	(0.64, 1.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.04	
95% CI of the inverse risk ratio	(0.73, 2.67)	(0.71, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.89	-1.01	
95% CI of the absolute risk difference	(-18.87, 5.10)	(-10.13, 8.11)	
p-value	0.2946	0.8276	
p-value of Breslow-Day Test for Homogeneity [3]	0.3827	NE	

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (5.8)	21 (13.9)	24 (12.9)
No	49 (94.2)	130 (86.1)	162 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.42	0.92	
95% CI of the inverse odds ratio	(0.70, 8.38)	(0.49, 1.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.24	0.93	
95% CI of the inverse risk ratio	(0.70, 7.14)	(0.54, 1.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.13	1.00	
95% CI of the absolute risk difference	(-15.09, 0.83)	(-6.32, 8.33)	
p-value	0.1516	0.7876	
p-value of Breslow-Day Test for Homogeneity [3]	0.3302	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (23.1)	35 (23.2)	47 (25.3)
No	40 (76.9)	116 (76.8)	139 (74.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	1.12	
95% CI of the inverse odds ratio	(0.55, 2.33)	(0.68, 1.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.09	
95% CI of the inverse risk ratio	(0.63, 1.91)	(0.74, 1.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.19	-2.09	
95% CI of the absolute risk difference	(-15.24, 10.85)	(-11.27, 7.09)	
p-value	0.7462	0.6566	
p-value of Breslow-Day Test for Homogeneity [3]	0.8283	NE	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.8)	12 (7.9)	20 (10.8)
No	50 (96.2)	139 (92.1)	166 (89.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.01	1.40	
95% CI of the inverse odds ratio	(0.68, 13.33)	(0.66, 2.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.80	1.35	
95% CI of the inverse risk ratio	(0.68, 11.57)	(0.68, 2.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.91	-2.81	
95% CI of the absolute risk difference	(-13.77, -0.04)	(-9.00, 3.39)	
p-value	0.1285	0.3823	
p-value of Breslow-Day Test for Homogeneity [3]	0.3774	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (17.3)	35 (23.2)	49 (26.3)
No	43 (82.7)	116 (76.8)	137 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	1.19	
95% CI of the inverse odds ratio	(0.78, 3.76)	(0.72, 1.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	1.14	
95% CI of the inverse risk ratio	(0.80, 2.89)	(0.78, 1.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.04	-3.17	
95% CI of the absolute risk difference	(-21.11, 3.04)	(-12.41, 6.07)	
p-value	0.1797	0.5041	
p-value of Breslow-Day Test for Homogeneity [3]	0.3126	NE	

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (9.6)	26 (17.2)	27 (14.5)
No	47 (90.4)	125 (82.8)	159 (85.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.60	0.82	
95% CI of the inverse odds ratio	(0.58, 4.37)	(0.45, 1.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	0.84	
95% CI of the inverse risk ratio	(0.61, 3.73)	(0.51, 1.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.90	2.70	
95% CI of the absolute risk difference	(-14.38, 4.58)	(-5.16, 10.57)	
p-value	0.3598	0.4980	
p-value of Breslow-Day Test for Homogeneity [3]	0.4147	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (23.1)	44 (29.1)	61 (32.8)
No	40 (76.9)	107 (70.9)	125 (67.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.63	1.19	
95% CI of the inverse odds ratio	(0.80, 3.32)	(0.74, 1.89)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	1.13	
95% CI of the inverse risk ratio	(0.83, 2.43)	(0.82, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.72	-3.66	
95% CI of the absolute risk difference	(-23.01, 3.57)	(-13.56, 6.25)	
p-value	0.1791	0.4710	
p-value of Breslow-Day Test for Homogeneity [3]	0.0873	NE	

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (8.7)	0	9 (7.7)
No	105 (91.3)	0	108 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse odds ratio	(0.34, 2.24)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.37, 2.10)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.00	NE	
95% CI of the absolute risk difference	(-6.06, 8.06)	NE	
p-value	0.7805	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0952	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (25.2)	0	31 (26.5)
No	86 (74.8)	0	86 (73.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	NE	
95% CI of the inverse odds ratio	(0.59, 1.92)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	NE	
95% CI of the inverse risk ratio	(0.68, 1.62)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.28	NE	
95% CI of the absolute risk difference	(-12.55, 9.99)	NE	
p-value	0.8241	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7365	NE	

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	23 (20.0)	0	20 (17.1)
No	92 (80.0)	0	97 (82.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	NE	
95% CI of the inverse odds ratio	(0.42, 1.60)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	NE	
95% CI of the inverse risk ratio	(0.50, 1.47)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.91	NE	
95% CI of the absolute risk difference	(-7.09, 12.90)	NE	
p-value	0.5690	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4634	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	41 (35.7)	0	33 (28.2)
No	74 (64.3)	0	84 (71.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	NE	
95% CI of the inverse odds ratio	(0.41, 1.23)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	NE	
95% CI of the inverse risk ratio	(0.54, 1.16)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.45	NE	
95% CI of the absolute risk difference	(-4.52, 19.41)	NE	
p-value	0.2237	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1931	NE	

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (13.0)	0	11 (9.4)
No	100 (87.0)	0	106 (90.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	NE	
95% CI of the inverse odds ratio	(0.30, 1.58)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	NE	
95% CI of the inverse risk ratio	(0.35, 1.50)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.64	NE	
95% CI of the absolute risk difference	(-4.47, 11.76)	NE	
p-value	0.3793	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5344	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	35 (30.4)	0	33 (28.2)
No	80 (69.6)	0	84 (71.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	NE	
95% CI of the inverse odds ratio	(0.51, 1.58)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	NE	
95% CI of the inverse risk ratio	(0.62, 1.38)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.23	NE	
95% CI of the absolute risk difference	(-9.48, 13.94)	NE	
p-value	0.7091	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6416	NE	

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (11.3)	0	12 (10.3)
No	102 (88.7)	0	105 (89.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	NE	
95% CI of the inverse odds ratio	(0.39, 2.06)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	NE	
95% CI of the inverse risk ratio	(0.43, 1.90)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.05	NE	
95% CI of the absolute risk difference	(-6.93, 9.03)	NE	
p-value	0.7969	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5861	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (23.5)	0	27 (23.1)
No	88 (76.5)	0	90 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	NE	
95% CI of the inverse odds ratio	(0.53, 1.80)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	NE	
95% CI of the inverse risk ratio	(0.62, 1.57)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.40	NE	
95% CI of the absolute risk difference	(-10.48, 11.28)	NE	
p-value	0.9423	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3827	NE	

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (10.4)	0	14 (12.0)
No	103 (89.6)	0	103 (88.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	NE	
95% CI of the inverse odds ratio	(0.51, 2.64)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	NE	
95% CI of the inverse risk ratio	(0.55, 2.37)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.53	NE	
95% CI of the absolute risk difference	(-9.64, 6.58)	NE	
p-value	0.7117	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3302	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (28.7)	0	34 (29.1)
No	82 (71.3)	0	83 (70.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	NE	
95% CI of the inverse odds ratio	(0.58, 1.80)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	NE	
95% CI of the inverse risk ratio	(0.68, 1.52)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.36	NE	
95% CI of the absolute risk difference	(-12.03, 11.30)	NE	
p-value	0.9512	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8283	NE	

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (5.2)	0	8 (6.8)
No	109 (94.8)	0	109 (93.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	NE	
95% CI of the inverse odds ratio	(0.45, 3.97)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	NE	
95% CI of the inverse risk ratio	(0.47, 3.66)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.62	NE	
95% CI of the absolute risk difference	(-7.74, 4.50)	NE	
p-value	0.6043	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3774	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (23.5)	0	28 (23.9)
No	88 (76.5)	0	89 (76.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	NE	
95% CI of the inverse odds ratio	(0.56, 1.88)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	NE	
95% CI of the inverse risk ratio	(0.64, 1.62)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.45	NE	
95% CI of the absolute risk difference	(-11.40, 10.49)	NE	
p-value	0.9353	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3126	NE	

AMNOG Table SE23.5.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	26 (22.6)	0	26 (22.2)
No	89 (77.4)	0	91 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	NE	
95% CI of the inverse odds ratio	(0.53, 1.81)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	NE	
95% CI of the inverse risk ratio	(0.61, 1.59)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.39	NE	
95% CI of the absolute risk difference	(-10.35, 11.12)	NE	
p-value	0.9437	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4147	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	45 (39.1)	0	38 (32.5)
No	70 (60.9)	0	79 (67.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	NE	
95% CI of the inverse odds ratio	(0.44, 1.28)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	NE	
95% CI of the inverse risk ratio	(0.59, 1.17)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.65	NE	
95% CI of the absolute risk difference	(-5.66, 18.96)	NE	
p-value	0.2906	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0873	NE	

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
CLDQ-NASH						
Baseline						
m	7	0	8			
n	7	0	8			
Mean (SD)	5.51 (1.65)	N/A	5.33 (0.71)			
Median	5.90	N/A	5.30			
IQR: Q1, Q3	5.70, 6.60	N/A	4.95, 5.85			
Min, Max	1.9, 6.8	N/A	4.1, 6.3			
Week 24						
m	6	0	7			
n	6	0	7	6	0	7
Mean (SD/SE)	5.13 (1.56)	N/A	5.40 (0.96)	-0.20 (0.27)	N/A	-0.10 (0.25)
Median	5.60	N/A	5.60	-0.15	N/A	0.10
IQR: Q1, Q3	5.10, 5.80	N/A	4.30, 5.80	-0.60, 0.20	N/A	-0.80, 0.50
Min, Max	2.1, 6.6	N/A	4.0, 6.8	-1.2, 0.7	N/A	-0.9, 0.8
Week 52						
m	6	0	6			
n	6	0	5	6	0	5
Mean (SD/SE)	5.52 (1.29)	N/A	5.36 (1.00)	0.18 (0.36)	N/A	-0.06 (0.36)
Median	5.55	N/A	5.70	-0.25	N/A	0.20
IQR: Q1, Q3	5.40, 6.40	N/A	5.70, 5.70	-0.50, 1.30	N/A	-0.40, 0.50
Min, Max	3.2, 7.0	N/A	3.6, 6.1	-0.5, 1.3	N/A	-1.3, 0.7

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Abdominal Symptoms						
Baseline						
m	7	0	8			
n	7	0	8			
Mean (SD)	5.67 (1.78)	N/A	5.20 (0.88)			
Median	6.30	N/A	5.30			
IQR: Q1, Q3	4.70, 6.70	N/A	4.50, 5.65			
Min, Max	2.0, 7.0	N/A	4.0, 6.7			
Week 24						
m	6	0	7			
n	6	0	7	6	0	7
Mean (SD/SE)	5.50 (1.80)	N/A	5.47 (1.20)	-0.07 (0.70)	N/A	0.10 (0.45)
Median	6.00	N/A	5.30	0.35	N/A	0.70
IQR: Q1, Q3	4.30, 7.00	N/A	4.30, 6.70	-1.70, 0.70	N/A	-1.00, 1.00
Min, Max	2.7, 7.0	N/A	3.7, 7.0	-2.4, 2.3	N/A	-1.4, 1.4
Week 52						
m	6	0	6			
n	6	0	5	6	0	5
Mean (SD/SE)	6.50 (0.58)	N/A	5.20 (1.60)	0.93 (0.77)	N/A	-0.20 (0.68)
Median	6.65	N/A	5.30	0.35	N/A	0.30
IQR: Q1, Q3	6.00, 7.00	N/A	5.00, 6.00	-0.40, 2.30	N/A	-0.70, 1.00
Min, Max	5.7, 7.0	N/A	2.7, 7.0	-1.0, 4.0	N/A	-2.6, 1.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Activity						
Baseline						
m	7	0	8			
n	7	0	8			
Mean (SD)	5.46 (1.90)	N/A	5.20 (1.07)			
Median	6.20	N/A	5.20			
IQR: Q1, Q3	4.20, 7.00	N/A	4.50, 5.80			
Min, Max	1.8, 7.0	N/A	3.6, 7.0			
Week 24						
m	6	0	7			
n	6	0	7	6	0	7
Mean (SD/SE)	4.67 (1.65)	N/A	5.26 (1.37)	-0.53 (0.17)	N/A	-0.17 (0.32)
Median	5.40	N/A	5.40	-0.40	N/A	-0.60
IQR: Q1, Q3	4.00, 5.80	N/A	3.80, 6.40	-0.80, -0.20	N/A	-0.80, 1.00
Min, Max	1.6, 5.8	N/A	3.4, 7.0	-1.2, -0.2	N/A	-1.0, 1.0
Week 52						
m	6	0	6			
n	6	0	5	6	0	5
Mean (SD/SE)	5.57 (1.74)	N/A	5.44 (1.03)	0.37 (0.53)	N/A	0.08 (0.39)
Median	5.90	N/A	5.80	0.10	N/A	-0.40
IQR: Q1, Q3	5.60, 6.80	N/A	4.80, 6.00	-0.20, 0.40	N/A	-0.40, 0.80
Min, Max	2.2, 7.0	N/A	4.0, 6.6	-1.0, 2.8	N/A	-0.8, 1.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Emotional Health						
Baseline						
m	7	0	8			
n	7	0	8			
Mean (SD)	5.74 (1.52)	N/A	5.59 (0.69)			
Median	6.10	N/A	5.50			
IQR: Q1, Q3	5.20, 7.00	N/A	5.00, 6.30			
Min, Max	2.6, 7.0	N/A	4.7, 6.4			
Week 24						
m	6	0	7			
n	6	0	7	6	0	7
Mean (SD/SE)	5.45 (1.47)	N/A	5.67 (0.98)	-0.18 (0.27)	N/A	-0.04 (0.22)
Median	5.85	N/A	6.00	-0.05	N/A	0.20
IQR: Q1, Q3	5.10, 6.40	N/A	4.60, 6.60	-0.60, 0.10	N/A	-0.60, 0.40
Min, Max	2.7, 6.8	N/A	4.1, 6.7	-1.2, 0.7	N/A	-0.9, 0.7
Week 52						
m	6	0	6			
n	6	0	5	6	0	5
Mean (SD/SE)	5.25 (1.37)	N/A	5.66 (1.09)	-0.38 (0.52)	N/A	-0.02 (0.37)
Median	5.45	N/A	5.90	-0.20	N/A	0.10
IQR: Q1, Q3	4.20, 6.20	N/A	5.90, 6.00	-1.70, 0.60	N/A	-0.40, 0.50
Min, Max	3.2, 7.0	N/A	3.8, 6.7	-1.9, 1.1	N/A	-1.2, 0.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Fatigue						
Baseline						
m	7	0	8			
n	7	0	8			
Mean (SD)	5.26 (1.88)	N/A	5.35 (0.70)			
Median	5.80	N/A	5.25			
IQR: Q1, Q3	5.20, 6.50	N/A	5.10, 5.60			
Min, Max	1.2, 6.8	N/A	4.2, 6.7			
Week 24						
m	6	0	7			
n	6	0	7	6	0	7
Mean (SD/SE)	4.92 (1.83)	N/A	5.06 (1.27)	-0.13 (0.25)	N/A	-0.46 (0.39)
Median	5.10	N/A	5.50	-0.15	N/A	0
IQR: Q1, Q3	4.80, 6.50	N/A	3.70, 5.80	-0.50, 0.30	N/A	-1.50, 0.30
Min, Max	1.5, 6.5	N/A	3.0, 6.7	-1.0, 0.7	N/A	-2.3, 0.5
Week 52						
m	6	0	6			
n	6	0	5	6	0	5
Mean (SD/SE)	4.77 (2.04)	N/A	5.12 (0.86)	-0.28 (0.63)	N/A	-0.20 (0.38)
Median	4.50	N/A	5.30	0.05	N/A	0.10
IQR: Q1, Q3	3.80, 7.00	N/A	5.00, 5.80	-2.00, 0.60	N/A	-0.50, 0.10
Min, Max	1.8, 7.0	N/A	3.7, 5.8	-2.2, 1.8	N/A	-1.5, 0.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Systemic Symptoms						
Baseline						
m	7	0	8			
n	7	0	8			
Mean (SD)	5.37 (1.67)	N/A	4.90 (0.90)			
Median	6.00	N/A	5.15			
IQR: Q1, Q3	4.70, 6.80	N/A	4.35, 5.50			
Min, Max	2.2, 7.0	N/A	3.2, 6.0			
Week 24						
m	6	0	7			
n	6	0	7	6	0	7
Mean (SD/SE)	4.95 (1.64)	N/A	4.90 (1.12)	-0.18 (0.21)	N/A	-0.24 (0.41)
Median	5.05	N/A	4.80	-0.20	N/A	-0.50
IQR: Q1, Q3	4.30, 6.30	N/A	4.00, 5.80	-0.70, 0.10	N/A	-0.80, 1.10
Min, Max	2.2, 6.8	N/A	3.5, 6.7	-0.7, 0.6	N/A	-1.8, 1.2
Week 52						
m	6	0	6			
n	6	0	5	6	0	5
Mean (SD/SE)	5.38 (1.42)	N/A	5.06 (0.93)	0.25 (0.47)	N/A	-0.14 (0.41)
Median	5.50	N/A	5.00	-0.15	N/A	-0.50
IQR: Q1, Q3	4.80, 6.50	N/A	4.30, 5.30	-0.50, 0.80	N/A	-0.70, 0.50
Min, Max	3.0, 7.0	N/A	4.2, 6.5	-0.8, 2.3	N/A	-1.1, 1.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Worry						
Baseline						
m	7	0	8			
n	7	0	8			
Mean (SD)	5.64 (1.72)	N/A	5.69 (1.03)			
Median	6.40	N/A	5.95			
IQR: Q1, Q3	5.00, 6.60	N/A	4.90, 6.50			
Min, Max	2.0, 7.0	N/A	3.9, 6.9			
Week 24						
m	6	0	7			
n	6	0	7	6	0	7
Mean (SD/SE)	5.38 (1.92)	N/A	5.99 (1.40)	-0.13 (0.41)	N/A	0.16 (0.21)
Median	6.00	N/A	6.40	0.05	N/A	0.40
IQR: Q1, Q3	4.30, 6.90	N/A	5.60, 7.00	0.00, 0.40	N/A	-0.20, 0.60
Min, Max	2.1, 7.0	N/A	3.0, 7.0	-2.1, 0.8	N/A	-0.9, 0.6
Week 52						
m	6	0	6			
n	6	0	5	6	0	5
Mean (SD/SE)	5.62 (1.38)	N/A	5.68 (1.17)	0.10 (0.25)	N/A	0.08 (0.30)
Median	5.85	N/A	6.10	0	N/A	0
IQR: Q1, Q3	5.60, 6.40	N/A	6.00, 6.30	-0.40, 0.60	N/A	-0.30, 0.00
Min, Max	3.0, 7.0	N/A	3.6, 6.4	-0.6, 1.0	N/A	-0.5, 1.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
CLDQ-NASH						
Baseline						
m	47	0	62			
n	44	0	54			
Mean (SD)	5.40 (1.16)	N/A	5.36 (1.18)			
Median	5.50	N/A	5.65			
IQR: Q1, Q3	4.85, 6.35	N/A	4.50, 6.20			
Min, Max	1.5, 7.0	N/A	2.0, 7.0			
Week 24						
m	46	0	59			
n	44	0	54	41	0	48
Mean (SD/SE)	5.41 (1.14)	N/A	5.66 (0.92)	0.08 (0.06)	N/A	0.21 (0.11)
Median	5.55	N/A	5.90	0	N/A	0
IQR: Q1, Q3	4.75, 6.35	N/A	5.10, 6.30	-0.20, 0.30	N/A	-0.25, 0.50
Min, Max	2.1, 7.0	N/A	2.6, 7.0	-0.7, 1.1	N/A	-0.9, 2.6
Week 52						
m	44	0	56			
n	42	0	46	39	0	40
Mean (SD/SE)	5.43 (1.21)	N/A	5.43 (1.18)	0.11 (0.08)	N/A	0.00 (0.11)
Median	5.85	N/A	5.50	0	N/A	-0.05
IQR: Q1, Q3	4.70, 6.40	N/A	5.00, 6.40	-0.20, 0.30	N/A	-0.35, 0.30
Min, Max	1.6, 7.0	N/A	2.2, 6.9	-1.4, 1.3	N/A	-1.5, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Abdominal Symptoms						
Baseline						
m	47	0	62			
n	44	0	54			
Mean (SD)	5.48 (1.63)	N/A	5.29 (1.63)			
Median	6.00	N/A	5.70			
IQR: Q1, Q3	4.15, 7.00	N/A	3.70, 7.00			
Min, Max	1.0, 7.0	N/A	1.0, 7.0			
Week 24						
m	46	0	59			
n	44	0	54	41	0	48
Mean (SD/SE)	5.42 (1.35)	N/A	5.63 (1.25)	0.02 (0.11)	N/A	0.25 (0.19)
Median	5.50	N/A	6.00	0	N/A	0
IQR: Q1, Q3	4.30, 6.70	N/A	4.70, 6.70	-0.30, 0.30	N/A	-0.45, 1.30
Min, Max	2.0, 7.0	N/A	3.0, 7.0	-2.0, 1.3	N/A	-2.6, 3.0
Week 52						
m	44	0	56			
n	42	0	46	39	0	40
Mean (SD/SE)	5.41 (1.43)	N/A	5.35 (1.56)	0.02 (0.15)	N/A	-0.14 (0.24)
Median	5.50	N/A	5.70	0	N/A	-0.15
IQR: Q1, Q3	4.70, 6.70	N/A	4.30, 7.00	-0.30, 0.70	N/A	-0.85, 0.65
Min, Max	1.3, 7.0	N/A	1.0, 7.0	-2.0, 2.7	N/A	-4.6, 3.3

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Activity						
Baseline						
m	47	0	62			
n	44	0	54			
Mean (SD)	5.50 (1.35)	N/A	5.41 (1.44)			
Median	5.80	N/A	5.80			
IQR: Q1, Q3	4.60, 6.60	N/A	4.40, 6.60			
Min, Max	1.4, 7.0	N/A	1.4, 7.0			
Week 24						
m	46	0	59			
n	44	0	54	41	0	48
Mean (SD/SE)	5.52 (1.52)	N/A	5.79 (1.24)	0.04 (0.12)	N/A	0.34 (0.15)
Median	5.90	N/A	6.20	0	N/A	0.10
IQR: Q1, Q3	4.80, 6.80	N/A	5.20, 6.80	-0.20, 0.40	N/A	-0.40, 0.80
Min, Max	1.8, 7.0	N/A	2.2, 7.0	-1.6, 1.6	N/A	-1.6, 3.2
Week 52						
m	44	0	56			
n	42	0	46	39	0	40
Mean (SD/SE)	5.58 (1.58)	N/A	5.53 (1.52)	0.05 (0.18)	N/A	0.15 (0.15)
Median	5.90	N/A	6.20	0.20	N/A	0
IQR: Q1, Q3	4.80, 7.00	N/A	4.40, 6.60	-0.40, 0.60	N/A	-0.20, 0.60
Min, Max	1.6, 7.0	N/A	1.4, 7.0	-4.4, 2.8	N/A	-2.2, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Emotional Health						
Baseline						
m	47	0	62			
n	44	0	54			
Mean (SD)	5.48 (1.14)	N/A	5.50 (1.12)			
Median	5.60	N/A	5.70			
IQR: Q1, Q3	4.75, 6.35	N/A	4.80, 6.30			
Min, Max	1.9, 7.0	N/A	2.8, 7.0			
Week 24						
m	46	0	59			
n	44	0	54	41	0	48
Mean (SD/SE)	5.56 (1.08)	N/A	5.70 (1.00)	0.17 (0.09)	N/A	0.07 (0.13)
Median	5.70	N/A	5.90	0.10	N/A	0
IQR: Q1, Q3	4.80, 6.50	N/A	5.20, 6.40	-0.20, 0.60	N/A	-0.40, 0.40
Min, Max	2.9, 7.0	N/A	2.9, 7.0	-1.0, 2.0	N/A	-1.9, 2.6
Week 52						
m	44	0	56			
n	42	0	46	39	0	40
Mean (SD/SE)	5.47 (1.15)	N/A	5.51 (1.28)	0.08 (0.12)	N/A	-0.04 (0.13)
Median	5.60	N/A	5.85	0	N/A	0
IQR: Q1, Q3	5.00, 6.20	N/A	4.80, 6.70	-0.60, 0.70	N/A	-0.50, 0.25
Min, Max	1.9, 7.0	N/A	1.7, 7.0	-1.6, 1.6	N/A	-1.6, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Fatigue						
Baseline						
m	47	0	62			
n	44	0	54			
Mean (SD)	4.85 (1.42)	N/A	4.98 (1.55)			
Median	5.10	N/A	5.50			
IQR: Q1, Q3	3.65, 6.10	N/A	3.80, 6.20			
Min, Max	2.2, 7.0	N/A	1.2, 7.0			
Week 24						
m	46	0	59			
n	44	0	54	41	0	48
Mean (SD/SE)	4.83 (1.39)	N/A	5.17 (1.33)	0.08 (0.13)	N/A	0.05 (0.15)
Median	4.80	N/A	5.50	0.20	N/A	0
IQR: Q1, Q3	4.10, 6.00	N/A	4.00, 6.20	-0.30, 0.30	N/A	-0.50, 0.30
Min, Max	1.7, 7.0	N/A	2.0, 7.0	-1.7, 3.2	N/A	-2.5, 3.0
Week 52						
m	44	0	56			
n	42	0	46	39	0	40
Mean (SD/SE)	4.96 (1.46)	N/A	4.82 (1.54)	0.21 (0.18)	N/A	-0.21 (0.18)
Median	5.25	N/A	5.10	0	N/A	-0.20
IQR: Q1, Q3	3.70, 6.20	N/A	3.80, 6.20	-0.40, 0.50	N/A	-0.90, 0.35
Min, Max	1.5, 7.0	N/A	1.0, 7.0	-2.3, 4.0	N/A	-2.6, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Systemic Symptoms						
Baseline						
m	47	0	62			
n	44	0	54			
Mean (SD)	5.29 (1.26)	N/A	5.26 (1.28)			
Median	5.40	N/A	5.60			
IQR: Q1, Q3	4.70, 6.40	N/A	4.20, 6.30			
Min, Max	1.5, 7.0	N/A	2.5, 7.0			
Week 24						
m	46	0	59			
n	44	0	54	41	0	48
Mean (SD/SE)	5.18 (1.33)	N/A	5.54 (1.05)	-0.07 (0.10)	N/A	0.16 (0.13)
Median	5.30	N/A	5.70	0	N/A	0.10
IQR: Q1, Q3	4.30, 6.25	N/A	4.50, 6.30	-0.30, 0.30	N/A	-0.25, 0.70
Min, Max	1.7, 7.0	N/A	2.7, 7.0	-2.0, 1.0	N/A	-2.5, 2.4
Week 52						
m	44	0	56			
n	42	0	46	39	0	40
Mean (SD/SE)	5.20 (1.35)	N/A	5.38 (1.24)	-0.04 (0.09)	N/A	0.04 (0.12)
Median	5.60	N/A	5.70	0	N/A	0
IQR: Q1, Q3	4.20, 6.20	N/A	4.70, 6.50	-0.50, 0.30	N/A	-0.35, 0.50
Min, Max	1.3, 7.0	N/A	2.8, 7.0	-1.6, 1.7	N/A	-2.4, 2.7

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Worry						
Baseline						
m	47	0	62			
n	44	0	54			
Mean (SD)	5.79 (1.43)	N/A	5.75 (1.28)			
Median	6.10	N/A	6.00			
IQR: Q1, Q3	5.30, 6.95	N/A	4.90, 6.70			
Min, Max	1.1, 7.0	N/A	1.3, 7.0			
Week 24						
m	46	0	59			
n	44	0	54	41	0	48
Mean (SD/SE)	5.95 (1.29)	N/A	6.12 (1.19)	0.23 (0.13)	N/A	0.33 (0.14)
Median	6.40	N/A	6.60	0.30	N/A	0.10
IQR: Q1, Q3	5.60, 6.80	N/A	6.00, 6.90	-0.10, 0.60	N/A	-0.10, 0.75
Min, Max	1.6, 7.0	N/A	2.1, 7.0	-2.3, 2.9	N/A	-2.6, 2.2
Week 52						
m	44	0	56			
n	42	0	46	39	0	40
Mean (SD/SE)	5.99 (1.30)	N/A	5.98 (1.29)	0.32 (0.15)	N/A	0.16 (0.14)
Median	6.50	N/A	6.50	0	N/A	0
IQR: Q1, Q3	5.10, 7.00	N/A	5.30, 7.00	-0.30, 0.80	N/A	-0.30, 0.55
Min, Max	1.9, 7.0	N/A	1.7, 7.0	-1.4, 3.8	N/A	-2.3, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
CLDQ-NASH						
Baseline						
m	113	151	233			
n	105	136	215			
Mean (SD)	5.13 (1.19)	5.27 (1.11)	5.18 (1.11)			
Median	5.20	5.60	5.30			
IQR: Q1, Q3	4.30, 6.20	4.50, 6.10	4.50, 6.10			
Min, Max	2.0, 6.9	2.1, 7.0	2.2, 7.0			
Week 24						
m	109	141	223			
n	105	136	202	100	125	189
Mean (SD/SE)	5.26 (1.13)	5.27 (1.03)	5.27 (1.14)	0.09 (0.08)	-0.02 (0.05)	0.10 (0.05)
Median	5.40	5.50	5.40	0.10	0	0
IQR: Q1, Q3	4.50, 6.20	4.50, 6.10	4.40, 6.20	-0.20, 0.55	-0.40, 0.30	-0.30, 0.50
Min, Max	2.1, 7.0	2.7, 7.0	2.3, 7.0	-2.6, 2.5	-1.6, 1.6	-2.3, 3.0
Week 52						
m	99	125	208			
n	89	113	183	83	106	172
Mean (SD/SE)	5.31 (1.14)	5.34 (1.03)	5.35 (1.09)	0.01 (0.08)	0.00 (0.06)	0.08 (0.05)
Median	5.50	5.60	5.50	0.10	0	0
IQR: Q1, Q3	4.60, 6.20	4.60, 6.10	4.60, 6.20	-0.20, 0.40	-0.30, 0.30	-0.30, 0.50
Min, Max	1.9, 6.9	2.2, 6.9	1.9, 7.0	-2.7, 2.7	-2.4, 1.8	-2.2, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Abdominal Symptoms						
Baseline						
m	113	151	233			
n	105	136	215			
Mean (SD)	5.17 (1.63)	5.57 (1.37)	5.19 (1.52)			
Median	5.70	6.00	5.30			
IQR: Q1, Q3	4.00, 6.30	4.70, 7.00	4.30, 6.70			
Min, Max	1.0, 7.0	1.7, 7.0	1.3, 7.0			
Week 24						
m	109	141	223			
n	105	136	202	100	125	189
Mean (SD/SE)	5.38 (1.50)	5.43 (1.47)	5.43 (1.52)	0.14 (0.13)	-0.10 (0.10)	0.20 (0.09)
Median	5.30	5.70	6.00	0	0	0
IQR: Q1, Q3	4.70, 6.70	4.50, 6.70	4.30, 7.00	-0.35, 0.70	-0.60, 0.40	-0.40, 0.70
Min, Max	1.0, 7.0	1.3, 7.0	1.0, 7.0	-4.7, 3.3	-4.0, 2.4	-3.0, 4.0
Week 52						
m	99	125	208			
n	89	113	183	83	106	172
Mean (SD/SE)	5.52 (1.52)	5.59 (1.28)	5.49 (1.35)	0.12 (0.15)	-0.07 (0.09)	0.16 (0.09)
Median	6.00	5.70	5.70	0	0	0
IQR: Q1, Q3	4.70, 7.00	5.00, 6.70	4.70, 6.70	-0.60, 1.00	-0.40, 0.30	-0.40, 0.70
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0	-3.3, 3.7	-3.0, 2.7	-3.3, 4.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Activity						
Baseline						
m	113	151	233			
n	105	136	215			
Mean (SD)	5.17 (1.40)	5.33 (1.33)	5.41 (1.38)			
Median	5.40	5.60	5.60			
IQR: Q1, Q3	4.20, 6.20	4.60, 6.40	4.60, 6.60			
Min, Max	2.0, 7.0	1.8, 7.0	2.0, 7.0			
Week 24						
m	109	141	223			
n	105	136	202	100	125	189
Mean (SD/SE)	5.21 (1.39)	5.41 (1.26)	5.41 (1.36)	0.01 (0.10)	0.04 (0.08)	0.02 (0.07)
Median	5.40	5.80	5.80	0	0	0
IQR: Q1, Q3	4.40, 6.20	4.60, 6.40	4.60, 6.60	-0.60, 0.60	-0.60, 0.60	-0.60, 0.60
Min, Max	1.2, 7.0	2.4, 7.0	1.2, 7.0	-3.2, 2.8	-2.4, 3.2	-3.0, 2.6
Week 52						
m	99	125	208			
n	89	113	183	83	106	172
Mean (SD/SE)	5.21 (1.44)	5.38 (1.25)	5.42 (1.35)	-0.13 (0.12)	-0.04 (0.09)	-0.17 (0.07)
Median	5.40	5.60	5.80	0	0	0
IQR: Q1, Q3	4.40, 6.40	4.60, 6.40	4.40, 6.40	-0.60, 0.40	-0.60, 0.60	-0.80, 0.40
Min, Max	1.0, 7.0	1.6, 7.0	1.8, 7.0	-3.6, 3.0	-2.8, 2.0	-3.4, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Emotional Health						
Baseline						
m	113	151	233			
n	105	136	215			
Mean (SD)	5.29 (1.27)	5.38 (1.29)	5.39 (1.24)			
Median	5.60	5.70	5.70			
IQR: Q1, Q3	4.60, 6.20	4.70, 6.35	4.70, 6.30			
Min, Max	1.3, 7.0	1.8, 7.0	1.8, 7.0			
Week 24						
m	109	141	223			
n	105	136	202	100	125	189
Mean (SD/SE)	5.38 (1.29)	5.35 (1.24)	5.39 (1.30)	0.07 (0.09)	-0.07 (0.06)	0.03 (0.07)
Median	5.90	5.40	5.70	0.10	0	0
IQR: Q1, Q3	4.40, 6.30	4.70, 6.30	4.70, 6.40	-0.35, 0.65	-0.40, 0.20	-0.50, 0.50
Min, Max	2.0, 7.0	1.0, 7.0	1.9, 7.0	-2.8, 2.5	-3.1, 2.4	-2.9, 3.3
Week 52						
m	99	125	208			
n	89	113	183	83	106	172
Mean (SD/SE)	5.45 (1.12)	5.47 (1.20)	5.49 (1.22)	0.00 (0.09)	0.03 (0.08)	0.02 (0.06)
Median	5.80	5.80	5.70	0	0	0
IQR: Q1, Q3	4.60, 6.30	4.70, 6.40	4.70, 6.60	-0.50, 0.20	-0.50, 0.40	-0.40, 0.40
Min, Max	2.8, 7.0	1.0, 7.0	1.3, 7.0	-2.5, 2.9	-1.9, 2.9	-2.0, 2.5

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Fatigue						
Baseline						
m	113	151	233			
n	105	136	215			
Mean (SD)	4.67 (1.52)	4.60 (1.45)	4.49 (1.40)			
Median	5.00	4.80	4.80			
IQR: Q1, Q3	3.70, 5.80	3.70, 5.70	3.30, 5.50			
Min, Max	1.2, 7.0	1.2, 7.0	1.0, 7.0			
Week 24						
m	109	141	223			
n	105	136	202	100	125	189
Mean (SD/SE)	4.71 (1.54)	4.56 (1.37)	4.55 (1.46)	-0.02 (0.12)	-0.11 (0.08)	0.08 (0.08)
Median	4.80	4.70	4.60	0	0	0.10
IQR: Q1, Q3	3.50, 6.00	3.70, 5.50	3.30, 5.80	-0.75, 0.70	-0.50, 0.40	-0.60, 0.70
Min, Max	1.3, 7.0	1.5, 7.0	1.2, 7.0	-2.7, 4.1	-4.2, 2.3	-3.8, 3.7
Week 52						
m	99	125	208			
n	89	113	183	83	106	172
Mean (SD/SE)	4.78 (1.52)	4.60 (1.45)	4.66 (1.43)	-0.05 (0.10)	-0.09 (0.11)	0.08 (0.08)
Median	5.00	4.80	4.80	0	0	0
IQR: Q1, Q3	3.70, 6.00	3.70, 5.80	3.70, 5.80	-0.50, 0.50	-0.50, 0.50	-0.50, 0.70
Min, Max	1.0, 7.0	1.2, 7.0	1.0, 7.0	-2.4, 3.4	-4.4, 2.5	-3.8, 2.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Systemic Symptoms						
Baseline						
m	113	151	233			
n	105	136	215			
Mean (SD)	5.10 (1.27)	5.09 (1.22)	5.02 (1.23)			
Median	5.50	5.20	5.20			
IQR: Q1, Q3	4.00, 6.20	4.50, 6.00	4.20, 6.00			
Min, Max	1.8, 7.0	1.8, 7.0	1.7, 7.0			
Week 24						
m	109	141	223			
n	105	136	202	100	125	189
Mean (SD/SE)	5.16 (1.18)	5.00 (1.21)	5.03 (1.28)	0.02 (0.09)	-0.16 (0.06)	-0.03 (0.06)
Median	5.50	5.20	5.20	0	-0.10	0
IQR: Q1, Q3	4.30, 6.00	4.10, 6.00	4.20, 6.00	-0.50, 0.50	-0.50, 0.20	-0.60, 0.50
Min, Max	2.3, 7.0	1.8, 7.0	1.5, 7.0	-1.9, 3.5	-2.0, 2.2	-2.5, 3.7
Week 52						
m	99	125	208			
n	89	113	183	83	106	172
Mean (SD/SE)	5.09 (1.27)	5.04 (1.22)	5.06 (1.37)	-0.23 (0.09)	-0.11 (0.08)	0.00 (0.07)
Median	5.30	5.20	5.20	-0.10	0	0
IQR: Q1, Q3	4.30, 6.20	4.20, 6.00	4.20, 6.20	-0.70, 0.30	-0.50, 0.30	-0.50, 0.50
Min, Max	1.3, 7.0	1.5, 7.0	1.3, 7.0	-2.7, 2.0	-2.5, 2.0	-2.7, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Worry						
Baseline						
m	113	151	233			
n	105	136	215			
Mean (SD)	5.40 (1.37)	5.60 (1.49)	5.59 (1.41)			
Median	5.70	6.05	6.00			
IQR: Q1, Q3	4.60, 6.40	4.65, 6.90	4.70, 6.70			
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0			
Week 24						
m	109	141	223			
n	105	136	202	100	125	189
Mean (SD/SE)	5.73 (1.38)	5.85 (1.31)	5.81 (1.39)	0.34 (0.11)	0.28 (0.09)	0.31 (0.07)
Median	6.00	6.30	6.30	0.20	0	0.10
IQR: Q1, Q3	5.30, 6.70	5.10, 7.00	5.30, 7.00	-0.30, 1.05	-0.20, 0.60	-0.10, 0.60
Min, Max	1.6, 7.0	1.0, 7.0	1.0, 7.0	-3.1, 3.3	-2.6, 3.6	-2.1, 3.5
Week 52						
m	99	125	208			
n	89	113	183	83	106	172
Mean (SD/SE)	5.86 (1.35)	5.96 (1.35)	6.00 (1.29)	0.34 (0.13)	0.36 (0.11)	0.37 (0.08)
Median	6.30	6.40	6.40	0.20	0	0.20
IQR: Q1, Q3	5.30, 7.00	5.40, 7.00	5.40, 7.00	-0.20, 0.90	-0.20, 0.80	0.00, 0.90
Min, Max	1.7, 7.0	1.0, 7.0	1.0, 7.0	-4.8, 3.0	-3.3, 3.6	-2.7, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 1 of 4
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE23.6.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by BMI
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
CLDQ-NASH			
Week 24			
m	6	0	7
n	6	0	7
Baseline Mean (SD)	5.33 (1.73)	N/A	5.50 (0.54)
Analysis Visit Mean (SD)	5.13 (1.56)	N/A	5.40 (0.96)
LS Mean of Change from Baseline (SE)	-0.35 (0.22)	NE	-0.03 (0.20)
95% CI	(-0.85, 0.14)	NE	(-0.48, 0.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.32 (0.29)	NE	
95% CI	(-0.98, 0.35)	NE	
p-value	0.3075	NE	
Corrected Hedge's g Statistics	-0.561	NE	
95% CI	(-1.67, 0.55)	NE	
Week 52			
m	6	0	6
n	6	0	5
Baseline Mean (SD)	5.33 (1.73)	N/A	5.42 (0.49)
Analysis Visit Mean (SD)	5.52 (1.29)	N/A	5.36 (1.00)
LS Mean of Change from Baseline (SE)	0.02 (0.28)	NE	0.02 (0.30)
95% CI	(-0.62, 0.66)	NE	(-0.67, 0.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.42)	NE	
95% CI	(-0.94, 0.94)	NE	
p-value	0.9971	NE	
Corrected Hedge's g Statistics	0.002	NE	
95% CI	(-1.18, 1.19)	NE	
Subgroup*Treatment Interaction p-value	0.9785	NE	

AMNOG Table SE23.6.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
CLDQ-NASH			
Week 24			
m	46	0	59
n	41	0	48
Baseline Mean (SD)	5.36 (1.18)	N/A	5.45 (1.19)
Analysis Visit Mean (SD)	5.44 (1.17)	N/A	5.66 (0.93)
LS Mean of Change from Baseline (SE)	0.08 (0.09)	NE	0.24 (0.09)
95% CI	(-0.10, 0.26)	NE	(0.07, 0.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (0.12)	NE	
95% CI	(-0.39, 0.09)	NE	
p-value	0.2033	NE	
Corrected Hedge's g Statistics	-0.262	NE	
95% CI	(-0.68, 0.16)	NE	
Week 52			
m	44	0	56
n	39	0	40
Baseline Mean (SD)	5.31 (1.19)	N/A	5.43 (1.26)
Analysis Visit Mean (SD)	5.41 (1.23)	N/A	5.44 (1.20)
LS Mean of Change from Baseline (SE)	0.10 (0.10)	NE	0.05 (0.10)
95% CI	(-0.09, 0.30)	NE	(-0.15, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.06 (0.13)	NE	
95% CI	(-0.21, 0.32)	NE	
p-value	0.6827	NE	
Corrected Hedge's g Statistics	0.089	NE	
95% CI	(-0.35, 0.53)	NE	
Subgroup*Treatment Interaction p-value	0.9785	NE	

AMNOG Table SE23.6.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
CLDQ-NASH			
Week 24			
m	109	141	223
n	100	125	189
Baseline Mean (SD)	5.16 (1.16)	5.27 (1.13)	5.20 (1.11)
Analysis Visit Mean (SD)	5.25 (1.13)	5.25 (1.04)	5.30 (1.13)
LS Mean of Change from Baseline (SE)	0.10 (0.07)	-0.01 (0.06)	0.10 (0.05)
95% CI	(-0.04, 0.24)	(-0.13, 0.11)	(0.00, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.08)	-0.11 (0.08)	
95% CI	(-0.16, 0.16)	(-0.26, 0.04)	
p-value	0.9867	0.1481	
Corrected Hedge's g Statistics	-0.002	-0.162	
95% CI	(-0.24, 0.24)	(-0.39, 0.06)	
Week 52			
m	99	125	208
n	83	106	172
Baseline Mean (SD)	5.28 (1.14)	5.29 (1.14)	5.29 (1.07)
Analysis Visit Mean (SD)	5.29 (1.13)	5.29 (1.03)	5.36 (1.08)
LS Mean of Change from Baseline (SE)	0.02 (0.07)	0.02 (0.06)	0.10 (0.05)
95% CI	(-0.13, 0.16)	(-0.11, 0.14)	(0.00, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.09 (0.09)	-0.09 (0.08)	
95% CI	(-0.26, 0.08)	(-0.24, 0.07)	
p-value	0.3043	0.2672	
Corrected Hedge's g Statistics	-0.133	-0.133	
95% CI	(-0.39, 0.13)	(-0.38, 0.11)	
Subgroup*Treatment Interaction p-value	0.9785	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Abdominal Symptoms			
Week 24			
m	6	0	7
n	6	0	7
Baseline Mean (SD)	5.57 (1.93)	N/A	5.37 (0.79)
Analysis Visit Mean (SD)	5.50 (1.80)	N/A	5.47 (1.20)
LS Mean of Change from Baseline (SE)	-0.15 (0.55)	NE	-0.01 (0.51)
95% CI	(-1.41, 1.10)	NE	(-1.15, 1.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (0.76)	NE	
95% CI	(-1.85, 1.56)	NE	
p-value	0.8516	NE	
Corrected Hedge's g Statistics	-0.100	NE	
95% CI	(-1.19, 0.99)	NE	
Week 52			
m	6	0	6
n	6	0	5
Baseline Mean (SD)	5.57 (1.93)	N/A	5.40 (0.97)
Analysis Visit Mean (SD)	6.50 (0.58)	N/A	5.20 (1.60)
LS Mean of Change from Baseline (SE)	0.88 (0.57)	NE	-0.33 (0.60)
95% CI	(-0.40, 2.17)	NE	(-1.69, 1.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.21 (0.83)	NE	
95% CI	(-0.68, 3.09)	NE	
p-value	0.1818	NE	
Corrected Hedge's g Statistics	0.803	NE	
95% CI	(-0.43, 2.04)	NE	
Subgroup*Treatment Interaction p-value	0.5971	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Activity			
Week 24			
m	6	0	7
n	6	0	7
Baseline Mean (SD)	5.20 (1.94)	N/A	5.43 (0.92)
Analysis Visit Mean (SD)	4.67 (1.65)	N/A	5.26 (1.37)
LS Mean of Change from Baseline (SE)	-0.69 (0.24)	NE	-0.10 (0.22)
95% CI	(-1.24, -0.15)	NE	(-0.58, 0.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.60 (0.32)	NE	
95% CI	(-1.33, 0.14)	NE	
p-value	0.0985	NE	
Corrected Hedge's g Statistics	-0.957	NE	
95% CI	(-2.11, 0.19)	NE	
Week 52			
m	6	0	6
n	6	0	5
Baseline Mean (SD)	5.20 (1.94)	N/A	5.36 (0.52)
Analysis Visit Mean (SD)	5.57 (1.74)	N/A	5.44 (1.03)
LS Mean of Change from Baseline (SE)	0.19 (0.43)	NE	0.07 (0.44)
95% CI	(-0.78, 1.17)	NE	(-0.94, 1.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.13 (0.62)	NE	
95% CI	(-1.27, 1.53)	NE	
p-value	0.8421	NE	
Corrected Hedge's g Statistics	0.113	NE	
95% CI	(-1.07, 1.30)	NE	
Subgroup*Treatment Interaction p-value	0.6549	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Emotional Health			
Week 24			
m	6	0	7
n	6	0	7
Baseline Mean (SD)	5.63 (1.64)	N/A	5.71 (0.64)
Analysis Visit Mean (SD)	5.45 (1.47)	N/A	5.67 (0.98)
LS Mean of Change from Baseline (SE)	-0.35 (0.17)	NE	0.03 (0.15)
95% CI	(-0.73, 0.03)	NE	(-0.31, 0.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.38 (0.22)	NE	
95% CI	(-0.89, 0.13)	NE	
p-value	0.1278	NE	
Corrected Hedge's g Statistics	-0.870	NE	
95% CI	(-2.01, 0.27)	NE	
Week 52			
m	6	0	6
n	6	0	5
Baseline Mean (SD)	5.63 (1.64)	N/A	5.68 (0.66)
Analysis Visit Mean (SD)	5.25 (1.37)	N/A	5.66 (1.09)
LS Mean of Change from Baseline (SE)	-0.56 (0.37)	NE	0.11 (0.40)
95% CI	(-1.39, 0.28)	NE	(-0.80, 1.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.67 (0.55)	NE	
95% CI	(-1.90, 0.57)	NE	
p-value	0.2521	NE	
Corrected Hedge's g Statistics	-0.677	NE	
95% CI	(-1.90, 0.54)	NE	
Subgroup*Treatment Interaction p-value	0.6802	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Fatigue			
Week 24			
m	6	0	7
n	6	0	7
Baseline Mean (SD)	5.05 (1.97)	N/A	5.51 (0.57)
Analysis Visit Mean (SD)	4.92 (1.83)	N/A	5.06 (1.27)
LS Mean of Change from Baseline (SE)	-0.24 (0.35)	NE	-0.38 (0.31)
95% CI	(-1.02, 0.55)	NE	(-1.09, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.14 (0.47)	NE	
95% CI	(-0.92, 1.21)	NE	
p-value	0.7696	NE	
Corrected Hedge's g Statistics	0.157	NE	
95% CI	(-0.93, 1.25)	NE	
Week 52			
m	6	0	6
n	6	0	5
Baseline Mean (SD)	5.05 (1.97)	N/A	5.32 (0.28)
Analysis Visit Mean (SD)	4.77 (2.04)	N/A	5.12 (0.86)
LS Mean of Change from Baseline (SE)	-0.42 (0.49)	NE	-0.14 (0.53)
95% CI	(-1.53, 0.70)	NE	(-1.34, 1.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.28 (0.73)	NE	
95% CI	(-1.92, 1.37)	NE	
p-value	0.7129	NE	
Corrected Hedge's g Statistics	-0.210	NE	
95% CI	(-1.40, 0.98)	NE	
Subgroup*Treatment Interaction p-value	0.5825	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Systemic Symptoms			
Week 24			
m	6	0	7
n	6	0	7
Baseline Mean (SD)	5.13 (1.69)	N/A	5.14 (0.62)
Analysis Visit Mean (SD)	4.95 (1.64)	N/A	4.90 (1.12)
LS Mean of Change from Baseline (SE)	-0.34 (0.29)	NE	-0.14 (0.26)
95% CI	(-1.00, 0.32)	NE	(-0.73, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.20 (0.39)	NE	
95% CI	(-1.08, 0.68)	NE	
p-value	0.6175	NE	
Corrected Hedge's g Statistics	-0.268	NE	
95% CI	(-1.36, 0.83)	NE	
Week 52			
m	6	0	6
n	6	0	5
Baseline Mean (SD)	5.13 (1.69)	N/A	5.20 (0.67)
Analysis Visit Mean (SD)	5.38 (1.42)	N/A	5.06 (0.93)
LS Mean of Change from Baseline (SE)	0.09 (0.38)	NE	0.15 (0.40)
95% CI	(-0.78, 0.95)	NE	(-0.75, 1.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.55)	NE	
95% CI	(-1.31, 1.18)	NE	
p-value	0.9125	NE	
Corrected Hedge's g Statistics	-0.062	NE	
95% CI	(-1.25, 1.12)	NE	
Subgroup*Treatment Interaction p-value	0.5723	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Worry			
Week 24			
m	6	0	7
n	6	0	7
Baseline Mean (SD)	5.52 (1.85)	N/A	5.83 (1.03)
Analysis Visit Mean (SD)	5.38 (1.92)	N/A	5.99 (1.40)
LS Mean of Change from Baseline (SE)	-0.24 (0.31)	NE	0.18 (0.28)
95% CI	(-0.93, 0.45)	NE	(-0.45, 0.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.42 (0.41)	NE	
95% CI	(-1.36, 0.52)	NE	
p-value	0.3349	NE	
Corrected Hedge's g Statistics	-0.530	NE	
95% CI	(-1.64, 0.58)	NE	
Week 52			
m	6	0	6
n	6	0	5
Baseline Mean (SD)	5.52 (1.85)	N/A	5.60 (1.11)
Analysis Visit Mean (SD)	5.62 (1.38)	N/A	5.68 (1.17)
LS Mean of Change from Baseline (SE)	-0.03 (0.25)	NE	0.10 (0.27)
95% CI	(-0.61, 0.54)	NE	(-0.51, 0.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.37)	NE	
95% CI	(-0.98, 0.70)	NE	
p-value	0.7222	NE	
Corrected Hedge's g Statistics	-0.202	NE	
95% CI	(-1.39, 0.99)	NE	
Subgroup*Treatment Interaction p-value	0.8429	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Abdominal Symptoms			
Week 24			
m	46	0	59
n	41	0	48
Baseline Mean (SD)	5.45 (1.64)	N/A	5.37 (1.63)
Analysis Visit Mean (SD)	5.47 (1.36)	N/A	5.61 (1.27)
LS Mean of Change from Baseline (SE)	0.06 (0.14)	NE	0.28 (0.13)
95% CI	(-0.21, 0.34)	NE	(0.01, 0.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.22 (0.19)	NE	
95% CI	(-0.59, 0.16)	NE	
p-value	0.2525	NE	
Corrected Hedge's g Statistics	-0.235	NE	
95% CI	(-0.65, 0.18)	NE	
Week 52			
m	44	0	56
n	39	0	40
Baseline Mean (SD)	5.37 (1.64)	N/A	5.40 (1.71)
Analysis Visit Mean (SD)	5.39 (1.46)	N/A	5.27 (1.60)
LS Mean of Change from Baseline (SE)	0.02 (0.18)	NE	-0.04 (0.18)
95% CI	(-0.33, 0.38)	NE	(-0.40, 0.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.07 (0.25)	NE	
95% CI	(-0.42, 0.56)	NE	
p-value	0.7875	NE	
Corrected Hedge's g Statistics	0.059	NE	
95% CI	(-0.38, 0.50)	NE	
Subgroup*Treatment Interaction p-value	0.5971	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Activity			
Week 24			
m	46	0	59
n	41	0	48
Baseline Mean (SD)	5.51 (1.38)	N/A	5.51 (1.41)
Analysis Visit Mean (SD)	5.55 (1.55)	N/A	5.85 (1.13)
LS Mean of Change from Baseline (SE)	0.06 (0.14)	NE	0.38 (0.13)
95% CI	(-0.21, 0.34)	NE	(0.12, 0.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.32 (0.19)	NE	
95% CI	(-0.69, 0.05)	NE	
p-value	0.0907	NE	
Corrected Hedge's g Statistics	-0.348	NE	
95% CI	(-0.77, 0.07)	NE	
Week 52			
m	44	0	56
n	39	0	40
Baseline Mean (SD)	5.48 (1.40)	N/A	5.42 (1.47)
Analysis Visit Mean (SD)	5.53 (1.62)	N/A	5.57 (1.52)
LS Mean of Change from Baseline (SE)	0.09 (0.17)	NE	0.17 (0.16)
95% CI	(-0.24, 0.42)	NE	(-0.15, 0.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.23)	NE	
95% CI	(-0.53, 0.38)	NE	
p-value	0.7341	NE	
Corrected Hedge's g Statistics	-0.074	NE	
95% CI	(-0.52, 0.37)	NE	
Subgroup*Treatment Interaction p-value	0.6549	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Emotional Health			
Week 24			
m	46	0	59
n	41	0	48
Baseline Mean (SD)	5.43 (1.16)	N/A	5.56 (1.14)
Analysis Visit Mean (SD)	5.61 (1.08)	N/A	5.63 (1.03)
LS Mean of Change from Baseline (SE)	0.14 (0.11)	NE	0.06 (0.10)
95% CI	(-0.07, 0.36)	NE	(-0.15, 0.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.15)	NE	
95% CI	(-0.21, 0.37)	NE	
p-value	0.5640	NE	
Corrected Hedge's g Statistics	0.118	NE	
95% CI	(-0.30, 0.54)	NE	
Week 52			
m	44	0	56
n	39	0	40
Baseline Mean (SD)	5.38 (1.16)	N/A	5.55 (1.23)
Analysis Visit Mean (SD)	5.47 (1.15)	N/A	5.51 (1.31)
LS Mean of Change from Baseline (SE)	0.05 (0.13)	NE	-0.05 (0.12)
95% CI	(-0.20, 0.30)	NE	(-0.29, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (0.17)	NE	
95% CI	(-0.25, 0.44)	NE	
p-value	0.5745	NE	
Corrected Hedge's g Statistics	0.123	NE	
95% CI	(-0.32, 0.56)	NE	
Subgroup*Treatment Interaction p-value	0.6802	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Fatigue			
Week 24			
m	46	0	59
n	41	0	48
Baseline Mean (SD)	4.79 (1.45)	N/A	5.12 (1.54)
Analysis Visit Mean (SD)	4.88 (1.43)	N/A	5.17 (1.38)
LS Mean of Change from Baseline (SE)	0.04 (0.14)	NE	0.08 (0.14)
95% CI	(-0.24, 0.33)	NE	(-0.19, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.19)	NE	
95% CI	(-0.42, 0.35)	NE	
p-value	0.8533	NE	
Corrected Hedge's g Statistics	-0.038	NE	
95% CI	(-0.45, 0.38)	NE	
Week 52			
m	44	0	56
n	39	0	40
Baseline Mean (SD)	4.72 (1.44)	N/A	5.08 (1.60)
Analysis Visit Mean (SD)	4.93 (1.47)	N/A	4.87 (1.59)
LS Mean of Change from Baseline (SE)	0.15 (0.17)	NE	-0.17 (0.17)
95% CI	(-0.20, 0.49)	NE	(-0.51, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.32 (0.24)	NE	
95% CI	(-0.16, 0.79)	NE	
p-value	0.1905	NE	
Corrected Hedge's g Statistics	0.289	NE	
95% CI	(-0.15, 0.73)	NE	
Subgroup*Treatment Interaction p-value	0.5825	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Systemic Symptoms			
Week 24			
m	46	0	59
n	41	0	48
Baseline Mean (SD)	5.23 (1.28)	N/A	5.38 (1.29)
Analysis Visit Mean (SD)	5.16 (1.38)	N/A	5.54 (1.09)
LS Mean of Change from Baseline (SE)	-0.08 (0.12)	NE	0.20 (0.11)
95% CI	(-0.32, 0.15)	NE	(-0.02, 0.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.28 (0.16)	NE	
95% CI	(-0.59, 0.03)	NE	
p-value	0.0805	NE	
Corrected Hedge's g Statistics	-0.364	NE	
95% CI	(-0.78, 0.06)	NE	
Week 52			
m	44	0	56
n	39	0	40
Baseline Mean (SD)	5.21 (1.29)	N/A	5.32 (1.35)
Analysis Visit Mean (SD)	5.17 (1.37)	N/A	5.36 (1.24)
LS Mean of Change from Baseline (SE)	-0.04 (0.11)	NE	0.06 (0.11)
95% CI	(-0.25, 0.18)	NE	(-0.15, 0.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.15)	NE	
95% CI	(-0.40, 0.20)	NE	
p-value	0.4955	NE	
Corrected Hedge's g Statistics	-0.149	NE	
95% CI	(-0.59, 0.29)	NE	
Subgroup*Treatment Interaction p-value	0.5723	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Worry			
Week 24			
m	46	0	59
n	41	0	48
Baseline Mean (SD)	5.73 (1.45)	N/A	5.80 (1.22)
Analysis Visit Mean (SD)	5.96 (1.31)	N/A	6.13 (1.16)
LS Mean of Change from Baseline (SE)	0.25 (0.13)	NE	0.40 (0.12)
95% CI	(0.00, 0.50)	NE	(0.16, 0.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (0.17)	NE	
95% CI	(-0.49, 0.19)	NE	
p-value	0.3923	NE	
Corrected Hedge's g Statistics	-0.175	NE	
95% CI	(-0.59, 0.24)	NE	
Week 52			
m	44	0	56
n	39	0	40
Baseline Mean (SD)	5.68 (1.47)	N/A	5.86 (1.29)
Analysis Visit Mean (SD)	6.00 (1.33)	N/A	6.02 (1.33)
LS Mean of Change from Baseline (SE)	0.30 (0.14)	NE	0.29 (0.14)
95% CI	(0.02, 0.57)	NE	(0.01, 0.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.19)	NE	
95% CI	(-0.37, 0.39)	NE	
p-value	0.9635	NE	
Corrected Hedge's g Statistics	0.010	NE	
95% CI	(-0.43, 0.45)	NE	
Subgroup*Treatment Interaction p-value	0.8429	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Abdominal Symptoms			
Week 24			
m	109	141	223
n	100	125	189
Baseline Mean (SD)	5.20 (1.62)	5.54 (1.40)	5.27 (1.50)
Analysis Visit Mean (SD)	5.35 (1.50)	5.44 (1.49)	5.47 (1.46)
LS Mean of Change from Baseline (SE)	0.12 (0.11)	-0.03 (0.10)	0.19 (0.08)
95% CI	(-0.10, 0.34)	(-0.22, 0.17)	(0.03, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.13)	-0.22 (0.13)	
95% CI	(-0.33, 0.20)	(-0.47, 0.03)	
p-value	0.6143	0.0820	
Corrected Hedge's g Statistics	-0.060	-0.196	
95% CI	(-0.30, 0.18)	(-0.42, 0.03)	
Week 52			
m	99	125	208
n	83	106	172
Baseline Mean (SD)	5.36 (1.56)	5.65 (1.33)	5.35 (1.42)
Analysis Visit Mean (SD)	5.47 (1.56)	5.58 (1.30)	5.52 (1.33)
LS Mean of Change from Baseline (SE)	0.12 (0.11)	0.01 (0.10)	0.20 (0.08)
95% CI	(-0.11, 0.34)	(-0.18, 0.21)	(0.04, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.14)	-0.18 (0.13)	
95% CI	(-0.34, 0.19)	(-0.43, 0.06)	
p-value	0.5627	0.1451	
Corrected Hedge's g Statistics	-0.075	-0.175	
95% CI	(-0.34, 0.19)	(-0.42, 0.07)	
Subgroup*Treatment Interaction p-value	0.5971	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Activity			
Week 24			
m	109	141	223
n	100	125	189
Baseline Mean (SD)	5.18 (1.37)	5.35 (1.32)	5.44 (1.36)
Analysis Visit Mean (SD)	5.20 (1.40)	5.40 (1.25)	5.45 (1.36)
LS Mean of Change from Baseline (SE)	-0.02 (0.09)	0.02 (0.08)	0.03 (0.07)
95% CI	(-0.20, 0.16)	(-0.13, 0.18)	(-0.10, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.11)	0.00 (0.10)	
95% CI	(-0.26, 0.17)	(-0.20, 0.20)	
p-value	0.6776	0.9733	
Corrected Hedge's g Statistics	-0.050	-0.004	
95% CI	(-0.29, 0.19)	(-0.23, 0.22)	
Week 52			
m	99	125	208
n	83	106	172
Baseline Mean (SD)	5.31 (1.32)	5.36 (1.34)	5.58 (1.27)
Analysis Visit Mean (SD)	5.18 (1.44)	5.32 (1.26)	5.41 (1.37)
LS Mean of Change from Baseline (SE)	-0.15 (0.10)	-0.03 (0.09)	-0.11 (0.07)
95% CI	(-0.35, 0.05)	(-0.21, 0.14)	(-0.25, 0.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.12)	0.08 (0.11)	
95% CI	(-0.29, 0.19)	(-0.15, 0.30)	
p-value	0.7084	0.5017	
Corrected Hedge's g Statistics	-0.049	0.081	
95% CI	(-0.31, 0.21)	(-0.16, 0.32)	
Subgroup*Treatment Interaction p-value	0.6549	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Emotional Health			
Week 24			
m	109	141	223
n	100	125	189
Baseline Mean (SD)	5.31 (1.25)	5.38 (1.31)	5.38 (1.25)
Analysis Visit Mean (SD)	5.37 (1.28)	5.31 (1.24)	5.41 (1.29)
LS Mean of Change from Baseline (SE)	0.06 (0.08)	-0.08 (0.07)	0.03 (0.06)
95% CI	(-0.11, 0.22)	(-0.23, 0.06)	(-0.08, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.10)	-0.11 (0.09)	
95% CI	(-0.17, 0.22)	(-0.30, 0.07)	
p-value	0.8012	0.2218	
Corrected Hedge's g Statistics	0.030	-0.137	
95% CI	(-0.21, 0.27)	(-0.36, 0.09)	
Week 52			
m	99	125	208
n	83	106	172
Baseline Mean (SD)	5.43 (1.23)	5.39 (1.36)	5.46 (1.25)
Analysis Visit Mean (SD)	5.43 (1.08)	5.41 (1.21)	5.48 (1.23)
LS Mean of Change from Baseline (SE)	0.00 (0.08)	0.03 (0.07)	0.03 (0.06)
95% CI	(-0.16, 0.16)	(-0.11, 0.17)	(-0.08, 0.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.10)	0.00 (0.09)	
95% CI	(-0.22, 0.16)	(-0.17, 0.18)	
p-value	0.7630	0.9859	
Corrected Hedge's g Statistics	-0.039	0.002	
95% CI	(-0.30, 0.22)	(-0.24, 0.24)	
Subgroup*Treatment Interaction p-value	0.6802	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Fatigue			
Week 24			
m	109	141	223
n	100	125	189
Baseline Mean (SD)	4.72 (1.49)	4.62 (1.47)	4.49 (1.42)
Analysis Visit Mean (SD)	4.69 (1.52)	4.52 (1.38)	4.57 (1.47)
LS Mean of Change from Baseline (SE)	0.04 (0.10)	-0.11 (0.09)	0.05 (0.07)
95% CI	(-0.16, 0.25)	(-0.29, 0.07)	(-0.10, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.12)	-0.16 (0.12)	
95% CI	(-0.25, 0.24)	(-0.39, 0.06)	
p-value	0.9443	0.1578	
Corrected Hedge's g Statistics	-0.008	-0.158	
95% CI	(-0.25, 0.23)	(-0.38, 0.07)	
Week 52			
m	99	125	208
n	83	106	172
Baseline Mean (SD)	4.81 (1.52)	4.64 (1.49)	4.59 (1.37)
Analysis Visit Mean (SD)	4.76 (1.50)	4.55 (1.45)	4.68 (1.42)
LS Mean of Change from Baseline (SE)	-0.01 (0.11)	-0.07 (0.09)	0.09 (0.07)
95% CI	(-0.22, 0.20)	(-0.26, 0.11)	(-0.05, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.13)	-0.16 (0.12)	
95% CI	(-0.35, 0.15)	(-0.39, 0.07)	
p-value	0.4301	0.1606	
Corrected Hedge's g Statistics	-0.102	-0.168	
95% CI	(-0.36, 0.16)	(-0.41, 0.07)	
Subgroup*Treatment Interaction p-value	0.5825	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Systemic Symptoms			
Week 24			
m	109	141	223
n	100	125	189
Baseline Mean (SD)	5.12 (1.24)	5.11 (1.23)	5.07 (1.21)
Analysis Visit Mean (SD)	5.14 (1.19)	4.96 (1.21)	5.04 (1.29)
LS Mean of Change from Baseline (SE)	0.06 (0.08)	-0.15 (0.07)	-0.02 (0.06)
95% CI	(-0.10, 0.22)	(-0.29, -0.01)	(-0.14, 0.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.10)	-0.13 (0.09)	
95% CI	(-0.11, 0.27)	(-0.30, 0.05)	
p-value	0.4116	0.1614	
Corrected Hedge's g Statistics	0.098	-0.157	
95% CI	(-0.14, 0.34)	(-0.38, 0.07)	
Week 52			
m	99	125	208
n	83	106	172
Baseline Mean (SD)	5.27 (1.17)	5.11 (1.21)	5.08 (1.23)
Analysis Visit Mean (SD)	5.04 (1.27)	5.00 (1.22)	5.08 (1.37)
LS Mean of Change from Baseline (SE)	-0.17 (0.09)	-0.12 (0.08)	0.03 (0.06)
95% CI	(-0.35, 0.01)	(-0.28, 0.04)	(-0.09, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.20 (0.11)	-0.15 (0.10)	
95% CI	(-0.41, 0.01)	(-0.35, 0.05)	
p-value	0.0642	0.1324	
Corrected Hedge's g Statistics	-0.241	-0.181	
95% CI	(-0.50, 0.02)	(-0.42, 0.06)	
Subgroup*Treatment Interaction p-value	0.5723	NE	

AMNOG Table SE23.6.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Worry			
Week 24			
m	109	141	223
n	100	125	189
Baseline Mean (SD)	5.41 (1.36)	5.55 (1.52)	5.54 (1.44)
Analysis Visit Mean (SD)	5.74 (1.33)	5.83 (1.34)	5.85 (1.38)
LS Mean of Change from Baseline (SE)	0.30 (0.10)	0.27 (0.08)	0.31 (0.07)
95% CI	(0.11, 0.49)	(0.11, 0.44)	(0.18, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.11)	-0.04 (0.11)	
95% CI	(-0.23, 0.22)	(-0.25, 0.17)	
p-value	0.9429	0.7102	
Corrected Hedge's g Statistics	-0.009	-0.042	
95% CI	(-0.25, 0.23)	(-0.27, 0.18)	
Week 52			
m	99	125	208
n	83	106	172
Baseline Mean (SD)	5.52 (1.37)	5.57 (1.55)	5.64 (1.38)
Analysis Visit Mean (SD)	5.85 (1.31)	5.94 (1.38)	6.02 (1.25)
LS Mean of Change from Baseline (SE)	0.29 (0.11)	0.37 (0.09)	0.38 (0.07)
95% CI	(0.08, 0.50)	(0.18, 0.55)	(0.23, 0.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.09 (0.13)	-0.01 (0.12)	
95% CI	(-0.34, 0.16)	(-0.24, 0.22)	
p-value	0.5018	0.9410	
Corrected Hedge's g Statistics	-0.087	-0.009	
95% CI	(-0.35, 0.18)	(-0.25, 0.23)	
Subgroup*Treatment Interaction p-value	0.8429	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (28.6)	0	0
No	5 (71.4)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.13	NE	
95% CI of the inverse odds ratio	(0.01, 3.24)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.18	NE	
95% CI of the inverse risk ratio	(0.01, 3.18)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	25.69	NE	
95% CI of the absolute risk difference	(-9.74, 61.13)	NE	
p-value	0.1654	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1053	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	2 (25.0)
No	5 (71.4)	0	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	NE	
95% CI of the inverse odds ratio	(0.08, 8.24)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.16, 4.68)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.57	NE	
95% CI of the absolute risk difference	(-41.38, 48.52)	NE	
p-value	0.8760	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5341	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (28.6)	0	2 (25.0)
No	5 (71.4)	0	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	NE	
95% CI of the inverse odds ratio	(0.08, 8.24)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.16, 4.68)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.57	NE	
95% CI of the absolute risk difference	(-41.38, 48.52)	NE	
p-value	0.8760	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7914	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (42.9)	0	3 (37.5)
No	4 (57.1)	0	5 (62.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	NE	
95% CI of the inverse odds ratio	(0.10, 6.35)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.25, 3.02)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.36	NE	
95% CI of the absolute risk difference	(-44.34, 55.05)	NE	
p-value	0.8327	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2563	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	1 (12.5)
No	6 (85.7)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	NE	
95% CI of the inverse odds ratio	(0.04, 16.85)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.07, 11.54)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.79	NE	
95% CI of the absolute risk difference	(-32.81, 36.39)	NE	
p-value	0.9192	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9573	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (42.9)	0	2 (25.0)
No	4 (57.1)	0	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	NE	
95% CI of the inverse odds ratio	(0.05, 3.98)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	NE	
95% CI of the inverse risk ratio	(0.13, 2.55)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	17.86	NE	
95% CI of the absolute risk difference	(-29.52, 65.23)	NE	
p-value	0.4642	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5590	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	1 (12.5)
No	6 (85.7)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	NE	
95% CI of the inverse odds ratio	(0.04, 16.85)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.07, 11.54)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.79	NE	
95% CI of the absolute risk difference	(-32.81, 36.39)	NE	
p-value	0.9192	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5216	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (42.9)	0	2 (25.0)
No	4 (57.1)	0	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	NE	
95% CI of the inverse odds ratio	(0.05, 3.98)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	NE	
95% CI of the inverse risk ratio	(0.13, 2.55)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	17.86	NE	
95% CI of the absolute risk difference	(-29.52, 65.23)	NE	
p-value	0.4642	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0731	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	0
No	6 (85.7)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	NE	
95% CI of the inverse odds ratio	(0.01, 7.34)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	NE	
95% CI of the inverse risk ratio	(0.01, 6.29)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.19	NE	
95% CI of the absolute risk difference	(-17.72, 44.11)	NE	
p-value	0.3993	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0395	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	1 (12.5)
No	5 (71.4)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	NE	
95% CI of the inverse odds ratio	(0.02, 5.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	NE	
95% CI of the inverse risk ratio	(0.05, 3.85)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.07	NE	
95% CI of the absolute risk difference	(-24.49, 56.63)	NE	
p-value	0.4376	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2384	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	1 (12.5)
No	6 (85.7)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	NE	
95% CI of the inverse odds ratio	(0.04, 16.85)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.07, 11.54)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.79	NE	
95% CI of the absolute risk difference	(-32.81, 36.39)	NE	
p-value	0.9192	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8439	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	2 (25.0)
No	5 (71.4)	0	6 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	NE	
95% CI of the inverse odds ratio	(0.08, 8.24)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.16, 4.68)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.57	NE	
95% CI of the absolute risk difference	(-41.38, 48.52)	NE	
p-value	0.8760	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4873	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (14.3)	0	1 (12.5)
No	6 (85.7)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	NE	
95% CI of the inverse odds ratio	(0.04, 16.85)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	NE	
95% CI of the inverse risk ratio	(0.07, 11.54)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.79	NE	
95% CI of the absolute risk difference	(-32.81, 36.39)	NE	
p-value	0.9192	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5553	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (28.6)	0	1 (12.5)
No	5 (71.4)	0	7 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	NE	
95% CI of the inverse odds ratio	(0.02, 5.11)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	NE	
95% CI of the inverse risk ratio	(0.05, 3.85)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.07	NE	
95% CI of the absolute risk difference	(-24.49, 56.63)	NE	
p-value	0.4376	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3086	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (6.4)	0	3 (4.8)
No	44 (93.6)	0	59 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	NE	
95% CI of the inverse odds ratio	(0.14, 3.87)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	NE	
95% CI of the inverse risk ratio	(0.16, 3.59)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.54	NE	
95% CI of the absolute risk difference	(-7.25, 10.34)	NE	
p-value	0.7263	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1053	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (23.4)	0	10 (16.1)
No	36 (76.6)	0	52 (83.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	NE	
95% CI of the inverse odds ratio	(0.24, 1.64)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	NE	
95% CI of the inverse risk ratio	(0.32, 1.49)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.28	NE	
95% CI of the absolute risk difference	(-7.90, 22.45)	NE	
p-value	0.3402	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5341	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (12.8)	0	10 (16.1)
No	41 (87.2)	0	52 (83.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	NE	
95% CI of the inverse odds ratio	(0.44, 3.92)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	NE	
95% CI of the inverse risk ratio	(0.49, 3.23)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.36	NE	
95% CI of the absolute risk difference	(-16.59, 9.86)	NE	
p-value	0.6232	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7914	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (31.9)	0	11 (17.7)
No	32 (68.1)	0	51 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.46	NE	
95% CI of the inverse odds ratio	(0.19, 1.13)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	NE	
95% CI of the inverse risk ratio	(0.28, 1.10)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.17	NE	
95% CI of the absolute risk difference	(-2.20, 30.54)	NE	
p-value	0.0855	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2563	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (12.8)	0	5 (8.1)
No	41 (87.2)	0	57 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	NE	
95% CI of the inverse odds ratio	(0.17, 2.10)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	NE	
95% CI of the inverse risk ratio	(0.21, 1.95)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.70	NE	
95% CI of the absolute risk difference	(-7.00, 16.40)	NE	
p-value	0.4197	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9573	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (34.0)	0	13 (21.0)
No	31 (66.0)	0	49 (79.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.51	NE	
95% CI of the inverse odds ratio	(0.22, 1.21)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	NE	
95% CI of the inverse risk ratio	(0.33, 1.15)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.07	NE	
95% CI of the absolute risk difference	(-3.84, 29.99)	NE	
p-value	0.1261	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5590	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (12.8)	0	3 (4.8)
No	41 (87.2)	0	59 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.35	NE	
95% CI of the inverse odds ratio	(0.08, 1.47)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	NE	
95% CI of the inverse risk ratio	(0.10, 1.44)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.93	NE	
95% CI of the absolute risk difference	(-3.01, 18.86)	NE	
p-value	0.1364	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5216	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (27.7)	0	10 (16.1)
No	34 (72.3)	0	52 (83.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	NE	
95% CI of the inverse odds ratio	(0.20, 1.28)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	NE	
95% CI of the inverse risk ratio	(0.28, 1.21)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.53	NE	
95% CI of the absolute risk difference	(-4.20, 27.26)	NE	
p-value	0.1440	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0731	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (14.9)	0	5 (8.1)
No	40 (85.1)	0	57 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	NE	
95% CI of the inverse odds ratio	(0.15, 1.69)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	NE	
95% CI of the inverse risk ratio	(0.18, 1.60)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.83	NE	
95% CI of the absolute risk difference	(-5.40, 19.06)	NE	
p-value	0.2593	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0395	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (31.9)	0	13 (21.0)
No	32 (68.1)	0	49 (79.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	NE	
95% CI of the inverse odds ratio	(0.24, 1.35)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	NE	
95% CI of the inverse risk ratio	(0.35, 1.24)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.95	NE	
95% CI of the absolute risk difference	(-5.79, 27.69)	NE	
p-value	0.1951	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2384	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.1)	0	3 (4.8)
No	46 (97.9)	0	59 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.34	NE	
95% CI of the inverse odds ratio	(0.24, 23.23)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.27	NE	
95% CI of the inverse risk ratio	(0.24, 21.18)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.71	NE	
95% CI of the absolute risk difference	(-9.46, 4.04)	NE	
p-value	0.4559	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8439	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (27.7)	0	15 (24.2)
No	34 (72.3)	0	47 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	NE	
95% CI of the inverse odds ratio	(0.35, 1.98)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	NE	
95% CI of the inverse risk ratio	(0.46, 1.66)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.47	NE	
95% CI of the absolute risk difference	(-13.18, 20.11)	NE	
p-value	0.6817	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4873	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (19.1)	0	7 (11.3)
No	38 (80.9)	0	55 (88.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	NE	
95% CI of the inverse odds ratio	(0.18, 1.57)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	NE	
95% CI of the inverse risk ratio	(0.24, 1.47)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.86	NE	
95% CI of the absolute risk difference	(-5.87, 21.59)	NE	
p-value	0.2509	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5553	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (36.2)	0	15 (24.2)
No	30 (63.8)	0	47 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	NE	
95% CI of the inverse odds ratio	(0.25, 1.29)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	NE	
95% CI of the inverse risk ratio	(0.37, 1.20)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	11.98	NE	
95% CI of the absolute risk difference	(-5.41, 29.36)	NE	
p-value	0.1739	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3086	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (5.3)	11 (7.3)	23 (9.9)
No	107 (94.7)	140 (92.7)	210 (90.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.95	1.39	
95% CI of the inverse odds ratio	(0.77, 4.94)	(0.66, 2.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.86	1.36	
95% CI of the inverse risk ratio	(0.78, 4.44)	(0.68, 2.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.56	-2.59	
95% CI of the absolute risk difference	(-10.20, 1.07)	(-8.23, 3.06)	
p-value	0.1510	0.3835	
p-value of Breslow-Day Test for Homogeneity [3]	0.1053	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (22.1)	31 (20.5)	58 (24.9)
No	88 (77.9)	120 (79.5)	175 (75.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	1.28	
95% CI of the inverse odds ratio	(0.68, 1.99)	(0.78, 2.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	1.21	
95% CI of the inverse risk ratio	(0.75, 1.70)	(0.83, 1.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.77	-4.36	
95% CI of the absolute risk difference	(-12.22, 6.69)	(-12.87, 4.14)	
p-value	0.5716	0.3223	
p-value of Breslow-Day Test for Homogeneity [3]	0.5341	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	23 (20.4)	17 (11.3)	42 (18.0)
No	90 (79.6)	134 (88.7)	191 (82.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.73	
95% CI of the inverse odds ratio	(0.49, 1.52)	(0.95, 3.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.60	
95% CI of the inverse risk ratio	(0.56, 1.40)	(0.95, 2.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.33	-6.77	
95% CI of the absolute risk difference	(-6.59, 11.24)	(-13.82, 0.29)	
p-value	0.6031	0.0724	
p-value of Breslow-Day Test for Homogeneity [3]	0.7914	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	38 (33.6)	30 (19.9)	82 (35.2)
No	75 (66.4)	121 (80.1)	151 (64.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	2.19	
95% CI of the inverse odds ratio	(0.67, 1.72)	(1.35, 3.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.77	
95% CI of the inverse risk ratio	(0.77, 1.43)	(1.23, 2.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.56	-15.33	
95% CI of the absolute risk difference	(-12.22, 9.09)	(-24.16, -6.49)	
p-value	0.7743	0.0012	
p-value of Breslow-Day Test for Homogeneity [3]	0.2563	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (9.7)	16 (10.6)	17 (7.3)
No	102 (90.3)	135 (89.4)	216 (92.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.66	
95% CI of the inverse odds ratio	(0.33, 1.61)	(0.32, 1.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.69	
95% CI of the inverse risk ratio	(0.36, 1.55)	(0.36, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.44	3.30	
95% CI of the absolute risk difference	(-3.97, 8.84)	(-2.64, 9.24)	
p-value	0.4354	0.2597	
p-value of Breslow-Day Test for Homogeneity [3]	0.9573	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (24.8)	37 (24.5)	51 (21.9)
No	85 (75.2)	114 (75.5)	182 (78.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.86	
95% CI of the inverse odds ratio	(0.50, 1.44)	(0.53, 1.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.89	
95% CI of the inverse risk ratio	(0.59, 1.32)	(0.62, 1.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.89	2.61	
95% CI of the absolute risk difference	(-6.68, 12.46)	(-6.06, 11.29)	
p-value	0.5481	0.5515	
p-value of Breslow-Day Test for Homogeneity [3]	0.5590	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (10.6)	14 (9.3)	22 (9.4)
No	101 (89.4)	137 (90.7)	211 (90.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	1.02	
95% CI of the inverse odds ratio	(0.42, 1.84)	(0.50, 2.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.02	
95% CI of the inverse risk ratio	(0.46, 1.73)	(0.54, 1.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.18	-0.17	
95% CI of the absolute risk difference	(-5.63, 7.99)	(-6.13, 5.79)	
p-value	0.7301	0.9553	
p-value of Breslow-Day Test for Homogeneity [3]	0.5216	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (17.7)	35 (23.2)	60 (25.8)
No	93 (82.3)	116 (76.8)	173 (74.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.61	1.15	
95% CI of the inverse odds ratio	(0.92, 2.84)	(0.71, 1.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	1.11	
95% CI of the inverse risk ratio	(0.92, 2.29)	(0.77, 1.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.05	-2.57	
95% CI of the absolute risk difference	(-17.05, 0.95)	(-11.34, 6.19)	
p-value	0.0957	0.5683	
p-value of Breslow-Day Test for Homogeneity [3]	0.0731	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (6.2)	21 (13.9)	33 (14.2)
No	106 (93.8)	130 (86.1)	200 (85.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.50	1.02	
95% CI of the inverse odds ratio	(1.07, 5.84)	(0.57, 1.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.29	1.02	
95% CI of the inverse risk ratio	(1.04, 5.01)	(0.61, 1.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.97	-0.26	
95% CI of the absolute risk difference	(-14.28, -1.66)	(-7.36, 6.85)	
p-value	0.0297	0.9438	
p-value of Breslow-Day Test for Homogeneity [3]	0.0395	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (24.8)	35 (23.2)	67 (28.8)
No	85 (75.2)	116 (76.8)	166 (71.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	1.34	
95% CI of the inverse odds ratio	(0.73, 2.05)	(0.83, 2.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.24	
95% CI of the inverse risk ratio	(0.79, 1.70)	(0.87, 1.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.98	-5.58	
95% CI of the absolute risk difference	(-13.83, 5.88)	(-14.47, 3.32)	
p-value	0.4370	0.2268	
p-value of Breslow-Day Test for Homogeneity [3]	0.2384	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (5.3)	12 (7.9)	24 (10.3)
No	107 (94.7)	139 (92.1)	209 (89.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.05	1.33	
95% CI of the inverse odds ratio	(0.81, 5.16)	(0.64, 2.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.94	1.30	
95% CI of the inverse risk ratio	(0.82, 4.61)	(0.67, 2.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.99	-2.35	
95% CI of the absolute risk difference	(-10.68, 0.69)	(-8.17, 3.46)	
p-value	0.1218	0.4396	
p-value of Breslow-Day Test for Homogeneity [3]	0.8439	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (18.6)	35 (23.2)	60 (25.8)
No	92 (81.4)	116 (76.8)	173 (74.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	1.15	
95% CI of the inverse odds ratio	(0.87, 2.65)	(0.71, 1.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	1.11	
95% CI of the inverse risk ratio	(0.89, 2.16)	(0.77, 1.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.17	-2.57	
95% CI of the absolute risk difference	(-16.28, 1.94)	(-11.34, 6.19)	
p-value	0.1398	0.5683	
p-value of Breslow-Day Test for Homogeneity [3]	0.4873	NE	

AMNOG Table SE23.6.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	21 (18.6)	26 (17.2)	45 (19.3)
No	92 (81.4)	125 (82.8)	188 (80.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.15	
95% CI of the inverse odds ratio	(0.59, 1.86)	(0.68, 1.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.12	
95% CI of the inverse risk ratio	(0.65, 1.66)	(0.72, 1.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.73	-2.09	
95% CI of the absolute risk difference	(-9.51, 8.05)	(-9.97, 5.78)	
p-value	0.8714	0.6055	
p-value of Breslow-Day Test for Homogeneity [3]	0.5553	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	38 (33.6)	44 (29.1)	83 (35.6)
No	75 (66.4)	107 (70.9)	150 (64.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.35	
95% CI of the inverse odds ratio	(0.68, 1.75)	(0.87, 2.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.22	
95% CI of the inverse risk ratio	(0.78, 1.45)	(0.90, 1.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.99	-6.48	
95% CI of the absolute risk difference	(-12.66, 8.67)	(-15.99, 3.02)	
p-value	0.7153	0.1872	
p-value of Breslow-Day Test for Homogeneity [3]	0.3086	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE23.7.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
CLDQ-NASH						
Baseline						
m	118	100	201			
n	111	89	184			
Mean (SD)	5.27 (1.12)	5.28 (1.16)	5.20 (1.12)			
Median	5.40	5.60	5.30			
IQR: Q1, Q3	4.50, 6.20	4.60, 6.20	4.50, 6.10			
Min, Max	2.0, 7.0	2.1, 7.0	2.0, 7.0			
Week 24						
m	115	92	189			
n	110	87	169	104	79	158
Mean (SD/SE)	5.30 (1.10)	5.27 (1.06)	5.27 (1.17)	0.05 (0.07)	-0.02 (0.07)	0.09 (0.06)
Median	5.40	5.50	5.40	0	-0.10	0
IQR: Q1, Q3	4.60, 6.20	4.40, 6.10	4.40, 6.20	-0.20, 0.40	-0.50, 0.40	-0.30, 0.40
Min, Max	2.1, 7.0	2.7, 7.0	2.3, 7.0	-2.6, 2.5	-1.6, 1.6	-2.3, 3.0
Week 52						
m	107	81	176			
n	97	74	152	90	69	140
Mean (SD/SE)	5.35 (1.10)	5.22 (1.08)	5.33 (1.17)	-0.02 (0.08)	-0.11 (0.08)	0.01 (0.06)
Median	5.50	5.50	5.60	0	-0.10	0
IQR: Q1, Q3	4.60, 6.20	4.60, 6.10	4.40, 6.30	-0.30, 0.30	-0.50, 0.30	-0.30, 0.40
Min, Max	2.4, 7.0	2.2, 6.8	1.9, 7.0	-2.7, 2.7	-2.4, 1.8	-2.2, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=118)	Visit Result: MGL-3196 100 mg (N=100)	Visit Result: Placebo (N=201)	Change from Baseline: MGL-3196 80 mg (N=118)	Change from Baseline: MGL-3196 100 mg (N=100)	Change from Baseline: Placebo (N=201)
Abdominal Symptoms						
Baseline						
m	118	100	201			
n	111	89	184			
Mean (SD)	5.32 (1.56)	5.60 (1.44)	5.20 (1.53)			
Median	6.00	6.00	5.30			
IQR: Q1, Q3	4.30, 6.70	4.70, 7.00	4.00, 6.70			
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0			
Week 24						
m	115	92	189			
n	110	87	169	104	79	158
Mean (SD/SE)	5.38 (1.42)	5.49 (1.48)	5.40 (1.55)	0.07 (0.11)	-0.05 (0.12)	0.15 (0.10)
Median	5.30	6.00	6.00	0	0	0
IQR: Q1, Q3	4.70, 6.70	4.30, 7.00	4.30, 7.00	-0.30, 0.70	-0.40, 0.40	-0.40, 0.70
Min, Max	1.0, 7.0	1.3, 7.0	1.0, 7.0	-4.7, 3.3	-3.3, 2.3	-3.0, 4.0
Week 52						
m	107	81	176			
n	97	74	152	90	69	140
Mean (SD/SE)	5.51 (1.42)	5.50 (1.43)	5.42 (1.45)	0.05 (0.13)	-0.19 (0.12)	0.04 (0.10)
Median	5.70	5.70	5.70	0	0	0
IQR: Q1, Q3	4.70, 6.70	4.70, 6.70	4.70, 6.70	-0.60, 0.70	-0.40, 0.00	-0.70, 0.70
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0	-3.3, 3.7	-3.0, 2.7	-3.7, 3.3

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=118)	Visit Result: MGL-3196 100 mg (N=100)	Visit Result: Placebo (N=201)	Change from Baseline: MGL-3196 80 mg (N=118)	Change from Baseline: MGL-3196 100 mg (N=100)	Change from Baseline: Placebo (N=201)
Activity						
Baseline						
m	118	100	201			
n	111	89	184			
Mean (SD)	5.20 (1.41)	5.29 (1.36)	5.33 (1.44)			
Median	5.40	5.60	5.50			
IQR: Q1, Q3	4.20, 6.40	4.40, 6.40	4.40, 6.60			
Min, Max	2.0, 7.0	2.0, 7.0	1.4, 7.0			
Week 24						
m	115	92	189			
n	110	87	169	104	79	158
Mean (SD/SE)	5.20 (1.41)	5.32 (1.31)	5.35 (1.42)	-0.01 (0.10)	0.02 (0.10)	0.03 (0.08)
Median	5.50	5.80	5.80	0	0	0
IQR: Q1, Q3	4.20, 6.40	4.40, 6.40	4.40, 6.60	-0.60, 0.60	-0.60, 0.60	-0.60, 0.60
Min, Max	1.4, 7.0	2.4, 7.0	1.2, 7.0	-3.2, 2.8	-2.4, 2.4	-3.0, 3.2
Week 52						
m	107	81	176			
n	97	74	152	90	69	140
Mean (SD/SE)	5.19 (1.48)	5.21 (1.28)	5.41 (1.41)	-0.13 (0.12)	-0.15 (0.11)	-0.11 (0.08)
Median	5.40	5.40	5.80	0	0	0
IQR: Q1, Q3	4.40, 6.40	4.40, 6.20	4.40, 6.60	-0.60, 0.40	-0.60, 0.40	-0.60, 0.40
Min, Max	1.0, 7.0	1.6, 7.0	1.4, 7.0	-4.4, 3.0	-2.8, 1.8	-2.4, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Emotional Health						
Baseline						
m	118	100	201			
n	111	89	184			
Mean (SD)	5.46 (1.13)	5.44 (1.31)	5.40 (1.20)			
Median	5.60	5.70	5.70			
IQR: Q1, Q3	4.80, 6.30	4.70, 6.40	4.75, 6.30			
Min, Max	1.3, 7.0	1.8, 7.0	1.8, 7.0			
Week 24						
m	115	92	189			
n	110	87	169	104	79	158
Mean (SD/SE)	5.50 (1.18)	5.45 (1.18)	5.38 (1.33)	0.08 (0.09)	-0.05 (0.08)	0.04 (0.07)
Median	5.90	5.40	5.80	0.10	0	0.10
IQR: Q1, Q3	4.80, 6.30	4.90, 6.40	4.60, 6.40	-0.30, 0.60	-0.30, 0.20	-0.50, 0.50
Min, Max	2.2, 7.0	2.2, 7.0	1.9, 7.0	-2.8, 2.5	-3.1, 2.4	-2.9, 3.3
Week 52						
m	107	81	176			
n	97	74	152	90	69	140
Mean (SD/SE)	5.51 (1.08)	5.44 (1.17)	5.51 (1.27)	-0.01 (0.09)	-0.08 (0.10)	0.01 (0.07)
Median	5.80	5.75	5.80	0	-0.10	0
IQR: Q1, Q3	4.70, 6.30	4.80, 6.30	4.75, 6.60	-0.50, 0.30	-0.60, 0.20	-0.40, 0.40
Min, Max	2.8, 7.0	2.1, 7.0	1.3, 7.0	-2.5, 2.9	-1.9, 2.9	-2.0, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=118)	Visit Result: MGL-3196 100 mg (N=100)	Visit Result: Placebo (N=201)	Change from Baseline: MGL-3196 80 mg (N=118)	Change from Baseline: MGL-3196 100 mg (N=100)	Change from Baseline: Placebo (N=201)
Fatigue						
Baseline						
m	118	100	201			
n	111	89	184			
Mean (SD)	4.82 (1.43)	4.63 (1.49)	4.64 (1.43)			
Median	5.00	5.00	4.80			
IQR: Q1, Q3	3.80, 6.00	3.70, 5.80	3.70, 5.75			
Min, Max	1.2, 7.0	1.5, 7.0	1.0, 7.0			
Week 24						
m	115	92	189			
n	110	87	169	104	79	158
Mean (SD/SE)	4.78 (1.46)	4.53 (1.37)	4.64 (1.49)	-0.04 (0.11)	-0.16 (0.11)	0.02 (0.08)
Median	4.80	4.70	4.80	0	-0.10	0
IQR: Q1, Q3	3.80, 6.00	3.70, 5.70	3.30, 5.80	-0.75, 0.45	-0.60, 0.30	-0.50, 0.50
Min, Max	1.7, 7.0	1.7, 7.0	1.2, 7.0	-2.7, 4.1	-4.2, 2.3	-3.8, 3.7
Week 52						
m	107	81	176			
n	97	74	152	90	69	140
Mean (SD/SE)	4.90 (1.41)	4.46 (1.42)	4.70 (1.48)	-0.02 (0.11)	-0.22 (0.13)	-0.04 (0.08)
Median	5.20	4.40	4.90	0	-0.10	0
IQR: Q1, Q3	3.80, 6.00	3.50, 5.70	3.70, 5.80	-0.40, 0.50	-0.60, 0.30	-0.55, 0.50
Min, Max	1.8, 7.0	1.3, 6.8	1.0, 7.0	-2.3, 4.0	-4.4, 2.0	-3.8, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=118)	Visit Result: MGL-3196 100 mg (N=100)	Visit Result: Placebo (N=201)	Change from Baseline: MGL-3196 80 mg (N=118)	Change from Baseline: MGL-3196 100 mg (N=100)	Change from Baseline: Placebo (N=201)
Systemic Symptoms						
Baseline						
m	118	100	201			
n	111	89	184			
Mean (SD)	5.17 (1.25)	4.99 (1.24)	5.03 (1.23)			
Median	5.30	5.20	5.20			
IQR: Q1, Q3	4.30, 6.20	4.30, 5.80	4.20, 6.00			
Min, Max	1.8, 7.0	1.8, 7.0	2.0, 7.0			
Week 24						
m	115	92	189			
n	110	87	169	104	79	158
Mean (SD/SE)	5.08 (1.20)	4.87 (1.23)	5.01 (1.30)	-0.06 (0.08)	-0.18 (0.08)	-0.04 (0.07)
Median	5.30	5.00	5.20	-0.10	-0.20	0
IQR: Q1, Q3	4.30, 6.00	4.00, 5.80	4.00, 6.00	-0.50, 0.35	-0.60, 0.20	-0.60, 0.50
Min, Max	2.3, 7.0	1.8, 7.0	1.5, 7.0	-2.0, 3.5	-1.8, 2.2	-2.5, 3.7
Week 52						
m	107	81	176			
n	97	74	152	90	69	140
Mean (SD/SE)	5.08 (1.25)	4.82 (1.26)	5.05 (1.40)	-0.22 (0.08)	-0.17 (0.10)	-0.05 (0.07)
Median	5.30	4.80	5.10	-0.15	-0.10	0
IQR: Q1, Q3	4.20, 6.20	4.00, 5.80	4.20, 6.25	-0.50, 0.20	-0.70, 0.30	-0.50, 0.50
Min, Max	2.3, 7.0	1.5, 7.0	1.3, 7.0	-2.7, 2.0	-2.5, 1.8	-2.7, 2.7

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=118)	Visit Result: MGL-3196 100 mg (N=100)	Visit Result: Placebo (N=201)	Change from Baseline: MGL-3196 80 mg (N=118)	Change from Baseline: MGL-3196 100 mg (N=100)	Change from Baseline: Placebo (N=201)
Worry						
Baseline						
m	118	100	201			
n	111	89	184			
Mean (SD)	5.65 (1.27)	5.66 (1.51)	5.61 (1.40)			
Median	5.90	6.00	6.00			
IQR: Q1, Q3	5.00, 6.70	4.90, 6.90	4.70, 6.70			
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0			
Week 24						
m	115	92	189			
n	110	87	169	104	79	158
Mean (SD/SE)	5.87 (1.29)	5.91 (1.35)	5.81 (1.46)	0.23 (0.10)	0.31 (0.13)	0.28 (0.08)
Median	6.30	6.40	6.30	0.10	0	0.20
IQR: Q1, Q3	5.30, 6.90	5.40, 7.00	5.30, 7.00	-0.30, 0.60	-0.20, 0.70	-0.10, 0.60
Min, Max	1.6, 7.0	2.0, 7.0	1.0, 7.0	-2.4, 3.3	-2.6, 3.6	-2.6, 3.5
Week 52						
m	107	81	176			
n	97	74	152	90	69	140
Mean (SD/SE)	5.96 (1.25)	5.93 (1.43)	5.88 (1.41)	0.22 (0.12)	0.21 (0.14)	0.20 (0.09)
Median	6.40	6.50	6.40	0	0	0
IQR: Q1, Q3	5.40, 7.00	5.40, 7.00	5.30, 7.00	-0.30, 0.70	-0.30, 0.40	-0.30, 0.65
Min, Max	1.9, 7.0	1.0, 7.0	1.0, 7.0	-4.8, 3.8	-3.3, 3.6	-2.7, 3.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
CLDQ-NASH						
Baseline						
m	49	51	102			
n	45	47	93			
Mean (SD)	5.11 (1.40)	5.24 (1.02)	5.26 (1.11)			
Median	5.40	5.40	5.40			
IQR: Q1, Q3	4.20, 6.30	4.50, 6.00	4.50, 6.00			
Min, Max	1.5, 6.7	3.0, 6.8	2.2, 7.0			
Week 24						
m	46	49	100			
n	45	49	94	43	46	86
Mean (SD/SE)	5.29 (1.28)	5.29 (0.99)	5.51 (0.94)	0.15 (0.09)	-0.01 (0.08)	0.17 (0.08)
Median	5.70	5.60	5.70	0.10	0.05	0.05
IQR: Q1, Q3	4.40, 6.40	4.60, 6.10	4.90, 6.20	-0.20, 0.60	-0.30, 0.30	-0.30, 0.50
Min, Max	2.1, 6.8	3.1, 6.8	2.4, 6.8	-2.0, 1.4	-1.3, 1.4	-1.6, 2.2
Week 52						
m	42	44	94			
n	40	39	82	38	37	77
Mean (SD/SE)	5.37 (1.31)	5.56 (0.90)	5.44 (0.96)	0.21 (0.11)	0.22 (0.09)	0.15 (0.08)
Median	5.75	5.60	5.50	0.10	0	0
IQR: Q1, Q3	4.70, 6.40	4.90, 6.10	5.00, 6.10	-0.10, 0.50	-0.10, 0.50	-0.30, 0.50
Min, Max	1.6, 7.0	3.3, 6.9	2.8, 6.9	-1.3, 1.9	-0.9, 1.5	-1.7, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Abdominal Symptoms						
Baseline						
m	49	51	102			
n	45	47	93			
Mean (SD)	5.16 (1.81)	5.50 (1.23)	5.23 (1.53)			
Median	5.70	6.00	5.30			
IQR: Q1, Q3	4.00, 7.00	4.30, 6.70	4.30, 6.70			
Min, Max	1.0, 7.0	2.0, 7.0	1.7, 7.0			
Week 24						
m	46	49	100			
n	45	49	94	43	46	86
Mean (SD/SE)	5.41 (1.57)	5.32 (1.45)	5.61 (1.28)	0.18 (0.18)	-0.19 (0.19)	0.31 (0.13)
Median	5.70	5.30	5.85	0	0	0
IQR: Q1, Q3	4.30, 6.70	4.70, 6.70	4.70, 7.00	-0.40, 0.70	-1.00, 0.40	-0.30, 1.00
Min, Max	1.3, 7.0	1.7, 7.0	2.3, 7.0	-2.4, 2.7	-4.0, 2.4	-3.0, 4.0
Week 52						
m	42	44	94			
n	40	39	82	38	37	77
Mean (SD/SE)	5.57 (1.60)	5.77 (0.91)	5.52 (1.28)	0.30 (0.20)	0.16 (0.13)	0.21 (0.15)
Median	6.00	6.00	5.70	0	0	0
IQR: Q1, Q3	5.00, 6.85	5.30, 6.70	4.70, 6.70	-0.30, 1.00	-0.30, 0.70	-0.30, 1.00
Min, Max	1.0, 7.0	3.3, 7.0	1.7, 7.0	-2.0, 4.0	-1.0, 2.0	-4.6, 4.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Activity						
Baseline						
m	49	51	102			
n	45	47	93			
Mean (SD)	5.45 (1.40)	5.41 (1.28)	5.57 (1.26)			
Median	5.80	5.80	5.80			
IQR: Q1, Q3	4.80, 6.60	4.80, 6.20	5.00, 6.60			
Min, Max	1.4, 7.0	1.8, 7.0	2.0, 7.0			
Week 24						
m	46	49	100			
n	45	49	94	43	46	86
Mean (SD/SE)	5.47 (1.49)	5.59 (1.18)	5.73 (1.17)	0.02 (0.13)	0.08 (0.13)	0.15 (0.09)
Median	5.80	5.80	6.00	0	0	0
IQR: Q1, Q3	4.80, 6.60	4.80, 6.60	5.20, 6.60	-0.40, 0.60	-0.40, 0.60	-0.40, 0.80
Min, Max	1.2, 7.0	2.4, 7.0	2.2, 7.0	-2.4, 1.8	-1.4, 3.2	-1.6, 2.6
Week 52						
m	42	44	94			
n	40	39	82	38	37	77
Mean (SD/SE)	5.70 (1.48)	5.70 (1.14)	5.50 (1.31)	0.15 (0.17)	0.17 (0.16)	-0.10 (0.11)
Median	6.00	6.00	5.80	0.20	0.20	0
IQR: Q1, Q3	5.10, 7.00	4.80, 6.80	4.80, 6.60	-0.20, 0.60	-0.40, 1.00	-0.40, 0.40
Min, Max	1.6, 7.0	3.4, 7.0	2.0, 7.0	-3.0, 2.8	-2.2, 2.0	-3.4, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Emotional Health						
Baseline						
m	49	51	102			
n	45	47	93			
Mean (SD)	5.12 (1.49)	5.26 (1.25)	5.45 (1.23)			
Median	5.60	5.40	5.70			
IQR: Q1, Q3	4.40, 6.20	4.70, 6.20	4.80, 6.30			
Min, Max	1.9, 7.0	2.1, 7.0	2.2, 7.0			
Week 24						
m	46	49	100			
n	45	49	94	43	46	86
Mean (SD/SE)	5.26 (1.36)	5.17 (1.34)	5.61 (1.04)	0.10 (0.09)	-0.12 (0.10)	0.03 (0.09)
Median	5.40	5.40	5.85	0	0	0
IQR: Q1, Q3	4.20, 6.60	4.20, 6.20	4.80, 6.40	-0.30, 0.60	-0.60, 0.20	-0.40, 0.50
Min, Max	2.0, 7.0	1.0, 7.0	2.8, 7.0	-1.0, 1.6	-2.0, 1.9	-2.4, 2.2
Week 52						
m	42	44	94			
n	40	39	82	38	37	77
Mean (SD/SE)	5.30 (1.24)	5.52 (1.27)	5.49 (1.14)	0.05 (0.14)	0.22 (0.11)	0.01 (0.10)
Median	5.45	5.80	5.60	-0.10	0.30	0
IQR: Q1, Q3	4.45, 6.25	4.70, 6.60	4.70, 6.40	-0.60, 0.80	-0.20, 0.70	-0.60, 0.30
Min, Max	1.9, 7.0	1.0, 7.0	2.7, 7.0	-1.9, 2.5	-1.1, 1.8	-1.5, 2.5

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Fatigue						
Baseline						
m	49	51	102			
n	45	47	93			
Mean (SD)	4.57 (1.68)	4.54 (1.37)	4.54 (1.45)			
Median	5.20	4.80	4.80			
IQR: Q1, Q3	3.00, 6.00	4.00, 5.30	3.30, 5.50			
Min, Max	1.2, 6.7	1.2, 7.0	1.2, 7.0			
Week 24						
m	46	49	100			
n	45	49	94	43	46	86
Mean (SD/SE)	4.70 (1.61)	4.61 (1.38)	4.77 (1.39)	0.11 (0.14)	-0.02 (0.12)	0.13 (0.13)
Median	4.80	5.00	4.80	0.20	0	0
IQR: Q1, Q3	3.50, 6.00	3.50, 5.30	3.80, 6.00	-0.50, 0.70	-0.50, 0.50	-0.60, 0.90
Min, Max	1.3, 7.0	1.5, 7.0	1.3, 7.0	-2.5, 2.2	-1.8, 1.9	-3.3, 3.5
Week 52						
m	42	44	94			
n	40	39	82	38	37	77
Mean (SD/SE)	4.68 (1.77)	4.88 (1.48)	4.71 (1.38)	0.12 (0.15)	0.15 (0.20)	0.15 (0.13)
Median	5.20	5.00	4.90	0.10	0	0
IQR: Q1, Q3	3.25, 6.20	4.00, 6.30	3.80, 5.80	-0.50, 0.70	-0.40, 1.00	-0.60, 0.80
Min, Max	1.0, 7.0	1.2, 7.0	1.0, 7.0	-2.4, 2.2	-2.8, 2.5	-2.6, 2.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Systemic Symptoms						
Baseline						
m	49	51	102			
n	45	47	93			
Mean (SD)	5.17 (1.38)	5.28 (1.16)	5.14 (1.25)			
Median	5.70	5.20	5.30			
IQR: Q1, Q3	4.30, 6.20	4.50, 6.20	4.30, 6.00			
Min, Max	1.5, 7.0	2.2, 7.0	1.7, 7.0			
Week 24						
m	46	49	100			
n	45	49	94	43	46	86
Mean (SD/SE)	5.35 (1.30)	5.22 (1.16)	5.36 (1.12)	0.10 (0.11)	-0.12 (0.11)	0.08 (0.10)
Median	5.50	5.30	5.50	0.10	0	0.05
IQR: Q1, Q3	4.70, 6.30	4.20, 6.00	4.70, 6.20	-0.30, 0.60	-0.50, 0.20	-0.50, 0.50
Min, Max	1.7, 7.0	3.0, 7.0	2.3, 7.0	-1.9, 1.6	-2.0, 1.7	-2.5, 3.0
Week 52						
m	42	44	94			
n	40	39	82	38	37	77
Mean (SD/SE)	5.30 (1.39)	5.46 (1.04)	5.26 (1.21)	0.03 (0.13)	0.00 (0.12)	0.10 (0.09)
Median	5.70	5.30	5.30	0.05	0.10	0
IQR: Q1, Q3	4.30, 6.25	4.80, 6.50	4.30, 6.20	-0.50, 0.50	-0.50, 0.30	-0.50, 0.50
Min, Max	1.3, 7.0	3.2, 7.0	2.5, 7.0	-1.7, 2.3	-2.0, 2.0	-2.0, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Worry						
Baseline						
m	49	51	102			
n	45	47	93			
Mean (SD)	5.19 (1.66)	5.50 (1.46)	5.64 (1.33)			
Median	5.70	6.10	6.00			
IQR: Q1, Q3	4.40, 6.40	4.60, 6.70	4.90, 6.70			
Min, Max	1.1, 7.0	1.0, 7.0	1.4, 7.0			
Week 24						
m	46	49	100			
n	45	49	94	43	46	86
Mean (SD/SE)	5.56 (1.56)	5.75 (1.25)	6.01 (1.12)	0.42 (0.16)	0.23 (0.13)	0.35 (0.10)
Median	6.00	6.00	6.35	0.30	0.05	0.10
IQR: Q1, Q3	5.10, 6.70	4.90, 6.90	5.60, 6.90	0.00, 0.90	-0.30, 0.60	-0.10, 0.70
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0	-3.1, 2.9	-1.7, 2.3	-1.3, 3.5
Week 52						
m	42	44	94			
n	40	39	82	38	37	77
Mean (SD/SE)	5.72 (1.49)	6.03 (1.21)	6.18 (1.00)	0.56 (0.16)	0.65 (0.17)	0.56 (0.11)
Median	5.85	6.30	6.40	0.30	0.40	0.30
IQR: Q1, Q3	5.30, 7.00	5.40, 7.00	5.70, 7.00	0.00, 1.00	0.00, 1.60	0.00, 1.00
Min, Max	1.7, 7.0	1.0, 7.0	3.0, 7.0	-2.4, 2.5	-1.2, 2.9	-1.2, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE23.7.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
CLDQ-NASH			
Week 24			
m	115	92	189
n	104	79	158
Baseline Mean (SD)	5.25 (1.11)	5.27 (1.19)	5.21 (1.13)
Analysis Visit Mean (SD)	5.30 (1.12)	5.25 (1.07)	5.30 (1.16)
LS Mean of Change from Baseline (SE)	0.02 (0.07)	-0.05 (0.08)	0.06 (0.06)
95% CI	(-0.11, 0.16)	(-0.20, 0.10)	(-0.05, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.09)	-0.11 (0.09)	
95% CI	(-0.21, 0.13)	(-0.30, 0.07)	
p-value	0.6608	0.2276	
Corrected Hedge's g Statistics	-0.054	-0.163	
95% CI	(-0.30, 0.19)	(-0.43, 0.11)	
Week 52			
m	107	81	176
n	90	69	140
Baseline Mean (SD)	5.34 (1.09)	5.30 (1.22)	5.33 (1.11)
Analysis Visit Mean (SD)	5.32 (1.10)	5.19 (1.10)	5.34 (1.17)
LS Mean of Change from Baseline (SE)	-0.04 (0.07)	-0.12 (0.08)	0.02 (0.06)
95% CI	(-0.18, 0.09)	(-0.28, 0.03)	(-0.09, 0.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.09)	-0.15 (0.10)	
95% CI	(-0.24, 0.11)	(-0.33, 0.04)	
p-value	0.4619	0.1267	
Corrected Hedge's g Statistics	-0.097	-0.220	
95% CI	(-0.36, 0.17)	(-0.51, 0.07)	
Subgroup*Treatment Interaction p-value	0.7678	0.7459	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
CLDQ-NASH			
Week 24			
m	46	49	100
n	43	46	86
Baseline Mean (SD)	5.14 (1.35)	5.26 (1.02)	5.34 (1.08)
Analysis Visit Mean (SD)	5.30 (1.25)	5.25 (0.99)	5.51 (0.96)
LS Mean of Change from Baseline (SE)	0.12 (0.09)	0.00 (0.09)	0.18 (0.06)
95% CI	(-0.05, 0.30)	(-0.18, 0.17)	(0.05, 0.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.11)	-0.18 (0.11)	
95% CI	(-0.27, 0.16)	(-0.40, 0.03)	
p-value	0.6188	0.0906	
Corrected Hedge's g Statistics	-0.092	-0.307	
95% CI	(-0.46, 0.27)	(-0.67, 0.05)	
Week 52			
m	42	44	94
n	38	37	77
Baseline Mean (SD)	5.17 (1.35)	5.26 (1.01)	5.29 (1.07)
Analysis Visit Mean (SD)	5.38 (1.30)	5.49 (0.87)	5.44 (0.96)
LS Mean of Change from Baseline (SE)	0.17 (0.10)	0.21 (0.10)	0.16 (0.07)
95% CI	(-0.02, 0.36)	(0.02, 0.40)	(0.02, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.12)	0.05 (0.12)	
95% CI	(-0.22, 0.24)	(-0.19, 0.28)	
p-value	0.9444	0.6906	
Corrected Hedge's g Statistics	0.014	0.078	
95% CI	(-0.37, 0.40)	(-0.31, 0.47)	
Subgroup*Treatment Interaction p-value	0.7678	0.7459	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.7.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Abdominal Symptoms			
Week 24			
m	115	92	189
n	104	79	158
Baseline Mean (SD)	5.31 (1.57)	5.58 (1.49)	5.29 (1.52)
Analysis Visit Mean (SD)	5.38 (1.43)	5.53 (1.50)	5.44 (1.50)
LS Mean of Change from Baseline (SE)	0.03 (0.10)	0.00 (0.12)	0.12 (0.09)
95% CI	(-0.17, 0.24)	(-0.24, 0.24)	(-0.05, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.09 (0.13)	-0.12 (0.15)	
95% CI	(-0.35, 0.17)	(-0.41, 0.16)	
p-value	0.5068	0.3971	
Corrected Hedge's g Statistics	-0.082	-0.114	
95% CI	(-0.33, 0.17)	(-0.38, 0.16)	
Week 52			
m	107	81	176
n	90	69	140
Baseline Mean (SD)	5.42 (1.53)	5.69 (1.44)	5.40 (1.44)
Analysis Visit Mean (SD)	5.48 (1.46)	5.50 (1.47)	5.44 (1.44)
LS Mean of Change from Baseline (SE)	0.04 (0.11)	-0.13 (0.13)	0.06 (0.09)
95% CI	(-0.18, 0.27)	(-0.38, 0.13)	(-0.12, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.14)	-0.18 (0.16)	
95% CI	(-0.30, 0.27)	(-0.49, 0.13)	
p-value	0.9230	0.2453	
Corrected Hedge's g Statistics	-0.013	-0.168	
95% CI	(-0.28, 0.25)	(-0.46, 0.12)	
Subgroup*Treatment Interaction p-value	0.8561	0.6214	

AMNOG Table SE23.7.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Activity			
Week 24			
m	115	92	189
n	104	79	158
Baseline Mean (SD)	5.20 (1.41)	5.29 (1.36)	5.34 (1.44)
Analysis Visit Mean (SD)	5.18 (1.43)	5.31 (1.29)	5.37 (1.41)
LS Mean of Change from Baseline (SE)	-0.07 (0.09)	-0.04 (0.11)	0.00 (0.07)
95% CI	(-0.25, 0.11)	(-0.24, 0.17)	(-0.14, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.12)	-0.04 (0.13)	
95% CI	(-0.31, 0.15)	(-0.29, 0.21)	
p-value	0.5159	0.7450	
Corrected Hedge's g Statistics	-0.080	-0.044	
95% CI	(-0.33, 0.17)	(-0.31, 0.23)	
Week 52			
m	107	81	176
n	90	69	140
Baseline Mean (SD)	5.28 (1.37)	5.30 (1.40)	5.51 (1.36)
Analysis Visit Mean (SD)	5.15 (1.49)	5.16 (1.31)	5.41 (1.44)
LS Mean of Change from Baseline (SE)	-0.18 (0.10)	-0.17 (0.11)	-0.08 (0.08)
95% CI	(-0.38, 0.01)	(-0.39, 0.05)	(-0.23, 0.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.12)	-0.09 (0.13)	
95% CI	(-0.35, 0.14)	(-0.36, 0.17)	
p-value	0.3865	0.4959	
Corrected Hedge's g Statistics	-0.115	-0.098	
95% CI	(-0.38, 0.15)	(-0.39, 0.19)	
Subgroup*Treatment Interaction p-value	0.6798	0.6068	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Emotional Health			
Week 24			
m	115	92	189
n	104	79	158
Baseline Mean (SD)	5.43 (1.14)	5.44 (1.34)	5.36 (1.23)
Analysis Visit Mean (SD)	5.51 (1.19)	5.39 (1.21)	5.40 (1.32)
LS Mean of Change from Baseline (SE)	0.08 (0.08)	-0.05 (0.09)	0.03 (0.07)
95% CI	(-0.08, 0.25)	(-0.24, 0.13)	(-0.10, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.10)	-0.09 (0.11)	
95% CI	(-0.15, 0.26)	(-0.31, 0.14)	
p-value	0.6182	0.4422	
Corrected Hedge's g Statistics	0.062	-0.104	
95% CI	(-0.19, 0.31)	(-0.37, 0.17)	
Week 52			
m	107	81	176
n	90	69	140
Baseline Mean (SD)	5.50 (1.15)	5.47 (1.37)	5.48 (1.22)
Analysis Visit Mean (SD)	5.49 (1.08)	5.39 (1.18)	5.49 (1.29)
LS Mean of Change from Baseline (SE)	-0.02 (0.08)	-0.06 (0.09)	0.02 (0.06)
95% CI	(-0.17, 0.14)	(-0.24, 0.12)	(-0.11, 0.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.10)	-0.08 (0.11)	
95% CI	(-0.23, 0.17)	(-0.29, 0.14)	
p-value	0.7437	0.4770	
Corrected Hedge's g Statistics	-0.043	-0.102	
95% CI	(-0.31, 0.22)	(-0.39, 0.19)	
Subgroup*Treatment Interaction p-value	0.9971	0.6818	

AMNOG Table SE23.7.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Fatigue			
Week 24			
m	115	92	189
n	104	79	158
Baseline Mean (SD)	4.81 (1.41)	4.65 (1.53)	4.66 (1.46)
Analysis Visit Mean (SD)	4.77 (1.49)	4.49 (1.40)	4.68 (1.50)
LS Mean of Change from Baseline (SE)	-0.05 (0.10)	-0.23 (0.11)	-0.04 (0.08)
95% CI	(-0.25, 0.14)	(-0.45, -0.01)	(-0.20, 0.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.13)	-0.19 (0.14)	
95% CI	(-0.26, 0.23)	(-0.46, 0.08)	
p-value	0.9039	0.1648	
Corrected Hedge's g Statistics	-0.015	-0.188	
95% CI	(-0.26, 0.23)	(-0.46, 0.08)	
Week 52			
m	107	81	176
n	90	69	140
Baseline Mean (SD)	4.89 (1.44)	4.64 (1.58)	4.79 (1.40)
Analysis Visit Mean (SD)	4.86 (1.43)	4.42 (1.44)	4.74 (1.48)
LS Mean of Change from Baseline (SE)	-0.05 (0.10)	-0.28 (0.12)	-0.05 (0.08)
95% CI	(-0.25, 0.15)	(-0.51, -0.05)	(-0.22, 0.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.13)	-0.23 (0.14)	
95% CI	(-0.25, 0.25)	(-0.50, 0.05)	
p-value	0.9849	0.1066	
Corrected Hedge's g Statistics	0.003	-0.233	
95% CI	(-0.26, 0.27)	(-0.52, 0.06)	
Subgroup*Treatment Interaction p-value	0.9669	0.4673	

AMNOG Table SE23.7.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Systemic Symptoms			
Week 24			
m	115	92	189
n	104	79	158
Baseline Mean (SD)	5.13 (1.24)	5.00 (1.27)	5.07 (1.22)
Analysis Visit Mean (SD)	5.07 (1.23)	4.82 (1.22)	5.03 (1.30)
LS Mean of Change from Baseline (SE)	-0.07 (0.08)	-0.22 (0.09)	-0.06 (0.06)
95% CI	(-0.23, 0.08)	(-0.40, -0.04)	(-0.19, 0.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.10)	-0.16 (0.11)	
95% CI	(-0.21, 0.19)	(-0.37, 0.05)	
p-value	0.9263	0.1436	
Corrected Hedge's g Statistics	-0.011	-0.197	
95% CI	(-0.26, 0.24)	(-0.47, 0.07)	
Week 52			
m	107	81	176
n	90	69	140
Baseline Mean (SD)	5.26 (1.18)	4.96 (1.27)	5.11 (1.23)
Analysis Visit Mean (SD)	5.03 (1.26)	4.79 (1.27)	5.06 (1.41)
LS Mean of Change from Baseline (SE)	-0.21 (0.09)	-0.23 (0.10)	-0.03 (0.07)
95% CI	(-0.38, -0.04)	(-0.43, -0.04)	(-0.16, 0.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.18 (0.11)	-0.21 (0.12)	
95% CI	(-0.40, 0.03)	(-0.44, 0.03)	
p-value	0.0937	0.0814	
Corrected Hedge's g Statistics	-0.223	-0.252	
95% CI	(-0.49, 0.04)	(-0.54, 0.04)	
Subgroup*Treatment Interaction p-value	0.6370	0.8409	

AMNOG Table SE23.7.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Worry			
Week 24			
m	115	92	189
n	104	79	158
Baseline Mean (SD)	5.62 (1.28)	5.59 (1.56)	5.57 (1.44)
Analysis Visit Mean (SD)	5.86 (1.30)	5.90 (1.38)	5.85 (1.43)
LS Mean of Change from Baseline (SE)	0.21 (0.09)	0.27 (0.11)	0.26 (0.08)
95% CI	(0.02, 0.39)	(0.06, 0.48)	(0.11, 0.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.12)	0.01 (0.13)	
95% CI	(-0.28, 0.18)	(-0.24, 0.26)	
p-value	0.6657	0.9360	
Corrected Hedge's g Statistics	-0.053	0.011	
95% CI	(-0.30, 0.19)	(-0.26, 0.28)	
Week 52			
m	107	81	176
n	90	69	140
Baseline Mean (SD)	5.71 (1.30)	5.70 (1.55)	5.71 (1.43)
Analysis Visit Mean (SD)	5.93 (1.28)	5.91 (1.46)	5.90 (1.40)
LS Mean of Change from Baseline (SE)	0.18 (0.11)	0.24 (0.12)	0.20 (0.08)
95% CI	(-0.02, 0.39)	(0.00, 0.47)	(0.03, 0.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.13)	0.04 (0.15)	
95% CI	(-0.28, 0.25)	(-0.25, 0.32)	
p-value	0.9086	0.7975	
Corrected Hedge's g Statistics	-0.015	0.037	
95% CI	(-0.28, 0.25)	(-0.25, 0.33)	
Subgroup*Treatment Interaction p-value	0.7666	0.4388	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Abdominal Symptoms			
Week 24			
m	46	49	100
n	43	46	86
Baseline Mean (SD)	5.23 (1.77)	5.48 (1.23)	5.30 (1.49)
Analysis Visit Mean (SD)	5.41 (1.57)	5.29 (1.49)	5.60 (1.24)
LS Mean of Change from Baseline (SE)	0.14 (0.16)	-0.11 (0.16)	0.31 (0.11)
95% CI	(-0.18, 0.46)	(-0.42, 0.20)	(0.08, 0.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.17 (0.20)	-0.42 (0.19)	
95% CI	(-0.56, 0.22)	(-0.80, -0.04)	
p-value	0.4004	0.0325	
Corrected Hedge's g Statistics	-0.156	-0.390	
95% CI	(-0.52, 0.21)	(-0.75, -0.03)	
Week 52			
m	42	44	94
n	38	37	77
Baseline Mean (SD)	5.24 (1.74)	5.57 (1.11)	5.29 (1.50)
Analysis Visit Mean (SD)	5.54 (1.64)	5.72 (0.91)	5.51 (1.29)
LS Mean of Change from Baseline (SE)	0.23 (0.16)	0.23 (0.16)	0.25 (0.11)
95% CI	(-0.09, 0.54)	(-0.09, 0.55)	(0.02, 0.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.20)	-0.01 (0.20)	
95% CI	(-0.40, 0.37)	(-0.40, 0.37)	
p-value	0.9298	0.9414	
Corrected Hedge's g Statistics	-0.017	-0.015	
95% CI	(-0.41, 0.37)	(-0.41, 0.38)	
Subgroup*Treatment Interaction p-value	0.8561	0.6214	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Activity			
Week 24			
m	46	49	100
n	43	46	86
Baseline Mean (SD)	5.47 (1.37)	5.46 (1.25)	5.65 (1.18)
Analysis Visit Mean (SD)	5.48 (1.52)	5.54 (1.18)	5.81 (1.09)
LS Mean of Change from Baseline (SE)	0.00 (0.12)	0.07 (0.12)	0.17 (0.09)
95% CI	(-0.24, 0.24)	(-0.17, 0.30)	(0.00, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.18 (0.15)	-0.11 (0.15)	
95% CI	(-0.47, 0.12)	(-0.40, 0.18)	
p-value	0.2444	0.4598	
Corrected Hedge's g Statistics	-0.216	-0.134	
95% CI	(-0.58, 0.15)	(-0.49, 0.22)	
Week 52			
m	42	44	94
n	38	37	77
Baseline Mean (SD)	5.54 (1.35)	5.46 (1.22)	5.60 (1.16)
Analysis Visit Mean (SD)	5.68 (1.50)	5.63 (1.13)	5.50 (1.30)
LS Mean of Change from Baseline (SE)	0.13 (0.15)	0.14 (0.15)	-0.08 (0.11)
95% CI	(-0.17, 0.44)	(-0.17, 0.44)	(-0.30, 0.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.22 (0.19)	0.22 (0.19)	
95% CI	(-0.16, 0.59)	(-0.15, 0.59)	
p-value	0.2539	0.2405	
Corrected Hedge's g Statistics	0.225	0.232	
95% CI	(-0.16, 0.61)	(-0.16, 0.63)	
Subgroup*Treatment Interaction p-value	0.6798	0.6068	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Emotional Health			
Week 24			
m	46	49	100
n	43	46	86
Baseline Mean (SD)	5.18 (1.44)	5.27 (1.27)	5.54 (1.20)
Analysis Visit Mean (SD)	5.27 (1.32)	5.15 (1.30)	5.57 (1.05)
LS Mean of Change from Baseline (SE)	0.05 (0.11)	-0.15 (0.10)	0.04 (0.08)
95% CI	(-0.17, 0.26)	(-0.35, 0.06)	(-0.11, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.13)	-0.19 (0.13)	
95% CI	(-0.26, 0.26)	(-0.45, 0.06)	
p-value	0.9834	0.1377	
Corrected Hedge's g Statistics	0.004	-0.269	
95% CI	(-0.36, 0.37)	(-0.63, 0.09)	
Week 52			
m	42	44	94
n	38	37	77
Baseline Mean (SD)	5.26 (1.37)	5.23 (1.34)	5.47 (1.25)
Analysis Visit Mean (SD)	5.31 (1.18)	5.45 (1.27)	5.48 (1.15)
LS Mean of Change from Baseline (SE)	0.02 (0.12)	0.17 (0.12)	0.01 (0.08)
95% CI	(-0.21, 0.25)	(-0.06, 0.40)	(-0.16, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (0.14)	0.17 (0.14)	
95% CI	(-0.26, 0.30)	(-0.11, 0.45)	
p-value	0.8949	0.2394	
Corrected Hedge's g Statistics	0.026	0.232	
95% CI	(-0.36, 0.41)	(-0.16, 0.63)	
Subgroup*Treatment Interaction p-value	0.9971	0.6818	

AMNOG Table SE23.7.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Fatigue			
Week 24			
m	46	49	100
n	43	46	86
Baseline Mean (SD)	4.62 (1.67)	4.58 (1.36)	4.62 (1.44)
Analysis Visit Mean (SD)	4.72 (1.53)	4.56 (1.36)	4.75 (1.41)
LS Mean of Change from Baseline (SE)	0.12 (0.14)	-0.02 (0.14)	0.13 (0.10)
95% CI	(-0.17, 0.40)	(-0.29, 0.26)	(-0.07, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.18)	-0.14 (0.17)	
95% CI	(-0.36, 0.34)	(-0.48, 0.20)	
p-value	0.9457	0.4060	
Corrected Hedge's g Statistics	-0.013	-0.150	
95% CI	(-0.38, 0.35)	(-0.51, 0.21)	
Week 52			
m	42	44	94
n	38	37	77
Baseline Mean (SD)	4.57 (1.65)	4.63 (1.33)	4.54 (1.43)
Analysis Visit Mean (SD)	4.70 (1.71)	4.78 (1.46)	4.69 (1.38)
LS Mean of Change from Baseline (SE)	0.10 (0.17)	0.18 (0.17)	0.12 (0.12)
95% CI	(-0.23, 0.43)	(-0.15, 0.52)	(-0.11, 0.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.20)	0.06 (0.20)	
95% CI	(-0.43, 0.38)	(-0.34, 0.46)	
p-value	0.8944	0.7673	
Corrected Hedge's g Statistics	-0.026	0.058	
95% CI	(-0.41, 0.36)	(-0.33, 0.45)	
Subgroup*Treatment Interaction p-value	0.9669	0.4673	

AMNOG Table SE23.7.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Systemic Symptoms			
Week 24			
m	46	49	100
n	43	46	86
Baseline Mean (SD)	5.20 (1.32)	5.32 (1.14)	5.25 (1.20)
Analysis Visit Mean (SD)	5.30 (1.31)	5.19 (1.15)	5.33 (1.16)
LS Mean of Change from Baseline (SE)	0.09 (0.12)	-0.10 (0.11)	0.09 (0.08)
95% CI	(-0.13, 0.32)	(-0.32, 0.12)	(-0.07, 0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.14)	-0.19 (0.14)	
95% CI	(-0.27, 0.29)	(-0.46, 0.09)	
p-value	0.9636	0.1772	
Corrected Hedge's g Statistics	0.008	-0.245	
95% CI	(-0.36, 0.37)	(-0.60, 0.11)	
Week 52			
m	42	44	94
n	38	37	77
Baseline Mean (SD)	5.21 (1.33)	5.39 (1.06)	5.16 (1.26)
Analysis Visit Mean (SD)	5.24 (1.40)	5.38 (1.02)	5.25 (1.21)
LS Mean of Change from Baseline (SE)	0.02 (0.12)	0.01 (0.12)	0.09 (0.09)
95% CI	(-0.22, 0.26)	(-0.23, 0.26)	(-0.08, 0.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.15)	-0.08 (0.15)	
95% CI	(-0.36, 0.23)	(-0.37, 0.22)	
p-value	0.6553	0.6114	
Corrected Hedge's g Statistics	-0.088	-0.100	
95% CI	(-0.48, 0.30)	(-0.49, 0.29)	
Subgroup*Treatment Interaction p-value	0.6370	0.8409	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.7.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Worry			
Week 24			
m	46	49	100
n	43	46	86
Baseline Mean (SD)	5.20 (1.64)	5.49 (1.47)	5.67 (1.31)
Analysis Visit Mean (SD)	5.62 (1.46)	5.72 (1.28)	6.02 (1.15)
LS Mean of Change from Baseline (SE)	0.33 (0.13)	0.23 (0.12)	0.40 (0.09)
95% CI	(0.08, 0.57)	(-0.01, 0.46)	(0.22, 0.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.15)	-0.17 (0.15)	
95% CI	(-0.38, 0.23)	(-0.47, 0.12)	
p-value	0.6388	0.2480	
Corrected Hedge's g Statistics	-0.087	-0.209	
95% CI	(-0.45, 0.28)	(-0.57, 0.15)	
Week 52			
m	42	44	94
n	38	37	77
Baseline Mean (SD)	5.22 (1.62)	5.33 (1.55)	5.64 (1.24)
Analysis Visit Mean (SD)	5.78 (1.38)	5.98 (1.22)	6.20 (0.95)
LS Mean of Change from Baseline (SE)	0.43 (0.13)	0.55 (0.13)	0.59 (0.09)
95% CI	(0.18, 0.68)	(0.30, 0.81)	(0.41, 0.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.16 (0.16)	-0.04 (0.16)	
95% CI	(-0.47, 0.15)	(-0.34, 0.27)	
p-value	0.2992	0.8154	
Corrected Hedge's g Statistics	-0.205	-0.046	
95% CI	(-0.59, 0.18)	(-0.44, 0.35)	
Subgroup*Treatment Interaction p-value	0.7666	0.4388	

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (5.1)	4 (4.0)	14 (7.0)
No	112 (94.9)	96 (96.0)	187 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.80	
95% CI of the inverse odds ratio	(0.52, 3.74)	(0.58, 5.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.37	1.74	
95% CI of the inverse risk ratio	(0.54, 3.47)	(0.59, 5.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.88	-2.97	
95% CI of the absolute risk difference	(-7.18, 3.42)	(-8.17, 2.24)	
p-value	0.5036	0.3068	
p-value of Breslow-Day Test for Homogeneity [3]	0.8167	0.3202	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (19.5)	18 (18.0)	40 (19.9)
No	95 (80.5)	82 (82.0)	161 (80.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.13	
95% CI of the inverse odds ratio	(0.58, 1.82)	(0.61, 2.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.11	
95% CI of the inverse risk ratio	(0.64, 1.62)	(0.67, 1.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.41	-1.90	
95% CI of the absolute risk difference	(-9.44, 8.62)	(-11.24, 7.44)	
p-value	0.9294	0.6938	
p-value of Breslow-Day Test for Homogeneity [3]	0.8621	0.8832	

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	20 (16.9)	9 (9.0)	30 (14.9)
No	98 (83.1)	91 (91.0)	171 (85.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.77	
95% CI of the inverse odds ratio	(0.46, 1.59)	(0.81, 3.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	1.66	
95% CI of the inverse risk ratio	(0.52, 1.48)	(0.82, 3.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.02	-5.93	
95% CI of the absolute risk difference	(-6.35, 10.40)	(-13.39, 1.54)	
p-value	0.6312	0.1494	
p-value of Breslow-Day Test for Homogeneity [3]	0.6834	0.9075	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	40 (33.9)	16 (16.0)	63 (31.3)
No	78 (66.1)	84 (84.0)	138 (68.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	2.40	
95% CI of the inverse odds ratio	(0.55, 1.44)	(1.30, 4.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.96	
95% CI of the inverse risk ratio	(0.67, 1.28)	(1.20, 3.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.56	-15.34	
95% CI of the absolute risk difference	(-8.13, 13.24)	(-24.97, -5.71)	
p-value	0.6375	0.0044	
p-value of Breslow-Day Test for Homogeneity [3]	0.8179	0.1907	

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (8.5)	6 (6.0)	12 (6.0)
No	108 (91.5)	94 (94.0)	189 (94.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.99	
95% CI of the inverse odds ratio	(0.29, 1.64)	(0.36, 2.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	1.00	
95% CI of the inverse risk ratio	(0.31, 1.58)	(0.38, 2.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.50	0.03	
95% CI of the absolute risk difference	(-3.49, 8.50)	(-5.66, 5.72)	
p-value	0.3941	0.9918	
p-value of Breslow-Day Test for Homogeneity [3]	0.8796	0.3187	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (25.4)	20 (20.0)	40 (19.9)
No	88 (74.6)	80 (80.0)	161 (80.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.99	
95% CI of the inverse odds ratio	(0.42, 1.25)	(0.55, 1.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.00	
95% CI of the inverse risk ratio	(0.52, 1.19)	(0.62, 1.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.52	0.10	
95% CI of the absolute risk difference	(-4.08, 15.12)	(-9.49, 9.69)	
p-value	0.2498	0.9838	
p-value of Breslow-Day Test for Homogeneity [3]	0.7908	0.4395	

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (9.3)	7 (7.0)	17 (8.5)
No	107 (90.7)	93 (93.0)	184 (91.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.23	
95% CI of the inverse odds ratio	(0.41, 1.99)	(0.49, 3.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.21	
95% CI of the inverse risk ratio	(0.44, 1.87)	(0.52, 2.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.86	-1.46	
95% CI of the absolute risk difference	(-5.64, 7.37)	(-7.77, 4.85)	
p-value	0.7923	0.6601	
p-value of Breslow-Day Test for Homogeneity [3]	0.3662	0.3210	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (20.3)	15 (15.0)	52 (25.9)
No	94 (79.7)	85 (85.0)	149 (74.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.37	1.98	
95% CI of the inverse odds ratio	(0.79, 2.37)	(1.05, 3.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	1.72	
95% CI of the inverse risk ratio	(0.83, 1.95)	(1.02, 2.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.53	-10.87	
95% CI of the absolute risk difference	(-14.99, 3.92)	(-20.12, -1.62)	
p-value	0.2629	0.0327	
p-value of Breslow-Day Test for Homogeneity [3]	0.2313	0.0007	

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (5.9)	11 (11.0)	19 (9.5)
No	111 (94.1)	89 (89.0)	182 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.66	0.84	
95% CI of the inverse odds ratio	(0.67, 4.06)	(0.39, 1.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	0.86	
95% CI of the inverse risk ratio	(0.69, 3.68)	(0.43, 1.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.52	1.55	
95% CI of the absolute risk difference	(-9.40, 2.36)	(-5.80, 8.89)	
p-value	0.2672	0.6730	
p-value of Breslow-Day Test for Homogeneity [3]	0.5965	0.8584	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (22.9)	18 (18.0)	48 (23.9)
No	91 (77.1)	82 (82.0)	153 (76.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.43	
95% CI of the inverse odds ratio	(0.62, 1.81)	(0.78, 2.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.33	
95% CI of the inverse risk ratio	(0.69, 1.58)	(0.82, 2.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.00	-5.88	
95% CI of the absolute risk difference	(-10.60, 8.60)	(-15.44, 3.68)	
p-value	0.8390	0.2455	
p-value of Breslow-Day Test for Homogeneity [3]	0.5838	0.4000	

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (5.1)	9 (9.0)	16 (8.0)
No	112 (94.9)	91 (91.0)	185 (92.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.61	0.87	
95% CI of the inverse odds ratio	(0.61, 4.25)	(0.37, 2.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.57	0.88	
95% CI of the inverse risk ratio	(0.63, 3.89)	(0.41, 1.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.88	1.04	
95% CI of the absolute risk difference	(-8.33, 2.58)	(-5.70, 7.78)	
p-value	0.3278	0.7582	
p-value of Breslow-Day Test for Homogeneity [3]	0.4702	0.2587	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (16.1)	22 (22.0)	45 (22.4)
No	99 (83.9)	78 (78.0)	156 (77.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.50	1.02	
95% CI of the inverse odds ratio	(0.83, 2.72)	(0.57, 1.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.39	1.02	
95% CI of the inverse risk ratio	(0.86, 2.26)	(0.65, 1.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.29	-0.39	
95% CI of the absolute risk difference	(-15.07, 2.50)	(-10.34, 9.57)	
p-value	0.1759	0.9392	
p-value of Breslow-Day Test for Homogeneity [3]	0.2408	0.5816	

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (15.3)	13 (13.0)	29 (14.4)
No	100 (84.7)	87 (87.0)	172 (85.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.13	
95% CI of the inverse odds ratio	(0.50, 1.77)	(0.56, 2.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	1.11	
95% CI of the inverse risk ratio	(0.55, 1.63)	(0.60, 2.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.83	-1.43	
95% CI of the absolute risk difference	(-7.28, 8.93)	(-9.62, 6.76)	
p-value	0.8407	0.7363	
p-value of Breslow-Day Test for Homogeneity [3]	0.8541	0.6716	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	36 (30.5)	24 (24.0)	57 (28.4)
No	82 (69.5)	76 (76.0)	144 (71.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.25	
95% CI of the inverse odds ratio	(0.55, 1.48)	(0.72, 2.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.18	
95% CI of the inverse risk ratio	(0.66, 1.32)	(0.78, 1.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.15	-4.36	
95% CI of the absolute risk difference	(-8.23, 12.54)	(-14.79, 6.08)	
p-value	0.6833	0.4220	
p-value of Breslow-Day Test for Homogeneity [3]	0.9365	0.7481	

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (10.2)	7 (13.7)	12 (11.8)
No	44 (89.8)	44 (86.3)	90 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.84	
95% CI of the inverse odds ratio	(0.39, 3.54)	(0.31, 2.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.86	
95% CI of the inverse risk ratio	(0.43, 3.09)	(0.36, 2.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.56	1.96	
95% CI of the absolute risk difference	(-12.09, 8.97)	(-9.37, 13.29)	
p-value	0.7764	0.7288	
p-value of Breslow-Day Test for Homogeneity [3]	0.8167	0.3202	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (30.6)	13 (25.5)	30 (29.4)
No	34 (69.4)	38 (74.5)	72 (70.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.22	
95% CI of the inverse odds ratio	(0.45, 1.98)	(0.57, 2.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.15	
95% CI of the inverse risk ratio	(0.57, 1.61)	(0.66, 2.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.20	-3.92	
95% CI of the absolute risk difference	(-14.44, 16.84)	(-18.80, 10.95)	
p-value	0.8800	0.6110	
p-value of Breslow-Day Test for Homogeneity [3]	0.8621	0.8832	

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (22.4)	8 (15.7)	24 (23.5)
No	38 (77.6)	43 (84.3)	78 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.65	
95% CI of the inverse odds ratio	(0.47, 2.39)	(0.68, 4.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.50	
95% CI of the inverse risk ratio	(0.56, 1.96)	(0.73, 3.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.08	-7.84	
95% CI of the absolute risk difference	(-15.37, 13.21)	(-20.78, 5.09)	
p-value	0.8829	0.2608	
p-value of Breslow-Day Test for Homogeneity [3]	0.6834	0.9075	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (32.7)	14 (27.5)	33 (32.4)
No	33 (67.3)	37 (72.5)	69 (67.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.26	
95% CI of the inverse odds ratio	(0.48, 2.04)	(0.60, 2.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.18	
95% CI of the inverse risk ratio	(0.61, 1.62)	(0.70, 2.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.30	-4.90	
95% CI of the absolute risk difference	(-15.66, 16.26)	(-20.15, 10.34)	
p-value	0.9706	0.5355	
p-value of Breslow-Day Test for Homogeneity [3]	0.8179	0.1907	

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (16.3)	10 (19.6)	11 (10.8)
No	41 (83.7)	41 (80.4)	91 (89.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.50	
95% CI of the inverse odds ratio	(0.23, 1.65)	(0.20, 1.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.55	
95% CI of the inverse risk ratio	(0.28, 1.54)	(0.25, 1.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.54	8.82	
95% CI of the absolute risk difference	(-6.43, 17.51)	(-3.63, 21.27)	
p-value	0.3363	0.1349	
p-value of Breslow-Day Test for Homogeneity [3]	0.8796	0.3187	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (34.7)	17 (33.3)	26 (25.5)
No	32 (65.3)	34 (66.7)	76 (74.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.68	
95% CI of the inverse odds ratio	(0.31, 1.35)	(0.33, 1.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.76	
95% CI of the inverse risk ratio	(0.44, 1.22)	(0.46, 1.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.20	7.84	
95% CI of the absolute risk difference	(-6.58, 24.99)	(-7.61, 23.30)	
p-value	0.2407	0.3090	
p-value of Breslow-Day Test for Homogeneity [3]	0.7908	0.4395	

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (16.3)	7 (13.7)	9 (8.8)
No	41 (83.7)	44 (86.3)	93 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	0.61	
95% CI of the inverse odds ratio	(0.18, 1.38)	(0.21, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	0.64	
95% CI of the inverse risk ratio	(0.22, 1.32)	(0.25, 1.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.50	4.90	
95% CI of the absolute risk difference	(-4.22, 19.22)	(-6.03, 15.83)	
p-value	0.1720	0.3503	
p-value of Breslow-Day Test for Homogeneity [3]	0.3662	0.3210	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (24.5)	20 (39.2)	20 (19.6)
No	37 (75.5)	31 (60.8)	82 (80.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.38	
95% CI of the inverse odds ratio	(0.33, 1.70)	(0.18, 0.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.50	
95% CI of the inverse risk ratio	(0.43, 1.50)	(0.30, 0.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.88	19.61	
95% CI of the absolute risk difference	(-9.41, 19.18)	(4.15, 35.06)	
p-value	0.4919	0.0093	
p-value of Breslow-Day Test for Homogeneity [3]	0.2313	0.0007	

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (16.3)	10 (19.6)	19 (18.6)
No	41 (83.7)	41 (80.4)	83 (81.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.94	
95% CI of the inverse odds ratio	(0.47, 2.91)	(0.40, 2.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	0.95	
95% CI of the inverse risk ratio	(0.54, 2.42)	(0.48, 1.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.30	0.98	
95% CI of the absolute risk difference	(-15.11, 10.51)	(-12.28, 14.24)	
p-value	0.7297	0.8840	
p-value of Breslow-Day Test for Homogeneity [3]	0.5965	0.8584	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (36.7)	17 (33.3)	33 (32.4)
No	31 (63.3)	34 (66.7)	69 (67.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.96	
95% CI of the inverse odds ratio	(0.40, 1.68)	(0.47, 1.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.97	
95% CI of the inverse risk ratio	(0.55, 1.40)	(0.60, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.38	0.98	
95% CI of the absolute risk difference	(-11.89, 20.65)	(-14.82, 16.79)	
p-value	0.5940	0.9030	
p-value of Breslow-Day Test for Homogeneity [3]	0.5838	0.4000	

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.1)	3 (5.9)	12 (11.8)
No	47 (95.9)	48 (94.1)	90 (88.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.13	2.13	
95% CI of the inverse odds ratio	(0.67, 14.59)	(0.57, 7.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.88	2.00	
95% CI of the inverse risk ratio	(0.67, 12.38)	(0.59, 6.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.68	-5.88	
95% CI of the absolute risk difference	(-16.04, 0.67)	(-14.87, 3.11)	
p-value	0.1275	0.2487	
p-value of Breslow-Day Test for Homogeneity [3]	0.4702	0.2587	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (34.7)	13 (25.5)	32 (31.4)
No	32 (65.3)	38 (74.5)	70 (68.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.34	
95% CI of the inverse odds ratio	(0.42, 1.77)	(0.63, 2.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.23	
95% CI of the inverse risk ratio	(0.56, 1.46)	(0.71, 2.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.32	-5.88	
95% CI of the absolute risk difference	(-12.76, 19.41)	(-20.85, 9.09)	
p-value	0.6832	0.4516	
p-value of Breslow-Day Test for Homogeneity [3]	0.2408	0.5816	

AMNOG Table SE23.7.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (26.5)	13 (25.5)	24 (23.5)
No	36 (73.5)	38 (74.5)	78 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.90	
95% CI of the inverse odds ratio	(0.39, 1.86)	(0.41, 1.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.92	
95% CI of the inverse risk ratio	(0.50, 1.59)	(0.51, 1.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.00	1.96	
95% CI of the absolute risk difference	(-11.85, 17.85)	(-12.56, 16.48)	
p-value	0.6881	0.7895	
p-value of Breslow-Day Test for Homogeneity [3]	0.8541	0.6716	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (42.9)	20 (39.2)	42 (41.2)
No	28 (57.1)	31 (60.8)	60 (58.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.09	
95% CI of the inverse odds ratio	(0.47, 1.86)	(0.55, 2.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.05	
95% CI of the inverse risk ratio	(0.65, 1.43)	(0.69, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.68	-1.96	
95% CI of the absolute risk difference	(-15.15, 18.51)	(-18.42, 14.49)	
p-value	0.8445	0.8158	
p-value of Breslow-Day Test for Homogeneity [3]	0.9365	0.7481	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE23.8.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
CLDQ-NASH						
Baseline						
m	64	53	111			
n	59	47	100			
Mean (SD)	5.07 (1.37)	5.24 (1.14)	5.16 (1.23)			
Median	5.50	5.50	5.45			
IQR: Q1, Q3	4.10, 6.30	4.70, 6.10	4.25, 6.10			
Min, Max	1.9, 6.9	2.1, 6.7	2.0, 7.0			
Week 24						
m	63	51	103			
n	60	48	95	56	44	85
Mean (SD/SE)	5.25 (1.23)	5.33 (1.02)	5.39 (1.20)	0.11 (0.10)	0.04 (0.10)	0.13 (0.08)
Median	5.45	5.60	5.70	0.10	0.05	0
IQR: Q1, Q3	4.40, 6.30	4.55, 6.10	4.60, 6.30	-0.10, 0.50	-0.40, 0.35	-0.30, 0.50
Min, Max	2.1, 6.8	2.7, 7.0	2.3, 7.0	-2.6, 2.5	-1.6, 1.4	-2.3, 3.0
Week 52						
m	56	44	94			
n	51	39	84	47	36	76
Mean (SD/SE)	5.17 (1.27)	5.32 (1.13)	5.28 (1.14)	-0.09 (0.12)	-0.05 (0.13)	0.01 (0.06)
Median	5.30	5.60	5.50	0	0	-0.10
IQR: Q1, Q3	4.30, 6.30	4.60, 6.20	4.55, 6.20	-0.40, 0.30	-0.35, 0.30	-0.30, 0.25
Min, Max	1.9, 6.9	2.2, 6.9	2.2, 7.0	-2.7, 1.4	-2.4, 1.5	-0.9, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Abdominal Symptoms						
Baseline						
m	64	53	111			
n	59	47	100			
Mean (SD)	5.13 (1.74)	5.66 (1.33)	5.03 (1.60)			
Median	5.70	6.00	5.30			
IQR: Q1, Q3	3.70, 6.70	4.70, 6.70	4.00, 6.30			
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0			
Week 24						
m	63	51	103			
n	60	48	95	56	44	85
Mean (SD/SE)	5.47 (1.46)	5.62 (1.37)	5.48 (1.55)	0.27 (0.17)	0.01 (0.17)	0.29 (0.12)
Median	5.50	6.00	6.00	0.15	0	0.30
IQR: Q1, Q3	4.70, 6.70	4.70, 6.85	4.00, 7.00	-0.30, 0.85	-0.50, 0.55	-0.30, 1.00
Min, Max	1.3, 7.0	2.3, 7.0	1.0, 7.0	-4.7, 3.3	-2.7, 2.4	-3.0, 4.0
Week 52						
m	56	44	94			
n	51	39	84	47	36	76
Mean (SD/SE)	5.31 (1.55)	5.73 (1.24)	5.47 (1.39)	-0.01 (0.21)	-0.05 (0.13)	0.31 (0.12)
Median	5.70	6.00	5.70	0	0	0.15
IQR: Q1, Q3	4.70, 6.70	5.30, 6.70	4.70, 6.70	-1.00, 1.00	-0.30, 0.15	-0.30, 1.00
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0	-3.3, 4.0	-1.7, 2.0	-2.3, 4.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Activity						
Baseline						
m	64	53	111			
n	59	47	100			
Mean (SD)	5.19 (1.57)	5.37 (1.24)	5.35 (1.55)			
Median	5.60	5.60	5.70			
IQR: Q1, Q3	4.20, 6.60	4.60, 6.40	4.40, 6.60			
Min, Max	1.8, 7.0	2.0, 7.0	1.4, 7.0			
Week 24						
m	63	51	103			
n	60	48	95	56	44	85
Mean (SD/SE)	5.22 (1.62)	5.67 (1.21)	5.47 (1.48)	-0.05 (0.13)	0.19 (0.15)	0.08 (0.11)
Median	5.60	6.10	6.00	0	0	0
IQR: Q1, Q3	4.10, 6.70	4.80, 6.60	4.40, 6.60	-0.60, 0.60	-0.40, 0.90	-0.60, 0.60
Min, Max	1.2, 7.0	2.4, 7.0	2.2, 7.0	-3.2, 1.8	-2.4, 2.4	-2.0, 2.6
Week 52						
m	56	44	94			
n	51	39	84	47	36	76
Mean (SD/SE)	5.21 (1.73)	5.42 (1.42)	5.29 (1.45)	-0.27 (0.15)	-0.18 (0.18)	-0.18 (0.09)
Median	5.60	5.60	5.80	0	0	0
IQR: Q1, Q3	4.00, 6.80	4.60, 6.80	4.40, 6.40	-0.80, 0.40	-1.00, 0.60	-0.60, 0.20
Min, Max	1.0, 7.0	1.6, 7.0	1.4, 7.0	-3.6, 1.2	-2.8, 1.2	-2.2, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Emotional Health						
Baseline						
m	64	53	111			
n	59	47	100			
Mean (SD)	5.20 (1.39)	5.24 (1.29)	5.35 (1.26)			
Median	5.60	5.70	5.65			
IQR: Q1, Q3	4.40, 6.30	4.60, 6.20	4.70, 6.30			
Min, Max	1.3, 7.0	2.1, 6.9	1.9, 7.0			
Week 24						
m	63	51	103			
n	60	48	95	56	44	85
Mean (SD/SE)	5.37 (1.32)	5.24 (1.32)	5.50 (1.25)	0.13 (0.11)	-0.02 (0.10)	0.07 (0.10)
Median	5.65	5.35	5.80	0.10	0	0.10
IQR: Q1, Q3	4.60, 6.35	4.65, 6.25	4.80, 6.60	-0.30, 0.60	-0.45, 0.45	-0.40, 0.50
Min, Max	2.0, 7.0	1.0, 7.0	2.0, 7.0	-2.2, 2.5	-1.5, 1.4	-2.9, 3.3
Week 52						
m	56	44	94			
n	51	39	84	47	36	76
Mean (SD/SE)	5.33 (1.21)	5.34 (1.35)	5.43 (1.24)	-0.02 (0.13)	0.00 (0.14)	-0.02 (0.09)
Median	5.80	5.70	5.70	-0.10	0.05	0
IQR: Q1, Q3	4.20, 6.20	4.40, 6.40	4.70, 6.40	-0.60, 0.50	-0.40, 0.40	-0.40, 0.40
Min, Max	2.8, 7.0	1.0, 7.0	1.7, 7.0	-2.5, 2.9	-1.9, 2.9	-1.7, 2.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Fatigue						
Baseline						
m	64	53	111			
n	59	47	100			
Mean (SD)	4.55 (1.67)	4.55 (1.36)	4.57 (1.48)			
Median	5.00	4.80	4.90			
IQR: Q1, Q3	3.30, 6.00	3.80, 5.50	3.40, 5.70			
Min, Max	1.2, 7.0	1.2, 6.7	1.0, 7.0			
Week 24						
m	63	51	103			
n	60	48	95	56	44	85
Mean (SD/SE)	4.77 (1.51)	4.50 (1.34)	4.71 (1.47)	0.07 (0.16)	-0.12 (0.18)	0.03 (0.12)
Median	4.90	4.30	4.80	0.20	0	0
IQR: Q1, Q3	3.50, 6.10	3.70, 5.40	3.30, 6.00	-0.40, 0.70	-0.85, 0.60	-0.60, 0.50
Min, Max	1.3, 7.0	1.5, 7.0	1.3, 7.0	-2.7, 4.1	-4.2, 2.3	-3.8, 3.7
Week 52						
m	56	44	94			
n	51	39	84	47	36	76
Mean (SD/SE)	4.62 (1.60)	4.49 (1.53)	4.54 (1.50)	-0.16 (0.13)	-0.23 (0.24)	-0.15 (0.10)
Median	5.00	4.50	4.70	0	-0.05	-0.10
IQR: Q1, Q3	3.30, 6.00	3.70, 5.70	3.50, 5.75	-0.70, 0.50	-0.70, 0.25	-0.65, 0.40
Min, Max	1.0, 7.0	1.2, 6.8	1.0, 7.0	-2.4, 1.7	-4.4, 2.5	-2.6, 2.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Systemic Symptoms						
Baseline						
m	64	53	111			
n	59	47	100			
Mean (SD)	4.98 (1.38)	5.14 (1.22)	5.01 (1.26)			
Median	5.50	5.30	5.20			
IQR: Q1, Q3	3.70, 6.00	4.70, 5.80	4.20, 5.90			
Min, Max	2.0, 7.0	1.8, 7.0	2.2, 7.0			
Week 24						
m	63	51	103			
n	60	48	95	56	44	85
Mean (SD/SE)	5.03 (1.32)	5.11 (1.25)	5.17 (1.34)	0.02 (0.11)	-0.11 (0.10)	0.01 (0.10)
Median	5.00	5.25	5.50	0	-0.05	0
IQR: Q1, Q3	4.20, 6.20	4.30, 6.00	4.30, 6.20	-0.45, 0.50	-0.70, 0.20	-0.60, 0.30
Min, Max	2.2, 7.0	1.8, 7.0	1.5, 7.0	-1.9, 3.5	-1.3, 1.7	-2.5, 3.7
Week 52						
m	56	44	94			
n	51	39	84	47	36	76
Mean (SD/SE)	4.92 (1.39)	5.20 (1.25)	4.99 (1.40)	-0.27 (0.12)	-0.06 (0.15)	-0.11 (0.08)
Median	5.30	5.30	5.10	-0.20	0	-0.20
IQR: Q1, Q3	4.00, 6.20	4.50, 6.20	4.00, 6.20	-0.70, 0.30	-0.60, 0.45	-0.50, 0.30
Min, Max	1.3, 7.0	1.5, 7.0	1.7, 7.0	-2.7, 2.0	-2.3, 2.0	-2.2, 1.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Worry						
Baseline						
m	64	53	111			
n	59	47	100			
Mean (SD)	5.34 (1.53)	5.45 (1.64)	5.67 (1.47)			
Median	5.70	6.00	6.10			
IQR: Q1, Q3	4.60, 6.40	4.70, 6.70	4.70, 6.90			
Min, Max	1.6, 7.0	1.0, 7.0	1.4, 7.0			
Week 24						
m	63	51	103			
n	60	48	95	56	44	85
Mean (SD/SE)	5.64 (1.43)	5.77 (1.42)	5.97 (1.42)	0.25 (0.16)	0.28 (0.15)	0.30 (0.10)
Median	5.95	6.25	6.40	0.10	0	0.10
IQR: Q1, Q3	5.00, 6.70	5.10, 6.95	5.60, 7.00	-0.15, 0.70	-0.30, 0.40	0.00, 0.60
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0	-3.1, 3.1	-1.2, 3.4	-2.0, 3.5
Week 52						
m	56	44	94			
n	51	39	84	47	36	76
Mean (SD/SE)	5.66 (1.49)	5.79 (1.54)	5.95 (1.37)	0.21 (0.19)	0.28 (0.17)	0.25 (0.11)
Median	6.10	6.30	6.40	0.10	0	0.05
IQR: Q1, Q3	5.00, 6.90	4.90, 7.00	5.50, 7.00	-0.30, 1.00	-0.20, 0.50	-0.15, 0.70
Min, Max	1.7, 7.0	1.0, 7.0	1.4, 7.0	-4.8, 3.0	-1.6, 2.9	-2.5, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
CLDQ-NASH						
Baseline						
m	103	98	192			
n	97	89	177			
Mean (SD)	5.32 (1.09)	5.28 (1.10)	5.26 (1.05)			
Median	5.30	5.60	5.30			
IQR: Q1, Q3	4.80, 6.20	4.40, 6.10	4.60, 6.10			
Min, Max	1.5, 7.0	2.2, 7.0	2.4, 7.0			
Week 24						
m	98	90	186			
n	95	88	168	91	81	159
Mean (SD/SE)	5.33 (1.10)	5.25 (1.05)	5.34 (1.04)	0.05 (0.07)	-0.05 (0.06)	0.11 (0.06)
Median	5.40	5.35	5.40	0	0	0.10
IQR: Q1, Q3	4.60, 6.20	4.40, 6.10	4.60, 6.20	-0.20, 0.40	-0.50, 0.30	-0.30, 0.50
Min, Max	2.1, 7.0	2.9, 6.8	2.6, 7.0	-1.8, 2.4	-1.4, 1.6	-1.8, 2.6
Week 52						
m	93	81	176			
n	86	74	150	81	70	141
Mean (SD/SE)	5.47 (1.08)	5.34 (0.98)	5.42 (1.08)	0.13 (0.07)	0.03 (0.07)	0.09 (0.06)
Median	5.60	5.60	5.60	0	0	0
IQR: Q1, Q3	4.80, 6.40	4.70, 6.10	4.70, 6.30	-0.10, 0.40	-0.30, 0.30	-0.40, 0.50
Min, Max	1.6, 7.0	3.1, 6.9	1.9, 7.0	-2.2, 2.7	-1.5, 1.8	-2.2, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Abdominal Symptoms						
Baseline						
m	103	98	192			
n	97	89	177			
Mean (SD)	5.37 (1.57)	5.52 (1.39)	5.32 (1.48)			
Median	6.00	6.00	5.70			
IQR: Q1, Q3	4.30, 6.70	4.30, 7.00	4.30, 6.70			
Min, Max	1.0, 7.0	2.0, 7.0	1.7, 7.0			
Week 24						
m	98	90	186			
n	95	88	168	91	81	159
Mean (SD/SE)	5.34 (1.46)	5.32 (1.51)	5.47 (1.41)	-0.01 (0.11)	-0.16 (0.13)	0.16 (0.10)
Median	5.30	5.70	6.00	0	0	0
IQR: Q1, Q3	4.30, 6.70	4.30, 6.70	4.50, 6.85	-0.40, 0.60	-0.70, 0.30	-0.60, 0.70
Min, Max	1.0, 7.0	1.3, 7.0	1.0, 7.0	-3.0, 3.0	-4.0, 2.3	-2.7, 4.0
Week 52						
m	93	81	176			
n	86	74	150	81	70	141
Mean (SD/SE)	5.66 (1.42)	5.53 (1.30)	5.45 (1.40)	0.20 (0.13)	-0.07 (0.13)	-0.01 (0.11)
Median	6.15	5.70	5.70	0	0	0
IQR: Q1, Q3	4.70, 7.00	5.00, 6.70	4.70, 6.70	-0.30, 0.70	-0.60, 0.30	-0.70, 0.70
Min, Max	1.3, 7.0	2.0, 7.0	1.0, 7.0	-2.7, 3.7	-3.0, 2.7	-4.6, 3.3

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Activity						
Baseline						
m	103	98	192			
n	97	89	177			
Mean (SD)	5.33 (1.30)	5.31 (1.38)	5.44 (1.28)			
Median	5.60	5.60	5.60			
IQR: Q1, Q3	4.40, 6.40	4.40, 6.40	4.60, 6.60			
Min, Max	1.4, 7.0	1.8, 7.0	2.0, 7.0			
Week 24						
m	98	90	186			
n	95	88	168	91	81	159
Mean (SD/SE)	5.31 (1.32)	5.28 (1.28)	5.49 (1.27)	0.03 (0.10)	-0.03 (0.10)	0.07 (0.08)
Median	5.60	5.60	5.80	0	0	0
IQR: Q1, Q3	4.40, 6.40	4.40, 6.20	4.60, 6.60	-0.60, 0.60	-0.60, 0.40	-0.40, 0.60
Min, Max	1.4, 7.0	2.4, 7.0	1.2, 7.0	-1.8, 2.8	-2.2, 3.2	-3.0, 3.2
Week 52						
m	93	81	176			
n	86	74	150	81	70	141
Mean (SD/SE)	5.42 (1.34)	5.35 (1.17)	5.52 (1.33)	0.08 (0.12)	0.04 (0.09)	-0.07 (0.09)
Median	5.70	5.60	5.80	0.20	0.10	0
IQR: Q1, Q3	4.80, 6.60	4.60, 6.20	4.60, 6.60	-0.40, 0.60	-0.40, 0.40	-0.60, 0.60
Min, Max	1.6, 7.0	2.4, 7.0	1.8, 7.0	-4.4, 3.0	-2.0, 2.0	-3.4, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Emotional Health						
Baseline						
m	103	98	192			
n	97	89	177			
Mean (SD)	5.46 (1.15)	5.46 (1.29)	5.45 (1.18)			
Median	5.60	5.70	5.70			
IQR: Q1, Q3	5.00, 6.20	4.80, 6.60	4.80, 6.40			
Min, Max	1.9, 7.0	1.8, 7.0	1.8, 7.0			
Week 24						
m	98	90	186			
n	95	88	168	91	81	159
Mean (SD/SE)	5.47 (1.19)	5.40 (1.20)	5.44 (1.23)	0.06 (0.09)	-0.10 (0.08)	0.02 (0.07)
Median	5.90	5.50	5.75	0	0	0
IQR: Q1, Q3	4.70, 6.40	4.70, 6.40	4.70, 6.40	-0.30, 0.50	-0.40, 0.20	-0.60, 0.50
Min, Max	2.3, 7.0	2.2, 7.0	1.9, 7.0	-2.8, 2.1	-3.1, 2.4	-2.4, 2.6
Week 52						
m	93	81	176			
n	86	74	150	81	70	141
Mean (SD/SE)	5.51 (1.08)	5.54 (1.11)	5.54 (1.22)	0.03 (0.09)	0.04 (0.09)	0.03 (0.07)
Median	5.70	5.80	5.80	0	0	0
IQR: Q1, Q3	5.00, 6.30	4.70, 6.40	4.80, 6.60	-0.40, 0.30	-0.60, 0.40	-0.40, 0.40
Min, Max	1.9, 7.0	2.7, 7.0	1.3, 7.0	-1.9, 2.5	-1.4, 2.0	-2.0, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Fatigue						
Baseline						
m	103	98	192			
n	97	89	177			
Mean (SD)	4.87 (1.39)	4.63 (1.50)	4.63 (1.41)			
Median	5.20	5.00	4.80			
IQR: Q1, Q3	4.00, 6.00	3.70, 5.70	3.70, 5.70			
Min, Max	2.0, 7.0	1.5, 7.0	1.2, 7.0			
Week 24						
m	98	90	186			
n	95	88	168	91	81	159
Mean (SD/SE)	4.75 (1.50)	4.59 (1.39)	4.67 (1.45)	-0.04 (0.11)	-0.10 (0.08)	0.07 (0.09)
Median	4.80	4.80	4.75	0	0	0
IQR: Q1, Q3	3.70, 6.00	3.70, 5.70	3.50, 5.80	-0.70, 0.50	-0.50, 0.30	-0.50, 0.70
Min, Max	1.5, 7.0	1.5, 7.0	1.2, 7.0	-2.4, 3.2	-2.4, 2.0	-3.3, 3.0
Week 52						
m	93	81	176			
n	86	74	150	81	70	141
Mean (SD/SE)	4.96 (1.46)	4.66 (1.41)	4.79 (1.40)	0.12 (0.12)	-0.02 (0.11)	0.12 (0.09)
Median	5.20	4.90	5.00	0	0	0.10
IQR: Q1, Q3	3.80, 6.20	3.70, 5.80	3.80, 5.80	-0.30, 0.50	-0.50, 0.50	-0.50, 0.70
Min, Max	1.5, 7.0	1.5, 7.0	1.2, 7.0	-2.3, 4.0	-2.8, 2.0	-3.8, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Systemic Symptoms						
Baseline						
m	103	98	192			
n	97	89	177			
Mean (SD)	5.29 (1.21)	5.06 (1.22)	5.09 (1.22)			
Median	5.50	5.20	5.30			
IQR: Q1, Q3	4.70, 6.20	4.30, 6.00	4.30, 6.00			
Min, Max	1.5, 7.0	2.2, 7.0	1.7, 7.0			
Week 24						
m	98	90	186			
n	95	88	168	91	81	159
Mean (SD/SE)	5.23 (1.18)	4.93 (1.20)	5.11 (1.19)	-0.03 (0.08)	-0.18 (0.08)	0.00 (0.07)
Median	5.50	5.00	5.20	0	-0.20	0
IQR: Q1, Q3	4.50, 6.00	4.00, 5.90	4.25, 5.90	-0.50, 0.40	-0.50, 0.20	-0.50, 0.50
Min, Max	1.7, 7.0	2.3, 7.0	2.3, 7.0	-2.0, 2.1	-2.0, 2.2	-2.5, 2.5
Week 52						
m	93	81	176			
n	86	74	150	81	70	141
Mean (SD/SE)	5.27 (1.22)	4.96 (1.21)	5.20 (1.30)	-0.08 (0.09)	-0.14 (0.09)	0.07 (0.08)
Median	5.50	5.20	5.50	0	0	0
IQR: Q1, Q3	4.30, 6.30	4.00, 5.80	4.30, 6.30	-0.50, 0.30	-0.50, 0.30	-0.50, 0.50
Min, Max	1.3, 7.0	2.7, 7.0	1.3, 7.0	-2.0, 2.3	-2.5, 1.3	-2.7, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Worry						
Baseline						
m	103	98	192			
n	97	89	177			
Mean (SD)	5.63 (1.31)	5.69 (1.40)	5.60 (1.32)			
Median	5.70	6.10	6.00			
IQR: Q1, Q3	5.00, 6.90	4.60, 6.90	4.90, 6.70			
Min, Max	1.1, 7.0	1.9, 7.0	1.1, 7.0			
Week 24						
m	98	90	186			
n	95	88	168	91	81	159
Mean (SD/SE)	5.87 (1.33)	5.90 (1.26)	5.83 (1.31)	0.31 (0.10)	0.28 (0.12)	0.31 (0.08)
Median	6.30	6.30	6.30	0.20	0.10	0.10
IQR: Q1, Q3	5.40, 6.90	5.10, 7.00	5.30, 6.90	-0.10, 0.70	-0.20, 0.70	-0.10, 0.70
Min, Max	1.6, 7.0	2.0, 7.0	1.0, 7.0	-2.4, 3.3	-2.6, 3.6	-2.6, 3.5
Week 52						
m	93	81	176			
n	86	74	150	81	70	141
Mean (SD/SE)	6.02 (1.21)	6.05 (1.25)	6.01 (1.24)	0.38 (0.11)	0.41 (0.15)	0.37 (0.09)
Median	6.40	6.50	6.40	0.10	0	0.10
IQR: Q1, Q3	5.40, 7.00	5.60, 7.00	5.30, 7.00	0.00, 0.80	-0.20, 0.90	0.00, 0.90
Min, Max	1.9, 7.0	1.0, 7.0	1.0, 7.0	-2.5, 3.8	-3.3, 3.6	-2.7, 3.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.8.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
CLDQ-NASH			
Week 24			
m	63	51	103
n	56	44	85
Baseline Mean (SD)	5.08 (1.37)	5.25 (1.15)	5.27 (1.23)
Analysis Visit Mean (SD)	5.19 (1.24)	5.29 (1.02)	5.40 (1.20)
LS Mean of Change from Baseline (SE)	0.11 (0.09)	0.05 (0.10)	0.16 (0.07)
95% CI	(-0.07, 0.29)	(-0.15, 0.26)	(0.02, 0.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.12)	-0.11 (0.13)	
95% CI	(-0.28, 0.18)	(-0.36, 0.14)	
p-value	0.6466	0.3834	
Corrected Hedge's g Statistics	-0.078	-0.161	
95% CI	(-0.42, 0.26)	(-0.53, 0.20)	
Week 52			
m	56	44	94
n	47	36	76
Baseline Mean (SD)	5.20 (1.36)	5.28 (1.23)	5.25 (1.22)
Analysis Visit Mean (SD)	5.11 (1.28)	5.23 (1.11)	5.26 (1.17)
LS Mean of Change from Baseline (SE)	-0.06 (0.09)	0.00 (0.10)	0.04 (0.07)
95% CI	(-0.23, 0.12)	(-0.19, 0.20)	(-0.09, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.11)	-0.04 (0.12)	
95% CI	(-0.32, 0.12)	(-0.28, 0.20)	
p-value	0.3591	0.7445	
Corrected Hedge's g Statistics	-0.168	-0.065	
95% CI	(-0.53, 0.20)	(-0.46, 0.33)	
Subgroup*Treatment Interaction p-value	0.6698	0.6353	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
CLDQ-NASH			
Week 24			
m	98	90	186
n	91	81	159
Baseline Mean (SD)	5.30 (1.05)	5.28 (1.13)	5.25 (1.05)
Analysis Visit Mean (SD)	5.36 (1.10)	5.23 (1.05)	5.36 (1.03)
LS Mean of Change from Baseline (SE)	0.07 (0.07)	-0.05 (0.07)	0.11 (0.05)
95% CI	(-0.06, 0.21)	(-0.19, 0.09)	(0.01, 0.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.08)	-0.15 (0.09)	
95% CI	(-0.20, 0.13)	(-0.32, 0.02)	
p-value	0.6675	0.0762	
Corrected Hedge's g Statistics	-0.055	-0.237	
95% CI	(-0.31, 0.20)	(-0.51, 0.03)	
Week 52			
m	93	81	176
n	81	70	141
Baseline Mean (SD)	5.34 (1.05)	5.30 (1.10)	5.35 (1.02)
Analysis Visit Mean (SD)	5.47 (1.07)	5.33 (0.99)	5.44 (1.06)
LS Mean of Change from Baseline (SE)	0.12 (0.07)	0.02 (0.08)	0.12 (0.06)
95% CI	(-0.03, 0.26)	(-0.14, 0.17)	(0.02, 0.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.09)	-0.11 (0.09)	
95% CI	(-0.19, 0.17)	(-0.29, 0.08)	
p-value	0.9302	0.2560	
Corrected Hedge's g Statistics	-0.012	-0.163	
95% CI	(-0.29, 0.26)	(-0.45, 0.12)	
Subgroup*Treatment Interaction p-value	0.6698	0.6353	

AMNOG Table SE23.8.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.8.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Abdominal Symptoms			
Week 24			
m	63	51	103
n	56	44	85
Baseline Mean (SD)	5.12 (1.75)	5.64 (1.35)	5.20 (1.56)
Analysis Visit Mean (SD)	5.39 (1.47)	5.65 (1.41)	5.49 (1.52)
LS Mean of Change from Baseline (SE)	0.26 (0.14)	0.16 (0.16)	0.29 (0.11)
95% CI	(-0.02, 0.53)	(-0.16, 0.47)	(0.06, 0.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.18)	-0.13 (0.19)	
95% CI	(-0.38, 0.32)	(-0.51, 0.25)	
p-value	0.8755	0.5059	
Corrected Hedge's g Statistics	-0.027	-0.123	
95% CI	(-0.36, 0.31)	(-0.49, 0.24)	
Week 52			
m	56	44	94
n	47	36	76
Baseline Mean (SD)	5.24 (1.72)	5.73 (1.36)	5.14 (1.56)
Analysis Visit Mean (SD)	5.23 (1.59)	5.67 (1.27)	5.45 (1.42)
LS Mean of Change from Baseline (SE)	0.03 (0.14)	0.10 (0.16)	0.28 (0.11)
95% CI	(-0.25, 0.31)	(-0.22, 0.42)	(0.06, 0.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.25 (0.18)	-0.18 (0.20)	
95% CI	(-0.60, 0.10)	(-0.57, 0.21)	
p-value	0.1612	0.3573	
Corrected Hedge's g Statistics	-0.256	-0.185	
95% CI	(-0.62, 0.11)	(-0.58, 0.21)	
Subgroup*Treatment Interaction p-value	0.6288	0.7813	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Activity			
Week 24			
m	63	51	103
n	56	44	85
Baseline Mean (SD)	5.24 (1.57)	5.42 (1.20)	5.46 (1.52)
Analysis Visit Mean (SD)	5.19 (1.64)	5.61 (1.22)	5.54 (1.42)
LS Mean of Change from Baseline (SE)	-0.06 (0.12)	0.18 (0.14)	0.10 (0.10)
95% CI	(-0.30, 0.19)	(-0.09, 0.45)	(-0.09, 0.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.16 (0.16)	0.08 (0.17)	
95% CI	(-0.47, 0.15)	(-0.26, 0.41)	
p-value	0.3148	0.6490	
Corrected Hedge's g Statistics	-0.171	0.084	
95% CI	(-0.51, 0.17)	(-0.28, 0.45)	
Week 52			
m	56	44	94
n	47	36	76
Baseline Mean (SD)	5.45 (1.47)	5.49 (1.30)	5.45 (1.46)
Analysis Visit Mean (SD)	5.18 (1.75)	5.31 (1.42)	5.27 (1.47)
LS Mean of Change from Baseline (SE)	-0.24 (0.13)	-0.11 (0.15)	-0.14 (0.11)
95% CI	(-0.50, 0.02)	(-0.41, 0.18)	(-0.35, 0.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.17)	0.03 (0.18)	
95% CI	(-0.43, 0.23)	(-0.33, 0.39)	
p-value	0.5542	0.8835	
Corrected Hedge's g Statistics	-0.108	0.029	
95% CI	(-0.47, 0.26)	(-0.37, 0.43)	
Subgroup*Treatment Interaction p-value	0.4995	0.4112	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Emotional Health			
Week 24			
m	63	51	103
n	56	44	85
Baseline Mean (SD)	5.18 (1.42)	5.23 (1.31)	5.41 (1.27)
Analysis Visit Mean (SD)	5.32 (1.33)	5.21 (1.29)	5.48 (1.25)
LS Mean of Change from Baseline (SE)	0.10 (0.11)	-0.05 (0.12)	0.10 (0.08)
95% CI	(-0.10, 0.31)	(-0.29, 0.18)	(-0.07, 0.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.13)	-0.15 (0.14)	
95% CI	(-0.26, 0.27)	(-0.44, 0.13)	
p-value	0.9632	0.2981	
Corrected Hedge's g Statistics	0.008	-0.192	
95% CI	(-0.33, 0.35)	(-0.56, 0.17)	
Week 52			
m	56	44	94
n	47	36	76
Baseline Mean (SD)	5.30 (1.39)	5.24 (1.41)	5.41 (1.27)
Analysis Visit Mean (SD)	5.28 (1.21)	5.24 (1.36)	5.39 (1.27)
LS Mean of Change from Baseline (SE)	-0.02 (0.11)	0.00 (0.13)	-0.01 (0.09)
95% CI	(-0.24, 0.20)	(-0.25, 0.25)	(-0.18, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.14)	0.01 (0.15)	
95% CI	(-0.29, 0.26)	(-0.30, 0.31)	
p-value	0.9138	0.9649	
Corrected Hedge's g Statistics	-0.020	0.009	
95% CI	(-0.38, 0.34)	(-0.39, 0.41)	
Subgroup*Treatment Interaction p-value	0.8811	0.8964	

AMNOG Table SE23.8.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Fatigue			
Week 24			
m	63	51	103
n	56	44	85
Baseline Mean (SD)	4.61 (1.66)	4.55 (1.33)	4.70 (1.49)
Analysis Visit Mean (SD)	4.68 (1.51)	4.44 (1.32)	4.73 (1.49)
LS Mean of Change from Baseline (SE)	0.09 (0.14)	-0.15 (0.16)	0.07 (0.11)
95% CI	(-0.18, 0.37)	(-0.46, 0.17)	(-0.16, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.18)	-0.21 (0.19)	
95% CI	(-0.33, 0.38)	(-0.59, 0.17)	
p-value	0.8759	0.2757	
Corrected Hedge's g Statistics	0.027	-0.201	
95% CI	(-0.31, 0.36)	(-0.57, 0.16)	
Week 52			
m	56	44	94
n	47	36	76
Baseline Mean (SD)	4.70 (1.69)	4.63 (1.45)	4.69 (1.45)
Analysis Visit Mean (SD)	4.54 (1.62)	4.40 (1.50)	4.54 (1.54)
LS Mean of Change from Baseline (SE)	-0.12 (0.14)	-0.15 (0.16)	-0.11 (0.11)
95% CI	(-0.40, 0.17)	(-0.47, 0.17)	(-0.33, 0.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.18)	-0.04 (0.20)	
95% CI	(-0.36, 0.35)	(-0.43, 0.35)	
p-value	0.9763	0.8481	
Corrected Hedge's g Statistics	-0.005	-0.038	
95% CI	(-0.37, 0.36)	(-0.43, 0.36)	
Subgroup*Treatment Interaction p-value	0.8530	0.8474	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Systemic Symptoms			
Week 24			
m	63	51	103
n	56	44	85
Baseline Mean (SD)	4.99 (1.39)	5.18 (1.23)	5.15 (1.26)
Analysis Visit Mean (SD)	5.01 (1.33)	5.07 (1.25)	5.16 (1.36)
LS Mean of Change from Baseline (SE)	0.04 (0.11)	-0.08 (0.12)	0.04 (0.09)
95% CI	(-0.18, 0.25)	(-0.32, 0.15)	(-0.13, 0.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.14)	-0.12 (0.15)	
95% CI	(-0.27, 0.27)	(-0.41, 0.17)	
p-value	0.9834	0.4037	
Corrected Hedge's g Statistics	-0.004	-0.154	
95% CI	(-0.34, 0.33)	(-0.52, 0.21)	
Week 52			
m	56	44	94
n	47	36	76
Baseline Mean (SD)	5.14 (1.36)	5.17 (1.24)	5.08 (1.27)
Analysis Visit Mean (SD)	4.86 (1.39)	5.10 (1.24)	4.97 (1.43)
LS Mean of Change from Baseline (SE)	-0.21 (0.11)	-0.04 (0.13)	-0.06 (0.09)
95% CI	(-0.44, 0.02)	(-0.30, 0.21)	(-0.24, 0.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.15)	0.02 (0.16)	
95% CI	(-0.43, 0.14)	(-0.29, 0.33)	
p-value	0.3200	0.8943	
Corrected Hedge's g Statistics	-0.182	0.026	
95% CI	(-0.55, 0.18)	(-0.37, 0.42)	
Subgroup*Treatment Interaction p-value	0.9590	0.2935	

AMNOG Table SE23.8.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Worry			
Week 24			
m	63	51	103
n	56	44	85
Baseline Mean (SD)	5.33 (1.55)	5.43 (1.69)	5.69 (1.49)
Analysis Visit Mean (SD)	5.58 (1.45)	5.71 (1.46)	5.99 (1.43)
LS Mean of Change from Baseline (SE)	0.21 (0.12)	0.27 (0.14)	0.38 (0.10)
95% CI	(-0.03, 0.46)	(0.00, 0.54)	(0.19, 0.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.17 (0.16)	-0.11 (0.17)	
95% CI	(-0.47, 0.14)	(-0.44, 0.22)	
p-value	0.2890	0.5129	
Corrected Hedge's g Statistics	-0.181	-0.120	
95% CI	(-0.52, 0.16)	(-0.48, 0.24)	
Week 52			
m	56	44	94
n	47	36	76
Baseline Mean (SD)	5.36 (1.62)	5.43 (1.78)	5.70 (1.44)
Analysis Visit Mean (SD)	5.57 (1.52)	5.71 (1.57)	5.95 (1.38)
LS Mean of Change from Baseline (SE)	0.17 (0.14)	0.31 (0.16)	0.31 (0.11)
95% CI	(-0.11, 0.45)	(0.00, 0.62)	(0.09, 0.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.18)	0.00 (0.19)	
95% CI	(-0.49, 0.21)	(-0.38, 0.38)	
p-value	0.4401	0.9889	
Corrected Hedge's g Statistics	-0.142	0.003	
95% CI	(-0.51, 0.22)	(-0.39, 0.40)	
Subgroup*Treatment Interaction p-value	0.3006	0.7699	

AMNOG Table SE23.8.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Abdominal Symptoms			
Week 24			
m	98	90	186
n	91	81	159
Baseline Mean (SD)	5.39 (1.55)	5.49 (1.43)	5.35 (1.48)
Analysis Visit Mean (SD)	5.38 (1.47)	5.33 (1.54)	5.50 (1.36)
LS Mean of Change from Baseline (SE)	-0.03 (0.12)	-0.15 (0.12)	0.13 (0.09)
95% CI	(-0.25, 0.20)	(-0.39, 0.08)	(-0.04, 0.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.16 (0.14)	-0.28 (0.15)	
95% CI	(-0.43, 0.12)	(-0.57, 0.00)	
p-value	0.2656	0.0541	
Corrected Hedge's g Statistics	-0.143	-0.258	
95% CI	(-0.40, 0.12)	(-0.53, 0.01)	
Week 52			
m	93	81	176
n	81	70	141
Baseline Mean (SD)	5.44 (1.52)	5.60 (1.33)	5.48 (1.39)
Analysis Visit Mean (SD)	5.65 (1.44)	5.53 (1.33)	5.47 (1.37)
LS Mean of Change from Baseline (SE)	0.16 (0.12)	-0.07 (0.13)	0.04 (0.09)
95% CI	(-0.08, 0.40)	(-0.32, 0.19)	(-0.14, 0.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.12 (0.15)	-0.10 (0.16)	
95% CI	(-0.17, 0.41)	(-0.41, 0.21)	
p-value	0.4220	0.5184	
Corrected Hedge's g Statistics	0.110	-0.093	
95% CI	(-0.16, 0.38)	(-0.38, 0.19)	
Subgroup*Treatment Interaction p-value	0.6288	0.7813	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.8.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Activity			
Week 24			
m	98	90	186
n	91	81	159
Baseline Mean (SD)	5.30 (1.29)	5.32 (1.38)	5.45 (1.27)
Analysis Visit Mean (SD)	5.32 (1.33)	5.28 (1.26)	5.52 (1.27)
LS Mean of Change from Baseline (SE)	0.02 (0.09)	-0.05 (0.10)	0.10 (0.07)
95% CI	(-0.16, 0.21)	(-0.24, 0.14)	(-0.04, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.11)	-0.15 (0.12)	
95% CI	(-0.30, 0.15)	(-0.38, 0.08)	
p-value	0.4986	0.2082	
Corrected Hedge's g Statistics	-0.087	-0.168	
95% CI	(-0.34, 0.17)	(-0.44, 0.10)	
Week 52			
m	93	81	176
n	81	70	141
Baseline Mean (SD)	5.30 (1.31)	5.29 (1.36)	5.59 (1.19)
Analysis Visit Mean (SD)	5.38 (1.35)	5.33 (1.19)	5.53 (1.34)
LS Mean of Change from Baseline (SE)	0.06 (0.11)	0.02 (0.11)	0.02 (0.08)
95% CI	(-0.15, 0.27)	(-0.20, 0.24)	(-0.14, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.13)	0.00 (0.14)	
95% CI	(-0.21, 0.30)	(-0.27, 0.27)	
p-value	0.7405	0.9957	
Corrected Hedge's g Statistics	0.045	-0.001	
95% CI	(-0.23, 0.32)	(-0.29, 0.29)	
Subgroup*Treatment Interaction p-value	0.4995	0.4112	

AMNOG Table SE23.8.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Emotional Health			
Week 24			
m	98	90	186
n	91	81	159
Baseline Mean (SD)	5.46 (1.11)	5.46 (1.31)	5.43 (1.20)
Analysis Visit Mean (SD)	5.52 (1.17)	5.36 (1.22)	5.45 (1.23)
LS Mean of Change from Baseline (SE)	0.06 (0.09)	-0.10 (0.09)	0.01 (0.06)
95% CI	(-0.11, 0.23)	(-0.28, 0.07)	(-0.12, 0.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.06 (0.10)	-0.11 (0.11)	
95% CI	(-0.15, 0.26)	(-0.32, 0.10)	
p-value	0.5893	0.3071	
Corrected Hedge's g Statistics	0.069	-0.137	
95% CI	(-0.19, 0.33)	(-0.40, 0.13)	
Week 52			
m	93	81	176
n	81	70	141
Baseline Mean (SD)	5.50 (1.12)	5.46 (1.33)	5.52 (1.21)
Analysis Visit Mean (SD)	5.53 (1.04)	5.50 (1.12)	5.54 (1.22)
LS Mean of Change from Baseline (SE)	0.02 (0.08)	0.04 (0.09)	0.03 (0.06)
95% CI	(-0.15, 0.18)	(-0.13, 0.21)	(-0.09, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.10)	0.01 (0.11)	
95% CI	(-0.21, 0.19)	(-0.20, 0.22)	
p-value	0.8849	0.9370	
Corrected Hedge's g Statistics	-0.020	0.011	
95% CI	(-0.29, 0.25)	(-0.28, 0.30)	
Subgroup*Treatment Interaction p-value	0.8811	0.8964	

AMNOG Table SE23.8.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Fatigue			
Week 24			
m	98	90	186
n	91	81	159
Baseline Mean (SD)	4.84 (1.37)	4.66 (1.54)	4.62 (1.43)
Analysis Visit Mean (SD)	4.80 (1.49)	4.56 (1.42)	4.69 (1.45)
LS Mean of Change from Baseline (SE)	0.00 (0.10)	-0.11 (0.11)	0.05 (0.08)
95% CI	(-0.20, 0.20)	(-0.32, 0.10)	(-0.10, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.12)	-0.16 (0.13)	
95% CI	(-0.29, 0.19)	(-0.41, 0.09)	
p-value	0.6842	0.2039	
Corrected Hedge's g Statistics	-0.052	-0.170	
95% CI	(-0.31, 0.21)	(-0.44, 0.10)	
Week 52			
m	93	81	176
n	81	70	141
Baseline Mean (SD)	4.84 (1.39)	4.65 (1.52)	4.70 (1.40)
Analysis Visit Mean (SD)	4.97 (1.43)	4.62 (1.43)	4.82 (1.39)
LS Mean of Change from Baseline (SE)	0.12 (0.11)	-0.05 (0.12)	0.13 (0.08)
95% CI	(-0.10, 0.34)	(-0.28, 0.19)	(-0.04, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.14)	-0.17 (0.14)	
95% CI	(-0.27, 0.26)	(-0.45, 0.11)	
p-value	0.9765	0.2232	
Corrected Hedge's g Statistics	-0.004	-0.175	
95% CI	(-0.28, 0.27)	(-0.46, 0.11)	
Subgroup*Treatment Interaction p-value	0.8530	0.8474	

AMNOG Table SE23.8.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Systemic Symptoms			
Week 24			
m	98	90	186
n	91	81	159
Baseline Mean (SD)	5.25 (1.17)	5.08 (1.23)	5.12 (1.19)
Analysis Visit Mean (SD)	5.22 (1.20)	4.90 (1.18)	5.12 (1.20)
LS Mean of Change from Baseline (SE)	0.01 (0.08)	-0.18 (0.09)	0.02 (0.06)
95% CI	(-0.15, 0.18)	(-0.35, -0.01)	(-0.11, 0.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.10)	-0.20 (0.11)	
95% CI	(-0.20, 0.20)	(-0.41, 0.01)	
p-value	0.9914	0.0606	
Corrected Hedge's g Statistics	-0.001	-0.251	
95% CI	(-0.26, 0.26)	(-0.52, 0.02)	
Week 52			
m	93	81	176
n	81	70	141
Baseline Mean (SD)	5.31 (1.14)	5.08 (1.20)	5.15 (1.23)
Analysis Visit Mean (SD)	5.23 (1.23)	4.94 (1.21)	5.22 (1.29)
LS Mean of Change from Baseline (SE)	-0.04 (0.09)	-0.16 (0.09)	0.11 (0.07)
95% CI	(-0.21, 0.14)	(-0.34, 0.03)	(-0.02, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.11)	-0.27 (0.11)	
95% CI	(-0.36, 0.07)	(-0.49, -0.04)	
p-value	0.1952	0.0209	
Corrected Hedge's g Statistics	-0.177	-0.332	
95% CI	(-0.45, 0.10)	(-0.62, -0.04)	
Subgroup*Treatment Interaction p-value	0.9590	0.2935	

AMNOG Table SE23.8.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Worry			
Week 24			
m	98	90	186
n	91	81	159
Baseline Mean (SD)	5.61 (1.30)	5.62 (1.43)	5.56 (1.34)
Analysis Visit Mean (SD)	5.92 (1.27)	5.90 (1.28)	5.87 (1.29)
LS Mean of Change from Baseline (SE)	0.33 (0.10)	0.29 (0.10)	0.31 (0.07)
95% CI	(0.14, 0.52)	(0.09, 0.49)	(0.17, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (0.12)	-0.02 (0.12)	
95% CI	(-0.21, 0.26)	(-0.26, 0.22)	
p-value	0.8408	0.8753	
Corrected Hedge's g Statistics	0.026	-0.021	
95% CI	(-0.23, 0.28)	(-0.29, 0.25)	
Week 52			
m	93	81	176
n	81	70	141
Baseline Mean (SD)	5.69 (1.28)	5.65 (1.43)	5.67 (1.32)
Analysis Visit Mean (SD)	6.07 (1.14)	6.05 (1.26)	6.04 (1.20)
LS Mean of Change from Baseline (SE)	0.39 (0.10)	0.40 (0.11)	0.40 (0.08)
95% CI	(0.18, 0.59)	(0.19, 0.62)	(0.24, 0.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.13)	0.01 (0.13)	
95% CI	(-0.26, 0.24)	(-0.25, 0.27)	
p-value	0.9368	0.9570	
Corrected Hedge's g Statistics	-0.011	0.008	
95% CI	(-0.28, 0.26)	(-0.28, 0.29)	
Subgroup*Treatment Interaction p-value	0.3006	0.7699	

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (6.3)	3 (5.7)	6 (5.4)
No	60 (93.8)	50 (94.3)	105 (94.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.95	
95% CI of the inverse odds ratio	(0.23, 3.16)	(0.23, 3.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.95	
95% CI of the inverse risk ratio	(0.25, 2.95)	(0.25, 3.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.84	0.25	
95% CI of the absolute risk difference	(-6.43, 8.12)	(-7.26, 7.76)	
p-value	0.8167	0.9465	
p-value of Breslow-Day Test for Homogeneity [3]	0.4393	0.7081	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (18.8)	11 (20.8)	19 (17.1)
No	52 (81.3)	42 (79.2)	92 (82.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.79	
95% CI of the inverse odds ratio	(0.40, 1.99)	(0.34, 1.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.82	
95% CI of the inverse risk ratio	(0.47, 1.76)	(0.42, 1.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.63	3.64	
95% CI of the absolute risk difference	(-10.22, 13.49)	(-9.34, 16.61)	
p-value	0.7852	0.5731	
p-value of Breslow-Day Test for Homogeneity [3]	0.7159	0.2595	

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (20.3)	4 (7.5)	22 (19.8)
No	51 (79.7)	49 (92.5)	89 (80.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	3.03	
95% CI of the inverse odds ratio	(0.45, 2.09)	(0.99, 9.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	2.63	
95% CI of the inverse risk ratio	(0.53, 1.80)	(0.95, 7.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.49	-12.27	
95% CI of the absolute risk difference	(-11.84, 12.83)	(-22.55, -2.00)	
p-value	0.9374	0.0442	
p-value of Breslow-Day Test for Homogeneity [3]	0.9585	0.2071	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (28.1)	9 (17.0)	38 (34.2)
No	46 (71.9)	44 (83.0)	73 (65.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	2.54	
95% CI of the inverse odds ratio	(0.68, 2.60)	(1.12, 5.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	2.02	
95% CI of the inverse risk ratio	(0.76, 1.95)	(1.05, 3.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.11	-17.25	
95% CI of the absolute risk difference	(-20.22, 8.01)	(-30.67, -3.83)	
p-value	0.4040	0.0223	
p-value of Breslow-Day Test for Homogeneity [3]	0.1708	0.3525	

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (9.4)	7 (13.2)	5 (4.5)
No	58 (90.6)	46 (86.8)	106 (95.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.46	0.31	
95% CI of the inverse odds ratio	(0.13, 1.56)	(0.09, 1.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	0.34	
95% CI of the inverse risk ratio	(0.15, 1.51)	(0.11, 1.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.87	8.70	
95% CI of the absolute risk difference	(-3.25, 12.99)	(-1.20, 18.60)	
p-value	0.2010	0.0453	
p-value of Breslow-Day Test for Homogeneity [3]	0.4622	0.1042	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (23.4)	13 (24.5)	18 (16.2)
No	49 (76.6)	40 (75.5)	93 (83.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.60	
95% CI of the inverse odds ratio	(0.29, 1.36)	(0.27, 1.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.66	
95% CI of the inverse risk ratio	(0.38, 1.28)	(0.35, 1.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.22	8.31	
95% CI of the absolute risk difference	(-5.22, 19.66)	(-5.15, 21.77)	
p-value	0.2395	0.2035	
p-value of Breslow-Day Test for Homogeneity [3]	0.7418	0.2750	

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (10.9)	3 (5.7)	10 (9.0)
No	57 (89.1)	50 (94.3)	101 (91.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	1.65	
95% CI of the inverse odds ratio	(0.29, 2.23)	(0.43, 6.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.59	
95% CI of the inverse risk ratio	(0.33, 2.06)	(0.46, 5.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.93	-3.35	
95% CI of the absolute risk difference	(-7.39, 11.25)	(-11.54, 4.84)	
p-value	0.6782	0.4579	
p-value of Breslow-Day Test for Homogeneity [3]	0.8119	0.2916	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (23.4)	12 (22.6)	25 (22.5)
No	49 (76.6)	41 (77.4)	86 (77.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.99	
95% CI of the inverse odds ratio	(0.46, 1.97)	(0.45, 2.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.99	
95% CI of the inverse risk ratio	(0.55, 1.68)	(0.54, 1.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.91	0.12	
95% CI of the absolute risk difference	(-12.05, 13.88)	(-13.57, 13.81)	
p-value	0.8896	0.9864	
p-value of Breslow-Day Test for Homogeneity [3]	0.5460	0.8998	

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (6.3)	6 (11.3)	9 (8.1)
No	60 (93.8)	47 (88.7)	102 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	0.69	
95% CI of the inverse odds ratio	(0.39, 4.48)	(0.23, 2.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	0.72	
95% CI of the inverse risk ratio	(0.42, 4.04)	(0.27, 1.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.86	3.21	
95% CI of the absolute risk difference	(-9.67, 5.95)	(-6.71, 13.14)	
p-value	0.6517	0.5045	
p-value of Breslow-Day Test for Homogeneity [3]	0.8721	0.5882	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (28.1)	9 (17.0)	24 (21.6)
No	46 (71.9)	44 (83.0)	87 (78.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	1.35	
95% CI of the inverse odds ratio	(0.35, 1.43)	(0.58, 3.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.27	
95% CI of the inverse risk ratio	(0.45, 1.30)	(0.64, 2.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.50	-4.64	
95% CI of the absolute risk difference	(-6.91, 19.92)	(-17.32, 8.04)	
p-value	0.3319	0.4882	
p-value of Breslow-Day Test for Homogeneity [3]	0.2486	0.7812	

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.1)	6 (11.3)	6 (5.4)
No	62 (96.9)	47 (88.7)	105 (94.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	0.45	
95% CI of the inverse odds ratio	(0.35, 9.05)	(0.14, 1.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.73	0.48	
95% CI of the inverse risk ratio	(0.36, 8.32)	(0.16, 1.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.28	5.92	
95% CI of the absolute risk difference	(-8.27, 3.71)	(-3.60, 15.43)	
p-value	0.4867	0.1737	
p-value of Breslow-Day Test for Homogeneity [3]	0.8622	0.0469	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (18.8)	12 (22.6)	21 (18.9)
No	52 (81.3)	41 (77.4)	90 (81.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.80	
95% CI of the inverse odds ratio	(0.46, 2.22)	(0.36, 1.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.84	
95% CI of the inverse risk ratio	(0.53, 1.91)	(0.45, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.17	3.72	
95% CI of the absolute risk difference	(-12.19, 11.85)	(-9.70, 17.14)	
p-value	0.9781	0.5781	
p-value of Breslow-Day Test for Homogeneity [3]	0.5501	0.2945	

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (18.8)	7 (13.2)	15 (13.5)
No	52 (81.3)	46 (86.8)	96 (86.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	1.03	
95% CI of the inverse odds ratio	(0.30, 1.55)	(0.39, 2.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	1.02	
95% CI of the inverse risk ratio	(0.36, 1.44)	(0.44, 2.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.24	-0.31	
95% CI of the absolute risk difference	(-6.25, 16.72)	(-11.42, 10.81)	
p-value	0.3557	0.9571	
p-value of Breslow-Day Test for Homogeneity [3]	0.3638	0.9989	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (32.8)	14 (26.4)	33 (29.7)
No	43 (67.2)	39 (73.6)	78 (70.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.18	
95% CI of the inverse odds ratio	(0.45, 1.68)	(0.57, 2.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.13	
95% CI of the inverse risk ratio	(0.58, 1.42)	(0.66, 1.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.08	-3.31	
95% CI of the absolute risk difference	(-11.22, 17.39)	(-17.92, 11.29)	
p-value	0.6707	0.6606	
p-value of Breslow-Day Test for Homogeneity [3]	0.7806	0.9872	

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (6.8)	8 (8.2)	20 (10.4)
No	96 (93.2)	90 (91.8)	172 (89.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	1.31	
95% CI of the inverse odds ratio	(0.65, 3.91)	(0.55, 3.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	1.28	
95% CI of the inverse risk ratio	(0.67, 3.50)	(0.58, 2.79)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.62	-2.25	
95% CI of the absolute risk difference	(-10.12, 2.88)	(-9.19, 4.68)	
p-value	0.3039	0.5388	
p-value of Breslow-Day Test for Homogeneity [3]	0.4393	0.7081	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (25.2)	20 (20.4)	51 (26.6)
No	77 (74.8)	78 (79.6)	141 (73.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.41	
95% CI of the inverse odds ratio	(0.62, 1.85)	(0.78, 2.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.30	
95% CI of the inverse risk ratio	(0.70, 1.58)	(0.82, 2.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.32	-6.15	
95% CI of the absolute risk difference	(-11.78, 9.14)	(-16.29, 3.98)	
p-value	0.8056	0.2490	
p-value of Breslow-Day Test for Homogeneity [3]	0.7159	0.2595	

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (17.5)	13 (13.3)	32 (16.7)
No	85 (82.5)	85 (86.7)	160 (83.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.31	
95% CI of the inverse odds ratio	(0.50, 1.78)	(0.65, 2.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	1.26	
95% CI of the inverse risk ratio	(0.56, 1.61)	(0.69, 2.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.81	-3.40	
95% CI of the absolute risk difference	(-8.22, 9.84)	(-11.94, 5.14)	
p-value	0.8599	0.4492	
p-value of Breslow-Day Test for Homogeneity [3]	0.9585	0.2071	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	38 (36.9)	21 (21.4)	58 (30.2)
No	65 (63.1)	77 (78.6)	134 (69.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.59	
95% CI of the inverse odds ratio	(0.45, 1.23)	(0.90, 2.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.41	
95% CI of the inverse risk ratio	(0.59, 1.14)	(0.91, 2.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.68	-8.78	
95% CI of the absolute risk difference	(-4.67, 18.04)	(-19.18, 1.62)	
p-value	0.2427	0.1122	
p-value of Breslow-Day Test for Homogeneity [3]	0.1708	0.3525	

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (11.7)	9 (9.2)	18 (9.4)
No	91 (88.3)	89 (90.8)	174 (90.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.02	
95% CI of the inverse odds ratio	(0.36, 1.70)	(0.44, 2.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.02	
95% CI of the inverse risk ratio	(0.40, 1.60)	(0.48, 2.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.28	-0.19	
95% CI of the absolute risk difference	(-5.17, 9.72)	(-7.24, 6.86)	
p-value	0.5376	0.9577	
p-value of Breslow-Day Test for Homogeneity [3]	0.4622	0.1042	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (31.1)	24 (24.5)	48 (25.0)
No	71 (68.9)	74 (75.5)	144 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.03	
95% CI of the inverse odds ratio	(0.44, 1.26)	(0.58, 1.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.02	
95% CI of the inverse risk ratio	(0.55, 1.17)	(0.67, 1.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.07	-0.51	
95% CI of the absolute risk difference	(-4.77, 16.90)	(-11.00, 9.98)	
p-value	0.2638	0.9242	
p-value of Breslow-Day Test for Homogeneity [3]	0.7418	0.2750	

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (11.7)	11 (11.2)	16 (8.3)
No	91 (88.3)	87 (88.8)	176 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.72	
95% CI of the inverse odds ratio	(0.31, 1.52)	(0.32, 1.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.74	
95% CI of the inverse risk ratio	(0.35, 1.45)	(0.36, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.32	2.89	
95% CI of the absolute risk difference	(-4.01, 10.64)	(-4.48, 10.26)	
p-value	0.3541	0.4229	
p-value of Breslow-Day Test for Homogeneity [3]	0.8119	0.2916	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (20.4)	23 (23.5)	47 (24.5)
No	82 (79.6)	75 (76.5)	145 (75.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	1.06	
95% CI of the inverse odds ratio	(0.71, 2.26)	(0.60, 1.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	1.04	
95% CI of the inverse risk ratio	(0.76, 1.89)	(0.67, 1.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.09	-1.01	
95% CI of the absolute risk difference	(-13.97, 5.78)	(-11.37, 9.35)	
p-value	0.4264	0.8492	
p-value of Breslow-Day Test for Homogeneity [3]	0.5460	0.8998	

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (10.7)	15 (15.3)	29 (15.1)
No	92 (89.3)	83 (84.7)	163 (84.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.49	0.98	
95% CI of the inverse odds ratio	(0.71, 3.12)	(0.50, 1.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	0.99	
95% CI of the inverse risk ratio	(0.74, 2.71)	(0.56, 1.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.42	0.20	
95% CI of the absolute risk difference	(-12.25, 3.40)	(-8.54, 8.95)	
p-value	0.2900	0.9638	
p-value of Breslow-Day Test for Homogeneity [3]	0.8721	0.5882	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (26.2)	26 (26.5)	57 (29.7)
No	76 (73.8)	72 (73.5)	135 (70.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	1.17	
95% CI of the inverse odds ratio	(0.69, 2.03)	(0.68, 2.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	1.12	
95% CI of the inverse risk ratio	(0.77, 1.67)	(0.75, 1.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.47	-3.16	
95% CI of the absolute risk difference	(-14.15, 7.20)	(-14.03, 7.71)	
p-value	0.5285	0.5737	
p-value of Breslow-Day Test for Homogeneity [3]	0.2486	0.7812	

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (5.8)	6 (6.1)	22 (11.5)
No	97 (94.2)	92 (93.9)	170 (88.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.09	1.98	
95% CI of the inverse odds ratio	(0.82, 5.34)	(0.78, 5.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.97	1.87	
95% CI of the inverse risk ratio	(0.82, 4.70)	(0.78, 4.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.63	-5.34	
95% CI of the absolute risk difference	(-12.02, 0.75)	(-11.88, 1.21)	
p-value	0.1156	0.1456	
p-value of Breslow-Day Test for Homogeneity [3]	0.8622	0.0469	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (23.3)	23 (23.5)	56 (29.2)
No	79 (76.7)	75 (76.5)	136 (70.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	1.34	
95% CI of the inverse odds ratio	(0.78, 2.36)	(0.77, 2.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.24	
95% CI of the inverse risk ratio	(0.83, 1.89)	(0.82, 1.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.87	-5.70	
95% CI of the absolute risk difference	(-16.26, 4.53)	(-16.27, 4.87)	
p-value	0.2800	0.3026	
p-value of Breslow-Day Test for Homogeneity [3]	0.5501	0.2945	

AMNOG Table SE23.8.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	19 (18.4)	19 (19.4)	38 (19.8)
No	84 (81.6)	79 (80.6)	154 (80.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.09	1.03	
95% CI of the inverse odds ratio	(0.59, 2.01)	(0.56, 1.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.02	
95% CI of the inverse risk ratio	(0.65, 1.76)	(0.62, 1.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.35	-0.40	
95% CI of the absolute risk difference	(-10.72, 8.03)	(-10.05, 9.24)	
p-value	0.7803	0.9347	
p-value of Breslow-Day Test for Homogeneity [3]	0.3638	0.9989	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	36 (35.0)	30 (30.6)	66 (34.4)
No	67 (65.0)	68 (69.4)	126 (65.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	1.19	
95% CI of the inverse odds ratio	(0.59, 1.61)	(0.70, 2.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.12	
95% CI of the inverse risk ratio	(0.71, 1.37)	(0.79, 1.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.58	-3.76	
95% CI of the absolute risk difference	(-10.82, 11.98)	(-15.09, 7.57)	
p-value	0.9210	0.5195	
p-value of Breslow-Day Test for Homogeneity [3]	0.7806	0.9872	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE23.9.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
CLDQ-NASH						
Baseline						
m	27	22	39			
n	27	18	36			
Mean (SD)	5.16 (1.28)	4.81 (1.36)	5.23 (1.23)			
Median	5.40	5.35	5.30			
IQR: Q1, Q3	4.50, 6.10	3.40, 5.60	4.15, 6.30			
Min, Max	2.0, 6.9	2.2, 7.0	3.0, 7.0			
Week 24						
m	27	22	37			
n	24	22	34	24	18	31
Mean (SD/SE)	5.10 (1.32)	4.96 (1.18)	5.25 (1.27)	-0.04 (0.15)	0.09 (0.16)	0.20 (0.12)
Median	5.50	5.20	5.30	0	-0.20	0.10
IQR: Q1, Q3	4.35, 6.20	4.00, 5.70	4.30, 6.30	-0.30, 0.30	-0.40, 0.60	-0.20, 0.60
Min, Max	2.5, 6.5	2.9, 6.8	2.6, 7.0	-2.6, 1.1	-0.8, 1.6	-0.9, 1.8
Week 52						
m	25	19	36			
n	23	19	32	23	16	29
Mean (SD/SE)	5.10 (1.17)	4.90 (1.11)	5.37 (1.34)	-0.01 (0.13)	-0.01 (0.20)	0.11 (0.10)
Median	5.40	4.80	5.70	0	-0.10	-0.10
IQR: Q1, Q3	4.30, 6.10	4.10, 5.70	4.35, 6.45	-0.30, 0.20	-0.45, 0.30	-0.20, 0.40
Min, Max	2.7, 6.7	3.1, 6.8	1.9, 6.9	-1.9, 1.1	-1.5, 1.8	-0.8, 1.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Abdominal Symptoms						
Baseline						
m	27	22	39			
n	27	18	36			
Mean (SD)	5.07 (1.65)	5.28 (1.68)	5.00 (1.68)			
Median	5.00	5.85	5.00			
IQR: Q1, Q3	3.70, 6.70	3.70, 7.00	3.65, 6.70			
Min, Max	1.0, 7.0	2.3, 7.0	1.3, 7.0			
Week 24						
m	27	22	37			
n	24	22	34	24	18	31
Mean (SD/SE)	5.23 (1.44)	5.18 (1.71)	5.15 (1.95)	0.15 (0.31)	-0.03 (0.29)	0.27 (0.27)
Median	5.50	5.70	6.00	0	0	0
IQR: Q1, Q3	4.15, 6.30	3.30, 6.70	3.30, 7.00	-0.30, 0.65	-0.30, 0.60	-0.60, 0.60
Min, Max	2.0, 7.0	2.0, 7.0	1.0, 7.0	-4.7, 3.3	-3.3, 2.0	-2.7, 4.0
Week 52						
m	25	19	36			
n	23	19	32	23	16	29
Mean (SD/SE)	5.26 (1.57)	5.23 (1.71)	5.32 (1.84)	0.17 (0.28)	-0.19 (0.28)	0.24 (0.22)
Median	5.30	5.70	5.70	0.30	-0.15	0
IQR: Q1, Q3	4.30, 6.70	3.70, 6.70	4.30, 7.00	0.00, 0.70	-0.70, 0.00	0.00, 1.00
Min, Max	1.0, 7.0	2.0, 7.0	1.0, 7.0	-3.3, 3.3	-2.0, 2.7	-3.3, 2.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Activity						
Baseline						
m	27	22	39			
n	27	18	36			
Mean (SD)	5.23 (1.52)	4.86 (1.64)	5.44 (1.52)			
Median	5.80	5.10	5.80			
IQR: Q1, Q3	4.20, 6.40	3.80, 6.20	4.60, 6.90			
Min, Max	2.0, 7.0	2.0, 7.0	2.2, 7.0			
Week 24						
m	27	22	37			
n	24	22	34	24	18	31
Mean (SD/SE)	4.92 (1.64)	4.97 (1.52)	5.29 (1.58)	-0.36 (0.17)	0.08 (0.19)	-0.01 (0.16)
Median	5.40	5.40	5.80	-0.20	-0.10	0
IQR: Q1, Q3	3.70, 6.40	3.40, 6.20	3.80, 6.80	-0.60, 0.20	-0.60, 0.80	-0.60, 0.40
Min, Max	1.4, 7.0	2.4, 7.0	1.2, 7.0	-3.2, 1.0	-1.2, 1.2	-1.4, 2.6
Week 52						
m	25	19	36			
n	23	19	32	23	16	29
Mean (SD/SE)	4.78 (1.80)	5.01 (1.36)	5.44 (1.49)	-0.40 (0.18)	0.08 (0.20)	-0.13 (0.12)
Median	4.80	5.20	5.80	-0.20	-0.10	0
IQR: Q1, Q3	3.20, 6.60	3.80, 6.00	4.20, 6.80	-1.00, 0.40	-0.50, 0.60	-0.40, 0.20
Min, Max	1.0, 7.0	2.4, 7.0	2.0, 7.0	-2.2, 0.6	-1.2, 1.8	-2.2, 0.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Emotional Health						
Baseline						
m	27	22	39			
n	27	18	36			
Mean (SD)	5.17 (1.42)	4.83 (1.46)	5.38 (1.42)			
Median	5.40	4.80	5.75			
IQR: Q1, Q3	4.60, 6.30	3.90, 5.80	4.75, 6.60			
Min, Max	1.3, 6.9	1.8, 7.0	2.0, 7.0			
Week 24						
m	27	22	37			
n	24	22	34	24	18	31
Mean (SD/SE)	5.25 (1.44)	5.03 (1.26)	5.37 (1.36)	0.17 (0.17)	0.06 (0.14)	0.16 (0.14)
Median	6.00	5.25	5.75	0.15	-0.10	0.20
IQR: Q1, Q3	4.45, 6.25	4.40, 5.80	4.40, 6.40	-0.25, 0.60	-0.30, 0.40	-0.60, 0.70
Min, Max	2.2, 7.0	2.2, 7.0	2.2, 7.0	-2.2, 2.0	-0.7, 1.3	-0.9, 1.8
Week 52						
m	25	19	36			
n	23	19	32	23	16	29
Mean (SD/SE)	5.36 (1.09)	5.01 (1.16)	5.53 (1.42)	0.30 (0.18)	0.01 (0.22)	0.06 (0.13)
Median	5.70	5.00	6.00	0	-0.20	0
IQR: Q1, Q3	4.60, 6.20	4.70, 5.90	4.70, 6.70	-0.30, 0.70	-0.55, 0.55	-0.10, 0.60
Min, Max	2.8, 6.8	3.0, 6.8	2.2, 7.0	-0.7, 2.9	-1.2, 2.0	-2.0, 1.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Fatigue						
Baseline						
m	27	22	39			
n	27	18	36			
Mean (SD)	4.66 (1.61)	4.01 (1.76)	4.59 (1.68)			
Median	5.00	4.35	4.40			
IQR: Q1, Q3	2.80, 6.30	2.20, 5.30	3.05, 6.00			
Min, Max	1.5, 7.0	1.5, 7.0	1.3, 7.0			
Week 24						
m	27	22	37			
n	24	22	34	24	18	31
Mean (SD/SE)	4.57 (1.45)	4.03 (1.48)	4.46 (1.67)	-0.08 (0.22)	-0.14 (0.17)	0.10 (0.15)
Median	4.80	4.20	4.10	-0.10	-0.05	0
IQR: Q1, Q3	3.15, 5.90	2.80, 5.00	3.20, 6.20	-0.70, 0.25	-0.50, 0.20	-0.30, 0.60
Min, Max	2.0, 7.0	1.7, 6.5	1.8, 7.0	-2.5, 3.2	-1.5, 2.0	-1.5, 1.6
Week 52						
m	25	19	36			
n	23	19	32	23	16	29
Mean (SD/SE)	4.66 (1.53)	3.92 (1.49)	4.72 (1.73)	0.04 (0.23)	-0.32 (0.32)	0.18 (0.15)
Median	5.00	3.70	5.05	0	-0.20	0.10
IQR: Q1, Q3	3.00, 6.20	2.80, 5.50	3.00, 6.20	-0.30, 0.20	-1.05, 0.55	-0.40, 0.60
Min, Max	1.8, 6.8	1.5, 6.5	1.2, 7.0	-2.0, 4.0	-2.8, 1.9	-1.0, 2.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Systemic Symptoms						
Baseline						
m	27	22	39			
n	27	18	36			
Mean (SD)	5.06 (1.27)	4.60 (1.55)	5.21 (1.33)			
Median	5.30	5.10	5.70			
IQR: Q1, Q3	4.00, 6.20	2.80, 5.30	4.25, 6.10			
Min, Max	2.0, 7.0	2.5, 7.0	2.5, 7.0			
Week 24						
m	27	22	37			
n	24	22	34	24	18	31
Mean (SD/SE)	4.86 (1.39)	4.55 (1.40)	5.21 (1.40)	-0.15 (0.15)	-0.19 (0.19)	0.14 (0.11)
Median	5.40	4.65	5.40	-0.30	-0.25	0.20
IQR: Q1, Q3	3.65, 5.85	3.50, 5.30	4.30, 6.50	-0.55, 0.30	-0.70, 0.00	-0.20, 0.60
Min, Max	2.3, 6.7	2.3, 6.8	2.3, 7.0	-1.5, 1.0	-1.3, 2.2	-1.5, 1.3
Week 52						
m	25	19	36			
n	23	19	32	23	16	29
Mean (SD/SE)	4.65 (1.23)	4.48 (1.42)	5.16 (1.58)	-0.29 (0.15)	-0.18 (0.23)	-0.04 (0.16)
Median	4.80	4.50	5.75	-0.30	-0.05	0
IQR: Q1, Q3	3.70, 5.70	3.00, 5.50	4.25, 6.50	-0.70, 0.00	-0.70, 0.25	-0.30, 0.50
Min, Max	2.3, 6.5	2.7, 7.0	1.3, 7.0	-1.5, 1.7	-2.5, 1.3	-2.2, 1.5

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Worry						
Baseline						
m	27	22	39			
n	27	18	36			
Mean (SD)	5.77 (1.23)	5.19 (1.60)	5.73 (1.44)			
Median	5.90	5.30	6.20			
IQR: Q1, Q3	5.10, 6.90	3.70, 6.70	4.80, 6.90			
Min, Max	2.7, 7.0	2.0, 7.0	1.1, 7.0			
Week 24						
m	27	22	37			
n	24	22	34	24	18	31
Mean (SD/SE)	5.78 (1.60)	5.98 (1.14)	6.00 (1.47)	0.04 (0.15)	0.83 (0.34)	0.49 (0.19)
Median	6.65	6.35	6.65	0	0.25	0.20
IQR: Q1, Q3	5.30, 6.90	5.10, 6.90	5.70, 7.00	-0.30, 0.60	0.00, 1.40	0.00, 0.90
Min, Max	2.0, 7.0	3.0, 7.0	1.0, 7.0	-1.8, 1.5	-1.2, 3.6	-2.1, 2.8
Week 52						
m	25	19	36			
n	23	19	32	23	16	29
Mean (SD/SE)	5.89 (1.32)	5.77 (1.23)	6.05 (1.64)	0.13 (0.18)	0.59 (0.37)	0.34 (0.18)
Median	6.30	6.00	6.90	0	0	0.10
IQR: Q1, Q3	5.10, 7.00	5.00, 6.70	5.95, 7.00	-0.30, 0.60	-0.20, 0.80	0.00, 0.70
Min, Max	2.1, 7.0	2.7, 7.0	1.0, 7.0	-1.1, 3.0	-1.0, 3.6	-1.9, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
CLDQ-NASH						
Baseline						
m	140	129	264			
n	129	118	241			
Mean (SD)	5.24 (1.19)	5.34 (1.06)	5.22 (1.10)			
Median	5.30	5.60	5.40			
IQR: Q1, Q3	4.50, 6.30	4.60, 6.10	4.50, 6.10			
Min, Max	1.5, 7.0	2.1, 6.9	2.0, 7.0			
Week 24						
m	134	119	252			
n	131	114	229	123	107	213
Mean (SD/SE)	5.33 (1.12)	5.33 (1.00)	5.37 (1.07)	0.10 (0.07)	-0.03 (0.06)	0.10 (0.05)
Median	5.40	5.55	5.50	0	0	0
IQR: Q1, Q3	4.50, 6.30	4.60, 6.10	4.60, 6.20	-0.20, 0.50	-0.40, 0.30	-0.30, 0.50
Min, Max	2.1, 7.0	2.7, 7.0	2.3, 7.0	-2.0, 2.5	-1.6, 1.4	-2.3, 3.0
Week 52						
m	124	106	234			
n	114	94	202	105	90	188
Mean (SD/SE)	5.41 (1.15)	5.42 (0.99)	5.37 (1.06)	0.06 (0.07)	0.01 (0.07)	0.05 (0.05)
Median	5.60	5.60	5.50	0.10	0	0
IQR: Q1, Q3	4.70, 6.40	4.80, 6.10	4.70, 6.20	-0.20, 0.40	-0.30, 0.30	-0.40, 0.50
Min, Max	1.6, 7.0	2.2, 6.9	2.2, 7.0	-2.7, 2.7	-2.4, 1.5	-2.2, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Abdominal Symptoms						
Baseline						
m	140	129	264			
n	129	118	241			
Mean (SD)	5.32 (1.63)	5.61 (1.32)	5.24 (1.50)			
Median	6.00	6.00	5.30			
IQR: Q1, Q3	4.00, 6.70	4.70, 7.00	4.30, 6.70			
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0			
Week 24						
m	134	119	252			
n	131	114	229	123	107	213
Mean (SD/SE)	5.42 (1.46)	5.47 (1.42)	5.52 (1.37)	0.09 (0.10)	-0.11 (0.11)	0.19 (0.08)
Median	5.30	5.70	5.70	0	0	0
IQR: Q1, Q3	4.70, 6.70	4.70, 6.70	4.70, 7.00	-0.40, 0.70	-0.70, 0.30	-0.40, 1.00
Min, Max	1.0, 7.0	1.3, 7.0	1.0, 7.0	-3.0, 3.0	-4.0, 2.4	-3.0, 4.0
Week 52						
m	124	106	234			
n	114	94	202	105	90	188
Mean (SD/SE)	5.58 (1.45)	5.67 (1.17)	5.48 (1.31)	0.12 (0.12)	-0.04 (0.10)	0.08 (0.09)
Median	6.00	5.70	5.70	0	0	0
IQR: Q1, Q3	4.70, 7.00	5.00, 6.70	4.70, 6.70	-0.60, 1.00	-0.40, 0.30	-0.70, 0.70
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0	-2.3, 4.0	-3.0, 2.0	-4.6, 4.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Activity						
Baseline						
m	140	129	264			
n	129	118	241			
Mean (SD)	5.28 (1.39)	5.41 (1.27)	5.40 (1.36)			
Median	5.40	5.60	5.60			
IQR: Q1, Q3	4.40, 6.40	4.60, 6.40	4.60, 6.60			
Min, Max	1.4, 7.0	1.8, 7.0	1.4, 7.0			
Week 24						
m	134	119	252			
n	131	114	229	123	107	213
Mean (SD/SE)	5.34 (1.39)	5.50 (1.20)	5.51 (1.31)	0.07 (0.08)	0.04 (0.09)	0.09 (0.07)
Median	5.60	5.80	5.80	0	0	0
IQR: Q1, Q3	4.40, 6.40	4.60, 6.60	4.80, 6.60	-0.40, 0.60	-0.60, 0.60	-0.40, 0.60
Min, Max	1.2, 7.0	2.4, 7.0	2.2, 7.0	-2.4, 2.8	-2.4, 3.2	-3.0, 3.2
Week 52						
m	124	106	234			
n	114	94	202	105	90	188
Mean (SD/SE)	5.45 (1.41)	5.45 (1.22)	5.44 (1.36)	0.03 (0.11)	-0.06 (0.10)	-0.10 (0.07)
Median	5.80	5.60	5.80	0.20	0.10	0
IQR: Q1, Q3	4.80, 6.60	4.80, 6.40	4.40, 6.60	-0.40, 0.60	-0.60, 0.60	-0.60, 0.40
Min, Max	1.2, 7.0	1.6, 7.0	1.4, 7.0	-4.4, 3.0	-2.8, 2.0	-3.4, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Emotional Health						
Baseline						
m	140	129	264			
n	129	118	241			
Mean (SD)	5.40 (1.21)	5.47 (1.25)	5.42 (1.17)			
Median	5.60	5.70	5.70			
IQR: Q1, Q3	4.70, 6.20	4.80, 6.40	4.80, 6.30			
Min, Max	1.9, 7.0	2.0, 7.0	1.8, 7.0			
Week 24						
m	134	119	252			
n	131	114	229	123	107	213
Mean (SD/SE)	5.47 (1.20)	5.41 (1.23)	5.47 (1.22)	0.07 (0.07)	-0.10 (0.07)	0.02 (0.06)
Median	5.70	5.50	5.80	0	0	0
IQR: Q1, Q3	4.70, 6.40	4.70, 6.30	4.80, 6.40	-0.30, 0.60	-0.50, 0.20	-0.50, 0.50
Min, Max	2.0, 7.0	1.0, 7.0	1.9, 7.0	-2.8, 2.5	-3.1, 2.4	-2.9, 3.3
Week 52						
m	124	106	234			
n	114	94	202	105	90	188
Mean (SD/SE)	5.46 (1.14)	5.56 (1.19)	5.50 (1.19)	-0.05 (0.08)	0.03 (0.08)	0.00 (0.06)
Median	5.75	5.90	5.75	0	0	0
IQR: Q1, Q3	4.80, 6.30	4.80, 6.40	4.70, 6.40	-0.60, 0.30	-0.50, 0.40	-0.55, 0.40
Min, Max	1.9, 7.0	1.0, 7.0	1.3, 7.0	-2.5, 2.5	-1.9, 2.9	-1.9, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Fatigue						
Baseline						
m	140	129	264			
n	129	118	241			
Mean (SD)	4.77 (1.49)	4.69 (1.38)	4.61 (1.40)			
Median	5.00	5.00	4.80			
IQR: Q1, Q3	3.80, 6.00	3.80, 5.70	3.70, 5.70			
Min, Max	1.2, 7.0	1.2, 7.0	1.0, 7.0			
Week 24						
m	134	119	252			
n	131	114	229	123	107	213
Mean (SD/SE)	4.79 (1.51)	4.66 (1.33)	4.72 (1.42)	0.02 (0.10)	-0.10 (0.09)	0.05 (0.08)
Median	4.80	4.80	4.80	0.10	0	0
IQR: Q1, Q3	3.70, 6.00	3.70, 5.70	3.50, 5.80	-0.60, 0.70	-0.60, 0.50	-0.60, 0.60
Min, Max	1.3, 7.0	1.5, 7.0	1.2, 7.0	-2.7, 4.1	-4.2, 2.3	-3.8, 3.7
Week 52						
m	124	106	234			
n	114	94	202	105	90	188
Mean (SD/SE)	4.87 (1.52)	4.74 (1.41)	4.70 (1.39)	0.02 (0.10)	-0.05 (0.12)	0.00 (0.08)
Median	5.20	5.00	4.90	0	0	0
IQR: Q1, Q3	3.80, 6.00	3.80, 5.80	3.80, 5.70	-0.50, 0.50	-0.50, 0.50	-0.60, 0.55
Min, Max	1.0, 7.0	1.2, 7.0	1.0, 7.0	-2.4, 3.5	-4.4, 2.5	-3.8, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Systemic Symptoms						
Baseline						
m	140	129	264			
n	129	118	241			
Mean (SD)	5.19 (1.29)	5.16 (1.15)	5.04 (1.22)			
Median	5.50	5.20	5.20			
IQR: Q1, Q3	4.30, 6.20	4.50, 6.00	4.20, 6.00			
Min, Max	1.5, 7.0	1.8, 7.0	1.7, 7.0			
Week 24						
m	134	119	252			
n	131	114	229	123	107	213
Mean (SD/SE)	5.21 (1.20)	5.08 (1.16)	5.12 (1.22)	0.01 (0.07)	-0.15 (0.07)	-0.02 (0.06)
Median	5.30	5.20	5.30	0	0	0
IQR: Q1, Q3	4.30, 6.20	4.30, 6.00	4.30, 6.00	-0.40, 0.50	-0.50, 0.20	-0.60, 0.50
Min, Max	1.7, 7.0	1.8, 7.0	1.5, 7.0	-2.0, 3.5	-2.0, 1.7	-2.5, 3.7
Week 52						
m	124	106	234			
n	114	94	202	105	90	188
Mean (SD/SE)	5.24 (1.29)	5.15 (1.15)	5.12 (1.30)	-0.12 (0.08)	-0.10 (0.08)	0.01 (0.06)
Median	5.50	5.25	5.30	0	0	0
IQR: Q1, Q3	4.30, 6.30	4.30, 6.00	4.20, 6.20	-0.50, 0.30	-0.50, 0.30	-0.50, 0.50
Min, Max	1.3, 7.0	1.5, 7.0	1.7, 7.0	-2.7, 2.3	-2.3, 2.0	-2.7, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Worry						
Baseline						
m	140	129	264			
n	129	118	241			
Mean (SD)	5.47 (1.43)	5.67 (1.47)	5.61 (1.37)			
Median	5.70	6.10	6.00			
IQR: Q1, Q3	4.60, 6.70	4.90, 6.90	4.70, 6.70			
Min, Max	1.1, 7.0	1.0, 7.0	1.3, 7.0			
Week 24						
m	134	119	252			
n	131	114	229	123	107	213
Mean (SD/SE)	5.78 (1.34)	5.83 (1.35)	5.86 (1.33)	0.34 (0.10)	0.19 (0.09)	0.28 (0.06)
Median	6.10	6.30	6.30	0.30	0	0.10
IQR: Q1, Q3	5.30, 6.70	5.00, 7.00	5.40, 6.90	-0.10, 0.80	-0.30, 0.60	-0.10, 0.60
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0	-3.1, 3.3	-2.6, 3.4	-2.6, 3.5
Week 52						
m	124	106	234			
n	114	94	202	105	90	188
Mean (SD/SE)	5.89 (1.33)	6.00 (1.38)	5.98 (1.23)	0.36 (0.11)	0.32 (0.12)	0.32 (0.08)
Median	6.40	6.60	6.40	0.20	0	0.10
IQR: Q1, Q3	5.30, 7.00	5.40, 7.00	5.40, 7.00	-0.10, 1.00	-0.20, 0.80	-0.10, 0.85
Min, Max	1.7, 7.0	1.0, 7.0	1.4, 7.0	-4.8, 3.8	-3.3, 3.5	-2.7, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.9.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
CLDQ-NASH			
Week 24			
m	27	22	37
n	24	18	31
Baseline Mean (SD)	5.14 (1.29)	4.81 (1.36)	5.20 (1.26)
Analysis Visit Mean (SD)	5.10 (1.32)	4.90 (1.17)	5.40 (1.21)
LS Mean of Change from Baseline (SE)	-0.05 (0.13)	-0.03 (0.16)	0.15 (0.12)
95% CI	(-0.30, 0.21)	(-0.34, 0.27)	(-0.10, 0.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.19 (0.17)	-0.18 (0.19)	
95% CI	(-0.54, 0.15)	(-0.55, 0.19)	
p-value	0.2680	0.3353	
Corrected Hedge's g Statistics	-0.290	-0.265	
95% CI	(-0.83, 0.25)	(-0.85, 0.32)	
Week 52			
m	25	19	36
n	23	16	29
Baseline Mean (SD)	5.11 (1.36)	4.77 (1.44)	5.39 (1.25)
Analysis Visit Mean (SD)	5.10 (1.17)	4.76 (1.11)	5.49 (1.24)
LS Mean of Change from Baseline (SE)	-0.02 (0.11)	-0.14 (0.14)	0.11 (0.11)
95% CI	(-0.24, 0.20)	(-0.42, 0.15)	(-0.11, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (0.15)	-0.25 (0.17)	
95% CI	(-0.44, 0.17)	(-0.58, 0.09)	
p-value	0.3934	0.1476	
Corrected Hedge's g Statistics	-0.227	-0.412	
95% CI	(-0.78, 0.32)	(-1.03, 0.20)	
Subgroup*Treatment Interaction p-value	0.2463	0.4485	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
CLDQ-NASH			
Week 24			
m	134	119	252
n	123	107	213
Baseline Mean (SD)	5.23 (1.17)	5.34 (1.07)	5.27 (1.10)
Analysis Visit Mean (SD)	5.33 (1.12)	5.31 (1.01)	5.37 (1.08)
LS Mean of Change from Baseline (SE)	0.10 (0.06)	-0.02 (0.06)	0.10 (0.05)
95% CI	(-0.02, 0.22)	(-0.15, 0.10)	(0.01, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.07)	-0.13 (0.08)	
95% CI	(-0.15, 0.14)	(-0.28, 0.02)	
p-value	0.9744	0.0996	
Corrected Hedge's g Statistics	-0.004	-0.192	
95% CI	(-0.23, 0.22)	(-0.43, 0.04)	
Week 52			
m	124	106	234
n	105	90	188
Baseline Mean (SD)	5.33 (1.13)	5.38 (1.06)	5.31 (1.07)
Analysis Visit Mean (SD)	5.39 (1.15)	5.39 (0.99)	5.36 (1.08)
LS Mean of Change from Baseline (SE)	0.06 (0.06)	0.02 (0.07)	0.07 (0.05)
95% CI	(-0.07, 0.18)	(-0.11, 0.16)	(-0.02, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.08)	-0.05 (0.08)	
95% CI	(-0.17, 0.14)	(-0.21, 0.11)	
p-value	0.8726	0.5553	
Corrected Hedge's g Statistics	-0.019	-0.074	
95% CI	(-0.26, 0.22)	(-0.33, 0.18)	
Subgroup*Treatment Interaction p-value	0.2463	0.4485	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.9.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Abdominal Symptoms			
Week 24			
m	27	22	37
n	24	18	31
Baseline Mean (SD)	5.08 (1.71)	5.28 (1.68)	5.15 (1.70)
Analysis Visit Mean (SD)	5.23 (1.44)	5.24 (1.78)	5.43 (1.76)
LS Mean of Change from Baseline (SE)	0.10 (0.26)	-0.06 (0.32)	0.28 (0.25)
95% CI	(-0.42, 0.62)	(-0.69, 0.58)	(-0.23, 0.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.18 (0.36)	-0.34 (0.38)	
95% CI	(-0.89, 0.53)	(-1.10, 0.43)	
p-value	0.6134	0.3832	
Corrected Hedge's g Statistics	-0.131	-0.238	
95% CI	(-0.66, 0.40)	(-0.82, 0.34)	
Week 52			
m	25	19	36
n	23	16	29
Baseline Mean (SD)	5.09 (1.71)	5.34 (1.69)	5.28 (1.58)
Analysis Visit Mean (SD)	5.26 (1.57)	5.15 (1.84)	5.52 (1.73)
LS Mean of Change from Baseline (SE)	0.15 (0.24)	-0.13 (0.30)	0.23 (0.24)
95% CI	(-0.32, 0.63)	(-0.73, 0.46)	(-0.24, 0.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.33)	-0.36 (0.35)	
95% CI	(-0.72, 0.58)	(-1.07, 0.35)	
p-value	0.8215	0.3137	
Corrected Hedge's g Statistics	-0.060	-0.284	
95% CI	(-0.61, 0.49)	(-0.90, 0.33)	
Subgroup*Treatment Interaction p-value	0.5802	0.4618	

AMNOG Table SE23.9.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Activity			
Week 24			
m	27	22	37
n	24	18	31
Baseline Mean (SD)	5.28 (1.50)	4.86 (1.64)	5.42 (1.49)
Analysis Visit Mean (SD)	4.92 (1.64)	4.93 (1.49)	5.41 (1.61)
LS Mean of Change from Baseline (SE)	-0.37 (0.17)	-0.09 (0.20)	-0.13 (0.16)
95% CI	(-0.70, -0.03)	(-0.49, 0.32)	(-0.45, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.23 (0.23)	0.05 (0.25)	
95% CI	(-0.69, 0.22)	(-0.44, 0.54)	
p-value	0.3066	0.8473	
Corrected Hedge's g Statistics	-0.268	0.053	
95% CI	(-0.80, 0.27)	(-0.53, 0.63)	
Week 52			
m	25	19	36
n	23	16	29
Baseline Mean (SD)	5.18 (1.61)	4.79 (1.74)	5.63 (1.53)
Analysis Visit Mean (SD)	4.78 (1.80)	4.86 (1.40)	5.50 (1.49)
LS Mean of Change from Baseline (SE)	-0.42 (0.15)	-0.09 (0.19)	-0.20 (0.14)
95% CI	(-0.72, -0.13)	(-0.46, 0.28)	(-0.49, 0.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.22 (0.20)	0.11 (0.22)	
95% CI	(-0.62, 0.18)	(-0.34, 0.55)	
p-value	0.2728	0.6334	
Corrected Hedge's g Statistics	-0.293	0.137	
95% CI	(-0.84, 0.26)	(-0.47, 0.75)	
Subgroup*Treatment Interaction p-value	0.1614	0.9499	

AMNOG Table SE23.9.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Emotional Health			
Week 24			
m	27	22	37
n	24	18	31
Baseline Mean (SD)	5.08 (1.46)	4.83 (1.46)	5.31 (1.48)
Analysis Visit Mean (SD)	5.25 (1.44)	4.88 (1.31)	5.47 (1.35)
LS Mean of Change from Baseline (SE)	0.17 (0.14)	0.02 (0.17)	0.25 (0.14)
95% CI	(-0.12, 0.45)	(-0.32, 0.37)	(-0.03, 0.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.20)	-0.23 (0.21)	
95% CI	(-0.47, 0.31)	(-0.65, 0.19)	
p-value	0.6748	0.2863	
Corrected Hedge's g Statistics	-0.109	-0.293	
95% CI	(-0.64, 0.42)	(-0.88, 0.29)	
Week 52			
m	25	19	36
n	23	16	29
Baseline Mean (SD)	5.07 (1.50)	4.81 (1.53)	5.55 (1.43)
Analysis Visit Mean (SD)	5.36 (1.09)	4.81 (1.13)	5.61 (1.42)
LS Mean of Change from Baseline (SE)	0.29 (0.14)	-0.03 (0.18)	0.22 (0.14)
95% CI	(0.01, 0.58)	(-0.39, 0.33)	(-0.06, 0.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.20)	-0.25 (0.22)	
95% CI	(-0.31, 0.47)	(-0.68, 0.19)	
p-value	0.6917	0.2586	
Corrected Hedge's g Statistics	0.106	-0.327	
95% CI	(-0.44, 0.65)	(-0.94, 0.29)	
Subgroup*Treatment Interaction p-value	0.8164	0.3947	

AMNOG Table SE23.9.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Fatigue			
Week 24			
m	27	22	37
n	24	18	31
Baseline Mean (SD)	4.64 (1.57)	4.01 (1.76)	4.50 (1.75)
Analysis Visit Mean (SD)	4.57 (1.45)	3.87 (1.51)	4.59 (1.69)
LS Mean of Change from Baseline (SE)	-0.06 (0.17)	-0.32 (0.20)	0.01 (0.16)
95% CI	(-0.40, 0.27)	(-0.73, 0.09)	(-0.32, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.23)	-0.33 (0.25)	
95% CI	(-0.53, 0.39)	(-0.82, 0.16)	
p-value	0.7623	0.1897	
Corrected Hedge's g Statistics	-0.079	-0.360	
95% CI	(-0.61, 0.45)	(-0.94, 0.23)	
Week 52			
m	25	19	36
n	23	16	29
Baseline Mean (SD)	4.62 (1.75)	3.91 (1.85)	4.70 (1.75)
Analysis Visit Mean (SD)	4.66 (1.53)	3.59 (1.38)	4.88 (1.65)
LS Mean of Change from Baseline (SE)	0.05 (0.18)	-0.55 (0.23)	0.14 (0.17)
95% CI	(-0.31, 0.41)	(-1.00, -0.10)	(-0.21, 0.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.09 (0.25)	-0.69 (0.27)	
95% CI	(-0.58, 0.40)	(-1.24, -0.15)	
p-value	0.7086	0.0129	
Corrected Hedge's g Statistics	-0.100	-0.735	
95% CI	(-0.65, 0.45)	(-1.36, -0.11)	
Subgroup*Treatment Interaction p-value	0.5977	0.1316	

AMNOG Table SE23.9.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Systemic Symptoms			
Week 24			
m	27	22	37
n	24	18	31
Baseline Mean (SD)	5.01 (1.27)	4.60 (1.55)	5.22 (1.30)
Analysis Visit Mean (SD)	4.86 (1.39)	4.41 (1.31)	5.36 (1.35)
LS Mean of Change from Baseline (SE)	-0.17 (0.14)	-0.35 (0.17)	0.04 (0.13)
95% CI	(-0.44, 0.10)	(-0.68, -0.02)	(-0.22, 0.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.22 (0.19)	-0.39 (0.20)	
95% CI	(-0.58, 0.15)	(-0.79, 0.01)	
p-value	0.2495	0.0556	
Corrected Hedge's g Statistics	-0.301	-0.531	
95% CI	(-0.84, 0.24)	(-1.12, 0.06)	
Week 52			
m	25	19	36
n	23	16	29
Baseline Mean (SD)	4.94 (1.34)	4.53 (1.64)	5.34 (1.34)
Analysis Visit Mean (SD)	4.65 (1.23)	4.35 (1.41)	5.30 (1.47)
LS Mean of Change from Baseline (SE)	-0.35 (0.16)	-0.40 (0.20)	-0.09 (0.15)
95% CI	(-0.66, -0.03)	(-0.79, 0.00)	(-0.39, 0.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.26 (0.22)	-0.31 (0.24)	
95% CI	(-0.69, 0.17)	(-0.79, 0.17)	
p-value	0.2326	0.2020	
Corrected Hedge's g Statistics	-0.323	-0.377	
95% CI	(-0.87, 0.23)	(-0.99, 0.24)	
Subgroup*Treatment Interaction p-value	0.1556	0.2442	

AMNOG Table SE23.9.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Worry			
Week 24			
m	27	22	37
n	24	18	31
Baseline Mean (SD)	5.75 (1.28)	5.19 (1.60)	5.62 (1.51)
Analysis Visit Mean (SD)	5.78 (1.60)	6.02 (1.15)	6.12 (1.39)
LS Mean of Change from Baseline (SE)	0.04 (0.20)	0.61 (0.24)	0.39 (0.19)
95% CI	(-0.35, 0.43)	(0.13, 1.09)	(0.01, 0.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.34 (0.27)	0.22 (0.29)	
95% CI	(-0.88, 0.19)	(-0.36, 0.79)	
p-value	0.2007	0.4516	
Corrected Hedge's g Statistics	-0.333	0.205	
95% CI	(-0.87, 0.20)	(-0.38, 0.79)	
Week 52			
m	25	19	36
n	23	16	29
Baseline Mean (SD)	5.77 (1.30)	5.19 (1.62)	5.80 (1.55)
Analysis Visit Mean (SD)	5.89 (1.32)	5.79 (1.28)	6.14 (1.48)
LS Mean of Change from Baseline (SE)	0.21 (0.20)	0.39 (0.25)	0.41 (0.19)
95% CI	(-0.18, 0.60)	(-0.10, 0.88)	(0.03, 0.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.20 (0.27)	-0.02 (0.29)	
95% CI	(-0.74, 0.33)	(-0.60, 0.57)	
p-value	0.4540	0.9530	
Corrected Hedge's g Statistics	-0.199	-0.017	
95% CI	(-0.75, 0.35)	(-0.63, 0.59)	
Subgroup*Treatment Interaction p-value	0.1468	0.4759	

AMNOG Table SE23.9.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Abdominal Symptoms			
Week 24			
m	134	119	252
n	123	107	213
Baseline Mean (SD)	5.33 (1.62)	5.59 (1.35)	5.32 (1.48)
Analysis Visit Mean (SD)	5.42 (1.47)	5.47 (1.45)	5.51 (1.36)
LS Mean of Change from Baseline (SE)	0.09 (0.09)	-0.04 (0.10)	0.18 (0.07)
95% CI	(-0.09, 0.27)	(-0.23, 0.16)	(0.04, 0.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.09 (0.12)	-0.22 (0.12)	
95% CI	(-0.32, 0.13)	(-0.45, 0.02)	
p-value	0.4234	0.0713	
Corrected Hedge's g Statistics	-0.089	-0.211	
95% CI	(-0.31, 0.13)	(-0.44, 0.02)	
Week 52			
m	124	106	234
n	105	90	188
Baseline Mean (SD)	5.43 (1.56)	5.70 (1.26)	5.38 (1.45)
Analysis Visit Mean (SD)	5.55 (1.49)	5.66 (1.18)	5.45 (1.33)
LS Mean of Change from Baseline (SE)	0.12 (0.10)	0.04 (0.11)	0.10 (0.08)
95% CI	(-0.07, 0.32)	(-0.17, 0.25)	(-0.05, 0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (0.12)	-0.06 (0.13)	
95% CI	(-0.22, 0.27)	(-0.32, 0.19)	
p-value	0.8646	0.6277	
Corrected Hedge's g Statistics	0.020	-0.061	
95% CI	(-0.22, 0.26)	(-0.31, 0.19)	
Subgroup*Treatment Interaction p-value	0.5802	0.4618	

AMNOG Table SE23.9.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Activity			
Week 24			
m	134	119	252
n	123	107	213
Baseline Mean (SD)	5.27 (1.38)	5.44 (1.24)	5.46 (1.34)
Analysis Visit Mean (SD)	5.34 (1.41)	5.47 (1.20)	5.54 (1.28)
LS Mean of Change from Baseline (SE)	0.04 (0.08)	0.03 (0.09)	0.10 (0.06)
95% CI	(-0.12, 0.20)	(-0.14, 0.20)	(-0.02, 0.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.10)	-0.07 (0.10)	
95% CI	(-0.26, 0.14)	(-0.27, 0.14)	
p-value	0.5486	0.5295	
Corrected Hedge's g Statistics	-0.067	-0.073	
95% CI	(-0.29, 0.16)	(-0.31, 0.16)	
Week 52			
m	124	106	234
n	105	90	188
Baseline Mean (SD)	5.39 (1.31)	5.46 (1.24)	5.53 (1.25)
Analysis Visit Mean (SD)	5.42 (1.42)	5.40 (1.23)	5.43 (1.38)
LS Mean of Change from Baseline (SE)	0.01 (0.09)	-0.04 (0.10)	-0.06 (0.07)
95% CI	(-0.18, 0.19)	(-0.24, 0.16)	(-0.20, 0.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.07 (0.12)	0.02 (0.12)	
95% CI	(-0.16, 0.30)	(-0.22, 0.26)	
p-value	0.5729	0.8678	
Corrected Hedge's g Statistics	0.068	0.021	
95% CI	(-0.17, 0.31)	(-0.23, 0.27)	
Subgroup*Treatment Interaction p-value	0.1614	0.9499	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Emotional Health			
Week 24			
m	134	119	252
n	123	107	213
Baseline Mean (SD)	5.41 (1.19)	5.47 (1.27)	5.44 (1.18)
Analysis Visit Mean (SD)	5.48 (1.19)	5.38 (1.22)	5.46 (1.22)
LS Mean of Change from Baseline (SE)	0.06 (0.07)	-0.10 (0.08)	0.01 (0.06)
95% CI	(-0.09, 0.20)	(-0.25, 0.05)	(-0.10, 0.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.09)	-0.11 (0.09)	
95% CI	(-0.13, 0.23)	(-0.30, 0.08)	
p-value	0.5786	0.2470	
Corrected Hedge's g Statistics	0.062	-0.135	
95% CI	(-0.16, 0.28)	(-0.37, 0.10)	
Week 52			
m	124	106	234
n	105	90	188
Baseline Mean (SD)	5.50 (1.15)	5.49 (1.31)	5.47 (1.20)
Analysis Visit Mean (SD)	5.45 (1.12)	5.52 (1.20)	5.47 (1.21)
LS Mean of Change from Baseline (SE)	-0.06 (0.07)	0.04 (0.08)	-0.01 (0.06)
95% CI	(-0.21, 0.08)	(-0.12, 0.19)	(-0.12, 0.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.09)	0.05 (0.10)	
95% CI	(-0.23, 0.12)	(-0.14, 0.23)	
p-value	0.5570	0.6265	
Corrected Hedge's g Statistics	-0.070	0.061	
95% CI	(-0.31, 0.17)	(-0.19, 0.31)	
Subgroup*Treatment Interaction p-value	0.8164	0.3947	

AMNOG Table SE23.9.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Fatigue			
Week 24			
m	134	119	252
n	123	107	213
Baseline Mean (SD)	4.77 (1.47)	4.73 (1.40)	4.67 (1.40)
Analysis Visit Mean (SD)	4.79 (1.51)	4.63 (1.34)	4.72 (1.43)
LS Mean of Change from Baseline (SE)	0.04 (0.09)	-0.12 (0.10)	0.03 (0.07)
95% CI	(-0.14, 0.22)	(-0.31, 0.08)	(-0.11, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.11)	-0.14 (0.12)	
95% CI	(-0.21, 0.24)	(-0.38, 0.09)	
p-value	0.9182	0.2334	
Corrected Hedge's g Statistics	0.011	-0.139	
95% CI	(-0.21, 0.23)	(-0.37, 0.09)	
Week 52			
m	124	106	234
n	105	90	188
Baseline Mean (SD)	4.83 (1.45)	4.77 (1.39)	4.70 (1.36)
Analysis Visit Mean (SD)	4.85 (1.51)	4.72 (1.41)	4.70 (1.41)
LS Mean of Change from Baseline (SE)	0.01 (0.10)	-0.03 (0.10)	-0.01 (0.07)
95% CI	(-0.18, 0.20)	(-0.24, 0.17)	(-0.15, 0.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (0.12)	-0.03 (0.13)	
95% CI	(-0.22, 0.26)	(-0.27, 0.22)	
p-value	0.8773	0.8349	
Corrected Hedge's g Statistics	0.019	-0.026	
95% CI	(-0.22, 0.26)	(-0.28, 0.22)	
Subgroup*Treatment Interaction p-value	0.5977	0.1316	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Systemic Symptoms			
Week 24			
m	134	119	252
n	123	107	213
Baseline Mean (SD)	5.18 (1.26)	5.20 (1.15)	5.12 (1.21)
Analysis Visit Mean (SD)	5.20 (1.22)	5.05 (1.17)	5.10 (1.24)
LS Mean of Change from Baseline (SE)	0.04 (0.07)	-0.14 (0.08)	-0.01 (0.06)
95% CI	(-0.10, 0.18)	(-0.29, 0.01)	(-0.12, 0.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.09)	-0.13 (0.09)	
95% CI	(-0.12, 0.23)	(-0.31, 0.06)	
p-value	0.5606	0.1815	
Corrected Hedge's g Statistics	0.065	-0.156	
95% CI	(-0.16, 0.29)	(-0.39, 0.08)	
Week 52			
m	124	106	234
n	105	90	188
Baseline Mean (SD)	5.31 (1.19)	5.22 (1.10)	5.09 (1.22)
Analysis Visit Mean (SD)	5.19 (1.30)	5.11 (1.15)	5.10 (1.32)
LS Mean of Change from Baseline (SE)	-0.07 (0.08)	-0.10 (0.08)	0.04 (0.06)
95% CI	(-0.22, 0.09)	(-0.27, 0.06)	(-0.08, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.10)	-0.14 (0.10)	
95% CI	(-0.29, 0.09)	(-0.34, 0.06)	
p-value	0.2829	0.1707	
Corrected Hedge's g Statistics	-0.129	-0.173	
95% CI	(-0.37, 0.11)	(-0.42, 0.08)	
Subgroup*Treatment Interaction p-value	0.1556	0.2442	

AMNOG Table SE23.9.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Worry			
Week 24			
m	134	119	252
n	123	107	213
Baseline Mean (SD)	5.45 (1.42)	5.61 (1.51)	5.60 (1.38)
Analysis Visit Mean (SD)	5.79 (1.30)	5.80 (1.37)	5.88 (1.33)
LS Mean of Change from Baseline (SE)	0.32 (0.08)	0.20 (0.09)	0.30 (0.06)
95% CI	(0.16, 0.48)	(0.03, 0.37)	(0.18, 0.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.10)	-0.10 (0.10)	
95% CI	(-0.18, 0.21)	(-0.31, 0.10)	
p-value	0.8915	0.3247	
Corrected Hedge's g Statistics	0.015	-0.115	
95% CI	(-0.21, 0.24)	(-0.35, 0.12)	
Week 52			
m	124	106	234
n	105	90	188
Baseline Mean (SD)	5.52 (1.44)	5.64 (1.54)	5.66 (1.33)
Analysis Visit Mean (SD)	5.89 (1.31)	5.96 (1.40)	5.99 (1.23)
LS Mean of Change from Baseline (SE)	0.31 (0.09)	0.35 (0.10)	0.34 (0.07)
95% CI	(0.13, 0.49)	(0.16, 0.54)	(0.20, 0.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.11)	0.01 (0.12)	
95% CI	(-0.25, 0.19)	(-0.22, 0.25)	
p-value	0.8089	0.9003	
Corrected Hedge's g Statistics	-0.029	0.016	
95% CI	(-0.27, 0.21)	(-0.24, 0.27)	
Subgroup*Treatment Interaction p-value	0.1468	0.4759	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.4)	2 (9.1)	4 (10.3)
No	25 (92.6)	20 (90.9)	35 (89.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.14	
95% CI of the inverse odds ratio	(0.24, 8.41)	(0.19, 6.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	1.13	
95% CI of the inverse risk ratio	(0.27, 7.03)	(0.22, 5.67)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.85	-1.17	
95% CI of the absolute risk difference	(-16.57, 10.87)	(-16.49, 14.16)	
p-value	0.6922	0.8833	
p-value of Breslow-Day Test for Homogeneity [3]	0.9385	0.9530	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (18.5)	4 (18.2)	10 (25.6)
No	22 (81.5)	18 (81.8)	29 (74.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	1.55	
95% CI of the inverse odds ratio	(0.45, 5.08)	(0.42, 5.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	1.41	
95% CI of the inverse risk ratio	(0.53, 3.60)	(0.50, 3.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.12	-7.46	
95% CI of the absolute risk difference	(-27.18, 12.94)	(-28.61, 13.70)	
p-value	0.4972	0.5059	
p-value of Breslow-Day Test for Homogeneity [3]	0.4832	0.6389	

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (14.8)	2 (9.1)	9 (23.1)
No	23 (85.2)	20 (90.9)	30 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.73	3.00	
95% CI of the inverse odds ratio	(0.47, 6.31)	(0.59, 15.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.56	2.54	
95% CI of the inverse risk ratio	(0.53, 4.54)	(0.60, 10.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.26	-13.99	
95% CI of the absolute risk difference	(-27.09, 10.56)	(-31.85, 3.88)	
p-value	0.4067	0.1725	
p-value of Breslow-Day Test for Homogeneity [3]	0.3264	0.4605	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (48.1)	3 (13.6)	13 (33.3)
No	14 (51.9)	19 (86.4)	26 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	3.17	
95% CI of the inverse odds ratio	(0.20, 1.47)	(0.79, 12.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	2.44	
95% CI of the inverse risk ratio	(0.38, 1.25)	(0.78, 7.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.81	-19.70	
95% CI of the absolute risk difference	(-9.15, 38.77)	(-40.30, 0.91)	
p-value	0.2259	0.0931	
p-value of Breslow-Day Test for Homogeneity [3]	0.2432	0.4194	

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	3 (13.6)	0
No	27 (100)	19 (86.4)	39 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.07	
95% CI of the inverse odds ratio	NE	(0.00, 1.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.08	
95% CI of the inverse risk ratio	NE	(0.00, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	13.97	
95% CI of the absolute risk difference	NE	(-1.11, 29.05)	
p-value	NE	0.0286	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0386	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (22.2)	5 (22.7)	6 (15.4)
No	21 (77.8)	17 (77.3)	33 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.62	
95% CI of the inverse odds ratio	(0.18, 2.24)	(0.16, 2.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	0.68	
95% CI of the inverse risk ratio	(0.25, 1.92)	(0.23, 1.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.84	7.34	
95% CI of the absolute risk difference	(-12.50, 26.18)	(-13.51, 28.20)	
p-value	0.4789	0.4738	
p-value of Breslow-Day Test for Homogeneity [3]	0.8724	0.6105	

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (14.8)	3 (13.6)	3 (7.7)
No	23 (85.2)	19 (86.4)	36 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	0.53	
95% CI of the inverse odds ratio	(0.10, 2.34)	(0.10, 2.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	0.56	
95% CI of the inverse risk ratio	(0.13, 2.14)	(0.12, 2.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.12	5.94	
95% CI of the absolute risk difference	(-8.67, 22.92)	(-10.66, 22.54)	
p-value	0.3555	0.4541	
p-value of Breslow-Day Test for Homogeneity [3]	0.5636	0.4800	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (29.6)	5 (22.7)	11 (28.2)
No	19 (70.4)	17 (77.3)	28 (71.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.34	
95% CI of the inverse odds ratio	(0.32, 2.75)	(0.40, 4.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	1.24	
95% CI of the inverse risk ratio	(0.44, 2.05)	(0.50, 3.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.42	-5.48	
95% CI of the absolute risk difference	(-20.85, 23.70)	(-27.97, 17.02)	
p-value	0.9000	0.6405	
p-value of Breslow-Day Test for Homogeneity [3]	0.6770	0.6567	

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.4)	4 (18.2)	3 (7.7)
No	25 (92.6)	18 (81.8)	36 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.38	
95% CI of the inverse odds ratio	(0.16, 6.69)	(0.08, 1.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.42	
95% CI of the inverse risk ratio	(0.19, 5.80)	(0.10, 1.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.28	10.49	
95% CI of the absolute risk difference	(-13.23, 12.66)	(-7.67, 28.65)	
p-value	0.9657	0.2171	
p-value of Breslow-Day Test for Homogeneity [3]	0.7205	0.2509	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (18.5)	4 (18.2)	13 (33.3)
No	22 (81.5)	18 (81.8)	26 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.20	2.25	
95% CI of the inverse odds ratio	(0.68, 7.14)	(0.63, 8.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.80	1.83	
95% CI of the inverse risk ratio	(0.73, 4.46)	(0.68, 4.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.81	-15.15	
95% CI of the absolute risk difference	(-35.64, 6.01)	(-37.03, 6.73)	
p-value	0.1839	0.2050	
p-value of Breslow-Day Test for Homogeneity [3]	0.1443	0.2976	

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.7)	3 (13.6)	4 (10.3)
No	26 (96.3)	19 (86.4)	35 (89.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.97	0.72	
95% CI of the inverse odds ratio	(0.31, 28.17)	(0.15, 3.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.77	0.75	
95% CI of the inverse risk ratio	(0.33, 23.44)	(0.18, 3.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.55	3.38	
95% CI of the absolute risk difference	(-18.44, 5.34)	(-13.83, 20.59)	
p-value	0.3226	0.6908	
p-value of Breslow-Day Test for Homogeneity [3]	0.7148	0.4997	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (18.5)	4 (18.2)	9 (23.1)
No	22 (81.5)	18 (81.8)	30 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	1.35	
95% CI of the inverse odds ratio	(0.39, 4.49)	(0.36, 5.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.27	
95% CI of the inverse risk ratio	(0.47, 3.31)	(0.44, 3.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.56	-4.90	
95% CI of the absolute risk difference	(-24.29, 15.18)	(-25.74, 15.95)	
p-value	0.6560	0.6539	
p-value of Breslow-Day Test for Homogeneity [3]	0.9065	0.7715	

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.4)	4 (18.2)	6 (15.4)
No	25 (92.6)	18 (81.8)	33 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.27	0.82	
95% CI of the inverse odds ratio	(0.42, 12.23)	(0.20, 3.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	0.85	
95% CI of the inverse risk ratio	(0.45, 9.53)	(0.27, 2.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.98	2.80	
95% CI of the absolute risk difference	(-23.00, 7.05)	(-16.90, 22.49)	
p-value	0.3289	0.7769	
p-value of Breslow-Day Test for Homogeneity [3]	0.2503	0.7404	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (25.9)	6 (27.3)	13 (33.3)
No	20 (74.1)	16 (72.7)	26 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.33	
95% CI of the inverse odds ratio	(0.48, 4.24)	(0.42, 4.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	1.22	
95% CI of the inverse risk ratio	(0.59, 2.80)	(0.54, 2.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.41	-6.06	
95% CI of the absolute risk difference	(-29.59, 14.78)	(-29.84, 17.71)	
p-value	0.5197	0.6236	
p-value of Breslow-Day Test for Homogeneity [3]	0.4046	0.8223	

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (6.4)	9 (7.0)	22 (8.3)
No	131 (93.6)	120 (93.0)	242 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	1.21	
95% CI of the inverse odds ratio	(0.59, 2.96)	(0.54, 2.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	1.19	
95% CI of the inverse risk ratio	(0.61, 2.74)	(0.57, 2.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.90	-1.36	
95% CI of the absolute risk difference	(-7.16, 3.35)	(-6.87, 4.16)	
p-value	0.4937	0.6394	
p-value of Breslow-Day Test for Homogeneity [3]	0.9385	0.9530	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (23.6)	27 (20.9)	60 (22.7)
No	107 (76.4)	102 (79.1)	204 (77.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	1.11	
95% CI of the inverse odds ratio	(0.59, 1.55)	(0.67, 1.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.09	
95% CI of the inverse risk ratio	(0.66, 1.40)	(0.73, 1.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.84	-1.80	
95% CI of the absolute risk difference	(-7.82, 9.50)	(-10.45, 6.85)	
p-value	0.8479	0.6870	
p-value of Breslow-Day Test for Homogeneity [3]	0.4832	0.6389	

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	27 (19.3)	15 (11.6)	45 (17.0)
No	113 (80.7)	114 (88.4)	219 (83.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.56	
95% CI of the inverse odds ratio	(0.51, 1.46)	(0.83, 2.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	1.47	
95% CI of the inverse risk ratio	(0.57, 1.36)	(0.85, 2.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.24	-5.42	
95% CI of the absolute risk difference	(-5.72, 10.20)	(-12.57, 1.74)	
p-value	0.5755	0.1609	
p-value of Breslow-Day Test for Homogeneity [3]	0.3264	0.4605	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	43 (30.7)	27 (20.9)	83 (31.4)
No	97 (69.3)	102 (79.1)	181 (68.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.73	
95% CI of the inverse odds ratio	(0.66, 1.61)	(1.05, 2.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.50	
95% CI of the inverse risk ratio	(0.75, 1.39)	(1.03, 2.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.73	-10.51	
95% CI of the absolute risk difference	(-10.20, 8.75)	(-19.49, -1.53)	
p-value	0.8810	0.0293	
p-value of Breslow-Day Test for Homogeneity [3]	0.2432	0.4194	

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (12.9)	13 (10.1)	23 (8.7)
No	122 (87.1)	116 (89.9)	241 (91.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	0.85	
95% CI of the inverse odds ratio	(0.34, 1.24)	(0.42, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.86	
95% CI of the inverse risk ratio	(0.38, 1.21)	(0.45, 1.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.15	1.37	
95% CI of the absolute risk difference	(-2.36, 10.65)	(-4.84, 7.57)	
p-value	0.1892	0.6595	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0386	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	41 (29.3)	32 (24.8)	60 (22.7)
No	99 (70.7)	97 (75.2)	204 (77.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.89	
95% CI of the inverse odds ratio	(0.45, 1.13)	(0.54, 1.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	0.92	
95% CI of the inverse risk ratio	(0.55, 1.09)	(0.63, 1.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.56	2.08	
95% CI of the absolute risk difference	(-2.52, 15.63)	(-6.93, 11.08)	
p-value	0.1474	0.6476	
p-value of Breslow-Day Test for Homogeneity [3]	0.8724	0.6105	

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (10.7)	11 (8.5)	23 (8.7)
No	125 (89.3)	118 (91.5)	241 (91.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.02	
95% CI of the inverse odds ratio	(0.40, 1.58)	(0.48, 2.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	1.02	
95% CI of the inverse risk ratio	(0.44, 1.51)	(0.51, 2.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.00	-0.18	
95% CI of the absolute risk difference	(-4.15, 8.15)	(-6.08, 5.71)	
p-value	0.5118	0.9512	
p-value of Breslow-Day Test for Homogeneity [3]	0.5636	0.4800	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (20.0)	30 (23.3)	61 (23.1)
No	112 (80.0)	99 (76.7)	203 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	0.99	
95% CI of the inverse odds ratio	(0.73, 1.99)	(0.60, 1.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	0.99	
95% CI of the inverse risk ratio	(0.78, 1.72)	(0.68, 1.46)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.11	0.15	
95% CI of the absolute risk difference	(-11.46, 5.25)	(-8.74, 9.04)	
p-value	0.4735	0.9736	
p-value of Breslow-Day Test for Homogeneity [3]	0.6770	0.6567	

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (9.3)	17 (13.2)	35 (13.3)
No	127 (90.7)	112 (86.8)	229 (86.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.49	1.01	
95% CI of the inverse odds ratio	(0.76, 2.93)	(0.54, 1.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.01	
95% CI of the inverse risk ratio	(0.78, 2.61)	(0.59, 1.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.97	-0.08	
95% CI of the absolute risk difference	(-10.28, 2.34)	(-7.21, 7.05)	
p-value	0.2404	0.9826	
p-value of Breslow-Day Test for Homogeneity [3]	0.7205	0.2509	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	40 (28.6)	31 (24.0)	68 (25.8)
No	100 (71.4)	98 (76.0)	196 (74.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.10	
95% CI of the inverse odds ratio	(0.55, 1.37)	(0.67, 1.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.07	
95% CI of the inverse risk ratio	(0.65, 1.26)	(0.74, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.81	-1.73	
95% CI of the absolute risk difference	(-6.34, 11.97)	(-10.79, 7.34)	
p-value	0.5431	0.7112	
p-value of Breslow-Day Test for Homogeneity [3]	0.1443	0.2976	

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (5.0)	9 (7.0)	24 (9.1)
No	133 (95.0)	120 (93.0)	240 (90.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.90	1.33	
95% CI of the inverse odds ratio	(0.80, 4.53)	(0.60, 2.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.82	1.30	
95% CI of the inverse risk ratio	(0.80, 4.11)	(0.62, 2.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.09	-2.11	
95% CI of the absolute risk difference	(-9.10, 0.91)	(-7.71, 3.49)	
p-value	0.1415	0.4779	
p-value of Breslow-Day Test for Homogeneity [3]	0.7148	0.4997	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	31 (22.1)	31 (24.0)	68 (25.8)
No	109 (77.9)	98 (76.0)	196 (74.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	1.10	
95% CI of the inverse odds ratio	(0.75, 1.98)	(0.67, 1.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.07	
95% CI of the inverse risk ratio	(0.80, 1.69)	(0.74, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.61	-1.73	
95% CI of the absolute risk difference	(-12.28, 5.05)	(-10.79, 7.34)	
p-value	0.4215	0.7112	
p-value of Breslow-Day Test for Homogeneity [3]	0.9065	0.7715	

AMNOG Table SE23.9.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	29 (20.7)	22 (17.1)	47 (17.8)
No	111 (79.3)	107 (82.9)	217 (82.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	1.05	
95% CI of the inverse odds ratio	(0.49, 1.39)	(0.60, 1.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.04	
95% CI of the inverse risk ratio	(0.57, 1.30)	(0.66, 1.65)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.91	-0.75	
95% CI of the absolute risk difference	(-5.23, 11.06)	(-8.71, 7.21)	
p-value	0.4761	0.8546	
p-value of Breslow-Day Test for Homogeneity [3]	0.2503	0.7404	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	50 (35.7)	38 (29.5)	86 (32.6)
No	90 (64.3)	91 (70.5)	178 (67.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.16	
95% CI of the inverse odds ratio	(0.57, 1.34)	(0.73, 1.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.11	
95% CI of the inverse risk ratio	(0.69, 1.21)	(0.80, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.14	-3.12	
95% CI of the absolute risk difference	(-6.61, 12.88)	(-12.81, 6.57)	
p-value	0.5253	0.5322	
p-value of Breslow-Day Test for Homogeneity [3]	0.4046	0.8223	

AMNOG Table SE23.10.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
CLDQ-NASH						
Baseline						
m	19	16	43			
n	18	15	38			
Mean (SD)	4.89 (1.26)	5.25 (0.93)	5.27 (0.97)			
Median	4.90	5.50	5.10			
IQR: Q1, Q3	4.20, 5.90	4.60, 5.80	4.60, 6.10			
Min, Max	1.9, 6.8	3.3, 6.7	3.0, 7.0			
Week 24						
m	19	15	41			
n	19	14	38	18	13	34
Mean (SD/SE)	5.01 (1.23)	5.45 (0.77)	5.14 (1.10)	0.10 (0.13)	0.08 (0.14)	-0.09 (0.10)
Median	5.10	5.65	5.20	0.15	0.10	-0.15
IQR: Q1, Q3	4.50, 5.80	4.80, 6.10	4.40, 5.90	-0.10, 0.30	-0.30, 0.20	-0.40, 0.10
Min, Max	2.1, 6.8	4.0, 6.6	2.9, 7.0	-1.2, 1.4	-0.6, 1.4	-1.2, 1.8
Week 52						
m	17	12	39			
n	17	12	34	16	11	31
Mean (SD/SE)	4.89 (0.94)	5.42 (0.69)	5.36 (1.06)	0.09 (0.18)	-0.10 (0.12)	-0.02 (0.12)
Median	4.80	5.50	5.60	-0.05	-0.10	-0.20
IQR: Q1, Q3	4.50, 5.40	4.75, 6.05	4.90, 6.00	-0.35, 0.20	-0.40, 0.10	-0.40, 0.40
Min, Max	3.2, 6.7	4.3, 6.3	1.9, 6.9	-0.7, 1.9	-0.9, 0.7	-1.4, 1.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Abdominal Symptoms						
Baseline						
m	19	16	43			
n	18	15	38			
Mean (SD)	4.79 (1.72)	5.75 (1.18)	5.09 (1.55)			
Median	4.50	6.00	5.30			
IQR: Q1, Q3	3.70, 6.30	5.00, 7.00	4.30, 6.70			
Min, Max	2.0, 7.0	3.3, 7.0	2.0, 7.0			
Week 24						
m	19	15	41			
n	19	14	38	18	13	34
Mean (SD/SE)	5.18 (1.49)	5.84 (1.34)	5.20 (1.57)	0.36 (0.26)	0.11 (0.27)	0.17 (0.23)
Median	5.70	6.30	5.30	0.15	0	0
IQR: Q1, Q3	4.00, 6.70	5.00, 7.00	4.00, 7.00	-0.30, 1.00	-0.30, 0.30	-1.00, 1.00
Min, Max	2.0, 7.0	2.3, 7.0	1.0, 7.0	-1.7, 2.7	-1.7, 2.0	-2.7, 2.7
Week 52						
m	17	12	39			
n	17	12	34	16	11	31
Mean (SD/SE)	5.16 (1.16)	5.62 (1.25)	5.31 (1.57)	0.61 (0.40)	-0.30 (0.22)	0.02 (0.23)
Median	5.00	5.70	5.85	0.50	-0.30	0
IQR: Q1, Q3	4.30, 6.00	5.30, 6.70	5.00, 6.30	-0.45, 1.35	-0.70, 0.00	-0.70, 1.00
Min, Max	2.7, 7.0	2.3, 7.0	1.0, 7.0	-2.7, 4.0	-1.7, 1.0	-3.3, 2.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Activity						
Baseline						
m	19	16	43			
n	18	15	38			
Mean (SD)	5.23 (1.62)	5.20 (1.28)	5.31 (1.25)			
Median	5.90	5.40	5.00			
IQR: Q1, Q3	4.00, 6.40	4.20, 6.40	4.40, 6.60			
Min, Max	1.8, 7.0	2.8, 7.0	2.4, 7.0			
Week 24						
m	19	15	41			
n	19	14	38	18	13	34
Mean (SD/SE)	5.07 (1.61)	5.53 (1.15)	5.17 (1.36)	-0.21 (0.16)	0.03 (0.32)	-0.11 (0.16)
Median	5.20	5.80	5.40	0.10	0	-0.30
IQR: Q1, Q3	4.60, 6.40	5.20, 6.20	3.80, 6.40	-0.80, 0.20	-0.60, 0.20	-0.80, 0.40
Min, Max	1.4, 7.0	3.2, 7.0	2.8, 7.0	-1.6, 0.6	-1.4, 3.2	-1.6, 2.6
Week 52						
m	17	12	39			
n	17	12	34	16	11	31
Mean (SD/SE)	4.89 (1.53)	5.38 (0.89)	5.39 (1.25)	-0.34 (0.32)	-0.22 (0.22)	-0.11 (0.17)
Median	5.20	5.60	5.60	0.20	-0.20	0
IQR: Q1, Q3	4.40, 5.60	5.00, 6.00	4.40, 6.40	-0.70, 0.40	-1.00, 0.20	-0.60, 0.40
Min, Max	2.0, 7.0	3.6, 6.8	1.8, 7.0	-4.4, 0.8	-1.6, 0.8	-2.4, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Emotional Health						
Baseline						
m	19	16	43			
n	18	15	38			
Mean (SD)	4.98 (1.24)	5.33 (1.13)	5.74 (0.88)			
Median	5.15	5.10	5.80			
IQR: Q1, Q3	4.10, 5.90	4.30, 6.30	5.10, 6.40			
Min, Max	2.6, 7.0	3.3, 6.9	3.8, 7.0			
Week 24						
m	19	15	41			
n	19	14	38	18	13	34
Mean (SD/SE)	5.15 (1.22)	5.59 (1.11)	5.45 (1.15)	0.24 (0.14)	0.15 (0.15)	-0.26 (0.13)
Median	5.70	5.75	5.70	0.20	0.10	-0.10
IQR: Q1, Q3	4.20, 6.10	5.10, 6.10	4.60, 6.40	-0.20, 0.70	0.00, 0.50	-0.80, 0.20
Min, Max	2.7, 6.9	2.6, 6.9	2.8, 7.0	-1.2, 1.3	-0.8, 0.9	-2.0, 1.8
Week 52						
m	17	12	39			
n	17	12	34	16	11	31
Mean (SD/SE)	4.94 (0.97)	5.52 (1.10)	5.69 (0.93)	0.13 (0.28)	0.07 (0.19)	-0.19 (0.15)
Median	5.00	5.80	5.90	0.20	-0.30	-0.20
IQR: Q1, Q3	4.20, 5.30	4.80, 6.20	5.30, 6.30	-0.65, 0.70	-0.50, 0.80	-0.70, 0.20
Min, Max	3.2, 6.9	3.0, 7.0	3.1, 7.0	-1.9, 2.5	-0.6, 1.0	-1.8, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Fatigue						
Baseline						
m	19	16	43			
n	18	15	38			
Mean (SD)	4.46 (1.48)	4.03 (1.62)	4.73 (1.25)			
Median	4.75	4.50	4.90			
IQR: Q1, Q3	3.20, 5.20	2.70, 5.20	3.80, 6.00			
Min, Max	1.2, 6.8	1.5, 6.7	2.5, 7.0			
Week 24						
m	19	15	41			
n	19	14	38	18	13	34
Mean (SD/SE)	4.49 (1.58)	4.23 (1.39)	4.44 (1.46)	0.04 (0.17)	0.05 (0.12)	-0.27 (0.19)
Median	4.50	4.70	4.40	0.05	0	-0.20
IQR: Q1, Q3	3.50, 6.20	3.20, 5.00	3.30, 5.70	-0.50, 0.30	-0.20, 0.40	-0.80, 0.50
Min, Max	1.5, 6.8	1.8, 6.3	1.3, 6.8	-1.0, 1.8	-0.6, 0.8	-2.5, 2.0
Week 52						
m	17	12	39			
n	17	12	34	16	11	31
Mean (SD/SE)	4.31 (1.51)	4.25 (1.39)	4.68 (1.50)	-0.11 (0.24)	-0.26 (0.20)	-0.13 (0.20)
Median	4.30	3.90	5.00	-0.05	-0.10	0
IQR: Q1, Q3	3.00, 5.00	3.75, 5.25	3.70, 5.80	-0.60, 0.40	-0.90, 0.10	-0.70, 0.40
Min, Max	1.8, 7.0	1.5, 6.8	1.0, 7.0	-2.0, 2.2	-1.4, 1.1	-2.6, 2.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Systemic Symptoms						
Baseline						
m	19	16	43			
n	18	15	38			
Mean (SD)	4.70 (1.38)	4.88 (1.10)	5.13 (1.13)			
Median	4.65	5.00	5.20			
IQR: Q1, Q3	3.70, 6.00	4.70, 5.80	4.50, 5.80			
Min, Max	2.2, 7.0	2.2, 6.5	2.5, 7.0			
Week 24						
m	19	15	41			
n	19	14	38	18	13	34
Mean (SD/SE)	4.74 (1.40)	5.02 (0.89)	4.91 (1.07)	-0.01 (0.15)	0.05 (0.19)	-0.19 (0.14)
Median	5.30	5.20	5.00	0.05	0	0
IQR: Q1, Q3	3.80, 5.70	4.80, 5.50	4.00, 5.50	-0.40, 0.30	-0.20, 0.60	-0.80, 0.50
Min, Max	2.2, 6.8	3.2, 6.3	2.7, 7.0	-1.3, 1.6	-1.2, 1.0	-2.5, 1.4
Week 52						
m	17	12	39			
n	17	12	34	16	11	31
Mean (SD/SE)	4.46 (1.19)	5.14 (0.82)	5.04 (1.37)	-0.23 (0.17)	-0.09 (0.16)	-0.07 (0.16)
Median	4.50	5.20	5.15	-0.30	0	-0.20
IQR: Q1, Q3	3.50, 5.50	4.60, 5.60	4.30, 6.00	-0.50, 0.00	-0.60, 0.40	-0.70, 0.50
Min, Max	2.7, 6.5	3.8, 6.5	1.3, 7.0	-1.5, 1.0	-0.9, 0.5	-1.5, 2.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Worry						
Baseline						
m	19	16	43			
n	18	15	38			
Mean (SD)	5.27 (1.48)	6.23 (0.68)	5.60 (1.54)			
Median	5.50	6.40	6.05			
IQR: Q1, Q3	4.70, 6.40	5.70, 7.00	4.70, 7.00			
Min, Max	2.0, 7.0	5.1, 7.0	1.1, 7.0			
Week 24						
m	19	15	41			
n	19	14	38	18	13	34
Mean (SD/SE)	5.37 (1.49)	6.46 (0.64)	5.59 (1.67)	0.05 (0.21)	0.13 (0.14)	0.11 (0.15)
Median	5.90	6.80	6.35	0.15	0	0
IQR: Q1, Q3	4.30, 6.60	6.00, 7.00	4.30, 6.90	-0.20, 0.60	-0.10, 0.40	-0.30, 0.40
Min, Max	2.1, 7.0	5.0, 7.0	1.0, 7.0	-2.1, 1.4	-1.0, 1.2	-1.3, 2.4
Week 52						
m	17	12	39			
n	17	12	34	16	11	31
Mean (SD/SE)	5.56 (1.28)	6.58 (0.52)	6.00 (1.49)	0.40 (0.32)	0.25 (0.22)	0.35 (0.20)
Median	5.70	6.85	6.40	0	0	0
IQR: Q1, Q3	4.30, 6.40	6.00, 7.00	5.90, 7.00	-0.35, 1.00	0.00, 0.60	-0.30, 0.50
Min, Max	3.0, 7.0	5.7, 7.0	1.0, 7.0	-1.4, 3.8	-1.0, 1.9	-0.9, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
CLDQ-NASH						
Baseline						
m	148	135	260			
n	138	121	239			
Mean (SD)	5.27 (1.20)	5.27 (1.14)	5.22 (1.14)			
Median	5.50	5.60	5.40			
IQR: Q1, Q3	4.50, 6.30	4.50, 6.10	4.50, 6.20			
Min, Max	1.5, 7.0	2.1, 7.0	2.0, 7.0			
Week 24						
m	142	126	248			
n	136	122	225	129	112	210
Mean (SD/SE)	5.34 (1.13)	5.25 (1.06)	5.39 (1.10)	0.07 (0.07)	-0.03 (0.06)	0.15 (0.05)
Median	5.55	5.50	5.60	0	-0.05	0.10
IQR: Q1, Q3	4.50, 6.30	4.40, 6.10	4.60, 6.20	-0.20, 0.40	-0.40, 0.40	-0.30, 0.50
Min, Max	2.1, 7.0	2.7, 7.0	2.3, 7.0	-2.6, 2.5	-1.6, 1.6	-2.3, 3.0
Week 52						
m	132	113	231			
n	120	101	200	112	95	186
Mean (SD/SE)	5.43 (1.18)	5.33 (1.06)	5.37 (1.11)	0.04 (0.07)	0.02 (0.07)	0.07 (0.05)
Median	5.60	5.60	5.50	0.05	0	0
IQR: Q1, Q3	4.75, 6.40	4.60, 6.10	4.60, 6.30	-0.20, 0.40	-0.30, 0.30	-0.30, 0.50
Min, Max	1.6, 7.0	2.2, 6.9	2.2, 7.0	-2.7, 2.7	-2.4, 1.8	-2.2, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Abdominal Symptoms						
Baseline						
m	148	135	260			
n	138	121	239			
Mean (SD)	5.34 (1.62)	5.55 (1.39)	5.23 (1.52)			
Median	6.00	6.00	5.30			
IQR: Q1, Q3	4.30, 6.70	4.70, 7.00	4.30, 6.70			
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0			
Week 24						
m	142	126	248			
n	136	122	225	129	112	210
Mean (SD/SE)	5.42 (1.46)	5.38 (1.48)	5.52 (1.44)	0.06 (0.10)	-0.13 (0.11)	0.21 (0.08)
Median	5.30	5.70	6.00	0	0	0
IQR: Q1, Q3	4.70, 6.70	4.30, 6.70	4.70, 7.00	-0.40, 0.70	-0.70, 0.40	-0.40, 0.70
Min, Max	1.0, 7.0	1.3, 7.0	1.0, 7.0	-4.7, 3.3	-4.0, 2.4	-3.0, 4.0
Week 52						
m	132	113	231			
n	120	101	200	112	95	186
Mean (SD/SE)	5.58 (1.51)	5.59 (1.29)	5.48 (1.36)	0.06 (0.11)	-0.04 (0.10)	0.11 (0.09)
Median	6.00	5.70	5.70	0	0	0
IQR: Q1, Q3	5.00, 7.00	5.00, 6.70	4.70, 6.70	-0.35, 0.70	-0.40, 0.40	-0.60, 0.70
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0	-3.3, 3.7	-3.0, 2.7	-4.6, 4.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Activity						
Baseline						
m	148	135	260			
n	138	121	239			
Mean (SD)	5.28 (1.38)	5.35 (1.34)	5.43 (1.40)			
Median	5.40	5.60	5.80			
IQR: Q1, Q3	4.40, 6.40	4.60, 6.40	4.60, 6.60			
Min, Max	1.4, 7.0	1.8, 7.0	1.4, 7.0			
Week 24						
m	142	126	248			
n	136	122	225	129	112	210
Mean (SD/SE)	5.30 (1.42)	5.40 (1.28)	5.54 (1.34)	0.03 (0.08)	0.04 (0.08)	0.10 (0.07)
Median	5.60	5.80	6.00	0	0	0
IQR: Q1, Q3	4.40, 6.40	4.60, 6.60	4.80, 6.60	-0.60, 0.60	-0.60, 0.60	-0.40, 0.60
Min, Max	1.2, 7.0	2.4, 7.0	1.2, 7.0	-3.2, 2.8	-2.4, 2.4	-3.0, 3.2
Week 52						
m	132	113	231			
n	120	101	200	112	95	186
Mean (SD/SE)	5.40 (1.49)	5.37 (1.29)	5.45 (1.40)	-0.01 (0.10)	-0.01 (0.10)	-0.10 (0.07)
Median	5.80	5.60	5.80	0	0	0
IQR: Q1, Q3	4.70, 6.60	4.60, 6.40	4.40, 6.60	-0.50, 0.50	-0.60, 0.60	-0.60, 0.40
Min, Max	1.0, 7.0	1.6, 7.0	1.4, 7.0	-3.6, 3.0	-2.8, 2.0	-3.4, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Emotional Health						
Baseline						
m	148	135	260			
n	138	121	239			
Mean (SD)	5.41 (1.24)	5.39 (1.31)	5.36 (1.24)			
Median	5.60	5.70	5.60			
IQR: Q1, Q3	4.80, 6.30	4.70, 6.40	4.60, 6.30			
Min, Max	1.3, 7.0	1.8, 7.0	1.8, 7.0			
Week 24						
m	142	126	248			
n	136	122	225	129	112	210
Mean (SD/SE)	5.47 (1.24)	5.32 (1.26)	5.46 (1.26)	0.07 (0.07)	-0.10 (0.07)	0.09 (0.06)
Median	5.90	5.40	5.80	0	-0.10	0.10
IQR: Q1, Q3	4.75, 6.40	4.60, 6.30	4.80, 6.40	-0.30, 0.50	-0.50, 0.20	-0.40, 0.50
Min, Max	2.0, 7.0	1.0, 7.0	1.9, 7.0	-2.8, 2.5	-3.1, 2.4	-2.9, 3.3
Week 52						
m	132	113	231			
n	120	101	200	112	95	186
Mean (SD/SE)	5.52 (1.13)	5.47 (1.22)	5.47 (1.27)	-0.01 (0.07)	0.02 (0.08)	0.04 (0.06)
Median	5.80	5.80	5.70	0	0	0
IQR: Q1, Q3	4.85, 6.30	4.70, 6.40	4.70, 6.60	-0.50, 0.25	-0.60, 0.40	-0.40, 0.40
Min, Max	1.9, 7.0	1.0, 7.0	1.3, 7.0	-2.5, 2.9	-1.9, 2.9	-2.0, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Fatigue						
Baseline						
m	148	135	260			
n	138	121	239			
Mean (SD)	4.79 (1.51)	4.67 (1.42)	4.59 (1.46)			
Median	5.20	5.00	4.80			
IQR: Q1, Q3	3.80, 6.00	3.80, 5.70	3.50, 5.70			
Min, Max	1.2, 7.0	1.2, 7.0	1.0, 7.0			
Week 24						
m	142	126	248			
n	136	122	225	129	112	210
Mean (SD/SE)	4.79 (1.49)	4.60 (1.37)	4.73 (1.45)	0.00 (0.10)	-0.12 (0.09)	0.11 (0.08)
Median	4.90	4.75	4.80	0	0	0.10
IQR: Q1, Q3	3.75, 6.00	3.70, 5.70	3.50, 6.00	-0.60, 0.50	-0.70, 0.40	-0.50, 0.60
Min, Max	1.3, 7.0	1.5, 7.0	1.2, 7.0	-2.7, 4.1	-4.2, 2.3	-3.8, 3.7
Week 52						
m	132	113	231			
n	120	101	200	112	95	186
Mean (SD/SE)	4.91 (1.51)	4.64 (1.46)	4.71 (1.43)	0.04 (0.10)	-0.07 (0.12)	0.05 (0.08)
Median	5.20	5.00	4.80	0	0	0
IQR: Q1, Q3	3.75, 6.20	3.70, 5.80	3.70, 5.80	-0.45, 0.50	-0.50, 0.50	-0.50, 0.60
Min, Max	1.0, 7.0	1.2, 7.0	1.0, 7.0	-2.4, 4.0	-4.4, 2.5	-3.8, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Systemic Symptoms						
Baseline						
m	148	135	260			
n	138	121	239			
Mean (SD)	5.23 (1.26)	5.11 (1.23)	5.05 (1.25)			
Median	5.50	5.20	5.30			
IQR: Q1, Q3	4.50, 6.20	4.50, 6.00	4.20, 6.00			
Min, Max	1.5, 7.0	1.8, 7.0	1.7, 7.0			
Week 24						
m	142	126	248			
n	136	122	225	129	112	210
Mean (SD/SE)	5.21 (1.21)	4.99 (1.25)	5.17 (1.27)	-0.01 (0.07)	-0.18 (0.07)	0.03 (0.06)
Median	5.50	5.10	5.30	0	-0.20	0
IQR: Q1, Q3	4.30, 6.20	4.00, 6.00	4.30, 6.20	-0.50, 0.50	-0.50, 0.20	-0.50, 0.50
Min, Max	1.7, 7.0	1.8, 7.0	1.5, 7.0	-2.0, 3.5	-2.0, 2.2	-2.5, 3.7
Week 52						
m	132	113	231			
n	120	101	200	112	95	186
Mean (SD/SE)	5.24 (1.28)	5.03 (1.26)	5.14 (1.34)	-0.14 (0.08)	-0.12 (0.09)	0.02 (0.06)
Median	5.50	5.20	5.30	0	0	0
IQR: Q1, Q3	4.30, 6.25	4.20, 6.00	4.20, 6.30	-0.50, 0.30	-0.50, 0.30	-0.50, 0.50
Min, Max	1.3, 7.0	1.5, 7.0	1.7, 7.0	-2.7, 2.3	-2.5, 2.0	-2.7, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Worry						
Baseline						
m	148	135	260			
n	138	121	239			
Mean (SD)	5.55 (1.39)	5.52 (1.54)	5.63 (1.35)			
Median	5.80	6.00	6.00			
IQR: Q1, Q3	4.70, 6.70	4.60, 6.90	4.90, 6.70			
Min, Max	1.1, 7.0	1.0, 7.0	1.3, 7.0			
Week 24						
m	142	126	248			
n	136	122	225	129	112	210
Mean (SD/SE)	5.84 (1.35)	5.78 (1.36)	5.93 (1.29)	0.32 (0.09)	0.30 (0.10)	0.34 (0.07)
Median	6.30	6.20	6.30	0.20	0	0.20
IQR: Q1, Q3	5.35, 6.90	5.00, 6.90	5.40, 7.00	-0.10, 0.70	-0.30, 0.70	-0.10, 0.70
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0	-3.1, 3.3	-2.6, 3.6	-2.6, 3.5
Week 52						
m	132	113	231			
n	120	101	200	112	95	186
Mean (SD/SE)	5.93 (1.33)	5.89 (1.40)	5.99 (1.25)	0.31 (0.10)	0.37 (0.12)	0.32 (0.07)
Median	6.40	6.30	6.40	0.15	0	0.15
IQR: Q1, Q3	5.35, 7.00	5.30, 7.00	5.40, 7.00	-0.20, 0.80	-0.20, 0.90	0.00, 0.90
Min, Max	1.7, 7.0	1.0, 7.0	1.4, 7.0	-4.8, 3.0	-3.3, 3.6	-2.7, 3.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Thyroxine at Baseline
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.10.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
CLDQ-NASH			
Week 24			
m	19	15	41
n	18	13	34
Baseline Mean (SD)	4.89 (1.26)	5.36 (0.92)	5.32 (0.93)
Analysis Visit Mean (SD)	4.99 (1.26)	5.44 (0.80)	5.24 (1.08)
LS Mean of Change from Baseline (SE)	0.19 (0.14)	0.13 (0.15)	-0.03 (0.09)
95% CI	(-0.09, 0.46)	(-0.18, 0.44)	(-0.22, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.22 (0.16)	0.16 (0.18)	
95% CI	(-0.11, 0.54)	(-0.19, 0.52)	
p-value	0.1823	0.3595	
Corrected Hedge's g Statistics	0.385	0.293	
95% CI	(-0.19, 0.96)	(-0.35, 0.93)	
Week 52			
m	17	12	39
n	16	11	31
Baseline Mean (SD)	4.80 (1.29)	5.51 (0.73)	5.49 (0.86)
Analysis Visit Mean (SD)	4.89 (0.97)	5.41 (0.72)	5.47 (0.90)
LS Mean of Change from Baseline (SE)	0.05 (0.15)	0.12 (0.17)	0.10 (0.10)
95% CI	(-0.25, 0.35)	(-0.22, 0.45)	(-0.10, 0.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.18)	0.01 (0.19)	
95% CI	(-0.41, 0.30)	(-0.37, 0.40)	
p-value	0.7750	0.9398	
Corrected Hedge's g Statistics	-0.088	0.026	
95% CI	(-0.69, 0.52)	(-0.66, 0.71)	
Subgroup*Treatment Interaction p-value	0.5715	0.2337	

AMNOG Table SE23.10.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
CLDQ-NASH			
Week 24			
m	142	126	248
n	129	112	210
Baseline Mean (SD)	5.27 (1.17)	5.25 (1.15)	5.25 (1.14)
Analysis Visit Mean (SD)	5.34 (1.14)	5.23 (1.06)	5.40 (1.10)
LS Mean of Change from Baseline (SE)	0.08 (0.06)	-0.03 (0.06)	0.15 (0.05)
95% CI	(-0.03, 0.20)	(-0.16, 0.09)	(0.06, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.07)	-0.18 (0.08)	
95% CI	(-0.21, 0.08)	(-0.33, -0.03)	
p-value	0.3805	0.0190	
Corrected Hedge's g Statistics	-0.095	-0.267	
95% CI	(-0.31, 0.12)	(-0.50, -0.04)	
Week 52			
m	132	113	231
n	112	95	186
Baseline Mean (SD)	5.36 (1.14)	5.27 (1.18)	5.29 (1.13)
Analysis Visit Mean (SD)	5.40 (1.17)	5.28 (1.06)	5.36 (1.13)
LS Mean of Change from Baseline (SE)	0.05 (0.06)	0.01 (0.07)	0.10 (0.05)
95% CI	(-0.07, 0.17)	(-0.12, 0.14)	(0.00, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.08)	-0.09 (0.08)	
95% CI	(-0.20, 0.11)	(-0.25, 0.07)	
p-value	0.5508	0.2802	
Corrected Hedge's g Statistics	-0.069	-0.132	
95% CI	(-0.30, 0.17)	(-0.38, 0.12)	
Subgroup*Treatment Interaction p-value	0.5715	0.2337	

AMNOG Table SE23.10.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.10.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Abdominal Symptoms			
Week 24			
m	19	15	41
n	18	13	34
Baseline Mean (SD)	4.79 (1.72)	5.79 (1.27)	5.22 (1.44)
Analysis Visit Mean (SD)	5.16 (1.53)	5.90 (1.37)	5.39 (1.47)
LS Mean of Change from Baseline (SE)	0.59 (0.27)	0.51 (0.30)	0.28 (0.18)
95% CI	(0.06, 1.13)	(-0.10, 1.11)	(-0.08, 0.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.31 (0.32)	0.22 (0.35)	
95% CI	(-0.32, 0.94)	(-0.48, 0.92)	
p-value	0.3305	0.5287	
Corrected Hedge's g Statistics	0.279	0.203	
95% CI	(-0.30, 0.85)	(-0.44, 0.84)	
Week 52			
m	17	12	39
n	16	11	31
Baseline Mean (SD)	4.58 (1.70)	5.97 (1.12)	5.45 (1.38)
Analysis Visit Mean (SD)	5.19 (1.19)	5.67 (1.29)	5.47 (1.43)
LS Mean of Change from Baseline (SE)	0.70 (0.27)	0.27 (0.30)	0.20 (0.18)
95% CI	(0.16, 1.23)	(-0.33, 0.88)	(-0.15, 0.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.50 (0.32)	0.07 (0.34)	
95% CI	(-0.13, 1.13)	(-0.61, 0.76)	
p-value	0.1212	0.8292	
Corrected Hedge's g Statistics	0.483	0.074	
95% CI	(-0.13, 1.09)	(-0.61, 0.76)	
Subgroup*Treatment Interaction p-value	0.3240	0.3865	

AMNOG Table SE23.10.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Activity			
Week 24			
m	19	15	41
n	18	13	34
Baseline Mean (SD)	5.23 (1.62)	5.45 (1.16)	5.39 (1.20)
Analysis Visit Mean (SD)	5.02 (1.64)	5.48 (1.18)	5.28 (1.35)
LS Mean of Change from Baseline (SE)	-0.13 (0.22)	0.06 (0.24)	-0.07 (0.15)
95% CI	(-0.56, 0.30)	(-0.43, 0.54)	(-0.36, 0.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.25)	0.13 (0.28)	
95% CI	(-0.56, 0.44)	(-0.43, 0.68)	
p-value	0.8175	0.6546	
Corrected Hedge's g Statistics	-0.065	0.143	
95% CI	(-0.64, 0.51)	(-0.50, 0.78)	
Week 52			
m	17	12	39
n	16	11	31
Baseline Mean (SD)	5.21 (1.65)	5.55 (0.82)	5.59 (1.04)
Analysis Visit Mean (SD)	4.88 (1.58)	5.33 (0.91)	5.48 (1.24)
LS Mean of Change from Baseline (SE)	-0.26 (0.26)	0.03 (0.30)	-0.01 (0.18)
95% CI	(-0.77, 0.26)	(-0.57, 0.63)	(-0.36, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.25 (0.31)	0.04 (0.35)	
95% CI	(-0.87, 0.37)	(-0.65, 0.73)	
p-value	0.4228	0.9068	
Corrected Hedge's g Statistics	-0.243	0.040	
95% CI	(-0.85, 0.36)	(-0.65, 0.73)	
Subgroup*Treatment Interaction p-value	0.6635	0.5432	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Emotional Health			
Week 24			
m	19	15	41
n	18	13	34
Baseline Mean (SD)	4.98 (1.24)	5.45 (1.16)	5.78 (0.85)
Analysis Visit Mean (SD)	5.22 (1.21)	5.59 (1.16)	5.52 (1.12)
LS Mean of Change from Baseline (SE)	0.27 (0.18)	0.18 (0.19)	-0.19 (0.12)
95% CI	(-0.08, 0.63)	(-0.21, 0.57)	(-0.43, 0.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.46 (0.21)	0.37 (0.22)	
95% CI	(0.03, 0.88)	(-0.08, 0.82)	
p-value	0.0353	0.1084	
Corrected Hedge's g Statistics	0.626	0.514	
95% CI	(0.04, 1.21)	(-0.13, 1.16)	
Week 52			
m	17	12	39
n	16	11	31
Baseline Mean (SD)	4.84 (1.25)	5.43 (1.14)	5.93 (0.79)
Analysis Visit Mean (SD)	4.97 (0.99)	5.50 (1.16)	5.74 (0.83)
LS Mean of Change from Baseline (SE)	-0.12 (0.21)	0.11 (0.24)	0.02 (0.15)
95% CI	(-0.55, 0.30)	(-0.36, 0.58)	(-0.27, 0.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.26)	0.09 (0.28)	
95% CI	(-0.67, 0.38)	(-0.47, 0.64)	
p-value	0.5853	0.7563	
Corrected Hedge's g Statistics	-0.173	0.105	
95% CI	(-0.78, 0.43)	(-0.58, 0.79)	
Subgroup*Treatment Interaction p-value	0.4287	0.1489	

AMNOG Table SE23.10.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Fatigue			
Week 24			
m	19	15	41
n	18	13	34
Baseline Mean (SD)	4.46 (1.48)	4.10 (1.64)	4.79 (1.26)
Analysis Visit Mean (SD)	4.49 (1.62)	4.15 (1.41)	4.52 (1.49)
LS Mean of Change from Baseline (SE)	-0.02 (0.22)	-0.08 (0.26)	-0.26 (0.15)
95% CI	(-0.47, 0.42)	(-0.59, 0.44)	(-0.57, 0.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.24 (0.26)	0.18 (0.30)	
95% CI	(-0.29, 0.77)	(-0.41, 0.78)	
p-value	0.3735	0.5366	
Corrected Hedge's g Statistics	0.254	0.199	
95% CI	(-0.32, 0.83)	(-0.44, 0.84)	
Week 52			
m	17	12	39
n	16	11	31
Baseline Mean (SD)	4.42 (1.57)	4.40 (1.58)	4.98 (1.17)
Analysis Visit Mean (SD)	4.31 (1.56)	4.14 (1.39)	4.85 (1.40)
LS Mean of Change from Baseline (SE)	-0.21 (0.26)	-0.33 (0.30)	-0.07 (0.18)
95% CI	(-0.72, 0.31)	(-0.93, 0.26)	(-0.43, 0.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.31)	-0.26 (0.35)	
95% CI	(-0.75, 0.48)	(-0.95, 0.43)	
p-value	0.6615	0.4515	
Corrected Hedge's g Statistics	-0.133	-0.259	
95% CI	(-0.74, 0.47)	(-0.95, 0.43)	
Subgroup*Treatment Interaction p-value	0.7386	0.6468	

AMNOG Table SE23.10.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Systemic Symptoms			
Week 24			
m	19	15	41
n	18	13	34
Baseline Mean (SD)	4.70 (1.38)	4.98 (1.11)	5.19 (1.09)
Analysis Visit Mean (SD)	4.69 (1.42)	5.02 (0.93)	5.00 (1.05)
LS Mean of Change from Baseline (SE)	0.01 (0.17)	0.05 (0.20)	-0.13 (0.12)
95% CI	(-0.34, 0.36)	(-0.34, 0.45)	(-0.37, 0.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.14 (0.21)	0.19 (0.23)	
95% CI	(-0.27, 0.55)	(-0.27, 0.64)	
p-value	0.5014	0.4173	
Corrected Hedge's g Statistics	0.193	0.259	
95% CI	(-0.38, 0.77)	(-0.38, 0.90)	
Week 52			
m	17	12	39
n	16	11	31
Baseline Mean (SD)	4.69 (1.40)	5.25 (0.80)	5.26 (1.11)
Analysis Visit Mean (SD)	4.46 (1.23)	5.15 (0.86)	5.19 (1.25)
LS Mean of Change from Baseline (SE)	-0.23 (0.19)	0.02 (0.22)	0.01 (0.13)
95% CI	(-0.60, 0.15)	(-0.41, 0.46)	(-0.25, 0.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.24 (0.22)	0.01 (0.25)	
95% CI	(-0.69, 0.21)	(-0.48, 0.51)	
p-value	0.2960	0.9540	
Corrected Hedge's g Statistics	-0.321	0.020	
95% CI	(-0.93, 0.29)	(-0.67, 0.71)	
Subgroup*Treatment Interaction p-value	0.9560	0.1667	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.10.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Worry			
Week 24			
m	19	15	41
n	18	13	34
Baseline Mean (SD)	5.27 (1.48)	6.34 (0.67)	5.54 (1.58)
Analysis Visit Mean (SD)	5.32 (1.52)	6.47 (0.67)	5.65 (1.67)
LS Mean of Change from Baseline (SE)	0.07 (0.21)	0.28 (0.24)	0.15 (0.14)
95% CI	(-0.35, 0.48)	(-0.21, 0.76)	(-0.14, 0.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.24)	0.13 (0.28)	
95% CI	(-0.56, 0.41)	(-0.42, 0.68)	
p-value	0.7520	0.6401	
Corrected Hedge's g Statistics	-0.090	0.152	
95% CI	(-0.66, 0.48)	(-0.49, 0.79)	
Week 52			
m	17	12	39
n	16	11	31
Baseline Mean (SD)	5.18 (1.51)	6.37 (0.70)	5.75 (1.55)
Analysis Visit Mean (SD)	5.58 (1.33)	6.63 (0.51)	6.10 (1.33)
LS Mean of Change from Baseline (SE)	0.25 (0.24)	0.67 (0.29)	0.39 (0.17)
95% CI	(-0.24, 0.74)	(0.10, 1.25)	(0.06, 0.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.29)	0.29 (0.33)	
95% CI	(-0.71, 0.44)	(-0.37, 0.94)	
p-value	0.6380	0.3828	
Corrected Hedge's g Statistics	-0.143	0.303	
95% CI	(-0.75, 0.46)	(-0.39, 0.99)	
Subgroup*Treatment Interaction p-value	0.7303	0.3014	

AMNOG Table SE23.10.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Abdominal Symptoms			
Week 24			
m	142	126	248
n	129	112	210
Baseline Mean (SD)	5.36 (1.61)	5.52 (1.41)	5.31 (1.52)
Analysis Visit Mean (SD)	5.42 (1.46)	5.39 (1.50)	5.52 (1.41)
LS Mean of Change from Baseline (SE)	0.05 (0.09)	-0.08 (0.10)	0.20 (0.07)
95% CI	(-0.13, 0.24)	(-0.28, 0.12)	(0.05, 0.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.14 (0.12)	-0.28 (0.12)	
95% CI	(-0.37, 0.09)	(-0.52, -0.04)	
p-value	0.2239	0.0240	
Corrected Hedge's g Statistics	-0.132	-0.258	
95% CI	(-0.35, 0.09)	(-0.49, -0.03)	
Week 52			
m	132	113	231
n	112	95	186
Baseline Mean (SD)	5.48 (1.55)	5.61 (1.35)	5.35 (1.48)
Analysis Visit Mean (SD)	5.54 (1.55)	5.57 (1.31)	5.46 (1.38)
LS Mean of Change from Baseline (SE)	0.06 (0.10)	-0.01 (0.11)	0.13 (0.08)
95% CI	(-0.13, 0.26)	(-0.22, 0.21)	(-0.02, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.12)	-0.14 (0.13)	
95% CI	(-0.31, 0.17)	(-0.40, 0.12)	
p-value	0.5711	0.2862	
Corrected Hedge's g Statistics	-0.066	-0.131	
95% CI	(-0.30, 0.17)	(-0.38, 0.12)	
Subgroup*Treatment Interaction p-value	0.3240	0.3865	

AMNOG Table SE23.10.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Activity			
Week 24			
m	142	126	248
n	129	112	210
Baseline Mean (SD)	5.28 (1.37)	5.34 (1.34)	5.46 (1.38)
Analysis Visit Mean (SD)	5.31 (1.43)	5.39 (1.26)	5.57 (1.31)
LS Mean of Change from Baseline (SE)	0.01 (0.08)	0.02 (0.08)	0.13 (0.06)
95% CI	(-0.15, 0.17)	(-0.14, 0.19)	(0.00, 0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.12 (0.10)	-0.10 (0.10)	
95% CI	(-0.31, 0.08)	(-0.31, 0.10)	
p-value	0.2410	0.3198	
Corrected Hedge's g Statistics	-0.127	-0.113	
95% CI	(-0.35, 0.09)	(-0.34, 0.12)	
Week 52			
m	132	113	231
n	112	95	186
Baseline Mean (SD)	5.38 (1.33)	5.34 (1.38)	5.54 (1.33)
Analysis Visit Mean (SD)	5.37 (1.50)	5.32 (1.30)	5.43 (1.42)
LS Mean of Change from Baseline (SE)	-0.02 (0.09)	-0.03 (0.10)	-0.05 (0.07)
95% CI	(-0.19, 0.16)	(-0.21, 0.16)	(-0.19, 0.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.11)	0.02 (0.12)	
95% CI	(-0.19, 0.25)	(-0.21, 0.25)	
p-value	0.7761	0.8416	
Corrected Hedge's g Statistics	0.033	0.025	
95% CI	(-0.20, 0.27)	(-0.22, 0.27)	
Subgroup*Treatment Interaction p-value	0.6635	0.5432	

AMNOG Table SE23.10.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Emotional Health			
Week 24			
m	142	126	248
n	129	112	210
Baseline Mean (SD)	5.41 (1.23)	5.37 (1.33)	5.36 (1.26)
Analysis Visit Mean (SD)	5.47 (1.23)	5.27 (1.25)	5.45 (1.25)
LS Mean of Change from Baseline (SE)	0.06 (0.07)	-0.12 (0.08)	0.07 (0.06)
95% CI	(-0.08, 0.20)	(-0.27, 0.03)	(-0.04, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.09)	-0.18 (0.09)	
95% CI	(-0.18, 0.17)	(-0.37, 0.00)	
p-value	0.9805	0.0486	
Corrected Hedge's g Statistics	-0.003	-0.225	
95% CI	(-0.22, 0.22)	(-0.45, 0.01)	
Week 52			
m	132	113	231
n	112	95	186
Baseline Mean (SD)	5.51 (1.20)	5.38 (1.39)	5.40 (1.28)
Analysis Visit Mean (SD)	5.50 (1.11)	5.40 (1.22)	5.45 (1.29)
LS Mean of Change from Baseline (SE)	0.00 (0.07)	0.02 (0.08)	0.03 (0.06)
95% CI	(-0.14, 0.14)	(-0.13, 0.16)	(-0.08, 0.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.09)	-0.01 (0.09)	
95% CI	(-0.20, 0.14)	(-0.19, 0.17)	
p-value	0.7363	0.8822	
Corrected Hedge's g Statistics	-0.039	-0.018	
95% CI	(-0.27, 0.20)	(-0.27, 0.23)	
Subgroup*Treatment Interaction p-value	0.4287	0.1489	

AMNOG Table SE23.10.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Fatigue			
Week 24			
m	142	126	248
n	129	112	210
Baseline Mean (SD)	4.79 (1.49)	4.68 (1.44)	4.62 (1.48)
Analysis Visit Mean (SD)	4.79 (1.48)	4.56 (1.38)	4.73 (1.46)
LS Mean of Change from Baseline (SE)	0.04 (0.09)	-0.13 (0.09)	0.09 (0.07)
95% CI	(-0.13, 0.22)	(-0.32, 0.05)	(-0.05, 0.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.11)	-0.22 (0.12)	
95% CI	(-0.26, 0.17)	(-0.45, 0.01)	
p-value	0.6764	0.0558	
Corrected Hedge's g Statistics	-0.045	-0.217	
95% CI	(-0.26, 0.17)	(-0.45, 0.01)	
Week 52			
m	132	113	231
n	112	95	186
Baseline Mean (SD)	4.85 (1.50)	4.67 (1.48)	4.65 (1.45)
Analysis Visit Mean (SD)	4.88 (1.50)	4.59 (1.46)	4.70 (1.45)
LS Mean of Change from Baseline (SE)	0.06 (0.09)	-0.06 (0.10)	0.05 (0.07)
95% CI	(-0.13, 0.24)	(-0.26, 0.14)	(-0.10, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.12)	-0.11 (0.12)	
95% CI	(-0.22, 0.24)	(-0.35, 0.13)	
p-value	0.9252	0.3704	
Corrected Hedge's g Statistics	0.011	-0.110	
95% CI	(-0.22, 0.25)	(-0.36, 0.14)	
Subgroup*Treatment Interaction p-value	0.7386	0.6468	

AMNOG Table SE23.10.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Systemic Symptoms			
Week 24			
m	142	126	248
n	129	112	210
Baseline Mean (SD)	5.22 (1.24)	5.13 (1.24)	5.12 (1.24)
Analysis Visit Mean (SD)	5.20 (1.22)	4.95 (1.24)	5.16 (1.29)
LS Mean of Change from Baseline (SE)	0.02 (0.07)	-0.17 (0.08)	0.05 (0.06)
95% CI	(-0.12, 0.16)	(-0.32, -0.03)	(-0.06, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.09)	-0.22 (0.09)	
95% CI	(-0.20, 0.15)	(-0.40, -0.04)	
p-value	0.7724	0.0158	
Corrected Hedge's g Statistics	-0.031	-0.275	
95% CI	(-0.25, 0.19)	(-0.51, -0.04)	
Week 52			
m	132	113	231
n	112	95	186
Baseline Mean (SD)	5.32 (1.18)	5.10 (1.25)	5.10 (1.26)
Analysis Visit Mean (SD)	5.19 (1.29)	4.98 (1.26)	5.12 (1.36)
LS Mean of Change from Baseline (SE)	-0.08 (0.08)	-0.13 (0.08)	0.05 (0.06)
95% CI	(-0.23, 0.07)	(-0.30, 0.03)	(-0.07, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (0.10)	-0.19 (0.10)	
95% CI	(-0.32, 0.06)	(-0.38, 0.01)	
p-value	0.1778	0.0655	
Corrected Hedge's g Statistics	-0.157	-0.226	
95% CI	(-0.39, 0.08)	(-0.47, 0.02)	
Subgroup*Treatment Interaction p-value	0.9560	0.1667	

AMNOG Table SE23.10.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Worry			
Week 24			
m	142	126	248
n	129	112	210
Baseline Mean (SD)	5.53 (1.39)	5.46 (1.57)	5.61 (1.36)
Analysis Visit Mean (SD)	5.86 (1.32)	5.76 (1.38)	5.95 (1.28)
LS Mean of Change from Baseline (SE)	0.31 (0.08)	0.25 (0.09)	0.35 (0.06)
95% CI	(0.15, 0.47)	(0.08, 0.42)	(0.22, 0.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.10)	-0.10 (0.11)	
95% CI	(-0.24, 0.16)	(-0.31, 0.11)	
p-value	0.6880	0.3469	
Corrected Hedge's g Statistics	-0.043	-0.107	
95% CI	(-0.26, 0.18)	(-0.34, 0.12)	
Week 52			
m	132	113	231
n	112	95	186
Baseline Mean (SD)	5.62 (1.40)	5.48 (1.60)	5.67 (1.33)
Analysis Visit Mean (SD)	5.93 (1.31)	5.86 (1.42)	5.99 (1.25)
LS Mean of Change from Baseline (SE)	0.29 (0.09)	0.33 (0.10)	0.34 (0.07)
95% CI	(0.11, 0.47)	(0.14, 0.52)	(0.20, 0.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.11)	-0.01 (0.12)	
95% CI	(-0.27, 0.17)	(-0.24, 0.22)	
p-value	0.6359	0.9372	
Corrected Hedge's g Statistics	-0.055	-0.010	
95% CI	(-0.29, 0.18)	(-0.26, 0.24)	
Subgroup*Treatment Interaction p-value	0.7303	0.3014	

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (15.8)	0	3 (7.0)
No	16 (84.2)	16 (100)	40 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	2.85	
95% CI of the inverse odds ratio	(0.07, 2.19)	(0.14, 58.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	2.70	
95% CI of the inverse risk ratio	(0.10, 1.99)	(0.15, 49.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.81	-5.01	
95% CI of the absolute risk difference	(-9.27, 26.89)	(-16.35, 6.32)	
p-value	0.2792	0.4782	
p-value of Breslow-Day Test for Homogeneity [3]	0.1202	0.3058	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (15.8)	1 (6.3)	9 (20.9)
No	16 (84.2)	15 (93.8)	34 (79.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	3.97	
95% CI of the inverse odds ratio	(0.34, 5.93)	(0.46, 34.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	3.35	
95% CI of the inverse risk ratio	(0.40, 4.36)	(0.46, 24.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.14	-14.68	
95% CI of the absolute risk difference	(-25.55, 15.27)	(-31.67, 2.31)	
p-value	0.6367	0.1815	
p-value of Breslow-Day Test for Homogeneity [3]	0.6444	0.2226	

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (31.6)	1 (6.3)	8 (18.6)
No	13 (68.4)	15 (93.8)	35 (81.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	3.43	
95% CI of the inverse odds ratio	(0.14, 1.70)	(0.39, 29.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	2.98	
95% CI of the inverse risk ratio	(0.24, 1.46)	(0.40, 21.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.97	-12.35	
95% CI of the absolute risk difference	(-10.94, 36.89)	(-28.97, 4.26)	
p-value	0.2600	0.2406	
p-value of Breslow-Day Test for Homogeneity [3]	0.2658	0.4987	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (57.9)	2 (12.5)	15 (34.9)
No	8 (42.1)	14 (87.5)	28 (65.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.39	3.75	
95% CI of the inverse odds ratio	(0.13, 1.18)	(0.75, 18.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	2.79	
95% CI of the inverse risk ratio	(0.34, 1.06)	(0.72, 10.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	23.01	-22.38	
95% CI of the absolute risk difference	(-3.37, 49.39)	(-43.96, -0.81)	
p-value	0.0905	0.0915	
p-value of Breslow-Day Test for Homogeneity [3]	0.1039	0.3603	

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	3 (7.0)
No	19 (100)	16 (100)	40 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.37	2.85	
95% CI of the inverse odds ratio	(0.17, 68.52)	(0.14, 58.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	2.70	
95% CI of the inverse risk ratio	(0.17, 58.74)	(0.15, 49.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.45	-5.01	
95% CI of the absolute risk difference	(-15.98, 5.07)	(-16.35, 6.32)	
p-value	0.4034	0.4782	
p-value of Breslow-Day Test for Homogeneity [3]	0.1425	0.1821	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (31.6)	2 (12.5)	8 (18.6)
No	13 (68.4)	14 (87.5)	35 (81.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.50	1.60	
95% CI of the inverse odds ratio	(0.14, 1.70)	(0.30, 8.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	1.49	
95% CI of the inverse risk ratio	(0.24, 1.46)	(0.35, 6.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.97	-6.10	
95% CI of the absolute risk difference	(-10.94, 36.89)	(-26.05, 13.84)	
p-value	0.2600	0.5785	
p-value of Breslow-Day Test for Homogeneity [3]	0.5374	0.4464	

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (15.8)	2 (12.5)	3 (7.0)
No	16 (84.2)	14 (87.5)	40 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	0.53	
95% CI of the inverse odds ratio	(0.07, 2.19)	(0.08, 3.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	0.56	
95% CI of the inverse risk ratio	(0.10, 1.99)	(0.10, 3.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.81	5.52	
95% CI of the absolute risk difference	(-9.27, 26.89)	(-12.38, 23.43)	
p-value	0.2792	0.4983	
p-value of Breslow-Day Test for Homogeneity [3]	0.4531	0.5327	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (42.1)	4 (25.0)	7 (16.3)
No	11 (57.9)	12 (75.0)	36 (83.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	0.58	
95% CI of the inverse odds ratio	(0.08, 0.90)	(0.15, 2.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.39	0.65	
95% CI of the inverse risk ratio	(0.16, 0.91)	(0.22, 1.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	25.83	8.72	
95% CI of the absolute risk difference	(1.03, 50.62)	(-15.19, 32.64)	
p-value	0.0286	0.4445	
p-value of Breslow-Day Test for Homogeneity [3]	0.0099	0.3835	

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (5.3)	1 (6.3)	4 (9.3)
No	18 (94.7)	15 (93.8)	39 (90.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.85	1.54	
95% CI of the inverse odds ratio	(0.19, 17.72)	(0.16, 14.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	1.49	
95% CI of the inverse risk ratio	(0.21, 14.78)	(0.18, 12.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.04	-3.05	
95% CI of the absolute risk difference	(-17.31, 9.23)	(-17.75, 11.65)	
p-value	0.5902	0.7082	
p-value of Breslow-Day Test for Homogeneity [3]	0.8358	0.6274	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (26.3)	1 (6.3)	12 (27.9)
No	14 (73.7)	15 (93.8)	31 (72.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	5.81	
95% CI of the inverse odds ratio	(0.32, 3.67)	(0.69, 48.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	4.47	
95% CI of the inverse risk ratio	(0.43, 2.59)	(0.63, 31.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-21.66	
95% CI of the absolute risk difference	(-25.50, 22.32)	(-39.56, -3.76)	
p-value	0.8970	0.0744	
p-value of Breslow-Day Test for Homogeneity [3]	0.8738	0.1009	

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (5.3)	0	5 (11.6)
No	18 (94.7)	16 (100)	38 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.37	4.71	
95% CI of the inverse odds ratio	(0.26, 21.79)	(0.25, 90.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.21	4.25	
95% CI of the inverse risk ratio	(0.28, 17.65)	(0.25, 72.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.36	-9.56	
95% CI of the absolute risk difference	(-20.24, 7.51)	(-22.21, 3.09)	
p-value	0.4345	0.2610	
p-value of Breslow-Day Test for Homogeneity [3]	0.8745	0.1629	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (15.8)	5 (31.3)	10 (23.3)
No	16 (84.2)	11 (68.8)	33 (76.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	0.67	
95% CI of the inverse odds ratio	(0.39, 6.70)	(0.19, 2.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	0.74	
95% CI of the inverse risk ratio	(0.46, 4.75)	(0.30, 1.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.47	7.99	
95% CI of the absolute risk difference	(-28.16, 13.23)	(-17.99, 33.98)	
p-value	0.5055	0.5307	
p-value of Breslow-Day Test for Homogeneity [3]	0.7045	0.3858	

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (26.3)	2 (12.5)	5 (11.6)
No	14 (73.7)	14 (87.5)	38 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.37	0.92	
95% CI of the inverse odds ratio	(0.09, 1.47)	(0.16, 5.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.44	0.93	
95% CI of the inverse risk ratio	(0.14, 1.35)	(0.20, 4.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	14.69	0.87	
95% CI of the absolute risk difference	(-7.31, 36.68)	(-17.95, 19.70)	
p-value	0.1472	0.9266	
p-value of Breslow-Day Test for Homogeneity [3]	0.1530	0.8908	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (31.6)	5 (31.3)	12 (27.9)
No	13 (68.4)	11 (68.8)	31 (72.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	0.85	
95% CI of the inverse odds ratio	(0.26, 2.71)	(0.24, 2.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.89	
95% CI of the inverse risk ratio	(0.39, 2.00)	(0.37, 2.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.67	3.34	
95% CI of the absolute risk difference	(-21.16, 28.50)	(-23.03, 29.72)	
p-value	0.7690	0.8010	
p-value of Breslow-Day Test for Homogeneity [3]	0.8367	0.5804	

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (5.4)	11 (8.1)	23 (8.8)
No	140 (94.6)	124 (91.9)	237 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.70	1.09	
95% CI of the inverse odds ratio	(0.74, 3.90)	(0.52, 2.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.64	1.09	
95% CI of the inverse risk ratio	(0.75, 3.57)	(0.55, 2.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.44	-0.70	
95% CI of the absolute risk difference	(-8.46, 1.58)	(-6.46, 5.06)	
p-value	0.2073	0.8145	
p-value of Breslow-Day Test for Homogeneity [3]	0.1202	0.3058	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	35 (23.6)	30 (22.2)	61 (23.5)
No	113 (76.4)	105 (77.8)	199 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.07	
95% CI of the inverse odds ratio	(0.62, 1.59)	(0.65, 1.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.06	
95% CI of the inverse risk ratio	(0.69, 1.43)	(0.72, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.19	-1.24	
95% CI of the absolute risk difference	(-8.38, 8.75)	(-9.94, 7.46)	
p-value	0.9658	0.7814	
p-value of Breslow-Day Test for Homogeneity [3]	0.6444	0.2226	

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	25 (16.9)	16 (11.9)	46 (17.7)
No	123 (83.1)	119 (88.1)	214 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.60	
95% CI of the inverse odds ratio	(0.62, 1.81)	(0.87, 2.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.49	
95% CI of the inverse risk ratio	(0.67, 1.63)	(0.88, 2.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.80	-5.84	
95% CI of the absolute risk difference	(-8.41, 6.81)	(-13.00, 1.32)	
p-value	0.8375	0.1302	
p-value of Breslow-Day Test for Homogeneity [3]	0.2658	0.4987	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	45 (30.4)	28 (20.7)	81 (31.2)
No	103 (69.6)	107 (79.3)	179 (68.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.73	
95% CI of the inverse odds ratio	(0.67, 1.60)	(1.06, 2.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.50	
95% CI of the inverse risk ratio	(0.76, 1.39)	(1.03, 2.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.75	-10.41	
95% CI of the absolute risk difference	(-10.06, 8.56)	(-19.27, -1.55)	
p-value	0.8750	0.0281	
p-value of Breslow-Day Test for Homogeneity [3]	0.1039	0.3603	

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (12.2)	16 (11.9)	20 (7.7)
No	130 (87.8)	119 (88.1)	240 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	0.62	
95% CI of the inverse odds ratio	(0.31, 1.18)	(0.31, 1.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.65	
95% CI of the inverse risk ratio	(0.35, 1.16)	(0.35, 1.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.47	4.16	
95% CI of the absolute risk difference	(-1.71, 10.65)	(-2.18, 10.50)	
p-value	0.1353	0.1731	
p-value of Breslow-Day Test for Homogeneity [3]	0.1425	0.1821	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	41 (27.7)	35 (25.9)	58 (22.3)
No	107 (72.3)	100 (74.1)	202 (77.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.82	
95% CI of the inverse odds ratio	(0.47, 1.19)	(0.51, 1.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.86	
95% CI of the inverse risk ratio	(0.57, 1.14)	(0.60, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.40	3.62	
95% CI of the absolute risk difference	(-3.41, 14.20)	(-5.34, 12.58)	
p-value	0.2216	0.4215	
p-value of Breslow-Day Test for Homogeneity [3]	0.5374	0.4464	

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (10.8)	12 (8.9)	23 (8.8)
No	132 (89.2)	123 (91.1)	237 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.99	
95% CI of the inverse odds ratio	(0.41, 1.57)	(0.48, 2.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.00	
95% CI of the inverse risk ratio	(0.45, 1.50)	(0.51, 1.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.96	0.04	
95% CI of the absolute risk difference	(-4.11, 8.04)	(-5.87, 5.96)	
p-value	0.5164	0.9887	
p-value of Breslow-Day Test for Homogeneity [3]	0.4531	0.5327	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (18.9)	31 (23.0)	65 (25.0)
No	120 (81.1)	104 (77.0)	195 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.12	
95% CI of the inverse odds ratio	(0.87, 2.35)	(0.69, 1.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	1.09	
95% CI of the inverse risk ratio	(0.89, 1.96)	(0.75, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.08	-2.04	
95% CI of the absolute risk difference	(-14.30, 2.14)	(-10.87, 6.80)	
p-value	0.1592	0.6544	
p-value of Breslow-Day Test for Homogeneity [3]	0.0099	0.3835	

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	14 (9.5)	20 (14.8)	34 (13.1)
No	134 (90.5)	115 (85.2)	226 (86.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	0.87	
95% CI of the inverse odds ratio	(0.75, 2.78)	(0.48, 1.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	0.88	
95% CI of the inverse risk ratio	(0.77, 2.49)	(0.53, 1.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.62	1.74	
95% CI of the absolute risk difference	(-9.86, 2.63)	(-5.52, 9.00)	
p-value	0.2755	0.6335	
p-value of Breslow-Day Test for Homogeneity [3]	0.8358	0.6274	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	40 (27.0)	34 (25.2)	69 (26.5)
No	108 (73.0)	101 (74.8)	191 (73.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.07	
95% CI of the inverse odds ratio	(0.62, 1.54)	(0.67, 1.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.05	
95% CI of the inverse risk ratio	(0.70, 1.37)	(0.74, 1.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.49	-1.35	
95% CI of the absolute risk difference	(-8.46, 9.43)	(-10.43, 7.73)	
p-value	0.9146	0.7714	
p-value of Breslow-Day Test for Homogeneity [3]	0.8738	0.1009	

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (4.7)	12 (8.9)	23 (8.8)
No	141 (95.3)	123 (91.1)	237 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.95	0.99	
95% CI of the inverse odds ratio	(0.82, 4.67)	(0.48, 2.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.87	1.00	
95% CI of the inverse risk ratio	(0.82, 4.25)	(0.51, 1.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.12	0.04	
95% CI of the absolute risk difference	(-8.98, 0.74)	(-5.87, 5.96)	
p-value	0.1256	0.9887	
p-value of Breslow-Day Test for Homogeneity [3]	0.8745	0.1629	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	33 (22.3)	30 (22.2)	67 (25.8)
No	115 (77.7)	105 (77.8)	193 (74.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	1.22	
95% CI of the inverse odds ratio	(0.75, 1.95)	(0.74, 1.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.16	
95% CI of the inverse risk ratio	(0.80, 1.66)	(0.80, 1.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.47	-3.55	
95% CI of the absolute risk difference	(-12.03, 5.09)	(-12.35, 5.25)	
p-value	0.4331	0.4373	
p-value of Breslow-Day Test for Homogeneity [3]	0.7045	0.3858	

AMNOG Table SE23.10.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	26 (17.6)	24 (17.8)	48 (18.5)
No	122 (82.4)	111 (82.2)	212 (81.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.05	
95% CI of the inverse odds ratio	(0.63, 1.80)	(0.61, 1.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.04	
95% CI of the inverse risk ratio	(0.68, 1.62)	(0.67, 1.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.89	-0.68	
95% CI of the absolute risk difference	(-8.63, 6.84)	(-8.67, 7.31)	
p-value	0.8217	0.8674	
p-value of Breslow-Day Test for Homogeneity [3]	0.1530	0.8908	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	51 (34.5)	39 (28.9)	87 (33.5)
No	97 (65.5)	96 (71.1)	173 (66.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.24	
95% CI of the inverse odds ratio	(0.62, 1.46)	(0.79, 1.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	1.16	
95% CI of the inverse risk ratio	(0.73, 1.29)	(0.85, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.00	-4.57	
95% CI of the absolute risk difference	(-8.57, 10.56)	(-14.13, 4.99)	
p-value	0.8377	0.3551	
p-value of Breslow-Day Test for Homogeneity [3]	0.8367	0.5804	

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
CLDQ-NASH						
Baseline						
m	30	31	35			
n	29	27	32			
Mean (SD)	5.36 (1.28)	5.55 (0.95)	5.30 (0.98)			
Median	5.70	5.80	5.35			
IQR: Q1, Q3	5.10, 6.30	4.90, 6.20	4.45, 6.20			
Min, Max	1.5, 6.8	3.1, 6.9	3.5, 6.8			
Week 24						
m	30	31	35			
n	29	31	30	28	27	28
Mean (SD/SE)	5.38 (1.22)	5.57 (0.80)	5.51 (0.88)	0.09 (0.14)	-0.06 (0.12)	0.24 (0.15)
Median	5.80	5.60	5.75	0.15	-0.20	0.15
IQR: Q1, Q3	4.90, 6.10	4.90, 6.30	4.70, 6.20	-0.45, 0.70	-0.40, 0.40	-0.25, 0.65
Min, Max	2.1, 6.8	4.0, 6.8	4.0, 6.9	-1.8, 1.5	-1.3, 1.4	-1.6, 2.4
Week 52						
m	29	30	35			
n	26	28	27	25	25	27
Mean (SD/SE)	5.55 (1.15)	5.79 (0.75)	5.44 (1.05)	0.20 (0.10)	0.12 (0.12)	0.15 (0.11)
Median	5.85	5.90	5.70	0.10	0.10	0.10
IQR: Q1, Q3	5.30, 6.20	5.40, 6.35	4.60, 6.40	-0.10, 0.40	-0.30, 0.50	-0.20, 0.50
Min, Max	1.6, 6.7	4.2, 6.9	2.8, 6.7	-0.9, 1.3	-0.9, 1.5	-0.8, 1.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Abdominal Symptoms						
Baseline						
m	30	31	35			
n	29	27	32			
Mean (SD)	5.49 (1.69)	6.06 (1.18)	5.30 (1.53)			
Median	6.30	6.30	5.50			
IQR: Q1, Q3	4.30, 7.00	5.70, 7.00	4.30, 6.85			
Min, Max	1.0, 7.0	3.3, 7.0	1.3, 7.0			
Week 24						
m	30	31	35			
n	29	31	30	28	27	28
Mean (SD/SE)	5.42 (1.43)	5.75 (1.28)	5.61 (1.54)	-0.01 (0.24)	-0.33 (0.25)	0.34 (0.17)
Median	5.70	6.00	6.15	0	0	0
IQR: Q1, Q3	4.70, 6.70	5.00, 7.00	5.00, 7.00	-0.65, 0.70	-1.00, 0.70	0.00, 0.60
Min, Max	2.0, 7.0	2.3, 7.0	1.3, 7.0	-3.0, 2.6	-4.0, 1.7	-1.3, 2.7
Week 52						
m	29	30	35			
n	26	28	27	25	25	27
Mean (SD/SE)	5.85 (1.21)	6.21 (0.90)	5.27 (1.76)	0.30 (0.26)	0.05 (0.16)	0.01 (0.21)
Median	6.00	6.70	6.00	0	0	0
IQR: Q1, Q3	5.30, 6.70	5.70, 7.00	4.30, 6.70	-0.30, 1.00	-0.30, 0.70	-0.70, 0.70
Min, Max	1.3, 7.0	4.0, 7.0	1.0, 7.0	-2.3, 4.0	-2.0, 1.7	-3.3, 2.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Activity						
Baseline						
m	30	31	35			
n	29	27	32			
Mean (SD)	5.34 (1.55)	5.64 (1.18)	5.21 (1.45)			
Median	5.80	5.80	4.80			
IQR: Q1, Q3	4.40, 6.60	4.80, 6.60	4.40, 6.80			
Min, Max	1.4, 7.0	2.8, 7.0	2.0, 7.0			
Week 24						
m	30	31	35			
n	29	31	30	28	27	28
Mean (SD/SE)	5.43 (1.57)	5.75 (0.99)	5.58 (1.29)	0.14 (0.17)	0.01 (0.21)	0.41 (0.23)
Median	5.80	5.80	6.00	0	-0.20	0.40
IQR: Q1, Q3	4.80, 6.60	4.80, 6.40	5.20, 6.40	-0.50, 0.70	-0.80, 0.80	-0.60, 1.30
Min, Max	1.6, 7.0	3.2, 7.0	2.4, 7.0	-1.8, 1.8	-1.4, 3.2	-1.4, 2.6
Week 52						
m	29	30	35			
n	26	28	27	25	25	27
Mean (SD/SE)	5.63 (1.56)	5.75 (1.12)	5.38 (1.52)	0.38 (0.16)	-0.04 (0.15)	0.16 (0.17)
Median	5.90	6.00	5.80	0.40	0	0
IQR: Q1, Q3	5.40, 6.80	5.20, 6.60	4.40, 6.60	0.00, 1.00	-0.40, 0.40	-0.40, 0.60
Min, Max	1.6, 7.0	2.2, 7.0	2.0, 7.0	-1.2, 2.0	-1.2, 1.2	-1.4, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Emotional Health						
Baseline						
m	30	31	35			
n	29	27	32			
Mean (SD)	5.50 (1.24)	5.79 (1.04)	5.55 (1.03)			
Median	5.60	5.90	5.80			
IQR: Q1, Q3	5.10, 6.40	5.40, 6.60	4.70, 6.35			
Min, Max	1.9, 7.0	2.9, 7.0	3.2, 7.0			
Week 24						
m	30	31	35			
n	29	31	30	28	27	28
Mean (SD/SE)	5.64 (1.21)	5.65 (1.15)	5.60 (1.20)	0.23 (0.17)	-0.24 (0.16)	0.10 (0.18)
Median	6.10	5.70	6.05	0.25	-0.30	0.10
IQR: Q1, Q3	5.10, 6.40	5.10, 6.60	5.10, 6.60	-0.15, 0.75	-0.60, 0.20	-0.45, 0.30
Min, Max	2.7, 7.0	2.3, 7.0	3.3, 7.0	-2.8, 1.8	-3.1, 1.4	-2.3, 2.4
Week 52						
m	29	30	35			
n	26	28	27	25	25	27
Mean (SD/SE)	5.44 (1.26)	5.88 (0.89)	5.56 (1.13)	-0.06 (0.16)	-0.02 (0.17)	-0.06 (0.15)
Median	5.80	6.05	5.90	0	-0.10	0
IQR: Q1, Q3	5.00, 6.30	5.55, 6.40	4.80, 6.40	-0.60, 0.40	-0.60, 0.30	-0.40, 0.30
Min, Max	1.9, 6.9	3.0, 7.0	2.2, 7.0	-1.9, 1.6	-1.3, 2.9	-2.0, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Fatigue						
Baseline						
m	30	31	35			
n	29	27	32			
Mean (SD)	5.02 (1.48)	4.78 (1.49)	4.80 (1.25)			
Median	5.50	5.00	4.75			
IQR: Q1, Q3	4.20, 6.00	4.50, 5.80	3.70, 6.00			
Min, Max	1.2, 6.8	1.5, 7.0	2.7, 6.7			
Week 24						
m	30	31	35			
n	29	31	30	28	27	28
Mean (SD/SE)	4.82 (1.63)	4.88 (1.19)	4.77 (1.30)	-0.13 (0.17)	-0.06 (0.11)	0.02 (0.22)
Median	5.20	5.20	4.75	0.20	0	0
IQR: Q1, Q3	4.00, 6.00	4.20, 6.00	3.80, 5.70	-0.80, 0.50	-0.50, 0.30	-0.65, 0.55
Min, Max	1.5, 7.0	1.8, 6.3	2.3, 7.0	-2.4, 1.2	-1.1, 1.5	-3.3, 2.3
Week 52						
m	29	30	35			
n	26	28	27	25	25	27
Mean (SD/SE)	5.09 (1.44)	5.11 (1.38)	4.90 (1.38)	0.02 (0.23)	0.13 (0.23)	0.20 (0.16)
Median	5.40	5.60	4.80	-0.10	0	0.20
IQR: Q1, Q3	4.80, 6.00	4.25, 6.20	3.80, 6.20	-0.70, 0.50	-0.50, 0.70	-0.40, 0.50
Min, Max	1.5, 6.8	1.5, 7.0	2.3, 7.0	-2.0, 3.5	-2.8, 2.5	-0.9, 2.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Systemic Symptoms						
Baseline						
m	30	31	35			
n	29	27	32			
Mean (SD)	5.38 (1.31)	5.27 (1.26)	5.30 (1.12)			
Median	5.80	5.30	5.50			
IQR: Q1, Q3	5.20, 6.20	4.70, 6.20	4.50, 6.25			
Min, Max	1.5, 7.0	2.2, 7.0	3.2, 6.8			
Week 24						
m	30	31	35			
n	29	31	30	28	27	28
Mean (SD/SE)	5.22 (1.35)	5.25 (1.03)	5.41 (0.95)	-0.11 (0.15)	-0.13 (0.13)	0.06 (0.17)
Median	5.50	5.30	5.60	-0.05	0	-0.05
IQR: Q1, Q3	4.80, 6.00	4.70, 6.00	4.70, 6.30	-0.70, 0.60	-0.30, 0.20	-0.30, 0.60
Min, Max	1.7, 7.0	3.0, 6.8	3.7, 7.0	-1.6, 1.2	-2.0, 1.0	-1.6, 2.1
Week 52						
m	29	30	35			
n	26	28	27	25	25	27
Mean (SD/SE)	5.51 (1.28)	5.38 (0.98)	5.26 (1.43)	0.11 (0.12)	-0.08 (0.15)	-0.04 (0.18)
Median	5.80	5.30	5.80	0	0.10	-0.20
IQR: Q1, Q3	5.30, 6.30	4.65, 6.00	4.00, 6.50	-0.30, 0.50	-0.60, 0.30	-0.60, 0.50
Min, Max	1.3, 7.0	3.2, 7.0	2.5, 7.0	-0.8, 1.7	-2.0, 1.8	-2.2, 2.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Worry						
Baseline						
m	30	31	35			
n	29	27	32			
Mean (SD)	5.46 (1.74)	5.75 (1.35)	5.66 (1.06)			
Median	6.10	6.10	5.80			
IQR: Q1, Q3	4.60, 6.90	4.60, 7.00	5.15, 6.35			
Min, Max	1.1, 7.0	1.9, 7.0	3.3, 7.0			
Week 24						
m	30	31	35			
n	29	31	30	28	27	28
Mean (SD/SE)	5.78 (1.40)	6.12 (0.99)	6.00 (0.97)	0.43 (0.22)	0.34 (0.20)	0.42 (0.18)
Median	6.00	6.30	6.20	0.05	0	0.35
IQR: Q1, Q3	5.40, 6.90	5.70, 6.90	5.30, 6.90	-0.30, 1.25	-0.30, 0.70	0.00, 0.85
Min, Max	1.6, 7.0	2.3, 7.0	3.9, 7.0	-1.2, 3.1	-1.1, 3.6	-2.1, 2.6
Week 52						
m	29	30	35			
n	26	28	27	25	25	27
Mean (SD/SE)	5.80 (1.45)	6.46 (0.70)	6.29 (1.11)	0.40 (0.15)	0.75 (0.27)	0.59 (0.20)
Median	6.25	6.90	6.70	0.20	0.40	0.40
IQR: Q1, Q3	5.30, 7.00	5.95, 7.00	5.90, 7.00	0.00, 0.70	0.00, 1.60	0.00, 1.00
Min, Max	1.9, 7.0	4.6, 7.0	1.9, 7.0	-0.6, 2.4	-1.5, 3.6	-1.9, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
CLDQ-NASH						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	5.65 (1.09)	5.99 (0.79)	5.18 (1.24)			
Median	6.20	6.25	5.35			
IQR: Q1, Q3	5.20, 6.40	5.70, 6.50	4.20, 6.15			
Min, Max	2.8, 6.5	4.3, 6.7	2.9, 6.9			
Week 24						
m	12	8	13			
n	12	8	12	11	8	12
Mean (SD/SE)	5.73 (1.13)	5.83 (1.02)	5.08 (1.28)	0.30 (0.15)	-0.16 (0.14)	-0.11 (0.17)
Median	6.25	6.10	5.20	0.30	-0.15	0
IQR: Q1, Q3	5.35, 6.50	5.35, 6.55	4.25, 6.00	0.00, 0.90	-0.55, 0.10	-0.30, 0.05
Min, Max	3.4, 6.7	3.8, 6.8	2.6, 7.0	-0.7, 1.0	-0.6, 0.5	-1.3, 1.2
Week 52						
m	12	8	12			
n	12	8	10	11	8	10
Mean (SD/SE)	5.53 (1.55)	5.49 (1.00)	5.17 (1.08)	0.05 (0.18)	-0.50 (0.33)	0.26 (0.23)
Median	6.15	5.85	5.20	0	-0.20	0.40
IQR: Q1, Q3	4.75, 6.50	4.60, 6.30	4.10, 6.00	-0.10, 0.40	-0.95, 0.00	-0.10, 0.70
Min, Max	1.9, 7.0	3.9, 6.5	3.8, 6.9	-0.9, 1.3	-2.4, 0.7	-1.4, 1.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Abdominal Symptoms						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	6.15 (1.43)	5.71 (1.25)	5.47 (1.28)			
Median	7.00	6.00	5.30			
IQR: Q1, Q3	5.30, 7.00	4.65, 6.85	5.00, 6.65			
Min, Max	3.0, 7.0	3.7, 7.0	2.7, 7.0			
Week 24						
m	12	8	13			
n	12	8	12	11	8	12
Mean (SD/SE)	6.14 (1.38)	5.84 (1.31)	5.30 (1.10)	0.19 (0.29)	0.13 (0.17)	-0.17 (0.28)
Median	6.70	6.35	5.15	0	0	-0.30
IQR: Q1, Q3	6.15, 7.00	5.00, 6.85	4.30, 6.00	-0.30, 0.70	-0.15, 0.35	-0.70, 0.15
Min, Max	2.7, 7.0	3.3, 7.0	3.7, 7.0	-0.7, 2.7	-0.4, 1.0	-1.7, 2.0
Week 52						
m	12	8	12			
n	12	8	10	11	8	10
Mean (SD/SE)	5.78 (1.87)	5.16 (1.27)	5.30 (1.35)	-0.33 (0.29)	-0.55 (0.31)	-0.03 (0.43)
Median	6.70	5.00	5.35	0	-0.20	0.35
IQR: Q1, Q3	5.30, 7.00	4.30, 6.20	4.70, 6.30	-1.00, 0.00	-1.50, 0.15	-0.30, 0.70
Min, Max	1.0, 7.0	3.3, 7.0	3.3, 7.0	-2.0, 1.4	-1.7, 0.4	-3.7, 1.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Activity						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	5.84 (1.00)	5.88 (0.86)	5.38 (1.49)			
Median	6.20	6.10	5.40			
IQR: Q1, Q3	5.80, 6.40	5.10, 6.60	4.70, 6.60			
Min, Max	3.6, 6.8	4.6, 6.8	2.2, 7.0			
Week 24						
m	12	8	13			
n	12	8	12	11	8	12
Mean (SD/SE)	5.92 (1.19)	5.53 (1.30)	4.87 (1.72)	0.20 (0.19)	-0.35 (0.31)	-0.52 (0.16)
Median	6.30	6.00	4.80	0.40	-0.50	-0.60
IQR: Q1, Q3	5.10, 7.00	4.50, 6.40	4.00, 6.20	-0.20, 0.80	-1.10, 0.60	-0.90, 0.00
Min, Max	3.8, 7.0	3.4, 7.0	1.2, 7.0	-1.2, 0.8	-1.4, 0.6	-1.4, 0.2
Week 52						
m	12	8	12			
n	12	8	10	11	8	10
Mean (SD/SE)	5.58 (1.38)	5.23 (1.28)	5.06 (1.52)	-0.18 (0.41)	-0.65 (0.47)	-0.04 (0.25)
Median	5.90	5.40	4.90	0	-1.10	0.10
IQR: Q1, Q3	4.80, 6.70	4.00, 6.20	4.00, 6.20	-0.60, 0.20	-1.30, 0.70	-0.40, 0.40
Min, Max	3.0, 7.0	3.6, 7.0	2.4, 7.0	-3.0, 2.8	-2.8, 1.0	-1.4, 1.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Emotional Health						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	5.50 (1.27)	6.15 (1.03)	5.29 (1.48)			
Median	5.90	6.40	5.65			
IQR: Q1, Q3	5.00, 6.20	6.20, 6.65	4.55, 6.10			
Min, Max	2.0, 6.7	3.7, 7.0	1.8, 7.0			
Week 24						
m	12	8	13			
n	12	8	12	11	8	12
Mean (SD/SE)	5.54 (1.17)	6.16 (1.04)	5.23 (1.42)	0.26 (0.21)	0.01 (0.14)	-0.07 (0.28)
Median	6.00	6.65	5.45	0	0	0.15
IQR: Q1, Q3	4.95, 6.40	5.80, 6.75	4.20, 6.25	0.00, 0.60	0.00, 0.15	-0.50, 0.30
Min, Max	3.1, 6.6	3.9, 7.0	2.7, 7.0	-1.0, 1.6	-0.8, 0.6	-2.4, 1.5
Week 52						
m	12	8	12			
n	12	8	10	11	8	10
Mean (SD/SE)	5.59 (1.32)	5.98 (1.15)	5.37 (1.06)	0.33 (0.22)	-0.18 (0.34)	0.32 (0.30)
Median	6.05	6.60	5.20	0.20	0	0.30
IQR: Q1, Q3	4.85, 6.50	4.80, 6.85	4.60, 6.30	-0.40, 1.10	-0.70, 0.55	-0.30, 0.60
Min, Max	3.0, 7.0	4.3, 7.0	3.8, 7.0	-0.7, 1.4	-1.9, 0.8	-1.1, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Fatigue						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	5.02 (1.78)	5.79 (0.83)	4.50 (1.52)			
Median	5.80	5.85	4.65			
IQR: Q1, Q3	3.80, 6.30	5.15, 6.40	2.90, 6.00			
Min, Max	1.3, 6.8	4.5, 7.0	2.5, 6.7			
Week 24						
m	12	8	13			
n	12	8	12	11	8	12
Mean (SD/SE)	4.99 (1.90)	5.26 (1.21)	4.32 (1.77)	0.29 (0.34)	-0.53 (0.26)	-0.18 (0.30)
Median	5.65	5.25	4.10	0	-0.20	0.10
IQR: Q1, Q3	4.00, 6.45	4.45, 6.30	3.15, 6.00	-0.50, 1.40	-1.10, -0.10	-0.85, 0.55
Min, Max	1.5, 6.8	3.3, 6.8	1.7, 7.0	-1.5, 2.2	-1.8, 0.4	-2.5, 1.0
Week 52						
m	12	8	12			
n	12	8	10	11	8	10
Mean (SD/SE)	4.92 (2.22)	4.81 (1.76)	4.53 (1.33)	0.19 (0.20)	-0.98 (0.53)	0.40 (0.37)
Median	5.90	4.75	4.30	0	-0.20	0.65
IQR: Q1, Q3	2.90, 6.75	4.15, 6.30	3.30, 5.80	-0.30, 0.70	-1.40, -0.10	0.10, 0.90
Min, Max	1.0, 7.0	1.3, 6.8	2.8, 6.5	-0.5, 1.8	-4.4, 0.0	-2.4, 2.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Systemic Symptoms						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	5.50 (1.18)	6.00 (0.57)	5.04 (1.52)			
Median	5.80	5.90	5.00			
IQR: Q1, Q3	4.80, 6.30	5.65, 6.35	3.90, 6.50			
Min, Max	2.5, 6.7	5.2, 7.0	2.5, 7.0			
Week 24						
m	12	8	13			
n	12	8	12	11	8	12
Mean (SD/SE)	5.89 (1.04)	5.89 (1.00)	4.83 (1.60)	0.41 (0.12)	-0.11 (0.28)	-0.21 (0.17)
Median	6.30	5.85	4.80	0.30	-0.05	-0.10
IQR: Q1, Q3	5.60, 6.60	5.45, 6.75	3.60, 6.35	0.00, 0.80	-0.80, 0.40	-0.50, 0.15
Min, Max	3.2, 6.8	4.0, 7.0	2.3, 7.0	0.0, 1.0	-1.2, 1.2	-1.5, 0.8
Week 52						
m	12	8	12			
n	12	8	10	11	8	10
Mean (SD/SE)	5.48 (1.62)	5.50 (0.91)	4.59 (1.43)	-0.05 (0.31)	-0.50 (0.31)	-0.11 (0.35)
Median	6.10	5.75	4.50	0	-0.35	0
IQR: Q1, Q3	4.85, 6.40	4.65, 6.15	3.70, 5.00	-0.50, 0.30	-0.85, 0.10	-0.10, 0.50
Min, Max	1.3, 7.0	4.2, 6.7	2.5, 7.0	-1.7, 2.3	-2.3, 0.5	-2.4, 1.3

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Worry						
Baseline						
m	12	8	13			
n	11	8	12			
Mean (SD)	5.80 (0.78)	6.25 (1.07)	5.42 (1.47)			
Median	5.70	6.70	5.45			
IQR: Q1, Q3	5.60, 6.00	5.75, 7.00	4.50, 6.70			
Min, Max	4.1, 7.0	4.1, 7.0	2.3, 7.0			
Week 24						
m	12	8	13			
n	12	8	12	11	8	12
Mean (SD/SE)	6.06 (1.50)	6.34 (0.97)	5.83 (1.46)	0.66 (0.21)	0.09 (0.10)	0.42 (0.31)
Median	6.55	6.95	6.30	0.70	0	0
IQR: Q1, Q3	5.80, 6.95	5.55, 7.00	5.10, 6.95	0.00, 1.30	-0.05, 0.25	-0.30, 1.20
Min, Max	1.6, 7.0	4.7, 7.0	1.9, 7.0	-0.4, 1.6	-0.3, 0.6	-0.8, 2.3
Week 52						
m	12	8	12			
n	12	8	10	11	8	10
Mean (SD/SE)	5.80 (1.95)	6.31 (0.62)	6.14 (0.91)	0.35 (0.34)	0.06 (0.44)	1.00 (0.32)
Median	6.70	6.15	6.35	0.80	-0.25	1.05
IQR: Q1, Q3	5.50, 7.00	5.90, 7.00	5.40, 6.90	-0.30, 1.30	-0.70, 1.05	0.20, 2.00
Min, Max	1.7, 7.0	5.4, 7.0	4.3, 7.0	-2.4, 1.4	-1.6, 1.9	-0.6, 2.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
CLDQ-NASH						
Baseline						
m	111	87	221			
n	103	82	202			
Mean (SD)	5.24 (1.11)	5.16 (1.20)	5.28 (1.12)			
Median	5.40	5.55	5.50			
IQR: Q1, Q3	4.50, 6.20	4.20, 6.10	4.60, 6.20			
Min, Max	2.0, 7.0	2.1, 7.0	2.0, 7.0			
Week 24						
m	111	87	221			
n	106	84	203	100	79	188
Mean (SD/SE)	5.32 (1.08)	5.15 (1.08)	5.40 (1.08)	0.06 (0.07)	0.01 (0.07)	0.13 (0.05)
Median	5.40	5.25	5.60	0	0	0
IQR: Q1, Q3	4.50, 6.30	4.35, 6.00	4.60, 6.30	-0.20, 0.35	-0.40, 0.40	-0.30, 0.50
Min, Max	2.1, 7.0	2.7, 7.0	2.3, 7.0	-2.6, 2.4	-1.6, 1.6	-1.8, 3.0
Week 52						
m	107	87	219			
n	98	77	196	91	73	179
Mean (SD/SE)	5.30 (1.11)	5.16 (1.07)	5.37 (1.12)	-0.01 (0.08)	0.02 (0.07)	0.04 (0.05)
Median	5.40	5.30	5.60	0	0	0
IQR: Q1, Q3	4.60, 6.30	4.40, 6.00	4.70, 6.25	-0.30, 0.30	-0.30, 0.30	-0.40, 0.40
Min, Max	2.4, 7.0	2.2, 6.9	1.9, 7.0	-2.7, 2.7	-1.5, 1.8	-2.2, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Abdominal Symptoms						
Baseline						
m	111	87	221			
n	103	82	202			
Mean (SD)	5.26 (1.55)	5.49 (1.37)	5.27 (1.50)			
Median	5.70	5.85	5.70			
IQR: Q1, Q3	4.30, 6.70	4.30, 6.70	4.30, 6.70			
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0			
Week 24						
m	111	87	221			
n	106	84	203	100	79	188
Mean (SD/SE)	5.42 (1.37)	5.39 (1.46)	5.48 (1.44)	0.13 (0.11)	-0.03 (0.13)	0.19 (0.09)
Median	5.30	5.70	5.70	0	0	0
IQR: Q1, Q3	4.70, 6.70	4.30, 6.70	4.30, 7.00	-0.30, 0.70	-0.40, 0.30	-0.40, 1.00
Min, Max	1.3, 7.0	2.0, 7.0	1.0, 7.0	-4.7, 3.3	-3.3, 2.4	-3.0, 4.0
Week 52						
m	107	87	219			
n	98	77	196	91	73	179
Mean (SD/SE)	5.43 (1.48)	5.42 (1.34)	5.48 (1.34)	0.12 (0.13)	-0.05 (0.12)	0.12 (0.09)
Median	5.70	5.70	5.70	0	0	0
IQR: Q1, Q3	4.70, 6.70	5.00, 6.70	4.70, 6.70	-0.60, 0.70	-0.40, 0.30	-0.70, 1.00
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0	-3.3, 3.7	-3.0, 2.7	-4.6, 4.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Activity						
Baseline						
m	111	87	221			
n	103	82	202			
Mean (SD)	5.30 (1.32)	5.25 (1.41)	5.55 (1.28)			
Median	5.40	5.60	5.80			
IQR: Q1, Q3	4.40, 6.40	4.40, 6.40	4.80, 6.60			
Min, Max	2.0, 7.0	1.8, 7.0	1.4, 7.0			
Week 24						
m	111	87	221			
n	106	84	203	100	79	188
Mean (SD/SE)	5.29 (1.36)	5.27 (1.36)	5.58 (1.26)	-0.04 (0.10)	0.06 (0.09)	0.07 (0.07)
Median	5.60	5.80	6.00	0	0	0
IQR: Q1, Q3	4.40, 6.40	4.20, 6.50	4.80, 6.60	-0.60, 0.40	-0.40, 0.60	-0.40, 0.60
Min, Max	1.4, 7.0	2.4, 7.0	2.2, 7.0	-3.2, 2.8	-2.4, 1.8	-3.0, 3.2
Week 52						
m	107	87	219			
n	98	77	196	91	73	179
Mean (SD/SE)	5.24 (1.50)	5.25 (1.28)	5.46 (1.36)	-0.16 (0.12)	0.03 (0.11)	-0.15 (0.07)
Median	5.40	5.40	5.80	0	0.20	0
IQR: Q1, Q3	4.40, 6.60	4.40, 6.40	4.60, 6.60	-0.60, 0.40	-0.40, 0.60	-0.60, 0.40
Min, Max	1.0, 7.0	1.6, 7.0	1.4, 7.0	-4.4, 3.0	-2.8, 2.0	-3.4, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Emotional Health						
Baseline						
m	111	87	221			
n	103	82	202			
Mean (SD)	5.41 (1.17)	5.22 (1.41)	5.44 (1.24)			
Median	5.60	5.50	5.80			
IQR: Q1, Q3	4.60, 6.30	4.60, 6.30	4.80, 6.40			
Min, Max	1.3, 7.0	1.8, 7.0	1.9, 7.0			
Week 24						
m	111	87	221			
n	106	84	203	100	79	188
Mean (SD/SE)	5.45 (1.21)	5.17 (1.26)	5.54 (1.19)	0.04 (0.08)	-0.06 (0.08)	0.07 (0.06)
Median	5.70	5.30	5.80	0	-0.10	0
IQR: Q1, Q3	4.70, 6.40	4.40, 6.10	4.80, 6.60	-0.35, 0.50	-0.40, 0.40	-0.45, 0.50
Min, Max	2.2, 7.0	1.0, 7.0	1.9, 7.0	-2.6, 2.1	-2.0, 2.4	-2.2, 3.3
Week 52						
m	107	87	219			
n	98	77	196	91	73	179
Mean (SD/SE)	5.43 (1.08)	5.27 (1.26)	5.50 (1.25)	-0.01 (0.09)	0.06 (0.09)	0.01 (0.06)
Median	5.65	5.40	5.75	-0.10	0	0
IQR: Q1, Q3	4.70, 6.20	4.70, 6.30	4.70, 6.60	-0.50, 0.30	-0.50, 0.60	-0.50, 0.40
Min, Max	2.8, 7.0	1.0, 7.0	1.3, 7.0	-2.5, 2.9	-1.3, 2.0	-1.9, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Fatigue						
Baseline						
m	111	87	221			
n	103	82	202			
Mean (SD)	4.71 (1.42)	4.50 (1.49)	4.67 (1.47)			
Median	5.00	4.80	5.00			
IQR: Q1, Q3	3.50, 5.80	3.30, 5.50	3.70, 5.70			
Min, Max	1.5, 7.0	1.2, 7.0	1.0, 7.0			
Week 24						
m	111	87	221			
n	106	84	203	100	79	188
Mean (SD/SE)	4.77 (1.43)	4.41 (1.46)	4.76 (1.45)	0.01 (0.10)	-0.11 (0.12)	0.10 (0.08)
Median	4.70	4.40	5.00	0	-0.10	0
IQR: Q1, Q3	3.70, 6.00	3.30, 5.50	3.50, 6.00	-0.55, 0.45	-0.80, 0.50	-0.50, 0.60
Min, Max	1.8, 7.0	1.5, 7.0	1.2, 7.0	-2.7, 3.2	-4.2, 2.3	-3.8, 3.7
Week 52						
m	107	87	219			
n	98	77	196	91	73	179
Mean (SD/SE)	4.76 (1.45)	4.40 (1.41)	4.68 (1.46)	-0.01 (0.11)	-0.07 (0.12)	-0.02 (0.08)
Median	5.00	4.30	5.00	0	0	0
IQR: Q1, Q3	3.50, 6.00	3.30, 5.50	3.70, 5.80	-0.40, 0.50	-0.50, 0.50	-0.70, 0.50
Min, Max	1.8, 7.0	1.2, 6.8	1.0, 7.0	-2.4, 4.0	-2.8, 2.5	-3.8, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Systemic Symptoms						
Baseline						
m	111	87	221			
n	103	82	202			
Mean (SD)	5.15 (1.21)	5.00 (1.27)	5.09 (1.23)			
Median	5.30	5.00	5.30			
IQR: Q1, Q3	4.30, 6.20	4.50, 5.80	4.50, 6.00			
Min, Max	1.8, 7.0	1.8, 7.0	1.7, 7.0			
Week 24						
m	111	87	221			
n	106	84	203	100	79	188
Mean (SD/SE)	5.11 (1.19)	4.87 (1.27)	5.13 (1.25)	-0.05 (0.08)	-0.15 (0.08)	0.01 (0.06)
Median	5.30	5.00	5.30	-0.10	-0.20	0
IQR: Q1, Q3	4.30, 6.00	4.00, 5.90	4.30, 6.20	-0.40, 0.30	-0.60, 0.20	-0.60, 0.50
Min, Max	2.3, 7.0	1.8, 7.0	1.5, 7.0	-2.0, 2.1	-1.8, 2.2	-2.5, 3.7
Week 52						
m	107	87	219			
n	98	77	196	91	73	179
Mean (SD/SE)	5.01 (1.25)	4.87 (1.30)	5.14 (1.33)	-0.25 (0.08)	-0.08 (0.10)	0.03 (0.06)
Median	4.80	5.20	5.30	-0.20	0	0
IQR: Q1, Q3	4.20, 6.00	3.80, 5.80	4.20, 6.20	-0.70, 0.30	-0.50, 0.40	-0.50, 0.50
Min, Max	2.3, 7.0	1.5, 7.0	1.3, 7.0	-2.7, 2.0	-2.5, 2.0	-2.7, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Worry						
Baseline						
m	111	87	221			
n	103	82	202			
Mean (SD)	5.60 (1.29)	5.47 (1.59)	5.64 (1.40)			
Median	5.90	6.00	6.05			
IQR: Q1, Q3	5.00, 6.60	4.60, 6.70	4.90, 6.70			
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0			
Week 24						
m	111	87	221			
n	106	84	203	100	79	188
Mean (SD/SE)	5.88 (1.26)	5.72 (1.38)	5.93 (1.32)	0.25 (0.10)	0.28 (0.12)	0.31 (0.07)
Median	6.30	6.10	6.40	0.20	0.10	0.10
IQR: Q1, Q3	5.30, 6.70	4.90, 7.00	5.60, 7.00	-0.10, 0.60	-0.20, 0.80	-0.10, 0.70
Min, Max	1.6, 7.0	1.0, 7.0	1.0, 7.0	-3.1, 3.3	-2.6, 3.6	-2.6, 3.5
Week 52						
m	107	87	219			
n	98	77	196	91	73	179
Mean (SD/SE)	5.94 (1.21)	5.75 (1.53)	5.94 (1.32)	0.29 (0.12)	0.26 (0.12)	0.25 (0.07)
Median	6.35	6.30	6.40	0	0	0
IQR: Q1, Q3	5.40, 7.00	4.90, 7.00	5.30, 7.00	-0.30, 0.70	-0.20, 0.60	-0.20, 0.70
Min, Max	1.9, 7.0	1.0, 7.0	1.0, 7.0	-4.8, 3.8	-3.3, 3.3	-2.7, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Weight Change at Week 52
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.11.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
CLDQ-NASH			
Week 24			
m	30	31	35
n	28	27	28
Baseline Mean (SD)	5.31 (1.28)	5.55 (0.95)	5.31 (0.93)
Analysis Visit Mean (SD)	5.40 (1.24)	5.49 (0.81)	5.55 (0.90)
LS Mean of Change from Baseline (SE)	0.10 (0.13)	-0.01 (0.13)	0.26 (0.13)
95% CI	(-0.15, 0.36)	(-0.26, 0.25)	(0.00, 0.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (0.17)	-0.26 (0.18)	
95% CI	(-0.50, 0.20)	(-0.62, 0.09)	
p-value	0.3881	0.1464	
Corrected Hedge's g Statistics	-0.222	-0.386	
95% CI	(-0.75, 0.30)	(-0.92, 0.15)	
Week 52			
m	29	30	35
n	25	25	27
Baseline Mean (SD)	5.36 (1.33)	5.61 (0.86)	5.29 (0.99)
Analysis Visit Mean (SD)	5.56 (1.18)	5.73 (0.75)	5.44 (1.05)
LS Mean of Change from Baseline (SE)	0.22 (0.11)	0.18 (0.11)	0.18 (0.11)
95% CI	(0.01, 0.43)	(-0.03, 0.39)	(-0.03, 0.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.14)	0.00 (0.15)	
95% CI	(-0.24, 0.33)	(-0.29, 0.30)	
p-value	0.7567	0.9898	
Corrected Hedge's g Statistics	0.082	0.003	
95% CI	(-0.46, 0.63)	(-0.54, 0.55)	
Subgroup*Treatment Interaction p-value	0.5106	0.9981	

AMNOG Table SE23.11.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
CLDQ-NASH			
Week 24			
m	12	8	13
n	11	8	12
Baseline Mean (SD)	5.65 (1.09)	5.99 (0.79)	5.18 (1.24)
Analysis Visit Mean (SD)	5.95 (0.90)	5.83 (1.02)	5.08 (1.28)
LS Mean of Change from Baseline (SE)	0.28 (0.16)	-0.17 (0.20)	-0.21 (0.17)
95% CI	(-0.06, 0.62)	(-0.57, 0.24)	(-0.55, 0.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.49 (0.22)	0.04 (0.25)	
95% CI	(0.03, 0.95)	(-0.48, 0.57)	
p-value	0.0370	0.8626	
Corrected Hedge's g Statistics	0.846	0.075	
95% CI	(-0.01, 1.70)	(-0.82, 0.97)	
Week 52			
m	12	8	12
n	11	8	10
Baseline Mean (SD)	5.65 (1.09)	5.99 (0.79)	4.91 (1.16)
Analysis Visit Mean (SD)	5.69 (1.51)	5.49 (1.00)	5.17 (1.08)
LS Mean of Change from Baseline (SE)	0.02 (0.23)	-0.53 (0.28)	0.15 (0.27)
95% CI	(-0.46, 0.50)	(-1.10, 0.04)	(-0.39, 0.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (0.35)	-0.68 (0.39)	
95% CI	(-0.85, 0.58)	(-1.49, 0.12)	
p-value	0.7044	0.0940	
Corrected Hedge's g Statistics	-0.160	-0.797	
95% CI	(-1.02, 0.70)	(-1.76, 0.17)	
Subgroup*Treatment Interaction p-value	0.5106	0.9981	

AMNOG Table SE23.11.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
CLDQ-NASH			
Week 24			
m	111	87	221
n	100	79	188
Baseline Mean (SD)	5.24 (1.11)	5.14 (1.21)	5.28 (1.12)
Analysis Visit Mean (SD)	5.30 (1.09)	5.14 (1.07)	5.41 (1.08)
LS Mean of Change from Baseline (SE)	0.08 (0.07)	-0.02 (0.07)	0.14 (0.05)
95% CI	(-0.05, 0.21)	(-0.16, 0.12)	(0.05, 0.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.08)	-0.16 (0.08)	
95% CI	(-0.22, 0.09)	(-0.33, 0.00)	
p-value	0.4104	0.0548	
Corrected Hedge's g Statistics	-0.099	-0.251	
95% CI	(-0.34, 0.14)	(-0.51, 0.01)	
Week 52			
m	107	87	219
n	91	73	179
Baseline Mean (SD)	5.25 (1.13)	5.11 (1.21)	5.34 (1.11)
Analysis Visit Mean (SD)	5.24 (1.11)	5.12 (1.08)	5.38 (1.12)
LS Mean of Change from Baseline (SE)	0.01 (0.07)	-0.01 (0.08)	0.08 (0.05)
95% CI	(-0.12, 0.15)	(-0.16, 0.14)	(-0.01, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.08)	-0.09 (0.09)	
95% CI	(-0.23, 0.09)	(-0.27, 0.08)	
p-value	0.4048	0.2939	
Corrected Hedge's g Statistics	-0.104	-0.142	
95% CI	(-0.36, 0.15)	(-0.41, 0.13)	
Subgroup*Treatment Interaction p-value	0.5106	0.9981	

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Abdominal Symptoms			
Week 24			
m	30	31	35
n	28	27	28
Baseline Mean (SD)	5.46 (1.72)	6.06 (1.18)	5.43 (1.46)
Analysis Visit Mean (SD)	5.45 (1.45)	5.73 (1.35)	5.76 (1.45)
LS Mean of Change from Baseline (SE)	-0.05 (0.21)	-0.18 (0.21)	0.30 (0.21)
95% CI	(-0.46, 0.35)	(-0.60, 0.23)	(-0.12, 0.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.35 (0.28)	-0.48 (0.29)	
95% CI	(-0.91, 0.21)	(-1.07, 0.10)	
p-value	0.2127	0.1042	
Corrected Hedge's g Statistics	-0.318	-0.435	
95% CI	(-0.84, 0.21)	(-0.97, 0.10)	
Week 52			
m	29	30	35
n	25	25	27
Baseline Mean (SD)	5.57 (1.69)	6.17 (1.08)	5.26 (1.61)
Analysis Visit Mean (SD)	5.87 (1.23)	6.22 (0.91)	5.27 (1.76)
LS Mean of Change from Baseline (SE)	0.29 (0.20)	0.23 (0.20)	-0.06 (0.20)
95% CI	(-0.10, 0.69)	(-0.17, 0.62)	(-0.46, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.35 (0.27)	0.29 (0.28)	
95% CI	(-0.18, 0.89)	(-0.27, 0.85)	
p-value	0.1928	0.3125	
Corrected Hedge's g Statistics	0.343	0.279	
95% CI	(-0.21, 0.89)	(-0.27, 0.83)	
Subgroup*Treatment Interaction p-value	0.6001	0.9221	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Activity			
Week 24			
m	30	31	35
n	28	27	28
Baseline Mean (SD)	5.29 (1.54)	5.64 (1.18)	5.14 (1.47)
Analysis Visit Mean (SD)	5.42 (1.60)	5.65 (1.01)	5.56 (1.33)
LS Mean of Change from Baseline (SE)	0.17 (0.18)	0.11 (0.19)	0.36 (0.18)
95% CI	(-0.20, 0.53)	(-0.27, 0.48)	(-0.01, 0.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.19 (0.25)	-0.25 (0.26)	
95% CI	(-0.70, 0.31)	(-0.77, 0.27)	
p-value	0.4435	0.3377	
Corrected Hedge's g Statistics	-0.197	-0.254	
95% CI	(-0.72, 0.33)	(-0.78, 0.28)	
Week 52			
m	29	30	35
n	25	25	27
Baseline Mean (SD)	5.23 (1.58)	5.70 (1.04)	5.21 (1.44)
Analysis Visit Mean (SD)	5.61 (1.59)	5.66 (1.14)	5.38 (1.52)
LS Mean of Change from Baseline (SE)	0.43 (0.16)	0.05 (0.16)	0.25 (0.16)
95% CI	(0.11, 0.75)	(-0.27, 0.37)	(-0.06, 0.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.18 (0.21)	-0.20 (0.22)	
95% CI	(-0.24, 0.61)	(-0.64, 0.24)	
p-value	0.3989	0.3633	
Corrected Hedge's g Statistics	0.222	-0.247	
95% CI	(-0.32, 0.77)	(-0.79, 0.30)	
Subgroup*Treatment Interaction p-value	0.2178	0.7753	

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Emotional Health			
Week 24			
m	30	31	35
n	28	27	28
Baseline Mean (SD)	5.45 (1.23)	5.79 (1.04)	5.56 (1.01)
Analysis Visit Mean (SD)	5.68 (1.22)	5.55 (1.19)	5.65 (1.16)
LS Mean of Change from Baseline (SE)	0.22 (0.17)	-0.14 (0.17)	0.15 (0.17)
95% CI	(-0.11, 0.55)	(-0.47, 0.20)	(-0.18, 0.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.07 (0.23)	-0.28 (0.23)	
95% CI	(-0.38, 0.52)	(-0.75, 0.18)	
p-value	0.7426	0.2296	
Corrected Hedge's g Statistics	0.084	-0.318	
95% CI	(-0.44, 0.61)	(-0.85, 0.21)	
Week 52			
m	29	30	35
n	25	25	27
Baseline Mean (SD)	5.51 (1.31)	5.84 (1.03)	5.61 (1.03)
Analysis Visit Mean (SD)	5.46 (1.28)	5.82 (0.92)	5.56 (1.13)
LS Mean of Change from Baseline (SE)	-0.04 (0.16)	0.10 (0.16)	-0.06 (0.15)
95% CI	(-0.35, 0.27)	(-0.21, 0.41)	(-0.36, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (0.21)	0.16 (0.22)	
95% CI	(-0.40, 0.44)	(-0.27, 0.59)	
p-value	0.9179	0.4616	
Corrected Hedge's g Statistics	0.027	0.200	
95% CI	(-0.52, 0.57)	(-0.35, 0.75)	
Subgroup*Treatment Interaction p-value	0.5361	0.8785	

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Fatigue			
Week 24			
m	30	31	35
n	28	27	28
Baseline Mean (SD)	4.96 (1.47)	4.78 (1.49)	4.79 (1.24)
Analysis Visit Mean (SD)	4.83 (1.66)	4.72 (1.19)	4.80 (1.33)
LS Mean of Change from Baseline (SE)	-0.05 (0.17)	-0.04 (0.17)	0.06 (0.17)
95% CI	(-0.39, 0.28)	(-0.38, 0.30)	(-0.28, 0.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.23)	-0.10 (0.24)	
95% CI	(-0.57, 0.35)	(-0.57, 0.37)	
p-value	0.6312	0.6790	
Corrected Hedge's g Statistics	-0.123	-0.108	
95% CI	(-0.65, 0.40)	(-0.64, 0.42)	
Week 52			
m	29	30	35
n	25	25	27
Baseline Mean (SD)	5.08 (1.55)	4.86 (1.41)	4.70 (1.23)
Analysis Visit Mean (SD)	5.10 (1.46)	4.99 (1.42)	4.90 (1.38)
LS Mean of Change from Baseline (SE)	0.10 (0.20)	0.15 (0.20)	0.21 (0.20)
95% CI	(-0.30, 0.51)	(-0.25, 0.56)	(-0.19, 0.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.28)	-0.06 (0.28)	
95% CI	(-0.67, 0.45)	(-0.62, 0.51)	
p-value	0.7005	0.8421	
Corrected Hedge's g Statistics	-0.103	-0.054	
95% CI	(-0.65, 0.44)	(-0.60, 0.49)	
Subgroup*Treatment Interaction p-value	0.6563	0.7863	

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Systemic Symptoms			
Week 24			
m	30	31	35
n	28	27	28
Baseline Mean (SD)	5.32 (1.30)	5.27 (1.26)	5.34 (1.04)
Analysis Visit Mean (SD)	5.21 (1.37)	5.14 (1.03)	5.40 (0.96)
LS Mean of Change from Baseline (SE)	-0.08 (0.14)	-0.14 (0.14)	0.10 (0.14)
95% CI	(-0.35, 0.20)	(-0.42, 0.14)	(-0.17, 0.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.18 (0.19)	-0.24 (0.20)	
95% CI	(-0.56, 0.20)	(-0.63, 0.15)	
p-value	0.3392	0.2184	
Corrected Hedge's g Statistics	-0.246	-0.325	
95% CI	(-0.77, 0.28)	(-0.86, 0.21)	
Week 52			
m	29	30	35
n	25	25	27
Baseline Mean (SD)	5.40 (1.37)	5.36 (1.14)	5.30 (1.11)
Analysis Visit Mean (SD)	5.51 (1.31)	5.28 (0.95)	5.26 (1.43)
LS Mean of Change from Baseline (SE)	0.15 (0.16)	-0.07 (0.16)	0.01 (0.15)
95% CI	(-0.16, 0.46)	(-0.38, 0.24)	(-0.29, 0.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.14 (0.21)	-0.09 (0.22)	
95% CI	(-0.29, 0.57)	(-0.52, 0.35)	
p-value	0.5110	0.6950	
Corrected Hedge's g Statistics	0.177	-0.107	
95% CI	(-0.37, 0.72)	(-0.65, 0.44)	
Subgroup*Treatment Interaction p-value	0.1509	0.6758	

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Worry			
Week 24			
m	30	31	35
n	28	27	28
Baseline Mean (SD)	5.41 (1.75)	5.75 (1.35)	5.65 (1.07)
Analysis Visit Mean (SD)	5.83 (1.40)	6.10 (1.05)	6.07 (0.96)
LS Mean of Change from Baseline (SE)	0.32 (0.17)	0.41 (0.17)	0.44 (0.17)
95% CI	(-0.01, 0.65)	(0.07, 0.75)	(0.10, 0.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.12 (0.23)	-0.03 (0.24)	
95% CI	(-0.58, 0.34)	(-0.50, 0.44)	
p-value	0.6033	0.8876	
Corrected Hedge's g Statistics	-0.133	-0.037	
95% CI	(-0.66, 0.39)	(-0.57, 0.49)	
Week 52			
m	29	30	35
n	25	25	27
Baseline Mean (SD)	5.43 (1.84)	5.70 (1.39)	5.70 (1.10)
Analysis Visit Mean (SD)	5.83 (1.47)	6.45 (0.73)	6.29 (1.11)
LS Mean of Change from Baseline (SE)	0.28 (0.17)	0.79 (0.17)	0.58 (0.17)
95% CI	(-0.06, 0.62)	(0.45, 1.13)	(0.24, 0.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.30 (0.23)	0.21 (0.24)	
95% CI	(-0.76, 0.17)	(-0.26, 0.69)	
p-value	0.2095	0.3712	
Corrected Hedge's g Statistics	-0.335	0.243	
95% CI	(-0.88, 0.21)	(-0.30, 0.79)	
Subgroup*Treatment Interaction p-value	0.7769	0.9058	

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Abdominal Symptoms			
Week 24			
m	12	8	13
n	11	8	12
Baseline Mean (SD)	6.15 (1.43)	5.71 (1.25)	5.47 (1.28)
Analysis Visit Mean (SD)	6.34 (1.26)	5.84 (1.31)	5.30 (1.10)
LS Mean of Change from Baseline (SE)	0.22 (0.24)	-0.01 (0.28)	-0.42 (0.24)
95% CI	(-0.28, 0.72)	(-0.58, 0.56)	(-0.92, 0.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.64 (0.33)	0.41 (0.35)	
95% CI	(-0.03, 1.31)	(-0.32, 1.14)	
p-value	0.0605	0.2556	
Corrected Hedge's g Statistics	0.752	0.483	
95% CI	(-0.09, 1.60)	(-0.42, 1.39)	
Week 52			
m	12	8	12
n	11	8	10
Baseline Mean (SD)	6.15 (1.43)	5.71 (1.25)	5.33 (1.31)
Analysis Visit Mean (SD)	5.82 (1.96)	5.16 (1.27)	5.30 (1.35)
LS Mean of Change from Baseline (SE)	-0.36 (0.35)	-0.68 (0.40)	-0.26 (0.37)
95% CI	(-1.09, 0.36)	(-1.50, 0.15)	(-1.03, 0.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.51)	-0.41 (0.54)	
95% CI	(-1.14, 0.94)	(-1.52, 0.69)	
p-value	0.8439	0.4516	
Corrected Hedge's g Statistics	-0.083	-0.337	
95% CI	(-0.94, 0.77)	(-1.27, 0.60)	
Subgroup*Treatment Interaction p-value	0.6001	0.9221	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Activity			
Week 24			
m	12	8	13
n	11	8	12
Baseline Mean (SD)	5.84 (1.00)	5.88 (0.86)	5.38 (1.49)
Analysis Visit Mean (SD)	6.04 (1.17)	5.53 (1.30)	4.87 (1.72)
LS Mean of Change from Baseline (SE)	0.14 (0.22)	-0.35 (0.26)	-0.54 (0.22)
95% CI	(-0.31, 0.60)	(-0.88, 0.17)	(-0.99, -0.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.68 (0.30)	0.18 (0.33)	
95% CI	(0.07, 1.29)	(-0.49, 0.86)	
p-value	0.0301	0.5799	
Corrected Hedge's g Statistics	0.873	0.236	
95% CI	(0.02, 1.73)	(-0.66, 1.13)	
Week 52			
m	12	8	12
n	11	8	10
Baseline Mean (SD)	5.84 (1.00)	5.88 (0.86)	5.10 (1.48)
Analysis Visit Mean (SD)	5.65 (1.42)	5.23 (1.28)	5.06 (1.52)
LS Mean of Change from Baseline (SE)	-0.17 (0.36)	-0.57 (0.42)	-0.22 (0.39)
95% CI	(-0.90, 0.56)	(-1.43, 0.28)	(-1.02, 0.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.53)	-0.35 (0.57)	
95% CI	(-1.03, 1.13)	(-1.53, 0.82)	
p-value	0.9265	0.5452	
Corrected Hedge's g Statistics	0.039	-0.276	
95% CI	(-0.82, 0.90)	(-1.21, 0.66)	
Subgroup*Treatment Interaction p-value	0.2178	0.7753	

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Emotional Health			
Week 24			
m	12	8	13
n	11	8	12
Baseline Mean (SD)	5.50 (1.27)	6.15 (1.03)	5.29 (1.48)
Analysis Visit Mean (SD)	5.76 (0.92)	6.16 (1.04)	5.23 (1.42)
LS Mean of Change from Baseline (SE)	0.29 (0.21)	0.15 (0.25)	-0.11 (0.21)
95% CI	(-0.15, 0.72)	(-0.37, 0.66)	(-0.54, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.39 (0.28)	0.25 (0.33)	
95% CI	(-0.19, 0.98)	(-0.41, 0.92)	
p-value	0.1773	0.4402	
Corrected Hedge's g Statistics	0.528	0.336	
95% CI	(-0.30, 1.36)	(-0.56, 1.24)	
Week 52			
m	12	8	12
n	11	8	10
Baseline Mean (SD)	5.50 (1.27)	6.15 (1.03)	5.05 (1.50)
Analysis Visit Mean (SD)	5.83 (1.09)	5.98 (1.15)	5.37 (1.06)
LS Mean of Change from Baseline (SE)	0.34 (0.24)	0.02 (0.29)	0.18 (0.27)
95% CI	(-0.16, 0.85)	(-0.58, 0.62)	(-0.38, 0.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.16 (0.35)	-0.16 (0.40)	
95% CI	(-0.56, 0.88)	(-0.99, 0.66)	
p-value	0.6483	0.6860	
Corrected Hedge's g Statistics	0.186	-0.185	
95% CI	(-0.67, 1.04)	(-1.12, 0.75)	
Subgroup*Treatment Interaction p-value	0.5361	0.8785	

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Fatigue			
Week 24			
m	12	8	13
n	11	8	12
Baseline Mean (SD)	5.02 (1.78)	5.79 (0.83)	4.50 (1.52)
Analysis Visit Mean (SD)	5.31 (1.62)	5.26 (1.21)	4.32 (1.77)
LS Mean of Change from Baseline (SE)	0.15 (0.34)	-0.46 (0.41)	-0.44 (0.34)
95% CI	(-0.54, 0.85)	(-1.31, 0.38)	(-1.13, 0.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.59 (0.46)	-0.03 (0.53)	
95% CI	(-0.36, 1.54)	(-1.13, 1.07)	
p-value	0.2140	0.9591	
Corrected Hedge's g Statistics	0.494	-0.023	
95% CI	(-0.34, 1.32)	(-0.92, 0.87)	
Week 52			
m	12	8	12
n	11	8	10
Baseline Mean (SD)	5.02 (1.78)	5.79 (0.83)	4.13 (1.37)
Analysis Visit Mean (SD)	5.21 (2.08)	4.81 (1.76)	4.53 (1.33)
LS Mean of Change from Baseline (SE)	0.05 (0.32)	-1.00 (0.39)	0.16 (0.37)
95% CI	(-0.60, 0.70)	(-1.80, -0.20)	(-0.59, 0.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.47)	-1.16 (0.55)	
95% CI	(-1.08, 0.85)	(-2.28, -0.04)	
p-value	0.8092	0.0423	
Corrected Hedge's g Statistics	-0.099	-0.976	
95% CI	(-0.96, 0.76)	(-1.96, 0.01)	
Subgroup*Treatment Interaction p-value	0.6563	0.7863	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Systemic Symptoms			
Week 24			
m	12	8	13
n	11	8	12
Baseline Mean (SD)	5.50 (1.18)	6.00 (0.57)	5.04 (1.52)
Analysis Visit Mean (SD)	5.91 (1.09)	5.89 (1.00)	4.83 (1.60)
LS Mean of Change from Baseline (SE)	0.36 (0.19)	-0.14 (0.23)	-0.32 (0.20)
95% CI	(-0.04, 0.75)	(-0.61, 0.33)	(-0.72, 0.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.68 (0.26)	0.18 (0.30)	
95% CI	(0.14, 1.21)	(-0.43, 0.79)	
p-value	0.0148	0.5563	
Corrected Hedge's g Statistics	0.987	0.254	
95% CI	(0.12, 1.85)	(-0.64, 1.15)	
Week 52			
m	12	8	12
n	11	8	10
Baseline Mean (SD)	5.50 (1.18)	6.00 (0.57)	4.70 (1.42)
Analysis Visit Mean (SD)	5.45 (1.70)	5.50 (0.91)	4.59 (1.43)
LS Mean of Change from Baseline (SE)	-0.09 (0.31)	-0.50 (0.37)	-0.27 (0.34)
95% CI	(-0.72, 0.54)	(-1.26, 0.27)	(-0.97, 0.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.17 (0.45)	-0.23 (0.52)	
95% CI	(-0.76, 1.11)	(-1.30, 0.84)	
p-value	0.7038	0.6620	
Corrected Hedge's g Statistics	0.159	-0.205	
95% CI	(-0.70, 1.02)	(-1.14, 0.73)	
Subgroup*Treatment Interaction p-value	0.1509	0.6758	

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Worry			
Week 24			
m	12	8	13
n	11	8	12
Baseline Mean (SD)	5.80 (0.78)	6.25 (1.07)	5.42 (1.47)
Analysis Visit Mean (SD)	6.46 (0.56)	6.34 (0.97)	5.83 (1.46)
LS Mean of Change from Baseline (SE)	0.70 (0.23)	0.16 (0.27)	0.30 (0.23)
95% CI	(0.23, 1.17)	(-0.41, 0.72)	(-0.17, 0.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.40 (0.31)	-0.15 (0.35)	
95% CI	(-0.24, 1.04)	(-0.87, 0.58)	
p-value	0.2093	0.6856	
Corrected Hedge's g Statistics	0.492	-0.176	
95% CI	(-0.34, 1.32)	(-1.07, 0.72)	
Week 52			
m	12	8	12
n	11	8	10
Baseline Mean (SD)	5.80 (0.78)	6.25 (1.07)	5.14 (1.46)
Analysis Visit Mean (SD)	6.15 (1.59)	6.31 (0.62)	6.14 (0.91)
LS Mean of Change from Baseline (SE)	0.40 (0.32)	0.22 (0.38)	0.70 (0.35)
95% CI	(-0.24, 1.05)	(-0.56, 1.00)	(-0.03, 1.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.30 (0.46)	-0.48 (0.53)	
95% CI	(-1.25, 0.66)	(-1.57, 0.61)	
p-value	0.5303	0.3726	
Corrected Hedge's g Statistics	-0.262	-0.415	
95% CI	(-1.12, 0.60)	(-1.35, 0.52)	
Subgroup*Treatment Interaction p-value	0.7769	0.9058	

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Abdominal Symptoms			
Week 24			
m	111	87	221
n	100	79	188
Baseline Mean (SD)	5.26 (1.56)	5.45 (1.39)	5.30 (1.52)
Analysis Visit Mean (SD)	5.39 (1.37)	5.42 (1.47)	5.49 (1.40)
LS Mean of Change from Baseline (SE)	0.15 (0.11)	0.05 (0.12)	0.22 (0.08)
95% CI	(-0.06, 0.36)	(-0.18, 0.28)	(0.07, 0.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.13)	-0.17 (0.14)	
95% CI	(-0.32, 0.18)	(-0.44, 0.10)	
p-value	0.6009	0.2190	
Corrected Hedge's g Statistics	-0.063	-0.161	
95% CI	(-0.31, 0.18)	(-0.42, 0.10)	
Week 52			
m	107	87	219
n	91	73	179
Baseline Mean (SD)	5.25 (1.54)	5.46 (1.38)	5.38 (1.45)
Analysis Visit Mean (SD)	5.37 (1.51)	5.41 (1.36)	5.49 (1.33)
LS Mean of Change from Baseline (SE)	0.13 (0.11)	0.01 (0.12)	0.18 (0.08)
95% CI	(-0.09, 0.35)	(-0.23, 0.26)	(0.02, 0.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.14)	-0.17 (0.15)	
95% CI	(-0.32, 0.22)	(-0.45, 0.12)	
p-value	0.7137	0.2565	
Corrected Hedge's g Statistics	-0.046	-0.154	
95% CI	(-0.30, 0.21)	(-0.43, 0.12)	
Subgroup*Treatment Interaction p-value	0.6001	0.9221	

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Activity			
Week 24			
m	111	87	221
n	100	79	188
Baseline Mean (SD)	5.32 (1.32)	5.23 (1.42)	5.54 (1.27)
Analysis Visit Mean (SD)	5.28 (1.37)	5.29 (1.33)	5.62 (1.23)
LS Mean of Change from Baseline (SE)	-0.05 (0.09)	-0.01 (0.10)	0.10 (0.06)
95% CI	(-0.23, 0.12)	(-0.21, 0.18)	(-0.03, 0.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (0.11)	-0.12 (0.12)	
95% CI	(-0.36, 0.06)	(-0.34, 0.11)	
p-value	0.1496	0.3188	
Corrected Hedge's g Statistics	-0.173	-0.130	
95% CI	(-0.42, 0.07)	(-0.39, 0.13)	
Week 52			
m	107	87	219
n	91	73	179
Baseline Mean (SD)	5.35 (1.34)	5.19 (1.44)	5.61 (1.25)
Analysis Visit Mean (SD)	5.19 (1.50)	5.22 (1.30)	5.46 (1.37)
LS Mean of Change from Baseline (SE)	-0.16 (0.10)	-0.04 (0.11)	-0.09 (0.07)
95% CI	(-0.36, 0.04)	(-0.26, 0.18)	(-0.23, 0.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.12)	0.05 (0.13)	
95% CI	(-0.31, 0.17)	(-0.21, 0.31)	
p-value	0.5840	0.7051	
Corrected Hedge's g Statistics	-0.069	0.051	
95% CI	(-0.32, 0.18)	(-0.22, 0.32)	
Subgroup*Treatment Interaction p-value	0.2178	0.7753	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Emotional Health			
Week 24			
m	111	87	221
n	100	79	188
Baseline Mean (SD)	5.40 (1.18)	5.18 (1.41)	5.45 (1.24)
Analysis Visit Mean (SD)	5.43 (1.21)	5.12 (1.26)	5.52 (1.19)
LS Mean of Change from Baseline (SE)	0.03 (0.08)	-0.13 (0.09)	0.07 (0.06)
95% CI	(-0.12, 0.18)	(-0.30, 0.04)	(-0.04, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.09)	-0.19 (0.10)	
95% CI	(-0.22, 0.15)	(-0.39, 0.01)	
p-value	0.7146	0.0561	
Corrected Hedge's g Statistics	-0.044	-0.250	
95% CI	(-0.29, 0.20)	(-0.51, 0.01)	
Week 52			
m	107	87	219
n	91	73	179
Baseline Mean (SD)	5.40 (1.21)	5.15 (1.43)	5.48 (1.25)
Analysis Visit Mean (SD)	5.39 (1.07)	5.21 (1.26)	5.48 (1.27)
LS Mean of Change from Baseline (SE)	-0.03 (0.08)	-0.02 (0.09)	0.03 (0.06)
95% CI	(-0.18, 0.13)	(-0.19, 0.16)	(-0.09, 0.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.10)	-0.04 (0.10)	
95% CI	(-0.24, 0.14)	(-0.25, 0.16)	
p-value	0.5917	0.6718	
Corrected Hedge's g Statistics	-0.067	-0.057	
95% CI	(-0.32, 0.19)	(-0.33, 0.21)	
Subgroup*Treatment Interaction p-value	0.5361	0.8785	

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Fatigue			
Week 24			
m	111	87	221
n	100	79	188
Baseline Mean (SD)	4.73 (1.41)	4.49 (1.50)	4.67 (1.49)
Analysis Visit Mean (SD)	4.73 (1.44)	4.38 (1.48)	4.77 (1.46)
LS Mean of Change from Baseline (SE)	0.04 (0.10)	-0.18 (0.11)	0.09 (0.07)
95% CI	(-0.16, 0.24)	(-0.40, 0.05)	(-0.05, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.12)	-0.27 (0.13)	
95% CI	(-0.30, 0.18)	(-0.53, -0.01)	
p-value	0.6503	0.0420	
Corrected Hedge's g Statistics	-0.055	-0.266	
95% CI	(-0.30, 0.19)	(-0.53, 0.00)	
Week 52			
m	107	87	219
n	91	73	179
Baseline Mean (SD)	4.69 (1.47)	4.44 (1.51)	4.73 (1.45)
Analysis Visit Mean (SD)	4.68 (1.45)	4.36 (1.41)	4.71 (1.47)
LS Mean of Change from Baseline (SE)	-0.01 (0.10)	-0.12 (0.11)	0.00 (0.07)
95% CI	(-0.21, 0.20)	(-0.34, 0.11)	(-0.14, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.12)	-0.12 (0.13)	
95% CI	(-0.25, 0.24)	(-0.38, 0.15)	
p-value	0.9398	0.3806	
Corrected Hedge's g Statistics	-0.009	-0.118	
95% CI	(-0.26, 0.24)	(-0.39, 0.15)	
Subgroup*Treatment Interaction p-value	0.6563	0.7863	

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Systemic Symptoms			
Week 24			
m	111	87	221
n	100	79	188
Baseline Mean (SD)	5.15 (1.21)	5.01 (1.29)	5.11 (1.23)
Analysis Visit Mean (SD)	5.10 (1.21)	4.85 (1.26)	5.13 (1.27)
LS Mean of Change from Baseline (SE)	0.00 (0.08)	-0.16 (0.09)	0.04 (0.06)
95% CI	(-0.16, 0.16)	(-0.33, 0.02)	(-0.07, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.10)	-0.20 (0.10)	
95% CI	(-0.23, 0.15)	(-0.40, 0.00)	
p-value	0.6559	0.0557	
Corrected Hedge's g Statistics	-0.054	-0.250	
95% CI	(-0.30, 0.19)	(-0.51, 0.01)	
Week 52			
m	107	87	219
n	91	73	179
Baseline Mean (SD)	5.19 (1.19)	4.93 (1.23)	5.12 (1.25)
Analysis Visit Mean (SD)	4.94 (1.23)	4.85 (1.30)	5.14 (1.33)
LS Mean of Change from Baseline (SE)	-0.18 (0.08)	-0.09 (0.09)	0.07 (0.06)
95% CI	(-0.34, -0.01)	(-0.27, 0.09)	(-0.05, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.25 (0.10)	-0.16 (0.11)	
95% CI	(-0.44, -0.05)	(-0.37, 0.05)	
p-value	0.0143	0.1352	
Corrected Hedge's g Statistics	-0.308	-0.202	
95% CI	(-0.56, -0.05)	(-0.47, 0.07)	
Subgroup*Treatment Interaction p-value	0.1509	0.6758	

AMNOG Table SE23.11.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Worry			
Week 24			
m	111	87	221
n	100	79	188
Baseline Mean (SD)	5.59 (1.30)	5.43 (1.60)	5.63 (1.41)
Analysis Visit Mean (SD)	5.84 (1.28)	5.71 (1.39)	5.94 (1.31)
LS Mean of Change from Baseline (SE)	0.27 (0.09)	0.24 (0.10)	0.34 (0.07)
95% CI	(0.09, 0.45)	(0.05, 0.44)	(0.21, 0.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.11)	-0.09 (0.12)	
95% CI	(-0.28, 0.15)	(-0.32, 0.13)	
p-value	0.5435	0.4184	
Corrected Hedge's g Statistics	-0.073	-0.105	
95% CI	(-0.32, 0.17)	(-0.37, 0.16)	
Week 52			
m	107	87	219
n	91	73	179
Baseline Mean (SD)	5.61 (1.33)	5.45 (1.64)	5.70 (1.39)
Analysis Visit Mean (SD)	5.89 (1.23)	5.72 (1.54)	5.96 (1.30)
LS Mean of Change from Baseline (SE)	0.31 (0.10)	0.24 (0.11)	0.31 (0.07)
95% CI	(0.12, 0.51)	(0.03, 0.46)	(0.17, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.12)	-0.07 (0.13)	
95% CI	(-0.23, 0.24)	(-0.32, 0.19)	
p-value	0.9479	0.6037	
Corrected Hedge's g Statistics	0.008	-0.070	
95% CI	(-0.24, 0.26)	(-0.34, 0.20)	
Subgroup*Treatment Interaction p-value	0.7769	0.9058	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	4 (12.9)	4 (11.4)
No	27 (90.0)	27 (87.1)	31 (88.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	0.87	
95% CI of the inverse odds ratio	(0.24, 5.66)	(0.20, 3.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	0.89	
95% CI of the inverse risk ratio	(0.28, 4.71)	(0.24, 3.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.43	1.47	
95% CI of the absolute risk difference	(-16.47, 13.62)	(-14.35, 17.30)	
p-value	0.8531	0.8546	
p-value of Breslow-Day Test for Homogeneity [3]	0.8961	0.5131	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (26.7)	9 (29.0)	10 (28.6)
No	22 (73.3)	22 (71.0)	25 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	0.98	
95% CI of the inverse odds ratio	(0.37, 3.28)	(0.34, 2.84)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.98	
95% CI of the inverse risk ratio	(0.49, 2.36)	(0.46, 2.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.90	0.46	
95% CI of the absolute risk difference	(-23.69, 19.88)	(-21.43, 22.35)	
p-value	0.8642	0.9671	
p-value of Breslow-Day Test for Homogeneity [3]	0.3948	0.1828	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (26.7)	4 (12.9)	5 (14.3)
No	22 (73.3)	27 (87.1)	30 (85.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.46	1.13	
95% CI of the inverse odds ratio	(0.13, 1.59)	(0.27, 4.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	1.11	
95% CI of the inverse risk ratio	(0.20, 1.46)	(0.33, 3.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.38	-1.38	
95% CI of the absolute risk difference	(-7.24, 32.00)	(-17.93, 15.16)	
p-value	0.2135	0.8703	
p-value of Breslow-Day Test for Homogeneity [3]	0.3515	0.5777	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (36.7)	7 (22.6)	13 (37.1)
No	19 (63.3)	24 (77.4)	22 (62.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	2.03	
95% CI of the inverse odds ratio	(0.37, 2.80)	(0.68, 6.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.64	
95% CI of the inverse risk ratio	(0.54, 1.92)	(0.75, 3.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.48	-14.56	
95% CI of the absolute risk difference	(-24.00, 23.05)	(-36.31, 7.18)	
p-value	0.9684	0.1989	
p-value of Breslow-Day Test for Homogeneity [3]	0.2395	0.8758	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (26.7)	3 (9.7)	4 (11.4)
No	22 (73.3)	28 (90.3)	31 (88.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.35	1.20	
95% CI of the inverse odds ratio	(0.09, 1.33)	(0.25, 5.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	1.18	
95% CI of the inverse risk ratio	(0.14, 1.28)	(0.29, 4.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.24	-1.75	
95% CI of the absolute risk difference	(-3.78, 34.25)	(-16.56, 13.06)	
p-value	0.1144	0.8176	
p-value of Breslow-Day Test for Homogeneity [3]	0.4141	0.6824	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (50.0)	7 (22.6)	10 (28.6)
No	15 (50.0)	24 (77.4)	25 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	1.37	
95% CI of the inverse odds ratio	(0.14, 1.11)	(0.45, 4.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	1.27	
95% CI of the inverse risk ratio	(0.30, 1.08)	(0.55, 2.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	21.43	-5.99	
95% CI of the absolute risk difference	(-1.90, 44.75)	(-26.98, 15.00)	
p-value	0.0767	0.5786	
p-value of Breslow-Day Test for Homogeneity [3]	0.2228	0.5445	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	2 (6.5)	3 (8.6)
No	27 (90.0)	29 (93.5)	32 (91.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.36	
95% CI of the inverse odds ratio	(0.16, 4.53)	(0.21, 8.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.33	
95% CI of the inverse risk ratio	(0.19, 3.94)	(0.24, 7.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.43	-2.12	
95% CI of the absolute risk difference	(-12.76, 15.62)	(-14.80, 10.56)	
p-value	0.8428	0.7453	
p-value of Breslow-Day Test for Homogeneity [3]	0.7045	0.3236	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	8 (25.8)	9 (25.7)
No	23 (76.7)	23 (74.2)	26 (74.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	1.00	
95% CI of the inverse odds ratio	(0.37, 3.54)	(0.33, 3.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	1.00	
95% CI of the inverse risk ratio	(0.47, 2.60)	(0.44, 2.26)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.38	0.09	
95% CI of the absolute risk difference	(-23.33, 18.56)	(-21.05, 21.23)	
p-value	0.8242	0.9932	
p-value of Breslow-Day Test for Homogeneity [3]	0.8954	0.9900	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (13.3)	6 (19.4)	3 (8.6)
No	26 (86.7)	25 (80.6)	32 (91.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	0.39	
95% CI of the inverse odds ratio	(0.13, 2.97)	(0.09, 1.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.44	
95% CI of the inverse risk ratio	(0.16, 2.65)	(0.12, 1.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.76	10.78	
95% CI of the absolute risk difference	(-10.53, 20.06)	(-5.93, 27.50)	
p-value	0.5370	0.2026	
p-value of Breslow-Day Test for Homogeneity [3]	0.3971	0.1693	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (33.3)	11 (35.5)	13 (37.1)
No	20 (66.7)	20 (64.5)	22 (62.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.07	
95% CI of the inverse odds ratio	(0.42, 3.29)	(0.39, 2.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.05	
95% CI of the inverse risk ratio	(0.57, 2.17)	(0.55, 1.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.81	-1.66	
95% CI of the absolute risk difference	(-27.06, 19.45)	(-24.90, 21.58)	
p-value	0.7488	0.8888	
p-value of Breslow-Day Test for Homogeneity [3]	0.5736	0.0898	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	2 (6.5)	4 (11.4)
No	28 (93.3)	29 (93.5)	31 (88.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.81	1.87	
95% CI of the inverse odds ratio	(0.31, 10.63)	(0.32, 11.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	1.77	
95% CI of the inverse risk ratio	(0.34, 8.71)	(0.35, 9.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	-4.98	
95% CI of the absolute risk difference	(-18.57, 9.05)	(-18.61, 8.66)	
p-value	0.5085	0.4827	
p-value of Breslow-Day Test for Homogeneity [3]	0.8811	0.3693	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (26.7)	10 (32.3)	8 (22.9)
No	22 (73.3)	21 (67.7)	27 (77.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.62	
95% CI of the inverse odds ratio	(0.26, 2.52)	(0.21, 1.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.71	
95% CI of the inverse risk ratio	(0.37, 2.01)	(0.32, 1.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.81	9.40	
95% CI of the absolute risk difference	(-17.26, 24.88)	(-12.15, 30.95)	
p-value	0.7223	0.3921	
p-value of Breslow-Day Test for Homogeneity [3]	0.3555	0.5376	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (13.3)	11 (35.5)	10 (28.6)
No	26 (86.7)	20 (64.5)	25 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.60	0.73	
95% CI of the inverse odds ratio	(0.72, 9.38)	(0.26, 2.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.14	0.81	
95% CI of the inverse risk ratio	(0.75, 6.14)	(0.40, 1.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.24	6.91	
95% CI of the absolute risk difference	(-34.52, 4.05)	(-15.62, 29.44)	
p-value	0.1363	0.5474	
p-value of Breslow-Day Test for Homogeneity [3]	0.3100	0.6266	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (36.7)	13 (41.9)	16 (45.7)
No	19 (63.3)	18 (58.1)	19 (54.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	1.17	
95% CI of the inverse odds ratio	(0.54, 3.94)	(0.44, 3.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	1.09	
95% CI of the inverse risk ratio	(0.69, 2.26)	(0.63, 1.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.05	-3.78	
95% CI of the absolute risk difference	(-32.92, 14.82)	(-27.74, 20.18)	
p-value	0.4606	0.7575	
p-value of Breslow-Day Test for Homogeneity [3]	0.7631	0.8387	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (8.3)	0	2 (15.4)
No	11 (91.7)	8 (100)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	3.70	
95% CI of the inverse odds ratio	(0.16, 25.40)	(0.16, 87.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.85	3.21	
95% CI of the inverse risk ratio	(0.19, 17.84)	(0.17, 59.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.05	-12.30	
95% CI of the absolute risk difference	(-32.14, 18.03)	(-37.33, 12.73)	
p-value	0.5878	0.3926	
p-value of Breslow-Day Test for Homogeneity [3]	0.8961	0.5131	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (25.0)	1 (12.5)	7 (53.8)
No	9 (75.0)	7 (87.5)	6 (46.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.50	8.17	
95% CI of the inverse odds ratio	(0.64, 19.19)	(0.77, 86.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.15	4.31	
95% CI of the inverse risk ratio	(0.72, 6.48)	(0.64, 28.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-28.85	-41.35	
95% CI of the absolute risk difference	(-65.38, 7.69)	(-76.84, -5.86)	
p-value	0.1413	0.0581	
p-value of Breslow-Day Test for Homogeneity [3]	0.3948	0.1828	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (8.3)	0	2 (15.4)
No	11 (91.7)	8 (100)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	3.70	
95% CI of the inverse odds ratio	(0.16, 25.40)	(0.16, 87.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.85	3.21	
95% CI of the inverse risk ratio	(0.19, 17.84)	(0.17, 59.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.05	-12.30	
95% CI of the absolute risk difference	(-32.14, 18.03)	(-37.33, 12.73)	
p-value	0.5878	0.3926	
p-value of Breslow-Day Test for Homogeneity [3]	0.3515	0.5777	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (16.7)	2 (25.0)	6 (46.2)
No	10 (83.3)	6 (75.0)	7 (53.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.29	2.57	
95% CI of the inverse odds ratio	(0.66, 27.78)	(0.37, 17.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.77	1.85	
95% CI of the inverse risk ratio	(0.69, 11.17)	(0.49, 7.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-29.49	-21.15	
95% CI of the absolute risk difference	(-63.82, 4.85)	(-61.59, 19.28)	
p-value	0.1143	0.3324	
p-value of Breslow-Day Test for Homogeneity [3]	0.2395	0.8758	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (8.3)	1 (12.5)	1 (7.7)
No	11 (91.7)	7 (87.5)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.58	
95% CI of the inverse odds ratio	(0.05, 16.49)	(0.03, 10.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.62	
95% CI of the inverse risk ratio	(0.06, 13.18)	(0.04, 8.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.64	4.81	
95% CI of the absolute risk difference	(-20.67, 21.96)	(-22.30, 31.92)	
p-value	0.9529	0.7155	
p-value of Breslow-Day Test for Homogeneity [3]	0.4141	0.6824	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (16.7)	3 (37.5)	4 (30.8)
No	10 (83.3)	5 (62.5)	9 (69.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.22	0.74	
95% CI of the inverse odds ratio	(0.33, 15.18)	(0.12, 4.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.85	0.82	
95% CI of the inverse risk ratio	(0.41, 8.32)	(0.24, 2.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.10	6.73	
95% CI of the absolute risk difference	(-46.88, 18.67)	(-35.16, 48.62)	
p-value	0.4095	0.7507	
p-value of Breslow-Day Test for Homogeneity [3]	0.2228	0.5445	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (33.3)	0	2 (15.4)
No	8 (66.7)	8 (100)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	3.70	
95% CI of the inverse odds ratio	(0.05, 2.50)	(0.16, 87.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.46	3.21	
95% CI of the inverse risk ratio	(0.10, 2.08)	(0.17, 59.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	17.95	-12.30	
95% CI of the absolute risk difference	(-15.16, 51.06)	(-37.33, 12.73)	
p-value	0.2938	0.3926	
p-value of Breslow-Day Test for Homogeneity [3]	0.7045	0.3236	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (41.7)	3 (37.5)	5 (38.5)
No	7 (58.3)	5 (62.5)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	1.04	
95% CI of the inverse odds ratio	(0.18, 4.34)	(0.17, 6.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.03	
95% CI of the inverse risk ratio	(0.35, 2.41)	(0.33, 3.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.21	-0.96	
95% CI of the absolute risk difference	(-35.23, 41.64)	(-43.68, 41.76)	
p-value	0.8702	0.9649	
p-value of Breslow-Day Test for Homogeneity [3]	0.8954	0.9900	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (8.3)	0	3 (23.1)
No	11 (91.7)	8 (100)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.30	5.67	
95% CI of the inverse odds ratio	(0.29, 37.10)	(0.26, 125.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.77	4.50	
95% CI of the inverse risk ratio	(0.33, 23.14)	(0.26, 77.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.74	-19.44	
95% CI of the absolute risk difference	(-42.48, 12.99)	(-46.62, 7.73)	
p-value	0.3151	0.2299	
p-value of Breslow-Day Test for Homogeneity [3]	0.3971	0.1693	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (25.0)	0	6 (46.2)
No	9 (75.0)	8 (100)	7 (53.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.57	14.73	
95% CI of the inverse odds ratio	(0.47, 14.10)	(0.71, 307.82)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.85	8.36	
95% CI of the inverse risk ratio	(0.59, 5.79)	(0.53, 130.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-21.15	-40.87	
95% CI of the absolute risk difference	(-57.69, 15.38)	(-70.98, -10.77)	
p-value	0.2709	0.0376	
p-value of Breslow-Day Test for Homogeneity [3]	0.5736	0.0898	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (8.3)	0	2 (15.4)
No	11 (91.7)	8 (100)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	3.70	
95% CI of the inverse odds ratio	(0.16, 25.40)	(0.16, 87.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.85	3.21	
95% CI of the inverse risk ratio	(0.19, 17.84)	(0.17, 59.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.05	-12.30	
95% CI of the absolute risk difference	(-32.14, 18.03)	(-37.33, 12.73)	
p-value	0.5878	0.3926	
p-value of Breslow-Day Test for Homogeneity [3]	0.8811	0.3693	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (33.3)	1 (12.5)	3 (23.1)
No	8 (66.7)	7 (87.5)	10 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	2.10	
95% CI of the inverse odds ratio	(0.10, 3.49)	(0.18, 24.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.85	
95% CI of the inverse risk ratio	(0.19, 2.48)	(0.23, 14.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.26	-10.58	
95% CI of the absolute risk difference	(-24.90, 45.41)	(-42.98, 21.82)	
p-value	0.5683	0.5489	
p-value of Breslow-Day Test for Homogeneity [3]	0.3555	0.5376	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (41.7)	2 (25.0)	5 (38.5)
No	7 (58.3)	6 (75.0)	8 (61.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	1.88	
95% CI of the inverse odds ratio	(0.18, 4.34)	(0.27, 13.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.54	
95% CI of the inverse risk ratio	(0.35, 2.41)	(0.39, 6.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.21	-13.46	
95% CI of the absolute risk difference	(-35.23, 41.64)	(-53.46, 26.54)	
p-value	0.8702	0.5251	
p-value of Breslow-Day Test for Homogeneity [3]	0.3100	0.6266	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (50.0)	3 (37.5)	7 (53.8)
No	6 (50.0)	5 (62.5)	6 (46.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	1.94	
95% CI of the inverse odds ratio	(0.24, 5.62)	(0.32, 11.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	1.44	
95% CI of the inverse risk ratio	(0.51, 2.30)	(0.51, 4.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.85	-16.35	
95% CI of the absolute risk difference	(-43.02, 35.33)	(-59.47, 26.78)	
p-value	0.8475	0.4664	
p-value of Breslow-Day Test for Homogeneity [3]	0.7631	0.8387	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (5.4)	7 (8.0)	20 (9.0)
No	105 (94.6)	80 (92.0)	201 (91.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.74	1.14	
95% CI of the inverse odds ratio	(0.68, 4.47)	(0.46, 2.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	1.12	
95% CI of the inverse risk ratio	(0.69, 4.05)	(0.49, 2.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.64	-1.00	
95% CI of the absolute risk difference	(-9.30, 2.01)	(-7.86, 5.85)	
p-value	0.2436	0.7791	
p-value of Breslow-Day Test for Homogeneity [3]	0.8961	0.5131	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (23.4)	21 (24.1)	53 (24.0)
No	85 (76.6)	66 (75.9)	168 (76.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.99	
95% CI of the inverse odds ratio	(0.60, 1.76)	(0.56, 1.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.99	
95% CI of the inverse risk ratio	(0.68, 1.54)	(0.64, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.56	0.16	
95% CI of the absolute risk difference	(-10.24, 9.12)	(-10.45, 10.76)	
p-value	0.9102	0.9770	
p-value of Breslow-Day Test for Homogeneity [3]	0.3948	0.1828	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	21 (18.9)	13 (14.9)	47 (21.3)
No	90 (81.1)	74 (85.1)	174 (78.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.54	
95% CI of the inverse odds ratio	(0.65, 2.06)	(0.79, 3.01)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	1.42	
95% CI of the inverse risk ratio	(0.71, 1.78)	(0.81, 2.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.35	-6.32	
95% CI of the absolute risk difference	(-11.41, 6.72)	(-15.56, 2.91)	
p-value	0.6170	0.2071	
p-value of Breslow-Day Test for Homogeneity [3]	0.3515	0.5777	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	42 (37.8)	21 (24.1)	76 (34.4)
No	69 (62.2)	66 (75.9)	145 (65.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.65	
95% CI of the inverse odds ratio	(0.54, 1.38)	(0.94, 2.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.42	
95% CI of the inverse risk ratio	(0.67, 1.23)	(0.94, 2.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.45	-10.25	
95% CI of the absolute risk difference	(-7.53, 14.43)	(-21.21, 0.71)	
p-value	0.5357	0.0812	
p-value of Breslow-Day Test for Homogeneity [3]	0.2395	0.8758	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (8.1)	12 (13.8)	18 (8.1)
No	102 (91.9)	75 (86.2)	203 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.55	
95% CI of the inverse odds ratio	(0.44, 2.32)	(0.25, 1.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.59	
95% CI of the inverse risk ratio	(0.47, 2.16)	(0.30, 1.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.04	5.65	
95% CI of the absolute risk difference	(-6.26, 6.19)	(-2.45, 13.74)	
p-value	0.9908	0.1323	
p-value of Breslow-Day Test for Homogeneity [3]	0.4141	0.6824	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (26.1)	27 (31.0)	52 (23.5)
No	82 (73.9)	60 (69.0)	169 (76.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.68	
95% CI of the inverse odds ratio	(0.51, 1.47)	(0.39, 1.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	0.76	
95% CI of the inverse risk ratio	(0.61, 1.33)	(0.51, 1.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.60	7.51	
95% CI of the absolute risk difference	(-7.31, 12.50)	(-3.71, 18.72)	
p-value	0.6033	0.1745	
p-value of Breslow-Day Test for Homogeneity [3]	0.2228	0.5445	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (10.8)	12 (13.8)	21 (9.5)
No	99 (89.2)	75 (86.2)	200 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.66	
95% CI of the inverse odds ratio	(0.41, 1.83)	(0.31, 1.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.69	
95% CI of the inverse risk ratio	(0.45, 1.72)	(0.35, 1.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.31	4.29	
95% CI of the absolute risk difference	(-5.64, 8.26)	(-3.92, 12.50)	
p-value	0.7070	0.2730	
p-value of Breslow-Day Test for Homogeneity [3]	0.7045	0.3236	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (21.6)	24 (27.6)	58 (26.2)
No	87 (78.4)	63 (72.4)	163 (73.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.93	
95% CI of the inverse odds ratio	(0.75, 2.22)	(0.53, 1.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	0.95	
95% CI of the inverse risk ratio	(0.80, 1.84)	(0.63, 1.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.62	1.34	
95% CI of the absolute risk difference	(-14.23, 4.98)	(-9.70, 12.38)	
p-value	0.3568	0.8104	
p-value of Breslow-Day Test for Homogeneity [3]	0.8954	0.9900	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (9.0)	15 (17.2)	32 (14.5)
No	101 (91.0)	72 (82.8)	189 (85.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	0.81	
95% CI of the inverse odds ratio	(0.81, 3.62)	(0.42, 1.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.61	0.84	
95% CI of the inverse risk ratio	(0.82, 3.15)	(0.48, 1.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.47	2.76	
95% CI of the absolute risk difference	(-12.53, 1.59)	(-6.43, 11.96)	
p-value	0.1572	0.5440	
p-value of Breslow-Day Test for Homogeneity [3]	0.3971	0.1693	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	31 (27.9)	24 (27.6)	62 (28.1)
No	80 (72.1)	63 (72.4)	159 (71.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.02	
95% CI of the inverse odds ratio	(0.61, 1.67)	(0.59, 1.78)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.02	
95% CI of the inverse risk ratio	(0.70, 1.45)	(0.68, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.13	-0.47	
95% CI of the absolute risk difference	(-10.36, 10.11)	(-11.57, 10.64)	
p-value	0.9807	0.9343	
p-value of Breslow-Day Test for Homogeneity [3]	0.5736	0.0898	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.6)	10 (11.5)	22 (10.0)
No	107 (96.4)	77 (88.5)	199 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.96	0.85	
95% CI of the inverse odds ratio	(0.99, 8.80)	(0.39, 1.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.76	0.87	
95% CI of the inverse risk ratio	(0.98, 7.82)	(0.43, 1.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.35	1.54	
95% CI of the absolute risk difference	(-11.60, -1.10)	(-6.24, 9.32)	
p-value	0.0421	0.6902	
p-value of Breslow-Day Test for Homogeneity [3]	0.8811	0.3693	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (20.7)	24 (27.6)	66 (29.9)
No	88 (79.3)	63 (72.4)	155 (70.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.63	1.12	
95% CI of the inverse odds ratio	(0.95, 2.80)	(0.64, 1.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.08	
95% CI of the inverse risk ratio	(0.95, 2.19)	(0.73, 1.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.14	-2.28	
95% CI of the absolute risk difference	(-18.80, 0.51)	(-13.44, 8.88)	
p-value	0.0760	0.6923	
p-value of Breslow-Day Test for Homogeneity [3]	0.3555	0.5376	

AMNOG Table SE23.11.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	21 (18.9)	13 (14.9)	38 (17.2)
No	90 (81.1)	74 (85.1)	183 (82.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.18	
95% CI of the inverse odds ratio	(0.49, 1.60)	(0.60, 2.35)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.15	
95% CI of the inverse risk ratio	(0.56, 1.47)	(0.65, 2.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.72	-2.25	
95% CI of the absolute risk difference	(-7.10, 10.55)	(-11.24, 6.74)	
p-value	0.6982	0.6322	
p-value of Breslow-Day Test for Homogeneity [3]	0.3100	0.6266	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	39 (35.1)	28 (32.2)	76 (34.4)
No	72 (64.9)	59 (67.8)	145 (65.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	1.10	
95% CI of the inverse odds ratio	(0.60, 1.56)	(0.65, 1.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.07	
95% CI of the inverse risk ratio	(0.72, 1.34)	(0.75, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.75	-2.21	
95% CI of the absolute risk difference	(-10.12, 11.61)	(-13.85, 9.44)	
p-value	0.8928	0.7126	
p-value of Breslow-Day Test for Homogeneity [3]	0.7631	0.8387	

AMNOG Table SE23.12.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
CLDQ-NASH						
Baseline						
m	91	67	0			
n	85	63	0			
Mean (SD)	5.29 (1.15)	5.27 (1.04)	N/A			
Median	5.50	5.60	N/A			
IQR: Q1, Q3	4.90, 6.10	4.60, 6.00	N/A			
Min, Max	1.9, 6.9	2.2, 7.0	N/A			
Week 24						
m	91	67	0			
n	89	65	0	84	61	0
Mean (SD/SE)	5.30 (1.14)	5.29 (0.98)	N/A	0.02 (0.07)	-0.01 (0.08)	N/A
Median	5.40	5.30	N/A	0	0	N/A
IQR: Q1, Q3	4.60, 6.20	4.50, 6.10	N/A	-0.20, 0.30	-0.40, 0.40	N/A
Min, Max	2.1, 7.0	3.0, 7.0	N/A	-2.6, 1.5	-1.6, 1.6	N/A
Week 52						
m	88	67	0			
n	80	60	0	75	57	0
Mean (SD/SE)	5.29 (1.19)	5.34 (0.93)	N/A	-0.03 (0.08)	0.05 (0.08)	N/A
Median	5.50	5.40	N/A	0	0.10	N/A
IQR: Q1, Q3	4.60, 6.25	4.65, 6.10	N/A	-0.30, 0.20	-0.30, 0.40	N/A
Min, Max	1.9, 7.0	2.6, 6.8	N/A	-2.7, 1.3	-1.5, 1.5	N/A

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.12.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Abdominal Symptoms						
Baseline						
m	91	67	0			
n	85	63	0			
Mean (SD)	5.26 (1.55)	5.62 (1.36)	N/A			
Median	5.70	6.00	N/A			
IQR: Q1, Q3	4.30, 6.70	4.30, 7.00	N/A			
Min, Max	1.0, 7.0	1.7, 7.0	N/A			
Week 24						
m	91	67	0			
n	89	65	0	84	61	0
Mean (SD/SE)	5.38 (1.35)	5.56 (1.50)	N/A	0.11 (0.12)	-0.04 (0.15)	N/A
Median	5.30	6.00	N/A	0	0	N/A
IQR: Q1, Q3	4.70, 6.70	4.30, 7.00	N/A	-0.30, 0.70	-0.40, 0.70	N/A
Min, Max	1.3, 7.0	2.3, 7.0	N/A	-4.7, 3.3	-4.0, 2.4	N/A
Week 52						
m	88	67	0			
n	80	60	0	75	57	0
Mean (SD/SE)	5.51 (1.53)	5.59 (1.41)	N/A	0.21 (0.15)	-0.04 (0.12)	N/A
Median	6.00	5.70	N/A	0	0	N/A
IQR: Q1, Q3	4.85, 6.70	5.00, 7.00	N/A	-0.30, 1.00	-0.30, 0.30	N/A
Min, Max	1.0, 7.0	1.7, 7.0	N/A	-3.3, 4.0	-3.0, 2.0	N/A

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.12.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Activity						
Baseline						
m	91	67	0			
n	85	63	0			
Mean (SD)	5.31 (1.44)	5.29 (1.25)	N/A			
Median	5.60	5.60	N/A			
IQR: Q1, Q3	4.40, 6.40	4.60, 6.20	N/A			
Min, Max	1.8, 7.0	2.0, 7.0	N/A			
Week 24						
m	91	67	0			
n	89	65	0	84	61	0
Mean (SD/SE)	5.21 (1.52)	5.35 (1.28)	N/A	-0.09 (0.10)	0.02 (0.11)	N/A
Median	5.60	5.80	N/A	0	0	N/A
IQR: Q1, Q3	4.00, 6.40	4.20, 6.40	N/A	-0.60, 0.40	-0.60, 0.60	N/A
Min, Max	1.4, 7.0	2.4, 7.0	N/A	-3.2, 1.8	-2.4, 2.4	N/A
Week 52						
m	88	67	0			
n	80	60	0	75	57	0
Mean (SD/SE)	5.22 (1.61)	5.32 (1.20)	N/A	-0.12 (0.11)	-0.01 (0.12)	N/A
Median	5.70	5.40	N/A	0	0.20	N/A
IQR: Q1, Q3	4.00, 6.60	4.50, 6.30	N/A	-0.60, 0.40	-0.40, 0.60	N/A
Min, Max	1.0, 7.0	2.2, 7.0	N/A	-3.6, 2.8	-2.8, 1.2	N/A

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.12.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Emotional Health						
Baseline						
m	91	67	0			
n	85	63	0			
Mean (SD)	5.45 (1.18)	5.43 (1.24)	N/A			
Median	5.60	5.70	N/A			
IQR: Q1, Q3	5.00, 6.20	4.70, 6.30	N/A			
Min, Max	1.3, 7.0	2.2, 7.0	N/A			
Week 24						
m	91	67	0			
n	89	65	0	84	61	0
Mean (SD/SE)	5.50 (1.20)	5.37 (1.21)	N/A	0.08 (0.08)	-0.10 (0.09)	N/A
Median	5.90	5.40	N/A	0.05	-0.10	N/A
IQR: Q1, Q3	4.80, 6.30	4.70, 6.30	N/A	-0.30, 0.50	-0.40, 0.20	N/A
Min, Max	2.2, 7.0	2.3, 7.0	N/A	-2.6, 2.0	-3.1, 1.4	N/A
Week 52						
m	88	67	0			
n	80	60	0	75	57	0
Mean (SD/SE)	5.43 (1.11)	5.51 (1.13)	N/A	-0.03 (0.10)	0.03 (0.10)	N/A
Median	5.75	5.80	N/A	-0.10	0	N/A
IQR: Q1, Q3	4.60, 6.20	4.85, 6.40	N/A	-0.60, 0.40	-0.40, 0.40	N/A
Min, Max	2.8, 7.0	2.1, 7.0	N/A	-2.5, 2.9	-1.3, 2.9	N/A

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.12.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Fatigue						
Baseline						
m	91	67	0			
n	85	63	0			
Mean (SD)	4.85 (1.44)	4.65 (1.42)	N/A			
Median	5.20	4.80	N/A			
IQR: Q1, Q3	4.00, 6.00	4.00, 5.70	N/A			
Min, Max	1.2, 7.0	1.5, 7.0	N/A			
Week 24						
m	91	67	0			
n	89	65	0	84	61	0
Mean (SD/SE)	4.79 (1.47)	4.58 (1.43)	N/A	-0.04 (0.11)	-0.09 (0.14)	N/A
Median	4.80	4.70	N/A	0.05	-0.10	N/A
IQR: Q1, Q3	4.00, 6.00	3.70, 5.50	N/A	-0.55, 0.45	-0.60, 0.30	N/A
Min, Max	1.5, 7.0	1.5, 7.0	N/A	-2.7, 3.2	-4.2, 2.3	N/A
Week 52						
m	88	67	0			
n	80	60	0	75	57	0
Mean (SD/SE)	4.84 (1.44)	4.58 (1.36)	N/A	-0.07 (0.12)	-0.04 (0.15)	N/A
Median	5.00	4.60	N/A	-0.10	0	N/A
IQR: Q1, Q3	3.75, 6.10	3.60, 5.80	N/A	-0.50, 0.40	-0.50, 0.50	N/A
Min, Max	1.0, 7.0	1.5, 7.0	N/A	-2.4, 4.0	-2.8, 2.5	N/A

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.12.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Systemic Symptoms						
Baseline						
m	91	67	0			
n	85	63	0			
Mean (SD)	5.23 (1.25)	5.03 (1.25)	N/A			
Median	5.50	5.00	N/A			
IQR: Q1, Q3	4.50, 6.20	4.30, 5.80	N/A			
Min, Max	2.0, 7.0	1.8, 7.0	N/A			
Week 24						
m	91	67	0			
n	89	65	0	84	61	0
Mean (SD/SE)	5.05 (1.28)	4.91 (1.18)	N/A	-0.15 (0.07)	-0.19 (0.09)	N/A
Median	5.30	5.00	N/A	-0.20	-0.20	N/A
IQR: Q1, Q3	4.30, 6.00	4.00, 5.70	N/A	-0.50, 0.30	-0.50, 0.20	N/A
Min, Max	2.2, 7.0	2.2, 7.0	N/A	-2.0, 1.4	-1.9, 2.2	N/A
Week 52						
m	88	67	0			
n	80	60	0	75	57	0
Mean (SD/SE)	5.00 (1.34)	4.89 (1.18)	N/A	-0.28 (0.09)	-0.15 (0.11)	N/A
Median	5.30	4.80	N/A	-0.20	0	N/A
IQR: Q1, Q3	4.20, 6.10	4.00, 5.80	N/A	-0.70, 0.20	-0.70, 0.30	N/A
Min, Max	1.3, 7.0	2.5, 7.0	N/A	-2.7, 1.7	-2.5, 2.0	N/A

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.12.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Worry						
Baseline						
m	91	67	0			
n	85	63	0			
Mean (SD)	5.66 (1.30)	5.58 (1.32)	N/A			
Median	6.00	5.90	N/A			
IQR: Q1, Q3	5.10, 6.70	4.70, 6.70	N/A			
Min, Max	1.6, 7.0	1.6, 7.0	N/A			
Week 24						
m	91	67	0			
n	89	65	0	84	61	0
Mean (SD/SE)	5.86 (1.29)	5.93 (1.12)	N/A	0.20 (0.11)	0.32 (0.13)	N/A
Median	6.30	6.30	N/A	0.05	0.10	N/A
IQR: Q1, Q3	5.30, 6.90	5.30, 6.90	N/A	-0.30, 0.60	-0.20, 0.60	N/A
Min, Max	1.6, 7.0	2.0, 7.0	N/A	-3.1, 3.1	-1.7, 3.6	N/A
Week 52						
m	88	67	0			
n	80	60	0	75	57	0
Mean (SD/SE)	5.79 (1.37)	6.17 (1.01)	N/A	0.09 (0.12)	0.56 (0.15)	N/A
Median	6.30	6.60	N/A	0	0.30	N/A
IQR: Q1, Q3	5.10, 7.00	5.70, 7.00	N/A	-0.40, 0.60	-0.20, 1.00	N/A
Min, Max	1.7, 7.0	2.0, 7.0	N/A	-4.8, 3.0	-1.5, 3.6	N/A

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.12.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
CLDQ-NASH						
Baseline						
m	61	57	266			
n	57	52	244			
Mean (SD)	5.30 (1.15)	5.36 (1.26)	5.28 (1.10)			
Median	5.50	5.85	5.50			
IQR: Q1, Q3	4.50, 6.30	4.65, 6.30	4.60, 6.20			
Min, Max	1.5, 7.0	2.1, 6.8	2.0, 7.0			
Week 24						
m	61	57	266			
n	57	56	243	54	51	226
Mean (SD/SE)	5.46 (1.07)	5.34 (1.10)	5.40 (1.07)	0.16 (0.10)	-0.02 (0.08)	0.12 (0.05)
Median	5.70	5.60	5.60	0.05	0	0
IQR: Q1, Q3	4.60, 6.40	4.65, 6.10	4.60, 6.20	-0.10, 0.50	-0.30, 0.20	-0.30, 0.50
Min, Max	2.1, 7.0	2.7, 6.8	2.3, 7.0	-1.8, 2.4	-1.3, 1.4	-1.8, 3.0
Week 52						
m	59	56	263			
n	55	51	230	51	47	214
Mean (SD/SE)	5.46 (1.13)	5.37 (1.12)	5.37 (1.11)	0.13 (0.10)	-0.03 (0.10)	0.06 (0.05)
Median	5.60	5.60	5.50	0.10	0	0
IQR: Q1, Q3	4.70, 6.40	4.50, 6.30	4.60, 6.30	-0.20, 0.40	-0.30, 0.20	-0.30, 0.50
Min, Max	1.6, 7.0	2.2, 6.9	1.9, 7.0	-2.2, 2.7	-2.4, 1.8	-2.2, 2.9

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.12.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Abdominal Symptoms						
Baseline						
m	61	57	266			
n	57	52	244			
Mean (SD)	5.53 (1.65)	5.70 (1.32)	5.30 (1.49)			
Median	6.00	6.00	5.70			
IQR: Q1, Q3	4.30, 7.00	4.70, 7.00	4.30, 6.70			
Min, Max	1.0, 7.0	2.7, 7.0	1.0, 7.0			
Week 24						
m	61	57	266			
n	57	56	243	54	51	226
Mean (SD/SE)	5.60 (1.44)	5.52 (1.29)	5.48 (1.44)	0.07 (0.16)	-0.13 (0.16)	0.18 (0.08)
Median	6.30	5.70	5.70	0	0	0
IQR: Q1, Q3	4.70, 7.00	4.70, 6.70	4.30, 7.00	-0.40, 0.70	-0.60, 0.30	-0.40, 0.70
Min, Max	1.7, 7.0	2.0, 7.0	1.0, 7.0	-3.0, 3.0	-3.3, 2.3	-3.0, 4.0
Week 52						
m	59	56	263			
n	55	51	230	51	47	214
Mean (SD/SE)	5.57 (1.42)	5.65 (1.13)	5.45 (1.40)	-0.03 (0.17)	-0.11 (0.15)	0.08 (0.08)
Median	5.70	5.70	5.70	0	0	0
IQR: Q1, Q3	4.70, 7.00	5.00, 6.70	4.70, 6.70	-0.70, 0.70	-0.70, 0.40	-0.70, 0.70
Min, Max	1.3, 7.0	2.7, 7.0	1.0, 7.0	-2.3, 3.7	-2.6, 2.7	-4.6, 4.0

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.12.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Activity						
Baseline						
m	61	57	266			
n	57	52	244			
Mean (SD)	5.41 (1.22)	5.47 (1.45)	5.50 (1.32)			
Median	5.80	5.70	5.80			
IQR: Q1, Q3	4.60, 6.40	4.80, 6.60	4.60, 6.60			
Min, Max	1.4, 7.0	1.8, 7.0	1.4, 7.0			
Week 24						
m	61	57	266			
n	57	56	243	54	51	226
Mean (SD/SE)	5.60 (1.12)	5.50 (1.31)	5.54 (1.29)	0.14 (0.13)	0.07 (0.13)	0.08 (0.07)
Median	5.80	5.80	6.00	0	0	0
IQR: Q1, Q3	5.00, 6.40	4.80, 6.60	4.80, 6.60	-0.20, 0.60	-0.80, 0.60	-0.40, 0.60
Min, Max	1.8, 7.0	2.4, 7.0	1.2, 7.0	-1.8, 2.8	-1.6, 3.2	-3.0, 3.2
Week 52						
m	59	56	263			
n	55	51	230	51	47	214
Mean (SD/SE)	5.51 (1.31)	5.47 (1.31)	5.43 (1.39)	0.01 (0.17)	-0.02 (0.14)	-0.11 (0.07)
Median	5.60	5.60	5.80	0.20	0	0
IQR: Q1, Q3	4.80, 6.60	4.60, 6.60	4.40, 6.60	-0.40, 0.60	-0.40, 0.60	-0.60, 0.40
Min, Max	1.6, 7.0	1.6, 7.0	1.4, 7.0	-4.4, 3.0	-2.8, 2.0	-3.4, 3.0

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.12.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Emotional Health						
Baseline						
m	61	57	266			
n	57	52	244			
Mean (SD)	5.41 (1.21)	5.45 (1.40)	5.46 (1.21)			
Median	5.60	5.80	5.80			
IQR: Q1, Q3	4.60, 6.40	4.80, 6.60	4.80, 6.40			
Min, Max	1.9, 7.0	1.8, 7.0	1.8, 7.0			
Week 24						
m	61	57	266			
n	57	56	243	54	51	226
Mean (SD/SE)	5.48 (1.21)	5.36 (1.31)	5.53 (1.20)	0.10 (0.11)	-0.12 (0.09)	0.06 (0.06)
Median	5.80	5.60	5.80	0.10	0	0
IQR: Q1, Q3	4.70, 6.60	4.70, 6.30	4.80, 6.60	-0.30, 0.60	-0.60, 0.20	-0.50, 0.50
Min, Max	2.9, 7.0	1.0, 7.0	1.9, 7.0	-2.8, 2.1	-2.0, 1.9	-2.4, 3.3
Week 52						
m	59	56	263			
n	55	51	230	51	47	214
Mean (SD/SE)	5.49 (1.17)	5.47 (1.25)	5.50 (1.22)	0.07 (0.10)	0.02 (0.12)	0.01 (0.06)
Median	5.80	5.80	5.80	0	0	0
IQR: Q1, Q3	4.80, 6.30	4.70, 6.40	4.70, 6.60	-0.40, 0.60	-0.60, 0.40	-0.40, 0.40
Min, Max	1.9, 7.0	1.0, 7.0	1.3, 7.0	-1.3, 2.5	-1.9, 2.0	-2.0, 3.1

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.12.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Fatigue						
Baseline						
m	61	57	266			
n	57	52	244			
Mean (SD)	4.71 (1.50)	4.65 (1.58)	4.69 (1.43)			
Median	5.00	5.10	5.00			
IQR: Q1, Q3	3.30, 6.00	3.50, 5.90	3.70, 5.80			
Min, Max	2.0, 7.0	1.2, 7.0	1.0, 7.0			
Week 24						
m	61	57	266			
n	57	56	243	54	51	226
Mean (SD/SE)	4.79 (1.56)	4.60 (1.40)	4.75 (1.45)	0.07 (0.14)	-0.14 (0.11)	0.07 (0.07)
Median	4.80	4.80	4.80	0	-0.20	0
IQR: Q1, Q3	3.70, 6.00	3.70, 5.70	3.70, 6.00	-0.60, 0.70	-0.70, 0.40	-0.50, 0.60
Min, Max	1.5, 7.0	1.5, 6.8	1.2, 7.0	-2.0, 3.0	-1.8, 1.7	-3.8, 3.7
Week 52						
m	59	56	263			
n	55	51	230	51	47	214
Mean (SD/SE)	4.81 (1.65)	4.62 (1.58)	4.70 (1.45)	0.12 (0.14)	-0.15 (0.17)	0.01 (0.07)
Median	5.30	5.00	4.90	0	0	0
IQR: Q1, Q3	3.20, 6.00	3.70, 5.80	3.70, 5.80	-0.50, 0.50	-0.60, 0.40	-0.60, 0.50
Min, Max	1.5, 7.0	1.2, 6.8	1.0, 7.0	-2.0, 3.4	-4.4, 2.5	-3.8, 3.2

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.12.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Systemic Symptoms						
Baseline						
m	61	57	266			
n	57	52	244			
Mean (SD)	5.21 (1.20)	5.24 (1.28)	5.13 (1.23)			
Median	5.50	5.50	5.30			
IQR: Q1, Q3	4.70, 6.00	4.70, 6.20	4.50, 6.00			
Min, Max	1.5, 7.0	2.2, 7.0	1.7, 7.0			
Week 24						
m	61	57	266			
n	57	56	243	54	51	226
Mean (SD/SE)	5.43 (1.11)	5.19 (1.29)	5.15 (1.24)	0.19 (0.11)	-0.07 (0.10)	0.00 (0.06)
Median	5.50	5.70	5.30	0.20	0	0
IQR: Q1, Q3	4.70, 6.20	4.30, 6.00	4.30, 6.20	-0.30, 0.60	-0.50, 0.40	-0.60, 0.50
Min, Max	1.7, 7.0	1.8, 7.0	1.5, 7.0	-1.6, 2.1	-2.0, 1.7	-2.5, 3.7
Week 52						
m	59	56	263			
n	55	51	230	51	47	214
Mean (SD/SE)	5.34 (1.23)	5.24 (1.25)	5.13 (1.35)	0.02 (0.12)	-0.04 (0.11)	0.01 (0.06)
Median	5.70	5.30	5.30	0	0	0
IQR: Q1, Q3	4.30, 6.30	4.80, 6.20	4.20, 6.30	-0.40, 0.50	-0.50, 0.40	-0.50, 0.50
Min, Max	1.3, 7.0	1.5, 7.0	1.3, 7.0	-2.0, 2.3	-2.3, 1.3	-2.7, 2.9

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.12.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Worry						
Baseline						
m	61	57	266			
n	57	52	244			
Mean (SD)	5.52 (1.43)	5.64 (1.68)	5.63 (1.36)			
Median	5.70	6.40	6.00			
IQR: Q1, Q3	4.70, 6.70	4.75, 6.95	4.80, 6.70			
Min, Max	1.1, 7.0	1.0, 7.0	1.1, 7.0			
Week 24						
m	61	57	266			
n	57	56	243	54	51	226
Mean (SD/SE)	5.89 (1.34)	5.83 (1.43)	5.93 (1.28)	0.46 (0.14)	0.25 (0.15)	0.33 (0.06)
Median	6.30	6.40	6.40	0.30	0	0.10
IQR: Q1, Q3	5.60, 6.90	5.05, 7.00	5.40, 7.00	0.00, 0.80	-0.20, 0.70	-0.10, 0.70
Min, Max	1.6, 7.0	1.0, 7.0	1.0, 7.0	-2.3, 3.3	-2.6, 3.6	-2.6, 3.5
Week 52						
m	59	56	263			
n	55	51	230	51	47	214
Mean (SD/SE)	6.05 (1.26)	5.81 (1.53)	5.98 (1.29)	0.61 (0.15)	0.18 (0.16)	0.32 (0.07)
Median	6.40	6.30	6.40	0.30	0	0.10
IQR: Q1, Q3	5.60, 7.00	5.10, 7.00	5.40, 7.00	0.00, 1.30	-0.10, 0.60	-0.10, 0.80
Min, Max	1.9, 7.0	1.0, 7.0	1.0, 7.0	-2.5, 3.8	-3.3, 3.3	-2.7, 3.8

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.12.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by SHBG at Week 52
(Label Population)

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.12.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
CLDQ-NASH			
Week 24			
m	91	67	0
n	84	61	0
Baseline Mean (SD)	5.27 (1.15)	5.25 (1.05)	N/A
Analysis Visit Mean (SD)	5.29 (1.17)	5.24 (0.98)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	75	57	0
Baseline Mean (SD)	5.31 (1.20)	5.26 (1.05)	N/A
Analysis Visit Mean (SD)	5.28 (1.20)	5.31 (0.94)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE23.12.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
CLDQ-NASH			
Week 24			
m	61	57	266
n	54	51	226
Baseline Mean (SD)	5.31 (1.16)	5.36 (1.27)	5.29 (1.10)
Analysis Visit Mean (SD)	5.47 (1.05)	5.34 (1.10)	5.41 (1.07)
LS Mean of Change from Baseline (SE)	0.16 (0.09)	0.00 (0.09)	0.13 (0.04)
95% CI	(-0.01, 0.34)	(-0.18, 0.18)	(0.04, 0.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.10)	-0.13 (0.10)	
95% CI	(-0.16, 0.23)	(-0.32, 0.07)	
p-value	0.7186	0.1937	
Corrected Hedge's g Statistics	0.052	-0.194	
95% CI	(-0.24, 0.35)	(-0.50, 0.11)	
Week 52			
m	59	56	263
n	51	47	214
Baseline Mean (SD)	5.30 (1.14)	5.35 (1.26)	5.32 (1.09)
Analysis Visit Mean (SD)	5.43 (1.11)	5.31 (1.12)	5.37 (1.10)
LS Mean of Change from Baseline (SE)	0.13 (0.09)	-0.04 (0.09)	0.09 (0.05)
95% CI	(-0.05, 0.31)	(-0.22, 0.15)	(-0.01, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.10)	-0.12 (0.10)	
95% CI	(-0.15, 0.25)	(-0.33, 0.08)	
p-value	0.6395	0.2420	
Corrected Hedge's g Statistics	0.070	-0.182	
95% CI	(-0.24, 0.38)	(-0.50, 0.13)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE23.12.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.12.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Abdominal Symptoms			
Week 24			
m	91	67	0
n	84	61	0
Baseline Mean (SD)	5.25 (1.55)	5.59 (1.37)	N/A
Analysis Visit Mean (SD)	5.37 (1.36)	5.54 (1.52)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	75	57	0
Baseline Mean (SD)	5.28 (1.58)	5.62 (1.37)	N/A
Analysis Visit Mean (SD)	5.49 (1.56)	5.58 (1.44)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE23.12.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Activity			
Week 24			
m	91	67	0
n	84	61	0
Baseline Mean (SD)	5.29 (1.44)	5.27 (1.25)	N/A
Analysis Visit Mean (SD)	5.20 (1.54)	5.29 (1.30)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	75	57	0
Baseline Mean (SD)	5.32 (1.46)	5.28 (1.27)	N/A
Analysis Visit Mean (SD)	5.19 (1.62)	5.27 (1.21)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE23.12.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Emotional Health			
Week 24			
m	91	67	0
n	84	61	0
Baseline Mean (SD)	5.43 (1.18)	5.39 (1.24)	N/A
Analysis Visit Mean (SD)	5.51 (1.21)	5.29 (1.21)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	75	57	0
Baseline Mean (SD)	5.46 (1.24)	5.43 (1.25)	N/A
Analysis Visit Mean (SD)	5.42 (1.11)	5.46 (1.13)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE23.12.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Fatigue			
Week 24			
m	91	67	0
n	84	61	0
Baseline Mean (SD)	4.83 (1.43)	4.62 (1.43)	N/A
Analysis Visit Mean (SD)	4.79 (1.50)	4.53 (1.44)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	75	57	0
Baseline Mean (SD)	4.88 (1.52)	4.62 (1.45)	N/A
Analysis Visit Mean (SD)	4.82 (1.47)	4.58 (1.37)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE23.12.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Systemic Symptoms			
Week 24			
m	91	67	0
n	84	61	0
Baseline Mean (SD)	5.20 (1.25)	5.04 (1.27)	N/A
Analysis Visit Mean (SD)	5.05 (1.31)	4.85 (1.17)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	75	57	0
Baseline Mean (SD)	5.26 (1.29)	4.99 (1.20)	N/A
Analysis Visit Mean (SD)	4.99 (1.35)	4.84 (1.19)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE23.12.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Worry			
Week 24			
m	91	67	0
n	84	61	0
Baseline Mean (SD)	5.64 (1.30)	5.56 (1.33)	N/A
Analysis Visit Mean (SD)	5.84 (1.31)	5.88 (1.14)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	75	57	0
Baseline Mean (SD)	5.68 (1.36)	5.58 (1.33)	N/A
Analysis Visit Mean (SD)	5.77 (1.40)	6.14 (1.02)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE23.12.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Abdominal Symptoms			
Week 24			
m	61	57	266
n	54	51	226
Baseline Mean (SD)	5.55 (1.66)	5.70 (1.33)	5.33 (1.49)
Analysis Visit Mean (SD)	5.62 (1.45)	5.57 (1.31)	5.51 (1.40)
LS Mean of Change from Baseline (SE)	0.16 (0.14)	0.00 (0.14)	0.19 (0.07)
95% CI	(-0.12, 0.43)	(-0.28, 0.28)	(0.05, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.15)	-0.19 (0.16)	
95% CI	(-0.34, 0.27)	(-0.50, 0.12)	
p-value	0.8318	0.2286	
Corrected Hedge's g Statistics	-0.031	-0.180	
95% CI	(-0.33, 0.27)	(-0.48, 0.12)	
Week 52			
m	59	56	263
n	51	47	214
Baseline Mean (SD)	5.55 (1.57)	5.73 (1.29)	5.37 (1.46)
Analysis Visit Mean (SD)	5.53 (1.45)	5.62 (1.15)	5.45 (1.39)
LS Mean of Change from Baseline (SE)	0.04 (0.15)	0.00 (0.15)	0.12 (0.07)
95% CI	(-0.25, 0.33)	(-0.30, 0.30)	(-0.03, 0.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.16)	-0.11 (0.17)	
95% CI	(-0.39, 0.24)	(-0.44, 0.21)	
p-value	0.6406	0.4941	
Corrected Hedge's g Statistics	-0.070	-0.107	
95% CI	(-0.38, 0.24)	(-0.42, 0.21)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE23.12.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Activity			
Week 24			
m	61	57	266
n	54	51	226
Baseline Mean (SD)	5.46 (1.20)	5.46 (1.47)	5.48 (1.31)
Analysis Visit Mean (SD)	5.60 (1.14)	5.53 (1.23)	5.57 (1.28)
LS Mean of Change from Baseline (SE)	0.13 (0.12)	0.06 (0.12)	0.09 (0.06)
95% CI	(-0.11, 0.36)	(-0.18, 0.30)	(-0.03, 0.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.13)	-0.03 (0.14)	
95% CI	(-0.22, 0.30)	(-0.30, 0.23)	
p-value	0.7821	0.8075	
Corrected Hedge's g Statistics	0.040	-0.036	
95% CI	(-0.26, 0.34)	(-0.34, 0.27)	
Week 52			
m	59	56	263
n	51	47	214
Baseline Mean (SD)	5.44 (1.22)	5.43 (1.44)	5.54 (1.29)
Analysis Visit Mean (SD)	5.45 (1.33)	5.41 (1.32)	5.43 (1.40)
LS Mean of Change from Baseline (SE)	0.02 (0.13)	-0.02 (0.14)	-0.07 (0.07)
95% CI	(-0.24, 0.29)	(-0.30, 0.25)	(-0.20, 0.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (0.15)	0.04 (0.15)	
95% CI	(-0.20, 0.38)	(-0.26, 0.34)	
p-value	0.5566	0.7784	
Corrected Hedge's g Statistics	0.089	0.044	
95% CI	(-0.22, 0.39)	(-0.27, 0.36)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE23.12.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Emotional Health			
Week 24			
m	61	57	266
n	54	51	226
Baseline Mean (SD)	5.40 (1.23)	5.44 (1.41)	5.47 (1.21)
Analysis Visit Mean (SD)	5.49 (1.18)	5.32 (1.34)	5.52 (1.20)
LS Mean of Change from Baseline (SE)	0.08 (0.11)	-0.13 (0.11)	0.05 (0.05)
95% CI	(-0.13, 0.30)	(-0.35, 0.09)	(-0.06, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.12)	-0.18 (0.12)	
95% CI	(-0.20, 0.27)	(-0.42, 0.06)	
p-value	0.7950	0.1463	
Corrected Hedge's g Statistics	0.038	-0.217	
95% CI	(-0.26, 0.33)	(-0.52, 0.09)	
Week 52			
m	59	56	263
n	51	47	214
Baseline Mean (SD)	5.40 (1.22)	5.39 (1.43)	5.49 (1.22)
Analysis Visit Mean (SD)	5.47 (1.13)	5.41 (1.27)	5.50 (1.23)
LS Mean of Change from Baseline (SE)	0.05 (0.11)	-0.01 (0.11)	0.01 (0.05)
95% CI	(-0.16, 0.26)	(-0.23, 0.21)	(-0.09, 0.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.12)	-0.02 (0.12)	
95% CI	(-0.20, 0.27)	(-0.26, 0.21)	
p-value	0.7565	0.8422	
Corrected Hedge's g Statistics	0.047	-0.031	
95% CI	(-0.26, 0.35)	(-0.35, 0.28)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE23.12.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Fatigue			
Week 24			
m	61	57	266
n	54	51	226
Baseline Mean (SD)	4.74 (1.50)	4.68 (1.59)	4.69 (1.45)
Analysis Visit Mean (SD)	4.80 (1.51)	4.53 (1.41)	4.76 (1.46)
LS Mean of Change from Baseline (SE)	0.06 (0.13)	-0.15 (0.13)	0.05 (0.07)
95% CI	(-0.20, 0.32)	(-0.42, 0.11)	(-0.08, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.14)	-0.21 (0.15)	
95% CI	(-0.28, 0.29)	(-0.50, 0.09)	
p-value	0.9757	0.1664	
Corrected Hedge's g Statistics	0.004	-0.207	
95% CI	(-0.29, 0.30)	(-0.51, 0.10)	
Week 52			
m	59	56	263
n	51	47	214
Baseline Mean (SD)	4.66 (1.52)	4.65 (1.55)	4.71 (1.40)
Analysis Visit Mean (SD)	4.78 (1.60)	4.50 (1.58)	4.72 (1.45)
LS Mean of Change from Baseline (SE)	0.09 (0.14)	-0.17 (0.14)	0.03 (0.07)
95% CI	(-0.19, 0.37)	(-0.46, 0.11)	(-0.11, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.06 (0.15)	-0.20 (0.16)	
95% CI	(-0.24, 0.37)	(-0.51, 0.11)	
p-value	0.6777	0.2089	
Corrected Hedge's g Statistics	0.063	-0.195	
95% CI	(-0.24, 0.37)	(-0.51, 0.12)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE23.12.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Systemic Symptoms			
Week 24			
m	61	57	266
n	54	51	226
Baseline Mean (SD)	5.20 (1.21)	5.25 (1.29)	5.15 (1.22)
Analysis Visit Mean (SD)	5.39 (1.12)	5.18 (1.27)	5.15 (1.26)
LS Mean of Change from Baseline (SE)	0.18 (0.11)	-0.04 (0.11)	0.01 (0.06)
95% CI	(-0.03, 0.40)	(-0.26, 0.18)	(-0.10, 0.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.17 (0.12)	-0.05 (0.12)	
95% CI	(-0.06, 0.41)	(-0.30, 0.19)	
p-value	0.1515	0.6577	
Corrected Hedge's g Statistics	0.210	-0.066	
95% CI	(-0.09, 0.51)	(-0.37, 0.24)	
Week 52			
m	59	56	263
n	51	47	214
Baseline Mean (SD)	5.24 (1.14)	5.24 (1.23)	5.13 (1.24)
Analysis Visit Mean (SD)	5.25 (1.23)	5.20 (1.24)	5.14 (1.35)
LS Mean of Change from Baseline (SE)	0.05 (0.11)	-0.05 (0.12)	0.03 (0.06)
95% CI	(-0.17, 0.28)	(-0.28, 0.18)	(-0.08, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (0.12)	-0.09 (0.13)	
95% CI	(-0.23, 0.26)	(-0.34, 0.16)	
p-value	0.8788	0.4885	
Corrected Hedge's g Statistics	0.023	-0.108	
95% CI	(-0.28, 0.33)	(-0.42, 0.21)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE23.12.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Worry			
Week 24			
m	61	57	266
n	54	51	226
Baseline Mean (SD)	5.49 (1.46)	5.62 (1.68)	5.62 (1.37)
Analysis Visit Mean (SD)	5.96 (1.23)	5.87 (1.46)	5.95 (1.28)
LS Mean of Change from Baseline (SE)	0.41 (0.12)	0.26 (0.12)	0.36 (0.06)
95% CI	(0.18, 0.64)	(0.02, 0.50)	(0.24, 0.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.13)	-0.10 (0.13)	
95% CI	(-0.20, 0.31)	(-0.36, 0.16)	
p-value	0.6762	0.4659	
Corrected Hedge's g Statistics	0.061	-0.109	
95% CI	(-0.24, 0.36)	(-0.41, 0.20)	
Week 52			
m	59	56	263
n	51	47	214
Baseline Mean (SD)	5.48 (1.47)	5.61 (1.75)	5.68 (1.36)
Analysis Visit Mean (SD)	6.09 (1.15)	5.79 (1.56)	6.00 (1.27)
LS Mean of Change from Baseline (SE)	0.53 (0.13)	0.18 (0.13)	0.36 (0.06)
95% CI	(0.28, 0.78)	(-0.08, 0.44)	(0.24, 0.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.17 (0.14)	-0.18 (0.14)	
95% CI	(-0.11, 0.44)	(-0.46, 0.10)	
p-value	0.2359	0.2063	
Corrected Hedge's g Statistics	0.179	-0.196	
95% CI	(-0.13, 0.48)	(-0.51, 0.12)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

Abbreviations: CFB = Change from Baseline; CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (6.6)	6 (9.0)	0
No	85 (93.4)	61 (91.0)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (19.8)	23 (34.3)	0
No	73 (80.2)	44 (65.7)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	20 (22.0)	9 (13.4)	0
No	71 (78.0)	58 (86.6)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	35 (38.5)	16 (23.9)	0
No	56 (61.5)	51 (76.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (8.8)	9 (13.4)	0
No	83 (91.2)	58 (86.6)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (26.4)	24 (35.8)	0
No	67 (73.6)	43 (64.2)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (12.1)	7 (10.4)	0
No	80 (87.9)	60 (89.6)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (22.0)	17 (25.4)	0
No	71 (78.0)	50 (74.6)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (6.6)	13 (19.4)	0
No	85 (93.4)	54 (80.6)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (27.5)	20 (29.9)	0
No	66 (72.5)	47 (70.1)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.2)	6 (9.0)	0
No	89 (97.8)	61 (91.0)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (19.8)	19 (28.4)	0
No	73 (80.2)	48 (71.6)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	13 (14.3)	19 (28.4)	0
No	78 (85.7)	48 (71.6)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (30.8)	29 (43.3)	0
No	63 (69.2)	38 (56.7)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (6.6)	5 (8.8)	25 (9.4)
No	57 (93.4)	52 (91.2)	241 (90.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.48	1.08	
95% CI of the inverse odds ratio	(0.49, 4.42)	(0.39, 2.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.07	
95% CI of the inverse risk ratio	(0.52, 3.97)	(0.43, 2.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.84	-0.63	
95% CI of the absolute risk difference	(-9.97, 4.29)	(-8.76, 7.51)	
p-value	0.4814	0.8824	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (29.5)	8 (14.0)	68 (25.6)
No	43 (70.5)	49 (86.0)	198 (74.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	2.10	
95% CI of the inverse odds ratio	(0.44, 1.52)	(0.95, 4.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.82	
95% CI of the inverse risk ratio	(0.56, 1.34)	(0.93, 3.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.94	-11.53	
95% CI of the absolute risk difference	(-8.64, 16.53)	(-21.96, -1.10)	
p-value	0.5280	0.0626	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (16.4)	8 (14.0)	52 (19.5)
No	51 (83.6)	49 (86.0)	214 (80.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	1.49	
95% CI of the inverse odds ratio	(0.59, 2.60)	(0.66, 3.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	1.39	
95% CI of the inverse risk ratio	(0.64, 2.21)	(0.70, 2.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.16	-5.51	
95% CI of the absolute risk difference	(-13.60, 7.29)	(-15.71, 4.69)	
p-value	0.5707	0.3314	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (32.8)	13 (22.8)	93 (35.0)
No	41 (67.2)	44 (77.2)	173 (65.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	1.82	
95% CI of the inverse odds ratio	(0.61, 1.99)	(0.93, 3.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.53	
95% CI of the inverse risk ratio	(0.72, 1.58)	(0.93, 2.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.18	-12.16	
95% CI of the absolute risk difference	(-15.28, 10.92)	(-24.46, 0.15)	
p-value	0.7473	0.0761	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (14.8)	7 (12.3)	23 (8.6)
No	52 (85.2)	50 (87.7)	243 (91.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	0.68	
95% CI of the inverse odds ratio	(0.24, 1.25)	(0.28, 1.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.70	
95% CI of the inverse risk ratio	(0.29, 1.20)	(0.32, 1.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.11	3.63	
95% CI of the absolute risk difference	(-3.41, 15.63)	(-5.53, 12.80)	
p-value	0.1476	0.3910	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (34.4)	13 (22.8)	65 (24.4)
No	40 (65.6)	44 (77.2)	201 (75.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	1.09	
95% CI of the inverse odds ratio	(0.34, 1.12)	(0.56, 2.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.07	
95% CI of the inverse risk ratio	(0.47, 1.06)	(0.64, 1.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.99	-1.63	
95% CI of the absolute risk difference	(-3.00, 22.98)	(-13.68, 10.43)	
p-value	0.1099	0.7943	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (13.1)	7 (12.3)	26 (9.8)
No	53 (86.9)	50 (87.7)	240 (90.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.77	
95% CI of the inverse odds ratio	(0.31, 1.67)	(0.32, 1.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.80	
95% CI of the inverse risk ratio	(0.35, 1.57)	(0.36, 1.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.34	2.51	
95% CI of the absolute risk difference	(-5.85, 12.53)	(-6.73, 11.74)	
p-value	0.4408	0.5707	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (26.2)	17 (29.8)	71 (26.7)
No	45 (73.8)	40 (70.2)	195 (73.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.86	
95% CI of the inverse odds ratio	(0.54, 1.93)	(0.46, 1.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.89	
95% CI of the inverse risk ratio	(0.64, 1.62)	(0.57, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.46	3.13	
95% CI of the absolute risk difference	(-12.71, 11.79)	(-9.88, 16.14)	
p-value	0.9413	0.6297	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (13.1)	8 (14.0)	37 (13.9)
No	53 (86.9)	49 (86.0)	229 (86.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.99	
95% CI of the inverse odds ratio	(0.47, 2.43)	(0.43, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.99	
95% CI of the inverse risk ratio	(0.52, 2.16)	(0.49, 2.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.80	0.13	
95% CI of the absolute risk difference	(-10.23, 8.64)	(-9.80, 10.06)	
p-value	0.8709	0.9802	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (29.5)	15 (26.3)	79 (29.7)
No	43 (70.5)	42 (73.7)	187 (70.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.18	
95% CI of the inverse odds ratio	(0.55, 1.86)	(0.62, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.13	
95% CI of the inverse risk ratio	(0.65, 1.55)	(0.70, 1.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.19	-3.38	
95% CI of the absolute risk difference	(-12.89, 12.50)	(-16.07, 9.30)	
p-value	0.9765	0.6098	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (8.2)	6 (10.5)	27 (10.2)
No	56 (91.8)	51 (89.5)	239 (89.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	0.96	
95% CI of the inverse odds ratio	(0.47, 3.43)	(0.38, 2.45)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	0.96	
95% CI of the inverse risk ratio	(0.50, 3.08)	(0.42, 2.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.95	0.38	
95% CI of the absolute risk difference	(-9.74, 5.83)	(-8.38, 9.13)	
p-value	0.6432	0.9322	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (27.9)	16 (28.1)	76 (28.6)
No	44 (72.1)	41 (71.9)	190 (71.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	1.03	
95% CI of the inverse odds ratio	(0.56, 1.92)	(0.54, 1.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	1.02	
95% CI of the inverse risk ratio	(0.66, 1.60)	(0.64, 1.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.70	-0.50	
95% CI of the absolute risk difference	(-13.20, 11.79)	(-13.37, 12.37)	
p-value	0.9126	0.9393	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE23.12.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (26.2)	7 (12.3)	52 (19.5)
No	45 (73.8)	50 (87.7)	214 (80.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	1.74	
95% CI of the inverse odds ratio	(0.36, 1.30)	(0.74, 4.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.59	
95% CI of the inverse risk ratio	(0.46, 1.21)	(0.76, 3.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.68	-7.27	
95% CI of the absolute risk difference	(-5.34, 18.70)	(-17.03, 2.49)	
p-value	0.2462	0.1975	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	27 (44.3)	15 (26.3)	97 (36.5)
No	34 (55.7)	42 (73.7)	169 (63.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	1.61	
95% CI of the inverse odds ratio	(0.41, 1.27)	(0.85, 3.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.39	
95% CI of the inverse risk ratio	(0.60, 1.14)	(0.87, 2.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.80	-10.15	
95% CI of the absolute risk difference	(-5.95, 21.54)	(-22.96, 2.66)	
p-value	0.2577	0.1440	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE23.13.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
CLDQ-NASH						
Baseline						
m	76	75	30			
n	71	66	29			
Mean (SD)	5.14 (1.25)	5.22 (1.10)	5.11 (1.21)			
Median	5.30	5.60	5.50			
IQR: Q1, Q3	4.50, 6.10	4.60, 6.00	4.40, 6.20			
Min, Max	1.5, 6.8	2.1, 7.0	2.2, 6.5			
Week 24						
m	76	74	29			
n	75	71	28	71	63	27
Mean (SD/SE)	5.33 (1.26)	5.23 (1.00)	5.32 (1.01)	0.18 (0.08)	-0.02 (0.07)	0.11 (0.12)
Median	5.70	5.30	5.35	0.10	-0.10	0.20
IQR: Q1, Q3	4.40, 6.40	4.60, 6.00	4.55, 6.30	-0.20, 0.60	-0.40, 0.30	-0.30, 0.60
Min, Max	2.1, 7.0	2.7, 7.0	3.1, 6.8	-2.0, 2.4	-1.4, 1.6	-1.6, 1.3
Week 52						
m	74	68	27			
n	70	62	22	65	57	22
Mean (SD/SE)	5.30 (1.25)	5.24 (1.03)	5.32 (0.94)	0.06 (0.08)	-0.04 (0.09)	0.13 (0.10)
Median	5.50	5.55	5.40	0.10	0.10	0
IQR: Q1, Q3	4.70, 6.30	4.40, 5.90	5.10, 6.10	-0.20, 0.40	-0.30, 0.30	-0.10, 0.50
Min, Max	1.6, 6.9	2.2, 6.8	3.2, 6.8	-2.2, 2.7	-2.4, 1.1	-0.9, 1.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Abdominal Symptoms						
Baseline						
m	76	75	30			
n	71	66	29			
Mean (SD)	5.18 (1.69)	5.62 (1.35)	5.34 (1.53)			
Median	5.70	6.00	5.30			
IQR: Q1, Q3	4.00, 6.30	4.70, 7.00	4.30, 6.70			
Min, Max	1.0, 7.0	1.7, 7.0	1.7, 7.0			
Week 24						
m	76	74	29			
n	75	71	28	71	63	27
Mean (SD/SE)	5.44 (1.47)	5.54 (1.36)	5.56 (1.52)	0.25 (0.13)	-0.03 (0.14)	0.18 (0.19)
Median	5.70	6.00	6.00	0	0	0
IQR: Q1, Q3	4.30, 7.00	4.70, 6.70	4.65, 6.70	-0.30, 0.70	-0.40, 0.30	-0.30, 0.70
Min, Max	1.3, 7.0	2.3, 7.0	2.3, 7.0	-2.0, 3.3	-4.0, 2.3	-2.0, 2.0
Week 52						
m	74	68	27			
n	70	62	22	65	57	22
Mean (SD/SE)	5.45 (1.58)	5.52 (1.32)	5.83 (1.12)	0.17 (0.16)	-0.12 (0.13)	0.21 (0.26)
Median	5.85	5.70	5.85	0	0	0.30
IQR: Q1, Q3	4.70, 6.70	5.00, 6.70	5.30, 7.00	-0.60, 1.00	-0.70, 0.00	-0.70, 1.00
Min, Max	1.0, 7.0	1.7, 7.0	2.7, 7.0	-2.7, 4.0	-2.0, 2.0	-2.0, 2.3

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Activity						
Baseline						
m	76	75	30			
n	71	66	29			
Mean (SD)	5.25 (1.46)	5.30 (1.32)	5.30 (1.47)			
Median	5.60	5.60	5.80			
IQR: Q1, Q3	4.40, 6.40	4.60, 6.40	4.60, 6.40			
Min, Max	1.4, 7.0	2.0, 7.0	2.0, 7.0			
Week 24						
m	76	74	29			
n	75	71	28	71	63	27
Mean (SD/SE)	5.41 (1.49)	5.35 (1.30)	5.51 (1.16)	0.12 (0.11)	0.01 (0.11)	0.05 (0.19)
Median	5.80	5.80	5.80	0.20	0	0
IQR: Q1, Q3	4.60, 6.60	4.60, 6.40	4.50, 6.50	-0.40, 0.60	-0.60, 0.60	-0.20, 0.80
Min, Max	1.6, 7.0	2.4, 7.0	3.2, 7.0	-2.4, 2.8	-1.4, 3.2	-3.0, 1.4
Week 52						
m	74	68	27			
n	70	62	22	65	57	22
Mean (SD/SE)	5.33 (1.66)	5.34 (1.22)	5.39 (1.31)	-0.02 (0.13)	-0.06 (0.12)	0.02 (0.14)
Median	5.80	5.50	5.60	0.20	0	0
IQR: Q1, Q3	4.60, 6.80	4.80, 6.20	4.60, 6.60	-0.60, 0.40	-0.80, 0.60	-0.20, 0.40
Min, Max	1.0, 7.0	1.6, 7.0	2.8, 7.0	-3.4, 3.0	-2.8, 2.0	-1.4, 1.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Emotional Health						
Baseline						
m	76	75	30			
n	71	66	29			
Mean (SD)	5.35 (1.27)	5.23 (1.29)	5.36 (1.28)			
Median	5.60	5.40	5.70			
IQR: Q1, Q3	4.70, 6.30	4.70, 6.20	4.70, 6.30			
Min, Max	1.3, 7.0	2.1, 7.0	2.3, 7.0			
Week 24						
m	76	74	29			
n	75	71	28	71	63	27
Mean (SD/SE)	5.54 (1.28)	5.21 (1.27)	5.41 (1.18)	0.21 (0.09)	-0.10 (0.09)	-0.04 (0.18)
Median	5.90	5.30	5.70	0.20	0	0
IQR: Q1, Q3	4.80, 6.60	4.40, 6.10	4.70, 6.20	-0.30, 0.70	-0.50, 0.30	-0.50, 0.40
Min, Max	2.2, 7.0	1.0, 7.0	1.9, 6.9	-1.2, 2.0	-3.1, 1.9	-2.3, 1.7
Week 52						
m	74	68	27			
n	70	62	22	65	57	22
Mean (SD/SE)	5.48 (1.12)	5.34 (1.30)	5.25 (1.16)	0.04 (0.11)	0.04 (0.11)	-0.12 (0.15)
Median	5.80	5.70	5.50	0	0	-0.15
IQR: Q1, Q3	4.90, 6.30	4.70, 6.30	4.30, 6.10	-0.50, 0.60	-0.50, 0.70	-0.40, 0.10
Min, Max	1.9, 7.0	1.0, 7.0	2.7, 6.8	-1.9, 2.9	-1.9, 1.8	-1.4, 1.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Fatigue						
Baseline						
m	76	75	30			
n	71	66	29			
Mean (SD)	4.65 (1.55)	4.52 (1.40)	4.30 (1.47)			
Median	5.00	4.80	4.70			
IQR: Q1, Q3	3.50, 6.00	3.70, 5.30	2.80, 5.50			
Min, Max	1.2, 6.8	1.2, 7.0	1.5, 6.2			
Week 24						
m	76	74	29			
n	75	71	28	71	63	27
Mean (SD/SE)	4.76 (1.58)	4.43 (1.37)	4.46 (1.28)	0.08 (0.14)	-0.15 (0.12)	0.06 (0.19)
Median	5.00	4.70	4.60	0	0	0.20
IQR: Q1, Q3	3.50, 6.00	3.70, 5.30	3.25, 5.50	-0.60, 0.70	-0.70, 0.30	-0.50, 0.50
Min, Max	1.5, 7.0	1.5, 7.0	2.7, 6.7	-2.7, 3.2	-4.2, 2.3	-3.3, 1.5
Week 52						
m	74	68	27			
n	70	62	22	65	57	22
Mean (SD/SE)	4.73 (1.57)	4.42 (1.49)	4.48 (1.28)	-0.03 (0.14)	-0.20 (0.17)	0.17 (0.18)
Median	5.10	4.30	4.75	-0.10	0	0.10
IQR: Q1, Q3	3.70, 6.00	3.30, 5.80	3.30, 5.50	-0.50, 0.50	-0.70, 0.40	-0.40, 0.50
Min, Max	1.0, 7.0	1.2, 7.0	2.3, 6.5	-2.4, 4.0	-4.4, 2.5	-1.1, 2.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Systemic Symptoms						
Baseline						
m	76	75	30			
n	71	66	29			
Mean (SD)	5.08 (1.35)	5.08 (1.23)	5.11 (1.30)			
Median	5.30	5.20	5.50			
IQR: Q1, Q3	4.30, 6.20	4.30, 6.00	4.50, 6.00			
Min, Max	1.5, 7.0	1.8, 7.0	2.2, 6.8			
Week 24						
m	76	74	29			
n	75	71	28	71	63	27
Mean (SD/SE)	5.09 (1.39)	4.96 (1.21)	5.22 (1.29)	-0.03 (0.10)	-0.19 (0.09)	-0.03 (0.13)
Median	5.50	5.00	5.25	0	-0.20	0
IQR: Q1, Q3	4.20, 6.20	4.00, 5.70	4.25, 6.30	-0.70, 0.60	-0.50, 0.20	-0.50, 0.30
Min, Max	1.7, 7.0	1.8, 7.0	2.2, 7.0	-1.9, 2.0	-2.0, 2.2	-1.6, 1.3
Week 52						
m	74	68	27			
n	70	62	22	65	57	22
Mean (SD/SE)	5.01 (1.40)	4.90 (1.25)	4.81 (1.30)	-0.19 (0.10)	-0.23 (0.09)	-0.28 (0.14)
Median	5.30	4.90	5.05	-0.20	-0.20	-0.25
IQR: Q1, Q3	4.20, 6.20	4.00, 5.80	4.20, 5.80	-0.70, 0.30	-0.70, 0.30	-0.50, 0.00
Min, Max	1.3, 7.0	1.5, 7.0	2.0, 6.7	-2.0, 2.0	-2.5, 1.1	-2.2, 1.3

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=76)	Visit Result MGL-3196 100 mg (N=75)	Visit Result Placebo (N=30)	Change from Baseline MGL-3196 80 mg (N=76)	Change from Baseline MGL-3196 100 mg (N=75)	Change from Baseline Placebo (N=30)
Worry						
Baseline						
m	76	75	30			
n	71	66	29			
Mean (SD)	5.34 (1.51)	5.53 (1.59)	5.29 (1.38)			
Median	5.70	6.00	5.60			
IQR: Q1, Q3	4.60, 6.60	4.60, 6.90	4.30, 6.40			
Min, Max	1.1, 7.0	1.0, 7.0	2.1, 7.0			
Week 24						
m	76	74	29			
n	75	71	28	71	63	27
Mean (SD/SE)	5.78 (1.46)	5.84 (1.36)	5.81 (1.19)	0.44 (0.13)	0.29 (0.14)	0.51 (0.18)
Median	6.40	6.30	6.00	0.30	0	0.30
IQR: Q1, Q3	5.00, 7.00	5.00, 6.90	5.40, 6.65	0.00, 0.90	-0.30, 0.70	0.00, 0.80
Min, Max	1.6, 7.0	1.0, 7.0	2.1, 7.0	-3.1, 3.3	-2.6, 3.6	-1.3, 3.5
Week 52						
m	74	68	27			
n	70	62	22	65	57	22
Mean (SD/SE)	5.82 (1.37)	5.94 (1.39)	6.12 (0.89)	0.39 (0.12)	0.42 (0.17)	0.69 (0.20)
Median	6.30	6.35	6.30	0.20	0	0.65
IQR: Q1, Q3	5.30, 7.00	5.40, 7.00	5.70, 6.90	0.00, 0.90	-0.30, 1.20	0.20, 1.00
Min, Max	1.7, 7.0	1.0, 7.0	4.1, 7.0	-2.5, 3.0	-3.3, 3.6	-1.3, 3.5

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
CLDQ-NASH						
Baseline						
m	42	25	179			
n	40	23	163			
Mean (SD)	5.54 (1.07)	5.54 (1.05)	5.32 (1.04)			
Median	5.85	5.80	5.50			
IQR: Q1, Q3	4.90, 6.35	4.80, 6.30	4.50, 6.20			
Min, Max	2.7, 6.9	3.1, 6.8	2.4, 7.0			
Week 24						
m	41	25	177			
n	39	25	158	37	23	148
Mean (SD/SE)	5.38 (0.99)	5.48 (1.08)	5.40 (1.08)	-0.07 (0.12)	-0.15 (0.13)	0.06 (0.06)
Median	5.40	6.00	5.70	0	-0.10	0
IQR: Q1, Q3	4.70, 6.30	4.50, 6.10	4.60, 6.20	-0.20, 0.30	-0.60, 0.20	-0.30, 0.40
Min, Max	2.5, 6.9	3.2, 6.8	2.4, 7.0	-2.6, 1.7	-1.4, 1.2	-1.8, 2.6
Week 52						
m	39	22	167			
n	37	20	148	35	18	137
Mean (SD/SE)	5.53 (1.04)	5.65 (1.02)	5.44 (1.10)	-0.07 (0.13)	0.04 (0.15)	0.06 (0.06)
Median	5.70	6.00	5.70	0	0	0
IQR: Q1, Q3	4.80, 6.40	4.70, 6.60	4.75, 6.30	-0.20, 0.30	-0.40, 0.30	-0.30, 0.50
Min, Max	2.8, 7.0	3.7, 6.9	1.9, 7.0	-2.7, 1.4	-1.0, 1.5	-2.2, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Abdominal Symptoms						
Baseline						
m	42	25	179			
n	40	23	163			
Mean (SD)	5.64 (1.44)	5.77 (1.39)	5.23 (1.50)			
Median	6.00	6.30	5.30			
IQR: Q1, Q3	4.70, 7.00	5.30, 7.00	4.30, 6.70			
Min, Max	1.7, 7.0	2.0, 7.0	1.3, 7.0			
Week 24						
m	41	25	177			
n	39	25	158	37	23	148
Mean (SD/SE)	5.40 (1.47)	5.51 (1.63)	5.44 (1.43)	-0.13 (0.19)	-0.30 (0.22)	0.14 (0.10)
Median	5.70	6.30	5.70	0	0	0
IQR: Q1, Q3	4.70, 6.70	4.00, 7.00	4.30, 7.00	-0.30, 0.30	-1.00, 0.30	-0.60, 0.70
Min, Max	1.3, 7.0	2.0, 7.0	1.0, 7.0	-4.7, 2.4	-3.3, 1.0	-3.0, 3.7
Week 52						
m	39	22	167			
n	37	20	148	35	18	137
Mean (SD/SE)	5.87 (1.20)	5.59 (1.63)	5.40 (1.44)	0.11 (0.20)	-0.33 (0.26)	0.04 (0.11)
Median	6.30	6.70	5.70	0	0	0
IQR: Q1, Q3	5.00, 7.00	4.15, 7.00	4.70, 6.70	0.00, 1.00	-0.30, 0.00	-0.70, 0.70
Min, Max	2.7, 7.0	2.7, 7.0	1.0, 7.0	-3.3, 3.0	-3.0, 1.0	-4.6, 3.3

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Activity						
Baseline						
m	42	25	179			
n	40	23	163			
Mean (SD)	5.58 (1.24)	5.56 (1.18)	5.53 (1.31)			
Median	6.00	5.60	5.80			
IQR: Q1, Q3	4.70, 6.60	4.60, 6.80	4.60, 6.60			
Min, Max	2.4, 7.0	3.2, 7.0	2.0, 7.0			
Week 24						
m	41	25	177			
n	39	25	158	37	23	148
Mean (SD/SE)	5.42 (1.21)	5.62 (1.20)	5.56 (1.32)	-0.12 (0.17)	-0.04 (0.22)	0.04 (0.08)
Median	5.60	6.00	6.00	0	0	0
IQR: Q1, Q3	4.60, 6.20	4.60, 6.80	4.80, 6.60	-0.80, 0.40	-1.00, 0.60	-0.40, 0.60
Min, Max	1.2, 7.0	3.4, 7.0	2.2, 7.0	-3.2, 1.8	-2.2, 2.4	-2.8, 3.2
Week 52						
m	39	22	167			
n	37	20	148	35	18	137
Mean (SD/SE)	5.37 (1.22)	5.49 (1.30)	5.55 (1.30)	-0.37 (0.21)	-0.03 (0.18)	-0.06 (0.08)
Median	5.60	5.60	5.80	0	0.20	0
IQR: Q1, Q3	4.80, 6.00	4.60, 6.70	4.60, 6.60	-0.80, 0.40	-0.20, 0.40	-0.60, 0.60
Min, Max	2.0, 7.0	2.2, 7.0	1.8, 7.0	-4.4, 1.4	-1.8, 1.0	-2.4, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Emotional Health						
Baseline						
m	42	25	179			
n	40	23	163			
Mean (SD)	5.62 (1.12)	5.77 (1.20)	5.52 (1.12)			
Median	5.80	6.20	5.80			
IQR: Q1, Q3	5.20, 6.40	4.80, 6.80	4.90, 6.40			
Min, Max	1.9, 7.0	2.9, 7.0	2.2, 7.0			
Week 24						
m	41	25	177			
n	39	25	158	37	23	148
Mean (SD/SE)	5.46 (1.22)	5.76 (1.09)	5.54 (1.22)	-0.06 (0.13)	-0.09 (0.12)	0.00 (0.07)
Median	5.80	6.00	5.85	0	-0.20	0
IQR: Q1, Q3	4.60, 6.40	4.90, 6.80	4.80, 6.60	-0.20, 0.20	-0.40, 0.00	-0.55, 0.50
Min, Max	2.0, 7.0	3.3, 7.0	1.9, 7.0	-2.8, 2.1	-1.1, 1.4	-2.2, 2.6
Week 52						
m	39	22	167			
n	37	20	148	35	18	137
Mean (SD/SE)	5.50 (1.13)	5.96 (0.99)	5.61 (1.18)	-0.18 (0.12)	0.13 (0.19)	0.03 (0.07)
Median	5.80	6.30	5.90	-0.10	0	0
IQR: Q1, Q3	4.80, 6.30	5.40, 6.80	4.95, 6.60	-0.50, 0.20	-0.40, 0.40	-0.40, 0.40
Min, Max	2.9, 7.0	3.7, 7.0	1.3, 7.0	-2.5, 1.0	-0.7, 2.9	-2.0, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Fatigue						
Baseline						
m	42	25	179			
n	40	23	163			
Mean (SD)	5.13 (1.44)	4.86 (1.72)	4.75 (1.32)			
Median	5.40	5.50	5.00			
IQR: Q1, Q3	4.50, 6.10	3.20, 6.20	3.80, 5.80			
Min, Max	1.5, 7.0	1.5, 7.0	1.3, 7.0			
Week 24						
m	41	25	177			
n	39	25	158	37	23	148
Mean (SD/SE)	4.87 (1.51)	4.71 (1.50)	4.78 (1.46)	-0.13 (0.15)	-0.30 (0.16)	0.04 (0.09)
Median	4.80	5.30	5.20	-0.10	-0.30	0
IQR: Q1, Q3	4.00, 6.00	3.80, 5.80	3.70, 6.00	-0.70, 0.40	-0.80, 0.00	-0.60, 0.65
Min, Max	1.3, 7.0	1.7, 7.0	1.2, 7.0	-2.5, 2.3	-2.4, 1.5	-3.8, 3.0
Week 52						
m	39	22	167			
n	37	20	148	35	18	137
Mean (SD/SE)	5.06 (1.50)	5.07 (1.47)	4.81 (1.44)	-0.09 (0.14)	0.00 (0.19)	0.03 (0.09)
Median	5.20	5.40	5.00	0	-0.10	0
IQR: Q1, Q3	3.80, 6.30	4.35, 6.20	3.80, 5.80	-0.40, 0.50	-0.50, 0.40	-0.60, 0.70
Min, Max	1.7, 7.0	1.5, 6.8	1.0, 7.0	-2.0, 1.8	-1.4, 2.0	-3.8, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Systemic Symptoms						
Baseline						
m	42	25	179			
n	40	23	163			
Mean (SD)	5.51 (1.12)	5.21 (1.21)	5.16 (1.20)			
Median	5.80	5.20	5.30			
IQR: Q1, Q3	4.70, 6.30	4.70, 6.20	4.50, 6.00			
Min, Max	3.2, 7.0	2.5, 7.0	1.7, 7.0			
Week 24						
m	41	25	177			
n	39	25	158	37	23	148
Mean (SD/SE)	5.44 (0.96)	5.06 (1.17)	5.14 (1.20)	-0.04 (0.12)	-0.28 (0.17)	-0.08 (0.07)
Median	5.50	5.20	5.30	0	-0.20	0
IQR: Q1, Q3	4.80, 6.20	4.20, 6.00	4.30, 6.00	-0.40, 0.30	-0.90, 0.50	-0.60, 0.40
Min, Max	3.3, 7.0	3.0, 7.0	2.0, 7.0	-1.6, 2.1	-1.8, 1.0	-2.5, 2.4
Week 52						
m	39	22	167			
n	37	20	148	35	18	137
Mean (SD/SE)	5.49 (1.18)	5.36 (1.14)	5.20 (1.36)	-0.15 (0.15)	0.09 (0.26)	0.02 (0.08)
Median	5.80	5.35	5.50	0	0.15	0
IQR: Q1, Q3	4.70, 6.50	4.50, 6.40	4.20, 6.30	-0.50, 0.30	-0.50, 1.00	-0.50, 0.60
Min, Max	2.8, 7.0	3.0, 7.0	1.3, 7.0	-2.7, 2.0	-2.3, 1.8	-2.7, 2.7

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Worry						
Baseline						
m	42	25	179			
n	40	23	163			
Mean (SD)	5.76 (1.31)	6.04 (1.00)	5.72 (1.31)			
Median	6.05	6.40	6.10			
IQR: Q1, Q3	5.10, 6.80	5.30, 6.90	5.00, 6.70			
Min, Max	1.6, 7.0	3.9, 7.0	1.3, 7.0			
Week 24						
m	41	25	177			
n	39	25	158	37	23	148
Mean (SD/SE)	5.71 (1.31)	6.13 (0.93)	5.90 (1.32)	0.09 (0.11)	0.09 (0.17)	0.21 (0.08)
Median	6.00	6.40	6.40	0	0	0
IQR: Q1, Q3	5.30, 6.60	5.60, 6.90	5.40, 6.90	-0.30, 0.40	-0.20, 0.40	-0.25, 0.60
Min, Max	1.6, 7.0	3.9, 7.0	1.1, 7.0	-1.2, 2.0	-1.6, 2.1	-2.6, 2.9
Week 52						
m	39	22	167			
n	37	20	148	35	18	137
Mean (SD/SE)	5.87 (1.42)	6.44 (0.79)	6.05 (1.22)	0.19 (0.23)	0.39 (0.22)	0.29 (0.09)
Median	6.40	6.90	6.40	0	0.15	0.10
IQR: Q1, Q3	5.10, 7.00	5.95, 7.00	5.40, 7.00	-0.30, 1.00	0.00, 0.80	-0.20, 0.70
Min, Max	1.9, 7.0	4.7, 7.0	1.4, 7.0	-4.8, 3.8	-1.0, 2.6	-2.7, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; CFB = Change from Baseline; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.13.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
CLDQ-NASH			
Week 24			
m	76	74	29
n	71	63	27
Baseline Mean (SD)	5.14 (1.25)	5.23 (1.12)	5.21 (1.12)
Analysis Visit Mean (SD)	5.32 (1.29)	5.20 (1.00)	5.32 (1.03)
LS Mean of Change from Baseline (SE)	0.16 (0.07)	-0.03 (0.08)	0.11 (0.12)
95% CI	(0.02, 0.31)	(-0.18, 0.13)	(-0.12, 0.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.14)	-0.14 (0.14)	
95% CI	(-0.22, 0.33)	(-0.41, 0.14)	
p-value	0.6963	0.3286	
Corrected Hedge's g Statistics	0.086	-0.221	
95% CI	(-0.36, 0.53)	(-0.67, 0.23)	
Week 52			
m	74	68	27
n	65	57	22
Baseline Mean (SD)	5.19 (1.26)	5.24 (1.14)	5.19 (1.06)
Analysis Visit Mean (SD)	5.25 (1.26)	5.20 (1.05)	5.32 (0.94)
LS Mean of Change from Baseline (SE)	0.04 (0.08)	-0.03 (0.08)	0.09 (0.13)
95% CI	(-0.11, 0.20)	(-0.19, 0.13)	(-0.17, 0.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.15)	-0.12 (0.15)	
95% CI	(-0.34, 0.25)	(-0.42, 0.18)	
p-value	0.7792	0.4403	
Corrected Hedge's g Statistics	-0.067	-0.189	
95% CI	(-0.55, 0.42)	(-0.68, 0.30)	
Subgroup*Treatment Interaction p-value	0.5079	0.9556	

AMNOG Table SE23.13.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
CLDQ-NASH			
Week 24			
m	41	25	177
n	37	23	148
Baseline Mean (SD)	5.52 (1.05)	5.54 (1.05)	5.35 (1.05)
Analysis Visit Mean (SD)	5.45 (0.96)	5.39 (1.08)	5.41 (1.07)
LS Mean of Change from Baseline (SE)	-0.01 (0.11)	-0.11 (0.14)	0.05 (0.06)
95% CI	(-0.22, 0.21)	(-0.38, 0.15)	(-0.06, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.12)	-0.16 (0.14)	
95% CI	(-0.29, 0.18)	(-0.44, 0.12)	
p-value	0.6375	0.2645	
Corrected Hedge's g Statistics	-0.082	-0.237	
95% CI	(-0.44, 0.28)	(-0.68, 0.20)	
Week 52			
m	39	22	167
n	35	18	137
Baseline Mean (SD)	5.61 (1.01)	5.48 (1.05)	5.40 (1.02)
Analysis Visit Mean (SD)	5.54 (0.99)	5.52 (1.00)	5.46 (1.07)
LS Mean of Change from Baseline (SE)	-0.01 (0.12)	0.08 (0.16)	0.07 (0.06)
95% CI	(-0.25, 0.23)	(-0.23, 0.40)	(-0.05, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.13)	0.02 (0.17)	
95% CI	(-0.34, 0.18)	(-0.31, 0.35)	
p-value	0.5481	0.9252	
Corrected Hedge's g Statistics	-0.109	0.022	
95% CI	(-0.48, 0.26)	(-0.47, 0.51)	
Subgroup*Treatment Interaction p-value	0.5079	0.9556	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; CFB = Change from Baseline; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.13.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Abdominal Symptoms			
Week 24			
m	76	74	29
n	71	63	27
Baseline Mean (SD)	5.18 (1.69)	5.62 (1.38)	5.51 (1.44)
Analysis Visit Mean (SD)	5.43 (1.50)	5.60 (1.37)	5.69 (1.41)
LS Mean of Change from Baseline (SE)	0.17 (0.12)	0.04 (0.12)	0.23 (0.19)
95% CI	(-0.06, 0.41)	(-0.21, 0.28)	(-0.14, 0.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.22)	-0.20 (0.22)	
95% CI	(-0.50, 0.37)	(-0.64, 0.24)	
p-value	0.7795	0.3760	
Corrected Hedge's g Statistics	-0.062	-0.200	
95% CI	(-0.50, 0.38)	(-0.65, 0.25)	
Week 52			
m	74	68	27
n	65	57	22
Baseline Mean (SD)	5.25 (1.64)	5.65 (1.38)	5.62 (1.15)
Analysis Visit Mean (SD)	5.41 (1.63)	5.53 (1.36)	5.83 (1.12)
LS Mean of Change from Baseline (SE)	0.09 (0.14)	-0.05 (0.14)	0.28 (0.23)
95% CI	(-0.18, 0.36)	(-0.34, 0.23)	(-0.17, 0.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.19 (0.26)	-0.34 (0.27)	
95% CI	(-0.72, 0.33)	(-0.87, 0.19)	
p-value	0.4697	0.2120	
Corrected Hedge's g Statistics	-0.174	-0.307	
95% CI	(-0.66, 0.31)	(-0.80, 0.19)	
Subgroup*Treatment Interaction p-value	0.7443	0.9601	

AMNOG Table SE23.13.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Activity			
Week 24			
m	76	74	29
n	71	63	27
Baseline Mean (SD)	5.25 (1.46)	5.34 (1.33)	5.44 (1.37)
Analysis Visit Mean (SD)	5.38 (1.53)	5.35 (1.27)	5.50 (1.18)
LS Mean of Change from Baseline (SE)	0.11 (0.10)	0.02 (0.11)	0.09 (0.17)
95% CI	(-0.09, 0.32)	(-0.20, 0.23)	(-0.24, 0.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (0.19)	-0.07 (0.20)	
95% CI	(-0.36, 0.41)	(-0.46, 0.32)	
p-value	0.9034	0.7148	
Corrected Hedge's g Statistics	0.027	-0.083	
95% CI	(-0.42, 0.47)	(-0.53, 0.37)	
Week 52			
m	74	68	27
n	65	57	22
Baseline Mean (SD)	5.28 (1.48)	5.35 (1.33)	5.37 (1.33)
Analysis Visit Mean (SD)	5.26 (1.69)	5.29 (1.24)	5.39 (1.31)
LS Mean of Change from Baseline (SE)	-0.02 (0.12)	-0.02 (0.12)	0.01 (0.19)
95% CI	(-0.25, 0.21)	(-0.27, 0.22)	(-0.37, 0.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.23)	-0.03 (0.23)	
95% CI	(-0.48, 0.42)	(-0.48, 0.42)	
p-value	0.8945	0.8935	
Corrected Hedge's g Statistics	-0.032	-0.033	
95% CI	(-0.52, 0.45)	(-0.52, 0.46)	
Subgroup*Treatment Interaction p-value	0.3868	0.9998	

AMNOG Table SE23.13.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Emotional Health			
Week 24			
m	76	74	29
n	71	63	27
Baseline Mean (SD)	5.35 (1.27)	5.22 (1.31)	5.41 (1.14)
Analysis Visit Mean (SD)	5.56 (1.28)	5.11 (1.30)	5.37 (1.18)
LS Mean of Change from Baseline (SE)	0.19 (0.09)	-0.15 (0.09)	-0.04 (0.14)
95% CI	(0.01, 0.37)	(-0.33, 0.04)	(-0.32, 0.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.23 (0.17)	-0.11 (0.17)	
95% CI	(-0.10, 0.56)	(-0.44, 0.23)	
p-value	0.1699	0.5303	
Corrected Hedge's g Statistics	0.305	-0.142	
95% CI	(-0.14, 0.75)	(-0.59, 0.31)	
Week 52			
m	74	68	27
n	65	57	22
Baseline Mean (SD)	5.41 (1.28)	5.22 (1.35)	5.37 (1.24)
Analysis Visit Mean (SD)	5.46 (1.12)	5.26 (1.32)	5.25 (1.16)
LS Mean of Change from Baseline (SE)	0.03 (0.09)	-0.02 (0.10)	-0.16 (0.16)
95% CI	(-0.15, 0.22)	(-0.21, 0.18)	(-0.47, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.19 (0.18)	0.14 (0.19)	
95% CI	(-0.17, 0.55)	(-0.22, 0.51)	
p-value	0.2969	0.4410	
Corrected Hedge's g Statistics	0.251	0.189	
95% CI	(-0.23, 0.74)	(-0.30, 0.68)	
Subgroup*Treatment Interaction p-value	0.1216	0.9001	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Fatigue			
Week 24			
m	76	74	29
n	71	63	27
Baseline Mean (SD)	4.65 (1.55)	4.52 (1.43)	4.39 (1.42)
Analysis Visit Mean (SD)	4.73 (1.60)	4.37 (1.41)	4.44 (1.30)
LS Mean of Change from Baseline (SE)	0.08 (0.12)	-0.18 (0.13)	-0.01 (0.19)
95% CI	(-0.16, 0.32)	(-0.43, 0.07)	(-0.39, 0.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (0.23)	-0.17 (0.23)	
95% CI	(-0.36, 0.54)	(-0.63, 0.28)	
p-value	0.6964	0.4516	
Corrected Hedge's g Statistics	0.086	-0.170	
95% CI	(-0.36, 0.53)	(-0.62, 0.28)	
Week 52			
m	74	68	27
n	65	57	22
Baseline Mean (SD)	4.69 (1.59)	4.57 (1.43)	4.30 (1.43)
Analysis Visit Mean (SD)	4.66 (1.58)	4.37 (1.52)	4.48 (1.28)
LS Mean of Change from Baseline (SE)	-0.03 (0.14)	-0.20 (0.14)	-0.01 (0.23)
95% CI	(-0.30, 0.24)	(-0.48, 0.09)	(-0.46, 0.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.26)	-0.19 (0.27)	
95% CI	(-0.55, 0.50)	(-0.72, 0.34)	
p-value	0.9275	0.4759	
Corrected Hedge's g Statistics	-0.022	-0.175	
95% CI	(-0.51, 0.46)	(-0.67, 0.32)	
Subgroup*Treatment Interaction p-value	0.7199	0.9026	

AMNOG Table SE23.13.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Systemic Symptoms			
Week 24			
m	76	74	29
n	71	63	27
Baseline Mean (SD)	5.08 (1.35)	5.10 (1.25)	5.20 (1.26)
Analysis Visit Mean (SD)	5.05 (1.41)	4.91 (1.20)	5.18 (1.29)
LS Mean of Change from Baseline (SE)	-0.04 (0.09)	-0.20 (0.09)	-0.02 (0.14)
95% CI	(-0.21, 0.14)	(-0.38, -0.02)	(-0.30, 0.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.16)	-0.18 (0.17)	
95% CI	(-0.34, 0.31)	(-0.51, 0.15)	
p-value	0.9329	0.2943	
Corrected Hedge's g Statistics	-0.019	-0.238	
95% CI	(-0.46, 0.42)	(-0.69, 0.21)	
Week 52			
m	74	68	27
n	65	57	22
Baseline Mean (SD)	5.12 (1.32)	5.10 (1.23)	5.09 (1.21)
Analysis Visit Mean (SD)	4.93 (1.40)	4.87 (1.27)	4.81 (1.30)
LS Mean of Change from Baseline (SE)	-0.18 (0.09)	-0.24 (0.10)	-0.29 (0.15)
95% CI	(-0.36, 0.00)	(-0.43, -0.04)	(-0.60, 0.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.11 (0.18)	0.05 (0.18)	
95% CI	(-0.25, 0.46)	(-0.31, 0.42)	
p-value	0.5450	0.7635	
Corrected Hedge's g Statistics	0.146	0.074	
95% CI	(-0.34, 0.63)	(-0.42, 0.57)	
Subgroup*Treatment Interaction p-value	0.9938	0.9307	

AMNOG Table SE23.13.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Worry			
Week 24			
m	76	74	29
n	71	63	27
Baseline Mean (SD)	5.34 (1.51)	5.52 (1.61)	5.33 (1.30)
Analysis Visit Mean (SD)	5.78 (1.49)	5.81 (1.40)	5.84 (1.21)
LS Mean of Change from Baseline (SE)	0.40 (0.12)	0.30 (0.12)	0.45 (0.19)
95% CI	(0.17, 0.63)	(0.06, 0.55)	(0.08, 0.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.22)	-0.14 (0.22)	
95% CI	(-0.47, 0.38)	(-0.58, 0.29)	
p-value	0.8334	0.5125	
Corrected Hedge's g Statistics	-0.046	-0.148	
95% CI	(-0.49, 0.40)	(-0.60, 0.30)	
Week 52			
m	74	68	27
n	65	57	22
Baseline Mean (SD)	5.40 (1.50)	5.51 (1.66)	5.44 (1.18)
Analysis Visit Mean (SD)	5.79 (1.39)	5.93 (1.42)	6.12 (0.89)
LS Mean of Change from Baseline (SE)	0.35 (0.12)	0.42 (0.13)	0.58 (0.20)
95% CI	(0.11, 0.58)	(0.17, 0.67)	(0.19, 0.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.24 (0.23)	-0.16 (0.23)	
95% CI	(-0.69, 0.22)	(-0.62, 0.30)	
p-value	0.3036	0.4886	
Corrected Hedge's g Statistics	-0.247	-0.170	
95% CI	(-0.73, 0.24)	(-0.66, 0.32)	
Subgroup*Treatment Interaction p-value	0.9110	0.4447	

AMNOG Table SE23.13.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Abdominal Symptoms			
Week 24			
m	41	25	177
n	37	23	148
Baseline Mean (SD)	5.61 (1.48)	5.77 (1.39)	5.32 (1.48)
Analysis Visit Mean (SD)	5.49 (1.46)	5.47 (1.69)	5.45 (1.40)
LS Mean of Change from Baseline (SE)	0.00 (0.18)	-0.14 (0.23)	0.12 (0.09)
95% CI	(-0.36, 0.36)	(-0.59, 0.31)	(-0.06, 0.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.12 (0.20)	-0.26 (0.24)	
95% CI	(-0.52, 0.27)	(-0.74, 0.22)	
p-value	0.5373	0.2807	
Corrected Hedge's g Statistics	-0.108	-0.230	
95% CI	(-0.47, 0.25)	(-0.67, 0.21)	
Week 52			
m	39	22	167
n	35	18	137
Baseline Mean (SD)	5.74 (1.35)	5.79 (1.22)	5.36 (1.46)
Analysis Visit Mean (SD)	5.86 (1.21)	5.47 (1.67)	5.40 (1.42)
LS Mean of Change from Baseline (SE)	0.31 (0.19)	-0.11 (0.26)	0.06 (0.10)
95% CI	(-0.07, 0.69)	(-0.62, 0.40)	(-0.14, 0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.25 (0.21)	-0.17 (0.27)	
95% CI	(-0.16, 0.66)	(-0.70, 0.36)	
p-value	0.2373	0.5321	
Corrected Hedge's g Statistics	0.214	-0.147	
95% CI	(-0.16, 0.59)	(-0.64, 0.34)	
Subgroup*Treatment Interaction p-value	0.7443	0.9601	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Activity			
Week 24			
m	41	25	177
n	37	23	148
Baseline Mean (SD)	5.60 (1.20)	5.56 (1.18)	5.55 (1.31)
Analysis Visit Mean (SD)	5.48 (1.20)	5.51 (1.19)	5.59 (1.29)
LS Mean of Change from Baseline (SE)	-0.11 (0.15)	-0.08 (0.19)	-0.01 (0.08)
95% CI	(-0.41, 0.19)	(-0.46, 0.30)	(-0.16, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.17)	-0.07 (0.20)	
95% CI	(-0.43, 0.22)	(-0.47, 0.33)	
p-value	0.5323	0.7213	
Corrected Hedge's g Statistics	-0.110	-0.076	
95% CI	(-0.47, 0.25)	(-0.52, 0.36)	
Week 52			
m	39	22	167
n	35	18	137
Baseline Mean (SD)	5.70 (1.17)	5.37 (1.18)	5.65 (1.21)
Analysis Visit Mean (SD)	5.34 (1.22)	5.33 (1.28)	5.59 (1.29)
LS Mean of Change from Baseline (SE)	-0.36 (0.16)	-0.09 (0.22)	-0.06 (0.08)
95% CI	(-0.69, -0.04)	(-0.52, 0.35)	(-0.22, 0.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.31 (0.18)	-0.03 (0.23)	
95% CI	(-0.66, 0.05)	(-0.48, 0.43)	
p-value	0.0884	0.9086	
Corrected Hedge's g Statistics	-0.309	-0.027	
95% CI	(-0.68, 0.06)	(-0.52, 0.46)	
Subgroup*Treatment Interaction p-value	0.3868	0.9998	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Emotional Health			
Week 24			
m	41	25	177
n	37	23	148
Baseline Mean (SD)	5.57 (1.14)	5.77 (1.20)	5.53 (1.14)
Analysis Visit Mean (SD)	5.51 (1.18)	5.68 (1.10)	5.53 (1.22)
LS Mean of Change from Baseline (SE)	-0.03 (0.14)	-0.04 (0.17)	-0.01 (0.07)
95% CI	(-0.30, 0.24)	(-0.38, 0.30)	(-0.15, 0.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.15)	-0.03 (0.18)	
95% CI	(-0.31, 0.28)	(-0.38, 0.33)	
p-value	0.9142	0.8846	
Corrected Hedge's g Statistics	-0.019	-0.031	
95% CI	(-0.38, 0.34)	(-0.47, 0.41)	
Week 52			
m	39	22	167
n	35	18	137
Baseline Mean (SD)	5.71 (1.00)	5.73 (1.22)	5.58 (1.15)
Analysis Visit Mean (SD)	5.53 (1.05)	5.87 (1.00)	5.61 (1.17)
LS Mean of Change from Baseline (SE)	-0.13 (0.14)	0.18 (0.18)	0.02 (0.07)
95% CI	(-0.39, 0.14)	(-0.17, 0.54)	(-0.12, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (0.15)	0.16 (0.19)	
95% CI	(-0.43, 0.14)	(-0.21, 0.54)	
p-value	0.3235	0.3860	
Corrected Hedge's g Statistics	-0.178	0.202	
95% CI	(-0.55, 0.19)	(-0.29, 0.69)	
Subgroup*Treatment Interaction p-value	0.1216	0.9001	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Fatigue			
Week 24			
m	41	25	177
n	37	23	148
Baseline Mean (SD)	5.12 (1.38)	4.86 (1.72)	4.75 (1.35)
Analysis Visit Mean (SD)	4.99 (1.43)	4.56 (1.46)	4.80 (1.46)
LS Mean of Change from Baseline (SE)	-0.05 (0.17)	-0.32 (0.21)	-0.02 (0.08)
95% CI	(-0.38, 0.28)	(-0.73, 0.09)	(-0.18, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.18)	-0.30 (0.22)	
95% CI	(-0.39, 0.33)	(-0.73, 0.13)	
p-value	0.8640	0.1681	
Corrected Hedge's g Statistics	-0.030	-0.294	
95% CI	(-0.39, 0.33)	(-0.73, 0.15)	
Week 52			
m	39	22	167
n	35	18	137
Baseline Mean (SD)	5.19 (1.38)	4.89 (1.73)	4.83 (1.29)
Analysis Visit Mean (SD)	5.10 (1.39)	4.89 (1.45)	4.86 (1.41)
LS Mean of Change from Baseline (SE)	-0.02 (0.17)	0.02 (0.22)	0.02 (0.09)
95% CI	(-0.35, 0.31)	(-0.42, 0.45)	(-0.15, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.18)	0.00 (0.23)	
95% CI	(-0.40, 0.32)	(-0.46, 0.46)	
p-value	0.8283	0.9978	
Corrected Hedge's g Statistics	-0.039	-0.001	
95% CI	(-0.41, 0.33)	(-0.49, 0.49)	
Subgroup*Treatment Interaction p-value	0.7199	0.9026	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Systemic Symptoms			
Week 24			
m	41	25	177
n	37	23	148
Baseline Mean (SD)	5.48 (1.10)	5.21 (1.21)	5.22 (1.18)
Analysis Visit Mean (SD)	5.44 (0.99)	4.93 (1.13)	5.14 (1.21)
LS Mean of Change from Baseline (SE)	0.08 (0.13)	-0.26 (0.16)	-0.07 (0.06)
95% CI	(-0.17, 0.33)	(-0.57, 0.05)	(-0.20, 0.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.15 (0.14)	-0.19 (0.17)	
95% CI	(-0.12, 0.43)	(-0.52, 0.14)	
p-value	0.2666	0.2667	
Corrected Hedge's g Statistics	0.195	-0.236	
95% CI	(-0.17, 0.56)	(-0.68, 0.20)	
Week 52			
m	39	22	167
n	35	18	137
Baseline Mean (SD)	5.59 (1.06)	5.11 (1.22)	5.20 (1.22)
Analysis Visit Mean (SD)	5.44 (1.19)	5.19 (1.08)	5.22 (1.34)
LS Mean of Change from Baseline (SE)	-0.04 (0.15)	0.10 (0.20)	0.04 (0.08)
95% CI	(-0.33, 0.26)	(-0.29, 0.50)	(-0.11, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.17)	0.06 (0.21)	
95% CI	(-0.41, 0.25)	(-0.36, 0.48)	
p-value	0.6371	0.7690	
Corrected Hedge's g Statistics	-0.086	0.069	
95% CI	(-0.46, 0.28)	(-0.42, 0.56)	
Subgroup*Treatment Interaction p-value	0.9938	0.9307	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Worry			
Week 24			
m	41	25	177
n	37	23	148
Baseline Mean (SD)	5.71 (1.33)	6.04 (1.00)	5.70 (1.35)
Analysis Visit Mean (SD)	5.80 (1.14)	6.13 (0.96)	5.91 (1.30)
LS Mean of Change from Baseline (SE)	0.10 (0.14)	0.18 (0.17)	0.20 (0.07)
95% CI	(-0.17, 0.37)	(-0.16, 0.51)	(0.06, 0.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.15)	-0.02 (0.18)	
95% CI	(-0.39, 0.19)	(-0.38, 0.33)	
p-value	0.5160	0.8986	
Corrected Hedge's g Statistics	-0.113	-0.027	
95% CI	(-0.47, 0.25)	(-0.47, 0.41)	
Week 52			
m	39	22	167
n	35	18	137
Baseline Mean (SD)	5.76 (1.37)	5.98 (1.07)	5.78 (1.27)
Analysis Visit Mean (SD)	5.95 (1.27)	6.38 (0.82)	6.07 (1.19)
LS Mean of Change from Baseline (SE)	0.18 (0.16)	0.50 (0.22)	0.27 (0.08)
95% CI	(-0.14, 0.50)	(0.07, 0.93)	(0.10, 0.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.09 (0.18)	0.23 (0.23)	
95% CI	(-0.44, 0.26)	(-0.22, 0.69)	
p-value	0.6187	0.3149	
Corrected Hedge's g Statistics	-0.091	0.237	
95% CI	(-0.46, 0.28)	(-0.26, 0.73)	
Subgroup*Treatment Interaction p-value	0.9110	0.4447	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; CFB = Change from Baseline; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (6.6)	5 (6.7)	1 (3.3)
No	71 (93.4)	70 (93.3)	29 (96.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.49	0.48	
95% CI of the inverse odds ratio	(0.05, 4.38)	(0.05, 4.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.51	0.50	
95% CI of the inverse risk ratio	(0.06, 4.16)	(0.06, 4.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.25	3.33	
95% CI of the absolute risk difference	(-5.26, 11.75)	(-5.22, 11.88)	
p-value	0.5148	0.5062	
p-value of Breslow-Day Test for Homogeneity [3]	0.2477	0.4663	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (26.3)	16 (21.3)	8 (26.7)
No	56 (73.7)	59 (78.7)	22 (73.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.34	
95% CI of the inverse odds ratio	(0.39, 2.65)	(0.50, 3.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.25	
95% CI of the inverse risk ratio	(0.50, 2.05)	(0.60, 2.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.35	-5.33	
95% CI of the absolute risk difference	(-19.02, 18.32)	(-23.67, 13.01)	
p-value	0.9706	0.5566	
p-value of Breslow-Day Test for Homogeneity [3]	0.7663	0.3529	

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	18 (23.7)	10 (13.3)	7 (23.3)
No	58 (76.3)	65 (86.7)	23 (76.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.98	
95% CI of the inverse odds ratio	(0.36, 2.66)	(0.67, 5.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	1.75	
95% CI of the inverse risk ratio	(0.46, 2.11)	(0.73, 4.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.35	-10.00	
95% CI of the absolute risk difference	(-17.55, 18.25)	(-26.98, 6.98)	
p-value	0.9694	0.2089	
p-value of Breslow-Day Test for Homogeneity [3]	0.7558	0.7991	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (42.1)	14 (18.7)	12 (40.0)
No	44 (57.9)	61 (81.3)	18 (60.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	2.90	
95% CI of the inverse odds ratio	(0.39, 2.17)	(1.14, 7.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	2.14	
95% CI of the inverse risk ratio	(0.57, 1.58)	(1.12, 4.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.11	-21.33	
95% CI of the absolute risk difference	(-18.64, 22.85)	(-40.96, -1.71)	
p-value	0.8429	0.0221	
p-value of Breslow-Day Test for Homogeneity [3]	0.9096	0.9798	

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (13.2)	10 (13.3)	2 (6.7)
No	66 (86.8)	65 (86.7)	28 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	0.46	
95% CI of the inverse odds ratio	(0.10, 2.29)	(0.10, 2.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.51	0.50	
95% CI of the inverse risk ratio	(0.12, 2.18)	(0.12, 2.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.49	6.67	
95% CI of the absolute risk difference	(-5.23, 18.21)	(-5.12, 18.45)	
p-value	0.3420	0.3321	
p-value of Breslow-Day Test for Homogeneity [3]	0.1524	0.1701	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (32.9)	20 (26.7)	6 (20.0)
No	51 (67.1)	55 (73.3)	24 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.51	0.69	
95% CI of the inverse odds ratio	(0.18, 1.41)	(0.25, 1.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	0.75	
95% CI of the inverse risk ratio	(0.28, 1.33)	(0.33, 1.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.89	6.67	
95% CI of the absolute risk difference	(-4.89, 30.68)	(-10.80, 24.13)	
p-value	0.1886	0.4746	
p-value of Breslow-Day Test for Homogeneity [3]	0.2134	0.6039	

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (15.8)	9 (12.0)	2 (6.7)
No	64 (84.2)	66 (88.0)	28 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	0.52	
95% CI of the inverse odds ratio	(0.08, 1.82)	(0.11, 2.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.42	0.56	
95% CI of the inverse risk ratio	(0.10, 1.78)	(0.13, 2.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.12	5.33	
95% CI of the absolute risk difference	(-3.00, 21.24)	(-6.23, 16.90)	
p-value	0.2114	0.4201	
p-value of Breslow-Day Test for Homogeneity [3]	0.1845	0.2042	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (25.0)	23 (30.7)	3 (10.0)
No	57 (75.0)	52 (69.3)	27 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	0.25	
95% CI of the inverse odds ratio	(0.09, 1.22)	(0.07, 0.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	0.33	
95% CI of the inverse risk ratio	(0.13, 1.25)	(0.11, 1.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.00	20.67	
95% CI of the absolute risk difference	(0.51, 29.49)	(5.70, 35.64)	
p-value	0.0863	0.0267	
p-value of Breslow-Day Test for Homogeneity [3]	0.0206	0.0377	

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (10.5)	11 (14.7)	4 (13.3)
No	68 (89.5)	64 (85.3)	26 (86.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	0.90	
95% CI of the inverse odds ratio	(0.36, 4.72)	(0.26, 3.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	0.91	
95% CI of the inverse risk ratio	(0.41, 3.90)	(0.31, 2.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.81	1.33	
95% CI of the absolute risk difference	(-16.79, 11.18)	(-13.23, 15.90)	
p-value	0.6812	0.8600	
p-value of Breslow-Day Test for Homogeneity [3]	0.3503	0.7527	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (26.3)	19 (25.3)	10 (33.3)
No	56 (73.7)	56 (74.7)	20 (66.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	1.47	
95% CI of the inverse odds ratio	(0.56, 3.49)	(0.59, 3.70)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	1.32	
95% CI of the inverse risk ratio	(0.67, 2.38)	(0.70, 2.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.02	-8.00	
95% CI of the absolute risk difference	(-26.58, 12.54)	(-27.53, 11.53)	
p-value	0.4700	0.4075	
p-value of Breslow-Day Test for Homogeneity [3]	0.4739	0.8808	

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (5.3)	2 (2.7)	1 (3.3)
No	72 (94.7)	73 (97.3)	29 (96.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	1.26	
95% CI of the inverse odds ratio	(0.07, 5.79)	(0.11, 14.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	1.25	
95% CI of the inverse risk ratio	(0.07, 5.44)	(0.12, 13.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.93	-0.67	
95% CI of the absolute risk difference	(-6.22, 10.08)	(-8.05, 6.72)	
p-value	0.6729	0.8530	
p-value of Breslow-Day Test for Homogeneity [3]	0.4256	0.5196	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (23.7)	17 (22.7)	3 (10.0)
No	58 (76.3)	58 (77.3)	27 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.36	0.38	
95% CI of the inverse odds ratio	(0.10, 1.32)	(0.10, 1.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.42	0.44	
95% CI of the inverse risk ratio	(0.13, 1.33)	(0.14, 1.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	13.68	12.67	
95% CI of the absolute risk difference	(-0.69, 28.06)	(-1.65, 26.99)	
p-value	0.1113	0.1354	
p-value of Breslow-Day Test for Homogeneity [3]	0.0688	0.2551	

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	17 (22.4)	17 (22.7)	9 (30.0)
No	59 (77.6)	58 (77.3)	21 (70.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.49	1.46	
95% CI of the inverse odds ratio	(0.58, 3.84)	(0.57, 3.78)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.34	1.32	
95% CI of the inverse risk ratio	(0.67, 2.67)	(0.67, 2.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.63	-7.33	
95% CI of the absolute risk difference	(-26.52, 11.25)	(-26.27, 11.61)	
p-value	0.4107	0.4316	
p-value of Breslow-Day Test for Homogeneity [3]	0.2759	0.6677	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (39.5)	25 (33.3)	16 (53.3)
No	46 (60.5)	50 (66.7)	14 (46.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.75	2.29	
95% CI of the inverse odds ratio	(0.75, 4.11)	(0.96, 5.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	1.60	
95% CI of the inverse risk ratio	(0.87, 2.09)	(1.01, 2.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-13.86	-20.00	
95% CI of the absolute risk difference	(-34.82, 7.10)	(-40.80, 0.80)	
p-value	0.1947	0.0577	
p-value of Breslow-Day Test for Homogeneity [3]	0.3288	0.1332	

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.8)	2 (8.0)	18 (10.1)
No	40 (95.2)	23 (92.0)	161 (89.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.24	1.29	
95% CI of the inverse odds ratio	(0.50, 10.03)	(0.28, 5.91)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.11	1.26	
95% CI of the inverse risk ratio	(0.51, 8.75)	(0.31, 5.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.29	-2.06	
95% CI of the absolute risk difference	(-13.10, 2.51)	(-13.57, 9.46)	
p-value	0.2818	0.7461	
p-value of Breslow-Day Test for Homogeneity [3]	0.2477	0.4663	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (21.4)	8 (32.0)	45 (25.1)
No	33 (78.6)	17 (68.0)	134 (74.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	0.71	
95% CI of the inverse odds ratio	(0.55, 2.77)	(0.29, 1.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	0.79	
95% CI of the inverse risk ratio	(0.62, 2.21)	(0.42, 1.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.71	6.86	
95% CI of the absolute risk difference	(-17.65, 10.23)	(-12.50, 26.22)	
p-value	0.6145	0.4637	
p-value of Breslow-Day Test for Homogeneity [3]	0.7663	0.3529	

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (21.4)	2 (8.0)	32 (17.9)
No	33 (78.6)	23 (92.0)	147 (82.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	2.50	
95% CI of the inverse odds ratio	(0.35, 1.83)	(0.56, 11.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.83	2.23	
95% CI of the inverse risk ratio	(0.43, 1.61)	(0.57, 8.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.55	-9.88	
95% CI of the absolute risk difference	(-10.07, 17.17)	(-21.90, 2.15)	
p-value	0.5941	0.2145	
p-value of Breslow-Day Test for Homogeneity [3]	0.7558	0.7991	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (35.7)	4 (16.0)	63 (35.2)
No	27 (64.3)	21 (84.0)	116 (64.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	2.85	
95% CI of the inverse odds ratio	(0.48, 1.97)	(0.94, 8.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	2.20	
95% CI of the inverse risk ratio	(0.63, 1.55)	(0.88, 5.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.52	-19.20	
95% CI of the absolute risk difference	(-15.57, 16.61)	(-35.18, -3.21)	
p-value	0.9495	0.0556	
p-value of Breslow-Day Test for Homogeneity [3]	0.9096	0.9798	

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.8)	1 (4.0)	18 (10.1)
No	40 (95.2)	24 (96.0)	161 (89.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.24	2.68	
95% CI of the inverse odds ratio	(0.50, 10.03)	(0.34, 21.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.11	2.51	
95% CI of the inverse risk ratio	(0.51, 8.75)	(0.35, 18.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.29	-6.06	
95% CI of the absolute risk difference	(-13.10, 2.51)	(-14.91, 2.80)	
p-value	0.2818	0.3291	
p-value of Breslow-Day Test for Homogeneity [3]	0.1524	0.1701	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (21.4)	6 (24.0)	43 (24.0)
No	33 (78.6)	19 (76.0)	136 (76.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.00	
95% CI of the inverse odds ratio	(0.51, 2.61)	(0.38, 2.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	1.00	
95% CI of the inverse risk ratio	(0.59, 2.12)	(0.48, 2.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.59	-0.02	
95% CI of the absolute risk difference	(-16.49, 11.30)	(-17.90, 17.85)	
p-value	0.7214	0.9980	
p-value of Breslow-Day Test for Homogeneity [3]	0.2134	0.6039	

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (7.1)	1 (4.0)	18 (10.1)
No	39 (92.9)	24 (96.0)	161 (89.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	2.68	
95% CI of the inverse odds ratio	(0.41, 5.18)	(0.34, 21.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.41	2.51	
95% CI of the inverse risk ratio	(0.43, 4.56)	(0.35, 18.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.91	-6.06	
95% CI of the absolute risk difference	(-11.86, 6.04)	(-14.91, 2.80)	
p-value	0.5623	0.3291	
p-value of Breslow-Day Test for Homogeneity [3]	0.1845	0.2042	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (14.3)	5 (20.0)	46 (25.7)
No	36 (85.7)	20 (80.0)	133 (74.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.08	1.38	
95% CI of the inverse odds ratio	(0.82, 5.24)	(0.49, 3.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.80	1.28	
95% CI of the inverse risk ratio	(0.82, 3.93)	(0.56, 2.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-11.41	-5.70	
95% CI of the absolute risk difference	(-23.78, 0.96)	(-22.63, 11.24)	
p-value	0.1166	0.5377	
p-value of Breslow-Day Test for Homogeneity [3]	0.0206	0.0377	

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.8)	3 (12.0)	25 (14.0)
No	40 (95.2)	22 (88.0)	154 (86.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.25	1.19	
95% CI of the inverse odds ratio	(0.74, 14.29)	(0.33, 4.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.93	1.16	
95% CI of the inverse risk ratio	(0.72, 11.90)	(0.38, 3.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.20	-1.97	
95% CI of the absolute risk difference	(-17.41, -1.00)	(-15.68, 11.75)	
p-value	0.1011	0.7890	
p-value of Breslow-Day Test for Homogeneity [3]	0.3503	0.7527	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (31.0)	5 (20.0)	52 (29.1)
No	29 (69.0)	20 (80.0)	127 (70.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.64	
95% CI of the inverse odds ratio	(0.44, 1.89)	(0.58, 4.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.45	
95% CI of the inverse risk ratio	(0.57, 1.56)	(0.64, 3.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.90	-9.05	
95% CI of the absolute risk difference	(-13.58, 17.38)	(-26.08, 7.98)	
p-value	0.8076	0.3448	
p-value of Breslow-Day Test for Homogeneity [3]	0.4739	0.8808	

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (7.1)	5 (20.0)	21 (11.7)
No	39 (92.9)	20 (80.0)	158 (88.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.73	0.53	
95% CI of the inverse odds ratio	(0.49, 6.09)	(0.18, 1.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.64	0.59	
95% CI of the inverse risk ratio	(0.51, 5.25)	(0.24, 1.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.59	8.27	
95% CI of the absolute risk difference	(-13.69, 4.52)	(-8.10, 24.64)	
p-value	0.3897	0.2455	
p-value of Breslow-Day Test for Homogeneity [3]	0.4256	0.5196	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (23.8)	8 (32.0)	55 (30.7)
No	32 (76.2)	17 (68.0)	124 (69.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	0.94	
95% CI of the inverse odds ratio	(0.65, 3.09)	(0.38, 2.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	0.96	
95% CI of the inverse risk ratio	(0.72, 2.31)	(0.52, 1.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.92	1.27	
95% CI of the absolute risk difference	(-21.46, 7.63)	(-18.22, 20.77)	
p-value	0.3760	0.8973	
p-value of Breslow-Day Test for Homogeneity [3]	0.0688	0.2551	

AMNOG Table SE23.13.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (21.4)	4 (16.0)	30 (16.8)
No	33 (78.6)	21 (84.0)	149 (83.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.06	
95% CI of the inverse odds ratio	(0.32, 1.70)	(0.34, 3.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.05	
95% CI of the inverse risk ratio	(0.40, 1.52)	(0.40, 2.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.67	-0.76	
95% CI of the absolute risk difference	(-8.89, 18.23)	(-16.14, 14.62)	
p-value	0.4750	0.9239	
p-value of Breslow-Day Test for Homogeneity [3]	0.2759	0.6677	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (33.3)	9 (36.0)	60 (33.5)
No	28 (66.7)	16 (64.0)	119 (66.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.90	
95% CI of the inverse odds ratio	(0.49, 2.06)	(0.37, 2.15)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	0.93	
95% CI of the inverse risk ratio	(0.63, 1.62)	(0.53, 1.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.19	2.48	
95% CI of the absolute risk difference	(-16.03, 15.66)	(-17.57, 22.53)	
p-value	0.9816	0.8060	
p-value of Breslow-Day Test for Homogeneity [3]	0.3288	0.1332	

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
CLDQ-NASH						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	5.06 (1.16)	5.44 (0.97)	5.17 (1.19)			
Median	5.20	5.60	5.40			
IQR: Q1, Q3	4.10, 6.10	4.60, 6.20	4.30, 6.20			
Min, Max	2.8, 6.8	2.9, 6.7	2.4, 7.0			
Week 24						
m	47	39	87			
n	46	38	85	43	34	81
Mean (SD/SE)	5.21 (1.03)	5.28 (1.01)	5.39 (1.11)	0.19 (0.13)	-0.14 (0.09)	0.22 (0.09)
Median	5.25	5.35	5.70	0.10	-0.20	0.20
IQR: Q1, Q3	4.40, 6.10	4.60, 6.10	4.50, 6.30	-0.20, 0.70	-0.40, 0.20	-0.20, 0.60
Min, Max	2.9, 6.9	3.2, 6.8	2.3, 7.0	-1.8, 2.5	-1.4, 1.3	-2.3, 3.0
Week 52						
m	45	35	81			
n	38	32	73	35	29	70
Mean (SD/SE)	5.23 (1.17)	5.28 (0.91)	5.32 (1.06)	0.11 (0.14)	-0.21 (0.12)	0.13 (0.09)
Median	5.30	5.40	5.60	0	-0.10	0.05
IQR: Q1, Q3	4.50, 6.20	4.60, 5.80	4.50, 6.10	-0.10, 0.50	-0.60, 0.10	-0.20, 0.50
Min, Max	1.9, 6.8	3.2, 6.9	2.8, 6.9	-2.2, 2.7	-1.5, 1.8	-1.5, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Abdominal Symptoms						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	5.21 (1.48)	5.81 (1.23)	5.26 (1.59)			
Median	5.70	6.00	5.70			
IQR: Q1, Q3	4.00, 6.30	5.30, 7.00	4.00, 6.70			
Min, Max	2.3, 7.0	2.0, 7.0	1.3, 7.0			
Week 24						
m	47	39	87			
n	46	38	85	43	34	81
Mean (SD/SE)	5.47 (1.31)	5.44 (1.48)	5.49 (1.63)	0.23 (0.20)	-0.22 (0.18)	0.18 (0.13)
Median	5.50	5.70	6.00	0	0	0
IQR: Q1, Q3	4.30, 6.70	4.70, 6.70	4.70, 7.00	-0.60, 1.00	-0.70, 0.30	-0.30, 1.00
Min, Max	2.7, 7.0	1.3, 7.0	1.0, 7.0	-3.0, 3.0	-2.7, 2.0	-3.0, 4.0
Week 52						
m	45	35	81			
n	38	32	73	35	29	70
Mean (SD/SE)	5.45 (1.50)	5.78 (1.08)	5.38 (1.36)	0.14 (0.23)	-0.06 (0.17)	0.04 (0.14)
Median	5.50	5.85	5.70	0	0	0
IQR: Q1, Q3	4.70, 7.00	5.15, 6.70	4.70, 6.30	-1.00, 1.00	-0.30, 0.00	-0.70, 0.70
Min, Max	1.0, 7.0	2.3, 7.0	1.3, 7.0	-2.0, 3.7	-1.7, 2.7	-3.7, 4.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Activity						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	4.98 (1.40)	5.51 (1.27)	5.23 (1.49)			
Median	5.20	5.60	5.60			
IQR: Q1, Q3	4.00, 6.00	5.00, 6.60	4.20, 6.60			
Min, Max	2.2, 7.0	2.8, 7.0	1.8, 7.0			
Week 24						
m	47	39	87			
n	46	38	85	43	34	81
Mean (SD/SE)	5.20 (1.43)	5.43 (1.29)	5.46 (1.49)	0.23 (0.15)	-0.11 (0.12)	0.23 (0.11)
Median	5.50	5.70	6.00	0.20	-0.20	0
IQR: Q1, Q3	3.80, 6.40	4.80, 6.40	4.40, 6.80	-0.40, 0.80	-0.60, 0.20	-0.20, 0.60
Min, Max	2.2, 7.0	2.4, 7.0	1.2, 7.0	-1.8, 2.8	-1.4, 1.2	-2.0, 3.2
Week 52						
m	45	35	81			
n	38	32	73	35	29	70
Mean (SD/SE)	5.23 (1.50)	5.37 (1.11)	5.30 (1.44)	0.06 (0.17)	-0.23 (0.15)	0.04 (0.11)
Median	5.30	5.60	5.80	0.20	0	0
IQR: Q1, Q3	4.40, 6.60	4.70, 6.20	4.20, 6.40	-0.40, 0.60	-1.00, 0.40	-0.40, 0.60
Min, Max	1.8, 7.0	3.0, 7.0	2.0, 7.0	-3.4, 3.0	-2.0, 1.8	-1.6, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Emotional Health						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	5.19 (1.23)	5.63 (1.25)	5.36 (1.28)			
Median	5.30	6.10	5.60			
IQR: Q1, Q3	4.60, 6.10	4.90, 6.60	4.70, 6.30			
Min, Max	2.0, 7.0	2.0, 7.0	1.9, 7.0			
Week 24						
m	47	39	87			
n	46	38	85	43	34	81
Mean (SD/SE)	5.22 (1.19)	5.47 (1.13)	5.55 (1.18)	0.11 (0.15)	-0.14 (0.12)	0.22 (0.12)
Median	5.10	5.40	5.80	0.10	-0.20	0.20
IQR: Q1, Q3	4.40, 6.30	4.70, 6.40	5.00, 6.40	-0.30, 0.90	-0.50, 0.00	-0.20, 0.70
Min, Max	2.3, 6.9	2.6, 7.0	2.2, 7.0	-2.8, 2.5	-1.5, 2.4	-2.9, 3.3
Week 52						
m	45	35	81			
n	38	32	73	35	29	70
Mean (SD/SE)	5.25 (0.96)	5.52 (1.11)	5.58 (1.03)	0.09 (0.15)	-0.18 (0.16)	0.17 (0.11)
Median	5.20	5.55	5.80	0	-0.20	0.05
IQR: Q1, Q3	4.60, 6.10	4.85, 6.40	4.70, 6.60	-0.40, 0.30	-0.80, 0.20	-0.40, 0.60
Min, Max	3.4, 7.0	2.7, 7.0	2.7, 7.0	-1.9, 2.5	-1.4, 2.0	-1.7, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Fatigue						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	4.55 (1.48)	4.76 (1.35)	4.54 (1.48)			
Median	4.70	5.20	4.90			
IQR: Q1, Q3	3.50, 5.80	3.80, 5.70	3.30, 5.70			
Min, Max	1.2, 7.0	1.5, 6.7	1.0, 7.0			
Week 24						
m	47	39	87			
n	46	38	85	43	34	81
Mean (SD/SE)	4.65 (1.44)	4.49 (1.25)	4.66 (1.40)	0.14 (0.19)	-0.39 (0.17)	0.14 (0.13)
Median	4.50	4.60	4.80	0.20	-0.15	0.20
IQR: Q1, Q3	3.50, 5.80	3.50, 5.50	3.30, 6.00	-0.80, 0.70	-0.90, 0.20	-0.50, 0.60
Min, Max	2.2, 7.0	1.8, 6.7	1.8, 7.0	-1.7, 4.1	-4.2, 0.9	-3.3, 3.7
Week 52						
m	45	35	81			
n	38	32	73	35	29	70
Mean (SD/SE)	4.69 (1.51)	4.20 (1.36)	4.60 (1.32)	0.13 (0.17)	-0.64 (0.21)	0.05 (0.12)
Median	5.00	3.80	4.50	0	-0.50	-0.10
IQR: Q1, Q3	3.70, 6.00	3.20, 5.25	3.50, 5.70	-0.30, 0.50	-1.50, 0.30	-0.50, 0.50
Min, Max	1.0, 7.0	1.5, 6.8	1.8, 7.0	-2.0, 3.4	-2.8, 1.2	-2.4, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Systemic Symptoms						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	4.98 (1.28)	5.23 (1.11)	4.99 (1.38)			
Median	5.30	5.30	5.30			
IQR: Q1, Q3	3.70, 6.00	4.70, 6.00	4.20, 6.00			
Min, Max	2.5, 7.0	2.7, 6.8	1.7, 7.0			
Week 24						
m	47	39	87			
n	46	38	85	43	34	81
Mean (SD/SE)	5.00 (1.16)	4.95 (1.29)	5.18 (1.32)	0.06 (0.15)	-0.30 (0.12)	0.13 (0.11)
Median	5.20	5.00	5.70	0	-0.30	0.10
IQR: Q1, Q3	4.20, 6.00	4.00, 6.00	4.30, 6.20	-0.60, 0.60	-0.70, 0.10	-0.30, 0.60
Min, Max	2.3, 7.0	2.2, 7.0	1.5, 7.0	-1.6, 3.5	-2.0, 1.2	-2.5, 3.7
Week 52						
m	45	35	81			
n	38	32	73	35	29	70
Mean (SD/SE)	4.92 (1.37)	4.98 (1.25)	4.98 (1.46)	-0.17 (0.13)	-0.29 (0.15)	0.00 (0.11)
Median	5.10	4.80	5.00	-0.10	-0.30	0
IQR: Q1, Q3	4.30, 5.80	4.25, 5.90	4.00, 6.30	-0.60, 0.30	-0.70, 0.20	-0.50, 0.50
Min, Max	1.3, 7.0	2.7, 7.0	2.0, 7.0	-2.0, 2.0	-2.5, 1.3	-2.7, 2.7

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Worry						
Baseline						
m	48	44	95			
n	45	39	90			
Mean (SD)	5.44 (1.36)	5.71 (1.40)	5.63 (1.34)			
Median	5.70	6.00	6.10			
IQR: Q1, Q3	4.60, 6.60	4.90, 6.90	4.90, 6.70			
Min, Max	2.0, 7.0	2.1, 7.0	1.9, 7.0			
Week 24						
m	47	39	87			
n	46	38	85	43	34	81
Mean (SD/SE)	5.78 (1.25)	5.88 (1.32)	6.03 (1.18)	0.39 (0.18)	0.28 (0.17)	0.42 (0.12)
Median	6.30	6.40	6.40	0.30	0	0.30
IQR: Q1, Q3	5.00, 6.70	5.00, 7.00	5.60, 7.00	-0.30, 0.80	-0.30, 0.60	0.00, 0.70
Min, Max	2.0, 7.0	2.0, 7.0	1.9, 7.0	-2.3, 3.3	-1.2, 3.6	-2.0, 3.5
Week 52						
m	45	35	81			
n	38	32	73	35	29	70
Mean (SD/SE)	5.85 (1.42)	5.86 (1.35)	6.09 (1.19)	0.41 (0.19)	0.17 (0.21)	0.44 (0.13)
Median	6.35	6.30	6.40	0.20	0	0.20
IQR: Q1, Q3	5.40, 7.00	4.90, 7.00	5.70, 7.00	-0.10, 1.00	-0.70, 0.60	0.00, 1.00
Min, Max	1.7, 7.0	1.0, 7.0	1.4, 7.0	-2.5, 2.4	-1.5, 3.3	-2.5, 3.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
CLDQ-NASH						
Baseline						
m	77	72	128			
n	72	65	115			
Mean (SD)	5.20 (1.21)	5.13 (1.18)	5.20 (1.13)			
Median	5.20	5.40	5.30			
IQR: Q1, Q3	4.35, 6.25	4.30, 6.00	4.40, 6.10			
Min, Max	1.9, 7.0	2.1, 7.0	2.0, 7.0			
Week 24						
m	76	68	125			
n	72	64	115	69	59	106
Mean (SD/SE)	5.19 (1.25)	5.27 (1.02)	5.24 (1.14)	0.01 (0.09)	0.12 (0.08)	0.03 (0.06)
Median	5.50	5.35	5.20	0	0.10	0
IQR: Q1, Q3	4.45, 6.20	4.45, 6.10	4.50, 6.20	-0.20, 0.40	-0.30, 0.50	-0.30, 0.30
Min, Max	2.1, 7.0	2.7, 6.8	2.4, 7.0	-2.6, 1.7	-1.6, 1.6	-1.6, 2.4
Week 52						
m	70	57	120			
n	67	51	101	63	49	93
Mean (SD/SE)	5.41 (1.11)	5.26 (1.11)	5.28 (1.20)	0.12 (0.07)	0.07 (0.10)	-0.01 (0.07)
Median	5.60	5.50	5.40	0.10	0	-0.10
IQR: Q1, Q3	4.70, 6.40	4.60, 6.10	4.40, 6.30	-0.20, 0.50	-0.30, 0.50	-0.40, 0.40
Min, Max	2.4, 7.0	2.2, 6.8	1.9, 7.0	-1.9, 1.4	-2.4, 1.5	-2.2, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=77)	Visit Result MGL-3196 100 mg (N=72)	Visit Result Placebo (N=128)	Change from Baseline MGL-3196 80 mg (N=77)	Change from Baseline MGL-3196 100 mg (N=72)	Change from Baseline Placebo (N=128)
Abdominal Symptoms						
Baseline						
m	77	72	128			
n	72	65	115			
Mean (SD)	5.17 (1.72)	5.42 (1.41)	5.21 (1.44)			
Median	5.50	5.70	5.30			
IQR: Q1, Q3	4.00, 7.00	4.30, 6.70	4.30, 6.30			
Min, Max	1.3, 7.0	1.7, 7.0	1.7, 7.0			
Week 24						
m	76	68	125			
n	72	64	115	69	59	106
Mean (SD/SE)	5.21 (1.58)	5.48 (1.39)	5.39 (1.45)	0.06 (0.14)	0.09 (0.15)	0.16 (0.12)
Median	5.30	5.70	5.70	0	0	0
IQR: Q1, Q3	4.50, 6.70	4.70, 6.70	4.30, 7.00	-0.30, 0.70	-0.30, 0.70	-0.40, 0.70
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0	-4.7, 3.3	-3.3, 2.4	-3.0, 4.0
Week 52						
m	70	57	120			
n	67	51	101	63	49	93
Mean (SD/SE)	5.55 (1.36)	5.56 (1.32)	5.43 (1.50)	0.25 (0.16)	0.00 (0.14)	0.07 (0.13)
Median	5.70	5.70	5.70	0	0	0
IQR: Q1, Q3	4.70, 6.70	5.00, 6.70	4.70, 6.70	-0.30, 1.00	-0.40, 0.70	-0.40, 1.00
Min, Max	2.0, 7.0	1.7, 7.0	1.0, 7.0	-3.3, 4.0	-2.6, 2.0	-4.6, 2.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Activity						
Baseline						
m	77	72	128			
n	72	65	115			
Mean (SD)	5.30 (1.40)	5.20 (1.36)	5.45 (1.32)			
Median	5.30	5.60	5.40			
IQR: Q1, Q3	4.30, 6.60	4.40, 6.40	4.40, 6.80			
Min, Max	1.8, 7.0	2.0, 7.0	1.8, 7.0			
Week 24						
m	76	68	125			
n	72	64	115	69	59	106
Mean (SD/SE)	5.17 (1.53)	5.44 (1.25)	5.41 (1.33)	-0.14 (0.11)	0.22 (0.12)	-0.06 (0.09)
Median	5.60	5.80	5.80	0	0.20	0
IQR: Q1, Q3	4.40, 6.40	4.60, 6.40	4.60, 6.60	-0.80, 0.20	-0.40, 0.80	-0.80, 0.60
Min, Max	1.2, 7.0	2.4, 7.0	2.2, 7.0	-3.2, 1.8	-2.4, 3.2	-2.8, 2.6
Week 52						
m	70	57	120			
n	67	51	101	63	49	93
Mean (SD/SE)	5.37 (1.45)	5.20 (1.35)	5.39 (1.39)	-0.03 (0.13)	-0.03 (0.15)	-0.21 (0.10)
Median	5.80	5.40	5.60	0	0.20	0
IQR: Q1, Q3	4.40, 6.60	4.20, 6.20	4.40, 6.60	-0.60, 0.40	-0.40, 0.80	-0.80, 0.20
Min, Max	1.2, 7.0	1.6, 7.0	1.4, 7.0	-4.4, 2.8	-2.8, 1.2	-2.4, 2.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=77)	Visit Result MGL-3196 100 mg (N=72)	Visit Result Placebo (N=128)	Change from Baseline MGL-3196 80 mg (N=77)	Change from Baseline MGL-3196 100 mg (N=72)	Change from Baseline Placebo (N=128)
Emotional Health						
Baseline						
m	77	72	128			
n	72	65	115			
Mean (SD)	5.36 (1.22)	5.22 (1.34)	5.37 (1.28)			
Median	5.60	5.30	5.60			
IQR: Q1, Q3	4.40, 6.35	4.40, 6.20	4.60, 6.30			
Min, Max	1.9, 7.0	2.1, 7.0	1.8, 7.0			
Week 24						
m	76	68	125			
n	72	64	115	69	59	106
Mean (SD/SE)	5.34 (1.31)	5.31 (1.28)	5.30 (1.35)	0.00 (0.09)	0.03 (0.08)	-0.09 (0.08)
Median	5.65	5.35	5.70	0	0	0
IQR: Q1, Q3	4.30, 6.30	4.65, 6.30	4.30, 6.40	-0.40, 0.40	-0.30, 0.40	-0.50, 0.30
Min, Max	2.0, 7.0	1.0, 7.0	1.9, 7.0	-2.2, 2.1	-1.5, 1.4	-2.4, 2.4
Week 52						
m	70	57	120			
n	67	51	101	63	49	93
Mean (SD/SE)	5.47 (1.17)	5.35 (1.32)	5.33 (1.41)	-0.01 (0.08)	0.08 (0.11)	-0.12 (0.09)
Median	5.80	5.70	5.70	-0.10	0	0
IQR: Q1, Q3	4.70, 6.30	4.40, 6.30	4.60, 6.40	-0.60, 0.40	-0.30, 0.40	-0.60, 0.30
Min, Max	2.8, 7.0	1.0, 7.0	1.3, 7.0	-1.2, 1.6	-1.9, 2.9	-2.0, 2.5

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Fatigue						
Baseline						
m	77	72	128			
n	72	65	115			
Mean (SD)	4.69 (1.53)	4.40 (1.51)	4.66 (1.47)			
Median	5.00	4.70	4.80			
IQR: Q1, Q3	3.40, 6.00	3.30, 5.50	3.50, 5.80			
Min, Max	1.2, 7.0	1.2, 7.0	1.2, 7.0			
Week 24						
m	76	68	125			
n	72	64	115	69	59	106
Mean (SD/SE)	4.69 (1.59)	4.51 (1.34)	4.66 (1.55)	-0.01 (0.12)	0.10 (0.12)	-0.02 (0.10)
Median	4.75	4.75	4.70	0.10	0	0
IQR: Q1, Q3	3.40, 6.00	3.70, 5.50	3.30, 6.00	-0.50, 0.50	-0.40, 0.60	-0.70, 0.50
Min, Max	1.3, 7.0	1.5, 6.7	1.2, 7.0	-2.7, 3.2	-3.1, 2.3	-2.5, 2.3
Week 52						
m	70	57	120			
n	67	51	101	63	49	93
Mean (SD/SE)	4.92 (1.50)	4.60 (1.49)	4.75 (1.57)	0.13 (0.14)	0.10 (0.17)	0.04 (0.11)
Median	5.20	4.80	5.00	0.10	0	0
IQR: Q1, Q3	3.50, 6.20	3.80, 5.80	3.70, 6.00	-0.40, 0.60	-0.40, 1.00	-0.60, 0.70
Min, Max	1.7, 7.0	1.2, 6.8	1.0, 7.0	-2.4, 4.0	-4.4, 2.5	-3.8, 2.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Systemic Symptoms						
Baseline						
m	77	72	128			
n	72	65	115			
Mean (SD)	5.12 (1.24)	4.95 (1.21)	4.99 (1.25)			
Median	5.30	5.20	5.00			
IQR: Q1, Q3	4.30, 6.10	4.30, 5.80	4.00, 6.00			
Min, Max	1.8, 7.0	1.8, 7.0	2.0, 7.0			
Week 24						
m	76	68	125			
n	72	64	115	69	59	106
Mean (SD/SE)	5.09 (1.25)	4.96 (1.20)	4.96 (1.26)	-0.05 (0.10)	-0.07 (0.10)	-0.09 (0.08)
Median	5.30	5.20	5.00	0	0	0
IQR: Q1, Q3	4.30, 6.00	4.10, 5.80	4.00, 6.00	-0.50, 0.50	-0.50, 0.30	-0.70, 0.50
Min, Max	2.2, 7.0	1.8, 7.0	2.0, 7.0	-2.0, 2.1	-1.8, 2.2	-2.0, 2.5
Week 52						
m	70	57	120			
n	67	51	101	63	49	93
Mean (SD/SE)	5.25 (1.23)	4.97 (1.21)	5.00 (1.36)	0.01 (0.09)	-0.09 (0.12)	-0.05 (0.09)
Median	5.50	5.20	5.00	0	0	-0.20
IQR: Q1, Q3	4.30, 6.20	4.20, 5.80	4.20, 6.20	-0.50, 0.40	-0.50, 0.30	-0.60, 0.50
Min, Max	2.3, 7.0	1.5, 7.0	1.3, 7.0	-1.5, 2.3	-2.3, 2.0	-1.8, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Worry						
Baseline						
m	77	72	128			
n	72	65	115			
Mean (SD)	5.54 (1.50)	5.55 (1.54)	5.48 (1.48)			
Median	5.90	6.00	5.90			
IQR: Q1, Q3	5.00, 6.80	4.60, 6.90	4.70, 6.70			
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0			
Week 24						
m	76	68	125			
n	72	64	115	69	59	106
Mean (SD/SE)	5.65 (1.54)	5.87 (1.35)	5.71 (1.48)	0.19 (0.12)	0.34 (0.13)	0.28 (0.10)
Median	6.00	6.30	6.10	0	0.10	0
IQR: Q1, Q3	5.20, 6.80	5.05, 7.00	5.00, 7.00	-0.10, 0.60	-0.10, 0.80	-0.20, 0.60
Min, Max	1.6, 7.0	1.0, 7.0	1.0, 7.0	-3.1, 3.1	-2.6, 3.6	-2.6, 3.5
Week 52						
m	70	57	120			
n	67	51	101	63	49	93
Mean (SD/SE)	5.90 (1.27)	5.90 (1.51)	5.76 (1.43)	0.34 (0.11)	0.42 (0.17)	0.21 (0.12)
Median	6.40	6.30	6.30	0.20	0	0
IQR: Q1, Q3	5.30, 7.00	5.40, 7.00	5.00, 7.00	-0.20, 0.70	0.00, 1.20	-0.20, 0.60
Min, Max	1.9, 7.0	1.0, 7.0	1.0, 7.0	-1.1, 3.8	-3.3, 3.6	-2.7, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
CLDQ-NASH						
Baseline						
m	30	22	63			
n	30	21	57			
Mean (SD)	5.43 (1.14)	5.37 (0.94)	5.24 (1.01)			
Median	5.55	5.60	5.10			
IQR: Q1, Q3	5.00, 6.20	4.80, 6.10	4.50, 6.20			
Min, Max	2.0, 6.8	3.3, 6.7	2.5, 6.9			
Week 24						
m	28	22	60			
n	27	22	54	27	21	49
Mean (SD/SE)	5.69 (0.92)	5.05 (0.99)	5.47 (0.99)	0.14 (0.08)	-0.37 (0.12)	0.16 (0.10)
Median	5.80	5.40	5.65	0.10	-0.50	0.10
IQR: Q1, Q3	5.10, 6.40	4.10, 5.80	5.10, 6.20	-0.20, 0.40	-0.80, 0.10	-0.30, 0.60
Min, Max	2.8, 7.0	3.1, 6.2	2.4, 6.9	-0.8, 1.0	-1.4, 0.7	-1.6, 2.1
Week 52						
m	27	22	54			
n	25	20	45	25	19	40
Mean (SD/SE)	5.50 (0.98)	5.51 (0.92)	5.50 (0.97)	-0.12 (0.13)	0.08 (0.11)	0.11 (0.10)
Median	5.70	5.60	5.60	0	0.10	0.05
IQR: Q1, Q3	4.70, 6.20	4.95, 6.20	5.10, 6.30	-0.50, 0.30	-0.10, 0.30	-0.25, 0.50
Min, Max	3.0, 6.7	3.7, 6.7	2.5, 6.8	-1.7, 1.0	-1.0, 1.1	-1.7, 1.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Abdominal Symptoms						
Baseline						
m	30	22	63			
n	30	21	57			
Mean (SD)	5.49 (1.58)	5.64 (1.20)	5.07 (1.65)			
Median	6.00	6.00	5.30			
IQR: Q1, Q3	4.30, 6.30	4.30, 7.00	3.70, 6.70			
Min, Max	1.0, 7.0	3.7, 7.0	1.0, 7.0			
Week 24						
m	28	22	60			
n	27	22	54	27	21	49
Mean (SD/SE)	5.85 (1.21)	5.06 (1.69)	5.57 (1.27)	0.18 (0.18)	-0.61 (0.30)	0.41 (0.19)
Median	6.30	5.35	5.85	0	-0.30	0
IQR: Q1, Q3	5.00, 7.00	3.30, 6.70	4.70, 6.70	-0.30, 0.70	-1.00, 0.00	-0.30, 1.00
Min, Max	3.3, 7.0	2.0, 7.0	3.0, 7.0	-1.7, 2.7	-4.0, 2.0	-2.3, 3.7
Week 52						
m	27	22	54			
n	25	20	45	25	19	40
Mean (SD/SE)	5.62 (1.51)	5.29 (1.30)	5.49 (1.33)	-0.10 (0.24)	-0.34 (0.24)	0.20 (0.18)
Median	6.00	5.30	5.70	0	0	0
IQR: Q1, Q3	5.00, 7.00	4.15, 6.35	4.70, 6.70	-0.70, 0.70	-0.60, 0.00	-0.50, 1.30
Min, Max	1.0, 7.0	2.7, 7.0	1.0, 7.0	-2.7, 3.0	-3.0, 1.3	-2.0, 2.3

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Activity						
Baseline						
m	30	22	63			
n	30	21	57			
Mean (SD)	5.56 (1.30)	5.41 (1.30)	5.44 (1.40)			
Median	5.90	5.80	5.80			
IQR: Q1, Q3	4.60, 6.60	4.80, 6.40	4.60, 6.40			
Min, Max	2.8, 7.0	1.8, 7.0	1.4, 7.0			
Week 24						
m	28	22	60			
n	27	22	54	27	21	49
Mean (SD/SE)	5.70 (1.15)	5.20 (1.28)	5.61 (1.17)	0.04 (0.14)	-0.30 (0.19)	0.13 (0.15)
Median	5.80	5.70	5.80	0	-0.20	0.20
IQR: Q1, Q3	4.80, 6.60	4.20, 6.00	5.00, 6.60	-0.40, 0.40	-1.00, 0.40	-0.40, 0.60
Min, Max	2.2, 7.0	2.4, 7.0	2.6, 7.0	-1.6, 1.6	-2.2, 1.4	-3.0, 2.6
Week 52						
m	27	22	54			
n	25	20	45	25	19	40
Mean (SD/SE)	5.47 (1.53)	5.83 (1.03)	5.60 (1.37)	-0.23 (0.27)	0.31 (0.20)	-0.10 (0.17)
Median	5.80	6.20	6.00	0	0.20	0
IQR: Q1, Q3	5.00, 6.60	5.10, 6.80	5.00, 6.60	-0.60, 0.40	-0.20, 1.20	-0.40, 0.50
Min, Max	1.0, 7.0	3.4, 7.0	1.6, 7.0	-3.6, 2.0	-1.4, 2.0	-3.4, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=30)	Visit Result: MGL-3196 100 mg (N=22)	Visit Result: Placebo (N=63)	Change from Baseline: MGL-3196 80 mg (N=30)	Change from Baseline: MGL-3196 100 mg (N=22)	Change from Baseline: Placebo (N=63)
Emotional Health						
Baseline						
m	30	22	63			
n	30	21	57			
Mean (SD)	5.53 (1.27)	5.35 (1.10)	5.47 (0.97)			
Median	5.75	5.60	5.70			
IQR: Q1, Q3	5.10, 6.20	5.00, 6.10	4.90, 6.20			
Min, Max	1.3, 7.0	2.2, 6.7	3.4, 7.0			
Week 24						
m	28	22	60			
n	27	22	54	27	21	49
Mean (SD/SE)	5.91 (1.02)	5.00 (1.16)	5.60 (1.06)	0.28 (0.11)	-0.40 (0.21)	0.04 (0.12)
Median	6.10	5.40	5.85	0.20	-0.30	0
IQR: Q1, Q3	5.60, 6.60	4.10, 5.90	5.00, 6.40	0.00, 0.70	-0.80, 0.00	-0.50, 0.50
Min, Max	2.2, 7.0	2.3, 6.7	2.4, 6.9	-1.0, 1.3	-3.1, 1.9	-1.9, 1.8
Week 52						
m	27	22	54			
n	25	20	45	25	19	40
Mean (SD/SE)	5.72 (0.90)	5.63 (0.97)	5.63 (1.04)	0.04 (0.21)	0.17 (0.16)	0.06 (0.11)
Median	5.90	5.80	5.90	-0.20	0.20	0
IQR: Q1, Q3	5.30, 6.30	4.75, 6.40	5.00, 6.40	-0.50, 0.70	-0.50, 0.70	-0.25, 0.35
Min, Max	3.9, 6.9	3.7, 6.9	3.2, 7.0	-1.7, 2.9	-0.7, 1.8	-1.4, 1.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=63)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=63)
Fatigue						
Baseline						
m	30	22	63			
n	30	21	57			
Mean (SD)	5.00 (1.47)	4.87 (1.22)	4.53 (1.40)			
Median	5.35	5.00	4.80			
IQR: Q1, Q3	4.30, 6.20	4.50, 5.30	3.50, 5.80			
Min, Max	1.5, 6.8	2.2, 7.0	1.3, 6.8			
Week 24						
m	28	22	60			
n	27	22	54	27	21	49
Mean (SD/SE)	5.03 (1.52)	4.58 (1.27)	4.76 (1.39)	-0.09 (0.18)	-0.37 (0.21)	0.10 (0.18)
Median	5.30	4.60	4.90	-0.20	-0.30	0
IQR: Q1, Q3	4.30, 6.20	3.70, 5.30	3.80, 5.80	-0.70, 0.30	-0.90, 0.20	-0.60, 0.80
Min, Max	1.5, 6.8	1.7, 6.8	1.5, 6.8	-2.4, 2.7	-2.4, 1.9	-3.8, 2.9
Week 52						
m	27	22	54			
n	25	20	45	25	19	40
Mean (SD/SE)	4.83 (1.56)	5.00 (1.32)	4.71 (1.33)	-0.34 (0.16)	0.03 (0.21)	-0.02 (0.16)
Median	5.20	5.10	5.20	-0.20	-0.10	-0.10
IQR: Q1, Q3	4.20, 6.00	4.50, 5.70	4.00, 5.70	-0.70, 0.20	-0.50, 0.50	-0.65, 0.50
Min, Max	1.8, 6.8	1.5, 7.0	1.3, 6.8	-2.3, 0.9	-2.3, 2.0	-2.6, 2.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=63)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=63)
Systemic Symptoms						
Baseline						
m	30	22	63			
n	30	21	57			
Mean (SD)	5.39 (1.26)	5.23 (1.29)	5.19 (1.04)			
Median	5.65	5.20	5.20			
IQR: Q1, Q3	5.20, 6.30	4.70, 6.50	4.50, 6.00			
Min, Max	2.0, 7.0	2.5, 6.8	2.7, 7.0			
Week 24						
m	28	22	60			
n	27	22	54	27	21	49
Mean (SD/SE)	5.54 (1.22)	5.02 (1.06)	5.35 (1.07)	0.03 (0.12)	-0.26 (0.17)	0.04 (0.12)
Median	5.70	5.00	5.40	0	-0.20	0
IQR: Q1, Q3	5.00, 6.70	4.20, 6.00	4.80, 6.30	-0.30, 0.30	-0.70, 0.30	-0.40, 0.50
Min, Max	2.7, 7.0	3.2, 6.8	2.3, 7.0	-1.3, 1.4	-1.9, 1.0	-2.5, 1.7
Week 52						
m	27	22	54			
n	25	20	45	25	19	40
Mean (SD/SE)	5.26 (1.12)	5.24 (1.21)	5.38 (1.10)	-0.38 (0.17)	-0.02 (0.18)	0.03 (0.13)
Median	5.50	5.30	5.70	-0.30	0.20	0
IQR: Q1, Q3	4.20, 6.20	4.10, 6.50	4.70, 6.30	-1.00, 0.00	-0.50, 0.30	-0.35, 0.50
Min, Max	3.3, 7.0	3.2, 7.0	2.8, 7.0	-1.8, 1.7	-2.3, 1.3	-2.2, 1.7

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=63)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=63)
Worry						
Baseline						
m	30	22	63			
n	30	21	57			
Mean (SD)	5.59 (1.14)	5.68 (1.39)	5.73 (1.27)			
Median	5.70	6.10	6.00			
IQR: Q1, Q3	5.00, 6.40	5.30, 6.70	5.10, 6.90			
Min, Max	2.9, 7.0	1.9, 7.0	2.1, 7.0			
Week 24						
m	28	22	60			
n	27	22	54	27	21	49
Mean (SD/SE)	6.10 (0.92)	5.36 (1.17)	5.94 (1.32)	0.42 (0.18)	-0.32 (0.18)	0.23 (0.10)
Median	6.40	5.60	6.35	0.20	-0.20	0.10
IQR: Q1, Q3	5.70, 6.70	5.00, 6.00	5.70, 6.90	0.00, 1.00	-0.80, 0.00	0.00, 0.70
Min, Max	3.1, 7.0	2.3, 6.9	2.1, 7.0	-1.2, 2.8	-1.7, 1.9	-1.4, 1.9
Week 52						
m	27	22	54			
n	25	20	45	25	19	40
Mean (SD/SE)	6.06 (0.93)	6.11 (0.96)	6.16 (1.11)	0.30 (0.24)	0.40 (0.26)	0.41 (0.11)
Median	6.10	6.05	6.70	0	0	0.25
IQR: Q1, Q3	5.30, 7.00	5.35, 7.00	5.60, 7.00	-0.40, 1.10	-0.10, 0.60	0.00, 0.95
Min, Max	3.9, 7.0	3.7, 7.0	3.0, 7.0	-2.0, 3.0	-1.0, 3.5	-1.1, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 1 of 4
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE23.14a.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
CLDQ-NASH			
Week 24			
m	47	39	87
n	43	34	81
Baseline Mean (SD)	5.03 (1.17)	5.45 (0.96)	5.24 (1.19)
Analysis Visit Mean (SD)	5.21 (1.07)	5.31 (0.97)	5.46 (1.08)
LS Mean of Change from Baseline (SE)	0.15 (0.11)	-0.03 (0.13)	0.24 (0.08)
95% CI	(-0.07, 0.37)	(-0.28, 0.22)	(0.08, 0.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.09 (0.13)	-0.27 (0.15)	
95% CI	(-0.35, 0.18)	(-0.56, 0.02)	
p-value	0.5177	0.0639	
Corrected Hedge's g Statistics	-0.119	-0.370	
95% CI	(-0.49, 0.25)	(-0.77, 0.03)	
Week 52			
m	45	35	81
n	35	29	70
Baseline Mean (SD)	5.15 (1.16)	5.44 (0.88)	5.22 (1.21)
Analysis Visit Mean (SD)	5.26 (1.21)	5.23 (0.90)	5.34 (1.07)
LS Mean of Change from Baseline (SE)	0.13 (0.12)	-0.17 (0.13)	0.15 (0.08)
95% CI	(-0.10, 0.36)	(-0.42, 0.09)	(-0.02, 0.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.14)	-0.31 (0.15)	
95% CI	(-0.29, 0.25)	(-0.60, -0.02)	
p-value	0.8940	0.0360	
Corrected Hedge's g Statistics	-0.027	-0.451	
95% CI	(-0.43, 0.38)	(-0.89, -0.01)	
Subgroup*Treatment Interaction p-value	0.9200	0.0470	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
CLDQ-NASH			
Week 24			
m	76	68	125
n	69	59	106
Baseline Mean (SD)	5.18 (1.21)	5.12 (1.22)	5.25 (1.11)
Analysis Visit Mean (SD)	5.19 (1.25)	5.24 (1.04)	5.28 (1.16)
LS Mean of Change from Baseline (SE)	0.02 (0.08)	0.10 (0.08)	0.05 (0.06)
95% CI	(-0.13, 0.17)	(-0.07, 0.26)	(-0.07, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.10)	0.05 (0.10)	
95% CI	(-0.23, 0.16)	(-0.16, 0.25)	
p-value	0.7314	0.6587	
Corrected Hedge's g Statistics	-0.051	0.070	
95% CI	(-0.35, 0.25)	(-0.25, 0.39)	
Week 52			
m	70	57	120
n	63	49	93
Baseline Mean (SD)	5.26 (1.17)	5.18 (1.26)	5.31 (1.09)
Analysis Visit Mean (SD)	5.38 (1.09)	5.24 (1.13)	5.30 (1.18)
LS Mean of Change from Baseline (SE)	0.11 (0.08)	0.06 (0.09)	0.05 (0.07)
95% CI	(-0.05, 0.27)	(-0.12, 0.24)	(-0.09, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.07 (0.10)	0.01 (0.11)	
95% CI	(-0.14, 0.27)	(-0.21, 0.23)	
p-value	0.5250	0.9111	
Corrected Hedge's g Statistics	0.101	0.019	
95% CI	(-0.22, 0.42)	(-0.33, 0.37)	
Subgroup*Treatment Interaction p-value	0.9200	0.0470	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
CLDQ-NASH			
Week 24			
m	28	22	60
n	27	21	49
Baseline Mean (SD)	5.55 (0.95)	5.37 (0.94)	5.22 (1.02)
Analysis Visit Mean (SD)	5.69 (0.92)	5.00 (0.98)	5.38 (0.99)
LS Mean of Change from Baseline (SE)	0.19 (0.11)	-0.38 (0.13)	0.12 (0.09)
95% CI	(-0.04, 0.42)	(-0.63, -0.13)	(-0.05, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.07 (0.14)	-0.50 (0.15)	
95% CI	(-0.21, 0.35)	(-0.80, -0.20)	
p-value	0.6149	0.0012	
Corrected Hedge's g Statistics	0.119	-0.832	
95% CI	(-0.35, 0.59)	(-1.36, -0.30)	
Week 52			
m	27	22	54
n	25	19	40
Baseline Mean (SD)	5.62 (1.00)	5.36 (0.97)	5.35 (0.97)
Analysis Visit Mean (SD)	5.50 (0.98)	5.44 (0.90)	5.46 (1.00)
LS Mean of Change from Baseline (SE)	-0.07 (0.12)	0.07 (0.13)	0.10 (0.09)
95% CI	(-0.30, 0.16)	(-0.18, 0.33)	(-0.08, 0.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.17 (0.15)	-0.02 (0.16)	
95% CI	(-0.46, 0.12)	(-0.33, 0.29)	
p-value	0.2513	0.8766	
Corrected Hedge's g Statistics	-0.290	-0.042	
95% CI	(-0.79, 0.21)	(-0.59, 0.50)	
Subgroup*Treatment Interaction p-value	0.9200	0.0470	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Abdominal Symptoms			
Week 24			
m	47	39	87
n	43	34	81
Baseline Mean (SD)	5.21 (1.48)	5.75 (1.29)	5.40 (1.56)
Analysis Visit Mean (SD)	5.44 (1.33)	5.52 (1.49)	5.58 (1.57)
LS Mean of Change from Baseline (SE)	0.20 (0.17)	-0.09 (0.19)	0.19 (0.12)
95% CI	(-0.14, 0.54)	(-0.47, 0.29)	(-0.06, 0.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.21)	-0.27 (0.22)	
95% CI	(-0.40, 0.42)	(-0.72, 0.17)	
p-value	0.9590	0.2247	
Corrected Hedge's g Statistics	0.009	-0.243	
95% CI	(-0.36, 0.38)	(-0.64, 0.16)	
Week 52			
m	45	35	81
n	35	29	70
Baseline Mean (SD)	5.33 (1.44)	5.83 (1.15)	5.37 (1.62)
Analysis Visit Mean (SD)	5.47 (1.56)	5.77 (1.12)	5.41 (1.38)
LS Mean of Change from Baseline (SE)	0.18 (0.18)	0.00 (0.20)	0.06 (0.13)
95% CI	(-0.18, 0.54)	(-0.39, 0.39)	(-0.20, 0.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.12 (0.22)	-0.06 (0.23)	
95% CI	(-0.30, 0.55)	(-0.51, 0.40)	
p-value	0.5754	0.8052	
Corrected Hedge's g Statistics	0.112	-0.053	
95% CI	(-0.29, 0.52)	(-0.49, 0.38)	
Subgroup*Treatment Interaction p-value	0.8688	0.1251	

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Activity			
Week 24			
m	47	39	87
n	43	34	81
Baseline Mean (SD)	4.97 (1.43)	5.57 (1.18)	5.35 (1.45)
Analysis Visit Mean (SD)	5.20 (1.45)	5.46 (1.22)	5.58 (1.42)
LS Mean of Change from Baseline (SE)	0.19 (0.14)	-0.01 (0.15)	0.27 (0.10)
95% CI	(-0.09, 0.46)	(-0.32, 0.29)	(0.07, 0.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.17)	-0.28 (0.18)	
95% CI	(-0.41, 0.24)	(-0.63, 0.07)	
p-value	0.6133	0.1148	
Corrected Hedge's g Statistics	-0.093	-0.314	
95% CI	(-0.46, 0.28)	(-0.72, 0.09)	
Week 52			
m	45	35	81
n	35	29	70
Baseline Mean (SD)	5.19 (1.35)	5.53 (1.12)	5.29 (1.43)
Analysis Visit Mean (SD)	5.26 (1.52)	5.30 (1.11)	5.33 (1.42)
LS Mean of Change from Baseline (SE)	0.05 (0.15)	-0.15 (0.16)	0.07 (0.10)
95% CI	(-0.24, 0.34)	(-0.47, 0.17)	(-0.14, 0.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.17)	-0.22 (0.19)	
95% CI	(-0.36, 0.33)	(-0.58, 0.15)	
p-value	0.9213	0.2447	
Corrected Hedge's g Statistics	-0.020	-0.249	
95% CI	(-0.43, 0.39)	(-0.68, 0.19)	
Subgroup*Treatment Interaction p-value	0.9431	0.2068	

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Emotional Health			
Week 24			
m	47	39	87
n	43	34	81
Baseline Mean (SD)	5.16 (1.24)	5.65 (1.28)	5.39 (1.32)
Analysis Visit Mean (SD)	5.27 (1.21)	5.51 (1.06)	5.60 (1.13)
LS Mean of Change from Baseline (SE)	0.04 (0.13)	-0.01 (0.15)	0.22 (0.09)
95% CI	(-0.22, 0.30)	(-0.30, 0.28)	(0.03, 0.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.18 (0.16)	-0.23 (0.17)	
95% CI	(-0.49, 0.13)	(-0.56, 0.11)	
p-value	0.2545	0.1821	
Corrected Hedge's g Statistics	-0.210	-0.267	
95% CI	(-0.58, 0.16)	(-0.67, 0.13)	
Week 52			
m	45	35	81
n	35	29	70
Baseline Mean (SD)	5.22 (1.25)	5.62 (1.27)	5.43 (1.33)
Analysis Visit Mean (SD)	5.31 (0.98)	5.44 (1.13)	5.60 (1.03)
LS Mean of Change from Baseline (SE)	0.06 (0.12)	-0.07 (0.14)	0.17 (0.09)
95% CI	(-0.19, 0.30)	(-0.34, 0.20)	(0.00, 0.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.12 (0.15)	-0.24 (0.16)	
95% CI	(-0.41, 0.17)	(-0.55, 0.07)	
p-value	0.4247	0.1215	
Corrected Hedge's g Statistics	-0.160	-0.332	
95% CI	(-0.57, 0.25)	(-0.77, 0.10)	
Subgroup*Treatment Interaction p-value	0.3216	0.0928	

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Fatigue			
Week 24			
m	47	39	87
n	43	34	81
Baseline Mean (SD)	4.49 (1.49)	4.90 (1.29)	4.60 (1.49)
Analysis Visit Mean (SD)	4.63 (1.48)	4.50 (1.24)	4.74 (1.39)
LS Mean of Change from Baseline (SE)	0.11 (0.16)	-0.28 (0.18)	0.13 (0.12)
95% CI	(-0.21, 0.43)	(-0.64, 0.08)	(-0.10, 0.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.19)	-0.41 (0.21)	
95% CI	(-0.41, 0.36)	(-0.82, 0.01)	
p-value	0.9121	0.0543	
Corrected Hedge's g Statistics	-0.020	-0.385	
95% CI	(-0.39, 0.35)	(-0.79, 0.02)	
Week 52			
m	45	35	81
n	35	29	70
Baseline Mean (SD)	4.59 (1.52)	4.74 (1.26)	4.60 (1.49)
Analysis Visit Mean (SD)	4.71 (1.57)	4.09 (1.33)	4.65 (1.30)
LS Mean of Change from Baseline (SE)	0.12 (0.16)	-0.59 (0.17)	0.04 (0.11)
95% CI	(-0.19, 0.43)	(-0.94, -0.25)	(-0.18, 0.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.19)	-0.63 (0.20)	
95% CI	(-0.30, 0.45)	(-1.03, -0.23)	
p-value	0.6834	0.0020	
Corrected Hedge's g Statistics	0.081	-0.668	
95% CI	(-0.32, 0.49)	(-1.11, -0.22)	
Subgroup*Treatment Interaction p-value	0.8465	0.0783	

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Systemic Symptoms			
Week 24			
m	47	39	87
n	43	34	81
Baseline Mean (SD)	4.93 (1.28)	5.27 (1.08)	5.09 (1.35)
Analysis Visit Mean (SD)	4.99 (1.18)	4.98 (1.25)	5.22 (1.32)
LS Mean of Change from Baseline (SE)	0.06 (0.14)	-0.17 (0.15)	0.16 (0.10)
95% CI	(-0.21, 0.33)	(-0.47, 0.14)	(-0.04, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.16)	-0.33 (0.18)	
95% CI	(-0.42, 0.23)	(-0.68, 0.02)	
p-value	0.5630	0.0675	
Corrected Hedge's g Statistics	-0.106	-0.366	
95% CI	(-0.48, 0.26)	(-0.77, 0.04)	
Week 52			
m	45	35	81
n	35	29	70
Baseline Mean (SD)	5.12 (1.27)	5.22 (1.06)	5.01 (1.37)
Analysis Visit Mean (SD)	4.95 (1.41)	4.93 (1.23)	5.01 (1.46)
LS Mean of Change from Baseline (SE)	-0.06 (0.15)	-0.25 (0.16)	0.06 (0.10)
95% CI	(-0.35, 0.23)	(-0.57, 0.06)	(-0.15, 0.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.12 (0.17)	-0.31 (0.19)	
95% CI	(-0.46, 0.23)	(-0.68, 0.06)	
p-value	0.5061	0.0991	
Corrected Hedge's g Statistics	-0.133	-0.355	
95% CI	(-0.54, 0.27)	(-0.79, 0.08)	
Subgroup*Treatment Interaction p-value	0.5882	0.2908	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Worry			
Week 24			
m	47	39	87
n	43	34	81
Baseline Mean (SD)	5.40 (1.36)	5.59 (1.45)	5.66 (1.31)
Analysis Visit Mean (SD)	5.78 (1.27)	5.87 (1.34)	6.08 (1.13)
LS Mean of Change from Baseline (SE)	0.34 (0.14)	0.32 (0.16)	0.47 (0.10)
95% CI	(0.05, 0.63)	(-0.01, 0.64)	(0.26, 0.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (0.17)	-0.15 (0.19)	
95% CI	(-0.47, 0.21)	(-0.52, 0.22)	
p-value	0.4629	0.4190	
Corrected Hedge's g Statistics	-0.134	-0.160	
95% CI	(-0.50, 0.24)	(-0.56, 0.24)	
Week 52			
m	45	35	81
n	35	29	70
Baseline Mean (SD)	5.47 (1.40)	5.68 (1.40)	5.64 (1.33)
Analysis Visit Mean (SD)	5.89 (1.47)	5.85 (1.37)	6.07 (1.21)
LS Mean of Change from Baseline (SE)	0.31 (0.17)	0.14 (0.19)	0.46 (0.12)
95% CI	(-0.03, 0.65)	(-0.23, 0.51)	(0.22, 0.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (0.20)	-0.32 (0.22)	
95% CI	(-0.55, 0.26)	(-0.75, 0.11)	
p-value	0.4741	0.1491	
Corrected Hedge's g Statistics	-0.144	-0.310	
95% CI	(-0.55, 0.26)	(-0.74, 0.13)	
Subgroup*Treatment Interaction p-value	0.6549	0.1104	

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Abdominal Symptoms			
Week 24			
m	76	68	125
n	69	59	106
Baseline Mean (SD)	5.14 (1.74)	5.41 (1.44)	5.29 (1.42)
Analysis Visit Mean (SD)	5.20 (1.60)	5.50 (1.43)	5.45 (1.38)
LS Mean of Change from Baseline (SE)	0.02 (0.13)	0.13 (0.14)	0.18 (0.11)
95% CI	(-0.23, 0.28)	(-0.14, 0.41)	(-0.03, 0.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (0.16)	-0.05 (0.17)	
95% CI	(-0.48, 0.17)	(-0.38, 0.29)	
p-value	0.3473	0.7936	
Corrected Hedge's g Statistics	-0.141	-0.041	
95% CI	(-0.44, 0.16)	(-0.36, 0.28)	
Week 52			
m	70	57	120
n	63	49	93
Baseline Mean (SD)	5.26 (1.65)	5.59 (1.36)	5.39 (1.32)
Analysis Visit Mean (SD)	5.51 (1.39)	5.59 (1.34)	5.46 (1.47)
LS Mean of Change from Baseline (SE)	0.19 (0.14)	0.07 (0.16)	0.15 (0.12)
95% CI	(-0.08, 0.47)	(-0.23, 0.38)	(-0.07, 0.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.18)	-0.08 (0.19)	
95% CI	(-0.31, 0.39)	(-0.46, 0.30)	
p-value	0.8321	0.6736	
Corrected Hedge's g Statistics	0.034	-0.072	
95% CI	(-0.29, 0.35)	(-0.42, 0.27)	
Subgroup*Treatment Interaction p-value	0.8688	0.1251	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Activity			
Week 24			
m	76	68	125
n	69	59	106
Baseline Mean (SD)	5.30 (1.39)	5.21 (1.37)	5.51 (1.28)
Analysis Visit Mean (SD)	5.16 (1.56)	5.43 (1.26)	5.45 (1.33)
LS Mean of Change from Baseline (SE)	-0.16 (0.11)	0.17 (0.12)	-0.03 (0.09)
95% CI	(-0.38, 0.07)	(-0.07, 0.40)	(-0.21, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (0.14)	0.19 (0.15)	
95% CI	(-0.41, 0.15)	(-0.10, 0.49)	
p-value	0.3621	0.2010	
Corrected Hedge's g Statistics	-0.137	0.202	
95% CI	(-0.44, 0.17)	(-0.12, 0.52)	
Week 52			
m	70	57	120
n	63	49	93
Baseline Mean (SD)	5.35 (1.39)	5.21 (1.42)	5.61 (1.22)
Analysis Visit Mean (SD)	5.32 (1.47)	5.18 (1.37)	5.39 (1.40)
LS Mean of Change from Baseline (SE)	-0.04 (0.12)	-0.08 (0.14)	-0.13 (0.10)
95% CI	(-0.28, 0.20)	(-0.35, 0.19)	(-0.33, 0.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.16)	0.05 (0.17)	
95% CI	(-0.22, 0.39)	(-0.29, 0.38)	
p-value	0.5894	0.7876	
Corrected Hedge's g Statistics	0.086	0.046	
95% CI	(-0.23, 0.41)	(-0.30, 0.39)	
Subgroup*Treatment Interaction p-value	0.9431	0.2068	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Emotional Health			
Week 24			
m	76	68	125
n	69	59	106
Baseline Mean (SD)	5.34 (1.24)	5.22 (1.37)	5.40 (1.27)
Analysis Visit Mean (SD)	5.34 (1.29)	5.25 (1.31)	5.30 (1.37)
LS Mean of Change from Baseline (SE)	0.00 (0.09)	0.00 (0.10)	-0.08 (0.08)
95% CI	(-0.18, 0.19)	(-0.20, 0.19)	(-0.23, 0.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (0.12)	0.08 (0.12)	
95% CI	(-0.14, 0.32)	(-0.16, 0.32)	
p-value	0.4552	0.5096	
Corrected Hedge's g Statistics	0.112	0.104	
95% CI	(-0.19, 0.42)	(-0.21, 0.42)	
Week 52			
m	70	57	120
n	63	49	93
Baseline Mean (SD)	5.46 (1.17)	5.24 (1.46)	5.44 (1.27)
Analysis Visit Mean (SD)	5.45 (1.14)	5.31 (1.33)	5.32 (1.42)
LS Mean of Change from Baseline (SE)	-0.02 (0.09)	0.06 (0.11)	-0.10 (0.08)
95% CI	(-0.21, 0.16)	(-0.15, 0.26)	(-0.26, 0.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.12)	0.16 (0.13)	
95% CI	(-0.16, 0.31)	(-0.10, 0.41)	
p-value	0.5283	0.2231	
Corrected Hedge's g Statistics	0.100	0.209	
95% CI	(-0.22, 0.42)	(-0.14, 0.56)	
Subgroup*Treatment Interaction p-value	0.3216	0.0928	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Fatigue			
Week 24			
m	76	68	125
n	69	59	106
Baseline Mean (SD)	4.71 (1.53)	4.36 (1.56)	4.71 (1.47)
Analysis Visit Mean (SD)	4.70 (1.55)	4.46 (1.37)	4.70 (1.58)
LS Mean of Change from Baseline (SE)	0.01 (0.12)	0.03 (0.12)	0.00 (0.09)
95% CI	(-0.22, 0.23)	(-0.21, 0.27)	(-0.19, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.14)	0.03 (0.15)	
95% CI	(-0.28, 0.29)	(-0.27, 0.33)	
p-value	0.9536	0.8382	
Corrected Hedge's g Statistics	0.009	0.032	
95% CI	(-0.29, 0.31)	(-0.29, 0.35)	
Week 52			
m	70	57	120
n	63	49	93
Baseline Mean (SD)	4.76 (1.54)	4.49 (1.60)	4.77 (1.44)
Analysis Visit Mean (SD)	4.90 (1.45)	4.59 (1.51)	4.80 (1.56)
LS Mean of Change from Baseline (SE)	0.15 (0.13)	0.05 (0.14)	0.06 (0.11)
95% CI	(-0.11, 0.40)	(-0.23, 0.34)	(-0.15, 0.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.16)	-0.01 (0.18)	
95% CI	(-0.24, 0.41)	(-0.36, 0.34)	
p-value	0.6185	0.9480	
Corrected Hedge's g Statistics	0.079	-0.011	
95% CI	(-0.24, 0.40)	(-0.36, 0.33)	
Subgroup*Treatment Interaction p-value	0.8465	0.0783	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Systemic Symptoms			
Week 24			
m	76	68	125
n	69	59	106
Baseline Mean (SD)	5.09 (1.23)	4.98 (1.25)	5.06 (1.20)
Analysis Visit Mean (SD)	5.05 (1.26)	4.91 (1.22)	4.97 (1.28)
LS Mean of Change from Baseline (SE)	-0.01 (0.09)	-0.07 (0.10)	-0.06 (0.08)
95% CI	(-0.20, 0.17)	(-0.27, 0.12)	(-0.21, 0.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.12)	-0.01 (0.12)	
95% CI	(-0.18, 0.28)	(-0.25, 0.23)	
p-value	0.6808	0.9315	
Corrected Hedge's g Statistics	0.062	-0.014	
95% CI	(-0.24, 0.36)	(-0.33, 0.30)	
Week 52			
m	70	57	120
n	63	49	93
Baseline Mean (SD)	5.17 (1.17)	5.06 (1.22)	5.07 (1.28)
Analysis Visit Mean (SD)	5.18 (1.23)	4.97 (1.24)	5.02 (1.34)
LS Mean of Change from Baseline (SE)	0.05 (0.10)	-0.08 (0.11)	0.01 (0.08)
95% CI	(-0.14, 0.25)	(-0.29, 0.13)	(-0.15, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.12)	-0.09 (0.13)	
95% CI	(-0.20, 0.28)	(-0.36, 0.17)	
p-value	0.7444	0.4774	
Corrected Hedge's g Statistics	0.052	-0.122	
95% CI	(-0.27, 0.37)	(-0.47, 0.22)	
Subgroup*Treatment Interaction p-value	0.5882	0.2908	

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Worry			
Week 24			
m	76	68	125
n	69	59	106
Baseline Mean (SD)	5.50 (1.51)	5.51 (1.59)	5.49 (1.49)
Analysis Visit Mean (SD)	5.69 (1.48)	5.86 (1.39)	5.77 (1.48)
LS Mean of Change from Baseline (SE)	0.22 (0.11)	0.36 (0.12)	0.31 (0.09)
95% CI	(-0.01, 0.44)	(0.13, 0.60)	(0.13, 0.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.14)	0.05 (0.15)	
95% CI	(-0.38, 0.18)	(-0.24, 0.35)	
p-value	0.4910	0.7356	
Corrected Hedge's g Statistics	-0.103	0.053	
95% CI	(-0.41, 0.20)	(-0.27, 0.37)	
Week 52			
m	70	57	120
n	63	49	93
Baseline Mean (SD)	5.58 (1.48)	5.45 (1.66)	5.59 (1.49)
Analysis Visit Mean (SD)	5.92 (1.19)	5.87 (1.53)	5.80 (1.40)
LS Mean of Change from Baseline (SE)	0.38 (0.12)	0.45 (0.13)	0.27 (0.10)
95% CI	(0.15, 0.61)	(0.19, 0.70)	(0.08, 0.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.11 (0.15)	0.18 (0.16)	
95% CI	(-0.18, 0.40)	(-0.13, 0.49)	
p-value	0.4492	0.2639	
Corrected Hedge's g Statistics	0.120	0.191	
95% CI	(-0.20, 0.44)	(-0.16, 0.54)	
Subgroup*Treatment Interaction p-value	0.6549	0.1104	

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Abdominal Symptoms			
Week 24			
m	28	22	60
n	27	21	49
Baseline Mean (SD)	5.67 (1.44)	5.64 (1.20)	5.05 (1.63)
Analysis Visit Mean (SD)	5.85 (1.21)	5.03 (1.73)	5.47 (1.29)
LS Mean of Change from Baseline (SE)	0.33 (0.22)	-0.49 (0.24)	0.32 (0.16)
95% CI	(-0.10, 0.76)	(-0.96, -0.01)	(-0.01, 0.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.27)	-0.80 (0.28)	
95% CI	(-0.52, 0.54)	(-1.37, -0.24)	
p-value	0.9596	0.0057	
Corrected Hedge's g Statistics	0.012	-0.707	
95% CI	(-0.46, 0.48)	(-1.23, -0.18)	
Week 52			
m	27	22	54
n	25	19	40
Baseline Mean (SD)	5.72 (1.47)	5.55 (1.22)	5.20 (1.58)
Analysis Visit Mean (SD)	5.62 (1.51)	5.21 (1.29)	5.40 (1.35)
LS Mean of Change from Baseline (SE)	0.03 (0.21)	-0.25 (0.24)	0.16 (0.16)
95% CI	(-0.39, 0.45)	(-0.72, 0.22)	(-0.16, 0.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (0.27)	-0.41 (0.28)	
95% CI	(-0.66, 0.40)	(-0.98, 0.15)	
p-value	0.6244	0.1499	
Corrected Hedge's g Statistics	-0.123	-0.392	
95% CI	(-0.62, 0.38)	(-0.94, 0.16)	
Subgroup*Treatment Interaction p-value	0.8688	0.1251	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Activity			
Week 24			
m	28	22	60
n	27	21	49
Baseline Mean (SD)	5.66 (1.20)	5.41 (1.30)	5.38 (1.42)
Analysis Visit Mean (SD)	5.70 (1.15)	5.11 (1.25)	5.52 (1.17)
LS Mean of Change from Baseline (SE)	0.15 (0.16)	-0.32 (0.18)	0.11 (0.12)
95% CI	(-0.17, 0.47)	(-0.67, 0.04)	(-0.13, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.20)	-0.43 (0.21)	
95% CI	(-0.36, 0.43)	(-0.84, -0.02)	
p-value	0.8661	0.0414	
Corrected Hedge's g Statistics	0.039	-0.508	
95% CI	(-0.43, 0.51)	(-1.03, 0.01)	
Week 52			
m	27	22	54
n	25	19	40
Baseline Mean (SD)	5.70 (1.20)	5.46 (1.33)	5.64 (1.26)
Analysis Visit Mean (SD)	5.47 (1.53)	5.77 (1.02)	5.54 (1.44)
LS Mean of Change from Baseline (SE)	-0.13 (0.22)	0.33 (0.25)	-0.05 (0.17)
95% CI	(-0.57, 0.31)	(-0.17, 0.82)	(-0.39, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.28)	0.38 (0.30)	
95% CI	(-0.63, 0.47)	(-0.21, 0.97)	
p-value	0.7736	0.2083	
Corrected Hedge's g Statistics	-0.072	0.344	
95% CI	(-0.57, 0.43)	(-0.21, 0.89)	
Subgroup*Treatment Interaction p-value	0.9431	0.2068	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Emotional Health			
Week 24			
m	28	22	60
n	27	21	49
Baseline Mean (SD)	5.63 (1.11)	5.35 (1.10)	5.45 (0.95)
Analysis Visit Mean (SD)	5.91 (1.02)	4.94 (1.15)	5.49 (1.05)
LS Mean of Change from Baseline (SE)	0.29 (0.15)	-0.44 (0.17)	0.01 (0.11)
95% CI	(-0.01, 0.58)	(-0.78, -0.11)	(-0.22, 0.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.28 (0.19)	-0.45 (0.20)	
95% CI	(-0.09, 0.65)	(-0.84, -0.06)	
p-value	0.1369	0.0238	
Corrected Hedge's g Statistics	0.351	-0.571	
95% CI	(-0.12, 0.82)	(-1.09, -0.05)	
Week 52			
m	27	22	54
n	25	19	40
Baseline Mean (SD)	5.69 (1.18)	5.41 (1.11)	5.52 (1.01)
Analysis Visit Mean (SD)	5.72 (0.90)	5.57 (0.97)	5.58 (1.08)
LS Mean of Change from Baseline (SE)	0.07 (0.15)	0.12 (0.17)	0.02 (0.12)
95% CI	(-0.23, 0.36)	(-0.21, 0.45)	(-0.20, 0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.19)	0.10 (0.20)	
95% CI	(-0.33, 0.41)	(-0.30, 0.49)	
p-value	0.8180	0.6299	
Corrected Hedge's g Statistics	0.058	0.130	
95% CI	(-0.44, 0.56)	(-0.42, 0.68)	
Subgroup*Treatment Interaction p-value	0.3216	0.0928	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Fatigue			
Week 24			
m	28	22	60
n	27	21	49
Baseline Mean (SD)	5.12 (1.32)	4.87 (1.22)	4.54 (1.43)
Analysis Visit Mean (SD)	5.03 (1.52)	4.50 (1.25)	4.63 (1.39)
LS Mean of Change from Baseline (SE)	0.05 (0.21)	-0.35 (0.23)	0.01 (0.16)
95% CI	(-0.37, 0.46)	(-0.81, 0.11)	(-0.30, 0.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.26)	-0.36 (0.27)	
95% CI	(-0.48, 0.55)	(-0.91, 0.18)	
p-value	0.8832	0.1881	
Corrected Hedge's g Statistics	0.035	-0.331	
95% CI	(-0.44, 0.50)	(-0.84, 0.18)	
Week 52			
m	27	22	54
n	25	19	40
Baseline Mean (SD)	5.18 (1.40)	4.89 (1.28)	4.66 (1.37)
Analysis Visit Mean (SD)	4.83 (1.56)	4.92 (1.30)	4.64 (1.39)
LS Mean of Change from Baseline (SE)	-0.30 (0.19)	0.08 (0.21)	-0.02 (0.15)
95% CI	(-0.68, 0.09)	(-0.34, 0.51)	(-0.31, 0.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.28 (0.24)	0.10 (0.25)	
95% CI	(-0.76, 0.20)	(-0.41, 0.60)	
p-value	0.2481	0.6980	
Corrected Hedge's g Statistics	-0.292	0.105	
95% CI	(-0.79, 0.21)	(-0.44, 0.65)	
Subgroup*Treatment Interaction p-value	0.8465	0.0783	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Systemic Symptoms			
Week 24			
m	28	22	60
n	27	21	49
Baseline Mean (SD)	5.51 (1.08)	5.23 (1.29)	5.23 (1.01)
Analysis Visit Mean (SD)	5.54 (1.22)	4.98 (1.07)	5.28 (1.09)
LS Mean of Change from Baseline (SE)	0.06 (0.15)	-0.31 (0.17)	-0.02 (0.11)
95% CI	(-0.24, 0.37)	(-0.64, 0.02)	(-0.25, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (0.19)	-0.29 (0.20)	
95% CI	(-0.28, 0.46)	(-0.68, 0.11)	
p-value	0.6386	0.1502	
Corrected Hedge's g Statistics	0.110	-0.360	
95% CI	(-0.36, 0.58)	(-0.87, 0.15)	
Week 52			
m	27	22	54
n	25	19	40
Baseline Mean (SD)	5.64 (1.08)	5.18 (1.30)	5.30 (0.99)
Analysis Visit Mean (SD)	5.26 (1.12)	5.16 (1.19)	5.33 (1.16)
LS Mean of Change from Baseline (SE)	-0.34 (0.16)	-0.08 (0.18)	0.00 (0.13)
95% CI	(-0.66, -0.02)	(-0.44, 0.28)	(-0.25, 0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.34 (0.20)	-0.08 (0.22)	
95% CI	(-0.75, 0.06)	(-0.51, 0.35)	
p-value	0.0985	0.7043	
Corrected Hedge's g Statistics	-0.420	-0.103	
95% CI	(-0.92, 0.09)	(-0.65, 0.44)	
Subgroup*Treatment Interaction p-value	0.5882	0.2908	

AMNOG Table SE23.14a.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Worry			
Week 24			
m	28	22	60
n	27	21	49
Baseline Mean (SD)	5.67 (1.02)	5.68 (1.39)	5.65 (1.31)
Analysis Visit Mean (SD)	6.10 (0.92)	5.35 (1.19)	5.88 (1.34)
LS Mean of Change from Baseline (SE)	0.40 (0.15)	-0.35 (0.16)	0.19 (0.11)
95% CI	(0.11, 0.69)	(-0.67, -0.03)	(-0.03, 0.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.21 (0.18)	-0.54 (0.19)	
95% CI	(-0.15, 0.57)	(-0.92, -0.16)	
p-value	0.2504	0.0057	
Corrected Hedge's g Statistics	0.271	-0.702	
95% CI	(-0.20, 0.74)	(-1.23, -0.18)	
Week 52			
m	27	22	54
n	25	19	40
Baseline Mean (SD)	5.76 (1.07)	5.66 (1.45)	5.80 (1.16)
Analysis Visit Mean (SD)	6.06 (0.93)	6.06 (0.96)	6.21 (1.04)
LS Mean of Change from Baseline (SE)	0.29 (0.16)	0.34 (0.18)	0.42 (0.13)
95% CI	(-0.03, 0.62)	(-0.02, 0.71)	(0.17, 0.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.13 (0.20)	-0.08 (0.22)	
95% CI	(-0.54, 0.28)	(-0.51, 0.36)	
p-value	0.5281	0.7204	
Corrected Hedge's g Statistics	-0.159	-0.097	
95% CI	(-0.66, 0.34)	(-0.64, 0.45)	
Subgroup*Treatment Interaction p-value	0.6549	0.1104	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (6.3)	2 (4.5)	10 (10.5)
No	45 (93.8)	42 (95.5)	85 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.76	2.47	
95% CI of the inverse odds ratio	(0.46, 6.74)	(0.52, 11.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.68	2.32	
95% CI of the inverse risk ratio	(0.49, 5.84)	(0.53, 10.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.28	-5.98	
95% CI of the absolute risk difference	(-13.49, 4.94)	(-14.70, 2.73)	
p-value	0.4009	0.2429	
p-value of Breslow-Day Test for Homogeneity [3]	0.6145	0.4795	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (25.0)	5 (11.4)	24 (25.3)
No	36 (75.0)	39 (88.6)	71 (74.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	2.64	
95% CI of the inverse odds ratio	(0.46, 2.26)	(0.93, 7.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	2.22	
95% CI of the inverse risk ratio	(0.55, 1.84)	(0.91, 5.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.26	-13.90	
95% CI of the absolute risk difference	(-15.31, 14.78)	(-26.72, -1.08)	
p-value	0.9727	0.0607	
p-value of Breslow-Day Test for Homogeneity [3]	0.9167	0.1564	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (18.8)	3 (6.8)	15 (15.8)
No	39 (81.3)	41 (93.2)	80 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	2.56	
95% CI of the inverse odds ratio	(0.33, 2.02)	(0.70, 9.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	2.32	
95% CI of the inverse risk ratio	(0.40, 1.78)	(0.71, 7.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.96	-8.97	
95% CI of the absolute risk difference	(-10.29, 16.22)	(-19.42, 1.48)	
p-value	0.6546	0.1428	
p-value of Breslow-Day Test for Homogeneity [3]	0.9737	0.7698	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (31.3)	6 (13.6)	28 (29.5)
No	33 (68.8)	38 (86.4)	67 (70.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	2.65	
95% CI of the inverse odds ratio	(0.43, 1.95)	(1.01, 6.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	2.16	
95% CI of the inverse risk ratio	(0.56, 1.59)	(0.97, 4.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.78	-15.84	
95% CI of the absolute risk difference	(-14.22, 17.78)	(-29.51, -2.17)	
p-value	0.8268	0.0433	
p-value of Breslow-Day Test for Homogeneity [3]	0.6762	0.6005	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (8.3)	1 (2.3)	9 (9.5)
No	44 (91.7)	43 (97.7)	86 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	4.50	
95% CI of the inverse odds ratio	(0.34, 3.95)	(0.55, 36.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	4.17	
95% CI of the inverse risk ratio	(0.37, 3.50)	(0.54, 31.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.14	-7.20	
95% CI of the absolute risk difference	(-10.93, 8.65)	(-14.55, 0.15)	
p-value	0.8228	0.1265	
p-value of Breslow-Day Test for Homogeneity [3]	0.2650	0.0415	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (31.3)	8 (18.2)	27 (28.4)
No	33 (68.8)	36 (81.8)	68 (71.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.79	
95% CI of the inverse odds ratio	(0.41, 1.86)	(0.74, 4.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.56	
95% CI of the inverse risk ratio	(0.54, 1.54)	(0.77, 3.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.83	-10.24	
95% CI of the absolute risk difference	(-13.11, 18.77)	(-24.80, 4.33)	
p-value	0.7258	0.1958	
p-value of Breslow-Day Test for Homogeneity [3]	0.6162	0.0548	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (12.5)	3 (6.8)	11 (11.6)
No	42 (87.5)	41 (93.2)	84 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.79	
95% CI of the inverse odds ratio	(0.32, 2.65)	(0.47, 6.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.70	
95% CI of the inverse risk ratio	(0.36, 2.35)	(0.50, 5.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.92	-4.76	
95% CI of the absolute risk difference	(-10.43, 12.28)	(-14.60, 5.08)	
p-value	0.8723	0.3857	
p-value of Breslow-Day Test for Homogeneity [3]	0.6803	0.4774	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (18.8)	7 (15.9)	30 (31.6)
No	39 (81.3)	37 (84.1)	65 (68.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	2.44	
95% CI of the inverse odds ratio	(0.86, 4.65)	(0.98, 6.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.68	1.98	
95% CI of the inverse risk ratio	(0.87, 3.26)	(0.95, 4.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-12.83	-15.67	
95% CI of the absolute risk difference	(-27.30, 1.64)	(-29.96, -1.38)	
p-value	0.1038	0.0519	
p-value of Breslow-Day Test for Homogeneity [3]	0.1119	0.0161	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (10.4)	1 (2.3)	11 (11.6)
No	43 (89.6)	43 (97.7)	84 (88.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	5.63	
95% CI of the inverse odds ratio	(0.37, 3.45)	(0.70, 45.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	5.09	
95% CI of the inverse risk ratio	(0.41, 3.02)	(0.68, 38.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.16	-9.31	
95% CI of the absolute risk difference	(-11.94, 9.61)	(-17.10, -1.51)	
p-value	0.8351	0.0692	
p-value of Breslow-Day Test for Homogeneity [3]	0.5547	0.1041	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	13 (27.1)	8 (18.2)	22 (23.2)
No	35 (72.9)	36 (81.8)	73 (76.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	1.36	
95% CI of the inverse odds ratio	(0.37, 1.80)	(0.55, 3.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.27	
95% CI of the inverse risk ratio	(0.47, 1.54)	(0.62, 2.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.93	-4.98	
95% CI of the absolute risk difference	(-11.24, 19.09)	(-19.18, 9.23)	
p-value	0.6062	0.5071	
p-value of Breslow-Day Test for Homogeneity [3]	0.7968	0.4219	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.2)	2 (4.5)	9 (9.5)
No	46 (95.8)	42 (95.5)	86 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.41	2.20	
95% CI of the inverse odds ratio	(0.50, 11.61)	(0.45, 10.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.27	2.08	
95% CI of the inverse risk ratio	(0.51, 10.11)	(0.47, 9.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.31	-4.93	
95% CI of the absolute risk difference	(-13.47, 2.86)	(-13.45, 3.59)	
p-value	0.2607	0.3168	
p-value of Breslow-Day Test for Homogeneity [3]	0.6993	0.5894	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (20.8)	7 (15.9)	26 (27.4)
No	38 (79.2)	37 (84.1)	69 (72.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.99	
95% CI of the inverse odds ratio	(0.62, 3.28)	(0.79, 5.02)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	1.72	
95% CI of the inverse risk ratio	(0.69, 2.49)	(0.81, 3.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.54	-11.46	
95% CI of the absolute risk difference	(-21.11, 8.04)	(-25.50, 2.58)	
p-value	0.3952	0.1397	
p-value of Breslow-Day Test for Homogeneity [3]	0.0850	0.1311	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (22.9)	7 (15.9)	19 (20.0)
No	37 (77.1)	37 (84.1)	76 (80.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.32	
95% CI of the inverse odds ratio	(0.36, 1.95)	(0.51, 3.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.26	
95% CI of the inverse risk ratio	(0.45, 1.68)	(0.57, 2.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.92	-4.09	
95% CI of the absolute risk difference	(-11.44, 17.27)	(-17.56, 9.38)	
p-value	0.6858	0.5651	
p-value of Breslow-Day Test for Homogeneity [3]	0.8899	0.3980	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (35.4)	11 (25.0)	34 (35.8)
No	31 (64.6)	33 (75.0)	61 (64.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.67	
95% CI of the inverse odds ratio	(0.49, 2.10)	(0.75, 3.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.43	
95% CI of the inverse risk ratio	(0.63, 1.61)	(0.80, 2.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.37	-10.79	
95% CI of the absolute risk difference	(-16.99, 16.24)	(-26.81, 5.23)	
p-value	0.9649	0.2060	
p-value of Breslow-Day Test for Homogeneity [3]	0.6453	0.5105	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (9.1)	6 (8.3)	10 (7.8)
No	70 (90.9)	66 (91.7)	118 (92.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.93	
95% CI of the inverse odds ratio	(0.31, 2.33)	(0.32, 2.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	0.94	
95% CI of the inverse risk ratio	(0.34, 2.16)	(0.36, 2.47)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.28	0.52	
95% CI of the absolute risk difference	(-6.65, 9.21)	(-7.38, 8.42)	
p-value	0.7479	0.8963	
p-value of Breslow-Day Test for Homogeneity [3]	0.6145	0.4795	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (24.7)	18 (25.0)	27 (21.1)
No	58 (75.3)	54 (75.0)	101 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.80	
95% CI of the inverse odds ratio	(0.42, 1.59)	(0.41, 1.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.84	
95% CI of the inverse risk ratio	(0.51, 1.43)	(0.50, 1.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.58	3.91	
95% CI of the absolute risk difference	(-8.36, 15.53)	(-8.34, 16.15)	
p-value	0.5517	0.5254	
p-value of Breslow-Day Test for Homogeneity [3]	0.9167	0.1564	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (20.8)	10 (13.9)	25 (19.5)
No	61 (79.2)	62 (86.1)	103 (80.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	1.50	
95% CI of the inverse odds ratio	(0.46, 1.87)	(0.68, 3.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.41	
95% CI of the inverse risk ratio	(0.54, 1.65)	(0.72, 2.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.25	-5.64	
95% CI of the absolute risk difference	(-10.12, 12.62)	(-16.18, 4.89)	
p-value	0.8287	0.3134	
p-value of Breslow-Day Test for Homogeneity [3]	0.9737	0.7698	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	31 (40.3)	18 (25.0)	42 (32.8)
No	46 (59.7)	54 (75.0)	86 (67.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	1.47	
95% CI of the inverse odds ratio	(0.40, 1.30)	(0.77, 2.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.31	
95% CI of the inverse risk ratio	(0.56, 1.18)	(0.82, 2.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.45	-7.81	
95% CI of the absolute risk difference	(-6.20, 21.09)	(-20.70, 5.08)	
p-value	0.2809	0.2472	
p-value of Breslow-Day Test for Homogeneity [3]	0.6762	0.6005	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (14.3)	10 (13.9)	7 (5.5)
No	66 (85.7)	62 (86.1)	121 (94.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.35	0.36	
95% CI of the inverse odds ratio	(0.13, 0.94)	(0.13, 0.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.38	0.39	
95% CI of the inverse risk ratio	(0.15, 0.95)	(0.16, 0.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.82	8.42	
95% CI of the absolute risk difference	(0.06, 17.57)	(-0.49, 17.33)	
p-value	0.0308	0.0404	
p-value of Breslow-Day Test for Homogeneity [3]	0.2650	0.0415	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (27.3)	19 (26.4)	23 (18.0)
No	56 (72.7)	53 (73.6)	105 (82.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.61	
95% CI of the inverse odds ratio	(0.30, 1.15)	(0.31, 1.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.68	
95% CI of the inverse risk ratio	(0.39, 1.11)	(0.40, 1.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	9.30	8.42	
95% CI of the absolute risk difference	(-2.66, 21.27)	(-3.74, 20.58)	
p-value	0.1161	0.1605	
p-value of Breslow-Day Test for Homogeneity [3]	0.6162	0.0548	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (10.4)	6 (8.3)	9 (7.0)
No	69 (89.6)	66 (91.7)	119 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	0.83	
95% CI of the inverse odds ratio	(0.24, 1.77)	(0.28, 2.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.84	
95% CI of the inverse risk ratio	(0.27, 1.68)	(0.31, 2.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.36	1.30	
95% CI of the absolute risk difference	(-4.77, 11.49)	(-6.47, 9.07)	
p-value	0.3984	0.7372	
p-value of Breslow-Day Test for Homogeneity [3]	0.6803	0.4774	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	17 (22.1)	16 (22.2)	24 (18.8)
No	60 (77.9)	56 (77.8)	104 (81.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.81	
95% CI of the inverse odds ratio	(0.41, 1.64)	(0.40, 1.64)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.84	
95% CI of the inverse risk ratio	(0.49, 1.48)	(0.48, 1.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.33	3.47	
95% CI of the absolute risk difference	(-8.14, 14.80)	(-8.27, 15.22)	
p-value	0.5640	0.5557	
p-value of Breslow-Day Test for Homogeneity [3]	0.1119	0.0161	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (11.7)	13 (18.1)	16 (12.5)
No	68 (88.3)	59 (81.9)	112 (87.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.65	
95% CI of the inverse odds ratio	(0.45, 2.58)	(0.29, 1.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.69	
95% CI of the inverse risk ratio	(0.50, 2.30)	(0.35, 1.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.81	5.56	
95% CI of the absolute risk difference	(-9.99, 8.37)	(-5.02, 16.13)	
p-value	0.8634	0.2841	
p-value of Breslow-Day Test for Homogeneity [3]	0.5547	0.1041	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (33.8)	16 (22.2)	39 (30.5)
No	51 (66.2)	56 (77.8)	89 (69.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	1.53	
95% CI of the inverse odds ratio	(0.47, 1.57)	(0.78, 3.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.37	
95% CI of the inverse risk ratio	(0.60, 1.36)	(0.83, 2.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.30	-8.25	
95% CI of the absolute risk difference	(-9.94, 16.53)	(-20.73, 4.24)	
p-value	0.6232	0.2100	
p-value of Breslow-Day Test for Homogeneity [3]	0.7968	0.4219	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (5.2)	7 (9.7)	13 (10.2)
No	73 (94.8)	65 (90.3)	115 (89.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.06	1.05	
95% CI of the inverse odds ratio	(0.65, 6.57)	(0.40, 2.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.96	1.04	
95% CI of the inverse risk ratio	(0.66, 5.78)	(0.44, 2.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.96	-0.43	
95% CI of the absolute risk difference	(-12.17, 2.25)	(-9.05, 8.18)	
p-value	0.2122	0.9218	
p-value of Breslow-Day Test for Homogeneity [3]	0.6993	0.5894	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (29.9)	15 (20.8)	29 (22.7)
No	54 (70.1)	57 (79.2)	99 (77.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.11	
95% CI of the inverse odds ratio	(0.36, 1.30)	(0.55, 2.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	1.09	
95% CI of the inverse risk ratio	(0.47, 1.21)	(0.63, 1.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.21	-1.82	
95% CI of the absolute risk difference	(-5.32, 19.75)	(-13.68, 10.03)	
p-value	0.2503	0.7652	
p-value of Breslow-Day Test for Homogeneity [3]	0.0850	0.1311	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (14.3)	14 (19.4)	18 (14.1)
No	66 (85.7)	58 (80.6)	110 (85.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.68	
95% CI of the inverse odds ratio	(0.44, 2.21)	(0.31, 1.46)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.72	
95% CI of the inverse risk ratio	(0.49, 1.97)	(0.38, 1.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.22	5.38	
95% CI of the absolute risk difference	(-9.64, 10.09)	(-5.57, 16.33)	
p-value	0.9646	0.3190	
p-value of Breslow-Day Test for Homogeneity [3]	0.8899	0.3980	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (36.4)	21 (29.2)	39 (30.5)
No	49 (63.6)	51 (70.8)	89 (69.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.06	
95% CI of the inverse odds ratio	(0.42, 1.39)	(0.57, 2.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.04	
95% CI of the inverse risk ratio	(0.56, 1.24)	(0.67, 1.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.89	-1.30	
95% CI of the absolute risk difference	(-7.49, 19.27)	(-14.49, 11.88)	
p-value	0.3835	0.8471	
p-value of Breslow-Day Test for Homogeneity [3]	0.6453	0.5105	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.3)	2 (9.1)	4 (6.3)
No	29 (96.7)	20 (90.9)	59 (93.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.97	0.68	
95% CI of the inverse odds ratio	(0.21, 18.39)	(0.12, 3.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.90	0.70	
95% CI of the inverse risk ratio	(0.22, 16.32)	(0.14, 3.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.02	2.74	
95% CI of the absolute risk difference	(-11.82, 5.79)	(-10.70, 16.18)	
p-value	0.5467	0.6656	
p-value of Breslow-Day Test for Homogeneity [3]	0.6145	0.4795	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	5 (22.7)	14 (22.2)
No	23 (76.7)	17 (77.3)	49 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.97	
95% CI of the inverse odds ratio	(0.33, 2.64)	(0.30, 3.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.98	
95% CI of the inverse risk ratio	(0.43, 2.11)	(0.40, 2.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.11	0.51	
95% CI of the absolute risk difference	(-17.18, 19.40)	(-19.79, 20.80)	
p-value	0.9046	0.9610	
p-value of Breslow-Day Test for Homogeneity [3]	0.9167	0.1564	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (20.0)	2 (9.1)	11 (17.5)
No	24 (80.0)	20 (90.9)	52 (82.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	2.12	
95% CI of the inverse odds ratio	(0.28, 2.56)	(0.43, 10.40)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.92	
95% CI of the inverse risk ratio	(0.36, 2.14)	(0.46, 8.00)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.54	-8.37	
95% CI of the absolute risk difference	(-14.57, 19.65)	(-23.61, 6.87)	
p-value	0.7671	0.3478	
p-value of Breslow-Day Test for Homogeneity [3]	0.9737	0.7698	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (26.7)	4 (18.2)	19 (30.2)
No	22 (73.3)	18 (81.8)	44 (69.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	1.94	
95% CI of the inverse odds ratio	(0.45, 3.14)	(0.58, 6.51)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	1.66	
95% CI of the inverse risk ratio	(0.56, 2.28)	(0.63, 4.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.49	-11.98	
95% CI of the absolute risk difference	(-22.96, 15.97)	(-31.68, 7.73)	
p-value	0.7287	0.2763	
p-value of Breslow-Day Test for Homogeneity [3]	0.6762	0.6005	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	5 (22.7)	6 (9.5)
No	27 (90.0)	17 (77.3)	57 (90.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.36	
95% CI of the inverse odds ratio	(0.22, 4.08)	(0.10, 1.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.42	
95% CI of the inverse risk ratio	(0.26, 3.55)	(0.14, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.48	13.20	
95% CI of the absolute risk difference	(-12.48, 13.43)	(-5.75, 32.16)	
p-value	0.9421	0.1122	
p-value of Breslow-Day Test for Homogeneity [3]	0.2650	0.0415	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (30.0)	8 (36.4)	11 (17.5)
No	21 (70.0)	14 (63.6)	52 (82.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.49	0.37	
95% CI of the inverse odds ratio	(0.18, 1.36)	(0.13, 1.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.48	
95% CI of the inverse risk ratio	(0.27, 1.25)	(0.22, 1.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	12.54	18.90	
95% CI of the absolute risk difference	(-6.35, 31.43)	(-3.28, 41.08)	
p-value	0.1689	0.0669	
p-value of Breslow-Day Test for Homogeneity [3]	0.6162	0.0548	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (16.7)	3 (13.6)	5 (7.9)
No	25 (83.3)	19 (86.4)	58 (92.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	0.55	
95% CI of the inverse odds ratio	(0.11, 1.62)	(0.12, 2.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	0.58	
95% CI of the inverse risk ratio	(0.15, 1.52)	(0.15, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.73	5.70	
95% CI of the absolute risk difference	(-6.18, 23.64)	(-10.12, 21.52)	
p-value	0.2039	0.4305	
p-value of Breslow-Day Test for Homogeneity [3]	0.6803	0.4774	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (30.0)	9 (40.9)	12 (19.0)
No	21 (70.0)	13 (59.1)	51 (81.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	0.34	
95% CI of the inverse odds ratio	(0.20, 1.50)	(0.12, 0.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.47	
95% CI of the inverse risk ratio	(0.30, 1.34)	(0.23, 0.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.95	21.86	
95% CI of the absolute risk difference	(-8.10, 30.00)	(-0.86, 44.58)	
p-value	0.2377	0.0407	
p-value of Breslow-Day Test for Homogeneity [3]	0.1119	0.0161	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.3)	3 (13.6)	7 (11.1)
No	29 (96.7)	19 (86.4)	56 (88.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.63	0.79	
95% CI of the inverse odds ratio	(0.43, 30.89)	(0.19, 3.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.33	0.81	
95% CI of the inverse risk ratio	(0.43, 25.88)	(0.23, 2.88)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-7.78	2.53	
95% CI of the absolute risk difference	(-17.85, 2.30)	(-13.78, 18.83)	
p-value	0.2111	0.7516	
p-value of Breslow-Day Test for Homogeneity [3]	0.5547	0.1041	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (20.0)	7 (31.8)	15 (23.8)
No	24 (80.0)	15 (68.2)	48 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.67	
95% CI of the inverse odds ratio	(0.43, 3.63)	(0.23, 1.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	0.75	
95% CI of the inverse risk ratio	(0.51, 2.76)	(0.35, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.81	8.01	
95% CI of the absolute risk difference	(-21.57, 13.95)	(-14.11, 30.13)	
p-value	0.6813	0.4603	
p-value of Breslow-Day Test for Homogeneity [3]	0.7968	0.4219	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	2 (9.1)	4 (6.3)
No	28 (93.3)	20 (90.9)	59 (93.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.68	
95% CI of the inverse odds ratio	(0.16, 5.49)	(0.12, 3.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.70	
95% CI of the inverse risk ratio	(0.18, 4.91)	(0.14, 3.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.32	2.74	
95% CI of the absolute risk difference	(-10.45, 11.08)	(-10.70, 16.18)	
p-value	0.9535	0.6656	
p-value of Breslow-Day Test for Homogeneity [3]	0.6993	0.5894	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (10.0)	9 (40.9)	16 (25.4)
No	27 (90.0)	13 (59.1)	47 (74.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.06	0.49	
95% CI of the inverse odds ratio	(0.82, 11.48)	(0.18, 1.37)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.54	0.62	
95% CI of the inverse risk ratio	(0.80, 8.05)	(0.32, 1.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-15.40	15.51	
95% CI of the absolute risk difference	(-30.59, -0.21)	(-7.67, 38.70)	
p-value	0.0852	0.1692	
p-value of Breslow-Day Test for Homogeneity [3]	0.0850	0.1311	

AMNOG Table SE23.14a.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	8 (26.7)	3 (13.6)	13 (20.6)
No	22 (73.3)	19 (86.4)	50 (79.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	1.65	
95% CI of the inverse odds ratio	(0.26, 1.97)	(0.42, 6.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.51	
95% CI of the inverse risk ratio	(0.36, 1.66)	(0.48, 4.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.03	-7.00	
95% CI of the absolute risk difference	(-12.68, 24.75)	(-24.48, 10.48)	
p-value	0.5155	0.4697	
p-value of Breslow-Day Test for Homogeneity [3]	0.8899	0.3980	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (26.7)	8 (36.4)	20 (31.7)
No	22 (73.3)	14 (63.6)	43 (68.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	0.81	
95% CI of the inverse odds ratio	(0.49, 3.37)	(0.29, 2.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	0.87	
95% CI of the inverse risk ratio	(0.59, 2.39)	(0.45, 1.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.08	4.62	
95% CI of the absolute risk difference	(-24.64, 14.48)	(-18.54, 27.77)	
p-value	0.6177	0.6916	
p-value of Breslow-Day Test for Homogeneity [3]	0.6453	0.5105	

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE23.14a.5
Chronic Liver Disease Questionnaire-NASH (SE23): Mean Profile of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation
CLDQ-NASH



Patients with result at given visit			
MGL-3196 80 mg	45	46	38
MGL-3196 100 mg	39	38	32
Placebo	90	85	73

Abbreviations: Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE23.14a.5
Chronic Liver Disease Questionnaire-NASH (SE23): Mean Profile of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous
CLDQ-NASH



Patients with result at given visit			
MGL-3196 80 mg	72	72	67
MGL-3196 100 mg	65	64	51
Placebo	115	115	101

Abbreviations: Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE23.14a.5
Chronic Liver Disease Questionnaire-NASH (SE23): Mean Profile of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous
CLDQ-NASH



Patients with result at given visit			
MGL-3196 80 mg	30	27	25
MGL-3196 100 mg	21	22	20
Placebo	57	54	45

Abbreviations: Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
CLDQ-NASH						
Baseline						
m	124	112	223			
n	118	103	206			
Mean (SD)	5.22 (1.18)	5.23 (1.11)	5.22 (1.10)			
Median	5.30	5.50	5.30			
IQR: Q1, Q3	4.30, 6.20	4.50, 6.20	4.50, 6.10			
Min, Max	1.9, 7.0	2.1, 7.0	2.0, 7.0			
Week 24						
m	121	106	214			
n	115	102	201	111	95	189
Mean (SD/SE)	5.30 (1.15)	5.24 (1.01)	5.33 (1.07)	0.08 (0.07)	-0.03 (0.07)	0.10 (0.05)
Median	5.50	5.45	5.50	0	0	0
IQR: Q1, Q3	4.50, 6.30	4.60, 6.00	4.60, 6.20	-0.30, 0.40	-0.40, 0.40	-0.30, 0.50
Min, Max	2.1, 7.0	2.7, 6.8	2.3, 7.0	-2.0, 2.5	-1.6, 1.6	-2.3, 3.0
Week 52						
m	112	96	200			
n	103	88	172	98	84	161
Mean (SD/SE)	5.44 (1.09)	5.33 (1.05)	5.34 (1.08)	0.09 (0.07)	0.04 (0.07)	0.05 (0.05)
Median	5.60	5.60	5.50	0	0	0
IQR: Q1, Q3	4.70, 6.40	4.55, 6.10	4.70, 6.20	-0.20, 0.40	-0.35, 0.30	-0.30, 0.40
Min, Max	1.9, 7.0	2.2, 6.9	2.2, 7.0	-2.2, 2.7	-2.4, 1.8	-1.7, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Abdominal Symptoms						
Baseline						
m	124	112	223			
n	118	103	206			
Mean (SD)	5.30 (1.63)	5.61 (1.25)	5.20 (1.54)			
Median	6.00	6.00	5.30			
IQR: Q1, Q3	4.00, 6.70	4.70, 6.70	4.30, 6.70			
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0			
Week 24						
m	121	106	214			
n	115	102	201	111	95	189
Mean (SD/SE)	5.42 (1.44)	5.47 (1.41)	5.46 (1.45)	0.10 (0.10)	-0.10 (0.12)	0.21 (0.09)
Median	5.30	5.70	6.00	0	0	0
IQR: Q1, Q3	4.30, 6.70	4.70, 6.70	4.30, 7.00	-0.40, 0.70	-0.60, 0.30	-0.40, 0.70
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0	-3.0, 3.3	-4.0, 2.4	-3.0, 4.0
Week 52						
m	112	96	200			
n	103	88	172	98	84	161
Mean (SD/SE)	5.61 (1.39)	5.69 (1.19)	5.42 (1.42)	0.16 (0.13)	0.05 (0.10)	0.07 (0.10)
Median	6.00	5.85	5.70	0	0	0
IQR: Q1, Q3	5.00, 6.70	5.00, 6.70	4.70, 6.70	-0.30, 1.00	-0.30, 0.50	-0.70, 1.00
Min, Max	1.0, 7.0	1.7, 7.0	1.0, 7.0	-2.7, 4.0	-2.6, 2.7	-4.6, 4.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Activity						
Baseline						
m	124	112	223			
n	118	103	206			
Mean (SD)	5.21 (1.42)	5.26 (1.37)	5.41 (1.38)			
Median	5.40	5.60	5.60			
IQR: Q1, Q3	4.20, 6.40	4.40, 6.40	4.60, 6.60			
Min, Max	1.8, 7.0	1.8, 7.0	1.4, 7.0			
Week 24						
m	121	106	214			
n	115	102	201	111	95	189
Mean (SD/SE)	5.28 (1.46)	5.39 (1.29)	5.47 (1.34)	0.03 (0.09)	0.05 (0.09)	0.04 (0.07)
Median	5.60	5.80	5.80	0	0	0
IQR: Q1, Q3	4.40, 6.40	4.60, 6.40	4.60, 6.60	-0.60, 0.60	-0.60, 0.60	-0.60, 0.60
Min, Max	1.2, 7.0	2.4, 7.0	1.2, 7.0	-2.4, 2.8	-2.4, 3.2	-3.0, 2.6
Week 52						
m	112	96	200			
n	103	88	172	98	84	161
Mean (SD/SE)	5.41 (1.47)	5.37 (1.28)	5.44 (1.41)	0.01 (0.11)	0.02 (0.11)	-0.08 (0.07)
Median	5.80	5.60	5.80	0.20	0.20	0
IQR: Q1, Q3	4.60, 6.80	4.50, 6.40	4.60, 6.60	-0.40, 0.40	-0.40, 0.60	-0.60, 0.40
Min, Max	1.0, 7.0	1.6, 7.0	1.4, 7.0	-4.4, 3.0	-2.8, 2.0	-2.4, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Emotional Health						
Baseline						
m	124	112	223			
n	118	103	206			
Mean (SD)	5.37 (1.27)	5.32 (1.33)	5.43 (1.17)			
Median	5.60	5.60	5.65			
IQR: Q1, Q3	4.70, 6.30	4.70, 6.40	4.80, 6.30			
Min, Max	1.3, 7.0	2.0, 7.0	1.9, 7.0			
Week 24						
m	121	106	214			
n	115	102	201	111	95	189
Mean (SD/SE)	5.43 (1.26)	5.26 (1.24)	5.43 (1.22)	0.07 (0.08)	-0.09 (0.07)	0.00 (0.07)
Median	5.80	5.30	5.70	0	0	0
IQR: Q1, Q3	4.70, 6.40	4.40, 6.20	4.70, 6.40	-0.40, 0.60	-0.50, 0.20	-0.50, 0.50
Min, Max	2.0, 7.0	1.0, 7.0	1.9, 7.0	-2.8, 2.5	-2.0, 2.4	-2.9, 3.3
Week 52						
m	112	96	200			
n	103	88	172	98	84	161
Mean (SD/SE)	5.52 (1.04)	5.42 (1.25)	5.48 (1.18)	0.04 (0.09)	0.05 (0.09)	-0.01 (0.06)
Median	5.80	5.75	5.80	0	0	0
IQR: Q1, Q3	5.00, 6.30	4.70, 6.40	4.70, 6.40	-0.50, 0.60	-0.50, 0.60	-0.40, 0.40
Min, Max	3.0, 7.0	1.0, 7.0	1.7, 7.0	-1.9, 2.9	-1.9, 2.9	-2.0, 2.5

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Fatigue						
Baseline						
m	124	112	223			
n	118	103	206			
Mean (SD)	4.75 (1.51)	4.56 (1.48)	4.59 (1.47)			
Median	5.20	4.80	4.80			
IQR: Q1, Q3	3.70, 6.00	3.70, 5.70	3.50, 5.70			
Min, Max	1.2, 7.0	1.2, 7.0	1.0, 7.0			
Week 24						
m	121	106	214			
n	115	102	201	111	95	189
Mean (SD/SE)	4.80 (1.55)	4.47 (1.33)	4.64 (1.46)	0.03 (0.11)	-0.15 (0.10)	0.02 (0.08)
Median	5.00	4.50	4.80	0.10	-0.20	0
IQR: Q1, Q3	3.50, 6.00	3.50, 5.50	3.30, 5.80	-0.70, 0.60	-0.80, 0.50	-0.60, 0.50
Min, Max	1.3, 7.0	1.5, 6.8	1.2, 7.0	-2.7, 4.1	-4.2, 2.3	-3.8, 3.7
Week 52						
m	112	96	200			
n	103	88	172	98	84	161
Mean (SD/SE)	4.93 (1.50)	4.56 (1.49)	4.64 (1.43)	0.06 (0.11)	-0.14 (0.13)	0.00 (0.08)
Median	5.20	4.60	4.80	0	-0.05	0
IQR: Q1, Q3	3.70, 6.20	3.60, 5.80	3.70, 5.80	-0.50, 0.50	-0.50, 0.35	-0.70, 0.60
Min, Max	1.0, 7.0	1.2, 7.0	1.0, 7.0	-2.4, 4.0	-4.4, 2.5	-2.6, 2.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Systemic Symptoms						
Baseline						
m	124	112	223			
n	118	103	206			
Mean (SD)	5.13 (1.28)	5.08 (1.25)	5.05 (1.23)			
Median	5.30	5.20	5.20			
IQR: Q1, Q3	4.30, 6.20	4.30, 6.00	4.20, 6.00			
Min, Max	1.8, 7.0	1.8, 7.0	2.0, 7.0			
Week 24						
m	121	106	214			
n	115	102	201	111	95	189
Mean (SD/SE)	5.18 (1.23)	4.96 (1.22)	5.11 (1.25)	0.01 (0.08)	-0.21 (0.08)	0.00 (0.06)
Median	5.30	5.00	5.30	0	-0.20	0
IQR: Q1, Q3	4.30, 6.20	4.00, 6.00	4.30, 6.20	-0.50, 0.50	-0.70, 0.20	-0.60, 0.50
Min, Max	2.2, 7.0	1.8, 7.0	1.5, 7.0	-2.0, 3.5	-2.0, 2.2	-2.5, 3.7
Week 52						
m	112	96	200			
n	103	88	172	98	84	161
Mean (SD/SE)	5.25 (1.24)	5.05 (1.26)	5.10 (1.36)	-0.08 (0.08)	-0.10 (0.08)	-0.01 (0.06)
Median	5.50	5.20	5.30	0	0	0
IQR: Q1, Q3	4.30, 6.20	4.10, 6.00	4.20, 6.25	-0.50, 0.40	-0.50, 0.30	-0.50, 0.50
Min, Max	1.3, 7.0	1.5, 7.0	1.7, 7.0	-2.0, 2.3	-2.3, 2.0	-2.7, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Worry						
Baseline						
m	124	112	223			
n	118	103	206			
Mean (SD)	5.54 (1.34)	5.57 (1.44)	5.62 (1.36)			
Median	5.70	6.00	6.00			
IQR: Q1, Q3	4.70, 6.70	4.60, 6.70	4.70, 6.70			
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0			
Week 24						
m	121	106	214			
n	115	102	201	111	95	189
Mean (SD/SE)	5.73 (1.33)	5.82 (1.27)	5.89 (1.31)	0.23 (0.10)	0.26 (0.10)	0.31 (0.07)
Median	6.00	6.10	6.30	0.10	0	0.20
IQR: Q1, Q3	5.10, 6.70	5.00, 6.90	5.40, 7.00	-0.20, 0.60	-0.30, 0.70	-0.10, 0.70
Min, Max	1.6, 7.0	1.0, 7.0	1.0, 7.0	-3.1, 3.3	-1.7, 3.6	-2.6, 3.5
Week 52						
m	112	96	200			
n	103	88	172	98	84	161
Mean (SD/SE)	5.95 (1.25)	5.93 (1.39)	5.95 (1.30)	0.34 (0.11)	0.41 (0.12)	0.32 (0.08)
Median	6.40	6.30	6.40	0	0	0.10
IQR: Q1, Q3	5.30, 7.00	5.35, 7.00	5.40, 7.00	-0.30, 0.80	-0.15, 0.95	-0.10, 0.80
Min, Max	1.7, 7.0	1.0, 7.0	1.0, 7.0	-2.5, 3.8	-1.6, 3.6	-2.5, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
CLDQ-NASH						
Baseline						
m	26	24	62			
n	24	20	55			
Mean (SD)	4.99 (1.18)	5.37 (0.97)	5.12 (1.23)			
Median	5.10	5.60	5.20			
IQR: Q1, Q3	4.40, 5.85	4.75, 6.05	4.10, 6.20			
Min, Max	2.2, 6.9	3.6, 6.8	2.4, 7.0			
Week 24						
m	25	21	58			
n	25	20	53	23	17	47
Mean (SD/SE)	5.18 (1.17)	5.15 (1.04)	5.37 (1.21)	0.23 (0.10)	-0.14 (0.11)	0.23 (0.11)
Median	5.30	5.25	5.50	0	-0.30	0.20
IQR: Q1, Q3	4.50, 6.10	4.40, 6.05	4.60, 6.40	-0.10, 0.70	-0.40, 0.10	-0.10, 0.80
Min, Max	2.1, 6.8	3.2, 6.8	2.4, 7.0	-0.3, 1.4	-0.8, 0.8	-1.6, 2.6
Week 52						
m	25	17	55			
n	22	14	47	20	12	42
Mean (SD/SE)	4.98 (1.17)	5.19 (0.75)	5.34 (1.21)	0.02 (0.12)	-0.34 (0.20)	0.08 (0.14)
Median	5.05	5.10	5.50	-0.05	-0.15	-0.10
IQR: Q1, Q3	4.10, 6.10	4.70, 5.60	4.40, 6.30	-0.15, 0.15	-0.95, 0.20	-0.30, 0.50
Min, Max	2.4, 6.6	4.0, 6.5	1.9, 6.9	-1.4, 1.1	-1.5, 0.6	-2.2, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=26)	Visit Result: MGL-3196 100 mg (N=24)	Visit Result: Placebo (N=62)	Change from Baseline: MGL-3196 80 mg (N=26)	Change from Baseline: MGL-3196 100 mg (N=24)	Change from Baseline: Placebo (N=62)
Abdominal Symptoms						
Baseline						
m	26	24	62			
n	24	20	55			
Mean (SD)	4.85 (1.58)	5.32 (1.66)	5.17 (1.54)			
Median	4.70	5.85	5.70			
IQR: Q1, Q3	4.00, 6.15	4.00, 6.85	4.00, 6.70			
Min, Max	1.3, 7.0	2.0, 7.0	1.7, 7.0			
Week 24						
m	25	21	58			
n	25	20	53	23	17	47
Mean (SD/SE)	5.38 (1.47)	4.92 (1.73)	5.47 (1.57)	0.49 (0.24)	-0.29 (0.25)	0.27 (0.16)
Median	5.30	5.00	6.00	0	-0.30	0.30
IQR: Q1, Q3	4.70, 6.70	3.65, 6.50	4.00, 7.00	0.00, 1.00	-1.00, 0.30	-0.30, 1.00
Min, Max	1.3, 7.0	1.3, 7.0	1.0, 7.0	-1.7, 2.7	-2.7, 1.7	-2.3, 3.7
Week 52						
m	25	17	55			
n	22	14	47	20	12	42
Mean (SD/SE)	5.03 (1.51)	4.89 (1.47)	5.46 (1.42)	0.09 (0.23)	-0.99 (0.29)	0.15 (0.20)
Median	5.15	5.15	5.70	0.15	-0.65	0.15
IQR: Q1, Q3	4.00, 6.30	3.70, 5.70	4.00, 6.70	-0.50, 0.65	-1.85, -0.15	-0.30, 0.70
Min, Max	2.3, 7.0	2.3, 7.0	1.0, 7.0	-2.0, 2.0	-3.0, 0.0	-3.7, 3.3

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=26)	Visit Result MGL-3196 100 mg (N=24)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=26)	Change from Baseline MGL-3196 100 mg (N=24)	Change from Baseline Placebo (N=62)
Activity						
Baseline						
m	26	24	62			
n	24	20	55			
Mean (SD)	5.28 (1.32)	5.69 (0.97)	5.19 (1.45)			
Median	5.40	5.80	5.40			
IQR: Q1, Q3	4.60, 6.20	4.90, 6.60	4.00, 6.40			
Min, Max	2.0, 7.0	3.8, 7.0	1.8, 7.0			
Week 24						
m	25	21	58			
n	25	20	53	23	17	47
Mean (SD/SE)	5.18 (1.39)	5.35 (1.19)	5.47 (1.41)	0.00 (0.16)	-0.15 (0.16)	0.25 (0.15)
Median	5.60	5.70	6.00	0	0	0
IQR: Q1, Q3	4.40, 6.00	4.30, 6.20	4.40, 6.60	-0.40, 0.60	-0.60, 0.20	-0.20, 0.80
Min, Max	1.8, 7.0	2.4, 7.0	2.2, 7.0	-1.4, 1.6	-1.4, 1.2	-1.4, 3.2
Week 52						
m	25	17	55			
n	22	14	47	20	12	42
Mean (SD/SE)	4.98 (1.60)	5.34 (0.94)	5.27 (1.36)	-0.21 (0.21)	-0.33 (0.23)	-0.18 (0.17)
Median	5.30	5.20	5.60	-0.10	-0.40	-0.20
IQR: Q1, Q3	3.80, 6.40	4.80, 6.20	4.00, 6.60	-0.80, 0.50	-1.00, 0.30	-0.80, 0.40
Min, Max	1.2, 7.0	3.8, 7.0	2.4, 7.0	-3.0, 1.2	-1.6, 1.0	-3.4, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Emotional Health						
Baseline						
m	26	24	62			
n	24	20	55			
Mean (SD)	5.12 (1.09)	5.57 (0.97)	5.25 (1.37)			
Median	5.05	5.70	5.60			
IQR: Q1, Q3	4.40, 5.95	4.85, 6.30	4.00, 6.30			
Min, Max	2.6, 7.0	3.9, 7.0	1.8, 7.0			
Week 24						
m	25	21	58			
n	25	20	53	23	17	47
Mean (SD/SE)	5.30 (1.16)	5.51 (1.14)	5.51 (1.32)	0.30 (0.14)	-0.13 (0.21)	0.22 (0.13)
Median	5.20	5.85	6.00	0.20	0	0.20
IQR: Q1, Q3	4.60, 6.10	4.80, 6.25	4.80, 6.60	-0.10, 0.60	-0.30, 0.30	-0.30, 0.50
Min, Max	3.0, 7.0	2.3, 7.0	1.9, 7.0	-1.1, 1.8	-3.1, 0.9	-2.1, 2.6
Week 52						
m	25	17	55			
n	22	14	47	20	12	42
Mean (SD/SE)	5.06 (1.21)	5.67 (0.77)	5.47 (1.40)	0.01 (0.12)	-0.12 (0.16)	0.09 (0.16)
Median	5.00	5.80	5.70	0.05	-0.05	0
IQR: Q1, Q3	4.30, 6.20	5.00, 6.20	4.60, 6.60	-0.30, 0.20	-0.50, 0.20	-0.50, 0.30
Min, Max	2.8, 6.9	4.4, 7.0	1.3, 7.0	-1.0, 1.1	-1.2, 1.0	-1.9, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Fatigue						
Baseline						
m	26	24	62			
n	24	20	55			
Mean (SD)	4.44 (1.39)	4.71 (1.16)	4.65 (1.38)			
Median	4.60	4.75	4.80			
IQR: Q1, Q3	3.40, 5.30	4.15, 5.60	3.70, 5.80			
Min, Max	1.7, 6.7	2.5, 6.5	1.7, 7.0			
Week 24						
m	25	21	58			
n	25	20	53	23	17	47
Mean (SD/SE)	4.50 (1.49)	4.68 (1.11)	4.83 (1.47)	0.04 (0.14)	-0.08 (0.14)	0.20 (0.15)
Median	4.50	4.70	5.20	0	0	0.40
IQR: Q1, Q3	4.20, 5.70	4.10, 5.50	3.50, 6.00	-0.50, 0.30	-0.30, 0.20	-0.50, 0.80
Min, Max	1.5, 7.0	2.2, 6.3	1.7, 7.0	-1.0, 1.4	-1.5, 1.0	-2.5, 3.0
Week 52						
m	25	17	55			
n	22	14	47	20	12	42
Mean (SD/SE)	4.45 (1.53)	4.46 (1.06)	4.87 (1.45)	0.03 (0.20)	-0.18 (0.31)	0.15 (0.17)
Median	5.00	4.55	5.20	0.10	0.10	0.10
IQR: Q1, Q3	3.00, 5.80	3.80, 5.20	3.80, 5.80	-0.35, 0.45	-0.70, 0.50	-0.30, 0.50
Min, Max	2.0, 6.5	2.5, 6.3	1.2, 7.0	-2.3, 1.8	-2.8, 1.2	-3.8, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Systemic Symptoms						
Baseline						
m	26	24	62			
n	24	20	55			
Mean (SD)	4.99 (1.18)	5.13 (1.00)	4.98 (1.34)			
Median	5.40	5.20	5.20			
IQR: Q1, Q3	3.90, 5.80	4.75, 5.65	4.00, 6.00			
Min, Max	2.7, 7.0	2.7, 7.0	1.7, 7.0			
Week 24						
m	25	21	58			
n	25	20	53	23	17	47
Mean (SD/SE)	4.92 (1.27)	4.96 (1.19)	5.16 (1.25)	0.00 (0.10)	-0.02 (0.14)	0.07 (0.14)
Median	5.00	5.20	5.30	0	0.10	0
IQR: Q1, Q3	4.00, 5.80	4.35, 5.75	4.20, 6.20	-0.30, 0.30	-0.50, 0.30	-0.30, 0.60
Min, Max	2.7, 7.0	2.7, 6.8	2.3, 7.0	-0.8, 0.9	-1.3, 1.0	-2.3, 2.4
Week 52						
m	25	17	55			
n	22	14	47	20	12	42
Mean (SD/SE)	4.67 (1.31)	4.86 (0.93)	4.98 (1.31)	-0.25 (0.16)	-0.33 (0.34)	-0.06 (0.15)
Median	4.70	5.00	4.80	-0.25	-0.20	-0.15
IQR: Q1, Q3	3.80, 5.80	4.30, 5.50	4.20, 6.20	-0.65, 0.30	-0.75, 0.60	-0.70, 0.50
Min, Max	2.3, 6.7	2.7, 6.3	1.3, 7.0	-1.7, 1.0	-2.5, 1.0	-2.4, 2.7

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Worry						
Baseline						
m	26	24	62			
n	24	20	55			
Mean (SD)	5.30 (1.64)	5.75 (1.61)	5.43 (1.49)			
Median	5.65	6.35	5.90			
IQR: Q1, Q3	4.45, 6.75	4.85, 7.00	4.70, 6.60			
Min, Max	1.6, 7.0	1.9, 7.0	1.4, 7.0			
Week 24						
m	25	21	58			
n	25	20	53	23	17	47
Mean (SD/SE)	5.89 (1.54)	5.48 (1.55)	5.77 (1.51)	0.62 (0.20)	-0.10 (0.24)	0.34 (0.15)
Median	6.60	5.95	6.40	0.30	-0.10	0.10
IQR: Q1, Q3	5.60, 6.90	4.40, 6.70	5.10, 7.00	0.00, 1.30	-0.40, 0.10	-0.40, 0.90
Min, Max	1.6, 7.0	2.0, 7.0	1.1, 7.0	-1.0, 2.9	-2.6, 2.3	-2.0, 3.5
Week 52						
m	25	17	55			
n	22	14	47	20	12	42
Mean (SD/SE)	5.72 (1.39)	5.86 (1.26)	5.97 (1.31)	0.45 (0.19)	-0.04 (0.43)	0.35 (0.18)
Median	6.35	6.05	6.60	0.50	0	0.10
IQR: Q1, Q3	5.10, 6.70	5.40, 7.00	5.30, 7.00	0.00, 0.80	-0.30, 0.15	0.00, 0.80
Min, Max	2.1, 7.0	2.7, 7.0	1.6, 7.0	-1.0, 2.1	-3.3, 3.5	-2.7, 3.5

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
CLDQ-NASH						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	5.84 (0.90)	5.95 (0.07)	5.00 (N/A)			
Median	5.50	5.95	5.00			
IQR: Q1, Q3	5.20, 6.70	5.90, 6.00	5.00, 5.00			
Min, Max	4.9, 6.9	5.9, 6.0	5.0, 5.0			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	5.48 (0.91)	6.00 (0.28)	N/A	-0.36 (0.60)	0.05 (0.25)	N/A
Median	5.50	6.00	N/A	0	0.05	N/A
IQR: Q1, Q3	4.90, 6.20	5.80, 6.20	N/A	-0.20, 0.00	-0.20, 0.30	N/A
Min, Max	4.3, 6.5	5.8, 6.2	N/A	-2.6, 1.0	-0.2, 0.3	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	5.68 (0.64)	5.60 (N/A)	N/A	-0.16 (0.45)	-0.40 (N/A)	N/A
Median	5.60	5.60	N/A	0.30	-0.40	N/A
IQR: Q1, Q3	5.20, 6.00	5.60, 5.60	N/A	-0.10, 0.40	-0.40, -0.40	N/A
Min, Max	5.0, 6.6	5.6, 5.6	N/A	-1.9, 0.5	-0.4, -0.4	N/A

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Abdominal Symptoms						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	6.06 (1.03)	6.50 (0.71)	5.70 (N/A)			
Median	6.30	6.50	5.70			
IQR: Q1, Q3	5.30, 7.00	6.00, 7.00	5.70, 5.70			
Min, Max	4.7, 7.0	6.0, 7.0	5.7, 5.7			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	5.28 (1.86)	6.35 (0.92)	N/A	-0.78 (0.99)	-0.15 (0.15)	N/A
Median	6.00	6.35	N/A	0	-0.15	N/A
IQR: Q1, Q3	4.70, 6.70	5.70, 7.00	N/A	-0.30, 0.40	-0.30, 0.00	N/A
Min, Max	2.3, 6.7	5.7, 7.0	N/A	-4.7, 0.7	-0.3, 0.0	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	6.28 (1.45)	5.30 (N/A)	N/A	0.22 (0.96)	-0.70 (N/A)	N/A
Median	7.00	5.30	N/A	0.70	-0.70	N/A
IQR: Q1, Q3	6.70, 7.00	5.30, 5.30	N/A	0.00, 1.40	-0.70, -0.70	N/A
Min, Max	3.7, 7.0	5.3, 5.3	N/A	-3.3, 2.3	-0.7, -0.7	N/A

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Activity						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	6.20 (0.66)	5.70 (0.99)	6.40 (N/A)			
Median	6.40	5.70	6.40			
IQR: Q1, Q3	6.00, 6.40	5.00, 6.40	6.40, 6.40			
Min, Max	5.2, 7.0	5.0, 6.4	6.4, 6.4			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	5.72 (1.30)	6.00 (0.57)	N/A	-0.48 (0.69)	0.30 (1.10)	N/A
Median	5.80	6.00	N/A	0	0.30	N/A
IQR: Q1, Q3	5.20, 6.80	5.60, 6.40	N/A	-0.20, 0.40	-0.80, 1.40	N/A
Min, Max	3.8, 7.0	5.6, 6.4	N/A	-3.2, 0.6	-0.8, 1.4	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	5.76 (0.65)	6.60 (N/A)	N/A	-0.44 (0.47)	0.20 (N/A)	N/A
Median	5.80	6.60	N/A	0	0.20	N/A
IQR: Q1, Q3	5.60, 6.00	6.60, 6.60	N/A	-0.60, 0.20	0.20, 0.20	N/A
Min, Max	4.8, 6.6	6.6, 6.6	N/A	-2.2, 0.4	0.2, 0.2	N/A

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Emotional Health						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	5.90 (0.97)	6.25 (0.07)	4.60 (N/A)			
Median	6.00	6.25	4.60			
IQR: Q1, Q3	5.60, 6.70	6.20, 6.30	4.60, 4.60			
Min, Max	4.4, 6.8	6.2, 6.3	4.6, 4.6			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	5.36 (1.23)	5.85 (0.64)	N/A	-0.54 (0.46)	-0.40 (0.40)	N/A
Median	5.90	5.85	N/A	-0.10	-0.40	N/A
IQR: Q1, Q3	4.60, 6.10	5.40, 6.30	N/A	-0.80, -0.10	-0.80, 0.00	N/A
Min, Max	3.6, 6.6	5.4, 6.3	N/A	-2.2, 0.5	-0.8, 0.0	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	5.76 (0.87)	5.20 (N/A)	N/A	-0.14 (0.15)	-1.00 (N/A)	N/A
Median	6.00	5.20	N/A	-0.10	-1.00	N/A
IQR: Q1, Q3	5.80, 6.10	5.20, 5.20	N/A	-0.10, 0.00	-1.00, -1.00	N/A
Min, Max	4.3, 6.6	5.2, 5.2	N/A	-0.7, 0.2	-1.0, -1.0	N/A

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Fatigue						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	4.94 (1.90)	4.95 (0.35)	2.30 (N/A)			
Median	5.30	4.95	2.30			
IQR: Q1, Q3	3.80, 6.30	4.70, 5.20	2.30, 2.30			
Min, Max	2.3, 7.0	4.7, 5.2	2.3, 2.3			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	4.70 (1.20)	5.30 (0.00)	N/A	-0.24 (0.66)	0.35 (0.25)	N/A
Median	5.30	5.30	N/A	0	0.35	N/A
IQR: Q1, Q3	4.50, 5.30	5.30, 5.30	N/A	-0.60, 0.40	0.10, 0.60	N/A
Min, Max	2.7, 5.7	5.3, 5.3	N/A	-2.5, 1.5	0.1, 0.6	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	4.62 (1.60)	5.50 (N/A)	N/A	-0.32 (0.43)	0.30 (N/A)	N/A
Median	5.00	5.50	N/A	0	0.30	N/A
IQR: Q1, Q3	3.80, 5.70	5.50, 5.50	N/A	0.00, 0.00	0.30, 0.30	N/A
Min, Max	2.3, 6.3	5.5, 5.5	N/A	-2.0, 0.4	0.3, 0.3	N/A

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Systemic Symptoms						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	5.82 (0.77)	5.25 (0.07)	4.20 (N/A)			
Median	5.70	5.25	4.20			
IQR: Q1, Q3	5.50, 6.30	5.20, 5.30	4.20, 4.20			
Min, Max	4.8, 6.8	5.2, 5.3	4.2, 4.2			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	5.56 (0.62)	5.50 (0.28)	N/A	-0.26 (0.38)	0.25 (0.15)	N/A
Median	5.50	5.50	N/A	-0.20	0.25	N/A
IQR: Q1, Q3	5.30, 5.70	5.30, 5.70	N/A	-0.30, -0.20	0.10, 0.40	N/A
Min, Max	4.8, 6.5	5.3, 5.7	N/A	-1.5, 0.9	0.1, 0.4	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	5.46 (0.69)	4.80 (N/A)	N/A	-0.36 (0.31)	-0.50 (N/A)	N/A
Median	5.70	4.80	N/A	-0.10	-0.50	N/A
IQR: Q1, Q3	4.80, 5.80	4.80, 4.80	N/A	-0.50, 0.10	-0.50, -0.50	N/A
Min, Max	4.7, 6.3	4.8, 4.8	N/A	-1.5, 0.2	-0.5, -0.5	N/A

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=5)	Visit Result: MGL-3196 100 mg (N=2)	Visit Result: Placebo (N=1)	Change from Baseline: MGL-3196 80 mg (N=5)	Change from Baseline: MGL-3196 100 mg (N=2)	Change from Baseline: Placebo (N=1)
Worry						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	6.08 (1.05)	7.00 (0.00)	7.00 (N/A)			
Median	6.40	7.00	7.00			
IQR: Q1, Q3	5.40, 7.00	7.00, 7.00	7.00, 7.00			
Min, Max	4.6, 7.0	7.0, 7.0	7.0, 7.0			
Week 24						
m	5	2	0			
n	5	2	0	5	2	0
Mean (SD/SE)	6.34 (0.83)	6.95 (0.07)	N/A	0.26 (0.43)	-0.05 (0.05)	N/A
Median	6.70	6.95	N/A	0.30	-0.05	N/A
IQR: Q1, Q3	5.90, 7.00	6.90, 7.00	N/A	0.00, 0.50	-0.10, 0.00	N/A
Min, Max	5.1, 7.0	6.9, 7.0	N/A	-1.1, 1.6	-0.1, 0.0	N/A
Week 52						
m	5	1	0			
n	5	1	0	5	1	0
Mean (SD/SE)	6.20 (0.58)	6.30 (N/A)	N/A	0.12 (0.44)	-0.70 (N/A)	N/A
Median	5.90	6.30	N/A	0	-0.70	N/A
IQR: Q1, Q3	5.90, 6.60	6.30, 6.30	N/A	-0.50, 1.00	-0.70, -0.70	N/A
Min, Max	5.6, 7.0	6.3, 6.3	N/A	-1.1, 1.2	-0.7, -0.7	N/A

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.14b.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
CLDQ-NASH			
Week 24			
m	121	106	214
n	111	95	189
Baseline Mean (SD)	5.23 (1.16)	5.25 (1.13)	5.25 (1.08)
Analysis Visit Mean (SD)	5.31 (1.14)	5.22 (1.02)	5.35 (1.07)
LS Mean of Change from Baseline (SE)	0.10 (0.06)	-0.04 (0.07)	0.12 (0.05)
95% CI	(-0.03, 0.22)	(-0.17, 0.10)	(0.02, 0.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.08)	-0.15 (0.08)	
95% CI	(-0.17, 0.14)	(-0.32, 0.01)	
p-value	0.8269	0.0626	
Corrected Hedge's g Statistics	-0.025	-0.229	
95% CI	(-0.26, 0.21)	(-0.48, 0.02)	
Week 52			
m	112	96	200
n	98	84	161
Baseline Mean (SD)	5.34 (1.12)	5.25 (1.15)	5.29 (1.07)
Analysis Visit Mean (SD)	5.43 (1.09)	5.29 (1.05)	5.34 (1.10)
LS Mean of Change from Baseline (SE)	0.11 (0.06)	0.02 (0.07)	0.08 (0.05)
95% CI	(-0.01, 0.24)	(-0.11, 0.15)	(-0.01, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.08)	-0.06 (0.08)	
95% CI	(-0.12, 0.18)	(-0.22, 0.10)	
p-value	0.6820	0.4844	
Corrected Hedge's g Statistics	0.051	-0.092	
95% CI	(-0.20, 0.30)	(-0.36, 0.17)	
Subgroup*Treatment Interaction p-value	0.8003	0.3370	

AMNOG Table SE23.14b.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
CLDQ-NASH			
Week 24			
m	25	21	58
n	23	17	47
Baseline Mean (SD)	4.93 (1.17)	5.27 (1.00)	5.19 (1.26)
Analysis Visit Mean (SD)	5.17 (1.22)	5.13 (0.98)	5.42 (1.20)
LS Mean of Change from Baseline (SE)	0.22 (0.14)	-0.07 (0.16)	0.23 (0.10)
95% CI	(-0.06, 0.50)	(-0.39, 0.26)	(0.03, 0.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.17)	-0.29 (0.18)	
95% CI	(-0.34, 0.32)	(-0.65, 0.07)	
p-value	0.9694	0.1098	
Corrected Hedge's g Statistics	-0.009	-0.426	
95% CI	(-0.51, 0.49)	(-0.99, 0.13)	
Week 52			
m	25	17	55
n	20	12	42
Baseline Mean (SD)	5.00 (1.23)	5.52 (0.67)	5.28 (1.25)
Analysis Visit Mean (SD)	5.02 (1.23)	5.18 (0.80)	5.36 (1.13)
LS Mean of Change from Baseline (SE)	0.01 (0.16)	-0.15 (0.20)	0.18 (0.11)
95% CI	(-0.32, 0.33)	(-0.55, 0.25)	(-0.05, 0.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.17 (0.19)	-0.33 (0.22)	
95% CI	(-0.56, 0.21)	(-0.77, 0.11)	
p-value	0.3778	0.1446	
Corrected Hedge's g Statistics	-0.232	-0.444	
95% CI	(-0.77, 0.30)	(-1.09, 0.20)	
Subgroup*Treatment Interaction p-value	0.8003	0.3370	

AMNOG Table SE23.14b.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
CLDQ-NASH			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	5.84 (0.90)	5.95 (0.07)	N/A
Analysis Visit Mean (SD)	5.48 (0.91)	6.00 (0.28)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	5.84 (0.90)	6.00 (N/A)	N/A
Analysis Visit Mean (SD)	5.68 (0.64)	5.60 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.8003	0.3370	

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Abdominal Symptoms			
Week 24			
m	121	106	214
n	111	95	189
Baseline Mean (SD)	5.33 (1.62)	5.60 (1.28)	5.29 (1.51)
Analysis Visit Mean (SD)	5.43 (1.45)	5.50 (1.44)	5.49 (1.42)
LS Mean of Change from Baseline (SE)	0.10 (0.10)	-0.02 (0.11)	0.20 (0.08)
95% CI	(-0.10, 0.31)	(-0.24, 0.20)	(0.04, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.09 (0.13)	-0.22 (0.13)	
95% CI	(-0.35, 0.16)	(-0.48, 0.05)	
p-value	0.4622	0.1088	
Corrected Hedge's g Statistics	-0.085	-0.198	
95% CI	(-0.32, 0.15)	(-0.44, 0.05)	
Week 52			
m	112	96	200
n	98	84	161
Baseline Mean (SD)	5.43 (1.55)	5.62 (1.30)	5.35 (1.47)
Analysis Visit Mean (SD)	5.59 (1.41)	5.67 (1.20)	5.41 (1.44)
LS Mean of Change from Baseline (SE)	0.16 (0.11)	0.10 (0.11)	0.09 (0.08)
95% CI	(-0.05, 0.37)	(-0.13, 0.32)	(-0.08, 0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.07 (0.13)	0.01 (0.14)	
95% CI	(-0.19, 0.33)	(-0.26, 0.28)	
p-value	0.5993	0.9467	
Corrected Hedge's g Statistics	0.066	0.009	
95% CI	(-0.19, 0.32)	(-0.25, 0.27)	
Subgroup*Treatment Interaction p-value	0.9533	0.0426	

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Activity			
Week 24			
m	121	106	214
n	111	95	189
Baseline Mean (SD)	5.24 (1.41)	5.31 (1.36)	5.46 (1.36)
Analysis Visit Mean (SD)	5.27 (1.48)	5.36 (1.29)	5.50 (1.31)
LS Mean of Change from Baseline (SE)	0.03 (0.09)	0.03 (0.09)	0.09 (0.07)
95% CI	(-0.14, 0.20)	(-0.15, 0.21)	(-0.04, 0.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.11)	-0.05 (0.11)	
95% CI	(-0.26, 0.15)	(-0.27, 0.17)	
p-value	0.6003	0.6276	
Corrected Hedge's g Statistics	-0.061	-0.059	
95% CI	(-0.30, 0.17)	(-0.31, 0.19)	
Week 52			
m	112	96	200
n	98	84	161
Baseline Mean (SD)	5.36 (1.36)	5.30 (1.37)	5.52 (1.30)
Analysis Visit Mean (SD)	5.37 (1.48)	5.31 (1.28)	5.44 (1.42)
LS Mean of Change from Baseline (SE)	0.03 (0.10)	0.00 (0.10)	-0.02 (0.08)
95% CI	(-0.16, 0.22)	(-0.20, 0.20)	(-0.17, 0.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.12)	0.02 (0.13)	
95% CI	(-0.19, 0.28)	(-0.23, 0.27)	
p-value	0.7204	0.8797	
Corrected Hedge's g Statistics	0.045	0.020	
95% CI	(-0.21, 0.30)	(-0.24, 0.28)	
Subgroup*Treatment Interaction p-value	0.6437	0.5439	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Emotional Health			
Week 24			
m	121	106	214
n	111	95	189
Baseline Mean (SD)	5.37 (1.25)	5.32 (1.36)	5.42 (1.17)
Analysis Visit Mean (SD)	5.45 (1.26)	5.23 (1.24)	5.42 (1.21)
LS Mean of Change from Baseline (SE)	0.07 (0.08)	-0.12 (0.08)	0.00 (0.06)
95% CI	(-0.09, 0.22)	(-0.28, 0.04)	(-0.11, 0.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.06 (0.09)	-0.12 (0.10)	
95% CI	(-0.12, 0.25)	(-0.32, 0.07)	
p-value	0.5076	0.2238	
Corrected Hedge's g Statistics	0.077	-0.150	
95% CI	(-0.16, 0.31)	(-0.40, 0.10)	
Week 52			
m	112	96	200
n	98	84	161
Baseline Mean (SD)	5.48 (1.21)	5.33 (1.40)	5.47 (1.17)
Analysis Visit Mean (SD)	5.52 (1.01)	5.38 (1.26)	5.47 (1.19)
LS Mean of Change from Baseline (SE)	0.05 (0.08)	0.01 (0.08)	-0.01 (0.06)
95% CI	(-0.10, 0.20)	(-0.15, 0.17)	(-0.12, 0.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.06 (0.09)	0.02 (0.10)	
95% CI	(-0.13, 0.24)	(-0.17, 0.21)	
p-value	0.5523	0.8289	
Corrected Hedge's g Statistics	0.074	0.028	
95% CI	(-0.18, 0.33)	(-0.24, 0.29)	
Subgroup*Treatment Interaction p-value	0.5175	0.6099	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Fatigue			
Week 24			
m	121	106	214
n	111	95	189
Baseline Mean (SD)	4.78 (1.49)	4.59 (1.50)	4.62 (1.47)
Analysis Visit Mean (SD)	4.81 (1.53)	4.43 (1.34)	4.64 (1.47)
LS Mean of Change from Baseline (SE)	0.08 (0.10)	-0.19 (0.10)	0.02 (0.08)
95% CI	(-0.11, 0.28)	(-0.39, 0.02)	(-0.12, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.06 (0.12)	-0.21 (0.13)	
95% CI	(-0.18, 0.30)	(-0.46, 0.04)	
p-value	0.6235	0.0958	
Corrected Hedge's g Statistics	0.057	-0.205	
95% CI	(-0.18, 0.29)	(-0.45, 0.04)	
Week 52			
m	112	96	200
n	98	84	161
Baseline Mean (SD)	4.86 (1.50)	4.64 (1.51)	4.66 (1.45)
Analysis Visit Mean (SD)	4.92 (1.47)	4.51 (1.48)	4.66 (1.45)
LS Mean of Change from Baseline (SE)	0.10 (0.10)	-0.14 (0.11)	0.00 (0.08)
95% CI	(-0.10, 0.30)	(-0.35, 0.07)	(-0.15, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (0.12)	-0.14 (0.13)	
95% CI	(-0.15, 0.34)	(-0.40, 0.11)	
p-value	0.4398	0.2736	
Corrected Hedge's g Statistics	0.096	-0.144	
95% CI	(-0.15, 0.35)	(-0.41, 0.12)	
Subgroup*Treatment Interaction p-value	0.3139	0.7568	

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Systemic Symptoms			
Week 24			
m	121	106	214
n	111	95	189
Baseline Mean (SD)	5.14 (1.26)	5.12 (1.25)	5.10 (1.20)
Analysis Visit Mean (SD)	5.15 (1.24)	4.91 (1.22)	5.10 (1.27)
LS Mean of Change from Baseline (SE)	0.05 (0.08)	-0.20 (0.08)	0.02 (0.06)
95% CI	(-0.10, 0.20)	(-0.36, -0.04)	(-0.10, 0.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.10)	-0.22 (0.10)	
95% CI	(-0.16, 0.22)	(-0.42, -0.02)	
p-value	0.7803	0.0285	
Corrected Hedge's g Statistics	0.032	-0.270	
95% CI	(-0.20, 0.27)	(-0.52, -0.02)	
Week 52			
m	112	96	200
n	98	84	161
Baseline Mean (SD)	5.28 (1.21)	5.11 (1.25)	5.10 (1.22)
Analysis Visit Mean (SD)	5.20 (1.25)	5.01 (1.26)	5.09 (1.38)
LS Mean of Change from Baseline (SE)	-0.01 (0.08)	-0.11 (0.08)	0.04 (0.06)
95% CI	(-0.17, 0.14)	(-0.28, 0.05)	(-0.08, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.10)	-0.15 (0.10)	
95% CI	(-0.25, 0.14)	(-0.36, 0.05)	
p-value	0.5742	0.1355	
Corrected Hedge's g Statistics	-0.070	-0.197	
95% CI	(-0.32, 0.18)	(-0.46, 0.07)	
Subgroup*Treatment Interaction p-value	0.6466	0.5990	

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Worry			
Week 24			
m	121	106	214
n	111	95	189
Baseline Mean (SD)	5.53 (1.33)	5.54 (1.48)	5.61 (1.35)
Analysis Visit Mean (SD)	5.77 (1.28)	5.80 (1.30)	5.93 (1.30)
LS Mean of Change from Baseline (SE)	0.23 (0.09)	0.25 (0.09)	0.34 (0.07)
95% CI	(0.07, 0.40)	(0.07, 0.43)	(0.21, 0.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.11)	-0.09 (0.11)	
95% CI	(-0.32, 0.10)	(-0.31, 0.12)	
p-value	0.3047	0.3923	
Corrected Hedge's g Statistics	-0.119	-0.105	
95% CI	(-0.35, 0.12)	(-0.35, 0.14)	
Week 52			
m	112	96	200
n	98	84	161
Baseline Mean (SD)	5.63 (1.31)	5.49 (1.54)	5.65 (1.37)
Analysis Visit Mean (SD)	5.97 (1.20)	5.90 (1.41)	5.97 (1.30)
LS Mean of Change from Baseline (SE)	0.34 (0.09)	0.36 (0.10)	0.35 (0.07)
95% CI	(0.16, 0.53)	(0.16, 0.56)	(0.20, 0.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.12)	0.01 (0.12)	
95% CI	(-0.24, 0.23)	(-0.23, 0.26)	
p-value	0.9669	0.9120	
Corrected Hedge's g Statistics	-0.005	0.015	
95% CI	(-0.26, 0.25)	(-0.25, 0.28)	
Subgroup*Treatment Interaction p-value	0.3292	0.3775	

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Abdominal Symptoms			
Week 24			
m	25	21	58
n	23	17	47
Baseline Mean (SD)	4.81 (1.61)	5.16 (1.74)	5.25 (1.56)
Analysis Visit Mean (SD)	5.30 (1.49)	4.87 (1.79)	5.52 (1.46)
LS Mean of Change from Baseline (SE)	0.43 (0.22)	-0.16 (0.26)	0.36 (0.16)
95% CI	(-0.01, 0.88)	(-0.67, 0.36)	(0.04, 0.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.27)	-0.52 (0.29)	
95% CI	(-0.46, 0.61)	(-1.09, 0.06)	
p-value	0.7786	0.0800	
Corrected Hedge's g Statistics	0.069	-0.472	
95% CI	(-0.43, 0.57)	(-1.03, 0.09)	
Week 52			
m	25	17	55
n	20	12	42
Baseline Mean (SD)	4.93 (1.65)	5.87 (1.09)	5.35 (1.49)
Analysis Visit Mean (SD)	5.02 (1.58)	4.88 (1.60)	5.50 (1.29)
LS Mean of Change from Baseline (SE)	0.11 (0.24)	-0.60 (0.31)	0.33 (0.17)
95% CI	(-0.36, 0.58)	(-1.21, 0.01)	(0.01, 0.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.22 (0.28)	-0.93 (0.34)	
95% CI	(-0.79, 0.34)	(-1.60, -0.27)	
p-value	0.4307	0.0067	
Corrected Hedge's g Statistics	-0.207	-0.859	
95% CI	(-0.74, 0.33)	(-1.52, -0.20)	
Subgroup*Treatment Interaction p-value	0.9533	0.0426	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Activity			
Week 24			
m	25	21	58
n	23	17	47
Baseline Mean (SD)	5.20 (1.30)	5.56 (0.99)	5.29 (1.39)
Analysis Visit Mean (SD)	5.20 (1.41)	5.41 (1.00)	5.54 (1.41)
LS Mean of Change from Baseline (SE)	-0.03 (0.19)	-0.11 (0.22)	0.20 (0.13)
95% CI	(-0.41, 0.34)	(-0.54, 0.33)	(-0.07, 0.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.24 (0.23)	-0.31 (0.25)	
95% CI	(-0.68, 0.21)	(-0.80, 0.18)	
p-value	0.2994	0.2159	
Corrected Hedge's g Statistics	-0.253	-0.330	
95% CI	(-0.75, 0.25)	(-0.89, 0.23)	
Week 52			
m	25	17	55
n	20	12	42
Baseline Mean (SD)	5.27 (1.38)	5.70 (0.83)	5.43 (1.35)
Analysis Visit Mean (SD)	5.06 (1.63)	5.37 (1.00)	5.25 (1.37)
LS Mean of Change from Baseline (SE)	-0.21 (0.22)	-0.26 (0.28)	-0.10 (0.16)
95% CI	(-0.66, 0.23)	(-0.82, 0.30)	(-0.41, 0.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.27)	-0.16 (0.31)	
95% CI	(-0.64, 0.42)	(-0.78, 0.46)	
p-value	0.6780	0.6072	
Corrected Hedge's g Statistics	-0.109	-0.158	
95% CI	(-0.64, 0.42)	(-0.80, 0.48)	
Subgroup*Treatment Interaction p-value	0.6437	0.5439	

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Emotional Health			
Week 24			
m	25	21	58
n	23	17	47
Baseline Mean (SD)	5.08 (1.10)	5.54 (0.95)	5.32 (1.43)
Analysis Visit Mean (SD)	5.38 (1.17)	5.41 (1.14)	5.54 (1.33)
LS Mean of Change from Baseline (SE)	0.29 (0.17)	-0.03 (0.20)	0.20 (0.12)
95% CI	(-0.05, 0.63)	(-0.42, 0.37)	(-0.04, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (0.20)	-0.23 (0.22)	
95% CI	(-0.32, 0.49)	(-0.67, 0.21)	
p-value	0.6759	0.3010	
Corrected Hedge's g Statistics	0.102	-0.276	
95% CI	(-0.40, 0.60)	(-0.83, 0.28)	
Week 52			
m	25	17	55
n	20	12	42
Baseline Mean (SD)	5.12 (1.18)	5.69 (0.75)	5.36 (1.50)
Analysis Visit Mean (SD)	5.13 (1.25)	5.58 (0.76)	5.45 (1.41)
LS Mean of Change from Baseline (SE)	-0.03 (0.19)	0.08 (0.23)	0.13 (0.13)
95% CI	(-0.40, 0.34)	(-0.39, 0.54)	(-0.13, 0.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.16 (0.22)	-0.06 (0.26)	
95% CI	(-0.60, 0.28)	(-0.57, 0.46)	
p-value	0.4735	0.8280	
Corrected Hedge's g Statistics	-0.187	-0.066	
95% CI	(-0.72, 0.35)	(-0.71, 0.58)	
Subgroup*Treatment Interaction p-value	0.5175	0.6099	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Fatigue			
Week 24			
m	25	21	58
n	23	17	47
Baseline Mean (SD)	4.40 (1.41)	4.73 (1.18)	4.70 (1.44)
Analysis Visit Mean (SD)	4.44 (1.53)	4.65 (1.10)	4.90 (1.46)
LS Mean of Change from Baseline (SE)	0.02 (0.19)	-0.01 (0.22)	0.23 (0.13)
95% CI	(-0.36, 0.39)	(-0.44, 0.42)	(-0.04, 0.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.21 (0.22)	-0.24 (0.24)	
95% CI	(-0.65, 0.24)	(-0.72, 0.25)	
p-value	0.3550	0.3380	
Corrected Hedge's g Statistics	-0.226	-0.255	
95% CI	(-0.73, 0.27)	(-0.81, 0.30)	
Week 52			
m	25	17	55
n	20	12	42
Baseline Mean (SD)	4.44 (1.50)	4.58 (1.00)	4.79 (1.43)
Analysis Visit Mean (SD)	4.47 (1.60)	4.41 (1.13)	4.95 (1.36)
LS Mean of Change from Baseline (SE)	-0.01 (0.22)	-0.17 (0.28)	0.27 (0.15)
95% CI	(-0.45, 0.42)	(-0.72, 0.38)	(-0.04, 0.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.28 (0.26)	-0.43 (0.31)	
95% CI	(-0.80, 0.24)	(-1.04, 0.17)	
p-value	0.2894	0.1599	
Corrected Hedge's g Statistics	-0.279	-0.434	
95% CI	(-0.81, 0.26)	(-1.08, 0.21)	
Subgroup*Treatment Interaction p-value	0.3139	0.7568	

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Systemic Symptoms			
Week 24			
m	25	21	58
n	23	17	47
Baseline Mean (SD)	4.92 (1.15)	5.05 (1.04)	5.12 (1.29)
Analysis Visit Mean (SD)	4.92 (1.31)	5.03 (1.11)	5.19 (1.24)
LS Mean of Change from Baseline (SE)	-0.02 (0.17)	0.02 (0.20)	0.06 (0.12)
95% CI	(-0.36, 0.32)	(-0.37, 0.42)	(-0.18, 0.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.20)	-0.03 (0.22)	
95% CI	(-0.49, 0.32)	(-0.48, 0.41)	
p-value	0.6904	0.8778	
Corrected Hedge's g Statistics	-0.097	-0.041	
95% CI	(-0.60, 0.40)	(-0.60, 0.51)	
Week 52			
m	25	17	55
n	20	12	42
Baseline Mean (SD)	4.98 (1.17)	5.25 (0.59)	5.07 (1.41)
Analysis Visit Mean (SD)	4.73 (1.36)	4.93 (0.95)	5.01 (1.23)
LS Mean of Change from Baseline (SE)	-0.30 (0.20)	-0.28 (0.25)	-0.02 (0.14)
95% CI	(-0.69, 0.10)	(-0.77, 0.21)	(-0.30, 0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.27 (0.24)	-0.25 (0.27)	
95% CI	(-0.74, 0.20)	(-0.80, 0.29)	
p-value	0.2500	0.3575	
Corrected Hedge's g Statistics	-0.302	-0.281	
95% CI	(-0.84, 0.23)	(-0.92, 0.36)	
Subgroup*Treatment Interaction p-value	0.6466	0.5990	

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Worry			
Week 24			
m	25	21	58
n	23	17	47
Baseline Mean (SD)	5.22 (1.63)	5.53 (1.66)	5.46 (1.55)
Analysis Visit Mean (SD)	5.84 (1.60)	5.43 (1.59)	5.80 (1.51)
LS Mean of Change from Baseline (SE)	0.60 (0.21)	-0.05 (0.24)	0.30 (0.15)
95% CI	(0.18, 1.02)	(-0.53, 0.44)	(0.01, 0.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.29 (0.25)	-0.35 (0.27)	
95% CI	(-0.20, 0.79)	(-0.89, 0.19)	
p-value	0.2452	0.2019	
Corrected Hedge's g Statistics	0.285	-0.341	
95% CI	(-0.22, 0.79)	(-0.90, 0.22)	
Week 52			
m	25	17	55
n	20	12	42
Baseline Mean (SD)	5.27 (1.75)	5.93 (1.53)	5.64 (1.41)
Analysis Visit Mean (SD)	5.72 (1.46)	5.89 (1.25)	5.99 (1.17)
LS Mean of Change from Baseline (SE)	0.38 (0.21)	0.32 (0.26)	0.40 (0.15)
95% CI	(-0.05, 0.80)	(-0.21, 0.85)	(0.10, 0.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.25)	-0.08 (0.29)	
95% CI	(-0.53, 0.48)	(-0.66, 0.50)	
p-value	0.9333	0.7919	
Corrected Hedge's g Statistics	-0.022	-0.079	
95% CI	(-0.55, 0.51)	(-0.72, 0.56)	
Subgroup*Treatment Interaction p-value	0.3292	0.3775	

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Abdominal Symptoms			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	6.06 (1.03)	6.50 (0.71)	N/A
Analysis Visit Mean (SD)	5.28 (1.86)	6.35 (0.92)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	6.06 (1.03)	6.00 (N/A)	N/A
Analysis Visit Mean (SD)	6.28 (1.45)	5.30 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.9533	0.0426	

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Activity			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	6.20 (0.66)	5.70 (0.99)	N/A
Analysis Visit Mean (SD)	5.72 (1.30)	6.00 (0.57)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	6.20 (0.66)	6.40 (N/A)	N/A
Analysis Visit Mean (SD)	5.76 (0.65)	6.60 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.6437	0.5439	

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Emotional Health			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	5.90 (0.97)	6.25 (0.07)	N/A
Analysis Visit Mean (SD)	5.36 (1.23)	5.85 (0.64)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	5.90 (0.97)	6.20 (N/A)	N/A
Analysis Visit Mean (SD)	5.76 (0.87)	5.20 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.5175	0.6099	

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Fatigue			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	4.94 (1.90)	4.95 (0.35)	N/A
Analysis Visit Mean (SD)	4.70 (1.20)	5.30 (0.00)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	4.94 (1.90)	5.20 (N/A)	N/A
Analysis Visit Mean (SD)	4.62 (1.60)	5.50 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.3139	0.7568	

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Systemic Symptoms			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	5.82 (0.77)	5.25 (0.07)	N/A
Analysis Visit Mean (SD)	5.56 (0.62)	5.50 (0.28)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	5.82 (0.77)	5.30 (N/A)	N/A
Analysis Visit Mean (SD)	5.46 (0.69)	4.80 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.6466	0.5990	

AMNOG Table SE23.14b.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Worry			
Week 24			
m	5	2	0
n	5	2	0
Baseline Mean (SD)	6.08 (1.05)	7.00 (0.00)	N/A
Analysis Visit Mean (SD)	6.34 (0.83)	6.95 (0.07)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	5	1	0
Baseline Mean (SD)	6.08 (1.05)	7.00 (N/A)	N/A
Analysis Visit Mean (SD)	6.20 (0.58)	6.30 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.3292	0.3775	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (7.3)	10 (8.9)	17 (7.6)
No	115 (92.7)	102 (91.1)	206 (92.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.84	
95% CI of the inverse odds ratio	(0.46, 2.44)	(0.37, 1.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.85	
95% CI of the inverse risk ratio	(0.48, 2.29)	(0.40, 1.80)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.37	1.31	
95% CI of the absolute risk difference	(-6.11, 5.38)	(-5.02, 7.63)	
p-value	0.9014	0.6789	
p-value of Breslow-Day Test for Homogeneity [3]	0.6931	0.0757	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	31 (25.0)	25 (22.3)	53 (23.8)
No	93 (75.0)	87 (77.7)	170 (76.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.08	
95% CI of the inverse odds ratio	(0.56, 1.56)	(0.63, 1.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	1.06	
95% CI of the inverse risk ratio	(0.65, 1.40)	(0.70, 1.62)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.23	-1.45	
95% CI of the absolute risk difference	(-8.22, 10.68)	(-10.97, 8.08)	
p-value	0.7972	0.7678	
p-value of Breslow-Day Test for Homogeneity [3]	0.4903	0.5576	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	25 (20.2)	15 (13.4)	41 (18.4)
No	99 (79.8)	97 (86.6)	182 (81.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.46	
95% CI of the inverse odds ratio	(0.51, 1.55)	(0.77, 2.76)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.37	
95% CI of the inverse risk ratio	(0.58, 1.42)	(0.80, 2.37)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.78	-4.99	
95% CI of the absolute risk difference	(-6.93, 10.48)	(-13.09, 3.11)	
p-value	0.6863	0.2479	
p-value of Breslow-Day Test for Homogeneity [3]	0.7370	0.0873	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	41 (33.1)	28 (25.0)	68 (30.5)
No	83 (66.9)	84 (75.0)	155 (69.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.32	
95% CI of the inverse odds ratio	(0.55, 1.42)	(0.79, 2.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.22	
95% CI of the inverse risk ratio	(0.67, 1.27)	(0.84, 1.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.57	-5.49	
95% CI of the absolute risk difference	(-7.68, 12.82)	(-15.53, 4.55)	
p-value	0.6210	0.2942	
p-value of Breslow-Day Test for Homogeneity [3]	0.5813	0.0054	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (12.9)	15 (13.4)	17 (7.6)
No	108 (87.1)	97 (86.6)	206 (92.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.53	
95% CI of the inverse odds ratio	(0.27, 1.15)	(0.26, 1.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.57	
95% CI of the inverse risk ratio	(0.31, 1.13)	(0.30, 1.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.28	5.77	
95% CI of the absolute risk difference	(-1.57, 12.13)	(-1.44, 12.97)	
p-value	0.1081	0.0901	
p-value of Breslow-Day Test for Homogeneity [3]	0.4975	0.2402	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	37 (29.8)	32 (28.6)	49 (22.0)
No	87 (70.2)	80 (71.4)	174 (78.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.70	
95% CI of the inverse odds ratio	(0.40, 1.09)	(0.42, 1.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.77	
95% CI of the inverse risk ratio	(0.51, 1.06)	(0.52, 1.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.87	6.60	
95% CI of the absolute risk difference	(-1.85, 17.58)	(-3.38, 16.57)	
p-value	0.1039	0.1833	
p-value of Breslow-Day Test for Homogeneity [3]	0.9222	0.2359	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	17 (13.7)	11 (9.8)	19 (8.5)
No	107 (86.3)	101 (90.2)	204 (91.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.86	
95% CI of the inverse odds ratio	(0.29, 1.17)	(0.39, 1.87)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.62	0.87	
95% CI of the inverse risk ratio	(0.34, 1.15)	(0.43, 1.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.19	1.30	
95% CI of the absolute risk difference	(-1.89, 12.27)	(-5.32, 7.92)	
p-value	0.1287	0.6940	
p-value of Breslow-Day Test for Homogeneity [3]	0.3889	0.3546	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	31 (25.0)	30 (26.8)	55 (24.7)
No	93 (75.0)	82 (73.2)	168 (75.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.89	
95% CI of the inverse odds ratio	(0.59, 1.63)	(0.53, 1.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.99	0.92	
95% CI of the inverse risk ratio	(0.67, 1.44)	(0.63, 1.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.34	2.12	
95% CI of the absolute risk difference	(-9.16, 9.83)	(-7.84, 12.09)	
p-value	0.9446	0.6737	
p-value of Breslow-Day Test for Homogeneity [3]	0.7835	0.2415	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (9.7)	15 (13.4)	26 (11.7)
No	112 (90.3)	97 (86.6)	197 (88.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	0.85	
95% CI of the inverse odds ratio	(0.60, 2.54)	(0.43, 1.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	0.87	
95% CI of the inverse risk ratio	(0.63, 2.30)	(0.48, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.98	1.73	
95% CI of the absolute risk difference	(-8.68, 4.71)	(-5.85, 9.32)	
p-value	0.5710	0.6478	
p-value of Breslow-Day Test for Homogeneity [3]	0.9202	0.4682	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	38 (30.6)	25 (22.3)	61 (27.4)
No	86 (69.4)	87 (77.7)	162 (72.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.31	
95% CI of the inverse odds ratio	(0.53, 1.38)	(0.77, 2.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.23	
95% CI of the inverse risk ratio	(0.64, 1.25)	(0.82, 1.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.29	-5.03	
95% CI of the absolute risk difference	(-6.71, 13.29)	(-14.71, 4.65)	
p-value	0.5153	0.3198	
p-value of Breslow-Day Test for Homogeneity [3]	0.8402	0.6313	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (5.6)	8 (7.1)	18 (8.1)
No	117 (94.4)	104 (92.9)	205 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	1.14	
95% CI of the inverse odds ratio	(0.60, 3.62)	(0.48, 2.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.13	
95% CI of the inverse risk ratio	(0.61, 3.33)	(0.51, 2.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.43	-0.93	
95% CI of the absolute risk difference	(-7.84, 2.98)	(-6.89, 5.03)	
p-value	0.4022	0.7644	
p-value of Breslow-Day Test for Homogeneity [3]	0.4226	0.9099	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (24.2)	26 (23.2)	58 (26.0)
No	94 (75.8)	86 (76.8)	165 (74.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	1.16	
95% CI of the inverse odds ratio	(0.66, 1.83)	(0.68, 1.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	1.12	
95% CI of the inverse risk ratio	(0.73, 1.58)	(0.75, 1.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.82	-2.79	
95% CI of the absolute risk difference	(-11.30, 7.67)	(-12.50, 6.92)	
p-value	0.7095	0.5777	
p-value of Breslow-Day Test for Homogeneity [3]	0.7221	0.8264	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	24 (19.4)	23 (20.5)	40 (17.9)
No	100 (80.6)	89 (79.5)	183 (82.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.85	
95% CI of the inverse odds ratio	(0.52, 1.60)	(0.48, 1.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.87	
95% CI of the inverse risk ratio	(0.59, 1.46)	(0.55, 1.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.42	2.60	
95% CI of the absolute risk difference	(-7.17, 10.00)	(-6.42, 11.62)	
p-value	0.7442	0.5658	
p-value of Breslow-Day Test for Homogeneity [3]	0.7388	0.1099	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	39 (31.5)	38 (33.9)	74 (33.2)
No	85 (68.5)	74 (66.1)	149 (66.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	0.97	
95% CI of the inverse odds ratio	(0.68, 1.73)	(0.60, 1.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.98	
95% CI of the inverse risk ratio	(0.77, 1.45)	(0.71, 1.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.73	0.74	
95% CI of the absolute risk difference	(-11.98, 8.51)	(-9.98, 11.47)	
p-value	0.7414	0.8916	
p-value of Breslow-Day Test for Homogeneity [3]	0.2884	0.0379	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.7)	0	7 (11.3)
No	24 (92.3)	24 (100)	55 (88.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	6.62	
95% CI of the inverse odds ratio	(0.30, 7.90)	(0.36, 120.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	5.95	
95% CI of the inverse risk ratio	(0.33, 6.60)	(0.35, 100.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.60	-9.90	
95% CI of the absolute risk difference	(-16.52, 9.32)	(-19.60, -0.21)	
p-value	0.6113	0.1450	
p-value of Breslow-Day Test for Homogeneity [3]	0.6931	0.0757	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (15.4)	3 (12.5)	12 (19.4)
No	22 (84.6)	21 (87.5)	50 (80.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.32	1.68	
95% CI of the inverse odds ratio	(0.38, 4.55)	(0.43, 6.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	1.55	
95% CI of the inverse risk ratio	(0.45, 3.54)	(0.48, 5.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.97	-6.85	
95% CI of the absolute risk difference	(-20.97, 13.03)	(-23.34, 9.63)	
p-value	0.6595	0.4524	
p-value of Breslow-Day Test for Homogeneity [3]	0.4903	0.5576	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (15.4)	0	10 (16.1)
No	22 (84.6)	24 (100)	52 (83.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	9.80	
95% CI of the inverse odds ratio	(0.30, 3.74)	(0.55, 174.11)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	8.33	
95% CI of the inverse risk ratio	(0.36, 3.04)	(0.51, 136.90)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.74	-14.67	
95% CI of the absolute risk difference	(-17.36, 15.87)	(-25.38, -3.95)	
p-value	0.9306	0.0606	
p-value of Breslow-Day Test for Homogeneity [3]	0.7370	0.0873	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (38.5)	0	21 (33.9)
No	16 (61.5)	24 (100)	41 (66.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	25.39	
95% CI of the inverse odds ratio	(0.32, 2.12)	(1.47, 437.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	17.06	
95% CI of the inverse risk ratio	(0.48, 1.60)	(1.07, 271.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.59	-32.13	
95% CI of the absolute risk difference	(-17.51, 26.69)	(-45.06, -19.20)	
p-value	0.6808	0.0017	
p-value of Breslow-Day Test for Homogeneity [3]	0.5813	0.0054	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.7)	1 (4.2)	5 (8.1)
No	24 (92.3)	23 (95.8)	57 (91.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	2.02	
95% CI of the inverse odds ratio	(0.19, 5.81)	(0.22, 18.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.94	
95% CI of the inverse risk ratio	(0.22, 5.06)	(0.24, 15.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.37	-3.90	
95% CI of the absolute risk difference	(-12.65, 11.91)	(-14.38, 6.58)	
p-value	0.9531	0.5245	
p-value of Breslow-Day Test for Homogeneity [3]	0.4975	0.2402	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (26.9)	3 (12.5)	12 (19.4)
No	19 (73.1)	21 (87.5)	50 (80.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	1.68	
95% CI of the inverse odds ratio	(0.22, 1.90)	(0.43, 6.57)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	1.55	
95% CI of the inverse risk ratio	(0.32, 1.62)	(0.48, 5.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.57	-6.85	
95% CI of the absolute risk difference	(-12.11, 27.25)	(-23.34, 9.63)	
p-value	0.4311	0.4524	
p-value of Breslow-Day Test for Homogeneity [3]	0.9222	0.2359	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.7)	1 (4.2)	6 (9.7)
No	24 (92.3)	23 (95.8)	56 (90.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.29	2.46	
95% CI of the inverse odds ratio	(0.24, 6.83)	(0.28, 21.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	2.32	
95% CI of the inverse risk ratio	(0.27, 5.83)	(0.29, 18.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.99	-5.51	
95% CI of the absolute risk difference	(-14.60, 10.63)	(-16.38, 5.36)	
p-value	0.7676	0.4019	
p-value of Breslow-Day Test for Homogeneity [3]	0.3889	0.3546	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (15.4)	2 (8.3)	11 (17.7)
No	22 (84.6)	22 (91.7)	51 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.19	2.37	
95% CI of the inverse odds ratio	(0.34, 4.14)	(0.49, 11.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	2.13	
95% CI of the inverse risk ratio	(0.40, 3.29)	(0.51, 8.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.36	-9.41	
95% CI of the absolute risk difference	(-19.17, 14.46)	(-23.99, 5.18)	
p-value	0.7885	0.2746	
p-value of Breslow-Day Test for Homogeneity [3]	0.7835	0.2415	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (11.5)	2 (8.3)	8 (12.9)
No	23 (88.5)	22 (91.7)	54 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	1.63	
95% CI of the inverse odds ratio	(0.28, 4.67)	(0.32, 8.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	1.55	
95% CI of the inverse risk ratio	(0.32, 3.89)	(0.35, 6.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.36	-4.57	
95% CI of the absolute risk difference	(-16.21, 13.48)	(-18.42, 9.28)	
p-value	0.8598	0.5532	
p-value of Breslow-Day Test for Homogeneity [3]	0.9202	0.4682	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (23.1)	5 (20.8)	15 (24.2)
No	20 (76.9)	19 (79.2)	47 (75.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.21	
95% CI of the inverse odds ratio	(0.36, 3.14)	(0.39, 3.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	1.16	
95% CI of the inverse risk ratio	(0.46, 2.40)	(0.47, 2.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.12	-3.36	
95% CI of the absolute risk difference	(-20.51, 18.27)	(-22.79, 16.07)	
p-value	0.9107	0.7408	
p-value of Breslow-Day Test for Homogeneity [3]	0.8402	0.6313	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.8)	3 (12.5)	8 (12.9)
No	25 (96.2)	21 (87.5)	54 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.70	1.04	
95% CI of the inverse odds ratio	(0.44, 31.24)	(0.25, 4.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.35	1.03	
95% CI of the inverse risk ratio	(0.44, 25.49)	(0.30, 3.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-9.06	-0.40	
95% CI of the absolute risk difference	(-20.20, 2.09)	(-16.05, 15.24)	
p-value	0.2008	0.9599	
p-value of Breslow-Day Test for Homogeneity [3]	0.4226	0.9099	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (23.1)	5 (20.8)	13 (21.0)
No	20 (76.9)	19 (79.2)	49 (79.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	1.01	
95% CI of the inverse odds ratio	(0.29, 2.65)	(0.32, 3.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.01	
95% CI of the inverse risk ratio	(0.39, 2.13)	(0.40, 2.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.11	-0.13	
95% CI of the absolute risk difference	(-16.99, 21.21)	(-19.28, 19.01)	
p-value	0.8263	0.9890	
p-value of Breslow-Day Test for Homogeneity [3]	0.7221	0.8264	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (15.4)	1 (4.2)	10 (16.1)
No	22 (84.6)	23 (95.8)	52 (83.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	4.42	
95% CI of the inverse odds ratio	(0.30, 3.74)	(0.53, 36.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	3.87	
95% CI of the inverse risk ratio	(0.36, 3.04)	(0.52, 28.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.74	-11.96	
95% CI of the absolute risk difference	(-17.36, 15.87)	(-24.12, 0.19)	
p-value	0.9306	0.1363	
p-value of Breslow-Day Test for Homogeneity [3]	0.7388	0.1099	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (46.2)	2 (8.3)	19 (30.6)
No	14 (53.8)	22 (91.7)	43 (69.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	4.86	
95% CI of the inverse odds ratio	(0.20, 1.32)	(1.04, 22.78)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	3.68	
95% CI of the inverse risk ratio	(0.38, 1.16)	(0.93, 14.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	15.51	-22.31	
95% CI of the absolute risk difference	(-6.83, 37.84)	(-38.25, -6.38)	
p-value	0.1647	0.0307	
p-value of Breslow-Day Test for Homogeneity [3]	0.2884	0.0379	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.6931	0.0757	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (60.0)	0	0
No	2 (40.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.24	NE	
95% CI of the inverse odds ratio	(0.01, 8.62)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	NE	
95% CI of the inverse risk ratio	(0.04, 5.19)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	33.33	NE	
95% CI of the absolute risk difference	(-38.48, 100.00)	NE	
p-value	0.4142	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4903	0.5576	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (40.0)	0	0
No	3 (60.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse odds ratio	(0.01, 16.89)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	NE	
95% CI of the inverse risk ratio	(0.05, 7.92)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	NE	
95% CI of the absolute risk difference	(-55.15, 88.48)	NE	
p-value	0.6733	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7370	0.0873	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (60.0)	0	0
No	2 (40.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.24	NE	
95% CI of the inverse odds ratio	(0.01, 8.62)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	NE	
95% CI of the inverse risk ratio	(0.04, 5.19)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	33.33	NE	
95% CI of the absolute risk difference	(-38.48, 100.00)	NE	
p-value	0.4142	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5813	0.0054	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4975	0.2402	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	0	0
No	4 (80.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse odds ratio	(0.02, 40.28)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse risk ratio	(0.06, 15.99)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	NE	
95% CI of the absolute risk difference	(-69.30, 69.30)	NE	
p-value	>0.9999	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9222	0.2359	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3889	0.3546	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7835	0.2415	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9202	0.4682	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	1 (50.0)	0
No	4 (80.0)	1 (50.0)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.33	
95% CI of the inverse odds ratio	(0.02, 40.28)	(0.01, 16.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	0.50	
95% CI of the inverse risk ratio	(0.06, 15.99)	(0.04, 7.10)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	25.00	
95% CI of the absolute risk difference	(-69.30, 69.30)	(-57.48, 100.00)	
p-value	>0.9999	0.5762	
p-value of Breslow-Day Test for Homogeneity [3]	0.8402	0.6313	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4226	0.9099	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7221	0.8264	

AMNOG Table SE23.14b.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (40.0)	0	0
No	3 (60.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse odds ratio	(0.01, 16.89)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	NE	
95% CI of the inverse risk ratio	(0.05, 7.92)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	NE	
95% CI of the absolute risk difference	(-55.15, 88.48)	NE	
p-value	0.6733	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7388	0.1099	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (40.0)	0	0
No	3 (60.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse odds ratio	(0.01, 16.89)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	NE	
95% CI of the inverse risk ratio	(0.05, 7.92)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	16.67	NE	
95% CI of the absolute risk difference	(-55.15, 88.48)	NE	
p-value	0.6733	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2884	0.0379	

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE23.14b.5
Chronic Liver Disease Questionnaire-NASH (SE23): Mean Profile of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation
Abdominal Symptoms



Patients with result at given visit			
MGL-3196 80 mg	118	115	103
MGL-3196 100 mg	103	102	88
Placebo	206	201	172

Abbreviations: Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE23.14b.5
Chronic Liver Disease Questionnaire-NASH (SE23): Mean Profile of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous
Abdominal Symptoms



Patients with result at given visit			
MGL-3196 80 mg	24	25	22
MGL-3196 100 mg	20	20	14
Placebo	55	53	47

Abbreviations: Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE23.14b.5
Chronic Liver Disease Questionnaire-NASH (SE23): Mean Profile of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous
Abdominal Symptoms



Patients with result at given visit			
MGL-3196 80 mg	5	5	5
MGL-3196 100 mg	2	2	1
Placebo	1	0	0

Abbreviations: Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
CLDQ-NASH						
Baseline						
m	53	45	90			
n	51	41	86			
Mean (SD)	5.27 (1.23)	5.19 (1.18)	5.23 (1.10)			
Median	5.40	5.40	5.20			
IQR: Q1, Q3	4.80, 6.30	4.20, 6.10	4.60, 6.20			
Min, Max	2.4, 7.0	2.1, 7.0	2.0, 6.9			
Week 24						
m	49	43	83			
n	48	42	78	46	39	76
Mean (SD/SE)	5.38 (1.21)	5.27 (1.11)	5.42 (1.09)	0.08 (0.10)	0.08 (0.08)	0.17 (0.09)
Median	5.60	5.50	5.65	0.05	0.10	0.10
IQR: Q1, Q3	4.60, 6.40	4.40, 6.20	4.60, 6.30	-0.20, 0.50	-0.30, 0.40	-0.30, 0.50
Min, Max	2.5, 7.0	2.7, 6.8	2.6, 7.0	-2.6, 1.5	-0.9, 1.3	-2.3, 3.0
Week 52						
m	47	38	75			
n	44	37	65	42	36	63
Mean (SD/SE)	5.40 (1.03)	5.34 (1.14)	5.35 (1.12)	-0.02 (0.10)	0.10 (0.09)	0.05 (0.09)
Median	5.40	5.60	5.50	0	0.15	0
IQR: Q1, Q3	4.70, 6.25	4.70, 6.30	4.70, 6.30	-0.20, 0.30	-0.20, 0.35	-0.30, 0.50
Min, Max	2.7, 7.0	2.2, 6.9	2.2, 6.9	-1.9, 1.4	-1.1, 1.4	-2.2, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Abdominal Symptoms						
Baseline						
m	53	45	90			
n	51	41	86			
Mean (SD)	5.26 (1.65)	5.38 (1.44)	5.28 (1.53)			
Median	5.70	5.30	5.70			
IQR: Q1, Q3	4.00, 6.70	4.30, 7.00	4.30, 6.70			
Min, Max	1.7, 7.0	1.7, 7.0	1.7, 7.0			
Week 24						
m	49	43	83			
n	48	42	78	46	39	76
Mean (SD/SE)	5.29 (1.43)	5.48 (1.44)	5.54 (1.41)	-0.05 (0.17)	0.11 (0.18)	0.17 (0.15)
Median	5.50	5.85	5.70	0	0	0
IQR: Q1, Q3	4.30, 6.30	4.70, 6.70	4.70, 7.00	-0.40, 0.70	-0.30, 0.40	-0.50, 1.00
Min, Max	1.3, 7.0	2.0, 7.0	1.0, 7.0	-4.7, 2.3	-3.3, 2.4	-3.0, 4.0
Week 52						
m	47	38	75			
n	44	37	65	42	36	63
Mean (SD/SE)	5.59 (1.24)	5.48 (1.36)	5.56 (1.28)	0.15 (0.19)	0.01 (0.16)	0.09 (0.18)
Median	5.70	5.30	5.70	0	0	0
IQR: Q1, Q3	5.00, 6.70	4.70, 6.70	4.70, 6.70	-0.30, 1.00	-0.30, 0.30	-0.70, 1.00
Min, Max	2.7, 7.0	1.7, 7.0	2.7, 7.0	-3.3, 3.0	-2.0, 2.0	-3.7, 4.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Activity						
Baseline						
m	53	45	90			
n	51	41	86			
Mean (SD)	5.39 (1.38)	5.36 (1.18)	5.43 (1.35)			
Median	5.60	5.60	5.60			
IQR: Q1, Q3	4.60, 6.80	4.60, 6.40	4.80, 6.60			
Min, Max	2.0, 7.0	2.0, 7.0	1.8, 7.0			
Week 24						
m	49	43	83			
n	48	42	78	46	39	76
Mean (SD/SE)	5.50 (1.48)	5.50 (1.29)	5.60 (1.27)	0.09 (0.14)	0.12 (0.13)	0.14 (0.12)
Median	5.80	5.90	5.90	0	0.20	0
IQR: Q1, Q3	4.80, 6.70	4.60, 6.80	5.00, 6.60	-0.40, 0.80	-0.20, 0.60	-0.40, 0.60
Min, Max	1.2, 7.0	2.4, 7.0	2.4, 7.0	-3.2, 1.8	-1.6, 1.6	-2.8, 2.6
Week 52						
m	47	38	75			
n	44	37	65	42	36	63
Mean (SD/SE)	5.53 (1.28)	5.51 (1.28)	5.47 (1.32)	0.00 (0.14)	0.13 (0.14)	-0.06 (0.12)
Median	5.80	5.60	5.80	0	0.20	0
IQR: Q1, Q3	4.90, 6.60	4.80, 6.60	4.40, 6.60	-0.40, 0.60	-0.20, 0.70	-0.40, 0.40
Min, Max	2.2, 7.0	1.6, 7.0	1.4, 7.0	-3.6, 1.4	-2.2, 1.2	-2.4, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Emotional Health						
Baseline						
m	53	45	90			
n	51	41	86			
Mean (SD)	5.35 (1.35)	5.26 (1.33)	5.44 (1.20)			
Median	5.60	5.40	5.70			
IQR: Q1, Q3	4.60, 6.30	4.40, 6.30	4.80, 6.30			
Min, Max	1.9, 7.0	2.2, 7.0	1.9, 7.0			
Week 24						
m	49	43	83			
n	48	42	78	46	39	76
Mean (SD/SE)	5.48 (1.37)	5.23 (1.31)	5.44 (1.22)	0.10 (0.12)	0.00 (0.08)	0.05 (0.11)
Median	5.75	5.30	5.75	0.15	0	0.10
IQR: Q1, Q3	4.50, 6.65	4.20, 6.30	4.70, 6.40	-0.20, 0.60	-0.30, 0.30	-0.50, 0.50
Min, Max	2.0, 7.0	2.6, 7.0	1.9, 7.0	-2.6, 1.4	-0.8, 1.2	-2.9, 3.3
Week 52						
m	47	38	75			
n	44	37	65	42	36	63
Mean (SD/SE)	5.48 (1.03)	5.40 (1.34)	5.39 (1.31)	-0.05 (0.11)	0.09 (0.11)	-0.04 (0.10)
Median	5.75	5.80	5.60	0	0	0
IQR: Q1, Q3	4.80, 6.20	4.40, 6.40	4.70, 6.30	-0.60, 0.20	-0.40, 0.55	-0.50, 0.40
Min, Max	2.8, 7.0	2.1, 7.0	1.3, 7.0	-1.6, 1.6	-1.4, 1.6	-1.9, 2.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Fatigue						
Baseline						
m	53	45	90			
n	51	41	86			
Mean (SD)	4.95 (1.46)	4.35 (1.45)	4.50 (1.51)			
Median	5.20	4.70	4.80			
IQR: Q1, Q3	4.20, 6.00	2.80, 5.20	3.30, 5.80			
Min, Max	1.5, 7.0	1.5, 6.8	1.0, 7.0			
Week 24						
m	49	43	83			
n	48	42	78	46	39	76
Mean (SD/SE)	5.06 (1.48)	4.48 (1.42)	4.73 (1.43)	0.04 (0.15)	0.09 (0.13)	0.16 (0.13)
Median	5.25	4.75	4.75	0.20	0	0.20
IQR: Q1, Q3	4.25, 6.35	3.30, 5.50	3.50, 6.00	-0.50, 0.70	-0.30, 0.50	-0.70, 0.80
Min, Max	1.3, 7.0	1.7, 6.7	1.2, 7.0	-2.5, 2.7	-1.5, 2.3	-2.5, 3.7
Week 52						
m	47	38	75			
n	44	37	65	42	36	63
Mean (SD/SE)	5.00 (1.33)	4.52 (1.56)	4.64 (1.45)	-0.13 (0.13)	0.07 (0.16)	0.02 (0.13)
Median	5.10	4.80	4.80	0	0	0
IQR: Q1, Q3	4.25, 6.00	3.80, 5.80	3.70, 5.80	-0.50, 0.40	-0.30, 0.65	-0.40, 0.60
Min, Max	2.2, 7.0	1.3, 6.8	1.0, 6.8	-2.3, 1.3	-2.8, 1.8	-3.8, 2.5

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Systemic Symptoms						
Baseline						
m	53	45	90			
n	51	41	86			
Mean (SD)	5.20 (1.21)	5.15 (1.26)	5.08 (1.27)			
Median	5.30	5.30	5.25			
IQR: Q1, Q3	4.30, 6.30	4.50, 6.00	4.20, 6.00			
Min, Max	2.3, 7.0	1.8, 7.0	2.0, 7.0			
Week 24						
m	49	43	83			
n	48	42	78	46	39	76
Mean (SD/SE)	5.30 (1.22)	5.12 (1.27)	5.26 (1.23)	0.05 (0.10)	-0.05 (0.10)	0.10 (0.11)
Median	5.40	5.30	5.50	0.10	-0.20	0.10
IQR: Q1, Q3	4.50, 6.50	4.20, 6.00	4.30, 6.30	-0.30, 0.50	-0.50, 0.20	-0.45, 0.50
Min, Max	2.3, 7.0	1.8, 7.0	2.5, 7.0	-1.6, 1.4	-0.9, 1.5	-2.5, 3.7
Week 52						
m	47	38	75			
n	44	37	65	42	36	63
Mean (SD/SE)	5.17 (1.20)	5.21 (1.34)	5.07 (1.34)	-0.16 (0.12)	0.04 (0.11)	-0.12 (0.11)
Median	5.35	5.50	5.00	0	0	-0.20
IQR: Q1, Q3	4.40, 6.10	4.00, 6.50	4.20, 6.20	-0.50, 0.30	-0.50, 0.35	-0.50, 0.40
Min, Max	2.3, 7.0	1.5, 7.0	2.2, 7.0	-1.8, 2.0	-0.9, 2.0	-2.4, 1.5

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Worry						
Baseline						
m	53	45	90			
n	51	41	86			
Mean (SD)	5.44 (1.56)	5.58 (1.47)	5.68 (1.34)			
Median	5.70	6.10	6.00			
IQR: Q1, Q3	4.60, 6.90	4.90, 6.70	5.00, 6.70			
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0			
Week 24						
m	49	43	83			
n	48	42	78	46	39	76
Mean (SD/SE)	5.70 (1.46)	5.75 (1.34)	5.96 (1.36)	0.29 (0.15)	0.19 (0.11)	0.39 (0.11)
Median	6.10	6.10	6.50	0.20	0	0.25
IQR: Q1, Q3	5.15, 6.80	5.00, 6.90	5.60, 6.90	-0.20, 0.60	-0.20, 0.50	0.00, 0.70
Min, Max	1.6, 7.0	2.0, 7.0	1.0, 7.0	-2.3, 3.1	-1.1, 1.9	-2.0, 3.5
Week 52						
m	47	38	75			
n	44	37	65	42	36	63
Mean (SD/SE)	5.67 (1.33)	5.93 (1.33)	5.96 (1.36)	0.13 (0.14)	0.37 (0.15)	0.37 (0.13)
Median	6.10	6.30	6.70	0	0	0.20
IQR: Q1, Q3	4.95, 6.95	5.60, 7.00	5.40, 7.00	-0.40, 0.70	-0.10, 0.75	-0.10, 0.90
Min, Max	2.1, 7.0	1.4, 7.0	1.0, 7.0	-2.0, 2.5	-1.4, 2.9	-2.7, 3.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
CLDQ-NASH						
Baseline						
m	72	65	139			
n	68	57	126			
Mean (SD)	5.14 (1.20)	5.41 (0.95)	5.19 (1.14)			
Median	5.20	5.70	5.45			
IQR: Q1, Q3	4.35, 6.20	4.80, 6.10	4.40, 6.10			
Min, Max	1.9, 6.8	3.2, 6.8	2.4, 7.0			
Week 24						
m	72	58	135			
n	70	56	126	67	50	116
Mean (SD/SE)	5.27 (1.18)	5.29 (0.98)	5.32 (1.09)	0.14 (0.10)	-0.18 (0.08)	0.10 (0.06)
Median	5.55	5.50	5.50	0.10	-0.25	0
IQR: Q1, Q3	4.50, 6.10	4.70, 6.05	4.60, 6.20	-0.20, 0.50	-0.50, 0.20	-0.30, 0.50
Min, Max	2.1, 7.0	3.0, 6.8	2.3, 7.0	-1.8, 2.5	-1.6, 1.6	-1.8, 2.1
Week 52						
m	69	51	128			
n	64	46	111	60	42	103
Mean (SD/SE)	5.35 (1.16)	5.39 (0.93)	5.31 (1.03)	0.15 (0.09)	-0.10 (0.10)	0.06 (0.06)
Median	5.60	5.60	5.40	0.10	0	0
IQR: Q1, Q3	4.60, 6.25	4.90, 6.10	4.50, 6.20	-0.20, 0.45	-0.40, 0.20	-0.30, 0.40
Min, Max	1.9, 7.0	3.1, 6.7	2.5, 7.0	-2.2, 2.7	-2.4, 1.1	-1.5, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Abdominal Symptoms						
Baseline						
m	72	65	139			
n	68	57	126			
Mean (SD)	5.20 (1.61)	5.80 (1.22)	5.22 (1.49)			
Median	5.70	6.00	5.30			
IQR: Q1, Q3	4.15, 6.30	5.00, 7.00	4.30, 6.70			
Min, Max	1.0, 7.0	2.0, 7.0	1.0, 7.0			
Week 24						
m	72	58	135			
n	70	56	126	67	50	116
Mean (SD/SE)	5.39 (1.58)	5.41 (1.60)	5.48 (1.43)	0.19 (0.15)	-0.33 (0.17)	0.23 (0.10)
Median	5.50	6.00	6.00	0	0	0
IQR: Q1, Q3	4.30, 6.70	4.30, 6.85	4.30, 7.00	-0.30, 0.70	-0.70, 0.30	-0.40, 1.00
Min, Max	1.0, 7.0	1.3, 7.0	1.3, 7.0	-3.0, 3.3	-4.0, 1.7	-2.6, 4.0
Week 52						
m	69	51	128			
n	64	46	111	60	42	103
Mean (SD/SE)	5.58 (1.51)	5.66 (1.24)	5.32 (1.45)	0.25 (0.18)	-0.24 (0.15)	0.04 (0.11)
Median	5.85	5.85	5.70	0	-0.15	0
IQR: Q1, Q3	4.85, 7.00	5.00, 6.70	4.30, 6.30	-0.65, 1.00	-0.70, 0.00	-0.70, 1.00
Min, Max	1.0, 7.0	2.3, 7.0	1.0, 7.0	-2.7, 4.0	-3.0, 2.0	-4.6, 2.6

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Activity						
Baseline						
m	72	65	139			
n	68	57	126			
Mean (SD)	5.23 (1.39)	5.40 (1.30)	5.34 (1.47)			
Median	5.40	5.80	5.60			
IQR: Q1, Q3	4.30, 6.40	4.60, 6.40	4.20, 6.60			
Min, Max	1.8, 7.0	2.0, 7.0	1.4, 7.0			
Week 24						
m	72	58	135			
n	70	56	126	67	50	116
Mean (SD/SE)	5.23 (1.39)	5.34 (1.31)	5.39 (1.36)	-0.01 (0.12)	-0.12 (0.13)	0.03 (0.09)
Median	5.50	5.80	5.80	0	0	0
IQR: Q1, Q3	4.40, 6.40	4.60, 6.40	4.60, 6.40	-0.80, 0.60	-0.80, 0.40	-0.60, 0.60
Min, Max	1.6, 7.0	2.4, 7.0	1.2, 7.0	-1.8, 2.8	-2.4, 2.4	-3.0, 2.6
Week 52						
m	69	51	128			
n	64	46	111	60	42	103
Mean (SD/SE)	5.29 (1.54)	5.44 (1.16)	5.33 (1.40)	0.00 (0.15)	-0.04 (0.14)	-0.10 (0.09)
Median	5.60	5.50	5.80	0.10	0	0
IQR: Q1, Q3	4.50, 6.60	4.80, 6.40	4.40, 6.40	-0.70, 0.40	-0.60, 0.40	-0.60, 0.60
Min, Max	1.0, 7.0	3.0, 7.0	1.6, 7.0	-3.4, 3.0	-2.8, 2.0	-3.4, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Emotional Health						
Baseline						
m	72	65	139			
n	68	57	126			
Mean (SD)	5.34 (1.17)	5.53 (1.18)	5.35 (1.24)			
Median	5.50	5.70	5.60			
IQR: Q1, Q3	4.75, 6.20	4.90, 6.30	4.60, 6.30			
Min, Max	1.3, 7.0	2.1, 7.0	1.8, 7.0			
Week 24						
m	72	58	135			
n	70	56	126	67	50	116
Mean (SD/SE)	5.41 (1.20)	5.45 (1.17)	5.49 (1.26)	0.11 (0.11)	-0.20 (0.11)	0.08 (0.08)
Median	5.90	5.40	5.80	0	0	0.10
IQR: Q1, Q3	4.80, 6.20	5.10, 6.30	4.70, 6.60	-0.40, 0.60	-0.50, 0.10	-0.40, 0.50
Min, Max	2.2, 7.0	1.0, 7.0	1.9, 7.0	-2.8, 2.5	-3.1, 1.9	-2.3, 1.8
Week 52						
m	69	51	128			
n	64	46	111	60	42	103
Mean (SD/SE)	5.47 (1.10)	5.51 (1.14)	5.47 (1.18)	0.10 (0.12)	-0.11 (0.12)	0.04 (0.08)
Median	5.70	5.75	5.70	0	-0.15	0
IQR: Q1, Q3	4.65, 6.30	5.00, 6.30	4.70, 6.40	-0.50, 0.60	-0.60, 0.40	-0.40, 0.50
Min, Max	2.8, 7.0	1.0, 7.0	1.7, 7.0	-1.9, 2.9	-1.9, 1.8	-2.0, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Fatigue						
Baseline						
m	72	65	139			
n	68	57	126			
Mean (SD)	4.52 (1.57)	4.86 (1.24)	4.64 (1.42)			
Median	4.75	4.80	4.80			
IQR: Q1, Q3	3.30, 6.00	4.30, 5.80	3.70, 5.70			
Min, Max	1.2, 7.0	1.2, 7.0	1.3, 7.0			
Week 24						
m	72	58	135			
n	70	56	126	67	50	116
Mean (SD/SE)	4.63 (1.60)	4.64 (1.19)	4.66 (1.49)	0.10 (0.13)	-0.37 (0.15)	0.00 (0.10)
Median	4.90	4.70	4.80	0	-0.25	0
IQR: Q1, Q3	3.20, 6.00	4.00, 5.40	3.30, 6.00	-0.60, 0.60	-0.80, 0.20	-0.55, 0.50
Min, Max	1.5, 7.0	1.5, 6.7	1.3, 7.0	-1.5, 4.1	-4.2, 2.0	-3.8, 2.9
Week 52						
m	69	51	128			
n	64	46	111	60	42	103
Mean (SD/SE)	4.72 (1.60)	4.65 (1.38)	4.69 (1.35)	0.12 (0.14)	-0.32 (0.18)	0.01 (0.10)
Median	5.20	4.75	4.80	0	-0.25	0
IQR: Q1, Q3	3.50, 6.00	3.70, 5.80	3.80, 5.80	-0.50, 0.50	-0.60, 0.30	-0.60, 0.70
Min, Max	1.0, 7.0	1.2, 7.0	1.0, 7.0	-2.2, 3.5	-4.4, 2.5	-2.4, 2.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Systemic Symptoms						
Baseline						
m	72	65	139			
n	68	57	126			
Mean (SD)	5.09 (1.35)	5.17 (1.13)	5.00 (1.25)			
Median	5.50	5.20	5.20			
IQR: Q1, Q3	4.30, 6.20	4.30, 6.00	4.20, 6.00			
Min, Max	1.8, 7.0	2.8, 7.0	1.7, 7.0			
Week 24						
m	72	58	135			
n	70	56	126	67	50	116
Mean (SD/SE)	5.10 (1.26)	5.03 (1.17)	5.05 (1.26)	-0.01 (0.12)	-0.25 (0.11)	-0.01 (0.08)
Median	5.50	5.30	5.20	-0.10	-0.15	0.05
IQR: Q1, Q3	4.30, 6.20	4.40, 5.80	4.30, 6.00	-0.70, 0.50	-0.80, 0.20	-0.60, 0.50
Min, Max	2.2, 7.0	2.2, 6.8	1.5, 7.0	-2.0, 3.5	-1.9, 2.2	-2.5, 2.2
Week 52						
m	69	51	128			
n	64	46	111	60	42	103
Mean (SD/SE)	5.15 (1.30)	5.08 (1.10)	5.03 (1.29)	-0.09 (0.11)	-0.19 (0.12)	0.02 (0.08)
Median	5.50	5.20	5.20	-0.15	0	0.10
IQR: Q1, Q3	4.20, 6.20	4.50, 5.80	4.20, 6.00	-0.50, 0.25	-0.50, 0.30	-0.50, 0.50
Min, Max	1.3, 7.0	2.7, 7.0	2.0, 7.0	-2.0, 2.3	-2.3, 1.3	-2.7, 2.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Worry						
Baseline						
m	72	65	139			
n	68	57	126			
Mean (SD)	5.47 (1.35)	5.71 (1.50)	5.58 (1.41)			
Median	5.70	6.10	5.95			
IQR: Q1, Q3	4.60, 6.70	5.30, 7.00	4.70, 6.90			
Min, Max	1.6, 7.0	1.0, 7.0	1.3, 7.0			
Week 24						
m	72	58	135			
n	70	56	126	67	50	116
Mean (SD/SE)	5.85 (1.36)	5.83 (1.40)	5.87 (1.29)	0.43 (0.13)	0.18 (0.15)	0.29 (0.08)
Median	6.30	6.10	6.30	0.20	0	0.10
IQR: Q1, Q3	5.40, 6.90	5.20, 7.00	5.40, 7.00	-0.10, 1.00	-0.40, 0.60	-0.20, 0.60
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0	-2.1, 3.3	-2.6, 3.6	-2.1, 2.8
Week 52						
m	69	51	128			
n	64	46	111	60	42	103
Mean (SD/SE)	5.94 (1.31)	5.98 (1.35)	6.02 (1.18)	0.45 (0.14)	0.29 (0.20)	0.38 (0.10)
Median	6.35	6.65	6.40	0.15	0	0.30
IQR: Q1, Q3	5.60, 7.00	5.30, 7.00	5.40, 7.00	0.00, 1.05	-0.30, 1.00	-0.10, 0.90
Min, Max	1.7, 7.0	1.0, 7.0	1.4, 7.0	-2.5, 3.0	-3.3, 3.6	-2.5, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
CLDQ-NASH						
Baseline						
m	30	28	57			
n	28	27	50			
Mean (SD)	5.23 (1.04)	5.09 (1.18)	5.14 (1.14)			
Median	5.10	5.40	5.20			
IQR: Q1, Q3	4.30, 6.20	3.90, 6.20	4.30, 6.30			
Min, Max	3.3, 6.7	2.9, 6.7	2.2, 7.0			
Week 24						
m	30	28	54			
n	27	26	50	26	25	44
Mean (SD/SE)	5.18 (0.92)	5.07 (0.89)	5.27 (1.17)	-0.02 (0.12)	0.02 (0.15)	0.10 (0.12)
Median	4.90	5.05	5.25	0	-0.20	0
IQR: Q1, Q3	4.30, 6.20	4.40, 5.90	4.40, 6.30	-0.20, 0.20	-0.50, 0.50	-0.25, 0.55
Min, Max	3.7, 6.5	3.1, 6.7	2.6, 7.0	-2.0, 1.1	-1.3, 1.4	-1.6, 2.6
Week 52						
m	26	25	52			
n	22	20	43	21	19	37
Mean (SD/SE)	5.37 (1.11)	5.10 (0.94)	5.40 (1.29)	0.02 (0.12)	-0.04 (0.21)	0.05 (0.14)
Median	5.10	5.20	5.80	0	-0.10	0
IQR: Q1, Q3	4.50, 6.40	4.50, 5.90	4.70, 6.30	-0.20, 0.50	-0.60, 0.30	-0.50, 0.50
Min, Max	3.7, 6.9	3.2, 6.9	1.9, 6.9	-1.3, 1.1	-1.5, 1.8	-1.7, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Abdominal Symptoms						
Baseline						
m	30	28	57			
n	28	27	50			
Mean (SD)	5.35 (1.61)	5.42 (1.32)	5.00 (1.67)			
Median	5.85	5.70	5.00			
IQR: Q1, Q3	3.85, 7.00	4.30, 6.70	3.30, 6.70			
Min, Max	2.3, 7.0	3.0, 7.0	1.7, 7.0			
Week 24						
m	30	28	54			
n	27	26	50	26	25	44
Mean (SD/SE)	5.66 (1.09)	5.23 (1.24)	5.31 (1.68)	0.31 (0.20)	-0.11 (0.23)	0.27 (0.20)
Median	5.30	5.00	5.85	0	0	0
IQR: Q1, Q3	4.70, 6.70	4.30, 6.00	4.00, 7.00	-0.30, 0.70	-1.00, 0.70	-0.30, 0.40
Min, Max	3.3, 7.0	2.7, 7.0	1.0, 7.0	-1.7, 2.7	-2.7, 2.3	-2.3, 3.7
Week 52						
m	26	25	52			
n	22	20	43	21	19	37
Mean (SD/SE)	5.30 (1.56)	5.56 (1.09)	5.50 (1.52)	-0.15 (0.22)	0.07 (0.25)	0.19 (0.19)
Median	5.15	5.50	5.70	0	0	0
IQR: Q1, Q3	4.30, 6.70	5.00, 6.70	5.00, 6.70	-0.30, 0.30	-0.40, 0.70	-0.40, 0.70
Min, Max	2.0, 7.0	2.7, 7.0	1.0, 7.0	-2.0, 1.6	-2.6, 2.7	-2.0, 3.3

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Activity						
Baseline						
m	30	28	57			
n	28	27	50			
Mean (SD)	5.07 (1.41)	5.16 (1.57)	5.33 (1.30)			
Median	5.10	5.40	5.30			
IQR: Q1, Q3	4.00, 6.40	4.00, 6.60	4.60, 6.40			
Min, Max	2.4, 7.0	1.8, 7.0	2.0, 7.0			
Week 24						
m	30	28	54			
n	27	26	50	26	25	44
Mean (SD/SE)	5.01 (1.49)	5.33 (1.12)	5.47 (1.45)	-0.08 (0.15)	0.17 (0.19)	0.12 (0.17)
Median	5.00	5.70	6.00	0	0	0
IQR: Q1, Q3	3.60, 6.40	4.40, 6.00	4.40, 6.80	-0.60, 0.40	-0.40, 0.80	-0.60, 0.90
Min, Max	2.8, 7.0	2.4, 7.0	2.6, 7.0	-2.4, 1.2	-1.2, 3.2	-2.0, 3.2
Week 52						
m	26	25	52			
n	22	20	43	21	19	37
Mean (SD/SE)	5.15 (1.67)	4.97 (1.28)	5.50 (1.53)	-0.25 (0.26)	-0.29 (0.28)	-0.18 (0.20)
Median	5.30	5.20	6.20	0	-0.20	0
IQR: Q1, Q3	4.00, 6.80	3.90, 6.00	4.40, 6.60	-0.60, 0.40	-1.20, 0.60	-0.80, 0.40
Min, Max	1.8, 7.0	2.2, 7.0	1.8, 7.0	-4.4, 1.4	-2.8, 1.8	-2.4, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Emotional Health						
Baseline						
m	30	28	57			
n	28	27	50			
Mean (SD)	5.36 (1.19)	5.21 (1.40)	5.39 (1.19)			
Median	5.70	5.40	5.40			
IQR: Q1, Q3	4.40, 6.40	4.30, 6.30	4.80, 6.30			
Min, Max	2.9, 6.8	2.0, 7.0	2.3, 7.0			
Week 24						
m	30	28	54			
n	27	26	50	26	25	44
Mean (SD/SE)	5.27 (1.13)	5.12 (1.15)	5.36 (1.25)	0.01 (0.15)	-0.06 (0.18)	-0.08 (0.16)
Median	5.30	5.10	5.80	-0.05	-0.30	-0.10
IQR: Q1, Q3	4.30, 6.30	4.30, 6.00	4.70, 6.30	-0.40, 0.40	-0.60, 0.20	-0.75, 0.35
Min, Max	3.2, 7.0	2.4, 7.0	2.6, 7.0	-1.4, 2.0	-2.0, 2.4	-2.4, 2.6
Week 52						
m	26	25	52			
n	22	20	43	21	19	37
Mean (SD/SE)	5.37 (1.10)	5.44 (1.06)	5.63 (1.21)	-0.03 (0.13)	0.17 (0.23)	0.03 (0.14)
Median	5.60	5.55	6.00	-0.10	0	0
IQR: Q1, Q3	4.40, 6.30	4.85, 6.25	4.90, 6.70	-0.50, 0.20	-0.40, 0.40	-0.60, 0.20
Min, Max	3.1, 6.8	2.7, 7.0	2.7, 7.0	-0.9, 1.5	-1.3, 2.9	-1.3, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Fatigue						
Baseline						
m	30	28	57			
n	28	27	50			
Mean (SD)	4.71 (1.38)	4.40 (1.67)	4.62 (1.48)			
Median	4.90	5.00	4.70			
IQR: Q1, Q3	3.65, 5.90	3.20, 5.70	3.80, 6.00			
Min, Max	2.0, 6.8	1.5, 7.0	1.2, 7.0			
Week 24						
m	30	28	54			
n	27	26	50	26	25	44
Mean (SD/SE)	4.46 (1.34)	4.33 (1.29)	4.65 (1.46)	-0.21 (0.23)	-0.01 (0.17)	0.05 (0.17)
Median	4.50	4.35	4.80	-0.05	0	-0.15
IQR: Q1, Q3	3.30, 5.30	3.50, 5.30	3.50, 5.80	-0.70, 0.40	-0.70, 0.70	-0.45, 0.60
Min, Max	2.0, 7.0	2.2, 6.8	2.0, 7.0	-2.7, 3.2	-1.8, 1.5	-2.5, 3.0
Week 52						
m	26	25	52			
n	22	20	43	21	19	37
Mean (SD/SE)	4.85 (1.59)	4.40 (1.32)	4.78 (1.64)	0.12 (0.26)	-0.13 (0.32)	0.08 (0.19)
Median	4.65	4.10	5.20	0	0	0
IQR: Q1, Q3	3.30, 6.30	3.60, 5.35	3.50, 6.20	-0.20, 0.60	-1.00, 0.70	-0.70, 0.50
Min, Max	2.0, 6.8	2.5, 6.8	1.2, 7.0	-2.4, 4.0	-2.8, 2.5	-1.8, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Systemic Symptoms						
Baseline						
m	30	28	57			
n	28	27	50			
Mean (SD)	5.10 (1.14)	4.81 (1.24)	5.04 (1.25)			
Median	5.30	5.00	5.00			
IQR: Q1, Q3	3.90, 6.10	4.50, 5.80	4.00, 6.20			
Min, Max	3.0, 6.8	2.2, 6.8	2.5, 7.0			
Week 24						
m	30	28	54			
n	27	26	50	26	25	44
Mean (SD/SE)	5.00 (1.16)	4.60 (1.08)	5.08 (1.24)	-0.07 (0.13)	-0.21 (0.18)	-0.07 (0.13)
Median	4.80	4.65	5.30	-0.10	-0.20	0
IQR: Q1, Q3	4.20, 6.00	4.00, 5.20	4.20, 5.80	-0.50, 0.30	-0.70, 0.50	-0.70, 0.40
Min, Max	2.3, 6.7	2.3, 6.7	2.5, 7.0	-1.9, 1.3	-2.0, 1.7	-2.0, 2.5
Week 52						
m	26	25	52			
n	22	20	43	21	19	37
Mean (SD/SE)	5.16 (1.29)	4.55 (1.14)	5.17 (1.53)	-0.13 (0.15)	-0.34 (0.25)	0.05 (0.16)
Median	5.40	4.65	5.70	0	-0.20	0
IQR: Q1, Q3	4.20, 6.30	3.60, 5.35	4.00, 6.50	-0.50, 0.40	-1.20, 0.40	-0.50, 0.50
Min, Max	2.3, 7.0	2.7, 6.8	1.3, 7.0	-1.5, 0.7	-2.5, 1.8	-2.0, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Worry						
Baseline						
m	30	28	57			
n	28	27	50			
Mean (SD)	5.76 (1.10)	5.50 (1.40)	5.46 (1.43)			
Median	5.95	5.90	5.75			
IQR: Q1, Q3	5.10, 6.55	4.60, 6.70	4.70, 6.70			
Min, Max	2.6, 7.0	2.1, 7.0	2.0, 7.0			
Week 24						
m	30	28	54			
n	27	26	50	26	25	44
Mean (SD/SE)	5.70 (1.15)	5.76 (1.13)	5.70 (1.51)	-0.04 (0.18)	0.26 (0.26)	0.28 (0.15)
Median	6.00	6.10	6.10	0.05	0.10	0.15
IQR: Q1, Q3	5.00, 6.70	4.90, 6.70	5.30, 7.00	-0.30, 0.30	-0.50, 1.20	-0.15, 0.70
Min, Max	3.3, 7.0	3.1, 7.0	2.1, 7.0	-3.1, 1.6	-1.7, 3.6	-2.6, 2.6
Week 52						
m	26	25	52			
n	22	20	43	21	19	37
Mean (SD/SE)	6.37 (0.76)	5.81 (1.48)	5.78 (1.51)	0.50 (0.21)	0.43 (0.30)	0.12 (0.17)
Median	6.80	6.15	6.40	0.20	0.10	0
IQR: Q1, Q3	5.70, 7.00	5.30, 6.95	5.00, 7.00	0.00, 0.90	-0.30, 0.90	-0.10, 0.30
Min, Max	4.6, 7.0	1.0, 7.0	1.6, 7.0	-0.5, 3.8	-1.2, 3.3	-2.3, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.14c.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
CLDQ-NASH			
Week 24			
m	49	43	83
n	46	39	76
Baseline Mean (SD)	5.28 (1.15)	5.15 (1.20)	5.29 (1.09)
Analysis Visit Mean (SD)	5.36 (1.21)	5.22 (1.10)	5.46 (1.05)
LS Mean of Change from Baseline (SE)	0.13 (0.10)	0.06 (0.11)	0.21 (0.08)
95% CI	(-0.07, 0.33)	(-0.16, 0.27)	(0.05, 0.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.13)	-0.15 (0.13)	
95% CI	(-0.32, 0.17)	(-0.41, 0.11)	
p-value	0.5578	0.2594	
Corrected Hedge's g Statistics	-0.106	-0.217	
95% CI	(-0.47, 0.26)	(-0.60, 0.17)	
Week 52			
m	47	38	75
n	42	36	63
Baseline Mean (SD)	5.39 (1.14)	5.19 (1.20)	5.33 (1.10)
Analysis Visit Mean (SD)	5.37 (1.03)	5.29 (1.13)	5.38 (1.13)
LS Mean of Change from Baseline (SE)	0.04 (0.10)	0.10 (0.10)	0.11 (0.08)
95% CI	(-0.15, 0.23)	(-0.10, 0.30)	(-0.05, 0.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.12)	-0.01 (0.13)	
95% CI	(-0.30, 0.17)	(-0.26, 0.24)	
p-value	0.5724	0.9580	
Corrected Hedge's g Statistics	-0.109	-0.011	
95% CI	(-0.50, 0.28)	(-0.42, 0.40)	
Subgroup*Treatment Interaction p-value	0.6910	0.8063	

AMNOG Table SE23.14c.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
CLDQ-NASH			
Week 24			
m	72	58	135
n	67	50	116
Baseline Mean (SD)	5.15 (1.21)	5.47 (0.94)	5.20 (1.15)
Analysis Visit Mean (SD)	5.29 (1.18)	5.30 (0.99)	5.31 (1.11)
LS Mean of Change from Baseline (SE)	0.14 (0.08)	-0.13 (0.09)	0.10 (0.06)
95% CI	(-0.02, 0.30)	(-0.31, 0.06)	(-0.02, 0.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.10)	-0.22 (0.11)	
95% CI	(-0.16, 0.23)	(-0.44, -0.01)	
p-value	0.6885	0.0413	
Corrected Hedge's g Statistics	0.060	-0.341	
95% CI	(-0.24, 0.36)	(-0.67, -0.01)	
Week 52			
m	69	51	128
n	60	42	103
Baseline Mean (SD)	5.21 (1.18)	5.46 (0.94)	5.23 (1.12)
Analysis Visit Mean (SD)	5.36 (1.16)	5.36 (0.95)	5.29 (1.04)
LS Mean of Change from Baseline (SE)	0.14 (0.08)	-0.06 (0.09)	0.08 (0.06)
95% CI	(-0.02, 0.29)	(-0.25, 0.12)	(-0.04, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.10)	-0.14 (0.11)	
95% CI	(-0.14, 0.25)	(-0.36, 0.07)	
p-value	0.5887	0.1913	
Corrected Hedge's g Statistics	0.086	-0.235	
95% CI	(-0.23, 0.40)	(-0.59, 0.13)	
Subgroup*Treatment Interaction p-value	0.6910	0.8063	

AMNOG Table SE23.14c.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
CLDQ-NASH			
Week 24			
m	30	28	54
n	26	25	44
Baseline Mean (SD)	5.19 (1.05)	5.04 (1.20)	5.23 (1.08)
Analysis Visit Mean (SD)	5.17 (0.94)	5.05 (0.90)	5.33 (1.15)
LS Mean of Change from Baseline (SE)	-0.02 (0.14)	-0.07 (0.14)	0.09 (0.11)
95% CI	(-0.29, 0.26)	(-0.34, 0.21)	(-0.14, 0.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.17)	-0.16 (0.17)	
95% CI	(-0.45, 0.23)	(-0.49, 0.18)	
p-value	0.5288	0.3654	
Corrected Hedge's g Statistics	-0.144	-0.208	
95% CI	(-0.63, 0.34)	(-0.70, 0.28)	
Week 52			
m	26	25	52
n	21	19	37
Baseline Mean (SD)	5.38 (1.04)	5.12 (1.22)	5.40 (1.11)
Analysis Visit Mean (SD)	5.40 (1.13)	5.08 (0.96)	5.45 (1.25)
LS Mean of Change from Baseline (SE)	0.08 (0.16)	-0.12 (0.17)	0.04 (0.13)
95% CI	(-0.24, 0.40)	(-0.45, 0.21)	(-0.22, 0.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.20)	-0.16 (0.20)	
95% CI	(-0.35, 0.44)	(-0.56, 0.24)	
p-value	0.8287	0.4222	
Corrected Hedge's g Statistics	0.055	-0.210	
95% CI	(-0.48, 0.59)	(-0.76, 0.34)	
Subgroup*Treatment Interaction p-value	0.6910	0.8063	

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Abdominal Symptoms			
Week 24			
m	49	43	83
n	46	39	76
Baseline Mean (SD)	5.31 (1.62)	5.34 (1.46)	5.40 (1.47)
Analysis Visit Mean (SD)	5.26 (1.43)	5.45 (1.49)	5.57 (1.39)
LS Mean of Change from Baseline (SE)	-0.04 (0.16)	0.09 (0.17)	0.19 (0.13)
95% CI	(-0.37, 0.28)	(-0.26, 0.43)	(-0.06, 0.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.23 (0.20)	-0.10 (0.21)	
95% CI	(-0.63, 0.17)	(-0.52, 0.32)	
p-value	0.2542	0.6333	
Corrected Hedge's g Statistics	-0.206	-0.092	
95% CI	(-0.57, 0.16)	(-0.48, 0.29)	
Week 52			
m	47	38	75
n	42	36	63
Baseline Mean (SD)	5.42 (1.55)	5.43 (1.40)	5.49 (1.42)
Analysis Visit Mean (SD)	5.57 (1.26)	5.44 (1.37)	5.58 (1.30)
LS Mean of Change from Baseline (SE)	0.15 (0.17)	0.02 (0.17)	0.19 (0.13)
95% CI	(-0.17, 0.48)	(-0.32, 0.37)	(-0.08, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.21)	-0.16 (0.22)	
95% CI	(-0.44, 0.37)	(-0.59, 0.26)	
p-value	0.8753	0.4484	
Corrected Hedge's g Statistics	-0.030	-0.155	
95% CI	(-0.42, 0.36)	(-0.56, 0.26)	
Subgroup*Treatment Interaction p-value	0.7156	0.9010	

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Activity			
Week 24			
m	49	43	83
n	46	39	76
Baseline Mean (SD)	5.39 (1.36)	5.34 (1.18)	5.51 (1.32)
Analysis Visit Mean (SD)	5.48 (1.51)	5.46 (1.32)	5.65 (1.23)
LS Mean of Change from Baseline (SE)	0.13 (0.14)	0.11 (0.14)	0.19 (0.11)
95% CI	(-0.14, 0.40)	(-0.18, 0.39)	(-0.02, 0.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.17)	-0.08 (0.18)	
95% CI	(-0.39, 0.28)	(-0.43, 0.27)	
p-value	0.7502	0.6547	
Corrected Hedge's g Statistics	-0.058	-0.086	
95% CI	(-0.42, 0.31)	(-0.47, 0.30)	
Week 52			
m	47	38	75
n	42	36	63
Baseline Mean (SD)	5.48 (1.34)	5.34 (1.17)	5.55 (1.25)
Analysis Visit Mean (SD)	5.48 (1.28)	5.48 (1.28)	5.49 (1.33)
LS Mean of Change from Baseline (SE)	0.06 (0.13)	0.14 (0.14)	-0.01 (0.11)
95% CI	(-0.20, 0.33)	(-0.14, 0.42)	(-0.23, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.17)	0.15 (0.18)	
95% CI	(-0.25, 0.41)	(-0.19, 0.50)	
p-value	0.6432	0.3869	
Corrected Hedge's g Statistics	0.089	0.177	
95% CI	(-0.30, 0.48)	(-0.23, 0.59)	
Subgroup*Treatment Interaction p-value	0.7461	0.8729	

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Emotional Health			
Week 24			
m	49	43	83
n	46	39	76
Baseline Mean (SD)	5.36 (1.31)	5.20 (1.34)	5.44 (1.22)
Analysis Visit Mean (SD)	5.46 (1.38)	5.20 (1.25)	5.49 (1.18)
LS Mean of Change from Baseline (SE)	0.12 (0.12)	-0.04 (0.13)	0.09 (0.09)
95% CI	(-0.11, 0.36)	(-0.29, 0.21)	(-0.09, 0.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.15)	-0.13 (0.15)	
95% CI	(-0.26, 0.32)	(-0.43, 0.18)	
p-value	0.8297	0.4068	
Corrected Hedge's g Statistics	0.039	-0.160	
95% CI	(-0.33, 0.40)	(-0.55, 0.23)	
Week 52			
m	47	38	75
n	42	36	63
Baseline Mean (SD)	5.50 (1.21)	5.27 (1.38)	5.46 (1.24)
Analysis Visit Mean (SD)	5.45 (1.03)	5.35 (1.33)	5.42 (1.32)
LS Mean of Change from Baseline (SE)	0.00 (0.11)	0.08 (0.12)	-0.01 (0.09)
95% CI	(-0.22, 0.23)	(-0.15, 0.32)	(-0.19, 0.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.14)	0.09 (0.15)	
95% CI	(-0.26, 0.29)	(-0.20, 0.39)	
p-value	0.9235	0.5210	
Corrected Hedge's g Statistics	0.018	0.131	
95% CI	(-0.37, 0.41)	(-0.28, 0.54)	
Subgroup*Treatment Interaction p-value	0.9899	0.6184	

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Fatigue			
Week 24			
m	49	43	83
n	46	39	76
Baseline Mean (SD)	4.99 (1.39)	4.31 (1.48)	4.61 (1.50)
Analysis Visit Mean (SD)	5.03 (1.48)	4.41 (1.40)	4.77 (1.43)
LS Mean of Change from Baseline (SE)	0.16 (0.15)	-0.01 (0.16)	0.15 (0.11)
95% CI	(-0.13, 0.45)	(-0.32, 0.30)	(-0.07, 0.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.18)	-0.16 (0.19)	
95% CI	(-0.35, 0.37)	(-0.54, 0.22)	
p-value	0.9716	0.4020	
Corrected Hedge's g Statistics	0.006	-0.161	
95% CI	(-0.36, 0.37)	(-0.55, 0.23)	
Week 52			
m	47	38	75
n	42	36	63
Baseline Mean (SD)	5.09 (1.37)	4.38 (1.46)	4.65 (1.49)
Analysis Visit Mean (SD)	4.95 (1.32)	4.45 (1.54)	4.67 (1.47)
LS Mean of Change from Baseline (SE)	-0.06 (0.14)	0.02 (0.15)	0.04 (0.11)
95% CI	(-0.34, 0.23)	(-0.28, 0.31)	(-0.19, 0.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.18)	-0.02 (0.19)	
95% CI	(-0.45, 0.26)	(-0.39, 0.35)	
p-value	0.5899	0.9044	
Corrected Hedge's g Statistics	-0.104	-0.025	
95% CI	(-0.49, 0.29)	(-0.43, 0.38)	
Subgroup*Treatment Interaction p-value	0.8533	0.8038	

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Systemic Symptoms			
Week 24			
m	49	43	83
n	46	39	76
Baseline Mean (SD)	5.20 (1.11)	5.12 (1.26)	5.20 (1.22)
Analysis Visit Mean (SD)	5.25 (1.22)	5.07 (1.26)	5.30 (1.22)
LS Mean of Change from Baseline (SE)	0.10 (0.12)	-0.05 (0.13)	0.12 (0.09)
95% CI	(-0.14, 0.33)	(-0.30, 0.20)	(-0.06, 0.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.15)	-0.17 (0.16)	
95% CI	(-0.32, 0.26)	(-0.48, 0.14)	
p-value	0.8611	0.2705	
Corrected Hedge's g Statistics	-0.032	-0.212	
95% CI	(-0.40, 0.33)	(-0.60, 0.18)	
Week 52			
m	47	38	75
n	42	36	63
Baseline Mean (SD)	5.28 (1.13)	5.13 (1.31)	5.21 (1.24)
Analysis Visit Mean (SD)	5.12 (1.19)	5.16 (1.33)	5.09 (1.36)
LS Mean of Change from Baseline (SE)	-0.11 (0.12)	0.04 (0.13)	-0.05 (0.10)
95% CI	(-0.35, 0.13)	(-0.22, 0.29)	(-0.24, 0.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.15)	0.08 (0.16)	
95% CI	(-0.36, 0.24)	(-0.23, 0.40)	
p-value	0.6865	0.6006	
Corrected Hedge's g Statistics	-0.078	0.107	
95% CI	(-0.47, 0.31)	(-0.30, 0.52)	
Subgroup*Treatment Interaction p-value	0.9870	0.4916	

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Worry			
Week 24			
m	49	43	83
n	46	39	76
Baseline Mean (SD)	5.41 (1.54)	5.50 (1.47)	5.63 (1.36)
Analysis Visit Mean (SD)	5.70 (1.47)	5.69 (1.37)	6.03 (1.31)
LS Mean of Change from Baseline (SE)	0.32 (0.13)	0.19 (0.14)	0.48 (0.10)
95% CI	(0.06, 0.58)	(-0.08, 0.47)	(0.27, 0.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.16 (0.16)	-0.28 (0.17)	
95% CI	(-0.47, 0.16)	(-0.62, 0.05)	
p-value	0.3388	0.0984	
Corrected Hedge's g Statistics	-0.173	-0.318	
95% CI	(-0.54, 0.19)	(-0.71, 0.07)	
Week 52			
m	47	38	75
n	42	36	63
Baseline Mean (SD)	5.52 (1.51)	5.53 (1.50)	5.64 (1.41)
Analysis Visit Mean (SD)	5.65 (1.34)	5.90 (1.34)	6.01 (1.35)
LS Mean of Change from Baseline (SE)	0.19 (0.14)	0.37 (0.14)	0.43 (0.11)
95% CI	(-0.08, 0.46)	(0.08, 0.65)	(0.21, 0.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.24 (0.17)	-0.06 (0.18)	
95% CI	(-0.57, 0.10)	(-0.41, 0.29)	
p-value	0.1692	0.7369	
Corrected Hedge's g Statistics	-0.266	-0.069	
95% CI	(-0.66, 0.13)	(-0.48, 0.34)	
Subgroup*Treatment Interaction p-value	0.2880	0.6674	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Abdominal Symptoms			
Week 24			
m	72	58	135
n	67	50	116
Baseline Mean (SD)	5.20 (1.63)	5.82 (1.25)	5.24 (1.52)
Analysis Visit Mean (SD)	5.40 (1.59)	5.49 (1.64)	5.47 (1.42)
LS Mean of Change from Baseline (SE)	0.18 (0.14)	-0.17 (0.16)	0.22 (0.10)
95% CI	(-0.09, 0.44)	(-0.48, 0.14)	(0.02, 0.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.05 (0.17)	-0.39 (0.19)	
95% CI	(-0.38, 0.28)	(-0.76, -0.02)	
p-value	0.7807	0.0367	
Corrected Hedge's g Statistics	-0.042	-0.350	
95% CI	(-0.34, 0.26)	(-0.68, -0.02)	
Week 52			
m	69	51	128
n	60	42	103
Baseline Mean (SD)	5.31 (1.56)	5.90 (1.10)	5.24 (1.46)
Analysis Visit Mean (SD)	5.55 (1.55)	5.67 (1.28)	5.29 (1.48)
LS Mean of Change from Baseline (SE)	0.23 (0.14)	-0.10 (0.17)	0.06 (0.11)
95% CI	(-0.05, 0.51)	(-0.43, 0.24)	(-0.15, 0.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.17 (0.18)	-0.16 (0.20)	
95% CI	(-0.18, 0.52)	(-0.56, 0.24)	
p-value	0.3486	0.4368	
Corrected Hedge's g Statistics	0.149	-0.141	
95% CI	(-0.17, 0.47)	(-0.50, 0.22)	
Subgroup*Treatment Interaction p-value	0.7156	0.9010	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Activity			
Week 24			
m	72	58	135
n	67	50	116
Baseline Mean (SD)	5.26 (1.38)	5.48 (1.25)	5.37 (1.45)
Analysis Visit Mean (SD)	5.25 (1.40)	5.36 (1.26)	5.40 (1.34)
LS Mean of Change from Baseline (SE)	-0.03 (0.11)	-0.09 (0.12)	0.03 (0.08)
95% CI	(-0.24, 0.19)	(-0.33, 0.16)	(-0.13, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.13)	-0.12 (0.15)	
95% CI	(-0.32, 0.21)	(-0.41, 0.17)	
p-value	0.6685	0.4236	
Corrected Hedge's g Statistics	-0.064	-0.133	
95% CI	(-0.37, 0.24)	(-0.46, 0.20)	
Week 52			
m	69	51	128
n	60	42	103
Baseline Mean (SD)	5.30 (1.37)	5.43 (1.30)	5.42 (1.40)
Analysis Visit Mean (SD)	5.30 (1.54)	5.40 (1.17)	5.32 (1.41)
LS Mean of Change from Baseline (SE)	-0.02 (0.12)	-0.03 (0.14)	-0.05 (0.09)
95% CI	(-0.26, 0.22)	(-0.32, 0.25)	(-0.23, 0.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.15)	0.02 (0.17)	
95% CI	(-0.27, 0.33)	(-0.32, 0.35)	
p-value	0.8298	0.9231	
Corrected Hedge's g Statistics	0.034	0.017	
95% CI	(-0.28, 0.35)	(-0.34, 0.38)	
Subgroup*Treatment Interaction p-value	0.7461	0.8729	

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Emotional Health			
Week 24			
m	72	58	135
n	67	50	116
Baseline Mean (SD)	5.34 (1.18)	5.61 (1.19)	5.37 (1.26)
Analysis Visit Mean (SD)	5.45 (1.19)	5.41 (1.21)	5.45 (1.27)
LS Mean of Change from Baseline (SE)	0.10 (0.10)	-0.16 (0.11)	0.07 (0.07)
95% CI	(-0.09, 0.29)	(-0.38, 0.06)	(-0.08, 0.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.12)	-0.23 (0.13)	
95% CI	(-0.20, 0.27)	(-0.49, 0.03)	
p-value	0.7838	0.0880	
Corrected Hedge's g Statistics	0.041	-0.284	
95% CI	(-0.26, 0.34)	(-0.62, 0.05)	
Week 52			
m	69	51	128
n	60	42	103
Baseline Mean (SD)	5.39 (1.20)	5.55 (1.21)	5.39 (1.27)
Analysis Visit Mean (SD)	5.50 (1.07)	5.43 (1.16)	5.43 (1.20)
LS Mean of Change from Baseline (SE)	0.08 (0.10)	-0.08 (0.12)	0.03 (0.08)
95% CI	(-0.12, 0.28)	(-0.31, 0.15)	(-0.12, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.12)	-0.11 (0.14)	
95% CI	(-0.20, 0.29)	(-0.38, 0.16)	
p-value	0.7046	0.4231	
Corrected Hedge's g Statistics	0.060	-0.143	
95% CI	(-0.26, 0.38)	(-0.50, 0.22)	
Subgroup*Treatment Interaction p-value	0.9899	0.6184	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Fatigue			
Week 24			
m	72	58	135
n	67	50	116
Baseline Mean (SD)	4.56 (1.56)	5.01 (1.18)	4.64 (1.44)
Analysis Visit Mean (SD)	4.66 (1.58)	4.64 (1.22)	4.63 (1.50)
LS Mean of Change from Baseline (SE)	0.10 (0.13)	-0.29 (0.15)	0.00 (0.10)
95% CI	(-0.16, 0.35)	(-0.58, 0.00)	(-0.19, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (0.16)	-0.28 (0.17)	
95% CI	(-0.21, 0.41)	(-0.62, 0.06)	
p-value	0.5232	0.1039	
Corrected Hedge's g Statistics	0.096	-0.271	
95% CI	(-0.20, 0.40)	(-0.60, 0.06)	
Week 52			
m	69	51	128
n	60	42	103
Baseline Mean (SD)	4.61 (1.58)	4.95 (1.24)	4.66 (1.41)
Analysis Visit Mean (SD)	4.73 (1.58)	4.63 (1.41)	4.67 (1.36)
LS Mean of Change from Baseline (SE)	0.09 (0.13)	-0.22 (0.15)	0.04 (0.10)
95% CI	(-0.16, 0.35)	(-0.52, 0.08)	(-0.15, 0.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.05 (0.16)	-0.26 (0.18)	
95% CI	(-0.26, 0.37)	(-0.61, 0.09)	
p-value	0.7456	0.1496	
Corrected Hedge's g Statistics	0.052	-0.259	
95% CI	(-0.27, 0.37)	(-0.62, 0.10)	
Subgroup*Treatment Interaction p-value	0.8533	0.8038	

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Systemic Symptoms			
Week 24			
m	72	58	135
n	67	50	116
Baseline Mean (SD)	5.11 (1.35)	5.27 (1.11)	5.02 (1.22)
Analysis Visit Mean (SD)	5.10 (1.28)	5.02 (1.17)	5.01 (1.29)
LS Mean of Change from Baseline (SE)	0.01 (0.10)	-0.20 (0.12)	-0.02 (0.08)
95% CI	(-0.19, 0.21)	(-0.43, 0.03)	(-0.17, 0.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.12)	-0.18 (0.14)	
95% CI	(-0.21, 0.28)	(-0.45, 0.09)	
p-value	0.7983	0.1949	
Corrected Hedge's g Statistics	0.038	-0.216	
95% CI	(-0.26, 0.34)	(-0.55, 0.12)	
Week 52			
m	69	51	128
n	60	42	103
Baseline Mean (SD)	5.21 (1.28)	5.25 (1.10)	5.00 (1.25)
Analysis Visit Mean (SD)	5.12 (1.30)	5.06 (1.10)	5.02 (1.31)
LS Mean of Change from Baseline (SE)	-0.04 (0.10)	-0.18 (0.12)	0.03 (0.08)
95% CI	(-0.24, 0.15)	(-0.41, 0.06)	(-0.12, 0.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.12)	-0.21 (0.14)	
95% CI	(-0.32, 0.17)	(-0.48, 0.07)	
p-value	0.5550	0.1385	
Corrected Hedge's g Statistics	-0.094	-0.266	
95% CI	(-0.41, 0.22)	(-0.63, 0.09)	
Subgroup*Treatment Interaction p-value	0.9870	0.4916	

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Worry			
Week 24			
m	72	58	135
n	67	50	116
Baseline Mean (SD)	5.48 (1.36)	5.66 (1.57)	5.57 (1.42)
Analysis Visit Mean (SD)	5.91 (1.29)	5.84 (1.43)	5.86 (1.32)
LS Mean of Change from Baseline (SE)	0.40 (0.11)	0.20 (0.13)	0.28 (0.08)
95% CI	(0.18, 0.62)	(-0.06, 0.45)	(0.11, 0.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.12 (0.14)	-0.08 (0.15)	
95% CI	(-0.15, 0.39)	(-0.38, 0.22)	
p-value	0.3667	0.5943	
Corrected Hedge's g Statistics	0.136	-0.088	
95% CI	(-0.17, 0.44)	(-0.42, 0.24)	
Week 52			
m	69	51	128
n	60	42	103
Baseline Mean (SD)	5.52 (1.39)	5.67 (1.56)	5.62 (1.38)
Analysis Visit Mean (SD)	5.97 (1.23)	5.95 (1.37)	6.00 (1.17)
LS Mean of Change from Baseline (SE)	0.39 (0.12)	0.34 (0.14)	0.39 (0.09)
95% CI	(0.16, 0.63)	(0.06, 0.62)	(0.21, 0.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.15)	-0.05 (0.17)	
95% CI	(-0.29, 0.29)	(-0.37, 0.28)	
p-value	0.9777	0.7704	
Corrected Hedge's g Statistics	0.004	-0.052	
95% CI	(-0.31, 0.32)	(-0.41, 0.31)	
Subgroup*Treatment Interaction p-value	0.2880	0.6674	

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Abdominal Symptoms			
Week 24			
m	30	28	54
n	26	25	44
Baseline Mean (SD)	5.35 (1.61)	5.35 (1.33)	5.17 (1.59)
Analysis Visit Mean (SD)	5.66 (1.11)	5.24 (1.27)	5.44 (1.55)
LS Mean of Change from Baseline (SE)	0.34 (0.21)	-0.06 (0.21)	0.28 (0.17)
95% CI	(-0.07, 0.75)	(-0.48, 0.35)	(-0.06, 0.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.07 (0.26)	-0.34 (0.26)	
95% CI	(-0.44, 0.57)	(-0.85, 0.17)	
p-value	0.7937	0.1887	
Corrected Hedge's g Statistics	0.060	-0.307	
95% CI	(-0.42, 0.55)	(-0.80, 0.19)	
Week 52			
m	26	25	52
n	21	19	37
Baseline Mean (SD)	5.48 (1.61)	5.52 (1.29)	5.40 (1.60)
Analysis Visit Mean (SD)	5.33 (1.59)	5.59 (1.11)	5.59 (1.39)
LS Mean of Change from Baseline (SE)	-0.01 (0.22)	0.11 (0.23)	0.24 (0.17)
95% CI	(-0.44, 0.42)	(-0.34, 0.56)	(-0.10, 0.59)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.26 (0.26)	-0.14 (0.27)	
95% CI	(-0.78, 0.27)	(-0.68, 0.40)	
p-value	0.3327	0.6184	
Corrected Hedge's g Statistics	-0.248	-0.131	
95% CI	(-0.78, 0.29)	(-0.68, 0.42)	
Subgroup*Treatment Interaction p-value	0.7156	0.9010	

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Activity			
Week 24			
m	30	28	54
n	26	25	44
Baseline Mean (SD)	5.05 (1.45)	5.13 (1.59)	5.43 (1.23)
Analysis Visit Mean (SD)	4.97 (1.50)	5.30 (1.13)	5.55 (1.44)
LS Mean of Change from Baseline (SE)	-0.13 (0.19)	0.07 (0.19)	0.12 (0.16)
95% CI	(-0.51, 0.25)	(-0.31, 0.45)	(-0.20, 0.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.25 (0.24)	-0.04 (0.24)	
95% CI	(-0.72, 0.22)	(-0.51, 0.43)	
p-value	0.2973	0.8573	
Corrected Hedge's g Statistics	-0.239	-0.041	
95% CI	(-0.73, 0.25)	(-0.53, 0.45)	
Week 52			
m	26	25	52
n	21	19	37
Baseline Mean (SD)	5.39 (1.33)	5.21 (1.62)	5.66 (1.13)
Analysis Visit Mean (SD)	5.14 (1.71)	4.92 (1.29)	5.48 (1.56)
LS Mean of Change from Baseline (SE)	-0.19 (0.25)	-0.31 (0.26)	-0.10 (0.20)
95% CI	(-0.69, 0.31)	(-0.83, 0.20)	(-0.50, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.31)	-0.21 (0.32)	
95% CI	(-0.70, 0.53)	(-0.85, 0.42)	
p-value	0.7857	0.5096	
Corrected Hedge's g Statistics	-0.070	-0.175	
95% CI	(-0.61, 0.47)	(-0.73, 0.38)	
Subgroup*Treatment Interaction p-value	0.7461	0.8729	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Emotional Health			
Week 24			
m	30	28	54
n	26	25	44
Baseline Mean (SD)	5.32 (1.22)	5.16 (1.42)	5.43 (1.16)
Analysis Visit Mean (SD)	5.33 (1.12)	5.10 (1.17)	5.34 (1.24)
LS Mean of Change from Baseline (SE)	-0.04 (0.17)	-0.18 (0.17)	-0.12 (0.14)
95% CI	(-0.38, 0.31)	(-0.52, 0.17)	(-0.40, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.21)	-0.06 (0.21)	
95% CI	(-0.34, 0.51)	(-0.49, 0.37)	
p-value	0.7013	0.7816	
Corrected Hedge's g Statistics	0.089	-0.065	
95% CI	(-0.40, 0.57)	(-0.56, 0.43)	
Week 52			
m	26	25	52
n	21	19	37
Baseline Mean (SD)	5.44 (1.21)	5.25 (1.55)	5.59 (1.21)
Analysis Visit Mean (SD)	5.41 (1.10)	5.43 (1.09)	5.62 (1.20)
LS Mean of Change from Baseline (SE)	-0.06 (0.17)	0.07 (0.17)	0.00 (0.13)
95% CI	(-0.39, 0.27)	(-0.27, 0.41)	(-0.27, 0.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.20)	0.07 (0.21)	
95% CI	(-0.46, 0.34)	(-0.34, 0.49)	
p-value	0.7747	0.7280	
Corrected Hedge's g Statistics	-0.072	0.090	
95% CI	(-0.61, 0.46)	(-0.46, 0.64)	
Subgroup*Treatment Interaction p-value	0.9899	0.6184	

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Fatigue			
Week 24			
m	30	28	54
n	26	25	44
Baseline Mean (SD)	4.67 (1.42)	4.30 (1.69)	4.69 (1.49)
Analysis Visit Mean (SD)	4.45 (1.36)	4.29 (1.30)	4.74 (1.48)
LS Mean of Change from Baseline (SE)	-0.20 (0.20)	-0.16 (0.20)	0.04 (0.16)
95% CI	(-0.59, 0.19)	(-0.55, 0.23)	(-0.29, 0.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.24 (0.24)	-0.19 (0.24)	
95% CI	(-0.72, 0.24)	(-0.68, 0.29)	
p-value	0.3331	0.4246	
Corrected Hedge's g Statistics	-0.221	-0.184	
95% CI	(-0.71, 0.26)	(-0.68, 0.31)	
Week 52			
m	26	25	52
n	21	19	37
Baseline Mean (SD)	4.76 (1.55)	4.47 (1.74)	4.84 (1.49)
Analysis Visit Mean (SD)	4.88 (1.62)	4.34 (1.33)	4.92 (1.61)
LS Mean of Change from Baseline (SE)	0.23 (0.24)	-0.22 (0.25)	0.02 (0.19)
95% CI	(-0.25, 0.72)	(-0.72, 0.28)	(-0.36, 0.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.21 (0.30)	-0.24 (0.31)	
95% CI	(-0.38, 0.80)	(-0.85, 0.36)	
p-value	0.4742	0.4318	
Corrected Hedge's g Statistics	0.184	-0.208	
95% CI	(-0.35, 0.72)	(-0.76, 0.35)	
Subgroup*Treatment Interaction p-value	0.8533	0.8038	

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Systemic Symptoms			
Week 24			
m	30	28	54
n	26	25	44
Baseline Mean (SD)	5.04 (1.15)	4.79 (1.28)	5.17 (1.22)
Analysis Visit Mean (SD)	4.97 (1.17)	4.58 (1.10)	5.10 (1.24)
LS Mean of Change from Baseline (SE)	-0.01 (0.16)	-0.28 (0.16)	-0.01 (0.13)
95% CI	(-0.32, 0.30)	(-0.59, 0.04)	(-0.27, 0.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.19)	-0.26 (0.19)	
95% CI	(-0.38, 0.39)	(-0.65, 0.12)	
p-value	0.9877	0.1777	
Corrected Hedge's g Statistics	0.004	-0.312	
95% CI	(-0.48, 0.49)	(-0.81, 0.18)	
Week 52			
m	26	25	52
n	21	19	37
Baseline Mean (SD)	5.32 (1.09)	4.86 (1.12)	5.17 (1.32)
Analysis Visit Mean (SD)	5.19 (1.31)	4.53 (1.17)	5.22 (1.46)
LS Mean of Change from Baseline (SE)	0.00 (0.19)	-0.37 (0.20)	0.11 (0.15)
95% CI	(-0.38, 0.38)	(-0.76, 0.02)	(-0.19, 0.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.23)	-0.48 (0.24)	
95% CI	(-0.57, 0.36)	(-0.95, 0.00)	
p-value	0.6539	0.0499	
Corrected Hedge's g Statistics	-0.115	-0.522	
95% CI	(-0.65, 0.42)	(-1.08, 0.04)	
Subgroup*Treatment Interaction p-value	0.9870	0.4916	

AMNOG Table SE23.14c.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Worry			
Week 24			
m	30	28	54
n	26	25	44
Baseline Mean (SD)	5.72 (1.11)	5.47 (1.46)	5.52 (1.39)
Analysis Visit Mean (SD)	5.68 (1.17)	5.74 (1.14)	5.79 (1.46)
LS Mean of Change from Baseline (SE)	0.00 (0.20)	0.21 (0.20)	0.23 (0.16)
95% CI	(-0.39, 0.39)	(-0.18, 0.60)	(-0.09, 0.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.23 (0.24)	-0.02 (0.24)	
95% CI	(-0.71, 0.24)	(-0.50, 0.45)	
p-value	0.3370	0.9220	
Corrected Hedge's g Statistics	-0.220	-0.022	
95% CI	(-0.71, 0.27)	(-0.51, 0.47)	
Week 52			
m	26	25	52
n	21	19	37
Baseline Mean (SD)	5.92 (1.04)	5.37 (1.61)	5.73 (1.31)
Analysis Visit Mean (SD)	6.42 (0.75)	5.80 (1.52)	5.85 (1.44)
LS Mean of Change from Baseline (SE)	0.55 (0.22)	0.24 (0.23)	0.10 (0.17)
95% CI	(0.11, 0.99)	(-0.21, 0.68)	(-0.24, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.45 (0.27)	0.13 (0.27)	
95% CI	(-0.08, 0.98)	(-0.41, 0.68)	
p-value	0.0984	0.6302	
Corrected Hedge's g Statistics	0.423	0.126	
95% CI	(-0.12, 0.96)	(-0.43, 0.68)	
Subgroup*Treatment Interaction p-value	0.2880	0.6674	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (5.7)	4 (8.9)	8 (8.9)
No	50 (94.3)	41 (91.1)	82 (91.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.63	1.00	
95% CI of the inverse odds ratio	(0.41, 6.42)	(0.28, 3.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.57	1.00	
95% CI of the inverse risk ratio	(0.44, 5.66)	(0.32, 3.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.23	0.00	
95% CI of the absolute risk difference	(-11.79, 5.33)	(-10.18, 10.18)	
p-value	0.4841	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.7941	0.0978	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	12 (22.6)	13 (28.9)	19 (21.1)
No	41 (77.4)	32 (71.1)	71 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.66	
95% CI of the inverse odds ratio	(0.40, 2.07)	(0.29, 1.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.73	
95% CI of the inverse risk ratio	(0.49, 1.76)	(0.40, 1.34)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.53	7.78	
95% CI of the absolute risk difference	(-12.54, 15.60)	(-7.92, 23.48)	
p-value	0.8302	0.3165	
p-value of Breslow-Day Test for Homogeneity [3]	0.8745	0.1660	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (20.8)	7 (15.6)	17 (18.9)
No	42 (79.2)	38 (84.4)	73 (81.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.26	
95% CI of the inverse odds ratio	(0.38, 2.08)	(0.48, 3.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	1.21	
95% CI of the inverse risk ratio	(0.46, 1.79)	(0.54, 2.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.87	-3.33	
95% CI of the absolute risk difference	(-11.72, 15.45)	(-16.66, 9.99)	
p-value	0.7860	0.6330	
p-value of Breslow-Day Test for Homogeneity [3]	0.6909	0.2417	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (34.0)	12 (26.7)	26 (28.9)
No	35 (66.0)	33 (73.3)	64 (71.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	1.12	
95% CI of the inverse odds ratio	(0.38, 1.64)	(0.50, 2.49)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.08	
95% CI of the inverse risk ratio	(0.52, 1.40)	(0.60, 1.94)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.07	-2.22	
95% CI of the absolute risk difference	(-10.75, 20.89)	(-18.18, 13.73)	
p-value	0.5255	0.7867	
p-value of Breslow-Day Test for Homogeneity [3]	0.6684	0.1312	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (11.3)	7 (15.6)	9 (10.0)
No	47 (88.7)	38 (84.4)	81 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	0.60	
95% CI of the inverse odds ratio	(0.29, 2.60)	(0.21, 1.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.64	
95% CI of the inverse risk ratio	(0.33, 2.34)	(0.26, 1.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.32	5.56	
95% CI of the absolute risk difference	(-9.22, 11.86)	(-6.71, 17.83)	
p-value	0.8034	0.3465	
p-value of Breslow-Day Test for Homogeneity [3]	0.5198	0.9876	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (30.2)	14 (31.1)	20 (22.2)
No	37 (69.8)	31 (68.9)	70 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.63	
95% CI of the inverse odds ratio	(0.31, 1.43)	(0.28, 1.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	0.71	
95% CI of the inverse risk ratio	(0.42, 1.29)	(0.40, 1.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.97	8.89	
95% CI of the absolute risk difference	(-7.08, 23.02)	(-7.13, 24.91)	
p-value	0.2891	0.2620	
p-value of Breslow-Day Test for Homogeneity [3]	0.7546	0.7789	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (11.3)	4 (8.9)	8 (8.9)
No	47 (88.7)	41 (91.1)	82 (91.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	1.00	
95% CI of the inverse odds ratio	(0.25, 2.34)	(0.28, 3.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	1.00	
95% CI of the inverse risk ratio	(0.29, 2.14)	(0.32, 3.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.43	0.00	
95% CI of the absolute risk difference	(-7.93, 12.79)	(-10.18, 10.18)	
p-value	0.6365	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.8017	0.7820	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (18.9)	12 (26.7)	20 (22.2)
No	43 (81.1)	33 (73.3)	70 (77.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.23	0.79	
95% CI of the inverse odds ratio	(0.53, 2.87)	(0.34, 1.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.83	
95% CI of the inverse risk ratio	(0.60, 2.32)	(0.45, 1.55)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.35	4.44	
95% CI of the absolute risk difference	(-16.95, 10.24)	(-11.07, 19.96)	
p-value	0.6342	0.5670	
p-value of Breslow-Day Test for Homogeneity [3]	0.8773	0.2991	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.8)	8 (17.8)	11 (12.2)
No	51 (96.2)	37 (82.2)	79 (87.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.55	0.64	
95% CI of the inverse odds ratio	(0.76, 16.68)	(0.24, 1.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.24	0.69	
95% CI of the inverse risk ratio	(0.75, 14.06)	(0.30, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.45	5.56	
95% CI of the absolute risk difference	(-16.94, 0.04)	(-7.50, 18.62)	
p-value	0.0896	0.3816	
p-value of Breslow-Day Test for Homogeneity [3]	0.1885	0.3796	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (26.4)	13 (28.9)	25 (27.8)
No	39 (73.6)	32 (71.1)	65 (72.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.95	
95% CI of the inverse odds ratio	(0.50, 2.30)	(0.43, 2.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.96	
95% CI of the inverse risk ratio	(0.60, 1.84)	(0.55, 1.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.36	1.11	
95% CI of the absolute risk difference	(-16.41, 13.69)	(-15.04, 17.27)	
p-value	0.8597	0.8924	
p-value of Breslow-Day Test for Homogeneity [3]	0.7647	0.3794	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.8)	5 (11.1)	9 (10.0)
No	51 (96.2)	40 (88.9)	81 (90.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.83	0.89	
95% CI of the inverse odds ratio	(0.59, 13.64)	(0.28, 2.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.65	0.90	
95% CI of the inverse risk ratio	(0.59, 11.81)	(0.32, 2.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.23	1.11	
95% CI of the absolute risk difference	(-14.27, 1.82)	(-9.97, 12.19)	
p-value	0.1772	0.8418	
p-value of Breslow-Day Test for Homogeneity [3]	0.3016	0.7769	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	11 (20.8)	13 (28.9)	17 (18.9)
No	42 (79.2)	32 (71.1)	73 (81.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	0.57	
95% CI of the inverse odds ratio	(0.38, 2.08)	(0.25, 1.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.91	0.65	
95% CI of the inverse risk ratio	(0.46, 1.79)	(0.35, 1.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.87	10.00	
95% CI of the absolute risk difference	(-11.72, 15.45)	(-5.52, 25.52)	
p-value	0.7860	0.1877	
p-value of Breslow-Day Test for Homogeneity [3]	0.2293	0.1110	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (13.2)	8 (17.8)	16 (17.8)
No	46 (86.8)	37 (82.2)	74 (82.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	1.00	
95% CI of the inverse odds ratio	(0.54, 3.72)	(0.39, 2.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	1.00	
95% CI of the inverse risk ratio	(0.59, 3.06)	(0.46, 2.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.57	0.00	
95% CI of the absolute risk difference	(-16.63, 7.49)	(-13.68, 13.68)	
p-value	0.4725	>0.9999	
p-value of Breslow-Day Test for Homogeneity [3]	0.4406	0.7172	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (30.2)	16 (35.6)	29 (32.2)
No	37 (69.8)	29 (64.4)	61 (67.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.10	0.86	
95% CI of the inverse odds ratio	(0.53, 2.29)	(0.41, 1.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	0.91	
95% CI of the inverse risk ratio	(0.64, 1.77)	(0.55, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.03	3.33	
95% CI of the absolute risk difference	(-17.72, 13.65)	(-13.66, 20.33)	
p-value	0.8003	0.6985	
p-value of Breslow-Day Test for Homogeneity [3]	0.5525	0.1182	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (9.7)	2 (3.1)	13 (9.4)
No	65 (90.3)	63 (96.9)	126 (90.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	3.25	
95% CI of the inverse odds ratio	(0.36, 2.52)	(0.71, 14.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	3.04	
95% CI of the inverse risk ratio	(0.40, 2.30)	(0.71, 13.08)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.37	-6.28	
95% CI of the absolute risk difference	(-8.01, 8.75)	(-12.68, 0.13)	
p-value	0.9307	0.1096	
p-value of Breslow-Day Test for Homogeneity [3]	0.7941	0.0978	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	19 (26.4)	10 (15.4)	36 (25.9)
No	53 (73.6)	55 (84.6)	103 (74.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	1.92	
95% CI of the inverse odds ratio	(0.51, 1.86)	(0.89, 4.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.68	
95% CI of the inverse risk ratio	(0.61, 1.58)	(0.89, 3.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.49	-10.51	
95% CI of the absolute risk difference	(-12.03, 13.01)	(-21.92, 0.89)	
p-value	0.9388	0.0940	
p-value of Breslow-Day Test for Homogeneity [3]	0.8745	0.1660	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	17 (23.6)	4 (6.2)	26 (18.7)
No	55 (76.4)	61 (93.8)	113 (81.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	3.51	
95% CI of the inverse odds ratio	(0.37, 1.49)	(1.17, 10.52)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	3.04	
95% CI of the inverse risk ratio	(0.46, 1.36)	(1.11, 8.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.91	-12.55	
95% CI of the absolute risk difference	(-6.85, 16.66)	(-21.28, -3.82)	
p-value	0.4016	0.0184	
p-value of Breslow-Day Test for Homogeneity [3]	0.6909	0.2417	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (40.3)	9 (13.8)	47 (33.8)
No	43 (59.7)	56 (86.2)	92 (66.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	3.18	
95% CI of the inverse odds ratio	(0.42, 1.36)	(1.45, 6.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	2.44	
95% CI of the inverse risk ratio	(0.58, 1.21)	(1.28, 4.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.46	-19.97	
95% CI of the absolute risk difference	(-7.33, 20.26)	(-31.47, -8.46)	
p-value	0.3537	0.0029	
p-value of Breslow-Day Test for Homogeneity [3]	0.6684	0.1312	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	10 (13.9)	6 (9.2)	9 (6.5)
No	62 (86.1)	59 (90.8)	130 (93.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	0.68	
95% CI of the inverse odds ratio	(0.17, 1.11)	(0.23, 2.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	0.70	
95% CI of the inverse risk ratio	(0.20, 1.10)	(0.26, 1.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.41	2.76	
95% CI of the absolute risk difference	(-1.56, 16.39)	(-5.38, 10.90)	
p-value	0.0745	0.4822	
p-value of Breslow-Day Test for Homogeneity [3]	0.5198	0.9876	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	23 (31.9)	15 (23.1)	30 (21.6)
No	49 (68.1)	50 (76.9)	109 (78.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.92	
95% CI of the inverse odds ratio	(0.31, 1.11)	(0.45, 1.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.94	
95% CI of the inverse risk ratio	(0.43, 1.07)	(0.54, 1.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.36	1.49	
95% CI of the absolute risk difference	(-2.40, 23.12)	(-10.82, 13.81)	
p-value	0.0999	0.8105	
p-value of Breslow-Day Test for Homogeneity [3]	0.7546	0.7789	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (15.3)	5 (7.7)	13 (9.4)
No	61 (84.7)	60 (92.3)	126 (90.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	1.24	
95% CI of the inverse odds ratio	(0.24, 1.35)	(0.42, 3.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	1.22	
95% CI of the inverse risk ratio	(0.29, 1.30)	(0.45, 3.27)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.93	-1.66	
95% CI of the absolute risk difference	(-3.69, 15.54)	(-9.75, 6.43)	
p-value	0.1987	0.6969	
p-value of Breslow-Day Test for Homogeneity [3]	0.8017	0.7820	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	20 (27.8)	13 (20.0)	37 (26.6)
No	52 (72.2)	52 (80.0)	102 (73.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	1.45	
95% CI of the inverse odds ratio	(0.50, 1.79)	(0.71, 2.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.33	
95% CI of the inverse risk ratio	(0.60, 1.52)	(0.76, 2.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.16	-6.62	
95% CI of the absolute risk difference	(-11.53, 13.85)	(-18.81, 5.57)	
p-value	0.8573	0.3058	
p-value of Breslow-Day Test for Homogeneity [3]	0.8773	0.2991	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	11 (15.3)	5 (7.7)	17 (12.2)
No	61 (84.7)	60 (92.3)	122 (87.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	1.67	
95% CI of the inverse odds ratio	(0.34, 1.75)	(0.59, 4.75)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.59	
95% CI of the inverse risk ratio	(0.40, 1.62)	(0.61, 4.12)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.05	-4.54	
95% CI of the absolute risk difference	(-6.89, 12.98)	(-13.00, 3.93)	
p-value	0.5361	0.3302	
p-value of Breslow-Day Test for Homogeneity [3]	0.1885	0.3796	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (33.3)	11 (16.9)	38 (27.3)
No	48 (66.7)	54 (83.1)	101 (72.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.85	
95% CI of the inverse odds ratio	(0.41, 1.39)	(0.87, 3.90)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.62	
95% CI of the inverse risk ratio	(0.54, 1.25)	(0.88, 2.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	6.00	-10.42	
95% CI of the absolute risk difference	(-7.18, 19.17)	(-22.16, 1.33)	
p-value	0.3647	0.1047	
p-value of Breslow-Day Test for Homogeneity [3]	0.7647	0.3794	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (8.3)	4 (6.2)	13 (9.4)
No	66 (91.7)	61 (93.8)	126 (90.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	1.57	
95% CI of the inverse odds ratio	(0.41, 3.12)	(0.49, 5.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	1.52	
95% CI of the inverse risk ratio	(0.45, 2.83)	(0.52, 4.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.02	-3.20	
95% CI of the absolute risk difference	(-9.03, 6.99)	(-10.79, 4.39)	
p-value	0.8063	0.4412	
p-value of Breslow-Day Test for Homogeneity [3]	0.3016	0.7769	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (20.8)	12 (18.5)	41 (29.5)
No	57 (79.2)	53 (81.5)	98 (70.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.59	1.85	
95% CI of the inverse odds ratio	(0.81, 3.12)	(0.90, 3.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	1.60	
95% CI of the inverse risk ratio	(0.84, 2.38)	(0.90, 2.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-8.66	-11.03	
95% CI of the absolute risk difference	(-20.72, 3.40)	(-23.14, 1.07)	
p-value	0.1766	0.0940	
p-value of Breslow-Day Test for Homogeneity [3]	0.2293	0.1110	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	17 (23.6)	11 (16.9)	27 (19.4)
No	55 (76.4)	54 (83.1)	112 (80.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.78	1.18	
95% CI of the inverse odds ratio	(0.39, 1.55)	(0.55, 2.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.15	
95% CI of the inverse risk ratio	(0.48, 1.41)	(0.61, 2.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.19	-2.50	
95% CI of the absolute risk difference	(-7.62, 16.00)	(-13.74, 8.74)	
p-value	0.4779	0.6690	
p-value of Breslow-Day Test for Homogeneity [3]	0.4406	0.7172	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	28 (38.9)	16 (24.6)	53 (38.1)
No	44 (61.1)	49 (75.4)	86 (61.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	1.89	
95% CI of the inverse odds ratio	(0.54, 1.74)	(0.98, 3.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	1.55	
95% CI of the inverse risk ratio	(0.68, 1.40)	(0.96, 2.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.76	-13.51	
95% CI of the absolute risk difference	(-13.10, 14.62)	(-26.74, -0.29)	
p-value	0.9144	0.0573	
p-value of Breslow-Day Test for Homogeneity [3]	0.5525	0.1182	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.3)	4 (14.3)	3 (5.3)
No	29 (96.7)	24 (85.7)	54 (94.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.61	0.33	
95% CI of the inverse odds ratio	(0.16, 16.19)	(0.07, 1.61)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.58	0.37	
95% CI of the inverse risk ratio	(0.17, 14.53)	(0.09, 1.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.93	9.02	
95% CI of the absolute risk difference	(-10.58, 6.72)	(-5.18, 23.22)	
p-value	0.6829	0.1550	
p-value of Breslow-Day Test for Homogeneity [3]	0.7941	0.0978	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	5 (17.9)	10 (17.5)
No	23 (76.7)	23 (82.1)	47 (82.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	0.98	
95% CI of the inverse odds ratio	(0.24, 2.07)	(0.30, 3.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	0.98	
95% CI of the inverse risk ratio	(0.32, 1.77)	(0.37, 2.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.79	0.31	
95% CI of the absolute risk difference	(-12.28, 23.86)	(-16.97, 17.60)	
p-value	0.5174	0.9716	
p-value of Breslow-Day Test for Homogeneity [3]	0.8745	0.1660	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (10.0)	4 (14.3)	8 (14.0)
No	27 (90.0)	24 (85.7)	49 (86.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.47	0.98	
95% CI of the inverse odds ratio	(0.36, 6.00)	(0.27, 3.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	0.98	
95% CI of the inverse risk ratio	(0.40, 4.90)	(0.32, 2.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.04	0.25	
95% CI of the absolute risk difference	(-18.05, 9.98)	(-15.54, 16.04)	
p-value	0.5904	0.9751	
p-value of Breslow-Day Test for Homogeneity [3]	0.6909	0.2417	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	7 (25.0)	16 (28.1)
No	23 (76.7)	21 (75.0)	41 (71.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	1.17	
95% CI of the inverse odds ratio	(0.46, 3.57)	(0.42, 3.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	1.12	
95% CI of the inverse risk ratio	(0.56, 2.60)	(0.52, 2.41)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.74	-3.07	
95% CI of the absolute risk difference	(-23.85, 14.37)	(-22.90, 16.76)	
p-value	0.6339	0.7646	
p-value of Breslow-Day Test for Homogeneity [3]	0.6684	0.1312	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	3 (10.7)	4 (7.0)
No	28 (93.3)	25 (89.3)	53 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.63	
95% CI of the inverse odds ratio	(0.18, 6.13)	(0.13, 3.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.65	
95% CI of the inverse risk ratio	(0.20, 5.42)	(0.16, 2.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.35	3.70	
95% CI of the absolute risk difference	(-11.47, 10.77)	(-9.54, 16.93)	
p-value	0.9510	0.5601	
p-value of Breslow-Day Test for Homogeneity [3]	0.5198	0.9876	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (20.0)	6 (21.4)	11 (19.3)
No	24 (80.0)	22 (78.6)	46 (80.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.88	
95% CI of the inverse odds ratio	(0.32, 2.90)	(0.29, 2.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.90	
95% CI of the inverse risk ratio	(0.40, 2.35)	(0.37, 2.18)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.70	2.13	
95% CI of the absolute risk difference	(-16.90, 18.30)	(-16.20, 20.46)	
p-value	0.9375	0.8175	
p-value of Breslow-Day Test for Homogeneity [3]	0.7546	0.7789	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	3 (10.7)	4 (7.0)
No	28 (93.3)	25 (89.3)	53 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.63	
95% CI of the inverse odds ratio	(0.18, 6.13)	(0.13, 3.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.05	0.65	
95% CI of the inverse risk ratio	(0.20, 5.42)	(0.16, 2.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.35	3.70	
95% CI of the absolute risk difference	(-11.47, 10.77)	(-9.54, 16.93)	
p-value	0.9510	0.5601	
p-value of Breslow-Day Test for Homogeneity [3]	0.8017	0.7820	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (16.7)	7 (25.0)	9 (15.8)
No	25 (83.3)	21 (75.0)	48 (84.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.56	
95% CI of the inverse odds ratio	(0.28, 3.10)	(0.18, 1.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.63	
95% CI of the inverse risk ratio	(0.35, 2.57)	(0.26, 1.52)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.88	9.21	
95% CI of the absolute risk difference	(-15.48, 17.23)	(-9.41, 27.83)	
p-value	0.9157	0.3073	
p-value of Breslow-Day Test for Homogeneity [3]	0.8773	0.2991	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	4 (14.3)	6 (10.5)
No	28 (93.3)	24 (85.7)	51 (89.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.65	0.71	
95% CI of the inverse odds ratio	(0.31, 8.71)	(0.18, 2.74)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.58	0.74	
95% CI of the inverse risk ratio	(0.34, 7.35)	(0.23, 2.40)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.86	3.76	
95% CI of the absolute risk difference	(-15.82, 8.10)	(-11.45, 18.97)	
p-value	0.5537	0.6131	
p-value of Breslow-Day Test for Homogeneity [3]	0.1885	0.3796	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (23.3)	7 (25.0)	13 (22.8)
No	23 (76.7)	21 (75.0)	44 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.89	
95% CI of the inverse odds ratio	(0.34, 2.77)	(0.31, 2.55)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.91	
95% CI of the inverse risk ratio	(0.44, 2.19)	(0.41, 2.03)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.53	2.19	
95% CI of the absolute risk difference	(-18.12, 19.17)	(-17.19, 21.58)	
p-value	0.9558	0.8227	
p-value of Breslow-Day Test for Homogeneity [3]	0.7647	0.3794	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (7.1)	4 (7.0)
No	30 (100)	26 (92.9)	53 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.13	0.98	
95% CI of the inverse odds ratio	(0.27, 98.56)	(0.17, 5.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.81	0.98	
95% CI of the inverse risk ratio	(0.27, 86.47)	(0.19, 5.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.15	0.13	
95% CI of the absolute risk difference	(-14.34, 2.04)	(-11.49, 11.74)	
p-value	0.2303	0.9831	
p-value of Breslow-Day Test for Homogeneity [3]	0.3016	0.7769	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (33.3)	6 (21.4)	13 (22.8)
No	20 (66.7)	22 (78.6)	44 (77.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	1.08	
95% CI of the inverse odds ratio	(0.22, 1.57)	(0.36, 3.24)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	1.06	
95% CI of the inverse risk ratio	(0.34, 1.37)	(0.45, 2.50)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.53	-1.38	
95% CI of the absolute risk difference	(-9.55, 30.61)	(-20.08, 17.32)	
p-value	0.2900	0.8860	
p-value of Breslow-Day Test for Homogeneity [3]	0.2293	0.1110	

AMNOG Table SE23.14c.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (20.0)	5 (17.9)	7 (12.3)
No	24 (80.0)	23 (82.1)	50 (87.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.64	
95% CI of the inverse odds ratio	(0.17, 1.85)	(0.18, 2.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	0.69	
95% CI of the inverse risk ratio	(0.23, 1.66)	(0.24, 1.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	7.72	5.58	
95% CI of the absolute risk difference	(-8.94, 24.38)	(-10.97, 22.12)	
p-value	0.3371	0.4877	
p-value of Breslow-Day Test for Homogeneity [3]	0.4406	0.7172	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	9 (30.0)	8 (28.6)	11 (19.3)
No	21 (70.0)	20 (71.4)	46 (80.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.60	
95% CI of the inverse odds ratio	(0.20, 1.55)	(0.21, 1.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	0.68	
95% CI of the inverse risk ratio	(0.30, 1.38)	(0.31, 1.49)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	10.70	9.27	
95% CI of the absolute risk difference	(-8.63, 30.04)	(-10.35, 28.89)	
p-value	0.2595	0.3348	
p-value of Breslow-Day Test for Homogeneity [3]	0.5525	0.1182	

AMNOG Table SE23.15.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
CLDQ-NASH						
Baseline						
m	75	87	147			
n	72	78	133			
Mean (SD)	5.27 (1.16)	5.32 (1.10)	5.25 (1.15)			
Median	5.35	5.60	5.50			
IQR: Q1, Q3	4.70, 6.30	4.60, 6.10	4.60, 6.20			
Min, Max	2.0, 6.8	2.1, 7.0	2.0, 7.0			
Week 24						
m	72	78	142			
n	69	74	127	67	69	120
Mean (SD/SE)	5.32 (1.15)	5.41 (1.05)	5.34 (1.08)	0.05 (0.09)	0.02 (0.07)	0.15 (0.06)
Median	5.50	5.60	5.50	0	0	0.10
IQR: Q1, Q3	4.70, 6.20	4.80, 6.20	4.50, 6.20	-0.30, 0.30	-0.40, 0.40	-0.20, 0.50
Min, Max	2.1, 7.0	2.7, 7.0	2.6, 7.0	-2.0, 2.5	-1.6, 1.6	-1.8, 2.6
Week 52						
m	64	70	135			
n	61	64	119	58	62	111
Mean (SD/SE)	5.33 (1.16)	5.34 (1.03)	5.34 (1.15)	0.01 (0.08)	-0.04 (0.08)	0.05 (0.06)
Median	5.50	5.60	5.60	0	0	0
IQR: Q1, Q3	4.70, 6.20	4.60, 6.10	4.50, 6.20	-0.20, 0.20	-0.30, 0.20	-0.30, 0.40
Min, Max	1.9, 6.8	2.2, 6.8	1.9, 7.0	-2.2, 1.1	-2.4, 1.8	-1.5, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Abdominal Symptoms						
Baseline						
m	75	87	147			
n	72	78	133			
Mean (SD)	5.40 (1.55)	5.69 (1.36)	5.32 (1.55)			
Median	6.00	6.00	5.70			
IQR: Q1, Q3	4.15, 6.70	4.70, 7.00	4.30, 6.70			
Min, Max	1.0, 7.0	2.0, 7.0	1.0, 7.0			
Week 24						
m	72	78	142			
n	69	74	127	67	69	120
Mean (SD/SE)	5.35 (1.43)	5.71 (1.40)	5.60 (1.44)	-0.08 (0.12)	0.03 (0.13)	0.28 (0.11)
Median	5.70	6.30	6.00	0	0	0
IQR: Q1, Q3	4.30, 6.70	4.70, 7.00	4.70, 7.00	-0.60, 0.30	-0.40, 0.70	-0.30, 0.85
Min, Max	1.0, 7.0	1.3, 7.0	1.0, 7.0	-2.4, 2.3	-2.7, 2.4	-3.0, 4.0
Week 52						
m	64	70	135			
n	61	64	119	58	62	111
Mean (SD/SE)	5.54 (1.46)	5.69 (1.25)	5.49 (1.42)	0.11 (0.13)	-0.04 (0.12)	0.13 (0.11)
Median	5.70	5.70	5.70	0	0	0
IQR: Q1, Q3	5.00, 6.70	5.00, 6.70	4.70, 6.70	-0.30, 0.70	-0.30, 0.30	-0.60, 0.70
Min, Max	1.0, 7.0	2.0, 7.0	1.0, 7.0	-2.0, 3.0	-3.0, 2.7	-3.7, 3.3

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Activity						
Baseline						
m	75	87	147			
n	72	78	133			
Mean (SD)	5.20 (1.42)	5.24 (1.34)	5.40 (1.41)			
Median	5.50	5.60	5.60			
IQR: Q1, Q3	4.20, 6.30	4.40, 6.40	4.60, 6.60			
Min, Max	2.0, 7.0	1.8, 7.0	1.4, 7.0			
Week 24						
m	72	78	142			
n	69	74	127	67	69	120
Mean (SD/SE)	5.26 (1.53)	5.37 (1.35)	5.44 (1.37)	0.05 (0.11)	0.05 (0.11)	0.11 (0.09)
Median	5.60	5.80	5.80	0	0	0
IQR: Q1, Q3	4.40, 6.60	4.40, 6.60	4.40, 6.60	-0.60, 0.60	-0.60, 0.60	-0.60, 0.70
Min, Max	1.4, 7.0	2.4, 7.0	1.2, 7.0	-2.4, 2.6	-2.4, 2.4	-3.0, 3.2
Week 52						
m	64	70	135			
n	61	64	119	58	62	111
Mean (SD/SE)	5.07 (1.64)	5.23 (1.28)	5.41 (1.42)	-0.23 (0.15)	-0.07 (0.12)	-0.11 (0.09)
Median	5.40	5.40	5.80	0	0	0
IQR: Q1, Q3	4.00, 6.40	4.30, 6.40	4.40, 6.60	-0.60, 0.40	-0.60, 0.60	-0.60, 0.40
Min, Max	1.0, 7.0	1.6, 7.0	1.4, 7.0	-4.4, 1.6	-2.8, 1.8	-2.4, 3.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Emotional Health						
Baseline						
m	75	87	147			
n	72	78	133			
Mean (SD)	5.46 (1.17)	5.44 (1.26)	5.47 (1.24)			
Median	5.80	5.70	5.80			
IQR: Q1, Q3	5.00, 6.30	4.70, 6.60	4.90, 6.40			
Min, Max	1.3, 7.0	1.8, 7.0	1.8, 7.0			
Week 24						
m	72	78	142			
n	69	74	127	67	69	120
Mean (SD/SE)	5.62 (1.12)	5.54 (1.23)	5.44 (1.21)	0.17 (0.10)	0.02 (0.07)	0.06 (0.08)
Median	6.00	5.65	5.70	0	0	0
IQR: Q1, Q3	5.10, 6.30	5.10, 6.70	4.80, 6.40	-0.20, 0.60	-0.30, 0.30	-0.60, 0.55
Min, Max	2.2, 7.0	2.2, 7.0	1.9, 7.0	-1.6, 2.5	-2.0, 1.4	-2.1, 2.6
Week 52						
m	64	70	135			
n	61	64	119	58	62	111
Mean (SD/SE)	5.58 (1.05)	5.55 (1.13)	5.57 (1.24)	0.08 (0.10)	0.05 (0.10)	0.05 (0.07)
Median	5.90	5.80	5.80	0	0	0
IQR: Q1, Q3	5.00, 6.30	4.70, 6.50	4.80, 6.60	-0.30, 0.30	-0.50, 0.60	-0.40, 0.40
Min, Max	2.8, 7.0	2.8, 7.0	1.3, 7.0	-1.6, 2.9	-1.9, 2.0	-1.9, 3.1

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Fatigue						
Baseline						
m	75	87	147			
n	72	78	133			
Mean (SD)	4.85 (1.53)	4.71 (1.36)	4.61 (1.47)			
Median	5.20	5.00	4.80			
IQR: Q1, Q3	4.10, 6.20	4.00, 5.70	3.50, 5.80			
Min, Max	1.2, 7.0	1.5, 7.0	1.2, 7.0			
Week 24						
m	72	78	142			
n	69	74	127	67	69	120
Mean (SD/SE)	4.97 (1.45)	4.71 (1.35)	4.61 (1.45)	0.07 (0.13)	-0.13 (0.10)	0.09 (0.09)
Median	5.20	5.00	4.70	0.10	-0.20	0
IQR: Q1, Q3	4.20, 6.00	3.70, 5.70	3.30, 5.80	-0.50, 0.40	-0.50, 0.30	-0.50, 0.55
Min, Max	1.7, 7.0	1.8, 7.0	1.3, 7.0	-2.5, 4.1	-3.1, 2.0	-2.0, 3.0
Week 52						
m	64	70	135			
n	61	64	119	58	62	111
Mean (SD/SE)	4.94 (1.50)	4.54 (1.49)	4.63 (1.53)	-0.02 (0.14)	-0.22 (0.14)	0.02 (0.10)
Median	5.20	4.40	4.80	0	-0.20	0
IQR: Q1, Q3	4.20, 6.20	3.30, 6.00	3.50, 5.80	-0.40, 0.40	-0.60, 0.30	-0.50, 0.50
Min, Max	1.0, 7.0	1.3, 6.8	1.0, 7.0	-2.4, 4.0	-4.4, 1.9	-2.4, 3.2

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Systemic Symptoms						
Baseline						
m	75	87	147			
n	72	78	133			
Mean (SD)	5.15 (1.29)	5.08 (1.18)	5.03 (1.25)			
Median	5.60	5.20	5.30			
IQR: Q1, Q3	4.00, 6.20	4.50, 6.00	4.20, 6.00			
Min, Max	2.0, 7.0	2.3, 7.0	2.3, 7.0			
Week 24						
m	72	78	142			
n	69	74	127	67	69	120
Mean (SD/SE)	5.03 (1.30)	5.07 (1.22)	5.03 (1.23)	-0.07 (0.11)	-0.14 (0.09)	0.03 (0.07)
Median	5.30	5.25	5.00	-0.20	-0.10	0
IQR: Q1, Q3	4.20, 6.20	4.20, 6.00	4.20, 6.20	-0.60, 0.40	-0.60, 0.20	-0.40, 0.50
Min, Max	2.3, 7.0	1.8, 7.0	2.3, 7.0	-1.9, 3.5	-1.8, 2.2	-2.5, 2.4
Week 52						
m	64	70	135			
n	61	64	119	58	62	111
Mean (SD/SE)	5.00 (1.34)	4.98 (1.24)	5.01 (1.38)	-0.22 (0.10)	-0.19 (0.10)	-0.01 (0.08)
Median	5.30	5.20	5.00	-0.20	-0.05	0
IQR: Q1, Q3	4.20, 6.20	4.20, 5.80	4.00, 6.20	-0.70, 0.30	-0.50, 0.20	-0.50, 0.50
Min, Max	1.3, 7.0	1.5, 7.0	1.3, 7.0	-2.0, 1.7	-2.5, 2.0	-2.7, 2.7

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Worry						
Baseline						
m	75	87	147			
n	72	78	133			
Mean (SD)	5.53 (1.27)	5.74 (1.41)	5.68 (1.43)			
Median	5.70	6.10	6.10			
IQR: Q1, Q3	4.80, 6.50	5.10, 7.00	4.70, 6.90			
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0			
Week 24						
m	72	78	142			
n	69	74	127	67	69	120
Mean (SD/SE)	5.74 (1.39)	6.04 (1.25)	5.94 (1.36)	0.21 (0.13)	0.34 (0.13)	0.38 (0.09)
Median	6.10	6.65	6.40	0.20	0.10	0.10
IQR: Q1, Q3	5.30, 6.70	5.30, 7.00	5.40, 7.00	-0.30, 0.60	0.00, 0.60	-0.10, 0.75
Min, Max	1.6, 7.0	2.0, 7.0	1.0, 7.0	-3.1, 3.3	-2.6, 3.6	-2.6, 3.5
Week 52						
m	64	70	135			
n	61	64	119	58	62	111
Mean (SD/SE)	5.89 (1.32)	6.05 (1.27)	5.94 (1.45)	0.31 (0.15)	0.27 (0.14)	0.29 (0.10)
Median	6.40	6.50	6.60	0.05	0	0
IQR: Q1, Q3	5.40, 7.00	5.65, 7.00	5.40, 7.00	-0.30, 0.90	-0.10, 0.60	-0.10, 0.70
Min, Max	1.7, 7.0	1.4, 7.0	1.0, 7.0	-2.5, 3.8	-3.3, 3.3	-2.5, 3.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
CLDQ-NASH						
Baseline						
m	92	64	156			
n	84	58	144			
Mean (SD)	5.19 (1.24)	5.19 (1.13)	5.19 (1.08)			
Median	5.45	5.40	5.20			
IQR: Q1, Q3	4.30, 6.20	4.40, 6.10	4.50, 6.10			
Min, Max	1.5, 7.0	2.2, 6.8	2.2, 7.0			
Week 24						
m	89	63	147			
n	86	62	136	80	56	124
Mean (SD/SE)	5.27 (1.15)	5.11 (0.99)	5.37 (1.12)	0.10 (0.08)	-0.06 (0.09)	0.08 (0.07)
Median	5.35	5.10	5.50	0.10	-0.10	0
IQR: Q1, Q3	4.50, 6.30	4.40, 5.90	4.70, 6.20	-0.10, 0.50	-0.40, 0.25	-0.30, 0.45
Min, Max	2.1, 7.0	3.2, 6.8	2.3, 7.0	-2.6, 2.4	-1.4, 1.4	-2.3, 3.0
Week 52						
m	85	55	135			
n	76	49	115	70	44	106
Mean (SD/SE)	5.38 (1.16)	5.33 (1.03)	5.40 (1.05)	0.08 (0.09)	0.07 (0.10)	0.07 (0.07)
Median	5.55	5.60	5.50	0.10	0.15	0
IQR: Q1, Q3	4.40, 6.40	4.70, 6.10	4.90, 6.30	-0.20, 0.40	-0.40, 0.45	-0.40, 0.50
Min, Max	1.6, 7.0	2.6, 6.9	2.4, 7.0	-2.7, 2.7	-1.4, 1.5	-2.2, 1.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Abdominal Symptoms						
Baseline						
m	92	64	156			
n	84	58	144			
Mean (SD)	5.17 (1.70)	5.41 (1.38)	5.11 (1.50)			
Median	5.70	5.70	5.30			
IQR: Q1, Q3	4.00, 6.70	4.30, 6.70	4.00, 6.30			
Min, Max	1.0, 7.0	1.7, 7.0	1.3, 7.0			
Week 24						
m	89	63	147			
n	86	62	136	80	56	124
Mean (SD/SE)	5.43 (1.48)	5.10 (1.49)	5.35 (1.47)	0.25 (0.15)	-0.26 (0.16)	0.13 (0.11)
Median	5.30	5.15	5.70	0	0	0
IQR: Q1, Q3	4.70, 7.00	4.00, 6.30	4.30, 6.70	-0.15, 0.70	-0.70, 0.30	-0.60, 0.85
Min, Max	1.3, 7.0	1.7, 7.0	1.0, 7.0	-4.7, 3.3	-4.0, 2.3	-3.0, 4.0
Week 52						
m	85	55	135			
n	76	49	115	70	44	106
Mean (SD/SE)	5.52 (1.49)	5.47 (1.33)	5.42 (1.37)	0.14 (0.18)	-0.10 (0.15)	0.07 (0.12)
Median	6.00	5.70	5.70	0	0	0
IQR: Q1, Q3	4.70, 7.00	5.00, 6.70	4.70, 6.70	-0.70, 1.00	-0.65, 0.30	-0.70, 1.00
Min, Max	1.3, 7.0	1.7, 7.0	1.0, 7.0	-3.3, 4.0	-2.6, 2.0	-4.6, 4.0

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Activity						
Baseline						
m	92	64	156			
n	84	58	144			
Mean (SD)	5.34 (1.40)	5.46 (1.31)	5.42 (1.36)			
Median	5.60	5.60	5.60			
IQR: Q1, Q3	4.40, 6.60	4.60, 6.60	4.40, 6.60			
Min, Max	1.4, 7.0	2.4, 7.0	1.8, 7.0			
Week 24						
m	89	63	147			
n	86	62	136	80	56	124
Mean (SD/SE)	5.29 (1.37)	5.47 (1.16)	5.53 (1.32)	-0.05 (0.11)	0.04 (0.12)	0.04 (0.08)
Median	5.60	5.80	6.00	0	0	0
IQR: Q1, Q3	4.40, 6.20	4.60, 6.40	4.80, 6.40	-0.60, 0.50	-0.50, 0.60	-0.40, 0.60
Min, Max	1.2, 7.0	2.4, 7.0	2.2, 7.0	-3.2, 2.8	-2.2, 3.2	-2.8, 2.6
Week 52						
m	85	55	135			
n	76	49	115	70	44	106
Mean (SD/SE)	5.56 (1.34)	5.56 (1.20)	5.47 (1.34)	0.10 (0.12)	0.01 (0.13)	-0.10 (0.09)
Median	5.80	6.00	5.80	0.10	0.10	0
IQR: Q1, Q3	4.80, 6.80	4.80, 6.40	4.60, 6.60	-0.40, 0.40	-0.40, 0.50	-0.40, 0.40
Min, Max	1.6, 7.0	2.2, 7.0	2.0, 7.0	-3.0, 3.0	-2.8, 2.0	-3.4, 2.4

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Emotional Health						
Baseline						
m	92	64	156			
n	84	58	144			
Mean (SD)	5.28 (1.31)	5.30 (1.34)	5.36 (1.17)			
Median	5.60	5.70	5.60			
IQR: Q1, Q3	4.50, 6.25	4.70, 6.20	4.60, 6.25			
Min, Max	1.9, 7.0	2.0, 7.0	1.9, 7.0			
Week 24						
m	89	63	147			
n	86	62	136	80	56	124
Mean (SD/SE)	5.28 (1.31)	5.11 (1.22)	5.48 (1.27)	0.02 (0.09)	-0.19 (0.11)	0.02 (0.08)
Median	5.40	5.20	5.80	0.10	-0.30	0
IQR: Q1, Q3	4.20, 6.40	4.40, 6.10	4.70, 6.50	-0.40, 0.60	-0.60, 0.05	-0.40, 0.50
Min, Max	2.0, 7.0	1.0, 7.0	1.9, 7.0	-2.8, 1.4	-3.1, 2.4	-2.9, 3.3
Week 52						
m	85	55	135			
n	76	49	115	70	44	106
Mean (SD/SE)	5.33 (1.18)	5.38 (1.29)	5.43 (1.21)	-0.05 (0.10)	-0.01 (0.12)	-0.03 (0.08)
Median	5.40	5.80	5.60	-0.10	-0.10	0
IQR: Q1, Q3	4.40, 6.20	4.80, 6.40	4.70, 6.40	-0.60, 0.60	-0.50, 0.35	-0.60, 0.50
Min, Max	1.9, 7.0	1.0, 7.0	1.7, 7.0	-2.5, 2.5	-1.3, 2.9	-2.0, 2.5

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Fatigue						
Baseline						
m	92	64	156			
n	84	58	144			
Mean (SD)	4.66 (1.48)	4.45 (1.55)	4.61 (1.40)			
Median	4.90	4.80	4.80			
IQR: Q1, Q3	3.50, 6.00	3.30, 5.70	3.70, 5.70			
Min, Max	1.2, 7.0	1.2, 7.0	1.0, 7.0			
Week 24						
m	89	63	147			
n	86	62	136	80	56	124
Mean (SD/SE)	4.58 (1.53)	4.38 (1.38)	4.76 (1.45)	-0.05 (0.12)	-0.08 (0.14)	0.03 (0.11)
Median	4.50	4.50	5.00	0	0	0
IQR: Q1, Q3	3.30, 5.80	3.50, 5.30	3.50, 6.00	-0.80, 0.70	-0.70, 0.50	-0.65, 0.60
Min, Max	1.3, 7.0	1.5, 6.7	1.2, 7.0	-2.7, 3.0	-4.2, 2.3	-3.8, 3.7
Week 52						
m	85	55	135			
n	76	49	115	70	44	106
Mean (SD/SE)	4.76 (1.53)	4.68 (1.40)	4.77 (1.34)	0.05 (0.12)	0.08 (0.18)	0.03 (0.10)
Median	5.10	5.00	5.00	0	0.05	0
IQR: Q1, Q3	3.60, 6.00	3.80, 5.70	4.00, 5.80	-0.50, 0.50	-0.50, 0.75	-0.60, 0.70
Min, Max	1.5, 7.0	1.2, 7.0	1.2, 7.0	-2.3, 3.4	-2.8, 2.5	-3.8, 2.8

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Systemic Symptoms						
Baseline						
m	92	64	156			
n	84	58	144			
Mean (SD)	5.18 (1.28)	5.10 (1.28)	5.10 (1.23)			
Median	5.30	5.20	5.20			
IQR: Q1, Q3	4.60, 6.20	4.50, 6.00	4.50, 6.00			
Min, Max	1.5, 7.0	1.8, 7.0	1.7, 7.0			
Week 24						
m	89	63	147			
n	86	62	136	80	56	124
Mean (SD/SE)	5.25 (1.18)	4.91 (1.22)	5.23 (1.26)	0.04 (0.08)	-0.17 (0.10)	-0.03 (0.09)
Median	5.50	4.90	5.50	0	-0.15	0
IQR: Q1, Q3	4.50, 6.00	4.00, 5.70	4.50, 6.20	-0.30, 0.45	-0.50, 0.20	-0.70, 0.45
Min, Max	1.7, 7.0	2.2, 7.0	1.5, 7.0	-2.0, 2.0	-2.0, 1.7	-2.5, 3.7
Week 52						
m	85	55	135			
n	76	49	115	70	44	106
Mean (SD/SE)	5.25 (1.26)	5.12 (1.21)	5.24 (1.29)	-0.09 (0.10)	-0.01 (0.13)	0.02 (0.08)
Median	5.50	5.20	5.30	0	0.10	0
IQR: Q1, Q3	4.30, 6.20	4.30, 6.00	4.30, 6.30	-0.50, 0.30	-0.65, 0.55	-0.50, 0.50
Min, Max	1.3, 7.0	2.5, 7.0	1.7, 7.0	-2.7, 2.3	-2.0, 1.8	-2.0, 2.9

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.1
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Worry						
Baseline						
m	92	64	156			
n	84	58	144			
Mean (SD)	5.51 (1.51)	5.42 (1.58)	5.58 (1.32)			
Median	5.80	5.95	5.90			
IQR: Q1, Q3	4.70, 6.70	4.60, 6.70	4.80, 6.70			
Min, Max	1.1, 7.0	1.0, 7.0	1.3, 7.0			
Week 24						
m	89	63	147			
n	86	62	136	80	56	124
Mean (SD/SE)	5.82 (1.37)	5.63 (1.36)	5.83 (1.34)	0.36 (0.11)	0.21 (0.14)	0.24 (0.08)
Median	6.30	5.95	6.30	0.30	0	0.10
IQR: Q1, Q3	5.10, 6.90	5.00, 6.70	5.40, 6.90	0.00, 0.70	-0.35, 0.70	-0.20, 0.60
Min, Max	1.6, 7.0	1.0, 7.0	1.1, 7.0	-2.4, 3.1	-1.6, 3.6	-2.1, 3.5
Week 52						
m	85	55	135			
n	76	49	115	70	44	106
Mean (SD/SE)	5.88 (1.34)	5.85 (1.46)	6.04 (1.09)	0.33 (0.12)	0.49 (0.18)	0.36 (0.09)
Median	6.35	6.30	6.40	0.20	0.25	0.30
IQR: Q1, Q3	5.30, 7.00	5.30, 7.00	5.60, 7.00	-0.10, 0.80	-0.25, 0.95	0.00, 0.90
Min, Max	1.9, 7.0	1.0, 7.0	2.7, 7.0	-4.8, 2.5	-1.5, 3.6	-2.7, 2.7

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Statin Status
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.15.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
CLDQ-NASH			
Week 24			
m	72	78	142
n	67	69	120
Baseline Mean (SD)	5.25 (1.15)	5.36 (1.13)	5.24 (1.18)
Analysis Visit Mean (SD)	5.31 (1.16)	5.38 (1.07)	5.40 (1.07)
LS Mean of Change from Baseline (SE)	0.07 (0.08)	0.05 (0.08)	0.17 (0.06)
95% CI	(-0.09, 0.22)	(-0.10, 0.20)	(0.04, 0.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.09)	-0.12 (0.09)	
95% CI	(-0.29, 0.08)	(-0.30, 0.06)	
p-value	0.2756	0.2000	
Corrected Hedge's g Statistics	-0.151	-0.176	
95% CI	(-0.45, 0.15)	(-0.47, 0.12)	
Week 52			
m	64	70	135
n	58	62	111
Baseline Mean (SD)	5.30 (1.14)	5.35 (1.15)	5.32 (1.16)
Analysis Visit Mean (SD)	5.31 (1.16)	5.31 (1.04)	5.37 (1.14)
LS Mean of Change from Baseline (SE)	0.03 (0.08)	-0.02 (0.08)	0.10 (0.07)
95% CI	(-0.14, 0.19)	(-0.18, 0.14)	(-0.03, 0.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (0.10)	-0.11 (0.10)	
95% CI	(-0.27, 0.12)	(-0.31, 0.08)	
p-value	0.4741	0.2443	
Corrected Hedge's g Statistics	-0.105	-0.169	
95% CI	(-0.42, 0.21)	(-0.48, 0.14)	
Subgroup*Treatment Interaction p-value	0.4592	0.9629	

AMNOG Table SE23.15.2
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of CLDQ-NASH - MMRM Model;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
CLDQ-NASH			
Week 24			
m	89	63	147
n	80	56	124
Baseline Mean (SD)	5.19 (1.22)	5.15 (1.13)	5.28 (1.06)
Analysis Visit Mean (SD)	5.29 (1.16)	5.09 (0.98)	5.35 (1.12)
LS Mean of Change from Baseline (SE)	0.10 (0.08)	-0.10 (0.09)	0.07 (0.06)
95% CI	(-0.05, 0.26)	(-0.28, 0.08)	(-0.05, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.03 (0.10)	-0.17 (0.11)	
95% CI	(-0.17, 0.22)	(-0.39, 0.05)	
p-value	0.7780	0.1213	
Corrected Hedge's g Statistics	0.040	-0.249	
95% CI	(-0.24, 0.32)	(-0.57, 0.07)	
Week 52			
m	85	55	135
n	70	44	106
Baseline Mean (SD)	5.28 (1.20)	5.20 (1.14)	5.31 (1.02)
Analysis Visit Mean (SD)	5.36 (1.16)	5.27 (1.03)	5.38 (1.06)
LS Mean of Change from Baseline (SE)	0.08 (0.08)	0.06 (0.10)	0.08 (0.06)
95% CI	(-0.08, 0.24)	(-0.14, 0.25)	(-0.04, 0.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.00 (0.10)	-0.03 (0.12)	
95% CI	(-0.20, 0.20)	(-0.26, 0.21)	
p-value	0.9812	0.8288	
Corrected Hedge's g Statistics	-0.004	-0.038	
95% CI	(-0.31, 0.30)	(-0.39, 0.31)	
Subgroup*Treatment Interaction p-value	0.4592	0.9629	

AMNOG Table SE23.15.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.15.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Abdominal Symptoms			
Week 24			
m	72	78	142
n	67	69	120
Baseline Mean (SD)	5.38 (1.57)	5.68 (1.41)	5.41 (1.54)
Analysis Visit Mean (SD)	5.30 (1.43)	5.71 (1.42)	5.68 (1.36)
LS Mean of Change from Baseline (SE)	-0.11 (0.13)	0.09 (0.12)	0.26 (0.10)
95% CI	(-0.36, 0.13)	(-0.15, 0.34)	(0.06, 0.45)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.37 (0.15)	-0.16 (0.15)	
95% CI	(-0.67, -0.07)	(-0.46, 0.13)	
p-value	0.0149	0.2842	
Corrected Hedge's g Statistics	-0.342	-0.149	
95% CI	(-0.64, -0.04)	(-0.45, 0.15)	
Week 52			
m	64	70	135
n	58	62	111
Baseline Mean (SD)	5.39 (1.58)	5.73 (1.37)	5.43 (1.53)
Analysis Visit Mean (SD)	5.50 (1.49)	5.69 (1.25)	5.55 (1.40)
LS Mean of Change from Baseline (SE)	0.08 (0.13)	0.01 (0.13)	0.13 (0.10)
95% CI	(-0.18, 0.33)	(-0.24, 0.26)	(-0.07, 0.33)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.15)	-0.12 (0.15)	
95% CI	(-0.36, 0.25)	(-0.42, 0.18)	
p-value	0.7223	0.4304	
Corrected Hedge's g Statistics	-0.053	-0.116	
95% CI	(-0.37, 0.26)	(-0.43, 0.20)	
Subgroup*Treatment Interaction p-value	0.0606	0.7307	

AMNOG Table SE23.15.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Activity			
Week 24			
m	72	78	142
n	67	69	120
Baseline Mean (SD)	5.20 (1.42)	5.30 (1.33)	5.38 (1.42)
Analysis Visit Mean (SD)	5.25 (1.53)	5.35 (1.37)	5.49 (1.37)
LS Mean of Change from Baseline (SE)	0.07 (0.12)	0.06 (0.12)	0.16 (0.09)
95% CI	(-0.17, 0.30)	(-0.16, 0.29)	(-0.02, 0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.14)	-0.10 (0.14)	
95% CI	(-0.37, 0.18)	(-0.37, 0.17)	
p-value	0.4890	0.4718	
Corrected Hedge's g Statistics	-0.096	-0.099	
95% CI	(-0.39, 0.20)	(-0.40, 0.20)	
Week 52			
m	64	70	135
n	58	62	111
Baseline Mean (SD)	5.28 (1.36)	5.27 (1.36)	5.53 (1.35)
Analysis Visit Mean (SD)	5.05 (1.64)	5.20 (1.29)	5.42 (1.44)
LS Mean of Change from Baseline (SE)	-0.22 (0.13)	-0.05 (0.12)	0.00 (0.10)
95% CI	(-0.47, 0.04)	(-0.29, 0.20)	(-0.20, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.22 (0.15)	-0.05 (0.15)	
95% CI	(-0.52, 0.08)	(-0.34, 0.25)	
p-value	0.1557	0.7580	
Corrected Hedge's g Statistics	-0.211	-0.045	
95% CI	(-0.53, 0.11)	(-0.36, 0.27)	
Subgroup*Treatment Interaction p-value	0.3777	0.5897	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Emotional Health			
Week 24			
m	72	78	142
n	67	69	120
Baseline Mean (SD)	5.44 (1.20)	5.48 (1.29)	5.43 (1.27)
Analysis Visit Mean (SD)	5.60 (1.12)	5.49 (1.25)	5.48 (1.20)
LS Mean of Change from Baseline (SE)	0.18 (0.09)	0.04 (0.09)	0.08 (0.07)
95% CI	(0.00, 0.36)	(-0.14, 0.22)	(-0.07, 0.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (0.11)	-0.04 (0.11)	
95% CI	(-0.12, 0.32)	(-0.26, 0.18)	
p-value	0.3585	0.7053	
Corrected Hedge's g Statistics	0.127	-0.052	
95% CI	(-0.17, 0.43)	(-0.35, 0.24)	
Week 52			
m	64	70	135
n	58	62	111
Baseline Mean (SD)	5.48 (1.20)	5.46 (1.30)	5.54 (1.27)
Analysis Visit Mean (SD)	5.56 (1.04)	5.50 (1.13)	5.59 (1.24)
LS Mean of Change from Baseline (SE)	0.08 (0.10)	0.08 (0.09)	0.07 (0.07)
95% CI	(-0.11, 0.27)	(-0.11, 0.26)	(-0.08, 0.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.02 (0.11)	0.01 (0.11)	
95% CI	(-0.21, 0.24)	(-0.21, 0.23)	
p-value	0.8805	0.9085	
Corrected Hedge's g Statistics	0.022	0.017	
95% CI	(-0.30, 0.34)	(-0.29, 0.33)	
Subgroup*Treatment Interaction p-value	0.5321	0.5037	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Fatigue			
Week 24			
m	72	78	142
n	67	69	120
Baseline Mean (SD)	4.87 (1.51)	4.80 (1.37)	4.57 (1.51)
Analysis Visit Mean (SD)	4.94 (1.46)	4.67 (1.38)	4.65 (1.46)
LS Mean of Change from Baseline (SE)	0.10 (0.12)	-0.12 (0.11)	0.04 (0.09)
95% CI	(-0.13, 0.33)	(-0.34, 0.10)	(-0.14, 0.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.06 (0.14)	-0.16 (0.14)	
95% CI	(-0.21, 0.33)	(-0.43, 0.11)	
p-value	0.6744	0.2377	
Corrected Hedge's g Statistics	0.058	-0.162	
95% CI	(-0.24, 0.36)	(-0.46, 0.13)	
Week 52			
m	64	70	135
n	58	62	111
Baseline Mean (SD)	4.93 (1.54)	4.74 (1.42)	4.66 (1.49)
Analysis Visit Mean (SD)	4.91 (1.52)	4.52 (1.50)	4.67 (1.53)
LS Mean of Change from Baseline (SE)	0.04 (0.14)	-0.23 (0.13)	0.00 (0.10)
95% CI	(-0.23, 0.30)	(-0.48, 0.03)	(-0.20, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.04 (0.16)	-0.23 (0.16)	
95% CI	(-0.28, 0.35)	(-0.54, 0.08)	
p-value	0.8203	0.1525	
Corrected Hedge's g Statistics	0.034	-0.210	
95% CI	(-0.28, 0.35)	(-0.52, 0.10)	
Subgroup*Treatment Interaction p-value	0.5625	0.6567	

AMNOG Table SE23.15.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Systemic Symptoms			
Week 24			
m	72	78	142
n	67	69	120
Baseline Mean (SD)	5.12 (1.29)	5.15 (1.19)	5.04 (1.26)
Analysis Visit Mean (SD)	5.05 (1.31)	5.01 (1.22)	5.08 (1.24)
LS Mean of Change from Baseline (SE)	-0.05 (0.10)	-0.12 (0.09)	0.04 (0.08)
95% CI	(-0.24, 0.14)	(-0.31, 0.06)	(-0.11, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.09 (0.11)	-0.17 (0.11)	
95% CI	(-0.32, 0.14)	(-0.39, 0.06)	
p-value	0.4298	0.1463	
Corrected Hedge's g Statistics	-0.109	-0.200	
95% CI	(-0.41, 0.19)	(-0.50, 0.10)	
Week 52			
m	64	70	135
n	58	62	111
Baseline Mean (SD)	5.21 (1.26)	5.13 (1.21)	5.05 (1.27)
Analysis Visit Mean (SD)	4.98 (1.34)	4.95 (1.23)	5.05 (1.37)
LS Mean of Change from Baseline (SE)	-0.17 (0.11)	-0.18 (0.11)	0.02 (0.08)
95% CI	(-0.39, 0.04)	(-0.39, 0.03)	(-0.14, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.20 (0.13)	-0.20 (0.13)	
95% CI	(-0.45, 0.06)	(-0.45, 0.05)	
p-value	0.1346	0.1144	
Corrected Hedge's g Statistics	-0.223	-0.231	
95% CI	(-0.54, 0.10)	(-0.54, 0.08)	
Subgroup*Treatment Interaction p-value	0.3507	0.8415	

AMNOG Table SE23.15.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Worry			
Week 24			
m	72	78	142
n	67	69	120
Baseline Mean (SD)	5.50 (1.28)	5.69 (1.46)	5.60 (1.47)
Analysis Visit Mean (SD)	5.70 (1.39)	6.03 (1.28)	5.98 (1.35)
LS Mean of Change from Baseline (SE)	0.21 (0.12)	0.39 (0.12)	0.44 (0.10)
95% CI	(-0.02, 0.45)	(0.16, 0.63)	(0.25, 0.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.23 (0.14)	-0.05 (0.14)	
95% CI	(-0.51, 0.05)	(-0.33, 0.23)	
p-value	0.1106	0.7282	
Corrected Hedge's g Statistics	-0.220	-0.048	
95% CI	(-0.52, 0.08)	(-0.34, 0.25)	
Week 52			
m	64	70	135
n	58	62	111
Baseline Mean (SD)	5.54 (1.30)	5.75 (1.43)	5.69 (1.49)
Analysis Visit Mean (SD)	5.85 (1.34)	6.02 (1.28)	5.97 (1.42)
LS Mean of Change from Baseline (SE)	0.33 (0.13)	0.37 (0.13)	0.37 (0.10)
95% CI	(0.06, 0.59)	(0.12, 0.63)	(0.16, 0.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.04 (0.16)	0.01 (0.16)	
95% CI	(-0.35, 0.28)	(-0.30, 0.32)	
p-value	0.8083	0.9620	
Corrected Hedge's g Statistics	-0.036	0.007	
95% CI	(-0.35, 0.28)	(-0.30, 0.32)	
Subgroup*Treatment Interaction p-value	0.2974	0.8257	

AMNOG Table SE23.15.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Abdominal Symptoms			
Week 24			
m	89	63	147
n	80	56	124
Baseline Mean (SD)	5.21 (1.68)	5.37 (1.38)	5.19 (1.47)
Analysis Visit Mean (SD)	5.46 (1.50)	5.11 (1.53)	5.32 (1.45)
LS Mean of Change from Baseline (SE)	0.27 (0.13)	-0.21 (0.15)	0.12 (0.10)
95% CI	(0.02, 0.52)	(-0.50, 0.08)	(-0.08, 0.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.15 (0.16)	-0.32 (0.18)	
95% CI	(-0.16, 0.47)	(-0.67, 0.02)	
p-value	0.3326	0.0682	
Corrected Hedge's g Statistics	0.138	-0.293	
95% CI	(-0.14, 0.42)	(-0.61, 0.02)	
Week 52			
m	85	55	135
n	70	44	106
Baseline Mean (SD)	5.36 (1.61)	5.52 (1.28)	5.30 (1.39)
Analysis Visit Mean (SD)	5.49 (1.53)	5.42 (1.37)	5.37 (1.38)
LS Mean of Change from Baseline (SE)	0.17 (0.14)	-0.01 (0.17)	0.10 (0.11)
95% CI	(-0.10, 0.44)	(-0.34, 0.32)	(-0.11, 0.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.07 (0.17)	-0.11 (0.20)	
95% CI	(-0.27, 0.41)	(-0.50, 0.28)	
p-value	0.6970	0.5735	
Corrected Hedge's g Statistics	0.060	-0.100	
95% CI	(-0.24, 0.36)	(-0.45, 0.25)	
Subgroup*Treatment Interaction p-value	0.0606	0.7307	

AMNOG Table SE23.15.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Activity			
Week 24			
m	89	63	147
n	80	56	124
Baseline Mean (SD)	5.34 (1.38)	5.41 (1.31)	5.52 (1.30)
Analysis Visit Mean (SD)	5.29 (1.40)	5.45 (1.10)	5.56 (1.27)
LS Mean of Change from Baseline (SE)	-0.07 (0.10)	0.00 (0.11)	0.05 (0.08)
95% CI	(-0.26, 0.12)	(-0.22, 0.23)	(-0.10, 0.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.11 (0.12)	-0.04 (0.14)	
95% CI	(-0.36, 0.13)	(-0.32, 0.23)	
p-value	0.3549	0.7462	
Corrected Hedge's g Statistics	-0.132	-0.052	
95% CI	(-0.41, 0.15)	(-0.37, 0.26)	
Week 52			
m	85	55	135
n	70	44	106
Baseline Mean (SD)	5.42 (1.38)	5.48 (1.31)	5.56 (1.23)
Analysis Visit Mean (SD)	5.52 (1.37)	5.49 (1.22)	5.46 (1.34)
LS Mean of Change from Baseline (SE)	0.10 (0.11)	0.02 (0.14)	-0.08 (0.09)
95% CI	(-0.12, 0.32)	(-0.25, 0.29)	(-0.25, 0.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.18 (0.14)	0.10 (0.16)	
95% CI	(-0.10, 0.45)	(-0.22, 0.42)	
p-value	0.2069	0.5319	
Corrected Hedge's g Statistics	0.194	0.111	
95% CI	(-0.11, 0.50)	(-0.24, 0.46)	
Subgroup*Treatment Interaction p-value	0.3777	0.5897	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Emotional Health			
Week 24			
m	89	63	147
n	80	56	124
Baseline Mean (SD)	5.29 (1.28)	5.26 (1.34)	5.41 (1.17)
Analysis Visit Mean (SD)	5.31 (1.31)	5.08 (1.20)	5.43 (1.27)
LS Mean of Change from Baseline (SE)	0.00 (0.09)	-0.22 (0.11)	0.01 (0.07)
95% CI	(-0.18, 0.19)	(-0.44, 0.00)	(-0.13, 0.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.01 (0.12)	-0.24 (0.13)	
95% CI	(-0.25, 0.23)	(-0.50, 0.03)	
p-value	0.9326	0.0790	
Corrected Hedge's g Statistics	-0.012	-0.282	
95% CI	(-0.29, 0.27)	(-0.60, 0.03)	
Week 52			
m	85	55	135
n	70	44	106
Baseline Mean (SD)	5.38 (1.25)	5.29 (1.45)	5.41 (1.19)
Analysis Visit Mean (SD)	5.33 (1.16)	5.28 (1.31)	5.38 (1.23)
LS Mean of Change from Baseline (SE)	-0.06 (0.09)	-0.02 (0.12)	-0.03 (0.08)
95% CI	(-0.24, 0.13)	(-0.25, 0.21)	(-0.18, 0.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.12)	0.01 (0.14)	
95% CI	(-0.27, 0.21)	(-0.27, 0.28)	
p-value	0.8118	0.9618	
Corrected Hedge's g Statistics	-0.037	0.009	
95% CI	(-0.34, 0.27)	(-0.34, 0.36)	
Subgroup*Treatment Interaction p-value	0.5321	0.5037	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Fatigue			
Week 24			
m	89	63	147
n	80	56	124
Baseline Mean (SD)	4.65 (1.47)	4.40 (1.56)	4.72 (1.39)
Analysis Visit Mean (SD)	4.60 (1.52)	4.32 (1.37)	4.75 (1.47)
LS Mean of Change from Baseline (SE)	-0.03 (0.12)	-0.18 (0.14)	0.02 (0.09)
95% CI	(-0.27, 0.21)	(-0.46, 0.10)	(-0.16, 0.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.06 (0.15)	-0.20 (0.17)	
95% CI	(-0.36, 0.25)	(-0.54, 0.14)	
p-value	0.7178	0.2406	
Corrected Hedge's g Statistics	-0.052	-0.189	
95% CI	(-0.33, 0.23)	(-0.50, 0.13)	
Week 52			
m	85	55	135
n	70	44	106
Baseline Mean (SD)	4.68 (1.47)	4.50 (1.58)	4.75 (1.34)
Analysis Visit Mean (SD)	4.73 (1.50)	4.58 (1.40)	4.78 (1.35)
LS Mean of Change from Baseline (SE)	0.01 (0.12)	0.07 (0.14)	0.04 (0.09)
95% CI	(-0.22, 0.25)	(-0.21, 0.36)	(-0.14, 0.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.03 (0.15)	0.03 (0.17)	
95% CI	(-0.32, 0.27)	(-0.31, 0.37)	
p-value	0.8650	0.8554	
Corrected Hedge's g Statistics	-0.026	0.032	
95% CI	(-0.33, 0.28)	(-0.32, 0.38)	
Subgroup*Treatment Interaction p-value	0.5625	0.6567	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Systemic Symptoms			
Week 24			
m	89	63	147
n	80	56	124
Baseline Mean (SD)	5.18 (1.25)	5.07 (1.29)	5.22 (1.17)
Analysis Visit Mean (SD)	5.21 (1.21)	4.90 (1.20)	5.19 (1.28)
LS Mean of Change from Baseline (SE)	0.06 (0.09)	-0.21 (0.11)	-0.02 (0.07)
95% CI	(-0.12, 0.24)	(-0.42, 0.01)	(-0.17, 0.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.08 (0.12)	-0.18 (0.13)	
95% CI	(-0.15, 0.31)	(-0.44, 0.07)	
p-value	0.4711	0.1594	
Corrected Hedge's g Statistics	0.103	-0.226	
95% CI	(-0.18, 0.38)	(-0.54, 0.09)	
Week 52			
m	85	55	135
n	70	44	106
Baseline Mean (SD)	5.28 (1.20)	5.08 (1.23)	5.20 (1.21)
Analysis Visit Mean (SD)	5.19 (1.26)	5.07 (1.21)	5.22 (1.30)
LS Mean of Change from Baseline (SE)	-0.04 (0.09)	-0.05 (0.12)	0.04 (0.08)
95% CI	(-0.23, 0.14)	(-0.28, 0.18)	(-0.11, 0.19)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (0.12)	-0.09 (0.14)	
95% CI	(-0.32, 0.15)	(-0.36, 0.19)	
p-value	0.4921	0.5301	
Corrected Hedge's g Statistics	-0.105	-0.112	
95% CI	(-0.41, 0.20)	(-0.46, 0.24)	
Subgroup*Treatment Interaction p-value	0.3507	0.8415	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.3
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Worry			
Week 24			
m	89	63	147
n	80	56	124
Baseline Mean (SD)	5.50 (1.50)	5.38 (1.59)	5.60 (1.32)
Analysis Visit Mean (SD)	5.86 (1.32)	5.59 (1.39)	5.84 (1.32)
LS Mean of Change from Baseline (SE)	0.35 (0.10)	0.15 (0.12)	0.25 (0.08)
95% CI	(0.15, 0.54)	(-0.08, 0.38)	(0.09, 0.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.10 (0.12)	-0.09 (0.14)	
95% CI	(-0.14, 0.34)	(-0.37, 0.18)	
p-value	0.4148	0.4975	
Corrected Hedge's g Statistics	0.117	-0.109	
95% CI	(-0.16, 0.40)	(-0.42, 0.21)	
Week 52			
m	85	55	135
n	70	44	106
Baseline Mean (SD)	5.59 (1.52)	5.33 (1.70)	5.68 (1.22)
Analysis Visit Mean (SD)	5.92 (1.29)	5.82 (1.50)	6.05 (1.08)
LS Mean of Change from Baseline (SE)	0.29 (0.11)	0.39 (0.13)	0.38 (0.08)
95% CI	(0.08, 0.49)	(0.13, 0.65)	(0.22, 0.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.10 (0.14)	0.01 (0.16)	
95% CI	(-0.36, 0.17)	(-0.30, 0.31)	
p-value	0.4714	0.9647	
Corrected Hedge's g Statistics	-0.111	0.008	
95% CI	(-0.41, 0.19)	(-0.34, 0.36)	
Subgroup*Treatment Interaction p-value	0.2974	0.8257	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Abbreviations: CLDQ-NASH = Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an increase of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi—square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (6.7)	5 (5.7)	13 (8.8)
No	70 (93.3)	82 (94.3)	134 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.36	1.59	
95% CI of the inverse odds ratio	(0.47, 3.96)	(0.55, 4.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	1.54	
95% CI of the inverse risk ratio	(0.49, 3.58)	(0.57, 4.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.18	-3.10	
95% CI of the absolute risk difference	(-9.45, 5.10)	(-9.80, 3.61)	
p-value	0.5741	0.3903	
p-value of Breslow-Day Test for Homogeneity [3]	0.9558	0.4276	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	14 (18.7)	14 (16.1)	31 (21.1)
No	61 (81.3)	73 (83.9)	116 (78.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.39	
95% CI of the inverse odds ratio	(0.58, 2.35)	(0.69, 2.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	1.31	
95% CI of the inverse risk ratio	(0.64, 1.99)	(0.74, 2.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.42	-5.00	
95% CI of the absolute risk difference	(-13.43, 8.59)	(-15.15, 5.16)	
p-value	0.6712	0.3486	
p-value of Breslow-Day Test for Homogeneity [3]	0.6547	0.3984	

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (16.0)	10 (11.5)	26 (17.7)
No	63 (84.0)	77 (88.5)	121 (82.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.13	1.65	
95% CI of the inverse odds ratio	(0.53, 2.39)	(0.76, 3.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.54	
95% CI of the inverse risk ratio	(0.59, 2.07)	(0.78, 3.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.69	-6.19	
95% CI of the absolute risk difference	(-12.03, 8.65)	(-15.30, 2.92)	
p-value	0.7523	0.2045	
p-value of Breslow-Day Test for Homogeneity [3]	0.5603	0.9026	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	26 (34.7)	18 (20.7)	47 (32.0)
No	49 (65.3)	69 (79.3)	100 (68.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.80	
95% CI of the inverse odds ratio	(0.49, 1.60)	(0.97, 3.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	1.55	
95% CI of the inverse risk ratio	(0.62, 1.36)	(0.96, 2.48)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.69	-11.28	
95% CI of the absolute risk difference	(-10.45, 15.84)	(-22.65, 0.09)	
p-value	0.6861	0.0626	
p-value of Breslow-Day Test for Homogeneity [3]	0.8721	0.8415	

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (8.0)	9 (10.3)	11 (7.5)
No	69 (92.0)	78 (89.7)	136 (92.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.93	0.70	
95% CI of the inverse odds ratio	(0.33, 2.62)	(0.28, 1.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.72	
95% CI of the inverse risk ratio	(0.36, 2.43)	(0.31, 1.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.52	2.86	
95% CI of the absolute risk difference	(-6.95, 7.99)	(-4.82, 10.55)	
p-value	0.8910	0.4492	
p-value of Breslow-Day Test for Homogeneity [3]	0.4489	0.9623	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	18 (24.0)	23 (26.4)	30 (20.4)
No	57 (76.0)	64 (73.6)	117 (79.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.71	
95% CI of the inverse odds ratio	(0.42, 1.58)	(0.38, 1.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.77	
95% CI of the inverse risk ratio	(0.51, 1.42)	(0.48, 1.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.59	6.03	
95% CI of the absolute risk difference	(-8.06, 15.25)	(-5.30, 17.36)	
p-value	0.5386	0.2870	
p-value of Breslow-Day Test for Homogeneity [3]	0.6242	0.3946	

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	7 (9.3)	9 (10.3)	13 (8.8)
No	68 (90.7)	78 (89.7)	134 (91.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.84	
95% CI of the inverse odds ratio	(0.36, 2.47)	(0.34, 2.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.85	
95% CI of the inverse risk ratio	(0.39, 2.27)	(0.38, 1.92)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.49	1.50	
95% CI of the absolute risk difference	(-7.54, 8.52)	(-6.37, 9.38)	
p-value	0.9040	0.7037	
p-value of Breslow-Day Test for Homogeneity [3]	0.4959	0.7326	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (20.0)	20 (23.0)	37 (25.2)
No	60 (80.0)	67 (77.0)	110 (74.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	1.13	
95% CI of the inverse odds ratio	(0.68, 2.65)	(0.60, 2.10)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	1.09	
95% CI of the inverse risk ratio	(0.74, 2.14)	(0.68, 1.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.17	-2.18	
95% CI of the absolute risk difference	(-16.62, 6.28)	(-13.47, 9.11)	
p-value	0.3896	0.7071	
p-value of Breslow-Day Test for Homogeneity [3]	0.4941	0.7104	

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (8.0)	11 (12.6)	19 (12.9)
No	69 (92.0)	76 (87.4)	128 (87.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.71	1.03	
95% CI of the inverse odds ratio	(0.65, 4.47)	(0.46, 2.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.62	1.02	
95% CI of the inverse risk ratio	(0.67, 3.87)	(0.51, 2.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.93	-0.28	
95% CI of the absolute risk difference	(-13.12, 3.27)	(-9.12, 8.56)	
p-value	0.2722	0.9504	
p-value of Breslow-Day Test for Homogeneity [3]	0.6574	0.5910	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	16 (21.3)	17 (19.5)	39 (26.5)
No	59 (78.7)	70 (80.5)	108 (73.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	1.49	
95% CI of the inverse odds ratio	(0.69, 2.58)	(0.78, 2.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.24	1.36	
95% CI of the inverse risk ratio	(0.75, 2.07)	(0.82, 2.25)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.20	-6.99	
95% CI of the absolute risk difference	(-16.90, 6.50)	(-17.96, 3.98)	
p-value	0.3962	0.2258	
p-value of Breslow-Day Test for Homogeneity [3]	0.2510	0.3269	

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (5.3)	5 (5.7)	15 (10.2)
No	71 (94.7)	82 (94.3)	132 (89.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.02	1.86	
95% CI of the inverse odds ratio	(0.65, 6.31)	(0.65, 5.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.91	1.78	
95% CI of the inverse risk ratio	(0.66, 5.56)	(0.67, 4.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.87	-4.46	
95% CI of the absolute risk difference	(-11.93, 2.19)	(-11.38, 2.46)	
p-value	0.2198	0.2386	
p-value of Breslow-Day Test for Homogeneity [3]	0.9918	0.2007	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	15 (20.0)	15 (17.2)	36 (24.5)
No	60 (80.0)	72 (82.8)	111 (75.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	1.56	
95% CI of the inverse odds ratio	(0.66, 2.56)	(0.80, 3.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	1.42	
95% CI of the inverse risk ratio	(0.72, 2.09)	(0.83, 2.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.49	-7.25	
95% CI of the absolute risk difference	(-15.90, 6.92)	(-17.80, 3.30)	
p-value	0.4520	0.1943	
p-value of Breslow-Day Test for Homogeneity [3]	0.8740	0.1455	

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	15 (20.0)	13 (14.9)	25 (17.0)
No	60 (80.0)	74 (85.1)	122 (83.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	1.17	
95% CI of the inverse odds ratio	(0.40, 1.67)	(0.56, 2.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.14	
95% CI of the inverse risk ratio	(0.48, 1.51)	(0.62, 2.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.99	-2.06	
95% CI of the absolute risk difference	(-7.91, 13.89)	(-11.71, 7.58)	
p-value	0.5831	0.6790	
p-value of Breslow-Day Test for Homogeneity [3]	0.6356	0.5607	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	25 (33.3)	22 (25.3)	44 (29.9)
No	50 (66.7)	65 (74.7)	103 (70.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	1.26	
95% CI of the inverse odds ratio	(0.47, 1.55)	(0.69, 2.30)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.18	
95% CI of the inverse risk ratio	(0.60, 1.35)	(0.76, 1.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.40	-4.64	
95% CI of the absolute risk difference	(-9.58, 16.39)	(-16.40, 7.11)	
p-value	0.6045	0.4454	
p-value of Breslow-Day Test for Homogeneity [3]	0.6641	0.6568	

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
CLDQ-NASH			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	6 (6.5)	6 (9.4)	13 (8.3)
No	86 (93.5)	58 (90.6)	143 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.30	0.88	
95% CI of the inverse odds ratio	(0.48, 3.55)	(0.32, 2.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	0.89	
95% CI of the inverse risk ratio	(0.50, 3.25)	(0.35, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.81	1.04	
95% CI of the absolute risk difference	(-8.46, 4.84)	(-7.31, 9.40)	
p-value	0.6044	0.8027	
p-value of Breslow-Day Test for Homogeneity [3]	0.9558	0.4276	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	24 (26.1)	17 (26.6)	39 (25.0)
No	68 (73.9)	47 (73.4)	117 (75.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	0.92	
95% CI of the inverse odds ratio	(0.52, 1.70)	(0.48, 1.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	0.94	
95% CI of the inverse risk ratio	(0.62, 1.49)	(0.58, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.09	1.56	
95% CI of the absolute risk difference	(-10.17, 12.34)	(-11.21, 14.34)	
p-value	0.8493	0.8091	
p-value of Breslow-Day Test for Homogeneity [3]	0.6547	0.3984	

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Abdominal Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	19 (20.7)	7 (10.9)	28 (17.9)
No	73 (79.3)	57 (89.1)	128 (82.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	1.78	
95% CI of the inverse odds ratio	(0.44, 1.61)	(0.74, 4.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.87	1.64	
95% CI of the inverse risk ratio	(0.52, 1.47)	(0.76, 3.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.70	-7.01	
95% CI of the absolute risk difference	(-7.53, 12.94)	(-16.74, 2.72)	
p-value	0.5998	0.1966	
p-value of Breslow-Day Test for Homogeneity [3]	0.5603	0.9026	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	30 (32.6)	12 (18.8)	49 (31.4)
No	62 (67.4)	52 (81.3)	107 (68.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	1.98	
95% CI of the inverse odds ratio	(0.55, 1.64)	(0.97, 4.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.96	1.68	
95% CI of the inverse risk ratio	(0.66, 1.40)	(0.96, 2.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.20	-12.66	
95% CI of the absolute risk difference	(-10.84, 13.23)	(-24.68, -0.64)	
p-value	0.8449	0.0568	
p-value of Breslow-Day Test for Homogeneity [3]	0.8721	0.8415	

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Activity			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (13.0)	7 (10.9)	12 (7.7)
No	80 (87.0)	57 (89.1)	144 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.68	
95% CI of the inverse odds ratio	(0.24, 1.29)	(0.25, 1.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.70	
95% CI of the inverse risk ratio	(0.28, 1.26)	(0.29, 1.71)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.35	3.25	
95% CI of the absolute risk difference	(-2.70, 13.40)	(-5.47, 11.96)	
p-value	0.1685	0.4364	
p-value of Breslow-Day Test for Homogeneity [3]	0.4489	0.9623	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (31.5)	14 (21.9)	36 (23.1)
No	63 (68.5)	50 (78.1)	120 (76.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	1.07	
95% CI of the inverse odds ratio	(0.37, 1.16)	(0.53, 2.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	1.05	
95% CI of the inverse risk ratio	(0.48, 1.11)	(0.61, 1.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	8.44	-1.20	
95% CI of the absolute risk difference	(-3.12, 20.01)	(-13.30, 10.89)	
p-value	0.1441	0.8468	
p-value of Breslow-Day Test for Homogeneity [3]	0.6242	0.3946	

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Emotional Health			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	12 (13.0)	5 (7.8)	13 (8.3)
No	80 (87.0)	59 (92.2)	143 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.61	1.07	
95% CI of the inverse odds ratio	(0.26, 1.39)	(0.37, 3.14)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	1.07	
95% CI of the inverse risk ratio	(0.30, 1.34)	(0.40, 2.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.71	-0.52	
95% CI of the absolute risk difference	(-3.42, 12.84)	(-8.40, 7.36)	
p-value	0.2340	0.8981	
p-value of Breslow-Day Test for Homogeneity [3]	0.4959	0.7326	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (22.8)	15 (23.4)	35 (22.4)
No	71 (77.2)	49 (76.6)	121 (77.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.94	
95% CI of the inverse odds ratio	(0.53, 1.81)	(0.47, 1.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.96	
95% CI of the inverse risk ratio	(0.61, 1.58)	(0.56, 1.63)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.39	1.00	
95% CI of the absolute risk difference	(-10.40, 11.18)	(-11.27, 13.27)	
p-value	0.9434	0.8721	
p-value of Breslow-Day Test for Homogeneity [3]	0.4941	0.7104	

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Fatigue			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	9 (9.8)	10 (15.6)	19 (12.2)
No	83 (90.2)	54 (84.4)	137 (87.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.28	0.75	
95% CI of the inverse odds ratio	(0.55, 2.96)	(0.33, 1.71)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.25	0.78	
95% CI of the inverse risk ratio	(0.59, 2.64)	(0.38, 1.58)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.40	3.45	
95% CI of the absolute risk difference	(-10.35, 5.55)	(-6.82, 13.72)	
p-value	0.5645	0.4926	
p-value of Breslow-Day Test for Homogeneity [3]	0.6574	0.5910	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	29 (31.5)	18 (28.1)	42 (26.9)
No	63 (68.5)	46 (71.9)	114 (73.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.94	
95% CI of the inverse odds ratio	(0.46, 1.41)	(0.49, 1.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	0.96	
95% CI of the inverse risk ratio	(0.57, 1.27)	(0.60, 1.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.60	1.20	
95% CI of the absolute risk difference	(-7.17, 16.37)	(-11.83, 14.23)	
p-value	0.4390	0.8557	
p-value of Breslow-Day Test for Homogeneity [3]	0.2510	0.3269	

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Systemic Symptoms			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (4.3)	7 (10.9)	13 (8.3)
No	88 (95.7)	57 (89.1)	143 (91.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.00	0.74	
95% CI of the inverse odds ratio	(0.63, 6.33)	(0.28, 1.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.92	0.76	
95% CI of the inverse risk ratio	(0.64, 5.70)	(0.32, 1.82)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.99	2.60	
95% CI of the absolute risk difference	(-10.00, 2.03)	(-6.19, 11.40)	
p-value	0.2302	0.5417	
p-value of Breslow-Day Test for Homogeneity [3]	0.9918	0.2007	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	21 (22.8)	20 (31.3)	41 (26.3)
No	71 (77.2)	44 (68.8)	115 (73.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	0.78	
95% CI of the inverse odds ratio	(0.66, 2.20)	(0.41, 1.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	0.84	
95% CI of the inverse risk ratio	(0.73, 1.82)	(0.54, 1.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.46	4.97	
95% CI of the absolute risk difference	(-14.47, 7.56)	(-8.32, 18.26)	
p-value	0.5437	0.4547	
p-value of Breslow-Day Test for Homogeneity [3]	0.8740	0.1455	

AMNOG Table SE23.15.4
Chronic Liver Disease Questionnaire-NASH (SE23): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Worry			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	16 (17.4)	13 (20.3)	28 (17.9)
No	76 (82.6)	51 (79.7)	128 (82.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.04	0.86	
95% CI of the inverse odds ratio	(0.53, 2.04)	(0.41, 1.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	0.88	
95% CI of the inverse risk ratio	(0.59, 1.80)	(0.49, 1.59)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.56	2.36	
95% CI of the absolute risk difference	(-10.37, 9.25)	(-9.19, 13.91)	
p-value	0.9116	0.6826	
p-value of Breslow-Day Test for Homogeneity [3]	0.6356	0.5607	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	32 (34.8)	22 (34.4)	55 (35.3)
No	60 (65.2)	42 (65.6)	101 (64.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.04	
95% CI of the inverse odds ratio	(0.59, 1.75)	(0.56, 1.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	1.03	
95% CI of the inverse risk ratio	(0.71, 1.44)	(0.69, 1.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.47	-0.88	
95% CI of the absolute risk difference	(-12.76, 11.81)	(-14.72, 12.96)	
p-value	0.9398	0.9009	
p-value of Breslow-Day Test for Homogeneity [3]	0.6641	0.6568	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.2.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Absenteeism						
Baseline						
m	124	126	224			
n	27	42	61			
Mean (SD)	3.63 (9.00)	2.39 (11.23)	2.90 (13.76)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 34.8	0.0, 68.1	0.0, 100.0			
Week 24						
m	119	119	214			
n	39	38	81	20	21	45
Mean (SD/SE)	1.13 (4.01)	1.32 (5.34)	0.00 (0.00)	-3.09 (1.98)	1.44 (1.40)	-3.86 (2.38)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 16.7	0.0, 29.4	0.0, 0.0	-26.7, 12.5	0.0, 29.4	-100.0, 0.0
Week 52						
m	108	107	201			
n	35	45	87	11	22	33
Mean (SD/SE)	3.93 (12.82)	4.04 (13.55)	4.19 (14.47)	0.16 (5.73)	6.70 (3.94)	2.13 (2.51)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-1.50, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 66.7	0.0, 75.0	-26.7, 50.0	0.0, 66.7	-33.3, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.2.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Presenteeism						
Baseline						
m	124	126	224			
n	27	42	60			
Mean (SD)	7.4 (18.1)	10.2 (16.2)	8.3 (16.5)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0			
Min, Max	0, 70	0, 70	0, 70			
Week 24						
m	119	119	214			
n	39	38	81	20	21	44
Mean (SD/SE)	10.5 (21.3)	12.4 (18.4)	7.5 (15.5)	7.0 (6.8)	4.3 (4.4)	1.4 (3.0)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 10.0	0.0, 0.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 90	0, 80	0, 70	-40, 90	-30, 60	-60, 70
Week 52						
m	108	107	201			
n	35	45	87	11	22	33
Mean (SD/SE)	12.0 (21.1)	10.7 (19.6)	7.8 (16.2)	8.2 (9.6)	-0.5 (2.8)	1.8 (3.7)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 10.0	0.0, 10.0	-10.0, 10.0	0.0, 0.0	0.0, 10.0
Min, Max	0, 90	0, 90	0, 80	-30, 90	-40, 30	-50, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.2.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=126)	Visit Result Placebo (N=224)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=126)	Change from Baseline Placebo (N=224)
Overall Work Impairment						
Baseline						
m	124	126	224			
n	27	42	60			
Mean (SD)	9.64 (20.96)	12.35 (19.14)	9.35 (17.64)			
Median	0	5.00	0			
IQR: Q1, Q3	0.00, 9.40	0.00, 14.30	0.00, 10.00			
Min, Max	0.0, 76.0	0.0, 70.0	0.0, 70.0			
Week 24						
m	119	119	214			
n	39	38	81	20	21	44
Mean (SD/SE)	11.11 (22.03)	13.52 (18.99)	7.53 (15.53)	4.90 (7.25)	5.59 (4.51)	0.02 (3.16)
Median	0	10.00	0	0	0	0
IQR: Q1, Q3	0.00, 10.00	0.00, 20.00	0.00, 10.00	-4.70, 0.00	0.00, 10.00	-2.20, 0.00
Min, Max	0.0, 91.3	0.0, 80.0	0.0, 70.0	-46.0, 91.3	-30.0, 60.0	-60.0, 70.0
Week 52						
m	108	107	201			
n	35	45	87	11	22	33
Mean (SD/SE)	14.71 (24.81)	13.84 (23.47)	10.87 (21.70)	9.79 (11.35)	5.27 (4.74)	3.08 (4.57)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 23.40	0.00, 20.00	0.00, 10.00	-7.30, 40.00	0.00, 0.00	0.00, 10.00
Min, Max	0.0, 90.0	0.0, 91.2	0.0, 87.5	-36.0, 90.0	-40.0, 63.4	-53.3, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.2.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Activity Impairment						
Baseline						
m	124	126	224			
n	47	64	97			
Mean (SD)	14.9 (24.7)	12.8 (18.9)	17.9 (27.0)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0			
Min, Max	0, 80	0, 80	0, 100			
Week 24						
m	119	119	214			
n	68	61	115	34	40	65
Mean (SD/SE)	14.0 (21.4)	12.6 (17.2)	14.3 (22.7)	2.4 (3.6)	2.5 (3.4)	-0.6 (2.7)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 25.0	0.0, 20.0	0.0, 20.0	0.0, 0.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 80	0, 70	0, 100	-40, 50	-60, 70	-80, 70
Week 52						
m	108	107	201			
n	67	68	124	23	36	49
Mean (SD/SE)	15.8 (22.3)	16.5 (20.8)	12.2 (19.9)	-3.5 (4.1)	4.4 (2.9)	-5.7 (3.6)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 30.0	0.0, 20.0	-10.0, 0.0	0.0, 10.0	-10.0, 0.0
Min, Max	0, 90	0, 80	0, 100	-40, 50	-50, 40	-90, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.2.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Absenteeism						
Baseline						
m	43	25	79			
n	1	2	6			
Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	42	22	75			
n	2	4	3	1	1	0
Mean (SD/SE)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)	0.00 (N/A)	0.00 (N/A)	N/A
Median	0	0	0	0	0	N/A
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	N/A
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	N/A
Week 52						
m	41	18	69			
n	2	3	9	0	2	3
Mean (SD/SE)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)	N/A	0.00 (0.00)	0.00 (0.00)
Median	0	0	0	N/A	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	N/A	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0	N/A	0.0, 0.0	0.0, 0.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.2.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Presenteeism						
Baseline						
m	43	25	79			
n	1	2	6			
Mean (SD)	0.0 (N/A)	10.0 (14.1)	0.0 (0.0)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 0.0			
Min, Max	0, 0	0, 20	0, 0			
Week 24						
m	42	22	75			
n	2	4	3	1	1	0
Mean (SD/SE)	10.0 (0.0)	0.0 (0.0)	3.3 (5.8)	10.0 (N/A)	0.0 (N/A)	N/A
Median	10.0	0	0	10.0	0	N/A
IQR: Q1, Q3	10.0, 10.0	0.0, 0.0	0.0, 10.0	10.0, 10.0	0.0, 0.0	N/A
Min, Max	10, 10	0, 0	0, 10	10, 10	0, 0	N/A
Week 52						
m	41	18	69			
n	2	3	9	0	2	3
Mean (SD/SE)	15.0 (21.2)	16.7 (28.9)	5.6 (7.3)	N/A	15.0 (15.0)	0.0 (0.0)
Median	15.0	0	0	N/A	15.0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 50.0	0.0, 10.0	N/A	0.0, 30.0	0.0, 0.0
Min, Max	0, 30	0, 50	0, 20	N/A	0, 30	0, 0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.2.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Overall Work Impairment						
Baseline						
m	43	25	79			
n	1	2	6			
Mean (SD)	0.00 (N/A)	10.00 (14.14)	0.00 (0.00)			
Median	0	10.00	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 20.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 20.0	0.0, 0.0			
Week 24						
m	42	22	75			
n	2	4	3	1	1	0
Mean (SD/SE)	10.00 (0.00)	0.00 (0.00)	3.33 (5.77)	10.00 (N/A)	0.00 (N/A)	N/A
Median	10.00	0	0	10.00	0	N/A
IQR: Q1, Q3	10.00, 10.00	0.00, 0.00	0.00, 10.00	10.00, 10.00	0.00, 0.00	N/A
Min, Max	10.0, 10.0	0.0, 0.0	0.0, 10.0	10.0, 10.0	0.0, 0.0	N/A
Week 52						
m	41	18	69			
n	2	3	9	0	2	3
Mean (SD/SE)	15.00 (21.21)	16.67 (28.87)	5.56 (7.26)	N/A	15.00 (15.00)	0.00 (0.00)
Median	15.00	0	0	N/A	15.00	0
IQR: Q1, Q3	0.00, 30.00	0.00, 50.00	0.00, 10.00	N/A	0.00, 30.00	0.00, 0.00
Min, Max	0.0, 30.0	0.0, 50.0	0.0, 20.0	N/A	0.0, 30.0	0.0, 0.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.2.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=79)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=79)
Activity Impairment						
Baseline						
m	43	25	79			
n	18	11	26			
Mean (SD)	14.4 (23.1)	11.8 (11.7)	16.2 (21.4)			
Median	0	10.0	10.0			
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0			
Min, Max	0, 80	0, 30	0, 70			
Week 24						
m	42	22	75			
n	22	12	37	17	7	14
Mean (SD/SE)	21.8 (25.4)	5.0 (8.0)	20.3 (24.1)	12.4 (6.3)	-4.3 (3.7)	2.9 (4.7)
Median	10.0	0	10.0	0	0	0
IQR: Q1, Q3	0.0, 40.0	0.0, 10.0	0.0, 30.0	0.0, 20.0	-10.0, 0.0	0.0, 10.0
Min, Max	0, 80	0, 20	0, 80	-10, 80	-20, 10	-40, 30
Week 52						
m	41	18	69			
n	25	12	44	8	5	14
Mean (SD/SE)	14.4 (22.0)	14.2 (22.7)	18.0 (19.8)	13.8 (9.4)	6.0 (10.8)	-0.7 (3.8)
Median	0	5.0	10.0	5.0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 15.0	0.0, 30.0	-5.0, 30.0	-10.0, 20.0	0.0, 10.0
Min, Max	0, 70	0, 70	0, 80	-10, 60	-20, 40	-40, 10

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.2.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.2.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Absenteeism			
Week 24			
m	119	119	214
n	20	21	45
Baseline Mean (SD)	4.55 (10.26)	0.23 (1.05)	3.86 (15.94)
Analysis Visit Mean (SD)	1.46 (4.55)	1.67 (6.47)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-1.50 (0.91)	-1.26 (0.83)	-2.86 (0.59)
95% CI	(-3.31, 0.31)	(-2.91, 0.38)	(-4.03, -1.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.36 (1.04)	1.60 (1.00)	
95% CI	(-0.71, 3.43)	(-0.39, 3.59)	
p-value	0.1951	0.1148	
Corrected Hedge's g Statistics	0.336	0.402	
95% CI	(-0.19, 0.87)	(-0.12, 0.92)	
Week 52			
m	108	107	201
n	11	22	33
Baseline Mean (SD)	7.41 (13.12)	0.00 (0.00)	2.04 (7.24)
Analysis Visit Mean (SD)	7.57 (17.26)	6.70 (18.49)	4.17 (13.32)
LS Mean of Change from Baseline (SE)	3.11 (4.47)	3.82 (3.22)	1.37 (2.55)
95% CI	(-5.77, 11.98)	(-2.57, 10.21)	(-3.70, 6.43)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.74 (5.18)	2.46 (4.08)	
95% CI	(-8.53, 12.01)	(-5.65, 10.56)	
p-value	0.7376	0.5491	
Corrected Hedge's g Statistics	0.116	0.163	
95% CI	(-0.57, 0.80)	(-0.38, 0.70)	
Subgroup*Treatment Interaction p-value	0.7858	0.7715	

AMNOG Table SE24.2.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Presenteeism			
Week 24			
m	119	119	214
n	20	21	44
Baseline Mean (SD)	7.5 (20.0)	8.1 (11.7)	7.5 (17.3)
Analysis Visit Mean (SD)	14.5 (27.6)	12.4 (17.3)	8.9 (16.2)
LS Mean of Change from Baseline (SE)	4.82 (4.42)	3.98 (3.96)	0.70 (2.88)
95% CI	(-3.95, 13.58)	(-3.88, 11.83)	(-5.01, 6.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.11 (5.13)	3.27 (4.84)	
95% CI	(-6.07, 14.29)	(-6.34, 12.88)	
p-value	0.4249	0.5010	
Corrected Hedge's g Statistics	0.210	0.172	
95% CI	(-0.32, 0.74)	(-0.35, 0.69)	
Week 52			
m	108	107	201
n	11	22	33
Baseline Mean (SD)	12.7 (26.1)	8.6 (12.5)	8.5 (19.2)
Analysis Visit Mean (SD)	20.9 (30.2)	8.2 (11.4)	10.3 (18.5)
LS Mean of Change from Baseline (SE)	10.64 (4.98)	-1.45 (3.63)	1.40 (2.92)
95% CI	(0.76, 20.51)	(-8.66, 5.75)	(-4.39, 7.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.23 (5.63)	-2.86 (4.58)	
95% CI	(-1.95, 20.41)	(-11.94, 6.23)	
p-value	0.1044	0.5341	
Corrected Hedge's g Statistics	0.543	-0.167	
95% CI	(-0.15, 1.23)	(-0.71, 0.37)	
Subgroup*Treatment Interaction p-value	0.8367	0.1557	

AMNOG Table SE24.2.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Age
(Label Population)

Age: < 65 years

Parameter / Visit / Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Overall Work Impairment			
Week 24			
m	119	119	214
n	20	21	44
Baseline Mean (SD)	10.17 (23.52)	8.30 (11.74)	8.85 (18.75)
Analysis Visit Mean (SD)	15.07 (28.37)	13.89 (18.04)	8.86 (16.17)
LS Mean of Change from Baseline (SE)	4.92 (4.59)	3.07 (4.07)	-0.72 (2.98)
95% CI	(-4.18, 14.03)	(-5.01, 11.15)	(-6.63, 5.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.65 (5.28)	3.80 (4.97)	
95% CI	(-4.84, 16.14)	(-6.07, 13.67)	
p-value	0.2880	0.4470	
Corrected Hedge's g Statistics	0.279	0.193	
95% CI	(-0.25, 0.81)	(-0.33, 0.71)	
Week 52			
m	108	107	201
n	11	22	33
Baseline Mean (SD)	16.72 (30.53)	8.64 (12.46)	10.15 (20.75)
Analysis Visit Mean (SD)	26.51 (33.21)	13.90 (21.15)	13.23 (23.16)
LS Mean of Change from Baseline (SE)	13.34 (6.58)	2.95 (4.79)	2.78 (3.86)
95% CI	(0.27, 26.40)	(-6.56, 12.47)	(-4.88, 10.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.56 (7.50)	0.17 (6.09)	
95% CI	(-4.32, 25.44)	(-11.91, 12.25)	
p-value	0.1623	0.9776	
Corrected Hedge's g Statistics	0.469	0.008	
95% CI	(-0.22, 1.16)	(-0.53, 0.55)	
Subgroup*Treatment Interaction p-value	0.8828	0.4350	

AMNOG Table SE24.2.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Activity Impairment			
Week 24			
m	119	119	214
n	34	40	65
Baseline Mean (SD)	12.6 (24.0)	11.8 (16.9)	14.5 (24.6)
Analysis Visit Mean (SD)	15.0 (23.4)	14.3 (18.4)	13.8 (22.9)
LS Mean of Change from Baseline (SE)	0.46 (3.28)	0.46 (2.95)	-0.20 (2.33)
95% CI	(-6.01, 6.94)	(-5.36, 6.28)	(-4.80, 4.40)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.67 (3.92)	0.66 (3.71)	
95% CI	(-7.08, 8.41)	(-6.66, 7.98)	
p-value	0.8654	0.8592	
Corrected Hedge's g Statistics	0.035	0.035	
95% CI	(-0.38, 0.45)	(-0.36, 0.43)	
Week 52			
m	108	107	201
n	23	36	49
Baseline Mean (SD)	17.4 (26.1)	11.9 (16.9)	18.2 (28.1)
Analysis Visit Mean (SD)	13.9 (18.3)	16.4 (16.6)	12.4 (18.2)
LS Mean of Change from Baseline (SE)	-1.64 (3.18)	2.49 (2.52)	-4.02 (2.14)
95% CI	(-7.92, 4.63)	(-2.49, 7.47)	(-8.25, 0.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.38 (3.70)	6.51 (3.27)	
95% CI	(-4.93, 9.68)	(0.05, 12.96)	
p-value	0.5219	0.0482	
Corrected Hedge's g Statistics	0.156	0.429	
95% CI	(-0.34, 0.65)	(-0.01, 0.86)	
Subgroup*Treatment Interaction p-value	0.2113	0.4251	

AMNOG Table SE24.2.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Absenteeism			
Week 24			
m	42	22	75
n	1	1	0
Baseline Mean (SD)	0.00 (N/A)	0.00 (N/A)	N/A
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	41	18	69
n	0	2	3
Baseline Mean (SD)	N/A	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	N/A	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.7858	0.7715	

AMNOG Table SE24.2.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Presenteeism			
Week 24			
m	42	22	75
n	1	1	0
Baseline Mean (SD)	0.0 (N/A)	0.0 (N/A)	N/A
Analysis Visit Mean (SD)	10.0 (N/A)	0.0 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	41	18	69
n	0	2	3
Baseline Mean (SD)	N/A	10.0 (14.1)	0.0 (0.0)
Analysis Visit Mean (SD)	N/A	25.0 (35.4)	0.0 (0.0)
LS Mean of Change from Baseline (SE)	NE	4.29 (0.00)	4.29 (0.00)
95% CI	NE	(4.28, 4.29)	(4.28, 4.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.00 (0.00)	
95% CI	NE	(0.00, 0.00)	
p-value	NE	>0.9999	
Corrected Hedge's g Statistics	NE	0.000	
95% CI	NE	(-1.79, 1.79)	
Subgroup*Treatment Interaction p-value	0.8367	0.1557	

AMNOG Table SE24.2.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Overall Work Impairment			
Week 24			
m	42	22	75
n	1	1	0
Baseline Mean (SD)	0.00 (N/A)	0.00 (N/A)	N/A
Analysis Visit Mean (SD)	10.00 (N/A)	0.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	41	18	69
n	0	2	3
Baseline Mean (SD)	N/A	10.00 (14.14)	0.00 (0.00)
Analysis Visit Mean (SD)	N/A	25.00 (35.36)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	4.29 (0.00)	4.29 (0.00)
95% CI	NE	(4.28, 4.29)	(4.28, 4.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	0.00 (0.00)	
95% CI	NE	(0.00, 0.00)	
p-value	NE	>0.9999	
Corrected Hedge's g Statistics	NE	0.000	
95% CI	NE	(-1.79, 1.79)	
Subgroup*Treatment Interaction p-value	0.8828	0.4350	

AMNOG Table SE24.2.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Activity Impairment			
Week 24			
m	42	22	75
n	17	7	14
Baseline Mean (SD)	12.4 (21.9)	10.0 (11.5)	22.9 (24.6)
Analysis Visit Mean (SD)	24.7 (26.2)	5.7 (9.8)	25.7 (25.6)
LS Mean of Change from Baseline (SE)	11.81 (5.31)	-5.82 (7.92)	6.09 (5.86)
95% CI	(1.09, 22.52)	(-21.81, 10.16)	(-5.75, 17.92)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.72 (7.47)	-11.91 (9.56)	
95% CI	(-9.36, 20.80)	(-31.22, 7.40)	
p-value	0.4479	0.2201	
Corrected Hedge's g Statistics	0.254	-0.529	
95% CI	(-0.46, 0.96)	(-1.45, 0.39)	
Week 52			
m	41	18	69
n	8	5	14
Baseline Mean (SD)	10.0 (16.0)	18.0 (13.0)	17.9 (21.5)
Analysis Visit Mean (SD)	23.8 (25.0)	24.0 (33.6)	17.1 (23.0)
LS Mean of Change from Baseline (SE)	13.76 (7.70)	6.94 (9.94)	0.14 (5.86)
95% CI	(-1.79, 29.32)	(-13.14, 27.02)	(-11.70, 11.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.63 (9.51)	6.80 (11.06)	
95% CI	(-5.58, 32.83)	(-15.54, 29.15)	
p-value	0.1596	0.5421	
Corrected Hedge's g Statistics	0.599	0.295	
95% CI	(-0.29, 1.49)	(-0.73, 1.32)	
Subgroup*Treatment Interaction p-value	0.2113	0.4251	

AMNOG Table SE24.2.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.2.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (1.6)	0	1 (0.4)
No	122 (98.4)	126 (100)	223 (99.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	NE	
95% CI of the inverse odds ratio	(0.02, 3.05)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	NE	
95% CI of the inverse risk ratio	(0.03, 3.02)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.17	-0.45	
95% CI of the absolute risk difference	(-1.22, 3.55)	(-1.32, 0.43)	
p-value	0.2596	0.4526	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (1.6)	0	2 (0.9)
No	122 (98.4)	126 (100)	222 (99.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	NE	
95% CI of the inverse odds ratio	(0.08, 3.95)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	NE	
95% CI of the inverse risk ratio	(0.08, 3.88)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.72	-0.89	
95% CI of the absolute risk difference	(-1.82, 3.26)	(-2.12, 0.34)	
p-value	0.5462	0.2875	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.2.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (0.8)	1 (0.8)	4 (1.8)
No	123 (99.2)	125 (99.2)	220 (98.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.24	2.27	
95% CI of the inverse odds ratio	(0.25, 20.23)	(0.25, 20.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.21	2.25	
95% CI of the inverse risk ratio	(0.25, 19.59)	(0.25, 19.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.98	-0.99	
95% CI of the absolute risk difference	(-3.32, 1.36)	(-3.32, 1.33)	
p-value	0.4622	0.4528	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (2.4)	5 (4.0)	5 (2.2)
No	121 (97.6)	121 (96.0)	219 (97.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.55	
95% CI of the inverse odds ratio	(0.22, 3.92)	(0.16, 1.95)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	0.56	
95% CI of the inverse risk ratio	(0.22, 3.80)	(0.17, 1.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.19	1.74	
95% CI of the absolute risk difference	(-3.14, 3.51)	(-2.18, 5.66)	
p-value	0.9111	0.3494	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.2.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (1.6)	1 (0.8)	4 (1.8)
No	122 (98.4)	125 (99.2)	220 (98.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	2.27	
95% CI of the inverse odds ratio	(0.20, 6.14)	(0.25, 20.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	2.25	
95% CI of the inverse risk ratio	(0.21, 5.96)	(0.25, 19.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.17	-0.99	
95% CI of the absolute risk difference	(-2.99, 2.64)	(-3.32, 1.33)	
p-value	0.9056	0.4528	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (2.4)	4 (3.2)	6 (2.7)
No	121 (97.6)	122 (96.8)	218 (97.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.84	
95% CI of the inverse odds ratio	(0.27, 4.52)	(0.23, 3.03)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.84	
95% CI of the inverse risk ratio	(0.28, 4.35)	(0.24, 2.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.26	0.50	
95% CI of the absolute risk difference	(-3.69, 3.17)	(-3.22, 4.22)	
p-value	0.8840	0.7892	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.2.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: < 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=126)	Placebo (N=224)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.0)	2 (1.6)	10 (4.5)
No	119 (96.0)	124 (98.4)	214 (95.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	2.90	
95% CI of the inverse odds ratio	(0.37, 3.33)	(0.62, 13.44)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	2.81	
95% CI of the inverse risk ratio	(0.39, 3.17)	(0.63, 12.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.43	-2.88	
95% CI of the absolute risk difference	(-4.83, 3.96)	(-6.35, 0.60)	
p-value	0.8493	0.1557	
p-value of Breslow-Day Test for Homogeneity [3]	0.3323	0.2711	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (6.5)	6 (4.8)	13 (5.8)
No	116 (93.5)	120 (95.2)	211 (94.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.89	1.23	
95% CI of the inverse odds ratio	(0.36, 2.22)	(0.46, 3.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.90	1.22	
95% CI of the inverse risk ratio	(0.38, 2.11)	(0.47, 3.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.65	-1.04	
95% CI of the absolute risk difference	(-4.65, 5.95)	(-5.86, 3.78)	
p-value	0.8079	0.6797	
p-value of Breslow-Day Test for Homogeneity [3]	0.9244	0.3411	

AMNOG Table SE24.2.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	43 (100)	25 (100)	79 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	43 (100)	25 (100)	79 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.2.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	43 (100)	25 (100)	79 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	43 (100)	25 (100)	79 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.2.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	43 (100)	25 (100)	79 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	43 (100)	25 (100)	79 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.2.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Age
(Label Population)

Age: >= 65 years

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=25)	Placebo (N=79)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (4.0)	2 (2.5)
No	43 (100)	24 (96.0)	77 (97.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.62	
95% CI of the inverse odds ratio	NE	(0.05, 7.18)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.63	
95% CI of the inverse risk ratio	NE	(0.06, 6.69)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.53	1.47	
95% CI of the absolute risk difference	(-6.00, 0.93)	(-6.96, 9.89)	
p-value	0.2928	0.7022	
p-value of Breslow-Day Test for Homogeneity [3]	0.3323	0.2711	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (4.7)	2 (8.0)	3 (3.8)
No	41 (95.3)	23 (92.0)	76 (96.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.45	
95% CI of the inverse odds ratio	(0.13, 5.04)	(0.07, 2.88)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.82	0.47	
95% CI of the inverse risk ratio	(0.14, 4.70)	(0.08, 2.68)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.85	4.20	
95% CI of the absolute risk difference	(-6.72, 8.43)	(-7.24, 15.64)	
p-value	0.8203	0.3920	
p-value of Breslow-Day Test for Homogeneity [3]	0.9244	0.3411	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.3.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Absenteeism						
Baseline						
m	43	86	132			
n	5	24	37			
Mean (SD)	5.34 (11.94)	0.20 (0.98)	3.12 (16.47)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 26.7	0.0, 4.8	0.0, 100.0			
Week 24						
m	40	82	129			
n	8	25	43	3	12	27
Mean (SD/SE)	0.00 (0.00)	0.23 (1.14)	0.00 (0.00)	-8.90 (8.90)	0.08 (0.08)	-4.27 (3.70)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-26.70, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 5.7	0.0, 0.0	-26.7, 0.0	0.0, 0.9	-100.0, 0.0
Week 52						
m	39	74	116			
n	10	31	43	2	15	19
Mean (SD/SE)	0.00 (0.00)	2.98 (10.92)	2.71 (10.99)	-13.35 (13.35)	5.37 (3.95)	0.32 (0.95)
Median	0	0	0	-13.35	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-26.70, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 55.6	0.0, 51.6	-26.7, 0.0	0.0, 55.6	-9.1, 15.1

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.3.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Presenteeism						
Baseline						
m	43	86	132			
n	5	24	36			
Mean (SD)	2.0 (4.5)	6.7 (9.2)	3.9 (12.9)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 0.0			
Min, Max	0, 10	0, 30	0, 70			
Week 24						
m	40	82	129			
n	8	25	43	3	12	26
Mean (SD/SE)	1.3 (3.5)	10.8 (19.8)	7.0 (15.5)	-3.3 (3.3)	5.8 (5.7)	3.5 (3.8)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0	-10.0, 0.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 10	0, 80	0, 70	-10, 0	-20, 60	-60, 70
Week 52						
m	39	74	116			
n	10	31	43	2	15	19
Mean (SD/SE)	7.0 (12.5)	11.9 (22.9)	6.3 (14.0)	-5.0 (5.0)	2.7 (2.7)	5.3 (5.0)
Median	0	0	0	-5.0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 10.0	-10.0, 0.0	0.0, 0.0	0.0, 10.0
Min, Max	0, 30	0, 90	0, 80	-10, 0	-10, 30	-40, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.3.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Overall Work Impairment						
Baseline						
m	43	86	132			
n	5	24	36			
Mean (SD)	6.80 (15.21)	6.85 (9.28)	4.26 (13.21)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 12.15	0.00, 0.00			
Min, Max	0.0, 34.0	0.0, 30.0	0.0, 70.0			
Week 24						
m	40	82	129			
n	8	25	43	3	12	26
Mean (SD/SE)	1.25 (3.54)	11.00 (19.79)	6.98 (15.51)	-11.33 (11.33)	5.90 (5.70)	2.94 (3.88)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 10.00	0.00, 10.00	-34.00, 0.00	0.00, 10.00	0.00, 0.00
Min, Max	0.0, 10.0	0.0, 80.0	0.0, 70.0	-34.0, 0.0	-20.0, 60.0	-60.0, 70.0
Week 52						
m	39	74	116			
n	10	31	43	2	15	19
Mean (SD/SE)	7.00 (12.52)	14.31 (24.78)	8.47 (17.70)	-17.00 (17.00)	7.50 (4.53)	4.94 (5.16)
Median	0	0	0	-17.00	0	0
IQR: Q1, Q3	0.00, 10.00	0.00, 20.00	0.00, 10.00	-34.00, 0.00	0.00, 12.50	0.00, 10.00
Min, Max	0.0, 30.0	0.0, 91.2	0.0, 83.0	-34.0, 0.0	-10.0, 60.0	-40.0, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.3.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Male

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=43)	Visit Result MGL-3196 100 mg (N=86)	Visit Result Placebo (N=132)	Change from Baseline MGL-3196 80 mg (N=43)	Change from Baseline MGL-3196 100 mg (N=86)	Change from Baseline Placebo (N=132)
Activity Impairment						
Baseline						
m	43	86	132			
n	12	37	54			
Mean (SD)	18.3 (25.2)	8.4 (13.2)	12.0 (24.4)			
Median	10.0	0	0			
IQR: Q1, Q3	0.0, 30.0	0.0, 10.0	0.0, 10.0			
Min, Max	0, 80	0, 50	0, 100			
Week 24						
m	40	82	129			
n	20	36	63	9	21	39
Mean (SD/SE)	13.5 (19.3)	8.3 (15.6)	8.9 (17.0)	4.4 (5.6)	0.5 (3.5)	-1.0 (3.2)
Median	5.0	0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 10.0	0.0, 10.0	-10.0, 10.0	0.0, 0.0	0.0, 0.0
Min, Max	0, 70	0, 60	0, 70	-10, 40	-20, 60	-70, 70
Week 52						
m	39	74	116			
n	25	46	71	5	20	29
Mean (SD/SE)	8.0 (14.4)	16.3 (22.4)	10.1 (17.4)	-2.0 (3.7)	3.5 (2.9)	-1.7 (5.0)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 20.0	-10.0, 0.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 50	0, 80	0, 80	-10, 10	-20, 40	-90, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.3.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Absenteeism						
Baseline						
m	124	65	171			
n	23	20	30			
Mean (SD)	3.10 (8.33)	4.77 (16.10)	2.04 (7.47)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 34.8	0.0, 68.1	0.0, 33.3			
Week 24						
m	121	59	160			
n	33	17	41	18	10	18
Mean (SD/SE)	1.34 (4.33)	2.61 (7.80)	0.00 (0.00)	-1.94 (1.72)	2.94 (2.94)	-3.24 (2.25)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 16.7	0.0, 29.4	0.0, 0.0	-20.0, 12.5	0.0, 29.4	-33.3, 0.0
Week 52						
m	110	51	154			
n	27	17	53	9	9	17
Mean (SD/SE)	5.10 (14.45)	5.25 (16.75)	4.67 (15.81)	3.17 (6.25)	7.41 (7.41)	3.78 (4.80)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 66.7	0.0, 75.0	-20.0, 50.0	0.0, 66.7	-33.3, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.3.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Presenteeism						
Baseline						
m	124	65	171			
n	23	20	30			
Mean (SD)	8.3 (19.5)	14.5 (20.9)	12.0 (18.1)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 15.0	0.0, 20.0			
Min, Max	0, 70	0, 70	0, 70			
Week 24						
m	121	59	160			
n	33	17	41	18	10	18
Mean (SD/SE)	12.7 (22.5)	11.8 (15.1)	7.8 (15.2)	8.9 (7.4)	2.0 (6.5)	-1.7 (4.9)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 20.0	0.0, 10.0	0.0, 10.0	-10.0, 10.0	-10.0, 0.0
Min, Max	0, 90	0, 60	0, 60	-40, 90	-30, 50	-50, 50
Week 52						
m	110	51	154			
n	27	17	53	9	9	17
Mean (SD/SE)	14.1 (23.1)	9.4 (13.4)	8.7 (16.9)	11.1 (11.6)	-2.2 (6.2)	-2.4 (4.4)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 20.0	0.0, 10.0	0.0, 10.0	-10.0, 0.0	0.0, 0.0
Min, Max	0, 90	0, 40	0, 70	-30, 90	-40, 30	-50, 30

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.3.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Overall Work Impairment						
Baseline						
m	124	65	171			
n	23	20	30			
Mean (SD)	9.84 (21.90)	18.73 (24.82)	13.57 (19.75)			
Median	0	10.00	0			
IQR: Q1, Q3	0.00, 9.40	0.00, 35.00	0.00, 20.00			
Min, Max	0.0, 76.0	0.0, 70.0	0.0, 70.0			
Week 24						
m	121	59	160			
n	33	17	41	18	10	18
Mean (SD/SE)	13.43 (23.32)	14.03 (16.79)	7.80 (15.25)	7.89 (7.73)	4.65 (6.90)	-4.21 (5.27)
Median	0	10.00	0	0	0	0
IQR: Q1, Q3	0.00, 20.00	0.00, 20.00	0.00, 10.00	0.00, 10.00	-10.00, 10.00	-10.00, 0.00
Min, Max	0.0, 91.3	0.0, 60.0	0.0, 60.0	-46.0, 91.3	-30.0, 50.0	-50.0, 50.0
Week 52						
m	110	51	154			
n	27	17	53	9	9	17
Mean (SD/SE)	17.59 (27.14)	13.48 (21.64)	11.91 (23.08)	15.74 (12.83)	3.71 (9.57)	0.45 (6.87)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 40.00	0.00, 20.00	0.00, 10.00	0.00, 40.00	-10.00, 0.00	0.00, 0.00
Min, Max	0.0, 90.0	0.0, 73.4	0.0, 87.5	-36.0, 90.0	-40.0, 63.4	-53.3, 70.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.3.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Sex
(Label Population)

Sex: Female

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=171)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=171)
Activity Impairment						
Baseline						
m	124	65	171			
n	53	38	69			
Mean (SD)	14.0 (24.0)	16.8 (20.9)	21.9 (26.2)			
Median	0	10.0	10.0			
IQR: Q1, Q3	0.0, 20.0	0.0, 30.0	0.0, 40.0			
Min, Max	0, 80	0, 80	0, 100			
Week 24						
m	121	59	160			
n	70	37	89	42	26	40
Mean (SD/SE)	16.6 (23.5)	14.3 (16.6)	20.7 (25.5)	6.0 (3.8)	2.3 (4.5)	1.0 (3.6)
Median	0	10.0	10.0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 40.0	0.0, 10.0	-10.0, 10.0	-10.0, 10.0
Min, Max	0, 80	0, 70	0, 100	-40, 80	-60, 70	-80, 50
Week 52						
m	110	51	154			
n	67	34	97	26	21	34
Mean (SD/SE)	18.2 (23.9)	15.9 (19.1)	16.3 (21.4)	1.5 (4.8)	5.7 (4.7)	-7.1 (3.4)
Median	10.0	10.0	10.0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 30.0	0.0, 30.0	-10.0, 10.0	0.0, 20.0	-10.0, 0.0
Min, Max	0, 90	0, 70	0, 100	-40, 60	-50, 40	-70, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.3.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.3.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Absenteeism			
Week 24			
m	40	82	129
n	3	12	27
Baseline Mean (SD)	8.90 (15.42)	0.40 (1.39)	4.27 (19.24)
Analysis Visit Mean (SD)	0.00 (0.00)	0.48 (1.65)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-2.24 (0.51)	-1.84 (0.26)	-2.24 (0.19)
95% CI	(-3.27, -1.20)	(-2.36, -1.32)	(-2.62, -1.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.54)	0.41 (0.31)	
95% CI	(-1.08, 1.09)	(-0.22, 1.04)	
p-value	0.9923	0.1976	
Corrected Hedge's g Statistics	0.005	0.420	
95% CI	(-1.19, 1.20)	(-0.27, 1.11)	
Week 52			
m	39	74	116
n	2	15	19
Baseline Mean (SD)	13.35 (18.88)	0.00 (0.00)	0.48 (2.09)
Analysis Visit Mean (SD)	0.00 (0.00)	5.37 (15.31)	0.79 (3.46)
LS Mean of Change from Baseline (SE)	-2.07 (9.31)	2.32 (2.97)	-1.43 (2.59)
95% CI	(-20.79, 16.66)	(-3.65, 8.30)	(-6.65, 3.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.63 (10.19)	3.75 (3.64)	
95% CI	(-21.12, 19.86)	(-3.57, 11.08)	
p-value	0.9507	0.3080	
Corrected Hedge's g Statistics	-0.053	0.322	
95% CI	(-1.51, 1.40)	(-0.36, 1.00)	
Subgroup*Treatment Interaction p-value	0.2789	0.1491	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.3.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Presenteeism			
Week 24			
m	40	82	129
n	3	12	26
Baseline Mean (SD)	3.3 (5.8)	5.0 (6.7)	4.6 (15.0)
Analysis Visit Mean (SD)	0.0 (0.0)	10.8 (16.8)	8.1 (16.0)
LS Mean of Change from Baseline (SE)	-4.60 (8.65)	6.47 (4.27)	1.18 (3.21)
95% CI	(-22.01, 12.81)	(-2.11, 15.06)	(-5.29, 7.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.78 (9.11)	5.29 (5.25)	
95% CI	(-24.10, 12.55)	(-5.27, 15.86)	
p-value	0.5290	0.3188	
Corrected Hedge's g Statistics	-0.345	0.325	
95% CI	(-1.54, 0.85)	(-0.36, 1.01)	
Week 52			
m	39	74	116
n	2	15	19
Baseline Mean (SD)	5.0 (7.1)	8.0 (10.1)	3.7 (16.1)
Analysis Visit Mean (SD)	0.0 (0.0)	10.7 (14.4)	8.9 (19.4)
LS Mean of Change from Baseline (SE)	-7.62 (10.05)	1.58 (4.01)	3.13 (3.52)
95% CI	(-27.84, 12.60)	(-6.49, 9.66)	(-3.94, 10.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.75 (10.42)	-1.55 (5.18)	
95% CI	(-31.72, 10.21)	(-11.97, 8.87)	
p-value	0.3075	0.7658	
Corrected Hedge's g Statistics	-0.676	-0.098	
95% CI	(-2.15, 0.80)	(-0.78, 0.58)	
Subgroup*Treatment Interaction p-value	0.1615	0.6590	

AMNOG Table SE24.3.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Overall Work Impairment			
Week 24			
m	40	82	129
n	3	12	26
Baseline Mean (SD)	11.33 (19.63)	5.36 (7.13)	5.13 (15.34)
Analysis Visit Mean (SD)	0.00 (0.00)	11.26 (16.81)	8.08 (16.00)
LS Mean of Change from Baseline (SE)	-5.77 (8.97)	4.18 (4.43)	0.40 (3.28)
95% CI	(-23.81, 12.27)	(-4.72, 13.09)	(-6.20, 7.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.17 (9.45)	3.79 (5.41)	
95% CI	(-25.17, 12.83)	(-7.09, 14.67)	
p-value	0.5168	0.4871	
Corrected Hedge's g Statistics	-0.360	0.227	
95% CI	(-1.56, 0.84)	(-0.46, 0.91)	
Week 52			
m	39	74	116
n	2	15	19
Baseline Mean (SD)	17.00 (24.04)	8.00 (10.14)	4.16 (16.08)
Analysis Visit Mean (SD)	0.00 (0.00)	15.50 (19.73)	9.11 (20.02)
LS Mean of Change from Baseline (SE)	-14.20 (12.92)	6.30 (4.86)	2.26 (4.33)
95% CI	(-40.21, 11.80)	(-3.47, 16.08)	(-6.45, 10.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	-16.46 (13.48)	4.05 (6.35)	
95% CI	(-43.57, 10.65)	(-8.73, 16.83)	
p-value	0.2280	0.5272	
Corrected Hedge's g Statistics	-0.839	0.210	
95% CI	(-2.32, 0.64)	(-0.47, 0.89)	
Subgroup*Treatment Interaction p-value	0.1611	0.8149	

AMNOG Table SE24.3.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Visit Statistic	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Activity Impairment			
Week 24			
m	40	82	129
n	9	21	39
Baseline Mean (SD)	17.8 (26.4)	6.7 (10.6)	10.3 (20.1)
Analysis Visit Mean (SD)	22.2 (24.4)	7.1 (15.2)	9.2 (17.4)
LS Mean of Change from Baseline (SE)	7.15 (5.11)	-2.64 (3.35)	-2.86 (2.54)
95% CI	(-3.02, 17.32)	(-9.30, 4.03)	(-7.92, 2.20)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.01 (5.61)	0.22 (4.07)	
95% CI	(-1.16, 21.18)	(-7.88, 8.32)	
p-value	0.0784	0.9568	
Corrected Hedge's g Statistics	0.624	0.014	
95% CI	(-0.11, 1.36)	(-0.52, 0.54)	
Week 52			
m	39	74	116
n	5	20	29
Baseline Mean (SD)	10.0 (12.2)	10.0 (13.4)	12.4 (26.0)
Analysis Visit Mean (SD)	8.0 (8.4)	13.5 (16.6)	10.7 (20.2)
LS Mean of Change from Baseline (SE)	0.82 (6.38)	-0.56 (3.51)	-1.39 (2.86)
95% CI	(-11.88, 13.53)	(-7.55, 6.42)	(-7.09, 4.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.21 (6.89)	0.82 (4.40)	
95% CI	(-11.50, 15.91)	(-7.93, 9.58)	
p-value	0.7491	0.8518	
Corrected Hedge's g Statistics	0.141	0.052	
95% CI	(-0.81, 1.09)	(-0.52, 0.62)	
Subgroup*Treatment Interaction p-value	0.7713	0.7648	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.3.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Absenteeism			
Week 24			
m	121	59	160
n	18	10	18
Baseline Mean (SD)	3.57 (9.30)	0.00 (0.00)	3.24 (9.53)
Analysis Visit Mean (SD)	1.62 (4.78)	2.94 (9.30)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-1.86 (1.34)	0.16 (1.57)	-2.98 (1.16)
95% CI	(-4.55, 0.84)	(-2.98, 3.31)	(-5.30, -0.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.13 (1.75)	3.15 (1.93)	
95% CI	(-2.39, 4.64)	(-0.72, 7.01)	
p-value	0.5229	0.1083	
Corrected Hedge's g Statistics	0.207	0.620	
95% CI	(-0.45, 0.86)	(-0.17, 1.41)	
Week 52			
m	110	51	154
n	9	9	17
Baseline Mean (SD)	6.09 (12.64)	0.00 (0.00)	3.43 (9.79)
Analysis Visit Mean (SD)	9.26 (18.83)	7.41 (22.23)	7.21 (17.92)
LS Mean of Change from Baseline (SE)	3.40 (5.60)	2.36 (5.79)	4.68 (4.22)
95% CI	(-7.84, 14.64)	(-9.25, 13.97)	(-3.79, 13.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.28 (6.98)	-2.32 (7.17)	
95% CI	(-15.28, 12.72)	(-16.72, 12.08)	
p-value	0.8550	0.7477	
Corrected Hedge's g Statistics	-0.072	-0.129	
95% CI	(-0.88, 0.74)	(-0.94, 0.68)	
Subgroup*Treatment Interaction p-value	0.2789	0.1491	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.3.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Presenteeism			
Week 24			
m	121	59	160
n	18	10	18
Baseline Mean (SD)	7.8 (21.0)	11.0 (15.2)	11.7 (19.8)
Analysis Visit Mean (SD)	16.7 (28.5)	13.0 (18.3)	10.0 (16.8)
LS Mean of Change from Baseline (SE)	6.29 (5.60)	1.46 (6.64)	0.18 (4.99)
95% CI	(-4.96, 17.53)	(-11.86, 14.77)	(-9.82, 10.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.11 (7.48)	1.28 (8.23)	
95% CI	(-8.89, 21.11)	(-15.23, 17.79)	
p-value	0.4176	0.8770	
Corrected Hedge's g Statistics	0.265	0.059	
95% CI	(-0.39, 0.92)	(-0.71, 0.83)	
Week 52			
m	110	51	154
n	9	9	17
Baseline Mean (SD)	14.4 (28.8)	10.0 (15.8)	12.4 (20.5)
Analysis Visit Mean (SD)	25.6 (31.7)	7.8 (13.9)	10.0 (16.6)
LS Mean of Change from Baseline (SE)	13.80 (6.17)	-3.44 (6.12)	-1.79 (4.45)
95% CI	(1.42, 26.17)	(-15.73, 8.84)	(-10.73, 7.15)
LS Mean of Change from Baseline Compared to Placebo (SE)	15.59 (7.61)	-1.65 (7.55)	
95% CI	(0.32, 30.86)	(-16.81, 13.51)	
p-value	0.0456	0.8275	
Corrected Hedge's g Statistics	0.820	-0.087	
95% CI	(-0.02, 1.66)	(-0.90, 0.72)	
Subgroup*Treatment Interaction p-value	0.1615	0.6590	

AMNOG Table SE24.3.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Overall Work Impairment			
Week 24			
m	121	59	160
n	18	10	18
Baseline Mean (SD)	9.41 (24.05)	11.00 (15.24)	14.21 (22.18)
Analysis Visit Mean (SD)	17.29 (29.26)	15.65 (19.67)	10.00 (16.80)
LS Mean of Change from Baseline (SE)	7.02 (5.86)	1.82 (6.66)	-2.38 (5.01)
95% CI	(-4.73, 18.77)	(-11.54, 15.17)	(-12.44, 7.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.41 (7.65)	4.20 (8.24)	
95% CI	(-5.95, 24.77)	(-12.32, 20.73)	
p-value	0.2247	0.6120	
Corrected Hedge's g Statistics	0.398	0.193	
95% CI	(-0.26, 1.06)	(-0.58, 0.97)	
Week 52			
m	110	51	154
n	9	9	17
Baseline Mean (SD)	16.66 (33.05)	10.00 (15.81)	15.05 (22.84)
Analysis Visit Mean (SD)	32.40 (34.12)	13.71 (25.97)	15.50 (25.08)
LS Mean of Change from Baseline (SE)	18.14 (8.21)	-0.85 (8.31)	1.76 (6.15)
95% CI	(1.66, 34.62)	(-17.54, 15.83)	(-10.59, 14.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	16.38 (10.24)	-2.61 (10.31)	
95% CI	(-4.17, 36.93)	(-23.31, 18.09)	
p-value	0.1158	0.8011	
Corrected Hedge's g Statistics	0.631	-0.100	
95% CI	(-0.19, 1.46)	(-0.91, 0.71)	
Subgroup*Treatment Interaction p-value	0.1611	0.8149	

AMNOG Table SE24.3.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Activity Impairment			
Week 24			
m	121	59	160
n	42	26	40
Baseline Mean (SD)	11.4 (22.6)	15.4 (18.8)	21.5 (27.6)
Analysis Visit Mean (SD)	17.4 (24.8)	17.7 (18.2)	22.5 (27.2)
LS Mean of Change from Baseline (SE)	3.17 (3.42)	1.12 (4.14)	3.72 (3.36)
95% CI	(-3.59, 9.94)	(-7.09, 9.32)	(-2.92, 10.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.55 (4.71)	-2.61 (5.27)	
95% CI	(-9.88, 8.78)	(-13.04, 7.83)	
p-value	0.9078	0.6222	
Corrected Hedge's g Statistics	-0.025	-0.121	
95% CI	(-0.46, 0.41)	(-0.62, 0.37)	
Week 52			
m	110	51	154
n	26	21	34
Baseline Mean (SD)	16.5 (25.6)	15.2 (18.9)	22.9 (26.6)
Analysis Visit Mean (SD)	18.1 (21.5)	21.0 (20.7)	15.9 (18.4)
LS Mean of Change from Baseline (SE)	2.01 (3.52)	4.67 (3.79)	-4.44 (2.98)
95% CI	(-4.96, 8.98)	(-2.83, 12.17)	(-10.34, 1.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.45 (4.54)	9.11 (4.80)	
95% CI	(-2.54, 15.43)	(-0.40, 18.61)	
p-value	0.1581	0.0603	
Corrected Hedge's g Statistics	0.361	0.516	
95% CI	(-0.15, 0.88)	(-0.04, 1.07)	
Subgroup*Treatment Interaction p-value	0.7713	0.7648	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.3.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.3.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	0	0
No	42 (97.7)	86 (100)	132 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.33	NE	
95% CI of the absolute risk difference	(-2.18, 6.83)	NE	
p-value	0.0789	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2461	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (2.3)	0	1 (0.8)
No	42 (97.7)	86 (100)	131 (99.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.32	NE	
95% CI of the inverse odds ratio	(0.02, 5.24)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	NE	
95% CI of the inverse risk ratio	(0.02, 5.10)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.57	-0.76	
95% CI of the absolute risk difference	(-3.17, 6.31)	(-2.24, 0.72)	
p-value	0.4008	0.4185	
p-value of Breslow-Day Test for Homogeneity [3]	0.6830	NE	

AMNOG Table SE24.3.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (0.8)
No	43 (100)	86 (100)	131 (99.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.76	-0.76	
95% CI of the absolute risk difference	(-2.24, 0.72)	(-2.24, 0.72)	
p-value	0.5671	0.4185	
p-value of Breslow-Day Test for Homogeneity [3]	0.6997	0.4781	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (2.3)	2 (2.3)	1 (0.8)
No	42 (97.7)	84 (97.7)	131 (99.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.32	0.32	
95% CI of the inverse odds ratio	(0.02, 5.24)	(0.03, 3.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	0.33	
95% CI of the inverse risk ratio	(0.02, 5.10)	(0.03, 3.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.57	1.57	
95% CI of the absolute risk difference	(-3.17, 6.31)	(-1.94, 5.08)	
p-value	0.4008	0.3314	
p-value of Breslow-Day Test for Homogeneity [3]	0.3431	0.7647	

AMNOG Table SE24.3.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.3)	0	1 (0.8)
No	42 (97.7)	86 (100)	131 (99.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.32	NE	
95% CI of the inverse odds ratio	(0.02, 5.24)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.33	NE	
95% CI of the inverse risk ratio	(0.02, 5.10)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.57	-0.76	
95% CI of the absolute risk difference	(-3.17, 6.31)	(-2.24, 0.72)	
p-value	0.4008	0.4185	
p-value of Breslow-Day Test for Homogeneity [3]	0.2682	0.4781	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (2.3)	1 (1.2)	2 (1.5)
No	42 (97.7)	85 (98.8)	130 (98.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	1.31	
95% CI of the inverse odds ratio	(0.06, 7.31)	(0.12, 14.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.65	1.30	
95% CI of the inverse risk ratio	(0.06, 7.01)	(0.12, 14.15)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.81	-0.35	
95% CI of the absolute risk difference	(-4.15, 5.77)	(-3.43, 2.73)	
p-value	0.7222	0.8272	
p-value of Breslow-Day Test for Homogeneity [3]	0.5859	0.4987	

AMNOG Table SE24.3.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Male

Parameter Response Statistic/Category	MGL-3196 80 mg (N=43)	MGL-3196 100 mg (N=86)	Placebo (N=132)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (1.2)	4 (3.0)
No	43 (100)	85 (98.8)	128 (97.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	2.66	
95% CI of the inverse odds ratio	NE	(0.29, 24.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	2.61	
95% CI of the inverse risk ratio	NE	(0.30, 22.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.03	-1.87	
95% CI of the absolute risk difference	(-5.95, -0.11)	(-5.57, 1.83)	
p-value	0.2482	0.3680	
p-value of Breslow-Day Test for Homogeneity [3]	0.2970	0.6945	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (4.7)	4 (4.7)	5 (3.8)
No	41 (95.3)	82 (95.3)	127 (96.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.81	
95% CI of the inverse odds ratio	(0.15, 4.32)	(0.21, 3.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.81	
95% CI of the inverse risk ratio	(0.16, 4.05)	(0.22, 2.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.86	0.86	
95% CI of the absolute risk difference	(-6.22, 7.95)	(-4.65, 6.38)	
p-value	0.8019	0.7542	
p-value of Breslow-Day Test for Homogeneity [3]	0.8294	0.7743	

AMNOG Table SE24.3.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (0.8)	0	1 (0.6)
No	123 (99.2)	65 (100)	170 (99.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	NE	
95% CI of the inverse odds ratio	(0.04, 11.68)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	NE	
95% CI of the inverse risk ratio	(0.05, 11.48)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.22	-0.58	
95% CI of the absolute risk difference	(-1.72, 2.17)	(-1.73, 0.56)	
p-value	0.8189	0.5367	
p-value of Breslow-Day Test for Homogeneity [3]	0.2461	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (0.8)	0	1 (0.6)
No	123 (99.2)	65 (100)	170 (99.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	NE	
95% CI of the inverse odds ratio	(0.04, 11.68)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	NE	
95% CI of the inverse risk ratio	(0.05, 11.48)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.22	-0.58	
95% CI of the absolute risk difference	(-1.72, 2.17)	(-1.73, 0.56)	
p-value	0.8189	0.5367	
p-value of Breslow-Day Test for Homogeneity [3]	0.6830	NE	

AMNOG Table SE24.3.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (0.8)	1 (1.5)	3 (1.8)
No	123 (99.2)	64 (98.5)	168 (98.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.20	1.14	
95% CI of the inverse odds ratio	(0.23, 21.37)	(0.12, 11.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.18	1.14	
95% CI of the inverse risk ratio	(0.23, 20.67)	(0.12, 10.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.95	-0.22	
95% CI of the absolute risk difference	(-3.47, 1.57)	(-3.80, 3.37)	
p-value	0.4871	0.9086	
p-value of Breslow-Day Test for Homogeneity [3]	0.6997	0.4781	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (1.6)	3 (4.6)	4 (2.3)
No	122 (98.4)	62 (95.4)	167 (97.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.46	0.50	
95% CI of the inverse odds ratio	(0.26, 8.11)	(0.11, 2.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	0.51	
95% CI of the inverse risk ratio	(0.27, 7.79)	(0.12, 2.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.73	2.28	
95% CI of the absolute risk difference	(-3.90, 2.44)	(-3.30, 7.86)	
p-value	0.6627	0.3572	
p-value of Breslow-Day Test for Homogeneity [3]	0.3431	0.7647	

AMNOG Table SE24.3.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (0.8)	1 (1.5)	3 (1.8)
No	123 (99.2)	64 (98.5)	168 (98.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.20	1.14	
95% CI of the inverse odds ratio	(0.23, 21.37)	(0.12, 11.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.18	1.14	
95% CI of the inverse risk ratio	(0.23, 20.67)	(0.12, 10.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.95	-0.22	
95% CI of the absolute risk difference	(-3.47, 1.57)	(-3.80, 3.37)	
p-value	0.4871	0.9086	
p-value of Breslow-Day Test for Homogeneity [3]	0.2682	0.4781	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (1.6)	3 (4.6)	4 (2.3)
No	122 (98.4)	62 (95.4)	167 (97.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.46	0.50	
95% CI of the inverse odds ratio	(0.26, 8.11)	(0.11, 2.27)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	0.51	
95% CI of the inverse risk ratio	(0.27, 7.79)	(0.12, 2.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.73	2.28	
95% CI of the absolute risk difference	(-3.90, 2.44)	(-3.30, 7.86)	
p-value	0.6627	0.3572	
p-value of Breslow-Day Test for Homogeneity [3]	0.5859	0.4987	

AMNOG Table SE24.3.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Sex
(Label Population)

Sex: Female

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=65)	Placebo (N=171)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (4.0)	2 (3.1)	8 (4.7)
No	119 (96.0)	63 (96.9)	163 (95.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	1.55	
95% CI of the inverse odds ratio	(0.37, 3.66)	(0.32, 7.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	1.52	
95% CI of the inverse risk ratio	(0.39, 3.46)	(0.33, 6.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.65	-1.60	
95% CI of the absolute risk difference	(-5.34, 4.04)	(-6.86, 3.66)	
p-value	0.7896	0.5853	
p-value of Breslow-Day Test for Homogeneity [3]	0.2970	0.6945	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (6.5)	4 (6.2)	11 (6.4)
No	116 (93.5)	61 (93.8)	160 (93.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.05	
95% CI of the inverse odds ratio	(0.39, 2.56)	(0.32, 3.42)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	1.05	
95% CI of the inverse risk ratio	(0.41, 2.41)	(0.35, 3.17)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.02	-0.28	
95% CI of the absolute risk difference	(-5.66, 5.70)	(-7.18, 6.62)	
p-value	0.9948	0.9375	
p-value of Breslow-Day Test for Homogeneity [3]	0.8294	0.7743	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.4.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Absenteeism						
Baseline						
m	94	119	198			
n	25	43	59			
Mean (SD)	3.92 (9.30)	2.33 (11.10)	1.30 (5.52)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 34.8	0.0, 68.1	0.0, 33.3			
Week 24						
m	91	110	187			
n	28	36	63	19	21	37
Mean (SD/SE)	1.58 (4.68)	1.39 (5.48)	0.00 (0.00)	-3.25 (2.08)	1.44 (1.40)	-1.99 (1.13)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 16.7	0.0, 29.4	0.0, 0.0	-26.7, 12.5	0.0, 29.4	-33.3, 0.0
Week 52						
m	85	97	175			
n	24	42	69	10	23	31
Mean (SD/SE)	1.57 (6.82)	4.32 (13.99)	2.74 (11.11)	-4.82 (3.13)	6.40 (3.78)	2.26 (2.68)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-1.50, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 33.3	0.0, 66.7	0.0, 66.7	-26.7, 0.0	0.0, 66.7	-33.3, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.4.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Presenteeism						
Baseline						
m	94	119	198			
n	25	43	59			
Mean (SD)	7.6 (18.8)	10.2 (16.1)	7.6 (15.7)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0			
Min, Max	0, 70	0, 70	0, 70			
Week 24						
m	91	110	187			
n	28	36	63	19	21	37
Mean (SD/SE)	13.2 (23.9)	12.5 (18.7)	8.9 (17.0)	8.4 (7.1)	4.8 (4.3)	2.2 (3.2)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 15.0	0.0, 20.0	0.0, 10.0	0.0, 10.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 90	0, 80	0, 70	-40, 90	-30, 60	-60, 70
Week 52						
m	85	97	175			
n	24	42	69	10	23	31
Mean (SD/SE)	14.2 (23.9)	10.2 (18.1)	6.1 (14.4)	8.0 (10.6)	0.9 (2.9)	2.6 (3.5)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 25.0	0.0, 20.0	0.0, 0.0	-10.0, 0.0	0.0, 0.0	0.0, 0.0
Min, Max	0, 90	0, 90	0, 80	-30, 90	-40, 30	-40, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.4.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Overall Work Impairment						
Baseline						
m	94	119	198			
n	25	43	59			
Mean (SD)	10.01 (21.72)	12.30 (19.04)	8.66 (16.96)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 7.00	0.00, 20.00	0.00, 10.00			
Min, Max	0.0, 76.0	0.0, 70.0	0.0, 70.0			
Week 24						
m	91	110	187			
n	28	36	63	19	21	37
Mean (SD/SE)	14.05 (24.75)	13.71 (19.36)	8.89 (17.05)	6.21 (7.60)	6.06 (4.45)	0.56 (3.45)
Median	0	10.00	0	0	0	0
IQR: Q1, Q3	0.00, 20.00	0.00, 20.00	0.00, 10.00	0.00, 10.00	0.00, 10.00	-4.40, 0.00
Min, Max	0.0, 91.3	0.0, 80.0	0.0, 70.0	-46.0, 91.3	-30.0, 60.0	-60.0, 70.0
Week 52						
m	85	97	175			
n	24	42	69	10	23	31
Mean (SD/SE)	15.00 (25.27)	13.64 (22.60)	8.08 (18.78)	5.27 (11.51)	6.34 (4.65)	3.92 (4.51)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 26.70	0.00, 20.00	0.00, 0.00	-7.30, 0.00	0.00, 12.50	0.00, 0.00
Min, Max	0.0, 90.0	0.0, 91.2	0.0, 83.0	-36.0, 90.0	-40.0, 63.4	-53.3, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.4.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Region
(Label Population)

Region: US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=94)	Visit Result MGL-3196 100 mg (N=119)	Visit Result Placebo (N=198)	Change from Baseline MGL-3196 80 mg (N=94)	Change from Baseline MGL-3196 100 mg (N=119)	Change from Baseline Placebo (N=198)
Activity Impairment						
Baseline						
m	94	119	198			
n	58	73	113			
Mean (SD)	13.4 (22.0)	12.2 (17.7)	17.2 (25.6)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0			
Min, Max	0, 80	0, 80	0, 100			
Week 24						
m	91	110	187			
n	61	65	110	45	46	69
Mean (SD/SE)	15.7 (21.6)	11.8 (16.8)	16.9 (24.2)	7.6 (3.5)	1.5 (3.0)	1.6 (2.4)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 30.0	0.0, 10.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 80	0, 70	0, 100	-40, 80	-60, 70	-80, 70
Week 52						
m	85	97	175			
n	54	69	110	28	40	55
Mean (SD/SE)	15.0 (19.7)	14.3 (19.2)	13.3 (19.9)	0.7 (4.5)	4.8 (2.8)	-3.6 (3.0)
Median	5.0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0	-10.0, 5.0	0.0, 15.0	-10.0, 0.0
Min, Max	0, 70	0, 80	0, 100	-40, 60	-50, 40	-90, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.4.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Absenteeism						
Baseline						
m	73	32	105			
n	3	1	8			
Mean (SD)	0.00 (0.00)	0.00 (N/A)	12.50 (35.36)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 100.0			
Week 24						
m	70	31	102			
n	13	6	21	2	1	8
Mean (SD/SE)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)	0.00 (N/A)	-12.50 (12.50)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	-100.0, 0.0
Week 52						
m	64	28	95			
n	13	6	27	1	1	5
Mean (SD/SE)	7.69 (18.78)	0.00 (0.00)	6.48 (19.11)	50.00 (N/A)	0.00 (N/A)	0.00 (0.00)
Median	0	0	0	50.00	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	50.00, 50.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 0.0	0.0, 75.0	50.0, 50.0	0.0, 0.0	0.0, 0.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.4.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Presenteeism						
Baseline						
m	73	32	105			
n	3	1	7			
Mean (SD)	3.3 (5.8)	10.0 (N/A)	7.1 (18.9)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 10.0	10.0, 10.0	0.0, 0.0			
Min, Max	0, 10	10, 10	0, 50			
Week 24						
m	70	31	102			
n	13	6	21	2	1	7
Mean (SD/SE)	4.6 (9.7)	3.3 (8.2)	2.9 (6.4)	-5.0 (5.0)	-10.0 (N/A)	-2.9 (8.4)
Median	0	0	0	-5.0	-10.0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 0.0	-10.0, 0.0	-10.0, -10.0	0.0, 10.0
Min, Max	0, 30	0, 20	0, 20	-10, 0	-10, -10	-50, 20
Week 52						
m	64	28	95			
n	13	6	27	1	1	5
Mean (SD/SE)	8.5 (13.4)	16.7 (31.4)	11.5 (18.1)	10.0 (N/A)	0.0 (N/A)	-4.0 (12.1)
Median	0	5.0	0	10.0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 20.0	10.0, 10.0	0.0, 0.0	0.0, 10.0
Min, Max	0, 40	0, 80	0, 70	10, 10	0, 0	-50, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.4.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=73)	Visit Result MGL-3196 100 mg (N=32)	Visit Result Placebo (N=105)	Change from Baseline MGL-3196 80 mg (N=73)	Change from Baseline MGL-3196 100 mg (N=32)	Change from Baseline Placebo (N=105)
Overall Work Impairment						
Baseline						
m	73	32	105			
n	3	1	7			
Mean (SD)	3.33 (5.77)	10.00 (N/A)	7.14 (18.90)			
Median	0	10.00	0			
IQR: Q1, Q3	0.00, 10.00	10.00, 10.00	0.00, 0.00			
Min, Max	0.0, 10.0	10.0, 10.0	0.0, 50.0			
Week 24						
m	70	31	102			
n	13	6	21	2	1	7
Mean (SD/SE)	4.62 (9.67)	3.33 (8.16)	2.86 (6.44)	-5.00 (5.00)	-10.00 (N/A)	-2.86 (8.37)
Median	0	0	0	-5.00	-10.00	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-10.00, 0.00	-10.00, -10.00	0.00, 10.00
Min, Max	0.0, 30.0	0.0, 20.0	0.0, 20.0	-10.0, 0.0	-10.0, -10.0	-50.0, 20.0
Week 52						
m	64	28	95			
n	13	6	27	1	1	5
Mean (SD/SE)	14.23 (23.62)	16.67 (31.41)	16.20 (24.70)	55.00 (N/A)	0.00 (N/A)	-4.00 (12.08)
Median	0	5.00	10.00	55.00	0	0
IQR: Q1, Q3	0.00, 20.00	0.00, 10.00	0.00, 20.00	55.00, 55.00	0.00, 0.00	0.00, 10.00
Min, Max	0.0, 70.0	0.0, 80.0	0.0, 87.5	55.0, 55.0	0.0, 0.0	-50.0, 20.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.4.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=73)	Visit Result: MGL-3196 100 mg (N=32)	Visit Result: Placebo (N=105)	Change from Baseline: MGL-3196 80 mg (N=73)	Change from Baseline: MGL-3196 100 mg (N=32)	Change from Baseline: Placebo (N=105)
Activity Impairment						
Baseline						
m	73	32	105			
n	7	2	10			
Mean (SD)	25.7 (37.8)	30.0 (28.3)	22.0 (29.7)			
Median	0	30.0	5.0			
IQR: Q1, Q3	0.0, 80.0	10.0, 50.0	0.0, 50.0			
Min, Max	0, 80	10, 50	0, 70			
Week 24						
m	70	31	102			
n	29	8	42	6	1	10
Mean (SD/SE)	16.2 (24.7)	7.5 (11.6)	12.9 (19.9)	-8.3 (4.0)	0.0 (N/A)	-11.0 (8.5)
Median	0	0	0	-5.0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 15.0	0.0, 20.0	-20.0, 0.0	0.0, 0.0	-10.0, 0.0
Min, Max	0, 70	0, 30	0, 70	-20, 0	0, 0	-70, 10
Week 52						
m	64	28	95			
n	38	11	58	3	1	8
Mean (SD/SE)	16.1 (25.4)	27.3 (28.3)	14.5 (20.3)	3.3 (3.3)	0.0 (N/A)	-11.3 (10.9)
Median	0	20.0	5.0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 50.0	0.0, 20.0	0.0, 10.0	0.0, 0.0	-25.0, 10.0
Min, Max	0, 90	0, 80	0, 80	0, 10	0, 0	-70, 10

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.4.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.4.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Absenteeism			
Week 24			
m	91	110	187
n	19	21	37
Baseline Mean (SD)	4.78 (10.48)	0.23 (1.05)	1.99 (6.89)
Analysis Visit Mean (SD)	1.54 (4.66)	1.67 (6.47)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-1.50 (0.98)	-0.68 (0.86)	-2.39 (0.68)
95% CI	(-3.45, 0.45)	(-2.39, 1.02)	(-3.73, -1.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.89 (1.13)	1.70 (1.06)	
95% CI	(-1.36, 3.13)	(-0.39, 3.80)	
p-value	0.4348	0.1101	
Corrected Hedge's g Statistics	0.210	0.416	
95% CI	(-0.34, 0.76)	(-0.13, 0.96)	
Week 52			
m	85	97	175
n	10	23	31
Baseline Mean (SD)	8.15 (13.58)	0.00 (0.00)	2.17 (7.46)
Analysis Visit Mean (SD)	3.33 (10.53)	6.40 (18.12)	4.44 (13.71)
LS Mean of Change from Baseline (SE)	-1.10 (4.52)	4.63 (2.98)	2.31 (2.51)
95% CI	(-10.08, 7.87)	(-1.29, 10.55)	(-2.67, 7.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.42 (5.16)	2.31 (3.89)	
95% CI	(-13.67, 6.84)	(-5.41, 10.03)	
p-value	0.5099	0.5534	
Corrected Hedge's g Statistics	-0.238	0.161	
95% CI	(-0.95, 0.48)	(-0.38, 0.70)	
Subgroup*Treatment Interaction p-value	0.7645	0.8997	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.4.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Presenteeism			
Week 24			
m	91	110	187
n	19	21	37
Baseline Mean (SD)	7.4 (20.5)	7.6 (11.8)	7.6 (17.2)
Analysis Visit Mean (SD)	15.8 (28.0)	12.4 (17.3)	9.7 (17.2)
LS Mean of Change from Baseline (SE)	6.90 (4.69)	4.82 (4.09)	1.34 (3.23)
95% CI	(-2.42, 16.22)	(-3.30, 12.94)	(-5.08, 7.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.56 (5.51)	3.48 (5.11)	
95% CI	(-5.38, 16.50)	(-6.68, 13.64)	
p-value	0.3152	0.4980	
Corrected Hedge's g Statistics	0.275	0.178	
95% CI	(-0.28, 0.83)	(-0.36, 0.71)	
Week 52			
m	85	97	175
n	10	23	31
Baseline Mean (SD)	14.0 (27.2)	8.7 (12.5)	7.4 (18.3)
Analysis Visit Mean (SD)	22.0 (31.6)	9.6 (14.3)	10.0 (19.0)
LS Mean of Change from Baseline (SE)	12.02 (5.39)	-0.39 (3.73)	1.81 (3.16)
95% CI	(1.31, 22.73)	(-7.79, 7.01)	(-4.46, 8.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.21 (6.10)	-2.20 (4.76)	
95% CI	(-1.90, 22.33)	(-11.66, 7.26)	
p-value	0.0976	0.6449	
Corrected Hedge's g Statistics	0.574	-0.123	
95% CI	(-0.15, 1.30)	(-0.66, 0.42)	
Subgroup*Treatment Interaction p-value	0.5883	0.9503	

AMNOG Table SE24.4.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Overall Work Impairment			
Week 24			
m	91	110	187
n	19	21	37
Baseline Mean (SD)	10.17 (24.17)	7.82 (11.87)	9.17 (18.97)
Analysis Visit Mean (SD)	16.38 (28.71)	13.89 (18.04)	9.73 (17.24)
LS Mean of Change from Baseline (SE)	5.95 (4.85)	3.91 (4.20)	-0.01 (3.34)
95% CI	(-3.67, 15.58)	(-4.43, 12.25)	(-6.64, 6.61)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.97 (5.64)	3.92 (5.23)	
95% CI	(-5.23, 17.17)	(-6.47, 14.32)	
p-value	0.2928	0.4556	
Corrected Hedge's g Statistics	0.286	0.194	
95% CI	(-0.27, 0.84)	(-0.34, 0.73)	
Week 52			
m	85	97	175
n	10	23	31
Baseline Mean (SD)	18.39 (31.64)	8.70 (12.54)	9.19 (20.05)
Analysis Visit Mean (SD)	23.66 (33.56)	15.04 (22.20)	13.11 (23.88)
LS Mean of Change from Baseline (SE)	11.57 (6.98)	4.23 (4.78)	3.51 (4.06)
95% CI	(-2.28, 25.43)	(-5.26, 13.72)	(-4.56, 11.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.07 (7.93)	0.72 (6.16)	
95% CI	(-7.68, 23.81)	(-11.50, 12.95)	
p-value	0.3115	0.9070	
Corrected Hedge's g Statistics	0.352	0.031	
95% CI	(-0.37, 1.07)	(-0.51, 0.57)	
Subgroup*Treatment Interaction p-value	0.9805	0.7592	

AMNOG Table SE24.4.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: US

Parameter Visit Statistic	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Activity Impairment			
Week 24			
m	91	110	187
n	45	46	69
Baseline Mean (SD)	10.2 (19.6)	11.5 (16.3)	15.1 (24.0)
Analysis Visit Mean (SD)	17.8 (23.5)	13.0 (17.7)	16.7 (24.0)
LS Mean of Change from Baseline (SE)	5.34 (2.93)	-0.10 (2.86)	2.22 (2.34)
95% CI	(-0.45, 11.12)	(-5.74, 5.53)	(-2.39, 6.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.11 (3.66)	-2.33 (3.62)	
95% CI	(-4.11, 10.33)	(-9.47, 4.82)	
p-value	0.3963	0.5214	
Corrected Hedge's g Statistics	0.158	-0.119	
95% CI	(-0.22, 0.53)	(-0.49, 0.25)	
Week 52			
m	85	97	175
n	28	40	55
Baseline Mean (SD)	17.1 (24.6)	12.8 (16.6)	17.1 (25.9)
Analysis Visit Mean (SD)	17.9 (20.8)	17.5 (19.2)	13.5 (18.1)
LS Mean of Change from Baseline (SE)	3.48 (3.19)	3.37 (2.68)	-2.37 (2.26)
95% CI	(-2.81, 9.78)	(-1.92, 8.66)	(-6.84, 2.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.86 (3.81)	5.74 (3.45)	
95% CI	(-1.65, 13.36)	(-1.06, 12.55)	
p-value	0.1256	0.0977	
Corrected Hedge's g Statistics	0.345	0.338	
95% CI	(-0.11, 0.80)	(-0.07, 0.75)	
Subgroup*Treatment Interaction p-value	0.8401	0.9388	

AMNOG Table SE24.4.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Absenteeism			
Week 24			
m	70	31	102
n	2	1	8
Baseline Mean (SD)	0.00 (0.00)	0.00 (N/A)	12.50 (35.36)
Analysis Visit Mean (SD)	0.00 (0.00)	0.00 (N/A)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	64	28	95
n	1	1	5
Baseline Mean (SD)	0.00 (N/A)	0.00 (N/A)	0.00 (0.00)
Analysis Visit Mean (SD)	50.00 (N/A)	0.00 (N/A)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.7645	0.8997	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.4.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Presenteeism			
Week 24			
m	70	31	102
n	2	1	7
Baseline Mean (SD)	5.0 (7.1)	10.0 (N/A)	7.1 (18.9)
Analysis Visit Mean (SD)	0.0 (0.0)	0.0 (N/A)	4.3 (7.9)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	64	28	95
n	1	1	5
Baseline Mean (SD)	0.0 (N/A)	10.0 (N/A)	10.0 (22.4)
Analysis Visit Mean (SD)	10.0 (N/A)	10.0 (N/A)	6.0 (8.9)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.5883	0.9503	

AMNOG Table SE24.4.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Overall Work Impairment			
Week 24			
m	70	31	102
n	2	1	7
Baseline Mean (SD)	5.00 (7.07)	10.00 (N/A)	7.14 (18.90)
Analysis Visit Mean (SD)	0.00 (0.00)	0.00 (N/A)	4.29 (7.87)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	64	28	95
n	1	1	5
Baseline Mean (SD)	0.00 (N/A)	10.00 (N/A)	10.00 (22.36)
Analysis Visit Mean (SD)	55.00 (N/A)	10.00 (N/A)	6.00 (8.94)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.9805	0.7592	

AMNOG Table SE24.4.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Visit Statistic	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Activity Impairment			
Week 24			
m	70	31	102
n	6	1	10
Baseline Mean (SD)	30.0 (39.5)	10.0 (N/A)	22.0 (29.7)
Analysis Visit Mean (SD)	21.7 (33.7)	10.0 (N/A)	11.0 (21.8)
LS Mean of Change from Baseline (SE)	-6.21 (6.87)	3.11 (18.21)	-11.06 (5.60)
95% CI	(-20.95, 8.54)	(-35.95, 42.17)	(-23.07, 0.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.85 (8.78)	14.16 (19.06)	
95% CI	(-13.98, 23.68)	(-26.71, 55.04)	
p-value	0.5896	0.4697	
Corrected Hedge's g Statistics	0.263	0.731	
95% CI	(-0.75, 1.28)	(-1.35, 2.81)	
Week 52			
m	64	28	95
n	3	1	8
Baseline Mean (SD)	0.0 (0.0)	10.0 (N/A)	25.0 (32.5)
Analysis Visit Mean (SD)	3.3 (5.8)	10.0 (N/A)	13.8 (27.7)
LS Mean of Change from Baseline (SE)	-3.32 (7.77)	4.22 (20.61)	-10.09 (6.37)
95% CI	(-19.99, 13.35)	(-39.99, 48.43)	(-23.76, 3.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.77 (9.98)	14.31 (21.58)	
95% CI	(-14.63, 28.17)	(-31.98, 60.60)	
p-value	0.5086	0.5180	
Corrected Hedge's g Statistics	0.362	0.706	
95% CI	(-0.97, 1.70)	(-1.40, 2.81)	
Subgroup*Treatment Interaction p-value	0.8401	0.9388	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.4.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.4.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.1)	0	1 (0.5)
No	92 (97.9)	119 (100)	197 (99.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.23	NE	
95% CI of the inverse odds ratio	(0.02, 2.61)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.24	NE	
95% CI of the inverse risk ratio	(0.02, 2.59)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.62	-0.51	
95% CI of the absolute risk difference	(-1.46, 4.70)	(-1.49, 0.48)	
p-value	0.1989	0.4375	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (2.1)	0	2 (1.0)
No	92 (97.9)	119 (100)	196 (99.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse odds ratio	(0.07, 3.38)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse risk ratio	(0.07, 3.32)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.12	-1.01	
95% CI of the absolute risk difference	(-2.12, 4.35)	(-2.40, 0.38)	
p-value	0.4427	0.2714	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.4.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.1)	1 (0.8)	3 (1.5)
No	93 (98.9)	118 (99.2)	195 (98.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.82	
95% CI of the inverse odds ratio	(0.15, 13.94)	(0.19, 17.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.42	1.80	
95% CI of the inverse risk ratio	(0.15, 13.51)	(0.19, 17.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.45	-0.67	
95% CI of the absolute risk difference	(-3.13, 2.23)	(-3.04, 1.69)	
p-value	0.7566	0.6022	
p-value of Breslow-Day Test for Homogeneity [3]	0.5080	0.6828	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (3.2)	5 (4.2)	4 (2.0)
No	91 (96.8)	114 (95.8)	194 (98.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.47	
95% CI of the inverse odds ratio	(0.14, 2.85)	(0.12, 1.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.63	0.48	
95% CI of the inverse risk ratio	(0.14, 2.77)	(0.13, 1.76)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.17	2.18	
95% CI of the absolute risk difference	(-2.89, 5.23)	(-1.92, 6.28)	
p-value	0.5410	0.2575	
p-value of Breslow-Day Test for Homogeneity [3]	0.3231	0.4352	

AMNOG Table SE24.4.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.1)	1 (0.8)	3 (1.5)
No	92 (97.9)	118 (99.2)	195 (98.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.82	
95% CI of the inverse odds ratio	(0.12, 4.31)	(0.19, 17.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	1.80	
95% CI of the inverse risk ratio	(0.12, 4.19)	(0.19, 17.14)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.61	-0.67	
95% CI of the absolute risk difference	(-2.76, 3.99)	(-3.04, 1.69)	
p-value	0.7062	0.6022	
p-value of Breslow-Day Test for Homogeneity [3]	0.3584	0.6828	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (3.2)	4 (3.4)	5 (2.5)
No	91 (96.8)	115 (96.6)	193 (97.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.74	
95% CI of the inverse odds ratio	(0.18, 3.36)	(0.20, 2.83)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.79	0.75	
95% CI of the inverse risk ratio	(0.19, 3.24)	(0.21, 2.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.67	0.84	
95% CI of the absolute risk difference	(-3.51, 4.84)	(-3.07, 4.74)	
p-value	0.7445	0.6643	
p-value of Breslow-Day Test for Homogeneity [3]	0.3699	0.5289	

AMNOG Table SE24.4.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=94)	MGL-3196 100 mg (N=119)	Placebo (N=198)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (5.3)	3 (2.5)	10 (5.1)
No	89 (94.7)	116 (97.5)	188 (94.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	2.06	
95% CI of the inverse odds ratio	(0.31, 2.85)	(0.55, 7.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	2.00	
95% CI of the inverse risk ratio	(0.33, 2.70)	(0.56, 7.13)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.27	-2.53	
95% CI of the absolute risk difference	(-5.20, 5.74)	(-6.68, 1.62)	
p-value	0.9226	0.2715	
p-value of Breslow-Day Test for Homogeneity [3]	0.2449	0.5839	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (10.6)	8 (6.7)	14 (7.1)
No	84 (89.4)	111 (93.3)	184 (92.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.64	1.06	
95% CI of the inverse odds ratio	(0.27, 1.50)	(0.43, 2.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	1.05	
95% CI of the inverse risk ratio	(0.31, 1.44)	(0.45, 2.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.57	-0.35	
95% CI of the absolute risk difference	(-3.62, 10.75)	(-6.09, 5.40)	
p-value	0.2997	0.9060	
p-value of Breslow-Day Test for Homogeneity [3]	0.1567	0.4484	

AMNOG Table SE24.4.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	73 (100)	32 (100)	105 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	73 (100)	32 (100)	105 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.4.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (1.0)
No	73 (100)	32 (100)	104 (99.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.95	-0.95	
95% CI of the absolute risk difference	(-2.81, 0.91)	(-2.81, 0.91)	
p-value	0.4031	0.5795	
p-value of Breslow-Day Test for Homogeneity [3]	0.5080	0.6828	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (1.0)
No	73 (100)	32 (100)	104 (99.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.95	-0.95	
95% CI of the absolute risk difference	(-2.81, 0.91)	(-2.81, 0.91)	
p-value	0.4031	0.5795	
p-value of Breslow-Day Test for Homogeneity [3]	0.3231	0.4352	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.4.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (1.0)
No	73 (100)	32 (100)	104 (99.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.95	-0.95	
95% CI of the absolute risk difference	(-2.81, 0.91)	(-2.81, 0.91)	
p-value	0.4031	0.5795	
p-value of Breslow-Day Test for Homogeneity [3]	0.3584	0.6828	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (1.0)
No	73 (100)	32 (100)	104 (99.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.95	-0.95	
95% CI of the absolute risk difference	(-2.81, 0.91)	(-2.81, 0.91)	
p-value	0.4031	0.5795	
p-value of Breslow-Day Test for Homogeneity [3]	0.3699	0.5289	

AMNOG Table SE24.4.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Region
(Label Population)

Region: Ex-US

Parameter Response Statistic/Category	MGL-3196 80 mg (N=73)	MGL-3196 100 mg (N=32)	Placebo (N=105)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (1.9)
No	73 (100)	32 (100)	103 (98.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.90	-1.90	
95% CI of the absolute risk difference	(-4.52, 0.71)	(-4.52, 0.71)	
p-value	0.2357	0.4316	
p-value of Breslow-Day Test for Homogeneity [3]	0.2449	0.5839	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (1.9)
No	73 (100)	32 (100)	103 (98.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.90	-1.90	
95% CI of the absolute risk difference	(-4.52, 0.71)	(-4.52, 0.71)	
p-value	0.2357	0.4316	
p-value of Breslow-Day Test for Homogeneity [3]	0.1567	0.4484	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.5.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Absenteeism						
Baseline						
m	52	151	186			
n	12	44	51			
Mean (SD)	4.48 (9.15)	2.28 (10.97)	2.32 (14.04)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 3.50	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 26.7	0.0, 68.1	0.0, 100.0			
Week 24						
m	51	141	178			
n	17	42	56	8	22	32
Mean (SD/SE)	0.74 (3.03)	1.19 (5.09)	0.00 (0.00)	-4.28 (4.48)	1.38 (1.34)	-3.61 (3.13)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-10.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 12.5	0.0, 29.4	0.0, 0.0	-26.7, 12.5	0.0, 29.4	-100.0, 0.0
Week 52						
m	46	125	165			
n	16	48	63	5	24	26
Mean (SD/SE)	0.00 (0.00)	3.78 (13.15)	3.13 (11.51)	-9.34 (5.82)	6.14 (3.63)	1.42 (1.36)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-20.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 66.7	0.0, 51.6	-26.7, 0.0	0.0, 66.7	-9.1, 30.8

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.5.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Presenteeism						
Baseline						
m	52	151	186			
n	12	44	50			
Mean (SD)	10.8 (21.1)	10.2 (15.9)	7.0 (16.6)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 15.0	0.0, 10.0	0.0, 0.0			
Min, Max	0, 70	0, 70	0, 70			
Week 24						
m	51	141	178			
n	17	42	56	8	22	31
Mean (SD/SE)	9.4 (23.0)	11.2 (17.8)	7.5 (15.4)	5.0 (13.1)	4.1 (4.2)	2.3 (3.3)
Median	0	5.0	0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 10.0	-5.0, 0.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 90	0, 80	0, 70	-40, 90	-30, 60	-60, 70
Week 52						
m	46	125	165			
n	16	48	63	5	24	26
Mean (SD/SE)	10.0 (15.1)	11.0 (19.9)	7.8 (15.0)	0.0 (11.4)	0.8 (2.8)	3.8 (3.8)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 15.0	0.0, 10.0	-10.0, 0.0	0.0, 0.0	0.0, 10.0
Min, Max	0, 40	0, 90	0, 80	-30, 40	-40, 30	-40, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.5.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Overall Work Impairment						
Baseline						
m	52	151	186			
n	12	44	50			
Mean (SD)	13.92 (23.27)	12.25 (18.82)	7.30 (16.75)			
Median	0	5.00	0			
IQR: Q1, Q3	0.00, 25.00	0.00, 17.15	0.00, 0.00			
Min, Max	0.0, 76.0	0.0, 70.0	0.0, 70.0			
Week 24						
m	51	141	178			
n	17	42	56	8	22	31
Mean (SD/SE)	9.49 (23.33)	12.23 (18.48)	7.50 (15.40)	1.41 (14.39)	5.33 (4.31)	1.82 (3.36)
Median	0	5.00	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 20.00	0.00, 10.00	-17.00, 0.00	0.00, 10.00	0.00, 0.00
Min, Max	0.0, 91.3	0.0, 80.0	0.0, 70.0	-46.0, 91.3	-30.0, 60.0	-60.0, 70.0
Week 52						
m	46	125	165			
n	16	48	63	5	24	26
Mean (SD/SE)	10.00 (15.06)	14.02 (23.49)	10.20 (19.05)	-6.00 (13.91)	6.08 (4.46)	4.32 (4.15)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 20.00	0.00, 20.00	0.00, 10.00	-34.00, 0.00	0.00, 6.25	0.00, 10.00
Min, Max	0.0, 40.0	0.0, 91.2	0.0, 83.0	-36.0, 40.0	-40.0, 63.4	-40.0, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.5.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=52)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=186)	Change from Baseline MGL-3196 80 mg (N=52)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=186)
Activity Impairment						
Baseline						
m	52	151	186			
n	19	75	89			
Mean (SD)	17.4 (26.0)	12.7 (18.0)	15.6 (24.8)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0			
Min, Max	0, 70	0, 80	0, 100			
Week 24						
m	51	141	178			
n	27	73	89	13	47	53
Mean (SD/SE)	11.9 (20.9)	11.4 (16.3)	12.6 (20.4)	1.5 (6.0)	1.5 (2.9)	0.0 (2.5)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0	0.0, 0.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 80	0, 70	0, 80	-40, 50	-60, 70	-70, 70
Week 52						
m	46	125	165			
n	31	80	100	10	41	44
Mean (SD/SE)	18.7 (22.6)	16.1 (21.0)	12.8 (19.5)	-2.0 (8.4)	4.6 (2.8)	-1.1 (3.1)
Median	10.0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 30.0	0.0, 20.0	-20.0, 0.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 80	0, 80	0, 80	-40, 50	-50, 40	-70, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.5.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Absenteeism						
Baseline						
m	115	0	117			
n	16	0	16			
Mean (SD)	2.76 (8.86)	N/A	3.64 (10.07)			
Median	0	N/A	0			
IQR: Q1, Q3	0.00, 0.00	N/A	0.00, 0.00			
Min, Max	0.0, 34.8	N/A	0.0, 33.3			
Week 24						
m	110	0	111			
n	24	0	28	13	0	13
Mean (SD/SE)	1.32 (4.48)	N/A	0.00 (0.00)	-2.12 (1.51)	N/A	-4.48 (3.07)
Median	0	N/A	0	0	N/A	0
IQR: Q1, Q3	0.00, 0.00	N/A	0.00, 0.00	0.00, 0.00	N/A	0.00, 0.00
Min, Max	0.0, 16.7	N/A	0.0, 0.0	-18.1, 0.0	N/A	-33.3, 0.0
Week 52						
m	103	0	105			
n	21	0	33	6	0	10
Mean (SD/SE)	6.55 (16.16)	N/A	5.05 (17.55)	8.08 (8.39)	N/A	3.34 (7.78)
Median	0	N/A	0	0	N/A	0
IQR: Q1, Q3	0.00, 0.00	N/A	0.00, 0.00	0.00, 0.00	N/A	0.00, 0.00
Min, Max	0.0, 50.0	N/A	0.0, 75.0	-1.5, 50.0	N/A	-33.3, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.5.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Presenteeism						
Baseline						
m	115	0	117			
n	16	0	16			
Mean (SD)	4.4 (15.0)	N/A	9.4 (13.9)			
Median	0	N/A	5.0			
IQR: Q1, Q3	0.0, 0.0	N/A	0.0, 10.0			
Min, Max	0, 60	N/A	0, 50			
Week 24						
m	110	0	111			
n	24	0	28	13	0	13
Mean (SD/SE)	11.3 (19.4)	N/A	7.1 (15.4)	8.5 (7.1)	N/A	-0.8 (6.5)
Median	0	N/A	0	0	N/A	0
IQR: Q1, Q3	0.0, 15.0	N/A	0.0, 10.0	0.0, 10.0	N/A	-10.0, 0.0
Min, Max	0, 80	N/A	0, 60	-20, 80	N/A	-50, 50
Week 52						
m	103	0	105			
n	21	0	33	6	0	10
Mean (SD/SE)	13.8 (24.6)	N/A	7.3 (17.0)	15.0 (15.2)	N/A	-4.0 (6.9)
Median	0	N/A	0	0	N/A	0
IQR: Q1, Q3	0.0, 20.0	N/A	0.0, 0.0	0.0, 10.0	N/A	0.0, 0.0
Min, Max	0, 90	N/A	0, 70	-10, 90	N/A	-50, 30

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.5.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Overall Work Impairment						
Baseline						
m	115	0	117			
n	16	0	16			
Mean (SD)	5.83 (18.45)	N/A	12.24 (17.89)			
Median	0	N/A	5.00			
IQR: Q1, Q3	0.00, 0.00	N/A	0.00, 15.00			
Min, Max	0.0, 73.9	N/A	0.0, 53.3			
Week 24						
m	110	0	111			
n	24	0	28	13	0	13
Mean (SD/SE)	12.17 (20.51)	N/A	7.14 (15.36)	7.44 (7.27)	N/A	-4.29 (7.16)
Median	0	N/A	0	0	N/A	0
IQR: Q1, Q3	0.00, 15.00	N/A	0.00, 10.00	0.00, 10.00	N/A	-10.00, 0.00
Min, Max	0.0, 80.0	N/A	0.0, 60.0	-23.9, 80.0	N/A	-50.0, 50.0
Week 52						
m	103	0	105			
n	21	0	33	6	0	10
Mean (SD/SE)	18.33 (29.45)	N/A	10.68 (24.12)	22.95 (16.35)	N/A	-1.08 (10.92)
Median	0	N/A	0	0	N/A	0
IQR: Q1, Q3	0.00, 30.00	N/A	0.00, 0.00	0.00, 55.00	N/A	0.00, 0.00
Min, Max	0.0, 90.0	N/A	0.0, 87.5	-7.3, 90.0	N/A	-53.3, 70.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.5.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=115)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=117)	Change from Baseline MGL-3196 80 mg (N=115)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=117)
Activity Impairment						
Baseline						
m	115	0	117			
n	46	0	34			
Mean (SD)	13.7 (23.4)	N/A	22.6 (28.1)			
Median	0	N/A	10.0			
IQR: Q1, Q3	0.0, 20.0	N/A	0.0, 50.0			
Min, Max	0, 80	N/A	0, 100			
Week 24						
m	110	0	111			
n	63	0	63	38	0	26
Mean (SD/SE)	17.6 (23.1)	N/A	20.3 (26.0)	7.1 (3.8)	N/A	0.0 (5.3)
Median	0	N/A	10.0	0	N/A	0
IQR: Q1, Q3	0.0, 30.0	N/A	0.0, 30.0	0.0, 10.0	N/A	-10.0, 20.0
Min, Max	0, 80	N/A	0, 100	-30, 80	N/A	-80, 50
Week 52						
m	103	0	105			
n	61	0	68	21	0	19
Mean (SD/SE)	13.8 (21.8)	N/A	15.0 (20.7)	2.4 (4.6)	N/A	-12.6 (6.4)
Median	0	N/A	10.0	0	N/A	0
IQR: Q1, Q3	0.0, 20.0	N/A	0.0, 25.0	-10.0, 10.0	N/A	-40.0, 0.0
Min, Max	0, 90	N/A	0, 100	-40, 60	N/A	-90, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.5.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.5.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Absenteeism			
Week 24			
m	51	141	178
n	8	22	32
Baseline Mean (SD)	5.84 (10.96)	0.22 (1.02)	3.61 (17.69)
Analysis Visit Mean (SD)	1.56 (4.42)	1.60 (6.33)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-0.60 (1.42)	-0.72 (0.84)	-1.88 (0.77)
95% CI	(-3.44, 2.24)	(-2.38, 0.95)	(-3.40, -0.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.28 (1.56)	1.16 (1.09)	
95% CI	(-1.83, 4.38)	(-1.02, 3.33)	
p-value	0.4151	0.2932	
Corrected Hedge's g Statistics	0.292	0.273	
95% CI	(-0.48, 1.07)	(-0.27, 0.82)	
Week 52			
m	46	125	165
n	5	24	26
Baseline Mean (SD)	9.34 (13.01)	0.00 (0.00)	0.35 (1.78)
Analysis Visit Mean (SD)	0.00 (0.00)	6.14 (17.77)	1.77 (6.62)
LS Mean of Change from Baseline (SE)	0.31 (5.75)	4.15 (2.48)	-0.30 (2.32)
95% CI	(-11.15, 11.77)	(-0.79, 9.09)	(-4.93, 4.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.61 (6.42)	4.45 (3.29)	
95% CI	(-12.18, 13.40)	(-2.10, 11.00)	
p-value	0.9245	0.1797	
Corrected Hedge's g Statistics	0.050	0.365	
95% CI	(-0.91, 1.01)	(-0.19, 0.92)	
Subgroup*Treatment Interaction p-value	0.9747	NE	

AMNOG Table SE24.5.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Presenteeism			
Week 24			
m	51	141	178
n	8	22	31
Baseline Mean (SD)	10.0 (24.5)	7.7 (11.5)	6.5 (18.2)
Analysis Visit Mean (SD)	15.0 (32.1)	11.8 (17.1)	8.7 (16.7)
LS Mean of Change from Baseline (SE)	5.45 (6.58)	4.02 (3.87)	0.95 (3.43)
95% CI	(-7.67, 18.56)	(-3.69, 11.74)	(-5.87, 7.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.49 (7.28)	3.07 (5.08)	
95% CI	(-10.01, 19.00)	(-7.06, 13.20)	
p-value	0.5389	0.5477	
Corrected Hedge's g Statistics	0.232	0.162	
95% CI	(-0.55, 1.01)	(-0.39, 0.71)	
Week 52			
m	46	125	165
n	5	24	26
Baseline Mean (SD)	16.0 (30.5)	8.8 (12.3)	6.9 (19.3)
Analysis Visit Mean (SD)	16.0 (21.9)	9.6 (14.0)	10.8 (19.6)
LS Mean of Change from Baseline (SE)	8.29 (6.77)	0.05 (3.26)	2.81 (3.13)
95% CI	(-5.19, 21.76)	(-6.44, 6.54)	(-3.42, 9.05)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.47 (7.37)	-2.76 (4.34)	
95% CI	(-9.20, 20.15)	(-11.41, 5.89)	
p-value	0.4597	0.5270	
Corrected Hedge's g Statistics	0.336	-0.170	
95% CI	(-0.62, 1.30)	(-0.73, 0.39)	
Subgroup*Treatment Interaction p-value	0.8425	NE	

AMNOG Table SE24.5.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Overall Work Impairment			
Week 24			
m	51	141	178
n	8	22	31
Baseline Mean (SD)	13.75 (27.82)	7.92 (11.60)	6.89 (18.34)
Analysis Visit Mean (SD)	15.16 (32.51)	13.25 (17.86)	8.71 (16.68)
LS Mean of Change from Baseline (SE)	4.34 (6.87)	3.85 (4.04)	0.47 (3.61)
95% CI	(-9.34, 18.03)	(-4.20, 11.91)	(-6.73, 7.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.88 (7.57)	3.39 (5.30)	
95% CI	(-11.21, 18.97)	(-7.17, 13.95)	
p-value	0.6101	0.5245	
Corrected Hedge's g Statistics	0.190	0.170	
95% CI	(-0.59, 0.97)	(-0.38, 0.72)	
Week 52			
m	46	125	165
n	5	24	26
Baseline Mean (SD)	22.00 (33.59)	8.75 (12.27)	7.27 (19.30)
Analysis Visit Mean (SD)	16.00 (21.91)	14.83 (21.74)	11.60 (21.37)
LS Mean of Change from Baseline (SE)	6.20 (9.03)	4.96 (4.22)	2.95 (4.06)
95% CI	(-11.80, 24.20)	(-3.44, 13.36)	(-5.13, 11.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.24 (9.84)	2.01 (5.68)	
95% CI	(-16.35, 22.84)	(-9.30, 13.31)	
p-value	0.7425	0.7246	
Corrected Hedge's g Statistics	0.153	0.096	
95% CI	(-0.80, 1.11)	(-0.46, 0.65)	
Subgroup*Treatment Interaction p-value	0.4516	NE	

AMNOG Table SE24.5.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Activity Impairment			
Week 24			
m	51	141	178
n	13	47	53
Baseline Mean (SD)	13.8 (26.3)	11.5 (16.1)	12.5 (23.9)
Analysis Visit Mean (SD)	15.4 (25.4)	13.0 (17.6)	12.5 (20.8)
LS Mean of Change from Baseline (SE)	0.41 (4.52)	-0.18 (2.44)	-0.42 (2.32)
95% CI	(-8.52, 9.34)	(-5.01, 4.66)	(-5.01, 4.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.83 (5.01)	0.24 (3.25)	
95% CI	(-9.08, 10.73)	(-6.20, 6.68)	
p-value	0.8692	0.9413	
Corrected Hedge's g Statistics	0.049	0.014	
95% CI	(-0.56, 0.66)	(-0.38, 0.41)	
Week 52			
m	46	125	165
n	10	41	44
Baseline Mean (SD)	25.0 (30.3)	12.7 (16.4)	15.2 (25.6)
Analysis Visit Mean (SD)	23.0 (19.5)	17.3 (19.0)	14.1 (21.5)
LS Mean of Change from Baseline (SE)	3.65 (5.17)	3.18 (2.62)	-0.58 (2.51)
95% CI	(-6.58, 13.88)	(-1.99, 8.36)	(-5.54, 4.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.23 (5.66)	3.76 (3.51)	
95% CI	(-6.96, 15.42)	(-3.19, 10.71)	
p-value	0.4560	0.2863	
Corrected Hedge's g Statistics	0.251	0.223	
95% CI	(-0.44, 0.94)	(-0.20, 0.65)	
Subgroup*Treatment Interaction p-value	0.5516	NE	

AMNOG Table SE24.5.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Absenteeism			
Week 24			
m	110	0	111
n	13	0	13
Baseline Mean (SD)	3.40 (9.79)	N/A	4.48 (11.08)
Analysis Visit Mean (SD)	1.28 (4.63)	N/A	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-3.09 (0.94)	NE	-4.67 (0.76)
95% CI	(-5.02, -1.16)	NE	(-6.24, -3.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.58 (1.27)	NE	
95% CI	(-1.05, 4.21)	NE	
p-value	0.2268	NE	
Corrected Hedge's g Statistics	0.498	NE	
95% CI	(-0.28, 1.28)	NE	
Week 52			
m	103	0	105
n	6	0	10
Baseline Mean (SD)	5.80 (14.21)	N/A	5.83 (12.45)
Analysis Visit Mean (SD)	13.88 (22.15)	N/A	9.17 (21.69)
LS Mean of Change from Baseline (SE)	7.02 (8.95)	NE	4.71 (6.96)
95% CI	(-11.46, 25.50)	NE	(-9.66, 19.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.31 (11.32)	NE	
95% CI	(-21.05, 25.68)	NE	
p-value	0.8398	NE	
Corrected Hedge's g Statistics	0.100	NE	
95% CI	(-0.91, 1.11)	NE	
Subgroup*Treatment Interaction p-value	0.9747	NE	

AMNOG Table SE24.5.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Presenteeism			
Week 24			
m	110	0	111
n	13	0	13
Baseline Mean (SD)	5.4 (16.6)	N/A	10.0 (15.3)
Analysis Visit Mean (SD)	13.8 (24.7)	N/A	9.2 (15.5)
LS Mean of Change from Baseline (SE)	2.17 (7.12)	NE	0.40 (5.82)
95% CI	(-12.52, 16.87)	NE	(-11.60, 12.41)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.77 (9.58)	NE	
95% CI	(-18.01, 21.55)	NE	
p-value	0.8550	NE	
Corrected Hedge's g Statistics	0.073	NE	
95% CI	(-0.70, 0.84)	NE	
Week 52			
m	103	0	105
n	6	0	10
Baseline Mean (SD)	10.0 (24.5)	N/A	10.0 (17.0)
Analysis Visit Mean (SD)	25.0 (37.3)	N/A	6.0 (12.6)
LS Mean of Change from Baseline (SE)	7.10 (8.46)	NE	-2.81 (6.32)
95% CI	(-10.35, 24.55)	NE	(-15.86, 10.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.91 (10.82)	NE	
95% CI	(-12.42, 32.24)	NE	
p-value	0.3690	NE	
Corrected Hedge's g Statistics	0.462	NE	
95% CI	(-0.56, 1.49)	NE	
Subgroup*Treatment Interaction p-value	0.8425	NE	

AMNOG Table SE24.5.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Overall Work Impairment			
Week 24			
m	110	0	111
n	13	0	13
Baseline Mean (SD)	7.18 (20.37)	N/A	13.52 (19.62)
Analysis Visit Mean (SD)	14.62 (25.70)	N/A	9.23 (15.53)
LS Mean of Change from Baseline (SE)	5.24 (7.35)	NE	-3.18 (6.02)
95% CI	(-9.92, 20.41)	NE	(-15.60, 9.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.42 (9.90)	NE	
95% CI	(-12.01, 28.85)	NE	
p-value	0.4033	NE	
Corrected Hedge's g Statistics	0.337	NE	
95% CI	(-0.44, 1.11)	NE	
Week 52			
m	103	0	105
n	6	0	10
Baseline Mean (SD)	12.32 (30.17)	N/A	14.58 (22.04)
Analysis Visit Mean (SD)	35.27 (40.24)	N/A	13.50 (26.25)
LS Mean of Change from Baseline (SE)	9.47 (9.49)	NE	2.48 (8.05)
95% CI	(-10.13, 29.06)	NE	(-14.13, 19.08)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.99 (12.74)	NE	
95% CI	(-19.30, 33.28)	NE	
p-value	0.5882	NE	
Corrected Hedge's g Statistics	0.268	NE	
95% CI	(-0.75, 1.28)	NE	
Subgroup*Treatment Interaction p-value	0.4516	NE	

AMNOG Table SE24.5.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Visit Statistic	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Activity Impairment			
Week 24			
m	110	0	111
n	38	0	26
Baseline Mean (SD)	12.1 (22.3)	N/A	23.1 (25.3)
Analysis Visit Mean (SD)	19.2 (24.5)	N/A	23.1 (27.7)
LS Mean of Change from Baseline (SE)	4.04 (4.13)	NE	2.87 (4.54)
95% CI	(-4.21, 12.28)	NE	(-6.20, 11.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.17 (6.12)	NE	
95% CI	(-11.05, 13.39)	NE	
p-value	0.8488	NE	
Corrected Hedge's g Statistics	0.047	NE	
95% CI	(-0.45, 0.55)	NE	
Week 52			
m	103	0	105
n	21	0	19
Baseline Mean (SD)	11.0 (19.5)	N/A	24.7 (28.6)
Analysis Visit Mean (SD)	13.3 (20.3)	N/A	12.1 (13.2)
LS Mean of Change from Baseline (SE)	-1.88 (4.12)	NE	-8.52 (3.92)
95% CI	(-10.09, 6.34)	NE	(-16.34, -0.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.64 (5.64)	NE	
95% CI	(-4.62, 17.90)	NE	
p-value	0.2430	NE	
Corrected Hedge's g Statistics	0.361	NE	
95% CI	(-0.26, 0.99)	NE	
Subgroup*Treatment Interaction p-value	0.5516	NE	

AMNOG Table SE24.5.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.5.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.8)	0	0
No	50 (96.2)	151 (100)	186 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.85	NE	
95% CI of the absolute risk difference	(-1.38, 9.07)	NE	
p-value	0.0072	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0199	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (3.8)	0	1 (0.5)
No	50 (96.2)	151 (100)	185 (99.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	NE	
95% CI of the inverse odds ratio	(0.01, 1.52)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.14	NE	
95% CI of the inverse risk ratio	(0.01, 1.51)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.31	-0.54	
95% CI of the absolute risk difference	(-2.02, 8.64)	(-1.59, 0.51)	
p-value	0.0587	0.3669	
p-value of Breslow-Day Test for Homogeneity [3]	0.0716	NE	

AMNOG Table SE24.5.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.9)	1 (0.7)	2 (1.1)
No	51 (98.1)	150 (99.3)	184 (98.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	1.63	
95% CI of the inverse odds ratio	(0.05, 6.24)	(0.15, 18.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	1.62	
95% CI of the inverse risk ratio	(0.05, 6.05)	(0.15, 17.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.85	-0.41	
95% CI of the absolute risk difference	(-3.17, 4.86)	(-2.38, 1.55)	
p-value	0.6281	0.6881	
p-value of Breslow-Day Test for Homogeneity [3]	0.1435	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (3.8)	5 (3.3)	3 (1.6)
No	50 (96.2)	146 (96.7)	183 (98.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.41	0.48	
95% CI of the inverse odds ratio	(0.07, 2.52)	(0.11, 2.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.42	0.49	
95% CI of the inverse risk ratio	(0.07, 2.44)	(0.12, 2.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.23	1.70	
95% CI of the absolute risk difference	(-3.30, 7.76)	(-1.68, 5.08)	
p-value	0.3209	0.3085	
p-value of Breslow-Day Test for Homogeneity [3]	0.2907	NE	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.5.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.8)	1 (0.7)	2 (1.1)
No	50 (96.2)	150 (99.3)	184 (98.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	1.63	
95% CI of the inverse odds ratio	(0.04, 1.98)	(0.15, 18.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	1.62	
95% CI of the inverse risk ratio	(0.04, 1.94)	(0.15, 17.73)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.77	-0.41	
95% CI of the absolute risk difference	(-2.66, 8.20)	(-2.38, 1.55)	
p-value	0.1694	0.6881	
p-value of Breslow-Day Test for Homogeneity [3]	0.0520	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (3.8)	4 (2.6)	4 (2.2)
No	50 (96.2)	147 (97.4)	182 (97.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	0.81	
95% CI of the inverse odds ratio	(0.10, 3.09)	(0.20, 3.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.81	
95% CI of the inverse risk ratio	(0.11, 2.97)	(0.21, 3.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.70	0.50	
95% CI of the absolute risk difference	(-3.93, 7.32)	(-2.80, 3.80)	
p-value	0.4905	0.7650	
p-value of Breslow-Day Test for Homogeneity [3]	0.3858	NE	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.5.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: > 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=52)	MGL-3196 100 mg (N=151)	Placebo (N=186)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (5.8)	3 (2.0)	6 (3.2)
No	49 (94.2)	148 (98.0)	180 (96.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	1.64	
95% CI of the inverse odds ratio	(0.13, 2.26)	(0.40, 6.69)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	1.62	
95% CI of the inverse risk ratio	(0.14, 2.16)	(0.41, 6.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.54	-1.24	
95% CI of the absolute risk difference	(-4.28, 9.37)	(-4.62, 2.14)	
p-value	0.3953	0.4829	
p-value of Breslow-Day Test for Homogeneity [3]	0.1039	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (7.7)	8 (5.3)	8 (4.3)
No	48 (92.3)	143 (94.7)	178 (95.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	0.80	
95% CI of the inverse odds ratio	(0.16, 1.87)	(0.29, 2.19)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.81	
95% CI of the inverse risk ratio	(0.18, 1.78)	(0.31, 2.11)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.39	1.00	
95% CI of the absolute risk difference	(-4.42, 11.20)	(-3.61, 5.61)	
p-value	0.3231	0.6687	
p-value of Breslow-Day Test for Homogeneity [3]	0.2783	NE	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.5.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (0.9)
No	115 (100)	0	116 (99.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.85	NE	
95% CI of the absolute risk difference	(-2.52, 0.81)	NE	
p-value	0.3204	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0199	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (0.9)
No	115 (100)	0	116 (99.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.85	NE	
95% CI of the absolute risk difference	(-2.52, 0.81)	NE	
p-value	0.3204	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0716	NE	

AMNOG Table SE24.5.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (1.7)
No	115 (100)	0	115 (98.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.71	NE	
95% CI of the absolute risk difference	(-4.06, 0.64)	NE	
p-value	0.1591	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1435	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (0.9)	0	2 (1.7)
No	114 (99.1)	0	115 (98.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.98	NE	
95% CI of the inverse odds ratio	(0.18, 22.17)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.97	NE	
95% CI of the inverse risk ratio	(0.18, 21.38)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.84	NE	
95% CI of the absolute risk difference	(-3.74, 2.06)	NE	
p-value	0.5713	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2907	NE	

AMNOG Table SE24.5.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (1.7)
No	115 (100)	0	115 (98.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.71	NE	
95% CI of the absolute risk difference	(-4.06, 0.64)	NE	
p-value	0.1591	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0520	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (0.9)	0	2 (1.7)
No	114 (99.1)	0	115 (98.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.98	NE	
95% CI of the inverse odds ratio	(0.18, 22.17)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.97	NE	
95% CI of the inverse risk ratio	(0.18, 21.38)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.84	NE	
95% CI of the absolute risk difference	(-3.74, 2.06)	NE	
p-value	0.5713	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3858	NE	

AMNOG Table SE24.5.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight
(Label Population)

Weight: <= 200 lbs

Parameter Response Statistic/Category	MGL-3196 80 mg (N=115)	MGL-3196 100 mg (N=0)	Placebo (N=117)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (1.7)	0	6 (5.1)
No	113 (98.3)	0	111 (94.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.05	NE	
95% CI of the inverse odds ratio	(0.60, 15.46)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.95	NE	
95% CI of the inverse risk ratio	(0.61, 14.31)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.39	NE	
95% CI of the absolute risk difference	(-8.05, 1.27)	NE	
p-value	0.1572	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1039	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (5.2)	0	8 (6.8)
No	109 (94.8)	0	109 (93.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.33	NE	
95% CI of the inverse odds ratio	(0.45, 3.97)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.31	NE	
95% CI of the inverse risk ratio	(0.47, 3.66)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.62	NE	
95% CI of the absolute risk difference	(-7.74, 4.50)	NE	
p-value	0.6043	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2783	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.6.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Absenteeism						
Baseline						
m	7	0	8			
n	0	0	1			
Mean (SD)	N/A	N/A	0.00 (N/A)			
Median	N/A	N/A	0			
IQR: Q1, Q3	N/A	N/A	0.00, 0.00			
Min, Max	N/A	N/A	0.0, 0.0			
Week 24						
m	6	0	7			
n	0	0	1	0	0	0
Mean (SD/SE)	N/A	N/A	0.00 (N/A)	N/A	N/A	N/A
Median	N/A	N/A	0	N/A	N/A	N/A
IQR: Q1, Q3	N/A	N/A	0.00, 0.00	N/A	N/A	N/A
Min, Max	N/A	N/A	0.0, 0.0	N/A	N/A	N/A
Week 52						
m	6	0	6			
n	0	0	2	0	0	1
Mean (SD/SE)	N/A	N/A	0.00 (0.00)	N/A	N/A	0.00 (N/A)
Median	N/A	N/A	0	N/A	N/A	0
IQR: Q1, Q3	N/A	N/A	0.00, 0.00	N/A	N/A	0.00, 0.00
Min, Max	N/A	N/A	0.0, 0.0	N/A	N/A	0.0, 0.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.6.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Presenteeism						
Baseline						
m	7	0	8			
n	0	0	1			
Mean (SD)	N/A	N/A	0.0 (N/A)			
Median	N/A	N/A	0			
IQR: Q1, Q3	N/A	N/A	0.0, 0.0			
Min, Max	N/A	N/A	0, 0			
Week 24						
m	6	0	7			
n	0	0	1	0	0	0
Mean (SD/SE)	N/A	N/A	0.0 (N/A)	N/A	N/A	N/A
Median	N/A	N/A	0	N/A	N/A	N/A
IQR: Q1, Q3	N/A	N/A	0.0, 0.0	N/A	N/A	N/A
Min, Max	N/A	N/A	0, 0	N/A	N/A	N/A
Week 52						
m	6	0	6			
n	0	0	2	0	0	1
Mean (SD/SE)	N/A	N/A	0.0 (0.0)	N/A	N/A	0.0 (N/A)
Median	N/A	N/A	0	N/A	N/A	0
IQR: Q1, Q3	N/A	N/A	0.0, 0.0	N/A	N/A	0.0, 0.0
Min, Max	N/A	N/A	0, 0	N/A	N/A	0, 0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.6.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Overall Work Impairment						
Baseline						
m	7	0	8			
n	0	0	1			
Mean (SD)	N/A	N/A	0.00 (N/A)			
Median	N/A	N/A	0			
IQR: Q1, Q3	N/A	N/A	0.00, 0.00			
Min, Max	N/A	N/A	0.0, 0.0			
Week 24						
m	6	0	7			
n	0	0	1	0	0	0
Mean (SD/SE)	N/A	N/A	0.00 (N/A)	N/A	N/A	N/A
Median	N/A	N/A	0	N/A	N/A	N/A
IQR: Q1, Q3	N/A	N/A	0.00, 0.00	N/A	N/A	N/A
Min, Max	N/A	N/A	0.0, 0.0	N/A	N/A	N/A
Week 52						
m	6	0	6			
n	0	0	2	0	0	1
Mean (SD/SE)	N/A	N/A	0.00 (0.00)	N/A	N/A	0.00 (N/A)
Median	N/A	N/A	0	N/A	N/A	0
IQR: Q1, Q3	N/A	N/A	0.00, 0.00	N/A	N/A	0.00, 0.00
Min, Max	N/A	N/A	0.0, 0.0	N/A	N/A	0.0, 0.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.6.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=7)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=8)	Change from Baseline MGL-3196 80 mg (N=7)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=8)
Activity Impairment						
Baseline						
m	7	0	8			
n	1	0	1			
Mean (SD)	0.0 (N/A)	N/A	0.0 (N/A)			
Median	0	N/A	0			
IQR: Q1, Q3	0.0, 0.0	N/A	0.0, 0.0			
Min, Max	0, 0	N/A	0, 0			
Week 24						
m	6	0	7			
n	4	0	3	1	0	0
Mean (SD/SE)	22.5 (32.0)	N/A	16.7 (28.9)	10.0 (N/A)	N/A	N/A
Median	10.0	N/A	0	10.0	N/A	N/A
IQR: Q1, Q3	5.0, 40.0	N/A	0.0, 50.0	10.0, 10.0	N/A	N/A
Min, Max	0, 70	N/A	0, 50	10, 10	N/A	N/A
Week 52						
m	6	0	6			
n	3	0	5	0	0	1
Mean (SD/SE)	26.7 (46.2)	N/A	20.0 (21.2)	N/A	N/A	0.0 (N/A)
Median	0	N/A	20.0	N/A	N/A	0
IQR: Q1, Q3	0.0, 80.0	N/A	0.0, 30.0	N/A	N/A	0.0, 0.0
Min, Max	0, 80	N/A	0, 50	N/A	N/A	0, 0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.6.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Absenteeism						
Baseline						
m	47	0	62			
n	6	0	6			
Mean (SD)	0.00 (0.00)	N/A	0.00 (0.00)			
Median	0	N/A	0			
IQR: Q1, Q3	0.00, 0.00	N/A	0.00, 0.00			
Min, Max	0.0, 0.0	N/A	0.0, 0.0			
Week 24						
m	46	0	59			
n	9	0	14	5	0	5
Mean (SD/SE)	0.00 (0.00)	N/A	0.00 (0.00)	0.00 (0.00)	N/A	0.00 (0.00)
Median	0	N/A	0	0	N/A	0
IQR: Q1, Q3	0.00, 0.00	N/A	0.00, 0.00	0.00, 0.00	N/A	0.00, 0.00
Min, Max	0.0, 0.0	N/A	0.0, 0.0	0.0, 0.0	N/A	0.0, 0.0
Week 52						
m	44	0	56			
n	11	0	14	3	0	3
Mean (SD/SE)	4.55 (15.08)	N/A	10.12 (25.78)	0.00 (0.00)	N/A	22.23 (22.23)
Median	0	N/A	0	0	N/A	0
IQR: Q1, Q3	0.00, 0.00	N/A	0.00, 0.00	0.00, 0.00	N/A	0.00, 66.70
Min, Max	0.0, 50.0	N/A	0.0, 75.0	0.0, 0.0	N/A	0.0, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.6.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Presenteeism						
Baseline						
m	47	0	62			
n	6	0	6			
Mean (SD)	0.0 (0.0)	N/A	1.7 (4.1)			
Median	0	N/A	0			
IQR: Q1, Q3	0.0, 0.0	N/A	0.0, 0.0			
Min, Max	0, 0	N/A	0, 10			
Week 24						
m	46	0	59			
n	9	0	14	5	0	5
Mean (SD/SE)	3.3 (7.1)	N/A	5.7 (15.0)	2.0 (2.0)	N/A	16.0 (10.3)
Median	0	N/A	0	0	N/A	0
IQR: Q1, Q3	0.0, 0.0	N/A	0.0, 0.0	0.0, 0.0	N/A	0.0, 30.0
Min, Max	0, 20	N/A	0, 50	0, 10	N/A	0, 50
Week 52						
m	44	0	56			
n	11	0	14	3	0	3
Mean (SD/SE)	7.3 (14.2)	N/A	10.7 (21.6)	0.0 (0.0)	N/A	3.3 (3.3)
Median	0	N/A	0	0	N/A	0
IQR: Q1, Q3	0.0, 10.0	N/A	0.0, 10.0	0.0, 0.0	N/A	0.0, 10.0
Min, Max	0, 40	N/A	0, 70	0, 0	N/A	0, 10

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.6.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Overall Work Impairment						
Baseline						
m	47	0	62			
n	6	0	6			
Mean (SD)	0.00 (0.00)	N/A	1.67 (4.08)			
Median	0	N/A	0			
IQR: Q1, Q3	0.00, 0.00	N/A	0.00, 0.00			
Min, Max	0.0, 0.0	N/A	0.0, 10.0			
Week 24						
m	46	0	59			
n	9	0	14	5	0	5
Mean (SD/SE)	3.33 (7.07)	N/A	5.71 (15.05)	2.00 (2.00)	N/A	16.00 (10.30)
Median	0	N/A	0	0	N/A	0
IQR: Q1, Q3	0.00, 0.00	N/A	0.00, 0.00	0.00, 0.00	N/A	0.00, 30.00
Min, Max	0.0, 20.0	N/A	0.0, 50.0	0.0, 10.0	N/A	0.0, 50.0
Week 52						
m	44	0	56			
n	11	0	14	3	0	3
Mean (SD/SE)	10.00 (21.91)	N/A	17.68 (31.96)	0.00 (0.00)	N/A	23.33 (23.33)
Median	0	N/A	0	0	N/A	0
IQR: Q1, Q3	0.00, 10.00	N/A	0.00, 10.00	0.00, 0.00	N/A	0.00, 70.00
Min, Max	0.0, 70.0	N/A	0.0, 87.5	0.0, 0.0	N/A	0.0, 70.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.6.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=47)	Visit Result MGL-3196 100 mg (N=0)	Visit Result Placebo (N=62)	Change from Baseline MGL-3196 80 mg (N=47)	Change from Baseline MGL-3196 100 mg (N=0)	Change from Baseline Placebo (N=62)
Activity Impairment						
Baseline						
m	47	0	62			
n	20	0	19			
Mean (SD)	14.5 (28.0)	N/A	25.3 (31.7)			
Median	0	N/A	10.0			
IQR: Q1, Q3	0.0, 15.0	N/A	0.0, 60.0			
Min, Max	0, 80	N/A	0, 100			
Week 24						
m	46	0	59			
n	27	0	32	17	0	15
Mean (SD/SE)	17.4 (25.5)	N/A	16.9 (25.5)	2.9 (4.2)	N/A	-2.0 (7.6)
Median	0	N/A	0	0	N/A	0
IQR: Q1, Q3	0.0, 20.0	N/A	0.0, 30.0	0.0, 0.0	N/A	-10.0, 20.0
Min, Max	0, 80	N/A	0, 100	-20, 60	N/A	-80, 40
Week 52						
m	44	0	56			
n	30	0	34	10	0	10
Mean (SD/SE)	11.0 (17.9)	N/A	14.4 (19.6)	5.0 (6.7)	N/A	-11.0 (9.2)
Median	0	N/A	10.0	0	N/A	0
IQR: Q1, Q3	0.0, 10.0	N/A	0.0, 20.0	0.0, 10.0	N/A	-10.0, 0.0
Min, Max	0, 70	N/A	0, 70	-20, 60	N/A	-90, 10

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.6.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Absenteeism						
Baseline						
m	113	151	233			
n	22	44	60			
Mean (SD)	4.45 (9.82)	2.28 (10.97)	2.94 (13.87)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 34.8	0.0, 68.1	0.0, 100.0			
Week 24						
m	109	141	223			
n	32	42	69	16	22	40
Mean (SD/SE)	1.38 (4.40)	1.19 (5.09)	0.00 (0.00)	-3.86 (2.46)	1.38 (1.34)	-4.34 (2.67)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-4.70, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 16.7	0.0, 29.4	0.0, 0.0	-26.7, 12.5	0.0, 29.4	-100.0, 0.0
Week 52						
m	99	125	208			
n	26	48	80	8	24	32
Mean (SD/SE)	3.37 (11.55)	3.78 (13.15)	2.78 (10.58)	0.23 (8.03)	6.14 (3.63)	0.11 (1.55)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-10.75, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 66.7	0.0, 51.6	-26.7, 50.0	0.0, 66.7	-33.3, 30.8

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.6.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Presenteeism						
Baseline						
m	113	151	233			
n	22	44	59			
Mean (SD)	9.1 (19.7)	10.2 (15.9)	8.3 (16.6)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 10.0			
Min, Max	0, 70	0, 70	0, 70			
Week 24						
m	109	141	223			
n	32	42	69	16	22	39
Mean (SD/SE)	12.5 (22.9)	11.2 (17.8)	7.8 (15.5)	8.8 (8.5)	4.1 (4.2)	-0.5 (3.1)
Median	0	5.0	0	0	0	0
IQR: Q1, Q3	0.0, 15.0	0.0, 20.0	0.0, 10.0	-5.0, 5.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 90	0, 80	0, 70	-40, 90	-30, 60	-60, 70
Week 52						
m	99	125	208			
n	26	48	80	8	24	32
Mean (SD/SE)	14.2 (23.0)	11.0 (19.9)	7.3 (14.6)	11.3 (13.3)	0.8 (2.8)	1.6 (3.8)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 15.0	0.0, 10.0	-10.0, 25.0	0.0, 0.0	0.0, 5.0
Min, Max	0, 90	0, 90	0, 80	-30, 90	-40, 30	-50, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.6.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Overall Work Impairment						
Baseline						
m	113	151	233			
n	22	44	59			
Mean (SD)	11.83 (22.73)	12.25 (18.82)	9.33 (17.79)			
Median	0	5.00	0			
IQR: Q1, Q3	0.00, 10.00	0.00, 17.15	0.00, 10.00			
Min, Max	0.0, 76.0	0.0, 70.0	0.0, 70.0			
Week 24						
m	109	141	223			
n	32	42	69	16	22	39
Mean (SD/SE)	13.23 (23.66)	12.23 (18.48)	7.83 (15.52)	6.13 (9.10)	5.33 (4.31)	-2.03 (3.21)
Median	0	5.00	0	0	0	0
IQR: Q1, Q3	0.00, 20.00	0.00, 20.00	0.00, 10.00	-9.70, 5.00	0.00, 10.00	-9.10, 0.00
Min, Max	0.0, 91.3	0.0, 80.0	0.0, 70.0	-46.0, 91.3	-30.0, 60.0	-60.0, 70.0
Week 52						
m	99	125	208			
n	26	48	80	8	24	32
Mean (SD/SE)	16.73 (25.48)	14.02 (23.49)	9.35 (18.42)	13.46 (15.69)	6.08 (4.46)	0.99 (4.20)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 30.00	0.00, 20.00	0.00, 10.00	-20.65, 47.50	0.00, 6.25	0.00, 5.00
Min, Max	0.0, 90.0	0.0, 91.2	0.0, 83.0	-36.0, 90.0	-40.0, 63.4	-53.3, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.6.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=113)	Visit Result MGL-3196 100 mg (N=151)	Visit Result Placebo (N=233)	Change from Baseline MGL-3196 80 mg (N=113)	Change from Baseline MGL-3196 100 mg (N=151)	Change from Baseline Placebo (N=233)
Activity Impairment						
Baseline						
m	113	151	233			
n	44	75	103			
Mean (SD)	15.2 (22.6)	12.7 (18.0)	16.3 (24.6)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0			
Min, Max	0, 80	0, 80	0, 100			
Week 24						
m	109	141	223			
n	59	73	117	33	47	64
Mean (SD/SE)	14.7 (20.7)	11.4 (16.3)	15.5 (22.5)	7.0 (4.5)	1.5 (2.9)	0.5 (2.4)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0	0.0, 20.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 80	0, 70	0, 80	-40, 80	-60, 70	-70, 70
Week 52						
m	99	125	208			
n	59	80	129	21	41	52
Mean (SD/SE)	17.1 (22.7)	16.1 (21.0)	13.3 (20.2)	-1.0 (5.1)	4.6 (2.8)	-3.5 (3.1)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 30.0	0.0, 20.0	-10.0, 0.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 90	0, 80	0, 100	-40, 50	-50, 40	-70, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.6.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.6.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Absenteeism			
Week 24			
m	6	0	7
n	0	0	0
Baseline Mean (SD)	N/A	N/A	N/A
Analysis Visit Mean (SD)	N/A	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	6	0	6
n	0	0	1
Baseline Mean (SD)	N/A	N/A	0.00 (N/A)
Analysis Visit Mean (SD)	N/A	N/A	0.00 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.4828	NE	

AMNOG Table SE24.6.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Presenteeism			
Week 24			
m	6	0	7
n	0	0	0
Baseline Mean (SD)	N/A	N/A	N/A
Analysis Visit Mean (SD)	N/A	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	6	0	6
n	0	0	1
Baseline Mean (SD)	N/A	N/A	0.0 (N/A)
Analysis Visit Mean (SD)	N/A	N/A	0.0 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.1113	NE	

AMNOG Table SE24.6.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Overall Work Impairment			
Week 24			
m	6	0	7
n	0	0	0
Baseline Mean (SD)	N/A	N/A	N/A
Analysis Visit Mean (SD)	N/A	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	6	0	6
n	0	0	1
Baseline Mean (SD)	N/A	N/A	0.00 (N/A)
Analysis Visit Mean (SD)	N/A	N/A	0.00 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.0960	NE	

AMNOG Table SE24.6.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Activity Impairment			
Week 24			
m	6	0	7
n	1	0	0
Baseline Mean (SD)	0.0 (N/A)	N/A	N/A
Analysis Visit Mean (SD)	10.0 (N/A)	N/A	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	6	0	6
n	0	0	1
Baseline Mean (SD)	N/A	N/A	0.0 (N/A)
Analysis Visit Mean (SD)	N/A	N/A	0.0 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.8508	NE	

AMNOG Table SE24.6.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Absenteeism			
Week 24			
m	46	0	59
n	5	0	5
Baseline Mean (SD)	0.00 (0.00)	N/A	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (0.00)	N/A	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	44	0	56
n	3	0	3
Baseline Mean (SD)	0.00 (0.00)	N/A	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (0.00)	N/A	22.23 (38.51)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.4828	NE	

AMNOG Table SE24.6.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Presenteeism			
Week 24			
m	46	0	59
n	5	0	5
Baseline Mean (SD)	0.0 (0.0)	N/A	0.0 (0.0)
Analysis Visit Mean (SD)	2.0 (4.5)	N/A	16.0 (23.0)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	44	0	56
n	3	0	3
Baseline Mean (SD)	0.0 (0.0)	N/A	0.0 (0.0)
Analysis Visit Mean (SD)	0.0 (0.0)	N/A	3.3 (5.8)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.1113	NE	

AMNOG Table SE24.6.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Overall Work Impairment			
Week 24			
m	46	0	59
n	5	0	5
Baseline Mean (SD)	0.00 (0.00)	N/A	0.00 (0.00)
Analysis Visit Mean (SD)	2.00 (4.47)	N/A	16.00 (23.02)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	44	0	56
n	3	0	3
Baseline Mean (SD)	0.00 (0.00)	N/A	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (0.00)	N/A	23.33 (40.41)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.0960	NE	

AMNOG Table SE24.6.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Activity Impairment			
Week 24			
m	46	0	59
n	17	0	15
Baseline Mean (SD)	15.9 (30.0)	N/A	21.3 (26.4)
Analysis Visit Mean (SD)	18.8 (28.9)	N/A	19.3 (26.3)
LS Mean of Change from Baseline (SE)	1.52 (5.85)	NE	-1.33 (5.78)
95% CI	(-10.44, 13.49)	NE	(-13.15, 10.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.85 (8.14)	NE	
95% CI	(-13.80, 19.50)	NE	
p-value	0.7287	NE	
Corrected Hedge's g Statistics	0.119	NE	
95% CI	(-0.58, 0.81)	NE	
Week 52			
m	44	0	56
n	10	0	10
Baseline Mean (SD)	11.0 (22.8)	N/A	24.0 (31.7)
Analysis Visit Mean (SD)	16.0 (24.6)	N/A	13.0 (13.4)
LS Mean of Change from Baseline (SE)	0.19 (6.37)	NE	-8.03 (6.06)
95% CI	(-12.84, 13.23)	NE	(-20.43, 4.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.22 (8.91)	NE	
95% CI	(-10.01, 26.45)	NE	
p-value	0.3640	NE	
Corrected Hedge's g Statistics	0.400	NE	
95% CI	(-0.48, 1.29)	NE	
Subgroup*Treatment Interaction p-value	0.8508	NE	

AMNOG Table SE24.6.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Absenteeism			
Week 24			
m	109	141	223
n	16	22	40
Baseline Mean (SD)	5.68 (11.24)	0.22 (1.02)	4.34 (16.87)
Analysis Visit Mean (SD)	1.83 (5.05)	1.60 (6.33)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-1.03 (1.07)	-1.66 (0.84)	-2.89 (0.66)
95% CI	(-3.16, 1.09)	(-3.33, 0.02)	(-4.19, -1.58)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.85 (1.21)	1.23 (1.04)	
95% CI	(-0.54, 4.25)	(-0.84, 3.30)	
p-value	0.1275	0.2421	
Corrected Hedge's g Statistics	0.436	0.296	
95% CI	(-0.15, 1.02)	(-0.23, 0.82)	
Week 52			
m	99	125	208
n	8	24	32
Baseline Mean (SD)	10.19 (14.61)	0.00 (0.00)	2.11 (7.35)
Analysis Visit Mean (SD)	10.41 (19.79)	6.14 (17.77)	2.22 (7.28)
LS Mean of Change from Baseline (SE)	4.13 (4.38)	3.41 (2.60)	-0.71 (2.17)
95% CI	(-4.58, 12.84)	(-1.74, 8.57)	(-5.01, 3.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.84 (4.92)	4.12 (3.36)	
95% CI	(-4.92, 14.60)	(-2.55, 10.79)	
p-value	0.3277	0.2229	
Corrected Hedge's g Statistics	0.386	0.326	
95% CI	(-0.39, 1.17)	(-0.21, 0.86)	
Subgroup*Treatment Interaction p-value	0.4828	NE	

AMNOG Table SE24.6.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Presenteeism			
Week 24			
m	109	141	223
n	16	22	39
Baseline Mean (SD)	9.4 (22.1)	7.7 (11.5)	8.5 (18.1)
Analysis Visit Mean (SD)	18.1 (29.9)	11.8 (17.1)	7.9 (15.2)
LS Mean of Change from Baseline (SE)	6.24 (4.91)	3.60 (3.85)	-1.45 (3.02)
95% CI	(-3.52, 15.99)	(-4.05, 11.25)	(-7.45, 4.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.69 (5.62)	5.05 (4.81)	
95% CI	(-3.47, 18.85)	(-4.50, 14.60)	
p-value	0.1745	0.2963	
Corrected Hedge's g Statistics	0.397	0.268	
95% CI	(-0.19, 0.98)	(-0.26, 0.79)	
Week 52			
m	99	125	208
n	8	24	32
Baseline Mean (SD)	17.5 (29.6)	8.8 (12.3)	8.8 (19.5)
Analysis Visit Mean (SD)	28.8 (32.3)	9.6 (14.0)	10.3 (18.7)
LS Mean of Change from Baseline (SE)	15.24 (5.89)	-0.93 (3.60)	0.70 (3.05)
95% CI	(3.54, 26.94)	(-8.09, 6.23)	(-5.36, 6.76)
LS Mean of Change from Baseline Compared to Placebo (SE)	14.54 (6.52)	-1.63 (4.61)	
95% CI	(1.58, 27.49)	(-10.79, 7.52)	
p-value	0.0283	0.7240	
Corrected Hedge's g Statistics	0.830	-0.092	
95% CI	(0.03, 1.63)	(-0.62, 0.44)	
Subgroup*Treatment Interaction p-value	0.1113	NE	

AMNOG Table SE24.6.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain; by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter / Visit / Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Overall Work Impairment			
Week 24			
m	109	141	223
n	16	22	39
Baseline Mean (SD)	12.71 (25.82)	7.92 (11.60)	9.98 (19.65)
Analysis Visit Mean (SD)	18.83 (30.73)	13.25 (17.86)	7.95 (15.25)
LS Mean of Change from Baseline (SE)	6.30 (5.13)	2.34 (4.03)	-2.97 (3.14)
95% CI	(-3.88, 16.48)	(-5.66, 10.35)	(-9.21, 3.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.27 (5.83)	5.31 (5.01)	
95% CI	(-2.31, 20.84)	(-4.64, 15.26)	
p-value	0.1153	0.2921	
Corrected Hedge's g Statistics	0.459	0.271	
95% CI	(-0.13, 1.05)	(-0.25, 0.80)	
Week 52			
m	99	125	208
n	8	24	32
Baseline Mean (SD)	22.99 (34.15)	8.75 (12.27)	10.47 (21.00)
Analysis Visit Mean (SD)	36.45 (34.08)	14.83 (21.74)	11.45 (21.13)
LS Mean of Change from Baseline (SE)	18.75 (7.53)	3.20 (4.48)	0.12 (3.81)
95% CI	(3.79, 33.71)	(-5.70, 12.10)	(-7.45, 7.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	18.63 (8.33)	3.07 (5.78)	
95% CI	(2.08, 35.17)	(-8.40, 14.54)	
p-value	0.0278	0.5961	
Corrected Hedge's g Statistics	0.848	0.139	
95% CI	(0.05, 1.65)	(-0.39, 0.67)	
Subgroup*Treatment Interaction p-value	0.0960	NE	

AMNOG Table SE24.6.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Visit Statistic	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Activity Impairment			
Week 24			
m	109	141	223
n	33	47	64
Baseline Mean (SD)	11.2 (19.3)	11.5 (16.1)	14.7 (24.3)
Analysis Visit Mean (SD)	18.2 (22.8)	13.0 (17.6)	15.2 (23.2)
LS Mean of Change from Baseline (SE)	4.69 (3.32)	-0.26 (2.74)	1.13 (2.36)
95% CI	(-1.85, 11.24)	(-5.67, 5.15)	(-3.53, 5.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.56 (3.96)	-1.39 (3.53)	
95% CI	(-4.26, 11.38)	(-8.35, 5.57)	
p-value	0.3695	0.6938	
Corrected Hedge's g Statistics	0.187	-0.073	
95% CI	(-0.23, 0.61)	(-0.45, 0.30)	
Week 52			
m	99	125	208
n	21	41	52
Baseline Mean (SD)	17.6 (24.7)	12.7 (16.4)	17.3 (25.9)
Analysis Visit Mean (SD)	16.7 (18.5)	17.3 (19.0)	13.8 (20.4)
LS Mean of Change from Baseline (SE)	1.86 (3.68)	3.15 (2.66)	-2.27 (2.35)
95% CI	(-5.41, 9.13)	(-2.11, 8.40)	(-6.91, 2.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.13 (4.24)	5.42 (3.47)	
95% CI	(-4.25, 12.51)	(-1.42, 12.26)	
p-value	0.3321	0.1197	
Corrected Hedge's g Statistics	0.241	0.316	
95% CI	(-0.27, 0.75)	(-0.10, 0.73)	
Subgroup*Treatment Interaction p-value	0.8508	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.6.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.6.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.6.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.6.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.6.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: <25 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=7)	MGL-3196 100 mg (N=0)	Placebo (N=8)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8691	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	7 (100)	0	8 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4344	NE	

AMNOG Table SE24.6.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	47 (100)	0	62 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	47 (100)	0	62 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.6.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	47 (100)	0	62 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	47 (100)	0	62 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.6.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	47 (100)	0	62 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	47 (100)	0	62 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.6.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 25 - < 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=47)	MGL-3196 100 mg (N=0)	Placebo (N=62)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.1)	0	2 (3.2)
No	46 (97.9)	0	60 (96.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.53	NE	
95% CI of the inverse odds ratio	(0.13, 17.43)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	NE	
95% CI of the inverse risk ratio	(0.14, 16.22)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.10	NE	
95% CI of the absolute risk difference	(-7.13, 4.93)	NE	
p-value	0.7285	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.8691	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (4.3)	0	4 (6.5)
No	45 (95.7)	0	58 (93.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	NE	
95% CI of the inverse odds ratio	(0.27, 8.85)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	NE	
95% CI of the inverse risk ratio	(0.29, 7.93)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.20	NE	
95% CI of the absolute risk difference	(-10.60, 6.21)	NE	
p-value	0.6185	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4344	NE	

AMNOG Table SE24.6.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (1.8)	0	1 (0.4)
No	111 (98.2)	151 (100)	232 (99.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.24	NE	
95% CI of the inverse odds ratio	(0.02, 2.67)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.24	NE	
95% CI of the inverse risk ratio	(0.02, 2.65)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.34	-0.43	
95% CI of the absolute risk difference	(-1.23, 3.91)	(-1.27, 0.41)	
p-value	0.2071	0.4202	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (1.8)	0	2 (0.9)
No	111 (98.2)	151 (100)	231 (99.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse odds ratio	(0.07, 3.46)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse risk ratio	(0.07, 3.40)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.91	-0.86	
95% CI of the absolute risk difference	(-1.79, 3.62)	(-2.04, 0.33)	
p-value	0.4570	0.2537	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.6.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (0.9)	1 (0.7)	4 (1.7)
No	112 (99.1)	150 (99.3)	229 (98.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.96	2.62	
95% CI of the inverse odds ratio	(0.22, 17.71)	(0.29, 23.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.94	2.59	
95% CI of the inverse risk ratio	(0.22, 17.16)	(0.29, 22.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.83	-1.05	
95% CI of the absolute risk difference	(-3.23, 1.57)	(-3.17, 1.06)	
p-value	0.5432	0.3733	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (2.7)	5 (3.3)	5 (2.1)
No	110 (97.3)	146 (96.7)	228 (97.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	0.64	
95% CI of the inverse odds ratio	(0.19, 3.43)	(0.18, 2.25)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	0.65	
95% CI of the inverse risk ratio	(0.20, 3.32)	(0.19, 2.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.51	1.17	
95% CI of the absolute risk difference	(-2.99, 4.01)	(-2.24, 4.57)	
p-value	0.7677	0.4837	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.6.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (1.8)	1 (0.7)	4 (1.7)
No	111 (98.2)	150 (99.3)	229 (98.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	2.62	
95% CI of the inverse odds ratio	(0.17, 5.37)	(0.29, 23.67)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	2.59	
95% CI of the inverse risk ratio	(0.18, 5.22)	(0.29, 22.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.05	-1.05	
95% CI of the absolute risk difference	(-2.90, 3.00)	(-3.17, 1.06)	
p-value	0.9717	0.3733	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (2.7)	4 (2.6)	6 (2.6)
No	110 (97.3)	147 (97.4)	227 (97.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.97	
95% CI of the inverse odds ratio	(0.24, 3.95)	(0.27, 3.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.97	0.97	
95% CI of the inverse risk ratio	(0.25, 3.81)	(0.28, 3.39)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.08	0.07	
95% CI of the absolute risk difference	(-3.51, 3.67)	(-3.20, 3.34)	
p-value	0.9651	0.9646	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.6.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by BMI
(Label Population)

BMI: >= 30 kg/m2

Parameter Response Statistic/Category	MGL-3196 80 mg (N=113)	MGL-3196 100 mg (N=151)	Placebo (N=233)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.5)	3 (2.0)	10 (4.3)
No	109 (96.5)	148 (98.0)	223 (95.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.22	2.21	
95% CI of the inverse odds ratio	(0.37, 3.98)	(0.60, 8.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	2.16	
95% CI of the inverse risk ratio	(0.39, 3.78)	(0.60, 7.72)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.75	-2.31	
95% CI of the absolute risk difference	(-5.04, 3.54)	(-5.73, 1.12)	
p-value	0.7392	0.2225	
p-value of Breslow-Day Test for Homogeneity [3]	0.8691	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (7.1)	8 (5.3)	12 (5.2)
No	105 (92.9)	143 (94.7)	221 (94.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.97	
95% CI of the inverse odds ratio	(0.28, 1.80)	(0.39, 2.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	0.97	
95% CI of the inverse risk ratio	(0.31, 1.73)	(0.41, 2.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.93	0.15	
95% CI of the absolute risk difference	(-3.59, 7.44)	(-4.41, 4.71)	
p-value	0.4708	0.9492	
p-value of Breslow-Day Test for Homogeneity [3]	0.4344	NE	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.7.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=118)	Visit Result: MGL-3196 100 mg (N=100)	Visit Result: Placebo (N=201)	Change from Baseline: MGL-3196 80 mg (N=118)	Change from Baseline: MGL-3196 100 mg (N=100)	Change from Baseline: Placebo (N=201)
Absenteeism						
Baseline						
m	118	100	201			
n	23	29	45			
Mean (SD)	3.39 (9.04)	0.94 (5.07)	3.12 (15.31)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 34.8	0.0, 27.3	0.0, 100.0			
Week 24						
m	115	92	189			
n	34	28	54	18	13	31
Mean (SD/SE)	1.30 (4.27)	1.59 (6.14)	0.00 (0.00)	-2.32 (1.97)	2.26 (2.26)	-4.53 (3.30)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 16.7	0.0, 29.4	0.0, 0.0	-26.7, 12.5	0.0, 29.4	-100.0, 0.0
Week 52						
m	107	81	176			
n	28	27	57	9	16	24
Mean (SD/SE)	4.76 (14.24)	5.36 (16.72)	3.36 (11.86)	2.42 (6.63)	7.64 (5.25)	0.25 (0.75)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 66.7	0.0, 51.6	-26.7, 50.0	0.0, 66.7	-9.1, 15.1

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.7.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Presenteeism						
Baseline						
m	118	100	201			
n	23	29	44			
Mean (SD)	3.5 (12.7)	11.7 (18.7)	4.1 (12.1)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 0.0			
Min, Max	0, 60	0, 70	0, 70			
Week 24						
m	115	92	189			
n	34	28	54	18	13	30
Mean (SD/SE)	10.6 (22.0)	9.6 (13.5)	8.1 (16.1)	10.6 (7.0)	5.4 (5.6)	4.0 (3.5)
Median	0	5.0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 10.0	0.0, 10.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 90	0, 60	0, 70	-20, 90	-30, 60	-60, 70
Week 52						
m	107	81	176			
n	28	27	57	9	16	24
Mean (SD/SE)	11.4 (22.2)	13.0 (19.8)	6.8 (14.0)	8.9 (10.3)	2.5 (4.1)	5.0 (4.1)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 15.0	0.0, 20.0	0.0, 10.0	0.0, 0.0	0.0, 10.0	0.0, 5.0
Min, Max	0, 90	0, 80	0, 80	-10, 90	-40, 30	-40, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.7.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Overall Work Impairment						
Baseline						
m	118	100	201			
n	23	29	44			
Mean (SD)	5.84 (16.61)	12.29 (19.82)	4.91 (13.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 10.00	0.00, 0.00			
Min, Max	0.0, 73.9	0.0, 70.0	0.0, 70.0			
Week 24						
m	115	92	189			
n	34	28	54	18	13	30
Mean (SD/SE)	11.27 (22.86)	11.02 (14.85)	8.15 (16.14)	8.56 (7.48)	7.42 (5.82)	2.80 (3.54)
Median	0	5.00	0	0	0	0
IQR: Q1, Q3	0.00, 10.00	0.00, 20.00	0.00, 10.00	0.00, 10.00	0.00, 10.00	0.00, 0.00
Min, Max	0.0, 91.3	0.0, 60.0	0.0, 70.0	-34.0, 91.3	-30.0, 60.0	-60.0, 70.0
Week 52						
m	107	81	176			
n	28	27	57	9	16	24
Mean (SD/SE)	14.70 (26.60)	17.38 (24.99)	9.46 (18.69)	11.52 (12.44)	8.96 (6.56)	4.43 (4.19)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 25.00	0.00, 30.00	0.00, 10.00	0.00, 0.00	0.00, 25.00	0.00, 5.00
Min, Max	0.0, 90.0	0.0, 80.0	0.0, 83.0	-34.0, 90.0	-40.0, 63.4	-40.0, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.7.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=118)	Visit Result MGL-3196 100 mg (N=100)	Visit Result Placebo (N=201)	Change from Baseline MGL-3196 80 mg (N=118)	Change from Baseline MGL-3196 100 mg (N=100)	Change from Baseline Placebo (N=201)
Activity Impairment						
Baseline						
m	118	100	201			
n	51	51	80			
Mean (SD)	12.0 (21.3)	13.3 (19.5)	17.3 (27.4)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 20.0	0.0, 20.0	0.0, 20.0			
Min, Max	0, 80	0, 80	0, 100			
Week 24						
m	115	92	189			
n	69	48	102	39	29	53
Mean (SD/SE)	15.1 (22.1)	10.2 (13.9)	18.1 (24.6)	7.4 (3.4)	-0.7 (3.6)	-0.4 (3.3)
Median	0	10.0	10.0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 15.0	0.0, 30.0	0.0, 20.0	-10.0, 10.0	0.0, 0.0
Min, Max	0, 80	0, 60	0, 100	-30, 60	-60, 60	-80, 70
Week 52						
m	107	81	176			
n	72	52	111	26	26	42
Mean (SD/SE)	14.2 (21.4)	16.9 (20.2)	15.8 (21.3)	1.9 (4.4)	6.2 (3.9)	-4.5 (4.1)
Median	0	10.0	10.0	0	5.0	0
IQR: Q1, Q3	0.0, 25.0	0.0, 30.0	0.0, 30.0	-10.0, 10.0	0.0, 20.0	-10.0, 10.0
Min, Max	0, 90	0, 80	0, 100	-40, 60	-50, 40	-90, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.7.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Absenteeism						
Baseline						
m	49	51	102			
n	5	15	22			
Mean (SD)	4.00 (8.94)	4.86 (17.54)	1.65 (7.10)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 20.0	0.0, 68.1	0.0, 33.3			
Week 24						
m	46	49	100			
n	7	14	30	3	9	14
Mean (SD/SE)	0.00 (0.00)	0.41 (1.52)	0.00 (0.00)	-6.67 (6.67)	0.10 (0.10)	-2.38 (2.38)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-20.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 5.7	0.0, 0.0	-20.0, 0.0	0.0, 0.9	-33.3, 0.0
Week 52						
m	42	44	94			
n	9	21	39	2	8	12
Mean (SD/SE)	0.48 (1.43)	1.75 (5.92)	4.42 (16.43)	-10.00 (10.00)	3.13 (3.13)	5.35 (6.83)
Median	0	0	0	-10.00	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-20.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 4.3	0.0, 25.0	0.0, 75.0	-20.0, 0.0	0.0, 25.0	-33.3, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.7.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Presenteeism						
Baseline						
m	49	51	102			
n	5	15	22			
Mean (SD)	24.0 (28.8)	7.3 (8.0)	14.5 (20.2)			
Median	20.0	10.0	5.0			
IQR: Q1, Q3	0.0, 30.0	0.0, 10.0	0.0, 20.0			
Min, Max	0, 70	0, 20	0, 70			
Week 24						
m	46	49	100			
n	7	14	30	3	9	14
Mean (SD/SE)	10.0 (14.1)	14.3 (24.7)	6.0 (13.8)	-13.3 (13.3)	2.2 (6.6)	-4.3 (5.7)
Median	0	5.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 10.0	0.0, 0.0	-40.0, 0.0	-10.0, 0.0	-10.0, 0.0
Min, Max	0, 30	0, 80	0, 50	-40, 0	-20, 50	-50, 50
Week 52						
m	42	44	94			
n	9	21	39	2	8	12
Mean (SD/SE)	14.4 (16.7)	8.6 (20.3)	8.7 (17.8)	5.0 (35.0)	-2.5 (1.6)	-5.0 (5.6)
Median	10.0	0	0	5.0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 10.0	0.0, 10.0	-30.0, 40.0	-5.0, 0.0	-10.0, 5.0
Min, Max	0, 40	0, 90	0, 70	-30, 40	-10, 0	-50, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.7.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Overall Work Impairment						
Baseline						
m	49	51	102			
n	5	15	22			
Mean (SD)	25.20 (31.23)	12.16 (17.37)	15.67 (21.69)			
Median	20.00	10.00	5.00			
IQR: Q1, Q3	0.00, 30.00	0.00, 20.00	0.00, 20.00			
Min, Max	0.0, 76.0	0.0, 68.1	0.0, 70.0			
Week 24						
m	46	49	100			
n	7	14	30	3	9	14
Mean (SD/SE)	10.00 (14.14)	14.65 (24.69)	6.00 (13.80)	-15.33 (15.33)	2.31 (6.62)	-5.95 (6.28)
Median	0	5.00	0	0	0	0
IQR: Q1, Q3	0.00, 30.00	0.00, 15.10	0.00, 0.00	-46.00, 0.00	-10.00, 0.80	-10.00, 0.00
Min, Max	0.0, 30.0	0.0, 80.0	0.0, 50.0	-46.0, 0.0	-20.0, 50.0	-50.0, 50.0
Week 52						
m	42	44	94			
n	9	21	39	2	8	12
Mean (SD/SE)	14.82 (16.85)	9.70 (21.21)	11.69 (23.76)	2.00 (38.00)	0.31 (2.14)	-0.40 (9.62)
Median	10.00	0	0	2.00	0	0
IQR: Q1, Q3	0.00, 23.40	0.00, 10.00	0.00, 10.00	-36.00, 40.00	0.00, 0.00	-10.00, 5.00
Min, Max	0.0, 40.0	0.0, 91.2	0.0, 87.5	-36.0, 40.0	-10.0, 12.5	-53.3, 70.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.7.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=49)	Visit Result MGL-3196 100 mg (N=51)	Visit Result Placebo (N=102)	Change from Baseline MGL-3196 80 mg (N=49)	Change from Baseline MGL-3196 100 mg (N=51)	Change from Baseline Placebo (N=102)
Activity Impairment						
Baseline						
m	49	51	102			
n	14	24	43			
Mean (SD)	25.0 (31.1)	11.3 (14.5)	18.1 (23.0)			
Median	15.0	10.0	10.0			
IQR: Q1, Q3	0.0, 30.0	0.0, 15.0	0.0, 40.0			
Min, Max	0, 80	0, 50	0, 80			
Week 24						
m	46	49	100			
n	21	25	50	12	18	26
Mean (SD/SE)	18.6 (24.3)	13.6 (20.2)	11.0 (18.9)	0.0 (8.3)	5.0 (4.9)	0.8 (3.0)
Median	10.0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0	-15.0, 0.0	0.0, 10.0	-10.0, 10.0
Min, Max	0, 80	0, 70	0, 80	-40, 80	-20, 70	-50, 30
Week 52						
m	42	44	94			
n	20	28	57	5	15	21
Mean (SD/SE)	20.0 (24.5)	14.6 (22.5)	9.6 (16.5)	-4.0 (11.2)	2.0 (3.4)	-4.8 (3.4)
Median	15.0	0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 10.0	-10.0, 0.0	-10.0, 0.0	0.0, 0.0
Min, Max	0, 80	0, 80	0, 70	-40, 30	-10, 40	-50, 10

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.7.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.7.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Absenteeism			
Week 24			
m	115	92	189
n	18	13	31
Baseline Mean (SD)	3.94 (10.10)	0.00 (0.00)	4.53 (18.36)
Analysis Visit Mean (SD)	1.62 (4.78)	2.26 (8.15)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-0.71 (1.04)	-0.90 (1.18)	-2.71 (0.80)
95% CI	(-2.78, 1.37)	(-3.26, 1.45)	(-4.31, -1.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.01 (1.31)	1.81 (1.42)	
95% CI	(-0.60, 4.62)	(-1.01, 4.63)	
p-value	0.1290	0.2054	
Corrected Hedge's g Statistics	0.446	0.404	
95% CI	(-0.14, 1.03)	(-0.25, 1.06)	
Week 52			
m	107	81	176
n	9	16	24
Baseline Mean (SD)	6.83 (13.71)	0.00 (0.00)	1.42 (5.35)
Analysis Visit Mean (SD)	9.26 (18.83)	7.64 (20.98)	1.67 (5.85)
LS Mean of Change from Baseline (SE)	3.40 (4.18)	5.27 (3.40)	-0.71 (2.64)
95% CI	(-4.94, 11.73)	(-1.51, 12.05)	(-5.98, 4.56)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.10 (5.00)	5.98 (4.26)	
95% CI	(-5.87, 14.08)	(-2.52, 14.47)	
p-value	0.4149	0.1650	
Corrected Hedge's g Statistics	0.312	0.444	
95% CI	(-0.46, 1.08)	(-0.20, 1.08)	
Subgroup*Treatment Interaction p-value	0.3263	0.5604	

AMNOG Table SE24.7.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Presenteeism			
Week 24			
m	115	92	189
n	18	13	30
Baseline Mean (SD)	4.4 (14.2)	6.9 (13.8)	4.0 (13.8)
Analysis Visit Mean (SD)	15.0 (28.5)	12.3 (16.4)	8.0 (15.2)
LS Mean of Change from Baseline (SE)	9.00 (4.48)	6.66 (4.99)	1.89 (3.49)
95% CI	(0.07, 17.93)	(-3.30, 16.61)	(-5.06, 8.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.10 (5.65)	4.76 (6.02)	
95% CI	(-4.17, 18.37)	(-7.25, 16.77)	
p-value	0.2129	0.4318	
Corrected Hedge's g Statistics	0.367	0.249	
95% CI	(-0.22, 0.96)	(-0.40, 0.90)	
Week 52			
m	107	81	176
n	9	16	24
Baseline Mean (SD)	7.8 (19.9)	8.8 (14.1)	4.2 (14.7)
Analysis Visit Mean (SD)	16.7 (32.0)	11.3 (16.3)	9.2 (18.6)
LS Mean of Change from Baseline (SE)	10.03 (5.50)	2.50 (5.02)	4.41 (3.78)
95% CI	(-0.94, 21.00)	(-7.51, 12.52)	(-3.12, 11.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.62 (6.64)	-1.91 (6.20)	
95% CI	(-7.63, 18.87)	(-14.27, 10.45)	
p-value	0.4003	0.7592	
Corrected Hedge's g Statistics	0.305	-0.098	
95% CI	(-0.47, 1.07)	(-0.73, 0.54)	
Subgroup*Treatment Interaction p-value	0.7197	0.7932	

AMNOG Table SE24.7.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Overall Work Impairment			
Week 24			
m	115	92	189
n	18	13	30
Baseline Mean (SD)	7.07 (18.64)	6.92 (13.77)	5.20 (14.98)
Analysis Visit Mean (SD)	15.63 (29.35)	14.35 (17.69)	8.00 (15.18)
LS Mean of Change from Baseline (SE)	9.49 (4.67)	5.80 (5.24)	0.73 (3.64)
95% CI	(0.19, 18.80)	(-4.65, 16.25)	(-6.53, 7.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.77 (5.90)	5.07 (6.31)	
95% CI	(-3.01, 20.54)	(-7.50, 17.65)	
p-value	0.1421	0.4238	
Corrected Hedge's g Statistics	0.434	0.254	
95% CI	(-0.16, 1.02)	(-0.40, 0.91)	
Week 52			
m	107	81	176
n	9	16	24
Baseline Mean (SD)	11.99 (25.80)	8.75 (14.08)	5.48 (15.77)
Analysis Visit Mean (SD)	23.51 (36.38)	17.71 (25.12)	9.92 (20.38)
LS Mean of Change from Baseline (SE)	12.31 (7.01)	8.26 (6.06)	3.86 (4.66)
95% CI	(-1.67, 26.29)	(-3.84, 20.35)	(-5.43, 13.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.45 (8.40)	4.39 (7.56)	
95% CI	(-8.31, 25.20)	(-10.69, 19.48)	
p-value	0.3182	0.5632	
Corrected Hedge's g Statistics	0.368	0.184	
95% CI	(-0.40, 1.14)	(-0.45, 0.82)	
Subgroup*Treatment Interaction p-value	0.1960	0.5038	

AMNOG Table SE24.7.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Activity Impairment			
Week 24			
m	115	92	189
n	39	29	53
Baseline Mean (SD)	10.3 (21.0)	12.4 (18.3)	17.7 (27.0)
Analysis Visit Mean (SD)	17.7 (24.3)	11.7 (16.3)	17.4 (26.0)
LS Mean of Change from Baseline (SE)	4.91 (3.14)	-1.59 (3.62)	1.16 (2.68)
95% CI	(-1.30, 11.11)	(-8.75, 5.58)	(-4.14, 6.46)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.75 (4.11)	-2.74 (4.47)	
95% CI	(-4.37, 11.87)	(-11.58, 6.09)	
p-value	0.3631	0.5403	
Corrected Hedge's g Statistics	0.190	-0.139	
95% CI	(-0.22, 0.60)	(-0.59, 0.31)	
Week 52			
m	107	81	176
n	26	26	42
Baseline Mean (SD)	13.5 (23.0)	10.4 (16.6)	19.5 (29.0)
Analysis Visit Mean (SD)	15.4 (21.4)	16.5 (17.4)	15.0 (20.6)
LS Mean of Change from Baseline (SE)	1.86 (3.40)	3.23 (3.52)	-2.22 (2.71)
95% CI	(-4.87, 8.58)	(-3.72, 10.19)	(-7.56, 3.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.07 (4.33)	5.45 (4.42)	
95% CI	(-4.49, 12.63)	(-3.30, 14.19)	
p-value	0.3489	0.2201	
Corrected Hedge's g Statistics	0.230	0.304	
95% CI	(-0.26, 0.72)	(-0.19, 0.80)	
Subgroup*Treatment Interaction p-value	0.7374	0.5748	

AMNOG Table SE24.7.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Absenteeism			
Week 24			
m	46	49	100
n	3	9	14
Baseline Mean (SD)	6.67 (11.55)	0.53 (1.60)	2.38 (8.90)
Analysis Visit Mean (SD)	0.00 (0.00)	0.63 (1.90)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-2.31 (0.74)	-1.70 (0.42)	-2.32 (0.31)
95% CI	(-3.83, -0.79)	(-2.56, -0.84)	(-2.95, -1.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (0.81)	0.62 (0.52)	
95% CI	(-1.64, 1.65)	(-0.45, 1.69)	
p-value	0.9920	0.2441	
Corrected Hedge's g Statistics	0.007	0.499	
95% CI	(-1.24, 1.25)	(-0.35, 1.35)	
Week 52			
m	42	44	94
n	2	8	12
Baseline Mean (SD)	10.00 (14.14)	0.00 (0.00)	2.78 (9.61)
Analysis Visit Mean (SD)	0.00 (0.00)	3.13 (8.84)	8.13 (20.46)
LS Mean of Change from Baseline (SE)	-0.47 (12.47)	0.07 (6.06)	5.92 (4.87)
95% CI	(-25.91, 24.97)	(-12.28, 12.43)	(-4.00, 15.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.39 (13.33)	-5.85 (7.80)	
95% CI	(-33.57, 20.79)	(-21.76, 10.07)	
p-value	0.6349	0.4592	
Corrected Hedge's g Statistics	-0.353	-0.330	
95% CI	(-1.86, 1.15)	(-1.23, 0.57)	
Subgroup*Treatment Interaction p-value	0.3263	0.5604	

AMNOG Table SE24.7.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Presenteeism			
Week 24			
m	46	49	100
n	3	9	14
Baseline Mean (SD)	23.3 (40.4)	8.9 (7.8)	15.0 (21.8)
Analysis Visit Mean (SD)	10.0 (17.3)	11.1 (19.0)	10.7 (18.6)
LS Mean of Change from Baseline (SE)	-10.27 (10.51)	0.50 (5.95)	-3.18 (4.59)
95% CI	(-31.70, 11.16)	(-11.64, 12.63)	(-12.54, 6.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.09 (11.46)	3.68 (7.52)	
95% CI	(-30.45, 16.28)	(-11.66, 19.02)	
p-value	0.5407	0.6282	
Corrected Hedge's g Statistics	-0.389	0.203	
95% CI	(-1.64, 0.87)	(-0.64, 1.04)	
Week 52			
m	42	44	94
n	2	8	12
Baseline Mean (SD)	35.0 (49.5)	8.8 (8.3)	15.0 (23.5)
Analysis Visit Mean (SD)	40.0 (0.0)	6.3 (7.4)	10.0 (17.1)
LS Mean of Change from Baseline (SE)	16.09 (9.38)	-5.76 (4.32)	-4.90 (3.44)
95% CI	(-3.03, 35.22)	(-14.57, 3.06)	(-11.93, 2.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	21.00 (9.84)	-0.85 (5.59)	
95% CI	(0.93, 41.06)	(-12.26, 10.55)	
p-value	0.0408	0.8796	
Corrected Hedge's g Statistics	1.632	-0.068	
95% CI	(0.02, 3.25)	(-0.96, 0.83)	
Subgroup*Treatment Interaction p-value	0.7197	0.7932	

AMNOG Table SE24.7.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Overall Work Impairment			
Week 24			
m	46	49	100
n	3	9	14
Baseline Mean (SD)	25.33 (43.88)	9.37 (8.02)	16.66 (23.78)
Analysis Visit Mean (SD)	10.00 (17.32)	11.68 (19.04)	10.71 (18.59)
LS Mean of Change from Baseline (SE)	-12.12 (11.01)	-0.21 (6.10)	-4.82 (4.58)
95% CI	(-34.58, 10.34)	(-12.65, 12.23)	(-14.17, 4.52)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.30 (11.92)	4.62 (7.64)	
95% CI	(-31.60, 17.01)	(-10.97, 20.20)	
p-value	0.5448	0.5501	
Corrected Hedge's g Statistics	-0.398	0.253	
95% CI	(-1.65, 0.86)	(-0.59, 1.09)	
Week 52			
m	42	44	94
n	2	8	12
Baseline Mean (SD)	38.00 (53.74)	8.75 (8.35)	16.94 (25.76)
Analysis Visit Mean (SD)	40.00 (0.00)	9.06 (11.95)	16.54 (26.52)
LS Mean of Change from Baseline (SE)	16.39 (15.33)	-5.03 (7.25)	0.22 (5.78)
95% CI	(-14.86, 47.65)	(-19.83, 9.76)	(-11.57, 12.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	16.17 (16.24)	-5.26 (9.34)	
95% CI	(-16.94, 49.28)	(-24.30, 13.78)	
p-value	0.3270	0.5775	
Corrected Hedge's g Statistics	0.750	-0.249	
95% CI	(-0.77, 2.27)	(-1.15, 0.65)	
Subgroup*Treatment Interaction p-value	0.1960	0.5038	

AMNOG Table SE24.7.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Activity Impairment			
Week 24			
m	46	49	100
n	12	18	26
Baseline Mean (SD)	20.0 (28.9)	10.0 (12.4)	12.3 (19.0)
Analysis Visit Mean (SD)	20.0 (26.3)	15.0 (19.8)	13.1 (18.3)
LS Mean of Change from Baseline (SE)	2.55 (5.12)	0.62 (4.29)	-0.65 (3.47)
95% CI	(-7.68, 12.77)	(-7.95, 9.19)	(-7.58, 6.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.20 (6.22)	1.27 (5.43)	
95% CI	(-9.22, 15.62)	(-9.58, 12.11)	
p-value	0.6087	0.8159	
Corrected Hedge's g Statistics	0.177	0.070	
95% CI	(-0.51, 0.86)	(-0.53, 0.67)	
Week 52			
m	42	44	94
n	5	15	21
Baseline Mean (SD)	26.0 (28.8)	16.7 (15.9)	15.2 (21.4)
Analysis Visit Mean (SD)	22.0 (13.0)	18.7 (22.0)	10.5 (16.3)
LS Mean of Change from Baseline (SE)	4.18 (6.44)	1.07 (3.70)	-4.83 (3.06)
95% CI	(-8.69, 17.05)	(-6.33, 8.47)	(-10.94, 1.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.01 (7.14)	5.90 (4.78)	
95% CI	(-5.25, 23.28)	(-3.65, 15.46)	
p-value	0.2114	0.2214	
Corrected Hedge's g Statistics	0.620	0.408	
95% CI	(-0.37, 1.61)	(-0.26, 1.08)	
Subgroup*Treatment Interaction p-value	0.7374	0.5748	

AMNOG Table SE24.7.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.7.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (0.8)	0	0
No	117 (99.2)	100 (100)	201 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.85	NE	
95% CI of the absolute risk difference	(-0.81, 2.50)	NE	
p-value	0.1911	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4221	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (0.8)	0	1 (0.5)
No	117 (99.2)	100 (100)	200 (99.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	NE	
95% CI of the inverse odds ratio	(0.04, 9.44)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	NE	
95% CI of the inverse risk ratio	(0.04, 9.30)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.35	-0.50	
95% CI of the absolute risk difference	(-1.57, 2.27)	(-1.47, 0.48)	
p-value	0.7022	0.4799	
p-value of Breslow-Day Test for Homogeneity [3]	0.9177	NE	

AMNOG Table SE24.7.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (1.0)	1 (0.5)
No	118 (100)	99 (99.0)	200 (99.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.50	
95% CI of the inverse odds ratio	NE	(0.03, 8.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.50	
95% CI of the inverse risk ratio	NE	(0.03, 7.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.50	0.50	
95% CI of the absolute risk difference	(-1.47, 0.48)	(-1.68, 2.68)	
p-value	0.4428	0.6133	
p-value of Breslow-Day Test for Homogeneity [3]	0.5422	0.1678	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (1.7)	3 (3.0)	2 (1.0)
No	116 (98.3)	97 (97.0)	199 (99.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.32	
95% CI of the inverse odds ratio	(0.08, 4.19)	(0.05, 1.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.33	
95% CI of the inverse risk ratio	(0.08, 4.11)	(0.06, 1.95)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.70	2.00	
95% CI of the absolute risk difference	(-2.00, 3.40)	(-1.61, 5.62)	
p-value	0.5876	0.1999	
p-value of Breslow-Day Test for Homogeneity [3]	0.5492	0.5251	

AMNOG Table SE24.7.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (0.8)	1 (1.0)	1 (0.5)
No	117 (99.2)	99 (99.0)	200 (99.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.50	
95% CI of the inverse odds ratio	(0.04, 9.44)	(0.03, 8.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.50	
95% CI of the inverse risk ratio	(0.04, 9.30)	(0.03, 7.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.35	0.50	
95% CI of the absolute risk difference	(-1.57, 2.27)	(-1.68, 2.68)	
p-value	0.7022	0.6133	
p-value of Breslow-Day Test for Homogeneity [3]	0.6162	0.1678	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (1.7)	3 (3.0)	3 (1.5)
No	116 (98.3)	97 (97.0)	198 (98.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.49	
95% CI of the inverse odds ratio	(0.14, 5.34)	(0.10, 2.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.50	
95% CI of the inverse risk ratio	(0.15, 5.19)	(0.10, 2.42)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.20	1.51	
95% CI of the absolute risk difference	(-2.67, 3.07)	(-2.23, 5.25)	
p-value	0.8883	0.3781	
p-value of Breslow-Day Test for Homogeneity [3]	0.7338	0.4218	

AMNOG Table SE24.7.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=118)	MGL-3196 100 mg (N=100)	Placebo (N=201)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.4)	3 (3.0)	8 (4.0)
No	114 (96.6)	97 (97.0)	193 (96.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	1.34	
95% CI of the inverse odds ratio	(0.35, 4.01)	(0.35, 5.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.17	1.33	
95% CI of the inverse risk ratio	(0.36, 3.82)	(0.36, 4.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.59	-0.98	
95% CI of the absolute risk difference	(-4.83, 3.65)	(-5.28, 3.32)	
p-value	0.7891	0.6695	
p-value of Breslow-Day Test for Homogeneity [3]	0.6938	0.2383	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	8 (6.8)	4 (4.0)	11 (5.5)
No	110 (93.2)	96 (96.0)	190 (94.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	1.39	
95% CI of the inverse odds ratio	(0.31, 2.04)	(0.43, 4.48)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.81	1.37	
95% CI of the inverse risk ratio	(0.33, 1.95)	(0.45, 4.19)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.31	-1.47	
95% CI of the absolute risk difference	(-4.21, 6.83)	(-6.44, 3.49)	
p-value	0.6339	0.5802	
p-value of Breslow-Day Test for Homogeneity [3]	0.6676	0.3605	

AMNOG Table SE24.7.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.0)	0	1 (1.0)
No	48 (98.0)	51 (100)	101 (99.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse odds ratio	(0.03, 7.76)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse risk ratio	(0.03, 7.52)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.06	-0.98	
95% CI of the absolute risk difference	(-3.34, 5.46)	(-2.89, 0.93)	
p-value	0.5936	0.4781	
p-value of Breslow-Day Test for Homogeneity [3]	0.4221	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (2.0)	0	1 (1.0)
No	48 (98.0)	51 (100)	101 (99.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse odds ratio	(0.03, 7.76)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.48	NE	
95% CI of the inverse risk ratio	(0.03, 7.52)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.06	-0.98	
95% CI of the absolute risk difference	(-3.34, 5.46)	(-2.89, 0.93)	
p-value	0.5936	0.4781	
p-value of Breslow-Day Test for Homogeneity [3]	0.9177	NE	

AMNOG Table SE24.7.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.0)	0	3 (2.9)
No	48 (98.0)	51 (100)	99 (97.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	NE	
95% CI of the inverse odds ratio	(0.15, 14.35)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	NE	
95% CI of the inverse risk ratio	(0.15, 13.50)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.90	-2.94	
95% CI of the absolute risk difference	(-6.04, 4.24)	(-6.22, 0.34)	
p-value	0.7470	0.2161	
p-value of Breslow-Day Test for Homogeneity [3]	0.5422	0.1678	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (2.0)	2 (3.9)	3 (2.9)
No	48 (98.0)	49 (96.1)	99 (97.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	0.74	
95% CI of the inverse odds ratio	(0.15, 14.35)	(0.12, 4.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	0.75	
95% CI of the inverse risk ratio	(0.15, 13.50)	(0.13, 4.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.90	0.98	
95% CI of the absolute risk difference	(-6.04, 4.24)	(-5.28, 7.24)	
p-value	0.7470	0.7478	
p-value of Breslow-Day Test for Homogeneity [3]	0.5492	0.5251	

AMNOG Table SE24.7.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.0)	0	3 (2.9)
No	48 (98.0)	51 (100)	99 (97.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	NE	
95% CI of the inverse odds ratio	(0.15, 14.35)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	NE	
95% CI of the inverse risk ratio	(0.15, 13.50)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.90	-2.94	
95% CI of the absolute risk difference	(-6.04, 4.24)	(-6.22, 0.34)	
p-value	0.7470	0.2161	
p-value of Breslow-Day Test for Homogeneity [3]	0.6162	0.1678	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (2.0)	1 (2.0)	3 (2.9)
No	48 (98.0)	50 (98.0)	99 (97.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	1.52	
95% CI of the inverse odds ratio	(0.15, 14.35)	(0.15, 14.94)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.44	1.50	
95% CI of the inverse risk ratio	(0.15, 13.50)	(0.16, 14.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.90	-0.98	
95% CI of the absolute risk difference	(-6.04, 4.24)	(-6.00, 4.04)	
p-value	0.7470	0.7201	
p-value of Breslow-Day Test for Homogeneity [3]	0.7338	0.4218	

AMNOG Table SE24.7.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Diabetes Status at Baseline
(Label Population)

Diabetes status at baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=49)	MGL-3196 100 mg (N=51)	Placebo (N=102)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.0)	0	4 (3.9)
No	48 (98.0)	51 (100)	98 (96.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.96	NE	
95% CI of the inverse odds ratio	(0.21, 18.01)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.92	NE	
95% CI of the inverse risk ratio	(0.22, 16.74)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.88	-3.92	
95% CI of the absolute risk difference	(-7.35, 3.58)	(-7.69, -0.15)	
p-value	0.5454	0.1518	
p-value of Breslow-Day Test for Homogeneity [3]	0.6938	0.2383	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (4.1)	4 (7.8)	5 (4.9)
No	47 (95.9)	47 (92.2)	97 (95.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.21	0.61	
95% CI of the inverse odds ratio	(0.23, 6.48)	(0.16, 2.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.20	0.63	
95% CI of the inverse risk ratio	(0.24, 5.97)	(0.18, 2.23)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.82	2.94	
95% CI of the absolute risk difference	(-7.77, 6.13)	(-5.54, 11.43)	
p-value	0.8224	0.4661	
p-value of Breslow-Day Test for Homogeneity [3]	0.6676	0.3605	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.8.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Absenteeism						
Baseline						
m	64	53	111			
n	14	11	25			
Mean (SD)	5.09 (10.33)	0.00 (0.00)	1.12 (5.01)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 7.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 34.8	0.0, 0.0	0.0, 25.0			
Week 24						
m	63	51	103			
n	17	15	35	12	7	19
Mean (SD/SE)	1.86 (5.27)	2.96 (8.27)	0.00 (0.00)	-3.96 (2.18)	4.20 (4.20)	-1.32 (1.32)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-4.70, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 16.7	0.0, 29.4	0.0, 0.0	-20.0, 0.0	0.0, 29.4	-25.0, 0.0
Week 52						
m	56	44	94			
n	15	18	39	5	6	16
Mean (SD/SE)	2.51 (8.59)	5.61 (16.32)	7.67 (19.54)	-4.30 (3.94)	11.12 (11.12)	6.09 (4.47)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-1.50, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 33.3	0.0, 66.7	0.0, 75.0	-20.0, 0.0	0.0, 66.7	0.0, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.8.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Presenteeism						
Baseline						
m	64	53	111			
n	14	11	25			
Mean (SD)	12.1 (23.9)	15.5 (23.4)	3.6 (10.8)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 0.0			
Min, Max	0, 70	0, 70	0, 50			
Week 24						
m	63	51	103			
n	17	15	35	12	7	19
Mean (SD/SE)	11.8 (21.3)	16.0 (19.9)	7.7 (16.6)	1.7 (8.1)	0.0 (5.8)	4.7 (3.0)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 10.0	-5.0, 0.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 80	0, 80	0, 60	-40, 80	-30, 20	-10, 50
Week 52						
m	56	44	94			
n	15	18	39	5	6	16
Mean (SD/SE)	20.0 (26.2)	12.2 (22.4)	7.4 (13.7)	18.0 (21.3)	3.3 (4.2)	5.0 (2.4)
Median	10.0	0	0	0	0	0
IQR: Q1, Q3	0.0, 40.0	0.0, 20.0	0.0, 10.0	-10.0, 40.0	0.0, 10.0	0.0, 5.0
Min, Max	0, 90	0, 90	0, 50	-30, 90	-10, 20	0, 30

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.8.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Overall Work Impairment						
Baseline						
m	64	53	111			
n	14	11	25			
Mean (SD)	14.74 (26.80)	15.45 (23.39)	4.56 (12.38)			
Median	0	10.00	0			
IQR: Q1, Q3	0.00, 10.00	0.00, 20.00	0.00, 0.00			
Min, Max	0.0, 76.0	0.0, 70.0	0.0, 51.4			
Week 24						
m	63	51	103			
n	17	15	35	12	7	19
Mean (SD/SE)	13.06 (22.67)	18.57 (20.85)	7.71 (16.64)	0.06 (8.43)	3.79 (6.90)	3.55 (3.11)
Median	0	10.00	0	0	0	0
IQR: Q1, Q3	0.00, 10.00	0.00, 30.00	0.00, 10.00	-9.70, 0.00	0.00, 20.00	0.00, 0.00
Min, Max	0.0, 80.0	0.0, 80.0	0.0, 60.0	-46.0, 80.0	-30.0, 26.5	-12.5, 50.0
Week 52						
m	56	44	94			
n	15	18	39	5	6	16
Mean (SD/SE)	21.33 (27.85)	16.13 (27.57)	12.88 (24.38)	17.34 (21.85)	12.23 (10.99)	9.44 (4.94)
Median	10.00	0	0	0	0	0
IQR: Q1, Q3	0.00, 40.00	0.00, 20.00	0.00, 10.00	-7.30, 40.00	0.00, 20.00	0.00, 10.00
Min, Max	0.0, 90.0	0.0, 91.2	0.0, 87.5	-36.0, 90.0	-10.0, 63.4	0.0, 70.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.8.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=64)	Visit Result MGL-3196 100 mg (N=53)	Visit Result Placebo (N=111)	Change from Baseline MGL-3196 80 mg (N=64)	Change from Baseline MGL-3196 100 mg (N=53)	Change from Baseline Placebo (N=111)
Activity Impairment						
Baseline						
m	64	53	111			
n	24	22	47			
Mean (SD)	10.0 (21.1)	10.9 (21.1)	16.8 (27.4)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 5.0	0.0, 10.0	0.0, 20.0			
Min, Max	0, 70	0, 80	0, 100			
Week 24						
m	63	51	103			
n	34	23	57	21	13	31
Mean (SD/SE)	13.2 (19.5)	10.9 (15.0)	16.5 (24.2)	1.9 (4.2)	0.0 (2.0)	3.2 (2.9)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 10.0	0.0, 30.0	0.0, 0.0	0.0, 0.0	0.0, 0.0
Min, Max	0, 70	0, 60	0, 100	-40, 50	-20, 10	-50, 50
Week 52						
m	56	44	94			
n	36	28	64	13	10	29
Mean (SD/SE)	16.7 (23.9)	15.0 (19.3)	12.2 (15.6)	5.4 (7.1)	5.0 (4.0)	-4.8 (4.4)
Median	0	10.0	5.0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 25.0	0.0, 20.0	-10.0, 10.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 90	0, 80	0, 50	-40, 50	-10, 30	-90, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.8.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Absenteeism						
Baseline						
m	103	98	192			
n	14	33	42			
Mean (SD)	1.91 (7.14)	3.04 (12.63)	3.54 (16.16)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 26.7	0.0, 68.1	0.0, 100.0			
Week 24						
m	98	90	186			
n	24	27	49	9	15	26
Mean (SD/SE)	0.52 (2.55)	0.21 (1.10)	0.00 (0.00)	-1.58 (3.43)	0.06 (0.06)	-5.72 (4.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 12.5	0.0, 5.7	0.0, 0.0	-26.7, 12.5	0.0, 0.9	-100.0, 0.0
Week 52						
m	93	81	176			
n	22	30	57	6	18	20
Mean (SD/SE)	4.55 (14.71)	2.69 (10.99)	1.14 (6.88)	3.88 (10.20)	4.48 (3.31)	-1.37 (1.91)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 55.6	0.0, 50.0	-26.7, 50.0	0.0, 55.6	-33.3, 15.1

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.8.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Presenteeism						
Baseline						
m	103	98	192			
n	14	33	41			
Mean (SD)	2.1 (5.8)	8.5 (12.5)	10.0 (18.0)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0			
Min, Max	0, 20	0, 50	0, 70			
Week 24						
m	98	90	186			
n	24	27	49	9	15	25
Mean (SD/SE)	9.6 (20.7)	8.5 (16.3)	7.1 (14.4)	14.4 (10.6)	6.0 (5.6)	-1.2 (4.8)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 10.0	0.0, 10.0	-10.0, 10.0	-10.0, 0.0
Min, Max	0, 90	0, 60	0, 70	-10, 90	-20, 60	-60, 70
Week 52						
m	93	81	176			
n	22	30	57	6	18	20
Mean (SD/SE)	6.8 (14.6)	10.3 (18.7)	7.7 (16.9)	0.0 (2.6)	0.0 (3.5)	-1.0 (5.8)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0	0.0, 0.0	0.0, 0.0	-5.0, 5.0
Min, Max	0, 50	0, 80	0, 80	-10, 10	-40, 30	-50, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.8.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Overall Work Impairment						
Baseline						
m	103	98	192			
n	14	33	41			
Mean (SD)	3.86 (10.18)	11.18 (17.32)	10.90 (19.06)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 14.30	0.00, 10.00			
Min, Max	0.0, 34.0	0.0, 68.1	0.0, 70.0			
Week 24						
m	98	90	186			
n	24	27	49	9	15	25
Mean (SD/SE)	9.64 (20.96)	8.71 (16.39)	7.14 (14.43)	11.92 (11.73)	6.05 (5.59)	-2.67 (5.02)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 10.00	0.00, 10.00	0.00, 10.00	0.00, 10.00	-10.00, 10.00	-10.00, 0.00
Min, Max	0.0, 91.3	0.0, 60.0	0.0, 70.0	-34.0, 91.3	-20.0, 60.0	-60.0, 70.0
Week 52						
m	93	81	176			
n	22	30	57	6	18	20
Mean (SD/SE)	10.23 (21.18)	12.75 (21.07)	8.65 (17.99)	3.50 (11.70)	4.03 (4.80)	-2.47 (6.28)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 20.00	0.00, 10.00	0.00, 0.00	0.00, 0.00	-9.55, 5.00
Min, Max	0.0, 70.0	0.0, 80.0	0.0, 83.0	-34.0, 55.0	-40.0, 60.0	-53.3, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.8.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=103)	Visit Result MGL-3196 100 mg (N=98)	Visit Result Placebo (N=192)	Change from Baseline MGL-3196 80 mg (N=103)	Change from Baseline MGL-3196 100 mg (N=98)	Change from Baseline Placebo (N=192)
Activity Impairment						
Baseline						
m	103	98	192			
n	41	53	76			
Mean (SD)	17.6 (25.5)	13.4 (16.6)	18.0 (25.0)			
Median	0	10.0	10.0			
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 30.0			
Min, Max	0, 80	0, 70	0, 80			
Week 24						
m	98	90	186			
n	56	50	95	30	34	48
Mean (SD/SE)	17.5 (24.2)	11.6 (16.9)	15.4 (22.5)	8.3 (4.6)	2.1 (4.0)	-2.1 (3.5)
Median	0	5.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0	-10.0, 20.0	-10.0, 10.0	-10.0, 10.0
Min, Max	0, 80	0, 70	0, 80	-30, 80	-60, 70	-80, 70
Week 52						
m	93	81	176			
n	56	52	104	18	31	34
Mean (SD/SE)	14.6 (21.1)	16.7 (21.9)	14.6 (22.3)	-2.2 (4.8)	4.5 (3.5)	-4.4 (4.0)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 30.0	0.0, 20.0	-10.0, 0.0	0.0, 20.0	-10.0, 10.0
Min, Max	0, 80	0, 80	0, 100	-40, 60	-50, 40	-70, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.8.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.8.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Absenteeism			
Week 24			
m	63	51	103
n	12	7	19
Baseline Mean (SD)	5.35 (11.10)	0.00 (0.00)	1.32 (5.74)
Analysis Visit Mean (SD)	1.39 (4.82)	4.20 (11.11)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-2.31 (1.54)	1.50 (1.88)	-2.41 (1.16)
95% CI	(-5.42, 0.79)	(-2.30, 5.29)	(-4.74, -0.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.09 (1.90)	3.91 (2.15)	
95% CI	(-3.75, 3.93)	(-0.44, 8.25)	
p-value	0.9617	0.0768	
Corrected Hedge's g Statistics	0.017	0.752	
95% CI	(-0.71, 0.74)	(-0.14, 1.64)	
Week 52			
m	56	44	94
n	5	6	16
Baseline Mean (SD)	10.96 (15.89)	0.00 (0.00)	1.56 (6.25)
Analysis Visit Mean (SD)	6.66 (14.89)	11.12 (27.23)	7.66 (18.41)
LS Mean of Change from Baseline (SE)	-4.29 (7.97)	5.82 (7.09)	5.88 (4.35)
95% CI	(-20.39, 11.81)	(-8.51, 20.14)	(-2.91, 14.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	-10.17 (9.22)	-0.06 (8.26)	
95% CI	(-28.79, 8.45)	(-16.75, 16.63)	
p-value	0.2765	0.9940	
Corrected Hedge's g Statistics	-0.558	-0.003	
95% CI	(-1.58, 0.46)	(-0.94, 0.93)	
Subgroup*Treatment Interaction p-value	0.8914	0.0420	

AMNOG Table SE24.8.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Presenteeism			
Week 24			
m	63	51	103
n	12	7	19
Baseline Mean (SD)	11.7 (25.2)	11.4 (17.7)	1.1 (3.2)
Analysis Visit Mean (SD)	13.3 (25.0)	11.4 (6.9)	5.8 (13.0)
LS Mean of Change from Baseline (SE)	4.29 (4.97)	1.95 (5.87)	1.68 (3.78)
95% CI	(-5.75, 14.33)	(-9.90, 13.80)	(-5.96, 9.32)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.61 (6.27)	0.26 (7.04)	
95% CI	(-10.06, 15.27)	(-13.96, 14.48)	
p-value	0.6798	0.9702	
Corrected Hedge's g Statistics	0.151	0.016	
95% CI	(-0.57, 0.88)	(-0.85, 0.88)	
Week 52			
m	56	44	94
n	5	6	16
Baseline Mean (SD)	26.0 (35.8)	6.7 (8.2)	2.5 (5.8)
Analysis Visit Mean (SD)	44.0 (32.1)	10.0 (11.0)	7.5 (13.9)
LS Mean of Change from Baseline (SE)	22.76 (7.09)	2.19 (6.19)	1.36 (3.97)
95% CI	(8.45, 37.08)	(-10.31, 14.69)	(-6.66, 9.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	21.40 (8.37)	0.82 (7.38)	
95% CI	(4.49, 38.32)	(-14.08, 15.73)	
p-value	0.0144	0.9116	
Corrected Hedge's g Statistics	1.294	0.051	
95% CI	(0.22, 2.37)	(-0.89, 0.99)	
Subgroup*Treatment Interaction p-value	0.9861	0.9950	

AMNOG Table SE24.8.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Overall Work Impairment			
Week 24			
m	63	51	103
n	12	7	19
Baseline Mean (SD)	14.11 (28.66)	11.43 (17.73)	2.24 (7.68)
Analysis Visit Mean (SD)	14.17 (26.10)	15.21 (11.63)	5.79 (13.05)
LS Mean of Change from Baseline (SE)	2.77 (5.14)	3.09 (5.80)	0.15 (3.82)
95% CI	(-7.61, 13.14)	(-8.62, 14.81)	(-7.57, 7.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.62 (6.39)	2.94 (6.94)	
95% CI	(-10.29, 15.53)	(-11.07, 16.95)	
p-value	0.6843	0.6736	
Corrected Hedge's g Statistics	0.149	0.174	
95% CI	(-0.57, 0.87)	(-0.69, 1.04)	
Week 52			
m	56	44	94
n	5	6	16
Baseline Mean (SD)	29.98 (41.06)	6.67 (8.16)	3.91 (9.35)
Analysis Visit Mean (SD)	47.32 (33.69)	18.90 (28.44)	13.34 (24.49)
LS Mean of Change from Baseline (SE)	12.60 (9.04)	8.29 (8.44)	6.44 (5.49)
95% CI	(-5.65, 30.86)	(-8.75, 25.34)	(-4.65, 17.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.16 (10.80)	1.85 (10.09)	
95% CI	(-15.66, 27.98)	(-18.53, 22.24)	
p-value	0.5715	0.8554	
Corrected Hedge's g Statistics	0.274	0.082	
95% CI	(-0.73, 1.28)	(-0.86, 1.02)	
Subgroup*Treatment Interaction p-value	0.6036	0.8577	

AMNOG Table SE24.8.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Visit Statistic	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Activity Impairment			
Week 24			
m	63	51	103
n	21	13	31
Baseline Mean (SD)	10.0 (21.9)	8.5 (16.8)	10.3 (22.0)
Analysis Visit Mean (SD)	11.9 (18.1)	8.5 (12.8)	13.5 (24.3)
LS Mean of Change from Baseline (SE)	-0.19 (3.24)	-2.77 (3.98)	2.05 (2.61)
95% CI	(-6.64, 6.26)	(-10.70, 5.17)	(-3.16, 7.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.24 (4.07)	-4.81 (4.71)	
95% CI	(-10.36, 5.88)	(-14.20, 4.57)	
p-value	0.5842	0.3101	
Corrected Hedge's g Statistics	-0.151	-0.326	
95% CI	(-0.71, 0.40)	(-0.98, 0.32)	
Week 52			
m	56	44	94
n	13	10	29
Baseline Mean (SD)	16.2 (26.3)	8.0 (10.3)	17.6 (28.6)
Analysis Visit Mean (SD)	21.5 (19.9)	13.0 (14.2)	12.8 (15.8)
LS Mean of Change from Baseline (SE)	5.53 (3.74)	1.07 (4.24)	-2.73 (2.58)
95% CI	(-1.92, 12.99)	(-7.37, 9.51)	(-7.88, 2.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.26 (4.46)	3.80 (4.96)	
95% CI	(-0.62, 17.14)	(-6.08, 13.69)	
p-value	0.0678	0.4459	
Corrected Hedge's g Statistics	0.588	0.270	
95% CI	(-0.08, 1.25)	(-0.45, 0.99)	
Subgroup*Treatment Interaction p-value	0.7052	0.4891	

AMNOG Table SE24.8.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Absenteeism			
Week 24			
m	98	90	186
n	9	15	26
Baseline Mean (SD)	2.97 (8.90)	0.32 (1.24)	5.72 (20.38)
Analysis Visit Mean (SD)	1.39 (4.17)	0.38 (1.47)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-0.83 (0.70)	-2.45 (0.48)	-2.57 (0.40)
95% CI	(-2.24, 0.57)	(-3.41, -1.49)	(-3.37, -1.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.74 (0.75)	0.13 (0.62)	
95% CI	(0.24, 3.24)	(-1.12, 1.37)	
p-value	0.0239	0.8414	
Corrected Hedge's g Statistics	0.826	0.062	
95% CI	(0.04, 1.61)	(-0.57, 0.70)	
Week 52			
m	93	81	176
n	6	18	20
Baseline Mean (SD)	4.45 (10.90)	0.00 (0.00)	2.12 (7.62)
Analysis Visit Mean (SD)	8.33 (20.41)	4.48 (14.05)	0.76 (3.38)
LS Mean of Change from Baseline (SE)	8.53 (5.04)	2.50 (3.07)	-1.88 (2.77)
95% CI	(-1.55, 18.61)	(-3.63, 8.64)	(-7.42, 3.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.41 (5.76)	4.39 (4.11)	
95% CI	(-1.11, 21.93)	(-3.84, 12.61)	
p-value	0.0758	0.2906	
Corrected Hedge's g Statistics	0.814	0.338	
95% CI	(-0.12, 1.75)	(-0.30, 0.98)	
Subgroup*Treatment Interaction p-value	0.8914	0.0420	

AMNOG Table SE24.8.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Presenteeism			
Week 24			
m	98	90	186
n	9	15	25
Baseline Mean (SD)	1.1 (3.3)	6.0 (7.4)	12.4 (21.7)
Analysis Visit Mean (SD)	15.6 (30.9)	12.0 (20.4)	11.2 (18.1)
LS Mean of Change from Baseline (SE)	6.14 (7.42)	4.55 (5.25)	-0.40 (4.35)
95% CI	(-8.70, 20.99)	(-5.96, 15.06)	(-9.10, 8.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.54 (8.37)	4.95 (6.79)	
95% CI	(-10.21, 23.29)	(-8.63, 18.52)	
p-value	0.4376	0.4688	
Corrected Hedge's g Statistics	0.292	0.228	
95% CI	(-0.47, 1.06)	(-0.41, 0.87)	
Week 52			
m	93	81	176
n	6	18	20
Baseline Mean (SD)	1.7 (4.1)	9.4 (13.5)	12.0 (23.8)
Analysis Visit Mean (SD)	1.7 (4.1)	9.4 (15.1)	11.0 (20.7)
LS Mean of Change from Baseline (SE)	-2.39 (6.75)	-1.52 (3.88)	-0.27 (3.72)
95% CI	(-15.89, 11.11)	(-9.28, 6.24)	(-7.72, 7.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.11 (7.34)	-1.25 (5.11)	
95% CI	(-16.79, 12.56)	(-11.47, 8.98)	
p-value	0.7741	0.8079	
Corrected Hedge's g Statistics	-0.123	-0.074	
95% CI	(-1.04, 0.79)	(-0.71, 0.56)	
Subgroup*Treatment Interaction p-value	0.9861	0.9950	

AMNOG Table SE24.8.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Overall Work Impairment			
Week 24			
m	98	90	186
n	9	15	25
Baseline Mean (SD)	3.78 (11.33)	6.29 (7.61)	13.87 (22.91)
Analysis Visit Mean (SD)	15.70 (31.26)	12.34 (20.43)	11.20 (18.10)
LS Mean of Change from Baseline (SE)	6.96 (7.68)	2.61 (5.44)	-0.85 (4.54)
95% CI	(-8.41, 22.32)	(-8.27, 13.49)	(-9.93, 8.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.81 (8.54)	3.46 (7.08)	
95% CI	(-9.27, 24.90)	(-10.69, 17.62)	
p-value	0.3640	0.6262	
Corrected Hedge's g Statistics	0.335	0.154	
95% CI	(-0.43, 1.10)	(-0.49, 0.79)	
Week 52			
m	93	81	176
n	6	18	20
Baseline Mean (SD)	5.67 (13.88)	9.44 (13.49)	13.62 (25.04)
Analysis Visit Mean (SD)	9.17 (22.45)	13.47 (19.84)	11.15 (21.28)
LS Mean of Change from Baseline (SE)	3.13 (8.58)	2.21 (4.91)	-0.67 (4.73)
95% CI	(-14.02, 20.28)	(-7.62, 12.04)	(-10.12, 8.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.80 (9.39)	2.88 (6.57)	
95% CI	(-14.98, 22.57)	(-10.27, 16.03)	
p-value	0.6871	0.6631	
Corrected Hedge's g Statistics	0.174	0.134	
95% CI	(-0.74, 1.09)	(-0.50, 0.77)	
Subgroup*Treatment Interaction p-value	0.6036	0.8577	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.8.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Visit Statistic	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Activity Impairment			
Week 24			
m	98	90	186
n	30	34	48
Baseline Mean (SD)	14.3 (24.2)	12.6 (16.0)	19.6 (25.8)
Analysis Visit Mean (SD)	22.7 (27.7)	14.7 (18.9)	17.5 (23.4)
LS Mean of Change from Baseline (SE)	7.68 (3.92)	0.56 (3.56)	0.55 (3.06)
95% CI	(-0.06, 15.43)	(-6.48, 7.60)	(-5.50, 6.60)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.13 (4.84)	0.01 (4.66)	
95% CI	(-2.44, 16.71)	(-9.21, 9.23)	
p-value	0.1429	0.9983	
Corrected Hedge's g Statistics	0.332	0.000	
95% CI	(-0.13, 0.79)	(-0.44, 0.44)	
Week 52			
m	93	81	176
n	18	31	34
Baseline Mean (SD)	15.0 (22.8)	14.2 (17.8)	18.5 (25.2)
Analysis Visit Mean (SD)	12.8 (20.2)	18.7 (20.3)	14.1 (22.0)
LS Mean of Change from Baseline (SE)	0.35 (4.42)	3.78 (3.26)	-3.01 (3.13)
95% CI	(-8.40, 9.10)	(-2.67, 10.24)	(-9.20, 3.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.36 (5.25)	6.80 (4.46)	
95% CI	(-7.03, 13.76)	(-2.03, 15.62)	
p-value	0.5233	0.1302	
Corrected Hedge's g Statistics	0.180	0.369	
95% CI	(-0.39, 0.75)	(-0.12, 0.86)	
Subgroup*Treatment Interaction p-value	0.7052	0.4891	

AMNOG Table SE24.8.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.8.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.6)	0	0
No	63 (98.4)	53 (100)	111 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.56	NE	
95% CI of the absolute risk difference	(-1.48, 4.60)	NE	
p-value	0.1866	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3980	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.6)	0	0
No	63 (98.4)	53 (100)	111 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.56	NE	
95% CI of the absolute risk difference	(-1.48, 4.60)	NE	
p-value	0.1866	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2598	NE	

AMNOG Table SE24.8.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.6)	0	0
No	63 (98.4)	53 (100)	111 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.56	NE	
95% CI of the absolute risk difference	(-1.48, 4.60)	NE	
p-value	0.1866	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0283	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (3.1)	1 (1.9)	0
No	62 (96.9)	52 (98.1)	111 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.13	1.89	
95% CI of the absolute risk difference	(-1.14, 7.39)	(-1.78, 5.55)	
p-value	0.0610	0.1466	
p-value of Breslow-Day Test for Homogeneity [3]	0.0384	0.2791	

AMNOG Table SE24.8.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.6)	0	0
No	63 (98.4)	53 (100)	111 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.56	NE	
95% CI of the absolute risk difference	(-1.48, 4.60)	NE	
p-value	0.1866	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1304	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (3.1)	1 (1.9)	0
No	62 (96.9)	52 (98.1)	111 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.13	1.89	
95% CI of the absolute risk difference	(-1.14, 7.39)	(-1.78, 5.55)	
p-value	0.0610	0.1466	
p-value of Breslow-Day Test for Homogeneity [3]	0.0259	0.1830	

AMNOG Table SE24.8.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=64)	MGL-3196 100 mg (N=53)	Placebo (N=111)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.1)	0	4 (3.6)
No	62 (96.9)	53 (100)	107 (96.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.16	NE	
95% CI of the inverse odds ratio	(0.21, 6.51)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	NE	
95% CI of the inverse risk ratio	(0.22, 6.12)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.48	-3.60	
95% CI of the absolute risk difference	(-5.97, 5.02)	(-7.07, -0.14)	
p-value	0.8669	0.1618	
p-value of Breslow-Day Test for Homogeneity [3]	0.8413	0.2537	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (6.3)	2 (3.8)	4 (3.6)
No	60 (93.8)	51 (96.2)	107 (96.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	0.95	
95% CI of the inverse odds ratio	(0.14, 2.32)	(0.17, 5.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.95	
95% CI of the inverse risk ratio	(0.15, 2.23)	(0.18, 5.05)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.65	0.17	
95% CI of the absolute risk difference	(-4.22, 9.52)	(-6.02, 6.36)	
p-value	0.4195	0.9568	
p-value of Breslow-Day Test for Homogeneity [3]	0.4604	0.9455	

AMNOG Table SE24.8.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.0)	0	1 (0.5)
No	102 (99.0)	98 (100)	191 (99.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	NE	
95% CI of the inverse odds ratio	(0.03, 8.63)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.54	NE	
95% CI of the inverse risk ratio	(0.03, 8.49)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.45	-0.52	
95% CI of the absolute risk difference	(-1.70, 2.60)	(-1.54, 0.50)	
p-value	0.6534	0.4742	
p-value of Breslow-Day Test for Homogeneity [3]	0.3980	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.0)	0	2 (1.0)
No	102 (99.0)	98 (100)	190 (99.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	NE	
95% CI of the inverse odds ratio	(0.10, 11.98)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	NE	
95% CI of the inverse risk ratio	(0.10, 11.69)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.07	-1.04	
95% CI of the absolute risk difference	(-2.45, 2.31)	(-2.48, 0.39)	
p-value	0.9539	0.3106	
p-value of Breslow-Day Test for Homogeneity [3]	0.2598	NE	

AMNOG Table SE24.8.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (1.0)	4 (2.1)
No	103 (100)	97 (99.0)	188 (97.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	2.06	
95% CI of the inverse odds ratio	NE	(0.23, 18.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	2.04	
95% CI of the inverse risk ratio	NE	(0.23, 18.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.08	-1.06	
95% CI of the absolute risk difference	(-4.10, -0.06)	(-3.90, 1.77)	
p-value	0.1402	0.5107	
p-value of Breslow-Day Test for Homogeneity [3]	0.0283	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.0)	4 (4.1)	5 (2.6)
No	102 (99.0)	94 (95.9)	187 (97.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.73	0.63	
95% CI of the inverse odds ratio	(0.31, 23.66)	(0.16, 2.39)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.68	0.64	
95% CI of the inverse risk ratio	(0.32, 22.65)	(0.18, 2.32)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.63	1.48	
95% CI of the absolute risk difference	(-4.58, 1.31)	(-3.04, 6.00)	
p-value	0.3435	0.4925	
p-value of Breslow-Day Test for Homogeneity [3]	0.0384	0.2791	

AMNOG Table SE24.8.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.0)	1 (1.0)	4 (2.1)
No	102 (99.0)	97 (99.0)	188 (97.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.17	2.06	
95% CI of the inverse odds ratio	(0.24, 19.67)	(0.23, 18.72)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.15	2.04	
95% CI of the inverse risk ratio	(0.24, 18.95)	(0.23, 18.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.11	-1.06	
95% CI of the absolute risk difference	(-3.88, 1.66)	(-3.90, 1.77)	
p-value	0.4804	0.5107	
p-value of Breslow-Day Test for Homogeneity [3]	0.1304	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.0)	3 (3.1)	6 (3.1)
No	102 (99.0)	95 (96.9)	186 (96.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.29	1.02	
95% CI of the inverse odds ratio	(0.39, 27.71)	(0.25, 4.17)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.22	1.02	
95% CI of the inverse risk ratio	(0.39, 26.38)	(0.26, 3.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.15	-0.06	
95% CI of the absolute risk difference	(-5.26, 0.95)	(-4.27, 4.14)	
p-value	0.2465	0.9764	
p-value of Breslow-Day Test for Homogeneity [3]	0.0259	0.1830	

AMNOG Table SE24.8.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only

Parameter Response Statistic/Category	MGL-3196 80 mg (N=103)	MGL-3196 100 mg (N=98)	Placebo (N=192)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (2.9)	3 (3.1)	8 (4.2)
No	100 (97.1)	95 (96.9)	184 (95.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.45	1.38	
95% CI of the inverse odds ratio	(0.38, 5.59)	(0.36, 5.31)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.43	1.36	
95% CI of the inverse risk ratio	(0.39, 5.28)	(0.37, 5.02)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.25	-1.11	
95% CI of the absolute risk difference	(-5.56, 3.05)	(-5.54, 3.32)	
p-value	0.5879	0.6411	
p-value of Breslow-Day Test for Homogeneity [3]	0.8413	0.2537	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (5.8)	6 (6.1)	12 (6.3)
No	97 (94.2)	92 (93.9)	180 (93.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.08	1.02	
95% CI of the inverse odds ratio	(0.39, 2.96)	(0.37, 2.81)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.02	
95% CI of the inverse risk ratio	(0.41, 2.78)	(0.40, 2.64)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.42	-0.13	
95% CI of the absolute risk difference	(-6.10, 5.25)	(-5.98, 5.73)	
p-value	0.8845	0.9660	
p-value of Breslow-Day Test for Homogeneity [3]	0.4604	0.9455	

Madrigal Pharmaceuticals, Inc. Page 1 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE24.8.5
Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F2 only
Absenteeism



Patients with result at given visit			
MGL-3196 80 mg	14	17	15
MGL-3196 100 mg	11	15	18
Placebo	25	35	39

Abbreviations: Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE24.8.5
Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain;
by Fibrosis Stage at Baseline
(Label Population)

Fibrosis Stage at Baseline: F3 only
Absenteeism



Patients with result at given visit			
MGL-3196 80 mg	14	24	22
MGL-3196 100 mg	33	27	30
Placebo	42	49	57

Abbreviations: Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.9.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Absenteeism						
Baseline						
m	27	22	39			
n	6	7	9			
Mean (SD)	1.17 (2.86)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 7.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	27	22	37			
n	9	6	14	4	5	7
Mean (SD/SE)	0.00 (0.00)	4.90 (12.00)	0.00 (0.00)	0.00 (0.00)	5.88 (5.88)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 29.4	0.0, 0.0	0.0, 0.0	0.0, 29.4	0.0, 0.0
Week 52						
m	25	19	36			
n	9	5	16	3	4	5
Mean (SD/SE)	5.56 (16.67)	13.34 (29.83)	0.00 (0.00)	16.67 (16.67)	16.68 (16.68)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 50.00	0.00, 33.35	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 66.7	0.0, 0.0	0.0, 50.0	0.0, 66.7	0.0, 0.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.9.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Presenteeism						
Baseline						
m	27	22	39			
n	6	7	9			
Mean (SD)	0.0 (0.0)	4.3 (5.3)	0.0 (0.0)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 0.0			
Min, Max	0, 0	0, 10	0, 0			
Week 24						
m	27	22	37			
n	9	6	14	4	5	7
Mean (SD/SE)	1.1 (3.3)	15.0 (23.5)	2.9 (8.3)	2.5 (2.5)	10.0 (12.6)	0.0 (0.0)
Median	0	5.0	0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 0.0	0.0, 5.0	0.0, 0.0	0.0, 0.0
Min, Max	0, 10	0, 60	0, 30	0, 10	-10, 60	0, 0
Week 52						
m	25	19	36			
n	9	5	16	3	4	5
Mean (SD/SE)	1.1 (3.3)	20.0 (34.6)	1.9 (5.4)	3.3 (3.3)	0.0 (4.1)	4.0 (4.0)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 0.0	0.0, 10.0	-5.0, 5.0	0.0, 0.0
Min, Max	0, 10	0, 80	0, 20	0, 10	-10, 10	0, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.9.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Overall Work Impairment						
Baseline						
m	27	22	39			
n	6	7	9			
Mean (SD)	1.17 (2.86)	4.29 (5.35)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 10.00	0.00, 0.00			
Min, Max	0.0, 7.0	0.0, 10.0	0.0, 0.0			
Week 24						
m	27	22	37			
n	9	6	14	4	5	7
Mean (SD/SE)	1.11 (3.33)	19.42 (24.78)	2.86 (8.25)	2.50 (2.50)	15.30 (12.71)	0.00 (0.00)
Median	0	10.00	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 36.50	0.00, 0.00	0.00, 5.00	0.00, 26.50	0.00, 0.00
Min, Max	0.0, 10.0	0.0, 60.0	0.0, 30.0	0.0, 10.0	-10.0, 60.0	0.0, 0.0
Week 52						
m	25	19	36			
n	9	5	16	3	4	5
Mean (SD/SE)	6.11 (18.33)	30.68 (42.08)	1.88 (5.44)	18.33 (18.33)	13.35 (16.85)	4.00 (4.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 73.40	0.00, 0.00	0.00, 55.00	-5.00, 31.70	0.00, 0.00
Min, Max	0.0, 55.0	0.0, 80.0	0.0, 20.0	0.0, 55.0	-10.0, 63.4	0.0, 20.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.9.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=27)	Visit Result MGL-3196 100 mg (N=22)	Visit Result Placebo (N=39)	Change from Baseline MGL-3196 80 mg (N=27)	Change from Baseline MGL-3196 100 mg (N=22)	Change from Baseline Placebo (N=39)
Activity Impairment						
Baseline						
m	27	22	39			
n	13	13	15			
Mean (SD)	17.7 (27.1)	13.8 (21.0)	8.7 (19.2)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 30.0	0.0, 10.0	0.0, 10.0			
Min, Max	0, 80	0, 70	0, 60			
Week 24						
m	27	22	37			
n	16	13	25	8	10	11
Mean (SD/SE)	10.6 (20.8)	14.6 (17.6)	14.0 (22.5)	1.3 (3.0)	1.0 (9.5)	1.8 (3.3)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 15.0	0.0, 20.0	0.0, 20.0	0.0, 0.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 70	0, 60	0, 80	-10, 20	-60, 60	-10, 30
Week 52						
m	25	19	36			
n	20	12	24	7	8	7
Mean (SD/SE)	5.5 (9.4)	25.0 (26.8)	11.3 (21.9)	-10.0 (6.9)	5.0 (8.7)	-10.0 (8.5)
Median	0	15.0	0	0	10.0	0
IQR: Q1, Q3	0.0, 10.0	5.0, 35.0	0.0, 20.0	-30.0, 0.0	0.0, 20.0	-40.0, 0.0
Min, Max	0, 30	0, 80	0, 100	-40, 10	-50, 30	-40, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.9.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Absenteeism						
Baseline						
m	140	129	264			
n	22	37	58			
Mean (SD)	4.13 (9.85)	2.71 (11.94)	3.04 (14.10)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 34.8	0.0, 68.1	0.0, 100.0			
Week 24						
m	134	119	252			
n	32	36	70	17	17	38
Mean (SD/SE)	1.38 (4.40)	0.58 (2.65)	0.00 (0.00)	-3.63 (2.32)	0.05 (0.05)	-4.57 (2.80)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 16.7	0.0, 15.0	0.0, 0.0	-26.7, 12.5	0.0, 0.9	-100.0, 0.0
Week 52						
m	124	106	234			
n	28	43	80	8	20	31
Mean (SD/SE)	3.13 (11.14)	2.67 (9.83)	4.55 (15.04)	-6.03 (3.84)	4.03 (2.99)	2.26 (2.68)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-10.75, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 55.6	0.0, 75.0	-26.7, 0.0	0.0, 55.6	-33.3, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.9.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Presenteeism						
Baseline						
m	140	129	264			
n	22	37	57			
Mean (SD)	9.1 (19.7)	11.4 (17.0)	8.8 (16.8)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 10.0			
Min, Max	0, 70	0, 70	0, 70			
Week 24						
m	134	119	252			
n	32	36	70	17	17	37
Mean (SD/SE)	13.1 (22.8)	10.6 (17.1)	8.3 (16.2)	8.2 (8.0)	2.4 (4.2)	1.6 (3.6)
Median	0	5.0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 15.0	0.0, 10.0	0.0, 0.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 90	0, 80	0, 70	-40, 90	-30, 50	-60, 70
Week 52						
m	124	106	234			
n	28	43	80	8	20	31
Mean (SD/SE)	15.7 (22.8)	10.0 (17.9)	8.8 (16.7)	10.0 (13.4)	1.0 (3.3)	1.3 (3.9)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 10.0	0.0, 10.0	-10.0, 20.0	0.0, 0.0	0.0, 10.0
Min, Max	0, 90	0, 90	0, 80	-30, 90	-40, 30	-50, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.9.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Overall Work Impairment						
Baseline						
m	140	129	264			
n	22	37	57			
Mean (SD)	11.51 (22.85)	13.75 (20.09)	9.84 (17.97)			
Median	0	10.00	0			
IQR: Q1, Q3	0.00, 10.00	0.00, 20.00	0.00, 10.00			
Min, Max	0.0, 76.0	0.0, 70.0	0.0, 70.0			
Week 24						
m	134	119	252			
n	32	36	70	17	17	37
Mean (SD/SE)	13.85 (23.57)	11.03 (17.38)	8.29 (16.24)	5.76 (8.55)	2.40 (4.16)	0.02 (3.76)
Median	0	5.00	0	0	0	0
IQR: Q1, Q3	0.00, 25.00	0.00, 17.55	0.00, 10.00	-9.40, 0.00	0.00, 10.00	-9.10, 0.00
Min, Max	0.0, 91.3	0.0, 80.0	0.0, 70.0	-46.0, 91.3	-30.0, 50.0	-60.0, 70.0
Week 52						
m	124	106	234			
n	28	43	80	8	20	31
Mean (SD/SE)	17.50 (25.68)	12.08 (20.29)	12.07 (22.30)	6.59 (14.55)	4.63 (4.39)	2.63 (4.84)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 30.00	0.00, 20.00	0.00, 10.00	-20.65, 20.00	0.00, 6.25	0.00, 10.00
Min, Max	0.0, 90.0	0.0, 91.2	0.0, 87.5	-36.0, 90.0	-40.0, 60.0	-53.3, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.9.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=140)	Visit Result MGL-3196 100 mg (N=129)	Visit Result Placebo (N=264)	Change from Baseline MGL-3196 80 mg (N=140)	Change from Baseline MGL-3196 100 mg (N=129)	Change from Baseline Placebo (N=264)
Activity Impairment						
Baseline						
m	140	129	264			
n	52	62	108			
Mean (SD)	14.0 (23.5)	12.4 (17.4)	18.8 (26.5)			
Median	0	5.0	10.0			
IQR: Q1, Q3	0.0, 25.0	0.0, 20.0	0.0, 35.0			
Min, Max	0, 80	0, 80	0, 100			
Week 24						
m	134	119	252			
n	74	60	127	43	37	68
Mean (SD/SE)	17.0 (22.9)	10.7 (16.0)	16.1 (23.3)	6.5 (3.8)	1.6 (2.8)	-0.3 (2.7)
Median	0	5.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 10.0	0.0, 20.0	-10.0, 10.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 80	0, 70	0, 100	-40, 80	-20, 70	-80, 70
Week 52						
m	124	106	234			
n	72	68	144	24	33	56
Mean (SD/SE)	18.2 (23.8)	14.6 (19.6)	14.1 (19.7)	4.2 (4.7)	4.5 (2.8)	-3.9 (3.1)
Median	10.0	10.0	5.0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 25.0	0.0, 20.0	-10.0, 10.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 90	0, 80	0, 80	-40, 60	-30, 40	-90, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.9.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.9.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Absenteeism			
Week 24			
m	27	22	37
n	4	5	7
Baseline Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (0.00)	5.88 (13.15)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	25	19	36
n	3	4	5
Baseline Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	16.67 (28.87)	16.68 (33.35)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.4331	0.0122	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.9.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Presenteeism			
Week 24			
m	27	22	37
n	4	5	7
Baseline Mean (SD)	0.0 (0.0)	4.0 (5.5)	0.0 (0.0)
Analysis Visit Mean (SD)	2.5 (5.0)	14.0 (26.1)	0.0 (0.0)
LS Mean of Change from Baseline (SE)	-1.23 (7.75)	17.15 (7.77)	-3.33 (5.92)
95% CI	(-17.85, 15.39)	(0.49, 33.82)	(-16.03, 9.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.10 (9.50)	20.48 (10.25)	
95% CI	(-18.28, 22.48)	(-1.49, 42.46)	
p-value	0.8283	0.0654	
Corrected Hedge's g Statistics	0.123	1.155	
95% CI	(-1.11, 1.35)	(-0.08, 2.39)	
Week 52			
m	25	19	36
n	3	4	5
Baseline Mean (SD)	0.0 (0.0)	5.0 (5.8)	0.0 (0.0)
Analysis Visit Mean (SD)	3.3 (5.8)	5.0 (10.0)	4.0 (8.9)
LS Mean of Change from Baseline (SE)	3.70 (5.32)	0.04 (5.95)	4.49 (4.35)
95% CI	(-7.70, 15.10)	(-12.71, 12.79)	(-4.85, 13.83)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.79 (6.55)	-4.45 (7.54)	
95% CI	(-14.84, 13.26)	(-20.62, 11.72)	
p-value	0.9057	0.5642	
Corrected Hedge's g Statistics	-0.072	-0.369	
95% CI	(-1.50, 1.36)	(-1.70, 0.96)	
Subgroup*Treatment Interaction p-value	0.6938	0.6027	

AMNOG Table SE24.9.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Overall Work Impairment			
Week 24			
m	27	22	37
n	4	5	7
Baseline Mean (SD)	0.00 (0.00)	4.00 (5.48)	0.00 (0.00)
Analysis Visit Mean (SD)	2.50 (5.00)	19.30 (27.70)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	2.48 (9.00)	20.23 (9.50)	-1.04 (6.88)
95% CI	(-16.83, 21.80)	(-0.15, 40.61)	(-15.81, 13.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.53 (11.25)	21.27 (11.97)	
95% CI	(-20.61, 27.67)	(-4.39, 46.94)	
p-value	0.7587	0.0972	
Corrected Hedge's g Statistics	0.178	1.008	
95% CI	(-1.05, 1.41)	(-0.21, 2.22)	
Week 52			
m	25	19	36
n	3	4	5
Baseline Mean (SD)	0.00 (0.00)	5.00 (5.77)	0.00 (0.00)
Analysis Visit Mean (SD)	18.33 (31.75)	18.35 (36.70)	4.00 (8.94)
LS Mean of Change from Baseline (SE)	22.77 (14.10)	-0.09 (15.18)	9.54 (11.33)
95% CI	(-7.48, 53.01)	(-32.65, 32.47)	(-14.76, 33.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.22 (17.45)	-9.63 (20.03)	
95% CI	(-24.21, 50.66)	(-52.59, 33.33)	
p-value	0.4611	0.6381	
Corrected Hedge's g Statistics	0.459	-0.310	
95% CI	(-0.99, 1.91)	(-1.63, 1.01)	
Subgroup*Treatment Interaction p-value	0.6359	0.1327	

AMNOG Table SE24.9.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Activity Impairment			
Week 24			
m	27	22	37
n	8	10	11
Baseline Mean (SD)	12.5 (28.2)	13.0 (22.1)	10.9 (22.1)
Analysis Visit Mean (SD)	13.8 (26.7)	14.0 (19.0)	12.7 (26.9)
LS Mean of Change from Baseline (SE)	1.23 (6.54)	0.67 (5.95)	1.31 (5.87)
95% CI	(-12.10, 14.56)	(-11.46, 12.81)	(-10.65, 13.27)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.08 (8.75)	-0.64 (8.12)	
95% CI	(-17.93, 17.76)	(-17.20, 15.92)	
p-value	0.9925	0.9378	
Corrected Hedge's g Statistics	-0.004	-0.032	
95% CI	(-0.91, 0.91)	(-0.89, 0.82)	
Week 52			
m	25	19	36
n	7	8	7
Baseline Mean (SD)	18.6 (24.8)	12.5 (23.8)	17.1 (26.3)
Analysis Visit Mean (SD)	8.6 (12.1)	17.5 (14.9)	7.1 (9.5)
LS Mean of Change from Baseline (SE)	-6.11 (4.35)	4.18 (4.47)	-7.19 (4.68)
95% CI	(-14.98, 2.76)	(-4.93, 13.29)	(-16.73, 2.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.08 (6.28)	11.37 (5.92)	
95% CI	(-11.73, 13.89)	(-0.71, 23.45)	
p-value	0.8644	0.0641	
Corrected Hedge's g Statistics	0.085	0.855	
95% CI	(-0.96, 1.13)	(-0.20, 1.91)	
Subgroup*Treatment Interaction p-value	0.6042	0.6222	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.9.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Absenteeism			
Week 24			
m	134	119	252
n	17	17	38
Baseline Mean (SD)	5.35 (10.97)	0.28 (1.16)	4.57 (17.29)
Analysis Visit Mean (SD)	1.72 (4.91)	0.34 (1.38)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-1.58 (0.63)	-2.85 (0.60)	-3.25 (0.41)
95% CI	(-2.83, -0.33)	(-4.04, -1.66)	(-4.05, -2.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.67 (0.73)	0.39 (0.72)	
95% CI	(0.23, 3.11)	(-1.05, 1.84)	
p-value	0.0237	0.5874	
Corrected Hedge's g Statistics	0.651	0.156	
95% CI	(0.07, 1.24)	(-0.42, 0.73)	
Week 52			
m	124	106	234
n	8	20	31
Baseline Mean (SD)	10.19 (14.61)	0.00 (0.00)	2.17 (7.46)
Analysis Visit Mean (SD)	4.16 (11.77)	4.03 (13.36)	4.44 (13.71)
LS Mean of Change from Baseline (SE)	-1.27 (4.89)	1.89 (3.04)	1.45 (2.37)
95% CI	(-11.00, 8.45)	(-4.15, 7.92)	(-3.27, 6.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.72 (5.50)	0.44 (3.81)	
95% CI	(-13.66, 8.22)	(-7.12, 8.01)	
p-value	0.6224	0.9076	
Corrected Hedge's g Statistics	-0.200	0.033	
95% CI	(-0.98, 0.58)	(-0.53, 0.59)	
Subgroup*Treatment Interaction p-value	0.4331	0.0122	

AMNOG Table SE24.9.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Presenteeism			
Week 24			
m	134	119	252
n	17	17	37
Baseline Mean (SD)	8.8 (21.5)	8.8 (12.7)	8.9 (18.5)
Analysis Visit Mean (SD)	17.1 (29.3)	11.2 (14.5)	10.5 (17.2)
LS Mean of Change from Baseline (SE)	5.67 (4.84)	2.41 (4.35)	0.69 (3.09)
95% CI	(-3.96, 15.29)	(-6.24, 11.06)	(-5.45, 6.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.98 (5.65)	1.72 (5.32)	
95% CI	(-6.25, 16.21)	(-8.86, 12.30)	
p-value	0.3804	0.7473	
Corrected Hedge's g Statistics	0.256	0.091	
95% CI	(-0.32, 0.83)	(-0.48, 0.67)	
Week 52			
m	124	106	234
n	8	20	31
Baseline Mean (SD)	17.5 (29.6)	9.5 (13.2)	9.0 (19.7)
Analysis Visit Mean (SD)	27.5 (33.3)	10.5 (14.7)	10.3 (18.9)
LS Mean of Change from Baseline (SE)	13.85 (5.88)	-0.17 (4.02)	0.30 (3.13)
95% CI	(2.15, 25.55)	(-8.15, 7.82)	(-5.93, 6.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.55 (6.59)	-0.47 (5.06)	
95% CI	(0.45, 26.65)	(-10.53, 9.59)	
p-value	0.0428	0.9268	
Corrected Hedge's g Statistics	0.767	-0.026	
95% CI	(-0.03, 1.56)	(-0.59, 0.54)	
Subgroup*Treatment Interaction p-value	0.6938	0.6027	

AMNOG Table SE24.9.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Overall Work Impairment			
Week 24			
m	134	119	252
n	17	17	37
Baseline Mean (SD)	11.96 (25.19)	9.08 (12.76)	10.52 (20.05)
Analysis Visit Mean (SD)	17.72 (30.10)	11.48 (14.55)	10.54 (17.15)
LS Mean of Change from Baseline (SE)	4.92 (4.95)	-0.14 (4.43)	-0.89 (3.14)
95% CI	(-4.92, 14.75)	(-8.95, 8.67)	(-7.13, 5.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.80 (5.74)	0.75 (5.42)	
95% CI	(-5.61, 17.22)	(-10.02, 11.52)	
p-value	0.3151	0.8904	
Corrected Hedge's g Statistics	0.293	0.039	
95% CI	(-0.28, 0.87)	(-0.54, 0.61)	
Week 52			
m	124	106	234
n	8	20	31
Baseline Mean (SD)	22.99 (34.15)	9.50 (13.17)	10.80 (21.26)
Analysis Visit Mean (SD)	29.58 (35.33)	14.13 (18.87)	13.44 (23.76)
LS Mean of Change from Baseline (SE)	13.35 (7.31)	2.67 (4.94)	1.85 (3.87)
95% CI	(-1.19, 27.88)	(-7.14, 12.49)	(-5.84, 9.54)
LS Mean of Change from Baseline Compared to Placebo (SE)	11.49 (8.20)	0.82 (6.24)	
95% CI	(-4.81, 27.80)	(-11.58, 13.22)	
p-value	0.1647	0.8957	
Corrected Hedge's g Statistics	0.527	0.037	
95% CI	(-0.26, 1.31)	(-0.53, 0.60)	
Subgroup*Treatment Interaction p-value	0.6359	0.1327	

AMNOG Table SE24.9.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Visit Statistic	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Activity Impairment			
Week 24			
m	134	119	252
n	43	37	68
Baseline Mean (SD)	12.6 (22.5)	11.1 (14.5)	16.8 (25.1)
Analysis Visit Mean (SD)	19.1 (24.4)	12.7 (17.4)	16.5 (23.3)
LS Mean of Change from Baseline (SE)	4.64 (3.01)	-0.83 (3.17)	0.61 (2.33)
95% CI	(-1.30, 10.58)	(-7.09, 5.42)	(-3.99, 5.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.03 (3.74)	-1.45 (3.91)	
95% CI	(-3.36, 11.41)	(-9.16, 6.27)	
p-value	0.2836	0.7116	
Corrected Hedge's g Statistics	0.206	-0.075	
95% CI	(-0.18, 0.59)	(-0.48, 0.33)	
Week 52			
m	124	106	234
n	24	33	56
Baseline Mean (SD)	14.6 (24.1)	12.7 (14.6)	18.2 (26.9)
Analysis Visit Mean (SD)	18.8 (21.7)	17.3 (20.0)	14.3 (20.1)
LS Mean of Change from Baseline (SE)	4.66 (3.50)	2.72 (3.03)	-2.82 (2.31)
95% CI	(-2.24, 11.56)	(-3.26, 8.70)	(-7.37, 1.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.47 (4.13)	5.54 (3.80)	
95% CI	(-0.68, 15.62)	(-1.96, 13.03)	
p-value	0.0720	0.1467	
Corrected Hedge's g Statistics	0.429	0.317	
95% CI	(-0.05, 0.91)	(-0.12, 0.75)	
Subgroup*Treatment Interaction p-value	0.6042	0.6222	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.9.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval;N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.9.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	27 (100)	22 (100)	39 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	27 (100)	22 (100)	39 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.9.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	27 (100)	22 (100)	39 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (4.5)	0
No	27 (100)	21 (95.5)	39 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	4.55	
95% CI of the absolute risk difference	NE	(-4.16, 13.25)	
p-value	NE	0.1794	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.3198	

AMNOG Table SE24.9.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	27 (100)	22 (100)	39 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (4.5)	0
No	27 (100)	21 (95.5)	39 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	4.55	
95% CI of the absolute risk difference	NE	(-4.16, 13.25)	
p-value	NE	0.1794	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2218	

AMNOG Table SE24.9.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=27)	MGL-3196 100 mg (N=22)	Placebo (N=39)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (7.4)	1 (4.5)	2 (5.1)
No	25 (92.6)	21 (95.5)	37 (94.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	1.14	
95% CI of the inverse odds ratio	(0.09, 5.12)	(0.10, 13.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.13	
95% CI of the inverse risk ratio	(0.10, 4.62)	(0.11, 11.75)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.28	-0.58	
95% CI of the absolute risk difference	(-9.78, 14.34)	(-11.70, 10.54)	
p-value	0.7028	0.9195	
p-value of Breslow-Day Test for Homogeneity [3]	0.4189	0.5880	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (11.1)	1 (4.5)	3 (7.7)
No	24 (88.9)	21 (95.5)	36 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	1.75	
95% CI of the inverse odds ratio	(0.12, 3.58)	(0.17, 17.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.69	1.69	
95% CI of the inverse risk ratio	(0.15, 3.18)	(0.19, 15.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.42	-3.15	
95% CI of the absolute risk difference	(-11.09, 17.93)	(-15.22, 8.92)	
p-value	0.6348	0.6335	
p-value of Breslow-Day Test for Homogeneity [3]	0.6915	0.6016	

AMNOG Table SE24.9.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (1.4)	0	1 (0.4)
No	138 (98.6)	129 (100)	263 (99.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.26	NE	
95% CI of the inverse odds ratio	(0.02, 2.92)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.27	NE	
95% CI of the inverse risk ratio	(0.02, 2.90)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.05	-0.38	
95% CI of the absolute risk difference	(-1.05, 3.15)	(-1.12, 0.36)	
p-value	0.2422	0.4840	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (1.4)	0	2 (0.8)
No	138 (98.6)	129 (100)	262 (99.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	NE	
95% CI of the inverse odds ratio	(0.07, 3.78)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	NE	
95% CI of the inverse risk ratio	(0.08, 3.72)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.67	-0.76	
95% CI of the absolute risk difference	(-1.56, 2.90)	(-1.80, 0.29)	
p-value	0.5168	0.3216	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.9.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (0.7)	1 (0.8)	4 (1.5)
No	139 (99.3)	128 (99.2)	260 (98.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.14	1.97	
95% CI of the inverse odds ratio	(0.24, 19.32)	(0.22, 17.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.12	1.95	
95% CI of the inverse risk ratio	(0.24, 18.80)	(0.22, 17.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.80	-0.74	
95% CI of the absolute risk difference	(-2.83, 1.23)	(-2.85, 1.37)	
p-value	0.4884	0.5388	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (2.1)	4 (3.1)	5 (1.9)
No	137 (97.9)	125 (96.9)	259 (98.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.60	
95% CI of the inverse odds ratio	(0.21, 3.74)	(0.16, 2.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.88	0.61	
95% CI of the inverse risk ratio	(0.21, 3.64)	(0.17, 2.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.25	1.21	
95% CI of the absolute risk difference	(-2.66, 3.16)	(-2.21, 4.62)	
p-value	0.8643	0.4526	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.3198	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.9.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (1.4)	1 (0.8)	4 (1.5)
No	138 (98.6)	128 (99.2)	260 (98.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.97	
95% CI of the inverse odds ratio	(0.19, 5.87)	(0.22, 17.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.95	
95% CI of the inverse risk ratio	(0.20, 5.72)	(0.22, 17.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.09	-0.74	
95% CI of the absolute risk difference	(-2.54, 2.37)	(-2.85, 1.37)	
p-value	0.9454	0.5388	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (2.1)	3 (2.3)	6 (2.3)
No	137 (97.9)	126 (97.7)	258 (97.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.98	
95% CI of the inverse odds ratio	(0.26, 4.31)	(0.24, 3.97)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	0.98	
95% CI of the inverse risk ratio	(0.27, 4.18)	(0.25, 3.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.13	0.05	
95% CI of the absolute risk difference	(-3.13, 2.87)	(-3.11, 3.21)	
p-value	0.9329	0.9738	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2218	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.9.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues

Parameter Response Statistic/Category	MGL-3196 80 mg (N=140)	MGL-3196 100 mg (N=129)	Placebo (N=264)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (2.1)	2 (1.6)	10 (3.8)
No	137 (97.9)	127 (98.4)	254 (96.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.80	2.50	
95% CI of the inverse odds ratio	(0.49, 6.64)	(0.54, 11.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	2.44	
95% CI of the inverse risk ratio	(0.49, 6.32)	(0.54, 10.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.65	-2.24	
95% CI of the absolute risk difference	(-4.97, 1.68)	(-5.38, 0.90)	
p-value	0.3726	0.2260	
p-value of Breslow-Day Test for Homogeneity [3]	0.4189	0.5880	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (5.0)	7 (5.4)	13 (4.9)
No	133 (95.0)	122 (94.6)	251 (95.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.90	
95% CI of the inverse odds ratio	(0.38, 2.53)	(0.35, 2.32)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.98	0.91	
95% CI of the inverse risk ratio	(0.40, 2.41)	(0.37, 2.22)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.08	0.50	
95% CI of the absolute risk difference	(-4.38, 4.53)	(-4.20, 5.20)	
p-value	0.9734	0.8316	
p-value of Breslow-Day Test for Homogeneity [3]	0.6915	0.6016	

Madrigal Pharmaceuticals, Inc. Page 1 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE24.9.5
Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Treated GLP-1 Analogues
Absenteeism



Patients with result at given visit			
MGL-3196 80 mg	6	9	9
MGL-3196 100 mg	7	6	5
Placebo	9	14	16

Abbreviations: Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE24.9.5
Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain;
by Baseline GLP-1 Analogues
(Label Population)

Baseline GLP-1 analogues: Not treated with GLP-1 Analogues
Absenteeism



Patients with result at given visit			
MGL-3196 80 mg	22	32	28
MGL-3196 100 mg	37	36	43
Placebo	58	70	80

Abbreviations: Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.10.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Absenteeism						
Baseline						
m	19	16	43			
n	1	3	7			
Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	19	15	41			
n	3	4	5	1	1	2
Mean (SD/SE)	0.00 (0.00)	11.10 (14.10)	0.00 (0.00)	0.00 (N/A)	29.40 (N/A)	0.00 (0.00)
Median	0	7.50	0	0	29.40	0
IQR: Q1, Q3	0.00, 0.00	0.00, 22.20	0.00, 0.00	0.00, 0.00	29.40, 29.40	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 29.4	0.0, 0.0	0.0, 0.0	29.4, 29.4	0.0, 0.0
Week 52						
m	17	12	39			
n	2	6	12	0	2	6
Mean (SD/SE)	0.00 (0.00)	14.87 (26.94)	8.13 (20.46)	N/A	33.35 (33.35)	16.25 (11.27)
Median	0	0	0	N/A	33.35	0
IQR: Q1, Q3	0.00, 0.00	0.00, 22.50	0.00, 0.00	N/A	0.00, 66.70	0.00, 30.80
Min, Max	0.0, 0.0	0.0, 66.7	0.0, 66.7	N/A	0.0, 66.7	0.0, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.10.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Presenteeism						
Baseline						
m	19	16	43			
n	1	3	7			
Mean (SD)	0.0 (N/A)	20.0 (26.5)	2.9 (7.6)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 50.0	0.0, 0.0			
Min, Max	0, 0	0, 50	0, 20			
Week 24						
m	19	15	41			
n	3	4	5	1	1	2
Mean (SD/SE)	13.3 (15.3)	10.0 (8.2)	12.0 (21.7)	10.0 (N/A)	0.0 (N/A)	25.0 (25.0)
Median	10.0	10.0	0	10.0	0	25.0
IQR: Q1, Q3	0.0, 30.0	5.0, 15.0	0.0, 10.0	10.0, 10.0	0.0, 0.0	0.0, 50.0
Min, Max	0, 30	0, 20	0, 50	10, 10	0, 0	0, 50
Week 52						
m	17	12	39			
n	2	6	12	0	2	6
Mean (SD/SE)	0.0 (0.0)	10.0 (12.6)	4.2 (11.6)	N/A	-15.0 (25.0)	5.0 (3.4)
Median	0	5.0	0	N/A	-15.0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	0.0, 0.0	N/A	-40.0, 10.0	0.0, 10.0
Min, Max	0, 0	0, 30	0, 40	N/A	-40, 10	0, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.10.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Overall Work Impairment						
Baseline						
m	19	16	43			
n	1	3	7			
Mean (SD)	0.00 (N/A)	20.00 (26.46)	2.86 (7.56)			
Median	0	10.00	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 50.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 50.0	0.0, 20.0			
Week 24						
m	19	15	41			
n	3	4	5	1	1	2
Mean (SD/SE)	13.33 (15.28)	19.63 (17.47)	12.00 (21.68)	10.00 (N/A)	26.50 (N/A)	25.00 (25.00)
Median	10.00	21.00	0	10.00	26.50	25.00
IQR: Q1, Q3	0.00, 30.00	5.00, 34.25	0.00, 10.00	10.00, 10.00	26.50, 26.50	0.00, 50.00
Min, Max	0.0, 30.0	0.0, 36.5	0.0, 50.0	10.0, 10.0	26.5, 26.5	0.0, 50.0
Week 52						
m	17	12	39			
n	2	6	12	0	2	6
Mean (SD/SE)	0.00 (0.00)	21.53 (30.99)	10.71 (25.13)	N/A	11.70 (51.70)	18.08 (12.14)
Median	0	5.00	0	N/A	11.70	0
IQR: Q1, Q3	0.00, 0.00	0.00, 45.80	0.00, 0.00	N/A	-40.00, 63.40	0.00, 38.50
Min, Max	0.0, 0.0	0.0, 73.4	0.0, 70.0	N/A	-40.0, 63.4	0.0, 70.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.10.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=19)	Visit Result MGL-3196 100 mg (N=16)	Visit Result Placebo (N=43)	Change from Baseline MGL-3196 80 mg (N=19)	Change from Baseline MGL-3196 100 mg (N=16)	Change from Baseline Placebo (N=43)
Activity Impairment						
Baseline						
m	19	16	43			
n	7	9	20			
Mean (SD)	10.0 (12.9)	10.0 (13.2)	19.5 (23.3)			
Median	0	10.0	10.0			
IQR: Q1, Q3	0.0, 20.0	0.0, 10.0	0.0, 40.0			
Min, Max	0, 30	0, 40	0, 80			
Week 24						
m	19	15	41			
n	12	10	24	6	5	9
Mean (SD/SE)	28.3 (24.4)	10.0 (10.5)	25.8 (26.2)	11.7 (6.5)	2.0 (6.6)	11.1 (4.2)
Median	30.0	10.0	15.0	5.0	0	10.0
IQR: Q1, Q3	5.0, 45.0	0.0, 20.0	0.0, 50.0	0.0, 20.0	0.0, 10.0	0.0, 20.0
Min, Max	0, 70	0, 30	0, 80	0, 40	-20, 20	0, 30
Week 52						
m	17	12	39			
n	12	9	26	2	4	12
Mean (SD/SE)	15.8 (25.4)	13.3 (15.8)	15.8 (22.1)	10.0 (0.0)	2.5 (13.8)	-5.0 (5.4)
Median	5.0	10.0	10.0	10.0	5.0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 30.0	0.0, 20.0	10.0, 10.0	-20.0, 25.0	-10.0, 5.0
Min, Max	0, 80	0, 40	0, 100	10, 10	-30, 30	-40, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.10.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Absenteeism						
Baseline						
m	148	135	260			
n	27	41	60			
Mean (SD)	3.63 (9.00)	2.44 (11.36)	2.94 (13.87)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 34.8	0.0, 68.1	0.0, 100.0			
Week 24						
m	142	126	248			
n	38	38	79	20	21	43
Mean (SD/SE)	1.16 (4.06)	0.15 (0.92)	0.00 (0.00)	-3.09 (1.98)	0.04 (0.04)	-4.04 (2.49)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 16.7	0.0, 5.7	0.0, 0.0	-26.7, 12.5	0.0, 0.9	-100.0, 0.0
Week 52						
m	132	113	231			
n	35	42	84	11	22	30
Mean (SD/SE)	3.93 (12.82)	2.20 (9.44)	3.18 (12.66)	0.16 (5.73)	3.66 (2.72)	-0.91 (1.27)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-1.50, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 55.6	0.0, 75.0	-26.7, 50.0	0.0, 55.6	-33.3, 15.1

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.10.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Presenteeism						
Baseline						
m	148	135	260			
n	27	41	59			
Mean (SD)	7.4 (18.1)	9.5 (15.2)	8.1 (16.6)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0			
Min, Max	0, 70	0, 70	0, 70			
Week 24						
m	142	126	248			
n	38	38	79	20	21	42
Mean (SD/SE)	10.3 (21.2)	11.3 (18.6)	7.1 (14.9)	7.0 (6.8)	4.3 (4.4)	0.2 (2.9)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 10.0	0.0, 0.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 90	0, 80	0, 70	-40, 90	-30, 60	-60, 70
Week 52						
m	132	113	231			
n	35	42	84	11	22	30
Mean (SD/SE)	12.9 (21.2)	11.2 (20.9)	8.1 (16.1)	8.2 (9.6)	2.3 (2.4)	1.0 (4.0)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 10.0	0.0, 10.0	-10.0, 10.0	0.0, 0.0	0.0, 0.0
Min, Max	0, 90	0, 90	0, 80	-30, 90	-10, 30	-50, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.10.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Overall Work Impairment						
Baseline						
m	148	135	260			
n	27	41	59			
Mean (SD)	9.64 (20.96)	11.68 (18.46)	9.16 (17.74)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 9.40	0.00, 14.30	0.00, 10.00			
Min, Max	0.0, 76.0	0.0, 70.0	0.0, 70.0			
Week 24						
m	142	126	248			
n	38	38	79	20	21	42
Mean (SD/SE)	10.88 (22.03)	11.45 (18.63)	7.09 (14.95)	4.90 (7.25)	4.32 (4.39)	-1.17 (3.07)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 10.00	0.00, 20.00	0.00, 10.00	-4.70, 0.00	0.00, 10.00	-4.40, 0.00
Min, Max	0.0, 91.3	0.0, 80.0	0.0, 70.0	-46.0, 91.3	-30.0, 60.0	-60.0, 70.0
Week 52						
m	132	113	231			
n	35	42	84	11	22	30
Mean (SD/SE)	15.57 (24.81)	12.95 (22.49)	10.32 (20.29)	9.79 (11.35)	5.57 (3.47)	-0.23 (4.29)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 30.00	0.00, 20.00	0.00, 10.00	-7.30, 40.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 90.0	0.0, 91.2	0.0, 87.5	-36.0, 90.0	-10.0, 60.0	-53.3, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.10.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=148)	Visit Result MGL-3196 100 mg (N=135)	Visit Result Placebo (N=260)	Change from Baseline MGL-3196 80 mg (N=148)	Change from Baseline MGL-3196 100 mg (N=135)	Change from Baseline Placebo (N=260)
Activity Impairment						
Baseline						
m	148	135	260			
n	58	66	103			
Mean (SD)	15.3 (25.1)	13.0 (18.6)	17.2 (26.4)			
Median	0	5.0	0			
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0			
Min, Max	0, 80	0, 80	0, 100			
Week 24						
m	142	126	248			
n	78	63	128	45	42	70
Mean (SD/SE)	14.0 (21.8)	11.6 (17.1)	13.9 (22.1)	4.9 (3.6)	1.4 (3.2)	-1.4 (2.6)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 20.0	0.0, 20.0	-10.0, 0.0	0.0, 10.0	-10.0, 0.0
Min, Max	0, 80	0, 70	0, 100	-40, 80	-60, 70	-80, 70
Week 52						
m	132	113	231			
n	80	71	142	29	37	51
Mean (SD/SE)	15.4 (21.8)	16.5 (21.6)	13.3 (19.6)	0.3 (4.3)	4.9 (2.8)	-4.5 (3.4)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 30.0	0.0, 20.0	-10.0, 0.0	0.0, 10.0	-10.0, 10.0
Min, Max	0, 90	0, 80	0, 80	-40, 60	-50, 40	-90, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.10.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.10.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Absenteeism			
Week 24			
m	19	15	41
n	1	1	2
Baseline Mean (SD)	0.00 (N/A)	0.00 (N/A)	0.00 (0.00)
Analysis Visit Mean (SD)	0.00 (N/A)	29.40 (N/A)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	17	12	39
n	0	2	6
Baseline Mean (SD)	N/A	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	N/A	33.35 (47.16)	16.25 (27.62)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.9267	<0.0001	

AMNOG Table SE24.10.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Presenteeism			
Week 24			
m	19	15	41
n	1	1	2
Baseline Mean (SD)	0.0 (N/A)	10.0 (N/A)	0.0 (0.0)
Analysis Visit Mean (SD)	10.0 (N/A)	10.0 (N/A)	25.0 (35.4)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	17	12	39
n	0	2	6
Baseline Mean (SD)	N/A	30.0 (28.3)	3.3 (8.2)
Analysis Visit Mean (SD)	N/A	15.0 (7.1)	8.3 (16.0)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.6759	0.3123	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.10.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Overall Work Impairment			
Week 24			
m	19	15	41
n	1	1	2
Baseline Mean (SD)	0.00 (N/A)	10.00 (N/A)	0.00 (0.00)
Analysis Visit Mean (SD)	10.00 (N/A)	36.50 (N/A)	25.00 (35.36)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	17	12	39
n	0	2	6
Baseline Mean (SD)	N/A	30.00 (28.28)	3.33 (8.16)
Analysis Visit Mean (SD)	N/A	41.70 (44.83)	21.42 (33.38)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.5306	0.9940	

AMNOG Table SE24.10.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Visit Statistic	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Activity Impairment			
Week 24			
m	19	15	41
n	6	5	9
Baseline Mean (SD)	8.3 (13.3)	14.0 (15.2)	28.9 (27.1)
Analysis Visit Mean (SD)	20.0 (19.0)	16.0 (11.4)	40.0 (28.3)
LS Mean of Change from Baseline (SE)	11.90 (6.90)	2.51 (7.06)	12.53 (5.41)
95% CI	(-2.40, 26.21)	(-12.13, 17.14)	(1.31, 23.74)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.63 (9.19)	-10.02 (9.06)	
95% CI	(-19.68, 18.43)	(-28.81, 8.77)	
p-value	0.9464	0.2806	
Corrected Hedge's g Statistics	-0.036	-0.584	
95% CI	(-1.07, 1.00)	(-1.70, 0.53)	
Week 52			
m	17	12	39
n	2	4	12
Baseline Mean (SD)	0.0 (0.0)	17.5 (15.0)	15.8 (19.8)
Analysis Visit Mean (SD)	10.0 (0.0)	20.0 (18.3)	10.8 (12.4)
LS Mean of Change from Baseline (SE)	-4.71 (10.41)	4.02 (7.11)	-6.45 (4.02)
95% CI	(-26.29, 16.87)	(-10.73, 18.76)	(-14.78, 1.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.74 (11.17)	10.46 (8.31)	
95% CI	(-21.43, 24.90)	(-6.78, 27.71)	
p-value	0.8779	0.2214	
Corrected Hedge's g Statistics	0.116	0.708	
95% CI	(-1.38, 1.61)	(-0.45, 1.87)	
Subgroup*Treatment Interaction p-value	0.6993	0.4766	

AMNOG Table SE24.10.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Absenteeism			
Week 24			
m	142	126	248
n	20	21	43
Baseline Mean (SD)	4.55 (10.26)	0.23 (1.05)	4.04 (16.30)
Analysis Visit Mean (SD)	1.46 (4.55)	0.27 (1.24)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-1.29 (0.55)	-2.63 (0.51)	-2.90 (0.37)
95% CI	(-2.37, -0.20)	(-3.64, -1.63)	(-3.63, -2.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.61 (0.63)	0.27 (0.61)	
95% CI	(0.36, 2.86)	(-0.95, 1.48)	
p-value	0.0119	0.6652	
Corrected Hedge's g Statistics	0.657	0.110	
95% CI	(0.11, 1.20)	(-0.41, 0.63)	
Week 52			
m	132	113	231
n	11	22	30
Baseline Mean (SD)	7.41 (13.12)	0.00 (0.00)	2.25 (7.58)
Analysis Visit Mean (SD)	7.57 (17.26)	3.66 (12.76)	1.34 (5.25)
LS Mean of Change from Baseline (SE)	3.35 (3.27)	1.64 (2.33)	-1.50 (1.94)
95% CI	(-3.13, 9.84)	(-2.98, 6.27)	(-5.34, 2.35)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.85 (3.81)	3.14 (3.01)	
95% CI	(-2.72, 12.42)	(-2.84, 9.12)	
p-value	0.2065	0.2998	
Corrected Hedge's g Statistics	0.446	0.288	
95% CI	(-0.25, 1.14)	(-0.27, 0.84)	
Subgroup*Treatment Interaction p-value	0.9267	<0.0001	

AMNOG Table SE24.10.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Presenteeism			
Week 24			
m	142	126	248
n	20	21	42
Baseline Mean (SD)	7.5 (20.0)	7.6 (11.8)	7.9 (17.6)
Analysis Visit Mean (SD)	14.5 (27.6)	11.9 (17.5)	8.1 (15.2)
LS Mean of Change from Baseline (SE)	4.21 (4.32)	4.66 (3.86)	-1.11 (2.93)
95% CI	(-4.38, 12.80)	(-3.00, 12.32)	(-6.92, 4.71)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.32 (5.02)	5.77 (4.76)	
95% CI	(-4.66, 15.29)	(-3.68, 15.22)	
p-value	0.2925	0.2285	
Corrected Hedge's g Statistics	0.275	0.307	
95% CI	(-0.26, 0.81)	(-0.22, 0.83)	
Week 52			
m	132	113	231
n	11	22	30
Baseline Mean (SD)	12.7 (26.1)	6.8 (8.9)	8.7 (20.0)
Analysis Visit Mean (SD)	20.9 (30.2)	9.1 (14.4)	9.7 (18.5)
LS Mean of Change from Baseline (SE)	9.92 (5.10)	-0.65 (3.76)	0.39 (3.19)
95% CI	(-0.20, 20.04)	(-8.11, 6.81)	(-5.94, 6.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.54 (5.81)	-1.03 (4.81)	
95% CI	(-1.99, 21.06)	(-10.58, 8.51)	
p-value	0.1038	0.8305	
Corrected Hedge's g Statistics	0.540	-0.058	
95% CI	(-0.16, 1.24)	(-0.61, 0.49)	
Subgroup*Treatment Interaction p-value	0.6759	0.3123	

AMNOG Table SE24.10.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Overall Work Impairment			
Week 24			
m	142	126	248
n	20	21	42
Baseline Mean (SD)	10.17 (23.52)	7.82 (11.87)	9.27 (19.10)
Analysis Visit Mean (SD)	15.07 (28.37)	12.15 (17.51)	8.10 (15.18)
LS Mean of Change from Baseline (SE)	4.16 (4.44)	2.41 (4.00)	-2.69 (3.00)
95% CI	(-4.65, 12.98)	(-5.53, 10.35)	(-8.64, 3.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.86 (5.14)	5.10 (4.91)	
95% CI	(-3.35, 17.07)	(-4.64, 14.85)	
p-value	0.1857	0.3013	
Corrected Hedge's g Statistics	0.346	0.264	
95% CI	(-0.19, 0.88)	(-0.26, 0.79)	
Week 52			
m	132	113	231
n	11	22	30
Baseline Mean (SD)	16.72 (30.53)	6.82 (8.94)	10.50 (21.56)
Analysis Visit Mean (SD)	26.51 (33.21)	12.39 (18.62)	10.27 (19.87)
LS Mean of Change from Baseline (SE)	12.25 (6.02)	1.76 (4.37)	-0.74 (3.71)
95% CI	(0.30, 24.21)	(-6.92, 10.43)	(-8.11, 6.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.99 (6.87)	2.49 (5.63)	
95% CI	(-0.65, 26.63)	(-8.68, 13.67)	
p-value	0.0616	0.6587	
Corrected Hedge's g Statistics	0.629	0.120	
95% CI	(-0.07, 1.33)	(-0.43, 0.67)	
Subgroup*Treatment Interaction p-value	0.5306	0.9940	

AMNOG Table SE24.10.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Visit Statistic	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Activity Impairment			
Week 24			
m	142	126	248
n	45	42	70
Baseline Mean (SD)	13.1 (24.2)	11.2 (16.4)	14.3 (24.1)
Analysis Visit Mean (SD)	18.0 (25.4)	12.6 (18.2)	12.9 (21.3)
LS Mean of Change from Baseline (SE)	3.33 (2.90)	-1.00 (2.94)	-1.42 (2.32)
95% CI	(-2.39, 9.05)	(-6.81, 4.81)	(-6.00, 3.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.75 (3.59)	0.42 (3.67)	
95% CI	(-2.34, 11.84)	(-6.82, 7.65)	
p-value	0.1876	0.9097	
Corrected Hedge's g Statistics	0.243	0.021	
95% CI	(-0.13, 0.62)	(-0.36, 0.40)	
Week 52			
m	132	113	231
n	29	37	51
Baseline Mean (SD)	16.6 (24.4)	12.2 (16.7)	18.6 (28.1)
Analysis Visit Mean (SD)	16.9 (20.9)	17.0 (19.3)	14.1 (20.6)
LS Mean of Change from Baseline (SE)	2.78 (3.21)	2.70 (2.86)	-3.09 (2.44)
95% CI	(-3.56, 9.12)	(-2.94, 8.34)	(-7.90, 1.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.87 (3.89)	5.79 (3.68)	
95% CI	(-1.81, 13.55)	(-1.47, 13.06)	
p-value	0.1331	0.1173	
Corrected Hedge's g Statistics	0.335	0.330	
95% CI	(-0.12, 0.79)	(-0.10, 0.76)	
Subgroup*Treatment Interaction p-value	0.6993	0.4766	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.10.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.10.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	19 (100)	16 (100)	43 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	19 (100)	16 (100)	43 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.10.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.3)	0
No	19 (100)	15 (93.8)	43 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.12	
95% CI of the inverse odds ratio	NE	(0.00, 3.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 3.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	7.69	
95% CI of the absolute risk difference	NE	(-6.15, 21.53)	
p-value	NE	0.1306	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0129	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.3)	0
No	19 (100)	15 (93.8)	43 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.12	
95% CI of the inverse odds ratio	NE	(0.00, 3.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 3.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	7.69	
95% CI of the absolute risk difference	NE	(-6.15, 21.53)	
p-value	NE	0.1306	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2165	

AMNOG Table SE24.10.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.3)	0
No	19 (100)	15 (93.8)	43 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.12	
95% CI of the inverse odds ratio	NE	(0.00, 3.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 3.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	7.69	
95% CI of the absolute risk difference	NE	(-6.15, 21.53)	
p-value	NE	0.1306	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0129	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (6.3)	0
No	19 (100)	15 (93.8)	43 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.12	
95% CI of the inverse odds ratio	NE	(0.00, 3.07)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.13	
95% CI of the inverse risk ratio	NE	(0.01, 3.01)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	7.69	
95% CI of the absolute risk difference	NE	(-6.15, 21.53)	
p-value	NE	0.1306	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1311	

AMNOG Table SE24.10.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes

Parameter Response Statistic/Category	MGL-3196 80 mg (N=19)	MGL-3196 100 mg (N=16)	Placebo (N=43)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (6.3)	3 (7.0)
No	19 (100)	15 (93.8)	40 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.37	1.13	
95% CI of the inverse odds ratio	(0.17, 68.52)	(0.11, 11.68)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	1.12	
95% CI of the inverse risk ratio	(0.17, 58.74)	(0.13, 9.97)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.45	-0.73	
95% CI of the absolute risk difference	(-15.98, 5.07)	(-14.82, 13.37)	
p-value	0.4034	0.9214	
p-value of Breslow-Day Test for Homogeneity [3]	0.2610	0.5954	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	2 (12.5)	3 (7.0)
No	19 (100)	14 (87.5)	40 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.37	0.53	
95% CI of the inverse odds ratio	(0.17, 68.52)	(0.08, 3.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.18	0.56	
95% CI of the inverse risk ratio	(0.17, 58.74)	(0.10, 3.04)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-5.45	5.52	
95% CI of the absolute risk difference	(-15.98, 5.07)	(-12.38, 23.43)	
p-value	0.4034	0.4983	
p-value of Breslow-Day Test for Homogeneity [3]	0.1832	0.4758	

AMNOG Table SE24.10.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (1.4)	0	1 (0.4)
No	146 (98.6)	135 (100)	259 (99.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	NE	
95% CI of the inverse odds ratio	(0.03, 3.14)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	NE	
95% CI of the inverse risk ratio	(0.03, 3.11)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.97	-0.38	
95% CI of the absolute risk difference	(-1.04, 2.97)	(-1.14, 0.37)	
p-value	0.2718	0.4706	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (1.4)	0	2 (0.8)
No	146 (98.6)	135 (100)	258 (99.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	NE	
95% CI of the inverse odds ratio	(0.08, 4.06)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	NE	
95% CI of the inverse risk ratio	(0.08, 4.00)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.58	-0.77	
95% CI of the absolute risk difference	(-1.56, 2.72)	(-1.83, 0.29)	
p-value	0.5661	0.3070	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.10.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (0.7)	0	4 (1.5)
No	147 (99.3)	135 (100)	256 (98.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.30	NE	
95% CI of the inverse odds ratio	(0.25, 20.74)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.28	NE	
95% CI of the inverse risk ratio	(0.26, 20.18)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.86	-1.54	
95% CI of the absolute risk difference	(-2.86, 1.13)	(-3.03, -0.04)	
p-value	0.4463	0.1475	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0129	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (2.0)	4 (3.0)	5 (1.9)
No	145 (98.0)	131 (97.0)	255 (98.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.64	
95% CI of the inverse odds ratio	(0.22, 4.02)	(0.17, 2.43)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.95	0.65	
95% CI of the inverse risk ratio	(0.23, 3.91)	(0.18, 2.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.10	1.04	
95% CI of the absolute risk difference	(-2.71, 2.92)	(-2.27, 4.35)	
p-value	0.9420	0.5112	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.2165	

AMNOG Table SE24.10.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (1.4)	0	4 (1.5)
No	146 (98.6)	135 (100)	256 (98.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	NE	
95% CI of the inverse odds ratio	(0.21, 6.30)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	NE	
95% CI of the inverse risk ratio	(0.21, 6.14)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.19	-1.54	
95% CI of the absolute risk difference	(-2.57, 2.20)	(-3.03, -0.04)	
p-value	0.8800	0.1475	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.0129	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (2.0)	3 (2.2)	6 (2.3)
No	145 (98.0)	132 (97.8)	254 (97.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	1.04	
95% CI of the inverse odds ratio	(0.28, 4.63)	(0.26, 4.22)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.14	1.04	
95% CI of the inverse risk ratio	(0.29, 4.49)	(0.26, 4.09)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.28	-0.09	
95% CI of the absolute risk difference	(-3.19, 2.63)	(-3.17, 3.00)	
p-value	0.8528	0.9569	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.1311	

AMNOG Table SE24.10.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No

Parameter Response Statistic/Category	MGL-3196 80 mg (N=148)	MGL-3196 100 mg (N=135)	Placebo (N=260)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	5 (3.4)	2 (1.5)	9 (3.5)
No	143 (96.6)	133 (98.5)	251 (96.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.03	2.38	
95% CI of the inverse odds ratio	(0.34, 3.12)	(0.51, 11.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	2.34	
95% CI of the inverse risk ratio	(0.35, 3.00)	(0.51, 10.66)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.08	-1.98	
95% CI of the absolute risk difference	(-3.75, 3.58)	(-5.00, 1.03)	
p-value	0.9646	0.2566	
p-value of Breslow-Day Test for Homogeneity [3]	0.2610	0.5954	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	10 (6.8)	6 (4.4)	13 (5.0)
No	138 (93.2)	129 (95.6)	247 (95.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.73	1.13	
95% CI of the inverse odds ratio	(0.31, 1.70)	(0.42, 3.05)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.74	1.13	
95% CI of the inverse risk ratio	(0.33, 1.65)	(0.44, 2.89)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.76	-0.56	
95% CI of the absolute risk difference	(-3.08, 6.59)	(-4.93, 3.82)	
p-value	0.4595	0.8067	
p-value of Breslow-Day Test for Homogeneity [3]	0.1832	0.4758	

Madrigal Pharmaceuticals, Inc. Page 1 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE24.10.5
Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: Yes
Absenteeism



Patients with result at given visit			
MGL-3196 80 mg	1	3	2
MGL-3196 100 mg	3	4	6
Placebo	7	5	12

Abbreviations: Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 2
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE24.10.5
Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain;
by Thyroxine at Baseline
(Label Population)

Thyroxine at Baseline: No
Absenteeism



Patients with result at given visit			
MGL-3196 80 mg	27	38	35
MGL-3196 100 mg	41	38	42
Placebo	60	79	84

Abbreviations: Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Absenteeism						
Baseline						
m	30	31	35			
n	6	10	8			
Mean (SD)	0.00 (0.00)	0.48 (1.52)	4.26 (8.96)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 4.55			
Min, Max	0.0, 0.0	0.0, 4.8	0.0, 25.0			
Week 24						
m	30	31	35			
n	6	14	15	4	8	6
Mean (SD/SE)	2.50 (6.12)	0.41 (1.52)	0.00 (0.00)	0.00 (0.00)	0.11 (0.11)	-5.68 (4.14)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	-9.10, 0.00
Min, Max	0.0, 15.0	0.0, 5.7	0.0, 0.0	0.0, 0.0	0.0, 0.9	-25.0, 0.0
Week 52						
m	29	30	35			
n	5	12	12	3	6	6
Mean (SD/SE)	10.00 (22.36)	0.00 (0.00)	6.38 (15.95)	16.67 (16.67)	0.00 (0.00)	-1.52 (1.52)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 50.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 0.0	0.0, 51.6	0.0, 50.0	0.0, 0.0	-9.1, 0.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Presenteeism						
Baseline						
m	30	31	35			
n	6	10	8			
Mean (SD)	0.0 (0.0)	10.0 (15.6)	3.8 (7.4)			
Median	0	5.0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 5.0			
Min, Max	0, 0	0, 50	0, 20			
Week 24						
m	30	31	35			
n	6	14	15	4	8	6
Mean (SD/SE)	13.3 (15.1)	7.9 (16.3)	12.7 (20.5)	12.5 (9.5)	1.3 (8.1)	0.0 (2.6)
Median	10.0	0	0	5.0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 10.0	0.0, 20.0	0.0, 25.0	-10.0, 5.0	0.0, 0.0
Min, Max	0, 40	0, 60	0, 60	0, 40	-30, 50	-10, 10
Week 52						
m	29	30	35			
n	5	12	12	3	6	6
Mean (SD/SE)	2.0 (4.5)	0.8 (2.9)	8.3 (15.9)	3.3 (3.3)	-1.7 (1.7)	5.0 (5.0)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 0.0	0.0, 10.0	0.0, 10.0	0.0, 0.0	0.0, 0.0
Min, Max	0, 10	0, 10	0, 40	0, 10	-10, 0	0, 30

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Overall Work Impairment						
Baseline						
m	30	31	35			
n	6	10	8			
Mean (SD)	0.00 (0.00)	10.43 (15.69)	7.70 (12.33)			
Median	0	5.00	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 14.30	0.00, 14.55			
Min, Max	0.0, 0.0	0.0, 50.0	0.0, 32.5			
Week 24						
m	30	31	35			
n	6	14	15	4	8	6
Mean (SD/SE)	15.33 (16.81)	8.22 (16.37)	12.67 (20.52)	12.50 (9.46)	1.35 (8.11)	-5.27 (2.40)
Median	10.00	0	0	5.00	0	-4.55
IQR: Q1, Q3	0.00, 32.00	0.00, 10.00	0.00, 20.00	0.00, 25.00	-10.00, 5.40	-10.00, 0.00
Min, Max	0.0, 40.0	0.0, 60.0	0.0, 60.0	0.0, 40.0	-30.0, 50.0	-12.5, 0.0
Week 52						
m	29	30	35			
n	5	12	12	3	6	6
Mean (SD/SE)	11.00 (24.60)	0.83 (2.89)	13.03 (24.02)	18.33 (18.33)	-1.67 (1.67)	2.23 (4.32)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 20.00	0.00, 55.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 55.0	0.0, 10.0	0.0, 61.3	0.0, 55.0	-10.0, 0.0	-9.1, 22.5

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=31)	Visit Result Placebo (N=35)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=31)	Change from Baseline Placebo (N=35)
Activity Impairment						
Baseline						
m	30	31	35			
n	13	15	18			
Mean (SD)	16.2 (28.4)	10.0 (16.5)	20.0 (26.6)			
Median	0	0	5.0			
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 40.0			
Min, Max	0, 80	0, 60	0, 80			
Week 24						
m	30	31	35			
n	14	17	23	10	12	13
Mean (SD/SE)	26.4 (29.8)	13.5 (19.0)	22.2 (27.8)	12.0 (6.8)	5.8 (6.8)	-1.5 (8.0)
Median	15.0	10.0	10.0	5.0	0	0
IQR: Q1, Q3	0.0, 50.0	0.0, 10.0	0.0, 50.0	0.0, 30.0	-5.0, 10.0	0.0, 0.0
Min, Max	0, 80	0, 70	0, 80	-20, 50	-20, 70	-80, 50
Week 52						
m	29	30	35			
n	16	17	22	7	9	13
Mean (SD/SE)	11.9 (23.7)	7.6 (12.0)	12.3 (21.4)	-8.6 (6.3)	2.2 (2.8)	-2.3 (4.1)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 20.0	-20.0, 0.0	0.0, 0.0	0.0, 0.0
Min, Max	0, 80	0, 30	0, 80	-40, 10	-10, 20	-40, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Absenteeism						
Baseline						
m	12	8	13			
n	2	2	2			
Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0			
Week 24						
m	12	8	13			
n	4	3	1	2	2	1
Mean (SD/SE)	0.00 (0.00)	0.00 (0.00)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)	0.00 (N/A)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0
Week 52						
m	12	8	12			
n	4	2	1	1	1	1
Mean (SD/SE)	0.00 (0.00)	0.00 (0.00)	0.00 (N/A)	0.00 (N/A)	0.00 (N/A)	0.00 (N/A)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Presenteeism						
Baseline						
m	12	8	13			
n	2	2	2			
Mean (SD)	0.0 (0.0)	0.0 (0.0)	30.0 (28.3)			
Median	0	0	30.0			
IQR: Q1, Q3	0.0, 0.0	0.0, 0.0	10.0, 50.0			
Min, Max	0, 0	0, 0	10, 50			
Week 24						
m	12	8	13			
n	4	3	1	2	2	1
Mean (SD/SE)	2.5 (5.0)	13.3 (5.8)	0.0 (N/A)	0.0 (0.0)	15.0 (5.0)	-50.0 (N/A)
Median	0	10.0	0	0	15.0	-50.0
IQR: Q1, Q3	0.0, 5.0	10.0, 20.0	0.0, 0.0	0.0, 0.0	10.0, 20.0	-50.0, -50.0
Min, Max	0, 10	10, 20	0, 0	0, 0	10, 20	-50, -50
Week 52						
m	12	8	12			
n	4	2	1	1	1	1
Mean (SD/SE)	12.5 (18.9)	10.0 (14.1)	0.0 (N/A)	40.0 (N/A)	20.0 (N/A)	-50.0 (N/A)
Median	5.0	10.0	0	40.0	20.0	-50.0
IQR: Q1, Q3	0.0, 25.0	0.0, 20.0	0.0, 0.0	40.0, 40.0	20.0, 20.0	-50.0, -50.0
Min, Max	0, 40	0, 20	0, 0	40, 40	20, 20	-50, -50

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Overall Work Impairment						
Baseline						
m	12	8	13			
n	2	2	2			
Mean (SD)	0.00 (0.00)	0.00 (0.00)	30.00 (28.28)			
Median	0	0	30.00			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	10.00, 50.00			
Min, Max	0.0, 0.0	0.0, 0.0	10.0, 50.0			
Week 24						
m	12	8	13			
n	4	3	1	2	2	1
Mean (SD/SE)	2.50 (5.00)	13.33 (5.77)	0.00 (N/A)	0.00 (0.00)	15.00 (5.00)	-50.00 (N/A)
Median	0	10.00	0	0	15.00	-50.00
IQR: Q1, Q3	0.00, 5.00	10.00, 20.00	0.00, 0.00	0.00, 0.00	10.00, 20.00	-50.00, -50.00
Min, Max	0.0, 10.0	10.0, 20.0	0.0, 0.0	0.0, 0.0	10.0, 20.0	-50.0, -50.0
Week 52						
m	12	8	12			
n	4	2	1	1	1	1
Mean (SD/SE)	12.50 (18.93)	10.00 (14.14)	0.00 (N/A)	40.00 (N/A)	20.00 (N/A)	-50.00 (N/A)
Median	5.00	10.00	0	40.00	20.00	-50.00
IQR: Q1, Q3	0.00, 25.00	0.00, 20.00	0.00, 0.00	40.00, 40.00	20.00, 20.00	-50.00, -50.00
Min, Max	0.0, 40.0	0.0, 20.0	0.0, 0.0	40.0, 40.0	20.0, 20.0	-50.0, -50.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=12)	Visit Result MGL-3196 100 mg (N=8)	Visit Result Placebo (N=13)	Change from Baseline MGL-3196 80 mg (N=12)	Change from Baseline MGL-3196 100 mg (N=8)	Change from Baseline Placebo (N=13)
Activity Impairment						
Baseline						
m	12	8	13			
n	4	4	5			
Mean (SD)	0.0 (0.0)	10.0 (20.0)	34.0 (23.0)			
Median	0	0	40.0			
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	10.0, 50.0			
Min, Max	0, 0	0, 40	10, 60			
Week 24						
m	12	8	13			
n	7	6	4	4	4	3
Mean (SD/SE)	1.4 (3.8)	8.3 (16.0)	15.0 (23.8)	0.0 (0.0)	0.0 (0.0)	-20.0 (15.3)
Median	0	0	5.0	0	0	-10.0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 30.0	0.0, 0.0	0.0, 0.0	-50.0, 0.0
Min, Max	0, 10	0, 40	0, 50	0, 0	0, 0	-50, 0
Week 52						
m	12	8	12			
n	7	7	7	2	3	3
Mean (SD/SE)	17.1 (29.8)	17.1 (23.6)	24.3 (21.5)	15.0 (15.0)	10.0 (5.8)	-26.7 (18.6)
Median	0	0	20.0	15.0	10.0	-40.0
IQR: Q1, Q3	0.0, 30.0	0.0, 50.0	0.0, 40.0	0.0, 30.0	0.0, 20.0	-50.0, 10.0
Min, Max	0, 80	0, 50	0, 60	0, 30	0, 20	-50, 10

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Absenteeism						
Baseline						
m	111	87	221			
n	17	27	50			
Mean (SD)	5.76 (10.89)	2.52 (13.11)	2.85 (14.81)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 7.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 34.8	0.0, 68.1	0.0, 100.0			
Week 24						
m	111	87	221			
n	29	23	61	14	11	33
Mean (SD/SE)	1.01 (3.81)	1.93 (6.75)	0.00 (0.00)	-4.41 (2.79)	2.67 (2.67)	-4.23 (3.16)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-9.40, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 16.7	0.0, 29.4	0.0, 0.0	-26.7, 12.5	0.0, 29.4	-100.0, 0.0
Week 52						
m	107	87	219			
n	28	34	82	7	17	28
Mean (SD/SE)	3.13 (11.14)	5.34 (15.41)	3.51 (13.72)	-6.89 (4.32)	8.66 (5.03)	2.83 (2.93)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-20.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 66.7	0.0, 75.0	-26.7, 0.0	0.0, 66.7	-33.3, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Presenteeism						
Baseline						
m	111	87	221			
n	17	27	49			
Mean (SD)	10.0 (22.1)	10.4 (16.8)	7.6 (16.8)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0			
Min, Max	0, 70	0, 70	0, 70			
Week 24						
m	111	87	221			
n	29	23	61	14	11	32
Mean (SD/SE)	10.7 (23.3)	13.0 (20.3)	6.4 (14.3)	7.9 (9.3)	4.5 (6.1)	2.8 (3.8)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 0.0	0.0, 0.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 90	0, 80	0, 70	-40, 90	-20, 60	-60, 70
Week 52						
m	107	87	219			
n	28	34	82	7	17	28
Mean (SD/SE)	13.9 (22.7)	14.7 (22.5)	7.7 (15.8)	5.7 (14.6)	0.6 (3.8)	2.9 (3.8)
Median	0	5.0	0	0	0	0
IQR: Q1, Q3	0.0, 25.0	0.0, 20.0	0.0, 10.0	-10.0, 0.0	0.0, 0.0	0.0, 10.0
Min, Max	0, 90	0, 90	0, 80	-30, 90	-40, 30	-40, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Overall Work Impairment						
Baseline						
m	111	87	221			
n	17	27	49			
Mean (SD)	13.55 (25.39)	12.89 (19.95)	8.14 (17.92)			
Median	0	10.00	0			
IQR: Q1, Q3	0.00, 9.40	0.00, 20.00	0.00, 10.00			
Min, Max	0.0, 76.0	0.0, 70.0	0.0, 70.0			
Week 24						
m	111	87	221			
n	29	23	61	14	11	32
Mean (SD/SE)	11.08 (23.96)	14.72 (21.19)	6.39 (14.26)	4.86 (10.06)	6.95 (6.37)	1.95 (3.97)
Median	0	10.00	0	0	0	0
IQR: Q1, Q3	0.00, 10.00	0.00, 20.00	0.00, 0.00	-9.40, 0.00	0.00, 10.00	0.00, 0.00
Min, Max	0.0, 91.3	0.0, 80.0	0.0, 70.0	-46.0, 91.3	-20.0, 60.0	-60.0, 70.0
Week 52						
m	107	87	219			
n	28	34	82	7	17	28
Mean (SD/SE)	15.71 (25.65)	18.91 (26.23)	10.23 (20.63)	1.81 (15.87)	7.99 (6.15)	4.94 (4.96)
Median	0	5.00	0	0	0	0
IQR: Q1, Q3	0.00, 26.70	0.00, 30.00	0.00, 10.00	-34.00, 0.00	0.00, 12.50	0.00, 10.00
Min, Max	0.0, 90.0	0.0, 91.2	0.0, 87.5	-36.0, 90.0	-40.0, 63.4	-53.3, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=111)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=221)	Change from Baseline MGL-3196 80 mg (N=111)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=221)
Activity Impairment						
Baseline						
m	111	87	221			
n	44	45	84			
Mean (SD)	14.5 (22.4)	13.8 (19.6)	15.8 (26.1)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0			
Min, Max	0, 80	0, 80	0, 100			
Week 24						
m	111	87	221			
n	66	44	114	36	28	55
Mean (SD/SE)	14.4 (20.7)	10.7 (15.2)	14.5 (22.2)	4.7 (4.2)	0.0 (3.8)	0.9 (2.7)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0	-10.0, 5.0	-5.0, 10.0	0.0, 10.0
Min, Max	0, 80	0, 60	0, 100	-40, 80	-60, 60	-70, 70
Week 52						
m	107	87	219			
n	68	56	138	22	29	46
Mean (SD/SE)	15.6 (20.9)	18.6 (22.4)	13.5 (19.7)	2.7 (5.1)	4.8 (3.8)	-3.7 (3.6)
Median	5.0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 30.0	0.0, 20.0	-10.0, 10.0	0.0, 20.0	0.0, 10.0
Min, Max	0, 90	0, 80	0, 100	-40, 60	-50, 40	-90, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.11.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Absenteeism			
Week 24			
m	30	31	35
n	4	8	6
Baseline Mean (SD)	0.00 (0.00)	0.60 (1.70)	5.68 (10.14)
Analysis Visit Mean (SD)	0.00 (0.00)	0.71 (2.02)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-1.39 (0.67)	-1.69 (0.50)	-2.40 (0.62)
95% CI	(-2.79, 0.01)	(-2.73, -0.64)	(-3.69, -1.11)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.01 (0.91)	0.71 (0.81)	
95% CI	(-0.90, 2.92)	(-0.98, 2.40)	
p-value	0.2812	0.3885	
Corrected Hedge's g Statistics	0.630	0.459	
95% CI	(-0.66, 1.93)	(-0.61, 1.53)	
Week 52			
m	29	30	35
n	3	6	6
Baseline Mean (SD)	0.00 (0.00)	0.00 (0.00)	5.68 (10.14)
Analysis Visit Mean (SD)	16.67 (28.87)	0.00 (0.00)	4.17 (10.21)
LS Mean of Change from Baseline (SE)	11.54 (7.15)	7.54 (5.40)	-3.01 (6.46)
95% CI	(-3.43, 26.50)	(-3.77, 18.85)	(-16.54, 10.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	14.55 (9.95)	10.55 (8.70)	
95% CI	(-6.27, 35.38)	(-7.65, 28.76)	
p-value	0.1600	0.2398	
Corrected Hedge's g Statistics	0.867	0.668	
95% CI	(-0.58, 2.31)	(-0.49, 1.83)	
Subgroup*Treatment Interaction p-value	0.6121	0.6429	

AMNOG Table SE24.11.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Presenteeism			
Week 24			
m	30	31	35
n	4	8	6
Baseline Mean (SD)	0.0 (0.0)	12.5 (16.7)	5.0 (8.4)
Analysis Visit Mean (SD)	12.5 (18.9)	13.8 (20.0)	5.0 (8.4)
LS Mean of Change from Baseline (SE)	3.81 (10.00)	7.25 (7.74)	-1.32 (8.02)
95% CI	(-17.13, 24.74)	(-8.95, 23.44)	(-18.12, 15.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.13 (12.55)	8.57 (10.94)	
95% CI	(-21.13, 31.39)	(-14.33, 31.47)	
p-value	0.6873	0.4431	
Corrected Hedge's g Statistics	0.234	0.382	
95% CI	(-1.04, 1.50)	(-0.69, 1.45)	
Week 52			
m	29	30	35
n	3	6	6
Baseline Mean (SD)	0.0 (0.0)	3.3 (5.2)	1.7 (4.1)
Analysis Visit Mean (SD)	3.3 (5.8)	1.7 (4.1)	6.7 (16.3)
LS Mean of Change from Baseline (SE)	9.42 (4.57)	3.81 (2.92)	6.50 (3.43)
95% CI	(-0.14, 18.98)	(-2.30, 9.92)	(-0.68, 13.67)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.92 (4.67)	-2.69 (4.76)	
95% CI	(-6.86, 12.70)	(-12.64, 7.27)	
p-value	0.5390	0.5788	
Corrected Hedge's g Statistics	0.314	-0.318	
95% CI	(-1.08, 1.71)	(-1.46, 0.82)	
Subgroup*Treatment Interaction p-value	0.7499	0.1786	

AMNOG Table SE24.11.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Overall Work Impairment			
Week 24			
m	30	31	35
n	4	8	6
Baseline Mean (SD)	0.00 (0.00)	13.04 (16.67)	10.27 (13.47)
Analysis Visit Mean (SD)	12.50 (18.93)	14.39 (19.90)	5.00 (8.37)
LS Mean of Change from Baseline (SE)	10.05 (9.37)	5.03 (6.62)	-1.70 (7.64)
95% CI	(-9.57, 29.67)	(-8.83, 18.90)	(-17.70, 14.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	11.75 (11.40)	6.74 (9.39)	
95% CI	(-12.11, 35.62)	(-12.91, 26.39)	
p-value	0.3157	0.4817	
Corrected Hedge's g Statistics	0.567	0.337	
95% CI	(-0.72, 1.86)	(-0.73, 1.40)	
Week 52			
m	29	30	35
n	3	6	6
Baseline Mean (SD)	0.00 (0.00)	3.33 (5.16)	6.93 (13.04)
Analysis Visit Mean (SD)	18.33 (31.75)	1.67 (4.08)	9.17 (22.45)
LS Mean of Change from Baseline (SE)	23.43 (10.92)	-0.49 (6.87)	4.45 (7.80)
95% CI	(0.58, 46.27)	(-14.87, 13.90)	(-11.87, 20.77)
LS Mean of Change from Baseline Compared to Placebo (SE)	18.98 (11.79)	-4.94 (10.88)	
95% CI	(-5.71, 43.66)	(-27.72, 17.85)	
p-value	0.1241	0.6553	
Corrected Hedge's g Statistics	0.886	-0.253	
95% CI	(-0.56, 2.33)	(-1.39, 0.88)	
Subgroup*Treatment Interaction p-value	0.8199	0.4676	

AMNOG Table SE24.11.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Activity Impairment			
Week 24			
m	30	31	35
n	10	12	13
Baseline Mean (SD)	16.0 (31.3)	12.5 (17.6)	22.3 (28.6)
Analysis Visit Mean (SD)	28.0 (30.1)	18.3 (20.8)	20.8 (31.5)
LS Mean of Change from Baseline (SE)	11.73 (7.68)	5.13 (6.99)	0.56 (6.89)
95% CI	(-3.82, 27.27)	(-9.02, 19.27)	(-13.37, 14.50)
LS Mean of Change from Baseline Compared to Placebo (SE)	11.16 (10.08)	4.57 (9.74)	
95% CI	(-9.22, 31.55)	(-15.13, 24.26)	
p-value	0.2748	0.6418	
Corrected Hedge's g Statistics	0.437	0.180	
95% CI	(-0.40, 1.27)	(-0.61, 0.97)	
Week 52			
m	29	30	35
n	7	9	13
Baseline Mean (SD)	17.1 (27.5)	7.8 (10.9)	18.5 (23.8)
Analysis Visit Mean (SD)	8.6 (18.6)	10.0 (13.2)	16.2 (26.0)
LS Mean of Change from Baseline (SE)	-7.82 (5.39)	0.78 (4.40)	-3.26 (4.19)
95% CI	(-18.71, 3.08)	(-8.12, 9.67)	(-11.72, 5.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.56 (6.04)	4.03 (6.11)	
95% CI	(-16.78, 7.66)	(-8.33, 16.39)	
p-value	0.4551	0.5132	
Corrected Hedge's g Statistics	-0.295	0.270	
95% CI	(-1.22, 0.63)	(-0.58, 1.12)	
Subgroup*Treatment Interaction p-value	0.9104	0.5982	

AMNOG Table SE24.11.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Absenteeism			
Week 24			
m	12	8	13
n	2	2	1
Baseline Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (N/A)
Analysis Visit Mean (SD)	0.00 (0.00)	0.00 (0.00)	0.00 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	12	8	12
n	1	1	1
Baseline Mean (SD)	0.00 (N/A)	0.00 (N/A)	0.00 (N/A)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (N/A)	0.00 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.6121	0.6429	

AMNOG Table SE24.11.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Presenteeism			
Week 24			
m	12	8	13
n	2	2	1
Baseline Mean (SD)	0.0 (0.0)	0.0 (0.0)	50.0 (N/A)
Analysis Visit Mean (SD)	0.0 (0.0)	15.0 (7.1)	0.0 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	12	8	12
n	1	1	1
Baseline Mean (SD)	0.0 (N/A)	0.0 (N/A)	50.0 (N/A)
Analysis Visit Mean (SD)	40.0 (N/A)	20.0 (N/A)	0.0 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.7499	0.1786	

AMNOG Table SE24.11.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Overall Work Impairment			
Week 24			
m	12	8	13
n	2	2	1
Baseline Mean (SD)	0.00 (0.00)	0.00 (0.00)	50.00 (N/A)
Analysis Visit Mean (SD)	0.00 (0.00)	15.00 (7.07)	0.00 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	12	8	12
n	1	1	1
Baseline Mean (SD)	0.00 (N/A)	0.00 (N/A)	50.00 (N/A)
Analysis Visit Mean (SD)	40.00 (N/A)	20.00 (N/A)	0.00 (N/A)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.8199	0.4676	

AMNOG Table SE24.11.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Visit Statistic	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Activity Impairment			
Week 24			
m	12	8	13
n	4	4	3
Baseline Mean (SD)	0.0 (0.0)	10.0 (20.0)	40.0 (26.5)
Analysis Visit Mean (SD)	0.0 (0.0)	10.0 (20.0)	20.0 (26.5)
LS Mean of Change from Baseline (SE)	5.53 (10.94)	0.85 (7.08)	-22.40 (11.43)
95% CI	(-20.34, 31.40)	(-15.90, 17.60)	(-49.43, 4.62)
LS Mean of Change from Baseline Compared to Placebo (SE)	27.93 (19.66)	23.25 (14.99)	
95% CI	(-18.55, 74.42)	(-12.19, 58.68)	
p-value	0.1983	0.1648	
Corrected Hedge's g Statistics	1.116	1.176	
95% CI	(-0.49, 2.72)	(-0.44, 2.79)	
Week 52			
m	12	8	12
n	2	3	3
Baseline Mean (SD)	0.0 (0.0)	13.3 (23.1)	40.0 (26.5)
Analysis Visit Mean (SD)	15.0 (21.2)	23.3 (25.2)	13.3 (11.5)
LS Mean of Change from Baseline (SE)	13.24 (15.44)	9.58 (10.77)	-20.61 (15.13)
95% CI	(-23.26, 49.75)	(-15.90, 35.06)	(-56.40, 15.18)
LS Mean of Change from Baseline Compared to Placebo (SE)	33.85 (25.53)	30.19 (19.81)	
95% CI	(-26.52, 94.23)	(-16.64, 77.02)	
p-value	0.2265	0.1712	
Corrected Hedge's g Statistics	0.991	1.062	
95% CI	(-0.90, 2.88)	(-0.65, 2.77)	
Subgroup*Treatment Interaction p-value	0.9104	0.5982	

AMNOG Table SE24.11.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Absenteeism			
Week 24			
m	111	87	221
n	14	11	33
Baseline Mean (SD)	6.49 (11.84)	0.00 (0.00)	4.23 (18.16)
Analysis Visit Mean (SD)	2.09 (5.37)	2.67 (8.86)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-2.02 (1.30)	-1.00 (1.32)	-3.50 (0.81)
95% CI	(-4.62, 0.57)	(-3.63, 1.62)	(-5.12, -1.88)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.47 (1.44)	2.50 (1.52)	
95% CI	(-1.39, 4.34)	(-0.53, 5.52)	
p-value	0.3084	0.1042	
Corrected Hedge's g Statistics	0.307	0.534	
95% CI	(-0.32, 0.94)	(-0.16, 1.23)	
Week 52			
m	107	87	219
n	7	17	28
Baseline Mean (SD)	11.64 (15.14)	0.00 (0.00)	1.19 (6.29)
Analysis Visit Mean (SD)	4.76 (12.59)	8.66 (20.75)	4.02 (13.84)
LS Mean of Change from Baseline (SE)	0.48 (6.10)	5.50 (3.93)	0.57 (2.96)
95% CI	(-11.70, 12.65)	(-2.35, 13.35)	(-5.33, 6.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.09 (6.95)	4.93 (4.81)	
95% CI	(-13.96, 13.77)	(-4.67, 14.53)	
p-value	0.9893	0.3093	
Corrected Hedge's g Statistics	-0.006	0.305	
95% CI	(-0.83, 0.82)	(-0.30, 0.91)	
Subgroup*Treatment Interaction p-value	0.6121	0.6429	

AMNOG Table SE24.11.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Presenteeism			
Week 24			
m	111	87	221
n	14	11	32
Baseline Mean (SD)	10.0 (23.5)	6.4 (6.7)	7.2 (18.2)
Analysis Visit Mean (SD)	17.9 (31.2)	10.9 (17.6)	10.0 (18.0)
LS Mean of Change from Baseline (SE)	7.16 (5.94)	2.69 (5.70)	0.67 (3.62)
95% CI	(-4.69, 19.01)	(-8.70, 14.07)	(-6.56, 7.90)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.49 (6.72)	2.02 (6.65)	
95% CI	(-6.92, 19.91)	(-11.24, 15.28)	
p-value	0.3374	0.7622	
Corrected Hedge's g Statistics	0.304	0.099	
95% CI	(-0.33, 0.93)	(-0.59, 0.78)	
Week 52			
m	107	87	219
n	7	17	28
Baseline Mean (SD)	20.0 (31.1)	11.2 (13.6)	7.9 (19.1)
Analysis Visit Mean (SD)	25.7 (35.5)	11.8 (15.5)	10.7 (18.8)
LS Mean of Change from Baseline (SE)	9.87 (6.61)	0.17 (4.84)	1.14 (3.43)
95% CI	(-3.32, 23.07)	(-9.48, 9.82)	(-5.72, 7.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.74 (7.28)	-0.97 (5.81)	
95% CI	(-5.78, 23.26)	(-12.56, 10.63)	
p-value	0.2340	0.8680	
Corrected Hedge's g Statistics	0.473	-0.051	
95% CI	(-0.36, 1.31)	(-0.65, 0.55)	
Subgroup*Treatment Interaction p-value	0.7499	0.1786	

AMNOG Table SE24.11.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Overall Work Impairment			
Week 24			
m	111	87	221
n	14	11	32
Baseline Mean (SD)	13.81 (27.47)	6.36 (6.74)	8.05 (19.71)
Analysis Visit Mean (SD)	18.66 (32.06)	13.32 (19.19)	10.00 (17.96)
LS Mean of Change from Baseline (SE)	5.93 (6.24)	1.24 (5.90)	-0.48 (3.76)
95% CI	(-6.52, 18.38)	(-10.53, 13.02)	(-7.99, 7.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.41 (6.98)	1.73 (6.86)	
95% CI	(-7.52, 20.34)	(-11.95, 15.41)	
p-value	0.3616	0.8019	
Corrected Hedge's g Statistics	0.288	0.081	
95% CI	(-0.34, 0.92)	(-0.60, 0.77)	
Week 52			
m	107	87	219
n	7	17	28
Baseline Mean (SD)	26.27 (35.50)	11.18 (13.64)	8.69 (20.57)
Analysis Visit Mean (SD)	28.09 (37.89)	19.17 (24.23)	13.63 (23.34)
LS Mean of Change from Baseline (SE)	9.47 (8.63)	7.65 (6.19)	2.76 (4.47)
95% CI	(-7.76, 26.70)	(-4.71, 20.01)	(-6.17, 11.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.72 (9.58)	4.90 (7.51)	
95% CI	(-12.40, 25.83)	(-10.10, 19.89)	
p-value	0.4857	0.5169	
Corrected Hedge's g Statistics	0.279	0.197	
95% CI	(-0.55, 1.11)	(-0.41, 0.80)	
Subgroup*Treatment Interaction p-value	0.8199	0.4676	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Visit Statistic	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Activity Impairment			
Week 24			
m	111	87	221
n	36	28	55
Baseline Mean (SD)	13.3 (22.0)	10.4 (15.5)	14.0 (24.4)
Analysis Visit Mean (SD)	18.1 (23.5)	10.4 (15.0)	14.9 (22.4)
LS Mean of Change from Baseline (SE)	4.36 (3.23)	-2.85 (3.53)	1.22 (2.53)
95% CI	(-2.01, 10.74)	(-9.83, 4.13)	(-3.78, 6.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.14 (3.97)	-4.07 (4.26)	
95% CI	(-4.71, 10.99)	(-12.50, 4.36)	
p-value	0.4301	0.3413	
Corrected Hedge's g Statistics	0.164	-0.215	
95% CI	(-0.26, 0.58)	(-0.67, 0.24)	
Week 52			
m	107	87	219
n	22	29	46
Baseline Mean (SD)	16.4 (24.0)	14.1 (17.4)	16.7 (27.6)
Analysis Visit Mean (SD)	19.1 (20.9)	19.0 (19.9)	13.0 (17.9)
LS Mean of Change from Baseline (SE)	6.07 (3.70)	3.98 (3.29)	-2.46 (2.51)
95% CI	(-1.24, 13.38)	(-2.52, 10.48)	(-7.43, 2.51)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.53 (4.38)	6.44 (4.08)	
95% CI	(-0.13, 17.19)	(-1.63, 14.51)	
p-value	0.0534	0.1169	
Corrected Hedge's g Statistics	0.492	0.368	
95% CI	(-0.02, 1.01)	(-0.10, 0.84)	
Subgroup*Treatment Interaction p-value	0.9104	0.5982	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.11.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	30 (100)	31 (100)	35 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (2.9)
No	30 (100)	31 (100)	34 (97.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.86	-2.86	
95% CI of the absolute risk difference	(-8.38, 2.66)	(-8.38, 2.66)	
p-value	0.3508	0.3430	
p-value of Breslow-Day Test for Homogeneity [3]	0.1583	NE	

AMNOG Table SE24.11.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	30 (100)	31 (100)	35 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4561	0.4855	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (3.2)	0
No	30 (100)	30 (96.8)	35 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	3.23	
95% CI of the absolute risk difference	NE	(-2.99, 9.45)	
p-value	NE	0.2843	
p-value of Breslow-Day Test for Homogeneity [3]	0.2692	0.3746	

AMNOG Table SE24.11.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	30 (100)	31 (100)	35 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3046	0.4855	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	1 (3.2)	1 (2.9)
No	30 (100)	30 (96.8)	34 (97.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.88	
95% CI of the inverse odds ratio	NE	(0.05, 14.73)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.89	
95% CI of the inverse risk ratio	NE	(0.06, 13.57)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.86	0.37	
95% CI of the absolute risk difference	(-8.38, 2.66)	(-7.95, 8.68)	
p-value	0.3508	0.9305	
p-value of Breslow-Day Test for Homogeneity [3]	0.3473	0.5786	

AMNOG Table SE24.11.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Loss

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=31)	Placebo (N=35)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (6.7)	0	2 (5.7)
No	28 (93.3)	31 (100)	33 (94.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	4.70	
95% CI of the inverse odds ratio	(0.11, 6.42)	(0.22, 101.79)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	4.44	
95% CI of the inverse risk ratio	(0.13, 5.72)	(0.22, 89.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.95	-5.38	
95% CI of the absolute risk difference	(-10.83, 12.73)	(-14.73, 3.97)	
p-value	0.8734	0.2807	
p-value of Breslow-Day Test for Homogeneity [3]	0.4251	0.2921	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (10.0)	1 (3.2)	3 (8.6)
No	27 (90.0)	30 (96.8)	32 (91.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.84	2.81	
95% CI of the inverse odds ratio	(0.16, 4.53)	(0.28, 28.54)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	2.66	
95% CI of the inverse risk ratio	(0.19, 3.94)	(0.29, 24.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.43	-5.35	
95% CI of the absolute risk difference	(-12.76, 15.62)	(-16.51, 5.82)	
p-value	0.8428	0.3637	
p-value of Breslow-Day Test for Homogeneity [3]	0.2934	0.1718	

AMNOG Table SE24.11.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	12 (100)	8 (100)	13 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	12 (100)	8 (100)	13 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1583	NE	

AMNOG Table SE24.11.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.7)
No	12 (100)	8 (100)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	2.04	
95% CI of the inverse odds ratio	(0.11, 80.95)	(0.07, 56.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.79	1.93	
95% CI of the inverse risk ratio	(0.12, 62.48)	(0.09, 42.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.87	-5.16	
95% CI of the absolute risk difference	(-26.15, 12.41)	(-27.21, 16.90)	
p-value	0.4959	0.6683	
p-value of Breslow-Day Test for Homogeneity [3]	0.4561	0.4855	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (7.7)
No	12 (100)	8 (100)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	2.04	
95% CI of the inverse odds ratio	(0.11, 80.95)	(0.07, 56.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.79	1.93	
95% CI of the inverse risk ratio	(0.12, 62.48)	(0.09, 42.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.87	-5.16	
95% CI of the absolute risk difference	(-26.15, 12.41)	(-27.21, 16.90)	
p-value	0.4959	0.6683	
p-value of Breslow-Day Test for Homogeneity [3]	0.2692	0.3746	

AMNOG Table SE24.11.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (7.7)
No	12 (100)	8 (100)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	2.04	
95% CI of the inverse odds ratio	(0.11, 80.95)	(0.07, 56.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.79	1.93	
95% CI of the inverse risk ratio	(0.12, 62.48)	(0.09, 42.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.87	-5.16	
95% CI of the absolute risk difference	(-26.15, 12.41)	(-27.21, 16.90)	
p-value	0.4959	0.6683	
p-value of Breslow-Day Test for Homogeneity [3]	0.3046	0.4855	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (7.7)
No	12 (100)	8 (100)	12 (92.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	3.00	2.04	
95% CI of the inverse odds ratio	(0.11, 80.95)	(0.07, 56.26)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.79	1.93	
95% CI of the inverse risk ratio	(0.12, 62.48)	(0.09, 42.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.87	-5.16	
95% CI of the absolute risk difference	(-26.15, 12.41)	(-27.21, 16.90)	
p-value	0.4959	0.6683	
p-value of Breslow-Day Test for Homogeneity [3]	0.3473	0.5786	

AMNOG Table SE24.11.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: >= 5% weight Gain

Parameter Response Statistic/Category	MGL-3196 80 mg (N=12)	MGL-3196 100 mg (N=8)	Placebo (N=13)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	2 (15.4)
No	12 (100)	8 (100)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.43	3.70	
95% CI of the inverse odds ratio	(0.24, 125.59)	(0.16, 87.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.64	3.21	
95% CI of the inverse risk ratio	(0.25, 87.91)	(0.17, 59.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.01	-12.30	
95% CI of the absolute risk difference	(-36.63, 8.61)	(-37.33, 12.73)	
p-value	0.2471	0.3926	
p-value of Breslow-Day Test for Homogeneity [3]	0.4251	0.2921	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (15.4)
No	12 (100)	8 (100)	11 (84.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.43	3.70	
95% CI of the inverse odds ratio	(0.24, 125.59)	(0.16, 87.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.64	3.21	
95% CI of the inverse risk ratio	(0.25, 87.91)	(0.17, 59.51)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-14.01	-12.30	
95% CI of the absolute risk difference	(-36.63, 8.61)	(-37.33, 12.73)	
p-value	0.2471	0.3926	
p-value of Breslow-Day Test for Homogeneity [3]	0.2934	0.1718	

AMNOG Table SE24.11.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (1.8)	0	1 (0.5)
No	109 (98.2)	87 (100)	220 (99.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	NE	
95% CI of the inverse odds ratio	(0.02, 2.76)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	NE	
95% CI of the inverse risk ratio	(0.02, 2.74)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.35	-0.45	
95% CI of the absolute risk difference	(-1.28, 3.98)	(-1.34, 0.43)	
p-value	0.2203	0.5297	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (1.8)	0	1 (0.5)
No	109 (98.2)	87 (100)	220 (99.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	NE	
95% CI of the inverse odds ratio	(0.02, 2.76)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	NE	
95% CI of the inverse risk ratio	(0.02, 2.74)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.35	-0.45	
95% CI of the absolute risk difference	(-1.28, 3.98)	(-1.34, 0.43)	
p-value	0.2203	0.5297	
p-value of Breslow-Day Test for Homogeneity [3]	0.1583	NE	

AMNOG Table SE24.11.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (0.9)	1 (1.1)	3 (1.4)
No	110 (99.1)	86 (98.9)	218 (98.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	1.18	
95% CI of the inverse odds ratio	(0.16, 14.72)	(0.12, 11.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.51	1.18	
95% CI of the inverse risk ratio	(0.16, 14.32)	(0.12, 11.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.46	-0.21	
95% CI of the absolute risk difference	(-2.78, 1.87)	(-2.92, 2.50)	
p-value	0.7191	0.8846	
p-value of Breslow-Day Test for Homogeneity [3]	0.4561	0.4855	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (2.7)	4 (4.6)	4 (1.8)
No	108 (97.3)	83 (95.4)	217 (98.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.38	
95% CI of the inverse odds ratio	(0.15, 3.02)	(0.09, 1.56)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.39	
95% CI of the inverse risk ratio	(0.15, 2.94)	(0.10, 1.54)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.89	2.79	
95% CI of the absolute risk difference	(-2.60, 4.38)	(-1.95, 7.53)	
p-value	0.5932	0.1661	
p-value of Breslow-Day Test for Homogeneity [3]	0.2692	0.3746	

AMNOG Table SE24.11.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (1.8)	1 (1.1)	3 (1.4)
No	109 (98.2)	86 (98.9)	218 (98.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.18	
95% CI of the inverse odds ratio	(0.12, 4.55)	(0.12, 11.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.75	1.18	
95% CI of the inverse risk ratio	(0.13, 4.44)	(0.12, 11.20)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.44	-0.21	
95% CI of the absolute risk difference	(-2.46, 3.35)	(-2.92, 2.50)	
p-value	0.7538	0.8846	
p-value of Breslow-Day Test for Homogeneity [3]	0.3046	0.4855	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (2.7)	3 (3.4)	4 (1.8)
No	108 (97.3)	84 (96.6)	217 (98.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.66	0.52	
95% CI of the inverse odds ratio	(0.15, 3.02)	(0.11, 2.36)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.67	0.52	
95% CI of the inverse risk ratio	(0.15, 2.94)	(0.12, 2.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.89	1.64	
95% CI of the absolute risk difference	(-2.60, 4.38)	(-2.58, 5.86)	
p-value	0.5932	0.3851	
p-value of Breslow-Day Test for Homogeneity [3]	0.3473	0.5786	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.11.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Weight Change at Week 52
(Label Population)

Weight Change at Week 52: Stable

Parameter Response Statistic/Category	MGL-3196 80 mg (N=111)	MGL-3196 100 mg (N=87)	Placebo (N=221)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (2.7)	3 (3.4)	8 (3.6)
No	108 (97.3)	84 (96.6)	213 (96.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.35	1.05	
95% CI of the inverse odds ratio	(0.35, 5.20)	(0.27, 4.06)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.34	1.05	
95% CI of the inverse risk ratio	(0.36, 4.95)	(0.29, 3.87)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.92	-0.17	
95% CI of the absolute risk difference	(-4.81, 2.98)	(-4.73, 4.39)	
p-value	0.6596	0.9417	
p-value of Breslow-Day Test for Homogeneity [3]	0.4251	0.2921	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (6.3)	7 (8.0)	10 (4.5)
No	104 (93.7)	80 (92.0)	211 (95.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	0.54	
95% CI of the inverse odds ratio	(0.26, 1.90)	(0.20, 1.47)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.72	0.56	
95% CI of the inverse risk ratio	(0.28, 1.83)	(0.22, 1.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.78	3.52	
95% CI of the absolute risk difference	(-3.51, 7.07)	(-2.82, 9.86)	
p-value	0.4872	0.2231	
p-value of Breslow-Day Test for Homogeneity [3]	0.2934	0.1718	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.12.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Absenteeism						
Baseline						
m	91	67	0			
n	17	23	0			
Mean (SD)	4.58 (10.32)	0.00 (0.00)	N/A			
Median	0	0	N/A			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	N/A			
Min, Max	0.0, 34.8	0.0, 0.0	N/A			
Week 24						
m	91	67	0			
n	25	20	0	15	12	0
Mean (SD/SE)	1.27 (4.40)	2.22 (7.22)	N/A	-3.61 (2.11)	2.45 (2.45)	N/A
Median	0	0	N/A	0	0	N/A
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	N/A	0.00, 0.00	0.00, 0.00	N/A
Min, Max	0.0, 16.7	0.0, 29.4	N/A	-26.7, 0.0	0.0, 29.4	N/A
Week 52						
m	88	67	0			
n	19	21	0	6	15	0
Mean (SD/SE)	7.02 (16.95)	5.44 (15.75)	N/A	3.63 (10.22)	6.11 (4.64)	N/A
Median	0	0	N/A	0	0	N/A
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	N/A	-1.50, 0.00	0.00, 0.00	N/A
Min, Max	0.0, 50.0	0.0, 66.7	N/A	-26.7, 50.0	0.0, 66.7	N/A

Abbreviations: CFB = Change from Baseline; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.12.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Presenteeism						
Baseline						
m	91	67	0			
n	17	23	0			
Mean (SD)	4.1 (14.6)	13.5 (19.2)	N/A			
Median	0	10.0	N/A			
IQR: Q1, Q3	0.0, 0.0	0.0, 20.0	N/A			
Min, Max	0, 60	0, 70	N/A			
Week 24						
m	91	67	0			
n	25	20	0	15	12	0
Mean (SD/SE)	6.0 (11.9)	8.0 (14.0)	N/A	2.0 (3.3)	0.8 (5.6)	N/A
Median	0	0	N/A	0	0	N/A
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	N/A	0.0, 0.0	-5.0, 5.0	N/A
Min, Max	0, 40	0, 60	N/A	-20, 40	-30, 50	N/A
Week 52						
m	88	67	0			
n	19	21	0	6	15	0
Mean (SD/SE)	10.0 (17.0)	6.2 (10.2)	N/A	5.0 (7.6)	-4.7 (2.9)	N/A
Median	0	0	N/A	0	0	N/A
IQR: Q1, Q3	0.0, 20.0	0.0, 10.0	N/A	-10.0, 10.0	-10.0, 0.0	N/A
Min, Max	0, 50	0, 30	N/A	-10, 40	-40, 10	N/A

Abbreviations: CFB = Change from Baseline; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.12.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Overall Work Impairment						
Baseline						
m	91	67	0			
n	17	23	0			
Mean (SD)	7.31 (19.11)	13.48 (19.21)	N/A			
Median	0	10.00	N/A			
IQR: Q1, Q3	0.00, 0.00	0.00, 20.00	N/A			
Min, Max	0.0, 73.9	0.0, 70.0	N/A			
Week 24						
m	91	67	0			
n	25	20	0	15	12	0
Mean (SD/SE)	6.88 (13.91)	9.93 (16.04)	N/A	-0.49 (4.15)	3.04 (5.96)	N/A
Median	0	0	N/A	0	0	N/A
IQR: Q1, Q3	0.00, 10.00	0.00, 10.00	N/A	0.00, 0.00	-5.00, 10.00	N/A
Min, Max	0.0, 50.0	0.0, 60.0	N/A	-34.0, 40.0	-30.0, 50.0	N/A
Week 52						
m	88	67	0			
n	19	21	0	6	15	0
Mean (SD/SE)	14.82 (24.82)	10.56 (19.62)	N/A	8.95 (13.36)	0.39 (5.38)	N/A
Median	0	0	N/A	0	0	N/A
IQR: Q1, Q3	0.00, 30.00	0.00, 10.00	N/A	-7.30, 40.00	-10.00, 0.00	N/A
Min, Max	0.0, 70.0	0.0, 73.4	N/A	-34.0, 55.0	-40.0, 63.4	N/A

Abbreviations: CFB = Change from Baseline; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.12.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=91)	Visit Result MGL-3196 100 mg (N=67)	Visit Result Placebo (N=0)	Change from Baseline MGL-3196 80 mg (N=91)	Change from Baseline MGL-3196 100 mg (N=67)	Change from Baseline Placebo (N=0)
Activity Impairment						
Baseline						
m	91	67	0			
n	36	41	0			
Mean (SD)	11.4 (20.6)	15.6 (20.7)	N/A			
Median	0	10.0	N/A			
IQR: Q1, Q3	0.0, 15.0	0.0, 20.0	N/A			
Min, Max	0, 70	0, 80	N/A			
Week 24						
m	91	67	0			
n	54	35	0	31	26	0
Mean (SD/SE)	13.5 (22.8)	12.0 (16.8)	N/A	4.8 (4.1)	0.0 (4.5)	N/A
Median	0	10.0	N/A	0	0	N/A
IQR: Q1, Q3	0.0, 20.0	0.0, 20.0	N/A	0.0, 0.0	-10.0, 10.0	N/A
Min, Max	0, 80	0, 70	N/A	-30, 80	-60, 70	N/A
Week 52						
m	88	67	0			
n	52	39	0	18	25	0
Mean (SD/SE)	13.8 (22.7)	14.1 (17.4)	N/A	-1.1 (5.2)	0.4 (3.5)	N/A
Median	0	10.0	N/A	0	0	N/A
IQR: Q1, Q3	0.0, 25.0	0.0, 30.0	N/A	-10.0, 0.0	-10.0, 10.0	N/A
Min, Max	0, 90	0, 70	N/A	-40, 60	-50, 40	N/A

Abbreviations: CFB = Change from Baseline; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.12.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Absenteeism						
Baseline						
m	61	57	266			
n	8	16	60			
Mean (SD)	2.50 (7.07)	4.56 (16.99)	2.94 (13.87)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 20.0	0.0, 68.1	0.0, 100.0			
Week 24						
m	61	57	266			
n	14	19	76	5	9	40
Mean (SD/SE)	0.89 (3.34)	0.30 (1.31)	0.00 (0.00)	-1.50 (5.22)	0.10 (0.10)	-4.34 (2.67)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 12.5	0.0, 5.7	0.0, 0.0	-20.0, 12.5	0.0, 0.9	-100.0, 0.0
Week 52						
m	59	56	263			
n	18	26	94	5	9	35
Mean (SD/SE)	0.24 (1.01)	2.59 (11.06)	3.87 (13.96)	-4.00 (4.00)	6.18 (6.18)	2.01 (2.37)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 4.3	0.0, 55.6	0.0, 75.0	-20.0, 0.0	0.0, 55.6	-33.3, 66.7

Abbreviations: CFB = Change from Baseline; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.12.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Presenteeism						
Baseline						
m	61	57	266			
n	8	16	59			
Mean (SD)	12.5 (25.5)	4.4 (7.3)	7.8 (16.5)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 15.0	0.0, 10.0	0.0, 10.0			
Min, Max	0, 70	0, 20	0, 70			
Week 24						
m	61	57	266			
n	14	19	76	5	9	39
Mean (SD/SE)	17.9 (30.4)	15.3 (21.7)	7.6 (15.7)	26.0 (25.2)	8.9 (7.2)	1.0 (3.4)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 10.0	0.0, 80.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 90	0, 80	0, 70	-40, 90	-10, 60	-60, 70
Week 52						
m	59	56	263			
n	18	26	94	5	9	35
Mean (SD/SE)	14.4 (24.5)	15.0 (25.0)	7.8 (15.7)	12.0 (20.3)	10.0 (4.4)	1.7 (3.5)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 20.0	0.0, 10.0	0.0, 0.0	0.0, 20.0	0.0, 10.0
Min, Max	0, 90	0, 90	0, 80	-30, 90	0, 30	-50, 80

Abbreviations: CFB = Change from Baseline; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.12.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Overall Work Impairment						
Baseline						
m	61	57	266			
n	8	16	59			
Mean (SD)	13.25 (27.44)	8.90 (17.46)	8.83 (17.72)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 15.00	0.00, 12.15	0.00, 10.00			
Min, Max	0.0, 76.0	0.0, 68.1	0.0, 70.0			
Week 24						
m	61	57	266			
n	14	19	76	5	9	39
Mean (SD/SE)	17.95 (30.67)	15.53 (21.66)	7.63 (15.74)	25.06 (26.18)	8.98 (7.14)	-0.49 (3.54)
Median	0	10.00	0	0	0.80	0
IQR: Q1, Q3	0.00, 30.00	0.00, 20.00	0.00, 10.00	0.00, 80.00	0.00, 10.00	-9.10, 0.00
Min, Max	0.0, 91.3	0.0, 80.0	0.0, 70.0	-46.0, 91.3	-10.0, 60.0	-60.0, 70.0
Week 52						
m	59	56	263			
n	18	26	94	5	9	35
Mean (SD/SE)	14.63 (24.61)	16.97 (26.63)	10.59 (20.97)	10.80 (20.99)	15.56 (7.09)	2.90 (4.31)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 23.40	0.00, 30.00	0.00, 10.00	0.00, 0.00	0.00, 30.00	0.00, 10.00
Min, Max	0.0, 90.0	0.0, 91.2	0.0, 87.5	-36.0, 90.0	0.0, 60.0	-53.3, 83.0

Abbreviations: CFB = Change from Baseline; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.12.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=61)	Visit Result MGL-3196 100 mg (N=57)	Visit Result Placebo (N=266)	Change from Baseline MGL-3196 80 mg (N=61)	Change from Baseline MGL-3196 100 mg (N=57)	Change from Baseline Placebo (N=266)
Activity Impairment						
Baseline						
m	61	57	266			
n	25	23	106			
Mean (SD)	17.6 (26.3)	7.4 (13.2)	17.2 (26.1)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 30.0	0.0, 10.0	0.0, 20.0			
Min, Max	0, 80	0, 50	0, 100			
Week 24						
m	61	57	266			
n	33	31	140	19	18	71
Mean (SD/SE)	18.2 (21.3)	10.6 (15.7)	15.9 (23.3)	7.4 (5.7)	3.9 (3.7)	-0.4 (2.6)
Median	10.0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0	-10.0, 30.0	0.0, 10.0	-10.0, 10.0
Min, Max	0, 70	0, 60	0, 100	-40, 50	-20, 60	-80, 70
Week 52						
m	59	56	263			
n	39	40	165	13	16	62
Mean (SD/SE)	16.7 (21.1)	18.3 (24.2)	13.8 (20.1)	3.8 (6.7)	11.3 (4.1)	-4.5 (3.0)
Median	10.0	10.0	0	0	10.0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 35.0	0.0, 20.0	-10.0, 10.0	0.0, 20.0	0.0, 10.0
Min, Max	0, 80	0, 80	0, 100	-40, 50	-20, 40	-90, 70

Abbreviations: CFB = Change from Baseline; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.12.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

Abbreviations: CFB = Change from Baseline; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.12.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Absenteeism			
Week 24			
m	91	67	0
n	15	12	0
Baseline Mean (SD)	4.73 (10.95)	0.00 (0.00)	N/A
Analysis Visit Mean (SD)	1.11 (4.31)	2.45 (8.49)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	6	15	0
Baseline Mean (SD)	10.25 (16.08)	0.00 (0.00)	N/A
Analysis Visit Mean (SD)	13.88 (22.15)	6.11 (17.95)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE24.12.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Presenteeism			
Week 24			
m	91	67	0
n	15	12	0
Baseline Mean (SD)	4.7 (15.5)	10.0 (14.1)	N/A
Analysis Visit Mean (SD)	6.7 (14.0)	10.8 (16.8)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	6	15	0
Baseline Mean (SD)	11.7 (24.0)	11.3 (14.1)	N/A
Analysis Visit Mean (SD)	16.7 (22.5)	6.7 (9.8)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE24.12.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Overall Work Impairment			
Week 24			
m	91	67	0
n	15	12	0
Baseline Mean (SD)	7.82 (20.33)	10.00 (14.14)	N/A
Analysis Visit Mean (SD)	7.33 (15.80)	13.04 (18.32)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	6	15	0
Baseline Mean (SD)	17.98 (30.58)	11.33 (14.07)	N/A
Analysis Visit Mean (SD)	26.93 (30.69)	11.73 (20.50)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE24.12.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Activity Impairment			
Week 24			
m	91	67	0
n	31	26	0
Baseline Mean (SD)	10.0 (19.3)	15.0 (18.8)	N/A
Analysis Visit Mean (SD)	14.8 (25.1)	15.0 (18.4)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	88	67	0
n	18	25	0
Baseline Mean (SD)	17.2 (26.1)	14.4 (17.3)	N/A
Analysis Visit Mean (SD)	16.1 (22.0)	14.8 (16.4)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE24.12.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Absenteeism			
Week 24			
m	61	57	266
n	5	9	40
Baseline Mean (SD)	4.00 (8.94)	0.53 (1.60)	4.34 (16.87)
Analysis Visit Mean (SD)	2.50 (5.59)	0.63 (1.90)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-0.15 (0.80)	-2.42 (0.62)	-2.78 (0.30)
95% CI	(-1.76, 1.46)	(-3.66, -1.18)	(-3.39, -2.17)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.63 (0.84)	0.36 (0.68)	
95% CI	(0.95, 4.30)	(-1.00, 1.72)	
p-value	0.0026	0.6024	
Corrected Hedge's g Statistics	1.353	0.183	
95% CI	(0.38, 2.32)	(-0.54, 0.91)	
Week 52			
m	59	56	263
n	5	9	35
Baseline Mean (SD)	4.00 (8.94)	0.00 (0.00)	1.93 (7.04)
Analysis Visit Mean (SD)	0.00 (0.00)	6.18 (18.53)	3.93 (12.96)
LS Mean of Change from Baseline (SE)	-1.54 (6.16)	4.01 (4.66)	1.29 (2.34)
95% CI	(-13.86, 10.77)	(-5.32, 13.33)	(-3.38, 5.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.84 (6.60)	2.71 (5.17)	
95% CI	(-16.04, 10.36)	(-7.63, 13.05)	
p-value	0.6688	0.6018	
Corrected Hedge's g Statistics	-0.201	0.192	
95% CI	(-1.14, 0.74)	(-0.54, 0.93)	
Subgroup*Treatment Interaction p-value	NE	NE	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.12.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Presenteeism			
Week 24			
m	61	57	266
n	5	9	39
Baseline Mean (SD)	14.0 (31.3)	5.6 (7.3)	7.9 (18.1)
Analysis Visit Mean (SD)	40.0 (43.0)	14.4 (18.8)	9.0 (16.7)
LS Mean of Change from Baseline (SE)	23.91 (9.01)	8.75 (6.83)	-0.22 (3.29)
95% CI	(5.89, 41.93)	(-4.90, 22.41)	(-6.81, 6.37)
LS Mean of Change from Baseline Compared to Placebo (SE)	24.14 (9.38)	8.98 (7.45)	
95% CI	(5.38, 42.90)	(-5.93, 23.89)	
p-value	0.0126	0.2331	
Corrected Hedge's g Statistics	1.155	0.430	
95% CI	(0.19, 2.12)	(-0.30, 1.16)	
Week 52			
m	59	56	263
n	5	9	35
Baseline Mean (SD)	14.0 (31.3)	4.4 (7.3)	8.0 (18.8)
Analysis Visit Mean (SD)	26.0 (39.7)	14.4 (18.8)	9.7 (18.1)
LS Mean of Change from Baseline (SE)	21.69 (8.71)	6.18 (6.64)	0.53 (3.24)
95% CI	(4.26, 39.12)	(-7.09, 19.46)	(-5.95, 7.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	21.16 (9.10)	5.65 (7.22)	
95% CI	(2.95, 39.37)	(-8.80, 20.10)	
p-value	0.0235	0.4371	
Corrected Hedge's g Statistics	1.080	0.287	
95% CI	(0.11, 2.05)	(-0.45, 1.02)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE24.12.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Overall Work Impairment			
Week 24			
m	61	57	266
n	5	9	39
Baseline Mean (SD)	15.20 (33.99)	6.03 (7.72)	9.47 (19.65)
Analysis Visit Mean (SD)	40.26 (43.39)	15.01 (18.71)	8.97 (16.67)
LS Mean of Change from Baseline (SE)	24.47 (9.06)	7.11 (6.90)	-1.14 (3.34)
95% CI	(6.34, 42.59)	(-6.70, 20.91)	(-7.83, 5.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	25.61 (9.40)	8.25 (7.54)	
95% CI	(6.79, 44.42)	(-6.84, 23.33)	
p-value	0.0085	0.2786	
Corrected Hedge's g Statistics	1.207	0.389	
95% CI	(0.24, 2.17)	(-0.34, 1.12)	
Week 52			
m	59	56	263
n	5	9	35
Baseline Mean (SD)	15.20 (33.99)	4.44 (7.26)	9.57 (20.27)
Analysis Visit Mean (SD)	26.00 (39.75)	20.00 (23.98)	12.47 (22.68)
LS Mean of Change from Baseline (SE)	23.64 (10.56)	11.25 (8.02)	2.30 (3.93)
95% CI	(2.51, 44.76)	(-4.80, 27.30)	(-5.56, 10.16)
LS Mean of Change from Baseline Compared to Placebo (SE)	21.34 (11.08)	8.95 (8.78)	
95% CI	(-0.82, 43.50)	(-8.61, 26.52)	
p-value	0.0588	0.3121	
Corrected Hedge's g Statistics	0.898	0.376	
95% CI	(-0.06, 1.86)	(-0.36, 1.11)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE24.12.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Activity Impairment			
Week 24			
m	61	57	266
n	19	18	71
Baseline Mean (SD)	17.4 (28.6)	5.0 (8.6)	16.6 (25.6)
Analysis Visit Mean (SD)	24.7 (23.2)	8.9 (14.9)	16.2 (24.2)
LS Mean of Change from Baseline (SE)	7.30 (4.32)	-0.34 (4.54)	0.32 (2.30)
95% CI	(-1.26, 15.86)	(-9.33, 8.65)	(-4.22, 4.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.98 (4.81)	-0.66 (4.99)	
95% CI	(-2.53, 16.50)	(-10.54, 9.22)	
p-value	0.1490	0.8955	
Corrected Hedge's g Statistics	0.360	-0.034	
95% CI	(-0.15, 0.87)	(-0.55, 0.48)	
Week 52			
m	59	56	263
n	13	16	62
Baseline Mean (SD)	13.1 (21.4)	10.0 (15.1)	18.2 (26.8)
Analysis Visit Mean (SD)	16.9 (18.4)	21.3 (22.5)	13.7 (19.4)
LS Mean of Change from Baseline (SE)	3.31 (4.54)	7.33 (4.29)	-3.83 (2.17)
95% CI	(-5.68, 12.31)	(-1.16, 15.82)	(-8.12, 0.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.14 (4.96)	11.15 (4.72)	
95% CI	(-2.68, 16.96)	(1.82, 20.49)	
p-value	0.1525	0.0196	
Corrected Hedge's g Statistics	0.417	0.646	
95% CI	(-0.19, 1.02)	(0.09, 1.21)	
Subgroup*Treatment Interaction p-value	NE	NE	

AMNOG Table SE24.12.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

Abbreviations: CFB = Change from Baseline; WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.12.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.1)	0	0
No	90 (98.9)	67 (100)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.1)	0	0
No	90 (98.9)	67 (100)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.12.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (1.5)	0
No	91 (100)	66 (98.5)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (2.2)	5 (7.5)	0
No	89 (97.8)	62 (92.5)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.12.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.1)	1 (1.5)	0
No	90 (98.9)	66 (98.5)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (2.2)	4 (6.0)	0
No	89 (97.8)	63 (94.0)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.12.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with >= 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=91)	MGL-3196 100 mg (N=67)	Placebo (N=0)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (4.4)	2 (3.0)	0
No	87 (95.6)	65 (97.0)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (6.6)	7 (10.4)	0
No	85 (93.4)	60 (89.6)	0
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.12.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.6)	0	1 (0.4)
No	60 (98.4)	57 (100)	265 (99.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.23	NE	
95% CI of the inverse odds ratio	(0.01, 3.67)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.23	NE	
95% CI of the inverse risk ratio	(0.01, 3.62)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.26	-0.38	
95% CI of the absolute risk difference	(-2.01, 4.53)	(-1.11, 0.36)	
p-value	0.2537	0.6429	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.6)	0	2 (0.8)
No	60 (98.4)	57 (100)	264 (99.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.45	NE	
95% CI of the inverse odds ratio	(0.04, 5.10)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.46	NE	
95% CI of the inverse risk ratio	(0.04, 4.98)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.89	-0.75	
95% CI of the absolute risk difference	(-2.46, 4.24)	(-1.79, 0.29)	
p-value	0.5120	0.5114	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.12.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.6)	0	4 (1.5)
No	60 (98.4)	57 (100)	262 (98.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	NE	
95% CI of the inverse odds ratio	(0.10, 8.34)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	NE	
95% CI of the inverse risk ratio	(0.10, 8.06)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.14	-1.50	
95% CI of the absolute risk difference	(-3.37, 3.64)	(-2.97, -0.04)	
p-value	0.9380	0.3515	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.6)	0	5 (1.9)
No	60 (98.4)	57 (100)	261 (98.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	NE	
95% CI of the inverse odds ratio	(0.13, 10.02)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.15	NE	
95% CI of the inverse risk ratio	(0.14, 9.64)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.24	-1.88	
95% CI of the absolute risk difference	(-3.82, 3.34)	(-3.51, -0.25)	
p-value	0.8996	0.2969	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.12.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.6)	0	4 (1.5)
No	60 (98.4)	57 (100)	262 (98.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	NE	
95% CI of the inverse odds ratio	(0.10, 8.34)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.92	NE	
95% CI of the inverse risk ratio	(0.10, 8.06)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.14	-1.50	
95% CI of the absolute risk difference	(-3.37, 3.64)	(-2.97, -0.04)	
p-value	0.9380	0.3515	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.6)	0	6 (2.3)
No	60 (98.4)	57 (100)	260 (97.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	NE	
95% CI of the inverse odds ratio	(0.16, 11.72)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	NE	
95% CI of the inverse risk ratio	(0.17, 11.22)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.62	-2.26	
95% CI of the absolute risk difference	(-4.27, 3.04)	(-4.04, -0.47)	
p-value	0.7642	0.2524	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

AMNOG Table SE24.12.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by SHBG at Week 52
(Label Population)

SHBG at Week 52: Patients with < 120% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=61)	MGL-3196 100 mg (N=57)	Placebo (N=266)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.6)	1 (1.8)	12 (4.5)
No	60 (98.4)	56 (98.2)	254 (95.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.83	2.65	
95% CI of the inverse odds ratio	(0.36, 22.23)	(0.34, 20.77)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.75	2.57	
95% CI of the inverse risk ratio	(0.36, 20.76)	(0.34, 19.38)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.87	-2.76	
95% CI of the absolute risk difference	(-6.92, 1.17)	(-6.98, 1.47)	
p-value	0.3005	0.3365	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (6.6)	1 (1.8)	15 (5.6)
No	57 (93.4)	56 (98.2)	251 (94.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.85	3.35	
95% CI of the inverse odds ratio	(0.27, 2.66)	(0.43, 25.86)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.86	3.21	
95% CI of the inverse risk ratio	(0.30, 2.50)	(0.43, 23.84)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.92	-3.88	
95% CI of the absolute risk difference	(-5.88, 7.72)	(-8.28, 0.51)	
p-value	0.7822	0.2200	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.13.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Absenteeism						
Baseline						
m	76	75	30			
n	13	25	12			
Mean (SD)	3.40 (9.79)	2.72 (13.62)	1.00 (2.68)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 34.8	0.0, 68.1	0.0, 9.1			
Week 24						
m	76	74	29			
n	21	21	9	10	12	6
Mean (SD/SE)	1.39 (4.44)	1.40 (6.42)	0.00 (0.00)	-1.50 (2.47)	2.45 (2.45)	-1.52 (1.52)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 16.7	0.0, 29.4	0.0, 0.0	-18.1, 12.5	0.0, 29.4	-9.1, 0.0
Week 52						
m	74	68	27			
n	20	22	9	2	14	4
Mean (SD/SE)	1.88 (7.46)	7.23 (18.46)	8.33 (25.00)	-0.75 (0.75)	10.52 (6.03)	-2.28 (2.28)
Median	0	0	0	-0.75	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-1.50, 0.00	0.00, 0.00	-4.55, 0.00
Min, Max	0.0, 33.3	0.0, 66.7	0.0, 75.0	-1.5, 0.0	0.0, 66.7	-9.1, 0.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.13.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Presenteeism						
Baseline						
m	76	75	30			
n	13	25	12			
Mean (SD)	8.5 (18.2)	9.6 (17.0)	9.2 (15.1)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 15.0			
Min, Max	0, 60	0, 70	0, 50			
Week 24						
m	76	74	29			
n	21	21	9	10	12	6
Mean (SD/SE)	9.5 (21.3)	12.9 (21.0)	1.1 (3.3)	9.0 (9.4)	3.3 (5.3)	-3.3 (2.1)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 0.0	0.0, 10.0	-10.0, 10.0	-10.0, 0.0
Min, Max	0, 90	0, 80	0, 10	-20, 90	-20, 50	-10, 0
Week 52						
m	74	68	27			
n	20	22	9	2	14	4
Mean (SD/SE)	11.5 (17.9)	9.5 (19.9)	17.8 (19.9)	15.0 (25.0)	-2.1 (3.7)	5.0 (5.0)
Median	0	0	10.0	15.0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 10.0	0.0, 20.0	-10.0, 40.0	-10.0, 0.0	0.0, 10.0
Min, Max	0, 50	0, 90	0, 50	-10, 40	-40, 20	0, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.13.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=76)	Visit Result: MGL-3196 100 mg (N=75)	Visit Result: Placebo (N=30)	Change from Baseline: MGL-3196 80 mg (N=76)	Change from Baseline: MGL-3196 100 mg (N=75)	Change from Baseline: Placebo (N=30)
Overall Work Impairment						
Baseline						
m	76	75	30			
n	13	25	12			
Mean (SD)	10.25 (21.38)	12.32 (20.45)	10.04 (15.12)			
Median	0	0	4.55			
IQR: Q1, Q3	0.00, 9.40	0.00, 10.00	0.00, 15.00			
Min, Max	0.0, 73.9	0.0, 70.0	0.0, 51.4			
Week 24						
m	76	74	29			
n	21	21	9	10	12	6
Mean (SD/SE)	10.06 (22.37)	14.12 (21.62)	1.11 (3.33)	7.80 (9.77)	5.54 (5.60)	-4.85 (2.17)
Median	0	10.00	0	0	0	-4.55
IQR: Q1, Q3	0.00, 10.00	0.00, 20.00	0.00, 0.00	0.00, 10.00	-10.00, 15.00	-10.00, 0.00
Min, Max	0.0, 91.3	0.0, 80.0	0.0, 10.0	-23.9, 91.3	-20.0, 50.0	-10.0, 0.0
Week 52						
m	74	68	27			
n	20	22	9	2	14	4
Mean (SD/SE)	12.50 (20.08)	15.32 (26.54)	21.94 (29.20)	16.35 (23.65)	6.85 (7.16)	2.73 (6.14)
Median	0	0	10.00	16.35	0	0
IQR: Q1, Q3	0.00, 21.70	0.00, 20.00	0.00, 20.00	-7.30, 40.00	0.00, 12.50	-4.55, 10.00
Min, Max	0.0, 66.6	0.0, 91.2	0.0, 87.5	-7.3, 40.0	-40.0, 63.4	-9.1, 20.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.13.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Activity Impairment						
Baseline						
m	76	75	30			
n	29	43	16			
Mean (SD)	16.2 (25.3)	13.3 (20.1)	16.3 (23.9)			
Median	0	0	5.0			
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 30.0			
Min, Max	0, 80	0, 80	0, 80			
Week 24						
m	76	74	29			
n	44	40	15	24	27	10
Mean (SD/SE)	15.7 (24.1)	12.5 (17.2)	8.7 (16.0)	5.8 (5.1)	1.9 (4.2)	0.0 (3.0)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 20.0	-5.0, 5.0	0.0, 10.0	-10.0, 0.0
Min, Max	0, 80	0, 70	0, 50	-20, 80	-60, 70	-10, 20
Week 52						
m	74	68	27			
n	50	42	14	13	25	6
Mean (SD/SE)	16.0 (24.6)	17.6 (20.7)	19.3 (23.4)	-2.3 (7.1)	4.0 (3.9)	5.0 (3.4)
Median	0	10.0	10.0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 30.0	0.0, 30.0	-20.0, 0.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 90	0, 80	0, 70	-40, 60	-50, 40	0, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.13.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=42)	Visit Result: MGL-3196 100 mg (N=25)	Visit Result: Placebo (N=179)	Change from Baseline: MGL-3196 80 mg (N=42)	Change from Baseline: MGL-3196 100 mg (N=25)	Change from Baseline: Placebo (N=179)
Absenteeism						
Baseline						
m	42	25	179			
n	13	10	44			
Mean (SD)	4.13 (8.85)	0.48 (1.52)	3.17 (15.78)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 26.7	0.0, 4.8	0.0, 100.0			
Week 24						
m	41	25	177			
n	14	12	57	9	8	33
Mean (SD/SE)	1.07 (4.01)	1.73 (4.49)	0.00 (0.00)	-5.19 (3.48)	0.11 (0.11)	-4.23 (3.16)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 15.0	0.0, 15.0	0.0, 0.0	-26.7, 0.0	0.0, 0.9	-100.0, 0.0
Week 52						
m	39	22	167			
n	13	11	65	8	5	27
Mean (SD/SE)	3.85 (13.87)	2.05 (6.78)	4.06 (13.81)	0.41 (8.03)	0.00 (0.00)	2.94 (3.04)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-10.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 22.5	0.0, 66.7	-26.7, 50.0	0.0, 0.0	-33.3, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.13.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Presenteeism						
Baseline						
m	42	25	179			
n	13	10	43			
Mean (SD)	6.2 (19.4)	11.0 (16.6)	8.4 (17.9)			
Median	0	5.0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0			
Min, Max	0, 70	0, 50	0, 70			
Week 24						
m	41	25	177			
n	14	12	57	9	8	32
Mean (SD/SE)	15.0 (23.5)	11.7 (17.5)	8.1 (16.1)	7.8 (11.3)	5.0 (8.9)	1.9 (4.1)
Median	0	5.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 10.0	0.0, 0.0	0.0, 5.0	0.0, 5.0
Min, Max	0, 80	0, 60	0, 70	-40, 80	-30, 60	-60, 70
Week 52						
m	39	22	167			
n	13	11	65	8	5	27
Mean (SD/SE)	11.5 (26.1)	10.0 (15.5)	6.0 (15.6)	7.5 (12.5)	4.0 (6.8)	-0.4 (4.3)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 30.0	0.0, 0.0	-5.0, 5.0	0.0, 0.0	0.0, 0.0
Min, Max	0, 90	0, 40	0, 80	-30, 90	-10, 30	-50, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.13.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=42)	Visit Result MGL-3196 100 mg (N=25)	Visit Result Placebo (N=179)	Change from Baseline MGL-3196 80 mg (N=42)	Change from Baseline MGL-3196 100 mg (N=25)	Change from Baseline Placebo (N=179)
Overall Work Impairment						
Baseline						
m	42	25	179			
n	13	10	43			
Mean (SD)	9.00 (22.23)	11.43 (16.66)	9.02 (18.98)			
Median	0	5.00	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 14.30	0.00, 10.00			
Min, Max	0.0, 76.0	0.0, 50.0	0.0, 70.0			
Week 24						
m	41	25	177			
n	14	12	57	9	8	32
Mean (SD/SE)	15.86 (23.86)	13.09 (18.33)	8.07 (16.08)	4.44 (12.41)	5.10 (8.86)	1.01 (4.24)
Median	0	5.00	0	0	0	0
IQR: Q1, Q3	0.00, 30.00	0.00, 20.00	0.00, 10.00	0.00, 0.00	0.00, 5.40	0.00, 5.00
Min, Max	0.0, 80.0	0.0, 60.0	0.0, 70.0	-46.0, 80.0	-30.0, 60.0	-60.0, 70.0
Week 52						
m	39	22	167			
n	13	11	65	8	5	27
Mean (SD/SE)	15.00 (28.72)	11.44 (18.05)	9.27 (21.09)	9.38 (15.16)	4.00 (6.78)	1.79 (5.46)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 10.00	0.00, 30.00	0.00, 0.00	-17.00, 27.50	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 90.0	0.0, 45.8	0.0, 83.0	-36.0, 90.0	-10.0, 30.0	-53.3, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 8 of 8
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.13.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Activity Impairment						
Baseline						
m	42	25	179			
n	25	16	82			
Mean (SD)	11.6 (18.2)	10.6 (16.1)	15.4 (23.1)			
Median	0	5.0	0			
IQR: Q1, Q3	0.0, 20.0	0.0, 15.0	0.0, 20.0			
Min, Max	0, 70	0, 60	0, 80			
Week 24						
m	41	25	177			
n	27	19	100	18	14	57
Mean (SD/SE)	14.8 (21.2)	8.4 (16.1)	15.6 (22.5)	4.4 (5.6)	0.7 (5.2)	-0.7 (2.9)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 10.0	0.0, 20.0	0.0, 10.0	0.0, 0.0	0.0, 10.0
Min, Max	0, 60	0, 60	0, 80	-40, 50	-20, 60	-80, 70
Week 52						
m	39	22	167			
n	23	15	110	13	7	44
Mean (SD/SE)	10.0 (15.7)	8.7 (13.6)	12.6 (19.9)	0.8 (5.5)	1.4 (5.9)	-3.9 (3.2)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 20.0	-10.0, 10.0	-10.0, 10.0	-10.0, 0.0
Min, Max	0, 50	0, 40	0, 100	-40, 50	-20, 30	-70, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; CFB = Change from Baseline; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.13.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; CFB = Change from Baseline; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.13.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Absenteeism			
Week 24			
m	76	74	29
n	10	12	6
Baseline Mean (SD)	4.42 (11.08)	0.00 (0.00)	1.52 (3.72)
Analysis Visit Mean (SD)	2.92 (6.23)	2.45 (8.49)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-1.01 (2.11)	0.96 (1.77)	-1.88 (2.51)
95% CI	(-5.32, 3.31)	(-2.65, 4.57)	(-7.00, 3.24)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.88 (3.23)	2.84 (3.03)	
95% CI	(-5.72, 7.47)	(-3.35, 9.04)	
p-value	0.7876	0.3561	
Corrected Hedge's g Statistics	0.128	0.442	
95% CI	(-0.89, 1.14)	(-0.55, 1.43)	
Week 52			
m	74	68	27
n	2	14	4
Baseline Mean (SD)	17.40 (24.61)	0.00 (0.00)	2.28 (4.55)
Analysis Visit Mean (SD)	16.65 (23.55)	10.52 (22.56)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	0.27 (14.95)	9.83 (5.09)	-1.69 (8.85)
95% CI	(-30.25, 30.80)	(-0.57, 20.23)	(-19.76, 16.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.96 (17.18)	11.52 (10.23)	
95% CI	(-33.13, 37.05)	(-9.37, 32.41)	
p-value	0.9098	0.2689	
Corrected Hedge's g Statistics	0.084	0.584	
95% CI	(-1.61, 1.78)	(-0.54, 1.71)	
Subgroup*Treatment Interaction p-value	0.1134	0.5748	

AMNOG Table SE24.13.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Presenteeism			
Week 24			
m	76	74	29
n	10	12	6
Baseline Mean (SD)	6.0 (19.0)	7.5 (7.5)	5.0 (8.4)
Analysis Visit Mean (SD)	15.0 (29.2)	10.8 (16.8)	1.7 (4.1)
LS Mean of Change from Baseline (SE)	6.51 (6.80)	4.81 (6.15)	-4.43 (8.70)
95% CI	(-7.38, 20.40)	(-7.75, 17.37)	(-22.21, 13.34)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.95 (10.99)	9.24 (10.64)	
95% CI	(-11.50, 33.39)	(-12.49, 30.97)	
p-value	0.3273	0.3920	
Corrected Hedge's g Statistics	0.483	0.413	
95% CI	(-0.54, 1.51)	(-0.58, 1.40)	
Week 52			
m	74	68	27
n	2	14	4
Baseline Mean (SD)	30.0 (42.4)	7.9 (13.7)	2.5 (5.0)
Analysis Visit Mean (SD)	45.0 (7.1)	5.7 (7.6)	7.5 (9.6)
LS Mean of Change from Baseline (SE)	31.53 (6.08)	-1.06 (2.09)	1.04 (3.87)
95% CI	(19.12, 43.94)	(-5.33, 3.21)	(-6.88, 8.95)
LS Mean of Change from Baseline Compared to Placebo (SE)	30.49 (7.65)	-2.10 (4.24)	
95% CI	(14.86, 46.12)	(-10.75, 6.56)	
p-value	0.0004	0.6244	
Corrected Hedge's g Statistics	3.061	-0.256	
95% CI	(0.64, 5.49)	(-1.37, 0.86)	
Subgroup*Treatment Interaction p-value	0.4236	0.9563	

AMNOG Table SE24.13.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Overall Work Impairment			
Week 24			
m	76	74	29
n	10	12	6
Baseline Mean (SD)	8.33 (23.23)	7.50 (7.54)	6.52 (8.10)
Analysis Visit Mean (SD)	16.13 (30.61)	13.04 (18.32)	1.67 (4.08)
LS Mean of Change from Baseline (SE)	4.97 (7.37)	5.01 (6.48)	-7.23 (9.12)
95% CI	(-10.08, 20.02)	(-8.23, 18.25)	(-25.85, 11.39)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.20 (11.59)	12.24 (11.12)	
95% CI	(-11.48, 35.88)	(-10.48, 34.96)	
p-value	0.3012	0.2801	
Corrected Hedge's g Statistics	0.502	0.520	
95% CI	(-0.52, 1.53)	(-0.47, 1.51)	
Week 52			
m	74	68	27
n	2	14	4
Baseline Mean (SD)	36.95 (52.26)	7.86 (13.69)	4.78 (5.53)
Analysis Visit Mean (SD)	53.30 (18.81)	14.71 (24.20)	7.50 (9.57)
LS Mean of Change from Baseline (SE)	38.71 (17.93)	6.08 (6.04)	-1.67 (11.25)
95% CI	(2.09, 75.34)	(-6.25, 18.41)	(-24.64, 21.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	40.39 (21.98)	7.75 (12.50)	
95% CI	(-4.50, 85.27)	(-17.78, 33.28)	
p-value	0.0761	0.5398	
Corrected Hedge's g Statistics	1.390	0.327	
95% CI	(-0.48, 3.26)	(-0.79, 1.44)	
Subgroup*Treatment Interaction p-value	0.5601	0.6350	

AMNOG Table SE24.13.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Activity Impairment			
Week 24			
m	76	74	29
n	24	27	10
Baseline Mean (SD)	14.2 (25.2)	11.1 (16.7)	8.0 (13.2)
Analysis Visit Mean (SD)	20.0 (27.8)	13.0 (17.7)	8.0 (13.2)
LS Mean of Change from Baseline (SE)	5.81 (3.95)	-0.39 (3.80)	-3.40 (6.12)
95% CI	(-2.08, 13.70)	(-7.97, 7.19)	(-15.61, 8.82)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.21 (7.28)	3.01 (7.12)	
95% CI	(-5.32, 23.73)	(-11.20, 17.21)	
p-value	0.2101	0.6741	
Corrected Hedge's g Statistics	0.464	0.150	
95% CI	(-0.28, 1.21)	(-0.58, 0.88)	
Week 52			
m	74	68	27
n	13	25	6
Baseline Mean (SD)	23.8 (28.1)	13.2 (18.9)	6.7 (8.2)
Analysis Visit Mean (SD)	21.5 (24.1)	17.2 (17.9)	11.7 (11.7)
LS Mean of Change from Baseline (SE)	3.37 (5.15)	2.66 (3.69)	1.43 (7.29)
95% CI	(-6.90, 13.64)	(-4.70, 10.02)	(-13.12, 15.97)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.94 (9.00)	1.23 (8.13)	
95% CI	(-16.02, 19.91)	(-14.99, 17.46)	
p-value	0.8296	0.8798	
Corrected Hedge's g Statistics	0.101	0.066	
95% CI	(-0.87, 1.07)	(-0.83, 0.96)	
Subgroup*Treatment Interaction p-value	0.5822	0.6324	

AMNOG Table SE24.13.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Absenteeism			
Week 24			
m	41	25	177
n	9	8	33
Baseline Mean (SD)	5.19 (10.43)	0.60 (1.70)	4.23 (18.16)
Analysis Visit Mean (SD)	0.00 (0.00)	0.71 (2.02)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-2.92 (0.26)	-2.19 (0.27)	-2.90 (0.14)
95% CI	(-3.44, -2.41)	(-2.73, -1.64)	(-3.18, -2.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.02 (0.28)	0.72 (0.30)	
95% CI	(-0.58, 0.54)	(0.12, 1.31)	
p-value	0.9387	0.0187	
Corrected Hedge's g Statistics	-0.027	0.898	
95% CI	(-0.76, 0.71)	(0.10, 1.69)	
Week 52			
m	39	22	167
n	8	5	27
Baseline Mean (SD)	5.84 (10.96)	0.00 (0.00)	1.23 (6.41)
Analysis Visit Mean (SD)	6.25 (17.68)	0.00 (0.00)	4.17 (14.08)
LS Mean of Change from Baseline (SE)	3.26 (5.88)	-12.09 (7.05)	1.15 (3.16)
95% CI	(-8.51, 15.04)	(-26.21, 2.04)	(-5.19, 7.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.12 (6.73)	-13.24 (7.67)	
95% CI	(-11.38, 15.61)	(-28.60, 2.13)	
p-value	0.7545	0.0900	
Corrected Hedge's g Statistics	0.125	-0.789	
95% CI	(-0.66, 0.92)	(-1.76, 0.18)	
Subgroup*Treatment Interaction p-value	0.1134	0.5748	

AMNOG Table SE24.13.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Presenteeism			
Week 24			
m	41	25	177
n	9	8	32
Baseline Mean (SD)	8.9 (23.2)	10.0 (16.9)	8.8 (19.8)
Analysis Visit Mean (SD)	16.7 (28.3)	15.0 (20.0)	10.6 (18.1)
LS Mean of Change from Baseline (SE)	5.46 (6.79)	6.42 (7.11)	1.51 (3.58)
95% CI	(-8.16, 19.07)	(-7.84, 20.68)	(-5.66, 8.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.95 (7.31)	4.91 (7.69)	
95% CI	(-10.71, 18.61)	(-10.50, 20.32)	
p-value	0.5916	0.5259	
Corrected Hedge's g Statistics	0.191	0.238	
95% CI	(-0.55, 0.93)	(-0.54, 1.01)	
Week 52			
m	39	22	167
n	8	5	27
Baseline Mean (SD)	10.0 (24.5)	10.0 (12.2)	9.6 (21.0)
Analysis Visit Mean (SD)	17.5 (32.4)	14.0 (19.5)	9.3 (19.2)
LS Mean of Change from Baseline (SE)	7.42 (7.04)	-2.23 (8.19)	-0.44 (3.74)
95% CI	(-6.68, 21.53)	(-18.66, 14.19)	(-7.94, 7.07)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.86 (7.58)	-1.80 (8.69)	
95% CI	(-7.34, 23.06)	(-19.21, 15.62)	
p-value	0.3045	0.8369	
Corrected Hedge's g Statistics	0.393	-0.091	
95% CI	(-0.40, 1.19)	(-1.05, 0.86)	
Subgroup*Treatment Interaction p-value	0.4236	0.9563	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.13.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Overall Work Impairment			
Week 24			
m	41	25	177
n	9	8	32
Baseline Mean (SD)	12.22 (26.43)	10.54 (16.97)	9.62 (21.15)
Analysis Visit Mean (SD)	16.67 (28.28)	15.64 (19.90)	10.63 (18.13)
LS Mean of Change from Baseline (SE)	7.84 (6.99)	7.02 (7.29)	0.67 (3.67)
95% CI	(-6.18, 21.85)	(-7.59, 21.63)	(-6.68, 8.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	7.17 (7.47)	6.35 (7.85)	
95% CI	(-7.82, 22.15)	(-9.38, 22.09)	
p-value	0.3417	0.4218	
Corrected Hedge's g Statistics	0.338	0.300	
95% CI	(-0.41, 1.08)	(-0.48, 1.08)	
Week 52			
m	39	22	167
n	8	5	27
Baseline Mean (SD)	13.75 (27.82)	10.00 (12.25)	10.49 (22.33)
Analysis Visit Mean (SD)	23.13 (34.74)	14.00 (19.49)	12.28 (23.97)
LS Mean of Change from Baseline (SE)	11.36 (8.18)	-3.48 (9.28)	1.82 (4.33)
95% CI	(-5.04, 27.76)	(-22.08, 15.12)	(-6.85, 10.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.55 (8.90)	-5.30 (9.98)	
95% CI	(-8.30, 27.39)	(-25.30, 14.71)	
p-value	0.2883	0.5978	
Corrected Hedge's g Statistics	0.412	-0.232	
95% CI	(-0.38, 1.21)	(-1.19, 0.72)	
Subgroup*Treatment Interaction p-value	0.5601	0.6350	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.13.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Visit Statistic	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Activity Impairment			
Week 24			
m	41	25	177
n	18	14	57
Baseline Mean (SD)	10.0 (18.1)	10.0 (16.2)	15.8 (23.9)
Analysis Visit Mean (SD)	14.4 (20.6)	10.7 (18.2)	15.1 (21.5)
LS Mean of Change from Baseline (SE)	1.69 (4.60)	-0.62 (5.09)	1.68 (2.58)
95% CI	(-7.44, 10.82)	(-10.72, 9.49)	(-3.44, 6.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.01 (5.08)	-2.30 (5.57)	
95% CI	(-10.07, 10.09)	(-13.36, 8.76)	
p-value	0.9983	0.6811	
Corrected Hedge's g Statistics	0.001	-0.117	
95% CI	(-0.53, 0.53)	(-0.70, 0.47)	
Week 52			
m	39	22	167
n	13	7	44
Baseline Mean (SD)	10.0 (20.0)	11.4 (10.7)	15.9 (23.3)
Analysis Visit Mean (SD)	10.8 (15.0)	12.9 (16.0)	12.0 (18.7)
LS Mean of Change from Baseline (SE)	0.27 (4.29)	-3.84 (5.39)	-3.56 (2.32)
95% CI	(-8.24, 8.78)	(-14.52, 6.85)	(-8.15, 1.04)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.83 (4.68)	-0.28 (5.72)	
95% CI	(-5.46, 13.11)	(-11.62, 11.06)	
p-value	0.4156	0.9610	
Corrected Hedge's g Statistics	0.245	-0.018	
95% CI	(-0.38, 0.87)	(-0.82, 0.78)	
Subgroup*Treatment Interaction p-value	0.5822	0.6324	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.13.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; CFB = Change from Baseline; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.13.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	76 (100)	75 (100)	30 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (3.3)
No	76 (100)	75 (100)	29 (96.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.33	-3.33	
95% CI of the absolute risk difference	(-9.76, 3.09)	(-9.76, 3.09)	
p-value	0.1098	0.1121	
p-value of Breslow-Day Test for Homogeneity [3]	0.0102	NE	

AMNOG Table SE24.13.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (1.3)	0
No	76 (100)	74 (98.7)	30 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	1.33	
95% CI of the absolute risk difference	NE	(-1.26, 3.93)	
p-value	NE	0.5251	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.3118	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.3)	4 (5.3)	0
No	75 (98.7)	71 (94.7)	30 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.26	
95% CI of the inverse odds ratio	NE	(0.01, 4.99)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.27	
95% CI of the inverse risk ratio	NE	(0.02, 4.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.32	4.31	
95% CI of the absolute risk difference	(-1.25, 3.88)	(-2.61, 11.22)	
p-value	0.5279	0.3382	
p-value of Breslow-Day Test for Homogeneity [3]	0.6300	0.2924	

AMNOG Table SE24.13.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (1.3)	0
No	76 (100)	74 (98.7)	30 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	1.33	
95% CI of the absolute risk difference	NE	(-1.26, 3.93)	
p-value	NE	0.5251	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.3118	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.3)	3 (4.0)	1 (3.3)
No	75 (98.7)	72 (96.0)	29 (96.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.59	0.83	
95% CI of the inverse odds ratio	(0.16, 42.73)	(0.08, 8.29)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	2.53	0.83	
95% CI of the inverse risk ratio	(0.16, 39.21)	(0.09, 7.70)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.02	0.67	
95% CI of the absolute risk difference	(-8.93, 4.90)	(-7.14, 8.47)	
p-value	0.4916	0.8719	
p-value of Breslow-Day Test for Homogeneity [3]	0.3499	0.9101	

AMNOG Table SE24.13.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: >= 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=76)	MGL-3196 100 mg (N=75)	Placebo (N=30)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (5.3)	2 (2.7)	0
No	72 (94.7)	73 (97.3)	30 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.26	NE	
95% CI of the inverse odds ratio	(0.01, 5.06)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.28	NE	
95% CI of the inverse risk ratio	(0.02, 4.98)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.23	2.67	
95% CI of the absolute risk difference	(-2.63, 11.10)	(-0.98, 6.31)	
p-value	0.3438	0.3665	
p-value of Breslow-Day Test for Homogeneity [3]	0.1539	0.3766	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (6.6)	5 (6.7)	0
No	71 (93.4)	70 (93.3)	30 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.21	0.21	
95% CI of the inverse odds ratio	(0.01, 3.97)	(0.01, 3.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.23	0.22	
95% CI of the inverse risk ratio	(0.01, 3.96)	(0.01, 3.91)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.53	5.62	
95% CI of the absolute risk difference	(-1.73, 12.79)	(-1.70, 12.94)	
p-value	0.2564	0.2514	
p-value of Breslow-Day Test for Homogeneity [3]	0.2395	0.2088	

AMNOG Table SE24.13.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.8)	0	1 (0.6)
No	40 (95.2)	25 (100)	178 (99.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.11	NE	
95% CI of the inverse odds ratio	(0.01, 1.27)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.12	NE	
95% CI of the inverse risk ratio	(0.01, 1.26)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.20	-0.56	
95% CI of the absolute risk difference	(-2.33, 10.74)	(-1.65, 0.53)	
p-value	0.0341	0.7079	
p-value of Breslow-Day Test for Homogeneity [3]	NE	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (4.8)	0	1 (0.6)
No	40 (95.2)	25 (100)	178 (99.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.11	NE	
95% CI of the inverse odds ratio	(0.01, 1.27)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.12	NE	
95% CI of the inverse risk ratio	(0.01, 1.26)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.20	-0.56	
95% CI of the absolute risk difference	(-2.33, 10.74)	(-1.65, 0.53)	
p-value	0.0341	0.7079	
p-value of Breslow-Day Test for Homogeneity [3]	0.0102	NE	

AMNOG Table SE24.13.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.4)	0	4 (2.2)
No	41 (97.6)	25 (100)	175 (97.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	NE	
95% CI of the inverse odds ratio	(0.10, 8.61)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.94	NE	
95% CI of the inverse risk ratio	(0.11, 8.18)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.15	-2.23	
95% CI of the absolute risk difference	(-4.95, 5.24)	(-4.40, -0.07)	
p-value	0.9542	0.4503	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.3118	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (4.8)	1 (4.0)	5 (2.8)
No	40 (95.2)	24 (96.0)	174 (97.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	0.69	
95% CI of the inverse odds ratio	(0.11, 3.07)	(0.08, 6.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.70	
95% CI of the inverse risk ratio	(0.12, 2.92)	(0.09, 5.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.97	1.21	
95% CI of the absolute risk difference	(-4.91, 8.85)	(-6.85, 9.26)	
p-value	0.5121	0.7380	
p-value of Breslow-Day Test for Homogeneity [3]	0.6300	0.2924	

AMNOG Table SE24.13.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.8)	0	4 (2.2)
No	40 (95.2)	25 (100)	175 (97.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.46	NE	
95% CI of the inverse odds ratio	(0.08, 2.58)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.47	NE	
95% CI of the inverse risk ratio	(0.09, 2.48)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.53	-2.23	
95% CI of the absolute risk difference	(-4.27, 9.32)	(-4.40, -0.07)	
p-value	0.3644	0.4503	
p-value of Breslow-Day Test for Homogeneity [3]	NE	0.3118	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (4.8)	1 (4.0)	5 (2.8)
No	40 (95.2)	24 (96.0)	174 (97.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	0.69	
95% CI of the inverse odds ratio	(0.11, 3.07)	(0.08, 6.16)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.70	
95% CI of the inverse risk ratio	(0.12, 2.92)	(0.09, 5.74)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.97	1.21	
95% CI of the absolute risk difference	(-4.91, 8.85)	(-6.85, 9.26)	
p-value	0.5121	0.7380	
p-value of Breslow-Day Test for Homogeneity [3]	0.3499	0.9101	

AMNOG Table SE24.13.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Reduction in MRI-PDFF at Week 16
(Label Population)

Reduction in MRI-PDFF at Week 16: < 30% CFB

Parameter Response Statistic/Category	MGL-3196 80 mg (N=42)	MGL-3196 100 mg (N=25)	Placebo (N=179)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (2.4)	1 (4.0)	8 (4.5)
No	41 (97.6)	24 (96.0)	171 (95.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.92	1.12	
95% CI of the inverse odds ratio	(0.23, 15.77)	(0.13, 9.38)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.88	1.12	
95% CI of the inverse risk ratio	(0.24, 14.60)	(0.15, 8.56)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.09	-0.47	
95% CI of the absolute risk difference	(-7.60, 3.43)	(-8.73, 7.79)	
p-value	0.5377	0.9148	
p-value of Breslow-Day Test for Homogeneity [3]	0.1539	0.3766	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	4 (9.5)	2 (8.0)	12 (6.7)
No	38 (90.5)	23 (92.0)	167 (93.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.68	0.83	
95% CI of the inverse odds ratio	(0.21, 2.23)	(0.17, 3.93)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	0.84	
95% CI of the inverse risk ratio	(0.24, 2.07)	(0.20, 3.53)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.82	1.30	
95% CI of the absolute risk difference	(-6.78, 12.42)	(-9.95, 12.54)	
p-value	0.5256	0.8102	
p-value of Breslow-Day Test for Homogeneity [3]	0.2395	0.2088	

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.14a.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Absenteeism						
Baseline						
m	48	44	95			
n	7	15	21			
Mean (SD)	1.00 (2.65)	0.32 (1.24)	1.49 (5.56)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 7.0	0.0, 4.8	0.0, 25.0			
Week 24						
m	47	39	87			
n	12	8	27	4	5	14
Mean (SD/SE)	0.00 (0.00)	4.39 (10.30)	0.00 (0.00)	0.00 (0.00)	6.06 (5.84)	-2.24 (1.81)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 2.85	0.00, 0.00	0.00, 0.00	0.00, 0.90	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 29.4	0.0, 0.0	0.0, 0.0	0.0, 29.4	-25.0, 0.0
Week 52						
m	45	35	81			
n	12	9	23	2	6	13
Mean (SD/SE)	0.00 (0.00)	7.41 (22.23)	3.33 (11.74)	0.00 (0.00)	11.12 (11.12)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 66.7	0.0, 51.6	0.0, 0.0	0.0, 66.7	0.0, 0.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Presenteeism						
Baseline						
m	48	44	95			
n	7	15	21			
Mean (SD)	1.4 (3.8)	4.7 (6.4)	7.6 (16.4)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0			
Min, Max	0, 10	0, 20	0, 70			
Week 24						
m	47	39	87			
n	12	8	27	4	5	14
Mean (SD/SE)	4.2 (9.0)	2.5 (4.6)	10.7 (16.4)	0.0 (4.1)	-2.0 (2.0)	1.4 (2.7)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 5.0	0.0, 5.0	0.0, 20.0	-5.0, 5.0	0.0, 0.0	0.0, 0.0
Min, Max	0, 30	0, 10	0, 60	-10, 10	-10, 0	-20, 20
Week 52						
m	45	35	81			
n	12	9	23	2	6	13
Mean (SD/SE)	10.0 (18.6)	10.0 (16.6)	10.4 (15.8)	20.0 (20.0)	6.7 (4.9)	1.5 (3.2)
Median	0	0	0	20.0	0	0
IQR: Q1, Q3	0.0, 15.0	0.0, 10.0	0.0, 10.0	0.0, 40.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 50	0, 50	0, 50	0, 40	0, 30	-20, 30

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Overall Work Impairment						
Baseline						
m	48	44	95			
n	7	15	21			
Mean (SD)	2.43 (4.24)	4.95 (6.74)	8.90 (17.57)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 7.00	0.00, 10.00	0.00, 10.00			
Min, Max	0.0, 10.0	0.0, 20.0	0.0, 70.0			
Week 24						
m	47	39	87			
n	12	8	27	4	5	14
Mean (SD/SE)	4.17 (9.00)	6.45 (13.24)	10.74 (16.39)	0.00 (4.08)	3.46 (6.10)	-0.49 (2.84)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 5.00	0.00, 7.55	0.00, 20.00	-5.00, 5.00	0.00, 0.80	-4.40, 0.00
Min, Max	0.0, 30.0	0.0, 36.5	0.0, 60.0	-10.0, 10.0	-10.0, 26.5	-20.0, 20.0
Week 52						
m	45	35	81			
n	12	9	23	2	6	13
Mean (SD/SE)	10.00 (18.59)	15.93 (26.93)	12.88 (20.19)	20.00 (20.00)	15.57 (10.75)	0.96 (2.77)
Median	0	0	0	20.00	0	0
IQR: Q1, Q3	0.00, 15.00	0.00, 10.00	0.00, 10.00	0.00, 40.00	0.00, 30.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 73.4	0.0, 61.3	0.0, 40.0	0.0, 63.4	-20.0, 22.5

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=48)	Visit Result MGL-3196 100 mg (N=44)	Visit Result Placebo (N=95)	Change from Baseline MGL-3196 80 mg (N=48)	Change from Baseline MGL-3196 100 mg (N=44)	Change from Baseline Placebo (N=95)
Activity Impairment						
Baseline						
m	48	44	95			
n	19	22	48			
Mean (SD)	14.7 (26.5)	7.7 (9.7)	17.1 (26.9)			
Median	0	5.0	0			
IQR: Q1, Q3	0.0, 30.0	0.0, 10.0	0.0, 20.0			
Min, Max	0, 80	0, 30	0, 100			
Week 24						
m	47	39	87			
n	27	18	47	15	14	30
Mean (SD/SE)	18.1 (25.3)	10.6 (14.3)	18.1 (22.4)	9.3 (4.9)	3.6 (2.7)	0.3 (3.3)
Median	0	5.0	10.0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 30.0	0.0, 10.0	0.0, 10.0	-10.0, 10.0
Min, Max	0, 80	0, 50	0, 70	-10, 60	-20, 20	-50, 50
Week 52						
m	45	35	81			
n	24	20	49	7	11	28
Mean (SD/SE)	19.2 (26.5)	14.5 (17.9)	16.1 (19.1)	4.3 (10.4)	10.0 (3.3)	-2.1 (3.4)
Median	0	5.0	10.0	0	10.0	0
IQR: Q1, Q3	0.0, 50.0	0.0, 30.0	0.0, 20.0	-20.0, 30.0	0.0, 20.0	0.0, 10.0
Min, Max	0, 90	0, 50	0, 80	-30, 50	0, 30	-70, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=77)	Visit Result: MGL-3196 100 mg (N=72)	Visit Result: Placebo (N=128)	Change from Baseline: MGL-3196 80 mg (N=77)	Change from Baseline: MGL-3196 100 mg (N=72)	Change from Baseline: Placebo (N=128)
Absenteeism						
Baseline						
m	77	72	128			
n	18	19	23			
Mean (SD)	5.05 (10.72)	1.44 (6.26)	0.52 (1.97)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 34.8	0.0, 27.3	0.0, 9.1			
Week 24						
m	76	68	125			
n	23	21	31	15	10	13
Mean (SD/SE)	1.27 (4.25)	0.71 (3.27)	0.00 (0.00)	-4.11 (2.61)	0.00 (0.00)	-0.70 (0.70)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-9.40, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 16.7	0.0, 15.0	0.0, 0.0	-26.7, 12.5	0.0, 0.0	-9.1, 0.0
Week 52						
m	70	57	120			
n	18	26	45	7	11	12
Mean (SD/SE)	4.87 (13.72)	3.46 (11.71)	2.00 (11.35)	-6.89 (4.32)	5.05 (5.05)	0.50 (1.53)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-20.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 55.6	0.0, 75.0	-26.7, 0.0	0.0, 55.6	-9.1, 15.1

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=77)	Visit Result: MGL-3196 100 mg (N=72)	Visit Result: Placebo (N=128)	Change from Baseline: MGL-3196 80 mg (N=77)	Change from Baseline: MGL-3196 100 mg (N=72)	Change from Baseline: Placebo (N=128)
Presenteeism						
Baseline						
m	77	72	128			
n	18	19	23			
Mean (SD)	10.6 (21.5)	14.2 (20.4)	6.1 (17.8)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 0.0			
Min, Max	0, 70	0, 70	0, 70			
Week 24						
m	76	68	125			
n	23	21	31	15	10	13
Mean (SD/SE)	15.7 (25.7)	12.4 (18.1)	4.2 (13.1)	10.0 (8.9)	1.0 (4.3)	3.1 (7.5)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 0.0	0.0, 10.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 90	0, 80	0, 70	-40, 90	-30, 20	-60, 70
Week 52						
m	70	57	120			
n	18	26	45	7	11	12
Mean (SD/SE)	15.0 (25.0)	11.5 (20.3)	7.3 (17.8)	5.7 (14.6)	5.5 (3.1)	5.0 (7.8)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 20.0	0.0, 0.0	-10.0, 0.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 90	0, 90	0, 80	-30, 90	0, 30	-40, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=77)	Visit Result: MGL-3196 100 mg (N=72)	Visit Result: Placebo (N=128)	Change from Baseline: MGL-3196 80 mg (N=77)	Change from Baseline: MGL-3196 100 mg (N=72)	Change from Baseline: Placebo (N=128)
Overall Work Impairment						
Baseline						
m	77	72	128			
n	18	19	23			
Mean (SD)	13.52 (24.84)	15.07 (21.81)	6.54 (17.89)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 20.00	0.00, 20.00	0.00, 0.00			
Min, Max	0.0, 76.0	0.0, 70.0	0.0, 70.0			
Week 24						
m	76	68	125			
n	23	21	31	15	10	13
Mean (SD/SE)	16.14 (26.41)	12.95 (18.58)	4.19 (13.11)	7.20 (9.66)	1.00 (4.33)	2.38 (7.60)
Median	0	10.00	0	0	0	0
IQR: Q1, Q3	0.00, 30.00	0.00, 20.00	0.00, 0.00	-9.40, 10.00	0.00, 10.00	0.00, 0.00
Min, Max	0.0, 91.3	0.0, 80.0	0.0, 70.0	-46.0, 91.3	-30.0, 20.0	-60.0, 70.0
Week 52						
m	70	57	120			
n	18	26	45	7	11	12
Mean (SD/SE)	17.78 (29.10)	14.12 (23.27)	8.23 (20.72)	1.81 (15.87)	10.00 (5.88)	4.49 (8.13)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 23.40	0.00, 20.00	0.00, 0.00	-34.00, 0.00	0.00, 20.00	0.00, 0.00
Min, Max	0.0, 90.0	0.0, 91.2	0.0, 87.5	-36.0, 90.0	0.0, 60.0	-40.0, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=77)	Visit Result: MGL-3196 100 mg (N=72)	Visit Result: Placebo (N=128)	Change from Baseline: MGL-3196 80 mg (N=77)	Change from Baseline: MGL-3196 100 mg (N=72)	Change from Baseline: Placebo (N=128)
Activity Impairment						
Baseline						
m	77	72	128			
n	33	32	41			
Mean (SD)	13.0 (21.0)	14.7 (20.9)	18.0 (28.2)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 30.0	0.0, 30.0	0.0, 40.0			
Min, Max	0, 70	0, 80	0, 100			
Week 24						
m	76	68	125			
n	45	31	63	26	15	26
Mean (SD/SE)	16.2 (21.6)	9.0 (14.5)	15.2 (23.5)	7.3 (5.2)	-2.0 (2.4)	-0.4 (4.7)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 10.0	0.0, 20.0	0.0, 10.0	-10.0, 0.0	0.0, 0.0
Min, Max	0, 80	0, 60	0, 80	-40, 80	-20, 10	-80, 70
Week 52						
m	70	57	120			
n	45	39	74	16	15	19
Mean (SD/SE)	15.6 (19.5)	17.2 (21.5)	15.7 (23.0)	-3.8 (5.2)	10.0 (4.0)	-5.3 (6.9)
Median	10.0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 30.0	0.0, 20.0	-10.0, 5.0	0.0, 20.0	-10.0, 0.0
Min, Max	0, 80	0, 80	0, 100	-40, 50	-10, 40	-90, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=30)	Visit Result: MGL-3196 100 mg (N=22)	Visit Result: Placebo (N=63)	Change from Baseline: MGL-3196 80 mg (N=30)	Change from Baseline: MGL-3196 100 mg (N=22)	Change from Baseline: Placebo (N=63)
Absenteeism						
Baseline						
m	30	22	63			
n	2	6	19			
Mean (SD)	0.00 (0.00)	11.35 (27.80)	7.02 (23.77)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 0.0	0.0, 68.1	0.0, 100.0			
Week 24						
m	28	22	60			
n	5	8	22	1	4	14
Mean (SD/SE)	3.00 (6.71)	0.00 (0.00)	0.00 (0.00)	0.00 (N/A)	0.00 (0.00)	-9.52 (7.35)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 15.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	-100.0, 0.0
Week 52						
m	27	22	54			
n	7	9	21	2	4	7
Mean (SD/SE)	7.14 (18.90)	0.00 (0.00)	4.64 (15.72)	25.00 (25.00)	0.00 (0.00)	9.17 (11.87)
Median	0	0	0	25.00	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 50.00	0.00, 0.00	0.00, 30.80
Min, Max	0.0, 50.0	0.0, 0.0	0.0, 66.7	0.0, 50.0	0.0, 0.0	-33.3, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=30)	Visit Result: MGL-3196 100 mg (N=22)	Visit Result: Placebo (N=63)	Change from Baseline: MGL-3196 80 mg (N=30)	Change from Baseline: MGL-3196 100 mg (N=22)	Change from Baseline: Placebo (N=63)
Presenteeism						
Baseline						
m	30	22	63			
n	2	6	18			
Mean (SD)	0.0 (0.0)	13.3 (18.6)	8.3 (11.0)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 20.0			
Min, Max	0, 0	0, 50	0, 30			
Week 24						
m	28	22	60			
n	5	8	22	1	4	13
Mean (SD/SE)	4.0 (8.9)	20.0 (25.6)	8.6 (17.5)	0.0 (N/A)	27.5 (16.0)	3.1 (5.1)
Median	0	10.0	0	0	25.0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 40.0	0.0, 10.0	0.0, 0.0	0.0, 55.0	-10.0, 0.0
Min, Max	0, 20	0, 60	0, 60	0, 0	0, 60	-20, 50
Week 52						
m	27	22	54			
n	7	9	21	2	4	7
Mean (SD/SE)	8.6 (12.1)	5.6 (10.1)	5.7 (12.5)	5.0 (5.0)	-15.0 (8.7)	2.9 (6.4)
Median	0	0	0	5.0	-10.0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 10.0	0.0, 0.0	0.0, 10.0	-25.0, -5.0	0.0, 20.0
Min, Max	0, 30	0, 30	0, 40	0, 10	-40, 0	-30, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=30)	Visit Result: MGL-3196 100 mg (N=22)	Visit Result: Placebo (N=63)	Change from Baseline: MGL-3196 80 mg (N=30)	Change from Baseline: MGL-3196 100 mg (N=22)	Change from Baseline: Placebo (N=63)
Overall Work Impairment						
Baseline						
m	30	22	63			
n	2	6	18			
Mean (SD)	0.00 (0.00)	24.68 (27.50)	9.63 (14.50)			
Median	0	10.00	0			
IQR: Q1, Q3	0.00, 0.00	10.00, 50.00	0.00, 20.00			
Min, Max	0.0, 0.0	0.0, 68.1	0.0, 53.3			
Week 24						
m	28	22	60			
n	5	8	22	1	4	13
Mean (SD/SE)	6.40 (14.31)	20.00 (25.63)	8.64 (17.54)	0.00 (N/A)	27.50 (16.01)	1.28 (6.02)
Median	0	10.00	0	0	25.00	0
IQR: Q1, Q3	0.00, 0.00	0.00, 40.00	0.00, 10.00	0.00, 0.00	0.00, 55.00	-10.00, 0.00
Min, Max	0.0, 32.0	0.0, 60.0	0.0, 60.0	0.0, 0.0	0.0, 60.0	-43.3, 50.0
Week 52						
m	27	22	54			
n	7	9	21	2	4	7
Mean (SD/SE)	15.00 (21.41)	5.56 (10.14)	9.45 (20.67)	27.50 (27.50)	-15.00 (8.66)	10.74 (14.49)
Median	0	0	0	27.50	-10.00	0
IQR: Q1, Q3	0.00, 30.00	0.00, 10.00	0.00, 0.00	0.00, 55.00	-25.00, -5.00	0.00, 38.50
Min, Max	0.0, 55.0	0.0, 30.0	0.0, 70.0	0.0, 55.0	-40.0, 0.0	-53.3, 70.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=30)	Visit Result: MGL-3196 100 mg (N=22)	Visit Result: Placebo (N=63)	Change from Baseline: MGL-3196 80 mg (N=30)	Change from Baseline: MGL-3196 100 mg (N=22)	Change from Baseline: Placebo (N=63)
Activity Impairment						
Baseline						
m	30	22	63			
n	11	15	29			
Mean (SD)	13.6 (24.2)	12.7 (15.8)	18.6 (22.0)			
Median	0	10.0	10.0			
IQR: Q1, Q3	0.0, 20.0	0.0, 20.0	0.0, 40.0			
Min, Max	0, 80	0, 50	0, 70			
Week 24						
m	28	22	60			
n	14	17	35	8	13	18
Mean (SD/SE)	10.7 (19.4)	17.6 (21.9)	16.6 (25.1)	0.0 (6.5)	10.8 (7.9)	2.8 (5.4)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 20.0	0.0, 30.0	-10.0, 10.0	0.0, 10.0	0.0, 20.0
Min, Max	0, 60	0, 70	0, 100	-30, 30	-20, 70	-70, 40
Week 52						
m	27	22	54			
n	21	16	35	8	11	12
Mean (SD/SE)	12.4 (23.0)	12.5 (20.5)	8.9 (15.1)	7.5 (7.7)	0.0 (5.7)	-7.5 (6.5)
Median	0	5.0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 10.0	0.0, 5.0	-10.0, 10.0	-15.0, 0.0
Min, Max	0, 80	0, 70	0, 50	-10, 60	-30, 40	-70, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.14a.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Absenteeism			
Week 24			
m	47	39	87
n	4	5	14
Baseline Mean (SD)	0.00 (0.00)	0.96 (2.15)	2.24 (6.76)
Analysis Visit Mean (SD)	0.00 (0.00)	7.02 (12.75)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	45	35	81
n	2	6	13
Baseline Mean (SD)	0.00 (0.00)	0.00 (0.00)	1.92 (6.93)
Analysis Visit Mean (SD)	0.00 (0.00)	11.12 (27.23)	1.92 (6.93)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.6475	0.0037	

AMNOG Table SE24.14a.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Presenteeism			
Week 24			
m	47	39	87
n	4	5	14
Baseline Mean (SD)	2.5 (5.0)	6.0 (5.5)	8.6 (19.6)
Analysis Visit Mean (SD)	2.5 (5.0)	4.0 (5.5)	10.0 (15.7)
LS Mean of Change from Baseline (SE)	-2.79 (3.64)	-1.75 (3.01)	0.90 (2.00)
95% CI	(-10.28, 4.70)	(-7.95, 4.44)	(-3.21, 5.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.69 (4.07)	-2.65 (3.71)	
95% CI	(-12.05, 4.67)	(-10.28, 4.98)	
p-value	0.3729	0.4813	
Corrected Hedge's g Statistics	-0.472	-0.347	
95% CI	(-1.59, 0.65)	(-1.37, 0.68)	
Week 52			
m	45	35	81
n	2	6	13
Baseline Mean (SD)	0.0 (0.0)	6.7 (8.2)	8.5 (19.5)
Analysis Visit Mean (SD)	20.0 (28.3)	13.3 (19.7)	10.0 (16.3)
LS Mean of Change from Baseline (SE)	17.61 (9.07)	6.44 (5.50)	2.09 (3.74)
95% CI	(-1.02, 36.25)	(-4.87, 17.74)	(-5.60, 9.78)
LS Mean of Change from Baseline Compared to Placebo (SE)	15.53 (9.79)	4.35 (6.66)	
95% CI	(-4.60, 35.65)	(-9.34, 18.04)	
p-value	0.1249	0.5193	
Corrected Hedge's g Statistics	1.087	0.308	
95% CI	(-0.45, 2.63)	(-0.66, 1.28)	
Subgroup*Treatment Interaction p-value	0.5119	0.9967	

AMNOG Table SE24.14a.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Overall Work Impairment			
Week 24			
m	47	39	87
n	4	5	14
Baseline Mean (SD)	2.50 (5.00)	6.86 (6.50)	10.49 (20.94)
Analysis Visit Mean (SD)	2.50 (5.00)	10.32 (16.03)	10.00 (15.69)
LS Mean of Change from Baseline (SE)	-3.41 (4.61)	2.53 (3.83)	-1.18 (2.53)
95% CI	(-12.88, 6.07)	(-5.34, 10.41)	(-6.39, 4.02)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.22 (5.16)	3.72 (4.72)	
95% CI	(-12.84, 8.39)	(-5.98, 13.41)	
p-value	0.6702	0.4381	
Corrected Hedge's g Statistics	-0.225	0.383	
95% CI	(-1.34, 0.89)	(-0.65, 1.41)	
Week 52			
m	45	35	81
n	2	6	13
Baseline Mean (SD)	0.00 (0.00)	6.67 (8.16)	10.19 (20.63)
Analysis Visit Mean (SD)	20.00 (28.28)	22.23 (31.69)	11.15 (18.95)
LS Mean of Change from Baseline (SE)	18.32 (11.61)	14.24 (6.99)	1.33 (4.76)
95% CI	(-5.55, 42.19)	(-0.13, 28.61)	(-8.45, 11.10)
LS Mean of Change from Baseline Compared to Placebo (SE)	16.99 (12.55)	12.91 (8.48)	
95% CI	(-8.81, 42.80)	(-4.52, 30.34)	
p-value	0.1875	0.1399	
Corrected Hedge's g Statistics	0.936	0.719	
95% CI	(-0.59, 2.46)	(-0.27, 1.71)	
Subgroup*Treatment Interaction p-value	0.3770	0.5314	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Activity Impairment			
Week 24			
m	47	39	87
n	15	14	30
Baseline Mean (SD)	14.7 (26.7)	8.6 (9.5)	17.0 (27.6)
Analysis Visit Mean (SD)	24.0 (28.7)	12.1 (15.3)	17.3 (22.0)
LS Mean of Change from Baseline (SE)	7.26 (3.87)	-0.83 (4.12)	0.58 (2.69)
95% CI	(-0.46, 14.98)	(-9.05, 7.39)	(-4.80, 5.96)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.69 (4.63)	-1.40 (4.80)	
95% CI	(-2.55, 15.93)	(-10.98, 8.18)	
p-value	0.1532	0.7707	
Corrected Hedge's g Statistics	0.443	-0.092	
95% CI	(-0.18, 1.07)	(-0.73, 0.54)	
Week 52			
m	45	35	81
n	7	11	28
Baseline Mean (SD)	18.6 (31.8)	8.2 (9.8)	17.5 (27.6)
Analysis Visit Mean (SD)	22.9 (22.9)	18.2 (18.3)	15.4 (20.5)
LS Mean of Change from Baseline (SE)	7.23 (5.15)	3.63 (4.48)	-2.35 (2.80)
95% CI	(-3.05, 17.51)	(-5.31, 12.58)	(-7.94, 3.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.57 (5.78)	5.98 (5.18)	
95% CI	(-1.97, 21.12)	(-4.36, 16.32)	
p-value	0.1024	0.2524	
Corrected Hedge's g Statistics	0.640	0.395	
95% CI	(-0.20, 1.48)	(-0.31, 1.10)	
Subgroup*Treatment Interaction p-value	0.5127	0.9669	

AMNOG Table SE24.14a.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Absenteeism			
Week 24			
m	76	68	125
n	15	10	13
Baseline Mean (SD)	6.06 (11.53)	0.00 (0.00)	0.70 (2.52)
Analysis Visit Mean (SD)	1.95 (5.20)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-1.88 (0.94)	-2.67 (0.98)	-2.71 (0.93)
95% CI	(-3.77, 0.00)	(-4.65, -0.70)	(-4.57, -0.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.82 (1.19)	0.03 (1.25)	
95% CI	(-1.58, 3.22)	(-2.49, 2.55)	
p-value	0.4939	0.9798	
Corrected Hedge's g Statistics	0.228	0.009	
95% CI	(-0.52, 0.97)	(-0.81, 0.83)	
Week 52			
m	70	57	120
n	7	11	12
Baseline Mean (SD)	11.64 (15.14)	0.00 (0.00)	0.76 (2.63)
Analysis Visit Mean (SD)	4.76 (12.59)	5.05 (16.76)	1.26 (4.36)
LS Mean of Change from Baseline (SE)	-1.58 (5.05)	3.64 (3.59)	-0.82 (3.41)
95% CI	(-11.77, 8.60)	(-3.60, 10.87)	(-7.70, 6.06)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.76 (6.33)	4.46 (4.84)	
95% CI	(-13.51, 11.98)	(-5.30, 14.21)	
p-value	0.9043	0.3622	
Corrected Hedge's g Statistics	-0.059	0.362	
95% CI	(-0.99, 0.87)	(-0.46, 1.19)	
Subgroup*Treatment Interaction p-value	0.6475	0.0037	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Presenteeism			
Week 24			
m	76	68	125
n	15	10	13
Baseline Mean (SD)	9.3 (22.8)	8.0 (16.2)	5.4 (19.4)
Analysis Visit Mean (SD)	19.3 (30.6)	9.0 (8.8)	8.5 (19.5)
LS Mean of Change from Baseline (SE)	7.90 (6.04)	-1.42 (5.54)	-1.88 (5.80)
95% CI	(-4.27, 20.08)	(-12.58, 9.75)	(-13.58, 9.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.79 (7.57)	0.47 (7.66)	
95% CI	(-5.48, 25.05)	(-14.97, 15.91)	
p-value	0.2030	0.9515	
Corrected Hedge's g Statistics	0.426	0.023	
95% CI	(-0.32, 1.18)	(-0.80, 0.85)	
Week 52			
m	70	57	120
n	7	11	12
Baseline Mean (SD)	20.0 (31.1)	6.4 (10.3)	5.8 (20.2)
Analysis Visit Mean (SD)	25.7 (35.5)	11.8 (14.0)	10.8 (23.9)
LS Mean of Change from Baseline (SE)	9.04 (6.90)	3.60 (6.19)	-0.06 (6.48)
95% CI	(-4.86, 22.95)	(-8.88, 16.07)	(-13.13, 13.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.10 (8.81)	3.66 (8.73)	
95% CI	(-8.65, 26.86)	(-13.94, 21.26)	
p-value	0.3070	0.6772	
Corrected Hedge's g Statistics	0.413	0.164	
95% CI	(-0.53, 1.35)	(-0.66, 0.98)	
Subgroup*Treatment Interaction p-value	0.5119	0.9967	

AMNOG Table SE24.14a.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Overall Work Impairment			
Week 24			
m	76	68	125
n	15	10	13
Baseline Mean (SD)	12.89 (26.71)	8.00 (16.19)	6.08 (19.37)
Analysis Visit Mean (SD)	20.09 (31.38)	9.00 (8.76)	8.46 (19.51)
LS Mean of Change from Baseline (SE)	6.19 (6.38)	-5.49 (6.04)	-3.88 (6.18)
95% CI	(-6.67, 19.04)	(-17.66, 6.69)	(-16.33, 8.57)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.07 (8.02)	-1.61 (8.21)	
95% CI	(-6.09, 26.22)	(-18.16, 14.94)	
p-value	0.2159	0.8455	
Corrected Hedge's g Statistics	0.414	-0.074	
95% CI	(-0.34, 1.16)	(-0.90, 0.75)	
Week 52			
m	70	57	120
n	7	11	12
Baseline Mean (SD)	26.27 (35.50)	6.36 (10.27)	6.59 (20.14)
Analysis Visit Mean (SD)	28.09 (37.89)	16.36 (20.14)	11.08 (24.71)
LS Mean of Change from Baseline (SE)	7.05 (8.26)	8.12 (7.08)	-1.73 (7.30)
95% CI	(-9.60, 23.71)	(-6.15, 22.38)	(-16.43, 12.98)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.78 (10.44)	9.84 (9.90)	
95% CI	(-12.25, 29.81)	(-10.11, 29.80)	
p-value	0.4047	0.3256	
Corrected Hedge's g Statistics	0.348	0.388	
95% CI	(-0.59, 1.29)	(-0.44, 1.21)	
Subgroup*Treatment Interaction p-value	0.3770	0.5314	

AMNOG Table SE24.14a.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Activity Impairment			
Week 24			
m	76	68	125
n	26	15	26
Baseline Mean (SD)	9.6 (20.9)	10.7 (18.3)	15.0 (25.0)
Analysis Visit Mean (SD)	16.9 (23.1)	8.7 (14.1)	14.6 (25.5)
LS Mean of Change from Baseline (SE)	4.73 (4.06)	-6.41 (5.03)	0.11 (3.98)
95% CI	(-3.34, 12.80)	(-16.42, 3.60)	(-7.81, 8.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.63 (5.45)	-6.52 (6.23)	
95% CI	(-6.22, 15.47)	(-18.91, 5.88)	
p-value	0.3987	0.2984	
Corrected Hedge's g Statistics	0.222	-0.320	
95% CI	(-0.32, 0.77)	(-0.96, 0.32)	
Week 52			
m	70	57	120
n	16	15	19
Baseline Mean (SD)	20.6 (24.6)	8.7 (13.6)	17.4 (27.9)
Analysis Visit Mean (SD)	16.9 (17.0)	18.7 (18.8)	12.1 (19.9)
LS Mean of Change from Baseline (SE)	2.49 (4.49)	6.61 (4.59)	-4.04 (4.04)
95% CI	(-6.45, 11.43)	(-2.52, 15.75)	(-12.09, 4.00)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.53 (5.73)	10.66 (5.95)	
95% CI	(-4.88, 17.95)	(-1.20, 22.51)	
p-value	0.2580	0.0773	
Corrected Hedge's g Statistics	0.359	0.588	
95% CI	(-0.31, 1.03)	(-0.10, 1.28)	
Subgroup*Treatment Interaction p-value	0.5127	0.9669	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Absenteeism			
Week 24			
m	28	22	60
n	1	4	14
Baseline Mean (SD)	0.00 (N/A)	0.00 (0.00)	9.52 (27.51)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	27	22	54
n	2	4	7
Baseline Mean (SD)	0.00 (0.00)	0.00 (0.00)	4.76 (12.59)
Analysis Visit Mean (SD)	25.00 (35.36)	0.00 (0.00)	13.93 (25.95)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.6475	0.0037	

AMNOG Table SE24.14a.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Presenteeism			
Week 24			
m	28	22	60
n	1	4	13
Baseline Mean (SD)	0.0 (N/A)	7.5 (5.0)	6.9 (10.3)
Analysis Visit Mean (SD)	0.0 (N/A)	35.0 (28.9)	10.0 (16.3)
LS Mean of Change from Baseline (SE)	-6.29 (19.56)	26.52 (9.55)	0.58 (5.59)
95% CI	(-47.57, 34.98)	(6.38, 46.66)	(-11.21, 12.36)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.87 (20.59)	25.95 (11.05)	
95% CI	(-50.31, 36.57)	(2.64, 49.26)	
p-value	0.7427	0.0312	
Corrected Hedge's g Statistics	-0.319	1.235	
95% CI	(-2.36, 1.72)	(0.04, 2.43)	
Week 52			
m	27	22	54
n	2	4	7
Baseline Mean (SD)	0.0 (0.0)	17.5 (22.2)	7.1 (12.5)
Analysis Visit Mean (SD)	5.0 (7.1)	2.5 (5.0)	10.0 (15.3)
LS Mean of Change from Baseline (SE)	4.30 (10.32)	-2.26 (7.70)	2.95 (5.10)
95% CI	(-17.47, 26.07)	(-18.51, 13.99)	(-7.82, 13.72)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.35 (11.37)	-5.21 (9.13)	
95% CI	(-22.64, 25.33)	(-24.48, 14.06)	
p-value	0.9070	0.5759	
Corrected Hedge's g Statistics	0.088	-0.336	
95% CI	(-1.48, 1.66)	(-1.57, 0.90)	
Subgroup*Treatment Interaction p-value	0.5119	0.9967	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Overall Work Impairment			
Week 24			
m	28	22	60
n	1	4	13
Baseline Mean (SD)	0.00 (N/A)	7.50 (5.00)	8.72 (15.42)
Analysis Visit Mean (SD)	0.00 (N/A)	35.00 (28.87)	10.00 (16.33)
LS Mean of Change from Baseline (SE)	12.08 (18.84)	27.61 (9.70)	-0.55 (6.07)
95% CI	(-27.67, 51.83)	(7.16, 48.07)	(-13.35, 12.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.63 (20.22)	28.16 (11.38)	
95% CI	(-30.04, 55.30)	(4.15, 52.18)	
p-value	0.5405	0.0242	
Corrected Hedge's g Statistics	0.541	1.249	
95% CI	(-1.50, 2.58)	(0.05, 2.45)	
Week 52			
m	27	22	54
n	2	4	7
Baseline Mean (SD)	0.00 (0.00)	17.50 (22.17)	10.47 (20.30)
Analysis Visit Mean (SD)	27.50 (38.89)	2.50 (5.00)	21.21 (30.47)
LS Mean of Change from Baseline (SE)	24.32 (20.72)	-11.01 (14.05)	8.71 (9.72)
95% CI	(-19.39, 68.03)	(-40.66, 18.64)	(-11.80, 29.22)
LS Mean of Change from Baseline Compared to Placebo (SE)	15.61 (23.03)	-19.73 (17.01)	
95% CI	(-32.98, 64.20)	(-55.62, 16.17)	
p-value	0.5070	0.2624	
Corrected Hedge's g Statistics	0.528	-0.679	
95% CI	(-1.06, 2.12)	(-1.94, 0.58)	
Subgroup*Treatment Interaction p-value	0.3770	0.5314	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Activity Impairment			
Week 24			
m	28	22	60
n	8	13	18
Baseline Mean (SD)	8.8 (11.3)	10.8 (12.6)	16.7 (21.4)
Analysis Visit Mean (SD)	8.8 (16.4)	21.5 (23.8)	19.4 (26.7)
LS Mean of Change from Baseline (SE)	2.56 (8.77)	7.47 (6.53)	4.62 (5.65)
95% CI	(-15.15, 20.27)	(-5.72, 20.67)	(-6.79, 16.03)
LS Mean of Change from Baseline Compared to Placebo (SE)	-2.06 (10.21)	2.85 (8.52)	
95% CI	(-22.68, 18.56)	(-14.35, 20.06)	
p-value	0.8411	0.7392	
Corrected Hedge's g Statistics	-0.082	0.117	
95% CI	(-0.92, 0.75)	(-0.60, 0.83)	
Week 52			
m	27	22	54
n	8	11	12
Baseline Mean (SD)	2.5 (4.6)	16.4 (16.9)	22.5 (25.6)
Analysis Visit Mean (SD)	10.0 (24.5)	16.4 (23.8)	15.0 (18.8)
LS Mean of Change from Baseline (SE)	8.05 (7.77)	-0.64 (6.10)	-2.60 (5.86)
95% CI	(-7.65, 23.75)	(-12.95, 11.67)	(-14.42, 9.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.65 (9.76)	1.96 (8.27)	
95% CI	(-9.06, 30.36)	(-14.74, 18.66)	
p-value	0.2817	0.8138	
Corrected Hedge's g Statistics	0.486	0.093	
95% CI	(-0.42, 1.39)	(-0.73, 0.91)	
Subgroup*Treatment Interaction p-value	0.5127	0.9669	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14a.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.14a.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	48 (100)	44 (100)	95 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0995	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	48 (100)	44 (100)	95 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2871	NE	

AMNOG Table SE24.14a.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (1.1)
No	48 (100)	44 (100)	94 (98.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.05	-1.05	
95% CI of the absolute risk difference	(-3.10, 1.00)	(-3.10, 1.00)	
p-value	0.4756	0.4946	
p-value of Breslow-Day Test for Homogeneity [3]	0.5604	0.4111	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (2.1)
No	48 (100)	44 (100)	93 (97.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.11	-2.11	
95% CI of the absolute risk difference	(-4.99, 0.78)	(-4.99, 0.78)	
p-value	0.3114	0.3323	
p-value of Breslow-Day Test for Homogeneity [3]	0.1704	0.0749	

AMNOG Table SE24.14a.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (1.1)
No	48 (100)	44 (100)	94 (98.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.05	-1.05	
95% CI of the absolute risk difference	(-3.10, 1.00)	(-3.10, 1.00)	
p-value	0.4756	0.4946	
p-value of Breslow-Day Test for Homogeneity [3]	0.3765	0.4111	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	2 (2.1)
No	48 (100)	44 (100)	93 (97.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.11	-2.11	
95% CI of the absolute risk difference	(-4.99, 0.78)	(-4.99, 0.78)	
p-value	0.3114	0.3323	
p-value of Breslow-Day Test for Homogeneity [3]	0.2800	0.0407	

AMNOG Table SE24.14a.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=48)	MGL-3196 100 mg (N=44)	Placebo (N=95)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (4.2)	0	4 (4.2)
No	46 (95.8)	44 (100)	91 (95.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	NE	
95% CI of the inverse odds ratio	(0.18, 5.73)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.01	NE	
95% CI of the inverse risk ratio	(0.19, 5.32)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.04	-4.21	
95% CI of the absolute risk difference	(-6.99, 6.90)	(-8.25, -0.17)	
p-value	0.9901	0.1672	
p-value of Breslow-Day Test for Homogeneity [3]	0.4599	0.0799	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (4.2)	0	6 (6.3)
No	46 (95.8)	44 (100)	89 (93.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.55	6.46	
95% CI of the inverse odds ratio	(0.30, 7.99)	(0.36, 117.33)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.52	6.09	
95% CI of the inverse risk ratio	(0.32, 7.23)	(0.35, 105.83)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-2.15	-5.66	
95% CI of the absolute risk difference	(-9.62, 5.33)	(-11.55, 0.23)	
p-value	0.5974	0.1492	
p-value of Breslow-Day Test for Homogeneity [3]	0.2723	0.0296	

AMNOG Table SE24.14a.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.6)	0	0
No	75 (97.4)	72 (100)	128 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.60	NE	
95% CI of the absolute risk difference	(-0.96, 6.15)	NE	
p-value	0.0669	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.0995	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (2.6)	0	1 (0.8)
No	75 (97.4)	72 (100)	127 (99.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	NE	
95% CI of the inverse odds ratio	(0.03, 3.31)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	NE	
95% CI of the inverse risk ratio	(0.03, 3.26)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.82	-0.78	
95% CI of the absolute risk difference	(-2.05, 5.68)	(-2.31, 0.74)	
p-value	0.2943	0.4521	
p-value of Breslow-Day Test for Homogeneity [3]	0.2871	NE	

AMNOG Table SE24.14a.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.3)	0	1 (0.8)
No	76 (98.7)	72 (100)	127 (99.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	NE	
95% CI of the inverse odds ratio	(0.04, 9.71)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.60	NE	
95% CI of the inverse risk ratio	(0.04, 9.48)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.52	-0.78	
95% CI of the absolute risk difference	(-2.44, 3.47)	(-2.31, 0.74)	
p-value	0.7151	0.4521	
p-value of Breslow-Day Test for Homogeneity [3]	0.5604	0.4111	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (3.9)	0	1 (0.8)
No	74 (96.1)	72 (100)	127 (99.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.19	NE	
95% CI of the inverse odds ratio	(0.02, 1.90)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.20	NE	
95% CI of the inverse risk ratio	(0.02, 1.89)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.11	-0.78	
95% CI of the absolute risk difference	(-1.47, 7.70)	(-2.31, 0.74)	
p-value	0.1184	0.4521	
p-value of Breslow-Day Test for Homogeneity [3]	0.1704	0.0749	

AMNOG Table SE24.14a.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.6)	0	1 (0.8)
No	75 (97.4)	72 (100)	127 (99.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	NE	
95% CI of the inverse odds ratio	(0.03, 3.31)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.30	NE	
95% CI of the inverse risk ratio	(0.03, 3.26)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.82	-0.78	
95% CI of the absolute risk difference	(-2.05, 5.68)	(-2.31, 0.74)	
p-value	0.2943	0.4521	
p-value of Breslow-Day Test for Homogeneity [3]	0.3765	0.4111	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (3.9)	0	2 (1.6)
No	74 (96.1)	72 (100)	126 (98.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.39	NE	
95% CI of the inverse odds ratio	(0.06, 2.40)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	NE	
95% CI of the inverse risk ratio	(0.07, 2.35)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.33	-1.56	
95% CI of the absolute risk difference	(-2.49, 7.16)	(-3.71, 0.59)	
p-value	0.2942	0.2864	
p-value of Breslow-Day Test for Homogeneity [3]	0.2800	0.0407	

AMNOG Table SE24.14a.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=77)	MGL-3196 100 mg (N=72)	Placebo (N=128)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (3.9)	0	4 (3.1)
No	74 (96.1)	72 (100)	124 (96.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	NE	
95% CI of the inverse odds ratio	(0.17, 3.65)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.80	NE	
95% CI of the inverse risk ratio	(0.18, 3.49)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.77	-3.13	
95% CI of the absolute risk difference	(-4.50, 6.04)	(-6.14, -0.11)	
p-value	0.7684	0.1297	
p-value of Breslow-Day Test for Homogeneity [3]	0.4599	0.0799	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (9.1)	1 (1.4)	5 (3.9)
No	70 (90.9)	71 (98.6)	123 (96.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.41	2.89	
95% CI of the inverse odds ratio	(0.12, 1.33)	(0.33, 25.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.43	2.81	
95% CI of the inverse risk ratio	(0.14, 1.31)	(0.34, 23.61)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.18	-2.52	
95% CI of the absolute risk difference	(-2.06, 12.43)	(-6.83, 1.79)	
p-value	0.1257	0.3165	
p-value of Breslow-Day Test for Homogeneity [3]	0.2723	0.0296	

AMNOG Table SE24.14a.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (1.6)
No	30 (100)	22 (100)	62 (98.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-1.59	
95% CI of the absolute risk difference	(-4.67, 1.50)	(-4.67, 1.50)	
p-value	0.4878	0.5522	
p-value of Breslow-Day Test for Homogeneity [3]	0.0995	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (1.6)
No	30 (100)	22 (100)	62 (98.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-1.59	
95% CI of the absolute risk difference	(-4.67, 1.50)	(-4.67, 1.50)	
p-value	0.4878	0.5522	
p-value of Breslow-Day Test for Homogeneity [3]	0.2871	NE	

AMNOG Table SE24.14a.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (4.5)	1 (1.6)
No	30 (100)	21 (95.5)	62 (98.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.34	
95% CI of the inverse odds ratio	NE	(0.02, 5.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.35	
95% CI of the inverse risk ratio	NE	(0.02, 5.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	2.96	
95% CI of the absolute risk difference	(-4.67, 1.50)	(-6.28, 12.19)	
p-value	0.4878	0.4307	
p-value of Breslow-Day Test for Homogeneity [3]	0.5604	0.4111	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	3 (13.6)	1 (1.6)
No	30 (100)	19 (86.4)	62 (98.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.10	
95% CI of the inverse odds ratio	NE	(0.01, 1.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.12	
95% CI of the inverse risk ratio	NE	(0.01, 1.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	12.05	
95% CI of the absolute risk difference	(-4.67, 1.50)	(-2.62, 26.72)	
p-value	0.4878	0.0216	
p-value of Breslow-Day Test for Homogeneity [3]	0.1704	0.0749	

AMNOG Table SE24.14a.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (4.5)	1 (1.6)
No	30 (100)	21 (95.5)	62 (98.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.34	
95% CI of the inverse odds ratio	NE	(0.02, 5.66)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.35	
95% CI of the inverse risk ratio	NE	(0.02, 5.35)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	2.96	
95% CI of the absolute risk difference	(-4.67, 1.50)	(-6.28, 12.19)	
p-value	0.4878	0.4307	
p-value of Breslow-Day Test for Homogeneity [3]	0.3765	0.4111	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	3 (13.6)	1 (1.6)
No	30 (100)	19 (86.4)	62 (98.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.10	
95% CI of the inverse odds ratio	NE	(0.01, 1.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.12	
95% CI of the inverse risk ratio	NE	(0.01, 1.06)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	12.05	
95% CI of the absolute risk difference	(-4.67, 1.50)	(-2.62, 26.72)	
p-value	0.4878	0.0216	
p-value of Breslow-Day Test for Homogeneity [3]	0.2800	0.0407	

AMNOG Table SE24.14a.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=22)	Placebo (N=63)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	2 (9.1)	3 (4.8)
No	30 (100)	20 (90.9)	60 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.50	
95% CI of the inverse odds ratio	NE	(0.08, 3.21)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	0.52	
95% CI of the inverse risk ratio	NE	(0.09, 2.93)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-4.76	4.33	
95% CI of the absolute risk difference	(-10.02, 0.50)	(-8.78, 17.44)	
p-value	0.2244	0.4575	
p-value of Breslow-Day Test for Homogeneity [3]	0.4599	0.0799	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (3.3)	4 (18.2)	4 (6.3)
No	29 (96.7)	18 (81.8)	59 (93.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.97	0.31	
95% CI of the inverse odds ratio	(0.21, 18.39)	(0.07, 1.34)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.90	0.35	
95% CI of the inverse risk ratio	(0.22, 16.32)	(0.10, 1.28)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-3.02	11.83	
95% CI of the absolute risk difference	(-11.82, 5.79)	(-5.37, 29.04)	
p-value	0.5467	0.1018	
p-value of Breslow-Day Test for Homogeneity [3]	0.2723	0.0296	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE24.14a.5
Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - No Mutation
Absenteeism



Patients with result at given visit			
MGL-3196 80 mg	7	12	12
MGL-3196 100 mg	15	8	9
Placebo	21	27	23

Abbreviations: Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE24.14a.5
Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Heterozygous
Absenteeism



Patients with result at given visit			
MGL-3196 80 mg	18	23	18
MGL-3196 100 mg	19	21	26
Placebo	23	31	45

Abbreviations: Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE24.14a.5
Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain;
by Genetic NASH SNP - PNPLA3
(Label Population)

Genetic NASH SNP: PNPLA3 rs738409 - Mutation - Homozygous
Absenteeism



Patients with result at given visit			
MGL-3196 80 mg	2	5	7
MGL-3196 100 mg	6	8	9
Placebo	19	22	21

Abbreviations: Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc.
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Table SE24.14b.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Absenteeism						
Baseline						
m	124	112	223			
n	19	33	52			
Mean (SD)	1.55 (4.96)	3.04 (12.63)	3.40 (14.86)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 20.0	0.0, 68.1	0.0, 100.0			
Week 24						
m	121	106	214			
n	29	28	65	14	14	33
Mean (SD/SE)	0.95 (3.56)	0.20 (1.08)	0.00 (0.00)	-1.21 (1.85)	0.06 (0.06)	-5.26 (3.22)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 15.0	0.0, 5.7	0.0, 0.0	-20.0, 12.5	0.0, 0.9	-100.0, 0.0
Week 52						
m	112	96	200			
n	27	35	70	7	16	25
Mean (SD/SE)	3.86 (13.32)	0.34 (1.99)	3.56 (13.95)	4.29 (8.12)	0.00 (0.00)	2.20 (3.28)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 11.8	0.0, 75.0	-20.0, 50.0	0.0, 0.0	-33.3, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Presenteeism						
Baseline						
m	124	112	223			
n	19	33	51			
Mean (SD)	6.8 (17.3)	11.2 (17.5)	7.1 (14.0)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0			
Min, Max	0, 70	0, 70	0, 70			
Week 24						
m	121	106	214			
n	29	28	65	14	14	32
Mean (SD/SE)	12.4 (22.9)	13.9 (20.8)	7.2 (14.2)	12.9 (9.3)	7.9 (6.1)	1.3 (3.0)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 10.0	0.0, 10.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 90	0, 80	0, 60	-40, 90	-30, 60	-60, 50
Week 52						
m	112	96	200			
n	27	35	70	7	16	25
Mean (SD/SE)	13.3 (22.2)	9.7 (19.0)	7.3 (14.6)	15.7 (14.6)	1.3 (4.1)	2.0 (2.8)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 10.0	0.0, 10.0	0.0, 40.0	0.0, 0.0	0.0, 10.0
Min, Max	0, 90	0, 90	0, 70	-30, 90	-40, 30	-40, 30

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Overall Work Impairment						
Baseline						
m	124	112	223			
n	19	33	51			
Mean (SD)	7.65 (18.49)	13.90 (20.80)	8.25 (15.71)			
Median	0	10.00	0			
IQR: Q1, Q3	0.00, 9.40	0.00, 20.00	0.00, 10.00			
Min, Max	0.0, 76.0	0.0, 70.0	0.0, 70.0			
Week 24						
m	121	106	214			
n	29	28	65	14	14	32
Mean (SD/SE)	12.87 (23.34)	14.11 (20.77)	7.23 (14.20)	11.85 (9.63)	7.91 (6.12)	-0.60 (3.30)
Median	0	10.00	0	0	0	0
IQR: Q1, Q3	0.00, 10.00	0.00, 20.00	0.00, 10.00	0.00, 10.00	0.00, 10.00	-6.75, 0.00
Min, Max	0.0, 91.3	0.0, 80.0	0.0, 60.0	-46.0, 91.3	-30.0, 60.0	-60.0, 50.0
Week 52						
m	112	96	200			
n	27	35	70	7	16	25
Mean (SD/SE)	16.24 (25.46)	9.75 (19.17)	9.75 (20.29)	21.29 (16.07)	1.25 (4.07)	3.54 (4.49)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 30.00	0.00, 10.00	0.00, 10.00	0.00, 55.00	0.00, 0.00	0.00, 10.00
Min, Max	0.0, 90.0	0.0, 91.2	0.0, 87.5	-36.0, 90.0	-40.0, 30.0	-53.3, 70.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=124)	Visit Result MGL-3196 100 mg (N=112)	Visit Result Placebo (N=223)	Change from Baseline MGL-3196 80 mg (N=124)	Change from Baseline MGL-3196 100 mg (N=112)	Change from Baseline Placebo (N=223)
Activity Impairment						
Baseline						
m	124	112	223			
n	48	57	91			
Mean (SD)	13.8 (23.8)	12.6 (18.1)	17.7 (26.4)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 25.0	0.0, 20.0	0.0, 20.0			
Min, Max	0, 80	0, 80	0, 100			
Week 24						
m	121	106	214			
n	66	52	114	36	35	58
Mean (SD/SE)	17.1 (23.5)	11.9 (18.7)	17.5 (24.3)	9.7 (4.1)	4.3 (3.3)	0.9 (2.8)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 30.0	0.0, 20.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 80	0, 70	0, 100	-40, 80	-20, 70	-80, 50
Week 52						
m	112	96	200			
n	71	61	124	23	30	46
Mean (SD/SE)	13.5 (20.7)	15.7 (21.2)	13.0 (18.7)	0.4 (4.6)	6.0 (2.8)	-5.4 (3.4)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 30.0	0.0, 20.0	-10.0, 10.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 90	0, 80	0, 80	-40, 50	-30, 40	-90, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=26)	Visit Result: MGL-3196 100 mg (N=24)	Visit Result: Placebo (N=62)	Change from Baseline: MGL-3196 80 mg (N=26)	Change from Baseline: MGL-3196 100 mg (N=24)	Change from Baseline: Placebo (N=62)
Absenteeism						
Baseline						
m	26	24	62			
n	6	6	11			
Mean (SD)	11.42 (15.43)	0.00 (0.00)	0.00 (0.00)			
Median	3.50	0	0			
IQR: Q1, Q3	0.00, 26.70	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 34.8	0.0, 0.0	0.0, 0.0			
Week 24						
m	25	21	58			
n	9	8	15	4	4	8
Mean (SD/SE)	1.86 (5.57)	5.55 (10.97)	0.00 (0.00)	-11.20 (6.70)	7.35 (7.35)	0.00 (0.00)
Median	0	0	0	-9.05	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 7.50	0.00, 0.00	-22.40, 0.00	0.00, 14.70	0.00, 0.00
Min, Max	0.0, 16.7	0.0, 29.4	0.0, 0.0	-26.7, 0.0	0.0, 29.4	0.0, 0.0
Week 52						
m	25	17	55			
n	10	8	19	4	4	7
Mean (SD/SE)	3.33 (10.53)	18.10 (27.84)	0.79 (3.46)	-7.05 (6.56)	30.58 (17.80)	2.16 (2.16)
Median	0	0	0	-0.75	27.80	0
IQR: Q1, Q3	0.00, 0.00	0.00, 39.05	0.00, 0.00	-14.10, 0.00	0.00, 61.15	0.00, 0.00
Min, Max	0.0, 33.3	0.0, 66.7	0.0, 15.1	-26.7, 0.0	0.0, 66.7	0.0, 15.1

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Presenteeism						
Baseline						
m	26	24	62			
n	6	6	11			
Mean (SD)	11.7 (24.0)	6.7 (12.1)	8.2 (21.4)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 0.0			
Min, Max	0, 60	0, 30	0, 70			
Week 24						
m	25	21	58			
n	9	8	15	4	4	8
Mean (SD/SE)	7.8 (15.6)	6.3 (7.4)	9.3 (21.2)	-7.5 (4.8)	2.5 (2.5)	7.5 (9.4)
Median	0	5.0	0	-5.0	0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0	-15.0, 0.0	0.0, 5.0	0.0, 5.0
Min, Max	0, 40	0, 20	0, 70	-20, 0	0, 10	-20, 70
Week 52						
m	25	17	55			
n	10	8	19	4	4	7
Mean (SD/SE)	9.0 (17.3)	11.3 (13.6)	9.5 (20.9)	-5.0 (2.9)	5.0 (2.9)	7.1 (12.5)
Median	0	5.0	0	-5.0	5.0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 25.0	0.0, 10.0	-10.0, 0.0	0.0, 10.0	-10.0, 0.0
Min, Max	0, 50	0, 30	0, 80	-10, 0	0, 10	-20, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Overall Work Impairment						
Baseline						
m	26	24	62			
n	6	6	11			
Mean (SD)	19.15 (29.89)	6.67 (12.11)	8.18 (21.36)			
Median	3.50	0	0			
IQR: Q1, Q3	0.00, 34.00	0.00, 10.00	0.00, 0.00			
Min, Max	0.0, 73.9	0.0, 30.0	0.0, 70.0			
Week 24						
m	25	21	58			
n	9	8	15	4	4	8
Mean (SD/SE)	8.89 (18.33)	11.06 (15.01)	9.33 (21.20)	-14.48 (8.61)	9.13 (6.25)	7.50 (9.40)
Median	0	5.00	0	-11.95	5.00	0
IQR: Q1, Q3	0.00, 0.00	0.00, 21.00	0.00, 10.00	-28.95, 0.00	0.00, 18.25	0.00, 5.00
Min, Max	0.0, 50.0	0.0, 36.5	0.0, 70.0	-34.0, 0.0	0.0, 26.5	-20.0, 70.0
Week 52						
m	25	17	55			
n	10	8	19	4	4	7
Mean (SD/SE)	10.66 (21.86)	26.15 (30.51)	9.63 (21.51)	-10.33 (8.08)	30.85 (17.82)	7.57 (12.90)
Median	0	15.00	0	-3.65	30.00	0
IQR: Q1, Q3	0.00, 10.00	0.00, 52.90	0.00, 10.00	-20.65, 0.00	0.00, 61.70	-10.00, 0.00
Min, Max	0.0, 66.6	0.0, 73.4	0.0, 83.0	-34.0, 0.0	0.0, 63.4	-20.0, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=26)	Visit Result: MGL-3196 100 mg (N=24)	Visit Result: Placebo (N=62)	Change from Baseline: MGL-3196 80 mg (N=26)	Change from Baseline: MGL-3196 100 mg (N=24)	Change from Baseline: Placebo (N=62)
Activity Impairment						
Baseline						
m	26	24	62			
n	10	10	26			
Mean (SD)	13.0 (22.1)	10.0 (11.5)	18.8 (25.7)			
Median	5.0	10.0	10.0			
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 40.0			
Min, Max	0, 70	0, 30	0, 70			
Week 24						
m	25	21	58			
n	15	13	31	8	6	16
Mean (SD/SE)	12.0 (19.0)	10.8 (6.4)	12.6 (19.7)	-1.3 (6.4)	1.7 (4.8)	0.0 (5.4)
Median	0	10.0	0	-5.0	5.0	0
IQR: Q1, Q3	0.0, 20.0	10.0, 10.0	0.0, 20.0	-10.0, 0.0	0.0, 10.0	-10.0, 0.0
Min, Max	0, 50	0, 20	0, 70	-20, 40	-20, 10	-40, 70
Week 52						
m	25	17	55			
n	18	13	34	7	6	13
Mean (SD/SE)	23.9 (26.8)	14.6 (16.6)	19.1 (25.5)	4.3 (10.0)	13.3 (8.0)	0.0 (7.0)
Median	10.0	10.0	10.0	0	10.0	0
IQR: Q1, Q3	0.0, 50.0	0.0, 30.0	0.0, 30.0	-10.0, 10.0	0.0, 30.0	-10.0, 0.0
Min, Max	0, 80	0, 40	0, 100	-20, 60	-10, 40	-40, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Absenteeism						
Baseline						
m	5	2	1			
n	2	1	0			
Mean (SD)	0.00 (0.00)	0.00 (N/A)	N/A			
Median	0	0	N/A			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	N/A			
Min, Max	0.0, 0.0	0.0, 0.0	N/A			
Week 24						
m	5	2	0			
n	2	1	0	2	1	0
Mean (SD/SE)	0.00 (0.00)	0.00 (N/A)	N/A	0.00 (0.00)	0.00 (N/A)	N/A
Median	0	0	N/A	0	0	N/A
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	N/A	0.00, 0.00	0.00, 0.00	N/A
Min, Max	0.0, 0.0	0.0, 0.0	N/A	0.0, 0.0	0.0, 0.0	N/A
Week 52						
m	5	1	0			
n	0	1	0	0	1	0
Mean (SD/SE)	N/A	0.00 (N/A)	N/A	N/A	0.00 (N/A)	N/A
Median	N/A	0	N/A	N/A	0	N/A
IQR: Q1, Q3	N/A	0.00, 0.00	N/A	N/A	0.00, 0.00	N/A
Min, Max	N/A	0.0, 0.0	N/A	N/A	0.0, 0.0	N/A

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Presenteeism						
Baseline						
m	5	2	1			
n	2	1	0			
Mean (SD)	0.0 (0.0)	10.0 (N/A)	N/A			
Median	0	10.0	N/A			
IQR: Q1, Q3	0.0, 0.0	10.0, 10.0	N/A			
Min, Max	0, 0	10, 10	N/A			
Week 24						
m	5	2	0			
n	2	1	0	2	1	0
Mean (SD/SE)	0.0 (0.0)	0.0 (N/A)	N/A	0.0 (0.0)	-10.0 (N/A)	N/A
Median	0	0	N/A	0	-10.0	N/A
IQR: Q1, Q3	0.0, 0.0	0.0, 0.0	N/A	0.0, 0.0	-10.0, -10.0	N/A
Min, Max	0, 0	0, 0	N/A	0, 0	-10, -10	N/A
Week 52						
m	5	1	0			
n	0	1	0	0	1	0
Mean (SD/SE)	N/A	10.0 (N/A)	N/A	N/A	0.0 (N/A)	N/A
Median	N/A	10.0	N/A	N/A	0	N/A
IQR: Q1, Q3	N/A	10.0, 10.0	N/A	N/A	0.0, 0.0	N/A
Min, Max	N/A	10, 10	N/A	N/A	0, 0	N/A

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Overall Work Impairment						
Baseline						
m	5	2	1			
n	2	1	0			
Mean (SD)	0.00 (0.00)	10.00 (N/A)	N/A			
Median	0	10.00	N/A			
IQR: Q1, Q3	0.00, 0.00	10.00, 10.00	N/A			
Min, Max	0.0, 0.0	10.0, 10.0	N/A			
Week 24						
m	5	2	0			
n	2	1	0	2	1	0
Mean (SD/SE)	0.00 (0.00)	0.00 (N/A)	N/A	0.00 (0.00)	-10.00 (N/A)	N/A
Median	0	0	N/A	0	-10.00	N/A
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	N/A	0.00, 0.00	-10.00, -10.00	N/A
Min, Max	0.0, 0.0	0.0, 0.0	N/A	0.0, 0.0	-10.0, -10.0	N/A
Week 52						
m	5	1	0			
n	0	1	0	0	1	0
Mean (SD/SE)	N/A	10.00 (N/A)	N/A	N/A	0.00 (N/A)	N/A
Median	N/A	10.00	N/A	N/A	0	N/A
IQR: Q1, Q3	N/A	10.00, 10.00	N/A	N/A	0.00, 0.00	N/A
Min, Max	N/A	10.0, 10.0	N/A	N/A	0.0, 0.0	N/A

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=5)	Visit Result MGL-3196 100 mg (N=2)	Visit Result Placebo (N=1)	Change from Baseline MGL-3196 80 mg (N=5)	Change from Baseline MGL-3196 100 mg (N=2)	Change from Baseline Placebo (N=1)
Activity Impairment						
Baseline						
m	5	2	1			
n	5	2	1			
Mean (SD)	14.0 (19.5)	5.0 (7.1)	0.0 (N/A)			
Median	0	5.0	0			
IQR: Q1, Q3	0.0, 30.0	0.0, 10.0	0.0, 0.0			
Min, Max	0, 40	0, 10	0, 0			
Week 24						
m	5	2	0			
n	5	1	0	5	1	0
Mean (SD/SE)	12.0 (16.4)	10.0 (N/A)	N/A	-2.0 (2.0)	0.0 (N/A)	N/A
Median	0	10.0	N/A	0	0	N/A
IQR: Q1, Q3	0.0, 30.0	10.0, 10.0	N/A	0.0, 0.0	0.0, 0.0	N/A
Min, Max	0, 30	10, 10	N/A	-10, 0	0, 0	N/A
Week 52						
m	5	1	0			
n	1	1	0	1	1	0
Mean (SD/SE)	30.0 (N/A)	10.0 (N/A)	N/A	-10.0 (N/A)	0.0 (N/A)	N/A
Median	30.0	10.0	N/A	-10.0	0	N/A
IQR: Q1, Q3	30.0, 30.0	10.0, 10.0	N/A	-10.0, -10.0	0.0, 0.0	N/A
Min, Max	30, 30	10, 10	N/A	-10, -10	0, 0	N/A

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.14b.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Absenteeism			
Week 24			
m	121	106	214
n	14	14	33
Baseline Mean (SD)	2.10 (5.73)	0.34 (1.28)	5.26 (18.49)
Analysis Visit Mean (SD)	0.89 (3.34)	0.41 (1.52)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-1.50 (0.48)	-2.43 (0.44)	-2.75 (0.31)
95% CI	(-2.46, -0.54)	(-3.31, -1.55)	(-3.37, -2.14)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.25 (0.55)	0.33 (0.53)	
95% CI	(0.15, 2.36)	(-0.74, 1.39)	
p-value	0.0266	0.5422	
Corrected Hedge's g Statistics	0.692	0.185	
95% CI	(0.05, 1.33)	(-0.44, 0.81)	
Week 52			
m	112	96	200
n	7	16	25
Baseline Mean (SD)	2.86 (7.56)	0.00 (0.00)	2.70 (8.25)
Analysis Visit Mean (SD)	7.14 (18.90)	0.00 (0.00)	4.90 (15.03)
LS Mean of Change from Baseline (SE)	7.07 (5.08)	-1.14 (3.62)	2.02 (2.78)
95% CI	(-3.05, 17.19)	(-8.34, 6.07)	(-3.52, 7.55)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.05 (5.79)	-3.15 (4.57)	
95% CI	(-6.48, 16.59)	(-12.26, 5.95)	
p-value	0.3854	0.4922	
Corrected Hedge's g Statistics	0.357	-0.219	
95% CI	(-0.49, 1.20)	(-0.85, 0.41)	
Subgroup*Treatment Interaction p-value	0.1504	0.0080	

AMNOG Table SE24.14b.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Presenteeism			
Week 24			
m	121	106	214
n	14	14	32
Baseline Mean (SD)	5.7 (18.7)	8.6 (13.5)	6.6 (14.5)
Analysis Visit Mean (SD)	18.6 (30.8)	16.4 (19.8)	7.8 (12.9)
LS Mean of Change from Baseline (SE)	10.66 (5.51)	9.66 (5.15)	0.84 (3.53)
95% CI	(-0.32, 21.64)	(-0.61, 19.93)	(-6.20, 7.87)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.82 (6.43)	8.83 (6.22)	
95% CI	(-2.99, 22.63)	(-3.58, 21.24)	
p-value	0.1308	0.1603	
Corrected Hedge's g Statistics	0.479	0.439	
95% CI	(-0.16, 1.11)	(-0.20, 1.07)	
Week 52			
m	112	96	200
n	7	16	25
Baseline Mean (SD)	10.0 (26.5)	8.1 (13.3)	5.6 (15.3)
Analysis Visit Mean (SD)	25.7 (33.6)	9.4 (15.7)	7.6 (12.7)
LS Mean of Change from Baseline (SE)	17.89 (6.15)	0.56 (4.19)	1.20 (3.31)
95% CI	(5.63, 30.14)	(-7.80, 8.92)	(-5.40, 7.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	16.69 (6.91)	-0.64 (5.30)	
95% CI	(2.92, 30.46)	(-11.22, 9.94)	
p-value	0.0182	0.9046	
Corrected Hedge's g Statistics	0.986	-0.038	
95% CI	(0.11, 1.86)	(-0.67, 0.59)	
Subgroup*Treatment Interaction p-value	0.0940	0.3673	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Overall Work Impairment			
Week 24			
m	121	106	214
n	14	14	32
Baseline Mean (SD)	6.81 (20.22)	8.88 (13.59)	8.42 (16.94)
Analysis Visit Mean (SD)	18.66 (31.08)	16.79 (19.77)	7.81 (12.89)
LS Mean of Change from Baseline (SE)	12.00 (5.51)	9.15 (5.00)	-0.49 (3.50)
95% CI	(1.01, 22.99)	(-0.82, 19.12)	(-7.46, 6.49)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.49 (6.38)	9.64 (6.07)	
95% CI	(-0.23, 25.20)	(-2.47, 21.74)	
p-value	0.0541	0.1168	
Corrected Hedge's g Statistics	0.613	0.486	
95% CI	(-0.03, 1.25)	(-0.15, 1.12)	
Week 52			
m	112	96	200
n	7	16	25
Baseline Mean (SD)	10.86 (28.73)	8.13 (13.28)	7.80 (18.10)
Analysis Visit Mean (SD)	32.14 (34.38)	9.38 (15.69)	11.34 (20.55)
LS Mean of Change from Baseline (SE)	23.17 (7.38)	-1.12 (5.13)	3.68 (4.04)
95% CI	(8.46, 37.89)	(-11.35, 9.10)	(-4.37, 11.73)
LS Mean of Change from Baseline Compared to Placebo (SE)	19.49 (8.32)	-4.80 (6.49)	
95% CI	(2.90, 36.08)	(-17.74, 8.14)	
p-value	0.0220	0.4617	
Corrected Hedge's g Statistics	0.948	-0.232	
95% CI	(0.08, 1.82)	(-0.86, 0.40)	
Subgroup*Treatment Interaction p-value	0.1059	0.9375	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Activity Impairment			
Week 24			
m	121	106	214
n	36	35	58
Baseline Mean (SD)	9.7 (21.4)	10.0 (14.6)	16.2 (25.0)
Analysis Visit Mean (SD)	19.4 (26.0)	14.3 (19.9)	17.1 (24.5)
LS Mean of Change from Baseline (SE)	8.11 (3.43)	2.60 (3.40)	2.24 (2.68)
95% CI	(1.32, 14.89)	(-4.11, 9.32)	(-3.05, 7.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.87 (4.25)	0.37 (4.27)	
95% CI	(-2.54, 14.27)	(-8.08, 8.81)	
p-value	0.1697	0.9320	
Corrected Hedge's g Statistics	0.284	0.018	
95% CI	(-0.13, 0.70)	(-0.40, 0.44)	
Week 52			
m	112	96	200
n	23	30	46
Baseline Mean (SD)	13.5 (24.0)	11.0 (14.7)	17.6 (27.3)
Analysis Visit Mean (SD)	13.9 (18.3)	17.0 (20.4)	12.2 (17.2)
LS Mean of Change from Baseline (SE)	2.31 (3.36)	4.04 (2.91)	-2.97 (2.37)
95% CI	(-4.32, 8.95)	(-1.71, 9.79)	(-7.65, 1.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.29 (3.99)	7.02 (3.72)	
95% CI	(-2.60, 13.18)	(-0.34, 14.37)	
p-value	0.1876	0.0613	
Corrected Hedge's g Statistics	0.325	0.434	
95% CI	(-0.18, 0.83)	(-0.03, 0.90)	
Subgroup*Treatment Interaction p-value	0.4911	0.8866	

AMNOG Table SE24.14b.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Absenteeism			
Week 24			
m	25	21	58
n	4	4	8
Baseline Mean (SD)	15.38 (18.06)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	4.18 (8.35)	7.35 (14.70)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-0.98 (5.24)	3.66 (4.21)	-0.91 (3.20)
95% CI	(-12.02, 10.07)	(-5.22, 12.54)	(-7.65, 5.84)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.07 (5.77)	4.57 (4.44)	
95% CI	(-12.25, 12.11)	(-4.81, 13.94)	
p-value	0.9901	0.3186	
Corrected Hedge's g Statistics	-0.007	0.476	
95% CI	(-1.21, 1.19)	(-0.74, 1.69)	
Week 52			
m	25	17	55
n	4	4	7
Baseline Mean (SD)	15.38 (18.06)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	8.33 (16.65)	30.58 (35.59)	2.16 (5.71)
LS Mean of Change from Baseline (SE)	-0.64 (10.60)	31.44 (8.93)	3.72 (6.90)
95% CI	(-22.99, 21.72)	(12.60, 50.28)	(-10.85, 18.29)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.36 (13.21)	27.72 (10.39)	
95% CI	(-32.22, 23.50)	(5.80, 49.64)	
p-value	0.7454	0.0162	
Corrected Hedge's g Statistics	-0.207	1.398	
95% CI	(-1.44, 1.02)	(0.04, 2.76)	
Subgroup*Treatment Interaction p-value	0.1504	0.0080	

AMNOG Table SE24.14b.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Presenteeism			
Week 24			
m	25	21	58
n	4	4	8
Baseline Mean (SD)	17.5 (28.7)	2.5 (5.0)	8.8 (24.7)
Analysis Visit Mean (SD)	10.0 (20.0)	5.0 (5.8)	16.3 (27.7)
LS Mean of Change from Baseline (SE)	-27.77 (10.26)	-22.72 (9.00)	-11.56 (7.04)
95% CI	(-49.43, -6.12)	(-41.70, -3.74)	(-26.42, 3.30)
LS Mean of Change from Baseline Compared to Placebo (SE)	-16.21 (11.45)	-11.16 (10.61)	
95% CI	(-40.37, 7.95)	(-33.56, 11.23)	
p-value	0.1749	0.3077	
Corrected Hedge's g Statistics	-0.744	-0.532	
95% CI	(-1.98, 0.49)	(-1.75, 0.69)	
Week 52			
m	25	17	55
n	4	4	7
Baseline Mean (SD)	17.5 (28.7)	10.0 (14.1)	12.9 (26.3)
Analysis Visit Mean (SD)	12.5 (25.0)	15.0 (12.9)	20.0 (32.1)
LS Mean of Change from Baseline (SE)	-23.42 (12.82)	-20.12 (11.49)	-14.62 (8.95)
95% CI	(-50.47, 3.62)	(-44.36, 4.13)	(-33.50, 4.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-8.81 (14.94)	-5.50 (13.95)	
95% CI	(-40.33, 22.72)	(-34.93, 23.94)	
p-value	0.5634	0.6984	
Corrected Hedge's g Statistics	-0.331	-0.214	
95% CI	(-1.57, 0.91)	(-1.45, 1.02)	
Subgroup*Treatment Interaction p-value	0.0940	0.3673	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Overall Work Impairment			
Week 24			
m	25	21	58
n	4	4	8
Baseline Mean (SD)	26.98 (35.15)	2.50 (5.00)	8.75 (24.75)
Analysis Visit Mean (SD)	12.50 (25.00)	11.63 (17.24)	16.25 (27.74)
LS Mean of Change from Baseline (SE)	-8.91 (13.20)	-7.23 (10.98)	3.63 (8.55)
95% CI	(-36.76, 18.94)	(-30.39, 15.93)	(-14.42, 21.68)
LS Mean of Change from Baseline Compared to Placebo (SE)	-12.54 (12.96)	-10.86 (11.44)	
95% CI	(-39.87, 14.80)	(-34.99, 13.28)	
p-value	0.3467	0.3560	
Corrected Hedge's g Statistics	-0.465	-0.426	
95% CI	(-1.68, 0.75)	(-1.64, 0.79)	
Week 52			
m	25	17	55
n	4	4	7
Baseline Mean (SD)	26.98 (35.15)	10.00 (14.14)	12.86 (26.28)
Analysis Visit Mean (SD)	16.65 (33.30)	40.85 (32.72)	20.43 (33.09)
LS Mean of Change from Baseline (SE)	-4.88 (14.81)	30.40 (13.07)	2.33 (10.11)
95% CI	(-36.13, 26.37)	(2.82, 57.99)	(-19.00, 23.66)
LS Mean of Change from Baseline Compared to Placebo (SE)	-7.21 (15.69)	28.07 (14.26)	
95% CI	(-40.32, 25.90)	(-2.00, 58.15)	
p-value	0.6519	0.0654	
Corrected Hedge's g Statistics	-0.238	0.967	
95% CI	(-1.47, 0.99)	(-0.33, 2.26)	
Subgroup*Treatment Interaction p-value	0.1059	0.9375	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Activity Impairment			
Week 24			
m	25	21	58
n	8	6	16
Baseline Mean (SD)	15.0 (24.5)	10.0 (11.0)	16.3 (25.8)
Analysis Visit Mean (SD)	13.8 (20.7)	11.7 (7.5)	16.3 (23.6)
LS Mean of Change from Baseline (SE)	-4.13 (6.44)	-3.22 (7.31)	-0.09 (4.38)
95% CI	(-17.22, 8.96)	(-18.07, 11.63)	(-8.98, 8.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.04 (7.43)	-3.13 (8.04)	
95% CI	(-19.15, 11.07)	(-19.48, 13.21)	
p-value	0.5902	0.6993	
Corrected Hedge's g Statistics	-0.220	-0.171	
95% CI	(-1.07, 0.63)	(-1.11, 0.77)	
Week 52			
m	25	17	55
n	7	6	13
Baseline Mean (SD)	18.6 (24.8)	10.0 (11.0)	21.5 (26.4)
Analysis Visit Mean (SD)	22.9 (26.9)	23.3 (18.6)	21.5 (26.1)
LS Mean of Change from Baseline (SE)	3.00 (8.58)	7.06 (9.34)	-0.63 (6.37)
95% CI	(-14.44, 20.43)	(-11.92, 26.04)	(-13.57, 12.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.63 (10.11)	7.69 (10.78)	
95% CI	(-16.91, 24.17)	(-14.23, 29.61)	
p-value	0.7219	0.4808	
Corrected Hedge's g Statistics	0.152	0.320	
95% CI	(-0.77, 1.07)	(-0.65, 1.29)	
Subgroup*Treatment Interaction p-value	0.4911	0.8866	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Absenteeism			
Week 24			
m	5	2	0
n	2	1	0
Baseline Mean (SD)	0.00 (0.00)	0.00 (N/A)	N/A
Analysis Visit Mean (SD)	0.00 (0.00)	0.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	0	1	0
Baseline Mean (SD)	N/A	0.00 (N/A)	N/A
Analysis Visit Mean (SD)	N/A	0.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.1504	0.0080	

AMNOG Table SE24.14b.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Presenteeism			
Week 24			
m	5	2	0
n	2	1	0
Baseline Mean (SD)	0.0 (0.0)	10.0 (N/A)	N/A
Analysis Visit Mean (SD)	0.0 (0.0)	0.0 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	0	1	0
Baseline Mean (SD)	N/A	10.0 (N/A)	N/A
Analysis Visit Mean (SD)	N/A	10.0 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.0940	0.3673	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Overall Work Impairment			
Week 24			
m	5	2	0
n	2	1	0
Baseline Mean (SD)	0.00 (0.00)	10.00 (N/A)	N/A
Analysis Visit Mean (SD)	0.00 (0.00)	0.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	0	1	0
Baseline Mean (SD)	N/A	10.00 (N/A)	N/A
Analysis Visit Mean (SD)	N/A	10.00 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.1059	0.9375	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Activity Impairment			
Week 24			
m	5	2	0
n	5	1	0
Baseline Mean (SD)	14.0 (19.5)	10.0 (N/A)	N/A
Analysis Visit Mean (SD)	12.0 (16.4)	10.0 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	5	1	0
n	1	1	0
Baseline Mean (SD)	40.0 (N/A)	10.0 (N/A)	N/A
Analysis Visit Mean (SD)	30.0 (N/A)	10.0 (N/A)	N/A
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.4911	0.8866	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.14b.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (0.8)	0	1 (0.4)
No	123 (99.2)	112 (100)	222 (99.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.55	NE	
95% CI of the inverse odds ratio	(0.03, 8.94)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	NE	
95% CI of the inverse risk ratio	(0.04, 8.81)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.36	-0.45	
95% CI of the absolute risk difference	(-1.44, 2.16)	(-1.33, 0.43)	
p-value	0.6729	0.4779	
p-value of Breslow-Day Test for Homogeneity [3]	0.3336	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (0.8)	0	2 (0.9)
No	123 (99.2)	112 (100)	221 (99.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	NE	
95% CI of the inverse odds ratio	(0.10, 12.40)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	NE	
95% CI of the inverse risk ratio	(0.10, 12.14)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.09	-0.90	
95% CI of the absolute risk difference	(-2.09, 1.91)	(-2.13, 0.34)	
p-value	0.9305	0.3148	
p-value of Breslow-Day Test for Homogeneity [3]	0.1961	NE	

AMNOG Table SE24.14b.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (0.8)	1 (0.9)	2 (0.9)
No	123 (99.2)	111 (99.1)	221 (99.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.00	
95% CI of the inverse odds ratio	(0.10, 12.40)	(0.09, 11.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.00	
95% CI of the inverse risk ratio	(0.10, 12.14)	(0.09, 10.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.09	0.00	
95% CI of the absolute risk difference	(-2.09, 1.91)	(-2.14, 2.13)	
p-value	0.9305	0.9971	
p-value of Breslow-Day Test for Homogeneity [3]	0.5538	0.5500	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (0.8)	3 (2.7)	2 (0.9)
No	123 (99.2)	109 (97.3)	221 (99.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.33	
95% CI of the inverse odds ratio	(0.10, 12.40)	(0.05, 2.00)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	0.33	
95% CI of the inverse risk ratio	(0.10, 12.14)	(0.06, 1.98)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.09	1.78	
95% CI of the absolute risk difference	(-2.09, 1.91)	(-1.45, 5.02)	
p-value	0.9305	0.2045	
p-value of Breslow-Day Test for Homogeneity [3]	0.5183	0.1854	

AMNOG Table SE24.14b.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (0.8)	1 (0.9)	2 (0.9)
No	123 (99.2)	111 (99.1)	221 (99.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.00	
95% CI of the inverse odds ratio	(0.10, 12.40)	(0.09, 11.20)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	1.00	
95% CI of the inverse risk ratio	(0.10, 12.14)	(0.09, 10.96)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.09	0.00	
95% CI of the absolute risk difference	(-2.09, 1.91)	(-2.14, 2.13)	
p-value	0.9305	0.9971	
p-value of Breslow-Day Test for Homogeneity [3]	0.5924	0.5500	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (0.8)	3 (2.7)	3 (1.3)
No	123 (99.2)	109 (97.3)	220 (98.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.68	0.50	
95% CI of the inverse odds ratio	(0.17, 16.30)	(0.10, 2.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.67	0.50	
95% CI of the inverse risk ratio	(0.18, 15.87)	(0.10, 2.45)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.54	1.33	
95% CI of the absolute risk difference	(-2.72, 1.64)	(-2.02, 4.68)	
p-value	0.6523	0.3854	
p-value of Breslow-Day Test for Homogeneity [3]	0.3437	0.2507	

AMNOG Table SE24.14b.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=124)	MGL-3196 100 mg (N=112)	Placebo (N=223)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	4 (3.2)	2 (1.8)	8 (3.6)
No	120 (96.8)	110 (98.2)	215 (96.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.12	2.05	
95% CI of the inverse odds ratio	(0.33, 3.78)	(0.43, 9.80)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.11	2.01	
95% CI of the inverse risk ratio	(0.34, 3.62)	(0.43, 9.30)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.36	-1.80	
95% CI of the absolute risk difference	(-4.32, 3.59)	(-5.26, 1.66)	
p-value	0.8598	0.3606	
p-value of Breslow-Day Test for Homogeneity [3]	0.9223	0.4497	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	6 (4.8)	4 (3.6)	11 (4.9)
No	118 (95.2)	108 (96.4)	212 (95.1)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.40	
95% CI of the inverse odds ratio	(0.37, 2.83)	(0.44, 4.50)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.38	
95% CI of the inverse risk ratio	(0.39, 2.69)	(0.45, 4.24)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.09	-1.36	
95% CI of the absolute risk difference	(-4.82, 4.63)	(-5.82, 3.10)	
p-value	0.9690	0.5698	
p-value of Breslow-Day Test for Homogeneity [3]	0.7123	0.9233	

AMNOG Table SE24.14b.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.8)	0	0
No	25 (96.2)	24 (100)	62 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.85	NE	
95% CI of the absolute risk difference	(-3.55, 11.24)	NE	
p-value	0.1204	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3336	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (3.8)	0	0
No	25 (96.2)	24 (100)	62 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.85	NE	
95% CI of the absolute risk difference	(-3.55, 11.24)	NE	
p-value	0.1204	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1961	NE	

AMNOG Table SE24.14b.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (1.6)
No	26 (100)	24 (100)	61 (98.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.61	-1.61	
95% CI of the absolute risk difference	(-4.75, 1.52)	(-4.75, 1.52)	
p-value	0.5149	0.5314	
p-value of Breslow-Day Test for Homogeneity [3]	0.5538	0.5500	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (7.7)	0	2 (3.2)
No	24 (92.3)	24 (100)	60 (96.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	NE	
95% CI of the inverse odds ratio	(0.05, 3.00)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.42	NE	
95% CI of the inverse risk ratio	(0.06, 2.82)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.47	-3.23	
95% CI of the absolute risk difference	(-6.68, 15.61)	(-7.62, 1.17)	
p-value	0.3588	0.3733	
p-value of Breslow-Day Test for Homogeneity [3]	0.5183	0.1854	

AMNOG Table SE24.14b.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.8)	0	1 (1.6)
No	25 (96.2)	24 (100)	61 (98.4)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.41	NE	
95% CI of the inverse odds ratio	(0.02, 6.81)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.42	NE	
95% CI of the inverse risk ratio	(0.03, 6.45)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.23	-1.61	
95% CI of the absolute risk difference	(-5.80, 10.26)	(-4.75, 1.52)	
p-value	0.5213	0.5314	
p-value of Breslow-Day Test for Homogeneity [3]	0.5924	0.5500	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (7.7)	0	2 (3.2)
No	24 (92.3)	24 (100)	60 (96.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.40	NE	
95% CI of the inverse odds ratio	(0.05, 3.00)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.42	NE	
95% CI of the inverse risk ratio	(0.06, 2.82)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	4.47	-3.23	
95% CI of the absolute risk difference	(-6.68, 15.61)	(-7.62, 1.17)	
p-value	0.3588	0.3733	
p-value of Breslow-Day Test for Homogeneity [3]	0.3437	0.2507	

Program: t-se21-02-04-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14b.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=26)	MGL-3196 100 mg (N=24)	Placebo (N=62)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (3.8)	0	3 (4.8)
No	25 (96.2)	24 (100)	59 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.27	NE	
95% CI of the inverse odds ratio	(0.13, 12.82)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.26	NE	
95% CI of the inverse risk ratio	(0.14, 11.54)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.99	-4.84	
95% CI of the absolute risk difference	(-10.11, 8.13)	(-10.18, 0.50)	
p-value	0.8384	0.2727	
p-value of Breslow-Day Test for Homogeneity [3]	0.9223	0.4497	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (11.5)	1 (4.2)	4 (6.5)
No	23 (88.5)	23 (95.8)	58 (93.5)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.53	1.59	
95% CI of the inverse odds ratio	(0.11, 2.55)	(0.17, 14.96)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.56	1.55	
95% CI of the inverse risk ratio	(0.13, 2.33)	(0.18, 13.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	5.09	-2.28	
95% CI of the absolute risk difference	(-8.63, 18.81)	(-12.35, 7.78)	
p-value	0.4210	0.6846	
p-value of Breslow-Day Test for Homogeneity [3]	0.7123	0.9233	

AMNOG Table SE24.14b.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3336	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.1961	NE	

AMNOG Table SE24.14b.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5538	0.5500	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5183	0.1854	

AMNOG Table SE24.14b.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.5924	0.5500	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3437	0.2507	

AMNOG Table SE24.14b.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=5)	MGL-3196 100 mg (N=2)	Placebo (N=1)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	0
No	5 (100)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	NE	NE	
95% CI of the absolute risk difference	NE	NE	
p-value	NE	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.9223	0.4497	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (20.0)	0	0
No	4 (80.0)	2 (100)	1 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse odds ratio	(0.02, 40.28)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.00	NE	
95% CI of the inverse risk ratio	(0.06, 15.99)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.00	NE	
95% CI of the absolute risk difference	(-69.30, 69.30)	NE	
p-value	>0.9999	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.7123	0.9233	

Madrigal Pharmaceuticals, Inc. Page 1 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE24.14b.5
Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - No Mutation
Absenteeism



Patients with result at given visit			
MGL-3196 80 mg	19	29	27
MGL-3196 100 mg	33	28	35
Placebo	52	65	70

Abbreviations: Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 2 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE24.14b.5
Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Heterozygous
Absenteeism



Patients with result at given visit			
MGL-3196 80 mg	6	9	10
MGL-3196 100 mg	6	8	8
Placebo	11	15	19

Abbreviations: Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

Madrigal Pharmaceuticals, Inc. Page 3 of 3
Protocol: MGL-3196-11 Data Cut-off Date: 13JAN2023

AMNOG Figure SE24.14b.5
Work Productivity and Activity Impairment-NASH (SE24): Mean Profile of Results by Domain;
by Genetic NASH SNP - TM6SF2
(Label Population)

Genetic NASH SNP: TM6SF2 rs58542926 - Mutation - Homozygous
Absenteeism



Patients with result at given visit			
MGL-3196 80 mg	2	2	0
MGL-3196 100 mg	1	1	1
Placebo	0	0	0

Abbreviations: Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; SD = standard deviation.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Note: Only parameters with significant subgroup-by-treatment interactions from the MMRM are included in the output.
Program: f-se21-02-05-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=53)	Visit Result: MGL-3196 100 mg (N=45)	Visit Result: Placebo (N=90)	Change from Baseline: MGL-3196 80 mg (N=53)	Change from Baseline: MGL-3196 100 mg (N=45)	Change from Baseline: Placebo (N=90)
Absenteeism						
Baseline						
m	53	45	90			
n	8	15	26			
Mean (SD)	2.50 (7.07)	0.00 (0.00)	0.35 (1.78)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 20.0	0.0, 0.0	0.0, 9.1			
Week 24						
m	49	43	83			
n	12	12	28	4	5	15
Mean (SD/SE)	0.00 (0.00)	3.70 (9.17)	0.00 (0.00)	-5.00 (5.00)	5.88 (5.88)	-0.61 (0.61)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-10.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 0.0	0.0, 29.4	0.0, 0.0	-20.0, 0.0	0.0, 29.4	-9.1, 0.0
Week 52						
m	47	38	75			
n	11	21	29	4	10	12
Mean (SD/SE)	4.55 (15.08)	4.25 (15.13)	3.88 (13.61)	7.50 (14.93)	6.67 (6.67)	8.63 (6.04)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-10.00, 25.00	0.00, 0.00	0.00, 7.55
Min, Max	0.0, 50.0	0.0, 66.7	0.0, 66.7	-20.0, 50.0	0.0, 66.7	-9.1, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Presenteeism						
Baseline						
m	53	45	90			
n	8	15	26			
Mean (SD)	15.0 (25.1)	14.0 (21.0)	6.5 (14.7)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 25.0	0.0, 20.0	0.0, 10.0			
Min, Max	0, 70	0, 70	0, 70			
Week 24						
m	49	43	83			
n	12	12	28	4	5	15
Mean (SD/SE)	12.5 (24.2)	15.0 (16.8)	5.7 (16.2)	10.0 (25.2)	14.0 (11.7)	2.7 (7.3)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	5.0, 20.0	0.0, 0.0	-20.0, 40.0	0.0, 10.0	0.0, 0.0
Min, Max	0, 80	0, 60	0, 70	-40, 80	0, 60	-60, 70
Week 52						
m	47	38	75			
n	11	21	29	4	10	12
Mean (SD/SE)	15.5 (28.4)	9.5 (12.4)	10.3 (18.4)	17.5 (25.6)	-4.0 (4.3)	6.7 (8.0)
Median	0	0	0	5.0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 10.0	-15.0, 50.0	0.0, 0.0	0.0, 15.0
Min, Max	0, 90	0, 30	0, 80	-30, 90	-40, 10	-40, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Overall Work Impairment						
Baseline						
m	53	45	90			
n	8	15	26			
Mean (SD)	15.75 (26.97)	14.00 (20.98)	6.89 (14.63)			
Median	0	10.00	0			
IQR: Q1, Q3	0.00, 25.00	0.00, 20.00	0.00, 10.00			
Min, Max	0.0, 76.0	0.0, 70.0	0.0, 70.0			
Week 24						
m	49	43	83			
n	12	12	28	4	5	15
Mean (SD/SE)	12.50 (24.17)	18.21 (18.28)	5.71 (16.20)	8.50 (26.18)	19.30 (11.27)	2.06 (7.31)
Median	0	10.00	0	0	10.00	0
IQR: Q1, Q3	0.00, 20.00	5.00, 31.00	0.00, 0.00	-23.00, 40.00	0.00, 26.50	-9.10, 0.00
Min, Max	0.0, 80.0	0.0, 60.0	0.0, 70.0	-46.0, 80.0	0.0, 60.0	-60.0, 70.0
Week 52						
m	47	38	75			
n	11	21	29	4	10	12
Mean (SD/SE)	19.55 (30.70)	12.82 (19.67)	13.16 (22.91)	27.25 (28.06)	1.34 (7.96)	12.70 (10.12)
Median	0	0	0	27.50	0	0
IQR: Q1, Q3	0.00, 40.00	0.00, 20.00	0.00, 10.00	-18.00, 72.50	0.00, 0.00	-4.55, 29.25
Min, Max	0.0, 90.0	0.0, 73.4	0.0, 83.0	-36.0, 90.0	-40.0, 63.4	-40.0, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=53)	Visit Result MGL-3196 100 mg (N=45)	Visit Result Placebo (N=90)	Change from Baseline MGL-3196 80 mg (N=53)	Change from Baseline MGL-3196 100 mg (N=45)	Change from Baseline Placebo (N=90)
Activity Impairment						
Baseline						
m	53	45	90			
n	23	23	46			
Mean (SD)	16.5 (24.2)	14.8 (20.4)	13.9 (25.0)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 30.0	0.0, 30.0	0.0, 10.0			
Min, Max	0, 80	0, 80	0, 100			
Week 24						
m	49	43	83			
n	29	22	47	17	14	27
Mean (SD/SE)	15.9 (23.2)	11.8 (16.5)	9.6 (19.0)	6.5 (7.1)	5.0 (5.2)	-1.9 (4.5)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 10.0	-10.0, 20.0	0.0, 10.0	-10.0, 0.0
Min, Max	0, 80	0, 60	0, 80	-40, 80	-20, 60	-80, 70
Week 52						
m	47	38	75			
n	29	29	45	12	15	18
Mean (SD/SE)	14.1 (19.2)	13.1 (16.9)	15.3 (20.0)	5.0 (8.1)	0.7 (4.0)	-1.1 (6.8)
Median	10.0	0	10.0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 30.0	0.0, 20.0	-5.0, 10.0	-10.0, 10.0	0.0, 0.0
Min, Max	0, 70	0, 50	0, 70	-40, 60	-30, 30	-90, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Absenteeism						
Baseline						
m	72	65	139			
n	17	18	26			
Mean (SD)	4.03 (10.30)	5.30 (16.94)	4.92 (20.00)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 34.8	0.0, 68.1	0.0, 100.0			
Week 24						
m	72	58	135			
n	22	19	38	14	10	19
Mean (SD/SE)	2.01 (5.22)	0.00 (0.00)	0.00 (0.00)	-2.31 (2.48)	0.00 (0.00)	-6.58 (5.35)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 16.7	0.0, 0.0	0.0, 0.0	-26.7, 12.5	0.0, 0.0	-100.0, 0.0
Week 52						
m	69	51	128			
n	19	19	47	6	9	15
Mean (SD/SE)	1.98 (7.65)	3.55 (12.89)	3.23 (13.53)	-4.70 (4.41)	6.18 (6.18)	0.00 (0.00)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-1.50, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 33.3	0.0, 55.6	0.0, 75.0	-26.7, 0.0	0.0, 55.6	0.0, 0.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=72)	Visit Result: MGL-3196 100 mg (N=65)	Visit Result: Placebo (N=139)	Change from Baseline: MGL-3196 80 mg (N=72)	Change from Baseline: MGL-3196 100 mg (N=65)	Change from Baseline: Placebo (N=139)
Presenteeism						
Baseline						
m	72	65	139			
n	17	18	25			
Mean (SD)	4.7 (14.6)	7.2 (11.3)	5.6 (16.9)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 0.0			
Min, Max	0, 60	0, 40	0, 70			
Week 24						
m	72	58	135			
n	22	19	38	14	10	18
Mean (SD/SE)	11.4 (21.9)	10.0 (22.1)	8.2 (16.4)	7.9 (7.3)	6.0 (5.6)	3.9 (2.8)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 10.0	0.0, 10.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 90	0, 80	0, 60	-20, 90	-10, 50	-20, 30
Week 52						
m	69	51	128			
n	19	19	47	6	9	15
Mean (SD/SE)	10.5 (17.8)	10.5 (22.7)	8.3 (16.3)	3.3 (7.6)	5.6 (4.1)	3.3 (2.9)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 10.0	0.0, 10.0	-10.0, 0.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 50	0, 90	0, 70	-10, 40	-10, 30	-20, 30

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Overall Work Impairment						
Baseline						
m	72	65	139			
n	17	18	25			
Mean (SD)	7.35 (19.12)	11.92 (19.94)	6.56 (17.82)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 20.00	0.00, 0.00			
Min, Max	0.0, 73.9	0.0, 68.1	0.0, 70.0			
Week 24						
m	72	58	135			
n	22	19	38	14	10	18
Mean (SD/SE)	12.42 (23.16)	10.00 (22.11)	8.16 (16.42)	5.96 (7.94)	6.00 (5.62)	2.64 (2.93)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 10.00	0.00, 10.00	0.00, 10.00	0.00, 10.00	0.00, 10.00	0.00, 0.00
Min, Max	0.0, 91.3	0.0, 80.0	0.0, 60.0	-34.0, 91.3	-10.0, 50.0	-20.0, 30.0
Week 52						
m	69	51	128			
n	19	19	47	6	9	15
Mean (SD/SE)	11.58 (20.19)	13.22 (25.60)	10.29 (21.09)	-0.22 (9.68)	11.11 (7.35)	2.83 (2.57)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 20.00	0.00, 10.00	0.00, 10.00	-7.30, 0.00	0.00, 20.00	0.00, 10.00
Min, Max	0.0, 66.6	0.0, 91.2	0.0, 87.5	-34.0, 40.0	-10.0, 60.0	-20.0, 22.5

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=72)	Visit Result MGL-3196 100 mg (N=65)	Visit Result Placebo (N=139)	Change from Baseline MGL-3196 80 mg (N=72)	Change from Baseline MGL-3196 100 mg (N=65)	Change from Baseline Placebo (N=139)
Activity Impairment						
Baseline						
m	72	65	139			
n	33	32	52			
Mean (SD)	11.5 (20.9)	10.3 (14.7)	17.7 (25.8)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 30.0			
Min, Max	0, 70	0, 50	0, 100			
Week 24						
m	72	58	135			
n	43	32	71	27	18	37
Mean (SD/SE)	14.7 (21.9)	10.0 (17.4)	20.3 (25.5)	7.4 (3.9)	3.3 (4.5)	3.5 (3.4)
Median	0	0	10.0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 10.0	0.0, 40.0	0.0, 10.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 80	0, 70	0, 100	-20, 60	-20, 70	-70, 50
Week 52						
m	69	51	128			
n	45	35	88	17	17	34
Mean (SD/SE)	14.2 (21.8)	17.1 (22.0)	14.9 (19.7)	-4.7 (3.5)	8.8 (3.4)	-5.3 (3.9)
Median	0	10.0	10.0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 30.0	0.0, 20.0	-10.0, 0.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 80	0, 80	0, 80	-40, 30	-10, 40	-70, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Absenteeism						
Baseline						
m	30	28	57			
n	2	7	11			
Mean (SD)	4.70 (6.65)	0.69 (1.81)	3.60 (10.03)			
Median	4.70	0	0			
IQR: Q1, Q3	0.00, 9.40	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 9.4	0.0, 4.8	0.0, 33.3			
Week 24						
m	30	28	54			
n	6	6	14	2	4	7
Mean (SD/SE)	0.00 (0.00)	0.95 (2.33)	0.00 (0.00)	-4.70 (4.70)	0.23 (0.23)	-5.66 (4.69)
Median	0	0	0	-4.70	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-9.40, 0.00	0.00, 0.45	-6.30, 0.00
Min, Max	0.0, 0.0	0.0, 5.7	0.0, 0.0	-9.4, 0.0	0.0, 0.9	-33.3, 0.0
Week 52						
m	26	25	52			
n	7	4	13	1	2	5
Mean (SD/SE)	7.14 (18.90)	0.00 (0.00)	0.00 (0.00)	0.00 (N/A)	0.00 (0.00)	-6.66 (6.66)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	0.0, 0.0	-33.3, 0.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result: MGL-3196 80 mg (N=30)	Visit Result: MGL-3196 100 mg (N=28)	Visit Result: Placebo (N=57)	Change from Baseline: MGL-3196 80 mg (N=30)	Change from Baseline: MGL-3196 100 mg (N=28)	Change from Baseline: Placebo (N=57)
Presenteeism						
Baseline						
m	30	28	57			
n	2	7	11			
Mean (SD)	0.0 (0.0)	11.4 (17.7)	12.7 (13.5)			
Median	0	10.0	10.0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 30.0			
Min, Max	0, 0	0, 50	0, 30			
Week 24						
m	30	28	54			
n	6	6	14	2	4	7
Mean (SD/SE)	5.0 (8.4)	11.7 (9.8)	10.0 (12.4)	0.0 (0.0)	-5.0 (8.7)	-1.4 (4.0)
Median	0	15.0	5.0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 20.0	0.0, 0.0	-15.0, 5.0	-10.0, 10.0
Min, Max	0, 20	0, 20	0, 30	0, 0	-30, 10	-20, 10
Week 52						
m	26	25	52			
n	7	4	13	1	2	5
Mean (SD/SE)	11.4 (16.8)	10.0 (20.0)	0.0 (0.0)	0.0 (N/A)	15.0 (15.0)	-6.0 (6.0)
Median	0	0	0	0	15.0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 0.0	0.0, 0.0	0.0, 30.0	0.0, 0.0
Min, Max	0, 40	0, 40	0, 0	0, 0	0, 30	-30, 0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under “Visit Result” is the number of subjects with a result at the given visit; n under “Change from Baseline” is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Overall Work Impairment						
Baseline						
m	30	28	57			
n	2	7	11			
Mean (SD)	4.70 (6.65)	12.04 (17.74)	15.25 (18.08)			
Median	4.70	10.00	10.00			
IQR: Q1, Q3	0.00, 9.40	0.00, 14.30	0.00, 30.00			
Min, Max	0.0, 9.4	0.0, 50.0	0.0, 53.3			
Week 24						
m	30	28	54			
n	6	6	14	2	4	7
Mean (SD/SE)	5.00 (8.37)	12.52 (9.88)	10.00 (12.40)	-4.70 (4.70)	-4.80 (8.70)	-5.39 (6.89)
Median	0	17.55	5.00	-4.70	0.40	0
IQR: Q1, Q3	0.00, 10.00	0.00, 20.00	0.00, 20.00	-9.40, 0.00	-15.00, 5.40	-10.00, 10.00
Min, Max	0.0, 20.0	0.0, 20.0	0.0, 30.0	-9.4, 0.0	-30.0, 10.0	-43.3, 10.0
Week 52						
m	26	25	52			
n	7	4	13	1	2	5
Mean (SD/SE)	15.71 (26.37)	10.00 (20.00)	0.00 (0.00)	0.00 (N/A)	15.00 (15.00)	-10.66 (10.66)
Median	0	0	0	0	15.00	0
IQR: Q1, Q3	0.00, 30.00	0.00, 20.00	0.00, 0.00	0.00, 0.00	0.00, 30.00	0.00, 0.00
Min, Max	0.0, 70.0	0.0, 40.0	0.0, 0.0	0.0, 0.0	0.0, 30.0	-53.3, 0.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=30)	Visit Result MGL-3196 100 mg (N=28)	Visit Result Placebo (N=57)	Change from Baseline MGL-3196 80 mg (N=30)	Change from Baseline MGL-3196 100 mg (N=28)	Change from Baseline Placebo (N=57)
Activity Impairment						
Baseline						
m	30	28	57			
n	7	14	20			
Mean (SD)	14.3 (29.9)	11.4 (16.6)	27.0 (28.1)			
Median	0	10.0	15.0			
IQR: Q1, Q3	0.0, 20.0	0.0, 10.0	5.0, 50.0			
Min, Max	0, 80	0, 60	0, 80			
Week 24						
m	30	28	54			
n	14	12	27	5	10	10
Mean (SD/SE)	20.0 (23.2)	15.8 (16.2)	18.5 (22.8)	4.0 (6.8)	3.0 (5.0)	-3.0 (5.0)
Median	15.0	15.0	10.0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 30.0	0.0, 0.0	0.0, 10.0	-10.0, 0.0
Min, Max	0, 70	0, 50	0, 80	-10, 30	-20, 40	-40, 20
Week 52						
m	26	25	52			
n	16	11	25	2	5	7
Mean (SD/SE)	23.1 (28.0)	16.4 (23.4)	10.4 (23.7)	25.0 (25.0)	20.0 (7.1)	-7.1 (2.9)
Median	10.0	0	0	25.0	20.0	-10.0
IQR: Q1, Q3	0.0, 50.0	0.0, 30.0	0.0, 0.0	0.0, 50.0	10.0, 30.0	-10.0, 0.0
Min, Max	0, 90	0, 70	0, 100	0, 50	0, 40	-20, 0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.14c.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Absenteeism			
Week 24			
m	49	43	83
n	4	5	15
Baseline Mean (SD)	5.00 (10.00)	0.00 (0.00)	0.61 (2.35)
Analysis Visit Mean (SD)	0.00 (0.00)	5.88 (13.15)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-1.22 (3.29)	2.45 (2.51)	-1.81 (1.56)
95% CI	(-7.93, 5.49)	(-2.67, 7.57)	(-5.00, 1.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.59 (3.50)	4.26 (2.78)	
95% CI	(-6.55, 7.73)	(-1.42, 9.94)	
p-value	0.8672	0.1358	
Corrected Hedge's g Statistics	0.092	0.685	
95% CI	(-1.01, 1.19)	(-0.35, 1.72)	
Week 52			
m	47	38	75
n	4	10	12
Baseline Mean (SD)	5.00 (10.00)	0.00 (0.00)	0.76 (2.63)
Analysis Visit Mean (SD)	12.50 (25.00)	6.67 (21.09)	9.38 (20.38)
LS Mean of Change from Baseline (SE)	11.85 (10.70)	3.55 (6.52)	7.33 (5.64)
95% CI	(-10.01, 33.70)	(-9.76, 16.87)	(-4.19, 18.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.51 (12.20)	-3.78 (8.55)	
95% CI	(-20.40, 29.42)	(-21.25, 13.68)	
p-value	0.7140	0.6615	
Corrected Hedge's g Statistics	0.214	-0.182	
95% CI	(-0.92, 1.35)	(-1.02, 0.66)	
Subgroup*Treatment Interaction p-value	0.4742	0.0894	

AMNOG Table SE24.14c.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Presenteeism			
Week 24			
m	49	43	83
n	4	5	15
Baseline Mean (SD)	17.5 (35.0)	4.0 (5.5)	6.0 (18.0)
Analysis Visit Mean (SD)	27.5 (37.7)	18.0 (23.9)	8.7 (21.3)
LS Mean of Change from Baseline (SE)	13.04 (12.39)	9.70 (9.79)	-0.72 (6.35)
95% CI	(-12.26, 38.34)	(-10.29, 29.69)	(-13.68, 12.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.75 (13.71)	10.42 (11.42)	
95% CI	(-14.24, 41.75)	(-12.91, 33.75)	
p-value	0.3236	0.3690	
Corrected Hedge's g Statistics	0.534	0.416	
95% CI	(-0.58, 1.65)	(-0.60, 1.44)	
Week 52			
m	47	38	75
n	4	10	12
Baseline Mean (SD)	17.5 (35.0)	13.0 (16.4)	9.2 (20.7)
Analysis Visit Mean (SD)	35.0 (40.4)	9.0 (11.0)	15.8 (24.3)
LS Mean of Change from Baseline (SE)	18.50 (11.27)	-2.41 (7.16)	3.46 (6.13)
95% CI	(-4.52, 41.51)	(-17.04, 12.21)	(-9.06, 15.99)
LS Mean of Change from Baseline Compared to Placebo (SE)	15.03 (12.68)	-5.88 (9.30)	
95% CI	(-10.86, 40.92)	(-24.87, 13.11)	
p-value	0.2451	0.5321	
Corrected Hedge's g Statistics	0.660	-0.258	
95% CI	(-0.49, 1.81)	(-1.10, 0.58)	
Subgroup*Treatment Interaction p-value	0.6410	0.8605	

AMNOG Table SE24.14c.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Overall Work Impairment			
Week 24			
m	49	43	83
n	4	5	15
Baseline Mean (SD)	19.00 (38.00)	4.00 (5.48)	6.61 (17.98)
Analysis Visit Mean (SD)	27.50 (37.75)	23.30 (24.59)	8.67 (21.34)
LS Mean of Change from Baseline (SE)	19.07 (12.43)	10.88 (9.58)	-1.09 (6.36)
95% CI	(-6.32, 44.46)	(-8.67, 30.44)	(-14.07, 11.89)
LS Mean of Change from Baseline Compared to Placebo (SE)	20.16 (13.64)	11.97 (11.15)	
95% CI	(-7.71, 48.02)	(-10.79, 34.74)	
p-value	0.1500	0.2912	
Corrected Hedge's g Statistics	0.781	0.479	
95% CI	(-0.35, 1.91)	(-0.54, 1.50)	
Week 52			
m	47	38	75
n	4	10	12
Baseline Mean (SD)	19.00 (38.00)	13.00 (16.36)	9.93 (20.45)
Analysis Visit Mean (SD)	46.25 (37.28)	14.34 (23.17)	22.63 (30.85)
LS Mean of Change from Baseline (SE)	27.37 (14.17)	2.67 (9.00)	8.61 (7.68)
95% CI	(-1.58, 56.32)	(-15.71, 21.04)	(-7.07, 24.28)
LS Mean of Change from Baseline Compared to Placebo (SE)	18.77 (15.93)	-5.94 (11.69)	
95% CI	(-13.76, 51.29)	(-29.81, 17.94)	
p-value	0.2479	0.6152	
Corrected Hedge's g Statistics	0.658	-0.208	
95% CI	(-0.50, 1.81)	(-1.05, 0.63)	
Subgroup*Treatment Interaction p-value	0.3161	0.9725	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Visit Statistic	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Activity Impairment			
Week 24			
m	49	43	83
n	17	14	27
Baseline Mean (SD)	12.4 (18.9)	10.0 (12.4)	8.1 (18.0)
Analysis Visit Mean (SD)	18.8 (24.2)	15.0 (19.5)	6.3 (14.7)
LS Mean of Change from Baseline (SE)	5.35 (4.66)	2.76 (4.93)	-5.69 (3.67)
95% CI	(-3.95, 14.65)	(-7.07, 12.59)	(-13.00, 1.63)
LS Mean of Change from Baseline Compared to Placebo (SE)	11.04 (5.77)	8.45 (6.03)	
95% CI	(-0.48, 22.56)	(-3.58, 20.48)	
p-value	0.0601	0.1657	
Corrected Hedge's g Statistics	0.567	0.440	
95% CI	(-0.05, 1.19)	(-0.21, 1.09)	
Week 52			
m	47	38	75
n	12	15	18
Baseline Mean (SD)	15.0 (25.0)	12.0 (12.6)	16.7 (28.1)
Analysis Visit Mean (SD)	20.0 (22.6)	12.7 (13.9)	15.6 (21.2)
LS Mean of Change from Baseline (SE)	9.31 (5.39)	-0.59 (4.78)	0.25 (4.29)
95% CI	(-1.44, 20.06)	(-10.13, 8.96)	(-8.31, 8.81)
LS Mean of Change from Baseline Compared to Placebo (SE)	9.06 (6.74)	-0.83 (6.35)	
95% CI	(-4.38, 22.50)	(-13.49, 11.82)	
p-value	0.1833	0.8958	
Corrected Hedge's g Statistics	0.479	-0.044	
95% CI	(-0.26, 1.22)	(-0.73, 0.64)	
Subgroup*Treatment Interaction p-value	0.3045	0.4795	

AMNOG Table SE24.14c.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Absenteeism			
Week 24			
m	72	58	135
n	14	10	19
Baseline Mean (SD)	4.39 (11.28)	0.00 (0.00)	6.58 (23.34)
Analysis Visit Mean (SD)	2.09 (5.37)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-1.81 (0.92)	-3.62 (1.03)	-3.94 (0.76)
95% CI	(-3.67, 0.04)	(-5.70, -1.54)	(-5.47, -2.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.13 (1.10)	0.33 (1.32)	
95% CI	(-0.08, 4.34)	(-2.33, 2.98)	
p-value	0.0583	0.8055	
Corrected Hedge's g Statistics	0.619	0.097	
95% CI	(-0.09, 1.33)	(-0.67, 0.86)	
Week 52			
m	69	51	128
n	6	9	15
Baseline Mean (SD)	10.25 (16.08)	0.00 (0.00)	1.67 (6.45)
Analysis Visit Mean (SD)	5.55 (13.59)	6.18 (18.53)	1.67 (6.45)
LS Mean of Change from Baseline (SE)	-2.93 (4.80)	4.81 (3.82)	-1.00 (2.91)
95% CI	(-12.59, 6.73)	(-2.87, 12.49)	(-6.87, 4.86)
LS Mean of Change from Baseline Compared to Placebo (SE)	-1.92 (5.75)	5.81 (4.70)	
95% CI	(-13.49, 9.64)	(-3.65, 15.27)	
p-value	0.7392	0.2227	
Corrected Hedge's g Statistics	-0.162	0.494	
95% CI	(-1.11, 0.79)	(-0.34, 1.33)	
Subgroup*Treatment Interaction p-value	0.4742	0.0894	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Presenteeism			
Week 24			
m	72	58	135
n	14	10	18
Baseline Mean (SD)	5.7 (16.0)	5.0 (7.1)	5.0 (16.5)
Analysis Visit Mean (SD)	13.6 (26.2)	11.0 (18.5)	8.9 (14.5)
LS Mean of Change from Baseline (SE)	6.45 (5.29)	6.72 (6.04)	2.74 (4.52)
95% CI	(-4.21, 17.11)	(-5.45, 18.88)	(-6.36, 11.85)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.70 (6.71)	3.97 (7.64)	
95% CI	(-9.80, 17.21)	(-11.40, 19.35)	
p-value	0.5834	0.6053	
Corrected Hedge's g Statistics	0.186	0.201	
95% CI	(-0.51, 0.89)	(-0.57, 0.98)	
Week 52			
m	69	51	128
n	6	9	15
Baseline Mean (SD)	11.7 (24.0)	4.4 (7.3)	6.0 (18.0)
Analysis Visit Mean (SD)	15.0 (23.5)	10.0 (16.6)	9.3 (15.8)
LS Mean of Change from Baseline (SE)	5.29 (5.60)	4.66 (4.48)	2.63 (3.61)
95% CI	(-5.99, 16.58)	(-4.36, 13.68)	(-4.65, 9.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.66 (6.30)	2.03 (5.76)	
95% CI	(-10.02, 15.35)	(-9.57, 13.63)	
p-value	0.6743	0.7264	
Corrected Hedge's g Statistics	0.184	0.142	
95% CI	(-0.76, 1.13)	(-0.69, 0.97)	
Subgroup*Treatment Interaction p-value	0.6410	0.8605	

AMNOG Table SE24.14c.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Overall Work Impairment			
Week 24			
m	72	58	135
n	14	10	18
Baseline Mean (SD)	8.42 (20.98)	5.00 (7.07)	6.25 (17.75)
Analysis Visit Mean (SD)	14.38 (27.37)	11.00 (18.53)	8.89 (14.51)
LS Mean of Change from Baseline (SE)	4.74 (5.48)	4.82 (6.23)	1.02 (4.65)
95% CI	(-6.29, 15.78)	(-7.73, 17.37)	(-8.35, 10.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	3.73 (6.86)	3.80 (7.90)	
95% CI	(-10.08, 17.54)	(-12.12, 19.72)	
p-value	0.5894	0.6328	
Corrected Hedge's g Statistics	0.181	0.187	
95% CI	(-0.52, 0.88)	(-0.59, 0.96)	
Week 52			
m	69	51	128
n	6	9	15
Baseline Mean (SD)	17.98 (30.58)	4.44 (7.26)	7.50 (19.30)
Analysis Visit Mean (SD)	17.77 (28.78)	15.56 (23.51)	10.33 (18.17)
LS Mean of Change from Baseline (SE)	2.40 (7.53)	9.25 (5.94)	1.72 (4.73)
95% CI	(-12.77, 17.57)	(-2.71, 21.22)	(-7.81, 11.25)
LS Mean of Change from Baseline Compared to Placebo (SE)	0.68 (8.54)	7.53 (7.60)	
95% CI	(-16.51, 17.87)	(-7.78, 22.84)	
p-value	0.9369	0.3271	
Corrected Hedge's g Statistics	0.036	0.401	
95% CI	(-0.91, 0.98)	(-0.43, 1.24)	
Subgroup*Treatment Interaction p-value	0.3161	0.9725	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Activity Impairment			
Week 24			
m	72	58	135
n	27	18	37
Baseline Mean (SD)	9.3 (20.6)	8.3 (12.0)	19.5 (27.3)
Analysis Visit Mean (SD)	16.7 (23.9)	11.7 (18.6)	23.0 (27.3)
LS Mean of Change from Baseline (SE)	4.92 (3.85)	1.02 (4.62)	5.07 (3.23)
95% CI	(-2.73, 12.56)	(-8.17, 10.20)	(-1.35, 11.48)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.15 (4.94)	-4.05 (5.64)	
95% CI	(-9.96, 9.66)	(-15.26, 7.16)	
p-value	0.9761	0.4747	
Corrected Hedge's g Statistics	-0.007	-0.203	
95% CI	(-0.50, 0.49)	(-0.77, 0.36)	
Week 52			
m	69	51	128
n	17	17	34
Baseline Mean (SD)	17.6 (24.6)	10.0 (15.8)	20.3 (28.3)
Analysis Visit Mean (SD)	12.9 (17.6)	18.8 (21.2)	15.0 (19.3)
LS Mean of Change from Baseline (SE)	-3.07 (3.71)	5.26 (3.66)	-2.86 (2.64)
95% CI	(-10.45, 4.31)	(-2.02, 12.53)	(-8.10, 2.38)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.21 (4.38)	8.11 (4.51)	
95% CI	(-8.91, 8.49)	(-0.84, 17.07)	
p-value	0.9617	0.0751	
Corrected Hedge's g Statistics	-0.014	0.523	
95% CI	(-0.60, 0.57)	(-0.07, 1.11)	
Subgroup*Treatment Interaction p-value	0.3045	0.4795	

AMNOG Table SE24.14c.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Absenteeism			
Week 24			
m	30	28	54
n	2	4	7
Baseline Mean (SD)	4.70 (6.65)	1.20 (2.40)	5.66 (12.41)
Analysis Visit Mean (SD)	0.00 (0.00)	1.43 (2.85)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Week 52			
m	26	25	52
n	1	2	5
Baseline Mean (SD)	0.00 (N/A)	0.00 (0.00)	6.66 (14.89)
Analysis Visit Mean (SD)	0.00 (N/A)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	NE	NE	NE
95% CI	NE	NE	NE
LS Mean of Change from Baseline Compared to Placebo (SE)	NE	NE	
95% CI	NE	NE	
p-value	NE	NE	
Corrected Hedge's g Statistics	NE	NE	
95% CI	NE	NE	
Subgroup*Treatment Interaction p-value	0.4742	0.0894	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Presenteeism			
Week 24			
m	30	28	54
n	2	4	7
Baseline Mean (SD)	0.0 (0.0)	17.5 (22.2)	14.3 (14.0)
Analysis Visit Mean (SD)	0.0 (0.0)	12.5 (9.6)	12.9 (12.5)
LS Mean of Change from Baseline (SE)	-4.87 (7.22)	-3.42 (4.96)	-1.16 (4.62)
95% CI	(-20.61, 10.87)	(-14.22, 7.37)	(-11.24, 8.91)
LS Mean of Change from Baseline Compared to Placebo (SE)	-3.71 (8.51)	-2.26 (6.16)	
95% CI	(-22.26, 14.84)	(-15.67, 11.15)	
p-value	0.6708	0.7200	
Corrected Hedge's g Statistics	-0.276	-0.179	
95% CI	(-1.85, 1.30)	(-1.41, 1.05)	
Week 52			
m	26	25	52
n	1	2	5
Baseline Mean (SD)	0.0 (N/A)	5.0 (7.1)	6.0 (13.4)
Analysis Visit Mean (SD)	0.0 (N/A)	20.0 (28.3)	0.0 (0.0)
LS Mean of Change from Baseline (SE)	-4.89 (12.04)	8.84 (8.35)	-6.82 (5.85)
95% CI	(-31.12, 21.34)	(-9.35, 27.03)	(-19.57, 5.94)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.93 (13.17)	15.66 (9.73)	
95% CI	(-26.76, 30.62)	(-5.53, 36.85)	
p-value	0.8861	0.1334	
Corrected Hedge's g Statistics	0.118	1.027	
95% CI	(-2.03, 2.27)	(-0.70, 2.75)	
Subgroup*Treatment Interaction p-value	0.6410	0.8605	

AMNOG Table SE24.14c.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Overall Work Impairment			
Week 24			
m	30	28	54
n	2	4	7
Baseline Mean (SD)	4.70 (6.65)	18.58 (21.79)	18.24 (20.39)
Analysis Visit Mean (SD)	0.00 (0.00)	13.78 (9.47)	12.86 (12.54)
LS Mean of Change from Baseline (SE)	-9.68 (8.05)	-3.62 (5.45)	-3.93 (5.16)
95% CI	(-27.23, 7.87)	(-15.49, 8.25)	(-15.17, 7.31)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.75 (9.37)	0.31 (6.89)	
95% CI	(-26.17, 14.67)	(-14.71, 15.33)	
p-value	0.5512	0.9647	
Corrected Hedge's g Statistics	-0.383	0.022	
95% CI	(-1.96, 1.20)	(-1.21, 1.25)	
Week 52			
m	26	25	52
n	1	2	5
Baseline Mean (SD)	0.00 (N/A)	5.00 (7.07)	10.66 (23.84)
Analysis Visit Mean (SD)	0.00 (N/A)	20.00 (28.28)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-9.99 (12.72)	8.37 (8.98)	-9.58 (6.24)
95% CI	(-37.71, 17.73)	(-11.19, 27.94)	(-23.16, 4.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.41 (14.11)	17.95 (10.53)	
95% CI	(-31.15, 30.33)	(-5.00, 40.90)	
p-value	0.9773	0.1141	
Corrected Hedge's g Statistics	-0.024	1.103	
95% CI	(-2.17, 2.12)	(-0.64, 2.84)	
Subgroup*Treatment Interaction p-value	0.3161	0.9725	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.14c.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Visit Statistic	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Activity Impairment			
Week 24			
m	30	28	54
n	5	10	10
Baseline Mean (SD)	16.0 (35.8)	13.0 (18.9)	26.0 (28.4)
Analysis Visit Mean (SD)	20.0 (30.8)	16.0 (17.8)	23.0 (24.5)
LS Mean of Change from Baseline (SE)	6.98 (6.44)	3.93 (4.73)	2.09 (4.93)
95% CI	(-6.25, 20.22)	(-5.79, 13.66)	(-8.03, 12.21)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.89 (7.55)	1.85 (6.06)	
95% CI	(-10.62, 20.41)	(-10.61, 14.30)	
p-value	0.5222	0.7631	
Corrected Hedge's g Statistics	0.303	0.116	
95% CI	(-0.78, 1.38)	(-0.76, 0.99)	
Week 52			
m	26	25	52
n	2	5	7
Baseline Mean (SD)	0.0 (0.0)	10.0 (12.2)	14.3 (17.2)
Analysis Visit Mean (SD)	25.0 (35.4)	30.0 (27.4)	7.1 (18.9)
LS Mean of Change from Baseline (SE)	31.67 (10.78)	26.51 (6.80)	-3.28 (5.88)
95% CI	(9.50, 53.84)	(12.54, 40.49)	(-15.36, 8.80)
LS Mean of Change from Baseline Compared to Placebo (SE)	34.95 (11.70)	29.79 (8.32)	
95% CI	(10.90, 59.00)	(12.70, 46.88)	
p-value	0.0061	0.0014	
Corrected Hedge's g Statistics	2.003	1.785	
95% CI	(0.18, 3.83)	(0.43, 3.14)	
Subgroup*Treatment Interaction p-value	0.3045	0.4795	

AMNOG Table SE24.14c.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; SNP = Single Nucleotide Polymorphism; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.14c.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.9)	0	0
No	52 (98.1)	45 (100)	90 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.89	NE	
95% CI of the absolute risk difference	(-1.78, 5.55)	NE	
p-value	0.1910	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2297	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.9)	0	1 (1.1)
No	52 (98.1)	45 (100)	89 (98.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	NE	
95% CI of the inverse odds ratio	(0.04, 9.54)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	NE	
95% CI of the inverse risk ratio	(0.04, 9.22)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.78	-1.11	
95% CI of the absolute risk difference	(-3.48, 5.03)	(-3.28, 1.05)	
p-value	0.7028	0.4779	
p-value of Breslow-Day Test for Homogeneity [3]	0.3615	NE	

AMNOG Table SE24.14c.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.9)	1 (2.2)	1 (1.1)
No	52 (98.1)	44 (97.8)	89 (98.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.49	
95% CI of the inverse odds ratio	(0.04, 9.54)	(0.03, 8.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.50	
95% CI of the inverse risk ratio	(0.04, 9.22)	(0.03, 7.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.78	1.11	
95% CI of the absolute risk difference	(-3.48, 5.03)	(-3.71, 5.93)	
p-value	0.7028	0.6144	
p-value of Breslow-Day Test for Homogeneity [3]	0.5404	0.5211	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.9)	2 (4.4)	2 (2.2)
No	52 (98.1)	43 (95.6)	88 (97.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.49	
95% CI of the inverse odds ratio	(0.10, 13.35)	(0.07, 3.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.50	
95% CI of the inverse risk ratio	(0.11, 12.68)	(0.07, 3.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.34	2.22	
95% CI of the absolute risk difference	(-5.10, 4.43)	(-4.53, 8.97)	
p-value	0.8925	0.4729	
p-value of Breslow-Day Test for Homogeneity [3]	0.4309	0.6386	

AMNOG Table SE24.14c.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.9)	1 (2.2)	1 (1.1)
No	52 (98.1)	44 (97.8)	89 (98.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.49	
95% CI of the inverse odds ratio	(0.04, 9.54)	(0.03, 8.09)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.50	
95% CI of the inverse risk ratio	(0.04, 9.22)	(0.03, 7.81)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.78	1.11	
95% CI of the absolute risk difference	(-3.48, 5.03)	(-3.71, 5.93)	
p-value	0.7028	0.6144	
p-value of Breslow-Day Test for Homogeneity [3]	0.6655	0.5211	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.9)	2 (4.4)	3 (3.3)
No	52 (98.1)	43 (95.6)	87 (96.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.79	0.74	
95% CI of the inverse odds ratio	(0.18, 17.69)	(0.12, 4.60)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.77	0.75	
95% CI of the inverse risk ratio	(0.19, 16.55)	(0.13, 4.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.45	1.11	
95% CI of the absolute risk difference	(-6.66, 3.77)	(-5.96, 8.18)	
p-value	0.6124	0.7473	
p-value of Breslow-Day Test for Homogeneity [3]	0.3394	0.6771	

AMNOG Table SE24.14c.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - No Mutation

Parameter Response Statistic/Category	MGL-3196 80 mg (N=53)	MGL-3196 100 mg (N=45)	Placebo (N=90)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (3.8)	2 (4.4)	2 (2.2)
No	51 (96.2)	43 (95.6)	88 (97.8)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.58	0.49	
95% CI of the inverse odds ratio	(0.08, 4.24)	(0.07, 3.59)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.50	
95% CI of the inverse risk ratio	(0.09, 4.06)	(0.07, 3.43)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.55	2.22	
95% CI of the absolute risk difference	(-4.41, 7.52)	(-4.53, 8.97)	
p-value	0.5869	0.4729	
p-value of Breslow-Day Test for Homogeneity [3]	0.5984	0.0754	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	3 (5.7)	4 (8.9)	3 (3.3)
No	50 (94.3)	41 (91.1)	87 (96.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	0.35	
95% CI of the inverse odds ratio	(0.11, 2.96)	(0.08, 1.65)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	0.38	
95% CI of the inverse risk ratio	(0.12, 2.81)	(0.09, 1.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.33	5.56	
95% CI of the absolute risk difference	(-4.92, 9.57)	(-3.55, 14.66)	
p-value	0.5026	0.1700	
p-value of Breslow-Day Test for Homogeneity [3]	0.1921	0.0474	

AMNOG Table SE24.14c.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.4)	0	0
No	71 (98.6)	65 (100)	139 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.39	NE	
95% CI of the absolute risk difference	(-1.31, 4.09)	NE	
p-value	0.1637	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2297	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.4)	0	0
No	71 (98.6)	65 (100)	139 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.39	NE	
95% CI of the absolute risk difference	(-1.31, 4.09)	NE	
p-value	0.1637	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.3615	NE	

AMNOG Table SE24.14c.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (0.7)
No	72 (100)	65 (100)	138 (99.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.72	-0.72	
95% CI of the absolute risk difference	(-2.12, 0.69)	(-2.12, 0.69)	
p-value	0.4706	0.4930	
p-value of Breslow-Day Test for Homogeneity [3]	0.5404	0.5211	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (2.8)	1 (1.5)	1 (0.7)
No	70 (97.2)	64 (98.5)	138 (99.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	0.46	
95% CI of the inverse odds ratio	(0.02, 2.85)	(0.03, 7.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.26	0.47	
95% CI of the inverse risk ratio	(0.02, 2.81)	(0.03, 7.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.06	0.82	
95% CI of the absolute risk difference	(-1.99, 6.11)	(-2.49, 4.12)	
p-value	0.2311	0.5801	
p-value of Breslow-Day Test for Homogeneity [3]	0.4309	0.6386	

AMNOG Table SE24.14c.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.4)	0	1 (0.7)
No	71 (98.6)	65 (100)	138 (99.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.51	NE	
95% CI of the inverse odds ratio	(0.03, 8.35)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.52	NE	
95% CI of the inverse risk ratio	(0.03, 8.16)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.67	-0.72	
95% CI of the absolute risk difference	(-2.38, 3.72)	(-2.12, 0.69)	
p-value	0.6342	0.4930	
p-value of Breslow-Day Test for Homogeneity [3]	0.6655	0.5211	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (2.8)	1 (1.5)	1 (0.7)
No	70 (97.2)	64 (98.5)	138 (99.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.25	0.46	
95% CI of the inverse odds ratio	(0.02, 2.85)	(0.03, 7.53)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.26	0.47	
95% CI of the inverse risk ratio	(0.02, 2.81)	(0.03, 7.36)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	2.06	0.82	
95% CI of the absolute risk difference	(-1.99, 6.11)	(-2.49, 4.12)	
p-value	0.2311	0.5801	
p-value of Breslow-Day Test for Homogeneity [3]	0.3394	0.6771	

AMNOG Table SE24.14c.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Heterozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=72)	MGL-3196 100 mg (N=65)	Placebo (N=139)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (4.2)	0	8 (5.8)
No	69 (95.8)	65 (100)	131 (94.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.40	8.47	
95% CI of the inverse odds ratio	(0.36, 5.46)	(0.48, 148.98)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.38	8.01	
95% CI of the inverse risk ratio	(0.38, 5.05)	(0.47, 136.78)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.59	-5.31	
95% CI of the absolute risk difference	(-7.61, 4.44)	(-9.79, -0.84)	
p-value	0.6226	0.0817	
p-value of Breslow-Day Test for Homogeneity [3]	0.5984	0.0754	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	7 (9.7)	1 (1.5)	8 (5.8)
No	65 (90.3)	64 (98.5)	131 (94.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.57	3.91	
95% CI of the inverse odds ratio	(0.20, 1.63)	(0.48, 31.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.59	3.74	
95% CI of the inverse risk ratio	(0.22, 1.57)	(0.48, 29.29)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	3.97	-4.22	
95% CI of the absolute risk difference	(-3.90, 11.83)	(-9.11, 0.68)	
p-value	0.2877	0.1718	
p-value of Breslow-Day Test for Homogeneity [3]	0.1921	0.0474	

AMNOG Table SE24.14c.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (1.8)
No	30 (100)	28 (100)	56 (98.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.75	-1.75	
95% CI of the absolute risk difference	(-5.16, 1.65)	(-5.16, 1.65)	
p-value	0.4656	0.4808	
p-value of Breslow-Day Test for Homogeneity [3]	0.2297	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (1.8)
No	30 (100)	28 (100)	56 (98.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.75	-1.75	
95% CI of the absolute risk difference	(-5.16, 1.65)	(-5.16, 1.65)	
p-value	0.4656	0.4808	
p-value of Breslow-Day Test for Homogeneity [3]	0.3615	NE	

AMNOG Table SE24.14c.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (1.8)
No	30 (100)	28 (100)	56 (98.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.75	-1.75	
95% CI of the absolute risk difference	(-5.16, 1.65)	(-5.16, 1.65)	
p-value	0.4656	0.4808	
p-value of Breslow-Day Test for Homogeneity [3]	0.5404	0.5211	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (1.8)
No	30 (100)	28 (100)	56 (98.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.75	-1.75	
95% CI of the absolute risk difference	(-5.16, 1.65)	(-5.16, 1.65)	
p-value	0.4656	0.4808	
p-value of Breslow-Day Test for Homogeneity [3]	0.4309	0.6386	

AMNOG Table SE24.14c.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (1.8)
No	30 (100)	28 (100)	56 (98.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.75	-1.75	
95% CI of the absolute risk difference	(-5.16, 1.65)	(-5.16, 1.65)	
p-value	0.4656	0.4808	
p-value of Breslow-Day Test for Homogeneity [3]	0.6655	0.5211	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	1 (1.8)
No	30 (100)	28 (100)	56 (98.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.75	-1.75	
95% CI of the absolute risk difference	(-5.16, 1.65)	(-5.16, 1.65)	
p-value	0.4656	0.4808	
p-value of Breslow-Day Test for Homogeneity [3]	0.3394	0.6771	

AMNOG Table SE24.14c.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Genetic NASH SNP - TMC4
(Label Population)

Genetic NASH SNP: TMC4 rs641738 - Mutation - Homozygous

Parameter Response Statistic/Category	MGL-3196 80 mg (N=30)	MGL-3196 100 mg (N=28)	Placebo (N=57)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	0	1 (1.8)
No	30 (100)	28 (100)	56 (98.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.75	-1.75	
95% CI of the absolute risk difference	(-5.16, 1.65)	(-5.16, 1.65)	
p-value	0.4656	0.4808	
p-value of Breslow-Day Test for Homogeneity [3]	0.5984	0.0754	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	0	0	4 (7.0)
No	30 (100)	28 (100)	53 (93.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	5.13	4.79	
95% CI of the inverse odds ratio	(0.27, 98.56)	(0.25, 92.23)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	4.81	4.50	
95% CI of the inverse risk ratio	(0.27, 86.47)	(0.25, 80.77)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-6.15	-6.03	
95% CI of the absolute risk difference	(-14.34, 2.04)	(-14.39, 2.32)	
p-value	0.2303	0.2543	
p-value of Breslow-Day Test for Homogeneity [3]	0.1921	0.0474	

AMNOG Table SE24.15.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Absenteeism						
Baseline						
m	75	87	147			
n	11	18	33			
Mean (SD)	5.59 (12.57)	1.52 (6.43)	2.32 (7.26)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 34.8	0.0, 27.3	0.0, 33.3			
Week 24						
m	72	78	142			
n	17	15	33	9	6	19
Mean (SD/SE)	0.98 (4.05)	1.00 (3.87)	0.00 (0.00)	-4.98 (3.37)	0.00 (0.00)	-3.88 (2.14)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 16.7	0.0, 15.0	0.0, 0.0	-26.7, 0.0	0.0, 0.0	-33.3, 0.0
Week 52						
m	64	70	135			
n	14	24	41	5	12	16
Mean (SD/SE)	2.38 (8.90)	3.25 (12.06)	3.05 (11.45)	-5.64 (5.27)	4.63 (4.63)	-2.65 (2.12)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	-1.50, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 33.3	0.0, 55.6	0.0, 50.0	-26.7, 0.0	0.0, 55.6	-33.3, 0.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.15.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Presenteeism						
Baseline						
m	75	87	147			
n	11	18	33			
Mean (SD)	7.3 (17.9)	9.4 (15.1)	7.9 (14.1)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 10.0	0.0, 20.0	0.0, 10.0			
Min, Max	0, 60	0, 50	0, 50			
Week 24						
m	72	78	142			
n	17	15	33	9	6	19
Mean (SD/SE)	5.3 (11.8)	6.0 (8.3)	8.2 (14.2)	-3.3 (2.9)	5.0 (4.3)	1.1 (3.7)
Median	0	0	0	0	5.0	0
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 10.0	-10.0, 0.0	0.0, 10.0	0.0, 10.0
Min, Max	0, 40	0, 20	0, 60	-20, 10	-10, 20	-50, 30
Week 52						
m	64	70	135			
n	14	24	41	5	12	16
Mean (SD/SE)	12.1 (20.4)	10.8 (19.3)	5.1 (10.0)	4.0 (9.3)	0.8 (4.8)	-1.9 (4.5)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 15.0	0.0, 10.0	-10.0, 0.0	0.0, 5.0	0.0, 0.0
Min, Max	0, 50	0, 80	0, 40	-10, 40	-40, 30	-50, 30

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.15.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Overall Work Impairment						
Baseline						
m	75	87	147			
n	11	18	33			
Mean (SD)	10.72 (23.35)	10.36 (17.41)	9.72 (16.48)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 10.00	0.00, 20.00	0.00, 10.00			
Min, Max	0.0, 73.9	0.0, 56.4	0.0, 53.3			
Week 24						
m	72	78	142			
n	17	15	33	9	6	19
Mean (SD/SE)	5.88 (13.72)	6.80 (10.11)	8.18 (14.24)	-6.43 (4.65)	5.00 (4.28)	-2.07 (4.31)
Median	0	0	0	0	5.00	0
IQR: Q1, Q3	0.00, 0.00	0.00, 10.00	0.00, 10.00	-10.00, 0.00	0.00, 10.00	-4.40, 0.00
Min, Max	0.0, 50.0	0.0, 32.0	0.0, 60.0	-34.0, 10.0	-10.0, 20.0	-50.0, 30.0
Week 52						
m	64	70	135			
n	14	24	41	5	12	16
Mean (SD/SE)	13.33 (23.12)	13.58 (22.53)	7.68 (15.66)	-0.26 (11.85)	5.00 (6.91)	-4.37 (5.09)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 30.00	0.00, 20.00	0.00, 10.00	-7.30, 0.00	0.00, 10.00	-4.55, 0.00
Min, Max	0.0, 66.6	0.0, 80.0	0.0, 60.0	-34.0, 40.0	-40.0, 60.0	-53.3, 22.5

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.15.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=75)	Visit Result MGL-3196 100 mg (N=87)	Visit Result Placebo (N=147)	Change from Baseline MGL-3196 80 mg (N=75)	Change from Baseline MGL-3196 100 mg (N=87)	Change from Baseline Placebo (N=147)
Activity Impairment						
Baseline						
m	75	87	147			
n	29	43	60			
Mean (SD)	10.7 (17.9)	12.6 (17.1)	13.5 (22.0)			
Median	0	0	0			
IQR: Q1, Q3	0.0, 20.0	0.0, 20.0	0.0, 20.0			
Min, Max	0, 70	0, 70	0, 100			
Week 24						
m	72	78	142			
n	38	36	74	22	24	38
Mean (SD/SE)	10.5 (20.9)	8.9 (12.6)	15.0 (22.2)	0.9 (4.4)	-2.1 (3.8)	2.9 (2.8)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 10.0	0.0, 10.0	0.0, 20.0	0.0, 0.0	-10.0, 10.0	0.0, 10.0
Min, Max	0, 80	0, 50	0, 100	-30, 80	-60, 40	-50, 50
Week 52						
m	64	70	135			
n	42	48	79	13	24	29
Mean (SD/SE)	13.3 (21.6)	16.5 (22.0)	14.4 (20.4)	-3.1 (4.6)	2.5 (4.0)	-4.5 (4.1)
Median	0	10.0	10.0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 30.0	0.0, 20.0	-10.0, 0.0	-5.0, 15.0	0.0, 0.0
Min, Max	0, 90	0, 80	0, 100	-40, 30	-50, 40	-90, 20

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.15.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Absenteeism						
Baseline						
m	92	64	156			
n	17	26	34			
Mean (SD)	2.14 (5.36)	2.80 (13.35)	2.94 (17.15)			
Median	0	0	0			
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00			
Min, Max	0.0, 20.0	0.0, 68.1	0.0, 100.0			
Week 24						
m	89	63	147			
n	24	27	51	12	16	26
Mean (SD/SE)	1.15 (3.90)	1.30 (5.72)	0.00 (0.00)	-1.41 (2.17)	1.89 (1.83)	-3.85 (3.85)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 15.0	0.0, 29.4	0.0, 0.0	-20.0, 12.5	0.0, 29.4	-100.0, 0.0
Week 52						
m	85	55	135			
n	23	24	55	6	12	20
Mean (SD/SE)	4.53 (14.37)	4.31 (14.40)	4.35 (15.44)	5.00 (9.57)	7.64 (5.76)	5.63 (3.62)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00	0.00, 0.00
Min, Max	0.0, 50.0	0.0, 66.7	0.0, 75.0	-20.0, 50.0	0.0, 66.7	0.0, 66.7

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.15.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Presenteeism						
Baseline						
m	92	64	156			
n	17	26	33			
Mean (SD)	7.1 (18.3)	10.8 (16.7)	7.3 (17.7)			
Median	0	10.0	0			
IQR: Q1, Q3	0.0, 0.0	0.0, 10.0	0.0, 0.0			
Min, Max	0, 70	0, 70	0, 70			
Week 24						
m	89	63	147			
n	24	27	51	12	16	25
Mean (SD/SE)	14.2 (24.8)	14.1 (21.0)	6.9 (16.1)	15.0 (10.7)	3.8 (5.6)	1.6 (4.5)
Median	0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 20.0	0.0, 10.0	0.0, 25.0	-5.0, 5.0	0.0, 0.0
Min, Max	0, 90	0, 80	0, 70	-40, 90	-30, 60	-60, 70
Week 52						
m	85	55	135			
n	23	24	55	6	12	20
Mean (SD/SE)	12.2 (21.5)	11.3 (20.9)	9.5 (18.6)	11.7 (16.6)	0.8 (3.1)	4.5 (4.9)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.0, 20.0	0.0, 15.0	0.0, 10.0	0.0, 10.0	-5.0, 0.0	0.0, 10.0
Min, Max	0, 90	0, 90	0, 80	-30, 90	-10, 30	-40, 80

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.15.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result MGL-3196 80 mg (N=92)	Visit Result MGL-3196 100 mg (N=64)	Visit Result Placebo (N=156)	Change from Baseline MGL-3196 80 mg (N=92)	Change from Baseline MGL-3196 100 mg (N=64)	Change from Baseline Placebo (N=156)
Overall Work Impairment						
Baseline						
m	92	64	156			
n	17	26	33			
Mean (SD)	8.38 (19.40)	13.55 (19.97)	7.27 (17.73)			
Median	0	10.00	0			
IQR: Q1, Q3	0.00, 7.00	0.00, 14.30	0.00, 0.00			
Min, Max	0.0, 76.0	0.0, 70.0	0.0, 70.0			
Week 24						
m	89	63	147			
n	24	27	51	12	16	25
Mean (SD/SE)	14.72 (25.25)	15.24 (21.38)	6.86 (16.06)	13.83 (11.13)	5.46 (5.78)	1.60 (4.53)
Median	0	10.00	0	0	0	0
IQR: Q1, Q3	0.00, 25.00	0.00, 20.00	0.00, 10.00	0.00, 25.00	-5.00, 10.00	0.00, 0.00
Min, Max	0.0, 91.3	0.0, 80.0	0.0, 70.0	-46.0, 91.3	-30.0, 60.0	-60.0, 70.0
Week 52						
m	85	55	135			
n	23	24	55	6	12	20
Mean (SD/SE)	15.58 (25.57)	14.46 (24.88)	12.37 (23.89)	18.17 (18.66)	7.16 (5.94)	8.58 (6.16)
Median	0	0	0	0	0	0
IQR: Q1, Q3	0.00, 23.40	0.00, 30.00	0.00, 10.00	0.00, 55.00	0.00, 6.25	0.00, 10.00
Min, Max	0.0, 90.0	0.0, 91.2	0.0, 87.5	-36.0, 90.0	-10.0, 63.4	-40.0, 83.0

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.15.1
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter / Visit / Statistic	Visit Result			Change from Baseline		
	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Activity Impairment						
Baseline						
m	92	64	156			
n	36	32	63			
Mean (SD)	18.1 (27.9)	12.8 (19.4)	21.4 (28.7)			
Median	0	10.0	10.0			
IQR: Q1, Q3	0.0, 30.0	0.0, 15.0	0.0, 40.0			
Min, Max	0, 80	0, 80	0, 100			
Week 24						
m	89	63	147			
n	52	37	78	29	23	41
Mean (SD/SE)	19.8 (23.1)	13.8 (19.1)	16.5 (24.1)	9.3 (4.6)	5.2 (4.4)	-2.7 (3.8)
Median	10.0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 20.0	0.0, 30.0	0.0, 30.0	0.0, 10.0	-10.0, 0.0
Min, Max	0, 80	0, 70	0, 80	-40, 60	-20, 70	-80, 70
Week 52						
m	85	55	135			
n	50	32	89	18	17	34
Mean (SD/SE)	17.2 (22.6)	15.6 (19.7)	13.0 (19.7)	3.9 (6.2)	7.6 (3.5)	-4.7 (4.2)
Median	10.0	10.0	0	0	0	0
IQR: Q1, Q3	0.0, 30.0	0.0, 30.0	0.0, 20.0	-10.0, 10.0	0.0, 10.0	-10.0, 10.0
Min, Max	0, 80	0, 80	0, 80	-40, 60	-10, 40	-70, 70

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; N = number of subjects in Label Population; SD = standard deviation; SE = standard error; IQR = interquartile range; Q1 = first quartile; Q3 = third quartile; Min = minimum; Max = maximum; N/A = Not Applicable; NE = Not estimable.
Note: SD is reported for observed values; SE is reported for change from baseline values.
Note: m is the number of subjects in the study at the given visit; n under "Visit Result" is the number of subjects with a result at the given visit; n under "Change from Baseline" is the number of subjects with results at both baseline and the given visit.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.
Program: t-se21-02-01-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.15.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MMRM = mixed model for repeated measurements; SD = standard deviation; SE = standard error; LS = least squares; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
Note: m is the number of subjects in the study at the given visit; n is the number of subjects with results at both baseline and the given visit.
Note: The LS means, CIs, and p-values were obtained using a MMRM approach with baseline value, visit, baseline type 2 diabetes status, fibrosis stage at baseline as covariates with interaction terms for baseline value and visit and treatment group and visit. Hedge's g was calculated from the LS Means and associated SE, and corrected by multiplying a correction term based on the pooled sample size to account for potential bias in small samples.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.15.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Absenteeism			
Week 24			
m	72	78	142
n	9	6	19
Baseline Mean (SD)	6.83 (13.71)	0.00 (0.00)	3.88 (9.34)
Analysis Visit Mean (SD)	1.86 (5.57)	0.00 (0.00)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-2.96 (0.94)	-3.53 (1.10)	-3.98 (0.66)
95% CI	(-4.86, -1.06)	(-5.74, -1.31)	(-5.31, -2.64)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.02 (1.05)	0.45 (1.15)	
95% CI	(-1.10, 3.14)	(-1.87, 2.77)	
p-value	0.3371	0.6977	
Corrected Hedge's g Statistics	0.345	0.153	
95% CI	(-0.45, 1.14)	(-0.77, 1.07)	
Week 52			
m	64	70	135
n	5	12	16
Baseline Mean (SD)	12.30 (17.08)	0.00 (0.00)	4.21 (10.11)
Analysis Visit Mean (SD)	6.66 (14.89)	4.63 (16.05)	1.56 (6.25)
LS Mean of Change from Baseline (SE)	-2.62 (5.23)	2.72 (3.34)	-2.36 (2.78)
95% CI	(-13.20, 7.95)	(-4.03, 9.48)	(-7.98, 3.26)
LS Mean of Change from Baseline Compared to Placebo (SE)	-0.26 (5.88)	5.08 (4.33)	
95% CI	(-12.15, 11.63)	(-3.66, 13.83)	
p-value	0.9648	0.2471	
Corrected Hedge's g Statistics	-0.022	0.436	
95% CI	(-1.03, 0.98)	(-0.32, 1.19)	
Subgroup*Treatment Interaction p-value	0.7024	0.1544	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.15.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Presenteeism			
Week 24			
m	72	78	142
n	9	6	19
Baseline Mean (SD)	8.9 (19.6)	1.7 (4.1)	7.4 (14.5)
Analysis Visit Mean (SD)	5.6 (13.3)	6.7 (8.2)	8.4 (12.1)
LS Mean of Change from Baseline (SE)	-6.43 (3.88)	2.76 (4.09)	-0.27 (2.66)
95% CI	(-14.27, 1.42)	(-5.51, 11.04)	(-5.65, 5.12)
LS Mean of Change from Baseline Compared to Placebo (SE)	-6.16 (4.32)	3.03 (4.44)	
95% CI	(-14.89, 2.56)	(-5.94, 12.00)	
p-value	0.1613	0.4991	
Corrected Hedge's g Statistics	-0.515	0.259	
95% CI	(-1.32, 0.29)	(-0.66, 1.18)	
Week 52			
m	64	70	135
n	5	12	16
Baseline Mean (SD)	14.0 (26.1)	9.2 (15.1)	6.9 (14.5)
Analysis Visit Mean (SD)	18.0 (24.9)	10.0 (14.8)	5.0 (11.0)
LS Mean of Change from Baseline (SE)	5.53 (5.98)	1.93 (4.43)	0.44 (3.59)
95% CI	(-6.56, 17.62)	(-7.02, 10.87)	(-6.81, 7.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.09 (6.73)	1.48 (5.36)	
95% CI	(-8.51, 18.68)	(-9.34, 12.31)	
p-value	0.4538	0.7830	
Corrected Hedge's g Statistics	0.345	0.098	
95% CI	(-0.66, 1.35)	(-0.65, 0.85)	
Subgroup*Treatment Interaction p-value	0.1757	0.6727	

AMNOG Table SE24.15.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Overall Work Impairment			
Week 24			
m	72	78	142
n	9	6	19
Baseline Mean (SD)	13.10 (25.43)	1.67 (4.08)	10.49 (18.22)
Analysis Visit Mean (SD)	6.67 (16.58)	6.67 (8.16)	8.42 (12.14)
LS Mean of Change from Baseline (SE)	-8.75 (4.08)	-1.25 (4.46)	-3.28 (2.82)
95% CI	(-17.00, -0.49)	(-10.26, 7.77)	(-8.98, 2.42)
LS Mean of Change from Baseline Compared to Placebo (SE)	-5.47 (4.53)	2.03 (4.79)	
95% CI	(-14.62, 3.69)	(-7.65, 11.71)	
p-value	0.2344	0.6735	
Corrected Hedge's g Statistics	-0.432	0.164	
95% CI	(-1.23, 0.37)	(-0.76, 1.08)	
Week 52			
m	64	70	135
n	5	12	16
Baseline Mean (SD)	21.58 (32.74)	9.17 (15.05)	10.31 (18.58)
Analysis Visit Mean (SD)	21.32 (30.67)	14.17 (20.65)	5.94 (14.29)
LS Mean of Change from Baseline (SE)	3.83 (8.10)	4.26 (5.64)	-1.34 (4.67)
95% CI	(-12.53, 20.20)	(-7.14, 15.66)	(-10.77, 8.09)
LS Mean of Change from Baseline Compared to Placebo (SE)	5.17 (9.12)	5.60 (7.01)	
95% CI	(-13.26, 23.60)	(-8.58, 19.77)	
p-value	0.5740	0.4296	
Corrected Hedge's g Statistics	0.268	0.285	
95% CI	(-0.74, 1.28)	(-0.47, 1.04)	
Subgroup*Treatment Interaction p-value	0.1150	0.9408	

AMNOG Table SE24.15.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Activity Impairment			
Week 24			
m	72	78	142
n	22	24	38
Baseline Mean (SD)	7.3 (16.4)	12.5 (18.0)	11.8 (18.6)
Analysis Visit Mean (SD)	8.2 (20.8)	10.4 (14.0)	14.7 (22.3)
LS Mean of Change from Baseline (SE)	-0.26 (3.78)	-0.73 (3.57)	4.67 (2.92)
95% CI	(-7.76, 7.24)	(-7.82, 6.36)	(-1.12, 10.47)
LS Mean of Change from Baseline Compared to Placebo (SE)	-4.93 (4.49)	-5.40 (4.35)	
95% CI	(-13.85, 3.99)	(-14.03, 3.22)	
p-value	0.2753	0.2169	
Corrected Hedge's g Statistics	-0.272	-0.299	
95% CI	(-0.80, 0.26)	(-0.81, 0.21)	
Week 52			
m	64	70	135
n	13	24	29
Baseline Mean (SD)	13.1 (21.4)	13.8 (18.6)	14.5 (25.2)
Analysis Visit Mean (SD)	10.0 (15.3)	16.3 (19.7)	10.0 (15.4)
LS Mean of Change from Baseline (SE)	0.93 (4.26)	5.35 (3.32)	-1.58 (2.93)
95% CI	(-7.52, 9.39)	(-1.24, 11.95)	(-7.39, 4.23)
LS Mean of Change from Baseline Compared to Placebo (SE)	2.51 (4.88)	6.93 (4.17)	
95% CI	(-7.18, 12.20)	(-1.35, 15.21)	
p-value	0.6079	0.0998	
Corrected Hedge's g Statistics	0.158	0.427	
95% CI	(-0.50, 0.81)	(-0.12, 0.97)	
Subgroup*Treatment Interaction p-value	0.0751	0.4495	

Program: t-se21-02-02-subgroup.sas Date of creation: 23JUN2025

AMNOG Table SE24.15.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Absenteeism			
Week 24			
m	89	63	147
n	12	16	26
Baseline Mean (SD)	2.45 (6.15)	0.30 (1.20)	3.85 (19.61)
Analysis Visit Mean (SD)	1.04 (3.61)	2.19 (7.39)	0.00 (0.00)
LS Mean of Change from Baseline (SE)	-0.70 (1.32)	0.38 (1.08)	-1.84 (0.86)
95% CI	(-3.35, 1.95)	(-1.78, 2.54)	(-3.56, -0.13)
LS Mean of Change from Baseline Compared to Placebo (SE)	1.14 (1.54)	2.22 (1.38)	
95% CI	(-1.93, 4.22)	(-0.54, 4.99)	
p-value	0.4601	0.1131	
Corrected Hedge's g Statistics	0.253	0.502	
95% CI	(-0.43, 0.94)	(-0.13, 1.13)	
Week 52			
m	85	55	135
n	6	12	20
Baseline Mean (SD)	3.33 (8.16)	0.00 (0.00)	0.00 (0.00)
Analysis Visit Mean (SD)	8.33 (20.41)	7.64 (19.94)	5.63 (16.21)
LS Mean of Change from Baseline (SE)	7.45 (6.52)	3.49 (4.82)	3.32 (3.84)
95% CI	(-5.59, 20.49)	(-6.14, 13.13)	(-4.37, 11.01)
LS Mean of Change from Baseline Compared to Placebo (SE)	4.13 (7.78)	0.18 (5.89)	
95% CI	(-11.44, 19.70)	(-11.61, 11.97)	
p-value	0.5977	0.9764	
Corrected Hedge's g Statistics	0.236	0.010	
95% CI	(-0.68, 1.15)	(-0.71, 0.73)	
Subgroup*Treatment Interaction p-value	0.7024	0.1544	

AMNOG Table SE24.15.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Presenteeism			
Week 24			
m	89	63	147
n	12	16	25
Baseline Mean (SD)	5.8 (20.2)	10.0 (12.6)	7.6 (19.4)
Analysis Visit Mean (SD)	20.8 (32.9)	13.8 (19.3)	9.2 (18.9)
LS Mean of Change from Baseline (SE)	11.56 (6.61)	4.90 (5.40)	1.01 (4.34)
95% CI	(-1.67, 24.78)	(-5.91, 15.71)	(-7.67, 9.69)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.55 (7.81)	3.90 (6.94)	
95% CI	(-5.08, 26.17)	(-9.99, 17.78)	
p-value	0.1820	0.5767	
Corrected Hedge's g Statistics	0.467	0.176	
95% CI	(-0.23, 1.16)	(-0.45, 0.81)	
Week 52			
m	85	55	135
n	6	12	20
Baseline Mean (SD)	11.7 (28.6)	8.3 (9.4)	8.5 (21.6)
Analysis Visit Mean (SD)	23.3 (36.1)	9.2 (13.8)	13.0 (21.5)
LS Mean of Change from Baseline (SE)	13.09 (7.63)	-2.25 (5.44)	2.29 (4.25)
95% CI	(-2.17, 28.35)	(-13.13, 8.62)	(-6.20, 10.79)
LS Mean of Change from Baseline Compared to Placebo (SE)	10.80 (8.63)	-4.55 (6.90)	
95% CI	(-6.47, 28.06)	(-18.35, 9.26)	
p-value	0.2158	0.5125	
Corrected Hedge's g Statistics	0.552	-0.234	
95% CI	(-0.37, 1.48)	(-0.95, 0.48)	
Subgroup*Treatment Interaction p-value	0.1757	0.6727	

AMNOG Table SE24.15.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Overall Work Impairment			
Week 24			
m	89	63	147
n	12	16	25
Baseline Mean (SD)	7.12 (21.86)	10.27 (12.69)	7.60 (19.43)
Analysis Visit Mean (SD)	20.94 (33.13)	15.73 (20.01)	9.20 (18.91)
LS Mean of Change from Baseline (SE)	13.39 (6.80)	5.80 (5.51)	0.84 (4.43)
95% CI	(-0.21, 27.00)	(-5.23, 16.82)	(-8.02, 9.70)
LS Mean of Change from Baseline Compared to Placebo (SE)	12.56 (7.99)	4.96 (7.08)	
95% CI	(-3.43, 28.54)	(-9.21, 19.13)	
p-value	0.1213	0.4865	
Corrected Hedge's g Statistics	0.544	0.220	
95% CI	(-0.16, 1.24)	(-0.41, 0.85)	
Week 52			
m	85	55	135
n	6	12	20
Baseline Mean (SD)	12.67 (31.03)	8.33 (9.37)	8.50 (21.59)
Analysis Visit Mean (SD)	30.83 (37.47)	15.49 (23.67)	17.08 (26.64)
LS Mean of Change from Baseline (SE)	18.93 (9.67)	2.86 (6.94)	5.56 (5.44)
95% CI	(-0.41, 38.28)	(-11.03, 16.76)	(-5.32, 16.44)
LS Mean of Change from Baseline Compared to Placebo (SE)	13.38 (11.01)	-2.69 (8.82)	
95% CI	(-8.65, 35.41)	(-20.34, 14.96)	
p-value	0.2292	0.7612	
Corrected Hedge's g Statistics	0.536	-0.108	
95% CI	(-0.39, 1.46)	(-0.82, 0.61)	
Subgroup*Treatment Interaction p-value	0.1150	0.9408	

AMNOG Table SE24.15.2
Work Productivity and Activity Impairment-NASH (SE24): Summary of Results - MMRM Model by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Visit Statistic	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Activity Impairment			
Week 24			
m	89	63	147
n	29	23	41
Baseline Mean (SD)	16.6 (26.8)	10.4 (14.3)	19.8 (28.9)
Analysis Visit Mean (SD)	25.9 (24.7)	15.7 (20.6)	17.1 (25.1)
LS Mean of Change from Baseline (SE)	7.27 (3.78)	1.09 (4.17)	-1.63 (3.11)
95% CI	(-0.23, 14.76)	(-7.19, 9.37)	(-7.79, 4.53)
LS Mean of Change from Baseline Compared to Placebo (SE)	8.90 (4.84)	2.72 (5.20)	
95% CI	(-0.70, 18.49)	(-7.60, 13.03)	
p-value	0.0688	0.6026	
Corrected Hedge's g Statistics	0.438	0.135	
95% CI	(-0.04, 0.92)	(-0.38, 0.65)	
Week 52			
m	85	55	135
n	18	17	34
Baseline Mean (SD)	17.2 (26.1)	11.2 (13.2)	21.2 (27.8)
Analysis Visit Mean (SD)	21.1 (22.5)	18.8 (18.3)	16.5 (21.9)
LS Mean of Change from Baseline (SE)	3.29 (4.38)	2.59 (4.46)	-3.61 (3.16)
95% CI	(-5.40, 11.97)	(-6.26, 11.44)	(-9.87, 2.65)
LS Mean of Change from Baseline Compared to Placebo (SE)	6.90 (5.34)	6.20 (5.49)	
95% CI	(-3.70, 17.50)	(-4.68, 17.09)	
p-value	0.1995	0.2612	
Corrected Hedge's g Statistics	0.368	0.332	
95% CI	(-0.21, 0.94)	(-0.25, 0.92)	
Subgroup*Treatment Interaction p-value	0.0751	0.4495	

AMNOG Table SE24.15.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Abbreviations: WPAI-NASH = Work Productivity and Activity Impairment for Non-Alcoholic Steatohepatitis; MCID = minimal clinically important difference; N = number of subjects in Label Population; n = number of subjects in the category; CI = confidence interval; N/A = Not Applicable; NE = Not estimable.
[1] For each score, the MCID of 15% (5%) is defined as 15% (5%) of the score range size. Meeting MCID is defined as an decrease of >= MCID from baseline.
[2] The inverse odds ratio, inverse risk ratio, absolute risk difference, 95% CIs, and p-values were obtained using an unadjusted approach and Chi-square Test. For this unadjusted analysis only Baseline and Week 52 data will be considered. Patients with no Week 52 change from baseline data will be considered as non-responders. A benefit in favour of the investigational treatment corresponds to a ratio below 1.
Note: Patients that were F3 at eligibility and re-evaluated as F4 at baseline by either pathologist are included in this analysis.

AMNOG Table SE24.15.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.3)	0	1 (0.7)
No	74 (98.7)	87 (100)	146 (99.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.51	NE	
95% CI of the inverse odds ratio	(0.03, 8.22)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.51	NE	
95% CI of the inverse risk ratio	(0.03, 8.04)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.65	-0.68	
95% CI of the absolute risk difference	(-2.26, 3.57)	(-2.01, 0.65)	
p-value	0.6262	0.4407	
p-value of Breslow-Day Test for Homogeneity [3]	0.4115	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.3)	0	2 (1.4)
No	74 (98.7)	87 (100)	145 (98.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	NE	
95% CI of the inverse odds ratio	(0.09, 11.44)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	NE	
95% CI of the inverse risk ratio	(0.09, 11.07)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.03	-1.36	
95% CI of the absolute risk difference	(-3.23, 3.17)	(-3.23, 0.51)	
p-value	0.9867	0.2745	
p-value of Breslow-Day Test for Homogeneity [3]	0.2737	NE	

AMNOG Table SE24.15.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	0	1 (1.1)	2 (1.4)
No	75 (100)	86 (98.9)	145 (98.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	1.19	
95% CI of the inverse odds ratio	NE	(0.11, 13.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	1.18	
95% CI of the inverse risk ratio	NE	(0.11, 12.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.36	-0.21	
95% CI of the absolute risk difference	(-3.23, 0.51)	(-3.13, 2.71)	
p-value	0.3102	0.8897	
p-value of Breslow-Day Test for Homogeneity [3]	0.3878	0.4308	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (2.7)	2 (2.3)	3 (2.0)
No	73 (97.3)	85 (97.7)	144 (98.0)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.76	0.89	
95% CI of the inverse odds ratio	(0.12, 4.65)	(0.15, 5.41)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.77	0.89	
95% CI of the inverse risk ratio	(0.13, 4.48)	(0.15, 5.21)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	0.63	0.26	
95% CI of the absolute risk difference	(-3.68, 4.93)	(-3.63, 4.15)	
p-value	0.7663	0.8950	
p-value of Breslow-Day Test for Homogeneity [3]	0.7740	0.3476	

AMNOG Table SE24.15.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.3)	1 (1.1)	2 (1.4)
No	74 (98.7)	86 (98.9)	145 (98.6)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.19	
95% CI of the inverse odds ratio	(0.09, 11.44)	(0.11, 13.28)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.18	
95% CI of the inverse risk ratio	(0.09, 11.07)	(0.11, 12.86)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.03	-0.21	
95% CI of the absolute risk difference	(-3.23, 3.17)	(-3.13, 2.71)	
p-value	0.9867	0.8897	
p-value of Breslow-Day Test for Homogeneity [3]	0.9330	0.4308	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	2 (2.7)	2 (2.3)	4 (2.7)
No	73 (97.3)	85 (97.7)	143 (97.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.19	
95% CI of the inverse odds ratio	(0.18, 5.71)	(0.21, 6.63)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	1.18	
95% CI of the inverse risk ratio	(0.19, 5.44)	(0.22, 6.33)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.05	-0.42	
95% CI of the absolute risk difference	(-4.55, 4.44)	(-4.53, 3.68)	
p-value	0.9811	0.8434	
p-value of Breslow-Day Test for Homogeneity [3]	0.9229	0.4118	

AMNOG Table SE24.15.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=75)	MGL-3196 100 mg (N=87)	Placebo (N=147)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	2 (2.7)	3 (3.4)	4 (2.7)
No	73 (97.3)	84 (96.6)	143 (97.3)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.78	
95% CI of the inverse odds ratio	(0.18, 5.71)	(0.17, 3.58)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.02	0.79	
95% CI of the inverse risk ratio	(0.19, 5.44)	(0.18, 3.44)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.05	0.73	
95% CI of the absolute risk difference	(-4.55, 4.44)	(-3.92, 5.38)	
p-value	0.9811	0.7523	
p-value of Breslow-Day Test for Homogeneity [3]	0.6851	0.0679	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (6.7)	6 (6.9)	7 (4.8)
No	70 (93.3)	81 (93.1)	140 (95.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.70	0.68	
95% CI of the inverse odds ratio	(0.21, 2.28)	(0.22, 2.08)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	0.71	0.69	
95% CI of the inverse risk ratio	(0.23, 2.17)	(0.24, 1.99)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.90	2.13	
95% CI of the absolute risk difference	(-4.71, 8.52)	(-4.21, 8.48)	
p-value	0.5528	0.4909	
p-value of Breslow-Day Test for Homogeneity [3]	0.6135	0.2846	

AMNOG Table SE24.15.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Absenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.1)	0	0
No	91 (98.9)	64 (100)	156 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.09	NE	
95% CI of the absolute risk difference	(-1.03, 3.21)	NE	
p-value	0.1920	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.4115	NE	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.1)	0	0
No	91 (98.9)	64 (100)	156 (100)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse odds ratio	NE	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	NE	NE	
95% CI of the inverse risk ratio	NE	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	1.09	NE	
95% CI of the absolute risk difference	(-1.03, 3.21)	NE	
p-value	0.1920	NE	
p-value of Breslow-Day Test for Homogeneity [3]	0.2737	NE	

AMNOG Table SE24.15.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Presenteeism			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.1)	0	2 (1.3)
No	91 (98.9)	64 (100)	154 (98.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	NE	
95% CI of the inverse odds ratio	(0.11, 13.22)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	NE	
95% CI of the inverse risk ratio	(0.11, 12.83)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.20	-1.28	
95% CI of the absolute risk difference	(-2.95, 2.56)	(-3.05, 0.48)	
p-value	0.8920	0.3628	
p-value of Breslow-Day Test for Homogeneity [3]	0.3878	0.4308	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.1)	3 (4.7)	2 (1.3)
No	91 (98.9)	61 (95.3)	154 (98.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.26	
95% CI of the inverse odds ratio	(0.11, 13.22)	(0.04, 1.62)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.27	
95% CI of the inverse risk ratio	(0.11, 12.83)	(0.05, 1.60)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.20	3.41	
95% CI of the absolute risk difference	(-2.95, 2.56)	(-2.07, 8.88)	
p-value	0.8920	0.1237	
p-value of Breslow-Day Test for Homogeneity [3]	0.7740	0.3476	

AMNOG Table SE24.15.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Overall Work Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	1 (1.1)	0	2 (1.3)
No	91 (98.9)	64 (100)	154 (98.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	NE	
95% CI of the inverse odds ratio	(0.11, 13.22)	NE	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	NE	
95% CI of the inverse risk ratio	(0.11, 12.83)	NE	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.20	-1.28	
95% CI of the absolute risk difference	(-2.95, 2.56)	(-3.05, 0.48)	
p-value	0.8920	0.3628	
p-value of Breslow-Day Test for Homogeneity [3]	0.9330	0.4308	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	1 (1.1)	2 (3.1)	2 (1.3)
No	91 (98.9)	62 (96.9)	154 (98.7)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.40	
95% CI of the inverse odds ratio	(0.11, 13.22)	(0.06, 2.92)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.18	0.41	
95% CI of the inverse risk ratio	(0.11, 12.83)	(0.06, 2.85)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.20	1.84	
95% CI of the absolute risk difference	(-2.95, 2.56)	(-2.77, 6.46)	
p-value	0.8920	0.3528	
p-value of Breslow-Day Test for Homogeneity [3]	0.9229	0.4118	

AMNOG Table SE24.15.3
Work Productivity and Activity Impairment-NASH (SE24): Summary of Response at Week 52 by Domain;
by Statin Status
(Label Population)

Statin Status: Not treated with Statins at baseline

Parameter Response Statistic/Category	MGL-3196 80 mg (N=92)	MGL-3196 100 mg (N=64)	Placebo (N=156)
Activity Impairment			
Minimal Clinically Important Difference of 15% [1], n (%)			
Yes	3 (3.3)	0	8 (5.1)
No	89 (96.7)	64 (100)	148 (94.9)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.60	7.38	
95% CI of the inverse odds ratio	(0.41, 6.20)	(0.42, 129.85)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.57	7.04	
95% CI of the inverse risk ratio	(0.43, 5.78)	(0.41, 120.16)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-1.87	-4.64	
95% CI of the absolute risk difference	(-6.88, 3.15)	(-8.77, -0.52)	
p-value	0.4902	0.1103	
p-value of Breslow-Day Test for Homogeneity [3]	0.6851	0.0679	
Minimal Clinically Important Difference of 5% [1], n (%)			
Yes	5 (5.4)	2 (3.1)	9 (5.8)
No	87 (94.6)	62 (96.9)	147 (94.2)
Inverse odds ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.07	1.90	
95% CI of the inverse odds ratio	(0.35, 3.28)	(0.40, 9.04)	
Inverse risk ratio, Chi-square, MGL-3196 treatment group / Placebo [2]	1.06	1.85	
95% CI of the inverse risk ratio	(0.37, 3.07)	(0.41, 8.31)	
Absolute risk difference, Chi-square, MGL-3196 treatment group - Placebo [2]	-0.33	-2.64	
95% CI of the absolute risk difference	(-6.24, 5.57)	(-8.26, 2.97)	
p-value	0.9122	0.4137	
p-value of Breslow-Day Test for Homogeneity [3]	0.6135	0.2846	